<SEC-DOCUMENT>0001193125-24-233296.txt : 20241007
<SEC-HEADER>0001193125-24-233296.hdr.sgml : 20241007
<ACCEPTANCE-DATETIME>20241007060805
ACCESSION NUMBER:		0001193125-24-233296
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		35
FILED AS OF DATE:		20241007
DATE AS OF CHANGE:		20241007

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Upstream Bio, Inc.
		CENTRAL INDEX KEY:			0002022626
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-282197
		FILM NUMBER:		241356049

	BUSINESS ADDRESS:	
		STREET 1:		460 TOTTEN POND ROAD, SUITE 420
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		781-208-2466

	MAIL ADDRESS:	
		STREET 1:		460 TOTTEN POND ROAD, SUITE 420
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>d843142ds1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<HTML><HEAD>
<TITLE>S-1/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>As filed with the Securities and Exchange Commission on October 7, 2024. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="right"><B>Registration No.&nbsp;333-282197 </B></P>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial" ALIGN="center"><B>SECURITIES AND EXCHANGE
COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:16pt; font-family:arial" ALIGN="center"><B>Amendment No. 1
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial" ALIGN="center"><B>to </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial" ALIGN="center"><B><I>THE SECURITIES ACT OF 1933
</I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:22pt; font-family:arial" ALIGN="center"><B>UPSTREAM BIO, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>(Exact Name of Registrant
as Specified in Its Charter) </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">38-4187694</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:arial" ALIGN="center"><B>(State or Other Jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:arial" ALIGN="center"><B>Incorporation or Organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:arial" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:arial" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:arial" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:arial" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>890 Winter Street, Suite 200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Waltham, MA 02451 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>(781) <FONT
STYLE="white-space:nowrap">208-2466</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:arial" ALIGN="center"><B>(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#146;s
Principal Executive Offices) </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>E. Rand Sutherland </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Chief Executive Officer
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Upstream Bio, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>890 Winter Street,
Suite 200 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Waltham, MA 02451 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>(781) <FONT
STYLE="white-space:nowrap">208-2466</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:arial" ALIGN="center"><B>(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)
</B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><I>Copies to:</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Gabriela Morales-Rivera</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>William D. Collins</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Kathryn W. Clerici</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Goodwin Procter LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>100 Northern Avenue</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Boston, MA 02210</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="center"><B>(617) <FONT
STYLE="white-space:nowrap">570-1000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Michael Paul Gray</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Chief Financial Officer</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Upstream Bio,
Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>890 Winter Street, Suite 200</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Waltham, MA 02451</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="center"><B>(781) <FONT
STYLE="white-space:nowrap">208-2466</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Kristin VanderPas</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Dave Peinsipp</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Denny Won</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Charles S. Kim</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Cooley LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>3 Embarcadero Center, 20th Floor</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>San Francisco,
CA 94111</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="center"><B>(415) <FONT STYLE="white-space:nowrap">693-2000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Approximate date of commencement of proposed sale to the public:</B> As soon as practicable after the effective date of this registration statement. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:arial">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the
following box.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:arial">If this Form is filed to register additional securities for an offering pursuant to
Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:arial">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the
Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:arial">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:arial">Indicate by
check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large
accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;Accelerated&nbsp;Filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;Filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-Accelerated</FONT> Filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;Reporting&nbsp;Company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;Growth&nbsp;Company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:arial">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a
further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective
on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><FONT COLOR="#de1a1e"><B>The information in this preliminary prospectus is not complete and may be changed. We may not sell
these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell securities and we are not soliciting offers to buy these securities in any
jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><FONT COLOR="#de1a1e"><B>Subject to Completion, dated October&nbsp;7, 2024 </B></FONT></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Preliminary prospectus </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><B><I>12,500,000 shares </I></B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g843142g22q66.jpg" ALT="LOGO" STYLE="width:2.17245in;height:0.393756in;">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><B><I>Common stock </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This is an initial
public offering of shares of common stock of Upstream Bio, Inc. We are offering 12,500,000 shares of our common stock to be sold in this offering. The initial public offering price is expected to be between $15.00 and $17.00 per share. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prior to this offering, there has been no public market for our common stock. We have applied to list our common stock on The Nasdaq Global Market under the symbol
&#147;UPB,&#148; and this offering is contingent upon obtaining such approval. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are an &#147;emerging growth company&#148; and a &#147;smaller reporting
company&#148; as defined under the U.S. federal securities laws and, as such, have elected to comply with certain reduced reporting requirements. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Per&nbsp;share</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Underwriting discounts and commissions<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Proceeds to Upstream Bio, Inc., before expenses</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See &#147;Underwriting&#148; for a description of the compensation payable to the underwriters. </TD></TR></TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have granted the
underwriters an option for a period of 30 days to purchase up to 1,875,000 additional shares of common stock. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Investing in our common stock involves a high
degree of risk. Please see &#147;<A HREF="#toc843142_2">Risk&nbsp;factors</A>&#148; beginning on page&nbsp;15. </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters expect to deliver the shares to purchasers on or about&#8195;&#8195;&#8195;&#8195; , 2024. </P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:16pt">
<TD VALIGN="bottom"><B>J.P.&nbsp;Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:16pt; font-family:arial" ALIGN="center"><B>TD&nbsp;Cowen</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:16pt; font-family:arial" ALIGN="center"><B>Piper&nbsp;Sandler</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>William&nbsp;Blair</B></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:arial"><B>&#8195;&#8195;&#8195;, 2024 </B></P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc"></A>Table of contents </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc843142_1">Prospectus summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc843142_2">Risk factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc843142_3">Special note regarding forward-looking statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc843142_4">Market, industry and other data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc843142_5">Use of proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc843142_6">Dividend policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc843142_7">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc843142_8">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc843142_9">Management&#146;s discussion and analysis of financial condition and results of operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc843142_10">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc843142_11">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc843142_12">Executive compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc843142_13">Director compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc843142_14">Certain relationships and related party transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc843142_15">Principal stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">210</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc843142_16">Description of capital stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc843142_17">Shares eligible for future sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc843142_18">Material U.S. federal income tax considerations <FONT STYLE="white-space:nowrap">for&nbsp;non-U.S.
</FONT> holders of common stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc843142_19">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc843142_20">Legal matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">240</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc843142_21">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">240</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc843142_22">Where you can find more information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">240</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc843142_23a">Index to consolidated financial statements </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Through and including&#8195;&#8195;&#8195;&#8195;, 2024 (the 25th day after the date of this prospectus), all dealers effecting
transactions in our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to a dealer&#146;s obligation to deliver a prospectus when acting as an underwriter
and with respect to an unsold allotment or subscription. </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Neither we nor the underwriters have authorized anyone to provide any information or make any
representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to
the reliability of, any other information that others may give you. We and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information
appearing in this prospectus or in any applicable free writing prospectus is current only as of the date on the front cover of this prospectus, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial
condition, results of operations and prospects may have changed since that date. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For investors outside of the United States: We have not, and the underwriters have
not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into
</P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
possession of this prospectus must inform themselves about, and observe, any restrictions relating to the offering of the shares of common stock and the distribution of this prospectus outside of
the United States. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upstream Bio, Inc. and our logo are our trademarks and are used in this prospectus. All other trademarks or trade names referred to in this
prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus are referred to without the symbols <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and <SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. </P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc843142_1"></A>Prospectus summary </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>This summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making your
investment decision. Before investing in our common stock, you should carefully read this entire prospectus, including our consolidated financial statements and the related notes included elsewhere in this prospectus. You should also consider, among
other things, the matters described under the sections titled &#147;Risk factors&#148; and &#147;Management&#146;s discussion and analysis of financial condition and results of operations,&#148; in each case appearing elsewhere in this prospectus.
Unless the context otherwise requires, the terms &#147;Upstream,&#148; &#147;the Company,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our&#148; in this prospectus refer to Upstream Bio, Inc. and its wholly owned subsidiary, or either or both of
them as the context may require. </I></P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Overview </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are a
clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. We are developing verekitug, the only known antagonist currently in clinical development that targets the
receptor for Thymic Stromal Lymphopoietin (&#147;TSLP&#148;), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.
Preclinical and clinical data to date demonstrate verekitug&#146;s highly potent inhibition of the TSLP receptor, which we believe will translate to a differentiated product profile, including improved clinical outcomes, substantially extended
dosing intervals and the potential to treat a broad spectrum of patients. We have advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps
(&#147;CRSwNP&#148;) and plan to initiate development in chronic obstructive pulmonary disease (&#147;COPD&#148;). Our experienced team is committed to maximizing verekitug&#146;s unique attributes to address the substantial unmet needs for patients
underserved by today&#146;s standard of care. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There are six biologics approved for the treatment of severe asthma; three of these are also approved for CRSwNP.
One biologic was recently approved for the treatment of COPD. Total estimated biologics sales in 2023 for asthma in the United States, Europe and Japan markets were approximately $7.5 billion. In December 2021, tezepelumab (marketed as Tezspire by
Amgen Inc. (&#147;Amgen&#148;) and AstraZeneca PLC (&#147;AstraZeneca&#148;)), a monoclonal antibody targeting the TSLP ligand, not the receptor, was approved by the U.S. Food and Drug Administration (&#147;FDA&#148;) as an add-on maintenance
treatment for patients with severe asthma. Tezepelumab is the first and only treatment for severe asthma without any phenotype or biomarker limitation, highlighting the benefit of blocking TSLP signaling early in the inflammatory cascade as compared
to other biologics&#146; mechanisms of action which are further downstream. In May 2024, Amgen and AstraZeneca reported Phase 2a proof-of-concept data for tezepelumab for the treatment of moderate to very severe COPD at the American Thoracic Society
(&#147;ATS&#148;) International Conference. This trial reported a reduction in the frequency of COPD exacerbations that has supported advancement of tezepelumab into Phase 3 development for COPD. These clinical data further demonstrate the potential
for a TSLP targeted therapy to treat a variety of inflammatory diseases. Despite the availability of existing biologics for severe respiratory disease, there remains a high unmet need that limits the utilization of these therapies, including
suboptimal symptom control and frequent dosing intervals. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Verekitug is, to our knowledge, the only monoclonal antibody currently in clinical development that
targets and inhibits the TSLP receptor. In May 2024, we presented full proof-of-concept data from our multicenter, randomized, double-blind, placebo-controlled Phase 1b multiple ascending dose (&#147;MAD&#148;) clinical trial in asthma patients
demonstrating that dosing with verekitug led to rapid and complete TSLP receptor occupancy, and reductions in fractional exhaled nitric oxide (&#147;FeNO,&#148; a disease-related biomarker) and blood eosinophil levels (&#147;eos,&#148; a
disease-related biomarker) that were rapid, substantial and sustained for up to 24&nbsp;weeks after the last dose. This study also demonstrated that verekitug is approximately 300-fold more potent than tezepelumab (based on published
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">1 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
tezepelumab data), which, combined with verekitug&#146;s pharmacokinetic (&#147;PK&#148;) profile, enables an extended dosing interval of up to 24&nbsp;weeks, compared to tezepelumab (four week
dosing interval). Furthermore, clinical data from our Phase&nbsp;1b MAD trial indicate an approximately 50% greater effect on FeNO than has previously been reported for tezepelumab. We have not conducted head-to-head clinical studies of verekitug
against tezepelumab, and note that ongoing and future clinical trials for verekitug may produce differing clinical activity and tolerability results. Three Phase 1 clinical trials have been completed for verekitug across a total of 120 participants,
including 32 patients with asthma. In these trials, which were not designed to support formal statistical comparisons, verekitug was well tolerated, demonstrated no evidence of clinically meaningful anti-drug antibodies (&#147;ADAs&#148;), and
showed a predictable and consistent PK profile with high subcutaneous bioavailability. Although competitive product candidates may be sponsored by organizations with greater financial resources and expertise to support regulatory approval and market
acceptance, we believe verekitug, if approved, will be the preferred biologic for the treatment of severe asthma, CRSwNP and COPD based on its extended dosing interval and effect on broadly accepted disease-associated biomarkers. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our current clinical development plan for verekitug is summarized in the pipeline chart below. Having established clinical proof-of-concept in asthma, we are currently
conducting two separate multi-national, placebo-controlled, randomized Phase 2 clinical trials to investigate the efficacy of two extended dosing intervals of 12 and 24 weeks for patients with severe asthma and 12 weeks for patients with CRSwNP.
These trials have been designed using endpoints that, pending interactions with regulatory authorities, could allow data from these trials to support submissions for product approval. Data from these trials are expected in the second half of 2026
for severe asthma and the second half of 2025 for CRSwNP. Based on available data from Phase 1 trials with verekitug, we plan to initiate our first clinical trial in COPD and have commenced planning activities for a Phase 2 clinical trial, including
development of a clinical trial protocol and regulatory approval strategy, and expect to dose the first COPD patient in the second half of 2025. Beyond these indications, we believe verekitug has broad potential, and we intend to leverage its unique
attributes to develop it as a potential therapy for numerous TSLP-driven diseases. </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g843142g03g03.jpg" ALT="LOGO" STYLE="width:6.31944in;height:2.28487in;">
 </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><B>&#134;</B></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 2 clinical trials in CRSwNP and severe asthma were initiated in January 2024 and March 2024, respectively, and enrollment is currently ongoing. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Planning activities for a Phase 2 clinical trial in COPD have commenced, including development of a clinical trial protocol and regulatory approval strategy. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">2 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Leveraging TSLP biology to address unmet needs in severe asthma, CRSwNP and COPD </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>TSLP overview </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Verekitug is a monoclonal antibody that targets and inhibits
the TSLP receptor. TSLP is a member of a class of epithelial cytokines, also including IL-25 and IL-33, commonly referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung, gastrointestinal tract and skin.
Dendritic cells, basophils, mast cells, keratinocytes and fibroblasts also produce TSLP with appropriate stimulation. In response to various environmental triggers, including viruses, bacteria, allergens, chemical irritants and physical injury, TSLP
can initiate and amplify a wide range of innate and adaptive immune responses, including supporting epithelial barrier function, dendritic cell activation, type 2 innate lymphoid cell activation and survival, immune cell recruitment, induction of
type 2 responses and regulation of B&nbsp;cell function. Beyond type&nbsp;2 inflammation, data also support a role for TSLP in propagating non-type 2 inflammatory processes, including IL-17 production, modulation of airway structural cells and the
promotion of fibrosis. As such, TSLP signaling is a central instigator of multiple downstream biologic pathways relevant to human diseases that are characterized by epithelial inflammation, including asthma, CRSwNP and COPD. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The TSLP signaling pathway is well-understood as a contributor to disease-driving proinflammatory pathways and is a clinically and commercially validated target for
therapeutic development. Historically, development of biologics for severe asthma and related conditions has focused on type 2 inflammatory cytokines that are activated downstream in the TSLP signaling pathway, for instance IL-4, IL-5 and IL-13.
However, in addition to its effect on type 2 inflammation, emerging evidence indicates that TSLP also impacts non-type 2 inflammation, which may result in broader downregulation of pathways relevant to the pathogenesis of multiple inflammatory
diseases. We believe verekitug has the potential, if approved, to address unmet needs in multiple diseases characterized by TSLP-driven pathobiology due to the high potency and potential for extended dosing intervals that we have observed in our
preclinical and clinical development to date. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Only one drug targeting the TSLP pathway has been approved for the treatment of severe asthma. In December 2021,
tezepelumab (marketed as Tezspire by Amgen and AztraZeneca), a monoclonal antibody targeting the TSLP ligand, was approved by the FDA as an add-on maintenance treatment for patients with severe asthma. Tezepelumab is the first and only treatment for
severe asthma without any phenotype or biomarker limitation, highlighting the benefit of blocking TSLP signaling early in the inflammatory cascade as compared to other biologics&#146; mechanisms of action which are further downstream. In the Phase 3
clinical trial of tezepelumab in adults and adolescents with severe, uncontrolled asthma, patients who received tezepelumab had fewer exacerbations and better lung function, asthma control and health-related quality of life than those who received
placebo. Based on pooled safety data from the clinical trials of tezepelumab, Tezspire&#146;s FDA approved label identifies hypersensitivity reactions following administration as a clinically significant adverse reaction, as well as pharyngitis,
arthralgia and back pain as additional adverse reactions that occurred at an incidence of greater than or equal to 3% and more common than the placebo group. Furthermore, a Phase 2a clinical trial for tezepelumab in COPD patients, which demonstrated
a clinically-significant reduction of COPD exacerbations, the most frequently reported adverse events for tezepelumab were worsening of COPD (12.1%) and incidents of COVID-19 infections (14.5%, trial commenced in July 2019), demonstrating a safety
and tolerability profile consistent with that observed for tezepelumab in severe asthma. These clinical data further demonstrate the potential for a TSLP targeted therapy to treat a variety of inflammatory diseases. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Severe asthma </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Asthma is a common respiratory disease characterized by
chronic airway inflammation that is often underdiagnosed and under-treated. For some people, asthma can simply be a nuisance, for others it can </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">3 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
interfere with daily life and potentially even be life-threatening. Of the more than 25 million Americans living with asthma, it is estimated that 5% to 10% suffer from severe asthma. Severe
asthma is defined as asthma that remains uncontrolled despite optimized treatment with high-dose inhaled corticosteroids or that requires high-dosed inhaled corticosteroids to prevent symptoms from becoming uncontrolled. It is estimated that
approximately 90% of people with severe asthma are eligible for biologics, but only 440,000 patients are currently treated with biologics, suggesting more than 80% of eligible patients are not being optimally treated. U.S. sales in 2023 of biologics
for the treatment of severe asthma is estimated to be approximately $6.0 billion. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These statistics show there is a large population of people living with
uncontrolled symptoms of severe asthma. Key areas of unmet need for people living with severe asthma include improved control of exacerbations and symptoms and reduced treatment burden (e.g. need for frequent injections). </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Chronic rhinosinusitis with nasal polyps (CRSwNP) </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">CRSwNP is an inflammatory
disease of the upper airway, marked by chronic sinonasal inflammation and the presence of inflammatory polyps in the nasal passages and paranasal sinuses. It is estimated by Sanofi that approximately 900,000 patients in the United States and Europe
suffer from CRSwNP. Nasal polyps are associated with significant morbidity and debilitating symptoms; it is estimated that 40% to 45% of people with severe asthma also have CRSwNP and that up to 65% of people with CRSwNP also have asthma,
demonstrating a strong association between the two conditions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The current treatment options for patients with CRSwNP are corticosteroids, surgery and, more
recently, biologics. Although a treatment option, surgery does not guarantee symptom relief. Even with surgery, many people with CRSwNP remain symptomatic, with the recurrence rate of CRSwNP ranging from 20% to 60% within 18 months to four years and
increasing to 79% after 12 years. Recurrence is particularly common for people with severe disease, including those also living with asthma or who have undergone prior surgeries. The recent FDA approvals of biologic treatments for CRSwNP have
established a well-understood regulatory pathway and route to commercialization. It is estimated that approximately 200,000 adult patients in the United States, major European markets and Japan with CRSwNP are eligible for biologics. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Despite these available treatments, the quality of life studies and post-surgical recurrence rates clearly show that many people with CRSwNP have uncontrolled symptoms
that are impacting their daily life and current treatments are not meeting their needs. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Chronic obstructive pulmonary disease (COPD) </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Similar to asthma, COPD is a chronic inflammatory disease that obstructs airflow from the lungs. Chronic inflammation causes structural changes within the lungs,
narrowing already small airways and damaging lung parenchyma which causes air sacs to lose functionality and decreases lung elasticity. It is typically caused by long-term exposure to irritants, most often cigarette smoke. People with a history of
asthma are also more likely to have COPD. Historically, COPD has been considered to have elements of both type 2 and non-type 2 immune responses. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">COPD is the third
leading cause of death worldwide, causing approximately 3.2 million deaths in 2019. Almost 14.2&nbsp;million Americans, or 6.5% of the adult population, reported they have been diagnosed with COPD, yet the actual number is likely higher given that
more than half of adults with low pulmonary function were not aware that they had COPD. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Treatments for COPD are similar to those for asthma and CRSwNP, including
inhaled steroids to reduce inflammation in the airways as well as bronchodilator inhalers to relax airways and improve airflow. Oxygen </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">4 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
and surgery may also be used for people with severe COPD. Dupilumab (marketed as Dupixent by Sanofi and Regeneron Pharmaceuticals, Inc.), an interleukin-4 receptor alpha antagonist, is the only
biologic approved for the treatment of COPD. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Despite available treatments, 60% of all COPD patients report some limitations in their daily activity, with 45%
being unable to work and 75% complaining of difficulty climbing stairs. Given the high levels of morbidity and mortality associated with COPD, the currently available medicines are not sufficient to control symptoms or disease progression. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Verekitug: Inhibiting TSLP signaling in severe asthma, CRSwNP and COPD </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Verekitug is a novel recombinant fully human immunoglobulin G1 monoclonal antibody that binds to the TSLP receptor and inhibits its signaling. In 2021, we acquired
verekitug from Astellas Pharma Inc. (&#147;Astellas&#148;). Astellas discovered the compound and completed preclinical studies and a Phase 1 single ascending dose (&#147;SAD&#148;) trial, providing the early foundational work for our Phase 1b MAD
trial. In those preclinical studies, which were not designed to support formal statistical comparisons, verekitug potently inhibited TSLP signaling. Additionally, verekitug inhibited cytokine production from CD4&#043; T cells, suggesting that it may
be effective against type 2 and non-type 2 inflammation. In the Phase 1 SAD trial in 56 healthy volunteers, verekitug demonstrated a favorable safety profile with no drug-related serious treatment-emergent adverse events, dose proportional PK and a
pharmacodynamic (&#147;PD&#148;) effect consistent with TSLP antagonism. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have conducted two additional clinical trials of verekitug: a Phase 1b MAD trial in
patients with asthma and a Japanese ethnobridging study in healthy volunteers. Across the three clinical trials, we have data from 120 total participants, including 32 patients with asthma. In these trials, verekitug was well tolerated, had no
clinically meaningful immunogenicity, and showed a predictable and consistent PK profile with high subcutaneous bioavailability. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our Phase 1b MAD clinical trial,
which enrolled 32 adult participants aged 18 to 60 with mild to moderate asthma, established clinical proof-of-concept for verekitug in asthma. In the trial, which was not designed to support formal statistical comparisons, verekitug demonstrated
rapid, substantial and sustained target engagement and maintained maximal inhibition of disease-related biomarkers in patients with asthma for up to 24 weeks after the last study dose. Results of the Phase 1b study also demonstrated that verekitug
is a potent inhibitor of the TSLP receptor and has the potential for an extending dosing interval compared to currently available treatments. Importantly, the PK/PD modeling that was done based on the preclinical data aligned very closely with these
early clinical results, strengthening our understanding of verekitug&#146;s attributes and behavior in humans. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are currently conducting two separate
multi-national, placebo-controlled, randomized Phase 2 clinical trials to investigate the efficacy of two extended dosing intervals of 12 and 24 weeks for patients with severe asthma and 12 weeks for patients with CRSwNP. These trials have been
designed using endpoints that, pending interactions with regulatory authorities, could allow data from these trials to support submissions for product approval. Data from these trials are expected in the second half of 2026 for severe asthma and the
second half of 2025 for CRSwNP. Based on available data from Phase 1 trials with verekitug, we plan to initiate our first clinical trial in COPD and have commenced planning activities for a Phase 2 clinical trial, including development of a clinical
trial protocol and regulatory approval strategy, and expect to dose the first COPD patient in the second half of 2025. Beyond these indications, we believe verekitug has broad potential, and we intend to leverage its unique attributes to develop it
as a potential therapy for other TSLP-driven diseases. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">5 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our team and investors </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have built a team with deep experience and a strong track record of execution that has allowed us to move from company inception to Phase 2 in less than three years.
Our leadership team and board of directors have significant experience developing and commercializing innovative medicines, with deep expertise in severe asthma and other respiratory diseases. E. Rand Sutherland, M.D., M.P.H., our Chief Executive
Officer (&#147;CEO&#148;), has more than 25 years of business and clinical experience, having most recently served as CEO of Seeker Biologics Inc., before that as President of Translate Bio, Inc. prior to its $3.2 billion acquisition by Sanofi, and
before that in research and development and business unit roles at Sanofi developing and launching innovative medicines in immunology and rare diseases, including dupilumab. Before joining the biopharma industry, Dr. Sutherland was a Professor of
Medicine at the University of Colorado and Chief of Pulmonary and Critical Care Medicine at National Jewish Health in Denver. Our Chief Medical Officer and Head of Research and Development, Aaron Deykin, M.D., leads our clinical development
activities and strategy. Prior to joining us, Dr. Deykin was Senior Vice President of Clinical Sciences at Biogen, Inc. (&#147;Biogen&#148;) overseeing biostatistics, statistical programming, biomarkers, clinical pharmacology, epidemiology and
clinical operations for Biogen&#146;s pipeline globally. Dr. Deykin was previously Assistant Professor of Medicine at Harvard Medical School and a member of the Pulmonary and Critical Care faculty at Brigham and Women&#146;s Hospital, where he
treated patients with asthma and other advanced respiratory diseases. Michael Paul Gray, M.B.A., our Chief Financial and Operating Officer, brings over 20 years of public and private leadership experience, including broad strategic, financial and
operating experience in global life science companies. Mr. Gray previously held the same roles at Carmot Therapeutics, Inc. prior to its $2.7&nbsp;billion acquisition by Roche Group. Our board of directors consists of highly experienced
biotechnology executives and investors, including Ronald C. Renaud, Jr., M.B.A., CEO of Kailera Therapeutics, Inc., and Marcella Kuhlman Ruddy, M.D., M.S., Chief Medical Officer of Tectonic Therapeutic, Inc. and formerly Regeneron, as our
independent directors. We have also assembled a team of well-known and respected advisors and investigators to provide perspective on our data and participate in our clinical program. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since our inception, we have raised approximately $400 million from premier biotechnology investors. Prospective investors should not rely on the past investment
decisions of our investors, as our investors may have different risk tolerances and have received their shares in prior offerings at prices lower than the price offered to the public in this offering. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Our strategy </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our mission is to develop verekitug to be the first approved
antagonist of the TSLP receptor to benefit patients suffering from severe inflammatory diseases that are underserved by today&#146;s standard of care. The key components of our strategy to achieve this mission are: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Leverage verekitug&#146;s unique mechanism of action to improve the treatment options for millions of patients living with
severe inflammatory diseases. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Advance our ongoing Phase 2 clinical trials for verekitug in severe asthma and CRSwNP. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Expand the impact of verekitug through initiation of an additional development program in COPD.</P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Maximize the potential of verekitug by identifying additional TSLP-driven diseases with high unmet needs that could be
addressed by our product candidate. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">6 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Recent developments </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Preliminary balance of cash, cash equivalents and short-term investments </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of September 30, 2024, we estimate that we had approximately $221.1&nbsp;million in cash, cash equivalents and short-term investments. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This estimate was prepared based on information available as of the date of this prospectus and may vary from our actual financial position as of September 30, 2024. Our
financial closing procedures as of and for the nine months ended September 30, 2024 are not yet complete and, as a result, our final results upon completion of those procedures may differ materially from our preliminary estimate. This preliminary
estimate is subject to change, and any changes may be material. Further, this preliminary estimate does not present all information necessary for an understanding of our financial condition and liquidity as of and for the nine months ended September
30, 2024. This preliminary estimate should not be viewed as a substitute for financial statements prepared in accordance with accounting principles generally accepted in the United States and they are not necessarily indicative of the results to be
achieved in any future period. Accordingly, you should not draw any conclusions based on the foregoing estimate and should not place undue reliance on this preliminary estimate. We assume no duty to update this preliminary estimate except as
required by law. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The preliminary financial data included in the registration statement of which this prospectus forms a part has been prepared by, and is the
responsibility of, our management. PricewaterhouseCoopers LLP has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to this preliminary financial data. Accordingly, PricewaterhouseCoopers LLP does not express
an opinion or any other form of assurance with respect thereto. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risk factors summary </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks include, but are not limited to, the
following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We are a clinical-stage biopharmaceutical company with a limited operating history, which may make it difficult to evaluate
our current business and predict our future success and viability. We have incurred significant financial losses since our inception and anticipate that we will continue to incur significant financial losses for the foreseeable future.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Even if this offering is successful, we will require additional funding in order to finance operations. If we are unable to
raise capital when needed, or on acceptable terms, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Verekitug is our only product candidate, and we are dependent on a third party having accurately generated, collected and
reported data from certain preclinical studies that were previously conducted for verekitug. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">If we are unable to advance verekitug in clinical development for one or more of the indications that we are pursuing,
obtain regulatory approval and ultimately commercialize verekitug, or experience significant delays in doing so, our business will be materially harmed. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">The successful development of pharmaceutical products involves a lengthy and expensive process and is highly uncertain.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">The regulatory approval processes of the U.S. Food and Drug Administration, the European Medicines Agency, and the European
Commission and other comparable foreign regulatory authorities are lengthy, </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">7 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for verekitug or any other potential future product candidates, our business will be
substantially harmed. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Verekitug represents a novel approach to the treatment of inflammatory diseases, which makes it difficult to predict its
likelihood of success and the timing and cost of development and obtaining regulatory approval. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">If our clinical trials fail to replicate positive results from earlier preclinical studies or clinical trials conducted by
us or third parties, we may be unable to successfully develop, obtain regulatory approval for or commercialize verekitug or any other potential future product candidates. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and
commercialization of verekitug or any other potential future product candidates, which could prevent us from achieving our projected development and commercialization goals in the timeframes we announce and expect, and harm our business and results
of operations. Many of the factors that cause or lead to a delay in the initiation or completion of clinical trials may also lead to the denial of regulatory approval or limit market acceptance of verekitug or any other potential future product
candidates. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Verekitug or any other potential future product candidates may cause undesirable side effects or have other properties that
could delay or prevent regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following regulatory approval, if obtained. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Even if verekitug or any other potential future product candidates receive regulatory approval, such product candidate may
fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, in which case we may not generate significant revenues or become profitable.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Competitive products may reduce or eliminate the commercial opportunity for verekitug or any other potential future product
candidates, if approved. If our competitors develop technologies or product candidates more rapidly than we do, or their technologies or product candidates are more effective or safer than ours, our ability to develop and successfully commercialize
verekitug or any other potential future product candidates may be adversely affected. Our competitors may have significantly greater financial resources and expertise such that they may be more successful than us in obtaining regulatory approval and
achieving widespread market acceptance. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We expect to expand our organization, and as a result, we may encounter difficulties in managing our growth, which could
disrupt our operations. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our ability to develop verekitug or any other potential future product candidates and our future growth depends on
attracting, hiring and retaining our key personnel and recruiting additional qualified personnel. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We currently rely, and plan to rely in the future, on third parties to conduct and support our clinical trials. If they do
not perform satisfactorily, we may not be able to obtain regulatory approval or commercialize verekitug or any other potential future product candidates, or such approval or commercialization may be delayed, and our business could be substantially
harmed. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our use of third parties to manufacture verekitug or any other potential future product candidates may increase the risk
that we will not have sufficient quantities of verekitug or any other potential future product candidates, raw materials, active pharmaceutical ingredients or drug products when needed or at an acceptable cost. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">8 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our success is largely based upon our intellectual property and proprietary technologies, and we may be unable to protect
and/or enforce our intellectual property. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The summary risk factors described above should be read together with the text of the full risk factors
in the section titled &#147;Risk factors&#148; and the other information set forth in this prospectus, including our consolidated financial statements and the related notes and condensed consolidated financial statements and the related notes, as
well as in other documents that we file with the Securities and Exchange Commission. The risks summarized above or described in full elsewhere in this prospectus are not the only risks that we face. Additional risks and uncertainties not presently
known to us, or that we currently deem to be immaterial, may also materially adversely affect our business, financial condition, results of operations, and future growth prospects. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Corporate information </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We were incorporated under the laws of the State of
Delaware in April 2021 under the name Upstream Bio, Inc. Our principal corporate office is located at 890 Winter Street, Suite 200, Waltham, MA 02451, and our telephone number is <FONT STYLE="white-space:nowrap">(781)&nbsp;208-2466.</FONT> We have
one subsidiary, Upstream Bio Securities Corporation, formed in November 2021 under the laws of the Commonwealth of Massachusetts. Our website address is www.upstreambio.com. We do not incorporate the information on or accessible through our website
into this prospectus, and you should not consider any information on, or that can be accessed through, our website as part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Implications of being an emerging growth company and a smaller reporting company </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the &#147;JOBS Act&#148;). As an emerging
growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">being permitted to present only two years of audited financial statements, in addition to any required unaudited interim
financial statements, with correspondingly reduced &#147;Management&#146;s discussion and analysis of financial condition and results of operations&#148; disclosure; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reduced disclosure about our executive compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">not being required to hold advisory votes on executive compensation or to obtain stockholder approval of any golden
parachute arrangements not previously approved; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting
pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 (the &#147;Sarbanes-Oxley Act&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an exemption from compliance with the requirements of the Public Company Accounting Oversight Board regarding the
communication of critical audit matters in the auditor&#146;s report on financial statements. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may take advantage of these exemptions for up to
five years or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company on the date that is the earliest of (i)&nbsp;the last day of the fiscal year in which we have total annual gross
revenues of $1.235&nbsp;billion or more; </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">9 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
(ii)&nbsp;the last day of our fiscal year following the fifth anniversary of the date of the completion of this offering; (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion
in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during the previous three years; or (iv)&nbsp;the date on which we are deemed to be a &#147;large accelerated filer&#148;, which would occur if the aggregate market value of our equity
securities held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700.0&nbsp;million as of the last business day of our most recently completed second fiscal quarter. We may choose to take advantage of some but not all of these
exemptions. We have taken advantage of reduced reporting requirements in this prospectus. Accordingly, the information contained herein may be different from the information you receive from other public companies in which you hold stock.
Additionally, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain
accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, while we are an emerging growth company we will not be subject to new or revised accounting
standards at the same time that they become applicable to other public companies that are not emerging growth companies. As a result of these elections, the information that we provide in this prospectus, including our financial statements, may be
different than the information you may receive from other public companies in which you hold equity interests. In addition, it is possible that some investors will find our common stock less attractive as a result of these elections, which may
result in a less active trading market for our common stock and higher volatility in our share price. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are also a &#147;smaller reporting company,&#148; meaning
that the market value of our shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700.0&nbsp;million and our annual revenue was
less than $100.0&nbsp;million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i)&nbsp;the market value of our shares held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million or (ii)&nbsp;our annual revenue was less than $100.0&nbsp;million during the most recently completed fiscal year and the market value of our shares held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure
requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">10 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>The offering </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="39%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:arial"><B>Common stock offered by us </B></P></TD>
<TD><FONT STYLE="font-size:10pt">12,500,000 shares. </FONT></TD></TR></TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="39%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:arial"><B>Option to purchase additional shares </B></P></TD>
<TD><FONT STYLE="font-size:10pt">We have granted the underwriters an option for a period of 30 days to purchase up to 1,875,000 additional shares of common stock from us at the public offering price, less underwriting discounts and commissions on
the same terms as set forth in this prospectus. </FONT></TD></TR></TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="39%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:arial"><B>Common stock to be outstanding immediately after this offering </B></P></TD>
<TD><FONT STYLE="font-size:10pt">48,841,695&nbsp;shares (or 50,716,695&nbsp;shares if the underwriters exercise their option to purchase additional shares in full). </FONT></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="39%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:arial"><B>Use of proceeds </B></P></TD>
<TD><FONT STYLE="font-size:10pt">We estimate that the net proceeds from the sale of shares of our common stock in this offering will be approximately $182.0&nbsp;million, or $209.9&nbsp;million if the underwriters exercise their option to purchase
additional shares in full, assuming an initial public offering price of $16.00&nbsp;per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus, and after deducting estimated underwriting
discounts and commissions and estimated offering expenses payable by us. The principal purposes of this offering are to create a public market for our common stock and thereby facilitate future access to the public equity markets, increase our
visibility in the marketplace and obtain additional capital. We currently intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and short-term investments: (i)&nbsp;to advance verekitug through the
completion of our multi-national, placebo-controlled, randomized Phase 2 clinical trial in severe asthma, and to initiate subsequent Phase 3 clinical development; (ii)&nbsp;to advance verekitug through the completion of our multi-national,
placebo-controlled, randomized Phase 2 clinical trial in CRSwNP, and to initiate subsequent Phase 3 clinical development; (iii)&nbsp;to expand the development of verekitug for the treatment of COPD, including for external clinical trial-related
costs for the initiation and ongoing conduct of a Phase 2 clinical trial; (iv)&nbsp;for external costs associated with verekitug drug substance, drug product, process development or other manufacturing activities to support the continued development
of verekitug in severe asthma, CRSwNP, COPD and potential future additional indications; and (v)&nbsp;the remainder for additional continued research and development efforts relating to verekitug, including expansion into potential additional
indications, as well as for working capital and other general corporate purposes. See the section titled &#147;Use of proceeds&#148; for additional information. </FONT></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">11 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="39%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:arial"><B>Risk factors </B></P></TD>
<TD><FONT STYLE="font-size:10pt">You should carefully read the &#147;Risk factors&#148; section of this prospectus for a discussion of factors that you should consider before deciding to invest in our common stock. </FONT></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="39%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:arial"><B>Proposed Nasdaq Global Market symbol </B></P></TD>
<TD><FONT STYLE="font-size:10pt">&#147;UPB&#148; </FONT></TD></TR></TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The number of shares of our common stock to be outstanding after this offering is based on
36,341,695&nbsp;shares of common stock outstanding as of June&nbsp;30, 2024, after giving effect to the automatic conversion of all outstanding shares of our redeemable convertible preferred stock as of June&nbsp;30, 2024 into the aggregate of
33,321,149&nbsp;shares of common stock immediately prior to the completion of this offering, and excludes: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">6,224,230&nbsp;shares of common stock issuable upon the exercise of outstanding stock options as of June&nbsp;30, 2024
under our 2021 Stock Option and Grant Plan (&#147;2021 Plan&#148;), with a weighted-average exercise price of $4.96&nbsp;per share; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">74,027&nbsp;shares of common stock reserved for future issuance as of June&nbsp;30, 2024 under the 2021 Plan, which will
cease to be available for issuance at the time that our 2024 Stock Option and Incentive Plan (&#147;2024 Plan&#148;) becomes effective (which includes options to purchase an aggregate of 35,666&nbsp;shares of our common stock, at a weighted-average
exercise price of $10.62 per share, that were granted subsequent to June&nbsp;30, 2024); </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">3,180,000&nbsp;shares of our common stock reserved for future issuance under our 2024 Plan, which will become effective on
the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2024 Plan and any
shares underlying outstanding stock awards granted under the 2021 Plan that expire or are repurchased, forfeited, cancelled, or withheld; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">488,467&nbsp;shares of common stock reserved for future issuance under our 2024 Employee Stock Purchase Plan
(&#147;ESPP&#148;), which will become effective on the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of common stock
reserved for future issuance under the ESPP. </P></TD></TR></TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Unless otherwise indicated, all information in this prospectus reflects or assumes the
following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the automatic conversion of all 31,764,693 outstanding shares of our Series&nbsp;A and Series&nbsp;B redeemable convertible
preferred stock in the aggregate, as of June&nbsp;30, 2024, into 33,321,149&nbsp;shares of common stock immediately prior to the completion of this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">no exercise of the outstanding options described above; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">no exercise by the underwriters of their option to purchase up to 1,875,000 additional shares of common stock in this
offering; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a 1.049-for-one split of our common stock, which was effected on October&nbsp;4, 2024 and a corresponding adjustment to the
ratio at which our redeemable convertible preferred stock will convert into common stock; and </P></TD></TR></TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the filing and effectiveness of our third amended and restated certificate of incorporation to be in effect immediately
prior to the completion of this offering and second amended and restated bylaws to be in effect upon effectiveness of the registration statement of which this prospectus forms a part. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">12 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Summary consolidated financial data </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth our summary consolidated statements of operations for the years ended December&nbsp;31, 2023 and 2022 and for the six months ended June
30, 2024 and 2023 and our summary condensed consolidated balance sheet data as of June&nbsp;30, 2024. The summary consolidated statements of operations data for the years ended December&nbsp;31, 2023 and 2022 have been derived from our audited
consolidated financial statements included elsewhere in this prospectus. The summary condensed consolidated statements of operations data for the six months ended June&nbsp;30, 2024 and 2023 and summary condensed consolidated balance sheet data as
of June&nbsp;30, 2024 have been derived from our unaudited condensed consolidated financial statements included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that should be expected in any future
periods, and our interim results are not necessarily indicative of the results that may be expected for the full year or any other period. Our unaudited interim financial statements were prepared on the same basis as our audited financial statements
and include, in the opinion of management, all adjustments, consisting of normal recurring adjustments, that are necessary for the fair statement of the financial information set forth in those financial statements. You should read the following
summary financial data together with &#147;Management&#146;s discussion and analysis of financial condition and results of operations&#148; and our consolidated financial statements and the related notes included elsewhere in this prospectus. The
summary consolidated financial data included in this section are not intended to replace the consolidated financial statements and are qualified in their entirety by our consolidated financial statements and the related notes included elsewhere in
this prospectus. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(in thousands, except per share amounts)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Consolidated statement of operations data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Collaboration revenue&#151;related party</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,114</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,909</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,398</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in fair value of preferred stock tranche right liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(115</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(92</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20,537</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,602</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Redeemable convertible preferred stock cumulative dividends</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,718</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,416</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(38,255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(33,572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,018</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss per share attributable to common stockholders, basic and diluted <SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12.95</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8.13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11.18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5.79</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,953,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,937,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,002,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,937,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Pro forma net loss per share attributable to common stockholders, basic and diluted (unaudited) <SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Pro forma weighted average common shares outstanding, basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,274,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,323,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="16" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">13 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See Note 12&#151;&#147;Net loss per share&#148; to our audited consolidated financial statements and Note&nbsp;12&#151;&#147;Net loss per share&#148; to our unaudited condensed consolidated financial statements,
included elsewhere in this prospectus for details on the calculation of basic and diluted net loss per share attributable to common stockholders. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Pro forma basic and diluted net loss per share attributable to common stockholders has been prepared to give effect to adjustments to our capital structure arising in connection with the completion of this offering and
is calculated by dividing the pro forma net loss attributable to common stockholders by the pro forma weighted-average common shares outstanding for the period. The pro forma net loss attributable to common stockholders used in the calculation of
pro forma basic and diluted net loss per share attributable to common stockholders adjusts net loss attributable to common stockholders to remove the cumulative dividends on redeemable convertible preferred stock of $17.7&nbsp;million and
$8.0&nbsp;million for the year ended December 31, 2023 and six months ended June 30, 2024, respectively. Pro forma weighted-average common shares outstanding is computed by adjusting the weighted-average common shares outstanding to give pro forma
effect to the automatic conversion of all shares of our redeemable convertible preferred stock outstanding as of June&nbsp;30, 2024 into 33,321,149 shares of common stock as if such conversion had occurred on January&nbsp;1, 2023. Pro forma basic
and diluted net loss per share attributable to common stockholders does not include the effect of the shares expected to be sold in this offering. </TD></TR></TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="12" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of June&nbsp;30, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(in thousands)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Pro&nbsp;forma<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Pro&nbsp;forma<BR>as&nbsp;adjusted<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Consolidated balance sheet data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash, cash equivalents and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;235,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;235,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">417,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Working capital<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">232,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">232,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">416,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">380,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(146,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">416,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="12" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Gives effect to (i)&nbsp;the automatic conversion of all 31,764,693 outstanding shares of our Series A and Series B redeemable convertible preferred stock in the aggregate, as of June 30, 2024, into 33,321,149 shares of
our common stock immediately prior to the completion of this offering, and (ii)&nbsp;the filing and effectiveness of our third amended and restated certificate of incorporation, which will occur immediately prior to the completion of this offering.
</TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Gives effect to (i)&nbsp;the pro forma adjustments set forth in footnote (1)&nbsp;above and (ii)&nbsp;the issuance and sale of 12,500,000&nbsp;shares of our common stock in this offering at an assumed initial public
offering price of $16.00 per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable
by us (of which $0.5&nbsp;million was recorded in accounts payable, $0.7&nbsp;million was recorded in accrued expenses and other current liabilities, and $0.1&nbsp;million was paid as of June&nbsp;30, 2024). Pro forma as adjusted balance sheet data
is illustrative only and will change based on the actual initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase or decrease in the assumed initial public offering price of $16.00&nbsp;per share,
which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, the pro forma as adjusted amount of each of cash, cash equivalents and short-term investments,
working capital, total assets and total stockholders&#146; (deficit) equity by approximately $11.6&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after
deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase or decrease of 1.0&nbsp;million shares in the number of shares offered by us, as set forth on the cover page of this
prospectus, would increase or decrease, as applicable, the pro forma as adjusted amount of each of cash, cash equivalents and short-term investments, working capital, total assets and total stockholders&#146; (deficit) equity by approximately $14.9
million, assuming no change in the assumed initial public offering price per share, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We define working capital as current assets less current liabilities. See our condensed consolidated financial statements and the related notes included elsewhere in this prospectus for further details regarding our
current assets and current liabilities. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">14 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc843142_2"></A>Risk factors </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Investing in our common stock involves a high degree of risk. You should consider and read carefully all of the risks and uncertainties described below, as well as
the other information in this prospectus, including our consolidated financial statements and the related notes appearing elsewhere in this prospectus and &#147;Management&#146;s discussion and analysis of financial condition and results of
operations&#148; before deciding whether to invest in our common stock. The risks described below are not the only ones facing us. The following risks or additional risks and uncertainties not presently known to us or that we currently believe to be
immaterial could materially and adversely affect our business, financial condition, results of operations and growth prospects. In such an event, the trading price of our common stock could decline, and you may lose all or part of your investment.
</I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>This prospectus also contains forward-looking statements and estimates that involve risks and uncertainties not presently known to us or that we currently
deem immaterial also may impair our business operations. Our actual results could differ materially from those anticipated in our forward-looking statements as a result of specific factors, including the risks and uncertainties described below.
</I></P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to our limited operating history, financial condition and need for additional capital </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are a clinical-stage biopharmaceutical company with a limited operating history, which may make it difficult to evaluate our current business and predict our
future success and viability. We have incurred significant financial losses since our inception and anticipate that we will continue to incur significant financial losses for the foreseeable future. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are a clinical-stage biopharmaceutical company with a limited operating history. We were formed in April 2021 and our operations to date have been limited to <FONT
STYLE="white-space:nowrap">pre-commercial</FONT> activities. We have not yet demonstrated an ability to generate revenues, obtain regulatory approvals, manufacture any product on a commercial scale or arrange for a third party to do so on our behalf
or conduct sales and marketing activities necessary for successful product commercialization. Our limited operating history as a company makes any assessment of our future success and viability subject to significant uncertainty. We will encounter
risks and difficulties frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields, and we have not yet demonstrated an ability to successfully overcome such risks and difficulties. If we do not address these risks
and difficulties successfully, our business will suffer. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have no products approved for commercial sale and have not generated any revenue from product sales to
date. Verekitug is currently our only product candidate. We will continue to incur significant research and development and other expenses related to our preclinical and clinical development of verekitug and ongoing operations. As a result, we are
not profitable and have incurred losses in each period since our inception. Net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#146; deficit and working capital. Our net losses totaled
$20.5&nbsp;million and $23.9&nbsp;million for the years ended December&nbsp;31, 2023 and 2022, respectively, and $25.6&nbsp;million and $5.6&nbsp;million for the six months ended June&nbsp;30, 2024 and 2023, respectively. As of June&nbsp;30, 2024,
we had an accumulated deficit of $153.5&nbsp;million. We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals
for, verekitug in multiple indications. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We anticipate that our expenses will increase substantially if, and as, we: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">advance verekitug through clinical development; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">seek regulatory approvals for verekitug in indications for which clinical trials are successful; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">15 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">hire additional clinical, quality control, medical, scientific and other technical personnel to support the ongoing
development of verekitug; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">experience an increase in headcount as we expand our research and development organization and market development and <FONT
STYLE="white-space:nowrap">pre-commercial</FONT> planning activities; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">undertake any <FONT STYLE="white-space:nowrap">pre-commercial</FONT> or commercial activities required to establish sales,
marketing and distribution capabilities; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">seek to identify, acquire and develop additional product candidates, including through business development efforts to
invest in or <FONT STYLE="white-space:nowrap">in-license</FONT> other technologies or product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">maintain, expand and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">make milestone, royalty or other payments due under our license agreements and any potential future <FONT
STYLE="white-space:nowrap">in-license</FONT> or collaboration agreements; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">make milestone, royalty, interest or other payments due under any potential future financing or other arrangements with
third parties. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Biopharmaceutical product development entails substantial upfront capital expenditures and significant risk that any potential
product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval, secure market access and reimbursement and become commercially viable, and therefore any investment in us is highly speculative.
Accordingly, before making an investment in us, you should consider our prospects, factoring in the costs, uncertainties, delays and difficulties frequently encountered by companies in clinical development, especially clinical-stage
biopharmaceutical companies such as ours. Any predictions you make about our future success or viability may not be as accurate as they would otherwise be if we had a longer operating history or a history of successfully developing and
commercializing pharmaceutical products. We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, our expenses could increase beyond our expectations if we are required by the U.S. Food and Drug Administration (&#147;FDA&#148;), the European Medicines
Agency (&#147;EMA&#148;), the European Commission, or other comparable foreign regulatory authorities to perform clinical trials in addition to those that we currently expect, or if there are any delays in establishing appropriate manufacturing
arrangements for or in completing our clinical trials or the development of verekitug. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Even if this offering is successful, we will require additional
funding in order to finance operations. If we are unable to raise capital when needed, or on acceptable terms, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Developing biopharmaceutical products, including conducting preclinical studies and clinical trials, is a time-consuming, expensive and uncertain process that takes
years to complete. We expect our expenses to continue to increase in connection with our ongoing activities, particularly as we conduct clinical trials of, and seek regulatory and marketing approval for, verekitug in multiple indications. Even if
verekitug or our potential future product candidates are approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. To date, we have funded our operations principally
through private financings. We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the clinical development of verekitug, and commence additional clinical trials. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2023 and June&nbsp;30, 2024, we had cash, cash equivalents and short-term investments in the amount of $109.8&nbsp;million and $235.8 million,
respectively. Based upon our current operating plan, we believe </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">16 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
that the net proceeds from this offering together with our existing cash, cash equivalents and short-term investments will enable us to fund our operating expenses and capital expenditure
requirements through <FONT STYLE="white-space:nowrap">mid-2027.</FONT> We have based this estimate on assumptions that may prove to be wrong, and we could expend our available capital resources sooner than we expect. We may also raise additional
financing on an opportunistic basis in the future. For example, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.
Attempting to secure additional financing may divert our management from our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop verekitug. Our
future capital requirements will depend on many factors, including but not limited to: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the scope, timing, progress, costs and results of the ongoing development of verekitug as well as for potential discovery,
preclinical development and clinical trials for other potential future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the number of clinical trials required for regulatory approval of verekitug or our potential future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs, timing and outcome of regulatory review of verekitug or our potential future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs associated with acquiring or licensing additional product candidates, technologies or assets, including the
timing and amount of any milestones, royalties or other payments due in connection with our acquisitions and licenses; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the cost of manufacturing clinical and commercial supplies of verekitug or our potential future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual
property rights and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the effectiveness of our approach to identifying target patient populations; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to maintain existing, and establish new, strategic collaborations or other arrangements and the financial terms
of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution,
for verekitug or any other potential future product candidates for which we receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the revenue, if any, received from commercial sales of verekitug or any other potential future product candidates for which
we receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">expenses to attract, hire and retain skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs of operating as a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate
reimbursement from third-party and government payors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the effect of macroeconomic trends including inflation and rising interest rates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">addressing any potential supply chain interruptions or delays; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the effect of competing technological and market developments; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the extent to which we acquire or invest in business, products and technologies. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">17 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Because of the numerous risks and uncertainties associated with research and development of product candidates, we are
unable to predict the timing or amount of our working capital requirements. In addition, if we obtain regulatory approval for verekitug or any other potential future product candidates, we expect to incur significant commercialization expenses
related to product manufacturing, marketing, sales and distribution which make it difficult to predict when or if we will be able to achieve or maintain profitability. Furthermore, upon the completion of this offering, we expect to incur additional
costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in order to support our continuing operations. Our ability to raise additional funds will depend on financial, economic,
political and market conditions and other factors, over which we may have no or limited control. Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. If we fail to obtain necessary capital when
needed on acceptable terms, or at all, it could force us to delay, limit, reduce or terminate our product development programs, future commercialization efforts or other operations. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to verekitug or any other potential
future product candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations with our existing
cash, cash equivalents and short-term investments, the net proceeds from this offering, any future equity or debt financings and upfront and milestone and royalties payments, if any, received under any future licenses or collaborations. If we raise
additional capital through the sale of equity or convertible debt securities, or issue any equity or convertible debt securities in connection with a collaboration agreement or other contractual arrangement, your ownership interest will be diluted,
and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of our common stock. In addition, the possibility of such issuance may cause the market price of our common stock to
decline. Debt financing, if available, may result in increased fixed payment obligations and involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital
expenditures, declaring dividends or acquiring, selling or licensing intellectual property rights or assets, which could adversely impact our ability to conduct our business. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to
relinquish valuable rights to our intellectual property, technologies, future revenue streams or verekitug or any other potential future product candidates or grant licenses on terms that may not be favorable to us. We could also be required to seek
funds through arrangements with collaborators or others at an earlier stage than otherwise would be desirable. Any of these occurrences may have a material adverse effect on our business, financial condition, results of operations and growth
prospects. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to our business </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Verekitug is our only
product candidate, and we are dependent on a third party having accurately generated, collected and reported data from certain preclinical studies that were previously conducted for verekitug. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We currently have a single product candidate, verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with
nasal polyps (&#147;CRSwNP&#148;), and we also plan to initiate development in chronic obstructive pulmonary disease (&#147;COPD&#148;). Our business presently depends entirely on our ability to successfully develop, obtain regulatory approval for,
and commercialize verekitug for one or more of the indications that we are pursuing in a timely manner. This may make an investment in our company riskier than similar companies that have multiple product candidates in active development and may be
able to better sustain the delay or failure of a lead product candidate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">18 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, our assumptions about verekitug&#146;s development potential are partially based on data generated from
preclinical studies conducted by Astellas Pharma, Inc. (&#147;Astellas&#148;), which sold the rights to verekitug to us pursuant to an asset purchase agreement in October 2021. We are dependent on Astellas having conducted its research and
development in accordance with the applicable protocols, informed consent, legal and regulatory requirements, and scientific standards; having accurately reported the results of all preclinical studies conducted with respect to verekitug and having
correctly collected the data from these studies. If these activities were not compliant, accurate or correct, the clinical development, regulatory approval or commercialization of verekitug will be adversely affected. Furthermore, we may observe
materially and adversely different results as we continue to conduct our clinical trials. If we are unable to develop, receive marketing approval for and successfully commercialize verekitug, or if we experience delays as a result of any of the
above factors or otherwise, our business would be significantly harmed. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we are unable to advance verekitug in clinical development for one or more of the
indications that we are pursuing, obtain regulatory approval and ultimately commercialize verekitug, or experience significant delays in doing so, our business will be materially harmed. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To date, as an organization, we have not completed the development of any product candidate, and verekitug remains in clinical development. Our future success and
ability to generate revenue is dependent on our ability to successfully develop, obtain regulatory approval for and commercialize verekitug or any other potential future product candidates. Verekitug and any other potential future product candidates
will require substantial additional investment for clinical development, regulatory review and approval in one or more jurisdictions. If verekitug or any other potential future product candidates encounter safety or efficacy problems, development
delays or regulatory issues or other problems, our development plans and business would be materially harmed. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may not have the financial resources to continue
development of verekitug or any other potential future product candidates if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, verekitug or any potential future product candidates, including:
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our inability to demonstrate to the satisfaction of the FDA, EMA, the European Commission, or other comparable foreign
regulatory authorities that verekitug is, or any other potential future product candidates are, safe and effective; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">insufficiency of our financial and other resources to complete the necessary clinical trials and preclinical studies;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">negative or inconclusive results from our clinical trials, preclinical studies or the clinical trials of others for product
candidates similar to ours, leading to a decision or requirement to conduct additional clinical trials or preclinical studies or abandon a program; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">product-related adverse events experienced by subjects in our clinical trials, or by individuals using drugs or therapeutic
biologics similar to verekitug or any other potential future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">delays in submitting an Investigational New Drug (&#147;IND&#148;) application or other regulatory submission to the FDA,
EMA, or other comparable foreign regulatory authorities, or delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial or a suspension, termination, or hold, of a clinical trial once commenced;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">conditions imposed by the FDA, the competent authorities of individual EU Member States or other comparable foreign
regulatory authorities regarding the scope or design of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">poor performance of verekitug or any other potential future product candidates during clinical trials;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">19 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">better than expected performance of control arms, such as placebo groups, which could lead to negative or inconclusive
results from our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">delays in enrolling subjects in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">high <FONT STYLE="white-space:nowrap">drop-out</FONT> rates of subjects from our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">inadequate supply or quality of verekitug or any other potential future product candidates or other materials necessary for
the conduct of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">higher than anticipated clinical trial or manufacturing costs; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">unfavorable FDA, EMA, competent authorities of individual EU Member States, or other comparable foreign regulatory
authority inspection and review of our clinical trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">failure of our third-party contractors or investigators to comply with regulatory requirements or the clinical trial
protocol or otherwise meet their contractual obligations in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">delays and changes in regulatory requirements, policies and guidelines, including the imposition of additional regulatory
oversight around clinical testing generally or with respect to our therapies in particular; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">varying interpretations of data by the FDA, EMA, the European Commission, and other comparable foreign regulatory
authorities. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are currently conducting, and may in the future conduct, clinical trials for verekitug or any other potential future
product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials. </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are
currently conducting, and may in the future conduct, clinical trials for verekitug or any other potential future product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such
trials. We are currently conducting clinical trials outside the United States, including but not limited to in Canada, Japan, South Korea, South Africa, the United Kingdom (&#147;UK&#148;) and countries in South America and the European Union, and
we expect to continue to conduct trials internationally in the future. The acceptance of data from clinical trials conducted outside the United States or another jurisdiction by the FDA or any other comparable foreign regulatory authorities may be
subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the
basis of foreign data alone unless the data are applicable to the U.S. population and U.S. medical practice, the trials were performed by clinical investigators of recognized competence and pursuant to Good Clinical Practice (&#147;GCP&#148;)
regulations, and the FDA can validate the data through <FONT STYLE="white-space:nowrap">on-site</FONT> inspections or other appropriate means. Additionally, the FDA&#146;s clinical trial requirements, including sufficient size of patient populations
and statistical powering, must be met. Many foreign regulatory authorities have similar approval requirements, including in relation to the use of data from clinical trials conducted in foreign jurisdictions. In addition, such foreign trials are
subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United
States or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in
verekitug or any other potential future product candidates that we may develop being delayed or not receiving approval for commercialization in the applicable jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">20 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The successful development of pharmaceutical products involves a lengthy and expensive process and is highly
uncertain. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Successful development of pharmaceutical products is highly uncertain and is dependent on numerous factors, many of which are beyond our control.
Product candidates that appear promising in the early phases of development may fail to reach the market for several reasons, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">clinical trial results may show product candidates to be less effective than expected (for example, a clinical trial could
fail to meet its primary or key secondary endpoint(s)) or have an unacceptable safety or tolerability profile; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">failure to receive the necessary regulatory approvals or a delay in receiving such approvals, which, among other things,
may be caused by patients who fail the trial screening process, slow enrollment in clinical trials, patients dropping out of trials, patients lost to <FONT STYLE="white-space:nowrap">follow-up,</FONT> length of time to achieve trial endpoints,
additional time requirements for data analysis or a Biologics License Application (&#147;BLA&#148;) or similar foreign application preparation, discussions with the FDA, an FDA request for additional preclinical or clinical data (such as long-term
toxicology studies) or unexpected safety or manufacturing issues; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">preclinical study results may show verekitug or any other potential future product candidates to have harmful side effects;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">post-marketing approval requirements; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the proprietary rights of others and their competing products and technologies that may prevent verekitug or any other
potential future product candidates from being commercialized. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The length of time necessary to complete clinical trials and submit an application
for marketing approval for a final decision by a regulatory authority varies significantly from one product candidate to the next and from one country or jurisdiction to the next and may be difficult to predict. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Furthermore, any product candidate we develop and the activities associated with its development and commercialization, including its design, testing, manufacture,
safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, and distribution, are subject to comprehensive regulation by the FDA and other regulatory authorities in the United States and by comparable authorities in
other countries. Failure to obtain marketing approval for verekitug or any other potential future product candidates will prevent us from commercializing the product candidate in a given jurisdiction. We have not received approval to market any
product candidates from regulatory authorities in any jurisdiction, and it is possible that verekitug or any of our other potential future product candidates will not ever obtain regulatory approval. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have no experience as an organization in submitting and supporting the applications necessary to gain marketing approvals and expect to rely on third-party contract
research organizations (&#147;CROs&#148;) or regulatory consultants to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory
authorities for each therapeutic indication to establish the product candidate&#146;s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of
manufacturing facilities by, the relevant regulatory authority. Any product candidates we develop may not be effective, may be only moderately effective, or may prove to have undesirable or unintended side effects, toxicities or other
characteristics that may preclude its obtaining marketing approval or prevent or limit commercial use. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The process of obtaining marketing approvals, both in the
United States and abroad, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">21 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
based upon a variety of factors, including the type, complexity, and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in
or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries
have discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the
data obtained from preclinical and clinical testing could delay, limit, or prevent marketing approval of a product candidate. Any marketing approval that we may ultimately obtain could be limited or subject to restrictions or post-approval
commitments that render the approved product not commercially viable. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even if we are successful in obtaining marketing approval, commercial success of any approved
products will also depend in large part on the availability of coverage and adequate reimbursement from third-party payors, including government payors such as the Medicare and Medicaid programs and comparable foreign programs and managed care
organizations in the United States or country-specific governmental organizations in foreign countries, which may be affected by existing and future healthcare reform measures designed to reduce the cost of healthcare. Third-party payors could
require us to conduct additional studies, including post-marketing studies related to the cost effectiveness of a product, to qualify for reimbursement, which could be costly and divert our resources. If government and other healthcare payors were
not to provide coverage and adequate reimbursement for our products once approved, market acceptance and commercial success would be reduced. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, if
verekitug or any other potential future product candidates receive marketing approval, we will be subject to significant regulatory obligations regarding the submission of safety and other post-marketing information and reports and registration, and
will need to continue to comply (or ensure that our third-party providers comply) with current Good Manufacturing Practices (&#147;cGMPs&#148;) and GCPs for any clinical trials that we conduct post-approval. In addition, there is always the risk
that we, a regulatory authority or a third party might identify previously unknown problems with a product post-approval, such as adverse events of unanticipated severity or frequency. Compliance with these requirements is costly, and any failure to
comply or other issues with verekitug or any other potential future product candidates post-approval could adversely affect our business, financial condition, results of operations and growth prospects. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Certain estimates of market opportunity and forecasts included in this prospectus may prove to be smaller than we believe. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The estimates of market opportunity and forecasts of market growth included in this prospectus may prove to be smaller than we believe, and even if the markets in which
we compete achieve the forecasted growth, our business may not grow at similar rates, or at all. Our initial focus is on the development of verekitug for the treatment of severe respiratory disorders, including severe asthma, CRSwNP and COPD. Our
projections of addressable patient populations within these indications are based on our estimates and independent market research, industry and general publications obtained from third parties. Market opportunity estimates and growth forecasts
included in this prospectus are subject to significant uncertainty and are based on assumptions and estimates. These estimates, which have been derived from a variety of sources, including scientific literature, surveys of clinics, patient
foundations and market research, may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these indications. Additionally, the potentially addressable patient population may not ultimately be amenable to
treatment with our product candidate if we cannot achieve our intended dosing interval. Our market opportunity may also be limited by current and future products of our competitors that are already available in the market or may enter the market for
such patients. If any of our estimates prove to be inaccurate, the market opportunity for verekitug could be significantly diminished and have an adverse material impact on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">22 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Due to the significant resources required for drug development and depending on our ability to access capital, we
must prioritize the development of verekitug. Moreover, we may fail to expend our limited resources on the development of verekitug for the treatment of additional indications or for the development of other potential future product candidates that
may have been more profitable or for which there is a greater likelihood of success. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our product candidate, verekitug for the treatment of severe asthma and
CRSwNP, is currently in Phase 2 clinical development in each of these indications, and we plan to initiate clinical development for verekitug in COPD. Our initial focus is on developing verekitug for the treatment of severe respiratory disorders.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Due to the significant resources required for the development of verekitug, we must decide which indications to pursue and advance and the amount of resources to
allocate to each. Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular indications may not lead to the development of viable commercial products and may divert
resources away from better opportunities. If we make incorrect determinations regarding the viability or market potential of verekitug or misread trends in the pharmaceutical industry, our business, financial condition, results of operations and
growth prospects could be materially and adversely affected. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities verekitug or any potential
future product candidates with other diseases and disease pathways that may later prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to verekitug through collaboration, licensing or royalty
arrangements in cases in which it would have been advantageous for us to invest additional resources to retain sole development and commercialization rights. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we successfully commercialize verekitug, our results of operations will be affected by the level of royalty payments that we are required to pay to Regeneron.
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with our Asset Purchase Agreement with Astellas, we also entered into a letter agreement (the &#147;Regeneron Letter Agreement&#148;) with
Astellas and Regeneron Pharmaceuticals Inc. (&#147;Regeneron&#148;). Under the Regeneron Letter Agreement, we assumed from Astellas an obligation to make <FONT STYLE="white-space:nowrap">mid-single-digit</FONT> percentage royalty payments to
Regeneron upon the commercialization of products developed from materials originally licensed to Astellas. The payment of royalties may have a negative effect on our results of operations and our ability to reinvest capital generated from
commercialization to develop verekitug in additional indications or grow our company. Furthermore, any failure on our part to pay royalties owed to Regeneron could impact our rights to verekitug, lead to the initiation of legal proceedings against
us and thereby adversely affect our business. For additional information on the Regeneron Letter Agreement, see the section titled &#147;Business&#151;Asset purchase and license agreements&#151;Asset acquisition from Astellas&#148; included
elsewhere in this prospectus. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may seek to grow our business through acquisitions or investments in new or complementary businesses, products or
technologies, through the licensing of products or technologies from third parties or other strategic alliances. The failure to manage acquisitions, investments, licenses or other strategic alliances, or the failure to integrate them with our
existing business, could have a material adverse effect on our operating results, dilute our stockholders&#146; ownership, increase our debt or cause us to incur significant expense. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our success depends on our ability to continually enhance and broaden our product offerings in response to changing clinician and patients&#146; needs, competitive
technologies and market pressures. Accordingly, from time to time we may consider opportunities to acquire, make investments in or license other technologies, products and businesses that may enhance our capabilities, complement our existing
products and technologies or expand the breadth of our markets or customer base. Potential and completed acquisitions, strategic investments, licenses and other alliances involve numerous risks, including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">difficulty assimilating or integrating acquired or licensed technologies, products, employees or business operations;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">23 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">issues maintaining uniform standards, procedures, controls and policies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">unanticipated costs associated with acquisitions or strategic alliances, including the assumption of unknown or contingent
liabilities and the incurrence of debt or future write-offs of intangible assets or goodwill; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">diversion of management&#146;s attention from our core business and disruption of ongoing operations;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">adverse effects on existing business relationships with suppliers, sales agents, healthcare facilities, surgeons and other
healthcare professionals; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">risks associated with entering new markets in which we have limited or no experience; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">potential losses related to investments in other companies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">potential loss of key employees of acquired businesses; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">increased legal and accounting compliance costs. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We do not know if we will be able to identify acquisitions or strategic relationships we deem suitable, whether we will be able to successfully complete any such
transactions on favorable terms, if at all, or whether we will be able to successfully integrate any acquired business, product or technology into our business or retain any key personnel, suppliers, sales agent, healthcare facilities, physicians or
other healthcare providers. Our ability to successfully grow through strategic transactions depends upon our ability to identify, negotiate, complete and integrate suitable target businesses, technologies or products and to obtain any necessary
financing. These efforts could be expensive and time-consuming and may disrupt our ongoing business and prevent management from focusing on our operations. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To
finance any acquisitions, investments or strategic alliances, we may choose to issue shares of our common stock as consideration, which could dilute the ownership of our stockholders. If the price of our common stock is low or volatile, we may be
unable to consummate any acquisitions, investments or strategic alliances using our common stock as consideration. Additional funds may not be available on terms that are favorable to us, or at all. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We, our collaborators, and our service providers are subject to a variety of stringent and evolving privacy and data security laws, regulations, and rules,
contractual obligations, industry standards, policies, and other obligations related to privacy and data security. Any actual or perceived failure to comply with such obligations could expose us to significant fines or other penalties and otherwise
harm our business and operations. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the ordinary course of our business, we and the third parties upon which we rely collect, receive, store, or otherwise
process personal data, including information we may collect about participants in our clinical trials. Our data processing activities subject us to numerous, evolving privacy and data security obligations, such as various laws, regulations,
guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to privacy and data security. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The legislative and regulatory framework for the processing of personal data worldwide is rapidly evolving in a manner that is increasingly stringent and, globally, this
legal and regulatory framework is likely to remain uncertain for the foreseeable future. In the United States, numerous federal, state and local laws and regulations, including federal health information privacy laws, state information security and
data breach notification laws, federal consumer protection laws (e.g., Section&nbsp;5 of the Federal Trade Commission Act), state consumer protection and privacy laws, and other similar laws (e.g., wiretapping and communications interception laws)
govern the processing of health-related and other personal data. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">At the state level, numerous U.S. states have enacted comprehensive privacy laws that impose
certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">24 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
individuals certain rights concerning their personal data. Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass
similar laws in the future. While existing state comprehensive privacy laws exempt some data processed in the context of clinical trials, these developments may further complicate compliance efforts, and increase legal risk and compliance costs for
us and the third parties upon whom we rely. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, we may be subject to new laws governing the privacy of consumer health data. These various privacy and
data security laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Outside the United States, an increasing number of laws, regulations, and industry standards may govern privacy, data security, and the transfer of personal data between
jurisdictions. For example, the European Union&#146;s General Data Protection Regulation (&#147;EU GDPR&#148;) and the United Kingdom&#146;s General Data Protection Regulation (&#147;UK GDPR&#148;, together with the EU GDPR, &#147;GDPR&#148;) impose
strict requirements for processing personal data including relating to processing of sensitive data (such as health data), ensuring there is a legal basis or condition to justify the processing of personal data, where required requirements relating
to obtaining consent of individuals, disclosures about how personal data is to be used, limitations on retention of information, implementing safeguards to protect the security and confidentiality of personal data, where required providing
notification of data breaches, maintaining records of processing activities and documenting data protection impact assessments where there is high risk processing and taking certain measures when engaging third-party processors. Under GDPR,
companies may face temporary or definitive bans on data processing and other corrective activities, fines of up to <FONT STYLE="font-family:Times New Roman">&#128;</FONT>20&nbsp;million (&pound;17.5&nbsp;million GBP) or 4% of annual global revenues,
whichever is greater, and private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.
<FONT STYLE="white-space:nowrap">Non-compliance</FONT> could also result in a material adverse effect on our business, financial position and results of operations. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the United States or other countries due to data localization requirements
or limitations on cross-border data flows. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the European Economic Area (&#147;EEA&#148;) and
the UK have significantly restricted the transfer of personal data to the United States and other countries. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Although
there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA&#146;s standard contractual clauses, the UK&#146;s International Data Transfer
Agreement / Addendum, and the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Data Privacy Framework (&#147;Framework&#148;) and the UK extension thereto (which allows for transfers to relevant U.S.-based organizations who self-certify compliance
and participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States. If there is no lawful manner for us
to transfer personal data from the EEA, the UK, or other jurisdictions to the United States (or other countries), or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the
interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial
fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Additionally, companies that
transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activities activist groups. Some European regulators have ordered
certain companies to suspend or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">25 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
permanently cease certain transfers of personal data out of Europe for allegedly violating the GDPR&#146;s cross-border data transfer limitations. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to privacy and data security laws, we are contractually subject to industry standards adopted by industry groups and may become subject to such obligations
in the future. We are also bound by other contractual obligations related to privacy and data security, and our efforts to comply with such obligations may not be successful. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We publish privacy policies and other statements, such as compliance with certain certifications or self-regulatory principles, regarding privacy and data security. If
these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse
consequences. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Obligations related to privacy and data security are quickly changing, becoming increasingly stringent, and creating uncertainty. Additionally, these
obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources and may necessitate
changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may at
times fail in our efforts to comply with our privacy and data security obligations. Moreover, despite our efforts, our personnel or third parties on whom we rely may fail to comply with such obligations, which could negatively impact our business
operations. If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable privacy and data security obligations, we could face significant consequences, including but not limited to:
government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims), and mass arbitration demands; additional reporting requirements and/or oversight; bans on
processing personal data; and orders to destroy or not use personal data. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands. Some
of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for significant statutory damages, depending on the volume of data and the number of violations. Any of these events could have
a material adverse effect on our reputation, business, financial condition, results of operations and growth prospects, including but not limited to: loss of customers; interruptions or stoppages in our business operations (including, as relevant,
clinical trials); inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or
substantial changes to our business model or operations. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Artificial intelligence presents risks and challenges that can impact our business including by
posing security risks to our confidential information, proprietary information, and personal data. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Issues in the development and use of artificial
intelligence, combined with an uncertain regulatory environment, may result in reputational harm, liability, or other adverse consequences to our business operations. As with many technological innovations, artificial intelligence presents risks and
challenges that could impact our business. We may adopt and integrate generative artificial intelligence tools into our systems for specific use cases reviewed by legal and information security. Our vendors may incorporate generative artificial
intelligence tools into their offerings without disclosing this use to us, and the providers of these generative artificial intelligence tools may not meet existing or rapidly evolving regulatory or industry standards with respect to privacy and
data protection and may inhibit our or our vendors&#146; ability to maintain an adequate level of service and experience. If we, our vendors, or our third-party partners experience an actual or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">26 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
perceived breach or privacy or security incident because of the use of generative artificial intelligence, we may lose valuable intellectual property and confidential information and our
reputation and the public perception of the effectiveness of our security measures could be harmed. Further, bad actors around the world use increasingly sophisticated methods, including the use of artificial intelligence, to engage in illegal
activities involving the theft and misuse of personal information, confidential information, and intellectual property. Any of these outcomes could damage our reputation, result in the loss of valuable property and information, and adversely impact
our business. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to the discovery and development of Verekitug or any other potential future product candidates </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The regulatory approval processes of the FDA, the EMA, and the European Commission and other comparable foreign regulatory authorities are lengthy, time-consuming
and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for verekitug or any other potential future product candidates, our business will be substantially harmed. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are not permitted to commercialize, market, promote or sell any product candidate in the United States without obtaining regulatory approval from the FDA. Regulatory
authorities outside of the United States impose similar requirements. The time required to obtain approval by the FDA, European Commission and other comparable foreign regulatory authorities is inherently unpredictable, but typically takes many
years following the commencement of clinical trials and depends upon numerous factors, including substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to
gain approval may change during the course of a product candidate&#146;s clinical development and may vary among jurisdictions. For instance, jurisdictions outside of the United States, such as the European Union or Japan, may have different
requirements for regulatory approval, which may require us to conduct additional clinical, nonclinical or chemistry, manufacturing and control studies. To date, we have not submitted a BLA to the FDA or similar drug approval submissions to
comparable foreign regulatory authorities for any product candidate. We must complete additional preclinical studies and clinical trials to demonstrate the safety and efficacy of verekitug or any other potential future product candidates in humans
before we will be able to obtain these approvals. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Clinical testing is expensive, difficult to design and implement, can take many years to complete and is
inherently uncertain as to outcome. The general approach for FDA approval of a new drug is dispositive data from two or more adequate and well-controlled clinical trials of the product candidate in the relevant patient population. The FDA, the EMA,
the European Commission, or other comparable foreign regulatory authorities may disagree with us about whether a clinical trial is adequate and well-controlled or may request that we conduct additional clinical trials prior to regulatory approval.
We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. In addition, there is no assurance that the doses, endpoints and trial designs that we intend to use for our planned clinical trials,
including those that we have developed based on feedback from regulatory agencies or those that have been used for the approval of similar drugs, will be acceptable for future approvals. The clinical development of verekitug or any other potential
future product candidates is also susceptible to the risk of failure inherent at any stage of development, including failure to demonstrate efficacy in a clinical trial or across a broad population of patients, the occurrence of adverse events that
are severe or medically or commercially unacceptable, failure to comply with protocols or applicable regulatory requirements and determination by the FDA or any comparable foreign regulatory authority that a product candidate may not continue
development or is not approvable. It is possible that even if verekitug or any other potential future product candidates have a beneficial effect, that effect will not be detected during clinical evaluation as a result of one or more of a variety of
factors, including the size, duration, design, measurements, conduct or analysis of our clinical trials. Conversely, as a result of the same </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">27 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
factors, our clinical trials may indicate an apparent positive effect of such product candidate that is greater than the actual positive effect, if any. Similarly, in our clinical trials we may
fail to detect toxicity of, or intolerability caused by, such product candidate, or mistakenly believe that verekitug or any other potential future product candidates are toxic or not well tolerated when that is not in fact the case. Serious adverse
events or other adverse events, as well as tolerability issues, could hinder or prevent market acceptance of the product candidate at issue. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Verekitug or any other
potential future product candidates could fail to receive regulatory approval, or regulatory approval could be delayed, for many reasons, including the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the FDA, the EMA, the competent authorities of individual EU Member States, or other comparable foreign regulatory
authorities may disagree with the dosing regimen, design or implementation of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may be unable to demonstrate to the satisfaction of the FDA, the EMA and the European Commission, or other comparable
foreign regulatory authorities that a product candidate is safe and effective for any of its proposed indications; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the results of clinical trials may not meet the level of statistical significance required by the FDA, the EMA and the
European Commission, or other comparable foreign regulatory authorities for approval; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may be unable to demonstrate that a product candidate&#146;s clinical and other benefits outweigh its safety risks;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the FDA, the EMA or the European Commission, or other comparable foreign regulatory authorities may disagree with our
interpretation of data from clinical trials or preclinical studies; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the data collected from clinical trials of verekitug or any other potential future product candidates may not be sufficient
to support the submission of a BLA to the FDA or other submission or to obtain regulatory approval in the United States, the European Union or elsewhere; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the FDA, the EMA or other comparable foreign regulatory authorities may not file or accept our BLA or marketing application
for substantive review; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the FDA, the competent authorities of individual EU Member States or other comparable foreign regulatory authorities may
find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the approval policies or regulations of the FDA, the EMA and the European Commission, or other comparable foreign
regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This lengthy approval process
as well as the unpredictability of clinical trial results may result in our failing to obtain regulatory approval to market any product candidate we develop, which would substantially harm our business, results of operations and prospects. The FDA
and other comparable foreign authorities have discretion in the approval process and determining when or whether regulatory approval will be granted for verekitug or any other potential future product candidates that we develop. Even if we believe
the data collected from future clinical trials verekitug or any other potential future product candidates are promising, such data may not be sufficient to support approval by the FDA, the European Commission, or any other comparable foreign
regulatory authority. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, even if we were to obtain approval, regulatory authorities may approve verekitug or any other potential future product candidates
for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">28 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
marketing clinical trials or may approve verekitug or any other potential future product candidates with a label that does not include the labeling claims necessary or desirable for the
successful commercialization. Any of the foregoing scenarios could materially harm the commercial prospects for verekitug or any other potential future product candidates. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Verekitug represents a novel approach to the treatment of inflammatory diseases, which makes it difficult to predict its likelihood of success and the timing and
cost of development and obtaining regulatory approval. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have concentrated our research and development efforts to develop the only known antagonist
currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (&#147;TSLP&#148;) and our future success depends on the successful development of this differentiated therapeutic approach. We are in the early stages of
developing verekitug and there can be no assurance that any development problems we have experienced or may experience in the future will not cause significant delays or result in unforeseen issues or unanticipated costs, or that any such
development problems or issues can be overcome. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners, which may prevent us from completing our
future clinical studies or commercializing our products on a timely or profitable basis, if at all. In addition, our expectations with regard to the advantages of inhibiting the TSLP receptor relative to the approach of other therapies may not
materialize or materialize to the degree we anticipate. Further, our scalability and costs of manufacturing may vary significantly as we develop verekitug and understand these critical factors. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the clinical study requirements of the FDA, the EMA and the European Commission, and other regulatory authorities and the criteria these regulators use to
determine the safety and efficacy of a product candidate are determined according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as ours can
be more complex and consequently more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates. Approvals by the European Commission and FDA for existing biologic treatments for asthma,
such as dupilumab and tezepelumab, as well as other pathways to approval, may not be indicative of what these regulators may require for approval of our therapy. More generally, approvals by any regulatory authority may not be indicative of what any
other regulatory authority may require for approval or what such regulatory authorities may require for approval in connection with new product candidates. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Verekitug may also not perform successfully in clinical trials or may be associated with adverse events that distinguish it from previously approved therapies or those
that may be approved in the future. Unexpected clinical outcomes could materially and adversely affect our business, results of operations and prospects. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If
our clinical trials fail to replicate positive results from earlier preclinical studies or clinical trials conducted by us or third parties, we may be unable to successfully develop, obtain regulatory approval for or commercialize verekitug or any
other potential future product candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The results observed from preclinical studies or early-stage clinical trials of verekitug or any other potential
future product candidates may not necessarily be predictive of the results of later-stage clinical trials that we conduct. Similarly, positive results from such preclinical studies or early-stage clinical trials may not be replicated in our
subsequent preclinical studies or clinical trials. For instance, results seen in our Phase 1b multiple ascending dose (&#147;MAD&#148;) clinical trial for verekitug in patients with asthma may not translate to similar results in our ongoing Phase 2
clinical trial in patients with severe asthma. Furthermore, verekitug or any other potential future product candidates may not be able to demonstrate similar activity or adverse event profiles as other product candidates that we believe may have
similar profiles. In addition, in our planned future clinical trials, we may utilize clinical trial designs or dosing regimens that have not been tested in prior clinical trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">29 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There can be no assurance that any of our clinical trials will ultimately be successful or support further clinical
development of verekitug or any other potential future product candidates. There is a high failure rate for drugs proceeding through clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant
setbacks in late-stage clinical trials after achieving positive results in early-stage development, and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, adverse safety or efficacy
observations made in clinical trials. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, we may utilize an &#147;open-label&#148; clinical trial design. An &#147;open-label&#148; clinical trial is one
where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most open-label clinical trials test only the investigational product candidate and
sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label
clinical trials may be subject to a &#147;patient bias&#148; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an
&#147;investigator bias&#148; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this
knowledge. The results from an open-label trial may not be predictive of future clinical trial results of a product candidate when studied in a controlled environment with a placebo or active control. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed
satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA, European Commission, or comparable foreign regulatory authority approval. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of verekitug or any
other potential future product candidates, which could prevent us from achieving our projected development and commercialization goals in the timeframes we announce and expect, and harm our business and results of operations. Many of the factors
that cause or lead to a delay in the initiation or completion of clinical trials may also lead to the denial of regulatory approval or limit market acceptance of verekitug or any other potential future product candidates. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may experience delays in completing our clinical trials or preclinical studies and initiating or completing additional clinical trials or preclinical studies,
including as a result of regulators not allowing or delay in allowing clinical trials to proceed under an IND or similar foreign authorization, or not approving or delaying approval for any clinical trial grant or similar approval we need to
initiate a clinical trial. We may also experience numerous unforeseen events during our clinical trials that could delay or prevent our ability to receive marketing approval or commercialize verekitug or any other potential future product candidates
we develop, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">regulators, institutional review boards (&#147;IRBs&#148;), ethics committees, or other reviewing bodies may not authorize
us or our investigators to commence a clinical trial, or to conduct or continue a clinical trial at a prospective or specific trial site, or provide a related positive opinion permitting such activities; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may not reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be
subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may experience challenges or delays in recruiting principal investigators or study sites to lead our clinical trials;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">30 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the number of subjects or patients required for clinical trials of verekitug or any other potential future product
candidates may be larger than we anticipate, enrollment in these clinical trials may be insufficient or slower than we anticipate, and the number of clinical trials being conducted at any given time may be high and result in fewer available patients
for any given clinical trial, or patients may drop out of these clinical trials at a higher rate than we anticipate; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our third-party contractors, including those manufacturing verekitug or any other potential future product candidates or
conducting clinical trials on our behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may have to amend clinical trial protocols submitted to regulatory authorities or conduct additional studies to reflect
changes in regulatory requirements or guidance, which may be required to resubmit to an IRB, ethics committee and regulatory authorities for <FONT STYLE="white-space:nowrap">re-examination;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">regulators or other reviewing bodies may find deficiencies with, fail to approve or subsequently find fault with the
manufacturing processes or facilities of third-party manufacturers with which we enter into agreements for clinical and commercial supplies, or the supply or quality of any product candidate or other materials necessary to conduct clinical trials of
verekitug or any other potential future product candidates may be insufficient, inadequate or not available at an acceptable cost, or we may experience interruptions in supply; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the potential for approval policies or regulations of the FDA, the EMA, and the European Commission, or the applicable
regulatory authorities to significantly change in a manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Regulators, IRBs, or ethics
committees of the institutions in which clinical trials are being conducted may suspend, limit or terminate a clinical trial, or data monitoring committees may recommend that we suspend or terminate a clinical trial, due to a number of factors,
including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, the competent authorities of individual EU Member States, or
other comparable foreign regulatory authorities resulting in the imposition of a clinical hold, safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions
or lack of adequate funding to continue the clinical trial. Negative or inconclusive results from our clinical trials or preclinical studies could mandate repeated or additional clinical trials and, to the extent we choose to conduct clinical trials
in other indications, could result in changes to or delays in clinical trials of verekitug or any other potential future product candidates in such other indications. We do not know whether any clinical trials that we conduct will demonstrate
adequate efficacy and safety to result in regulatory approval to market verekitug or any other potential future product candidates for the indications that we are pursuing. If later-stage clinical trials do not produce favorable results, our ability
to obtain regulatory approval for verekitug or any other potential future product candidates will be adversely impacted. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For planning purposes, we sometimes
estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product development objectives. These milestones may include our expectations regarding the commencement or completion of scientific studies and clinical
trials, the submission of regulatory filings or commercialization objectives. From time to time, we may publicly announce the expected timing of some of these milestones, such as the completion of an ongoing clinical trial, the initiation of other
clinical programs, receipt of marketing approval or a commercial launch of a product. The achievement of many of these milestones may be outside of our control. All of these milestones are based on a variety of assumptions
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">31 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
which, if not realized as expected, may cause the timing of achievement of the milestones to vary considerably from our estimates, including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our available capital resources or capital constraints we experience; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the rate of progress, costs and results of our clinical trials and research and development activities, including the
extent of scheduling conflicts with participating clinicians and collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to identify and enroll patients who meet clinical trial eligibility criteria; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our receipt of approvals by the FDA and other comparable foreign regulatory authorities and the timing thereof;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">other actions, decisions or rules issued by regulators; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to access sufficient, reliable and affordable supplies of materials used to manufacture verekitug or any other
potential future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the efforts of our collaborators with respect to the commercialization of verekitug or any other potential future product
candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the securing of, costs related to, and timing issues associated with, product manufacturing as well as sales and marketing
activities. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we fail to achieve announced milestones in the timeframes we expect, the development and commercialization of verekitug or any
other potential future product candidates may be delayed, and our business, financial condition, results of operations and growth prospects may be harmed. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our
failure to successfully initiate and complete clinical trials and to demonstrate the efficacy and safety necessary to obtain regulatory approval to market verekitug or any other potential future product candidates would also significantly harm our
business. Our development costs will also increase if we experience delays in testing or regulatory approvals and we may be required to obtain additional funds to complete clinical trials. We cannot assure you that our clinical trials will begin as
planned or be completed on schedule, if at all, or that we will not need to restructure or otherwise modify our trials after they have begun. Significant clinical trial delays also could shorten any periods during which we may have the exclusive
right to commercialize verekitug or any other potential future product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize verekitug or any other potential future product
candidates, which may harm our business, financial condition, results of operations and growth prospects. In addition, many of the factors that cause, or lead to, delays of clinical trials may ultimately lead to the denial of regulatory approval of
verekitug or any other potential future product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we experience delays in obtaining approval or if we fail to obtain approval of verekitug or any other
potential future product candidates we may develop, the commercial prospects for such product candidate may be harmed, and our ability to generate revenues will be materially impaired. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Interim, initial, top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becomes
available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Interim, initial, top-line and
preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
From time to time, we publicly disclose preliminary or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">32 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
<FONT STYLE="white-space:nowrap">top-line</FONT> data from our preclinical studies and clinical trials, which are based on preliminary analyses of then-available data, and the results and related
findings and conclusions are subject to change following a more comprehensive review of the data related to the particular preclinical study or clinical trial. We also make assumptions, estimations, calculations and conclusions as part of our
analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the <FONT STYLE="white-space:nowrap">top-line</FONT> or preliminary results that we report may differ from future results of
the same studies or trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. <FONT STYLE="white-space:nowrap">Top-line</FONT> data also remain subject to audit and
verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, <FONT STYLE="white-space:nowrap">top-line</FONT> data should be viewed with caution until the final
data are available. From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may
materially change as participants enrollment continues and more participants&#146; data become available or as participants from our clinical trials continue other treatments for their disease. Adverse differences between interim data and final data
could significantly harm our business prospects. Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data
differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate and could adversely affect the success of our business. In addition, the information we choose to
publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our
disclosure. If the interim, <FONT STYLE="white-space:nowrap">top-line</FONT> or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain
approval for, and commercialize, verekitug or any other potential future product candidates may be harmed, which could harm our business, financial condition, results of operations and growth prospects. Further, disclosure of interim, <FONT
STYLE="white-space:nowrap">top-line</FONT> or preliminary data by us or by our competitors could result in volatility in the price of our common stock after this offering. Furthermore, if we fail to replicate the positive results from our
preclinical studies or clinical trials in our future clinical trials, we may be unable to successfully develop, obtain regulatory approval for and commercialize verekitug or any other potential future product candidates. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance
with our protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. Patient enrollment is affected by many factors, including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the patient eligibility and exclusion criteria defined in the protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the size of the patient population required for analysis of the trial&#146;s primary endpoints; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the number and location of study sites and proximity of patients to study sites; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the design of the trial; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">competing clinical trials and clinicians&#146; and patients&#146; perceptions as to the potential advantages and risks of
the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications that we are investigating; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">33 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to obtain and maintain patient consents; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the risk that patients enrolled in our clinical trials will drop out of the trials before completion.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may experience challenges in recruiting principal investigators and patients to participate in ongoing and future clinical trials for verekitug
or any other potential future product candidates if we are unable to sufficiently demonstrate the potential of such product candidate. In addition, our clinical trials may compete with other clinical trials for product candidates that are in the
same therapeutic areas as verekitug or any other potential future product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead
opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we may conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which
will reduce the number of patients who are available for our clinical trials in such clinical trial site. Furthermore, if significant adverse events or other side effects are observed in any of our clinical trials, we may have difficulty recruiting
patients to our trials and patients may drop out of our trials. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we are unable to enroll a sufficient number of patients for our clinical trials, it would result
in significant delays or might require us to abandon one or more clinical trials or our development efforts altogether. Delays in patient enrollment may result in increased costs, affect the timing or outcome of the planned clinical trials, product
candidate development and approval process and jeopardize our ability to seek and obtain the regulatory approval required to commence product sales and generate revenue, which could prevent completion of these trials, adversely affect our ability to
advance the development of verekitug or any other potential future product candidates, cause the value of the company to decline and limit our ability to obtain additional financing if needed. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Verekitug or any other potential future product candidates may cause undesirable side effects or have other properties that could delay or prevent regulatory
approval, limit the commercial profile of an approved label, or result in significant negative consequences following regulatory approval, if obtained. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Undesirable side effects caused by verekitug or any other potential future product candidates could cause us or regulatory authorities to interrupt, delay or halt
clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, European Commission, or other comparable foreign regulatory authorities. We may also observe additional safety or tolerability
issues with verekitug or any other potential future product candidates in ongoing or future clinical trials. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Many compounds that initially showed promise in
clinical or earlier-stage testing are later found to cause undesirable or unexpected side effects that prevented further development of the compound. Results of ongoing or future clinical trials of verekitug or any other potential future product
candidates could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics, despite a favorable tolerability profile observed in earlier-stage testing. In addition, although we believe that verekitug&#146;s
mechanism of action may differentiate it from other products that address the TSLP signaling pathway, such as tezepelumab, adverse events observed in clinical studies or postmarket use of these products may also be observed with verekitug, which
could impact our ability to recruit patients to our clinical trials and our clinical development strategy. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If unacceptable side effects arise in the development of
verekitug or any other potential future product candidates, we, the FDA, competent authorities of individual EU Member States, or other comparable foreign regulatory authorities, the IRBs, or independent ethics committees at the institutions in
which our trials are conducted, could suspend, limit or terminate our clinical trials, or the independent safety monitoring committee could recommend that we suspend, limit or terminate our trials, or the FDA, competent authorities of individual EU
Member States or other comparable foreign regulatory authorities could order us to cease clinical trials, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">34 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
the FDA, the European Commission, or other comparable foreign regulatory authorities could deny approval of verekitug or any other potential future product candidates for any or all targeted
indications. Treatment-emergent side effects that are deemed to be drug-related could delay recruitment of clinical trial subjects or may cause subjects that enroll in our clinical trials to discontinue participation in our clinical trials. In
addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We may need to train medical personnel using verekitug or any other potential future product candidates to understand the side effect profiles
for our clinical trials and upon any commercialization of verekitug or any other potential future product candidates. Inadequate training in recognizing or managing the potential side effects of verekitug or any other potential future product
candidates could result in harm to patients that are administered verekitug or any other potential future product candidates. Any of these occurrences may adversely affect our business, financial condition, results of operations and growth prospects
significantly. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, clinical trials are conducted in carefully defined sets of patients who have agreed to enter into clinical trials. Consequently, it is
possible that our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we fail to expand our development of verekitug into additional indications, or discover or acquire, and subsequently develop and commercialize other product
candidates, we may be unable to grow our business and our ability to achieve our strategic objectives would be impaired. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Although the development and
commercialization of verekitug in severe asthma, CRSwNP and COPD are our initial focus, as part of our longer-term growth strategy, we plan to initiate and advance development of verekitug in additional indications. Expansion into new indications
will require additional, time-consuming development efforts prior to commercial sale, including preclinical studies, clinical trials and approval by the FDA, the European Commission, and comparable foreign regulatory authorities. All product
candidates are prone to the risks of failure that are inherent in pharmaceutical product development, including the possibility that the product candidate will not be shown to be sufficiently safe and effective for approval by regulatory
authorities. In addition, we cannot assure you that any such products that are approved will be manufactured or produced economically, successfully commercialized or widely accepted in the marketplace or be more effective than other commercially
available alternatives. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to the commercialization of Verekitug or any other potential future product candidates </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Even if verekitug or any other potential future product candidates receive regulatory approval, such product candidate may fail to achieve the degree of market
acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, in which case we may not generate significant revenues or become profitable. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have never commercialized a product, and even if verekitug or any other potential future product candidate is approved by the appropriate regulatory authorities for
marketing and sale, such product candidate may nonetheless fail to achieve sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. Many of the indications for verekitug have well-established
standards of care that physicians, patients and payors are familiar with. Even if verekitug or any other potential future product candidates are successful in registrational clinical trials, such product candidate may not be successful in displacing
these current standards of care if we are unable to demonstrate superior efficacy, safety, ease of administration and/or cost-effectiveness. For example, physicians may be reluctant to take their patients off their current medications and switch
their treatment regimen to verekitug or any other potential future product candidates. Further, patients often acclimate to the treatment regimen that they are currently taking and do </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">35 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
not want to switch unless their physicians recommend switching products or they are required to switch due to lack of coverage and adequate reimbursement. Even if we are able to demonstrate
verekitug&#146;s or any other potential future product candidates&#146; safety and efficacy to the FDA, the European Commission, and other regulators, safety or efficacy concerns in the medical community may hinder market acceptance. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Efforts to educate the medical community and third-party payors on the benefits of verekitug or any other potential future product candidates may require significant
resources, including management time and financial resources, and may not be successful. If verekitug or any other potential future product candidates are approved but do not achieve an adequate level of market acceptance, we may not generate
significant revenues and we may not become profitable. The degree of market acceptance of verekitug or any other potential future product candidates, if approved for commercial sale, will depend on a number of factors, including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the efficacy and safety of the product; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the potential advantages of the product compared to competitive therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the prevalence and severity of any side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">whether the product is designated under physician treatment guidelines as a first-, second- or third-line therapy;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability, or the ability of any future collaborators, to offer the product for sale at competitive prices;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the product&#146;s convenience and ease of administration compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the willingness of the target patient population to try, and of physicians to prescribe, the product;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">limitations or warnings, including distribution or use restrictions contained in the product&#146;s approved labeling;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the strength of sales, marketing and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">changes in the standard of care for the targeted indications for the product; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">availability and adequacy of coverage and reimbursement from government payors, managed care plans and other third-party
payors. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any failure by verekitug or any other potential future product candidate that obtains regulatory approval to achieve market acceptance or
commercial success would adversely affect our business prospects. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Competitive products may reduce or eliminate the commercial opportunity for verekitug or
any other potential future product candidates, if approved. If our competitors develop technologies or product candidates more rapidly than we do, or their technologies or product candidates are more effective or safer than ours, our ability to
develop and successfully commercialize verekitug or any other potential future product candidates may be adversely affected. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The clinical and commercial
landscapes for the treatment of inflammatory diseases are highly competitive and subject to rapid and significant technological change. We face competition with respect to our indications for verekitug and will face competition with respect to any
other drug candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and
biotechnology companies, such as Sanofi, Regeneron, AstraZeneca and Amgen, that currently market and sell drugs or are pursuing the development of drug candidates for the treatment of the indications that we are pursuing. Potential competitors also
include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and
commercialization. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">36 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe that a significant number of product candidates are currently under development for the same indications we
are currently pursuing, and some or all may become commercially available in the future for the treatment of conditions for which we are trying or may try to develop product candidates. Our potential competitors include large pharmaceutical and
biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and research institutions. See the section titled &#147;<I></I>Business&#151;Competition<I></I>&#148; included elsewhere in this
prospectus for examples of the competition that verekitug faces. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In most cases, we do not currently plan to run <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">head-to-head</FONT></FONT> clinical trials evaluating verekitug or any other potential future product candidates against the current standards of care, which may make it more challenging for verekitug or any other
potential future product candidates to compete against the current standards of care due to the lack of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> clinical trial data. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our competitors may have significantly greater financial resources, established presence in the market, expertise in research and development, manufacturing, preclinical
and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than we do. Accordingly, our competitors may be more successful than we may be in obtaining regulatory approval for therapies and achieving
widespread market acceptance. Our competitors&#146; products may be more effective, or more effectively marketed and sold, than verekitug or any other potential future product candidates we may commercialize and may render our therapies obsolete or <FONT
STYLE="white-space:nowrap">non-competitive</FONT> before we can recover development and commercialization expenses. If verekitug or any other potential future product candidates are approved, it could compete with a range of therapeutic treatments
that are in development. In addition, our competitors may succeed in developing, acquiring or licensing technologies and drug products that are more effective or less costly than verekitug or any other potential future product candidates, which
could render verekitug or any other potential future product candidates obsolete and noncompetitive. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we obtain approval for verekitug or any other potential
future product candidates, we may face competition based on many different factors, including the efficacy, safety and tolerability of our products, the ease with which our products can be administered, the timing and scope of regulatory approvals
for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Existing and future competing products could present superior treatment alternatives, including
being more effective, safer, less expensive or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and
commercializing verekitug or any other potential future product candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, our competitors may obtain patent protection, regulatory exclusivities or FDA approval and commercialize products more rapidly than we do, which may impact
future approvals or sales of verekitug or any other potential future product candidates that receive regulatory approval. If the FDA approves the commercial sale of verekitug or any other potential future product candidates, we will also be
competing with respect to marketing capabilities and manufacturing efficiency. We expect competition among products will be based on product efficacy and safety, the timing and scope of regulatory approvals, availability of supply, marketing and
sales capabilities, product price, reimbursement coverage by government and private third-party payors, regulatory exclusivities and patent position. Our profitability and financial position will suffer if verekitug or any other potential future
product candidates receives regulatory approval but cannot compete effectively in the marketplace. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Mergers and acquisitions in the pharmaceutical and biotechnology
industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">37 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites, as well as in
acquiring technologies complementary to, or necessary for, our programs. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we are unable to develop our sales, marketing and distribution capability on our
own or through collaborations with marketing partners, we will not be successful in commercializing verekitug or any other potential future product candidates. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We currently have no marketing, sales or distribution capabilities. We intend to establish a sales and marketing organization, either on our own or in collaboration with
third parties, with technical expertise and supporting distribution capabilities to commercialize verekitug or any other potential future product candidates that may receive regulatory approval in key territories. These efforts will require
substantial additional resources, some or all of which may be incurred in advance of any approval of the product candidate. Any failure or delay in the development of our or third parties&#146; internal sales, marketing and distribution capabilities
would adversely impact the commercialization of verekitug or any other potential future product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Factors that may inhibit our efforts to commercialize
verekitug or any other potential future product candidates on our own include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our inability to recruit and retain an adequate number of effective sales and marketing personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the inability of sales personnel to obtain access to or persuade an adequate number of physicians to prescribe any future
products; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage
relative to companies with more extensive product lines; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">With respect to verekitug or any other potential future product candidates, we may choose to collaborate with third parties that have direct sales
forces and established distribution systems to serve as an alternative to our own sales force and distribution systems. Our future product revenue may be lower than if we directly marketed or sold verekitug or any other potential future product
candidates, if approved. In addition, any revenue we receive will depend in whole or in part upon the efforts of these third parties, which may not be successful and are generally not within our control. If we are not successful in commercializing
any approved products, our future product revenue will suffer and we may incur significant additional losses. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we do not establish sales and marketing
capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing verekitug or any other potential future product candidates. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The increasing use of social media platforms presents new risks and challenges. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Social media is increasingly being used to communicate about our clinical development programs and the diseases our therapeutics are being developed to treat, and we
intend to utilize appropriate social media in connection with our commercialization efforts following approval of our product candidates, if any. Social media practices in the biopharmaceutical industry continue to evolve and regulations and
regulatory guidance relating to such use are evolving and not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us, along with
the potential for litigation related to <FONT STYLE="white-space:nowrap">off-label</FONT> marketing or other prohibited activities. For example, patients may use social media channels to comment on their experience in an ongoing blinded clinical
trial or to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">38 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
report an alleged adverse event. When such disclosures occur, there is a risk that trial enrollment may be adversely impacted, that we fail to monitor and comply with applicable adverse event
reporting obligations or that we may not be able to defend our business or the public&#146;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our product
candidates. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with
applicable regulations, we could incur liability, face regulatory actions or incur other harm to our business. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to employee matters and managing
growth </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We expect to expand our organization, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of regulatory affairs
and sales, marketing and distribution, as well as to support our public company operations. To manage these growth activities, we must continue to implement and improve our managerial, operational, quality and financial systems, expand our
facilities and continue to recruit and train additional qualified personnel. Our management may need to devote a significant amount of its attention to managing these growth activities. Due to our limited financial resources and the limited
experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion or relocation of our operations, retain key employees, or identify, recruit and train additional qualified
personnel. Our inability to manage the expansion or relocation of our operations effectively may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced
productivity among remaining employees. Our expected growth could also require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If we are unable to
effectively manage our expected growth, our expenses may increase more than expected, our ability to generate revenues could be reduced and we may not be able to implement our business strategy, including the successful commercialization of
verekitug or any other potential future product candidates. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our ability to develop verekitug or any other potential future product candidates and our future
growth depends on attracting, hiring and retaining our key personnel and recruiting additional qualified personnel. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our success depends upon the continued
contributions of our key management and scientific personnel, many of whom have been instrumental for us and have substantial experience with developing therapies, identifying potential product candidates and building the technologies related to the
clinical development of verekitug or any other potential future product candidates. As we continue developing verekitug or any other potential future product candidates, we will require personnel with medical, scientific, or technical qualifications
specific to each program. The loss of key personnel would delay our research and development activities. Despite our efforts to retain valuable employees, members of our team may terminate their employment with us on short notice. The competition
for qualified personnel in the biotechnology and biopharmaceutical industries is intense, and our future success depends upon our ability to attract, retain, and motivate highly skilled scientific, technical and managerial employees. We face
competition for personnel from other companies, universities, public and private research institutions, and other organizations. If our recruitment and retention efforts are unsuccessful in the future, it may be difficult for us to implement our
business strategy, which would have a material adverse effect on our business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, our clinical operations and research and development programs depend on
our ability to attract and retain highly skilled scientists, data scientists, and engineers, particularly in Massachusetts. There is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">39 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
powerful competition for skilled personnel in these geographical markets, and we have from time to time experienced, and we expect to continue to experience, difficulty in hiring and retaining
employees with appropriate qualifications on acceptable terms, or at all. Many of the companies with which we compete for experienced personnel have greater resources than we do, and any of our employees may terminate their employment with us at any
time. If we hire employees from competitors or other companies, their former employers may attempt to assert that these employees or we have breached legal obligations, resulting in a diversion of our time and resources and, potentially, damages. In
addition, job candidates and existing employees often consider the value of the stock awards they receive in connection with their employment. If the perceived benefits of our stock awards decline, it may harm our ability to recruit and retain
highly skilled employees. If we fail to attract new personnel or fail to retain and motivate our current personnel, our business and future growth prospects would be harmed. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to our dependence on third parties </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We currently rely,
and plan to rely in the future, on third parties to conduct and support our clinical trials. If they do not perform satisfactorily, we may not be able to obtain regulatory approval or commercialize verekitug or any other potential future product
candidates, or such approval or commercialization may be delayed, and our business could be substantially harmed. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have relied upon and plan to continue
to rely on third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators, to conduct our clinical trials and expect to rely on these third parties to conduct clinical trials for verekitug or any
other potential future product candidates that we develop. Our ability to complete clinical trials in a timely fashion depends on a number of key factors. These factors include protocol design, regulatory and IRB approval, or positive opinions from
ethics committees, patient enrollment rates and compliance with GCPs. We have opened clinical trial sites and are enrolling patients in a number of countries where our experience is limited. In most cases, we use the services of third parties,
including CROs, to carry out our clinical trial-related activities and rely on such parties to accurately report their results. Our reliance on third parties for clinical development activities may impact or limit our control over the timing,
conduct, expense and quality of our clinical trials. Moreover, the FDA requires us to comply with GCPs for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that
the rights, integrity and confidentiality of trial participants are protected. The FDA enforces these GCPs through periodic inspections of clinical trial sponsors, principal investigators, clinical trial sites and IRBs. For certain commercial
prescription drug products, manufacturers and other parties involved in the supply chain must also meet chain of distribution requirements and build electronic, interoperable systems for product tracking and tracing and for notifying the FDA of
counterfeit, diverted, stolen and intentionally adulterated products or other products that are otherwise unfit for distribution in the United States. Comparable requirements and enforcement actions apply in foreign countries. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, informed consent forms submitted to competent
regulatory authorities, legal and regulatory requirements and scientific standards. Our failure or the failure of third parties to comply with the applicable protocol, informed consent forms, legal and regulatory requirements and scientific
standards can result in rejection of our clinical trial data or other sanctions. If we or our third-party clinical trial providers or third-party CROs do not successfully carry out these clinical activities, our clinical trials or the potential
regulatory approval of a product candidate may be delayed or be unsuccessful. Additionally, if we or our third-party contractors fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the
FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving verekitug or any other potential future product candidates, which would delay the regulatory approval process. We cannot be
certain that, upon inspection, the FDA or comparable foreign </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">40 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
regulatory authorities will determine that any of our clinical trials comply with GCPs. We are also required to register certain clinical trials and post the results of completed clinical trials
on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. Comparable transparency and publication requirements apply in foreign
countries. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Furthermore, the third parties conducting clinical trials on our behalf are not our employees, and except for remedies available to us under our
agreements with such contractors, we cannot control whether or not they devote sufficient time, skill and resources to our ongoing development programs. Moreover, many CROs, including some of those that we have engaged to conduct our clinical
trials, are experiencing enrollment challenges as a result of, among other things, high employee turnover driven by the post-COVID macroeconomic environment and the inexperience of new employees. Furthermore, at clinical trial sites, the
availability of staff and trial participants has been limited due to a decrease in the number of clinical investigative sites across the globe. These contractors may also have relationships with other commercial entities, including our competitors,
for whom they may also be conducting clinical trials or other drug development activities, which could impede their ability to devote appropriate time to our clinical programs. If these third parties, including clinical investigators, do not
successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we may not be able to obtain, or may be delayed in obtaining, regulatory
approvals for verekitug or any other potential future product candidates. If that occurs, we will not be able to, or may be delayed in our efforts to, successfully commercialize verekitug or any other potential future product candidates. In such an
event, our financial results and the commercial prospects for verekitug or any other potential future product candidates that we seek to develop could be harmed, our costs could increase and our ability to generate revenues could be delayed,
impaired or foreclosed. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We also rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of
our distributors could delay clinical development or regulatory approval of verekitug or any other potential future product candidates or commercialization of any resulting products, producing additional losses and depriving us of potential product
revenue. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any of the third-party organizations we utilize may terminate their engagements with us under certain circumstances. The replacement of an existing CRO or
other third party may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize verekitug or any other potential future product candidates. For example, although we believe
there are a number of other CROs we could engage, we may not be able to enter into alternative arrangements or do so on commercially reasonable terms. In addition, while we believe there may be suitable replacements for one or more of these service
providers, there is a natural transition period when a new service provider begins work. As a result, delays may occur, which could negatively impact our ability to meet our expected clinical development timelines and harm our business, financial
condition, results of operations and growth prospects. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our information technology systems, or those used by our CROs or other contractors or consultants, may
fail or suffer security breaches, which could adversely affect our business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our information technology systems and data and those of our current or future
contract research organizations or other contractors and consultants are vulnerable to compromise or damage from computer hacking, computer viruses, and malware (e.g., ransomware malicious software), fraudulent activity, employee misconduct, human
error, telecommunication and electrical failures, natural disasters, or other cybersecurity attacks or accidents. Future acquisitions could expose us to additional cybersecurity risks and vulnerabilities from any newly acquired information
technology infrastructure. Cybersecurity attacks are increasing in frequency and sophistication and are made by groups and individuals with a wide range of motives (including </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">41 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
industrial espionage) and expertise, including by organized criminal groups, &#147;hacktivists,&#148; nation states, and others. As a result of a continued hybrid working environment, we may also
face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the
techniques used to obtain unauthorized access to, or to sabotage systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures.
Further, as a company with an increasingly global presence, our systems are subject to frequent attacks, which are becoming more commonplace in the industry, including attempted hacking, phishing attempts, such as cyber-related threats involving
spoofed or manipulated electronic communications, which increasingly represent considerable risk. Due to the nature of some of the attacks described herein, there is a risk that an attack may remain undetected for a period of time. Even if
identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic
evidence. While we continue to make investments to improve the protection of data and information technology, including in the hiring of information technology (&#147;IT&#148;) personnel, periodic cyber security awareness trainings, improvements to
IT infrastructure and controls, and conduct regular testing of our systems, there can be no assurance that our efforts will prevent service interruptions or security breaches. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We and certain of our service providers are from time to time subject to cyberattack attempts or incidents and security incidents. Any cybersecurity incident could
adversely affect our business, by leading to, for example, the loss of trade secrets or other intellectual property, demands for ransom or other forms of blackmail, or the unauthorized disclosure of personal or other sensitive information of our
employees, clinical trial patients, customers, and others. Although to our knowledge we have not experienced any significant cybersecurity incident to date, if such an event were to occur, it could seriously harm our development programs and our
business operations. We could be subject to breach notification requirements, regulatory actions taken by governmental authorities, litigation under laws that protect the privacy of personal information, or other forms of legal proceedings, which
could result in significant liabilities or penalties, result in substantial costs and distract management. Further, a cybersecurity incident may disrupt our business or damage our reputation, which could have a material adverse effect on our
business, financial condition, results of operations, growth prospects, share price and shareholder value. We could also incur substantial remediation costs, including the costs of investigating the incident, repairing or replacing damaged systems,
restoring normal business operations, implementing increased cybersecurity protections, and paying increased insurance premiums. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For example, the loss of clinical
trial data from completed, ongoing or future clinical trials could result in delays in or denials of our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. If a security breach or other incident were
to result in the unauthorized access to or unauthorized use, disclosure, release or other processing of clinical trial data or personal data, it may be necessary to notify individuals, governmental authorities, supervisory bodies, the media, and
other parties pursuant to privacy and security laws. Likewise, we rely on our third-party research collaborators for research and development of verekitug and other third parties to conduct clinical trials, and similar events relating to their
information technology systems could also seriously harm our business. Any security compromise affecting us, our collaborators or our industry, whether real or perceived, could harm our reputation, erode confidence in the effectiveness of our
security measures, and lead to regulatory scrutiny. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or systems, or inappropriate disclosure of confidential or proprietary or personal
information, we could incur liability, our competitive position could be harmed, and the further development and commercialization of verekitug or any other potential future product candidates could be delayed, result in substantial costs and
distract management. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">42 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may seek to establish collaborations and, if we are not able to establish them on commercially reasonable terms,
we may have to alter our development and commercialization plans. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The advancement, development programs and potential commercialization of verekitug or any
other potential future product candidates will require substantial additional cash to fund expenses. For some of our programs, we may decide to collaborate with other pharmaceutical and biotechnology companies with respect to development and
potential commercialization. Likely collaborators may include large and <FONT STYLE="white-space:nowrap">mid-size</FONT> pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. In addition, if we are
able to obtain regulatory approval for verekitug or any other potential future product candidates from foreign regulatory authorities, we may enter into collaborations with international biotechnology or pharmaceutical companies for the
commercialization of such product candidate. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a
collaboration will depend, among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation of a number of factors.
Those factors may include the potential differentiation of verekitug or any other potential future product candidates from competing product candidates, design or results of clinical trials, the likelihood of approval by the FDA, the European
Commission, or other comparable foreign regulatory authorities and the regulatory pathway for any such approval, the potential market for the product candidate, the costs and complexities of manufacturing and delivering the product to patients and
the potential of competing products. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available for collaboration and whether such a collaboration could be more attractive than the
one with us for verekitug or any other potential future product candidates. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available
to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop verekitug or any other potential future product candidates or bring them to market and generate product revenue. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Collaborations are complex and time-consuming to negotiate and document. Further, there have been a significant number of recent business combinations among large
pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Any collaboration agreements that we enter into in the future may contain restrictions on our ability to enter into potential collaborations or to
otherwise develop specified product candidates. We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of verekitug or any other potential
future product candidates for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing
activities, or increase our expenditures and undertake development or commercialization activities at our own expense. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our existing research and development
arrangement as well as any future collaborations with third parties for the development and commercialization of verekitug or any other potential future product candidates may not be successful, which could adversely affect our ability to advance
verekitug or any other potential future product candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have entered into a research and development arrangement and may in the future enter into
collaborations for the development and commercialization of verekitug or any other potential future product candidates. Any collaborations may limit our control over the amount and timing of resources that our collaborators will dedicate to the
development or commercialization of verekitug or any other potential future product candidates. Our ability to generate revenues from these arrangements will depend on any future collaborators&#146; </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">43 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
abilities to successfully perform the functions assigned to them in these arrangements. For example, we granted Maruho Co., Ltd. (&#147;Maruho&#148;) an exclusive, irrevocable, perpetual,
royalty-free, sublicensable license for the development and commercialization of verekitug in Japan (the &#147;Maruho License Agreement&#148;). Under the Maruho License Agreement, we are responsible for and control the global research and
development of verekitug in Japan. In addition, any future collaborators may have the right to abandon research or development projects and terminate applicable agreements, including funding obligations, prior to or upon the expiration of the agreed
upon terms. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Collaborations involving verekitug or any other potential future product candidates pose a number of risks, including the following: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these
collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">collaborators may not perform their obligations as expected; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">collaborators may not pursue development and commercialization of verekitug or any other potential future product
candidates or may elect not to continue or renew development or commercialization programs, based on clinical trial results, changes in the collaborators&#146; strategic focus or available funding or external factors, such as an acquisition, which
divert resources or create competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial
or abandon verekitug or any other potential future product candidates, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with
verekitug or any other potential future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to the
marketing and distribution of such product or products; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">disagreements with collaborators, including disagreements over proprietary rights, including trade secrets and intellectual
property rights, contract interpretation, or the preferred course of development might cause delays or termination of the research, development or commercialization of verekitug or any other potential future product candidates, might lead to
additional responsibilities for us with respect to such product candidate, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information
in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and
potential liability; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further
development or commercialization of the applicable product candidate. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Collaboration agreements may not lead to development or commercialization of
verekitug or any other potential future product candidates in the most efficient manner or at all. If any future collaborator of ours is involved in a business combination, it could decide to delay, diminish or terminate the development or
commercialization of verekitug or any other potential future product candidates licensed to it by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">44 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our use of third parties to manufacture verekitug or any other potential future product candidates may increase the
risk that we will not have sufficient quantities of verekitug or any other potential future product candidates, raw materials, active pharmaceutical ingredients (&#147;APIs&#148;) or drug products when needed or at an acceptable cost. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We do not own or operate manufacturing facilities for the production of clinical or commercial quantities of verekitug or any other potential future product candidates,
and we lack the resources and the capabilities to do so. Our current strategy is to outsource all manufacturing of verekitug or any other potential future product candidates to third parties. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We currently rely on and engage third-party manufacturers to provide all of the APIs and the final drug product formulation of verekitug that is being used in our
clinical trials and preclinical studies. Although we believe that there are several potential alternative manufacturers who could manufacture verekitug, we primarily rely on one manufacturer, WuXi Biologics (Hong Kong) Limited (&#147;WuXi&#148;),
for the production of product necessary to complete our ongoing clinical trials. If a replacement manufacturer becomes necessary in the future, we may incur added costs and delays in identifying and qualifying another manufacturer. There have been
Congressional legislative proposals, such as the bill titled the BIOSECURE Act, which would, among other things, prohibit U.S. federal funding in connection with biotechnology equipment or services produced or provided by certain named Chinese
&#147;biotechnology companies of concern&#148; (which includes WuXi) and loans and grants to, and federal contracts with any entity that uses biotechnology equipment or services from one of these entities in performance of the government contract,
grant, or loan. The legislation also gives the federal government the authority to name additional &#147;biotechnology companies of concern&#148; that are engaged in research activities with the Chinese government and that pose a risk of U.S.
national security. We continue to monitor the status of the BIOSECURE Act, the implementation of which could materially impact our agreement with WuXi. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition,
we typically order raw materials, APIs and drug product and services on a purchase order basis and do not enter into long-term dedicated capacity or minimum supply arrangements with any commercial manufacturer. We may not be able to timely secure
needed supply arrangements on satisfactory terms, or at all. Our failure to secure these arrangements as needed could have a material adverse effect on our ability to complete the development of verekitug or any other potential future product
candidates or, to commercialize them, if approved. We may be unable to conclude agreements for commercial supply with third-party manufacturers or may be unable to do so on acceptable terms. There may be difficulties in scaling up to commercial
quantities and formulation of verekitug or any other potential future product candidates, and the costs of manufacturing could be prohibitive. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If our manufacturers
have difficulty or suffer delays in successfully manufacturing material that meets our specifications, it may limit supply of verekitug or any other potential future product candidates and could delay our clinical trials. For example, during routine
evaluation of drug samples as part of stability testing of material produced by a previous manufacturing process, particles were observed. This resulted in a brief pause in dosing in our Phase 1b MAD clinical trial of verekitug for the treatment of
asthma while a standard investigation was conducted, after which dosing resumed. We cannot assure you that similar or longer delays will not be necessary in the future. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even if we are able to establish and maintain arrangements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the failure of the third-party manufacturer to comply with applicable regulatory requirements and reliance on third parties
for manufacturing process development, regulatory compliance and quality assurance; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">manufacturing delays if our third-party manufacturers give greater priority to the supply of other products over verekitug
or any other potential future product candidates or otherwise do not satisfactorily perform according to the terms of the agreement between us; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">45 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">limitations on supply availability resulting from capacity and scheduling constraints of third parties;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the possible breach of manufacturing agreements by third parties because of factors beyond our control;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the possible termination or <FONT STYLE="white-space:nowrap">non-renewal</FONT> of the manufacturing agreements by the
third party, at a time that is costly or inconvenient to us; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the possible misappropriation of our proprietary information, including our trade secrets and <FONT
STYLE="white-space:nowrap">know-how.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we are unable to maintain our key manufacturing relationships, we may fail to find replacement
manufacturers or develop our own manufacturing capabilities, which could delay or impair our ability to obtain regulatory approval for verekitug or any other potential future product candidates. If we do find replacement manufacturers, we may not be
able to enter into agreements with them on terms and conditions favorable to us and there could be a substantial delay before new facilities could be qualified and registered with the FDA and comparable foreign regulatory authorities. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, if any third-party manufacturer with whom we contract fails to perform its obligations, we may be forced to manufacture the materials ourselves, for which
we may not have the capabilities or resources, or enter into an agreement with a different manufacturer. In either scenario, our clinical trials supply could be delayed significantly as we establish alternative supply sources. In some cases, the
technical skills required to manufacture verekitug or any other potential future product candidates may be unique or proprietary to the original manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from,
transferring such skills to a <FONT STYLE="white-space:nowrap">back-up</FONT> or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change third-party manufacturers for any reason, we will be
required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new
manufacturing process will produce verekitug or any other potential future product candidates according to the specifications previously submitted to the FDA, the EMA and the European Commission, or another comparable foreign regulatory authority.
We may be unsuccessful in demonstrating the comparability of clinical supplies, which could require the conduct of additional clinical trials. The delays associated with the verification of a new third-party manufacturer could negatively affect our
ability to develop or commercialize verekitug or any other potential future product candidates in a timely manner or within budget. Furthermore, a third-party manufacturer may possess technology related to the manufacture of verekitug or any other
potential future product candidates that such third party owns independently. This would increase our reliance on such third-party manufacturer or require us to obtain a license from such third-party manufacturer in order to have another third party
manufacture verekitug or any other potential future product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If verekitug is approved by any regulatory authority, we intend to utilize arrangements with
third-party contract manufacturers for the commercial production of that product. This process is difficult and time consuming and we may face competition for access to manufacturing facilities as there are a limited number of contract manufacturers
operating under cGMPs that are capable of manufacturing verekitug. Consequently, we may not be able to reach agreement with third-party manufacturers on satisfactory terms, which could delay our commercialization. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Some of our manufacturers are located outside of the United States. There is currently significant uncertainty about the future relationship between the United States
and various other countries, including China, with respect to trade policies, treaties, government regulations and tariffs. It is possible further tariffs may be imposed that could affect imports of APIs used in verekitug or any other potential
future product candidates, or our business may be adversely impacted by retaliatory trade measures taken by China or other countries, including restricted access to such raw materials used in verekitug or any other potential future product
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">46 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
candidates. Given the unpredictable regulatory environment in China and the United States and uncertainty regarding how the U.S. or foreign governments will act with respect to tariffs,
international trade agreements and policies, further governmental action related to tariffs, additional taxes, contracting matters, regulatory changes or other retaliatory trade measures in the future could occur with a corresponding detrimental
impact on our business, financial condition, results of operations and growth prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our failure, or the failure of our third-party manufacturers, to comply
with applicable regulations could result in sanctions being imposed on us, including shutdown of the third-party vendor or rejection of drug product lots or processes, clinical holds, fines, injunctions, civil penalties, delays, suspension,
variation or withdrawal of approvals, license revocation, seizures or voluntary recalls of product candidates or drugs if approved, operating restrictions and criminal prosecutions, any of which could significantly affect supplies of verekitug or
any other potential future product candidates. The facilities used by our contract manufacturers to manufacture verekitug or any other potential future product candidates must be evaluated by the FDA and comparable foreign regulatory authorities. We
have limited control over the manufacturing process of, and are dependent on, our contract manufacturing partners for compliance with cGMPs. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications
and the strict regulatory requirements of the FDA, the European Union, or other comparable foreign regulatory authorities, we may not be able to secure and/or maintain regulatory approval for verekitug or any other potential future product
candidates manufactured at these facilities. In addition, we limited control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign
regulatory authority finds deficiencies or does not approve these facilities for the manufacture of verekitug or any other potential future product candidates or if it withdraws any such approval in the future, we may need to find alternative
manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market verekitug or any other potential future product candidates, if approved. Contract manufacturers may face manufacturing or
quality control problems causing drug substance production and shipment delays or a situation where the contractor may not be able to maintain compliance with the applicable cGMP requirements. Any failure to comply with cGMP requirements or other
FDA, European Union, and comparable foreign regulatory requirements could adversely affect our clinical research activities and our ability to develop, and if approved, market verekitug or any other potential future product candidates. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA and comparable foreign regulatory authorities require manufacturers to register manufacturing facilities. The FDA and corresponding foreign regulators also
inspect these facilities to confirm and monitor compliance with cGMPs. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If any third-party manufacturer of verekitug or any other potential future product
candidates is unable to increase the scale of its production or the product yield of its manufacturing, then our manufacturing costs may increase and commercialization may be delayed. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In order to produce sufficient quantities to meet the demand for clinical trials and, if approved, subsequent commercialization of verekitug or any other potential
future product candidates, our third-party manufacturers will be required to increase their production and optimize their manufacturing processes while maintaining the quality of verekitug or any other potential future product candidates. The
transition to larger scale production could prove difficult. In addition, if our third-party manufacturers are not able to optimize their manufacturing processes to increase the product yield for verekitug or any other potential future product
candidates, or if they are unable to produce increased amounts of verekitug or any other potential future product candidates while maintaining the same quality then we may not be able to meet the demands of clinical trials or market demands, which
could decrease our ability to generate profits and have a material adverse impact on our business and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">47 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As verekitug or any other potential future product candidates proceed through preclinical studies to late-stage clinical trials towards potential approval
and commercialization, it is common that various aspects of the development program, such as the vendors used to manufacture drug product or manufacturing methods and formulation, are altered along the way in an effort to optimize processes and
results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause verekitug or any other potential future product candidates to perform differently and affect the results of planned clinical
trials or other future clinical trials conducted with the materials manufactured using altered processes. Such changes may also require additional testing, notification or approval by the FDA, or comparable foreign regulatory authorities. This could
delay or prevent completion of clinical trials, require conducting bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay or prevent approval of verekitug or any other potential future product
candidates and jeopardize our ability to commence sales and generate revenue. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to government regulation </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Obtaining and maintaining regulatory approval of verekitug or any other potential future product candidates in one jurisdiction does not mean that we will be
successful in obtaining regulatory approval in other jurisdictions. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Obtaining and maintaining regulatory approval of verekitug or any other potential future
product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative
effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, the European Commission, or other comparable foreign regulatory authorities must also approve the manufacturing and
marketing of the product candidate in those territories. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional
preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for
reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of
product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and
could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our
ability to realize the full market potential of verekitug or any other potential future product candidates will be harmed. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Even if we receive regulatory
approval of verekitug or any other potential future product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we
fail to comply with regulatory requirements or experience unanticipated problems with verekitug or any other potential future product candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If
verekitug or any other potential future product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">48 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and
requirements of comparable foreign regulatory authorities. In addition, we will be subject to continued compliance with cGMP and GCP requirements for any clinical trials that we conduct post-approval. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Manufacturers and manufacturers&#146; facilities are required to comply with extensive FDA, European Union, and comparable foreign regulatory requirements, including
ensuring that quality control and manufacturing procedures conform to cGMP regulations and applicable product tracking and tracing requirements. As such, we and our contract manufacturers will be subject to continual review and inspections to assess
continuous compliance with cGMP and adherence to commitments made in any BLA, other marketing application and previous responses to inspection observations. Accordingly, we and others with whom we work must continue to expend time, money and effort
in all areas of regulatory compliance, including manufacturing, production and quality control. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any regulatory approvals that we receive for verekitug or any other
potential future product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including
Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the product candidate. Certain endpoint data we hope to include in any approved product labeling also may not make it into such labeling, including exploratory or
secondary endpoint data such as patient-reported outcome measures. The FDA may also require Risk Evaluation and Mitigation Strategies (&#147;REMS&#148;) as a condition of approval of verekitug or any other potential future product candidates, which
could entail requirements for long-term patient <FONT STYLE="white-space:nowrap">follow-up,</FONT> a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient
registries and other risk minimization tools. Comparable requirements may apply in foreign countries. In addition, if the FDA, the European Commission, or a comparable foreign regulatory authority approves verekitug or any other potential future
product candidates, we will have to comply with requirements including submissions of safety and other post-marketing information and reports and registration. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
FDA or comparable foreign regulatory authorities may impose consent decrees or withdraw or vary approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later
discovery of previously unknown problems with verekitug or any other potential future product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure
to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical trials to assess new safety risks or imposition of distribution restrictions or
other restrictions under a REMS program or a comparable foreign program. Other potential consequences include, among other things: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary
product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">fines, warning letters or holds on clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">refusal by the FDA or comparable foreign regulatory authorities to approve pending applications or supplements to approved
applications filed by us or suspension, variation or withdrawal of approvals; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">product seizure or detention or refusal to permit the import or export of verekitug or any other potential future product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">total or partial suspension of production, distribution, manufacturing or clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">49 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">operating restrictions; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">suspension of licenses; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">injunctions, fines or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, the FDA and comparable foreign regulatory authorities strictly regulate marketing, labeling, advertising and promotion of products that are placed on the
market. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The policies of the FDA, the
EMA, and the European Commission, and comparable foreign regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of verekitug or any other potential future product
candidates. In addition, the U.S. Supreme Court&#146;s July 2024 decision to overturn established case law giving deference to regulatory agencies&#146; interpretations of ambiguous statutory language has introduced uncertainty regarding the extent
to which the FDA&#146;s regulations, policies and decisions may become subject to increasing legal challenges, delays, and/or changes. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation
or administrative action, either in the United States or abroad. For more information, see the section titled &#147;Business&#151;Government regulation&#148; included elsewhere in this prospectus. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory
compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Verekitug or any other potential
future product candidates for which we intend to seek approval as biological products may face competition sooner than anticipated. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Biologics Price
Competition and Innovation Act of 200 (the &#147;BPCIA&#148;) created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological
product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not
be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity, another company may still market a competing version of
the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#146;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its
product. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe any of our potential future product candidates approved as a biological product under a BLA should qualify for the <FONT
STYLE="white-space:nowrap">12-year</FONT> period of exclusivity. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, or that the FDA will not consider verekitug or any other potential future
product candidates to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, could be substituted for any one
of our reference products in a way that is similar to traditional generic substitution for <FONT STYLE="white-space:nowrap">non-biological</FONT> products will depend on a number of marketplace and regulatory factors that are still developing. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the European Union, there is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not meet
the definition of a generic medicinal product. For such products, the results of appropriate preclinical or clinical trials must be provided in support of an application. Guidelines from the EMA detail the type of quantity of supplementary data to
be provided for different types of biological product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">50 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>While we may in the future seek designations for verekitug or any other potential future product candidates with the
FDA and comparable foreign regulatory authorities that are intended to confer benefits such as a faster development process, an accelerated regulatory pathway or regulatory exclusivity, there can be no assurance that we will successfully obtain such
designations. In addition, even if verekitug or any other potential future product candidates are granted such designations, we may not be able to realize the intended benefits of such designations. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA and comparable foreign regulatory authorities offer certain designations for product candidates that are designed to encourage the research and development of
product candidates that are intended to address conditions with significant unmet medical need. These designations may confer benefits such as additional interaction with regulatory authorities, a potentially accelerated regulatory pathway and
priority review. However, there can be no assurance that we will successfully obtain such designations for verekitug or any other potential future product candidates. In addition, while such designations could expedite the development or approval
process, they generally do not change the standards for approval. Even if we obtain such designations for verekitug or any other potential future product candidates, there can be no assurance that we will realize their intended benefits. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For example, we may seek a Fast Track Designation for verekitug or any other potential future product candidates we develop. If a product is intended for the treatment
of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition, the product sponsor may apply for Fast Track Designation. The FDA has broad discretion whether
or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience
a faster development process, review or approval compared to conventional FDA procedures. The FDA may rescind the Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development activities.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We also may seek Breakthrough Therapy Designation for verekitug or any other potential future product candidates we develop. A breakthrough therapy is defined as a
drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over
currently approved therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication
between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA
are also eligible for accelerated approval and priority review. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we
believe a product candidate we develop meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of Breakthrough Therapy Designation for a product
candidate may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if any product candidate we
develop qualifies as a breakthrough therapy, the FDA may later decide that the drug no longer meets the conditions for qualification and rescind the designation. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even in the absence of obtaining fast track and/or breakthrough therapy designations, a sponsor can seek priority review at the time of submitting a marketing
application. The FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness when compared with other available therapies.
Significant improvement may be illustrated by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">51 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting adverse reaction, documented enhancement of patient compliance
that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation of such applications, and to
shorten the FDA&#146;s goal for taking action on a marketing application from ten months to six months. Priority review designation may be rescinded if a product no longer meets the qualifying criteria. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may be unsuccessful in obtaining or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market
exclusivity. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which
is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the
drug will be recovered from sales in the U.S. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user fee waivers. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Similarly, in the EU, a medicinal product can be designated as an orphan medicinal product by the European Commission if its sponsor can establish that: (i)&nbsp;the
product is intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions; (ii)&nbsp;either (a) such conditions affect not more than 5 in 10,000 persons in the EU when the application is made, or
(b)&nbsp;the product without the benefits derived from orphan status, would not generate sufficient return in the EU to justify the necessary investment in developing the medicinal product; and (iii)&nbsp;there exists no satisfactory authorized
method of diagnosis, prevention, or treatment of the condition that has been authorized in the EU, or even if such method exists, the product will be of significant benefit to those affected by that condition. In the EU, orphan medicinal product
designation entitles a party to incentives such as reduction of fees or fee waivers protocol assistance, and access to the centralized marketing authorization procedure. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug
is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same product and indication for that time period, except in limited circumstances. In the EU, marketing exclusivity
prevents the EMA from accepting another marketing authorization application or accepting an application to extend for a similar product and the European Commission cannot grant a marketing authorization for the same indication. The applicable period
is seven years in the U.S. and ten years in the EU. The EU exclusivity period is extended by two years for orphan medicinal products that have also complied with an agreed Pediatric Investigation Plan. However, the EU exclusivity period can be
reduced to six years, if at the end of the fifth, it is established that a product no longer meets the criteria on the basis of which it received orphan medicinal product designation, including where it can be demonstrated on the basis of available
evidence that the product is sufficiently profitable so that market exclusivity is no longer justified or where the prevalence of the condition has increased above the threshold. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even if we obtain orphan drug exclusivity for a drug, that exclusivity may not effectively protect the designated drug from competition because different drugs can be
approved for the same condition. Even after an orphan drug is approved, the FDA or the European Commission can subsequently approve the same drug for the same condition if the FDA or the European Commission concludes that the later drug is
clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">52 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Where appropriate, we may secure approval from the FDA, the European Commission or other comparable foreign
regulatory authorities through the use of expedited approval pathways, such as accelerated approval or comparable foreign abbreviated pathways. If we are unable to obtain such approvals, we may be required to conduct additional preclinical studies
or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA or approval following comparable
foreign abbreviated pathways by foreign regulatory authorities, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA or such comparable foreign regulatory authorities
may seek to withdraw the accelerated approval. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Where possible, we plan to pursue accelerated development strategies in areas of high unmet need. We may seek
an accelerated approval pathway for our one or more of our potential future product candidates from the FDA, EMA or other comparable foreign regulatory authorities. Under the accelerated approval provisions in the Federal Food, Drug, and Cosmetic
Act, and the FDA&#146;s implementing regulations, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a
determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is
clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or
other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality
that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct
therapeutic advantage but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#146;s agreement to conduct, in a diligent manner, additional
post-approval confirmatory studies to verify and describe the drug&#146;s clinical benefit. Under the Food and Drug Omnibus Reform Act of 2022 (&#147;FDORA&#148;), the FDA is permitted to require, as appropriate, that a post-approval confirmatory
study or studies be underway prior to approval or within a specified time period after the date of approval for a product granted accelerated approval. FDORA also gives the FDA increased authority to withdraw approval of a drug or biologic granted
accelerated approval on an expedited basis if the sponsor fails to conduct such studies in a timely manner, send status updates on such studies to the FDA every 180 days to be publicly posted by the agency, or if such post-approval studies fail to
verify the drug&#146;s predicted clinical benefit. The FDA is empowered to take action, such as issuing fines, against companies that fail to conduct with due diligence any post-approval confirmatory study or submit timely reports to the agency on
their progress. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prior to seeking accelerated approval, or approval following comparable foreign abbreviated pathways, we would seek feedback from the FDA or other
comparable foreign regulatory authorities and would otherwise evaluate our ability to seek and receive such accelerated approval or approval following comparable foreign abbreviated pathways. There can be no assurance that after our evaluation of
the feedback and other factors we will decide to pursue or submit a BLA for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent feedback from the FDA, or
other comparable foreign regulatory authorities, we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit
an application for accelerated approval, or comparable foreign abbreviated pathways, there can be no assurance that such application will be accepted or that any approval will be granted on a timely basis, or at all. The FDA, the EMA, or the
European Commission, or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">53 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
approval of any type, including, for example, if other products are approved via the accelerated pathway, or comparable foreign abbreviated pathway, and subsequently converted by FDA or
comparable foreign regulatory authorities to full approval. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidate would result in a longer time period to commercialization
of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our
relationships with healthcare professionals and physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties,
contractual damages, reputational harm and diminished profits and future earnings. </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">It is possible that governmental and enforcement authorities will
conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. Healthcare professionals, physicians and third-party
payors in the United States and elsewhere play a primary role in the recommendation and prescription of pharmaceutical products. Arrangements with third-party payors and customers can expose pharmaceutical manufacturers to broadly applicable fraud
and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we conduct research and would sell, market and distribute our products. As a pharmaceutical company, even
though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, supranational, national, federal and state healthcare laws and regulations that may affect our ability to
operate may apply. For more information on healthcare laws and regulations that may impact our company, see the section titled &#147;Business&#151;Government regulation&#151;Other healthcare laws&#148; included elsewhere in this prospectus. </P>
 <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the
lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare professionals, which has led to a number of investigations,
prosecutions, convictions and settlements in the healthcare industry. Ensuring business arrangements comply with applicable healthcare and privacy laws, as well as responding to possible investigations by government authorities, can be time and
resource-consuming and can divert a company&#146;s attention from the business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Ensuring that our internal operations and future business arrangements with third
parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency
or other competent authority guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental laws and regulations that
may apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, the exclusion from participation in federal and state healthcare programs, individual imprisonment,
reputational harm and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with these laws. Further, defending against any such actions can be costly and time consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in
defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other professionals or entities with whom we expect to do business is found to not be in compliance with applicable laws,
they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of the above occur, our ability to operate our business and our results of operations could
be adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">54 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Coverage and reimbursement may be limited or unavailable in certain market segments for verekitug or any other
potential future product candidates, if approved, which could make it difficult for us to sell them profitably. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The success of verekitug or any other
potential future product candidates, if approved, depends on the availability of coverage and adequate reimbursement from third-party payors. Patients who are provided medical treatment for their conditions generally rely on third-party payors to
reimburse all or part of the costs associated with their treatment. Coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which drugs and treatments they will
cover and the amount of reimbursement. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#146;s determination that use of a product is: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors, and the principal decisions about reimbursement for
new medicines are typically made by the Centers for Medicare&nbsp;&amp; Medicaid Services (&#147;CMS&#148;). CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to
a substantial degree. Even if we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate for us to achieve or sustain profitability or may require <FONT STYLE="white-space:nowrap">co-payments</FONT> that
patients find unacceptably high. Additionally, third-party payors may not cover, or provide adequate reimbursement for, long-term <FONT STYLE="white-space:nowrap">follow-up</FONT> evaluations required following the use of product candidates, once
approved. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for verekitug or any other potential future product candidates. Even if we do receive a favorable coverage
determination for our products by third-party payors, coverage policies and third-party payor reimbursement rates may change at any time. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net prices for drugs may
be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the
United States. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be
available for verekitug or any other potential future product candidates that we commercialize and, if reimbursement is available, the level of reimbursement. In addition, many pharmaceutical manufacturers must calculate and report certain price
reporting metrics to the government, such as average sales price and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or
rebates required by government healthcare programs. Payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover,
increasing efforts by governmental and other third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as
a result, they may not cover or provide adequate payment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">55 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
for verekitug or any other potential future product candidates. There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing
practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription
drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. At the state level, legislatures have increasingly passed legislation and
implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency
measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect that healthcare reform measures that may be
adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. The implementation of cost containment measures or other healthcare reforms may prevent us
from being able to generate revenue, attain profitability, or commercialize our products. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical
products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals or clearances of verekitug
or any other potential future product candidates, if any, may be. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, in some foreign countries, the proposed pricing for a product must be approved before
it may be lawfully marketed. The requirements governing product pricing vary widely from country to country. For example, the European Union provides options for its Member States to restrict the range of medicinal products for which their national
health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost
effectiveness of a particular product candidate to currently available therapies. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the
company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for
verekitug or any other potential future product candidates. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For more information on the laws and regulations that may impact coverage and reimbursement of verekitug or any other potential future product candidates, see the
section titled &#147;Business&#151;Government regulation&#151;Coverage and reimbursement&#148; included elsewhere in this prospectus. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Ongoing healthcare
legislative and regulatory reform measures may have a material adverse effect on our business and results of operations. </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Changes in regulations,
statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example, (1)&nbsp;changes to our manufacturing arrangements, (2)&nbsp;additions or modifications to product labeling, (3)&nbsp;the
recall or discontinuation of our products or (4)&nbsp;additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. See the sections titled &#147;Business&#151;Government
regulation&#151;Coverage and reimbursement&#148; and &#147;&#151;Healthcare reform&#148; included elsewhere in this prospectus. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The containment of healthcare
costs has become a priority of federal, state and foreign governments, and the prices of products have been a focus in this effort. There have been a number of federal and state proposals </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">56 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
during the last few years regarding the pricing of pharmaceutical products, limiting coverage and the amount of reimbursement for drugs and other medical products, government control and other
changes to the healthcare system in the United States. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic
products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our revenue generated from the sale of any approved products.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and
delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products, which has resulted in several Congressional
inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program
reimbursement methodologies for pharmaceutical products. Congress has indicated that it will continue to seek new legislative measures to control drug costs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In
December 2021, Regulation No 2021/2282 on Health Technology Assessment (&#147;HTA&#148;) amending Directive 2011/24/EU, was adopted in the EU. This Regulation, which entered into force in January 2022 and will apply in January 2025, is intended to
boost cooperation among EU Member States in assessing health technologies, including new medicinal products, and providing the basis for cooperation at EU level for joint clinical assessments in these areas. The Regulation foresees a three-year
transitional period and will permit EU Member States to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the most
potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in
other areas. Individual EU Member States will continue to be responsible for assessing <FONT STYLE="white-space:nowrap">non-clinical</FONT> (e.g., economic, social, ethical) aspects of health technologies, and making decisions on pricing and
reimbursement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These laws, and future supranational, national state and federal healthcare reform measures may be adopted in the future, any of which may result in
additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for verekitug or any other potential future product candidates for which we may obtain regulatory approval or the frequency with which any
such product candidate is prescribed or used. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our employees, independent contractors, consultants, and vendors may engage in misconduct or other improper
activities, including noncompliance with regulatory standards and requirements. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are exposed to the risk of employee fraud or other illegal activity by
our current and any future employees, independent contractors, consultants, contract manufacturing organizations, CROs and vendors. Misconduct by these parties could include intentional, reckless, and/or negligent conduct that fails to comply with
FDA or other regulations, provide true, complete and accurate information to the FDA, the national competent authorities of individual EU Member States, and other comparable foreign regulatory authorities, comply with manufacturing standards we may
establish, comply with healthcare fraud and abuse laws and regulations, report financial information or data accurately, or disclose unauthorized activities to us. If we obtain FDA approval of verekitug or any other potential future product
candidates and begin commercializing those products in the United States, our potential exposure under these laws will increase significantly, and our costs associated with compliance with these laws are likely to increase. Employee misconduct could
also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Additionally, we are subject to the risk that a person could allege such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">57 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
fraud or other misconduct, even if none occurred. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be
effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. If any such actions are instituted
against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material and adverse effect on our business, financial condition, results of operations and growth prospects. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I><FONT STYLE="white-space:nowrap">Off-label</FONT> use or misuse of verekitug or any other potential future product candidates may harm our reputation in the
marketplace or result in injuries that lead to costly product liability suits. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If verekitug or any other potential future product candidates are approved by
the FDA, we may only promote or market them in a manner consistent with their <FONT STYLE="white-space:nowrap">FDA-approved</FONT> labeling. We will train our marketing and sales force against promoting verekitug or any other potential future
product candidates for uses outside of the approved indications for use, known as <FONT STYLE="white-space:nowrap">&#147;off-label</FONT> uses.&#148; We cannot, however, prevent a physician from verekitug or any other potential future product
candidates <FONT STYLE="white-space:nowrap">off-label,</FONT> when in the physician&#146;s independent professional medical judgment he or she deems it appropriate. Furthermore, the use of verekitug or any other potential future product candidates
for indications other than those approved by the FDA may not effectively treat such conditions. Any such <FONT STYLE="white-space:nowrap">off-label</FONT> use of verekitug or any other potential future product candidates could harm our reputation in
the marketplace among physicians and patients. There may also be increased risk of injury to patients if physicians attempt to use verekitug or any other potential future product candidates for these uses for which they are not approved, which could
lead to product liability suits that might require significant financial and management resources and that could harm our reputation. Similar requirements and considerations apply abroad. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Inadequate funding for the FDA, other government agencies or comparable foreign regulatory authorities could hinder their ability to hire and retain key
leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may
rely, which could negatively impact our business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The ability of the FDA or comparable foreign regulatory authorities to review and approve new products can
be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have
fluctuated in recent years as a result. In addition, government funding of other government agencies or comparable foreign regulatory authorities on which our operations may rely, including those that fund research and development activities, is
subject to the political process, which is inherently fluid and unpredictable. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Disruptions at the FDA, other government agencies or comparable foreign regulatory
authorities may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down
several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, including as a result of reaching the debt ceiling, it could
significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public
markets and obtain necessary capital in order to properly capitalize and continue our operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">58 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>EU drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for
our products in the EU Member States. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend to seek approval to market verekitug or any other potential future product candidates in both the United
States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for verekitug or any other potential future product candidates, we will be subject to rules and regulations in those jurisdictions. In some
foreign countries, particularly those in the European Union, the pricing of products is subject to governmental control and other market regulations which could put pressure on the pricing and usage of verekitug or any other potential future product
candidates. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. In addition, market acceptance and sales of verekitug or any other potential
future product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for them and may be affected by existing and future healthcare reform measures. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Much like the federal Anti-Kickback Statute prohibition in the United States, the provision of benefits or advantages to physicians and other healthcare professionals to
induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the European Union. Interactions between pharmaceutical companies and healthcare professionals, including
the provision of benefits or advantages, are governed by strict laws, such as national anti-bribery laws of individual EU Member States and the Bribery Act 2010 in the UK, national sunshine rules, regulations, industry self-regulation codes of
conduct and physicians&#146; codes of professional conduct. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. Infringement of these laws could result in
substantial fines and imprisonment. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Payments made to physicians and other healthcare professionals in certain EU Member States must be publicly disclosed.
Moreover, agreements with physicians often may require prior notification or approval by the healthcare professional&#146;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member
States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In
addition, in some foreign countries, including some countries in the European Union, the proposed pricing for a product must be approved before it may be lawfully marketed. The requirements governing product pricing and reimbursement vary widely
from country to country. The European Union provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products
for human use. An EU Member State may approve a specific price for the medicinal product, it may refuse to reimburse a product at the price set by the manufacturer or it may instead adopt a system of direct or indirect controls on the profitability
of the company placing the medicinal product on the market. Many EU Member States also periodically review their reimbursement procedures for medicinal products, which could have an adverse impact on reimbursement status. We expect that legislators,
policymakers and healthcare insurance funds in the individual EU Member States will continue to propose and implement cost-containing measures, such as lower maximum prices, lower or lack of reimbursement coverage and incentives to use cheaper,
usually generic, products as an alternative to branded products, and/or branded products available through parallel import to keep healthcare costs down. Moreover, in order to obtain reimbursement for our products in some European countries,
including some EU Member States, we may be required to compile additional data comparing the cost-effectiveness of our products to other available therapies. This HTA of medicinal products is becoming an increasingly common part of the pricing and
reimbursement procedures in some EU Member States, including those representing the larger markets. The HTA process is the procedure to assess therapeutic, economic and societal impact of a given medicinal product in the national healthcare systems
of the individual country. The outcome of an HTA will often influence the pricing and reimbursement status granted to these medicinal products by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">59 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
competent authorities of individual EU Member States. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product currently varies between
EU Member States. Reference pricing used by various EU Member States and parallel distribution, or arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced EU Member States, can further reduce prices. There can be no
assurance that any country that has price controls or reimbursement limitations for biopharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union
do not follow price structures of the United States and generally prices tend to be significantly lower. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the
country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales and the potential profitability of verekitug or any
other potential future product candidates in those countries would be negatively affected. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are subject to export and import controls, economic sanctions,
and anti-corruption laws and regulations of the United States and other jurisdictions. We can face criminal liability and other serious consequences for violations of these laws and regulations, which can harm our business. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic
and trade sanctions regulations administered by the U.S. Treasury Department&#146;s Office of Foreign Assets Control. Export controls and trade sanctions laws and regulations may restrict or prohibit altogether the provision, sale, or supply of our
products to certain governments, persons, entities, countries, and territories, including those that are the target of comprehensive sanctions or an embargo. We are also subject to anti-corruption and anti-bribery laws, including the U.S. Foreign
Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, and other state and national anti-bribery laws in the countries in which we conduct activities. Anti-corruption laws
are interpreted broadly and prohibit companies and their employees, agents, contractors, and other partners from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the
public or private sector. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting
controls. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other partners, even if we do not explicitly authorize or have actual knowledge of such activities. Any violation of the laws and
regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other
consequences. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we or any third-party manufacturer we engage now or in the future fail to comply with environmental, health and safety laws and regulations,
we could become subject to fines or penalties or incur costs or liabilities that could have a material adverse effect on our business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We and third-party
manufacturers we engage now are, and any third-party manufacturer we may engage in the future will be, subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use,
storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally
contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could
be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">60 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Although we maintain general liability insurance as well as workers&#146; compensation insurance to cover us for costs and
expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic
tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, we may incur
substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with
these laws and regulations also may result in substantial fines, penalties or other sanctions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Further, with respect to the operations of our current and any future
third-party contract manufacturers, it is possible that if they fail to operate in compliance with applicable environmental, health and safety laws and regulations or properly dispose of wastes associated with our products, we could be held liable
for any resulting damages, suffer reputational harm or experience a disruption in the manufacture and supply of verekitug or any other potential future product candidates. In addition, our supply chain may be adversely impacted if any of our
third-party contract manufacturers become subject to injunctions or other sanctions as a result of their <FONT STYLE="white-space:nowrap">non-compliance</FONT> with environmental, health and safety laws and regulations. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to our intellectual property </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our success is largely
based upon our intellectual property and proprietary technologies, and we may be unable to protect and/or enforce our intellectual property. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our success
will depend, in large part, on obtaining and maintaining patent protection and trade secret protection for verekitug or any other potential future product candidates and their formulations and uses, as well as successfully enforcing our patents
against third-party infringers and/or defending these patents against third-party challenges. If we (or our licensees should such licensees be granted the right to prosecute or enforce certain patents within our portfolio) fails to appropriately
prosecute or is unable to obtain and maintain patent protection for verekitug or any other potential future product candidates (or aspects thereof), our ability to develop, license and/or commercialize these product candidates may be adversely
affected and we may not be able to prevent competitors from making, using, selling or importing competing products. This failure or inability to properly or adequately protect the intellectual property rights relating to these product candidates
could have a material adverse effect on our business, financial condition, results of operations and growth prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The patent application process is subject to
numerous risks and uncertainties, and there can be no assurance that we or our partners will be successful in protecting verekitug or any other potential future product candidates by obtaining, enforcing and defending patents. These risks and
uncertainties include the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">patent applications may not result in any patent being issued; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">patents that may be issued may not include claims that cover a broad enough scope to prevent design around solutions by
competitors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">patents that may be issued may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable, or
otherwise may not provide adequate barriers to entry or any competitive advantage; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">because of the extensive time required for development, testing and regulatory review of a potential product, it is
possible that before a potential product can be commercialized, any related patent may expire, or remain in existence for only a short period following commercialization, reducing, or eliminating any advantage of the patent; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">61 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our&nbsp;competitors, many of which have substantially greater resources than us or our partners do, and many of which have
made significant investments in competing technologies, may seek, or may already have sought or obtained, patents that will limit, interfere with, or eliminate our ability to make, use, and sell our potential products; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">there may be significant pressure on the U.S. government and other international governmental bodies to limit the scope of
patent protection for disease treatments that prove successful as a matter of public policy regarding worldwide health concerns; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">countries other than the United States may have patent laws less favorable to patentees than those upheld by United States
courts, allowing foreign competitors a better opportunity to create, develop, and market competing products; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may be involved in lawsuits to protect or enforce our patents or the patents we have rights to enforce, which could be
expensive, time consuming and/or unsuccessful. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to patents, we also rely on trade secrets and proprietary <FONT
STYLE="white-space:nowrap">know-how.</FONT> Although we have taken steps to protect our trade secrets and unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> including entering into confidentiality agreements with third parties, and
confidential information and assignment agreements with employees, consultants, and advisors, there exists the potential that third parties may still somehow obtain this information or arrive at the same or similar information independently, which
would reduce or eliminate our competitive advantage. Moreover, we may become subject to claims that we directly or indirectly (through our consultants, advisors, or independent contractors that we may engage to assist us in developing verekitug or
any other potential future product candidates) have wrongfully or inadvertently disclosed, acquired or used trade secrets or other proprietary information of third parties. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may be forced to litigate to enforce or defend our intellectual property rights. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may be forced to litigate to enforce or defend our intellectual property rights against infringement by competitors, and to protect our trade secrets against
unauthorized use. In so doing, we may place our intellectual property at risk of being invalidated, rendered unenforceable, or limited or narrowed in scope such that we may no longer be used to adequately prevent the manufacture, sale or import of
competitive product. Further, an adverse result in any litigation or other proceedings before government agencies such as the United States Patent and Trademark Office (the &#147;USPTO&#148;), may place pending applications at risk of <FONT
STYLE="white-space:nowrap">non-issuance</FONT> or limitations in scope. Further, derivation proceedings, entitlement proceedings, ex parte reexamination, inter partes review, post grant review, and opposition proceedings provoked by third parties or
brought by the USPTO or any foreign patent authority may be used to challenge the inventorship, ownership, claim scope, or validity of our patents. Additionally, because of the substantial amount of discovery typically required in connection with
intellectual property litigation, there is a risk that some of our confidential and proprietary information or trade secrets could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the
results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the value of the company. Such litigation or
proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to
conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed
intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">62 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we enter into future arrangements involving government funding, and we make inventions as a result of such funding, our
intellectual property rights to such discoveries may be subject to the applicable provisions of the Bayh Dole Act of 1980. To the extent any of our current or future intellectual property is generated through the use of U.S. government funding, the
provisions of the Bayh Dole Act may similarly apply. Any exercise by the government of certain of our rights could harm our competitive position, business, financial condition, results of operations and growth prospects. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we or our partners are sued for infringing or misappropriating the intellectual property rights of third parties, it could be costly and time consuming, and an
unfavorable outcome in any such litigation could have a material adverse effect on our business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our success also depends upon our ability and the ability
of us any of our future partners to develop, manufacture, market and sell verekitug or any other potential future product candidates without infringing on the proprietary rights of third parties. Numerous United States and foreign issued patents and
pending patent applications, which are owned by third parties, exist in the fields in which we are developing products, some of which may be directed at claims that overlap with the subject matter of our intellectual property. Because patent
applications can take many years to issue, there may be currently pending applications, now unknown to us, which may later result in issued patents that verekitug or any other potential future product candidates or proprietary technologies may be
alleged to infringe upon. Similarly, there may be issued patents relevant to verekitug or any other potential future product candidates of which we are not aware. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, third parties may sue us alleging that we infringe, or have infringed, on their patents. Even if we are successful in defending any claims of infringement,
the defense of such claims may be costly and present a time consuming distraction. In the event of a successful claim of infringement against us, we may be required to: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">pay substantial damages and/or ongoing royalty payments; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">stop using some or all of our technologies and methods; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">stop certain research and development efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">develop non infringing products or methods (i.e., develop or design around); and/or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">obtain one or more licenses from third parties for an upfront lump sum, an ongoing royalty, or a combination thereof.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If required, we cannot assure you that we will be able to obtain such licenses on acceptable terms, or at all. If we are sued for infringement, we
could encounter substantial delays in the development, manufacture, and commercialization of verekitug or any other potential future product candidates. Any litigation, whether to enforce our patent rights or to defend against allegations that we
allegedly infringe on third-party rights, could be costly, time consuming, and may distract management from other important tasks. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As is commonplace in the
biotechnology and pharmaceutical industry, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. To the extent our employees are involved in
research endeavors that are similar to those which they were involved in at their former place of employment, we may be subject to claims that such employees and/or we have inadvertently or otherwise used or disclosed the alleged trade secrets or
other proprietary information of such former employers. Litigation may be necessary to defend against such claims, which could result in substantial costs, be a distraction to management and ultimately have a material adverse effect on us, even if
we are successful in defending such claims. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">63 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The biotechnology and pharmaceutical industries have experienced substantial litigation and other proceedings concerning
intellectual property rights, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which could be uncertain and may prevent,
delay, or otherwise interfere with our product discovery and development efforts. Our commercial success depends upon our ability or may depend on the ability of future collaborators to develop, manufacture, market, and sell our products. The
biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights as well as administrative proceedings for challenging patents, including derivation, inter partes review,
post grant review, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may be subject to, and may in the future become party to, or threatened with, adversarial proceedings or
litigation concerning intellectual property rights with respect to verekitug or any other potential future product candidates we may develop, including interference proceedings, post grant review, inter partes review, and derivation proceedings
before the USPTO and similar proceedings in foreign jurisdictions such as oppositions before the European Patent Office. Numerous United States and foreign issued patents and pending patent applications that are owned by third parties exist in the
fields in which we are developing verekitug or any other potential future product candidates and infringement claims may be asserted against us or our partners based on existing patents or patents that may be granted in the future, regardless of
their merit. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">It is not always clear to industry participants, including us, which patents cover various types of therapies, products or their methods of use or
manufacture. Moreover, as with many technology-based products, there may be third-party patent applications that, if issued, may include the claims that could be or are construed to cover components of verekitug or any other potential future product
candidates. There may also be third-party patents of which we are currently unaware with claims to our technologies, compositions, methods of manufacture or methods of use. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our ability to commercialize verekitug or any other potential future product candidates in the United States and abroad may be adversely affected if we cannot
successfully defend against infringement claims or obtain a license on commercially reasonable terms to relevant third-party patents that cover verekitug or any other potential future product candidates. Even if we have a strong defense and/or
believe that third-party intellectual property claims are without merit, there can be no assurance that a court would find in our favor on questions of infringement, validity, enforceability, and/or priority. A court of competent jurisdiction could
hold that these third-party patents are valid and enforceable and have been infringed upon, which could materially and adversely affect our ability to commercialize verekitug or any other potential future product candidates or technologies covered
by the asserted third-party patents. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and
convincing evidence as to the invalidity of any such U.S. patent claims, there is no assurance that a court of competent jurisdiction would invalidate the asserted claims of any such U.S. patent. If we are found to be infringing on a third
party&#146;s intellectual property rights, and we are unsuccessful in demonstrating that any such patents are invalid or unenforceable, we could be required to pay damages and/or an ongoing royalty or obtain a license from such third party to
continue developing, manufacturing, and marketing verekitug or any other potential future product candidates and our technologies. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were
able to obtain such a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors and other third parties access to the same technologies licensed to it, and it could require us to pay substantial
licensing fees and/or make ongoing royalty payments. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize verekitug or any other potential future product
candidates or such commercialization efforts may be significantly delayed, which could in turn significantly harm our business. While less likely given the high bar required for injunction, we also could be temporarily or permanently forced,
including by court order, to cease developing, manufacturing, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">64 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
commercializing the infringing technology or product candidates. In addition, we could be found liable for significant monetary damages, including treble damages and attorneys&#146; fees, if we
are found to have willfully infringed on a patent or other intellectual property right. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business,
financial condition, results of operations and growth prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The defense of third-party claims of alleged infringement or misappropriation of a third
party&#146;s intellectual property rights often involves substantial litigation expense and could also be a substantial diversion of management and employee time and resources from our business. Some third parties may be able to sustain the costs of
complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our
ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, financial condition, results of operations and growth prospects. There could also be public announcements of the
results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, this could have a substantial adverse effect on the price of our common stock. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by
government patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications are due to be paid to the USPTO and foreign patent
agencies outside of the United States over the lifetime of our patents and applications. If, in the future, we <FONT STYLE="white-space:nowrap">in-license</FONT> patent rights, in the case of any <FONT STYLE="white-space:nowrap">in-licensed</FONT>
patent rights, we generally rely on our licensors to pay these fees due to U.S. and non U.S. patent agencies. For patent rights we own, we may rely on our outside patent counsel and/or annuity services in the United States and foreign countries to
monitor these deadlines and to pay these fees when so instructed by us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The USPTO and foreign patent agencies require compliance with procedural, documentary, fee
payment, and other similar provisions, such as the requirement to disclose known prior art, during the patent application process. In the case of any <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights, we will generally depend on our
licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property, and for our owned patent applications, we engage counsel and other professionals to help us comply with these requirements.
While certain inadvertent lapses can be cured by payment of a late fee, by petition, or by other means in accordance with the applicable rules, there are situations in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in a
partial or complete loss of patent rights in the relevant jurisdiction. In the unlikely event that a <FONT STYLE="white-space:nowrap">non-compliance</FONT> event were to occur, our competitors might be able to enter the market with similar or
identical products or technology given our partial or complete loss of patent rights, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Patent terms may be inadequate to protect our competitive position on verekitug or any other potential future product candidates for an adequate amount of time.
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Patents have a limited lifespan. The terms of individual patents depend upon the legal term for patents in the countries in which they are granted. In most
countries, including the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from the earliest non provisional filing date in the applicable country. However, the actual protection
afforded by a patent varies from country to country, and also depends upon many factors, including the type of patent, the scope of coverage, the availability of regulatory related extensions, the availability of legal remedies in a particular
country and the validity and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">65 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
enforceability of the patent, and whether a portion of the patent term has been terminally disclaimed based on other patents. Various extensions including patent term extension and patent term
adjustment may be available, but the lives of such extensions, and the protections they afford, are limited. Even if patents covering verekitug or any other potential future product candidates are obtained, once the patent life has expired, we may
be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting verekitug or any other potential
future product candidates might expire before or shortly after we or our partners commercialize those candidates. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or
identical to ours for an adequate time period. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we do not obtain sufficient patent term protections for verekitug or any other potential future product
candidates, our business may be materially harmed. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Patents have a limited term. In the United States, the statutory expiration of a patent is generally 20
years after it is filed. Additional patent terms may be available through a patent term adjustment process, resulting from USPTO delays during prosecution. Although various extensions may be available, the life of a patent, and the protection it
affords, is limited. Even if patents covering verekitug or any other potential future product candidates are obtained, once the patent life has expired for a product candidate, we may be open to competition from generics or biosimilars. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Depending upon the timing, duration, and specifics of FDA regulatory approval of verekitug or any other potential future product candidates, one or more patents issued
from U.S. patent applications that we file or those of our future licensors may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984 (the &#147;Hatch-Waxman Amendments&#148;). The
Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during the FDA regulatory review process based on the first regulatory approval for a particular drug or biologic. A maximum of one
patent may be extended per <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a
total of 14 years from the date of drug approval, and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign
countries upon regulatory approval of verekitug or any other potential future product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Despite the possibility of an extension,&nbsp;we may not be
granted an extension for which it applies in the United States or any other jurisdiction because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines,
failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time or the scope of patent protection afforded could be less than we request. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we are unable to obtain patent term extension or restoration, or the foreign equivalent, or the term of any such extension is less than we request, our competitors or
other third parties may obtain approval of competing drugs following our patent expiration, and our revenue could be reduced, possibly materially. Further, if this occurs, our competitors or other third parties may take advantage of our investment
in development and trials by referencing our clinical and preclinical data and launch their drug earlier than might otherwise be the case. Any of the foregoing could materially harm our business, financial condition, results of operations and growth
prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">66 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Changes in patent law in the United States and in non U.S. jurisdictions could diminish the value of patents in
general, thereby impairing our ability to protect our technologies and verekitug or any other potential future product candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As is the case with other
biotech and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity, and are
therefore costly, time consuming and inherently uncertain. Recent rulings from the U.S. Supreme Court and the Court of Appeals for the Federal Circuit have narrowed the scope of patent protection available in specified circumstances and weakened the
rights of patent owners in specified situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once
obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing
patents and patents that we might obtain in the future. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, U.S. Supreme Court rulings over the past decade have narrowed the scope of patent protection
available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty
with respect to the validity and enforceability of issued patents. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken
our ability to obtain new patents or to enforce and/or defend our existing patents and patents that we might obtain in the future. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The USPTO has issued subject
matter eligibility guidance instructing USPTO examiners on the ramifications of the Supreme Court rulings in <I>Mayo Collaborative Services v. Prometheus Laboratories, Inc.</I> and <I>Association for Molecular Pathology v. Myriad Genetics, Inc.</I>,
and applied the <I>Myriad</I> ruling to natural products and principles including all naturally occurring molecules. In addition, the USPTO continues to provide updates to its guidance continues to be a developing area. The USPTO guidance may make
it impossible for us to obtain similar patent claims in future patent applications. Currently, our patent portfolio contains claims of various types and scope, including methods of medical treatment. The presence of varying types of claims in our
patent portfolio significantly reduces, but may not eliminate, our exposure to potential validity challenges. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On May&nbsp;10, 2024, the USPTO issued a proposed rule
to change terminal disclaimer practice to add a new requirement for terminal disclaimers filed to obviate (overcome) nonstatutory double patenting. Under the proposed rule, to overcome double patenting a patentee would need to agree that a patent
with a terminal disclaimer will be enforceable only if the patent is not tied and has never been tied through one or more terminal disclaimers to a patent in which any claim has been finally held unpatentable or invalid over prior art. If this
proposed rule becomes a final rule, it could significantly limit our patent rights and the ability to enforce them. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For our U.S. patent applications, which contain
claims entitled to priority after March&nbsp;16, 2013, there is a greater level of uncertainty due to the Leahy-Smith Act. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way
patent applications will be prosecuted and may also affect patent litigation. The USPTO has promulgated regulations and developed procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law
associated with the Leahy-Smith Act, and in particular, the first to file provisions, did not come into effect until March&nbsp;16, 2013. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the
prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">An important change introduced by the Leahy-Smith Act is that, as of March&nbsp;16, 2013, the United States transitioned to a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system for deciding which party should be granted a patent when two or more </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">67 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
patent applications are filed by different parties claiming the same invention. This will require us to be cognizant going forward of the time from invention to filing of a patent application.
Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the
United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to either: (i)&nbsp;file any patent application related to verekitug or any other potential future product
candidates or (ii)&nbsp;invent any of the inventions claimed in our patents or patent applications. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Among some of the other changes introduced by the Leahy-Smith
Act are changes that limit where a patentee may file a patent infringement suit and new procedures providing opportunities for third parties to challenge any issued patent in the USPTO. Included in these new procedures is a process known as Inter
Partes Review (&#147;IPR&#148;), which has been generally used by many third parties since the enactment of the Leahy-Smith Act to invalidate patents. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard
in U.S. federal court necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate
the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in
a district court action. Additionally, the rights of review and appeal for IPR decisions is an area of law that is still developing. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Geopolitical actions in the
United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of patent applications and the maintenance, enforcement or defense of issued patents. For example, the United States and
foreign government actions related to Russia&#146;s invasion of Ukraine may limit or prevent filing, prosecution and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These
actions could result in abandonment or lapse of patents or patent applications, resulting in partial or complete loss of patent rights in Russia. If such an event were to occur, it could have a material adverse effect on our business. In addition, a
decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of
business or profit-making activities in the United States and other countries that Russia has deemed unfriendly without consent or compensation. Consequently, we would not be able to prevent third parties from practicing its inventions in Russia or
from selling or importing products made using its inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and growth prospects may be adversely affected. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, a European Unified Patent Court (&#147;UPC&#148;) came into force on June&nbsp;1, 2023. The UPC will be a common patent court to hear patent infringement
and revocation proceedings effective for member states of the European Union. This could enable third parties to seek revocation of a European patent in a single proceeding at the UPC rather than through multiple proceedings in each of the
jurisdictions in which the European patent is validated. Although we do not currently own any European patents, if we obtain such patents and applications in the future, any such revocation and loss of patent protection could have a material adverse
impact on our business and our ability to commercialize or license our technology and products. Moreover, the controlling laws and regulations of the UPC will develop over time and may adversely affect our ability to enforce or defend the validity
of any European patents obtained. We may decide to opt out from the UPC for any future European patent applications that we may file and any patents we may obtain. If certain formalities and requirements are not met, however, such European patents
and patent applications could be challenged for <FONT STYLE="white-space:nowrap">non-compliance</FONT> and brought under the jurisdiction of the UPC. We cannot be certain that future European patents and patent applications will avoid falling under
the jurisdiction of the UPC, if we decide to opt out of the UPC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">68 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position could be
harmed.</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to seeking patents for our technologies and verekitug or any other potential future product candidates, we also rely on trade secret
protection, as well as confidentiality agreements, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreements and assignment agreements with our employees, consultants and third parties, to protect our
<FONT STYLE="white-space:nowrap">know-how</FONT> and other confidential and proprietary information, especially where we do not believe patent protection is appropriate or obtainable. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">It is our policy to require our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors, and other
third parties to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements generally provide that all confidential information concerning our business or financial affairs developed
by or made known to an individual or entity during the course of that party&#146;s relationship with us are to be kept confidential and not disclosed to third parties, except in certain specified circumstances. In the case of employees, the
agreements also provide that all inventions conceived by the individual, and that are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary
information, are our exclusive property. In the case of consultants and other third-party service providers, the agreements provide us with certain rights to all inventions arising from the services provided to us by those individuals or entities.
However, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technologies and processes. Additionally, the assignment of intellectual property rights may
not be self-executing, or assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property.
We may not be able to obtain adequate remedies for any breaches of such agreements. Ultimately, enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time consuming, and the outcome is
unpredictable. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to contractual measures, we protect the confidential nature of our proprietary information through other appropriate precautions, such as
physical and technological security measures. However, trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to protect despite these precautions. These measures may not, for example, in the case of misappropriation of
a trade secret by an employee or third party with authorized access, provide adequate protection for our proprietary information. our security measures may not prevent an employee or consultant from misappropriating our trade secrets and providing
them to a competitor, and any recourse we might take against this type of misconduct may not provide an adequate remedy to protect our interests fully. In addition, our trade secrets may be independently developed by others in a manner that could
prevent us from receiving legal recourse. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any of that information was independently developed by a competitor, our
competitive position could be harmed. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we choose to go to court to stop a third party from using any of our trade secrets, we may incur substantial costs. In
addition, courts inside and outside the United States are sometimes less willing or unwilling to protect trade secrets. Even if we are successful, these types of lawsuits may consume, in addition to substantial costs, significant amounts of our time
and other resources. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and growth prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">69 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Third parties may assert that our employees, consultants, or advisors have wrongfully used or disclosed confidential
information or misappropriated trade secrets. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As is common in the biotechnology and pharmaceutical industries, we employ individuals that are currently or
were previously employed at universities, research institutions or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we employ measures to ensure that our employees, consultants, and
advisors do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that we or these individuals have inadvertently or otherwise used or disclosed
intellectual property, including trade secrets or other proprietary information, of any such individual&#146;s current or former employer. We may then be directly or indirectly involved in litigation proceedings to defend against these claims. If we
fail in defending against any such claims, in addition to potentially paying monetary damages, we may lose valuable intellectual property rights and/or personnel. Even if we are successful in defending against such claims, litigation could result in
substantial costs and distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if
securities analysts or investors perceive these results to be negative, that perception could have a substantial adverse effect on the price of our common stock. Ultimately, any such litigation could substantially increase our operating losses and
reduce our resources available for development activities, and we may not have sufficient financial or other resources to adequately engage in such litigation. For example, some of our competitors may be able to sustain the costs of such litigation
more effectively than we can because of their substantially greater financial resources. In any case, uncertainties resulting from the initiation and continuation of intellectual property litigation or other intellectual property related proceedings
could adversely affect our ability to compete in the marketplace. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Any trademarks we may obtain may be infringed or successfully challenged, resulting in harm
to our business.</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect to rely on trademarks as one means to distinguish verekitug or any other potential future product candidates that are approved for
marketing from the products of our competitors. However, our trademarks or trade names may be challenged, infringed, circumvented, or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these
trademarks and trade names, which we benefit from to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby
impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be allegations of trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that
incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our
business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and
diversions of resources and could adversely affect our business, financial condition, results of operations and growth prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, any proprietary name
we propose to use with verekitug or any other potential future product candidates in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a
review of proposed product names, including an evaluation of the potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in
an effort to identify a suitable proprietary product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties, and be acceptable to the FDA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">70 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Intellectual property rights do not necessarily address all potential threats. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately
protect our business or permit it to maintain our competitive advantage. For example: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">verekitug or any other potential future product candidates, if approved, may eventually become commercially available in
generic or biosimilar product forms; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">others may be able to make similar antibodies to verekitug or any other potential future product candidates that are not
covered by the claims of the patents that we license or may own in the future; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we, or current or future licensors or collaborators, might not have been the first to make the inventions covered by the
issued patent or pending patent application that we license or may own in the future, potentially resulting in the invalidation of such patents or refusal of such applications; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we, or current or future licensors or collaborators, might not have been the first to file patent applications covering
certain of our or their inventions; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we, or current or future licensors or collaborators, may fail to meet our obligations to the U.S. government regarding any
in licensed patents and patent applications funded by U.S. government grants, leading to the loss or unenforceability of patent rights; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing on our owned or licensed intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">it is possible that our pending patent applications or those that we may own or license in the future will not lead to
issued patents; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">it is possible that there are prior public disclosures that could invalidate our patents; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">it is possible that there are unpublished patent applications that may later issue with claims covering verekitug or any
other potential future product candidates or technology similar to ours; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">it is possible that our patents or patent applications omit individual(s) that should be listed as inventor(s) or include
individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable or result in a change in ownership; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">issued patents to which we hold rights may be held invalid, unenforceable, or narrowed in scope, including as a result of
legal challenges by our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the claims of our issued patents or patent applications, if and when issued, may not cover verekitug or any other potential
future product candidates or narrowly cover them in such a way that competitors may be able to design around to avoid infringement allegations; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the laws of foreign countries may not protect our proprietary rights or the proprietary rights of current or future
licensors or collaborators to the same extent as the laws of the United States; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the inventors of our patents or patent applications may become involved with competitors, develop products or processes
that design around our patents, or become hostile to it or the patents or patent applications on which they are named as inventors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our competitors might conduct research and development activities in countries where we do not have patent rights and then
use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">71 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we have engaged in scientific collaborations in the past and we intend to continue to do so in the future, and our
collaborators may develop adjacent or competing products that are outside the scope of our patents; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may not develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">verekitug or any other potential future product candidates we develop may be covered by third-party patents or other
exclusive rights; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the patents of others may prohibit or otherwise harm our business; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may choose not to file a patent in order to maintain certain trade secrets or
<FONT STYLE="white-space:nowrap">know-how,</FONT> and a third party may subsequently commercialize the technology and/or file a patent covering such intellectual property. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and growth prospects. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to this offering and ownership of our common stock </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>There
has been no prior public market for our common stock, and an active trading market may not develop or be sustained. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There has been no public market for our
common stock prior to this offering. The initial public offering price for our common stock was determined through negotiations among the underwriters and us and may vary from the market price of our common stock following this offering. An active
or liquid market in our common stock may not develop upon closing of this offering or, if it does develop, it may not be sustainable. The lack of an active market may impair the value of your shares, your ability to sell your shares at the time you
wish to sell them and the prices that you may obtain for your shares. An inactive market may also impair our ability to raise capital by selling our common stock and our ability to acquire other companies, products, or technologies by using our
common stock as consideration. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The price of our stock may be volatile, and you could lose all or part of your investment. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The trading price of our common stock following this offering is likely to be highly volatile and could be subject to wide fluctuations in response to various factors,
some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this section and elsewhere in this prospectus, these factors include: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the commencement, enrollment, completion or results of our current or future preclinical and clinical trials for verekitug
or any other potential future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any delay in identifying and advancing a clinical candidate for our other programs; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any delay in our regulatory filings for verekitug or any other potential future product candidates and any adverse
development or perceived adverse development with respect to the applicable regulatory authority&#146;s review of such filings, including without limitation the FDA&#146;s issuance of a &#147;refusal to file&#148; letter or a request for additional
information; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">adverse results or delays, suspensions or terminations in future preclinical studies or clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">adverse regulatory decisions, including failure to receive regulatory approval of verekitug or any other potential future
product candidates or the failure of a regulatory authority to accept data from preclinical studies or clinical trials conducted in other countries; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">72 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">changes in laws or regulations applicable to verekitug or any other potential future product candidates, including but not
limited to clinical trial requirements for approvals; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">adverse developments concerning our manufacturers; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our inability to establish collaborations, if needed; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our failure to commercialize verekitug or any other potential future product candidates, if approved;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">additions or departures of key scientific or management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">unanticipated serious safety concerns related to verekitug or any other potential future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">introduction of new products or services offered by us or our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our
competitors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to effectively manage our growth; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">actual or anticipated variations in quarterly operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our cash position; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the
public; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">publication of research reports about us or our industry, or verekitug or any other potential future product candidates in
particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">changes in the market valuations of similar companies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">changes in the structure of the healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">overall performance of the equity markets; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">sales of our common stock by us or our stockholders in the future; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">trading volume of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">changes in accounting practices, such as the adoption of a new accounting standard; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">ineffectiveness of our internal controls; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to
obtain patent protection for our technologies; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">significant lawsuits, including patent or stockholder litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">general political and economic conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">other events or factors, many of which are beyond our control. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">73 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the stock market in general, and the market for biopharmaceutical companies in particular, have experienced
extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our
actual operating performance. If the market price of our common stock after this offering does not exceed the initial public offering price, you may not realize any return on your investment in us and may lose some or all of your investment. In the
past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#146;s securities. This type of litigation, if instituted, could result in substantial costs and a
diversion of management&#146;s attention and resources. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our operating results may fluctuate significantly, which makes our future operating results difficult
to predict and could cause our operating results to fall below expectations. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our quarterly and annual operating results may fluctuate significantly, due to
a variety of factors, many of which are outside of our control and may be difficult to predict, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing and cost of, and level of investment in, research, development and, if approved, commercialization activities
relating to verekitug or any other potential future product candidates, which may change from time to time; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing and status of enrollment for clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the cost of manufacturing verekitug or any other potential future product candidates, as well as building out our supply
chain, which may vary depending on the quantity of production and the terms of our agreements with manufacturers; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">expenditures that we may incur to acquire, develop or commercialize additional product candidates and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">timing and amount of any milestone, royalty or other payments due under any collaboration or license agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">future accounting pronouncements or changes in our accounting policies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing and success or failure of preclinical studies and clinical trials for verekitug or any other potential future
product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing of receipt of approvals for verekitug or any other potential future product candidates from regulatory
authorities in the United States and internationally; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">exchange rate fluctuations; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">coverage and reimbursement policies with respect to verekitug or any other potential future product candidates, if
approved, and potential future drugs that compete with our products; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the level of demand for verekitug or any other potential future product candidates, if approved, which may vary
significantly over time. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and
annual operating results. As a result, comparing our operating results on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> basis may not be meaningful. Investors should not rely on our past results
as an indication of our future performance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">74 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial
analysts or investors for any period. If our future revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if any forecasts we provide to the market are below the
expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume
could decline. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us
or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no securities or industry analysts commence coverage of our company, the trading price for our stock would likely be negatively
impacted. In the event securities or industry analysts initiate coverage, if one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or
more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our executive officers, directors, principal stockholders and their respective affiliates own a significant percentage of our stock and will be able to exert
significant control over matters subject to stockholder approval. </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on the beneficial ownership of our common stock as of August&nbsp;1, 2024, prior
to this offering, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 92.8% of our voting stock and, upon the completion of this offering, that same group
will hold approximately 69.4% of our outstanding voting stock (assuming no exercise of the underwriters&#146; option to purchase additional shares, no exercise of outstanding options and no purchases of shares in this offering by any of this group),
in each case assuming the conversion of all outstanding shares of our preferred stock into shares of our common stock. As a result, these stockholders, if acting together, will continue to have significant influence over the outcome of corporate
actions requiring stockholder approval, including the election of directors, amendment of our organizational documents, any merger, consolidation or sale of all or substantially all of our assets and any other significant corporate transaction. In
addition, certain of our principal stockholders, including Maruho Deutschland GmbH, entities affiliated with OrbiMed, AI Upstream LLC, Decheng Capital Global Life Sciences Fund IV, L.P., entities affiliated with Enavate Sciences, and entities
affiliated with Venrock Healthcare Capital Partners, have designated certain members of our board of directors. The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders
could delay or prevent a change of control of our company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of
our company or our assets and might affect the prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors&#146; perception that conflicts
of interest may exist or arise. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Future sales of our common stock in the public market could cause our common stock price to fall. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our common stock price could decline as a result of sales of a large number of shares of common stock after this offering or the perception that these sales could occur.
These sales, or the possibility that these sales may occur, might also make it more difficult for us to sell equity securities in the future at a time and price that we deem appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">75 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the completion of this offering, 48,841,695&nbsp;shares of common stock will be outstanding (or
50,716,695&nbsp;shares if the underwriters exercise their option to purchase additional shares from us in full), based on the number of shares outstanding as of June&nbsp;30, 2024. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">All shares of common stock expected to be sold in this offering will be freely tradable without restriction or further registration under the Securities Act of 1933, as
amended (&#147;Securities Act&#148;) unless held by our &#147;affiliates&#148; as defined in Rule 144 under the Securities Act. The resale of the remaining 36,341,695&nbsp;shares, or 74.4% of our outstanding shares of common stock following this
offering, is currently prohibited or otherwise restricted, subject to certain limited exceptions, as a result of securities law provisions, market standoff agreements entered into by certain of our stockholders with us or <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements entered into by our stockholders with the underwriters in connection with this offering. However, subject to applicable securities law restrictions, these shares will be able to be sold in the
public market beginning on the 181st day after the date of this prospectus. Shares issued upon the exercise of stock options outstanding under our equity incentive plans or pursuant to future awards granted under those plans will become available
for sale in the public market to the extent permitted by the provisions of applicable vesting schedules, market <FONT STYLE="white-space:nowrap">stand-off</FONT> agreements and/or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, as well
as Rules 144 and 701 under the Securities Act. For more information, see the section titled &#147;Shares eligible for future sale&#148; included elsewhere in this prospectus. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the completion of this offering, the holders of approximately 34,579,952&nbsp;shares, or 70.8% of our outstanding shares following this offering, of our common
stock will have rights, subject to some conditions, to require us to file registration statements covering the sale of their shares or to include their shares in registration statements that we may file for ourselves or our other stockholders. We
also intend to register the offer and sale of all shares of common stock that we may issue under our equity compensation plans. Once we register the offer and sale of shares for the holders of registration rights and shares that may be issued under
our equity incentive plans, these shares will be able to be sold in the public market upon issuance, subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described in the section titled &#147;Underwriting&#148; included
elsewhere in this prospectus. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, in the future, we may issue additional shares of common stock, or other equity or debt securities convertible into
common stock, in connection with a financing, acquisition, employee arrangement, or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and could cause the price of our common stock to decline. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We will have broad discretion in how we use the proceeds of this offering and may not use these proceeds effectively, which could affect our results of operations
and cause our stock price to decline. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will have considerable discretion in the application of the net proceeds of this offering, including for any of the
purposes described in the section of this prospectus titled &#147;Use of proceeds,&#148; and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are being used appropriately. As a result,
investors will be relying upon management&#146;s judgment with only limited information about our specific intentions for the use of the net proceeds of this offering. We may use the net proceeds for purposes that do not yield a significant return
or any return at all for our stockholders. In addition, pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If you purchase shares of our common stock in our initial public offering, you will experience substantial and immediate dilution. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The assumed initial public offering price of $16.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, is substantially
higher than the pro forma as adjusted net tangible book </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">76 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
value per share of our outstanding common stock immediately following the completion of this offering. If you purchase shares of common stock in this offering, you will experience substantial and
immediate dilution in the pro forma as adjusted net tangible book value per share of $7.48 per share as of June&nbsp;30, 2024. That is because the price that you pay will be substantially greater than the pro forma as adjusted net tangible book
value per share of the common stock that you acquire. This dilution is due in large part to the fact that our earlier investors paid substantially less than the initial public offering price when they purchased their shares of our capital stock. You
will experience additional dilution if the underwriters exercise their option to purchase additional shares in this offering, when those holding stock options exercise their right to purchase common stock under our equity incentive plans, upon the
vesting of outstanding restricted stock awards or when we otherwise issue additional shares of common stock. For additional details see the section titled &#147;Dilution&#148; included elsewhere in this prospectus. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Participation in this offering by our existing stockholders and/or their affiliated entities may reduce the public float for our common stock. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To the extent our existing stockholders who are our affiliates or their affiliated entities participate in this offering, such purchases would reduce the <FONT
STYLE="white-space:nowrap">non-affiliate</FONT> public float of our common stock after this offering, which is the number of shares of common stock that are not held by our officers, directors and affiliated stockholders. A reduction in the public
float could reduce the number of shares of common stock that can be traded at any given time, which could adversely impact the liquidity of our common stock and depress the price at which you may be able to sell shares of common stock purchased in
this offering. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our issuance of additional capital stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will
dilute all other stockholders. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect to issue additional capital stock in the future that will result in dilution to all other stockholders. We expect
to grant equity awards to employees, directors and consultants under our stock incentive plans. We may also raise capital through equity financings in the future. As part of our business strategy, we may acquire or make investments in complementary
companies, products or technologies and issue equity securities to pay for any such acquisition or investment. Any such issuances of additional capital stock may cause stockholders to experience significant dilution of their ownership interests and
the per share value of our common stock to decline. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We do not currently intend to pay dividends on our common stock and, consequently, our stockholders&#146;
ability to achieve a return on their investment will depend on appreciation of the value of our common stock. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have never declared or paid cash dividends
on our common stock. We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business. We do not intend to declare or pay any cash dividends on our capital
stock in the foreseeable future. As a result, any investment return on our common stock will depend upon increases in the value for our common stock, which is not certain. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more
difficult and may prevent attempts by our stockholders to replace or remove our current directors and members of management. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our third amended and restated
certificate of incorporation, which will become effective immediately prior to the completion of this offering, and amended and restated bylaws, which will become effective upon the effectiveness of the registration statement of which this
prospectus forms a part, will contain provisions that may discourage, delay or prevent a merger, acquisition or other change in control of our company that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">77 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that
investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team,
these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establish a classified board of directors such that only one of three classes of directors is elected each year;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">allow the authorized number of our directors to be changed only by resolution of our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">limit the manner in which stockholders can remove directors from our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and
nominations to our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our
stockholders by written consent; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">limit who may call stockholder meetings; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a
&#147;poison pill&#148; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">require the approval of not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes that all our
stockholders would be entitled to cast to amend or repeal specified provisions of our third amended and restated certificate of incorporation or amended and restated bylaws. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law (the &#147;DGCL&#148;),
which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding
voting stock, unless the merger or combination is approved in a prescribed manner. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our amended and restated bylaws that will become effective upon the
effectiveness of this registration statement designate certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#146; ability to obtain
a favorable judicial forum for disputes with us or our directors, officers, or employees. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our amended and restated bylaws that will become effective upon
the effectiveness of the registration statement of which this prospectus forms a part provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any
state law claims for (i)&nbsp;any derivative action or proceeding brought on our behalf, (ii)&nbsp;any action asserting a claim of breach of, or a claim based on, fiduciary duty owed by any of our current or former directors, officers, and employees
to us or our stockholders, (iii)&nbsp;any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our third amended and restated certificate of incorporation or our amended and restated bylaws (including
the interpretation, validity or enforceability thereof), or (iv)&nbsp;any action asserting a claim that is governed by the internal affairs doctrine (the &#147;Delaware Forum Provision&#148;). The Delaware Forum Provision will not apply to any
causes of action arising under the Securities Act or the Exchange Act. Our amended and restated bylaws further provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States
shall be the sole and exclusive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">78 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
forum for resolving any complaint asserting a cause or causes of action arising under the Securities Act (the &#147;Federal Forum Provision&#148;). In addition, our amended and restated bylaws
provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing provisions; provided, however, that stockholders cannot and will not be deemed
to have waived our compliance with the federal securities laws and the rules and regulations thereunder. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Delaware Forum Provision and the Federal Forum
Provision in our bylaws may impose additional litigation costs on stockholders in pursuing any such claims. Additionally, the forum selection clauses in our bylaws may limit our stockholders&#146; ability to bring a claim in a judicial forum that
they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. In
addition, while the Delaware Supreme Court and others state courts have upheld the validity of federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court, there is uncertainty as to whether
other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The Federal Forum Provision may also impose additional
litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the federal district courts of the United States may also reach different judgments or results than
would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may not be able to satisfy listing requirements of Nasdaq or obtain or maintain a listing of our common stock on Nasdaq. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If our common stock is listed on Nasdaq, we must meet certain financial and liquidity criteria to maintain such listing. If we violate Nasdaq&#146;s listing
requirements, our common stock may be delisted. If we fail to meet any of Nasdaq&#146;s listing standards, our common stock may be delisted. In addition, our board of directors may determine that the cost of maintaining our listing on a national
securities exchange outweighs the benefits of such listing. A delisting of our common stock from Nasdaq may materially impair our stockholders&#146; ability to buy and sell our common stock and could have an adverse effect on the market price of,
and the efficiency of the trading market for, our common stock. The delisting of our common stock could significantly impair our ability to raise capital and the value of your investment. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Other general risks </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Unfavorable global economic and geopolitical
conditions could adversely affect our business, financial condition, stock price, and results of operations. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The global credit and financial markets have
experienced extreme volatility and disruptions (including as a result of actual or perceived changes in interest rates, inflation and macroeconomic uncertainties), which has included severely diminished liquidity and credit availability, declines in
consumer confidence, declines in economic growth, high inflation, uncertainty about economic stability, global supply chain disruptions, and increases in unemployment rates. The financial markets and the global economy may also be adversely affected
by the current or anticipated impact of the 2024 presidential election in the United States, military conflict, including the ongoing conflicts between Russia and Ukraine, and Israel and Hamas, terrorism, or other geopolitical events. Sanctions
imposed by the United States and other countries in response to such conflicts, including the one in Ukraine, may also continue to adversely impact the financial markets and the global economy, and any economic countermeasures by the affected
countries or others could exacerbate market and economic instability. There can be no assurance that further deterioration in credit and financial markets and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">79 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
confidence in economic conditions will not occur. A severe or prolonged economic downturn could result in a variety of risks to our business, including a decrease in the demand for verekitug or
any other potential future product candidates and in our ability to raise additional capital when needed on acceptable terms, if at all. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There are also current
geopolitical tensions with China that may affect our operations. For example, there have been Congressional legislative proposals, such as the bill titled the BIOSECURE Act, which would, among other things, prohibit U.S. federal funding in
connection with biotechnology equipment or services produced or provided by certain named Chinese &#147;biotechnology companies of concern&#148; (which includes WuXi) and loans and grants to, and federal contracts with any entity that uses
biotechnology equipment or services from one of these entities. The legislation also gives the federal government the authority to name additional &#147;biotechnology companies of concern&#148; that are engaged in research activities with the
Chinese government and that pose a risk of U.S. national security. The most recent version of the BIOSECURE Act which would delay the application of the BIOSECURE Act&#146;s provisions (1)&nbsp;until January&nbsp;1, 2032, with respect to
biotechnology equipment and services provided or produced by WuXi and other named biotechnology companies of concern under a contract or agreement entered before the effective date of the legislation and (2)&nbsp;for a period of five years after the
identification of new biotechnology companies of concern, with respect to biotechnology equipment and services provided or produced by an entity that the government identifies in the future as a biotechnology company of concern. Any additional
executive action, legislative action or potential sanctions with China could materially impact one of our current manufacturing partners, WuXi, and our agreement with them. We continue to assess the legislation as it develops to determine the
effect, if any, on our contractual relationships. Furthermore, any disruptions to our supply chain as a result of unfavorable global economic conditions, including due to geopolitical conflicts or public health crises, could negatively impact the
timely execution of our ongoing and future clinical trials. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, current inflationary trends in the global economy may impact salaries and wages, costs of
goods and transportation expenses, among other things, and recent and potential future disruptions in access to bank deposits or lending commitments due to bank failures may create market and economic instability. We cannot anticipate all of the
ways in which the foregoing, and the current economic climate and financial market conditions generally, could adversely impact our business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We maintain the
majority of our cash and cash equivalents in accounts with major U.S. and multi-national financial institutions, and our deposits at certain of these institutions may exceed insured limits. Market conditions and changes in financial regulations and
policies can impact the viability of these institutions. In the event of failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we would be able to access uninsured funds in a
timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect our business and financial position. In addition, changes in regulations governing financial institutions are beyond our control and difficult
to predict; consequently, the impact of such changes on our business and results of operations is difficult to predict and may have an adverse effect on us. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We, or the third parties upon whom we depend, may be adversely affected by natural disasters, public health crises or other business interruptions and our
business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Natural disasters or public health crises could
severely disrupt our operations, and have a material adverse impact on our business, financial condition, results of operations and growth prospects. If a natural disaster, power outage, public health crisis or other event occurred that prevented us
from conducting our clinical trials, releasing clinical trial results or delaying our ability to obtain regulatory approval for verekitug or any other potential future product candidates, it may be difficult or, in certain cases, impossible for us
to continue our business for a substantial period of time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">80 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are eligible to be treated as an &#147;emerging growth company&#148; and a &#147;smaller reporting company&#148;
and our election of reduced reporting requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act (&#147;JOBS Act&#148;). For as long as we continue to be an emerging
growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports, proxy
statements and registration statements; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval
of any golden parachute payments not previously approved; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">being permitted to provide only two years of audited financial statements in addition to any required unaudited interim
financial statements and a correspondingly reduced &#147;Management&#146;s discussion and analysis of financial condition and results of operations&#148; disclosure in this prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an exemption from compliance with the auditor attestation requirements of Section&nbsp;404 in the assessment of our
internal control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an exemption from compliance with the requirements of the Public Company Accounting Oversight Board regarding the
communication of critical audit matters in the auditor&#146;s report on the financial statements. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may take advantage of these exemptions for up
to five years or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company on the date that is the earliest of (i)&nbsp;the last day of the fiscal year in which we have total annual gross
revenue of $1.235&nbsp;billion; (ii)&nbsp;the last day of our fiscal year following the fifth anniversary of the date of the completion of this offering; (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt during any three-year period before that time; or (iv)&nbsp;the date on which we are deemed to be a &#147;large accelerated filer&#148;, which would occur if the aggregate market value of our
equity securities held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700.0&nbsp;million as of the last business day of our most recently completed second fiscal quarter. For so long as we remain an emerging growth company, we
are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the JOBS Act provides that an emerging growth company can also take advantage of an extended transition period for complying with new or revised accounting
standards until such time as those standards apply to private companies. We have elected to avail ourselves of this exemption from new or revised accounting standards, and therefore we will not be subject to the same requirements to adopt new or
revised accounting standards as other public companies that are not emerging growth companies. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even after we no longer qualify as an emerging growth company, we
could still qualify as a &#147;smaller reporting company,&#148; which would allow us to take advantage of many of the same exemptions from disclosure requirements and reduced disclosure obligations regarding executive compensation in this prospectus
and our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a
less active trading market for our common stock and our share price may be more volatile. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">81 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We will incur significant increased costs as a result of operating as a public company, and our management will be
required to devote substantial time to new compliance initiatives and corporate governance practices. </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As a public company, we will incur significant
legal, accounting and other expenses that we did not incur as a private company. We will be subject to the reporting requirements of the Exchange Act, which will require, among other things, that we file with the Securities and Exchange Commission
(&#147;SEC&#148;) annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act of 2002, as amended (the &#147;Sarbanes-Oxley Act&#148;), as well as rules subsequently adopted by the
SEC and The Nasdaq Global Market to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial reporting controls and
changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act (the &#147;Dodd-Frank Act&#148;) was enacted. There are significant corporate governance and executive compensation
related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#147;say on pay&#148; and proxy access. Recent legislation permits emerging growth companies to implement many of these
requirements over a longer period and up to five years from the pricing of this offering. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new
regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more
time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have an adverse effect on our business. The increased costs will decrease our net income or increase our
net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director
and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The
impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we fail to establish and maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial
results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Ensuring that we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis
is a costly and time-consuming effort that needs to be reevaluated frequently. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements in accordance with generally accepted accounting principles. In connection with this offering, we intend to begin the process of documenting, reviewing and improving our internal controls and procedures for compliance with
Section&nbsp;404 of the Sarbanes-Oxley Act, which will require annual management assessment of the effectiveness of our internal control over financial reporting. Any failure to implement required new or improved controls, or difficulties
encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section&nbsp;404, or any subsequent testing by our independent registered public accounting
firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">82 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose
confidence in our reported financial information, which could have a negative effect on the trading price of our stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will be required to disclose changes made
in our internal controls and procedures on a quarterly basis and our management will be required to assess the effectiveness of these controls annually. However, for as long as we are an emerging growth company or a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section&nbsp;404(b) of
the Sarbanes-Oxley Act. We could be an emerging growth company for up to five years following completion of this initial public offering. An independent assessment of the effectiveness of our internal controls over financial reporting could detect
problems that our management&#146;s assessment might not. Undetected material weaknesses in our internal controls over financial reporting could lead to restatements of our financial statements and require us to incur the expense of remediation.
</P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the completion of this offering, we will become subject to the periodic reporting requirements of the Exchange Act. We must design our disclosure controls and
procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized, and reported within the time periods specified
in the rules and forms of the SEC. We believe that any disclosure controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These
inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new
relationship or arrangement causing us to fail to make a required related party transaction disclosure. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized
override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our ability to use our net operating loss carryforwards and other tax attributes may be limited. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2023, we had federal and state net operating loss (&#147;NOLs&#148;) carryforwards of $25.0&nbsp;million and $27.6&nbsp;million, respectively.
The federal NOLs are not subject to expiration and are limited in utilization to 80% of our taxable income and the state NOLs begin to expire in 2041. As of December&nbsp;31, 2023, we had $0.8&nbsp;million of federal and state research and
development credits, which will begin to expire in 2043 and 2037, respectively. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a
corporation undergoes an &#147;ownership change,&#148; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by &#147;5&nbsp;percent shareholders&#148; over a three-year period, the corporation&#146;s
ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes (such as research and development tax credits) to offset its post-change income or taxes may be
limited. A corporation that experiences an ownership change will generally be subject to an annual limitation on the use of its <FONT STYLE="white-space:nowrap">pre-ownership</FONT> change NOLs equal to the value of the corporation immediately
before the ownership change, multiplied by the long-term <FONT STYLE="white-space:nowrap">tax-exempt</FONT> rate (subject to certain adjustments). We may have experienced ownership changes in the past and may experience ownership changes as a result
of our acquisitions of assets and as a result of this offering and/or subsequent shifts in our stock ownership (some of which are outside our control). There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs by
federal or state taxing authorities or other unforeseen reasons, our existing NOLs could expire or otherwise be unavailable to reduce future income tax liabilities. As a result, our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">83 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
ability to use our <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs and tax credits to offset future taxable income, if any, could be subject to limitations. Similar provisions of state
tax law may also apply. As a result, even if we attain profitability, we may be unable to use a material portion of our NOLs and tax credits. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Changes in tax
law could adversely affect our business and financial condition. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The rules dealing with U.S. federal, state, and local income taxation are constantly under
review by persons involved in the legislative process and by the U.S. Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application), including with respect to net operating losses and
research and development tax credits, could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in tax laws could have a
material adverse effect on our business, cash flow, financial condition or results of operations. We urge investors to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an investment in our
common stock. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may become involved in securities class action litigation that could divert management&#146;s attention and harm our business, and insurance
coverage may not be sufficient to cover all costs and damages. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the past, securities class action litigation has often followed certain significant
business transactions, such as the sale of a company or announcement of any other strategic transaction, or the announcement of negative events, such as negative results from clinical trials. These events may also result in or be concurrent with
investigations by the SEC. We may be exposed to such litigation or investigation even if no wrongdoing occurred. Litigation and investigations are usually expensive and divert management&#146;s attention and resources, which could adversely affect
our business and cash resources and our ability to consummate a potential strategic transaction or the ultimate value our stockholders receive in any such transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">84 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc843142_3"></A>Special note regarding forward-looking statements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus, including the sections titled &#147;Prospectus summary,&#148; &#147;Risk factors,&#148; &#147;Management&#146;s discussion and analysis of financial
condition and results of operations,&#148; and &#147;Business,&#148; contains express or implied forward-looking statements that are based on our management&#146;s belief and assumptions and on information currently available to our management.
These statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially
different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements in this prospectus include, but are not limited to, statements about: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the initiation, timing, progress, and results of our planned and future clinical trials for verekitug, including our
ongoing Phase 2 clinical trials in severe asthma and CRSwNP and the planned initiation of an additional development program in COPD; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to replicate positive results from earlier preclinical studies or clinical trials conducted by us or third
parties in current or future clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to demonstrate that verekitug and any potential future product candidates are safe and effective for their
proposed indications and our expectations around their beneficial characteristics and therapeutic effects; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to advance verekitug and any potential future product candidates through applicable regulatory approval
processes, including timing of INDs and final FDA approval of verekitug or any future product candidate; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our estimates of the number of patients that we will enroll and our ability to initiate, recruit and enroll patients in and
conduct and successfully complete our clinical trials at the pace we project; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the implementation of our business model and strategic plans; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to rely on third-party manufacturers and successfully manufacture verekitug for preclinical use, for clinical
trials and on a larger scale for commercial use, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to commercialize verekitug, if approved, and obtain favorable pricing and reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the size and growth potential of the markets for verekitug and our ability to serve those markets; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to realize the benefits of collaborations for the development and commercialization of verekitug or any other
potential future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to maintain, expand and protect our intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">developments relating to our competitors and our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">existing regulations and regulatory developments in the United States and other jurisdictions; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">general economic, industry, and market conditions, including rising interest rates and inflation; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to attract, hire, and retain our key personnel and additional qualified personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our anticipated use of our existing cash, cash equivalents and short-term investments and the net proceeds from this
offering; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">85 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">other risks and uncertainties, including those listed under the caption &#147;Risk factors.&#148; </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In some cases, forward-looking statements can be identified by terminology such as &#147;may,&#148; &#147;should,&#148; &#147;expects,&#148; &#147;intends,&#148;
&#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential,&#148; &#147;continue,&#148; or the negative of these terms or other comparable terminology. These statements are only
predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results.
Factors that may cause actual results to differ materially from those implied or projected by forward-looking statements include, among other things, those listed under the section titled &#147;Risk factors&#148; and elsewhere in this prospectus. If
one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking
statement is a guarantee of future performance. You should read this prospectus and the documents that we reference in this prospectus and have filed with the SEC as exhibits to the registration statement, of which this prospectus is a part,
completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by
applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this prospectus. You should, however, review the factors and risks and other information we describe
in the reports we will file from time to time with the Securities and Exchange Commission (&#147;SEC&#148;) after the date of this prospectus. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition,
statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such
information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available
relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">86 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc843142_4"></A>Market, industry and other data </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus contains estimates, statistical data and other information concerning our industry, market and competitive position, including data regarding the
estimated size and patient populations of those and related markets, existing therapeutic options and the incidence of certain medical conditions, from our own internal estimates and research, as well as from independent market research, industry
and general publications and surveys, governmental agencies and publicly available information in addition to research, surveys and studies conducted by third parties. Internal estimates are derived from publicly available information released by
industry analysts and third-party sources, our internal research and our industry experience, and are based on assumptions made by us based on such data and our knowledge of our industry and market, which we believe to be reasonable. In some cases,
we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is
derived from the same sources, unless otherwise expressly stated or the context otherwise requires. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While we believe the industry, market and competitive
position data included in this prospectus is reliable and based on reasonable assumptions, such data involve risks and uncertainties and are subject to change based on various factors, including those discussed in the section titled &#147;Risk
factors&#148; included elsewhere in this prospectus. These and other factors could cause results to differ materially from those expressed in the estimates and observations made by the independent parties or by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">87 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc843142_5"></A>Use of proceeds </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We estimate that our net proceeds from the sale of shares of our common stock in this offering will be approximately $182.0 million, or $209.9&nbsp;million if the
underwriters exercise their option to purchase additional shares in full, assuming an initial public offering price of $16.00 per share, the midpoint of the estimated offering price range set forth on the cover page of this prospectus, and after
deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each $1.00 increase or decrease in the assumed initial
public offering price of $16.00 per share, the midpoint of the estimated offering price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, our net proceeds from this offering by $11.6 million, assuming
the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each
1.0&nbsp;million share increase or decrease in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase or decrease our net proceeds from this offering by $14.9&nbsp;million, assuming no change in the
assumed initial public offering price of $16.00 per share, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The principal purposes of this offering are to create a public market for our common stock and thereby facilitate future access to the public equity markets, increase
our visibility in the marketplace and obtain additional capital. We currently intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and short-term investments, for the following: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">approximately $150.0 million to advance verekitug through the completion of our multi-national, placebo-controlled,
randomized Phase 2 clinical trial in severe asthma, and to initiate subsequent Phase 3 clinical development; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">approximately $40.0 million to advance verekitug through the completion of our multi-national, placebo-controlled,
randomized Phase 2 clinical trial in chronic rhinosinusitis with nasal polyps (&#147;CRSwNP&#148;), and to initiate subsequent Phase 3 clinical development; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">approximately $80.0&nbsp;million to expand the development of verekitug for the treatment of chronic obstructive pulmonary
disease (&#147;COPD&#148;), including for external clinical trial-related costs for the initiation and ongoing conduct of a Phase 2 clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">approximately $50.0&nbsp;million in external costs associated with verekitug drug substance, drug product, process
development or other manufacturing activities to support the continued development of verekitug in severe asthma, CRSwNP, COPD and potential future additional indications; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the remainder for additional continued research and development efforts relating to verekitug, including expansion into
potential additional indications, as well as for working capital and other general corporate purposes. </P></TD></TR></TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on our current plans, we believe
that our existing cash, cash equivalents and short-term investments, together with the net proceeds from this offering, will be sufficient to enable us to fund our operating expenses and capital expenditure requirements through mid-2027. We have
based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. We do not have any committed external source of funds. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions. As of the date of this
prospectus, we cannot predict with certainty all of the particular </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">88 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
uses for the net proceeds to be received upon the completion of this offering or the amounts that we will actually spend on the uses set forth above and we expect that we will require additional
funds in order to fully accomplish the specified uses of the proceeds of this offering. We may also use a portion of the net proceeds to <FONT STYLE="white-space:nowrap">in-license,</FONT> acquire, or invest in complementary businesses or
technologies to continue to build our pipeline, research and development capabilities and our intellectual property position, although we currently have no agreements, commitments, or understandings with respect to any such transaction. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Due to the many inherent uncertainties in the development of verekitug and other potential future product candidates, the amounts and timing of our actual expenditures
may vary significantly depending on numerous factors, including the progress of our research and development, the timing of patient enrollment and evolving regulatory requirements, the timing and success of preclinical studies, our ongoing clinical
studies or clinical studies we may commence in the future, the timing of regulatory submissions, any strategic alliances that we may enter into with third parties for verekitug and other potential future product candidates, or strategic
opportunities that become available to us, and any unforeseen cash needs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pending our use of the net proceeds from this offering, we intend to invest the net
proceeds in a variety of capital preservation instruments, including direct or guaranteed obligations of the U.S. government, money market fund shares, and bank accounts that are insured by the Federal Deposit Insurance Corporation. We cannot
predict whether the proceeds invested will yield a favorable return. Our management will retain broad discretion in the application of the net proceeds we receive from our initial public offering, and investors will be relying on the judgment of our
management regarding the application of the net proceeds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">89 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc843142_6"></A>Dividend policy </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have never declared or paid cash dividends on our capital stock. We do not intend to pay cash dividends to our stockholders in the foreseeable future. We currently
intend to retain all available funds and any future earnings to fund the growth and development of our business. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on then-existing
conditions, including our financial condition, operating results, contractual restrictions, capital requirements, general business conditions and other factors that our board of directors may deem relevant. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, our ability to pay cash dividends on our capital stock in the future may be limited by the terms of any future debt or preferred securities we issue or any
credit facilities we enter into. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">90 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc843142_7"></A>Capitalization </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth our cash, cash equivalents and short-term investments and our capitalization as of June&nbsp;30, 2024: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">on a pro forma basis, to give effect to (i)&nbsp;the automatic conversion of all 31,764,693 outstanding shares of our
Series&nbsp;A and Series&nbsp;B redeemable convertible preferred stock in the aggregate, as of June&nbsp;30, 2024, into 33,321,149&nbsp;shares of common stock prior to the completion of this offering and (ii)&nbsp;the filing and effectiveness of our
third amended and restated certificate of incorporation, which will occur immediately prior to the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">on a pro forma as adjusted basis to give further effect to (i)&nbsp;the pro forma adjustments set forth above and
(ii)&nbsp;the issuance and sale of 12,500,000 shares of common stock in this offering at an assumed initial public offering price of $16.00 per share, which is the midpoint of the estimated offering price range set forth on the cover page of this
prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The pro forma and
pro forma as adjusted information below is illustrative only, and our capitalization following the completion of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing.
You should read the information in this table together with our consolidated financial statements and the related notes and &#147;Management&#146;s discussion and analysis of financial condition and results of operations&#148; included elsewhere in
this prospectus. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="12" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of June&nbsp;30, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(in thousands, except share and per share amounts)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Pro&nbsp;forma</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Pro&nbsp;forma<BR>as&nbsp;adjusted<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash, cash equivalents and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">235,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">235,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">417,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Redeemable convertible preferred stock (Series A, B), $0.001 par value; 31,764,693 shares authorized,
31,764,693 shares issued and outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">380,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Stockholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Preferred stock, $0.001 par value, no shares authorized, issued or outstanding, actual; 10,000,000 shares
authorized and no shares issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Common stock, $0.001 par value, 40,684,346 shares authorized, 3,020,546&nbsp;shares issued and outstanding,
actual; 500,000,000 shares authorized, 36,341,695&nbsp;shares issued and outstanding, pro forma; 500,000,000 shares authorized, 48,841,695&nbsp;shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">387,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">569,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(153,546</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(153,546</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(153,546</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(146,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">416,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">234,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">234,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">416,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="12" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:8pt">Each $1.00 increase or decrease in the assumed initial public offering price of $16.00&nbsp;per share, which is the midpoint
of the estimated offering price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, the pro forma as </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">91 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:8pt">
adjusted amount of each of cash, cash equivalents and short-term investments, total stockholders&#146; (deficit) equity and total capitalization by $11.6&nbsp;million, assuming that the number of
shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase or decrease of
1.0&nbsp;million shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase or decrease, as applicable, the pro forma as adjusted amount of each of cash, cash equivalents and short-term
investments, total stockholders&#146; (deficit) equity and total capitalization by $14.9&nbsp;million, assuming no change in the assumed initial public offering price per share and after deducting estimated underwriting discounts and commissions and
estimated offering expenses payable by us. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The number of shares of our common stock in the table above is based on 36,341,695 shares of common
stock outstanding as of June&nbsp;30, 2024, after giving effect to the automatic conversion of all outstanding shares of our redeemable convertible preferred stock as of June&nbsp;30, 2024 into the aggregate of 33,321,149&nbsp;shares of common stock
immediately prior to the completion of this offering, and excludes: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">6,224,230&nbsp;shares of common stock issuable upon the exercise of outstanding stock options as of June&nbsp;30, 2024
under our 2021 Stock Option and Grant Plan (&#147;2021 Plan&#148;), with a weighted-average exercise price of $4.96 per share; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">74,027 shares of common stock reserved for future issuance as of June&nbsp;30, 2024 under the 2021 Plan, which will cease
to be available for issuance at the time that our 2024 Stock Option and Incentive Plan (&#147;2024 Plan&#148;) becomes effective (which includes options to purchase an aggregate of 35,666 shares of our common stock, at a weighted-average exercise
price of $10.62 per share, that were granted subsequent to June 30, 2024); </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">3,180,000&nbsp;shares of our common stock reserved for future issuance under our 2024 Plan, which will become effective on
the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2024 Plan and any
shares underlying outstanding stock awards granted under the 2021 Plan that expire or are repurchased, forfeited, cancelled, or withheld; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">488,467&nbsp;shares of common stock reserved for future issuance under our 2024 Employee Stock Purchase Plan
(&#147;ESPP&#148;), which will become effective on the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of common stock
reserved for future issuance under the ESPP. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">92 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc843142_8"></A>Dilution </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the initial public
offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our historical net tangible book value as of June&nbsp;30, 2024 was a deficit of $148.0&nbsp;million, or $(48.98)&nbsp;per share of our common stock. Our historical net
tangible book value (deficit) is the amount of our total tangible assets less our total liabilities, excluding the deferred offering costs, and the carrying values of our redeemable convertible preferred stock, which is not included within
stockholders&#146; deficit. Our historical net tangible book value per share represents historical net tangible book value (deficit) divided by the number of shares of our common stock outstanding as of June&nbsp;30, 2024. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our pro forma net tangible book value as of June&nbsp;30, 2024 was $232.9&nbsp;million, or $6.41&nbsp;per share of our common stock. Pro forma net tangible book value
represents the amount of our total tangible assets less our total liabilities, excluding the deferred offering costs, after giving effect to the automatic conversion of all 31,764,693 outstanding shares of our Series&nbsp;A and Series&nbsp;B
redeemable convertible preferred stock in the aggregate into 33,321,149 shares of common stock prior to the completion of this offering. Pro forma net tangible book value per share represents pro forma net tangible book value divided by the total
number of shares outstanding as of June&nbsp;30, 2024, after giving effect to the pro forma adjustments described above. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">After giving further effect to our issuance
and sale of&nbsp;shares of our common stock in this offering at an assumed initial public offering price of $16.00&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of June&nbsp;30, 2024 would have been $416.3&nbsp;million, or $8.52&nbsp;per share. This amount represents an
immediate increase in pro forma as adjusted net tangible book value per share of $2.11 to our existing stockholders and immediate dilution of $7.48 in pro forma as adjusted net tangible book value per share to new investors purchasing common stock
in this offering. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Dilution per share to new investors is determined by subtracting pro forma as adjusted net tangible book value per share after this offering
from the initial public offering price per share paid by new investors. The following table illustrates this dilution (without giving effect to any exercise by the underwriters of their option to purchase additional shares): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Historical net tangible book value (deficit) per share as of June&nbsp;30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(48.98</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Pro forma increase in net tangible book value per share as of June&nbsp;30, 2024 attributable to the pro
forma adjustments described above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Pro forma net tangible book value per share as of June&nbsp;30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Increase in pro forma net tangible book value per share attributable to new investors participating in this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Dilution per share to new investors purchasing common stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The dilution information discussed above is illustrative only and will change based on the actual initial public offering price and
other terms of this offering determined at pricing.</P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each $1.00 increase (decrease) in the assumed initial public offering price of $16.00&nbsp;per share, which
is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) our pro </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">93 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
forma as adjusted net tangible book value per share after this offering by $0.24 and dilution per share to new investors purchasing common stock in this offering by $0.76, assuming that the
number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase of
1.0&nbsp;million shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase our pro forma as adjusted net tangible book value per share after this offering by $0.13 and decrease dilution per share
to new investors purchasing common stock in this offering by $0.13, assuming no change in the assumed initial public offering price per share and after deducting estimated underwriting discounts and commissions and estimated offering expenses
payable by us. Each decrease of 1.0&nbsp;million shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would decrease our pro forma as adjusted net tangible book value per share after this offering by $0.13
and increase dilution per share to new investors purchasing common stock in this offering by $0.13, assuming no change in the assumed initial public offering price and after deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If the underwriters exercise their option to purchase up to 1,875,000 additional shares of our common stock in full, our pro forma
as adjusted net tangible book value per share after this offering would be $8.76&nbsp;per share, representing an immediate increase in pro forma as adjusted net tangible book value per share of $0.24 per share to existing stockholders and immediate
dilution in pro forma as adjusted net tangible book value per share of $0.24&nbsp;per share&nbsp;to new investors purchasing common stock in this offering, based on the assumed initial public offering price of $16.00&nbsp;per share, which is the
midpoint of the estimated price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes on the pro forma as adjusted basis described above, as of June&nbsp;30, 2024, the total number of shares of common stock purchased from us
on an as converted basis to common stock, the total consideration paid or to be paid, and the average price per share paid or to be paid by existing stockholders and by new investors in this offering at an assumed initial public offering price of
$16.00&nbsp;per share, which is the midpoint of the estimated price range set forth on the cover of this prospectus, before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. New investors
purchasing shares of our common stock in this offering will pay an average price per share substantially higher than our existing stockholders paid. </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Shares&nbsp;purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Total&nbsp;consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Weighted-<BR>average</B><br><B>price&nbsp;per<BR>share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(in thousands, except share, per share and percent<BR>data)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,341,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">400,231,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="17" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,841,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">600,231,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="20" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The table above assumes no exercise of the underwriters&#146; option to purchase additional shares in this offering. If the
underwriters&#146; option to purchase additional shares of our common stock is exercised in full, the number of shares of our common stock held by existing stockholders would be reduced to 72% of the total number of shares of our common stock
outstanding after this offering, and the number of shares of common stock held by new investors purchasing common stock in this offering would be increased to 28% of the total number of shares of our common stock outstanding after this offering.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The foregoing discussion and calculations above (other than the historical net tangible book value calculations) are based on 36,341,695&nbsp;shares of common stock
outstanding as of June&nbsp;30, 2024, after giving effect to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">94 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
automatic conversion of all outstanding shares of our redeemable convertible preferred stock into the aggregate of 33,321,149&nbsp;shares of common stock immediately prior to the completion of
this offering, and excludes: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">6,224,230&nbsp;shares of common stock issuable upon the exercise of outstanding stock options as of June&nbsp;30, 2024
under our 2021 Plan, with a weighted-average exercise price of $4.96&nbsp;per share; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">74,027&nbsp;shares of common stock reserved for future issuance as of June&nbsp;30, 2024 under the 2021 Plan, which will
cease to be available for issuance at the time that our 2024 Plan becomes effective (which includes options to purchase an aggregate of 35,666&nbsp;shares of our common stock, at a weighted-average exercise price of $10.62&nbsp;per share, that were
granted subsequent to June 30, 2024); </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">3,180,000&nbsp;shares of our common stock reserved for future issuance under our 2024 Plan, which will become effective on
the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2024 Plan and any
shares underlying outstanding stock awards granted under the 2021 Plan that expire or are repurchased, forfeited, cancelled, or withheld; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">488,467&nbsp;shares of common stock reserved for future issuance under our ESPP, which will become effective on the date
immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the ESPP.
</P></TD></TR></TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To the extent that new stock options are issued or any outstanding options are exercised, or we issue additional shares of common stock in
the future, there will be further dilution to new investors. In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future
operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">95 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc843142_9"></A>Management&#146;s discussion and analysis of financial condition and results of operations
</B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>The following discussion and analysis of our financial condition and results of operations should be read, considered and evaluated together with our
audited consolidated financial statements as of and for the years ended December&nbsp;31, 2023 and 2022 and the related notes included elsewhere in this prospectus and our unaudited condensed consolidated financial statements as of June&nbsp;30,
2024 and for the six months ended June&nbsp;30, 2024 and 2023 and the related notes included elsewhere in this prospectus. This discussion and analysis as well as other parts of this prospectus contain forward-looking statements that involve risks
and uncertainties, including but not limited to, information with respect to our plans and strategy for our business and related financing. As a result of many factors, including those factors set forth in the section titled &#147;Risk
factors,&#148; our actual results could differ materially from the results described in or implied by the forward-looking statements. You should carefully read, consider and evaluate the section titled &#147;Risk factors&#148; to gain an
understanding of the factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section titled &#147;Special note regarding forward-looking statements&#148; included elsewhere in this
prospectus. Our historical results are not necessarily indicative of the results that may be expected for any period in the future. For convenience of presentation, some of the numbers have been rounded in the text below. </I></P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Overview </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are a clinical-stage biotechnology company developing treatments
for inflammatory diseases, with an initial focus on severe respiratory disorders. We are developing verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (&#147;TSLP&#148;),
a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. Preclinical and clinical data to date demonstrate verekitug&#146;s
highly potent inhibition of the TSLP receptor, which we believe will translate to a differentiated product profile, including improved clinical outcomes, substantially extended dosing intervals and the potential to treat a broad spectrum of
patients. We have advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps (&#147;CRSwNP&#148;) and plan to initiate development in chronic
obstructive pulmonary disease (&#147;COPD&#148;). Our experienced team is committed to maximizing verekitug&#146;s unique attributes to address the substantial unmet needs for patients underserved by today&#146;s standard of care. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Through the date of this filing, we have historically financed our operations principally through the issuance and sale of our Series A redeemable convertible preferred
stock (&#147;Series A Preferred Stock&#148;) and Series B redeemable convertible preferred stock (&#147;Series B Preferred Stock&#148;), which are collectively referred to as the &#147;Preferred Stock.&#148; As of June&nbsp;30, 2024, we have
received total gross proceeds of $400.0&nbsp;million from the issuance and sale of our Preferred Stock and we have also received cash of $4.2&nbsp;million in connection with research and development services we provided to Maruho Co., Ltd
(&#147;Maruho&#148;), a related party. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have incurred significant net operating losses and negative cash flows since our inception. Since our inception, we have
devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, establishing licensing, building our proprietary platform technologies, developing verekitug, establishing our intellectual
property portfolio, conducting research, preclinical studies, and clinical trials, establishing arrangements with third parties for the manufacture of verekitug and related raw materials, and providing general and administrative support for these
operations. Our ability to generate product revenue sufficient to achieve profitability, if ever, will depend on the successful development, regulatory approval and eventual commercialization of verekitug and any other potential future product
candidates, which we expect will take a number of years. For the six months ended June&nbsp;30, 2024 and 2023, we reported net losses of $25.6&nbsp;million and $5.6&nbsp;million, respectively. For the years ended December&nbsp;31, 2023 and 2022, we
reported net </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">96 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
losses of $20.5&nbsp;million and $23.9&nbsp;million, respectively. Our net losses have resulted principally from costs incurred in our research and development activities. As of June&nbsp;30,
2024, we had an accumulated deficit of $153.5&nbsp;million, and we had cash, cash equivalents and short-term investments of $235.8&nbsp;million. We believe that the anticipated net proceeds from this offering, together with our existing cash, cash
equivalents and short-term investments, will enable us to fund our operating expenses and capital expenditure requirements through mid-2027. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available
capital resources sooner than we expect. See the subsection titled &#147;&#151;Liquidity and Capital Resources&#148; below. Even if this offering is successful, we will require additional funding in order to finance operations and complete our
ongoing and planned clinical trials. Access to such funding on acceptable terms cannot be assured. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect to continue to incur significant net operating
losses for the foreseeable future. We anticipate that our expenses will increase substantially if, and as we: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">continue to conduct our ongoing clinical trials of verekitug, including advancement into global Phase 2 clinical trials, as
well as initiate and complete additional clinical trials of verekitug in new indications or patient populations; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">conduct larger-scale clinical trials for verekitug or any potential future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">manufacture, or have manufactured, clinical and commercial supplies of verekitug; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">seek regulatory approvals, prepare for and, if approved, proceed to commercialization for verekitug in current or new
indications or any potential future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">attract, hire and retain additional clinical, scientific, and management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">implement operational, financial, and management information systems; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">add quality control, quality assurance, legal, compliance, and other groups to support our operations;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">obtain, maintain, protect, expand and enforce our intellectual property portfolio, including intellectual property obtained
through license agreements; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">defend against any claims by third parties that we have infringed, misappropriated or otherwise violated any intellectual
property of any such third party; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">make royalty, milestone or other payments under current, and any future, license or collaboration agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establish a sales, marketing and distribution infrastructure, either ourselves or in partnership with others, to
commercialize verekitug, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">potentially experience any delays, challenges, or other issues associated with the clinical development of verekitug and
any potential future product candidates, including with respect to our regulatory strategies; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">incur additional legal, accounting, investor relations and other general and administrative expenses associated with
operating as a public company. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our net operating losses may fluctuate significantly from period to period, depending upon the timing of our
expenditures on research and development activities. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our accounts payable and accrued expenses and other current liabilities.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">97 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As a result, we will need additional financing to support our continuing operations. To date, we have funded our operations
primarily with the proceeds from the issuance and sale of our Preferred Stock. We do not have any products approved for sale and have not generated any revenue from product sales since our inception. We do not expect to generate revenue from any
product candidates that we develop until we obtain regulatory approval for one or more of such product candidates and commercialize our products or enter into collaboration arrangements with third parties. Until we can generate sufficient product
revenue to finance our cash requirements, if ever, we expect to fund our operations through equity offerings or debt financings, credit or loan facilities, potentially other capital resources, or a combination of one or more of these funding
sources. We may be unable to raise additional funds or enter into other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly
delay, scale back, or discontinue the development or commercialization of verekitug and one or more potential future product candidates, which could have a material adverse effect on our business, results of operations or financial condition. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Because of the numerous risks and uncertainties associated with research and development of product candidates, we are unable to predict the timing or amount of
increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability
on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Asset purchase
and license agreements </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Below is a summary of the key terms for certain of our asset purchase and license agreements. For a more detailed description of
these agreements, see the section titled &#147;Business&#151;Asset purchase and license agreements&#148; included elsewhere in this prospectus. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Asset
purchase agreement with Astellas and related letter agreement with Astellas and Regeneron </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October 2021, we entered into an asset purchase agreement (the
&#147;Astellas Asset Purchase Agreement&#148;) with Astellas Pharma, Inc. (&#147;Astellas&#148;). Pursuant to the Astellas Asset Purchase Agreement, we purchased from Astellas the compound designated by Astellas as ASP7266 (the &#147;Compound,&#148;
which was subsequently renamed by us as verekitug). There are no future payments owed to Astellas under the Astellas Asset Purchase Agreement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with
the Astellas Asset Purchase Agreement, we concurrently entered into a letter agreement (the &#147;Regeneron Letter Agreement&#148;) with Astellas and Regeneron Pharmaceuticals, Inc. (&#147;Regeneron&#148;). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Regeneron Letter Agreement relates to a prior <FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> License and Material Transfer Agreement (the &#147;Terminated
Regeneron License Agreement&#148;) that Regeneron and Astellas entered into in March 2007, as amended in July 2010 and subsequently terminated in June 2018, subject to certain surviving rights and obligations of both Regeneron and Astellas. Under
the Terminated Regeneron License Agreement, Astellas utilized Regeneron&#146;s human antibody technology in its internal research programs to discover certain product candidates, including the Compound, which it sold to us under the Astellas Asset
Purchase Agreement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the Regeneron Letter Agreement, Astellas assigned and transferred to us and we assumed and accepted certain of Astellas&#146; surviving
rights and obligations under the Terminated Regeneron License Agreement, including Astellas&#146; royalty payment, reporting and indemnification obligations in connection with activities conducted by us or on our behalf with respect to the Compound.
By assuming and accepting Astellas&#146; surviving obligations under the Terminated Regeneron License Agreement, we are required to pay Regeneron <FONT STYLE="white-space:nowrap">mid-single-</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">98 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
digit percentage royalties on aggregate worldwide net sales of any product developed by or on behalf of us that contains the Compound as an ingredient or component of the materials sold (a
&#147;Royalty Product&#148;) during the royalty term. The royalties are determined on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis and expire on the later of (i)&nbsp;a specified number of years after the launch of a given Royalty Product in a given country and (ii)&nbsp;the expiration of the last valid claim of
royalty bearing company patent rights claiming or covering such Royalty Product in such country. To date, we have not made any royalty payments to Regeneron under the Regeneron Letter Agreement. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Exclusive license agreement with Maruho </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October 2021, we entered into a
license agreement with Maruho (as amended, the &#147;Maruho License Agreement&#148;), under which we granted Maruho an exclusive, irrevocable, perpetual, royalty-free, sublicensable (subject to our right of first negotiation) license. Under the
Maruho License Agreement, Maruho is responsible for and controls, at its sole expense, (i)&nbsp;the preparation, filing, prosecution, obtaining and maintaining all regulatory approvals in Japan and (ii)&nbsp;the promotion, marketing, sale and
commercialization in Japan. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the Maruho License Agreement, we maintain our responsibility for and control the global research and development of the
Maruho license product, including in Japan. We will conduct specified clinical trial activities for Japan as part of our global research and development plan. Maruho will reimburse us for the costs of these research and development activities,
including the cost of drug supply. Apart from reimbursement of qualifying research and development expenses, Maruho is not obligated to make any future payments under the Maruho License Agreement. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the year ended December&nbsp;31, 2023, we received payments from Maruho in the amount of $2.7&nbsp;million which was received during the six months ended
June&nbsp;30, 2023. During the year ended December&nbsp;31, 2022, we received payments from Maruho in the amount of $0.8&nbsp;million. During the six months ended June&nbsp;30, 2024, we received payments from Maruho in the amount of
$0.7&nbsp;million. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>License agreement with Lonza </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October 2021, in
connection with the Astellas Asset Purchase Agreement, we entered into a license agreement with Lonza Sales AG (&#147;Lonza&#148;) (as amended, the &#147;Lonza License Agreement&#148;). Pursuant to the Lonza License Agreement, we obtained a
worldwide, <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> sublicensable (subject to Lonza&#146;s right of <FONT STYLE="white-space:nowrap">pre-approval</FONT> with respect to any sublicense of manufacturing activities) license to certain
intellectual property rights owned by Lonza. Lonza was the originator of the master cell bank for the Compound developed by Astellas. As consideration for the rights and licenses granted to us under the Lonza License Agreement, we agreed to pay
Lonza certain royalties and annual payments, both payable in swiss francs, in respect of the manufacturing and sale of the Compound, such amounts to be determined by the party manufacturing the Compound, and range from no annual payment to up to a <FONT
STYLE="white-space:nowrap">mid-six</FONT> figure annual payment, and a <FONT STYLE="white-space:nowrap">less-than-one</FONT> percent to a <FONT STYLE="white-space:nowrap">low-single-digit</FONT> percentage royalty on net sales of the Compound. In
accordance with the Lonza License Agreement, we entered into a sublicense with Wuxi Biologics (Hong Kong) Limited to manufacture the Compound, requiring us to pay a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mid-six-figure</FONT></FONT> annual fee to Lonza pursuant to this provision. Any royalties due under the Lonza License Agreement are payable on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until ten years from the first commercial sale of the Compound in that particular country. The Lonza agreement continues for an indefinite period of time unless otherwise terminated.
We have the right to terminate the Lonza License Agreement at any time by providing prior written notice to Lonza. During the year ended December&nbsp;31, 2023, we made an annual payment to Lonza in the amount of $0.4&nbsp;million, which was paid
during the six months ended June&nbsp;30, 2023. During the year ended December&nbsp;31, 2022, we made an annual payment to Lonza in the amount of $0.4&nbsp;million. During the six months ended June&nbsp;30, 2024, we made an annual payment to Lonza
in the amount of $0.5&nbsp;million. These payments are recognized as research and development expense in the consolidated statements of operations and comprehensive loss. To date, we have not made any royalty payments to Lonza under the Lonza
License Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">99 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Components of our results of operations </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Collaboration revenue&#151;related party </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To date, we have not
generated any revenue from product sales and do not expect to generate any revenue from product sales in the foreseeable future. All of our collaboration revenue has been derived from the Maruho License Agreement. If our development efforts for
verekitug or any potential future product candidates are successful and result in regulatory approval, or if we enter into collaboration or license agreements with third parties, we may generate revenue in the future from product sales, royalties or
payments from such collaboration or license agreements, or a combination of product sales and payments from such agreements. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Operating expenses </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Research and development expenses </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Research and development expenses consist
primarily of costs incurred for our preclinical research and clinical development of verekitug, which include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">expenses incurred under agreements with third parties, including contract research organizations (&#147;CROs&#148;),
contract manufacturing organizations (&#147;CMOs&#148;), and investigative sites that conduct clinical trials on our behalf, and costs related to the Maruho License Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research
and development functions and costs related to the Maruho License Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">costs of outside consultants, including their fees and related travel expenses; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">costs associated with license agreements to support the development of our technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expense all research and development expenses in the periods in which they are incurred. Our direct research and development expenses are tracked on an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">indication-by-indication</FONT></FONT> basis and consist of costs that include CROs and investigative sites that conduct clinical trials on our behalf, third party vendors that conduct
research and preclinical studies on our behalf and outside consulting costs directly allocable to an indication. We do not allocate costs related to CMOs that manufacture verekitug for use in our preclinical studies and clinical trials as they are
not distinguishable by indication but support all current and potential indications under our verekitug program. Additionally, we do not allocate costs for employee costs, including stock-based compensation, consulting, or other indirect costs that
cannot be directly allocated to a specific indication. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect that our research and development expenses will increase in the future as we advance verekitug
through clinical trials and any potential future product candidates that we may develop through preclinical studies and clinical trials, in pursuit of regulatory approval. Product candidates in later stages of clinical development generally have
higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">At
this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of verekitug and any potential future product candidates. We are also unable to predict when,
if ever, material net cash inflows will commence from sales or licensing of verekitug or any potential future product candidates. This is due to the numerous risks and uncertainties associated with drug development, including the uncertainty of:
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the scope, timing, progress, costs and results of the ongoing development of verekitug as well as for potential discovery,
preclinical development and clinical trials for other potential future product candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">100 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the number of clinical trials required for regulatory approval of verekitug or our potential future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs, timing and outcome of regulatory review of verekitug or our potential future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs associated with acquiring or licensing additional product candidates, technologies or assets, including the
timing and amount of any milestones, royalties or other payments due in connection with our acquisitions and licenses; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the cost of manufacturing clinical supplies of verekitug or our potential future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs associated with hiring additional clinical, quality control, medical, scientific and other technical personnel to
support the ongoing development of verekitug; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs associated with increasing our headcount as we expand our research and development organization and market
development and <FONT STYLE="white-space:nowrap">pre-commercial</FONT> planning activities; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the effectiveness of our approach to identifying target patient populations; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to maintain existing, and establish new, strategic collaborations or other arrangements and the financial terms
of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement prior to regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the effect of macroeconomic trends including inflation and rising interest rates; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">addressing any potential supply chain interruptions or delays. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A change in the outcome of any of these factors or underlying variables with respect to the development of a product candidate could significantly change the costs and
timing associated with the development of that product candidate. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>General and administrative expenses </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">General and administrative expenses consist primarily of salaries and benefits, including stock-based compensation expense, for personnel in executive, finance,
accounting, legal, human resources, business development, information technology, and other administrative functions. General and administrative expenses also include legal fees relating to patents and corporate matters; professional fees for
accounting, auditing, tax, and consulting services; insurance costs; travel expenses; and facility-related expenses, which include depreciation costs and expenses for rent and maintenance of facilities and other operating costs. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect that our general and administrative expenses will increase in the future as we increase our headcount and expand our infrastructure to support the continued
research and development of our programs and the growth of our business. We also expect to incur increased expenses associated with operating as a public company, including costs of accounting, audit, legal, regulatory, <FONT
STYLE="white-space:nowrap">tax-related</FONT> services, compliance with Securities and Exchange Commission rules and regulations and listing requirements, director and officer insurance premiums and investor relations costs. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Other income (expense) </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Change in fair value of preferred stock
tranche right liability </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with our Preferred Stock financings, we issued shares under stock purchase agreements that provided an obligation for us
to issue additional Preferred Stock in subsequent closings upon the satisfaction of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">101 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
certain conditions. The Series A and Series B tranche right liabilities were settled in February 2023 and April 2024, respectively, upon the satisfaction of relevant conditions. We classified the
preferred stock tranche rights as liabilities on our consolidated balance sheets and initially recorded them at fair value upon the issuance date of the rights. We remeasured the tranche right liabilities to fair value at each reporting date and
immediately prior to being settled, and recognized changes in the fair value of the preferred stock tranche right liability as a component of other income (expense) in our consolidated statements of operations and comprehensive loss. Upon settlement
of the tranche rights, we derecognized the related liability, and stopped recognizing changes in the fair value of the preferred stock tranche right liability. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Interest income </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Interest income consists of interest earned on money market
funds, U.S. treasury bills and U.S. government agency bond investments. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Other income (expense), net </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Other income (expense), net consists of miscellaneous income and expense unrelated to our core operations. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Income taxes </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We recorded a full valuation allowance of our deferred
tax asset position as of June&nbsp;30, 2024 and December&nbsp;31, 2023 and 2022 as we believe it was more likely than not that we would not be able to utilize our deferred tax assets. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2023, we had federal and state net operating losses (&#147;NOLs&#148;) carryforwards of $25.0&nbsp;million and $27.6&nbsp;million, respectively.
The federal NOLs are not subject to expiration and are limited in utilization to 80% of taxable income and the state NOLs begin to expire in 2041. As of December&nbsp;31, 2023, we had federal and state research and development credits of
$0.8&nbsp;million which will begin to expire in 2043 and 2037, respectively. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Results of operations </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Comparison of the six months ended June&nbsp;30, 2024 and 2023 </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
following table summarizes our results of operations for the six months ended June&nbsp;30, 2024 and 2023: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:10pt"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Collaboration revenue&#151;related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,398</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,155</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in fair value of preferred stock tranche right liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,910</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(92</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,815</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,602</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,970</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="12" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">102 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Collaboration revenue&#151;related party </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Related party collaboration revenue was $1.2&nbsp;million for the six months ended June&nbsp;30, 2024 compared to $1.3&nbsp;million for the six months ended
June&nbsp;30, 2023. Revenue during the six months ended June&nbsp;30, 2024 was primarily related to the work performed associated with our Phase 2 clinical trial in patients with severe asthma and the revenue during the six months ended
June&nbsp;30, 2023 was related to the work performed associated with our Phase 1 clinical trial in patients with severe asthma under the Maruho License Agreement. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Research and development expenses </I></B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:10pt"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Direct research and development expenses by program:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Verekitug program:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Asthma indication</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 4,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 8,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">CRSwNP indication</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unallocated research and development expense:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Personnel expenses (including stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Manufacturing costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other unallocated expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="12" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Research and development expenses were $25.8&nbsp;million for the six months ended June&nbsp;30, 2024 compared to $12.5&nbsp;million for
the six months ended June&nbsp;30, 2023. The increase of $13.3&nbsp;million was primarily driven by an increase of $11.9&nbsp;million in expenses directly related to our verekitug program and $1.4&nbsp;million of unallocated research and development
expenses. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The increase in direct costs of $8.6&nbsp;million and $3.3&nbsp;million related to the asthma indication and CRSwNP indication, respectively, were
primarily due to continued progress associated with our Phase&nbsp;2 clinical trials during the six months ended June&nbsp;30, 2024 compared to the same period in 2023. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The increase in personnel expenses of $1.4&nbsp;million was primarily due to increased headcount in our research and development function. Personnel expenses for the six
months ended June&nbsp;30, 2024 and 2023 included stock-based compensation expense of $0.5&nbsp;million and $0.6&nbsp;million, respectively. The increase of $0.3&nbsp;million in professional fees was related to quality and manufacturing services to
support our verekitug program. The increase in other unallocated expenses of $0.9&nbsp;million was primarily driven by an increase in preclinical studies to support our verekitug clinical trials. The decrease in manufacturing costs of
$1.2&nbsp;million was attributable to a decrease of $2.1&nbsp;million in CMO costs for the development of Phase 2 clinical trial material during the six months ended June&nbsp;30, 2024 compared to the same period in 2023, offset by an increase of
$0.9&nbsp;million in CMO costs for the development of Phase 3 clinical material during the six months ended June&nbsp;30, 2024 for which there was no comparable expense during the same period in 2023. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We begin to separately track program expenses at development candidate nomination. Through June&nbsp;30, 2024, we have incurred approximately $36.0&nbsp;million and
$7.0&nbsp;million in direct external expenses for the development of verekitug for severe asthma and CRSwNP, respectively, since their development candidate nominations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">103 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>General and administrative expenses </I></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:10pt"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Personnel expenses (including stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total general and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="12" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">General and administrative expenses were $7.9&nbsp;million for the six months ended June&nbsp;30, 2024 compared to $5.3&nbsp;million for
the six months ended June&nbsp;30, 2023. The increase of $2.7&nbsp;million was primarily driven by an increase in personnel expenses of $1.4&nbsp;million due to increased headcount in our general and administrative functions. Personnel expenses for
the six months ended June&nbsp;30, 2024 and 2023 included stock-based compensation expense of $1.5&nbsp;million and $1.4&nbsp;million, respectively. Additionally, there was an increase of $1.0&nbsp;million of professional fees including increased
consulting and audit fees. Facility-related and other expenses increased by $0.3&nbsp;million primarily due to an increase in franchise taxes. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Other income
(expense) </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Change in fair value of preferred stock tranche right liabilities </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We recorded other income for the change in the fair value of the preferred stock tranche right liabilities of $2.9&nbsp;million for the six months ended June&nbsp;30,
2024, related to the Series B preferred stock tranche right liability, as compared to other income of $9.8&nbsp;million for the six months ended June&nbsp;30, 2023, including $6.6&nbsp;million related to the Series A preferred stock tranche right
liability and $3.1&nbsp;million related to the Series B preferred stock tranche right liability. The change in the fair value of the Series A preferred stock tranche right liability was due to changes in the assumptions used in the valuation model
during the periods, including the expected fair value of the Series A Preferred Stock and the probability and expected timing of achieving certain milestone events. The change in fair value of the Series B preferred stock tranche right liability was
due to changes in the assumptions used in the valuation model during the periods, including the estimated fair value of the Series B Preferred Stock, volatility and estimated time to the tranche closing. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Interest income </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Interest income was $4.1&nbsp;million and $1.1&nbsp;million
for the six months ended June&nbsp;30, 2024 and 2023, respectively, representing an increase of $3.0&nbsp;million. The increase in interest income was due to increased balances in our money market funds, U.S. treasury bills and U.S. government
agency bonds held during the six&nbsp;months ended June&nbsp;30, 2024, as compared to the six months ended June&nbsp;30, 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">104 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Comparison of the years ended December&nbsp;31, 2023 and 2022 </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes our results of operations for the years ended December&nbsp;31, 2023 and 2022: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:10pt"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Collaboration revenue&#151;related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,114</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,909</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in fair value of preferred stock tranche right liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(115</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20,537</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="12" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Collaboration revenue&#151;related party </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Related party collaboration revenue was $2.4&nbsp;million for the year ended December&nbsp;31, 2023 compared to $1.2&nbsp;million for the year ended December&nbsp;31,
2022. The increase of $1.2&nbsp;million was due to the continued progress under the Maruho License Agreement. This progress is primarily related to the work performed associated with our Phase 2 clinical trial in patients with severe asthma. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Research and development expenses </I></B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:10pt"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Direct research and development expenses by program:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Verekitug program:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Asthma indication</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">CRSwNP indication</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unallocated research and development expense:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Personnel expenses (including stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Manufacturing costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other unallocated expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="12" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Research and development expenses were $31.8&nbsp;million for the year ended December&nbsp;31, 2023 compared to $18.7&nbsp;million for
the year ended December&nbsp;31, 2022. The increase of $13.1&nbsp;million was primarily driven by an increase of $10.1&nbsp;million in expenses directly related to our verekitug program and $3.0&nbsp;million of unallocated research and development
expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">105 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The increase in direct costs of $6.9&nbsp;million related to the asthma indication are primarily due to costs
associated with our Phase&nbsp;1 clinical trial and preparing for our Phase&nbsp;2 clinical trial during the year ended December&nbsp;31, 2023 compared to only incurring Phase 1 clinical trial costs during the same period in 2022. The increase in
direct costs related to the CRSwNP indication are primarily due to a $3.2&nbsp;million increase in costs associated with preparing for our CRSwNP Phase 2 clinical trial at the end of 2023 for which there were no comparable expenses during the same
period of 2022. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The increase in personnel expenses of $5.3&nbsp;million was primarily due to increased headcount in our research and development function.
Personnel expenses for the year ended December&nbsp;31, 2023 and 2022 included stock-based compensation expense of $1.1&nbsp;million and $0.4&nbsp;million, respectively. The increase of $0.4&nbsp;million in professional fees was related to quality
and manufacturing services to support our verekitug program. The increase in other unallocated expenses was primarily driven by a $0.7&nbsp;million increase in preclinical studies to support our verekitug clinical trials and a $0.2&nbsp;million
increase in clinical trial insurance. The decrease in manufacturing costs of $3.8&nbsp;million was attributable to a decrease in CMO costs for the development of Phase 2 clinical trial material during the year ended December&nbsp;31, 2023 compared
to the same period in 2022. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We begin to separately track program expenses at development candidate nomination. Through December&nbsp;31, 2023, we have incurred
approximately $22.9&nbsp;million and $3.4&nbsp;million in direct external expenses for the development of verekitug for severe asthma and CRSwNP, respectively, since their development candidate nominations. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>General and administrative expenses </I></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:10pt"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Personnel expenses (including stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Facility-related and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total general and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="12" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">General and administrative expenses were $10.7&nbsp;million for the year ended December&nbsp;31, 2023 compared to $6.5&nbsp;million for
the year ended December&nbsp;31, 2022. The increase of $4.2&nbsp;million was primarily driven by an increase in personnel expenses of $2.6&nbsp;million due to increased headcount in our general and administrative functions. Personnel expenses for
the year ended December&nbsp;31, 2023 and 2022 included stock-based compensation expense of $2.4&nbsp;million and $0.9&nbsp;million, respectively. Additionally, there was an increase of $1.1&nbsp;million of professional fees including increased
legal and audit fees. Facility-related and other expenses increased by $0.5&nbsp;million primarily due to an increase in rent in connection with additional leased office space at the same location on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">month-to-month</FONT></FONT> basis during the year ended December&nbsp;31, 2023. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Other income (expense) </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Change in fair value of preferred stock tranche right liabilities </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We recorded
other income for the change in the fair value of the preferred stock tranche right liabilities of $15.5&nbsp;million for the year ended December&nbsp;31, 2023, including $6.6&nbsp;million related to the Series A preferred stock tranche right
liability and $8.9&nbsp;million related to the Series B preferred stock tranche right liability, as compared to other expense of $0.1&nbsp;million for the year ended December&nbsp;31, 2022 related to the Series A preferred stock tranche right
liability. The change in the fair value of the Series A preferred stock tranche right </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">106 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
liability was due to changes in the assumptions used in the valuation model during the periods, including the expected fair value of the Series A Preferred Stock and the probability and expected
timing of achieving certain milestone events. The change in fair value of the Series B preferred stock tranche right liability was due to changes in the assumptions used in the valuation model from its issuance date in June 2023 through
December&nbsp;31, 2023, including the estimated fair value of the Series B Preferred Stock, volatility and estimated time to the tranche closing. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Interest
income </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Interest income was $4.2&nbsp;million and $0.2&nbsp;million for the years ended December&nbsp;31, 2023 and 2022, respectively, representing an increase
of $4.0&nbsp;million. The increase in interest income was due to the increased balances in our money market funds, U.S. treasury bills and U.S. government agency bonds held during 2023, as compared to 2022. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Liquidity and capital resources </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since our inception, we have incurred
significant operating losses. We have not yet commercialized verekitug and we do not expect to generate revenue from product sales of verekitug for the next several years, if at all. We have financed our operations primarily through the issuance and
sale of our Preferred Stock. As of June&nbsp;30, 2024, we have received gross proceeds of $400.0&nbsp;million from sales of our Preferred Stock and received $4.2&nbsp;million in connection with our research and development arrangement with Maruho.
As of June&nbsp;30, 2024, we had cash, cash equivalents and short-term investments of $235.8&nbsp;million. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Cash flows </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes our sources and uses of cash for each of the periods presented: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(in thousands)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(37,926</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,598</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,997</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(82,842</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(82</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102,802</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(89,849</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 8,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,140</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 21,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 22,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Operating activities </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the six months
ended June 30, 2024, operating activities used $25.6 million of cash, resulting primarily from our net loss of $25.6 million, non-cash changes in fair value of the preferred stock tranche right liability of $2.9&nbsp;million, and non-cash
amortization of premiums and accretion of discounts on short-term investments of $1.8&nbsp;million, partially offset by changes in operating assets and liabilities of $2.5 million and non-cash stock-based compensation expense of $2.1 million. Net
cash provided by changes in operating assets and liabilities was primarily driven by a $3.1&nbsp;million increase in accounts payable and a $0.4&nbsp;million decrease in prepaid expenses and other current assets, partially offset by a
$0.5&nbsp;million decrease in accrued expenses and other current liabilities and a $0.4&nbsp;million increase in related party accounts receivable. The increase in related party accounts receivable resulted primarily from the timing of revenue
recognition compared to the timing of payments from Maruho for qualifying reimbursable expenses related to the Maruho License Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">107 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the six months ended June 30, 2023, operating activities used $17.0 million of cash, resulting primarily from our
net loss of $5.6 million, non-cash changes in fair value of the preferred stock tranche right liability of $9.8&nbsp;million, changes in operating assets and liabilities of $3.3 million and non-cash amortization of premiums and accretion of
discounts on short-term investments of $0.3&nbsp;million, partially offset by non-cash stock-based compensation expense of $1.9 million. Net cash used by changes in operating assets and liabilities was driven by a $3.2&nbsp;million increase in
prepaid expenses and other current assets and a $1.5&nbsp;million decrease in accrued expenses and other current liabilities, partially offset by a $1.1&nbsp;million increase in related party deferred revenue and a $0.3&nbsp;million decrease in
related party accounts receivable. The increase in related party deferred revenue and decrease in related party accounts receivable resulted primarily from the timing of revenue recognition compared to the timing of payments from Maruho for
qualifying reimbursable expenses related to the Maruho License Agreement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the year ended December&nbsp;31, 2023, operating activities used $37.9&nbsp;million
of cash, primarily resulting from our net loss of $20.5&nbsp;million, net <FONT STYLE="white-space:nowrap">non-cash</FONT> gains of $13.1&nbsp;million and net cash used by changes in our operating assets and liabilities of $4.3&nbsp;million. Net <FONT
STYLE="white-space:nowrap">non-cash</FONT> gains included a gain related to the change in fair value of preferred stock tranche right liabilities of $15.5&nbsp;million, stock-based compensation expense of $3.4&nbsp;million, a gain of
$1.3&nbsp;million related to amortization of premiums and accretion of discounts on short-term investments, issuance costs allocated to the Series B preferred stock tranche right liability of $0.1&nbsp;million, depreciation and amortization expense
of $0.1&nbsp;million and $0.1&nbsp;million of <FONT STYLE="white-space:nowrap">non-cash</FONT> lease expense. Net cash used by changes in operating assets and liabilities was primarily driven by a $6.2&nbsp;million increase in prepaid expenses and
other current assets due to payments made to a CRO for <FONT STYLE="white-space:nowrap">start-up</FONT> costs related to our Phase 2 clinical trials, partially offset by a $1.3&nbsp;million increase in accounts payable, a $0.4&nbsp;million increase
in accrued expenses and other current liabilities and a $0.3&nbsp;million decrease in related party accounts receivable. The decrease in related party accounts receivable resulted primarily from the timing of revenue recognition compared to the
timing of payments from Maruho for qualifying reimbursable expenses related to the Maruho License Agreement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the year ended December&nbsp;31, 2022, operating
activities used $19.0&nbsp;million of cash, primarily resulting from our net loss of $23.9&nbsp;million, partially offset by changes in our operating assets and liabilities of $3.4&nbsp;million and <FONT STYLE="white-space:nowrap">non-cash</FONT>
charges of $1.4&nbsp;million. Net <FONT STYLE="white-space:nowrap">non-cash</FONT> charges included stock-based compensation expense of $1.3&nbsp;million, a charge related to the change in fair value of preferred stock tranche rights liabilities of
$0.1&nbsp;million and <FONT STYLE="white-space:nowrap">non-cash</FONT> lease expense of $0.1&nbsp;million. Net cash provided by changes in operating assets and liabilities was driven by a $4.0&nbsp;million increase in accrued expenses and other
current liabilities primarily related to manufacturing and clinical costs and a $0.5&nbsp;million increase in accounts payable, partially offset by a $0.6&nbsp;million increase in prepaid expenses and other current assets and a $0.4&nbsp;million
increase in related party accounts receivable. The increase in related party accounts receivable resulted primarily from the timing of revenue recognition compared to the timing of payments from Maruho for qualifying reimbursable expenses related to
the Maruho License Agreement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For all periods presented, changes in prepaid expenses and other assets, accounts payable and accrued expenses and other current
liabilities not described above were generally due to the growth in our business, the advancement of our clinical programs, and the timing of vendor invoicing and payments. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Investing activities </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the six months ended June&nbsp;30, 2024, net
cash used in investing activities was $102.8&nbsp;million, consisting primarily of purchases of short-term investments of $175.0&nbsp;million, net of maturities of short-term investments of $72.2&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">108 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the six months ended June&nbsp;30, 2023, net cash used in investing activities was $89.8&nbsp;million, consisting
primarily of purchases of short-term investments of $89.7&nbsp;million and purchases of property and equipment of $0.1&nbsp;million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the year ended
December&nbsp;31, 2023, net cash used in investing activities was $82.8&nbsp;million, consisting primarily of purchases of short-term investments of $129.0&nbsp;million, net of maturities of short-term investments of $46.3&nbsp;million and purchases
of property and equipment of $0.1&nbsp;million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the year ended December&nbsp;31, 2022, net cash used in investing activities was not significant. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Financing activities </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the six months ended June&nbsp;30, 2024, net
cash provided by financing activities was $149.9&nbsp;million, consisting of $149.9&nbsp;million in net proceeds from the issuance of Series B Preferred Stock and $0.1&nbsp;million in net proceeds from the exercise of stock options, partially offset
by $0.1&nbsp;million in payments of deferred offering costs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the six months ended June&nbsp;30, 2023, net cash provided by financing activities was
$129.6&nbsp;million, consisting of $80.0&nbsp;million in proceeds from the issuance of Series A Preferred Stock and $49.6&nbsp;million in net proceeds from the issuance of Series B Preferred Stock, including the Series B preferred stock tranche
right liability. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the year ended December&nbsp;31, 2023, net cash provided by financing activities was $129.6&nbsp;million, consisting of $80.0&nbsp;million
in proceeds from the issuance of Series A Preferred Stock, $49.4&nbsp;million in net proceeds from the issuance of Series B Preferred Stock, including the Series B preferred stock tranche right liability, and $0.1&nbsp;million in net proceeds from
the exercise of stock options. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the year ended December&nbsp;31, 2022, net cash provided by financing activities was $10.0&nbsp;million, all of which
consisted of net proceeds from the issuance of Series A Preferred Stock. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Funding requirements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect our research and development and general and administrative expenses and our operating losses will increase in the future as we advance verekitug through
clinical trials and any potential future product candidates that we may develop through preclinical studies and clinical trials, in pursuit of regulatory approval. Due to the numerous risks and uncertainties associated with research, development and
commercialization of product candidates, changes in the outcome of any factors with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate.
In addition, upon the completion of this offering, we expect to incur increased expenses associated with operating as a public company. Our future capital requirements, both short- and long-term, will depend on a variety of factors, including, but
not limited to: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the rate of progress in the development of verekitug and our potential future product candidates, if any;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the scope, progress, results and costs of <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies, preclinical
development, laboratory testing and clinical trials for verekitug and any potential future product candidates and associated development programs; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the number and scope of preclinical studies and clinical trials that we pursue; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs, timing, and outcomes of seeking and obtaining approvals by the FDA and comparable foreign regulatory
authorities, including the potential for such authorities to require that we perform more preclinical studies or clinical trials than those that we currently expect or for such authorities to change their requirements on studies that had previously
been agreed to; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">109 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to establish licensing or collaboration agreements or other strategic agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the achievement of milestones or other developments under any licensing or collaboration agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under any license
or collaboration agreements; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs to establish, maintain, expand, enforce, and defend the scope of our intellectual property portfolio, including
the amount and timing of any payments we may be required to make, or that we may receive, in connection with licensing, preparing, filing, prosecuting, defending and enforcing any patents or other intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs associated with successfully defending against any claims by third parties that we have infringed,
misappropriated or otherwise violated any intellectual property of any such third party; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs of acquiring, licensing, or investing in additional businesses, products, product candidates, and technologies
that we may identify; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs to manufacture or to have manufactured sufficient, reliable, timely, and affordable supply of materials including
commercial-grade product formulations that can be used in clinical trials and for commercial launch; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs of commercializing product candidates, if approved, whether alone or in collaboration with others;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product
candidates receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs of building or contracting sales, marketing, and/or distribution capabilities, systems, and internal
infrastructure for any product candidate that receives marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the impact of competitors&#146; product candidates and technological advances and other market developments;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the expenses needed to attract and retain skilled personnel; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the size of the markets and degree of market acceptance of any product candidates in territories in which we receive
regulatory approval, including product pricing, product coverage, and the adequacy of reimbursement by third-party payors. </P></TD></TR></TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our business plans
may change in the future and we will continue to require additional capital to meet the needs of our operating expenses. See the section titled &#147;Risk factors&#151;Risks related to our limited operating history, financial condition and need for
additional capital&#148; included elsewhere in this prospectus. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe that the net proceeds from this offering, together with our existing cash, cash
equivalents and short-term investments, will enable us to fund our operating expenses and capital expenditure requirements through mid-2027. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available
capital resources sooner than we expect. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through
a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities,
your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may
involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">110 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we
may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or
debt financings or other arrangements when needed, we would be required to delay, scale back or discontinue our research, product development or future commercialization efforts, or grant rights to develop and market product candidates that we would
otherwise prefer to develop and market ourselves. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Contractual obligations and other commitments </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Asset acquisition from Astellas and related letter agreement with Astellas and Regeneron </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October 2021, we entered into the Astellas Asset Purchase Agreement with Astellas, and concurrently entered into the Regeneron Letter Agreement with Astellas and
Regeneron. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the Regeneron Letter Agreement, Astellas assigned and transferred to us and we assumed and accepted certain of Astellas&#146; surviving rights and
obligations under the Terminated Regeneron License Agreement. By assuming and accepting Astellas&#146; surviving obligations under the Terminated Regeneron License Agreement, we are required to pay Regeneron
<FONT STYLE="white-space:nowrap">mid-single-digit</FONT> percentage royalties on aggregate worldwide net sales of a Royalty Product during the royalty term. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
royalties are determined on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis and expire
on the later of (i)&nbsp;a specified number of years after the launch of a given Royalty Product in a given country and (ii)&nbsp;the expiration of the last valid claim of royalty bearing company patent rights claiming or covering such Royalty
Product in such country. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To date, we have not made any royalty payments to Regeneron under the Regeneron Letter Agreement. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>License agreement with Lonza </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As consideration for the rights and
licenses granted to us under the Lonza License Agreement, we agreed to pay Lonza certain royalties and annual payments, both payable in swiss francs, in respect of the manufacturing and sale of the Compound, such amounts to be determined by the
party manufacturing the Compound, and range from no annual payment to up to a <FONT STYLE="white-space:nowrap">mid-six</FONT> figure annual payment, and a <FONT STYLE="white-space:nowrap">less-than-one</FONT> percent to a <FONT
STYLE="white-space:nowrap">low-single-digit</FONT> percentage royalty on net sales of the Compound. In accordance with the Lonza License Agreement, we entered into a sublicense with Wuxi Biologics (Hong Kong) Limited to manufacture the Compound,
requiring us to pay a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mid-six-figure</FONT></FONT> annual fee to Lonza pursuant to this provision. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any royalties due under the Lonza License Agreement are payable on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT>
basis until ten years from the first commercial sale of the Compound in that particular country. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the year ended December&nbsp;31, 2023, we made an annual
payment to Lonza in the amount of $0.4&nbsp;million, which was paid during the six months ended June&nbsp;30, 2023. During the year ended December&nbsp;31, 2022, we made an annual payment to Lonza in the amount of $0.4&nbsp;million. During the six
months ended June&nbsp;30, 2024, we made an annual payment to Lonza in the amount of $0.5&nbsp;million. These payments were recognized as research and development expense in the condensed consolidated statements of operations and comprehensive loss.
To date, we have not made any royalty payments to Lonza under the Lonza License Agreement. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Lease agreement </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On July&nbsp;3, 2024, we entered into a three-year agreement for office space located at 890 Winter Street in Waltham, Massachusetts. We began paying monthly rent
starting one month after lease commencement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">111 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
Initial base rent is approximately $0.7&nbsp;million for the first year and approximately $0.8&nbsp;million for the second and third year. The lease commenced in September 2024. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On July&nbsp;8, 2024, we provided notice of termination of our current operating lease and sublease of office space at 460 Totten Pond Road, Waltham, Massachusetts. This
notice is effective on October&nbsp;9, 2024, after which our rights and obligations under this lease and sublease will cease. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Research and development
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We enter into contracts in the normal course of business with CROs and investigator sites that conduct clinical trials on our behalf, CMOs that manufacture
product candidates for use in our preclinical studies and clinical trials, and third-party vendors, including CROs, that conduct research and preclinical studies on our behalf. Prepayments under these arrangements can generally be repurposed or the
services themselves cancelable upon prior written notice, though cancellation fees are likely. Payments due upon cancellation consist only of payments for services provided and expenses incurred up to the date of cancellation. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Critical accounting estimates and significant judgments </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our
management&#146;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. Generally Accepted Accounting Principles (&#147;U.S.
GAAP&#148;). The preparation of our financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and the disclosure of contingent assets
and liabilities at the date of the consolidated financial statements. We base our estimates on historical experience, known trends and events, and on various other factors that we believe are reasonable under the circumstances, the results of which
form the basis for making judgments about the carrying values of assets and liabilities and revenues and expenses that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may
differ from these estimates under different assumptions or conditions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While our significant accounting policies are described in more detail in Note 2 to our
consolidated financial statements included elsewhere in this prospectus, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Prepaid and accrued research and development expenses </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As part of the
process of preparing our consolidated financial statements, we are required to estimate our research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services
that have been performed on our behalf, and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. The majority of our service
providers invoice us in arrears for services performed, on a <FONT STYLE="white-space:nowrap">pre-determined</FONT> schedule or when contractual milestones are met; however, some require advanced payments. We make estimates of our accrued expenses
as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. Examples of estimated accrued research and development expenses include: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">expenses incurred under agreements with third parties, including CROs and investigative sites that conduct research,
preclinical studies and clinical trials on our behalf, and in connection with the Maruho License Agreement; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">112 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">expenses incurred under agreements with third parties, including CMOs, that develop and manufacture our product candidate
for use in our preclinical studies and clinical trials; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">other providers and vendors in connection with research and development activities. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We base our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant to quotes and contracts
with multiple CROs, investigative sites, CMOs, and third-party vendors that conduct research, preclinical studies, and conduct clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to
contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing fees,
we estimate the time period over which services will be performed, enrollment of patients, number of sites activated, and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort
varies from our estimate, we adjust the accrual or amount of prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services
performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low in any particular period. To date, we have not made any material adjustments to our prior estimates
of accrued research and development expenses. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We also record advance payments to service providers as prepaid expenses and other current assets, which are expensed
as the contracted services are performed. If the actual timing of the performance of services varies from the estimate, then we adjust the amount of the accrued expense or the prepaid expense accordingly. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Stock-based compensation </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We measure stock-based awards granted to
employees, directors, and <FONT STYLE="white-space:nowrap">non-employee</FONT> service providers based on their fair value on the date of the grant and recognize compensation expense for those awards over the requisite service period, which is
generally the vesting period of the respective award. Generally, we issue stock option awards with service-based vesting conditions and record the expense for these awards using the straight-line method such that the aggregate amount of expense
recognized is at least the fair value of what was legally vested. Certain personnel (including our former Chief Executive Officer, current Chief Executive Officer, current Chief Financial Officer, current Chief Medical Officer, current Chief
Business Officer and former Chief Operating Officer) were issued stock option awards with performance-based vesting conditions, in addition to continued service, that are monitored for when it is considered probable that the performance condition
will be achieved and we recognize stock-based compensation expense using graded vesting. After the&nbsp;achievement of the performance condition in February 2023, the stock-based compensation for our performance-based stock options was solely
subject to continued service until the fourth anniversary of the second closing of our Series A Preferred Stock. In March and April 2024, we granted awards with performance-based conditions to our current Chief Executive Officer and current Chief
Financial Officer. Upon achievement of the performance condition, in April 2024, the stock-based compensation for our performance-based stock options was solely subject to continued service until the fourth anniversary of the issuance of Series B
Preferred Stock to settle the Series B tranche right. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions. These
assumptions include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Fair value of common stock</I>.&#8195;See the subsection titled &#147;&#151;Determination of fair value of common
stock&#148; below. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">113 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Expected term</I>.&#8195;The expected term represents the period that our stock option awards granted are expected to be
outstanding and is determined using the simplified method (based on the <FONT STYLE="white-space:nowrap">mid-point</FONT> between the vesting date and the end of the contractual term). </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Expected volatility</I>.&#8195;Because we do not have any trading history for our common stock, the expected volatility
is estimated using averages of the historical volatility of our peer group of companies for a period equal to the expected term of the stock options granted. Our peer group of publicly traded companies was chosen based on their similar size, stage
in the life cycle or area of specialty. We intend to continue to consistently apply this process using the same or a similar peer group of public companies, until a sufficient amount of historical information regarding the volatility of our own
common stock price becomes available. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Risk-free interest rate</I>.&#8195;The risk-free interest rate is based on the interest rates paid on securities issued
by the U.S. Treasury with a term approximating the expected term of stock options granted. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Expected dividend</I>.&#8195;We have never paid, and do not anticipate paying, cash dividends on our common stock.
Therefore, the expected dividend yield was assumed to be zero. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Changes in the foregoing assumptions can materially affect the estimate of fair
value and ultimately how much share-based compensation expense is recognized; and the resulting change in fair value, if any, is recognized in our statements of operations during the period the related services are rendered. These inputs are
subjective and generally require significant analysis and judgment to develop. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On the effective date of the registration statement of which this prospectus
forms a part, we will issue certain directors and employees, stock options to purchase an aggregate of 141,161 shares of our common stock, under the 2024 Plan, subject to continued service through such grant date. Based on an assumed exercise price
of $16.00 per share, which is the midpoint of the estimated price range set forth on the cover page of this prospectus, we estimate that the aggregate grant-date fair value of the options to be granted in connection with this offering is
$1.5&nbsp;million, which is expected to be recognized as stock-based compensation expense over a period of one to four years. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">See the sections titled
&#147;Executive compensation&#151;Employee benefit and equity compensation plans&#151;Equity grants to employees&#148; and &#147;Director compensation&#151;2023 director compensation table&#148; included elsewhere in this prospectus for additional
information. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Determination of fair value of common stock </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As a
privately held company, there has been no public market for our common stock to date. The estimated fair value of our common stock has been determined by our board of directors as of the date of each option grant, with input from management,
considering the most recently available third-party valuations of our common stock and our board of directors&#146; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of
the most recent valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#146; Accounting and Valuation Guide, Valuation
of Privately-Held-Company Equity Securities Issued as Compensation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our third-party valuations of common stock were prepared using either the option-pricing method,
or OPM, or the hybrid method, both of which used a market approach to estimate our enterprise value. For valuations performed after March&nbsp;2, 2024, in accordance with the Practice Aid, we determined the hybrid method was the most appropriate
method for determining the fair value of our common unit based on our stage of development and other relevant factors. The OPM treats common stock and preferred stock as call options on the total equity value of a company, with exercise prices based
on the value thresholds at which the allocation among the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">114 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
various holders of a company&#146;s securities changes. Under this method, the common stock has value only if the funds available for distribution to stockholders exceeded the value of the
preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. The hybrid method is a probability-weighted expected return method (&#147;PWERM&#148;) where the equity value in one or more of the
scenarios is calculated using an OPM. The PWERM is a scenario-based methodology that estimates the fair value of common stock based upon an analysis of future values for us, assuming various outcomes. The common stock value is based on the
probability-weighted present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class of stock. The future value of the common stock under each outcome is discounted back to
the valuation date at an appropriate risk-adjusted discount rate and probability weighted to arrive at an indication of value for the common stock. A discount for lack of marketability of the common stock is then applied to arrive at an indication
of value for the common stock. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These third-party valuations resulted in a valuation of our common stock of $3.32, $4.27, $4.87, $5.69, $6.59, $9.15, and $10.62
per share as of October&nbsp;31, 2022, February&nbsp;17, 2023, June&nbsp;6, 2023, March&nbsp;1, 2024, April&nbsp;22, 2024, May&nbsp;20, 2024 and July 19, 2024, respectively. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to considering the results of these third-party valuations, our board of directors considered various objective and subjective factors to determine the fair
value of our common stock as of each grant date, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the prices at which we sold shares of preferred stock and the superior rights and preferences of the preferred stock
relative to our common stock at the time of each grant; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the lack of an active public market, for our common stock and preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the progress of our research and development programs, including the status and results of preclinical studies and clinical
trials for our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our stage of development and commercialization and our business strategy, and material risks to our business;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">external market conditions affecting the pharmaceutical and biopharmaceutical industry and trends within each industry;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our financial position, including cash on hand, and our historical and forecasted performance and operating results;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the likelihood of achieving a liquidity event, such as an initial public offering or sale of our company in light of
prevailing market conditions; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the analysis of initial public offerings and the market performance of similar companies in the biopharmaceutical industry.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The assumptions underlying these valuations represented management&#146;s best estimate, which involved inherent uncertainties and the application
of management&#146;s judgment. As a result, if we had used significantly different assumptions or estimates, the fair value of our common stock and our stock-based compensation expense could have been materially different. For the year ended
December&nbsp;31, 2023 and the six months ended June&nbsp;30, 2024, if there was a 10% increase in the valuation of our common stock at each of the valuation dates listed above and to the underlying exercise price of stock options granted during the
year assuming that such options were granted with an exercise price equal to the fair value of common stock, the impact to our stock-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">115 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
based compensation expense would have been an increase of $3.8&nbsp;million and $0.2&nbsp;million, respectively. If there was a 10% decrease in the valuation of our common stock at each of the
valuation dates listed above and to the underlying exercise price of stock options granted during the year assuming that such options were granted with an exercise price equal to the fair value of common stock, the impact to our stock-based
compensation expense would have been a decrease of $3.1&nbsp;million and $0.2&nbsp;million for the year ended December&nbsp;31, 2023 and the six months ended June&nbsp;30, 2024, respectively. Our estimate of fair value is reviewed and approved by
our board of directors. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Once a public trading market for our common stock has been established in connection with the completion of this offering, it will no longer
be necessary for our board of directors to estimate the fair value of our common stock in connection with our accounting for stock options and other such awards we may grant, as the fair value of our common stock will be determined based on the
quoted market price of our common stock. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Options granted </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following
table summarizes by grant date the number of shares subject to options granted between January&nbsp;1, 2023 and June&nbsp;30, 2024, the per share exercise price of the options, the per share fair value of common stock underlying the options on each
grant date, and the per share estimated fair value of the options: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Number of shares<BR>subject&nbsp;to&nbsp;options<BR>granted</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Per share<BR>exercise&nbsp;price<BR>of options</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Per share fair<BR>value of<BR>common&nbsp;stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Per share<BR>estimated&nbsp;fair<BR>value of<BR>options</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">January&nbsp;6, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">March&nbsp;2, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">March&nbsp;3, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">580,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">March&nbsp;14, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">April&nbsp;8, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">June&nbsp;12, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">July&nbsp;18, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">August&nbsp;9, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">August&nbsp;10, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">August&nbsp;14, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">301,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">August&nbsp;15, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">September&nbsp;6, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">March&nbsp;27, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">778,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">April&nbsp;4, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">866,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">April&nbsp;25, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,053,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">May&nbsp;2, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">325,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">May&nbsp;5, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">May&nbsp;7, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">June&nbsp;11, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">June&nbsp;19, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">July 31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="16" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Valuation of preferred stock tranche right liabilities </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with our Preferred Stock financings, we issued shares under stock purchase agreements that provided an obligation for us to issue additional Preferred
Stock in subsequent closings upon the satisfaction of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">116 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
certain conditions. We classified each of the Series A and Series B preferred stock tranche rights as a liability on our consolidated balance sheets and initially recorded them at fair value upon
the issuance date of the rights. We remeasured the preferred stock tranche right liabilities to fair value at each reporting date and recognized changes in the fair values as a component of other income, net in our consolidated statements of
operations and comprehensive loss. We continued to recognize changes in the fair value of the preferred stock tranche right liabilities at each reporting date until settled. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the satisfaction of relevant conditions in February 2023 and April 2024, respectively, the Series A and Series B preferred stock tranche right liabilities were
remeasured to fair value for the last time and the change in fair value was recognized as a component of other income, net in our consolidated statements of operations and comprehensive loss. The balance of the respective preferred stock tranche
right liability was derecognized upon settlement and the shares of the respective Preferred Stock issued were recorded at fair value. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The fair value of the Series A
preferred stock tranche right liability was determined using a probability-weighted expected return method, which considered as inputs the fair value of the Series A Preferred Stock as of each measurement date, the fair value per share of the Series
A Preferred Stock if the milestone is not met, probability of meeting certain milestone events, the expecting time until certain milestone events would be met, and the discount rate. The most significant assumptions in the valuation model impacting
the fair value of the Series A preferred stock tranche right liability were the fair value of our Series A Preferred Stock and the probably and timing of achieving certain milestone events as of each measurement date. Changes in these inputs could
have a significant impact on the fair value of the Series A preferred stock tranche right liability. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The fair value of the Series B preferred stock tranche right
liability was determined using an option pricing model, which considered as inputs the estimated fair value of the Series B Preferred Stock as of each valuation date, the risk-free interest rate, volatility, expected dividends, and estimated time to
the tranche closing. The most significant assumption in the valuation model impacting the fair value of the Series B preferred stock tranche right liability is the fair value of our Series B Preferred Stock as of each measurement date. The risk-free
interest rate was determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the remaining estimated time period of achievement of the specified milestones underlying the preferred stock tranche rights. The
volatility was based on the historical volatility of publicly traded peer companies adjusted for the seniority of the Series B Preferred Stock. The expected dividend yield is based on the fact that we have never paid cash dividends and do not expect
to pay any cash dividends in the foreseeable future. Changes in these inputs could have a significant impact on the fair value of the Series B preferred stock tranche right liability. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We determined the fair value per share of the underlying Preferred Stock by taking into consideration the most recent sales of our Preferred Stock, results obtained from
third-party valuations and additional factors we deemed relevant. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Recently issued and adopted accounting pronouncements </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our
consolidated financial statements included elsewhere in this prospectus. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Quantitative and qualitative disclosures about market risks </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Market risk represents the risk of loss that may impact our financial position because of adverse changes in financial market prices and rates. Our market risk exposure
is primarily a result of exposure resulting from potential changes in interest rates, exchange rates or inflation. We do not hold financial instruments for trading purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">117 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Interest rate risk </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of
June&nbsp;30, 2024 and December&nbsp;31, 2023, we had $235.8&nbsp;million and $109.8&nbsp;million, respectively, in cash, cash equivalents and short-term investments, which consisted of cash, money market funds, U.S. treasury bills and U.S.
government agency bonds. Our cash and cash equivalents are primarily maintained in accounts with multiple financial institutions in the United States. We may maintain cash and cash equivalent balances in excess of Federal Deposit Insurance
Corporation (FDIC) limits. We do not believe that we are subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Our primary exposure to market risk is interest rate sensitivity, which is
affected by changes in the general level of U.S. interest rates. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, we believe an immediate 10% change in interest rates would not have a material
effect on the fair market value of our investment portfolio. We have the ability to hold our investments until maturity, and therefore, we would not expect our operating results or cash flows to be affected to any significant degree by the effect of
a change in market interest rates on our investment portfolio. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Foreign currency exchange risk </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">All of our employees and our operations are currently located in the United States and our expenses are generally denominated in U.S. dollars. However, we do utilize
certain vendors outside of the United States in connection with our research and development activities. As such, our expenses are denominated in both U.S. dollars and foreign currencies. Therefore, our operations are and will continue to be subject
to fluctuations in foreign currency exchange rates. To date, foreign currency transaction gains and losses have not been material to our consolidated financial statements, and we have not had a formal hedging program with respect to foreign
currency. We do not believe that a hypothetical 10% increase or decrease in exchange rates during any of the periods presented would have had a material effect on our consolidated financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Effects of inflation </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Inflation generally affects us by increasing our labor
and research and development expenses. We do not believe that inflation had a material effect on our business, financial condition, or results of operations during the years ended December&nbsp;31, 2023 and 2022 or the six months ended June&nbsp;30,
2024 and 2023. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Emerging growth company and smaller reporting company status </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Jumpstart Our Business Startups Act of 2012 (the &#147;JOBS Act&#148;), permits an &#147;emerging growth company&#148; such as us to take advantage of an extended
transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected not to &#147;opt out&#148; of such extended transition period,
which means that when a standard is issued or revised and it has different effective dates for public and private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so
until the earlier of the date that we (i)&nbsp;are no longer an emerging growth company or (ii)&nbsp;irrevocably elect to &#147;opt out&#148; of the extended transition period provided in the JOBS Act. As a result, our consolidated financial
statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. We may choose to early adopt any new or revised accounting standards whenever such early adoption is
permitted for <FONT STYLE="white-space:nowrap">non-public</FONT> companies. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are also a &#147;smaller reporting company,&#148; meaning that the market value of
our common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> plus the proposed aggregate amount of gross proceeds to us as
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">118 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
a result of this offering is less than $700.0&nbsp;million and our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year. We may continue to be a smaller
reporting company after this offering if either (i)&nbsp;the market value of our common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than
$250.0&nbsp;million or (ii)&nbsp;our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and the market value of our common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure
requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">119 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc843142_10"></A>Business </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Overview </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are a clinical-stage biotechnology company developing treatments
for inflammatory diseases, with an initial focus on severe respiratory disorders. We are developing verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (&#147;TSLP&#148;),
a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. Preclinical and clinical data to date demonstrate verekitug&#146;s
highly potent inhibition of the TSLP receptor, which we believe will translate to a differentiated product profile, including improved clinical outcomes, substantially extended dosing intervals and the potential to treat a broad spectrum of
patients. We have advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps (&#147;CRSwNP&#148;) and plan to initiate development in chronic
obstructive pulmonary disease (&#147;COPD&#148;). Our experienced team is committed to maximizing verekitug&#146;s unique attributes to address the substantial unmet needs for patients underserved by today&#146;s standard of care. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There are six biologics approved for the treatment of severe asthma; three of these are also approved for CRSwNP. One biologic was recently approved for the treatment of
COPD. Total estimated biologics sales in 2023 for asthma in the United States, Europe and Japan markets were approximately $7.5&nbsp;billion. In December 2021, tezepelumab (marketed as Tezspire by Amgen Inc. (&#147;Amgen&#148;) and AstraZeneca PLC
(&#147;AstraZeneca&#148;)), a monoclonal antibody targeting the TSLP ligand, not the receptor, was approved by the U.S. Food and Drug Administration (&#147;FDA&#148;) as an <FONT STYLE="white-space:nowrap">add-on</FONT> maintenance treatment for
patients with severe asthma. Tezepelumab is the first and only treatment for severe asthma without any phenotype or biomarker limitation, highlighting the benefit of blocking TSLP signaling early in the inflammatory cascade as compared to other
biologics&#146; mechanisms of action which are further downstream. Tezepelumab is projected to reach peak global annual sales of over $3.0&nbsp;billion for severe asthma alone in 2032 and, according to Amgen, achieved more than 20% of new to brand
share of prescriptions in the United States in its first commercial year. In May 2024, Amgen and AstraZeneca reported Phase 2a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data for tezepelumab for
the treatment of moderate to very severe COPD at the American Thoracic Society (&#147;ATS&#148;) International Conference. This trial reported a reduction in the frequency of COPD exacerbations that has supported advancement of tezepelumab into
Phase 3 development for COPD. These clinical data further demonstrate the potential for a TSLP targeted therapy to treat a variety of inflammatory diseases. Based on these recent COPD data, tezepelumab is projected to achieve peak sales in the
United States of approximately $6.0&nbsp;billion to $10.0&nbsp;billion according to third-party research analyst reports. The projections for tezepelumab&#146;s peak sales are not indicative of the potential market opportunity for verekitug and are
subject to a number of assumptions, risks and uncertainties that could cause them to be smaller than currently estimated. Despite the availability of existing biologics for severe respiratory disease, there remains a high unmet need that limits the
utilization of these therapies, including suboptimal symptom control and frequent dosing intervals. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Verekitug is, to our knowledge, the only monoclonal
antibody currently in clinical development that targets and inhibits the TSLP receptor. In May 2024, we presented full <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data from our multicenter,
randomized, double-blind, placebo-controlled Phase 1b multiple ascending dose (&#147;MAD&#148;) clinical trial in asthma patients demonstrating that dosing with verekitug led to rapid and complete TSLP receptor occupancy, and reductions in
fractional exhaled nitric oxide (&#147;FeNO,&#148; a disease-related biomarker) and blood eosinophil levels (&#147;eos,&#148; a disease-related biomarker) that were rapid, substantial and sustained for up to 24&nbsp;weeks after the last dose. This
study also demonstrated that verekitug is approximately <FONT STYLE="white-space:nowrap">300-fold</FONT> more potent than tezepelumab (based on published tezepelumab data), which, combined with verekitug&#146;s pharmacokinetic (&#147;PK&#148;)
profile, enables an extended dosing interval of up to 24&nbsp;weeks, compared to tezepelumab (four week dosing interval). Furthermore, clinical data from our MAD trial indicate an approximately 50% greater effect on FeNO than has previously been
reported for tezepelumab. We have not conducted head-to-head clinical studies of verekitug against tezepelumab, and note that ongoing and future clinical trials for verekitug may produce differing clinical activity and tolerability results. Three
Phase 1 clinical trials have been completed for verekitug across a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">120 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
total of 120 participants, including 32 patients with asthma. In these trials, which were not designed to support formal statistical comparisons, verekitug was well tolerated, demonstrated no
evidence of clinically meaningful anti-drug antibodies (&#147;ADAs&#148;), and showed a predictable and consistent PK profile with high subcutaneous bioavailability. Based on its extended dosing interval and effect on broadly accepted
disease-associated biomarkers, we believe verekitug, if approved, will be the preferred biologic for the treatment of severe asthma, CRSwNP and COPD. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our current
clinical development plan for verekitug is summarized in the pipeline chart below. Having established clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in asthma, we are currently conducting
two separate multi-national, placebo-controlled, randomized Phase 2 clinical trials to investigate the efficacy of two extended dosing intervals of 12 and 24 weeks for patients with severe asthma and 12 weeks for patients with CRSwNP. These trials
have been designed using endpoints that, pending interactions with regulatory authorities, could allow data from these trials to support submissions for product approval. Data from these trials are expected in the second half of 2026 for severe
asthma and the second half of 2025 for CRSwNP. Based on available data from Phase 1 trials with verekitug, we plan to initiate our first clinical trial in COPD and have commenced planning activities for a Phase 2 clinical trial, including
development of a clinical trial protocol and regulatory approval strategy, and expect to dose the first COPD patient in the second half of 2025. Beyond these indications, we believe verekitug has broad potential, and we intend to leverage its unique
attributes to develop it as a potential therapy for numerous TSLP-driven diseases. </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g843142g03g03.jpg" ALT="LOGO" STYLE="width:6.31944in;height:2.28487in;">
 </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><B>&#134;</B></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 2 clinical trials in CRSwNP and severe asthma were initiated in January 2024 and March 2024, respectively, and enrollment is currently ongoing. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Planning activities for a Phase 2 clinical trial in COPD have commenced, including development of a clinical trial protocol and regulatory approval strategy. </TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Leveraging TSLP biology to address unmet needs in severe asthma, CRSwNP and COPD </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>TSLP overview </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Verekitug is a monoclonal antibody that targets and inhibits
the TSLP receptor. TSLP is a member of a class of epithelial cytokines, also including IL-25 and <FONT STYLE="white-space:nowrap">IL-33,</FONT> commonly referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung,
gastrointestinal tract and skin. Dendritic cells, basophils, mast cells, keratinocytes and fibroblasts also produce TSLP with appropriate stimulation. In response to various environmental triggers, including viruses, bacteria, allergens, chemical
irritants and physical injury, TSLP can initiate and amplify a wide range of innate and adaptive immune responses, including supporting epithelial barrier function, dendritic cell activation, type 2 innate lymphoid cell activation and survival,
immune cell recruitment, induction of type 2 responses and regulation of B cell function. Beyond type 2 inflammation, data </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">121 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
also support a role for TSLP in propagating <FONT STYLE="white-space:nowrap">non-type</FONT> 2 inflammatory processes, including <FONT STYLE="white-space:nowrap">IL-17</FONT> production,
modulation of airway structural cells and the promotion of fibrosis. As such, TSLP signaling is a central instigator of multiple downstream biologic pathways relevant to human diseases that are characterized by epithelial inflammation, including
asthma, CRSwNP and COPD. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The TSLP signaling pathway is well-understood as a contributor to disease-driving proinflammatory pathways and is a clinically and
commercially validated target for therapeutic development. Historically, development of biologics for severe asthma and related conditions has focused on type 2 inflammatory cytokines that are activated downstream in the TSLP signaling pathway, for
instance IL-4, <FONT STYLE="white-space:nowrap">IL-5</FONT> and <FONT STYLE="white-space:nowrap">IL-13.</FONT> However, in addition to its effect on type 2 inflammation, emerging evidence indicates that TSLP also impacts <FONT
STYLE="white-space:nowrap">non-type</FONT> 2 inflammation, which may result in broader downregulation of pathways relevant to the pathogenesis of multiple inflammatory diseases. We believe verekitug has the potential, if approved, to address unmet
needs in multiple diseases characterized by TSLP-driven pathobiology due to the high potency and potential for extended dosing intervals that we have observed in our preclinical and clinical development to date. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Only one drug targeting the TSLP pathway has been approved for the treatment of severe asthma. In December 2021, tezepelumab (marketed as Tezspire by Amgen and
AztraZeneca), a monoclonal antibody targeting the TSLP ligand, was approved by the FDA as an add-on maintenance treatment for patients with severe asthma. Tezepelumab is the first and only treatment for severe asthma without any phenotype or
biomarker limitation, highlighting the benefit of blocking TSLP signaling early in the inflammatory cascade as compared to other biologics&#146; mechanisms of action which are further downstream. In the Phase 3 clinical trial of tezepelumab in
adults and adolescents with severe, uncontrolled asthma, patients who received tezepelumab had fewer exacerbations and better lung function, asthma control and health-related quality of life than those who received placebo. Based on pooled safety
data from the clinical trials of tezepelumab, Tezspire&#146;s FDA approved label identifies hypersensitivity reactions following administration as a clinically significant adverse reaction, as well as pharyngitis, arthralgia and back pain as
additional adverse reactions that occurred at an incidence of greater than or equal to 3% and more common than the placebo group. Furthermore, a Phase 2a clinical trial for tezepelumab in COPD patients, which demonstrated a clinically-significant
reduction of COPD exacerbations, the most frequently reported adverse events for tezepelumab were worsening of COPD (12.1%) and incidents of COVID-19 infections (14.5%, trial commenced in July 2019), demonstrating a safety and tolerability profile
consistent with that observed for tezepelumab in severe asthma. These clinical data further demonstrate the potential for a TSLP targeted therapy to treat a variety of inflammatory diseases. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Severe asthma </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Asthma is a common respiratory disease characterized by
chronic airway inflammation that is often underdiagnosed and under-treated. For some people, asthma can simply be a nuisance, for others it can interfere with daily life and potentially even be life-threatening. Of the more than 25&nbsp;million
Americans living&nbsp;with asthma, it is estimated that 5% to 10% suffer from severe asthma. Severe asthma is defined as asthma that remains uncontrolled despite optimized treatment with high-dose inhaled corticosteroids or that&nbsp;requires
high-dosed inhaled corticosteroids to prevent symptoms from becoming uncontrolled. It is estimated that approximately 90% of people with severe asthma are eligible for biologics, but only 440,000 patients are currently treated with biologics,
suggesting more than 80% of eligible patients are not being optimally treated. U.S. sales in 2023 of biologics for the treatment of severe asthma is estimated to be approximately $6.0&nbsp;billion. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These statistics show there is a large population of people living with uncontrolled symptoms of severe asthma. Key areas of unmet need for people living with severe
asthma include improved control of exacerbations and symptoms and reduced treatment burden (e.g., need for frequent injections). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">122 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Chronic rhinosinusitis with nasal polyps (CRSwNP) </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">CRSwNP is an inflammatory disease of the upper airway, marked by chronic sinonasal inflammation and the presence of inflammatory polyps in the nasal passages and
paranasal sinuses. It is estimated by Sanofi that approximately 900,000 patients in the United States and Europe suffer from CRSwNP. Nasal polyps are associated with significant morbidity and debilitating symptoms; it is estimated that 40% to 45% of
people with severe asthma also have CRSwNP and that up to 65% of people with CRSwNP also have asthma, demonstrating a strong association between the two conditions. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The current treatment options for patients with CRSwNP are corticosteroids, surgery and, more recently, biologics. Although a treatment option, surgery does not
guarantee symptom relief. Even with surgery, many people with CRSwNP remain symptomatic, with the recurrence rate of CRSwNP ranging from 20% to 60% within 18 months to four years and increasing to 79% after 12 years. Recurrence is particularly
common for people with severe disease, including those also living with asthma or who have undergone prior surgeries. The recent FDA approvals of biologic treatments for CRSwNP have established a well-understood regulatory pathway and route to
commercialization. It is estimated that approximately 200,000 adult patients in the United States, major European markets and Japan with CRSwNP are eligible for biologics. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Despite these available treatments, the quality of life (&#147;QoL&#148;) studies and post-surgical recurrence rates clearly show that many people with CRSwNP have
uncontrolled symptoms that are impacting their daily life and current treatments are not meeting their needs. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Chronic obstructive pulmonary disease (COPD)
</I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Similar to asthma, COPD is a chronic inflammatory disease that obstructs airflow from the lungs. Chronic inflammation causes structural changes within the
lungs, narrowing already small airways and damaging lung parenchyma which causes air sacs to lose functionality and decreases lung elasticity. It is typically caused by long-term exposure to irritants, most often cigarette smoke. People with a
history of asthma are also more likely to have COPD. Historically, COPD has been considered to have elements of both type 2 and <FONT STYLE="white-space:nowrap">non-type</FONT> 2 immune responses. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">COPD is the third leading cause of death worldwide, causing approximately 3.2&nbsp;million deaths in 2019. Almost 14.2&nbsp;million Americans, or 6.5% of the adult
population, reported in one study that they have been diagnosed with COPD, yet the actual number is likely higher given that more than half of adults with low pulmonary function in another study reported that they were not aware that they had COPD.
</P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Treatments for COPD are similar to those for asthma and CRSwNP, including inhaled steroids to reduce inflammation in the airways as well as bronchodilator
inhalers to relax airways and improve airflow. Oxygen and surgery may also be used for people with severe COPD. Dupilumab (marketed as Dupixent by Sanofi and Regeneron Pharmaceuticals, Inc. (&#147;Regeneron&#148;)), an interleukin (&#147;IL&#148;)-4
receptor alpha antagonist (&#147;IL-4R<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT>&#148;), is the only biologic approved for the treatment of COPD. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Despite available treatments, 60% of all COPD patients report some limitations in their daily activity, with 45% being unable to work and 75% complaining of difficulty
climbing stairs. Given the high levels of morbidity and mortality associated with COPD, the currently available medicines are not sufficient to control symptoms or disease progression. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Verekitug: Inhibiting TSLP signaling in severe asthma, CRSwNP and COPD </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Verekitug is a novel recombinant fully human immunoglobulin G1 (&#147;IgG1&#148;) monoclonal antibody that binds to the TSLP receptor and inhibits its signaling. In
2021, we acquired verekitug from Astellas Pharma Inc. (&#147;Astellas&#148;). Astellas discovered the compound and completed preclinical studies and a Phase 1 single ascending dose (&#147;SAD&#148;) </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">123 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
trial, providing the early foundational work for our Phase 1b MAD trial. In those preclinical studies, which were not designed to support formal statistical comparisons, verekitug potently
inhibited TSLP signaling. Additionally, verekitug inhibited cytokine production from CD4&#043; T cells, suggesting that it may be effective against type 2 and <FONT STYLE="white-space:nowrap">non-type</FONT> 2 inflammation. In the Phase 1 SAD trial
in healthy volunteers, verekitug demonstrated a favorable safety profile with no drug-related serious treatment-emergent adverse events, dose proportional pharmacokinetics and a pharmacodynamic effect consistent with TSLP antagonism. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have conducted two additional clinical trials of verekitug: a Phase 1b MAD trial in patients with asthma and a Japanese ethnobridging study in healthy volunteers.
Across the three clinical trials, we have data from 120 total participants, including 32 patients with asthma. In these trials, verekitug was well tolerated, had no clinically meaningful immunogenicity, and showed a predictable and consistent PK
profile with high subcutaneous bioavailability. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our Phase 1b MAD clinical trial established clinical
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> for verekitug in asthma. In the trial, which was not designed to support formal statistical comparisons, verekitug demonstrated rapid, substantial and
sustained target engagement and maintained maximal inhibition of disease-related biomarkers in patients with asthma for up to 24 weeks after the last study dose. Results of the Phase 1b study also demonstrated that verekitug is a potent inhibitor of
the TSLP receptor and has the potential for an extending dosing interval compared to currently available treatments. Importantly, the PK/pharmacodynamic (&#147;PD&#148;) modeling that was done based on the preclinical data aligned very closely with
these early clinical results, strengthening our understanding of verekitug&#146;s attributes and behavior in humans. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are currently conducting two separate
multi-national, placebo-controlled, randomized Phase 2 clinical trials to investigate the efficacy of two extended dosing intervals of 12 and 24 weeks for patients with severe asthma and 12 weeks for patients with CRSwNP. These trials have been
designed using endpoints that, pending interactions with regulatory authorities, could allow data from these trials to support submissions for product approval. Data from these trials are expected in the second half of 2026 for severe asthma and the
second half of 2025 for CRSwNP. Based on available data from Phase 1 trials with verekitug, we plan to initiate our first clinical trial in COPD and have commenced planning activities for a Phase 2 clinical trial, including development of a clinical
trial protocol and regulatory approval strategy, and expect to dose the first COPD patient in the second half of 2025. Beyond these indications, we believe verekitug has broad potential, and we intend to leverage its unique attributes to develop it
as a potential therapy for other TSLP-driven diseases. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our team and investors </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have built a team with deep experience and a strong track record of execution that has allowed us to move from company inception to Phase 2 in less than three years.
Our leadership team and board of directors have significant experience developing and commercializing innovative medicines, with deep expertise in severe asthma and other respiratory diseases. E. Rand Sutherland, M.D., M.P.H., our Chief Executive
Officer (&#147;CEO&#148;), has more than 25 years of business and clinical experience, having most recently served as CEO of Seeker Biologics Inc., before that as President of Translate Bio, Inc. prior to its $3.2&nbsp;billion acquisition by Sanofi,
and before that in research and development and business unit roles at Sanofi developing and launching innovative medicines in immunology and rare diseases, including dupilumab. Before joining the biopharma industry, Dr.&nbsp;Sutherland was a
Professor of Medicine at the University of Colorado and Chief of Pulmonary and Critical Care Medicine at National Jewish Health in Denver. Our Chief Medical Officer and Head of Research and Development, Aaron Deykin, M.D., leads our clinical
development activities and strategy. Prior to joining us, Dr.&nbsp;Deykin was Senior Vice President of Clinical Sciences at Biogen, Inc. (&#147;Biogen&#148;) overseeing biostatistics, statistical programming, biomarkers, clinical pharmacology,
epidemiology and clinical operations for Biogen&#146;s pipeline globally. Dr.&nbsp;Deykin was previously Assistant Professor of Medicine at Harvard Medical School and a member of the Pulmonary and Critical Care faculty at Brigham and Women&#146;s
Hospital, where he treated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">124 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
patients with asthma and other advanced respiratory diseases. Michael Paul Gray, M.B.A., our Chief Financial and Operating Officer, brings over 20 years of public and private leadership
experience, including broad strategic, financial and operating experience in global life science companies. Mr.&nbsp;Gray previously held the same roles at Carmot Therapeutics, Inc. prior to its $2.7&nbsp;billion acquisition by Roche Group. Our
board of directors consists of highly experienced biotechnology executives and investors, including Ronald C. Renaud,&nbsp;Jr., M.B.A., CEO of Kailera Therapeutics, Inc., and Marcella Kuhlman Ruddy, M.D., M.S. of Tectonic Therapeutic, Inc. and
formerly Regeneron, as our independent directors. We have also assembled a team of well-known and respected advisors and investigators to provide perspective on our data and participate in our clinical program. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since our inception, we have raised approximately $400&nbsp;million from premier biotechnology investors. Prospective investors should not rely on the past investment
decisions of our investors, as our investors may have different risk tolerances and have received their shares in prior offerings at prices lower than the price offered to the public in this offering. Please see the section titled &#147;Certain
relationships and related party transactions&#148; included elsewhere in this prospectus for a description of the financings we have conducted to date. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Our
strategy </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our mission is to develop verekitug to be the first approved antagonist of the TSLP receptor to benefit patients suffering from severe inflammatory
diseases that are underserved by today&#146;s standard of care. The key components of our strategy to achieve this mission are: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Leverage verekitug&#146;s unique mechanism of action to improve the treatment options for millions of patients living
with severe inflammatory diseases.</B>&#8195;Preclinical and early clinical data demonstrate that verekitug is a highly potent inhibitor of the TSLP receptor. Verekitug is, to our knowledge, the only monoclonal antibody currently in clinical
development that targets the TSLP receptor. We believe these characteristics will translate into a differentiated profile, including improved clinical outcomes, substantially extended dosing intervals, and the potential to treat for a broad spectrum
of TSLP-driven inflammatory diseases.&nbsp;For example, our data support evaluating two extended dosing intervals of 12 and 24 weeks as compared to the current standard of care, including tezepelumab (four week dosing interval).
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Advance our ongoing Phase 2 clinical trials for verekitug in severe asthma and CRSwNP.&#8195;</B>We are currently
conducting two separate multi-national, placebo-controlled, randomized Phase 2 clinical trials for verekitug in severe asthma and CRSwNP.&nbsp;We have designed our trials to leverage established biomarkers, clinical trial paradigms and validated
regulatory pathways to rapidly generate data to further establish the unique therapeutic profile of verekitug. In addition, these trials have been designed using endpoints that, pending interactions with regulatory authorities, could allow data from
these trials to support submissions for product approval. Data from these trials are expected in the second half of 2026 for severe asthma and the second half of 2025 for CRSwNP. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Expand the impact of verekitug through initiation of an additional development program in
COPD.</B><B></B>&#8195;Dupilumab was recently approved by the FDA as an <FONT STYLE="white-space:nowrap">add-on</FONT> maintenance treatment of patients with inadequately controlled COPD and an eosinophilic phenotype. Based on this and recent Phase
2a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data from tezepelumab validating the role of TSLP in COPD, we<B> </B>plan to evaluate verekitug for the treatment of COPD. Similar to severe asthma
and CRSwNP, we are designing a robust clinical development plan that will allow us to extend verekitug&#146;s unique attributes and impact into COPD. Based on available data from Phase 1 trials with verekitug, we plan to initiate our first clinical
trial in COPD and expect to dose the first COPD patient in the second half of 2025. </P></TD></TR></TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Maximize the potential of verekitug by identifying additional TSLP-driven diseases with high unmet needs that could be
addressed by our product candidate.&#8195;</B>The TSLP signaling pathway is well understood to be </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">125 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
either a risk factor for or a key driver of inflammatory diseases across multiple therapeutic areas, including respiratory, dermatology, gastroenterology, nephrology and allergy/immunology. Thus,
we believe there is a significant opportunity to expand the impact of verekitug beyond our initial indications of focus in respiratory disease. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Overview of TSLP </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">TSLP is a member of a class of epithelial cytokines, also
including <FONT STYLE="white-space:nowrap">IL-25</FONT> and <FONT STYLE="white-space:nowrap">IL-33,</FONT> commonly referred to as alarmins. In response to various environmental triggers, including viruses, bacteria, allergens, chemical irritants
and physical injury, TSLP is produced by the epithelium and can initiate and amplify a wide range of innate and adaptive immune responses including supporting epithelial barrier function, dendritic cell activation, type 2 innate lymphoid cell
activation and survival, immune cell recruitment, induction of type 2 responses and regulation of B cell function. Beyond type 2 inflammation, data also support a role for TSLP in propagating <FONT STYLE="white-space:nowrap">non-type</FONT> 2
inflammatory processes including <FONT STYLE="white-space:nowrap">IL-17</FONT> production, modulation of airway structural cells and the promotion of fibrosis. As such, TSLP signaling is a central instigator of multiple downstream biologic pathways
relevant to human diseases that are characterized by epithelial inflammation, including asthma, CRSwNP and potentially COPD. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">TSLP is primarily produced by
epithelial cells, especially in the lung, gastrointestinal tract and skin. Dendritic cells, basophils, mast cells keratinocytes and fibroblasts also produce TSLP with appropriate stimulation. Relevant stimuli include mechanical injury, <FONT
STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokines, allergen proteases and viral infections, among others. The breadth of TSLP effects suggests it is involved in tissue homeostasis and host defense and acts as an early alarm signal for the
immune system. TSLP plays a critical role in many diseases, including asthma, allergic diseases and chronic inflammatory diseases. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to type 2 mediators,
TSLP has been shown to drive T helper (&#147;Th&#148;) 17 cell polarization of naive CD4 helper cells. As severe asthma phenotypes have been associated with increased Th17 cells and neutrophilic inflammation, in addition to eosinophilic
inflammation, interruption of TSLP signaling has the potential to provide benefit to patients whose disease is driven by both type 2 and <FONT STYLE="white-space:nowrap">non-type</FONT> 2 inflammatory processes. Tezepelumab, an approved antibody
against TSLP without restriction to patients with only type 2 inflammation, has been shown to have clinical benefits in patients with severe asthma who do not have elevated type 2 biomarkers as with all other approved therapies. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Beyond its role in inflammation, TSLP also acts on airway structural cells. Airway smooth muscle cells express TSLP receptor and when stimulated by TSLP, they increase
production of <FONT STYLE="white-space:nowrap">IL-6</FONT> and <FONT STYLE="white-space:nowrap">IL-8.</FONT> Bronchial fibroblasts also produce TSLP and express TSLP receptor. With TSLP receptor signaling, the bronchial fibroblasts produce collagen,
<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT> smooth muscle actin, arginase 1 and transforming growth factor
<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT></FONT>1. Taken together, this indicates </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">126 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
that TSLP plays a pivotal role in promoting structural changes in asthmatic airways. A summary of the TSLP signaling pathway is illustrated in Figure 1 below. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g843142g00u68.jpg" ALT="LOGO" STYLE="width:6.30499in;height:3.60804in;">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 1: TSLP signaling pathway </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">TSLP
initiates intracellular signaling through the binding of its TSLP receptor and the recruitment of the <FONT STYLE="white-space:nowrap">IL-7</FONT> receptor alpha-chain <FONT STYLE="white-space:nowrap">(&#147;IL-7R</FONT><FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT>&#148;). TSLP receptor is expressed on many different cell types, including dendritic cells, T and B cells, natural killer T cells, eosinophils, basophils and
epithelial cells. Once activated, the TSLP receptor complex then activates a signaling cascade that results in the production of type 2 <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokines, including
<FONT STYLE="white-space:nowrap">IL-5,</FONT> <FONT STYLE="white-space:nowrap">IL-9,</FONT> <FONT STYLE="white-space:nowrap">IL-4</FONT> and <FONT STYLE="white-space:nowrap">IL-13.</FONT> <FONT STYLE="white-space:nowrap">IL-5</FONT> is a key
cytokine in eosinophilic inflammation. <FONT STYLE="white-space:nowrap">IL-9</FONT> is important in allergic inflammation, while <FONT STYLE="white-space:nowrap">IL-4</FONT> and <FONT STYLE="white-space:nowrap">IL-13</FONT> are both critical to type
2 inflammation. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>The role of TSLP in severe asthma, CRSwNP, COPD and related inflammatory diseases </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Airway biopsies of people with asthma have shown overexpression of TSLP and type 2 cytokines, particularly in those with severe disease. Type 2 cytokines have enhanced
release in the presence of TSLP and therefore are an additional indicator of TSLP expression. Blocking TSLP is expected to reduce type 2 cytokine production by Th2 memory cells, innate lymphoid type 2 cells and mast cells, all of which are involved
in inflammation. Additionally, several single nucleotide polymorphisms at the TSLP genomic locus were associated with increased asthma susceptibility or protection. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">TSLP may also play a role in the efficacy of corticosteroid treatments for people with asthma. In an animal model, the absence of TSLP signaling results in a significant
increase in the anti-inflammatory effects of corticosteroids. These results appear to be relevant for people with asthma as well given that TSLP concentration in the bronchoalveolar lavage (&#147;BAL&#148;) fluid from people with severe asthma were
inversely correlated with corticosteroid-mediated inhibition of <FONT STYLE="white-space:nowrap">IL-5</FONT> production. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The therapeutic potential of inhibiting
TSLP in people with asthma is supported by significant clinical data, including a Phase 3 trial of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Tezepelumab is a fully human monoclonal antibody that binds to the TSLP ligand
and prevents its interaction </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">127 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
with the TSLP receptor. The study met its primary endpoint of reduction in rate of asthma exacerbations, including for those participants with low blood eos at baseline. The study also met
several secondary endpoints showing improvements across multiple measures of disease, including lung function, asthma control and health-related quality of life. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">TSLP has been implicated in many diseases beyond asthma as well, as shown in Figure 2 below. While the cause of CRSwNP is not fully understood, the role played by the
immune system in the condition has been well studied. CRSwNP is predominantly a type 2 inflammatory response with elevated levels of TSLP. Lung epithelium and submucosa samples from people with COPD also contained a greater number of TSLP
mRNA-positive cells and BAL samples from these patients had higher concentration of TSLP compared to healthy samples. TSLP has also been indicated as a driver of atopic dermatitis (&#147;AD&#148;), a chronic inflammatory disease of the skin. TSLP
was found to be highly expressed in acute and chronic AD lesions but was undetectable in nonlesional skin. Figure 2 below shows many of the diseases in which TSLP has been implicated, including the three indications we are targeting, severe asthma,
CRSwNP and COPD. </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g843142g20g20.jpg" ALT="LOGO" STYLE="width:6.30976in;height:2.94101in;">
 </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Target indications for verekitug based on our current development strategy </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 2: Selected diseases in which TSLP
has been shown to play a role</I> </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Overview of severe asthma </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Disease overview </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Asthma is a common disease of the lungs characterized
by chronic airway inflammation that is often underdiagnosed and under-treated. With the narrowing of the bronchioles, people with asthma can experience edema or swelling due to fluid accumulation, hyperresponsiveness of the airway resulting in
muscle contraction and excess mucus production. People living with asthma experience respiratory symptoms, such as wheeze, shortness of breath, chest tightness and cough, that vary over time and in intensity and also experience airflow limitations
mostly with expiration. Asthma attacks can be triggered by infections or environmental irritants. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Approximately 350&nbsp;million people live with asthma around the
world, including more than 25&nbsp;million Americans. For some people, asthma can simply be a nuisance, for others it can interfere with daily life and potentially even be life-threatening. Of the more than 25&nbsp;million Americans living with
asthma, it is estimated that 5% to 10% suffer from severe asthma. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">128 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Severe asthma is defined as someone diagnosed with asthma who requires high-dose inhaled corticosteroids in order to
control symptoms. Asthma is also considered severe when it is uncontrolled despite proper use of these medications.&nbsp;Individuals who suffer from severe uncontrolled asthma may experience symptoms throughout most days and every night. Their
symptoms are also more intense and last for longer periods than with regular asthma. Severe asthma attacks can result in confusion or agitation, being unable to speak in full sentences, a bluish tint to the lips, face or fingernails, rapid breathing
and having symptoms that don&#146;t improve after using a rescue inhaler. These attacks can last from hours to days, compared to mild asthma attacks which typically last only a few minutes. In rare instances, severe asthma attacks can result in
death. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There are two main categories of severe asthma, <FONT STYLE="white-space:nowrap">type-2</FONT> inflammation and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">non-type-2</FONT></FONT> inflammation. Both types of asthma are assessed using eos and FeNO as common biomarkers. Type 2 inflammation refers to a specific type of immune response pattern where Th cells release cytokines
such as <FONT STYLE="white-space:nowrap">IL-4,</FONT> <FONT STYLE="white-space:nowrap">IL-5,</FONT> <FONT STYLE="white-space:nowrap">IL-9</FONT> and <FONT STYLE="white-space:nowrap">IL-13</FONT> and also promote the formation of anti-immunoglobin E
(&#147;IgE&#148;) antibodies. Additionally, certain immune cells, specifically mast cells, basophils and eosinophils, become activated. Collectively, these cells help to secrete mucus, promote swelling and contract smooth muscle cells, all of which
are symptoms of asthma. A high eosinophil blood count is characteristic of type 2 inflammation and an important measure as eosinophils play a vital role in sustaining and enhancing chronic inflammatory asthmatic response. Elevated FeNO levels act as
another important measure, as <FONT STYLE="white-space:nowrap">IL-13,</FONT> mainly secreted by eosinophils, activates the expression of inducible nitric oxide synthase and increases the production of nitric oxide. It is estimated that 55% to 70% of
people with severe asthma have type 2 inflammation as a major contributing cause. Understanding of the type 2 inflammation pathway has allowed for the development of targeted therapies for the treatment. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">Non-type</FONT> 2 inflammation asthma is assessed by a lower blood eosinophil count and lower exhaled nitric oxide. It is characterized
by Th1 and/or Th17-cell mediated inflammation rather than the <FONT STYLE="white-space:nowrap">Th2-cell</FONT> mediated inflammation seen in type 2 inflammation. People with <FONT STYLE="white-space:nowrap">non-type</FONT> 2 asthma typically have
poor steroid response and have historically not been candidates for biologic treatments. Recently tezepelumab was approved by the FDA for people with severe asthma irrespective of their blood eosinophil count given the results of the Phase 3 trial
showed improvement in asthma symptoms for both type 2 and <FONT STYLE="white-space:nowrap">non-type</FONT> 2 patient populations. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Overview of current asthma
treatments </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Asthma cannot be cured, but for many people it can be controlled. The long-term goals of asthma management from a clinical perspective are to
achieve good control of symptoms to allow for normal daily activities and to minimize the risk of asthma-related deaths, exacerbations, persistent airflow limitations and side effects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The standard of care for asthma includes three main categories of treatment: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Controller medications, which contain inhaled corticosteroids (&#147;ICS&#148;), are used to reduce airway inflammation,
control symptoms and reduce future risks of exacerbations and related decline in lung function. Patients with mild asthma can typically control symptoms as they occur with <FONT STYLE="white-space:nowrap">low-dose</FONT> ICS. Patients with severe
asthma require high doses of ICS and may not be able to control their symptoms even with proper use of inhaler. Importantly, people with <FONT STYLE="white-space:nowrap">non-type</FONT> 2 inflammation asthma are not responsive to steroid treatment.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Reliever medications are provided to all patients for <FONT STYLE="white-space:nowrap">as-needed</FONT> relief of
breakthrough symptoms. These treatments could be <FONT STYLE="white-space:nowrap">ICS-formoterol,</FONT> <FONT STYLE="white-space:nowrap">ICS-long-acting</FONT> beta-agonist (&#147;LABA&#148;) or <FONT STYLE="white-space:nowrap">as-needed</FONT>
short-acting beta2 agonist (&#147;SABA&#148;). <FONT STYLE="white-space:nowrap">Over-use</FONT> of SABA can lead to an increased risk of asthma exacerbations and therefore reducing the need for reliever medications is an important goal in asthma
treatment. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Biologic therapies for patients with severe asthma whose persistent symptoms and exacerbations are not controlled with high
dose controller medications. Add on therapies include biologics such as IgE, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-IL-4,</FONT></FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">129 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
<FONT STYLE="white-space:nowrap">anti-IL5,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-IL-13</FONT></FONT> and anti-TSLP; bronchodilators, such as long-acting
muscarinic antagonists (&#147;LAMA&#148;); antibiotics, such as azithromycin; bronchial thermoplasty; and low dose oral corticosteroids. Similar to ICS, people with <FONT STYLE="white-space:nowrap">non-type</FONT> 2 inflammation asthma do not
respond well to most biologic therapies, with the exception of the only currently approved TSLP signaling inhibitor, tezepelumab. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Biologic
therapies for severe asthma </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the past few years, several new biologics have been approved by the FDA for the treatment of severe asthma. Most of these
therapies work by targeting specific cells or proteins in the body involved in the type 2 inflammatory response triggered with asthma, including eosinophils, IgE and several ILs or their receptors. In clinical trials, biologics have shown to reduce
airway hyperactivity and the number of asthma attacks. They may allow for the reduction or even discontinuation of long-term oral steroid use. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Biologics are
administered either subcutaneously or intravenously on a <FONT STYLE="white-space:nowrap">bi-weekly,</FONT> monthly, or <FONT STYLE="white-space:nowrap">bi-monthly</FONT> basis, depending on the specific product. Table 1 below identifies
FDA-approved biologic treatments for asthma and each product&#146;s mechanism of action, specific asthma indication and dosing interval. Despite the efficacy shown in clinical trials, it is estimated that less than 20% of people with severe asthma
receive biologic treatment. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:2.00pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:2.00pt solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:2.00pt solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><B>FDA approved biologic<BR>treatments</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Mechanism of action</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Type of asthma</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>Dosing&nbsp;interval</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Omalizumab / Xolair</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap">Anti-IgE</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Moderate to severe persistent allergic asthma</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">2&nbsp;or&nbsp;4&nbsp;weeks</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Dupilumab / Dupixent</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Blocks <FONT STYLE="white-space:nowrap">IL-4</FONT> and <FONT STYLE="white-space:nowrap">IL-13</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Moderate to severe eosinophilic asthma</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">2 weeks</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Mepolizumab / NUCALA</P></TD>
<TD VALIGN="bottom" ROWSPAN="3" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Blocks <FONT STYLE="white-space:nowrap">IL-5</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="3" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Severe eosinophilic asthma</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">4 weeks</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Reslizumab / Cinqair</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">4 weeks (IV)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Benralizumab / Fasenra</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">8 weeks</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Tezepelumab / Tezspire</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Blocks TSLP</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Severe asthma (without restriction to type 2 patients only)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">4 weeks</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Table 1: Overview of FDA approved biologic treatments for asthma </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Tezepelumab is a human monoclonal antibody that binds to the TSLP ligand and prevents its interaction with the TSLP receptor. While tezepelumab has a different mechanism
of action compared to verekitug, which inhibits the TSLP receptor itself, both antibodies work at the same point in the TSLP signaling pathway which is upstream of other competitor biologics currently approved for the treatment of asthma, CRSwNP and
COPD. We believe the biologic validation for efficacy in patients with severe asthma without elevated type 2 markers as well as the clinical and regulatory progress of tezepelumab provide a strong rationale for our own development program. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In 2021, the results of a Phase 3 trial of tezepelumab in participants with severe, uncontrolled asthma were published in the <I>New England Journal of Medicine</I>.
Participants were dosed every four weeks (&#147;Q4W&#148;) with tezepelumab or placebo. The trial met its primary endpoint of reduction in annualized asthma exacerbation rate (&#147;AAER&#148;) with a 56% reduction in AAER over 52 weeks compared to
placebo. Tezepelumab also achieved a statistically significant reduction in AAER in participants with low baseline eosinophil counts. In addition, the study included biomarker endpoints that have been found to be clinically relevant in asthma:
change from baseline in eosinophil count and change in baseline in FeNO. Both endpoints showed a significant improvement in the biomarkers with a decrease of 150 cells/&micro;l from baseline for the eosinophil count and a decrease of 17 parts per
billion (&#147;ppb&#148;) for baseline for FeNO. There were no clinically meaningful differences in safety results </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">130 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
between the tezepelumab and placebo groups. The most frequently reported adverse events were nasopharyngitis, upper respiratory tract infection and headache. As reported in the <I>New</I>
<I>England Journal of Medicine</I>, patients who received tezepelumab had fewer exacerbations and better lung function, asthma control and health-related quality of life than those who received placebo. Based on pooled safety data from the clinical
trials of tezepelumab, the resulting FDA approved label for Tezspire identifies hypersensitivity reactions following administration as a clinically significant adverse reaction, as well as pharyngitis, arthralgia and back pain as additional adverse
reactions that occurred at an incidence of greater than or equal to 3% and more common than the placebo group. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Dupilumab (Q2W), mepolizumab (Q4W), reslizumab (Q4W)
and benralizumab (Q8W) are biologics that target cytokines acting downstream of the TSLP receptor. These treatments, which produce a 48% to 81% reduction in asthma exacerbation rates, have all been approved by the FDA for the treatment of asthma,
but all have labels that are restricted to people with high eosinophilic levels, thereby limiting their use in a substantial portion of severe asthma patients. We believe this is due to their downstream mechanism which is restricted to the type 2
inflammation pathway. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The clinical program for tezepelumab and other biologics have established clinical endpoints that were found to be acceptable for approval by
the FDA, providing a strong rationale for our own development program. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Unmet need for people living with severe asthma </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While there are many approved asthma treatments, there remains a significant unmet need for people living with severe asthma. Despite the use of high dose medicines,
avoiding triggers and following treatment plans, many people with severe asthma continue to have uncontrolled symptoms. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Severe asthma may impact normal daily
activities, resulting in missing work or school and can directly impact a person&#146;s quality of life. People with severe asthma often demonstrate significant reduction of their lung function when tested by&nbsp;spirometry&nbsp;or a&nbsp;pulmonary
function test. Despite the fact that severe asthma accounts for a small percentage of people with asthma, half of all asthma-related healthcare costs are attributed to their treatment. In the United States, asthma is responsible for $80&nbsp;billion
in annual costs due to care, absenteeism and mortality. Asthma also results in over 1.0&nbsp;million emergency department visits each year and over 3,500 deaths per year in the United States alone. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">People living with uncontrolled symptoms despite compliance with their treatment plan are in need of options with greater efficacy than those that are currently
available. This has the potential to not only better control symptoms and improve quality of life but to also reduce the burden on our healthcare system. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even
though increased medicine adherence leads to better symptoms control and health outcomes, complying with a treatment plan can be challenging for severe asthma patients. A recent study looked at compliance with biologic treatments using proportion
days covered (&#147;PDC&#148;) as a surrogate measure for adherence. The study authors set 0.75 as the mark of good adherence. In the first six months of being prescribed a biologic treatment for asthma, only 61% of people achieved a PDC of <FONT
STYLE="font-family:Times New Roman">&#8805;</FONT>0.75. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our internal market research shows that the dosing intervals for currently available biologics do not match
the desired dosing interval of the majority of patients. In fact, the current dosing of every 2, 4 or 8 weeks only satisfies approximately one-third of patients according to physician-reported &#147;ideal&#148; dosing interval. Our research shows
that approximately 90% of asthma treaters would be highly willing to use verekitug across both Q12W and Q24W dosing intervals, approximately 90% of asthma patients would consider switching to a product with a less-frequent dosing interval and more
than 95% of asthma patients are moderately or highly likely to ask their provider about a treatment option with a longer dosing interval. Approximately 85% of asthma treaters believe that the TSLP mechanism of action has high clinical utility and
that less-frequent dosing is considered more attractive than all other biologic therapeutics brands. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">131 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe that by reducing the frequency of dosing we can increase patient compliance with biologic treatments for severe
asthma. Additionally, a less frequent dose interval may appeal to patients that are not satisfied with their current treatment plan or are unwilling to take current biologics due to the treatment burden that comes with frequent dosing. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There is also a subpopulation of patients that live with uncontrolled symptoms due to the limitation of currently available treatments. These patients often have an
absence of biomarkers associated with type 2 inflammation and, perhaps unsurprisingly, do not respond to treatments that target molecules downstream in the type 2 inflammation pathway. These patients are in need of a highly effective treatment which
has a broad impact on the inflammation pathway. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Market opportunity for severe asthma </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Asthma is a large and growing market as new treatments become available and diagnoses continue to increase. In 2018, 13% of Americans had been diagnosed with asthma at
one point in their lives, which is a 43% increase in total asthma diagnoses compared to 9.1% of Americans in 1999. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The major asthma markets, including the
United States, France, Spain, Germany, Italy, the United Kingdom (&#147;UK&#148;) and Japan, have estimated annual sales of approximately $7.5&nbsp;billion for 2023 with a compound annual growth rate (&#147;CAGR&#148;) of approximately 5.9% through
2032. The United States alone is estimated to have approximately $6.0&nbsp;billion in asthma market sales for 2023. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Of the more than 50&nbsp;million people
diagnosed with asthma in these major markets, it is estimated that only 440,000 patients are treated with biologics currently, or less than 20% of eligible patients. This creates a significant opportunity for a biologic that meets patients&#146;
needs in terms of efficacy and the reduced burden of a longer dosing interval. We believe the longer dosing interval will increase adherence and potentially provide a treatment option for asthma sufferers who were unwilling to take treatments with
more frequent dosing. Additionally, because severe asthma is typically treated by specialty care providers rather than primary care physicians, we believe that commercialization can be successfully executed with a focused strategy and sale force.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the past several years, six biologic treatments for asthma have been approved by the FDA and five of these have achieved or are projected to achieve greater than
$1.0&nbsp;billion in annual sales by 2025, underscoring the need for new treatments and the large size of the market. Tezepelumab, the most recent of the FDA approvals in asthma, is projected to reach peak global annual sales of over
$3.0&nbsp;billion for severe asthma alone in 2032, and had achieved more than 20% of new to brand share of prescriptions in the United States in its first commercial year. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Taken together, we believe the strength of the biologic market has demonstrated there is room for multiple entrants into the market and the opportunity for rapid
acceleration for market share. The opportunity in asthma is shown in Figure 3, which summarizes 2023 estimates of biologics eligible patients and patients treated with biologics. We believe the potency and safety clinical data that we have generated
for verekitug to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">132 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
date, along with the expected extended dosing interval, means we are well positioned to capitalize on this market opportunity. </P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g843142g33n33.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 3: Biologics-eligible vs. currently-treated severe asthma patients </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">By acting upstream in the signaling pathway, we believe verekitug, similar to tezepelumab, has the potential to treat a broader asthma population than other available
biologics. This would address a population that is refractory to existing treatments and in need of new therapies. We believe verekitug has a potency advantage over tezepelumab and will also have an extended dosing interval. Given this, we are
confident in the ability of verekitug to gain market share if approved by regulatory agencies. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Overview of CRSwNP </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Disease overview </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">CRSwNP is an inflammatory disease of the upper
airway, marked by chronic sinonasal inflammation and the presence of inflammatory polyps in the nasal passages and paranasal sinuses. CRSwNP is associated with significant morbidity and debilitating symptoms, and it is estimated that approximately
900,000 patients in the United States and Europe suffer from this disease. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">CRSwNP has four main symptoms: runny nose or postnasal drip, nasal congestion, facial
pressure and/or pain and loss of smell and/or taste. Patients may also experience ear pain, sneezing, severe difficulty breathing through the nose and sleep disturbances. These symptoms can have a significant impact on quality of life. It is
estimated that 40% to 45% of people with severe asthma also have CRSwNP and that up to 65% of people with CRSwNP also have asthma, demonstrating a strong association between the two conditions and an increase in comorbid asthma severity. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The cause of CRSwNP is not fully understood although the role of the immune system in the condition has been well studied. CRSwNP is predominantly a type 2 inflammatory
response with elevated levels of TSLP as well as <FONT STYLE="white-space:nowrap">IL-5,</FONT> <FONT STYLE="white-space:nowrap">IL-13,</FONT> eosinophilic granule proteins, eosinophil chemotactic proteins, basophils, innate type 2 lymphoid cells and
mast cells. Additional studies have shown that certain populations lack increased eosinophils and have lower levels of <FONT STYLE="white-space:nowrap">IL-5,</FONT> indicating a <FONT STYLE="white-space:nowrap">non-type</FONT> 2 inflammatory
response as well. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Overview of current CRSwNP treatments </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Treatment for CRSwNP often begins with medical management, primarily involving topical corticosteroids and nasal saline irrigations. Intranasal corticosteroids have been
shown to decrease nasal polyp size, lessen </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">133 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
sinonasal symptoms and improve quality of life. Patients who are unable to manage their symptoms with medical management may undergo sinus surgery; however, polyps and symptoms can recur
post-surgery. People with both asthma and CRSwNP are more likely to undergo sinus surgery than those with only CRSwNP. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Recently, biologics targeting the type 2
inflammation pathway have been approved by the FDA as treatments for CRSwNP. Similar to asthma, biologic treatments targeting IgE, <FONT STYLE="white-space:nowrap">IL-5</FONT> and <FONT STYLE="white-space:nowrap">IL-4R</FONT><FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT> have been approved for CRSwNP. Omalizumab, an <FONT STYLE="white-space:nowrap">anti-IgE</FONT> monoclonal antibody, was shown to reduce nasal polyp size and
improve symptoms compared to placebo in CRSwNP. Mepolizumab, a humanized <FONT STYLE="white-space:nowrap">anti-IL5</FONT> antibody, was shown to reduce nasal polyps and improve sense of smell, post-nasal drip and nasal congestion compared to placebo
for CRSwNP patients with severe nasal polyposis refractory to corticosteroid therapy. Dupilumab, a human monoclonal antibody that binds <FONT STYLE="white-space:nowrap">IL-4R</FONT><FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT> and inhibits <FONT STYLE="white-space:nowrap">IL-4</FONT> and <FONT STYLE="white-space:nowrap">IL-13</FONT> signaling, reduced nasal polyp burden and improved nasal symptoms when used in conjunction
with intranasal steroids in patients with refractory CRSwNP. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These FDA approvals have established a well-understood regulatory pathway and route to
commercialization. The primary endpoints of the trials were similar as well, including reduction in nasal polyp score and nasal congestion/obstruction. The trials recruited a significant proportion of patients with comorbid asthma (58% to 71%) and
with prior surgery (58% to 100%), highlighting the benefit that biologics can provide to a broad population of people with CRSwNP. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Unmet need for people
living with CRSwNP </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While there are several treatments available, there remains a significant disease and treatment burden for people living with CRSwNP. QoL
studies show that the burden of living with CRSwNP is comparable to other chronic diseases such as COPD, asthma and diabetes. People with CRSwNP even had significantly worse social functioning scores than those with congestive heart failure. One of
the most troublesome symptoms in terms of QoL for people with CRSwNP is loss of smell, which correlates with disease severity. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Beyond the burden of the disease,
there are significant risks associated with current standard of care treatments for CRSwNP as well. Corticosteroid use, even in the short term, is associated with an increased risk of acute complications such as sepsis, venous thromboembolism and
fracture. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">People with serious CRSwNP requiring sinus surgery face an additional burden. While endoscopic sinonasal surgery is generally safe, risk exists with any
surgical procedure. Minor complications are reported in 5% of routine endoscopic surgeries and major complications are reported in 0.5% to 1%. Even with a successful surgery, the recurrence rate of CRSwNP ranges from 20% to 60% within 18 months to
four years and increases to 79% after 12 years. 37% of patients are found to have revision surgery over a <FONT STYLE="white-space:nowrap">12-year</FONT> period, and it is not uncommon for patients to have multiple surgeries. Recurrence is
particularly common for people with severe disease, including those also living with asthma or who have undergone prior surgeries. Even with surgery, many people with CRSwNP remain symptomatic. One study reported that 23% of patients continued to
have persistent symptoms post-surgery. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The recurrence of symptoms and need for multiple surgeries demonstrates that people living with CRSwNP do not have access to
treatments that effectively manage their disease. A therapy with strong efficacy that provides better symptom control is a significant need for this patient population. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Similarly to asthma, our internal market research shows that the less frequent dosing regimen for verekitug would be attractive to both patients and physicians with
approximately 75% to 80% of CRSwNP treaters highly willing to use verekitug across Q12W and Q24W dosing intervals, respectively, and approximately 90% of patients would consider switching to a product with a less-frequent dosing interval and more
than 95% of CRSwNP patients are moderately or highly likely to ask their provider about a treatment option with a longer dosing interval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">134 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Market opportunity for CRSwNP </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the major markets for CRSwNP, which include the United States, the five major European markets (France, Spain, Germany, Italy and the UK) and Japan, there are an
estimated 900,000 people diagnosed with CRSwNP. Sales in these markets are expected to exceed $4.0 billion by 2030. Dupilumab alone has an annual global sales estimate for the treatment of CRSwNP of up to $1.5&nbsp;billion by 2030 according to
third-party research analyst reports. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Of the 900,000 people diagnosed with CRSwNP in the United States, major European markets and Japan, it is estimated that
approximately 200,000 adults are eligible for biologics. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe there is a significant opportunity for additional biologic entrants into this market given the
large unmet medical need that remains as many people with CRSwNP continue to live with uncontrolled symptoms despite surgery, as shown in Figure 4, and corticosteroid treatment. </P>
<P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g843142g35n35.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 4: Number of CRSwNP patients eligible for biologics </I> </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Overview of COPD </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Disease overview </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Like asthma, COPD is a chronic inflammatory disease of the airways, associated with airflow worsening and episodic exacerbations that drive morbidity, mortality, and
health care utilization. Chronic inflammation causes structural changes within the lungs, narrowing already small airways and damaging lung parenchyma which causes air sacs to lose functionality and decrease lung elasticity. It is typically caused
by long-term exposure to irritants, most often cigarette smoke. Air pollution is also a major risk factor, primarily in lower and middle-income countries. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">COPD is
the third leading cause of death worldwide, causing approximately 3.2&nbsp;million deaths in 2019. Almost 14.2&nbsp;million Americans, or 6.5% of the adult population, reported in one study that they have been diagnosed with COPD, however, the true
prevalence is likely higher given that more than half of adults with low pulmonary function in another study reported that they were not aware that they had COPD. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">People living with COPD may experience daily cough, difficulty breathing, mucus production, chest tightness, wheezing, lack of energy and frequent respiratory
infections. Symptoms often don&#146;t appear until significant lung damage has already occurred and will worsen over time. Despite the progressive nature of COPD, good symptom control can be achieved with proper treatment. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">With moderate to severe COPD (stages 2 and 3) everyday activities may result in shortness of breath and frequent exacerbations, including increased and discolored
phlegm. With very severe, or stage 4, COPD almost any activity results in shortness of breath, which limits mobility and may require supplemental oxygen. People with moderate to very severe COPD are also more likely to acquire lung infections like
bronchitis and pneumonia. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">135 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Historically, COPD has been considered a disease driven by <FONT STYLE="white-space:nowrap">non-type</FONT> 2 immune
responses. Recently it has been shown that 20% to 40% of COPD patients also exhibit type 2 inflammation. Published research has shown that <FONT STYLE="white-space:nowrap">IL-4</FONT> and <FONT STYLE="white-space:nowrap">IL-13,</FONT> cytokines in
the type 2 inflammation pathway, may play a role in COPD pathogenesis. Elevated levels of TSLP have been found in the airways of people with COPD. In bronchial biopsies, TSLP receptor expression was highest in patients with severe COPD compared to
healthy controls. Viral infection can also increase TSLP expression in epithelial cells, suggesting the potential role of TSLP in COPD exacerbations. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Overview of current COPD treatments </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Currently available
treatments for COPD include inhaled steroids to reduce airway inflammation and bronchodilator inhalers to improve airflow. Oxygen and surgery may also be used for some patients with severe COPD. Similar to asthma and CRSwNP, biologics are also being
developed as new and potentially transformative treatments, and recently, dupilumab became the first biologic approved for the treatment of COPD. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In May 2023, Phase
3 clinical trial results in the <I>New England Journal of Medicine </I>showed that dupilumab, an anti-IL4R<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT> antibody, was the first biologic to demonstrate
a significant reduction in moderate or severe acute exacerbations of COPD by 30%, when compared to placebo. Additionally, dupilumab also significantly improved lung function at 12 and 52 weeks. On the basis of these data, dupilumab was recently
approved by the FDA as an add-on maintenance treatment of patients with inadequately controlled COPD and an eosinophilic phenotype. In May 2024, Phase 2a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data for tezepelumab for the treatment of moderate to very severe COPD were presented at the ATS International Conference. This trial reported a
reduction in the frequency of COPD exacerbations that has supported advancement of tezepelumab into Phase 3 development in COPD. The most frequently reported adverse events for tezepelumab were worsening of COPD (12.1%) and incidents of COVID-19
infections (14.5%, trial commenced in July 2019), demonstrating a safety and tolerability profile consistent with that observed for tezepelumab in severe asthma. By contrast, previous trials of biologic agents targeting <FONT
STYLE="white-space:nowrap">IL-5</FONT> or its receptors have shown mixed results with respect to clinical activity and adverse events. Taken together, these clinical trial data reinforce our plan to develop verekitug for the treatment of COPD. </P>
 <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Unmet need for people living with COPD </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">COPD is the third leading
cause of death worldwide and is also associated with significant morbidity. Population studies have shown among patients hospitalized with COPD, 50% are readmitted in the future and approximately 13% will be hospitalized in a three-year period. In
total, 60% of all COPD patients will report some limitations in their daily activity, with 45% being unable to work and 75% complaining of difficulty climbing stairs. These increases in hospitalizations and limitations to daily life are reported
despite the currently available treatments. The CDC estimates that approximately 2.0 million to 2.5&nbsp;million Americans live with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> COPD that is not
adequately controlled with current therapeutics. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">With the emerging data that type 2 inflammation plays a role in COPD, particularly exacerbations, for a portion of
patients, there is a need to develop therapies that can address this patient population whose symptoms are inadequately managed with currently available therapies. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Market opportunity for COPD </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Millions of people worldwide continue
to suffer from COPD despite currently available treatments, underscoring the large need for more effective treatments for this patient population. Dupilumab, is currently the only biologic approved for the treatment of COPD and others are in
late-stage clinical development. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">136 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Dupilumab is projected to reach peak sales of approximately $4.0 billion in COPD, while only penetrating 20% of the
market, according to third-party research analyst reports. Tezepelumab, which recently shared positive Phase 2a data indicating it may be effective in patients with eosinophil counts at 150 or greater, is projected to have annual peak sales in the
United States of $6.0 billion to $10.0 billion according to third-party research analyst reports, given the broader patient population it may be able to address. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Given the size of the COPD patient population, high rates of morbidity and mortality despite currently available treatments, we believe COPD represents one of the
largest unmet needs worldwide. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Verekitug, the only known antagonist of the TSLP receptor currently in clinical development </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our product candidate, verekitug, is a novel recombinant fully human IgG1 monoclonal antibody that we are developing as a potential treatment for multiple
inflammation-related diseases across a broad spectrum of patients. Verekitug binds to the TSLP receptor and inhibits its signaling, and to our knowledge, it is the only monoclonal antibody that targets and inhibits the TSLP receptor currently in
clinical development. TSLP is a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. In preclinical studies, which were not
designed to support formal statistical comparisons, verekitug demonstrated very high occupancy of the TSLP receptor and potent inhibition of TSLP signaling. Additionally, verekitug inhibited cytokine production from CD4&#043; T cells, suggesting
that it may be effective against both type 2 and <FONT STYLE="white-space:nowrap">non-type</FONT> 2 inflammation. Currently available biologics that target cytokines downstream of TSLP appear to only be effective against type 2 inflammation. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In May 2024, we presented full <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data from our randomized, double-blind,
placebo-controlled Phase 1b MAD clinical trial in asthma patients demonstrating that dosing with verekitug led to rapid and complete TSLP receptor occupancy, and reductions in disease-related biomarkers, FeNO and blood eos, that were rapid,
substantial and sustained for up to 24 weeks after the last dose. This study also demonstrated that verekitug is significantly more potent than tezepelumab (based on published tezepelumab data), which, combined with verekitug&#146;s PK profile,
enables an extended dosing interval of up to 24 weeks, compared to tezepelumab (four week dosing interval). Furthermore, clinical data from our MAD trial indicate an approximately 50% greater effect on FeNO than has previously been reported for
tezepelumab. We have not conducted head-to-head clinical studies of verekitug against tezepelumab, and note that ongoing and future clinical trials for verekitug may produce differing clinical activity and tolerability results. Three Phase 1
clinical trials have been completed for verekitug across a total of 120 participants, including 32 patients with asthma. In the Phase 1 SAD trial in healthy volunteers, verekitug demonstrated a favorable tolerability profile with no drug-related
serious treatment-emergent adverse events, dose proportional pharmacokinetics and a pharmacodynamic effect consistent with TSLP antagonism. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Verekitug&#146;s
preclinical and clinical data suggest: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">1.</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Verekitug is an extremely potent inhibitor of TSLP signaling. </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">2.</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Verekitug&#146;s potency translates to a significant impact on biomarkers of severe asthma which are correlated with both disease severity and treatment response. Based on these clinical data verekitug&#146;s potency is
more than <FONT STYLE="white-space:nowrap">300-fold</FONT> greater than that reported for tezepelumab. </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">3.</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Verekitug&#146;s potency enables an extended dosing interval of up to 24 weeks, currently being investigated in our Phase 2 clinical trial in people with severe asthma. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">137 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on the consistency from preclinical to clinical results as well as the potent inhibition of TSLP signaling, we
believe verekitug has the potential to be a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> treatment for severe asthma, CRSwNP, COPD and other inflammatory diseases. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g843142g09d27.jpg" ALT="LOGO" STYLE="width:6.305in;height:3.559in;">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 5: Verekitug neutralizes TSLP, a cytokine upstream of those targeted by existing biologics </I></P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Preclinical data </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Target engagement and inhibition </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In preclinical studies conducted by Astellas, which were not designed to support formal statistical comparisons, verekitug was able to efficiently bind and inhibit the
TSLP receptor. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Verekitug inhibited the interaction between TSLP and TSLP receptor in a dose-dependent manner with a 50% inhibitory concentration (&#147;IC<SUB
STYLE="font-size:75%; vertical-align:bottom">50</SUB>&#148;) of 208 ng/mL and a 90% inhibitory concentration (IC<SUB STYLE="font-size:75%; vertical-align:bottom">90</SUB>) of 462 ng/mL. Verekitug also inhibited TSLP-induced proliferation of Ba/F3
cells (IC<SUB STYLE="font-size:75%; vertical-align:bottom">50</SUB> &#061; 90.7 ng/mL, IC<SUB STYLE="font-size:75%; vertical-align:bottom">90</SUB> &#061; 200 ng/mL). Studies also showed that verekitug inhibited TSLP-induced production of <FONT
STYLE="white-space:nowrap">CCL-17</FONT> in a human cell line in a dose dependent manner. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These studies were conducted using tezepelumab as an active comparator.
Across multiple experiments, verekitug was found to be at least more than four times more potent based on the IC<SUB STYLE="font-size:75%; vertical-align:bottom">50</SUB> and IC<SUB STYLE="font-size:75%; vertical-align:bottom">90</SUB> values for
both the Ba/F3 cell proliferation and CCL17 production assays. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">138 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The IC<SUB STYLE="font-size:75%; vertical-align:bottom">90</SUB> values from the <I>in vitro </I>assays suggest a target
trough concentration of approximately 0.3 &micro;g/mL as an effective dose for verekitug. These results, as shown in Figure 6 below, underscore the potency of verekitug and the potential for sufficient efficacy even at low drug concentrations. </P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g843142g76t53.jpg" ALT="LOGO" STYLE="width:6.31091in;height:2.85091in;">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 6: Left panel: In a competitive ELISA study, verekitug was shown to inhibit the interaction between TSLP and TSLP receptor
in a dose-dependent manner. Right panel: Ba/F3 cells were <FONT STYLE="white-space:nowrap">co-transfected</FONT> with human <FONT STYLE="white-space:nowrap">IL-7R</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> and TSLP receptor. When treated
with verekitug, inhibition of TSLP-induced proliferation was seen. </I></P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Toxicology </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The safety of verekitug has been evaluated in multiple <I>in vitro </I>and <I>in vivo </I>studies conducted by Astellas. In single-dose toxicity studies, doses up to 50
mg/kg were not associated with system toxicity findings and verekitug showed no discernible subcutaneous irritation at the injection site in cynomolgus monkeys. Repeat-dose toxicology studies of <FONT STYLE="white-space:nowrap">4-,</FONT> <FONT
STYLE="white-space:nowrap">13-</FONT> and <FONT STYLE="white-space:nowrap">26-weeks</FONT> duration were conducted in cynomolgus monkeys. In the <FONT STYLE="white-space:nowrap">26-week</FONT> study, dose levels of 25, 50 and 100 mg/kg once weekly
were evaluated with no treatment-related findings seen for: clinical signs, body weight, food consumption, ophthalmology, electrocardiography, urinalysis, hematology, blood chemistry, gross pathology, organ weights or histopathology. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Clinical data </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Phase 1 SAD clinical trial design </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Verekitug was investigated in a Phase 1 SAD clinical trial conducted by Astellas, which enrolled 56 healthy volunteers aged 18 to 55. The primary objective of the study
was safety, tolerability and PK following single intravenous (&#147;IV&#148;) and subcutaneous (&#147;SC&#148;) doses of verekitug. Secondary and exploratory objectives were absolute bioavailability following a single SC dose and PD following single
IV and SC doses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">139 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Participants were randomized three to one to verekitug or placebo. In the first six cohorts, verekitug was delivered via IV
in ascending doses beginning at 0.03 mg/kg and ending at 10 mg/kg. The final cohort was a 1&nbsp;mg/kg SC dose. Figure 7 below summarizes the Phase 1 SAD trial design. </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g843142g21m48.jpg" ALT="LOGO" STYLE="width:6.30667in;height:2.58889in;">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:8pt; font-family:arial">BMI, body mass index; IV, intravenous; PD, pharmacodynamics; PK, pharmacokinetics; R, randomization; SC, subcutaneous; ULN, upper limit
of normal. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 7: Trial design schematic for Phase 1 SAD trial </I></P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Phase 1 SAD clinical trial safety and tolerability data </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We presented
the results from the Phase 1 SAD clinical trial of verekitug at the ATS International Conference in May 2023. The data showed a favorable tolerability profile at all dose levels in healthy participants. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As summarized in Figure 8 below, treatment-emergent adverse events (&#147;TEAEs&#148;) were reported by 21 of 42 participants receiving verekitug (50%) and 3 of 14 (21%)
participants receiving placebo. The majority of TEAEs were mild in severity and less than half of all reported TEAEs were considered to be related to the study drug. There was no clinically relevant increase in the frequency of TEAEs with the
increase of dose. No drug-related serious TEAEs occurred during the study. One participant experienced a serious TEAE of nephrolithiasis which was deemed not related to the study drug by the investigator. The most frequently reported TEAEs were
headache and dysmenorrhea (menstrual cramps). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">No clinically relevant trends in clinical laboratory analyses, including hematology, biochemistry and urinalysis, were
seen. Additionally, there were no clinically relevant trends in vital signs, physical assessments or electrocardiograms (&#147;ECGs&#148;) detected. No injection site reactions were reported at the SC dose given in the final cohort. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">140 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">ADAs were detected in 13 participants dosed with verekitug. Titers were low, less than 129, and the presence of ADAs did
not significantly impact the serum PK profile in these individuals. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g843142g26g26.jpg" ALT="LOGO" STYLE="width:6.31944in;height:2.33469in;">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:8pt; font-family:arial">Data indicated are number and percentage of subjects with specific TEAEs. Multiple occurrences of the same AE in the same subject are
not reflected. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><SUP STYLE="font-size:75%; vertical-align:top">a</SUP> Defined as any adverse event that started or worsened in severity after dose of study drug
through end of study. <SUP STYLE="font-size:75%; vertical-align:top"> </SUP></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><SUP STYLE="font-size:75%; vertical-align:top">b</SUP>&nbsp;Possible or probable, as
assessed by the investigator or records where relationship was missing. <SUP STYLE="font-size:75%; vertical-align:top"> </SUP></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><SUP
STYLE="font-size:75%; vertical-align:top">c</SUP>&nbsp;Included serious adverse events upgraded by the sponsor based on review of the sponsor&#146;s list of Always Serious terms, if any upgrade was done. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:8pt; font-family:arial">IV, intravenous; SC, subcutaneous; SOC, System Organ Class (per MedDRA v18.1); TEAE, treatment-emergent adverse event. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 8: Incidence of treatment-emergent adverse events by cohort </I></P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Phase 1 SAD clinical trial PK data </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the six IV cohorts, there was a
linear and dose-proportional increase in maximum serum concentration (&#147;C<SUB STYLE="font-size:75%; vertical-align:bottom">max</SUB>&#148;) and total drug exposure over time (area under the curve) over the
<FONT STYLE="white-space:nowrap">0.1-10</FONT> mg/kg dose range. The mean terminal half-life was approximately 20 days for the 1, 3 and 10 mg/kg IV dose groups. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There was evidence of more rapid elimination of verekitug at serum concentrations below approximately 1.0&nbsp;&micro;g/mL, which may be attributed to target mediated
drug disposition. Target-mediated drug disposition occurs when a drug binds with such high affinity to its pharmacological target site, in this case TSLP receptor, that it affects its PK characteristics. The PK profile of verekitug was linear and
dose-proportional at </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">141 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
concentrations exceeding the conservatively estimated therapeutic threshold (1.0 &micro;g/mL). Figure 9 below illustrates the PK profiles for the six IV cohorts and one SC cohort in our Phase 1
SAD trial. </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g843142g42a01.jpg" ALT="LOGO" STYLE="width:5in;height:2.32283in;">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><SUP STYLE="font-size:75%; vertical-align:top">a</SUP> Projected conservative therapeutic threshold at time of study </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 9: Single dose PK profiles for six IV cohorts and one SC cohort </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Data
from the SC cohort showed the absolute bioavailability after a dose of 1 mg/kg of verekitug was approximately 70%. A PK model fitted to the single dose SC PK data was used to predict the PK profiles after repeat SC administration at different dose
levels and dose intervals, as illustrated in Figure 10 below. The then-anticipated therapeutic threshold concentration (1.0 &micro;g/mL), conservatively estimated as a
<SUP STYLE="vertical-align:top">1</SUP>&#8260;<SUB STYLE="vertical-align:bottom">2</SUB><FONT STYLE="white-space:nowrap">-log</FONT> escalation from the 0.3 &micro;g/mL concentration derived from <I>in vitro</I> pharmacology assays, was predicted to
be maintained with a <FONT STYLE="white-space:nowrap">12-week</FONT> dosing interval. </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g843142g42b02.jpg" ALT="LOGO" STYLE="width:5in;height:2.39075in;">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><SUP STYLE="font-size:75%; vertical-align:top">a</SUP> Projected conservative therapeutic threshold at time of study </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 10: Simulated PK profiles for repeated SC administration based on Phase 1 SAD clinical trial data </I></P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Phase 1b MAD clinical trial design </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We conducted a multicenter,
randomized, double-blind, placebo-controlled Phase 1b MAD clinical trial of verekitug in asthma patients. The trial enrolled 32 adult participants aged 18 to 60 with mild to moderate asthma across four dosing cohorts. The primary objective of the
study was to assess the safety and tolerability of verekitug. Secondary objectives included assessments of TSLP receptor occupancy, immunogenicity and PK, and exploratory objectives included assessments of PD. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">142 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Participants were randomized three to one verekitug to placebo. In the first two cohorts, participants were dosed
subcutaneously every four weeks (Q4W, three total doses) with 100 mg and 200 mg of verekitug, respectively. Participants in the third cohort were dosed subcutaneously with 300 mg every 12 weeks (Q12W, two total doses). The final cohort was a single
low dose of 25 mg subcutaneously. The <FONT STYLE="white-space:nowrap">32-week</FONT> trial included an observation period of up to 24 weeks after the last dose in the multi-dose cohorts. Figure 11 below summarizes this trial design. </P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g843142g04f18.jpg" ALT="LOGO" STYLE="width:6.30756in;height:1.85808in;">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:8pt; font-family:arial">PD, pharmacodynamics; PK, pharmacokinetics; SC, subcutaneous; PBO, placebo </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 11: Trial design schematic for Phase 1b MAD trial</I> </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Phase 1b MAD
safety and tolerability data </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Similar to the Phase 1 SAD clinical trial, the data from the Phase 1b MAD clinical trial showed a favorable tolerability
profile for verekitug at all dose levels. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As summarized in Figure 12 below, TEAEs were reported by 21 of 24 (87.5%) participants receiving verekitug and 7 of 8
(87.5%) patients receiving placebo. TEAEs were mild to moderate in severity with no severe TEAEs reported. Over 90% of the TEAEs were deemed unrelated to study drug. There were no reported serious TEAEs and there were no withdrawals from the trial
or treatment discontinuations due to TEAEs. The most frequently reported TEAE was headache. Several participants had mild, short-lived and self-limited injection site reactions; none were reported as an adverse event. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There were no clinically relevant trends observed in clinical laboratory analyses, including hematology, biochemistry and urinalysis. Additionally, there were no
clinically relevant trends in vital signs, physical assessments or ECGs were observed. There was no clinically relevant immunogenicity observed in the trial. </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g843142g70c41.jpg" ALT="LOGO" STYLE="width:6.30556in;height:2.03917in;">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 12: Treatment emergent adverse events observed in Phase 1b MAD clinical trial</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">143 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>PK/PD data demonstrated substantial and sustained receptor occupancy and biomarker suppression, supporting dosing
intervals of up to Q24W </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We observed a desirable pharmacokinetics profile for verekitug that is supportive of extended dosing intervals up to every 24 weeks.
In the first three cohorts, there was a dose-dependent increase in verekitug exposure with increasing dose levels across 100 mg Q4W (three total doses), 200 mg dosed Q4W (three total doses) and 300 mg dosed Q12W (two total doses). However, given
serum concentrations for the first three cohorts remained above the projected therapeutic threshold, a single dose administration (25 mg) cohort was included to generate data in support of PK/PD. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As shown in Figure 13, observed mean serum concentrations from the Phase 1b MAD study replicated the modeled PK from the Phase 1 SAD clinical trial in healthy
volunteers. </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g843142g45n45.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:8pt; font-family:arial">Symbols: observed mean values from Phase 1b MAD study; Solid lines: predicted PK from Phase 1 SAD clinical trial in healthy volunteers;
LLOQ: lower limit of PK quantification </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 13: Post-dose serum concentration of verekitug for each Phase 1b MAD cohort, overlayed with PK model based on Phase
1 SAD trial data</I> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We demonstrated that dosing with verekitug led to rapid and complete TSLP receptor occupancy and reductions in FeNO and eos that were rapid,
substantial and sustained for up to 24 weeks after last dose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">144 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The pharmacodynamics of verekitug were assessed over the <FONT STYLE="white-space:nowrap">32-week</FONT> observation period
by measuring TSLP receptor occupancy in CD14&#043; monocytes. As summarized in Figure 14 below, the first three cohorts (verekitug doses <FONT STYLE="font-family:Times New Roman">&#8805;</FONT>100 mg) had substantial occupancy through the end of the
observation period. The fourth single low dose cohort, added to interrogate the minimal concentration required to maintain full receptor saturation, produced substantial occupancy for 12 to 16 weeks supporting the high potency of verekitug at low
doses. All cohorts demonstrated 100% TSLP receptor occupancy by verekitug within two weeks after first dose. </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g843142g17j14.jpg" ALT="LOGO" STYLE="width:5in;height:3.21315in;">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 14: Percent of free TSLP receptors for each Phase 1b MAD cohort compared to placebo over 32 weeks </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">145 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As shown in Figures 15A and 15B below, reductions in blood eos and FeNO levels were rapid, substantial and sustained.
Additionally, these key disease-related biomarkers remained below baseline in all cohorts receiving <FONT STYLE="font-family:Times New Roman">&#8805;</FONT>100 mg of verekitug through the <FONT STYLE="white-space:nowrap">32-week</FONT> observation
period, up to 24 weeks past the last dose. In the single low dose cohort, blood eos and FeNO levels remained below baseline for 18 and 20 weeks of observation, respectively. The loss of the suppression of biomarkers in this cohort, which occurred
shortly after the loss of receptor saturation, allowed determination of the minimal concentration required for the efficacy of verekitug. </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g843142g47a01.jpg" ALT="LOGO" STYLE="width:6.305in;height:3.53858in;">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 15A: Levels of blood eosinophils compared to baseline for each cohort in Phase 1b MAD trial over 32 weeks</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">146 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g843142g47b02.jpg" ALT="LOGO" STYLE="width:6.3in;height:3.71in;">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 15B: Levels of fraction of exhaled nitric oxide (right column) compared to baseline for each cohort in the Phase 1b MAD
trial over 32 weeks</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">147 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Patients receiving verekitug doses of 100 mg or greater experienced reductions in blood eos of up to 52% and FeNO
reductions of up to 49% at 32 weeks. As seen in Figure 16 below, at week&nbsp;12, the change from baseline in blood eos was <FONT STYLE="white-space:nowrap">-164</FONT> cells/&micro;l for cohort 1, <FONT STYLE="white-space:nowrap">-204</FONT>
cells/&micro;l for cohort 2, and <FONT STYLE="white-space:nowrap">-77</FONT> cells/&micro;l for cohort 3. Of note, cohort&nbsp;3 had a lower baseline value for blood eos which may affect the absolute value change from baseline. For context,
dupilumab has been observed to increase blood eos by approximately 30%, whereas mepolizumab (an eosinophil depleter) has been observed to reduce blood eos by 84%. In these same patients, the change from baseline in FeNO at week 12 was <FONT
STYLE="white-space:nowrap">-28</FONT> ppb (a -54% change from baseline) for cohort 1, <FONT STYLE="white-space:nowrap">-47</FONT> ppb (a -51% change from baseline) for cohort&nbsp;2 and <FONT STYLE="white-space:nowrap">-37</FONT> ppb (a -51% change
from baseline) for cohort 3. The Phase 2 and 3 trials of tezepelumab in severe asthma reported a less substantial effect on FeNO, with a change from baseline in FeNO at week 12 of -17 ppb (a -25% change from baseline). Dupilumab&#146;s effect on
FeNO has been observed to be similar to that of tezepelumab, at an approximately -27% change from baseline, whereas mepolizumab has been observed to have no effect on FeNO. These data are presented for reference purposes only and do not represent
results of head-to-head comparative studies among these product candidates or relative to verekitug. Differences exist between trial designs, subject characteristics and timing of data, and caution should be exercised when comparing data across
studies. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g843142g31l12.jpg" ALT="LOGO" STYLE="width:6.25in;height:2.33463in;">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:8pt; font-family:arial">For the pharmacodynamic population, data collected after the dosing pause were excluded (n&#061;2 in 100 mg cohort after Week 8 and
n&#061;2 mg cohort after Week 4). </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><SUP STYLE="font-size:75%; vertical-align:top">a</SUP> Data from the placebo groups in all cohorts were pooled for analysis. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial">FeNo, fractional exhaled nitric oxide; Q4W, every 4 weeks; Q12, every 12 weeks; SEM, standard error of mean. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 16: Percent change from baseline through 32 weeks in eosinophils (left) and fraction of exhaled nitric oxide (right)</I> </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our PK/PD modeling of the data generated in the Phase 1b MAD trial, as summarized in Figure 17 below, provides clinical <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> that verekitug has high potency in asthma patients. In particular, the potency of verekitug as assessed by suppression of FeNO is substantially greater than that reported for tezepelumab.
Indeed, the half-maximal effective concentration (&#147;EC<SUB STYLE="font-size:75%; vertical-align:bottom">50</SUB>&#148;) of verekitug, 0.008 &micro;g/ml is <FONT STYLE="white-space:nowrap">300-fold</FONT> lower than that of tezepelumab, an
anti-TSLP ligand antibody approved for use in severe asthma. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">148 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g843142g25s47.jpg" ALT="LOGO" STYLE="width:5.34473in;height:1.59369in;">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><SUP STYLE="font-size:75%; vertical-align:top">a</SUP> No head-to-head clinical studies have been conducted. Differences exist between
modeled data and trial design, and caution should be exercised when comparing data across studies. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 17: Maximal, 50% and 90% effective concentrations of
verekitug</I> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Data from the Phase 1 SAD and Phase 1b MAD clinical trials enabled for further PK simulations of verekitug to determine the doses for a Phase 2
clinical trial, as shown in Figure 18 below. Doses of 100 mg Q12W SC and 400&nbsp;mg SC every 24 weeks (Q24W) were projected to sustain serum concentrations of verekitug above the <FONT STYLE="white-space:nowrap">MAD-derived</FONT> FeNO EC<SUB
STYLE="font-size:75%; vertical-align:bottom">90</SUB> of 0.07 mg/L that was established in the MAD study for the entirely of the dosing interval, including at trough. For this reason, these doses are being tested in our Phase 2 trial in severe
asthma. </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g843142g49n49.jpg" ALT="LOGO" STYLE="width:6.305in;height:2.2335in;">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 18: PK simulations of verekitug. Solid line &#061; median, Shadow &#061; <FONT STYLE="white-space:nowrap">5-95</FONT>
percentile prediction range</I> </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Japan PK trial </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We also completed
a third Phase 1 clinical trial of verekitug to support clinical development in Japan and other Asian countries. This study was an open-label, single dose, randomized PK and safety study to enable a comparison of verekitug&#146;s profile in Japanese
vs. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-Japanese/non-East</FONT></FONT> Asian participants. The study enrolled 32 healthy adult volunteers with eight participants in each of four treatment groups. Three cohorts (100
mg, 200 mg, 300&nbsp;mg dose) were enrolled with Japanese participants and the fourth cohort enrolled solely <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-Japanese/non-East</FONT></FONT> Asian participants. The study showed a
comparable verekitug PK profile between the two groups. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Summary of clinical results </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To date, verekitug has demonstrated a favorable tolerability profile and unique pharmacology that is consistent across preclinical and clinical studies. The high potency
seen in preclinical studies, which were not designed to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">149 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
support formal statistical comparisons, has accompanied clinical evidence of rapid and complete TSLP receptor occupancy, and reductions in disease-associated biomarkers, including FeNO and eos,
that were rapid, substantial and sustained for up to 24&nbsp;weeks after the last dose. These data underpin our clinical development strategy for verekitug in severe asthma and CRSwNP and support our Phase 2 trial designs investigating <FONT
STYLE="white-space:nowrap">12-</FONT> and <FONT STYLE="white-space:nowrap">24-week</FONT> dosing. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Ongoing and planned clinical trials </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are currently enrolling two Phase 2 clinical trials of verekitug. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Severe
asthma </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">VALIANT is a Phase 2 multicenter, randomized, placebo-controlled, parallel group clinical trial to assess the efficacy and safety of verekitug in
participants with severe asthma. We expect to enroll an estimated 436 adults, aged 18 to 75 years, that will be randomized 1:1:1:1 to receive verekitug at doses of 100 mg Q12W, 400 mg Q24W and 100 mg Q24W and placebo administered SC. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The primary endpoint of the trial is annual AAER measured up to week 60. This primary endpoint has been used in several registrational trials for other biologic
treatments for asthma. The trial&#146;s secondary endpoints include the following changes from baseline to week 60: forced expiratory volume in one second of <FONT STYLE="white-space:nowrap">pre-bronchodilator,</FONT> change in FeNO, change in
asthma control <FONT STYLE="white-space:nowrap">questionnaire-6,</FONT> and characterization of safety. We have designed this trial using endpoints that, pending interactions with regulatory authorities, could allow data from this trial to support
submissions for product approval. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We previously announced initiation of this trial in March 2024 and, based on the current rate of enrollment, expect to announce <FONT
STYLE="white-space:nowrap">top-line</FONT> data in the second half of 2026. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>CRSwNP </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">VIBRANT is a Phase 2 multicenter, randomized, placebo-controlled, parallel group clinical trial designed to assess the efficacy and safety of verekitug in participants
with CRSwNP. We expect to enroll approximately 70 adults, aged 18 to 75 years, that will be randomized to receive either 100 mg Q12W of verekitug or placebo administered SC over a <FONT STYLE="white-space:nowrap">24-week</FONT> treatment period.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The primary endpoint of the trial is change from baseline in nasal polyp score (&#147;NPS&#148;) at week 24. This primary endpoint has been used in several
registrational trials for other biologic treatments for CRSwNP. The secondary endpoints include the following changes from baseline to week 24: nasal congestion score evaluated by the nasal polyposis symptom diary (&#147;NPSD&#148;), opacification
of sinuses measured by Lund Mackay Score, difficulty with sense of smell evaluated by the NPSD, percentage of participants requiring systemic corticosteroids or NP surgery, time to NP surgery and/or time to systemic corticosteroids for NP, NPSD
&#150; Total Symptom Score, and characterization of safety. We have designed this trial using endpoints that, pending interactions with regulatory authorities, could allow data from this trial to support submissions for product approval. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We previously announced initiation of this trial in January 2024 and, based on the current rate of enrollment, expect to announce
<FONT STYLE="white-space:nowrap">top-line</FONT> data in the second half of 2025. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>COPD </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on available data from Phase 1 trials with verekitug, we plan to initiate a clinical development program in COPD. We are currently planning a Phase 2 multicenter,
randomized, placebo-controlled, parallel group clinical trial designed to assess the efficacy and safety of verekitug in participants with uncontrolled COPD. The primary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">150 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
analysis population will include patients with elevated eos. Subjects will be randomized 1:1:1 to receive verekitug at doses of 100 mg Q12W, 400 mg Q24W and placebo administered SC. Given
verekitug&#146;s potency, we also plan to enroll a subset of patients without elevated eos at baseline to explore the potential for efficacy in this expanded population. Aligned with recent registrational trials of biologics in this condition, the
primary endpoint will be the annualized COPD exacerbation rate, which we plan to assess over at least 60&nbsp;weeks. Additional planned secondary endpoints will capture elements of COPD that are important to patients and have been used in previous
phase 3 studies, including lung function, patient symptoms and quality of life as reflected by the St. George&#146;s Respiratory Questionnaire, and characterization of safety. We have designed this trial using endpoints that, pending interactions
with regulatory authorities, could allow data from this trial to support submissions for product approval. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect to dose the first COPD patient in the second
half of 2025. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Future opportunities </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Research has shown TSLP to be either
a risk factor for or a key driver of inflammatory diseases across several therapeutic areas, including respiratory, gastroenterology, dermatology, nephrology and allergy/immunology. Thus, we believe there is a significant opportunity to expand the
impact of verekitug beyond severe respiratory diseases, including dermatology (e.g., atopic dermatitis) and gastroenterology. For example, other TSLP pathway-directed biologics are pursuing indications such as chronic urticaria, bullous pemphigoid,
chronic pruritis and eosinophilic esophagitis. In parallel to conducting our own preclinical work in target indications, we will carefully monitor the results of these trials which have the potential to inform our selection of future indications for
verekitug. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Manufacturing and supply </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our current strategy is to
outsource all manufacturing of verekitug or any other potential future product candidates to third parties. We leverage third-party manufacturers to support the manufacturing of verekitug for clinical trials and, if we receive regulatory approval,
we intend to rely on such third parties for commercial manufacture. We have manufactured sufficient supply for our two ongoing Phase 2 trials as well as our planned COPD trial. We do not own or operate any manufacturing facilities for the production
of clinical or commercial quantities of verekitug or any other potential future product candidates. We believe this strategy will enable us to maintain a nimble, efficient and effective working model without making significant internal capital
investments.&nbsp;We currently obtain our supplies from these manufacturers on a purchase order basis and do not have any long-term supply agreements in place. In order <FONT STYLE="white-space:nowrap">to&nbsp;de-risk&nbsp;our</FONT> supply chain,
and as we advance toward potential commercialization, we intend to enter into long-term supply agreements as well as evaluate additional product manufacturing sources. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We rely, and expect to continue to rely, on third-party manufacturers to provide all of the active pharmaceutical ingredients and the final drug product formulation of
verekitug that is being used in our clinical trials and preclinical studies in compliance with FDA and other foreign regulatory requirements, and on contract development and manufacturing organizations (&#147;CDMOs&#148;) to manufacture and supply
our preclinical and clinical materials. We have made technical development a major focus of our efforts and have worked to improve the formulation and manufacturing process in place at the time of our acquisition of verekitug in 2021. This effort
has resulted in a greater than <FONT STYLE="white-space:nowrap">6-fold</FONT> improvement in the concentration of the formulation of verekitug, from 30 mg/mL to 200 mg/mL, which has enabled the ability to employ both a 0.5mL (100 mg) and a 2.0mL
(400 mg) SC injection in our severe asthma Phase 2 clinical trial. These 0.5mL and 2.0mL injection volumes are comparable to or smaller than those of other biologics approved for the treatment of severe asthma, including tezepelumab (1.91mL),
dupilumab (2.0mL) and mepolizumab (1.0mL). These process improvements have led to an approximately 35% increase in yield as well, while maintaining comparable product quality. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">151 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have personnel with significant technical, manufacturing, analytical, quality, regulatory, including current Good
Manufacturing Practices (&#147;cGMP&#148;), and project management experience to oversee our third-party manufacturers and to manage manufacturing and quality data and information for regulatory compliance purposes. At the appropriate time, we will
determine whether to establish <FONT STYLE="white-space:nowrap">in-house</FONT> manufacturing capabilities or continue to rely on third parties to manufacture commercial quantities for verekitug or any future products for which we may successfully
develop and obtain regulatory approval. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Competition </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
biopharmaceutical industry is characterized by rapid advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products,
product candidates and processes competitive with verekitug. Verekitug and any future product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.
Our competitors include larger and better-funded pharmaceutical, biopharmaceutical, biotechnological and therapeutics companies. Moreover, we may also compete with universities, governmental agencies and other public and private research
institutions who may be active in research in our target indications and could be in direct competition with us. We also compete with these organizations to recruit management, scientists and clinical development personnel, and our inability to
compete successfully could negatively affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites, enrolling subjects for clinical trials and in identifying and <FONT
STYLE="white-space:nowrap">in-licensing</FONT> intellectual property related to new product candidates, as well as entering into collaborations, joint ventures, license agreements and other similar arrangements. Smaller or early-stage companies may
also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Existing therapeutics for asthma
include controller medications, reliever medications and more recently, biologics from Genentech, Inc. (&#147;Genentech&#148;) and Novartis Pharmaceuticals Corporation (&#147;Novartis&#148;) (Xolair), Sanofi and Regeneron (Dupixent), GlaxoSmithKline
(&#147;GSK&#148;) (Nucala), AstraZeneca (Fasenra), and Amgen and AstraZeneca (Tezspire). Existing therapeutics for CRSwNP include topical corticosteroids, nasal saline irrigations and more recently, biologics from Genentech and Novartis (Xolair),
Sanofi and Regeneron (Dupixent) and GSK (Nucala). Existing therapeutics for COPD include inhaled steroids and bronchodilator inhalers and more recently, a biologic from Sanofi and Regeneron (Dupixent). A biologic targeting the TSLP ligand is also in
development by Amgen and AstraZeneca (Tezspire). </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While there are numerous biologics approved for the treatment of severe asthma, tezepelumab, a monoclonal
antibody targeting the TSLP ligand, is the first and only treatment for severe asthma without any biomarker limitation. To our knowledge, verekitug is the only monoclonal antibody currently in clinical development that targets and inhibits the TSLP
receptor. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we successfully obtain approval for verekitug and any future product candidates, we believe that the key competitive factors that will affect the
success of these candidates will be efficacy, safety, tolerability, convenience, price, the level of generic competition and the availability of reimbursement from commercial, government and other third-party payors relative to such competing
products. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are superior in one or more of these categories. Our competitors also may obtain FDA or other regulatory approval for
their products more rapidly than we do, which could result in our competitors establishing a strong market position before we are able to enter the market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">152 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Intellectual property </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We strive
to protect and enhance the proprietary technology, inventions and improvements that are commercially important to the development of our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed
from third parties. We may also rely on trademarks, copyrights and trade secrets relating to our proprietary technology platform and on <FONT STYLE="white-space:nowrap">know-how,</FONT> continuing technological innovation and <FONT
STYLE="white-space:nowrap">in-licensing</FONT> opportunities to develop, strengthen and maintain our proprietary and intellectual property position. We additionally may rely on regulatory and other protections afforded through data exclusivity,
market exclusivity and patent term extensions, where available. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our commercial success depends in part upon our ability to obtain and maintain patent and other
proprietary protection for commercially important technologies, inventions and trade secrets related to our business, defend and enforce our intellectual property rights, particularly our patent rights, preserve the confidentiality of our trade
secrets and operate without infringing valid and enforceable intellectual property rights of others. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The patent positions for biotechnology and pharmaceutical
companies like us are generally uncertain and can involve complex legal, scientific and factual issues. In addition, the coverage claimed in a patent application can be significantly reduced before a patent is issued, and its scope can be
reinterpreted and even challenged after issuance. As a result, we cannot guarantee that any of our product candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently
pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties.
</P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Verekitug program </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We own 12 patent families directed to
verekitug. A first patent family is directed to compositions of matter of verekitug and methods of using the same for treating asthma and expire in 2034, without taking a potential patent term extension into account. As of August&nbsp;1, 2024, this
first patent family has two issued U.S. patents, 20 issued patents in foreign jurisdictions, including Argentina, Australia, Brazil, Canada, a European patent (validated in Albania, Austria, Belgium, Bulgaria, Switzerland, Cyprus, Czech Republic,
Germany, Denmark, Estonia, Spain, Finland, France, Great Britain, Greece, Hungary, Croatia, Ireland, Iceland, Italy, Liechtenstein, Latvia, Lithuania, Luxembourg, Monaco, Malta, Macedonia, Netherlands, Norway, Poland, Portugal, Romania, Serbia,
Sweden, Slovenia, Slovakia, and Turkey), Hong Kong, Indonesia, Israel, India, Japan, South Korea, Malaysia, Mexico, Philippines, Russia, Singapore, Taiwan, Ukraine, Vietnam and South Africa, and one pending application in a foreign jurisdiction in
Thailand. A second patent family is directed to certain pharmaceutical formulations comprising verekitug and methods of treating humans with asthma with such formulations, which expire in 2037, without taking a potential patent term extension into
account. As of August&nbsp;1, 2024, this second family includes 2 issued U.S. patents, one pending U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> application, 11 issued patents in foreign jurisdictions, including China, Hong Kong, two
in Japan, Macao, Mexico, Philippines, Russia, Singapore, and two in Taiwan, and 7 pending applications in foreign jurisdictions, including in Canada, Europe, Indonesia, South Korea, Singapore, Thailand, and Vietnam, of which Canada, Europe and
Vietnam have been allowed. The third patent family is directed to certain formulations that could be used with verekitug and methods of using the same and, if the patents were to issue from this third patent family they would expire in 2042. As of
August&nbsp;1, 2024, this third family has one pending U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> application, two applications pending in foreign jurisdictions, Taiwan and Argentina, and one pending PCT application. The other nine
patent families are directed to methods of using verekitug and comprise 9 pending U.S. provisional patent applications. Should any patents issue based on these other nine patent families they would expire in 2044, without taking a potential patent
term extension into account. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">153 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In
most countries in which we file, the patent term is 20 years from the earliest date of filing a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the United States, the term of a patent covering an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug may be eligible for a patent term extension under the
Hatch-Waxman Act as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five years beyond the expiration of the patent, but cannot extend the remaining term of a patent beyond a
total of 14 years from the date of product approval. Only one patent among those eligible for an extension may be extended, and a given patent may only be extended once. Similar provisions are available in Europe and in certain other jurisdictions
to extend the term of a patent that covers an approved drug. If our product candidates receive FDA approval, we intend to apply for patent term extensions, if available, to extend the term of patents that cover the approved product candidates. We
also intend to seek patent term extensions in any jurisdictions where they are available, however, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted,
and even if granted, the length of such extensions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to patent protection, we also rely on <FONT STYLE="white-space:nowrap">know-how</FONT> and trade
secret protection for our proprietary information to develop and maintain our proprietary position. However, trade secrets can be difficult to protect. Although we take steps to protect our proprietary information, including restricting access to
our premises and our confidential information, as well as entering into agreements with our employees, consultants, advisors and potential collaborators, third parties may independently develop the same or similar proprietary information or may
otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, and other proprietary information. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, we plan to rely on regulatory protection based on orphan drug exclusivities, data exclusivities, and market exclusivities. See the section titled
&#147;&#151;Government regulation&#148; below for additional information. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Asset purchase and license agreements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Asset acquisition from Astellas </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October 2021, we entered into an
asset purchase agreement with Astellas Pharma, Inc. (&#147;Astellas&#148;), which we refer to as the &#147;Astellas Asset Purchase Agreement.&#148; Pursuant to the Astellas Asset Purchase Agreement, we purchased from Astellas the compound designated
by Astellas as ASP7266 (the &#147;Compound&#148;), the corresponding patent rights and any unregistered intellectual property rights, inventory related to the Compound, documents, data and copies of all filings and material correspondence with
regulatory agencies (and the data included therein), and obtained an exclusive license under certain processes and methods of manufacture, testing, qualifying and use of the Compound to manufacture the Compound, with an upfront cash payment of
$81.1&nbsp;million. The Compound was renamed by us as verekitug <FONT STYLE="white-space:nowrap">(UPB-101).</FONT> There are no future payments owed to Astellas under the Astellas Asset Purchase Agreement. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Related letter agreement with Astellas and Regeneron </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection
with the Astellas Asset Purchase Agreement, we concurrently entered into a letter agreement with Astellas and Regeneron Pharmaceuticals, Inc. (&#147;Regeneron&#148;), which we refer to as the &#147;Regeneron Letter Agreement.&#148; The Regeneron
Letter Agreement relates to a prior <FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> License and Material Transfer Agreement (the &#147;Terminated Regeneron License Agreement&#148;) that Regeneron and Astellas entered into in March 2007, as
amended in July 2010 and subsequently terminated in June 2018, subject to certain surviving rights and obligations of both Regeneron and Astellas. Under the Terminated Regeneron License Agreement, Astellas utilized Regeneron&#146;s human antibody
technology in its internal research programs to discover certain product candidates, including the Compound, which it sold to us under the Astellas Asset Purchase Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">154 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the Regeneron Letter Agreement, Astellas assigned and transferred to us and we assumed and accepted certain of
Astellas&#146; surviving rights and obligations under the Terminated Regeneron License Agreement, including Astellas&#146; royalty payment, reporting and indemnification obligations in connection with activities conducted by us or on our behalf with
respect to the Compound. By assuming and accepting Astellas&#146; surviving obligations under the Terminated Regeneron License Agreement, we are required to pay Regeneron <FONT STYLE="white-space:nowrap">mid-single-digit</FONT> percentage royalties
on aggregate worldwide net sales of any product developed by or on behalf of us that contains the Compound as an ingredient or component of the materials sold (a &#147;Royalty Product&#148;) during the royalty term. The royalties are determined on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis and expire on the later of (i)&nbsp;a
specified number of years after the launch of a given Royalty Product in a given country and (ii)&nbsp;the expiration of the last valid claim of royalty bearing company patent rights claiming or covering such Royalty Product in such country. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Exclusive license agreement with Maruho </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October 2021, we entered
into a license agreement with Maruho Co., Ltd. (&#147;Maruho&#148;), as amended on May&nbsp;30, 2023, which we refer to as the &#147;Maruho License Agreement,&#148; under which we granted to Maruho an exclusive, irrevocable, perpetual, royalty-free,
sublicensable (subject to our right of first negotiation as described below) license. The license was under certain intellectual property rights controlled by us or our affiliates to research, develop, manufacture via a third party contract
manufacturer, sell and import any pharmaceutical, biologic or medical device product (or any combination thereof), which (i)&nbsp;was or is developed by or on behalf of us or our affiliates, and (ii)&nbsp;incorporates or uses the compound designated
by Astellas as ASP7266 in Japan (collectively, the &#147;Maruho License Product&#148;). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the Maruho License Agreement, we are responsible for and control
the global research and development of the Maruho License Product, including in Japan. We will develop the Maruho License Product for use in Japan as part of our global development strategy, and as much as possible on a similar schedule as we
develop the Maruho License Product for our initial territory(ies). Maruho will reimburse us for all costs reasonably necessary for any development activities for the Maruho License Product that are specific to Japan, including the cost of the supply
of Maruho License Product for use in any preclinical and clinical research and development activities in Japan. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the Maruho License Agreement, Maruho is
responsible for and controls, at its sole expense, (i)&nbsp;the preparation, filing, prosecution, obtaining and maintaining all regulatory approvals for the Maruho License Product in Japan and (ii)&nbsp;the promotion, marketing, sale and
commercialization of the Maruho License Product in Japan. Maruho shall procure the supply of Maruho License Product for commercialization in Japan by purchasing from a contract manufacturing organization (&#147;CMO&#148;) used by us, from us
directly, or in the event the supply from the foregoing sources doesn&#146;t meet the legal requirements in Japan, from a new third-party CMO selected by Maruho in consultation with us. In addition, under the Maruho License Agreement, we granted
Maruho a right of first negotiation, exercisable between the effective date of the Maruho License Agreement and the earlier of (a)&nbsp;October&nbsp;11, 2027 and (b)&nbsp;the occurrence of a merger and acquisition of us by a third party, such that,
in the event of our actual liquidation (not including deemed liquidation events such as a merger and acquisition by third parties), Maruho has the right to first negotiate to purchase all of our asset relating to the Maruho License Product. Maruho
also granted us a right of first negotiation, exercisable between the effective date of the Maruho License Agreement and the earlier of (a)&nbsp;the fifth anniversary of such effective date and (b)&nbsp;a change of control of us, such that, in the
event Maruho desires to sell, assign sublicense or otherwise transfer any or all of Maruho&#146;s rights under the Maruho License Agreement, we have a right to first negotiate to acquire such rights. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Both parties waive their right to termination of the Maruho License Agreement for any reason, except that Maruho has the right to terminate the Maruho License Agreement
at any time by providing 60&nbsp;days prior written notice to us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">155 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the year ended December 31, 2021, we did not receive any payments from Maruho. During the year ended
December&nbsp;31, 2023, we received payments from Maruho in the amount of $2.7&nbsp;million, which was received during the six months ended June&nbsp;30, 2023. During the year ended December&nbsp;31, 2022, we received payments from Maruho in the
amount of $0.8&nbsp;million. During the six months ended June&nbsp;30, 2024, we received payments from Maruho in the amount of $0.7&nbsp;million. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>License
agreement with Lonza </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October 2021, in connection with the Astellas Asset Purchase Agreement, we entered into a license agreement with Lonza Sales AG
(&#147;Lonza&#148;), as amended on March&nbsp;18, 2022 and April&nbsp;19, 2022, which we refer to as the &#147;Lonza License Agreement.&#148; Pursuant to the Lonza License Agreement, we obtained a worldwide,
<FONT STYLE="white-space:nowrap">non-exclusive,</FONT> sublicensable (subject to Lonza&#146;s right of <FONT STYLE="white-space:nowrap">pre-approval</FONT> with respect to any sublicense of manufacturing activities) license to certain intellectual
property rights owned by Lonza. The license allows us to use Lonza&#146;s glutamine synthetase gene expression system (&#147;Lonza System&#148;) to develop, manufacture and commercialize the Compound, including any part of such system that is
embodied within or otherwise used to create the cell lines expressing the Compound or a component thereof. Lonza was the originator of the master cell bank for the Compound developed by Astellas, and we are required to comply with certain
restrictions with regard to the use of Lonza System, including not to transfer, reverse engineer or modify the Lonza System without Lonza&#146;s prior written consent. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As consideration for the rights and licenses granted to us under the Lonza License Agreement, we agreed to pay Lonza certain royalties and annual payments, both payable
in swiss francs, in respect of the manufacturing and sale of the Compound, such amounts to be determined by the party manufacturing the Compound, and range from no annual payment to up to a mid-six-figure annual payment, and a less-than-one percent
to a low-single-digit percentage royalty on net sales of the Compound. In accordance with the Lonza License Agreement, we entered into a sublicense with Wuxi Biologics (Hong Kong) Limited to manufacture the Compound, requiring us to pay a
mid-six-figure annual fee to Lonza pursuant to this provision. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any royalties due under the Lonza License Agreement are payable on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until ten years from the first commercial sale of the Compound in that particular country. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Lonza agreement continues for an indefinite period of time unless otherwise terminated. We have the right to terminate the Lonza License Agreement at any time by
providing prior written notice to Lonza. Furthermore, we and Lonza each have the right to terminate the Lonza License Agreement upon the occurrence of a material breach of such agreement by the other party that is irremediable or not remedied within
a certain period of time, or the other party&#146;s failure to pay debts or entry into liquidation. Lonza also may terminate the Lonza License Agreement by providing written notice to us if we contest the secret or substantial nature of the <FONT
STYLE="white-space:nowrap">know-how</FONT> relating to the Lonza System that is licensed to us under the Lonza License Agreement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the year ended December 31,
2021, we did not make any payments to Lonza. During the year ended December 31, 2023, we made an annual payment to Lonza in the amount of $0.4 million, which was paid during the six months ended June 30, 2023. During the year ended December 31,
2022, we made an annual payment to Lonza in the amount of $0.4 million. During the six months ended June 30, 2024, we made an annual payment to Lonza in the amount of $0.5 million. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Government regulation </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Regulation of biological products in the United
States </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the United States, the FDA regulates biological products under the Federal Food, Drug, and Cosmetic Act (&#147;FDCA&#148;), the Public Health
Service Act (&#147;PHSA&#148;), and their implementing regulations. Biological products are also subject to other federal, state and local statutes and regulations. Verekitug is in clinical development and has not been approved by the FDA for
marketing in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">156 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">An applicant seeking approval to market and distribute a new biological product in the United States generally must
satisfactorily complete each of the following steps: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">preclinical laboratory tests, animal studies and formulation studies performed in accordance with the FDA&#146;s Good
Laboratory Practices (&#147;GLP&#148;) regulations, as applicable; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">completion of the manufacture, under cGMP conditions, of the product candidate that the sponsor intends to use in human
clinical trials along with required analytical and stability testing; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">submission to the FDA of an Investigational New Drug application (&#147;IND&#148;), for human clinical testing, which must
become effective before human clinical trials may begin; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">approval by an independent institutional review board (&#147;IRB&#148;) representing each clinical trial site before each
clinical trial site may be initiated; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">performance of adequate and well-controlled human clinical trials, in accordance with current Good Clinical Practices
(&#147;GCP&#148;) and any additional nonclinical studies required to establish the safety and effectiveness of the product candidate for each proposed indication; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">preparation and submission to the FDA of a biologics license application (&#147;BLA&#148;), as applicable, requesting
approval to market the product candidate for one or more proposed indications, including submission of detailed information on the manufacture and composition of the product and proposed labeling; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">review of the product by an FDA advisory committee, where appropriate and as applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities, including those of
third parties, at which the product, or components thereof, are produced to assess compliance with cGMP and to assure that the facilities, methods and controls are adequate to preserve the product&#146;s identity, strength, quality and purity;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">satisfactory completion of any FDA audits of the preclinical studies and clinical trial sites to assure compliance with
GLP, as applicable, and GCP, and the integrity of clinical data in support of the BLA; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">payment of user fees under the Prescription Drug User Fee Act (&#147;PDUFA&#148;), unless exempted; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">obtaining FDA approval, or licensure, of the BLA; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and
Mitigation Strategy (&#147;REMS&#148;) and any post-approval studies or other post-marketing commitments required by the FDA. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The failure to
comply with the applicable U.S. requirements at any time during the product development process, including preclinical testing, clinical testing, and the approval process, or the post-approval process, may subject an applicant to delays in
development, regulatory review or approval and/or administrative or judicial sanctions. These sanctions may include, but are not limited to, the FDA&#146;s refusal to allow an applicant to proceed with clinical testing, refusal to approve pending
applications, license suspension or revocation, withdrawal of an approval, issuance of warning or untitled letters, adverse publicity, product recalls, marketing restrictions, product seizures, import detentions and refusals, total or partial
suspension of production or distribution, injunctions, fines and civil or criminal investigations and penalties brought by the FDA or the Department of Justice (&#147;DOJ&#148;), and other governmental entities, including state agencies. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Preclinical studies and investigational new drug application </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Before
testing any product candidate in humans, the product candidate must undergo preclinical testing. Preclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">157 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
studies to evaluate the potential for efficacy and toxicity in animal studies. The conduct of the preclinical tests and formulation of the compounds for testing must comply with federal
regulations and requirements. The results of the preclinical tests, together with manufacturing information, analytical data, and plans for the proposed clinical studies, are submitted to the FDA as part of an IND application. Some preclinical
testing may continue after an IND is submitted. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises
concerns or questions about the product candidate or conduct of the proposed clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks, and places the clinical trial on a partial or complete
clinical hold. In that case, the IND sponsor and the FDA must resolve the clinical hold issues before the clinical trials can begin. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Clinical holds also may be
imposed by the FDA after clinical trials have begun, including if there is concern for patient safety, as a result of new data, findings, or developments in clinical, preclinical and/or chemistry, manufacturing and controls, or where there is <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with regulatory requirements. A separate submission to an existing IND must be made for each successive clinical trial conducted during development, and the FDA reviews such submissions before each
clinical trial can begin. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Human clinical trials in support of a BLA </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Clinical trials involve the administration of the investigational product candidate to healthy volunteers or patients with the disease or condition to be treated under
the supervision of qualified investigators in accordance with GCP requirements. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, dosing procedures, inclusion and exclusion criteria, the
parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. Clinical testing also must satisfy
extensive GCP rules and the requirements for informed consent. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A sponsor who wishes to conduct a clinical trial outside the United States may, but need not, obtain
FDA authorization to conduct the clinical trial under an IND. When a foreign clinical trial is conducted under an IND, all FDA IND requirements must be met unless waived. The FDA will accept a well-designed and well-conducted foreign clinical study
not conducted under an IND if the study was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary. The GCP requirements encompass both ethical and data integrity
standards for clinical trials. The FDA&#146;s regulations are intended to help ensure the protection of human subjects enrolled in <FONT STYLE="white-space:nowrap">non-IND</FONT> foreign clinical trials, as well as the quality and integrity of the
resulting data. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Further, each clinical trial must be reviewed and approved by an IRB either centrally or individually at each institution at which the clinical
trial will be conducted. The IRB will consider, among other things, clinical trial design, patient informed consent, ethical factors, the safety of human subjects and the possible liability of the institution. An IRB must operate in compliance with
FDA regulations. The FDA, IRB, or the clinical trial sponsor may suspend or discontinue a clinical trial at any time for various reasons, including a finding that the clinical trial is not being conducted in accordance with GCP requirements or that
the participants are being exposed to an unacceptable health risk. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, some clinical trials are overseen by an independent group of qualified experts
organized by the clinical trial sponsor, known as a data safety monitoring board (&#147;DSMB&#148;), or data monitoring committee (&#147;DMC&#148;). This group may recommend continuation of the trial as planned, changes in trial conduct, or
cessation of the trial at designated check points based on certain available data from the trial to which only the DSMB/DMC has access. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">158 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Additional
studies may be required after approval. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Phase 1 clinical trials are initially conducted in a limited population of healthy subjects or disease-affected patients to
test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion and pharmacodynamics. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Phase 2 clinical trials are generally conducted in a limited patient population to identify possible adverse effects and
safety risks, evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning
larger and more costly Phase 3 clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Phase 3 clinical trials typically proceed if the Phase 2 clinical trials demonstrate that a dose range of the product
candidate is potentially effective and has an acceptable safety profile. Phase 3 clinical trials are generally undertaken within an expanded patient population to provide substantial evidence of clinical efficacy and further test for safety in an
expanded and diverse patient population at multiple, geographically dispersed clinical trial sites to provide a basis for physician labeling and for submitting a BLA to seek regulatory approval for a biological product. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In some cases, the FDA may approve a BLA but require the sponsor to conduct additional clinical trials to further assess the product&#146;s safety and effectiveness
after approval. Such post-approval trials are typically referred to as Phase 4 clinical trials. These studies are used to gain additional experience from the treatment of patients in the approved indication and, where applicable, to confirm a
clinical benefit for products approved under accelerated approval. The failure to exercise due diligence with regard to conducting Phase 4 clinical trials could result in withdrawal of approval for products. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Information about applicable clinical trials must be submitted within specific timeframes to the National Institutes of Health (&#147;NIH&#148;) for public dissemination
on its ClinicalTrials.gov website. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to
the FDA and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse events, findings from other studies or animal or<I></I><I>&nbsp;in vitro</I>&nbsp;testing that suggest a
significant risk for human subjects and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar
days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#146;s initial
receipt of the information. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the Pediatric Research Equity Act, a BLA or supplement thereto must contain data that are adequate to assess the safety and
effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDCA requires that a sponsor
who is planning to submit a marketing application for a product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan (&#147;PSP&#148;) within
60&nbsp;days of an <FONT STYLE="white-space:nowrap">end-of-phase</FONT> 2 meeting or as may be agreed between the sponsor and FDA. Those plans must contain an outline of the proposed pediatric study or studies the applicant plans to conduct,
including study objectives and design, any deferral or waiver requests and other information required by regulation. The sponsor and the FDA must reach agreement on the PSP. The FDA or the sponsor may request an amendment to the plan at any time.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA may, on its own initiative or at the request of the sponsor, grant deferrals for submission of some or all pediatric data until after approval of the
product for use in adults, or full or partial waivers from the pediatric </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">159 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
data requirements. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Compliance with cGMP requirements </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Concurrent with clinical trials,
companies must finalize a process for manufacturing the product candidate in commercial quantities in accordance with cGMP requirements. To help reduce the risk of introduction of adventitious agents with the use of biological products, the PHSA
emphasizes the importance of manufacturing controls for products with attributes that cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, companies
must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does
not undergo unacceptable deterioration over its shelf life. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the
manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Manufacturers and others involved in the manufacture and distribution of products must also register their establishments with the FDA and certain state agencies. Both
domestic and foreign manufacturing establishments must register and provide additional information to the FDA upon their initial participation in the manufacturing process. Establishments may be subject to periodic unannounced inspections by
government authorities to ensure compliance with cGMPs and other laws. Noncompliance with such requirements can lead to adverse findings by the FDA during these inspections; in instances of significant or continued noncompliance, such adverse
findings can serve as the basis for additional regulatory action by the FDA, including but not limited to warning letters, recalls, seizure, consent decrees, fines, and/or criminal penalties. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Review and approval of a BLA </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The results of product candidate
development, preclinical testing and clinical trials, including negative or ambiguous results as well as positive findings, are submitted to the FDA as part of a BLA requesting approval to market the product for one or more specified indications.
The BLA must contain extensive manufacturing information and detailed information on the composition of the product and proposed labeling as well as payment of a user fee. Under federal law, the submission of most BLAs are subject to an application
user fee. The sponsor of an approved BLA is also subject to an annual program fee. Certain exceptions and waivers are available for some of these fees, such as an exception from the application fee for products with orphan designation and a waiver
for certain small businesses. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA has 60 days after submission of the application to conduct an initial review to determine whether to accept it for filing
based on the agency&#146;s threshold determination that it is sufficiently complete to permit substantive review. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request
additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. If the submission has been accepted for filing, the FDA
begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> review of the application. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has ten months in which to complete its initial review of a standard application and respond
to the applicant, and six months for a priority review of the application. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs. The review process may be significantly extended by FDA requests for additional information
or clarification. The review process and the PDUFA goal date may be extended by three months if the FDA requests or if the applicant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">160 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
otherwise provides additional or clarifying information within the last three months before the PDUFA goal date. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA reviews a BLA to determine, among other things, whether the product is safe and effective and whether the facility in which it is manufactured, processed,
packaged or held meets standards designed to assure the product&#146;s continued safety, quality and purity. The FDA likely will reanalyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during
the review process. On the basis of the FDA&#146;s evaluation of the application and accompanying information, including the results of the inspection of the manufacturing facilities and any FDA audits of preclinical and clinical trial sites to
assure compliance with GCPs, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. If the application is
not approved, the FDA will issue a complete response letter, which will contain the conditions that must be met in order to secure final approval of the application, and when possible, will outline recommended actions the sponsor might take to
obtain approval of the application. The complete response letter may require additional clinical data and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. Sponsors that receive a
complete response letter may submit to the FDA information that represents a complete response to the deficiencies identified by the FDA. The FDA will then <FONT STYLE="white-space:nowrap">re-review</FONT> the application, taking into consideration
the response, and determine whether the application meets the criteria for approval. The FDA will not approve an application until issues identified in any complete response letters have been addressed. Failure to respond to a complete response
letter may be considered by the FDA as a request to withdraw the application. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA may refer applications for novel products or products that present difficult
questions of safety or efficacy to an advisory committee. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the
application should be approved and under what conditions, if any. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even if the FDA approves a new product, the approval may be limited to specific disease states, patient populations and dosages, or the indications for use may otherwise
be limited. It may also require that contraindications, warnings, or precautions be included in the product labeling. In addition, the FDA may require post-approval studies, including phase 4 clinical trials, to further assess the product&#146;s
efficacy and/or safety after approval. The agency may also require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms,
including a REMS, to help ensure that the benefits of the product outweigh the potential risks. A REMS can include medication guides, communication plans for healthcare professionals and elements to assure safe use (&#147;ETASU&#148;). ETASU can
include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patent registries. The FDA may prevent or limit further marketing of a
product based on the results of post-market studies or surveillance programs. After approval, many types of changes to the approved product, such as adding new indications, certain manufacturing changes and additional labeling claims, are subject to
further testing requirements and FDA review and approval. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Fast track, breakthrough therapy and priority review designations </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">FDA provides programs intended to facilitate and expedite development and review of new products that are intended to address an unmet medical need in the treatment of a
serious or life-threatening disease or condition. These programs are referred to as fast track designation, breakthrough therapy designation and priority review designation. These designations are not mutually exclusive, and a product candidate may
qualify </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">161 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
for one or more of these programs. While these programs are intended to expedite product development and approval, they do not alter the standards for FDA approval. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA may designate a product for fast track designation if it is intended, whether alone or in combination with one or more other products, for the treatment of a
serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For products with fast track designation, sponsors may have more frequent interactions with the FDA,
the product is potentially eligible for accelerated approval and priority review, if relevant criteria are met, and the FDA may initiate review of sections of a product with fast track designation&#146;s application before the application is
complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a product with fast track designation may be effective. The sponsor must also provide, and the FDA
must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. However, the FDA&#146;s time period goal for reviewing a fast track application does not begin until the last section of the
application is submitted. In addition, the fast track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A product may be designated as a breakthrough therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or
life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects
observed early in clinical development. The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding
development and approval; involving more senior staff managers in the review process; assigning a cross-disciplinary lead for the review team; and taking other steps to design the clinical trials in an efficient manner. Breakthrough designation may
be rescinded if a product no longer meets the qualifying criteria. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA may designate a product for priority review if it is a product that treats a serious
condition and, if approved, would provide a significant improvement in safety or effectiveness when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a
condition, elimination or substantial reduction of a treatment-limiting adverse reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes and evidence of safety and effectiveness in a new subpopulation.
A priority review designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#146;s goal for taking action on a marketing application from ten months to six months. Priority
review designation may be rescinded if a product no longer meets the qualifying criteria. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Accelerated approval pathway </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA may grant accelerated approval to a product for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over existing
treatments based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory
measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. The FDA may also grant accelerated approval for such a condition when the product has an
effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality (&#147;IMM&#148;), and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into
account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. The FDA has limited experience with accelerated approvals based on intermediate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">162 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
clinical endpoints but has indicated that such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and
basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a product. Products granted accelerated approval must meet the same statutory standards
for safety and effectiveness as those granted traditional approval. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The accelerated approval pathway is most often used in settings in which the course of a disease
is long, and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. The accelerated approval pathway is usually contingent
on a sponsor&#146;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product&#146;s clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous
post-marketing compliance requirements, including the completion of phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, confirm a clinical benefit during
post-marketing studies or dissemination of false or misleading promotional materials would allow the FDA to withdraw the product from the market on an expedited basis. All promotional materials for therapeutic candidates approved under accelerated
regulations are subject to prior review by the FDA. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Orphan drug designation </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Orphan drug designation in the United States is designed to encourage sponsors to develop products intended for treatment of rare diseases or conditions. In the United
States, a rare disease or condition is statutorily defined as a condition that affects fewer than 200,000 individuals in the United States or that affects 200,000 or more individuals in the United States and for which there is no reasonable
expectation that the cost of developing and making available the biological product for the disease or condition will be recovered from sales of the product in the United States. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Orphan drug designation qualifies a sponsor for tax credits and the product for market exclusivity for seven years following the date of the product&#146;s marketing
approval if granted by the FDA. An application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. After FDA grants orphan designation, the product must then go through
the review and approval process like any other product. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A sponsor may request orphan drug designation of a previously unapproved product or new orphan indication
for an already marketed product. In addition, a sponsor of a product that is otherwise the same product as an already approved orphan drug may seek and obtain orphan drug designation for the subsequent product for the same rare disease or condition
if it can present a plausible hypothesis that its product may be clinically superior to the first drug. More than one sponsor may receive orphan drug designation for the same product for the same rare disease or condition, but each sponsor seeking
orphan drug designation must file a complete request for designation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If a product with orphan designation receives the first FDA approval for the disease or
condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan drug exclusivity. Orphan drug exclusivity means that the FDA
may not approve another sponsor&#146;s marketing application for the same product for the same indication for seven years, except in certain limited circumstances. If a product designated as an orphan drug ultimately receives marketing approval for
an indication broader than what was designated in its orphan drug application, it may not be entitled to exclusivity. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The period of exclusivity begins on the date
that the marketing application is approved by the FDA and applies only to the indication for which the product has been designated. The FDA may approve a second application </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">163 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
for the same product for a different use or a second application for a clinically superior version of the product for the same use. The FDA cannot, however, approve the same product made by
another manufacturer for the same indication during the market exclusivity period unless it has the consent of the sponsor, or the sponsor is unable to provide sufficient quantities. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Pediatric exclusivity </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pediatric exclusivity is another type of <FONT
STYLE="white-space:nowrap">non-patent</FONT> marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity, including
orphan exclusivity. This <FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity may be granted if a BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the
product to be safe and effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#146;s request, the additional protection is granted and extends whatever statutory or regulatory periods of
exclusivity that cover the product by six months. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>U.S. patent term extension and marketing exclusivity </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the United States, a patent claiming a new biological product, its method of use or its method of manufacture may be eligible for a limited patent term extension
under the Hatch-Waxman Act, which permits a patent extension of up to five years for patent term lost during product development and FDA regulatory review. The extension period is typically <FONT STYLE="white-space:nowrap">one-half</FONT> the time
between the effective date of the IND and the submission date of the BLA, plus the time between the submission date of the BLA and the ultimate approval date, except that the review period is reduced by any time during which the applicant failed to
exercise due diligence. Patent term extension cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#146;s approval date in the United States. Only one patent applicable to an approved product is eligible
for the extension, and the application for the extension must be submitted prior to the expiration of the patent for which extension is sought. A patent that covers multiple products for which approval is sought can only be extended in connection
with one of the approvals. The United States Patent and Trademark Office (&#147;USPTO&#148;) reviews and approves the application for any patent term extension in consultation with the FDA. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Biosimilars and exclusivity </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Biologics Price Competition and
Innovation Act of 2009 (&#147;BPCIA&#148;) established a regulatory framework authorizing the FDA to approve biosimilars and interchangeable biosimilars. A biosimilar is a biological product that is highly similar to an already <FONT
STYLE="white-space:nowrap">FDA-licensed</FONT> biological product, called the &#147;reference product.&#148; The FDA has issued multiple guidance documents outlining an approach to review and approval of biosimilars. Under the BPCIA, a manufacturer
may submit an application for licensure of a biologic product that is &#147;biosimilar to&#148; or &#147;interchangeable with&#148; a reference product. In order for the FDA to approve a biosimilar product, it must find that there are no clinically
meaningful differences between the reference product and proposed biosimilar product in terms of safety, purity and potency. For the FDA to approve a biosimilar product as interchangeable with a reference product, the agency must find that the
biosimilar product can be expected to produce the same clinical results as the reference product, and (for products administered multiple times) that the biosimilar product and the reference product may be switched without increasing safety risks or
risks of diminished efficacy relative to exclusive use of the reference biologic. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the BPCIA, an application for a biosimilar product may not be submitted to
the FDA until four years following the date of approval of the reference product. The FDA may not approve a biosimilar product until 12 years from the date on which the reference product was approved. Even if a product is considered to be a
reference product eligible for exclusivity, another company could market a competing version of that product if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">164 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
the FDA approves a full BLA for such product containing the sponsor&#146;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and
potency of their product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products, which may be substituted by pharmacies for the reference product, subject to state pharmacy law. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Post-approval regulation </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If regulatory approval for a product or new
indication for an existing product is obtained, the sponsor will be required to comply with all generally applicable post-approval regulatory requirements as well as any specific post-approval requirements that the FDA may impose as part of the
approval process. The sponsor will be required to report certain adverse reactions and production problems to the FDA, provide updated safety and efficacy information and comply with advertising and promotional labeling requirements and
record-keeping requirements. Manufacturers and certain of their subcontractors must register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for
compliance with ongoing regulatory requirements, including cGMP regulations. Accordingly, the sponsor and its third-party manufacturers must continue to expend time, money and effort to maintain compliance with cGMP regulations and other regulatory
requirements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if
problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with
regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical trials to assess new safety risks, or imposition of distribution or other restrictions under a
REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">restrictions on the marketing or manufacturing of the product; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">fines, warning letters or holds on post-approval clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of
product licenses; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">product recall, seizure or detention, or refusal to permit the import or export of products; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">withdrawal of the product from the market; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA strictly regulates the marketing, labeling, advertising and promotion of prescription biological products placed on the market. This regulation includes, among
other things, standards and regulations for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, communications regarding unapproved uses, industry-sponsored scientific and educational
activities and promotional activities involving the internet and social media. Promotional claims about a product&#146;s safety or effectiveness are prohibited before it is approved. After approval, a product generally may be promoted for uses or
patient populations consistent with the product&#146;s prescribing information. In the United States, healthcare professionals are generally permitted to prescribe products for uses that are not approved by the FDA (sometimes called <FONT
STYLE="white-space:nowrap">&#147;off-label</FONT> use&#148;) because the FDA does not regulate the practice of medicine. However, FDA regulations restrict manufacturers&#146; communications about <FONT STYLE="white-space:nowrap">off-label</FONT>
uses. Promotional materials for approved biological products generally must be submitted to the FDA in conjunction with their first use. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">165 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If a company, including any representative of the company or anyone speaking on behalf of the company, is found to have
promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses, the company may become subject to adverse public relations and administrative and judicial enforcement by the FDA, the DOJ, or the Office of the Inspector General of the Department of
Health and Human Services, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in
which a company promotes or distributes its products. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Data privacy and security laws </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the ordinary course of business, we collect, receive, or otherwise process personal data, including information we may collect about participants in our clinical
trials. Accordingly, we are, or may be become, subject to numerous data privacy and security obligations, including global, federal, state, and local laws, regulations, guidance, industry standards, external and internal privacy and security
policies, contractual requirements and other obligations related to privacy and data security. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the federal Health Insurance Portability and Accountability Act
of 1996 (&#147;HIPAA&#148;), the U.S. Department of Health and Human Services (&#147;HHS&#148;), has issued regulations to protect the privacy and security of protected health information (&#147;PHI&#148;), used or disclosed by covered entities
including certain healthcare providers, health plans and healthcare clearinghouses. HIPAA also regulates standardization of data content, codes and formats used in healthcare transactions and standardization of identifiers for health plans and
providers. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#147;HITECH&#148;), and their regulations, including the final omnibus rule published on January&nbsp;25, 2013, also imposes certain
obligations on the business associates of covered entities and their subcontractors that obtain protected health information in providing services to or on behalf of covered entities. In addition to federal privacy regulations, there are a number of
state laws governing confidentiality and security of health information that are applicable to our business. In addition to possible federal administrative, civil and criminal penalties for HIPAA violations, state attorneys general are authorized to
file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#146;s fees and costs associated with pursuing federal civil actions. Accordingly, state attorneys general have brought civil actions seeking
injunctions and damages resulting from alleged violations of HIPAA&#146;s privacy and security rules. New laws and regulations governing privacy and security may be adopted in the future as well. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, states, such as California, Virginia and Colorado have recently enacted the consumer privacy laws that grant rights to data subjects and place increased
privacy and security obligations on entities handling personal data of consumers or households. While we are not currently subject to laws such as the California Consumer Privacy Act (&#147;CCPA&#148;), some observers note that the CCPA and similar
legislation could mark the beginning of a trend toward more stringent privacy legislation in the U.S., which could increase our potential liability and adversely affect our business. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Because of the breadth of these laws and the narrowness of the statutory exceptions under such laws, it is possible that some of our current or future business
activities, including certain clinical research, sales and marketing practices and the provision of certain items and services to our customers, could be subject to challenge under one or more of such privacy and data security laws. The heightening
compliance environment and the need to build and maintain robust and secure systems to comply with different privacy compliance and/or reporting requirements in multiple jurisdictions could increase the possibility that we may fail to comply fully
with one or more of these requirements. If our operations are found to be in violation of any applicable privacy or data security laws or regulations, we may be subject to penalties, including potentially significant criminal, civil and
administrative penalties, damages, fines, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and/or oversight if we become
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">166 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
subject to a consent decree or similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and the curtailment or restructuring of our
operations, any of which could adversely affect our ability to operate our business and our results of operations. While there are some exemptions for certain data processed in the context of clinical trials, developments in data privacy and
security laws may further complicate compliance efforts. The impact these increasingly stringent laws and evolving regulatory frameworks related to personal data processing may have on us is more fully discussed in the section titled &#147;Risk
factors&#148; appearing elsewhere in this prospectus. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, to the extent we collect personal data from individuals outside of the United States, through
clinical trials or otherwise, we are, or may become, subject to foreign data privacy and security laws, such as the European Union&#146;s General Data Protection Regulation 2016/679 (&#147;EU GDPR&#148;) and other national data protection
legislation in force in relevant EEA Member States, and the EU GDPR as it forms part UK law by virtue of section 3 of the European Union (Withdrawal) Act 2018 (&#147;UK GDPR&#148;). Foreign privacy and data security laws impose significant and
complex compliance obligations on entities that are subject to those laws, as more fully discussed in the section titled &#147;Risk factors&#148; appearing elsewhere in this prospectus. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Regulation and procedures governing approval of medicinal products outside the United States </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and
jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, an applicant will
need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. For example, the process governing approval of medicinal
products in the European Union generally follows the same lines as in the United States. It entails satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the product
for each proposed indication. It also requires the submission to the relevant competent authorities of a marketing authorization application (&#147;MAA&#148;) and granting of a marketing authorization by these authorities before the product can be
marketed and sold in the European Union. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Clinical trial approval </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In April 2014, the European Union adopted the Clinical Trials Regulation (EU) No 536/2014 (&#147;CTR&#148;), which entered into application on January&nbsp;31, 2022
repealing and replacing the Clinical Trials Directive 2001/20/EC. The CTR is directly applicable in all European Union Member States meaning no national implementing legislation in each European Union Member State is required. The CTR aims at
harmonizing and streamlining the approval of clinical trials in the European Union, simplifying adverse-event reporting procedures, improving the supervision of clinical trials and increasing their transparency. For instance, the CTR provides for a
streamlined application procedure via a single-entry point and strictly defined deadlines for the assessment of clinical trial applications. Parties conducting certain clinical trials must, as in the United States, post clinical trial information in
the European Union on the Clinical Trials Information System. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>PRIME designation in the European Union </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The PRIority MEdicines (&#147;PRIME&#148;), scheme is intended to encourage product development in areas of unmet medical need and provides accelerated assessment of
products representing substantial innovation reviewed under the centralized procedure. Eligible products must target conditions for which there is an unmet medical need (there is no satisfactory method of diagnosis, prevention or treatment in the
European Union or, if there is, the new medicine will bring a major therapeutic advantage) and they must demonstrate the potential to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">167 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
address the unmet medical need by introducing new methods of therapy or improving existing ones. Products from small- and <FONT STYLE="white-space:nowrap">medium-sized</FONT> enterprises may
qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of therapeutic candidates with PRIME designation, including but not limited to early and proactive regulatory dialogue with the European
Medicines Agency (&#147;EMA&#148;), frequent discussions on clinical trial designs and other development program elements, and potentially accelerated MAA assessment once a dossier has been submitted. Importantly, a dedicated EMA contact and
rapporteur from the Committee for Medicinal Products for Human Use (&#147;CHMP&#148;) are appointed early in the PRIME scheme facilitating increased understanding of the product at the EMA&#146;s Committee level. A
<FONT STYLE="white-space:nowrap">kick-off</FONT> meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies. Where, during the course of
development, a medicine no longer meets the eligibility criteria, support under the PRIME scheme may be withdrawn. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Marketing authorization </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To obtain a marketing authorization for a product under the European Union regulatory system, an applicant must submit an MAA, either under a centralized procedure
administered by the EMA or one of the procedures administered by competent authorities in European Union Member States (decentralized procedure, national procedure, or mutual recognition procedure). A marketing authorization may be granted only to
an applicant established in the European Union. Regulation (EC) No 1901/2006 provides that prior to obtaining a marketing authorization in the European Union, an applicant must demonstrate compliance with all measures included in an <FONT
STYLE="white-space:nowrap">EMA-approved</FONT> Pediatric Investigation Plan (&#147;PIP&#148;), covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, class waiver or a deferral for one or more of the
measures included in the PIP. The Paediatric Committee of the EMA (&#147;PDCO&#148;), may grant deferrals for some medicines, allowing a company to delay development of the medicine for children until there is enough information to demonstrate its
effectiveness and safety in adults. The PDCO may also grant waivers when development of a medicine for children is not needed or is not appropriate, such as for diseases that only affect the elderly population. The respective requirements for all
marketing authorization procedures are laid down in Regulation (EC) No 1901/2006, the <FONT STYLE="white-space:nowrap">so-called</FONT> Paediatric Regulation. This requirement also applies when a company wants to add a new indication, pharmaceutical
form or route of administration for a medicine that is already authorized. Products that are granted a marketing authorization with the results of the pediatric clinical trials conducted in accordance with the PIP (even where such results are
negative) are eligible for six months&#146; supplementary protection certificate extension. In the case of orphan medicinal products, a <FONT STYLE="white-space:nowrap">two-year</FONT> extension of the orphan market exclusivity may be available.
This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all European Union Member States, as well as the countries of the EFTA Pillar of the European Economic Area (Norway,
Iceland and Liechtenstein) (&#147;EEA&#148;). Pursuant to Regulation (EC) No.&nbsp;726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated
as orphan medicinal products, advanced therapy medicinal products (gene-therapy, somatic cell-therapy or tissue-engineered medicines) and products with a new active substance indicated for the treatment of certain diseases, including products for
the treatment of cancer, HIV, AIDS, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and viral diseases. The centralized procedure is optional for products containing a new active substance not yet authorized in the
European Union, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the European Union. Manufacturers must demonstrate the quality, safety and efficacy of
their products to the EMA. The CHMP provides an opinion regarding the MAA. The European Commission grants or refuses a marketing authorization in light of the opinion delivered by the EMA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">168 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the centralized procedure, the CHMP is responsible for conducting an initial assessment of a product. The maximum
timeframe for the evaluation of an MAA is 210 days, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Clock stops may extend the timeframe of
evaluation of an MAA considerably beyond 210 days. Where the CHMP gives a positive opinion, the EMA provides the opinion together with supporting documentation to the European Commission, who makes the final decision to grant a marketing
authorization, which is issued within 67 days of receipt of the EMA&#146;s recommendation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Accelerated evaluation may be granted by the CHMP in exceptional cases,
when a medicinal product is of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation. If the CHMP accepts such a request, the time limit of 210 days will be reduced to 150 days
(excluding clock stops), but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that it is no longer appropriate to conduct an accelerated assessment. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">National marketing authorizations, which are issued by the competent authorities of the Member States of the European Union and only cover their respective territory,
are available for products not falling within the mandatory scope of the centralized procedure. Where a product has already been authorized for marketing in a Member State of the European Union, this national authorization can be recognized in other
Member States through the mutual recognition procedure. If the product has not received a national authorization in any Member State at the time of application, it can be approved simultaneously in various Member States through the decentralized
procedure. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Now that the UK (which comprises Great Britain and Northern Ireland) has left the European Union, Great Britain is no longer covered by centralized
marketing authorizations (under the Northern Irish Protocol, centralized marketing authorizations currently continue to be recognized in Northern Ireland). On January&nbsp;1, 2024, a new International Recognition Procedure was put in place by the
UK&#146;s medicines regulator, the Medicines and Healthcare products Regulatory Agency (&#147;MHRA&#148;), under which the MHRA may base a decision to grant a marketing authorization on the positive opinion of the EMA or the approval granted by
certain other third country regulators. The MHRA also has the power to have regard to marketing authorizations approved in European Union Member States through decentralized or mutual recognition procedures with a view to more quickly granting a
marketing authorization in the UK or Great Britain. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Regulatory data protection in the European Union </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the European Union, new chemical entities (including both small molecules and biological medicinal products) approved on the basis of a complete and independent data
package, and existing chemical entities for which a previously <FONT STYLE="white-space:nowrap">non-existing</FONT> therapeutic indication is sought, qualify for eight years of data exclusivity upon marketing authorization and an additional two
years of market exclusivity pursuant to Regulation (EC) No 726/2004, as amended, and Directive 2001/83/EC, as amended. Data exclusivity, if granted, prevents generic or biosimilar applicants from referencing the innovator&#146;s preclinical and
clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization, for a period of eight years from the date on which the reference product was first authorized in the European
Union. During the additional <FONT STYLE="white-space:nowrap">two-year</FONT> period of market exclusivity, a generic or biosimilar MAA can be submitted, and the innovator&#146;s data may be referenced, but no medicinal product can be marketed until
the expiration of the market exclusivity. The overall <FONT STYLE="white-space:nowrap">ten-year</FONT> period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder
obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to authorization, is held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is
considered to be a new chemical entity so that the innovator gains the prescribed period of data exclusivity, another company may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">169 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
market another version of the product if such company obtained marketing authorization based on an MAA with a complete and independent data package of pharmaceutical tests, preclinical tests and
clinical trials. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Patent term extensions in the European Union and other jurisdictions </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The European Union also provides for patent term extension through supplementary protection certificates (&#147;SPCs&#148;). The rules and requirements for obtaining an
SPC are similar to those in the United States. An SPC may extend the term of a patent for up to five years after its originally scheduled expiration date and can provide up to a maximum of fifteen years of marketing exclusivity for a product. In
certain circumstances, the period of SPC protection may be extended for six additional months if pediatric exclusivity is obtained; and in the case of orphan medicinal products, a <FONT STYLE="white-space:nowrap">two-year</FONT> extension of the
orphan market exclusivity may be available. Although SPCs are available throughout the European Union, sponsors must apply on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis. Similar patent
term extension rights exist in certain other foreign jurisdictions outside the European Union. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Periods of authorization and renewals </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A marketing authorization is valid for five years, in principle, and it may be renewed indefinitely after five years on the basis of a
<FONT STYLE="white-space:nowrap">re-evaluation</FONT> of the risk-benefit balance by the EMA or by the competent authority of the authorizing Member State. To that end, the marketing authorization holder must provide the EMA or the competent
authority with a consolidated version of the Common Technical Document in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least nine months before the marketing
authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one
additional five-year renewal period. Any authorization that is not followed by the placement of the product on the European Union market (in the case of the centralized procedure) or on the market of the authorizing Member State (in the case of a
national procedure) within three years after authorization, or which is not placed on the market for a consecutive period of three years at any time during its authorization, ceases to be valid. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Regulatory requirements after marketing authorization </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Following
approval, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of the medicinal product, and must adhere in strict compliance with the applicable
European Union laws, regulations and guidance, including Directive 2001/83/EC, Directive (EU) 2017/157, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice. These include compliance with the European
Union&#146;s stringent pharmacovigilance or safety reporting rules, pursuant to which post-authorization studies and additional monitoring obligations can be imposed. In addition, the manufacturing of authorized products, for which a separate
manufacturer&#146;s license is mandatory, must also be conducted in strict compliance with the EMA&#146;s GMP requirements and comparable requirements of other regulatory bodies in the European Union, which mandate the methods, facilities and
controls used in manufacturing, processing and packing of products to assure their safety and identity. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Much like the Anti-Kickback Statue prohibition in the
United States, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the European Union. The provision
of benefits or advantages to induce or reward improper performance generally is usually governed by the national anti-bribery laws of European Union Member States and the Bribery Act 2010 in the UK. Infringement of these laws could result in
substantial fines and imprisonment. EU Directive 2001/83/EC, which is the EU Directive governing medicinal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">170 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
products for human use, further provides that, where medicinal products are being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or benefits in kind may
be supplied, offered or promised to such persons unless they are inexpensive and relevant to the practice of medicine or pharmacy. This provision has been transposed into the Human Medicines Regulations 2012 and so remains applicable in the UK
despite its departure from the European Union. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Payments made to physicians in certain European Union Member States must be publicly disclosed. Moreover,
agreements with physicians often must be the subject of prior notification and approval by the physician&#146;s employer, his or her competent professional organization and/or the regulatory authorities of the individual European Union Member
States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the European Union Member States. Failure to comply with these requirements could result in reputational risk, public
reprimands, administrative penalties, fines or imprisonment. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The advertising and promotion of medicinal products is also subject to laws concerning promotion of
medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. All advertising and promotional activities for the product must be consistent with the approved summary of product
characteristics, and therefore all <FONT STYLE="white-space:nowrap">off-label</FONT> promotion is prohibited. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Direct-to-consumer</FONT></FONT> advertising of prescription medicines is
also prohibited in the European Union. Although general requirements for advertising and promotion of medicinal products are established under European Union directives, the details are governed by regulations in each Member State and can differ
from one country to another. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Orphan designation and exclusivity </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Regulation (EC) No 141/2000 and Regulation (EC) No.&nbsp;847/2000 provide that a product can be designated as an orphan product by the European Commission if its sponsor
can establish that the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition, where either (i)&nbsp;such condition affects not more than five in ten thousand persons in the
European Union when the application is made, or (ii)&nbsp;without incentives it is unlikely that the marketing of the product in the European Union would generate sufficient return to justify the necessary investment in its development. For either
of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the European Union or, if such method exists, the product
will be of significant benefit to those affected by that condition. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">An orphan designation provides a number of benefits, including fee reductions, regulatory
assistance and the possibility to apply for a centralized marketing authorization. Marketing authorization for an orphan product leads to a <FONT STYLE="white-space:nowrap">ten-year</FONT> period of market exclusivity being granted following
marketing approval of the orphan product. During this market exclusivity period, the EMA, the European Commission or the European Union Member States may only grant a marketing authorization to a &#147;similar medicinal product&#148; for the same
therapeutic indication as an authorized orphan product if: (i)&nbsp;a second applicant can establish that its product, although similar to the authorized orphan product, is safer, more effective or otherwise clinically superior; (ii)&nbsp;the
marketing authorization holder for the authorized orphan product consents to a second orphan medicinal product application; or (iii)&nbsp;the marketing authorization holder for the authorized orphan product cannot supply enough orphan medicinal
product. A &#147;similar medicinal product&#148; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication.
The market exclusivity period for the authorized therapeutic indication may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, including if the
product is sufficiently profitable not to justify market exclusivity. Orphan designation must be requested before </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">171 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
submitting an application for marketing approval. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The aforementioned European Union rules are applicable in the EFTA Pillar of the EEA (Iceland, Liechtenstein and Norway). </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Reform of the regulatory framework in the European Union </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The European
Commission introduced legislative proposals in April 2023 that, if implemented, will replace the current regulatory framework in the European Union for all medicines (including those for rare diseases and for children). The European Commission has
provided the legislative proposals to the European Parliament and the European Council for their review and approval and, in April 2024, the European Parliament proposed amendments to the legislative proposals. Once the European Commission&#146;s
legislative proposals are approved (with or without amendment), they will be adopted into European Union law. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Brexit and the regulatory framework in the
United Kingdom </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The UK formally left the European Union on January&nbsp;31, 2020, and the European Union and the UK have concluded a trade and
cooperation agreement (&#147;TCA&#148;) which was provisionally applicable since January&nbsp;1, 2021 and has been formally applicable since May&nbsp;1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual
recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not provide for wholesale mutual recognition of UK and European Union pharmaceutical regulations. At present, Great Britain has
implemented European Union legislation on the marketing, promotion and sale of medicinal products through the Human Medicines Regulations 2012 (as amended) (under the Northern Ireland Protocol, the European Union regulatory framework currently
continues to apply in Northern Ireland). The regulatory regime in Great Britain therefore aligns in many ways with current European Union regulations, however it is likely that these regimes will diverge significantly in the future now that Great
Britain&#146;s regulatory system is independent from the European Union and the TCA does not provide for mutual recognition of UK and European Union pharmaceutical legislation. However, notwithstanding that there is no wholesale recognition of
European Union pharmaceutical legislation under the TCA, under a new international recognition procedure which was put in place by the MHRA on January&nbsp;1, 2024, the MHRA may take into account decisions on the approval of a marketing
authorization from the EMA (and certain other regulators) when considering an application for a Great Britain marketing authorization. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On February&nbsp;27, 2023,
the UK government and the European Commission announced a political agreement in principle to replace the Northern Ireland Protocol with a new set of arrangements, known as the &#147;Windsor Framework&#148;. This new framework fundamentally changes
the existing system under the Northern Ireland Protocol, including with respect to the regulation of medicinal products in the UK. In particular, the MHRA will be responsible for approving all medicinal products destined for the UK market
(<I>i.e.</I>, Great Britain and Northern Ireland), and the EMA will no longer have any role in approving medicinal products destined for Northern Ireland. A single <FONT STYLE="white-space:nowrap">UK-wide</FONT> marketing authorization will be
granted by the MHRA for all medicinal products to be sold in the UK, enabling products to be sold in a single pack and under a single authorization throughout the UK. The Windsor Framework was approved by the
<FONT STYLE="white-space:nowrap">EU-UK</FONT> Joint Committee on March&nbsp;24, 2023, so the UK government and the European Union will enact legislative measures to bring it into law. On June&nbsp;9, 2023, the MHRA announced that the medicines
aspects of the Windsor Framework will apply from January&nbsp;1, 2025. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Coverage and reimbursement </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the United States and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with their treatment.
Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">172 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
product acceptance. Our ability to successfully commercialize verekitug and any potential future product candidates will depend in part on the extent to which coverage and adequate reimbursement
for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Even if coverage is provided, the approved reimbursement amount may not be high enough to
allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they
will pay for and establish reimbursement levels. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There is also significant uncertainty related to the insurance coverage and reimbursement of newly approved
products and coverage may be more limited than the purposes for which the medicine is approved by the FDA or comparable foreign regulatory authorities. In the United States, the principal decisions about reimbursement for new medicines are typically
made by the Centers for Medicare&nbsp;&amp; Medicaid Services (&#147;CMS&#148;), an agency within the HHS. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a
substantial degree. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Factors payors consider in determining reimbursement are based on whether the product is: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">cost-effective; and </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Further, net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation
of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list
prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. In addition,
many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price (&#147;ASP&#148;) and best price. Penalties may apply in some cases when such metrics are not submitted
accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In some foreign
countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its Member States to
restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may
require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A Member State may approve a specific price for the medicinal product or it may instead adopt a system
of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow
favorable reimbursement and pricing arrangements for verekitug and any potential future product candidates. Historically, products launched in the European Union do not follow price structures of the U.S. and generally prices tend to be
significantly lower. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Other healthcare laws </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pharmaceutical
companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business that
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">173 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
may constrain the financial arrangements and relationships through which we research, as well as sell, market and distribute any products for which we obtain marketing authorization. Such laws
include, without limitation: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully
soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, the purchase, lease, order, arrangement, or
recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of
the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment,
and exclusion from government healthcare programs. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes
of the federal False Claims Act or federal civil monetary penalties; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the federal civil and criminal false claims laws and civil monetary penalty laws, such as the federal False Claims Act,
which impose criminal and civil penalties and authorize civil whistleblower or qui tam actions, against individuals or entities for, among other things: knowingly presenting, or causing to be presented, to the federal government, claims for payment
that are false or fraudulent; knowingly making, using or causing to be made or used, a false statement of record material to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government or knowingly
concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. Manufacturers can be held liable under the federal False Claims Act even when they do not submit claims directly to government payors
if they are deemed to &#147;cause&#148; the submission of false or fraudulent claims. The federal False Claims Act also permits a private individual acting as a &#147;whistleblower&#148; to bring actions on behalf of the federal government alleging
violations of the federal False Claims Act and to share in any monetary recovery; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">HIPAA, which created new federal criminal statutes that prohibit a person from knowingly and willfully executing, or
attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare
benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious, or fraudulent statements or
representations in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the
statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the U.S. Physician Payments Sunshine Act and its implementing regulations, which requires certain manufacturers of drugs,
devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#146;s Health Insurance Program, with specific exceptions, to report annually to CMS information related to certain payments and other transfers
of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other licensed health care practitioners and teaching hospitals, as well as ownership and investment interests held by the physicians
described above and their immediate family members; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate
and timely manner to government programs; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that
potentially harm customers. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">174 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, we are subject to state and foreign equivalents of each of the healthcare laws and regulations described
above, among others, some of which may be broader in scope and may apply regardless of the payor. Many U.S. states have adopted laws similar to the federal Anti-Kickback Statute and False Claims Act, and may apply to our business practices,
including, but not limited to, research, distribution, sales or marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> payors, including private insurers. In
addition, some states have passed laws that require pharmaceutical companies to comply with the April 2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and/or the Pharmaceutical Research and Manufacturers
of America&#146;s Code on Interactions with Healthcare Professionals. Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price disclosures to the state and require the registration of
pharmaceutical sales representatives. There are ambiguities as to what is required to comply with these state requirements and if we fail to comply with an applicable state law requirement we could be subject to penalties. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Finally, there are state and foreign laws, including for example the European Union General Data Protection Regulation, which became effective May 2018, governing the
privacy and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. If our operations are found to be in violation of any of such laws or
any other governmental regulations that apply, we may be subject to penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity
oversight and reporting obligations, exclusion from participation in federal and state healthcare programs and responsible individuals may be subject to imprisonment. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Healthcare reform </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Payors, whether domestic or foreign, or
governmental or private, are developing increasingly sophisticated methods of controlling healthcare costs and those methods are not always specifically adapted for new technologies such as gene therapy and therapies addressing rare diseases such as
those we are developing. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our products profitably. For
example, in the United States, in 2010 the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the &#147;ACA&#148;), was enacted, which, among other things, subjected
biologic products to potential competition by lower-cost biosimilars; increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; extended the Medicaid Drug Rebate program to utilization of prescriptions
of individuals enrolled in Medicaid managed care organizations; subjected manufacturers to new annual fees and taxes for certain branded prescription drugs; created a Medicare Part D coverage gap discount program, in which manufacturers must agree
to offer 70% <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the
manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; and provided incentives to programs that increase the federal government&#146;s comparative effectiveness research. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">The Budget Control Act of 2011 and subsequence legislation, among other things, created measures for spending reductions by
Congress that include aggregate reductions of Medicare payments to providers of 2% per fiscal year, which remain in effect through 2032. The U.S. American Taxpayer Relief Act of 2012 further reduced Medicare payments to several types of providers
and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">175 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">On April&nbsp;13, 2017, CMS, an agency within the HHS, published a final rule that gives states greater flexibility in
setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">On March&nbsp;11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the
statutory Medicaid drug rebate cap, previously set at 100% of a drug&#146;s average manufacturer price, for single source and innovator multiple source drugs, effective January&nbsp;1, 2024. Due to the Statutory <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Pay-As-You-Go</FONT></FONT></FONT> Act of 2010, estimated budget deficit increases resulting from the American Rescue Plan Act of 2021, and subsequent legislation, Medicare payments to
providers will be further reduced starting in 2025 absent further legislation. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These laws and regulations may result in additional reductions in
Medicare and other healthcare funding and otherwise affect the prices we may obtain for verekitug and any potential future product candidates for which we may obtain regulatory approval or the frequency with which verekitug or any potential future
product candidates is prescribed or used. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, there has been increasing legislative and enforcement interest in the U.S. with respect to drug pricing
practices. Specifically, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and
state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, and review the relationship between pricing and manufacturer patient programs. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In August 2022, the Inflation Reduction Act of 2022 (the &#147;IRA&#148;) was signed into law. The IRA includes several provisions that may impact our business,
depending on how various aspects of the IRA are implemented. Provisions that may impact our business include a $2,000 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> cap for Medicare Part D
beneficiaries, the imposition of new manufacturer financial liability on most drugs in Medicare Part D, permitting the U.S. government to negotiate Medicare Part B and Part D pricing for certain high-cost drugs and biologics without generic or
biosimilar competition, requiring companies to pay rebates to Medicare for drug prices that increase faster than inflation, and delay until January&nbsp;1, 2032 the implementation of the HHS rebate rule that would have limited the fees that pharmacy
benefit managers can charge. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one orphan designation and for which the only approved indication is for that disease or
condition. If a product receives multiple orphan designations or has multiple approved indications, it may not qualify for the orphan drug exemption. The implementation of the IRA is currently subject to ongoing litigation challenging the
constitutionality of the IRA&#146;s Medicare drug price negotiation program. The effects of the IRA on our business and the healthcare industry in general is not yet known. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, President Biden has issued multiple executive orders that have sought to reduce prescription drug costs. Although a number of these and other proposed
measures may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that they will continue to
seek new legislative measures to control drug costs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Individual states in the United States have also become increasingly active in passing legislation and
implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain drug access and marketing cost disclosure and transparency measures,
and designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations and
prospects. In addition, regional healthcare </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">176 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other
healthcare programs. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Employees and human capital resources </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of
August&nbsp;1, 2024, we had 38 full-time employees and three full-time consultants, and 13 of our employees have M.D. or Ph.D. degrees. Within our workforce, 23 employees are engaged in research and development and 15 are engaged in business
development, finance, legal, and general management and administration. Our human capital resources objectives include identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. None
of our employees are represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be good. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Facilities </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our corporate headquarters is presently located in Waltham,
Massachusetts, where we lease and occupy 16,801 square feet of office space. The initial term of the lease expires on November 1, 2027, with an option to extend the lease for an additional three years thereafter. We previously leased and occupied
8,146 square feet of office space and subleased an additional 3,405 square feet of office space in Waltham, Massachusetts. The initial term of this lease and sublease expired on June&nbsp;30, 2023 and 2024, respectively, with an option to continue
each thereafter on a month to month basis unless terminated by either party upon written notice. In July 2024, we provided written notice of our intent to terminate this lease and sublease. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe that our leased premises will be sufficient for our needs for the foreseeable future. To meet the future needs of our business, we may lease additional or
alternate space, and we believe suitable additional or alternative space will be available in the future on commercially reasonable terms. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Legal proceedings
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in
the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense
and settlement costs, diversion of management resources and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">177 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc843142_11"></A>Management </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Executive officers and directors </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth the name, age
and position of each of our executive officers, directors and director nominees as of August&nbsp;1, 2024: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="56%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Position(s)</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" COLSPAN="7"><B></B><B><I>Executive officers and employee director</I></B><B></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">E. Rand Sutherland, M.D., M.P.H.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer and Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Michael Paul Gray, M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial and Operating Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Aaron Deykin, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer and Head of Research and Development</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Adam Houghton, Ph.D., M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Business Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" COLSPAN="7"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B></B><B><I><FONT STYLE="white-space:nowrap">Non-employee</FONT> directors and director
nominee</I></B><B></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Ronald C. Renaud, Jr., M.B.A.<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chairman of the Board</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Daniella Beckman<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director Nominee*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Erez Chimovits, M.B.A., M.Sc.<SUP STYLE="font-size:75%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">H. Edward Fleming, Jr., M.D.<SUP STYLE="font-size:75%; vertical-align:top">(2)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Dayton Misfeldt&#043;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Liam Ratcliffe, M.B.Ch.B., Ph.D., M.B.A.<SUP STYLE="font-size:75%; vertical-align:top">(1)(3)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Marcella Kuhlman Ruddy, M.D., M.S.<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Atsushi Sugita, M.B.A.&#043;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Andy Wardle, M.B.Ch.B., M.B.A.&#043;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="7" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the compensation committee. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the nominating and corporate governance committee. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the audit committee. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Ms. Beckman has been appointed to serve as a member of our board of directors, effective upon the effectiveness of the registration statement of which this prospectus is a part. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#043;</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr. Misfeldt, Mr. Sugita and Dr. Wardle have each notified us that they will resign from our board of directors immediately prior to the effectiveness of the registration statement of which this prospectus forms a part.
</TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Executive officers and employee director </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>E.
Rand</B><B></B><B>&nbsp;Sutherland, M.D., M.P.H. </B>Dr.&nbsp;Sutherland has served as our Chief Executive Officer and a member of our board of directors since April 2024. From May 2022 until June 2023, Dr.&nbsp;Sutherland&nbsp;served as Chief
Executive Officer of Seeker Biologics Inc., a privately held biotechnology company. Dr.&nbsp;Sutherland&nbsp;served as President of Translate Bio, Inc. (&#147;Translate Bio&#148;), from March 2021 until the company&#146;s acquisition in September
2021. From February 2014 to March 2021, Dr.&nbsp;Sutherland served in various research and development and medical affairs roles at Sanofi, most recently as Senior Vice President and Global Head of Medical Affairs for Sanofi Genzyme from July 2018
to March 2021. Previously, Dr.&nbsp;Sutherland&nbsp;was Professor of Medicine at the University of Colorado and Chief of Pulmonary and Critical Care Medicine at National Jewish Health in Denver, where he
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">178 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
treated patients and led an <FONT STYLE="white-space:nowrap">NIH-funded</FONT> translational research program in severe asthma. Dr.&nbsp;Sutherland&nbsp;has served as a director of Krystal
Biotech, Inc. since January 2022. He previously served on the board of directors of Allakos Inc. from August 2023 until May 2024. Dr.&nbsp;Sutherland&nbsp;holds a B.A. from Oberlin College, an M.P.H. from the Harvard School of Public Health and an
M.D. from the University of Chicago. Dr.&nbsp;Sutherland completed his post-doctoral training in Internal Medicine at the University of California, San Francisco, where he also served as Chief Medical Resident, followed by a fellowship in Pulmonary
and Critical Care Medicine at the University of Colorado. We believe Dr.&nbsp;Sutherland is qualified to serve as a member of our board of directors because of his scientific and professional background, and his familiarity with our Company as Chief
Executive Officer. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Michael Paul Gray, M.B.A.</B> Mr.&nbsp;Gray has served as our Chief Financial Officer and Chief Operating Officer since March 2024.
Mr.&nbsp;Gray was Chief Financial Officer and Chief Operating Officer of Carmot Therapeutics, Inc. from June 2023 until February 2024. Mr.&nbsp;Gray was Chief Financial Officer and Chief Operating Officer of Imara, Inc. from April 2019 until March
2023 and Chief Financial Officer and Chief Operating Officer of Arsanis, Inc. from March 2016 until March 2022. Prior to this, Mr.&nbsp;Gray held a number of leadership positions at Curis, Inc., including most recently as Chief Financial Officer and
Chief Business Officer from February 2013 until February 2016. Mr.&nbsp;Gray previously served on the board of directors of Therapeutics Acquisition Corporation, from May 2020 until its merger in July 2021. He received his B.S. in business
administration (accounting) from Bryant College and an M.B.A. in corporate finance and entrepreneurial management from the F.W. Olin Graduate School of Business at Babson College. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Aaron Deykin, M.D.</B> Dr.&nbsp;Deykin has served as our Chief Medical Officer and Head of Research and Development since April 2022. From March 2020 until April
2022, Dr.&nbsp;Deykin was Senior Vice President of Clinical Sciences overseeing Biostatistics, Statistical Programming, Biomarkers, Clinical Pharmacology, Epidemiology, and Clinical Operations for Biogen, Inc.&#146;s (&#147;Biogen&#148;) pipeline
globally. Prior to this, Dr.&nbsp;Deykin was a member of the faculty of Medicine at Harvard Medical School and a member of the Pulmonary and Critical Care faculty at Brigham and Women&#146;s Hospital from September 1999 until March 2010. In that
capacity, he treated patients with asthma and other advanced respiratory diseases while leading the medical activities of the Lung Transplantation Program, directing the Pulmonary Function Testing Laboratory and serving as the Associate Director of
the Asthma Research Center. Dr.&nbsp;Deykin has been awarded board certification in Internal Medicine, Pulmonary Disease, and Critical Care Medicine, and holds an M.D. from Harvard Medical School and a B.A. from Dartmouth College. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Adam Houghton, Ph.D., M.B.A.</B> Dr.&nbsp;Houghton has served as our Chief Business Officer since October 2021.&nbsp;From March 2019 until September 2021,
Dr.&nbsp;Houghton was Vice President, Corporate Strategy, and Head of AbbVie Ventures, AbbVie Inc.&#146;s corporate venture investment group and served as Senior Director and Head, Immunology Search and Evaluation from February 2015 until March
2019. Prior to this, Dr.&nbsp;Houghton was Senior Director and Head of Search and Evaluation at Biogen from July 2017 until February 2018. From November 2013 until February 2015, Dr.&nbsp;Houghton was Senior Director, Global External Research and
Development, BioMedicines and Tailored Therapeutics at Eli Lilly and Company.&nbsp;Prior to this, Dr.&nbsp;Houghton was Section Head, Bone and Inflammation Drug Discovery at Procter&nbsp;&amp; Gamble Pharmaceuticals from April 2000 until July 2005
and Research Assistant at Zeneca (now AstraZeneca) from October 1988 until September 1994. Dr.&nbsp;Houghton received a B.S. from Manchester Metropolitan University, a Ph.D. in Cell and Molecular Biology from the University of Sheffield, performed
post-doctoral research at Yale School of Medicine and received an M.B.A. from Xavier University. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I><FONT STYLE="white-space:nowrap">Non-employee</FONT>
directors and director nominee </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Ronald C. Renaud, Jr., M.B.A.</B> Mr.&nbsp;Renaud is Chair of our board of directors and has been a member of our
board of directors since November 2021. Since October 2024, Mr. Renaud has served as President and Chief Executive Officer and a member of the board of directors at Kailera Therapeutics, Inc. Prior to this, Mr.&nbsp;Renaud
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">179 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
served as President and Chief Executive Officer and a member of the board of directors of Cerevel Therapeutics Holdings, Inc. from June 2023 until August 2024. Prior to this, Mr.&nbsp;Renaud was
a partner at Bain Capital Life Sciences from September 2022 through June 2023. Prior to this, he served as Chair and Chief Executive Officer of Translate Bio from 2014 until the close of its acquisition by Sanofi in September 2021. Prior to this,
Mr.&nbsp;Renaud was at Idenix Pharmaceuticals, Inc. from 2007 through 2014, where he served as Chief Financial Officer, Chief Business Officer and, finally, President and Chief Executive Officer at the time of its acquisition by Merck&nbsp;&amp;
Company, Inc. (&#147;Merck&#148;). Prior to this, Mr.&nbsp;Renaud was a biotechnology equity research analyst at J.P. Morgan, Schwab Soundview and Bear Stearns from January 2000 until February 2006. Mr.&nbsp;Renaud also served in various positions
at Amgen Inc. from April 1994 until December 1999. Mr.&nbsp;Renaud previously served on the boards of Atara Biotherapeutics, Inc. from April 2020 until December 2022, Ikena Oncology, Inc. from March 2018 until December 2022, Chimerix, Inc. from
December 2014 until November 2021, and Akebia Therapeutics, Inc. from September 2014 until December 2018. Mr.&nbsp;Renaud holds a B.A. from St. Anselm College and an M.B.A. from the Marshall School of Business at the University of Southern
California. We believe Mr.&nbsp;Renaud is qualified to serve on our board of directors because of his leadership and management experience and his extensive knowledge of the biopharmaceutical industry. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Daniella Beckman.</B> Ms. Beckman has been appointed to serve as a member of our board of directors, effective upon the effectiveness of the registration statement of
which this prospectus is a part. Ms. Beckman has served as the Chief Financial Officer of Tango Therapeutics, Inc. (Nasdaq: TNGX) since September 2019, where she previously served as interim Chief Financial Officer from October 2016 to September
2019. From November 2015 to September 2019, she provided consulting and interim chief financial officer services for early-stage biotechnology companies. From June 2011 until August 2014, Ms. Beckman served as Chief Financial Officer of Idenix
Pharmaceuticals, Inc., where she previously served as Corporate Controller from March 2008 until June 2011. Ms. Beckman has served on the boards of directors of Blueprint Medicines Corporation (Nasdaq: BPMC) since December 2021 and Vor Biopharma
Inc. (Nasdaq: VOR) since July 2020, and previously served on the boards of directors of 5:01 Acquisition Corp. from October 2020 to October 2022 and Translate Bio from October 2017 to September 2021. Ms. Beckman holds a B.S. from Boston University.
We believe Ms. Beckman is qualified to serve as a member of our board of directors because of her financial expertise and leadership experience in the biopharmaceutical industry. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Erez Chimovits, M.B.A., M.Sc. </B>Mr.&nbsp;Chimovits has been a member of our board of directors since October 2021. Mr.&nbsp;Chimovits is a Partner at OrbiMed, an
investment firm, where he has served in various roles of increasing responsibility since November 2010. Mr.&nbsp;Chimovits previously served on the boards of directors of Adicet Bio, Inc. from January 2016 until March 2021, BiomX, Inc. from December
2015 until October 2020, LogicBio Therapeutics, Inc. from January 2016 until December 2020, and Novus Therapeutics, Inc. (now Eledon Pharmaceuticals, Inc) from June 2017 until September 2020. Mr.&nbsp;Chimovits served as Chief Executive Officer of
NasVax Ltd. (now SciSparc Ltd.) from January 2007 to November 2010. Previously, Mr.&nbsp;Chimovits served as President of Compugen USA Inc., a subsidiary of Compugen Ltd., from January 2001 to January 2007, and as Executive Vice President in
Commercial Operations from December 1999 to January 2007. Mr.&nbsp;Chimovits earned his M.B.A., M.Sc. in Microbiology, and B.Sc. from Tel Aviv University. We believe Mr.&nbsp;Chimovits is qualified to serve as a member of our board of directors
because of his professional background in the biopharmaceutical industry. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>H. Edward Fleming, Jr., M.D.</B> Dr.&nbsp;Fleming has served on our board of directors
since June 2023. Since November 2022, Dr.&nbsp;Fleming has served as the Executive Vice President of Enavate Sciences where he works closely to invest in and build therapeutic companies. From January 1997 until August 2022, Dr.&nbsp;Fleming held
multiple positions at McKinsey&nbsp;&amp; Company (&#147;McKinsey&#148;), most recently as Senior Partner and global leader of McKinsey&#146;s research and development practice. Dr.&nbsp;Fleming has served on the board of directors of CRISPR
Therapeutics AG since June 2021. Dr.&nbsp;Fleming earned his B.A. in Chemistry from Harvard University, his M.D. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">180 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
from Vanderbilt University, and completed internal medicine training at Johns Hopkins Hospital and subspecialty training in Pulmonary and Critical Care Medicine at the University of California,
San Francisco. We believe Dr.&nbsp;Fleming is qualified to serve on our board of directors because of his experience in the healthcare industry, including working closely with biopharmaceutical companies on strategy, operational performance and
research and development innovation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Dayton</B><B></B><B>&nbsp;Misfeldt.</B> Mr.&nbsp;Misfeldt has served on our board of directors since October 2021. Since
January 2021, Mr.&nbsp;Misfeldt has served as a Partner at Decheng Capital, an investment firm, and focuses on biopharmaceutical investment opportunities. Previously, Mr.&nbsp;Misfeldt was Managing Director at Bay City Capital, a venture capital
firm he worked at from May 2000 to December 2020. Mr.&nbsp;Misfeldt previously served as a member of the board of directors of Sunesis Pharmaceuticals, Inc. (&#147;Sunesis&#148;) from April 2009 until December 2020 and as Sunesis&#146; interim Chief
Executive Officer from January 2018 until December 2020. Before joining Bay City Capital, Mr.&nbsp;Misfeldt was a Vice President at Roth Capital Partners, where he worked as a sell-side analyst covering the biopharmaceutical industry from October
1997 until April 2000. Mr.&nbsp;Misfeldt received a B.A. in Economics from the University of California, San Diego. We believe that Mr.&nbsp;Misfeldt is qualified to serve as a member of our board of directors because of his venture capital
experience in the biopharmaceutical industry. Mr. Misfeldt has notified us that he will resign from our board of directors immediately prior to the effectiveness of the registration statement of which this prospectus forms a part. Mr.
Misfeldt&#146;s resignation is not due to any disagreement with us or any matters relating to our operations, policies or practices. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Liam Ratcliffe, M.B.Ch.B.,
Ph.D., M.B.A.</B>&nbsp;Dr.&nbsp;Ratcliffe has served as a member of our board of directors since October 2021. Since April 2019, Dr.&nbsp;Ratcliffe has served as Head of Biotechnology at Access Industries, a privately held industrial group. From
September 2008 until March 2019, Dr.&nbsp;Ratcliffe held various positions at New Leaf Venture Partners, most recently as Managing Director. From January 1997 until August 2008, Dr.&nbsp;Ratcliffe was Worldwide Head of Clinical Research and
Development at Pfizer Inc. Dr.&nbsp;Ratcliffe has served as a member of the boards of directors of Disc Medicine, Inc. since September 2019 and Eliem Therapeutics, Inc. since October 2019. Previously, Dr.&nbsp;Ratcliffe served as a member of the
boards of directors of Arvinas, Inc. from October 2015 until August 2022, Passage Bio, Inc. from September 2019 until March 2022, Unum Therapeutics, Inc. from March 2018 until April 2019, Deciphera Pharmaceuticals, Inc. from September 2017 until
March 2019, Aptinyx, Inc. from June 2018 until April 2019 and Edge Therapeutics, Inc. (now PDS Biotechnology Corp.,) from October 2015 until November 2018. Dr.&nbsp;Ratcliffe received an M.B.Ch.B. and a Ph.D. in immunology from University of Cape
Town and an M.B.A. from the University of Michigan. We believe Dr.&nbsp;Ratcliffe is qualified to serve as a member of our board of directors because of his extensive clinical development and venture capital experience in the life sciences
industry.</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Marcella Kuhlman Ruddy, M.D., M.S.</B> Dr.&nbsp;Ruddy has served on our board of directors since January 2023. Since July 2021, Dr.&nbsp;Ruddy has
served as Chief Medical Officer at Tectonic Therapeutic, Inc. From June 2016 until June 2021, Dr.&nbsp;Ruddy was at Regeneron Pharmaceuticals, Inc. where she was the Head of Clinical Development for the Immunology/Inflammation Therapeutic Area.
Previously, Dr.&nbsp;Ruddy held positions of increasing responsibility, including Head of Early Clinical Development for Immunology, from November 2004 until June of 2014 at Merck. From November 2015 until June 2016, Dr.&nbsp;Ruddy served as Vice
President, Clinical Development and Head of Pharmacovigilance at Alnylam Pharmaceuticals, Inc. From June 2014 until November 2014, Dr.&nbsp;Ruddy served as Vice President of Clinical Immunology at EMD Serono, Inc., Merck&#146;s healthcare business.
From June 1996 until October 2004, Dr.&nbsp;Ruddy held a staff position in the Pulmonary Unit at Massachusetts General Hospital/Harvard Medical School where she founded and directed the Adult Cystic Fibrosis Program. Dr.&nbsp;Ruddy holds a B.A. from
Princeton University and a M.D. and M.S. from Washington University, St. Louis and completed her Internal Medicine and Pulmonary fellowship training at Harvard Medical School affiliated hospitals. We believe Dr.&nbsp;Ruddy is qualified to serve as a
member of our board of directors because of her extensive experience in both drug development and the biopharmaceutical industry. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">181 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Atsushi Sugita, M.B.A.</B> Mr.&nbsp;Sugita has served on our board of directors since December 2021. Since December
2020, Mr.&nbsp;Sugita has served as President and Chief Executive Officer of Maruho Co., Ltd. (&#147;Maruho&#148;), a privately held Japanese pharmaceutical company. Mr.&nbsp;Sugita has served on the board of directors of Maruho since December 2014
and as Executive Vice President from January 2020 until December 2020. From December 2016 until October 2018, Mr.&nbsp;Sugita served as Maruho&#146;s Senior Corporate Officer in charge of Global Strategy and Business Development, Finance and
Accounting, and Human Resources and from October 2018 until January 2020, he served as Executive Corporate Officer of Business Operations&nbsp;&amp; Administration. From July 2005 until February 2012, Mr.&nbsp;Sugita was employed by Janssen
Pharmaceutical K.K. in Japan in managerial positions in corporate planning and marketing, and was dispatched to Johnson&nbsp;&amp; Johnson in the U.S. from September 2008 until August 2009. Mr.&nbsp;Sugita has a bachelor&#146;s degree in economics
from Kyoto University and an M.B.A. from the Kellogg School of Management at Northwestern University. We believe Mr.&nbsp;Sugita is qualified to serve as a member of our board of directors because of his experience serving as an officer of a
pharmaceutical company. Mr. Sugita has notified us that he will resign from our board of directors immediately prior to the effectiveness of the registration statement of which this prospectus forms a part. Mr. Sugita&#146;s resignation is not due
to any disagreement with us or any matters relating to our operations, policies or practices. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Andy Wardle, M.B.Ch.B., M.B.A. </B>Dr.&nbsp;Wardle has served as a
member of our board of directors since December 2023. Since September 2021, Dr.&nbsp;Wardle has served as an investor in late-stage biotechnology at Venrock Healthcare Capital Partners. From January 2019 until August 2021, Dr.&nbsp;Wardle served as
director of clinical development at Mirum Pharmaceuticals, Inc. From August 2015 until May 2017, Dr.&nbsp;Wardle served as senior associate in the healthcare practice at Boston Consulting Group (London). From August 2013 until July 2015,
Dr.&nbsp;Wardle was a practicing physician in London at Hammersmith Hospital. Dr.&nbsp;Wardle has an M.B.Ch.B. and B.S. from the University of Bristol and an M.B.A. from Stanford Graduate School of Business. We believe Dr.&nbsp;Wardle is qualified
to serve as a member of our board of directors because of his investment experience in biotechnology. Dr. Wardle has notified us that he will resign from our board of directors immediately prior to the effectiveness of the registration statement of
which this prospectus forms a part. Dr. Wardle&#146;s resignation is not due to any disagreement with us or any matters relating to our operations, policies or practices. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Composition of our board of directors </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board currently consists of
nine<B> </B>members, each of whom are members pursuant to the board composition provisions of our second amended and restated certificate of incorporation and agreements with our stockholders. These board composition provisions will terminate upon
the completion of this offering. Upon the termination of these provisions, there will be no further contractual obligations regarding the election of our directors. Our nominating and corporate governance committee and our board of directors may
therefore consider a broad range of factors relating to the qualifications and background of nominees. Our nominating and corporate governance committee&#146;s and our board of directors&#146; priority in selecting board members is identification of
persons who will further the interests of our stockholders through their established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of our business,
understanding of the competitive landscape, professional and personal experiences, and expertise relevant to our growth strategy. Our directors hold office until their successors have been elected and qualified or until the earlier of their
resignation or removal. Our third amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, and second amended and restated bylaws, which will become effective upon
effectiveness of the registration statement of which this prospectus forms a part, also provide that our directors may be removed only for cause by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of
the votes that all our stockholders would be entitled to cast in an annual election of directors, and that any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote
of a majority of our directors then in office. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">182 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Director independence </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board
of directors has determined that all members of the board of directors, except Dr.&nbsp;Sutherland, our Chief Executive Officer, are independent directors, including for purposes of the rules of the Nasdaq Global Market (&#147;Nasdaq&#148;) and the
Securities and Exchange Commission (&#147;SEC&#148;). Our board of directors also determined that Ms. Beckman, who has been appointed to serve as a member of our board of directors effective upon the effectiveness of the registration statement of
which this prospectus is a part, is an independent director. In making such independence determination, our board of directors considered the relationships that each <FONT STYLE="white-space:nowrap">non-employee</FONT> director and director nominee
has with us and all other facts and circumstances that our board of directors deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each <FONT STYLE="white-space:nowrap">non-employee</FONT>
director and director nominee. In considering the independence of the directors and director nominee listed above, our board of directors considered their association with the holders of more than 5% of our common stock. Upon the completion of this
offering, we expect that the composition and functioning of our board of directors and each of our committees will comply with all applicable requirements of the Nasdaq Global Market and the rules and regulations of the SEC. Dr.&nbsp;Sutherland is
not an independent director under these rules because he is the Chief Executive Officer of the Company. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Family relationships </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There are no family relationships among any of our executive officers or directors. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Staggered board </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In accordance with the terms of our third amended and
restated certificate of incorporation to be in effect immediately prior to the completion of this offering and second amended and restated bylaws to be in effect upon effectiveness of the registration statement of which this prospectus forms a part,
our board of directors will be divided into three staggered classes of directors and each will be assigned to one of the three classes. At each annual meeting of the stockholders, a class of directors will be elected for a three-year term to succeed
the directors of the same class whose terms are then expiring. The terms of the directors will expire upon the election and qualification of successor directors at the annual meeting of stockholders to be held during the years 2025 for Class&nbsp;I
directors, 2026 for Class&nbsp;II directors and 2027 for Class&nbsp;III directors. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our Class&nbsp;I directors will be Erez Chimovits, M.B.A., M.Sc. and Marcella Kuhlman Ruddy, M.D., M.S.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our Class&nbsp;II directors will be H. Edward Fleming, Jr., M.D. and Liam Ratcliffe, M.B.Ch.B., Ph.D., M.B.A.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our Class&nbsp;III directors will be Daniella Beckman, Ronald C. Renaud, Jr., M.B.A. and E. Rand Sutherland, M.D., M.P.H.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our third amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, and
second amended and restated bylaws, which will become effective upon effectiveness of the registration statement of which this prospectus forms a part, provide that the number of our directors shall be fixed from time to time by a resolution of the
majority of our board of directors. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The division of our board of directors into three classes with staggered three-year terms may delay or prevent stockholder
efforts to effect a change of our management or a change in control. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Board leadership structure </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Currently, the role of chairperson of the board of directors is separated from the role of Chief Executive Officer. Our Chief Executive Officer is responsible for
recommending strategic decisions and capital allocation to the board of directors and to ensure the execution of the recommended plans. The chairperson of the board of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">183 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
directors is responsible for leading the board of directors in its fundamental role of providing advice to and independent oversight of management. Our board of directors recognizes the time,
effort and energy that the Chief Executive Officer is required to devote to his position in the current business environment, as well as the commitment required to serve as our chairperson, particularly as the board of directors&#146; oversight
responsibilities continue to grow. While our second amended and restated bylaws and corporate governance guidelines will not require that our chairperson and Chief Executive Officer positions be separate, our board of directors believes that having
separate positions is the appropriate leadership structure for us at this time and demonstrates our commitment to good corporate governance. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Role of the board
in risk oversight </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Risk is inherent with every business, and how well a business manages risk can ultimately determine its success. We face a number of
risks, including the risks relating to our financial condition, development and commercialization activities, operations, strategic direction, and intellectual property as more fully discussed in the section titled &#147;Risk factors&#148; included
elsewhere in this prospectus. Management is responsible for the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> management of risks we face, while our board of directors, as a whole and through its
committees, has responsibility for the oversight of risk management. In its risk oversight role, our board of directors has the responsibility to satisfy itself that the risk management processes designed and implemented by management are adequate
and functioning as designed. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The role of the board of directors in overseeing the management of our risks is conducted primarily through committees of the
board of directors, as disclosed in the descriptions of each of the committees below and in the charters of each of the committees. The full board of directors (or the appropriate board committee in the case of risks that are under the purview of a
particular committee) discusses with management our major risk exposures, their potential impact on us, and the steps we take to manage them. When a board committee is responsible for evaluating and overseeing the management of a particular risk or
risks, the chairperson of the relevant committee reports on the discussion to the full board of directors during the committee reports portion of the next board meeting. This enables the board of directors and its committees to coordinate the risk
oversight role, particularly with respect to risk interrelationships. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Committees of our board of directors </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee, each of which will operate
pursuant to a charter to be adopted by our board of directors that will be effective upon the effectiveness of the registration statement of which this prospectus is a part. The board of directors may also establish other committees from time to
time to assist the Company and the board of directors. Upon the effectiveness of the registration statement of which this prospectus is a part, the composition and functioning of all of our committees will comply with all applicable requirements of
the Sarbanes-Oxley Act of 2002, as amended (the &#147;Sarbanes-Oxley Act&#148;), Nasdaq and SEC rules and regulations, if applicable. Upon our listing on Nasdaq, each committee&#146;s charter will be available on our website at www.upstreambio.com.
We do not incorporate the information on or accessible through our website into this prospectus, and you should not consider any information on, or that can be accessed through, our website as part of this prospectus. We have included our website
address in this prospectus solely as an inactive textual reference. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Audit committee </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Effective upon the effectiveness of the registration statement of which this prospectus is a part, Ms. Beckman, Dr. Fleming and Dr. Ratcliffe will serve on the audit
committee, which will be chaired by Ms. Beckman. Our board of directors has determined that&nbsp;each member of the audit committee is &#147;independent&#148; for audit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">184 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
committee purposes as that term is defined by the rules of the SEC and Nasdaq, and that each has sufficient knowledge in financial and auditing matters to serve on the audit committee. Our board
of directors has designated Ms.&nbsp;Beckman as an &#147;audit committee financial expert,&#148; as defined under the applicable rules of the SEC. The audit committee&#146;s responsibilities include: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">appointing, approving the compensation of, and assessing the independence of our independent registered public accounting
firm; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><FONT STYLE="white-space:nowrap">pre-approving</FONT> auditing and permissible
<FONT STYLE="white-space:nowrap">non-audit</FONT> services, and the terms of such services, to be provided by our independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing the overall audit plan with our independent registered public accounting firm and members of management
responsible for preparing our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly
financial statements and related disclosures as well as critical accounting policies and practices used by us; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">coordinating the oversight and reviewing the adequacy of our internal control over financial reporting;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establishing policies and procedures for the receipt and retention of accounting-related complaints and concerns;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">recommending, based upon the audit committee&#146;s review and discussions with management and our independent registered
public accounting firm, whether our audited financial statements shall be included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as they
relate to our financial statements and accounting matters; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">preparing the audit committee report required by SEC rules to be included in our annual proxy statement;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing all related person transactions for potential conflict of interest situations and approving all such
transactions; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing quarterly earnings releases; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing our major risk exposures, including financial, operational, cybersecurity, competition, legal and regulatory
exposures. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Compensation committee </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Effective upon the
effectiveness of the registration statement of which this prospectus is a part, Mr. Chimovits, Dr. Ratcliffe and Mr. Renaud will serve on the compensation committee, which will be chaired by Mr. Renaud. Our board of directors has determined that
each member of the compensation committee is &#147;independent&#148; as defined in the Nasdaq listing standards. The compensation committee&#146;s responsibilities include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">annually reviewing and recommending to the board of directors the corporate goals and objectives relevant to the
compensation of our Chief Executive Officer; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">evaluating the performance of our Chief Executive Officer in light of such corporate goals and objectives and based on such
evaluation (i)&nbsp;reviewing and recommending to the board of directors the cash compensation of our Chief Executive Officer, and (ii)&nbsp;reviewing and recommending to the board of directors grants and awards to our Chief Executive Officer under
equity-based plans; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">185 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and approving the compensation of our other executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">developing and implementing compensation policies and plans; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">overseeing and administering our compensation and similar plans; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">evaluating and assessing potential and current compensation advisors in accordance with the independence standards
identified in the applicable Nasdaq listing rules; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">retaining and approving the compensation of any compensation advisors; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and recommending to the board of directors our policies and procedures for the grant of equity-based awards;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and recommending to the board of directors the compensation of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">preparing our compensation committee report if and when required by SEC rules; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and discussing annually with management our Compensation Discussion and Analysis, if and when required, to be
included in our annual proxy statement; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and approving the retention or termination of any consulting firm or outside advisor to assist in the evaluation
of compensation matters. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Nominating and corporate governance committee </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Effective upon the effectiveness of the registration statement of which this prospectus is a part, Mr. Chimovits, Dr. Fleming and Dr. Ruddy will serve on the nominating
and corporate governance committee, which will be chaired by Dr. Ruddy. Our board of directors has determined that each member of the nominating and corporate governance committee is &#147;independent&#148; as defined in the Nasdaq listing
standards. The nominating and corporate governance committee&#146;s responsibilities include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">developing and recommending to the board of directors criteria for board and committee membership, including any specific
qualities or skills, and reassessing such criteria on an ongoing basis; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establishing procedures for identifying and evaluating board of director candidates, including nominees recommended by
stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">identifying individuals qualified to become members of the board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">recommending to the board of directors the persons to be nominated for election as directors and to each of the
board&#146;s committees; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">developing and recommending to the board of directors a code of business conduct and ethics and a set of corporate
governance guidelines; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and discussing with the board of directors succession plans for our key officers; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">overseeing the evaluation of our board of directors, its committees and management. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Compensation committee interlocks and insider participation </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">None of the
members of our compensation committee is currently, or has at any time during the prior three years been, one of our officers or employees. None of our executive officers currently serves, or in the past fiscal year has served, as a member of the
board of directors or compensation committee of any entity that has one or more executive officers serving on our board of directors or compensation committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">186 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Corporate governance </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Effective
upon the effectiveness of the registration statement of which this prospectus is a part, we have adopted a written code of business conduct and ethics that applies to our directors, officers, and employees, including our principal executive officer,
principal financial officer, principal accounting officer, or controller, or persons performing similar functions. Following the effectiveness of the registration statement of which this prospectus is a part, a current copy of this code will be
posted on the Corporate Governance section of our website, which is located at www.upstreambio.com. We do not incorporate the information on or accessible through our website into this prospectus, and you should not consider any information on, or
that can be accessed through, our website as part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. If we make any substantive amendments to, or grant any waivers from, the code of
business conduct and ethics for any officer or director, we will disclose the nature of such amendment or waiver on our website or in a current report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Limitations on liability and indemnification agreements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As permitted by
Delaware law, provisions in our third amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, and second amended and restated bylaws, which will become effective upon the
effectiveness of the registration statement of which this prospectus forms a part, limit or eliminate the personal liability of directors and officers for a breach of their fiduciary duty of care as a director or officer. The duty of care generally
requires that, when acting on behalf of the corporation, a director and or officer exercise an informed business judgment based on all material information reasonably available to him or her. Consequently, a director or officer will not be
personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as a director or officer, except for liability for: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any breach of the director or officer&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">for our directors, unlawful payments of dividends or unlawful stock repurchases, or redemptions as provided in
Section&nbsp;174 of the Delaware General Corporation Law (&#147;DGCL&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">for our officers, any derivative action by or in the right of the corporation; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any transaction from which the director or officer derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These limitations of liability do not limit or eliminate our rights or any stockholder&#146;s rights to seek <FONT STYLE="white-space:nowrap">non-monetary</FONT> relief,
such as injunctive relief or rescission. These provisions will not alter a director or officer&#146;s liability under other laws, such as the federal securities laws or other state or federal laws. Our third amended and restated certificate of
incorporation that will become effective upon the completion of this offering also authorizes us to indemnify our officers, directors and other agents to the fullest extent permitted under Delaware law. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As permitted by Delaware law, our second amended and restated bylaws will provide that: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we will indemnify our directors, officers, employees and other agents to the fullest extent permitted by law;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we must advance expenses to our directors and officers, and may advance expenses to our employees and other agents, in
connection with a legal proceeding to the fullest extent permitted by law; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the rights provided in our second amended and restated bylaws are not exclusive. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">187 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a
director or officer, then the liability of our directors or officers will be so eliminated or limited to the fullest extent permitted by Delaware law, as so amended. Our second amended and restated bylaws will also permit us to secure insurance on
behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in connection with their services to us, regardless of whether our second amended and restated bylaws permit such indemnification. We have
obtained such insurance. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to the indemnification that will be provided for in our third amended and restated certificate of incorporation and second
amended and restated bylaws, we plan to enter into separate indemnification agreements with each of our directors and executive officers, which may be broader than the specific indemnification provisions contained in the DGCL. These indemnification
agreements may require us, among other things, to indemnify our directors and executive officers for some expenses, including attorneys&#146; fees, expenses, judgments, fines and settlement amounts incurred by a director or executive officer in any
action or proceeding arising out of his service as one of our directors or executive officers or any other company or enterprise to which the person provides services at our request. We believe that these provisions and agreements are necessary to
attract and retain qualified individuals to serve as directors and executive officers. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This description of the indemnification provisions of our third amended and
restated certificate of incorporation, our second amended and restated bylaws and our indemnification agreements is qualified in its entirety by reference to these documents, each of which is attached as an exhibit to the registration statement of
which this prospectus forms a part. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and
controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being sought, nor are we aware of any pending or
threatened litigation that may result in claims for indemnification by any director or officer. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Compensation recovery </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with this offering, we have adopted a compensation recovery policy that applies to our officers. Under the Sarbanes-Oxley Act, in the event of misconduct
that results in a financial restatement that would have reduced a previously paid incentive amount, we can recoup those improper payments from our chief executive officer and chief financial officer. The SEC also recently adopted rules which direct
national stock exchanges to require listed companies to implement policies intended to recoup bonuses paid to executives if the company is found to have misstated its financial results. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">188 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc843142_12"></A>Executive compensation </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following discussion contains forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding our future
compensation programs. The actual amount and form of compensation and the compensation policies and practices that we adopt in the future may differ materially from currently planned programs as summarized in this discussion. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As an emerging growth company and smaller reporting company, we have opted to comply with the executive compensation disclosure rules applicable to &#147;smaller
reporting companies,&#148; as such term is defined in the rules promulgated under the Securities Act. The compensation provided to our named executive officers for the fiscal year ended December&nbsp;31, 2023 is detailed in the 2023 Summary
Compensation Table and accompanying footnotes and narrative that follow. Further, the employment terms ended for each of Mses. Truex and Beachell following the end of fiscal year ended December&nbsp;31, 2023. Our named executive officers for the
fiscal year ended December&nbsp;31, 2023 are: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Samantha Truex, Former Chief Executive Officer; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Aaron Deykin, M.D., Chief Medical Officer; and </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Jennifer Beachell, Former Chief Operating Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To date, the compensation of our named executive officers has consisted of a combination of base salary, cash bonuses and long-term incentive compensation in the form of
stock options. Our named executive officers, like all of our full-time employees, are eligible to participate in our health and welfare benefit plans and 401(k) plan. As we transition from a private company to a publicly traded company, we intend to
evaluate our compensation values and philosophy and compensation plans and arrangements as circumstances require. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>2023 summary compensation table </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table shows the total compensation earned by, or paid to, our named executive officers for services rendered to us in all capacities during the fiscal year
ended December&nbsp;31, 2023. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name and principal position</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Bonus<BR>($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Option<BR>awards<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP><BR>($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B><FONT STYLE="white-space:nowrap">Non-equity</FONT><BR>incentive plan<BR>compensation<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP><BR>($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>All other<BR>compensation<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP><BR>($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Samantha Truex<BR><I>Former Chief Executive Officer</I><SUP STYLE="font-size:75%; vertical-align:top">(4)<FONT
STYLE="font-size:6.5pt"><I> </I></FONT></SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">475,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">943,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,663,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Aaron Deykin, M.D.<BR><I>Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">470,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">823,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Jennifer Beachell<BR><I>Former Chief Operating
Officer</I><SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">730,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="28" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported in this column represent the aggregate grant date fair value of stock options granted to the named executive officers during 2023, as calculated in accordance with Financial Accounting Standards
Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) Topic 718. Such grant date value does not take into account any estimated forfeitures related to service-based vesting conditions. The assumptions used in the grant date
fair value of the awards in this column are described in Note 10 to our consolidated financial statements included elsewhere in this prospectus. The amounts reported in this column reflect the accounting cost for these stock option awards and do not
correspond to the actual economic value that may be received by our named executive officers upon the exercise of the stock option awards or any sale of the underlying shares. These awards are described in more detail in the section titled
&#147;Narrative disclosure to summary compensation table&#151;Equity-based compensation&#148; below. </TD></TR></TABLE>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported represent annual performance bonuses earned based on achievement of company performance during the year ended December&nbsp;31, 2023. For more information on these bonuses, see description of the
annual performance bonuses under the section titled &#147;Narrative disclosure to summary compensation table&#151;2023 non-equity compensation (cash bonuses)&#148; below. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">189 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported represent an employer matching contribution on the employee&#146;s behalf under our 401(k) plan. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Ms.&nbsp;Truex ceased being our Chief Executive Officer in March 2024. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amount reported represents a $50,000 signing bonus paid to Dr.&nbsp;Deykin in connection with the commencement of his employment pursuant to the terms of his offer letter, as described below under the section titled
&#147;Executive compensation arrangements&#151;Employment compensation arrangements in place prior to the offering for our named executive officers, and our current Chief Executive Officer and Chief Financial and Operating Officer.&#148;
</TD></TR></TABLE>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(6)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Ms.&nbsp;Beachell ceased being our Chief Operating Officer in March 2024. </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Narrative disclosure to summary
compensation table </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Compensation philosophy </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our executive
compensation philosophy is to provide a competitive and market-based total compensation program to attract, motivate, and retain our executive team. Our compensation is based heavily on performance, which aligns with our goal to drive long-term
growth and value creation. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>2023 base salaries </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our named
executive officers each receive a base salary to compensate them for services rendered to our Company. The base salary payable to each named executive officer is intended to provide a fixed component of compensation reflecting the executive&#146;s
skill set, experience, role and responsibilities. Base salaries are expected to be reviewed annually, typically in connection with our annual performance review process, approved by our board of directors or the compensation committee of the board
of directors, and may be adjusted from time to time to realign salaries with market levels after taking into account individual responsibilities, performance and experience, except in the case of Dr.&nbsp;Deykin whose base salary may be subject to
upward adjustment from time to time at the Company&#146;s discretion. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The annual base salaries for each of our named executive officers for the fiscal year ended
December&nbsp;31, 2023 are set forth in the table below: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Annual</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>base&nbsp;salary</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Samantha Truex</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">475,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Aaron Deykin, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">470,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Jennifer Beachell</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">374,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="4" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>2023 non-equity compensation (cash bonuses) </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the fiscal year ended December&nbsp;31, 2023, each of the named executive officers was eligible to earn an annual cash bonus determined by our board of directors in
its sole discretion, based on achievement of certain corporate performance milestones primarily focused on the advancement of our program and completion of financing strategies. The target annual bonus for each of our named executive officers for
the fiscal year ended December&nbsp;31, 2023 was equal to the percentage of the executive&#146;s respective annual base salary specified below: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Target</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>bonus</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>percentage</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Samantha Truex</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Aaron Deykin, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Jennifer Beachell</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="4" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">190 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the first quarter of 2024, our board of directors determined that we had achieved 110% of our performance goals for 2023
and, accordingly, paid each of our named executives officers a bonus as specified in the Summary Compensation Table above. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Equity-based compensation
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Although we do not yet have a formal policy with respect to the grant of equity incentive awards to our executive officers, we believe that equity grants
provide our executives with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executives and our stockholders. In addition, we believe that equity grants promote executive retention
because they incentivize our executive officers to remain in our employment during the vesting period. To date, we have granted our named executive officers stock option awards. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For additional information regarding outstanding equity awards held by our named executive officers as of December&nbsp;31, 2023, see the &#147;Outstanding equity awards
at 2023 fiscal year end&#148; table below. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>401(k) plan </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We
maintain a retirement savings plan (&#147;401(k) plan&#148;) that is intended to qualify for favorable tax treatment under Section&nbsp;401(a) of the Code, and contains a cash or deferred feature that is intended to meet the requirements of
Section&nbsp;401(k) of the Code. U.S. employees are generally eligible to participate in the 401(k) plan, subject to certain criteria. Participants may make <FONT STYLE="white-space:nowrap">pre-tax</FONT> and certain
<FONT STYLE="white-space:nowrap">after-tax</FONT> (Roth) salary deferral contributions to the plan from their eligible earnings up to the statutorily prescribed annual limit under the Code. Participants who are 50 years of age or older may
contribute additional amounts based on the statutory limits for <FONT STYLE="white-space:nowrap">catch-up</FONT> contributions. Participant contributions are held in trust as required by law. We make matching contributions equal to 50% of each
participant&#146;s elective deferrals on the first 6% of the participant&#146;s compensation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">191 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Outstanding equity awards at 2023 fiscal year end </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table lists all outstanding equity awards held by our named executive officers as of December&nbsp;31, 2023. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Option&nbsp;awards<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Vesting</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>commencement</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>date</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Number of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>securities</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>underlying</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>unexercised</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>options&nbsp;(#)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>exercisable</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Number of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>securities</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>underlying</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>unexercised</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>options (#)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>unexercisable</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Option</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>exercise</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>price</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>($)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Option</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>expiration</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>date</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Samantha Truex</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUB STYLE="font-size:75%; vertical-align:bottom"></SUB>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/13/2021<SUB STYLE="font-size:75%; vertical-align:bottom"></SUB></TD>
<TD NOWRAP VALIGN="bottom"><SUB STYLE="font-size:75%; vertical-align:bottom">(2)(3)</SUB>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">628,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">01/01/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><SUB STYLE="font-size:75%; vertical-align:bottom"></SUB>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">02/14/2023<SUB STYLE="font-size:75%; vertical-align:bottom"></SUB></TD>
<TD NOWRAP VALIGN="top"><SUB STYLE="font-size:75%; vertical-align:bottom">(2)(4)</SUB>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">429,250</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">3.45</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">01/01/2032</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><SUB STYLE="font-size:75%; vertical-align:bottom"></SUB>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">03/02/2023<SUB STYLE="font-size:75%; vertical-align:bottom"></SUB></TD>
<TD NOWRAP VALIGN="top"><SUB STYLE="font-size:75%; vertical-align:bottom">(2)(4)</SUB>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">38,254</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">4.27</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">03/01/2033</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">08/10/2023</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">262,250</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">4.87</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">08/13/2033</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Aaron Deykin, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">04/27/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">06/03/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">02/14/2023</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">182,431</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">3.45</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">06/03/2032</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">03/03/2023</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">16,258</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">4.27</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">03/02/2033</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">08/10/2023</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">11,853</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">4.87</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">08/09/2033</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Jennifer Beachell</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/29/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">01/01/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">07/21/2022</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">8,739</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">15,936</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">2.96</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">09/15/2032</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">02/14/2023</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">107,312</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">3.45</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">01/01/2032</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">03/03/2023</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">55,232</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">4.27</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">03/02/2033</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">08/10/2023</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">11,853</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">4.87</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">08/09/2033</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="20" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each stock option award is subject to the terms of the Company&#146;s 2021 Stock Option and Grant Plan, as amended (the &#147;2021 Plan&#148;). Each stock option vests as follows: 25% of the shares subject to the stock
option vested on the one year anniversary of the vesting commencement date, and the remaining 75% of the shares subject to the stock option vest on a monthly basis thereafter, in each case, subject to the NEO&#146;s continuous service relationship
with the company through each applicable vesting date. Each stock option is subject to acceleration in the event of a qualified termination within the change in control period, as described below under the section titled &#147;&#151;Executive
compensation arrangements&#151;Employment compensation arrangements in place prior to the offering for our named executive officers, and our current Chief Executive Officer and Chief Financial and Operating Officer.&#148; </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each stock option was early exercisable. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2023, 327,363&nbsp;shares subject to this stock option were vested and 301,588&nbsp;shares were unvested. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2023, all of the shares underlying this stock option were unvested. </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Executive compensation
arrangements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have entered into an employment agreement or offer letter with each of our named executive officers. Each employment agreement or offer letter
provides for <FONT STYLE="white-space:nowrap">&#147;at-will&#148;</FONT> employment and the compensation and benefits described below. In connection with this offering, we intend to enter into a new severance and change in control plan effective as
of the effectiveness of the registration statement of which this prospectus forms a part, in which Dr.&nbsp;Deykin will participate. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Employment
compensation arrangements in place prior to the offering for our named executive officers, and our current Chief Executive Officer and Chief Financial and Operating Officer </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Samantha Truex </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On October&nbsp;14, 2021, we entered into an executive
employment agreement with Ms.&nbsp;Truex (the &#147;Truex Employment Agreement&#148;) for the position of Chief Executive Officer. The Truex Employment Agreement provided for Ms.&nbsp;Truex&#146;s <FONT STYLE="white-space:nowrap">at-will</FONT>
employment, base salary and annual bonus eligibility, as well as a signing bonus of $125,000 and an initial option grant, which is reflected in the &#147;Outstanding equity awards at 2023 fiscal year end&#148; table above. The Truex Employment
Agreement provides that Ms.&nbsp;Truex was eligible to participate in the employee benefit plans available to our employees, subject to the terms of such plans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">192 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon a termination of Ms.&nbsp;Truex&#146;s employment by us without &#147;cause&#148; or her resignation for &#147;good
reason,&#148; each as defined in the Truex Employment Agreement, more than one month prior to a &#147;change in control&#148; (each term as defined in the Truex Employment Agreement) or more than twelve months following a change in control, subject
to (i)&nbsp;signing a general release of claims in favor of the Company and (ii)&nbsp;not breaching any of the post-employment covenants and contractual obligations to the Company, Ms.&nbsp;Truex is entitled to (A)&nbsp;continued payment of her then
current base salary for a period of twelve months and (B)&nbsp;if Ms.&nbsp;Truex was participating in the Company&#146;s group health plan immediately prior to the termination date and timely elects continuation coverage under the Consolidated
Omnibus Budget Reconciliation Act (&#147;COBRA&#148;), a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to Ms.&nbsp;Truex had Ms.&nbsp;Truex remained employed by the Company
until the earliest of (a)&nbsp;the twelve-month anniversary of the date of termination; (b)&nbsp;Ms.&nbsp;Truex&#146;s eligibility for group health plan benefits under any other employer&#146;s group health plan; or (c)&nbsp;cessation of the
continuation rights under COBRA and (C)&nbsp;a single lump sum payment equal to 100% of Ms.&nbsp;Truex&#146;s target bonus for the calendar year in which termination of employment occurs (collectively, the &#147;Truex Severance Benefits&#148;). In
addition, and subject to the same conditions, upon a termination by us without cause or Ms.&nbsp;Truex&#146;s resignation for good reason within one month prior to, or within twelve months after, a change in control, in addition to the severance pay
and benefits set forth in (A), (B) and (C)&nbsp;above, Ms.&nbsp;Truex is entitled to full acceleration of her then outstanding and unvested time-based equity awards. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Ms.&nbsp;Truex has entered into a Proprietary Rights, Inventions, <FONT STYLE="white-space:nowrap">Non-Competition,</FONT> and
<FONT STYLE="white-space:nowrap">Non-Solicitation</FONT> Agreement that contains various restrictive covenants, including <FONT STYLE="white-space:nowrap">non-competition</FONT> and <FONT STYLE="white-space:nowrap">non-solicitation.</FONT> </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Ms.&nbsp;Truex&#146;s employment was terminated as of March&nbsp;22, 2024. In connection with such termination, we entered into a separation agreement with
Ms.&nbsp;Truex, dated as of March&nbsp;13, 2024 (the &#147;Truex Separation Agreement&#148;), including a release of claims, providing for (i)&nbsp;the Truex Severance Benefits, (ii)&nbsp;acceleration of her then outstanding and unvested time-based
equity awards granted on August&nbsp;14, 2023, such that options to purchase 38,245&nbsp;shares vested as of the date of termination, (iii)&nbsp;an extension of the exercise period of Ms.&nbsp;Truex&#146;s vested options from 90 days to 24 months
from the date of termination, provided that such period may be shortened consistent with the provisions of the applicable equity documents in the event of a change of control or sale event and (iv)&nbsp;a reimbursement of legal fees of up to $10,000
incurred in connection with the review of the Truex Separation Agreement. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Aaron Deykin, M.D. </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On March&nbsp;10, 2022, we entered into an offer letter with Dr.&nbsp;Deykin (the &#147;Deykin Offer Letter&#148;) for the position of Chief Medical Officer and Head of
Research and Development. The Deykin Offer Letter provides for Dr.&nbsp;Deykin&#146;s <FONT STYLE="white-space:nowrap">at-will</FONT> employment, base salary and annual bonus eligibility. In addition, the Deykin Offer Letter provides for a $100,000
signing bonus, payable in two equal installments, with the first such installment having been paid shortly following Dr.&nbsp;Deykin&#146;s commencement of employment with us and the remainder becoming payable one year thereafter, subject to
Dr.&nbsp;Deykin&#146;s continued employment with us through such date. The Deykin Offer Letter also provides for an initial option grant, which is reflected in the &#147;Outstanding equity awards at 2023 fiscal year end&#148; table above.
Dr.&nbsp;Deykin is eligible to participate in the employee benefit plans available to our senior executives, subject to the terms of such plans. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon a termination
of Dr.&nbsp;Deykin&#146;s employment by us without &#147;cause&#148; or his resignation for &#148;good reason&#148; more than three months prior to a &#147;change in control&#148; (each term as defined in the Deykin Offer Letter) or more than twelve
months following a change in control, subject to (i)&nbsp;signing a general release of claims in favor of the Company and (ii)&nbsp;not breaching any of the post-employment covenants and contractual obligations to the Company, Dr.&nbsp;Deykin shall
be entitled to (A)&nbsp;continued payment of his then current base salary for a period of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">193 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
six months, (B)&nbsp;if Dr.&nbsp;Deykin was participating in the Company&#146;s group health plan immediately prior to the termination date and timely elects continuation coverage under COBRA, a
monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to Dr.&nbsp;Deykin had Dr.&nbsp;Deykin remained employed by the Company until the earliest of (a)&nbsp;the six-month anniversary
of the date of termination; (b)&nbsp;Dr.&nbsp;Deykin&#146;s eligibility for group health plan benefits under any other employer&#146;s group health plan; or (c)&nbsp;cessation of the continuation rights under COBRA and (C)&nbsp;a single lump sum
payment equal to the prorated amount of Dr.&nbsp;Deykin&#146;s target bonus for the calendar year in which termination of employment occurs. In addition, and subject to the same conditions, upon a termination by us without cause or
Dr.&nbsp;Deykin&#146;s resignation for good reason within three months prior to, or within twelve months after, a change in control, in addition to the severance pay and benefits set forth in (A), (B) and (C)&nbsp;above, Dr.&nbsp;Deykin shall be
entitled to full acceleration of his then outstanding and unvested time-based equity awards. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Dr.&nbsp;Deykin has entered into an Employee Confidentiality,
Assignment, Nonsolicitation and Noncompetition Agreement that contains various restrictive covenants, including confidentiality, <FONT STYLE="white-space:nowrap">non-competition</FONT> and <FONT STYLE="white-space:nowrap">non-solicitation.</FONT>
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with this offering, we will enter into a new employment agreement with Dr. Deykin providing for substantially similar terms as described above, except
that such employment agreement does not provide severance benefits. However, Dr. Deykin will be eligible to participate in our severance and change in control plan, as further described below. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Jennifer Beachell </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On November&nbsp;1, 2021, we entered into an offer letter
with Ms.&nbsp;Beachell (the &#147;Beachell Offer Letter&#148;) for the position of Chief Commercial Officer. The Beachell Offer Letter provided for Ms.&nbsp;Beachell&#146;s <FONT STYLE="white-space:nowrap">at-will</FONT> employment, base salary and
annual bonus eligibility. The Beachell Offer Letter also provides for an initial option grant, which is reflected in the &#147;Outstanding equity awards at 2023 fiscal year end&#148; table above. The Beachell Offer Letter provides that
Ms.&nbsp;Beachell is eligible to participate in the employee benefit plans available to our senior executives, subject to the terms of such plans. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon a
termination of Ms.&nbsp;Beachell&#146;s employment by us without &#147;cause&#148; or her resignation for &#148;good reason&#148; more than one month prior to a &#147;change in control&#148; (each term as defined in the Beachell Offer Letter) or
more than twelve months following a change in control, subject to (i)&nbsp;signing a general release of claims in favor of the Company and (ii)&nbsp;not breaching any of the post-employment covenants and contractual obligations to the Company,
Ms.&nbsp;Beachell was entitled to (A)&nbsp;continued payment of her then current base salary for a period of six months, (B)&nbsp;if Ms.&nbsp;Beachell was participating in the Company&#146;s group health plan immediately prior to the termination
date and timely elects continuation coverage under COBRA, a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to Ms.&nbsp;Beachell had Ms.&nbsp;Beachell remained employed by the
Company until the earliest of (a)&nbsp;the six-month anniversary of the date of termination; (b)&nbsp;Ms.&nbsp;Beachell&#146;s eligibility for group health plan benefits under any other employer&#146;s group health plan; or (c)&nbsp;cessation of the
continuation rights under COBRA and (C)&nbsp;a single lump sum payment equal to the prorated amount of Ms.&nbsp;Beachell&#146;s target bonus for the calendar year in which termination of employment occurs and the payment of any earned but unpaid
annual bonus for the year prior to the year in which termination occurs (collectively, the &#147;Beachell Severance Benefits&#148;). In addition, and subject to the same conditions, upon a termination by us without cause or Ms.&nbsp;Beachell&#146;s
resignation for good reason within one month prior to, or within twelve months after, a change in control, in addition to the severance pay and benefits set forth in (A), (B) and (C)&nbsp;above, Ms.&nbsp;Beachell is entitled to full acceleration of
her then outstanding and unvested time-based equity awards. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Ms.&nbsp;Beachell has entered into an Employee Confidentiality, Assignment, Nonsolicitation and
Noncompetition Agreement that contains various restrictive covenants, including confidentiality, <FONT STYLE="white-space:nowrap">non-competition</FONT> and <FONT STYLE="white-space:nowrap">non-solicitation.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">194 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Ms.&nbsp;Beachell&#146;s employment was terminated as of March&nbsp;8, 2024. In connection with her termination of
employment, we entered into a separation agreement with Ms.&nbsp;Beachell, including a release of claims, providing for (i)&nbsp;the Beachell Severance Benefits, (ii)&nbsp;the extension of the post-termination exercise period of certain stock
options held by Ms.&nbsp;Beachell from 90 days to twelve months, provided that such period may be shortened consistent with the provisions of the applicable equity documents in the event of a change of control or sale event and
(iii)&nbsp;reimbursement for outplacement costs in an amount not to exceed $5,000. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Current employment agreements with E. Rand Sutherland, M.D., M.P.H., our
Chief Executive Officer, and Michael Paul Gray, M.B.A., our Chief Financial and Operating Officer </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prior to this offering, we entered into employment agreements
with E. Rand Sutherland, M.D., M.P.H., our current Chief Executive Officer, and Michael Paul Gray, M.B.A., our current Chief Financial and Operating Officer, setting forth terms of at-will employment, including base salary, annual target bonus
eligibility, initial equity grants and severance upon a termination of employment without cause or resignation for good reason, each as defined in the applicable agreement filed as an exhibit to the registration statement of which this prospectus is
part. Further, each executive entered into an Employee Confidentiality, Assignment, Nonsolicitation and Noncompetition Agreement, that contains various restrictive covenants, including confidentiality, noncompetition and non-solicitation. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Amended and restated employment agreements </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Effective as of and
subject to the closing of this offering, we entered into new employment agreements with Dr. Sutherland, Mr. Gray and Dr. Deykin (each, an &#147;Amended Employment Agreement,&#148; and collectively, the &#147;Amended Employment Agreements&#148;) that
supersede in all respects all prior employment agreements, offer letters and severance agreements between Dr. Sutherland, Mr. Gray and Dr. Deykin and us, including those summarized above. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the Amended Employment Agreements, each of Dr. Sutherland, Mr. Gray and Dr. Deykin will continue to serve in their respective roles on an at-will basis. The
Amended Employment Agreements provide for each of Dr. Sutherland, Mr. Gray and Dr. Deykin&#146;s initial Base Salary (as defined in the applicable Amended Employment Agreement) of $630,000, $460,000, and $488,800, respectively, target annual bonus
eligibility of 50%, 40%, and 40% of base salary, respectively, and continued compliance with restrictive covenants. In addition, each such executive will be eligible to participate in our severance and change in control plan, as further described
below, which is filed as an exhibit to the registration statement of which this prospectus is a part. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Employee benefit and equity compensation plans
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>2021 stock option and grant plan </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our 2021 Stock Option
and Grant Plan was adopted by our board of directors on December&nbsp;7, 2021 and approved by our stockholders on January&nbsp;19, 2022. On March&nbsp;13, 2024, our board of directors adopted and our stockholders approved an amendment to the 2021
Stock Option and Grant Plan (as amended, the &#147;2021 Plan&#148;). The 2021 Plan will continue to govern outstanding equity awards granted thereunder. As of June&nbsp;30, 2024, 74,027 shares of our common stock remained available for future
issuance under the 2021 Plan. Following this offering, we will not grant any further awards under our 2021 Plan, but all outstanding awards under the 2021 Plan will continue to be governed by their existing terms. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock underlying any awards under the 2021 Plan that are forfeited, canceled, reacquired by the Company prior to vesting, satisfied without the
issuance of stock or otherwise terminated (other than by exercise) and shares withheld upon exercise of an option or settlement of an award to cover the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">195 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
exercise price or tax withholding, are currently added back to the shares of common stock available for issuance under the 2021 Plan. Following this offering, such shares will be added to the
shares of common stock available for issuance under the 2024 Plan. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors and our compensation committee have acted as administrators of the 2021
Plan. The administrator has the full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted and the number of shares subject to such awards, to make any combination of awards to participants,
to accelerate at any time the exercisability or vesting of any award and to determine the specific terms and conditions of each award, subject to the provisions of the 2021 Plan. Persons eligible to participate in the 2021 Plan are officers,
employees, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, consultants and advisors as selected from time to time by the administrator in its discretion. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The 2021 Plan permits the granting of nonqualified stock options and options intended to qualify as incentive stock options under Section&nbsp;422 of the Code. The per
share exercise price of each option is determined by our board of directors but may not be less than 100% of the fair market value of the common stock on the date of grant. The term of each option is fixed by the administrator but may not exceed 10
years from the date of grant. The administrator determines at what time or times each option may be exercised. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the 2021 Plan permits the granting of
restricted shares of common stock, unrestricted stock awards and restricted stock units. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The 2021 Plan provides that upon the effectiveness of a &#147;sale
event,&#148; as defined in the 2021 Plan, the administrator may take any one or more of the following actions as to all or any (or any portion of) outstanding awards: (i)&nbsp;provide that all such awards will be assumed or substituted with
substantially equivalent awards by the acquiring or succeeding corporation (or affiliate thereof); (ii) provide that all such awards will terminate or forfeit upon the effective time of any such sale event unless assumed or continued by the
successor entity, or new stock options or other awards are substituted therefor; or (iii)&nbsp;provide for a cash payment to the holders of common stock for each vested award canceled in the sale event. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the occurrence of any reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar change in common stock,
the administrator will equitably adjust the outstanding awards, which may include adjustments to the number and type of securities subject to such outstanding award and/or the exercise price or grant price, thereof. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Unless otherwise determined by the administrator, awards may generally not be sold, assigned, transferred, pledged or otherwise encumbered by the person to whom they are
granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The board of directors may amend, suspend or terminate
the 2021 Plan at any time, subject to stockholder approval where such approval is required by applicable law. The administrator of the 2021 Plan may also amend, modify or cancel any outstanding award, provided that no amendment to an award may
adversely affect a participant&#146;s rights without his or her consent. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>2024 stock option and incentive plan </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our 2024 Plan was adopted by our board of directors on August 19, 2024, approved by our stockholders on October&nbsp;4, 2024 and will become effective upon the date
immediately preceding the date on which the registration statement of which this prospectus is a part is declared effective by the SEC. The 2024 Plan will replace the 2021 Plan as our board of directors has determined not to make additional awards
under the 2021 Plan following the closing of our initial public offering. However, the 2021 Plan will continue to govern outstanding equity awards granted thereunder. The 2024 Plan allows us to make equity-based and cash-based incentive awards to
our officers, employees, directors and consultants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">196 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have initially reserved 3,180,000&nbsp;shares of our common stock for the issuance of awards under the 2024 Plan
(the &#147;Initial Limit&#148;). The 2024 Plan provides that the number of shares reserved and available for issuance under the 2024 Plan will automatically increase on January&nbsp;1, 2025 and each January&nbsp;1 thereafter, by five percent of the
outstanding number of shares of our common stock on the immediately preceding December&nbsp;31 or such lesser number of shares as determined by our compensation committee (the &#147;Annual Increase&#148;). The number of shares reserved under the
2024 Plan is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares we issue under the 2024 Plan
will be authorized but unissued shares or shares that we reacquire. The shares of common stock underlying any awards under the 2024 Plan and the 2021 Plan that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy
the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without the issuance of stock, expire or are otherwise terminated (other than by exercise) will be added back to the shares of common stock available for issuance
under the 2024 Plan. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The maximum number of shares of common stock that may be issued in the form of incentive stock options shall not exceed the Initial Limit,
cumulatively increased on January&nbsp;1, 2025 and on each January&nbsp;1 thereafter by the lesser of the Annual Increase for such year or 3,180,000 shares of common stock. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The grant date fair value of all awards made under our 2024 Plan and all other cash compensation paid by us to any <FONT STYLE="white-space:nowrap">non-employee</FONT>
director in any calendar year for services as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director shall not exceed $750,000; provided, however, that such amount shall be $1,000,000 for the calendar year in which the applicable <FONT
STYLE="white-space:nowrap">non-employee</FONT> director is initially elected or appointed to the board of directors. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The 2024 Plan will be administered by our
compensation committee. Our compensation committee has the full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted and the number of shares subject to such awards, to make any combination
of awards to participants, to accelerate at any time the exercisability or vesting of any award and to determine the specific terms and conditions of each award, subject to the provisions of the 2024 Plan. Persons eligible to participate in the 2024
Plan will be those full or part-time officers, employees, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and consultants as selected from time to time by our compensation committee in its discretion. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The 2024 Plan permits the granting of both options to purchase common stock intended to qualify as incentive stock options under Section&nbsp;422 of the Code and options
that do not so qualify. The option exercise price of each option will be determined by our compensation committee but generally may not be less than 100&nbsp;percent of the fair market value of our common stock on the date of grant unless the option
(i)&nbsp;is granted pursuant to a transaction described in, and in a manner consistent with Section&nbsp;424(a) of the Code, (ii)&nbsp;is granted to an individual who is not subject to U.S. income tax or (iii)&nbsp;complies with Section&nbsp;409A of
the Code. The term of each option will be fixed by our compensation committee and may not exceed 10 years from the date of grant. Our compensation committee will determine at what time or times each option may be exercised. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our compensation committee may award stock appreciation rights under the 2024 Plan subject to such conditions and restrictions as it may determine. Stock appreciation
rights entitle the recipient to shares of common stock, or cash, equal to the value of the appreciation in our stock price over the exercise price. The exercise price of each stock appreciation right will be determined by our compensation committee
but generally may not be less than 100&nbsp;percent of the fair market value of our common stock on the date of grant unless the stock appreciation right (i)&nbsp;is granted pursuant to a transaction described in, and in a manner consistent with
Section&nbsp;424(a) of the Code, (ii)&nbsp;is granted to an individual who is not subject to U.S. income tax or (iii)&nbsp;complies with Section&nbsp;409A of the Code. The term of each stock appreciation right will be fixed by our compensation
committee and may not exceed 10 years from the date of grant. Our compensation committee will determine at what time or times each stock appreciation right may be exercised. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">197 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our compensation committee may award restricted shares of common stock and restricted stock units to participants subject
to such conditions and restrictions as it may determine. These conditions and restrictions may include the achievement of certain performance goals and/or continued employment with us through a specified vesting period. Our compensation committee
may also grant shares of common stock that are free from any restrictions under the 2024 Plan. Unrestricted stock may be granted to participants in recognition of past services or for other valid consideration and may be issued in lieu of cash
compensation due to such participant. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our compensation committee may grant dividend equivalent rights to participants that entitle the recipient to receive credits
for dividends that would be paid if the recipient had held a specified number of shares of common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our compensation committee may grant cash bonuses under the
2024 Plan to participants, subject to the achievement of certain performance goals. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The 2024 Plan provides that upon the effectiveness of a &#147;sale event,&#148;
as defined in the 2024 Plan, an acquirer or successor entity may assume, continue or substitute outstanding awards under the 2024 Plan. To the extent that awards granted under the 2024 Plan are not assumed or continued or substituted by the
successor entity, upon the effective time of the sale event, such awards shall terminate and all awards subject solely to time-based vesting conditions will fully vest and, if applicable, become nonforfeitable. In the event of such termination,
(i)&nbsp;individuals holding options and stock appreciation rights will be permitted to exercise such options and stock appreciation rights (to the extent exercisable) within a specified period of time prior to the sale event or (ii)&nbsp;we may
make or provide for a payment, in cash or in kind, to participants holding vested and exercisable options and stock appreciation rights equal&nbsp;(A) the difference between the per share cash consideration payable to stockholders in the sale event
and the per share exercise price of the options or stock appreciation rights, multiplied by (B)&nbsp;the number of shares subject to such outstanding vested and exercisable options and stock appreciation rights (to the extent exercisable at prices
not in excess of the per share cash consideration), and we may make or provide for a payment, in cash or in kind, to participants holding other vested awards equal to the per share cash consideration multiplied by the number of vested shares
underlying such awards. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors may amend or discontinue the 2024 Plan and our compensation committee may amend or cancel outstanding awards for
purposes of satisfying changes in law or any other lawful purpose, but no such action may adversely affect rights under an award without the holder&#146;s consent. Certain amendments to the 2024 Plan require the approval of our stockholders. The
administrator of the 2024 Plan is specifically authorized to exercise its discretion to reduce the exercise price of outstanding stock options and stock appreciation rights or effect the repricing of such awards through cancellation and <FONT
STYLE="white-space:nowrap">re-grants</FONT> without stockholder consent. No awards may be granted under the 2024 Plan after the date that is 10 years from the effective date of the 2024 Plan. No awards under the 2024 Plan have been made prior to the
date of this prospectus. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>2024 employee stock purchase plan </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our ESPP was adopted by our board of directors on August 19, 2024, approved by our stockholders on October&nbsp;4, 2024 and will become effective on the date immediately
preceding the date on which the registration statement of which this prospectus forms a part is declared effective by the SEC. The ESPP is intended to qualify as an &#147;employee stock purchase plan&#148; within the meaning of Section&nbsp;423 of
the Code. The ESPP initially reserves and authorizes the issuance of up to a total of 488,467 shares of our common stock to participating employees. The ESPP provides that the number of shares reserved and available for issuance will automatically
increase on January&nbsp;1, 2025 and each January&nbsp;1 thereafter through January&nbsp;1, 2034, by the least </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">198 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
of (i) 976,934 shares of common stock, (ii) one percent of the outstanding number of shares of common stock on the immediately preceding December&nbsp;31, or (iii)&nbsp;such lesser number of
shares of common stock as determined by the administrator of the ESPP. The number of shares reserved under the ESPP is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">All employees employed by us or any designated subsidiary as of the first day of an offering are eligible to participate; provided that the administrator of the ESPP may
determine that employees must satisfy one or more of the following service requirements before participating in the ESPP: (1)&nbsp;customary employment with us for more than 20 hours per week and 5 or more months per calendar year,
(2)&nbsp;continuous employment with us for a minimum period of time, not to exceed two years, prior to the first date of an offering or (3)&nbsp;such other criteria as the administrator of the ESPP may determine consistent with the requirements of
section 423 of the Code.&nbsp;However, any employee who owns&nbsp;5&nbsp;percent or more of the total combined voting power or value of all classes of our stock will not be eligible to purchase shares of common stock under the ESPP. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may make one or more offerings each year to our employees to purchase shares under the ESPP, consisting of one or more purchase periods. Each eligible employee may
elect to participate in any offering by submitting an enrollment form at least&nbsp;15&nbsp;business days before the applicable offering date </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each employee who is a
participant in the ESPP may purchase shares of our common stock by authorizing payroll deductions of up to percent of his or her eligible compensation during an offering period. Unless the participating employee has previously withdrawn from the
offering, his or her accumulated payroll deductions will be used to purchase shares of our common stock on the last business day of the offering period at a price equal to&nbsp;85&nbsp;percent of the fair market value of the shares of our common
stock on the first business day of the offering period or the last business day of the purchase period, whichever is lower, provided that no more than a number of shares of common stock determined by dividing $25,000 by the fair market value of our
common stock on the offering date of the offering (or such other number as established by the administrator in advance of the offering period) may be purchased by any one employee during each offering period. Under applicable tax rules, an employee
may purchase no more than $25,000 worth of shares of our common stock, valued at the start of the purchase period, under the ESPP in any calendar year. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
accumulated payroll deductions of any employee who is not a participant on the last day of an offering period will be refunded. An employee&#146;s rights under the ESPP terminate upon voluntary withdrawal from the plan or when the employee ceases
employment with us for any reason. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The ESPP may be terminated or amended by our board of directors at any time. An amendment that increases the number of shares of
our common stock authorized under the ESPP and certain other amendments require the approval of our stockholders. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Senior executive cash incentive bonus plan
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On August 19, 2024, our board of directors adopted the Senior Executive Cash Incentive Bonus Plan (the &#147;Bonus Plan&#148;), subject to the effectiveness
of the registration statement of which this prospectus forms a part. The Bonus Plan provides for annual cash bonus payments based upon the attainment of Company and individual performance targets established by our compensation committee. The
payment targets will be related to financial and operational measures or objectives with respect to our Company (the &#147;Corporate Performance Goals&#148;) as well as individual performance objectives. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our compensation committee may select Corporate Performance Goals from among the following: developmental, publication, clinical or regulatory milestones; cash flow
(including, but not limited to, operating cash flow and free cash flow); revenue; corporate revenue; earnings before interest, taxes, depreciation and amortization; net income (loss) (either before or after interest, taxes, depreciation and/or
amortization); changes in the market price of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">199 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
common stock; economic value-added; acquisitions, licenses, collaborations or strategic transactions; financing or other capital raising transactions; operating income (loss); return on capital,
assets, equity, or investment; stockholder returns; return on sales; total shareholder return; gross or net profit levels; productivity; expense efficiency; margins; operating efficiency; customer satisfaction; working capital; earnings (loss) per
share of the company&#146;s common stock; bookings, new bookings or renewals; sales or market shares; number of prescriptions or prescribing physicians; coverage decisions; leadership development, employee retention and recruiting and other human
resources matters; operating income and/or net annual recurring revenue; or any other performance goal as selected by the compensation committee, any of which may be measured in absolute terms, as compared to any incremental increase, in terms of
growth, as compared to results of a peer group, against the market as a whole, compared to applicable market indices, and/or measured on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> or <FONT STYLE="white-space:nowrap">post-tax</FONT> basis.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each executive officer who is selected to participate in the Bonus Plan will have a target bonus opportunity set for each performance period. The bonus formulas
will be adopted in each performance period by the compensation committee and communicated to each executive. The Corporate Performance Goals will be measured at the end of each performance period after our financial reports have been published or
such other appropriate time as the compensation committee determines. If the Corporate Performance Goals and individual performance objectives are met, payments will be made as soon as practicable following the end of each performance period, but no
later than two and one-half months after the end of the fiscal year in which such performance period ends. Subject to the rights contained in any agreement between the executive officer and us, an executive officer must be employed by us on the
bonus payment date to be eligible to receive a bonus payment. The Bonus Plan also permits the compensation committee to approve additional bonuses to executive officers in its sole discretion. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Executive severance plan </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On August 19, 2024, our board of directors
adopted the Executive Severance Plan (the "Severance Plan"), subject to the effectiveness of the registration statement of which this prospectus forms a part, in which our currently employed named executive officer and certain other executives are
expected to participate. The benefits provided in the Severance Plan will replace any severance for which such named executive officer may be eligible under their existing severance and change in control agreements (unless otherwise specified). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Severance Plan provides that upon a termination by us for any reason other than for Cause, death or Disability, or resignation for Good Reason, each as defined in
the Severance Plan (a "Qualifying Termination"), in each case outside of the period commencing three months prior to and ending on the first month anniversary following a Change in Control, as defined in the Severance Plan (the "Change in Control
Period"), eligible participants will be entitled to receive, subject to the execution and delivery of a release of claims in favor of the company and continued compliance with all applicable restrictive covenants, (a) 12 months of continued base
salary (or the annual base salary in effect for the year immediately prior to the year in which the date of termination occurs) ("Base Salary") for the Chief Executive Officer, nine months for each other chief executive other than the Chief
Executive Officer, and six months for each senior vice president of the Company, and (b) an amount equal to the monthly employer contribution that we would have made to provide health insurance for the applicable participant if he or she had
remained employed by us while receiving payments of Base Salary. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Severance Plan also provides that upon a Qualifying Termination within the Change in Control
Period, an eligible participant will be entitled to receive, in lieu of the payments and benefits above and subject to the execution and delivery of a release of claims in favor of the company and continued compliance with all applicable restrictive
covenants, (a) a lump sum payment equal to the sum of (i) 18 months&#146; Base Salary for the Chief Executive Officer, 12 months&#146; Base Salary for each chief executive other than the Chief Executive Officer and nine months&#146; Base Salary for
each senior vice president (such periods, the "CIC Periods") and (ii)&nbsp;1.5 times </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">200 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
the target annual bonus in effect immediately prior to the date of termination (or immediately prior to the change in control if higher) for the Chief Executive Officer, 1.0 times for each chief
executive other than the Chief Executive Officer and 0.75 times for each senior vice president, (b) an amount equal to the monthly employer contribution, based on the premiums as of the date of termination, that we would have made to provide health
insurance for the applicable participant if he or she had remained employed by us for the duration of the applicable CIC Period and (c) for all outstanding and unvested equity awards of the company that are subject to time-based vesting held by the
participant, full accelerated vesting of such awards. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The payments and benefits provided under the Severance Plan in connection with a Change in Control may not be
eligible for a federal income tax deduction by us pursuant to Section 280G of the Code. These payments and benefits may also subject an eligible participant, including named executive officers, to an excise tax under Section 4999 of the Code. If the
payments or benefits payable in connection with a Change in Control would be subject to the excise tax imposed under Section 4999 of the Code, then those payments or benefits will be reduced if such reduction would result in a higher net after-tax
benefit to the participant. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Equity grants to employees </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
Company has granted certain recently hired employees options to purchase an aggregate of 21,000&nbsp;shares of Company common stock (collectively, the &#147;Employee IPO Grants&#148;). The Employee IPO Grants will each have an exercise price per
share equal to the per share &#147;price to the public&#148; (or equivalent) set forth on the cover page of the final prospectus relating to our initial public offering, expire ten years from the date of grant and vest as follows: 25% on the first
anniversary of the vesting commencement date (as set forth in the applicable option award agreement) and the remaining 75% in 36 equal monthly installments thereafter, subject to the applicable employee&#146;s continued service with the Company
through each applicable vesting date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">201 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc843142_13"></A>Director compensation </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>2023 director compensation table </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table presents the total
compensation for each person who served as a <FONT STYLE="white-space:nowrap">non-employee</FONT> member of our board of directors during the year ended December&nbsp;31, 2023. Other than as set forth in the table and described more fully below, we
did not pay any compensation, make any equity awards or <FONT STYLE="white-space:nowrap">non-equity</FONT> awards to, or pay any other compensation to any of the <FONT STYLE="white-space:nowrap">non-employee</FONT> members of our board of directors
in 2023. We reimburse <FONT STYLE="white-space:nowrap">non-employee</FONT> members of our board of directors for reasonable travel and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in
attending meetings of our board of directors and committees of our board of directors. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Fees&nbsp;earned<BR>or paid in<BR>cash ($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Option<BR>awards($)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>All other<BR>compensation<BR>($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Ronald C. Renaud Jr., M.B.A.<SUB STYLE="font-size:75%; vertical-align:bottom">(2)</SUB></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Marcella Kuhlman Ruddy, M.D., M.S.<SUB STYLE="font-size:75%; vertical-align:bottom">(3)(4)</SUB></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">H. Edward Fleming, Jr., M.D.<SUB STYLE="font-size:75%; vertical-align:bottom">(5)(6)</SUB></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Liam Ratcliffe, M.B.Ch.B., Ph.D., M.B.A.<SUB STYLE="font-size:75%; vertical-align:bottom">(5)</SUB></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Erez Chimovits, M.B.A., M.Sc.<SUB STYLE="font-size:75%; vertical-align:bottom">(5)</SUB></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Dayton Misfeldt<SUB STYLE="font-size:75%; vertical-align:bottom">(5)</SUB></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Andy Wardle, M.B.Ch.B., M.B.A.<SUB STYLE="font-size:75%; vertical-align:bottom">(5)(7)</SUB></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Atsushi Sugita, M.B.A.<SUB STYLE="font-size:75%; vertical-align:bottom">(5)</SUB></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Srinivas Akkaraju<SUB STYLE="font-size:75%; vertical-align:bottom">(5)(8)</SUB></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Emil Bujak<SUB STYLE="font-size:75%; vertical-align:bottom">(5)(8)</SUB></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Bernard Davitian<SUB STYLE="font-size:75%; vertical-align:bottom">(5)(8)</SUB></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Eran Perry<SUB STYLE="font-size:75%; vertical-align:bottom">(5)(8)</SUB></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Chen Yu<SUB STYLE="font-size:75%; vertical-align:bottom">(5)(8)</SUB></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Alex Rosen<SUB STYLE="font-size:75%; vertical-align:bottom">(5)(9)</SUB></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="16" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported in this column represent the aggregate grant date fair value of the stock option awards granted to our directors during 2023, as calculated in accordance with FASB ASC Topic 718. Such grant date
fair values do not take into account any estimated forfeitures related to service-based vesting conditions. The assumptions used in the grant date fair value of the awards reported in this column are described in Note 10 to our consolidated
financial statements included elsewhere in this prospectus. The amounts reported in this column reflect the accounting cost for these stock option awards and do not correspond to the actual economic value that may be received by our directors upon
the exercise of the stock option awards or any sale of the underlying shares. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Renaud holds option to purchase 312,847 shares as of December<U></U>&nbsp;31, 2023. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Ruddy holds option to purchase 64,141 shares as of December<U></U>&nbsp;31, 2023. </TD></TR></TABLE>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The director joined the board of directors in January 2023. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Such director does not hold any equity awards as of December&nbsp;31, 2023. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(6)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The director joined the board of directors in June 2023. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(7)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The director joined the board of directors in December 2023. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(8)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The director resigned from the board of directors in June 2023. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(9)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The director resigned from the board of directors in November 2023. </TD></TR></TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In August 2024, in connection with the approval
of the non-employee director compensation policy described below, our board of directors approved option grants to certain members of our board of directors, with each of Mr. Renaud, Dr. Ruddy, Dr. Fleming, Dr. Ratcliffe and Mr. Chimovits being
granted options to purchase 17,096 shares of our common stock each, respectively, contingent on, and effective immediately following, the time the registration statement of which this prospectus is a part is declared effective by the SEC, or the IPO
Effective Date, subject to the applicable directors&#146; continuous service with the Company through such date. The options will be granted under our 2024 Plan and have an exercise price per share equal to the per share &#147;price to the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">202 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
public&#148; (or equivalent) set forth on the cover page of the final prospectus relating to the Company&#146;s initial public offering, which will be the fair market value of a share of our
common stock on the grant date of the option. Subject to the applicable directors&#146; continued service relationship with us, the options will vest in full and become exercisable on the earlier of (i) our next annual meeting of stockholders
following our initial public offering or (ii) the one-year anniversary of the grant. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><FONT STYLE="white-space:nowrap">Non-employee</FONT> director
compensation policy </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with this offering, we adopted a <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy that will
become effective upon the effectiveness of the registration statement of which this prospectus forms a part and will be designed to enable us to attract and retain, on a long-term basis, highly qualified
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors. Under the policy, each director who is not an employee will be paid cash compensation as set forth below: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Annual</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>retainer</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Board of Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Additional retainer for <FONT STYLE="white-space:nowrap">non-executive</FONT> chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Audit Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Retainer for chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Compensation Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Retainer for chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Nominating and Corporate Governance Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Retainer for chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="4" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy will provide that, upon initial
election to our board of directors, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will be granted a one-time stock option award to purchase 34,681&nbsp;shares of our common stock (the &#147;Initial Grant&#148;). The Initial
Grant will vest in equal monthly installments over three years from the date of grant, subject to continued service on our board through the applicable vesting date. The Initial Grant will expire ten years from the date of grant and have an exercise
price per share equal to the fair market value of our common stock on the date of grant. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Furthermore, on the date of each annual meeting of stockholders following
the completion of this offering, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director who continues as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director (other than a director receiving an Initial Grant) following such
meeting will be granted an annual stock option award to purchase 17,096&nbsp;shares of our common stock (the &#147;Annual Grant&#148;). The Annual Grant will vest in full upon the earlier of the following annual meeting of the stockholders or the
first anniversary of the date of grant and have an exercise price per share equal to the fair market value of our common stock on the date of grant. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Finally,
upon the effectiveness of the registration statement of which this prospectus forms a part, each non-employee director then serving on our board (except Daniella Beckman who will receive the award described below) will receive an Annual Grant with
an exercise price per share equal to the price set forth on the cover page of this prospectus, which shall vest in full on the earlier of the first anniversary of the date of grant or the next annual meeting of stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">203 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">All awards granted under the non-employee director compensation policy will vest in full upon the occurrence of a
&#147;sale event&#148; as defined in our 2024 stock option and incentive plan. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The aggregate amount of compensation, including both equity compensation and cash
compensation, paid to any non-employee director for service as a non-employee director in a calendar year period will not exceed $1,000,000 in the first calendar year such individual becomes a non-employee director and $750,000 in any other calendar
year. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will reimburse all reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors in attending meetings of the board of directors and committees thereof. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company has appointed Daniella
Beckman as a non-employee director, effective upon the effectiveness of the registration statement of which this prospectus forms a part. At the effectiveness of her appointment to our board of directors, Ms. Beckman will receive an award consistent
with the terms of the Initial Grant set forth above, with an exercise price per share equal to the price set forth on the cover page of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">204 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc843142_14"></A>Certain relationships and related party transactions </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following is a description of transactions or series of transactions since our incorporation in April 2021, to which we were or will be a party, in which: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the amount involved in the transaction exceeds, or will exceed, the lesser of $120,000 or one percent of the average of the
Company&#146;s total assets for the last two completed fiscal years; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">in which any of our executive officers, directors or holder of five percent or more of any class of our capital stock,
including their immediate family members or affiliated entities, had or will have a direct or indirect material interest. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Compensation
arrangements for our named executive officers and our directors are described elsewhere in this prospectus under &#147;Executive compensation&#148; and &#147;Director compensation.&#148; </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Private placement of securities </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Series A redeemable convertible
preferred stock financings </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>First closing </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October 2021, in
connection with the initial closing of our Series A redeemable convertible preferred stock financing, we issued and sold an aggregate of 11,000,000 shares of our Series A redeemable convertible preferred stock at a purchase price of $10.00 per share
for an aggregate purchase price of $110.0&nbsp;million. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each share of our Series A redeemable convertible preferred stock will automatically convert into
1.049&nbsp;shares of our common stock immediately prior to the completion of this offering. The following table summarizes purchases of our Series A redeemable convertible preferred stock by related persons: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Participant</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Affiliated&nbsp;director(s)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>or officer(s)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Shares of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>series A</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>redeemable<BR>convertible<BR>preferred</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>stock</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Total</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>purchase<BR>price ($)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">AI Upstream LLC<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Liam&nbsp;Ratcliffe,&nbsp;M.B.Ch.B.,&nbsp;Ph.D.,&nbsp;M.B.A.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Altshuler Shaham Provident Fund and Pension
Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,375,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Decheng Global Life Sciences Fund IV, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Dayton Misfeldt</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,375,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">HBM Healthcare Investments (Cayman) Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Maruho Deutschland GmbH<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Atsushi Sugita, M.B.A.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,375,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Omega Fund VII, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">825,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">OrbiMed Israel Partners II, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Erez Chimovits, M.B.A., M.Sc.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">OrbiMed Private Investments VIII, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Erez Chimovits, M.B.A., M.Sc.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Samsara BioCapital, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">825,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">TCG Crossover Fund I, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="12" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">AI Upstream LLC is a holder of five percent or more of our capital stock. Dr.&nbsp;Ratcliffe is head of biotech at Access Industries and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Altshuler Shaham Provident Fund and Pension Ltd. is a holder of five percent or more of our capital stock. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">205 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Decheng Global Life Sciences Fund IV, L.P. is a holder of five percent or more of our capital stock. Mr.&nbsp;Misfeldt is a partner at Decheng Capital and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HBM Healthcare Investments (Cayman) Ltd. is a holder of five percent or more of our capital stock. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Maruho Deutschland GmbH is a holder of five percent or more of our capital stock. Mr.&nbsp;Sugita is president and chief executive officer of Maruho Co. and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(6)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Omega Fund VII, L.P. is a holder of five percent or more of our capital stock. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(7)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Entities affiliated with OrbiMed hold five percent or more of our capital stock. Mr.&nbsp;Chimovits is a partner at OrbiMed and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(8)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Samsara BioCapital, L.P. is a holder of five percent or more of our capital stock. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(9)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">TCG Crossover Fund I, L.P. is a holder of five percent or more of our capital stock. </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Milestone closings </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October 2022, in connection with the interim milestone closing of our Series A redeemable convertible preferred stock financing, we issued and sold an aggregate of
1,000,000 shares of Series A redeemable convertible preferred stock at a purchase price of $10.00 per share for an aggregate purchase price of $10.0&nbsp;million. In February 2023, in connection with the second milestone closing of our Series A
redeemable convertible preferred stock financing, we issued and sold an aggregate of 8,000,000 shares of Series A redeemable convertible preferred stock at a purchase price of $10.00 per share for an aggregate purchase price of $80.0&nbsp;million.
</P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each share of our Series A redeemable convertible preferred stock will automatically convert into 1.049&nbsp;shares of our common stock immediately prior to the
completion of this offering. The following table summarizes purchases of our Series A redeemable convertible preferred stock by related persons: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Participant</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Affiliated&nbsp;director(s)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>or officer(s)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Shares of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>series A</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>redeemable<BR>convertible<BR>preferred</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>stock</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Total</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>purchase<BR>price ($)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">AI Upstream LLC<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Liam&nbsp;Ratcliffe,&nbsp;M.B.Ch.B.,&nbsp;Ph.D.,&nbsp;M.B.A.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Altshuler Shaham Provident Fund and Pension
Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,125,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Decheng Global Life Sciences Fund IV, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Dayton Misfeldt</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,125,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">HBM Healthcare Investments (Cayman) Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">900,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Maruho Deutschland GmbH<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Atsushi Sugita,&nbsp;M.B.A.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,125,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Omega Fund VII, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">675,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">OrbiMed Israel Partners II, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Erez Chimovits, M.B.A., M.Sc.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">OrbiMed Private Investments VIII, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Erez Chimovits, M.B.A., M.Sc.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">900,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Samsara BioCapital, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">675,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">TCG Crossover Fund I, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">900,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="12" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">AI Upstream LLC is a holder of five percent or more of our capital stock. Dr.&nbsp;Ratcliffe is head of biotech at Access Industries and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Altshuler Shaham Provident Fund and Pension Ltd. is a holder of five percent or more of our capital stock. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Decheng Global Life Sciences Fund IV, L.P. is a holder of five percent or more of our capital stock. Mr.&nbsp;Misfeldt is a partner at Decheng Capital and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HBM Healthcare Investments (Cayman) Ltd. is a holder of five percent or more of our capital stock. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Maruho Deutschland GmbH is a holder of five percent or more of our capital stock. Mr.&nbsp;Sugita is president and chief executive officer of Maruho Co. and a member of our board of directors. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">206 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(6)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Omega Fund VII, L.P. is a holder of five percent or more of our capital stock. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(7)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Entities affiliated with OrbiMed hold five percent or more of our capital stock. Mr.&nbsp;Chimovits is a partner at OrbiMed and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(8)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Samsara BioCapital, L.P. is a holder of five percent or more of our capital stock. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(9)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">TCG Crossover Fund I, L.P. is a holder of five percent or more of our capital stock. </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Series B redeemable
convertible preferred stock financing </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>First closing </I></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In June
2023, we issued and sold an aggregate of 2,941,170 shares of our Series B redeemable convertible preferred stock at a purchase price of $17.00 per share for an aggregate purchase price of $50.0&nbsp;million. Each share of our Series B redeemable
convertible preferred stock will automatically convert into 1.049 shares of our common stock immediately prior to the completion of this offering. The following table summarizes purchases of our Series B redeemable convertible preferred stock by
related persons: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Participant</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Affiliated&nbsp;director(s)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>or officer(s)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Shares of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>series B</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>redeemable<BR>convertible<BR>preferred</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>stock</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Total</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>purchase<BR>price ($)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">AI Upstream LLC<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Liam&nbsp;Ratcliffe,&nbsp;M.B.Ch.B.,&nbsp;Ph.D.,&nbsp;M.B.A.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,749,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Altshuler Shaham Provident Fund and Pension
Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,124,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">BCLS Fund III Investments, LP</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,374,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Decheng Global Life Sciences Fund IV, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Dayton Misfeldt</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,874,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">HBM Healthcare Investments (Cayman) Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,499,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Omega Fund VII, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,874,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">OrbiMed Israel Partners II, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Erez Chimovits, M.B.A., M.Sc.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">799,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">OrbiMed Private Investments VIII, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Erez Chimovits, M.B.A., M.Sc.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,199,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Samsara BioCapital, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">TCG Crossover Fund I, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,749,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entities affiliated with Enavate Sciences<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">H. Edward Fleming, Jr., M.D.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,749,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Venrock Healthcare Capital Partners EG,
L.P.<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Andy Wardle, M.B.Ch.B., M.B.A.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,242,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Venrock Healthcare Capital Partners III,
L.P.<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Andy Wardle, M.B.Ch.B., M.B.A.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,938,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">VHCP <FONT STYLE="white-space:nowrap">Co-Investment</FONT> Holdings III, LLC<SUP
STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Andy&nbsp;Wardle,&nbsp;M.B.Ch.B.,&nbsp;M.B.A.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="12" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">AI Upstream LLC is a holder of five percent or more of our capital stock. Dr.&nbsp;Ratcliffe is head of biotech at Access Industries and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Altshuler Shaham Provident Fund and Pension Ltd. is a holder of five percent or more of our capital stock. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Decheng Global Life Sciences Fund IV, L.P. is a holder of five percent or more of our capital stock. Mr.&nbsp;Misfeldt is a partner at Decheng Capital and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HBM Healthcare Investments (Cayman) Ltd. is a holder of five percent or more of our capital stock. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Entities affiliated with OrbiMed hold five percent or more of our capital stock. Mr.&nbsp;Chimovits is a partner at OrbiMed and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(6)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">TCG Crossover Fund I, L.P. is a holder of five percent or more of our capital stock. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(7)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">UpStream Aggregator, LP, an entity affiliated with Enavate Sciences, holds five percent or more of our capital stock. Dr.&nbsp;Fleming is an executive vice president at Enavate Sciences and a member of our board of
directors. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(8)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Wardle is an investor at Venrock Healthcare Capital Partners and a member of our board of directors. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">207 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Series B option closing </I></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In
April 2024, in connection with the Series B option closing of our Series B redeemable convertible preferred stock financing, we issued and sold an aggregate of 8,823,523 shares of our Series B redeemable convertible preferred stock at a purchase
price of $17.00 per share for an aggregate purchase price of $150.0&nbsp;million. Each share of our Series B redeemable convertible preferred stock will automatically convert into 1.049&nbsp;shares of our common stock immediately prior to the
completion of this offering. The following table summarizes purchases of our Series B redeemable convertible preferred stock by related persons: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Participant</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Affiliated&nbsp;director(s)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>or officer(s)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Shares of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>series B</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>redeemable<BR>convertible<BR>preferred</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>stock</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Total</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>purchase<BR>price ($)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">AI Upstream LLC<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Liam&nbsp;Ratcliffe,&nbsp;M.B.Ch.B.,&nbsp;Ph.D.,&nbsp;M.B.A.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">838,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,249,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Altshuler Shaham Provident Fund and Pension
Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">551,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,374,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">BCLS Fund III Investments, LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,301,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,124,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Decheng Global Life Sciences Fund IV, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Dayton Misfeldt</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">330,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,624,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">HBM Healthcare Investments (Cayman) Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">441,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,499,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">OrbiMed Israel Partners II, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Erez Chimovits, M.B.A., M.Sc.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,399,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">OrbiMed Private Investments VIII, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Erez Chimovits, M.B.A., M.Sc.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">564,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,599,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">TCG Crossover Fund I, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">485,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,249,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entities affiliated with Enavate Sciences<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">H. Edward Fleming, Jr., M.D.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,544,117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,249,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Venrock Healthcare Capital Partners EG,
L.P.<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Andy Wardle, M.B.Ch.B., M.B.A.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">989,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,821,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Venrock Healthcare Capital Partners III,
L.P.<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Andy Wardle, M.B.Ch.B., M.B.A.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">283,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,821,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">VHCP <FONT STYLE="white-space:nowrap">Co-Investment</FONT> Holdings III, LLC<SUP
STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Andy&nbsp;Wardle,&nbsp;M.B.Ch.B.,&nbsp;M.B.A.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">482,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="12" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">AI Upstream LLC is a holder of five percent or more of our capital stock. Dr.&nbsp;Ratcliffe is head of biotech at Access Industries and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Altshuler Shaham Provident Fund and Pension Ltd. is a holder of five percent or more of our capital stock. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Decheng Global Life Sciences Fund IV, L.P. is a holder of five percent or more of our capital stock. Mr.&nbsp;Misfeldt is a partner at Decheng Capital and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HBM Healthcare Investments (Cayman) Ltd. is a holder of five percent or more of our capital stock. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Entities affiliated with OrbiMed hold five percent or more of our capital stock. Mr.&nbsp;Chimovits is a partner at OrbiMed and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(6)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">TCG Crossover Fund I, L.P. is a holder of five percent or more of our capital stock. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(7)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">UpStream Aggregator, LP, an entity affiliated with Enavate Sciences, holds five percent or more of our capital stock. Dr.&nbsp;Fleming is an executive vice president at Enavate Sciences and a member of our board of
directors. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(8)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Wardle is an investor at Venrock Healthcare Capital Partners and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Investors&#146; rights, voting and right of first refusal agreements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In
connection with our redeemable convertible preferred stock financings, we entered into an investors&#146; rights agreement, voting agreement and right of first refusal agreement, in each case, with the purchasers of our redeemable convertible
preferred stock and certain holders of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">208 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our amended and restated investors&#146; rights agreement (&#147;Investor Rights Agreement&#148;) provides certain
holders of our redeemable convertible preferred stock with a participation right to purchase their pro rata share of new securities that we may propose to sell and issue, subject to certain exceptions. Such participation right will terminate upon
the completion of this offering. The Investor Rights Agreement further provides certain holders of our capital stock with the right to demand that we file a registration statement, subject to certain limitations, and to request that their shares be
covered by a registration statement that we are otherwise filing. See the section titled &#147;Description of capital stock&#151;Registration rights&#148; included elsewhere in this prospectus, for additional information regarding such registration
rights. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our amended and restated voting agreement (&#147;Voting Agreement&#148;) provides for drag-along rights in respect of sales by certain holders of our
capital stock. The Voting Agreement also contains provisions with respect to the elections of our board of directors and its composition. The rights under the Voting Agreement will terminate upon the completion of this offering. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our amended and restated right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreement (&#147;Right of First Refusal and <FONT
STYLE="white-space:nowrap">Co-Sale</FONT> Agreement&#148;) provides for rights of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> rights in respect of sales by certain holders of our capital stock. The rights under the Right of
First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement will terminate upon the completion of this offering. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Maruho license agreement
</B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October 2021, we entered into a license agreement with Maruho Co. Ltd (&#147;Maruho&#148;) (as amended, the &#147;Maruho License Agreement&#148;). Mr.
Sugita, a member of our board of directors, is president and chief executive officer of Maruho. Maruho is a co-founder of our company and affiliated with Maruho Deutschland GmbH, a holder of more than 5% of our outstanding capital stock. Please see
the section titled &#147;Business&#151;Asset purchase and license agreements&#148; included elsewhere in this prospectus for a description of the Maruho License Agreement. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Indemnification agreements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with this offering, we intend to
enter into new agreements to indemnify our directors and executive officers. These agreements will, among other things, require us to indemnify these individuals for certain expenses (including attorneys&#146; fees), judgments, fines and settlement
amounts reasonably incurred by such person in any action or proceeding, including any action by or in our right, on account of any services undertaken by such person on behalf of our company or that person&#146;s status as a member of our board of
directors or executive officer to the maximum extent allowed under Delaware law. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Policies for approval of related party transactions </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors reviews and approves transactions with directors, officers and holders of 5% or more of our voting securities and their affiliates, each a related
party. Prior to this offering, the material facts as to the related party&#146;s relationship or interest in the transaction are disclosed to our board of directors prior to their consideration of such transaction, and the transaction is not
considered approved by our board of directors unless a majority of the directors who are not interested in the transaction approve the transaction. Further, when stockholders are entitled to vote on a transaction with a related party, the material
facts of the related party&#146;s relationship or interest in the transaction are disclosed to the stockholders, who must approve the transaction in good faith. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with this offering, we will adopt a written related party transactions policy that all such transactions must be approved by our audit committee. This
policy will become effective on the date on which the registration statement of which this prospectus is a part is declared effective by the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">209 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc843142_15"></A>Principal stockholders </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth certain information known to us regarding beneficial ownership of our capital stock as of August&nbsp;1, 2024, and as adjusted to reflect
the sale of common stock offered by us in this offering, for: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">each person or group of affiliated persons known by us to be the beneficial owner of more than 5% of our capital stock;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">each of our directors and director nominees; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">all of our current executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. Under those
rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power. Except as noted by footnote, and subject to community property laws where applicable, we believe, based on the
information provided to us, that the persons and entities named in the table below have sole voting and investment power with respect to all common stock shown as beneficially owned by them. We have deemed shares of common stock subject to options
that are currently exercisable or exercisable within 60 days of August&nbsp;1, 2024 to be outstanding and to be beneficially owned by the person holding the option for the purpose of computing the percentage ownership of that person but have not
treated them as outstanding for the purpose of computing the percentage ownership of any other person. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The percentage of beneficial ownership prior to this
offering in the table below is based on 36,343,454 shares of common stock deemed to be outstanding as of August&nbsp;1, assuming the automatic conversion of all outstanding shares of our Series A and Series B redeemable convertible preferred stock
immediately prior to the completion of this offering, and the percentage of beneficial ownership after this offering in the table below is based on 48,843,454 shares of common stock assumed to be outstanding after the completion of the offering. The
information in the table below assumes no exercise of the underwriters&#146; option to purchase additional shares. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Unless otherwise noted below, the address
for each beneficial owner listed in the table below is c/o Upstream Bio, Inc., 890 Winter Street, Suite 200, Waltham, MA 02451. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">210 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Shares&nbsp;beneficially</B><br><B>owned&nbsp;prior&nbsp;to&nbsp;offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Shares beneficially</B><br><B>owned&nbsp;after&nbsp;offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Percent<BR>(%)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Percent<BR>(%)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Name of beneficial owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B><I>5% or greater shareholders:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entities affiliated with OrbiMed<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,868,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,868,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">AI Upstream LLC<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,319,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,319,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Altshuler Shaham Provident Fund and Pension
Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,393,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,393,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Decheng Capital Global Life Sciences Fund IV,
L.P.<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,085,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,085,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">TCG Crossover Fund I, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,776,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,776,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">HBM Healthcare Investments (Cayman) Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,715,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,715,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Maruho Deutschland GmbH<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,622,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,622,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entities affiliated with Enavate Sciences<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,159,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,159,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Samsara BioCapital, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,067,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,067,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Omega Fund VII, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,036,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,036,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">BCLS Fund III Investments, LP<SUP STYLE="font-size:75%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,820,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,820,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entities affiliated with Venrock Healthcare Capital
Partners<SUP STYLE="font-size:75%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,820,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,820,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B><I>Named executive officers, directors and director nominees:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Jennifer Beachell, <I>Former Chief Operating
Officer</I><SUP STYLE="font-size:75%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Aaron Deykin, M.D., <I>Chief Medical
Officer</I><SUP STYLE="font-size:75%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Samantha Truex, <I>Former Chief Executive
Officer</I><SUP STYLE="font-size:75%; vertical-align:top">(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">561,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">561,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">E. Rand Sutherland, M.D., M.P.H., <I>Chief Executive Officer and Director </I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Ronald C. Renaud, Jr., M.B.A.<SUP STYLE="font-size:75%; vertical-align:top">(16)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Daniella Beckman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Erez Chimovits, M.B.A.,&nbsp;M.Sc.<SUP STYLE="font-size:75%; vertical-align:top">(17)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">973,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">973,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">H. Edward Fleming, Jr., M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Dayton Misfeldt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Liam Ratcliffe, M.B.Ch.B., Ph.D.,&nbsp;M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Marcella Kuhlman Ruddy, M.D., M.S.<SUP STYLE="font-size:75%; vertical-align:top">(18)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Atsushi Sugita,&nbsp;M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Andy Wardle, M.B.Ch.B., M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B><I>All current executive officers and directors as a group (12&nbsp;persons)</I></B><SUP
STYLE="font-size:75%; vertical-align:top">(19)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,631,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,631,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="16" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents beneficial ownership of less than one percent. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i)&nbsp;251,760 shares of common stock held by OrbiMed Israel Partners II, L.P. (&#147;OIP II&#148;), (ii)&nbsp;1,007,040 shares of common stock held by OrbiMed Private Investments VIII, LP (&#147;OPI
VIII&#148;), (iii)&nbsp;524,500 shares of common stock issuable upon conversion of Series&nbsp;A preferred stock held by OIP II, (iv)&nbsp;2,098,000 shares of common stock issuable upon conversion of Series A preferred stock held by OPI VIII,
(v)&nbsp;197,456 shares of common stock issuable upon conversion of Series B preferred stock held by OIP II and (vi)&nbsp;789,833 shares of common stock issuable upon conversion of Series B preferred stock held by OPI VIII. OrbiMed Israel GP II,
L.P. (&#147;Israel GP&#148;) is the general partner of OIP II and OrbiMed Advisors Israel II Limited (&#147;Advisors Israel&#148;) is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors Israel may be deemed to
have investment and voting power with respect to the shares held by OIP II and as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel exercises this investment and voting power through a management committee
comprised of Carl&nbsp;L. Gordon, David P. Bonita and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II. OrbiMed Capital GP VIII LLC (&#147;GP VIII&#148;) is the general partner of OPI VIII and OrbiMed Advisors
LLC (&#147;OrbiMed Advisors&#148;) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have investment and voting power with respect to the shares held by OPI VIII and as a result, may be
deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and W. Carter Neild, each of whom disclaims beneficial
ownership of the shares held by OPI VIII. Mr. Chimovits is an employee of OrbiMed and a member of our board of directors. The address for each of the entities and individuals identified in this footnote is c/o OrbiMed Advisors LLC, 601 Lexington
Avenue 54th Floor, New York, NY 10022. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">211 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 3,147,000 shares of common stock issuable upon conversion of Series A preferred stock held by AI Upstream LLC (&#147;AIU&#148;) and (ii) 1,172,410 shares of common stock issuable upon conversion of
Series B preferred stock held by AIU. The shares held by AIU may be deemed to be beneficially owned by Access Industries Holdings LLC (&#147;AIH&#148;), Access Industries Management, LLC (&#147;AIM&#148;) and Len Blavatnik (collectively, the
&#147;Access Reporting Persons&#148;) because (i) AIH indirectly controls all of the outstanding voting interests in AIU, (ii) AIM controls AIH and (iii) Mr. Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH.
Each of the Access Reporting Persons, and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of the shares held by AIU. Liam Ratcliffe, M.B.Ch.B., Ph.D., M.B.A. is head of
biotechnology at Access Industries, Inc., an affiliate of AIU, and a member of our board of directors. The address for each of the Access Reporting Persons is c/o Access Industries, Inc., 40 West 57th Street, 28th Floor, New York, NY 10019.
</TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 2,622,500 shares of common stock issuable upon conversion of Series A preferred stock held by provident and pension funds managed by Altshuler Shaham Provident &amp; Pension Funds Ltd. (&#147;Altshuler
Funds&#148;) and (ii) 771,322 shares of common stock issuable upon conversion of Series B preferred stock held by provident and pension funds managed by Altshuler Funds. The provident and pension funds are managed by employees of Altshuler Funds and
its indirect parent company, Altshuler- Shaham Ltd., for the benefit of public investors and not for the economic benefit of Altshuler Funds. Altshuler Funds possesses sole authority with respect to the voting of all shares, but shares authority
with Altshuler Shaham Ltd. concerning the disposition of such shares. The address of each of Altshuler Funds and Altshuler Shaham Ltd. is 19 A Habarzel St. Ramat Hahayal, Tel Aviv, 6971026, Israel. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 2,622,500 shares of common stock issuable upon conversion of Series A preferred stock held by Decheng Capital Global Life Sciences Fund IV, L.P. (&#147;Decheng Fund IV&#148;) and (ii) 462,793 shares of
common stock issuable upon conversion of Series B preferred stock held by Decheng Fund IV. Decheng Capital Management IV (Cayman), LLC (&#147;Decheng Fund GP&#148;) is the general partner of Decheng Fund IV. Xiangmin Cui is the manager of Decheng
Fund GP. Each of Decheng Fund GP and Dr. Cui may be deemed to beneficially own the securities held by Decheng Fund IV. Each of Decheng Fund GP and Dr. Cui disclaim beneficial ownership of these securities, except to the extent of their respective
pecuniary interests therein. Dayton Misfeldt is a partner at Decheng Capital LLC, the service company of Decheng Fund IV, and a member of our board of directors. The address for each of the entities and individuals identified in this footnote is
3000 Sand Hill Road, Building 2, Suite 110, Menlo Park, CA 94025. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 2,098,000 shares of common stock issuable upon conversion of Series A preferred stock held by TCG Crossover Fund I, L.P. (&#147;TCGX Fund I&#148;) and (ii) 678,763 shares of common stock issuable upon
conversion of Series B preferred stock held by TCGX Fund I. TCG Crossover GP I, LLC (&#147;TCGX GP I&#148;) is the general partner of TCGX Fund I and may be deemed to have voting, investment and dispositive power with respect to these securities.
Chen Yu is the sole managing member of TCGX GP I and may be deemed to share voting investment and dispositive power with respect to these securities. The address for each of the entities and individuals identified in this footnote is 705 High St.,
Palo Alto, CA 94301. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(6)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 2,098,000 shares of common stock issuable upon conversion of Series A preferred stock held by HBM Healthcare Investments (Cayman) Ltd. (&#147;HBM Healthcare&#148;) and (ii) 617,056 shares of common stock
issuable upon conversion of Series B preferred stock held by HBM Healthcare. Voting and investment power over the shares held by HBM Healthcare is exercised by its board of directors, which consists of Jean Marc Lesieur, Sophia Harris, Richard
Coles, Dr. Andreas Wicki, Paul Woodhouse and Dr. Mark Kronenfeld, none of whom has individual voting or investment power with respect to the shares. The address for each of the entities and individuals identified in this footnote is Governors
Square, 23 Lime Tree Bay Avenue, PO Box 30852, Grand Cayman, KY1-1204, Cayman Islands. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(7)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 3 shares of common stock held by Maruho Deutschland GmbH and (ii) 2,622,500 shares of common stock issuable upon conversion of Series A preferred stock held by Maruho Deutschland GmbH. Atsushi Sugita,
M.B.A. is president and chief executive officer of Maruho Co., Ltd., the sole owner of Maruho Deutschland GmbH, and a member of our board of directors. The address for Maruho Deutschland GmbH is Berliner Allee 29 40212 D&uuml;sseldorf Germany.
</TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(8)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 2,159,703 shares of common stock issuable upon conversion of Series B preferred stock held by UpStream Aggregator, LP (&#147;UpStream LP&#148;), a limited partnership affiliated with Enavate Sciences.
Enavate Sciences GP, LLC (&#147;Enavate GP&#148;) is the general partner of UpStream LP. Voting, investment and dispositive power with respect to the shares held by UpStream LP are made collectively by the managers of Enavate GP: Jim Momtazee, Laura
Furmanski, Neel Varshney and James P. Boylan, each of whom expressly disclaims beneficial ownership of the shares. H. Edward Fleming, Jr., M.D. is an executive vice president of Enavate Sciences Management Inc., which is solely owned by Enavate
Sciences, LP, and a member of our board of directors. UpStream LP is a wholly owned subsidiary of Enavate Sciences, LP. The address for each of the entities and individuals identified in this footnote is c/o Enavate Sciences, LP, 106 W 56th Street,
8th Floor, New York, NY 10019. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(9)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 1,573,500 shares of common stock issuable upon conversion of Series A preferred stock held by Samsara BioCapital, L.P. (&#147;Samsara LP&#148;) and (ii) 493,646 shares of common stock issuable upon
conversion of Series B preferred stock held by Samsara LP. Samsara BioCapital GP, LLC (&#147;Samsara GP&#148;) is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, M.D.,
Ph.D., has voting and investment power over the shares held by Samsara GP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Samsara GP and Dr. Akkaraju disclaim beneficial ownership in these shares except to the
extent of its or his respective pecuniary interest therein. The address for each of the entities and individuals identified in this footnote is 628 Middlefield Road, Palo Alto, CA 94301. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(10)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 1,573,500 shares of common stock issuable upon conversion of Series A preferred stock held by Omega Fund VII, L.P. (&#147;Omega Fund&#148;) and (ii) 462,793 shares of common stock issuable upon
conversion of Series B preferred stock held by Omega Fund.&nbsp;Omega Fund VII&nbsp;GP Manager, Ltd. (&#147;Omega Ltd.&#148;) is the sole general partner of&nbsp;Omega Fund VII&nbsp;GP, L.P. (&#147;Omega GP&#148;), which is the sole general partner
of Omega Fund; and each of Omega Ltd. and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Claudio Nessi, Francesco Draetta and Otello Stampacchia are the directors of Omega Ltd. and, as a result, may be deemed to share
voting and investment power over the shares held directly by Omega Fund. Each of Dr. Nessi, Mr. Draetta, Dr. Stampacchia, Omega Ltd. and Omega GP disclaim beneficial ownership of the shares held by Omega Fund except to the extent of their pecuniary
interest therein. The address for each of the entities and individuals identified in this footnote is 888 Boylston Street, Suite 1111, Boston, MA 02199. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(11)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 1,820,322 shares of common stock issuable upon conversion of Series B preferred stock held by BCLS Fund III Investments, LP (&#147;BCLS III&#148;). Bain Capital Life Sciences Investors, LLC
(&#147;BCLSI&#148;) is the manager of Bain Capital Life Sciences III General Partner, LLC, which is the general partner of Bain Capital Life Sciences Fund III, L.P., which is the managing member of BCLS Fund III Investments GP, LLC, which is the
general partner of BCLS III. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by BCLS III. The address for each of the entities identified in this footnote is c/o Bain Capital Life Sciences,
LP, 200 Clarendon Street, Boston, MA 02116. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">212 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(12)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 1,361,463&nbsp;shares of common stock issuable upon conversion of Series B preferred stock held by Venrock&nbsp;Healthcare Capital Partners EG, L.P. (&#147;VHCP EG&#148;), (ii) 417,125&nbsp;shares of
common stock issuable upon conversion of Series B preferred stock held by Venrock&nbsp;Healthcare Capital Partners III, L.P. (&#147;VHCP III&#148;) and (iii) 41,731&nbsp;shares of common stock issuable upon conversion of Series B preferred stock
held by VHCP&nbsp;Co-Investment&nbsp;Holdings III, LLC (&#147;VHCP&nbsp;Holdings&nbsp;III&#148;).VHCP Management III, LLC (&#147;VHCPM&#148;) is the sole general partner of VHCP III and the sole manager of VHCP&nbsp;Holdings&nbsp;III. VHCP
Management EG, LLC (&#147;VHCPM EG&#148;) is the sole general partner of VHCP EG. Dr. Bong Koh and Nimish Shah are the voting members of VHCPM and VHCPM EG. Andy Wardle, M.B.Ch.B., is an investor at Venrock Healthcare Capital Partners and a member
of our board of directors. The address for each of the entities and individuals identified in this footnote is 7 Bryant Park, 23rd Floor, New York, NY 10018. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(13)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 13,075&nbsp;shares of common stock and (ii) 129,860&nbsp;shares of common stock issuable upon the exercise of options exercisable within 60 days of August 1, 2024 held by Ms. Beachell. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(14)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 250,474&nbsp;shares of common stock issuable upon the exercise of options exercisable within 60 days of August 1, 2024 held by Dr. Deykin. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(15)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 29,057&nbsp;shares of common stock and (ii) 532,553&nbsp;shares of common stock issuable upon the exercise of options exercisable within 60 days of August 1, 2024 held by Ms. Truex. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(16)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 171,106&nbsp;shares of common stock issuable upon the exercise of options exercisable within 60 days of August 1, 2024 held by Mr. Renaud. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(17)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 251,760&nbsp;shares of common stock held by OIP II, (ii) 524,500&nbsp;shares of common stock issuable upon conversion of Series A preferred stock held by OIP II and (iii) 197,456&nbsp;shares of common
stock issuable upon conversion of Series B preferred stock held by OIP II. Israel GP is the general partner of OIP II and Advisors Israel is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors Israel may be
deemed to have investment and voting power with respect to the shares held by OIP II and as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel exercises this investment and voting power through a management
committee comprised of Carl L. Gordon, David P. Bonita and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II. Mr. Chimovits is an employee of OrbiMed and a member of our board of directors. The address for each
of the entities and individuals identified in this footnote is c/o&nbsp;OrbiMed&nbsp;Advisors LLC, 601 Lexington Avenue 54th Floor, New York, NY 10022. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(18)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 25,425&nbsp;shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days of August&nbsp;1, 2024 held by Dr. Ruddy. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(19)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 251,760&nbsp;shares of common stock, (ii) 524,500&nbsp;shares of common stock issuable upon conversion of Series A preferred stock, (iii) 197,456&nbsp;shares of common stock issuable upon conversion of
Series B preferred stock and (iv) 657,729&nbsp;shares of common stock issuable upon the exercise of options exercisable within 60 days of August 1, 2024 held by our current executive officers, Dr. Sutherland, Mr. Gray, Dr. Deykin and Dr. Houghton,
and current directors. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">213 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc843142_16"></A>Description of capital stock </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>The following descriptions are summaries of the material terms of our third amended and restated certificate of incorporation, which will become effective immediately
prior to the completion of this offering, and second amended and restated bylaws, which will become effective upon effectiveness of the registration statement of which this prospectus forms a part. The descriptions of the common stock and preferred
stock give effect to changes to our capital structure that will occur immediately prior to the completion of this offering. We refer in this section to our third amended and restated certificate of incorporation as our certificate of incorporation,
and we refer to our second amended and restated bylaws as our bylaws. </I></P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>General </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon filing of our certificate of incorporation and the completion of this offering, our authorized capital stock will consist of 500,000,000 shares of common stock, par
value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share, all of which shares of preferred stock will be undesignated. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of
June&nbsp;30, 2024, 36,341,695 shares of our common stock were outstanding and held by 65 stockholders of record. This amount assumes the conversion of all outstanding shares of our redeemable convertible preferred stock into common stock, which
will occur immediately prior to the completion of this offering. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Common stock </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock do not
have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any
outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In
the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding
preferred stock. The shares to be issued by us in this offering will be, when issued and paid for, validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Preferred stock </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Immediately prior to the completion of this offering, all
outstanding shares of our redeemable convertible preferred stock will be converted into shares of our common stock. Upon the consummation of this offering, our board of directors will have the authority, without further action by our stockholders,
to issue up to shares of preferred stock in one or more series and to fix the rights, preferences, privileges, and restrictions thereof. These rights, preferences, and privileges could include dividend rights, conversion rights, voting rights, terms
of redemption, liquidation preferences, sinking fund terms, and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could
adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying,
deferring or preventing a change in control of our Company or other corporate action. Immediately after consummation of this offering, no shares of preferred stock will be outstanding, and we have no present plan to issue any shares of preferred
stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">214 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Stock options </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of
June&nbsp;30, 2024, 6,224,230&nbsp;shares of common stock were issuable upon the exercise of outstanding stock options under the 2021 Plan, at a weighted-average exercise price of $4.96&nbsp;per share. Following this offering, 3,180,000&nbsp;shares
of our common stock will be reserved for future issuance under the 2024 Plan, which will become effective on the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any future
automatic annual increases in the number of shares of common stock reserved for issuance under the 2024 Plan and any shares underlying outstanding stock awards granted under the 2021 Plan, that expire or are repurchased, forfeited, cancelled, or
withheld. For additional information regarding terms of our equity incentive plans, see the section titled &#147;Executive compensation&#151;Employee benefit and equity compensation plans&#148; included elsewhere in this prospectus. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Registration rights </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the completion of this offering, certain holders of
our common stock, including those issuable upon the conversion of redeemable convertible preferred stock, will be entitled to rights with respect to the registration of these securities under the Securities Act. These rights are provided under the
terms of an investors&#146; rights agreement between us and the holders of our redeemable convertible preferred stock. The investors&#146; rights agreement includes demand registration rights, short-form registration rights and piggyback
registration rights. All fees, costs and expenses of underwritten registrations under this agreement will be borne by us and all selling expenses, including underwriting discounts and selling commissions, will be borne by the holders of the shares
being registered. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Demand registration rights </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Beginning six
months after the completion of this offering, certain holders of our common stock, including those issuable upon the conversion of shares of our redeemable convertible preferred stock upon completion of this offering, will be entitled to demand
registration rights. Under the terms of the investors&#146; rights agreement, we will be required, upon the written request of a majority of holders of the registerable securities then outstanding that would result in an aggregate offering price of
at least $5&nbsp;million, to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> with respect to the registrable securities then outstanding and to use commercially reasonable efforts to effect the registration of all
or a portion of these shares for public resale. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Short-form registration rights </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the completion of this offering, certain holders of our common stock, including those issuable upon the conversion of shares of our redeemable convertible preferred
stock upon completion of this offering, are also entitled to short-form registration rights. Pursuant to the investors&#146; rights agreement, if we are eligible to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT>
upon the written request of at least 30% in interest of these holders to sell registrable securities at an aggregate price of at least $1&nbsp;million, we will be required to use commercially reasonable efforts to effect a registration of such
shares. We are required to effect only one registration in any twelve month period pursuant to this provision of the investor rights agreement. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Piggyback
registration rights </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the completion of this offering, certain holders of our common stock, including those issuable upon the conversion of shares of our
redeemable convertible preferred stock upon completion of this offering, are entitled to piggyback registration rights. If we register any of our securities either for our own account or for the account of other security holders, the holders of
these shares are entitled to include their shares in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">215 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
registration. Subject to certain exceptions contained in the investors&#146; rights agreement, we and the underwriters may limit the number of shares included in the underwritten offering to the
number of shares which we and the underwriters determine in our sole discretion will not jeopardize the success of the offering. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Indemnification </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our investors&#146; rights agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of registrable securities in
the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Expiration of registration rights </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The demand registration rights and
short-form registration rights granted under the investor rights agreement will terminate on the fifth anniversary of the completion of this offering. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Anti-takeover effects of our certificate of incorporation and bylaws and Delaware law </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our certificate of incorporation and bylaws will include a number of provisions that may have the effect of delaying, deferring or preventing another party from
acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue <FONT STYLE="white-space:nowrap">non-negotiated</FONT> takeover
attempts. These provisions include the items described below. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Board composition and filling vacancies </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our certificate of incorporation will provide for the division of our board of directors into three classes serving staggered three-year terms, with one class being
elected each year. Our certificate of incorporation also will provide that directors may be removed only for cause and then only by the affirmative vote of the holders of <FONT STYLE="white-space:nowrap">two-thirds</FONT> or more of the shares then
entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled by the affirmative vote of a majority of
our directors then in office even if less than a quorum. The classification of directors, together with the limitations on removal of directors and treatment of vacancies, has the effect of making it more difficult for stockholders to change the
composition of our board of directors. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>No written consent of stockholders </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our certificate of incorporation provides that all stockholder actions are required to be taken by a vote of the stockholders at an annual or special meeting, and that
stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our bylaws or removal of directors by our stockholders
without holding a meeting of stockholders. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Meetings of stockholders </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our certificate of incorporation and bylaws provide that only a majority of the members of our board of directors then in office may call special meetings of
stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our bylaws limit the business that may be conducted at an annual meeting of stockholders to
those matters properly brought before the meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">216 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Advance notice requirements </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to
be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be
timely, notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual meeting for the preceding year. Our bylaws specify the requirements as to form and
content of all stockholders&#146; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Amendment to certificate of incorporation and bylaws </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any amendment of
our certificate of incorporation must first be approved by a majority of our board of directors, and if required by law or our certificate of incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the
amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment of the provisions relating to stockholder action, board composition, and limitation of liability must be approved by not
less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares entitled to vote on the amendment, and not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares of each class entitled to vote
thereon as a class. Our bylaws may be amended by the affirmative vote of a majority of the directors then in office, subject to any limitations set forth in the bylaws; and may also be amended by the affirmative vote of a majority of the outstanding
shares entitled to vote on the amendment, voting together as a single class, except that the amendment of the provisions relating to notice of stockholder business and nominations and special meetings must be approved by not less than <FONT
STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares entitled to vote on the amendment, and not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares of each class entitled to vote thereon as a
class, or, if our board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Undesignated preferred stock </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our certificate of incorporation
provides for 10,000,000 authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to discourage an attempt to obtain control of us by means of a merger, tender offer,
proxy contest, or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause
shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this
regard, our certificate of incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of
earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing
a change in control of us. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Choice of forum </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our bylaws will provide
that the Court of Chancery of the State of Delaware is the sole and exclusive forum for the following claims or causes of action under the Delaware statutory or common law: (i)&nbsp;any derivative action or proceeding brought on our behalf,
(ii)&nbsp;any action asserting a claim of, or a claim based on, a breach of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">217 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
fiduciary duty owed by any of our current or former directors, officers, or other employees or stockholders to us or our stockholders, (iii)&nbsp;any action asserting a claim arising pursuant to
any provision of the Delaware General Corporation Law (&#147;DGCL&#148;) or our certificate of incorporation or amended and restated bylaws (including the interpretation, validity or enforceability thereof) or as to which the DGCL confers
jurisdiction on the Court of Chancery of the State of Delaware, or (iv)&nbsp;any action asserting a claim governed by the internal affairs doctrine. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">However,
Section&nbsp;27 of the Exchange Act creates exclusive federal jurisdiction over all claims brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Consequently, this choice of forum provision
would not apply to claims or causes of action brought to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction or the Securities Act. Moreover, Section&nbsp;22 of the
Securities Act creates concurrent jurisdiction for federal and state courts over all claims brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, our bylaws will provide that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal
district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause or causes of action arising under the Securities Act, including all causes of action asserted against any defendant to
such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by us, our officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose
profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While
the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance
that such provisions will be enforced by a court in those other jurisdictions. We note that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, our bylaws will provide that any person or entity holding, owning or otherwise acquiring any interest in any of our securities shall be deemed to have
notice of and consented to these provisions. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Section&nbsp;203 of the Delaware General Corporation Law </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon completion of this offering, we will be subject to the provisions of Section&nbsp;203 of the DGCL. In general, Section&nbsp;203 prohibits a publicly held Delaware
corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is
approved in a prescribed manner. Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">before the stockholder became interested, our board of directors approved either the business combination or the
transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested
stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers,
and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">218 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">at or after the time the stockholder became interested, the business combination was approved by our board of directors and
authorized at an annual or special meeting of the stockholders by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Section&nbsp;203 defines a business combination to include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any sale, transfer, lease, pledge, or other disposition involving the interested stockholder of 10% or more of the assets
of the corporation; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the
corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share
of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges, or other financial
benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In general, Section&nbsp;203 defines an interested stockholder as any entity or person
beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Limitations on liability and indemnification </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">See the section titled
&#147;Management&#151;Limitations on liability and indemnification&#148; included elsewhere in this prospectus. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Nasdaq Global Market listing </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our common stock is currently not listed on any securities exchange. We have applied to list our common stock on the Nasdaq Global Market under the trading symbol
&#147;UPB,&#148; and this offering is contingent upon obtaining approval of such listing. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Transfer agent and registrar </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the completion of this offering, the transfer agent and registrar for our common stock will be Computershare Trust Company, N.A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">219 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc843142_17"></A>Shares eligible for future sale </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prior to this offering, there has been no public market for our shares. Future sales of our common stock in the public market, or the availability of such shares for
sale in the public market, could adversely affect market prices prevailing from time to time. As described below, only a limited number of shares will be available for sale shortly after this offering due to contractual and legal restrictions on
resale. Nevertheless, sales of our common stock in the public market after such restrictions lapse, or the perception that those sales may occur, could adversely affect the prevailing market price at such time and our ability to raise equity capital
in the future. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on the number of shares outstanding as of June&nbsp;30, 2024, upon the completion of this offering, 48,841,695 shares of our common stock
will be outstanding, assuming the automatic conversion of all outstanding shares of our Series A and Series B redeemable convertible preferred stock into shares of common stock, no exercise of the underwriters&#146; option to purchase additional
shares and no exercise of outstanding options. Of the outstanding shares, all of the shares sold in this offering will be freely tradable, except that any shares held by our affiliates, as that term is defined in Rule&nbsp;144 under the Securities
Act, may only be sold in compliance with the limitations described below. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Rule&nbsp;144 </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In general, a person who has beneficially owned restricted stock for at least six months would be entitled to sell their securities provided that (i)&nbsp;such person is
not deemed to have been one of our affiliates at the time of, or at any time during the 90 days preceding, a sale, and (ii)&nbsp;we are subject to the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), periodic reporting
requirements for at least 90 days before the sale. Persons who have beneficially owned restricted shares for at least six months but who are our affiliates at the time of, or any time during the 90 days preceding, a sale, would be subject to
additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of either of the following: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">1% of the number of shares then outstanding, which will equal 488,416 shares immediately after this offering assuming no
exercise of the underwriters&#146; option to purchase additional shares, based on the number of shares outstanding as of June&nbsp;30, 2024; or </P></TD></TR></TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the average weekly trading volume of our common stock on the Nasdaq Global Market during the four calendar weeks preceding
the filing of a notice on Form&nbsp;144 with respect to the sale; </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">provided, in each case, that we are subject to the Exchange Act periodic
reporting requirements for at least 90&nbsp;days before the sale. Such sales both by affiliates and by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> must also comply with the manner of sale, current public information and notice provisions
of Rule&nbsp;144. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Rule&nbsp;701 </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Rule&nbsp;701 under the Securities
Act, as in effect on the date of this prospectus, permits resales of shares in reliance upon Rule&nbsp;144 but without compliance with certain restrictions of Rule&nbsp;144, including the holding period requirement. Most of our employees, executive
officers, or directors who purchased shares under a written compensatory plan or contract may be entitled to rely on the resale provisions of Rule&nbsp;701, but all holders of Rule&nbsp;701 shares are required to wait until 90 days after the date of
this prospectus before selling their shares. However, substantially all Rule&nbsp;701 shares are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements as described below and under the section titled &#147;Underwriting&#148; included
elsewhere in this prospectus and will become eligible for sale upon the expiration of the restrictions set forth in those agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">220 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> agreements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We, all of our directors and executive officers, and the holders of all of our capital stock and securities convertible into or exchangeable for our capital stock have
entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters and/or are subject to market standoff agreements or other agreements with us, which prevents them from selling any of our common stock or any securities
convertible into or exercisable or exchangeable for common stock for a period of not less than 180&nbsp;days from the date of this prospectus without the prior written consent of the representatives, subject to certain exceptions. See the section
titled &#147;Underwriting&#148; included elsewhere in this prospectus for more information. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Registration rights </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon completion of this offering, certain holders of our securities will be entitled to various rights with respect to registration of their shares under the Securities
Act. Registration of these shares under the Securities Act would result in these shares becoming fully tradable without restriction under the Securities Act immediately upon the effectiveness of the registration. See the section titled
&#147;Description of capital stock&#151;Registration rights&#148; included elsewhere in this prospectus for more information. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Equity incentive plans
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend to file one or more registration statements on <FONT STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> under the Securities Act to register our shares
issued or reserved for issuance under our equity incentive plans. The first such registration statement is expected to be filed soon after the date of this prospectus and will automatically become effective upon filing with the SEC. Accordingly,
shares registered under such registration statement will be available for sale in the open market, unless such shares are subject to vesting restrictions with us or the <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions described above.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">221 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc843142_18"></A>Material U.S. federal income tax considerations for&nbsp;non-U.S. holders of common stock
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following discussion is a summary of material U.S. federal income tax consequences to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders (as defined
below) of the purchase, ownership and disposition of our common stock issued pursuant to this offering. This discussion is based on the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), Treasury Regulations promulgated thereunder,
judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service (the &#147;IRS&#148;), all as in effect on the date hereof. These authorities are subject to differing interpretations and may change,
possibly retroactively, resulting in U.S. federal income tax consequences different from those discussed below. We have not requested a ruling from the IRS with respect to the statements made and the conclusions reached in the following summary, and
there can be no assurance that the IRS or a court will agree with such statements and conclusions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This discussion is limited to
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders who purchase our common stock pursuant to this offering and who hold our common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property
held for investment). This discussion is not a complete analysis of all potential U.S. federal income tax consequences relating thereto, does not address the potential application of the Medicare contribution tax on net investment income, the
alternative minimum tax, or the special tax accounting rules under Section&nbsp;451(b) of the Code, and also does not address any U.S. federal <FONT STYLE="white-space:nowrap">non-income</FONT> tax consequences, such as estate or gift tax
consequences, or any tax consequences arising under any state, local or foreign tax laws. This discussion does not address all of the U.S. federal income tax consequences that may be relevant to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder in light of such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s particular circumstances. This discussion also does not consider any specific facts or circumstances that may be relevant to
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders subject to special rules under the U.S. federal income tax laws, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">U.S. expatriates, former citizens, or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">partnerships or other entities or arrangements treated as pass-through or disregarded entities for U.S. federal income tax
purposes (and investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#147;controlled foreign corporations&#148;; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#147;passive foreign investment companies&#148;; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">corporations that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">banks, financial institutions, investment funds, insurance companies, brokers, dealers or traders in securities;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations and governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons who acquire our common stock through the exercise of an option or otherwise as compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">qualified foreign pension funds as defined in Section&nbsp;897(l)(2) of the Code and entities all of the interests of which
are held by qualified foreign pension funds; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons that elect to apply <FONT STYLE="white-space:nowrap">Section&nbsp;1400Z-2</FONT> of the Code to gains recognized
with respect to shares of our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons that own or have owned, actually or constructively, more than 5% of our common stock; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">222 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons who have elected to mark securities to market; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons holding our common stock as part of a hedging or conversion transaction or straddle, or synthetic security or a
constructive sale, or other risk reduction strategy or integrated investment. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If an entity or arrangement that is classified as a partnership for
U.S. federal income tax purposes holds our common stock, the U.S. federal income tax treatment of a partner in the partnership will generally depend on the status of the partner, the activities of the partnership and certain determinations made at
the partner level. Partnerships holding our common stock and the partners in such partnerships are urged to consult their tax advisors about the particular U.S. federal income tax consequences to them of holding and disposing of our common stock.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. PROSPECTIVE INVESTORS SHOULD CONSULT THEIR TAX ADVISORS REGARDING THE PARTICULAR U.S.
FEDERAL INCOME TAX CONSEQUENCES TO THEM OF ACQUIRING, OWNING AND DISPOSING OF OUR COMMON STOCK, AS WELL AS ANY TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL OR FOREIGN TAX LAWS AND ANY OTHER U.S. FEDERAL TAX LAWS OR UNDER ANY APPLICABLE INCOME TAX
TREATY. </B></P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Definition of <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is any beneficial owner of our common stock that is for U.S. federal income
tax purposes: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a <FONT STYLE="white-space:nowrap">non-resident</FONT> alien individual; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a corporation or any organization taxable as a corporation for U.S. federal income taxes that is not created or organized
under the laws of the United States, any state thereof, or the District of Columbia; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a foreign trust or estate, the income of which is not subject to U.S. federal income tax on a net income basis.
</P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Distributions on our common stock </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As described under
&#147;Dividend policy,&#148; we do not currently anticipate declaring or paying, for the foreseeable future, any distributions on our capital stock. However, if we were to distribute cash or other property on our common stock, such distributions
will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Subject to the discussion below regarding effectively connected income, backup withholding and FATCA (as defined below), dividends paid to a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder of our common stock generally will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends or such lower rate specified by an applicable income tax treaty. To
receive the benefit of a reduced treaty rate, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder must furnish us or our withholding agent with a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> (in the case of individuals) or IRS
Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (in the case of entities), or other appropriate form, certifying such holder&#146;s qualification for the reduced rate. This certification must be provided
to us or our withholding agent before the payment of the dividends and must be updated periodically. If the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds our common stock through a financial institution or other agent acting on the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s behalf, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be required to provide appropriate documentation to the agent, which then will be required to provide certification to
us or our withholding agent, either directly or through other intermediaries. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds our common stock in
connection with the conduct of a trade or business in the United States, and dividends paid on our common stock are effectively connected with such holder&#146;s U.S. trade or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">223 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
business (and are attributable to such holder&#146;s permanent establishment or fixed base in the United States if required by an applicable tax treaty), the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be exempt from U.S. federal withholding tax. To claim the exemption, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder must generally furnish a valid IRS Form <FONT
STYLE="white-space:nowrap">W-8ECI</FONT> (or applicable successor form) , certifying that the dividends are effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the
United States to the applicable withholding agent. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">However, any such effectively connected dividends paid on our common stock generally will be subject to U.S.
federal income tax on a net income basis at the regular U.S. federal income tax rates in the same manner as if such holder were a resident of the United States. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a foreign corporation
also may be subject to an additional branch profits tax equal to 30% (or such lower rate specified by an applicable income tax treaty) of its effectively connected dividends, as adjusted for certain items. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders that do not provide the required certification on a timely basis, but that qualify for a reduced treaty rate,
may obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding any applicable income tax treaties
that may provide for different rules. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and will first
be applied against and reduce a holder&#146;s tax basis in our common stock, but not below zero. Any excess will be treated as gain realized on the sale or other disposition of our common stock and will be treated as described under the section
titled &#147;<I>&#151;</I>Gain on disposition of our common stock&#148; below. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Gain on disposition of our common stock </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Subject to the discussion below regarding backup withholding and FATCA (as defined below), a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will not
be subject to U.S. federal income tax on any gain realized on the sale or other taxable disposition of our common stock, unless: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct of a
trade or business in the United States and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual who is present in the United
States for a period or periods aggregating 183 days or more during the taxable year of the disposition, and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our common stock constitutes a &#147;United States real property interest&#148; by reason of our status as a United States
real property holding corporation (&#147;USRPHC&#148;) for U.S. federal income tax purposes at any time within the shorter of the five-year period preceding the disposition or the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s
holding period for our common stock, and our common stock is not &#147;regularly traded&#148; on an established securities market during the calendar year in which the sale or other disposition occurs. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Gain described in the first bullet point above generally will be subject to U.S. federal income tax on a net income basis at the regular U.S. federal income tax rates in
the same manner as if such holder were a resident of the United States. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a foreign corporation also may be subject to an additional branch profits tax equal to 30% (or such lower rate
specified by an applicable income tax treaty) of its effectively connected earnings and profits for the taxable year, as adjusted for certain items. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Gain described
in the second bullet point above will be subject to U.S. federal income tax at a flat 30% rate (or such lower rate specified by an applicable income tax treaty), but may be offset by certain U.S.-source capital losses of the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> Holder (even though the individual is not considered a resident of the United States), provided that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder has timely filed U.S. federal income tax
returns with respect to such losses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">224 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Determining whether we are a USRPHC depends on the fair market value of our U.S. real property interests relative to the
fair market value of our worldwide real property interests and our other trade or business assets. We believe that we are not currently and we do not anticipate becoming a USRPHC for U.S. federal income tax purposes, although there can be no
assurance we will not in the future become a USRPHC. Even if we are treated as a USRPHC, gain realized by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder on a disposition of our common stock will not be subject to U.S. federal income tax
so long as (1)&nbsp;the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder owned, directly, indirectly and constructively, no more than 5% of our common stock at all times within the shorter of (a)&nbsp;the five-year period preceding the
disposition or (b)&nbsp;the holder&#146;s holding period and (2)&nbsp;our common stock is &#147;regularly traded&#148; on an established securities market within the meaning of applicable U.S. Treasury regulations. There can be no assurance that our
common stock qualifies as regularly traded on an established securities market for purposes of the rules described above. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding any applicable income tax treaties that may provide for different
rules. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Information reporting and backup withholding </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Annual reports are
required to be filed with the IRS and provided to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder indicating the amount of distributions on our common stock paid to such holder and the amount of any tax withheld with respect to those
distributions. These information reporting requirements apply even if no withholding was required because the distributions were effectively connected with the holder&#146;s conduct of a U.S. trade or business, or withholding was reduced or
eliminated by an applicable income tax treaty. This information also may be made available under a specific treaty or agreement with the tax authorities in the country in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or
is established. Backup withholding, currently at a 24% rate, generally will not apply to payments to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of distributions on or the gross proceeds of a disposition of our common stock provided
the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder furnishes the required certification for its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status, such as by providing a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT>
IRS Form <FONT STYLE="white-space:nowrap">W-8BEN-E</FONT> or IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> or otherwise establishes an exemption, and if the payor does not have actual knowledge, or reason to know, that the holder is a
U.S. person who is not an exempt recipient. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Backup withholding is not an additional tax. If any amount is withheld under the backup withholding rules, the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder should consult with a U.S. tax advisor regarding the possibility of and procedure for obtaining a refund or a credit against the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s U.S.
federal income tax liability, if any. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Withholding on foreign entities </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Sections 1471 through 1474 of the Code, which are commonly referred to as FATCA, impose a U.S. federal withholding tax of 30% on certain payments made to a &#147;foreign
financial institution&#148; (as specially defined under these rules) unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect and provide to the U.S. tax authorities substantial
information regarding certain U.S. account holders of such institution (which includes certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or an exemption applies. FATCA
also generally imposes a U.S. federal withholding tax of 30% on certain payments made to a <FONT STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (as specially defined under these rules) unless such entity provides the
withholding agent a certification that it does not have any &#147;substantial United States owners&#148; or provides information identifying certain direct and indirect U.S. owners of the entity or an exemption applies. An intergovernmental
agreement between the United States and an applicable foreign country may modify these requirements. Under certain circumstances, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder might be eligible for refunds or credits of such taxes. FATCA
currently applies to dividends paid on our common stock and would have applied also to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">225 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
payments of gross proceeds from the sale or other disposition of our common stock. However, proposed regulations under FATCA provide for the elimination of the federal withholding tax of 30%
applicable to gross proceeds of a sale or other disposition of from property of a type that can produce U.S. source dividends or interest. Under these proposed Treasury Regulations (which may be relied upon by taxpayers prior to finalization), FATCA
withholding does not apply to gross proceeds from sales or other dispositions of our common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prospective investors are encouraged to consult with their tax
advisors regarding the possible implications of FATCA on their investment in our common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS TAX ADVISOR REGARDING
THE TAX CONSEQUENCES OF PURCHASING, HOLDING AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY RECENT AND PROPOSED CHANGE IN APPLICABLE LAW, AS WELL AS TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL,
<FONT STYLE="white-space:nowrap">NON-U.S.</FONT> OR U.S. FEDERAL <FONT STYLE="white-space:nowrap">NON-INCOME</FONT> TAX LAWS. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">226 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc843142_19"></A>Underwriting </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are offering the shares of common stock described in this prospectus through a number of underwriters. J.P. Morgan Securities LLC, TD Securities (USA) LLC, Piper
Sandler&nbsp;&amp; Co. and William Blair&nbsp;&amp; Company, L.L.C. are acting as joint book-running managers of the offering and as representatives of the underwriters. We have entered into an underwriting agreement with the underwriters. Subject
to the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the public offering price less the underwriting discounts and commissions set forth on
the cover page of this prospectus, the number of shares of common stock listed next to its name in the following table: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Number&nbsp;of&nbsp;shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">TD Securities (USA) LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Piper Sandler&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">William Blair&nbsp;&amp; Company, L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="4" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters are committed to purchase all the shares of common stock offered by us if they purchase any shares. The
underwriting agreement also provides that if an underwriter defaults, the purchase commitments of <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may also be increased or the offering may be terminated. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters propose to offer the common stock directly to the public at the initial public offering price set forth on the cover page of this prospectus and to
certain dealers at that price less a concession not in excess of $&#8195;&#8195;&#8195;&#8195;per share. After the initial offering of the shares to the public, if all of the shares of common stock are not sold at the initial public offering price,
the underwriters may change the offering price and the other selling terms. Sales of any shares made outside of the United States may be made by affiliates of the underwriters. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters have an option to buy up to 1,875,000 additional shares of common stock from us to cover sales of shares by the underwriters which exceed the number of
shares specified in the table above. The underwriters have 30 days from the date of this prospectus to exercise this option to purchase additional shares. If any shares are purchased with this option to purchase additional shares, the underwriters
will purchase shares in approximately the same proportion as shown in the table above. If any additional shares of common stock are purchased, the underwriters will offer the additional shares on the same terms as those on which the shares are being
offered. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriting fee is equal to the public offering price per share of common stock less the amount paid by the underwriters to us per share of
common stock. The underwriting fee is $&#8195;&#8195;&#8195;&#8195;per share. The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters assuming both no exercise and full exercise of the
underwriters&#146; option to purchase additional shares. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Without&nbsp;option&nbsp;to<BR>purchase&nbsp;additional<BR>shares exercise</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>With full option to<BR>purchase&nbsp;additional<BR>shares exercise</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We estimate that the total expenses of this offering, including registration, filing and listing fees, printing fees and legal and
accounting expenses, but excluding the underwriting discounts and commissions, will be approximately $4.0 million. We have agreed to reimburse the underwriters for expenses relating to the clearance of this offering with the Financial Industry
Regulatory Authority, Inc. in an amount up to $40,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">227 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A prospectus in electronic format may be made available on the web sites maintained by one or more underwriters, or selling
group members, if any, participating in the offering. The underwriters may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by
the representatives to underwriters and selling group members that may make Internet distributions on the same basis as other allocations. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have agreed that we
will not, subject to certain exceptions, (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, hedge, lend, or otherwise
transfer or dispose of, directly or indirectly, or submit to, or file with, the SEC a registration statement under the Securities Act relating to, any shares of our common stock or any securities convertible into or exercisable or exchangeable for
any shares of our common stock, or (ii)&nbsp;enter into any swap, hedging, or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of any shares of common stock or any such other securities, or publicly
disclose the intention to undertake any of the foregoing (regardless of whether any of these transactions are to be settled by the delivery of shares of common stock or such other securities, in cash or otherwise), in each case without the prior
written consent of J.P. Morgan Securities LLC, TD Securities (USA) LLC, Piper Sandler&nbsp;&amp; Co. and William Blair&nbsp;&amp; Company, L.L.C. for a period of 180 days after the date of this prospectus, other than the shares of our common stock
to be sold in this offering. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The restrictions on our actions, as described above, do not apply to certain transactions, including (i)&nbsp;the issuance of
shares of common stock or securities convertible into or exercisable for shares of our common stock pursuant to the conversion or exchange of convertible or exchangeable securities or the exercise of warrants or options (including net exercise) or
the settlement of RSUs (including net settlement), in each case outstanding on the date of the underwriting agreement and described in this prospectus; (ii)&nbsp;grants of stock options, stock awards, restricted stock, RSUs, or other equity awards
and the issuance of shares of common stock or securities convertible into or exercisable or exchangeable for shares of our common stock (whether upon the exercise of stock options or otherwise) to our employees, officers, directors, advisors, or
consultants pursuant to the terms of an equity compensation plan in effect as of the closing date of this offering and described in this prospectus; (iii)&nbsp;the issuance of up to 10% of the outstanding shares of common stock, or securities
convertible into, exercisable for, or which are otherwise exchangeable for, common stock, immediately following the closing date of this offering, in acquisitions or other similar strategic transactions, provided that such recipients enter into a <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreement with the underwriters; or (iv)&nbsp;the filing of any registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> relating to securities granted or to be granted pursuant to any plan
in effect on the date of the underwriting agreement and described in this prospectus or any assumed benefit plan pursuant to an acquisition or similar strategic transaction. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our directors and executive officers, and all of our securityholders (such persons, the <FONT STYLE="white-space:nowrap">&#147;lock-up</FONT> parties&#148;) have entered
into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters prior to the commencement of this offering pursuant to which each <FONT STYLE="white-space:nowrap">lock-up</FONT> party, with limited exceptions, for a period of
180 days after the date of this prospectus (such period, the &#147;restricted period&#148;), may not and may not cause any of their direct or indirect affiliates to, without the prior written consent of J.P. Morgan Securities LLC, TD Securities
(USA) LLC, Piper Sandler&nbsp;&amp; Co. and William Blair&nbsp;&amp; Company, L.L.C., (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to
purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any securities convertible into or exercisable or exchangeable for our common stock (including without limitation, our common stock or
such other securities which may be deemed to be beneficially owned by the <FONT STYLE="white-space:nowrap">lock-up</FONT> party in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock
option or warrant) (collectively with the common stock, the <FONT STYLE="white-space:nowrap">&#147;lock-up</FONT> securities&#148;), (ii) enter into any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">228 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic consequences of ownership of the <FONT STYLE="white-space:nowrap">lock-up</FONT>
securities, whether any such transaction described in clause (i)&nbsp;or (ii) above is to be settled by delivery of the <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, in cash or otherwise, (iii)&nbsp;make any demand for or exercise any
right with respect to the registration of any the <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, or (iv)&nbsp;publicly disclose the intention to do any of the foregoing. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Such persons or entities have further acknowledged that these undertakings preclude them from engaging in any hedging or other transactions or arrangements (including,
without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) designed or intended, or
which could reasonably be expected to lead to or result in, a sale or disposition or transfer (whether by the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or any other person) of any economic consequences of ownership, in whole or in part,
directly or indirectly, of any <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of
<FONT STYLE="white-space:nowrap">lock-up</FONT> securities, in cash or otherwise. Such persons or entities further confirm that they have furnished the representatives with the details of any transaction such persons or entities, or any of their
respective affiliates, is a party to as of the date hereof, which transaction would have been restricted by the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements if it had been entered into by such persons or entities during the restricted
period. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The restrictions described in the immediately preceding paragraph and contained in the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements between
the underwriters and the <FONT STYLE="white-space:nowrap">lock-up</FONT> parties do not apply, subject in certain cases to various conditions, to certain transactions, including (a)&nbsp;transfers or disposals of
<FONT STYLE="white-space:nowrap">lock-up</FONT> securities: (i)&nbsp;as bona fide gifts, as a charitable contribution or for bona fide estate planning purposes, (ii)&nbsp;by will or intestacy or any other testamentary document, (iii)&nbsp;to any
trust for the direct or indirect benefit of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or any immediate family member, (iv)&nbsp;to a corporation, partnership, limited liability company, investment fund or other entity (A)&nbsp;of
which the <FONT STYLE="white-space:nowrap">lock-up</FONT> party and/or its immediate family members are the legal and beneficial owner of all of the outstanding equity securities or similar interests, or (B)&nbsp;controlled by, or under common
control with, the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or the immediate family of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party, (v)&nbsp;to a nominee or custodian of a person or entity to whom a disposition or transfer
would be permissible under clauses (i)&nbsp;through (iv), (vi) in the case of a corporation, partnership, limited liability company, trust or other business entity, (A)&nbsp;to another corporation, partnership, limited liability company, trust or
other business entity that is a wholly owned subsidiary or an affiliate of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party, or to any investment fund or other entity controlling, controlled by, managing or managed by or under common
control with the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or its affiliates or (B)&nbsp;as part of a dispositions, transfer or distribution to limited partners, members or stockholders of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> party; (vii)&nbsp;by operation of law, (viii)&nbsp;to us (A) from an employee upon death, disability or termination of employment of such employee or (B) pursuant to a right of first refusal that we
have with respect to transfers of such shares of our common stock or other securities, provided that such right is described in this prospectus, (ix)&nbsp;after the completion of this offering, as part of a transaction related to of <FONT
STYLE="white-space:nowrap">lock-up</FONT> securities acquired in (A) this offering or (B) open market transactions on or after the date of this prospectus, (x)&nbsp;to us in connection with the vesting, settlement or exercise of restricted stock
units, options, warrants or other rights to purchase shares of our common stock (including &#147;net&#148; or &#147;cashless&#148; exercise), including for the payment of exercise price and tax and remittance payments, (xi)&nbsp;pursuant to a bona
fide third-party tender offer, merger, consolidation or other similar transaction approved by our board of directors and made to all stockholders involving a change in control, and enter into any <FONT STYLE="white-space:nowrap">lock-up,</FONT>
voting or similar agreement pursuant to which the <FONT STYLE="white-space:nowrap">lock-up</FONT> party may agree to transfer, sell, tender or otherwise dispose of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities in connection with such a
transaction, provided that if such transaction is not completed, all such <FONT STYLE="white-space:nowrap">lock-up</FONT> securities would remain subject to the restrictions in the immediately preceding paragraph (xii) to an immediate family member
of the lock-up party; or (xiii) to us in connection with the transfer of shares of our common stock pursuant to option agreements relating to the early exercise by the lock-up party of unvested options issued pursuant to the our equity incentive
plans, which plans are in each case described in this prospectus, under which we have the right to repurchase such shares and only </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">229 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
to the extent we elect to exercise such right; (b)&nbsp;exercise of the options, settlement of RSUs or other equity awards, or the exercise of warrants granted pursuant to plans described in in
this prospectus, provided that any <FONT STYLE="white-space:nowrap">lock-up</FONT> securities received upon such exercise, vesting or settlement would be subject to restrictions similar to those in the immediately preceding paragraph; (c)&nbsp;the
conversion of outstanding preferred stock, warrants to acquire preferred stock, or convertible securities into shares of our common stock or warrants to acquire shares of our common stock, provided that any common stock or warrant received upon such
conversion would be subject to restrictions similar to those in the immediately preceding paragraph; (d)&nbsp;the establishment or modification by <FONT STYLE="white-space:nowrap">lock-up</FONT> parties of trading plans under Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act, provided that such plan does not provide for the transfer of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities during the restricted period; and (e) sell shares of our common
stock to be sold by the undersigned pursuant to the terms of the underwriting agreement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">J.P. Morgan Securities LLC, TD Securities (USA) LLC, Piper
Sandler&nbsp;&amp; Co. and William Blair&nbsp;&amp; Company, L.L.C., in their sole discretion, may release the securities subject to any of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters described above, in
whole or in part at any time. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have applied to have our common stock approved for listing on the Nasdaq Global Market (&#147;Nasdaq&#148;) under the symbol &#147;UPB,&#148; and this offering is
contingent upon obtaining such approval. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with this offering, the underwriters may engage in stabilizing transactions, which involves making bids for,
purchasing and selling shares of common stock in the open market for the purpose of preventing or retarding a decline in the market price of the common stock while this offering is in progress. These stabilizing transactions may include making short
sales of common stock, which involves the sale by the underwriters of a greater number of shares of common stock than they are required to purchase in this offering, and purchasing shares of common stock on the open market to cover positions created
by short sales. Short sales may be &#147;covered&#148; shorts, which are short positions in an amount not greater than the underwriters&#146; option to purchase additional shares referred to above, or may be &#147;naked&#148; shorts, which are short
positions in excess of that amount. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters may close out any covered short position either by exercising their option to purchase additional shares, in
whole or in part, or by purchasing shares in the open market. In making this determination, the underwriters will consider, among other things, the price of shares available for purchase in the open market compared to the price at which the
underwriters may purchase shares through the option to purchase additional shares. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open
market that could adversely affect investors who purchase in this offering. To the extent that the underwriters create a naked short position, they will purchase shares in the open market to cover the position. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters have advised us that, pursuant to Regulation M of the Securities Act, they may also engage in other activities that stabilize, maintain or otherwise
affect the price of the common stock, including the imposition of penalty bids. This means that if the representatives of the underwriters purchase common stock in the open market in stabilizing transactions or to cover short sales, the
representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discount received by them. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These activities
may have the effect of raising or maintaining the market price of the common stock or preventing or retarding a decline in the market price of the common stock, and, as a result, the price of the common stock may be higher than the price that
otherwise might exist in the open market. If the underwriters </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">230 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
commence these activities, they may discontinue them at any time. The underwriters may carry out these transactions on Nasdaq, in the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prior to this offering, there has been no public market for our common stock. The
initial public offering price will be determined by negotiations between us and the representatives of the underwriters. In determining the initial public offering price, we and the representatives of the underwriters expect to consider a number of
factors including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the information set forth in this prospectus and otherwise available to the representatives; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our prospects and the history and prospects for the industry in which we compete; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an assessment of our management; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our prospects for future earnings; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the general condition of the securities markets at the time of this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the recent market prices of, and demand for, publicly traded common stock of generally comparable companies; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">other factors deemed relevant by the underwriters and us. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Neither we nor the underwriters can assure investors that an active trading market will develop for shares of our common stock, or that the shares will trade in the
public market at or above the initial public offering price. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Other relationships </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may provide from time to time in the future certain commercial
banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and may continue to receive customary fees and commissions. In addition, from time
to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or their customers, long or short positions in our debt or equity securities or
loans, and may do so in the future. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Selling restrictions </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Other than in
the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this
prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction,
except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions
relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a
solicitation is unlawful. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in the European Economic Area </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In relation to each Member State of the European Economic Area (each a &#147;Relevant State&#148;), no shares have been offered or will be offered pursuant to the
offering to the public in that Relevant State prior to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">231 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
publication of a prospectus in relation to the shares which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and
notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that offers of shares may be made to the public in that Relevant State at any time under the following exemptions under the
Prospectus Regulation: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined under Article 2 of the Prospectus Regulation; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the Prospectus Regulation), subject to obtaining the prior consent of the underwriters; or </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">provided that no such offer of
shares shall require us or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation, and each person who initially acquires any shares
or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the underwriters and to us that it is a &#147;qualified investor&#148; within the meaning of Article 2(e) of the Prospectus Regulation. In
the case of any shares being offered to a financial intermediary as that term is used in the Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the
offer have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any
shares to the public other than their offer or resale in a Relevant State to qualified investors as so defined or in circumstances in which the prior consent of the underwriters have been obtained to each such proposed offer or resale. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to shares in any Relevant State means the communication in any form and
by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU)
2017/1129. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in the United Kingdom </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">No
shares have been offered or will be offered pursuant to the offering to the public in the United Kingdom prior to the publication of a prospectus in relation to the shares which (i)&nbsp;has been approved by the Financial Conduct Authority or
(ii)&nbsp;is to be treated as if it had been approved by the Financial Conduct Authority in accordance with the transitional provisions in Article 74 (transitional provisions) of the Prospectus Amendment etc (EU Exit) Regulations 2019/1234, except
that the shares may be offered to the public in the United Kingdom at any time: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK Prospectus Regulation), subject to obtaining the prior consent of underwriters for any such offer; or
</TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Section&nbsp;86 of the FSMA. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">provided that no such offer of the shares shall
require the Issuer or any Manager to publish a prospectus pursuant to Section&nbsp;85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">232 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
Regulation. For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to the shares in the United Kingdom means the communication in any form and by any
means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares and the expression &#147;UK Prospectus Regulation&#148; means Regulation (EU)
2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, in the United Kingdom, this document is being
distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Regulation)&nbsp;(i) who have professional experience in matters
relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#147;Order&#148;) and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may
otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)&nbsp;of the Order (all such persons together being referred to as &#147;relevant persons&#148;) or otherwise in circumstances which have not resulted and will not result in
an offer to the public of the shares in the United Kingdom within the meaning of the Financial Services and Markets Act 2000. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any person in the United Kingdom that
is not a relevant person should not act or rely on the information included in this document or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken
exclusively by relevant persons. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Canada </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument <FONT
STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> Registration
Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any
amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The
purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts
<FONT STYLE="white-space:nowrap">(&#147;NI&nbsp;33-105&#148;),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in
connection with this offering. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Switzerland </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus does not constitute an offer to the public or a solicitation to purchase or invest in any shares. No shares have been offered or will be offered to the
public in Switzerland, except that offers of shares may be made to the public in Switzerland at any time under the following exemptions under the Swiss Financial Services Act (&#147;FinSA&#148;): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to any person which is a professional client as defined under the FinSA; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 500 persons (other than professional clients as defined under the FinSA), subject to obtaining the prior consent of the representatives of the underwriters for any such offer; or </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">233 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 36 FinSA in connection with Article 44 of the Swiss Financial Services Ordinance, provided that no such offer of shares shall require the Company or any investment bank
to publish a prospectus pursuant to Article 35 FinSA. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares have not been and will not be listed or admitted to trading on a trading venue in
Switzerland. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Neither this document nor any other offering or marketing material relating to the shares constitutes a prospectus as such term is understood pursuant
to the FinSA and neither this document nor any other offering or marketing material relating to the shares may be publicly distributed or otherwise made publicly available in Switzerland. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in the Dubai International Financial Centre </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This document relates to an Exempt Offer in accordance with the Markets Law, DIFC Law No.&nbsp;1 of 2012, as amended. This document is intended for distribution only to
persons of a type specified in the Markets Law, DIFC Law No.&nbsp;1 of 2012, as amended. It must not be delivered to, or relied on by, any other person. The Dubai Financial Services Authority (&#147;DFSA&#148;) has no responsibility for reviewing or
verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify the information set forth herein and has no responsibility for this document. The securities to which this
document relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand the contents of this document you
should consult an authorized financial advisor. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In relation to its use in the DIFC, this document is strictly private and confidential and is being distributed to a
limited number of investors and must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose. The interests in the securities may not be offered or sold directly or indirectly to the
public in the DIFC. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in the United Arab Emirates </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates (including the Dubai International Financial
Centre) other than in compliance with the laws of the United Arab Emirates (and the Dubai International Financial Centre) governing the issue, offering and sale of securities. Further, this prospectus does not constitute a public offer of securities
in the United Arab Emirates (including the Dubai International Financial Centre) and is not intended to be a public offer. This prospectus has not been approved by or filed with the Central Bank of the United Arab Emirates, the Securities and
Commodities Authority, Financial Services Regulatory Authority (&#147;FSRA&#148;) or the DFSA. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Australia </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">does not constitute a disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001 (Cth) (the
&#147;Corporations Act&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">has not been, and will not be, lodged with the Australian Securities and Investments Commission (&#147;ASIC&#148;), as a
disclosure document for the purposes of the Corporations Act and does not purport to include the information required of a disclosure document for the purposes of the Corporations Act; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">may only be provided in Australia to select investors who are able to demonstrate that they fall within one or more of the
categories of investors, available under section 708 of the Corporations Act (&#147;Exempt Investors&#148;). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">234 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares may not be directly or indirectly offered for subscription or purchased or sold, and no invitations to subscribe
for or buy the shares may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any shares may be distributed in Australia, except where disclosure to investors is not required under Chapter
6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the shares, you represent and warrant to us that you are an Exempt Investor. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As any offer of shares of our common stock under this prospectus will be made without disclosure in Australia under Chapter 6D.2 of the Corporations Act, the offer of
those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter 6D.2 if none of the exemptions in section 708 applies to that resale. By applying for the shares
of our common stock you undertake to us that you will not, for a period of 12 months from the date of issue of the shares, offer, transfer, assign or otherwise alienate those shares of our common stock to investors in Australia except in
circumstances where disclosure to investors is not required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Japan </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares have not been and will
not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act. Accordingly, none of the shares nor any interest therein may be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any
&#147;resident&#148; of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or
resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any
other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Hong Kong </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to &#147;professional
investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the &#147;SFO&#148;) of Hong Kong and any rules made thereunder; or (b)&nbsp;in other circumstances which do not result in the document being a
&#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong) (the &#147;CO&#148;) or which do not constitute an offer to the public within the meaning of the CO. No advertisement,
invitation or document relating to the shares has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to
be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to
&#147;professional investors&#148; as defined in the SFO and any rules made thereunder. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Singapore </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each underwriter has acknowledged that this prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, each underwriter
has represented and agreed that it has not offered or sold any shares or caused the shares to be made the subject of an invitation for subscription or purchase and will not offer or sell any shares or cause the shares to be made the subject of an
invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this prospectus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">235 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
or any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares, whether directly or indirectly, to any person in Singapore other
than: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289) of Singapore, as modified or amended from time to time (the &#147;SFA&#148;)) pursuant to Section&nbsp;274 of
the SFA; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified
in Section&nbsp;275 of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals,
each of whom is an accredited investor; or </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, </TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">securities or securities-based derivatives contracts (each term as defined in Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries&#146; rights and
interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section&nbsp;275 of the SFA except: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(c)(ii) of the SFA; </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where no consideration is or will be given for the transfer; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where the transfer is by operation of law; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as specified in Section&nbsp;276(7) of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives Contracts) Regulations 2018. </TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Singapore SFA Product Classification</I>&#151;In connection with Section&nbsp;309B of the SFA and the CMP Regulations 2018, unless otherwise specified before an offer
of shares of our common stock, we have determined, and hereby notify all relevant persons (as defined in Section&nbsp;309A(1) of the SFA), that the shares of common stock are &#145;&#145;prescribed capital markets products&#146;&#146; (as defined in
the CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA <FONT STYLE="white-space:nowrap">04-N12:</FONT> Notice on the Sale of Investment Products and MAS Notice <FONT STYLE="white-space:nowrap">FAA-N16:</FONT> Notice
on Recommendations on Investment Products). </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Bermuda </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Shares may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of Bermuda which regulates the sale of securities
in Bermuda. Additionally, <FONT STYLE="white-space:nowrap">non-Bermudian</FONT> persons (including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted to do so under applicable Bermuda
legislation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">236 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Saudi Arabia </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This document may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Rules on the Offer of Securities and Continuing
Obligations Regulations as issued by the board of the Saudi Arabian Capital Market Authority (&#147;CMA&#148;) pursuant to resolution number <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">3-123-2017</FONT></FONT> dated
27&nbsp;December 2017, as amended (the &#147;CMA Regulations&#148;). The CMA does not make any representation as to the accuracy or completeness of this document and expressly disclaims any liability whatsoever for any loss arising from, or incurred
in reliance upon, any part of this document. Prospective purchasers of the securities offered hereby should conduct their own due diligence on the accuracy of the information relating to the securities. If you do not understand the contents of this
document, you should consult an authorised financial adviser. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in the British Virgin Islands </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares are not being, and may not be offered to the public or to any person in the British Virgin Islands for purchase or subscription by or on behalf of us. The
shares may be offered to companies incorporated under the BVI Business Companies Act, 2004 (British Virgin Islands), &#147;BVI Companies&#148;), but only where the offer will be made to, and received by, the relevant BVI Company entirely outside of
the British Virgin Islands. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in China </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus will not be circulated or distributed in the PRC and the shares will not be offered or sold, and will not be offered or sold to any person for <FONT
STYLE="white-space:nowrap">re-offering</FONT> or resale directly or indirectly to any residents of the PRC (for such purposes, not including the Hong Kong and Macau Special Administrative Regions or Taiwan), except pursuant to any applicable laws
and regulations of the PRC. Neither this prospectus nor any advertisement or other offering material may be distributed or published in the PRC, except under circumstances that will result in compliance with applicable laws and regulations. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Korea </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares have not been and will
not be registered under the Financial Investments Services and Capital Markets Act of Korea and the decrees and regulations thereunder (the &#147;FSCMA&#148;), and the shares have been and will be offered in Korea as a private placement under the
FSCMA. None of the shares may be offered, sold or delivered directly or indirectly, or offered or sold to any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Korea or to any resident of Korea
except pursuant to the applicable laws and regulations of Korea, including the FSCMA and the Foreign Exchange Transaction Law of Korea and the decrees and regulations thereunder (the &#147;FETL&#148;). Furthermore, the purchaser of the shares shall
comply with all applicable regulatory requirements (including but not limited to requirements under the FETL) in connection with the purchase of the shares. By the purchase of the shares, the relevant holder thereof will be deemed to represent and
warrant that if it is in Korea or is a resident of Korea, it purchased the shares pursuant to the applicable laws and regulations of Korea. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to
prospective investors in Malaysia </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">No prospectus or other offering material or document in connection with the offer and sale of the shares has been or will be
registered with the Securities Commission of Malaysia (&#147;Commission&#148;) for the Commission&#146;s approval pursuant to the Capital Markets and Services Act 2007. Accordingly, this prospectus and any other document or material in connection
with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or
indirectly, to persons in Malaysia other than (i)&nbsp;a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">237 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
closed end fund approved by the Commission; (ii)&nbsp;a holder of a Capital Markets Services Licence; (iii)&nbsp;a person who acquires the shares, as principal, if the offer is on terms that the
shares may only be acquired at a consideration of not less than RM250,000 (or its equivalent in foreign currencies) for each transaction; (iv)&nbsp;an individual whose total net personal assets or total net joint assets with his or her spouse
exceeds RM3&nbsp;million (or its equivalent in foreign currencies), excluding the value of the primary residence of the individual; (v)&nbsp;an individual who has a gross annual income exceeding RM300,000 (or its equivalent in foreign currencies)
per annum in the preceding twelve months; (vi)&nbsp;an individual who, jointly with his or her spouse, has a gross annual income of RM400,000 (or its equivalent in foreign currencies), per annum in the preceding twelve months; (vii)&nbsp;a
corporation with total net assets exceeding RM10&nbsp;million (or its equivalent in a foreign currencies) based on the last audited accounts; (viii)&nbsp;a partnership with total net assets exceeding RM10&nbsp;million (or its equivalent in foreign
currencies); (ix) a bank licensee or insurance licensee as defined in the Labuan Financial Services and Securities Act 2010; (x) an Islamic bank licensee or takaful licensee as defined in the Labuan Financial Services and Securities Act 2010; and
(xi)&nbsp;any other person as may be specified by the Commission; provided that, in the each of the preceding categories (i)&nbsp;to (xi), the distribution of the shares is made by a holder of a Capital Markets Services License who carries on the
business of dealing in securities. The distribution in Malaysia of this prospectus is subject to Malaysian laws. This prospectus does not constitute and may not be used for the purpose of public offering or an issue, offer for subscription or
purchase, invitation to subscribe for or purchase any securities requiring the registration of a prospectus with the Commission under the Capital Markets and Services Act 2007. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Taiwan </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares have not been and will
not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an offer
within the meaning of the Securities and Exchange Act of Taiwan that requires a registration or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorised to offer, sell, give advice regarding or
otherwise intermediate the offering and sale of the shares in Taiwan. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in South Africa </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Due to restrictions under the securities laws of South Africa, no &#147;offer to the public&#148; (as such term is defined in the South African Companies Act,
No.&nbsp;71 of 2008 (as amended or <FONT STYLE="white-space:nowrap">re-enacted)</FONT> (the &#147;South African Companies Act&#148;) is being made in connection with the issue of the shares in South Africa. Accordingly, this document does not, nor
is it intended to, constitute a &#147;registered prospectus&#148; (as that term is defined in the South African Companies Act) prepared and registered under the South African Companies Act and has not been approved by, and/or filed with, the South
African Companies and Intellectual Property Commission or any other regulatory authority in South Africa. The shares are not offered, and the offer shall not be transferred, sold, renounced or delivered, in South Africa or to a person with an
address in South Africa, unless one or other of the following exemptions stipulated in section 96 (1) applies: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="81%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">Section&nbsp;96 (1) (a)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">the offer, transfer, sale, renunciation or delivery is to:</P> <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(i) persons whose ordinary business, or part of whose ordinary business, is to deal in securities, as principal or agent;</P>
<P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(ii) the South African Public Investment Corporation;</P>
<P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(iii) persons or entities regulated by the Reserve Bank of South Africa;</P>
<P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial">(iv) authorised financial service providers under South African
law;</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">238 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="81%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(v) financial institutions recognised as such under South African law;</P>
<P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(vi) a wholly-owned subsidiary of any person or entity contemplated in (c), (d) or (e), acting as
agent in the capacity of an authorised portfolio manager for a pension fund, or as manager for a collective investment scheme (in each case duly registered as such under South African law); or</P>
<P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial">(vii) any combination of the person in (i)&nbsp;to (vi); or</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">Section&nbsp;96 (1) (b)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">the total contemplated acquisition cost of the securities, for any single addressee acting as principal is equal to or greater than ZAR1,000,000 or such higher amount as may be promulgated by notice in the Government Gazette of
South Africa pursuant to section 96(2)(a) of the South African Companies Act.</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Information made available in this prospectus should not be considered as &#147;advice&#148; as defined in the South African Financial
Advisory and Intermediary Services Act, 2002. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Israel </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Israeli Securities Law, and has not been filed with or approved by
the Israel Securities Authority. In Israel, this prospectus is being distributed only to, and is directed only at, and any offer of the shares is directed only at, (i)&nbsp;a limited number of persons in accordance with the Israeli Securities Law
and (ii)&nbsp;investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors,
members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50&nbsp;million and &#147;qualified individuals,&#148; each as defined in the Addendum (as it may be amended from time to time), or,
collectively referred to as qualified investors (in each case, purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors are required to
submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">239 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc843142_20"></A>Legal matters </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The validity of the shares of common stock offered by this prospectus will be passed upon for us by Goodwin Procter LLP, Boston, Massachusetts. Certain legal matters
related to this offering will be passed upon for the underwriters by Cooley LLP, San Francisco, California. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc843142_21"></A>Experts </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The financial statements as of December&nbsp;31, 2023 and 2022 and for the years then ended included in this prospectus have been so included in reliance on the report
of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc843142_22"></A>Where you can find more information </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have filed with the SEC a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> (File
Number <FONT STYLE="white-space:nowrap">333-282197)</FONT> under the Securities Act with respect to the common stock we are offering by this prospectus. This prospectus does not contain all of the information included in the registration statement.
For further information pertaining to us and our common stock, you should refer to the registration statement and to its exhibits. Whenever we make reference in this prospectus to any of our contracts, agreements or other documents, the references
are not necessarily complete, and you should refer to the exhibits attached to the registration statement for copies of the actual contract, agreement or other document. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the completion of the offering, we will be subject to the informational requirements of the Exchange Act and will file annual, quarterly and current reports, proxy
statements and other information with the SEC. You can read our SEC filings, including the registration statement, at the SEC&#146;s website at www.sec.gov. We also maintain a website at www.upstreambio.com. We do not incorporate the information on
or accessible through our website into this prospectus, and you should not consider any information on, or that can be accessed through, our website as part of this prospectus. We have included our website address in this prospectus solely as an
inactive textual reference. Upon completion of the offering, you may access, free of charge, our annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current
reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and amendment to those reported filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after such material is electronically filed
with, or furnished to, the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">240 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A><A NAME="toc843142_23a"></A>Index to consolidated financial statements
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin843142_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin843142_2">Consolidated Balance Sheets as of December&nbsp;31, 2023 and
2022</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin843142_3">Consolidated Statements of Operations and Comprehensive Loss for the Years
 Ended December&nbsp;31, 2023 and 2022</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin843142_4">Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#146;
 Deficit for the Years Ended December&nbsp;31, 2023 and 2022</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin843142_5">Consolidated Statements of Cash Flows for the Years Ended December&nbsp;
31, 2023 and 2022</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin843142_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin843142_7">Unaudited Condensed Consolidated Balance Sheets as of June&nbsp;
30, 2024 and December&nbsp;31, 2023</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-39</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin843142_8">Unaudited Condensed Consolidated Statements of Operations and Comprehensive
 Loss for the Six&nbsp;Months Ended June&nbsp;30, 2024 and 2023</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-40</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin843142_9">Unaudited Condensed Consolidated Statements of Redeemable Convertible Preferred
 Stock and Stockholders&#146; Deficit for the Six Months Ended June&nbsp;30, 2024 and 2023</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-41</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin843142_10">Unaudited Condensed Consolidated Statements of Cash Flows for the Six Months
 Ended June&nbsp;30, 2024 and 2023</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-42</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin843142_11">Notes to Unaudited Condensed Consolidated Financial
Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-43</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin843142_1"></A>Report of independent registered public accounting firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Board of Directors and Stockholders of Upstream Bio, Inc.<B>&nbsp;</B> </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Opinion on the financial statements</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the
accompanying consolidated balance sheets of Upstream Bio, Inc. and its subsidiary (the &#147;Company&#148;) as of December&nbsp;31, 2023 and 2022, and the related consolidated statements of operations and comprehensive loss, of redeemable
convertible preferred stock and stockholders&#146; deficit and of cash flows for the years then ended, including the related notes (collectively referred to as the &#147;consolidated financial statements&#148;). In our opinion, the consolidated
financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended in conformity with accounting
principles generally accepted in the United States of America.&#8195; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Basis for opinion</I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These consolidated financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the
Company&#146;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the
Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and
perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the
accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June 12, 2024, except for the effects of the stock split discussed in Note 18 to the consolidated financial statements, as to which the date is October&nbsp;7,
2024</P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2022.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin843142_2"></A>Consolidated balance sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 25,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 17,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable - related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock tranche right liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock (Series A, B), $0.001 par value; 31,764,693 shares and
20,000,000 shares authorized at December&nbsp;31, 2023 and 2022, respectively; 22,941,170 shares and 12,000,000 shares issued and outstanding at December&nbsp;31, 2023 and 2022, respectively; aggregate liquidation preference of $267,718 and $126,886
at December&nbsp;31, 2023 and 2022, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">230,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;112,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value; 40,664,346 shares and 28,000,000 shares authorized at
December&nbsp;31, 2023 and 2022, respectively; 2,992,479 and 2,937,197 shares issued and outstanding at December&nbsp;31, 2023 and 2022, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(127,974</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(107,437</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(123,126</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(106,155</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, redeemable convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;117,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin843142_3"></A>Consolidated statements of operations and comprehensive loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue - related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(40,114</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,909</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock tranche right liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(115</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,537</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock cumulative dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,718</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(38,255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12.95</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8.13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8194;&#8195;2,953,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8194;&#8195;2,937,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,537</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gain on investments, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,516</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes related party amounts of $0.1&nbsp;million for the year ended December&nbsp;31, 2023 (Note&nbsp;16).
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin843142_4"></A>Consolidated statements of redeemable convertible preferred stock and stockholders&#146; deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands, except share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable Convertible<BR>Preferred Stock<BR></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Income</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balances at December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,937,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> -</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(83,569</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(83,566</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of Series A redeemable convertible preferred stock in connection with the partial
settlement of the tranche right liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8196;&#8199;&#8199;1,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balances at December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,937,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(107,437</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(106,155</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of Series A redeemable convertible preferred stock in connection with the settlement of
the tranche right liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of Series B redeemable convertible preferred stock, net of preferred stock tranche right
liability of $11,774 and issuance costs of $434</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,941,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Exercise of stock options, net of tax withholding</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation expense - related party</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Unrealized gain on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,537</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,537</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balances at December&nbsp;31, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8194;&#8195;22,941,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8194;&#8195;230,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;2,992,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8195;3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8195;4,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8201;(127,974</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8201;(123,126</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin843142_5"></A>Consolidated statements of cash flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,537</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense - related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock tranche right liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,527</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B issuance costs allocated to tranche right liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net amortization of premiums and accretion of discounts on short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,260</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable - related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(412</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,237</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(585</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other non-current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(82</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(37,926</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(128,990</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maturities of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(144</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(82</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(82,842</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(82</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the issuance of Series A redeemable convertible preferred stock<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments of issuance costs of Series A redeemable convertible preferred stock issued in prior
period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the issuance of Series B redeemable convertible preferred stock including tranche
right, net of issuance costs paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercises of stock options, net of tax withholding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8199;&#8199;129,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase (decrease) in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,140</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8199;&#8199;&#8199;26,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8194;&#8195;&#8195;25,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8194;&#8195;&#8195;17,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> asset
obtained in exchange for operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of <FONT STYLE="white-space:nowrap">non-cash</FONT> investing and
financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Settlement of Series A preferred stock tranche right liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes related party amounts of $10.0&nbsp;million and $1.3&nbsp;million for the years ended
December&nbsp;31, 2023 and 2022, respectively (Note&nbsp;16). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these
consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin843142_6"></A>Notes to consolidated financial statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Nature of the business and basis of presentation </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upstream Bio, Inc. was incorporated in April 2021, under the laws of the State of Delaware, and along with its consolidated subsidiary (collectively, the
&#147;Company&#148; or &#147;Upstream&#148;), is focused on developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. Since its inception, the Company has devoted substantially all of its efforts to
raising capital and incurring research and development expenses related to advancing verekitug, a clinical-stage monoclonal antibody that targets and inhibits the Thymic Stromal Lymphopoietin receptor. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks and uncertainties </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The global economy has
experienced extreme volatility and disruptions due to the military conflict between Russia and Ukraine and the war between Israel and Hamas. These conditions have impacted, and may continue to impact, the capital and credit markets, which may reduce
the Company&#146;s ability to raise additional capital through equity, equity-linked instruments or debt financings which could negatively impact the Company&#146;s short-term and long-term liquidity. Additionally, the Company&#146;s results of
operations could be adversely affected by general conditions in the global economy and financial markets. A severe or prolonged economic downturn could result in a variety of risks to the Company&#146;s business, including a reduced ability to raise
additional capital when needed on favorable terms, if at all. The Federal Reserve has raised interest rates multiple times in response to concerns about inflation and it may raise them again. Higher interest rates, coupled with reduced government
spending and volatility in financial markets, may increase economic uncertainty and affect consumer spending. Any of the foregoing could harm the Company&#146;s business, and it cannot anticipate all of the ways in which the current economic climate
and financial market conditions could adversely impact its ability to raise capital, business, results of operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited to, successful development of verekitug, the development of new technological innovations by competitors, dependence
on key personnel, the ability to attract and retain qualified employees, protection of proprietary technology, compliance with governmental regulations and the ability to secure additional capital to fund operations and commercial success of
verekitug. There can be no assurance that the Company&#146;s research and development will be successfully completed, that adequate protection for the Company&#146;s intellectual property will be maintained, that any therapeutic products developed
will obtain required regulatory approval or that any approved or consumer products will be commercially viable. Even if the Company&#146;s development efforts are successful, it is uncertain when, if ever, the Company will generate significant
product sales. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has
evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#146;s ability to continue as a going concern within one year after the date that the consolidated financial statements
are available to be issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization
of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has historically financed its operations principally through the issuance and sale of Series A redeemable convertible preferred stock
(&#147;Series A Preferred Stock&#148;) and Series B redeemable convertible preferred stock (&#147;Series B Preferred Stock&#148;), which are collectively referred to as the &#147;Preferred Stock.&#148; The Company has incurred recurring losses and
negative cash flows from operations since its inception and expects to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
continue to incur losses and negative cash flows for the foreseeable future as it continues the research and development of verekitug. During the years ended December&nbsp;31, 2023 and 2022, the
Company incurred a net loss of $20.5&nbsp;million and $23.9&nbsp;million, respectively. As of December&nbsp;31, 2023, the Company had an accumulated deficit of $128.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date the consolidated financial statements for the year ended December&nbsp;31, 2023 were available to be issued, the Company expects its existing
cash, cash equivalents and short-term investments, which includes $150.0&nbsp;million in gross cash proceeds from the issuance and sale of 8,823,523 shares of Series B Preferred Stock in connection with the Series B Preferred Stock Purchase
Agreement (the &#147;Series B Agreement&#148;) in April 2024 (Note 18), will be sufficient to fund its operating expenses and capital expenditures requirements for at least the next twelve months from the date the annual consolidated financial
statements were available to be issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is seeking to complete an initial public offering (&#147;IPO&#148;) of its common stock. Upon the
completion of a qualified public offering on specified terms (Note 8), the Company&#146;s outstanding Preferred Stock will automatically convert into shares of common stock. In the event the Company does not complete an IPO, until such time as the
Company can generate significant product revenue, if ever, the Company expects to fund its operations through equity offerings or debt financings, credit or loan facilities, potentially other capital resources, or a combination of one or more of
these funding sources. The terms of any financing may adversely affect the holdings or the rights of the Company&#146;s stockholders. The Company&#146;s failure to raise capital as and when needed could have a negative impact on its financial
condition and its ability to pursue its business strategies. If adequate funds are not available to the Company, the Company may be required to delay, reduce or eliminate clinical programs, obtain funds through arrangements with collaborators on
terms unfavorable to the Company or pursue merger or acquisition strategies. There can be no assurances the Company will be able to obtain additional funding. Although management continues to pursue these plans, there is no assurance that the
Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of
presentation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements reflect the operations of the Company. Intercompany balances and transactions have
been eliminated in consolidation. The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#147;U.S. GAAP&#148;). Any reference in these notes
to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#147;ASC&#148;) and Accounting Standards Update (&#147;ASU&#148;) of the Financial Accounting Standards Board
(&#147;FASB&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revision of prior year financial statements</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the preparation of its consolidated financial statements for the year ended December&nbsp;31, 2023, the Company identified a
$0.8&nbsp;million error related to changes in fair value of the preferred stock tranche right liabilities in connection with the October 2022 closing of its Series A Preferred Stock during the year ended December&nbsp;31, 2022 (Note 8). The Company
determined that the related impact was not material to its consolidated financial statements for the year ended December&nbsp;31, 2022. Accordingly, the Company revised the previously issued consolidated statement of operations and comprehensive
loss, consolidated balance sheet, and statement of redeemable convertible preferred stock and stockholders&#146; deficit as of and for the year ended December&nbsp;31, 2022.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and the disclosure of contingent assets and liabilities as of and
during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company assesses estimates on an ongoing basis;
however, actual results could materially differ from those estimates. Significant estimates and assumptions reflected within these consolidated financial statements include, but are not limited to, prepaid and accrued research and development
expenses, including those related to contract research organizations (&#147;CROs&#148;), contract manufacturing organizations (&#147;CMOs&#148;) and other third-party vendors, the valuation of the Company&#146;s common stock and stock-based awards
and the valuation of the preferred stock tranche right liabilities. Changes in estimates are recorded in the period in which they become known. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of credit risk and of significant suppliers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and
short-term investments. The Company deposits its cash and cash equivalents in financial institutions in amounts that may exceed federally insured limits, and has not experienced any losses on such accounts and does not believe it is exposed to any
unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company&#146;s short-term investments consist of U.S. treasury bills and U.S. government agency bonds which the Company believes represent
minimal credit risk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is dependent on third-party manufacturers to supply products for research and development activities related to
verekitug, including preclinical and clinical studies and testing. In particular, the Company relies and expects to continue to rely on a small number of manufacturers for the supply of verekitug. The Company&#146;s preclinical and clinical studies
and testing could be adversely affected by a significant interruption in the supply. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign currency gains and losses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The functional currency and the reporting currency of the Company is the U.S. dollar. Adjustments that arise from exchange rate changes on transactions
denominated in a currency other than the functional currency are included as foreign exchange gains and losses in other expense, net in the consolidated statements of operations and comprehensive loss. The Company has not recognized material foreign
currency transaction gains or losses during the years ended December&nbsp;31, 2023 and 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and cash equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all short-term, highly liquid investments, with an original maturity of three months or less, to be cash equivalents, and includes
amounts held in money market funds in the amount of $23.3&nbsp;million and $10.0&nbsp;million as of December&nbsp;31, 2023 and 2022, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Short-term investments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Available-for-sale</FONT></FONT> securities consist of investments with original maturities greater than 90 days at acquisition date. The Company classifies any investments with maturities
beyond one year as short term, based on their highly liquid nature and because such <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities represent the investment of cash that is available for
current operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s debt security investments are classified as <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">available-for-sale</FONT></FONT> and are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive income in stockholders&#146; deficit. Realized gains and
losses and declines in fair value due to credit-related factors are based on the specific identification method and are included as other expense, net in the consolidated statements of operations and comprehensive loss. The Company recorded interest
income on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> investments of $4.2&nbsp;million and $0.2&nbsp;million during the years ended December&nbsp;31, 2023 and 2022, respectively, which is
classified as interest income in the consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At each balance sheet date, the Company assesses <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities in an unrealized loss position to determine whether the unrealized loss or any potential credit losses should be recognized in other
expense, net. The Company evaluates whether it intends to sell, or it is more likely than not that it will be required to sell, the security before recovery of its amortized cost basis. The Company also evaluates whether the decline in fair value
has resulted from credit losses or other factors. In making this assessment, the Company considers the severity of the impairment, any changes in interest rates, changes to the underlying credit ratings and forecasted recovery, among other factors.
The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in other expense, net. The portion that is not credit-related is treated in accordance with other unrealized losses as a component of accumulated other
comprehensive income in stockholders&#146; deficit. There have been no impairment or credit losses recognized during any of the periods presented. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deferred offering costs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company capitalizes
certain legal, professional accounting and other third-party fees that are directly associated with in process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these
costs are recorded as a reduction of the proceeds from the offering, either as a reduction of the carrying value of the Preferred Stock or in stockholders&#146; deficit as a reduction of additional <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">paid-in-capital</FONT></FONT> generated as a result of the offering. Should the planned equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the
consolidated statements of operations and comprehensive loss. The Company did not record any deferred offering costs as of December&nbsp;31, 2023 and 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair value measurements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain assets and
liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for
the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial
assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Level&nbsp;1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Quoted prices in active markets for identical assets or liabilities.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Level&nbsp;2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Observable inputs (other than Level&nbsp;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or
other inputs that are observable or can be corroborated by observable market data.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Level&nbsp;3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar
techniques.</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The carrying values of the Company&#146;s prepaid expenses and other current assets, accounts payable and
accrued expenses and other current liabilities approximate their fair values due to the short-term nature of these assets and liabilities. The Company&#146;s cash equivalents, short-term investments and preferred stock tranche right liabilities are
carried at fair value (Note 3). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records property and equipment at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using
the straight-line method over the estimated useful life of each asset, as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated Useful Life</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5 years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Shorter&nbsp;of&nbsp;remaining&nbsp;lease&nbsp;term<BR>or estimated useful life</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Estimated useful lives are periodically assessed to determine if changes are appropriate. Leasehold improvements are amortized
using the straight-line method over the lesser of the lease term or its estimated economic useful life. Lease terms are based upon the initial lease agreement and do not consider potential renewals or extensions until such time that the renewals or
extensions are contracted. Expenditures for maintenance and repairs that do not improve or extend the life of the respective assets are expensed as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related
accumulated depreciation or amortization are eliminated from the consolidated balance sheets and any resulting gains or losses are included in the consolidated statements of operations and comprehensive loss in the period of disposal. Costs for
capital assets not yet placed into service are capitalized as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">construction-in-progress</FONT></FONT> and depreciated once placed into service. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of long-lived assets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Factors that the Company considers in deciding when to perform an impairment review
include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate
a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be
recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its
fair value. For the years ended December&nbsp;31, 2023 and 2022, the Company did not record any impairment losses on long-lived assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating
leases</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determines if an arrangement is or contains a lease, as defined by ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT>
<I>Leases </I>(Topic&nbsp;842) (&#147;ASC 842&#148;), at the lease inception date by evaluating whether the arrangement conveys the right to use an identified asset and whether the Company obtains substantially all of the economic benefits from and
has the ability to direct the use of the asset. If an arrangement is determined to be or contain a lease, the lease is assessed for classification as either an operating or finance lease at the lease commencement date, defined as the date on which
the leased asset is made available for use by the Company, based on the economic characteristics of the lease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASC 842 includes certain practical expedients that can be elected for new leases that are executed after the
adoption of the new requirements. The Company elected the practical expedient to not separate lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components. The Company also elected to apply the short-term lease recognition exemption which
eliminates the requirement to present on the consolidated balance sheets leases with a term of 12 months or less. These two practical expedients were elected for all classes of underlying assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the lease commencement date, the Company recognizes a lease liability and a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> (&#147;ROU&#148;) asset representing its right to use the underlying asset over the lease term. The initial measurement of the lease liability is calculated
as the present value of the future lease payments in the contract and the ROU asset is measured as the lease liability plus initial direct costs and prepaid lease payments, less lease incentives granted by the lessor. The subsequent measurement of a
lease is dependent on whether the lease is classified as an operating lease or a finance lease. Operating lease cost is recognized on a straight-line basis over the lease term in the consolidated statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s leases require other payments such as costs related to taxes, insurance, maintenance, and other expenses. These costs are generally
variable in nature and based on the actual costs incurred and required by the lease. As the Company has elected to not separate lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components for all classes of underlying asset, all variable
costs associated with the lease are expensed in the period incurred and presented and disclosed as variable lease costs. The Company&#146;s lease agreements do not contain any material residual value guarantees or material restrictive financial
covenants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASC 842 requires that a lessee use the rate implicit in the lease when measuring the lease liability and ROU asset. If the rate implicit in
the lease is not readily determinable, the Company is permitted to use its incremental borrowing rate, which is defined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term an amount
equal to the lease payments in a similar economic environment. Since the rate implicit in the lease is not readily determinable, the Company uses its incremental borrowing rate when measuring its leases. The incremental borrowing rate is calculated
by considering the Company&#146;s credit standing, the lease term and the impact of collateral. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Most leases include options to renew and, or, terminate
the lease, which can impact the lease term. The exercise of these options is at the Company&#146;s discretion. Periods covered by an option to extend a lease are not included in the lease term as the Company is not reasonably certain it will
exercise this option. Additionally, periods covered by an option to terminate the lease are included in the lease term as it is reasonably certain that the Company will not exercise this option. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segment information </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating segments are
defined as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker (&#147;CODM&#148;) in deciding how to allocate resources and assess performance. The
Company&#146;s CODM, its Chief Executive Officer, views the Company&#146;s operations and manages its business as a single operating segment, which is the business of developing treatments for inflammatory diseases, with an initial focus on severe
respiratory disorders. Revenue is generated exclusively from transactions with a related party located in Japan, and all assets are held in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Classification and accretion of redeemable convertible preferred stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of Preferred Stock have certain redemption rights in the event of a deemed liquidation event that, in certain situations, are not solely within the
control of the Company and would call for the redemption of the then outstanding Preferred Stock (Note 8). Therefore, the Preferred Stock is classified as mezzanine equity outside of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholders&#146; deficit on the consolidated balance sheets. The Company recorded the Preferred Stock at fair value upon issuance, net of tranche right liabilities (Note 8) and associated
issuance costs. The Preferred Stock is not currently redeemable, and a deemed liquidation event is not currently probable. As such, the carrying values of the Preferred Stock are not being accreted to the redemption values. Subsequent adjustments to
the carrying values of the Preferred Stock would be made only when a deemed liquidation event becomes probable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred stock tranche right
liabilities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purchase agreements for the Company&#146;s Preferred Stock provide the Company an obligation to issue additional Preferred Stock
in subsequent closings upon the satisfaction of certain conditions (the &#147;preferred stock tranche rights&#148;) (Note 8). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company classified such
preferred stock tranche rights as liabilities on its consolidated balance sheets (the&nbsp;&#147;preferred stock tranche right liabilities&#148;) as each preferred stock tranche right was determined to be a freestanding financial instrument that may
require the Company to transfer assets to settle its obligation upon events outside of its control. The preferred stock tranche right liabilities were initially recorded at fair value upon the issuance date and are subsequently remeasured to fair
value at each reporting date and immediately prior to being settled. Changes in fair value of the preferred stock tranche right liabilities are recognized as a component of other income, net in the consolidated statements of operations and
comprehensive loss. Upon settlement of the tranche rights, the Company derecognized the related liability, and stopped recognizing changes in the fair value of the preferred stock tranche right liability. Any issuance costs allocated to the
preferred stock tranche right liabilities were immediately expensed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company enters into license arrangements, pursuant to which it may provide research and development services for third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC&nbsp;606, Revenue from Contracts with Customers,
(&#147;ASC 606&#148;), the Company performs the following five steps: (i)&nbsp;identify the promised goods or services in the contract; (ii)&nbsp;determine whether the promised goods or services are performance obligations including whether they are
distinct in the context of the contract; (iii)&nbsp;measure the transaction price, including the constraint on variable consideration; (iv)&nbsp;allocate the transaction price to the performance obligations; and (v)&nbsp;recognize revenue when, or
as, the Company satisfies each performance obligation. At contract inception, the Company assesses whether the goods or services promised within each contract are a separate performance obligation. Goods and services that are determined not to be
distinct are combined with other promised goods and services until a distinct bundle is identified. The Company then allocates the transaction price, the amount of consideration the Company expects to be entitled to from a customer in exchange for
the promised goods or services, to each performance obligation and recognizes the associated revenue when each performance obligation is satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
determining the appropriate amount of revenue to be recognized, the Company uses judgment to determine: (a)&nbsp;the number of performance obligations; (b)&nbsp;the transaction price; (c)&nbsp;the stand-alone selling price for each performance
obligation identified in the contract; and (d)&nbsp;the contract term and pattern of satisfaction of the performance obligations. The Company uses judgment to determine whether milestones or other variable consideration should be included in the
transaction price. The transaction price is allocated to the identified performance obligations on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are
satisfied. At contract inception, the Company estimates the total costs required to satisfy the performance obligation and subsequently updates the estimate at </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
each reporting period. Accordingly, the Company&#146;s estimates may change in the future and those changes could result in a change in amounts of revenue recognized and could be material. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2023 and 2022, the Company generated revenue from a research and development arrangement with Maruho Co., Ltd
(&#147;Maruho&#148;), a related party, which is accounted for under ASC&nbsp;606. Pursuant to the agreement, the Company provides to Maruho research and development services related to verekitug in Japan, and Maruho reimburses the Company for these
costs incurred in performing the research and development services (Note 15). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records accounts receivable when its right to receive
consideration is solely based on the passage of time. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&#146;s consolidated balance sheets. Amounts expected to be recognized as
revenue within one year following the balance sheet date are classified as current deferred revenue. Amounts not expected to be recognized as revenue within one year following the balance sheet date are classified as deferred revenue, net of current
portion. Payment terms and conditions generally require payment within 60 days of invoicing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and development expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses are expensed as incurred. Research and development expenses include salaries and benefits, stock-based compensation expense,
licensed technology, external costs of third-party vendors that conduct research and development activity on behalf of the Company, and other operational costs related to the Company&#146;s research and development activities including costs related
to a research and development arrangement with Maruho. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Prepaid and accrued research and development expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes research and development expense and records accruals for estimated costs of research and development activities conducted by
third-party service providers, which include CROs that conduct research, preclinical studies and clinical trials on the Company&#146;s behalf, including in connection with the Company&#146;s research and development arrangement, and CMOs that
manufacture the Company&#146;s product candidate for use in preclinical and clinical trials. The majority of the Company&#146;s service providers invoice in arrears for services performed, on a <FONT STYLE="white-space:nowrap">pre-determined</FONT>
schedule or when contractual milestones are met; however, some require advanced payments. The Company makes estimates of the accrued expenses and includes these costs in accrued liabilities in the consolidated balance sheets and within research and
development expense in the consolidated statements of operations and comprehensive loss based on facts and circumstances known to the Company at that time. These costs are a significant component of the Company&#146;s research and development
expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accrues for these costs based on factors such as estimates of the amount of work completed through discussions with internal
personnel and external service providers as to the progress or stage of completion of the services and in accordance with agreements established with its third-party service providers for such services. The Company makes significant judgments and
estimates in determining the accrued research and development liabilities balance at each reporting period. As actual costs become known, the Company adjusts its accrued estimates. To date, there have been no material adjustments to the
Company&#146;s estimates of accrued research and development expenses. The Company records advance payments to service providers as prepaid expenses and other current assets, which are expensed as the contracted services are performed. If the actual
timing of the performance of services varies from the estimate, then the Company adjusts the amount of the accrued expense or the prepaid expense accordingly. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Asset acquisition and acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and
development expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for acquisitions of assets or a group of assets as asset acquisitions when substantially all of the fair
value of the gross assets acquired are concentrated in a single asset or group of assets or when the definition of a business is not met. The Company accounts for asset acquisitions based on the cost to acquire the asset or group of assets, which
include certain transaction costs. In an asset acquisition, the cost to acquire is allocated to the identifiable assets acquired and liabilities assumed based on their relative fair values as of the acquisition date. No goodwill is recorded in an
asset acquisition. Assets that are acquired in an asset acquisition for use in research and development activities that have an alternative future use are capitalized as <FONT STYLE="white-space:nowrap">in-process</FONT> research and development
(&#147;IPR&amp;D&#148;) assets. Acquired IPR&amp;D that has no alternative future use as of the acquisition date is recognized as acquired research and development expense as of the acquisition date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and administrative expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and
administrative expenses consist primarily of salaries and benefits, including stock-based compensation expense; professional fees for legal, accounting, auditing, tax and consulting services; travel expenses; and facility-related expenses, which
include expenses for rent and maintenance of facilities and other operating costs. The Company expenses all general and administrative expenses as incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent and trademarks </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs to secure, defend and
maintain patents, including those in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative
expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based compensation expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company measures all stock-based awards granted to employees, directors, and <FONT STYLE="white-space:nowrap">non-employee</FONT> service providers based
on fair value on the date of the grant, and recognizes the resulting fair value over the requisite service period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of stock options granted. The Company has elected
to recognize stock-based compensation expense for service-based stock options with graded vesting on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes expense related to stock
options that contain performance conditions only when it is considered probable that the performance condition will be achieved. Stock-based compensation expense for stock options with performance conditions is recognized using graded vesting. The
Company accounts for forfeitures as they occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company classifies stock-based compensation expense in its consolidated statements of operations and
comprehensive loss in the same manner in which the award recipient&#146;s payroll costs are classified or in which the award recipient&#146;s service payments are classified. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive loss </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Comprehensive loss is defined
as the change in equity of a business enterprise during a period from transactions and other events and circumstances from nonowner sources, including unrealized gains and losses on marketable securities held as available for sale. There was no
difference between net loss and comprehensive loss for the year ended December&nbsp;31, 2022. For the year ended December&nbsp;31, 2023, comprehensive loss includes net loss and unrealized gains (losses) on short-term investments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net loss per share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company calculated basic and diluted net loss per share attributable to common stockholders in conformity with the
<FONT STYLE="white-space:nowrap">two-class</FONT> method required for companies with participating securities. The Company&#146;s Preferred Stock is considered to be a participating security as the holders are entitled to receive dividends at a
dividend rate payable in preference and priority to the holders of common stock. The <FONT STYLE="white-space:nowrap">two-class</FONT> method determines net loss per share for each class of common and participating securities according to dividends
declared or accumulated and participation rights in undistributed earnings. The <FONT STYLE="white-space:nowrap">two-class</FONT> method requires income available to common stockholders for the period to be allocated between common and participating
securities based upon their respective rights to receive dividends as if all income for the period has been distributed. There is no allocation required under <FONT STYLE="white-space:nowrap">the&nbsp;two-class&nbsp;method</FONT> during periods of
loss since the participating securities do not have a contractual obligation to share in the losses of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the <FONT
STYLE="white-space:nowrap">two-class</FONT> method, basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock
outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by (i)&nbsp;adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of
dilutive securities and (ii)&nbsp;dividing the diluted net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, including potential dilutive common shares. For purposes of this
calculation, Preferred Stock and stock options to purchase common stock are considered potential dilutive common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has generated a net
loss for each of the periods presented. Accordingly, basic and diluted net loss per share attributable to common stockholders are the same because the inclusion of the potentially dilutive securities would be anti-dilutive. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for income
taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax reporting bases of assets and liabilities and are measured using enacted tax
rates and laws that are expected to be in effect when the differences are expected to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain. The effect of a change in tax rates on
deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes,
based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery
of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company utilizes a <FONT STYLE="white-space:nowrap">two-step</FONT> approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence
indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest
amount that is more than 50% likely of being realized upon ultimate settlement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently adopted accounting pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2020, the FASB issued ASU <FONT STYLE="white-space:nowrap">2020-06,</FONT> <I>Debt with Conversion and Other Options (Subtopic <FONT
STYLE="white-space:nowrap">470-20)</FONT> and Derivatives and Hedging-Contracts in Entity&#146;s Own Equity (Subtopic <FONT STYLE="white-space:nowrap">815-40):</FONT> Accounting for Convertible</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<I>Instruments and Contracts in an Entity&#146;s Own Equity</I> (&#147;ASU <FONT STYLE="white-space:nowrap">2020-06&#148;),</FONT> which is intended to simplify the accounting for certain
financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#146;s own equity. The guidance allows for either full retrospective adoption or modified retrospective adoption. For
public entities except smaller reporting companies, the guidance is effective for annual reporting periods beginning after December&nbsp;15, 2021, and for interim periods within those fiscal years. Early adoption is allowed. The Company adopted ASU <FONT
STYLE="white-space:nowrap">2020-06</FONT> effective April&nbsp;21, 2021 and it did not have a material impact on the Company&#146;s consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> Leases, which requires lessees to recognize most leases on their
balance sheet as a ROU asset and a lease liability. The standard, including subsequently issued amendments, collectively referred to as ASC 842, established principles of recognition, measurement, presentation and disclosure of lease arrangements
applicable to lessees and lessors in order to enhance the transparency and compatibility of financial reporting related to the arrangements, including with respect to the amount, timing and uncertainty of cash flows arising from a lease. The Company
adopted ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> using a modified retrospective transition approach effective January&nbsp;1, 2022 and it did not have a material impact on the Company&#146;s consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">2019-12,</FONT> <I>Income Taxes (Topic 740)&#151;Simplifying the Accounting for Income
Taxes</I> (&#147;ASU <FONT STYLE="white-space:nowrap">2019-12&#148;),</FONT> which simplifies the accounting for income taxes by removing certain exceptions to the general principles of ASC 740, Income Taxes. The amendments also improve consistent
application of and simplify U.S. GAAP for other areas of ASC 740 by clarifying and amending existing guidance. ASU <FONT STYLE="white-space:nowrap">2019-12</FONT> is effective for fiscal years and interim periods beginning after December&nbsp;15,
2020 for public companies and for fiscal years beginning after December&nbsp;15, 2021 for nonpublic companies, with early adoption permitted. Depending on the amendment, adoption may be applied on a retrospective, modified retrospective, or
prospective basis. The Company adopted ASU <FONT STYLE="white-space:nowrap">2019-12</FONT> effective January&nbsp;1, 2022 and it did not have a material impact on the Company&#146;s consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-13,</FONT> <I>Financial Instruments&#151;Credit Losses (Topic 326) </I><FONT
STYLE="white-space:nowrap">(&#147;ASU&nbsp;2016-13&#148;).</FONT> The new standard changes the accounting for assets held at amortized costs basis, including marketable securities accounted for as <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">available-for-sale,</FONT></FONT> and trade receivables. The standard eliminates the probable initial recognition threshold and requires an entity to reflect its current estimate of all expected credit losses. The
allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For public entities except smaller reporting companies, the guidance is
effective for annual reporting periods beginning after December&nbsp;15, 2019, and for interim periods within those fiscal years. In November 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">2019-10,</FONT> which deferred the effective
date for <FONT STYLE="white-space:nowrap">non-public</FONT> entities to annual reporting periods beginning after December&nbsp;15, 2022, including interim periods within those fiscal years. Early application is allowed. The Company adopted ASU <FONT
STYLE="white-space:nowrap">2016-13</FONT> effective January&nbsp;1, 2023 and it did not have a material impact on its consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently issued accounting pronouncements not yet adopted </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified
effective date. The Company qualifies as an &#145;&#145;emerging growth company&#146;&#146; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#145;&#145;opt out&#146;&#146; of the extended transition related to
complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and <FONT STYLE="white-space:nowrap">non-public</FONT> companies, the Company can adopt the
new or revised standard at the time <FONT STYLE="white-space:nowrap">non-public</FONT> companies adopt the new or revised standard and can do so until such time that the Company either (i)&nbsp;irrevocably elects to &#145;&#145;opt out&#146;&#146;
of such extended transition period or (ii)&nbsp;no longer qualifies as an emerging growth company. The Company may choose </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to early adopt any new or revised accounting standards whenever such early adoption is permitted for <FONT STYLE="white-space:nowrap">non-public</FONT> companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2023, the FASB issued ASU <FONT STYLE="white-space:nowrap">2023-07,</FONT> <I>Segment Reporting (Topic 280): Improvements to Reportable Segment
Disclosures </I>(&#147;ASU <FONT STYLE="white-space:nowrap">2023-07&#148;).</FONT> ASU <FONT STYLE="white-space:nowrap">2023-07</FONT> expands public entities&#146; segment disclosures by requiring disclosure of significant segment expenses that are
regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable
segment&#146;s profit or loss and assets. All disclosure requirements under ASU <FONT STYLE="white-space:nowrap">2023-07</FONT> are also required for public entities with a single reportable segment. ASU
<FONT STYLE="white-space:nowrap">2023-07</FONT> is effective for public business entities with fiscal years beginning after December&nbsp;15, 2023, and interim periods within fiscal years beginning after December&nbsp;15, 2024. The Company is
currently evaluating the impact of adopting ASU <FONT STYLE="white-space:nowrap">2023-07</FONT> on its consolidated financial statements and related disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2023, the FASB issued ASU <FONT STYLE="white-space:nowrap">2023-09,</FONT> <I>Improvements to Income Tax Disclosures</I> (&#147;ASU <FONT
STYLE="white-space:nowrap">2023-09&#148;).</FONT> ASU <FONT STYLE="white-space:nowrap">2023-09</FONT> requires public business entities to disclose additional information in specified categories with respect to the reconciliation of the effective
tax rate to the statutory rate (the rate reconciliation) for federal, state, and foreign income taxes. It also requires greater detail about individual reconciling items in the rate reconciliation to the extent the impact of those items exceeds a
specified threshold (if the effect of those reconciling items is equal to or greater than 5% of the amount computed by multiplying pretax income or loss by the applicable statutory income tax rate). In addition to new disclosures associated with the
rate reconciliation, ASU <FONT STYLE="white-space:nowrap">2023-09</FONT> requires information pertaining to taxes paid (net of refunds received) to be disaggregated for federal, state, and foreign taxes and further disaggregated for specific
jurisdictions to the extent the related amounts exceed a quantitative threshold. The amendments are effective for public business entities for annual periods beginning after December&nbsp;15, 2024. For entities other than public business entities,
the amendments are effective for annual periods beginning after December&nbsp;15, 2025. Early adoption is permitted. The Company is currently evaluating the impact of adopting ASU <FONT STYLE="white-space:nowrap">2023-09</FONT> on its consolidated
financial statements and related disclosures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Fair value measurements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables present information about the Company&#146;s financial assets and liabilities measured at fair value on a recurring basis and indicate the
level of the fair value hierarchy used to determine such fair values (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements at<BR>December&nbsp;31, 2023 Using:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8196;&#8196;&#8199;&#8199;23,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. treasury bills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government agency bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8196;&#8194;&#8199;&#8199;83,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8201;&#8199;&#8194;&#8199;107,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock tranche right liability (Series&nbsp;B)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8201;&#8196;&#8194;&#8199;&#8199;2,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements at<BR>December&nbsp;31, 2022 Using:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8201;&#8199;&#8194;&#8199;&#8199;10,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock tranche right liability (Series&nbsp;A)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8199;&#8201;&#8199;&#8201;&#8199;&#8199;&#8199;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8199;&#8195;&#8199;&#8199;6,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no transfers between Level&nbsp;1, Level&nbsp;2 and Level&nbsp;3 during the years ended December&nbsp;31, 2023 and
2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company classifies its U.S. treasury bills and U.S. government agency bonds as short-term based on each instrument&#146;s availability for use
in current operations. The fair value of the Company&#146;s U.S. treasury bills and U.S. government agency bonds are classified as Level&nbsp;2 because they are valued using observable inputs to quoted market prices, benchmark yields, reported
trades, broker/dealer quotes or alternative pricing sources with reasonable levels of price transparency and U.S. treasury bills. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Short-term investments
consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized&nbsp;Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized&nbsp;Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. treasury bills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government agency bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total short-term investments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8194;&#8194;&#8194;&#8194;&#8194;83,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8194;&#8194;&#8194;&#8194;&#8194;&#8194;&#8194;&#8194;32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8194;&#8194;&#8194;&#8194;&#8194;&#8194;&#8194;(11)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8194;&#8194;83,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company did not have short-term investments during the year ended December&nbsp;31, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The contractual maturities of the Company&#146;s short-term investments in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities held were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Due within one year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;&#8195;83,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Valuation of preferred stock tranche right liabilities
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preferred stock tranche right liabilities in the table above are composed of the fair value of obligations to issue Series A and Series B
Preferred Stock (Note 8). The fair value of the preferred stock tranche right liabilities was based on significant inputs not observable in the market, which represented a Level&nbsp;3 measurement within the fair value hierarchy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Series A preferred stock tranche right liability </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
fair value of the Series A preferred stock tranche right liability was determined using a probability-weighted expected return method as it represents a contingent commitment for the Milestone Shares (as defined in Note&nbsp;8).
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The valuation considered as inputs the fair value per share of the Series A Preferred Stock as of each measurement date, the fair value per share of the Series A Preferred Stock if the milestone
is not met, probability of meeting certain milestone events, the expected time until certain milestone events would be met, and the discount rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
most significant assumptions in the valuation model impacting the fair value of the preferred stock tranche right liability were the fair value of the Company&#146;s Series A Preferred Stock and the probability and expected timing of achieving
certain milestone events as of the measurement dates. The Company determined the fair value per share of the underlying Series A Preferred Stock by taking into consideration the most recent sales of its Series A Preferred Stock, results obtained
from third-party valuations and additional factors the Company deemed relevant. In October 2022, the interim second closing of the Series A Preferred Stock was completed and the fair value of each share of Series A Preferred Stock was $8.80 per
share. As of December&nbsp;31, 2022, the fair value of the Series A Preferred Stock was $9.53 per share. In February 2023, upon satisfaction of certain conditions, the second closing of the Series A Preferred Stock was completed and the associated
Series A preferred stock tranche right liability was settled. The fair value of Series A Preferred Stock was $10.04 per share upon the second closing. Changes in these inputs can have a significant impact on the fair value of the preferred stock
tranche right liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the assumptions used in the probability-weighted expected return model to determine the fair value
of the Series A preferred stock tranche right liability during the years presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8194;&#8195;February&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;&#8201;October&#8195;&#8194;&#8201;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;&#8201;December&#8195;&#8194;&#8201;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Probability of achieving milestone</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74.0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82.0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Value of Preferred Stock if milestone not met</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$2.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$2.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated time until milestone is achieved (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.3%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.4%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Series B preferred stock tranche right liability </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the Series B preferred stock tranche right liability was determined using an option pricing model as it represents an option for the
Series&nbsp;B Option Shares (as defined in Note&nbsp;8). The valuation considered as inputs the estimated fair value of the Series B Preferred Stock as of each valuation date, the risk-free interest rate, volatility, expected dividends, and
estimated time to the tranche closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The most significant assumption in the valuation model impacting the fair value of the preferred stock tranche
right liability is the fair value of the Company&#146;s Series B Preferred Stock as of each measurement date. The Company determined the fair value per share of the underlying Series B Preferred Stock by taking into consideration the most recent
sales of its Series B Preferred Stock, results obtained from third-party valuations and additional factors the Company deemed relevant. In June 2023, the initial tranche of the Series B Preferred Stock closed with a fair value of $13.00 per share.
As of December&nbsp;31, 2023, the fair value of Series B Preferred Stock was $15.86 per share. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the remaining estimated
time to the tranche closing. The volatility is based on the historical volatility of publicly traded peer companies adjusted for the seniority of the Series B Preferred Stock. The expected dividend yield is based on the fact that the Company has
never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. Changes in these inputs can have a significant impact on the fair value of the preferred stock tranche right liability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the assumptions used in the option-pricing model to determine the fair value of
the Series B preferred stock tranche right liability during the year presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;&#8195;June&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;December&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51.0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.2%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.3%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.4%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents a roll-forward of the aggregate fair value of the Series A and Series B preferred stock tranche
right liabilities, for which fair value is determined using Level&nbsp;3 inputs (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred Stock<BR>Tranche&nbsp;Right&nbsp;Liability</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value at December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8196;&#8196;&#8201;&#8195;&#8195;&#8195;7,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock tranche right liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Partial settlement of the Series A preferred stock tranche right liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(782</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value at December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of Series B preferred stock tranche right liability at issuance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8196;&#8201;&#8196;11,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock tranche right liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,627</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,900</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Final settlement of Series A preferred stock tranche right liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value at December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8199;2,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Prepaid expenses and other current assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets consisted of the following (in thousands):</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8194;&#8194;6,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8194;&#8194;&#8194;&#8201;521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid employee-related costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Property and equipment, net </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment, net consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2023&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2022&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8199;&#8195;&#8194;&#8194;163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">&#8195;&#8199;&#8195;&#8195;&#8201;&#8195;&#8194;&#8194;-</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense related to property and equipment, net was less than $0.1&nbsp;million for each of the
years ended December&nbsp;31, 2023 and 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Accrued expenses and other current liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2023&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2022&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued employee compensation and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8194;&#8194;&#8195;2,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8194;&#8201;&#8194;&#8194;893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued external research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued consultant and professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;4,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Leases </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2023, the Company was a party to a lease related to commercial real estate under a <FONT STYLE="white-space:nowrap">non-cancelable</FONT> lease term and a short-term lease related to commercial real estate. The Company does not
have any leases that have not yet commenced that create significant rights and obligations for the lessee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has an operating lease for office
space at 460 Totten Pond Road, Waltham, Massachusetts. The lease expires on June&nbsp;30, 2024, after which the Company will continue to pay rent on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">month-to-month</FONT></FONT>
basis until either party provides notice of termination. Under its lease, the Company pays a proportional share of operating expenses. Such operating expenses are subject to annual adjustment and are accounted for as variable payments in the period
in which they are incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of lease cost, which are included in the consolidated statement of operations and comprehensive loss, were as
follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8194;&#8195;2023&#8194;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;2022&#8194;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Lease Cost:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Variable lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8194;&#8194;299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8194;&#8194;115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Supplemental disclosure of cash flow information related to leases was as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8194;2023&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8194;2022&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for amounts included in the measurement of lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8199;&#8195;&#8194;&#8194;&#8195;92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets obtained in exchange for new operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;&#8194;&#8195;&#8195;161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The weighted-average discount rate and remaining lease term were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8194;2023&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8194;2022&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average discount rate &#151; operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8199;&#8195;&#8195;&#8195;&#8194;&#8201;15.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8199;&#8195;&#8195;&#8195;&#8194;&#8201;10.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average remaining lease term &#151; operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The maturities of operating lease liabilities were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Year Ended December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8194;&#8194;&#8195;46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Present value of lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: operating lease liabilities, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Redeemable convertible preferred stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has issued Series A Preferred Stock and Series B Preferred Stock, which are collectively referred to as the Preferred Stock. As of
December&nbsp;31, 2023, the Company authorized the issuance of 31,764,693 shares of Preferred Stock, par value of $0.001 per share, of which 20,000,000 have been designated Series A Preferred Stock and 11,764,693 have been designated Series B
Preferred Stock. As of December&nbsp;31, 2022, the Company authorized the issuance of 20,000,000 shares of Preferred Stock, par value of $0.001 per share, all of which were designated Series A Preferred Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuance and sale of Series A redeemable convertible preferred stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2021, the Company executed the Series A Preferred Stock Purchase Agreement (the &#147;Series A Agreement&#148;) to issue and sell up to 20,000,000
shares of Series A Preferred Stock at a price of $10.00 per share. In the initial closing in October 2021, the Company issued 11,000,000 shares of Series A Preferred Stock resulting in gross cash proceeds of $110.0&nbsp;million and incurred
$0.2&nbsp;million of issuance costs. Pursuant to the Series A Agreement, the Company was obligated to issue and the Series A investors were obligated to purchase an additional 9,000,000 shares of Series A Preferred Stock (&#147;Milestone
Shares&#148;) at the same purchase price of $10.00 per share (the &#147;Series A preferred stock tranche right&#148;), after the initial closing and upon the satisfaction of certain conditions at a date which would occur at the earlier of
(i)&nbsp;immediately prior to the Company&#146;s first underwritten public offering of its common stock under the Securities Act; (ii)&nbsp;the resolution of the board of directors that the pharmacokinetics, pharmacodynamics, immunogenicity and
safety profile of verekitug (formerly referred to as ASP7266), when administered as multiple ascending doses, supports further clinical development (&#147;Second Closing Milestone&#148;) has been achieved; or (iii)&nbsp;the written consent of the
purchasers </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
holding a majority of the Series A Preferred Stock that the Second Closing Milestone has been waived (collectively, the &#147;Second Closing&#148;). The board of directors may determine at any
time prior to the Second Closing to issue and sell up to 1,000,000 of the Milestone Shares at a price of $10.00 per share for gross cash proceeds of $10.0&nbsp;million (&#147;Interim Second Closing&#148;) and the number of Milestone Shares to be
issued in the Second Closing will be reduced accordingly. Upon the initial closing of the Series A Preferred Stock, the Company recorded a preferred stock tranche right liability of $7.8&nbsp;million. The fair value of the Series A preferred stock
tranche right was allocated from the gross cash proceeds of $110.0&nbsp;million of the Series A Preferred Stock issuance, and the residual value was then allocated to the Series A Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2022, the Interim Second Closing was completed and 1,000,000 of the Milestone Shares on a <FONT STYLE="white-space:nowrap">pro-rata</FONT> basis to
the purchasers of the Series A Preferred Stock were issued at a price of $10.00 per share, which resulted in gross cash proceeds of $10.0 million and partial settlement of the Series A preferred stock tranche right liability of $0.8&nbsp;million
(Note 3). As a result of this issuance, the related Series A Preferred Stock was recorded at its fair value of $10.8&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2023, upon
the satisfaction of the Second Closing Milestone, the remaining 8,000,000 of the Milestone Shares on a <FONT STYLE="white-space:nowrap">pro-rata</FONT> basis to the purchasers of the Series A Preferred Stock were issued at a price of $10.00 per
share, which resulted in gross cash proceeds of $80.0&nbsp;million. As a result of this issuance, the Series&nbsp;A preferred stock tranche right liability of $0.3&nbsp;million was settled and the Series A Preferred Stock was recorded at its fair
value of $80.3&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuance and sale of Series B redeemable convertible preferred stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2023, the Company executed the Series B Agreement to issue and sell up to 11,764,693 shares of Series&nbsp;B Preferred Stock at a price of $17.00 per
share. In the initial closing in June 2023, the Company issued 2,941,170 shares of Series B Preferred Stock resulting in gross cash proceeds of $50.0&nbsp;million and incurred $0.6&nbsp;million of issuance costs, of which $0.1&nbsp;million was
allocated to the preferred stock tranche right liability and recognized in the consolidated statement of operations and comprehensive loss as general and administrative expense. Pursuant to the Series B Agreement, the Company has the right
(&#147;Series B Option&#148;) to issue and sell an additional 8,823,523 shares of Series B Preferred Stock (&#147;Series B Option Shares&#148;) at the same price of $17.00 per share after the initial closing but prior to March&nbsp;31, 2024 upon
approval of at least six (6)&nbsp;board of directors of which at least one (1)&nbsp;has to be appointed by the holders of Series B Preferred Stock. If the Company does not exercise the Series B Option prior or at a date which would occur at the
earlier of (i)&nbsp;March&nbsp;31, 2024 or (ii)&nbsp;the closing of an acquisition agreement signed prior to March&nbsp;31, 2024, the holders of Series B Preferred Stock will have the right but not obligation to require the Company to issue and sell
the Series B Option Shares at the same purchase price of $17.00 per share (the &#147;Series B preferred stock tranche right&#148;). Upon the initial closing of the Series B Preferred Stock, the Company recorded a preferred stock tranche right
liability of $11.8&nbsp;million and a corresponding reduction to the carrying value of the Series B Preferred Stock. The fair value of the Series B preferred stock tranche right was allocated from the gross cash proceeds of $50.0&nbsp;million of the
Series B Preferred Stock issuance, and the residual value was then allocated to the Series B Preferred Stock. As of December&nbsp;31, 2023, none of the Series B preferred stock tranche right had been settled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon issuance of the Preferred Stock, the Company assessed the embedded conversion and liquidation features of the securities and determined that such
features did not require the Company to separately account for these features. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preferred Stock consisted of the following (dollar amounts in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock Issued<BR>and&nbsp;Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Stock<BR>Issuable Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8194;20,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8194;20,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;&#8194;&#8194;193,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;&#8194;&#8194;216,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;&#8194;20,980,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,764,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,941,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,085,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,764,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,941,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">230,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">267,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,065,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock Issued<BR>and&nbsp;Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Stock<BR>Issuable Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8194;20,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8194;12,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;&#8194;&#8194;112,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;&#8194;&#8194;126,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;&#8194;12,588,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">126,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,588,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of the Preferred Stock have the following rights and preferences: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of Preferred Stock are
entitled to a cumulative dividend from and after the date of the share issuance at the rate per annum of 5% of the Original Issue Price (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar
recapitalization with respect to the Preferred Stock), provided that the total accrued amount will not exceed 15% of the Original Issue Price in aggregate (the &#147;Accruing Dividend&#148;). Such dividends shall be accrued, whether or not declared.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of any dividend being payable to common stockholders, the holders of Preferred Stock shall be entitled to receive, prior to any such
dividend being paid to the common stockholders, the greater of (i)&nbsp;the Accruing Dividend then accrued and not previously paid, and (ii)&nbsp;the amount of any dividend being paid to the common stockholders (determined on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> basis with respect to the holders of Preferred Stock). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of the Preferred Stock are entitled to vote together with all other classes and series of stock as a single class on all matters, except those
matters requiring a separate class vote, and are entitled to the number of votes equal to the number of shares of common stock into which each share of the applicable series of Preferred Stock is then convertible. The holders of Series A Preferred
Stock as a separate class are entitled to elect four&nbsp;(4)&nbsp;board of directors, and the holders of Series B Preferred Stock as a separate class are entitled to elect two&nbsp;(2)&nbsp;board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation preference </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of any
voluntary or involuntary liquidation, dissolution or winding up of the Company or in the event of a Deemed Liquidation Event (&#147;DLE&#148;) which is defined as a merger or consolidation in which the Company issues shares of its capital stock
(other than one in which stockholders of the Company own a majority by voting power of the outstanding shares of the surviving or acquiring corporation), and the sale, lease, transfer, exclusive license or other disposition of substantially all of
the Company&#146;s assets, the holders of shares of Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
distribution to its shareholders or consideration payable to stockholders in such DLE or out of the available proceeds as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Before any payment is made to the holders of Series A Preferred Stock and common stock, an amount equal to any
Accruing Dividends on the Series B Preferred Stock accrued but unpaid, whether or not declared, together with any other dividends that are declared but unpaid (&#147;Series B Dividend Payment&#148;); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the assets available are not sufficient for the Company to pay the Series B Dividend Payment to the holders of
Series B Preferred Stock in full, holders of Series B Preferred Stock will share ratably in the assets available for distribution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">After the Series B Dividend Payment is paid in full, holders of Preferred Stock will be entitled to be paid out
of the assets of the Company available for distribution to its stockholders before any payment is made to the holders of common stock, on a pari passu basis, an amount per share equal to (i)&nbsp;with respect to the Series A Preferred Stock, the
greater of (a)&nbsp;the Original Issue Price, plus any Accruing Dividends on the Series A Preferred Stock accrued but unpaid, whether or not declared, together with any other dividends declared but unpaid, or (b)&nbsp;such amount per share as would
have been payable had all shares of Series A Preferred Stock been converted in common stock, and (ii)&nbsp;with respect to the Series B Preferred Stock, (1)&nbsp;the greater of (a)&nbsp;the Original Issue Price, plus any Accruing Dividends on the
Series B Preferred Stock accrued but unpaid, whether or not declared, together with any other dividends declared but unpaid thereon, or (b)&nbsp;such amount per share as would have been payable had all shares of Series B Preferred Stock been
converted in common stock, less (2)&nbsp;Series B Dividend Payment that was paid. (&#147;Liquidation Amount&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the assets available are not sufficient for the Company to pay holders of Preferred Stock the Liquidation
Amount in full, holders of Preferred Stock will share ratably in the assets available for distribution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">After payment of Liquidation Amounts is paid in full to the holders of Preferred Stock, the remaining assets of
the Company available for distribution to its stockholders, or in the case of a DLE, the consideration not payable to the holders of shares of Preferred Stock or the remaining available proceeds, will be distributed among the holders of the shares
of common stock on a pro rata basis. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#147;Original Issue Price&#148; is defined as (i)&nbsp;with respect to the Series A Preferred
Stock, $10.00 per share, and (ii)&nbsp;with respect to the Series B Preferred Stock, $17.00 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Optional conversion </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each share of Preferred Stock is
convertible at the option of the holder and at any time into common stock as determined by dividing the Preferred Stock Original Issue Price by the Preferred Stock Conversion Price. &#147;Conversion Price&#148; is defined as initially the applicable
Original Issue Price for the applicable series of Preferred Stock, subject to certain adjustments in the event of any down round, stock dividend, stock split, combination or other similar recapitalization. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Mandatory conversion </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each share of Preferred Stock
will automatically be converted into shares of common stock, at the conversion ratio of dividing the Original Issue Price by the Preferred Stock Conversion Price, upon either (a)&nbsp;the closing of the sale of shares of common stock to the public
at a price of at least $21.07 per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the common stock) in a firm commitment underwritten public
offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $100.0&nbsp;million of gross </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proceeds to the Company and after which the common stock is listed on the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange or (b)&nbsp;the date and time, or
the occurrence of an event specified by vote or written consent of the Requisite Holders (which is defined as at least a majority of the outstanding shares of Preferred Stock, voting together as a single class on an as converted to common stock
basis, which majority must include holders of at least a majority of the outstanding shares of Series B Preferred Stock) voting together as a single class on an as converted to common stock basis, then all outstanding shares of Preferred Stock will
automatically be converted into shares of common stock, at the then effective conversion rate and such shares of Preferred Stock may not be reissued by the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Special mandatory conversion </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of
the Series A Agreement, if a Series A Preferred Shareholder fails to purchase all of the Milestone Shares allocated to such shareholder at or prior to the Second Closing Milestone or breaches its obligations set forth in the Series A Agreement, then
such investor will be deemed a Defaulting Purchaser. As of December&nbsp;31, 2023, all of the Milestone Shares had been issued without triggering the special mandatory conversion provision under the Series A Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Series B Agreement, if a Series B Preferred Shareholder fails to purchase all of the Series B Option Shares allocated to such
shareholder at or prior to the closing of the Series B Option or breaches its obligations set forth in the Series B Agreement, then such investor will be deemed a Defaulting Purchaser. Each ten shares of Preferred Stock held by the Defaulting
Purchaser will automatically, and without any further action on the part of such holder, be converted into one share of common stock. In April 2024, all of the Series B Option Shares had been issued without triggering the special mandatory
conversion provision under the Series B Agreement (Note 18). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Modification to Series A preferred stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2023, in connection with the issuance of the Company&#146;s Series B Preferred Stock, the rights of the Company&#146;s Series A Preferred Stock were
amended to entitle holders to a cumulative dividend from and after the date of the share issuance at the rate per annum of 5% of the Original Issue Price (subject to appropriate adjustment in the event of any stock dividend, stock split, combination
or other similar recapitalization with respect to the Preferred Stock), provided that the total accrued amount will not exceed 15% of the Original Issue Price in aggregate. The dividend replaced the original accrued return definition within the
liquidation preference terms of the Series A Preferred Stock. Previously, holders were entitled to a liquidation preference per share equal to the greater of (a)&nbsp;the Original Issue Price, plus an accrued return of 5% of the Original Issue Price
per annum, provided that the total of such accrued return shall not exceed 15% of the Original Issue Price in the aggregate, or (b)&nbsp;such amount per share as would have been payable had all shares of Series A Preferred Stock been converted in
common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The changes to the rights of the Company&#146;s Series A Preferred Stock were not considered to be a significant change to the contractual
terms of the Company&#146;s Series A Preferred Stock because the accrued return of the liquidation preference and the cumulative dividend definitions will result in the same amount to be received in a liquidation event, and accordingly, the Company
accounted for the change as a modification. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Common stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#146;s stockholders. Common stockholders are
entitled to receive dividends, as may be declared by the board of directors, if any, subject to the preferential dividend rights of the Preferred Stock. When dividends are declared </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on shares of common stock, the Company must declare at the same time a dividend payable to the holders of Preferred Stock equivalent to the dividend amount they would receive if each share of
Preferred Stock were converted into common stock. The Company may not pay dividends to common stockholders until all dividends accrued or declared but unpaid on the Preferred Stock have been paid in full. As of December&nbsp;31, 2023 and 2022, no
dividends were declared. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023 and 2022, the Company&#146;s amended and restated certificate of incorporation authorized the
issuance of 40,664,346 and 28,000,000 shares, respectively, of $0.001 par value common stock. As of December&nbsp;31, 2023 and 2022, there were 2,992,479 shares and 2,937,197 shares of common stock issued and outstanding, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2023, the Company issued 20,980 shares of common stock to a related party investor. The Company recorded stock-based compensation expense of
$0.1&nbsp;million in connection with the issuance of these shares (Note 16). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023 and 2022, the Company had reserved 38,051,952
and 25,200,664 shares of common stock, respectively, for the conversion of shares of Preferred Stock into common stock (including committed but unissued shares under future tranche obligations for the Preferred Stock), the exercise of outstanding
stock options for common stock, and the issuance of common stock options remaining available for grant under its equity incentive plan. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.
Stock-based compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock incentive plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2021, the board of directors approved the 2021 Stock Option and Grant Plan (the &#147;2021 Plan&#148;) under which the Company may grant incentive
stock options, nonqualified stock options, restricted stock awards, unrestricted stock awards and restricted stock units (collectively, the &#147;Awards&#148;) to among others, members of the board of directors, employees, consultants and other key
persons to the Company and its affiliates. The 2021 Plan is administered by the board of directors, or at the discretion of the board of directors, by a committee of the board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023 and 2022, the total number of shares of common stock reserved for issuance under the 2021 Plan was 4,765,105 shares and 4,220,664
shares, respectively. Shares of unused common stock underlying any Awards that are forfeited, canceled or reacquired by the Company prior to vesting will again be available for the grant of awards under the 2021 Plan. Shares underlying any awards
that are forfeited, canceled, or reacquired by the Company prior to vesting, satisfied without the issuance of stock or otherwise terminated and shares that are withheld upon exercise of an option of settlement of an award to cover the exercise
price or tax withholding shall be added back to the shares available for issuance under the 2021 Plan. As of December&nbsp;31, 2023 and 2022, the Company had 564,696 shares and 991,180, respectively, remaining available for grant under the 2021
Plan. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exercise price for stock options granted may not be less than the fair market value of the Company&#146;s common stock on the date of
grant, as determined by the board of directors, or at least 110% of the fair market value of the Company&#146;s common stock on the date of grant in the case of an incentive stock option granted to an employee who owns stock representing more than
10% of the voting power of all classes of stock as determined by the board of directors as of the date of grant (&#147;10% Owner&#148;). The Company&#146;s board of directors determines the fair value the Company&#146;s common stock, taking into
consideration its most recently available valuation of common stock performed by third parties as well as additional factors which may have changed since the date of the most recent contemporaneous valuation through the date of grant. Stock options
granted under the 2021 Plan </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expire after ten years, or 5 years for a 10% Owner, and typically vest over a&nbsp;four-year period with the first 25% vesting upon the first anniversary of a specified vesting commencement date
and the remainder vesting in 36 equal monthly installments over the succeeding three years, contingent on the recipient&#146;s continued employment or service. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair value inputs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of stock option
grants is estimated using the Black-Scholes option-pricing model. The Company historically has been a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility
based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected option term is
calculated based on the simplified method for awards with service-based conditions, which uses the midpoint between the vesting date and the contractual term, as the Company does not have sufficient historical data to develop an estimate based on
participant behavior. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield
is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following table presents, on a weighted-average basis, the assumptions used in the Black-Scholes option-pricing model to determine the fair value of stock options granted: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8194;2023&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8194;2022&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per share fair value of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8196;&#8194;&#8194;&#8194;&#8194;&#8194;&#8194;&#8199;&#8201;77.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8196;&#8194;&#8194;&#8194;&#8194;&#8194;&#8199;&#8201;78.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividends</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.94</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.82</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company generally grants stock-based awards with service-based vesting. During the year ended December&nbsp;31, 2022, the Company granted performance-based
stock options to certain employees and directors for the purchase of an aggregate 1,061,316 shares of common stock with a vesting commencement date contingent upon the achievement of the Second Closing Milestone of the Series A Preferred Stock,
which was achieved in February 2023. The Company determined that it met all the conditions to establish a grant date for these performance-based stock options at the original issuance date. The vesting of the performance-based stock options is also
subject to the grantees&#146; continued service until the fourth anniversary of the Second Closing Milestone. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There was no compensation expense
related to these performance-based options recognized during the year ended December&nbsp;31, 2022, as the achievement of the Second Closing Milestone was not considered probable for accounting purposes on the date of grant and through the year
ended December&nbsp;31, 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the activity of stock options with service-based and performance-based vesting
conditions during the year ended December&nbsp;31, 2023: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-</FONT></B><br><B>Average<BR>Exercise</B><br><B>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>&#8194;&#8194;Contractual&#8194;&#8194;<BR>Term&nbsp;(Years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8194;Intrinsic&nbsp;Value&#8194;<BR>(In&nbsp;Thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,229,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8194;&#8194;&#8194;&#8196;&#8196;3.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,275,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34,302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited or expired</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(304,696</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,166,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8202;&#8194;&#8194;&#8194;&#8194;&#8194;&#8194;&#8194;&#8196;&#8196;4,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,707,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8194;&#8196;&#8196;4,166,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options
and the estimated fair value of the Company&#146;s common stock for those stock options that had exercise prices lower than the estimated fair value of the Company&#146;s common stock. The aggregate intrinsic value of stock options exercised during
the year ended December&nbsp;31, 2023 was less than $0.1&nbsp;million. There were no stock options exercised during the year ended December&nbsp;31, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The weighted-average grant-date fair value of options granted during the years ended December&nbsp;31, 2023 and 2022 was $3.08 and $2.35, respectively. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023, there was $6.2&nbsp;million of total unrecognized compensation cost related to unvested stock options, which is expected to
be recognized over a weighted-average period of 2.9 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table illustrates the classification of stock-based compensation in the
consolidated statements of operations and comprehensive loss (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8194;&#8196;&#8196;&#8195;&#8195;2,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8194;&#8196;&#8196;&#8195;&#8195;1,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes related party amounts of $0.1&nbsp;million for the year ended December&nbsp;31, 2023 (Note 16)
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Income taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the years
ended December&nbsp;31, 2023 and 2022, the Company did not record a provision for income taxes because it has incurred net operating losses since inception and maintains a full valuation allowance against its deferred tax assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the U.S. federal statutory income tax rate to the Company&#146;s effective income tax
rate is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8194;2023&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8194;2022&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">US Federal statutory income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State income taxes, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in deferred tax asset valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8196;&#8196;&#8201;51.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8196;&#8196;&#8201;27.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other permanent differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The significant components of the Company&#146;s deferred tax assets and liabilities are summarized as follows (in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8196;&#8196;&#8196;6,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8196;&#8196;&#8196;3,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development tax credit carryforward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of acquired IPR&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8199;&#8195;18,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8199;&#8195;20,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets before valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(39,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,086</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets - net of valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ROU asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax asset (liability)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023, the Company had federal and state net operating loss (&#147;NOLs&#148;) carryforwards of
$25.0&nbsp;million and $27.6&nbsp;million, respectively. As of December&nbsp;31, 2022, the Company had federal and state NOLs carryforwards of $14.5&nbsp;million and $14.6&nbsp;million, respectively. The federal NOLs are not subject to expiration
and are limited in utilization to 80% of taxable income and the state NOLs begin to expire in 2041. The Company also has federal and state research and development credits of $0.8&nbsp;million which will begin to expire in 2043 and 2037,
respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Under
the applicable accounting standards, management has considered the Company&#146;s history of losses and concluded that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets.
Accordingly, a full valuation allowance of $39.7&nbsp;million and $29.1&nbsp;million has been established as of December&nbsp;31, 2023 and 2022, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in valuation allowance for deferred tax assets during the years ended December&nbsp;31, 2023 and 2022
related primarily to the increase in NOL carryforwards and capitalized research and development expenditures offset by amortization of acquired IPR&amp;D in 2023 and were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8194;2023&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8194;2022&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance at beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;&#8194;&#8196;&#8196;&#8195;(29,086</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8196;&#8194;&#8194;&#8196;(22,859</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases recorded to income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,609</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,227</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance at end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(39,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,086</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Utilization of the NOL and research and development credit carryforwards may be subject to a substantial annual limitation
under Section&nbsp;382 of the Internal Revenue Code of 1986 due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes may limit the amount of NOL and research and development credit
carryforwards that can be utilized annually to offset future taxable income and tax, respectively. The Company has not completed a study to assess whether a change of ownership has occurred, or whether there have been multiple ownership changes
since its formation, due to the significant cost and complexity associated with a study. There could also be additional ownership changes in the future which may result in additional limitations on the utilization of NOL carryforwards and credits.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023, the Company has not recorded any amounts for uncertain tax positions. The Company&#146;s policy is to recognize interest
and penalties accrued on any uncertain tax positions as a component of income tax expense, if any, in its consolidated statements of operations and comprehensive loss. For the years ended December&nbsp;31, 2023 and 2022, no estimated interest or
penalties were recognized on uncertain tax positions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it
operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company&#146;s tax years are still open under statute from
December&nbsp;31, 2020, to the present. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Net loss per share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (dollar amounts in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,537</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred Stock cumulative dividends</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,718</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(38,255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8194;&#8194;&#8196;&#8196;2,953,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8194;&#8194;&#8194;&#8196;2,937,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12.95</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8.13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to June 2023, the Company&#146;s Series A Preferred Stock holders were not entitled to cumulative dividends. In
connection with the Series B Agreement in June 2023, the Company modified the dividend rights for its Series&nbsp;A </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Preferred Stock holders such that they became entitled to cumulative dividends based on the original issuance dates of the respective Series A Preferred Stock (Note 8). As such, the Company
calculated its net loss attributable to common stockholders for the year ended December&nbsp;31, 2023 by adjusting its net loss for the aggregate cumulative dividends that had accrued since the original issuances dates in the period in which the
Preferred Stock holders became legally entitled to such dividends. No such adjustment was made for the year ended December&nbsp;31, 2022 as the holders of Series A Preferred Stock were not legally entitled to cumulative dividends until June 2023.
Similarly, cumulative dividends for the Series B Preferred Stock were included in the net loss attributable to common stockholders for the year ended December&nbsp;31, 2023 based on the issuance date for the Series B Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s potentially dilutive securities, which include stock options to purchase common stock and Preferred Stock, have been excluded from the
computation of diluted net loss per share as the effect would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is
the same. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following potentially dilutive securities have been excluded from the calculation of diluted net loss per share due to their anti-dilutive
effect: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred Stock (as converted to common
stock)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8194;&#8194;&#8196;&#8196;24,065,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8202;&#8194;&#8194;&#8194;&#8196;&#8196;12,588,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,166,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,229,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,231,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,817,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of December&nbsp;31, 2023, the Preferred Stock excludes 8,823,523 shares of Series B Preferred Stock (or
9,255,869&nbsp;shares as converted to common stock) that were contingently issuable upon settlement of the Series B preferred stock tranche right liability (Note 8). As of December&nbsp;31, 2022, the Preferred Stock excludes 8,000,000 shares of
Series A Preferred Stock (or 8,392,000 shares as converted to common stock) that were contingently issuable upon settlement of the Series A preferred stock tranche right liability (Note&nbsp;8). </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Commitments and contingencies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal matters
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities.
The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded
as a liability on the consolidated balance sheets. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but not probable; however, it discloses the range of reasonably possible losses. As
of December&nbsp;31, 2023 and 2022, the Company was not a party to any material legal proceedings or claims and no liabilities were recorded for loss contingencies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contracts </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company enters into contracts in
the normal course of business with various third parties for preclinical research studies, clinical trials, testing, manufacturing, and other services. These contracts generally provide for termination upon notice and are cancellable without
significant penalty or payment, and do not contain any minimum purchase commitments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Guarantees and indemnifications </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties
with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification
agreements with all board of directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors. The maximum potential amount of future payments
the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under
indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of
December&nbsp;31, 2023 and 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Asset purchase and license agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Asset acquisition from Astellas Pharma, Inc. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
October 2021, the Company and Astellas Pharma, Inc. (&#147;Astellas&#148;) entered into an asset purchase agreement (the &#147;Astellas Asset Purchase Agreement&#148;). Pursuant to the Astellas Asset Purchase Agreement, the Company purchased from
Astellas the compound designated by Astellas as ASP7266 (the &#147;Compound&#148;), the corresponding patent rights and any unregistered intellectual property rights, inventory related to the Compound, documents, data and copies of all filings and
material correspondence with regulatory agencies (and the data included therein), and obtained an exclusive license under certain processes and methods of manufacture, testing, qualifying and use of the Compound to manufacture the Compound, with an
upfront cash payment of $81.1&nbsp;million. The Compound was renamed by the Company as verekitug (UPB-101). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, the Company will be solely
responsible for conducting the global research and development of the Compound. In connection with the Astellas Asset Purchase Agreement, Maruho, <FONT STYLE="white-space:nowrap">co-founder</FONT> of the Company and a related party, obtained from
the Company an exclusive, irrevocable, perpetual, royalty-free, sublicensable license to research, develop, manufacture, and commercialize verekitug with respect to Japan at its sole expense (Note&nbsp;15). There are no future payments owed to
Astellas under the Astellas Asset Purchase Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Letter agreement with Astellas and Regeneron </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2021, in connection with the Astellas Asset Purchase Agreement, the Company, Astellas and Regeneron Pharmaceuticals, Inc. (&#147;Regeneron&#148;)
entered into a letter agreement (the &#147;Regeneron Letter Agreement&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Regeneron Letter Agreement relates to a prior <FONT
STYLE="white-space:nowrap">Non-Exclusive</FONT> License and Material Transfer Agreement (the &#147;Terminated Regeneron License Agreement&#148;) that Regeneron and Astellas entered into in March 2007, as amended in July 2010 and subsequently
terminated in June 2018, subject to certain surviving rights and obligations of both Regeneron and Astellas. Under the Terminated Regeneron License Agreement, Astellas utilized Regeneron&#146;s human antibody technology in its internal research
programs to discover certain product candidates, including the Compound, which it sold to the Company under the Astellas Asset Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under
the Regeneron Letter Agreement, Astellas assigned and transferred to the Company and the Company assumed and accepted certain of Astellas&#146; surviving rights and obligations under the Terminated Regeneron License Agreement, including
Astellas&#146; royalty payment, reporting and indemnification obligations in connection with activities conducted by or on behalf of the Company with respect to the Compound. By assuming and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accepting Astellas&#146; surviving obligations under the Terminated Regeneron License Agreement, the Company is required to pay Regeneron <FONT STYLE="white-space:nowrap">mid-single-digit</FONT>
percentage royalties on aggregate worldwide net sales of any product developed by or on behalf of the Company that contains the Compound as an ingredient or component of the materials sold (a &#147;Royalty Product&#148;) during the royalty term. The
royalties are determined on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis and expire
on the later of (i)&nbsp;a specified number of years after the launch of a given Royalty Product in a given country and (ii)&nbsp;the expiration of the last valid claim of royalty bearing company patent rights claiming or covering such Royalty
Product in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no payments made to Regeneron pursuant to the Regeneron Letter Agreement during the years ended December&nbsp;31,
2023 and 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License agreement with Lonza </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2021, in connection with the Astellas Asset Purchase Agreement, the Company and Lonza Sales AG (&#147;Lonza&#148;) entered into a license agreement
(as amended, the &#147;Lonza License Agreement&#148;). Pursuant to the Lonza License Agreement, the Company obtained a worldwide, <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> sublicensable (subject to Lonza&#146;s right of pre-approval
with respect to any sublicense of manufacturing activities) license to certain intellectual property rights owned by Lonza. Lonza was the originator of the master cell bank for the Compound developed by Astellas. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for the rights and licenses granted to the Company under the Lonza License Agreement, the Company agreed to pay Lonza certain royalties and
annual payments, both payable in swiss francs, in respect of the manufacturing and sale of the Compound, such amounts to be determined by the party manufacturing the Compound, and range from no annual payment to up to a mid-six-figure annual
payment, and a less-than-one percent to a low-single-digit percentage royalty on net sales of the Compound. In accordance with the Lonza License Agreement, the Company entered into a sublicense with Wuxi Biologics (Hong Kong) Limited to manufacture
the Compound, requiring the Company to pay a mid-six-figure annual fee to Lonza pursuant to this provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any royalties due under the Lonza License
Agreement are payable on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until ten years from the first commercial sale of the Compound in that particular country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2023 and 2022, the Company did not make any royalty payments to Lonza under the Lonza License Agreement. The Lonza
agreement continues for an indefinite period of time unless otherwise terminated. The Company has the right to terminate the Lonza License Agreement at any time by providing prior written notice to Lonza. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During each of the years ended December&nbsp;31, 2023 and 2022, the Company made an annual payment in the amount of $0.4&nbsp;million to Lonza pursuant to the
Lonza License Agreement and recognized it as research and development expense in the consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.
Revenue </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Maruho agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2021,
in connection with the Astellas Asset Purchase Agreement (Note 14), the Company entered into an agreement (as amended, the &#147;Maruho Agreement&#148;), under which it granted Maruho an exclusive, irrevocable, perpetual, royalty-free, sublicensable
(subject to its right of first negotiation) license. Pursuant to the Maruho Agreement, the Company maintains its responsibility for and controls the global research and development of the Maruho license product, including in Japan. The Company will
conduct specified clinical trial activities for Japan as part of its global research and development plan. Maruho will reimburse the Company for the costs of these research and development activities, including the cost of drug supply. Maruho has
the right to terminate the Maruho Agreement at any time by providing 60&nbsp;days prior written notice to the Company with no substantial penalty. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company concluded that Maruho is a customer under the Maruho Agreement, and as such, the Maruho Agreement
falls within the scope of ASC 606. The Company identified one performance obligation under the Maruho Agreement related to the performance of research and development services, which are an output of the Company&#146;s ordinary activities, in Japan.
The Company determined that the transaction price of the Maruho Agreement as of December&nbsp;31, 2023 consisted solely of variable consideration. The variable consideration was estimated using the expected value method based on the Company&#146;s
experience and best judgment of the total reimbursable costs expected to be incurred through the period of performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transaction price is being
recognized as revenue over time using the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> input method, which the Company believes best depicts the transfer of control to the customer. Under the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> input method, the extent of progress towards completion is measured based on the ratio of actual costs incurred in Japan to the total estimated costs expected to
satisfy the performance obligation. The calculation of the total estimated costs to fulfill the performance obligation includes costs associated with employees, clinical and development, manufacturing, and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs expected to be paid to third parties. The estimate of the Company&#146;s measure of progress and estimate of variable consideration to be included in the transaction price will be updated
at each reporting period as a change in estimate. The Company excludes disclosures related to the aggregate amount of the transaction price allocated to the performance obligation that are unsatisfied as of the end of the reporting period because
the contract has an initial expected term of one year or less. The Company currently expects to continue providing research and development services to Maruho under the Maruho Agreement through the completion of its Phase 2 clinical trials, and if
successful, through any Phase 3 clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2023 and 2022, the Company received prepayments of
$2.4&nbsp;million and $0.8&nbsp;million, respectively, from Maruho for research and development services to be provided by the Company under the Maruho Agreement. During the years ended December&nbsp;31, 2023 and 2022, the Company recognized all of
the related revenue from the prepayments, resulting in no deferred revenue as of December&nbsp;31, 2023 and 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Related parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2021, the Company entered into the Maruho Agreement (Note 15). Maruho is considered to be a related party because it is one of the <FONT
STYLE="white-space:nowrap">co-founders</FONT> of the Company and has representation on the Company&#146;s board of directors. During the years ended December&nbsp;31, 2023 and 2022, the Company received payments of $2.7&nbsp;million and
$0.8&nbsp;million, respectively, in cost reimbursements from Maruho. The Company recorded related party collaboration revenue of $2.4&nbsp;million and $1.2&nbsp;million during the years ended December&nbsp;31, 2023 and 2022, respectively. As of
December&nbsp;31, 2023 and 2022, there was $0.1&nbsp;million and $0.4&nbsp;million in related party accounts receivable, respectively, representing amounts due for qualifying reimbursable expenses related to the Maruho Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2023 and October 2022, the Company issued 1,000,000 shares and 125,000 shares, respectively, of Series A Preferred Stock to Maruho for gross
proceeds of $10.0&nbsp;million and $1.3&nbsp;million, respectively. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2023, the Company issued 20,980 shares of common stock to a related
party investor. The Company recorded stock-based compensation expense of $0.1&nbsp;million in connection with the issuance of these shares (Note 9). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. Employee benefit plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company established a
defined contribution savings plan under Section&nbsp;401(k) of the Code. This plan covers all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a <FONT
STYLE="white-space:nowrap">pre-tax</FONT> basis. Matching contributions to the plan may be made at the discretion of the Company&#146;s board of directors. The Company made $0.2&nbsp;million in contributions to the plan during the year ended
December&nbsp;31, 2023. The Company did not make contributions to the plan during the year ended December&nbsp;31, 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. Subsequent events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has evaluated all events subsequent to December&nbsp;31, 2023, and through June&nbsp;12, 2024, which represents the date these consolidated
financial statements were available to be issued, and, only with respect to the stock split, through October&nbsp;7, 2024, the date the consolidated financial statements were available to be reissued. The Company has concluded that no subsequent
events have occurred that require disclosure except as disclosed below. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Modification of certain stock-based compensation awards </I></B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2024, the Company entered into a separation agreement with the Company&#146;s former Chief Operating Officer (&#147;COO&#148;), effective March
2024. Under the terms of the separation agreement, stock options for the purchase of 142,935&nbsp;shares of common stock, representing all of the vested options held by the former COO as of the date of her termination, became exercisable for one
year following her termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2024, the Company entered into a separation agreement with the Company&#146;s former Chief Executive Officer
(&#147;CEO&#148;), effective March 2024. Under the terms of the separation agreement, vesting of options for the purchase of 38,245&nbsp;shares of common stock held by the former CEO were accelerated with no change to the exercise price of such
options. In addition, stock options for the purchase of 532,553&nbsp;shares of common stock, representing all of the vested options held by the former CEO as of the date of her termination, became exercisable for two years following her termination.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of these modifications, the Company expects to recognize approximately $0.7&nbsp;million of
<FONT STYLE="white-space:nowrap">stock-based</FONT> compensation in the first quarter of 2024. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series B option closing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2024, pursuant to the satisfaction of the Series B Option contemplated in the Series B Agreement, the Company issued and sold 8,823,523 shares of
Series B Preferred Stock at a price of $17.00 per share, which resulted in gross cash proceeds of $150.0&nbsp;million. The Company incurred less than $0.1&nbsp;million of issuance costs in connection with the Series B Option closing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Increase in Shares Reserved for Issuance under the 2021 Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Series B Option, the Company&#146;s board of directors effected an increase of 1,595,521 in the total number of shares of common stock
reserved for issuance under the 2021 Plan. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Grant of options to employees </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March and April 2024, the Company granted options for the purchase of an aggregate of 1,645,671&nbsp;shares of common stock, at an exercise price of
$5.68&nbsp;per share, to certain employees, including the CEO and Chief Financial Officer. The aggregate <FONT STYLE="white-space:nowrap">grant-date</FONT> fair value of these options has not yet been determined but is expected to be recognized as <FONT
STYLE="white-space:nowrap">stock-based</FONT> compensation expense over a period of four years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April and May 2024, the Company granted options for
the purchase of an aggregate of 1,505,754&nbsp;shares of common stock, at an exercise price of $6.59&nbsp;per share, to certain employees, including the CEO. The aggregate <FONT STYLE="white-space:nowrap">grant-date</FONT> fair value of these
options has not yet been determined but is expected to be recognized as <FONT STYLE="white-space:nowrap">stock-based</FONT> compensation expense over a period of four years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock split </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;4, 2024, the Company effected a 1.049-for-one stock split of its issued and outstanding shares of common stock and a proportional adjustment to
the existing conversion ratios of each series of the Company&#146;s preferred stock (see Note&nbsp;8). Accordingly, all share and per share amounts for all periods presented in the accompanying consolidated financial statements and notes thereto
have been adjusted retroactively, where applicable, to reflect this stock split and adjustment of the preferred stock conversion ratios. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin843142_7"></A>Condensed consolidated balance sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands, except share and per share amounts) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">188,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable - related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">243,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;&#8202;244,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8195;&#8202;117,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock tranche right liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock (Series A, B), $0.001 par value; 31,764,693 shares
authorized at June&nbsp;30, 2024 and December 31, 2023; 31,764,693 shares and 22,941,170 shares issued and outstanding at June&nbsp;30, 2024 and December&nbsp;31, 2023, respectively; aggregate liquidation preference of $425,718 and $267,718 at
June&nbsp;30, 2024 and December&nbsp;31, 2023, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">380,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">230,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value; 40,684,346 shares and 40,664,346 shares authorized at
June&nbsp;30, 2024 and December&nbsp;31, 2023, respectively; 3,020,546 and 2,992,479&nbsp;shares issued and outstanding at June&nbsp;30, 2024 and December&nbsp;31, 2023, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(153,546</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(127,974</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(146,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(123,126</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, redeemable convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">244,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these unaudited condensed</I><B> </B><I>consolidated
financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin843142_8"></A>Condensed consolidated statements of operations and comprehensive loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands, except share and per share amounts) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue - related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,398</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock tranche right liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(92</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,602</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock cumulative dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,416</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(33,572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,018</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11.18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5.79</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8194;&#8201;&#8195;3,002,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8194;&#8201;&#8195;2,937,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,602</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized loss on investments, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(76</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,648</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,660</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these unaudited condensed</I><B> </B><I>consolidated
financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin843142_9"></A>Condensed consolidated statements of redeemable convertible preferred stock and stockholders&#146; deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands, except share amounts) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7.5pt"><B>Redeemable Convertible<BR>Preferred Stock</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7.5pt"><B>Common Stock</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7.5pt"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ROWSPAN="2" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><FONT STYLE="font-size:7.5pt"><B>Accumulated<BR>Deficit</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ROWSPAN="2" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><FONT STYLE="font-size:7.5pt"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Income (Loss)</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7.5pt"><B>Total<BR>Stockholders&#146;<BR>Deficit</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balances&nbsp;at&nbsp;December&nbsp;31,&nbsp;2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,937,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(107,437</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(106,155</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series A redeemable convertible preferred stock in connection with the settlement of
the tranche right liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series B redeemable convertible preferred stock, net of preferred stock tranche right
liability of $11,774 and issuance costs of $385</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,941,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise of stock options, net of tax withholding</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Unrealized loss on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8199;&#8199;&#8199;&#8201;&#8199;(58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,602</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,602</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balances at June&nbsp;30, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;&#8194;&#8194;22,941,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;&#8194;&#8201;&#8198;230,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;&#8194;&#8194;&#8202;2,942,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;&#8194;3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;&#8201;3,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8201;&#8194;&#8202;&#8201;(113,039</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8194;&#8194;&#8201;&#8201;(58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8201;&#8198;&#8194;&#8201;(109,866</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7.5pt"><B>Redeemable Convertible<BR>Preferred Stock</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7.5pt"><B>Common Stock</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7.5pt"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ROWSPAN="2" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><FONT STYLE="font-size:7.5pt"><B>Accumulated<BR>Deficit</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ROWSPAN="2" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><FONT STYLE="font-size:7.5pt"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Income (Loss)</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7.5pt"><B>Total<BR>Stockholders&#146;<BR>Deficit</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balances&nbsp;at&nbsp;December&nbsp;31,&nbsp;2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,941,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">230,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,992,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(127,974</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(123,126</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series B redeemable convertible preferred stock in connection with the settlement of
the tranche right liability, net of issuance costs of $75</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,823,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">149,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise of stock options, net of tax withholding</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Unrealized loss on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8199;&#8199;&#8199;&#8201;&#8199;(76</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(76</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balances at June&nbsp;30, 2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;&#8194;&#8194;31,764,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;&#8194;&#8201;&#8198;380,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;&#8194;&#8194;&#8202;3,020,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;&#8194;3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;&#8201;6,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8201;&#8194;&#8202;&#8201;(153,546</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8194;&#8194;&#8201;&#8201;(55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8201;&#8198;&#8194;&#8201;(146,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these unaudited condensed</I><B> </B><I>consolidated
financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin843142_10"></A>Condensed consolidated statements of cash flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="8" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,602</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock tranche right liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,859</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,769</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net amortization of premiums and accretion of discounts on short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,765</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable - related party</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(412</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(502</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue - related party</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,598</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,997</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(174,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(89,705</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maturities of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(144</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(102,802</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(89,849</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the issuance of Series A redeemable convertible preferred stock<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the issuance of Series B redeemable convertible preferred stock including tranche
right, net of issuance costs paid</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the issuance of Series B redeemable convertible preferred stock, net of issuance
costs paid</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">149,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercises of stock options, net of tax withholding</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments of deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(133</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;149,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;129,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 47,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 39,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> asset
obtained in exchange for operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> -</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of <FONT STYLE="white-space:nowrap">non-cash</FONT> investing and
financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Settlement of Series A preferred stock tranche right liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> -</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Settlement of Series B preferred stock tranche right liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> -</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs included in accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> -</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes related party amount of $10.0&nbsp;million for the six months ended June&nbsp;30, 2023 (Note&nbsp;16).
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these unaudited condensed</I><B> </B><I>consolidated financial
statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin843142_11"></A>Notes to condensed consolidated financial statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Nature of the business
and basis of presentation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upstream Bio, Inc. was incorporated in April 2021, under the laws of the State of Delaware, and along with its consolidated
subsidiary (collectively, the &#147;Company&#148; or &#147;Upstream&#148;), is focused on developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. Since its inception, the Company has devoted
substantially all of its efforts to raising capital and incurring research and development expenses related to advancing verekitug, a clinical-stage monoclonal antibody that targets and inhibits the Thymic Stromal Lymphopoietin receptor. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks and uncertainties </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The global economy has
experienced extreme volatility and disruptions due to the military conflict between Russia and Ukraine and the war between Israel and Hamas. These conditions have impacted, and may continue to impact, the capital and credit markets, which may reduce
the Company&#146;s ability to raise additional capital through equity, equity-linked instruments or debt financings which could negatively impact the Company&#146;s short-term and long-term liquidity. Additionally, the Company&#146;s results of
operations could be adversely affected by general conditions in the global economy and financial markets. A severe or prolonged economic downturn could result in a variety of risks to the Company&#146;s business, including a reduced ability to raise
additional capital when needed on favorable terms, if at all. The Federal Reserve has raised interest rates multiple times in response to concerns about inflation and it may raise them again. Higher interest rates, coupled with reduced government
spending and volatility in financial markets, may increase economic uncertainty and affect consumer spending. Any of the foregoing could harm the Company&#146;s business, and it cannot anticipate all of the ways in which the current economic climate
and financial market conditions could adversely impact its ability to raise capital, business, results of operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited to, the successful development of verekitug, the development of new technological innovations by competitors,
dependence on key personnel, the ability to attract and retain qualified employees, protection of proprietary technology, compliance with governmental regulations and the ability to secure additional capital to fund operations and commercial success
of verekitug. There can be no assurance that the Company&#146;s research and development will be successfully completed, that adequate protection for the Company&#146;s intellectual property will be maintained, that any therapeutic products
developed will obtain required regulatory approval or that any approved or consumer products will be commercially viable. Even if the Company&#146;s development efforts are successful, it is uncertain when, if ever, the Company will generate
significant product sales. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#146;s ability to continue as a going concern within one year after the date that the condensed consolidated
financial statements are available to be issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying condensed consolidated financial statements have been prepared on the basis of
continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has historically financed its operations principally through the issuance and sale of Series A
redeemable convertible preferred stock (&#147;Series A Preferred Stock&#148;) and Series B redeemable convertible preferred stock (&#147;Series B Preferred Stock&#148;), which are collectively referred to as the &#147;Preferred Stock.&#148; The
Company has incurred recurring losses and negative cash flows from operations since its inception </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to condensed consolidated financial statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and expects to continue to incur losses and negative cash flows for the foreseeable future as it continues the research and development of verekitug. The Company incurred a net loss of
$25.6&nbsp;million and $5.6&nbsp;million for the six months ended June&nbsp;30, 2024 and 2023, respectively. As of June&nbsp;30, 2024, the Company had an accumulated deficit of $153.5&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date the condensed consolidated financial statements for the six months ended June&nbsp;30, 2024 were available to be issued, the Company expects
its existing cash, cash equivalents and short-term investments will be sufficient to fund its operating expenses and capital expenditures requirements for at least the next twelve months from the date the condensed consolidated financial statements
were available to be issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is seeking to complete an initial public offering (&#147;IPO&#148;) of its common stock. Upon the completion of
a qualified public offering on specified terms (Note 8), the Company&#146;s outstanding Preferred Stock will automatically convert into shares of common stock. In the event the Company does not complete an IPO, until such time as the Company can
generate significant product revenue, if ever, the Company expects to fund its operations through equity offerings or debt financings, credit or loan facilities, potentially other capital resources, or a combination of one or more of these funding
sources. The terms of any financing may adversely affect the holdings or the rights of the Company&#146;s stockholders. The Company&#146;s failure to raise capital as and when needed could have a negative impact on its financial condition and its
ability to pursue its business strategies. If adequate funds are not available to the Company, the Company may be required to delay, reduce or eliminate clinical programs, obtain funds through arrangements with collaborators on terms unfavorable to
the Company or pursue merger or acquisition strategies. There can be no assurances the Company will be able to obtain additional funding. Although management continues to pursue these plans, there is no assurance that the Company will be successful
in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of presentation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying unaudited condensed consolidated financial statements reflect the operations of the Company. Intercompany balances and transactions have been
eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#147;U.S. GAAP&#148;) for interim
financial reporting and as required by Regulation <FONT STYLE="white-space:nowrap">S-X,</FONT> Rule <FONT STYLE="white-space:nowrap">10-01.</FONT> Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP
as found in the Accounting Standards Codification (&#147;ASC&#148;) and Accounting Standards Update (&#147;ASU&#148;) of the Financial Accounting Standards Board (&#147;FASB&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The condensed consolidated interim financial statements have been prepared on the same basis as the audited annual financial statements and, in the opinion of
management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company&#146;s financial position as of June&nbsp;30, 2024 and the results of operations for the six month interim periods
ended June&nbsp;30, 2024 and 2023. The condensed balance sheet as of December&nbsp;31, 2023 was derived from audited annual financial statements but does not include all disclosures required by U.S. GAAP. The results of operations for the interim
periods are not necessarily indicative of results to be expected for the year ending December&nbsp;31, 2024, any other interim periods, or any future year or period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other
than policies noted below, there have been no significant changes from the significant accounting policies and estimates disclosed in Note 2 of the &#147;Notes to Consolidated Financial Statements&#148; in our audited annual financial statements
included elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to condensed consolidated financial statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets, liabilities, revenue and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases estimates and assumptions on historical experience when available and
on various factors that it believes to be reasonable under the circumstances. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates. Significant estimates and assumptions reflected
within these condensed consolidated financial statements include, but are not limited to, prepaid and accrued research and development expenses, including those related to contract research organizations (&#147;CROs&#148;), contract manufacturing
organizations (&#147;CMOs&#148;) and other third-party vendors, the valuation of the Company&#146;s common stock and stock-based awards and the valuation of the preferred stock tranche right liabilities. Changes in estimates are recorded in the
period in which they become known. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of credit risk and of significant suppliers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and
short-term investments. The Company deposits its cash and cash equivalents in financial institutions in amounts that may exceed federally insured limits, and has not experienced any losses on such accounts and does not believe it is exposed to any
unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company&#146;s short-term investments consist of U.S. treasury bills and U.S. government agency bonds which the Company believes represent
minimal credit risk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is dependent on third-party manufacturers to supply products for research and development activities related to
verekitug, including preclinical and clinical studies and testing. In particular, the Company relies and expects to continue to rely on a small number of manufacturers for the supply of verekitug. The Company&#146;s preclinical and clinical studies
and testing could be adversely affected by a significant interruption in the supply. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and cash equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all short-term, highly liquid investments, with an original maturity of three months or less, to be cash equivalents, and includes
amounts held in money market funds in the amount of $25.8&nbsp;million and $23.3&nbsp;million as of June&nbsp;30, 2024 and December&nbsp;31, 2023, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Short-term investments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Available-for-sale</FONT></FONT> securities consist of investments with original maturities greater than 90 days at acquisition date. The Company classifies any investments with maturities
beyond one year as short term, based on their highly liquid nature and because such <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities represent the investment of cash that is available for
current operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s debt security investments are classified as
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> and are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in
stockholders&#146; deficit. Realized gains and losses and declines in fair value due to credit-related factors are based on the specific identification method and are included as other expense, net in the condensed consolidated statements of
operations and comprehensive loss. The Company recorded interest income on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> investments of $4.1&nbsp;million and $1.1&nbsp;million during the six
months ended June&nbsp;30, 2024 and 2023, respectively, which is classified as interest income in the condensed consolidated statements of operations and comprehensive loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to condensed consolidated financial statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At each balance sheet date, the Company assesses <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities in an unrealized loss position to determine whether the unrealized loss or any potential credit losses should be recognized in other expense, net. The Company evaluates
whether it intends to sell, or it is more likely than not that it will be required to sell, the security before recovery of its amortized cost basis. The Company also evaluates whether the decline in fair value has resulted from credit losses or
other factors. In making this assessment, the Company considers the severity of the impairment, any changes in interest rates, changes to the underlying credit ratings and forecasted recovery, among other factors. The credit-related portion of
unrealized losses, and any subsequent improvements, are recorded in other expense, net. The portion that is not credit-related is treated in accordance with other unrealized losses as a component of accumulated other comprehensive income (loss) in
stockholders&#146; deficit. There have been no impairment or credit losses recognized during any of the periods presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deferred offering costs
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with <FONT
STYLE="white-space:nowrap">in-process</FONT> equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds from the offering,
either as a reduction of the carrying value of the Preferred Stock or in stockholders&#146; deficit as a reduction of additional <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-capital</FONT></FONT> generated as a result of
the offering. Should the planned equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the condensed consolidated statements of operations and comprehensive loss. The Company
recorded deferred offering costs of $1.3&nbsp;million and $0 as of June&nbsp;30, 2024 and December&nbsp;31, 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently issued accounting
pronouncements not yet adopted </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2023, the FASB issued ASU <FONT STYLE="white-space:nowrap">2023-07,</FONT> <I>Segment Reporting (Topic
280): Improvements to Reportable Segment Disclosures </I>(&#147;ASU <FONT STYLE="white-space:nowrap">2023-07&#148;).</FONT> ASU <FONT STYLE="white-space:nowrap">2023-07</FONT> expands public entities&#146; segment disclosures by requiring disclosure
of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim
disclosures of a reportable segment&#146;s profit or loss and assets. All disclosure requirements under ASU <FONT STYLE="white-space:nowrap">2023-07</FONT> are also required for public entities with a single reportable segment. ASU <FONT
STYLE="white-space:nowrap">2023-07</FONT> is effective for public business entities with fiscal years beginning after December&nbsp;15, 2023, and interim periods within fiscal years beginning after December&nbsp;15, 2024. The Company is currently
evaluating the impact of adopting ASU <FONT STYLE="white-space:nowrap">2023-07</FONT> on its consolidated financial statements and related disclosures.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
December 2023, the FASB issued ASU <FONT STYLE="white-space:nowrap">2023-09,</FONT> <I>Improvements to Income Tax Disclosures</I> (&#147;ASU <FONT STYLE="white-space:nowrap">2023-09&#148;).</FONT> ASU <FONT STYLE="white-space:nowrap">2023-09</FONT>
requires entities to disclose additional information in specified categories with respect to the reconciliation of the effective tax rate to the statutory rate (the rate reconciliation) for federal, state, and foreign income taxes. It also requires
greater detail about individual reconciling items in the rate reconciliation to the extent the impact of those items exceeds a specified threshold (if the effect of those reconciling items is equal to or greater than 5% of the amount computed by
multiplying pretax income or loss by the applicable statutory income tax rate). In addition to new disclosures associated with the rate reconciliation, ASU <FONT STYLE="white-space:nowrap">2023-09</FONT> requires information pertaining to taxes paid
(net of refunds received) to be disaggregated for federal, state, and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold. The amendments are effective for public
business entities for annual periods beginning after December&nbsp;15, 2024. For entities other than public business entities, the amendments are effective for annual periods beginning after December&nbsp;15, 2025. Early adoption is permitted. The
Company is currently evaluating the timing and impact of adopting ASU <FONT STYLE="white-space:nowrap">2023-09</FONT> on its consolidated financial statements and related disclosures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to condensed consolidated financial statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Fair value measurements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables present information about the Company&#146;s financial assets and liabilities measured at fair value on a recurring basis and indicate the
level of the fair value hierarchy used to determine such fair values (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements at<BR>June&nbsp;30, 2024 Using:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8199;&#8194;&#8201;&#8195;25,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. treasury bills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government agency bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8201;&#8195;188,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8201;&#8195;214,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements at<BR>December&nbsp;31, 2023 Using:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8201;&#8195;&#8199;23,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. treasury bills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government agency bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">23,314</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#8194;&#8201;&#8195;&#8199;83,977</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#8195;&#8201;&#8195;107,291</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock tranche right liability (Series&nbsp;B)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8201;&#8194;&#8194;&#8195;&#8199;2,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the six months ended June&nbsp;30, 2024 and for the year ended December&nbsp;31, 2023, there were no transfers between
Level&nbsp;1, Level&nbsp;2 and Level&nbsp;3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company classifies its U.S. treasury bills and U.S. government agency bonds as short-term based on each
instrument&#146;s availability for use in current operations. The fair value of the Company&#146;s U.S. treasury bills and U.S. government agency bonds are classified as Level&nbsp;2 because they are valued using observable inputs to quoted market
prices, benchmark yields, reported trades, broker/dealer quotes or alternative pricing sources with reasonable levels of price transparency and U.S. treasury bills. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to condensed consolidated financial statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Short-term investments consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized&nbsp;Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized&nbsp;Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized&nbsp;Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. treasury bills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8199;&#8199;&#8199;&#8201;(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government agency bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total short-term investments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8201;&#8195;188,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8199;&#8195;&#8199;&#8195;&#8199;&#8199;&#8201;&#8199;&#8199;1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(56</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;188,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized&nbsp;Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized&nbsp;Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized&nbsp;Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. treasury bills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8199;&#8195;&#8201;&#8195;45,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8199;&#8199;&#8199;&#8201;&#8195;&#8199;&#8199;&#8201;&#8199;&#8199;9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government agency bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total short-term investments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8199;&#8195;&#8199;&#8201;&#8201;&#8195;&#8199;&#8199;&#8201;(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8201;&#8195;&#8199;83,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The contractual maturities of the Company&#146;s short-term investments in <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities held were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Due within one year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;&#8201;&#8195;188,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8199;&#8195;&#8199;83,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Valuation of preferred stock tranche right liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023, the preferred stock tranche right liability in the table above is composed of the fair value of the obligation to issue Series B
Preferred Stock (Note 8). The fair value of the preferred stock tranche right liabilities was based on significant inputs not observable in the market, which represented a Level&nbsp;3 measurement within the fair value hierarchy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Series A preferred stock tranche right liability </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
February 2023, upon satisfaction of certain conditions, the second closing of the Series A Preferred Stock was completed. The Company issued and sold 8,000,000 shares of Series A Preferred Stock at a price of $10.00 per share, which resulted in the
settlement of the associated Series A preferred stock tranche right liability. The fair value of Series A Preferred Stock was $10.04 per share upon the second closing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Series B preferred stock tranche right liability </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
fair value of the Series B preferred stock tranche right liability was determined using an option pricing model as it represents an option for the Series&nbsp;B Option Shares (as defined in Note&nbsp;8). The valuation considered as inputs the
estimated fair value of the Series B Preferred Stock as of each valuation date, the risk-free interest rate, volatility, expected dividends, and estimated time to the tranche closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The most significant assumption in the valuation model impacting the fair value of the preferred stock tranche right liability is the fair value of the
Company&#146;s Series B Preferred Stock as of each measurement date. The Company determined the fair value per share of the underlying Series B Preferred Stock by taking into </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to condensed consolidated financial statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consideration the most recent sales of its Series B Preferred Stock, results obtained from third-party valuations and additional factors the Company deemed relevant. In June 2023, the initial
tranche of the Series B Preferred Stock closed with a fair value of $13.00 per share. As of December&nbsp;31, 2023, the fair value of Series B Preferred Stock was $15.86 per share. In April 2024, upon satisfaction of certain conditions, the Company
issued and sold 8,823,523 shares of Series B Preferred Stock at a price of $17.00 per share, which resulted in the settlement of the associated Series B preferred stock tranche right liability. The fair value of Series B Preferred Stock was $17.002
per share upon the closing. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the remaining estimated time to the tranche closing. The volatility is based on the
historical volatility of publicly traded peer companies adjusted for the seniority of the Series B Preferred Stock. The expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash
dividends in the foreseeable future. Changes in these inputs can have a significant impact on the fair value of the preferred stock tranche right liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the assumptions used in the option-pricing model to determine the fair value of the Series B preferred stock tranche right
liability during the periods presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June</B><br><B></B><B><I>(Issuance&nbsp;Date)</I></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June 30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51.0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36.2%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.2%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividends</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.3%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.4%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.4%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents a roll-forward of the fair value of the Series B preferred stock tranche right liability during
the six months ended June&nbsp;30, 2024, for which fair value is determined using Level&nbsp;3 inputs (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;B&nbsp;Preferred&nbsp;Stock<BR>Tranche Right Liability</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value at December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8199;&#8199;&#8195;&#8195;2,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of Series B preferred stock tranche right liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,859</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Final settlement of Series B preferred stock tranche right liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value at June&nbsp;30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> -</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents a roll-forward of the fair value of the Series A and Series B preferred stock tranche right
liabilities during the six months ended June&nbsp;30, 2023, for which fair value is determined using Level&nbsp;3 inputs (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred Stock Tranche&nbsp;Right&nbsp;Liability</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value at December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8194;&#8195;&#8199;6,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of Series B preferred stock tranche right liability at issuance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;11,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock tranche right liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,627</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Final settlement of Series A preferred stock tranche right liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value at June&nbsp;30, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to condensed consolidated financial statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Prepaid expenses and other current assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8199;&#8195;&#8195;&#8195;5,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8199;6,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid employee-related costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">6,717</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">7,088</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Property and equipment, net </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment, net consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8201;&#8195;&#8195;&#8195;&#8199;&#8199;163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8201;&#8195;&#8195;&#8195;&#8199;&#8199;163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense related to property and equipment, net was less than $0.1&nbsp;million for each of the
six months ended June&nbsp;30, 2024 and 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Accrued expenses and other current liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued employee compensation and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8199;&#8195;&#8195;&#8195;1,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8199;&#8195;&#8195;&#8195;2,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued consultant and professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued external research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4,684</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4,480</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Leases </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2023, the Company was a party to a lease related to commercial real estate under a <FONT STYLE="white-space:nowrap">non-cancelable</FONT> lease term and a short-term lease related to commercial real estate. In July 2024, the
Company entered into a lease for office space which has not yet commenced (Note 17). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to condensed consolidated financial statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has an operating lease for office space at 460 Totten Pond Road, Waltham, Massachusetts. The
lease expired on June&nbsp;30, 2024, after which the Company will continue to pay rent on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">month-to-month</FONT></FONT> basis until either party provides notice of termination. Under
its lease, the Company pays a proportional share of operating expenses. Such operating expenses are subject to annual adjustment and are accounted for as variable payments in the period in which they are incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Redeemable convertible preferred stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
has issued Series A Preferred Stock and Series B Preferred Stock, which are collectively referred to as the Preferred Stock. As of June&nbsp;30, 2024 and December&nbsp;31, 2023, the Company authorized the issuance of 31,764,693 shares of Preferred
Stock, par value of $0.001 per share, of which 20,000,000 have been designated Series A Preferred Stock and 11,764,693 have been designated Series B Preferred Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuance and sale of Series A redeemable convertible preferred stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2021, the Company issued and sold 11,000,000 shares of Series A Preferred Stock at $10.00 per share. Pursuant to the Series A Preferred Stock
Purchase Agreement (the &#147;Series A Agreement&#148;), the Company was obligated to issue and the Series A investors were obligated to purchase an additional 9,000,000 shares of Series A Preferred Stock (&#147;Milestone Shares&#148;) at the same
purchase price of $10.00 per share (the &#147;Series A preferred stock tranche right&#148;), after the initial closing and upon the satisfaction of certain conditions at a date which would occur at the earlier of (i)&nbsp;immediately prior to the
Company&#146;s first underwritten public offering of its common stock under the Securities Act; (ii)&nbsp;the resolution of the board of directors that the pharmacokinetics, pharmacodynamics, immunogenicity and safety profile of verekitug (formerly
referred to as ASP7266), when administered as multiple ascending doses, supports further clinical development (&#147;Second Closing Milestone&#148;) has been achieved; or (iii)&nbsp;the written consent of the purchasers holding a majority of the
Series A Preferred Stock that the Second Closing Milestone has been waived (collectively, the &#147;Second Closing&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The board of directors may
determine at any time prior to the Second Closing to issue and sell up to 1,000,000 of the Milestone Shares at a price of $10.00 per share for gross cash proceeds of $10.0&nbsp;million (&#147;Interim Second Closing&#148;) and the number of Milestone
Shares to be issued in the Second Closing will be reduced accordingly. In October 2022, the Interim Second Closing was completed and 1,000,000 of the Milestone Shares on a <FONT STYLE="white-space:nowrap">pro-rata</FONT> basis to the purchasers of
the Series A Preferred Stock were issued at a price of $10.00 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2023, upon the satisfaction of the Second Closing Milestone, the
remaining 8,000,000 of the Milestone Shares on a <FONT STYLE="white-space:nowrap">pro-rata</FONT> basis to the purchasers of the Series A Preferred Stock were issued at a price of $10.00 per share, which resulted in gross cash proceeds of
$80.0&nbsp;million. As a result of this issuance, the Series&nbsp;A preferred stock tranche right liability of $0.3&nbsp;million was settled and the Series A Preferred Stock was recorded at its fair value of $80.3&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuance and sale of Series B redeemable convertible preferred stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2023, the Company executed the Series B Stock Preferred Purchase Agreement (the &#147;Series B Agreement&#148;) to issue and sell up to 11,764,693
shares of Series&nbsp;B Preferred Stock at a price of $17.00 per share. In the initial closing in June 2023, the Company issued 2,941,170 shares of Series B Preferred Stock resulting in gross cash proceeds of $50.0&nbsp;million and incurred
$0.6&nbsp;million of issuance costs, of which $0.1&nbsp;million was allocated to the preferred stock tranche right liability and recognized in the condensed consolidated statement of operations and comprehensive loss as general and administrative
expense. Pursuant to the Series B Agreement, the Company has the right (&#147;Series B Option&#148;) to issue and sell an additional 8,823,523 shares of Series B </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to condensed consolidated financial statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Preferred Stock (&#147;Series B Option Shares&#148;) at the same price of $17.00 per share after the initial closing but prior to March&nbsp;31, 2024 upon approval of at least six (6)&nbsp;board
of directors of which at least one (1)&nbsp;has to be appointed by the holders of Series B Preferred Stock. If the Company does not exercise the Series B Option prior or at a date which would occur at the earlier of (i)&nbsp;March&nbsp;31, 2024 or
(ii)&nbsp;the closing of an acquisition agreement signed prior to March&nbsp;31, 2024, the holders of Series B Preferred Stock will have the right but not obligation to require the Company to issue and sell the Series B Option Shares at the same
purchase price of $17.00 per share (the &#147;Series B preferred stock tranche right&#148;). Upon the initial closing of the Series B Preferred Stock, the Company recorded a preferred stock tranche right liability of $11.8&nbsp;million and a
corresponding reduction to the carrying value of the Series B Preferred Stock. The fair value of the Series B preferred stock tranche right was allocated from the gross cash proceeds of $50.0&nbsp;million of the Series B Preferred Stock issuance,
and the residual value was then allocated to the Series B Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2024, pursuant to the satisfaction of the Series B Option
contemplated in the Series B Agreement, the Company issued and sold 8,823,523 shares of Series B Preferred Stock at a price of $17.00 per share, which resulted in gross cash proceeds of $150.0&nbsp;million. As a result of this issuance, the Series B
preferred stock tranche right liability of less than $0.1&nbsp;million was settled and the Series B Preferred Stock was recorded at its fair value of $150.0&nbsp;million. The Company incurred less than $0.1&nbsp;million of issuance costs in
connection with the Series B Option closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon issuance of the Preferred Stock, the Company assessed the embedded conversion and liquidation features
of the securities and determined that such features did not require the Company to separately account for these features. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preferred Stock consisted of
the following (dollar amounts in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="19" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30, 2024</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock Issued<BR>and&nbsp;Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Stock<BR>Issuable Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8194;20,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8194;20,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;&#8194;&#8194;193,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;&#8194;&#8194;221,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;&#8194;20,980,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,764,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,764,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">187,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">204,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,341,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,764,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,764,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">380,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">425,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,321,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="19" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2023</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock Issued<BR>and&nbsp;Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Stock<BR>Issuable Upon<BR>Conversion</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8194;20,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8194;20,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;&#8194;&#8194;193,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;&#8194;&#8194;216,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;&#8194;20,980,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,764,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,941,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,085,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,764,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,941,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">230,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">267,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,065,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of the Preferred Stock have the following rights and preferences: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of Preferred Stock are
entitled to a cumulative dividend from and after the date of the share issuance at the rate per annum of 5% of the Original Issue Price (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar
recapitalization with respect to the Preferred Stock), </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to condensed consolidated financial statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provided that the total accrued amount will not exceed 15% of the Original Issue Price in aggregate (the &#147;Accruing Dividend&#148;). Such dividends shall be accrued, whether or not declared.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of any dividend being payable to common stockholders, the holders of Preferred Stock shall be entitled to receive, prior to any such
dividend being paid to the common stockholders, the greater of (i)&nbsp;the Accruing Dividend then accrued and not previously paid, and (ii)&nbsp;the amount of any dividend being paid to the common stockholders (determined on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> basis with respect to the holders of Preferred Stock). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of the Preferred Stock are entitled to vote together with all other classes and series of stock as a single class on all matters, except those
matters requiring a separate class vote, and are entitled to the number of votes equal to the number of shares of common stock into which each share of the applicable series of Preferred Stock is then convertible. The holders of Series A Preferred
Stock as a separate class are entitled to elect four&nbsp;(4)&nbsp;board of directors, and the holders of Series B Preferred Stock as a separate class are entitled to elect two&nbsp;(2)&nbsp;board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation preference </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of any
voluntary or involuntary liquidation, dissolution or winding up of the Company or in the event of a Deemed Liquidation Event (&#147;DLE&#148;) which is defined as a merger or consolidation in which the Company issues shares of its capital stock
(other than one in which stockholders of the Company own a majority by voting power of the outstanding shares of the surviving or acquiring corporation), and the sale, lease, transfer, exclusive license or other disposition of substantially all of
the Company&#146;s assets, the holders of shares of Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its shareholders or consideration payable to stockholders in such DLE or
out of the available proceeds as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Before any payment is made to the holders of Series A Preferred Stock and common stock, an amount equal to any
Accruing Dividends on the Series B Preferred Stock accrued but unpaid, whether or not declared, together with any other dividends that are declared but unpaid (&#147;Series B Dividend Payment&#148;); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the assets available are not sufficient for the Company to pay the Series B Dividend Payment to the holders of
Series B Preferred Stock in full, holders of Series B Preferred Stock will share ratably in the assets available for distribution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">After the Series B Dividend Payment is paid in full, holders of Preferred Stock will be entitled to be paid out
of the assets of the Company available for distribution to its stockholders before any payment is made to the holders of common stock, on a pari passu basis, an amount per share equal to (i)&nbsp;with respect to the Series A Preferred Stock, the
greater of (a)&nbsp;the Original Issue Price, plus any Accruing Dividends on the Series A Preferred Stock accrued but unpaid, whether or not declared, together with any other dividends declared but unpaid, or (b)&nbsp;such amount per share as would
have been payable had all shares of Series A Preferred Stock been converted in common stock, and (ii)&nbsp;with respect to the Series B Preferred Stock, (1)&nbsp;the greater of (a)&nbsp;the Original Issue Price, plus any Accruing Dividends on the
Series B Preferred Stock accrued but unpaid, whether or not declared, together with any other dividends declared but unpaid thereon, or (b)&nbsp;such amount per share as would have been payable had all shares of Series B Preferred Stock been
converted in common stock, less (2)&nbsp;Series B Dividend Payment that was paid. (&#147;Liquidation Amount&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the assets available are not sufficient for the Company to pay holders of Preferred Stock the Liquidation
Amount in full, holders of Preferred Stock will share ratably in the assets available for distribution; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to condensed consolidated financial statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">After payment of Liquidation Amounts is paid in full to the holders of Preferred Stock, the remaining assets of
the Company available for distribution to its stockholders, or in the case of a DLE, the consideration not payable to the holders of shares of Preferred Stock or the remaining available proceeds, will be distributed among the holders of the shares
of common stock on a pro rata basis. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#147;Original Issue Price&#148; is defined as (i)&nbsp;with respect to the Series A Preferred
Stock, $10.00 per share, and (ii)&nbsp;with respect to the Series B Preferred Stock, $17.00 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Optional conversion </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each share of Preferred Stock is
convertible at the option of the holder and at any time into common stock as determined by dividing the Preferred Stock Original Issue Price by the Preferred Stock Conversion Price. &#147;Conversion Price&#148; is defined as initially the applicable
Original Issue Price for the applicable series of Preferred Stock, subject to certain adjustments in the event of any down round, stock dividend, stock split, combination or other similar recapitalization. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Mandatory conversion </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each share of Preferred Stock
will automatically be converted into shares of common stock, at the conversion ratio of dividing the Original Issue Price by the Preferred Stock Conversion Price, upon either (a)&nbsp;the closing of the sale of shares of common stock to the public
at a price of at least $21.07&nbsp;per&nbsp;share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the common stock) in a firm commitment underwritten
public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $100.0&nbsp;million of gross proceeds to the Company and after which the common stock is listed on the Nasdaq Global
Market, the Nasdaq Global Select Market or the New York Stock Exchange or (b)&nbsp;the date and time, or the occurrence of an event specified by vote or written consent of the Requisite Holders (which is defined as at least a majority of the
outstanding shares of Preferred Stock, voting together as a single class on an as converted to common stock basis, which majority must include holders of at least a majority of the outstanding shares of Series B Preferred Stock) voting together as a
single class on an as converted to common stock basis, then all outstanding shares of Preferred Stock will automatically be converted into shares of common stock, at the then effective conversion rate and such shares of Preferred Stock may not be
reissued by the Company. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Special mandatory conversion </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Series A Agreement, if a Series A Preferred Shareholder fails to purchase all of the Milestone Shares allocated to such
shareholder at or prior to the Second Closing Milestone or breaches its obligations set forth in the Series A Agreement, then such investor will be deemed a Defaulting Purchaser. As of December&nbsp;31, 2023, all of the Milestone Shares had been
issued without triggering the special mandatory conversion provision under the Series A Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Series B Agreement, if a
Series B Preferred Shareholder fails to purchase all of the Series B Option Shares allocated to such shareholder at or prior to the closing of the Series B Option or breaches its obligations set forth in the Series B Agreement, then such investor
will be deemed a Defaulting Purchaser. Each ten shares of Preferred Stock held by the Defaulting Purchaser will automatically, and without any further action on the part of such holder, be converted into one share of common stock. In April 2024, all
of the Series B Option Shares had been issued without triggering the special mandatory conversion provision under the Series B Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to condensed consolidated financial statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Modification to Series A preferred stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2023, in connection with the issuance of the Company&#146;s Series B Preferred Stock, the rights of the Company&#146;s Series A Preferred Stock were
amended to entitle holders to a cumulative dividend from and after the date of the share issuance at the rate per annum of 5% of the Original Issue Price (subject to appropriate adjustment in the event of any stock dividend, stock split, combination
or other similar recapitalization with respect to the Preferred Stock), provided that the total accrued amount will not exceed 15% of the Original Issue Price in aggregate. The dividend replaced the original accrued return definition within the
liquidation preference terms of the Series A Preferred Stock. Previously, holders were entitled to a liquidation preference per share equal to the greater of (a)&nbsp;the Original Issue Price, plus an accrued return of 5% of the Original Issue Price
per annum, provided that the total of such accrued return shall not exceed 15% of the Original Issue Price in the aggregate, or (b)&nbsp;such amount per share as would have been payable had all shares of Series A Preferred Stock been converted in
common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The changes to the rights of the Company&#146;s Series A Preferred Stock were not considered to be a significant change to the contractual
terms of the Company&#146;s Series A Preferred Stock because the accrued return of the liquidation preference and the cumulative dividend definitions will result in the same amount to be received in a liquidation event, and accordingly, the Company
accounted for the change as a modification. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Common stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#146;s stockholders. Common stockholders are
entitled to receive dividends, as may be declared by the board of directors, if any, subject to the preferential dividend rights of the Preferred Stock. When dividends are declared on shares of common stock, the Company must declare at the same time
a dividend payable to the holders of Preferred Stock equivalent to the dividend amount they would receive if each share of Preferred Stock were converted into common stock. The Company may not pay dividends to common stockholders until all dividends
accrued or declared but unpaid on the Preferred Stock have been paid in full. As of June&nbsp;30, 2024 and December&nbsp;31, 2023, no dividends were declared. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2024 and December&nbsp;31, 2023, the Company&#146;s amended and restated certificate of incorporation authorized the issuance of
40,684,346 and 40,664,346 shares, respectively, of $0.001 par value common stock. As of June&nbsp;30, 2024 and December&nbsp;31, 2023, there were 3,020,546 shares and 2,992,479 shares of common stock issued and outstanding, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2024 and December&nbsp;31, 2023, the Company had reserved 39,619,406 and 38,051,952&nbsp;shares of common stock, respectively, for the
conversion of shares of Preferred Stock into common stock (including committed but unissued shares under future tranche obligations for the Preferred Stock as of December&nbsp;31, 2023), the exercise of outstanding stock options for common stock,
and the issuance of common stock options remaining available for grant under its equity incentive plan. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Stock-based compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock incentive plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s 2021 Stock
Option and Grant Plan (the &#147;2021 Plan&#148;) provides for the Company to grant incentive stock options, nonqualified stock options, restricted stock awards, unrestricted stock awards and restricted stock units (collectively, the
&#147;Awards&#148;) to among others, members of the board of directors, employees, consultants and other key persons to the Company and its affiliates. The 2021 Plan is administered by the board of directors, or at the discretion of the board of
directors, by a committee of the board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to condensed consolidated financial statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2024 and December&nbsp;31, 2023, the total number of shares of common stock reserved
for issuance under the 2021 Plan was 6,360,626 shares and 4,765,105 shares, respectively. In April 2024, upon the satisfaction of the Series B Option contemplated in the Series B Agreement, the Company&#146;s board of directors increased the number
of shares of common stock reserved for issuance under the plan from 4,765,105 to 6,360,626&nbsp;shares. As of June&nbsp;30, 2024 and December&nbsp;31, 2023, 74,027&nbsp;shares and 564,696&nbsp;shares remain available for future grants, respectively.
Shares of unused common stock underlying any Awards that are forfeited, canceled or reacquired by the Company prior to vesting will again be available for the grant of awards under the 2021 Plan. Shares underlying any awards that are forfeited,
canceled, or reacquired by the Company prior to vesting, satisfied without the issuance of stock or otherwise terminated and shares that are withheld upon exercise of an option of settlement of an award to cover the exercise price or tax withholding
shall be added back to the shares available for issuance under the 2021 Plan. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair value inputs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents, on a weighted-average basis, the assumptions used in the Black-Scholes option-pricing model to determine the fair value of stock
options granted: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per share fair value of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8201;&#8195;&#8195;6.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8194;&#8194;&#8199;&#8195;&#8195;4.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72.8%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80.4%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.35%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.94%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company generally grants stock-based awards with service-based vesting. During the six months ended June&nbsp;30, 2024, the Company granted
performance-based stock options to certain employees and directors for the purchase of an aggregate 1,206,249&nbsp;shares of common stock with a vesting commencement date contingent upon the achievement of the Series B Option closing, which was
achieved in April 2024. The Company determined that it met all the conditions to establish a grant date for these performance-based stock options at the original issuance date and that the performance condition was deemed probable of achievement, as
the board of directors had approved the Series B Option closing prior to the grant date. The vesting of the performance-based stock options is also subject to the grantees&#146; continued service until the fourth anniversary of the Series B Option
closing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to condensed consolidated financial statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the activity of stock options with service-based and performance-based vesting
conditions during the six months ended June&nbsp;30, 2024: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Term&nbsp;(Years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Intrinsic&nbsp;Value<BR>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,166,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8194;&#8194;&#8194;&#8196;&#8196;3.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 4,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,173,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28,067</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited or expired</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,087,264</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of June&nbsp;30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,224,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8194;&#8194;&#8194;&#8194;&#8194;&#8196;&#8196;26,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable as of June&nbsp;30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,674,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 9,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest as of June&nbsp;30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8194;&#8196;&#8196;6,224,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options
and the estimated fair value of the Company&#146;s common stock for those stock options that had exercise prices lower than the estimated fair value of the Company&#146;s common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The weighted-average grant-date fair value of options granted during the six months ended June&nbsp;30, 2024 and 2023 was $4.14 and $3.01, respectively. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2024, there was $15.1&nbsp;million of total unrecognized compensation cost related to unvested stock options, which is expected to be
recognized over a weighted-average period of 3.4 years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Modification of certain stock-based compensation awards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2024, the Company entered into a separation agreement with the Company&#146;s former Chief Operating Officer (&#147;COO&#148;), effective March
2024. Under the terms of the separation agreement, stock options for the purchase of 142,935 shares of common stock, representing all of the vested options held by the former COO as of the date of her termination, became exercisable for one year
following her termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2024, the Company entered into a separation agreement with the Company&#146;s former Chief Executive Officer
(&#147;CEO&#148;), effective March 2024. Under the terms of the separation agreement, vesting of options for the purchase of 38,245 shares of common stock held by the former CEO were accelerated with no change to the exercise price of such options.
In addition, stock options for the purchase of 532,553 shares of common stock, representing all of the vested options held by the former CEO as of the date of her termination, became exercisable for two years following her termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of these modifications, the Company recognized $0.7&nbsp;million of incremental stock-based compensation during the six months ended June&nbsp;30,
2024. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to condensed consolidated financial statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table illustrates the classification of stock-based compensation in the condensed consolidated
statements of operations and comprehensive loss (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8194;&#8194;&#8194;&#8194;&#8194;&#8199;&#8199;1,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8194;&#8194;&#8194;&#8194;&#8194;&#8199;&#8199;1,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Income Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company&#146;s tax provision for interim periods is determined using an estimate of its annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, the Company updates its estimate of the annual
effective tax rate and, if the estimated annual effective tax rate changes, the Company makes a cumulative adjustment in such period. No such adjustment was made as of June&nbsp;30, 2024. The Company&#146;s effective federal and state tax rate for
the six months ended June&nbsp;30, 2024 and 2023 was 0%, and the Company did not record any income tax expense or benefit during the six months ended June&nbsp;30, 2024 and 2023, primarily as a result of estimated net operating losses for the fiscal
year to date offset by the increase in the valuation allowance against its deferred tax asset. All losses before income taxes arose in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Net loss per share </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per
share attributable to common stockholders was calculated as follows (dollar amounts in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,602</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred Stock cumulative dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,416</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(33,572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,018</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8196;&#8201;3,002,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;&#8196;2,937,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11.18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5.79</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to June 2023, the Company&#146;s Series A Preferred Stockholders were not entitled to cumulative dividends. In
connection with the Series B Agreement in June 2023, the Company modified the dividend rights for its Series&nbsp;A Preferred Stockholders such that they became entitled to cumulative dividends based on the original issuance dates of the respective
Series A Preferred Stock (Note 8). As such for the six months ended June&nbsp;30, 2023, the Company calculated its net loss attributable to common stockholders by adjusting its net loss for the aggregate cumulative dividends that had accrued since
the original issuances dates in the period in which the Preferred Stockholders became legally entitled to such dividends. For the six months ended June&nbsp;30, 2024, the Company calculated its net loss attributable to common stockholders by
adjusting its net loss for the aggregate cumulative dividends that accrued during the period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to condensed consolidated financial statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s potentially dilutive securities, which include stock options to purchase common stock and
Preferred Stock, have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per
share attributable to common stockholders is the same. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following potentially dilutive securities have been excluded from the calculation of diluted
net loss per share due to their anti-dilutive effect: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred Stock (as converted to common
stock)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;33,321,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;24,065,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,224,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,707,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,545,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,773,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the six months ended June&nbsp;30, 2023, the Preferred Stock excludes 8,823,523 shares of Series B
Preferred Stock (or 9,255,869 shares as converted to common stock) that were contingently issuable upon settlement of the Series B preferred stock tranche right liability (Note 8). </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Commitments and contingencies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal matters
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities.
The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded
as a liability on the condensed consolidated balance sheets. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but not probable; however, it discloses the range of reasonably possible
losses. As of June&nbsp;30, 2024 and December&nbsp;31, 2023, the Company was not a party to any material legal proceedings or claims and no liabilities were recorded for loss contingencies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contracts </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company enters into contracts in
the normal course of business with various third parties for preclinical research studies, clinical trials, testing, manufacturing, and other services. These contracts generally provide for termination upon notice and are cancellable without
significant penalty or payment, and do not contain any minimum purchase commitments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Guarantees and indemnifications </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties
with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification
agreements with all board of directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors. The maximum potential amount of future payments
the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to condensed consolidated financial statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any claims under indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to
such obligations in its condensed consolidated financial statements as of June&nbsp;30, 2024 and December&nbsp;31, 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. License agreements
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License agreement with Lonza </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October
2021, in connection with an asset purchase agreement entered into with Astellas Pharma, Inc. (&#147;Astellas&#148;), the Company and Lonza Sales AG (&#147;Lonza&#148;) entered into a license agreement (as amended, the &#147;Lonza License
Agreement&#148;). Pursuant to the Lonza License Agreement, the Company obtained a worldwide, <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> sublicensable (subject to Lonza&#146;s right of <FONT STYLE="white-space:nowrap">pre-approval</FONT>
with respect to any sublicense of manufacturing activities) license to certain intellectual property rights owned by Lonza. Lonza was the originator of the master cell bank for verekitug (formerly referred to as ASP7266 and <FONT
STYLE="white-space:nowrap">UPB-101,</FONT> collectively referred to as &#147;the Compound&#148;) developed by Astellas. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for the rights
and licenses granted to the Company under the Lonza License Agreement, the Company agreed to pay Lonza certain royalties and annual payments, both payable in swiss francs, in respect of the manufacturing and sale of the Compound, such amounts to be
determined by the party manufacturing the Compound, and range from no annual payment to up to a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mid-six-figure</FONT></FONT> annual payment, and a
<FONT STYLE="white-space:nowrap">less-than-one</FONT> percent to a <FONT STYLE="white-space:nowrap">low-single-digit</FONT> percentage royalty on net sales of the Compound. In accordance with the Lonza License Agreement, the Company entered into a
sublicense with Wuxi Biologics (Hong Kong) Limited to manufacture the Compound, requiring the Company to pay a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mid-six-figure</FONT></FONT> annual fee to Lonza pursuant to this
provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any royalties due under the Lonza License Agreement are payable on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until ten years from the first commercial sale of the Compound in that particular country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2024 and 2023, the Company did not make any royalty payments to Lonza under the Lonza License Agreement. The Lonza
agreement continues for an indefinite period of time unless otherwise terminated. The Company has the right to terminate the Lonza License Agreement at any time by providing prior written notice to Lonza. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2024 and 2023, the Company made an annual payment in the amount of $0.5&nbsp;million and $0.4&nbsp;million,
respectively, to Lonza pursuant to the Lonza License Agreement and recognized it as research and development expense in the condensed consolidated statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Revenue </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Maruho agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2021, in connection with an asset purchase agreement entered into with Astellas, the Company entered into an agreement (as amended, the &#147;Maruho
Agreement&#148;), under which it granted Maruho an exclusive, irrevocable, perpetual, royalty-free, sublicensable (subject to its right of first negotiation) license. Pursuant to the Maruho Agreement, the Company maintains its responsibility for and
controls the global research and development of the Maruho license product, including in Japan. The Company will conduct specified clinical trial activities for Japan as part of its global research and development plan. Maruho will reimburse the
Company for the costs of these research and development activities, including the cost of drug supply. Maruho has the right to terminate the Maruho Agreement at any time by providing 60&nbsp;days prior written notice to the Company with no
substantial penalty. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to condensed consolidated financial statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company concluded that Maruho is a customer under the Maruho Agreement, and as such, the Maruho Agreement
falls within the scope of ASC 606. The Company identified one performance obligation under the Maruho Agreement related to the performance of research and development services, which are an output of the Company&#146;s ordinary activities, in Japan.
The Company determined that the transaction price of the Maruho Agreement as of June&nbsp;30, 2024 consisted solely of variable consideration. The variable consideration was estimated using the expected value method based on the Company&#146;s
experience and best judgment of the total reimbursable costs expected to be incurred through the period of performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transaction price is being
recognized as revenue over time using the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> input method, which the Company believes best depicts the transfer of control to the customer. Under the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> input method, the extent of progress towards completion is measured based on the ratio of actual costs incurred in Japan to the total estimated costs expected to
satisfy the performance obligation. The calculation of the total estimated costs to fulfill the performance obligation includes costs associated with employees, clinical and development, manufacturing, and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs expected to be paid to third parties. The estimate of the Company&#146;s measure of progress and estimate of variable consideration to be included in the transaction price will be updated
at each reporting period as a change in estimate. The Company excludes disclosures related to the aggregate amount of the transaction price allocated to the performance obligation that are unsatisfied as of the end of the reporting period because
the contract has an initial expected term of one year or less. The Company currently expects to continue providing research and development services to Maruho under the Maruho Agreement through the completion of its Phase 2 clinical trials, and if
successful, through any Phase 3 clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2023, the Company received a prepayment of $2.4&nbsp;million
from Maruho for research and development services to be provided by the Company under the Maruho Agreement. During the six months ended June&nbsp;30, 2023, the Company recognized $1.3&nbsp;million of related revenue from the prepayments, resulting
in $1.1&nbsp;million in deferred revenue as of June&nbsp;30, 2023. There was no deferred revenue as of December&nbsp;31, 2022. The Company did not receive any prepayments or recognize any deferred revenue during the six months ended June&nbsp;30,
2024. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Related parties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2021, the
Company entered into the Maruho Agreement (Note 15). Maruho is considered to be a related party because it is one of the <FONT STYLE="white-space:nowrap">co-founders</FONT> of the Company and has representation on the Company&#146;s board of
directors. During the six months ended June&nbsp;30, 2024 and 2023, the Company received payments of $0.7&nbsp;million and $2.7&nbsp;million, respectively, in cost reimbursements from Maruho. The Company recorded related party collaboration revenue
of $1.2&nbsp;million and $1.3&nbsp;million during the six months ended June&nbsp;30, 2024 and 2023, respectively. As of June&nbsp;30, 2024 and 2023, there was $0.5&nbsp;million and $0.1&nbsp;million in related party accounts receivable,
respectively, representing amounts due for qualifying reimbursable expenses related to the Maruho Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2023, the Company issued
1,000,000 shares of Series A Preferred Stock to Maruho for gross proceeds of $10.0&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. Subsequent events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has evaluated all events subsequent to June&nbsp;30, 2024, and through August&nbsp;9, 2024, which represents the date these condensed consolidated
financial statements were available to be issued, and through October 7, 2024, the date the condensed consolidated financial statements were available to be reissued. The Company has concluded that no subsequent events have occurred except as
disclosed below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to condensed consolidated financial statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Waltham Lease </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;3, 2024, the Company entered into a three-year agreement for office space located at 890 Winter Street in Waltham, Massachusetts. The Company will
begin paying monthly rent starting one month after the lease commences. Initial base rent shall be approximately $0.7&nbsp;million for the first year and approximately $0.8&nbsp;million for the second and third year. The lease is expected to
commence in September 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;8, 2024, the Company provided notice of termination of its current operating lease and sublease of office space
at 460 Totten Pond Road, Waltham, Massachusetts. This notice is effective on October&nbsp;9, 2024, after which the Company&#146;s rights and obligations under this lease and sublease will cease. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock split </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October 4, 2024, the Company
effected a&nbsp;1.049-for-one stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios of each series of the Company&#146;s preferred stock (see Note 8). Accordingly, all share
and per share amounts for all periods presented in the accompanying condensed consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this stock split and adjustment of the preferred stock
conversion ratios. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the stock split, the Company&#146;s board of directors adopted, and its stockholders approved, the third amended
and restated certificate of incorporation, which, among other things, increased the number of shares of common stock authorized for issuance to 500,000,000 shares of common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Written consent for the conversion of preferred stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October 4, 2024, the Company obtained written consent from the Requisite Holders (as defined in the Company&#146;s second amended and restated certificate
of incorporation) for the conversion of the preferred stock into common stock in connection with the Company&#146;s IPO (see Note 8). Pursuant to such consent, the Company&#146;s preferred stock will convert into common stock immediately prior to
the completion of the Company&#146;s IPO. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2024 Stock option and incentive plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August 19, 2024, the Company&#146;s board of directors adopted, and on October 4, 2024 its stockholders approved, the 2024 Stock Option and Incentive Plan
(the &#147;2024 Plan&#148;), which will become effective upon the date immediately preceding the date on which the registration statement of which this prospectus is a part is declared effective by the Securities and Exchange Commission (the
&#147;SEC&#148;). The 2024 Plan allows the Company to make equity-based and cash-based incentive awards to its officers, employees, directors, and consultants. The 2024 Plan provides for the grant of incentive stock options, non-qualified stock
options, stock appreciation rights, restricted stock units, restricted shares of common stock and other stock-based awards. The number of shares initially reserved for issuance under the 2024 Plan is 3,180,000 shares. The number of shares reserved
under the 2024 Plan is subject to adjustment in the event of a stock split, stock dividend or other change in the Company&#146;s capitalization. In addition, the number of shares reserved and available for issuance under the 2024 Plan will
automatically increase on January 1, 2025 and each January 1 thereafter, by five percent of the outstanding number of shares of its common stock on the immediately preceding December 31 or such lesser number of shares as determined by the
Company&#146;s compensation committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of common stock underlying any awards under the 2024 Plan and the 2021 Plan that are forfeited,
cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to condensed consolidated financial statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reacquired by the Company prior to vesting, satisfied without the issuance of stock, expire or are otherwise terminated (other than by exercise) will be added back to the shares of common stock
available for issuance under the 2024 Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2024 Employee stock purchase plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August 19, 2024, the Company&#146;s board of directors adopted, and on October 4, 2024 its stockholders approved, the 2024 Employee Stock Purchase Plan (the
&#147;2024 ESPP&#148;), which will become effective on the date immediately preceding the date on which the registration statement of which this prospectus forms a part is declared effective by the SEC. A total of 488,467 shares of common stock were
initially reserved for issuance to participating employees under this plan. The 2024 ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2025 and each January 1 thereafter through
January 1, 2034, by the least of (i) 976,934 shares of common stock, (ii) one percent of the outstanding number of shares of common stock on the immediately preceding December 31, or (iii) such lesser number of shares of common stock as determined
by the administrator of the 2024 ESPP. The number of shares reserved under the 2024 ESPP is subject to adjustment in the event of a stock split, stock dividend or other change in the Company&#146;s capitalization. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial" ALIGN="center"><B><I>12,500,000&nbsp;shares </I></B></P>
<P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g843142g22q66.jpg" ALT="LOGO" STYLE="width:2.17245in;height:0.393756in;">
 </P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:18pt; font-family:arial" ALIGN="center"><B><I>Common stock </I></B></P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:arial" ALIGN="center"><B>Preliminary prospectus </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:16pt">
<TD VALIGN="top"><B>J.P. Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:16pt; font-family:arial" ALIGN="center"><B>TD Cowen</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:16pt; font-family:arial" ALIGN="center"><B>Piper&nbsp;Sandler</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>William&nbsp;Blair</B></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Through and including &#8195;&#8195;&#8195;&#8195;&#8195; , 2024 (the 25th day after the date of this prospectus), all dealers
effecting transactions in our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to a dealer&#146;s obligation to deliver a prospectus when acting as an
underwriter and with respect to an unsold allotment or subscription. </B></P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8195;&#8195;&#8195;&#8195;, 2024 </P>
<P STYLE="font-size:48pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Part&nbsp;II </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Information not
required in prospectus </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Item&#8201;13. Other expenses of issuance and distribution. </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth the fees and expenses, other than underwriting discounts and commissions, payable in connection with the registration of the common stock
hereunder. All amounts are estimates except for the Securities and Exchange Commission (the &#147;SEC&#148;) registration fee, the Financial Industry Regulatory Authority, Inc. (&#147;FINRA&#148;) filing fee and The Nasdaq Global Market
(&#147;Nasdaq&#148;) listing fee. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Amount<BR>paid&nbsp;or</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>to&nbsp;be&nbsp;paid</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Nasdaq listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">295,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Printing and mailing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,835,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Transfer agent and registrar fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">395,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,010,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="4" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>    <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Item&#8201;14. Indemnification of directors and officers. </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Section&nbsp;145 of the Delaware General Corporation Law (&#147;DGCL&#148;) authorizes a corporation to indemnify its directors and officers against liabilities arising
out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover expenses (including
attorneys&#146; fees) judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding. Section&nbsp;145 permits corporations to pay expenses
(including attorneys&#146; fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section&nbsp;145 provides that a corporation has the power to purchase and maintain insurance on
behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the corporation would have the power to
indemnify the director or officer against such liability under Section&nbsp;145. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will adopt provisions in our third amended and restated certificate of
incorporation, which will become effective immediately prior to the completion of this offering, and our second amended and restated bylaws, which will become effective upon effectiveness of the registration statement of which this prospectus forms
a part, that limit or eliminate the personal liability of our directors and officers to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. Consequently, our directors and officers will not be personally
liable to us or our stockholders for monetary damages or breach of fiduciary duty as directors or officers, except for liability for: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any breach of their duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-1 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">for our directors, any unlawful payments related to dividends or unlawful stock purchases, redemptions or other
distributions; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any transaction from which the director derived an improper personal benefit; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">for our officers, any derivative action by or in the right of the corporation. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These limitations of liability do not alter director and officer liability under the federal securities laws and do not affect the availability of equitable remedies
such as an injunction or rescission. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, our second amended and restated bylaws will provide that: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we will indemnify our directors, officers and, in the discretion of our board of directors, certain employees to the
fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we will advance reasonable expenses, including attorneys&#146; fees, to our directors and, in the discretion of our board
of directors, to our officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of us, subject to limited exceptions. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have entered into indemnification agreements with each of our directors and intend to enter into such agreements with our executive officers. These agreements provide
that we will indemnify each of our directors, our executive officers and, at times, their affiliates to the fullest extent permitted by Delaware law. We will advance expenses, including attorneys&#146; fees (but excluding judgments, fines and
settlement amounts), to each indemnified director, executive officer or affiliate in connection with any proceeding in which indemnification is available and we will indemnify our directors and officers for any action or proceeding arising out of
that person&#146;s services as a director or officer brought on behalf of us or in furtherance of our rights. Additionally, certain of our directors or officers may have certain rights to indemnification, advancement of expenses or insurance
provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director&#146;s or officer&#146;s services as a director referenced herein. Nonetheless, we have agreed
in the indemnification agreements that our obligations to those same directors or officers are primary and any obligation of such affiliates or other third parties to advance expenses or to provide indemnification for the expenses or liabilities
incurred by those directors are secondary. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We also maintain general liability insurance which covers certain liabilities of our directors and officers arising out
of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriting agreement filed as Exhibit&nbsp;1.1 to this registration statement provides for indemnification of us and our directors and officers by the underwriters
against certain liabilities under the Securities Act and the Securities Exchange Act of 1934. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Item&#8201;15. Recent sales of unregistered securities. </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the three years preceding the filing of this registration statement, we have issued the following securities that were not registered under the Securities Act: </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>(a)&nbsp;Issuances of capital stock </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Set forth below is information
regarding securities we have issued within the past three years that were not registered under the Securities Act. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October 2021, we issued and sold an
aggregate of 1,258,800&nbsp;shares of common stock to accredited investors for no consideration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-2 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October 2021, we issued and sold an aggregate of 11,000,000 shares of Series A redeemable convertible preferred stock to
accredited investors at a purchase price of $10.00 per share for an aggregate purchase price of $110.0&nbsp;million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October 2022, in connection with the interim
milestone closing of our Series A redeemable convertible preferred stock financing, we issued and sold an aggregate of 1,000,000 shares of Series A redeemable convertible preferred stock to accredited investors at a purchase price of $10.00 per
share for an aggregate purchase price of $10.0&nbsp;million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In February 2023, in connection with the second milestone closing of our Series A redeemable
convertible preferred stock financing, we issued and sold an aggregate of 8,000,000 shares of Series A redeemable convertible preferred stock to accredited investors at a purchase price of $10.00 per share for an aggregate purchase price of
$80.0&nbsp;million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In June 2023, we issued and sold an aggregate of 2,941,170 shares of our Series B redeemable convertible preferred stock to accredited investors
at a purchase price of $17.00 per share for an aggregate purchase price of $50.0&nbsp;million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In April 2024, in connection with the Series B option closing of our
Series B redeemable convertible preferred stock financing, we issued and sold an aggregate of 8,823,523 shares of our Series B redeemable convertible preferred stock to accredited investors at a purchase price of $17.00 per share for an aggregate
purchase price of $150.0&nbsp;million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">No underwriters were involved in the foregoing sales of securities. Unless otherwise stated, the sales of securities
described above were deemed to be exempt from registration pursuant to Section&nbsp;4(a)(2) of the Securities Act, including Regulation D and Rule 506 promulgated thereunder, as transactions by an issuer not involving a public offering. All of the
purchasers in these transactions represented to us in connection with their purchase that they were acquiring the securities for investment and not distribution, that they could bear the risks of the investment and could hold the securities for an
indefinite period of time. Such purchasers received written disclosures that the securities had not been registered under the Securities Act and that any resale must be made pursuant to a registration or an available exemption from such
registration. All of the foregoing securities are deemed restricted securities for the purposes of the Securities Act. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>(b)&nbsp;Grants and exercises of stock
options </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Between January&nbsp;2, 2022 and December&nbsp;31, 2023, we granted stock options to purchase an aggregate of 4,599,470&nbsp;shares of our
common stock, with a weighted-average exercise price of $3.73&nbsp;per share, to employees, directors and consultants pursuant to the 2021 Stock Option and Grant Plan (&#147;2021 Plan&#148;). From January&nbsp;1, 2024 through the date of this
registration statement, we granted stock options to purchase an aggregate of 3,209,120&nbsp;shares of our common stock, with a weighted-average exercise price of $6.19&nbsp;per share, to employees, directors and consultants pursuant to the 2021
Plan. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From January&nbsp;1, 2022 through the date of this registration statement, 67,275&nbsp;shares of common stock have been issued upon the exercise of stock
options by our employees and former employees, which were granted pursuant to the 2021 Plan for aggregate consideration of approximately $0.2&nbsp;million. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
issuances of the securities described above were deemed to be exempt from registration pursuant to Section&nbsp;4(a)(2) of the Securities Act or Rule 701 promulgated under the Securities Act as transactions pursuant to compensatory benefit plans.
The shares of common stock issued upon the exercise of options are deemed to be restricted securities for purposes of the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-3 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Item&#8201;16. Exhibits and financial statement schedules. </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>(a)&nbsp;Exhibits </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit<BR>number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;&#8199;1.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="d843142dex11.htm">Form of Underwriting Agreement. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;&#8199;3.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="d843142dex31.htm">Second Amended and Restated Certificate of Incorporation, as amended and currently
 in effect. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;&#8199;3.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="d843142dex32.htm">Form of Third Amended and Restated Certificate of Incorporation, to be in effect
 immediately prior to the completion of this offering. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;&#8199;3.3*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="http://www.sec.gov/Archives/edgar/data/2022626/000119312524221372/d843142dex33.htm">Amended and Restated
 Bylaws, as amended and currently in effect. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;&#8199;3.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="d843142dex34.htm">Form of Second Amended and Restated Bylaws, to be in effect upon the effectiveness
 of this registration statement. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;&#8199;4.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="http://www.sec.gov/Archives/edgar/data/2022626/000119312524221372/d843142dex41.htm">Specimen Common
 Stock Certificate. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;&#8199;4.2&#043;*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="http://www.sec.gov/Archives/edgar/data/2022626/000119312524221372/d843142dex42.htm">Amended and Restated
 Investors&#146; Rights Agreement, among the registrant and certain of its stockholders, dated June&nbsp;6, 2023. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;&#8199;5.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="d843142dex51.htm">Opinion of Goodwin Procter LLP. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;10.1#*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="http://www.sec.gov/Archives/edgar/data/2022626/000119312524221372/d843142dex101.htm">2021 Stock Option
 and Grant Plan, as amended, and form of award agreements thereunder. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;10.2#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="d843142dex102.htm">Upstream Bio, Inc. 2024 Stock Option and Incentive Plan and form of award agreements
 thereunder. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;10.3#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="d843142dex103.htm">Upstream Bio, Inc. 2024 Employee Stock Purchase Plan. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;10.4#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="d843142dex104.htm">Form of Indemnification Agreement, by and between the registrant and each of its
 directors and executive officers.</A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;10.5#*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="http://www.sec.gov/Archives/edgar/data/2022626/000119312524221372/d843142dex105.htm">Senior Executive
 Cash Incentive Bonus Plan. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;10.6#*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="http://www.sec.gov/Archives/edgar/data/2022626/000119312524221372/d843142dex106.htm">Executive Severance
 Plan. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;10.7#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="d843142dex107.htm">Non-Employee Director Compensation Policy. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;10.8#*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="http://www.sec.gov/Archives/edgar/data/2022626/000119312524221372/d843142dex108.htm">Compensation Recovery
 Policy. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;10.9#*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="http://www.sec.gov/Archives/edgar/data/2022626/000119312524221372/d843142dex109.htm">Separation Agreement,
 by and between the registrant and Samantha Truex, M.B.A., dated March&nbsp;13, 2024. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;10.10#*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="http://www.sec.gov/Archives/edgar/data/2022626/000119312524221372/d843142dex1010.htm">Separation Agreement,
by and between the registrant and Jennifer Beachell, dated February&nbsp;26, 2024. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;10.11#*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="http://www.sec.gov/Archives/edgar/data/2022626/000119312524221372/d843142dex1011.htm">Form of Employment
 Agreement for Executive Officers, to be in effect upon the completion of this offering. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;10.12&#134;&#043;*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="http://www.sec.gov/Archives/edgar/data/2022626/000119312524221372/d843142dex1012.htm">Asset Purchase
 Agreement, by and between the registrant and Astellas Pharma Inc., dated October&nbsp;14, 2021. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;10.13&#134;*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="http://www.sec.gov/Archives/edgar/data/2022626/000119312524221372/d843142dex1013.htm">Letter Agreement,
 by and among the registrant, Astellas Pharma Inc. and Regeneron Pharmaceuticals Inc., dated October&nbsp;19, 2021.</A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;10.14&#134;&#043;*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="http://www.sec.gov/Archives/edgar/data/2022626/000119312524221372/d843142dex1014.htm">Exclusive License
 Agreement, by and between the registrant and Maruho Co., Ltd., dated October&nbsp;14, 2021, as amended. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;10.15&#134;&#043;*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="http://www.sec.gov/Archives/edgar/data/2022626/000119312524221372/d843142dex1015.htm">License Agreement,
 by and between the registrant and Lonza Sales AG, dated October&nbsp;21, 2021, as amended. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;10.16&#043;*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="http://www.sec.gov/Archives/edgar/data/2022626/000119312524221372/d843142dex1016.htm">License Agreement,
 by and between the registrant and NWALP TPOP Property Owner LLC, dated as of September&nbsp;13, 2022, as amended.</A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;10.17&#043;*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="http://www.sec.gov/Archives/edgar/data/2022626/000119312524221372/d843142dex1017.htm">Sublease Agreement,
 by and between the registrant and Imaging Endpoints, LLC, dated as of December&nbsp;27, 2021, as amended. </A></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-4 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="88%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit<BR>number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8194;10.18&#043;*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="http://www.sec.gov/Archives/edgar/data/2022626/000119312524221372/d843142dex1018.htm">Lease Agreement,
 by and between the registrant and BXP Waltham Woods LLC, dated as of July&nbsp;3, 2024. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8194;10.19#&#043;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="d843142dex1019.htm">Offer Letter, by and between the registrant and E. Rand Sutherland, M.D., M.P.H.,
 dated March 27, 2024, as amended. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8194;10.20#&#043;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="d843142dex1020.htm">Offer Letter, by and between the registrant and Michael Paul Gray, M.B.A., dated
 March 11, 2024. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;21.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="http://www.sec.gov/Archives/edgar/data/2022626/000119312524221372/d843142dex211.htm">Subsidiary of
 the registrant. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="d843142dex231.htm">Consent of PricewaterhouseCoopers LLP, independent registered public accounting
 firm.</A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="d843142dex51.htm">Consent of Goodwin Procter LLP (included in Exhibit&nbsp;5.1).</A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;24.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="http://www.sec.gov/Archives/edgar/data/2022626/000119312524221372/d843142ds1.htm#sig">Power of attorney
 (included on signature page).</A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&#8199;99.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="http://www.sec.gov/Archives/edgar/data/2022626/000119312524221372/d843142dex991.htm">Consent of Daniella
 Beckman to be Named as a Director Nominee. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">107.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="d843142dexfilingfees.htm">Filing fee table.</A></P></TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Previously filed. </TD></TR></TABLE>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to Item 601(b)(10) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">#</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Indicates a management contract or any compensatory plan, contract or arrangement. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#043;</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Certain exhibits and schedules to these agreements have been omitted pursuant to Item 601(a)(5) and (6)&nbsp;of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> The registrant will furnish copies of any of the
exhibits and schedules to the Securities and Exchange Commission upon request. </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>(b)&nbsp;Financial statement schedules </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the consolidated financial statements or notes
thereto. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Item&#8201;17. Undertakings. </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Insofar as indemnification for
liabilities arising under the Securities Act of 1933, as amended, may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the
opinion of the Securities and Exchange Commission (the &#147;SEC&#148;) such indemnification is against public policy as expressed in the Securities Act of 1933, as amended, and is therefore unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted
by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933, as amended, and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The registrant hereby undertakes that: </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(a)&nbsp;The registrant will provide to the
underwriter at the closing as specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(b)&nbsp;For purposes of determining any liability under the Securities Act of 1933, as amended, the information omitted from a form of prospectus filed as part of this
registration statement in reliance upon Rule 430A and contained in the form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as
of the time it was declared effective. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-5 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(c)&nbsp;For the purpose of determining any liability under the Securities Act of 1933, as amended, each post-effective
amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-6 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><A NAME="sig"></A>Signatures </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement on Form
<FONT STYLE="white-space:nowrap">S-1</FONT> to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, Massachusetts, on the 7th day of October, 2024. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>UPSTREAM BIO, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ E. Rand Sutherland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">E. Rand Sutherland, M.D., M.P.H.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Chief Executive Officer and Director</TD></TR>
</TABLE></DIV>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Signatures </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the
requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Title</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Date</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial" ALIGN="center">/s/ E. Rand Sutherland</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial" ALIGN="center">E. Rand Sutherland, M.D., M.P.H.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">Chief Executive Officer and Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial" ALIGN="center">(<I>Principal Executive Officer</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">October&nbsp;7,&nbsp;2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial" ALIGN="center">/s/ Michael Paul Gray</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial" ALIGN="center">Michael Paul Gray, M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">Chief Financial and Operations Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">(<I>Principal Financial Officer and</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial" ALIGN="center"><I>Principal
Accounting Officer</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">October 7, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial" ALIGN="center">Ronald C. Renaud, Jr., M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director and Chairman</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">October 7, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial" ALIGN="center">Erez Chimovits, M.B.A., M.Sc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">October 7, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial" ALIGN="center">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial" ALIGN="center">H.
Edward Fleming, Jr., M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">October 7, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial" ALIGN="center">Dayton Misfeldt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">October&nbsp;7,&nbsp;2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial" ALIGN="center">Liam Ratcliffe, M.B.Ch.B., Ph.D., M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">October&nbsp;7,&nbsp;2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial" ALIGN="center">Marcella Kuhlman Ruddy, M.D., M.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">October&nbsp;7,&nbsp;2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial" ALIGN="center">Atsushi Sugita, M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">October&nbsp;7,&nbsp;2024</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-7 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="21%"></TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Title</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Date</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial" ALIGN="center">Andy Wardle, M.B.Ch.B., M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">October&nbsp;7,&nbsp;2024</TD></TR>
</TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">*By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">/s/ E. Rand Sutherland</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">E. Rand Sutherland, M.D., M.P.H.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attorney-in-Fact</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-8 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d843142dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Upstream Bio, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[&#149;]
Shares of Common Stock, par value $0.001 per share </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Underwriting Agreement </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">[&#149;], 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TD Securities (USA) LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">William Blair&nbsp;&amp; Company, L.L.C. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of
the </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">several Underwriters listed </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">in Schedule 1 hereto </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P. Morgan Securities
LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">383 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10179 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o TD Securities (USA) LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1 Vanderbilt Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10017 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Piper Sandler&nbsp;&amp; Co. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">800 Nicollet Mall, Suite 800 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Minneapolis, Minnesota 55402 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o William Blair&nbsp;&amp; Company, L.L.C. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">150 N. Riverside
Plaza </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chicago, Illinois 60606 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upstream Bio, Inc., a Delaware corporation (the &#147;Company&#148;), proposes to issue and sell to the several underwriters listed in Schedule
1 hereto (the &#147;Underwriters&#148;), for whom J.P. Morgan Securities LLC (&#147;JPM&#148;), TD Securities (USA) LLC (&#147;TD Cowen&#148;), Piper Sandler&nbsp;&amp; Co. (&#147;Piper&#148;) and William Blair&nbsp;&amp; Company, L.L.C.
(&#147;William Blair&#148;) are acting as Representatives (the &#147;Representatives&#148;), an aggregate of [&#149;] shares of common stock, par value $0.001 per share (&#147;Common Stock&#148;), of the Company (the &#147;Underwritten Shares&#148;)
and, at the option of the Underwriters, up to an additional [&#149;] shares of Common Stock (the &#147;Option Shares&#148;). The Underwritten Shares and the Option Shares are herein referred to as the &#147;Shares.&#148; The shares of Common Stock
to be outstanding after giving effect to the sale of the Shares are referred to herein as the &#147;Stock.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby confirms its agreement with the several Underwriters concerning the
purchase and sale of the Shares, as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Registration Statement</U>. The Company has prepared and filed with the Securities and
Exchange Commission (the &#147;Commission&#148;) under the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;Securities Act&#148;), a registration statement on Form <FONT
STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-282197),</FONT> including a prospectus, relating to the Shares. Such registration statement, as amended at the time it became effective, including the
information, if any, deemed pursuant to Rule 430A, 430B or 430C under the Securities Act to be part of the registration statement at the time of its effectiveness (&#147;Rule 430 Information&#148;), is referred to herein as the &#147;Registration
Statement&#148;; and as used herein, the term &#147;Preliminary Prospectus&#148; means each prospectus included in such registration statement (and any amendments thereto) before effectiveness, any prospectus filed with the Commission pursuant to
Rule 424(a) under the Securities Act and the prospectus included in the Registration Statement at the time of its effectiveness that omits Rule 430 Information, and the term &#147;Prospectus&#148; means the prospectus in the form first used (or made
available upon request of purchasers pursuant to Rule 173 under the Securities Act) in connection with confirmation of sales of the Shares. If the Company has filed an abbreviated registration statement pursuant to Rule 462(b) under the Securities
Act (the &#147;Rule 462 Registration Statement&#148;), then any reference herein to the term &#147;Registration Statement&#148; shall be deemed to include such Rule 462 Registration Statement. Capitalized terms used but not defined herein shall have
the meanings given to such terms in the Registration Statement and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or prior to the Applicable Time (as defined below),
the Company had prepared the following information (collectively with the pricing information set forth on Annex A, the &#147;Pricing Disclosure Package&#148;): a Preliminary Prospectus dated [&#149;], 2024 and each &#147;free-writing
prospectus&#148; (as defined pursuant to Rule 405 under the Securities Act) listed on Annex A hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Applicable Time&#148; means
[&#149;] [A/P].M., New York City time, on [&#149;], 2024. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Purchase of the Shares</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company agrees to issue and sell the Underwritten Shares to the several Underwriters as provided in this underwriting agreement (this
&#147;Agreement&#148;), and each Underwriter, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees, severally and not jointly, to purchase at a price per share of
$[&#149;] (the &#147;Purchase Price&#148;) from the Company the respective number of Underwritten Shares set forth opposite such Underwriter&#146;s name in Schedule 1 hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company agrees to issue and sell the Option Shares to the several Underwriters as provided in this Agreement, and the
Underwriters, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, shall have the option to purchase, severally and not jointly, from the Company the Option Shares at the
Purchase Price less an amount per share equal to any dividends or distributions declared by the Company and payable on the Underwritten Shares but not payable on the Option Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any Option Shares are to be purchased, the number of Option Shares to be purchased by
each Underwriter shall be the number of Option Shares which bears the same ratio to the aggregate number of Option Shares being purchased as the number of Underwritten Shares set forth opposite the name of such Underwriter in Schedule 1 hereto (or
such number increased as set forth in Section&nbsp;10 hereof) bears to the aggregate number of Underwritten Shares being purchased from the Company by the several Underwriters, subject, however, to such adjustments to eliminate any fractional Shares
as the Representatives in their sole discretion shall make. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Underwriters may exercise the option to purchase Option Shares at any
time in whole, or from time to time in part, on or before the thirtieth day following the date of the Prospectus, by written notice from the Representatives to the Company. Such notice shall set forth the aggregate number of Option Shares as to
which the option is being exercised and the date and time when the Option Shares are to be delivered and paid for, which may be the same date and time as the Closing Date (as hereinafter defined) but shall not be earlier than the Closing Date nor
later than the tenth full business day (as hereinafter defined) after the date of such notice (unless such time and date are postponed in accordance with the provisions of Section&nbsp;10 hereof). Any such notice shall be given at least two business
days prior to the date and time of delivery specified therein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company understands that the Underwriters intend to make a public
offering of the Shares, and initially to offer the Shares on the terms set forth in the Pricing Disclosure Package. The Company acknowledges and agrees that the Underwriters may offer and sell Shares to or through any affiliate of an Underwriter.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Payment for the Shares shall be made by wire transfer in immediately available funds to the account specified by the Company to the
Representatives, in the case of the Underwritten Shares, at the offices of Cooley LLP, counsel for the Underwriters, at 3 Embarcadero Center, 20th Floor, San Francisco, CA 94111-4004, at 10:00 A.M., New York City time, on [&#149;], 2024, or at such
other time or place on the same or such other date, not later than the fifth business day thereafter, as the Representatives and the Company may agree upon in writing or, in the case of the Option Shares, on the date and at the time and place
specified by the Representatives in the written notice of the Underwriters&#146; election to purchase such Option Shares. The time and date of such payment for the Underwritten Shares is referred to herein as the &#147;Closing Date,&#148; and the
time and date for such payment for the Option Shares, if other than the Closing Date, is herein referred to as the &#147;Additional Closing Date.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment for the Shares to be purchased on the Closing Date or the Additional Closing Date, as the case may be, shall be made against delivery
to the Representatives for the respective accounts of the several Underwriters of the Shares to be purchased on such date or the Additional Closing Date, as the case may be, with any transfer taxes payable in connection with the sale of such Shares
duly paid by the Company. Delivery of the Shares shall be made through the facilities of The Depository Trust Company unless the Representatives shall otherwise instruct. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Company acknowledges and agrees that the Representatives and the other Underwriters
are acting solely in the capacity of an arm&#146;s length contractual counterparty to the Company with respect to the offering of Shares contemplated hereby (including in connection with determining the terms of the offering) and not as a financial
advisor or a fiduciary to, or an agent of, the Company or any other person. Additionally, neither the Representatives nor any other Underwriter is advising the Company or any other person as to any legal, tax, investment, accounting or regulatory
matters in any jurisdiction. The Company shall consult with its own advisors concerning such matters and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and neither the
Representatives nor the other Underwriters shall have any responsibility or liability to the Company with respect thereto. Any review by the Representatives and the other Underwriters of the Company, the transactions contemplated hereby or other
matters relating to such transactions will be performed solely for the benefit of the Underwriters and shall not be on behalf of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Representations and Warranties of the Company</U>. The Company represents and warrants to each Underwriter that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Preliminary Prospectus.</I> No order preventing or suspending the use of any Preliminary Prospectus has been issued by the Commission,
and each Preliminary Prospectus included in the Pricing Disclosure Package, at the time of filing thereof, complied in all material respects with the Securities Act, and no Preliminary Prospectus, at the time of filing thereof, contained any untrue
statement of a material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company makes no
representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly
for use in any Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Pricing Disclosure Package</I>. The Pricing Disclosure Package as of the Applicable Time did not, and as of the Closing Date and as of
the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were
made, not misleading; <U>provided</U> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in
writing by such Underwriter through the Representatives expressly for use in such Pricing Disclosure Package, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in
Section&nbsp;7(b) hereof. No statement of material fact included in the Prospectus has been omitted from the Pricing Disclosure Package and no statement of material fact included in the Pricing Disclosure Package that is required to be included in
the Prospectus has been omitted therefrom. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Issuer Free Writing Prospectus. </I>Other than the Registration Statement, the
Preliminary Prospectus and the Prospectus, the Company (including its agents and representatives, other than the Underwriters in their capacity as such) has not prepared, made, used, authorized, approved or referred to and will not prepare, make,
use, authorize, approve or refer to any &#147;written communication&#148; (as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Shares (each such communication by the Company or
its agents and representatives (other than a communication referred to in clause (i)&nbsp;below) an &#147;Issuer Free Writing Prospectus&#148;) other than (i)&nbsp;any document not constituting a prospectus pursuant to Section&nbsp;2(a)(10)(a) of
the Securities Act or Rule 134 under the Securities Act or (ii)&nbsp;the documents listed on Annex A hereto, each electronic road show and any other written communications approved in writing in advance by the Representatives. Each such Issuer Free
Writing Prospectus complies in all material respects with the Securities Act, has been or will be (within the time period specified in Rule 433 under the Securities Act) filed in accordance with the Securities Act (to the extent required thereby)
and does not conflict with the information contained in the Registration Statement or the Pricing Disclosure Package, and, when taken together with the Preliminary Prospectus accompanying, or delivered prior to delivery of, such Issuer Free Writing
Prospectus, did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company makes no representation or warranty with respect to any statements or omissions made in each such Issuer Free Writing Prospectus or
Preliminary Prospectus in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in such Issuer Free Writing Prospectus or
Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Emerging Growth Company</I>. From the time of initial confidential submission of the Registration Statement to the Commission (or, if
earlier, the first date on which the Company engaged directly or through any person authorized to act on its behalf in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication undertaken in
reliance on Section&nbsp;5(d) of the Securities Act) through the date hereof, the Company has been and is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act (an &#147;Emerging Growth Company&#148;). <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;Testing-the-Waters</FONT></FONT> Communication&#148; means any oral or written communication with potential investors undertaken in reliance on either Section&nbsp;5(d) of, or Rule
163B under, the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Materials. </I>The Company (i)&nbsp;has not alone engaged in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications other than <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications with the consent of the Representatives (x)&nbsp;with entities that are qualified institutional buyers (&#147;QIBs&#148;) within the meaning of Rule 144A under the Securities
Act or institutions that are accredited investors within the meaning of Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act (&#147;IAIs&#148;) and otherwise in compliance with the requirements of Section&nbsp;5(d) of the
Securities Act or (y)&nbsp;with entities that the Company reasonably believed to be QIBs or IAIs and otherwise in compliance with the requirements of Rule 163B under the Securities Act and (ii)&nbsp;has not authorized anyone other than the
Representatives to engage in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. The Company reconfirms that the Representatives have been authorized to act on its behalf in undertaking <FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Communications by virtue of a writing substantially in the form of Exhibit D hereto. The Company has not distributed or approved for distribution any Written <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications other than those listed on Annex B hereto. &#147;Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communication&#148; means any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is a written communication within the meaning of Rule 405 under the Securities Act. Any individual
Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication does not conflict with the information contained in the Registration Statement or the Pricing Disclosure Package, complied in
all material respects with the Securities Act, and when taken together with the Pricing Disclosure Package as of the Applicable Time, did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain
any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Registration Statement and Prospectus.</I> The Registration Statement has been declared effective by the Commission. No order suspending
the effectiveness of the Registration Statement has been issued by the Commission, and no proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act against the Company or related to the offering of the Shares has been
initiated or, to the knowledge of the Company, threatened by the Commission; as of the applicable effective date of the Registration Statement and any post-effective amendment thereto, the Registration Statement and any such post-effective amendment
complied and will comply in all material respects with the Securities Act, and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the
statements therein not misleading; and as of the date of the Prospectus and any amendment or supplement thereto and as of the Closing Date and as of the Additional Closing Date, as the case may be, the Prospectus will comply in all material respects
with the Securities Act and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;
<U>provided</U> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such
Underwriter through the Representatives expressly for use in the Registration Statement and the Prospectus and any amendment or supplement thereto, it being understood and agreed that the only such information furnished by any Underwriter consists
of the information described as such in Section&nbsp;7(b) hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Financial Statements</I>. The financial statements (including the
related notes thereto) of the Company and its consolidated subsidiaries<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>included in the Registration Statement, the Pricing Disclosure Package and the Prospectus comply in all material respects
with the applicable requirements of the Securities Act and present fairly in all material respects the financial position of the Company and its consolidated subsidiaries as of the dates indicated and the results of their operations and the changes
in their cash flows for the periods specified; such financial statements have been prepared in conformity with generally accepted accounting principles (&#147;GAAP&#148;) in the United States applied on a consistent basis throughout the periods
covered thereby, except in the case of any unaudited financial statements, which are subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and do not contain certain footnotes as permitted by the applicable rules of the Commission, and any supporting schedules included in the Registration Statement present fairly in all material
respects the information required to be stated therein; and the other financial information included in the Registration Statement, the Pricing Disclosure Package and the Prospectus has been derived from the accounting records of the Company and its
consolidated subsidiaries and presents fairly in all material respects the information shown thereby; and there are no disclosures included in the Registration Statement, the Pricing Disclosure Package or the Prospectus regarding <FONT
STYLE="white-space:nowrap">&#147;non-GAAP</FONT> financial measures&#148; (as such term is defined by the rules and regulations of the Commission) that are subject to Regulation G of the Securities Exchange Act of 1934, as amended (the
&#147;Exchange Act&#148;), and Item 10(e) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> of the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>No
Material Adverse Change.</I> Since the date of the most recent financial statements of the Company included in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (i)&nbsp;there has not been any change in the capital stock
(other than the issuance of shares of Common Stock upon exercise of stock options and warrants described as outstanding in, and the grant of options and awards under existing equity incentive plans described in, the Registration Statement, the
Pricing Disclosure Package and the Prospectus), short-term debt or long-term debt of the Company or any of its subsidiaries, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of
capital stock, or any material adverse change, or any development involving a prospective material adverse change, in or affecting the business, properties, management, financial position, stockholders&#146; equity, results of operations or
prospects of the Company and its subsidiaries taken as a whole; (ii)&nbsp;neither the Company nor any of its subsidiaries has entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the
Company and its subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that is material to the Company and its subsidiaries taken as a whole; and (iii)&nbsp;neither the Company nor any of its subsidiaries has
sustained any loss or interference with its business that is material to the Company and its subsidiaries taken as a whole and that is either from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor
disturbance or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Organization and Good Standing.</I> The Company and each of its subsidiaries have been duly organized and are validly existing and
in good standing under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction in which their respective ownership or lease of property or the conduct of their
respective businesses requires such qualification, and have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they are engaged, except where the failure to be so qualified or in good
standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect on the business, properties, management, financial position, stockholders&#146; equity, results of operations or prospects of the
Company and its subsidiaries taken as a whole or on the performance by the Company of its obligations under this Agreement (a &#147;Material Adverse Effect&#148;). The Company does not own or control, directly or indirectly, any corporation,
association or other entity other than the subsidiaries listed in Exhibit 21 to the Registration Statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Capitalization.</I> The Company has an authorized capitalization as set forth in the
Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading &#147;Capitalization&#148; and &#147;Description of capital stock&#148;; all the outstanding shares of capital stock of the Company have been duly and
validly authorized and issued and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and are not subject to any <FONT STYLE="white-space:nowrap">pre-emptive</FONT> or similar rights that have not been duly waived or satisfied;
except as described in or expressly contemplated by the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no outstanding rights (including, without limitation, <FONT STYLE="white-space:nowrap">pre-emptive</FONT>
rights), warrants or options to acquire, or instruments convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company or any of its subsidiaries, or any contract, commitment, agreement, understanding or
arrangement of any kind relating to the issuance of any capital stock of the Company or any such subsidiary, any such convertible or exchangeable securities or any such rights, warrants or options; the capital stock of the Company conforms in all
material respects to the description thereof contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and all the outstanding shares of capital stock or other equity interests of each subsidiary owned, directly or
indirectly, by the Company have been duly and validly authorized and issued, are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and are owned directly or indirectly by the Company, free and clear of any lien, charge,
encumbrance, security interest, restriction on voting or transfer or any other claim of any third party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Stock Options. </I>With
respect to the stock options (the &#147;Stock Options&#148;) granted pursuant to the stock-based compensation plans of the Company and its subsidiaries (the &#147;Company Stock Plans&#148;), except as would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect, (i)&nbsp;each Stock Option intended to qualify as an &#147;incentive stock option&#148; under Section&nbsp;422 of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;) so
qualifies, (ii)&nbsp;each grant of a Stock Option was duly authorized no later than the date on which the grant of such Stock Option was by its terms to be effective by all necessary corporate action, including, as applicable, approval by the board
of directors of the Company (or a duly constituted and authorized committee thereof) and any required stockholder approval by the necessary number of votes or written consents, and the award agreement governing such grant (if any) was duly executed
and delivered by each party thereto, (iii)&nbsp;each such grant was made in accordance with the terms of the Company Stock Plans and all other applicable laws and regulatory rules or requirements, including the rules of the Nasdaq Global Market
(&#147;Nasdaq Market&#148;) and any other exchange on which Company securities are traded, and (iv)&nbsp;each such grant was properly accounted for in accordance with GAAP in the financial statements (including the related notes) of the Company.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Due Authorization.</I> The Company has full right, power and authority to execute and deliver this Agreement and to perform its
obligations hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement and the consummation by it of the transactions contemplated hereby has been duly and validly taken. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Underwriting Agreement. </I>This Agreement has been duly authorized, executed and
delivered by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>The Shares. </I>The Shares to be issued and sold by the Company hereunder have been duly authorized by
the Company and, when issued and delivered and paid for as provided herein, will be duly and validly issued, will be fully paid and nonassessable and will conform to the descriptions thereof in the Registration Statement, the Pricing Disclosure
Package and the Prospectus; and the issuance of the Shares is not subject to any preemptive or similar rights that have not been duly waived or satisfied. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>Listing</I>. The Shares have been approved for listing on Nasdaq Market, subject to notice of issuance. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <I>Description of the Underwriting Agreement.</I> This Agreement conforms in all material respects to the description thereof contained in
the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <I>No Violation or Default.</I> Neither the Company nor
any of its subsidiaries is (i)&nbsp;in violation of its charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents; (ii)&nbsp;in default, and no event has occurred that, with notice or lapse of time or both, would
constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries
is a party or by which the Company or any of its subsidiaries is bound or to which any property or asset of the Company or any of its subsidiaries is subject; or (iii)&nbsp;in violation of any law or statute or any judgment, order, rule or
regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (ii)&nbsp;and (iii) above, for any such default or violation that would not, individually or in the aggregate, have a Material Adverse
Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <I>No Conflicts. </I>The execution, delivery and performance by the Company of this Agreement, the issuance and sale of the
Shares by the Company and the consummation by the Company of the transactions contemplated by this Agreement or the Pricing Disclosure Package and the Prospectus will not (i)&nbsp;conflict with or result in a breach or violation of any of the terms
or provisions of, or constitute a default under, result in the termination, modification or acceleration of, or result in the creation or imposition of any lien, charge or encumbrance upon any property, right or asset of the Company or any of its
subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any
property, right or asset of the Company or any of its subsidiaries is subject, (ii)&nbsp;result in any violation of the provisions of the charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents of the Company
or any of its subsidiaries or (iii)&nbsp;result in the violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (i)&nbsp;and (iii)
above, for any such conflict, breach, violation, default, lien, charge or encumbrance that would not, individually or in the aggregate, have a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <I>No Consents Required.</I> No consent, approval, authorization, order, registration or
qualification of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Shares and the consummation of the
transactions contemplated by this Agreement, except for the registration of the Shares under the Securities Act and such consents, approvals, authorizations, orders and registrations or qualifications as may be required by the Financial Industry
Regulatory Authority, Inc. (&#147;FINRA&#148;) and under applicable state securities laws in connection with the purchase and distribution of the Shares by the Underwriters. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <I>Legal Proceedings.</I> There are no legal, governmental or regulatory investigations, actions, demands, claims, suits, arbitrations,
inquiries or proceedings (&#147;Actions&#148;) pending to which the Company or any of its subsidiaries is or may be a party or to which any property of the Company or any of its subsidiaries is or may be the subject that, individually or in the
aggregate, if determined adversely to the Company or any of its subsidiaries, could reasonably be expected to have a Material Adverse Effect; to the knowledge of the Company, no such Actions are threatened or contemplated by any governmental or
regulatory authority or threatened by others; and (i)&nbsp;there are no current or pending Actions that are required under the Securities Act to be described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are
not so described in the Registration Statement, the Pricing Disclosure Package and the Prospectus and (ii)&nbsp;there are no statutes, regulations or contracts or other documents that are required under the Securities Act to be filed as exhibits to
the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <I>Independent Accountants</I>. PricewaterhouseCoopers LLP, who has certified certain financial
statements of the Company and its subsidiaries, is an independent registered public accounting firm with respect to the Company and its subsidiaries within the applicable rules and regulations adopted by the Commission and the Public Company
Accounting Oversight Board (United States) and as required by the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <I>Title to Real and Personal Property</I>. The
Company and its subsidiaries have good and marketable title in fee simple to, or have valid rights to lease or otherwise use, all items of real and personal property that are material to the respective businesses of the Company and its subsidiaries,
in each case free and clear of all liens, encumbrances, claims and defects and imperfections of title except those that (i)&nbsp;do not materially interfere with the use made and proposed to be made of such property by the Company and its
subsidiaries or (ii)&nbsp;could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) <I>Title to Intellectual Property</I>. The Company and its subsidiaries own, or possess
valid and enforceable licensed rights to use, all patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, trade dress, designs, data, database rights, Internet domain names,
copyrights, works of authorship, licenses, proprietary information and <FONT STYLE="white-space:nowrap">know-how</FONT> (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures)
necessary for the conduct of their respective businesses as currently conducted and as proposed to be conducted (collectively, &#147;Intellectual Property&#148;), and, to the Company&#146;s knowledge, the conduct of their respective businesses does
not and will not infringe, misappropriate or otherwise conflict with any such rights of others. The Intellectual Property of the Company has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part,
and the Company is unaware of any facts which would form a reasonable basis for any such adjudication. The Company and its subsidiaries have not received any notice of any claim of infringement, misappropriation or conflict with any intellectual
property rights of another, and the Company is unaware of any facts which would form a reasonable basis for any such notice or claim. To the Company&#146;s knowledge: (i)&nbsp;there are no third parties who have rights to any Intellectual Property,
except for customary reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus (&#147;Disclosure Documents&#148;) as owned by
or licensed to the Company or its subsidiaries; and (ii)&nbsp;there is no infringement by third parties of any Intellectual Property. There is no pending or, to the Company&#146;s knowledge, threatened action, suit, proceeding or claim by others:
(A)&nbsp;challenging the Company&#146;s rights in or to any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; (B)&nbsp;challenging the validity,
enforceability or scope of any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim, other than comments made during routine patent prosecution activities;
or (C)&nbsp;asserting that the Company or its subsidiaries infringe, misappropriate, or otherwise violate, or would, upon the commercialization of any product or service described in the Disclosure Documents as under development, infringe,
misappropriate, or otherwise violate, any intellectual property rights of others, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim. The Company and its subsidiaries have
complied with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or its subsidiaries, and all such agreements are in full force and effect. To the Company&#146;s knowledge, there are no material
defects in any of the patents or patent applications included in the Intellectual Property. The Company and its subsidiaries have taken all reasonable steps to protect, maintain and safeguard their Intellectual Property, including the execution of
appropriate nondisclosure, confidentiality agreements and invention assignment agreements and invention assignments with their employees, and, to the Company&#146;s knowledge, no employee of the Company is in or has been in violation of any term of
any employment contract, patent disclosure agreement, invention assignment agreement, <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, nondisclosure agreement, or
any restrictive covenant to or with a former employer where the basis of such violation relates to such employee&#146;s employment with the Company. To the Company&#146;s knowledge, the duty of candor and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
good faith as required by the United States Patent and Trademark Office during the prosecution of the United States patents and patent applications included in the Intellectual Property have been
complied with; and in all foreign offices having similar requirements, all such requirements have been complied with. To the Company&#146;s knowledge, none of the Company owned Intellectual Property or technology (including information technology
and outsourced arrangements) employed by the Company or its subsidiaries has been obtained or is being used by the Company or its subsidiary in violation of any contractual obligation binding on the Company or its subsidiaries or any of their
respective officers, directors or employees or otherwise in violation of the rights of any persons. All licenses for the use of the Intellectual Property Rights described in the Disclosure Documents are valid, binding upon, and enforceable by or
against the parties thereto in accordance to its terms. The Company has complied in all material respects with, and is not in breach nor has received any asserted or threatened claim of breach of any Intellectual Property license, and the Company
has no knowledge of any breach or anticipated breach by any other person to any Intellectual Property license. The product candidates described in the Disclosure Documents as under development by the Company or its subsidiaries fall within the scope
of the claims of one or more patents or patent applications owned by, or exclusively licensed to, the Company or its subsidiaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x)
<I>Trade Secrets</I>. The Company and its subsidiaries have taken reasonable and customary actions to protect their rights in and prevent the unauthorized use and disclosure of material trade secrets and confidential business information (including
confidential source code, ideas, research and development information, <FONT STYLE="white-space:nowrap">know-how,</FONT> formulas, compositions, technical data, designs, drawings, specifications, research records, records of inventions, test
information, financial, marketing and business data, customer and supplier lists and information, pricing and cost information, business and marketing plans and proposals) owned by the Company and its subsidiaries, and, there has been no
unauthorized use or disclosure. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) <I>IT Assets, Data Privacy and Security</I>. The computers, websites, applications, databases,
software, servers, networks, data communications lines, and other information technology systems owned, licensed, leased or otherwise used by the Company and its subsidiaries (including any third party technology or services used by the Company but
excluding any public networks) (collectively, the &#147;IT Assets&#148;) are, in all material respects, adequate for, and operate and perform for, the operation of the business of the Company and its subsidiaries as currently conducted and as
proposed to be conducted as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus. To the Company&#146;s knowledge, the IT Assets are free and clear of all viruses, vulnerabilities, bugs, errors, defects, Trojan
horses, time bombs, malware and other corruptants. The Company and its subsidiaries have at all times implemented and maintained reasonable controls, policies, procedures, and safeguards designed to maintain and protect the privacy, confidentiality,
integrity, continuous operation, redundancy and security of all IT Assets, Personal Data (defined below), and sensitive, confidential, or regulated data (collectively, &#147;Confidential Data&#148;)) used in connection with their businesses. There
have been no actual breaches of, violations of, outages of, or unlawful or unauthorized uses of, destruction of, losses of, alterations of, or accesses to IT Assets and no unlawful or unauthorized uses of, destruction of, losses of, alterations of,
or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accesses to Confidential Data, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor are any such incidents under internal review
or investigation. Except as would not reasonably be expected to have a Material Adverse Effect, the Company and its subsidiaries comply, and have at all times complied in all material respects, with all (i)&nbsp;applicable laws, statutes,
regulations, directives, and industry standards that are binding upon the Company or its subsidiaries concerning the protection, collection, use, disclosure, transfer, storage, disposal, privacy, confidentiality, integrity and security of Personal
Data (including without limitation, in each case as applicable, the Health Insurance Portability and Accountability Act of 1996 (&#147;HIPAA&#148;) as amended by the Health Information Technology for Economic and Clinical Health Act (the
&#147;HITECH Act&#148;); the European Union General Data Protection Regulation (&#147;GDPR&#148;) (EU 2016/679); and the California Consumer Privacy Act (&#147;CCPA&#148;) as modified by the California Privacy Rights Act (&#147;CPRA&#148;), and
other similar state privacy laws (collectively, the &#147;Privacy Laws&#148;)), and (ii)&nbsp;all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, their published policies and procedures,
and contractual obligations relating to the privacy and security of IT Assets and Confidential Data and to the protection of such IT Assets and Confidential Data from unlawful or unauthorized use, destruction, loss, alteration, access,
misappropriation or modification (collectively, the &#147;Data Protection Requirements&#148;). The Company and its subsidiaries have taken reasonable steps to require third parties processing Personal Data on behalf of the Company or any subsidiary
to protect the confidentiality and security of such Personal Data. The Company and its subsidiaries have at all times made all required disclosures to and obtained all consents from individuals required under Privacy Laws (including, without
limitation, clinical trial participants, customers, users, and personnel) for the Company&#146;s and its subsidiaries&#146; collection, use, disclosure, transfer, and other processing of Personal Data, and complied with all such disclosures and
consents in all material respects. To the Company&#146;s knowledge, none of such disclosures made or contained in any policies or notices have been inaccurate, misleading, deceptive, incomplete, or in violation of any Privacy Laws or Data Protection
Requirements. &#147;Personal Data&#148; means (i)&nbsp;any information which would qualify as &#147;personally identifying information&#148; under the Federal Trade Commission Act, as amended; (ii)&nbsp;Protected Health Information as defined by
HIPAA; (iii) &#147;personal data&#148; as defined by GDPR; (iv) &#147;personal information&#148; as defined by CCPA; and (v)&nbsp;any other information that constitutes &#147;personal data,&#148; &#147;personal information,&#148; &#147;personally
identifiable information,&#148; &#147;nonpublic personal information,&#148; &#147;customer proprietary network information,&#148; &#147;individually identifiable health information,&#148; &#147;protected health information&#148; or similar
information under any Privacy Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) <I>No Complaints</I>. The Company and each of its subsidiaries have no knowledge of any fact or
circumstance that would reasonably indicate the Company or one of its subsidiaries is not in compliance with any Privacy Laws or the Data Protection Requirements. There has been no complaint or audit, proceeding, investigation (formal or informal),
written demand or claim made against the Company or its subsidiaries or to the knowledge of the Company, any of its (I)&nbsp;customers (specific to the customer&#146;s use of products or services of the Company or (II)&nbsp;suppliers, and none are
currently pending against, the Company or its subsidiaries, by any person, government entity, regulator, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
group or other party in respect of the collection, use, disclosure, transfer or other processing of Personal Data by the Company or its subsidiaries, including without limitation, by any state
Attorney General or related office, the Federal Trade Commission, the U.S. Department of Health and Human Services and any office contained therein (&#147;HHS&#148;), or any similar authority in any jurisdiction other than the United States or any
other governmental entity, and, no such complaint, audit, proceeding, investigation or claim is or has been threatened in writing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa)
<I>FDA Compliance</I>. The Company and each of its subsidiaries: (A)&nbsp;is and at all times has been in material compliance with all statutes, rules or regulations of the U.S. Food and Drug Administration (&#147;FDA&#148;) and other comparable
governmental entities applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product candidate under
development or manufactured or distributed by the Company to the extent applicable (&#147;Applicable Laws&#148;); (B) has not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other written correspondence or
notice from the FDA or any other comparable governmental entity alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, exemptions, authorizations, permits and supplements or
amendments thereto required by any such Applicable Laws (&#147;Authorizations&#148;); (C) possesses all material Authorizations and such Authorizations are valid and in full force and effect and the Company is not in material violation of any term
of any such Authorizations; (D)&nbsp;has not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA or any other comparable governmental entity or third party
alleging that any product operation or activity is in material violation of any Applicable Laws or Authorizations; (E)&nbsp;has not received written notice that the FDA or any governmental entity has taken, is taking or intends to take action to
limit, suspend, modify or revoke any material Authorizations; and (F)&nbsp;has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as
required by any Applicable Laws or Authorizations and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or
supplemented by a subsequent submission). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) <I>Tests and Preclinical and Clinical Trials</I>. The studies, tests and preclinical and
clinical trials conducted with the product candidates described in the Disclosure Documents, or to the Company&#146;s knowledge, on behalf of the Company, were and, if still ongoing, are being conducted in all material respects in accordance with
all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and current Good Clinical Practices and Good Laboratory Practices and any applicable
rules, regulations and policies of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Pricing Disclosure Package and
the Prospectus are, to the Company&#146;s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies, tests and trials; the Company is not aware of any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
studies, tests or trials, the results of which the Company believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement, the
Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical state of development; and the Company has not received any written notices or correspondence from the FDA or any
governmental entity requiring the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with
the design and implementation of such trials. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) <I>Compliance with Health Care Laws</I>. The Company and its subsidiaries and their
respective directors, officers, employees, and to the Company&#146;s Knowledge, independent contractors, agents and affiliates are, and at all times have been, in material compliance with all Health Care Laws. For purposes of this Agreement,
&#147;Health Care Laws&#148; means: (i)&nbsp;the applicable provisions of the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act and the regulations promulgated thereunder; (ii)&nbsp;all applicable federal, state, local and foreign
health care fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback Statute (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(b)),</FONT> the U.S. Civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), the
criminal False Statements Law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(a)),</FONT> all criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286, 287 and 1349, the health care
fraud criminal provisions under HIPAA, the civil monetary penalties law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7a),</FONT> the exclusions law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7),</FONT> the U.S.
Physician Payments Sunshine Act (42 U.S.C <FONT STYLE="white-space:nowrap">Section&nbsp;1320-7h),</FONT> and applicable laws governing U.S. government funded or sponsored healthcare programs; and (iii)&nbsp;all other local, state, federal, national,
supranational and foreign health care laws, to the extent applicable to the Company or its subsidiaries. Neither the Company, nor any of its subsidiaries, nor, to the Company&#146;s Knowledge, any of their respective officers, directors, employees
or agents have engaged in activities which could reasonably be concluded are, as applicable, cause for liability under a Health Care Law. Neither the Company nor any of its subsidiaries has received written notice of any claim, action, suit,
proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging that any product, operation or activity is in violation of any Health Care Laws
nor, to the Company&#146;s knowledge, has any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action been threatened. The Company and its subsidiaries have filed, maintained or submitted all material
reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and
supplements or amendments were complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent submission). Neither the Company nor any of its subsidiaries is a party to any corporate integrity
agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority or body. Additionally, neither the Company, nor any of its subsidiaries, nor, to the
Company&#146;s Knowledge, any of their respective employees, officers, directors, independent contractors, affiliates or agents has been </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or is subject to a governmental inquiry, investigation, proceeding, or other
similar action that could reasonably be expected to result in debarment, suspension or exclusion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) <I>No Undisclosed
Relationships</I>. No relationship, direct or indirect, exists between or among the Company or any of its subsidiaries, on the one hand, and the directors, officers, stockholders, customers, suppliers or other affiliates of the Company or any of its
subsidiaries, on the other, that is required by the Securities Act to be described in each of the Registration Statement and the Prospectus and that is not so described in such documents and in the Pricing Disclosure Package. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) <I>Investment Company Act</I>. The Company is not and, after giving effect to the offering and sale of the Shares and the application of
the proceeds thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be required to register as an &#147;investment company&#148; or an entity &#147;controlled&#148; by an &#147;investment
company&#148; within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;Investment Company Act&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) <I>Taxes.</I> The Company and its subsidiaries have paid all federal, state, local and foreign taxes and filed all tax returns required to
be paid or filed through the date hereof, and there is no tax deficiency that has been, or could reasonably be expected to be, asserted against the Company or any of its subsidiaries or any of their respective properties or assets, in each case to
the extent the failure to pay or such tax deficiency would be materially adverse to the Company or its Subsidiaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) <I>Licenses and
Permits.</I> The Company and its subsidiaries possess, and are in compliance with the terms of, all licenses, <FONT STYLE="white-space:nowrap">sub-licenses,</FONT> certificates, permits and other authorizations issued by, and have made all
declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses as
described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, except where the failure to possess or make the same would not, individually or in the aggregate, have a Material Adverse Effect; and neither the
Company nor any of its subsidiaries has received notice of any revocation or modification of any such license, <FONT STYLE="white-space:nowrap">sub-license,</FONT> certificate, permit or authorization or has any reason to believe that any such
license, <FONT STYLE="white-space:nowrap">sub-license,</FONT> certificate, permit or authorization will not be renewed in the ordinary course, except where such revocation, modification or nonrenewal would not reasonably be expected to, individually
or in the aggregate, have a Material Adverse Effect. Each of the Company and its subsidiaries has fulfilled and performed all of its respective obligations with respect to the Licenses, and to the Company&#146;s knowledge, no event has occurred
which allows, or after notice or lapse of time would allow, revocation or termination thereof or results in any other impairment of the rights of the holder. No party granting any such licenses, certificates, permits and other authorizations has
taken any action to limit, suspend or revoke the same in any material respect. The Company and its subsidiaries have filed, obtained, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required and that all such reports, documents,
forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission) as required for maintenance of their
licenses, certificates, permits and other authorizations that are necessary for the conduct of their respective businesses. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) <I>No
Labor Disputes.</I> No labor disturbance by or dispute with employees of the Company or any of its subsidiaries exists or, to the knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor
disturbance by, or dispute with, the employees of any of its or its subsidiaries&#146; principal suppliers, contractors or customers, except as would not have a Material Adverse Effect. Neither the Company nor any of its subsidiaries has received
any notice of cancellation or termination with respect to any collective bargaining agreement to which it is a party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>Certain
Environmental Matters</I>. (i)&nbsp;The Company and its subsidiaries (x)&nbsp;are in compliance with all, and have not violated any, applicable federal, state, local and foreign laws (including common law), rules, regulations, requirements,
decisions, judgments, decrees, orders and other legally enforceable requirements relating to pollution or the protection of human health or safety, the environment, natural resources, hazardous or toxic substances or wastes, pollutants or
contaminants (collectively, &#147;Environmental Laws&#148;); (y) have received and are in compliance with all, and have not violated any, permits, licenses, certificates or other authorizations or approvals required of them under any Environmental
Laws to conduct their respective businesses; and (z)&nbsp;have not received notice of any actual or potential liability or obligation under or relating to, or any actual or potential violation of, any Environmental Laws, including for the
investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, and have no knowledge of any event or condition that would reasonably be expected to result in any such notice;
(ii)&nbsp;there are no costs or liabilities associated with Environmental Laws of or relating to the Company or its subsidiaries, except in the case of each of (i)&nbsp;and (ii) above, for any such matter as would not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect; and (iii)&nbsp;(x) there is no proceeding that is pending, or that is known to be contemplated, against the Company or any of its subsidiaries under any Environmental Laws in which
a governmental entity is also a party, other than such proceeding regarding which it is reasonably believed no monetary sanctions of $100,000 or more will be imposed, (y)&nbsp;the Company and its subsidiaries are not aware of any facts or issues
regarding compliance with Environmental Laws, or liabilities or other obligations under Environmental Laws or concerning hazardous or toxic substances or wastes, pollutants or contaminants, that could reasonably be expected to have a material effect
on the capital expenditures, earnings or competitive position of the Company and its subsidiaries, and (z)&nbsp;none of the Company or its subsidiaries anticipates material capital expenditures relating to any Environmental Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) <I>Compliance with ERISA</I>. (i)&nbsp;Each employee benefit plan, within the meaning
of Section&nbsp;3(3) of the Employee Retirement Income Security Act of 1974, as amended (&#147;ERISA&#148;), for which the Company or any member of its &#147;Controlled Group&#148; (defined as any entity, whether or not incorporated, that is under
common control with the Company within the meaning of Section&nbsp;4001(a)(14) of ERISA or any entity that would be regarded as a single employer with the Company under Section&nbsp;414(b),(c),(m) or (o)&nbsp;of the Code) would have any liability
(each, a &#147;Plan&#148;) has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code; (ii)&nbsp;no prohibited transaction, within
the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred with respect to any Plan, excluding transactions effected pursuant to a statutory or administrative exemption; (iii)&nbsp;for each Plan that is subject to the
funding rules of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA, no Plan has failed (whether or not waived), or is reasonably expected to fail, to satisfy the minimum funding standards (within the meaning of Section&nbsp;302 of ERISA or
Section&nbsp;412 of the Code) applicable to such Plan; (iv)&nbsp;no Plan is, or is reasonably expected to be, in &#147;at risk status&#148; (within the meaning of Section&nbsp;303(i) of ERISA) and no Plan that is a &#147;multiemployer plan&#148;
within the meaning of Section&nbsp;4001(a)(3) of ERISA is in &#147;endangered status&#148; or &#147;critical status&#148; (within the meaning of Sections 304 and 305 of ERISA); (v) the fair market value of the assets of each Plan exceeds the present
value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (vi) no &#147;reportable event&#148; (within the meaning of Section&nbsp;4043(c) of ERISA and the regulations promulgated thereunder) has
occurred or is reasonably expected to occur; (vii)&nbsp;each Plan that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified, and nothing has occurred, to the knowledge of the Company, whether by action or by failure to
act, which would cause the loss of such qualification; (viii)&nbsp;neither the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan
or premiums to the Pension Benefit Guarantee Corporation, in the ordinary course and without default) in respect of a Plan (including a &#147;multiemployer plan&#148; within the meaning of Section&nbsp;4001(a)(3) of ERISA); and (ix)&nbsp;none of the
following events has occurred or is reasonably likely to occur: (A)&nbsp;a material increase in the aggregate amount of contributions required to be made to all Plans by the Company or its Controlled Group affiliates in the current fiscal year of
the Company and its Controlled Group affiliates compared to the amount of such contributions made in the Company&#146;s and its Controlled Group affiliates&#146; most recently completed fiscal year; or (B)&nbsp;a material increase in the Company and
its subsidiaries&#146; &#147;accumulated post-retirement benefit obligations&#148; (within the meaning of Accounting Standards Codification Topic <FONT STYLE="white-space:nowrap">715-60)</FONT> compared to the amount of such obligations in the
Company and its subsidiaries&#146; most recently completed fiscal year, except in each case with respect to the events or conditions set forth in (i)&nbsp;through (ix) hereof, as would not, individually or in the aggregate, have a Material Adverse
Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) <I>Disclosure Controls</I>. The Company and its subsidiaries maintain an effective system of &#147;disclosure controls and
procedures&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> of the Exchange Act) that complies with the requirements of the Exchange Act and that has been designed to ensure that information required to be disclosed by the
Company in reports that it files or submits under the Exchange Act is recorded, processed, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
summarized and reported within the time periods specified in the Commission&#146;s rules and forms, including controls and procedures designed to ensure that such information is accumulated and
communicated to the Company&#146;s management as appropriate to allow timely decisions regarding required disclosure. To the extent applicable as of the date of this Agreement, the Company and its subsidiaries have carried out evaluations of the
effectiveness of their disclosure controls and procedures as required by Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> of the Exchange Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) <I>Accounting Controls.</I> The Company and its subsidiaries maintain systems of &#147;internal control over financial reporting&#148; (as
defined in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> of the Exchange Act) that are designed to comply with the applicable requirements of the Exchange Act and have been designed by, or under the supervision of, their respective
principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with GAAP. The Company and its subsidiaries maintain internal accounting controls sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorizations;
(ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general
or specific authorization; and (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. There are no material weaknesses in the
Company&#146;s internal controls. The Company&#146;s auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i)&nbsp;all significant deficiencies and material weaknesses in the design or operation of internal
controls over financial reporting which have adversely affected or are reasonably likely to adversely affect the Company&#146;s ability to record, process, summarize and report financial information; and (ii)&nbsp;any fraud, whether or not material,
that involves management or other employees who have a significant role in the Company&#146;s internal controls over financial reporting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) <I>Insurance. </I>The Company and its subsidiaries have insurance covering their respective properties, operations, personnel and
businesses, including business interruption insurance, which insurance is in amounts and insures against such losses and risks as the Company reasonably believes are adequate to protect the Company and its subsidiaries and their respective
businesses; and neither the Company nor any of its subsidiaries has (i)&nbsp;received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such
insurance or (ii)&nbsp;any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue
its business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) <I>No Unlawful Payments.</I> Neither the Company nor any of its subsidiaries nor any
director, officer or employee of the Company or any of its subsidiaries nor, to the knowledge of the Company, any agent or other person, in each case, while acting on behalf of the Company or any of its subsidiaries has (i)&nbsp;used any corporate
funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii)&nbsp;made or taken an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or
benefit to any foreign or domestic government official or employee, including of any government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the
foregoing, or any political party or party official or candidate for political office; (iii)&nbsp;violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing
the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or anti-corruption law; or
(iv)&nbsp;made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper payment or
benefit. Neither the Company nor any of its subsidiaries will use, directly or indirectly, the proceeds of the offering in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of
value, to any person in violation of any applicable anti-bribery or anti-corruption laws. The Company and its subsidiaries have instituted, maintain and enforce, and will continue to maintain and enforce policies and procedures designed to promote
compliance with all applicable anti-bribery and anti-corruption laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) <I>Compliance with Anti-Money Laundering Laws</I>. The
operations of the Company and its subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements, including those of the Bank Secrecy Act, as amended by Title III of the Uniting
and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), and the applicable money laundering statutes of all jurisdictions where the Company or any of its subsidiaries
conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by any governmental agency (collectively, the &#147;Anti-Money Laundering Laws&#148;) and no action,
suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company,
threatened. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) <I>No Conflicts with Sanctions Laws. </I>Neither the Company nor any of its subsidiaries, nor any of their respective
directors or officers, nor, to the knowledge of the Company, any agent or other person acting on behalf of the Company or any of its subsidiaries, is owned or controlled by one or more persons that are currently the subject or the target of any
sanctions administered or enforced by the U.S. government, (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State and including, without limitation, the designation
as a &#147;specially designated national&#148; or &#147;blocked person&#148;), the United Nations Security Council, the European Union, His Majesty&#146;s Treasury or other relevant sanctions authority (collectively, &#147;Sanctions&#148;), nor is
the Company or any of its subsidiaries, directors, officers or employees, or to the knowledge of the Company, any agent or other person acting on behalf of the Company or any of its subsidiaries, located,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
organized or ordinarily resident in a country or territory that is the subject or target of comprehensive Sanctions, including, without limitation, the Crimea Region of Ukraine, the <FONT
STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic and Luhansk People&#146;s Republic regions of Ukraine, Cuba, Iran, North Korea and Syria (each, a &#147;Sanctioned Country&#148;); and the Company will not directly or
knowingly indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i)&nbsp;to fund or facilitate any
unlawful activities of or business with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii)&nbsp;to fund or facilitate any unlawful activities of or business in any Sanctioned Country or
(iii)&nbsp;in any other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. For the past five years, the Company and its
subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any Sanctioned Country or with any person that at the time of the dealing or transaction is or was the subject or the target of
Sanctions in violation of Sanctions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) <I>No Restrictions on Subsidiaries</I>. No subsidiary of the Company is currently prohibited,
directly or indirectly, under any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on such subsidiary&#146;s capital stock or similar ownership interest,
from repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary&#146;s properties or assets to the Company or any other subsidiary of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr) <I>No Broker&#146;s Fees.</I> Neither the Company nor any of its subsidiaries is a party to any contract, agreement or understanding with
any person (other than this Agreement) that would give rise to a valid claim against any of them or any Underwriter for a brokerage commission, finder&#146;s fee or like payment in connection with the offering and sale of the Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) <I>No Registration Rights</I>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, no
person has the right to require the Company or any of its subsidiaries to register any securities for sale under the Securities Act by reason of the filing of the Registration Statement with the Commission or the issuance and sale of the Shares.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt) <I>No Stabilization.</I> Neither the Company nor any of its subsidiaries or affiliates has taken, directly or indirectly, any action
designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu)
<I>Margin Rules</I>. Neither the issuance, sale and delivery of the Shares nor the application of the proceeds thereof by the Company as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus will violate
Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other regulation of such Board of Governors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv) <I>Forward-Looking Statements.</I> No forward-looking statement (within the meaning of
Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act) included in any of the Registration Statement, the Pricing Disclosure Package or the Prospectus has been made or reaffirmed without a reasonable basis or has been
disclosed other than in good faith. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ww) <I>Statistical and Market Data.</I> Nothing has come to the attention of the Company that has
caused the Company to believe that the statistical and market-related data included in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus is not based on or derived from sources that are reliable and accurate in
all material respects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx) <I>Sarbanes-Oxley Act</I>. There is and has been no failure on the part of the Company or any of the
Company&#146;s directors or officers, in their capacities as such, to comply with any applicable provision of the Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations promulgated in connection therewith (the &#147;Sarbanes-Oxley
Act&#148;), including Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(yy) <I>Status under the
Securities Act</I>. At the time of filing the Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Company or any offering participant made a <I>bona fide</I> offer (within the meaning of Rule
164(h)(2) under the Securities Act) of the Shares and at the date hereof, the Company was not and is not an &#147;ineligible issuer,&#148; as defined in Rule 405 under the Securities Act. The Company has paid the registration fee for this offering
pursuant to Rule 456(b)(1) under the Securities Act or will pay such fee within the time period required by such rule (without giving effect to the proviso therein) and in any event prior to the Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(zz) <I>No Ratings</I>. There are (and prior to the Closing Date, will be) no debt securities, convertible securities or preferred stock issued
or guaranteed by the Company or any of its subsidiaries that are rated by a &#147;nationally recognized statistical rating organization&#148;, as such term is defined in Section&nbsp;3(a)(62) under the Exchange Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Further Agreements of the Company</U>. The Company covenants and agrees with each Underwriter that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Required Filings.</I> The Company will file the final Prospectus with the Commission prior to the time of the Closing Date and in any
event within the time periods specified by Rule 424(b) and Rule 430A, 430B or 430C under the Securities Act, will file any Issuer Free Writing Prospectus to the extent required by Rule 433 under the Securities Act; and the Company will furnish
copies of the Prospectus and each Issuer Free Writing Prospectus (to the extent not previously delivered) to the Underwriters in New York City prior to 10:00 A.M., New York City time, on the business day next succeeding the date of this Agreement in
such quantities as the Representatives may reasonably request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Delivery of Copies.</I> The Company will deliver, without charge, (i)&nbsp;to the
Representatives, two signed copies of the Registration Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith; and (ii)&nbsp;to each Underwriter (A)&nbsp;a conformed copy of the
Registration Statement as originally filed and each amendment thereto (without exhibits) and (B)&nbsp;during the Prospectus Delivery Period (as defined below), as many copies of the Prospectus (including all amendments and supplements thereto and
each Issuer Free Writing Prospectus) as the Representatives may reasonably request. As used herein, the term &#147;Prospectus Delivery Period&#148; means such period of time after the first date of the public offering of the Shares as in the opinion
of counsel for the Underwriters a prospectus relating to the Shares is required by law to be delivered (or required to be delivered but for Rule 172 under the Securities Act) in connection with sales of the Shares by any Underwriter or dealer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Amendments or Supplements, Issuer Free Writing Prospectuses.</I> Before making, preparing, using, authorizing, approving, referring to
or filing any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company will furnish to the Representatives and counsel for the
Underwriters a copy of the proposed Issuer Free Writing Prospectus, amendment or supplement for review and will not make, prepare, use, authorize, approve, refer to or file any such Issuer Free Writing Prospectus or file any such proposed amendment
or supplement to which the Representatives reasonably object. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Notice to the Representatives.</I> The Company will advise the
Representatives promptly, and confirm such advice in writing (which may be by email), (i) when the Registration Statement has become effective; (ii)&nbsp;when any amendment to the Registration Statement has been filed or becomes effective;
(iii)&nbsp;when any supplement to the Pricing Disclosure Package, the Prospectus, any Issuer Free Writing Prospectus, any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or any
amendment to the Prospectus has been filed or distributed; (iv)&nbsp;of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus or the receipt of any comments from the Commission
relating to the Registration Statement or any other request by the Commission for any additional information including, but not limited to, any request for information concerning any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication; (v)&nbsp;of the issuance by the Commission or any other governmental or regulatory authority of any order suspending the effectiveness
of the Registration Statement or preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure Package, the Prospectus or any Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or the initiation or, to the knowledge of the Company, threatening of any proceeding for that purpose or pursuant to Section&nbsp;8A of
the Securities Act; (vi)&nbsp;of the occurrence of any event or development within the Prospectus Delivery Period as a result of which the Prospectus, any of the Pricing Disclosure Package, any Issuer Free Writing Prospectus or any Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact necessary in order to
make the statements therein, in the light of the circumstances existing when the Prospectus, the Pricing Disclosure Package, any such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Issuer Free Writing Prospectus or any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication is delivered to a purchaser, not
misleading; and (vii)&nbsp;of the receipt by the Company of any notice with respect to any suspension of the qualification of the Shares for offer and sale in any jurisdiction or the initiation or, to the knowledge of the Company, threatening of any
proceeding for such purpose; and the Company will use its reasonable best efforts to prevent the issuance of any such order suspending the effectiveness of the Registration Statement, preventing or suspending the use of any Preliminary Prospectus,
any of the Pricing Disclosure Package or the Prospectus or any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or suspending any such qualification of the Shares and, if any
such order is issued, will obtain as soon as possible the withdrawal thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Ongoing Compliance.</I> (1)&nbsp;If during the
Prospectus Delivery Period (i)&nbsp;any event or development shall occur or condition shall exist as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state any material
fact necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or supplement the Prospectus to comply with law,
the Company will, as soon as practicable, notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission and furnish to the Underwriters and to such dealers as the Representatives may
designate such amendments or supplements to the Prospectus as may be necessary so that the statements in the Prospectus as so amended or supplemented will not, in the light of the circumstances existing when the Prospectus is delivered to a
purchaser, be misleading or so that the Prospectus will comply with law and (2)&nbsp;if at any time prior to the Closing Date (i)&nbsp;any event or development shall occur or condition shall exist as a result of which the Pricing Disclosure Package
as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Pricing Disclosure
Package is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or supplement the Pricing Disclosure Package to comply with law, the Company will immediately notify the Underwriters thereof and forthwith prepare and,
subject to paragraph (c)&nbsp;above, file with the Commission (to the extent required) and furnish to the Underwriters and to such dealers as the Representatives may designate such amendments or supplements to the Pricing Disclosure Package as may
be necessary so that the statements in the Pricing Disclosure Package as so amended or supplemented will not, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, be misleading or so that the
Pricing Disclosure Package will comply with law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Blue Sky Compliance.</I> The Company will use commercially reasonable efforts with
the Underwriters&#146; cooperation, if necessary, to qualify the Shares for offer and sale under the securities or Blue Sky laws of such jurisdictions as the Representatives shall reasonably request and will use commercially reasonable efforts, with
the Underwriters&#146; cooperation, if necessary, to continue such qualifications in effect so long as required for distribution of the Shares; <U>provided</U> that the Company shall not be required to (i)&nbsp;qualify as a foreign corporation or
other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii)&nbsp;file any general consent to service of process in any such jurisdiction or (iii)&nbsp;subject itself to taxation in
any such jurisdiction if it is not otherwise so subject. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Earning Statement. </I>The Company will make generally available to its security
holders and the Representatives as soon as practicable an earning statement that satisfies the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 of the Commission promulgated thereunder covering a period of at least twelve months
beginning with the first fiscal quarter of the Company occurring after the &#147;effective date&#148; (as defined in Rule 158) of the Registration Statement; provided that the Company will be deemed to have furnished such statements to its security
holders and the Representatives to the extent they are filed on the Commission&#146;s Electronic Data Gathering, Analysis and Retrieval system (&#147;EDGAR&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Clear Market.</I> For a period of 180 days after the date of the Prospectus (the &#147;Restricted Period&#148;), the Company will not
(i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, hedge, lend, or otherwise transfer or dispose of, directly or
indirectly, or submit to, or file with, the Commission a registration statement under the Securities Act relating to, any shares of Stock or any securities convertible into or exercisable or exchangeable for Stock, or (ii)&nbsp;enter into any swap,
hedging or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Stock or any such other securities, or publicly disclose the intention to undertake any of the foregoing in clause (i)&nbsp;or (ii),
whether any such transaction described in clause (i)&nbsp;or (ii) above is to be settled by delivery of Stock or such other securities, in cash or otherwise, without the prior written consent of the Representatives, other than the Shares to be sold
hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restrictions described above do not apply to (i)&nbsp;the issuance of shares of Stock or securities convertible into or
exercisable for shares of Stock pursuant to the conversion or exchange of convertible or exchangeable securities or the exercise of warrants or options (including net exercise) or the settlement of RSUs (including net settlement), in each case
outstanding on the date of this Agreement and described in the Prospectus; (ii)&nbsp;grants of stock options, stock awards, restricted stock, RSUs, or other equity awards and the issuance of shares of Stock or securities convertible into or
exercisable or exchangeable for shares of Stock (whether upon the exercise of stock options or otherwise) to the Company&#146;s employees, officers, directors, advisors, or consultants pursuant to the terms of an equity compensation plan in effect
as of the Closing Date and described in the Prospectus; (iii)&nbsp;the issuance of up to 10% of the outstanding shares of Stock, or securities convertible into, exercisable for, or which are otherwise exchangeable for, Stock, immediately following
the Closing Date, in connection with any bona fide licensing, commercialization, joint venture, technology transfer, acquisition, development collaboration or other strategic transaction, provided that such recipients enter into a <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreement with the Underwriters; or (iv)&nbsp;the filing of any registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> relating to securities granted or to be granted pursuant to any plan
in effect on the date of this Agreement and described in the Prospectus or any assumed benefit plan pursuant to an acquisition or similar strategic transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Representatives, in their sole discretion, agree to release or waive the restrictions
set forth in a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement described in Section&nbsp;6(l) hereof for an officer or director of the Company and provide the Company with notice of the impending release or waiver substantially in the form
of Exhibit B hereto at least three business days before the effective date of the release or waiver, the Company agrees to announce the impending release or waiver substantially in the form of Exhibit C hereto through a major news service at least
two business days before the effective date of the release or waiver. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Use of Proceeds.</I> The Company will apply the net proceeds
from the sale of the Shares as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading &#147;Use of proceeds&#148;. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>No Stabilization.</I> Neither the Company nor its subsidiaries or affiliates will take, directly or indirectly, any action designed to
or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Exchange
Listing.</I> The Company will use its reasonable best efforts to list, subject to notice of issuance, the Shares on the Nasdaq Global Market. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Reports.</I> For a period of three years from the date of this Agreement, the Company will furnish to the Representatives, as soon as
they are available, copies of all reports or other communications (financial or other) furnished to holders of the Shares, and copies of any reports and financial statements furnished to or filed with the Commission or any national securities
exchange or automatic quotation system; <U>provided</U> the Company will be deemed to have furnished such reports and financial statements to the Representatives to the extent they are filed on EDGAR. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Record Retention</I>. The Company will, pursuant to reasonable procedures developed in good faith, retain copies of each Issuer Free
Writing Prospectus that is not filed with the Commission in accordance with Rule 433 under the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Filings.</I> The
Company will file with the Commission such reports as may be required by Rule 463 under the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>Emerging Growth
Company</I>. The Company will promptly notify the Representatives if the Company ceases to be an Emerging Growth Company at any time prior to the later of (i)&nbsp;completion of the distribution of Shares within the meaning of the Securities Act and
(ii)&nbsp;completion of the Restricted Period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <I>Transfer Restrictions</I>. Until the expiration of the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period, the Company will (A)&nbsp;enforce all existing agreements between the Company and any of its securityholders that prohibit the sale, transfer, assignment, pledge or hypothecation of any of the
Company&#146;s securities; (B)&nbsp;direct the transfer agent and/or equity plan administrator to place stop transfer restrictions upon any such securities of the Company that are bound by such existing
<FONT STYLE="white-space:nowrap">&#147;lock-up&#148;,</FONT> &#147;market <FONT STYLE="white-space:nowrap">stand-off&#148;,</FONT> &#147;holdback&#148; or similar provisions of such agreements for the duration of the
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period; and (C)&nbsp;not release or otherwise grant any waiver of such provisions in such agreements without the prior written consent of the Representatives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Certain Agreements of the Underwriters</U>. Each Underwriter hereby represents and
agrees that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) It has not and will not use, authorize use of, refer to or participate in the planning for use of, any &#147;free writing
prospectus&#148;, as defined in Rule 405 under the Securities Act (which term includes use of any written information furnished to the Commission by the Company and not incorporated by reference into the Registration Statement and any press release
issued by the Company) other than (i)&nbsp;a free writing prospectus that contains no &#147;issuer information&#148; (as defined in Rule 433(h)(2) under the Securities Act) that was not included (including through incorporation by reference) in the
Preliminary Prospectus or a previously filed Issuer Free Writing Prospectus, (ii)&nbsp;any Issuer Free Writing Prospectus listed on Annex A or prepared pursuant to Section&nbsp;3(c) or Section&nbsp;4(c) above (including any electronic road show), or
(iii)&nbsp;any free writing prospectus prepared by such underwriter and approved by the Company in advance in writing (each such free writing prospectus referred to in clauses (i)&nbsp;or (iii), an &#147;Underwriter Free Writing Prospectus&#148;).
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) It has not and will not, without the prior written consent of the Company, use any free writing prospectus that contains the final
terms of the Shares unless such terms have previously been included in a free writing prospectus filed with the Commission; <I>provided</I> that Underwriters may use a term sheet substantially in the form of Annex C hereto without the consent of the
Company; <I>provided further</I> that any Underwriter using such term sheet shall notify the Company, and provide a copy of such term sheet to the Company, prior to, or substantially concurrently with, the first use of such term sheet. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) It is not subject to any pending proceeding under Section&nbsp;8A of the Securities Act with respect to the offering (and will promptly
notify the Company if any such proceeding against it is initiated during the Prospectus Delivery Period). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Conditions of
Underwriters&#146; Obligations.</U> The obligation of each Underwriter to purchase the Underwritten Shares on the Closing Date or the Option Shares on the Additional Closing Date, as the case may be, as provided herein is subject to the performance
by the Company of its covenants and other obligations hereunder and to the following additional conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Registration
Compliance; No Stop Order.</I> No order suspending the effectiveness of the Registration Statement shall be in effect, and no proceeding for such purpose or pursuant to Section&nbsp;8A under the Securities Act shall be pending before or threatened
by the Commission; the Prospectus and each Issuer Free Writing Prospectus shall have been timely filed with the Commission under the Securities Act (in the case of an Issuer Free Writing Prospectus, to the extent required by Rule 433 under the
Securities Act) and in accordance with Section&nbsp;4(a) hereof; and all requests by the Commission for additional information shall have been complied with to the reasonable satisfaction of the Representatives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Representations and Warranties.</I> The representations and warranties of the Company
contained herein shall be true and correct on the date hereof and on and as of the Closing Date or the Additional Closing Date, as the case may be; and the statements of the Company and its officers made in any certificates delivered pursuant to
this Agreement shall be true and correct on and as of the Closing Date or the Additional Closing Date, as the case may be. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>No
Material Adverse Change.</I> No event or condition of a type described in Section&nbsp;3(h) hereof shall have occurred or shall exist, which event or condition is not described in the Pricing Disclosure Package (excluding any amendment or supplement
thereto) and the Prospectus (excluding any amendment or supplement thereto) and the effect of which in the judgment of the Representatives makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on the
Closing Date or the Additional Closing Date, as the case may be, on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Officer&#146;s Certificate.</I> The Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as
the case may be, a certificate of the chief financial officer or chief accounting officer of the Company and one additional senior executive officer of the Company who is satisfactory to the Representatives (i)&nbsp;confirming that such officers
have carefully reviewed the Registration Statement, the Pricing Disclosure Package and the Prospectus and, to the knowledge of such officers, the representations set forth in Sections 3(b) and 3(f) hereof are true and correct, (ii)&nbsp;confirming
that the other representations and warranties of the Company in this Agreement are true and correct and that the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to
the Closing Date or the Additional Closing Date, as the case may be, and (iii)&nbsp;to the effect set forth in paragraphs (a), (b) and (c)&nbsp;above. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Comfort Letters.</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;On the date of this Agreement and on the Closing Date or the Additional Closing Date, as the case may be,
PricewaterhouseCoopers LLP shall have furnished to the Representatives, at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the Underwriters, in form and substance reasonably satisfactory to the
Representatives, containing statements and information of the type customarily included in accountants&#146; &#147;comfort letters&#148; to underwriters with respect to the financial statements and certain financial information contained in each of
the Registration Statement, the Pricing Disclosure Package and the Prospectus; provided, that the letter delivered on the Closing Date or the Additional Closing Date, as the case may be, shall use a
<FONT STYLE="white-space:nowrap">&#147;cut-off&#148;</FONT> date no more than two business days prior to such Closing Date or such Additional Closing Date, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) On the date of this Agreement and on the Closing Date or the Additional Closing Date, as the case may be, the Company
shall have furnished to the Representatives a certificate, dated the respective dates of delivery thereof and addressed to the Underwriters, of its chief financial officer with respect to certain financial data contained in the Pricing Disclosure
Package and the Prospectus, providing &#147;management comfort&#148; with respect to such information, in form and substance reasonably satisfactory to the Representatives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> Statement of Counsel for
the Company.</I> Goodwin Procter LLP, counsel for the Company, shall have furnished to the Representatives, at the request of the Company, their written opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> statement, dated the Closing Date or
the Additional Closing Date, as the case may be, and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Opinion of Intellectual Property Counsel for the Company</I>. Goodwin Procter LLP, intellectual property counsel for the Company, shall
have furnished to the Representatives, at the request of the Company, their written opinion, dated the Closing Date or the Additional Closing Date, as the case may be, and addressed to the Underwriters, in form and substance reasonably satisfactory
to the Representatives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> Statement of Counsel for the Underwriters.</I>
The Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, an opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> statement, addressed to the Underwriters, of Cooley LLP, counsel
for the Underwriters, with respect to such matters as the Representatives may reasonably request, and such counsel shall have received such documents and information as they may reasonably request to enable them to pass upon such matters. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>No Legal Impediment to Issuance and Sale.</I> No action shall have been taken and no statute, rule, regulation or order shall have been
enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent the issuance or sale of the Shares; and no injunction or
order of any federal, state or foreign court shall have been issued that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent the issuance or sale of the Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Good Standing</I>. The Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case may
be, satisfactory evidence of the good standing of the Company and its subsidiaries in their respective jurisdictions of organization and their good standing in such other jurisdictions as the Representatives may reasonably request, in each case in
writing or any standard form of telecommunication from the appropriate governmental authorities of such jurisdictions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Exchange
Listing.</I> The Shares to be delivered on the Closing Date or the Additional Closing Date, as the case may be, shall have been approved for listing on the Nasdaq Global Market, subject to official notice of issuance. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements</I>. The <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT>
agreements, each substantially in the form of Exhibit A hereto, between the Representatives and the officers, directors and substantially all of the securityholders of the Company, relating to sales and certain other dispositions of shares of Stock
or certain other securities, delivered to you on or before the date hereof, shall be full force and effect on the Closing Date or the Additional Closing Date, as the case may be. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Additional</I><I> Documents.</I> On or prior to the Closing Date or the Additional
Closing Date, as the case may be, the Company shall have furnished to the Representatives such further certificates and documents as the Representatives may reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All opinions, letters, certificates and evidence mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the
provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Underwriters. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Indemnification
and Contribution</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Indemnification of the Underwriters.</I> The Company agrees to indemnify and hold harmless each Underwriter,
its affiliates, directors and officers and each person, if any, who controls such Underwriter within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, from and against any and all losses, claims, damages
and liabilities (including, without limitation, reasonable and documented legal fees and other expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and expenses are incurred), joint or several, that
arise out of, or are based upon, (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or caused by any omission or alleged omission to state therein a material fact required to be
stated therein or necessary in order to make the statements therein, not misleading, or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Prospectus (or any amendment or supplement thereto), any
Preliminary Prospectus, any Issuer Free Writing Prospectus, any &#147;issuer information&#148; filed or required to be filed pursuant to Rule 433(d) under the Securities Act, any Written <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, any road show as defined in Rule 433(h) under the Securities Act (a &#147;road show&#148;) or any Pricing Disclosure Package (including any Pricing Disclosure Package that
has subsequently been amended), or caused by any omission or alleged omission to state therein a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading, in each case
except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to any
Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein, it being understood and agreed that the only such information furnished by any Underwriter consists of the information
described as such in paragraph (b)&nbsp;below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Indemnification of the Company.</I> Each Underwriter agrees, severally and not
jointly, to indemnify and hold harmless the Company, its directors, its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20
of the Exchange Act to the same extent as the indemnity set forth in paragraph (a)&nbsp;above, but only with respect to any losses, claims, damages or liabilities that arise out of, or are based upon, any untrue statement or omission or alleged
untrue statement or omission made in reliance upon and in conformity with any information relating to such Underwriter furnished to the Company in writing by such Underwriter through </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Representatives expressly for use in the Registration Statement, the Prospectus (or any amendment or supplement thereto), any Preliminary Prospectus, any Issuer Free Writing Prospectus, any
Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, any road show or any Pricing Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended),
it being understood and agreed upon that the only such information furnished by any Underwriter consists of the following information in the Prospectus furnished on behalf of each Underwriter: the concession and reallowance figures appearing in the
[&#149;] paragraph under the caption &#147;Underwriting&#148; and the information contained in the [&#149;] paragraph under the caption &#147;Underwriting.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Notice and Procedures.</I> If any suit, action, proceeding (including any governmental or regulatory investigation), claim or demand
shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to the preceding paragraphs of this Section&nbsp;7, such person (the &#147;Indemnified Person&#148;) shall promptly notify the person against
whom such indemnification may be sought (the &#147;Indemnifying Person&#148;) in writing; <U>provided</U> that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have under the preceding paragraphs of
this Section&nbsp;7 except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and <U>provided</U>, <U>further</U>, that the failure to notify the Indemnifying Person shall
not relieve it from any liability that it may have to an Indemnified Person otherwise than under the preceding paragraphs of this Section&nbsp;7. If any such proceeding shall be brought or asserted against an Indemnified Person and it shall have
notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not, without the consent of the Indemnified Person, be counsel to the Indemnifying Person) to
represent the Indemnified Person and any others entitled to indemnification pursuant to this Section&nbsp;7 that the Indemnifying Person may designate in such proceeding and shall pay the reasonable and documented fees and expenses in such
proceeding, including the reasonable and documented fees and expenses of such counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses
of such counsel shall be at the expense of such Indemnified Person unless (i)&nbsp;the Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary; (ii)&nbsp;the Indemnifying Person has failed within a reasonable time
to retain counsel reasonably satisfactory to the Indemnified Person; (iii)&nbsp;the Indemnified Person shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to the
Indemnifying Person; or (iv)&nbsp;the named parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified Person and representation of both parties by the same counsel would be
inappropriate due to actual or potential differing interests between them. It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceeding in the same jurisdiction, be liable for the fees
and expenses of more than one separate firm (in addition to any local counsel) for all Indemnified Persons, and that all such fees and expenses shall be paid or reimbursed as they are incurred. Any such separate firm for any Underwriter, its
affiliates, directors and officers and any control persons of such Underwriter shall be designated in writing by the Representatives and any such separate firm for the Company, its directors, its officers who signed the Registration Statement and
any control persons of the Company shall be designated in writing by the Company. The Indemnifying Person shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consent, the Indemnifying Person agrees to indemnify each Indemnified Person from and against any loss or liability by reason of such settlement. Notwithstanding the foregoing sentence, if at any
time an Indemnified Person shall have requested that an Indemnifying Person reimburse the Indemnified Person for fees and expenses of counsel as contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any
proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 30 days after receipt by the Indemnifying Person of such request and (ii)&nbsp;the Indemnifying Person shall not have reimbursed the Indemnified
Person in accordance with such request prior to the date of such settlement. No Indemnifying Person shall, without the written consent of the Indemnified Person, effect any settlement of any pending or threatened proceeding in respect of which any
Indemnified Person is or could have been a party and indemnification could have been sought hereunder by such Indemnified Person, unless such settlement (x)&nbsp;includes an unconditional release of such Indemnified Person, in form and substance
reasonably satisfactory to such Indemnified Person, from all liability on claims that are the subject matter of such proceeding and (y)&nbsp;does not include any statement as to or any admission of fault, culpability or a failure to act by or on
behalf of any Indemnified Person. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Contribution.</I> If the indemnification provided for in paragraphs (a)&nbsp;or (b) above is
unavailable to an Indemnified Person or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of indemnifying such Indemnified Person thereunder, shall
contribute to the amount paid or payable by such Indemnified Person as a result of such losses, claims, damages or liabilities (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand,
and the Underwriters on the other, from the offering of the Shares or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred
to in clause (i)&nbsp;but also the relative fault of the Company, on the one hand, and the Underwriters on the other, in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other
relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Underwriters on the other, shall be deemed to be in the same respective proportions as the net proceeds (before deducting expenses) received
by the Company from the sale of the Shares and the total underwriting discounts and commissions received by the Underwriters in connection therewith, in each case as set forth in the table on the cover of the Prospectus, bear to the aggregate
offering price of the Shares. The relative fault of the Company, on the one hand, and the Underwriters on the other, shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the
omission or alleged omission to state a material fact relates to information supplied by the Company or by the Underwriters and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement
or omission. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Limitation on Liability.</I> The Company and the Underwriters agree that it would not be just and equitable if
contribution pursuant to paragraph (d)&nbsp;above were determined by <U>pro</U> <U>rata</U> allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take account of the
equitable considerations referred to in paragraph (d)&nbsp;above. The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities referred to in paragraph (d)&nbsp;above shall be deemed to include,
subject to the limitations set forth above, any reasonable and documented legal or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expenses incurred by such Indemnified Person in connection with any such action or claim. Notwithstanding the provisions of paragraphs (d)&nbsp;and (e), in no event shall an Underwriter be
required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the offering of the Shares exceeds the amount of any damages that such Underwriter has
otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled
to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#146; obligations to contribute pursuant to paragraphs (d)&nbsp;and (e) are several in proportion to their respective purchase obligations
hereunder and not joint. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I><FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Remedies.</I> The remedies provided for in this
Section&nbsp;7 are not exclusive and shall not limit any rights or remedies which may otherwise be available to any Indemnified Person at law or in equity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Effectiveness of Agreement</U>. This Agreement shall become effective as of the date first written above. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Termination</U>. This Agreement may be terminated in the absolute discretion of the Representatives, by notice to the Company, if after
the execution and delivery of this Agreement and on or prior to the Closing Date or, in the case of the Option Shares, prior to the Additional Closing Date, (i)&nbsp;trading generally shall have been suspended or materially limited on or by any of
the New York Stock Exchange or The Nasdaq Stock Market; (ii)&nbsp;trading of any securities issued or guaranteed by the Company shall have been suspended on any exchange or in any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; (iii)&nbsp;a general moratorium on commercial banking activities shall have been declared by federal or New York State authorities; or
(iv)&nbsp;there shall have occurred any outbreak or escalation of hostilities or any change in financial markets or any calamity or crisis, either within or outside the United States, that, in the judgment of the Representatives, is material and
adverse and makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing Date or the Additional Closing Date, as the case may be, on the terms and in the manner contemplated by this Agreement, the
Pricing Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Defaulting Underwriter</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) If, on the Closing Date or the Additional Closing Date, as the case may be, any Underwriter defaults on its obligation to purchase the
Shares that it has agreed to purchase hereunder on such date, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters may in their discretion arrange for the purchase of such Shares by other persons satisfactory to the Company on the
terms contained in this Agreement. If, within 36 hours after any such default by any Underwriter, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters do not arrange for the purchase of such Shares, then the Company shall be
entitled to a further period of 36 hours within which to procure other persons satisfactory to the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters to purchase such Shares on such terms. If other persons become obligated or agree
to purchase the Shares of a defaulting Underwriter, either the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters or the Company may postpone the Closing Date or the Additional Closing Date, as the case may be, for up to five full
business days in order to effect any changes that in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
opinion of counsel for the Company or counsel for the Underwriters may be necessary in the Registration Statement and the Prospectus or in any other document or arrangement, and the Company
agrees to promptly prepare any amendment or supplement to the Registration Statement and the Prospectus that effects any such changes. As used in this Agreement, the term &#147;Underwriter&#148; includes, for all purposes of this Agreement unless
the context otherwise requires, any person not listed in Schedule 1 hereto that, pursuant to this Section&nbsp;10, purchases Shares that a defaulting Underwriter agreed but failed to purchase. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by the <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of Shares that remain unpurchased on the Closing Date or the Additional Closing Date, as the case may be,
does not exceed <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate number of Shares to be purchased on such date, then the Company shall have the right to require each <FONT STYLE="white-space:nowrap">non-defaulting</FONT>
Underwriter to purchase the number of Shares that such Underwriter agreed to purchase hereunder on such date plus such Underwriter&#146;s pro rata share (based on the number of Shares that such Underwriter agreed to purchase on such date) of the
Shares of such defaulting Underwriter or Underwriters for which such arrangements have not been made. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If, after giving effect to any
arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of
Shares that remain unpurchased on the Closing Date or the Additional Closing Date, as the case may be, exceeds <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate amount of Shares to be purchased on such date, or if the Company
shall not exercise the right described in paragraph (b)&nbsp;above, then this Agreement or, with respect to any Additional Closing Date, the obligation of the Underwriters to purchase Shares on the Additional Closing Date, as the case may be, shall
terminate without liability on the part of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters. Any termination of this Agreement pursuant to this Section&nbsp;10 shall be without liability on the part of the Company, except that
the Company will continue to be liable for the payment of expenses as set forth in Section&nbsp;11 hereof and except that the provisions of Section&nbsp;7 hereof shall not terminate and shall remain in effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Nothing contained herein shall relieve a defaulting Underwriter of any liability it may have to the Company or any <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter for damages caused by its default. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Payment of Expenses</U><I>.</I>
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company will pay
or cause to be paid all costs and expenses incident to the performance of its obligations hereunder, including without limitation, (i)&nbsp;the costs incident to the authorization, issuance, sale, preparation and delivery of the Shares and any taxes
payable in that connection; (ii)&nbsp;the costs incident to the preparation, printing and filing under the Securities Act of the Registration Statement, the Preliminary Prospectus, any Issuer Free Writing Prospectus, any Pricing Disclosure Package
and the Prospectus (including all exhibits, amendments and supplements thereto) and the distribution thereof; (iii)&nbsp;the fees and expenses of the Company&#146;s counsel and independent accountants; (iv)&nbsp;the fees and expenses incurred in
connection with the registration or qualification and determination of eligibility for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
investment of the Shares under the laws of such jurisdictions as the Representatives may designate and the preparation, printing and distribution of a Blue Sky Memorandum (including the related
reasonable and documented fees and expenses of counsel for the Underwriters);&nbsp;(v) the cost of preparing stock certificates; (vi)&nbsp;the costs and charges of any transfer agent and any registrar; (vii)&nbsp;all expenses and application fees
incurred in connection with any filing with, and clearance of the offering by, FINRA (in an amount not to exceed, when taken together with all costs, fees and expenses incurred pursuant to clause (iv), $40,000 (exclusive of filing fees) without the
prior written consent of the Company); (viii) all expenses incurred by the Company in connection with any &#147;road show&#148; presentation to potential investors, provided, however, that the Company and the Underwriters shall each pay 50% of the
total costs of chartering any aircraft to be used in connection with any such &#147;road shows&#148;; and (ix)&nbsp;all expenses and application fees related to the listing of the Shares on the Nasdaq Global Market. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If (i)&nbsp;this Agreement is terminated pursuant to Section&nbsp;9, (ii) the Company for any reason fails to tender the Shares for
delivery to the Underwriters or (iii)&nbsp;the Underwriters decline to purchase the Shares for any reason permitted under this Agreement, the Company agrees to reimburse the Underwriters for all reasonable and documented <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses (including the reasonable and documented fees and expenses of their counsel) incurred by the Underwriters in connection with this Agreement
and the offering contemplated hereby. For the avoidance of doubt, the Company will not be required to pay or reimburse any costs, fees or expenses incurred by any Underwriter that defaults on its obligations to purchase the Shares, as described in
Section&nbsp;10 hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Persons Entitled to Benefit of Agreement</U>. This Agreement shall inure to the benefit of and be binding
upon the parties hereto and their respective successors and the officers and directors and any controlling persons referred to herein, and the affiliates of each Underwriter referred to in Section&nbsp;7 hereof. Nothing in this Agreement is intended
or shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Shares from any Underwriter shall be deemed to be a successor
merely by reason of such purchase. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Survival</U>. The respective indemnities, rights of contribution, representations, warranties
and agreements of the Company and the Underwriters contained in this Agreement or made by or on behalf of the Company or the Underwriters pursuant to this Agreement or any certificate delivered pursuant hereto shall survive the delivery of and
payment for the Shares and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company or the Underwriters or the directors, officers, controlling persons or
affiliates referred to in Section&nbsp;7 hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Certain Defined Terms</U>. For purposes of this Agreement, (a)&nbsp;except where
otherwise expressly provided, the term &#147;affiliate&#148; has the meaning set forth in Rule 405 under the Securities Act; (b)&nbsp;the term &#147;business day&#148; means any day other than a day on which banks are permitted or required to be
closed in New York City; and (c)&nbsp;the term &#147;subsidiary&#148; has the meaning set forth in Rule 405 under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Compliance with USA Patriot Act</U>. In accordance with the requirements of the USA
Patriot Act (Title III of Pub. L. <FONT STYLE="white-space:nowrap">107-56</FONT> (signed into law October&nbsp;26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the
Company, which information may include the name and address of their respective clients, as well as other information that will allow the Underwriters to properly identify their respective clients. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Miscellaneous</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
<I>Notices.</I> All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or transmitted and confirmed by any standard form of telecommunication. Notices to the Underwriters shall be
given to the Representatives c/o J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179 (fax: (212) <FONT STYLE="white-space:nowrap">622-8358),</FONT> Attention: Equity Syndicate Desk; c/o TD Securities (USA) LLC, Attention: Head
of Equity Capital Markets, Fax: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">646-562-1249</FONT></FONT> with a copy to the General Counsel, Fax:
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">646-562-1130;</FONT></FONT> c/o Piper Sandler&nbsp;&amp; Co., 800 Nicollet Mall, Minneapolis, Minnesota 55402, Attention: Equity Capital Markets with a separate notice to: General
Counsel, Legal capmarkets@psc.com; and c/o William Blair&nbsp;&amp; Company, L.L.C., 150 N. Riverside Plaza, Chicago, IL 60606, Attention: Equity Capital Markets and separately, General Counsel. Notices to the Company shall be given to it at
Upstream Bio, Inc., 890 Winter Street, Suite 200, Waltham, MA 02451; Attention: Michael Gray. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Governing Law.</I> This Agreement and
any claim, controversy or dispute arising under or related to this Agreement shall be governed by and construed in accordance with the laws of the State of New York. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Submission to Jurisdiction</I>. The Company hereby submits to the exclusive jurisdiction of the U.S. federal and New York state courts
in the Borough of Manhattan in The City of New York in any suit or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. The Company waives any objection which it may now or hereafter have to the laying of
venue of any such suit or proceeding in such courts. The Company agrees that final judgment in any such suit, action or proceeding brought in such court shall be conclusive and binding upon the Company and may be enforced in any court to the
jurisdiction of which Company is subject by a suit upon such judgment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Waiver of Jury Trial.</I> Each of the parties hereto hereby
waives any right to trial by jury in any suit or proceeding arising out of or relating to this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Recognition of the U.S.
Special Resolution Regimes</I>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) In the event that any Underwriter that is a Covered Entity becomes subject to a
proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the
U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) In the event that any Underwriter that is a Covered Entity or a BHC Act
Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such
Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">As used in this Section&nbsp;16(e): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;BHC Act Affiliate&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be interpreted in accordance with, 12
U.S.C. &#167; 1841(k). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;Covered Entity&#148; means any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(i) a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(iii) a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;Default Right&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81,
47.2 or 382.1, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;U.S. Special Resolution Regime&#148; means each of (i)&nbsp;the Federal Deposit Insurance Act and the
regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Counterparts.</I> This Agreement may be signed in counterparts (which may include counterparts delivered by any standard form of
telecommunication), each of which shall be an original and all of which together shall constitute one and the same instrument. The words &#147;execution,&#148; &#147;signed,&#148; &#147;signature,&#148; and words of like import in this Agreement or
in any other certificate, agreement or document related to this Agreement, if any, shall include images of manually executed signatures transmitted by facsimile or other electronic format (including, without limitation, &#147;pdf,&#148;
&#147;tif&#148; or &#147;jpg&#148;) and other electronic signatures (including, without limitation, DocuSign and AdobeSign). The use of electronic signatures and electronic records (including, without limitation, any contract or other record
created, generated, sent, communicated, received, or stored by electronic means) shall be of the same legal effect, validity and enforceability as a manually executed signature or use of a paper-based record-keeping system to the fullest extent
permitted by applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act and any other applicable law, including, without limitation, any state law based
on the Uniform Electronic Transactions Act or the Uniform Commercial Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Amendments or Waivers.</I> No amendment or waiver of any provision of this Agreement,
nor any consent or approval to any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Headings.</I> The headings herein are included for convenience of reference only and are not intended to be part of, or to affect the
meaning or interpretation of, this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding, please indicate your acceptance
of this Agreement by signing in the space provided below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">UPSTREAM BIO, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Accepted: As of the date first written above</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">J.P. MORGAN SECURITIES LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">TD SECURITIES (USA) LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">PIPER SANDLER&nbsp;&amp; CO.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">WILLIAM BLAIR&nbsp;&amp; COMPANY, L.L.C.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For themselves and on behalf of the</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">several Underwriters listed</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">in Schedule 1 hereto.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">J.P. MORGAN SECURITIES LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">TD SECURITIES (USA) LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">PIPER SANDLER&nbsp;&amp; CO.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">WILLIAM BLAIR&nbsp;&amp; COMPANY, L.L.C.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Authorized Signatory</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Schedule 1 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Underwriter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number&nbsp;of&nbsp;Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#149;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TD Securities (USA) LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#149;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#149;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William Blair&nbsp;&amp; Company, L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#149;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#149;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#149;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#149;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex A </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Pricing Disclosure Package</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[None.] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Pricing Information Provided Orally by Underwriters</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Number of Underwritten Shares: [&#149;] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Number of Option Shares: [&#149;] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Public Offering Price: $[&#149;] per Share </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex B </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upstream Bio &#150; <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Presentation (July 2024 &#150;
September 2024) </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex C </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pricing Term Sheet </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[None.] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">[&#149;], 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. MORGAN SECURITIES LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TD SECURITIES (USA) LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PIPER SANDLER&nbsp;&amp; CO. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WILLIAM BLAIR&nbsp;&amp; COMPANY, L.L.C. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the several Underwriters listed in </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule 1 to the
Underwriting </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agreement referred to below </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P. Morgan
Securities LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">383 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10179
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o TD Securities (USA) LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1 Vanderbilt Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10017 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Piper Sandler&nbsp;&amp; Co. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">800 Nicollet Mall, Suite 800 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Minneapolis, Minnesota 55402 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o William Blair&nbsp;&amp; Company, L.L.C. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">150 N. Riverside
Plaza </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chicago, Illinois 60606 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Re: Upstream
Bio, Inc. &#151; Initial Public Offering </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that you, as representatives (the &#147;Representatives&#148;) of the several Underwriters (as defined below),
propose to enter into an underwriting agreement (the &#147;Underwriting Agreement&#148;) with Upstream Bio, Inc., a Delaware corporation (the &#147;Company&#148;), providing for the initial public offering (the &#147;Public Offering&#148;) by the
several Underwriters named in Schedule 1 to the Underwriting Agreement (the &#147;Underwriters&#148;), of common stock, par value $0.001 per share (the &#147;Common Stock&#148;), of the Company (the &#147;Securities&#148;). Capitalized terms used
herein and not otherwise defined shall have the meanings set forth in the Underwriting Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the Underwriters&#146; agreement to purchase and make the Public
Offering of the Securities, and for other good and valuable consideration receipt of which is hereby acknowledged, the undersigned hereby agrees that, without the prior written consent of the Representatives on behalf of the Underwriters, the
undersigned will not, and will not cause any direct or indirect affiliate to, during the period beginning on the date of this letter agreement (this &#147;Letter Agreement&#148;) and ending at the close of business 180 days after the date of the
final prospectus relating to the Public Offering (the &#147;Prospectus&#148;) (such period, the &#147;Restricted Period&#148;), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to
sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock (including without
limitation, Common Stock or such other securities which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission and securities which may be issued upon exercise
of a stock option or warrant) (collectively with the Common Stock, the <FONT STYLE="white-space:nowrap">&#147;Lock-Up</FONT> Securities&#148;), (2) enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part,
any of the economic consequences of ownership of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, whether any such transaction described in clause (1)&nbsp;or (2) above is to be settled by delivery of
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, in cash or otherwise, (3)&nbsp;make any demand for or exercise any right with respect to the registration of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, or
(4)&nbsp;publicly disclose the intention to do any of the foregoing. The undersigned acknowledges and agrees that the foregoing precludes the undersigned from engaging in any hedging or other transactions or arrangements (including, without
limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) designed or intended, or which could
reasonably be expected to lead to or result in, a sale or disposition or transfer (whether by the undersigned or any other person) of any economic consequences of ownership, in whole or in part, directly or indirectly, of any <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, in cash or
otherwise. The undersigned further confirms that it has furnished the Representatives with the details of any transaction the undersigned, or any of its affiliates, is a party to as of the date hereof, which transaction would have been restricted by
this Letter Agreement if it had been entered into by the undersigned during the Restricted Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the
undersigned may: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;transfer or dispose of the undersigned&#146;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) as a bona fide gift or gifts, as a charitable contribution, or for bona fide estate planning purposes, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) by will or intestacy or any other testamentary document, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned, or if the undersigned is a
trust, to a trustor, trustee (or <FONT STYLE="white-space:nowrap">co-trustee)</FONT> or beneficiary of the trust or to the estate of a beneficiary of such trust (for purposes of this Letter Agreement, &#147;immediate family&#148; shall mean any
relationship by blood, current or former marriage, domestic partnership or adoption, not more remote than first cousin), </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) to a corporation, partnership, limited liability company, investment fund or other
entity (A)&nbsp;of which the undersigned and/or the immediate family of the undersigned are the legal and beneficial owner of all of the outstanding equity securities or similar interests, or (B)&nbsp;controlled by, or under common control with, the
undersigned or the immediate family of the undersigned, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) to a nominee or custodian of a person or entity to whom a disposition or
transfer would be permissible under clauses (i)&nbsp;through (iv) above, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;if the undersigned is a corporation, partnership,
limited liability company, trust or other business entity, (A)&nbsp;to another corporation, partnership, limited liability company, trust or other business entity that is a wholly owned subsidiary or an affiliate (as defined in Rule 405 promulgated
under the Securities Act of 1933, as amended) of the undersigned, or to any investment fund or other entity controlling, controlled by, managing or managed by or under common control with the undersigned or affiliates of the undersigned (including,
for the avoidance of doubt, where the undersigned is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), or (B)&nbsp;as part of a disposition, transfer or distribution to limited
partners, members or shareholders of the undersigned, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) by operation of law, such as pursuant to a qualified domestic order, divorce
settlement, divorce decree or separation agreement, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) to the Company from an employee of the Company upon death, disability or
termination of employment, in each case, of such employee, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) as part of a transaction related to the undersigned&#146;s <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities acquired (A)&nbsp;from the Underwriters in the Public Offering or (B)&nbsp;in open market transactions after the closing date for the Public Offering, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) to the Company in connection with the vesting, settlement, or exercise of restricted stock units, options, warrants or other rights to
purchase shares of Common Stock (including, in each case, by way of &#147;net&#148; or &#147;cashless&#148; exercise), including for the payment of exercise price and tax and remittance payments due as a result of the vesting, settlement, or
exercise of such restricted stock units, options, warrants or rights, provided that any such shares of Common Stock received upon such exercise, vesting or settlement shall be subject to the terms of this Letter Agreement, and provided further that
any such restricted stock units, options, warrants or rights are held by the undersigned pursuant to an agreement or equity awards granted under a stock incentive plan or other equity award plan, each such agreement or plan which is described in the
Registration Statement, the Pricing Disclosure Package and the Prospectus, or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) pursuant to a bona fide third-party tender offer,
merger, consolidation or other similar transaction that is approved by the Board of Directors of the Company and made to all holders of the Company&#146;s capital stock involving a Change of Control (as defined below) of the Company (for purposes
hereof, &#147;Change of Control&#148; shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons, of
shares of capital stock if, after such transfer, such person or group of affiliated persons would hold more than 50% of the outstanding voting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities of the Company (or the surviving entity)); and enter into any <FONT STYLE="white-space:nowrap">lock-up,</FONT> voting or similar agreement pursuant to which the undersigned may agree
to transfer, sell, tender or otherwise dispose of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities in connection with such a transaction; <U>provided</U> that in the event that such tender offer, merger, consolidation or other similar
transaction is not completed, the undersigned&#146;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities shall remain subject to the provisions of this Letter Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>provided</U> that (A)&nbsp;in the case of any transfer or distribution pursuant to clause (a)(i), (ii), (iii), (iv), (v), (vi) and (vii), such transfer
shall not involve a disposition for value and each donee, devisee, transferee or distributee shall execute and deliver to the Representatives a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter in the form of this Letter Agreement, (B)&nbsp;in
the case of any transfer or distribution pursuant to clause (a)(iii), (iv), (v), (vi) and (ix), no filing by any party (donor, donee, devisee, transferor, transferee, distributer or distributee) under the Securities Exchange Act of 1934, as amended
(the &#147;Exchange Act&#148;), or other public announcement shall be required or shall be made voluntarily in connection with such transfer or distribution (other than a filing on a Form 5 or a filing required pursuant to Section&nbsp;13 of the
Exchange Act and the rules and regulations promulgated thereunder made after the expiration of the Restricted Period referred to above) and (C)&nbsp;in the case of any transfer or distribution pursuant to clause (a)(i), (ii), (vii), (viii) and
(x)&nbsp;it shall be a condition to such transfer that no public filing, report or announcement shall be voluntarily made and if any filing under Section&nbsp;16(a) of the Exchange Act, or other public filing, report or announcement reporting a
reduction in beneficial ownership of shares of Common Stock in connection with such transfer or distribution shall be legally required during the Restricted Period, such filing, report or announcement shall clearly indicate in the footnotes thereto
the nature and conditions of such transfer; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) exercise outstanding options, settle restricted stock units or other equity awards or
exercise warrants pursuant to plans described in the Registration Statement, the Pricing Disclosure Package and the Prospectus; provided that any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities received upon such exercise, vesting or
settlement shall be subject to the terms of this Letter Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) convert outstanding preferred stock, warrants to acquire preferred
stock or convertible securities into shares of Common Stock or warrants to acquire shares of Common Stock; provided that any such shares of Common Stock or warrants received upon such conversion shall be subject to the terms of this Letter
Agreement; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) establish or modify trading plans pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange
Act for the transfer of shares of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities; <U>provided</U> that (1)&nbsp;such plans do not provide for the transfer of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities during the
Restricted Period and (2)&nbsp;no filing under the Exchange Act or other public announcement shall be made voluntarily during the Restricted Period by or on behalf of the undersigned or the Company regarding the establishment of any such trading
plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1,</FONT> <U>provided</U> that if a filing under the Exchange Act or other public announcement is required, such announcement or filing shall include a statement to the effect that no
transfer of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities may be made under such Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> trading plan during the Restricted Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the undersigned is not a natural person, the undersigned represents and warrants that no single natural person, entity or &#147;group&#148;
(within the meaning of Section&nbsp;13(d)(3) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;)) beneficially owns, directly or indirectly, 50% or more of the common equity interests, or 50% or more of the voting
power, in the undersigned. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the undersigned is an officer or director of the Company, the undersigned further agrees
that the foregoing provisions shall be equally applicable to any Company-directed Securities the undersigned may purchase in the Public Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the undersigned is an officer or director of the Company, (i)&nbsp;the Representatives on behalf of the Underwriters agree that, at least
three business days before the effective date of any release or waiver of the foregoing restrictions in connection with a transfer of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, the Representatives on behalf of the Underwriters will
notify the Company of the impending release or waiver, and (ii)&nbsp;the Company has agreed in the Underwriting Agreement to announce the impending release or waiver through a major news service at least two business days before the effective date
of the release or waiver. Any release or waiver granted by the Representatives on behalf of the Underwriters hereunder to any such officer or director shall only be effective two business days after the publication date of such announcement. The
provisions of this paragraph will not apply if (a)&nbsp;the release or waiver is effected solely to permit a transfer not for consideration or that is to an immediate family member as defined in FINRA Rule 5130(i)(5) and (b)&nbsp;the transferee has
agreed in writing to be bound by the same terms described in this Letter Agreement to the extent and for the duration that such terms remain in effect at the time of the transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In furtherance of the foregoing, the Company, and any duly appointed transfer agent for the registration or transfer of the securities
described herein, are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Letter Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Letter Agreement. All
authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that the Underwriters have not provided any recommendation or investment advice nor have the
Underwriters solicited any action from the undersigned with respect to the Public Offering of the Securities and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to the extent deemed appropriate. The
undersigned further acknowledges and agrees that, although the Representatives may be required or choose to provide certain Regulation Best Interest and Form CRS disclosures to you in connection with the Public Offering, the Representatives and the
other Underwriters are not making a recommendation to you to enter into this Letter Agreement, and nothing set forth in such disclosures is intended to suggest that the Representatives or any Underwriter is making such a recommendation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that, if the Underwriting Agreement does not become effective by
December&nbsp;31, 2024 (provided, however, that the undersigned agrees that this Letter Agreement shall be automatically extended by three months if the Company provides written notice to the undersigned that the Company is still pursuing the Public
Offering contemplated by the Underwriting Agreement), or if the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Common Stock to be sold
thereunder, the undersigned shall be released from all obligations under this Letter Agreement. The undersigned understands that the Underwriters are entering into the Underwriting Agreement and proceeding with the Public Offering in reliance upon
this Letter Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Letter Agreement may be delivered via facsimile, electronic mail (including pdf or any electronic signature
complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all
purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Letter Agreement and any claim, controversy or dispute arising under or related to this
Letter Agreement shall be governed by and construed in accordance with the laws of the State of New York. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name of Security Holder <I>(Print exact name</I>)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">If not signing in an individual capacity:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name of Authorized Signatory <I>(Print</I>)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title of Authorized Signatory <I>(Print</I>)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>(indicate capacity of person signing if signing as custodian, trustee, or on behalf of an entity)</I></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit B </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Waiver of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>J.P. MORGAN SECURITIES LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TD SECURITIES (USA) LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PIPER SANDLER&nbsp;&amp; CO. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WILLIAM BLAIR&nbsp;&amp; COMPANY, L.L.C. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Upstream Bio, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Public
Offering of Common Stock </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">[Date] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Name and
Address of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Officer or Director </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Requesting Waiver] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Mr./Ms.&nbsp;[Name]: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This letter is being
delivered to you in connection with the offering by Upstream Bio, Inc. (the &#147;Company&#148;) of shares of common stock, $0.001 par value per share (the &#147;Common Stock&#148;), of the Company and the
<FONT STYLE="white-space:nowrap">lock-up</FONT> letter dated [&#149;], 2024 (the <FONT STYLE="white-space:nowrap">&#147;Lock-up</FONT> Letter&#148;), executed by you in connection with such offering, and your request for a [waiver] [release] dated
[&#149;], 2024, with respect to [&#149;]&nbsp;shares of Common Stock (the &#147;Shares&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC, TD Securities
(USA) LLC, Piper Sandler&nbsp;&amp; Co. and William Blair&nbsp;&amp; Company, L.L.C. hereby agree to [waive] [release] the transfer restrictions set forth in the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Letter, but only with respect to the
Shares, effective [&#149;], 2024; <U>provided</U>, <U>however</U>, that such [waiver] [release] is conditioned on the Company announcing the impending [waiver] [release] by press release through a major news service at least two business days before
effectiveness of such [waiver] [release]. This letter will serve as notice to the Company of the impending [waiver] [release]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as
expressly [waived] [released] hereby, the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Letter shall remain in full force and effect. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Yours very truly,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">J.P. MORGAN SECURITIES LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">TD SECURITIES (USA) LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">PIPER SANDLER&nbsp;&amp; CO.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">WILLIAM BLAIR&nbsp;&amp; COMPANY, L.L.C.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Signatory</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">cc: Upstream Bio, Inc. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit C </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Press Release </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Upstream Bio,
Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>[Date] </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upstream Bio, Inc. (the
&#147;Company&#148;) announced today that J.P. Morgan Securities LLC, TD Securities (USA) LLC, Piper Sandler&nbsp;&amp; Co. and William Blair&nbsp;&amp; Company, L.L.C., the book-running managers in the Company&#146;s recent public sale of
[&#149;]&nbsp;shares of common stock, is [waiving] [releasing] a <FONT STYLE="white-space:nowrap">lock-up</FONT> restriction with respect to&nbsp;[&#149;]&nbsp;shares of the Company&#146;s common stock held by [certain officers or directors] [an
officer or director] of the Company. The [waiver] [release] will take effect on [&#149;], 2024, and the shares may be sold on or after such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This
press release is not an offer for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from
registration under the United States Securities Act of 1933, as amended. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit D </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Authorization </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In reliance on Section&nbsp;5(d) of the Securities Act of 1933, as amended (the &#147;Act&#148;), Upstream Bio, Inc. (the &#147;Issuer&#148;) hereby
authorizes J.P. Morgan Securities LLC (&#147;J.P. Morgan&#148;), TD Securities (USA) LLC (&#147;TD Cowen&#148;), Piper Sandler&nbsp;&amp; Co. (&#147;Piper&#148;) and William Blair&nbsp;&amp; Company, L.L.C. (&#147;William Blair&#148;), and their
respective affiliates and employees, to engage on behalf of the Issuer in oral and written communications with potential investors that are &#147;qualified institutional buyers&#148;, as defined in Rule 144A under the Act, or institutions that are
&#147;accredited investors&#148;, within the meaning of Rule 501(a)(1), (a)(2), (a)(3), (a)(7), (a)(8), (a)(9), (a)(12) or (a)(13) under the Act, to determine whether such investors might have an interest in the Issuer&#146;s contemplated initial
public offering <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(&#147;Testing-the-Waters</FONT></FONT> Communications&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A
&#147;Written <FONT STYLE="white-space:nowrap">Testing-the</FONT> Waters Communication&#148; means any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is a written communication
within the meaning of Rule 405 under the Act. Each of J.P. Morgan, TD Cowen, Piper and William Blair, individually and not jointly, agrees that it shall not distribute any Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that has not been approved by the Issuer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Issuer represents that it is an &#147;emerging growth company&#148; as defined in Section&nbsp;2(a)(19) of the Act (&#147;Emerging Growth Company&#148;)
and agrees to promptly notify J.P. Morgan, TD Cowen, Piper and William Blair in writing if the Issuer hereafter ceases to be an Emerging Growth Company while this authorization is in effect. If at any time following the distribution of any Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication there occurs an event or development as a result of which such Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to
make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Issuer will promptly notify J.P. Morgan, TD Cowen, Piper and William Blair and will promptly amend or supplement, at its own
expense, such Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication to eliminate or correct such untrue statement or omission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nothing in this authorization is intended to limit or otherwise affect the ability of J.P. Morgan, TD Cowen, Piper and William Blair, and their respective
affiliates and employees, to engage in communications in which they could otherwise lawfully engage in the absence of this authorization, including, without limitation, any written communication containing only one or more of the statements
specified under Rule 134(a) under the Act. This authorization shall remain in effect until the Issuer has provided to J.P. Morgan, TD Cowen, Piper and William Blair a written notice revoking this authorization. All notices as described herein shall
be sent by email to the attention of Pete Castoro at peter.j.castoro@jpmorgan.com, Mariel Healy at mariel.healy@tdsecurities.com, Chad Huber at chad.huber@psc.com and Kevin Eisele at keisele@williamblair.com. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>3
<FILENAME>d843142dex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Execution Version </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SECOND AMENDED AND RESTATED </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATE OF INCORPORATION </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OF
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">UPSTREAM BIO, INC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Pursuant
to Sections 242 and 245 of the </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">General Corporation Law of the State of Delaware) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upstream Bio, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of
Delaware (the &#147;<B>General Corporation Law</B>&#148;), </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>DOES HEREBY CERTIFY: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.</B> That the name of this corporation is Upstream Bio, Inc., and that this corporation was originally incorporated pursuant to the
General Corporation Law on April&nbsp;21, 2021 under the name Upstream Bio, Inc., and an Amended and Restated Certificate of Incorporation was filed on October&nbsp;13, 2021. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.</B> That the Board of Directors duly adopted resolutions proposing to amend and restate the Amended and Restated Certificate of
Incorporation of this corporation, declaring said amendment and restatement to be advisable and in the best interests of this corporation and its stockholders, and authorizing the appropriate officers of this corporation to solicit the consent of
the stockholders therefor, which resolution setting forth the proposed amendment and restatement is as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED, </B>that the
Amended and Restated Certificate of Incorporation of this corporation be amended and restated in its entirety to read as follows (the &#147;<B>Certificate of Incorporation</B>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>FIRST: </B>The name of this corporation is Upstream Bio, Inc. (the &#147;<B>Corporation</B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SECOND: </B>The address of the registered office of the Corporation in the State of Delaware is 1209 Orange Street, in the
City of Wilmington, County of New Castle, Delaware 19801, and its registered agent at such address is: The Corporation Trust Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>THIRD: </B>The nature of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for
which corporations may be organized under the General Corporation Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>FOURTH: </B>The total number of shares of all
classes of stock which the Corporation shall have authority to issue is (i) 40,664,346 shares of Common Stock, $0.001 par value per share (&#147;<B>Common Stock</B>&#148;) and (ii) 31,764,693 shares of Preferred Stock, $0.001 par value per share
(&#147;<B>Preferred Stock</B>&#148;). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a statement of the designations and the powers, privileges and rights, and
the qualifications, limitations or restrictions thereof in respect of each class of capital stock of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. COMMON STOCK
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. <U>General</U>. The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by the
rights, powers and preferences of the holders of the Preferred Stock set forth herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <U>Voting</U>. The holders of the Common Stock
are entitled to one vote for each share of Common Stock held at all meetings of stockholders (and written actions in lieu of meetings); <U>provided</U>, <U>however</U>, that, except as otherwise required by law, holders of Common Stock, as such,
shall not be entitled to vote on any amendment to this Certificate of Incorporation that relates solely to the terms of one (1)&nbsp;or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately
or together with the holders of one (1)&nbsp;or more other such series, to vote thereon pursuant to this Certificate of Incorporation or pursuant to the General Corporation Law. There shall be no cumulative voting. The number of authorized shares of
Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by (in addition to any vote of the holders of one or more series of Preferred Stock that may be required by the terms of this Certificate of
Incorporation) the affirmative vote of the holders of shares of capital stock of the Corporation representing a majority of the votes represented by all outstanding shares of capital stock of the Corporation entitled to vote, irrespective of the
provisions of Section&nbsp;242(b)(2) of the General Corporation Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. PREFERRED STOCK </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11,764,693 shares of the authorized and unissued Preferred Stock of the Corporation are hereby designated &#147;<B>Series B Preferred
Stock</B>&#148;, and 20,000,000 shares of the authorized Preferred Stock of the Corporation are hereby designated &#147;<B>Series A Preferred Stock</B>&#148;, in each case, with the following rights, preferences, powers, privileges and restrictions,
qualifications and limitations. Unless otherwise indicated, references to &#147;sections&#148; or &#147;subsections&#148; in this Part B of this <U>Article Fourth</U> refer to sections and subsections of Part B of this <U>Article Fourth</U>.
References to &#147;<B>Preferred Stock</B>&#148; mean, collectively, the Series B Preferred Stock and the Series A Preferred Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.
<U>Dividends</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From and after the date of the issuance of a share of Preferred Stock, dividends at the rate per annum of five percent
(5%) of the Original Issue Price (as defined below) for such share of Preferred Stock shall accrue on such share of Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar
recapitalization with respect to the Preferred Stock), <U>provided</U> that the total of such accrued return shall not exceed fifteen percent (15%) of the applicable Original Issue Price in the aggregate on such share of Preferred Stock (the
&#147;<B>Accruing Dividends</B>&#148;). Accruing Dividends shall accrue from day to day, whether or not declared, and shall be cumulative; <U>provided</U>, <U>however</U>, that except as set forth in the following sentence of this
<U>Section&nbsp;1</U>, in <U>Section&nbsp;2.1</U> or <U>Section&nbsp;2.2</U>, such Accruing Dividends shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be payable only when, as, and if declared by the Board of Directors and the Corporation shall be under no obligation to pay such Accruing Dividends. The Corporation shall not declare, pay or set
aside any dividends on shares of any other class or series of capital stock of the Corporation (other than dividends on shares of Common Stock payable in shares of Common Stock) unless (in addition to the obtaining of any consents required elsewhere
in this Certificate of Incorporation) the holders of the Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend, paid in accordance with <U>Subsections 2.1</U> and <U>2.2</U>, <I>mutatis mutandis</I>, on each
outstanding share of Preferred Stock in an amount at least equal to the greater of (i)&nbsp;the amount of the aggregate Accruing Dividends then accrued on such share of Preferred Stock and not previously paid and (ii)&nbsp;(A) in the case of a
dividend on Common Stock or any class or series that is convertible into Common Stock, that dividend per share of Preferred Stock as would equal the product of (1)&nbsp;the dividend payable on each share of such class or series determined, if
applicable, as if all shares of such class or series had been converted into Common Stock and (2)&nbsp;the number of shares of Common Stock issuable upon conversion of a share of Preferred Stock, in each case calculated on the record date for
determination of holders entitled to receive such dividend or (B)&nbsp;in the case of a dividend on any class or series that is not convertible into Common Stock, at a rate per share of Preferred Stock determined by (1)&nbsp;dividing the amount of
the dividend payable on each share of such class or series of capital stock by the original issuance price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or
other similar recapitalization with respect to such class or series) and (2)&nbsp;multiplying such fraction by an amount equal to the applicable Original Issue Price (as defined below); provided that if the Corporation declares, pays or sets aside,
on the same date, a dividend on shares of more than one (1)&nbsp;class or series of capital stock of the Corporation, the dividend payable to the holders of Preferred Stock pursuant to this <U>Section&nbsp;1</U> shall be calculated based upon the
dividend on the class or series of capital stock that would result in the highest Preferred Stock dividend. The &#147;<B>Original Issue Price</B>&#148; shall mean, (i)&nbsp;with respect to the Series A Preferred Stock, $10.00 per share, subject to
appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series A Preferred Stock, and (ii)&nbsp;with respect to the Series B Preferred Stock, $17.00 per share, subject
to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series B Preferred Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <U>Liquidation, Dissolution or Winding Up; Certain Mergers, Consolidations and Asset Sales</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.1 <U>Preferential Dividend Payments to Holders of Series B Preferred Stock</U>. In the event of any voluntary or involuntary liquidation,
dissolution or winding up of the Corporation, the holders of shares of Series B Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders, and in the event of a
Deemed Liquidation Event (as defined below), the holders of shares of Series B Preferred Stock then outstanding shall be entitled to be paid out of the consideration payable to stockholders in such Deemed Liquidation Event or out of the Available
Proceeds (as defined below), as applicable, before any payment shall be made to the holders of Series A Preferred Stock and Common Stock by reason of their ownership thereof, an amount per share of Series B Preferred Stock equal to any Accruing
Dividends on the Series B Preferred Stock accrued but unpaid thereon, whether or not declared, together with any other dividends declared but unpaid thereon (the &#147;<B>Series B Dividend Payment</B>&#148;). If upon any such liquidation,
dissolution or winding up of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Corporation or Deemed Liquidation Event, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of shares of Series B Preferred
Stock the full amount to which they shall be entitled under this <U>Section&nbsp;2.1</U>, the holders of shares of Series B Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the
respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to the Series B Dividend Payment on such shares were paid in full. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.2 <U>Preferential Payments to Holders of Preferred Stock</U>. After such payment in full of the Series B Dividend Payment, if any, to the
holders of Series B Preferred Stock as set forth in <U>Section&nbsp;2.1</U>, in the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of shares of Preferred Stock then outstanding shall be
entitled to be paid out of the assets of the Corporation available for distribution to its stockholders, and in the event of a Deemed Liquidation Event (as defined below), the holders of shares of Preferred Stock then outstanding shall be entitled
to be paid out of the consideration payable to stockholders in such Deemed Liquidation Event or out of the Available Proceeds (as defined below), as applicable, before any payment shall be made to the holders of Common Stock by reason of their
ownership thereof, on a pari passu basis, an amount per share equal to (i)&nbsp;with respect to the Series A Preferred Stock, the greater of (a)&nbsp;the Original Issue Price, plus any Accruing Dividends on the Series A Preferred Stock accrued but
unpaid thereon, whether or not declared, together with any other dividends declared but unpaid thereon, or (b)&nbsp;such amount per share as would have been payable had all shares of Series A Preferred Stock been converted into Common Stock pursuant
to <U>Section&nbsp;4</U> immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event; and (ii)&nbsp;with respect to the Series B Preferred Stock, (1)&nbsp;the greater of (a)&nbsp;the Original Issue Price of the Series
B Preferred Stock, plus any Accruing Dividends on the Series B Preferred Stock accrued but unpaid thereon, whether or not declared, together with any other dividends declared but unpaid thereon or (b)&nbsp;such amount per share as would have been
payable had all shares of Preferred Stock been converted into Common Stock pursuant to Section&nbsp;4 immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event, less (2)&nbsp;the Series B Dividend Payment actually
paid pursuant to Section&nbsp;2.1 (the amount payable pursuant to <U>Section&nbsp;2.1</U> and this sentence is hereinafter collectively referred to as the &#147;<B>Liquidation Amount</B>&#148;). If upon any such liquidation, dissolution or winding
up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of shares of Preferred Stock the full amount to which they shall be entitled
under this <U>Section&nbsp;2.2</U>, the holders of shares of Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the
shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.3 <U>Payments to
Holders of Common Stock</U>. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, after the payment in full of all Liquidation Amounts required to be paid to the holders of shares of Preferred
Stock, the remaining assets of the Corporation available for distribution to its stockholders or, in the case of a Deemed Liquidation Event, the consideration not payable to the holders of shares of Preferred Stock pursuant to
<U>Section&nbsp;2.1</U> or <U>Section&nbsp;2.2</U> or the remaining Available Proceeds, as the case may be, shall be distributed among the holders of shares of Common Stock, pro rata based on the number of shares held by each such holder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.4 <U>Deemed Liquidation Events</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.4.1 <U>Definition</U>. Each of the following events shall be considered a &#147;<B>Deemed Liquidation Event</B>&#148; unless the holders of
at least a majority of the outstanding shares of Preferred Stock, voting together as a single class on an as converted to Common Stock basis, which majority must include holders of at least a majority of the outstanding shares of Series B Preferred
Stock, voting together as a single class on an as converted to Common Stock basis (collectively, &#147;<B>Requisite Holders</B>&#148;) elect otherwise by written notice sent to the Corporation at least three days prior to the effective date of any
such event: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) a merger or consolidation in which </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Corporation is a constituent party; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a subsidiary of the Corporation is a constituent party and the Corporation issues shares of its capital stock
pursuant to such merger or consolidation, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">except any such merger or consolidation involving the Corporation or a subsidiary in which
the shares of capital stock of the Corporation outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock that represent, immediately following such merger or
consolidation, at least a majority, by voting power, of the capital stock of (1)&nbsp;the surviving or resulting corporation; or (2)&nbsp;if the surviving or resulting corporation is a wholly owned subsidiary of another corporation immediately
following such merger or consolidation, the parent corporation of such surviving or resulting corporation; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;(1) the sale,
lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Corporation or any subsidiary of the Corporation of all or substantially all the assets of the Corporation and its
subsidiaries taken as a whole, or (2)&nbsp;the sale or disposition (whether by merger, consolidation or otherwise, and whether in a single transaction or a series of related transactions) of one or more subsidiaries of the Corporation if
substantially all of the assets of the Corporation and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary of
the Corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.4.2 <U>Effecting a Deemed Liquidation Event</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) The Corporation shall not have the power to effect a Deemed Liquidation Event referred to in <U>Subsection 2.4.1(a)(i)</U> unless the
agreement or plan of merger or consolidation for such transaction provides that the consideration payable to the stockholders of the Corporation in such Deemed Liquidation Event shall be allocated among the holders of capital stock of the
Corporation in accordance with <U>Subsections 2.1</U>, <U>2.2</U> and <U>2.3</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) In the event of a Deemed Liquidation Event referred to in <U>Subsection
2.4.1(a)(ii)</U> or <U>2.4.1(b)</U>, if the Corporation does not effect a dissolution of the Corporation under the General Corporation Law within 90 days after such Deemed Liquidation Event, then (i)&nbsp;the Corporation shall send a written notice
to each holder of Preferred Stock no later than the 90th day after the Deemed Liquidation Event advising such holders of their right (and the requirements to be met to secure such right) pursuant to the terms of the following clause; (ii)&nbsp;to
require the redemption of such shares of Preferred Stock, and (iii)&nbsp;if the Requisite Holders so request in a written instrument delivered to the Corporation not later than 120 days after such Deemed Liquidation Event, the Corporation shall use
the consideration received by the Corporation for such Deemed Liquidation Event (net of any retained liabilities associated with the assets sold or technology licensed), as determined in good faith by the Qualified Board Majority (as defined in the
Series B Preferred Stock Purchase Agreement entered into by the Corporation on or about the date of the filing of this Certificate of Incorporation (the &#147;<B>Series B Purchase Agreement</B>&#148;)), together with any other assets of the
Corporation available for distribution to its stockholders, all to the extent permitted by Delaware law governing distributions to stockholders (the &#147;<B>Available Proceeds</B>&#148;), on the 150th day after such Deemed Liquidation Event (the
<B>&#147;</B><B>Redemption Date</B>&#148;),<B> </B>to redeem all outstanding shares of Preferred Stock at a price per share equal to the applicable Liquidation Amount (the &#147;<B>Redemption Price</B>&#148;). Notwithstanding the foregoing, in the
event of a redemption pursuant to the preceding sentence, if the Available Proceeds are not sufficient to redeem all outstanding shares of Preferred Stock, the Corporation shall redeem, in accordance with <U>Subsections 2.1</U>, <U>2.2</U> and
<U>2.3</U>, a pro rata portion of each holder&#146;s shares of Preferred Stock to the fullest extent of such Available Proceeds based on the respective amounts which would otherwise be payable in respect of the shares to be redeemed if the Available
Proceeds were sufficient to redeem all such shares, and shall redeem the remaining shares as soon as it may lawfully do so under Delaware law governing distributions to stockholders. On or before the Redemption Date, each holder of shares of
Preferred Stock to be redeemed on such Redemption Date shall surrender the certificate or certificates representing such shares (or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate
affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation,
and thereupon the Redemption Price for such shares shall be payable to the order of the person whose name appears on such certificate or certificates as the owner thereof. In the event less than all of the shares of Preferred Stock represented by a
certificate are redeemed, a new certificate representing the unredeemed shares of Preferred Stock shall promptly be issued to such holder. If on the Redemption Date the Redemption Price payable upon redemption of the shares of Preferred Stock to be
redeemed on such Redemption Date is paid or tendered for payment or deposited with an independent payment agent so as to be available therefor in a timely manner, then notwithstanding that the certificates evidencing any of the shares of Preferred
Stock so called for redemption shall not have been surrendered, dividends with respect to such shares of Preferred Stock shall cease to accrue after the Redemption Date and all rights with respect to such shares shall forthwith after the Redemption
Date terminate, except only the right of the holders to receive the Redemption Price without interest upon surrender of their certificate or certificates therefor. Prior to the distribution or redemption provided for in this Subsection 2.4.2(b), the
Corporation shall not expend or dissipate the consideration received for such Deemed Liquidation Event, except to discharge expenses incurred in connection with such Deemed Liquidation Event or in the ordinary course of business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.4.3 <U>Amount Deemed Paid or Distributed</U>. Subject to <U>Subsection&nbsp;2.4.4</U>,
the amount deemed paid or distributed to the holders of capital stock of the Corporation upon any Deemed Liquidation Event shall be the cash or the value of the property, rights or securities to be paid or distributed to such holders pursuant to
such Deemed Liquidation Event. The value of such property, rights or securities shall be determined in good faith by the Qualified Board Majority. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.4.4 <U>Allocation of Escrow and Contingent Consideration</U>. In the event of a Deemed Liquidation Event, if any portion of the
consideration payable to the Corporation or the stockholders of the Corporation is payable only upon satisfaction of contingencies (the &#147;<B>Additional Consideration</B>&#148;), the definitive agreements related to such Deemed Liquidation Event
shall provide that (a)&nbsp;the portion of such consideration that is not Additional Consideration (such portion, the &#147;<B>Initial Consideration</B>&#148;) shall be allocated among the holders of capital stock of the Corporation in accordance
with <U>Subsections 2.1</U>, <U>2.2</U> and <U>2.3</U> as if the Initial Consideration were the only consideration payable in connection with such Deemed Liquidation Event; and (b)&nbsp;any Additional Consideration which becomes payable to the
Corporation or the stockholders of the Corporation upon satisfaction of such contingencies shall be allocated among the holders of capital stock of the Corporation in accordance with <U>Subsections&nbsp;2.1</U>, <U>2.2</U> and <U>2.3</U> after
taking into account the previous payment of the Initial Consideration as part of the same transaction. For purposes of this <U>Subsection 2.4.4</U>, consideration placed into escrow or retained as a holdback to be available for satisfaction of
indemnification or similar obligations in connection with such Deemed Liquidation Event shall be deemed to be Additional Consideration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.
<U>Voting</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.1 <U>General</U>. On any matter presented to the stockholders of the Corporation for their action or consideration at
any meeting of stockholders of the Corporation (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of
Common Stock into which the shares of Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of this Certificate of
Incorporation, holders of Preferred Stock shall vote together with the holders of Common Stock as a single class and on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.2 <U>Election of Directors</U>. The holders of record of the shares of Common Stock, exclusively and as a separate class, shall be entitled
to elect one director of the Corporation (the &#147;<B>Common Director</B>&#148;), the holders of record of the shares of Series A Preferred Stock, exclusively and as a separate class, shall be entitled to elect four directors of the Corporation
(the &#147;<B>Series A Directors</B>&#148;), and the holders of record of the shares of Series B Preferred Stock, exclusively and as a separate class, shall be entitled to elect two directors of the Corporation (the &#147;<B>Series B
Directors</B>&#148;, and together with the Series A Directors, the &#147;<B>Preferred Directors</B>&#148;). Any director elected as provided in the preceding sentence may be removed without cause by, and only by, the affirmative vote of the holders
of the shares of the class or series of capital stock entitled to elect such director or directors, given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders. If the holders
of shares of Series A Preferred Stock, Series B Preferred Stock or Common Stock, as the case may be, fail to elect a sufficient number of directors to fill all directorships for which they are entitled to elect directors, voting exclusively and as a
separate class, pursuant to the first sentence of this <U>Subsection 3.2</U>, then </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any directorship not so filled shall remain vacant until such time as the holders of the Series A Preferred Stock, Series B Preferred Stock or Common Stock, as the case may be, elect a person to
fill such directorship by vote or written consent in lieu of a meeting; and no such directorship may be filled by stockholders of the Corporation other than by the stockholders of the Corporation that are entitled to elect a person to fill such
directorship, voting exclusively and as a separate class. The holders of record of the shares of Common Stock and of any other class or series of voting stock (including the Preferred Stock), exclusively and voting together as a single class, shall
be entitled to elect the balance of the total number of directors of the Corporation. At any meeting held for the purpose of electing a director, the presence in person or by proxy of the holders of a majority of the outstanding shares of the class
or series entitled to elect such director shall constitute a quorum for the purpose of electing such director. Except as otherwise provided in this <U>Subsection 3.2</U>, a vacancy in any directorship filled by the holders of any class or series
shall be filled only by vote or written consent in lieu of a meeting of the holders of such class or series or by any remaining director or directors elected by the holders of such class or series pursuant to this <U>Subsection 3.2</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.3 <U>Preferred Stock Protective Provisions</U>. At any time when shares of Preferred Stock are outstanding, the Corporation shall not,
either directly or indirectly by amendment, merger, conversion, consolidation, recapitalization, reclassification, or otherwise, do any of the following without (in addition to any other vote required by law or this Certificate of Incorporation) the
written consent or affirmative vote of the Requisite Holders given in writing or by vote at a meeting, consenting or voting (as the case may be) separately as a class, and any such act or transaction entered into without such consent or vote shall
be null and void <I>ab initio,</I> and of no force or effect: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.1 liquidate, dissolve or
<FONT STYLE="white-space:nowrap">wind-up</FONT> the business and affairs of the Corporation, effect any merger, conversion or consolidation (whether or not the Corporation or a subsidiary thereof is the surviving corporation) or any Deemed
Liquidation Event, or consent to any of the foregoing, provided that if such transaction (i)&nbsp;is effected pursuant to a definitive agreement executed no later than the Reference Date (as defined in the Series B Purchase Agreement) and
(ii)&nbsp;would result in upfront gross proceeds payable to each share of Series B Preferred Stock greater than or equal to $34.00 per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other
similar recapitalization affecting such shares and after taking into account any <FONT STYLE="white-space:nowrap">re-allocation</FONT> of proceeds from holders of Series A Preferred Stock or Common Stock to holders of Series B Preferred Stock in
connection with the applicable transaction), then &#147;Requisite Holders&#148; for purposes of this <U>Subsection 3.3.1</U> shall mean the holders of at least a majority of the outstanding shares of Preferred Stock, voting together as a single
class on an as converted to Common Stock basis; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.2 amend, alter or repeal any provision of this Certificate of Incorporation or Bylaws
of the Corporation; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.3 create, or authorize the creation of, or issue or obligate itself to issue shares of (by recapitalization,
reclassification or otherwise), any additional class or series of capital stock of the Corporation, or any other security convertible or exercisable for capital stock of the Corporation (except for Exempted Securities (as defined below)) unless the
same ranks junior to Preferred Stock with respect to its rights, preferences and privileges, or increase or decrease the authorized number of shares of Preferred Stock, Common Stock or any additional class or series of capital stock of the
Corporation; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.4 create, or authorize the creation of, or issue or obligate itself to issue shares of
(by recapitalization, reclassification or otherwise), any additional class or series of capital stock of the Corporation, or any other security convertible or exercisable for capital stock of the Corporation prior to the Call Option Closing (as
defined in the Series B Purchase Agreement); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.5 cause or permit any of its subsidiaries to, without approval of the Qualified Board
Majority, sell, issue, sponsor, create or distribute any digital tokens, cryptocurrency or other blockchain-based assets (collectively, &#147;<B>Tokens</B>&#148;), including through a <FONT STYLE="white-space:nowrap">pre-sale,</FONT> initial coin
offering, token distribution event or crowdfunding, or through the issuance of any instrument convertible into or exchangeable for Tokens; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.6 (i) reclassify, alter or amend any existing security of the Corporation that is pari passu with the Preferred Stock in respect of the
distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption, if such reclassification, alteration or amendment would render such other security senior to the Preferred
Stock in respect of any such right, preference, or privilege or (ii)&nbsp;reclassify, alter or amend any existing security of the Corporation that is junior to the Preferred Stock in respect of the distribution of assets on the liquidation,
dissolution or winding up of the Corporation, the payment of dividends or rights of redemption, if such reclassification, alteration or amendment would render such other security senior to or pari passu with the Preferred Stock in respect of any
such right, preference or privilege; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.7 purchase or redeem (or permit any subsidiary to purchase or redeem) or pay or declare any
dividend or make any distribution on, any shares of capital stock of the Corporation other than (i)&nbsp;redemptions of or dividends or distributions on the Preferred Stock as expressly authorized herein, (ii)&nbsp;dividends or other distributions
payable on the Common Stock solely in the form of additional shares of Common Stock or (iii)&nbsp;repurchases of stock from former employees, officers, directors, consultants or other persons who performed services for the Corporation or any
subsidiary in connection with the cessation of such employment or service at the lower of the original purchase price or the then-current fair market value thereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.8 create, or authorize the creation of, or issue, or authorize the issuance of any debt security or create any lien or security interest
(except for purchase money liens or statutory liens of landlords, mechanics, materialmen, workmen, warehousemen and other similar persons arising or incurred in the ordinary course of business) or incur other indebtedness for borrowed money,
including but not limited to obligations and contingent obligations under guarantees, or permit any subsidiary to take any such action with respect to any debt security lien, security interest or other indebtedness for borrowed money, if the
aggregate indebtedness of the Corporation and its subsidiaries for borrowed money following such action would exceed $1,000,000; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.9 create, or hold capital stock in, any subsidiary that is not wholly owned (either
directly or through one or more other subsidiaries) by the Corporation, or permit any subsidiary to create, or authorize the creation of, or issue or obligate itself to issue, any shares of any class or series of capital stock, or sell, transfer or
otherwise dispose of any capital stock of any direct or indirect subsidiary of the Corporation, or permit any direct or indirect subsidiary to sell, lease, transfer, exclusively license or otherwise dispose (in a single transaction or series of
related transactions) of all or substantially all of the assets of such subsidiary; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.10 change the principal business of the
Corporation, enter new lines of business or exit the current line of business; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.11 increase or decrease the authorized number of
directors constituting the Board of Directors; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.12 sell, assign, license, pledge or encumber (or permit any direct or indirect
subsidiary of the Corporation to sell, assign, license, pledge or encumber) material technology or intellectual property, other than <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses granted in the ordinary course of business; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.13 enter into (or permit any direct or indirect subsidiary of the Corporation to enter into) a corporate strategic relationship involving
the payment, contribution or assignment by the Corporation (or any subsidiary) or to the Corporation (or any subsidiary) of, or otherwise involve any, assets or commitments with an aggregate value in excess of $4,000,000, other than vendor
transactions included in a budget that is approved by the Qualified Board Majority; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.14 enter into or be a party to any transaction
with any stockholder, director, officer or employee of the Corporation or any &#147;associate&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> promulgated under the Exchange Act) of any such person, except for
(a)&nbsp;transactions contemplated by the License Agreement, dated as of October&nbsp;14, 2021, between the Corporation and Maruho Co., Ltd., a Japanese corporation (the &#147;<B>License Agreement</B>&#148;), as such License Agreement is in effect
on the date of the filing of this Certificate of Incorporation or (b)&nbsp;transactions made in the ordinary course of business and pursuant to reasonable requirements of the Corporation&#146;s business and upon fair and reasonable terms that are
approved by the Qualified Board Majority; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.15 consummate an underwritten public offering of the Common Stock under the Securities
Act of 1933, as amended, that is not a Qualified Public Offering. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4. <U>Optional Conversion</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the Preferred Stock shall have conversion rights as follows (the &#147;<B>Conversion Rights</B>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.1 <U>Right to Convert</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.1.1 <U>Conversion Ratio</U>. Each share of Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from
time to time, and without the payment of additional consideration by the holder thereof, into such number of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock as is determined by dividing the applicable
Original Issue </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Price by the applicable Conversion Price (as defined below) in effect at the time of conversion. The &#147;<B>Conversion Price</B>&#148; shall, with respect to any series of Preferred Stock,
initially be equal to the applicable Original Issue Price for such series of Preferred Stock. Such initial applicable Conversion Price, and the rate at which shares of Preferred Stock may be converted into shares of Common Stock, shall be subject to
adjustment as provided below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.1.2 <U>Termination of Conversion Rights</U>. In the event of a liquidation, dissolution or winding up of
the Corporation or a Deemed Liquidation Event, the Conversion Rights shall terminate at the close of business on the last full day preceding the date fixed for the final payment of any such amounts distributable on such event to the holders of
Preferred Stock; provided that the foregoing termination of Conversion Rights shall not affect the amount(s) otherwise paid or payable in accordance with <U>Section&nbsp;2.1</U> or <U>Section&nbsp;2.2</U> to holders of Preferred Stock pursuant to
such liquidation, dissolution or winding up of the Corporation or a Deemed Liquidation Event. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.2 <U>Fractional Shares</U>. No fractional
shares of Common Stock shall be issued upon conversion of the Preferred Stock. In lieu of any fractional shares to which the holder would otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the fair market
value of a share of Common Stock as determined in good faith by the Board of Directors. Whether or not fractional shares would be issuable upon such conversion shall be determined on the basis of the total number of shares of Preferred Stock the
holder is at the time converting into Common Stock and the aggregate number of shares of Common Stock issuable upon such conversion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.3
<U>Mechanics of Conversion</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.1 <U>Notice of Conversion</U>. In order for a holder of Preferred Stock to voluntarily convert shares
of Preferred Stock into shares of Common Stock, such holder shall (a)&nbsp;provide written notice to the Corporation&#146;s transfer agent at the office of the transfer agent for the Preferred Stock (or at the principal office of the Corporation if
the Corporation serves as its own transfer agent) that such holder elects to convert all or any number of such holder&#146;s shares of Preferred Stock and, if applicable, any event on which such conversion is contingent and (b), if such
holder&#146;s shares are certificated, surrender the certificate or certificates for such shares of Preferred Stock (or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and
agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate), at the office of the transfer agent
for the Preferred Stock (or at the principal office of the Corporation if the Corporation serves as its own transfer agent). Such notice shall state such holder&#146;s name or the names of the nominees in which such holder wishes the shares of
Common Stock to be issued. If required by the Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by a written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the
registered holder or his, her or its attorney duly authorized in writing. The close of business on the date that is 120 days after the date of receipt by the transfer agent (or by the Corporation if the Corporation serves as its own transfer agent)
of such notice and, if applicable, certificates (or lost certificate affidavit and agreement) shall be the time of conversion (the &#147;<B>Conversion Time</B>&#148;), and the shares of Common Stock issuable upon conversion of the specified shares
shall be deemed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to be outstanding of record as of such date. The Corporation shall, as soon as practicable after the Conversion Time (i)&nbsp;issue and deliver to such holder of Preferred Stock, or to his, her
or its nominees, a certificate or certificates for the number of full shares of Common Stock issuable upon such conversion in accordance with the provisions hereof and a certificate for the number (if any) of the shares of Preferred Stock
represented by the surrendered certificate that were not converted into Common Stock, (ii)&nbsp;pay in cash such amount as provided in <U>Subsection 4.2</U> in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion
and (iii)&nbsp;in accordance with <U>Subsections 2.1</U> and <U>2.2</U>, <I>mutatis mutandis</I>, pay all declared but unpaid dividends on the shares of Preferred Stock converted. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.2 <U>Reservation of Shares</U>. The Corporation shall at all times when the Preferred Stock is outstanding, reserve and keep available out
of its authorized but unissued capital stock, for the purpose of effecting the conversion of the Preferred Stock, such number of its duly authorized shares of Common Stock as shall from time to time be sufficient to effect the conversion of all
outstanding Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding shares of the Preferred Stock, the Corporation shall take such
corporate action as may be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes, including, without limitation, engaging in best efforts to obtain the requisite
stockholder approval of any necessary amendment to this Certificate of Incorporation. Before taking any action which would cause an adjustment reducing the applicable Conversion Price below the then par value of the shares of Common Stock issuable
upon conversion of the Preferred Stock, the Corporation will take any corporate action which may, in the opinion of its counsel, be necessary in order that the Corporation may validly and legally issue fully paid and
<FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock at such adjusted applicable Conversion Price. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.3
<U>Effect of Conversion</U>. All shares of Preferred Stock which shall have been surrendered for conversion as herein provided shall no longer be deemed to be outstanding and all rights with respect to such shares shall immediately cease and
terminate at the Conversion Time, except only the right of the holders thereof to receive shares of Common Stock in exchange therefor, to receive payment in lieu of any fraction of a share otherwise issuable upon such conversion as provided in
<U>Subsection 4.2</U> and to receive payment of any dividends declared but unpaid thereon. Any shares of Preferred Stock so converted shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter
take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock accordingly. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.4 <U>No Further Adjustment</U>. Upon any such conversion, no adjustment to the Conversion Price shall be made for any declared but unpaid
dividends on the Preferred Stock surrendered for conversion or on the Common Stock delivered upon conversion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.5 <U>Taxes</U>. The
Corporation shall pay any and all issue and other similar taxes that may be payable in respect of any issuance or delivery of shares of Common Stock upon conversion of shares of Preferred Stock pursuant to this <U>Section&nbsp;4</U>. The Corporation
shall not, however, be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of shares of Common Stock in a name other than that in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which the shares of Preferred Stock so converted were registered, and no such issuance or delivery shall be made unless and until the person or entity requesting such issuance has paid to the
Corporation the amount of any such tax or has established, to the satisfaction of the Corporation, that such tax has been paid. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.4
<U>Adjustments to Applicable Conversion Price for Diluting Issues</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.1 <U>Special Definitions</U>. For purposes of this Article
Fourth, the following definitions shall apply: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B>Additional Shares of Common Stock</B>&#148;<B> </B>shall mean all shares of
Common Stock issued (or, pursuant to <U>Subsection 4.4.3</U> below, deemed to be issued) by the Corporation after the Original Issue Date, other than (1)&nbsp;the following shares of Common Stock and (2)&nbsp;shares of Common Stock deemed issued
pursuant to the following Options and Convertible Securities <U>(clauses (1)</U>&nbsp;and <U>(2)</U>, collectively, &#147;<B>Exempted Securities</B>&#148;): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as to any series of Preferred Stock, shares of Common Stock, Options or Convertible Securities issued as a
dividend or distribution on such series of Preferred Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued by reason of a dividend, stock split, <FONT
STYLE="white-space:nowrap">split-up,</FONT> or subdivision, in each case, approved by the Qualified Board Majority, or other distribution on shares of Common Stock that is covered by <U>Subsection 4.5</U>, <U>4.6</U>, <U>4.7</U> or <U>4.8</U>;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or shares of Common Stock or Convertible Securities issued upon exercise of
Options actually issued to employees or directors of, or consultants or advisors to, the Corporation or any of its subsidiaries pursuant to a plan, agreement or arrangement that is either in effect on the Original Issue Date or approved by the
Qualified Board Majority; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Series B Preferred Stock sold pursuant to the Series B Purchase Agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B>Convertible Securities</B>&#148; shall mean any evidences of indebtedness, shares or other securities directly or indirectly
convertible into or exchangeable for Common Stock, but excluding Options. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Option</B>&#148; shall mean rights, options or
warrants to subscribe for, purchase or otherwise acquire Common Stock or Convertible Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Original Issue Date</B>&#148; shall mean the date on which the first share of
Series B Preferred Stock was issued. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.2 <U>No Adjustment of Conversion Price</U>. No adjustment in the Conversion Price shall be made
as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the Requisite Holders agreeing that no such adjustment shall be made as the result of the issuance or deemed
issuance of such Additional Shares of Common Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.3 <U>Deemed Issue of Additional Shares of Common Stock</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) If the Corporation at any time or from time to time after the Original Issue Date shall issue any Options or Convertible Securities
(excluding Options or Convertible Securities which are themselves Exempted Securities) or shall fix a record date for the determination of holders of any class of securities entitled to receive any such Options or Convertible Securities, then the
maximum number of shares of Common Stock (as set forth in the instrument relating thereto, assuming the satisfaction of any conditions to exercisability, convertibility or exchangeability but without regard to any provision contained therein for a
subsequent adjustment of such number) issuable upon the exercise of such Options or, in the case of Convertible Securities and Options therefor, the conversion or exchange of such Convertible Securities, shall be deemed to be Additional Shares of
Common Stock issued as of the time of such issue or, in case such a record date shall have been fixed, as of the close of business on such record date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) If the terms of any Option or Convertible Security, the issuance of which resulted in an adjustment to the applicable Conversion Price
pursuant to the terms of <U>Subsection 4.4.4</U>, are revised as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms
pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1)&nbsp;any increase or decrease in the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any
such Option or Convertible Security or (2)&nbsp;any increase or decrease in the consideration payable to the Corporation upon such exercise, conversion and/or exchange, then, effective upon such increase or decrease becoming effective, the
applicable Conversion Price computed upon the original issue of such Option or Convertible Security (or upon the occurrence of a record date with respect thereto) shall be readjusted to such applicable Conversion Price as would have obtained had
such revised terms been in effect upon the original date of issuance of such Option or Convertible Security. Notwithstanding the foregoing, no readjustment pursuant to this <U>clause (b)</U>&nbsp;shall have the effect of increasing the applicable
Conversion Price to an amount which exceeds the lower of (i)&nbsp;the applicable Conversion Price in effect immediately prior to the original adjustment made as a result of the issuance of such Option or Convertible Security, or (ii)&nbsp;the
applicable Conversion Price that would have resulted from any issuances of Additional Shares of Common Stock (other than deemed issuances of Additional Shares of Common Stock as a result of the issuance of such Option or Convertible Security)
between the original adjustment date and such readjustment date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) If the terms of any Option or Convertible Security (excluding Options or Convertible
Securities which are themselves Exempted Securities), the issuance of which did not result in an adjustment to the applicable Conversion Price pursuant to the terms of <U>Subsection 4.4.4</U> (either because the consideration per share (determined
pursuant to <U>Subsection 4.4.5</U>) of the Additional Shares of Common Stock subject thereto was equal to or greater than the applicable Conversion Price then in effect, or because such Option or Convertible Security was issued before the Original
Issue Date), are revised after the Original Issue Date as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant to
anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1)&nbsp;any increase in the number of shares of Common Stock issuable upon the exercise, conversion or exchange of any such Option or Convertible
Security or (2)&nbsp;any decrease in the consideration payable to the Corporation upon such exercise, conversion or exchange, then such Option or Convertible Security, as so amended or adjusted, and the Additional Shares of Common Stock subject
thereto (determined in the manner provided in <U>Subsection 4.4.3(a))</U> shall be deemed to have been issued effective upon such increase or decrease becoming effective. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) Upon the expiration or termination of any unexercised Option or unconverted or unexchanged Convertible Security (or portion thereof) which
resulted (either upon its original issuance or upon a revision of its terms) in an adjustment to the applicable Conversion Price pursuant to the terms of <U>Subsection 4.4.4</U>, the applicable Conversion Price shall be readjusted to such applicable
Conversion Price as would have obtained had such Option or Convertible Security (or portion thereof) never been issued. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e) If the number
of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, is calculable at the time such
Option or Convertible Security is issued or amended but is subject to adjustment based upon subsequent events, any adjustment to the applicable Conversion Price provided for in this <U>Subsection 4.4.3</U> shall be effected at the time of such
issuance or amendment based on such number of shares or amount of consideration without regard to any provisions for subsequent adjustments (and any subsequent adjustments shall be treated as provided in <U>clauses (b)</U>&nbsp;and <U>(c)</U> of
this <U>Subsection 4.4.3</U>). If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion
and/or exchange, cannot be calculated at all at the time such Option or Convertible Security is issued or amended, any adjustment to the applicable Conversion Price that would result under the terms of this <U>Subsection 4.4.3</U> at the time of
such issuance or amendment shall instead be effected at the time such number of shares and/or amount of consideration is first calculable (even if subject to subsequent adjustments), assuming for purposes of calculating such adjustment to the
applicable Conversion Price that such issuance or amendment took place at the time such calculation can first be made. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.4
<U>Adjustment of Applicable Conversion Price Upon Issuance of Additional Shares of Common Stock</U>. In the event the Corporation shall at any time after the Original Issue Date issue Additional Shares of Common Stock (including Additional Shares of
Common Stock deemed to be issued pursuant to <U>Subsection 4.4.3</U>), without consideration or for a consideration per share less than the applicable Conversion Price in effect immediately prior to such issuance or deemed issuance, then the
applicable Conversion Price shall be reduced, concurrently with such issue, to a price (calculated to the nearest <FONT STYLE="white-space:nowrap">one-hundredth</FONT> of a cent) determined in accordance with the following formula: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CP<SUB STYLE="font-size:75%; vertical-align:bottom">2</SUB> = (CP<SUB STYLE="font-size:75%; vertical-align:bottom">1</SUB>* (A + B)) &divide;
(A + C). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the foregoing formula, the following definitions shall apply: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) &#147;CP2&#148; shall mean the applicable Conversion Price in effect immediately after such issuance or deemed issuance of Additional
Shares of Common Stock </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) &#147;CP1&#148; shall mean the applicable Conversion Price in effect immediately prior to such issuance or
deemed issuance of Additional Shares of Common Stock; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) &#147;A&#148; shall mean the number of shares of Common Stock outstanding
immediately prior to such issuance or deemed issuance of Additional Shares of Common Stock (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of Options outstanding immediately prior to such issuance or
deemed issuance or upon conversion or exchange of Convertible Securities (including the Preferred Stock) outstanding (assuming exercise of any outstanding Options therefor) immediately prior to such issue); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) &#147;B&#148; shall mean the number of shares of Common Stock that would have been issued if such Additional Shares of Common Stock had
been issued or deemed issued at a price per share equal to CP1 (determined by dividing the aggregate consideration received by the Corporation in respect of such issue by CP1); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e) &#147;C&#148; shall mean the number of such Additional Shares of Common Stock issued in such transaction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.5 <U>Determination of Consideration</U>. For purposes of this <U>Subsection 4.4</U>, the consideration received by the Corporation for the
issuance or deemed issuance of any Additional Shares of Common Stock shall be computed as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) <U>Cash and Property</U>: Such
consideration shall: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">insofar as it consists of cash, be computed at the aggregate amount of cash received by the Corporation,
excluding amounts paid or payable for accrued interest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">insofar as it consists of property other than cash, be computed at the fair market value thereof at the time of
such issue, as determined in good faith by the Board of Directors of the Corporation; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event Additional Shares of Common Stock are issued together with other shares or securities or other
assets of the Corporation for consideration which covers both, be the proportion of such consideration so received, computed as provided in <U>clauses (i)</U>&nbsp;and (ii) above, as determined in good faith by the Board of Directors of the
Corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) <U>Options and Convertible Securities</U>. The consideration per share received by the Corporation for
Additional Shares of Common Stock deemed to have been issued pursuant to <U>Subsection 4.4.3</U>, relating to Options and Convertible Securities, shall be determined by dividing: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The total amount, if any, received or receivable by the Corporation as consideration for the issue of such
Options or Convertible Securities, plus the minimum aggregate amount of additional consideration (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of such consideration)
payable to the Corporation upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options for Convertible Securities and the
conversion or exchange of such Convertible Securities, by </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the maximum number of shares of Common Stock (as set forth in the instruments relating thereto, without regard
to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the
exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.6 <U>Multiple Closing Dates</U>. In the event the Corporation shall issue on more than one date Additional Shares of Common Stock that are
a part of one transaction or a series of related transactions and that would result in an adjustment to the applicable Conversion Price pursuant to the terms of <U>Subsection 4.4.4</U>, and such issuance dates occur within a period of no more than
90 days from the first such issuance to the final such issuance, then, upon the final such issuance, the applicable Conversion Price shall be readjusted to give effect to all such issuances as if they occurred on the date of the first such issuance
(and without giving effect to any additional adjustments as a result of any such subsequent issuances within such period). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.5 <U>Adjustment for Stock Splits and Combinations</U>. If the Corporation shall at any
time or from time to time after the Original Issue Date effect a subdivision of the outstanding Common Stock, the applicable Conversion Price in effect immediately before that subdivision shall be proportionately decreased so that the number of
shares of Common Stock issuable on conversion of each share of such series shall be increased in proportion to such increase in the aggregate number of shares of Common Stock outstanding. If the Corporation shall at any time or from time to time
after the Original Issue Date combine the outstanding shares of Common Stock, the applicable Conversion Price in effect immediately before the combination shall be proportionately increased so that the number of shares of Common Stock issuable on
conversion of each share of such series shall be decreased in proportion to such decrease in the aggregate number of shares of Common Stock outstanding. Any adjustment under this subsection shall become effective at the close of business on the date
the subdivision or combination becomes effective. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.6 <U>Adjustment for Certain Dividends and Distributions</U>. In the event the
Corporation at any time or from time to time after the Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable on the Common Stock
in additional shares of Common Stock, then and in each such event the applicable Conversion Price in effect immediately before such event shall be decreased as of the time of such issuance or, in the event such a record date shall have been fixed,
as of the close of business on such record date, by multiplying the applicable Conversion Price then in effect by a fraction: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(1) the
numerator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(2) the denominator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such
issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such dividend or distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing (a)&nbsp;if such record date shall have been fixed and such dividend is not fully paid or if such distribution
is not fully made on the date fixed therefor, the applicable Conversion Price shall be recomputed accordingly as of the close of business on such record date and thereafter the applicable Conversion Price shall be adjusted pursuant to this
subsection as of the time of actual payment of such dividends or distributions; and (b)&nbsp;that no such adjustment shall be made if the holders of Preferred Stock simultaneously receive a dividend or other distribution of shares of Common Stock in
a number equal to the number of shares of Common Stock as they would have received if all outstanding shares of Preferred Stock had been converted into Common Stock on the date of such event. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.7 <U>Adjustments for Other Dividends and Distributions</U>. In the event the Corporation
at any time or from time to time after the Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in securities of the Corporation
(other than a distribution of shares of Common Stock in respect of outstanding shares of Common Stock) or in other property and the provisions of <U>Section&nbsp;1</U> do not apply to such dividend or distribution, then and in each such event the
holders of Preferred Stock shall receive, simultaneously with the distribution to the holders of Common Stock, a dividend or other distribution of such securities or other property in an amount equal to the amount of such securities or other
property as they would have received if all outstanding shares of Preferred Stock had been converted into Common Stock on the date of such event. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.8 <U>Adjustment for Merger or Reorganization, etc</U>. Subject to the provisions of <U>Subsection 2.3</U>, if there shall occur any
reorganization, recapitalization, reclassification, consolidation or merger involving the Corporation in which the Common Stock (but not the Preferred Stock) is converted into or exchanged for securities, cash or other property (other than a
transaction covered by <U>Subsections 4.4</U>, <U>4.6</U> or <U>4.7</U>), then, following any such reorganization, recapitalization, reclassification, consolidation or merger, each share of Preferred Stock shall thereafter be convertible in lieu of
the Common Stock into which it was convertible prior to such event into the kind and amount of securities, cash or other property which a holder of the number of shares of Common Stock of the Corporation issuable upon conversion of one share of
Preferred Stock immediately prior to such reorganization, recapitalization, reclassification, consolidation or merger would have been entitled to receive pursuant to such transaction; and, in such case, appropriate adjustment (as determined in good
faith by the Qualified Board Majority) shall be made in the application of the provisions in this <U>Section&nbsp;4</U> with respect to the rights and interests thereafter of the holders of the Preferred Stock, to the end that the provisions set
forth in this <U>Section&nbsp;4</U> (including provisions with respect to changes in and other adjustments of the applicable Conversion Price) shall thereafter be applicable, as nearly as reasonably may be, in relation to any securities or other
property thereafter deliverable upon the conversion of the Preferred Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.9 <U>Certificate as to Adjustments</U>. Upon the occurrence
of each adjustment or readjustment of the applicable Conversion Price pursuant to this <U>Section&nbsp;4</U>, the Corporation at its expense shall, as promptly as reasonably practicable but in any event not later than 10 days thereafter, compute
such adjustment or readjustment in accordance with the terms hereof and furnish to each holder of Preferred Stock a certificate setting forth such adjustment or readjustment (including the kind and amount of securities, cash or other property into
which the Preferred Stock is convertible) and showing in detail the facts upon which such adjustment or readjustment is based. The Corporation shall, as promptly as reasonably practicable after the written request at any time of any holder of
Preferred Stock (but in any event not later than 10 days thereafter), furnish or cause to be furnished to such holder a certificate setting forth (i)&nbsp;the applicable Conversion Price then in effect, and (ii)&nbsp;the number of shares of Common
Stock and the amount, if any, of other securities, cash or property which then would be received upon the conversion of Preferred Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.10 <U>Notice of Record Date. In the event</U>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(a) the Corporation shall take a record of the holders of its Common Stock (or other capital stock or securities at the time issuable upon
conversion of the Preferred Stock) for the purpose of entitling or enabling them to receive any dividend or other distribution, or to receive any right to subscribe for or purchase any shares of capital stock of any class or any other securities, or
to receive any other security; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(b) of any capital reorganization of the Corporation, any reclassification of the Common Stock of the
Corporation, or any Deemed Liquidation Event; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(c) of the voluntary or involuntary dissolution, liquidation or <FONT
STYLE="white-space:nowrap">winding-up</FONT> of the Corporation, then, and in each such case, the Corporation will send or cause to be sent to the holders of the Preferred Stock a notice specifying, as the case may be, (i)&nbsp;the record date for
such dividend, distribution or right, and the amount and character of such dividend, distribution or right, or (ii)&nbsp;the effective date on which such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or <FONT
STYLE="white-space:nowrap">winding-up</FONT> is proposed to take place, and the time, if any is to be fixed, as of which the holders of record of Common Stock (or such other capital stock or securities at the time issuable upon the conversion of the
Preferred Stock) shall be entitled to exchange their shares of Common Stock (or such other capital stock or securities) for securities or other property deliverable upon such reorganization, reclassification, consolidation, merger, transfer,
dissolution, liquidation or <FONT STYLE="white-space:nowrap">winding-up,</FONT> and the amount per share and character of such exchange applicable to the Preferred Stock and the Common Stock. Such notice shall be sent at least 10 days prior to the
record date or effective date for the event specified in such notice. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5. <U>Mandatory Conversion</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.1 <U>Trigger Events</U>. Upon either (a)&nbsp;the closing of the sale of shares of Common Stock to the public at a price of at least $22.10
per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Common Stock), in a firm-commitment underwritten public offering pursuant to an effective
registration statement under the Securities Act of 1933, as amended, resulting in at least $100&nbsp;million of gross proceeds to the Corporation and in connection with such offering the Common Stock is listed for trading on the Nasdaq Global
Market, the Nasdaq Global Select Market or the New York Stock Exchange or another exchange or marketplace approved by the Qualified Board Majority (a &#147;<B>Qualified Public Offering</B>&#148;), or (b)&nbsp;the date and time, or the occurrence of
an event, specified by vote or written consent of the Requisite Holders (the time of such closing or the date and time specified or the time of the event specified in such vote or written consent is referred to herein as the &#147;<B>Mandatory
Conversion Time</B>&#148;), then (i)&nbsp;all outstanding shares of Preferred Stock shall automatically be converted into shares of Common Stock, at the then effective conversion rate as calculated pursuant to <U>Subsection 4.1.1</U> and
(ii)&nbsp;such shares may not be reissued by the Corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.2 <U>Procedural Requirements</U>. All holders of record of shares of
Preferred Stock shall be sent written notice of the Mandatory Conversion Time and the place designated for mandatory conversion of all such shares of Preferred Stock pursuant to this <U>Section&nbsp;5</U>. Such notice need not be sent in advance of
the occurrence of the Mandatory Conversion Time. Upon receipt of such notice, each holder of shares of Preferred Stock in certificated form shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
surrender his, her or its certificate or certificates for all such shares (or, if such holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and
agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation at the place
designated in such notice. If so required by the Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by
the registered holder or by his, her or its attorney duly authorized in writing. All rights with respect to the Preferred Stock converted pursuant to <U>Subsection&nbsp;5.1</U>, including the rights, if any, to receive notices and vote (other than
as a holder of Common Stock), will terminate at the Mandatory Conversion Time (notwithstanding the failure of the holder or holders thereof to surrender any certificates at or prior to such time), except only the rights of the holders thereof, upon
surrender of any certificate or certificates of such holders (or lost certificate affidavit and agreement) therefor, to receive the items provided for in the next sentence of this <U>Subsection 5.2</U>. As soon as practicable after the Mandatory
Conversion Time and, if applicable, the surrender of any certificate or certificates (or lost certificate affidavit and agreement) for Preferred Stock, the Corporation shall (a)&nbsp;issue and deliver to such holder, or to his, her or its nominees,
a certificate or certificates for the number of full shares of Common Stock issuable on such conversion in accordance with the provisions hereof and (b)&nbsp;pay cash as provided in <U>Subsection 4.2</U> in lieu of any fraction of a share of Common
Stock otherwise issuable upon such conversion and the payment of any declared but unpaid dividends on the shares of Preferred Stock converted. Such converted Preferred Stock shall be retired and cancelled and may not be reissued as shares of such
series, and the Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock accordingly. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5A. <U>Special Mandatory Conversion</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5A.1. <U>Trigger Event</U>. In the event any holder of Series B Preferred Stock becomes a Defaulting Purchaser (as defined in the Series B
Purchase Agreement) pursuant to the terms of the Series B Purchase Agreement, then, solely with respect to the Pro Rata Portion (as defined in the Series B Purchase Agreement) of such holder&#146;s Call Option Shares (as defined in the Series B
Purchase Agreement) that such holder did not purchase at the Call Option Closing (as defined in the Series B Purchase Agreement), each ten shares of Series B Preferred Stock then held immediately prior to such Default Event (as defined in the Series
B Purchase Agreement) by such holder and any assignee or transferee of the shares of Series B Preferred Stock of such holder shall automatically, and without any further action on the part of such holder, be converted into one share of Common Stock,
effective on the calendar day immediately following the date on which such holder became a Defaulting Purchaser. For purposes of determining the number of shares of Series B Preferred Stock held by a holder, all shares of Series B Preferred Stock
held by Affiliates (as defined below) of such holder shall be aggregated with the shares of Series B Preferred Stock held by such holder (provided that no shares shall be attributed to more than one entity or person within any such group of
affiliated entities or persons). Such conversion is referred to as a &#147;<B>Special Mandatory Conversion</B>.&#148; If any holder of Series B Preferred Stock or transferee or assignee thereof that is subject to a Special Mandatory Conversion
converted any shares of Series B Preferred Stock into shares of Common Stock within one hundred and twenty (120)&nbsp;days prior to the Call Option Closing (as defined in the Series B Purchase Agreement), then such shares of Series B Preferred Stock
that were so converted shall be deemed to have been converted pursuant to a Special Mandatory Conversion (and 90% of the number of shares of Common Stock issued upon conversion of such shares of Series B Preferred Stock shall be forfeited by such
holder and its transferees and assignees and cancelled immediately). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5A.2. <U>Procedural Requirements</U>. Upon a Special Mandatory Conversion, each holder of
shares of Series B Preferred Stock converted pursuant to <U>Subsection 5A.1</U> shall be sent written notice of such Special Mandatory Conversion and the place designated for mandatory conversion of all such shares of Series B Preferred Stock
pursuant to this <U>Section&nbsp;5A</U>. Upon receipt of such notice, each holder of such shares of Series B Preferred Stock in certificated form shall surrender his, her or its certificate or certificates for all such shares (or, if such holder
alleges that any such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on
account of the alleged loss, theft or destruction of such certificate) to the Corporation at the place designated in such notice. If so required by the Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by
written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or by his, her or its attorney duly authorized in writing. All rights with respect to the Series B Preferred Stock
converted pursuant to <U>Subsection 5A.1</U>, including the rights, if any, to receive notices and vote (other than as a holder of Common Stock), will terminate at the time of the Special Mandatory Conversion (notwithstanding the failure of the
holder or holders thereof to surrender any certificates for such shares at or prior to such time), except only the rights of the holders thereof, upon surrender of any certificate or certificates of such holders therefor (or lost certificate
affidavit and agreement), to receive the items provided for in the next sentence of this <U>Subsection 5A.2</U>. As soon as practicable after the Special Mandatory Conversion and, if applicable, the surrender of any certificate or certificates (or
lost certificate affidavit and agreement) for Series B Preferred Stock so converted, the Corporation shall (a)&nbsp;issue and deliver to such holder, or to his, her or its nominees, a certificate or certificates for the number of full shares of
Common Stock issuable on such conversion in accordance with the provisions hereof and (b)&nbsp;pay cash as provided in <U>Subsection 4.2</U> in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion and the payment
of any declared but unpaid dividends on the shares of Series B Preferred Stock converted. Such converted Series B Preferred Stock shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter
take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Series B Preferred Stock accordingly. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5A.3. <U>Definitions</U>. For purposes of this <U>Section&nbsp;5A</U>: &#147;<B>Affiliate</B>&#148;<B> </B>shall mean, with respect to any
holder of shares of Preferred Stock, any person, entity or firm which, directly or indirectly, controls, is controlled by or is under common control with such holder, including, without limitation, any entity of which the holder is a partner or
member, any partner, officer, director, member or employee of such holder and any venture capital fund or registered investment company now or hereafter existing of which the holder is a partner or member which is controlled by or under common
control with one or more general partners, managing members or investment advisors of such holder or shares the same management company or investment advisor with such holder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6. <U>Redemption</U>. The Preferred Stock is not redeemable except as expressly set forth
herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7. <U>Redeemed or Otherwise Acquired Shares</U>. Any shares of Preferred Stock that are redeemed, converted or otherwise acquired
by the Corporation or any of its subsidiaries shall be automatically and immediately cancelled and retired and shall not be reissued, sold or transferred. Neither the Corporation nor any of its subsidiaries may exercise any voting or other rights
granted to the holders of Preferred Stock following redemption, conversion or acquisition. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8. <U>Waiver</U>. Any of the rights, powers,
preferences and other terms of the Preferred Stock set forth herein may be waived on behalf of all holders of Preferred Stock by the affirmative written consent or vote of the Requisite Holders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9. <U>Notices</U>. Any notice required or permitted by the provisions of this Article Fourth to be given to a holder of shares of Preferred
Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by electronic communication in compliance with the provisions of the General Corporation Law, and shall be deemed sent upon
such mailing or electronic transmission. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>FIFTH: </B>Subject to any additional vote required by this Certificate of
Incorporation or Bylaws, in furtherance and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to make, repeal, alter, amend and rescind any or all of the Bylaws of the Corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SIXTH: </B>Subject to any additional vote required by this Certificate of Incorporation, the number of directors of the
Corporation shall be determined in the manner set forth in the Bylaws of the Corporation. Each director shall be entitled to one vote on each matter presented to the Board of Directors; provided, however, that, so long as the holders of Preferred
Stock are entitled to elect at least one Preferred Director, the affirmative vote of the Qualified Board Majority shall be required for the authorization by the Board of Directors of any of the matters set forth in Section&nbsp;5.5 of the Amended
and Restated Investors&#146; Rights Agreement, dated as of June&nbsp;6, 2023, by and among the Corporation and the other parties thereto, as such agreement may be amended from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SEVENTH: </B>Elections of directors need not be by written ballot unless the Bylaws of the Corporation shall so provide.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>EIGHTH: </B>Meetings of stockholders may be held within or without the State of Delaware, as the Bylaws of the
Corporation may provide. The books of the Corporation may be kept outside the State of Delaware at such place or places as may be designated from time to time by the Board of Directors or in the Bylaws of the Corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>NINTH: </B>To the fullest extent permitted by law, a director of the Corporation shall not be personally liable to the
Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. If the General Corporation Law or any other law of the State of Delaware is amended after approval by the stockholders of this <U>Article Ninth</U> to
authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law as so
amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any repeal or modification of the foregoing provisions of this <U>Article Ninth</U> by the
stockholders of the Corporation shall not adversely affect any right or protection of a director of the Corporation existing at the time of, or increase the liability of any director of the Corporation with respect to any acts or omissions of such
director occurring prior to, such repeal or modification. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>TENTH: </B>To the fullest extent permitted by applicable law,
the Corporation shall provide indemnification of (and advancement of expenses to) directors of the Corporation and the Corporation is authorized to provide indemnification of (and advancement of expenses to) officers and agents of the Corporation
(and any other persons to which General Corporation Law permits the Corporation to provide indemnification) through Bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise, in
excess of the indemnification and advancement otherwise permitted by Section&nbsp;145 of the General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any amendment,
repeal or modification of the foregoing provisions of this <U>Article Tenth</U> shall not (a)&nbsp;adversely affect any right or protection of any director, officer or other agent of the Corporation existing at the time of such amendment, repeal or
modification or (b)&nbsp;increase the liability of any director of the Corporation with respect to any acts or omissions of such director, officer or agent occurring prior to, such amendment, repeal or modification. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>ELEVENTH: </B>The Corporation renounces, to the fullest extent permitted by law, any interest or expectancy of the
Corporation in, or in being offered an opportunity to participate in, any Excluded Opportunity. An &#147;<B>Excluded Opportunity</B>&#148;<B> </B>is any matter, transaction or interest that is presented to, or acquired, created or developed by, or
which otherwise comes into the possession of (i)&nbsp;any director of the Corporation who is not an employee of the Corporation or any of its subsidiaries, or (ii)&nbsp;any holder of Preferred Stock or any partner, member, director, stockholder,
employee, affiliate or agent of any such holder, other than someone who is an employee of the Corporation or any of its subsidiaries (collectively, the persons referred to in <U>clauses (i)</U>&nbsp;and <U>(ii)</U> are &#147;<B>Covered
Persons</B>&#148;), unless such matter, transaction or interest is presented to, or acquired, created or developed by, or otherwise comes into the possession of, a Covered Person expressly and solely in such Covered Person&#146;s capacity as a
director of the Corporation while such Covered Person is performing services in such capacity. Any repeal or modification of this <U>Article Eleventh</U> will only be prospective and will not affect the rights under this <U>Article Eleventh</U> in
effect at the time of the occurrence of any actions or omissions to act giving rise to liability. Notwithstanding anything to the contrary contained elsewhere in this Certificate of Incorporation, the affirmative vote of the Requisite Holders will
be required to amend or repeal, or to adopt any provisions inconsistent with this <U>Article Eleventh</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>TWELFTH:
</B>Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i)&nbsp;any
derivative action or proceeding brought on behalf of the Corporation, (ii)&nbsp;any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of the Corporation to the Corporation or the Corporation&#146;s
stockholders, (iii)&nbsp;any action asserting a claim against the Corporation, its directors, officers or employees arising </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
pursuant to any provision of the Delaware General Corporation Law or the Corporation&#146;s certificate of incorporation or bylaws or (iv)&nbsp;any action asserting a claim against the
Corporation, its directors, officers or employees governed by the internal affairs doctrine, except for, as to each of (i)&nbsp;through (iv) above, any claim as to which the Court of Chancery determines that there is an indispensable party not
subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination), which is vested in the exclusive jurisdiction of
a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. If any provision or provisions of this <U>Article Twelfth</U> shall be held to be invalid, illegal or unenforceable as
applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this
<U>Article Twelfth</U> (including, without limitation, each portion of any sentence of this <U>Article Twelfth</U> containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or
unenforceable) and the application of such provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&#8195;*&#8195;* </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3. </B>That
the foregoing amendment and restatement was approved by the holders of the requisite number of shares of this corporation in accordance with Section&nbsp;228 of the General Corporation Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4. </B>That this Amended and Restated Certificate of Incorporation, which restates and integrates and further amends the provisions of this
Corporation&#146;s Certificate of Incorporation, has been duly adopted in accordance with Sections 242 and 245 of the General Corporation Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF, </B>this Amended and Restated Certificate of Incorporation has been
executed by a duly authorized officer of this corporation on this 6th day of June, 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Samantha Truex</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Samantha Truex</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: &#8194;Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">SIGNATURE PAGE TO SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECOND AMENDED AND
RESTATED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UPSTREAM BIO, INC.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(<I>Pursuant to Section</I><I></I><I>&nbsp;242 of the General </I> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Corporation Law of the State of Delaware</I>) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upstream Bio, Inc. (the &#147;<B><I>Corporation</I></B>&#148;), a corporation organized and existing under and by virtue of the General
Corporation Law of the State of Delaware (the &#147;<B><I>DGCL</I></B>&#148;), </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>DOES HEREBY CERTIFY</B>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&#8195;That, pursuant to Section&nbsp;242 of the DGCL, this Certificate of Amendment (this &#147;<B><I>Amendment</I></B>&#148;) of Second
Amended and Restated Certificate of Incorporation of the Corporation, as amended and currently in effect (the &#147;<B><I>Certificate</I></B>&#148;) amends certain provisions of the Certificate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&#8195;That, pursuant to Section&nbsp;242 of the DGCL, the Corporation&#146;s Board of Directors (the &#147;<B><I>Board</I></B>&#148;) duly
adopted resolutions approving this Amendment, declaring this Amendment to be advisable and in the best interests of the Corporation and its stockholders, and authorizing the appropriate officers of the Corporation to solicit the consent of the
stockholders therefor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&#8195;That, in lieu of a meeting and vote of the stockholders of the Corporation, such stockholders have given
written consent to this Amendment in accordance with the provisions of Section&nbsp;228 of the DGCL and the provisions of the Certificate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&#8195;That the first paragraph of Article Fourth is hereby amended to read in its entirety as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">&#147;<B>FOURTH</B>: The total number of shares of all classes of stock which the Corporation shall have authority to issue is (i) 40,684,346
shares of Common Stock, $0.001 par value per share (&#147;<B>Common Stock</B>&#148;) and (ii) 31,764,693 shares of Preferred Stock, $0.001 par value per share (&#147;<B>Preferred Stock</B>&#148;).&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&#8195;That all other provisions of the Certificate shall remain in full force and effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the undersigned authorized officer of the Corporation has executed this
Certificate of Amendment as of April&nbsp;5, 2024. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>UPSTREAM BIO, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Adam Houghton</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Adam Houghton</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Chief Business Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Certificate of Amendment</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECOND AMENDED
AND RESTATED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UPSTREAM BIO, INC.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upstream Bio, Inc. (the &#147;<B>Corporation</B>&#148;), a corporation organized and existing under and by virtue of the General
Corporation Law of the State of Delaware (the &#147;<B>General Corporation Law</B>&#148;), </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>DOES HEREBY CERTIFY: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&#8195;That the name of the Corporation is Upstream Bio, Inc., and that this corporation was originally incorporated pursuant to the General
Corporation Law on April&nbsp;21, 2021 under the name Upstream Bio, Inc. The Corporation&#146;s Certificate of Incorporation was amended and restated by that certain Amended and Restated Certificate of Incorporation dated as of October&nbsp;13,
2021, and further amended and restated by that certain Second Amended and Restated Certificate of Incorporation dated as of June&nbsp;6, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&#8195;That the Board of Directors of the Corporation duly adopted resolutions proposing to amend the Second Amended and Restated
Certificate of Incorporation of the Corporation, declaring said amendment to be advisable and in the best interests of the Corporation and its stockholders, and authorizing the appropriate officers of the Corporation to solicit the consent of the
stockholders therefor, which resolutions setting forth the proposed amendments are as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED</B>, that the first paragraph
of Article FOURTH is hereby amended to read in its entirety as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Effective upon the filing of this
Certificate of Amendment of the Second Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the &#147;<B>Effective Time</B>&#148;), every one share of Common Stock then issued and outstanding or
held in the treasury of the Corporation immediately prior to the Effective Time shall automatically be split into 1.049 shares of Common Stock, without any further action by the holders of such shares (the &#147;<B>Stock Split</B>&#148;). The Stock
Split will be effected on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">certificate-by-certificate</FONT></FONT> basis, and any fractional shares resulting from the Stock Split shall be rounded down to the nearest whole share
on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">certificate-by-certificate</FONT></FONT> basis. No fractional shares shall be issued in connection with the Stock Split. In lieu of any fractional shares to which a holder would
otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the fair market value of a share of Common Stock as determined in good faith by the Corporation&#146;s Board of Directors. The Stock Split shall occur
automatically without any further action by the holders of the shares of Common Stock and Preferred Stock affected thereby. All rights, preferences and privileges of the Common Stock and the Preferred Stock shall be appropriately adjusted to reflect
the Stock Split in accordance with this Second Amended and Restated Certificate of Incorporation. The total number of shares of all classes of stock which the Corporation shall have authority to issue is (i) 46,350,000 shares of
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Common Stock, $0.001 par value per share (&#147;<B>Common Stock</B>&#148;) and (ii) 31,764,693 shares of Preferred Stock, $0.001 par value per share (&#147;<B>Preferred Stock</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&#8195;That the foregoing amendment was approved by the holders of the requisite number of shares of the Corporation in accordance with
Section&nbsp;228 of the General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&#8195;That said amendment has been duly adopted in accordance with Section&nbsp;242
of the General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&#8195;All other provisions of the Second Amended and Restated Certificate of Incorporation shall
remain in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Follow] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, this Certificate of Amendment has been executed by a duly
authorized officer of the Corporation on this 4th day of October, 2024. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U>/s/ E. Rand Sutherland&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">E. Rand Sutherland, M.D., M.P.H.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:240pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> C<SMALL>ERTIFICATE</SMALL> <SMALL>OF</SMALL> A<SMALL>MENDMENT</SMALL> </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>4
<FILENAME>d843142dex32.htm
<DESCRIPTION>EX-3.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THIRD AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UPSTREAM BIO, INC.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upstream Bio, Inc., a corporation organized and existing under the laws of the State of Delaware (the
&#147;<B>Corporation</B>&#148;), hereby certifies as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The name of the Corporation is Upstream Bio, Inc. The date of the filing
of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was April&nbsp;21, 2021 (the &#147;<B>Original Certificate</B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The Original Certificate was amended by that certain Amended and Restated Certificate of Incorporation dated as of October&nbsp;13, 2021.
This Third Amended and Restated Certificate of Incorporation (this &#147;<B>Certificate</B>&#148;) amends, restates and integrates the provisions of the Second Amended and Restated Certificate of Incorporation that was filed with the Secretary of
State of the State of Delaware on June&nbsp;6, 2023 (the &#147;<B>Amended and Restated Certificate</B>&#148;), and was duly adopted in accordance with the provisions of Sections 228, 242 and 245 of the General Corporation Law of the State of
Delaware (the &#147;<B>DGCL</B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The text of the Amended and Restated Certificate is hereby amended, restated and integrated in
its entirety to provide as follows. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE I </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The name of the Corporation is Upstream Bio, Inc. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE II </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The address of the
Corporation&#146;s registered office in the State of Delaware is 1209 Orange Street, in the City of Wilmington, County of New Castle, 19801. The name of its registered agent at such address is The Corporation Trust Company. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE III </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the
Corporation is to engage in any lawful act or activity for which corporations may be organized under the DGCL. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE IV </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>CAPITAL STOCK </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total
number of shares of capital stock which the Corporation shall have authority to issue is five hundred ten million (510,000,000), of which (i)&nbsp;five hundred million (500,000,000) shares shall be a class designated as common stock, par value
$0.001 per share (the &#147;<B>Common Stock</B>&#148;), and (ii)&nbsp;ten million (10,000,000) shares shall be a class designated as undesignated preferred stock, par value $0.001 per share (the &#147;<B>Preferred Stock</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in any certificate of designation of any series of Preferred Stock, the number of authorized shares of the class
of Common Stock or Preferred Stock may be increased or decreased (but not below the number of shares of such class then outstanding) by the affirmative vote of the holders of a majority in voting power of the outstanding shares of capital stock of
the Corporation entitled to vote thereon irrespective of the provisions of Section&nbsp;242(b)(2) of the DGCL, and no vote of the holders of any of the Common Stock or the Preferred Stock voting separately as a class shall be required therefor. For
the avoidance of doubt, the elimination and reduction of the voting requirements of Section&nbsp;242 of the DGCL, as permitted by Section&nbsp;242(d) of the DGCL, shall apply to any amendments to this Certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The powers, preferences and rights of, and the qualifications, limitations and restrictions upon, each class or series of stock shall be
determined in accordance with, or as set forth below in, this Article&nbsp;IV. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A. <U>COMMON STOCK</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Subject to all the rights, powers and preferences of the Preferred Stock and except as provided by law or in this Certificate (including any
certificate of designation of any series of Preferred Stock): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) the holders of the Common Stock shall have the exclusive right to vote
for the election of directors of the Corporation (the &#147;<B>Directors</B>&#148;) and on all other matters requiring stockholder action, each outstanding share entitling the holder thereof to one vote on each matter properly submitted to the
stockholders of the Corporation for their vote; <U>provided</U>, <U>however</U>, that, except as otherwise required by law, holders of Common Stock, as such, shall not be entitled to vote on any amendment to this Certificate (including any amendment
to a certificate of designation of any series of Preferred Stock) that alters or changes the powers, preferences, rights or other terms of one or more outstanding series of Preferred Stock if the holders of such affected series of Preferred Stock
are entitled to vote, either separately or together with the holders of one or more other such series, on such amendment pursuant to this Certificate (including any certificate of designation of any series of Preferred Stock) or pursuant to the
DGCL; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) dividends may be declared and paid or set apart for payment upon the shares of Common
Stock out of any assets or funds of the Corporation legally available for the payment of dividends, but only when, as and if declared by the Board of Directors of the Corporation (the &#147;<B>Board</B>&#148;) or any authorized committee thereof;
and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) upon the voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the net assets of the Corporation
shall be distributed pro rata to the holders of the Common Stock. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B. <U>PREFERRED STOCK</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors or any authorized committee thereof is expressly authorized to provide by resolution or resolutions for, out of the unissued shares of
Preferred Stock, the issuance of the shares of Preferred Stock in one or more series of such stock, and by filing a certificate of designation pursuant to applicable law of the State of Delaware, to establish or change from time to time the number
of shares of each such series, and to fix the designations, powers, including voting powers, full or limited, or no voting powers, preferences and the relative, participating, optional or other special rights of the shares of each series and any
qualifications, limitations and restrictions thereof, all to the fullest extent now or hereafter permitted by the DGCL. The powers, preferences and relative, participating, optional and other special rights of each such series of Preferred Stock,
and the qualifications, limitations or restrictions thereof, if any, may differ from those of any and all other series at any time outstanding. Without limiting the generality of the foregoing, the resolution or resolutions providing for the
issuance of any series of Preferred Stock may provide that such series shall be superior or rank equally or be junior to any other series of Preferred Stock to the extent permitted by law. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE V </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>STOCKHOLDER ACTION
</U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Action without Meeting</U>. Subject to the rights, if any, of the holders of shares of any series of Preferred Stock, any
action required or permitted to be taken by the stockholders of the Corporation at any annual or special meeting of stockholders of the Corporation must be effected at a duly called annual or special meeting of stockholders and may not be taken or
effected by a consent of stockholders in lieu thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Special Meetings</U>. Except as otherwise required by statute and subject to
the rights, if any, of the holders of shares of any series of Preferred Stock, special meetings of the stockholders of the Corporation may be called only by the Board of Directors, and special meetings of stockholders may not be called by any other
person or persons. Only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders of the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE VI </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>DIRECTORS </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.
<U>General</U>. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors except as otherwise provided herein or required by law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Number of Directors; Term of Office.</U><B><I> </I></B>Except as otherwise provided for or fixed pursuant to the provisions of Article IV
(including any certificate of designation with respect to any series of Preferred Stock) and this Article VII relating to the rights of the holders of any series of Preferred Stock to elect additional Directors, the number of Directors shall be
fixed solely and exclusively by resolution duly adopted from time to time by the Board of Directors. The Directors, other than those who may be elected by the holders of any series of Preferred Stock, shall be classified, with respect to the term
for which they severally hold office, into three classes. The term of office of the initial Class&nbsp;I Directors shall expire at the first regularly-scheduled annual meeting of stockholders following the closing of the Corporation&#146;s sale of a
class of its capital stock to the public pursuant to a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act (the &#147;<B>IPO Time</B>&#148;). The term of office of the initial Class&nbsp;II Directors
shall expire at the second annual meeting of stockholders following the IPO Time. The term of office of the initial Class&nbsp;III Directors shall expire at the third annual meeting of stockholders following the IPO Time. The Board of Directors is
authorized to assign members of the Board of Directors already in office to such classes at the time the classification of the Board of Directors becomes effective. At each annual meeting of stockholders, Directors elected to succeed those Directors
whose terms expire shall be elected for a term of office to expire at the third succeeding annual meeting of stockholders after their election. Notwithstanding the foregoing, the Directors elected to each class shall hold office until their
successors are duly elected and qualified or until their earlier resignation, death, disqualification or removal. No decrease in the number of Directors shall shorten the term of any incumbent Director. There shall be no cumulative voting in the
election of Directors. Election of Directors need not be by written ballot unless the Bylaws of the Corporation so provide. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, whenever, pursuant to the provisions of Article&nbsp;IV of this Certificate, the holders of any one or more
series of Preferred Stock shall have the right, voting separately as a series or together with holders of other such series, to elect additional Directors, the election, term of office, filling of vacancies and other features of such directorships
shall be governed by the terms of this Certificate, including any certificate of designation applicable to such series of Preferred Stock. During any period when the holders of any series of Preferred Stock, voting separately as a series or together
with one or more series, have the right to elect additional Directors, then upon commencement and for the duration of the period during which such right continues: (i)&nbsp;the then otherwise total authorized number of Directors shall automatically
be increased by such specified number of Directors, and the holders of such Preferred Stock shall be entitled to elect the additional Directors so provided for or fixed pursuant to said provisions, and (ii)&nbsp;each such additional Director shall
serve until such Director&#146;s successor shall have been duly elected and qualified, or until such Director&#146;s right to hold </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
such office terminates pursuant to said provisions, whichever occurs earlier, subject to such Director&#146;s earlier death, resignation, retirement, disqualification or removal. Notwithstanding
any other provision of this Certificate of Incorporation, except as otherwise provided by the Board in the resolution or resolutions establishing such series, whenever the holders of any series of Preferred Stock having such right to elect
additional Directors are divested of such right pursuant to the provisions of such stock, the terms of office of all such additional Directors elected by the holders of such stock, or elected to fill any vacancies resulting from the death,
resignation, disqualification or removal of such additional Directors, shall forthwith terminate (in which case each such Director shall thereupon cease to be qualified as, and shall cease to be, a Director) and the total authorized number of
Directors shall automatically be reduced accordingly. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Vacancies and Newly Created Directorships</U>. Subject to the rights, if any,
of the holders of any series of Preferred Stock to elect Directors and to fill vacancies in the Board of Directors relating thereto, any and all vacancies and newly created directorships in the Board of Directors, however occurring, including,
without limitation, by reason of an increase in the size of the Board of Directors, or the death, resignation, disqualification or removal of a Director, shall be filled solely and exclusively by the affirmative vote of a majority of the remaining
Directors then in office, even if less than a quorum of the Board of Directors, or by a sole remaining Director, and not by the stockholders. Any Director appointed in accordance with the preceding sentence shall hold office for the remainder of the
full term of the class of Directors in which the new directorship was created or the vacancy occurred and until such Director&#146;s successor shall have been duly elected and qualified or until such Director&#146;s earlier resignation,
disqualification, death or removal. Subject to the rights, if any, of the holders of any series of Preferred Stock to elect Directors, when the number of Directors is increased or decreased, the Board of Directors shall, subject to Article VI.3
hereof, determine the class or classes to which the increased or decreased number of Directors shall be apportioned. In the event of a vacancy in the Board of Directors, the remaining Directors, except as otherwise provided by law, shall exercise
the powers of the full Board of Directors until the vacancy is filled. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Removal</U>. Subject to the rights, if any, of any series of
Preferred Stock to elect Directors and to remove any Director whom the holders of any such series have the right to elect, any Director may be removed from office (i)&nbsp;only for cause and (ii)&nbsp;only by the affirmative vote of the holders not
less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3)<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>of the voting power of the outstanding shares of capital stock then entitled to vote at an election of Directors. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE VII </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>LIMITATION OF
LIABILITY </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Directors.</U> To the fullest extent permitted by the DGCL, as the same exists or may hereafter be amended from time
to time, a Director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of such Director&#146;s fiduciary duty as a Director, except for liability (a)&nbsp;for any breach of the
Director&#146;s duty of loyalty to the Corporation or its stockholders, (b)&nbsp;for acts or omissions not in good faith or which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
involve intentional misconduct or a knowing violation of law, (c)&nbsp;under Section&nbsp;174 of the DGCL or (d)&nbsp;for any transaction from which the Director derived an improper personal
benefit. If the DGCL is amended after the effective date of this Certificate to authorize corporate action further eliminating or limiting the personal liability of Directors, then the liability of a Director of the Corporation shall be eliminated
or limited to the fullest extent permitted by the DGCL, as so amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Officers</U>. To the fullest extent permitted by the DGCL, as
the same exists or may thereafter be amended from time to time, an Officer (as defined below) of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of such Officer&#146;s fiduciary
duty as an officer of the Corporation, except for liability (a)&nbsp;for any breach of the Officer&#146;s duty of loyalty to the Corporation or its stockholders, (b)&nbsp;for acts or omissions not in good faith or which involve intentional
misconduct or a knowing violation of law, (c)&nbsp;for any transaction from which the Officer derived an improper personal benefit, or (d)&nbsp;arising from any claim brought by or in the right of the Corporation. If the DGCL is amended after the
effective date of this Certificate to authorize corporate action further eliminating or limiting the personal liability of Officers, then the liability of an Officer of the Corporation shall be eliminated or limited to the fullest extent permitted
by the DGCL, as so amended. For purposes of this Article VII, &#147;Officer&#148; shall mean an individual who has been duly appointed as an officer of the Corporation and who, at the time of an act or omission as to which liability is asserted, is
deemed to have consented to service by the delivery of process to the registered agent of the Corporation as contemplated by 10&nbsp;Del. C.&nbsp;&#167; 3114(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Amendment or Modification</U>. Any amendment, repeal or modification of this Article&nbsp;VII or any amendment to the DGCL, shall not
adversely affect any right or protection existing at the time of such amendment, repeal or modification with respect to any acts or omissions occurring before such amendment, repeal or modification of a person serving as a Director or Officer, as
applicable, at the time of such amendment, repeal or modification. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE VIII </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>AMENDMENT OF BYLAWS </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.
<U>Amendment by Directors</U>. Except as otherwise provided by law, the Bylaws of the Corporation may be adopted, amended or repealed by the Board of Directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Amendment by Stockholders</U>. Except as otherwise provided therein, the Bylaws of the Corporation may be amended or repealed by the
stockholders by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) of the voting power of the outstanding shares of capital stock entitled to vote on such amendment or repeal, voting together as
a single class; provided, however, that if the Board of Directors recommends that stockholders approve such amendment or repeal, such amendment or repeal shall only require the affirmative vote of the holders of a majority of the voting power of the
outstanding shares of capital stock entitled to vote on such amendment or repeal, voting together as a single class. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE IX </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>AMENDMENT OF CERTIFICATE OF INCORPORATION </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation reserves the right to amend or repeal this Certificate in the manner now or hereafter prescribed by statute and this
Certificate, and all rights conferred upon stockholders herein are granted subject to this reservation.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>For the avoidance of doubt, the provisions of Sections 242(d)(1) and (d)(2) of the DGCL
shall apply to the Corporation.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[End of Text] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION is executed as of this
&#8195;&#8195;&#8195;day of &#8195;&#8195;&#8195;, 2024. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">UPSTREAM BIO, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: E. Rand Sutherland, M.D., M.P.H.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.4
<SEQUENCE>5
<FILENAME>d843142dex34.htm
<DESCRIPTION>EX-3.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.4 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BYLAWS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UPSTREAM BIO, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(the
&#147;<B>Corporation</B>&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE I </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Stockholders </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.
<U>Annual Meeting</U>. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an &#147;<B>Annual Meeting</B>&#148;) shall be held at the hour, date and place within or without the United States that is fixed by or
in the manner determined by the Board of Directors and stated in the notice of the meeting, which time, date and place may subsequently be changed at any time, before or after the notice for such meeting has been sent to the stockholders, by vote of
the Board of Directors. The Board of Directors may, in its sole discretion, determine that a meeting of stockholders shall not be held at any place, but may instead be held solely by means of remote communication as authorized by
Section&nbsp;211(a)(2) of the General Corporation Law of the State of Delaware (the &#147;<B>DGCL</B>&#148;). In the absence of any such designation or determination, stockholders&#146; meetings shall be held at the Corporation&#146;s principal
executive office. If no Annual Meeting has been held for a period of thirteen (13)&nbsp;months after the Corporation&#146;s last Annual Meeting, a special meeting in lieu thereof may be held, and such special meeting shall have, for the purposes of
these Bylaws or otherwise, all the force and effect of an Annual Meeting. Any and all references hereafter in these Bylaws to an Annual Meeting or Annual Meetings also shall be deemed to refer to any special meeting(s) in lieu thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Notice of Stockholder Business and Nominations</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Annual Meetings of Stockholders</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) Nominations of persons for election to the Board of Directors of the Corporation (the &#147;<B>Board of
Directors</B>&#148;) and the proposal of other business to be considered by the stockholders may be brought before an Annual Meeting (i)&nbsp;by or at the direction of the Board of Directors or (ii)&nbsp;by any stockholder of the Corporation who was
a stockholder of record at the time of giving of notice of the Annual Meeting provided for in this Bylaw, who is entitled to vote at the meeting, who is present (in person or by proxy) at the meeting and who complies with the notice procedures set
forth in this Bylaw as to such nomination or business. For the avoidance of doubt, the foregoing clause (ii)&nbsp;shall be the exclusive means for a stockholder to bring nominations or business properly before an Annual Meeting (other than matters
properly brought under <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-8</FONT> (or any successor rule) under the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;)), and such stockholder must comply with the notice and
other procedures set forth in Article I, Section&nbsp;2(a)(2), (3) and (4)&nbsp;of this Bylaw to bring such nominations or business properly before an Annual Meeting. In addition to the other requirements set forth in this Bylaw, for any proposal of
business to be considered at an Annual Meeting, it must be a proper subject for action by stockholders of the Corporation under Delaware law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) For nominations or other business to be properly brought before an
Annual Meeting by a stockholder pursuant to clause (ii)&nbsp;of Article I, Section&nbsp;2(a)(1) of this Bylaw, the stockholder must (i)&nbsp;have given Timely Notice (as defined below) thereof in writing to the Secretary of the Corporation,
(ii)&nbsp;have provided any updates or supplements to such notice at the times and in the forms required by this Bylaw and (iii)&nbsp;together with the beneficial owner(s), if any, on whose behalf the nomination or business proposal is made, have
acted in accordance with the representations set forth in the Solicitation Statement (as defined below) required by this Bylaw. To be timely, a stockholder&#146;s written notice must be received by the Secretary at the principal executive offices of
the Corporation not later than 5:00 p.m. Eastern time on the ninetieth (90th) day nor earlier than 5:00 p.m. Eastern time on the one hundred twentieth (120th) day prior to the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the
preceding year&#146;s Annual Meeting; provided, however, that in the event the Annual Meeting is first convened more than thirty (30)&nbsp;days before or more than sixty (60)&nbsp;days after such anniversary date, or if no Annual Meeting was held in
the preceding year, notice by the stockholder to be timely must be received by the Secretary of the Corporation not later than 5:00 p.m. Eastern time on the later of the ninetieth (90th) day prior to the scheduled date of such Annual Meeting or the
tenth (10th) day following the day on which public announcement of the date of such meeting is first made (such notice within such time periods shall be referred to as &#147;<B>Timely Notice</B>&#148;). Notwithstanding anything to the contrary
provided herein, for the first Annual Meeting following the initial public offering of common stock of the Corporation, a stockholder&#146;s notice shall be timely if received by the Secretary at the principal executive offices of the Corporation
not later than 5:00 p.m. Eastern time on the later of the ninetieth (90th) day prior to the scheduled date of such Annual Meeting or the tenth (10th) day following the day on which public announcement of the date of such Annual Meeting is first made
or sent by the Corporation. Such stockholder&#146;s Timely Notice shall set forth or include: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) as to each person whom
the stockholder proposes to nominate for election or reelection as a director, (i)&nbsp;the name, age, business address and residence address of the nominee, (ii)&nbsp;the principal occupation or employment of the nominee, (iii)&nbsp;the class and
number of shares of capital stock of the Corporation that are held of record or are beneficially owned by the nominee or its Affiliates or Associates (each as defined below) and any Synthetic Equity Interest (as defined below) held or beneficially
owned by the nominee or its Affiliates or Associates, (iv)&nbsp;a description of all agreements, arrangements or understandings between or among the stockholder and each nominee and any other person or persons (naming such person or persons)
pursuant to which the nominations are to be made by the stockholder or concerning the nominee&#146;s potential service on the Board of Directors, (v)&nbsp;a questionnaire with respect to the background and qualifications of the nominee completed by
the nominee in the form provided by the Corporation (which questionnaire shall be provided by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
Secretary upon written request of any stockholder of record identified by name within five (5)&nbsp;business days of such written request), (vi) a representation and agreement in the form
provided by the Corporation (which form shall be provided by the Secretary upon written request of any stockholder of record identified by name within five (5)&nbsp;business days of such written request) that: (a)&nbsp;such proposed nominee is not
and will not become party to any agreement, arrangement or understanding with any person or entity as to how such proposed nominee, if elected as a director of the Corporation, will act or vote on any issue or question (a &#147;<B>Voting
Commitment</B>&#148;) that has not been disclosed to the Corporation in the questionnaire described in clause (v)&nbsp;herein; (b) such proposed nominee is not and will not become a party to any agreement, arrangement or understanding with any
person or entity other than the Corporation with respect to any direct or indirect compensation, reimbursement or indemnification in connection with service or action as a director that has not been disclosed to the Corporation in the questionnaire
described in clause (v)&nbsp;herein; (c) such proposed nominee would, if elected as a director, comply with all applicable rules and regulations of the exchanges upon which shares of the Corporation&#146;s capital stock trade, each of the
Corporation&#146;s corporate governance, ethics, conflict of interest, confidentiality, stock ownership and trading policies and guidelines applicable generally to the Corporation&#146;s directors and, if elected as a director of the Corporation,
such person currently would be in compliance with any such policies and guidelines that have been publicly disclosed; (d)&nbsp;such proposed nominee intends to serve as a director for the full term for which he or she is to stand for election; and
(e)&nbsp;such proposed nominee will promptly provide to the Corporation such other information as it may reasonably request to determine the eligibility of such proposed nominee to serve on any committee or
<FONT STYLE="white-space:nowrap">sub-committee</FONT> of the Board of Directors under any applicable stock exchange listing requirements or applicable law, or that the Board of Directors reasonably determines could be material to a reasonable
stockholder&#146;s understanding of the background, qualifications, experience, independence, or lack thereof, of such proposed nominee; and (vii)&nbsp;any other information relating to such proposed nominee that is required to be disclosed in
solicitations of proxies for election of directors in an election contest, or is otherwise required, in each case pursuant to Regulation 14A under the Exchange Act (including, without limitation, such person&#146;s written consent to being named in
the proxy statement as a nominee and to serving as a director if elected); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) as to any other business that the
stockholder proposes to bring before the meeting: a brief description of the business desired to be brought before the meeting, the reasons for conducting such business at the meeting, the text, if any, of any resolutions or Bylaw amendment proposed
for adoption, and any material interest in such business of each Proposing Person (as defined below); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) (i) the name and address of the stockholder giving the notice, as they
appear on the Corporation&#146;s books, and the names and addresses of the other Proposing Persons (if any) and (ii)&nbsp;as to each Proposing Person, the following information: (a)&nbsp;the class or series and number of all shares of capital stock
of the Corporation that are, directly or indirectly, owned beneficially or of record by such Proposing Person or any of its Affiliates or Associates, including any shares of any class or series of capital stock of the Corporation as to which such
Proposing Person or any of its Affiliates or Associates has a right to acquire beneficial ownership at any time in the future (whether or not such right is exercisable immediately or only after the passage of time or upon the satisfaction of any
conditions or both) pursuant to any agreement, arrangement or understanding (whether or not in writing), (b) all Synthetic Equity Interests (as defined below) in which such Proposing Person or any of its Affiliates or Associates, directly or
indirectly, holds an interest including a description of the material terms of each such Synthetic Equity Interest, including, without limitation, identification of the counterparty to each such Synthetic Equity Interest and disclosure, for each
such Synthetic Equity Interest, as to (1)&nbsp;whether or not such Synthetic Equity Interest conveys any voting rights, directly or indirectly, in such shares to such Proposing Person or any of its Affiliates or Associates and (2)&nbsp;whether or
not such Synthetic Equity Interest is required to be, or is capable of being, settled through delivery of such shares, (c)&nbsp;any proxy (other than a revocable proxy given in response to a public proxy solicitation made pursuant to, and in
accordance with, the Exchange Act), agreement, arrangement, understanding or relationship pursuant to which such Proposing Person or any of its Affiliates or Associates has or shares a right to, directly or indirectly, vote any shares of any class
or series of capital stock of the Corporation, (d)&nbsp;any rights to dividends or other distributions on the shares of any class or series of capital stock of the Corporation, directly or indirectly, owned beneficially by such Proposing Person or
any of its Affiliates or Associates that are separated or separable from the underlying shares of the Corporation, (e)&nbsp;if such Proposing Person is not a natural person, the identity of the natural person or persons responsible for making voting
and investment decisions (including director nominations and any other business that the stockholder proposes to bring before a meeting) on behalf of the Proposing Person (irrespective of whether such person or persons have &#147;beneficial
ownership&#148; for purposes of Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> of the Exchange Act of any securities owned of record or beneficially by the Proposing Person) (such person or persons, the &#147;<B>Responsible Person</B>&#148;),
(f) any pending or threatened litigation in which such Proposing Person or any of its Affiliates or Associates or any Responsible Person is a party involving the Corporation or any of its officers or directors, or any Affiliate of the Corporation,
and (g)&nbsp;any other information relating to such Proposing Person or any of its Affiliates or Associates that would be required to be disclosed in a proxy statement or other filing required to be made in connection with solicitations of proxies
or consents by such Proposing Person in support of the business proposed to be brought before the meeting pursuant to Section&nbsp;14(a) of the Exchange Act (the disclosures to be made pursuant to the foregoing clauses (a)&nbsp;through (g) are
referred to, collectively, as &#147;<B>Material Ownership Interests</B>&#148;); provided, however, that the Material Ownership Interests shall not include any such disclosures with respect to the ordinary course business activities of any broker,
dealer, commercial bank, trust company or other nominee who is a Proposing Person solely as a result of being the stockholder of record directed to prepare and submit the notice required by these Bylaws on behalf of a beneficial owner; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) (i) a description of all agreements, arrangements or understandings to
which any Proposing Person or any of its Affiliates or Associates is a party (whether the counterparty or counterparties are a Proposing Person or any Affiliate or Associate thereof, on the one hand, or one or more other third parties, on the other
hand, (including any proposed nominee(s)) (a) pertaining to the nomination(s) or other business proposed to be brought before the meeting of stockholders or (b)&nbsp;entered into for the purpose of acquiring, holding, disposing or voting of any
shares of any class or series of capital stock of the Corporation (which description shall identify the name of each other person who is party to such an agreement, arrangement or understanding) and (ii)&nbsp;identification of the names and
addresses of other stockholders (including beneficial owners) known by any of the Proposing Persons to be providing financial support or meaningful assistance in furtherance of the nomination(s) or other business proposed to be brought before the
meeting of stockholders and, to the extent known, the class and number of all shares of the Corporation&#146;s capital stock owned beneficially or of record by such other stockholder(s) or other beneficial owner(s); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(E) a statement (i)&nbsp;that the stockholder is a holder of record of capital stock of the Corporation entitled to vote at
such meeting, a representation that such stockholder intends to appear in person or by proxy at the meeting to propose such business or nominees and an acknowledgement that, if such stockholder (or a qualified representative of such stockholder)
does not appear to present such business or proposed nominees, as applicable, at such meeting, the Corporation need not present such business or proposed nominees for a vote at such meeting, notwithstanding that proxies in respect of such vote may
have been received by the Corporation, (ii)&nbsp;whether or not the stockholder giving the notice and/or the other Proposing Person(s), if any, (a)&nbsp;will deliver a proxy statement and form of proxy to holders of, in the case of a business
proposal, at least the percentage of voting power of all of the shares of capital stock of the Corporation required under applicable law to approve the proposal or, in the case of a nomination or nominations, at least 67&nbsp;percent of the voting
power of all of the shares of capital stock of the Corporation entitled to vote on the election of directors or (b)&nbsp;otherwise solicit proxies or votes from stockholders in support of such proposal or nomination, as applicable,
(iii)&nbsp;providing a representation as to whether or not such Proposing Person intends to solicit proxies in support of director nominees other than the Corporation&#146;s director nominees in accordance with Rule
<FONT STYLE="white-space:nowrap">14a-19</FONT> promulgated under the Exchange Act and (iv)&nbsp;that the stockholder will provide any other information relating to such item of business that would be required to be disclosed in a proxy statement or
other filing required to be made in connection with solicitations of proxies in support of the business proposed to be brought before the meeting pursuant to Section&nbsp;14(a) of the Exchange Act (such statement, the &#147;<B>Solicitation
Statement</B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Article I, the term &#147;Proposing Person&#148; shall mean the
following persons: (i)&nbsp;the stockholder of record providing the notice of nominations or business proposed to be brought before a stockholders&#146; meeting and (ii)&nbsp;the beneficial owner(s), if different, on whose behalf the nominations or
business proposed to be brought before a stockholders&#146; meeting is made. For purposes of this Section&nbsp;2, each of the terms &#147;Affiliates&#148; and &#147;Associates&#148; shall have the meaning attributed to such term in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act. For purposes of this Section&nbsp;2, the term &#147;Synthetic Equity Interest&#148; shall mean any transaction, agreement or arrangement (or series of transactions, agreements or
arrangements), including, without limitation, any derivative, swap, hedge, repurchase or <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;stock borrowing&#148; or securities lending agreement or arrangement, the purpose or effect of which is
to, directly or indirectly: (a)&nbsp;give a person or entity economic benefit and/or risk similar to ownership of shares of any class or series of capital stock of the Corporation, in whole or in part, including due to the fact that such
transaction, agreement or arrangement provides, directly or indirectly, the opportunity to profit, or share in any profit, or avoid a loss from any increase or decrease in the value of any shares of any class or series of capital stock of the
Corporation, (b)&nbsp;mitigate loss to, reduce the economic risk of, or manage the risk of share price changes for, any person or entity with respect to any shares of any class or series of capital stock of the Corporation, or (c)&nbsp;increase or
decrease the voting power of any person or entity with respect to any shares of any class or series of capital stock of the Corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) A stockholder providing Timely Notice of nominations or business proposed to be brought before an Annual Meeting shall
further update and supplement such notice, if necessary, so that the information (including, without limitation, the Material Ownership Interests information) provided or required to be provided in such notice pursuant to this Bylaw shall be true
and correct as of the record date for the meeting and as of the date that is ten (10)&nbsp;business days prior to such Annual Meeting, and such update and supplement shall be received by the Secretary at the principal executive offices of the
Corporation not later than 5:00 p.m. Eastern time on the fifth (5th) business day after the record date for the Annual Meeting (in the case of the update and supplement required to be made as of the record date), and not later than 5:00 p.m. Eastern
time on the eighth (8th) business day prior to the date of the Annual Meeting (in the case of the update and supplement required to be made as of ten (10)&nbsp;business days prior to the meeting). For the avoidance of doubt, the obligation to update
as set forth in this Section&nbsp;2(a)(3) shall not limit the Corporation&#146;s rights with respect to any deficiencies in any notice provided by a stockholder, extend any applicable deadlines hereunder, or enable or be deemed to permit a
stockholder who has previously submitted notice hereunder to amend or update any proposal or nomination or to submit any new proposal, including by changing or adding nominees, matters, business and/or resolutions proposed to be brought before a
meeting of the stockholders. Notwithstanding the foregoing, if a Proposing Person no longer plans to solicit proxies in accordance with its representation pursuant to Article I, Section&nbsp;2(a)(2)(E), such Proposing Person shall inform the
Corporation of this change by delivering a written notice to the Secretary at the principal executive offices of the Corporation no later than two (2)&nbsp;business days after making the determination not to proceed with a solicitation of proxies. A
Proposing Person shall also update its notice so that the information required by Article I, Section&nbsp;2(a)(2)(C) is current through the date of the meeting or any adjournment, postponement or rescheduling thereof, and such update shall be
delivered in writing to the secretary at the principal executive offices of the Corporation no later than two (2)&nbsp;business days after the occurrence of any material change to the information previously disclosed pursuant to Article I,
Section&nbsp;2(a)(2)(C). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) Notwithstanding anything in the second sentence of Article I,
Section&nbsp;2(a)(2) of this Bylaw to the contrary, in the event that the number of directors to be elected to the Board of Directors is increased and there is no public announcement naming all of the nominees for director or specifying the size of
the increased Board of Directors made by the Corporation at least ten (10)&nbsp;days before the last day a stockholder may deliver a notice of nomination in accordance with the second sentence of Article I, Section&nbsp;2(a)(2), a stockholder&#146;s
notice required by this Bylaw shall also be considered timely, but only with respect to nominees for any new positions created by such increase, if it shall be received by the Secretary of the Corporation not later than 5:00 p.m. Eastern time on the
tenth (10th) day following the day on which such public announcement is first made by the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>General</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) Only such persons who are nominated in accordance with the provisions of this Bylaw shall be eligible for election and to
serve as directors, and only such business shall be conducted at an Annual Meeting as shall have been brought before the meeting in accordance with the provisions of this Bylaw or in accordance with Rule <FONT STYLE="white-space:nowrap">14a-8</FONT>
under the Exchange Act. The Board of Directors or a designated committee thereof shall have the power to determine whether a nomination or any business proposed to be brought before the meeting was made in accordance with the provisions of this
Bylaw. If neither the Board of Directors nor such designated committee makes a determination as to whether any stockholder proposal or nomination was made in accordance with the provisions of this Bylaw, the chair of the meeting (as defined in
Section&nbsp;9 of this Article I) shall have the power and duty to determine whether the stockholder proposal or nomination was made in accordance with the provisions of this Bylaw. If the Board of Directors or a designated committee thereof or the
chair of the meeting, as applicable, determines that any stockholder proposal or nomination was not made in accordance with the provisions of this Bylaw, such proposal or nomination shall be disregarded and shall not be presented for action at the
Annual Meeting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) Except as otherwise required by law, nothing in this Article I, Section&nbsp;2 shall obligate the
Corporation or the Board of Directors to include in any proxy statement or other stockholder communication distributed on behalf of the Corporation or the Board of Directors information with respect to any nominee for director or any other matter of
business submitted by a stockholder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) Notwithstanding the foregoing provisions of this Article I, Section&nbsp;2, if
the nominating or proposing stockholder (or a qualified representative of the stockholder) does not appear at the Annual Meeting to present a nomination or any business, such nomination or business shall be disregarded, notwithstanding that proxies
in respect of such vote may have been received by the Corporation. For purposes of this Article I, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Section&nbsp;2, to be considered a qualified representative of the proposing stockholder, a person must be authorized by a written instrument executed by such stockholder or an electronic
transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders, and such person must produce such written instrument or electronic transmission, or a reliable reproduction of the written instrument or
electronic transmission, to the chair of the meeting at the meeting of stockholders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) For purposes of this Bylaw,
&#147;public announcement&#148; shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange
Commission pursuant to Section&nbsp;13, 14 or 15(d) of the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(5) Notwithstanding the foregoing provisions of
this Bylaw, a stockholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder, including, but not limited to, Rule <FONT STYLE="white-space:nowrap">14a-19</FONT> of the Exchange Act, with
respect to the matters set forth in this Bylaw. If a stockholder fails to comply with any applicable requirements of the Exchange Act, including, but not limited to, Rule <FONT STYLE="white-space:nowrap">14a-19</FONT> promulgated thereunder, such
stockholder&#146;s proposed nomination or proposed business shall be deemed to have not been made in compliance with this Bylaw and shall be disregarded. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(6) Further notwithstanding the foregoing provisions of this Bylaw, unless otherwise required by law, (i)&nbsp;no Proposing
Person shall solicit proxies in support of director nominees other than the Corporation&#146;s nominees unless such Proposing Person has complied with Rule <FONT STYLE="white-space:nowrap">14a-19</FONT> promulgated under the Exchange Act in
connection with the solicitation of such proxies, including the provision to the Corporation of notices required thereunder with timely notice and (ii)&nbsp;if any Proposing Person (A)&nbsp;provides notice pursuant to Rule <FONT
STYLE="white-space:nowrap">14a-19(b)</FONT> promulgated under the Exchange Act, (B)&nbsp;subsequently fails to comply with the requirements of Rule <FONT STYLE="white-space:nowrap">14a-19(a)(2)</FONT> or Rule
<FONT STYLE="white-space:nowrap">14a-19(a)(3)</FONT> promulgated under the Exchange Act, including the provision to the Corporation of notices required thereunder with timely notice and (C)&nbsp;no other Proposing Person has provided notice pursuant
to, and in compliance with, Rule <FONT STYLE="white-space:nowrap">14a-19</FONT> under the Exchange Act that it intends to solicit proxies in support of the election of such proposed nominee in accordance with Rule
<FONT STYLE="white-space:nowrap">14a-19(b)</FONT> under the Exchange Act, then such proposed nominee shall be disqualified from nomination, the Corporation shall disregard the nomination of such proposed nominee and no vote on the election of such
proposed nominee shall occur. Upon request by the Corporation, if any Proposing Person provides notice pursuant to Rule <FONT STYLE="white-space:nowrap">14a-19(b)</FONT> promulgated under the Exchange Act, such Proposing Person shall deliver to the
Corporation, no later than five (5)&nbsp;business days prior to the applicable meeting date, reasonable evidence that it has met the requirements of Rule <FONT STYLE="white-space:nowrap">14a-19(a)(3)</FONT> promulgated under the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(7) The number of nominees a stockholder may nominate for election at the
Annual Meeting (or in the case of a stockholder giving the notice on behalf of a beneficial owner, the number of nominees a stockholder may nominate for election at the Annual Meeting on behalf of such beneficial owner) shall not exceed the number
of directors to be elected at such Annual Meeting. A stockholder may not designate any substitute nominees unless the stockholder provides timely notice of such substitute nominee(s) in accordance with these
<FONT STYLE="white-space:nowrap">By-laws</FONT> (and such notice contains all of the information, representations, questionnaires and certifications with respect to such substitute nominee(s) that are required by the
<FONT STYLE="white-space:nowrap">By-laws</FONT> with respect to nominees for director). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Special Meetings</U>. Except as
otherwise required by statute and subject to the rights, if any, of the holders of any series of Preferred Stock, special meetings of the stockholders of the Corporation may be called only by or at the direction of the Board of Directors. The Board
of Directors may postpone or reschedule any previously scheduled special meeting of stockholders. Only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders of the
Corporation. Nominations of persons for election to the Board of Directors and stockholder proposals of other business shall not be brought before a special meeting of stockholders to be considered by the stockholders unless such special meeting is
held in lieu of an annual meeting of stockholders in accordance with Article I, Section&nbsp;1 of these Bylaws, in which case such special meeting in lieu thereof shall be deemed an Annual Meeting for purposes of these Bylaws and the provisions of
Article I, Section&nbsp;2 of these Bylaws shall govern such special meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Notice of Meetings; Adjournments</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) A notice of each Annual Meeting stating the hour, date and place, if any, of such Annual Meeting, the means of remote communication, if
any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, and the record date for determining the stockholders entitled to vote at the meeting, if such date is different from the record date for
determining stockholders entitled to notice of the meeting, shall be given not less than ten (10)&nbsp;days nor more than sixty (60)&nbsp;days before the Annual Meeting, to each stockholder entitled to vote thereat by delivering such notice to such
stockholder or by mailing it, postage prepaid, addressed to such stockholder at the address of such stockholder as it appears on the Corporation&#146;s stock transfer books. Without limiting the manner by which notice may otherwise be given to
stockholders, any notice to stockholders may be given by electronic transmission in the manner provided in Section&nbsp;232 of the DGCL. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Notice of all special meetings of stockholders shall be given in the same manner as provided for Annual Meetings, except that the notice of
all special meetings shall also state the purpose or purposes for which the meeting has been called. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Notice of an Annual Meeting or
special meeting of stockholders need not be given to a stockholder if a waiver of notice is executed, or waiver of notice by electronic transmission is provided, before or after such meeting by such stockholder or if such stockholder attends such
meeting, unless such attendance is for the express purpose of objecting at the beginning of the meeting to the transaction of any business because the meeting was not lawfully called or convened. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Board of Directors may postpone and reschedule or cancel any previously scheduled
Annual Meeting or special meeting of stockholders and any record date with respect thereto, regardless of whether any notice or public disclosure with respect to any such meeting has been sent or made pursuant to Section&nbsp;2 of this
Article&nbsp;I or otherwise. In no event shall the public announcement of an adjournment, postponement or rescheduling of any previously scheduled meeting of stockholders commence a new time period for the giving of a stockholder&#146;s notice under
this Article I. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) When any meeting is convened, the chair of the meeting or the stockholders present or represented by proxy at such
meeting may adjourn the meeting from time to time for any reason, regardless of whether a quorum is present, to reconvene at any other time and at any place at which a meeting of stockholders may be held under these Bylaws. When any Annual Meeting
or special meeting of stockholders is adjourned to another hour, date or place (including an adjournment taken to address a technical failure to convene or continue a meeting using remote communication), notice need not be given of the adjourned
meeting if the time, place, if any, thereof and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting are (i)&nbsp;announced at the meeting at
which the adjournment is taken, (ii)&nbsp;displayed, during the time scheduled for the meeting, on the same electronic network used to enable stockholders and proxy holders to participate in the meeting by means of remote communication or
(iii)&nbsp;set forth in the notice of meeting given in accordance with this Section&nbsp;4; provided, however, that if the adjournment is for more than thirty (30)&nbsp;days from the meeting date, or if after the adjournment a new record date is
fixed for the adjourned meeting, notice of the adjourned meeting and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting shall be given to each
stockholder of record entitled to vote thereat and each stockholder who, by law or under the Certificate of Incorporation of the Corporation (as the same may hereafter be amended and/or restated, the &#147;<B>Certificate</B>&#148;) or these Bylaws,
is entitled to such notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Quorum</U>. Except as otherwise provided by law, the certificate of incorporation or these
Bylaws, at each meeting of stockholders, the presence in person or by remote communication, if applicable, or represented by proxy, of the holders of a majority in voting power of the outstanding shares of stock entitled to vote at the meeting shall
be necessary and sufficient to constitute a quorum. If less than a quorum is present at a meeting, the chair of the meeting or the holders of voting stock, by the affirmative vote of a majority of the voting power present in person or by proxy and
entitled to vote thereon, may adjourn the meeting from time to time, and the meeting may be held as adjourned without further notice, except as otherwise provided in Section&nbsp;4 of this Article&nbsp;I. At such adjourned meeting at which a quorum
is present, any business may be transacted which might have been transacted at the meeting as originally noticed. The stockholders present at a duly constituted meeting may continue to transact business until adjournment, notwithstanding the
withdrawal of enough stockholders to leave less than a quorum. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Voting and Proxies</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The stockholders entitled to vote at any meeting of stockholders shall be determined in accordance with the provisions of Article IV,
Section&nbsp;4<B> </B>of these Bylaws, subject to Section&nbsp;217 (relating to voting rights of fiduciaries, pledgors and joint owners of stock) and Section&nbsp;218 (relating to voting trusts and other voting agreements) of the DGCL. Stockholders
shall have one vote for each share of stock entitled to vote owned by them of record according to the stock ledger of the Corporation as of the record date, unless otherwise provided by law or by the Certificate. Stockholders may vote either
(i)&nbsp;in person, (ii)&nbsp;by written proxy or (iii)&nbsp;by a transmission permitted by Section&nbsp;212(c) of the DGCL. Any copy, facsimile telecommunication or other reliable reproduction of the writing or transmission permitted by
Section&nbsp;212(c) of the DGCL may be substituted for or used in lieu of the original writing or transmission for any and all purposes for which the original writing or transmission could be used, provided that such copy, facsimile
telecommunication or other reproduction shall be a complete reproduction of the entire original writing or transmission. Proxies shall be filed in accordance with the procedures established for the meeting of stockholders. A proxy with respect to
stock held in the name of two or more persons shall be valid if executed by or on behalf of any one of them unless at or prior to the exercise of the proxy the Corporation receives a specific written notice to the contrary from any one of them. In
the event the Corporation receives proxies for disqualified or withdrawn nominees for the Board of Directors, such votes for such disqualified or withdrawn nominees in the proxies will be treated as abstentions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Any stockholder directly or indirectly soliciting proxies from other stockholders must use a proxy card color other than white, which shall
be reserved for the exclusive use by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>Action at Meeting</U>. When a quorum is present at any meeting
of stockholders, any matter before any such meeting (other than an election of a director or directors) shall be decided by a majority of the votes properly cast for and against such matter, except where a larger vote is required by law, by the
Certificate or by these Bylaws. Any election of directors by stockholders shall be determined by a plurality of the votes properly cast on the election of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8. <U>Stockholder Lists</U>. The Corporation shall prepare, no later than the tenth
(10<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) day before each Annual Meeting or special meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the
address of each stockholder and the number of shares registered in the name of each stockholder; provided, however, that if the record date for determining the stockholders entitled to vote is less than ten (10)&nbsp;days before the meeting date,
the list shall reflect the stockholders entitled to vote as of the tenth (10th) day before the meeting date. Such list shall be open to the examination of any stockholder for any purpose germane to the meeting for a period of ten (10)&nbsp;days
ending on the day before the meeting date in the manner provided by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9. <U>Conduct of Meeting</U>. The Board of Directors may
adopt by resolution such rules, regulations and procedures for the conduct of any meeting of stockholders as it shall deem appropriate. Except to the extent inconsistent with rules, regulations and procedures adopted by the Board of Directors, the
chair of the meeting shall have the right to prescribe such rules, regulations and procedures and to do all such acts, as, in the judgment of such chair, are necessary, appropriate or convenient for the proper conduct of the meeting. Such rules,
regulations or procedures, whether adopted by the Board of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Directors or the chair of the meeting, may include, without limitation, the following: (a)&nbsp;the establishment of an agenda for the meeting; (b)&nbsp;rules and procedures for maintaining order
at the meeting and the safety of those present at the meeting; (c)&nbsp;limitations on attendance at or participation in the meeting to stockholders of record of the Corporation, their duly authorized and constituted proxies, or such other persons
as the chair of the meeting shall determine; (d)&nbsp;restrictions on entry to the meeting after the time fixed for the commencement thereof; (e)&nbsp;the determination of the circumstances in which any person may make a statement or ask questions
and limitations on the time allotted to questions or comments; (f)&nbsp;the determination of when the polls shall open and close for any given matter to be voted on at the meeting; (g)&nbsp;the exclusion or removal of any stockholders or any other
individual who refuses to comply with meeting rules, regulations, or procedures; (h)&nbsp;restrictions on the use of audio and video recording devices, cell phones and other electronic devices; (i)&nbsp;rules, regulations and procedures for
compliance with any federal, state or local laws or regulations (including those concerning safety, health or security); (j) procedures (if any) requiring attendees to provide the Corporation advance notice of their intent to attend the meeting; and
(k)&nbsp;rules, regulations or procedures regarding the participation by means of remote communication of stockholders and proxy holders not physically present at a meeting, whether such meeting is to be held at a designated place or solely by means
of remote communication. The chair of the meeting shall be: (i)&nbsp;such person as the Board of Directors shall have designated to preside over all meetings of the stockholders; (ii)&nbsp;if the Board of Directors has not so designated such a chair
of the meeting or if the chair of the meeting is unable to so preside or is absent, then the Chairperson of the Board, if one is elected; (iii)&nbsp;if the Board of Directors has not so designated a chair of the meeting and there is no Chairperson
of the Board, or if the chair of the meeting or the Chairperson of the Board is unable to so preside or is absent, then the Chief Executive Officer, if one is elected; or (iv)&nbsp;in the absence or inability to serve of any of the aforementioned
persons, the President of the Corporation. Unless and to the extent determined by the Board of Directors or the chair of the meeting, the chair of the meeting shall not be obligated to adopt or follow any technical, formal or parliamentary rules or
principles of procedure. In the absence of the Secretary of the Corporation, the secretary of the meeting shall be such person as the chair of the meeting appoints. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10. <U>Inspectors of Elections</U>. The Corporation shall, in advance of any meeting of stockholders, appoint one or three inspectors
to act at the meeting and make a written report thereof. The Corporation may designate one or more persons as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders,
the chair of the meeting officer shall appoint one or more inspectors to act at the meeting. Any inspector may, but need not, be an officer, employee or agent of the Corporation. Each inspector, before entering upon the discharge of his or her
duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of his or her ability. The inspectors shall perform such duties as are required by the DGCL, including the counting
of all votes and ballots. The inspectors may appoint or retain other persons or entities to assist the inspectors in the performance of the duties of the inspectors. The chair of the meeting may review all determinations made by the inspectors, and
in so doing the chair of the meeting shall be entitled to exercise his or her sole judgment and discretion and he or she shall not be bound by any determinations made by the inspectors. All determinations by the inspectors and, if applicable, the
chair of the meeting, shall be subject to further review by any court of competent jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE II </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Directors </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.
<U>Powers</U>. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors, except as otherwise provided by the Certificate or required by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Number and Terms</U>. The number of directors of the Corporation shall be fixed solely and exclusively by resolution duly
adopted from time to time by the Board of Directors, provided the Board of Directors shall consist of at least one (1)&nbsp;member. The directors shall hold office in the manner provided in the Certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Qualification</U>. No director need be a stockholder of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Vacancies</U>. Vacancies in the Board of Directors shall be filled in the manner provided in the Certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Removal</U>. Directors may be removed from office only in the manner provided in the Certificate or by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Resignation</U>. A director may resign at any time by electronic transmission or by giving written notice to the Chairperson of
the Board, if one is elected, the President or the Secretary. A resignation shall be effective upon receipt, unless the resignation otherwise provides. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>Regular Meetings</U>. Regular meetings of the Board of Directors may be held at such hour, date and place (if any) as the Board
of Directors may from time to time determine and publicize by means of reasonable notice given to any director who is not present when such determination is made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8. <U>Special Meetings</U>. Special meetings of the Board of Directors may be called, orally or in writing, by or at the request of a
majority of the directors, the Chairperson of the Board, if one is elected, or the President. The person calling any such special meeting of the Board of Directors may fix the hour, date and place (if any) thereof. Notice thereof shall be given to
each director as provided in Section&nbsp;9 of this Article II. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9. <U>Notice of Meetings</U>. Notice of the hour, date and place
(if any) of all special meetings of the Board of Directors shall be given to each director by the Secretary or an Assistant Secretary, or in case of the death, absence, incapacity or refusal of such persons, by the Chairperson of the Board, if one
is elected, the President or such other officer designated by the Chairperson of the Board, if one is elected, or any one of the directors calling the meeting. Notice of any special meeting of the Board of Directors shall be given to each director
in person, by telephone, or by facsimile, electronic mail or other form of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
electronic communication, sent to his or her business or home address, at least twenty-four (24)&nbsp;hours in advance of the meeting, or by written notice mailed to his or her business or home
address, at least forty-eight (48)&nbsp;hours in advance of the meeting provided, however, that if the person or persons calling the meeting determine that it is otherwise necessary or advisable to hold the meeting sooner, then such person or
persons may prescribe a shorter time period for notice to be given personally or by telephone, facsimile, electronic mail or other similar means of communication. Such notice shall be deemed to be delivered when hand-delivered to such address; read
to such director by telephone; deposited in the mail so addressed, with postage thereon prepaid, if mailed; or dispatched or transmitted if sent by facsimile transmission or by electronic mail or other form of electronic communication. A written
waiver of notice signed or electronically transmitted before or after a meeting by a director and filed with the records of the meeting shall be deemed to be equivalent to notice of the meeting. The attendance of a director at a meeting shall
constitute a waiver of notice of such meeting, except where a director attends a meeting for the express purpose of objecting at the beginning of the meeting to the transaction of any business because such meeting is not lawfully called or convened.
Except as otherwise required by law, by the Certificate or by these Bylaws, neither the business to be transacted at, nor the purpose of, any meeting of the Board of Directors need be specified in the notice or waiver of notice of such meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10. <U>Quorum</U>. At any meeting of the Board of Directors, a majority of the total number of directors shall constitute a quorum for
the transaction of business, but if less than a quorum is present at a meeting, a majority of the directors present may adjourn the meeting from time to time, and the meeting may be held as adjourned without further notice. Any business that might
have been transacted at the meeting as originally noticed may be transacted at such adjourned meeting at which a quorum is present. For purposes of this Article II, the total number of directors includes any unfilled vacancies on the Board of
Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 11. <U>Action at Meeting</U>. At any meeting of the Board of Directors at which a quorum is present, the affirmative
vote of a majority of the directors present shall constitute action by the Board of Directors, unless otherwise required by law, by the Certificate or by these Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 12. <U>Action by Consent</U>. Any action required or permitted to be taken at any meeting of the Board of Directors may be taken
without a meeting if all members of the Board of Directors consent thereto in writing or by electronic transmission. After such action is taken, the writing or writings or electronic transmission or transmissions shall be filed with the records of
the meetings of the Board of Directors. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form. Such consent shall be treated as a resolution of
the Board of Directors for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 13. <U>Manner of Participation</U>. Directors may participate in meetings of the Board
of Directors by means of video conference, conference telephone or other communications equipment by means of which all directors participating in the meeting can hear each other, and participation in a meeting in accordance herewith shall
constitute presence in person at such meeting for purposes of these Bylaws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 14. <U>Presiding Director</U>. The Board of Directors shall designate a
representative to preside over all meetings of the Board of Directors, provided that if the Board of Directors does not so designate such a presiding director or such designated presiding director is unable to so preside or is absent, then the
Chairperson of the Board, if one is elected, shall preside over all meetings of the Board of Directors. If both the designated presiding director, if one is so designated, and the Chairperson of the Board, if one is elected, are unable to preside or
are absent, the Board of Directors shall designate an alternate representative to preside over a meeting of the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 15. <U>Committees</U>. The Board of Directors may designate one or more committees, including, without limitation, a Compensation
Committee, a Nominating&nbsp;&amp; Corporate Governance Committee and an Audit Committee, and may delegate thereto some or all of its powers to such committee(s) except those which by law, by the Certificate or by these Bylaws may not be delegated.
Except as the Board of Directors may otherwise determine, any such committee may make rules for the conduct of its business, but unless otherwise provided by the Board of Directors or in such rules, its business shall be conducted so far as possible
in the same manner as is provided by these Bylaws for the Board of Directors. All members of such committees shall hold such offices at the pleasure of the Board of Directors. The Board of Directors may abolish any such committee at any time. Any
committee to which the Board of Directors delegates any of its powers or duties shall keep records of its meetings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 16.
<U>Compensation of Directors</U>. Directors shall receive such compensation for their services as shall be determined by the Board of Directors, or a designated committee thereof, provided that directors who are serving the Corporation as employees
shall not receive any salary or other compensation for their services as directors of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 17. <U>Emergency <FONT
STYLE="white-space:nowrap">By-laws</FONT></U>. In the event of any emergency, disaster, catastrophe or other similar emergency condition of a type described in Section&nbsp;110(a) of the DGCL (an &#147;<B>Emergency</B>&#148;), notwithstanding any
different or conflicting provisions in the DGCL, the Certificate or these <FONT STYLE="white-space:nowrap">By-laws,</FONT> during such Emergency: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) A meeting of the Board of Directors or a committee thereof may be called by any director, the Chairperson of the Board, the Chief Executive
Officer, the President or the Secretary by such means as, in the judgment of the person calling the meeting, may be feasible at the time, and notice of any such meeting of the Board of Directors or any committee may be given, in the judgment of the
person calling the meeting, only to such directors as it may be feasible to reach at the time and by such means as may be feasible at the time. Such notice shall be given at such time in advance of the meeting as, in the judgment of the person
calling the meeting, circumstances permit. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The director or directors in attendance at a meeting called in accordance with
Section&nbsp;17(a) of this Article II shall constitute a quorum. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) No officer, director or employee acting in accordance with this Section&nbsp;17 shall be
liable except for willful misconduct. No amendment, repeal or change to this Section&nbsp;17 shall modify the prior sentence with regard to actions taken prior to the time of such amendment, repeal or change. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE III </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Officers
</U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1. <U>Enumeration</U>. The officers of the Corporation shall consist of a President, a Treasurer, a Secretary and such other
officers, including, without limitation, a Chairperson of the Board, a Chief Executive Officer and one or more Vice Presidents (including Executive Vice Presidents or Senior Vice Presidents), Assistant Vice Presidents, Assistant Treasurers and
Assistant Secretaries, as the Board of Directors may determine. Any number of offices may be held by the same person. The salaries and other compensation of the officers of the Corporation will be fixed by or in the manner designated by the Board of
Directors or a committee thereof to which the Board of Directors has delegated such responsibility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Election</U>. The Board
of Directors shall elect the President, the Treasurer and the Secretary. Other officers may be elected by the Board of Directors or by such officers delegated such authority by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Qualification</U>. No officer need be a stockholder or a director.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Tenure</U>. Except as otherwise provided by the Certificate or by these Bylaws, each of the officers of the Corporation shall
hold office until his or her successor is elected and qualified or until his or her earlier death, resignation or removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5.
<U>Resignation and Removal</U>. Any officer may resign by delivering his or her written or electronically transmitted resignation to the Corporation addressed to the President or the Secretary, and such resignation shall be effective upon receipt,
unless the resignation otherwise provides. Any resignation is without prejudice to the rights, if any, of the Corporation under any contract to which the officer is a party. Except as otherwise provided by law or by resolution of the Board of
Directors, the Board of Directors may remove any officer. Except as the Board of Directors may otherwise determine, no officer who resigns or is removed shall have any right to any compensation as an officer for any period following his or her
resignation or removal, or any right to damages on account of such removal, whether his or her compensation be by the month or by the year or otherwise, unless such compensation is expressly provided in a duly authorized written agreement with the
Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Absence or Disability</U>. In the event of the absence or disability of any officer, the Board of Directors
may designate another officer to act temporarily in place of such absent or disabled officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>Vacancies</U>. Any vacancy in
any office may be filled for the unexpired portion of the term by the Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8. <U>President</U>. The President shall, subject to the direction of the Board of
Directors, have such powers and shall perform such duties as the Board of Directors may from time to time designate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9.
<U>Chairperson of the Board</U>. The Chairperson of the Board, if one is elected, shall have such powers and shall perform such duties as the Board of Directors may from time to time designate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10. <U>Chief Executive Officer</U>. The Chief Executive Officer, if one is elected, shall have such powers and shall perform such
duties as the Board of Directors may from time to time designate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 11. <U>Vice Presidents and Assistant Vice Presidents</U>. Any
Vice President (including any Executive Vice President or Senior Vice President) and any Assistant Vice President shall have such powers and shall perform such duties as the Board of Directors or the Chief Executive Officer may from time to time
designate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 12. <U>Treasurer and Assistant Treasurers</U>. The Treasurer shall, subject to the direction of the Board of Directors
and except as the Board of Directors or the Chief Executive Officer may otherwise provide, have general charge of the financial affairs of the Corporation and shall cause to be kept accurate books of account. The Treasurer shall have custody of all
funds, securities and valuable documents of the Corporation. He or she shall have such other duties and powers as may be designated from time to time by the Board of Directors or the Chief Executive Officer. Any Assistant Treasurer shall have such
powers and perform such duties as the Board of Directors or the Chief Executive Officer may from time to time designate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 13.
<U>Secretary and Assistant Secretaries</U>. The Secretary shall record all the proceedings of the meetings of the stockholders and the Board of Directors (including committees of the Board of Directors) in books kept for that purpose. In his or her
absence from any such meeting, a temporary secretary chosen at the meeting shall record the proceedings thereof. The Secretary shall have charge of the stock ledger (which may, however, be kept by any transfer or other agent of the Corporation). The
Secretary shall have custody of the seal of the Corporation, and the Secretary or an Assistant Secretary shall have authority to affix it to any instrument requiring it, and, when so affixed, the seal may be attested by his or her signature or that
of an Assistant Secretary. The Secretary shall have such other duties and powers as may be designated from time to time by the Board of Directors or the Chief Executive Officer. In the absence of the Secretary, any Assistant Secretary may perform
his or her duties and responsibilities. Any Assistant Secretary shall have such powers and perform such duties as the Board of Directors or the Chief Executive Officer may from time to time designate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 14. <U>Other Powers and Duties</U>. Subject to these Bylaws and to such limitations as the Board of Directors may from time to time
prescribe, the officers of the Corporation shall each have such powers and duties as generally pertain to their respective offices, as well as such powers and duties as from time to time may be conferred by the Board of Directors or the Chief
Executive Officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 15. <U>Representation of Shares of Other Corporations</U>. The Chairperson of the
Board, the President, any Vice President, the Treasurer, the Secretary or Assistant Secretary of this Corporation, or any other person authorized by the Board of Directors or the President or a Vice President, is authorized to vote, represent and
exercise on behalf of this Corporation all rights incident to any and all securities of any other entity or entities standing in the name of this Corporation. The authority granted herein may be exercised either by such person directly or by any
other person authorized to do so by proxy or power of attorney duly executed by such person having the authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 16. <U>Bonded
Officers</U>. The Board of Directors may require any officer to give the Corporation a bond in such sum and with such surety or sureties as shall be satisfactory to the Board of Directors upon such terms and conditions as the Board of Directors may
specify, including, without limitation, a bond for the faithful performance of his or her duties and for the restoration to the Corporation of all property in his or her possession or under his or her control belonging to the Corporation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE IV </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Capital
Stock </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1. <U>Certificates of Stock</U>. Each stockholder shall be entitled to a certificate of the capital stock of the
Corporation in such form as may from time to time be prescribed by the Board of Directors. Such certificate shall be signed by any two authorized officers of the Corporation. The Corporation seal and the signatures by the Corporation&#146;s
officers, the transfer agent or the registrar may be facsimiles. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed on such certificate shall have ceased to be such officer, transfer agent or
registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if he or she were such officer, transfer agent or registrar at the time of its issue. Every certificate for shares of stock which are subject to
any restriction on transfer and every certificate issued when the Corporation is authorized to issue more than one class or series of stock shall contain such legend with respect thereto as is required by law. Notwithstanding anything to the
contrary provided in these Bylaws, the Board of Directors may provide by resolution or resolutions that some or all of any or all classes or series of its stock shall be uncertificated shares (except that the foregoing shall not apply to shares
represented by a certificate until such certificate is surrendered to the Corporation), and by the approval and adoption of these Bylaws, the Board of Directors has determined that all classes or series of the Corporation&#146;s stock may be
uncertificated, whether upon original issuance, <FONT STYLE="white-space:nowrap">re-issuance</FONT> or subsequent transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2.
<U>Transfers</U>. Subject to any restrictions on transfer and unless otherwise provided by the Board of Directors, shares of stock that are represented by a certificate may be transferred on the books of the Corporation by the surrender to the
Corporation or its transfer agent of the certificate therefor properly endorsed or accompanied by a written assignment or power of attorney properly executed, with transfer stamps (if necessary) affixed, and with such proof of the authenticity of
signature as the Corporation or its transfer agent may reasonably require. Shares of stock that are not represented by a certificate may be transferred on the books of the Corporation by submitting to the Corporation or its transfer agent such
evidence of transfer and following such other procedures as the Corporation or its transfer agent may require. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Stock Transfer Agreements</U>. The Corporation shall have power to enter into
and perform any agreement with any number of stockholders of any one or more classes of stock of the Corporation to restrict the transfer of shares of stock of the Corporation of any one or more classes owned by such stockholders in any manner not
prohibited by the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Record Holders</U>. Except as may otherwise be required by law, by the Certificate or by these
Bylaws, the Corporation shall be entitled to treat the record holder of stock as shown on its books as the owner of such stock for all purposes, including the payment of dividends and the right to vote with respect thereto, regardless of any
transfer, pledge or other disposition of such stock, until the shares have been transferred on the books of the Corporation in accordance with the requirements of these Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Record Date</U>. In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of
stockholders or any adjournment thereof or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose
of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date: (a)&nbsp;in the case
of determination of stockholders entitled to vote at any meeting of stockholders, shall, unless otherwise required by law, not be more than sixty (60)&nbsp;nor less than ten (10)&nbsp;days before the date of such meeting and (b)&nbsp;in the case of
any other action, shall not be more than sixty (60)&nbsp;days prior to such other action. If no record date is fixed: (i)&nbsp;the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at
5:00 p.m. Eastern time on the day next preceding the day on which notice is given, or, if notice is waived, at 5:00 p.m. Eastern time on the day next preceding the day on which the meeting is held; and (ii)&nbsp;the record date for determining
stockholders for any other purpose shall be at 5:00 p.m. Eastern time on the day on which the Board of Directors adopts the resolution relating thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Replacement of Certificates</U>. In case of the alleged loss, destruction or mutilation of a certificate of stock of the
Corporation, a duplicate certificate may be issued in place thereof, upon such terms as the Board of Directors may prescribe. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE V </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Indemnification </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION
1. <U>Definitions</U>. For purposes of this Article V: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &#147;Corporate Status&#148; describes the status of a person who is serving or
has served (i)&nbsp;as a Director of the Corporation, (ii)&nbsp;as an Officer of the Corporation, (iii)&nbsp;as a <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee of the Corporation or (iv)&nbsp;as a director, partner, trustee, officer,
employee or agent of any other corporation, partnership, limited liability company, joint venture, trust, employee benefit plan, foundation, association, organization or other legal entity which such person is or was serving at the request of the
Corporation. For purposes of this Section&nbsp;1(a), a Director, Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee of the Corporation who is serving or has served as a director, partner, trustee, officer, employee or agent of a
Subsidiary shall be deemed to be serving at the request of the Corporation. Notwithstanding the foregoing, &#147;Corporate Status&#148; shall not include the status of a person who is serving or has served as a director, officer, employee or agent
of a constituent corporation absorbed in a merger or consolidation transaction with the Corporation with respect to such person&#146;s activities prior to said transaction, unless specifically authorized by the Board of Directors or the stockholders
of the Corporation; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) &#147;Director&#148; means any person who serves or has served the Corporation as a director on the Board of
Directors of the Corporation; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) &#147;Disinterested Director&#148; means, with respect to each Proceeding in respect of which
indemnification is sought hereunder, a Director of the Corporation who is not and was not a party to such Proceeding; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)
&#147;Expenses&#148; means all attorneys&#146; fees, retainers, court costs, transcript costs, fees of expert witnesses, private investigators and professional advisors (including, without limitation, accountants and investment bankers), travel
expenses, duplicating costs, printing and binding costs, costs of preparation of demonstrative evidence and other courtroom presentation aids and devices, costs incurred in connection with document review, organization, imaging and computerization,
telephone charges, postage, delivery service fees, and all other disbursements, costs or expenses of the type customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a
witness in, settling or otherwise participating in, a Proceeding; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) &#147;Liabilities&#148; means judgments, damages, liabilities,
losses, penalties, excise taxes, fines and amounts paid in settlement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <FONT STYLE="white-space:nowrap">&#147;Non-Officer</FONT>
Employee&#148; means any person who serves or has served as an employee or agent of the Corporation, but who is not or was not a Director or Officer; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) &#147;Officer&#148; means any person who serves or has served the Corporation as an officer of the Corporation appointed by the Board of
Directors of the Corporation; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) &#147;Proceeding&#148; means any threatened, pending or completed action, suit, arbitration, alternate
dispute resolution mechanism, inquiry, investigation, administrative hearing or other proceeding, whether civil, criminal, administrative, arbitrative or investigative; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) &#147;Subsidiary&#148; means any corporation, partnership, limited liability company, joint venture, trust or other entity of which the
Corporation owns (either directly or through or together with another Subsidiary of the Corporation) either (i)&nbsp;a general partner, managing member or other similar interest or (ii)&nbsp;(A) fifty percent (50%) or more of the voting power of the
voting capital equity interests of such corporation, partnership, limited liability company, joint venture or other entity, or (B)&nbsp;fifty percent (50%) or more of the outstanding voting capital stock or other voting equity interests of such
corporation, partnership, limited liability company, joint venture or other entity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Indemnification of Directors and Officers</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Subject to the operation of Section&nbsp;4 of this Article V, each Director and Officer shall be indemnified and held harmless by the
Corporation to the fullest extent authorized by the DGCL, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification
rights than such law permitted the Corporation to provide prior to such amendment), and to the extent authorized in this Section&nbsp;2. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) <U>Actions, Suits and Proceedings Other than By or In the Right of the Corporation</U>. Each Director and Officer shall be
indemnified and held harmless by the Corporation against any and all Expenses and Liabilities that are incurred or paid by such Director or Officer or on such Director&#146;s or Officer&#146;s behalf in connection with any Proceeding or any claim,
issue or matter therein (other than an action by or in the right of the Corporation), which such Director or Officer is, or is threatened to be made, a party to or participant in by reason of such Director&#146;s or Officer&#146;s Corporate Status,
if such Director or Officer acted in good faith and in a manner such Director or Officer reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect to any criminal proceeding, had no reasonable cause to
believe his or her conduct was unlawful. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) <U>Actions, Suits and Proceedings By or In the Right of the Corporation</U>.
Each Director and Officer shall be indemnified and held harmless by the Corporation against any and all Expenses that are incurred by such Director or Officer or on such Director&#146;s or Officer&#146;s behalf in connection with any Proceeding or
any claim, issue or matter therein by or in the right of the Corporation, which such Director or Officer is, or is threatened to be made, a party to or participant in by reason of such Director&#146;s or Officer&#146;s Corporate Status, if such
Director or Officer acted in good faith and in a manner such Director or Officer reasonably believed to be in or not opposed to the best interests of the Corporation; provided, however, that no indemnification shall be made under this
Section&nbsp;2(a)(2) in respect of any claim, issue or matter as to which such Director or Officer shall have been finally adjudged by a court of competent jurisdiction to be liable to the Corporation, unless, and only to the extent that, the Court
of Chancery of the State of Delaware or another court in which such Proceeding was brought shall determine upon application that, despite adjudication of liability, but in view of all the circumstances of the case, such Director or Officer is fairly
and reasonably entitled to indemnification for such Expenses that such court deems proper.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) <U>Survival of Rights</U>. The rights of indemnification provided by this Section&nbsp;2 shall continue as to a Director or
Officer after he or she has ceased to be a Director or Officer and shall inure to the benefit of his or her heirs, executors, administrators and personal representatives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) <U>Actions by Directors or Officers</U>. Notwithstanding the foregoing,
the Corporation shall indemnify any Director or Officer seeking indemnification in connection with a Proceeding initiated by such Director or Officer only if such Proceeding (including any parts of such Proceeding not initiated by such Director or
Officer) was authorized in advance by the Board of Directors, unless such Proceeding was brought to enforce such Officer&#146;s or Director&#146;s rights to indemnification or, in the case of Directors, advancement of Expenses under these Bylaws in
accordance with the provisions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Indemnification of <FONT STYLE="white-space:nowrap">Non-Officer</FONT>
Employees</U>. Subject to the operation of Section&nbsp;4 of this Article V, each <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee may, in the discretion of the Board of Directors, be indemnified by the Corporation to the fullest extent
authorized by the DGCL, as the same exists or may hereafter be amended, against any or all Expenses and Liabilities that are incurred by such <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee or on such
<FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee&#146;s behalf in connection with any threatened, pending or completed Proceeding, or any claim, issue or matter therein, which such <FONT STYLE="white-space:nowrap">Non-Officer</FONT>
Employee is, or is threatened to be made, a party to or participant in by reason of such <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee&#146;s Corporate Status, if such <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee acted
in good faith and in a manner such <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect to any criminal proceeding, had no reasonable
cause to believe his or her conduct was unlawful. The rights of indemnification provided by this Section&nbsp;3 shall exist as to a <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee after he or she has ceased to be a <FONT
STYLE="white-space:nowrap">Non-Officer</FONT> Employee and shall inure to the benefit of his or her heirs, personal representatives, executors and administrators. Notwithstanding the foregoing, the Corporation may indemnify any <FONT
STYLE="white-space:nowrap">Non-Officer</FONT> Employee seeking indemnification in connection with a Proceeding initiated by such <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee only if such Proceeding was authorized in advance by the
Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Determination</U>. Unless ordered by a court, no indemnification shall be provided pursuant to this
Article V to a Director, to an Officer or to a <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee unless a determination shall have been made that such person acted in good faith and in a manner such person reasonably believed to be in or
not opposed to the best interests of the Corporation and, with respect to any criminal Proceeding, such person had no reasonable cause to believe his or her conduct was unlawful. Such determination shall be made by (a)&nbsp;a majority vote of the
Disinterested Directors, even though less than a quorum of the Board of Directors, (b)&nbsp;a committee comprised of Disinterested Directors, such committee having been designated by a majority vote of the Disinterested Directors (even though less
than a quorum), (c) if there are no such Disinterested Directors, or if a majority of Disinterested Directors so directs, by independent legal counsel in a written opinion or (d)&nbsp;by the stockholders of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Advancement of Expenses to Directors Prior to Final Disposition</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Corporation shall advance all Expenses incurred by or on behalf of any Director in connection with any Proceeding in which such
Director is involved by reason of such Director&#146;s Corporate Status within thirty (30)&nbsp;days after the receipt by the Corporation of a written statement from such Director requesting such advance or advances from time to time,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by such Director and shall be preceded or accompanied
by an undertaking by or on behalf of such Director to repay any Expenses so advanced if it shall ultimately be determined that such Director is not entitled to be indemnified against such Expenses. Notwithstanding the foregoing, the Corporation
shall advance all Expenses incurred by or on behalf of any Director seeking advancement of expenses hereunder in connection with a Proceeding initiated by such Director only if such Proceeding (including any parts of such Proceeding not initiated by
such Director) was (i)&nbsp;authorized by the Board of Directors or (ii)&nbsp;brought to enforce such Director&#146;s rights to indemnification or advancement of Expenses under these Bylaws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If a claim for advancement of Expenses hereunder by a Director is not paid in full by the Corporation within thirty (30)&nbsp;days after
receipt by the Corporation of documentation of Expenses and the required undertaking, such Director may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim and, if successful in whole or in part, such
Director shall also be entitled to be paid the expenses of prosecuting such claim. The failure of the Corporation (including its Board of Directors or any committee thereof, independent legal counsel or stockholders) to make a determination
concerning the permissibility of such advancement of Expenses under this Article V shall not be a defense to an action brought by a Director for recovery of the unpaid amount of an advancement claim and shall not create a presumption that such
advancement is not permissible. The burden of proving that a Director is not entitled to an advancement of expenses shall be on the Corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) In any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall
be entitled to recover such expenses upon a final adjudication that the Director has not met any applicable standard for indemnification set forth in the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Advancement of Expenses to Officers and <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employees Prior to Final
Disposition</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Corporation may, at the discretion of the Board of Directors, advance any or all Expenses incurred by or on
behalf of any Officer or any <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee in connection with any Proceeding in which such person is involved by reason of his or her Corporate Status as an Officer or
<FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee upon the receipt by the Corporation of a statement or statements from such Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee requesting such advance or advances from
time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by such Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee and shall be
preceded or accompanied by an undertaking by or on behalf of such person to repay any Expenses so advanced if it shall ultimately be determined that such Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee is not entitled to be
indemnified against such Expenses. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms
of an undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that the Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee has not met any applicable standard for indemnification set
forth in the DGCL. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>Contractual Nature of Rights</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The provisions of this Article&nbsp;V shall be deemed to be a contract between the Corporation and each Director and Officer entitled to
the benefits hereof at any time while this Article&nbsp;V is in effect, in consideration of such person&#146;s past or current and any future performance of services for the Corporation. Neither amendment, repeal or modification of any provision of
this Article&nbsp;V nor the adoption of any provision of the Certificate inconsistent with this Article&nbsp;V shall eliminate or reduce any right conferred by this Article&nbsp;V in respect of any act or omission occurring, or any cause of action
or claim that accrues or arises or any state of facts existing, at the time of or before such amendment, repeal, modification or adoption of an inconsistent provision (even in the case of a proceeding based on such a state of facts that is commenced
after such time), and all rights to indemnification and advancement of Expenses granted herein or arising out of any act or omission shall vest at the time of the act or omission in question, regardless of when or if any proceeding with respect to
such act or omission is commenced. The rights to indemnification and to advancement of expenses provided by, or granted pursuant to, this Article&nbsp;V shall continue notwithstanding that the person has ceased to be a director or officer of the
Corporation and shall inure to the benefit of the estate, heirs, executors, administrators, legatees and distributees of such person. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
If a claim for indemnification hereunder by a Director or Officer is not paid in full by the Corporation within sixty (60)&nbsp;days after receipt by the Corporation of a written claim for indemnification, such Director or Officer may at any time
thereafter bring suit against the Corporation to recover the unpaid amount of the claim, and if successful in whole or in part, such Director or Officer shall also be entitled to be paid the expenses of prosecuting such claim. The failure of the
Corporation (including its Board of Directors or any committee thereof, independent legal counsel or stockholders) to make a determination concerning the permissibility of such indemnification under this Article V shall not be a defense to an action
brought by a Director or Officer for recovery of the unpaid amount of an indemnification claim and shall not create a presumption that such indemnification is not permissible. The burden of proving that a Director or Officer is not entitled to
indemnification shall be on the Corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) In any suit brought by a Director or Officer to enforce a right to indemnification
hereunder, it shall be a defense that such Director or Officer has not met any applicable standard for indemnification set forth in the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8. <U><FONT STYLE="white-space:nowrap">Non-Exclusivity</FONT> of Rights</U>. The rights to indemnification and to advancement of
Expenses set forth in this Article V shall not be exclusive of any other right that any Director, Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee may have or hereafter acquire under any statute, provision of the Certificate
or these Bylaws, agreement, vote of stockholders or Disinterested Directors or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9. <U>Insurance</U>. The Corporation
may maintain insurance, at its expense, to protect itself and any Director, Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee against any liability of any character asserted against or incurred by the Corporation or any such
Director, Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee, or arising out of any such person&#146;s Corporate Status, whether or not the Corporation would have the power to indemnify such person against such liability under
the DGCL or the provisions of this Article&nbsp;V. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10. <U>Other Indemnification</U>. The Corporation&#146;s obligation, if any, to
indemnify or provide advancement of Expenses to any person under this Article V as a result of such person serving, at the request of the Corporation, as a director, partner, trustee, officer, employee or agent of another corporation, partnership,
joint venture, trust, employee benefit plan or other enterprise shall be reduced by any amount such person may collect as indemnification or advancement of Expenses from such other corporation, partnership, joint venture, trust, employee benefit
plan or enterprise (the &#147;<B>Primary Indemnitor</B>&#148;). Any indemnification or advancement of Expenses under this Article V owed by the Corporation as a result of a person serving, at the request of the Corporation, as a director, partner,
trustee, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall only be in excess of, and shall be secondary to, the indemnification or advancement of Expenses available
from the applicable Primary Indemnitor(s) and any applicable insurance policies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 11. <U>Savings Clause</U>. If this Article V or
any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the Corporation shall nevertheless indemnify each indemnitee as to any expenses (including, without limitation, attorneys&#146; fees), liabilities,
losses, judgments, fines (including, without limitation, excise taxes and penalties arising under the Employee Retirement Income Security Act of 1974, as amended) and amounts paid in settlement in connection with any action, suit, proceeding or
investigation, whether civil, criminal or administrative, including, without limitation, an action by or in the right of the Corporation, to the fullest extent permitted by any applicable portion of this Article V that shall not have been
invalidated and to the fullest extent permitted by applicable law. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE VI </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Miscellaneous Provisions </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1. <U>Fiscal Year</U>. The fiscal year of the Corporation shall be determined by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Seal</U>. The Board of Directors shall have power to adopt and alter the seal of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Execution of Instruments</U>. All deeds, leases, transfers, contracts, bonds, notes and other obligations to be entered into by
the Corporation in the ordinary course of its business without director action may be executed on behalf of the Corporation by the Chairperson of the Board, if one is elected, the President or the Treasurer or any other officer, employee or agent of
the Corporation as the Board of Directors or an executive committee of the Board of Directors may authorize or determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4.
<U>Voting of Securities</U>. Unless the Board of Directors otherwise provides, the Chairperson of the Board, if one is elected, the President or the Treasurer may waive notice of, and act on behalf of the Corporation, or appoint another person or
persons to act as proxy or attorney in fact for the Corporation with or without discretionary power and/or power of substitution, at any meeting of stockholders or stockholders of any other corporation or organization, any of whose securities are
held by the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Resident Agent</U>. The Board of Directors may appoint a resident agent upon
whom legal process may be served in any action or proceeding against the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Corporate Records</U>. The original
or attested copies of the Certificate, Bylaws and records of all meetings of the incorporators, stockholders and the Board of Directors and the stock transfer books, which shall contain the names of all stockholders, their record addresses and the
amount of stock held by each, may be kept outside the State of Delaware and shall be kept at the principal office of the Corporation, at an office of its counsel, at an office of its transfer agent or in such manner as may be permitted by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>Certificate</U>. All references in these Bylaws to the Certificate shall be deemed to refer to the Certificate, as amended
and/or restated and in effect from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8. <U>Exclusive Jurisdiction of Delaware Courts or the United States Federal
District Courts</U>. Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i)&nbsp;any derivative action or proceeding brought
on behalf of the Corporation, (ii)&nbsp;any action asserting a claim of, or a claim based on, a breach of a fiduciary duty owed by any current or former director, officer or other employee or stockholder of the Corporation to the Corporation or the
Corporation&#146;s stockholders, (iii)&nbsp;any action asserting a claim arising pursuant to any provision of the DGCL or the Certificate or these Bylaws (including the interpretation, validity or enforceability thereof) or as to which the DGCL
confers jurisdiction on the Court of Chancery of the State of Delaware or (iv)&nbsp;any action asserting a claim governed by the internal affairs doctrine; provided, however, that this sentence will not apply to any causes of action arising under
the Securities Act of 1933, as amended, or the Exchange Act, or to any claim for which the federal courts have exclusive jurisdiction. Unless the Corporation consents in writing to the selection of an alternative forum, the federal district courts
of the United States of America shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, the Exchange Act, or the respective rules and regulations promulgated
thereunder. To the fullest extent permitted by law, any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this
Section&nbsp;8. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9. <U>Amendment of Bylaws</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Amendment by Directors</U>. Except as otherwise required by law, these Bylaws may be amended or repealed by the Board of Directors. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Amendment by Stockholders</U>. Except as otherwise provided herein, the Bylaws of the
Corporation may be amended or repealed at any annual meeting of stockholders, or at any special meeting of stockholders called for such purpose, by the affirmative vote of the holders of not less than
<FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) of the voting power of the outstanding shares of capital stock entitled to vote on such amendment or repeal, voting together as a single class; provided, however, that if the Board of
Directors recommends that stockholders approve such amendment or repeal at such meeting of stockholders, such amendment or repeal shall only require the affirmative vote of the majority of outstanding shares of capital stock entitled to vote on such
amendment or repeal, voting together as a single class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10. <U>Notices</U>. If mailed, notice to stockholders shall be deemed
given when deposited in the mail, postage prepaid, directed to the stockholder at such stockholder&#146;s address as it appears on the records of the Corporation. Without limiting the manner by which notice otherwise may be given to stockholders,
any notice to stockholders may be given by electronic transmission in the manner provided in Section&nbsp;232 of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 11.
<U>Waivers</U>. A written waiver of any notice, signed by a stockholder or director, or waiver by electronic transmission by such person, whether given before or after the time of the event for which notice is to be given, shall be deemed equivalent
to the notice required to be given to such person. Neither the business to be transacted at, nor the purpose of, any meeting need be specified in such a waiver. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adopted on August&nbsp;19, 2024 and effective upon the effectiveness of the <FONT STYLE="white-space:nowrap">S-1</FONT> registration statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>6
<FILENAME>d843142dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">October&nbsp;7, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upstream Bio, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">890 Winter Street, Suite 200 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Waltham, Massachusetts 02451 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Re: <U>Securities Registered under Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT></U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as counsel to you in connection with your filing of a Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-282197)</FONT> (as amended or supplemented, the &#147;Registration Statement&#148;) pursuant to the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), relating to the registration of the
offering by Upstream Bio, Inc, a Delaware corporation (the &#147;Company&#148;), of up to 14,375,000 shares (the &#147;Shares&#148;) of the Company&#146;s Common Stock, par value $0.001 per share, including Shares purchasable by the underwriters
upon their exercise of an option to purchase additional shares granted to the underwriters by the Company. The Shares are being sold to the several underwriters named in, and pursuant to, an underwriting agreement among the Company and such
underwriters (the &#147;Underwriting Agreement&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have reviewed such documents and made such examination of law as we have deemed appropriate to
give the opinions set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinions set forth below, on certificates of officers of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The opinion set forth below is limited to the Delaware General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, when delivered and paid for in accordance with the terms of the
Underwriting Agreement, will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion letter and the
opinion it contains shall be interpreted in accordance with the Core Opinion Principles as published in 74 <I>Business Lawyer</I> 815 (Summer 2019). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
hereby consent to the inclusion of this opinion as Exhibit&nbsp;5.1 to the Registration Statement and to the references to our firm under the caption &#147;Legal Matters&#148; in the Registration Statement. In giving our consent, we do not admit
that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Goodwin Procter LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GOODWIN PROCTER LLP</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>7
<FILENAME>d843142dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UPSTREAM BIO, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2024 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">SECTION&#8201;1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>GENERAL PURPOSE OF THE PLAN; DEFINITIONS</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The name of the plan is the Upstream Bio, Inc. 2024 Stock Option and Incentive Plan (the &#147;Plan&#148;). The purpose of the Plan is to
encourage and enable the officers, employees, <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors and Consultants of Upstream Bio, Inc. (the &#147;Company&#148;) and its Affiliates upon whose judgment, initiative and efforts the Company
largely depends for the successful conduct of its business to acquire a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company&#146;s welfare will assure a closer identification of their
interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company&#146;s behalf and strengthening their desire to remain with the Company or one of its Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following terms shall be defined as set forth below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Act&#148;</I> means the U.S. Securities Act of 1933, as amended, and the rules and regulations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Administrator&#148;</I> means either the Board or the compensation committee of the Board or a similar committee performing the
functions of the compensation committee and which is comprised of not less than two <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors who are independent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Affiliate</I>&#148; means, at the time of determination, any &#147;parent&#148; or &#147;subsidiary&#148; of the Company as such
terms are defined in Rule 405 of the Act. The Board will have the authority to determine the time or times at which &#147;parent&#148; or &#147;subsidiary&#148; status is determined within the foregoing definition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Award&#148;</I> or <I>&#147;Awards,&#148;</I> except where referring to a particular category of grant under the Plan, shall include
Incentive Stock Options, <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Options, Stock Appreciation Rights, Restricted Stock Units, Restricted Stock Awards, Unrestricted Stock Awards, Cash-Based Awards, and Dividend Equivalent Rights.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Award Agreement&#148;</I> means a written or electronic document setting forth the terms and provisions applicable to an Award
granted under the Plan. Each Award Agreement is subject to the terms and conditions of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Board&#148;</I> means the Board
of Directors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Cash-Based Award&#148;</I> means an Award entitling the recipient to receive a cash-denominated
payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Code&#148;</I> means the U.S. Internal Revenue Code of 1986, as amended, and any successor Code, and related rules,
regulations and interpretations. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Consultant&#148;</I> means a consultant or adviser who provides <I>bona fide</I>
services to the Company or an Affiliate as an independent contractor and who qualifies as a consultant or advisor under Instruction A.1.(a)(1) of Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Dividend Equivalent Right&#148;</I> means an Award entitling the grantee to receive credits based on ordinary cash dividends that
would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other award to which it relates) if such shares had been issued to and held by the grantee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Effective Date&#148;</I> means the date on which the Plan becomes effective as set forth in Section&nbsp;19. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Exchange Act&#148;</I> means the U.S. Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Fair Market Value&#148;</I> of the Stock on any given date means the fair market value of the Stock determined in good faith by the
Administrator; provided, however, that if the Stock is listed on the National Association of Securities Dealers Automated Quotation System (&#147;NASDAQ&#148;), NASDAQ Global Market, The New York Stock Exchange or another national securities
exchange or traded on any established market, the determination shall be made by reference to the closing price. If there is no closing price for such date, the determination shall be made by reference to the last date preceding such date for which
there is a closing price; provided further, however, that if the date for which Fair Market Value is determined is the Registration Date, the Fair Market Value shall be the &#147;Price to the Public&#148; (or equivalent) set forth on the cover page
for the final prospectus relating to the Company&#146;s initial public offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Incentive Stock Option&#148;</I> means any
Stock Option designated and qualified as an &#147;incentive stock option&#148; as defined in Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT
STYLE="white-space:nowrap">&#147;Non-Employee</FONT> Director&#148;</I> means a member of the Board who is not also an employee of the Company or any Subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">&#147;Non-Qualified</FONT> Stock Option&#148;</I> means any Stock Option that is not an Incentive Stock
Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Option&#148;</I> or <I>&#147;Stock Option&#148;</I> means any option to purchase shares of Stock granted pursuant to
Section&nbsp;5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;</I><I>Outstanding Shares</I><I>&#148;</I><I> </I>means, as of a specified date, the sum of (a)&nbsp;the number
of shares of Stock issued and outstanding and (b)&nbsp;the number of shares of Stock issuable pursuant to the exercise of any outstanding, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to acquire Stock for a nominal exercise price.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Registration Date&#148; </I>means the date upon which the registration statement on Form
<FONT STYLE="white-space:nowrap">S-1</FONT> that is filed by the Company with respect to its initial public offering is declared effective by the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Restricted Shares&#148;</I> means the shares of Stock underlying a Restricted Stock Award that remain subject to a risk of forfeiture
or the Company&#146;s right of repurchase. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Restricted Stock Award&#148;</I> means an Award of Restricted Shares subject to
such restrictions and conditions as the Administrator may determine at the time of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Restricted Stock Units&#148;</I> means
an Award of stock units subject to such restrictions and conditions as the Administrator may determine at the time of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Sale Event&#148;</I> shall mean (i)&nbsp;the sale of all or substantially all of the assets of the Company on a consolidated basis to
an unrelated person or entity, (ii)&nbsp;a merger, reorganization or consolidation pursuant to which the holders of the Company&#146;s outstanding voting power and outstanding stock immediately prior to such transaction do not own a majority of the
outstanding voting power and outstanding stock or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable) immediately upon completion of such transaction, (iii)&nbsp;the sale of all of the Stock of the
Company to an unrelated person, entity or group thereof acting in concert, or (iv)&nbsp;any other transaction in which the owners of the Company&#146;s outstanding voting power immediately prior to such transaction do not own at least a majority of
the outstanding voting power of the Company or any successor entity immediately upon completion of the transaction other than as a result of the acquisition of securities directly from the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Sale Price</I>&#148; means the value as determined by the Administrator of the consideration payable, or otherwise to be received by
stockholders, per share of Stock pursuant to a Sale Event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Section</I><I></I><I>&nbsp;409A&#148;</I> means Section&nbsp;409A of
the Code and the regulations and other guidance promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Service Relationship&#148; </I>means any relationship as
an employee, <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director or Consultant of the Company or any Affiliate. Unless as otherwise set forth in the Award Agreement, a Service Relationship shall be deemed to continue without interruption
in the event a grantee&#146;s status changes from full-time employee to part-time employee or a grantee&#146;s status changes from employee to Consultant or <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director or vice versa, provided that
there is no interruption or other termination of Service Relationship in connection with the grantee&#146;s change in capacity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Stock&#148;</I> means the Common Stock, par value $0.001 per share, of the Company, subject to adjustments pursuant to
Section&nbsp;3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Stock Appreciation Right&#148;</I> means an Award entitling the recipient to receive shares of Stock (or cash,
to the extent explicitly provided for in the applicable Award Agreement) having a value equal to the excess of the Fair Market Value of the Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by the
number of shares of Stock with respect to which the Stock Appreciation Right shall have been exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Subsidiary&#148;</I>
means any corporation or other entity (other than the Company) in which the Company has at least a 50&nbsp;percent interest, either directly or indirectly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Substitute Awards&#148; </I>means Awards granted or Stock issued by the Company in assumption of, or in substitution or exchange for,
awards previously granted, in each case by a company acquired by the Company or any Affiliate or with which the Company or any Affiliate combines. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Ten Percent Owner&#148;</I> means an employee who owns or is deemed to own (by
reason of the attribution rules of Section&nbsp;424(d) of the Code) more than 10&nbsp;percent of the combined voting power of all classes of stock of the Company or any parent or subsidiary corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Unrestricted Stock Award&#148;</I> means an Award of shares of Stock free of any restrictions. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">SECTION&#8201;2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>ADMINISTRATION OF PLAN; ADMINISTRATOR AUTHORITY TO SELECT GRANTEES AND DETERMINE AWARDS</U>
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Administration of Plan</U>. The Plan shall be administered by the Administrator. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Powers of Administrator</U>. The Administrator shall have the power and authority to grant Awards consistent with the terms of the Plan,
including the power and authority: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) to select the individuals to whom Awards may from time to time be granted; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) to determine the time or times of grant, and the extent, if any, of Incentive Stock Options,
<FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Restricted Stock Units, Unrestricted Stock Awards, Cash-Based Awards, and Dividend Equivalent Rights, or any combination of the
foregoing, granted to any one or more grantees; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) to determine the number of shares of Stock to be covered by any Award; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) to determine and modify from time to time the terms and conditions, including restrictions, not inconsistent with the terms of the Plan,
of any Award, which terms and conditions may differ among individual Awards and grantees, and to approve the forms of Award Agreements; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) to accelerate at any time the exercisability or vesting of all or any portion of any Award; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) subject to the provisions of Section&nbsp;5(c) or 6(d), to extend at any time the period in which Stock Options or Stock Appreciation
Rights, respectively, may be exercised; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) at any time to adopt, alter and repeal such rules, guidelines and practices for
administration of the Plan and for its own acts and proceedings as it shall deem advisable; to interpret the terms and provisions of the Plan and any Award (including related written instruments); to make all determinations it deems advisable for
the administration of the Plan; to decide all disputes arising in connection with the Plan; and to otherwise supervise the administration of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All decisions and interpretations of the Administrator shall be binding on all persons, including the Company and Plan grantees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Delegation of Authority to Grant Awards</U>. Subject to applicable law, the
Administrator, in its discretion, may delegate to a committee consisting of one or more officers of the Company including the Chief Executive Officer of the Company all or part of the Administrator&#146;s authority and duties with respect to the
granting of Awards to individuals who are (i)&nbsp;not subject to the reporting and other provisions of Section&nbsp;16 of the Exchange Act and (ii)&nbsp;not members of the delegated committee. Any such delegation by the Administrator shall include
a limitation as to the amount of Stock underlying Awards that may be granted during the period of the delegation and shall contain guidelines as to the determination of the exercise price and the vesting criteria. The Administrator may revoke or
amend the terms of a delegation at any time but such action shall not invalidate any prior actions of the Administrator&#146;s delegate or delegates that were consistent with the terms of the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Award Agreement</U>. Awards under the Plan shall be evidenced by Award Agreements that set forth the terms, conditions and limitations
for each Award which may include, without limitation, the term of an Award and the provisions applicable in the event the Service Relationship terminates. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Indemnification</U>. Neither the Board nor the Administrator, nor any member of either or any delegate thereof, shall be liable for any
act, omission, interpretation, construction or determination made in good faith in connection with the Plan, and the members of the Board and the Administrator (and any delegate thereof) shall be entitled in all cases to indemnification and
reimbursement by the Company in respect of any claim, loss, damage or expense (including, without limitation, reasonable attorneys&#146; fees) arising or resulting therefrom to the fullest extent permitted by law and/or under the Company&#146;s
articles or bylaws or any directors&#146; and officers&#146; liability insurance coverage which may be in effect from time to time and/or any indemnification agreement between such individual and the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Award Recipients</U>. Notwithstanding any provision of the Plan to the contrary, in
order to comply with the laws in other countries in which the Company and its Affiliates operate or have employees or other individuals eligible for Awards, the Administrator, in its sole discretion, shall have the power and authority to:
(i)&nbsp;determine which Affiliates shall be covered by the Plan; (ii)&nbsp;determine which individuals outside the United States are eligible to participate in the Plan; (iii)&nbsp;modify the terms and conditions of any Award granted to individuals
outside the United States to comply with applicable laws; (iv)&nbsp;establish subplans and modify exercise procedures and other terms and procedures, to the extent the Administrator determines such actions to be necessary or advisable (and such
subplans and/or modifications shall be incorporated into and made part of this Plan); provided, however, that no such subplans and/or modifications shall increase the share limitations contained in Section&nbsp;3(a) hereof; and (v)&nbsp;take any
action, before or after<B> </B>an Award is made, that the Administrator determines to be necessary or advisable to obtain approval or comply with any local governmental regulatory exemptions or approvals. Notwithstanding the foregoing, the
Administrator may not take any actions hereunder, and no Awards shall be granted, that would violate the Exchange Act or any other applicable United States securities law, the Code, or any other applicable United States governing statute or law.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">SECTION&#8201;3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>STOCK ISSUABLE UNDER THE PLAN; MERGERS; SUBSTITUTION</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Stock Issuable</U>. The maximum number of shares of Stock reserved and available for issuance under the Plan shall be
3,180,000&nbsp;shares (the &#147;Initial Limit&#148;), plus on January&nbsp;1, 2025 and on each January&nbsp;1 thereafter, the number of shares of Stock reserved and available for issuance under the Plan shall be automatically cumulatively increased
by five (5%)&nbsp;percent of the Outstanding Shares on the immediately preceding December&nbsp;31, or such lesser number of shares as approved by the Administrator, in all cases subject to adjustment as provided in Section&nbsp;3(c) (the
&#147;Annual Increase&#148;). Subject to such overall limitation, the maximum aggregate number of shares of Stock that may be issued in the form of Incentive Stock Options shall not exceed the Initial Limit cumulatively increased on January&nbsp;1,
2025 and on each January&nbsp;1 thereafter by the lesser of the Annual Increase for such year or 3,180,000&nbsp;shares of Stock, subject in all cases to adjustment as provided in Section&nbsp;3(c). For purposes of this limitation, the shares of
Stock underlying any awards under the Plan and the shares of Common Stock of the Company underlying the Company&#146;s 2021 Stock Option and Grant Plan, as amended from time to time that are forfeited, canceled, held back upon exercise of an Option
or settlement of an Award to cover the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise) shall be added back to the shares of Stock
available for issuance under the Plan and, to the extent permitted under Section&nbsp;422 of the Code and the regulations promulgated thereunder, the shares of Stock that may be issued as Incentive Stock Options. In the event the Company repurchases
shares of Stock on the open market, such shares shall not be added to the shares of Stock available for issuance under the Plan. Subject to such overall limitations, shares of Stock may be issued up to such maximum number pursuant to any type or
types of Award.&nbsp;The shares available for issuance under the Plan may be authorized but unissued shares of Stock or shares of Stock reacquired by the Company. Awards that may be settled solely in cash shall not be counted against the share
reserve, nor shall they reduce the shares of Stock authorized for grant to a grantee in any calendar year. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Maximum Awards to <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Directors</U>. Notwithstanding anything to the contrary in this Plan, the value of all Awards awarded under this Plan and all other cash compensation paid by the Company to any <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director for services as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director in any calendar year shall not exceed: (i) $1,000,000 in the first calendar year an individual becomes a <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director and (ii) $750,000 in any other calendar year. For the purpose of this limitation, the value of any Award shall be its grant date fair value, as determined in accordance with ASC Topic 718 or
successor provision but excluding the impact of estimated forfeitures related to service-based vesting provisions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Changes in
Stock</U>. Subject to Section&nbsp;3(d) hereof, if, as a result of any reorganization, recapitalization, reclassification, stock dividend, extraordinary cash dividend, stock split, reverse stock split or other similar change in the Company&#146;s
capital stock, the outstanding shares of Stock are increased or decreased or are exchanged for a different number or kind of shares or other securities of the Company, or additional shares or new or different shares or other securities of the
Company or other <FONT STYLE="white-space:nowrap">non-cash</FONT> assets are distributed with respect to such shares of Stock or other securities, or, if, as a result of any merger or consolidation, sale of all or substantially all of the assets of
the Company, the outstanding shares of Stock are converted into or exchanged for securities of the Company or any successor entity (or a parent or subsidiary thereof), the Administrator shall make an appropriate or proportionate adjustment in
(i)&nbsp;the maximum number of shares reserved for issuance under the Plan, including the maximum number of shares that may be issued in the form of Incentive Stock Options, (ii)&nbsp;the number and kind of shares or other securities subject to any
then outstanding Awards under the Plan, (iii)&nbsp;the repurchase price, if any, per share subject to each outstanding Restricted Stock Award, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(iv)&nbsp;the exercise price for each share subject to any then outstanding Stock Options and Stock Appreciation Rights under the Plan, without changing the aggregate exercise price (i.e., the
exercise price multiplied by the number of shares subject to Stock Options and Stock Appreciation Rights) as to which such Stock Options and Stock Appreciation Rights remain exercisable. The Administrator shall also make equitable or proportionate
adjustments in the number of shares subject to outstanding Awards and the exercise price and the terms of outstanding Awards to take into consideration cash dividends paid other than in the ordinary course or any other extraordinary corporate event.
The adjustment by the Administrator shall be final, binding and conclusive. No fractional shares of Stock shall be issued under the Plan resulting from any such adjustment, but the Administrator in its discretion may make a cash payment in lieu of
fractional shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Mergers and Other Transactions</U>. In the case of and subject to the consummation of a Sale Event, the parties
thereto may cause the assumption or continuation of Awards theretofore granted by the successor entity, or the substitution of such Awards with new Awards of the successor entity or parent thereof, with appropriate adjustment as to the number and
kind of shares and, if appropriate, the per share exercise prices, as such parties shall agree. To the extent that the parties to such Sale Event do not provide for the assumption, continuation or substitution of Awards, upon the effective time of
the Sale Event, the Plan and all outstanding Awards granted hereunder shall terminate. In such case, except as may be otherwise provided in the relevant Award Agreement, all Options and Stock Appreciation Rights with time-based vesting conditions or
restrictions that are not vested and/or exercisable immediately prior to the effective time of the Sale Event shall become fully vested and exercisable as of the effective time of the Sale Event, all other Awards with time-based vesting, conditions
or restrictions shall become fully vested and nonforfeitable as of the effective time of the Sale Event, and all Awards with conditions and restrictions relating to the attainment of performance goals may become vested and nonforfeitable in
connection with a Sale Event in the Administrator&#146;s discretion or to the extent specified in the relevant Award Agreement. In the event of such termination, (i)&nbsp;the Company shall have the option (in its sole discretion) to make or provide
for a payment, in cash or in kind, to the grantees holding Options and Stock Appreciation Rights, in exchange for the cancellation thereof, in an amount equal to the difference between (A)&nbsp;the Sale Price multiplied by the number of shares of
Stock subject to outstanding Options and Stock Appreciation Rights (to the extent then exercisable at prices not in excess of the Sale Price) and (B)&nbsp;the aggregate exercise price of all such outstanding Options and Stock Appreciation Rights
(provided that, in the case of an Option or Stock Appreciation Right with an exercise price equal to or greater than the Sale Price, such Option or Stock Appreciation Right shall be cancelled for no consideration); or (ii)&nbsp;each grantee shall be
permitted, within a specified period of time prior to the consummation of the Sale Event as determined by the Administrator, to exercise all outstanding Options and Stock Appreciation Rights (to the extent then exercisable) held by such grantee. The
Company shall also have the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding other Awards in an amount equal to the Sale Price multiplied by the number of vested shares of Stock under such
Awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Substitute Awards</U>. Substitute Awards shall not reduce the shares of Stock
authorized for grant under the Plan, nor shall shares subject to a Substitute Award be added to the shares of Stock available for Awards under the Plan as provided in Section&nbsp;3(a) above. Additionally, in the event that a company acquired by the
Company or any Affiliate or with which the Company or any Affiliate combines has shares available under a <FONT STYLE="white-space:nowrap">pre-existing</FONT> plan approved by stockholders and not adopted in contemplation of such acquisition or
combination, the shares available for grant pursuant to the terms of such <FONT STYLE="white-space:nowrap">pre-existing</FONT> plan (as adjusted, to the extent appropriate, using the exchange ratio or other adjustment or valuation ratio or formula
used in such acquisition or combination to determine the consideration payable to the holders of common stock of the entities party to such acquisition or combination) may be used for Awards under the Plan and shall not reduce the shares authorized
for grant under the Plan (and shares subject to such Awards shall not be added to the shares available for Awards under the Plan as provided in Section&nbsp;3(a) above); provided that Awards using such available shares shall not be made after the
date awards or grants could have been made under the terms of the <FONT STYLE="white-space:nowrap">pre-existing</FONT> plan, absent the acquisition or combination, and shall only be made to individuals who were not employees or directors prior to
such acquisition or combination. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">SECTION&#8201;4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>ELIGIBILITY</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Grantees under the Plan will be such employees, <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors or Consultants of the Company
and its Affiliates as are selected from time to time by the Administrator in its sole discretion; provided that Awards may not be granted to employees, <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors or Consultants who are providing
services only to any &#147;parent&#148; of the Company, as such term is defined in Rule 405 of the Act, unless (i)&nbsp;the stock underlying the Awards is treated as &#147;service recipient stock&#148; under Section&nbsp;409A or (ii)&nbsp;the
Company has determined that such Awards are exempt from or otherwise comply with Section&nbsp;409A. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">SECTION&#8201;5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>STOCK OPTIONS</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Award of Stock Options</U>. The Administrator may grant Stock Options under the Plan. Any Stock Option granted under the Plan shall be
in such form as the Administrator may from time to time approve. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock Options granted under the Plan may be either Incentive Stock
Options or <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Options. Incentive Stock Options may be granted only to employees of the Company or any Subsidiary that is a &#147;subsidiary corporation&#148; within the meaning of
Section&nbsp;424(f) of the Code. To the extent that any Option does not qualify as an Incentive Stock Option, it shall be deemed a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock Options granted pursuant to this Section&nbsp;5 shall be subject to the following terms and conditions and shall contain such additional
terms and conditions, not inconsistent with the terms of the Plan, as the Administrator shall deem desirable. If the Administrator so determines, Stock Options may be granted in lieu of cash compensation at the optionee&#146;s election, subject to
such terms and conditions as the Administrator may establish. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Exercise Price</U>. The exercise price per share for the Stock
covered by a Stock Option granted pursuant to this Section&nbsp;5 shall be determined by the Administrator at the time of grant but shall not be less than 100&nbsp;percent of the Fair Market Value on the date of grant. In the case of an Incentive
Stock Option that is granted to a Ten Percent Owner, the exercise price of such Incentive Stock Option shall be not less than 110&nbsp;percent of the Fair Market Value on the date of grant. Notwithstanding the foregoing, Stock Options may be granted
with an exercise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
price per share that is less than 100&nbsp;percent of the Fair Market Value on the date of grant (i)&nbsp;pursuant to a transaction described in, and in a manner consistent with,
Section&nbsp;424(a) of the Code, (ii)&nbsp;to individuals who are not subject to U.S. income tax on the date of grant or (iii)&nbsp;if the Stock Option is otherwise exempt from or compliant with Section&nbsp;409A. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Option Term</U>. The term of each Stock Option shall be fixed by the Administrator, but no Stock Option shall be exercisable more than
ten years after the date the Stock Option is granted. In the case of an Incentive Stock Option that is granted to a Ten Percent Owner, the term of such Stock Option shall be no more than five years from the date of grant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Exercisability; Rights of a Stockholder</U>. Stock Options shall become exercisable at such time or times, whether or not in
installments, as shall be determined by the Administrator at or after the date of grant. The Administrator may at any time accelerate the exercisability of all or any portion of any Stock Option. An optionee shall have the rights of a stockholder
only as to shares acquired upon the exercise of a Stock Option and not as to unexercised Stock Options. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Method of Exercise</U>.
Stock Options may be exercised in whole or in part, by giving written or electronic notice of exercise to the Company, specifying the number of shares to be purchased. Payment of the purchase price may be made by one or more of the following methods
except to the extent otherwise provided in the Award Agreement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) In cash, by certified or bank check or other instrument acceptable to
the Administrator; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Through the delivery (or attestation to the ownership following such procedures as the Company may prescribe) of
shares of Stock that are not then subject to restrictions under any Company plan. Such surrendered shares shall be valued at Fair Market Value on the exercise date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) By the optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to
promptly deliver to the Company cash or a check payable and acceptable to the Company for the purchase price; provided that in the event the optionee chooses to pay the purchase price as so provided, the optionee and the broker shall comply with
such procedures and enter into such agreements of indemnity and other agreements as the Company shall prescribe as a condition of such payment procedure; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) With respect to Stock Options that are not Incentive Stock Options, by a &#147;net exercise&#148; arrangement pursuant to which the
Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment instruments will be received subject to collection. The transfer to the optionee on the records of the Company or of the transfer agent of the shares
of Stock to be purchased pursuant to the exercise of a Stock Option will be contingent upon receipt from the optionee (or a purchaser acting in his stead in accordance with the provisions of the Stock Option) by the Company of the full purchase
price for such shares and the fulfillment of any other requirements contained in the Award Agreement or applicable provisions of laws (including the satisfaction of any taxes that the Company or an Affiliate is obligated to withhold with respect to
the optionee). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event an optionee chooses to pay the purchase price by previously-owned shares of Stock through the
attestation method, the number of shares of Stock transferred to the optionee upon the exercise of the Stock Option shall be net of the number of attested shares. In the event that the Company establishes, for itself or using the services of a third
party, an automated system for the exercise of Stock Options, such as a system using an internet website or interactive voice response, then the paperless exercise of Stock Options may be permitted through the use of such an automated system. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Annual Limit on Incentive Stock Options</U>. To the extent required for &#147;incentive stock option&#148; treatment under
Section&nbsp;422 of the Code, the aggregate Fair Market Value (determined as of the time of grant) of the shares of Stock with respect to which Incentive Stock Options granted under this Plan and any other plan of the Company or its parent and
subsidiary corporations become exercisable for the first time by an optionee during any calendar year shall not exceed $100,000. To the extent that any Stock Option exceeds this limit, it shall constitute a
<FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">SECTION&#8201;6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>STOCK APPRECIATION RIGHTS</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Award of Stock Appreciation Rights</U>. The Administrator may grant Stock Appreciation Rights under the Plan. A Stock Appreciation Right
is an Award entitling the recipient to receive shares of Stock (or cash, to the extent explicitly provided for in the applicable Award Agreement) having a value equal to the excess of the Fair Market Value of a share of Stock on the date of exercise
over the exercise price of the Stock Appreciation Right multiplied by the number of shares of Stock with respect to which the Stock Appreciation Right shall have been exercised. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Exercise Price of Stock Appreciation Rights</U>. The exercise price of a Stock Appreciation Right shall not be less than
100&nbsp;percent of the Fair Market Value of the Stock on the date of grant. Notwithstanding the foregoing, Stock Appreciation Rights may be granted with an exercise price per share that is less than 100&nbsp;percent of the Fair Market Value on the
date of grant (i)&nbsp;pursuant to a transaction described in, and in a manner consistent with, Section&nbsp;424(a) of the Code, (ii)&nbsp;to individuals who are not subject to U.S. income tax on the date of grant or (iii)&nbsp;if the Stock
Appreciation Right is otherwise exempt from or compliant with Section&nbsp;409A. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Grant and Exercise of Stock Appreciation
Rights</U>. Stock Appreciation Rights may be granted by the Administrator independently of any Stock Option granted pursuant to Section&nbsp;5 of the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Terms and Conditions of Stock Appreciation Rights</U>. Stock Appreciation Rights shall be subject to such terms and conditions as shall
be determined on the date of grant by the Administrator. The term of a Stock Appreciation Right may not exceed ten years. The terms and conditions of each such Award shall be determined by the Administrator, and such terms and conditions may differ
among individual Awards and grantees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">SECTION&#8201;7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>RESTRICTED STOCK AWARDS</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Nature of Restricted Stock Awards</U>. The Administrator may grant Restricted Stock Awards under the Plan. A Restricted Stock Award is
any Award of Restricted Shares subject to such restrictions and conditions as the Administrator may determine at the time of grant. Conditions may be based on continuing employment (or other Service Relationship) and/or achievement of <FONT
STYLE="white-space:nowrap">pre-established</FONT> performance goals and objectives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Rights as a Stockholder</U>. Upon the grant of
the Restricted Stock Award and payment of any applicable purchase price, a grantee shall have the rights of a stockholder with respect to the voting of the Restricted Shares and receipt of dividends; provided that if the lapse of restrictions with
respect to the Restricted Stock Award is tied to the attainment of vesting conditions, any dividends paid by the Company shall accrue and shall not be paid to the grantee until and to the extent the vesting conditions are met with respect to the
Restricted Stock Award. Unless the Administrator shall otherwise determine, (i)&nbsp;uncertificated Restricted Shares shall be accompanied by a notation on the records of the Company or the transfer agent to the effect that they are subject to
forfeiture until such Restricted Shares are vested as provided in Section&nbsp;7(d) below, and (ii)&nbsp;certificated Restricted Shares shall remain in the possession of the Company until such Restricted Shares are vested as provided in
Section&nbsp;7(d) below, and the grantee shall be required, as a condition of the grant, to deliver to the Company such instruments of transfer as the Administrator may prescribe. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Restrictions</U>. Restricted Shares may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of except as
specifically provided herein or in the Restricted Stock Award Agreement. Except as may otherwise be provided by the Administrator either in the Award Agreement or, subject to Section&nbsp;16 below, in writing after the Award is issued, if a
grantee&#146;s employment (or other Service Relationship) with the Company and its Affiliates terminates for any reason, any Restricted Shares that have not vested at the time of termination shall automatically and without any requirement of notice
to such grantee from or other action by or on behalf of, the Company be deemed to have been reacquired by the Company at its original purchase price (if any) from such grantee or such grantee&#146;s legal representative simultaneously with such
termination of employment (or other Service Relationship), and thereafter shall cease to represent any ownership of the Company by the grantee or rights of the grantee as a stockholder. Following such deemed reacquisition of Restricted Shares that
are represented by physical certificates, a grantee shall surrender such certificates to the Company upon request without consideration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Vesting of Restricted Shares</U>. The Administrator at the time of grant shall specify the date or dates and/or the attainment of <FONT
STYLE="white-space:nowrap">pre-established</FONT> performance goals, objectives and other conditions on which the <FONT STYLE="white-space:nowrap">non-transferability</FONT> of the Restricted Shares and the Company&#146;s right of repurchase or
forfeiture shall lapse. Subsequent to such date or dates and/or the attainment of such <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals, objectives and other conditions, the shares on which all restrictions have lapsed shall
no longer be Restricted Shares and shall be deemed &#147;vested.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">SECTION&#8201;8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>RESTRICTED STOCK UNITS</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Nature of Restricted Stock Units</U>. The Administrator may grant Restricted Stock Units under the Plan. A Restricted Stock Unit is an
Award of stock units that may be settled in shares of Stock (or cash, to the extent explicitly provided for in the Award Agreement) upon the satisfaction of such restrictions and conditions at the time of grant. Conditions may be based on continuing
employment (or other Service Relationship) and/or achievement of <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals and objectives. The terms and conditions of each such Award shall be determined by the Administrator, and such
terms and conditions may differ among individual Awards and grantees. Restricted Stock Units with deferred settlement dates are subject to Section&nbsp;409A and shall contain such additional terms and conditions as the Administrator shall determine
in its sole discretion in order to comply with the requirements of Section&nbsp;409A. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Election to Receive Restricted Stock Units in
Lieu of Compensation</U>. The Administrator may, in its sole discretion, permit a grantee to elect to receive a portion of future cash compensation otherwise due to such grantee in the form of an award of Restricted Stock Units. Any such election
shall be made in writing and shall be delivered to the Company no later than the date specified by the Administrator and in accordance with Section&nbsp;409A and such other rules and procedures established by the Administrator. Any such future cash
compensation that the grantee elects to defer shall be converted to a fixed number of Restricted Stock Units based on the Fair Market Value of Stock on the date the compensation would otherwise have been paid to the grantee if such payment had not
been deferred as provided herein. The Administrator shall have the sole right to determine whether and under what circumstances to permit such elections and to impose such limitations and other terms and conditions thereon as the Administrator deems
appropriate. Any Restricted Stock Units that are elected to be received in lieu of cash compensation shall be fully vested, unless otherwise provided in the Award Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Rights as a Stockholder</U>. A grantee shall have the rights as a stockholder only as to shares of Stock acquired by the grantee upon
settlement of Restricted Stock Units; provided, however, that the grantee may be credited with Dividend Equivalent Rights with respect to the stock units underlying his or her Restricted Stock Units, subject to the provisions of Section&nbsp;11 and
such terms and conditions as the Administrator may determine. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Termination</U>. Except as may otherwise be provided by the
Administrator either in the Award Agreement or, subject to Section&nbsp;16 below, in writing after the Award is issued, a grantee&#146;s right in all Restricted Stock Units that have not vested shall automatically terminate upon the grantee&#146;s
termination of employment (or cessation of Service Relationship) with the Company and its Affiliates for any reason. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">SECTION&#8201;9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>UNRESTRICTED STOCK AWARDS</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Grant or Sale of Unrestricted Stock</U>. The Administrator may grant (or sell at par value or such higher purchase price determined by the
Administrator) an Unrestricted Stock Award under the Plan. An Unrestricted Stock Award is an Award pursuant to which the grantee may receive shares of Stock free of any restrictions under the Plan. Unrestricted Stock Awards may be granted in respect
of past services or other valid consideration, or in lieu of cash compensation due to such grantee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">SECTION&#8201;10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>CASH-BASED AWARDS</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Grant of Cash-Based Awards</U>. The Administrator may grant Cash-Based Awards under the Plan. A Cash-Based Award is an Award that entitles
the grantee to a payment in cash upon the attainment of specified performance goals, including continued employment (or other Service Relationship). The Administrator shall determine the maximum duration of the Cash-Based Award, the amount of cash
to which the Cash-Based Award pertains, the conditions upon which the Cash-Based Award shall become vested or payable, and such other provisions as the Administrator shall determine. Each Cash-Based Award shall specify a cash-denominated payment
amount, formula or payment ranges as determined by the Administrator. Payment, if any, with respect to a Cash-Based Award shall be made in accordance with the terms of the Award and may be made in cash. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 11. <U>DIVIDEND EQUIVALENT RIGHTS</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Dividend Equivalent Rights</U>. The Administrator may grant Dividend Equivalent Rights under the Plan. A Dividend Equivalent Right is an
Award entitling the grantee to receive credits based on cash dividends that would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other Award to which it relates) if such shares had been issued to the grantee. A
Dividend Equivalent Right may be granted hereunder to any grantee as a component of an award of Restricted Stock Units or as a freestanding award. The terms and conditions of Dividend Equivalent Rights shall be specified in the Award Agreement.
Dividend equivalents credited to the holder of a Dividend Equivalent Right may be paid currently or may be deemed to be reinvested in additional shares of Stock, which may thereafter accrue additional equivalents. Any such reinvestment shall be at
Fair Market Value on the date of reinvestment or such other price as may then apply under a dividend reinvestment plan sponsored by the Company, if any. Dividend Equivalent Rights may be settled in cash or shares of Stock or a combination thereof,
in a single installment or installments. A Dividend Equivalent Right granted as a component of an Award of Restricted Stock Units shall provide that such Dividend Equivalent Right shall be settled only upon settlement or payment of, or lapse of
restrictions on, such other Award, and that such Dividend Equivalent Right shall expire or be forfeited or annulled under the same conditions as such other Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination</U>. Except as may otherwise be provided by the Administrator either in the Award Agreement or, subject to Section&nbsp;16
below, in writing after the Award is issued, a grantee&#146;s rights in all Dividend Equivalent Rights shall automatically terminate upon the grantee&#146;s termination of employment (or cessation of Service Relationship) with the Company and its
Affiliates for any reason. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">SECTION&#8201;12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>TRANSFERABILITY OF AWARDS</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Transferability</U>. Except as provided in Section&nbsp;12(b) below or otherwise determined by the Administrator, during a
grantee&#146;s lifetime, his or her Awards shall be exercisable only by the grantee, or by the grantee&#146;s legal representative or guardian in the event of the grantee&#146;s incapacity. No Awards shall be sold, assigned, transferred or otherwise
encumbered or disposed of by a grantee other than by will or by the laws of descent and distribution or pursuant to a domestic relations order. No Awards shall be subject, in whole or in part, to attachment, execution, or levy of any kind, and any
purported transfer in violation hereof shall be null and void. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Administrator Action</U>. Notwithstanding Section&nbsp;12(a), the Administrator, in
its discretion, may provide either in the Award Agreement regarding a given Award or by subsequent written approval that the grantee (who is an employee or <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director) may transfer his or her <FONT
STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Options to his or her immediate family members, to trusts for the benefit of such family members, or to partnerships in which such family members are the only partners, provided that the
transferee agrees in writing with the Company to be bound by all of the terms and conditions of this Plan and the applicable Award Agreement. In no event may an Award be transferred by a grantee for value. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Family Member</U>. For purposes of Section&nbsp;12(b), &#147;family member&#148; shall mean a grantee&#146;s child, stepchild,
grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mother-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">father-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">son-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">daughter-in-law,</FONT></FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">brother-in-law,</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">sister-in-law,</FONT></FONT> including adoptive relationships, any person sharing the
grantee&#146;s household (other than a tenant of the grantee), a trust in which these persons (or the grantee) have more than 50&nbsp;percent of the beneficial interest, a foundation in which these persons (or the grantee) control the management of
assets, and any other entity in which these persons (or the grantee) own more than 50&nbsp;percent of the voting interests. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)
<U>Designation of Beneficiary</U>. To the extent permitted by the Company and valid under applicable law, each grantee to whom an Award has been made under the Plan may designate a beneficiary or beneficiaries to exercise any Award or receive any
payment under any Award payable on or after the grantee&#146;s death. Any such designation shall be on a form provided for that purpose by the Administrator and shall not be effective until received by the Administrator. If no beneficiary has been
designated by a deceased grantee, or if the designated beneficiaries have predeceased the grantee, the beneficiary shall be the grantee&#146;s estate or legal heirs. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">SECTION&#8201;13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>TAX WITHHOLDING</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Payment by Grantee</U>. Each grantee shall, no later than the date as of which the value of an Award or of any Stock or other amounts
received thereunder first becomes includable in the gross income of the grantee for tax purposes, pay to the Company or any applicable Affiliate, or make arrangements satisfactory to the Administrator regarding payment of, any U.S. and <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> federal, state, or local taxes of any kind required by law to be withheld by the Company or any applicable Affiliate with respect to such income. The Company and its Affiliates shall, to the extent
permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to the grantee or to satisfy any applicable withholding obligations by any other method of withholding that the Company and its Affiliates deem
appropriate. The Company&#146;s obligation to deliver evidence of book entry (or stock certificates) to any grantee is subject to and conditioned on tax withholding obligations being satisfied by the grantee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Payment in Stock</U>. The Administrator may cause any tax withholding obligation of
the Company or any applicable Affiliate to be satisfied, in whole or in part, by the Company withholding from shares of Stock to be issued pursuant to any Award a number of shares with an aggregate Fair Market Value (as of the date the withholding
is effected) that would satisfy the withholding amount due; provided, however, that the amount withheld does not exceed the maximum statutory rate or such lesser amount as is necessary to avoid liability accounting treatment. For purposes of share
withholding, the Fair Market Value of withheld shares shall be determined in the same manner as the value of Stock includible in income of the grantees. The Administrator may also require any tax withholding obligation of the Company or any
applicable Affiliate to be satisfied, in whole or in part, by an arrangement whereby a certain number of shares of Stock issued pursuant to any Award are immediately sold and proceeds from such sale are remitted to the Company or any applicable
Affiliate in an amount that would satisfy the withholding amount due. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION&#8201;14. <U>SECTION</U><U></U><U>&nbsp;409A AWARDS</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Awards are intended to be exempt from Section&nbsp;409A to the greatest extent possible and to otherwise comply with Section&nbsp;409A. The
Plan and all Awards shall be interpreted in accordance with such intent. To the extent that any Award is determined to constitute &#147;nonqualified deferred compensation&#148; within the meaning of Section&nbsp;409A (a &#147;409A Award&#148;), the
Award shall be subject to such additional rules and requirements as specified by the Administrator from time to time in order to comply with Section&nbsp;409A. In this regard, if any amount under a 409A Award is payable upon a &#147;separation from
service&#148; (within the meaning of Section&nbsp;409A) to a grantee who is then considered a &#147;specified employee&#148; (within the meaning of Section&nbsp;409A), then no such payment shall be made prior to the date that is the earlier of
(i)&nbsp;six months and one day after the grantee&#146;s separation from service, or (ii)&nbsp;the grantee&#146;s death, but only to the extent such delay is necessary to prevent such payment from being subject to interest, penalties and/or
additional tax imposed pursuant to Section&nbsp;409A. Further, the settlement of any 409A Award may not be accelerated except to the extent permitted by Section&nbsp;409A. The Company makes no representation that any or all of the payments or
benefits described in the Plan will be exempt from or comply with Section&nbsp;409A of the Code and makes no undertaking to preclude Section&nbsp;409A of the Code from applying to any such payment. The grantee shall be solely responsible for the
payment of any taxes and penalties incurred under Section&nbsp;409A. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">SECTION&#8201;15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>TERMINATION OF SERVICE RELATIONSHIP, TRANSFER, LEAVE OF ABSENCE, ETC.</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Termination of Service Relationship</U>. If the grantee&#146;s Service Relationship is with an Affiliate and such Affiliate ceases to be
an Affiliate, the grantee shall be deemed to have terminated his or her Service Relationship for purposes of the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) For purposes of
the Plan, the following events shall not be deemed a termination of a Service Relationship: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) a transfer to the Service Relationship of
the Company from an Affiliate or from the Company to an Affiliate, or from one Affiliate to another; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) an approved leave of absence
for military service or sickness, or for any other purpose approved by the Company, if the employee&#146;s right to <FONT STYLE="white-space:nowrap">re-employment</FONT> is guaranteed either by a statute or by contract or under the policy pursuant
to which the leave of absence was granted or if the Administrator otherwise so provides in writing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">SECTION&#8201;16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>AMENDMENTS AND TERMINATION</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board may, at any time, amend or discontinue the Plan and the Administrator may, at any time, amend or cancel any outstanding Award for the
purpose of satisfying changes in law or for any other lawful purpose, but no such action shall materially and adversely affect rights under any outstanding Award without the holder&#146;s consent. The Administrator is specifically authorized to
exercise its discretion to reduce the exercise price of outstanding Stock Options or Stock Appreciation Rights, or effect the repricing of such Awards through cancellation and <FONT STYLE="white-space:nowrap">re-grants</FONT> or cancellation of
Stock Options or Stock Appreciation Rights in exchange for cash or other Awards. To the extent required under the rules of any securities exchange or market system on which the Stock is listed, or to the extent determined by the Administrator to be
required by the Code to ensure that Incentive Stock Options granted under the Plan are qualified under Section&nbsp;422 of the Code, Plan amendments shall be subject to approval by Company stockholders. Nothing in this Section&nbsp;16 shall limit
the Administrator&#146;s authority to take any action permitted pursuant to Section&nbsp;3(c) or 3(d). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">SECTION&#8201;17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>STATUS OF PLAN</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the portion of any Award that has not been exercised and any payments in cash, Stock or other consideration not received by a
grantee, a grantee shall have no rights greater than those of a general creditor of the Company unless the Administrator shall otherwise expressly determine in connection with any Award or Awards. In its sole discretion, the Administrator may
authorize the creation of trusts or other arrangements to meet the Company&#146;s obligations to deliver Stock or make payments with respect to Awards hereunder, provided that the existence of such trusts or other arrangements is consistent with the
foregoing sentence. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">SECTION&#8201;18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>GENERAL PROVISIONS</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>No Distribution</U>. The Administrator may require each person acquiring Stock pursuant to an Award to represent to and agree with the
Company in writing that such person is acquiring the shares without a view to distribution thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Issuance of Stock</U>. To the
extent certificated, stock certificates to grantees under this Plan shall be deemed delivered for all purposes when the Company or a stock transfer agent of the Company shall have mailed such certificates in the United States mail, addressed to the
grantee, at the grantee&#146;s last known address on file with the Company. Uncertificated Stock shall be deemed delivered for all purposes when the Company or a Stock transfer agent of the Company shall have given to the grantee by electronic mail
(with proof of receipt) or by United States mail, addressed to the grantee, at the grantee&#146;s last known address on file with the Company, notice of issuance and recorded the issuance in its records (which may include electronic &#147;book
entry&#148; records). Notwithstanding anything herein to the contrary, the Company shall not be required to issue or deliver any evidence of book entry or certificates evidencing shares of Stock pursuant to the exercise or settlement of any Award,
unless and until the Administrator has determined, with advice of counsel (to the extent the Administrator deems </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such advice necessary or advisable), that the issuance and delivery is in compliance with all applicable laws, regulations of governmental authorities and, if applicable, the requirements of any
exchange on which the shares of Stock are listed, quoted or traded. Any Stock issued pursuant to the Plan shall be subject to any stop-transfer orders and other restrictions as the Administrator deems necessary or advisable to comply with federal,
state or foreign jurisdiction, securities or other laws, rules and quotation system on which the Stock is listed, quoted or traded. The Administrator may place legends on any Stock certificate or notations on any book entry to reference restrictions
applicable to the Stock. In addition to the terms and conditions provided herein, the Administrator may require that an individual make such reasonable covenants, agreements, and representations as the Administrator, in its discretion, deems
necessary or advisable in order to comply with any such laws, regulations, or requirements. The Administrator shall have the right to require any individual to comply with any timing or other restrictions with respect to the settlement or exercise
of any Award, including a window-period limitation, as may be imposed in the discretion of the Administrator. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Stockholder
Rights</U>. Until Stock is deemed delivered in accordance with Section&nbsp;18(b), no right to vote or receive dividends or any other rights of a stockholder will exist with respect to shares of Stock to be issued in connection with an Award,
notwithstanding the exercise of a Stock Option or any other action by the grantee with respect to an Award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Other Incentive
Arrangements; No Rights to Continued Service Relationship</U>. Nothing contained in this Plan shall prevent the Board from adopting other or additional incentive arrangements, including trusts, and such arrangements may be either generally
applicable or applicable only in specific cases. The adoption of this Plan and the grant of Awards do not confer upon any grantee any right to continued employment or other Service Relationship with the Company or any Affiliate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Trading Policy Restrictions</U>. Option exercises and other Awards under the Plan shall be subject to the Company&#146;s insider trading
policies and procedures, as in effect from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Clawback Policy</U>. Awards under the Plan shall be subject to the
Company&#146;s clawback policy, as in effect from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Fractional Shares</U>. No fractional Shares shall be issued or
delivered pursuant to the Plan or any Award, and the Administrator shall determine whether cash, other securities or other property shall be paid or transferred in lieu of any fractional Shares, or whether such fractional Shares or nay rights
thereto shall be cancelled, terminated or otherwise eliminated. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">SECTION&#8201;19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>EFFECTIVE DATE OF PLAN</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Plan shall become effective upon the date immediately preceding the Registration Date subject to prior stockholder approval in accordance
with applicable state law, the Company&#146;s bylaws and articles of incorporation, and applicable stock exchange rules. No grants of Awards may be made hereunder after the tenth anniversary of the Effective Date and no grants of Incentive Stock
Options may be made hereunder after the tenth anniversary of the date the Plan is approved by the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">SECTION&#8201;20.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>GOVERNING LAW</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Plan and all Awards and actions taken thereunder shall be governed by, and construed in accordance with, the General Corporation Law of
the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the State of Delaware, applied without regard to conflict of law principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DATE APPROVED BY BOARD OF DIRECTORS: August&nbsp;19, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DATE
APPROVED BY STOCKHOLDERS: October&nbsp;4, 2024 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INCENTIVE STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE UPSTREAM BIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2024 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="69%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Optionee:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No. of Option Shares:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Option Exercise Price per Share:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>[FMV on Grant Date (110% of FMV if a 10% owner)]</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Grant Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Expiration Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>[up to 10 years (5 if a 10% owner)]</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Upstream Bio, Inc. 2024 Stock Option and Incentive Plan as amended through the date hereof
(the &#147;Plan&#148;), Upstream Bio, Inc. (the &#147;Company&#148;) hereby grants to the Optionee named above an option (the &#147;Stock Option&#148;) to purchase on or prior to the Expiration Date specified above all or part of the number of
shares of Common Stock, par value $0.001 per share (the &#147;Stock&#148;), of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Exercisability Schedule</U>. No portion of this Stock Option may be exercised until such portion shall have become exercisable. Except as
set forth below, and subject to the discretion of the Administrator (as defined in Section&nbsp;2 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable as follows: __________________, so long as the
Optionee continues to have a Service Relationship with the Company or a Subsidiary on such dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once exercisable, this Stock Option
shall continue to be exercisable at any time or times prior to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Manner of Exercise</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this
Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be
purchased. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment of the purchase price for the Option Shares may be made by one or more of the
following methods: (i)&nbsp;in cash, by certified or bank check or other instrument acceptable to the Administrator; (ii)&nbsp;through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the
open market or that are beneficially owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; or (iii)&nbsp;by the Optionee
delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that
in the event the Optionee chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as
a condition of such payment procedure; or (iv)&nbsp;a combination of (i), (ii) and (iii)&nbsp;above. Payment instruments will be received subject to collection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i)&nbsp;the
Company&#146;s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii)&nbsp;the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws and
(iii)&nbsp;the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent
resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock
transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The shares of Stock
purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or
regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder
of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have
transferred the shares to the Optionee, and the Optionee&#146;s name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect
to such shares of Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be
exercisable after the Expiration Date hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination of Service Relationship</U>. If the Optionee&#146;s Service Relationship
with the Company or a Subsidiary (as defined in the Plan) is terminated, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Termination Due to Death</U>. If the Optionee&#146;s Service Relationship with the Company or a Subsidiary terminates by reason of the
Optionee&#146;s death, any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of death, may thereafter be exercised by the Optionee&#146;s legal representative or legatee for a period of 12 months from the
date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of death shall terminate immediately and be of no further force or effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination Due to Disability</U>. If the Optionee&#146;s Service Relationship with
the Company or a Subsidiary terminates by reason of the Optionee&#146;s disability (as determined by the Administrator), any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of such termination, may
thereafter be exercised by the Optionee for a period of 12 months from the date the Optionee&#146;s Service Relationship is terminated by reason of the Optionee&#146;s disability or until the Expiration Date, if earlier. Any portion of this Stock
Option that is not exercisable on the date of the termination of the Optionee&#146;s Service Relationship by reason of the Optionee&#146;s disability shall terminate immediately and be of no further force or effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Termination for Cause</U>. If the Optionee&#146;s Service Relationship with the Company or a Subsidiary terminates for Cause, any
portion of this Stock Option outstanding on such date shall terminate immediately and be of no further force and effect. For purposes hereof, &#147;Cause&#148; shall mean, unless otherwise provided in an employment or service agreement between the
Company and the Optionee, a determination by the Administrator<B> </B>that the Optionee shall be dismissed as a result of (i)&nbsp;any material breach by the Optionee of any agreement between the Optionee and the Company; (ii)&nbsp;the conviction
of, indictment for or plea of nolo contendere by the Optionee to a felony or a crime involving moral turpitude; or (iii)&nbsp;any material misconduct or willful and deliberate <FONT STYLE="white-space:nowrap">non-performance</FONT> (other than by
reason of disability) by the Optionee of the Optionee&#146;s duties to the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Other Termination</U>. If the Optionee&#146;s
Service Relationship with the Company or a Subsidiary terminates for any reason other than the Optionee&#146;s death, the Optionee&#146;s disability, or Cause, and unless otherwise determined by the Administrator, any portion of this Stock Option
outstanding on such date may be exercised, to the extent exercisable on the date of termination, for a period of three (3)&nbsp;months from the date of termination or until the Expiration Date, if earlier. Any portion of this Stock Option that is
not exercisable on the date of termination shall terminate immediately and be of no further force or effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator&#146;s
determination of the reason for termination of the Optionee&#146;s Service Relationship with the Company or a Subsidiary shall be conclusive and binding on the Optionee and his or her representatives or legatees. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Incorporation of Plan</U>. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the
terms and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Transferability</U>. This Agreement is personal to the Optionee, is <FONT STYLE="white-space:nowrap">non-assignable</FONT> and is
not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee&#146;s lifetime, only by the Optionee, and thereafter, only by the
Optionee&#146;s legal representative or legatee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Status of the Stock Option</U>. This Stock Option is intended to qualify as an
&#147;incentive stock option&#148; under Section&nbsp;422 of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), but the Company does not represent or warrant that this Stock Option qualifies as such. The Optionee should consult
with his or her own tax advisors regarding the tax effects of this Stock Option and the requirements necessary to obtain favorable income tax treatment under Section&nbsp;422 of the Code, including, but not limited to, holding period requirements
and that <B><I>this Stock Option must be exercised within three months after termination of employment as an employee (or 12 months in the case of death or disability) to qualify as an &#147;incentive stock option&#148;</I></B>. To the extent any
portion of this Stock Option does not so qualify as an &#147;incentive stock option,&#148; such portion shall be deemed to be a <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock option. If the Optionee intends to dispose or does dispose
(whether by sale, gift, transfer or otherwise) of any Option Shares within the <FONT STYLE="white-space:nowrap">one-year</FONT> period beginning on the date after the transfer of such shares to him or her, or within the <FONT
STYLE="white-space:nowrap">two-year</FONT> period beginning on the day after the grant of this Stock Option, he or she will so notify the Company within 30 days after such disposition. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Tax Withholding</U>. The Optionee shall, not later than the date as of which the exercise of this Stock Option becomes a taxable event
for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state and local taxes required by law to be withheld on account of such taxable event. The Company shall have the
authority to cause the required tax withholding obligation to be satisfied, in whole or in part, by (i)&nbsp;withholding from shares of Stock to be issued to the Optionee a number of shares of Stock with an aggregate Fair Market Value that would
satisfy the withholding amount due; or (ii)&nbsp;causing its transfer agent to sell from the number of shares of Stock to be issued to the Optionee, the number of shares of Stock necessary to satisfy the Federal, state and local taxes required by
law to be withheld from the Optionee on account of such transfer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>No Obligation to Continue Service Relationship</U>. Neither the
Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Optionee in a Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the
right of the Company or any Subsidiary to terminate the Optionee&#146;s Service Relationship with the Company or a Subsidiary at any time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Integration</U>. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes all
prior agreements and discussions between the parties concerning such subject matter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Data Privacy Consent</U>. In order to
administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#147;Relevant Companies&#148;) may process any and all personal or
professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this
Agreement (the &#147;Relevant Information&#148;). By entering into this Agreement, the Optionee (i)&nbsp;authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii)&nbsp;waives any
privacy rights the Optionee may have with respect to the Relevant Information; (iii)&nbsp;authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv)&nbsp;authorizes the transfer of the Relevant Information
to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Notices</U>. Notices hereunder shall be mailed or delivered to the Company at its
principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. [<U>Clawback Acknowledgement</U>. The Optionee acknowledges that the Optionee may become subject to the Upstream Bio, Inc. Compensation
Recovery Policy adopted pursuant to Rule <FONT STYLE="white-space:nowrap">10D-1</FONT> promulgated under the Exchange Act and Nasdaq Rule 5608, or any successor rule (the &#147;Clawback Policy&#148;). The Optionee understands that if the Optionee is
or becomes subject to the Clawback Policy, the Company and/or the Board shall be entitled to recover all Erroneously Awarded Compensation (as defined in the Clawback Policy) from the Optionee pursuant to such means as the Company and/or the Board
may elect. The Optionee agrees that the Optionee shall take all required action to enable such recovery. The Optionee understands that such recovery may be sought and occur after the Optionee&#146;s employment or service with the Company terminates.
The Optionee further agrees that the Optionee is not entitled to indemnification for any Erroneously Awarded Compensation or for any claim or losses arising out of or in any way related to Erroneously Awarded Compensation recovered pursuant to the
Clawback Policy and, to the extent any agreement or organizational document purports to provide otherwise, the Optionee hereby irrevocably agrees to forego such indemnification. The Optionee acknowledges and agrees that the Optionee has received and
has had an opportunity to review the Clawback Policy. Any action by the Company to recover Erroneously Awarded Compensation under the Clawback Policy from the Optionee shall not, whether alone or in combination with any other action, event or
condition, be deemed (i)&nbsp;an event giving rise to a right to resign for Good Reason (as defined in the Upstream Bio, Inc. Executive Severance Plan) or serve as a basis for a claim of constructive termination under any benefits or compensation
arrangement applicable to the Optionee, or (ii)&nbsp;to constitute a breach of a contract or other arrangement to which the Optionee is a party. This Section&nbsp;12 is a material term of this
Agreement.]<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For Section 16 officers only. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>Upstream Bio, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#146;s instructions to the Optionee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8195;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Optionee&#146;s Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Optionee&#146;s name and address:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">NON-QUALIFIED</FONT> STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR COMPANY EMPLOYEES AND CONSULTANTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE UPSTREAM BIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2024 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="73%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Optionee:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No. of Option Shares:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Option Exercise Price per Share:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>[FMV on Grant Date]</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Grant Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Expiration Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Upstream Bio, Inc. 2024 Stock Option and Incentive Plan as amended through the date hereof
(the &#147;Plan&#148;), Upstream Bio, Inc. (the &#147;Company&#148;) hereby grants to the Optionee named above an option (the &#147;Stock Option&#148;) to purchase on or prior to the Expiration Date specified above all or part of the number of
shares of Common Stock, par value $0.001 per share (the &#147;Stock&#148;) of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan. This Stock Option
is not intended to be an &#147;incentive stock option&#148; under Section&nbsp;422 of the Internal Revenue Code of 1986, as amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.
<U>Exercisability Schedule</U>. No portion of this Stock Option may be exercised until such portion shall have become exercisable. Except as set forth below, and subject to the discretion of the Administrator (as defined in Section&nbsp;2 of the
Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable as follows: __________________________, so long as Optionee continues to have a Service Relationship with the Company or a Subsidiary on such dates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the close of business on the
Expiration Date, subject to the provisions hereof and of the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Manner of Exercise</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this
Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be
purchased. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment of the purchase price for the Option Shares may be made by one or more of the
following methods: (i)&nbsp;in cash, by certified or bank check or other instrument acceptable to the Administrator; (ii)&nbsp;through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the
open market or that are beneficially owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii)&nbsp;by the Optionee
delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that
in the event the Optionee chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as
a condition of such payment procedure; (iv)&nbsp;by a &#147;net exercise&#148; arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value
that does not exceed the aggregate exercise price; or (v)&nbsp;a combination of (i), (ii), (iii) and (iv)&nbsp;above. Payment instruments will be received subject to collection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i)&nbsp;the
Company&#146;s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii)&nbsp;the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and
(iii)&nbsp;the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent
resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock
transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The shares of Stock
purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or
regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder
of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have
transferred the shares to the Optionee, and the Optionee&#146;s name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect
to such shares of Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be
exercisable after the Expiration Date hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination of Service Relationship</U>. If the Optionee&#146;s Service Relationship
with the Company or a Subsidiary (as defined in the Plan) is terminated, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Termination Due to Death</U>. If the Optionee&#146;s Service Relationship with the Company or a Subsidiary terminates by reason of the
Optionee&#146;s death, any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of death, may thereafter be exercised by the Optionee&#146;s legal representative or legatee for a period of twelve
(12)&nbsp;months from the date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of death shall terminate immediately and be of no further force or effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination Due to Disability</U>. If the Optionee&#146;s Service Relationship with the Company or a Subsidiary terminates by reason of
the Optionee&#146;s disability (as determined by the Administrator), any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of such termination, may thereafter be exercised by the Optionee for a period of
twelve (12)&nbsp;months from the date the Optionee&#146;s Service Relationship is terminated by reason of the Optionee&#146;s disability or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date
of the termination of the Optionee&#146;s Service Relationship by reason of disability shall terminate immediately and be of no further force or effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Termination for Cause</U>. If the Optionee&#146;s Service Relationship with the Company or a Subsidiary terminates for Cause, any
portion of this Stock Option outstanding on such date shall terminate immediately and be of no further force and effect. For purposes hereof, &#147;Cause&#148; shall mean, unless otherwise provided in an employment or other service agreement between
the Company and the Optionee, a determination by the Administrator that the Optionee shall be dismissed as a result of (i)&nbsp;any material breach by the Optionee of any agreement between the Optionee and the Company; (ii)&nbsp;the conviction of,
indictment for or plea of nolo contendere by the Optionee to a felony or a crime involving moral turpitude; or (iii)&nbsp;any material misconduct or willful and deliberate <FONT STYLE="white-space:nowrap">non-performance</FONT> (other than by reason
of disability) by the Optionee of the Optionee&#146;s duties to the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Other Termination</U>. If the Optionee&#146;s Service
Relationship with the Company or a Subsidiary terminates for any reason other than the Optionee&#146;s death, the Optionee&#146;s disability or Cause, and unless otherwise determined by the Administrator, any portion of this Stock Option outstanding
on such date may be exercised, to the extent exercisable on the date of termination, for a period of three (3)&nbsp;months from the date of termination or until the Expiration Date, if earlier. Any portion of this Stock Option that is not
exercisable on the date of termination shall terminate immediately and be of no further force or effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator&#146;s
determination of the reason for termination of the Optionee&#146;s Service Relationship with the Company or a Subsidiary shall be conclusive and binding on the Optionee and his or her representatives or legatees. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Incorporation of Plan</U>. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the
terms and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Transferability</U>. This Agreement is personal to the Optionee, is <FONT
STYLE="white-space:nowrap">non-assignable</FONT> and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee&#146;s
lifetime, only by the Optionee, and thereafter, only by the Optionee&#146;s legal representative or legatee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Tax Withholding</U>.
The Optionee shall, not later than the date as of which the exercise of this Stock Option becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal,
state and local taxes required by law to be withheld on account of such taxable event. The Company shall have the authority to cause the required tax withholding obligation to be satisfied, in whole or in part, by (i)&nbsp;withholding from shares of
Stock to be issued to the Optionee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due; or (ii)&nbsp;causing its transfer agent to sell from the number of shares of Stock to be issued to the
Optionee, the number of shares of Stock necessary to satisfy the Federal, state and local taxes required by law to be withheld from the Optionee on account of such transfer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>No Obligation to Continue Service Relationship</U>. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or
this Agreement to continue the Optionee in a Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Optionee&#146;s
Service Relationship with the Company or a Subsidiary at any time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Integration</U>. This Agreement constitutes the entire agreement
between the parties with respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Data Privacy Consent</U>. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the
Company, its subsidiaries and affiliates and certain agents thereof (together, the &#147;Relevant Companies&#148;) may process any and all personal or professional data, including but not limited to, Social Security or other identification number,
home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#147;Relevant Information&#148;). By entering into this Agreement, the Optionee
(i)&nbsp;authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii)&nbsp;waives any privacy rights the Optionee may have with respect to the Relevant Information; (iii)&nbsp;authorizes
the Relevant Companies to store and transmit such information in electronic form; and (iv)&nbsp;authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have
access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Notices</U>. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or
delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. [<U>Clawback Acknowledgement</U>. The Optionee acknowledges that the Optionee may become
subject to the Upstream Bio, Inc. Compensation Recovery Policy adopted pursuant to Rule <FONT STYLE="white-space:nowrap">10D-1</FONT> promulgated under the Exchange Act and Nasdaq Rule 5608, or any successor rule (the &#147;Clawback Policy&#148;).
The Optionee understands that if the Optionee is or becomes subject to the Clawback Policy, the Company and/or the Board shall be entitled to recover all Erroneously Awarded Compensation (as defined in the Clawback Policy) from the Optionee pursuant
to such means as the Company and/or the Board may elect. The Optionee agrees that the Optionee shall take all required action to enable such recovery. The Optionee understands that such recovery may be sought and occur after the Optionee&#146;s
employment or service with the Company terminates. The Optionee further agrees that the Optionee is not entitled to indemnification for any Erroneously Awarded Compensation or for any claim or losses arising out of or in any way related to
Erroneously Awarded Compensation recovered pursuant to the Clawback Policy and, to the extent any agreement or organizational document purports to provide otherwise, the Optionee hereby irrevocably agrees to forego such indemnification. The Optionee
acknowledges and agrees that the Optionee has received and has had an opportunity to review the Clawback Policy. Any action by the Company to recover Erroneously Awarded Compensation under the Clawback Policy from the Optionee shall not, whether
alone or in combination with any other action, event or condition, be deemed (i)&nbsp;an event giving rise to a right to resign for Good Reason (as defined in the Upstream Bio, Inc. Executive Severance Plan) or serve as a basis for a claim of
constructive termination under any benefits or compensation arrangement applicable to the Optionee, or (ii)&nbsp;to constitute a breach of a contract or other arrangement to which the Optionee is a party. This Section&nbsp;11 is a material term of
this Agreement.]<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For Section&nbsp;16 officers only. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>Upstream Bio, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#146;s instructions to the Optionee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8195;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Optionee&#146;s Signature</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Optionee&#146;s name and address:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">NON-QUALIFIED</FONT> STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR <FONT STYLE="white-space:nowrap">NON-EMPLOYEE</FONT> DIRECTORS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE UPSTREAM BIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2024 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Optionee:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No. of Option Shares:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Option Exercise Price per Share:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>[FMV on Grant Date]</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Grant Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Expiration Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>[No more than 10 years]</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Upstream Bio, Inc. 2024 Stock Option and Incentive Plan as amended through the date hereof
(the &#147;Plan&#148;), Upstream Bio, Inc. (the &#147;Company&#148;) hereby grants to the Optionee named above, who is a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director of the Company but is not an employee of the Company, an option
(the &#147;Stock Option&#148;) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value $0.001 per share (the &#147;Stock&#148;), of the Company specified above at the Option
Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan. This Stock Option is not intended to be an &#147;incentive stock option&#148; under Section&nbsp;422 of the Internal Revenue Code of 1986,
as amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Exercisability Schedule</U>. No portion of this Stock Option may be exercised until such portion shall have become
exercisable. Except as set forth below, and subject to the discretion of the Administrator (as defined in Section&nbsp;2 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable as follows:
__________________________, so long as the Optionee remains in service as a member of the Board on such dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the
foregoing, in the event of a Sale Event, 100% of the then-outstanding and unvested Option Shares shall immediately be deemed vested and exercisable on the date of such Sale Event; provided, that the Optionee remains in service as a member of the
Board until the date of such Sale Event. Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Manner of Exercise</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this
Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be
purchased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i)&nbsp;in cash, by
certified or bank check or other instrument acceptable to the Administrator; (ii)&nbsp;through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially
owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii)&nbsp;by the Optionee delivering to the Company a properly
executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to
pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment
procedure; (iv)&nbsp;by a &#147;net exercise&#148; arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the
aggregate exercise price; or (v)&nbsp;a combination of (i), (ii), (iii) and (iv)&nbsp;above. Payment instruments will be received subject to collection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i)&nbsp;the
Company&#146;s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii)&nbsp;the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws and
(iii)&nbsp;the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent
resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock
transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The shares of Stock
purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or
regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder
of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have
transferred the shares to the Optionee, and the Optionee&#146;s name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect
to such shares of Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be
exercisable after the Expiration Date hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination as <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director</U>. If
the Optionee ceases to be a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director of the Company, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Termination Due to Death</U>. If the Optionee&#146;s service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director
terminates by reason of the Optionee&#146;s death, any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of death, may thereafter be exercised by the Optionee&#146;s legal representative or legatee for a
period of twelve (12)&nbsp;months from the date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of death shall terminate immediately and be of no further force or effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Other Termination</U>. If the Optionee ceases to be a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director for any reason other
than the Optionee&#146;s death, any portion of this Stock Option outstanding on such date may be exercised, to the extent exercisable on the date the Optionee ceased to be a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director, for a period
of six (6)&nbsp;months from the date the Optionee ceased to be a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date the
Optionee ceases to be a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director shall terminate immediately and be of no further force or effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Incorporation of Plan</U>. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the
terms and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Transferability</U>. This Agreement is personal to the Optionee, is <FONT STYLE="white-space:nowrap">non-assignable</FONT> and is
not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee&#146;s lifetime, only by the Optionee, and thereafter, only by the
Optionee&#146;s legal representative or legatee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>No Obligation to Continue Service Relationship</U>. Neither the Company nor any
Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Optionee in a Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the
Company or any Subsidiary to terminate the Optionee&#146;s Service Relationship with the Company or a Subsidiary at any time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.
<U>Integration</U>. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Data Privacy Consent</U>. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the
Company, its subsidiaries and affiliates and certain agents thereof (together, the &#147;Relevant Companies&#148;) may process any and all personal or professional data, including but not limited to Social Security or other identification number,
home address and telephone number, date of birth and other information that is necessary or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
desirable for the administration of the Plan and/or this Agreement (the &#147;Relevant Information&#148;). By entering into this Agreement, the Optionee (i)&nbsp;authorizes the Company to
collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii)&nbsp;waives any privacy rights the Optionee may have with respect to the Relevant Information; (iii)&nbsp;authorizes the Relevant Companies to store and
transmit such information in electronic form; and (iv)&nbsp;authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have access to, and the right to change, the
Relevant Information. Relevant Information will only be used in accordance with applicable law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Notices</U>. Notices hereunder shall
be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the
other party in writing. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>Upstream Bio, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#146;s instructions to the Optionee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8195;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Optionee&#146;s Signature</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Optionee&#146;s name and address:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTRICTED STOCK UNIT AWARD AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR COMPANY EMPLOYEES AND CONSULTANTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE UPSTREAM BIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2024 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="70%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name of Grantee:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No. of Restricted Stock Units:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant Date:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Upstream Bio, Inc. 2024 Stock Option and Incentive Plan as amended through the date hereof
(the &#147;Plan&#148;), Upstream Bio, Inc. (the &#147;Company&#148;) hereby grants an award of the number of Restricted Stock Units listed above (an &#147;Award&#148;) to the Grantee named above. Each Restricted Stock Unit shall relate to one share
of Common Stock, par value $0.001 per share (the &#147;Stock&#148;) of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Restrictions on Transfer of Award</U>. This
Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise encumbered or
disposed of until (i)&nbsp;the Restricted Stock Units have vested as provided in Paragraph 2 of this Agreement and (ii)&nbsp;shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Vesting of Restricted Stock Units</U>. The restrictions and conditions of Paragraph&nbsp;1 of this Agreement shall lapse as follows:
________________ (each such date, a &#147;Vesting Date&#148;), so long as the Grantee continues to have a Service Relationship with the Company or a Subsidiary on such Vesting Dates. If a series of Vesting Dates is specified, then the restrictions
and conditions in Paragraph&nbsp;1 shall lapse only with respect to the number of Restricted Stock Units specified as vested on such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 2. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination of Service Relationship</U>. If the Grantee&#146;s Service Relationship with the Company or a Subsidiary terminates for any
reason (including death or disability) prior to the satisfaction of the vesting conditions set forth in Paragraph 2 above, any Restricted Stock Units that have not vested as of such date shall automatically and without notice terminate and be
forfeited, and neither the Grantee nor any of his or her successors, heirs, assigns, or personal representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Issuance of Shares of Stock</U>. As soon as practicable following each Vesting Date (but in no event later than two and <FONT
STYLE="white-space:nowrap">one-half</FONT> months after the end of the year in which the Vesting Date occurs), the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate number of Restricted Stock Units that have
vested pursuant to Paragraph 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Incorporation of Plan</U>. Notwithstanding anything herein to the contrary, this
Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the
Plan, unless a different meaning is specified herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Tax Withholding</U>. The Grantee shall, not later than the date as of which
the receipt of this Award becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state and local taxes required by law to be withheld on account
of such taxable event. The Company shall have the authority to cause the required tax withholding obligation to be satisfied, in whole or in part, by (i)&nbsp;withholding from shares of Stock to be issued to the Grantee a number of shares of Stock
with an aggregate Fair Market Value that would satisfy the withholding amount due; or (ii)&nbsp;causing its transfer agent to sell from the number of shares of Stock to be issued to the Grantee, the number of shares of Stock necessary to satisfy the
Federal, state and local taxes required by law to be withheld from the Grantee on account of such transfer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Section 409A of the
Code.</U> This Agreement shall be interpreted in such a manner that all provisions relating to the settlement of the Award are exempt from the requirements of Section&nbsp;409A of the Code as &#147;short-term deferrals&#148; as described in
Section&nbsp;409A of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>No Obligation to Continue Service Relationship</U>. Neither the Company nor any Subsidiary is
obligated by or as a result of the Plan or this Agreement to continue the Grantee in a Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any
Subsidiary to terminate the Grantee&#146;s Service Relationship with the Company or a Subsidiary at any time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Integration</U>. This
Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Data Privacy Consent</U>. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the
Company, its subsidiaries and affiliates and certain agents thereof (together, the &#147;Relevant Companies&#148;) may process any and all personal or professional data, including but not limited to, Social Security or other identification number,
home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#147;Relevant Information&#148;). By entering into this Agreement, the Grantee
(i)&nbsp;authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii)&nbsp;waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii)&nbsp;authorizes
the Relevant Companies to store and transmit such information in electronic form; and (iv)&nbsp;authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have
access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Notices</U>. Notices hereunder shall be mailed or delivered to the Company at its
principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. [<U>Clawback Acknowledgement</U>. The Grantee acknowledges that the Grantee may become subject to the Upstream Bio, Inc. Compensation
Recovery Policy adopted pursuant to Rule <FONT STYLE="white-space:nowrap">10D-1</FONT> promulgated under the Exchange Act and Nasdaq Rule 5608, or any successor rule (the &#147;Clawback Policy&#148;). The Grantee understands that if the Grantee is
or becomes subject to the Clawback Policy, the Company and/or the Board shall be entitled to recover all Erroneously Awarded Compensation (as defined in the Clawback Policy) from the Grantee pursuant to such means as the Company and/or the Board may
elect. The Grantee agrees that the Grantee shall take all required action to enable such recovery. The Grantee understands that such recovery may be sought and occur after the Grantee&#146;s employment or service with the Company terminates. The
Grantee further agrees that the Grantee is not entitled to indemnification for any Erroneously Awarded Compensation or for any claim or losses arising out of or in any way related to Erroneously Awarded Compensation recovered pursuant to the
Clawback Policy and, to the extent any agreement or organizational document purports to provide otherwise, the Grantee hereby irrevocably agrees to forego such indemnification. The Grantee acknowledges and agrees that the Grantee has received and
has had an opportunity to review the Clawback Policy. Any action by the Company to recover Erroneously Awarded Compensation under the Clawback Policy from the Grantee shall not, whether alone or in combination with any other action, event or
condition, be deemed (i)&nbsp;an event giving rise to a right to resign for Good Reason (as defined in the Upstream Bio, Inc. Executive Severance Plan) or serve as a basis for a claim of constructive termination under any benefits or compensation
arrangement applicable to the Grantee, or (ii)&nbsp;to constitute a breach of a contract or other arrangement to which the Grantee is a party. This Section&nbsp;12 is a material term of this
Agreement.]<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For Section&nbsp;16 officers only. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>Upstream Bio, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#146;s instructions to the Grantee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8195;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grantee&#146;s Signature</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grantee&#146;s name and address:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTRICTED STOCK UNIT AWARD AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR <FONT STYLE="white-space:nowrap">NON-EMPLOYEE</FONT> DIRECTORS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE UPSTREAM BIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2024 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="73%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name of Grantee:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No. of Restricted Stock Units:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant Date:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Upstream Bio, Inc. 2024 Stock Option and Incentive Plan as amended through the date hereof
(the &#147;Plan&#148;), Upstream Bio, Inc. (the &#147;Company&#148;) hereby grants an award of the number of Restricted Stock Units listed above (an &#147;Award&#148;) to the Grantee named above. Each Restricted Stock Unit shall relate to one share
of Common Stock, par value $0.001 per share (the &#147;Stock&#148;) of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Restrictions on Transfer of Award</U>. This
Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise encumbered or
disposed of until (i)&nbsp;the Restricted Stock Units have vested as provided in Paragraph 2 of this Agreement and (ii)&nbsp;shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Vesting of Restricted Stock Units</U>. The restrictions and conditions of Paragraph&nbsp;1 of this Agreement shall lapse as follows:
_________________ (each such date, a &#147;Vesting Date&#148; ), so long as the Grantee remains in service as a member of the Board on such Vesting Dates. If a series of Vesting Dates is specified, then the restrictions and conditions in
Paragraph&nbsp;1 shall lapse only with respect to the number of Restricted Stock Units specified as vested on such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding
the foregoing, in the event of a Sale Event, 100% of the then-outstanding and unvested Restricted Stock Units shall immediately be deemed vested on the date of such Sale Event; provided, that the Grantee remains in service as a member of the Board
until the date of such Sale Event. The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 2. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.
<U>Termination of Service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director</U>. If the Grantee&#146;s service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director terminates for any reason (including death or
disability) prior to the satisfaction of the vesting conditions set forth in Paragraph 2 above, any Restricted Stock Units that have not vested as of such date shall automatically and without notice terminate and be forfeited, and neither the
Grantee nor any of his or her successors, heirs, assigns or personal representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Issuance of Shares of Stock</U>. As soon as practicable following each Vesting Date
(but in no event later than two and <FONT STYLE="white-space:nowrap">one-half</FONT> months after the end of the year in which the Vesting Date occurs), the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate
number of Restricted Stock Units that have vested pursuant to Paragraph 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Incorporation of Plan</U>. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the
terms and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Section 409A of the Code.</U> This Agreement shall be interpreted in such a manner that all provisions relating to the settlement of
the Award are exempt from the requirements of Section&nbsp;409A of the Code as &#147;short-term deferrals&#148; as described in Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>No Obligation to Continue Service Relationship</U>. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or
this Agreement to continue the Grantee in a Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Grantee&#146;s
Service Relationship with the Company or a Subsidiary at any time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Integration</U>. This Agreement constitutes the entire agreement
between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Data Privacy Consent</U>. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the
Company, its subsidiaries and affiliates and certain agents thereof (together, the &#147;Relevant Companies&#148;) may process any and all personal or professional data, including but not limited to, Social Security or other identification number,
home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#147;Relevant Information&#148;). By entering into this Agreement, the Grantee
(i)&nbsp;authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii)&nbsp;waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii)&nbsp;authorizes
the Relevant Companies to store and transmit such information in electronic form; and (iv)&nbsp;authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have
access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Notices</U>. Notices hereunder shall be mailed or delivered to the Company at its
principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>Upstream Bio, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#146;s instructions to the Grantee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8195;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grantee&#146;s Signature</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grantee&#146;s name and address:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>8
<FILENAME>d843142dex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UPSTREAM BIO, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2024 EMPLOYEE STOCK PURCHASE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the Upstream Bio, Inc. 2024 Employee Stock Purchase Plan (the &#147;Plan&#148;) is to provide eligible employees of Upstream
Bio, Inc. (the &#147;Company&#148;) and each Designated Company (as defined in Section&nbsp;11) with opportunities to purchase shares of the Company&#146;s common stock, par value $0.001 per share (the &#147;Common Stock&#148;). 488,467&nbsp;shares
of Common Stock in the aggregate have been approved and reserved for this purpose, plus on January&nbsp;1, 2025 and each January&nbsp;1 thereafter until the Plan terminates pursuant to Section&nbsp;20, the number of shares of Common Stock reserved
and available for issuance under the Plan shall be cumulatively increased by the least of (i)&nbsp;976,934&nbsp;shares of Common Stock, (ii)&nbsp;1% of the number of Outstanding Shares on the immediately preceding December&nbsp;31, and
(iii)&nbsp;such number of shares of Common Stock as determined by the Administrator (as defined in Section&nbsp;1). The Plan includes two components: a Code Section&nbsp;423 Component (the &#147;423 Component&#148;) and a <FONT
STYLE="white-space:nowrap">non-Code</FONT> Section&nbsp;423 Component (the <FONT STYLE="white-space:nowrap">&#147;Non-423</FONT> Component&#148;). It is intended for the 423 Component to constitute an &#147;employee stock purchase plan&#148; within
the meaning of Section&nbsp;423(b) of the U.S. Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), and the 423 Component shall be interpreted in accordance with that intent. Under the <FONT STYLE="white-space:nowrap">Non-423</FONT>
Component, which does not qualify as an &#147;employee stock purchase plan&#148; within the meaning of Section&nbsp;423(b) of the Code, options will be granted pursuant to rules, procedures or <FONT STYLE="white-space:nowrap">sub-plans</FONT>
adopted by the Administrator designed to comply with appliable laws to achieve tax and other objectives for eligible employees. Except as otherwise provided herein or by the Administrator, the <FONT STYLE="white-space:nowrap">Non-423</FONT>
Component will operate and be administered in the same manner as the 423 Component. Unless otherwise defined herein, capitalized terms in this Plan shall have the meaning ascribed to them in Section&nbsp;11. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Administration</U>. The Plan will be administered by the person or persons (the &#147;Administrator&#148;) appointed by the
Company&#146;s Board of Directors (the &#147;Board&#148;) for such purpose. The Administrator has authority at any time to: (i)&nbsp;adopt, alter and repeal such rules, guidelines and practices for the administration of the Plan and for its own acts
and proceedings as it shall deem advisable; (ii)&nbsp;interpret the terms and provisions of the Plan; (iii)&nbsp;make all determinations it deems advisable for the administration of the Plan, including to accommodate the specific requirements of
applicable laws, regulations and procedures for jurisdictions outside the United States; (iv)&nbsp;decide all disputes arising in connection with the Plan; and (v)&nbsp;otherwise supervise the administration of the Plan. All interpretations and
decisions of the Administrator shall be binding on all persons, including the Company and the Participants. No member of the Board or individual exercising administrative authority with respect to the Plan shall be liable for any action or
determination made in good faith with respect to the Plan or any option granted hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Offerings</U>. The Company may make one
or more offerings to eligible employees to purchase Common Stock under the Plan (&#147;Offerings&#148;) consisting of one or more Purchase Periods. Each Offering will begin and end on the dates to be determined by the Administrator, provided that no
Offering shall exceed 27 months in duration or overlap any other Offering. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Unless the Administrator, in its sole discretion, chooses otherwise prior to an Offering Date (as defined below), and to the extent an Offering has more than one Purchase Period and to the extent
permitted by applicable law, if the Fair Market Value of the Common Stock on any Exercise Date in an Offering is lower than the Fair Market Value of the Common Stock on the Offering Date, then all participants in such Offering automatically will be
withdrawn from such Offering immediately after the exercise of their option on such Exercise Date and automatically <FONT STYLE="white-space:nowrap">re-enrolled</FONT> in the immediately following Offering as of the first day thereof and the
preceding Offering will terminate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Eligibility</U>. All individuals classified as employees on the payroll records of the Company
and each Designated Company are eligible to participate in any one or more of the Offerings under the Plan, provided that, the Administrator may determine, in advance of any Offering, that employees are eligible only if, as of the first day of the
applicable Offering (the &#147;Offering Date&#148;) (a) they are customarily employed by the Company or a Designated Company for more than twenty (20)&nbsp;hours a week (or such lesser number of hours per week consistent with Section&nbsp;423 of the
Code), (b) they are customarily employed by the Company or a Designated Company for more than five months per calendar year, (c)&nbsp;they have completed such minimum period of service prior to the Offering Date (provided such service requirement
does not exceed two years of employment) and/or (d)&nbsp;they satisfy such other criteria as the Administrator may determine consistent with Section&nbsp;423 of the Code. Notwithstanding any other provision herein, individuals who are not
contemporaneously classified as employees of the Company or a Designated Company for purposes of the Company&#146;s or applicable Designated Company&#146;s payroll system are not considered to be eligible employees of the Company or any Designated
Company and shall not be eligible to participate in the Plan. In the event any such individuals are reclassified as employees of the Company or a Designated Company for any purpose, including, without limitation, common law or statutory employees,
by any action of any third party, including, without limitation, any government agency, or as a result of any private lawsuit, action or administrative proceeding, such individuals shall, notwithstanding such reclassification, remain ineligible for
participation. Notwithstanding the foregoing, the exclusive means for individuals who are not contemporaneously classified as employees of the Company or a Designated Company on the Company&#146;s or Designated Company&#146;s payroll system to
become eligible to participate in this Plan is through an amendment or subplan to this Plan, duly executed by the Company, which specifically renders such individuals eligible to participate herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Participation</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>Participants</U>. An eligible employee who is not a Participant in any prior Offering may participate in a subsequent Offering by submitting an enrollment form to the Company or an agent designated by the Company (in the manner described in
Section&nbsp;4(b)) at least 15 business days before the Offering Date (or by such other deadline as shall be established by the Administrator for the Offering). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Enrollment</U>. The enrollment form (which may be in an electronic format or such other method as determined by the Company in
accordance with the Company&#146;s practices) will (a)&nbsp;state a whole percentage or amount to be deducted from an eligible employee&#146;s Compensation (as defined in Section&nbsp;11) per pay period, (b)&nbsp;authorize the purchase
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of Common Stock in each Offering in accordance with the terms of the Plan and (c)&nbsp;specify the exact name or names in which shares of Common Stock purchased for such individual are to be
issued pursuant to Section&nbsp;10. An employee who does not enroll in accordance with these procedures will be deemed to have waived the right to participate. Unless a Participant files a new enrollment form or withdraws from the Plan, such
Participant&#146;s deductions or contributions and purchases will continue at the same percentage or amount of Compensation for future Offerings, provided he or she remains eligible. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding the foregoing, participation in the Plan will neither be permitted nor be denied contrary to the requirements of the Code.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Employee Contributions</U>. Each eligible employee may authorize payroll deductions at a minimum of 1&nbsp;percent up to a maximum
of 15&nbsp;percent of such employee&#146;s Compensation for each pay period. The Company will maintain book accounts showing the amount of payroll deductions made by each Participant for each Offering. No interest will accrue or be paid on payroll
deductions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Deduction Changes</U>. Except as may be determined by the Administrator in advance of an Offering, a Participant may not
increase or decrease his or her payroll deduction or contributions during any Offering, but may increase or decrease his or her payroll deduction or contributions with respect to the next Offering (subject to the limitations of Section&nbsp;5) by
filing a new enrollment form at least 15 business days before the next Offering Date (or by such other deadline as shall be established by the Administrator for the Offering). The Administrator may, in advance of any Offering, establish rules
permitting a Participant to increase, decrease or terminate his or her payroll deduction or contributions during an Offering. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.
<U>Withdrawal</U>. A Participant may withdraw from participation in the Plan by delivering a written notice of withdrawal to the Company or an agent designated by the Company (in accordance with such procedures as may be established by the
Administrator). The Participant&#146;s withdrawal will be effective as of the next business day (or such other date established by the Administrator). Following a Participant&#146;s withdrawal, the Company will promptly refund such individual&#146;s
entire account balance under the Plan to him or her (after payment for any Common Stock purchased before the effective date of withdrawal). Partial withdrawals are not permitted. Such an employee may not begin participation again during the
remainder of the Offering, but may enroll in a subsequent Offering in accordance with Section&nbsp;4. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Grant of Options</U>. On each
Offering Date, the Company will grant to each eligible employee who is then a Participant in the Plan an option (&#147;Option&#148;) to purchase on the last day of a Purchase Period (the &#147;Exercise Date&#148;) at the Option Price hereinafter
provided for, the lower of (a)&nbsp;a number of shares of Common Stock determined by dividing such Participant&#146;s accumulated payroll deductions on such Exercise Date by the Option Price (as defined herein) or (b)&nbsp;the number of shares of
Common Stock determined by dividing $25,000 by the Fair Market Value of the Common Stock on the Offering Date for such Offering (or such other maximum number of shares as shall have been established by the Administrator in advance of the Offering);
provided, however, that such Option shall be subject to the limitations set forth below. Each Participant&#146;s Option shall be exercisable only to the extent of such Participant&#146;s accumulated payroll deductions on the Exercise Date. The
purchase price for each share purchased under each Option (the &#147;Option Price&#148;) will be 85&nbsp;percent of the Fair Market Value of the Common Stock on the Offering Date or the Exercise Date, whichever is less. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, no Participant may be granted an Option hereunder if such
Participant, immediately after the Option was granted, would be treated as owning stock possessing 5&nbsp;percent or more of the total combined voting power or value of all classes of stock of the Company or any Parent or Subsidiary (as defined in
Section&nbsp;11). For purposes of the preceding sentence, the attribution rules of Section&nbsp;424(d) of the Code shall apply in determining the stock ownership of a Participant, and all stock which the Participant has a contractual right to
purchase shall be treated as stock owned by the Participant. In addition, no Participant may be granted an Option which permits his or her rights to purchase stock under the Plan, and any other employee stock purchase plan of the Company and its
Parents and Subsidiaries, to accrue at a rate which exceeds $25,000 of the Fair Market Value of such stock (determined on the option grant date or dates) for each calendar year in which the Option is outstanding at any time. The purpose of the
limitation in the preceding sentence is to comply with Section&nbsp;423(b)(8) of the Code and shall be applied taking Options into account in the order in which they were granted. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Exercise of Option and Purchase of Shares</U>. Each employee who continues to be a Participant in the Plan on the Exercise Date shall be
deemed to have exercised his or her Option on such date and shall acquire from the Company such number of whole shares of Common Stock reserved for the purpose of the Plan as his or her accumulated payroll deductions or contributions on such date
will purchase at the Option Price, subject to any other limitations contained in the Plan. Unless otherwise determined by the Administrator in advance of an Offering, any amount remaining in a Participant&#146;s account after the purchase of shares
at the end of an Offering solely by reason of the inability to purchase a fractional share will be carried forward to the next Offering; any other balance remaining in a Participant&#146;s account at the end of an Offering will be refunded to the
Participant promptly. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Issuance of Certificates</U>. Certificates or book-entries at the Company&#146;s transfer agent representing
shares of Common Stock purchased under the Plan may be issued only in the name of the employee, in the name of the employee and another person of legal age as joint tenants with rights of survivorship or in the name of a broker authorized by the
employee to be his, her or their nominee for such purpose. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Definitions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Affiliate&#148; means any entity that, directly or indirectly through one or more intermediaries, controls, is controlled by or
is under the common control with, the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Compensation&#148; means the amount of base pay, prior to salary reduction
pursuant to Sections&nbsp;125, 132(f) or 401(k) of the Code, but excluding overtime, commissions, incentive or bonus awards, allowances and reimbursements for expenses such as relocation allowances or travel expenses, income or gains on the exercise
of Company stock options and similar items. The Administrator shall have the discretion to determine the application of this definition to Participants outside the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Designated Company&#148; means any present or future Subsidiary or Affiliate
that has been designated by the Administrator to participate in the Plan. The Administrator may so designate any Subsidiary or Affiliate, or revoke any such designation, at any time and from time to time, either before or after the Plan is approved
by the stockholders, and may further designate such companies or Participants as participating in the 423 Component or the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. The Administrator may also determine which Affiliates or eligible
employees may be excluded from participation in the Plan, to the extent consistent with Section&nbsp;423 of the Code or as implemented under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component, and determine which Designated Company or
Companies will participate in separate Offerings (to the extent that the Company makes separate Offerings). For purposes of the 423 Component, only the Company and its Subsidiaries may be Designated Companies; provided, however, that at any given
time, a Subsidiary that is a Designated Company under the 423 Component will not be a Designated Company under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. The current list of Designated Companies is attached hereto as Appendix A.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Fair Market Value of the Common Stock&#148; on any given date means the fair market value of the Common Stock determined
in good faith by the Administrator; provided, however, that if the Common Stock is admitted to quotation on the National Association of Securities Dealers Automated Quotation System (&#147;Nasdaq&#148;), Nasdaq Global Market or another national
securities exchange, the determination shall be made by reference to the closing price on such date. If there is no closing price for such date, the determination shall be made by reference to the last date preceding such date for which there is a
closing price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Initial Public Offering&#148; means the first underwritten, firm commitment public offering pursuant to an
effective registration statement under the U.S. Securities Act of 1933, as amended, covering the offer and sale by the Company of its Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;New Exercise Date&#148; means a new Exercise Date if the Administrator shortens any Offering then in progress. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Outstanding Shares&#148; means, as of a specified date, the sum of (a)&nbsp;the number of shares of Common Stock issued and
outstanding and (b)&nbsp;the number of shares of Common Stock issuable pursuant to the exercise of any outstanding, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to acquire Common Stock for a nominal exercise price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Parent&#148; means a &#147;parent corporation&#148; with respect to the Company, as defined in Section&nbsp;424(e) of the Code.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Participant&#148; means an individual who is eligible as determined in Section&nbsp;3 and who has complied with the
provisions of Section&nbsp;4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Purchase Period&#148; means a period of time within an Offering, as may be specified by the
Administrator in accordance with Section&nbsp;2, generally beginning on the Offering Date or the next day following an Exercise Date within an Offering, and ending on an Exercise Date. An Offering may consist of one or more Purchase Periods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Registration Date&#148; means the date on which the registration statement on
Form <FONT STYLE="white-space:nowrap">S-1</FONT> that is filed by the Company with respect to its Initial Public Offering is declared effective by the U.S. Securities and Exchange Commission (the &#147;SEC&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Sale Event&#148; means (i)&nbsp;the sale of all or substantially all of the assets of the Company on a consolidated basis to an
unrelated person or entity, (ii)&nbsp;a merger, reorganization, statutory share exchange, consolidation, or similar transaction pursuant to which the holders of the Company&#146;s outstanding voting power and outstanding stock immediately prior to
such transaction do not own a majority of the outstanding voting power and outstanding stock or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable) immediately upon completion of such transaction,
(iii)&nbsp;the sale of all of the Common Stock to an unrelated person, entity or group thereof acting in concert, (iv)&nbsp;any other transaction in which the owners of the Company&#146;s outstanding voting power immediately prior to such
transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon completion of the transaction other than as a result of the acquisition of securities directly from the Company, or
(v)&nbsp;the approval by the stockholders of the Company of a complete liquidation or dissolution of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term
&#147;Subsidiary&#148; means a &#147;subsidiary corporation&#148; with respect to the Company, as defined in Section&nbsp;424(f) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Rights on Termination or Transfer of Employment</U>. If a Participant&#146;s employment terminates for any reason before the Exercise
Date for any Offering, no payroll deduction or contributions will be taken from any pay due and owing to the Participant and the balance in the Participant&#146;s account will be paid to such Participant or, in the case of such Participant&#146;s
death, if permitted by the Administrator and valid under applicable law, to his or her designated beneficiary or to the legal representative of his or her estate as if such Participant had withdrawn from the Plan under Section&nbsp;7. An employee
will be deemed to have terminated employment, for this purpose, if the corporation that employs him or her, having been a Designated Company, ceases to be a Subsidiary or Affiliate, or if the employee is transferred to any corporation other than the
Company or a Designated Company. Unless otherwise determined by the Administrator, a Participant whose employment transfers between, or whose employment terminates with an immediate rehire (with no break in service) by, Designated Companies or a
Designated Company and the Company will not be treated as having terminated employment for purposes of participating in the Plan or an Offering; provided, however, that if a Participant transfers from an Offering under the 423 Component to an
Offering under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component, the exercise of the Participant&#146;s Option will be qualified under the 423 Component only to the extent that such exercise complies with Section&nbsp;423 of the Code.
If a Participant transfers from an Offering under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component to an Offering under the 423 Component, the exercise of the Participant&#146;s Option will remain
<FONT STYLE="white-space:nowrap">non-qualified</FONT> under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. Further, an employee will not be deemed to have terminated employment for purposes of this Section&nbsp;12 if the employee is
on an approved leave of absence for military service or sickness or for any other purpose approved by the Company, if the employee&#146;s right to reemployment is guaranteed either by a statute or by contract or under the policy pursuant to which
the leave of absence was granted or if the Administrator otherwise provides in writing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Special Rules and <FONT STYLE="white-space:nowrap">Sub-Plans</FONT></U>.
Notwithstanding anything herein to the contrary, the Administrator may adopt special rules or <FONT STYLE="white-space:nowrap">sub-plans</FONT> applicable to the employees of a particular Designated Company, whenever the Administrator determines
that such rules are necessary or appropriate for the implementation of the Plan in a jurisdiction where such Designated Company has employees, regarding, without limitation, eligibility to participate in the Plan, handling and making of payroll
deductions or contributions by other means, establishment of bank or trust accounts to hold payroll deductions or contributions, payment of interest, conversion of local currency, obligation to pay payroll tax, withholding procedures and handling of
share issuances, any of which may vary according to applicable requirements; provided that if such special rules or <FONT STYLE="white-space:nowrap">sub-plans</FONT> are inconsistent with the requirements of Section&nbsp;423(b) of the Code, the
employees subject to such special rules or <FONT STYLE="white-space:nowrap">sub-plans</FONT> will participate in the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Optionees Not Stockholders</U>. Neither the granting of an Option to a Participant nor the deductions or contributions from his or her
pay shall result in such Participant becoming a holder of the shares of Common Stock covered by an Option under the Plan until such shares have been purchased by and issued to him or her. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Rights Not Transferable</U>. Rights under the Plan are not transferable by a Participant other than by will or the laws of descent and
distribution, and are exercisable during the Participant&#146;s lifetime only by the Participant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Application of Funds</U>. All
funds received or held by the Company under the Plan may be combined with other corporate funds and may be used for any corporate purpose, unless otherwise required under applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>Adjustment in Case of Changes Affecting Common Stock</U>. In the event of a subdivision of outstanding shares of Common Stock, the
payment of a dividend in Common Stock or any other change affecting the Common Stock, the number of shares approved for the Plan and the share limitation set forth in Section&nbsp;8 shall be equitably or proportionately adjusted to give proper
effect to such event. In the case of and subject to the consummation of a Sale Event, the Administrator, in its discretion, and on such terms and conditions as it deems appropriate, is hereby authorized to take any one or more of the following
actions whenever the Administrator determines that such action is appropriate in order to prevent the dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan or with respect to any right under the
Plan or to facilitate such transactions or events: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) To provide for either (i)&nbsp;termination of any outstanding Option in exchange
for an amount of cash, if any, equal to the amount that would have been obtained upon the exercise of such Option had such Option been currently exercisable or (ii)&nbsp;the replacement of such outstanding Option with other options or property
selected by the Administrator in its sole discretion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) To provide that the outstanding Options under the Plan shall be assumed by the
successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted for similar options covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the
number and kind of shares and prices. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To make adjustments in the number and type of shares of Common Stock (or other
securities or property) subject to outstanding Options under the Plan and/or in the terms and conditions of outstanding Options and Options that may be granted in the future. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) To provide that the Offering with respect to which an Option relates will be shortened by setting a New Exercise Date on which such
Offering will end. The New Exercise Date will occur before the date of the Sale Event. The Administrator will notify each Participant in writing or electronically prior to the New Exercise Date, that the Exercise Date for the Participant&#146;s
Option has been changed to the New Exercise Date and that the Participant&#146;s Option will be exercised automatically on the New Exercise Date, unless prior to such date the Participant has withdrawn from the Offering as provided in Section&nbsp;7
hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) To provide that all outstanding Options shall terminate without being exercised and all amounts in the accounts of
Participants shall be promptly refunded. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>Amendment of the Plan</U>. The Board may at any time and from time to time amend the Plan
in any respect, except that without the approval within 12 months of such Board action by the stockholders, no amendment shall be made increasing the number of shares approved for the Plan or making any other change that would require stockholder
approval in order for the 423 Component of the Plan, as amended, to qualify as an &#147;employee stock purchase plan&#148; under Section&nbsp;423(b) of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <U>Insufficient Shares</U>. If the total number of shares of Common Stock that would otherwise be purchased on any Exercise Date plus the
number of shares purchased under previous Offerings under the Plan exceeds the maximum number of shares issuable under the Plan, the shares then available shall be apportioned among Participants in proportion to the amount of payroll deductions or
contributions accumulated on behalf of each Participant that would otherwise be used to purchase Common Stock on such Exercise Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20.
<U>Termination of the Plan</U>. The Plan may be terminated at any time by the Board. Upon termination of the Plan, all amounts in the accounts of Participants shall be promptly refunded. Unless terminated earlier, the Plan shall expire on the <FONT
STYLE="white-space:nowrap">ten-year</FONT> anniversary of the Registration Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <U>Governmental Regulations</U>. The Company&#146;s
obligation to sell and deliver Common Stock under the Plan is subject to applicable laws and the completion of any registration or qualification of the Common Stock under any U.S. or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> local, state or
federal securities or exchange control law, or under rulings or regulations of the SEC or of any other governmental regulatory body, and to obtaining any approval or other clearance from any U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
local, state or federal governmental agency, which registration, qualification or approval the Company shall, in its absolute discretion, deem necessary or advisable. The Company is under no obligation to register or qualify the Common Stock with
the SEC or any other U.S. or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> securities commission or to seek approval or clearance from any governmental authority for the issuance or sale of such stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. <U>Governing Law</U>. This Plan and all Options and actions taken thereunder shall be
governed by, and construed in accordance with, the laws of the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal
laws of the State of Delaware applied without regard to conflict of law principles. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23. <U>Issuance of Shares</U>. Shares may be issued
upon exercise of an Option from authorized but unissued Common Stock, from shares held in the treasury of the Company or from any other proper source. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24. <U>Tax Withholding</U>. Participation in the Plan is subject to any applicable U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
federal, state or local tax withholding requirements on income the Participant realizes in connection with the Plan. Each Participant agrees, by entering the Plan, that the Company or any Subsidiary or Affiliate may, but will not be obligated to,
withhold from a Participant&#146;s wages, salary or other compensation at any time the amount necessary for the Company or any Subsidiary or Affiliate to meet applicable withholding obligations, including any withholding required to make available
to the Company or any Subsidiary or Affiliate any tax deductions or benefits attributable to the sale or disposition of Common Stock by such Participant. In addition, the Company or any Subsidiary or Affiliate may, but will not be obligated to,
withhold from the proceeds of the sale of Common Stock or use any other method of withholding that the Company or any Subsidiary or Affiliate deems appropriate to the extent permitted by U.S. Treasury Regulation
<FONT STYLE="white-space:nowrap">Section&nbsp;1.423-2(f)</FONT> with respect to the 423 Component. The Company will not be required to issue any Common Stock under the Plan until such obligations are satisfied. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25. <U>Notification Upon Sale of Shares Under the 423 Component</U>. Each Participant agrees, by entering the 423 Component of the Plan, to
give the Company prompt notice of any disposition of shares purchased under the Plan where such disposition occurs within two years after the date of grant of the Option pursuant to which such shares were purchased or within one year after the date
such shares were purchased. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">26. <U>Effective Date and Approval of Stockholders</U>. The Plan shall take effect on the date immediately
preceding the Registration Date, subject to approval by the holders of a majority of the votes cast at a meeting of stockholders at which a quorum is present or by written consent of the stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Designated Companies </U></B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>9
<FILENAME>d843142dex104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.4 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UPSTREAM BIO, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM
OF EMPLOYEE DIRECTOR / OFFICER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Indemnification Agreement (&#147;<B>Agreement</B>&#148;) is made as of [&#149;], 2024, by and between Upstream Bio, Inc., a Delaware
corporation (the &#147;<B>Company</B>&#148;), and [Name] (&#147;<B>Indemnitee</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">RECITALS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Company;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in order to induce Indemnitee to [continue to] provide services to the Company, the Company wishes to provide for the
indemnification of, and advancement of expenses to, Indemnitee to the maximum extent permitted by law; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Third Amended and
Restated Certificate of Incorporation (as amended and in effect from time to time, the &#147;<B>Charter</B>&#148;) and the Amended and Restated Bylaws (as amended and in effect from time to time, the &#147;<B>Bylaws</B>&#148;) of the Company require
indemnification of the officers and directors of the Company, and Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware (the &#147;<B>DGCL</B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Charter, the Bylaws and the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive, and
thereby contemplate that contracts may be entered into between the Company and members of the board of directors, officers and other persons with respect to indemnification; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Board of Directors of the Company (the &#147;<B>Board</B>&#148;) has determined that the increased difficulty in attracting and
retaining highly qualified persons such as Indemnitee is detrimental to the best interests of the Company&#146;s stockholders; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS,
it is reasonable and prudent for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law, regardless of any amendment or revocation of the
Charter or the Bylaws, so that they will [continue to] serve the Company free from undue concern that they will not be so indemnified; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, this Agreement is a supplement to and in furtherance of the indemnification provided in the Charter, the Bylaws and any resolutions
adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree
as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1. <U>Services to the Company</U>. Indemnitee agrees to [continue to] serve as
[a director and] an officer of the Company. Indemnitee may at any time and for any reason resign from [any] such position (subject to any other contractual obligation or any obligation imposed by law), in which event the Company shall have no
obligation under this Agreement to continue Indemnitee in such position. This Agreement shall not be deemed an employment contract between the Company (or any of its subsidiaries or any Enterprise) and Indemnitee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2. <U>Definitions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
&#147;Affiliate&#148; and &#147;Associate&#148; shall have the respective meanings ascribed to such terms in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the General Rules and Regulations under the Securities Exchange Act of 1934, as
amended (the &#147;<B>Exchange Act</B>&#148;), as in effect on the date of this Agreement; provided, however, that no Person who is a director or officer of the Company shall be deemed an Affiliate or an Associate of any other director or officer of
the Company solely as a result of his or her position as director or officer of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) A Person shall be deemed the
&#147;Beneficial Owner&#148; of, and shall be deemed to &#147;Beneficially Own&#148; and have &#147;Beneficial Ownership&#148; of, any securities: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) which such Person or any of such Person&#146;s Affiliates or Associates, directly or indirectly, Beneficially Owns (as determined pursuant
to Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> of the Rules under the Exchange Act, as in effect on the date of this Agreement); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) which such Person or any of such Person&#146;s Affiliates or Associates, directly or indirectly, has: (A)&nbsp;the legal, equitable or
contractual right or obligation to acquire (whether directly or indirectly and whether exercisable immediately or only after the passage of time, compliance with regulatory requirements, satisfaction of one or more conditions (whether or not within
the control of such Person) or otherwise) upon the exercise of any conversion rights, exchange rights, rights, warrants or options, or otherwise; (B)&nbsp;the right to vote pursuant to any agreement, arrangement or understanding (whether or not in
writing); or (C)&nbsp;the right to dispose of pursuant to any agreement, arrangement or understanding (whether or not in writing) (other than customary arrangements with and between underwriters and selling group members with respect to a bona fide
public offering of securities); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) which are Beneficially Owned, directly or indirectly, by any other Person (or any Affiliate or
Associate thereof) with which such Person or any of such Person&#146;s Affiliates or Associates has any agreement, arrangement or understanding (whether or not in writing) (other than customary agreements with and between underwriters and selling
group members with respect to a bona fide public offering of securities) for the purpose of acquiring, holding, voting or disposing of any securities of the Company; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) that are the subject of a derivative transaction entered into by such Person or any of such Person&#146;s Affiliates or Associates,
including, for these purposes, any derivative security acquired by such Person or any of such Person&#146;s Affiliates or Associates that gives such Person or any of such Person&#146;s Affiliates or Associates the economic equivalent of ownership of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
an amount of securities due to the fact that the value of the derivative security is explicitly determined by reference to the price or value of such securities, or that provides such Person or
any of such Person&#146;s Affiliates or Associates an opportunity, directly or indirectly, to profit or to share in any profit derived from any change in the value of such securities, in any case without regard to whether (A)&nbsp;such derivative
security conveys any voting rights in such securities to such Person or any of such Person&#146;s Affiliates or Associates; (B)&nbsp;the derivative security is required to be, or capable of being, settled through delivery of such securities; or
(C)&nbsp;such Person or any of such Person&#146;s Affiliates or Associates may have entered into other transactions that hedge the economic effect of such derivative security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, no Person engaged in business as an underwriter of securities shall be deemed the Beneficial Owner of any
securities acquired through such Person&#146;s participation as an underwriter in good faith in a firm commitment underwriting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) A
&#147;Change in Control&#148; shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events<I>:</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Acquisition of Stock by Third Party</U>. Any Person is or becomes the Beneficial Owner (as defined above), directly or indirectly, of
securities of the Company representing fifty percent (50%) or more of the combined voting power of the Company&#146;s then outstanding securities unless the change in relative Beneficial Ownership of the Company&#146;s securities by any Person
results solely from a reduction in the aggregate number of outstanding shares of securities entitled to vote generally in the election of directors, provided that a Change of Control shall be deemed to have occurred if subsequent to such reduction
such Person becomes the Beneficial Owner, directly or indirectly, of any additional securities of the Company conferring upon such Person any additional voting power; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) <U>Change in Board of Directors</U>. During any period of two (2)&nbsp;consecutive years (not including any period prior to the execution
of this Agreement), individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated by a Person who has entered into an agreement with the Company to effect a transaction described in
Sections 2(c)(i), 2(c)(iii) or 2(c)(iv)) whose election by the Board or nomination for election by the Company&#146;s stockholders was approved by a vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the directors then still in
office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the members of the Board; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) <U>Corporate Transactions</U>. The effective date of a merger or consolidation of the Company with any other entity, other than a merger
or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the
surviving or successor entity) more than 50% of the combined voting power of the voting securities of the surviving or successor entity outstanding immediately after such merger or consolidation and with the power to elect at least a majority of the
board of directors or other governing body of such surviving or successor entity; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) <U>Liquidation</U>. The approval by the stockholders of the Company of a complete
liquidation of the Company or an agreement for the sale, lease, exchange or other transfer by the Company, in one or a series of related transactions, of all or substantially all of the Company&#146;s assets; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) <U>Other Events</U>. There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule
14A of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act whether or not the Company is then subject to such reporting requirement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) &#147;<U>Corporate Status</U>&#148; describes the status of a person as a current or former [director or] officer of the Company or current
or former director, manager, partner, officer, employee, agent or trustee of any other Enterprise which such person is or was serving at the request of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) &#147;<U>Enforcement Expenses</U>&#148; shall include all reasonable attorneys&#146; fees, court costs, transcript costs, fees of experts,
travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> disbursements or expenses
of the types customarily incurred in connection with an action to enforce indemnification or advancement rights, or an appeal from such action. Expenses, however, shall not include fees, salaries, wages or benefits owed to Indemnitee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) &#147;<U>Enterprise</U>&#148; shall mean any corporation (other than the Company), partnership, joint venture, trust, employee benefit
plan, limited liability company, or other legal entity of which Indemnitee is or was serving at the request of the Company as a director, manager, partner, officer, employee, agent or trustee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) &#147;<U>Expenses</U>&#148; shall include all reasonable attorneys&#146; fees, court costs, transcript costs, fees of experts, travel
expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> disbursements or expenses of the
types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding or an appeal resulting from a Proceeding.
Expenses, however, shall not include amounts paid in settlement by Indemnitee, the amount of judgments or fines against Indemnitee or fees, salaries, wages or benefits owed to Indemnitee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) &#147;<U>Independent Counsel</U>&#148; means a law firm, or a partner (or, if applicable, member or shareholder) of such a law firm, that
is experienced in matters of Delaware corporation law and neither presently is, nor in the past five (5)&nbsp;years has been, retained to represent: (i)&nbsp;the Company, any subsidiary of the Company, any Enterprise or Indemnitee in any matter
material to any such party; or (ii)&nbsp;any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term &#147;Independent Counsel&#148; shall not include any Person who, under the
applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee&#146;s rights under this Agreement. The Company agrees to pay the
reasonable fees and expenses of the Independent Counsel referred to above and to fully indemnify such counsel against any and all expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant
hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) &#147;Person&#148; shall mean (i)&nbsp;an individual, a corporation, a partnership, a
limited liability company, an association, a joint stock company, a trust, a business trust, a government or political subdivision, any unincorporated organization or any other association or entity including any successor (by merger or otherwise)
thereof or thereto, and (ii)&nbsp;a &#147;group&#148; as that term is used for purposes of Section&nbsp;13(d)(3) of the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)
The term &#147;Proceeding&#148; shall include any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed
proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative, regulatory or investigative nature, and whether formal or informal, in which Indemnitee was, is or will be involved as a party or
otherwise by reason of the fact that Indemnitee is or was [a director or] an officer of the Company or is or was serving at the request of the Company as a director, manager, partner, officer, employee, agent or trustee of any Enterprise or by
reason of any action taken by Indemnitee or of any action taken on his or her part while acting as [a director or] an officer of the Company or while serving at the request of the Company as a director, manager, partner, officer, employee, agent or
trustee of any Enterprise, in each case whether or not serving in such capacity at the time any liability or expense is incurred for which indemnification, reimbursement or advancement of expenses can be provided under this Agreement; provided,
however, that the term &#147;Proceeding&#148; shall not include any action, suit or arbitration, or part thereof, initiated by Indemnitee to enforce Indemnitee&#146;s rights under this Agreement as provided for in Section&nbsp;12(a) of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3. <U>Indemnity in Third-Party Proceedings</U>. The Company shall indemnify Indemnitee to the extent set forth in
this Section&nbsp;3 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section&nbsp;3,
Indemnitee shall be indemnified against all Expenses, judgments, fines, penalties, excise taxes, and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim,
issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal proceeding, had no reasonable cause to believe that
his or her conduct was unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4. <U>Indemnity in Proceedings by or in the Right of the Company</U>. The Company shall
indemnify Indemnitee to the extent set forth in this Section&nbsp;4 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this
Section&nbsp;4, Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith
and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company. No indemnification for Expenses shall be made under this Section&nbsp;4 in respect of any claim, issue or matter as to which Indemnitee shall
have been finally adjudged by a court to be liable to the Company, unless and only to the extent that the Delaware Court of Chancery (the &#147;<B>Delaware Court</B>&#148;) shall determine upon application that, despite the adjudication of liability
but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification for such expenses as the Delaware Court shall deem proper. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5. <U>Indemnification for Expenses of a Party Who is Wholly or Partly
Successful</U>. Notwithstanding any other provisions of this Agreement and except as provided in Section&nbsp;7, to the extent that Indemnitee is a party to or a participant in any Proceeding and is successful in such Proceeding or in defense of any
claim, issue or matter therein, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him or her in connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful as to one
or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee or on his or her behalf in connection with each successfully resolved
claim, issue or matter. For purposes of this Section and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim,
issue or matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6. <U>Reimbursement for Expenses of a Witness or in Response to a Subpoena</U>. Notwithstanding any other
provision of this Agreement, to the extent that Indemnitee, by reason of his or her Corporate Status, (i)&nbsp;is a witness in any Proceeding to which Indemnitee is not a party and is not threatened to be made a party or (ii)&nbsp;receives a
subpoena with respect to any Proceeding to which Indemnitee is not a party and is not threatened to be made a party, the Company shall reimburse Indemnitee for all Expenses actually and reasonably incurred by him or her or on his or her behalf in
connection therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7. <U>Exclusions</U>. Notwithstanding any provision in this Agreement to the contrary, the Company
shall not be obligated under this Agreement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) to indemnify for amounts otherwise indemnifiable hereunder (or for which advancement is
provided hereunder) if and to the extent that Indemnitee has otherwise actually received such amounts under any insurance policy, contract, agreement or otherwise; provided that the foregoing shall not apply to any personal or umbrella liability
insurance maintained by Indemnitee; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) to indemnify for an accounting of profits made from the purchase and sale (or sale and purchase)
by Indemnitee of securities of the Company within the meaning of Section&nbsp;16(b) of the Exchange Act or similar provisions of state statutory law or common law; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) to indemnify for any reimbursement of, or repayment to, the Company by Indemnitee of (i)&nbsp;any bonus or other incentive-based or
equity-based compensation or of any profits realized by Indemnitee from the sale of securities of the Company pursuant to the terms of (A)&nbsp;Section&nbsp;304 of SOX, (B)&nbsp;Exchange Act Rule <FONT STYLE="white-space:nowrap">10D-1</FONT> or
(C)&nbsp;any formal policy of the Company adopted by the Board (or a committee thereof) or (ii)&nbsp;any other remuneration paid to Indemnitee if it shall be determined by a final judgment or other final adjudication that payment of such
remuneration was or would have been in violation of law; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) to indemnify with respect to any Proceeding, or part thereof, brought by Indemnitee
against the Company, any legal entity which it controls, any director or officer thereof or any third party, unless (i)&nbsp;the Board has consented to the initiation of such Proceeding or part thereof and (ii)&nbsp;the Company provides the
indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law; provided, however, that this Section&nbsp;7(d) shall not apply to (A)&nbsp;counterclaims or affirmative defenses asserted by Indemnitee in an
action brought against Indemnitee or (B)&nbsp;any action brought by Indemnitee for indemnification or advancement from the Company under this Agreement or under any directors&#146; and officers&#146; liability insurance policies maintained by the
Company in the suit for which indemnification or advancement is being sought as described in Section&nbsp;12; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) to provide any
indemnification or advancement of expenses that is prohibited by applicable law (as such law exists at the time payment would otherwise be required pursuant to this Agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8. <U>Advancement of Expenses</U>. Subject to Section&nbsp;9(b), the Company shall advance the Expenses incurred by Indemnitee in
connection with any Proceeding, and such advancement shall be made within thirty (30)&nbsp;days after the receipt by the Company of a statement or statements requesting such advances (including any invoices received by Indemnitee, which such
invoices may be redacted as necessary to avoid the waiver of any privilege accorded by applicable law) from time to time, whether prior to or after final disposition of any Proceeding. Advances shall be unsecured and interest free. Advances shall be
made without regard to Indemnitee&#146;s (i)&nbsp;ability to repay the expenses, (ii)&nbsp;ultimate entitlement to indemnification under the other provisions of this Agreement and (iii)&nbsp;entitlement to and availability of insurance coverage,
including advancement, payment or reimbursement of defense costs, expenses or covered loss under the provisions of any applicable insurance policy (including, without limitation, whether such advancement, payment or reimbursement is withheld,
conditioned or delayed by the insurer(s)). Indemnitee shall qualify for advances upon the execution and delivery to the Company of this Agreement which shall constitute an undertaking providing that Indemnitee undertakes to the fullest extent
required by law to repay the advance if and to the extent that it is ultimately determined by a court of competent jurisdiction in a final judgment, not subject to appeal, that Indemnitee is not entitled to be indemnified by the Company. No other
form of undertaking shall be required. The right to advances under this paragraph shall in all events continue until final disposition of any Proceeding, including any appeal therein. Nothing in this Section&nbsp;8 shall limit Indemnitee&#146;s
right to advancement pursuant to Section&nbsp;12(e) of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9. <U>Procedure for Notification and Defense of
Claim</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request therefor
specifying the basis for the claim, the amounts for which Indemnitee is seeking payment under this Agreement, and all documentation related thereto as reasonably requested by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In the event that the Company shall be obligated hereunder to provide indemnification
for or make any advancement of Expenses with respect to any Proceeding, the Company shall be entitled to assume the defense of such Proceeding, or any claim, issue or matter therein, with counsel approved by Indemnitee (which approval shall not be
unreasonably withheld or delayed) upon the delivery to Indemnitee of written notice of the Company&#146;s election to do so. After delivery of such notice, approval of such counsel by Indemnitee and the retention of such counsel by the Company, the
Company will not be liable to Indemnitee under this Agreement for any fees or expenses of separate counsel subsequently employed by or on behalf of Indemnitee with respect to the same Proceeding; provided that (i)&nbsp;Indemnitee shall have the
right to employ separate counsel in any such Proceeding at Indemnitee&#146;s expense and (ii)&nbsp;if (A) the employment of separate counsel by Indemnitee has been previously authorized by the Company, (B)&nbsp;Indemnitee shall have reasonably
concluded that there may be a conflict of interest between the Company and Indemnitee in the conduct of such defense, (C)&nbsp;the Company shall not continue to retain such counsel to defend such Proceeding, or (D)&nbsp;a Change in Control shall
have occurred, then the fees and expenses actually and reasonably incurred by Indemnitee with respect to his or her separate counsel shall be Expenses hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In the event that the Company does not assume the defense in a Proceeding pursuant to paragraph (b)&nbsp;above, then the Company will be
entitled to participate in the Proceeding at its own expense. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company shall not be liable to indemnify Indemnitee under this
Agreement for any amounts paid in settlement of any Proceeding effected without its prior written consent (which consent shall not be unreasonably withheld or delayed). Without limiting the generality of the foregoing, the fact that an insurer under
an applicable insurance policy delays or is unwilling to consent to such settlement or is or may be in breach of its obligations under such policy, or the fact that directors&#146; and officers&#146; liability insurance is otherwise unavailable or
not maintained by the Company, may not be taken into account by the Company in determining whether to provide its consent. The Company shall not, without the prior written consent of Indemnitee (which consent shall not be unreasonably withheld or
delayed), enter into any settlement which (i)&nbsp;includes an admission of fault of Indemnitee, any <FONT STYLE="white-space:nowrap">non-monetary</FONT> remedy imposed on Indemnitee or any monetary damages for which Indemnitee is not wholly and
actually indemnified hereunder or (ii)&nbsp;with respect to any Proceeding with respect to which Indemnitee may be or is made a party or may be otherwise entitled to seek indemnification hereunder, does not include the full release of Indemnitee
from all liability in respect of such Proceeding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10. <U>Procedure Upon Application for Indemnification.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Upon written request by Indemnitee for indemnification pursuant to Section&nbsp;9(a), a determination, if such determination is required by
applicable law, with respect to Indemnitee&#146;s entitlement to indemnification hereunder shall be made in the specific case by one of the following methods: (x)&nbsp;if a Change in Control shall have occurred and indemnification is being requested
by Indemnitee hereunder in his or her capacity as a director of the Company, by Independent Counsel in a written opinion to the Board; or (y)&nbsp;in any other case, (i)&nbsp;by a majority vote of the disinterested directors, even though less than a
quorum; (ii)&nbsp;by a committee of disinterested directors designated by a majority vote of the disinterested directors, even though less than a quorum; or (iii)&nbsp;if there are no disinterested directors or if the disinterested directors so
direct, by Independent Counsel in a written opinion to the Board. For purposes hereof, disinterested directors are those members of the Board who are not parties to the action, suit or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proceeding in respect of which indemnification is sought. In the case that such determination is made by Independent Counsel, a copy of Independent Counsel&#146;s written opinion shall be
delivered to Indemnitee and, if it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within thirty (30)&nbsp;days after such determination. Indemnitee shall cooperate with the Independent Counsel or
the Company, as applicable, in making such determination with respect to Indemnitee&#146;s entitlement to indemnification, including providing to such counsel or the Company, upon reasonable advance request, any documentation or information which is
not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. The Company shall likewise cooperate with Indemnitee and Independent Counsel, if applicable, in
making such determination with respect to Indemnitee&#146;s entitlement to indemnification, including providing to such counsel and Indemnitee, upon reasonable advance request, any documentation or information which is not privileged or otherwise
protected from disclosure and which is reasonably available to the Company and reasonably necessary to such determination. Any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs or expenses (including
reasonable attorneys&#146; fees and disbursements) actually and reasonably incurred by Indemnitee in so cooperating with the Independent Counsel or the Company shall be borne by the Company (irrespective of the determination as to Indemnitee&#146;s
entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If the
determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section&nbsp;10(a), the Independent Counsel shall be selected by the Board; <U>provided</U> that, if a Change in Control shall have occurred and
indemnification is being requested by Indemnitee hereunder in his or her capacity as a director of the Company, the Independent Counsel shall be selected by Indemnitee. Indemnitee or the Company, as the case may be, may, within ten (10)&nbsp;days
after written notice of such selection, deliver to the Company or Indemnitee, as the case may be, a written objection to such selection; provided, however, that such objection may be asserted only on the ground that the Independent Counsel so
selected does not meet the requirements of &#147;Independent Counsel&#148; as defined in Section&nbsp;2 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely
objection, the Person so selected shall act as Independent Counsel. If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or the
Delaware Court has determined that such objection is without merit. If, within twenty (20)&nbsp;days after the later of (i)&nbsp;submission by Indemnitee of a written request for indemnification pursuant to Section&nbsp;9(a), and (ii)&nbsp;the final
disposition of the Proceeding, including any appeal therein, no Independent Counsel shall have been selected without objection, either Indemnitee or the Company may petition the Delaware Court for resolution of any objection which shall have been
made by Indemnitee or the Company to the selection of Independent Counsel and/or for the appointment as Independent Counsel of a Person selected by the court or by such other Person as the court shall designate. The Person with respect to whom all
objections are so resolved or the Person so appointed shall act as Independent Counsel under Section&nbsp;10(a) hereof. Upon the due commencement of any judicial proceeding or arbitration pursuant to Section&nbsp;12(a) of this Agreement, Independent
Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding anything to the contrary contained in this Agreement, the determination
of entitlement to indemnification under this Agreement shall be made without regard to the Indemnitee&#146;s entitlement to and availability of insurance coverage, including advancement, payment or reimbursement of defense costs, expenses or covered
loss under the provisions of any applicable insurance policy (including, without limitation, whether such advancement, payment or reimbursement is withheld, conditioned or delayed by the insurer(s)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11. <U>Presumptions and Effect of Certain Proceedings.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) To the extent permitted by applicable law, in making a determination with respect to entitlement to indemnification hereunder, it shall be
presumed that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section&nbsp;9(a) of this Agreement, and the Company shall have the burden of proof and the
burden of persuasion by clear and convincing evidence to overcome that presumption in connection with the making of any determination contrary to that presumption. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of
guilty, <U>nolo contendere</U> or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good
faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his or her conduct was unlawful.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Indemnitee shall be deemed to have acted in good faith if Indemnitee&#146;s actions were based on the records or books of account of
the Company or any other Enterprise, including financial statements, or on information supplied to Indemnitee by the directors, officers, agents or employees of the Company or any other Enterprise in the course of their duties, or on the advice of
legal counsel for the Company or any other Enterprise or on information or records given or reports made to the Company or any other Enterprise by an independent certified public accountant or by an appraiser or other expert selected with reasonable
care by the Company or any other Enterprise. The provisions of this Section&nbsp;11(c) shall not be deemed to be exclusive or to limit in any way the other circumstances in which Indemnitee may be deemed to have met the applicable standard of
conduct set forth in this Agreement. In addition, the knowledge and/or actions, or failure to act, of any director, manager, partner, officer, employee, agent or trustee of the Company, any subsidiary of the Company, or any Enterprise shall not be
imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement. Whether or not the foregoing provisions of this Section&nbsp;11(c) are satisfied, it shall in any event be presumed that Indemnitee has at all times
acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company. Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and
convincing evidence. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12. <U>Remedies of Indemnitee.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to Section&nbsp;12(f), in the event that (i)&nbsp;a determination is made pursuant to Section&nbsp;10 of this Agreement that
Indemnitee is not entitled to indemnification under this Agreement, (ii)&nbsp;advancement of Expenses is not timely made pursuant to Section&nbsp;8 of this Agreement, (iii)&nbsp;no determination of entitlement to indemnification shall have been made
pursuant to Section&nbsp;10(a) of this Agreement within sixty (60)&nbsp;days after receipt by the Company of the request for indemnification for which a determination is to be made other than by Independent Counsel, (iv)&nbsp;payment of
indemnification or reimbursement of expenses is not made pursuant to Section&nbsp;5 or 6 or the last sentence of Section&nbsp;10(a) of this Agreement within thirty (30)&nbsp;days after receipt by the Company of a written request therefor (including
any invoices received by Indemnitee, which such invoices may be redacted as necessary to avoid the waiver of any privilege accorded by applicable law) or (v)&nbsp;payment of indemnification pursuant to Section&nbsp;3 or 4 of this Agreement is not
made within thirty (30)&nbsp;days after a determination has been made that Indemnitee is entitled to indemnification, Indemnitee shall be entitled to an adjudication by the Delaware Court of his or her entitlement to such indemnification or
advancement. Alternatively, Indemnitee, at his or her option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association. Indemnitee shall commence
such proceeding seeking an adjudication or an award in arbitration within 180 days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section&nbsp;12(a); provided, however, that the foregoing time
limitation shall not apply in respect of a proceeding brought by Indemnitee to enforce his or her rights under Section&nbsp;5 of this Agreement. The Company shall not oppose Indemnitee&#146;s right to seek any such adjudication or award in
arbitration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In the event that a determination shall have been made pursuant to Section&nbsp;10(a) of this Agreement that Indemnitee
is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;12 shall be conducted in all respects as a de novo trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by
reason of that adverse determination. In any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;12, the Company shall have the burden of proving Indemnitee is not entitled to indemnification or advancement, as the case may
be. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If a determination shall have been made pursuant to Section&nbsp;10(a) of this Agreement that Indemnitee is entitled to
indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;12, absent (i)&nbsp;a misstatement by Indemnitee of a material fact, or an omission of a material
fact necessary to make Indemnitee&#146;s statement not materially misleading, in connection with the request for indemnification or (ii)&nbsp;a prohibition of such indemnification under applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company shall be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;12 that the
procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Company shall indemnify Indemnitee to the fullest extent permitted by law against any and all Enforcement Expenses and, if requested by
Indemnitee, shall (within thirty (30)&nbsp;days after receipt by the Company of a written request therefor) advance, to the extent not prohibited by law, such Enforcement Expenses to Indemnitee, which are incurred by
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Indemnitee in connection with any action brought by Indemnitee for indemnification or advancement from the Company under this Agreement or under any directors&#146; and officers&#146; liability
insurance policies maintained by the Company in the suit for which indemnification or advancement is being sought. Such written request for advancement shall include invoices received by Indemnitee in connection with such Enforcement Expenses but,
in the case of invoices in connection with legal services, any references to legal work performed or to expenditures made that would cause Indemnitee to waive any privilege accorded by applicable law need not be included with the invoice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to indemnification under this Agreement
shall be required to be made prior to the final disposition of the Proceeding, including any appeal therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;13. <U><FONT
STYLE="white-space:nowrap">Non-exclusivity;</FONT> Survival of Rights; Insurance; Subrogation.</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The rights of indemnification and
to receive advancement as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Charter, the Bylaws, any agreement, a vote of stockholders or a
resolution of directors, or otherwise. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee
in his or her Corporate Status prior to such amendment, alteration or repeal. To the extent that a change in Delaware law, whether by statute or judicial decision, permits greater indemnification or advancement than would be afforded currently under
the Charter, Bylaws and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any
other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or
remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) To the extent
that the Company maintains an insurance policy or policies providing liability insurance for directors, managers, partners, officers, employees, agents or trustees of the Company or of any other Enterprise, Indemnitee shall be covered by such policy
or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director, manager, partner, officer, employee, agent or trustee under such policy or policies. If, at the time of the receipt of a notice
of a claim pursuant to the terms hereof, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of such claim to the insurers in accordance with the procedures set forth in the respective policies.
The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies. Upon request of
Indemnitee, the Company shall also promptly provide to Indemnitee: (i)&nbsp;copies of all of the Company&#146;s potentially applicable directors&#146; and officers&#146; liability insurance policies, (ii)&nbsp;copies of such notices delivered to the
applicable insurers, and (iii)&nbsp;copies of all subsequent communications and correspondence between the Company and such insurers regarding the Proceeding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In the event of any payment under this Agreement, the Company shall be subrogated to the
extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring
suit to enforce such rights. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company&#146;s obligation to provide indemnification or advancement hereunder to Indemnitee who is or
was serving at the request of the Company as a director, manager, partner, officer, employee, agent or trustee of any other Enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement from such other
Enterprise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14. <U>Duration of Agreement</U>. This Agreement shall continue until and terminate upon the later of:
(a)&nbsp;ten (10) years after the date that Indemnitee shall have ceased to serve as [both a director and] an officer of the Company or (b)&nbsp;one (1) year after the final termination of any Proceeding, including any appeal, then pending in
respect of which Indemnitee is granted rights of indemnification or advancement hereunder and of any proceeding commenced by Indemnitee pursuant to Section&nbsp;12 of this Agreement relating thereto. This Agreement shall be binding upon the Company
and its successors and assigns and shall inure to the benefit of Indemnitee and his or her heirs, executors and administrators. The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation or
otherwise) to all, substantially all or a substantial part, of the business and/or assets of the Company, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to perform this Agreement in the same
manner and to the same extent that the Company would be required to perform if no such succession had taken place. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.
<U>Severability</U>. If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a)&nbsp;the validity, legality and enforceability of the remaining provisions of this Agreement
(including, without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or
impaired thereby and shall remain enforceable to the fullest extent permitted by law; (b)&nbsp;such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of
the parties hereto; and (c)&nbsp;to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or
unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;16. <U>Enforcement.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order
to induce Indemnitee [continue to] serve as [a director and] an officer of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as [a director and] an officer of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) This Agreement constitutes the entire agreement between the parties hereto with respect
to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof; provided, however, that this Agreement is a supplement to and in
furtherance of the Charter, the Bylaws and applicable law, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;17. <U>Modification and Waiver</U>. No supplement, modification or amendment, or waiver of any provision, of this Agreement shall
be binding unless executed in writing by the parties thereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing
waiver. No supplement, modification or amendment of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee prior to such supplement,
modification or amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;18. <U>Notice by Indemnitee</U>. Indemnitee agrees promptly to notify the Company in writing upon
being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification, reimbursement or advancement as provided hereunder. The failure of
Indemnitee to so notify the Company or any delay in notification shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement or otherwise, unless, and then only to the extent that, the Company did not
otherwise learn of the Proceeding and such delay is materially prejudicial to the Company&#146;s ability to defend such Proceeding or matter; and, provided, further, that notice will be deemed to have been given without any action on the part of
Indemnitee in the event the Company is a party to the same Proceeding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;19. <U>Notices</U>. All notices, requests, demands
and other communications under this Agreement shall be in writing and shall be deemed to have been duly given if (i)&nbsp;delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed,
(ii)&nbsp;mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed, (iii)&nbsp;mailed by reputable overnight courier and receipted for by the party to whom said notice or other
communication shall have been directed or (iv)&nbsp;sent by facsimile transmission, with receipt of oral confirmation that such transmission has been received: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If to Indemnitee, at such address as Indemnitee shall provide to the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If to the Company to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Upstream Bio, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">890 Winter
Street, Suite 200 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Waltham, MA 02451 USA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Chief Financial Officer </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to any
other address as may have been furnished to Indemnitee by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;20. <U>Contribution</U>. To the fullest extent permissible under applicable
law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines,
penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any Proceeding in such proportion as is deemed fair and reasonable in light of all of the circumstances in order to reflect (i)&nbsp;the
relative benefits received by the Company and Indemnitee in connection with the event(s) and/or transaction(s) giving rise to such Proceeding; and/or (ii)&nbsp;the relative fault of the Company (and its directors, officers, employees and agents) and
Indemnitee in connection with such event(s) and/or transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;21. <U>Internal Revenue Code Section&nbsp;409A</U>. The
Company intends for this Agreement to comply with the Indemnification exception under <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(10)</FONT> of the regulations promulgated under the Internal Revenue Code of 1986, as amended (the
&#147;<B>Code</B>&#148;), which provides that indemnification of, or the purchase of an insurance policy providing for payments of, all or part of the expenses incurred or damages paid or payable by Indemnitee with respect to a bona fide claim
against Indemnitee or the Company do not provide for a deferral of compensation, subject to Section&nbsp;409A of the Code, where such claim is based on actions or failures to act by Indemnitee in his or her capacity as a service provider of the
Company. The parties intend that this Agreement be interpreted and construed with such intent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;22. <U>Applicable Law and
Consent to Jurisdiction</U>. This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with
respect to any arbitration commenced by Indemnitee pursuant to Section&nbsp;12(a) of this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally (i)&nbsp;agree that any action or proceeding arising out of or in connection with
this Agreement shall be brought only in the Delaware Court, and not in any other state or federal court in the United States of America or any court in any other country, (ii)&nbsp;consent to submit to the exclusive jurisdiction of the Delaware
Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii)&nbsp;consent to service of process at the address set forth in Section&nbsp;19 of this Agreement with the same legal force and validity as if
served upon such party personally within the State of Delaware, (iv)&nbsp;waive any objection to the laying of venue of any such action or proceeding in the Delaware Court and (v)&nbsp;waive, and agree not to plead or to make, any claim that any
such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;23.
<U>Headings</U>. The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;24. <U>Identical Counterparts</U>. This Agreement may be executed in one or more counterparts, each of which shall for all
purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this
Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;25. <U>Monetary Damages Insufficient/Specific Enforcement</U>. The Company and
Indemnitee agree that a monetary remedy for breach of this Agreement may be inadequate, impracticable and difficult of proof, and further agree that such breach may cause Indemnitee irreparable harm. Accordingly, the parties hereto agree that
Indemnitee may enforce this Agreement by seeking injunctive relief and/or specific performance hereof, without any necessity of showing actual damage or irreparable harm (having agreed that actual and irreparable harm will result in not forcing the
Company to specifically perform its obligations pursuant to this Agreement) and that by seeking injunctive relief and/or specific performance, Indemnitee shall not be precluded from seeking or obtaining any other relief to which he may be entitled.
The Company and Indemnitee further agree that Indemnitee shall be entitled to such specific performance and injunctive relief, including temporary restraining orders, preliminary injunctions and permanent injunctions, without the necessity of
posting bonds or other undertakings in connection therewith. The Company acknowledges that in the absence of a waiver, a bond or undertaking may be required of Indemnitee by the Court, and the Company hereby waives any such requirement of a bond or
undertaking. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of Page Intentionally Left Blank] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this Agreement to be signed as of the day
and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>UPSTREAM BIO, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[Name]</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UPSTREAM BIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF <FONT STYLE="white-space:nowrap">NON-EMPLOYEE</FONT> DIRECTOR </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Indemnification Agreement (&#147;<B>Agreement</B>&#148;) is made as of [&#149;], 2024, by and between Upstream Bio, Inc., a Delaware
corporation (the &#147;<B>Company</B>&#148;), and [Name] (&#147;<B>Indemnitee</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">RECITALS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Company;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in order to induce Indemnitee to provide or continue to provide services to the Company, the Company wishes to provide for the
indemnification of, and advancement of expenses to, Indemnitee to the maximum extent permitted by law; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Third Amended and
Restated Certificate of Incorporation (as amended and in effect from time to time, the &#147;<B>Charter</B>&#148;) and the Amended and Restated Bylaws (as amended and in effect from time to time, the &#147;<B>Bylaws</B>&#148;) of the Company require
indemnification of the officers and directors of the Company, and Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware (the &#147;<B>DGCL</B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Charter, the Bylaws and the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive, and
thereby contemplate that contracts may be entered into between the Company and members of the board of directors, officers and other persons with respect to indemnification; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Board of Directors of the Company (the &#147;<B>Board</B>&#148;) has determined that the increased difficulty in attracting and
retaining highly qualified persons such as Indemnitee is detrimental to the best interests of the Company&#146;s stockholders; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS,
it is reasonable and prudent for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law, regardless of any amendment or revocation of the
Charter or the Bylaws, so that they will [continue to] serve the Company free from undue concern that they will not be so indemnified; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, this Agreement is a supplement to and in furtherance of the indemnification provided in the Charter, the Bylaws and any resolutions
adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[WHEREAS, Indemnitee has certain rights to indemnification and/or insurance provided by
[Affiliated Entity] (&#147;<B>[Affiliated Entity]</B>&#148;) which Indemnitee and [Affiliated Entity] intend to be secondary to the primary obligation of the Company to indemnify Indemnitee as provided in this Agreement, with the Company&#146;s
acknowledgment and agreement to the foregoing being a material condition to Indemnitee&#146;s willingness to [continue to] serve on the Board.]<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree
as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1. <U>Services to the Company</U>. Indemnitee agrees to [continue to] serve as a director of the Company.
Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by law), in which event the Company shall have no obligation under this Agreement to continue Indemnitee
in such position. This Agreement shall not be deemed an employment contract between the Company (or any of its subsidiaries or any Enterprise) and Indemnitee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2. <U>Definitions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
&#147;Affiliate&#148; and &#147;Associate&#148; shall have the respective meanings ascribed to such terms in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the General Rules and Regulations under the Securities Exchange Act of 1934, as
amended (the &#147;<B>Exchange Act</B>&#148;), as in effect on the date of this Agreement; provided, however, that no Person who is a director or officer of the Company shall be deemed an Affiliate or an Associate of any other director or officer of
the Company solely as a result of his or her position as director or officer of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) A Person shall be deemed the
&#147;Beneficial Owner&#148; of, and shall be deemed to &#147;Beneficially Own&#148; and have &#147;Beneficial Ownership&#148; of, any securities: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) which such Person or any of such Person&#146;s Affiliates or Associates, directly or indirectly, Beneficially Owns (as determined pursuant
to Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> of the Rules under the Exchange Act, as in effect on the date of this Agreement); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) which such Person or any of such Person&#146;s Affiliates or Associates, directly or indirectly, has: (A)&nbsp;the legal, equitable or
contractual right or obligation to acquire (whether directly or indirectly and whether exercisable immediately or only after the passage of time, compliance with regulatory requirements, satisfaction of one or more conditions (whether or not within
the control of such Person) or otherwise) upon the exercise of any conversion rights, exchange rights, rights, warrants or options, or otherwise; (B)&nbsp;the right to vote pursuant to any agreement, arrangement or understanding (whether or not in
writing); or (C)&nbsp;the right to dispose of pursuant to any agreement, arrangement or understanding (whether or not in writing) (other than customary arrangements with and between underwriters and selling group members with respect to a <I>bona
fid</I>e public offering of securities); </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This recital should be included if the director is affiliated with a fund or other entity that provides
indemnification to the director that is intended to backstop the indemnification provided by the Company. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) which are Beneficially Owned, directly or indirectly, by any other Person (or any
Affiliate or Associate thereof) with which such Person or any of such Person&#146;s Affiliates or Associates has any agreement, arrangement or understanding (whether or not in writing) (other than customary agreements with and between underwriters
and selling group members with respect to a <I>bona fide</I> public offering of securities) for the purpose of acquiring, holding, voting or disposing of any securities of the Company; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) that are the subject of a derivative transaction entered into by such Person or any of such Person&#146;s Affiliates or Associates,
including, for these purposes, any derivative security acquired by such Person or any of such Person&#146;s Affiliates or Associates that gives such Person or any of such Person&#146;s Affiliates or Associates the economic equivalent of ownership of
an amount of securities due to the fact that the value of the derivative security is explicitly determined by reference to the price or value of such securities, or that provides such Person or any of such Person&#146;s Affiliates or Associates an
opportunity, directly or indirectly, to profit or to share in any profit derived from any change in the value of such securities, in any case without regard to whether (A)&nbsp;such derivative security conveys any voting rights in such securities to
such Person or any of such Person&#146;s Affiliates or Associates; (B)&nbsp;the derivative security is required to be, or capable of being, settled through delivery of such securities; or (C)&nbsp;such Person or any of such Person&#146;s Affiliates
or Associates may have entered into other transactions that hedge the economic effect of such derivative security; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the
foregoing, no Person engaged in business as an underwriter of securities shall be deemed the Beneficial Owner of any securities acquired through such Person&#146;s participation as an underwriter in good faith in a firm commitment underwriting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) A &#147;Change in Control&#148; shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the
following events: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Acquisition of Stock by Third Party</U>. Any Person is or becomes the Beneficial Owner (as defined above),
directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the combined voting power of the Company&#146;s then outstanding securities unless the change in relative Beneficial Ownership of the Company&#146;s
securities by any Person results solely from a reduction in the aggregate number of outstanding shares of securities entitled to vote generally in the election of directors, provided that a Change of Control shall be deemed to have occurred if
subsequent to such reduction such Person becomes the Beneficial Owner, directly or indirectly, of any additional securities of the Company conferring upon such Person any additional voting power; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) <U>Change in Board of Directors</U>. During any period of two (2)&nbsp;consecutive years (not including any period prior to the execution
of this Agreement), individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated by a Person who has entered into an agreement with the Company to effect a transaction described in
Sections 2(c)(i), 2(c)(iii) or 2(c)(iv)) whose election by the Board or nomination for election by the Company&#146;s stockholders was approved by a vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the directors then still in
office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the members of the Board; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) <U>Corporate Transactions</U>. The effective date of a merger or consolidation of the
Company with any other entity, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or
by being converted into voting securities of the surviving or successor entity) more than 50% of the combined voting power of the voting securities of the surviving or successor entity outstanding immediately after such merger or consolidation and
with the power to elect at least a majority of the board of directors or other governing body of such surviving or successor entity; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv)
<U>Liquidation</U>. The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement for the sale, lease, exchange or other transfer by the Company, in one or a series of related transactions, of all or
substantially all of the Company&#146;s assets; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) <U>Other Events</U>. There occurs any other event of a nature that would be
required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act whether or not the Company is then subject to such reporting
requirement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) &#147;Corporate Status&#148; describes the status of a person as a current or former director of the Company or current
or former director, manager, partner, officer, employee, agent or trustee of any other Enterprise which such person is or was serving at the request of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) &#147;Enforcement Expenses&#148; shall include all reasonable attorneys&#146; fees, court costs, transcript costs, fees of experts, travel
expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> disbursements or expenses of the
types customarily incurred in connection with an action to enforce indemnification or advancement rights, or an appeal from such action. Expenses, however, shall not include fees, salaries, wages or benefits owed to Indemnitee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) &#147;Enterprise&#148; shall mean any corporation (other than the Company), partnership, joint venture, trust, employee benefit plan,
limited liability company, or other legal entity of which Indemnitee is or was serving at the request of the Company as a director, manager, partner, officer, employee, agent or trustee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) &#147;Expenses&#148; shall include all reasonable attorneys&#146; fees, court costs, transcript costs, fees of experts, travel expenses,
duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees and all other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> disbursements or expenses of the types
customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding or an appeal resulting from a Proceeding. Expenses,
however, shall not include amounts paid in settlement by Indemnitee, the amount of judgments or fines against Indemnitee or fees, salaries, wages or benefits owed to Indemnitee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) &#147;Independent Counsel&#148; means a law firm, or a partner (or, if applicable,
member or shareholder) of such a law firm, that is experienced in matters of Delaware corporation law and neither presently is, nor in the past five (5)&nbsp;years has been, retained to represent: (i)&nbsp;the Company, any subsidiary of the Company,
any Enterprise or Indemnitee in any matter material to any such party; or (ii)&nbsp;any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term &#147;Independent Counsel&#148; shall
not include any Person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee&#146;s rights under this
Agreement. The Company agrees to pay the reasonable fees and expenses of the Independent Counsel referred to above and to fully indemnify such counsel against any and all expenses, claims, liabilities and damages arising out of or relating to this
Agreement or its engagement pursuant hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) &#147;Person&#148; shall mean (i)&nbsp;an individual, a corporation, a partnership, a
limited liability company, an association, a joint stock company, a trust, a business trust, a government or political subdivision, any unincorporated organization or any other association or entity including any successor (by merger or otherwise)
thereof or thereto, and (ii)&nbsp;a &#147;group&#148; as that term is used for purposes of Section&nbsp;13(d)(3) of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)
The term &#147;Proceeding&#148; shall include any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed
proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative, regulatory or investigative nature, and whether formal or informal, in which Indemnitee was, is or will be involved as a party or
otherwise by reason of the fact that Indemnitee is or was a director of the Company or is or was serving at the request of the Company as a director, manager, partner, officer, employee, agent or trustee of any Enterprise or by reason of any action
taken by Indemnitee or of any action taken on his or her part while acting as a director of the Company or while serving at the request of the Company as a director, manager, partner, officer, employee, agent or trustee of any Enterprise, in each
case whether or not serving in such capacity at the time any liability or expense is incurred for which indemnification, reimbursement or advancement of expenses can be provided under this Agreement; provided, however, that the term
&#147;Proceeding&#148; shall not include any action, suit or arbitration, or part thereof, initiated by Indemnitee to enforce Indemnitee&#146;s rights under this Agreement as provided for in Section&nbsp;12(a) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3. <U>Indemnity in Third-Party Proceedings</U>. The Company shall indemnify Indemnitee to the extent set forth in this
Section&nbsp;3 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section&nbsp;3, Indemnitee
shall be indemnified against all Expenses, judgments, fines, penalties, excise taxes and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or
matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal proceeding, had no reasonable cause to believe that his or
her conduct was unlawful. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4. <U>Indemnity in Proceedings by or in the Right of the Company</U>. The
Company shall indemnify Indemnitee to the extent set forth in this Section&nbsp;4 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the Company to procure a judgment in its favor.
Pursuant to this Section&nbsp;4, Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee
acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company. No indemnification for Expenses shall be made under this Section&nbsp;4 in respect of any claim, issue or matter as to
which Indemnitee shall have been finally adjudged by a court to be liable to the Company, unless and only to the extent that the Delaware Court of Chancery (the &#147;<B>Delaware Court</B>&#148;) shall determine upon application that, despite the
adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification for such expenses as the Delaware Court shall deem proper. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5. <U>Indemnification for Expenses of a Party Who is Wholly or Partly Successful</U>. Notwithstanding any other provisions of
this Agreement and except as provided in Section&nbsp;7, to the extent that Indemnitee is a party to or a participant in any Proceeding and is successful in such Proceeding or in defense of any claim, issue or matter therein, the Company shall
indemnify Indemnitee against all Expenses actually and reasonably incurred by him or her in connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful as to one or more but less than all claims, issues or
matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee or on his or her behalf in connection with each successfully resolved claim, issue or matter. For purposes of this
Section and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6. <U>Reimbursement for Expenses of a Witness or in Response to a Subpoena</U>. Notwithstanding any other provision of this
Agreement, to the extent that Indemnitee, by reason of his or her Corporate Status, (i)&nbsp;is a witness in any Proceeding to which Indemnitee is not a party and is not threatened to be made a party or (ii)&nbsp;receives a subpoena with respect to
any Proceeding to which Indemnitee is not a party and is not threatened to be made a party, the Company shall reimburse Indemnitee for all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7. <U>Exclusions</U>. Notwithstanding any provision in this Agreement to the contrary, the Company shall not be obligated under
this Agreement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) to indemnify for amounts otherwise indemnifiable hereunder (or for which advancement is provided hereunder) if and to
the extent that Indemnitee has otherwise actually received such amounts under any insurance policy, contract, agreement or otherwise; provided that the foregoing shall not [(i)] apply to any personal or umbrella liability insurance maintained by
Indemnitee, [or, (ii)&nbsp;affect the rights of Indemnitee or the Fund Indemnitors as set forth in Section&nbsp;13(c)]; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) to indemnify
for an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section&nbsp;16(b) of the Exchange Act or similar provisions of state statutory law or common law;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) to indemnify with respect to any Proceeding, or part thereof, brought by Indemnitee
against the Company, any legal entity which it controls, any director or officer thereof or any third party, unless (i)&nbsp;the Board has consented to the initiation of such Proceeding or part thereof and (ii)&nbsp;the Company provides the
indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law; provided, however, that this Section&nbsp;7(c) shall not apply to (A)&nbsp;counterclaims or affirmative defenses asserted by Indemnitee in an
action brought against Indemnitee or (B)&nbsp;any action brought by Indemnitee for indemnification or advancement from the Company under this Agreement or under any directors&#146; and officers&#146; liability insurance policies maintained by the
Company in the suit for which indemnification or advancement is being sought as described in Section&nbsp;12; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) to provide any
indemnification or advancement of expenses that is prohibited by applicable law (as such law exists at the time payment would otherwise be required pursuant to this Agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8. <U>Advancement of Expenses</U>. Subject to Section&nbsp;9(b), the Company shall advance the Expenses incurred by Indemnitee in
connection with any Proceeding, and such advancement shall be made within thirty (30)&nbsp;days after the receipt by the Company of a statement or statements requesting such advances (including any invoices received by Indemnitee, which such
invoices may be redacted as necessary to avoid the waiver of any privilege accorded by applicable law) from time to time, whether prior to or after final disposition of any Proceeding. Advances shall be unsecured and interest free. Advances shall be
made without regard to Indemnitee&#146;s (i)&nbsp;ability to repay the expenses, (ii)&nbsp;ultimate entitlement to indemnification under the other provisions of this Agreement, and (iii)&nbsp;entitlement to and availability of insurance coverage,
including advancement, payment or reimbursement of defense costs, expenses or covered loss under the provisions of any applicable insurance policy (including, without limitation, whether such advancement, payment or reimbursement is withheld,
conditioned or delayed by the insurer(s)). Indemnitee shall qualify for advances upon the execution and delivery to the Company of this Agreement which shall constitute an undertaking providing that Indemnitee undertakes to the fullest extent
required by law to repay the advance if and to the extent that it is ultimately determined by a court of competent jurisdiction in a final judgment, not subject to appeal, that Indemnitee is not entitled to be indemnified by the Company. No other
form of undertaking shall be required. The right to advances under this paragraph shall in all events continue until final disposition of any Proceeding, including any appeal therein. Nothing in this Section&nbsp;8 shall limit Indemnitee&#146;s
right to advancement pursuant to Section&nbsp;12(e) of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9. Procedure for Notification and Defense of Claim.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request therefor specifying the basis
for the claim, the amounts for which Indemnitee is seeking payment under this Agreement, and all documentation related thereto as reasonably requested by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In the event that the Company shall be obligated hereunder to provide indemnification
for or make any advancement of Expenses with respect to any Proceeding, the Company shall be entitled to assume the defense of such Proceeding, or any claim, issue or matter therein, with counsel approved by Indemnitee (which approval shall not be
unreasonably withheld or delayed) upon the delivery to Indemnitee of written notice of the Company&#146;s election to do so. After delivery of such notice, approval of such counsel by Indemnitee and the retention of such counsel by the Company, the
Company will not be liable to Indemnitee under this Agreement for any fees or expenses of separate counsel subsequently employed by or on behalf of Indemnitee with respect to the same Proceeding; provided that (i)&nbsp;Indemnitee shall have the
right to employ separate counsel in any such Proceeding at Indemnitee&#146;s expense and (ii)&nbsp;if (A) the employment of separate counsel by Indemnitee has been previously authorized by the Company, (B)&nbsp;Indemnitee shall have reasonably
concluded that there may be a conflict of interest between the Company and Indemnitee in the conduct of such defense, (C)&nbsp;the Company shall not continue to retain such counsel to defend such Proceeding or (D)&nbsp;a Change in Control shall have
occurred, then the fees and expenses actually and reasonably incurred by Indemnitee with respect to his or her separate counsel shall be Expenses hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In the event that the Company does not assume the defense in a Proceeding pursuant to paragraph (b)&nbsp;above, then the Company will be
entitled to participate in the Proceeding at its own expense. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company shall not be liable to indemnify Indemnitee under this
Agreement for any amounts paid in settlement of any Proceeding effected without its prior written consent (which consent shall not be unreasonably withheld or delayed). Without limiting the generality of the foregoing, the fact that an insurer under
an applicable insurance policy delays or is unwilling to consent to such settlement or is or may be in breach of its obligations under such policy, or the fact that directors&#146; and officers&#146; liability insurance is otherwise unavailable or
not maintained by the Company, may not be taken into account by the Company in determining whether to provide its consent. The Company shall not, without the prior written consent of Indemnitee (which consent shall not be unreasonably withheld or
delayed), enter into any settlement which (i)&nbsp;includes an admission of fault of Indemnitee, any <FONT STYLE="white-space:nowrap">non-monetary</FONT> remedy imposed on Indemnitee or any monetary damages for which Indemnitee is not wholly and
actually indemnified hereunder or (ii)&nbsp;with respect to any Proceeding with respect to which Indemnitee may be or is made a party or may be otherwise entitled to seek indemnification hereunder, does not include the full release of Indemnitee
from all liability in respect of such Proceeding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10. Procedure Upon Application for Indemnification. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Upon written request by Indemnitee for indemnification pursuant to Section&nbsp;9(a), a determination, if such determination is required by
applicable law, with respect to Indemnitee&#146;s entitlement to indemnification hereunder shall be made in the specific case by one of the following methods: (x)&nbsp;if a Change in Control shall have occurred, by Independent Counsel in a written
opinion to the Board; or (y)&nbsp;if a Change in Control shall not have occurred: (i)&nbsp;by a majority vote of the disinterested directors, even though less than a quorum; (ii)&nbsp;by a committee of disinterested directors designated by a
majority vote of the disinterested directors, even though less than a quorum; or (iii)&nbsp;if there are no disinterested directors or if the disinterested directors so direct, by Independent Counsel in a written opinion to the Board. For purposes
hereof, disinterested directors are those members of the Board who are not parties to the action, suit or proceeding in respect of which indemnification is sought. In the case that such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
determination is made by Independent Counsel, a copy of Independent Counsel&#146;s written opinion shall be delivered to Indemnitee and, if it is so determined that Indemnitee is entitled to
indemnification, payment to Indemnitee shall be made within thirty (30)&nbsp;days after such determination. Indemnitee shall cooperate with the Independent Counsel or the Company, as applicable, in making such determination with respect to
Indemnitee&#146;s entitlement to indemnification, including providing to such counsel or the Company, upon reasonable advance request, any documentation or information which is not privileged or otherwise protected from disclosure and which is
reasonably available to Indemnitee and reasonably necessary to such determination. The Company shall likewise cooperate with Indemnitee and Independent Counsel, if applicable, in making such determination with respect to Indemnitee&#146;s
entitlement to indemnification, including providing to such counsel and Indemnitee, upon reasonable advance request, any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to
the Company and reasonably necessary to such determination. Any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs or expenses (including reasonable attorneys&#146; fees and disbursements) actually
and reasonably incurred by Indemnitee in so cooperating with the Independent Counsel or the Company shall be borne by the Company (irrespective of the determination as to Indemnitee&#146;s entitlement to indemnification) and the Company hereby
indemnifies and agrees to hold Indemnitee harmless therefrom. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If the determination of entitlement to indemnification is to be made by
Independent Counsel pursuant to Section&nbsp;10(a), the Independent Counsel shall be selected by the Board if a Change in Control shall not have occurred or, if a Change in Control shall have occurred, by Indemnitee. Indemnitee or the Company, as
the case may be, may, within ten (10)&nbsp;days after written notice of such selection, deliver to the Company or Indemnitee, as the case may be, a written objection to such selection; provided, however, that such objection may be asserted only on
the ground that the Independent Counsel so selected does not meet the requirements of &#147;Independent Counsel&#148; as defined in Section&nbsp;2 of this Agreement, and the objection shall set forth with particularity the factual basis of such
assertion. Absent a proper and timely objection, the Person so selected shall act as Independent Counsel. If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and
until such objection is withdrawn or the Delaware Court has determined that such objection is without merit. If, within twenty (20)&nbsp;days after the later of (i)&nbsp;submission by Indemnitee of a written request for indemnification pursuant to
Section&nbsp;9(a), and (ii)&nbsp;the final disposition of the Proceeding, including any appeal therein, no Independent Counsel shall have been selected without objection, either Indemnitee or the Company may petition the Delaware Court for
resolution of any objection which shall have been made by Indemnitee or the Company to the selection of Independent Counsel and/or for the appointment as Independent Counsel of a Person selected by the court or by such other Person as the court
shall designate. The Person with respect to whom all objections are so resolved or the Person so appointed shall act as Independent Counsel under Section&nbsp;10(a) hereof. Upon the due commencement of any judicial proceeding or arbitration pursuant
to Section&nbsp;12(a) of this Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding anything to the contrary contained in this Agreement, the determination
of entitlement to indemnification under this Agreement shall be made without regard to the Indemnitee&#146;s entitlement to and availability of insurance coverage, including advancement, payment or reimbursement of defense costs, expenses or covered
loss under the provisions of any applicable insurance policy (including, without limitation, whether such advancement, payment or reimbursement is withheld, conditioned or delayed by the insurer(s)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11. Presumptions and Effect of Certain Proceedings. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) To the extent permitted by applicable law, in making a determination with respect to entitlement to indemnification hereunder, it shall be
presumed that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section&nbsp;9(a) of this Agreement, and the Company shall have the burden of proof and the
burden of persuasion by clear and convincing evidence to overcome that presumption in connection with the making of any determination contrary to that presumption. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of
guilty, nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith
and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his or her conduct was unlawful. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Indemnitee shall be deemed to have acted in good faith if Indemnitee&#146;s actions were based on the records or books of account of the
Company or any other Enterprise, including financial statements, or on information supplied to Indemnitee by the directors, officers, agents or employees of the Company or any other Enterprise in the course of their duties, or on the advice of legal
counsel for the Company or any other Enterprise or on information or records given or reports made to the Company or any other Enterprise by an independent certified public accountant or by an appraiser or other expert selected with reasonable care
by the Company or any other Enterprise. The provisions of this Section&nbsp;11(c) shall not be deemed to be exclusive or to limit in any way the other circumstances in which Indemnitee may be deemed to have met the applicable standard of conduct set
forth in this Agreement. In addition, the knowledge and/or actions, or failure to act, of any director, manager, partner, officer, employee, agent or trustee of the Company, any subsidiary of the Company, or any Enterprise shall not be imputed to
Indemnitee for purposes of determining the right to indemnification under this Agreement. Whether or not the foregoing provisions of this Section&nbsp;11(c) are satisfied, it shall in any event be presumed that Indemnitee has at all times acted in
good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company. Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing
evidence. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12. Remedies of Indemnitee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to Section&nbsp;12(f), in the event that (i)&nbsp;a determination is made pursuant to Section&nbsp;10 of this Agreement that
Indemnitee is not entitled to indemnification under this Agreement, (ii)&nbsp;advancement of Expenses is not timely made pursuant to Section&nbsp;8 of this Agreement, (iii)&nbsp;no determination of entitlement to indemnification shall have been made
pursuant to Section&nbsp;10(a) of this Agreement within sixty (60)&nbsp;days after receipt by the Company of the request for indemnification for which a determination is to be made other than by Independent Counsel, (iv)&nbsp;payment of
indemnification or reimbursement of expenses is not made pursuant to Section&nbsp;5 or 6 or the last sentence of Section&nbsp;10(a) of this Agreement within thirty (30)&nbsp;days after receipt by the Company of a written request therefor (including
any invoices received by Indemnitee, which such invoices may be redacted as necessary to avoid the waiver of any privilege accorded by applicable law) or (v)&nbsp;payment of indemnification pursuant to Section&nbsp;3 or 4 of this Agreement is not
made within thirty (30)&nbsp;days after a determination has been made that Indemnitee is entitled to indemnification, Indemnitee shall be entitled to an adjudication by the Delaware Court of his or her entitlement to such indemnification or
advancement. Alternatively, Indemnitee, at his or her option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association. Indemnitee shall commence
such proceeding seeking an adjudication or an award in arbitration within 180 days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section&nbsp;12(a); provided, however, that the foregoing time
limitation shall not apply in respect of a proceeding brought by Indemnitee to enforce his or her rights under Section&nbsp;5 of this Agreement. The Company shall not oppose Indemnitee&#146;s right to seek any such adjudication or award in
arbitration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In the event that a determination shall have been made pursuant to Section&nbsp;10(a) of this Agreement that Indemnitee
is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;12 shall be conducted in all respects as a de novo trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by
reason of that adverse determination. In any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;12, the Company shall have the burden of proving Indemnitee is not entitled to indemnification or advancement, as the case may
be. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If a determination shall have been made pursuant to Section&nbsp;10(a) of this Agreement that Indemnitee is entitled to
indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;12, absent (i)&nbsp;a misstatement by Indemnitee of a material fact, or an omission of a material
fact necessary to make Indemnitee&#146;s statement not materially misleading, in connection with the request for indemnification or (ii)&nbsp;a prohibition of such indemnification under applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company shall be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;12 that the
procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Company shall indemnify Indemnitee to the fullest extent permitted by law against any and all Enforcement Expenses and, if requested by
Indemnitee, shall (within thirty (30)&nbsp;days after receipt by the Company of a written request therefor) advance, to the extent not prohibited by law, such Enforcement Expenses to Indemnitee, which are incurred by Indemnitee in connection with
any action brought by Indemnitee for indemnification or advancement from the Company under this Agreement or under any directors&#146; and officers&#146; liability insurance policies maintained by the Company in the suit for which indemnification or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
advancement is being sought. Such written request for advancement shall include invoices received by Indemnitee in connection with such Enforcement Expenses but, in the case of invoices in
connection with legal services, any references to legal work performed or to expenditures made that would cause Indemnitee to waive any privilege accorded by applicable law need not be included with the invoice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to indemnification under this Agreement
shall be required to be made prior to the final disposition of the Proceeding, including any appeal therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;13. <U><FONT
STYLE="white-space:nowrap">Non-exclusivity;</FONT> Survival of Rights; Insurance; [Primacy of Indemnification;] Subrogation</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The
rights of indemnification and to receive advancement as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Charter, the Bylaws, any agreement, a vote
of stockholders or a resolution of directors, or otherwise. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or
omitted by such Indemnitee in his or her Corporate Status prior to such amendment, alteration or repeal. To the extent that a change in Delaware law, whether by statute or judicial decision, permits greater indemnification or advancement than would
be afforded currently under the Charter, Bylaws and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended
to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or
employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, managers, partners,
officers, employees, agents or trustees of the Company or of any other Enterprise, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director,
manager, partner, officer, employee, agent or trustee under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has director and officer liability insurance in effect, the Company
shall give prompt notice of such claim to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the
Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies. Upon request of Indemnitee, the Company shall also promptly provide to Indemnitee: (i)&nbsp;copies of all of the Company&#146;s potentially
applicable directors&#146; and officers&#146; liability insurance policies, (ii)&nbsp;copies of such notices delivered to the applicable insurers and (iii)&nbsp;copies of all subsequent communications and correspondence between the Company and such
insurers regarding the Proceeding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) [The Company hereby acknowledges that Indemnitee has certain rights to indemnification,
advancement of expenses and/or insurance provided by [Affiliated Entity] and certain of its affiliates (collectively, the &#147;<B>Fund Indemnitors</B>&#148;). The Company hereby agrees (i)&nbsp;that it is the indemnitor of first resort
(i.e<I>.</I>, its obligations to Indemnitee are primary and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by Indemnitee are secondary), (ii) that it shall be
required to advance the full amount of expenses incurred by Indemnitee and shall be liable for the full amount of all Expenses, judgments, penalties, fines and amounts paid in settlement to the extent legally permitted and as required by the terms
of this Agreement and the Charter and/or Bylaws (or any other agreement between the Company and Indemnitee), without regard to any rights Indemnitee may have against the Fund Indemnitors, and (iii)&nbsp;that it irrevocably waives, relinquishes and
releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Fund Indemnitors
on behalf of Indemnitee with respect to any claim for which Indemnitee has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such
advancement or payment to all of the rights of recovery of Indemnitee against the Company. The Company and Indemnitee agree that the Fund Indemnitors are express third party beneficiaries of the terms of this Section&nbsp;13(c).]<SUP
STYLE="font-size:75%; vertical-align:top">2</SUP> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) [Except as provided in paragraph (c)&nbsp;above,] in the event of any payment under
this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee [(other than against the Fund Indemnitors)], who shall execute all papers required and take all action necessary to secure
such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)
[Except as provided in paragraph (c)&nbsp;above,] the Company&#146;s obligation to provide indemnification or advancement hereunder to Indemnitee who is or was serving at the request of the Company as a director, manager, partner, officer, employee,
agent or trustee of any other Enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement from such other Enterprise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14. <U>Duration of Agreemen</U>t. This Agreement shall continue until and terminate upon the later of: (a)&nbsp;ten (10) years
after the date that Indemnitee shall have ceased to serve as a director of the Company or (b)&nbsp;one (1) year after the final termination of any Proceeding, including any appeal, then pending in respect of which Indemnitee is granted rights of
indemnification or advancement hereunder and of any proceeding commenced by Indemnitee pursuant to Section&nbsp;12 of this Agreement relating thereto. This Agreement shall be binding upon the Company and its successors and assigns and shall inure to
the benefit of Indemnitee and his or her heirs, executors and administrators. The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all, substantially all or a substantial
part, of the business and/or assets of the Company, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be
required to perform if no such succession had taken place. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This provision is intended to be used for directors appointed by investment funds. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;15. <U>Severability</U>. If any provision or provisions of this Agreement shall
be held to be invalid, illegal or unenforceable for any reason whatsoever: (a)&nbsp;the validity, legality and enforceability of the remaining provisions of this Agreement (including, without limitation, each portion of any section of this Agreement
containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by
law; (b)&nbsp;such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c)&nbsp;to the fullest extent possible, the provisions
of this Agreement (including, without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so
as to give effect to the intent manifested thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;16. Enforcement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in
order to induce Indemnitee to [continue to] serve as a director of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all
prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof; provided, however, that this Agreement is a supplement to and in furtherance of the Charter, the Bylaws and
applicable law, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;17. <U>Modification and Waiver</U>. No supplement, modification or amendment, or waiver of any provision, of this Agreement shall
be binding unless executed in writing by the parties thereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing
waiver. No supplement, modification or amendment of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee prior to such supplement,
modification or amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;18. <U>Notice by Indemnitee</U>. Indemnitee agrees promptly to notify the Company in writing upon
being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification, reimbursement or advancement as provided hereunder. The failure of
Indemnitee to so notify the Company or any delay in notification shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement or otherwise, unless, and then only to the extent that, the Company did not
otherwise learn of the Proceeding and such delay is materially prejudicial to the Company&#146;s ability to defend such Proceeding or matter; and, provided, further, that notice will be deemed to have been given without any action on the part of
Indemnitee in the event the Company is a party to the same Proceeding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;19. <U>Notices</U>. All notices, requests, demands and other communications
under this Agreement shall be in writing and shall be deemed to have been duly given if (i)&nbsp;delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, (ii)&nbsp;mailed by certified or
registered mail with postage prepaid, on the third business day after the date on which it is so mailed, (iii)&nbsp;mailed by reputable overnight courier and receipted for by the party to whom said notice or other communication shall have been
directed or (iv)&nbsp;sent by facsimile transmission, with receipt of oral confirmation that such transmission has been received: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If
to Indemnitee, at such address as Indemnitee shall provide to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If to the Company to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Upstream Bio, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">890 Winter
Street, Suite 200 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Waltham, MA 02451 USA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Chief Financial Officer </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to any
other address as may have been furnished to Indemnitee by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;20. <U>Contribution</U>. To the fullest extent
permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee,
whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any Proceeding in such proportion as is deemed fair and reasonable in light of all of the circumstances in order
to reflect (i)&nbsp;the relative benefits received by the Company and Indemnitee in connection with the event(s) and/or transaction(s) giving rise to such Proceeding; and/or (ii)&nbsp;the relative fault of the Company (and its directors, officers,
employees and agents) and Indemnitee in connection with such event(s) and/or transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;21. <U>Internal Revenue Code
Section&nbsp;409A</U>. The Company intends for this Agreement to comply with the Indemnification exception under <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(10)</FONT> of the regulations promulgated under the Internal Revenue Code of
1986, as amended (the &#147;<B>Code</B>&#148;), which provides that indemnification of, or the purchase of an insurance policy providing for payments of, all or part of the expenses incurred or damages paid or payable by Indemnitee with respect to a
bona fide claim against Indemnitee or the Company do not provide for a deferral of compensation, subject to Section&nbsp;409A of the Code, where such claim is based on actions or failures to act by Indemnitee in his or her capacity as a service
provider of the Company. The parties intend that this Agreement be interpreted and construed with such intent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;22. <U>Applicable Law and Consent to Jurisdiction</U>. This Agreement and the
legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee
pursuant to Section&nbsp;12(a) of this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally (i)&nbsp;agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the
Delaware Court, and not in any other state or federal court in the United States of America or any court in any other country, (ii)&nbsp;consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding
arising out of or in connection with this Agreement, (iii)&nbsp;consent to service of process at the address set forth in Section&nbsp;19 of this Agreement with the same legal force and validity as if served upon such party personally within the
State of Delaware, (iv)&nbsp;waive any objection to the laying of venue of any such action or proceeding in the Delaware Court, and (v)&nbsp;waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the
Delaware Court has been brought in an improper or inconvenient forum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;23. <U>Headings</U>. The headings of the paragraphs of
this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;24. <U>Identical Counterparts</U>. This Agreement may be executed in one or more counterparts, each of which shall for all
purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;25. <U>Monetary Damages Insufficient/Specific Enforcement</U>. The Company and Indemnitee agree that a monetary
remedy for breach of this Agreement may be inadequate, impracticable and difficult of proof, and further agree that such breach may cause Indemnitee irreparable harm. Accordingly, the parties hereto agree that Indemnitee may enforce this Agreement
by seeking injunctive relief and/or specific performance hereof, without any necessity of showing actual damage or irreparable harm (having agreed that actual and irreparable harm will result in not forcing the Company to specifically perform its
obligations pursuant to this Agreement) and that by seeking injunctive relief and/or specific performance, Indemnitee shall not be precluded from seeking or obtaining any other relief to which he may be entitled. The Company and Indemnitee further
agree that Indemnitee shall be entitled to such specific performance and injunctive relief, including temporary restraining orders, preliminary injunctions and permanent injunctions, without the necessity of posting bonds or other undertaking in
connection therewith. The Company acknowledges that in the absence of a waiver, a bond or undertaking may be required of Indemnitee by the Court, and the Company hereby waives any such requirement of a bond or undertaking. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of Page Intentionally Left Blank] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this Agreement to be signed as of the day
and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>UPSTREAM BIO, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[Name]</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>10
<FILENAME>d843142dex107.htm
<DESCRIPTION>EX-10.7
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.7</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UPSTREAM BIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NON-EMPLOYEE DIRECTOR COMPENSATION POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of this <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy (the &#147;Policy&#148;) of Upstream Bio, Inc., a
Delaware corporation (the &#147;Company&#148;), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its
subsidiaries (&#147;Outside Directors&#148;). This Policy will become effective as of the effective time of the registration statement for the Company&#146;s initial public offering of its equity securities (the &#147;Effective Date&#148;). In
furtherance of the purpose stated above, all Outside Directors shall be paid compensation for services provided to the Company as Outside Directors as set forth below: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Cash Retainers</U> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Annual Retainer
for Board Membership</U>: $40,000 for general availability and participation in meetings and conference calls of our Board of Directors, to be paid quarterly in arrears, <FONT STYLE="white-space:nowrap">pro-rated</FONT> based on the number of actual
days served by the director during such calendar quarter. No additional compensation will be paid for attending individual meetings of the Board of Directors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>Additional Annual Retainer for <FONT STYLE="white-space:nowrap">Non-Executive</FONT>
Chair</U>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$30,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>Additional Annual Retainers for Committee Membership</U>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee Chairperson:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$15,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee member (other than Chairperson):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$7,500</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation Committee Chairperson:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$12,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation Committee member (other than Chairperson):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$6,000</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Corporate Governance Committee Chairperson:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$10,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Corporate Governance Committee member (other than Chairperson):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$5,000</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Chair and committee member retainers are in addition to retainers for members of the Board of Directors. No
additional compensation will be paid for attending individual committee meetings of the Board of Directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Equity Retainers</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All grants of equity retainer awards to Outside Directors pursuant to this Policy will be automatic and nondiscretionary and will be made in accordance with
the following provisions: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>IPO Award</U>. Upon the Effective Date, (i)&nbsp;each Outside Director serving as a
member of the Board of Directors as of such date will receive an Annual Award (as defined below) (the &#147;<I>IPO Award</I>&#148;). IPO Awards will have an exercise price per share equal to the per share &#147;price to the public&#148; (or
equivalent) set forth on the cover page for the final prospectus relating to the Company&#146;s initial public offering, expire ten years from the date of grant and vest in full on the earlier of (A)&nbsp;the
<FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the grant date or (B)&nbsp;the next Annual Meeting of Stockholders; provided, however, that all vesting will cease if the director ceases to have a Service Relationship (as defined in
the 2024 Plan), unless otherwise determined by the Board of Directors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Initial Award</U>: Upon his or her initial election to the Board
of Directors, each Outside Director will receive an initial, <FONT STYLE="white-space:nowrap">one-time</FONT> stock option award (the &#147;Initial Award&#148;) to purchase/covering 34,681 shares, which shall vest in equal monthly installments over
three years from the date of grant, provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as on the Board of Directors of the Company, unless the Board of Directors
determines that the circumstances warrant continuation of vesting. The Initial Award shall expire ten years from the date of grant, and shall have a per share exercise price equal to the Fair Market Value (as defined in the Company&#146;s 2024 Stock
Option and Incentive Plan, as amended from to time (the &#147;2024 Plan&#148;)) of the Company&#146;s common stock on the date of grant. This Initial Award applies only to Outside Directors who are first elected to the Board of Directors subsequent
to the Effective Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Annual Award</U>: On each date of each Annual Meeting of Stockholders of the Company following the Effective
Date (the &#147;Annual Meeting&#148;), each continuing Outside Director, other than a director receiving an Initial Award, will receive an annual stock option award (the &#147;Annual Award&#148;) to purchase/covering 17,096 shares, which shall vest
in full upon the earlier of (i)&nbsp;the date of the next Annual Meeting or (ii)&nbsp;the first anniversary of the date of grant; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases
to serve on the Board of Directors of the Company, unless the Board of Directors determines that the circumstances warrant continuation of vesting. Such Annual Award shall expire ten years from the date of grant, and shall have a per share exercise
price equal to the Fair Market Value of the Company&#146;s common stock on the date of grant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Sale Event Acceleration</U>: All
outstanding Initial Awards and Annual Awards held by an Outside Director shall become fully vested and exercisable upon a Sale Event (as defined in the Company&#146;s 2024 Stock Option and Incentive Plan, as amended from time to time). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Expenses</U> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company will
reimburse all reasonable out-of-pocket expenses incurred by Outside Directors in attending meetings of the Board of Directors or any committee thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Maximum Annual Compensation </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The aggregate amount of compensation, including both equity compensation and cash compensation, paid by the Company to any Outside Director in
a calendar year for services as an Outside Director shall not exceed $750,000; provided, however, that such amount shall be $1,000,000 for the calendar year in which the applicable Outside Director is initially elected or appointed to the Board of
Directors (or such other limits as may be set forth in Section&nbsp;3(b) of the Company&#146;s 2024 Stock Option and Incentive Plan, as amended from time to time, or any similar provision of a successor plan). For this purpose, the
&#147;amount&#148; of equity compensation paid in a calendar year shall be determined based on the grant date fair value thereof, as determined in accordance with FASB ASC Topic 718 or its successor provision, but excluding the impact of estimated
forfeitures related to service-based vesting conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adopted August&nbsp;19, 2024. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>11
<FILENAME>d843142dex1019.htm
<DESCRIPTION>EX-10.19
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.19</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.19 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;27, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E. Rand Sutherland, MD, MPH </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Re: Employment Offer </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Rand: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I am pleased to confirm the below terms of your employment with Upstream Bio, Inc. (the &#147;<U>Company</U>&#148;) as set forth below (this
&#147;<U>Agreement</U>&#148;). <B></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Position.</B> Your position is Chief Executive Officer of the Company (&#147;<U>CEO</U>&#148;), reporting to
the Company&#146;s Board of Directors (the &#145;Board&#148;). This is a full-time position. While you render services to the Company, you will not engage in any other employment, consulting or other business activities (whether full-time or
part-time) without the Board&#146;s prior consent. You may engage in religious, charitable or other community activities and the Board approves your continued service as a director of Krystal Biotech and Vanqua Bio, provided none of your current or
future outside activities interferes with the performance of your duties to the Company. <B></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Start Date</B>. The first day of your employment
for purposes of this Agreement will be April&nbsp;1, 2024, or as otherwise mutually agreed to by the parties (such actual first day of employment, the &#147;<U>Start Date</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Salary.</B> Initially, the Company will pay you a base salary at the rate of $510,000 annually. Your base salary will be reviewed on an annual basis and
may be subject to adjustment from time to time at the Company&#146;s discretion. Your base salary in effect from time to time is referred to herein as the &#147;<U>Base Salary</U>.&#148; The Base Salary shall be payable in accordance with the
Company&#146;s standard payroll schedule and shall be subject to applicable deductions and withholdings. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Annual Bonus</B>. For each year of your
continued employment commencing in calendar year 2024 (prorated based on the Start Date) you will be eligible for an annual cash bonus of up to 45% of your Base Salary (the &#147;<U>Target Bonus</U>&#148;). The criteria for any bonus, whether a
bonus is awarded, and the amount of any bonus each shall be determined by the Board in its sole discretion. The bonus target percentage will be reviewed on an annual basis and may be subject to adjustment from time to time at the Company&#146;s
discretion. To earn any bonus, you must be employed with the Company on the date the bonus is paid, except as provided in Section&nbsp;8. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.
Equity</B>.<B> </B>Subject to the approval of the<B> </B>Board of Directors (including any committee thereof, the &#147;<U>Board</U>&#148;) in its discretion and subject to your continuous employment with the Company as of each applicable grant
date, the Company will grant you an option to purchase an aggregate of 1,830,375 shares of Common Stock of the Company, which is equal to 4.5% of the outstanding Common Stock, calculated on a fully diluted basis, giving effect to the closing of the
first and second tranches of the Company&#146;s Series B preferred stock financing contemplated by the Series B Preferred Stock Purchase Agreement (the &#147;<U>SPA</U>&#148;) entered into by the Company and various investors on or about
June&nbsp;6, 2023 (the &#147;<U>Option</U>&#148;). The portion of the Option as is equal to 4.5% of the outstanding Common Stock, calculated on a fully diluted basis, as of the date of grant (the &#147;<U>Initial Portion</U>&#148;) shall be subject
to time-based vesting as of the date of grant. The balance of the Option (the &#147;<U>Second Closing Portion</U>&#148;) shall become subject to time-based vesting effective at the consummation of the Second Closing (as defined in the SPA). Once
subject to time-based vesting, the Initial Portion and the Second Closing Portion will each vest as follows: (i)&nbsp;twenty five percent (25%) of the shares subject to the applicable portion of the Option shall vest on the first (1st) anniversary
of the applicable Vesting Commencement Date (as defined below) and (ii)&nbsp;the remaining seventy five percent (75%) of the shares subject to the applicable portion of the Option will vest in a series of successive equal monthly installments of
1/48 of the shares upon the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
completion of each month of service to the Company over the thirty six (36) month period measured from the first (1st) anniversary of the applicable Vesting Commencement Date. For the sake of
clarity, in no event shall the total shares of Common Stock underlying the Option exceed 4.5% of the fully diluted share capital of the Company after giving effect to the closing of the first and second tranches of the Company&#146;s Series B
preferred stock financing. For purposes hereof, the term &#147;<U>Vesting Commencement Date</U>&#148; means your Start Date for purposes of the Initial Portion and the date of the second closing of the Series B financing for purposes of the Second
Closing Portion. The Option shall be subject in all respects (including with respect to applicable vesting requirements) to the Company&#146;s stock plan and the stock option agreement provided by the Company (collectively, the &#147;<U>Equity
Documents</U>&#148;), which will include the vesting acceleration events set forth in Section&nbsp;8. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Benefits and Indemnification. </B>You will be
eligible for the employee benefits the Company provides to senior executives from time to time, subject to the terms and conditions of the Company&#146;s benefit plans and other applicable policies. You will be entitled to the same indemnification
rights as the Company grants to other senior executives and Board members of the Company and, in addition, the Company shall indemnify you to the fullest extent permitted under the Company&#146;s <FONT STYLE="white-space:nowrap">by-laws</FONT>
and/or Delaware law. Furthermore, the Company maintains a directors and officers liability policy and will provide you with such coverage to the same extent as provided by the Company to other senior executives and Board members of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. <FONT STYLE="white-space:nowrap">At-Will</FONT> Employment; Accrued Obligations; Resignation(s) in Connection with Termination</B>. Your employment with
the Company is <FONT STYLE="white-space:nowrap">at-will,</FONT> meaning either you or the Company may terminate your employment at any time and for any reason, with or without notice (except as required under the Cause definition set forth below)
and with or without cause. Likewise, the terms and conditions of your employment, including without limitation your compensation, benefits and job duties, are subject to change by the Company in its discretion; provided, however, that certain
changes may trigger Good Reason, as defined below). In the event of the ending of your employment for any reason, the Company shall pay you (i)&nbsp;your Base Salary through your last day of employment (the &#147;<U>Date of Termination</U>&#148;),
and (ii)&nbsp;the amount of any documented expenses properly incurred by you on behalf of the Company prior to any such termination and not yet reimbursed (the &#147;<U>Accrued Obligations</U>&#148;). In connection with the ending of your employment
for any reason, you shall be deemed to have resign from the Board and any other director or officer position or other position you have with the Company or any Company affiliate, effective as of the Date of Termination, and execute any document
reasonably requested by the Company to effectuate such resignation(s). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Severance.</B> In the event the Company terminates your employment without
Cause (as defined below) or you resign for Good Reason (as defined below) and provided you (i)&nbsp;enter into, do not revoke and comply with the terms of a separation agreement and release in the form provided by the Company which shall include,
without limitation, a general release of claims against the Company and related persons and entities, nondisparagement obligations, a seven-business day revocation period and a twelve-month post-employment noncompetition obligation that mirrors the
language in the Restrictive Covenant Agreement described below (the &#147;<U>Release</U>&#148;) within the time period provided in the Release but in no event later than 60 days after the Date of Termination (the &#147;<U>Release
Requirement</U>&#148;); (ii) comply with the Ongoing Obligations (as defined below), then in addition to the Accrued Obligations, the Company will provide you with the following &#147;<U>Severance Benefits</U>&#148;: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) continuation of your Base Salary as of the Date of Termination for the twelve (12)&nbsp;month period that immediately follows the Date of
Termination (the &#147;<U>Salary Continuation Payments</U>,&#148; and such period, the &#147;<U>Severance Period</U>&#148;); provided in the event you breach any of the Ongoing Obligations, all payments of the Salary Continuation Payments shall
immediately cease; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) if elected, continuation of group health plan benefits to the extent authorized by and consistent with 29 U.S.C.
&#167; 1161 et seq. (commonly known as &#147;<U>COBRA</U>&#148;), with the cost of the regular premium for such benefits shared in the same relative proportion by the Company and you as in effect on the Date of Termination until the earliest of
(i)&nbsp;the end of the Severance Period; (ii)&nbsp;the date you become eligible for health benefits through another employer or (iii)&nbsp;the date you otherwise become ineligible for COBRA; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c) provided you have not breached any of the Ongoing Obligations, payment of your annual
bonus for the calendar year in which the termination occurs which shall be based on the Target Bonus amount and prorated for the number of days actually employed in said calendar year through the Date of Termination (the &#147;<U>Final
Bonus</U>&#148;). The Final Bonus shall be paid to you by the Company in a single lump sum along with the first Salary Continuation Payment; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(d) if, at any time prior to the first (1st) anniversary of the Vesting Commencement Date, the Company terminates your employment without Cause
or you resign for Good Reason, the then-unvested equity awards that vest based solely on the passage of time which would have vested through the date of termination had the equity award not been subject to a
<FONT STYLE="white-space:nowrap">one-year</FONT> vesting &#147;cliff&#148; will be deemed vested and exercisable as of the Date of Termination (e.g., if the Date of Termination is 6 months following the Vesting Commencement Date, then 12.5% of such
equity award shall be deemed vested and exercisable as of the Date of Termination); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(e) if the Company terminates your employment
without Cause or you resign for Good Reason less than three (3)&nbsp;months prior to Change in Control or within twelve (12)&nbsp;months following a Change in Control, the Company shall provide that the vesting of 100% of your then unvested equity
awards that vest based solely on the passage of time shall be accelerated, such that all then-unvested equity awards that vest based solely on the passage of time vest and become fully exercisable and
<FONT STYLE="white-space:nowrap">non-forfeitable</FONT> as of the Date of Termination. For purposes of this Agreement, the term &#147;<U>Change in Control</U>&#148; shall mean the sale of all or substantially all of the outstanding shares of capital
stock, assets or business of the Company by merger, consolidation, sale of assets or otherwise (other than a merger or consolidation in which all or substantially all of the individuals and entities who were beneficial owners of the Company&#146;s
voting securities immediately prior to such transaction beneficially own, directly or indirectly, more than 50% (determined on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis) of the outstanding securities entitled to vote generally in
the election of directors of the resulting, surviving or acquiring corporation in such transaction); provided, however, that the issuance and sale of securities of the Company for bona fide financing purposes shall not constitute a Change in Control
and provided further that such event or occurrence constitutes a change in the ownership or effective control of the Company, or a change in the ownership of a substantial portion of the assets of the Company, as defined in Treasury Regulation
Sections <FONT STYLE="white-space:nowrap">1.409A-3(i)(5)(v),</FONT> (vi) and (vii). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Salary Continuation Payments shall commence within 60 days after
the Date of Termination and shall be made on the Company&#146;s regular payroll dates; provided, however, that if the <FONT STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year and ends in a second calendar year, the Salary
Continuation Payments shall begin to be paid in the second calendar year. In the event you miss a regular payroll period between the Date of Termination and first Salary Continuation Payment date, the first Salary Continuation Payment shall include
a &#147;catch up&#148; payment. Solely for purposes of Section&nbsp;409A of the Internal Revenue Code of 1986, as amended (&#147;<U>Section&nbsp;409A</U>&#148;), each Salary Continuation Payment is considered a separate payment. Notwithstanding the
foregoing, in the event you are entitled to any payments pursuant to the Restrictive Covenants Agreement (as defined below) (including without limitation Garden Leave Pay as defined therein), the Severance Benefits to be paid to you in any calendar
year will be reduced by the amount that you are paid in the same such calendar year pursuant to the Restrictive Covenants Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the avoidance of
doubt, in the event your employment is terminated by the Company for Cause, by you for any reason, or due to your death or Disability (the latter as determined by the Company in good faith), you will be entitled to the Accrued Obligations but not to
the Severance Benefits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Definitions. </B>For purposes of this Agreement, the following terms shall have the following
meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) &#147;<U>Cause</U>&#148; shall mean any of (a)&nbsp;your conviction of, or plea of guilty or <I>nolo contendere </I>to, any
felony or any crime involving dishonesty, deceit, moral turpitude or fraud; or (b)&nbsp;a good faith finding by the Company that you have (i)&nbsp;engaged in dishonesty, willful misconduct or gross negligence with respect to the Company,
(ii)&nbsp;negligently or purposefully engaged in conduct that has materially injured or would reasonably be expected to materially injure the reputation, business or business relationships of the Company, (iii)&nbsp;materially breached any provision
of any agreement(s) between you and the Company relating to noncompetition, nonsolicitation, nondisclosure and/or assignment of inventions, (iv)&nbsp;willfully violated Company policies or procedures that has injured or would reasonably be expected
to injure the reputation, business or business relationships of the Company, and/or (v)&nbsp;your willful failure or refusal to substantially perform your reasonably assigned duties for the Company, which failure or refusal is not cured within 30
days following your receipt of written notice from the Company describing in reasonable detail the nature of such failure or refusal. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b)
&#147;<U>Disability</U>&#148; shall mean any physical or mental disability or infirmity that prevents the performance of your duties for a period of (i) 120 consecutive days or (ii) 180 <FONT STYLE="white-space:nowrap">non-consecutive</FONT> days
during any <FONT STYLE="white-space:nowrap">12-month</FONT> period. Any question as to the existence, extent, or potentiality of your Disability upon which you and the Company cannot agree shall be determined by a qualified, independent physician
selected by the Company and approved by you (which approval shall not be unreasonably withheld). The determination of any such physician shall be final and conclusive for all purposes of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c) &#147;<U>Good Reason</U>&#148; shall mean any of the following events: (i)&nbsp;a material diminution of your duties, title, reporting
structure, authority and responsibilities; (ii)&nbsp;the Company&#146;s material breach of this Agreement which has or could reasonably have a detrimental impact on you; (iii)&nbsp;a requirement that your principal place of providing services to the
Company change by more than fifty (50)&nbsp;miles, other than in a direction that reduces your daily commuting distance; or (iv)&nbsp;any reduction in your Base Salary or Target Bonus other than a reduction of not more than ten percent that is
implemented pursuant to salary reduction program impacting all or certain officers of the Company in like proportion as determined by the Board in its good faith discretion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Confidential Information and Other Ongoing Obligations</B>. As a condition of the commencement of your employment, you are required to enter into the
Employee Confidentiality, Assignment, Nonsolicitation and Noncompetition Agreement (the &#147;<U>Restrictive Covenant Agreement</U>&#148;) attached hereto. The Restrictive Covenant Agreement, along any other confidentiality, restrictive covenant and
other ongoing obligations you have to the Company or any of its affiliates, are referred to as the &#147;<U>Ongoing Obligations</U>.&#148; You agree without reservation that these restraints are necessary for the reasonable and proper protection of
the Company and its affiliates, and that each and every one of the restraints is reasonable in respect to subject matter, length of time and geographic area. <B><I></I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Obligations to Third Parties</B>. Except as may be set forth in <U>Schedule I</U> attached hereto, by signing this Agreement, you represent to the
Company that you have no contractual commitments or other legal obligations (including with respect to noncompetition, nonsolicitation, invention assignment and the nondisclosure of confidential information) that would or may prohibit or materially
inhibit you from performing your duties for the Company. You further agree that you will not disclose or use confidential information of any former employer or other third party and that you will respect any other restrictive covenant obligation you
have to any former employer or other third party. <B><I></I></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Section</B><B></B><B>&nbsp;409A; Taxes</B>. It is intended that the benefits
provided under this Agreement and the Restrictive Covenant Agreement shall comply with the provisions of Section&nbsp;409A or qualify for an exemption to Section&nbsp;409A, and this Agreement and the Restrictive Covenant Agreement shall be construed
and interpreted in accordance with such intent. Any payments that qualify for the &#147;short term deferral&#148; exception or another exception under Section&nbsp;409A shall be paid under the applicable exception. Each payment provided under this
Agreement or the Restrictive Covenant Agreement shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be treated as a separate payment for Section&nbsp;409A purposes. Neither the Company (or its affiliates), the Board, or any employee, officer or director of the Company (or its affiliates) shall
be held liable for any taxes, interest, penalties or other monetary amounts owed by you as a result of this Agreement or the Restrictive Covenant Agreement. All forms of compensation referred to in this Agreement are subject to reduction to reflect
applicable withholding and payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make
any claim against the Company or the Board related to tax liabilities arising from your compensation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Interpretation and Enforcement</B>. This
Agreement, including the Restrictive Covenant Agreement and the Equity Documents, constitutes the complete agreement between you and the Company, contains all of the terms of your employment with the Company and supersedes any prior agreements,
representations or understandings (whether written, oral or implied) between you and the Company. In entering into this Agreement, you agree that you have conducted your own diligence with respect to this opportunity and that you are not relying on
any promises or representations of the Company or any Company affiliate (including, without limitation, any member of the Board) any expect as are expressly contained herein. Except as may otherwise be expressly provided in the Restrictive Covenant
Agreement or the Equity Documents, (i)&nbsp;the terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement or arising out of, related to, or in any way connected with this
Agreement, your employment with the Company or any other relationship between you and the Company (the &#147;<U>Disputes</U>&#148;) will be governed by Massachusetts law, excluding laws relating to conflicts or choice of law; (ii)&nbsp;you and the
Company submit to the exclusive personal jurisdiction of the federal and state courts located in Massachusetts in connection with any Dispute or any claim related to any Dispute, and (iii)&nbsp;you and the Company waive any right to trial by jury
with respect to such Dispute. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Assignment</B>. You may not make any assignment of this Agreement, the Restrictive Covenant Agreement or any interest
herein or therein. The Company may assign its rights and obligations under this Agreement (including the Ongoing Obligations) without your consent to any affiliate or to any other person or entity. This Agreement shall inure to the benefit of and be
binding upon you and the Company, and each of your and its respective successors, executors, administrators, heirs and permitted assigns. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.
Miscellaneous</B>. This Agreement may not be modified or amended by either you or the Company, and no breach or provision shall be deemed to be waived by the Company, unless agreed to in writing by you and the Board. This Agreement may be executed
in two or more counterparts, including by the use of PDFs or DocuSign, each of which shall be an original and all of which together shall constitute one and the same instrument. The Company hereby agrees to reimburse you for reasonable and
documental legal expenses in connection with the negotiation of this letter, up to $10,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You acknowledge that Restrictive Covenant Agreement will
become effective as of the Start Date, except that the noncompete provision in the Restrictive Covenant Agreement will not become effective until ten (10)&nbsp;business days from the date you received it. Please indicate your acceptance of this
offer by signing below and returning a copy of this Agreement and the signed Restrictive Covenant Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">UPSTREAM BIO, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ronald C. Renaud, Jr.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ron Renaud</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Member, Board of Directors</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">I have read and accept this employment offer:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ E. Rand Sutherland</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">E. Rand Sutherland, MD, MPH</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">4/1/2024</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Enclosure: &#8195;&#8195;Restrictive Covenant Agreement </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Upstream Bio, Inc. </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Effective Date: April&nbsp;4, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Via Email </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rand Sutherland </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Re: Amendment to Offer Letter </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Dr. Sutherland: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This letter serves as an amendment to your March&nbsp;27, 2024 offer letter (the &#147;<B><I>Offer Letter</I></B>&#148;) with Upstream Bio,
Inc. (the &#147;<B><I>Company</I></B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The parties hereby agree that Section&nbsp;5 of the Offer Letter is hereby amended and
restated as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Equity</B>. Subject to the approval of the Board of Directors (including any committee thereof, the
&#147;<U>Board</U>&#148;) in its discretion and subject to your continuous employment with the Company as of each applicable grant date, the Company will grant you an option to purchase an aggregate of 1,830,795 shares of Common Stock of the
Company, which is equal to 4.5% of the outstanding Common Stock, calculated on a fully diluted basis, giving effect to the closing of the first and second tranches of the Company&#146;s Series B preferred stock financing contemplated by the Series B
Preferred Stock Purchase Agreement (the &#147;<U>SPA</U>&#148;) entered into by the Company and various investors on or about June&nbsp;6, 2023 (the &#147;<U>Option</U>&#148;). An initial grant of 826,220 options (the &#147;<U>Initial
Portion</U>&#148;), which represents the maximum available shares available for grant as of your Start Date under the Company&#146;s 2021 Stock Option and Grant Plan (as amended, the &#147;<U>Plan</U>&#148;), shall be subject to time-based vesting
as of the date of grant with a strike price equal to the then-current fair market value of one share of Common Stock as determined by the Board. The remaining 1,004,575 options (the &#147;<U>Second Closing Portion</U>&#148;) shall be granted as
promptly as practicable following the second tranche closing of the Series B financing under the SPA subject to time-based vesting as of the date of grant with a strike price equal to the then-current fair market value of one share of Common Stock
as determined by the Board. Once granted, the Initial Portion and the Second Closing Portion will each vest as follows: (i)&nbsp;twenty five percent (25%) of the shares subject to the applicable portion of the Option shall vest on the first (1st)
anniversary of the applicable Vesting Commencement Date (as defined below) and (ii)&nbsp;the remaining seventy five percent (75%) of the shares subject to the applicable portion of the Option will vest in a series of successive equal monthly
installments of 1/48 of the shares upon the completion of each month of service to the Company over the thirty six (36)&nbsp;month period measured from the first (1st) anniversary of the applicable Vesting Commencement Date. For the sake of clarity,
in no event shall the total shares of Common Stock underlying the Option exceed 4.5% of the fully diluted share capital of the Company after giving effect to the closing of the first and second tranches of the Company&#146;s Series B preferred stock
financing. For purposes hereof, the term &#147;<U>Vesting Commencement Date</U>&#148; means (i)&nbsp;your Start Date for purposes of the Initial Portion, and (ii)&nbsp;the date of the second closing of the Series B financing for purposes of the
Second Closing Portion. The Option shall be subject in all respects (including with respect to applicable vesting requirements) to the Plan and the stock option agreement provided by the Company (collectively, the &#147;<U>Equity
Documents</U>&#148;), which will include the vesting acceleration events set forth in Section&nbsp;8.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This amendment to your Offer
Letter supersedes any prior representations or agreements relating to the subject matter hereof. Except as otherwise provided herein, the terms of your Offer Letter remain unchanged and your Offer Letter shall remain in full force and effect
following the execution and delivery of this amendment in all respects. From and after the date hereof, each reference in the Offer Letter to &#147;this Agreement&#148;, &#147;hereunder&#148;, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;herein&#148; or words of like import shall mean and be a reference to your Offer Letter as amended by
this amendment. No reference to this amendment need be made in any instrument or document at any time referring to your Offer Letter, and a reference to your Offer Letter in any such instrument or document shall be deemed a reference to your Offer
Letter as amended hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you have any questions about the terms of this letter, please let me know and I will be happy to discuss
them with you. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ronald C. Renaud, Jr.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ronald Renaud, Chairman of the Board</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I acknowledge and accept the terms of this amendment to my Offer Letter: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="70%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ E. Rand Sutherland</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Printed&nbsp;Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">E. Rand Sutherland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">4/12/2024</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>12
<FILENAME>d843142dex1020.htm
<DESCRIPTION>EX-10.20
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.20</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.20 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;11, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael Gray </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Re: Employment Offer </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Mike: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I am pleased to confirm the below terms of your employment with Upstream Bio, Inc. (the &#147;<U>Company</U>&#148;) as set forth below (this
&#147;<U>Agreement</U>&#148;). <B></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Position.</B> Your position is Chief Financial Officer and Chief Operation Officer of the Company. You will
report to the Chief Executive Officer of the Company and will have such duties as the Company determines. This is a full-time position. While you render services to the Company, you will not engage in any other employment, consulting or other
business activities (whether full-time or part-time); provided that you may engage in religious, charitable or other community activities and join one corporate board of a company that is not competitive with Upstream Bio as long as such services
and activities are disclosed to the Chief Executive Officer and do not interfere with the performance of your duties to the Company. <B></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Start
Date</B>. The first day of your employment for purposes of this Agreement will be March&nbsp;26, 2024, or as otherwise mutually agreed to by the parties (such actual first day of employment, the &#147;<U>Start Date</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Salary.</B> Initially, the Company will pay you a base salary at the rate of $460,000 annually. Your base salary will be subject to adjustment from time
to time at the Company&#146;s discretion. Your base salary in effect from time to time is referred to herein as the &#147;<U>Base Salary</U>.&#148; The Base Salary shall be payable in accordance with the Company&#146;s standard payroll schedule and
shall be subject to applicable deductions and withholdings. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Annual Bonus</B>. You will be eligible for an annual cash bonus of up to 40% of your
Base Salary. The criteria for any bonus, whether a bonus is awarded, and the amount of any bonus each shall be determined by the Company in its sole discretion. The bonus target percentage is subject to change. To earn any bonus, you must be
employed with the Company on the date the bonus is paid. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Equity</B>.<B> </B>Subject to the approval of the<B> </B>Board of Directors (including any
committee thereof, the &#147;<U>Board</U>&#148;) in its discretion and subject to your continuous employment with the Company as of each applicable grant date, the Company will grant you an option to purchase the aggregate number of shares of Common
Stock of the Company as is equal to 1.4% of the outstanding Common Stock, calculated on a fully diluted basis, giving effect to the closing of the first and second tranches of the Company&#146;s Series B preferred stock financing contemplated by the
Series B Preferred Stock Purchase Agreement (the &#147;<U>SPA</U>&#148;) entered into by the Company and various investors on or about June&nbsp;6, 2023 (the &#147;<U>Option</U>&#148;). The portion of the Option as is equal to 1.4% of the
outstanding Common Stock, calculated on a fully diluted basis, as of the date of grant (the &#147;<U>Initial Portion</U>&#148;) shall be subject to time-based vesting as of the date of grant. The balance of the Option (the &#147;<U>Second Closing
Portion</U>&#148;) shall not be subject to time-based vesting as of the date of the grant but shall become subject to time-based vesting effective at the consummation of the Second Closing (as defined in the SPA). Once subject to time-based vesting,
the First Portion and the Second Closing Portion will each vest as follows: (i)&nbsp;twenty five percent (25%) of the shares subject to the applicable portion of the Option shall vest on the first (1st) anniversary of the applicable Vesting
Commencement Date (as defined below) and (ii)&nbsp;the remaining seventy five percent (75%) of the shares subject to the applicable portion of the Option will vest in a series of successive equal monthly installments of 1/48 of the shares upon the
completion of each month of service to the Company over the thirty six (36)&nbsp;month period measured from the first (1st) anniversary of the applicable Vesting Commencement Date. For the sake of clarity, in no event shall the total shares of
Common </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock underlying the Option exceed 1.4% of the fully diluted share capital of the Company after giving effect to the closing of the first and second tranches of the Company&#146;s Series B
preferred stock financing. For purposes hereof, the term &#147;<U>Vesting Commencement Date</U>&#148; means your Start Date for purposes of the Initial Portion and the date of the second closing of the Series B financing for purposes of the Second
Closing Portion. The Option shall be subject in all respects (including with respect to applicable vesting requirements) to the Company&#146;s stock plan and the stock option agreement provided by the Company (collectively, the &#147;<U>Equity
Documents</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Benefits. </B>You will be eligible for the employee benefits the Company provides to senior executives from time to time,
subject to the terms and conditions of the Company&#146;s benefit plans and other applicable policies. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.
<FONT STYLE="white-space:nowrap">At-Will</FONT> Employment; Accrued Obligations; Resignation(s) in Connection with Termination</B>. Your employment with the Company is <FONT STYLE="white-space:nowrap">at-will,</FONT> meaning either you or the
Company may terminate your employment at any time and for any reason, with or without notice and with or without cause. Likewise, the terms and conditions of your employment, including without limitation your compensation, benefits and job duties,
are subject to change by the Company in its discretion. In the event of the ending of your employment for any reason, the Company shall pay you (i)&nbsp;your Base Salary through your last day of employment (the &#147;<U>Date of
Termination</U>&#148;), and (ii)&nbsp;the amount of any documented expenses properly incurred by you on behalf of the Company prior to any such termination and not yet reimbursed (the &#147;<U>Accrued Obligations</U>&#148;). In connection with the
termination of your employment for any reason, you agree to resign from any officer position or other position you have with the Company or any Company affiliate, effective as of the Date of Termination, and execute any document reasonably requested
by the Company to effectuate such resignation(s). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Severance.</B> In the event the Company terminates your employment without Cause (as defined
below) or you resign for Good Reason (as defined below) and provided you (i)&nbsp;enter into, do not revoke and comply with the terms of a separation agreement and release in the form provided by the Company which shall include, without limitation,
a general release of claims against the Company and related persons and entities, nondisparagement obligations, a seven-business day revocation period and a twelve-month post-employment noncompetition obligation (the &#147;<U>Release</U>&#148;)
within the time period provided in the Release but in no event later than 60 days after the Date of Termination (the &#147;<U>Release Requirement</U>&#148;); (ii) resign from any and all positions, including, without implication of limitation, as a
director, trustee or officer, that you then hold with the Company and any affiliate of the Company; and (iii)&nbsp;comply with the Ongoing Obligations (as defined below), then in addition to the Accrued Obligations, the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company will provide you with the following &#147;<U>Severance Benefits</U>&#148;: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) continuation of your Base Salary as of the Date of Termination for the six (6)&nbsp;month period that immediately follows the Date of
Termination (the &#147;<U>Salary Continuation Payments</U>,&#148; and such period, the &#147;<U>Severance Period</U>&#148;); provided in the event you breach any of the Ongoing Obligations, all payments of the Salary Continuation Payments shall
immediately cease; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) if elected, continuation of group health plan benefits to the extent authorized by and consistent with 29 U.S.C.
&#167; 1161 et seq. (commonly known as &#147;<U>COBRA</U>&#148;), with the cost of the regular premium for such benefits shared in the same relative proportion by the Company and you as in effect on the Date of Termination until the earliest of
(i)&nbsp;the end of the Severance Period; (ii)&nbsp;the date you become eligible for health benefits through another employer or (iii)&nbsp;the date you otherwise become ineligible for COBRA; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c) provided you have not breached any of the Ongoing Obligations, payment of your annual bonus for the calendar year in which the termination
occurs which shall be <FONT STYLE="white-space:nowrap">pro-rated</FONT> for the number of days actually employed in said calendar year through the Date of Termination (the &#147;<U>Final Bonus</U>&#148;). The Final Bonus shall be paid to you by the
Company in a single lump sum within 60 days after the Date of Termination and shall be subject to applicable deductions and withholdings; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(d) if the Company terminates your employment without Cause or you resign for Good Reason
less than three (3)&nbsp;months prior to Change in Control or within twelve (12)&nbsp;months following a Change in Control, the Company shall provide that the vesting of 100% of your then unvested equity awards that vest based solely on the passage
of time shall be accelerated, such that all then-unvested equity awards that vest based solely on the passage of time vest and become fully exercisable and <FONT STYLE="white-space:nowrap">non-forfeitable</FONT> as of the Date of Termination. For
purposes of this Agreement, the term &#147;<U>Change in Control</U>&#148; shall mean the sale of all or substantially all of the outstanding shares of capital stock, assets or business of the Company by merger, consolidation, sale of assets or
otherwise (other than a merger or consolidation in which all or substantially all of the individuals and entities who were beneficial owners of the Company&#146;s voting securities immediately prior to such transaction beneficially own, directly or
indirectly, more than 50% (determined on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis) of the outstanding securities entitled to vote generally in the election of directors of the resulting, surviving or acquiring corporation in
such transaction); provided, however, that the issuance and sale of securities of the Company for bona fide financing purposes shall not constitute a Change in Control and provided further that such event or occurrence constitutes a change in the
ownership or effective control of the Company, or a change in the ownership of a substantial portion of the assets of the Company, as defined in Treasury Regulation Sections <FONT STYLE="white-space:nowrap">1.409A-3(i)(5)(v),</FONT> (vi) and (vii).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Salary Continuation Payments shall commence within 60 days after the Date of Termination and shall be made on the Company&#146;s regular payroll
dates; provided, however, that if the <FONT STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year and ends in a second calendar year, the Salary Continuation Payments shall begin to be paid in the second calendar year. In the
event you miss a regular payroll period between the Date of Termination and first Salary Continuation Payment date, the first Salary Continuation Payment shall include a &#147;catch up&#148; payment. Solely for purposes of Section&nbsp;409A of the
Internal Revenue Code of 1986, as amended (&#147;<U>Section&nbsp;409A</U>&#148;), each Salary Continuation Payment is considered a separate payment. Notwithstanding the foregoing, in the event you are entitled to any payments pursuant to the
Restrictive Covenants Agreement (as defined below) (including without limitation Garden Leave Pay as defined therein), the Severance Benefits to be paid to you in any calendar year will be reduced by the amount that you are paid in the same such
calendar year pursuant to the Restrictive Covenants Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, in the event your employment is terminated by the Company for
Cause, by you for any reason, or due to your death or disability (the latter as determined by the Company in good faith), you will be entitled to the Accrued Obligations but not to the Severance Benefits. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Definitions. </B>For purposes of this Agreement, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) &#147;<U>Cause</U>&#148; shall mean any of (a)&nbsp;your conviction of, or plea of guilty or <I>nolo contendere </I>to, any felony or any
crime involving dishonesty, deceit, moral turpitude or fraud; or (b)&nbsp;a good faith finding by the Company that you have (i)&nbsp;engaged in dishonesty, willful misconduct or gross negligence with respect to the Company, (ii)&nbsp;negligently or
purposefully engaged in conduct that has materially injured or would reasonably be expected to materially injure the reputation, business or business relationships of the Company, (iii)&nbsp;materially breached any provision of any agreement(s)
between you and the Company relating to noncompetition, nonsolicitation, nondisclosure and/or assignment of inventions, (iv)&nbsp;materially violated material Company policies or procedures, and/or (v)&nbsp;failed to perform your assigned duties to
the Company&#146;s reasonable satisfaction, following notice of such failure and, if reasonably curable, a period of thirty (30)&nbsp;days to cure in the Company&#146;s reasonable satisfaction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) &#147;<U>Good Reason</U>&#148; shall mean any of the following events: (i)&nbsp;a material diminution of your duties, title, reporting
structure, authority and responsibilities; (ii)&nbsp;the Company&#146;s material breach of this Agreement which has or could reasonably have a detrimental impact on you; (iii)&nbsp;a requirement that your principal place of providing services to the
Company change by more than fifty (50)&nbsp;miles, other than in a direction that reduces your daily commuting distance; or (iv)&nbsp;any material reduction in your Base Salary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Confidential Information and Other Ongoing Obligations</B>. As a condition of the commencement of
your employment, you are required to enter into the Employee Confidentiality, Assignment, Nonsolicitation and Noncompetition Agreement (the &#147;<U>Restrictive Covenant Agreement</U>&#148;) attached hereto. The Restrictive Covenant Agreement, along
any other confidentiality, restrictive covenant and other ongoing obligations you have to the Company or any of its affiliates, are referred to as the &#147;<U>Ongoing Obligations</U>.&#148; You agree without reservation that these restraints are
necessary for the reasonable and proper protection of the Company and its affiliates, and that each and every one of the restraints is reasonable in respect to subject matter, length of time and geographic area. <B><I></I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Obligations to Third Parties</B>. Except as may be set forth in <U>Schedule I</U> attached hereto, by signing this Agreement, you represent to the
Company that you have no contractual commitments or other legal obligations (including with respect to noncompetition, nonsolicitation, invention assignment and the nondisclosure of confidential information) that would or may prohibit or materially
inhibit you from performing your duties for the Company. You further agree that you will not disclose or use confidential information of any former employer or other third party and that you will respect any other restrictive covenant obligation you
have to any former employer or other third party. <B><I></I></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Section</B><B></B><B>&nbsp;409A; Taxes</B>. It is intended that the benefits
provided under this Agreement and the Restrictive Covenant Agreement shall comply with the provisions of Section&nbsp;409A or qualify for an exemption to Section&nbsp;409A, and this Agreement and the Restrictive Covenant Agreement shall be construed
and interpreted in accordance with such intent. Any payments that qualify for the &#147;short term deferral&#148; exception or another exception under Section&nbsp;409A shall be paid under the applicable exception. Each payment provided under this
Agreement or the Restrictive Covenant Agreement shall be treated as a separate payment for Section&nbsp;409A purposes. Neither the Company (or its affiliates), the Board, or any employee, officer or director of the Company (or its affiliates) shall
be held liable for any taxes, interest, penalties or other monetary amounts owed by you as a result of this Agreement or the Restrictive Covenant Agreement. All forms of compensation referred to in this Agreement are subject to reduction to reflect
applicable withholding and payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make
any claim against the Company or the Board related to tax liabilities arising from your compensation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Interpretation and Enforcement</B>. This
Agreement, including the Restrictive Covenant Agreement and the Equity Documents, constitutes the complete agreement between you and the Company, contains all of the terms of your employment with the Company and supersedes any prior agreements,
representations or understandings (whether written, oral or implied) between you and the Company. In entering into this Agreement, you agree that you are not relying on any promises or representations of the Company or any Company affiliate, expect
as are expressly contained herein. Except as may otherwise be expressly provided in the Restrictive Covenant Agreement or the Equity Documents, (i)&nbsp;the terms of this Agreement and the resolution of any disputes as to the meaning, effect,
performance or validity of this Agreement or arising out of, related to, or in any way connected with this Agreement, your employment with the Company or any other relationship between you and the Company (the &#147;<U>Disputes</U>&#148;) will be
governed by Massachusetts law, excluding laws relating to conflicts or choice of law; (ii)&nbsp;you and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in Massachusetts in connection with any Dispute
or any claim related to any Dispute, and (iii)&nbsp;you and the Company waive any right to trial by jury with respect to such Dispute. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.
Assignment</B>. You may not make any assignment of this Agreement, the Restrictive Covenant Agreement or any interest herein or therein. The Company may assign its rights and obligations under this Agreement (including the Ongoing Obligations)
without your consent to any affiliate or to any other person or entity. This Agreement shall inure to the benefit of and be binding upon you and the Company, and each of your and its respective successors, executors, administrators, heirs and
permitted assigns. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Miscellaneous</B>. This Agreement may not be modified or amended by either you or the Company, and no
breach or provision shall be deemed to be waived by the Company, unless agreed to in writing by you and the Chief Executive Officer of the Company. This Agreement may be executed in two or more counterparts, including by the use of PDFs, each of
which shall be an original and all of which together shall constitute one and the same instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You acknowledge that you received the Restrictive
Covenant Agreement at least ten (10)&nbsp;business days before its effective date. Please indicate your acceptance of this offer by signing below and returning a copy of this Agreement and the signed Restrictive Covenant Agreement by March&nbsp;12,
2024. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">UPSTREAM BIO, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Samantha Truex</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Samantha Truex</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="78%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">I have read and accept this employment offer:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Gray</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Michael Gray</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">3/12/2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Enclosure:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Restrictive Covenant Agreement</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>13
<FILENAME>d843142dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the use in this Amendment No. 1 to the Registration Statement on Form S-1 of Upstream Bio, Inc. of our report dated June&nbsp;12, 2024,
except for the effects of the stock split discussed in Note&nbsp;18 to the consolidated financial statements, as to which the date is October&nbsp;7, 2024, relating to the financial statements of Upstream Bio, Inc., which appears in this
Registration Statement. We also consent to the reference to us under the heading &#147;Experts&#148; in such Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/
PricewaterhouseCoopers LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October&nbsp;7, 2024 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>14
<FILENAME>d843142dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 107 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Filing Fee Table </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT STYLE="white-space:nowrap">S-1</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Form Type) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upstream Bio, Inc.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Charter) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table 1: Newly Registered Securities </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>&#8194;Security&#8194;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Type</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Security&nbsp;Class&nbsp;Title</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Fee</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>&#8194;Calculation&#8194;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Rule</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Amount</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Offering</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Price Per</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Unit</B></P></TD>

<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Offering</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>&#8194;Price<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP>&#8194;</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Fee&nbsp;Rate</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Amount&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>&#8194;Registration&#8194;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Fee</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fees to be</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Paid</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Common&nbsp;Stock,&nbsp;par&nbsp;value $0.001 per share</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">457(a)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">14,375,000<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$17.00<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$244,375,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$0.00015310</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$22,103.81<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt">Fees Previously Paid</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Common Stock, $0.001 par value per share</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">457(a)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$100,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$0.00014760</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$14,760.00</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="6" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="padding-bottom:1pt ;"><B>Total Offering Amounts&#8201;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$244,375,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$36,863.81</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="6" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="padding-bottom:1pt ;"><B>Total&nbsp;Fees&nbsp;Previously&nbsp;Paid&#8201;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$14,760.00</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="6" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="padding-bottom:1pt ;"><B>Total Fee Offsets&#8201;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;&#8195;&#8195;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="6" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000"><B>Net Fee Due&#8201;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">$22,103.81</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 1,875,000 shares that the underwriters have the option to purchase. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of computing the registration fee in accordance with Rule 457(a) under the
Securities Act of 1933, as amended. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This registration fee only includes the payment of $22,103.81 for an additional $144,375,000 of shares, as the
registrant previously paid $14,760.00 for the registration of $100,000,000 of shares under the Securities and Exchange Commission&#146;s prior fee rate in effect until September&nbsp;30, 2024. </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g843142g00u68.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g843142g00u68.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_[2364&AO=&]S:&]P(#,N,  X0DE-! 0
M     $,< 5H  QLE1QP"   "   < E  #$IE;B!"96%C:&5L;!P"!0 >5&AI
M<R!I<R!T:&4@<')E<V5N=&%T:6]N('1I=&QE #A"24T$)0      $!\R=$PZ
MG._6X&,R$4,++5TX0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q =*7WT         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ %*7WP  0 ! 4I??  !  $X0DE-
M!"8       X             /X   #A"24T$#0      !    %HX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M T$    &              2H   ((P    8 9P P #  =0 V #@    !
M                      $             "",   2H
M      $                         $     $       !N=6QL     @
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M      !,969T;&]N9P          0G1O;6QO;F<   2H     %)G:'1L;VYG
M   ((P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I
M9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4
M>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG   $J     !29VAT;&]N9P  "",    #=7)L5$58
M5     $       !N=6QL5$585     $       !-<V=E5$585     $
M  9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (
M8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E
M2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI
M8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    1
M15-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M      IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M       +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M       X0DE-!!$       $! #A"24T$%       !     0X0DE-! P
M&E$    !    H    %P   '@  "L@   &C4 &  !_]C_[0 ,061O8F5?0TT
M O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3
M$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+
M#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,
M# P,# P,# P,# P,# P,#/_  !$( %P H ,!(@ "$0$#$0'_W0 $  K_Q $_
M   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
M  $  @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B
M<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V
M%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G
M=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1
M%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1E
MXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>G
MM\?_V@ , P$  A$#$0 _ /3']0Q&&QKK-:OYP $[?-T#Z*&_K& T?3<[W-9
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M_P!+^VL^KI+<P/RF.=C"6M:]K0X/F/5<VNS;M_2;/>S_ *:Z6$.\?H_[3?\
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ML?,ZS)9NW?UD\OJT<"^OLX:N']<?G?UT@3U/]BN&.\0 3_SDJ'?_ #?]IO\
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M]_4W?X#_ *"L8WV+7[+Z7 W>EMX]VR=G]M-_5\73B6O_V0 X0DE-!"$
M %<    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     4
M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  ,@ P #( ,0    $
M.$))300B      %*34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    ?    ?@$R  (    4
M    G0$[  (    -    L8=I  0    !    P    .P   %*     0   4H
M   !061O8F4@4&AO=&]S:&]P(#(R+C @*%=I;F1O=W,I #(P,C0Z,#8Z,3$@
M,3DZ,3 Z,#, 2F5N($)E86-H96QL      .@ 0 #     ?__  "@ @ $
M 0  "".@ P $     0  !*@         !@$#  ,    !  8   $:  4    !
M   !.@$;  4    !   !0@$H  ,    !  (   (!  0    !   !2@("  0
M   !              !(     0   $@    !.$))30/]       (
M  #_X0%217AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    ?    ?@$R  (    4
M    G0$[  (    -    L8=I  0    !    P    .P   %*     0   4H
M   !061O8F4@4&AO=&]S:&]P(#(R+C @*%=I;F1O=W,I #(P,C0Z,#8Z,3$@
M,3DZ,3 Z,#, 2F5N($)E86-H96QL      .@ 0 #     ?__  "@ @ $
M 0  "".@ P $     0  !*@         !@$#  ,    !  8   $:  4    !
M   !.@$;  4    !   !0@$H  ,    !  (   (!  0    !   !2@("  0
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MMZ=,J4MI"UH*%*2"4'JD^5$75%5F1.N:>)I*&5*5;XR$+=1I3C24*)Q^T59
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ME:EMK .4C( \SZ_N-(S)-UENMM&0[N#L#@;#KM4'&")#2@PIFY"T418R9"I
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M U[C\6 !GK@50D.SF)J6D.R-;FHY"]CMW_6G"W+DEG!D/X3W"]^A_C6 Q?\
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M?=274TU81IG2B.X1^^F%QF*]ZG-\\LICI!3IZK5UWKQ<PJAK>U%!=4RE1'4
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MR5L26.[/8C7YQ7?AFDTB1QTW46R&A8;NI*$%:7$E*B-QDD9%2K3C,R.(BE)
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M02&D@Z2,*&.A_.I&%,:3;I;*% <Q\G_* !^ZJY:X=RGNR4);:T,C)5DI( .
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M_P"<4PGS'Y##*&UJ2ZHG\(TYR=CGM656DTLAWD.5K=5I2J.#\S?,\^*CF+/
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M15Y5,!=\E>-M*>R'RK8Y':@(4@N*<)T8Z9ZUT5.(U+V.KI7IU+*"<#5U&:F
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MGIBILHND5:$(U25*U ^'SQ7!<0S#>DK4I;6G5L"2?E4?>+G$B$M/JUOX*@$
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M"6B,H82_)5H!'FE(R3^7QJ8@1'(Z%^^/(=*CD80$I3\!U_,TJV$Z](2!H3C
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M-22,G<GL,XK3+;:QP[8Y.7PX4IPDE.-.<_'/7RJ9M%I@6E 9A,)1A(05X\1
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MJ(P.H&<9Q^==E)F8+=@RTY N5L%RM\941:#H6RXDY2K<&JG)6VT.0WC2WAL
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M]/Q+3N?@*4B:@F(5:P%$D$RIRBJB[=)C*@4+D)![. $&G4;B122$S&/\S?\
M _QK8TW+ 5V%62BD8LIF6WKCN)6GOCJ/B.U+5FMM444441%%<NKY;2UD$Z4E
M6!U.*^?[!*XV0NPLSDW(QX4MBZ2'%)7EYN4MM/)/GR^8^2#T"4T1;-Q18W+P
MR@,23'=0=E =?2N+;PS&8@%F60^ZK\:TC3FLWB\8<8/%S4ZEJ0N'*><8=M+R
M407D+2&T%8!UY!)V!\^E37L_FWR?Q'<+E/\ ?%MNV:*I#+T<L)+H6\%8&2 3
MIS\%)]*Q.'IEV<BZC*)E'$/"EV-V2BWMH<@N%(UYW0.^<G\ZTJ.CEL-H)R4I
M SYUDR.+.*?^#YEP8>]ZNY2P7(:K2ZT(!6L!S?<N: 3M@G;5TVJ&ES^*[H[9
M)$X/J4#H+D-MU"7$"?#PI:2D8.GF=L%()&Q-11P[*));NH#0-%NM%%%;JR87
M_P#J>5_A_?3\4PO_ /4\K_#^^GXJ@\9Z#W5SX!U/LBBBBKJB****(BBBBB(H
MHHHB****(BBBBB+Q:TMH*EJ"4I&22< 5GO&37"MREZI2B)>!EYCJ0 >N^_Q^
M%<\;W21-N:[=&?"([8 <TK*22?/TILJTL>[/# 5(" I"4J_9'7'GD&NAC,O>
M)6K&Q<IG:^![)/Y09O2UO:]^Q4,;@#YUS:H#=HF/PBE+>A1!4K?('0TQ#@;\
M;*RVM .'$D;'OWV.#VJZVJ-'XJM ]\5IEL**>8C.3ZG-7+S%S9:DENNBB%!#
M+#A7J<4VK5E*AA7E\.OZ4[X:BNS)5P6P0A)8*4G<)U'ML<U)L\%HU#GSG7&]
MBI & HBK3%C-164M,(2A"1@ "LG/ %EFYXBRPA2BQ>9+2@@.-*W()P2#MOWR
M#_\ 56"*LRH320E#J@VL>)1.E(&QZ_B"L8SYCU-.N.>%Y*;B[<(;#88)*W5%
M62<^?SV_^J@;/Q&N"MMIEU:6PO.D)R#CK\=L[GR%=)[[<S5TCOMMJI6Q-D^]
MOR)2A,)2Z%I)&OJ,$9QT&=^GPKULM6U"H8G!^804.(2X0T0<$G5U"LD>6<TU
M1+CORU#G--./M!*QJV0I7X@-P-]_.HN;(;E7A2HL?4X,I&V2G89"=MNGQJ T
ME(DIS98ZI/$R(R&AX5Z2DKPI)_M:OH?RK7'+' <EMRE1TA]!R5 ?BV[CO57X
M*X:>C71=SN##:9!R 1UW W'QR<U>ZY<1EJ$ WA85*IS=TKA#3:!A"$I'H*R.
M%?Y$'VAQT72?);@.7.XQTI<4HH/@C\I..F,E6/B:U^C%9KG61>UJ^<5)ML(0
M+/=($5#Z'9+T9QM:U8>2E#>0O9*@23C)_"#C)PM[:.)9UDN_"XARI\6,'3(E
MB,C476TK;!0!^VK!5X?(D[X%:O1BB+-O:C=IBK-9)=FD2F426Y;GW*BDD>XO
MK1G2>R@DCU JP\+7M5XM5J$1EZ5">B /7!+J0$.@8*2"=95D=0*M&**(L-OL
M^3&]F$=#EWNL>YHE3DPWE/O?>EM]80A:TY4I>D#0E1PHC<$5M<!Q3T&.ZXAQ
M"UMI44.#"DDCH?6E\"BB(J-XB_JB1_E_U"I*HWB(_P#9#_\ E_U"J5/ >BTI
M>-O4*2HH!HJZS11111%1/:A=IUL=M0@2G& ZU.*]!_$41'5I^BD@_*E+=Q<)
M'![$J(52L6KGKN@6A49#R4;I6H$J"M6Y\)Q5U6VA>-:$JQTR,UXVTVVC0VVA
M"/[*1@4147V-7&3<.')0G3G+A)C2BRY+]Z$EIY0;02II82GP^+IC8ZADU?2,
MC!KEIIME 0TA*$#HE(P!75$1@4W?A1GWD.OL(<<0,)*QG3\*<45! .JD$C15
M/B)]$:](*P<&. DCMXE?[5ED:VKF<2K8D*;&M2U*4!@J2"<8\^WYUL7%MJ7<
M(0=BC,IC)0!^T#U'Y5F\B$I\EQD-L3492'-.%I.3D9ZC?>NJDZ!9=U!H>RVH
M5CB*9;80ELM,N-MZ='+P1G.DX!VW![^>]5V],KG6B1</"I+:W VO3I!RLI('
M<X .Y[FNK;/N2VBY<X&IUOP_=.)PKZXV]:3NTM5[=BHNKJ(+ 4HMQTJ)4M0R
M#D],=<4:V""M(<##1=4F+&7(N#:F1H0V0X2KOY#ZXK5O98YS)\\))*4IQGL?
M%5-N#"G7&;;:FG%K<=!T(5@@=/W9/SK5N".'$<.VLM%6N2[A3J_7L!\*O7>"
MU*Y%.CD.I5BHHHKC7F(K.?:U<;A!<8^SI4EC-IN;AY*RG*T,I*#MW!SBM&H(
M!ZBB*M6"]?;<""F"T_)@2(GCN;+R E#@\)3UUZLCJ!CUJDS8TVZ\)\)0H]TO
M+5WENED/M3'$%+25E3KCF#XB$)P,]U"M;  &!1@419"GBB\)]J8E!%R/"R7_
M +%)*<QM?3FYSG7SON\XQCO6O48'E11$44441%%%(S2Z(KI8!+F-@.ORSWHB
MB>(IY;3[JPO"U?C4/V1Y?.D;) ;"%OA',6D>$'N:C;A.A&$TXAM;:4**GM?X
MMNN?6G?"'$C5T<=BK0AAQ/B:0G]I'\16\%K++F;_ +'R=E2;Y<;R[*4B>X^P
MXG<-I&@ ?+K3JR71<T*C2!J>0G4E8'XAZ^M:+?)4>+;WER5H2G3I\7K5+X1A
M6LW]1BOE:4QRK2>FHG!P?0?K6C7RV81[ XY4D;@N Z)$96EQ'4=E#R/I6A09
M*)D)B2U_1O-I<3\",UDGM#D,VRYLL1G4+Y^O*0=Q@$_S\:T;@515P=9E'J8C
M9_\ B*SJ@0"JX8D$M*G****P76BBBBB(HHHHB****(BBBBB)A?\ ^IY7^']]
M/QWJ.XA6E-HD!2@"4[9/7>G[:TK3J0H*'F#FJ#QGH/=7/@'4^RZHHHJZHBBB
MBB(HHHHB****(BBBBB(KETZ6EDYP$D[=:ZHHBQ-J0GW^0ETE2-9W*_%U.,D]
M<4_>=?):B-.N%2R$CE[=-77Z@ 4KQG8G[==),]"%^YO+U*<U?M=O6F N;$EA
M!"0TMM6-8)WW'GGU-=I[PS!=@N 0G1YY=?6I12EI.-2FL#4<'??SP/E4K[,G
M?^U9B,$Y1DX5L#D9V[_$57ITI3\R*AEUUUP>();.4[DD8^M7[@.QO6MN6_+0
M6WI"LZ"0=(R=JH_NM,JKS#;JQ(GPUSEPD2XZIC8U+8#@+B1YE.<@;BG-91_P
MM>A[;7+\U!7]GEU*O>%J:Y?+]UY:L8/,UZ@  ?#C)ZX-34B#>S[0'GY+-X?@
MEQLPG8LU+<5AL( 6EYHJ!4=>H]%9!&",5RKE5WEO1V6A[VZTVVM0;'-4 %*)
MP$[]23MBJ9<>!K5=&$RK.ZVVEQL*:<;7J0K8X(.^VXW'E5)M'"_'+Z"+Z_,E
M*1/B/.-O+06UJ0^%+=:/-40D)'X=*,Y'AR*G/9K9>)+->;8S<&)R;<U9V8[J
M79*2RR\E"!AM"5G))"LDI&-\*(( LU[F>$J0XMT3ISV:$LG$XE[4#DDXQE)_
M_M^72K+P_P (P;0ZIT O/9R'%'<_$=.M6-1"1E1 'F:]JSJSW""58U'&THHH
MKQ2@E)4H@ =2:S5%[17B5)5G20<'!P>E>T1%%%%$117@4"2 02#@X/2O:(BB
MBN4+2O\  I*O@<T1(3;A#@E(FRV(Y4E:T\UP(RE(RHC)Z ;GR%1O$]O1=[0%
M-/(04X<0[J\.GN<^6-ZKWM.X=N5]?@JMK*70U"N#*LK"<*=CE"!N>ZOI4OPT
MQ>7(=M-P0B!':C<A^WN(2ZM2@,!8=2K !';!JKV![2UVA5F/--P<W4)W&O-C
M@VNWJ^UH"8LC#49U4A 2^>F$G.%'/E4U60W_ (2O;_ =OLC%F9?D /CFI?;0
MJ.HO:T!6H'4TH8U!)SL!6N-Z@VGF8UX&<=,U($6"J3-RNJ***E$44441%%%%
M$11111$E[PQSRQSF^=C/+U#5CX=:B[UP_&N67$88E?\ 52.O^(=ZSF^V6_M<
M><5W.S0I*9;\9 A21&84@X92E0#JO&E6Q 'X2<9I-Q'&B(K2X:>(UQ$7-M49
MB0ID27&= UAY8/A1KU$9"O(C&*D$C16:XM,A2SO"5P4-<'W.0V5'"V7 .A.>
MV.N:0;]GUSF2>?,=CLJ&R5:BI2!Y#'\:C(=FXS8BE49RX0_=$H<9BL<M+;KB
MISQ<U)QO]R4'MU!ZTWXAE\;6V#>I3CUV8* L/.*4URM:I388]U[C[LJ!U;;C
M.]7[5RZ!C*H"TWAKANW\/8TN!V:]D<UT^)6V2$CX"IP2HY?+(?:+P."@+&K.
M <8^!!^=8^FP\37>; +CM^C0(\Y]<9^2XV)C2#$*3J4,C27=AWP>PQ2W!-EX
ME5QA:+I?H+B5@*7(>4E"?&J#'2HG'7[Q+@^7EBJ$DW*YW.+S+EL%%%%0JHHH
MHHB****(BBL0]I,'BA%YXRFV5N;(A/LQ8JXJ$J\0*/Z5K'52%;* [*/E3R;?
MO: OB;B"/$1RVV&Y?NL<Q%J!2EM7)6A?*TE2E:=BX<Y(T@BB+8Z*Q"_W7BN\
M2(]WM:;HRS">?5$0J 4J4H6]1.I"DY(+V4#(P2K;M4O)O/&,2\Q(JG9SSF(G
M);3;06I@61SU..@8:* 2 ,IQI'XLT1:Q17S^Y?>+.)>%;BVAV?-0]&*EG[.+
M26'4RT);#2D@<T%&LG&<:>W2GU\;XHE7E4><U,G>YOEEN8F(6RXV)D)8/A&/
MPESIU"#Y&B*Z<3Q@F=.9.R'@2#_B'7ZYK/XRWV9*&&PM,E*NO3'KFM>XKM+L
MUI+\-(5(;&"C.-:?3U_C69R;RW <=:FMK;4GKK00I'Q'6NRDX%L+@J%U)QYJ
M6XGFR[C!:<DAH\O=26U$E1Z XQ56>NIM*_>4J4V$ @GIU&,4[9O3$ELK:="D
M>8-4#CN[F1-C10E/NX<"E!&ZW#V2!ZU>S0J-J.=W4]D(=D3V9$AY3ERN3B(T
M=)W#25D#8?F:^GK=$:M]OC0XXPS';2T@>B1@?I6(^S/@R\W"^1;O?;>[!886
M'4)?V5A.Z4I3U&^"2<=,5NU<M5P)LNK#L+09111162Z$44441%%%%$11111$
M5X5)'4CZU[6#'A*\18:IB(/->FWJ:M;8A'G-MA,P(6I9))!U(TD 8"@-\T1;
M-Q!:T7>VKCDA*\A2%^1_^LT]A1FXD5N.RG2VVD) K&>%9'&8;LUOCO7M-O3[
MFU*<EP$-+85I7S&T91NWA*,J.<''B.:68NW'*X=QYCMV:E"*XJ3KMJ2B*^'4
MAM,;2DEU)1KR?'@ *Z[&H8T.S1=7+W%N2;+9L@D@'<45A_OW%S"';BQ$N\>3
M(?@EUM$%"GI*1'PM*EALI3XNY2!VRCMN Z59411111$44441%%%%$1136XS4
M08RGEMNN ?LMIR:H5PX_,U?*LBVV5#PJ,E.#J]-\?6JN=E$K6E1=5,-6CT5D
MUZN7%+BHJ[?]H) 2.:K2%(4?32,8J1M?&EPMZRQ?F0M0&0<!+G3;(^GE535:
M(G=;C!5' Y;Q\LM$?9;D-*;?;2XVKJE0R#5:<X%LZY!=Y;B01^!*L)'K_/E5
M6XBXXNUKGQC_ ,MRG@%!I(U8!\SUIPOC*YW-]M%MY+040"T,<T^8!5L?EO5C
M6-, W$I3PM1TY2+:\E;K)PM;;0I*X[6MU(P%N;D?#RJ<K'[I=^)D7K,-R>RP
M>C;J<G/PQBK!:>-)VOW*X1FU3LZ$D*TC/][RJ'UA/>*?1U7-S#YSZ+0**R9[
MV@76%?'HLD,N)3D:4I&!\#_&I%-]O\UL2+=)9E,#=Q$=L!U(]4G)^F:.?D,.
M!E0S!N>,P<(XK2**QJ[<17\W<+MK\UJ,,92Z,G/PQ5GL'&,SD+1=T1]:4Y0H
MNI;4X?+2?UVH:C00)0X*IES)U[78'VCP<XR(DR6M+R'$-1F><%*2<@.(R"IL
MG8XW&<CID5DM\:RKFE3<FYVJ&9<.,(C++:T,L+C)+R@M2"24.9 5G ([U(W3
MBV<_)::>:=MT)9PIU'B*AZ*Z?2JI<.(+M;[N4VJZ2Y$?/XG#D?G1CP\D#;R4
MG!O:!._"_P"$^7<./D1X:7#=_?4,)3%#4-LM27@\XE7O1*? .6&SD:1@DC)V
MI+BI'&5WA<2V]:;LKFLRTK9$9 82@+'NX87IRM2D[*&2=U?A(%73A'B^3/0M
MJ?$4M3:"KG-#96.V/,^E-KQQHX]+1#CH>MZ2K"WGD84!Z#M5>V;$J!@JN<LC
M11?"5LXBM/%JW.?<%VV7>)*9#+K*.66O=P4/DA(.2M(&<X[8I2X1^,97$SG(
MNMUB6YV[+B:&H[12W%]V"PZDJ03GF#3J)(WQ4!?.(;M:;N$P+N_+;4<YR5#\
M]JN'#_&LZX-"*((>N'905I0H8ZG;8_E\*NYV2,VZ@85S@7,O&NWY4'9KKQNI
MVW0Y[%R#[RHC[C_NB>6AH1SSPHXP%%P?AZ[C&U,K?<N,E6F FZN<3-QPZ^EZ
M7%@MJE.K ;+7W1;\#9)<['=(&K&";)*XCO##[J+N'+<@)/++304%*[#4<_E5
M9MO&]_:FN<UWGL!7A2Z@>(?+>JBH""[@K#!5"0!OZ>NB\XA'&5OD75RQ-W%E
MF7<^8Z^W&"WE 1& @Z=*AI*TK!(&,C&0,U<.+I'$+%GX?^\GMI7M='[3&2Z^
ME7+VT(4%825]< D;>IJ5:XAF/6A$M-O0PLG&F2\&P?49&X^E5USBR]OR-"&V
M$M ^(Q2EY0'U/Z4-5H5682H^=!'-1=UF<<GBFT-6]VXHMJF8Q0MZ&DATD_>^
M\:4$(5C&V4@=LFI+V0Q)-L?G1KBTN-)<92M#3OA4I(?D9(!WP-:-_P"\/.H3
MB/BV[-3D?9,^0MK;5S$)3CXC%)W#B.[/H@WAN%S[C:7-8=00CG,*P'63V)(
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MTQ,E0FE,@8Y.05CS.U/K=<Y/##+#\R;(,)>Z6D *"O\ W'(^0H'R0T"2CL&
MPNS=.:UM1"02H@ =2:8"ZVQ]98]\B.*S^#F)._PK-WKM/OB/N+FW(;.#[JL!
ME2O3'17UJ"XC@39\IM42U/0U) "@EM6YHVH'.@V4G!%HO<\O[6Z@Y&U%9-PQ
M=+G:'4(F35(A-XYB%I+F!Y#&=/U%.+IQ//N)6B),B.QB<*1'.E:AY85@_2JB
ML,LPH.!<'Y9"T;[3@\WE>^1^;TT<P9^F:=@Y&U8)Q.MF4IK[+BN1G  %ZE'K
M5CX4EW^,RAEV2689 !<D$)TCS1J[^F"*MV@ !F9X;*3@C!VCCOT6L$XKA#J%
MJ(2M)([ UF5UFK8G)"KVW<0-_=W]30/_ /&JX;3>TW)4YAIZ.RHY2I"M*!_F
MSC\Z"H+SLH&"T[VOS>#]EN=%4*RWB7[HN-<+L')2L!I,5"7'!\3C2?YWJO7&
M^N&X*BNWJ<A8.-+S>E/ST']U!4D2 JC!G-E<X#UOT6LK?:;.%N(23_:4!2B2
M%#(W%8[?;3=+O&:5;XK*DI&.=$7K"_4[Y!^-/^&6;Y:BA,FXHA1Q^)+Z@LGX
M(W/Z4-0  J?H['O:?-I/V6J5PIU"2$J6D$]B:S>?,GS'%BV\1(FX.["?N5GT
M VS5/XGE.SGFDQF/=%( "\J.K(ZFC:@)@VZJ1@G$2+]/[A;K#BQX<=#$-EMA
MA&=+;:0E(R<G 'J:6K.^ T\0E+:G7U(MJ=S[P,E0_N]_W4^N;O$I>48DN)(:
M2=VXI2%X^"L_K4"I(F%1V%AY9F"NU1UYL=NO+7+N41I\#HHC"D_!0W%91Q)=
M[R+DTJWN7&*!@*2ZXK.>^U7'A:_74I";XAIN/C^G>(;4?\O?Z5;M "+Z_+J'
M8-^4N_._3BFDGV2</O+)2_<V4$_@;D;?F"?SJ7X:]GO#7#L@2;?;DJF#I(?4
M77!\"KI\L4PN%UNTV2M-DNEO>0#LTT0ES'^;.:J_%5TO2%1Q%-RBR$?TG,<4
M 3Z=L5(JYC!/JJMP4"1Z#7V6Q450>$+QQ"Z4)GL<R(>LAX<O2///[7\[TA?K
MK<XKN47V&ZT3_1M8;5]=_P!:IVHB85_HW9\DCY\W6BT5B-YN%WEW!F1:C.9;
MP,D.*7D]\'O5^X.E<1.(4;LSF,E.0MT!#A/8#_>K9Q:+S\NH?A',:7$Q''V5
MPHJCWB[WYQ\MPEP8XQ^!,AM2_P _W52.*)][C/('/EON;%2' I./S_,5+79C
M 5.P.Y]UM]%9;PK>;T4I(=PR@!3HD*U(;'JKK]*G+AQ>I[F-P#RL#PO*1JU'
MT'8?&H#PH-!P,!7:BLCM/$/&#]U+*D.NL*W"N2D8'TWJUN<2O66.IZ_K&^$H
M9;1EPD],XV%6>X,U*H60))5QI*5(9B1UOR7$--(&5+4< 50)W&]V2W+5'MK+
M820&"XK.L=R=QBF24R.(PX+S<&W8Q<"V6>B1CL2D>?\ ]UCVT^ 'V50UQL I
MYV\<17$S'K%"CB-'<"6N>K!DC'BQY?&GL+BOFW2/ D6V4TX\,<U*=3:5;[*(
MZ?[U&W.3>H,9OW1*EHQ@!"04X]"-JB[;9(Q+LI4=YB8^G"U)>45)]1DD>7:J
M.;5;#FF>*GLW;%:916=MWFY\)V\?:3CUTBZL!TX*VQG]K_?\JD5\3RI4U$>V
MM<[*-:U)&[?ED'S^-3]4P>*QX*O57.BJ1 XEEL(3]MH7$4M>A.I).3V^7PJ?
M;OD)+;BWIT;2WLH:QE)]?*KMQ%-VZE3%%5=_BA;LUJ-:HCDL+05J<2-DCM]?
M7%-(7%RG6PY+08BPYREM.I.0K]:J,52)B?UZJ)5SHH'2BNA% <<*"+ \M064
MI()T.\L_7!^E978GN')*70N._&=5D)4XYK;"O-6D X^%:AQZ(OV OWY#ZVM:
M=F2 <[]<]JRMN-"%OE26'$M*:(T,.'4I7KL!FL:A![@%SZ+U,$V*9>XP!PU^
M>2FKA!DLVER.9-O?;=&6'&Y(2&QDYPDXZFHJV,RH"DLS)L5*M.>7+&H+^ ((
M_2N[3>TW)MEB[6E#V!H08Z>6ZGX8V/P(J0O5OL,A3#J[G,D2< (:5A2D>BE=
M!BL["6.-ATU^<UU#,"' 7/XZ?L!<N28$M3@5 BP-+94A2DE7,5Z;X J CW5R
M4L%QKW31X-4= 1J'F1MFI5VXM<./KB+BY<< TJ><#K>//0 !GU-.X/O$U#WN
M[420^ZG#7NRT,J0?\. 34%I#<KA<[JS7@$O:9 VD?/4IK>[0_-B0Y+DN!&;2
M@%.%%M:QYE)&:7MJ&(D1<JYI5/@(\/W:.A]%G!&/2HV)$NYD\F7(:D.ZM(;<
M6ETCTP,FG@:M3\>1$EW,Q'DG*H[:%J0<>BL8/SJ=70;M'#Y^571EK%WS;V3-
MA<.X/ZX,-C<].8K6H>F3N?2G,R3<K7<$*L4:1&;P LNL */ITI*%;[?&=:0M
M$@LJ/A<=3RF_B<9)^1%.;_Q/*3*3; F/(@HP$\D*"0 ,#!SG\Z4Q)<6WCBIJ
MGPM._7^_O">QH;EW*W;J5V]X KY[KF$+/^!6_P!-O2HOB"WF>\RZ_=(;^CPI
M$;4< =R G:G=F8<EQ9@MLA4=!;^_#Z"H >BP#],#YU$VZSLHF\EB>E;RE9"D
MY S\58Q4,?D;F!O^5)9FJ97>$?;YU4Q8E1H460^7URHS0U.1ED-H7\CDGZ"F
M"KS"N2]4"'&MZ3L MO7@_P"+'[J4F7QF%,3;KA;HTY220IY2B7#_ )@:]AP&
MYSZ?LE2'7#XC%<1I7@;D G(/U!H]A8P-(N?GRZ4W![S4FWSY<+V4VM%K4Q(M
MJW)"_$W*020H?$=13&TVV\N1REXK,<'.J0=+:1\5?NWIU?G;O]HMJ8]Y@-(P
M.6IU7;XFG84AYL/\5.K2P4Z42$Y*SCIN,I(^.]29RBF+SR]X4 P35<(\Y]!,
M)V6>'H]N2J4V\'\8,AM"U-:O, D$BDX#SI<2JW3X\Z+GQ1HY]W4K_+MGY9KA
M4,S+:[&MU\BO6_\ %H<)0L#X8S]*A8-IBM/HC,RD.+4K]G*4_P#N4!^E5.4,
M_P"RE@<YQDRWG/ZMZA$AB[&\O.QV93#2B<-:59'QS4\W<6VH!-U4F&\DX0_!
M:2EPGOJ(P/H0:C;[=6$RDV^>B8TIL!"2W)YJ-MOPG^(KR2B3>K6FWQI#"V6@
M5#5AI83WSJ.#\B:T<#G':6!Y+,$&E_KO'/WOZ)TT7H:7)\9Q%TCK24*6L$K;
M)_M ]/CT]:KUKMTR1.=<8U*63J)1X4H]2>@J<X:MZH,UC3<D-.CPZ&#S5K'E
M@>'ZFEN);LB9=%Q')JXR$KREE;&A(^.DG)^54:797-;I\]%IW>U!=KQO^-#Y
M+N7>W(L)IB3);?D+/],[&2O \@I6Y^.*\"I3ELDK=8^T@XG2V^THJ#7H4C=/
MT%(<06ZX7F RO_E%Q8R0"['=3@CMD9R#\J5X1C1V9R#[R^Z\D;,QE:,X_M+.
M/H,T,#*0;_/55 EKY  Y?U$*OVB%<6M8T+.3N%#PX\B3M5J;MMF8C-*?=9=N
M!W5%]YT-_P#NQ^_YU&2KA:)%V6E*IL60VK.IQ8?3GUZ']:<3>&KGQ'-3,8?B
M2=.-V'4@#X@X(Z5<MFH35L>GLH-3_6W(;=?>\J=^WYD1E3$EA-JCA!Y(98"D
MK/\ B.0?B*I4*\.KGNJFP(TAK5T6V$%7S3BK)%>?X5D.1)Q<DIT_T"OZ#)'7
M)&_R IK?>(';;(CO6M%O4IP J$>.GP^8SU!J&2\%F_/;V52&TW9P+'AH?L3]
MU+FW"1%1/BIC6R," (TA&DK_ ,PRI0/PJF71*V+^IUQY,52U>%+>I*4_#O5D
MX>9;O\L!Q$YJ9U]X;7S$#_%JW'UIKQ=96F;B5W"Y*DRDX_\ !(^I.U0P@-).
MAZ>_LK014#=2.NGE,^:EXJ[I*0RI-P1=XJ1XF&7M#GS!P359<M]Y:FN\^,\B
M,590V^/"/FK:G8G-\--MOMM1I:7T:2M+AYB =B 0?":D[.NU37.=$NK]ODK&
M"B6D.@Y\E''YTAP9<:_+* X!Y+?_ )Y'[@?F$T=A6V7;$(E+><?"CB+$?2X$
M^N#N/EFD[6B#$+K[20P_&&M")*R22/( #\\TG=.&&;3<G#)>EK*B,N\G2V<^
M2LG]*Z<O$.W33#E1#=6B  M3^H)']TXVJ8ET-N I#NY.[N']^Z9M\2R;K(6Y
M,=D,@JQED^$?Y3_$5*W?A^==K2S,:D14Q$#^E2E2%JWZD8SFO;;&=FZW[+;H
MBDHW4E*2I:1__L)&?A3;B=%\?ELJM\6ZM!( 5S-1W],=OA4TS+RYME6I :UF
ML:Z?C9.N&FAK$:1+1.C)!4J,E!4-O56-/Q%1<Z5P[*?<8:C3$N(.R5N@H'Y$
MU.V"R7&YN:;K;UAL DOJ^Z<SC89_:^8^=-9?#WN,D_\ 8<M+9.[BE\T8\_ !
M^M4;9A,7V5R0:L9NHM^Q^$6UEJ,"^+<%-I&4/LCWCQ=L[X'S&:C'[Y=[G(4W
M<D./-()T) T*Q_E_?FN;U=95KEH:L$B0EG8JTIY>3ZC^-2UK;D<12$)FPI"G
MED S&<@#U4#X3\L&I+2UF6UT:07FJX&!\W]BN6FW(<',6Y,142,I5'E*&H?,
M#^!J,1PPS#4)4ZY,);=W"VLO:OA@8S\33_B^S.!;<>XW+F(9 "0EE:=NV^,?
MG2-M+%IB*GMR><E!&8Y<".9Z%.^14R0.S:==1\*J+S6,<C%_Q^U/VR[N1+.]
M]F-,O1V=U>]N9<4#Y8Z#T%5B/>;3.D*48TJ#(2<\QISFISYX5O\ G3N-<K#=
MUZY=O?MRU#&8ZO"3ZIQM\J[DVI,!(6FT2D,*PKGN'F )\\) 'UJ"0&EI%PI8
MW_9FF ?OYS?T\DWO%H5<WFKA(O$)Q!_"2HH)QYHQFIBS&)9[>[)?5)N,/\*F
MPC#.?@HY)]<"H._WEZ/R&K:^F=%Q_1/1TX1Z#;;Y4YL\%R^8CF)*89</B4QD
MM#U(5^X_*K&9:7&1U50/];@.[Y0/;[)ZPY8KPKG6&0NUSP<I0X<(6?('L:C'
M^$9C4MR9=%M1TDDJ?<<"L_X0-R:7-EA6=S3)A7!: K&7$<EOYD9S]12/%5W8
M$]AKW:-);"$H26%N>%.-@-\5#07%PI_JW-3(;E),\XGT.OJEIROL:RE^)&*H
MSQPIYQ1"W /( C ]-Z2L,R*^DKAR_<9+B2G$@:VE _WNJ?GGXTZM]O@<0L>Z
M-2YS2P"H1G$!Q)(\E; ?/%*0(4>QR6^?:WTE*@ _,20TCUTIV/UJO=R @7X[
M*TNS.:X^6_WL?D*!<L:8EQ=]XN#"G%'Q%M17CZ"K/+NT>P6]IN>S(?<= 4B4
MYH*T#MI!!V^)J.OO%;CEV5'>AP)\?.-89(V]%9S^=.8EDMO$K"S"1-1(:3J2
MPZ0IL>@7C;YUKI4FI>?59&]( " .5O8^R7@N/W-Q,B'<$W,C_P#9RU<M?R&<
M'Y5795EO4:Z.3%L/0T:MCG0E)_Q$XJ5B17K!<&C.A+B@*&)"T\S3ZI/X<_*F
M=UXLNHO"VXDMR1#SOSD I4/AC%4IR6N MQ^%7?:HTM$C;7VLK59KJY,@N0KG
M+=FN$>$1,I6D#KE>P/YU5X]SB1[@\BWR'&W#E"DS$!0P?[P_A5BX=AL<1)*E
M6URWNI&?>XAT(4?+!V^E05RX:CVJ:ZI;%Q=0"=3G)"$J_P V_P"E1;))UV_M
M0V!5+!:=1^HLFK7"DMITS7YL1EETY#Q?3I^6-R:O?#]Z;C1%14RY%W?2"HJ"
M=*4@#L5;FJK.O[5BMK+5OBV^2P]XG&U!3BL_WCY_2DHKD2\+0FV-.6RXN;<M
M!):<S^:?TJSB^14.ZKE;4::<0!\OOZ%-;C=8%PG.H#\UEY)Z/KYR/X@?6F=^
M5-O*&&2@:6AH!91D*^E.?^'&;9+7]J2$-*SXDL_>+/[A\S5@<XD:X:M+3EJB
M1>4X<G6[K<5CNK'0U+">U_TR/RK/+11 J#-^/75=<'667:E-RKA<?LZ/L2RI
MP!3F/,'I^M'$[EN#@=^W)N%'*4OH4ML_IM]:81I%EX@.M0>MEP<.4D$K;63Z
M=137BBR7Z2&V;@TZME@:0XV/ 1ZG^-58&SE?IZJ'!Q=G![W P+<M9]4UNMCN
M'$$I,JWAK2D :HAR/H3D?.I2W71B"VVS>I!EQ5*#26 C7A1Z>(XT].QJ-M2F
MK0\VX7"X\W@I0RYA(/DI0Z_ ?6G%^XFCF<U]NVN*YOE*V1A:3YA0)_0U8%]1
ML-U7/7;D) 4RWQY#CLJ8C6EMF.B1R E2P"5>>"/SIBYQ%<+A(918'I#A<>+:
MT.E"=&.N%#8^G?TKMBQ6J^I7($Q]"&@%J,EO.GR\0./WTX9?@6T$6I#;SS2<
MAZ0D@$_W$]OB:SR5#8N^RYQ3-[_95R_VV[:WW67IBISRTJ5J)26])V )._\
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M]3O3^0PU(:+;[2'4'?2M((^E*44  L$<]SC)-TQ<L]N=04N08JA_Z0_A4?\
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M0;M<XEP02V?NPSR\I/F3H._K6BT419Y:_9Z]#GVF0J:ROW*\S+HH!LY6E\+
M3\1J&_I4?"]G-YLTB)<+!=X35S:<F(69,93C2V7WN;C 4"%).-\[UJ=%$621
MO91-:L5O@.79A;L:W7*$MP,D!:I2LA0&=@GN*5F^S*ZN,W*U1+S$;X?N[C3T
M]M<8JD!24H2L-KS@!6@=0<9VK5J*(L\7[/GRI\B<T.9Q*U?1]V=D("1R^O7P
M]?6M#HHHB****(BBBBB(HHHHB****(BBBBB(HHHHB****(BBBBB(HHHHB***
(*(BBBBB+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g843142g03g03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g843142g03g03.jpg
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MU'87U;Z:5\?]%*XDAKL;6 TX_P#JJMKY3XWW2*BO-IFMID(:'O>3LYX$@M!
M]ZQ"T:BI=-<HM_K:V*:6-\D\0$(!.3*#VD;MQ7K55VDY0[U;J6S6^9@BRTR/
M R XC)=C<&C'?VJ4-J:WU"[35EZ>RF%2>=;'L%^SQSOS@]RL= :Q&JVU@?2B
MEEIRWT1)M[0=G?P'<H_EF&SHMK<YQ41C/Y.6*:&E;I[6=")3S=+<+9%)D\/Z
ML.)^9COBH&0ZKY3/L2_55NAMS:EL!#3(9MG)P"1C!X9PLNOEZ-LTO+=Q )"R
M)LO-%V,YQNSCWK0MSC?76:OODP].JN6PTGL]%[G#_F;\%N/6O^C*J_X6+^]J
M#'J7E,NU7"):72T\T1W!\;WN'Q#%D6C]57*^7*6FKK%/;HFQ&02R;6"<@;.]
MH[S\%@FA]4WRU:?BI;=IVHKZ=KW$3L8\@DG>-S2-RV%HR_W6]2U3;M99K:V)
MK2PR,>W;SG/[0'# ^*)1VK=?-TYJ*&W34/.P.8Q[YA)@M!)!PW&_&.]91=[H
MRBL%5<X VH9% 9V .P'@#(W^]:LY1;9]L<IE);]OFS/3-:'=QP\C^("^:>OD
MT.DM1:9NN65E'33<R''>6@':;^7$>[\%(V#IO4LEZTI-=V46S*P2%M.UY=M%
MHW#..W\%B-7RG72CC$E9IB:",G9#I7N:">[)8IOD;_S)A_WTG]ZM.7#_ #4I
MO^,;_P!#U \V77]VN5=11'3-1'35$C&\^"\M:UQ'I9V,8QOXK8BA]&?YHV7_
M (.'_H"F$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0:LY=
M8I)8+/S<;WX=+G9&>QJ^GE.J74@@H+!5.JM@,87$N&<8S@-R?P6TD08#R3Z9
MJ[12U=PNK#'6UA&(W?M-:,G?W$D\/<%BFJ:Z2S<K,MSZ)-41P[)V6#&UF'9X
MX]ZW2B#6?WJM\!K/G_\ X5L&T5GVC:Z2LYMT7/Q-DYMW%N1G!5VB#0/*%:ZR
MT:KN<5"R7HUP:'X8TD.:YP<6_.U;ITI:Q9M/4%   Z*,;>.UYWN/Q)4JB#37
M*%4R6WE-I+B*:6=E.R)Y:P?M8SNRIG[U6^ UGS__ ,*V8B#&ZNXF\Z KZUL#
MX3/0S$1.WN'HN&%K'0.L':7M4])+:JFH,DQEVFG9QZ(&.'N6\D08?I#6PU'<
MWT8ME12;,1DVY'9!P0,</>L4U1;+II'64FH[13.JJ*=Q=*QH)QM?M-=C@"=X
M/_V.VT0:ENW*7/>;?);[%:JD5E0TQEV=LL!W'9 &\^_<LKY,=-2Z=L;Q6 "M
MJ7"21H.=@ 8#?RW_ !67@ < B#4N@J=QY4M0.FA/-GI&"YNX_P!,U;98QK!A
MC6M'N&%]1!@O++&^31X;&QSG=)9N:,]CEANO[;-U4TE7P1R<XVC93R;(.1Z
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M4T](VCB?M;,#0 &8<1V =V?S02B(B B(@(B("(B B(@(B("(B B(@(B("(B
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M8U@(=AV>]92@(B("(B B(@(B("(B B(@(B("A:C55BIYY(9[M1QRQN+'L=(
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MGC?2;!DYT'T=D<3GNW*E:[K076-[[;5PU+6'#C$X.P?>L9T]_HH9_P##I?\
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MR-OM+/%40N ;-)$6"9I[>'$8WX]R#+46L;!=*^7E;N-%+6U#Z-G.;,+I"6#
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M/605VC;167^.\21R-K6/9)EC\-+FG<2/R"OM26"BU%0LI+B)#$R02#FW;)R
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MW<5BD^C*ZFU]#?;-)1PTA+3-"XN:2"-EX #2-XW_ (J4+KE>_P QJS_>1_\
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M9UHUVJW551UHC@;!L#FN;V/VL[_V3W(,K1:SOVM[M<+_ "6;1U.R66(EKYW
M.R1Q(SN#0=V3Q_OM*S46MM+F.IO]/!5T+G!KBT-&/=EO _B,(-KHK&T7.GNU
MHAN%$XF&9FTW/$'M!]X.Y:WY/>4.LN5[%!?)(BVH&S"]K W#^X_C_?CO0;61
M8+REZDN-@J[+';I(V-JGO;+M,#L@%F,=W[14GRC7BKL6FI*VWN:V<2L:"YNT
M,$[]R#)T6J;9<^42YT$-91QTCZ>9NTQQ$8R/P)67:,=JATE7UI9"UF&\SS>Q
MQWYSLG\$&4(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B"RO514TMKJ9Z&#I%2QN618)VCGA@;UXL%55UMIIZBXT_
M1JI^UMQ8(V<.(&X[^ !7N]=--KJ?LLM%;L_T6UC&<^_<O%@%P%II_M@M-?Z7
M.;.,?M''#=PP@D$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$004URNC=50T+* NMCFY=5;#MQV2<9X<0!^:G5!3"^]:H3$6?8FSZ8]':S
MLG\^.%.H"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@*SO-1
M44MKJ9Z*#GZEC<QQ8)VCW8"O%9WGIAM=3]F$"MV?Z+.,;7Y[D%/3]55UMH@J
M+C3=&JG[6W%@C9PX@;COX '\U(*/T^+@+1!]LEIK_2YS9QC]HXX;N&%(("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@*"J+E=&:I@H8Z NM
MKVY?4[#O1."<9X<0/BIU050+[UI@,)9]B;/](/1SG!_/CA!.HB("(B B(@+S
M-_4O_P!DKTO,H)B>!Q(*#FZAHW2:0KJ^+=+1UL1VAV!P</[PU97=*YNK-90S
M,PZGH[89W < [FB__J<T?DI+1ND[E'I#4EON5&Z&:J:#"UQ!VG-!(X'OPOO)
MQI.Y6R@OTMPHW0U,],8(&$@EV0XG@>_94H2/(;_FM6?\8[_H8HG0/^EG47XU
M'_="R3DEM%=9M/U-/<Z9U/,ZJ<\-<0<MV6C.[\"H[1UAN=#RC7JX55(^.BG,
MW-RDC#MJ0$=N>"@1>J/],UI_&'_%;;6JM=6:_NUW!=[+;C4M@9&6.)&R7#.X
MC(*N?MWE$\ H_E__ .BE*2Y9_P#,P_\ $1_XK&M,LU\;#0FTRTHH.;',APCS
ML_F,K*^46W7&]:,B@IJ4RUSGQ/?$P@8.#M<3V%8W9ZW7UJME-0TUBIG0P,V&
MEXRXCWX>$0SC1K=0-HY^L[HG5'.?T?-[.-G'_A]ZQ;6&BZJLU ^[Z9N,<%Q(
MVI(N<V79 QD$<,]H.Y3^C;AJ:MJ:ENI+=!21-8#$Z,8VG9WC]HK%KWIR_P"G
MM6U%\TO"VJAJ2YTD/$C:.7-+<@D9WC"A*P=JO56F:F!FJZ%M52EV ][&YQV[
M+V[L_BMO4LT=3313PG,4K ]A[P1D+4EWHM8:XFI:6XVZ.W443]LN<-D \,G)
M))QG "VS0TS*.BIZ6+/-PQMC;GN P/[D&JM6?Z9+/^,']Y6UZ@N%/*8_VPT[
M/XXW+7>HK#<ZKE/MER@I'OH8C%MS C P3GMRMD(-2\@XC<^]/=@S_P!$,GCC
MTL_QPLZY0&Q.T7>!/C9Z.XC/K#]G^.%A5TTK?M,ZBFN^D6MGIYB2^GW>B"<E
MI:2,MSPQO"H76/6^L8V4%7;X[=1%P,A(+ <=IR23^ 4H3G(PYYT5,'YV6U,@
M9^&RW_'*UKI_3K[KI6YW"BVNG6^9LC=GBYF"2![QC(_ K>VG[/#8[%!;J4ES
M8F$%QXO<=Y/YDK%.2&R7&RT%QCNE*^G=+(TL#B#D 'N*)8+JG4;=1T&EI9'#
MIL$DD=0W_P 68\._ \?CW+8/+)_F5+_OX_[RL.U5R?W"GU2)[+1NFM\LC91L
M$#FCG>W>>'=[BL]Y3[967;2LE+;H'3U!E8X,:0#@'?Q1#"]+,UZ;!1&SRTHH
M-C^A#A'G9R>\96?Z-;J%M+4=:'Q.GVQS7-[/[.-_[/O6#V6LU]:+73T%-8J=
MT,#=EID&7$9[</"R[1MQU/6U=0W4EM@I(&L!C=&,%SL\/VCV(EE:(B@$1$!$
M1 1$0<^_?_7^!4OZ[O)/O_K_  *E_7=Y+='5/3O@-J^DC\DZIZ=\!M7TD?D@
MTO\ ?_7^!4OZ[O)/O_K_  *E_7=Y+='5/3O@-J^DC\DZIZ=\!M7TD?D@TO\
M?_7^!4OZ[O)/O_K_  *E_7=Y+='5/3O@-J^DC\DZIZ=\!M7TD?D@TO\ ?_7^
M!4OZ[O)/O_K_  *E_7=Y+='5/3O@-J^DC\DZIZ=\!M7TD?D@TO\ ?_7^!4OZ
M[O)/O_K_  *E_7=Y+='5/3O@-J^DC\DZIZ=\!M7TD?D@TO\ ?_7^!4OZ[O)/
MO_K_  *E_7=Y+='5/3O@-J^DC\DZIZ=\!M7TD?D@TO\ ?_7^!4OZ[O)/O_K_
M  *E_7=Y+='5/3O@-J^DC\DZIZ=\!M7TD?D@TO\ ?_7^!4OZ[O)/O_K_  *E
M_7=Y+='5/3O@-J^DC\DZIZ=\!M7TD?D@TO\ ?_7^!4OZ[O)/O_K_  *E_7=Y
M+='5/3O@-J^DC\DZIZ=\!M7TD?D@TO\ ?_7^!4OZ[O)/O_K_  *E_7=Y+='5
M/3O@-J^DC\DZIZ=\!M7TD?D@TO\ ?_7^!4OZ[O)/O_K_  *E_7=Y+='5/3O@
M-J^DC\DZIZ=\!M7TD?D@TO\ ?_7^!4OZ[O)/O_K_  *E_7=Y+='5/3O@-J^D
MC\DZIZ=\!M7TD?D@TO\ ?_7^!4OZ[O)/O_K_  *E_7=Y+='5/3O@-J^DC\DZ
MIZ=\!M7TD?D@TO\ ?_7^!4OZ[O)/O_K_  *E_7=Y+='5/3O@-J^DC\DZIZ=\
M!M7TD?D@TO\ ?_7^!4OZ[O)/O_K_  *E_7=Y+='5/3O@-J^DC\DZIZ=\!M7T
MD?D@TO\ ?_7^!4OZ[O)/O_K_  *E_7=Y+='5/3O@-J^DC\DZIZ=\!M7TD?D@
MTO\ ?_7^!4OZ[O)/O_K_  *E_7=Y+='5/3O@-J^DC\DZIZ=\!M7TD?D@TO\
M?_7^!4OZ[O)/O_K_  *E_7=Y+='5/3O@-J^DC\DZIZ=\!M7TD?D@TO\ ?_7^
M!4OZ[O)/O_K_  *E_7=Y+='5/3O@-J^DC\DZIZ=\!M7TD?D@TO\ ?_7^!4OZ
M[O)/O_K_  *E_7=Y+='5/3O@-J^DC\DZIZ=\!M7TD?D@TO\ ?_7^!4OZ[O)/
MO_K_  *E_7=Y+='5/3O@-J^DC\DZIZ=\!M7TD?D@TO\ ?_7^!4OZ[O)/O_K_
M  *E_7=Y+='5/3O@-J^DC\DZIZ=\!M7TD?D@TO\ ?_7^!4OZ[O)/O_K_  *E
M_7=Y+='5/3O@-J^DC\DZIZ=\!M7TD?D@TO\ ?_7^!4OZ[O)/O_K_  *E_7=Y
M+='5/3O@-J^DC\DZIZ=\!M7TD?D@TO\ ?_7^!4OZ[O)/O_K_  *E_7=Y+='5
M/3O@-J^DC\DZIZ=\!M7TD?D@TO\ ?_7^!4OZ[O)/O_K_  *E_7=Y+='5/3O@
M-J^DC\DZIZ=\!M7TD?D@TO\ ?_7^!4OZ[O)/O_K_  *E_7=Y+='5/3O@-J^D
MC\DZIZ=\!M7TD?D@TO\ ?_7^!4OZ[O)/O_K_  *E_7=Y+='5/3O@-J^DC\DZ
MIZ=\!M7TD?D@TO\ ?_7^!4OZ[O)/O_K_  *E_7=Y+='5/3O@-J^DC\DZIZ=\
M!M7TD?D@TO\ ?_7^!4OZ[O)/O_K_  *E_7=Y+='5/3O@-J^DC\DZIZ=\!M7T
MD?D@TO\ ?_7^!4OZ[O)/O_K_  *E_7=Y+='5/3O@-J^DC\DZIZ=\!M7TD?D@
MTO\ ?_7^!4OZ[O)/O_K_  *E_7=Y+='5/3O@-J^DC\DZIZ=\!M7TD?D@TO\
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M[_Z_P*E_7=Y+='5/3O@-J^DC\DZIZ=\!M7TD?D@T;<^76Y5E!-3Q6J*F?(W
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M5/3O@-J^DC\D&E_O_K_ J7]=WDGW_P!?X%2_KN\ENCJGIWP&U?21^2=4].^
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M]_\ 7^!4OZ[O)/O_ *_P*E_7=Y+='5/3O@-J^DC\DZIZ=\!M7TD?D@TO]_\
M7^!4OZ[O)/O_ *_P*E_7=Y+='5/3O@-J^DC\DZIZ=\!M7TD?D@TO]_\ 7^!4
MOZ[O)/O_ *_P*E_7=Y+='5/3O@-J^DC\DZIZ=\!M7TD?D@TO]_\ 7^!4OZ[O
M)/O_ *_P*E_7=Y+='5/3O@-J^DC\DZIZ=\!M7TD?D@TO]_\ 7^!4OZ[O)/O_
M *_P*E_7=Y+='5/3O@-J^DC\DZIZ=\!M7TD?D@TO]_\ 7^!4OZ[O)/O_ *_P
M*E_7=Y+='5/3O@-J^DC\DZIZ=\!M7TD?D@TO]_\ 7^!4OZ[O)/O_ *_P*E_7
M=Y+='5/3O@-J^DC\DZIZ=\!M7TD?D@TO]_\ 7^!4OZ[O)/O_ *_P*E_7=Y+=
M'5/3O@-J^DC\DZIZ=\!M7TD?D@TO]_\ 7^!4OZ[O)/O_ *_P*E_7=Y+='5/3
MO@-J^DC\DZIZ=\!M7TD?D@TO]_\ 7^!4OZ[O)/O_ *_P*E_7=Y+='5/3O@-J
M^DC\DZIZ=\!M7TD?D@TO]_\ 7^!4OZ[O)1,W+5=9+]%<!2;$+&X-(*E_-NW$
M9(_//#L6_NJ>G? ;5])'Y* J-&:5.JX)716Z.H#=U ((PU^X[]G'Y_DB&MOO
M_K_ J7]=WDGW_P!?X%2_KN\ENCJGIWP&U?21^2=4].^ VKZ2/R1+2_W_ -?X
M%2_KN\D^_P#K_ J7]=WDMT=4].^ VKZ2/R3JGIWP&U?21^2#2_W_ -?X%2_K
MN\D^_P#K_ J7]=WDMT=4].^ VKZ2/R3JGIWP&U?21^2#2_W_ -?X%2_KN\D^
M_P#K_ J7]=WDMT=4].^ VKZ2/R3JGIWP&U?21^2#2_W_ -?X%2_KN\D^_P#K
M_ J7]=WDMT=4].^ VKZ2/R3JGIWP&U?21^2#2_W_ -?X%2_KN\D^_P#K_ J7
M]=WDMT=4].^ VKZ2/R3JGIWP&U?21^2#2_W_ -?X%2_KN\D^_P#K_ J7]=WD
MMT=4].^ VKZ2/R3JGIWP&U?21^2#2_W_ -?X%2_KN\D^_P#K_ J7]=WDMT=4
M].^ VKZ2/R3JGIWP&U?21^2#2_W_ -?X%2_KN\D^_P#K_ J7]=WDMT=4].^
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MGU4GFH=$[*GI@WK=4QUIO_CET^JD\TZTW_QRZ?52>:AT3LJ>F#>MU3'6F_\
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MQW\<J447IFHI:NR4TUOI^CTKMK8BP!LX<0>'O!/YJ40$1$!$1 1$0$1$!$1
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MIJBD!+)'G+L-=LN:3VX)&/S1+9"+2E>+I<.5.X6VWW":EYY[F.>'$[#-@%Q
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M_)ZT@Z\5YO8N4M.+;5,)IVLRV;=G><C'P*LKY27&O_R@*ZDLM6:*NGJW1MJ
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M1$'.NK=3C4&I1/6B22UPO+8H(W;)+,]_83C>?);"T?RA4==<:"RT5G-)"_\
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MN2IMD#XYGQF-Q=(YWHY![?> I]$2U'R-?YS7[_9_\Y0_Z>!_M?\ [NMN  <
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M[2W6U-22T+G75S,LJ<##1LNW9SG@#V=J#)D1$!$1 1$0:OY=_P#V7:O]\_\
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MIABCIXS92WTY=VT#LGWYXX[%.("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M.BOMMKH*J:EJFR1THS,X-<-@8)[1[CP52FM-#37">N@IVLJYP1)("<NR0?\
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ML'O'%5*F[T-+<H*">H#*N< QQ[).T"2..,=A7BLL=NK8:6*JI6R1TPQ""3Z
MW#O]P7NIM-#4W&"NGIVOJX0!'(2<M&2?\2@^1WBADNLEM94 US!M.BV3D# /
M'&.!"^45YM];/50TM2)):4D3-#2-C!([1[CP7IEIH8[H^XLIVBM>-ETN3DC
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M$'NJO%!2W&"@J*@,JY\&./9)VLG WXQV%&7B@?=GVQM0#7-&T8MDY QGCC'
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MEPW?EV!>**R6ZBCJF4M*V-M4,3 $^GQ]_O*#Q%?[9-:Y;C'5-=11.V7R[+L
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MVTT==()*IL;1*\'(<[&\JZ0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MV.*.[T456R(DL$@_9)XK/3VNM>SS'Y<_*UM*9WO=#T'^BJ#_ .#-_P"PM?\
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MW[A\%3^PKOX57_3O\E]=74KNQQ>1-9SR1J*2^PKOX57_ $[_ "3["N_A5?\
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M^>#C\EO75-[IM.V*LN=6YNQ PEK"[!D?_JM'O)W+$^4/DQH-5U'3Z><T%SP
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M2TQ(YH.SG+1C(WD]O:5DB*U;VK$Q$\T3$3Q$1%5(B(@(B("(B B(@(B("(B
MB(@+&[SH^AO&I[=>J^:HD?0#^AILCF@[).T1C.<X/'L"R1%:M[4G-91,1/,1
M$54B(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M*,U'55]':I)K33"IJPYH;&03D9W\"%)J,U&RY/M4C;(]K*W:;LN=C&,[^.[@
M@N;5+43VVFEK8Q%4OC:Z1@&-EV-X5TK6U-J6VVF%>X.JQ&T2D8P78W\%=("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@CM104U39:N&OG,%
M*]F)) <;(SQWJGI:FI*2PTL%MJ#4TC-K8E)!VO2)/#WY"J:B-&VRU9NC7.H@
MS^E#<Y(S[MZIZ6=0.L5*;.US:'TN;#LY'I'/'?QR@E41$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$08S46^U.UO3UCZ\MNC68939&"-DC.
M,9X$G\EDRQFH?8^N].V2.3[;V/0?Z6SC9/OQPSV+)D!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%'Z@@IJFRU<-=-S%,]F)),XV1WJ04?J
M T;;+5FYM<ZB#/Z4-SDC\MZ"CI6FHZ2PTL%MJ#4TC=K8E)!VLN)/#WY"EE$Z
M5=;W6&E-F:]E!Z7-A^<_MG/'?QRI9 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M962*""T4<5'+SU.R)K8Y,_M- W%7J B(@(B("(B B(@(B("(B B(@(B("(B
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MBKU6=EGCJ;31SP0B"*2)KFQ 8# 1PW*\0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MP6RANE+'4RO;7M+7.<!EFXC=\R^0Z2@CTO-9!52F*1^V9<#:&\'_  09(7-
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MIT[%/J>GO1GD$L+-@1@#9.XC_P R";#@3@$9[E&:BKJNBM4L]KIA5U+7- B
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MZF61M<TM<YP&6Y!&[XKQ#I&"/3$UE%5,8I'[9EP-H;P?\$&2ES0,EPQWY0N
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ME7>&SR.EJ&EIC(&R,D</E038<TYP0<<=Z;3<9VACORL>L^EH+9'=F1U,L@N
MP_: ]#]KA\W\%XI-)04^F:JS-JI713OVS(0-H;V_RH,DVF@9VACORA<T8R0,
M\-ZQNMTE!5::I+,ZJE;%3OVQ( -H_M?S*I>-+07/[*YRIEC^SQANR!Z?[/'Y
M4&0;0!QD9[D4)6Z<AJM2TMY=/(V6!H:(P!LG&?YD03B(B B(@(B("(B B(@(
MB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(
MB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("B]2455<+5)3T%6:.=
MSFD2AQ& #OWC>I10VKZ.CKK'+!<:L4E,7-)E) P0=W%!?VJ"6FMM+!43&>:.
M-K7RDD[9 WG>KI65DAAI[/1PTLW/0,B:UDGKM W%7J B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B(([4533TEEJYZRG%13L9E\1 .T,\-ZIZ
M6JJ:ML-+44-,*6F?M;$(  ;AQ!X;N()_-7%ZJ9Z2U5,])3FHGC;ED0!.T<\,
M!>-/U=376BGJ*ZF-+4/VMJ$@C9PX@;COX '\T$@B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B#&:BYVYNMZ>@?;FNN#F9;5[+<M&R3C/'
M@"/S63*!FNEP9JN&@9;G.H'-RZKV'8:=DG&>'$ ?FIY 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!1^H*B"DLM7/5P"HIXV9?$0#MCNWJ0
M5G>:B>DM=3/20&HGC9ED0!.T>[ 06NE:NEKK#2U%!2BDIG[6Q"  &X>0>&[B
M"?S4LH[3U74UUH@J*ZF-+4/VMJ$@C9PX@;COX '\U(H"(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@+&:JYVYFMJ:@DMS77![,MJMEN6C9<<
M9X\ 1^:R90-1=+@S54% RW.=0/;EU5LNPTX)QGAQ 'YH)Y$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 4-JXVT627[;
M#S1;3=K8SG.=W#?Q4RH;5U;24%DEGN-(*NG:YH,1 .23NXH+RR=&^R*/[/VN
MB<TWFMK.=G&[BKU1UFKJ.>TT<M/S=/"^)KF1;0&P,;@KSI,'MH_F""JBI=)@
M]M'\P3I,'MH_F""JBI=)@]M'\P3I,'MH_F""JBI=)@]M'\P3I,'MH_F""JBI
M=)@]M'\P3I,'MH_F""JBI=)@]M'\P3I,'MH_F""JBI=)@]M'\P3I,'MH_F""
MJBI=)@]M'\P3I,'MH_F""JBI=)@]M'\P3I,'MH_F""JBI=)@]M'\P3I,'MH_
MF""JBI=)@]M'\P3I,'MH_F""JBI=)@]M'\P3I,'MH_F""JBI=)@]M'\P3I,'
MMH_F""JBI=)@]M'\P3I,'MH_F""JBI=)@]M'\P3I,'MH_F""WO/31:ZC[+#3
M6[/]%M8QG/OW+S8.GFTP?; :*_TN<V<8_:..&[AA>+UM5=KJ8**MCIZE[<,E
MYS&R<\<C>O%@$E%:*>GN%?'4U3-K;E,F=K+B1O._A@()5%2Z3![:/Y@G28/;
M1_,$%5%2Z3![:/Y@G28/;1_,$%5%2Z3![:/Y@G28/;1_,$%5%2Z3![:/Y@G2
M8/;1_,$%5%2Z3![:/Y@G28/;1_,$%5%2Z3![:/Y@G28/;1_,$%5%2Z3![:/Y
M@G28/;1_,$%5%2Z3![:/Y@G28/;1_,$%5%2Z3![:/Y@G28/;1_,$%5%2Z3![
M:/Y@G28/;1_,$%5%2Z3![:/Y@G28/;1_,$%5%2Z3![:/Y@G28/;1_,$%5%2Z
M3![:/Y@G28/;1_,$%5%2Z3![:/Y@G28/;1_,$%5%2Z3![:/Y@G28/;1_,$$1
M,;YUIA$8C^Q-GTSZ.UG9/Y\<*<6.S4M8[54->R[,;;6MPZEYT^D=DC..'$@_
MDIWI,'MH_F""JBI=)@]M'\P3I,'MH_F""JBI=)@]M'\P3I,'MH_F""JBI=)@
M]M'\P3I,'MH_F""JBI=)@]M'\P3I,'MH_F""JBI=)@]M'\P3I,'MH_F""JBI
M=)@]M'\P3I,'MH_F""JBI=)@]M'\P3I,'MH_F""JBI=)@]M'\P3I,'MH_F""
MJBI=)@]M'\P3I,'MH_F""JBI=)@]M'\P3I,'MH_F""JBI=)@]M'\P3I,'MH_
MF""JBI=)@]M'\P3I,'MH_F""JBI=)@]M'\P3I,'MH_F""JBI=)@]M'\P3I,'
MMH_F""JK.\=,%LJ?LP--;L_T6UC&?SW*OTF#VT?S!6=Y)JK74P45;'!4O;AD
MO.8V3WY&]!]T_P#:!M,'VR&BO]+G-G&/VCCANX84@HG3[9**T04]QKXZJJ9M
M;<IDSM9<2-YW\" I'I,'MH_F""JBI=)@]M'\P3I,'MH_F""JBI=)@]M'\P3I
M,'MH_F""JBI=)@]M'\P3I,'MH_F""JBI=)@]M'\P3I,'MH_F""JBI=)@]M'\
MP3I,'MH_F""JBI=)@]M'\P3I,'MH_F""JBI=)@]M'\P3I,'MH_F""JBI=)@]
MM'\P3I,'MH_F""JBI=)@]M'\P3I,'MH_F""JBI=)@]M'\P3I,'MH_F""JBI=
M)@]M'\P3I,'MH_F""JBI=)@]M'\P3I,'MH_F""JBI=)@]M'\P3I,'MH_F""J
MBI=)@]M'\P3I,'MH_F""JH.<WSK1 (1']B[/](3L[6<'\^.%+])@]M'\P4))
M15\^JH*V"YM^SF,P^E;(?2.",X&[B1\$&0(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("A]7U531V"JEHJ<U$NSL[ !
M.&G<3N[AO4PH;5_3NK]7]E[)J-G?M8_8_P!;C[LJ8YHGDT$:B;/]=)\Q7SI$
MWMI/F*IGBOB^MK$8A\;:T[TJO2)O;2?,4Z1-[:3YBJ2*V['1&]/55Z1-[:3Y
MBG2)O;2?,521-V.AO3U5>D3>VD^8ITB;VTGS%4D3=CH;T]57I$WMI/F*=(F]
MM)\Q5)$W8Z&]/55Z1-[:3YBG2)O;2?,521-V.AO3U5>D3>VD^8ITB;VTGS%4
MD3=CH;T]57I$WMI/F*=(F]M)\Q5)$W8Z&]/55Z1-[:3YBG2)O;2?,521-V.A
MO3U5>D3>VD^8ITB;VTGS%4D3=CH;T]57I$WMI/F*=(F]M)\Q5)$W8Z&]/55Z
M1-[:3YBG2)O;2?,521-V.AO3U5>D3>VD^8ITB;VTGS%4D3=CH;T]57I$WMI/
MF*=(F]M)\Q5)$W8Z&]/55Z1-[:3YBG2)O;2?,521-V.AO3U5>?F.XRR$=Q<4
M$\K1ALLC1W!Q5,<=R'CO6.[7M>4<OYY].C;>MV/.>?\ '+KU5.D3>VD^8ITB
M;VTGS%4D6V['1CO3U5>D3>VD^8ITB;VTGS%4D3=CH;T]57I$WMI/F*=(F]M)
M\Q5)$W8Z&]/55Z1-[:3YBG2)O;2?,521-V.AO3U5>D3>VD^8ITB;VTGS%4D3
M=CH;T]57I$WMI/F*=(F]M)\Q5)$W8Z&]/55Z1-[:3YBG2)O;2?,521-V.AO3
MU5>D3>VD^8ITB;VTGS%4D3=CH;T]57I$WMI/F*=(F]M)\Q5)$W8Z&]/55Z1-
M[:3YBG2)O;2?,521-V.AO3U5>D3>VD^8ITB;VTGS%4D3=CH;T]57I$WMI/F*
M=(F]M)\Q5)$W8Z&]/55Z1-[:3YBG2)O;2?,521-V.AO3U5>D3>VD^8ITB;VT
MGS%4D3=CH;T]5Q'65,;MJ.IF:[O#R%D^G=92TDK8KM&*JF.XOX2-]_O_ #^*
MQ!%GJ:&GJQBT--+:-32G-);BBMUHK=1TMR@N,3GNCRRF#AZ8V2,XSGW_ )+)
M.AP>S"U3R8NI>L#&U+7=(V2:=P)P#@[0(_ GX+;R^9U]+LM2:9SA]3L^KVVG
M%\8RM^AP>S"=#@]F%<(L6RWZ'![,)T.#V85PB"WZ'![,)T.#V85PB"WZ'![,
M)T.#V85PB"WZ'![,)T.#V85PB"WZ'![,)T.#V85PB"WZ'![,)T.#V85PB"WZ
M'![,)T.#V85PB"WZ'![,)T.#V85PB"WZ'![,)T.#V85PB"WZ'![,)T.#V85P
MB"WZ'![,)T.#V85PB"WZ'![,)T.#V85PB"WZ'![,)T.#V85PB"WZ'![,*RO5
MMHY[54Q3O;31N9ATI.-@=^]2JL+Z*0VBJ%Q+A2;'](6YSC\D%KIVV45+9Z>&
MFF95Q-VL3 Y#O2)[#C=P_)2/0X/9A6>F10BR4PM)<ZB]+FR[.?VCGCOXY4H@
MM^AP>S"=#@]F%<(@M^AP>S"=#@]F%<(@M^AP>S"=#@]F%<(@M^AP>S"=#@]F
M%<(@M^AP>S"=#@]F%<(@M^AP>S"=#@]F%<(@M^AP>S"=#@]F%<(@M^AP>S"=
M#@]F%<(@M^AP>S"=#@]F%<(@M^AP>S"=#@]F%<(@M^AP>S"=#@]F%<(@M^AP
M>S"=#@]F%<(@M^AP>S"=#@]F%<(@M^AP>S"=#@]F%<(@M^AP>S"@HK71=>8:
MKIK(JB./T*;(R_T2._/ D_DLE6-@6GKY"9W2?:?-_P!$!G'[)_+AE!F2(B)$
M1$!$1!B&O=9]5)*)O0>E=(#S_6[&SLX]QSQ6-OY5YXFATVG961^L9B/[V*UY
M>?Z^S?[,O][%-5W*/IPV62 .EJGNAV.9YD@..,8).["(91I+4M%J:WNJ:+:8
M^,[,L3_VF'_$'L*C+#K+[5U=<+'T'FNB&0<]SN=K8>&\,;LY[UB_(315$<5T
MK7M<VFEV(V$\'D;1./PR/BH&UONHY3;Y%81"*V>:HC$DO[,3><R7?P_B@WHB
MU)'?=3:7UC16Z^US*ZGJG,S@#&RYVSD' ((/8LWUW67REMC&Z;HW3U,CL.D
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MQC<0X.:<.:X<"%>^TT[U&K'+Z5ILMXV2=&>?VA[=6T\7)W!.^5@C;0;))/\
MK!F,?CG<L4Y(6.DHK^R,X>YD;6GWD/4U;.3>W4M0)*FIGJHVG+8G -;GW]ZF
MM*:7I=-BJZ)--+TC9VN=QNV<\, =ZFVKI5T[UI.9F8GE[HIHZU]33M>,16)C
MG[,'Y'JF*FN=RI:AS8ZB1K=AKMQ.R3D?CO&Y9K6:NMM+?X[21-)4O+6[430Y
MH<3N!WYSYJRU%H&VW>L?5QR24E0\Y>8P"UQ[\=ZK:8T1;K%4BJ:^2IJ@,-?)
M@!GX =J:VIL^K,ZLS.9CE[_N:&GM&C$:58C$3S]OV8CKEP;RE6MSB T.IR2>
MSTRLAY6G!VE&EI!'26#<?<Y7^K-'4>HIXJB2:2GJ&-V-M@!#FYSO'YE>3HND
M=IF*ROJJ@PLEYWG!@.SOW<.&]3&OI?\ E:9XUYHG9]7_ -:Q'"W*<OFBZ2.N
MY/Z2EG&8IH7L=^!<X+63+G4V*U7RPR;0?+*&9' 8)#OB %NJR6V.T6NGH8'O
M?'"" Y^,G))WX_%0=YT1;KM>OM*HDF;(2TOC;C9?L]^[.\ !1H;3IUU+[_Y9
MG/\ .37V74MITW/S1&/XQQ6VG;+)0<GL].QI%754TDKAC?M.:<#X8"PGD[H*
MRX],AM][?;96[+G1M9M&0;]_$</\5NCAP6%WGD]MU=6OJJ6>:BE>2YPCP6Y/
M$@=GQ4:.U1^.+SC>XYQGX3K[),;DZ<9W>&,X^4);+-3==(7U&IFU=T@E&U&:
M<AS\#AM9QP6SUC>E]'V_3\KIX723U3AL\[)C</<!P62+#:M6-2T8G,1'M'^'
M1LFE.G6=Z,3,]9G_ "U#RF1-GUS1Q29+)(XFNQW%Y"S!G)YI]K@33S.'<9G?
MX*ZOFD*2[WJ&Y3U%0R6(- :S&R=DY'$+)%KJ;5,:=*Z=IC$<66ELD=I>VK6)
MS/!;T%%36^E9344+(8&<&,& M6\DSVQ:HN,4C@U[HG  ]I#QD+;2PJ\\GEON
M%QDK(*F>E?(XO>U@!&3Q([E79]6D5O34G&]Y\UMIT;S:E].,[OER8OREU$4V
MMJ%D3VO,3(V/P<[+MLG'P(4CRT_L6G\9?_*IEW)W:<TIBEJ8W0':+@03(<YR
M[(_N4KJK3%+J,4PJYIHN8VMGFL;\XXY![ET5VG2K?3Q/"N7-;9=:U-7,<;88
MGRF?YEV7_:C_ .V5.P@#DNW>&'_H*D+_ *9IKU:J2@J)IHXZ<M+7,QDX;L[\
MCWJ[;:(6Z>^R!))S'1^C[>[:V<8SW96$Z].SK7SB<MXT+QJ7MY37##N1@#[*
MN)[>?'_2HS2O^E:X_P"]J/[RL[TMIVGTY33PTLTTK97AY,F,@XQV *WMVDJ2
MAU'/>(YYW3RN>XL=C9&UQ[,K2VTTF^K;U1P9UV74BFE7TSQ8+99H[7RIU9N+
MA&'S2AKW[@-O):<^\$?%9)RM5M,S3@I72,=42RM<Q@.2 .+OP[/S4SJ?25NU
M 6R5(?%4M&!-$<$CN/85"VODUME+4MFJYYJL-.1&X!K3^..*M&OHWM75M,Q-
M?+KA7N^O2M]&D1,6GGGEE&302T_(V&S ASMEX!]4RY'\-_YJ>Y*0!I"+';*_
M^]3U]M,-XM,MOF<^*&39WQX!&"",?!>=.6>&Q6QM%32221M<7;4F,[S[EC?:
M*WT;5\YMEOI[-:FM6WE%<-=Z(_TFW3_;J/\ K5T^]WG4NJZFU6^O%MIHB\!S
M6^DX-.,]Y)[@0LJM.DJ2V7^HNT,\[YYB\ECL;(VCDXW95A>] 4-PN;ZZGJIZ
M.:1VV\1X(+NTCN)6\[1HVU-Z>D1$XSB?V<\;-KUT]V.LS,9QF/W8)J:VBUZM
MH*=]PFKYLQNEDE.2'%_#B<;L'\U,\M'_ *[:_P#=O_O"GI.3BU.; 8ZBKCFC
M)<Z4.!<\]YR.SW*4U3I.EU%)3/JZB>-T#2T<WC?GOR#W*T;7I]IIVF<XSG@K
M.QZO9ZE8C&]C'%/P-#(8VMX-: %JBY2C1_*+)5;)Z'4-=(0WM:[.1^3@MKO>
MV&%SWG#&-R3W +4W*C>;9=W6^*VR"IGC+LO8#@ XPWWG(_\ ME8;!$VU)K,9
MK,8ET?U"8KIQ:)Q:)S"2Y):)]767*]U0VI)'&-KCVN)VG'^[^*V4HG2=L^R-
M/T=&1B1K-J3_ &SO/\3A2RPVK5[75FT<O)T;)I=EI16>?G^XB(N=T"(B B(@
M(B("@M;BA.FZK[4<X4^[!;G.W_J\/?A3JAM75=%0V26>Y4O2Z8.:#%@'))W<
M4@ES_L//^J?@OFP_U7?!=$69E%56JDGIJ2.*&2)KF,+1Z((W!7G1*?V$7RA>
MO']5Q&-SY^GC3_2,SG?^/MS7L/\ 5=\$V'^J[X+I3HE/["+Y0G1*?V$7RA3X
MM^CY^D>#QZ_C[<U[#_5=\$V'^J[X+I3HE/["+Y0G1*?V$7RA/%OT?/T>#QZ_
MC[<U[#_5=\$V'^J[X+I3HE/["+Y0G1*?V$7RA/%OT?/T>#QZ_C[<U[#_ %7?
M!-A_JN^"Z4Z)3^PB^4)T2G]A%\H3Q;]'S]'@\>OX^W->P_U7?!-A_JN^"Z4Z
M)3^PB^4)T2G]A%\H3Q;]'S]'@\>OX^W->P_U7?!-A_JN^"Z4Z)3^PB^4)T2G
M]A%\H3Q;]'S]'@\>OX^W->P_U7?!-A_JN^"Z4Z)3^PB^4)T2G]A%\H3Q;]'S
M]'@\>OX^W->P_P!5WP38?ZKO@NE.B4_L(OE"=$I_81?*$\6_1\_1X/'K^/MS
M7L/]5WP38?ZKO@NE.B4_L(OE"=$I_81?*$\6_1\_1X/'K^/MS7L/]5WP38?Z
MKO@NE.B4_L(OE"=$I_81?*$\6_1\_1X/'K^/MS7L/]5WP38?ZKO@NE.B4_L(
MOE"=$I_81?*$\6_1\_1X/'K^/MS7L/\ 5=\$V'^J[X+I3HE/["+Y0G1*?V$7
MRA/%OT?/T>#QZ_C[<U[#_5=\$V'^J[X+I3HE/["+Y0G1*?V$7RA/%OT?/T>#
MQZ_C[<U[#_5=\$V'^J[X+I3HE/["+Y0G1*?V$7RA/%OT?/T>#QZ_C[<V!CL[
MVN^"%CL[FN^"Z&O5M=4VNIAMXB@JGMQ'(1C9.>\!>+!;)*2T4\%S,515LVMN
M4#.UZ1(WD=V%7Q2=[>W?GA_A;PF-W=WOYQQ_RY[V'^J[X)L/]5WP72G1*?V$
M7RA.B4_L(OE"MXM^CY^E?!X]?Q]N:]A_JN^";#_5=\%TIT2G]A%\H3HE/["+
MY0GBWZ/GZ/!X]?Q]N:]A_JN^";#_ %7?!=*=$I_81?*$Z)3^PB^4)XM^CY^C
MP>/7\?;FO8?ZKO@FP_U7?!=*=$I_81?*$Z)3^PB^4)XM^CY^CP>/7\?;FO8?
MZKO@FP_U7?!=*=$I_81?*$Z)3^PB^4)XM^CY^CP>/7\?;FO8?ZKO@FP_U7?!
M=*=$I_81?*$Z)3^PB^4)XM^CY^CP>/7\?;FO8?ZKO@FP_P!5WP72G1*?V$7R
MA.B4_L(OE">+?H^?H\'CU_'VYKV'^J[X)L/]5WP72G1*?V$7RA.B4_L(OE">
M+?H^?H\'CU_'VYKV'^J[X)L/]5WP72G1*?V$7RA.B4_L(OE">+?H^?H\'CU_
M'VYKV'^J[X)L/]5WP72G1*?V$7RA.B4_L(OE">+?H^?H\'CU_'VYKV'^J[X)
ML/\ 5=\%TIT2G]A%\H3HE/["+Y0GBWZ/GZ/!X]?Q]N:]A_JN^";#_5=\%TIT
M2G]A%\H3HE/["+Y0GBWZ/GZ/!X]?Q]N:]A_JN^";#_5=\%TIT2G]A%\H3HE/
M["+Y0GBWZ/GZ/!X]?Q]N:]A_JN^";#_5=\%TIT2G]A%\H3HE/["+Y0GBWZ/G
MZ/!X]?Q]N;HZ>:5VS%%(]W<UI)63Z=T;45LK9+F\4E,-Y:?ZQWN [/S6ZNB4
M_L(OE"=$I_81?*%GJ?U2]HQ2,--+^DZ=9S><_##X)*RBOE+24+(([#&S!QLY
M!V3[\\<+(>E0>U:K&:RUSM50UD<\+;4UN'TV_).R1G&,<2#Q4[T2G]A%\H7F
M3.>,O5B(B,0L.E0>U:G2H/:M5_T2G]A%\H3HE/["+Y0H2L.E0>U:G2H/:M5_
MT2G]A%\H3HE/["+Y0@L.E0>U:G2H/:M5_P!$I_81?*$Z)3^PB^4(+#I4'M6I
MTJ#VK5?]$I_81?*$Z)3^PB^4(+#I4'M6ITJ#VK5?]$I_81?*$Z)3^PB^4(+#
MI4'M6ITJ#VK5?]$I_81?*$Z)3^PB^4(+#I4'M6ITJ#VK5?\ 1*?V$7RA.B4_
ML(OE""PZ5![5J=*@]JU7_1*?V$7RA.B4_L(OE""PZ5![5J=*@]JU7_1*?V$7
MRA.B4_L(OE""PZ5![5J=*@]JU7_1*?V$7RA.B4_L(OE""PZ5![5J=*@]JU7_
M $2G]A%\H3HE/["+Y0@L.E0>U:G2H/:M5_T2G]A%\H3HE/["+Y0@L.E0>U:G
M2H/:M5_T2G]A%\H3HE/["+Y0@L.E0>U:G2H/:M5_T2G]A%\H3HE/["+Y0@L.
ME0>U:K2[5DC;;4&W/8ZK#?Z,'&"?SW*:Z)3^PB^4*RO-N-3:ZF&@$4%4]N(Y
M",;)[]P01UBK)W6J W9\;:WTN<#2,?M''#=PPK_I4'M6KSIZV2TEH@@N9BJ:
MQNUMR@9VLN)&\CNP%(]$I_81?*$0L.E0>U:G2H/:M5_T2G]A%\H3HE/["+Y0
MB5ATJ#VK4Z5![5JO^B4_L(OE"=$I_81?*$%ATJ#VK4Z5![5JO^B4_L(OE"=$
MI_81?*$%ATJ#VK4Z5![5JO\ HE/["+Y0G1*?V$7RA!8=*@]JU.E0>U:K_HE/
M["+Y0G1*?V$7RA!8=*@]JU.E0>U:K_HE/["+Y0G1*?V$7RA!8=*@]JU.E0>U
M:K_HE/["+Y0G1*?V$7RA!8=*@]JU.E0>U:K_ *)3^PB^4)T2G]A%\H06'2H/
M:M3I4'M6J_Z)3^PB^4)T2G]A%\H06'2H/:M3I4'M6J_Z)3^PB^4)T2G]A%\H
M06'2H/:M3I4'M6J_Z)3^PB^4)T2G]A%\H06'2H/:M3I4'M6J_P"B4_L(OE"=
M$I_81?*$%ATJ#VK4Z5![5JO^B4_L(OE"=$I_81?*$%ATJ#VK4Z5![5JO^B4_
ML(OE"=$I_81?*$%ATJ#VK5#T\UT?K%G16L=:C'_2OW9&X^_/'"R?HE/["+Y0
MH22TW%NJH*VFJHXK6UFS)3@D%QP>S&...WL09"B(@(B("(L$Y9Y'Q:08Z-[F
M.Z4P9:<=CD&=HM-:<Y/JF]6&DN++[-"^=A<(S&2&[R..U[E=<F5WN=!JVJTY
M<JE]1&TR,&TXNV'L[6D]A .[\$&VT45?-0VJQ-8;K61P%^]K<%SB._ R5;67
M5]BO-2*>WW!CYSPC<US"?PV@,_D@GD6O^5;5DMEHXJ.UU38KA*07^CES8R#O
M!X#>,=ZG-+7FCO.F6""MYV6&E8RH>0[+'[&_.>)W%!DB+!.2JDHZ2"Y"AO?V
ML'.9M'FG,YO<['[1WY_P60WW5%FL<C8[G7,BE<,B, O=COPT$A!-(HZR7RVW
MN%TMKJXZAK=S@,AS?Q!WA>*W4%KH;G#;ZNL9%62@.9&X'>"2 <XQV%!*(L:;
MKO3;JWHHNL7.9V=K9=L9_P!K&S_%7FKKW%8K#4UCY6,EV'-I]L$A\FR2T;N_
M""91:ZY*M5BYPSTUVKS+=9ZASXXW _L!@.[ P!N.Y;%0$6F^65TKM6VR".:2
M(24[&^B2.,CAE7M7R87.F@?-;;_+)4L&6,+71[1[MH..$&UT6O>2;5-5>(:F
MVW5YDK:4!S9'?M/9G!VO>#C?[UF=YO-OLU.)KI5QT[#N;M'>[\ -Y_)!?HH"
MS:PL5XJ!3T%PC?.?V8WM<PN_#: S^2F:RJ@HJ:2HJYF0P1C+GO.  @K(L4CY
M0M,/FYH71H.<9=$\-^)&%E,4C)HF21/:^-X#FN:<@@]H*#TBQVZ:UT_:ZMU+
M67%C9VG#FL8Y^R>XEH.%,VZOI;E2,J:"HCJ('<'L.1^'N/N07**&ONI[/8GL
M9=*UD,CAD,#2]V._#03A:RY4[W37.LL=1:*WG8'!X)C<1@[3=Q'$'\4&YD1$
M!$1 1$0$1$%C7W>W6^5L==6T]/(X;0;(\-)'>K=NI;(YP NU#D__ *9H_P 5
MKKE@ =J*@!X&G _YW+(Y^3.S/B<(9JR-^-SML. /X87?W?1KIUOJ6F-YY_>-
M>^I>FG6)W6;12,EC:^)[7L<,AS3D'\U:3W:WT]8RDGK((ZIY ;$YX#CGAN]Z
MUKH"NJK%JR>P54A? ][HP,[@\;PX=V0/XA3&HQ8NO=%TTW#[2VX>;YO9YO.U
MZ.<[^/%5G9(KJ329S&,QA:NV3?3B\1B<XG+/T4+J/4UNT^QG3GO,L@RR*,9<
M1W^X?BH2AY2+-4U#8I655,'' ?*P;(_'!.%A79]6]=ZM9PWOM.E2VY:T1+-4
M5"KK*>DHWU53,R.G8W:=(3NPL//*99>D<WS588\XYSFQC\<9S_!1IZ&IJ<:1
ME;4U]/2X7MAFZ*WH:VGKJ..JI)FR4[QM->#NQ_@L3K^4BS4M0Z*)E34AIP7Q
M-&R?PR1E*:.IJ3,5C.#4U]/3B)M;$2S1%":;U-;M0-DZ"][98QET4C<. [^T
M$?@K&_:YM-GK'TK^>J*AFY[86@AI[B21O2-#4FVY%>*)VC2BF_-HPRE%C.GM
M;6J]U0I83-!4._99,T#:_ @D*3OU\H;%2B>X2[(<<,8T9<\^X).CJ5MN3'%-
M=?3M7?BW!)HL-MO*+9:RI;#(*BEVC@/F:-G\R"<+,@<C(X*-32OI3B\83IZU
M-6,TG(K-ETHGW)]O94,=6,;M.B&\M'O^(2\5S+;:ZJMDWM@C+\=Y' ?F<+#.
M2BF?/#<;S5';J:N4LVCW#>?B3_!7II1.G;4MY?Y9ZFM,:E=.OGS_ &9U4U$-
M+"Z:IFCAB;Q?(X- _,J)BU98I9A&RZ4VT3C>[ ^)W+7=UDJ=:ZW-N;,Z.A@>
MYK<;PUK?VG8[23_>%D5TY-K8ZW2"WNG95M;ECGOV@X]Q&.WW+H[MI:<1&M:8
MF>GE^[G[SK:LVG1K$Q'7S_9GK2'-!:00=X([50K:RFH83-65$4$0W;4C@T?Q
M6+\G5#>+5;)J>]-#(&D.A!D#G,':-W9P_BL(@94Z_P!6R-EF?'11@N '_P!W
M&#@ #UCN_P#L%2FRQ:]LV_#7S6U-KFM*XK^*WDV7#JRQ32B-ETIMH[O2=LCX
MG<IIK@YH<T@M(R".U8/7<FMHDHW,HWU$-0!Z,CG[0)]X\L*(Y+[O54EWJ+!7
M.):W:$;2<[#VGTFCW<?A[U-MGT[TF^C,\.<25VC5IJ137K$9Y3#/JJ_6FDJ'
MP5-QI8IF;G,?( 1^(7B+4=FE>&QW6B+CP'/-W_Q6K[S00W/E1FHZG:YF:8-=
MLG!QL!3&K- VRWV.JK:*>H9+ W;Q(X.:X9X<!O6G==&N[%K3FT1\LHVO7MOV
MI6,5F?ALM\C&1.D>X"-HVBXG<!WJ*ZSV/Q:B_6"Q'D^KYZK0]V@G<Y[:9DC8
MR>QI9G'Y;_BL<Y.=-4.H>G_:!F',;&QS;MGCM9SN]P45V2E=^=2?R]/=:=LO
M;<C2C\W7V;;H;M;Z]Q;15U-.\?ZL<H<?@JMPKJ:W4KJFME$,#2 7NS@9W!:K
MUKHYFG*:*Z6>IG#8Y '![O283P<" .W^]9M9*@:LT5BJQSD\3H93C@\;MK^X
MK/4V>E:QJ5G-9G$]8::>T:EK6TKUQ:(S'261T\T=1!'- ]LD4C0YKFG((/:J
M%5<:2DJJ:GJ)VQSU!(B8>+R.[XA83R37*5]%66BH=B:D=F/._#2<$?D?[UC%
M[GN=)> (+I)<F6EQ>ZI=#GHY>=D@Y)SC=\%:NQYU;:<SR_Z/]*6V[&E74B.?
M_3_MN=%$:4BFCL\;JBY&Y&4F5L^SC+3V<2I=<=J[LS#NI;>K$B(BJL(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B#X]C9&.8\9:X8([PH.W:1L=OJFU%+0
M,$S3EKG.<_9/>,DJ=16K>U8F*SC*EM.MIB;1G B(JKB(B B(@(B("(B HO4M
M;46^TR5%'1FLF:YH$(:3G)XX"E%&:C=<FVN0V1C'UNTW9#L8QG?QW<$%S:9Y
M*FV4L\\)@EDC:YT6,;!(X;U=*VM9J3;J8W !M68V\Z!C =C?P5R@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B"/U!315=FJX)ZD4L3V8=,2
M &;^.]4],4D-%8Z:GIJL5D3-K9G!!#\N)[">_'Y+WJ)M&^R5;;F]S*(L_I7-
MSD#/N5/2S*!EAI6VA[Y*$;7-N?G)](YX@=N4$JB(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B#&Y[92NUI!7NNC6U368%%M#+ALD9QG/;G
MAV+)%C-1%9#K>GDDFE%Z#/0CW[)&R?=CAGM63("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@*PO]/'5V:K@GJ1312,PZ8G&P._>K]1^H6T;
M[+6-N3W,HRS^E<W.0/R04]+TD-#8J:GIJL5D3-K9G!!#LN)[">&<?DI11.E&
M4$=AI6V>1\E"-KFW/SD^F<\0.W*ED!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0%C=3;*5^LZ:O==&LJF,P*/:&7#9<,XSGM)X=BR18S516
M0ZVII)II1>0S^CC&=DC9=[L<,]J#)D1$!$1 6 \M?^9[/^*9_<Y9\L2Y3K-7
M7W3C:2V1"6<5#7[)>&[@'9WD^\(,%TS!KV73](+/-&RW%AYG)B! R>\9XY63
M\GFAZFRW":ZWF=LU?("&M:XNV<G+G%QXD^:R71-!46O2UOHJU@CJ(6%KVAP.
M#M$\1N[5-H-9ZVDTM3ZL9/<(:VYW4!HZ'$ ]G#T00?C@?!8?<I,Z\LDT%D=9
M ^:$MA(V2_\ I,;6,#&>'Y+*K[IS4-KUS)?[!315S927;#W ;.6X(()'Y$*V
MN^FM6W2_VV]UM-3/EB>QQIX9&M$+6.! R3O)W]I4H7/+G1T[;?0U@A:*ITW-
M&7M+0UQQ^&5EFF;91T&CXGT5/'"^HHF22EH_;=S?$_$JTY4M/UFH+#%%;6M?
M403"01EP;M#!! )W9WA-$1ZA^PJFCO\ 2QP"*%L%* 6Y< T@YP3W-[E"6-\@
MW_JEY_VXO[G+$],W&"JU)<;E>+157B1Y+A'''S@82>)'X# 6P^2;3MST_!<F
MW6 0NF=&68D:[. [/ GO"BI],ZBTMJ2JN.E88:NDJ<[4#W ;()SLD$C@>!!4
MH16F>?@Y1X*RTV:X6^VU!YN2*2%S6M!&_P!P&<%>^5&E;7<I-HI)"0R>.")Q
M!P<.D<#_  *RK2%NU5/?9;IJ.K?34YWMH62983C ]$$@ <>.25;ZNTS=+CR@
MVBZ4E.U]%3\SSCS(T8V9"X[B<G<42BN5_3UJMFGJ*HMU%#32MJ!%F-N-II:X
M[^_@-Y60UU-#<.2>-];&V9\5L$S"_>6O$1P[\56Y4K'7WZP04MKA$LS*ELA:
M7AOHAKAG)/O"D:2T3OT)':)\15+J#HSLG(:XLV>(]Z@8?R)6RCDM$UPDIXW5
ML52YC)B/2:W8;N_B?BMH+5_)O:]56"X"@JJ&-EI=*Z2:0N:3G9P-D@YQD-[%
MM!!ISE?_ ,][-_N8_P#NN6XUK+E/TO>KSJ"BK+/3-E9# UNT9&MPX/<>!/O"
MMJBCY2J^%]-/+%#%(-ES@^)N[\6[Q^2D6')5_3<H=XF@WP&.8Y'#!D;A*FG;
MJGE=FH[H7.I*=SF-BS@%K!P_,[RL[Y/])1Z6M\C9)&S5LY!ED:-P X-'NWG\
M5!:RT?=1J-FH=+R,%9D.?$2&DN QD9W$$<0?\5"$7RMZ;MMHME'<K3 RCG;.
M(B(?1!W$@_B"WBI;5=)<]5<FMLFI&F2K+8YY8QN,GHD''YG.%%U>G]7ZQJZ:
M/43(:"@A=M$,+=_>0 22?QW!9IJJQ5M5IZ&CT]72T$U, V(,D+ ]H&-DD;^[
M>@U0R^VV&WQVG4>E8X71AK3/ SF9MW;O&23C?O6R:>XT%+R:U55II\@IH*>3
MFMMQ+XW;^.>T$Y_^BQNNBUW<;,;-66>DD:6",U3W-+L#MSM8S[\++M)Z49:M
M(26>M>)34AYG+>&7#!#?P &]2-6Z%J+;3V^J?<=-UMWFED(YYD/.-:W W ]A
MR2<_@LDY(F5M'J&Z4_0JVFMDS#+$VHC<W9(< T9.[.R=_P""\VFT:TT<^JH[
M-2T]PHI7[3'.(P#PVL%P(. ,\1N65Z M-]H8JBHU'<)9YICZ%.Z3;;$,Y)SP
MS[AN 08)HZA@U-RD7>:\,%0V(R2-B?O!(>&M!': .S\%0Y5[)0VG4-N?;H&4
M[*AN7QQC#0X.X@=F<CX*>O6E;_8]637O2C&3LJ"YSX7$#&T<N:02,M)W[C_<
MH[46D]77ZKH[E<(H'U!.R:>.1K6P,!!'$[R27<">'%!N-$10D1$0$1$!$1!J
M7E?_ ,X[?_PX_P"MRVTM<\I6G;M=[Q2SVRDYZ.. -+N<:W#MHGM([PK>0<HD
M[3&X<V';BYIA:1^8WKT[:==;1TXB\1C/.7E4U+:&MJ3-)G.,8A'D]*Y7<P>D
M&U0SC_PM]+^XJOK#_2C;?]Y3_P#4LDT'HY]DEDKKC*V6OD&R-DY# >.\\258
M:DT]=*S7U%<::EVZ.-\)=)MM& UV3N)RM:Z^G.KB)X17&64Z&I&CF8XS;..B
MERBV*Z/OE->;7":H1-:"P-VRTM)(]'M&]0L^KZ>MEAAU588Y#"?VH]J-S?\
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ML;&QK(VAK&C :T8 "^HBXG>(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M%!RK4,E5''<+=4T<,A]&4NVP!WD8&[\,K,M27J.RV&HNAC-1%$&D-8[&T'.
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#@?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g843142g04f18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g843142g04f18.jpg
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M_\0 &@$!  ,! 0$               $" P0%!O_$ #L1  (! @('!@4$ @,
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M=>M"&01L(/ -RX#F[VD\]USG_*+#QI7$"0M+_2QQ%HV!/ [?9=9J_P#=8?Z
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M?IM3YTJ?V;8_3:FXU^D;_H_5[G1$7._G2I_9MC]-J?.E3^S;'Z;4W&OTC?\
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M]+/U[>I+^&9%*VQ38U[WG;A<" >7/?\ C("81%BMV8:=66Q:E;%!$TN>]QV
M" RHHK3.<KZAQGIU1DC(3(Y@$FVYV/5:NH]54<'8AJR1V+5Z8;QUJS..0CSV
M\N2 GT5<P.KJ66R#L?)7MT,@UO%Z/;CX'.'F/-6- $6"_<KT*<MJY*V*O$WB
M>]W0!5$]HE$,%A^+RS,:3L+IK_N?MWWZ("ZHM87JIQ_IPGC]#[OO>^W^CP;;
M[[^Q5(]HM#A-@8W*G&AW#Z:*_P"Y==M]]^GW^I 79%BJ68;E6*Q5D;+!*T/8
M]O1P*RH B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B +#=MUZ-9]B[/
M%7@8-W22N#6CVDJ UYK"AH_$^DW/W6Q)NV"NT[.D=_<!XE<;QF#U5VK7OE#+
M634Q#7'@<0>[;ZHF>)_G'X^"ZJ&BZ\=I-ZL>?\&4ZNJ]6*NSH&;[9--8][HZ
M?I.1>.6\+.%GZ3B/N!5<?V\Q<?T-/O+/,VP#_85VT_V8:7P\;?\ X>R[,.LM
MS]T)_P!WZH^"M+,1C8X^[CQ]-K/S6PM ^&RTVFB1P4&_%V*ZM5YNQS;%=M^"
ML/#,A2NTM_XX E:/;ML?N4AKK66.O:5#<'?AL^F.[MQC=S:P<W;CJ-^0YCQ*
ML&9T%IG+1N;:PU1KC_\ ,@9W3_;NW;?WKD6MNR3(8)K\CIB>6Y69])T)'[LP
M>K;D\??ZBMJ&Z3J)J\7WY&->-9TY17$AD45ALL+G[E-LRP/@[V*57NGS,X.#
MM(*3T_\ )8O%^;[XU6,+@R+K([<;-]0Z^2C$426LK$1EJNYT?5>1CRG9U4L0
M5F58!<[N.%G1K0'@*,[.6-K0YO+\(=+1JDQ;C?9S@>?_ )=O>OMO^"BE_7C^
MQZ:#_=\!JFFSG+)5#VM\3PAV_P"T?%>=JJ-"<5EK>ET>EK.5>$GGJ^MF1VD<
MY>@U14EDM32"Q,V.8/<2'AQV._QW5DP6'KT^T?*[Q@P4&/LL;X#< @>[B^Y4
MO2\+I]1XR.,$N-F,^X.!/W+H6/L,M=HVI(&.&\]5T+/6YK6@C[BITGY92U>G
M'S_](T3YHQUNK#R?X*'4U'D8LZS)/M2F4R<3QQ'8MWYMV\MO!;_:51CHZKL]
MRT-9.ULP \">OW@GWJMP0/FM1P-:>\>\,#=N>Y.VRMG:M,V75CV-.YAA8P^W
MF?[UT-*-:.KR?V.=-RH2UN:^]RMX6C\IY6K2$G=]_(&<>V^V_CLK.[1^/J73
M3RN>AK6W/X8XVQ%W+?Z)<=]F[\CMZU#:*_?7BOZPW]J]:R>YVK\F222+#AO[
M#L$FYRJZD965K^HIJ$:6O*-W>W$E)]'08NP]FH,O!287;0\##(Z4?G;#H/;Z
MU%ZFT[+A;E:..9MN"TT/KRQCZX/AMY\Q\0I;M9<3JO8G<"NP#U=5,SF,/[/C
M/MP<(Z^?T-OOV6$*U11A4;O=/#Z7-Y4:;E.G%6U6L?K8A)=)8_'MCAS>>BIW
MY&AW<MA,@9OTXB.BT=3Z6DP%&E8EM1S.LN< (Q]$ ="#OSW!!6+7396ZMRG?
M[\7?$C?\W^+]VRF-6-E;H72XGWX]I-M_S>7#]VRO&51.FW*^MX<KX%)1IM5$
MHVU<L^=L2F0M8Z5C9'\#"X!S@-]AXG92NJ<&_ 9,573">-T;9(Y0W8.:?5S\
M05#J^S59-4Z/P\D/TKM.<4I#_,<0&D^SZ/WK:K-TY1;RR?V,*--5(RBE\V:^
MY7+>"-33=/*36-I+<A;%!P<RT;_2WW_N\0I1NE*=&K!)J++LQ\T[>)D#8C(\
M#S=MT6SJRY7DUEC,>PCT#&NBK@>'(CB/]WN4GKJU@(M26&Y;&W9K(:S]T9-P
MM<WA&VP_QSW7-MJCU5CC=X6O;@L3I5&E'6>&%EC>U^+P*CJ+3\F(97L16([F
M/L#>&S'T=ZB/ J;&B*T$%6SD\U#4JV(6/8][.9>X;\(&_@-N?K7S-9.I-HMM
M3'8F]!2](#XYY3Q,#N>X!^/WK[VD.)IZ<9O]$46D#UD#\%*J59:L+VNWRX!T
MZ4=:=KV2Y\2-Q>EQ=-ZS+?BKXFK(8S<>WE)L?XK=^>_+Q\5ELZ7K6,?8MZ>R
MK,B*XXI8C$8Y&M\P#U"GXIL9#V:8DY&K/9K=^_B$+^$A_$_8GW?W+#I?,8:I
MD)),'@LG+8[HA[6R=YNS<;[CV[*KK57K25\';A;#GQ+*C26K&5L5?C?'EP-#
M3O\ !UJ7_:1?V@HR+3G=8 Y7*6O0XW\JT7=\3Y_8-QL/7_TWL6A;%2KI'/V+
MM<SU8Y6.,/YW,<(/OV6KV@Q'+5*6H:4CY*4K!$^,G?T=X\/4/[_:%,:DE5E!
M8)O/Z+ B5.+HQF\6HY?5XD1#C[+M%27OE"1M,6Q&:NQX2[8?3Z]?<K1G\?C/
MR#Q4?RNWN83*Z"7N'?N[MW?1V_B\^6Y43!_!38_\0'[&IG_X.-.?[67^TY)7
ME)8V^9\N0BHP@\+_ "+GS(7)8,TM/XS)]_QBZ7#N^#;@V.W7?FOF)P9R&$RN
M0[_N_00T\'!OQ[[^._+HIO4@_P#R]TT? .D'WE?=)L<-"ZI>1]$MC /K&_XA
M:;66SUKXZUO_ .K>QGL8;75MAJW_ /YO[D9@--B_CYLED+D>/QL;N#OGMXB]
MWDT>*DJVBZU^O9MXK,Q6:<,3GN=W1:\.',-+2>6XWY^I>M0[N[.=/&#_ ##9
M'B3;IQ[GK_YD[,FR_P#QYS=^Y%%X=Y<7A]W$J3J5'"512M9VMASMYEX4Z>O&
MDXWNKWQY7\BDJU=GU.)V0M9.RT.KXR%U@@^+P#PC[B?<JJKKI#]Y&JN#_.<$
M>_LY_P#5=&DMJFTN-EYNQS:*DZB;X7?DKD'AJ4NI=1M@GL=W-;>][I2WBY[%
MQY;^I3,>DL;#8%/)Z@@KY!QV$+8B\-)Z!SM]@?4M3LT_?IC_ /\ >?V'*'SK
MG.SF0<XDN-B0D_[Q5):\JKA&5DDN7>7CJ1I*I*-VV^?<;=W3\M#40Q-VQ#"2
MX#OW'9G"1N'>Q2_Y&U?_ -IL1^M'XK<[1VU7ZWK-R$DD=4P1]X^,;N ^ET6G
MZ'HG[3ROZL?_ &K-59RA&5WBN"N:NC",Y1LL'Q=B/R^G(J+:WH^7HWGS2B(,
MKOXBW?Q/J5KU5B<Q?O,P^!@D;C<?&QG)X8USR-R221N>8_P56;K=.T[%&?#7
M+D\K+#'2"=H # =]^@]2ENUJ[:.?CK&1[:C8FOC:T[-<3ON[UGEM[E5N<YP7
MCFO#@62A"G-^&3\>)&ZIMY:#%5,/G:9;-7<7Q6'NXG.;SY ]".GP"S::C^6=
M*9?%O^E-4'IM;S&WU@/;R]Y6U;FDO]ET<V0<7S06^[KR/YN+=NF_Q^'J6+LF
M_?#:XO\ -^AOX_9Q-1NU&3M9Q?K?[D15Z\5>ZDN/)K[%*4WIO3TV:[^4S1U:
M-<;S6)?JM]0\RH17>MN>RBUZ/U%T=]MY?1VW_P#*NJO-QBM7-M(Y='A&4FY9
M)-F!FDZ.1BF&GLU'>M1-XC ^$Q.<!^;OU4?I?3,V?]/9%,(9JS00Q[?K$DC8
MG?ET7KL]$IUAC>YWWXSQ;?F\)W^Y6G"O:S(:\?7.S1'*6D>UZYJM2I2UHJ5\
M$T_K8Z:5*G5U9N-L6FOI<J6H\/CL9#"ZCF(K\KG%LC(V[<.WCON>2U=+?OEQ
M/]:B_MA1:E-+?OEQ/]:B_MA=3BXTVF[X,Y8R4JB<5;%$UV@Y"Y#J_(QPV[$<
M8+-FMD< /H#PW4OH6W<OZ?U!%EI99\<VN2'S$NX7;'H3\?5R6;6&LKN,U%<I
MPT\?)'$6@.EB)<=V@\SOZU5LYJ_*Y>H:LSXH:IZQ0,X0?;XKCA3G5I1CJI98
MW_!W3J0I5I2UF\\+?DGM)BP>SC.BD)38[]O!W6_%_$Z;<^BB\"S50RM;T<90
M'O&[]YQAFV_/BWY;*5TA<L8_L[SEJG(8IXYVEKP =M^ >*A:^NM0Q2M<Z_WH
M!YL?&TAWJ/)3&,Y2J**3QX^"*N5.,:;FVL.'BS:UA#6RW: :U!S=IY8XGO9T
MXSL''W?W%9]?YF:G=^0L4]U7'TV-86Q'AXW$;G<^/7X[K;U3'3PVK\%DHX6U
MFS!D\\+1L&'?F=O9^Q0_:71DJZHL3D;P6@)8GCHX; 'G[?[E%'5G*FGE;"_-
M8$UM:$:C6;EC;D\31TUJ6]A<A%(V>1]8N EA<XEKF^/+S]:W.T;%0XO43O1&
MAM:RP3L:.C=R00/>-_>J_CJ<V0O05*S"^:5P:T#]OL5J[5;,4FH(:L+@X5*[
M8G'^=S/["%NTHUXZO%._V.>+<M'EK<&K?<J$$3YYHXHQN][@UH\R3L%:>T L
MI6:6#K'_ +/CX6AVW\:1PW<[]BA]*</Y38KCVX?2H^O](+;U_P 7Y893CZ]X
M/APC96EC64>2;^Q6*U:$I+BTON2#-'0Q8ZED<AEH:M&Q"V0O=&2X.//A:T'=
MW+Q6KGM,14\0S*XK(,R&/+^[<X,+',/K'^.H6_KIQ_)O2;=SP^B$[>O9B^8D
M_P#Y6YL>'I<?[6+",ZFK&HY9NUL.=CHE3IZTJ:CDKWQSM<TL7I>O>H0V7Y[&
MUG2#<Q2R .;S\>:V3HVJ 3^4N(.W_P#%'XK6Q=72KZ$+LE?R$=LC]T9&P%H.
M_A]'R6R:>BMCMD\KOX?N8_\ M5I3GK/%_P#U*QA3U5=1_P#L:&)U#\E:<O4:
M<;X[UF0$V6NV(8/XH\1X_%3/9;/=ES<\<DKWX[N7&R)';LVVY;[\M]_NW5>T
MS@+&>N.CA<(JT0XIIW_5C;^/J4MG\_4IXYV#TT"RETGLGZ]@^/N_QTZJL8RU
MJ4%B\^[^\$11G*.K5F\(Y=_]XLB<!D6XK4L-J _]G;,6D'^-&3L0?<O>L\4W
M#ZBMU8QM#OWD7]%W,#W=/<H-77M6V^6J&_\ G/0H^/V[N6LOEK1MQ3]#*/S4
M97X->MRE(B+H.8+J_8Q_HW)?[5O[%RA=7[&/]&Y+_:M_8N'XC_H?T]SO^&?\
MA?7V.BHB+YP^G"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (H/4^H6X$5
MB['WKO?<7_=8^/AVVZ^W?[E7']IM5EAD#\+EVSO&[8S$ YP]0WW/0H"_HJUI
MW5C<U?-5N)R50AA?WEF+A;RVY;[]>:LJ (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (BJ-'6\>1S)I8W%7[5=LP@?<8S]S:=]B2?) 6Y$1 $6C1RM.]=NU*D
MPDFIEK9@ =FN._+?Q/(K>0!$1 $1$ 1$0!$4/FL_7Q.2Q5*>*5\F0D,4;F;;
M-((Z[G^<@)A$6C>RM.C<IU+$P;8MO+(8P"2XCK[ @-Y$1 $4/G\_7PL^-BL1
M2R.O3BNPLV^B20-SN>G-3" (B( B(@"+5RMUF-QEJ[*USHZ\3I7-;U( WY?!
M8\'DHLQB:V0@8]D4[>)K7[;CGMSV0&\B\RO$<3WD$AH)V"KL&KJLNDYL_P"C
M66UHB08G <?)P;Y[>/F@+(B@,GJ>MC\/C<C)7L217G1M8U@!<WC;Q GGZE(Y
M+*T\;)4CMS!DEN5L,+-B2]Q(']_5 ;R(B (B( B**U-G:NGL4^]=#W,#@QK&
M#=SW'H!\#\$!*HJK0U7;M0=X=.96+GL ]FVX\^:(#7U#KZEALNZ@:TLYCV$K
MVN X=^>P'C]RMU6>.U6AL0.XHI6![#Y@C<*J:@T'C\SEC>?/-"Y^W>L9ML_;
MEN-^A5KK01UJ\4$+>&*)@8QOD -@%T5=CJ1V>?$YJ.WUY;3]/ R(BU,M>BQF
M,M79_P#-UXW2'U[#I[USG24N\!J+M-@J$!]'#0F20'F#*[P_L_HE?>S>5V)R
MV:TQ.X_]EE,];?QB=_[M/O*AM%:9S60QTF:ASTN.FR4CII&,A#N+Z1V))/K/
MQ6/4&-R.C\]BM17<I)DF&45YWNBX"UA!Y<B=^7%[P%(+AJW4-VIE*6%P4$4V
M5MM+^*4_0B8-_I';V'X>*IG:5+J.KI]M7.^AVJ\LS2RS6!:6.&_T7 ^8WV/J
M4]9E93[7*EBP\""]1[N"0GZ)=OT!]W_F'FLG;-:@BTF*\CV]]-.SNV^)V.Y/
M^/- 26I\Y;Q.2TW5JB(QWYQ#+QM)(;]'ISY'F5(ZQR4^'TU?OU PSP-!:'C<
M?6 YCWJL=HKVPY;1L\I#8F7!Q//(-YLZ_>I/M5M0U]$9!LKVM?,&QQM)YN/$
M#R]P)4 A.T2U)=T3IVU-P][/8K2OX1L-W1DG;XK'VHMRISNGS#)4$!N1BJ'!
MW$)=QS?_ #=]NG->-:_P=Z4_VE3_ -(J4[32&Y+29)V R3"2?Z35)!LY_/9C
M%0X?&M;2ESF0>YG>GB$#-CUVZ]"/O6)U[5V%NTSDHJV5I3RB.0TXG=Y%O_&V
MVZ?XY+:UQ!@LG:QN)S9ECLV'.-6:/Z/ [Q^ETY\N7L5:SU;.:$J1WZ>>DO4A
M*UAJVQN2#X [GR\-D).I*L?+EN#7_P BVA%Z'8K=]6<&D.XAU!._/H[[E98G
M<<3'EI:7 '8]0J3VEM-"Q@L\SD:%L,E(_DW\C^S;WJ ><[K*Q0UY3Q,;(C0+
MHXK#RT\37R;\//?8<MC\5*ZDS=JIJ#!XK'"(RW9"Z8O:3PQ-ZD<^O7X*C3T7
M9C1VIL\S?OY;WI4#O*.([#X O^"G-$VAJ;6%_/;?N%>K%6AW\'.'$_X'<>]2
M02E#-Y3(:BU)BZ_HK74F,]&<]IVXG#^/L>8]BK_98S,?*>7)EI>AB](+8X7<
M;G['FSPVWVZJ3TC_  CZN_\ W7[$[+2._P!3#?F,E(=O>4)*_HN?.R7=04\!
M'5C_ .WR22VK.Y:W<D!K0.IY%6G2V?ROY1VL!J*.N;<<7?13P;ALC>7A[_5T
M*UNRKKJ3_P 2D1_\,;/_  S_ )B@+VJ?D\OGK^H+.*T]7@KQ56@S7+;'%I)\
M&#Q_Z'WW!<\AN9G5>I,Q2IY4XJCCI.YX8HPZ20[D;[GI]4_<H!LT\[G\1J>A
MB=1^AV8;^XAL5P6D.'@1\/#QZK/F,YE[NJ9L#IXU()*\(EGL603UVV#0/:/\
M=:OE<?%B^T+35<Y6YD+?>\4QLR\99OMP@#PWY\O8K!G<3@M2ZGL566;5+.U(
MVDRPG@+F^'7ZVVXZ;=>JD&_@\CJ*OGODO/58K$+XS)'>JQN# ?S7^ /(^7AU
MW55P\>H?G-RH$V-]-$$9L.X7\!C^AR;X\6VW7UK?I6<YIC5N+Q%W*_*U*]N
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M;(W,%D+N,RD$QCL&(EN[_$EO(]0?$<P4!/Z5R>:FO7L?GZ38YJVQ9:A8X0S
M^1/CS'X#9654+2>1S-'6%C3N6NLR4;*_?,G#=GLZ<G?'QW\.:OJ@!$1 $1$
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MJSA?5>?U]R>U'J.;,0UZL=>*GCZ_^:K1= ?,GQ/XE8M0YQV9CQ['0"+T2 0
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M OR8VY\LZRRV3&_!+-)*WU!SCPCX+3X2GKR?<8?$9)4F3"(B]L^9"(B (B(
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M"KY30V'OWI+C19J6)><CZLICX_:.BD]/:?QV KOBQD'=\9WD>X\3WGUDJ51
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MW8D,S2-@"#RV\^7WK-HC6 U3-<:S'RU65PT\;GAP=Q;[#H-CR* M:(B (B(
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MY')= YAWAC/F7#ZQ]0^(6M.-6LE2CBO0K)PA\S/G;CK!F%P+\14D'RC?86N
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M3^N\K#F-26;-7G  (V._. '7X[JOHBUA!0BHK@8U)NI)S>;"(BL4"(B (B(
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M@F;W?#)&XM</IM'(A2&CYY+.EL3-,XOD?5C+G'J3PCFHGM7_ 'B9+VQ_^HU
M:'91E;EFG>Q^5GDFN5GMD#Y7%SG1O:"WF?\ ',*3[1LE8HZ?$&/>YE^],RM
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ML[ZEVJ[CKV8ASC/L\1R'P0$=VLLB=H7(&4#=IC+"?!W&!R]Q*L6#_P!"X_\
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MDN8V<.2([Y"Q/V71_P"'9^"?(6)^RZ/_  [/P4BB;27,;.')$=\A8G[+H_\
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M=)#(QCBQSFD!P\#MU7,]&6+VD:D^-NZ:R-BUWKG"S4A[QLH/3=W@NGHH!SO
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M?,>1]:Y]G<7#HUKK&$U(<;_&%&R[O6/]C>;A[=C[5=]24+V2H-K8W(.Q[W2
MR3,;N[@V.X'D=]N:CL'HG#XJ3OS"ZY=)W=8M'O'D^?/D/VH#SH?,V]2X227,
M8YL(XN#8M/!,W;J [P^*WM09O':7Q(EG#(V-'!!7C !>?!K1_C9;.H<K%A,+
M;R,[2YD#.+A'\8D[ >\D!<ETYJ;"29-^;U58FLY0N_<8A$3'7;ORX1Y_L]O-
M2"\=GF*NP-R6:RL?=W\H\2]ST,;!OPCU'G^Q0FE=,ZNAI6VG(PX<S6'SN:(F
MS/D<=N9.^P'+P]:MF"U50U*RY%A9I!/%'OQ21[!I.X!]?,*#T_KJ.E!-2UE*
MZGE:[W!Q=">&1N_(MX1MZO6@-K2&>R8SUO3VHC')?@9WL5B,;"5G+P\^8\//
MR5T7/])MEU#K:YJ5L$D..CA]&JF1NQE\W;>77XCUKH"@'+,!A9-1:GU+%D+=
MGY*KW7;UV2%HD>2=MR.>P Z>M;\$+]&ZUQM"I8F?ALJ',$$KR[NI!XM)]K?C
MZ@H[3.I:V"U7JB/)]Y%3FNN(L!A<UCPYWT7;>8Z>Q2#;3=9ZXQEK&LD=B<2'
M/=9<TM:^0^#=_8W[_4I(-9V,L9WM*S]&6[9BQC&1/GCB>6]Y]!O"W?P',D^Q
M9LG2_(7/8FSB9YQBKLXK6*LDA>T$]'#?QZGW>M:S<_#@>U'4$EUL@HRLB;),
MQA<(CP-X2[;PZA;&9R$.M\_B*.%#YZ%.<6;5G@+6#;HT;^/7X^U"3#J#&39?
MM6%2&U+6B=1!G?$=GF/<[M!\-SL%ZU/B1H5M3-8&>RR!LS8[59\A>V1IWY\_
M'E]Z9W+#"]JIN2Q22510:V=T;>(QL+OK;>0.VZ^ZOS-?6K:F!TZY]KO9FR6)
MPQP9$P;]=P/\#;Q0'2V.#VAS3N"-P5]7QC0QC6MY-:-@OJ@!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$!AO68Z5*Q:F.T4$;I'GU-!)_8N-]@523*9C4&IK@XII9
M#$UQ_.<>-_\ R?%7SM:MFEV=9R1IV+H1%^FX,/W.4?V%TQ5[.J+P-G69))G?
MI%H^YH7;3^31IRYM+[F,L:B7+$OR(BXC8(B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M-B-PB(!L-MO!  !L.01$   Z !>1&P/+PQO&>1=MS7I$   &P ";#??8;HB
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MOA<CAWM;DJLD'%]4G8AWL(Y*WZ]R5JO@M.U*\SXHI*3'OX#MQ_1  /J'/XK
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M@ 03RZ @^I7K:*]>6JUA?#C8K"K\JOYEEUED-2U,]@XL!4[_ !\T@%U_=\7
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M:3_2(V^]6*26.*)TLKVLC:.)SW'8 >9* ](JW%KG3<MH5V9:#O"=@2'!N_\
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MC<>1=ZSMT42YQ<XN<27$[DGQ5]1NIK/)+W*:Z5+56;>/TR/B(BV, NM=C/\
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MMJQ<6*G@KWO1V>BR6!NQIV>?(^._AU70^R?34NF=(PU[L?!D)WNGL#<$AQY
M;CR 'OW6IVH:+LZA-+*8.=M?.8\[PN<=@\ [@;^!!YCPYG?JIC7A&O:_RI:J
M#@W3[\R/^3.U/[=POZH?_P!-?>S31V<P>J\MELS<H6/38W=Z*SCOWI>';D<(
M _C?%:QU3VB^B^A_DBST_;A])[P=WO\ G;;[?^;93/99HNSIN*[?S,XGS.0=
MQS$'<,&^^V_B23N3[/+G6I*4*<E)Q5^5L?(12<E:_P!2^(J97GU<>T6:*:!H
MTL >"3:/??NQZ^+ZV_@KFN&<-2V-[G0G<(B*A(1$0!$1 $1$ 1$0!$1 $1$
M1$0!8+[6.HV&RS.@C,;@Z5K@TL&QW<">FW59U':CQ[LK@K]".3NWV(G,:X]
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M]:_<EN6FC>2:1Q=N3X GGL.B DT1% "(B (B( B(@"(B (B( B(@"(B (B(
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MXV-C8UC  UHV '@%[^A:-N].SS>9X?Q'25-ZD3ZB(NL\D(B( B(@"(B (B(
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M=^?,=1X\^J Z6BYK1LY74VJ,N(\^_'5*-@0PPP@?NHW(\QOOMZ^JZ)9M5ZK
M^U/%"P\N*1X:/O0&9%XAECFC$D+VR1NZ.:=P?>OEBQ#6C,EB6.*,?QI'!H^)
M0&1%BALP3P]]#-%)$/X['@M^*K>E=1R9?-9VM.Z!D52P(:[6GF\ N!/KWV"
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MJIV*TACLE+$)[UR.(10MY!\CV@_#_P!EH6'ZYI4G9&6;&3]VWO)*+8R-F]2
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MYSV#LIQ$$0CAMW&L'0#A_!>_FNQ?^NW?BW\%?T6>^U^HIN-!_P#4H'S78O\
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MU#=G>#GP.G&P72/2YI'3S '?A<[8;;^P!>^T.E=R&D<A6QH<ZPYK3P-ZO:'
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MOU,A$Z2A:@LQM=PN="\/ /D=O%<XTYE7X+0VI*,S]K&)EDA9_OG9A_2)*=G
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0%:U+JGY,R$&,QU*3(Y
M:<<38&.X0UOFYWAT_P#9:$.L+^/R%:KJG$?)T=EW!%9CE$D?%Y.VZ?%:F"V;
MVN:@%C_.NK1F'?Q;LS?;[EG[9'1#1DC9-N\=/&(AX\6_A[MU(-_5>KFZ?RM"
MF^E)9%ICBTQ.^GQ#DUH;MSW.PZJ,M:TR^(E@FU#I\T\=,\,[Z.<2&/?\X#_H
ML&>8XZ]T6VP-Y!$_BW_.#?Q6]VP#_P# ]KU2Q_VD!=000"#N"J%VU?O/9_6H
M_P!CE=Z/_<J_^S;^Q4CMJ_>>S^M1_L<H0)Z&YIONF;V,/OPC^/&I.F_'LJOL
MTG516V)=+#P\.PZ[D<N7-0,6@M,F)A.)CW('_P Q_P"*]:EQD&+T%EJ>(A[F
M)M>0AC23R.Y=UY]-T!H0:OR^7,LVF\ ;="-Q:)YYQ%WNW7A!4WI74<.?@G'<
MR5;M9_=V*TGUHW?WCD?@JAHS':EGTQCY,7GZD-,Q_0C-1KBSF=P3XG?=26CL
M5+4UAE;5S-5+U^2$,L0PQ\#FD<.SB!RZ#[U(*#A8KN)DNZHQW%(*>0DAM0C^
M-$=CO\3[N1\%U+4UZ#)=G^2N4WA\$U)[VG_=/(^M0O93$R;&9^*9C7QOR$K7
M-<-P00-P57,L^71L6<T_9+G8F_7DDHR'GP.(/T/[O;L?%""P5\O)A.Q^M<@.
MTXKB.,^3G.VW]V^_N4MH#353%X6M9DA;+D;,8FFGD'$_=PWVW/3JJ_;Q\N1[
M%JT<#2Z2*!LP:/$-<2?NW5RT9E(,MIJA8KO#B(FQR 'FU[0 04)(?M&TY6O8
M2SD*T38,G389XIXQPN/#S()'7D.7D5+Z*RK\UIBA>EV[Z1G#)ZW-):3[R-_>
ML6OLI#B]*9&29X#Y870Q-\7/<"!M\=_8%C[.*$N-T9C8)VELI897-/4<3BX#
MX$* 2F>RU;"8J?(72[N8AT;S+B3L /62JL[4^IW4_3XM+#T+A[P-=:'>%O7?
M;;?IX;*7U[FH,'@'6)ZC+CI)!%%#( 6N>=R-_5L"HI]765BH^6]EL;C(0PN>
MV"#O',;MS&[N7WH"4KZK@MZ-FS]6%SFQ1.>87.V(<WJTGG\5#U]8YK*TF6\%
MIQ]BL& ODDG#.)VWTFL!YNV.XW\?)0>E/X&<M[)_V!7C0+0W1F'#0 /1VGWG
MFI!]TMJ:MGL+)D. U>X+FSQR'_-EHW//RV\5"5M89C*"2U@M.OM8R-Q EDG$
M;I=NI:T_]5 8=LATCKUM<'B]*GY#R\?NW5X[/G1.T7AS 1PBNT';\X?6^_=
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M)5Z1(EJMYNY_Q@/'_H%>T0'.]5W,[J? 6J6-P5NG"6\4K[>S'OX3OP,;U))
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M?L$,<X;"1AXP2/<?O5V1 <ZP%G-Z.JOQ-O#6\G3B>XUK-,<6[2=]G#PY[_\
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MQ.ZN:("$OZ?BMZEQN8,[F/I,<QL0:-G;@CK[U]@T_'#JRSG1.\R3P" Q<(V
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MF!_-)\>GQ\-D!9$6&Z9Q3G-3@])$;NZXQNWBV.V_JW5?TCJ4Y723LK>:R.6
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MR/=]Y/+.3W<+?7MS)YCXCJM.;4&?TU=JC5,=*QC;+Q%Z75!;W3C^<#X?X]2
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MU/6N3]Y#3LB.!O"!P-W?RY#GT'56J66.( RR,8#R'$0$![1 =QN.87B66.(
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MY:U6[7N=L<OHKVO$- Q/<T[CB!W/PWV]RCGS:4S=^W+J&$X7+PR&.9@G<SO
M/'<  [_%9M!TZ5G6]R_@:_=X6K5%:.3A($CR02=SS/CS/J0&P-/8G4>2R&0T
MWE;N,R$<Q98[K=HX_$EO(\SOX[=5M:1RF9JZLMZ=S-N/("*#OF6&MV<WIR=\
M?%2F6T3BLAD)+S76Z5N3_.25)N[+_;R*W].Z;QV ;*:,;S--SEFE>7R/]I4
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M^:?O7>IPTI6J.T^?!^)AJRI8QQ7([2BY%ICMC@$GH.L*<N.NL/"^5L;N#?\
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MF2,.['@.!VVW!5=GUSIR":2*7*1-DC<6N' _D0=B.B LB*L?E[IG[6B_0?\
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MX1-P'@)\M^FZUU==:.^3]+Z=Q Y.[KTJ5OK=T^\N5*5Z-1U(ZWB9UJ:IRU?
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M+!&T>H#9>5\4J)05/GB>Q\(I-SE4Y8&9$1>&>\$1$ 1$0!$1 $1$ 1$0!$1
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MS:GQ>,I6(-+XV2O-8;P/M3NW>&^0YG;XKSI4Y26$+3YK+Q/2A4C!XSO#D\_
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M%6_@;K,;F:=R1CGL@E#RUO4@+6HFX-+D8TFE--\T;NM_WV97_;N6SIC37RA
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MQ3YNL_\ R5?]:$^;K/\ \E7_ %H7:T3M.MW#LJAWG%/FZS_\E7_6A/FZS_\
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M<4^;K/\ \E7_ %H3YNL__)5_UH7:T3M.MW#LJAWG%/FZS_\ )5_UH3YNL_\
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M8162^[*TZ>KC+,(B+E-0B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M@=^?M7!%V'L<_>Y:_K1_LM7)IVBTJ=)RA&S.W0-*K5:VK.5T7M$1>(>Z$1$
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M9BBFF#G1L>[8N#1N2/8$!M(H>AJC"9"[Z)3R=:6QT#&N^M[//W+R_56"9?\
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MQD[2QTD;2' <_4=A[-E+/U'JEU(U6Z8G;DRW@[[O&]R'?G;_ '[;^];DN&U
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MC%,Q(T^^O<$0@=<EE'=-&VW&!XGU K'@<'D:W9=D,9-5>V\]LH9$2-W;]/%
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MQ'$(I"1L\AHW_8ONK,9<N:MTQ:K0.DKU99'3/!&S >';?X(2:3?X8W?^&_\
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M#S'7X*CC*FU.5KW?JN9=3C43A&]M5+R?(QZ,KS-T9JF=S7"!\(8TGH2 [?\
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 7Q[&R,<Q[0YCAL6D;@CR7U$!S75G9!@LPY\^,+L5;//]Q;O$3ZV>'N(
M599A>T_27T<9<&5ILZ,XQ+R\N%^SA[&KN"+KAIE1+5E:2[\3)T8MW6'@<2;V
ML:HQGT<[I1P<.I#)(/[0<H76/:9B]5XEU+*:9F$HW,,S;(XXG>8/!\1XK]#J
ML=HFHX-*Z8LY M8;3OW*LPCZTAWV]PYD^Q:TJ]-S6K3^;N;124)*+O+#P.-]
MB.L,K2SE;3_=R7*%AY C)^E7\2X;_P 7J2/ASZVW_*/R;H,!C,:QQ'I4[I'[
M>+6#I\7 ^Y9^PC3,E7'SZCR8<Z_D=S&Y_P!81D[EWM<>?L \U7O\I'?Y9P/'
M_F^ZD_M#?^Y=-X5--6JLO<S^:-!W.L: Q#<)H[%46MX7M@:^3UO=])WWDJP+
MXS;@&W3;DOJ\B<G*3D^)UI65D?EG6E./(]L%NE.7"*SD8X7EAV(:XM!V]?-=
M/L=ANGW1.$%_*1R;?1<Y[' 'UC@&_P 5SG4/\.1_\7A_MM7Z=7K:77J4HT]1
MVP.2C3C-RUEQ/R_A[F1[,.T%]2Q,75FR-98:W?@FA/,.V\P#N/([CS7Z@!#@
M"#N#S!7YL_RA>'\O(^';?T*/B]O$_P#NV7Z%P1><)CS)]?T>/B]O"-UEIWST
MZ=5YM8EZ'RRE#@C+DZ4.1QUJE9;Q06(W1/'J(V*_)V#CDH9;(8Z;Z\3W,</Y
MS7<)7ZZ7Y4S?#\YN?[OZOIEC?],[_>M?A,G>43G^)13I7-]$1>R?-!$1 $1$
M 1$0!$1 %)QY_+Q0""/)W&Q ;!HF=R'EU48BAQ4LT6C)QR=CZYQ<XN<27$[D
MGQ7Q$4E0B(@"(B (B( B+Z.1W0'Q%;^T"C4C9A\ACJ\<%>Y6#BR-NPXAS/\
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MT90"L:NU)/C+=/%XBJVWE[FYCC>=F,:/XSO5R/P*B<AF]5:;C9=SL&/NXWB
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M.BW] :FMZD.5=;KQUQ6F#&1@'B:#OR=N>9&WJ4KI>_5M:8Q]J&6,0-KL#CN
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MW'P6_2SU)F@N]=8B&6AK/HLCXQQEKG#8@=>0V^!55T3F68/.QV9VEU9[3%*
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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?$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g843142g09d27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g843142g09d27.jpg
M_]C_X  02D9)1@ ! 0$!S@'.  #_[2.<4&AO=&]S:&]P(#,N,  X0DE-! 0
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M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q ?.?7$         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ '.?7   0 " <Y]<  !  (X0DE-
M!"8       X             /X   #A"24T$#0      !    %HX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$1       $     (   )    "0
M   X0DE-!!X       0     .$))300:      -!    !@             &
M;@  "V0    & &< ,  Y &0 ,@ W     0                         !
M              MD   &;@                     !
M         !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   &;@    !29VAT;&]N9P  "V0    &<VQI8V5S5FQ,
M<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M       '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E
M3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E
M5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M!FX     4F=H=&QO;F<   MD     W5R;%1%6%0    !        ;G5L;%1%
M6%0    !        37-G951%6%0    !       &86QT5&%G5$585     $
M      YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
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M 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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MM8^E&YK?HJ%O5JWU.;BL>^]PBENV-SC[9E_MVU3OM_D,64;,C;O?8 [:6UN
MTWR[>]S?YS;Z?_3_ .MJ%KW$#;:^MS&?HH@/#A[;^_YS7.J9_P -^B_G*TAE
M%ZSC2/8'8IZ[^H[V%_6)K&S>/L1!<)_?W.V^LK6'G/ILL=FYIRFV;6TL;C.J
M#2W=ZD?SCK=__HM9X?:P >LS8" '?FEH.QD.)V_H]OOW_P#GM.++PTN<^;&,
MAH#70''Z=MK(]5M7I.^GL0]W^O#^15[(['^7^"[;>J8;Y+'.=#=[O:X0T?2L
M]P;[6I-ZK@N,"SL3]%W &[=]']UJP-S[F@C(+-XVG9^=4Z/69_6W?I&^G_Z6
M5MEN0,KW-@.)BL@M>6;+-K6L<W<]^]KOHIPR B-2CK\W[$2P@#KU?__0]*RV
M@VL.T$AIEQT^'T?>L?+LKP\H6S^C:T5.):YS&DC<QKW#;NWM_<9ZM7_;:WK!
M+AJ1IXQ^1<OF];S*^I/QWUMBE\UU6-[3[+G&';?W]Z8)C'/C(N_[O_=*R>K'
MPW77_%98UF80<JEEE]7M)%;6;GN]386M%A9=^CJ_.]2K\RQ61U%\S7TK++''
MW/BN),M=N].]^_9M_3,9_P (M%F*[,PPSJ>,P.L)-M$[V>UWZ/W?G^S9[T;'
MPZ,2EN/C5MHHKG977[6@$[CMV_R_<CE]<S(Q Z:>'C^DG$."  )/77Q]6WZ+
MF]0W49/KCJ+J&V:"LMM>P0*60T5OV-^CZG_7E:IK9Z&,T6OOVU-:+K"?4?#=
MVY\;7N=9_)_/69DY=3<J\N,FQH=2S('I'7<QCZV6>W<UWL]]=5WI?X/_ $HV
MXK^JXAQVU5V-KN<667^I92TM9Z;ZZFTV8]U&S?\ H_\ !_33Y<L1#B)WK2O\
M;])$>:XI"%;7VZ?+^C_W3K_9X+@:PT/DG\V9/N]M7N_S_P#TFD:*W0Y[&NV&
M6[AN[[OSO8W_ %_X1 Q/J[TS'--[L>O[97#G7LWL!LAN]];=[]M;GL_FUHFO
MV_ZG\/H*O[89A,M+)QK[JZ13E.Q7U @M;O<'$NJ=+FL<S?M;78S9_P *@Y55
MM/2[SDY)O?:XN.X[&M#F^CZ5.\.=L_/V/=_I5IN :"YSH:V227:0/-<_U/(K
MR.IAF\.JKK K]PC=8'>I9K[7.9M_K_HTI1])'<<*_&29 = >+^4G2QO3R,5C
MW;7-L: ^#N:8]A:[TSL^A_@]Z+Z<]@"TDM:"1W\OHM_,6/@VNKSF-I_1OOH>
MZ\/!%0#&[J+=H]/VM=^?_HWK4Z=;F9#GG*LQ[ &B!1OD&2'[O6&_T=FS_P $
M0C 4K)<9>&_DO=77379D "0QSB0#J0'%HG^<[?OK/Q<KT<"O91;E;"6%N,-S
MFL][ZG:NJK?_ #>W;6_\_P#PGJ*QU>YK+J _=6QMD;K(%3G%N\>\'U?^#?9_
M-*C7^S\S*]'*I:[%=+S4 VRL3^BHLOV?1_G'5L>S_KJG')W'W+_1/IKQBUCS
M=2]NMR-;UVE^BVJ<OU,BJMO3<MC"X!MQJK%;?HPX;7/L;7_PE;_S%:RL?,=:
MRS%R_0#&AIJ.[9+?5W%S?Y7J4_2^AZ:NU8]5-;*:F!E5;0QE;9VAK0&-:UO[
MK6-4O3!D'43XG_7_ #E'PULRB9\VFRFQE-;+;G9-K?4+['>V-YW[1HUWIU_S
M+/\ P55\W&JJP,CTV!K0V!IH 2-Y,#_SY^XM3T]=/P_U/BL;JG4FLNLP&N9:
M+V0 UPW5V1]!\G:[?M_1_P"%_P# DV6$S$J%RX3_ -%?CF>(>8D?\9/AT^IA
M5&UFXO:''3VD_F;OWMO_  OY_P#71F8M+'F*PTO86N]C&R(_D-_2>QOYS-BJ
M]/ZOCVBG!KJN?DM:&/;MVM;M&OJ.+O3V;?\ MQ:VPZ'O!TDQ,?O'W_VDHX3$
M1XA1H;[JG,W+I=O_T?4W3*P\_J-=.8XUU5NR&$!MK2'O('M]NFRKZ5U5FYZU
MW9N&UY8ZY@<T%SAN&@ WESOW?9[E@=4Z1D77O=C7>N^XN>YE8:S8QP=L+MKV
M>IO]VVQWTU%F$J% [ZF/S*/2]%^D870LCU;&4>D6$DD7VQ^DW>H_:ZQOIN]1
MUE:VL+ Q<"GT,1GIUEQ<07.<2X_2<7V.>_LN5Q^GLS,AW3<P7U6EM;A97I4&
M.'J5MS<6S:WU;(=5^D;9^D]-=7FXV3?0VO%RG8=C7 ^JUC'R "W8YEK7,VN3
MX@\$3(^HB_\ !/RHC.R=-!I;7ZBWIK"'Y8JWW.:TEY]VT'\PGZ.V?\&KE;V/
M8'U%KF.U#FF09[C:N;Z@7XV38S,L+K0VL5WN]H>T-%=O_!LWN_G*V?R_36ET
M,7/Q+7TGTJGV32'-);$-WNKDL=L<]2SQD0$K)VTZ?X*(R!E5 ;Z_Q;61U&BB
MPU!K[K6P75U#<1N^CNU;])%HR*<AA?49VG:X$$%KN=KFN^BL0V&K+RZLC]':
M^QUC2^ '-+MM+V.<?H-_._G$;#9DYUN3;@W_ &2K]&&7UM#VO+-_J>VT;'[M
MS?4>FF I;'(3*NYV[-_JE-]V+%(W%KVO<R=7!OYHG^4LZOIGVPO?D5/I96QP
M99K7:73N]I_T;:]S/>Q;E%=E=%==MGK6,8UK[2-N]P$.LVCZ.]/:/T3_ .J?
MR)ACU;$<A H=]W*/1**<.QN&TFZS:YSK7%SG $6>EO=[6?V4_3\;*^U"ZRLT
ML8UP]T;G%^W3VD_HVQN5^G+Q+'BBNYC[0'2QK@7?HBVN[VC_ $5EC&6(\)<(
MT*CDE1!UOJ4-N-1>0;JF6;00 ]NX .^GS^\FIQJ,=H%-;60T,W >[:WZ+2_Z
M3MJED9./C-#KG;=QAH@DD_R6MESE5MR*^H4.9B9;L.UI#R_:-X:#_H\AI:ZJ
MQ&^E_1976FQ?D48[/4OL;4R8!>8$_-2KL98P65N:]AX<TR#'FU<]U(VT/K^U
MVNMBEHIRG#9NL;I8[;[:JWV*_P#5V7,OLK:6XSRWT^=I< ?5LKW^[W>Q2'$.
M#BO^"WC]7#2;)SL(EU&11=:&F'#[-;:TQI,MJL8Y8W4^A8V0VJ_I-;L9[[&M
M<W::ZR'!SG/]%XW5>AM_2M].O_MQ=+E6.JQ[+&-<]S1[6,@N)[-9N+6[_P"L
MY43U1L>G]AS&Q[6N-4CC;NG=YID92B="R1D1J'$I&%T;J.Y_4IR*VS;79C6-
M:]CPU[ME]>_^1]#UO>MO'Z_TC)]4T9&\45NNM.QXVUM +GG<S^5]!:58]C?@
M$Z,I&5$HE(DZO__2[Q_U5Z2]Y?Z36[G%Y#6@@N<2][SZOJNW.<?<J^=B7=,G
M(;EMHQJVT4X[O1WN :7 XS_L[:WMIM_1?I?4_P#1:Z%8'UDSKJK:L0$UTW5O
M)=[0'N!:UM>ZUKF^R?4?7_A4^))-)EQ3]-^(3=)N>S'NIZDVZNMENVJS.=7N
M?!T;7L)W5U;&;+WNWW_SZU-EK?H/D>#]?^G_ .27.#*'4>F-R,FXMOQVV"=L
MMN87-9+/H,:]SVUL_<_X/TU8IZSD8IIKM])^.&L:X,W;ZQ_-^][C^E<WZ7\T
M@<9.O5<($"ATZ.B_,99D_9'XS['M>&[BQQK!+'9#;?6<S9Z?L]+?_P!R/T2M
MS>> UOG)/X0U/ZU1X>#!B 9,@[>R#><JS:,8FJ#[G.:#(C]QWN3+\;6UX(\F
MEMKFLL#+BTS#V-+02##&[@[;O_.5JKT_3;Z8#61HT"(_D[53]#+:0'6R"[]T
M DD'WEX_[ZC447TUB;?5L_/+A =K_)^CM^C_ -6F@D&J->:36G?N@N&8YE;L
M?+;WET,VF2-OTM_\K\]-B_:WFXV90O97OK?6UK1M?#707- ^BW\W^6JIZ'C_
M $;,BY@YAU>/$GON&*YGYR>W*JPW,Q799N;EO</5N#'-&A#J6#'91^<WWIPL
MZ"EW@/QC'\W5JQZ&$6,K8VP@DO#0"2[:7^[^7L9O15F=+ZHS(M.*XM]1K2Y@
M&AVM(9[V?F\^S]]::-5NME$Q-%PNLN>WJ5)>#Z99MK<0=N]Q.\:?G[$#$B[/
MQJJVASF[C8_0D,@^F+6^YK?=Z7]M;KZZLHOKM8'TM]KF/&A=H[\[Z6S]Y19C
MX^%M./4VJMQVO#&\EQACCM&[VN*C,=;Z)!Z=4./C=4/I#.OIN8UI%S65%H>?
M=M=[WV;/S/\ ,5]"&5CE^P6#<3 \SQ#?WD52++!V>:S>OY(N=Z9::ZGDCVEH
M(!]L^JYK['^YGZ/97^E_PBU>F9YSL!UKQM>TN:X01QK^=_)<W<N;RF]#S7OL
MP\PSL-CO5%P<7[V_SC[:MU->YS/<NEZ99@6=-%F![J""-^TM+BW]&Y[O4:Q[
M_H?SB@QC)Q'BOK>OI_P5!NU_S;?@/R*2C7_-M^ _(I*<;*.[_]/U5<[US,?]
MK?CW.#*F-8^H.V[3RY]NVQKO6V_S6Q6NN]4OP[:::[&T,M:\NM< 2""UE8:7
M'8S<Y_Y];_["R[NM=0> RQU3;*V^X[&N<Q[9:VYO\[NKL?L;O;C_ )B0F(G7
M5FQX9$"6FNR=[NE##LKS6WU6OIKWM958X,-H+VC&%=;_ '?HOH>_T/YI+"Z1
M=G,8ZR]AQ'^YQ8Q]=KP/T8;95<-U.[T_TG_%H;NO=2<2SUJZR_96QP:V?4<#
M+V![K/78W\YC&;U3S,MF?97=ELIM?4"'2S7T6[O?:-[+Z76._F_3K_D)>\O]
MG+K1#U67TS S@&Y%8>&"QD!SFZ7-].YI]-S/YRMR%^PNE$6 TDBP.;8"]YD/
ML^U/'T_].[U6_P"C_P &N6#<6MCB[%Q@UX-HJ#2&ML8(]1V;N:[<ZAVSWIPW
M%%)K9C4'>#7;=L(<X-:^VAM-!LVW[/4N^@[T[4WB"S[O/P>GRL_&P]M#6/+<
M>MMT,8]X]($T_HWM#FOL9^YN5Q[*LK&=78TFJ]A:YIEI+7B'-_->SVN7+X/4
M\W'95CU65U8M6US6,JWD5.#G;;&->/LU-+O\):^OZ%:(.N=3-#IN8 ^UU;[F
MM:?LY <=CWMWX]C6[=Z7$/M2>7GMIH]%BX6-AAXH:6^H0YY<YSB2UC*&F;'.
M_P %36Q8O7<C#&:P"YU.7CP6@U6/8=_[CZJK??M.URK6=9ZGN+Q<6.MKBNMH
M8YKG$GT[<9UC:V6_O;-]O\WL3NZMU)A=;]H/IM<:K'E@-3=OOLNDUU.9;^XS
M]/7_ ,:D)TF."8-W%?ZO.P/VF^WU?4R[@Y@;57:*X:-[G67755M]38&-]/\
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MD8WHU[MEM+&OL!]3]'2QCW[W_H_YM_\ I:UJI(&KUI#_ /_9.$))300A
M  !7     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
M% !! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ #( ,  R #(    !
M #A"24T$(@     !2DU- "H    (  @!$@ #     0 !   !&@ %     0
M &X!&P %     0   '8!*  #     0 "   !,0 "    'P   'X!,@ "
M%    )T!.P "    #0   +&':0 $     0   ,    #L   !S@    $   '.
M     4%D;V)E(%!H;W1O<VAO<" R,RXU("A7:6YD;W=S*0 R,#(T.C V.C$Q
M(#$Y.C(T.C,U $IE;B!"96%C:&5L;      #H $  P    '__P  H ( !
M  $   MDH , !     $   9N          8! P #     0 &   !&@ %
M 0   3H!&P %     0   4(!*  #     0 "   " 0 $     0   4H" @ $
M     0              2     $   !(     3A"24T#_0      "
M    _^$!4D5X:68  $U- "H    (  @!$@ #     0 !   !&@ %     0
M &X!&P %     0   '8!*  #     0 "   !,0 "    'P   'X!,@ "
M%    )T!.P "    #0   +&':0 $     0   ,    #L   !S@    $   '.
M     4%D;V)E(%!H;W1O<VAO<" R,RXU("A7:6YD;W=S*0 R,#(T.C V.C$Q
M(#$Y.C(T.C,U $IE;B!"96%C:&5L;      #H $  P    '__P  H ( !
M  $   MDH , !     $   9N          8! P #     0 &   !&@ %
M 0   3H!&P %     0   4(!*  #     0 "   " 0 $     0   4H" @ $
M     0              2     $   !(     ?_B__])0T-?4%)/1DE,10 !
M"0 (@'!!1$)% A   '!R=')#35E+3&%B( ?0  < &@ % "D -6%C<W!!4%!,
M     $%$0D4                    !  #VU@ !     -,M041"10
M                                                        "F1E
M<V,   #\    =&-P<G0   %P    *W=T<'0   &<    %$$R0C    &P  "B
M!D$R0C(   &P  "B!D$R0C$  *.X  "B!D(R03   47   (XM$(R03$  WYT
M  (XM$(R03( !;<H  (XM&=A;70 !^_<  "0D61E<V,         &E4N4RX@
M5V5B($-O871E9" H4U=/4"D@=C(
M
M            =&5X=     !#;W!Y<FEG:'0@,C P,"!!9&]B92!3>7-T96US
M+"!);F,N  !865H@        M5H  +QG  "2,&UF=#(     ! ,)   !
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MJ&ZI>*J"JXZLG*VKKKNOS+#?L?.S";0@M3BV4;=LN(>YI+K"N^&] ;XAOT/
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MG7-ZYCH?FO9[C2 IFIA\<0  E=-_RJS.KRB"@YMHJN2!F8E^IMJ X';[HQ.
M8V.HGYN )D]3G'^ (SETF@6 3!^AF9:!%P  E(Z  *O?KCV++IJ*J?Z)C8B]
MI>V(&G8QHC"&^V+DGKR&($Z?FZ:%CCC5F2R%2Q\NF*N&1@  DW"  *L2K6J3
MYYFJJ3>1FH?,I3"/A'50H6B-O6(2G?R,44WHFNB+.#A!F&J*HA[*E]>+LP
MDGB  *I!K,J<M)C:J)B9PH;SI)27%W1UH,^4P&%-G4N2L$U"FCV1*#>_E[B0
M:QYUEQ2080 +D9* !ZF0K"RES)@OI_RB,89(H_F>XG/*H#6;[V"JG+*97$RO
MF8^7:S=-EPJ6Y1XHEE^46  ;D,2 $JCBJ[FO Y>BIWVJN(7"HW*FPW- GZRC
M0V IG#:@3TQ!F1R>.S;VEH"=?1WSE<B40  HD!F &ZA"JV&X=)<9IQNS>X5#
MHPVNYW+(GTBJY%^[F]:GJ4OAF,6EXS:PEB.BZQW,E4^4)@ SCX^ (J>YJQ7"
M7I:FIL2\JX36HK:W<7)BGO:R^E]CFX:ONDN<F'6M'S9[E=VDUAVGE0F4#0 \
MCR" *)^PNH1Y=([5M:MY.GW1L/QY,FQDK(MY9UHXJ&1YU$;OI*YZ:C'KH>9[
M!Q?PHG)[O@  D2B  )ZFN;:!I(Y"M,* O7UBL 6 #6OSJXQ_GEFXIV1_<D9L
MHZY_@S%LH-Y_P1>PH3N N@  D&Z  )WWN,N)U8V:L]Z(27S/KQJ&[FM5JJ.%
M[5D>IGJ%-$7AHL:$S##ZG^R$Q!>!H!R&!   C\N  )UHM_.2$(SXLP^/YWP:
MKE*-^VJJJ<Z,8UA]I:N++459H?:*5S"5GQ.*+!=<GQR*L   CSZ  )S5MT::
M:8QBLF&7IGM[K::5-&H&J223&%?MI/"1743AH3^0-3 ^GE*0*A<^GC:.N
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M&((?O])XRW(6NGQXN6&CM6EXZE!QL*=Y4SX+K'-YY"FFJ99Z:@]FJUE["P
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M8H!"N[6=-W!-MD":<U_/L0F8+$ZNK":6<3R5I]"5LBC"I):5O! KI..*[@
MC#B  (]FP-6HE'_\NRJDT' 6M:JAAU^BL&^>WTZ)JY.=!SQ]ISJ<K"BXH^":
M;A!.I :+!@  C!F  (\FP%&P]7_,NJ&LDV_VM1^HRU^-K^.EV$YWJPFD&CQO
MIKRB_RBSHU.;A1!LHT2+&P  B_^  ([4O_"YR7^NNBVTFV_MM)NP+5^'KU&L
M^DY[JG"K7#R IB"G]2C<HLB;H!"PHKB+2   B^N  (2TT)]X\W77REEX@V:N
MQ&]X6U<1OM9X?4:SN9-XVC4'M0AY6"#VLG=YK@?KLME[10  B?F  (1BSY^
M;G6;R7Y_9V9PPXQ^K5;.O=9^1$9QN'1^*339L\Q^4"#VL/Y^GPAGL.I_YP
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MSW5*Q.^B.68WOLR?.U:AN.F<_49<LVZ;N34.KIJ;K2'-JS*6VPJ1JA^')0
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M@EUZ2U5@@D][ CDF@IE[TQ/?A)U\CN ?@J""O<KW@BF!][3=@<6!39W?@7F
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MB)(_I.2$A8%LH6:#I&^RGC&"_ET?FSR"B$EYF*."1#0LEK*"*QIMEQF"Q@
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M-([FH:2N$'WTGB.J%6Q(FMJF>EGUE^"CE$:^E4RB#C(1DRZ?=!DFDQ"1 0
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M4X3LK<^*PG3[J:2)8&19I;&(/U+6HAB':$ ]GO*&V"O2G+J&P1(KG@:&R@
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M;(+*JQ>S$7+5IM"N\6(JHK^K?%#<GPFI<SZ>F]2FS2J\F62<Y1(&F>:,,
MA>*  (AVO^5S47GANO5SK6K9MD-T*ULGL<ITS$J*K9YUASB3JA1V1B12J"MV
MMPI8J@=W%P  A@R  (@>OP5[+GFYN@AZU&JNM3QZK%KTL*MZMDI/K&YZ[CA?
MJ-5[0R0TIL=[@0J?J"Y\8@  A;:  (?>O?*"Z7EBN/V!]&I>M":!+EJ6KX^
MM4GVJTR =#@:IZR ;"03I8& E K?IH.!)@  A6N  (>7O.>*F'D!M_6)&VGG
MLR*'U%HLKH&&UTF4JD&&+3?/IIV%U2/RI%N&& L7I0>%40  A2F  (<^O J2
M8'BEMQ:08FF$LD&.IEG K9Z-,TD_J4Z,'#>/I:R+EB/7HU:,/@M*H[F'H@
MA/&  (;?NV*:4WA0MF>7UFDUL8B5G%EUK-^3O4CYJ(R253==I-.1QB/#HFN1
MZ MTHI2'OP  A,*  (:'NMZB7W@)M=J?9&CUL.^<KEDYK#Z::TC"I^R8VS<Y
MI"R8JB.ZH9B6HPN<H92'V0  A)J  (9-NF*JE7?5M5JG'FC&L&NC]ED/J[.A
M94B:IUZ?Y3<4HZ:?"B.JH/R8'0O H+2'\@  A'N  (8-NA&S/G? M/BO.6BW
MK_.K@UCUJR.HJ$B(IKVG.3<3HOVD#R/"H&"8+0OQH!V($P  A&&  'MNRS%R
M_6V9Q;9S-U]8P']SFE!SNX)T)T">MM]TRR]%LR%U9!L&L?AU:P-OL$UWB0
M@R2  'MHRD!ZB&VKQ,)Z$5]>OVMYV5!PNDEYVD"9M8=Z#2]2L:AZ5AM'L#%Z
M7P0+KB]\1@  @R*  'MRR1*!V6V7PYZ V%]'OCV #U!.N0M_H$!]M#I_;2]0
ML$=_=QM]KI)_JP27K$F =0  @R&  'MPQ^B)%&U]PG.'GE\7O1&&9U EM]2%
MA4!>LP&% B]*KP*$WQNMK1V%A 42JIN#;@  @Q^  'M;QNR096UEP7".@%[^
MO 2,Z% "ML*+I4!/L=^*SR]0K=R*K!O?J]"+, 6!J22#N0  @QZ  'LYQB67
MY&U4P)J5D%[WNQ^3CE #M=61]D!/L.Z0["]AK-*1 1P5JJ:0"P7DI^&#^P
M@QV  'L7Q82?=6U'O^J<LU[WNF":1U *M0R89D!;L"6772]YK "7>1Q+J:.3
M(08[ILZ$-P  @QV  'KVQ0:G,&T_OUNC_5[\N<&A+% 6M&&?%$!GKW6>62^-
MJU:<TQQXJ."30 :'I>N$:@  @QR  'K<Q)VO/FT^ON&KDU\)N3BH6U JL\RF
M,T"%KM>DSB^YJK"@11RSJ#&39P;(I4:$E@  @QR  .8?=G!S&- ;=TMS\;F
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M")B.F'-P08>EECQQ:76PE#QRC&*UDFASMTZ2D-5TYSC4C\)U]!ZCD(9VA
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MQI0-DR^:48,*D0Z7WG$DCQJ5AEYWC5J3:$K*B]^1KC68BL60QQPCBO*/D0
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M+HJTH*1WA7K#G<%WZ6GDFQ%X7E?\F)MXYT3=EH)Y>B_JE2IY[16FEM1YW
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MCX<8G"B?SW<5F42=#68YEHJ:=%2=E!6804'_D?R6R2VTD&V6A11AD3B-R
M@4N  )7.GK&KEX:=F[VH3G:2F-*D^66VE@ZAUU0>DY6?44&'D8*>$"U8C^F;
MX!0YD(2-K   @."  )5UGF*T\(8[FVNQ*78BF'BM1F5!E:JIKE.TDRJG#D$O
MD1*E.BT.CWV>=A0"D R-AP  @(N  (R<KS1N 'Y7JWMO%V]=J -P+U]YI,!Q
M2TZ,H;MR:#Q!GS=S=R?-G?=T) TOH+ASQ0  @G^  (PLKCEV07X&JGIVCF\
MINUV\E\:HY5W;$XKH(-W^SOHG?1XC">$G)EXY TZGN)XT0  @<6  (NZK0U^
M77USJ5A]_VY\I<)]NUZ+HFE]HDVGGU9]J#MYG,=]QB<SFU=]W@T_G39^.P
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MIWL%I8JDO6OGH>2ASEOXGF*?(TM*FSF=.3F*F)F<K"7SELN9<@U*ESF(_
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MDG$%LG&#L&+&KCV"\5/*JCB"9D/)II:"%#)RHZ2!\!ZDHF*"%@:VH7^!Y
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M1V_0KRNI5F&$JL&F75)DIH*CZT*0HJVBPS&4GX^?\QYVG<F4F0>@F\6%*
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M"V5?O >(R%? MT6'MDEULJB&VCI1KG.&42F>JT>&217MJJ^&D &1I%6!#P
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M6IFDA@^%MXB0A3Z% ':+A(:$4V-Y@^V#PT]<@WF#23FF@SB"XQ_&@YB"N
M@F^  *BEA<./VYB8A.".BH>#A!>-(G5B@V>+MF)O@M:*9$YK@G6)2CCA@C*(
M;A\R@F:(>P  @2Z  *>KA->9?I>6@_J7?H:!@S"57'1O@H"3,V&,@?&1,$VJ
M@8:/>#A%@46.4AZU@5B-W0  @""  *;BA!RC,I;(@T6@B(6M@G:=K'.9@<*:
MRF#$@3>8)DT @,V5\C?'@':4NAY1@&R25P  @ "  *9*@X^M")8C@KZINH3X
M@>>F)G+A@2:BC& 2@)>?5DQ3@#F<V3<W?]^;M1WX?Z>41   @ "  *7C@RVW
M&I6D@F"S,X1>@7RNZW(\@*FJH%]\@!"F[TO7?Z^D>C;-?UBA>1V>?PV4!P
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M+(P C>*,$'OXC%Z*Z6L(BO:)OUDMB;6(LD8<B+Z'W#%9B!>'4!>PB,:'6
M@ "  )I2CJ"648L_C0:4F'LWBWZ2Q&HUBA20\%A>B-6/1D5MA]2-\3#+ARF-
M31=)AZR,!0  @ "  )FDC>^?@HJ'C%J=,'IYBLV:M6EZB5Z8/5>MB"&6"D35
MAQR46S!>AE>3]!;_AK*/C0  @ "  )D<C6BHS(GUB]BEZ7G<BD2BS6C<B,F?
MMU<2AXB=#T1 AHN;22_FA;V:*1:^A>&/80  @ "  )B]C0BR5HF$BWNN\7E6
MB=RK.6A.B%*GD%:1AP:DE$/5A@2B]B^&A3B?'19KA4B/*   @ "  )#8GN%H
MS(+7G$QJC7/?F@)L-&/$E^]MQ5*'E@MO23_LE(9PL2M*D^AQLQ!LEMYQ+P
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M1W\7EGB1RW !E#R00& *DA^.ND\SD#.-8#TECI^,:BDBC;:,70^+CL")D0
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M9W7>I-9Q1V>MH>=R+%B!GR=S%D@PG*MS_C9GFL-TRR(KFD=U'@B FW1U,0
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MAW+WGYF6SF2XG*B5 E6=F=J3346FEU&1\C1WE3R16R$5E!Z0Z CBDPZ& @
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MZ&E@K=AW&UP"JD=W8$V@INMWPSXHH^QX+2T0H<=XA!CNH>EX5 )>G?EZ6
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M F>QJ2V;.UHRI8:95DO8H@:7HSR4GNR6M2OKG).6=AB[F\:0N0.)EE."9
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M:UUAMV9\'E"'LUU[Z4+RKW=[WC0MK!1[\".3J?)[^ ]GJN)[V   FVA_H0
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MZUTCLQ.?25!1KK6=?$*6JIN<)3/IIPN;;B.QI)28(A!6I(.+#   E[*
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M8*T$=8)GOIIL=G%I[X:^=UIK_7(/>$)M^UQ:>2QO[D53>@]QNRL#>M]S&0>
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MT5^XA MLRDOQ@_)NK#:!A"!P2!QEA6%PY@  @$QVNJ&8@[AM@Y*G@T5O"8*
M@NAP;7$U@I]QOE[#@FMS!$L7@EIT.S7 @GUU.!O(@V]U9@  @ !ZN:"+@=EV
MU9%F@8AWBX%=@3MX*W 2@0-XP%W @-YY54HX@-=YY#4%@/-Z3QLW@9IZ+
M@ !^.I]F@!F )9 S?]V (H 7?Z>  V\3?WE_WES;?V1_PDF ?V9_K31X?WY_
ME!K*?^%_5P  @ "  )X[?K")?8\D?GV(SW\'?E"'_VWD?BN''5O6?AZ&2DB1
M?C*%F3.R?D*%#1HY?EF%#   @ "  )U$?9"2[HXD?661E7X*?3J0#VSR?1F.
M=UKU?0Z,^$?7?1F+L3,<?22*W1G'?/N*9@  @ "  )Q]?*J<9XU9?(:::7T]
M?%>8+FPF?#25Y%HT?"Z3R4<T?#B2"C*E?"N1)AEQ>\>.V0  @ "  )OE>_NE
M\XRV>]RC57R.>Z>@:VMW>WF=<EF)>W&:R4:/>X.8PS(?>VV7^1D@>L20_0
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M^X0+B+)^)'3RA\%^-63JAN)^.U.IABY^1T$NA:E^52S+A79^5!*YAJ!^!@
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M]X"7A&6H5W%C@V*E16$_@F*B(5!8@9>?F#Y6@0J>92J;@(Z;-1%Q@$6+RP
M@ "  (=\F)UC%7IIEIAE66Q$E.-G>%SADV1I<DQ)D@]K33HVD2!L]279D3AN
M 0L\DY5M=   @ !]1H;5EOUKBGG/E1]M FN9DVEN9UQ%D=MOOTN\D'MQ!CF^
MCX%R)R5XCW9RR LND1AR10  @ "  (8@E4ASVWCNDXATI6K2D=EU9%M[D%%V
M'DL,CO5VU#DNC?IW="4.C=1WNPL<CLAW?0  @ "  (5(D[!\%G?^D?Q\3&G,
MD%U\<UJFCMI\ETI+C8Q\P#B1C)1\Y22<C%A\Y@L!C+Q]#   @ "  (1ODEV$
M67<JD+&$!VCXCQB#H5G&C9J#,4FHC$&"R3@%BU&"AR0XBOZ"9PKMBO&![@
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M<&X3H"9DE6"KG>YFH%(@F^=HBD)8FAYJ3C#BF/YKPQR!F<%L/P/?F*%LO@
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MWVKZF7.).%V3ES"(=4\ZE0F'K3_BDR*'!R\9D;F&L1N/D9V'%@2HCG:#)@
M@ "  '<1FMV1UVJ F)Z0Q%T5EEB/ADZZE"N.2#]MDD"-3B[$D,J,]!N&D&6,
MI 3'C2F#.P  @ "  ':SFD69ZVI+F :8@US=E:Z6RTYSDV&5##\>D663UBYC
MC_N3TALPCXR1/035C!R#10  @ "  '9KF=:B*VH"EXV@>UR+E2>>7$X<DLR<
M1#[2D,2;&2XGCTN9\!L'CLV21@38BU*#1@  @ "  &X&K3EADV(#JEUCDE4Z
MI[=E@T=II3MG5SA-HQUH]R<VHA=J&Q(JI']IIP  F--N8@  @ "  &V#K!!I
M/V&ZJ1MJCU3]ID9KX4= HZ!M*C@WH6!N4R<_H#%O&Q)QHBUNB@  ERUS:0
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M?5^1HM*-KU+?G^>,LD4ZG1Z+NS:&FKR+&R8[F26+2A*EF:B)H0  D-N
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M[%5WLK]ODDE=KW)P13Q#K%%Q!RW6J<YQIQT4J05QR0E<J:5QG0  D.%[@
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M1E2RK,N1?DB8J4B0=CN%I?F/B2U+HT&/91T8H>R.O I\H1^'%P  C)R
M@ "  %_!K]V9H%2[K"R8O4BCJ)&7@3N'I326A"U2HFV6+1TSH0&33@J2H"*'
M)@  C "     @ "  ,$39Q5?[:[3:3EBM)OM:SYE8(@B;21G[G-I;OAJ:5VW
M<+ELT4;'<D5O$"S/<R9PW0H$=BIQ%+\@9"5JT:U+9HILA9J.:+]N+(;H:M)O
MRW)&;,]Q8%RH;K%RZT7)<$ET4ROH</%U70EM=&AU:[U)895UIZN&9"!V3ID'
M9GUV\X5S:+-WI7#X:M)X7%N!;-!Y$43*;G!YKRL/;MEZ"@CI<MQZ+;MW7TN
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MPY9Z=Z]ANH8T>%QD='2G>11F^V'P>=-I9TX&>IMKMSB+>V9MOQ[+?#MNTP
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M5I @;>^./G_X;Q.,]V[-<"R+G5R]<46*54F-<DR)-C3;<O*(8QOO<<N(2P
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MF(E&?3EII'H!?61KAVF1?9QM35?M?>-N_D3[?D%PCS Y?KUQR18V?[-QNP
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MB8/;=0R4(W2W=7V2?&21=>Z0P5-]=FR/*4%!=N*-X2U:=OR-4Q0Y=GZ+%@
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M4WP=@Z1PHVWM@T)QVUYW@O-R^DW?@KMT"SO8@K%T^B>S@O=UAPV>@^=T[P
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MU7?G?/N91&FP?+>77UIY?&^58DI)?$:3LCC3?#22L26">^:22@S+?">(I@
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MZ6]$BNYVJF'>B?EW5%.%B1-W\4/7B%UX>S*CA_9XYQ[=B$9X[09\AY)YOP
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M36Q2A;Z=RU[JA+B;QE""@Z69HD$V@L*8)3"&@B:7MAV!@:^3\P9]@12$8P
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MD&,7DPQ[XE9QD8)\'4C0D E\0SH2CL]\9REUCC%\?!6<CPY\.@##BJI]I@
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ML%H2I!]>%4WPHB-@94"KH%MBC3'RGP5D:"#GGQ-EB@O[H;ME&@  C91MT@
M@ "  &2SI,QC)UFFHHYD\4V3H&UFL$!LGGMH5C'2G/]IOR#SG-5JB@Q/GOII
M_0  B_MRS   @ "  &0KHNAJ=5D,H+AKN$T9GI1L\3_XG)IN'C%_FQ%O&B#0
MFL%OE0Q]G&QO!@  BGMWH@  @ "  &.=H0=QJUAKGN)R>DQHG,ES/#]UFM%S
M]3$1F4ATC2"0F-YTPPR.FAET50  B11[Y0  @ "  &,.GVYX\%?AG5-Y6$O>
MFSMYK3[CF3]Y[#"TEZEZ)R!-ERUZ,0R.F %Z*@  A]%_G   @ "  &*0GBR
M5E=QG!: 84MUF?B 2#Y\E_. &C!5EDY_^B EE:)_^ R5EAZ $0  AK2
M@ "  &(FG2V'OU<9FQB'>4LDF/"&^#XHEMR&9B_ZE3*&#A_FE&V&1 RLE'2%
M#0  A<Z     @ "  &'5G%Z/*U;,FDJ.FTK3F!R-OCW8E?V,VR^NE$2,=A^+
MDWZ,KPR)DR6(>@  A2&     @ "  &&5F\N6S5:_F:Z6)$K%EVR4[SV]E2B3
MK"^KDTJ39Q^QDEN1[PR_D>R(GP  A)R     @ "  %DCL:U:9$X:KU)<C4)D
MK1E>JC6<JQA@GB<LJ>-B(Q63JV%B: -%J;9C6@  B.=Q_0  @ "  %APL&=A
M?4VZK>)C&T(CJVIDN35_J2YF.B<ZI[UG8!7JJ,]G< /2IK]H40  AZ!VL@
M@ "  %@(KI)H:$U*K MID$'0J8EJM#4XISAKSB<8I:QLFA8*IG-L? 0YH_-M
M>   AF=ZW0  @ "  %>NK*=O.DS?JB9O_4%7IZAPN33GI55Q;2;?H[QQ[!8*
MI$YQJP2$H5QR_   A4%^B@  @ "  %=2JOUV'$R*J()VBD$$I?]VZC2*HZ9W
M,R:ZH?5W;18)HEUW*03"GP9XX0  A#Z     @ "  %;_J:U](TQ0IRI]2D#5
MI)U]3C1>HC=]/R:2H'1],Q8;H)=]%@3_G.]^%@  @UZ     @ "  %:ZJ*"$
M+4PIIA*$%D"YHW6#QS1!H0*#;"9TGS2#1Q8=GRV#AP4^FR&">@  @JV
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M?E1\9J&H77^!?9)@8!F!78(M8GR!)G#^9+B XE[H9N& I$N7:-2 =S;H:@.
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M#H=G9Z9_/'@S:5Y_1F?X:OE_.5;&;(A_+$0Y;>U_*# :;IY_'A=2;@9^\
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ML8$G>5)<"7*W>>%?*&+^>H1B$U(!>S%DU#^=>^]G7BL\?,5I6Q#>?E!I8
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MMGM';>.%>FT.;O^%#%W'< F$@DU_<0>#_SOC<=N#F2A;<?^#90]:<Z&"^@
M@ "  (>R:RR.NGIU;'F-WFQ!;9R,PUT";JN+D4S&;["*>SM(<'Z)IB?Z<'")
M:0\N<EF'<   @ "  (<,:@*7N7G-:UB61&N5;'R4@5Q=;8F2J4PC;HZ1#SJJ
M;UN/]B> ;R>/[ \ <5"*)0  @ "  (:7:22@LWE/:G^>M&L*:YZ<45O0;*&9
MWDNG;9V7TCI%;E^6KB<5;@F590ZG<)&)Z   @ "  ('7@8M87758@5A;EV?&
M@5I>H5CL@7UA=TC!@;AD&S<#@B=F<2+1@QUG^ CGA*1GWP  @ !Y<X#+?K9@
MXG1H?LIC7V;4?NUEM5@7?QYGYT@+?V!I\C9P?\IKN2)G@(1LR0C?@>ELF@
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M:F]F=1"*WF(,=8F*$%.E=?&)*$0T=EB(73-<=J"'V2!*=CN(#PAR>-B%50
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MYV>LA3YILUL+A.EK9DTCA*%L^3WXA'AN9"T'A*%O?1D A9EOH ).A1-Q-@
M@ "  ')P@S]OWV:A@PAQ&5GV@L=R.$Q*@HQS/CTT@G!T(RQM@HYTRAB<@S9T
ML@)=@PIVS0  @ "  '%]@4)WX&6Y@1UXD5D.@.IY(DM=@+=YF#R9@)-Y_"OH
M@*EZ0AA(@/]Z$P)N@41[P   @ "  '"F?Y!_\F3O?W^ (UA2?U6 )TJU?R&
M##P'?OA_\"NS?NE_Y1@S?O-_Z *-?[U_^   @ "  &_V?CF("V1A?CJ'QE?/
M?@V'/4HK?<J&E#MR?9N&"RLI?7V%U!?W?2J&'0*6?G:!P   @ "  &]I?2:0
M)&/7?2^/<E=%?0".9TFJ?+6-/#KU?'R,8"JD?%&,/!>0>[2+6P*??6J!Q@
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MO%M>C)YN_T]BB\EP*D)EBP5Q/#/LBH!R("-OBIARG0\WB\]R#@  @KQXF@
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M&5BMAB&3?$S+A4V24S_AA$^1!C'C@W.0;B("@NV0*@[;@EV*"P  @ "
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M@4^2E01S6T0PD[=T'#?&DGQTMRH"D:MU+1F4DAQU(0<QD"IUW@  @ !_+@
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M349BJ)A6TCM-IPU9/2[LI>1;:2"&I=E<]PZ7J*-="   H A@?   @ !Q+@
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M8$/*GM-V\#CDG2AW52SKFYYWD1]8FM=WG [8FZEW7@!QD]IZ5   @ "
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M68N>74-I9GQ/7_5K7&O,8GYM/%H\9.)O"4=W9OMPO#,K:"UR+AJZ9Y%RSP
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M&H5[46V61':(5,6426:15]N24E6=6K>0DT.,7/J/+3 L77B.?!BY7SF,[0
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M;G]386APUW#^8ZMR)6&A9<9S6%#^9\-T>#\;:6-U@"MQ:>MV11*2;$=V#
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MF7JJ5[V;GVR"6F>95EU>7-*7"$U%7P.5%COZ8(^3TRD)7^^3:!$D9>^+EP
M@ "  (4P<9)30'AJ<I96\VJE<[-:>%NE=-A=R4M>=?=@YSF7=PYCNR69=_EE
MUPNZ>L1F @  @ !UPH/';=)<#G<W;S!? VF!<(1ASEJE<<UD<TJ"<P9F[3CA
M=")I)"4+=,AJM@N-=_=JJ@  @ !YX8)P:EUDW772; %G%VA8;8-I,EF-;NYK
M*4F8<$!L_S@C<5YNGB2"<;QOL@ME=8)OB@  @ !]@($.9S-ML'1P:0QO-V<
M:K9PH5B5;$!Q\DB];:YS(C=];LQT*R07;N%TRPM.<UYTLP  @ "  '^Z9')V
M@'-(9G-W8V7<:#YX(E=@:=UXP4?/:UIY5#:D;'AYTR-M;#EZ%0L*<9MZ90
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M_FT$>F)6CV ->P!9]E'7>[!=*4)'?&A@'S#_?4%BKASB?FQD(P2$@.ED[0
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MGF=O;(]]$UK:;<]]6DTR;N)]?CYJ;\Y]G"X <%)]O1KA;XA]P@28>#Q^@@
M@ "  '(Z:3.$^6:A:KZ$Y%H6; J$D4QX;26$(CVZ;A"#Q"UN;G6#EQJ8;8B#
MW@2:>#B"@P  @ "  '&29Z>-1F8 :4.,L5EX:I:+S4OD:["*SCTH;).*!BS<
M;-^)NAHK:_:)S 29>#J#'   @ "  '$59G&5C66$:!J4CECW:7"3(DME:H.1
MGCR]:UB0@"R*:X607QG0:K2.B 1L>(>"_0  @ "  &S%@ME2>V&"@LU5YU5(
M@O19+$?+@SE</3C6@Z%? 2?9A'AA+!+TAKMAE0  @SIEK@  @ !\ VN6?X1:
M3F"0?\%=(51F@ =?T$<0@%5B4SA#@+EDD"=T@6MF1!+7@OMF7P  @0EJ8@
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MLUO+<[V!VT_V=&N!Q4,+=..!C#3I=3F!8R3W=2^!9!&I==J!B0  @ "
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M8U0MAC%BF$C7AA=DKSPOA@1FEBX%AB1H*1UBAO5H_0FCAU%HZP  @ !S9
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MRU!T>_F%SD5&?!N%>#D&>_&$_2MO>[:$PQN->UJ%&PE2?%R#WP  @ "
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M0$@&C<AF\3THC4MH@3$OC.EIX2-4C0%JT!)*CI-JG0(?BO!LI   @ ![/
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M,T5:A4:)0#JYA/.(O2\0A#B(%"'M@X.(&A'D@QV') +7@;2![   @ "
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MZ#O=EPQJ*3%>EEAK0"6HE=)L"A?[EDQL2PAUE0]LKP  A\9T+P  @ "
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M2GEW]6F]3H]XJEC84EQY7D:<56AZ$#,75F9ZLQP*6--[*@&Q?21]B)5G/:F
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MF8/56+M:_G4M6[9>2F5_7HUA=E2C83%D>$* 8VIG2BZY9%UIMQ9.9F!JV@
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MGGQ^1P:'#6Z72T2&;5^>3QZ%S4^44GZ%0SY85-2$WRN;5$R$Q!157:*$^@
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M1G>T6UMBWVHM7AQE8UM<8*-GQ4MI8NAJ SH+9*%L#2:Y9))MF0X3:X=MQ0
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MI7'23 J,PV2J3[:+LE9W4OB*G$<G5:J)N#:$5PJ)*R0W5L*)8@TE:<B'-@
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MTVN:7MIIOE[D841KEU$[8W)M6$(794MNZS%M9F5P11Y89=YQ 0<.=!-QS@
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MFF<M4>V1HEJP5/602TTO5X*.XCZ866&-TBZ*692->1Q 6YZ-&0:==-.$>0
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M1E^X8V9OI%.[961P[4;*9Q=R%CBC:&YS(BAM:,-SYQ4;:LESV@$3?BYW'@
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M6EG<>KA0^$X'>XA4@D$#?&17W3)T?4Q:VR&4?H!=#0S,@*!=>   @ !EG0
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MLE0&:1ETI$B^:IQU=#QJ:\=V(B[/;'1VL!\#:]MV_0OT<9EW'P  @ !]TP
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M?$V$?]56BD)Y@&!9<38L@/%<&R@3@;%>21;Q@S-?0P2-A A@;@  @ !M\0
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M"DAS;^=XJ3W$</9Y&C'U<99Y:R2A<9MYGQ2B<B9Y@ 20>$I[<P  @ "
M@ "  %&F;"=_=$?O;<Q_N#U8;O=_L3&H;XE_C21E;U)_B11"<#I_L 1<>**
M)P  @ "     @ "  %$E:C^&\D=O; &&Z3S<;4&&>#$Y;<Z%\R01;62%VQ00
M;J2%N 11>+6"ZP  @ "     @ "  $SOC:!*UT-@C6I.-CC5C8-1:2R]C?]4
M1!Y5CU]65PR D=U6]@  B8I<-   @ !LK0  @ "  $N3B<M1E$(XB>94BS>U
MBA=74"O%BG]9OAV9BYA;; PYC15;U@  ADY@WP  @ !QC@  @ "  $J%A?I8
M9T$<ADM:Z3:\AI1=/"K7AO-?.QS<A]1@A ODB)Y@OP  @U1EN@  @ !VB
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M;#SK> -[T#*]>+Q[^"==>.U\ !GZ>(1[^PIM>F]\K0  @ !_>   @ "
M@ "  $73=-N"O#R'=D2"X#)O=R""GR<Z=SF"2QHD=G*"6PK.>+6"!@  @ "
M    @ "     @ "  $"9F45(JS>RF*U+Y2VCF)1.U"&JF5%1.Q)YG#)24P-2
MF;Y48   A+)?B@  @ !P#0  @ "  #\WE;Q/!#94E8Y1V2PLE9E48B!+ED!6
M9A%NF*%7+P,)E159/P  @:YD0   @ !U 0  @ "  #Y!DA95>#4ZDAE7X2L>
MDCY: A\ZDM=;H!"@E,-<'P+2D,]>+@  @ !I(P  @ !Y=   @ "  #UOCGU;
M_310CI]=]BH8CM5?J1YGCV1@Z __D-=A*@*JC09C.@  @ !N5@  @ !]6
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M)S#G@?9^3R<+@JQ^,1OC@LQ^ 0Z1@EQ^+@*)@8A^_P  @ "     @ "
M@ "     __\  /__  #__P  ;69T,@     $ PD   $
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MN____P"  (  YD]_SG]8S9E_J'[-M-I_F7YYG!1_HWYE@TQ_QGZ%:H5__G[
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MT!N#!*VZN<V".JA8HS*!HZ,MC'N!-IX@=<B [ID47TJ OI/;2.2 KXXZ,KF
MP8?/Y-6#<[WXSOJ"A[=6N+6!O+#BHB^!)JJHBY^ Q*2*=1& @YY57J> 5)?1
M2&F 4Y#9,F" <HC[X]:##LBES@6"),#BM\:!5[E3H4J O['ZBM" 8:J[=&N
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M68L\C0R!W(FG>9^!?X@V9B>!.(;.4N*! X5>/]Z [H/8+9V ]H(>PPZ"I)A
ML4Z!]I6^GN"!99,VB]N \I"P>)6 GHXV94N <8O34CN 48E2/VV 4X:@+6:
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M.*2 MH9O*:Z F(-?J;:#ZJ#'FG:#%9W-BGN"2)J*>>Z!EY<9:3F!#I.C6)B
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ME$A_WX @A5-_KH #==Q_AW_B9=I_>G_+5<=_AG^^1@5_IG^U-J9_\7^L*&N
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MBH7#J(=WB& &FBYX,&,;BOAX[V8#>N)YPFC1:C]ZIFNG66U[HVZ>2.5\O7'
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M,+:!Q'KE)0&!VGS<C.V![WAP@**!GGDN<\&!4'G89FJ!"'IY6)B VGLE2L:
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M<\&%JY*0: *$I9"%6]2#EXXT3YR"LXOF0XN" 8F>.""!7H=>+5F [H4!(^^
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MUX0J++R+VX,^)>"($8)7($2$J(%_8%FB&(ZD5].>KXV'3N*:_XOA1=.7%XH
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M]GPC31YNQGS%/'ERZ7V"+0!W8WY;L$%7JX/$H)=;18-$D&!>O(+!?Y]B+X)
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MSWA!A?E^T&*X>JE^Z&5I;H=_#F@+8<E_06JN5)]_@FUC1V9_VG ].J: 2G-
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MB6;&44R,)&F21G2*KFQ].[&).6^7,8:'R'+9*!2&<'9E( F%/GHC;O:-_FB
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M8IJ%[(G$6+Z% 8BJ3I2#](=51'6#!H83.HJ"283G,4N!GH/2*,.!*H*K(9F
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M?8+&C']8?)J5@%E;^9@W<Y!?695V9DIBTI*&6-!FDH^;2V1JHHRR/HIN[(G
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M6[M]RW[24K)^ 7[[26U^(7\10"1^4'\P-RA^F']?+M!^]'^?)P1_B7_<()V
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MV'O2,]5U2WS8*I!XYGWR(K5\8'\/<%-@:W[29L5CG'\97,=FN7\U4F5IX']
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M3)1[N'> 14)\>WAT/=E]#'EN-GM]EWJ#+VM^,GNR*0A^UGSN(T1_JGXA'K"
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M"7H^3'B+$6'01>J*?&2D/S&)KV>/.'N(K&J?,<F'B6W@*V6&;W%&):^%:G3
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M(9J GH ;'@6 Q(!4  #__P  __\  /__  !M9G0Q      ,$(0   0
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ML[MMLZNU>+NEL8#!GZZ$QIBKA,J0J(3.B*:&T8*DC-. I)+3@*22TX"DDM.
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MDK*%P(VQAL&)L(?#AJ^(Q(*NBL6 KHS%@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,6
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M-6R,Y41ZA-Y3@X#98HI\U6R/>-)QDW70=95SSWB7<<YZF'#-?)EOS7Z:;LR
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M047_KSU0_K@[6?/$/&'FT4-DV=]#<\C<2H6WT%>5JL=EHJ# <*R9NGFTE+:
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MOKY]HK^]>JC O'FOP;1YL,&P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K#
ML'JPP+!ZL,"P>K# L'JPP+!ZL,#_G3<:_YM%+O^93D#_GDY._Z%06_>B4VGN
MHU=WYJ)=@]Z?9H_7G&^:T9AYH\N5@JO'DHFQQ(Z/ML*)D[J_A)B]O8"=P+Q]
MH\*[>ZK$M'JMQ*U[KL.J>Z_!JGNOP:I[K\&J>Z_!JGNOP:I[K\&J>Z_!JGNO
MP:I[K\&J>Z_!JGNOP:I[K\'_GC<:_YM$+O^:34#_GTU-_Z).6_>D46COI55U
MYZ5:@M^C8HW8H&N8TIQUH<R9?JG(E8:PQ)*-ML&,D;N^AI:_O(&<P[I^I,6W
M?*O'K7NKQJ=\K<2D?:[#I'VNPZ1]KL.D?:[#I'VNPZ1]KL.D?:[#I'VNPZ1]
MKL.D?:[#I'VNPZ1]KL/_GC<:_YM$+O^;3$#_H$Q-_Z1-6OBF3V?PJ%-TZ*A7
M@."G7HS:I&B6TZ%QG\Z=>J?)F8.OQ96*M<&/C[N]B97!NH6=Q+:"I,>P@*K(
MIWVJR*)^K,6??Z[#GW^NPY]_KL.??Z[#GW^NPY]_KL.??Z[#GW^NPY]_KL.?
M?Z[#GW^NPY]_KL/_GC<:_YM$+O^<2S__H4I,_Z5+6?FH3F;QJE%SZ:M5?^*K
M6XK;J664U:9NG<^C=Z7*GX"LQ9F&M+^3C+RXC9/!LHF9Q:Z&H<BJA*G)H8"I
MRIR!K,:;@:W$FX&MQ)N!K<2;@:W$FX&MQ)N!K<2;@:W$FX&MQ)N!K<2;@:W$
MFX&MQ)N!K<3_GC8:_YQ$+O^<2C__HDE,_Z9*6?FI3&7QK$]QZJY4?>.O68C=
MKF*1UJUKFM&J=:++I7VKP9V#M+F6B;RRD9#!K(R6QJ>)G<BCAZ;*FX.HRYB#
MJ\>6A*W%EH2MQ9:$K<66A*W%EH2MQ9:$K<66A*W%EH2MQ9:$K<66A*W%EH2M
MQ9:$K<7_GC8:_YQ#+O^=23__HTA+_Z=)6/JK2V3RKDYPZ[%2>^2S5X7?M&".
MV;-JEM&Q=9[&J'NKO*"!M+.:A[RLE(W"II"4QJ"-F\F<BZ3+EH>HRY.'J\B2
MAZS%DH>LQ9*'K,62AZS%DH>LQ9*'K,62AZS%DH>LQ9*'K,62AZS%DH>LQ9*'
MK,7_GS8:_YQ#+O^>2#__HT=+_ZA(5_NM26/SL$QO[+10>>:X5H/ANUZ+VKMJ
MDLVT<Y[!JWFJMZ1_M*Z=A+RFF(K!H)21QIJ1F,F6CZ'+D8RHS(^*JLB.BJS&
MCHJLQHZ*K,:.BJS&CHJLQHZ*K,:.BJS&CHJLQHZ*K,:.BJS&CHJLQHZ*K,;_
MGS8:_YQ#+O^>1S[_I$9*_ZI&5ORN2&+TLTMM[KA/=^B]57_AP5Z&UL!LCLBW
M<9V]KG>JLJ=]M*FA@KNAG(C!FIB/QI26ELF0E)_+C)*HS(J/JLF*CJS&BHZL
MQHJ.K,:*CJS&BHZLQHJ.K,:*CJS&BHZLQHJ.K,:*CJS&BHZLQHJ.K,;_GS8:
M_YQ#+O^?1C[_I45*_ZM%5?RP1F'VMDEK\+Q.=.?"57O?R&& T<-JC<2Z<)VX
MLG6IK:M[LZ.E@+N;H8;!E)V-Q8Z;E,B*F9W*AIFHRX:4JLF&DJO&AI*KQH:2
MJ\:&DJO&AI*KQH:2J\:&DJO&AI*KQH:2J\:&DJO&AI*KQH:2J\;_GS4:_YU"
M+O^@13W_IT1)_ZU#5/ZS1%_WND=H[\%-<.7)5G7<SF1ZS,9IC;Z^;IRRMG2H
MI[!YLIZK?KJ5IH3 CJ.+Q(BADL>$GYK)@)^GRH&:JLB"F*O&@IBKQH*8J\:"
MF*O&@IBKQH*8J\:"F*O&@IBKQH*8J\:"F*O&@IBKQH*8J\;_H#4:_YU"+O^A
M1#W_J$)(_Z]!4_^V0EWWOD9E[,=-:^/26&W6TV%ZQ\IGC+G";9NLO'*GH;9W
ML9BQ?;F/K8*^B*J)PX*HD,9]IYG(>J>ER7NBJ\A]GJS&?9ZLQGV>K,9]GJS&
M?9ZLQGV>K,9]GJS&?9ZLQGV>K,9]GJS&?9ZLQGV>K,;_H#4:_YU"+O^B0CS_
MJD!'_[(^4?VZ0%GSPT1@Z,].8]_<66?/V&!YP,]FBK+(:YJFPG"FF[QVKY&X
M>[>)M8&\@K*'P'VPCL-XKI;%=JVAQG6LK,9WIJW%=Z:MQ7>FK<5WIJW%=Z:M
MQ7>FK<5WIJW%=Z:MQ7>FK<5WIJW%=Z:MQ7>FK<7_H#0:_YY!+O^D0#O_K#U%
M_[4[3O>_/E7LRT19X=I/6M3?46S&VEI]N--BBZO.:9B?QG&DE<!WK8Z[?K2'
MMX.Y@;2'O7RRC+]YL9/!=K";PG2PIL)RL*W"<K"MPG*PK<)RL*W"<K"MPG*P
MK<)RL*W"<K"MPG*PK<)RL*W"<K"MPG*PK<+_H3,:_YY!+_^G/3K_L#I#_;HX
M2O#&.T_CU45.U>%&7\CB2W&ZW5*!K-5;CY_,9IN6QG"DC\!XJXJ\?[&$N8.U
M@+>'N'RVB[MYM)"\=[27O7:TH;UTLZ6^=+.EOG2SI;YTLZ6^=+.EOG2SI;YT
MLZ6^=+.EOG2SI;YTLZ6^=+.EOG2SI;[_HC,:_Z ^+O^J.3?_M#4_]L U1.?/
M.477WSQ0R>=!9+OE1G:LW$Z%G]-:DI7,9YR.QG&DBL)YJH6_?JZ O(*R?;J&
MM'JYBK9WN(ZX=;>3N7.WFKESMZ"Y<[>@N7.WH+ESMZ"Y<[>@N7.WH+ESMZ"Y
M<[>@N7.WH+ESMZ"Y<[>@N7.WH+G_HS(:_Z,Z+/^N-#3^NC$Z[<HP.]K=,C_*
MYSA5O.P]::WE1'F?VTZ'E--<DHW,:)N(R'*AA,1YIH#"?:I\P(&M>;Z%KW>]
MB+!TO(NR<KN0LW"[E;1ONIJT;[J:M&^ZFK1ONIJT;[J:M&^ZFK1ONIJT;[J:
MM&^ZFK1ONIJT;[J:M&^ZFK3_I# :_Z<U*O^T+S#TPRHQWM@K+<SF+D6]\C5:
MK>X[;)_D1'N3VU&'B]1>D(;/:IB"RW.=?LAXH7K&?*1WQ("F=<.#J'/"AJEQ
MP8FK;\"-K&W DJULOY6M;+^5K6R_E:ULOY6M;+^5K6R_E:ULOY6M;+^5K6R_
ME:ULOY6M;+^5K6R_E:W_I2\:_ZTM)?R\)RCET"$DSN0D,[[Q+$JN^#-=H.T]
M;9/D1WJ*W52%@]=AC'_2;))[SW*7=\UWFG3+>YQRRGZ><,F!H&[(A*%MQX>B
M:\:*HVG&CJ1HQ9&E:,61I6C%D:5HQ9&E:,61I6C%D:5HQ9&E:,61I6C%D:5H
MQ9&E:,61I6C%D:7_IRP:_[4E'^S)&AS0XADAO_ B.*_]*TV@^#5>D^Y!;(GF
M37>!X%B ?=QDAGC8:XMSU7&.<--UD6[2>9-LT7R4:M!_EFG/@I=HSX689LZ(
MF67-C)IDS8Z:9,V.FF3-CIIDS8Z:9,V.FF3-CIIDS8Z:9,V.FF3-CIIDS8Z:
M9,V.FF3-CIK_KB06]<$7%-3?#A# [Q@FL/TC/*'_+4Z4^3I=B?%':('K4G%Z
MYEUX=.)D?7#?:X%MW7"$:MQTAFC;>(AFVGN)9=E]BF38@(MBV(.,8=:%C6#6
MB8Y?U8N.7]6+CE_5BXY?U8N.7]6+CE_5BXY?U8N.7]6+CE_5BXY?U8N.7]6+
MCE_5BX[^N18-U-(+!L+N#A:Q_!DJHO\E/93_,DR)_$!9@?9-8GKP6&ES[%]O
M;.ED<VCG:G9FY6]Y9.1S>F+C=GQAXWE]8.)[?E_A?GY>X8!_7>"#@%S@A8%;
MWXB!6]^(@5O?B(%;WXB!6]^(@5O?B(%;WXB!6]^(@5O?B(%;WXB!6]^(@5O?
MB('4R D#Q-<*![+[$!FC_QPKE?\H.XK_.$B!_T52>OQ26G+W66!K]%YD9O)D
M:&+P:6I@[FUL7NUQ;5SM=&Y;['9O6NQY<%GK>W%8ZWUQ6.I_<E?J@G-6Z81S
M5NF$<U;IA'-6Z81S5NF$<U;IA'-6Z81S5NF$<U;IA'-6Z81S5NF$<U;IA'/$
MS0@!M-T("Z3_$AJ7_Q\JB_\N-H'_/4%Y_TI)<?]24&G_6%5C_5U87_MC6USY
M9UU:^&M?6/=N8%?W<6%6]G1A5?9V8E3U=V-3]7EC4_1\9%+T?F11](!E4?2
M95'T@&51](!E4?2 95'T@&51](!E4?2 95'T@&51](!E4?2 95'T@&7_EC,4
M_Y5#)?^243?_EU-%_YE74_V96V#UF&%M[95H>>62<H3?CWR.VHR%EM6'BYS1
M@Y"ASX"5ILU]FJG+>YZKRGFAK<EWI:_(=:FPQW2NL<=SL[+&<[JRP76[LL%U
MN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+_EC,4_Y5#
M)?^243?_EU-%_YE74_V96V#UF&%M[95H>>62<H3?CWR.VHR%EM6'BYS1@Y"A
MSX"5ILU]FJG+>YZKRGFAK<EWI:_(=:FPQW2NL<=SL[+&<[JRP76[LL%UN[+!
M=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+_EC,4_Y5#)?^2
M43?_EU-%_YE74_V96V#UF&%M[95H>>62<H3?CWR.VHR%EM6'BYS1@Y"ASX"5
MILU]FJG+>YZKRGFAK<EWI:_(=:FPQW2NL<=SL[+&<[JRP76[LL%UN[+!=;NR
MP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+_EC,4_Y5#)?^243?_
MEU-%_YE74_V96V#UF&%M[95H>>62<H3?CWR.VHR%EM6'BYS1@Y"ASX"5ILU]
MFJG+>YZKRGFAK<EWI:_(=:FPQW2NL<=SL[+&<[JRP76[LL%UN[+!=;NRP76[
MLL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+_EC,4_Y5#)?^243?_EU-%
M_YE74_V96V#UF&%M[95H>>62<H3?CWR.VHR%EM6'BYS1@Y"ASX"5ILU]FJG+
M>YZKRGFAK<EWI:_(=:FPQW2NL<=SL[+&<[JRP76[LL%UN[+!=;NRP76[LL%U
MN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+_EC,4_Y5#)?^243?_EU-%_YE7
M4_V96V#UF&%M[95H>>62<H3?CWR.VHR%EM6'BYS1@Y"ASX"5ILU]FJG+>YZK
MRGFAK<EWI:_(=:FPQW2NL<=SL[+&<[JRP76[LL%UN[+!=;NRP76[LL%UN[+!
M=;NRP76[LL%UN[+!=;NRP76[LL%UN[+_EC,4_Y5#)?^343?_EU-%_YE64OV9
M6V#UF&!M[99G>>63<83?D'N.VHV$EM6(BIS1A)"BSX"5ILQ]F:G+>YVLR7FA
MKLAWI:_(=JJQQW2NLL=SM++$=+JROW6ZLK]UNK*_=;JROW6ZLK]UNK*_=;JR
MOW6ZLK]UNK*_=;JROW6ZLK]UNK+_EC,4_Y9#)?^54#?_F5%$_YM44OZ<6%_U
MFUUL[9ED>.:6;(/?DW:-VH^ EM2,B)W1AXZCS8.3J,N F*O)?9RNR'JAL<9X
MI;+&=ZJTQ76PM<5TN+6]=[BUN'>XM;AWN+6X=[BUN'>XM;AWN+6X=[BUN'>X
MM;AWN+6X=[BUN'>XM;AWN+7_ES,4_Y9#)?^63C?_FD]$_YU24?Z>55[VGEIJ
M[IQ@=N>:9X+@EG*,VI)[E=2.A)W0BHNCS8:1J<J"EJW(?INPQGN@L\5YIK7$
M=ZRVPW:SM[YWM[>W>+:XLGFVN+)YMKBR>;:XLGFVN+)YMKBR>;:XLGFVN+)Y
MMKBR>;:XLGFVN+)YMKC_F#,4_Y=#)?^733?_FTU#_Y]04/^@4UWWH%AI[Y]=
M=>B=9(#AFFZ+VY9WE-61@)S0CHFCS(F/J<F$E:['@)JRQ7V@M<-ZI[?">*ZY
MP'>UN;AXM;FQ>;6YK'JUN:QZM;FL>K6YK'JUN:QZM;FL>K6YK'JUN:QZM;FL
M>K6YK'JUN:QZM;G_F#,4_YA#)?^83#;_G$Q#_Z!.3_^B45SXHU5H\*);=.FA
M87_BGFJ)W)ISD]:5?)O1D86CS(R,J<F'DZ_&@IFSPWZ@M\)ZJ+G!>+&[N7BS
MO+%YL[NK>K2[IWNUNJ=[M;JG>[6ZIWNUNJ=[M;JG>[6ZIWNUNJ=[M;JG>[6Z
MIWNUNJ=[M;K_F3,4_YA#)?^92S;_GDM"_Z%,3O^D3UOYI5-F\:58<NJD7GWC
MHF:'W9YPD=>9>)G2E8&AS8^)J<F*D:_%@YBTPG^?N+U\I[NZ>K"]LGJROJM[
MLKVF?+.\HWVTNJ-]M+JC?;2ZHWVTNJ-]M+JC?;2ZHWVTNJ-]M+JC?;2ZHWVT
MNJ-]M+K_F3,4_YA#)O^92C;_GTI"_Z-+3O^F3EGZJ%%E\JA6<.NH7'OEIV*%
MWZ-LCMF?=9?3FGZ?S9.&J,6-C:^_AY2UN8.<N;5_H[RQ?:R^K'RQOZ5\L;^A
M?K.]GGZTNYY^M+N>?K2[GGZTNYY^M+N>?K2[GGZTNYY^M+N>?K2[GGZTNYY^
MM+O_F3,4_YE#)O^:237_H$A!_Z1)3?^G3%CZJE!D\ZM4;NVL6GGFK&""X*II
MB]JF<Y3/GWR=QI>#J+Z0BK"XBY&VLH:8NJV#H+VI@:B_I8"PP)]_L,"<@+*]
MFH&SNYJ!L[N:@;.[FH&SNYJ!L[N:@;.[FH&SNYJ!L[N:@;.[FH&SNYJ!L[O_
MFC,4_YE#)O^;2#7_H4=!_Z5(3/^I2E?[K$YB]:]2;.ZP6';HL5Y_W[!HB-6L
M=)#*HWJ=P)N!J+B4A["QCXZVJXJ5NZ:'G;ZBA:7 GX2OP9F!K\&7@K*^E8.S
MO)6#L[R5@[.\E8.SO)6#L[R5@[.\E8.SO)6#L[R5@[.\E8.SO)6#L[S_FC,4
M_YE#)O^<1S7_HD9 _Z='2_^K25;]KTQ@]K)1:NZT5W/EMUY\W;9J@\^O<I#%
MIGB=NYY^I[*8A;"KDXNVI8Z3NY^+FKZ;B:+!F(BLPI.%K\*2AK&_D8:SO)&&
ML[R1AK.\D8:SO)&&L[R1AK.\D8:SO)&&L[R1AK.\D8:SO)&&L[S_FC,4_YE"
M)O^<1C3_HT5 _ZA%2O^M1U7^L4I?];50:.NY5G#CO5YWV;MJ@,NR<)# J7:=
MMJ)\IZV<@J^EEXFVGI.0NYF/F+Z4C:#!D8RIPHV*KL*-B;&_C8FRO8V)LKV-
MB;*]C8FRO8V)LKV-B;*]C8FRO8V)LKV-B;*]C8FRO8V)LKW_FS,4_YI")O^=
M133_I$0__ZI$2?^O15/\M$E=\KE/9>F^5FSAPV!RT[YI@,:U;H^[K72<L*9Z
MIZ>@@*^?FX:UF)>.NY.5E;Z.DIW!BI*GPHB0KL*(CK# B(VRO8B-LKV(C;*]
MB(VRO8B-LKV(C;*]B(VRO8B-LKV(C;*]B(VRO8B-LKW_FS,4_YI")O^>1#/_
MI4(^_ZM"2/^Q1%+ZMTA:\+U.8>;$5F?>R6)MSL%G?\&Y;8ZVL7*;JZIXIJ*E
M?JZ9H(2UDIV+NHR:D[Z'F)O A)>DPH*6K\*#D[# A)&ROH21LKZ$D;*^A)&R
MOH21LKZ$D;*^A)&ROH21LKZ$D;*^A)&ROH21LK[_FS,4_YI!)O^?0C/_ID ]
M_ZU 1_^T0D_WNT=7[<--7>3,6&#9S6!LR<5F?KR]:XVPM7&:I:]VI9RJ?*V3
MIH*TC**)N8:@D+V!GIF_?9ZBP7N>K\%]F;# ?Y:ROG^6LKY_EK*^?Y:ROG^6
MLKY_EK*^?Y:ROG^6LKY_EK*^?Y:ROG^6LK[_G#,4_YI!)O^@03+_J#\\_[ ^
M1?^W04WTP$53ZLE.5N+56E?2T5YKQ,ED?;;!:HRJNV^9G[5TI):P>JR-K("R
MAJF'MW^GCKMZII:^=Z6@OW2FK;]WH;&_>IVROGJ=LKYZG;*^>IVROGJ=LKYZ
MG;*^>IVROGJ=LKYZG;*^>IVROGJ=LK[_G3,4_YM!)O^B/S'_JCPZ_[,\0ON[
M/DGPQD1-YM)/3=S<5U;,U5UJOLUC>[#':(NDP6V7F;QSHH^X>*J&M'ZP?[*%
MM7FPC+ATKY6[<:Z?O&ZOJ[UQJK.\=*6SO'2EL[QTI;.\=*6SO'2EL[QTI;.\
M=*6SO'2EL[QTI;.\=*6SO'2EL[S_G3,4_YM )O^D/##_K3DX_[8Y/_7!/$/I
MSD1$WMU-1]+@4UC%VUQHM]-A>JG-9HF<R&N5D<1QGXC =J=_O7VM>+N$L7.Z
MB[1ON)2W;+>=N&JWJ+EIMK:X;:^UN6VOM;EMK[6Y;:^UN6VOM;EMK[6Y;:^U
MN6VOM;EMK[6Y;:^UN6VOM;G_GC(4_YT^)?^G.2[_L38U^[PV.NW).CS@VD0Z
MTN)'3,?B35ZYWE1NK-E;?)_48HB4T&B3BLQOFX+'=Z)\PWZH=L"$K'*^BJ]O
MO)&Q;;R8LFN[H;-JNZVR9[JVM&>ZMK1GNK:T9[JVM&>ZMK1GNK:T9[JVM&>Z
MMK1GNK:T9[JVM&>ZMK3_GS(4_Z Z)/^J-"S_M3(Q\\,R,^/4.##3X3P_QNA"
M4KGE2&.LXDURG]]4?Y/978J)TF>3@\UPFGW)=Y]XQGVD=,2#IW#"B*ENP8ZK
M;,"4K&J_FZUIOZ6M:+^NK6B_KJUHOZZM:+^NK6B_KJUHOZZM:+^NK6B_KJUH
MOZZM:+^NK6B_KJW_H# 4_Z,V(O^O,"C[O"TKZ,TL*-7@,##'Z3A$N>P^5ZSI
M16>>YTMUDN!3@(G97HF"U&B1?-!QEGC,=YMTRGV><,B"H6['AZ-KQ8NE:<20
MIFC$EJ=FPYZH9<.EJ&7#I:AEPZ6H9<.EJ&7#I:AEPZ6H9<.EJ&7#I:AEPZ6H
M9<.EJ&7#I:C_H2\4_Z@O'_^U*B+PQB0AV-TC(,CI+36Z\C5)K/$\6I[P0VF2
MZ$QUB.%5?X';88=[UVJ-=M-QD7+1=Y5OSWR7;,V FFK,A9MHRXF=9LJ-GF7)
MDI]CR9B@8LB>H6+(GJ%BR)ZA8LB>H6+(GJ%BR)ZA8LB>H6+(GJ%BR)ZA8LB>
MH6+(GJ'_HRT4_ZXI&OB_(!K>UA@3R>@B);KT*SJL^#1-GO<\7)+Q1FF(Z5!S
M?^-9>WK?9()TW&N&<-EQBFW6=HUJU7N/:--_D6;2@Y)DT8>48]&*E6'0CY9@
MSY277L^9F%[/F9A>SYF87L^9F%[/F9A>SYF87L^9F%[/F9A>SYF87L^9F%[/
MF9C_IR@2_[<?$N;.$0W+YA46N_0A*JS^*SZ>_S1.DOH_7(CR2F9_[%5O>>A>
M=7+D9'MNX6M^:M]P@6C>=81EW'F%8]M]AV+:@8A@VH2)7]F'BEW8BXM<UY",
M6]:4C5O6E(U;UI2-6]:4C5O6E(U;UI2-6]:4C5O6E(U;UI2-6]:4C5O6E(W_
ML!X+[<8.",W;"PB[\Q4:K/\A+I[_+#^2_S=-A_U$6'_V3V%X\5EH<>U?;6KK
M9'%GZ&IT9.=O=V+E='E@Y'AZ7^-[>UWC?GQ<XH%]6^&$?EKAB']9X(R 6."/
M@5C@CX%8X(^!6."/@5C@CX%8X(^!6."/@5C@CX%8X(^!6."/@5C@CX'SO0T$
MS,\) ;WE# RL_Q<>GO\D+Y+_+SV'_SU)?_])4GC\5%IP^%I?:?1?9&3R96=A
M\&II7N]N:USN<FU;[79N6NQY;UCL?'!7ZWYP5NN!<57JA')4ZHAS4^F+=%/I
MBW13Z8MT4^F+=%/IBW13Z8MT4^F+=%/IBW13Z8MT4^F+=%/IBW3,Q@@ O=0(
M ZWU#@^?_QH?D_\G+8C_-#E^_T)#=_]-2F[_4U!G_UE58OQ>6%[[9%M;^6A=
M6?AL7E?W<&!6]W-A5?9V8E3U>&)3]7MC4O1]9%'T@&10\X-E3_.&9D_SAF9/
M\X9F3_.&9D_SAF9/\X9F3_.&9D_SAF9/\X9F3_.&9D_SAF:]RP8 KML&!)__
M$!"3_QT=B/\J*'[_.#)V_T0Z;?]+067_449?_U=)6_]=3%C_8DY5_V904_]J
M45+_;5)0_W!33_]R5$[_=51-_W=53?]Y54S^>U9+_GY72OV!5TK]@5=*_8%7
M2OV!5TK]@5=*_8%72OV!5TK]@5=*_8%72OV!5TK]@5?_C2T._XP^'?^*3"[_
MDE,[_Y172/^57%3]DV)@]9%J:^^-<G;IB7Q_Y(6$AN" BXW<?)&2VGF7EMAV
MG)G5<Z";U'&EG=-OJ9_2;JZ@TFVSH=%LN:+1:\"CS6S%H\ANQJ+(;L:BR&[&
MHLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+_C2T._XP^'?^*3"[_DE,[
M_Y172/^57%3]DV)@]9%J:^^-<G;IB7Q_Y(6$AN" BXW<?)&2VGF7EMAVG)G5
M<Z";U'&EG=-OJ9_2;JZ@TFVSH=%LN:+1:\"CS6S%H\ANQJ+(;L:BR&[&HLAN
MQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+_C2T._XP^'?^*3"[_DE,[_Y17
M2/^57%3]DV)@]9%J:^^-<G;IB7Q_Y(6$AN" BXW<?)&2VGF7EMAVG)G5<Z";
MU'&EG=-OJ9_2;JZ@TFVSH=%LN:+1:\"CS6S%H\ANQJ+(;L:BR&[&HLANQJ+(
M;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+_C2T._XP^'?^*3"[_DE,[_Y172/^5
M7%3]DV)@]9%J:^^-<G;IB7Q_Y(6$AN" BXW<?)&2VGF7EMAVG)G5<Z";U'&E
MG=-OJ9_2;JZ@TFVSH=%LN:+1:\"CS6S%H\ANQJ+(;L:BR&[&HLANQJ+(;L:B
MR&[&HLANQJ+(;L:BR&[&HLANQJ+_C2T._XP^'?^*3"[_DE,[_Y172/^57%3]
MDV)@]9%J:^^-<G;IB7Q_Y(6$AN" BXW<?)&2VGF7EMAVG)G5<Z";U'&EG=-O
MJ9_2;JZ@TFVSH=%LN:+1:\"CS6S%H\ANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&
MHLANQJ+(;L:BR&[&HLANQJ+_C2T._XT^'?^,3"[_E%,[_Y561_^66U3]E6%@
M]I)H:^^/<'7IBWI_Y(>#A]^"BHW<?I"2V7J6E]9WFYK5=*"=TW*EG])PJ:'1
M;JZBT&VTH]!LNJ30;,*DRF[$I,1OQ*3$;\2DQ&_$I,1OQ*3$;\2DQ&_$I,1O
MQ*3$;\2DQ&_$I,1OQ*3_CBT._XX^'?^.2R[_E5$Z_YA41_^86%/^F%Y?]I5D
M:N^2;'7ICG9^Y(J A]^%AX[;@(Z4V'R4F-5YFIS3=I^?T7.DHM!QJJ3/;Z^E
MSFZVILYMO:?*;L*GPW#"I[UQPJ>]<<*GO7'"I[UQPJ>]<<*GO7'"I[UQPJ>]
M<<*GO7'"I[UQPJ?_CRT._XX^'O^02BW_ET\Z_YE11O^;5E+^FEM>]YAA:?"5
M:'3JD7%^Y(Y\AM^)A([;@XN4UW^2FM1[F)[2=YZAT'2DI,YRJJ;-<+&HS6^Y
MJ<MOP:G#<<&IO'+ JK=SP*JW<\"JMW/ JK=SP*JW<\"JMW/ JK=SP*JW<\"J
MMW/ JK=SP*K_CRT._X\^'O^22BW_F$TY_YM/1?^=4U'_G5A<^)M>:/&997+J
ME6U\Y)%WAM^,@8[;AXF5UH&0FM-]EI_0>9VCSG6CILURJZG,<+.JRV^]J\5R
MOZN]<[^LMG2^K+%UOJVQ=;ZML76^K;%UOJVQ=;ZML76^K;%UOJVQ=;ZML76^
MK;%UOJW_D"T._Y ^'O^322W_F4PY_YU.1/^?45#_GU9;^9Y<9O*<8G'KF&E[
MY91SA."/?8W;BH:4UH2-F])_E:#/>IRES7:CJ,MSJZO*<;6MQG&^K;YTO:ZV
M=;VNL':]KJQWO:ZL=[VNK'>]KJQWO:ZL=[VNK'>]KJQWO:ZL=[VNK'>]KJQW
MO:[_D"T._Y ^'O^522S_FTHX_YY,0_^A3T__HE1:^J%99?.@7V_LG69YYIAO
M@^"3>8S;CH*3UH>*F]*!DJ'/?)JFRGBBJL=UJZW#<[2OOW.\L+=UO+"P=[NP
MJGB[L*=YO+"G>;RPIWF\L*=YO+"G>;RPIWF\L*=YO+"G>;RPIWF\L*=YO+#_
MD2T._Y$^'O^62"S_G$@W_Z!*0O^C34W_I%)8^Z578_2D76WNH6-WZ)YK@.*8
M=8G<DGZ2TXR'FLR&CZ'&@)>GP7R>K+UYIJ^Y=J^QMW:ZLJ]WNK*J>;JRI7JZ
MLJ)[N[&B>[NQHGN[L:)[N[&B>[NQHGN[L:)[N[&B>[NQHGN[L:)[N['_D2T.
M_Y$^'O^81RS_G4<W_Z%(0?^E2TS_IU!6_*A58?6H6VOMIV%TY:1I?MZ?<X?4
MF'V0RY&$FL2*C**^A).HN(":K;1\HK"P>JNSK7FUM*AZN;2D>[FTH'VYLYU]
MNK.=?;JSG7VZLYU]NK.=?;JSG7VZLYU]NK.=?;JSG7VZLYU]NK/_DBT._Y(^
M'O^81BO_GD8V_Z-'0?^G24O_JDY5^JM37O*L66CIK&!QXJEH>MFE<X/-G'J/
MQ96!FKV.B**WB)"IL827KJR G[&H?J>TI7VQM:%]N+:=?KBUFG^YM)F NK.9
M@+JSF8"ZLYF NK.9@+JSF8"ZLYF NK.9@+JSF8"ZLYF NK/_DBT._Y(^'O^9
M12O_GT0U_Z1%0/^I2$G_K$Q3^*Y27.^P6&7FL5]MWK!I=M*I<8+(H'B/OYA^
MFK>2A:*PC(RIJHB4KJ2%G+*@@J2UG8&NMIJ M[>7@;>VE8*YM)2"N;.4@KFS
ME(*YLY2"N;.4@KFSE(*YLY2"N;.4@KFSE(*YLY2"N;/_DRT._Y(]'O^:1"K_
MH$,U_Z9$/O^K1DC_KDM1];)06>RU5V'DMUYIVK1I<\VL;X+"I':/N9Q\F;&6
M@Z*JD8JIHXR1KIZ)F;*9AZ&UEH6KMY.%MK>1A+>WD(6XM9"%N;20A;FTD(6Y
MM)"%N;20A;FTD(6YM)"%N;20A;FTD(6YM)"%N;3_DRT._Y,]'O^;0RK_HD(T
M_ZA"/?^M14;\L4I/\K5/5NFZ5EWAO6!DU+AG<LBO;8&]IW2.M*!ZF:N:@**D
ME8>IG9&.KI>.EK*2BY^UCXJHMXR*L[B+B;>WBXBXM8N(N;2+B+FTBXBYM(N(
MN;2+B+FTBXBYM(N(N;2+B+FTBXBYM(N(N;3_DRT._Y,]'O^<02K_HT S_ZE!
M//^O1$7ZM$A,\+I.4^>_5EG>PF!@S[MF<<.S;(&XJW*.KJ1XF*6>?J&>FH2H
MEY:,KI&3E+*,D9RUB(^FMX6/L;B%CK:WAHVXMH>,N+6'C+BUAXRXM8>,N+6'
MC+BUAXRXM8>,N+6'C+BUAXRXM8>,N+7_E"P._Y0]'O^=0"G_I#XR_ZL_._^Q
M0D+XN$=)[;Y.3^7&5U/:QEY?R[YD<;ZV:H"SKW"-J:EVF*"C?*&8GX*HD9N)
MK8J9DK*%EIJU@96DMW^5KK=^E+>W@9&WMH*0N+6"D+BU@I"XM8*0N+6"D+BU
M@I"XM8*0N+6"D+BU@I"XM8*0N+7_E"P._Y0]'O^>/RC_ICTQ_ZT^.?^T04#T
MO$9%Z\1-2>+.6$O3REQ>QL)C<+FZ:'^NM&Z,HZYTEYJI>I^2I8"GBJ&'K(2?
MC[%_G9>T>YRAMGB;K+=WF[>V>I>XM7R5N;1\E;FT?)6YM'R5N;1\E;FT?)6Y
MM'R5N;1\E;FT?)6YM'R5N;3_E2P._Y4]'O^@/2?_J#LP_[ \-_VX/SSQP41
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M8_\Z)%S_0BA6_TDL4?]/+T[_53%+_UHS2/]>-4;_8C9$_V8W0_]I.$'_;#A
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M/#;_ISTU_[$^-/^^/C/_RC\S_\H_,__*/S/_RC\S_\H_,__*/S/_RC^XL@
MJKT  )W*  "1V ( B/L- 7__&0)V_R0&;O\M#&;_-1)?_SP76/]#&U/_21Y.
M_T\A2O]5)$;_6R9#_V G0/]F*3[_:RH[_W(K.?]Y+3;_@2XT_XHO,?^4,##_
MG#$N_Z4R+?^O,RS_MS,L_[<S+/^W,RS_MS,L_[<S+/^W,RS_MS.KN   GL4
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M6S/Y=F0Z]7!N0?%L>4CM:(--ZF2,4>=AE57E7YU8XUVE6N%;K5S>6K9>W%G
M7]I9SF#56>)@T5GO8<I:]&+"7/1CO%WT9+=>\V2V7_-DME_S9+9?\V2V7_-D
MME_S9+9?\V3_7"0#_V,F!/]O)@7_>R\+_X(Y$?^&01C_ATD@_X51*/B"63#R
M?6 X[7=J0.AR=4?D;G]-X6F(4MUFD5?98YE:U6"A7=)?J&#/7;%BS5R[8\M<
MQV3)7-MEQ5WK9;]=\F:X7_%GLV#Q9Z]A\6>N8O%GKF+Q9ZYB\6>N8O%GKF+Q
M9ZYB\6?_720#_V8D!/]R) 7_?BX*_X<W$/^+/Q;_C$<=^8M/)?*(5BWL@UTV
MYGYG/N!X<4;;<WM-U6Z#4]!JC%C,9Y1=R66<8,9CHV/#8:QEP6"U9[]?P6B]
M7]!INF#F:;5A[VJO8N]JJV/O:J=D[VFF9?!IIF7P::9E\&FF9?!IIF7P::9E
M\&G_7B,#_VDB!/]V(P3_@BP)_XLV#O^//A3]D44;])%,(NV.4RKFBEHRWX5E
M.]=^;470>'9-RW1_5,9PAUK";(]>OVF78KMGGV6X9:=HMF2P:K-CNVNQ8\IL
MKV/A;*MD[6VF9NULHV?M;*!H[FN?:.YKGVCN:Y]H[FN?:.YKGVCN:Y]H[FO_
M7R,#_VL@ _]Y(@3_A2L(_XXT#/^3/!+XED,8[Y9*'N>54";@D5@NUXIA.LZ$
M:D7(?G--PGE[5;YU@UNY<8M@M6Z29+)LFF>O:J-JK&BL;*EGMFZG9\1OI6?:
M;Z)HZV^>:>QOFVKL;IEK[6V8:^UMF&OM;9AK[6V8:^UMF&OM;9AK[6W_7R,#
M_VX> _][(03_B"H'_Y$R"_^7.@_TFD$5ZYM'&N.;32':EE4MSX]>.<B)9T3!
M@V]-NWYW5;9Y?UNQ=H=@K7./9:EPEFBF;I]LHVRH;J!KLG"=:\!QG&O2<IIL
MZ7&7;>IPE&WK<))N[&^2;NQNDF[L;I)N[&Z2;NQNDF[L;I)N[&[_82$#_W =
M _]^( /_BRD&_Y4Q"?N;. WPGCX1YZ!$%M^@2AW3FE(KRI-<.,*-9$.[AVU-
MM()T5*]^?%NJ>H1AIG>+9:)TDVF><IMMFG"D<)=OKW*5;[QSDV_-<Y)PYG.0
M<.ERCG'J<8UQZW",<>MPC''K<(QQZW",<>MPC''K<(QQZW#_8R #_W(; _^
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M6DC%^UI(Q?M:2,7[6DC%^UKWD00 U*(" ,>O! "ZN0, L,0% *?0"0"?X1
MF.$A X_@, F&X#L2?=]$&W7>321NW54K9]Q<,F+;9#==VVL[6=IR/U7:>D-2
MVH-%3MJ-2$S:F$I)VJ5+2-NS3$?<Q$Q&W-Y,1MKM3$38^4]#V/M/0]C[3T/8
M^T]#V/M/0]C[3T/8^T_;F@  RJD" +NS @"PO0, I<D% )O6"0"4Z!0!C.DE
M!(3H,PM[Z#P4<^A$&VOH2R)DYU(H7N=9+5GG8#)5YV@U4N=O.$_G=SM,YX ]
M2>>)/T?HE$%$Z)]"0NFL0T'IND1 ZLU$0.KD1$#H]41 Y_A#0.?X0T#G^$-
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M9F^"\F5P@?-D<('S9'"!\V1P@?-D<('S9'"!\V3_:Q0!_WL2 ?^*$@#_EA(
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M7U><]U]7G/=?5YSW7U><]U__>@P _8L) -J;! #.IP8 Q+ & +RY! "UP0X
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M1<+_3D7"_T[?D   S)\  +^J 0"SLP$ J;T" )_'!0"6T@D CMH2 (C;) *
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M(S+^I"0Q_[$E,/^_)B__SR8N_^,F+O_C)B[_XR8N_^,F+O_C)B[_XR:MK0
MG[<  )+"  "&S0  >=H  '#R" !H_Q$ 8?\: 5K_(P-4_RL$3_\S!DK_.PA&
M_T(+0_])#4#_3PX]_U40.O];$3C_81,U_V@4,_]O%3#_>!8N_X(7+/^-&2K_
MF1HI_Z0:*/^O&R?_NAPF_\<<)O_''";_QQPF_\<<)O_''";_QQRAM   D[\
M (;*  !XU@  ;.(  &/\!P!<_P\ 5?\6 4__'@))_R8#1/\N!$#_- 4\_SL&
M.?]!!S;_1@@S_TP(,?]1"2[_5PHL_UT**O]D"RC_; PE_W4-(_]_#B'_B@\@
M_Y40'O^@$![_J!$=_[$1'?^Q$1W_L1$=_[$1'?^Q$1W_L1&5O   AL<  'G3
M  !KX   7NT  %;_ P!/_PP 2?\2 4/_&0$^_R ".?\G S7_+0,R_S,$+O\X
M!"O_/04H_T(%)O]'!23_3 8B_U$&(/]7!AW_7@<;_V4'&?]N"!?_> @5_X,(
M$_^-"1/_E@D2_YX)$O^>"1+_G@D2_YX)$O^>"1+_G@G_0BT#_T(R!/](,@3_
M3#8&_TX\"/]01P[_4%(5_TY?&O]+:Q__2'<D_T6#)_]"CBK_09<L_S^@+O\_
MIR__/JXP_SVU,?\]O#+_/,4R_SS.,_\[WS/_.^HT_SOS-/\[^S3_//\S_CS_
M,_P]_S3V/_\U]3__-?4__S7U/_\U]3__-?4__S7_0RP#_T0P!/]*, 3_3C0&
M_U$Z"/]31@[_4E$5_U%=&O].:2#_2W0D_TB */]%BRO_0Y4M_T*=+_]!I3#_
M0*PQ_S^S,O\_NC/_/L(T_S[,-/\^W#7_/>@U_SWQ-?\^^C7]/O\U^S__-/@_
M_S;R0?\W\$'_-_!!_S?P0?\W\$'_-_!!_S?_1"P#_T<N _]-+@3_43(%_U0Y
M"/]71 [_5D\5_U1:&_]19B#_3G(E_TM]*?](B"S_1I(N_T6;,/]$HC+_0ZDS
M_T*P-/]"MS7_0;\V_T')-O] US?_0.4W_4#P-_I ^#?W0?\V]D'_-_)!_SCL
M0_\YZD3_.>I$_SGJ1/\YZD3_.>I$_SG_12L#_TDL _]0+ 3_52\%_UDW"/]<
M0@[_6TT5_UA7&_]68R#_4F\E_T]Z*O],A2W_2H\P_TB8,O]'GS3_1J8U_T6M
M-O]%M#?_1+PX_D3&./Q$TCGY0^(Y]D3N.?-$]SGQ1/\Y[T3_.NM%_SOD1O\\
MXT;_/.-&_SSC1O\\XT;_/.-&_SS_1BL#_TTI _]4*03_62P%_UXU!_]A0 W_
M84H4_UY4&O]:7R#_5VLF_U1V*O]1@2[_3HLQ_DR4-/Q+G#7[2J,W^DFJ./A(
ML3GW2+DZ]D?"._5'S3OR1]\[[D?L.^M(]COI1_\]YT?_/N%(_S_:2O] V$K_
M0-A*_T#82O] V$K_0-A*_T#_1RH#_U G _]8)@/_7BH$_V,S!_]F/0W_9D<3
M_V11&O]@6R#_7&<F_5ER*_I6?2_X4X<S]E&0-?10F#?R3I\Y\4VF.^],K3SN
M3+4][$N^/>M+RC[I2]P^Y4SJ/>)+]3_?2_Y!W$K_0M1,_T/-3?]#RT[_0\M.
M_T/+3O]#RT[_0\M._T/_2B@#_U0D _]<(P/_8R@$_V@P!O]L.PO_;$02_VI.
M&?YF6!_Y86(E]5YM*_);>##O6((T[%:+-^I4E#GH4YL[YE&C/>51JC[C4+(_
MX4^[0.!/QT#>3]A!V4_H0=1/]$/03OY%SD[_1LA0_T;"4?]'P%'_1\!1_T?
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M6GQR_%E\<OQ7?'+]5WQR_5=\<OU7?'+]5WQR_5?_8A0!_W$1 ?]]$0#_B!(
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M5V>#_%=G@_Q79X/\5V>#_%?_; X _WL, /*)"0#9E08 SYX( ,FF" #!JQ
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M-4+.N#9!S\TU0<[H-4#-]3<_R_XY/LO_.3[+_SD^R_\Y/LO_.3[+_SG*E@
MO*(  *^J  "CLP  F+P  (W& P""SP< >-D+ '/>& !NWB8":-XS!6+>/@I=
MWD@/6=Y0%%7>6!=1WF ;3MYG'DO=;R!(WG@C1MZ!)4/>C"=!WI@I/]ZF*C[?
MM2H]X,@J/=_C*CS=\2L[W/LM.MS]+CK<_2XZW/TN.MS]+CK<_2[ GP  L:<
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M+?N^&BS[SQLK^^<;*_OK&RO[ZQLK^^L;*_OK&RO[ZQNHJ@  FK0  (V_  "
MR0  =-,  &?>  !>\@@ 6?X1 %/_&@%._R,"2?\K T7_,P1!_SH%/O]!!CO_
M1P<X_TX(-?]4"3/_6@DQ_V$*+_]I"RS_<@PJ_WT-*/^(#B;_E0\E_Z$0)/^N
M$2/_NA(B_\H2(O_0$B+_T!(B_] 2(O_0$B+_T!*<L@  CKP  (''  !ST0
M9]T  %GC  !3_08 3?\. $C_%@!#_QX!/_\F CK_+0(W_S,#,_\Y S#_/P0N
M_T0$*_]*!2G_4 4G_U8&)/]=!B+_90<@_VX''?]Y"!O_A0@:_Y()&?^>"1C_
MJ D7_[,)%_^W"1?_MPD7_[<)%_^W"1?_MPF0N@  @L4  '30  !GW   6.,
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M2XUC_TJ,9/])BV3_28MD_TF+9/])BV3_28MD_TG_6A,!_V80 /]Q$0#_>A(
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M3'1S_TQT<_],='/_3'1S_TS_8@X _V\, /Q["@#>A@8 U8X( ,^4"0#'F!$
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M0DVCM$-,H\A#3*/D0TNA]$-+H/]$2Z#_1$N@_T1+H/]$2Z#_1$N@_T3C?0
MSXL  ,*6  "WGP  K:8  *.M  "9M0  D+D. (NZ'@&$NBT#?;DY"7>X0Q!Q
MMDP7:[53'6:T6B)BLV$F7K)H*UJQ;RY6L'<R4["!-4^OBSA,KY<Z2JZD/$BN
MLSU'KL<]1Z[C/$:M\SU&J_X^1:O_/T6K_S]%J_\_1:O_/T6K_S_:@P  QY$
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M(#G7[R XU?DB-]3_(S?4_R,WU/\C-]3_(S?4_R.YG   JZ0  )^L  "3M0
MA[X  'O&  !PS@, 9=8' %WC#@!:XQL 5N,G 5+D,@).Y#P$2N1$!D?E30A%
MY54*0N5<#$#E9 X^YFP0.^9V$CGF@!0WYXP5->>9%C3GJ!<RZ+@8,NC,&#'H
MY1@QYO08,>7\&#'E_!@QY?P8,>7\&#'E_!BNH@  H:H  )2S  "(O0  >\8
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M!1'_O 41_[P%$?^\!1'_O 6,N   ?<(  &_,  !BV   5-\  $?E   ^\0
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M.:-3_SFB4_\YH53_.*%4_SBA5/\XH53_.*%4_SC_3Q0!_UD0 /]C$@#_:A0
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M$0#9?1@ SGTJ L5[.0:^=T4.MW10%;%P61RM;6(BJ&II)Z5H<2RA9G@OGF2
M,YMBAS:888\XEF"8.Y-?H3V17JL_CUZX0(U>R$&+7N%!BE_S0(E?_S^)8/\^
MB&#_/HA@_SV(8/\]B&#_/8A@_SW_5P\ _V(, /]L# #X= P Z7H, -Y^# #2
M@14 R($G <!_-@:X?$(-LGA-%:QU5ANG<E\BHF]F)YYL;BR;:G4PEVA\,Y1G
MA#:198PYCF25/(QCGCZ)8JA AV*U0H5BQ4*$8MY#@V/Q0H)C_4&"9/] @F3_
M/X)D_S^"9/\_@F3_/X)D_S__60X _V0+ /]N"@#J=P@ VWT( -2""@#,A!(
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M/7EPED!V;Z%"=&ZN1')NO45P;M%%<&_K1'!O^D-Q;_]!<6__0'%P_T!Q</]
M<7#_0'%P_T#_7P@ _VL$ .%V  #4?P, RX8% ,6+!@"^C0T M8\> *Z.+0.F
MC#H)GXE%$9F&3AB3@U8>CH!=)(E^9"F%?&LM@7IR,GUX>35Z=X(Y=W:+/'-U
ME3]Q=)]";G.L1&QSNT5K<\Y%:W/I1&MS^$-K<_]";'/_06QS_T!L<_] ;'/_
M0&QS_T#_804 ^FX! -UY  #0@@( QXD$ ,".! "YD0P L9(; *F2*P.BD#@(
MFXU##Y2*3!>.B%0=B85;(X2#8BB @6DM?']P,7A^=S5U?'\X<7N(/&YZDC]K
M>9U!:'BJ0V9XN$1E>,Q%97CG1&5X]T-F>/]"9GC_069X_T!F>/] 9GC_0&9X
M_T#_9 , [G$  -A\  #+A0( PXP# +N1 P"SE D K)88 *66* *=E#8'EI)!
M#I"/2A6*C5(<A(M:(G^)8"=[AV<L=X5N,'.#=31O@GTW;(&&.VE_D#YF?IM!
M8WZH0V%]MD1@?<E$7WWE0V!]]D)@??]!87W_0&%]_T!A??] 87W_0&%]_T#_
M9P  XW0  -)_  #'B $ OH\" +:5 0"NF 8 IIH5 )^:)@*8F3,&D9<_#(N5
M2!2%DU :?Y%8('J/7R5VC64J<HML+FZ*<S)JB'LV9H>$.6.&CCQ@A9D_782F
M05N$M$):A,=#6H3C0EJ#]$%;@_] 6X/_0%N#_S];@_\_6X/_/UN#_S__:@
MWG@  ,V#  #"C   N9,  +"8  "GG0( H)\2 )F?(P&3GC$%C)T\"X6;1A)_
MF4X8>I=6'G6672-PE&,H;))J+&B1<3!ED'DT88Z"-UZ-C#I:C)<]6(RD/U:+
MLD!4B\5 5(OA0%2*\S]5BOX_58G_/E6)_SY5B?\^58G_/E6)_S[O;P  UGP
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M,D2H[S)#I_LS0Z;_,T.E_S1#I?\T0Z7_-$.E_S30@0  P8X  +68  "IGP
MGJ4  ).L  "(L@  ?+D" ':Z$0!RNR$ ;KLN FB[.@9DND,*7[I,#ENY4Q)7
MN%H65+AA&5&W:1Q.MW$?2[9Z(DBVA"5%MI G0[6=*4&UK"I MKXJ/[;8*C^T
M[BH^L_HL/;+_+3VQ_RT]L?\M/;'_+3VQ_RW'B0  N94  *R=  "AI   EJL
M (JR  !_N   <[\# &K$# !GQ1H 8\4H 5_%-0-;Q3\%5\5("53$4 Q0Q%@/
M3<1?$DK#9A5(PVX71<-X&D+#@AQ PXX>/L.<'SS#JR [P[PA.L/5(3O"[B$Y
MP/DB.+__)#B__R0XO_\D.+__)#B__R2]D0  L)L  *2B  "8J@  C+$  ("Y
M  !UOP  :L8$ %[," !9SQ( 5] A %70+@%1T#D"3M!#!$O03 9)T%,(1M!;
M"T/08PU!T&L//M!U$3S1@!,ZT8P4.-&:%C;1J1<UT;L7--+2%S70[!8TS_<8
M,\[_&C/._QHSSO\:,\[_&C/._QJSF0  IJ$  )JI  ".L0  @;D  '7   !J
MQP  7LT# %34" !,W0T 2MT8 $C>)@!&WC(!1-\\ D+?10,_WTT$/>!5!3O@
M708YX&8(-^!O"37A>@HSX88,,>&4#3#BHPXNXK,.+N/'#BWCXPXMX/(.+-_[
M#RS?_1 LW_T0+-_]$"S?_1"HH   G*<  (^P  "#N   =L$  &K)  !>SP
M4]4! $G<!@!%Z0\ 0ND9 $#J)  ]ZBX .NLV 3CL/@$V[$8",^U- S'M50,O
M[ET$+>YE!2ON< 4I[WL&*.^)!R;PEP<E\*<()/&X""/QS @B\N4((O#S""+O
M]0@B[_4((N_U""+O]0B>I@  D:\  (2X  !WP0  :LD  %W0  !1UP  1MT
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M(\!!_R2^0?\DO4'_);U!_R6]0?\EO4'_);U!_R7_0A@!_TD3 /]0% #_5AD
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M,)14_S"45/\PE%3_,)14_S#_3PX _U@+ /]@"P#[9@P \&L- .1M#@#6;A8
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M.&EOM3IH;\<Z9V_B.F=O]#AH;_\W:&__-FAO_S9H;_\V:&__-FAO_S;_7@
MY&H  --T  #(?   OX$! +>% 0"OAP< J(D5 *&))0&;B#,$E(8^"8Z$1P^)
M@5 5A']7&G]^7AY[?&4B>'IL)G1Y<RIQ>'LM;G>$,&MVCC-H=9DV9G2E.&1S
MLSEB<\0Z8G/@.F)S\SAC<_\W8W/_-F-S_S9C<_\V8W/_-F-S_S;_80  X&T
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M-5&&[C52A?LT4H7_-%*%_S-2A?\S4H7_,U*%_S/C;   SGD  ,&#  "VBP
MK)$  **5  "7F0  CYL+ (J=& "$G2<!?IPT!'F;/@ASFD<-;YE/$FJ85A=F
MEUT;8Y5C'E^4:B)<DW(E69)[*%61A2M2D9 N4)"=,$Z0JS%,D+PR3)#3,DR/
M[3),COHR3(W_,4R,_S%,C/\Q3(S_,4R,_S'<<0  R'X  +N(  "QD0  II8
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M(CJL_R,ZK/\C.JS_(SJL_R/ A@  LY(  *>9  "<GP  D*8  (2L  !YL0
M;;<  &&\!0!=O1( 6KX@ %B^+0%4OC@"4;Y"!$Z^2@9,OE((2;Y9"D:^8 Q$
MOF@.0;UQ$3^]?!,\O8@5.KV5%CB]I!<WO;48-KW*&#>\YQ<UN_89-;K_&C2Y
M_QLTN?\;-+G_&S2Y_QNXCP  JI@  )^?  "3I@  AZP  'NS  !ON0  8[X
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M QOI^0.:I   C:P  '^U  !RO0  9<4  %G+  !,T   0=4  #C<   OX0(
M+?$- "OQ$P H\AP )O(D "3S*P B]#( (?0Y !_U00 =]4D &_91 !GW6@$7
M]V4!%?AR 13Y@0$3^9(!$OJB A'ZLP(0^\8"$/O= A#[Z0(0^^D"$/OI A#[
MZ0*/JP  @;0  '.]  !FQ@  6<T  $O3  ! V0  -=X  "SC   F\0  )/X*
M "'_$  ?_Q8 '/\< !G_(@ 7_R@ %?\N !/_-0 2_SP $/]#  [_3  -_U8
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M'JQ!_QZL0?\>K$'_'JQ!_Q[_0A$ _T<- /]/#@#_4Q$ _U85 /-7' #H5B4
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M+79>M2YU7L8O=%[A+W1?\RYT7_\L=&#_*W1@_RMT8/\K=&#_*W1@_RO_4P
MZ%X  -EG  #+;0  PW$! +MS @"U<PD K747 *=U)P&A=#0#FW(_!Y5P20N1
M;E(0C&Q9%(EJ8!B%:6<;@FAN'G]F=2%]97TD>F2%)G=DCREU8YHK<F*E+7!B
MLR]O8L0O;F+>+VYC\BYN8_XM;F/_+&YC_RMN8_\K;F/_*VYC_RO_50  Y6
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M8VO8,&-K[R]D:_PM9&O_+65K_RQE:_\L96O_+&5K_RST6P  W68  ,MO  #
M=@  MWL  *]^  "F?@$ GW\0 )F 'P"3@"T"C7\Y!8A]0PF#>TL-?GI3$GIX
M6A9V=V$9<W5G''!T;A]M<W8B:G)_)FAQB2AE<)0K8G"@+6!OK2]?;[TO7F_4
M+UYO[2]?;_LM7V__+&!O_RQ@;_\L8&__+&!O_RSK7@  V&D  ,=R  "\>0
MLW\  *N"  "A@@  F8,. )2$'0".A"L!B(,V!(."0 A^@$D,>7]1$'5]6!1R
M?%\8;GME&VMZ;!YH>70B97A])6)WAR=@=I(J776>+%MUJRY:=+LO6771+UET
M["Y9=/HM6G3_+%IT_RM:=/\K6G3_*UIT_ROF80  T6T  ,-V  "Y?0  KX,
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M)TF'_R=)A_\G28?_)TF'_R?1;P  P7L  +6$  "KC   H)   )64  ")EP
M?IH  '>;#@!SG!P ;YTI 6N<-0)FG#\%8IM'"%^:3PM<FE8/6)E<$E688Q53
MF&L74)=S&DV6?1U*E8D?1Y65(465I"-$E+,C0Y3((T.4Y2-#DO4D0Y'_)$.0
M_R1#D/\D0Y#_)$.0_R3*=0  NX$  +"+  "DD0  FI4  (^9  "#G0  =*(
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M$S"S_Q.RC@  I94  )J;  ".H@  @J@  '6M  !ILP  7K<  %.[  !'P 4
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M !CDB $7Y9H!%N:L 17FP $4Y]T!$^7O 1/C^@$3X_H!$^/Z 1/C^@&6H@
MB:D  'NQ  !NN0  8<   %3&  !(R@  /<\  #/3   JV0  (MX" ![K"@ <
M[!  &^T7 !GM'P 7[B8 %>XM !3O-0 3\#T $?!& !#Q4  /\EL #O)I  WS
M>  ,](H "_6<  KUK@ )]L( "?;9  CU[0 (]>T "/7M  CU[0"+J0  ?;(
M &^Z  !BP@  5<D  $?.   [T@  ,=@  "?=   ?X0  &>@  !;X!@ 4^@T
M$OL2 !#\%P ._!T #?TC  S]*0 *_C  "/\X  ;_00 #_TP  /]8  #_9@
M_W<  /^)  #_FP  _ZL  /^[  #_S@  _\\  /_/  #_SP!_L@  <;H  &/#
M  !6RP  2-$  #K6   OW0  )>$  !SE   4Z0  $?<   __ 0 -_PD "_\-
M  C_$  &_Q0  _\8  #_'@  _R,  /\J  #_,@  _SP  /]'  #_5   _V,
M /]S  #_A0  _Y<  /^D  #_L@  _[(  /^R  #_L@#_(BD!_R,G ?\C* '_
M("L!_QPQ ?\:/0'_&$D!_Q96 O\48@+_$VX"_Q)X O\2@@+_$HL"_Q*2 O\2
MF0+_$IX"_Q*D O\2J0+_$J\"_Q*V O\2O0+_$L<"_Q+4 OT2Y0+Z$O$"]Q+Z
M O43_P+T$_\#]!/_ _03_P/T$_\#]!/_ _03_P/_)"<!_R8D ?\F) '_)"<!
M_R(O ?\@.@'_'D8!_QQ3 O\:7P+_&&H"_Q=U O\7?P+_%X@"_Q>/ O\7E@+_
M%YP"_Q>A O\7IP+_%ZT"_Q>S _X7NP/]%\4#^A?1 _<7Y +T%^\"\1CZ N\8
M_P/N&/\$[AC_!.T8_P7M&/\%[1C_!>T8_P7_)R,!_RD@ /\I( #_*", _RDM
M ?\G-P'_)4,!_R-/ O\A6P+_'V8"_QUQ O\=>P/_'80#_QV, _X=DP/\')D#
M^QR? _H<I /Y'*H#]QRQ _8<N0/U'<(#\QW. _ =X0/L'>X#Z1[Y!.@>_P7F
M'O\&Y1[_!N4>_P?E'O\'Y1[_!^4>_P?_*Q\ _RT< /\M&P#_+B  _R\I /\O
M- '_+#\!_RI+ O\H5P+_)F("_25M _HD=P/X(X #]B.( _4CCP/S(Y4$\B.;
M!/$CH03O(Z@$[B.N!.TCM@3K([\$ZB/,!.<CX 3C).T$X"3Y!MXD_P?<)/\(
MVR3_"=HD_PG:)/\)VB3_"=HD_PG_+AL _S$7 /\R%@#_-1P _S8E /\V+P'_
M-#H!_S%& ?LO4@+W+5T"\RQH _ K<@/N*GL$["J$!.HJBP3H*I(%YRF8!>8I
MG@7D*:4%XRFL!>$IM 7@*KT%WBK*!=LJW@76*NT'TBKX"<\K_PK-*O\+S"K_
M#,LJ_PS+*O\,RRK_#,LJ_PS_,A< _S42 /\X$@#_.Q@ _ST@ /\\*@#^.S4!
M]SE! ?$V30+L-%@"Z#-C ^4R;03C,G8$X#%_!=XQAP7<,(X&VC"5!M@PFP?6
M+Z('U"^I"-(OL0C0+[H)SS#&"<TPV G),>H*QC'W#,,Q_P[!,?\/P#'_#[\Q
M_P^_,?\0OS'_$+\Q_Q#_-A, _SD/ /\^$ #_010 _T,: /]"(P#U02X [3XZ
M ><]1@'A/%,"W3I> ]DY: 34.'$&T3AZ!\\W@0C--X@)RS:/"LHVE@K(-IT+
MQC6D#,4UK S#-;4-P37 #< VSPZ]-N8.N3;T$+<V_Q&U-O\2M#;_$[,V_Q.S
M-O\3LS;_$[,V_Q/_.1  _ST+ /]##0#_1Q  _T@4 /5'' #K1B8 XT0R -Q$
M00'40TT"ST%8!,M 8@;(/VL(Q3YT"<,]>PO!/8,,OSR*#;T\D Z[/)</NCN?
M$+@[IQ"V.[ 1M3N[$K,[R1*Q.^ 3KCSQ%*L\_16I//\6J#S_%J@\_Q:G//\6
MISS_%J<\_Q;_/0T _T(( /]("@#_2PP ^DP/ .Q,% #A2AT UDHL ,Y+.P')
M2D@"Q$A3!,!'70>\1F8)ND1N"[=#=@VU0WT.LT*$$+%!BQ&P09(2KD":$ZQ
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M'XA.MR"'3L@AA4[B(81/\R"#3_\@@T__'X)0_Q^"4/\>@E#_'H)0_Q[_1P
M\U$  -]8  #170  R6 " ,-@! "]7@T M6 : *YA*@"I8#<"I%Y#!)]=30B;
M6U4+F%E=#I589!&25VL3CU9R%HU5>1B+5($:B%.)'(93DAZ$4IP?@E*G(8!2
MM")_4L0C?5+>(WQ3\2)\4_XA>U3_(7M4_R![5/\@>U3_('M4_R#_2@  Z50
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M)FE>["5J7_LD:E__(VI?_R)J7_\B:E__(FI?_R+P4@  W5T  ,ME  # :P
MMVX  *]O  "G;@$ H&\0 )IP'P"4<"P!CV\X XIM0@:&;$L)@FI2#'YI60][
M:& 2=V9F%'5F;A=R974:<&1^'6UCB!]K8Y(B:6*>)&=BJR5E8KHF9&+/)F1B
MZB9E8OHD96/_(V5C_R)E8_\B96/_(F5C_R+K50  V&   ,AH  "\;@  LW$
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M(U9O_R)7;_\B5V__(E=O_R+?7P  RFD  +QR  "R>   J7T  )]_  "2?@
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M&S^+_QO"<P  M7X  *J'  "?C   E)   (B3  ![E0  ;)D  &6;! !@G!
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M!R^QE@@NLJ8(+;*X"2RRT @LL.P)*Z_Y"BNN_PLJK?\+*JW_"RJM_PNMBP
MH)(  )68  ")G0  ?:,  '&H  !DK0  6;$  $VT  !"N   .[H* #B[$P W
MO!X -;PI #2],@ SO3L ,KU$ #&^3  OOE4!+KY> 2R^: $JOG0"*;Z" B>_
MD0,FOZ(#)+^T R._RP,CON@#([SW!"*[_P4BN_\%(KO_!2*[_P6DD@  F)@
M (R>  " I0  <ZL  &>P  !;M0  3[D  $2\   ZP   ,,0$ "K'"P HR!,
M)\D= ";))P ER3  ),HY "/*0@ BRTL (<M5 "#,7P ?S&P '<UZ !S-B@ ;
MS9P &<ZN 1C.Q0 8S>0 &,ST 1C*_ $8RO\"&,K_ AC*_P*;F0  CY\  (*F
M  !UK0  :+,  %RY  !0O0  1,$  #G$   PR   *,P! "#0!@ 9U0L %M<0
M !78&0 5V2( %-DK !/:-  3VCT $MM( !'<4P 1W5\ $-UM !#>?@ .WY$
M#N"D  W@N  ,X-( "]_M  S>]P ,W?L #-W[  S=^P"2GP  A:<  '>N  !J
MM0  7;P  %#!  !$Q0  .,D  "[-   ET0  'M4  !;: 0 1W@8 $.<-  [G
M$@ -Z!D #.@A  OI*0 *ZC$ ">H[  ?K10 %ZU$ !.M>  /K;@ !ZX   .J4
M  #JIP  Z[P  .O2  #KZ0  [.\  .SO  #L[P"'IP  >:\  &NW  !>O@
M4<4  $/)   WS0  +=$  "/6   ;VP  $]\   [C   ,[@( "O8*  ?V#@ %
M]A(  _88  #U'@  ]24  /4N  #U-P  ]D(  /9.  #V70  ]FX  /:!  #V
ME0  ]Z<  />W  #XQP  ^-   /C0  #XT ![KP  ;;@  &#   !2R   1,T
M #?1   KUP  (=P  !C@   1Y   #.<   ?O   $^@   ?\#  #_"   _PT
M /X0  #^%   _QH  /\A  #_*0  _S,  /\^  #_2P  _UL  /]L  #_@
M_Y(  /^A  #_K0  _[,  /^S  #_LP#_'"8 _QPD /\:)0#_%2< _Q$N /\0
M.@#_#D<!_PU3 ?\+7P'_"FL!_PIU ?\*?P'_"H<!_PJ. ?\*E0'_"IL!_PF@
M ?\)I0#_":L _PFQ /\)N #_"<$ _@G, /P)W@#Y">L ]0GV /,)_P#R"O\
M\0K_ ?$+_P'Q"_\!\0O_ ?$+_P'_'R, _Q\A /\>(0#_&20 _Q<L /\5-P#_
M$T0 _Q%0 ?\07 '_#F<!_PYR ?\.>P'_#H0!_PZ+ ?\.D@'_#I@!_PZ= ?\.
MHP'^#J@!_ ZN ?L.M0#Z#KX ^ [) /4.VP#R#NH [@[U .P._P'K#_\!Z@__
M >H0_P'I$/\!Z1#_ >D0_P'_(A\ _R(< /\A' #_'R  _Q\I /\<- #_&D
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M";DJ_PG_, \ _S(+ /\V#0#_.!  _SD5 /DW'@#O-2@ YS,U . R0@#;,D\
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M-P< _SL" /]  P#R0@4 Z4() .4_#@#8/A8 SD G ,=!-@#"040!O4%/ KE
M60.V/V$$M#YI!K$]<0>O/7@(KCQ_":P\A@JJ.XT+J3N5#*<[G0VE.Z8-HSJP
M#J([O ^@.\T/GCOF$)L\]1&://\1F3S_$9@\_Q&8//\1F#S_$9@\_Q'_.@$
M_T   .]%  #A2   V4@% --&"0#,11( Q$<B +U(,0"X2#\!LT=* K!&5 2L
M15T%JD1D!Z=#; BE0G,*HT)Z"Z%!@0R@08@-GD"0#YQ F!":0*$1F$"L$I=
MN!*50,@3DT#A$Y%!\Q200?\4CT'_%(Y"_Q..0O\3CD+_$XY"_Q/_/   ^40
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M&G=.ZQIW3_H9=D__&79/_QAV3_\7=D__%W9/_Q?X1@  XE   -!7  #$7
MNUX  +1=  "N6@8 IEL3 *!<(@";7"\ EUL[ I):10./64T&BUA5"(A77 J&
M5F,,@U5J#H%4<1!^5'@2?%. %'I2B19X4I08=E*?&712JQIR4KH;<5+-''!2
MZ!MP4_D:<%/_&G!3_QEP4_\8<%/_&'!3_QCO20  W5,  ,M:  # 7P  MV(
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M&V!>_QIA7O\:85[_&F%>_QKD4@  SUP  ,!D  "V:0  K&P  *-L  "9:0
MDFH+ (QJ%@"':R0 @FLP 7YJ.@)Z:4,$=FA+!G-G4@AP9UD*;69@#6ME9@]H
M9&X19F1V%&1C@!9B8XL88&*7&EYBI!Q<8K(=6V+%'5MBX1U;8O0<6V+_&UQB
M_QI<8O\:7&+_&EQB_QK@50  RU\  +UG  "R;   J7   )]O  "4;   C&T(
M (9N$P"";R$ ?6\M 7EO. )U;D$#<FU)!6YL4 =K:U<*:6M>#&9J90YD:6P1
M86ET$U]H?A9=9XD86V>5&EEFHAM79K <5F;#'59FWQU69O,<5V;_&U=F_QI7
M9O\:5V;_&E=F_QK;60  QV(  +IJ  "O<   IG,  )IS  "/<   AW$% (%R
M$0!\<QX >',J '1S-0%P<S\#;7)'!6IQ3@=G<54)9'!<"V)O8PY?;VH076YR
M$EIM?!58;8875FR3&51LH!M2:Z\<46O!'%%KW!Q1:_$;4FO^&E)J_QI2:O\9
M4FK_&5)J_QG47   PV8  +9N  "L=   HG<  )9V  ")=0  @78! 'IW#P!V
M>!L <GDG &]Y,@%K>#P":'A$!&5W3 9B=U,(7W9:"EUU80Q:=6@/6'1P$55S
M>1-3<X0647*0&$]RGAE-<:T:3'&_&TMQV1M,<? :3'#]&DUP_QE-;_\936__
M&4UO_QG.8   OFH  +)R  "H>   G7L  )!Z  "$>@  >GL  '1\# !O?A<
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M#SZ*F!$\BJ<2.XJX$CJ*SQ([B.L2.X?Z$SN&_Q,[AO\3.X;_$SN&_Q.\<0
MKWL  *6#  "9AP  C(@  '^)  !SC   99   %R3  !7E0P 5)86 %*6(@!0
MERT 39<V $N7/P%)ET<"1Y=. T66501#EET%099E!CZ5;P@\E7H).I6'"SB5
ME0PVE*4--92V#C24S TTD^D--)+X#C20_P\TD/\/-)#_#S20_P^U>   JH(
M )Z(  "3C0  AHX  'F0  !MDP  89<  %6;  !-G@8 29\0 $>?&P!&H"8
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M 1RYP $<N-\!'+;R 1NU_ (;M/\"&[3_ ANT_P*?CP  E)4  (B;  ![H0
M;J8  &*K  !6L   2K,  #^V   UN0  ++P  "2_!@ ?P@T '<(4 !S"'@ ;
MPR8 &L,O !G$.  8Q$$ %\1* !;%50 5Q6$ %,9O !/&?P 2QI$ $<>D !#'
MN0 /Q]0 $,;N !#$^@ 0P_\ $,/_ !##_P"7E@  BYP  'ZB  !QJ0  9*\
M %BT  !+N   0+L  #6^   KP0  (\4  !O) 0 4S 8 $- +  [1$0 -T1D
M#=$A  S1*@ ,T30 "](^  K220 )TU4 "=-B  C3<@ &U(0 !=28  34JP #
MU<   =7<  '5[0 !U?8  =7V  '5]@".G0  @*0  '.K  !FL0  6;@  $R]
M   _P   -,,  "K'   AR@  &<X  !+2   -U@$ "=L%  ;<#0 $W!$  ]T8
M  '>(   WB@  -\Q  #@/   X4<  .)4  #C8P  XW0  .2(  #DFP  Y:X
M .7!  #EU0  YN<  .;G  #FYP"#I   =:P  &BS  !:NP  3<$  $#$   S
MR   *,P  !_0   7U   $-D   O=   %X0   .0   #E!P  Y@T  .<1  #H
M%@  Z1T  .HE  #K+@  [3D  .]%  #P4P  \60  /%V  #RB@  \YP  /.M
M  #TNP  ],@  /3(  #TR !WK0  :K4  %R]  !/Q   0,D  #/-   GT0
M'=8  !3<   .X   ".,   'F    Z@   .X   #N    [P0  / *  #Q#@
M\Q(  /08  #V(   ^"H  /HU  #]0P  _E(  /]C  #_=@  _XD  /^:  #_
MI@  _[   /^P  #_L #_%B, _Q4A /\1(0#_#20 _PDK /\&-P#_ T0 _P!1
M /\ 70#_ &@ _P!R /\ >P#_ (, _P"* /\ D0#_ )8 _P"< /\ H0#] *8
M^P"L /D LP#W +L ]0#% /, T0#R .0 \0#Q .\ ^@#N /\ [@#_ .T _P#M
M /\ [0#_ .T _P#_&2  _Q@= /\5'0#_$!\ _PXI /\,- #_"D$ _P=- /\%
M60#_!&0 _P1N /\#=P#_ X  _P.' /\#C0#] I, ^P*9 /D"G@#W J0 ]0*J
M /,!L #Q ;@ [P'" .T!SP#K >, Z@'O .@"^P#G!/\ Y@7_ .8&_P#F!O\
MY@;_ .8&_P#_'!L _QL9 /\7& #_%1T _Q,E /\1, #_$#T _PY) /\,50#_
M"V  _PMJ /T+<P#["WP ^0J# /<*B@#U"I  ] J6 /,*FP#Q"J$ [PFG .T)
MK@#K";8 Z G  .8)S0#D">( X@KP -\+^P#>#/\ W W_ -P-_P#;#?\!VPW_
M =L-_P'_'Q< _QX3 /\;$@#_'!D _QLB /\8+ #_%3@ _Q-$ /X24 #Y$5L
M]1!F /,0;P#P$'< [A!_ .P0A@#J$(P Z1"2 .@0F #F#YX Y0^E .,/K #A
M#[0 X ^^ -X/S #:$.$ U1'P -(2^P#/$O\!SA/_ <T3_P'-$_\!S!/_ <P3
M_P'_(A( _R(/ /\A#P#_(A0 _R(< /\@)P#_'3( ^!L^ /(92P#N&%8 ZA=@
M .<6:@#D%G( XA9Z . 6@@#>%H@ W!:/ -L6E0#9%IL UA:B -06J0#2%K$
MT!>[ ,X7R0#,&-X R!GN <4:^P'#&O\"P1O_ L ;_P+ &_\"P!O_ L ;_P+_
M)@X _R4+ /\H# #_*1  _R@6 /XF( #T)"L ["$X .8@1 #A'U  W1]; -D>
M90#5'FT TA]U - ??0#.'X, S!^* <L?D ')'Y<!R!^> <8?I0'%(*T!PR"W
M <$@Q ' (=8!O"+J KDB^ .V(O\#M2/_ [0C_P2S(_\$LR/_!+,C_P3_*0L
M_RH% /\N" #_+PP _RT0 /,K%P#H*"( X"8O -DF/0#2)TH S2=5 ,HH7P#'
M*&@!Q2AO <,G=P'!)WX!OR>$ ;XGBP*\)Y("NR>9 KDGH *W)ZD#MBBS [0H
MOP.S*,\#L"GF!*TI]@2K*O\%J2K_!J@J_P:H*O\&J"K_!J@J_P;_+04 _S
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M#(P\[ V*//L-B3S_#8D\_PR(//\,B#S_#(@\_PS_-P  ZC\  -Q%  #.20
MQ4D  +]& @"Z0PP LT09 *U%)P"H1C4 I$5! :!%2P*=1%,"FD-; YA#8@66
M0FD&E$%P!Y)!=@B00'X)CD"&"HU C@N+0)@,B4"B#8= K@Z%0+P/A$#/#X)!
MZ0^!0?D/@$'_#X!"_PZ 0O\.@$+_#H!"_P[Z.P  Y40  --+  #'3@  OD\
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M$FM._Q)K3O\1:T[_$6M._Q'H1@  TU   ,16  "Y6@  L%P  *9:  "?5@
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M$E==_Q+64P  Q%P  +=C  "L:   H&@  )5G  "*8P  @V4" 'UF#P!X9AH
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M$$IMF!%);*<22&RX$T=LS1-';.H32&OZ$DAK_Q)(:O\12&K_$4AJ_Q''7@
MN&<  *QN  "A<@  DW(  (=Q  !Z<0  <7(  &MT!P!F=1$ 8W8= &!W* !>
M=S, 6W@\ 5EW0P)6=TL#5'=2!%)V6050=F '3G5H"$MU<0I)='P,1W2(#D5S
ME@]#<Z400G.V$4%SRQ%"<N@10G+X$4)Q_Q!#</\00W#_$$-P_Q#!8P  LVP
M *AS  ";=@  CG4  (%V  !U=@  :7@  &-Z @!>? X 7'T9 %E^) !7?R\
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M!R^.PP<OCN$'+XST""^+_P@OBO\(+XK_"2^*_PFP=@  I7\  )B$  "*A
M?84  '"'  !EB@  6HX  $^2  !&E0  09@, #Z8%  ]F1\ .YDH #J:,0 Y
MFCH -YI" #::2@ UFE(!,YI: 3&:9 $OFF\"+9I[ BR:B@,JFIH#*9JL!"B:
MP 0GF=X#)Y?R!">6_04GE?\%)Y7_!2>5_P6I?@  GH4  )*)  "$B@  =HP
M &J/  !>DP  5)<  $F;  ! GP  -Z($ #*C#@ QHQ< ,*0A "ZD*@ MI#(
M+*4Z "NE0P JI4L *:54 "BE7@ FI6D ):5V 2.EA0$BI98!(*:H 1^ENP$>
MI=<!'J3O 1ZB^P(>H?\"'J'_ AZA_P*BA@  EXP  (N/  !]D0  ;Y0  &.8
M  !7G0  3:$  $.E   XJ   ,*L  "BN!P DKQ  (Z\7 "&O(0 @L"D '[ Q
M !ZP.@ =L4( '+%, !NQ5@ :L6$ &;)O !BR?@ 6LI  %;*B !2RM@ 3LLX
M$['K !.O^0 3KO\!$Z[_ 1.N_P&:C0  D)(  (27  !UF@  :)\  %NC  !0
MJ   1:P  #NP   QL@  )[4  ""X   8N@< %+P. !.\%0 2O!X $;TF !&]
M+@ 0O3< $+Y!  Z^3  .OE< #;YE  R_=  +OX8 "KZ9  B^K  'OL( ![[?
M  B^\  (O?H "+W\  B]_ "3E   AYD  'J?  !LI0  8*H  %.O  !'LP
M/+8  #&X   GNP  '[X  !?!   1Q $ #,@(  C)#@ 'R10 !LD<  7))  $
MRBP  \HV  +*0   RTP  ,M9  #+:   RWD  ,R,  #+GP  R[,  ,O(  #,
MX@  S.\  ,SQ  #,\0"*F@  ?*$  &^G  !BK0  5;,  $BX   [NP  ,+X
M ";!   =Q   %<@   _+   *S@  !-("  #3"@  TP\  -04  #5&@  UB(
M -<J  #9-   VC\  -Q+  #<6@  W6H  -U]  #=D0  W:0  -ZV  #>R
MWMX  -[B  #>X@!_H@  <:D  &2P  !6MP  2;P  #S    OQ   ),<  !O+
M   3SP  #=(   ?6    VP   -X   #? P  X D  .$.  #B$@  XQ<  .4>
M  #F)P  Z#$  .H]  #L2P  [%H  .UL  #N@   [I0  .ZE  #NM   [L(
M .[&  #NQ@!TJ@  9K(  %BY  !+P   /<4  "_)   DS0  &=$  !'6   +
MVP   ]X   #A    Y0   .@   #I    Z@   .L&  #M"P  [P\  / 3  #R
M&@  ]",  /<N  #Y.P  ^TH  /Q;  #];0  _8   /Z3  #^H@  _JT  /ZO
M  #^KP#_$!\ _PX= /\*'0#_ 2  _P H /\ -0#_ $$ _P!. /\ 6@#_ &4
M_P!N /\ =P#_ '\ _@"& /P C #[ )( ^0"7 /@ G #W *( ]@"G /4 K0#S
M +4 \@"] /$ R0#O -P [@#K .T ]P#L /\ ZP#_ .H _P#J /\ Z@#_ .H
M_P#_$QP _Q$9 /\-&0#_!AP _P,E /\ ,0#_ #X _P!* /\ 5@#_ &$ _P!K
M /T <P#Z 'L ]P"# /4 B0#T (\ \@"4 /$ F0#P )\ [@"D .T JP#L +(
MZ@"Z .@ Q@#G -8 Y0#H .0 ]0#C /X X@#_ .$ _P#A /\ X0#_ .$ _P#_
M%1@ _Q,4 /\/% #_#1D _PLB /\(+0#_!#D _P%& /\ 40#^ %P ^@!F /8
M;P#R '< [P!^ .T A0#K (L Z@"1 .@ E@#G )P Y@"A .0 J #C *\ X0"X
M -\ PP#= -$ VP#F -D \P#7 /T U0+_ -0"_P#4 _\ U /_ -0#_P#_&!,
M_Q40 /\2#P#_$A4 _Q$= /\.* #_##0 _PI! /D(3 #U!E< \09A .T&:@#I
M!7( Y@5Z .0%@0#B!8< X :- -\&D@#=!I@ VP:> -D&I0#7!JT U :U -(&
MP #0!\\ S@CE ,P)] #*"_\ R S_ ,<,_P#'#/\ Q@S_ ,8,_P#_&PX _QD,
M /\8#0#_&!$ _Q<8 /\4(@#[$2X \Q Z .T.1@#H#5( Y0U< .$-90#>#6T
MVPUU -@-? #5#8( TPV) -$-CP#0#94 S@V< ,T.HP#+#JL R0ZT ,@.P #&
M#L\ PQ#F , 1]0"]$O\ O!+_ +L2_P"Z$O\!NA+_ ;H2_P'_'PH _QP$ /\?
M" #_'PT _QT2 /@:&P#N%B8 YA0S . 3/P#:$TL U!-6 - 37P#.%&@ RQ1O
M ,D4=P#'%7T QA6$ ,05B@##%9$ P1:8 , 6GP"^%J< O!>P +L7O "Y%\L
MMQCB +,9\@&Q&O\!KQO_ :X;_P&N&_\!K1O_ :T;_P'_(@0 _R(  /\E @#\
M) < ]R$, .P=$@#A&AP V!HJ - ;. #+'44 QQU0 ,,>6@# 'F( OAYJ +P?
M<0"Z'W@ N1]^ +<?A0"V'XP M!^3 +,?F@&Q(*,!L""L :X@MP&L(<8!JR'=
M :<B[P*E(OT"HR/_ J(C_P*B(_\"H2/_ J$C_P+_)0  _R@  /(J  #E*P
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M"7H\_PAZ//\(>CS_"'H\_PCN-P  W4$  ,M&  "_20  MDD  *Y&  "I000
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M"V!-_PO<1P  QU   +E6  "N60  HE@  )A6  "040  B5(& (-3$0!_4QT
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M"U19F U36*8.4EFV#E%9R@]16><.45CX#5)8_PU26/\,4EC_#%)8_PS-40
MO%D  +!?  "C80  EF   (M?  "!6P  >5T  '-># !O7A4 :U\@ &A?*P!F
M8#4 8V ] 6%?10%?7TP"75]3 UM?6@197F$%5UYI!E5><@A37GT)45V)"U!=
ME@Q.7:0-35VT#DQ=R Y,7>8.35WW#4U<_PQ-7/\,3ES_#$Y<_PS)5   N5P
M *UC  "?8P  DF,  (=B  !\8   =&$  &YB"0!I8Q( 9F,= &-D* !A9#(
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M"CUNP@H\;N */6WT"CUL_PH]:_\*/FO_"CYK_PJZ8   K6D  *!N  "1;0
MA&T  'AM  !L;@  87   %MR  !6= H 4G42 %!V'0!.=R< 3'<Q $MX.0!)
M>$$ 2'A) 49X4 %$=U<"0G=? T!W: ,^=W,$/'9_!CIVC0<Y=IP(-W6M"#=U
MP @V==X(-W3R"#=S_@@W<O\(-W+_"#=R_PBU9@  J6\  )IQ  "+<0  ?G$
M '-R  !H<P  7'8  %1Y  !.>P4 2GT/ $A^& !&?R, 17\L $. -0!"@#T
M08!% #^ 3 $]@%0!/(!< CI_90(X?V\#-G]\!#1_B@0R?YH%,7ZJ!C!^O08P
M?MH&,'WP!C![_08P>_\&,'K_!C!Z_P:P;   I'4  )1U  "&=0  >78  &YW
M  !C>0  5WT  $^!  !'A   0H8, #^'$P ]B!T /(@G #N),  ZB3@ .(E
M #>)2  VB4\ -(E8 3.)80$QB6P!+XEX BV)AP(LB9<#*HBG RF(N@,IB-0#
M*8;N RF%_ 0IA/\$*83_!"F$_P2J=   GGL  (YZ  " >@  ='L  &A^  !=
M@0  4H4  $F)  !!C   .9 % #61#P SDA< ,I(A #&2*0 PDS( +I,Z "V3
M00 LDTH *Y12 "J47  HE&< )Y1S 264@@$DE),!(I.D 2&3MP$@D\\!(9+L
M 2"0^@(@C_\"((__ B"/_P*D?   EX   (=_  ![@   ;H(  &*%  !7B0
M38X  $*2   ZE@  ,ID  "J<"0 HG1$ )IT9 "6=(@ DGBH (YXR "*>.@ A
MGD( ()Y+ !^?50 >GV  ')]M !N??  :GXT &)^? !>?L@ 6G\D %I[H !:<
M]P 6F_\!%YO_ 1>;_P&=@P  CX8  (*&  !TAP  9XL  %N/  !0DP  1I@
M #R<   SH   *Z,  ".F   <J L &JD1 !BI&  7J2$ %JHI !6J,0 4JCD
M$ZI# !.K30 2JU@ $:ME !"K=  .JX8 #JN9  VKK  ,J\$ #*K?  RI\@ -
MJ/P #:C_  VH_P"6B@  B8P  'J-  !LD0  8)4  %2:  !)GP  /Z,  #6G
M   KJ@  (ZX  !NP   4LP$ #[4*  VV$  ,MA8 "[8?  JV)P )MB\ "+8Y
M  >W0P &MT\ !+=;  .W:@ "MWL  +>.  "WH0  MK0  +;+  "VY0  M?$
M +7W  "U]P"/D0  @90  '*7  !EG   6*$  $RF  !!JP  -Z\  "RR   C
MM0  &K@  !.[   .O0  "< %  /!#0  P1$  ,$7  #"'@  PB8  ,(O  ##
M.0  Q$0  ,10  #$7@  Q6\  ,6!  #%E0  Q:@  ,6\  #$T0  Q.8  ,3N
M  #$[@"&F   >9X  &NC  !=J0  4*X  $2S   WM@  ++D  "*\   9OP
M$<(   S%   &R    ,L   #,!P  S T  ,T1  #-%@  SAT  ,\D  #0+0
MTC@  -1$  #44@  U6$  -5S  #6AP  UIL  -:M  #7OP  V,X  -C=  #8
MW0![H   ;J8  &"M  !3LP  1;@  #B\   KOP  (<(  !?&   0R0  "LP
M  +0    U    -<   #8    V@4  -L+  #<#@  WA,  -\9  #A(0  XRH
M .4V  #G0P  YU,  .AD  #I=P  Z8P  .J?  #JK@  ZKH  .K#  #JPP!P
MJ   8J\  %6V  !'O   .<   "S$   @R   %LP   [0   'U    -D   #=
M    X0   .,   #D    Y@   .<!  #I!P  ZPP  .P0  #N%0  \!T  /,G
M  #V,P  ]T,  /A4  #Y9@  ^7H  /J.  #ZG@  ^ZD  /NP  #[L #_"QL
M_P<9 /\ &0#_ !P _P E /\ ,@#_ #\ _P!+ /\ 5P#_ &( _P!K /\ <P#]
M 'L ^P"" /H B #X (T ]P"2 /8 F #U )T ] "B /, J0#Q +  [P"X .X
MPP#L -$ ZP#F .D \P#H /X Z #_ .@ _P#H /\ Z #_ .@ _P#_#A@ _PH5
M /\!% #_ !@ _P B /\ +@#_ #L _P!' /\ 4P#] %X ^@!G /< ;P#U '<
M\P!^ /( A #P (D [P"/ .X E #L )H ZP"? .D I0#H *P Y@"T .0 OP#C
M ,P X0#B -\ \ #> /L W@#_ -T _P#= /\ W #_ -P _P#_$!, _PT1 /\&
M$ #_ A4 _P > /\ *0#_ #8 _P!" /H 3@#T %D \0!B .X :P#L '( Z@!Y
M .@ ?P#G (4 Y0"+ .0 D #B )8 X0"< -\ H@#= *D V@"Q -@ NP#5 ,@
MT@#= -$ [0#0 /D SP#_ ,X _P#- /\ S0#_ ,T _P#_$0\ _PX- /\,#0#_
M"Q( _P<9 /\") #_ #  ]@ \ .\ 20#J %, YP!= .0 9@#A &T WP!T -T
M>P#; ($ V0"& -8 C #4 )( T@"8 -  G@#. *8 S "N ,H N #( ,0 Q@#7
M ,4 Z@## /< P@#_ ,$!_P#  O\ P +_ , "_P#_% L _Q & /\0"0#_$ X
M_PX4 /\*'@#U!BD ZP0V .,#0@#? TX VP17 -8$8 #3!&@ T 1O ,X%=@#,
M!7P R@6" ,D%B #'!8X Q@64 ,0%FP#"!:, P :K +X&M0"]!L( NPC4 +H)
MZ0"W"_@ M0S_ +0,_P"T#/\ M S_ +0,_P#_%P0 _Q0  /\6 P#_% D _Q$.
M /(.%0#H#"$ W@HN -8+.P#0#$< S Q1 ,D,6@#&#6( Q UJ ,(-<0# #7<
MOPU] +T.@P"\#HH N@Z1 +D.F "W#J  M@ZI +0/M "R#\$ L1#4 *X1ZP"K
M$OH J1+_ *@3_P"G$_\ IQ/_ *<3_P#_&@  _QL  /D;  #K&0  Y10& .40
M#@#9#A< SQ$F ,@2- #$$T  OQ1+ +P45 "Y%5T MQ5D +45:P"T%7$ LA5X
M +$6?@"O%H4 KA:, *P6E "K%YP J1>F *<8L "F&+T I!C/ *(:YP"?&O<
MG1O_ 9P;_P&<&_\!FQO_ 9L;_P'_'0  ]R$  .@D  #=)0  U"$! ,\;" #*
M%Q$ PAH@ +P<+0"W'3H LQY% + >3P"M'E< JQY? *D?9@"H'VP IA]S *4?
M>0"C'X  HA^' * @CP"?()@ G2"B )L@K &:(;D!F"'* 98BY &4(_4!DB/_
M 9$C_P&0(_\!D"/_ 9 C_P'_(@  ZRD  -TN  #/+P  QRT  ,$G P"](@T
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M!6P\_P7B.0  S$(  +Y'  "Q2   I48  )U#  "7/P  DCX+ (T_%0")/R$
MA4 M () -P!_0$  ?4!( 'M 3P%Y0%8!=S]= 74_8P)S/VH"<3]R W _>@-N
M/X0$;#^0!6L_G 9I/ZD&:#^X!V= S =F0.@'9D#Y!F5 _P9E0/\&94#_!65
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M!EY(EP==2*4(6TBT"%M(QPE:2.0(6DGV"%I)_P=:2/\&6DC_!EI(_P;110
MOTP  +)2  "C40  EU   (U.  "&2@  @$H! 'I+#@!V3!< <DPC &],+0!M
M338 :DP_ &A,1@!F3$T!9$Q3 6),6@)A3&$"7TQI UY,<@1<3'P%6DR(!EE,
ME0=73*,(5DRR"%5,Q@E53.()54SU"%5,_P=53/\'5DS_!E9,_P;,2   O%
M *]5  "@5   DU,  (E1  "!30  >DX  '5/# !P3Q4 ;5 @ &I0*@!G4#,
M95 \ &-00P!A4$H!7U!1 5U06 )<4%\"6E!G UE0< 174'H%55"&!E10DP=2
M4*$(45"Q"5!0Q E04.$)4%#T"%%0_P=13_\'44__!E%/_P;)2P  N5,  *M7
M  "<5@  CU4  (54  !\4   =5$  '!2"0!K4Q( :%0= &54)P!B5#$ 8%0Y
M %Y400!<5$@!6E1/ 5E45@%75%T"5E1E U14;@125'@%452$!D]4D0=.5* (
M3%2O"$Q4P@E+5-\)3%3S"$Q3_P=,4_\'35/_!DU3_P;%3@  ME8  *=:  "8
M60  BU@  (%7  !W5   <%4  &I6!@!F5Q  8E<: &!8) !=6"X 6UDW %E9
M/P!7648 5EE- 5195 %365L"45EC D]8; -.6'8$3%B"!4I8CP9)6)X'2%BN
M"$=8P A'6-T(1UCR"$=7_P=(5_\'2%?_!DA7_P;!40  LED  *-<  "46P
MAUL  'U:  !R6   :UD  &5: P!@6PX 75P7 %I<(0!872L 5ETT %1>/ !3
M7D0 45Y+ 5!>4@%.7ED"3%YA DM=:@-)770$1UV !45=C09$79P'0UVL!T)=
MO@A"7=H(0ESQ!T)<_@=#6_\&0UO_!D-;_P:]50  KUT  )]?  "07@  @UX
M 'A=  !M7   95T  %]?  !:8 P 5V$4 %5B'@!28B@ 46,Q $]C.0!.8T$
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M!#%N^P0Q;?\$,6S_!#%L_P2O9   H6D  (]H  "!:   =6D  &MI  !@:P
M56X  $UQ  !&<P  0G4+ #]V$@ ]=QP /'<E #IX+0 Y>#4 .'D] #=Y10 V
M>4T -7E5 #-Y7@ Q>6@!,'ET 2YY@P(M>9("*WBC BIXM0(J>,P"*G?J BIV
M^0,J=?\#*G3_ RIT_P.J:@  FFT  (EL  !\;0  <&T  &9N  !;<0  4'4
M $AX  !!>P  .GX% #9_#@ T@!8 ,X$@ #*!*  P@3  +X(X "Z"0  M@D@
M+()0 "N"6@ J@F0 *()P ":"?P$E@H\!)(*@ 2."L@$B@LD!(H'G 2)_]P$B
M?O\"(GW_ B)]_P*E<0  DW$  (-Q  !V<0  ;'(  &!U  !6>   3'P  $.
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M !"4_P"5?0  A7P  'A\  !K?@  7X$  %2&  !*B@  0(\  #:3   MEP
M)IH  !Z=   7H , $J(, !"C$@ 0HQD #Z,A  ZD*0 .I#$ #:0Z  RD10 +
MI%  "J1<  FD:@ 'I'L !J..  2CH0 "H[0  Z++  .BY@ #H?,  Z'[  .A
M^P"-@P  ?X(  '&$  !DAP  6(P  $V1  !"E@  .)H  "^>   FH@  'J4
M !>H   1JP  #*X'  >O#0 #KQ(  J\9  &O(0  KRD  + R  "P/   L$<
M +!3  "P80  L'$  +"#  "OEP  KZH  *^_  "NV0  KNL  *[T  "N] "'
MB0  >(H  &J.  !=DP  49@  $6=   [H@  ,*8  ">J   >K@  %K$  !"T
M   +M@  !;D#  "Z"@  N@X  +H3  "[&0  NR$  +PH  "\,0  O3P  +Y(
M  "^5@  OF4  +YW  "^C   OI\  +VS  "^QP  OMX  +WK  "]ZP!_D@
M<)4  &*:  !5GP  2:4  #VK   RKP  *+0  !ZV   5N0  #KP   F_   "
MP@   ,0   #%!   Q@H  ,8.  #'$@  R!@  ,D?  #*)P  S#   ,X\  #.
M20  SUD  ,]J  #/?@  SY,  ,^F  #/N   S\@  ,_;  #/VP!WG   :*$
M %NG  !.K@  0;0  #2W   HN@  ';T  !/    -Q   !L<   #*    S@
M -    #1    T@(  -,(  #5#   UA   -D5  #;'   W20  . O  #B/
MXTL  .1<  #D;P  Y8,  .68  #EJ0  Y;8  .7#  #EPP!LI0  7ZP  %&R
M  !$N0  -;P  "C    <Q   $L@   S+   #SP   -,   #8    W    -\
M  #?    X0   .,   #D P  Y@@  .@-  #I$0  [!@  .XB  #Q+@  \SP
M /1-  #U7P  ]G,  />'  #WF0  ^*4  /BP  #XL #_ Q< _P 5 /\ %0#_
M !@ _P C /\ +P#_ #P _P!( /\ 5 #_ %X _P!G /T ;P#[ '8 ^0!] /@
M@P#V (@ ]0". /0 DP#R )@ \0"> /  I #N *L [0"S .L O0#J ,L Z #A
M .< \0#F /T Y0#_ .0 _P#D /\ Y #_ .0 _P#_!Q, _P 1 /\ $0#_ !4
M_P ? /\ *P#_ #< _P!$ /X 3P#Z %H ]P!C /0 :P#R '( \ !Y .\ ?P#M
M (0 ZP"* .H CP#H )0 YP": .4 H #D *< X@"O .  N0#> ,8 W #: -H
M[ #8 /D U@#_ -8 _P#7 /\ V #_ -@ _P#_"A  _P,. /\ #0#_ !( _P :
M /\ )@#\ #( ]P _ /0 2@#Q %4 [0!> .H 9@#H &X Y0!T ., >@#B (
MX "% -X BP#< )  VP"6 -@ G #5 *, TP"K -$ M0#. ,$ S #1 ,L YP#)
M /4 R #_ ,@ _P#( /\ R #_ ,@ _P#_# P _P8( /\""@#_  \ _P 5 /P
M( #Q "P [  Y .D 10#E $\ X0!9 -X 80#; &@ UP!O -0 =0#2 'L T "
M ,X A@#, (P RP"2 ,D F #' *  Q0"H ,, L0#! +P OP#+ +T XP"\ /(
MNP#] +L _P"Z /\ N@#_ +H _P#_#@4 _PD  /\)!0#_!@L _P$0 /  &0#F
M "4 X0 R -P /P#6 $D T0!3 ,X 6P#+ &, R !J ,8 < #% '8 PP![ ,$
M@0#  (< O@". +P E "[ )P N0"D +< K@"U +D LP#( +$ WP"P >\ KP'[
M *X"_P"M _\ K0/_ *T#_P#_$   _PX  /\-  #V"P, \@<* .(!$0#; AT
MT@,K ,P#-P#(!$, Q 1- ,$$5@"^!5T O 5D +H%:P"X!7$ MP5V +4%? "S
M!H, L@:) + &D0"O!YD K0>A *L'JP"I"+< J G& *8*W0"E"_  HPS] *(-
M_P"A#?\ H0W_ * -_P#_$0  _!(  .P3  #B$P  VP\# -8)"P#."!0 Q@HB
M , ,, "\#3P N U& +4-3P"R#E< L Y? *X.90"M#FL JPYQ *H.> "H#GX
MIP^% *4/C0"D#Y8 HA"? * 0J0"?$+4 G1'% )L1W@"9$O$ EQ/_ )84_P"5
M%/\ E13_ )04_P#_%0  [1L  . ?  #2'P  R1L  ,04!0#!$ X NA(; +03
M*0"P%#4 K!5  *D520"F%5( I!99 *(68 "A%F8 GQ9L )X6<@"<%GD FQ>
M )D7B "8%Y$ EAB; )08I@"3&;( D1G! ) :V "-&^X BQS] (H<_P"*'/\
MB1S_ (D<_P#T'0  Y"4  -,I  #'*@  O"8  +8@  "T&0L KAH5 *@<(P"D
M'2\ H1XZ )X>1 ";'DP F1Y4 )<?6P"5'V$ E!]G )(?;0"1'W0 CR!\ (X@
MA ",((T BB"7 (DAH@"'(:X AB*] (4BT0&"(^L!@23[ 8 D_P%_)/\!?R3_
M 7\D_P'L)0  VRT  ,DQ  "\,0  L2X  *LI  "G) 4 HR,1 )XD'0":)2H
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M FPTF )J-:4":36S V@UQ@-G-N(#9C;U V8V_P)F-O\"9C;_ F8V_P+8-P
MQ#X  +5"  "F00  FS\  ),\  "-.   B#8' (0W$0" -QP ?#@G 'HX,0!W
M.3H =3E" ',Y20!Q.5  <#E7 &XY70!L.60!:SEK 6DY= %H.7X"9CF) F0Y
ME0-C.J(#8CJQ V$ZPP-@.^ $7SOS U\[_P-?._\#7SO_ E\[_P+1.P  P$(
M +!%  "A1   E4,  (U   "'/0  @CL" 'T[#@!Y/!@ =3TC ',]+0!P/38
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M!%!'O01/1]8%3T?O!$]'_01/1_\#3T?_ U!'_P/$10  M4T  *--  "53
MB4L  ']*  !X1@  <4<  &Q'!P!H2!  9$@: &%)) !?22T 74DU %M)/0!9
M240 5TE* %9)40!52ED!5$IA 5)*:0%12G0"3TI_ TY*C --2IL$3$NJ!$M+
MO 1*2],%2DON!$M+_01+2O\#2TK_ TM*_P/!2   LE   *!/  "13P  A4X
M 'M-  !S20  ;$H  &=+! !B3 X 7TP7 %Q-(0!:32H 6$TR %9-.@!434$
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M SQ7^@,]5O\#/5;_ SU6_P.V4P  I5<  )17  "%5@  >58  &]6  !E50
M7%8  %=8  !260< 3EH0 $Q:& !*6R$ 2%PJ $=<,@!%7#H 1%U! $-=2 !"
M75  0%U8 #]=80$]76L!/%UV CI=A (Y79,".%VC S==M0,V7<L#-ESH S=<
M^0,W6_\#.%O_ SA:_P.R5P  H%H  (]9  "!60  =5D  &M9  !@6@  5EL
M %%=  !,7@( 2& - $5@% !$81X 0F(F $!B+@ _8C8 /F,^ #UC10 \8TT
M.V-5 #EC7@ X8V@!-F-T 35C@0$S8Y$",F.A C%CLP(Q8\@",6+G C%A^ (Q
M8?\",F#_ C)@_P*N7   FUT  (I=  !\70  <%T  &9=  !<7@  4F   $QB
M  !%90  068* #YG$0 \:!H .V@B #EI*P X:3( -VHZ #9J00 U:DD -&I2
M #-J6P Q:F4 ,&IP 2YJ?@$M:HX!+&J? 2MJL $J:L8!*FGE 2IH]@(K9_\"
M*V?_ BMG_P*I80  E6   (1@  !W8   ;&$  &)A  !88P  3F8  $=H  !
M:P  .FX% #9O#@ T<!4 ,W > #)Q)@ P<2X +W$U "YR/0 M<D4 +')- "MR
M5P J<F$ *7)M "=R>P F<HL )'*< 2-RK@$C<L,!(W'B 2-P] $C;_\!(V[_
M 2-N_P&A90  CF0  ']D  !R9   :&4  %YF  !4:0  26P  $)O   [<@
M-'4  "YX"@ K>1$ *GD8 "EZ(0 G>B@ )GHP "5[.  D>T  (WM( ")[4@ A
M>UP ('MH !]\=@ =?(8 ''N8 !M[J@ :>[\ &GO> !IY\@ ;>/X &W?_ 1MW
M_P&9:0  B&D  'EI  !M:0  8VH  %EL  !/;P  17,  #UW   U>@  +GT
M ">! P B@PT ((02 !^$&@ =A"( '(4J !N%,0 :A3D &85" !B&3  7AE8
M%H9C !6&<0 4AH$ $H:3 !&&I@ 1A;L $(76 !&#[P 1@OL $H+_ !*!_P"1
M;@  @6T  '1N  !I;@  77   %-S  !)=P  0'P  #>    O@P  )X<  "&*
M   :C08 %8\- !.0$P 2D!H $I B !&0*@ 0D3( $)$[  ^11  .D4\ #9%<
M  R1:@ +D7H "I&-  B0GP 'D+, !X_)  >/Y@ 'CO0 "(W\  B-_P")<P
M>W,  &]S  !C=0  5W@  $U]  !#@0  .88  #"*   HC@  (9$  !J5   3
MEP  #IH(  N<#@ )G!, ")P:  ><(@ &G"H !)PS  .</0 "G4@  )U4  "=
M8@  G'(  )R$  "<EP  FZH  )N_  ":VP  FNP  )KU  "9^ "">0  =GD
M &AZ  !<?@  48(  $:'   \C   ,I$  "F5   AF0  &9T  !*@   .HP
M":8%  .G#   IQ   *<5  "H'   J",  *@K  "I-   J3\  *E+  "I60
MJ6@  *EZ  "IC@  J:$  *BU  "HRP  I^0  *?O  "G\P!]@   ;X$  &&$
M  !5B0  28X  #Z4   TF0  *IX  "&B   9I@  $JD   VL   'KP   +(
M  "S!P  LPP  +,0  "T%0  M!L  +4B  "V*P  MS4  +=   "X3@  N%T
M +AN  "X@@  N)<  +BJ  "WO@  M](  +?F  "WZ@!VB   9XL  %J0  !.
ME@  0IP  #>B   LIP  (JL  !FO   1LP  "[8   2Y    O    +X   "^
M    OP8  , +  #!#P  PA,  ,,9  #$(   Q2D  ,<T  #(0@  R5$  ,EB
M  #)=0  R8H  ,F?  #*L0  RL$  ,G1  #)V0!NDP  8)@  %.>  !&I
M.JL  "^P   DM0  &;@  !"\   *OP   <$   #$    R    ,H   #*
MS    ,T#  #."   T T  -$0  #3%@  UAX  -HH  #=-   WD,  -]4  #?
M9P  X'P  ."1  #@I   X+(  ."^  #@PP!FGP  6:8  $RM   _M   ,K@
M "2\   8OP  $,,   C'    R@   ,T   #1    U0   -@   #9    VP
M -T   #?    X00  .,*  #E#@  YQ,  .H<  #M)P  \#4  /%&  #R6
M\VL  /.   #TE   ]*,  /2N  #TL@#_ !, _P 1 /\ $0#_ !4 _P ? /\
M+ #_ #D _P!% /\ 4 #_ %H _@!C /L :P#Y '( ]P!X /4 ?@#T (0 \@")
M /$ C@#P ), [@"9 .T GP#L *8 Z@"N .@ N #F ,4 Y0#; ., [0#B /L
MX@#_ .$ _P#A /\ X0#_ .$ _P#_ !  _P . /\ #0#_ !( _P ; /\ * #_
M #0 _@!! /L 3 #W %8 ] !? /$ 9@#O &T [ !T .H >@#I '\ YP"% .8
MB@#E (\ XP"5 .$ FP#@ *( W@"J -L M #9 ,  U@#0 -, Z #2 /< T0#_
M -$ _P#0 /\ T #_ -  _P#_  T _P ) /\ "@#_  \ _P 6 /L (@#W "\
M]  [ /  1P#M %$ Z0!: .4 8@#B &D X !O -X =0#< 'H V@"  -@ A0#5
M (L TP"1 -$ EP#/ )X S0"F ,L KP#) +H QP#) ,4 X@#$ /( PP#^ ,(
M_P#! /\ P@#_ ,( _P#_ P8 _P ! /\ !@#_  P ^0 1 /$ '0#K "D YP V
M ., 00#? $L VP!4 -4 7 #2 &, SP!J ,T < #+ '4 R0![ ,@ @ #& (8
MQ0", ,, DP#! )H OP"B +T JP"[ +8 N0#$ +< V@"V .T M #Z +0 _P"T
M /\ M #_ +0 _P#_!   _P   /\   #_  8 [  - .4 %@#> "( UP O -$
M.P#- $4 R@!. ,8 5P#$ %X P0!D +\ :@"] '  O !U +H >P"Y ($ MP"'
M +4 C@"S )4 L@"> +  IP"N +( K "_ *H T0"H .@ J #W *< _P"G /\
MI@#_ *8 _P#_!@  _P4  /$#  #H    X0 ' -4 $ #- !L QP G ,, ,P"_
M #X O !( +D 40"V %@ M !? +( 90"P &H KP!P *T =@"L 'P J@"" *D
MB0"G )$ I0": *, I "A *X H "[ )X!S0"= N8 G 3T )L$_P":!?\ F@7_
M )D%_P#_"@  \0X  .00  #9#P  S@L  ,@#"P#" !, O (? +<#+ "S!#<
ML 5" *T&2@"J!E( J =9 *8'7P"E!V4 HP=K *((<0"@"'< GPA^ )T(A0";
M"8X F@F7 )@*H0"6"JP E0NZ ),+S "2#.4 D WV (\._P".#O\ C@[_ (T.
M_P#V$0  YA<  -8;  #'&0  OA4  +D0  "W"@T L0L7 *P-) "H#C  I0X[
M *(.1 "?#TP G0]3 )L/6@":#V  F!!F )<0; "5$'( DQ!Y )(0@0"0$(H
MCQ&4 (T1GP"+$:H BA*X (@2RP"&$^8 A13W (,5_P"#%?\ @A7_ ((5_P#M
M&@  W"$  ,HE  "[(@  L1\  *L:  "I% 8 I1(1 * 4'@"<%2H F14U )86
M/@"4%D< DA9. ) 650".%UL C!=A (L79P")%VT B!=T (88? "%&(8 @QF0
M ($9FP" &J< ?AJU 'T;QP!\'.( >AWU 'D=_P!X'?\ >!W_ '@=_P#E(@
MT"D  +\L  "P*@  IR<  * C  "='P  FAH. )4<& "1'20 CAXO (P>.0")
M'D$ AQ]) (4?4 "#'U8 @A]< ( ?8@!_'VD ?2!P 'P@> !Z(($ >2&, '<A
MEP!U(J0 ="*R ',CPP!R(]\ <"3S &\D_P!O)/\ ;B3_ &XD_P#=*0  R#
M +<R  "H,   GBX  )<J  "3)P  D",* (PC$P"()!\ A"4J ((E- " )CT
M?29$ 'PF2P!Z)E( >"98 '<F7@!U)F4 ="=L '(G= !Q)WT ;RB( &XHE !L
M**$ :RFO 6HIP %I*ML!9RKQ 6<K_P%F*_\!9BK_ 68J_P'4+P  PC8  *\V
M  "A-0  EC0  ) P  "*+0  ARH& (,I$ !_*AH ?"LE 'DK+P!W+#@ =2Q
M ',L1P!Q+$T <"Q4 &XL6@!M+&$ :RUH &HM< !H+7H 9RZ% &4ND0%D+IX!
M8B^L 6$OO0%A,-4!8##O 5\P_0%?,/\!7S#_ 5\P_P'--   O#L  *DZ  ";
M.@  D#@  (DU  "#,@  ?S ! 'LO#@!W,!8 =# A '$Q*P!O,30 ;3$\ &LQ
M0P!J,4H :#)0 &<R5P!E,ET 9#)E &(R;0!A,W< 7S." 5XSC@%=-)P!6S2J
M 5HUNP%:-=(!637M 5DU_ %8-?\!6#7_ 5DU_P'(.   MSX  *0^  "6/0
MBSP  (,Z  !]-P  >#0  '0T"P!P-1, ;34= &HU)P!H-C  9C8X &0V/P!C
M-D8 839- & V4P!>-UH 73=B %PW:@!:.'0!63A_ 5<XC %6.9D!53FH E0Y
MN0)3.L\"4SKK E,Z^P%3.O\!4SG_ 5,Y_P'$/   LD$  *!   "20   AC\
M 'X]  !X.@  <S@  &XY" !J.1$ 9SD: &0Z) !B.BP 8#HT %XZ/ !=.T,
M6SM* %H[4 !8.U< 5SM? %8\9P!4/'$!4SQ\ 5(]B0%1/9<!3SVF DX^MP).
M/LT"3C[I DT^^@)./O\!3CW_ 4X]_P' /P  KD,  )Q#  ".0P  @D(  'I
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M D1%^ )$1?\"147_ D5%_P&Z1@  ID@  )1(  "&2   >T<  ')&  !J0@
M8T,  %Y$  !:10L 5D42 %1&&P!11B, 3T8K $Y&,P!,1SH 2T=! $I'20!)
M2%  2$A8 $=(80!&26L 1$EV 4-)@P%"29(!04FB D!)LP(_2L<"/TKE C])
M]P) 2?\"0$C_ D!(_P&V20  HDH  )%*  "#2@  =TH  &Y)  !E10  7D<
M %E(  !520@ 44H0 $]*& !,2B$ 2DLI $E+,0!'2S@ 1DP_ $5,1@!$3$X
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M 3%5_P&H4@  E5(  (12  !W4@  ;%(  &)2  !84P  3U0  $E6  !$5P
M0%D( #U:$  [6A< .5L@ #A;)P W7"\ -EPV #5</@ T7$8 ,UU. #%=5P P
M76$ +UUL "Y=>@ L78D *UV: 2I=JP$J7;\!*5W> 2I<\@$J6_X!*UO_ 2M:
M_P&C50  CU4  ']5  !R50  9U8  %Y6  !45P  3%D  $5;   _70  .E\$
M #9@#0 T81, ,F(< #%B(P P8BL +V,R "YC.@ M8T( +&-* "ID4P I9%T
M*&1I "=D=@ F9(8 )627 "1DJ0 C9+T (F3: "-C\0 C8OT!)&'_ 21A_P&<
M6   B5@  'I9  !N60  8UD  %I:  !07   2%X  $%@   Z8P  -&8  "]H
M"@ L:1  *FD7 "EJ'P H:B8 )VHN "9K-0 E:ST )&M& "-K3P B;%D (&QE
M !]L<@ >;(( '6R4 !QLI@ ;:[H &FO4 !MJ[@ <:?P '&C_ !QH_P"57
M@UP  '5<  !I70  7UT  %9>  !,80  0V0  #QG   U:@  +VT  "AP!  C
M<@T (7(2 "!S&@ ?<R$ 'G,H !UT,  <=#@ &W1  !IT2@ 9=%0 %W5@ !9U
M;@ 5=7X %'60 !-TH@ 2=+8 $73/ !)S[  2<OH $W'_ !-Q_P".8   ?6
M &]A  !E80  6V(  %%D  !(9P  /FL  #=N   P<0  *74  ")X   <>P<
M%WT. !9]$P 5?1L %'XB !-^*@ 2?C$ $7XZ !%^1  0?TX #W]:  Y_:  -
M?W@ #'^*  M^G0 *?K  "7W&  I]Y  *?/0 "WO]  MZ_P"&90  =V4  &IE
M  !A9@  5F@  $QK  !";P  .7,  #%W   J>@  (WX  !R!   5A   $(<(
M  V)#@ ,B10 #(D;  N)(P *B2L "8DS  B)/0 &B4@ !8E4  2)80 "B7$
M 8F#  ")E@  B*D  (>^  "'V@  ANP  (;U  "&^@!^:@  <6H  &=K  !;
M;   4'   $9T   \>   ,WT  "J!   CA0  '(@  !6,   0CP  #)(&  :3
M#  "DQ$  )06  "4'0  E"0  )4L  "5-0  E4   )5,  "660  EFD  )5Z
M  "5C@  E*$  )2U  "3S   DN8  )+R  "2]P!X<   ;7   &!R  !4=0
M27D  #]^   U@P  +(@  ".-   ;D0  %)0   ^7   *F@  !)T#  ">"0
MGPX  )\2  "@%P  H!T  *$E  "B+0  HC<  *-#  "C4   HU\  *-Q  "C
MA   HID  **M  "AP@  H=P  *'K  "@\@!S=@  9G<  %E[  !-@   0H4
M #B+   ND   ))4  !N:   4G@  #J$   FD   "IP   *H   "K!   JPH
M *P-  "M$0  K18  *X<  "O)   L"T  +$Y  "Q1@  LE4  +)F  "R>0
MLHX  +&C  "RMP  L<H  +'@  "QZ0!L?@  7X(  %*'  !&C0  .Y,  #"9
M   FG@  '*,  !.G   -JP  !ZX   "R    M0   +<   "X    N0(  +D(
M  "Z#   NQ   +P4  "]&P  OR,  ,$M  #".@  PDD  ,-:  ##;   Q((
M ,27  #$JP  Q+P  ,3+  #$V@!EB0  6(X  $N5   _FP  ,Z(  "BH   =
MK0  %+$   VV   &N0   +P   "_    PP   ,0   #%    Q@   ,<   #)
M!   R@D  ,L-  #-$0  SQ@  -(A  #5+0  UCP  -A-  #97P  VG,  -J*
M  #;G@  VZX  -NZ  #<PP!>E@  49P  $2C   XJ@  ++$  ""W   5NP
M#;X   3"    Q0   ,D   #-    T    -(   #2    U0   -8   #9
MVP   -X%  #@"@  X@\  .46  #H(   ["T  .T^  #M40  [F4  .]Z  #O
MCP  \)\  /"K  #PLP#_ !  _P . /\ #@#_ !( _P = /\ *0#_ #4 _P!!
M /\ 30#^ %8 ^P!? /@ 9@#V &T ] !T /( >0#Q '\ \ "$ .X B0#M (\
MZP"5 .H FP#H *( Y@"J .4 LP#C ,  X0#2 .  Z@#? /D W0#_ -T _P#=
M /\ W@#_ -X _P#_  T _P * /\ "0#_  \ _P 8 /\ ) #^ #$ ^P ] /@
M2 #T %( \ !: .T 8@#K &D Z0!O .< =0#E 'H XP!_ .( A0#@ (H W@"0
M -P E@#: )T V "E -4 KP#2 +H T #* ,X XP#- /0 RP#_ ,L _P#+ /\
MRP#_ ,L _P#_  @ _P # /\ !0#_  P _  4 /< 'P#R "L [P W .L 0@#G
M $P Y !5 .  70#= &0 V@!J -@ < #5 '4 T@!Z -  @ #/ (4 S0"+ ,L
MD@#) )D QP"A ,4 J@## +4 P0## +\ V@"^ .X O0#\ +P _P"\ /\ O #_
M +P _P#_    _P   /\   #Y  < \0 0 .H &@#D "4 WP Q -L / #7 $<
MT@!0 ,X 5P#+ %X R0!E ,8 :@#% '  PP!U ,$ >@#  (  O@"& +P C0"Z
M )0 N0"< +< I0"U +  LP"] +$ SP"O .@ K@#X *X _P"M /\ K0#_ *T
M_P#_    _P   /T   #N  $ XP , -H % #1 !\ S  K ,@ -@#% $  P@!*
M +\ 4@"\ %D N@!? +@ 90"V &H M !O +, =0"Q 'H L "! *X B "M (\
MJP"8 *D H0"G *L I0"X *, R "B .( H0#S *  _@"@ /\ H #_ *  _P#_
M    ]@   .H   #@    TP & ,D #P#" !@ O0 D +D +P"V #H M !# +$
M3 "N %, K !9 *H 7P"I &0 IP!J *8 ;P"D '4 HP![ *$ @@"@ (H G@"3
M )P G0": *< F "T )8 PP"5 -P E #O ), ^P"3 /\ DP#_ )( _P#Y!0
MZ@L  -P-  #+"@  P@4  +P "@"V !$ L0 < *X * "J #, IP ] *0 10"B
M $T H !3 )X 60"< %\ FP!D )H :@"8 '  EP!V )4 ?@"3 (8 D@&/ ) !
MF0". J0 C *Q (L#P ")!=8 B ;M (@'^@"'"/\ A@C_ (8(_P#O#P  WA0
M ,H5  "\$@  LQ   *X,  "K!@T IP,5 *(%( "?!RP G @V )D(/P"7"4<
ME0E. ),)5 "1"EH D I? (X*90"-"FL BPIR (H+>0"("X( APN, (4,EP"#
M#*( @0VP ( -P !_#=@ ?0[O 'P/_0![#_\ >Q#_ 'L0_P#F%P  T1X  +T=
M  "O'   IAD  *$5  ">$ 0 G0T/ )@.&0"4#B4 D0\O (\0.0",$$$ BA!(
M (@03P"'$%4 A1!; (0180""$6< @!%N '\1=0!]$7X ?!*( 'H2E !X$J
M=Q.N '43O@!T%-4 <Q7N '$6_0!Q%O\ <1;_ ' 6_P#<'P  QB4  +,E  "E
M(P  G"$  )8>  "2&0  D10+ (T4% ")%1\ AA8I (,6,P"!%SP @!=# 'X7
M2@!\%U  >A=6 'D87 !W&&( =AAI '08<0!S&7H <1F$ &\:D !N&IT ;!NK
M &L<NP!J'-  :1WL &@>^P!H'O\ 9Q[_ &<>_P#1)@  O2H  *LJ  "=*@
MDR@  (TE  "((@  AAT& (,;$ !_'!H ?!TD 'H=+@!W'C8 =AX^ '0>10!R
M'TL <1]1 &\?6 !N'UX ;!]E &L@;0!I('8 :"&! &8AC0!E(IH 8R*H &(C
MN !A(\T 8"3I & D^@!?)/\ 7R3_ %\D_P#*+   MB\  *0O  "6+P  C"T
M (4J  " *   ?20  'HB#0!V(Q4 <R,@ '$D*0!O)#( ;20Z &LE00!J)4<
M:"5- &8E5 !E)5H 9"9A &(F:0!A)G( 7R=] %XGB@!=*)< 6RFE %HIM0!:
M*LH 62KG %@J^ !8*O\ 6"K_ %@J_P#%,0  KS,  )XS  "0,P  AC(  '\O
M  !Y+0  =2H  '(H"@!O*!( :RD; &DI)0!G*BT 92HU &,J/0!B*D, 8"I*
M %\K4 !>*U< 7"M> %LL9@!9+&\ 6"UZ %<MAP!6+I4 5"ZC %,OLP!3+\<
M4B_E %(O]P!2+_\ 4B__ %(O_P#!-@  JC8  )DV  "+-@  @34  'DS  !S
M,0  ;R\  &LN!@!H+1  9"X8 &(N(0!@+RH 7B\Q %PO.0!;+T  62]& %@O
M30!7,%, 5C!; %0Q8P!3,6P 4C)W %$RA !/,Y( 3C.A $TSL0!--,4!3#3C
M 4PT]@!,-/\ 3#3_ $PS_P"[.0  ICD  )4Y  "'.0  ?#D  '0W  !N-
M:3,  &4R @!A,@T 7C(4 %PS'@!:,R8 6#,N %8S-0!5-#P 4S1# %(T2@!1
M-%  4#58 $XU8 !--FH 3#9U $LW@@!*-Y  23B? $@XL %'.,,!1SCA 4<X
M]0%'./\!1SC_ 4<X_P&W.P  HCP  )$\  "#/   >#P  ' Z  !J-P  9#8
M & V  !<-@L 63<2 %8W&@!4-R, 4C<K % W,@!/.#D 33A  $PX1P!+.$X
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M 3E#_P&J0@  ED,  (9#  !X0P  ;D,  &5#  !=0   5D   %%"  !-0@(
M24,, $9#$@!$1!H 0D0B $%$*@ _13$ /D4X #U%/P \1D< .T9/ #I&5P Y
M1V$ .$=L #='>@ V2(D -4B9 #1(J@ T2+T ,TC9 #1(\  T1_T -$?_ #5&
M_P"F1   DD4  ()&  !U1@  :D8  &%%  !91   440  $Q&  !(1P  1$<*
M $%($  _21@ /4D@ #Q))P Z2BX .4HV #A*/0 W2T0 -DM, #5+50 T3%\
M,TQJ #),=P Q3(8 ,$R7 "]-J  N3;L +DW5 "Y,[P O3/T +TO_ #!+_P"A
M1P  CD@  'Y(  !Q2   9DD  %U(  !52   3$D  $=*  !"2P  /TP& #M-
M#@ Y3A4 -TX= #9/)  U3RL ,T\S #)0.@ Q4$( ,%!* "]14@ N45P +5%G
M "Q1=0 K480 *E*5 "E2I@ I4KD *%+2 "E1[@ I4/P *E#_ "I/_P"<2@
MB4H  'I+  !M2P  8TP  %I,  !13   2$T  $-/   ]4   .5(" #53#  S
M5!( ,509 #!5(0 N52@ +54O "Q6-P K5CX *E9& "E63P H5UD )U=D "97
M<@ E5X$ )%>2 "-7I  B5[< (E?/ ")7[  C5OH (U7_ "15_P"630  A$X
M '5.  !I3@  7T\  %9/  !-4   15(  #]3   Y5@  ,U@  "]:"  K6P\
M*EL5 "A<'0 G7"0 )EPK "5<,P D73H (UU# ")=3  A758 (%YA !]>;@ >
M7GX '5Z/ !Q>H0 ;7K0 &EW, !M=Z0 ;7/D '%O_ !Q;_P"040  ?E$  '!1
M  !D4@  6U(  %)3  !*5   05<  #M9   U6P  +EX  "A@ P D8@P (F,1
M "%C&  ?9"  'F0G !UD+@ <9#8 &V4^ !IE1P 995$ &&5= !=E:@ 697H
M%66+ !1EG@ 39;$ $F7( !)DYP 38_< %&+_ !1B_P")5   >%4  &M5  !@
M5@  5U8  $]7  !&60  /5P  #9?   P8@  *60  "-G   =:@< &6P. !AL
M$P 6;1H %6TA !1M*0 4;3  $VTY !)N0@ 1;DP $&Y8  ]N90 .;G4 #6Z'
M  UNF@ ,;:T "VW"  MLX  ,:_, #6O]  UJ_P""60  <ED  &99  !<6@
M5%H  $I<  !!7P  .6,  #%F   J:0  )&P  !UO   7<@  $G4)  ]W#P .
M=Q0 #G<;  UW(P ,=RH "W<S  IW/  )=T< "'=2  =W7P %=V\ !'>   -W
ME  !=J<  ':[  %UU0 !=.L  G3V  )T_ ![70  ;5T  &)>  !97@  3F
M $5C   \9P  ,VL  "MN   D<@  'G4  !=Y   2?   #7\&  F!#  %@1$
M X$6  *!'0 !@20  ($M  ""-@  @D   (),  ""60  @F@  ()Y  ""C0
M@:   ("T  " RP  ?^<  '[R  !^^0!T8@  :&(  %YB  !39   26<  #]K
M   V<   +70  "5X   >?   %X   !&#   -A@  "(D$  *+"@  BPX  (L3
M  ",&   C!\  (TF  "-+P  CCD  (Y$  ".40  CF   (YQ  ".A0  CID
M (VM  ",PP  C-\  (ON  "+]@!N:   9&<  %AI  !-;   0G$  #AV   O
M>P  )G\  !Z$   6B   $(P   R/   &D@   )4   "6!P  EPP  )</  "8
M$P  F1@  )H?  ";)@  FS   )P[  "<2   G%<  )QH  "<>P  G)   )NE
M  ";N@  FM   )KG  ":\0!J;0  7F\  %%R  !&=P  .WP  #&"   GAP
M'HP  !:1   0E0  "ID   2<    H    *(   "C 0  HP8  *0+  "E#@
MIA(  *<7  "H'@  JB8  *LQ  "K/@  K$T  *Q=  "L<   K(4  *R;  "K
MKP  J\,  *O9  "JZ !D=0  5WD  $M^   _A   -(H  "F0   ?E@  %IL
M !"?   )HP   :<   "J    K@   +    "P    L0   +(#  "T"   M0T
M +80  "W%0  N1T  +LF  "\,P  O4$  +U2  "]9   OGD  +Z0  "]I
MO;<  +W&  "]UP!<?P  4(4  $2+   XD@  +)D  "&?   7I   $*D   FN
M    L@   +8   "Y    O0   +\   "_    P    ,$   ##    Q 4  ,8*
M  #'#@  R1,  ,L<  #.)@  T#4  -%%  #25P  TFL  -."  #3EP  TZD
M -*X  #2Q !5C   29,  #V:   PH@  ):@  !JN   1M   ";D   "]
MP0   ,0   #(    RP   ,T   #-    SP   -    #2    U    -@   #:
M!@  W0P  . 1  #C&@  YB<  .<X  #H2@  Z5T  .IR  #KB   ZYL  .RH
M  #LL@#_  T _P + /\ "P#_ !  _P : /\ )@#_ #( _P ] /\ 2 #[ %(
M^ !: /8 8@#S &D \0!O /  =0#N 'H [ !_ .L A #I (H Z "0 .8 E@#D
M )T X@"E .$ KP#? +L W0#+ -L Y@#9 /< V #_ -@ _P#7 /\ UP#_ -0
M_P#_  @ _P $ /\ ! #_  T _P 5 /X (0#Z "P ]P X /0 0P#P $T [0!5
M .H 70#G &0 Y !J .( < #@ '4 W@!Z -T ?P#; (4 V0"+ -4 D0#3 )D
MT0"@ ,\ J@#- +4 RP#$ ,D W0#( /$ QP#_ ,8 _P#& /\ Q@#_ ,< _P#_
M    _P   /\   #_  H ^  1 /$ ' #L "< Z0 R .8 /0#B $< W0!0 -D
M6 #5 %\ T@!E -  :@#. '  S !U ,H >@#) '\ QP"% ,4 C ## )0 P0"<
M +\ I0"] +  NP"] +H T "X .L MP#[ +8 _P"V /\ M@#_ +8 _P#_
M_P   /T   #S  4 Z0 . .$ %@#; "$ U0 M -$ -P#. $$ R@!* ,< 4@#$
M %D P@!? ,  90"^ &H O !O +L = "Y 'H MP"  +8 AP"T (X L@"7 +
MH "N *H K0"W *L R "I ., J #U *< _P"G /\ IP#_ *8 _P#_    _@
M /$   #E    UP * ,T $0#' !P P@ F +\ ,0"\ #L N@!$ +< 3 "T %,
ML@!9 +$ 7P"O &0 K0!I *P ;P"J '0 J0!Z *< @0"F (D I "1 *( FP"@
M *4 G@"R )T P0"; -H F@#O )D _0"8 /\ F #_ )@ _P#]    \    .$
M  #1    Q@ $ +T #0"W !4 LP @ +  *P"M #4 JP ^ *@ 1@"F $T I !4
M *, 60"A %\ H !D )X :0"= &X FP!U )H >P"8 (, E@", )4 E@"3 *$
MD0"M (\ NP"- ,\ C #I (L ^ ", /\ C #_ (P _P#S @  X@<  ,P'  "_
M!   MP   +$ " "K !  IP 9 *0 ) "@ "X G@ W )P 0 ": $< F !. )8
M5 "5 %D DP!> )( 9 "0 &D CP!O (T =@"+ 'X B@"( (@ D@"& )T A0"I
M (, N "! ,H @ #E (  ]0!_ /\ ?P#_ '\ _P#H#0  T!   +X0  "Q#@
MJ T  *,(  "@ @P G  3 )@ '0"5 "< D@ Q )  .0". 4$ C %( (H"3@")
M E0 AP)9 (8"7P"$ V0 @P-K ($#<@" !'H ?@2$ 'T%C@![!9H >0:G '@&
MM0!V!\@ =0CC '4)] !T"O\ <PK_ ',*_P#=%0  Q!<  +$7  "E%@  G!,
M )81  "4#00 DP@- (X'%0"+"2  B DJ (4*,P"#"SL @0M" ( +20!^"T\
M?0Q4 'L,6@!Z#&  > QG '<,;@!U#78 = V  '(-C !P#9D ;PZF &T.M0!L
M#LD :P_F &H0]P!I$/\ :1#_ &D0_P#0'0  N1X  *@>  ";'0  DAL  (L9
M  "(%0  AQ$' (4.$ "!#QH ?A D 'L0+0!Y$#8 =Q$] '811 !T$4H <Q%0
M '$15@!P$5P ;A)B &T2:@!K$G, :1-] &@3B0!F$Y8 912C &,5LP!B%<8
M8A;C &$6]@!@%_\ 8!?_ & 7_P#'(@  L",  )\D  "2(P  B2(  ((@  !^
M'0  ?!D  'H5#0!W%14 =!8? '$6* !O%S  ;A<X &P7/P!K%T4 :1A+ &@8
M40!F&%@ 91A> &,99@!B&6\ 8!EY %\:A0!=&Y( 7!NA %L<L !:',, 61W@
M %@>] !8'O\ 6![_ %@>_P"_)P  J2@  )DH  "+*   @B<  'LE  !V(P
M<R   '$<"0!N'!$ :QP: &D=(P!G'2P 91TS &,>.@!B'D$ 8!Y' %\>30!>
M'E0 7!]; %L?8@!9(&L 6"!V %8A@@!5(9  5"*> %,BK@!2(\  42/= %$D
M\@!1)/\ 423_ %$C_P"Y*P  HRP  ),L  "&+0  ?"P  '0J  !O*   :R4
M &DB!0!F(0X 8R(6 &$B'P!?(R< 72,O %PC-@!:(ST 621# %<D2@!6)%
M5217 %,E7P!2)6@ 429S $\F?P!.)XT 32B< $PHK !+*;X 2RG: $HI\0!*
M*?\ 2RG_ $LI_P"S+@  GB\  (XP  "!,   =R\  &\N  !J*P  92H  &,G
M 0!?)PP 7"<3 %HG&P!8*"0 5B@K %4H,@!3*#D 4BE  % I1@!/*4T 3BE4
M $TJ7 !,*F4 2BMP $DK? !(+(L 1RV: $8MJ@!%+KP 12[6 $4N[P!%+OX
M12[_ $4M_P"N,0  FC(  (DS  !\,P  <C,  &LQ  !E+P  8"T  %TL  !9
M+ D 5BP0 %0L& !2+"  4"PH $XM+P!-+38 3"T\ $HM0P!)+4H 2"Y1 $<N
M60!&+V, 13!M $,P>@!",8D 03&8 $$RJ ! ,KL /S+3 #\R[@! ,OT 0#+_
M $ R_P"J,P  EC4  (8U  !Y-@  ;C4  &8U  !A,@  7#   %<P  !4, 8
M43 . $XP%0!,,1T 2C$E $@Q+ !',3( 1C$Y $0Q0 !#,D< 0C)/ $$S5P!
M,V  /S1K #XU>  ]-8< /#:6 #LVIP [-KD .C;1 #HV[0 [-OP .S;_ #LV
M_P"F-@  DC<  ((X  !U.   :S@  &,W  !=-@  5S,  %,T  !/- , 2S0,
M $DT$@!&-1H 134B $,U*0!!-2\ 0#4V #\V/0 ^-D0 /3=, #PW50 [.%X
M.CAI #DY=@ X.84 -SJ5 #<ZI0 V.K@ -3K/ #8Z[  V.OL -CG_ #<Y_P"B
M.   CCD  'XZ  !R.P  :#L  %\Z  !9.0  4S8  $XW  !*.   1C@* $0Y
M$ !!.1< /SD? #XY)@ \.2T .SHT #HZ.P Y.T( .#M* #<[4P V/%P -3QG
M #0]=  S/8, ,SZ3 #(^I  Q/K8 ,3[- #$^Z@ Q/OH ,CW_ #(]_P">.P
MBSP  'L\  !N/0  9#T  %P]  !5/   3CH  $D[  !%/   03T' #X]#@ \
M/14 .CX< #D^(P W/BH -C\Q #4_.  T/T  ,T!( #) 4  Q0%H ,$%E "]!
M<@ N0H$ +4*1 "U"H@ L0K4 *T++ "Q"Z0 L0OD +4'_ "U!_P"9/0  ASX
M '<_  !K/P  84   %D_  !2/P  23X  $0_  ! 0   /$$$ #E"#0 W0A(
M-4,9 #-#(0 R0R@ ,40O #!$-@ O1#T +D5% "U%3@ L15@ *T9C "I&;P I
M1GX *$:/ "='H0 F1[, )D?) "9&YP G1O@ *$7_ "A%_P"50   @D$  '-"
M  !G0@  7D(  %5"  !.0@  14(  #]$   [10  -T8  #1'"@ Q2!  +T@6
M "Y)'@ L224 *TDL "I),P I2CH *$I" "=*2P F2U4 )4M@ "1+;0 C2WP
M(DN- "%,GP A3+$ ($S' "!+Y@ A2_< (DK_ ")*_P"00P  ?D0  &]$  !D
M10  6D4  %)%  !*1@  04<  #Q(   W20  ,DL  "Y-!P K3@X *4X3 "=/
M&@ F3R$ )4\H "1/,  C4#< (E _ "%02  @4%( 'U%= !Y1:@ =47D '%&*
M !M1G  :4:\ &5'% !E1Y  :4/8 &T__ !Q/_P"*1@  >4<  &M'  !@2
M5D@  $Y(  !'20  /DL  #E,   S3@  +E   "A3 @ D5 L (E40 "!5%@ ?
M5AX 'E8D !U6+  <5C, &U<[ !I71  95TX &%=9 !=89@ 56'4 %%B' !18
MF@ 35ZP $E?" !)7X0 35O0 %%7_ !15_P"$20  =$H  &9+  !<2P  4TL
M $M,  !$30  /$\  #51   O5   *58  "19   >6P< &ET- !A=$@ 771D
M%EX@ !5>)P 47BX $UXW !)>0  17TH $5]5 !!?8@ /7W$ #E^#  U?E@ -
M7ZD #%Z^  Q>V@ -7?  #5S\  Y<_P!^30  ;DX  &).  !83P  3T\  $A0
M  ! 4@  .%0  #!7   J6@  )%T  !]?   98@$ $V4) !%F#P 09A0 #V8;
M  YG(@ -9RD #6<R  QG.P +9T4 "F=0  EG70 '9VP !F=]  5GD  $9J,
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M  5X"P !> \  'D3  !Y&0  >1\  'HF  !Z+P  >CD  'I$  !Z4   >E\
M 'IP  !Z@P  >I@  'JL  !YP@  >-\  'CO  !W]P!J6P  7UL  %9;  !,
M7   0F   #EC   P:   *&P  "!P   9=   $W<   Y[   )?@  !($"  ""
M"   @PT  (,0  "$%   A1D  (8@  "&*   AS$  (<\  "'20  AU<  (=H
M  "'>P  AY   (:E  "%N@  A=,  (3J  "$] !E8   7&   %%A  !&9
M/&D  #)M   I<@  (7<  !E[   2@   #8,   B'   "B@   (T   ".!
MC@D  (\-  "0$   D10  )(9  "3(   E"D  )4S  "50   EDX  )9?  "5
M<@  E8@  )6=  "4L@  E,@  )/B  "3[@!A90  5F8  $IJ   _;@  -70
M "MY   A?P  &80  !&)   ,C0  !I$   "4    F    )H   ";    G (
M )T'  ">"P  GPX  *$2  "B&   HR   *4I  "F-@  ID0  *95  "F:
MIGT  *:4  "EJ0  I+T  *31  "DY !;;   3W   $-U   X>P  +8$  ".'
M   9C0  $9(   N7   $G    *    "C    I@   *@   "I    J@   *P
M  "M!   K@D  + -  "Q$0  LQ<  +4@  "V*P  MSH  +=+  "X7   N'$
M +B(  "XG0  N+$  +?"  "WT !4=@  2'P  #R"   QB0  )I   !N7   2
MG0  #*(   .G    JP   *X   "R    M@   +@   "X    N@   +L   "]
M    O@   , %  #!"P  PQ   ,86  #)(   RBX  ,L^  #,4   S&0  ,UZ
M  #-D0  S:0  ,VT  #-P !-@P  08H  #61   IF0  'J   !.F   ,K
M [$   "V    N@   +X   #"    Q@   ,@   #(    R@   ,L   #-
MS@   -    #2 0  U0@  -D.  #=%0  X2$  .(Q  #D0P  Y58  .9K  #F
M@@  YY8  .>E  #FL #_  D _P % /\ !@#_  X _P 6 /\ (0#_ "T _P X
M /T 0P#Y $T ]0!5 /( 70#P &, [@!I .P ;P#J '0 Z0!Z .< ?P#F (4
MY "+ ., D0#A )D WP"A -P J@#: +8 UP#& -4 X0#3 /0 T@#_ -$ _P#1
M /\ SP#_ ,H _P#_  $ _P   /\  0#_  P _P 2 /H '0#V "@ \P S /
M/@#L $@ Z !0 .4 6 #B %X WP!D -T :@#; &\ V0!T -8 >@#4 '\ T@"%
M -  C #. ), S "< ,D I0#' +  Q@"^ ,0 U #" .X P0#^ ,  _P#  /\
MOP#_ +X _P#_    _P   /\   #Z  < \0 / .L & #F ", X@ N .  . #;
M $( U0!+ -$ 4@#. %D RP!? ,D 90#' &H Q@!O ,0 = #" 'H P0"  +\
MA@"] (X NP"6 +D H "W *H M@"W +0 R@"R .8 L0#X +  _P"O /\ KP#_
M +  _P#_    _P   /<   #J  ( X0 , -< $P#0 !T S  H ,D ,@#& #P
MP@!% +\ 30"\ %, N@!9 +@ 7P"W &0 M0!I +0 ;@"R '0 L0!Z *\ @ "M
M (@ K "1 *H F@"H *4 I@"Q *0 P0"C -P H0#R *$ _P"@ /\ H #_ *$
M_P#_    ]P   .@   #9    RP ( ,, $ "] !@ N0 B +8 + "T #8 L@ _
M *\ 1P"L $T JP!4 *D 60"G %X I@!C *4 : "C &X H@!T *  >@"> ((
MG "+ )L E0"9 )\ F "L )8 N@"4 ,\ DP#K )( ^P"2 /\ D@#_ )$ _P#W
M    YP   -,   #&    NP " +, # "M !( J@ < *< )@"D #  HP X *
M0 "> $< G !. )H 4P"9 %@ EP!= )8 8P"5 &@ DP!N )( = "0 'P CP"%
M (T CP"+ )H B@"G (@ M0"& ,< A0#D (0 ]0"$ /\ @P#_ (, _P#L
MTP   ,$!  "T    K    *8 !P"@  X G0 6 )H ( "7 "D E0 R ), .@"1
M $$ CP!( (T 30", %, BP!8 (D 70"( &, AP!I (4 ;P"# '< @@"  (
MB@!^ )8 ?0"C 'L L !Z ,( >0#= '@ \0!W /T > #_ '@ _P#>"@  Q L
M +(,  "F"P  G0@  )D$  "5  H D0 1 (X &0"+ ", B0 L (< - "% #L
M@P!" (( 2 "  $X ?P!3 'T 6 !\ %X >P!D 'D :@!X '( =@![ '0 A@!S
M )( <0"? '  K0!N +X ;0'6 &T"[0!L _H ; /_ &P#_P#.$   MQ$  *82
M  ":$0  D1   (L.  ")"P, AP4, (0!$P"! 1P ?@(E 'P#+@!Z S8 > 0\
M '<$0P!U!4@ = 5. ',%5 !Q!5D < 9? &X&9@!M!FX :P=X &H'@P!H")
M9PF= &4)K !D";P 8PK4 &,+[ !B#/H 8@S_ &(,_P##%@  K1<  )T8  "0
M&   AQ8  ($4  !]$0  ? X& 'P*#@!X"A8 =0L? '(+* !P##  ;PPW &T,
M/@!L#$0 :PU* &D-3P!H#54 9PU< &4-8P!C#FL 8@YU & .@0!?#HX 70^<
M %P0JP!;$+T 6A#6 %D1\ !9$?T 61'_ %D1_P"Y&P  I1T  )0>  "('@
M?AT  '@;  !T&   <14  '$1"0!O$!$ ;! 9 &D0(@!G$2H 9A$R &01.0!C
M$3\ 8A%% & 22P!?$E$ 71)8 %P27P!:$V@ 61-R %<4?0!6%(L 5!69 %,5
MJ0!2%KH 41;2 %$7[0!1%_T 41?_ %$7_P"R(   GB(  (XB  "!(P  =R(
M ' A  !L'@  :1L  &<8! !F%0X 8Q85 &$6'@!?%B8 718M %P7- !:%SL
M61=! %@81P!6&$T 51A4 %,87 !2&60 41EN $\:>@!.&X@ 31N7 $L<I@!*
M'+@ 2AW/ $D=ZP!)'?L 21W_ $H=_P"L)   F"4  (@F  ![)P  <28  &HE
M  !F(P  8B$  & >  !>' L 6QL2 %D<&@!7'"( 51PI %0<, !3'3< 41T]
M % =0P!/'4H 31Y1 $P>6 !+'V$ 21]K $@@=P!'((4 1B&4 $0BI !$(K8
M0R+, $,CZ0!#(_H 0R/_ $,B_P"F)P  DRD  (,J  !V*@  ;2H  &4I  !@
M)P  7"4  %DC  !7(0< 52$/ %(A%@!0(1X 3B$E $TB+ !,(C, 2B(Y $DB
M0 !((D8 1R-- $4C50!$)%X 0R1I $(E=0! )H, /R:2 #XGHP ^)[0 /2?*
M #THZ  ]*/D /2?_ #XG_P"B*@  CBL  '\M  !R+0  :"T  &$L  !<*P
M6"@  %0F  !1)@0 3B4- $PE$P!*)AH 2"8B $<F*0!%)B\ 1"8V $,G/ !!
M)T, 0"=+ #\H4P ^*5P /2EF #PJ<@ [*H$ .BN0 #DKH0 X++( -RS( #<L
MY@ X+/@ ."S_ #@L_P"=+   BBX  'LO  !O,   93   %TO  !8+@  4RL
M % J  !,*@  22H+ $8J$0!$*A< 0BH? $$J)0 _*BP /BLS #TK.0 \*T
M.RQ( #HL4  Y+5D ."YD #<N<  V+W\ -2^/ #0PGP S,+$ ,C#' #(PY0 S
M,/< ,S#_ #0O_P"9+P  AS$  '<R  !K,@  8C(  %HR  !4,0  3R\  $LM
M  !'+@  1"X( $$N#@ _+A0 /2X< #LN(@ Y+RD ."\O #<O-@ V,#X -3!&
M #4Q3@ T,5< ,S)B #(R;@ Q,WT ,#.- "\TG@ N-+  +33% "TTXP N-/8
M+S/_ "\S_P"5,0  @S,  '0T  !H-0  7C4  %<T  !1-   2S(  $8Q  !"
M,@  /S(% #PR#0 Y,Q( .#,9 #8S(  T,R8 ,S,M #(T-  Q-#L ,#5# # U
M3  O-E4 +C9@ "TW;  L-WL *S>+ "HXG  I.*X *#C# "@XX@ I./4 *C?_
M "HW_P"2-   ?S4  '$V  !E-P  6S<  %0W  !--@  1S8  $(U   ]-@
M.C8" #<W"P T-Q  ,C<6 #$X'0 O."0 +C@K "TY,@ L.3D *SE! "HZ20 J
M.E, *3M> "@[:@ G.WD )CR) "4\FP D/*T (SS" ",\X  D//0 )3O_ "4[
M_P"--@  ?#@  &TY  !B.0  6#H  %$Y  !*.0  1#D  #TY   Y.@  -3L
M #(["  O/ X +3T4 "P]&@ J/2$ *3TH "@^+P G/C8 )CX^ "4_1P D/U
M(T!; ") :  A0'8 ($"' !]!F0 ?0:L 'D'  !Y!W@ ?0/, 'T#^ " __P")
M.0  >#H  &D[  !>/   53P  $T\  !'/   0#P  #@]   T/@  ,$   "U!
M!0 J0@P )T(1 "9#&  D0QX (T,E ")#+  A1#, ($0[ !]$1  >14X '459
M !Q%90 ;170 &D6% !E&EP 91JD &$:^ !=%W  81?$ &43] !I$_P"$/
M<ST  &8^  !;/P  4C\  $H_  !$/P  /4   #9!   Q0P  +$0  "=& 0 D
M1PH (4@/ "!)%  >21L '4DB !Q)*0 ;2C  &DHX !E*00 82DL %TM5 !9+
M8@ 52W$ %$N" !-+E  22Z< $DN\ !%+V0 22O  $TK\ !1)_P!_/P  ;T
M &%!  !70@  3D(  $="  !!0@  .D,  #)%   M1P  *$D  "-+   >308
M&T\- !A0$0 74!< %E > !50)0 44"P $U$T !)1/0 144< $5%2 !!17P /
M4FT #E)^  U1D0 -4:0 #%&X  Q1T0 -4.P #5#Z  Y/_P!Y0P  :D0  %U$
M  !310  2T4  $1%   ^1@  -D@  "]*   I3   )$\  !]1   :4P  %%8)
M !%7#@ 06!, $%@9  ]8(  .6"@ #5@P  U8.0 ,6$, "UA.  I86@ (6&@
M!UAY  98C  %6)\ !%BS  17R@ %5^8 !5?S  96_ !S1@  9$<  %E(  !0
M2   2$@  $%)   Z2@  ,DT  "M0   E4@  (%4  !I8   56@  $%T&  Q@
M#  *8!  "6 5  A@'  '8", !6 K  1@-  #8#T  6!)  !@50  8&,  &!S
M  !@A@  7YH  %^N  !?Q   7N(  %[P  !>^ !L2@  7TL  %5+  !,3
M14P  #U.   U4   +E,  "=6   @60  &EP  !5?   08@  #64$  AG"P #
M9PX  &@3  !H&   :!\  &DF  !I+@  :3@  &E#  !I3P  :5T  &EM  !I
M@   :90  &BI  !HOP  9]P  &;N  !F]P!F3P  6D\  %%/  !*3P  05$
M #A4   P5P  *%L  "%>   :8@  %&4  !!H   ,:P  !VX#  %P"0  < T
M '$0  !Q%   <AH  ',A  !S*   <S$  ',\  !T2   <U8  '-F  !S>0
M<XX  '.C  !RN0  <=(  ''K  !P] !A4P  5E,  $]3  !%50  .U@  #)<
M   J8   (F0  !MH   4;   #V\   MR   &=@   'D   !Z!@  >@H  'L.
M  !\$0  ?14  'X;  !_(@  @"H  ( U  " 00  @$\  (!?  " <0  @(8
M ("=  !_L@  ?LH  '[E  !]\0!<6   5%@  $E:   _70  -6$  "QE   C
M:@  &V\  !1S   .=P  "7L   -_    @@   (0   "& 0  A@8  (@*  ")
M#0  BA   (L5  ",&P  CB(  (\L  "/.   CT8  (]6  "/:   CWX  (^5
M  ".JP  C<$  (W<  ",ZP!970  3E\  $-B   X9@  +FP  "1Q   <=P
M%'P   Z!   (A0   (D   "-    D    )(   "3    E    )8#  "7"
MF P  )H/  ";$P  G1H  )\C  "@+@  H#P  *!,  "@7@  H'0  )^,  "?
MH@  G[<  )[+  ">X !39   1V@  #QM   Q<P  )WD  !U_   4A0  #8L
M  :0    E    )@   "<    GP   *$   "B    I    *4   "G    J 0
M *H)  "L#0  K1(  + 9  "R(P  LC$  +)"  "R5   LFD  +*   "RF
ML:P  +*_  "QS@!,;@  0',  #5Z   J@0  'X@  !6.   .E0  !IH   "?
M    I    *@   "L    KP   +$   "Q    LP   +4   "V    N    +H
M  "\!@  O@P  , 1  ##&0  Q28  ,4W  #&20  QET  ,=R  #'B@  R)\
M ,BO  #(O !&>@  .8$  "Z)   BD   %Y@   ^?   'I0   *H   "O
MLP   +<   "\    OP   ,$   #"    Q    ,4   #'    R0   ,L   #-
M    SP,  -(*  #6$   W!H  -TJ  #>/   WU   .!E  #A>P  X9$  .*B
M  #BK0#_  ( _P   /\  P#_  P _P 3 /\ '0#_ "@ _@ S /L /@#W $@
M\P!0 /  5P#M %X ZP!D .@ :0#G &\ Y0!T ., >0#B '\ X "% -X C #<
M ), V0"< -8 I@#3 +$ T0#  ,\ V@#. /$ S #_ ,L _P#+ /\ Q@#_ ,$
M_P#_    _P   /\   #_  @ ^P 0 /8 &0#R "0 [P N .T .0#H $( XP!+
M .  4@#= %D V0!? -8 9 #3 &D T0!N ,\ = #. 'D S !_ ,H A@#( (X
MQ@"6 ,0 H #" *L P "Y +X S0"\ .H NP#\ +H _P"Z /\ N@#_ +8 _P#_
M    _P   /X   #T  0 ZP - .0 % #? !\ VP I -@ ,P#3 #T S@!% ,H
M30#' %, Q0!9 ,, 7P#! &0 OP!I +T ;@"[ ', N@!Y +@ @ "V (@ M "0
M +( F@"Q *4 KP"R *T Q "L .$ JP#V *H _P"J /\ J@#_ *H _P#_
M_0   .X   #B    U0 * ,T $0#' !D Q  C ,$ +0"_ #< NP _ +< 1P"U
M $X L@!3 +  60"O %X K0!C *P : "K &T J0!S *@ >@"F ($ I "* *,
ME "A )\ GP"L )X NP"< -( FP#N )H _P": /\ F0#_ )D _P#^    [@
M -X   #+    P0 % +D #0"T !0 L0 > *X )P"K #  J@ Y *< 00"D $@
MH@!- *$ 4P"? %@ G@!= )T 8@"; &< F@!M )@ <P"7 'L E0"$ )0 C@"2
M )D D "F (X M "- ,@ C #F (L ^0"* /\ B@#_ (L _P#P    VP   ,<
M  "Z    L    *@ "@"D !  H  8 )T (0"; "H F@ S )@ .P"6 $$ E !(
M )( 30"1 %( CP!7 (X 7 ", &$ BP!G (H ;@"( '4 AP!^ (4 B "# )0
M@@"@ (  KP!_ ,  ?@#= 'T \@!] /\ ?0#_ 'T _P#@    Q@   +4   "J
M    H@   )L !0"5  T D@ 3 )  ' "- "0 BP M (H - "( #L A@!" (4
M1P"# $T @@!2 ($ 5P!_ %P ?@!B 'T : ![ '  >@!Y '@ @P!V (\ =0"<
M '0 J@!R +H <0#1 '  [ !P /L < #_ '  _P#-!   MP8  *<'  ";!@
MDP0  (X   "*  @ A@ / (0 %@"! !X ?P G 'T +@!\ #8 >@ \ 'D 0@!W
M $< =@!, '4 4@!S %< <@!= '$ 8P!O &L ;@!T &P ?@!K (H :0"8 &@
MI@!G +8 9@#+ &4 YP!E /< 90#_ &4 _P# #   JPT  )L.  "/#@  A@T
M ($+  !^!P$ ? $+ 'D $0!W !@ =0 A ', *0!Q #  ;P V &X / !L $(
M:P!' &H 30!I %( : !8 &8 7P!E &< 8P!P &(!>@!@ 8< 7P*5 %X"HP!<
M [, 7 /' %L$Y !;!?0 6P;^ %L&_P"U$   H1(  )$3  "%$P  ?!(  '81
M  !S#@  <@P$ '$'#0!N!!( ; 0; &D%(P!G!2H 9@8Q &0&-P!C!CT 8@=#
M &$'20!?!TX 7@A5 %T(7 !;"6, 6@EM %@*> !7"H4 5@N3 %0+H@!3"[,
M4@S' %(,Y !1#?4 40W_ %$-_P"M%0  F1<  (D8  !]&0  =!@  &T7  !J
M%   9Q$  &<.!P!F# X 8PP5 &$,'0!?#"4 70TL %P-,P!;#3D 6@T_ %@-
M10!7#4L 5@Y1 %4.60!3#F$ 4@YK % /=@!.$(, 31"2 $P0H@!+$+( 2A'(
M $D1Y0!)$?< 21+_ $D1_P"E&0  DAP  (,=  !V'@  ;1T  &8<  !B&@
M7Q<  %X4 0!>$0H 6Q 1 %D1& !7$2  51$G %01+@!3$30 41$[ % 200!/
M$D< 3A). $P250!+$UX 21-G $@4<P!&%(  116/ $05GP!#%K  0A;% $(7
MXP!"%_8 0A?_ $(7_P"?'0  C"   'TA  !Q(@  :"(  &$A  !<'P  61P
M %<9  !5%@8 5!4. %$5% !/%AP 3A8C $P6*@!+%C  2A8W $D7/0!'%T,
M1A=* $484@!#&%H 0AED $$9<  _&GT /AN- #T;G0 \'*X .QS# #L<X0 [
M'?4 .QS_ #P<_P":(0  AR,  '@D  !L)0  8R4  %PD  !7(P  4R   %$>
M  !/' ( 31L, $L:$0!(&Q@ 1QL@ $4;)@!$&RT 0QPS $(<.0! '$  /QU'
M #X=3P ]'E@ /!YB #H?;0 Y'WL .""+ #<AFP V(:T -2'! #4AWP U(?,
M-B'_ #8A_P"6(P  @R8  '0G  !H*   7R@  %@G  !3)@  3R0  $PB  !)
M(   1R ) $0?#P!"'Q4 0" < #\@(P ^("D /" O #LA-@ Z(3T .2%$ #@B
M3  W(E4 -B-? #0C:P S)'D ,B6) #$EF@ P):L ,":_ "\FW  P)O( ,";_
M #$E_P"1)@  ?R@  '$J  !E*@  7"H  %4J  !/*0  2R@  $@E  !$)
M020% #\D#0 ])!( .R09 #DD'P W)"8 -B0L #4E,P T)3H ,R9! #(F2@ Q
M)U, ,"== "\H:0 N*7< +2F' "PIF  K*JH *BJ] "HJV@ K*O$ *RK^ "PI
M_P"-*   ?"H  &TL  !B+0  62T  %$M  !,+   1RL  $,H   _*   /"@"
M #DH"P W*!  -2@6 #,H'  R*", ,"@I "\I,  O*C< +BH_ "TK1P L*U$
M*RQ; "HL9P I+74 *"V% "<MEP F+J@ )2Z\ "4NV  F+O  )B[] "<M_P"*
M*P  >"T  &HN  !?+P  5B\  $XO  !(+@  0RT  #\L   [+   -RP  #0L
M"0 R+ X ,"T3 "XM&@ M+2  *RTG "HN+0 J+C4 *2\] "@O10 G,$X )C!9
M "4Q90 D,7, (S&# "(RE0 A,J< (3*[ " RU  A,N\ (C'\ "(Q_P"&+0
M=2\  &<P  !<,0  4S$  $LQ  !%,0  0#   #LP   V,   ,S   # Q!@ M
M,0T *S$1 "DR%P H,AX )S(D "4S*P E,S( )#,Z ",T0P B-$P (357 " U
M8P ?-7$ 'C:! !TVDP <-J4 &S:Y !LVT@ <-NT '3;[ !TU_P"",   <3(
M &,S  !9-   4#0  $DT  !",P  /3,  #<S   Q-   +C4  "LU @ H-@L
M)3<0 "0W%0 B-QL (3@B " X*  ?.#  'C@W !TY0  <.4D &SI4 !HZ8  9
M.FX &#I_ !<[D0 7.Z0 %CNW !4[T  6.NP %SKZ !@Y_P!],@  ;30  & U
M  !5-@  338  $8V  ! -@  .C8  #0V   N.   *CD  "8Z   C.P@ (#P.
M !X]$@ =/1@ '#T? !L^)0 :/BT &3XT !<^/0 6/T< %3]1 !0_7@ 4/VP
M$T!\ !) CP 10*( $4"V !! S@ 1/^L $C_Y !(^_P!Y-0  :3<  %PX  !2
M.0  2CD  $,Y   ].0  -SD  #$Z   K/   )ST  "(_   >000 &D(+ !A#
M$  70Q4 %40; !1$(@ 31"D $T0Q !)$.@ 114, $$5. !!%6P .16D #D5Y
M  U%C  -19\ #$6R  M%R0 ,1>4 #43V  U$_P!T.0  93H  %@[  !/.P
M1SP  $ \   Z/   -#P  "X^   H0   (T(  !]$   :1@  %4@( !)*#0 1
M2A( $$H8  ]+'@ .2R4 #4LM  U+-@ ,2T  "TM*  I+5@ )2V0 "$MT  =+
MAP %2YH !$NN  1*Q  %2N  !4KP  9)^@!N/   8#T  %0^  !+/@  1#X
M #T^   W/P  ,4   "I"   D10  'T<  !I)   53   $4X%  Y1"P +41
M"E$4  E1&P (42( !U$I  51,@ $4CL  U)&  %24@  4E\  %)O  !2@0
M498  %&I  !1OP  4-P  %#N  !0]P!H0   6T$  %!!  !(00  04$  #M"
M   T0P  +44  "9(   @2P  &TT  !90   14P  #E4$  I8"@ &6 X  E@2
M  !9%P  61T  %DE  !9+0  638  %E!  !930  6EH  %II  !9?   69
M %FE  !8N@  6-4  %?L  !7]@!C1   5D4  $U%  !%10  /T4  #='   O
M20  *$P  ")/   ;4@  %E4  !%8   -6@  "5T#  1?"0  8 T  & 0  !A
M%   81D  &(@  !B)P  8C$  &([  !B1P  8E4  &-D  !B=@  8HL  &*@
M  !AM@  8<\  &#J  !@]0!=2   4DD  $I(  !#2   .DH  #)-   J4
M(U,  !Q7   66@  $5T   U@   (8P   V8!  !G!@  : L  &D.  !J$0
M:Q4  &P;  !M(@  ;2H  &TT  !M0   ;4X  &U=  !M;P  ;80  &R:  !L
ML   :\@  &OF  !J\P!830  3DT  $A,   ^3@  -5$  "Q4   D6   '5P
M !9@   09   #&<   =K   !;@   '    !R P  <@<  ',+  !U#@  =A$
M '<6  !X'   >2,  'HM  !Z.0  >D<  'I6  !Y:   >GP  'F4  !XJ@
M>,$  '??  !W[P!440  3%$  $)2   X50  +UD  "9>   >8@  %F<  !!K
M   +;P  !7,   !W    >@   'P   !^    ?P(  ( &  "!"@  @PT  (01
M  "&%0  B!P  (DE  "*,   BCX  (E-  ")7P  B7,  (B+  "(H@  A[D
M (?1  "&Z !25@  1U<  #Q:   R7P  *&0  !]I   6;P  $'0   IY   "
M?0   ($   "%    B    (H   ",    C0   (\   "0!   D@@  ),,  "5
M$   EQ4  )D=  ";)P  FS0  )M$  ":5@  FFH  )F"  ":F@  F+   )C'
M  "7W@!+7   0&   #5E   K:@  (7$  !=W   0?0  "8,   &(    C
M )$   "5    F    )H   ";    G0   )\   "@    H@   *0%  "F"@
MJ X  *H4  "M'0  K2H  *TY  "M2P  K5\  *UW  "LD   JZ<  *NZ  "K
MRP!%9@  .6L  "YQ   C>   &7\  !"&   )C0   ),   "8    G0   *$
M  "E    J    *L   "K    K@   *\   "Q    LP   +4   "W 0  N0<
M +P-  "_$P  PA\  ,(N  #"0   PE0  ,%K  #!@P  P)L  ,&M  #!O  ^
M<@  ,G@  ">    <B   $I    J7    G0   *,   "H    K0   +(   "V
M    N0   +L   "\    O@   ,    #"    Q    ,8   #(    RP   ,X%
M  #1#0  UA0  -<C  #8-0  V4D  -I>  #;=0  VXP  -R?  #<JP#_
M_P   /\   #_  D _P 0 /\ &0#^ "0 _  O /D .0#T $, \ !+ .T 4@#J
M %D YP!? .0 9 #B &D X !N -X <P#< 'D V@!_ -< A@#4 (X T0"6 ,\
MH0#, *P R@"[ ,@ T@#& .X Q@#_ ,4 _P#% /\ OP#_ +H _P#_    _P
M /\   #^  4 ]P . /( %0#N !\ ZP J .D - #C #T W@!% -D 30#4 %,
MT0!9 ,X 7@#, &, R@!H ,D ;0#' ', Q0!Y ,, @ #! (@ OP"0 +T FP"[
M *8 N0"T +< R "V .8 M0#[ +0 _P"T /\ LP#_ *X _P#_    _P   /@
M  #M    Y0 + -T $0#7 !H T@ D ,\ +@#+ #< QP!  ,, 1P#  $X O@!3
M +P 60"Z %X N !C +8 : "U &T LP!S +$ >0"O ($ K0"* *L E "I *
MJ "M *8 O@"E -L I #T *0 _P"C /\ HP#_ *( _P#_    ]@   .8   #7
M    RP & ,0 #@"^ !4 NP ? +D * "W #$ M  Z +  00"M $@ JP!. *D
M4P"G %@ I@!< *0 80"C &< H0!L *  <P"> 'H G0"# )L C@"9 )D EP"F
M )8 M@"5 ,P E #K ), _0"3 /\ DP#_ ), _P#W    Y    -    #!
MMP " *\ "P"K !$ IP 9 *4 (@"C "L H@ S )\ .P"< $( FP!( )D 30"7
M %( E@!7 )4 6P"3 &$ D@!F )  ;0"/ '0 C0!] (P AP"* ), B "@ (<
MKP"% ,( A0#B (0 ]P"$ /\ A #_ (0 _P#E    S0   +P   "O    I@
M )X !P":  X E@ 4 )0 '0"2 "4 D0 M )  -0"- #P C !" (H 1P"( $P
MAP!1 (8 5@"$ %L @P!@ ($ 9P"  &X ?@!W 'T @0![ (T >@": '@ J0!W
M +H =@#3 '8 [P!V /X =0#_ '4 _P#0    NP   *L   "?    EP   )
M @"+  L B  0 (8 %P"$ "  @@ G ($ +P!_ #4 ?0 \ 'P 00![ $8 >0!+
M '@ 4 !W %4 =@!; '0 80!S &D <0!Q '  >P!N (< ;0"5 &L HP!J +0
M:@#) &D Z !I /D :0#_ &D _P#     K    )P"  "0 @  B    (,   !_
M  8 >P - 'D $@!W !H =@ B '0 *0!S #  <0 V '  / !O $$ ;0!& &P
M2P!K %  :@!6 &@ 7 !G &0 90!L &0 =@!C (( 80"0 &  GP!? *\ 7@##
M %X X0!> /0 70#_ %T _P"T!P  H D  ) +  "$"P  ? H  '<'  !T!
M<0 ) &\ #P!M !4 :P < &D (P!H "H 9P Q &4 -@!D #P 8P!! &( 1@!@
M $P 7P!2 %X 6 != %\ 6P!H %H <@!8 'X 5P", %8 FP!5 *L 5 "^ %0
MV@!3 .\ 5 #[ %0 _P"I#0  E@X  (<0  !Z$   <A   &P.  !I#   9PD#
M &8$"P!D !  8@ 7 &  '@!> "4 70 K %P ,0!: #< 60 \ %@ 0@!7 4<
M5@%. %4"5 !3 EP 4@-E %$#;P!/!'L 3@2* $T%F0!,!:D 2P6\ $H&U !*
M!^T 2@?Y $H'_P"A$   CA(  'X4  !S%   :A0  &03  !@$0  7@\  %T-
M!0!="0T 6@82 %@'&0!6!R  50<G %,'+0!2"#, 40@X % (/@!/"40 3@E*
M $P)40!+"ED 2@IB $@+;0!'"WH 1@R( $0,F !##*D 0@V\ $(-U0!"#>X
M0@W[ $(-_P":%   AQ8  '@8  !L&0  8QD  %T8  !9%@  5A,  %01  !4
M#@@ 4PT. %$-% !/#1L 30TB $P-* !+#2X 2@TT $D-.@!'#D$ 1@Y' $4.
M3P!$#E< 0@]A $$0;  _$'D /A"( #T1F  [$:D .Q&\ #H1U@ Z$?  .A+]
M #L1_P"3&   @1H  ',<  !G'0  7AT  %@<  !3&P  4!@  $X6  !,$P,
M3!$+ $H0$ !($1< 1A$> $41) !$$2H 0A$P $$1-P! $CT /Q)$ #T23  \
M$U0 .Q-> #D4:0 X%'8 -Q6% #85E@ T%J< -!:Z #,6TP S%NX -!;\ #06
M_P".&P  ?!T  &X?  !C(   6B   %,@  !.'@  2AT  $@:  !&&   118'
M $,5#@!!%1, /Q4: #X5(  ]%2< .Q4M #H6,P Y%CH .!9! #<720 U%U$
M-!A; #,99@ R&7, ,!J# "\:E  N&Z4 +1NX "T;T  M&^P +AO[ "X;_P"*
M'@  >"   &HB  !?(P  5B,  $\B  !*(0  1B   $,>  !!&P  /QH# #T:
M#  [&1$ .1D6 #<:'0 V&B, -1HI #0:,  S&S8 ,1L^ # <1@ O'$\ +AU9
M "T=9  L'G$ *Q^! "H?D@ I'Z0 *""W "<@S@ G(.L *"#Z "D?_P"&(
M=",  &<D  !<)0  4R4  $PE  !')   0B,  #\A   ]'P  .AX  #<>"0 U
M'@X ,QX3 #$>&@ P'B  +QXF "X?+0 M'S, +" [ "L@0P J(4P *2%6 "@B
M8@ F(F\ )2-_ "0CD  C(Z( (B2U "(DS  B).D (R3Y "0C_P""(P  <24
M &,F  !9)P  4"@  $DG  !#)P  /R8  #LD   X(@  -2(  #(B!@ P(@T
M+B(1 "PB%P J(AT *2(C "@C*@ G(S$ )B0X "4E00 D)4H (R94 "(F8  A
M)VT ("=] !\GCP >**$ 'BBT !THR@ =*.@ 'BCX !\G_P!^)0  ;B<  & I
M  !6*0  32H  $8J  !!*0  /"@  #<G   T)@  ,"8  "TF P K)PL *"<0
M "<G%  E)QH )"<A ",H)P B*"X (2DV " I/@ ?*D@ 'BI2 !TK7@ <*VL
M&RM[ !HLC0 9+)\ &"RR !@LR0 8+.< &2OW !HK_P!Z)P  :BH  %TK  !3
M+   2BP  $,L   ^*P  .2L  #0J   P*@  *RH  "DK   F*P@ (RP. "(L
M$@ @+!@ 'RP> !XM)0 =+2P '"TS !LN/  :+D4 &2]0 !@O7  7+VD %C!Y
M !4PBP 4,)X %#"Q !,PQP 3,.4 %##V !4O_P!V*@  9RP  %HM  !0+@
M2"X  $$N   [+@  -BT  #$M   L+0  )R\  "0O   A, 4 'S$, !PQ$  ;
M,A4 &C(< !DR(@ 8,BD %S,Q !8S.0 5,T, %#1- !,T60 2-&< $35W !$U
MB0 0-9P $#6P  XUQ@ /-.0 $#3U ! T_P!R+   8RX  %<P  !-,   13
M #XP   X,   ,S   "\P   I,0  )#(  "$S   =-0( &C8) !<W#@ 5-Q,
M%#@9 !,X'P 2."8 $C@N !$Y-@ 0.4  $#E+  XY5P ..F0 #3IT  PZA@ ,
M.ID "SFL  HYP0 *.=X "SGQ  PX_ !N+P  7S$  %,R  !*,P  0C,  #LS
M   V,P  ,3(  "PS   G-   (38  !TX   9.0  %3L& !(]#  0/A  $#X5
M  X^'  ./B, #3XJ  P^,P ,/CP "S]'  H_4@ (/V  !S]O  8_@0 %/Y0
M!#^H  ,^O  $/M< !3[L  4^]P!I,P  6S0  % U  !'-0  /S4  #DU   T
M-0  +C4  "DW   C.   'CL  !H\   6/P  $D$$  Y#"@ ,1 X "D03  E$
M&0 (1"  !T0G  9$+P %1#@  T5"  )%3@  15L  $5J  !%?   19   $2D
M  !$N0  1-$  $3J  !#]0!D-@  5S<  $PX  !#.   /#@  #<X   Q.
M*SD  "4[   @/0  &D   !9"   21   #D<$  M)"0 '2@T !$L1  %+%@
M2QP  $LC  !+*P  2S0  $L^  !,20  3%<  $QF  !,=P  2XP  $NA  !+
MM0  2LX  $KI  !*]0!?.@  4CL  $@[  ! .P  .CL  #0[   N/   )SX
M ")!   <0P  %D8  !))   .2P  "TX#  =0"  "40P  %$0  !2$P  4Q@
M %,?  !3)@  4R\  %,Y  !310  4U(  %-A  !3<@  4X<  %*<  !2L0
M4<H  %'G  !1] !9/@  3CX  $4^   ^/@  .#X  #!    I0@  (T0  !U'
M   72@  $DT   Y0   +4P  !E4"  !7!P  6 L  %D.  !:$0  6A4  %L:
M  !<(0  7"H  %PT  !</P  7$T  %Q;  !<;   7($  %N7  !;K0  6L4
M %KD  !9\P!40@  2D(  $)"   \0@  -$,  "Q&   E20  'DP  !=/   2
M4P  #E8   I9   %6P   %X   !@!   80@  &(,  !C#@  9!$  &46  !F
M'   9R,  &<M  !G.0  9T8  &=5  !G9@  9WH  &:1  !EJ   9<   &3>
M  !D\ !/1@  1T8  $!%   W1P  +TH  "9-   ?40  &%4  !)9   -7
M"&    )C    9@   &@   !J    :P0  &P(  !M#   ;PX  ' 2  !R%P
M<QT  '0F  !T,@  =#\  '1.  !S7P  ='(  '.*  !RH0  <;@  ''4  !P
M[ !,2@  14H  #M+   R3@  *5(  "!6   86P  $E\   UD   ':    &L
M  !O    <@   '4   !V    =P   'D"  !Z!@  ? H  'X.  " $0  @A8
M (0>  "$*0  A#8  (1%  "$5@  @VH  (.!  ""F0  @;$  (#)  " Y0!*
M3@  /U   #53   K5P  (EP  !EB   29P  #&P   5Q    =0   'D   !]
M    @0   (,   "%    A@   (@   ")    BP0  (T(  "/#0  DA   )06
M  "6(   EBP  )8[  "63   E6   )5V  "4D   DZ<  )*]  "2U0!$50
M.5D  "]=   D8P  &FD  !)O   ,=0  !'L   "     A0   (D   "-
MD0   ),   "4    E@   )@   ":    G    )X   "@!@  H@L  *40  "H
M%P  J2,  *DQ  "I0P  J58  *AM  "FAP  IYX  *:S  "EQP ^7@  ,F,
M "=J   =<   $W@   Q_   #A0   (L   "1    E@   )L   "?    H@
M *0   "E    IP   *D   "K    K0   +    "R    M0(  +<)  "[$
MOA@  +XF  "^.   ODL  +UA  "\>@  NY0  +JI  "ZN0 W:@  *W   "!X
M   6@   #8@   6/    E@   )P   "B    IP   *P   "P    LP   +8
M  "W    N0   +L   "]    OP   ,(   #%    R    ,H   #."   TA
M -4;  #5+   U$   -17  #3;@  U(8  -2;  #3JP#_    _P   /\   #_
M  4 _P . /\ %0#\ "  ^0 J /8 - #Q #T [0!& .D 30#F %, Y !9 .$
M7@#> &, W !H -D ;@#5 ', TP!Y -  @ #. (@ RP"1 ,D G #& *< Q "W
M ,( S #  .P OP#_ +X _P"] /\ MP#_ +( _P#_    _P   /\   #Z  $
M\P + .T $@#H !L Y0 E .0 +@#? #@ V !  -( 1P#. $X RP!4 ,@ 60#&
M %X Q !C ,( 9P#  &T OP!S +T >@"[ ($ N0"+ +8 E0"T *$ L@"O +
MP@"N ., K@#Z *P _P"M /\ J0#_ *8 _P#_    _P   /(   #F    W0 '
M -( #@#- !8 R@ @ ,@ *0#% #( P  Z +P 0@"Y $@ MP!. +4 4P"S %@
ML0!= +  8@"N &< K !L *H <P"I 'L IP"$ *4 C@"C )H H0"H )\ N0">
M -( G0#R )P _P"= /\ G #_ )D _P#\    [@   -T   #,    P0 " +H
M# "V !( L@ : +  (P"O "P K0 T *D / "F $( I !( *( 30"@ %( G@!7
M )T 6P"< &  F@!F )D ; "7 '0 E0!] ), AP"1 ), D "A (X L0"- ,8
MC #H (L _0", /\ C #_ (P _P#M    V    ,4   "W    K    *8 " "A
M  X GP 5 )T '@"; "8 F@ N )< -0"5 #P DP!" )$ 1P"0 $P C@!1 (T
M50"+ %H B@!@ (D 9@"' &T A0!V (0 @ "" (P @ ": '\ J0!] +P ? #<
M 'P ]0!\ /\ ? #_ 'P _P#9    P0   +$   "D    G    )0  P"0  P
MC0 1 (L & ") "  B0 H (< +P"% #8 @P \ (( 00"  $8 ?P!+ 'T 3P!\
M %0 >P!: 'D 8 !X &< =@!P '4 >@!S (8 <0"3 '  H@!O +0 ;@#, &X
M[0!N /X ;@#_ &X _P#$    KP   *    "4    C    (8   "!  @ ?@ .
M 'P % ![ !L >0 B '@ *0!W #  =0 V '0 .P!R $  <0!% '  2@!O $\
M;0!4 &P 6P!K &( :0!J &@ = !F (  90". &, G0!B *T 80#" &$ Y !A
M /@ 80#_ &$ _P"T    H    )$   "&    ?@   'D   !U  , <0 + &\
M$ !M !8 ;  = &L ) !K "H :0 P &@ -@!F #L 90!  &0 10!C $H 80!/
M &  5@!? %T 70!E %P ;P!: 'H 60"( %@ F !7 *@ 5@"[ %8 V !6 /$
M5@#_ %8 _P"H 0  E 4  (4'  !Z!P  <@8  &P$  !I 0  9P ' &0 #0!C
M !$ 80 8 &  'P!? "4 7@ K %T , !; #8 6@ [ %D 0 !8 $4 5P!+ %8
M40!5 %@ 4P!A %( :@!0 '8 3P"$ $X DP!- *0 3 "V $P S0!, .L 3 #Z
M $P _P"="0  BPL  'P-  !P#0  : T  &(,  !?"@  708! %P!"0!:  X
M6  3 %< &0!6 "  50 F %, *P!2 #$ 40 V %  .P!/ $$ 3@!' $T 30!+
M %4 2@!= $D 9P!' ', 1@"  $4 D !$ *$ 0P"R $, R !# .8 0P#U $,
M_P"5#0  @P\  '00  !I$0  8!$  %H0  !6#@  5 T  %,*! !3!@L 40,0
M $\!%0!. 1L 3 $A $L!)P!* BP 20(R $@"-P!' ST 10-# $0#2@!#!%$
M0@1: $ %9  _!7  /@9^ #T&C@ \!Y\ .P>Q #H'Q@ Z!^, .@?S #H(_ ".
M$   ?!(  &X4  !B%0  6A4  %04  !0$P  31$  $L.  !+#08 2@H, $D(
M$0!'"!8 10@= $0((P!"""@ 00DN $ ),P _"3D /@I  #T*1P \"D\ .@M8
M #D+8P X#&\ -@Q^ #4,C@ T#9\ ,PVQ #(-QP R#>, ,@WT #(-_@"($P
M=Q4  &D7  !>&   51@  $\8  !*%@  1Q4  $43  !#$ ( 0PX( $(-#@!
M#1( /PT8 #T-'P \#20 .PTJ #D-,  X#C< -PX] #8.10 U#DT ,P]7 #(/
M8@ Q$&X +Q!] "X0C@ M$:  +!&R "L1R  K$>8 *Q'V "P1_P"#%@  <AD
M &0:  !9&P  41L  $L;  !&&@  0A@  #\7   ^%   /!($ #L1"@ Z$!
M.! 5 #<0&P U$2$ -!$G #,1+0 R$3, ,!$Z "\20@ N$DL +1-4 "L37P J
M%&P *11[ "@4C  G%9X )A6P "45Q@ E%>0 )17V "85_P!^&0  ;AL  & =
M  !6'@  31X  $<>  !"'0  /AP  #H:   X&   -Q8  #45!P T% T ,A02
M # 4%P O%!T +10C "P5*@ K%3  *A4W "D6/P H%D@ )Q=2 "8870 D&&H
M(QEY "(9B@ A&9P (!FO !\9Q  ?&>( (!GT " 9_P!Z&P  :AX  %T?  !3
M(   2B   $0@   ^'P  .AX  #<=   T'   ,AD  # 9!  N& L +!@0 "H8
M%  I&!H )Q@@ "89)@ E&2T )!HU ",:/0 B&T8 (1M0 " <6P ?'6@ 'AUW
M !T=B  <'IL &QZM !H>PP :'N  &AWS !L=_P!W'0  9R   %HA  !0(@
M2"(  $$B   [(@  -R$  #,@   P'P  +1T  "L=   H'0@ )AT. "4=$@ C
M'1< (1T= "$=)  @'BH 'QXR !X?.@ ='T, '"!- !LA60 :(68 &2%U !@B
MAP 7(ID %B*L !4BP0 5(M\ %2'R !8A_@!S(   9"(  %<C  !-)   124
M #XD   Y)   -",  # B   L(@  *2$  "8A   D(08 (B$, " A$  >(14
M'2(; !LB(0 ;(B@ &B,O !DC.  8)$$ %R1+ !8E5P 5)60 %"9S !,FA0 2
M)I@ $2:K !$FP  0)MT $27Q !(E_0!P(@  820  %0F  !*)@  0B<  #PF
M   V)@  ,24  "TE   I)   )B0  "(E   ?)0, '28* !LF#@ 9)Q( &"<8
M !<G'P 6)R4 %2@M !0H-0 3*3X $BE) !$I50 1*F( $"IQ  \J@P .*I8
M#BJI  TJO0 -*M< #2KN  XI^P!L)   728  %$H  !(*   0"D  #DH   T
M*   +R@  "LG   G)P  (B@  !XI   ;*@  &"L' !8K#0 4+!$ $RP6 !(L
M'  1+2, $"TJ ! M,@ /+CP #BY&  TN4@ -+E\ #"]N  LO?P *+Y( "2^E
M  DNN0 (+M  "2[I  HN]P!H)P  6BD  $XJ  !%*P  /2L  #<K   Q*@
M+2H  "DJ   D*@  ("L  !LM   8+@  %2\$ !(Q"@ 0,@X #S(3  XR&0 -
M,B  #3(G  PR+P +,S@ "C-"  DS3@ (,UL !C1J  4T>P $,XX  S.B  (S
MM@ ",\T  S/G  0R\P!D*@  5BP  $LM  !"+0  .BT  #0M   O+   *RP
M "8L   B+0  '2\  !DQ   5,@  $C0#  \V"0 ,. T "C@1  DX%@ (.!T
M!S@D  8X+  $.#0  S@^  (Y2@  .5<  #EE   Y=P  .8L  #B?   XLP
M.,H  #CF   W\@!?+0  4BX  $@O   _,   ."\  #(O   M+P  *2\  "0P
M   ?,0  &C,  !4U   2-P  #SD#  P["  (/0T !3X0  ,^%   /AH  #XA
M   ^*   /C$  #\[   _1@  /U,  #]A   _<P  /X<  #Z<   ^L   /<<
M #WD   ]\@!:,   3C(  $0R   \,@  -3(  # Q   K,0  )C(  " T   ;
M-@  %C@  !([   //0  ##\#  A!"  $0PP  $,.  !$$@  118  $4=  !%
M)   12T  $8V  !&0@  1DX  $9=  !&;@  18(  $68  !$K0  1,0  $/C
M  !#\@!5-   2C4  $$U   Y-0  ,S0  "XT   H-0  (C<  !TZ   7/
M$C\   ]!   ,1   "$8!  -(!@  20H  $H-  !+$   3!0  $T9  !.(
M3B@  $XR  !-/0  3DH  $Y8  !-:0  37T  $R4  !,J@  2\$  $OA  !*
M\@!0.   1C@  #TX   W.   ,3<  "HY   D.P  'CT  !A    30P  #T8
M  M)   '2P   DX   !0!   40@  %(+  !3#@  5!$  %45  !6&P  5R,
M %<L  !7.   5T0  %=2  !68P  5G<  %:.  !5I0  5+T  %/=  !3\ !+
M/   0CP  #L[   U.P  +3P  "8_   ?0@  &44  !-(   .2P  "T\   51
M    5    %<   !8 0  6@4  %L(  !<#   70X  %\1  !@%@  8AT  &(F
M  !B,0  8CX  &%,  !A70  87   &"(  !@H   7[<  %[4  !=[@!'0
M/S\  #H_   Q0   *4,  "%&   :2@  $TX   Y1   *50  !%@   !;
M7@   &$   !C    9 $  &4$  !G"   : L  &H.  !L$@  ;A<  &\@  !O
M*@  ;S8  &Y%  !N50  ;F@  &U_  !MF   ;+   &O*  !JZ !$1   /D,
M #5$   K1P  (TL  !M/   35   #E@   A<   "8    &0   !G    :P
M &T   !O    <    '(   !T @  =08  '<*  !Y#@  ?!(  'X8  !_(@
M?RX  '\]  !^30  ?6$  'UW  !\D   >Z@  'K   !YWP!#1P  .4D  "],
M   E4   '%4  !1;   .8   !V4   !J    ;@   '(   !V    >0   'P
M  !^    ?P   ($   "#    A0   (<#  "*"   C T  (\1  "2&0  DB4
M )(S  "21   D5<  )!M  "/A@  CI\  (VU  ",S0 ]3@  ,E$  "A6   >
M7   %6(   YH   ';@   '0   !Y    ?@   ((   "&    B0   (P   ".
M    D    )(   "4    E@   )@   ";    G@8  *$,  "D$0  IAL  *8I
M  "F.@  I4T  *5B  "D>P  HY0  *&K  "AOP V5P  +%P  "%B   7:0
M#W    =W    ?@   (0   "*    CP   )0   "8    FP   )X   "?
MH@   *0   "F    J    *L   "M    L    +,$  "W#   NQ(  +L?  "[
M,   NT,  +I8  "Y<   MXL  +>A  "WLP P8@  )6D  !IP   0>   "8
M  "(    CP   )8   ";    H0   *8   "J    K@   +    "Q    M
M +8   "X    NP   +T   #     PP   ,<   #+ P  SPP  -,5  #2)0
MTC@  -%.  #090  SWX  ,V6  #,J0#_    _P   /\   #_  , _P + /P
M$0#Y !L ]P E /, +P#N #@ Z0!  .8 2 #B $X WP!4 -P 60#9 %X U0!C
M -, : #0 &T S@!S ,L >@#( (( Q@", ,, EP#  *, O@"R +P R "Z .H
MN0#_ +@ _P"Q /\ J@#_ *< _P#_    _P   /L   #V    [0 ' .< #P#B
M !8 WP @ -X *0#9 #, T0 [ ,P 0@#( $@ Q0!. ,( 4P#  %@ O@!= +P
M8@"Z &< N0!M +< = "U 'L L@"% +  D "N )P K "J *D O0"G -X I@#Y
M *4 _P"C /\ G0#_ )L _P#]    ]@   .L   #?    T0 # ,H # #% !(
MPP ; ,  ) "^ "P N0 U +8 / "S $, L !( *X 3@"L %( JP!7 *D 7 "G
M &$ I@!G *0 ;0"B '0 H !] )X B "< )4 F@"C )@ M "6 ,T E0#Q )0
M_P"5 /\ D #_ (X _P#S    Y@   -$   #"    N    +$ " "M  \ J@ 6
M *@ '@"H "< I@ O *( -@"? #P G0!" )L 1P"9 $P EP!1 )8 50"4 %H
MDP!@ )$ 9@"0 &X C@!V (P @0"* (T B "; (8 K "% ,$ A #F (, _0"$
M /\ @P#_ ($ _P#D    RP   +H   "L    H@   )P ! "8  P E@ 1 )0
M&0"3 "$ D@ H (\ , "- #8 BP \ (D 00"( $8 A@!+ (4 3P"$ %0 @@!:
M ($ 8 !_ &< ?@!O 'P >@!Z (8 > "4 '< I !U +< = #4 ', ] !T /\
M= #_ '0 _P#+    M@   *8   ":    D@   (H   "&  @ @P . ($ % "!
M !L @  C '\ *@!] #  >P V 'H .P!X $  =P!% '4 20!T $X <P!4 '$
M6@!P &$ ;@!I &T <P!K '\ :0"- &@ G0!G *X 9@#' &4 Z@!F /\ 9@#_
M &< _P"X    I    )4   "*    @0   'P   !V  0 =  , '( $ !Q !8
M<  = '  ) !N "H ;0 P &L -0!J #H :0 _ &@ 1 !G $D 90!. &0 5 !C
M %L 80!C &  ;0!> 'D 70"' %L E@!: *@ 60"] %D WP!9 /@ 6@#_ %H
M_P"H    E0   (<   ![    <P   &X   !J  $ 9P ( &4 #@!D !( 8P 8
M &, 'P!B "4 80 J %\ , !> #4 70 Z %P /@!; $0 60!) %@ 3P!7 %8
M5@!> %0 : !3 ', 40"! %  D0!/ *( 3@"U $X T !. /  3@#_ $\ _P"<
M    B0   'L#  !P P  : ,  &(!  !?    70 $ %L "P!9  \ 6  4 %<
M&0!7 "  5@ E %4 *@!3 #  4@ T %$ .0!0 #\ 3P!$ $X 2P!- %( 2P!:
M $H 8P!) &\ 1P!\ $8 C !% )T 10"P $0 QP!$ .@ 1 #Z $4 _P"2!
M@ <  '$*  !F"@  7@H  %D)  !5!P  5 0  %( !P!0  P 3P 0 $X %0!-
M !L 3  @ $L )@!* "L 20 P $@ -0!' #H 1@!  $4 1@!# $X 0@!6 $$
M7P!  &L /@!X #T B  \ )D / "K #P P0 [ .  .P#T #L _P")"@  > P
M &H.  !?#@  5PX  %$.  !-#   2PL  $H( @!)! D 2  - $8 $0!% !8
M1  < $, (0!" "8 00 K #\ ,0 ^ #8 /0 \ #P 0P [ $H .@!2 #D 7  X
M &@ -@!U #4 A0 T )8 - "H #, O  S -@ ,P#O #, ^P""#0  <0\  &00
M  !9$0  41$  $L1  !'$   1 X  $(-  !!"P4 00<+ #\%#@ ^ Q( / (8
M #L"'0 Z R( .0,H #@#+0 W S( -@0Y #4$/P T!4< ,P50 #$&6@ P!F8
M+P=S "X'@P M!Y4 + >G "L'N@ K!]( *P?K "L']P!]$   ;!$  %\3  !4
M%   3!0  $84  !"$P  /A(  #P0   Z#@$ .@T& #H*#  X"1  -@@4 #4(
M&0 T"1\ ,@DD #$)*0 P"2\ +PHV "X*/0 M"D4 + M. "L+60 I#&4 * QS
M "<,@P F#94 )0VG "0-NP C#=( (PWK ",-]P!X$@  :!0  %L6  !1%P
M2!<  $(6   ]%@  .14  #<3   U$0  ,Q # #,."  R#0T , T1 "\-%@ M
M#1L + TA "L-)P J#2T *0XT "@..P G#D0 )0Y. "0/60 C$&4 (1!S " 0
MA  ?$)8 'A"I !T0O0 <$-@ '1#N !T0^0!S%   9!8  %<8  !-&0  11D
M #\9   Z&   -1<  #(6   P%0  +A,  "T1!  L$ H *Q . "D0$@ H$!@
M)A > "40)  D$"H (Q$Q "(1.0 A$4( (!)+ !X25@ =$V, '!-Q !H3@@ 9
M%)4 &!2G !<4NP 7$]0 %Q/N !@3^@!P%@  8!D  %0:  !*&P  0AP  #P;
M   V&P  ,AH  "\9   L&   *A8  "@4 0 F$P< )1,, ",3$  B$Q4 (!,:
M !\3(0 >%"< '10N !P5-@ ;%3\ &A9) !D65  8%V$ %A=P !48@0 4&),
M$QBF !(8N@ 2%]( $A?L !,7^@!L&0  71L  %$=  !''0  /QX  #D=   T
M'0  +QP  "L;   H&@  )AD  "08   B%P0 (!<* !X7#@ <%Q( &A<7 !D8
M'@ 9&"0 &!DL !<9-  6&CT %1I' !0;4@ 3&U\ $AQN !$<?P 0')( $!RE
M  \<N0 .'-  #AOJ  \;^ !I&P  6AT  $X?  !%'P  /2   #8?   Q'P
M+1X  "D=   E'0  (QP  " ;   =&P$ &QL' !D<#0 7'!  %AP5 !4<&P 4
M'2( $QTI !(>,0 1'CH $1]% ! ?4  /(%T #B!L  T@?  -((\ #""B  L@
MM0 +(,H "R#E  P?] !E'0  5Q\  $PA  !"(0  .B$  #0A   O(0  *B
M "8?   C'P  (!X  !T>   9(   %B $ !0@"P 2(0X $2$3 !$B&0 0(A\
M#R(F  XC+P .(S< #2-!  PD30 +)%D "B1G  DD>  ()(L !R2>  <DL0 &
M),< !B/C  <C\0!B'P  5"$  $DC  ! (P  .",  #(C   L(P  *"(  "0A
M   A(0  'B$  !HA   6(P  $R0# !$E"  /)@T #B<1  TG%@ ,)QT "R<C
M  HG*P )*#0 ""@^  <H20 &*%4 !2ED  0I=  #*8<  BF;  $HKP  *,4
M 2CA  $G\ !>(@  420  $8E   ])0  -24  "\E   J)   )B0  "(C   ?
M(P  &R0  !@E   4)@  $2@#  \I"  ,+ P "BP0  @L%  '+!H !BPA  4L
M*  #+3   BTZ  $M10  +5(  "Y@   N<0  +80  "V9   MK0  +,(  "S@
M   L\ !:)   328  $,G   Z)P  ,R<  "TG   H)@  )"8  "$F   =)@
M&2<  !4I   1*P  #RP#  TN!P ), P !C$.  ,Q$@ !,A<  #(>   R)0
M,BT  #(V   S0@  ,TX  #-=   S;0  ,X$  #*6   RJP  ,<$  #'?   Q
M\ !6)P  2BD  #\J   W*@  ,"H  "LI   G*   (R@  !XI   :*@  %BP
M !(N   /,   #3$"  HT!P %-0L  C8.   W$   .!0  #@:   X(@  ."H
M #DS   Y/@  .4H  #E9   Y:0  .7T  #B3   XJ   -[\  #?>   V\ !1
M*P  1BP  #PL   T+   +BP  "HK   E*P  ("P  !LM   7+P  $S$  ! S
M   --0  "3<"  4Z!@ !.PH  #P-   ]#P  /A(  #\7  ! '@  0"4  $ O
M  ! .@  0$8  $!4  ! 90  /W@  #^/   ^I@  /KT  #W<   ]\ !-+@
M0B\  #DO   R+P  +2X  "@N   B+P  '3   !@R   3-0  $#<   PZ   )
M/   !3X   !!!   0@@  $,+  !$#0  1A   $<4  !(&0  2"$  $@J  !(
M-0  2$$  $A/  !(8   1W,  $>*  !&H@  1;D  $79  !$\ !(,@  /C(
M #8R   P,0  *S$  "4R   ?-   &38  !,Y   0/   ##\   A"   #1
M $8   !( @  2@4  $L(  !,"P  3@X  $\1  !1%0  4AP  %(E  !2,
M4CP  %%*  !16@  46T  %"$  !/G0  3K4  $W2  !-[@!#-@  .S8  #0U
M   O-   )S4  "$X   :.P  %#X  !!!   ,1   !T<   )*    30   $\
M  !1    4P(  %0%  !5"   5PL  %D.  !;$0  71<  %T?  !=*@  738
M %Q$  !<5   6V<  %M^  !:EP  6:\  %C+  !7Z@ _.0  .#D  #,X   K
M.0  (SP  !P_   50P  $$<   M*   %3@   %$   !4    5P   %H   !<
M    70   %\   !@!   8@<  &0+  !F#@  :!(  &L9  !K(P  :BX  &H\
M  !J30  :5\  &AU  !GCP  9J@  &7"  !DXP ]/0  -SP  "X]   E0
M'40  !9)   030  "E$   15    6@   %T   !@    8P   &8   !H
M:@   &L   !M    ;P(  '$&  !T"@  =@X  'D3  ![&P  >R<  'HU  !Y
M10  >%D  'AM  !WA@  =I\  '6W  !TT@ \00  ,D(  "A%   @2@  %TX
M !!4   *60   EX   !C    9P   &L   !O    <@   '4   !W    >0
M 'L   !]    ?P   ((   "$ P  APD  (H.  ".$P  CQX  (XK  "..P
MC4X  (MC  "*?   BI4  (BM  "'Q0 V1P  +$L  ")/   950  $%L   IA
M   !9P   &T   !R    =P   'L   !_    @P   (8   "(    B@   (T
M  "/    D0   )0   "7    F@$  )T'  "A#0  I10  *0A  "D,0  HT0
M *)9  "@<   GXL  )VB  "=MP P4   )54  !M;   28@  "VD   %P
M=P   'T   "#    B    (T   "1    E0   )@   ":    G    )\   "A
M    HP   *8   "I    K    +    "T!P  N X  +H8  "Z)P  N3D  +A.
M  "W90  MGX  +66  "SJP I6P  'F(  !1I   ,<0   GD   "!    B0
M (\   "6    FP   *    "D    J    *L   "L    KP   +(   "T
MM@   +D   "\    P    ,0   #(    S0<  -(0  #2'0  T2\  -!$  #/
M6P  S7,  ,N-  #*H0#_    _P   /L   #Z    _  ( /@ #P#U !< ]  @
M /$ *@#K #, Y@ [ .( 0P#> $D V@!/ -8 5 #3 %D T !> ,X 8P#+ &@
MR0!N ,8 =0## 'T P0"& +X D@"[ )X N0"N +8 PP"T .@ LP#_ *\ _P"E
M /\ G@#_ )L _P#]    ]P   /(   #P    YP # .$ # #< !( V  ; -8
M) #2 "T S  V ,8 /0#" $, OP!) +P 3@"Z %, N !8 +8 70"U &( LP!G
M +$ ;@"O '8 K !_ *H B@"H )< I0"F *, N0"A -D H #Y )X _P"8 /\
MD@#_ (\ _P#S    [    .,   #3    R    ,$ "0"]  \ NP 6 +D 'P"W
M "< LP O *\ -P"L #T J@!# *@ 2 "F $T I !2 *, 5@"A %L GP!A )X
M9P"< &\ F@!X )< @P"5 )  DP"> )$ L "0 ,@ C@#P (T _P"* /\ A0#_
M (( _P#G    W0   ,8   "X    K@   *@ ! "E  P H0 2 *$ &0"@ "(
MGP I )L , "8 #< E@ ] ), 0@"2 $< D !+ (\ 4 "- %4 C !: (H 80"(
M &@ AP!P (4 >P"# (@ @0"6 '\ IP!] +P ? #C 'P _0!\ /\ > #_ '8
M_P#6    P    *\   "C    F0   ),   "/  D C0 . (L % "* !P B@ C
M (@ *@"% #  @P V (( .P"  $  ?P!% 'X 2@!\ $\ >P!4 'H 6@!X &$
M=@!I '4 <P!S (  <0". &\ GP!N +( ;0#/ &P ] !L /\ :P#_ &D _P#
M    JP   )L   "/    AP   (    !\  0 >@ , '@ $0!X !< >  > '<
M) !U "H <P P '$ -0!P #H ;@ _ &T 1 !L $D :P!. &H 5 !H %L 9P!C
M &4 ;0!D '@ 8@"' &  EP!? *H 7@#" %X Z0!> /\ 7@#_ %T _P"L
MF0   (H   !_    =P   '$   !M    :@ ( &D #@!H !( 9P 8 &< 'P!G
M "4 90 J &, +P!B #0 80 Y &  /@!? $, 7@!( %T 3@!; %4 6@!= %@
M9P!7 '( 50"! %0 D0!3 *, 4@"X %$ W !1 /D 4@#_ %( _P"=    BP
M 'P   !Q    :0   &0   !@    7@ % %P "P!;  \ 6P 4 %H &0!: !\
M60 E %< *@!6 "\ 50 T %0 . !3 #T 4@!# %  20!/ %  3@!8 $T 8@!+
M &T 2@!Z $D BP!( )T 1P"Q $< S !& /  1P#_ $< _P"0    ?@   '
M  !F    7@   %D   !6    4P ! %( " !0  T 3P 0 $\ %0!. !H 3@ @
M $T )0!, "H 2@ N $D ,P!( #@ 1P ^ $8 1 !% $L 1 !3 $, 70!! &@
M0 !U #\ A0 ^ )< /0"K #T PP ] .8 /0#[ #X _P"'    =0,  &@&  !=
M!P  508  % &  !,!   2@$  $D ! !'  H 1@ . $4 $0!% !8 1  ; $,
M( !" "4 00 J $  +P _ #0 /@ Z #T 0  [ $< .@!/ #D 60 X &0 -P!Q
M #8 @0 U ), - "F #0 NP T -T - #U #4 _P!^!@  ;0D  & +  !6#
M3@P  $@+  !$"@  0@@  $ % 0 _ 0< /@ + #T #@ \ !( .P 7 #L '  Z
M "$ .0 E #< *@ V #  -0 U #0 /  S $, ,@!, #$ 50 P &  +P!M "X
M?0 M (\ + "B "P M@ L -  + #N "P _ !W"@  9PP  %H.  !0#@  20X
M $,.   ^#0  .PP  #D+   X"0, -P4( #8"#0 U 1  -  3 #, &  R !T
M,0 B #  )P O "P +@ R "T .  L $  *P!) "H 4@ I %T * !K "<!>@ F
M 8P )0"? "4 L@ E ,H )0#H "4 ]P!R#0  8@X  %80  !,$0  1!$  #X1
M   Y$   -@\  #,.   Q#0$ , L% # ("@ O!@T +@41 "P$%  K QD *@,>
M "D#(P H!"D )P0O "8%-0 E!3T ) 5& ",&4  B!EP (0=I " '>0 ?!XL
M'@>= !X'L  =!L8 '0;C !T%\P!M#@  7A$  %(2  !($P  0!,  #H3   U
M$@  ,1$  "X0   L#P  *@X# "H-!P I"PL * D. "<)$0 E"!8 ) @; ",)
M(  B"28 (0DL " *,P ?"CL '@M$ !T+3P <#%L &PQI !H,>0 8#(L & R>
M !<,L  6#,4 %@SA !8+\ !I$   6A(  $X4  !%%0  /14  #<5   Q%
M+1,  "H2   H$0  )A ! "00!  C#@@ (PT, "(,#P @#!, 'PP8 !X-'0 =
M#2, ' TJ !L-,@ :#CH & Y$ !<.4  6#UP %0]J !,0>P 2$(T $1"@ !$0
MLP 0#\D $ _D !$/\@!E$@  5Q0  $L6  !"%P  .A<  #07   O%@  *A4
M "<4   D$P  (A,  " 2 P >$08 '1 ) !P0#0 ;#Q  &1 5 !@0&P 7$"$
M%A H !41,  4$3D $Q%# !(23@ 1$EH $!)I ! 3>0 .$XP #A.>  T3L0 -
M$L4 #!+A  T2\0!B%   5!8  $D8   _&0  -QD  #$9   L&   *!<  "06
M   A%@  'Q4  !P4 @ :$P0 &1(& !<2"P 5$@X %!(2 !,3&  2$Q\ $1,F
M !$4+0 0%#8 #Q5!  X53  .%E< #19E  P7=0 +%X< "A>:  D6K0 (%L$
M"!;=  D5[@!?%@  41@  $8:   ]&@  -1L  "\:   J&@  )1D  "(8   ?
M&   '!<  !D6 0 7%@, %18$ !,6"0 1%@T $!<1  \7%@ .%QP #A@C  T8
M*@ ,&3, #!D\  L:1P *&E, "1IA  <;<0 &&X, !1N7  0:J@ #&K\  QG:
M  09[ !<&   3AH  $,<   Z'   ,QP  "P<   G'   (QL  " :   =&0
M&AD  !<8 0 5& ( $AD$ ! ;!P .&PP #1P0  P<$P +'!D "AP?  D=)P (
M'2\ !QXY  8>0P $'E   Q]>  (?;@ !'X   !^5   >J0  'KT  !W8   =
M[ !8&@  2QP  $$>   X'@  ,!X  "H>   E'0  (1P  !X<   ;&P  &!L
M !8; 0 3&P( $1P$  X>!P ,'PL "B .  @@$@ &(1< !2$=  0A)  "(BP
M 2(U   B0   (TT  "-:   C:P  (WX  ".3   BIP  (KP  "'7   A[0!5
M'0  2!\  #X@   U(   +B   "@@   C'P  (!X  !T=   :'0  %AT  !,>
M   1'P( #B $  TB!P *) L !B4-  0E$  ")A0  "8:   F(0  )RD  "<R
M   G/0  )TD  "A7   H9P  )WL  ">0   GI0  )KL  ";6   E[0!1(
M12$  #LB   R(@  +"(  "8A   B(0  'B   !L?   8(   %"   !$B   /
M(P  #24#  HF!@ &* H  RD-   K#P  +!(  "P7   L'@  +"8  "TO   M
M.0  +48  "U4   M9   +7<  "R-   LI   *[H  "O6   J[@!-(@  020
M #@D   P)   *20  "0C   A(@  '2(  !DB   5(P  $B0   \F   -*
M"BH"  8L!0 "+@D  "\+   P#@  ,A   #,5   S&P  ,R(  #,K   S-@
M,T(  #-0   S8   ,W,  #**   RH0  ,;@  ##6   P[P!))0  /B8  #0G
M   M)P  *"8  ",E   ?)   &R4  !8F   2*   $"H   TL   *+@  !C !
M  (R!   - <  #4*   W#   . X  #H2   Z%P  .A\  #HG   Z,@  .CX
M #I,   Z7   .F\  #F&   XG@  .+8  #?4   V[P!$*0  .BD  #$I   K
M*0  )B@  "(G   =*   &"D  !,K   0+@  #3    DR   %-0   3<    Y
M @  .P4  #P(   ^"P  /PT  $$0  !#%   0QL  $,C  !#+@  0SD  $-'
M  !"5P  0FH  $&!  ! F@  /[(  #[/   ^[P _+   -BP  "\L   J*P
M)2H  !\K   9+0  %"\  ! R   --0  "#@   0Z    /    #\   !!
M0P(  $4%  !&"   2 L  $H.  !,$0  318  $T>  !-*   330  $Q"  !,
M40  2V0  $M[  !*E   2:T  $C*  !'[  [,   ,R\  "TO   H+0  (B\
M !LQ   5-   $#<   TZ   (/0   D    !#    1@   $@   !*    3
M $X!  !/!   40<  %,+  !5#@  6!(  %D9  !8(@  6"X  %<\  !72P
M5EX  %9S  !5C0  5*<  %+"  !2Y@ X,P  ,3(  "PQ   E,@  '34  !8X
M   1/   #$    =$    1P   $H   !-    4    %,   !5    5P   %D
M  !:    7 ,  %X'  !A"P  9 X  &83  !G'   9B<  &8T  !E1   9%<
M &1K  !BA0  89\  &"Y  !>W  U-P  ,#4  "@W   @.@  &#T  !%"   ,
M1@  !DH   !/    4P   %8   !9    7    %\   !A    9    &4   !G
M    :0   &P!  !N!@  <0L  '0/  !W%0  =R   '8M  !V/0  =4\  '1C
M  !S>P  <I4  '"O  !OR0 U.@  *SL  "(_   :0P  $D@   Q-   %4@
M %<   !<    8    &0   !H    :P   &X   !Q    <P   '4   !W
M>@   'P   !_    @@0  (8*  "*#P  C!<  (LD  "*,P  B44  (=;  "&
M<@  A8L  (.E  ""O  O0   )40  !Q)   33@  #50   1:    80   &8
M  !K    ;P   '0   !Y    ?0   (    "#    A0   (<   "*    C
M (\   "2    E@   )D"  ">"0  HA   *(:  "A*0  H#L  )]0  "=9P
MFH$  )J9  "9KP I20  'TX  !54   .6P  !6(   !I    <    '<   !]
M    @@   (8   "+    CP   ),   "5    EP   )H   "=    H    *,
M  "F    J@   *X   "R    MPH  +L1  "Z'P  N3   +=%  "U7   M'0
M +&.  "OI  B5   &%L  !!B   ':@   ',   ![    @@   (D   "0
ME0   )H   "?    HP   *8   "H    JP   *X   "P    LP   +8   "Z
M    O0   ,(   #'    S $  -,+  #4%0  TR8  -$Z  #040  S6@  ,N!
M  #*E@#\    ]@   /(   #Q    \P % /0 # #R !, \  < .T )0#H "X
MX@ V -X /@#9 $0 U !* -$ 3P#. %0 RP!9 ,D 7@#& &, Q !I ,$ < "^
M '@ O "! +D C0"V )H LP"K +$ P "O .8 K@#_ *4 _P": /\ E #_ (\
M_P#T    [    .@   #G    WP   -D "0#2 !  SP 7 ,\ ( #, "@ Q@ P
M ,  -P"\ #X N0!$ +< 20"U $X LP!3 +$ 5P"O %T K0!B *L :0"I '$
MIP!Z *4 A0"B ), H "B )T M@"; -0 F0#Y )8 _P"- /\ B #_ (0 _P#H
M    WP   -D   #)    OP   +@ ! "U  T LP 2 +$ &@"P "( K0 J *D
M,0"F #@ I  ] *( 0P"@ $@ G@!, )P 40"; %8 F0!< )< 8@"5 &D DP!R
M )$ ?0"/ (L C0": (L K ") ,4 B #N (8 _P!_ /\ >@#_ '@ _P#9
MS0   +L   "N    I0   )\   "<  D F0 / )D %0"9 !T F  D )0 *P"1
M #$ C@ W (P / "+ $$ B0!& (@ 2P"& %  A0!5 (, 6P"" &( @ !K 'X
M=0!\ (( >@"2 '@ HP!W +D =@#@ '4 _P!R /\ ;@#_ &P _P#'    M0
M *4   "9    CP   (D   "%  0 A  , (( $0"" !< @@ > (  )0!^ "L
M?  Q 'H -@!Y #L =P!  '8 1 !U $D <P!/ '( 50!P %P ;P!D &T ;@!L
M 'H :@"* &@ FP!G *\ 9@#, &4 ]0!D /\ 80#_ &  _P"T    H    )
M  "%    ?0   '<   !S    <  ( &\ #@!O !( ;P 8 &\ 'P!M "4 :P J
M &D , !H #0 9P Y &8 /@!E $, 8P!( &( 3@!A %4 7P!> %X 9P!< ',
M6P"" %D DP!8 *8 5P"_ %< Z@!7 /\ 5@#_ %0 _P"A    C@   '\   !U
M    ;    &@   !D    80 $ &  "P!?  \ 7P 3 %\ &0!? !\ 70 E %P
M*@!; "\ 60 S %@ . !7 #T 5@!# %4 20!3 %  4@!8 %$ 80!0 &T 3@![
M $T C !, )\ 2P"U $H W !* /H 2@#_ $H _P"2    @    '(   !G
M7P   %H   !7    50 ! %, !P!2  P 4@ 0 %( % !2 !H 40 ? $\ ) !.
M "D 30 N $P ,P!+ #@ 2@ ] $D 0P!( $H 1@!2 $4 7 !$ &< 0P!U $(
MA@!! )@ 0 "N $  RP _ /( 0 #_ $  _P"%    =    &<   !=    50
M $\   !,    2@   $@ ! !'  H 1P - $8 $0!& !4 1@ : $4 'P!$ "0
M0P I $( +0!! #, /P X #X /@ ] $4 / !. #L 5P Z &( .0!O #@ @  W
M ), -@"G #8 P  V .@ -@#^ #8 _P!\    :P   %X"  !4 P  30,  $<#
M  !# 0  00   #\  0 ^  < /0 + #T #@ \ !$ /  6 #P &@ Z !\ .0 D
M #@ *0 W "X -@ S #4 .@ T $$ ,P!) #( 4P Q %X , !K "\ >P N (X
M+0"B "T N  M -T +0#X "X _P!S 0  9 4  %<'  !-"   1@@  $ (   [
M!P  . 4  #<#   V  0 -0 ( #0 #  T  \ -  2 #, %@ R !L ,0 @ #
M)  O "D +@ O "T -@ L #T *P!% "H 3P I %H * !G "< =P F (D )@"=
M "4 LP E ,\ )0#P "8 _P!M!@  7@D  %(+  !(#   0 P  #H+   V"P
M,@H  # (   N!@( +@,& "T "@ L  T +  0 "L $P J !< *0 < "@ (  G
M "4 )@ K "4 ,@ D #D (P!" "( 2P B %< (0!D "  <P ? (4 'P"9 !X
MK@ > ,< '@#I !\ ^@!H"0  60P  $T-  !##@  / X  #8.   Q#0  +0T
M "H,   H"P  )PD$ "8&"  F! L )0,. "0!$  D 10 (@$8 "$!'0 A "(
M(  H !\ +@ > 38 '0$_ !P!20 ; 50 &@%A !H!<  9 8( & "6 !@ J@ 8
M ,$ & #A !@ ] !C#   50X  $D/  ! $   .!   #(0   M#P  *0X  "8.
M   C#0  (@P# " +!@ @"0D 'P<, !X&#@ >!1$ ' 45 !L%&@ :!1\ &@4E
M !D%*P 8!3, %P8\ !8&1@ 6!E( %0=? !0';@ 3!X  $@>4 !(&IP 2!;P
M$@39 !(#[P!?#@  40\  $80   \$0  -1$  "\1   J$0  )A   "(0   @
M#P  '0X" !P-!0 :#0< &@L* !D*#0 8"1  %PD2 !8)%P 5"1P % DB !0*
M*0 3"C$ $@HZ !(+10 1"U$ $ Q?  \,;@ .#(  #@R4  T+IP -"[H #0K2
M  T*Z@!<#P  3A$  $,2   Z$P  ,A,  "P3   G$@  (Q$  !\1   <$
M&A " !@/!  6#@< %0X) !0-"P 3# T $@P0 !(,%  1#!H $0T@ ! -*  /
M#3  #@X[  T.1@ -#E$ # ]>  L/;0 *#W\ "0^3  D/I@ (#KD " [0  <.
MZ !8$0  2Q(  $ 3   W%   ,!0  "D4   E%   (1,  !T2   :$@  %Q$"
M !41!0 3$ < $A ) !$/"@ 0#@P #@X.  X/$@ -$!@ #1 >  P0)0 ,$"T
M"Q$V  H100 )$4T "!):  <2:@ &$GP !1*0  02I  #$;@  Q'/  (1Z !5
M$@  210  #X5   U%@  +18  "<6   B%0  'A0  !L4   8$P  %1(# !,2
M!0 2$0< $!$)  \1"@ -$0L #!(.  L2$0 *$A4 "1,;  D3(@ ($RH !Q0S
M  44/@ $%4H  Q58  (59P !%7H  !6.   5HP  %+<  !3/   3Z0!2%
M1A8  #L7   R%P  *Q<  "47   A%@  '!8  !D5   6% $ %!,$ !(3!@ 1
M$@@ #Q((  X3"0 ,% H "A4-  @6$  &%A, !189  07'P #%R<  A@P  $8
M.P  &4<  !E5   99   &7<  !F,   8H@  &+<  !?/   7Z@!/%@  0Q@
M #D9   P&0  *1D  ",9   ?&   &Q<  !@6   5%0( $Q4% !$4!@ 0% 8
M#A4'  P6"  *%PH !QD,  0:#@ "&Q(  1L6   ;'0  '"0  !PM   <.
M'40  !U2   =8@  '74  !V*   <H   '+8  !O0   :ZP!,&   0!H  #8;
M   M&P  )AL  "$:   =&0  &1D  !<8   4%P, $A8$ ! 7!  .%P0 #!D%
M  H:!P '' D  QT+   ?#0  (!   " 4   A&@  (2(  "$J   A-0  (D$
M ")/   B7P  (G(  "&(   AGP  (+8  !_1   ?[0!(&@  /1P  #,=   K
M'0  )!T  " <   <&P  &!H  !89 0 3&0$ $1D!  X: 0 ,' ( "AT#  <?
M!0 #(0@  "(*   D#   )@X  "82   F&   )Q\  "<G   G,@  )SX  "=+
M   G7   )VX  ":%   FG0  );0  "31   C[@!$'0  .1\  # ?   H'P
M(QX  !X=   ;'   &!L  !0<   1'   #AT   T?   *(0  !B(!  ,D!
M)@8  "@(   J"P  *PT  "T0   M%0  +1P  "TD   N+@  +CH  "Y(   M
M6   +6H  "V!   LF@  *[(  "K0   I[P! (   -B$  "TA   F(0  (2
M !T?   :'@  %AX  !(?   /(0  #2(   HD   &)@   B@    K @  +00
M "\&   P"0  ,@P  #0.   U$@  -1@  #4@   U*@  -38  #5#   U4P
M-&8  #1\   SE@  ,J\  #'-   P[P \(P  ,B0  "HD   D(P  ("(  !PA
M   7(0  $R,  ! E   -)P  "2D   4K   !+@   #     R    - $  #8$
M   X!@  .@D  #P-   ^$   /A0  #X<   ^)@  /C$  #X_   ]3@  /6$
M #QW   [D0  .JL  #G)   X[0 W)P  +R<  "@F   C)0  'R0  !DE   4
M)@  $"@   TK   )+@  !3     S    -0   #@    Z    /    #X!  !
M P  0@<  $0*  !&#0  21$  $D7  !((0  2"P  $<Z  !'20  1EL  $5Q
M  !$BP  0Z4  $+#  !!Z  T*@  +"H  "<H   B)P  '"@  !8J   1+0
M#3    DS   #-@   #D    \    /@   $$   !#    1@   $@   !*
M3 ,  $X&  !0"@  4PX  %03  !4'   4R<  %,T  !30P  4E4  %%J  !0
M@P  3YX  $VY  !,X  P+0  *RP  "8K   ?+   &"X  !(R   --0  "#D
M  (]    0    $,   !&    20   $P   !.    40   %,   !5    5P
M %D!  !<!@  7PH  &(.  !C%0  8Q\  &(L  !A/   8$X  %]B  !>>P
M7)8  %NP  !9SP O,   *B\  "(P   :,P  $S<   X[   (/P   40   !(
M    3    $\   !2    50   %@   !;    70   &    !B    9    &8
M  !I    ;04  ' +  !T$   =!@  ',E  !R-   <D4  '!9  !O<0  ;8L
M &NF  !JP  N,P  )34  !TX   4/   #D$   ='    3    %$   !5
M60   %T   !A    90   &@   !K    ;0   &\   !R    =    '<   !Z
M    ?@   (($  "&"P  BA$  (D<  "(*P  ACT  (12  "#9P  @8$  '^;
M  !^L@ I.@  (#T  !9"   /2   "$X   !4    6@   &    !D    :0
M &X   !R    =@   'H   !]    @    ((   "%    B    (L   ".
MD@   )8   "; P  H P  *(3  "@(0  GS,  )U'  ":7@  F'<  )>/  "5
MIP C0P  &4@  !%.   )50   %P   !C    :@   '$   !V    >P   (
M  "&    B@   (X   "1    DP   )8   "9    G    *    "C    IP
M *L   "P    M@0  +P-  "Z%P  N2@  +<\  "T4@  LFH  *^%  "MG  <
M3@  $U0   M<   !9    &P   !T    ?    (,   ")    CP   )0   ":
M    GP   *(   "D    IP   *H   "N    L0   +0   "X    O    ,$
M  #'    S0   -0%  #8$   U1X  -,Q  #02   S5\  ,MV  #(C@
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M^_S^______________________________________________________\
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MXN/DY>;GZ.GJZ^SM[N_P\?+S]/7V]_CY^OO\_?[_;69T,0     #!"$   $
M                   !                     0    $" P0%!@<(" D*
M"PP-#@\0$1(3%!46%Q@9&AH;'!T>'R A(B,D)28G*"DJ*RPM+B\P,3$R,S0U
M-C<X.3H[/#T^/T!!0D-$149'2$E*2TQ-3D]045)35%565UA96EM<75Y?8&%B
M8V1E9F=H:6IK;&UN;W!Q<G-T=79W>'EZ>WQ]?G^ @8*#A(6&AXB)BHN,C8Z/
MD)&2DY25EI>8F9J;G)V>GZ"AHJ.DI::GJ*FJJZRMKK"QLK.TM;:WN+FZN[R]
MOK_ P<+#Q,7&Q\C)RLO,S<[/T-'3U-76U]C9VMO<W=[?X.'BX^3EYN?HZ>KK
M[.WN[_'R\_3U]O?X^?K[_/W^_P ! 0(" P,$! 4&!@<'" @)"0H+"PP,#0T.
M#P\0$!$1$A,3%!05%A87%Q@9&1H:&QP<'1X>'R @(2(B(R0D)28F)R@I*2HK
M+"TM+B\P,3(R,S0U-C<X.3H[/#T^/T!"0T1%1DA)2DQ-3U!24U576%I<7F!B
M9&9H:FUO<71V>7Q^@8.&B8N.D)*5EYF;G9^AHZ6GJ*JLK:^PLK.UMK>YNKN\
MO;_ P<+#Q,7&Q\C)RLO,S<W.S]#1TM+3U-76UM?8V=G:V]O<W=W>W]_@X>'B
MX^/DY>7FYN?HZ.GIZNOK[.SM[N[O[_#P\?+R\_/T]/7V]O?W^/CY^?K[^_S\
M_?W^_O\  0$" @,#! 0%!@8'!P@("0D*"PL,# T-#@\/$! 1$1(3$Q04%186
M%Q<8&1D:&AL<'!T>'A\@("$B(B,D)"4F)B<H*2DJ*RPM+2XO,#$R,C,T-38W
M.#DZ.SP]/C] 0D-$149(24I,34]04E-55UA:7%Y@8F1F:&IM;W%T=GE\?H&#
MAHF+CI"2E9>9FYV?H:.EIZBJK*VOL+*SM;:WN;J[O+V_P,'"P\3%QL?(R<K+
MS,W-SL_0T=+2T]35UM;7V-G9VMO;W-W=WM_?X.'AXN/CY.7EYN;GZ.CIZ>KK
MZ^SL[>[N[^_P\/'R\O/S]/3U]O;W]_CX^?GZ^_O\_/W]_O[_VLL)&^C-#CKI
MS!!@W,@.DLNZ,JS&MU"TP+-HO+NN>\2UJ(C+LZ6'T;"BA]6MGXC9JYV)W*J<
MB]ZHFHWAIYF/XZ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2
MYJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FVLL)&^C-#CKIS!!@
MW,@.DLNZ,JS&MU"TP+-HO+NN>\2UJ(C+LZ6'T;"BA]6MGXC9JYV)W*J<B]ZH
MFHWAIYF/XZ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67
MDN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FVLL)&^C-#CKIS!!@W,@.
MDLNZ,JS&MU"TP+-HO+NN>\2UJ(C+LZ6'T;"BA]6MGXC9JYV)W*J<B]ZHFHWA
MIYF/XZ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:E
MEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FVLL)&^C-#CKIS!!@W,@.DLNZ
M,JS&MU"TP+-HO+NN>\2UJ(C+LZ6'T;"BA]6MGXC9JYV)W*J<B]ZHFHWAIYF/
MXZ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+F
MI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FVLL)&^C-#CKIS!!@W,@.DLNZ,JS&
MMU"TP+-HO+NN>\2UJ(C+LZ6'T;"BA]6MGXC9JYV)W*J<B]ZHFHWAIYF/XZ67
MDN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2
MYJ67DN:EEY+FI9>2YJ67DN:EEY+FVLL)&^C-#CKIS!!@W,@.DLNZ,JS&MU"T
MP+-HO+NN>\2UJ(C+LZ6'T;"BA]6MGXC9JYV)W*J<B]ZHFHWAIYF/XZ67DN:E
MEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67
MDN:EEY+FI9>2YJ67DN:EEY+FVLL)&^C-#CKIS!!@W,@.DLNZ,JS&MU"TP+-H
MO+NN>\2UJ(C+LZ6'T;"BA]6MGXC9JYV)W*J<B]ZHFHWAIYF/XZ67DN:EEY+F
MI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:E
MEY+FI9>2YJ67DN:EEY+FVLL)&^C-#CKIS!!@W,@.DLNZ,JS&MU"TP+-HO+NN
M>\2UJ(C+LZ6'T;"BA]6MGXC9JYV)W*J<B]ZHFHWAIYF/XZ67DN:EEY+FI9>2
MYJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+F
MI9>2YJ67DN:EEY+FVLL)&^C-#CKIS!!@W,@.DLNZ,JS&MU"TP+-HO+NN>\2U
MJ(C+LZ6'T;"BA]6MGXC9JYV)W*J<B]ZHFHWAIYF/XZ67DN:EEY+FI9>2YJ67
MDN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2
MYJ67DN:EEY+FVLL)&^C-#CKIS!!@W,@.DLNZ,JS&MU"TP+-HO+NN>\2UJ(C+
MLZ6'T;"BA]6MGXC9JYV)W*J<B]ZHFHWAIYF/XZ67DN:EEY+FI9>2YJ67DN:E
MEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67
MDN:EEY+FVLL)&^C-#CKIS!!@W,@.DLNZ,JS&MU"TP+-HO+NN>\2UJ(C+LZ6'
MT;"BA]6MGXC9JYV)W*J<B]ZHFHWAIYF/XZ67DN:EEY+FI9>2YJ67DN:EEY+F
MI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:E
MEY+FVLL)&^C-#CKIS!!@W,@.DLNZ,JS&MU"TP+-HO+NN>\2UJ(C+LZ6'T;"B
MA]6MGXC9JYV)W*J<B]ZHFHWAIYF/XZ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2
MYJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+F
MVLL)&^C-#CKIS!!@W,@.DLNZ,JS&MU"TP+-HO+NN>\2UJ(C+LZ6'T;"BA]6M
MGXC9JYV)W*J<B]ZHFHWAIYF/XZ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67
MDN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FVLL)
M&^C-#CKIS!!@W,@.DLNZ,JS&MU"TP+-HO+NN>\2UJ(C+LZ6'T;"BA]6MGXC9
MJYV)W*J<B]ZHFHWAIYF/XZ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:E
MEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FVLL)&^C-
M#CKIS!!@W,@.DLNZ,JS&MU"TP+-HO+NN>\2UJ(C+LZ6'T;"BA]6MGXC9JYV)
MW*J<B]ZHFHWAIYF/XZ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+F
MI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FVLL)&^C-#CKI
MS!!@W,@.DLNZ,JS&MU"TP+-HO+NN>\2UJ(C+LZ6'T;"BA]6MGXC9JYV)W*J<
MB]ZHFHWAIYF/XZ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2
MYJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FVLL)&^C-#CKIS!!@
MW,@.DLNZ,JS&MU"TP+-HO+NN>\2UJ(C+LZ6'T;"BA]6MGXC9JYV)W*J<B]ZH
MFHWAIYF/XZ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67
MDN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FV<L)&^?.#3GHS1!@W,D-
MDLN[,*O&N$^TP+-GO;NN>\2UJ8C+LJ:'T:^CA]6MH(C9JYZ)W*F<BMZGFXS@
MI9F/XZ&8D.2AF)#DH9B0Y*&8D.2AF)#DH9B0Y*&8D.2AF)#DH9B0Y*&8D.2A
MF)#DH9B0Y*&8D.2AF)#DH9B0Y*&8D.2AF)#DV<L)&N3.#3GGS@Y@VLH,DLN\
M+JO%N4VTP+1FO;JN>L6UJ8?+L::'T:ZCA]6LH(C9JIZ)W*><BMZEFXO@HIJ-
MXIZ9C^.>F8_CGIF/XYZ9C^.>F8_CGIF/XYZ9C^.>F8_CGIF/XYZ9C^.>F8_C
MGIF/XYZ9C^.>F8_CGIF/XYZ9C^.>F8_CV,L)&N'/##GESPY@V<H,D<N^+*O%
MN4RUOK1GO;FN>\6TJH?,L*:'T:VCA]6KH(C9J)Z(VZ6=B=VCG(K?GYJ+X9N9
MCN*;F8[BFYF.XIN9CN*;F8[BFYF.XIN9CN*;F8[BFYF.XIN9CN*;F8[BFYF.
MXIN9CN*;F8[BFYF.XIN9CN*;F8[BV,L)&MS0"SGCT U@V,L+D<N_*ZO$NDRU
MO;-GOKBN>\6TJ8?,L*:'T:RCA]6IH(?8II^(VZ.=B-V@G(G>G9N*X)B:C>&8
MFHWAF)J-X9B:C>&8FHWAF)J-X9B:C>&8FHWAF)J-X9B:C>&8FHWAF)J-X9B:
MC>&8FHWAF)J-X9B:C>&8FHWAU\P)&MK1"SC>T0Q?ULL+D<O *:S"N4VVO+-H
MOK>N>\:SJ8?,KZ:'T:JCAM6GH8?8I)^'VJ&>A]R>G8C=FIR)WI6;C."5FXS@
ME9N,X)6;C."5FXS@E9N,X)6;C."5FXS@E9N,X)6;C."5FXS@E9N,X)6;C."5
MFXS@E9N,X)6;C."5FXS@ULP)&=G1"SC:TPQ?U,P+D<G *:W N4ZVNK-IO[6N
M?,:RJ8?,K::&T:FCAM2EH8;7HJ"&V9^?AMJ;GH?<EYV(W9.<B]Z3G(O>DYR+
MWI.<B]Z3G(O>DYR+WI.<B]Z3G(O>DYR+WI.<B]Z3G(O>DYR+WI.<B]Z3G(O>
MDYR+WI.<B]Z3G(O>U<P)&=C2"S?8TPM>TLP+D\>_*ZV^N%"WN;)JO[2M?,:P
MJ8?,JZ:&T*>DA=2CHH76GZ&%V)R@A=F8GX;:E)Z'W)"=BMV0G8K=D)V*W9"=
MBMV0G8K=D)V*W9"=BMV0G8K=D)V*W9"=BMV0G8K=D)V*W9"=BMV0G8K=D)V*
MW9"=BMV0G8K=U,T)&=;2"S?6U M>T,L*E<2^+:Z\N%&XM[)JP+.M?,:NJ8?,
MJ::&T*6DA=.@HX35G:*$UIFAA=B5H(79D9^'VHZ>B=N.GHG;CIZ)VXZ>B=N.
MGHG;CIZ)VXZ>B=N.GHG;CIZ)VXZ>B=N.GHG;CIZ)VXZ>B=N.GHG;CIZ)VXZ>
MB=N.GHG;T\T*&-73"S;4U M?SLL)E\&^,*^ZMU.XM;)LP+"M?<>LJH;+IZ>%
MSZ*EA-&>I(33FJ.$U9:BA-:3H877CZ"&V(N@B=F+H(G9BZ")V8N@B=F+H(G9
MBZ")V8N@B=F+H(G9BZ")V8N@B=F+H(G9BZ")V8N@B=F+H(G9BZ")V8N@B=F+
MH(G9TLX*%]/4"S71TPIBR\P)F;Z],[&WMU6YLK%MP:VM?<:JJH;+I*B$SI^G
MA-";I8/2EZ2#TY.CA-20HX75C**&UHFAB->)H8C7B:&(UXFAB->)H8C7B:&(
MUXFAB->)H8C7B:&(UXFAB->)H8C7B:&(UXFAB->)H8C7B:&(UXFAB->)H8C7
MT,\*%M'4"S?.TPIEQLH+G;F\.+*TMEBZK;%NP:JN?<:GJX7)H:F$S)RH@\Z7
MIX//DZ:#T9"EA-*-I873BJ2&TX>CB-2'HXC4AZ.(U(>CB-2'HXC4AZ.(U(>C
MB-2'HXC4AZ.(U(>CB-2'HXC4AZ.(U(>CB-2'HXC4AZ.(U(>CB-2'HXC4SM *
M%<[4"CK*TPIHP,@/H;6[/K2MM5N[J;%OP::O?<2CK83'G:N#RIBJ@\N3J8/-
MD*B$SHVGA,^*IX7/AZ:'T(6FB-&%IHC1A::(T86FB-&%IHC1A::(T86FB-&%
MIHC1A::(T86FB-&%IHC1A::(T86FB-&%IHC1A::(T86FB-&%IHC1S- )&,K4
M"C[%TPIMN,46I:ZY1+6GM5Z[H[)PP*&P?<.?KH3%F:V#QY2LA,F0JX3*C:J%
MRXJJA<N(J8;,A:F'S8.HB<V#J(G-@ZB)S8.HB<V#J(G-@ZB)S8.HB<V#J(G-
M@ZB)S8.HB<V#J(G-@ZB)S8.HB<V#J(G-@ZB)S8.HB<V#J(G-R-$)&\75"D*_
MTPIRL<0>IZ6Y2;:AMF"[GK-POIVQ?<&;L(3#E:^$Q)&NA,:-K87'BJV&QXBL
MALB&K(?(A*N)R8*KBLF"JXK)@JN*R8*KBLF"JXK)@JN*R8*KBLF"JXK)@JN*
MR8*KBLF"JXK)@JN*R8*KBLF"JXK)@JN*R8*KBLF"JXK)Q-(((,#6"4BXU IX
MJ<\7F)Z^1ZZ:MF*ZF+5QO)>S?+Z7LH3 DK&%PHVPA<.*KX;$B*^'Q(:OB,6$
MKHG%@ZZ*Q8&NB\6!KHO%@:Z+Q8&NB\6!KHO%@:Z+Q8&NB\6!KHO%@:Z+Q8&N
MB\6!KHO%@:Z+Q8&NB\6!KHO%@:Z+Q8&NB\6!KHO%O]0');K7"4ZNV@MPH-L3
MAY?-.9J2PUBHD;QLLI&W>KF2M(.]CK.&OXNRA\"(L8? AK&(P82QB<&#L8K!
M@K&+PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,*
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MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:]\ 0%?C
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MP(JL<<"+K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K''
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ML'ZDT;!^I-&P?J31_[@4#O^X'B?_M"I&]Z\V:=ZG0H_'FV*QQ)MRML*;?[G
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MB9#.LX>2T+*$E=*Q@IG3L8&>U*Z HM2L@*/2K("CTJR H]*L@*/2K("CTJR
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MUI.2H-:3DJ#6_;L1#?V\&2;^N21&]K0N:MRK.I+'H%RQQ*%HML&E<;J^IWK
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MB:N&RH>KALJ%JHC*@ZJ)RX&JB\N JHS+@*J,RX"JC,N JHS+@*J,RX"JC,N
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M"?^Q(Q[_KC$Z_ZD^6>VB2WG9FER7R)5RL,65?;7#EX6XP9>+N[^3C+V^CX[
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MQ+%ZK<2Q>JW$L7JMQ+%ZK<2Q>JW$_ZL:!?^K)1?_J30O_Z1"2OF?3V;HF5R
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M[))I>N&1<XK8CWR8T(Z$I,J.C*W&C9"TQ(J3M\.&E;C"A)BYP8&;NL%_G;O
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MO+R;B,*YE8K'M8V-SK"&EM2I@J#6H8*DT)V"J,N:@ZK(F8.MQ9>$K\*6A+#
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M\[8Y<.J_-WWCRC6'U-$WE;["2ZFPN6"UJ+1PO:.P?L*=K83'DJJ$RXBGALZ
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MHJ;-=*:HS7*IJ<QQK:K,<+*KRW"VJ\MOO*O(<,"KQ'' JL1QP*K$<<"JQ''
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MM+J*B[2ZBHNTNHJ+M+J*B[2Z_YP0 ?^A)@K_H#8<_YY",?^E0#[_JT!,_[%
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M;,R:_X82 ?^((0;_B#44_X9&)?^'4S7_BUM#_XQB4?Z*:E[VAW%J\(1Z=.J
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M2CO_HTL[_Z-+._^C2SO_HTL[_Z-+._^C2SO_HTL[_Z-+MKH" *;*  "8W
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M9T7NYV=&Z^AG1NOH9T;KZ&=&Z^AG1NOH9T;KZ&=&Z^AG[J(  ,VT @"\O@0
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M2X#48%=VT6AA;<]P:67->G!>S(9U6,R5>53,IGM1S;Q\4,SB?%/!X']5M]^
M6+'>@5JKWH%<IM^!7*;?@5RFWX%<IM^!7*;?@5RFWX%<IM^!_X / ?^.#@'_
MH@T V[4( ,[!" #&T D OND2 K3I)0JJZ#,7H.8^)9;E1S*+XTX_@.%527;@
M75-MWF9;9=UO85[=>F=8W(9K4]R5;U#=IG%-WKMR3=_A<4[1YW10QN9W4K[D
M>%.XY'E5LN-Z5;+C>E6RXWI5LN-Z5;+C>E6RXWI5LN-Z_X,. ?^6"P#=JP0
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MYW68;N=UF&[G=9ANYW68;N=U_V<6 ?]D( /_<!X#_WXB!?^++ G_DS<0_YA
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M@(#;A8" W8. ?]Z!@'[@?X!]X7V ?>-[@'SD>H!\Y'J ?.1Z@'SD>H!\Y'J
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M>F.7Y'EFE.5W9I+F=V:2YG=FDN9W9I+F=V:2YG=FDN9W_W 2 ?^ #@'_D@X
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M8$N]]F!+O?9@2[WV8$N]]F!+O?9@_XD  -F>  #'K $ N;8" *[! P"ES@8
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M;W*#[6US@>YK=(#P:72 \&ET@/!I=(#P:72 \&ET@/!I_V$7 ?]Q$ '_@@X
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M9%R7\V1<E_-D7)?S9%R7\V1<E_-D_W - /^$! #=E@  SJ,# ,2N! "[MP0
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MD@\;_Z(0&O^R$1G_R!(8_^43%__Z%!?_^A07__H4%__Z%!?_^A07__H4G[,
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M8']S^%Y^<_E<?G+Z6GYR^UE^<OM9?G+[67YR^UE^<OM9_U@7 ?]G$ '_=0X
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M6FN!^UIK@?M::X'[6FN!^UIK@?M:_V(0 /]R!P#X@@, VX\" ,^:!0#)HP8
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M45&>_U%1GO]1_W8  -V)  #*EP  OJ(  +.J  "ILP  H+P" )C&!@"1S!(
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MMB8U\=(F-._S)C3L_R8RZ_\H,N?_*S/D_RPSY/\L,^3_+#/D_RPSY/\LP9P
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M"13_PPD3_^,)$__X"1/__PH3__\*$___"A/__PH3__\*FK$  (N]  !\R
M;=0  %_@  !1Y@  1_4  $'_   \_PD -_\0 #+_%0$N_QT!*O\C 2;_*0$B
M_R\"'_\U AS_.P(9_T(#%O]) Q/_40,1_UH##_]F! W_= 0+_X4$"O^6!0G_
MJ 4(_[D%!__0!0?_XP4'_^,%!__C!0?_XP4'_^,%C;H  'W'  !MTP  7^
M %#G  !"[0  .O\  #7_   O_P( *O\* ";_#P B_Q0 'O\: 1K_'P$6_R,!
M$_\H 1#_+0$._S,!#/\Y @K_00('_TD" _]3 @#_7@( _VP" /]\ P#_C0,
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M3I!C_TR.9/]+C&3_2HMD_TB+9/](BV3_2(MD_TB+9/](_U 6 ?]<$ #_: T
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M379Q_TQV<?],=G'_3'9Q_TQV<?],_UD0 /]F!P#_<P0 X7\! -:(! #/D 8
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M2V&#_TMA@_]+_V0% /5T  #:@@  RXX  ,&7  "XG@$ L:4  *FK!P"CK1H
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MN#I$NM<Y0[CU.T*V_SU"L_\^1*[_/D6I_SY%J?\^1:G_/D6I_SY%J?\^X'T
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M&3'E_ADOY/\<+N3_'BWB_R MXO\@+>+_("WB_R MXO\@NIH  *JC  "=JP
MD+0  (.]  !WQ@  :\\  %_6  !4W@0 4? 0 $WP&P!*\"8!1O$P D+R.@,^
M\D,$._-+!3CS5 <V]%T(,_1H"3#U= LN]8$,+/:1#BKVH@\H][<0)_C6$2?V
M]!$F\_\1)O'_$27Q_Q,E\?\3)?'_$R7Q_Q,E\?\3K:$  *"I  "2LP  A+P
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M P#_[ , _^P# /_L P#_[ , _^P#B+D  'C$  !IT   6]T  $OC   ^Z0
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M.*Q0_SBG4?\WHU+_-J!3_S6?4_\UGU/_-9]3_S6?4_\U_T87 ?]0$0#_6 T
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M/H)C_SV"8_\\@F/_/()C_SR"8_\\_U / /];!P#_9@, [&\" -QV P#4? <
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M/VUR_S]M<O\__UD' /]E  #B<@  T7P  ,>$  # B@( N8\" +.2# "LE!T
MII,O!)Z1/ N8CT@4D8Q1'(N)6B2&AV(J@85I,'R"<35X@7HZ='^#/G!]CD)L
M?)I%:7NG1V9ZN$AD>]!(9'OP1V5[_T1F>O]#9WC_06AV_S]H=O\_:';_/VAV
M_S]H=O\__UL$ /=I  #==@  S8   ,.(  "[C@  M),! *V7"0"GF!H H)@L
M YF6.@J2E$42C))/&H:/5R* C5\H>XMG+G:);S-RAW<X;86!/&F$BT!F@I=#
M8H&E1F"!MD=>@<U'7H'O1E^!_T1@?_]"87W_06)[_S]C>O\_8WK_/V-Z_S]C
M>O\__UX  .EM  #6>0  R(0  +Z,  "VDP  KI<  *:;! "@G1< FITI I.<
M-PB,FD,0AIA-&("651]ZE%TF=9)E+'"0;#%LCG4V9XU^.F.+B3Y?BI5!7(FC
M1%J)M$58B<M%6(CM1%B(_T-9AO]!6X/_0%V!_SY=@/\^78#_/EV _SY=@/\^
M_V(  .1Q  #/?@  PX@  +F1  "PEP  IYL  )ZA  "8HQ, DZ,E 8VB- :&
MH4 -@)]*%7F=4QQTFUHC;YEB*&J8:BYFEG(R895\-UV4ACI9DI,^5I*A0%.1
MLD%2DLE"4I'K05*0_T!2C_\_58O_/E:(_SU7A_\]5X?_/5>'_SU7A_\]^6<
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M+4"P_B\_K_\Q/JW_,D"H_S)!IO\R0:;_,D&F_S)!IO\RU7P  ,**  "UE@
MJ)T  )VC  "2J@  A[$  'RW  !PO@, :,(. &;#'0!CPRT!7L,Y!%K#1 A6
MPDX,4L)7$$_!7Q1+P6D72,%S&D7 ?AU"P(P@/\";(CW K2,\P<0C/,#I(SJ^
M_B8XO/\H-[O_*3BX_RHXMO\K.+;_*SBV_RLXMO\KR84  +F3  "LG   H*(
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M""#K_PH?ZO\+'^K_"Q_J_PL?ZO\+J)\  )NF  "-KP  ?[@  ''!  !DR@
M6-   $S6  !!W0  ..0  #7V#  S]Q0 ,/<> "[X)P K^3  */DX 2;Z0 $C
M^TD!(?M2 1[\70(<_6D"&OUY QC^BP,7_YX#%?^S!!3_TP04_O0$$_S_ Q/Z
M_P,3^?\#$_G_ Q/Y_P,3^?\#G:4  (^N  " N   <L(  &3+  !6TP  2=H
M #[?   TY   +O0  "O_"@ H_Q  )?\7 "+_'P ?_R8 '/\M !G_-  7_SP
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M',TZ_Q[+.O\>RCK_'\0[_Q_ //\>P#S_'L \_Q[ //\>_SD; ?] %0#_11$
M_TH3 /].&0#_4"(!_U L ?U.-P+V2T,$\$E0!^M(70KG1FD-XT5T$.!$?A/=
M0X<5VT*0%]A!F!C50* 9TT"I&]% LAS/0+T=S4#,'<I!Y![&0/0@PD#_(K]
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M+992_RR44O\KE%+_*Y12_RN44O\K_T80 /]."0#_5@4 _EX& .]B!P#G90H
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M,7EB_S%Y8O\Q_T\' /]9  #F9   UVP  ,QS  #$=P( OWD$ +EZ#@"R?"
MK'PQ Z5Z/@F?>$H0FG53%Y5S7!V1<60BC6]L)XEM="N%;'PO@FJ%,G]ICS5\
M:)LX>6>G.G9FMCMT9LP\<V?K.W-G_SAS:/\V<VC_-7-G_S-S9O\R<V;_,G-F
M_S)S9O\R_U$$ /]<  #B9P  TG   ,=V  # >@  NGT" +1_# "M@1T IX$N
M J!_/ B:?4</E7I1%I!X6AR+=F(AAW1I)H-R<2M_<7HO?&^#,GANC35U;9@X
M<FRE.W!KM#QN:\D\;6OI.VUL_CEM;/\W;FS_-6YK_S1N:O\R;FK_,FYJ_S)N
M:O\R_U,  /1?  #>:@  S7,  ,-Z  "[?@  M8$  *Z#"0"HA1H HH4K IN$
M.@>5@D4.D']/%8I]6!N&>U\@@7EG)7UW;RIZ=G<N=G2 ,G-SBS5O<I8X;'&C
M.FEPLCQH<,8\9W#G.V=Q_#EH<?\W:'#_-6EO_S1I;O\S:6[_,VEN_S-I;O\S
M_U8  .MB  #8;@  R78  +]]  "W@@  L(4  *B'!@"BB1< G(HI 9:)-P:0
MAT,,BX5-$X6"51F @%T??']E)'A];2ET>W4M<'I^,6UYB#1I=Y0W9G:A.F-V
ML#MA=L0\87;E.V%V^SEB=O\W8W7_-6-S_S1D<O\S9'+_,V1R_S-D<O\S_U@
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M-4^+]S1/BO\S4(G_,E&&_S%2A/\Q4H3_,5*$_S%2A/\QZF4  -)S  #"?P
MMH@  *R0  "BE   F)@  (R<  "$GPH @* 9 'RA*0%WH#8%<I]!"FV>2P]H
MG5,49)Q;&6";8QU<FFLA6)ET)568?BE1EXHL3I:8+DN6J#!*EKPQ29;<,$F4
M]C!)D_\P29+_,$J0_R]+C?\O2XW_+TN-_R]+C?\OXFL  ,IY  "\A0  L8\
M *:4  ";F0  D9T  (:B  !ZI@, =J<3 '.H) !NJ#(#:J@]!F6G1PMAIE /
M7:58%%FD8!A5HV@<4J-Q'TZB?"-+H8@F2*&6*$6@IBI$H;HK0Z':*D.?]2M"
MG?\K0IS_+$*;_RQ$E_\K1)?_*T27_RM$E_\KUW(  ,.   "VC   JI0  )^9
M  "4G@  B:,  'ZH  !PK@  :K . &BQ'0!EL2P!8;$X UVP0P99L$P*5:]4
M#E*O71%.KF452ZYO&$BM>1M%K88>0JR5(#^LI2(^K;DC/:W8(CVK]2,\J?\E
M.Z?_)CNF_R8[I/\F.Z3_)CND_R8[I/\FS'H  +N(  "ND@  HID  )>>  ",
MI   @*H  '6O  !IM   7KD& %NZ% !9NR0 5KLQ 5.[/0-0NT<%3;M0!TJZ
M60I'NF(-1+IL$$&Z=Q,^N805/+F3%SFYHQ@XN;<9-[K6&3>X]!HUMO\<-+3_
M'C.S_Q\SLO\@,[+_(#.R_R SLO\@P8,  +21  "FF   FYX  (^E  ""JP
M=K$  &NV  !?O   5,$# $S%#0!+Q1D 2<8H $C&-0!%QT !0\=* T#'4P0^
MQUT&.\=G"#G'<PHWQX ,-,>0#3+'H0XQR+4/,,C3#S#&]! NQ/\3+<+_%2S!
M_Q8KP/\7*\#_%RO _Q<KP/\7N(T  *J7  ">G@  D:4  (2L  !XL@  :[D
M &"_  !4PP  2L@" $#-!P ZT@X .=(; #C3*  WTS4 -M1  #352P$SU54!
M,=9@ B_6; ,MUWH$*]B+!2K8G04HV;$&)]K-!B?7[P8FU/\))=+_"R31_PPC
MT/\-(]#_#2/0_PTCT/\-KI8  *"=  "4I   AJP  'FT  !LNP  8,(  %3&
M  !(RP  /M   #75!  MW0H +.$3 "OB'P IXRH *.0U "?D/P FY4H ).95
M "/F80$AYVX!(.=^ A[HD (=Z:0"&^F\ AKJX@(:YOP"&>7_ QGD_P08X_\%
M&./_!1CC_P48X_\%HYT  ):D  "(K   >K4  &R]  !?Q   4\H  $?.   \
MTP  ,MH  "K?   E[@D (_ 1 "'Q&0 ?\2( '?(K !OS-  9]#X %_1( !7U
M4@ 3]E\ $O9N 1'W@ $0^)0!#_FJ 0[YQ@$.^>T!#?;_ 0WT_P$-\_\!#?/_
M 0WS_P$-\_\!F:,  (NL  !\M0  ;;X  %_&  !2S0  1=(  #G8   OW@
M)N(  !_J   <^P8 &?\. !?_$P 4_QH $O\A !#_*  ._S  #?\Y  O_0P )
M_TX !O]<  3_;  "_X   ?^6  #_K0  _\H  /_P  #__P  __\  /__  #_
M_P  __\ C:L  'VU  !NOP  8,@  %+0  !#UP  -]T  "OB   BY@  &>H
M !7Y   2_P  $/\(  [_#@ ,_Q$ "?\6  ;_'  #_R(  /\J  #_,P  _ST
M /])  #_5P  _VD  /]^  #_E0  _ZP  /_'  #_Z   __H  /_Z  #_^@
M__H @+4  '"_  !AR0  4M,  $/;   UX0  *>8  ![J   5[@  $/@   [_
M   +_P  "/\   3_!@  _PH  /\.  #_$0  _Q4  /\;  #_(P  _RL  /\V
M  #_0P  _U,  /]E  #_>@  _Y$  /^F  #_N   _\\  /_/  #_SP  _\\
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M!?$<_P;P'/\'[QW_".\=_PGO'/\)[AS_">X<_PGN'/\)_RHB ?\N'0#_,!L
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M&;4Z_QBR._\8L3O_&+$[_QBQ._\8_SD2 /\_#0#_0PD _T@, /]+$ #_3!4
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M(XA2_R.(4O\C_T4' /]+  #P50  WUL  --@  #,80, R&$& ,-A$0"[9"0
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MKR]P8L$P;V+?,&YC]RYO8_\L;V/_*F]C_RAO8O\G;V+_)V]B_R=O8O\G_TT
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M,%UQ\BY><?\L7G#_*U]P_RE@;_\H8&[_*&!N_RA@;O\H\54  -YB  #*;0
MO74  +-[  "K@   HH(  )B!  "1@P\ C84? (B%+@*#A#L%?H-%"GJ!3@]U
M@%84<7]>&&Y]9AQJ?&T@9WMV(V-Z@"=@>8LJ77B8+%IWIBY8=[@O5W?1+U=W
M\2Y8=O\L6';_*EEU_RE:=/\H6G3_)UIT_R=:=/\G[5D  -=F  #%<0  N7H
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M)4:+_R1&BO\D1HK_)$:*_R1&BO\DV&D  ,-V  "U@0  JXH  )^/  "5DP
MBI8  'Z:  !PG0  :Y\. &B?' !FH"H!8J W E^?005;GTH(6)Y2"U2>6@Y1
MG6(23IQK%4N<=1A(FX$:19N/'4*:GQ] FK @/YK((#^9ZQ\_F/\@/I;_(3Z5
M_R$_E/\A/Y3_(3^4_R$_E/\AS7   +Q]  "PB   I(\  )F4  ".F   @YT
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MM   3K<  $.\!0! O1$ /[T> #Z^*P \OC8 .[]! #F_2P$WOU0"-<!? C/
M:@0QP'<%+\"&!BW EP<KP*H(*L'"""K YP<IO?T**+S_#">Z_PTGN?\.)[G_
M#B>Y_PXGN?\.LHP  *64  "9F@  C:$  '^G  !RK0  9K,  %JX  !/NP
M1+\  #K$ @ PR0@ +LH1 "W*'0 LRRD *\LU "O,0  JS4H *,U6 "?.80 F
MSF\!),Y_ 2//D0(ASZ4"(-"] B#/Y (?S?H#'LO_!![*_P4=R?\&'<G_!AW)
M_P8=R?\&J)0  )R:  "0H0  @J@  '2O  !GM@  6[P  $[   !#PP  .<<
M "_,   GT 0 ']8* !O:$  ;VQH &MLF !K<,0 9W3P &-U( !C>50 7WV(
M%N!R !7@A0 4X9H $^*Q !+CSP 2X/0 $M[_ 1'=_P$1V_\"$=O_ A';_P(1
MV_\"GIH  )*A  "$J0  =K$  &BX  !;OP  3L0  $+(   WS   +=   "35
M   <VP  %=\% !3I#@ 2ZA0 $>L= !#K)@ .[#  #NTZ  WN1@ +[E, "N]B
M  GP=  (\8D !_*@  7RN@ $\>0  O']  +O_P #[?\  ^W_  /M_P #[?\
ME:$  (:I  !XL@  :;H  %O"  !-R   0,P  #31   JU@  (=L  !G@   2
MY   #_ !  WY"@ +^@\ "?L5  ?['  $_"0  ?PL  #\-P  _$(  /Q0  #\
M80  _74  /R,  #\I   _,$  /SK  #\_P  _?\  /W_  #]_P  _?\ B:D
M 'FR  !JNP  7,0  $[,   _T0  ,M<  "?=   =X0  %>4   [H   *\0
M"/T   7_ P !_PD  /\.  #_$@  _Q<  /\?  #_)P  _S$  /\^  #_30
M_U\  /]U  #_C0  _Z8  /_"  #_YP  __P  /__  #__P  __\ ?+,  &R\
M  !=Q@  3L\  #_6   QW0  )>(  !KF   1Z@  #.X   7R    _P   /\
M  #_    _P   /\%  #_"@  _PX  /\2  #_&   _R$  /\K  #_.0  _TH
M /]=  #_<P  _XP  /^D  #_N0  _]0  /_>  #_W@  _]X _Q@L /\9*0#_
M&2@ _Q4K /\0, #_"S@!_P-$ ?\ 40'_ %X!_P!L ?\ > '_ ((!_P", ?\
ME '_ )P _P"B /\ J #_ *\ _P"V /\ O@#_ ,@ _P#7 /\ YP#_ /, _P#]
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _QLI /\=)@#_'"4
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M!=P<_P7<'/\%VQS_!=L<_P7;'/\%_RH9 /\M$P#_+1$ _RT1 /\N&0#_+2(
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M$J([_Q*B._\2_S@* /\\  #_00  ]44  .9& @#A10< XT(- -5#&0#,12P
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ML"""4,$A@%#=(7Y1]"!]4?\??5'_'7U1_QQ]4?\;?5'_&GU1_QI]4?\:_T(
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M)FE>[B1I7O\B:E[_(&I>_Q]J7O\>:E[_'6I>_QUJ7O\=^4H  .-5  #/7P
MP64  +=J  "O;   IVP  )]J 0"9:Q$ E&TB )!N,0&+;3T$AVQ'!X-K4 M_
M:E@/?&A@$WAG9Q9V9V\9<V9X''!E@1YM9(PA:F.8(VABIB5F8K8F9&+,)F1B
M["5D8O\C9&+_(65B_Q]E8O\>96+_'65B_QUE8O\=\DP  -]8  #*8@  O6D
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M(%1P_Q]5</\>56__'55O_QU5;_\=Y5<  ,UD  "^;0  LG4  *A[  "??@
MDWT  (=]  " ?P< ?( 5 'B!) !U@C(!<8$]!&V 1@=I@$\*9G]6#6-^7A%@
M?68477QN%UI[=QI7>H(=5'J/'U%YG2%/>:XB3GG#(DUXY2)-=_LA3G?_'TYV
M_QY/=?\=3W7_'4]U_QU/=?\=WUP  ,AH  "Y<@  KGH  *6   ":@@  CH(
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M%SJ._Q<ZCO\7Q6X  +9[  "JA0  GHL  )2/  "(D@  >Y0  &Z7  !BFP
M5YX  %*@#@!1H!L 3Z$H $VA- !+H3X!2:%' D>A4 -$H5@%0J%A!S^@:PD]
MH'<+.J"%#3B@E XVH*8/-:"[$#2@W0\TG?<0,YS_$C.:_Q(SF?\3,YG_$S.9
M_Q,SF?\3O7<  *^#  "CBP  F)$  (V5  "!F0  <YP  &>?  !;H@  3Z8
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MA0 9QYD &,BN !?(RP 7QO$!%\3_ 1;#_P(6P?\#%L'_ Q;!_P,6P?\#HY$
M )B8  "+G@  ?:4  '"K  !BL0  5K8  $JY   ^O0  -,   "K$   BR
M&<P$ !/0"@ 1TA$ $-(: !#3)0 /TS  #M0\  [42  -U58 #=5E  S6>  ,
MUHT "]BD  K8O@ )V>8 "M;^  O4_P +TO\ "]+_ 0O2_P$+TO\!FI@  (Z?
M  " I@  <JT  &2T  !7N@  2;\  #W"   RQ@  *,D  !_-   7T0  $=8
M  S;!0 (W@L !M\1  7?&@ $X"0  N$N  'B.@  XT<  .16  #D9P  Y7L
M .:2  #FJ@  Y\@  .?P  #H_P  Z/\  .C_  #H_P  Z/\ D9\  (*G  !T
MKP  9;<  %>^  !)PP  /,<  ##+   ESP  '-0  !39   .W0  ">$   +E
M    Z08  .D-  #I$0  ZA@  .LA  #M*P  [S<  /%%  #R5@  \V@  /-^
M  #TEP  ];   /;0  #W\P  ]_\  /?_  #W_P  ]_\ A:<  ':P  !FN
M6,$  $K(   [S   +M$  "/6   9W   $>    SC   $YP   .H   #U
M]    /4%  #U"P  ]@\  /84  #X'0  ^B<  /PT  #_0P  _U4  /]I  #_
M@0  _YH  /^R  #_SP  _^T  /_Y  #_^0  __D >+   &BZ  !9PP  2\L
M #O1   MV   (=T  !;B   .Y@  ".H   #M    \    /@   #_    _P
M /\   #_    _P8  /\,  #_$   _Q@  /\B  #_,   _T   /]3  #_:0
M_X$  /^9  #_KP  _\,  /_5  #_U0  _]4 _Q,H /\3)0#_$24 _PTG /\&
M+0#_ #4 _P!! /\ 3P#_ %P _P!I /\ = #_ 'X _P"( /\ D #_ )< _P"=
M /\ I #_ *H _P"P /\ MP#_ ,  _P#, /\ WP#_ .P _P#X /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _Q8E /\6(@#_%"$ _Q C /\** #_
M #  _P ] /\ 2P#_ %@ _P!D /\ < #_ 'H _P"$ /\ C #_ ), _P": /\
MH #_ *8 _P"M /\ M #_ +P _@#( /T V0#[ .D ^@#V /D _P#X /\ ^ #_
M /@ _P#X /\ ^0#_ /D _P#Y /\ _QHB /\:'@#_&!T _Q,> /\.(@#_"BP
M_P<Y /\#1@#_ %, _P!@ /\ :P#_ '8 _P!_ /\ B #_ (\ _P"6 /\ G0#_
M *, _@"I /P L #Z +D ]P#$ /4 T@#S .8 \@#T /$ _P#P /\ [P#_ .\
M_P#O /\ \ #_ /  _P#P /\ _QX= /\>&0#_'!< _Q<8 /\3'@#_$2@ _PXT
M /\,00#_"DX _PA; /\'9@#_!G$ _P9Z /\&@P#^!HL _ :2 /H&F0#X!I\
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M \,<_P/#'/\#_R@0 /\I"P#_* 8 _RL+ /\K$ #_*1< _28B /0C+@#L(3L
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MM Z;.\4.F3O@#I8[] ^4//\/DCS_#Y(\_PZ1//\-D3S_#9$\_PV1//\-_S4
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M&'E,ZQAX3/X7=TS_%7=,_Q1W3/\3=TS_$G=,_Q)W3/\2_SX  .A'  #54
MQE8  +Q8  "T60  K58  *=3!P"A5!4 G%8E )A7- &45T "D%=*!(U64P:*
M55L)AU1C"X14:@Z"4W(0@%)Z$GU2@Q1[48X6>%"9&'90IAET4+4:<U#)&G%0
MZ!IP4?P8<%'_%W!1_Q5P4?\4<5#_$W%0_Q-Q4/\3]4   .1+  #/5   P5H
M +==  "O7@  IUL  *%8 P";61( EELB ))<,0&.7#T"BEQ'!(=;4 :#6E@)
M@5E@#'Y99PY[6&\0>5=W$W96@!5T5HL7<E66&6]5HQIM5+(;;%3&&VI5YAMJ
M5?L9:E7_%VI5_Q9J5?\5:U7_%&M5_Q1K5?\4\D,  -]/  #+6   O5T  +-A
M  "K8@  HF   )M<  "57A  D& ? (QA+@"(83H"A&!%!(%@3@9^7U8)>UY=
M"WA=90YV7&P0<UQT$W!;?15N6H@7:UJ4&6E9H1MG6; <95G#'&19XQQD6?H:
M9%G_&&19_Q=E6?\595G_%&59_Q1E6?\4[T8  -I2  #&6P  NF$  +!E  "F
M9@  G6,  )5A  "/8@X BV0< (=E*P"#93<!?V5" WQD2P9X8U,(=6-;"W-B
M8@YP86H0;6!R$VM@>Q5H7X879EZ1&6->GQMA7:X<8%W!'%]=X1Q?7?@:7UW_
M&%]=_Q=@7?\68%W_%6!=_Q5@7?\5ZTH  -16  ##7@  MF4  *QI  "B:0
MF&<  (]E  ")9@P A6@9 (%I* !^:C4!>FD_ W9I205S:%$(<&=9"FUG8 UK
M9F<0:&5P$F5D>15C9(,78&./&5YBG1M<8JP<6F*_'%EBWQQ98O<:6F+_&5IA
M_Q=;8?\66V'_%5MA_Q5;8?\5YTT  ,]9  "_8@  LV@  *EM  ">;0  DVL
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M%$MP_Q1+</\4U%H  ,!F  "S;P  J'8  )UY  "/>   A'@  '=Y  !O?
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M#P!2CQL 4(\G $^0,P!-D#T!2Y!% DF03@-&D%8$1(]?!4*/: <_CW,)/8Z
M"SJ.CPPXCJ --XZS#C:.S XVC>\.-8O_#C6)_P\UB/\/-H?_#S:'_P\VA_\/
MOFT  +!Y  "E@@  F8<  (R(  !_B   <HH  &:-  !:D0  4)4  $F7"0!'
MF!, 19@@ $29*P!#F38 09I  $":2 $^FE$"/)I: CJ:9 ,WFF\%-9E]!C.9
MC <QF9T(+YFP""Z9R@@NF.T(+I;_"BV4_PHMD_\++9+_"RV2_PLMDO\+MG4
M *J!  ">B   DXT  (:.  !XCP  :Y(  %^5  !4F0  29T  $"@   ZH@T
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M  [ N@ .P.$ #[W[  ^\_P 0NO\!$+K_ 1"Z_P$0NO\!GX\  )25  "'FP
M>:$  &NG  !>K   4K$  $6T   ZM@  +[D  "6\   =OP  %<,   _&!0 +
MR@T "<H4  C*'0 'RB< !\HR  ;+/@ %RTL !,Q:  /,:@ "S'X  <R4  #,
MJP  S<@  ,SM  #,_P  R_\  <K_  '*_P !RO\ EY8  (J<  !\HP  ;JH
M &"P  !2M@  1;D  #F\   NOP  (\,  !O&   3R@  #<T   C1   !U D
M -0.  #5%0  UAX  -@G  #9,0  VSX  -Q+  #=6P  WFX  -Z$  #?FP
MW[0  -[9  #?]P  W_\  -__  #?_P  W_\ C9T  '^E  !PK   8;,  %.Z
M  !%OP  .,(  "S&   AR0  &,T  !#1   +U0  !-H   #>    X $  .$)
M  #B#@  Y!,  .4;  #G)   Z2\  .L\  #M2P  [ET  .YQ  #OB0  \*(
M /"\  #PXP  [_D  /#_  #P_P  \/\ @:4  '*M  !CM0  5+T  $;$   W
MR   *LP  !_0   5U0  #MH   ?>    X@   .8   #I    Z@   .P   #N
M!0  [PP  /$0  #S%P  ]2   /@K  #[.0  _4H  /Y>  #_=   _XT  /^F
M  #_P   _^$  /_U  #_]0  __4 =*X  &6W  !6P   1\@  #C-   JT@
M'=@  !/=   ,X@   ^8   #I    [    /    #S    ]    /8   #X
M^@   /T'  #_#0  _Q(  /\;  #_*   _S<  /]*  #_7@  _W8  /^/  #_
MI@  _[H  /_1  #_T0  _]$ _P\D /\.(@#_"R$ _P,D /\ *0#_ #( _P ^
M /\ 3 #_ %D _P!E /\ < #_ 'H _P"$ /\ C #_ )( _P"9 /\ GP#_ *4
M_P"K /\ L@#_ +H _P#% /\ TP#_ .< _P#T /\ _P#^ /\ _P#_ /X _P#^
M /\ _@#_ /X _P#^ /\ _Q$A /\0'@#_#1T _P<? /\ (P#_ "T _P Z /\
M2 #_ %4 _P!A /\ ; #_ '8 _P!_ /\ AP#_ (X _P"5 /\ FP#_ *$ _P"G
M /X K@#] +8 _ #  /L S0#Y .( ^ #P /< _ #V /\ ]0#_ /4 _P#U /\
M]0#_ /4 _P#U /\ _Q4= /\3&@#_$!D _PL9 /\ '0#_ "D _P V /\ 0P#_
M %  _P!< /\ 9P#_ '$ _P!Z /X @P#\ (H ^@"1 /D EP#X )T ]P"C /4
MJ@#T +( \@"[ /$ R #O -P [@#L .T ^@#K /\ Z@#_ .H _P#J /\ Z@#_
M .H _P#J /\ _Q@9 /\6%0#_$Q, _PX3 /\+&@#_!R0 _P(P /\ /@#_ $L
M_P!7 /\ 8@#\ &P ^ !U /4 ?@#R (4 \0", .\ DP#N )D [ "@ .L I@#I
M *X YP"W .8 PP#D -0 X@#I .$ ]P#? /\ W0#_ -T _P#= /\ W0#_ -T
M_P#= /\ _QL3 /\:$ #_%@X _Q(. /\2%0#_#Q\ _PPK /\). #_!D4 ^P-1
M /<"7 #R F8 [@)P .H"> #G H  Y@.' .0#C@#B Y4 X0.< -\$HP#=!*L
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M /\E  #_)@  ^R<  /$E P#P(0L Z!P2 -X9'0#4&RT S1T\ ,@?20#%(%4
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M") U[ B.-OX(C#;_"(LV_PB+-O\'BC7_!XHU_P>*-?\'_R\  /(T  #B/
MTD$  ,="  # 0   NSH! +8V#@"P.1P JCLL *8\.@"C/48 GSU0 9T]60*:
M/6$#F#UH!)8\< 64/'<&DCR !Y$\B >/.Y((C3N="8L[J0J).[<+B#O*"X4\
MZ N#//L+@CS_"H$\_PJ!//\)@3S_"($\_PB!//\(_S,  .PZ  #:0P  RD<
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M#VI,_PYJ2_\-:DO_#&I+_PQJ2_\,\#T  -M(  #'4   NE4  +!8  "E5@
MG%,  )=/  "14 X C%(< (E4*P"%5#< @E1" 7]42P-\5%,$>E-:!GA38@AU
M4FD)<U)Q"W%1>@UN480/;%"0$&I0G!)H4*L39E"\$V50V!-D4/,29%#_$&10
M_P]D4/\.94__#65/_PQE3_\,[$$  -1,  ##5   MED  *Q<  "@6@  EU<
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M#E9;_PU66_\-WDP  ,=6  "X7P  K60  *!E  "39   B6,  ']A  !Y8@,
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MC0Q!=9T./W6N#CYUQ0X]=>@./G/]#3YR_PT^<?\,/W'_##]P_PP_</\,Q5X
M +5I  "I<0  G'4  (UT  " =   =70  &EV  !>>0  6'P! %1]#@!2?AH
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M RB2O00HDN$#)Y#Z!">._P4GC?\%)XS_!2>,_P4GC/\%L70  *5^  "9A0
MBH0  'V$  !OA0  8X@  %B+  !-CP  0Y,  #J7   RF@< +IL0 "V;&@ L
MG"0 *YPN "J=.  IG4$ *)U+ ">>50 FGF$ )9YN ".>?@$BGI !()ZC 1^>
MN0$>GMT!'ISX AZ:_P(>F?\#'I?_ QZ7_P,>E_\#JGT  )Z%  "3BP  A8H
M '6+  !HC@  6Y$  %"5  !&F0  .YT  #*@   JHP  (J8) !^G$0 >IQH
M':@D !RH+0 ;J#< &JE! !FI3  8J5@ %ZIF !:J=@ 5JHD %*J> !.KM  2
MJ], $JCU !.G_P$3I?\!$Z7_ 1.D_P$3I/\!HX8  )>,  "-D0  ?9(  &V5
M  !@F   5)P  $B@   ^I   -*<  "JK   AK@  &;$  !*S!P /M1  #K47
M  ZU(0 -M2L #;4V  RV00 +MDX "K9<  FV;  (MG\ ![:4  :VJ@ %ML4
M!K;J  >U_P (M/\ "+/_  FR_P )LO\ FHT  )"3  "$F   =)P  &6@  !7
MI   2Z@  $"L   UL   *K,  "&U   8N   $;L   R^ @ &P L  L 1  '!
M&0  P2(  ,(K  #"-@  PT(  ,-0  #$7P  Q'$  ,2'  #$G0  Q+4  ,3:
M  #$]@  P_\  ,/_  ##_P  P_\ DY0  (>:  !XH   :J8  %RL  !/L0
M0;4  #6W   IN@  '[T  !;    0PP  "L8   /*    S 4  ,P,  #-$0
MSA@  ,XA  #0*@  T34  --#  #44@  U&,  -5X  #5CP  U:<  -;"  #6
MZ0  UOT  -;_  #6_P  UO\ BIL  'NB  !LJ0  7K   %"V  !"N@  -+T
M "C!   =Q   %,<   W+   &S@   -(   #7    V0   -H%  #<"P  W1
M -\5  #A'0  XR<  .4S  #G0@  Z%0  .AG  #I?@  Z9<  .JO  #JS@
MZ^\  .O^  #K_P  Z_\ ?:,  &ZK  !?L@  4;H  $+    TPP  )\<  !O+
M   2SP  "],   +8    W0   .$   #D    Y0   .<   #I    ZP<  .T-
M  #O$0  \1D  /0D  #W,0  ^4$  /I5  #Z:@  ^X0  /N=  #\M@  _-(
M /WM  #]]   _?0 <:P  &&U  !2O0  1,0  #3)   FS0  &M(  !#8   (
MW0   .$   #E    Z    .P   #O    \0   /,   #U    ]P   /D!  #[
M"   _@X  /\5  #_(0  _R\  /]!  #_5@  _VT  /^'  #_H   _[8  /_*
M  #_U   _]0 _PL@ /\''@#_ !T _P @ /\ )0#_ "X _P [ /\ 20#_ %8
M_P!B /\ ;0#_ '8 _P!_ /\ AP#_ (X _P"4 /\ F@#_ *  _P"F /\ K0#_
M +4 _P"^ /\ RP#_ .$ _P#P /X _0#] /\ _0#_ /T _P#] /\ _ #_ /D
M_P#Y /\ _PT= /\+&@#_!!D _P : /\ 'P#_ "H _P W /\ 10#_ %$ _P!>
M /\ : #_ '( _P!Z /\ @@#_ (D _P"0 /\ E@#_ )P _@"B /P J0#[ +
M^0"Y /@ Q@#V -D ]0#K /0 ^0#S /\ \@#_ /, _P#S /\ \P#_ /, _P#S
M /\ _Q 9 /\.%0#_"!0 _P 4 /\ &0#_ "4 _P R /\ 0 #_ $P _P!9 /\
M8P#^ &T _ !U /H ?0#Y (0 ]P"+ /8 D0#T )< \P"> /( I #P *P [@"T
M .T P #K ,\ Z0#F .@ ]0#F /\ YP#_ .8 _P#E /\ Y0#_ .4 _P#E /\
M_Q(4 /\0$ #_# \ _P,0 /\ %0#_ "  _P L /\ .@#_ $< ^@!3 /< 7@#T
M &< \0!P .\ > #M '\ ZP"& .H C #H ), YP"9 .4 H #C *< X0"P -\
MN@#= ,D VP#@ -@ \ #7 /X U0#_ -0 _P#3 /\ TP#_ -, _P#3 /\ _Q40
M /\2# #_#@D _PL, /\)$@#_ QH _P F /T ,P#T $  [P!- .L 6 #H &$
MY0!J .( <@#@ 'H W@"  -P AP#: (X V "5 -0 G #2 *, T "L ,X M@#,
M ,0 R@#9 ,@ [0#' /L Q0#_ ,0!_P## ?\ Q '_ ,0!_P#$ ?\ _Q@+ /\5
M!0#_$   _Q & /\/#0#_#!0 _ <? /$#*P#G #D X@!& -X!40#: EL U0)D
M -(#; #/ W0 S01[ ,L$@@#*!(D R 60 ,8%F #$!:  P@:I ,$&M "_!L$
MO0C5 +L)[ "X"_T M@S_ +4-_P"T#?\ M W_ +0-_P"T#?\ _QL% /\8  #_
M%P  _Q8  /L3!@#Z$ X [@P6 .,)(@#:"3  TPH^ ,X+2@#*#%4 QPU> ,4-
M9P#"#F\ P0YV +\.?@"]#X4 O ^- +H0E0"X$)T MQ"G +41L@"S$<  LA'5
M *X3[@"K%/X J17_ *<5_P"G%?\ IA3_ :84_P&F%/\!_Q\  /\<  #Z'@
MZQX  .,<  #?%04 W@X- -,.& #+$2@ Q1,W , 41 "\%D\ N1=9 +<780"T
M&&D LQEQ +$9> "O&H  KAJ( *P;D "K&YD J1NC *<<K@"F'+P I!W/ *$>
MZ@&>'OP!G!__ 9L?_P&:'_\!FA[_ 9D>_P&9'O\!_R(  /\A  #L)P  X"H
M -0I  #-)   RAP( ,09$@"]'"( MQXQ +,@/@"O(4D K2)3 *HC7 "H)&0
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M!7LV_P5Z-O\$>C;_!'HU_P1Z-?\$]2T  .0W  #0/P  PD,  +=$  "M0
MISH  *,V!@"=-Q, F3DB )4Z+P"2/#L CSQ& (P\3P&*/%<!B#Q> H8\90*$
M/&T#@CQU!( \?01_/(<%?3R2!GL[G@=Y.ZP'=SN\"'8\U0AT//$(<SS_!W(\
M_P9R//\%<CS_!7([_P5R._\%\3(  -X]  #)1   O$@  +!)  "F1@  GT$
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M!UY*_P=>2O\'XS\  ,M)  "\40  L%4  *%4  "64@  C5   (=,  "!30@
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MC0I-79P+2UVL#$I=P0Q)7>,,25SZ"DE;_PE*6_\(2EK_"$I:_P=*6O\'SDX
M +Q8  "N8   GV$  )%@  "%7P  >U\  '!=  !J7P  96$* &)B% !@8R$
M7F0M %QD-P!:9$ !6&1( 59D4 )49%<#4F1?!%!D9P5.8W$&3&-]"$EBBPE'
M8IH*1F*J"T1BOPM$8N$+1&'Y"D1@_PE$8/\(15__!T5?_P=%7_\'R%(  +A<
M  "K9   FV0  (QC  " 8P  =F,  &IB  !C9   7V8& %MG$0!9:!T 5VDI
M %9J,P!4:CP 4FI% 5!J3 %.:E0"3&I< TIJ901(:6\%1FEZ!T1IB A":)@)
M0&BI"C]HO0H^:-X)/F?W"3YF_P@_9?\'/V7_!S]D_P<_9/\'PU<  +-A  "G
M:0  EF@  (=G  ![9P  <6<  &5H  !<:@  6&P! %1N#@!2;Q@ 4&\D $YP
M+@!-<#@ 2W%! $IQ20%(<5$!1G%9 D1P8@-"<&P$0'!X!3YPA@8\;Y4'.F^F
M"#AONP@X;]L'.&[V!SAM_P<X;/\&.6O_!CEJ_P8Y:O\&O5P  *]F  "B;0
MD6P  ()K  !W:P  ;&P  &%N  !7<   4',  $QU"@!)=A, 1W<? $9W*0!%
M>#, 0W@\ $)X1 !!>$T!/WA5 3UX7@([>&@".7AT S=X@@0U>),%,W>D!3)W
MN04Q>-<%,7;U!3%T_P4Q<_\%,7+_!3)R_P4R<O\%MV,  *IM  "<<0  BW
M 'UP  !R<   9W$  %QS  !1=P  2GH  $)] P _?@X /7\8 #Q_(P [@"T
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M !:3_P$6DO\!%I'_ 1:0_P$6D/\!I7L  )F#  ")@0  >X   &R"  !?A
M5(@  $F+   _D   -90  "V7   EF@  '9X! !:@#  4H1( %*$; !.A)0 2
MH2X $:(X !&B0P 0HD\ #Z)<  ZC:P -HWT #:.2  RCIP *HL  "Z+F  R@
M_@ -G_\ #9[_  V=_P -G?\ GH0  )*)  "#B   <X@  &6+  !8C@  3)(
M $&7   WFP  +IX  "2B   <I0  %:@   ^K!  *K@P !ZT2  :M&P %K20
M!*XN  *N.0 !KD4  *Y2  "N80  KG,  *Z'  "NG0  KK0  *[5  "M]
MK?\  *S_  "K_P  J_\ EHL  (R0  ![D   :Y(  %V6  !0F@  1)\  #FC
M   OIP  ):L  !RN   4L0  #K0   FW   !N D  +@.  "Y%   N1P  +HE
M  "Z+P  NSH  +Q'  "\5@  O&<  +Q[  "\D0  O*D  +S$  "\ZP  N_X
M +O_  "[_P  N_\ D)(  (.8  !SFP  8Y\  %6C  !'J   .ZT  #"Q   E
MM   &[<  !*Z   ,O0  !;\   ##    Q (  ,4*  #%#@  QA0  ,<;  #(
M)   RBX  ,PZ  #-20  S5D  ,UL  #.@P  SIL  ,VU  #.V@  SO8  ,W_
M  #-_P  S?\ AID  '>@  !II@  6JP  $RR   ^M@  ,+D  "2\   9OP
M$<(   K%   "R0   ,P   #0    T0   -(!  #3"   U0T  -<1  #:&
MW"$  -\L  #A.@  XDH  .-=  #D<@  Y(L  .6E  #EP   Y>8  .7X  #E
M_P  Y?\ >J$  &NI  !<KP  3;8  #^\   POP  (\,  !?'   /R@  !\X
M  #1    U@   -P   #?    X    .(   #D    Y@,  .@)  #I#@  [!4
M .X>  #Q*P  ]#H  /5-  #V80  ]WD  /B3  #XK0  ^<8  /GD  #Y\P
M^?, ;:H  %ZR  !/N@  0,$  #'%   BR0  %LX   W2   $V    -T   #A
M    Y    .@   #K    [0   .\   #Q    \P   /8   #X P  ^@L  /T1
M  #_&P  _RD  /\[  #_3P  _V8  /]_  #_F0  _Z\  /_#  #_U@  _]8
M_P0< /\ &0#_ !D _P < /\ (@#_ "L _P X /\ 1@#_ %, _P!> /\ :0#_
M '( _P!Z /\ @@#_ (D _P"/ /\ E0#_ )L _P"A /\ J #_ *\ _P"Y /\
MQ0#_ -D _@#L /T ^P#[ /\ ^P#_ /L _P#Z /\ ] #_ /  _P#P /\ _P<8
M /\!%0#_ !0 _P 6 /\ &P#_ "8 _P T /\ 0@#_ $X _P!: /\ 9 #_ &T
M_P!U /\ ?0#_ (0 _P"* /T D #\ )8 ^@"= /D HP#X *L ]P"T /4 OP#T
M ,X \P#F /$ ]@#P /\ [P#_ .\ _P#N /\ [@#_ .H _P#J /\ _PL4 /\&
M$0#_ !  _P 0 /\ %@#_ "( _P N /\ / #_ $D _P!4 /X 7P#[ &@ ^0!P
M /< > #U '\ \P"% /( BP#P )( [P"8 .T GP#L *8 Z@"N .@ N0#G ,<
MY0#> ., \ #B /X X #_ .  _P#A /\ X0#_ .$ _P#A /\ _PT0 /\)#0#_
M 0P _P , /\ $@#_ !P _P H /P -@#Y $, ]@!. /( 60#O &( [ !K .H
M<@#H 'D Y@"  .0 A@#B (P X0"3 -\ F@#= *$ VP"J -@ M #5 ,  T@#3
M -  Z@#. /H S0#_ ,T _P#- /\ S #_ ,P _P#, /\ _Q , /\,!P#_ P(
M_P ( /\ #@#_ !8 ]@ B /  +P#L #P Z0!( .4 4P#A %P W@!E -L ; #7
M ', U !Z -( @ #0 (< S@". ,P E0#* )T R "E ,8 KP#$ +L P@#+ ,
MY0"^ /4 O0#_ +P _P"\ /\ O #_ +P _P"\ /\ _Q$% /\.  #_"@  _P@!
M /\$"@#X !  Z0 : ., * #> #4 V0!! -, 3 #/ %8 RP!? ,D 9@#& &X
MQ !T ,( >P#! (( OP") +T D "\ )@ N@"A +@ JP"V +< M #' +( X "Q
M ?( KP+_ *X#_P"M!/\ K03_ *T$_P"M!/\ _Q0  /\0  #_#P  \@T  .H*
M  #I PD W0 2 -0 'P#- 2T R (Z ,0#10#  U  O019 +L%80"Y!6@ MP9O
M +4&=@"T!WT L@>$ +$(C "O")4 K0F> *L)J "J"K4 J K% *8+WP"D#?0
MH@[_ * ._P"?#O\ GP[_ )\._P"?#O\ _Q<  /\3  #O&   Y!D  -L6  #2
M$ ( SPD+ ,@(%@#!"B0 O PR +<-/@"T#DD L0Y3 *\06P"M$&, JQ!J *D1
M<0"H$7@ IA&  *41B "C$I$ H1*; * 3I@">$[, G!/# )L4W@"7%O0 E1;_
M )07_P"3%_\ DA?_ )(6_P"2%O\ _QH  /0=  #E(P  U24  ,HD  #"'0
MOA8$ +L0$ "T$QT KQ4K *L6. "G&$, I1E- *(95@"@&ET GAME )T;; ";
M'', FAQ[ )@<@P"7'8T E1V7 ),>H@"2'J\ D!Z_ (\?V ",(/$!B2#_ 8@@
M_P&'(/\!AR#_ 88@_P&&(/\!^AX  .LF  #:+0  RC   +XN  "U*   L"(
M *X;# "H'1< HQ\F )\A,P"<(CX F2-( )<D40"5)%D DR5@ )(E9P"0)FX
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M FHU_P)J-?\"ZC   -,Z  #"00  LT,  *5!  ";/@  E3H  ) V  ",-0T
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MC 572IH&54JJ!U1*O0=32MP'4DKV!E)*_P522?\$4DG_ U)(_P-32/\#U$$
M ,!+  "R40  H%   ))/  "'3@  ?DP  'A(  !R2@  ;DL- &M-& !H3B0
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M!D17N 9#6-(&0U?R!D-6_P5#5?\$1%7_!$14_P-$5/\#QDP  +56  "E6@
ME%D  (98  ![6   <5<  &96  !A6   75D$ %E:$ !76QL 55PF %-=, !2
M73D 45Y! $]>20!-7E$!3%Y8 4I>80)(76L#1EUV T1=@P1"79(%0%VC!C]=
MM@8^7= &/5SQ!3Y;_P0^6O\$/EK_ SY9_P,_6?\#P5   +%:  "A70  D%P
M ();  !V6P  ;5L  &%;  !;70  5EX  %)@#0!081< 3F(B $UB+ !,8S4
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M BIO_P(J;?\"*FS_ BML_P(K;/\"L6$  *1I  "0:   @&<  '1G  !I9P
M7V@  %5K  !+;@  0W$  #QT   W=@H -'<2 #-X'  R>"4 ,7DN #!Y-P O
M>3\ +GE( "QZ4@ K>EP *GIH "AZ=@ F>H<!)7J9 2-ZK $B>L4!(GGI 2)W
M_P$B=O\!(G7_ B)T_P(C=/\"K&@  )UN  "*;0  >VP  &]L  !E;   6FX
M %!Q  !%=0  /7@  #9\   N?P( *8$- ">"%  F@AX )8(G "2"+P C@S@
M(H-" "&#2P @A%8 'X1B !Z$<0 <A(( &X25 !J$J0 8A,$ &(/F !B!_0 9
M@/\!&7__ 1E^_P$9?O\!IG   )5S  "$<@  =G$  &MQ  !><P  5'8  $EY
M   _?0  -X$  "^$   GB   ((L% !N-#@ :C14 &8T> !B.)P 7CC  %HXY
M !6.0P 4CT\ $X]; !*/:@ 1CWL $(^/  ^/I  .C[L #8_@  Z-^@ /B_\
M$(K_ !")_P 0B?\ H7H  (YY  !^=P  <G<  &1X  !8>P  37X  $*"   Y
MA@  +XH  ">.   @D0  &)4  !*8!0 .F@X #9H4  R:'0 +FB8 "YHP  J:
M.P )FD8 ")I3  :;80 %FG( !)J&  *:FP  FK$  9G/  *9\  "F/\ !)?_
M  66_P %EO\ F8$  (=_  !Z?@  :WX  %V!  !0A0  18D  #N-   QD@
M*)8  !^9   8G0  $:    RC @ &I0H  :40  "E%@  IA\  *8H  "F,@
MIST  *=*  "G6   IV@  *=\  "GD0  IJ@  *;#  "EZ0  I?P  *7_  "D
M_P  I/\ D8<  (*&  !RA@  8X@  %6,  !)D0  /98  #*:   HG@  'Z(
M !>F   0J0  "ZP   2O    L08  +$,  "R$0  LA<  +,?  "S*   M#(
M +4_  "U30  M5T  +5P  "UA@  M9T  +6V  "UW   M/<  +3_  "T_P
MM/\ BX\  'J.  !JD0  6Y4  $V:  ! GP  -:0  "JH   @K   %K    ^T
M   )MP   ;D   "]    O@   +X&  "_#   P!   ,$6  #"'0  PR<  ,4R
M  #&0   QE$  ,=C  #'>   QY$  ,>I  #'QP  Q^P  ,?^  #'_P  Q_\
M@Y<  '&:  !AG@  4J,  $6I   XK@  ++,  ""W   6N@  #KT   ;
MPP   ,<   #)    R@   ,P   #- P  S@D  - .  #2$P  U!L  -@E  #;
M,@  W4(  -U4  #>:0  WH$  -Z<  #?M0  W]D  -_S  #?_P  W_\ =Y\
M &BF  !9K0  2K,  #NX   MNP  '[\  !3"   ,Q@   \D   #,    T
M -4   #9    V@   -P   #>    X    .(%  #D"P  YQ   .H8  #M)
M\#(  /%$  #R6   \V\  /2*  #TI   ]+\  /3?  #T\P  ]/0 :J@  %NO
M  !,MP  /;T  "W!   ?Q@  $\H   O.    T@   -<   #<    X    .4
M  #G    Z0   .L   #M    [P   /$   #S    ]@<  /D.  #\%@  _R(
M /\S  #_1P  _UT  /]V  #_D0  _ZD  /^^  #_V   _]L _P 8 /\ %@#_
M !4 _P 8 /\ '@#_ "< _P V /\ 0P#_ $\ _P!: /\ 9 #_ &T _P!U /\
M?0#_ (0 _P"* /\ D #_ )8 _P"< /\ HP#_ *L _P"T /X OP#] ,\ ^P#G
M /H ^ #Y /\ ^0#_ /D _P#U /\ [@#_ .D _P#G /\ _P 4 /\ $0#_ !$
M_P 2 /\ %P#_ ", _P Q /\ /@#_ $H _P!6 /\ 8 #_ &@ _P!P /\ > #]
M 'X _ "% /H BP#Y )$ ^ "8 /< G@#U *8 ] "N /( N0#Q ,< [P#@ .X
M\@#L /\ [ #_ .P _P#K /\ Y0#_ .  _P#> /\ _P,0 /\ #@#_  T _P -
M /\ $P#_ !X _P K /\ . #_ $4 _@!0 /L 6@#X &, ]0!K /, <@#Q 'D
M[P!_ .X A@#L (P Z@"2 .D F0#G *  Y@"I .0 LP#A ,  X #3 -X ZP#<
M /L VP#_ -H _P#: /\ V0#_ -0 _P#2 /\ _P<- /\ "0#_  8 _P ) /\
M#P#_ !@ ^P E /@ ,@#U #\ \@!* .T 5 #J %T YP!E .0 ; #B ', X !Z
M -X @ #< (8 V@"- -< E #4 )L T@"D ,\ K0#- +D RP#) ,D Y #( /8
MQ@#_ ,4 _P#& /\ QP#_ ,< _P#' /\ _PH& /\!  #_    _P $ /\ "P#T
M !( [P ? .H + #E #@ X@!# -T 3@#9 %< U !? -$ 9P#. &T S !T ,H
M>@#( (  Q@"' ,4 C@## )8 P0"> +\ J "] +, N@#" +D VP"W /  M0#_
M +8 _P"U /\ M0#_ +4 _P"U /\ _PP  /\$  #_    _@   /8  P#H  T
MX  7 -D ) #1 #$ S0 \ ,H 1P#& %$ PP!9 ,  8 "^ &< O !N +H = "Y
M 'L MP"" +4 B0"S )$ L@": +  I "N *\ K "] *H T "H .L IP#[ *8
M_P"F /\ I0#_ *4 _P"E /\ _PT  /\'  #T"0  Z@D  .($  #:  < SP 1
M ,@ ' #" "D O@ U +L 0 "W $H M !3 +( 6P"P &( K@!H *P ;P"K '4
MJ0!] *@ A "F (T I "6 *, H "A *L GP&Y )T#S "<!.@ F@;Y )D'_P"8
M"/\ EPC_ )<(_P"7"/\ _Q   /<0  #H%   W!4  ,X1  #&#0  P@0+ +P
M% "W 2$ L@,N *X%.@"K!D0 J A- *8(50"D"5P H@IC * *:@"?"W$ G0MX
M )P+@ ":#(D F0R3 )<,G@"5#:H E VX )(-S "0#NH CA#\ (P0_P"+$/\
MBQ#_ (L0_P"*$/\ ^Q,  .T:  #=(   S"$  +\=  "W%P  LQ$  +(+#0"K
M#1D IPXF *,/,P"?$#X G1%' )H14 "8$E< EA)> )4390"3$VP DA-S ) 4
M? "/%(4 C16/ (L5F@"*%:< B!:U (86R0"$%^< @AC[ ( 9_P!_&?\ ?QG_
M '\8_P!_&/\ ]1H  .0C  #/*0  P"H  +,F  "J(@  I1P  *05" "@%!,
MFQ8A )<8+0"4&3@ D1I" (\;2P"-'%( BQQ9 (D=8 "('6< AAYO (4>=P"#
M'X  @A^+ ( ?EP!^(*, ?2"R 'L@Q0!Y(>0 =R+Y '8B_P!U(O\ ="'_ '0A
M_P!T(?\ [R$  -LK  #',0  MC$  *DN  "@*@  FR8  )@A 0"5'A  D" ;
M (TA* ")(S, AR0] (4D1@"#)4X @295 '\F7 !^)F, ?"=K 'LG<P!Y)WP
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MC %C-9H"83:I F VNP)?-M8"73;S ETV_P)<-O\!7#7_ 5PU_P%<-/\!W#,
M ,4\  "T00  HD   )4^  "+/   A#D  '\V  ![- 0 =S40 '0W' !Q."<
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M E$^_P%1/O\!SSL  +U%  "J1P  F48  (M%  "!1   >4(  '0^  !O/P
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M?@)!4HT"/U*= SY2KP,]4L8#/%+I CQ1_@(\4/\"/4__ CU/_P(]3O\"ODL
M *Y3  ":4@  B5$  'Q1  !Q4   :%   %Y.  !840  5%(  %%3# !.5!0
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M 2QCJ0$K8[\!*F/C 2IB^P$J8/\!*U__ 2M?_P$K7O\!L5D  )Y<  "+7
M>UL  &];  !E6P  7%P  %%>  !)8   0V(  #QE   X9PH -6@2 #1H&P S
M:20 ,FDM #%I-0 O:CT +FI& "UJ3P L:ED *VME "EK<@ H:X( )FN3 "1K
MIP C:[T (FK@ "-I^0$C9_\!(V;_ 2-F_P$D9?\!K&   )A@  "%8   =E\
M &I?  !A8   5V   $UC  !$9@  /6@  #9K   P;@0 +' . "IQ%0 I<1X
M*'$F "=R+P F<C< )7)  "1R2@ B<E0 (7-@ "!S;0 ><WT '7.0 !MSHP :
M<[D &7/< !IQ]P :</\ &V__ !MN_P$;;?\!IF8  )%E  !_9   <60  &9D
M  !=9   4F8  $AI   _;   -V\  #!S   I=@  (GD( !][$  >>Q< ''L?
M !M[*  :>S  &7PY !A\0P 7?$X %GQ: !5\9P 4?7@ $GV+ !%]GP 0?;4
M#WW5 !![]0 1>?\ $7C_ !)W_P 2=_\ GFL  (IJ  !Z:0  ;6D  &)I  !7
M:@  3&T  $-P   Y=   ,7@  "E[   B?P  &X(  !2%"0 1AA  $887 !"'
M'P 0AR@ #H<Q  Z'.P -AT8 #(=3  N'80 *AW$ "8>$  >'F  &AJX !8;)
M  :%[  'A/\ "(/_  F"_P )@O\ E7$  (-O  !T;@  :6X  %QO  !0<@
M1G4  #QY   R?0  *H$  "*%   ;B0  %(P   ^/ P *D@L !I(1  22&  "
MDB   9(I  "2,P  DSX  )-+  "360  DVD  )-[  "2D   DJ8  )&_  "1
MY0  D/H  (__  "/_P  C_\ C7<  'UU  !P=   8G4  %5X  !)?   /X
M #2$   KB0  (HT  !J1   3E   #I<   F;   !G0@  )T.  "=$P  GAH
M )XB  "?*P  GS4  *!"  "@4   H%\  *!Q  "@AP  GYT  )^U  ">V@
MG?8  )W_  "<_P  G/\ AGT  'A\  !I?   6W\  $Z#  !!B   -HP  "R1
M   CE@  &IH  !*>   -H0  !J0   "G    J0,  *D*  "J#@  JQ,  *P9
M  "M(@  KBL  *\W  "O10  KU0  *]F  "O>P  KI0  *ZK  "NR0  KN\
M *W_  "M_P  K?\ @80  '&$  !AAP  4XL  $:0   YE@  +IL  ".@   :
MI   $J@   RL   $KP   +(   "V    MP   +<"  "X"   N0T  +H2  "[
M&   O2$  +XK  # .   P$@  ,!:  #!;@  P88  ,&@  #!N@  P>,  ,#Y
M  # _P  P/\ >8T  &B0  !9E   2YH  #V@   QI0  ):L  !JO   1LP
M"[@   *[    O@   ,$   #$    Q0   ,8   #'    R 4  ,H+  #,#P
MSA4  - ?  #3*P  U3H  -5,  #68   V'<  -B2  #8K   V<D  -GL  #9
M^P  V/\ <)D  &">  !1I   0ZH  #6P   HM@  '+H  !&^   )P0   ,4
M  #(    RP   ,\   #2    TP   -8   #8    VP   -T   #?!P  X@T
M .43  #H'0  ["H  .T\  #M40  [F<  .^!  #OG   \+<  /#3  #P[
M\/0 9Z8  %BM  !)M   .KH  "J^   <P@  $,8   ?*    S@   -(   #6
M    W    .    #C    Y    .8   #H    ZP   .T   #O    \@(  /4*
M  #X$0  _!P  /\L  #_/P  _U4  /]N  #_B@  _Z0  /^Z  #_T0  _^$
M_P 4 /\ $@#_ !( _P 4 /\ &0#_ "4 _P R /\ /P#_ $L _P!6 /\ 8 #_
M &@ _P!P /\ > #_ '\ _P"% /\ BP#_ )$ _P"8 /\ G@#^ *8 _0"N /P
MN0#Z ,@ ^0#B /@ ] #W /\ ]@#_ /8 _P#O /\ YP#_ .( _P#> /\ _P 1
M /\ #@#_  X _P / /\ % #_ "  _P M /\ .@#_ $8 _P!1 /\ 6P#_ &,
M_@!K /P <P#Z 'D ^0"  /< A@#V (P ]0"2 /, F0#R *  \ "I .X LP#M
M ,$ ZP#6 .H [@#I /X YP#_ .< _P#E /\ W0#_ -4 _P#1 /\ _P - /\
M"@#_  @ _P ) /\ $ #_ !L _P H /\ -0#_ $  ^@!+ /8 50#S %X \0!F
M .X ;0#L '0 ZP!Z .D @ #G (8 Y@"- .0 DP#B )L X "C -X K0#< +D
MV@#* -< Y@#4 /@ T@#_ -( _P#2 /\ S@#_ ,D _P#& /\ _P ( /\  P#_
M    _P # /\ #0#\ !8 ]P B /, +@#O #H [ !% .@ 3P#D %@ X0!@ -X
M9P#; &T V0!T -4 >@#3 (  T0"' ,\ C@#- )4 RP"> ,D IP#' +, Q0#"
M ,, W #! /$ OP#_ +\ _P"^ /\ O@#_ +T _P"[ /\ _P   /\   #_
M_P   /8 " #N !$ YP ; .$ )P#= #, V0 ^ -, 20#/ %( RP!9 ,@ 80#&
M &< Q !M ,( <P#  'H OP"  +T B "[ )  N0"8 +@ H@"U *T LP"[ +$
MS@"P .H KP#\ *T _P"M /\ K@#_ *X _P"N /\ _P(  /\   #]    \@
M .@   #>  P TP 5 ,P (0#( "P Q  X ,$ 0@"] $L N@!3 +@ 6@"V &$
MM !G +( ;0"P '0 KP!Z *T @@"L (H J@"3 *@ G0"F *@ I "U *( Q@"A
M ., GP#V )X _P"> /\ G@#_ )X _P"> /\ _P8  /L   #N!0  X@0  -4
M  #+  8 PP / +T &0"X "4 M  Q +$ .P"N $4 K !- *D 50"G %L I0!B
M *0 : "B &X H0!U )\ ? "> (4 G ". )H F "8 *0 E@"P )4 P0"3 -P
MD@#R )$ _P"0 /\ D #_ (\ _P"/ /\ _0H  / .  #A$0  SA   ,(-  "[
M!P  MP * +$ $@"L !X J  I *4 - "B #X GP!' )T 3P"; %8 F0%< )<!
M8P"6 FD E )P ),#> "1 X  D 2* (X$E0",!:$ B@6N (D&O@"'"-@ A@GP
M (0*_P"#"_\ @PO_ (,+_P"#"_\ ]A   .87  #2'   P!H  +,6  "L$@
MJ T  *8'#0"B!18 G0<B )D)+@"6"C@ E M! )(,2@"0#%$ C@U8 (P-7@"+
M#64 B0UL (@.= "&#GT A0Z' (,.DP"!#Y\ @!"M 'X0O@!]$-L >A'T '@2
M_P!W$O\ =Q+_ '<2_P!W$O\ [Q<  -LA  #&)   M",  *@@  "@'   FQ<
M )D1! "8#A  DQ ; (\1)P",$C( B1,\ (<31 "%%$P @Q13 ($56@" %6
M?A9H 'T6;P![%G@ >1># '@7CP!V&)P =!BJ ',9NP!R&=0 ;QKQ &X;_P!M
M&_\ ;1K_ &T:_P!M&O\ YR   - I  "\*P  JRH  )XH  "6)   D"   (T<
M  ",%PP B!@6 (0:(@"!&RT ?APW 'P=0 !Z'4@ >1Y/ '<>50!V'UP =!]C
M ',?:P!Q('0 <"!_ &XABP!L(9@ :R&G &DBN !H(L\ 9B+N &4C_P!D(_\
M9"+_ &0B_P!D(?\ X"8  ,@O  "T,0  HS   )8N  "-*P  AR@  (0D  ""
M( @ ?B 2 'LB'@!X(RD =20S ',E/ !Q)4, <"9+ &XF4@!M)UD :R=@ &HG
M: !I*'$ 9RA[ &4HB !D*94 8BFD & IM0!?*<L 7BKL %PJ_P!<*?\ 7"G_
M %PI_P!<*/\ V"P  ,,U  "M-0  G30  ) S  "&,0  @"T  'PK  !Y* ,
M=B<0 '(I&@!P*B4 ;2LO &LL. !J+$  :"U' &<M3@!E+E4 9"Y= &,N90!A
M+VX 7R]X %XOA !<+Y( 6B^A 5DOL@%8,,@!5C#I 54P_@%5+_\ 52__ %4N
M_P!5+O\ T#$  +TZ  "H.0  ES@  (HW  " -@  >C(  '4P  !R+@  ;BX-
M &LO%@!I,"$ 9C$K &0R- !C,CT 83-$ & S2P!?-%( 731: %PT8@!:-&L
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M?0%*/XL!2#^; 4<_K %%/\$!1#_C 40^^P%$/O\!1#W_ 40]_P%%//\!PSX
M *]#  ":0@  BD(  'U!  !S0   :S\  &4\  !@/   7#X$ %D^#P!7/Q@
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M 3=,IP$V3+P!-4S= 35+]P$U2_\!-4K_ 39)_P$V2?\!N$D  *)+  ".2@
M?DH  ')*  !H2@  7TD  %5(  !02@  3$L  $E,!P!&31  1$X9 $)/(@!!
M3RL 0% S #]0.P ^4$, /%%* #M14P Z45P .%%G #=1<P U48( ,U&3 3)1
MI0$P4;H!+U': 2]0]@$O3_\!,$[_ 3!._P$P3?\!M$T  )U-  "*30  >DT
M &Y-  !D30  6TT  %%-  !+3P  1E   $)2 P _4PT /505 #Q4'@ Z52<
M.54O #A5-P W5C\ -E9' #564  S5ED ,E=D #!7<0 O5X  +5>1 "M7HP J
M5[@ *5?6 "E6]0 I5?\ *E3_ 2I3_P$J4O\!KU$  )A1  "%40  =E   &I0
M  !@4   6%$  $Y2  !'4P  054  #M8   X60H -5H1 #1:&@ S6R( ,ELK
M #%;,P O7#L +EQ# "U<3  L7%8 *UU@ "E=;0 H77P )EV. "1=H0 C7;4
M(EW2 ")<\P B6_\ (UK_ "-9_P D6/\ J%4  ))4  " 5   <50  &94  !<
M5   5%4  $I6  !#6   /%L  #9=   P8 4 +6$. "MA%0 J8AT *6(E "AB
M+@ G8S8 )F,^ "5C1P C8U$ (F1< "%D:0 ?9'D 'F2* !QDG@ ;9+, &63.
M !IC\0 ;8?\ &V#_ !Q@_P <7_\ H5D  (Q8  ![6   ;5@  &)8  !96
M4%D  $=;   ^7@  -V   #%C   J9@  )&D) "%J$  @:A< 'VH@ !YK*  =
M:S  '&LY !MK0@ :;$P &6Q8 !=L90 6;'0 %&R& !-LF@ 2;*\ $6S* !%K
M[P 2:?\ $VC_ !-H_P 39_\ F5T  (5=  !U7   :%P  %Y<  !57   2UX
M $)A   Y9   ,F<  "MJ   D;0  'G ! !=S"P 5=!$ %'08 !-T(0 2=2D
M$74R !%U.P 0=48 #W52  YU7P -=6X #'6!  MUE0 *=:H "'3#  ETYP *
M<_T "W'_  QQ_P ,</\ D6(  ']A  !P80  9&$  %IA  !/8@  164  #QH
M   S;   *V\  "1R   ==@  %WD  !%\!  -?PP "W\2  I_&0 )?R( "'\J
M  9_-  %?S\ !']+  )_6  !?V<  ']Y  !_C@  ?Z,  'Z[  !]X   ??<
M 'S_  ![_P  >_\ B6<  'AG  !K9@  868  %1G  !):0  /VT  #5Q   L
M=0  )'D  !U\   6@   $(,   R& @ &B0H  8D/  ")%   BAL  (HC  "+
M+   BS<  (M#  "+4   BU\  (MQ  "+A@  BYP  (JS  ")TP  B/,  (C_
M  "'_P  A_\ @FT  '-L  !H;   6FT  $YO  !"<P  .'<  "Y[   E@
M'80  !6(   0C   "X\   22    E 8  )4,  "5$   EA4  )<<  "8)
MF"X  )DY  "91P  F58  )EH  "9?0  F90  )BK  "7R   ENX  );_  "5
M_P  E?\ >W0  &]S  !A<P  4W8  $9Z   [?P  ,(0  ":(   =C0  %)(
M  Z6   )F0   9P   "@    H0   *(&  "B#   I!   *44  "E'   IR0
M *@O  "H/0  J4P  *E>  "I<@  J(D  *BB  "HO   I^4  *;[  "F_P
MI?\ =WL  &A[  !9?@  2X(  #Z'   RC0  )Y(  !V7   4G   #J    >D
M    J    *L   "N    KP   +    "Q!   LPH  +0.  "U$P  MAL  +@D
M  "Z,0  ND   +I2  "[90  NWT  +J7  "ZL0  NM(  +KS  "Y_P  N?\
M;X,  %^&  !1BP  0Y   #:7   JG0  'Z(  !6G   -K   !;    "T
MMP   +L   "^    OP   ,    #!    PP$  ,0'  #%#0  QQ$  ,H9  #-
M)   SC,  ,]$  #06   T&X  -&(  #0I   T,$  -'F  #1^   T?\ 9X\
M %>4  !)F@  .Z$  "ZG   AK0  %K,   ZX   &O    ,    ##    Q@
M ,L   #-    S@   -    #1    U    -8   #: @  W D  -\/  #C%P
MYB0  .<V  #H20  Z5\  .IX  #KE   ZZ\  .O,  #LZ   [/8 7YX  %"D
M  !"JP  -+(  ":Y   9O@  #L(   3%    R@   ,T   #1    V    -L
M  #?    X    .(   #D    Y@   .D   #K    [@   /$%  #U#0  ^18
M /PE  #].0  _D\  /]G  #_@@  _YT  /^U  #_RP  _^0 _P 1 /\ #P#_
M  \ _P 1 /\ %@#_ "( _P O /\ .P#_ $< _P!2 /\ 6P#_ &0 _P!L /\
M<P#_ 'H _P"  /\ A@#_ (P _@"3 /T F0#[ *$ ^@"I /@ M #W ,( ]@#:
M /4 \0#T /\ \P#_ /, _P#I /\ X #_ -@ _P#3 /\ _P . /\ "P#_  H
M_P + /\ $0#_ !T _P J /\ -@#_ $$ _P!, /\ 5@#^ %\ ^P!F /D ;0#W
M '0 ]0!Z /0 @ #R (8 \ "- .\ E #M )L [ "D .H K@#I +H YP#- .4
MZ0#D /L XP#_ .( _P#> /\ T0#_ ,P _P#( /\ _P ) /\ ! #_  $ _P $
M /\ #@#_ !@ _P D /T , #[ #L ]P!& /, 4 #O %D [ !@ .H 9P#G &X
MY@!T .0 >@#B (  X "' -X C@#< )4 V@"> -8 J #4 +, T0## ,\ WP#.
M /0 S #_ ,L _P#+ /\ Q0#_ +\ _P"\ /\ _P " /\   #_    _P   /T
M"P#W !, \0 > .T *@#J #4 YP!  .( 2@#= %( V0!: -4 80#2 &< T !M
M ,X <P#, 'H R@"  ,@ AP#& (\ Q "8 ,( H0#  *T O@"[ +P T "Z .T
MN0#^ +@ _P"X /\ MP#_ +, _P"P /\ _P   /\   #_    ^0   .X !0#E
M  X W@ 8 -@ (P#2 "X SP Y ,L 0P#' $P Q !4 ,$ 6P"_ &$ O !G +L
M;0"Y ', MP!Z +4 @0"T (D L@"2 +  FP"O *< K "T *L Q@"I .0 IP#X
M *8 _P"F /\ I0#_ *4 _P"D /\ _P   /\   #U    Z@   -X   #0  H
MR  2 ,( '0"^ "@ NP S +D /0"U $8 L@!- +  50"M %L K !A *H 9P"H
M &T IP!S *4 >@"D (( H@", *  E@"? *$ G0"N )L O@"9 -@ EP#Q )8
M_P"6 /\ EP#_ )< _P"7 /\ _P   /4   #G 0  U    ,D   #   0 N  .
M +, %@"O "$ JP L *@ -@"F #\ HP!' *$ 3P"? %4 G0!; )L 80": &<
MF !N )< =0"5 'T E "& )( D0"0 )P C@"I (P N "+ ,T B0#K (@ _0"(
M /\ B #_ (@ _P"( /\ ^08  .D,  #4#@  PPP  +<)  "P @  JP ) *8
M$ "B !H G@ E )L , "8 #D E@!! )0 20"2 %  D !6 (X 7 "- &( BP!I
M (H < "( '@ AP"! (4 C "$ )@ @@"E (  M !^ ,@ ?0'G 'P"^0![ _\
M>P3_ 'L$_P![!/\ \0X  -X5  #%%0  M!0  *D1  "A#@  G@H  )L## "7
M !, DP > ) !*0"- C, B@,\ (@$0P"&!4L A091 (,&5P""!UX @ =D '\(
M; !]"'0 ? A^ 'H)B0!X"98 =PJC '4*LP!S"\< <@SF ' -^P!P#?\ ;PW_
M &\-_P!O#?\ Z!8  - >  "Y'0  J1P  )T:  "5%@  D!,  (\. P"."@X
MB0L7 (8,(P"##2T @ TV 'X./@!\#D8 >PY- 'D/4P!X$%H =A!A '40: !S
M$'$ <1%[ ' 1AP!N$90 ;!&B &L2L@!I$L< :!/G &83_0!E%/\ 913_ &43
M_P!E$_\ WQX  ,8D  "P)   H",  )0A  "+'P  AAL  (,7  ""$@@ ?Q$2
M 'P2'0!Y%"@ =A0Q '05.@!R%D$ <19( &\73P!N%U8 ;!== &L89 !I&&T
M:!EW &89@P!D&9  8QJ? &$:KP!@&L0 7AOD %T<^P!<'/\ 7!O_ %P;_P!<
M&_\ U24  +TJ  "H*0  F"D  (PH  "#)0  ?2(  'D?  !X&P, =AD/ '(:
M& !O'", ;1TM &L=-0!I'CT :!Y$ &8?2P!E'U( 8R!9 &(@80!A(&D 7R%S
M %TA?P!<(8T 6B*< %DBK !7(L  5B/A %4C^0!4(_\ 5"+_ %0B_P!4(O\
MS2L  +8N  "B+@  DBX  (4M  !\*P  =B@  '(F  !O(P  ;2$, &HB%0!G
M(Q\ 920I &,D,0!B)3D 8"9! %\F2 !=)D\ 7"=6 %LG70!9)V8 6"AP %8H
M? !4*(H 4RF9 %$IJ@!0*;X 3RG> $XI]P!-*?\ 32G_ $TH_P!.*/\ R#
M + R  "<,@  C#(  ( Q  !V,   <"T  &LK  !H*0  9B@) &,H$0!@*1P
M7BHE %PK+@!;*S8 62P] %@L1 !7+4P 52U3 %0M6P!3+6, 42YN % N>@!.
M+H@ 3"^7 $LOJ !)+[L 2"_; $@O]@!'+_\ 1R[_ $<M_P!(+?\ Q#0  *LU
M  "7-0  AS4  'LU  !R-   :S(  &8O  !B+@  7RT% %PN$ !:+Q@ 6# B
M %8P*P!5,3, 4S$Z %(R0@!1,DD 4#)0 $XS6 !-,V$ 2S-K $HS=P!(-(4
M1S25 $4TI@!#-+D 0C36 $(T] !"-/\ 0C/_ $(R_P!",O\ P#@  *<X  "3
M.   @S@  '<X  !M-P  9C8  &$S  !=,@  63(" %<S#0!4-!4 4C4? %$U
M* !/-C  3C8X $PW/P!+-T8 2C=. $DX5@!'.%\ 1CAI $0X=0!#.(, 03F3
M $ YI  ^.;@ /3G3 #PY\P \./\ /3?_ #TW_P ]-O\ NSL  *([  "/.P
M?SL  ',[  !J.@  8CD  %TW  !8-@  5#<  %$X"P!/.1, 33D< $LZ)0!*
M.BT 2#LU $<[/ !&/$0 13Q+ $0\4P!"/%P 03UG #\]<P ^/8$ /#V1 #H]
MHP Y/;8 .#W1 #<]\@ W//\ .#O_ #@[_P X.O\ MCT  )X^  "+/@  ?#X
M &\^  !F/0  7CT  %@[  !3.@  3SL  $P\" !)/1$ 1SX9 $8_(@!$/RH
M0S\R $) .@!!0$$ 0$!) #Y!40 ]05H /$%D #I!<  X07\ -T&/ #5"H0 T
M0K0 ,D+. #)!\  R0/\ ,T#_ #,__P T/O\ L4   )I   "'0   >$$  &Q!
M  !B0   6T   %0_  !./P  2D   $9!!0!$0@X 0D,6 $!#'P _1"< /D0O
M #Q$-P [13X .D5& #E%3@ X1E@ -D9B #5&;@ S1GP ,4:- #!&GP N1K,
M+4;, "U&[P M1?\ +D3_ "Y#_P N0_\ K$,  )9#  "#0P  =$,  &A#  !?
M0P  5T,  %!#  !(0P  1$4  $%& 0 ^1PP /$@3 #I('  Y220 .$DL #9)
M-  U2CL -$I# #-*3  R2E4 ,$M? "]+:P M2WH +$N+ "I+G0 H2[$ )TO*
M "=+[0 G2O\ *$G_ "A(_P I1_\ IT8  )%&  !_1@  <$8  &5&  !;1@
M5$8  $Q'  !$2   /TH  #M+   W3 D -4T0 #-.&  R3B  ,4\H #!/,  O
M3S@ +D]  "Q02  K4%( *E!< "A0:  G4'< )5"( "10FP B4*\ (5#( "!0
MZP A3_\ (D[_ ")-_P C3?\ H4D  (Q)  !Z20  ;$H  &%*  !82@  4$H
M $E+  ! 3   .TX  #50   Q4@0 +5,- "Q4%  J5!P *54D "A5+  G53,
M)E4\ "5610 D5DX (E99 "%690 ?5G0 'E:% !Q6F  ;5JP &5;% !E6Z0 :
M5?\ &U3_ !M3_P <4O\ FTT  (9-  !U30  :$T  %U-  !430  34X  $5/
M   \40  -E,  #%5   K6   )EH) "-;$  B6Q< (5P? "!<)P ?7"X '5PW
M !Q=0  ;74H &EU5 !A=80 777  %5V! !1=E0 37:H $5W" !%=YP 26_X
M$UK_ !-:_P 46?\ E%$  (!1  !P40  9%$  %E1  !140  25(  $%3   X
M5@  ,ED  "M;   E7@  'V$# !IC#  89!$ %V09 !9D(0 59"D %&4Q !-E
M.@ 2940 $650 !!E70 /96L #F5]  UED0 ,9:4 "F2\  IDX  +8_D #&+_
M  UA_P -8?\ C54  'I5  !K50  7U4  %95  !.50  1%<  #Q9   T7
M+%\  "9B   ?90  &6@  !-K!0 0;0T #FX2  UN&@ ,;B( #&XK  MN-  *
M;CX "&Y*  =N5P &;F4 !&YV  )NB@  ;9\  &VV  !LU@  ;/,  6O_  )J
M_P #:O\ A5H  '1:  !F6@  7%D  %-9  !(6@  /UT  #9@   N8P  )F<
M !]J   9;0  $W$   YT P *=PH !7<0  %W%0  =QP  '<D  !X+0  >#<
M 'A#  !X4   >%X  'AO  !XA   >)D  '>P  !VS0  =?   '7_  !T_P
M=/\ ?E\  &Y?  !B7@  65X  $U?  !"8@  .64  #!H   G;   'W   !AT
M   2=P  #7L   A^   "@ @  ($-  "!$0  @A<  (,>  "#)@  A#   (0[
M  "$2   A%<  (1H  "$?   A),  (.J  ""Q0  @>L  ('^  " _P  @/\
M=V4  &ED  !?8P  4F0  $=G   \:P  ,6\  "AS   @=P  &'P  !%_   ,
M@P  !H<   "*    C ,  (P)  "-#@  CA$  (\7  "0'@  D2<  )(R  "2
M/P  DDX  ))?  "2<P  DHL  )&B  "1O   D.4  (_\  "._P  CO\ <6L
M &9J  !8:P  2VT  #]Q   T=@  *GL  ""    7A0  $(D   N-   $D0
M )4   "8    F0   )H#  ";"   G T  )X1  "?%@  H!X  *(H  "B-0
MHT0  *-5  "C:0  HH   **:  "ALP  H-@  *#V  "?_P  G_\ ;G$  %]R
M  !1=0  1'D  #=^   LA   (8H  !>/   0E   "ID   &=    H    *0
M  "G    J    *D   "J    K 8  *T+  "O$   L!4  +(>  "T*0  M#D
M +1*  "U70  M7,  +6.  "UJ   M,8  +/M  "R_P  LO\ 9GH  %=]  !)
M@@  /(<  "^.   CE   &)H  !"?   )I    *D   "M    L    +0   "W
M    N    +D   "[    O    +X"  # "   P@X  ,04  #''@  R"P  ,D]
M  #*4   RF8  ,I_  #*FP  RK@  ,K=  #*]0  RO\ 7H8  $^+  !!D0
M,Y@  ">?   ;I0  $:L   FP    M0   +D   "]    P0   ,8   #(
MR0   ,L   #,    S@   -    #2    U 4  -D,  #=$@  X1X  .(N  #C
M0@  Y%<  .5O  #FC   YJ@  .7%  #EYP  YO8 5I0  $B;   ZH@  +*D
M !^P   3M@  "[P   #!    Q0   ,D   #-    T@   -8   #:    VP
M -X   #@    X@   .0   #G    Z0   .T   #P"@  ]!$  /@?  #Y,@
M^D@  /M?  #\>@  _9<  /VO  #]QP  _>0 _P . /\ #0#_  P _P . /\
M$P#_ !X _P J /\ -@#_ $( _P!- /\ 5P#_ %\ _P!G /\ ;@#_ '0 _P!Z
M /\ @0#] (< _ "- /H E #Y )P ]P"E /4 KP#T +P \P#/ /$ [ #P /X
M[P#_ .\ _P#C /\ UP#_ ,X _P#* /\ _P * /\ !@#_  0 _P ( /\ $ #_
M !D _P E /\ ,0#_ #T _P!' /X 40#[ %D ^0!A /8 : #T &X \P!T /$
M>@#O ($ [@"' .P C@#J )8 Z "? .8 J0#C +4 X@#& .  XP#? /@ W0#_
M -T _P#4 /\ R0#_ ,( _P"^ /\ _P # /\   #_    _P ! /\ #0#_ !0
M_0 @ /H *P#W #8 \P!! .\ 2P#L %0 Z !; .8 8@#C &@ X0!N -\ = #<
M 'H V@"! -@ B #4 )  T@"8 ,\ H@#- *X RP"\ ,D TP#' /  Q@#_ ,0
M_P#$ /\ NP#_ +8 _P"S /\ _P   /\   #_    _P   /< " #P !  ZP :
M .< )0#D #  X0 [ -P 10#5 $T T0!5 ,X 6P#+ &( R0!G ,< ;0#% ',
MPP!Z ,$ @0"_ (D O0"2 +L G "Y *< MP"U +4 R "S .8 L@#[ +$ _P"P
M /\ K@#_ *H _P"G /\ _P   /\   #^    \0   .4  @#<  T TP 4 ,T
M'P#* "H QP T ,0 /@#  $< O !. +H 50"W %L M0!A +, 9P"R &T L !S
M *X >@"L (( J@"+ *@ E0"G *  I0"M *, O@"A -L H #T )\ _P"> /\
MGP#_ )T _P"; /\ _P   /P   #N    X    -    #%  @ O@ 0 +D &0"U
M ", LP N +  -P"M $  J@!( *@ 3P"E %4 HP!; *( 8 "@ &8 GP!L )T
M<P"; 'L F@"$ )@ C@"6 )H E0"G ), MP"1 ,P D #L (\ _P". /\ C@#_
M (X _P"/ /\ _    .\   #;    R0   +T   "U  ( K@ , *D $P"E !T
MH@ G *  ,0"= #H F@!" )@ 20"6 $\ E !5 ), 6P"1 &  D !G (X ;0"-
M '4 BP!^ (D B0"( )4 A@"B (4 L0"# ,0 @0#D (  ^0!_ /\ @ #_ (
M_P"  /\ ] (  . )  #'"   MP<  *P#  "F    H  ' )L #P"8 !< E0 A
M )( *@"/ #, C0 \ (L 0P") $D AP!0 (8 50"$ %L @P!A ($ : "  '
M?@!Y 'P A ![ )  >0"= '@ K !V +X =0#= ', ] !S /\ <P#_ ', _P!S
M /\ Z0T  ,\0  "Y$   J1   )X.  "7"P  DP8  )  "P", !$ B0 : (8
M) "# "X @0 V '\ /@!] $0 ? !+ 'H 40!Y %< =P!= '8 9 !T &P <P%U
M '$!@ !O HT ;@*: &P#J@!K [L :036 &@&\0!H!_\ 9P?_ &<'_P!G!_\
MWQ0  ,,7  "N%P  GA8  ),5  "+$@  AA   (0, @"#!@T @ ,4 'P%'@!Y
M!R@ =P@P '4(. !S"4  <@E& ' *3 !O"E, ;0M9 &P+80!J"VD :0QR &<,
M?@!F#(L 9 V9 &(-J0!A#;L 8 W8 %X.\P!=#O\ 70[_ %T._P!=#O\ U!P
M +D=  "D'@  E1T  (D<  "!&@  >Q<  '@3  !X$ 8 =PT/ ',.& !P#B(
M;@\K &P0,P!J$#L :1!" &<120!F$4\ 9!%6 &,270!A$F8 8!)O %X2>P!<
M$X@ 6Q.7 %D3IP!7%+H 5A35 %45\P!4%?\ 5!7_ %05_P!4%/\ RB(  + B
M  "=(P  C2,  ($B  !Y(0  <QX  &\;  !N%P  ;1,, &H4% !G%1X 918G
M &,6+P!A%S< 8!<^ %X810!=&$L 7!E2 %H96@!9&6( 5QIL %8:=P!4&H4
M4AN4 %$;I !/&[< 3AO0 $T<\0!,'/\ 3!S_ $T<_P!-&_\ PR8  *HG  "6
M)P  AR@  'LG  !R)@  ;"0  &@A  !F'@  9!L( &(;$0!?'!H 71TC %L>
M*P!:'C, 6!\Z %<?00!6($@ 5"!/ %,@5P!1(5\ 4"%I $XA= !-(8( 2R*1
M $DBH@!((K0 1R+- $8C[P!%(_\ 12+_ $8B_P!&(?\ O"H  *0K  "1*P
M@BP  '8K  !M*@  9BD  &(F  !?)   72($ %LA#@!8(A8 5B,? %0D* !3
M)#  4B4W % E/@!/)D4 3B9, $PF5 !+)UP 22=F $@G<0!&)W\ 12B/ $,H
MH !!*+( 0"C+ #\H[0 _*/\ /RC_ $ G_P! )_\ MRT  )\N  ",+P  ?2\
M '$O  !H+@  82T  %TK  !:*   5R<  %0G# !2*!, 4"D< $XI)0!-*BP
M2RHT $HK.P!)*T( 2"Q) $8L40!%+%H 1"QD $(M;P! +7T /RV- #TMG@ \
M+;  .BW( #HMZP Z+?\ .BW_ #HL_P Z+/\ LC   )LQ  "(,@  >3(  &TR
M  !D,@  73$  %@O  !5+   42P  $\M"0!,+1$ 2BX9 $DO(@!'+RH 1C Q
M $4P. !#,#\ 0C%' $$Q3P! ,5< /C%A #TR;0 [,GL .3*+ #@RG  V,J\
M-3+' #0RZ0 T,O\ -3'_ #4Q_P U,/\ K3,  )8T  "$-0  =34  &DU  !@
M-0  630  %0S  !0,   3#$  $DQ!@!',@\ 13,6 $,S'P!"-"< 0#0N #\U
M-@ ^-3T /35$ #PV3  Z-E4 .39? #<V:P V-G@ -#>) #(WF@ Q-ZT +S?%
M "\WZ  O-OX ,#7_ # U_P P-/\ J38  )(V  " -P  <C@  &8X  !=-P
M5C<  % V  !+-   1S4  $0V P!!-PT /S@4 #XX'  \.20 .SDL #HY,P Y
M.CH .#I" #8Z2@ U.E, -#M= #([:  P.W8 +SN' "T[F0 L.ZP *CO# "D[
MY@ J.OT *CK_ "LY_P L./\ I#@  (XY  !\.@  ;CH  &,Z  !:.@  4SH
M $TZ  !&.   0CH  #\[   \/ L .CP1 #@]&0 W/2$ -CXI #0^,  S/C<
M,C\_ #$_1P P/U  +C]: "U 9@ K0'0 *4"$ "A EP F0*H )4#! "1 Y0 D
M/_P )3[_ "8]_P F/?\ GSL  (H\  !X/0  :CT  %\]  !6/0  3ST  $D]
M  !"/0  /#X  #D_   V00@ -$$/ #)"%@ Q0AX +T,E "Y#+0 M0S0 +$0\
M "M$1  J1$T *$18 "=%8P E17$ (T6" ")%E0 @1:@ 'T6_ !Y$XP ?1/L
M'T/_ "!"_P A0?\ FCX  (4_  !T0   9T   %Q   !30   3$   $9    ^
M00  .$,  #1%   P1@, +4<- "M($@ J2!H *4@B "A)*0 G23$ )4DY "1)
M00 C2DH (DI5 "!*80 ?2F\ '4I_ !M*D@ :2J8 &$J] !=*X  82?H &4C_
M !I'_P :1_\ E4(  (!"  !P0P  8T,  %A#  !00P  24,  $)$   [10
M-4<  #!)   K2P  )DT) "1.$  B3A8 (4\= "!/)0 ?3RP 'D\U !U//0 <
M4$< &E!1 !E070 74&L %E!\ !10CP 34*0 $5"Z !%0W@ 13_@ $D[_ !--
M_P 43?\ CT4  'M&  !K1@  7T<  %5'  !-1P  1D<  #]'   W2@  ,4P
M "M.   F4   (%,# !Q5#  :5A$ &588 !=6(  65B< %58P !16.0 35T(
M$E=- !%760 05V@ #U=Y  Y7C  -5Z  "U>V  M6U  +5O0 #%7_  U4_P .
M4_\ B$D  '9*  !G2@  6TH  %%*  !*2@  0TH  #M,   S3@  +%$  "94
M   A5@  &UD  !5<!P 17@T $%X3 !!>&@ .7B( #EXJ  U>,P ,7CT "UY(
M  I>5  (7F( !UYS  5>A@ #7IL  EZQ  )=S  "7>X  US_  1;_P %6_\
M@4X  '!.  !B3@  5TX  $Y.  !'3@  /D\  #91   N5   )U<  "%:   ;
M70  %6   !!C P ,9@L "&<0  9G%0 %9QP !&<D  )G+0 !9S<  &="  !G
M3@  9UP  &=M  !G@   9I4  &:L  !EQP  9>L  &3\  !D_P  8_\ >E(
M &I3  !=4@  5%(  $M2  !"4P  .54  #!8   H6P  (5\  !IB   490
M$&@   QK 0 &;@D  &\.  !O$@  ;Q@  ' ?  !P)P  <3   '$[  !Q2
M<58  '%F  !Q>0  <8\  '"G  !OP0  ;^<  &[\  !M_P  ;?\ <U@  &57
M  !:5P  458  $97   \6@  ,ET  "IA   B9   &F@  !1L   .;P  "G(
M  1V    > 4  '@+  !Y#@  >A,  'L9  !\(   ?2D  'TS  !]0   ?4X
M 'U>  !]<@  ?8@  'RA  !\N@  >^(  'KZ  !Y_P  >/\ ;5T  &!<  !7
M7   2UT  $!?   U8P  *V<  "-K   :;P  $W,   YW   (>P   GX   ""
M    @P$  (0&  "%"P  A@\  (@3  ")&0  BB$  (LK  "+-P  C$8  (M6
M  "+:0  BX   (N9  "*LP  B=@  (CW  "(_P  A_\ :&,  %YB  !18@
M1&4  #AI   N;@  )',  !IX   3?0  #8$   :%    B0   (T   "0
MD@   )(   "4!0  E0H  )<.  "8$@  FA@  )LA  "<+0  G3P  )U,  "<
M7P  G'8  )N1  ";JP  FLD  )KP  "9_P  F/\ 96D  %=I  !);   /7$
M #!V   E?   &X$  !*'   ,C   !)$   "5    F0   )T   "@    H0
M *(   "D    I0$  *<'  "I#   JA$  *T8  "O(@  KS   *]!  "O5
MKVL  *Z%  "NH0  KKX  *WF  "L_   K/\ 7G$  $]T  !">0  -7\  "B%
M   =C   $Y(   R8   #G0   *(   "F    J@   *X   "P    L0   +,
M  "T    M@   +@   "Z!   O H  +X0  #!%P  PR0  ,,U  #$20  Q%X
M ,5W  #%DP  Q:\  ,71  ##\@  P_\ 5GP  $>"   ZB   +(\  ""6   4
MG0  #:,   .I    K@   +(   "W    NP   +\   #"    P@   ,4   #&
M    R    ,H   #-    SP   -((  #5#@  VQ@  -TG  #>.@  WU   .!H
M  #@A   X:$  .&]  #AX@  X/0 3HL  $"2   RF0  ):$  !BH   .KP
M!;4   "Z    OP   ,0   #(    S@   -$   #4    U0   -@   #:
MW0   -\   #B    Y    .<   #K!0  [PX  /09  #U*P  ]D$  /=8  #X
M<@  ^9   /FK  #XQ   ^.$ _P + /\ " #_  D _P , /\ $@#_ !H _P F
M /\ ,@#_ #X _P!( /\ 4@#_ %H _P!B /\ :0#_ &\ _P!U /X >P#\ ($
M^P"( /D CP#W )< ]0"@ /, J@#R +< [P#) .T Y@#L /L ZP#_ .L _P#=
M /\ S@#_ ,8 _P#" /\ _P $ /\   #_    _P % /\ #0#_ !4 _P A /\
M+ #_ #@ _P!# /T 3 #Y %0 ]P!< /0 8P#R &D \ !O .X =0#L 'L Z@""
M .@ B0#G )$ Y ": .( I #@ +  W0#  -H W #8 /0 U0#_ -, _P#+ /\
MP0#_ +L _P"W /\ _P   /\   #_    _P   /\ "@#] !$ ^0 ; /8 )P#T
M #( \  \ .P 1@#H $X Y !6 .$ 7 #> &, W !H -D ;@#5 '0 T@![ -
M@@#- (H RP"3 ,@ G0#& *@ Q "W ,$ S #  .L O@#_ +T _P"] /\ M #_
M *X _P"K /\ _P   /\   #_    ^@   /( !0#J  X Y0 6 .  (0#= "L
MVP V -, /P#. $@ R@!/ ,< 5@#$ %P P@!A ,  9P"^ &T O !S +H >@"X
M (( M@"+ +0 E@"R *$ L "O *X P0"M .  JP#W *H _P"I /\ I@#_ *$
M_P"? /\ _P   /\   #W    Z    -P   #0  H R@ 1 ,4 &P#" "4 OP O
M +P . "X $$ M0!( +( 3P"P %4 K@!; *P 80"J &8 J !L *< <P"E 'L
MHP"$ *$ C@"? )H G0"G )L N ": -  F0#O )@ _P"7 /\ E@#_ )0 _P"2
M /\ _P   /8   #D    T@   ,4   "[  4 M0 . +  %0"L !\ J@ I *@
M,@"E #H H@!" *  20"> $\ G !5 )H 6@"8 &  E@!F )4 ; "3 '0 D@!]
M )  AP". ), C "A (L L "* ,4 B #F (< ^P"& /\ AP#_ (< _P"& /\
M^    .4   #-    O0   +,   "J    HP * )\ $0"; !D F0 C )< + "5
M #0 D@ \ )  0P". $D C !/ (H 5 ") %H AP!@ (8 9@"$ &X @P!W ($
M@0!_ (T ?@"; 'P J@![ +P >@#; '@ ]0!X /\ > #_ '@ _P!X /\ [0
M -$"  "[ @  K $  *(   ";    E@ % )$ #0"- !0 BP = (@ )@"& "X
MA  V (( /0"  $, ?@!) 'T 3P!\ %4 >@!; 'D 80!W &D =0!Q '0 ? !R
M (@ <0"6 &\ I0!N +8 ;0#. &P [@!K /\ :P#_ &L _P!K /\ WPL  ,(,
M  "N#   G@P  ),+  ",!P  B (  (4 "0"! !  ?P 7 'P ( !Z "@ >  P
M '8 . !T #X <P!$ '$ 2@!P %  ;@!6 &T 70!L &0 :@!M &@ =P!G (0
M90"2 &0 H0!C +( 80#) &  Z0!@ /P 8 #_ &  _P!@ /\ T!   +81  "B
M$@  DQ(  (@1  " #P  ? T  'D) 0!X PL =0 1 ', &@!P ", ;@$K &P!
M,P!J CD :0-  &<#1@!F!$P 9012 &,%60!B!6$ 8 5J %\&= !=!H$ 7 >/
M %H'GP!9![  5P?& %8)YP!6"OL 50K_ %4*_P!6"O\ QA4  *T7  "9&
MBA@  '\7  !V%@  <1,  &X0  !M#04 ;0D- &H)% !G"AT 90HF &,++@!B
M##4 8 P\ %\,0@!>#4@ 7 U/ %L-5@!9#5X 6 YH %8.<P!5#H  4PZ/ %$.
MGP!0#K$ 3@[( $T0Z@!-$/T 31#_ $T0_P!-$/\ O!L  *4<  "2'0  @QX
M '<=  !O'   :1H  &87  !D%   9! ( &(/$ !?$!@ 71 A %L1*0!:$3$
M6!(X %<2/@!6$D4 5!), %,34P!1$UL 4!-E $X4< !,%'T 2Q2, $D4G !'
M%:X 1A7% $45Z !%%OX 11;_ $45_P!%%?\ M1\  )XA  "+(@  ?"(  '$B
M  !H(0  8A\  %\=  !<&@  6Q<" %H5#0!7%A0 518= %07)0!2&"T 41@T
M $\8.P!.&4( 31E( $L:4 !*&E@ 2!IB $<:;0!%&WH 0QN) $(;F@! &ZP
M/QO" #X<Y0 ]'/P /AS_ #X;_P ^&_\ KR,  )@D  "&)0  =R8  &PF  !C
M)0  720  %DB  !6'P  5!T  %,<"P!1'!( 3AT: $T=(@!+'BD 2AXQ $D?
M-P!''SX 1B!% $4@30!#(%4 0B!? $ A:@ _(7< /2&' #LAF  Y(:H ."+
M #<BXP W(OL -R+_ #@A_P X(?\ JB8  )0G  "!*0  <RD  &<I  !?*0
M6"@  %0F  !1(P  3R(  $PB!P!*(A  2"(7 $<C'P!%)"8 1"0N $(D- !!
M)3L 0"5# #\E2@ ])E, /"9< #HF9P Y)G4 -R>$ #4GE@ T)Z@ ,B>^ #$G
MX0 Q)_D ,B;_ #(F_P S)?\ I2D  (\J  !]+   ;RP  &0M  !;+   52L
M % J  !,*   2B8  $<G! !$)PT 0B@4 $$H'  _*2, /BDK #TI,@ \*CD
M.RI  #DJ2  X*U  -BM: #4K90 S*W( ,2N" # LE  N+*< +"R\ "LLW@ L
M+/@ +"O_ "TJ_P M*O\ H2P  (LM  !Y+@  :R\  & O  !8+P  42X  $PN
M  !(+   12L  $$K   _+ L /2P1 #LM&0 Z+B$ .2XH #<N+P V+S8 -2\^
M #0O10 S+TX ,3!8 # P8P N,'  +#"  "HPD@ I,*4 )S"Z "8PW  F,/<
M)R__ "@O_P H+O\ G"X  (<P  !V,0  :#(  %TR  !5,@  3C$  $@Q  !$
M,   0"\  #PP   Z,0D -S$0 #8R%@ U,AX ,S,E #(S+  Q,S, ,#0[ "\T
M0P M-$P +#16 "HU80 I-6X )S5^ "4UD  C-:, (C6Y "$UV0 A-/8 (C3_
M ",S_P C,O\ F#$  (,S  !R-   930  %HU  !1-0  2S0  $4T  ! -
M.C,  #<T   T-08 ,C8. # W$P O-QL +C<B "TX*0 K.#$ *C@X "DY0  H
M.4D )CE3 "4Y7P C.6P (3I\ " ZC@ >.J( '#JW !LYU0 <.?4 '3C_ !TX
M_P >-_\ DS0  '\V  !N-P  83<  %<W  !.-P  2#<  $(W   \-P  -3@
M #(Y   O.@( +#L+ "H\$0 I/!@ *#T? "8])@ E/2X )#TU ",^/0 B/D8
M(#Y0 !\^7  =/VD &S]Y !H_C  8/Z  %C^U !4^T@ 6/O, %SW_ !@\_P 8
M//\ CC<  'HX  !J.0  7CH  %,Z  !+.@  13H  #\Z   Y.@  ,CP  "X^
M   I0   )D$( "1"#@ B0A0 (4(; "!#(P ?0RH 'D,R !Q#.@ ;1$, &D1-
M !A$60 71&< %41W !-$B@ 21)X $42S !!$T  00_( $4+_ !)"_P 30?\
MB3L  '8\  !F/0  6CT  % ]  !(/0  0CT  #P]   V/@  +T   "I"   E
M1   (48# !U(#  ;21$ &4D7 !A)'@ 7228 %DDN !5*-@ 42D  $TI* !%*
M5@ 02F0 #TIT  Y*AP -2IL #$JP  I*R@ +2>P #$C_  U'_P -1_\ @SX
M '$_  !B0   5D   $U   !%0   /T   #E!   R0@  *T4  "9'   A20
M'$L  !9.!P 34 X $E 3 !%0&0 04"$ #U I  Y0,0 -4#L #5%&  M140 *
M45\ "5%O  =0@0 %4)8  U"K  )0Q0 #3^@  T_[  5._P &3?\ ?4(  &M#
M  !=1   4D0  $I$  !#0P  /$0  #5%   N1P  )TH  "%,   <3P  %U$
M !)4 P .5PH "U@0  I8%0 (6!P !U@D  98+  %6#8  UA   %83   6%H
M %AI  !8?   6)$  %>G  !7P   5N4  %;Y  !5_P  5?\ =D<  &9'  !9
M2   3T<  $='  ! 1P  .$@  #!*   I30  (E   !Q3   650  $5@   U;
M @ )7@D !%\.  !?$@  7Q@  & ?  !@)P  8#   & [  !@1P  8%0  &!C
M  !@=@  8(L  %^B  !?NP  7^(  %[Y  !=_P  7?\ ;TL  &%,  !53
M3$L  $1+   [3   ,DX  "M1   C5   '%<  !9;   17@  #6    AC   "
M9@<  &<,  !G#P  :!,  &D9  !J(0  :BD  &HT  !J0   :DT  &I=  !J
M;P  :H4  &J=  !IM@  :-T  &CW  !G_P  9O\ :5$  %Q0  !24   2D\
M #]0   U4P  +58  "19   =70  %F   !!D   ,9P  !FH   !N    ;P,
M ' (  !Q#0  <A   '04  !U&P  =B,  '<L  !W.   =D8  '96  !V:
M=GX  ':7  !UL0  =-,  '/U  !S_P  <O\ 8U8  %A5  !05   1%4  #E8
M   O6P  )E\  !UC   59P  $&P   IP   $<P   '8   !Z    ?    'P#
M  !^"   ?PP  ($0  ""%   A!L  (4D  "&+P  ACT  (9-  "%7P  A74
M (6/  "$J0  @\D  (+Q  "!_P  @/\ 7UL  %9:  !)6P  /5X  #)A   G
M9@  'FL  !5P   .=0  "7D   %^    @0   (4   "(    B@   (L   "-
M 0  C@8  ) +  "1#P  DQ0  )4;  "7)@  ES0  )=$  "75@  EFP  )6&
M  "5H@  E,$  )/J  "2_P  DO\ 76$  $]A  !"9   -FD  "IN   ?=
M%7D   Y_   'A    (D   ".    D@   )8   "8    F@   )L   "=
MGP   *$#  "C"   I0T  *<3  "I'   JB@  *HY  "J2P  JF$  *EZ  "H
MF0  J+4  *?=  "G^   IO\ 5F@  $AL   Z<   +G8  ")]   7A   #HH
M  >0    E@   )H   "?    HP   *<   "J    JP   *T   "O    L0
M +,   "U    N 4  +H,  "]$@  P!P  , M  # 0   OU4  +]N  "^BP
MOJ@  +[)  "][P  O/X 3G0  $!Y   R?P  )8<  !F.   0E0  !YP   "B
M    IP   *P   "P    M0   +D   "\    O0   +\   #!    PP   ,8
M  #(    R@   ,T"  #0"P  U1(  -8A  #7-   V$D  -E@  #:?   VIH
M -NU  #;V0  V_( 1H(  #B)   KD   '9@  !*@   *IP   *X   "T
MN0   +X   #"    R    ,L   #.    SP   -(   #4    U@   -H   #=
M    WP   .(   #F    Z@H  .\3  #P)0  \CH  /-1  #T:P  ](D  /6E
M  #UOP  ]=T _P & /\  P#_  4 _P + /\ $ #_ !< _P B /\ +0#_ #D
M_P!$ /\ 30#_ %4 _P!= /\ 9 #_ &H _P!P /T =@#[ 'P ^0"# /< B@#U
M )( \P"; /  I@#N +, ZP#$ .D Y #G /D Y@#_ .4 _P#3 /\ QP#_ +\
M_P"[ /\ _P   /\   #_    _P " /\ "P#_ !( _P = /\ * #_ #, _P ^
M /P 1P#X $\ ] !7 /$ 70#N &, [ !I .H ;P#H '4 Y@!\ .0 @P#B (L
MWP"5 -P GP#9 *L U0"[ -( U #/ /( S0#_ ,P _P#% /\ N@#_ +0 _P"P
M /\ _P   /\   #_    _P   /\ !@#Y  \ ]0 7 /, (@#Q "T [0 W .<
M0 #B $D WP!0 -L 5P#7 %T U !C -$ : #/ &X S !U ,H ? #( (0 Q0"-
M ,( F #  *0 O0"R +L Q@"Y .@ N #] +< _P"V /\ K0#_ *< _P"C /\
M_P   /\   #_    ]0   .L  0#D  P W@ 3 -D ' #3 "8 T0 P ,P .@#(
M $( Q !* ,  4 "] %8 NP!< +D 80"W &< M0!M +, = "Q 'P KP"% *T
MD "J )P J "J *8 NP"E -H HP#U *, _P"B /\ G@#_ )H _P"7 /\ _P
M /X   #O    WP   -    #'  < P0 / +P %P"Y "  MP J +4 ,P"P #L
MK0!# *L 20"H $\ I@!5 *0 6@"C &  H0!F )\ ;0"= '0 G !] )H B "8
M )0 E@"B )0 L@"2 ,D D0#K )$ _P"0 /\ D #_ (P _P"* /\ _    .P
M  #9    QP   +H   "Q  ( JP , *< $@"D !L H0 D *  + "> #4 FP \
M )@ 0P"6 $D E !/ )( 5 "0 %H CP!? (T 9@"+ &T B0!V (@ @ "& (P
MA ": (( J@"! +X @ #@ (  ^0!_ /\ ?P#_ '\ _P!^ /\ \0   -@   #"
M    LP   *@   "@    F0 ' )4 #@"2 !4 D  > (X )@"- "X B@ V (<
M/0"% $, A !) (( 3@"! %0 ?P!9 'X 8 !\ &< >@!O 'D >@!W (8 =0"4
M '0 HP!R +4 <@#/ '$ \0!P /\ < #_ '  _P!Q /\ X0   ,0   "P
MH@   )<   "1    BP " (8 "P"# !$ @0 8 '\ (0!] "D ?  P 'D -P!X
M #T =@!# '0 20!S $X <@!4 '  6@!O &( ;0!J &L = !J (  : ". &<
MG0!E *\ 90#& &0 Z !D /T 8P#_ &, _P!D /\ SP4  +8'  "C"   E @
M (D'  "" P  ?@   'L !@!W  X =0 3 '( &P!Q ", ;P K &T ,@!L #@
M:@ ^ &D 1 !G $D 9@!/ &4 5@!C %T 8@!E &  ;P!? 'L 70") %P F0!;
M *H 60"_ %D X0!8 /@ 6 #_ %@ _P!9 /\ P@P  *H-  "7#@  B0X  'T.
M  !V#0  <0H  &\&  !M  H :P 0 &D %@!G !X 90 F &, +0!A #, 8  Y
M %\ /P!= $4 7 !+ %L 4@!: %D 6 !B %< ; !5 '@ 4P"& %( E@!1 *<
M4 "[ $\!VP!. O0 3@/_ $X$_P!. _\ N!   *$2  ".$P  ?Q,  '03  !L
M$@  9Q   &4.  !C"P, 8P8, &$$$0!> QD 7 0A %L%* !9!B\ 6 8U %8'
M.P!5!T( 5 =( %,(3P!1"%8 4 E? $X):0!-"78 2PJ$ $D*E !("J8 1PJZ
M $8*V !%"_, 10S_ $4,_P!%#/\ L!0  )D6  "'&   >!D  &T8  !E%P
M7Q8  %P3  !:$0  6@X& %H,#0!7#!0 50P< %,-) !2#2L 4 TQ $\.. !.
M#CX 30Y% $L.30!*#E4 2 ]> $</: !%#W4 0Q"$ $$0E0! $*8 /A"[ #T0
MW  ]$?8 /1'_ #T0_P ^$/\ J1D  )(;  "!'   <AT  &<=  !?'   61L
M %49  !3%@  4A,  %(1"@!0$!  3A$8 $P1( !*$B< 21(N $@3- !'$SL
M11-" $0320!#%%( 011; #\490 ^%7( /!6! #H5D@ X%:0 -Q6Y #45V  U
M%O4 -A;_ #86_P W%?\ HQP  (T>  ![(   ;2$  &(A  !:(0  5!\  % >
M  !-&P  3!D  $L6!@!)%@X 1Q<5 $47' !$&"0 0A@J $$8,0! &3@ /QD_
M #T91@ \&D\ .AI8 #D:8P W&V\ -1M^ #,;D  R&Z( ,!NW "\;TP O'/,
M+QO_ # ;_P P&_\ G1\  (@B  !W(P  :20  %XD  !6)   4",  $LB  !(
M(   1AT  $4< @!#' P 01P2 #\=&0 ^'2$ /!XG #L>+@ Z'S4 .1\\ #<?
M1  V'TP -"!6 #,@8  Q(&T +R!\ "TAC@ L(:  *B&U "DAT  I(?( *2'_
M "H@_P K(/\ F2(  (0E  !S)@  92<  %LG  !3)P  3"8  $<E  !$)
M0B$  #\A   ](0D .R$0 #DB%@ X(AX -B,E #4C*P T)#( ,R0Y #(D00 P
M)$H +R53 "TE7@ K)6L *B5Z "@EC  F)9\ )"6S ",ES@ C)?  )"7_ "4D
M_P E)/\ E"4  ( G  !O*0  8BH  %<J  !/*@  22D  $0H  ! )P  /28
M #HE   W)@8 -28. #0G%  R)QL ,2@B # H*0 O*#  +2DW "PI/P K*4<
M*2E1 "@J7  F*FD )"IX ",JB@ A*IT 'RJR !XJS  >*N\ 'RG_ " I_P A
M*/\ D"@  'PJ  !L*P  7RP  %0L  !,+   1BP  $$K   \*P  ."H  #4J
M   R*P, ,"L, "XL$0 M+!@ +"P? "HM)@ I+2T *"TT "<N/  F+D4 )"Y/
M ",N6@ A+V< 'R]V !TOB  <+YL &B^P !@OR@ 8+NT &2[_ !LM_P ;+?\
MC"L  '@M  !H+@  6R\  %$O  !)+P  0R\  #XN   Y+@  -"X  # N   M
M+P  *S * "DQ$  G,14 )C$< "4R(P D,BH (S(Q "$S.0 @,T( 'S-, !TS
M5P ;,V0 &C1T !@TA@ 6-)H %#.N !,SR  3,^P %#/_ !4R_P 6,?\ ARX
M '0O  !E,0  6#$  $XR  !&,@  0#$  #LQ   V,0  ,3$  "LS   H-
M)34& ",V#0 A-A( (#<9 !\W(  >-R< '3@N !LX-@ :.#\ &3A) !<Y50 5
M.6( %#EQ !(YA  1.9@ $#FM  XXQP ...L $#C_ ! W_P 1-O\ @S$  ' R
M  !A-   530  $LT  !$-   /30  #@T   S-   +34  "@W   D.0  (#H"
M !T["P ;/!  &3T5 !@]'  7/2, %CTK !4^,P 4/CP $CY& !$^4@ 0/E\
M#SYO  X^@0 ,/I4 "SZI  H^P0 */>0 "SW[  P\_P -._\ ?30  &LV  !=
M-P  43<  $@W  !!-P  .S<  #4W   P-P  *CD  "4[   @/0  '#\  !=!
M!@ 40PT $D,2 !%#&  10Q\ $$0G  ]$+P .1#D #41#  Q$3@ +1%L "41J
M  =$?  &1)  !$.E  )#O0 #0^   T/V  1"_P &0?\ >#@  &<Y  !9.@
M3CH  $4Z   ^.@  .#H  #,Z   M.P  )ST  "%    <0@  %T0  !-& P /
M20H #4H/  Q*%  +2AL "4HC  A**P '2C0 !4H^  1*20 "2E8  $IE  !*
M=P  2HL  $JA  !)N0  2=T  $GU  !(_P  2/\ <CP  &(]  !5/@  2CX
M $(]   \/0  -CT  "\^   I0   (T(  !U%   71P  $TH   ], @ +3PD
M!U -  -1$0  41<  %$>  !1)@  42\  %$Y  !11   4E$  %)@  !1<@
M48<  %&=  !1M0  4-@  %#U  !/_P  3_\ ;$   %U!  !100  1T$  $!
M   Y0   ,D$  "I#   D1@  'D@  !=+   23@  #E$   M3 0 &5@<  %<,
M  !8$   6!,  %D9  !:(0  6BD  %HS  !:/P  6DP  %I:  !:;   6H$
M %F9  !9L0  6-$  %CT  !7_P  5_\ 944  %A%  !-10  140  #Y$   U
M10  +4<  "5*   >30  &%   !)3   .5@  "ED   1<    7@0  %\)  !@
M#0  81   &(5  !C&P  9",  &0M  !D.   9$4  &14  !D9@  9'L  &.3
M  !CK0  8LP  &'R  !A_P  8/\ 7TH  %-*  !*20  0T@  #E)   O3
M)T\  !]2   850  $ED   U=   (8    F,   !F    : $  &D%  !J"@
M:PT  &T1  !N%@  <!T  '$F  !Q,0  <#X  '!.  !P7P  <',  &^-  !O
MIP  ;L8  &WO  !L_P  ;/\ 6D\  %!.  !(30  /4X  #-1   I5   (%@
M !A<   18   #&0   9H    :P   &\   !R    =    '4   !W!   > D
M 'H-  !\$   ?18  '\>  " *   @#4  (!%  !_5@  ?VL  '^$  !^H
M?;X  'SI  ![_P  >O\ 5E0  $Y3  !"5   -U8  "Q:   B7P  &&,  !%H
M   +;0   W(   !V    >@   'T   "     @P   (0   "&    AP(  (D'
M  "+#   C1   ) 6  "2'P  DBP  )([  "230  D6(  )%Z  "/EP  C[0
M ([A  ",^P  C/\ 55D  $A:   [70  +V$  "1F   9;   $7(   IW   "
M?0   ((   "&    BP   (X   "1    DP   )4   "7    F0   )L   "=
M!   GPH  *(/  "D%@  IB$  *8Q  "F0P  I5<  *1P  "CC@  HZL  *'0
M  "@]0  G_\ 3F$  $!D   S:0  )VX  !MU   1?   "X,   ")    C@
M ),   "8    G0   *$   "D    I0   *<   "I    JP   *T   "P
ML@   +4(  "X#@  O!8  +PE  "\-P  NTP  +ID  "Y@0  MZ(  +?   "W
MZ@  M_P 1FL  #EP   K=P  'W\  !.&   +C@   94   ";    H0   *8
M  "K    L    +,   "W    MP   +H   "\    OP   ,$   #$    QP
M ,H   #-!0  T0X  -09  #4*P  U$   --8  #3=   TY(  -*P  #2TP
MTO( /GD  #&    CB   %Y$   V9   #H    *<   "N    LP   +@   "]
M    P@   ,8   #*    R@   ,T   #/    T@   -4   #9    W0   -\
M  #C    YP4  .L/  #L'P  [3,  .Y+  #O9   [X(  /"?  #QN0  \=@
M_P   /\   #_  0 _P ) /\ #@#_ !4 _P > /\ *0#_ #0 _P _ /\ 2 #_
M %  _P!8 /\ 7@#_ &4 _0!K /L <0#Y '< ^ !^ /8 A0#S (T \0"7 .X
MH@#K *\ Z #  .8 X #C /@ X@#_ -L _P#+ /\ P0#_ +D _P"T /\ _P
M /\   #_    _P   /\ "0#_ !  _P 9 /\ (P#_ "X _0 Y /D 0@#U $H
M\@!2 .X 6 #K %X Z0!D .8 :@#D '  X@!V -\ ?0#= (8 V0"/ -4 F@#1
M *< S@"V ,L S@#) /  QP#_ ,4 _P"[ /\ M #_ *T _P"I /\ _P   /\
M  #_    _P   /L  @#V  T \0 3 .T '@#L "@ Z0 R ., .P#= $0 V !+
M -, 40#0 %@ S0!= ,L 8P#) &@ Q@!O ,0 =@#" 'X OP"' +P D@"Z )\
MMP"M +4 P0"R .0 L0#] *\ _P"L /\ I0#_ *  _P"< /\ _P   /\   #[
M    [@   .0   #<  @ TP 0 ,\ & #+ "( R0 K ,8 - #! #T O0!$ +H
M2P"W %$ M0!6 +( 7 "P &$ K@!G *P ;@"J '8 J !_ *8 B@"C )8 H0"E
M )\ M@"= -$ G #S )L _P"< /\ E@#_ ), _P"0 /\ _P   /8   #G
MTP   ,8   "]  , N  - +, $P"Q !P KP E *X +@"I #8 I@ ] *, 1 "A
M $H GP!/ )T 50"; %H F@!@ )@ 9@"6 &X E !W )( @0"0 (X C@"< (P
MK0"* ,, B0#H (@ _P") /\ AP#_ (4 _P"" /\ \P   .,   #,    O
M +    "G    H0 ( )X #P"; !8 F0 ? )@ )P"6 "\ DP W )$ /0". $,
MC !) (L 3@") %0 AP!9 (4 8 "$ &< @@!O (  >@!^ (8 ? "4 'H I !Y
M +@ > #8 '< ]P!X /\ > #_ '< _P!U /\ Y@   ,L   "W    J    )X
M  "6    CP $ (L # "( !( AP 9 (4 (0"$ "D @@ P '\ -P!] #T ? !#
M 'H 2 !Y $T =P!3 '8 60!T &$ <@!I '$ <P!O '\ ;0"- &P G0!J *\
M:0#( &@ [0!I /\ :0#_ &D _P!I /\ T@   +@   "E    EP   (T   "&
M    @0   'P " !Y  X =P 4 '8 ' !T ", <P K '$ ,0!O #< ;@ ] &P
M0P!K $@ :@!. &@ 5 !G %L 90!C &, ;0!B '@ 8 "' %\ E@!= *@ 70"^
M %P Y !< /L 7 #_ %P _P!< /\ P@   *H!  "8 P  B00  '\"  !X
M=    '  ! !M  P :P 1 &D %P!H !X 9@ E &4 + !C #( 8@ X &  /0!?
M $, 7@!) %P 3P!; %8 6@!> %@ : !7 ', 50"! %0 D0!2 *, 40"W %$
MU@!1 /4 40#_ %$ _P!2 /\ M@<  )\)  "-"P  ?@P  ',+  !L"@  : <
M &4#  !C  < 80 - %\ $P!= !H 7  A %L )P!9 "T 6  S %8 .0!5 #\
M5 !% %, 2P!1 %( 4 !: $\ 9 !- &\ 3 !] $H C0!) )\ 2 "R $< S !'
M .\ 1@#_ $< _P!' /\ K P  )4.  "#$   =1   &L0  !C#P  7@X  %L,
M  !:"0( 600* %< #P!5 !4 4P < %( (P!1 "D 3P O $X -0!- 3L 3 %!
M $H"2 !) D\ 2 )7 $8#80!% VT 0P-Z $(#BP!  YP /P.O #X#R  ]!.H
M/07\ #T&_P ^!O\ I!   (X2  !\$P  ;A0  &04  !<$P  5A(  %,1  !1
M#@  4 P% % )# !/!Q$ 30<7 $L('P!)""4 2 DK $<),0!&"3@ 1 H^ $,*
M10!""DT 0 M5 #\+7P ]"VL / MY #H,B@ X#)P -PRO #4,QP U#.D -0W]
M #4-_P V#/\ G1,  (<5  !V%P  :1@  %X8  !6&   4!<  $T5  !*$P
M21$  $D.!P!(#0X 1@T3 $0-&@!##B$ 0@XH $ .+@ _#C4 /@\\ #T/0P [
M$$L .A!4 #@07@ V$&L -!!Y #(0B@ Q$)P +Q"P "T0R0 M$>P +1'_ "X1
M_P O$/\ EQ8  ((9  !Q&P  9!P  %D<  !1'   3!L  $<:  !$&   0Q4
M $(3 @!!$@L 0!$0 #X2%P \$AX .Q,E #H3*P X$S( -Q,Y #840  T%$@
M,Q11 #$47  P%6@ +A5W "P5B  J%9H *!6N "<5QP F%>H )Q7_ "@5_P I
M%?\ D1H  'T<  !M'@  8!\  %8?  !.'P  2!X  $,=  ! '   /AH  #T8
M   [%P< .18. #@7%  V%QL -1@B #,8*  R&"\ ,1DV # 9/0 N&48 +1I/
M "L:60 J&F8 *!IT "8:A@ D&ID (AJM "$:Q0 @&N@ (1K^ "(:_P C&O\
MC1T  'D?  !I(0  7"(  %(B  !*(@  1"$  #\A   \(   .1X  #@;   U
M' 0 -!P- #(<$@ P'1@ +QT? "X=)0 M'BP *QXS "H>.P I'T, )Q]- "8?
M5P D'V0 (A]R " ?A  ?'Y< '1^K !L?PP ;'^< &Q_] !T?_P >'O\ B2
M '4B  !E(P  620  $\E  !')0  020  #PC   X(P  -2(  #,@   P( $
M+B$* "PA$  K(14 *B(< "@B(P G(BD )B,P "4C.  C(T$ (B1* "$D50 ?
M)&$ '21P !LD@@ 9))4 %R2J !8DP0 5).4 %B3\ !<C_P 9(_\ A2(  '$D
M  !B)@  5B<  $PG  !$)P  /B<  #DF   U)@  ,24  "XD   K)0  *24'
M "<F#@ E)A, )"<9 ",G(  B)R< (2@N " H-@ >*#X '2A( !LI4P 9*5\
M&"EN !8I@  4*90 $BFH !$IP  1*.0 $2C[ !,H_P 4)_\ @"4  &XG  !?
M*   4RD  $DJ  !"*0  .RD  #8I   R*   +B@  "HH   F*0  )"H$ "(K
M#  @*Q$ 'RP6 !TL'0 <+"0 &RTK !HM,P 8+3P %RU% !8N4  4+ET $BYL
M !$N?@ 0+I( #BZG  TMO0 -+=\ #2WY  XL_P 0+/\ ?"@  &HJ  !;*P
M4"P  $8L   _+   .2P  #0K   O*P  *RL  "8L   B+@  'R\  !PP"0 :
M,0X &3$3 !<Q&@ 6,B$ %3(H !0R,  3,CD $C-# !$S3@ 0,UL #C-I  TS
M>@ ,,XX "C.B  @RN0 (,MD "#+T  HQ_P +,?\ =RL  &8M  !8+@  32\
M $,O   \+@  -BX  #$N   M+@  *2X  ",P   ?,@  &S,  !<U!0 4-@P
M$C<1 !$W%@ 1-QT $#@D  \X+  ..#4 #3@_  PX2@ +.%< "3AE  <X=@ %
M.(H  SB?  $WM0 !-],  C?Q  ,V_P %-O\ <RX  &(P  !4,0  23$  $$Q
M   Y,0  -#$  "\P   K,   )3(  " S   ;-@  %S@  !,Z @ 0/ D #3T.
M  P]$P +/1D "CTA  D]*0 (/3$ !CX[  4^1@ #/E(  3YA   ^<@  /H8
M #V<   ]L@  /=   #SP   \_P  //\ ;3(  %TS  !0-   1C0  #XT   W
M-   ,C,  "TS   G-   (C8  !TX   8.@  %#T  ! _ @ -00@ "4,-  9$
M$0 #1!8  D0=  !$)   1"T  $0V  !$00  1$X  $1<  !$;0  1($  $28
M  !#KP  0\T  $+P  !"_P  0O\ :#8  %@W  !,.   0S@  #LW   U-@
M,#8  "DW   C.0  'CL  !@]   30   $$(   U% 0 (1P<  TD,  !)#P
M2A,  $L9  !+(   2R@  $LR  !+/0  3$D  $Q7  !+:   2WT  $N4  !*
MK   2LH  $GO  !)_P  2?\ 8CH  %0[  !).P  0#L  #DZ   S.0  +#H
M "4\   ?/P  &4$  !-$   01P  #$D   A,   "3P4  % *  !0#0  41
M %(5  !4&P  5",  %0L  !4-P  5$0  %12  !48P  5'<  %2/  !3J
M4L8  %+M  !1_P  4?\ 7#\  $\_  !%/P  /CX  #<]   O/@  )T   "!#
M   91@  $TD   ],   +3P  !E(   !4    5P(  %@'  !9"P  6@X  %L1
M  !=%@  7AT  %\F  !?,0  7CT  %Y,  !>70  7G$  %V)  !=HP  7,$
M %OK  !:_P  6O\ 5D0  $M#  !#0@  /$$  #)"   I10  (4@  !I+   3
M3@  #E(   I5   #60   %L   !>    8    &("  !C!@  90H  &8.  !H
M$0  :A<  &L?  !K*0  :S8  &M%  !K5@  :FH  &J"  !IG0  :+L  &?G
M  !F_P  9?\ 44@  $A(  !!1@  -T<  "Q*   C30  &U$  !-5   .60
M"%T   %A    9    &<   !J    ;    &X   !P    <@4  ',)  !U#0
M=Q$  'H8  ![(0  >RX  'H]  !Z3@  >6(  'EY  !XE@  =[,  '7@  !T
M_   <_\ 3DT  $=,   [30  ,$\  "93   <6   $UP   UA   &9@   &H
M  !O    <@   '8   !Y    ?    'T   !_    @0   (,"  "&!P  B P
M (L1  ".&   CB0  (XS  "-1   C%@  (MO  "*C   B:H  (C/  "&]P
MA?\ 35$  $%3   T50  *5H  !Y?   490  #6H   5P    =@   'L   !_
M    @P   (<   "*    C0   (X   "1    DP   )4   "8    F@4  )T,
M  "@$0  HQH  *,H  "B.@  H4X  *!E  "@@0  GJ   )W!  ";[@  FO\
M1ED  #E<   M80  (6<  !9N   .=0  !7L   "!    AP   (T   "2
ME@   )H   "=    GP   *$   "D    I@   *@   "K    K@   +$#  "T
M"P  N!$  +D>  "Y+P  N$,  +=:  "U=@  M)<  +2U  "QX@  L/P /V0
M #%I   E;P  &'<   ]_   &AP   (X   "4    F@   *    "E    J@
M *X   "Q    L@   +4   "W    N@   +P   "_    PP   ,8   #)
MS@H  -(3  #2(P  T3<  -!/  #.:@  S8H  ,JK  #+RP  R^\ -W$  "EX
M   =@   $8D   B1    F@   *$   "G    K0   +,   "Y    O@   ,(
M  #%    Q@   ,D   #,    S@   -(   #5    V@   -X   #A    Y0
M .H+  #K%P  ZBL  .I#  #J7@  ZGH  .N9  #KM0  Z]4 _P   /\   #_
M  $ _P ' /\ #0#_ !( _P ; /\ )0#_ "\ _P Z /\ 0P#_ $L _P!3 /\
M6@#] &  ^P!F /H :P#X '( ]@!X /0 @ #Q (D [P"2 .P G0#I *H Y@"\
M ., W #? /< W0#_ ,P _P"^ /\ M0#_ +  _P"M /\ _P   /\   #_
M_P   /\ !@#_  T _P 4 /\ 'P#_ "D ^P S /< /0#S $4 [P!- .P 4P#H
M %D Y0!? ., 90#@ &H W0!Q -H > #6 (  T@"* ,\ E0#, *( R "R ,4
MR0#" .T P #_ +L _P"P /\ J #_ *0 _P"A /\ _P   /\   #]    ^@
M /@   #P  D [  1 .@ &0#G ", Y0 M -X -@#6 #X T0!& ,T 3 #* %(
MR !8 ,4 70## &, P !I +X < "\ '@ N0"! +< C0"T )H L0"I *X O "L
M .$ J@#\ *@ _P"@ /\ F0#_ )8 _P"4 /\ _P   /D   #R    YP   -L
M  #1  0 R@ - ,< % #$ !T P@ F +\ +P"[ #< MP _ +0 10"Q $L K@!1
M *P 5@"J %P J !A *8 : "C '  H0!Y )\ A "= )$ F@"@ )@ L0"6 ,P
ME0#Q )0 _P"1 /\ BP#_ (@ _P"& /\ ]P   .P   #>    R0   +P   "T
M    KP * *L $ "I !< J  @ *< * "B #  GP X )P /@": $0 F !* )8
M3P"4 %4 DP!: )$ 80"/ &@ C0!Q (L >P") (@ AP"7 (4 J "# +X @0#D
M (  _P"  /\ ? #_ 'L _P!Y /\ Z0   -<   #!    L0   *8   "=
MEP % )0 #0"2 !( D  : (\ (@". "H BP Q (D . "' #X A0!# (, 2 "!
M $X ?P!4 'X 6@!\ &$ >@!I '@ <P!V '\ =0". ', GP!Q +, < #0 &\
M]@!O /\ ;P#_ &T _P!L /\ V@   +\   "L    G@   ),   ",    A0
M (( "0!_  \ ?@ 5 'T ' !\ "0 >@ K '< ,0!U #< =  ] '( 0@!Q $@
M;P!- &X 4P!L %H :P!B &D ; !G '@ 9@"& &0 EP!B *H 80#" &  ZP!A
M /\ 80#_ &$ _P!@ /\ Q0   *T   ";    C0   (,   !\    =P   '(
M!0!P  P ;@ 1 &P %P!L !X :P E &D + !G #$ 9@ W &0 /0!C $( 8@!(
M &  3@!? %4 70!= %P 9@!: '( 60"  %< D !6 *, 50"Y %0 W@!4 /L
M5 #_ %4 _P!5 /\ M@   )\   "-    ?P   '4   !N    :0   &8  0!C
M  D 80 . &  $P!? !D 7@ @ %T )@!; "P 6@ R %@ -P!7 #T 5@!# %4
M20!3 %  4@!8 %$ 80!/ &P 3@!Z $P B@!+ )P 2@"Q $D S@!) /, 20#_
M $D _P!* /\ J@$  )0%  ""!P  = @  &H(  !C!@  7@0  %L   !9  4
M5P , %8 $ !4 !4 4P ; %( (@!1 "@ 4  M $X ,P!- #@ 3  ^ $L 10!*
M $P 2 !4 $< 70!& &@ 1 !U $, A0!! )@ 0 "K $  Q0 _ .H /P#_ $
M_P!  /\ H @  (H+  !Y#0  ; T  &$-  !:#0  50L  %()  !0!@  3P((
M $X #0!, !( 2P 7 $H '@!) ", 1P I $8 +P!% #0 1  Z $( 00!! $@
M0 !0 #X 6@ ] &0 / !R #H @@ Y )0 . "G #< O@ V ., -@#Y #8 _P W
M /\ F T  (,.  !R$   91$  %L1  !3$   3A   $H.  !(#0  1PH# $<'
M"@!%! X 1 (3 $("&@!! B  0 ,E #X#*P ]!#$ / 0W #L$/@ Z!44 .05.
M #<%5P V!6( - 9P #(&@  Q!I( , :E "\%NP N!=T +@;U "T'_P N!_\
MD1   'T1  !L$P  7Q0  %44  !.%   2!,  $02  !!$   0 X  $ -!@!
M"@P /@D0 #P)%@ ["AP .0HB #@**  W"RX -@LU #4+.P S"T, ,@Q, # ,
M5@ O#&$ +0QO "L,?P J#)( * RE "<,NP E#-T )0WU "8-_P G#?\ BQ(
M '<4  !G%@  6Q<  %$8  !)%P  0Q<  #\5   \%   .A(  #D1 0 Y#P@
M. X- #<.$@ U#A@ - X? #(.)0 Q#RP , \R "\0.@ M$$( +!!+ "H050 H
M$&$ )A!O "00@  C$), (1"G !\0O0 >$.  'A'W !\0_P @$/\ AA0  ',7
M  !C&0  5QH  $T;  !%&@  0!H  #L9   X&   -18  #04   S$@0 ,A(+
M #$2$  O$A4 +1(< "P3(@ K$RD *A,P "@3-P G%#\ )A1( "044P B%%\
M(!5M !\5?@ =%9$ &Q6E !D5NP 8%=X &!7X !D4_P :%/\ @A<  &\:  !?
M'   4QT  $H=  !"'0  /!T  #<<   T&P  ,1H  "\9   N%@  +!<( "L6
M#@ I%Q, *!<9 "<8(  E&"8 )!@M ",8-  B&3T (!E& !X940 =&5T &QIK
M !D:?  7&H\ %1JC !09N@ 2&=L $QGV !09_P 5&/\ ?1H  &L=  !<'P
M4"   $<@   _(   .1\  #0?   Q'@  +1T  "L<   I&P  )QL% "4;#  D
M'!$ (AP6 "$<'0 @'2, 'QTJ !X=,@ <'CH &QY$ !D>3@ 7'EL %AYI !0?
M>@ 2'HT $1ZB ! >N  .'M@ #Q[U ! =_P 1'?\ >AT  &<?  !9(0  32(
M $0B   \(@  -B(  #(A   N(0  *B   "<@   D'P  (B " " @"@ >(0\
M'2$4 !PA&@ ;(B$ &2(G !@B+P 7(C@ %2-! !0C3  2(U@ $2-G ! C>  .
M(XL #2.?  PCM  +(]  "R+P  PB_P -(?\ =A\  &0B  !6(P  2R0  $$D
M   Z)   -"0  "\C   K(P  *",  "0C   @(P  '20  !LE!P 9)@T %R81
M !8F%P 5)QX %"<E !,G+  2)S4 $2@_ ! H2@ .*%8 #2AD  PH=  **(<
M"2B;  <GL0 %)\P !B?L  <F_@ ()O\ <2(  & D  !3)@  2"<  #\G   W
M)@  ,28  "TF   I)0  )24  "(E   =)P  &2@  !8J!  4*PL $BP0 !$L
M%  0+!L $"PB  XL*0 .+3( #2T[  LM1@ *+5( ""U@  8M<  $+8,  BV8
M   LK@  +,D  "SK  $K_  "*_\ ;24  %TG  !/*   12D  #PI   U*0
M+R@  "LH   G)P  (R<  !\H   ;*@  %RP  !,N @ 0, @ #C$-  TQ$@ ,
M,1< "S$>  HQ)@ (,BX !S(W  4R0@ #,DX  3)<   R;   ,G\  #*5   Q
MK   ,<<  ##J   P_   ,/\ :"D  %@J  !,*P  02P  #DL   R*P  +2L
M "DJ   E*@  ("L  !PL   7+@  $S   ! R @ .- < "C<,  <W$  %-Q0
M S<;  (W(@  -RH  #@S   X/@  .$H  #A8   X:   .'P  #>2   WJ0
M-L4  #;J   V_0  -?\ 8RP  %0N  !(+P  /B\  #8N   P+@  *RT  "<M
M   B+0  '2\  !@Q   4,P  $#4   XW 0 *.@< !CL+  (\#@  /1(  #X7
M   ^'@  /B8  #XO   ^.@  /D8  #Y4   ^9   /G<  #Z/   ]IP  /<,
M #SI   \_0  ._\ 7C   % Q  !$,@  .S(  #0Q   N,   *2\  "0P   >
M,@  &30  !0V   0.0  #3L   H]   %0 4  $$*  !"#0  0Q   $04  !%
M&@  1B(  $8K  !&-0  1D$  $9/  !&7P  1G,  $6*  !%I   1,   $/H
M  !#_@  0O\ 6#0  $LU  !!-0  .34  #(T   M,P  )C0  " U   :.
M%#H  ! ]   -0   "4(   1%    1P,  $@'  !*"P  2PX  $P1  !.%0
M3QP  $\E  !/+P  3SP  $]*  !/6@  3FT  $Z%  !-H   3+P  $OG  !+
M_@  2O\ 4SD  $<Y   ^.0  -S@  #$W   I-P  (3D  !L\   5/P  $$(
M  Q%   '2    DH   !-    3P   %$$  !2!P  5 L  %4.  !7$0  61<
M %H?  !9*0  638  %E$  !95   6&<  %A_  !7F@  5K<  %7C  !4_0
M5/\ 3CT  $,]   \/   -3L  "P\   D/@  '$$  !5$   02   "TL   5.
M    40   %0   !7    60   %L   != @  7@8  & +  !B#@  9!(  &<8
M  !G(@  9BX  &8\  !F30  96   &5W  !DDP  8[$  &'=  !@_   7_\
M24(  $%!   Z/P  ,$   "9#   >1@  %4H  !!.   *4@   U8   !:
M70   &    !C    90   &<   !I    :P$  &T%  !O"@  <@X  '42  !W
M&P  =B8  '8U  !U1@  =%D  '1O  !SBP  <JD  '#-  !O]P  ;O\ 1D8
M $!%   U1@  *D@  "!,   740  $%8   E:   !7P   &,   !H    :P
M &\   !R    =0   '<   !Y    >P   'T   "  P  @P@  (8-  ")$P
MBAT  (HK  ")/   B$\  (9F  "%@0  A*   (+"  "!\   ?_\ 1DL  #I,
M   N3P  (U,  !A8   07@  "60   !I    ;P   '0   !X    ?    ($
M  "$    AP   (@   "+    C@   )    "3    E@   )D'  "=#0  H10
M * A  "@,0  GD0  )U;  "<=@  F98  )FU  "6Y0  E?X /U(  #)5   F
M6@  &V   !%G   );0   '0   ![    @0   (8   "+    D    )0   "7
M    F0   )P   "?    H0   *0   "G    J@   *T   "Q!@  M0T  +@6
M  "W)@  MCD  +50  "T:@  LHD  +"J  "NSP  K?4 -UP  "MA   >:
M$W    MX    @    (<   ".    E0   )H   "?    I    *@   "L
MK0   +    "S    M0   +@   "[    OP   ,,   #'    RP4  -$.  #1
M&P  T"X  ,]%  #-7P  RWX  ,F>  #(O@  Q>D +VD  "-P   6>0  #8$
M  &+    DP   )L   "B    J    *X   "T    N    +T   #     P@
M ,4   #(    RP   ,X   #1    U@   -L   #?    Y    .@&  #K$0
MZB,  .HZ  #I5   YW(  .63  #CLP  X]0 _P   /\   #_    _P $ /\
M"P#_ !  _P 7 /\ (0#_ "L _P U /\ /@#_ $< _P!. /\ 50#\ %L ^@!A
M /@ 9@#V &T ] !S /( >P#O (0 [0". .H F0#F *< XP"Y -\ U0#; /<
MU@#_ ,  _P"R /\ J@#_ *4 _P"B /\ _P   /\   #^    _    /P  P#^
M  L _P 1 /\ &@#] "0 ^0 N /0 . #P $  [ !( .D 3@#F %0 X@!: -\
M7P#< &4 V !K -0 <@#0 'L S0"% ,H D0#' )X PP"N ,  Q0"] .L NP#_
M +  _P"D /\ G #_ )@ _P"5 /\ _P   /H   #T    \0   /(   #J  4
MYP . .( %0#A !X X0 H -@ ,0#0 #D RP!  ,@ 1P#% $T P@!3 +\ 6 "]
M %X NP!D +D :P"V ', M !\ +$ B "N )4 JP"D *@ N "F -P HP#[ )\
M_P"5 /\ CP#_ (L _P") /\ ^0   .\   #G    WP   ,\   #(    P0 *
M +\ $0"\ !@ NP A +D *@"T #( L0 Z *X 0 "K $8 J !, *8 40"C %8
MH0!< )\ 8P"= &H FP!S )D ?@"6 (P E "; )( K0"0 ,< C@#P (T _P"&
M /\ @ #_ 'T _P!\ /\ [0   .    #1    OP   +,   "J    I@ % *(
M#0"A !, H  ; )\ (P"; "L F  R )4 .0"3 #\ D0!$ (\ 2@". $\ C !5
M (H 6P"( &, A@!K (0 =@"" (( @ "2 'X HP!\ +H >@#A 'D _P!W /\
M<@#_ '  _P!O /\ W0   ,L   "V    IP   )T   "4    C@ ! (L "@")
M !  B  5 (< '0"' "4 A  L (( ,@!_ #@ ?0 ] 'L 0P!Y $@ > !. '8
M5 !U %L <P!C '$ ;@!O 'H ;0") &P F@!J *X :0#, &@ ]@!G /\ 90#_
M &0 _P!C /\ R@   +0   "A    DP   (D   ""    >P   '@ !0!V  P
M=0 1 '0 & !S !\ <@ E '  + !N #( ;  W &H / !I $( : !( &8 3@!E
M %4 8P!= &( 9@!@ '( 7@"  %T D@!; *4 6@"^ %D Z0!9 /\ 60#_ %@
M_P!8 /\ N0   *(   "0    @P   'D   !Q    ;0   &D  0!F  D 90 .
M &0 $P!C !D 8P @ &$ )@!@ "P 7@ Q %P -P!; #P 6@!" %@ 2 !7 $\
M5@!7 %0 8 !3 &P 40!Y %  B@!/ )X 3@"T $T V@!- /L 30#_ $T _P!-
M /\ J@   )0   ""    =0   &L   !D    8    %T   !:  4 6  , %<
M$ !6 !4 5@ ; %4 (0!3 "< 4@ L %$ ,0!/ #< 3@ ] $T 0P!, $H 2@!2
M $D 6P!( &8 1@!S $4 A !$ )< 0P"L $( R0!" /$ 0@#_ $, _P!# /\
MG@   (D   !X P  :@0  &$$  !: P  50$  %(   !0  ( 3@ ) $T #0!,
M !$ 2P 7 $H ' !) "( 2  G $< +0!% #( 1  X $, /@!" $4 00!- #\
M5@ ^ &$ /0!N #L ?@ Z )$ .0"F #@ OP X .@ . #_ #D _P Y /\ E0,
M ( '  !O"0  8@H  %@+  !1"@  3 @  $D&  !' P  1@ & $0 "P!#  \
M0@ 3 $$ & !! !X /P C #X *0 ] "X .P T #H .@ Y $$ . !) #< 4@ V
M %T - !J #, >@ R (P ,0"A #  N  O -X +P#Y "\ _P P /\ C D  '@,
M  !H#0  7 X  %(.  !+#@  10T  $$,   _"@  /@@" #T$"  \ 0T .P 0
M #H %0 Y !H .  @ #8 )0 U "L -  P #, -P R #X ,0!& "\ 4  N %H
M+0!G "L =P J (D *0"= "@ LP G -$ )P#R "< _P G /\ A@P  '(.  !C
M$   5A$  $T1  !%$0  0!   #P/   Y#@  -PT  #8+!  V" H -08. #0%
M$@ R!!< ,04< # %(@ O!2@ +@8N "T&-  K!CP *@9$ "D'3@ G!UD )@=E
M "0'=0 C!X< (@>; " &L  @!LL 'P7M !\&_@ ?!_\ @ X  &T1  !>$@
M4A,  $@3  !!$P  .Q,  #<2   T$0  ,A   # / 0 P#08 , L+ "\*$  M
M"A0 + L9 "H+'P I"R4 * PK "<,,@ F##H ) Q# ",,30 A#5@ ( UE !X-
M=0 <#8@ &@V< !D-L0 8#,H %PSK !<-_  8#/\ >Q$  &D3  !:%0  3A8
M $46   ]%@  .!4  #,5   P%   +1,  "L2   J$ , *@\( "D.#0 H#A$
M)@X6 "4/'0 D#R, (P\I "$0,0 @$#D 'A!" !T03  ;$%@ &1!F !<0=@ 5
M$(D %!"> !(0LP 1$,X $1#N !(0_@ 2$/\ =Q,  &45  !7%P  2Q@  $(9
M   Z&0  -!@  # 7   L%P  *18  "<5   F% $ )1($ ",2"P B$@\ (1(4
M " 2&@ >$R  '1,G !P3+@ :$S8 &11  !<42@ 6%%8 %!1D !(4=  1%(<
M$!2<  X4L0 -%,H #13K  X3_@ .$_\ <Q4  &$8  !3&@  2!L  #\;   W
M&P  ,AH  "T:   I&0  )A@  "08   B%P  (!8! !X6"  =%@T &Q<2 !H7
M%P 9%QT &!@D !88*P 5&#0 %!@] !(92  1&50 $!EB  X9<@ -&80 #!F8
M  H9K0 )&,8 "1CG  D8^@ *%_\ ;Q@  %X:  !0'   11T  #P=   U'0
M+QT  "H<   F&P  (QL  "$:   >&@  '!H  !H;!0 8&PP %AP0 !4<%0 4
M'!L $QPB !(=*0 1'3$ $!T[  X=10 -'E$ #!Y>  H>;0 )'H  !QZ4  4=
MJ@ #'<(  QWF  0<^  %'/\ :QH  %L=  !-'@  0A\  #H?   R'P  +1\
M "@>   D'@  (1T  !X=   <'0  &!X  !4? @ 3( D $B$. ! A$@ 0(1@
M#B$?  XB)@ -(BX #"(W  HB00 )(DT !R):  4B:0 #(GP  2*1   BJ
M(<   "'E   @^   (/\ 9QT  %<?  !*(0  0"$  #<B   P(0  *B$  "8@
M   B(   'Q\  !P?   9(   %B$  !(C @ 0) < #B8,  PF$  +)A4 "B8<
M  DF(@ ()BH !B<S  0G/0 #)TD  2=6   G9@  )WD  ">/   FI@  )K\
M "7D   E^0  )/\ 8R   %0B  !'(P  /20  #0D   N(P  *",  "0B   A
M(@  'B$  !HB   7(P  $R0  ! F @ .* < "RH+  @K#@ &*Q, !"L8  (K
M'P !+"<  "PP   L.@  +$4  "Q3   L8P  +'8  "R,   KI   *[X  "KD
M   J^@  *?\ 7R,  % E  !$)@  .B8  #(F   K)@  )B4  ",D   ?)
M&R0  !<E   4)P  $2D   XK @ ++08 !R\+  0P#@  ,!$  #$5   Q'
M,2,  #(L   R-@  ,D(  #)/   R7P  ,G(  #&)   QH@  ,+P  ##D   O
M^P  +_\ 6B<  $PH  ! *0  -RD  "\I   I*   )2<  "$F   <)P  &"@
M !0J   1+   #BX   LP 0 ',@4  S0)   U#   -@\  #<2   X&   ."
M #@H   X,@  .3T  #E+   Y6P  .&X  #B%   WGP  -[H  #;D   U_
M-?\ 52H  $@L   ]+   -"P  "TK   H*@  )"D  !XJ   9*P  %"T  !$O
M   -,0  "C0   <V   ". 0  #H'   ["@  /0T  #X0  ! %   0!L  $ D
M  ! +@  0#D  $!'  ! 5@  0&D  $"    _FP  /K<  #WC   \_   //\
M4"\  $,O   Y+P  ,B\  "PM   G+   ("T  !HO   5,0  $3,   TV   )
M.   !3L    ]    0 $  $$$  !#!P  10L  $8.  !($0  2A8  $H>  !*
M*   2C0  $E"  !)40  260  $A[  !(EP  1[0  $;@  !%_   1/\ 2C,
M #\S   V,P  ,#$  "HP   C,0  '#,  !8U   1.   #3L   @^   #00
M $,   !&    2    $H   !,!   3@<  $\+  !1#@  5!(  %49  !5(@
M5"X  %0\  !42P  4UX  %-T  !2D   4:X  %#7  !/^P  3O\ 13<  #PW
M   U-@  +S0  "8U   >-P  %SH  !$]   ,00  !T0   !(    2@   $T
M  !0    4P   %4   !7    6 (  %L&  !="P  7PX  &(3  !B&P  8B<
M &(T  !A10  8%<  &!M  !?B0  7:<  %S,  !:^   6?\ 03P  #H[   T
M.0  *CH  "$\   80   $4,   Q'   &2P   $\   !3    5@   %D   !<
M    7P   &$   !C    90   &<!  !J!0  ;0H  ' .  !S%0  <B   '(M
M  !Q/0  <$\  &]E  !N@   ;9\  &O!  !I\0  :/\ /T   #D^   N/P
M)$(  !I&   22@  #$\   14    6    %T   !A    90   &@   !K
M;@   '$   !S    =0   '@   ![    ?@,  ($*  "%#P  AQ<  (8D  "%
M-   A$8  ()=  "!=@  ?Y8  'ZV  !\YP  >O\ /T0  #-%   H2   '4P
M !-2   ,5P   UT   !C    :    &T   !Q    =@   'H   !^    @0
M (,   "&    B0   (L   ".    D@   )4!  "9"0  GA   )X:  "=*0
MG#P  )I2  "8;   EHL  )2J  "2U   D/H .$L  "Q.   @4P  %5D   U@
M   #9P   &X   !T    >@   (    "$    B@   (X   "2    E0   )<
M  ":    G0   *    "C    IP   *L   "O    M D  +@0  "W'@  M3
M +-&  "Q8   KWX  *R@  "KP0  J>X ,54  "1;   880  #FD   5Q
M>0   ($   "(    CP   )0   ":    GP   *0   "H    J0   *P   "O
M    LP   +4   "Y    O0   ,$   #&    RP   -$*  #3%   T24  - [
M  #-5   RG$  ,B2  #%LP  P]X *6(  !QI   1<0  !WL   "$    C0
M )4   "=    HP   *D   "O    M    +D   "\    O@   ,(   #%
MR    ,P   #0    U    -H   #?    Y    .H   #N#   [1H  .PO  #J
M20  Z&4  .:&  #DI0  XL8 _P   /\   #_    _  ! /P " #^  X _P 4
M /\ '0#_ "8 _P P /\ .@#_ $( _P!) /X 4 #[ %8 ^0!< /8 8@#T &@
M\@!O /  =@#M '\ Z@") .< E0#D *, X "U -L T #5 /8 R@#_ +8 _P"H
M /\ GP#_ )H _P"6 /\ _P   /L   #V    \P   /,   #V  D ^@ . /T
M%@#[ "  ]P J /( ,P#M #L Z0!# .8 20#B $\ W@!5 -L 6P#6 &  T@!G
M ,\ ;@#, '8 R0"  ,8 C #" )H OP"J +L P0"X .D M@#_ *< _P": /\
MD@#_ (T _P"* /\ ^@   /$   #J    YP   .<   #D  $ X  + -L $0#:
M !H VP C -$ + #* #0 Q@ [ ,( 0@"_ $@ O !. +H 4P"X %D M@!? +,
M9@"Q &X K@!W *P @P"I )$ I@"A *, M0"@ -@ G@#[ )4 _P"+ /\ A0#_
M (  _P!^ /\ [P   .,   #:    TP   ,8   "_    N0 & +< #@"T !0
MM  = +, )0"N "T JP T *< .P"D $$ H0!& )\ 3 "= %$ FP!7 )D 7@"7
M &4 E0!N ), >0"0 (< C@"7 (P J0") ,0 B #O (4 _P!\ /\ =@#_ ',
M_P!R /\ X    -    #&    M@   *D   "A    G0 ! )D "@"8 !  F  6
M )< '@"4 "8 D0 M (\ - ", #H B@ _ (@ 10"' $H A0!0 (, 5@"! %X
M@ !F 'X <0!\ 'T >0"- '< H !U +8 <P#? '( _P!N /\ :0#_ &< _P!E
M /\ S    +X   "K    G0   ),   "*    A0   (( !0"   T ?P 1 '\
M& "  "  ?0 F 'H +0!W #, =0 X '0 /@!R $, < !) &\ 3P!M %8 ; !>
M &H : !H '4 9P"$ &4 E@!D *L 8@#) &$ ]@!@ /\ 7 #_ %L _P!: /\
MO0   *D   "7    B0   'X   !X    <P   &\  0!M  D ;  . &L $P!K
M !D :@ @ &@ )@!F "P 90 R &, -P!B #P 8 !" %\ 2 != $\ 7 !7 %H
M80!9 &T 5P![ %8 C@!5 *( 4P"[ %( Z0!2 /\ 4 #_ $\ _P!/ /\ K0
M )@   "&    >    &X   !G    8P   &    !=  4 7  + %L $ !; !4
M6P ; %H (0!8 "8 5@ L %0 ,0!3 #8 4@ \ %$ 0@!/ $D 3@!1 $T 6P!+
M &8 2@!T $D A0!( )D 1P"Q $8 V !& /P 10#_ $4 _P!% /\ GP   (D
M  !X    ;    &(   !;    5@   %,   !1  ( 3P ( $\ #0!. !$ 3@ 6
M $T ' !, "$ 2@ F $D + !( #$ 1P W $4 /0!$ $0 0P!, $( 50!  &
M/P!N #X ?@ ] )( / "I #L QP [ /, .P#_ #L _P \ /\ DP   'X   !N
M    80   %@   !1    3    $D   !'    10 % $0 "P!#  X 0P 2 $,
M%P!" !T 0  B #\ )P ^ "P /0 R #L .  Z #\ .0!' #@ 4  W %L -0!H
M #0 >  S (P ,@"B #$ O  Q .< ,0#_ #( _P S /\ B0   '8#  !F!0
M60<  % '  !)!@  0P4  $ #   ^ 0  /  # #L "  Z  T .@ 0 #D %  Y
M !D -P > #8 (P U "@ -  N #, -  R #L , !# "\ 3  N %< +0!D "P
M<P K (< *@"< "D M0 I -P *0#[ "D _P J /\ @00  &X(  !?"@  4PL
M $H+  !""P  /0H  #D)   V"   -04  #0"!@ S  H ,@ . #$ $0 Q !4
M,  : "\ 'P N "0 +  J "L ,  J #< *0 _ "@ 20 G %0 )@!@ "0 ;P C
M (( (@"7 "$ K@ A ,P (0#S "$ _P B /\ >PD  &@,  !:#0  3@X  $4.
M   ]#@  . T  #,-   P#   +@L  "T) P M!@@ + 0, "L"#P J 1( *0$7
M "@!'  G "$ )@ G "4 +0 D #0 (P$] "(!1@ A 5$ 'P%= !X!;  < 7\
M&P"4 !H J@ : ,4 &@#K !D _P : /\ =0P  &0.  !5#P  2A   $ 0   Y
M$   ,Q   "\/   L#@  *0X  "<- 0 G# 4 )PH* "8(#0 E!Q  ) 84 "(&
M&0 A!A\ ( <D !\'*P >!S( '0<Z !P(1  :"$\ &0A< !<(:P 6"'T %0>1
M !0'IP 3!K\ $@7D !(%^@ 2!?\ <0X  %\0  !1$0  1A(  #T2   V$@
M,!(  "L1   H$0  )1   ",0   B#@0 (0T' "$,"P @"PX 'PL2 !T+%P <
M#!P &PPB !H,*0 9##$ & PY !8-0P 5#4\ $PU< !(-:P 0#7X #PV2  X-
MIP -#+X #0S@  T,]0 -#/\ ;1   %P1  !.$P  0Q0  #H4   R%   +10
M "@3   E$P  (A(  " 1   >$0, '! % !P/"  ;#PP &@X0 !D/%  7#QH
M%@\A !40*  4$#  $A Y !$01  0$%  #A!=  T0:P ,$'P "Q"0  D0I0 (
M$+P !Q#?  <0]  '#_\ :1$  %@4  !+%0  0!8  #<6   P%@  *A8  "85
M   B%0  'Q0  !T3   :$P( &1($ !<2!@ 6$@H %1(. !02$@ 2$A@ $1,>
M !$3)0 0$RX #A,W  T40  ,%$L "Q18  D49P '%'@ !A2-  04HP #$[L
M A/=  $2]  "$O\ 91,  %46  !(%P  /1@  #08   M&   *!@  ",7   @
M%P  '18  !H5   8%0( %A4$ !05!0 2%@@ $18- ! 7$  .%Q4 #A<;  T7
M(@ ,%RD "Q@R  D8/  '&$< !1A4  088P "&'4  1B+   7H0  %[D  !?=
M   6]0  %O\ 818  %(8  !%&@  .QH  #(:   K&@  )1H  "$9   >&
M&Q@  !@7   6%P( %!<# !(8!0 0&0< #AL+  P;#P +&Q, "AL8  @<'P '
M'"8 !1PO  0<.  "'$0  !U1   =8   '7(  !R(   <H   &[D  !O>   :
M]@  &O\ 7A@  $\:  !"'   .!P  "\=   I'   (QP  !\;   <&@  &1D
M !<9 0 4&0( $AH# ! ;!  .'0< #!X+  D?#@ &(!$ !2 6  ,@'  !(2,
M "$K   A-0  (4   "%.   A70  (6\  "&&   @G@  (+@  !_>   >^
M'O\ 6AL  $L=   _'@  -1\  "T?   G'@  (AT  !X=   ;'   &!L  !4;
M   2'   $!T"  X?!  ,(08 "2(*  4C#0 ")!   "43   E&0  )B   "8H
M   F,@  )CT  "9*   F6@  )FP  ":#   EG   );<  "3?   C^0  (_\
M51X  $<@   \(0  ,B$  "LA   E(   (!\  !T>   :'0  %AX  !,>   0
M(   #B$   PC @ ()04 !2<)   H"P  *@X  "L1   L%@  +!T  "PE   L
M+@  +#H  "Q'   L5@  +&D  "R    KF@  *K4  "G?   I^P  */\ 42(
M $0C   X)   +R0  "@C   C(@  'R$  !P@   7(   $R$  ! C   .)
M"R8   @H   $*@0  "P'   N"0  , P  #$/   S$P  ,QD  #,A   S*@
M,S4  #-#   S4@  ,V4  #)[   REP  ,;,  ##>   O^P  +O\ 3"4  #\F
M   U)P  +28  "<E   B)   'B,  !DC   4)   $28   XH   +*@  !RP
M  ,O    ,0(  #,$   U!P  -PH  #D-   Z$   .Q4  #L=   [)@  .S$
M #L^   [3@  .V   #IW   YD@  .+   #?;   V_   -?\ 1RD  #LJ   R
M*@  *RD  "4G   A)@  &R<  !4H   1*@  #BP   HO   &,0   30    V
M    .    #L!   ]!   /P<  $$*  !##@  11$  $48  !%(0  12P  $0Y
M  !$2   1%L  $-Q  !"C0  0:L  $#2   _^@  /O\ 0BT  #@N   O+0
M*2L  "0J   =*@  %RP  !$N   -,0  "30   0W    .@   #P    _
M00   $0   !&    2 ,  $H'  !,"P  3@X  % 3  !0'   4"<  $\T  !/
M0P  3U4  $YJ  !-A@  3*0  $K*  !)^   2/\ /C(  #4Q   N+P  *2X
M " N   9,0  $C,   XW   ).@   CT   !     1    $<   !)    3
M $\   !1    4P   %4!  !8!@  6@L  %T.  !?%0  7B   %XL  !=/
M7$X  %MC  !:?@  6)T  %?   !5\@  5/\ .C8  #,T   M,@  )#,  !LV
M   3.0  #CT   A!    10   $D   !,    4    %,   !6    60   %L
M  !=    8    &(   !E    : 4  &L+  !O$   ;Q@  &XE  !M-   ;48
M &M;  !J=0  :)0  &:V  !DZ0  8O\ .#D  #(W   H.0  'CL  !4_   .
M1   !TD   !-    4@   %8   !:    7@   &(   !E    :    &L   !M
M    <    ',   !V    >0   'T$  "!"P  A1$  (0=  ""+   @#X  'Y4
M  !^:P  >XH  'JJ  !WU@  =?T .#T  "P^   B00  %T8   ]+   '40
M %<   !<    8@   &8   !K    ;P   '0   !X    >P   'X   "
M@P   (8   "*    C0   )$   "6 P  FPP  )T3  ";(0  FC,  )=)  "4
M8@  DW\  )"@  ".Q0  C/, ,40  "5(   :30  $%,   A:    80   &@
M  !N    =    'D   !_    A    (D   "-    D0   ),   "6    F0
M )T   "@    I    *@   "L    L@,  +<-  "W%P  M2@  +(^  "P5@
MK',  *J4  "IM   I>4 *D\  !Y4   26P  "F(   !J    <P   'L   ""
M    B0   (X   "4    F@   )\   "D    I@   *D   "M    L    +,
M  "W    NP   ,    #%    RP   -$$  #5#@  TQT  - R  #-2P  RF8
M ,:'  #"J0  P<L (EL  !9B   ,:P   70   !]    AP   )    "7
MG@   *0   "K    L0   +8   "Z    O    ,    #$    R    ,L   #/
M    U    -H   #@    Y@   .L   #Q!@  \!,  .XG  #L/P  ZEL  .=Z
M  #DFP  X+L _P   /L   #V    \P   /0 !0#V  P ^@ 1 /\ &0#_ "(
M_P L /\ -0#_ #T _P!% /P 3 #Z %( ]P!8 /4 7@#S &0 \0!J .X <@#L
M 'H Z0"% .4 D0#A *  W0"R -@ S@#2 /8 P0#_ *T _P"> /\ E@#_ )
M_P", /\ ^@   /(   #L    Z0   .D   #L  4 \@ , /@ $@#W !L ]0 E
M /  +@#K #< Y@ ^ .( 10#= $L V !0 -, 5@#0 %P S0!B ,H :@#( '(
MQ0!\ ,( B "^ )8 N@"H +< OP"T .@ K@#_ )T _P"0 /\ B #_ (, _P"
M /\ \    .4   #>    V@   -L   #<    V  ' -$ #@#1 !4 T@ > ,L
M)P#% "\ P  W +T /0"Z $0 MP!) +4 3P"R %4 L !; *X 80"L &D J0!S
M *< ?P"D (T H0"> )X L@"; -4 F0#\ (P _P"" /\ >P#_ '8 _P!T /\
MX@   -,   #*    QP   +P   "V    L  ! *\ "P"L !$ K0 8 *T ( "H
M "@ I  O *  -@"= #P FP!" )D 1P"7 $T E0!3 ), 60"1 &$ CP!J (P
M=0"* (, B "4 (8 IP"# ,( @@#P 'P _P!S /\ ;0#_ &H _P!H /\ SP
M ,$   "Y    K0   *    "8    E    )$ !@"0  T D  2 (\ &0". "$
MBP H (@ +P"& #4 A  Z (( 0 "  $4 ?@!+ 'P 4@!Z %D > !B '8 ; !T
M 'D <@") '$ G0!O +0 ;0#? &P _P!E /\ 8 #_ %X _P!< /\ O@   +$
M  "@    D@   (D   ""    ?    'H  0!X  D =P . '@ % !W !H =  A
M '( )P!P "T ;@ S &P . !K #X :0!$ &@ 2@!F %$ 9 !: &, 9 !A '
M7P!_ %X DP!= *D 7 #( %L ]P!7 /\ 5 #_ %( _P!1 /\ L    )\   "-
M    ?P   '0   !N    :@   &8   !E  0 8P + &, $ !C !4 8P ; &$
M(0!? "< 70 L %P ,@!: #< 60 ] %< 0P!6 $L 50!3 %, 7 !2 &@ 4 !W
M $\ B0!. )\ 30"Z $P Z0!+ /\ 20#_ $< _P!' /\ H@   (T   !\
M;@   &4   !>    60   %<   !5  $ 5  ' %, #0!3 !$ 5  6 %( &P!1
M "$ 3P F $X *P!, #$ 2P W $H /0!) $0 1P!, $8 5@!$ &$ 0P!P $(
M@0!! )< 0 "O #\ UP _ /\ /@#_ #T _P ^ /\ E    '\   !O    8P
M %D   !1    30   $H   !(    1P $ $< "@!&  X 1@ 1 $< %@!% !P
M1  A $( )@!! "L 0  Q #X -P ] #X / !' #H 4  Y %L . !I #< >@ V
M (\ -0"G #4 Q@ T /4 - #_ #0 _P U /\ B    '0   !E    6    $\
M  !(    0P   #\    ]    /  " #P !P [  P .P / #L $@ Z !< .0 <
M #< (0 V "8 -0 L #0 ,@ S #D ,0!! #  2P O %8 +@!C "T <P L (@
M+ "@ "L NP K .H *P#_ "L _P L /\ ?P   &P   != 0  40(  $@#  !
M P  .P(  #<    T    ,P   #( !0 R  D ,@ - #$ $  Q !, ,  8 "\
M'0 M "( +  H "L +@ J #4 *0 ] "@ 1@ G %$ )@!> "4 ;@ D (( (P"9
M ", LP B -X (@#_ ", _P D /\ =P   &4$  !6!@  2P<  $((   Z"
M-0<  # &   M!0  + ,  "L  P J  < *0 + "D #@ I !$ *  5 "< &0 F
M !X )0 D "0 *@ C #$ (@ Y "$ 0P @ $X 'P!: !X :0 = 'P ' "3 !L
MK  ; ,T &P#V !L _P < /\ < 4  %\(  !1"@  1@L  #T+   U"P  , L
M "L*   H"0  )0@  "0' @ C! 8 (P() "(!#  B  \ (0 2 "  %@ ? !L
M'@ @ !T )@ < "X &P V !H /P 9 $H & !7 !< 9@ 6 '@ %0"/ !4 I@ 4
M ,, % #N !0 _P 5 /\ :P@  %L+  !-#   0@T  #D-   Q#0  + T  "<-
M   C#   (0P  !\+ 0 >"@4 '0@( !T&"P <!0T ' 00 !L$%  9!!@ &00>
M !@$(P 7!"L %@0S !4$/  4!$< $P-4 !(#8P 1 W4 $ ** ! !H@ / +P
M#P#E  \ _@ 0 /\ 9PL  %<-  !)#@  /@\  #4/   N#P  * \  "0.   @
M#@  '0X  !L- 0 9#00 & P' !@+"0 7"0P %PD. !8)$@ 5"18 % D; !,)
M(0 2"2@ $@DP !$).@ 0"44 #PE2  X)80 -"7, # B(  L(GP *![< "@;;
M  H%]@ *!/\ 8PT  %,.  !&$   .Q$  #(1   K$0  )1   "$0   =$
M&@\  !@/ 0 6#@0 %0X' !0-"0 3#0L $PP- !(,$  1#!0 $ P9 ! ,'P /
M#"< #@TO  T-.0 ,#44 "PU1  D-8  (#7$ !@V&  4-G0 $#+0  PS2  (,
M\0 ""_\ 7PX  % 0  !#$0  .!(  "\2   H$@  (Q(  !X1   ;$0  &!$
M !40 @ 4$ 4 $A ' !$/"0 0#PH $ X,  X.#@ .#Q( #0\7  P0'0 ,$"0
M"A L  D0-@ ($$$ !A!.  4070 #$&\  1"$   0G   #[0   [4   .\P
M#O\ 7!   $T2  ! $P  -A0  "T4   F%   (1,  !P3   9$@  %A(  !01
M P 2$08 $1$( ! 0"@ .$ L #1$+  P1#0 +$A$ "A(5  D2&@ ($B$ !A,I
M  43,P #$SX  A-+   36@  $VP  !."   2FP  $K0  !'7   1]0  $?\
M6!(  $D4   ]%0  ,Q8  "L6   D%0  'Q4  !H4   7%   %!,! !,2!  1
M$@< $!()  X2"0 -$@D "Q,*  D4#0 '%0\ !A83  06&  #%A\  A8G   7
M,   %SL  !=(   76   %VH  !:    6F0  %;0  !79   4]P  $_\ 510
M $86   Z%P  ,!@  "@8   B%P  '18  !D6   6%0  $Q0# !(3!@ 0$P<
M#Q,'  T4!P +%0@ "18)  88#  #&@X  1H1   :%@  &QP  !LD   ;+0
M&S@  !M&   <50  &V<  !M]   ;EP  &K,  !G;   8^0  %_\ 418  $,8
M   W&0  +AH  "8:   @&0  &Q@  !@7   5%@$ $Q4% !$5!  /%00 #18$
M  L7!0 )&08 !AH(  (<"@  '@T  " 0   @$P  (!D  " A   A*@  (34
M "%"   A4@  (&0  "!Z   ?E0  '[$  ![;   =^@  '/\ 31D  #\;   T
M'   *QP  "0<   >&P  &AH  !<8   4%P( $A<" ! 8 0 -&0$ "QH"  @<
M P %'00  A\&   A"   (PL  "4.   F$0  )A8  "8>   G)P  )S(  "<_
M   F3@  )F   "9W   ED@  )*\  "/:   B^P  (?\ 2!T  #P>   Q'P
M*!X  "(>   ='   &1L  !8:   2&@  $!L   T<   +'0  "!\   0A   !
M(P(  "4$   G!@  *0D  "P,   N#P  +A,  "X:   N(P  +BX  "X[   N
M2@  +5P  "UR   LC@  *ZP  "K4   I^P  */\ 1"   #@A   N(0  )B$
M " @   <'@  &!T  !0=   0'@  #A\   LA   '(P   R4    G    *0
M "P!   N P  , 8  #,*   U#0  -A$  #87   V'P  -BD  #8V   V10
M-5<  #5M   TB0  ,J@  #'/   P^@  +_\ /R0  #0D   K)   )",  !\A
M   ;(   %B   !$A   .(P  "B4   8H   "*@   "T    O    ,@   #0
M   W    .0,  #L&   ^"@  0 X  $$2  !!&@  0"4  $ Q  ! 0   /U(
M #YG   ]@@  /*(  #K'   Y^   ./\ .B@  # H   I)P  (R4  !\C   8
M)   $B4   XH   **@  !2T    P    ,P   #8    X    .P   #X   !
M    0@   $4"  !'!@  2@H  $T.  !-%0  3!\  $PK  !+.@  2DP  $EA
M  !(?   1YL  $6_  !#\P  0O\ -BP  "TK   G*0  (R<  !LH   4*@
M#BT   HP   $,P   #<    Z    /0   $    !#    1@   $@   !+
M30   %    !3 0  5@8  %D+  !;$   6QD  %HE  !9-   6$8  %=:  !5
M=   5),  %*U  !0Z@  3_\ ,S   "PN   G+   'BT  !8O   0,@  "C8
M  ,Z    /P   $(   !&    20   $P   !/    4@   %4   !8    6@
M %T   !@    8P   &<&  !K#   ;!(  &L>  !K+   :3T  &=2  !F:@
M9(D  &&K  !?W   7?\ ,3,  "PQ   B,@  &34  !$Y   */0   D(   !'
M    3    %    !4    6    %L   !?    8@   &4   !H    :P   &X
M  !Q    =0   'D   !]!@  @@T  ((6  " )   ?C4  'Q)  ![80  >'\
M ':?  !SQ@  </< ,38  "8X   <.P  $D    M%   "2P   %$   !6
M6P   &    !E    :0   &X   !R    =@   'D   !\    ?@   ((   "%
M    B0   (X   "3    F 8  )P.  ";&@  F"L  )9   "260  D7,  (V5
M  "+M0  B.@ *SX  "!!   51P  #4T   )4    6P   &$   !H    ;@
M ',   !Y    ?@   (,   "(    C    (\   "2    E0   )D   "=
MH0   *4   "J    L    +<'  "X$0  M2$  +(U  "O30  JFD  *B(  "F
MJ   HM$ (T@  !A.   .5   !%P   !D    ;0   '4   !\    @P   (D
M  "/    E0   )L   "@    HP   *8   "I    K0   +$   "U    N0
M +X   #$    R@   -(   #:"@  UA8  -(I  #.00  REP  ,5\  #"G0
MP;T '%4  !%<   '90   &X   !W    ?P   (@   "0    F    )\   "E
M    K0   +,   "X    N@   +X   #"    Q@   ,H   #.    TP   -H
M  #@    YP   .T   #S    ] X  /(>  #O-@  [%$  .AN  #DD   W[$
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M_________________________________________P
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M[8Z(>.>'CX'B@)6*W7N:D-IWH);6=*::U'&LGM)OLJ'0;;FCSVS#IL5GPZ;
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MBI6[IH>=OJ*%I<"?A*_!EGZPP91_MKB3@+NRDX"[LI. N[*3@+NRDX"[LI.
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M-1EQ_ST>:?]%(V+_329;_U8I6/]?+%;_:"U4_VXO4_]S,%+_>#%1_WPQ4/^
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MC"(&_YTG!_^J+@G_MC8.]\$^%NW,1B#DV$LNV=Q01,G46%B[S5YKKL9E>J+
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M*3S_L"H\_[0J//^T*CS_M"H\_[0J//^T*CS_M"H\_[0J//^T*K.X 0"EQ@
ME]4  (OO! &$_Q,"=_\:!&W_(@=D_RH+7/\R#E7_.1%0_T$32_](%4C_3Q=%
M_U880O]<&4#_81H^_V<://]M&SO_<QPY_WD<./^ '3;_B!TU_X\>-/^7'C+_
MH!\R_Z0?,O^D'S+_I!\R_Z0?,O^D'S+_I!\R_Z0?,O^D'Z;   "7S@  B=X
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M34GXX$U(]_--2/?T34CW]$U(]_1-2/?T34CW]$U(]_1-2/?T3=JC  #'L0(
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M:D_%[6A0P/-D4;WU85&]]6%1O?5A4;WU85&]]6%1O?5A4;WU8?^&"@#PF@0
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M-3__[S4__^\U/__O-3__[S4__^\U/__O-<2J  "SLP  I[\  )K+  "/V@(
MAO\/ 7[_' -U_R4&;/\M"F3_-@Y=_SX26/]%%5+_31A/_U4:3/]<'$G_9!Y'
M_VL?1/]S($+_?")!_X4C/_^/)#W_FB4[_Z0F.O^O)CG_NB<X_\HG./_<*#C_
MW"@X_]PH./_<*#C_W"@X_]PH./_<*+6O  "GN@  FL8  (W4  "!Y@$ >O\0
M 7#_& )G_R$%7_\I!UC_,0I2_SD-3?]!#TG_2!%%_T\30O]5%$#_7!4]_V(6
M._]I%SG_<!@W_WD9-?^"&3/_C!HR_Y<;,/^A&R__JAPO_[4<+O^_'"[_OQPN
M_[\<+O^_'"[_OQPN_[\<+O^_'*FU  ":P@  C,\  '_>  !V_P4 ;/\. 6+_
M% ):_QL#4_\D!4W_*P='_S,)0_\Z"C__00L[_T<,./]-#37_4PXS_U@/,?]>
M#R__9! M_VL1*_]S$2G_?!(G_X82)?^0$R3_F1,C_Z,4(O^K%"+_JQ0B_ZL4
M(O^K%"+_JQ0B_ZL4(O^K%)R^  "-RP  ?MH  '#F  !G_P  7?\* 53_$ %-
M_Q4"1_\= T'_) 0\_RL%-_\R!C3_. <P_ST(+?]#""K_2 DH_TT))O]2"B3_
M5PHB_UT+(/]C"Q[_:PL<_W,,&O]\#!C_A P7_XX-%?^5#17_E0T5_Y4-%?^5
M#17_E0T5_Y4-%?^5#?]2)0/_32\$_U$R!O]7-0?_6CP*_UM%#O]:3Q/_65T7
M_UAM&_]6>Q__58DB_U.5)?]2H"?_4:@I_U"Q*O]0N"O_3\$L_T_*+?].UB[_
M3N0N_T[M+_].\R__3?@P_TW\,/],_S#\3/\P^4S_+_A,_R_X3/\O^$S_+_A,
M_R_X3/\O^$S_+_]3) /_32\$_U0P!?]9- ?_73H*_U]##O]>3A/_75H8_UMJ
M'/]:>2'_6(8D_U:2)_]5G2G_5*8K_U.N+?]2MB[_4KXO_U'',/]1TC'_4.$R
M_U#K,O]/\C/_3_<S_T[\-/M._S3X3?\T]4[_,O1._S+T3O\R]$[_,O1._S+T
M3O\R]$[_,O]3) /_3BX$_U8O!?]<,@?_8#@*_V)!#O]B3!/_8%@8_U]H'?]=
M=B+_6X,F_UF/*?]8FBS_5J,N_U6L,/]5LS'_5+LS_U/$-/]3SC7_4MXV_U+I
M-_]1\3?_4?8X^U#[./=/_SCT3_\W\5#_-?!0_S3P4/\T\%#_-/!0_S3P4/\T
M\%#_-/]4(P/_4"T$_UDM!?]?, ?_8S8*_V9 #O]F2A/_9549_V-E'O]A<R/_
M7H H_UR,+/];ER__6:$Q_UBI-/]7L#7_5K@W_U7!./]5RSG_5-HZ_U3G._]3
M\#S[4O8]]E'[/?)1_SWO4O\[[%+_..M2_SCK4O\XZU+_..M2_SCK4O\XZU+_
M./]5(P/_4BL$_UPK!?]C+@?_9S0*_VH^#O]K2!/_:E,9_VAA'_]F<"7_8WTJ
M_V"(+_]>DS/_7)TV_UNE./]:K3K_6+4\_U>]/O]7QS__5M-!_%7D0OE5[D/U
M5/9$\%/\1.Q4_T'I5?\_YE7_/.55_SOE5?\[Y57_.^55_SOE5?\[Y57_._]6
M(@/_52D$_U\H!?]G*P;_;#()_V\\#?]P1A/_<% 9_VY=(/]K:R?_:'DM_V6$
M,O]BCS?_8)D[_EZA/OU<J4'[6[%#^EFY1?E8PD?W5\Y(]5;@2O%6[$ON5?9,
MZ5;\2N57_T;B6/]#WEG_0-U9_S_=6?\_W5G_/]U9_S_=6?\_W5G_/_]7(@/_
M62<$_V,F!/]K* ;_<3 (_W0Y#?]U0Q/_=4T9_W59(?]Q9RG_;70P_6J -OIF
MBCSX8Y1 ]F&<1/1>I$CR7*Q+\5NT3>]9O5#M6,E2ZU?:4^=6Z57D5_54X5G]
M3]M:_TO56_](T%S_1,]<_T3/7/]$SUS_1,]<_T3/7/]$SUS_1/]8(@/_7"0#
M_V8C!/]O)@7_=BX(_WHW#/][01+_>TL9_WM5(?YW8RKY<V\R]FY[.O)JA4'O
M9H]'[&.73.I@GU#H7:=4Y5NO5^-9N%KA5\-=WU?27MI6YE[66?-:TES\5<U>
M_U#)7O],Q5__2<1?_TC$7_](Q%__2,1?_TC$7_](Q%__2/]9(0+_7R(#_VHA
M!/]T) 7_>RP'_W\U"_^!/A'_@D@9_8)2(?=^7ROR>6LU[7-U/NEN@$;E:8E-
MX6615-YAF5G:7Z)<UEVJ7]-<LV'06[YBSEO,8\M:XF/(7/%@QE_Z6L%@_E6]
M8?]1NF+_3;EB_TNY8O]+N6+_2[EB_TNY8O]+N6+_2_]9(0+_8B #_VX? _]X
M(P3_?RL&_X0S"O^'/!#^B$47]XA.(?"$6ROJ?F8VY'AP0=]R>DO9;8-2TVF,
M6,]FE5S,9)U?R6*E8L9@KF3#7[AFP5[$9[]>V&B\7^MFNF/W7[9D^UFS9?Y5
ML&7_4*]E_T^O9?]/KV7_3Z]E_T^O9?]/KV7_3_]:( +_91X#_W$< _]\(@/_
MA"D%_XDQ"?^,.@[YCD,6\8Y,(.J*6"OCA&(WVWYL0]-X=DS-<W]3R&^'6<1K
MD%[ :9ABO6:@9;IEJ&BW8[)JM6*^:[-BSFRP8N5KKV;T9*QG^%VI:/Q8IVG_
M4Z9I_U*F:?]2IFG_4J9I_U*F:?]2IFG_4O];( +_9QP"_W0: O]_( /_B"<$
M_XXO!_V2-PSTE$ 4[)5)'N2052K;BE\WT81I0\I]<DS$>'M4OW2#6KIQBU^V
M;I-DLVN;9Z]II&JM9ZULJF:X;JAFQV^E9M]OI6KQ:*)K]F&@;/E;GFS]5IYL
M_E6>;/Y5GFS^59YL_E6>;/Y5GFS^5?]<'P+_:AH"_W<9 O^#'P/_C"4$_Y(M
M!OF7-0OOF3X2YYM&'-Z64BG2D%PWRHEF0L.#;TR\?G=4MWE_6[)UAV"N<H]E
MJG"7:*9MGVRC;*ENH&NT<)YJPG&<:M=QG&[N:YIO\V29;_A>EW#\6)=P_5>7
M</U7EW#]5Y=P_5>7</U7EW#]5_]>'@+_;!D"_WH8 O^&'0+_CR,#_Y8K!?6;
M,PGKGSL0XJ!%&=>;4"C,E%HVQ(UC0KR(;$RU@G14L'Y\6ZMZA&"F=XMEHG23
M:9YRG&V;<*5PF&^P<I5NO7.3;]!SE'+K;I-S\F:2<_9@D'/Z6I!S^UF0<_M9
MD'/[69!S^UF0<_M9D'/[6?]?'0+_;A<"_WT7 O^)' +_DB("_9HI!/&@, ?G
MI#D-WJ5#%]&?3B?'F%@UOI)A0;:,:4NOAW%4J8)Y6Z1_@&"??(AEFWF0:I=V
MF6V3=:)QD'.L<XUSNG2+<\MUC';G<(QW\&B+=_5BBG?Y7(IW^EJ*=_I:BG?Z
M6HIW^EJ*=_I:BG?Z6O]A&P+_<18"_W\6 ?^+&@'_E2 "^9XF ^VD+@7CJ38*
MV*E %LRC3";"G%8TN99?0+&09TJJBV]3I(=V6IZ#?F"9@(5EE'V-:I![EFZ,
M>9]QB7BJ=(9WMG6$=\=VA7KD<H9[[VJ%>_1DA7OX785[^5R%>_E<A7OY7(5[
M^5R%>_E<A7OY7/]C&@+_<Q0!_X$5 ?^.&0'_F1X!]J$C NJI*@3@KS('TJP^
M%<>F2R2]H%4SM)I>/ZR594JED&U2GHQT69B(>V"3A8-ECH*+:HJ DVZ&?IUQ
M@GVG=']\M'9]?,5V?7[@<W]_[FM_?_-E?W[W7G]^^%U_?OA=?W[X77]^^%U_
M?OA=?W[X7?]E& +_=1,!_X04 ?^1%P'_G!L!\J4@ >:N)@+;M"X&SJ\]%,.J
M22.YI%,QKYY</J>99$F@E&M1F9!R69.->5^.BH!DB8>(:82%D6Z @YIQ?(*E
M='F!LG9W@<)V=H+=='F$[6QY@_)F>H+W7WJ"^%YZ@OA>>H+X7GJ"^%YZ@OA>
M>H+X7O]G%P+_=Q$!_X<3 ?^4%0#^GQ@ [JH< >*S(0'5MRH%R;,[$[ZN2"*T
MJ%(PJZ-:/:*>8D>;F6E0E)5P6(Z2=UZ(CWYD@XV&:7Z+CVUYB9AQ=H>C<W*&
MKW5PAK]V;X?7=7.)[6USB/)F=(?V8'2']U]TA_=?=(?W7W2']U]TA_=?=(?W
M7_]I%0'_>A !_XH1 /^7$@#YHQ0 ZJX5 -VY%P#/NB@$Q+<Y$;FR1B"OK% O
MIJ=8.YVC8$:5GV=/CIMN5HB8=5V"E7QC?9.$:'B1C&QSCY9P;XZ@<FR-K71J
MC;UU:8W2=6R0[6UMCO%G;HSV8&Z,]U]NC/=?;HSW7VZ,]U]NC/=?;HSW7_]L
M$P'_?0\!_XT0 /^;$ #TJ \ Y;4- -6_$ #*OB8#O[LW$+2V1!ZJL4XMH:U7
M.9BI7D20I65-B:)L58*?<UM\G'IA=YJ!9G*8BFIMEI1N:96><6:4JW-CE+IS
M8I7/<V:7[&QGE?%F:)/V8&B2]U]HDO=?:)+W7VB2]U]HDO=?:)+W7_]O$0'_
M@0X _Y$. /*@# #:K0D T[@* ,[##@#$PB,#N;\U#J^[0ARDMTPJF[-5-Y*O
M7$&*K&-*@ZEJ4GRF<5EVI'A><*)_8VN@B&=GGI%K8YV=;E^=J7!=G;EP7)W-
M<%^?ZVMAG?)E8IKV8&*9]UYBF?=>8IGW7F*9]UYBF?=>8IGW7O]S$ '_A0P
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M3DK*_TU*RO]-2LK_34K*_TU*RO]-2LK_3>>/  #1GP  PZL! +>T @"MOP,
MH\L& )O9"@"4Y1H!C>4K!H3D-0U[XS\6<^)('FSA4B9FX5HL8.!B,EO@:C97
MX'(Z4]][/5#?A4!-WX]#2N";14C@J$9&X+A'1>',1T7@Z$=%W_9&1=[_1$7>
M_T1%WO]$1=[_1$7>_T1%WO]$1=[_1-F7  #'I@  N+   *RY 0"BQ0( F-$&
M (_K#0")[A\"@.XK!GCM- QP[3T3:.U&&6+M3AY=[5<C6>U@)U7M:"I2[7$M
M3^UY+TSM@S)*[HTT1^Z8-47NI3=#[[,X0O#$.$'PWSE![^\X0.W].$#L_SA
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M:6^&ZV-RA_E<<X;]5G.%_U)SA?]2<X7_4G.%_U)SA?]2<X7_4O]H$0'_> T
M_X8- /:3# #>H D UJD* -*R#0#'LB("O:\S"K.K01>JITPDH:)5,)F>73J2
MFF1"BY=K2864<E" DGE5>X^!6G:-B5YRC))B;HJ=96N)J6=HB;AH9XG+:&F+
MZ6-LC?E<;8S]5VV*_U)MBO]2;8K_4FV*_U)MBO]2;8K_4O]K$ '_>PL _XH*
M .*8!@#6HP@ T*P) ,NU"P#!MA\!N+0Q":ZP/Q:DK$HBG*A3+I2D6SB,H&)
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M5%NA_U!;H?]06Z'_4%NA_U!;H?]06Z'_4/]W!P#PB0  UI@  ,ND P#!K00
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M.4/8_SE#V/\Y0]C_.="6  #!HP  LJP  *>U  "<P   D<H# (?6!P" Z1$
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M7']S[%:!=OM/@WC_2H-X_T6">/]$@GC_1()X_T2">/]$@GC_1/]?$0'_;0P
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M36R*_TALB?]';(G_1VR)_T=LB?]';(G_1_]I"P#_> 0 Y8<  -:2 P#-G 4
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M0E*I_T)2J?]"4JG_0O)\  #7C   R)D  +VC  "RJP  J;(  *"[ @"7Q D
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M"AW_HPH<_[$*&__ "QK_U@L:_]\+&O_?"QK_WPL:_]\+&O_?"YNQ  "-O
M?L<  '#2  !CW@  5>0  $OU  !&_P4 0/\. #O_%  W_QL!,_\C 2__*0(K
M_S "*/\U B7_.P,B_T$#'_]' QW_3@,:_U4$&/]>!!7_: 43_W0%$?^"!1#_
MD 80_YT&#_^I!@[_M08._[H&#O^Z!@[_N@8._[H&#O^Z!HZZ  !_Q0  <-$
M &+>  !4Y0  1NL  #_^   Y_P  -/\) "__#@ K_Q0 )_\: 2/_(0$?_R4!
M'/\J 1G_+P$6_S0"%/\Z A'_0 (0_T8"#O]. @S_5@()_V #!_]L P3_> ,#
M_X8# O^1 P'_G0,!_Z$# ?^A P'_H0,!_Z$# ?^A _\V+0+_.2X"_SXN _]
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M3)%C[T>29?U!DF?_/)-I_SB3:O\UDVK_-9-J_S63:O\UDVK_-?]7$0'_8PT
M_VX, /]W#@#_?P\ \(41 ..)%@#6BR,!RX@U!L*$0Q"Z@$\:LWM9(ZUW8BJH
M=&HQHW%Q-I]N>3N<;($_F&J(0I5ID4629YI(CV:C2HUEKTR*9;U-B6713HEG
M[$J*:?M#BVO_/HQM_SJ,;O\WC&[_-XQN_S>,;O\WC&[_-_]9$ #_90L _W$+
M /]Z"P#Q@@P Z(D- -V.#@#/CR !QHTR!KV)00^UA$T9KH!6(J=\7RJB>&<P
MG75O-IES=CJ5<7T_DF^%0HYMCD:+;)9)B&J@2X5JK$V#:;I/@6G,3X%JZ$R#
M;?E%A&__/X5P_SN&<?\XAG'_.(9Q_SB&<?\XAG'_./];#P#_9P@ _W,( /-]
M" #>A@< V8P) -61"P#*DAX P9 P!;B-/PZPB$H8J814(:* 72F=?64PF'IL
M-9-W<SJ/=7L^C'."0HARBT:%<)1)@F^>3']NJ4Y\;;=/>VW)4'INYDU\<?A&
M?G/_07]T_SV =?\Z@'7_.H!U_SJ =?\Z@'7_.O]=#@#_:@8 _W8& .2  P#9
MB08 TH\( ,^4"@#%EAL O)0N!+.1/0VKC4@7I(A2()Z%6RB8@6,ODWYJ-8Y\
M<3F*>G@]AGB 0H-VB$5_=9%)?'.;3'ERITYV<K50='+&4'1RXT]V=?9'>'?_
M0GIX_SY[>?\Z>WG_.GMY_SI[>?\Z>WG_.O]?# #_; 0 ]7D" -Z# @#3BP4
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M/&.,_SQCC/\\8XS_//]J  #F>@  U88  ,F1  # F0$ N)\! +"E  "HJ0X
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M&C;AS1HVW^P:-=[Y&C3=_QLTW/\;--S_&S3<_QLTW/\;--S_&[F<  "JI
MGJL  )*U  "%O@  ><<  &W/  !BU@, 6.$( %7J$P!1ZR  3>LK 4GK-0)%
M[#X$0NQ'!3_L3P<][5@).NU@"CCM:@PV[G0-,^Z #C+NC@\P[YT0+N^M$2WP
MP!$M\-X1+.[Q$2SL_A$LZ_\0+.O_$"SK_Q LZ_\0+.O_$*VB  "@J0  D[,
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M PG_M0,(_\(#"/_" PC_P@,(_\(#"/_" XJX  ![PP  ;,X  %[;  !/X@
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M-ZI2]#.I5/\NJ%;_*ZA7_RBH5_\EJ%?_):A7_R6H5_\EJ%?_)?]-$P#_5@X
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M-8=G_S&':/\NAVG_+8=I_RV':?\MAVG_+?]7# #_800 _FP# .1U 0#;>P4
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M,7%X_S%Q>/\Q<7C_,?]? @#W;   WG<  -"!  #'B $ P(T# +F1 P"RDQ$
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M+T.MR"]"K.<O0ZOY+42K_RM$JO\I1*K_*42J_RE$JO\I1*K_*=&   #!C0
MM9@  *F?  ">I0  DZP  (BR  !]N   <;X& &Z_%0!JOR8!9K\S V&^/P==
MOD@+6;U1#U6]61-1O& 73KQH&DN[<1U(NWL?1;J'(D*ZE"1 NJ(F/KJS)CVZ
MR"8]NN@F/;CY)3VW_R0]MO\C/;;_(SVV_R,]MO\C/;;_(\>(  "YE0  K)T
M *&D  "6JP  BK(  '^Y  !SOP$ :,8% &#*#@!>RAT 6\HL 5?*. -4RD,%
M4,I,"$W)50M*R5T.1\EF$43);Q1!R7D6/\B%&#S(DQHZR*(;.<FS'#C)R1PX
MR.@<-\?Y'#?%_QPVQ/\<-L3_'#;$_QPVQ/\<-L3_'+Z1  "PFP  I*,  )BJ
M  ",L@  @+D  '3   !HQP  7<T% %/3"@!/UQ( 3=@B $O8, !)V#P"1MA&
M T393P1!V5@&/]EA"#S9:PHZV78,-]F"#C7:D \TVJ 0,MJQ$3';QQ$QVN<1
M,-CV$C#6_Q,OU/\3+]3_$R_4_Q,OU/\3+]3_$[.:  "FH0  FJD  (VQ  "
MN@  =,$  &C)  !<SP  4M4# $C<" !%Y1( 0^4> $'F*@ ^YC4!.^<^ 3GG
M1P(WYU #-.A9!#+H8@4PZ&T&+NEY!RSIAP@KZI8)*>JG"BCJN@HGZ]8*)^GP
M"B?G_0DFYO\*)N;_"B;F_PHFYO\*)N;_"JB@  "<IP  C[   (*Y  !TP@
M:,H  %O1  !/UP  1=T  #[N"0 \\A$ .?,; #;S)0 T]"X ,?0W 2[U/P$L
M]4<!*?9/ B?V5P(E]V$#(_=L R'X>@0?^(D$'OF:!1SYJP4;^L %&OK>!1KY
M\@4:]_T%&?;_!1GV_P49]O\%&?;_!9ZF  "1KP  @[D  '7"  !GRP  6M,
M $W:  !"WP  ..4  #7[!P Q_P\ +O\6 "O_'P I_R8 )?\M "/_-  @_SL!
M'O]# 1O_2P$9_U,!%O]= A3_:@(2_W@"$?^( A#_F@(0_ZL##O^^ P[_U0,.
M_^T##O_P P[_\ ,.__ ##O_P Y.N  "$N   =L(  &?,  !:U0  3-P  #_A
M   UY@  +?0  "K_ @ F_PL (_\1 "#_%P =_QT &?\C !;_*0 4_R\ $O\U
M !#_/0 ._T4!#/]. 0K_6 $'_V4!!?]T 0/_A0$"_Y8! ?^F 0#_M0$ _\8!
M /_* 0#_R@$ _\H! /_* 8:W  !WP0  :,P  %K7  !+W@  /N0  #+I   G
M[0  (_\  !__   ;_P4 %_\, !3_$  1_Q0 #_\8  W_'0 +_R( "/\H  7_
M+@ "_S4  /\]  #_1P  _U(  /]>  #_;0  _WX! /^. 0#_FP$ _ZD! /^K
M 0#_JP$ _ZL! /^K ?\J+0'_+BL!_S K ?\P+@+_+C4"_RD] _\E203_(U<$
M_R%D!?\?<@;_'7\&_QV*!O\=E ;_'9P'_QRC!_\<J@?_'+$'_QRX!O\<OP;_
M',D&_QS6!O\=Y0;_'>\&_QWY!?\=_P7_'?\%_QW_!?\=_P7_'?\%_QW_!?\=
M_P7_'?\%_QW_!?\L*P'_,"@!_S,H ?\S*P+_,3$"_RTZ _\K1P3_*%0%_R9A
M!?\D;P;_(GP'_R*'!_\BD0?_(9D'_R&A"/\AIPC_(:X(_R&U"/\AO C_(<8'
M_R'1!_\AX@?_(NT'_R+W!_\B_P;](O\&_"+_!OPB_P;\(O\&^R+_!OLB_P;[
M(O\&^R+_!O\N* '_,R4!_S8E ?\W)P'_-2T"_S0X _\R1 3_+U$%_RQ>!O\J
M:P?_*7<'_RB#"/\GC0C_)Y8)_R>="?\GI G_)ZL)_R>R"?\GN0G_)\()_R?-
M"?\GW@G_)^L)_"?V"/DH_@CW*/\(]BC_"/4H_PCU*/\(]2C_"/4H_PCU*/\(
M]2C_"/\R)0'_-R(!_SHA ?\[(P'_.RD"_SLT O\Y0 3_-DT%_S1:!O\Q9@?_
M,',(_RY_"?\NB0K_+I(*_RV9"_\MH0O_+:<+_RVN"_\MM0S_+;X,_BW)#/LM
MV0SX+>@+]"[T"_$N_@OO+O\+[B[_"^TN_POL+O\*["[_"NPN_PKL+O\*["[_
M"O\U(@'_.QX!_S\= ?] 'P'_0B8!_T(Q O] / /_/D@%_SM5!O\Y8@C_-VX*
M_S9Y"_\UA S]-(T-_#25#?HTG [Y,Z,.]S.J#_8SL@_U,[H/\S/%#_(ST@_N
M,^4/ZC3R#^<T_0_E-/\/Y#3_#N(U_P[B-?\-X37_#>$U_PWA-?\-X37_#?\Y
M'@'_/QH!_T,8 ?]&&@'_22,!_TDM O](. /_140%_T-0!_] 70G[/FD+^#UT
M#?4\?P[S.X@/\3N0$.\ZF!'M.I\2[#FF$^HYKA/I.;84YSG!%.8YSA7B.>,5
MWCGQ%=LZ_!38.O\3U3O_$M,[_Q+2._\1TCO_$-([_Q#2._\0TCO_$/\]&P'_
M0Q8 _T@4 /],%P'_3Q\!_U H ?]/,P+_33\$^TI*!O5'5PGQ1F0,[41O#NE#
M>1'G0H,3Y$&+%.) DQ;@/YL7WS^B&-T^JAG;/K,:V#Z]&M8^RAO2/M\;SC[O
M&\L_^QK)0/\8QT#_%\9!_Q7%0?\4Q$'_%,1!_Q3$0?\4Q$'_%/]!%P#_1Q(
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M)IE6_R.95O\AF5?_'YE7_Q^95_\?F5?_'_]-#0#_508 _UT% /MD!P#O:0D
MZ6L, .%L$ #3;1X R6PQ L)J0 >[9TP-M617$[!A8!FL7VD=J%UQ(:5<>"2B
M6H GH%F'*IU8D"R;5Y@NF5:B,)95K#*45;DSDU7*,Y%5Y3.15_<MD5G_*9%:
M_R616_\CD5O_(9%;_R&16_\AD5O_(?]/"P#_5P( _V$" .IH 0#>;00 V' (
M -5P"P#+<AL PG$N KIO/0:T;$D-KFE4$ZEG71FD9&4=H6)M(9UA="6:7WPH
MF%Z#*Y5=BRV26Y0PD%N>,HU:J#2+6;4UBEG&-HA9X3:(7/0PB%W_*XE>_RB)
M7_\EB5__(XE?_R.)7_\CB5__(_]1"0#_6@  ]60  .!L  #7<0, T'0& ,UU
M"0#$=A< O'8J ;1T.@6N<48,IVY1$J)K6AB>:6(=FF=I(99E<2639'@HD&*
M*XUAB"Z+8)$QB%^:,X9>I36#7K(W@E["-X!>W#B 7_(S@6'_+8)B_RF"8_\F
M@F3_)8)D_R6"9/\E@F3_)?]3!@#_70  YV<  -MO  #0= ( RG@% ,9Y!P"^
M>A4 MGHH :]X-P6H=D0+HG-.$IQP5QB8;5\=E&MG(9!J;B6-:'4HBF=]*X=E
MA2Z$9(XQ@6.7-']BHC9\8J\X>F*^.7EBU3EY8^\T>F7^+WMF_RM\9_\H?&?_
M)GQG_R9\9_\F?&?_)O]5 P#_8   XVH  -5R  #,> $ Q7L# ,!]!0"Y?A(
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M-%&(PS50B.(T4HCV,%.(_RQ4B/\I58C_*%6(_RA5B/\H58C_*.9K  #0>
MPH,  +>,  "MD@  HY8  )J:  ".G@  AY\0 (.?( !^GR\">)T[!W.<10QN
MFTT1:9E5%F687!IAEV,>7I9J(5N5<B57E'PH5).&*U&2DBY.DJ P3)*O,4N2
MPC%*D> Q3)'U+4V1_RI.D/\H3I#_)DZ0_R9.D/\F3I#_)MYP  #)?0  O(D
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M'#FR_QPYL?\;.;#_&SFP_QLYL/\;.;#_&\&&  "TDP  IYH  )R@  "1IP
MA:T  'FS  !MN   8KT! %;"!P!3PQ0 4L,C %#$, %-Q#L"2L1% T?$3@5%
MQ%<'0L-?"4##: L]PW(-.\-^#SC#C!$VPYL2-<.K$S/#P!,SP^ 3,\'U$S+
M_Q0RO_\4,;[_%#&^_Q0QOO\4,;[_%+B0  "KF0  GZ   ).G  "'K@  >[0
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M A+P_P(2\/\"$O#_ IJD  "-K0  ?[8  '&_  !CQP  5LX  $G3   ]V@
M,]\  "KC   F] 4 )/L- "'\$P >_1L '/TB !G^*0 7_C$ %?\Y !/_00 1
M_TH $/]5  [_80 ,_V\!#/^  0K_DP$)_Z8!"/^Z 0?_U $'_^L!!O_V 0;_
M]@$&__8!!O_V 8^L  " M@  <K\  &/)  !6T0  2-@  #O=   PX@  )N8
M !_P   <_P  &?\) !;_#@ 4_Q, $?\9  __'@ -_R0 "_\K  G_,@ &_SL
M _]$  #_3P  _UP  /]K  #_?0  _Y   /^C  #_M   _\8  /_6  #_U@
M_]8  /_6 (*U  !SOP  9,D  %;3  !'VP  .N   "[E   CZ0  &NT  !7]
M   2_P  $/\"  [_"0 +_PT "/\0  3_$P !_Q@  /\>  #_)   _RL  /\S
M  #_/0  _TD  /]6  #_9@  _W@  /^*  #_FP  _Z@  /^Q  #_L0  _[$
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M)@'_+B,!_R\B ?\O)0'_+"L!_RHU O\G00+_)$X#_R); _\@: 3_'G0$_QV
M!/\=B@3_'9(%_QV:!?\=H07_':<%_QVM!?\=M 3_';T$_QW'!/\=U 3^'>8$
M^QWR!/<>^P/U'O\$]![_!/,>_P3S'O\$\A[_!/(>_P3R'O\$\A[_!/\N(@'_
M,A\!_S0> ?\S( '_,B8!_S(R ?\O/@+_+$H#_RI7 _\G9 3_)G %_R5[!?\D
MA07_)(X&_R26!O\DG0;_)*,&_R2J!OTDL0;\)+D&^R3#!ODDSP;V).,&\B3P
M!>XE^@7M)?\&ZR7_!NHE_P;I)?\&Z27_!NDE_P;I)?\&Z27_!O\R'@'_-AL
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M3A8 _T\? /U.*0'T3#0![$A! N9'3@3@15L&VT1F"=9"< S207D.ST""$,U
MBA'*/Y$3R3^9%,<^H!7%/J@6PSZQ%\$^O!? /LL8O3[B&+H^\A>W/_\6M4#_
M%+1 _Q.S0?\1LT'_$+-!_Q"S0?\0LT'_$/] $ #_1@P _TL* /]1#0#_4Q$
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M&HM6_QJ+5O\:BU;_&O],! #_4P  [%P  -]B  #49@$ SF@% ,MG" #"9Q8
MNF@H ;-G. .M944'J&-0#*-A61&?7V$5FUUH&)A<<!N56G<>DUE_(9!8AR..
M5X\EC%>9)XE6HRF'5J\JA56_*X16U2R#5^\I@UC^)(-9_R"$6O\>A%K_'(1:
M_QR$6O\<A%K_'/]. 0#_5P  Y5\  -AF  #.:@  QVP# ,-K!0"\;!( M&TE
M *UL-0.G:D('H6=-#)QE5A&88UX5E&)E&)%@;!N.7W0>C%Y[(8E=@R2&7(PF
MA%N5*(%:H"I_6JPL?5J[+7Q:SRY[6^PK?%S\)GQ=_R)]7O\??5[_'7U>_QU]
M7O\=?5[_'?]0  #U60  X6,  -)J  #);@  PG ! +UP P"V<!  KG$B *AP
M,@*A;C\&G&Q*"Y=J4Q"2:%L4CF9B&(ME:1N(8W >A6)X(8)A@"2 8(DF?5^2
M*7M>G2MX7JDM=EZX+G5>S"]T7NDM=6#Z)W9A_R-W8O\@=V+_'G=B_QYW8O\>
M=V+_'O]2  #L7   W&8  ,YM  #$<@  O70  +=T 0"P= X J74? *)T+P*<
M<CT%EW!'"I%N40^-;%D4B6I@%X5I9QN":&X>?V9U(7UE?21Z9(8G=V.0*75C
MFRQR8J<N<&*V+V]BR2]N8N8N;V3Y*'!E_R1Q9O\A<6;_'W%F_Q]Q9O\?<6;_
M'_]4  #H7P  UVD  ,IP  # =0  N7@  +)X  "K> T I'D= )YX+0&7=SH%
MDG5%"HQR3@Z(<%83A&]>%X!M9!I];&L=>FMS('=J>R-T:8,F<FB-*6]GF2QL
M9J4N:F:S+VEFQC!H9N0O:FCW*6MI_R5L:?\B;&K_(&QJ_R!L:O\@;&K_(/]7
M  #D8@  TFP  ,9S  "]>   M7L  *U\  "E? H GWT: )E\*@&3>S@$C7E#
M"8AW3 Z#=502?W-;%GMR8AEX<&D==6]P(')N>"-O;8$F;&R+*6ILERQG:Z,N
M96NR+V1KQ#!B:^$O9&SV*F9M_R9F;?\C9V[_(&=N_R!G;O\@9V[_(/99  #@
M90  SF\  ,)V  "Y?   L7\  *F   "@@ < F8$7 )2!* &.@#4#B'Y!"(-\
M2@U^>E(1>GA9%79W8!ES=F<<<'1N'VUS=B-J<G\F9W&)*61QE2MB<*$M8'"P
M+UYPPB]=<-\O7W'U*F!Q_R9A<O\C8G+_(&)R_R!B<O\@8G+_(.]<  #<:0
MRG(  +YZ  "U@   K80  *2%  ":A0, E(44 (Z&)0&)A#,#@X,^!WZ!2 MY
M?U 0=7Y7%'%]7AAN>V4;:WIL'FAY=")E>'TE8G>'*%]VDRI<=I\L6G6N+EEU
MP"Y8==TN67;S*EMV_R9<=_\C7'?_(%QW_R!<=_\@7'?_(.I@  #5;   Q78
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M)$B,_R))B_\@2HO_'DJ+_QY*B_\>2HO_'M5N  ##>P  MX4  *R-  "BD@
MEY8  (R9  !_G   =9X% '"?$P!MGR, :9\P 66>.P1AGD4'79U-"EJ<5 U7
MFUP15)IC%%&::Q=.F7092YA_'$B8BQY%EYD@0Y>H(4*7NB)!E],B09;O($*5
M_AY"E?\=0Y3_'$.4_QQ#E/\<0Y3_',QU  "\@0  L8P  *:2  ";EP  D9L
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M#BRX_PXLN/\.++C_#K./  "FEP  FYT  (^C  "#J@  =K   &JU  !>N@
M4KX  $?" 0 ]QP8 .,D0 #?)&P VRB< -<HS #3+/0 SRT< ,<M1 3#+6P$N
MS&4"+,QQ BK,?P,IS) $)\RA!";-M 0ES<X$)<ON!"3)_ 8CR/\'(\?_!R/'
M_P<CQ_\'(\?_!ZF6  ">G0  DJ,  (6K  !XL@  :[@  %^^  !2P@  1\8
M #W*   TSP0 *]0) ";9#P EV1D )=HE "3:,  CVSL (]M% "+<4  AW5L
M(-UH ![>=@ =WH<!'-^9 1K?K $9W\0!&-[G 1C<^ $8V_\"%]K_ A?:_P(7
MVO\"%]K_ J"<  "4HP  AZL  'FS  !LN@  7\$  %+&  !&R@  .\X  #'3
M   IV0  (=X% ![H#@ =Z!4 &^D> !GI)P 8ZC  %NHY !7K0P 4[$X $NQ:
M !'M9P 0[G< $.Z*  [OG@ .\+, #?#-  SO[  ,[?P #.O_  SK_P ,Z_\
M#.O_ )>C  ")JP  >[0  &V\  !?Q   4LH  $7.   YTP  +]@  "7=   =
MX0  &.P" !;W"P 4]Q$ $?@7 !#X'@ .^24 #?DM  OZ-0 )^S\ !_M*  3\
M5P #_68  OYW  #]BP  _9\  /RU  #\T0  _.T  /S\  #\_0  _/T  /S]
M (NK  !]M   ;KT  &#&  !2S0  1-(  #?8   LW0  (N$  !GE   3Z@
M$/H   [_!@ -_PP "O\0  ?_%  $_QH  ?\@  #_)P  _S   /\Z  #_10
M_U,  /]B  #_=0  _XH  /^?  #_LP  _\<  /_E  #_Y0  _^4  /_E '^T
M  !PO0  8<<  %/0  !#U@  -MT  "KB   ?Y@  %NH  !#M   ,^@  "?\
M  ;_   "_P0  /\)  #_#0  _Q   /\4  #_&@  _R$  /\I  #_-   _T
M /].  #_7@  _W(  /^'  #_F@  _ZH  /^Y  #_N0  _[D  /^Y /\@*0'_
M(B<!_R(G ?\?*@'_&3 !_Q(Y ?\010'_#5,!_PQ@ ?\*;0+_"7D"_PF$ O\)
MC@'_"98!_PF= ?\)HP'_":D!_PFP ?\(MP'_"+X!_PC( ?\(U@'_".8!_PCQ
M ?\(^P#_"/\ _PC_ /\)_P'_"?\!_PG_ ?\)_P'_"?\!_PG_ ?\C)@'_)20
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M!-DD_P38)/\$UR3_!-8D_P36)/\$UB3_!/\Q%@#_-!( _S81 /\W$P#_.1L
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M#J)!_PZB0?\.HD'_#O\_"0#_1   _TH  /=. @#L4 8 ZD\+ .-,$ #63!X
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M)6M>P29I7MXF:E_T(6M@_QUK8?\;;&'_&6QA_QAL8?\8;&'_&/51  #B7
MSV4  ,-K  "Y;P  L7$  *IQ  "B;P@ FV\7 )9P)P"0;S4"BVY !89L20B"
M:E(,?FE9#WMH8!)W9F84=69N%W)E=AIP9'X=;6.('VMCDR)I8J D9F*N)65B
MOR9D8MHF9&/R(F5D_QYF9/\;9V3_&6=E_QAG9?\89V7_&/!3  #=7P  RV@
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M(E9Q_AY7<?\<5W'_&EAQ_QE8<?\96''_&>->  #-:0  OW,  +1Z  "K?P
MHH(  )B#  "+@0  A($- '^"&@![@BD!=H$V G*!0 5N?TD(:GY0"V=]5PYD
M?%X187MF%%YZ;1=;>G8967F '%9XBQ]3>)@A47>F(E!WMR-/=\XC3W?L(5!W
M_1Y1=_\;4G?_&5)W_QE2=_\94G?_&=YB  #(;@  NW<  +!_  "GA   G8<
M )*'  "$AP  ?8<) 'B(%@!TB"8 <(@R FR'/01HAD8&985."6&%50Q>A%P/
M6X-C$EF":Q56@7074X!^&E" B1Q.?Y8>3'^E($I_MB%)?\PA27[K'TI^_!Q+
M?O\:2W[_&4Q^_QA,?O\83'[_&-5G  ##<P  MGP  *R$  "BB0  F(L  (V-
M  !\C0  =8X$ &^/$@!MD"$ :9 N 66/.0)BCD($7HY+!UN-4@I8C%D,5HMA
M#U.+:!)0BG$438E[%TJ)AQE(B)4;1HBC'42(M!U#B,H=0X?J'$2&^QI$AO\8
M18;_%T6%_Q=%A?\7187_%\UM  "]>   L8(  *>*  "<C@  DI   (:3  !Y
ME0  ;)<  &:7#@!CF!L 89@I %Z8-0%:ESX#5Y='!5663P=2EE8)3Y5>#$R4
M9@Y*E&\01Y-Y$T23A15"DI,70)*B&#Z2LQD]DLD9/9'I&#V0^A<^C_\6/H__
M%3Z/_Q4^C_\5/H__%<5S  "W?P  K(D  *&/  "6DP  BY8  '^9  !SG
M9)\  %R@"0!9H!0 5Z$B %6A+P!2H3D!4*%# DV@2P1*H%,%2*!:!T6?8PE#
MGVP+0)YV#CZ>@Q [GI$1.9V@$CB=LA,WGL@3-YWH$C:;^A(VFO\2-IG_$3>9
M_Q$WF?\1-YG_$;Y[  "QAP  I8\  )N4  "0F   A)P  '>@  !KI   7Z<
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M!*64  ":F@  CJ$  (&G  !SK@  9[0  %JY  !.O0  0L   #C#   OQP
M)LL$ ![0"@ ;T1$ &M(: !G2)0 8TR\ &-,Z !?41  6U%  %=5= !35:P 3
MUGP $M>/ !'8I  0V;L $-G> !#5\P 0T_\ $-+_ 1#1_P$0T?\!$-'_ 9R:
M  "1H0  @Z@  '6P  !HMP  6[T  $[!  !"Q0  -\@  "W,   DT   '-4
M !7:!0 0X@L $.,1  [D&@ .Y", #>4M  SE-P +YD( "N9/  GG70 (YVT
M!N:   7FE0 $YJL  N;$  'FY@  Y_D  .?_  #F_P  YO\  .;_ ).A  "%
MJ0  =[$  &FY  !;P   3L8  $'*   US@  *M(  "'6   9VP  $M\   WC
M   +\0@ "?,.  ?S$P $\AH  O(B  #R*@  \C0  /(_  #R3   \EP  /)M
M  #R@@  \I@  /.M  #SQ@  ].4  /3V  #T^P  ]/L  /3[ (>I  !YL@
M:KH  %S"  !.R0  0,X  #/3   HV   'MT  !7A   /Y   "N@   7S   #
M_0$  /P(  #[#0  ^Q$  /L6  #\'@  _"8  /PP  #]/   _DD  /Y:  #^
M;0  _X(  /^8  #_K   _\   /_8  #_Y   _^0  /_D 'NR  !LNP  7<0
M $_-  ! T@  ,MD  ";>   ;X@  $N8   SJ   %[0   /0   #_    _P
M /\   #_!   _PD  /\.  #_$@  _Q@  /\A  #_*P  _S<  /]&  #_6
M_VL  /^   #_E0  _Z8  /^S  #_NP  _[L  /^[ /\;)@#_'"0 _QHD /\5
M)P#_$"T _PHV /\%0P#_ 5 !_P!> ?\ :P'_ '8!_P"! /\ B@#_ )( _P":
M /\ H #_ *8 _P"L /\ L@#_ +D _P#" /\ S0#_ -\ _P#L /\ ^ #_ /\
M_0#_ /T _P#] /\ _0#_ /T _P#] /\ _0#_ /\?(P#_'R$ _QXA /\9(P#_
M$RD _PXR /\,0 #_"4T!_P=: ?\$9P'_ W,!_P-] ?\#AP'_ X\ _P*6 /\"
MG #_ J( _P*H /\"KP#_ ;8 _P&^ /\!R0#_ =L _P#J /P ]@#X /\ ]P+_
M /<#_P#V!/\ ]@3_ /8%_P#V!?\ ]@7_ /\B'P#_(AP _R$< /\>'P#_&"0
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M \$D_P/!)/\#P23_ _\P#P#_,@L _S,( /\V#0#_-A( _S4: /TR)0#T,#(
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M0ZP4CT.Z%8U#S16+1.@5BD7Z$HE&_Q")1O\.B$;_#8A&_PV(1O\-B$;_#?]
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M&7I-PQIY3=\:>$[T%WA/_Q1X3_\2>%#_$'A0_P]X4/\/>%#_#_U&  #G3P
MUE<  ,A<  "_7P  MU\  +%<  "J60P I%H: )Y;*@"96S@!E%I# Y!93 6,
M6%4(B5=<"H968PR#56H.@51Q$']3>1)]4X$4>E*+%GA2E1AV4:$9=%&O&W-1
MP!MQ4=L<<5+R&7%3_Q5Q5/\3<E3_$7)4_Q!R5/\0<E3_$/-(  #C4P  T%L
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M&V!?_1AA7_\585__$V)?_Q)B7_\28E__$NI1  #47   Q&0  +EJ  "P;@
MIW   )YN  "4:P  C6H0 (=K'@"#:RP ?FLX GIJ0@-V:4H&<VA2"'!G60IM
M9F -:V5G#VAD;A%F9'<49&.!%F%CC!A?8I@:76*F'%MBMAU:8LP=6F+J'%MC
M_!A<8_\67&/_%%UC_Q-=8_\376/_$^95  #/7P  P6@  +9N  "L<@  I'0
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M$TUR_Q)-<O\237+_$M1@  #":P  M70  *M[  "B?P  EX$  (R!  !Z?@
M<W\" &Y_$0!K@!X :( L &6 -P%B@$ #7W](!%Q^4 99?E<(5WU>"U1\9@U1
M?&X/3WMX$4Q[@Q1*>I$62'J?%T9ZKQA%>L081'KD&$5Y^!9&>?\41GC_$D=X
M_Q%'>/\11WC_$<UE  "]<   L7D  *>   "<A   DH8  (:&  !WA@  :X8
M &:'#0!CAQD 8(@G %Z(,P%;B#P"6(=% U:'3013AE0&4(9;"$Z%8PI+A&P,
M281V#T:#@1%$@X\30H.=%$""KA4_@\(5/H+B%3^!]Q,_@?\20(#_$4" _Q!
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M"[AZ  "LA0  H8L  ):0  "+E   ?Y<  '*;  !FG0  6J   $ZB  !%I D
M0J03 $"D'P _I"H /J4T #RE/@ [I4<!.:5/ 3>E6 (UI6$",Z5L S&E>00O
MI(<%+:27!BRDJ08KI+T&*J3>!BJB]0<IH?\'*:#_""F?_P@IG_\(*9__"+&"
M  "EBP  FI$  )"6  "#F@  =I\  &JB  !>I@  4JD  $:K   \K0  -:\,
M #.P%0 RL"$ ,; K "^P-0 NL3X +;%( "RQ40 KL5L *;%G 2>Q= $FL8,!
M)+&4 B.QI@(BLKL"(;+; B&O\P,@KO\#(*W_!!^L_P0?K/\$'ZS_!*J+  "=
MD0  DY<  (><  !ZH@  ;:<  &"K  !5KP  2;$  #ZT   SMP  *KH# "2\
M#0 BO14 (;T@ "&]*@ @O3, '[X] !Z^1P =OE( '+]> !J_;  9OWP &+^.
M !? H0 6P+8 %,#3 !6^\0 5O/\!%;O_ 12Z_P(4NO\"%+K_ J&2  "6F
MBIX  'VD  !OJ@  8J\  %:T  !*MP  /KH  #.]   JP   (<0  !G'!0 3
MRPL $<P2 !',&P 0S"4 #\TO  [-.@ .S48 #<U2  W.8  ,SG  "\Z#  K.
MEP )SJP ",[&  C.Z  (S?L "<O_  G+_P )R_\ "<O_ )B8  "-G@  ?Z4
M '&L  !DLP  5[D  $J]   ^P   ,L,  "C&   ?R@  %\T  !'1   ,U@4
M"-D,  ;9$@ %VAL !-HD  /;+@ !VSD  -Q%  #=4@  WF(  -YS  #>B
MWYT  -^S  #?S@  X.X  -_Z  #?_P  W_\  -__ (^?  "!I@  <ZX  &6U
M  !8O0  2L(  #W%   QR0  )LP  !W0   4U   #MD   G=   #X0   .,'
M  #C#0  Y!(  .49  #F(@  YRL  .DV  #K0P  [%(  .QB  #M=@  [HP
M .ZA  #OMP  []$  ._K  #P]@  \/8  /#V (2G  !UKP  9[<  %F_  !+
MQ@  /,H  "_.   DT@  &M@  !+<   ,X   !>,   #G    ZP   .L   #M
M!0  [@L  / 0  #Q%0  \QX  /0G  #W,P  ^4   /I1  #[8P  _'<  /V-
M  #]HP  _K8  /[)  #_WP  _]\  /_? '>P  !HN0  6L$  $S*   \SP
M+M0  "+:   7W@  $.(   GF    Z0   .P   #P    ]@   /8   #W
M^    /H'  #[#0  _1$  /\9  #_(P  _R\  /\^  #_3P  _V(  /]W  #_
MC0  _Y\  /^N  #_N@  _[H  /^Z /\6(P#_%2$ _Q(A /\.) #_!BH _P S
M /\ 00#_ $X _P!< /\ : #_ '0 _P!^ /\ AP#_ (\ _P"6 /\ G #_ *(
M_P"H /\ K@#_ +4 _P"] /\ QP#_ -8 _P#G /X \P#^ /X _0#_ /P _P#[
M /\ ^P#_ /L _P#[ /\ ^P#_ /\:( #_&1X _Q8> /\0( #_"B4 _P0P /\
M/0#_ $L _P!8 /\ 9 #_ '  _P!Z /\ @P#_ (L _P"2 /\ F #_ )X _P"D
M /\ J@#_ +$ _0"Y /L PP#Z -  ^ #C /< \0#V /P ] #_ /0 _P#S /\
M\P#_ /, _P#S /\ \P#_ /\=' #_'!D _QD9 /\4&P#_#B$ _PPL /\).0#_
M!48 _P)3 /\ 7P#_ &L _P!U /\ ?@#_ (8 _P". /\ E #^ )L _ "A /H
MIP#X *X ]0"U /, OP#Q ,L \ #? .X [@#L /D ZP#_ .H _P#J ?\ Z0'_
M .D!_P#I ?\ Z0'_ /\@%P#_'Q0 _QP3 /\7%0#_%AT _Q,H /\0- #_#4$
M_PQ. /\)6@#_"&8 _PAP /X'>0#\!X$ ^@>) /@'D #V!I8 \P:= /$&HP#O
M!JH [0:R .H&NP#H_^+__TE#0U]04D]&24Q%  @)!L@ Y@;< .0&[ #B"/H
MX K_ -X+_P#="_\ W0S_ -P,_P#<#/\ W S_ /\C$@#_(Q  _R$. /\>$ #_
M'A@ _QPC /\8+P#_%#L _Q)) /P050#X#V  ] ]J /$/= #O#GP [0Z$ .L.
MBP#I#I( YPZ9 .8.H #D#J< X@ZO . .N #>#L4 W [: -80[ #2$?H SQ+_
M ,T2_P',$O\!RQ/_ <H3_P'*$O\!RA+_ ?\G#P#_)PP _R4) /\F#0#_)1,
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M!I8T_P66-/\%EC3_!?\U  #_.   ZCX  -]"  #50@  SS\# ,TX" #%.!4
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M"O)"  #@3   SE,  ,%8  "X6@  L%D  *E6  "B4@< FU(5 )93) "14S(
MC5,^ 8E21P*&45 $@U%7!8!07@9^3V4(>T]L"7E.<PMW3GL-=4V%#G--D!!Q
M39P2;TVI$VY-N11L3<X4;$WK$VQ._1!L3_\.;$__#&Q/_PML3_\+;$__"^Y%
M  #<4   R5<  +U<  "T7@  K%X  *1;  "<5@0 E582 )!7(0"+6"\ AU<[
M 8-61 )_5DT#?%54!7I46P9W5&((=5-H"7-3< MQ4G@-;U*"#VU1C1%K49D2
M:5&F%&=1MA5F4<L595+I%&52^Q%F4_\/9E/_#693_PQF4_\,9E/_#.I)  #5
M4P  Q5H  +I?  "P8@  J&(  )]?  "66@  CUH0 (I;'@"%6RP @5LX 7U;
M00)Z6DH#=UE1!'186 9Q6%\';U=F"6U7;0MK5G8-:59_#V=5BA%E59<38U6D
M%&%5M!5@5<@67U7G%6!6^A)@5O\/85?_#F%7_PUA5_\,85?_#.=,  #15@
MP5X  +9C  "M9@  I&8  )MD  "07@  B5X. (1?&P" 7RD ?%\U 7A?/P)T
M7D<#<5U/!&]<5@5L7%P':EMC"6A;:PMF6G,-9%I]#V):B!%?69037EFB%%Q9
MLA5;6<866EGE%5M:^1);6O\07%K_#EQ:_PU<6O\-7%K_#>-/  #-60  OF$
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M%$MG]1),9_\/3&?_#DUG_PU-9_\-36?_#=):  # 9   LVP  *ER  "@=@
MEG<  (IV  !Y<0  <7$  &MQ#P!H<1P 9G(H &-R- !@<CT!7G)% EMQ30-9
M<50%5W!;!E1P8PA2;VL*4&]T#$UN@ Y+;HT026Z;$4=MJQ)&;KX316[<$D9M
M]!%&;?\/1VW_#D=L_PU';/\-1VS_#<Q?  "\:0  L'$  *5W  "<>P  D7P
M (9[  !U>   :W<  &5W# !A>!< 7W@D %UY, !:>3H!6'E" E9X2@)3>%$$
M47=8!4]W8 =,=F@(2G9R"DAU?0Q%=8H.0W69#T)UJ1! =;P00'79$$!T\P]
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M"3.#_PDS@_\),X/_";EP  "M>@  HH(  )>'  "-B@  @8P  '6.  !HCP
M6I   $^1  !'D@H 1)(3 $.3'P!!DRH 0),T #^3/0 ]DT4 .Y-- 3J35@$X
MDU\"-I-I S23=0,RDH,$,)*3!2Z2I 8MDK<&+)+1!BR1[P8KC_\&*X[_!BN-
M_P<KC?\'*XW_![-X  "G@@  G(@  )&,  "'D   >I,  &V5  !AEP  59D
M $F;   _G $ .9T. #>=%P VGB( -)XL #.>-0 RGCX ,9Y' #"?4  NGUH
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M )R0  "2E0  AIL  'F@  !KI@  7JL  %*O  !&L@  .K4  "^W   EN@
M';T  !7    0PP8 "\8.  K%%0 )Q1X ",4H  ?%,@ &QCT !<9)  7&5P #
MQF8  L9W  '&BP  QJ   ,6V  #&T@  Q>\  ,7\  #%_P  Q?\  ,7_ )66
M  ")G   >Z,  &VI  !@KP  4[0  $:X   ZNP  +KX  "3!   ;Q   $\<
M  [*   (S@$  = *  #0$   T!8  -$>  #2)P  TS$  -0\  #520  UE@
M -9I  #6?   UI(  -:G  #6OP  UN   -;S  #6_@  UO\  -;_ (R=  !^
MI   ;ZL  &&R  !4N0  1KT  #G!   MQ   (L<  !G+   1S@  #-(   75
M    VP   -P#  #="@  W@\  -\4  #A'   XB0  .0N  #F.@  YTD  .A9
M  #H:P  Z8$  .F8  #IK0  Z<4  .GB  #I\@  Z?4  .GU ("E  !QK0
M8[4  %6\  !'P@  .<8  "S*   @S@  %M(   _6   (VP   -\   #C
MY0   .<   #H 0  Z@<  .L-  #M$0  [Q@  /$A  #S*P  ]C@  /=(  #X
M6@  ^6T  /J$  #ZFP  ^J\  /K"  #ZV@  ^M\  /K? '2N  !EM@  5KX
M $C&   YRP  *]   !_4   4V@  #=\   7C    Y@   .D   #M    [P
M /$   #S    ]0   /8"  #X"0  ^@X  /T3  #_'   _R@  /\V  #_1P
M_UH  /]N  #_A0  _YH  /^K  #_N0  _[P  /^\ /\1( #_$!X _PP> /\$
M(0#_ "< _P P /\ /@#_ $P _P!9 /\ 90#_ '  _P!Z /\ @P#_ (L _P"2
M /\ F #_ )X _P"D /\ J@#_ +  _P"X /\ P@#_ ,X _P#B /X \ #] /L
M^P#_ /L _P#[ /\ ^@#_ /H _P#Z /\ ^@#_ /\4' #_$AH _PX: /\(' #_
M "$ _P M /\ .@#_ $@ _P!5 /\ 80#_ &P _P!V /\ ?P#_ (< _P". /\
ME #_ )H _@"@ /T I@#\ *P ^P"T /D O0#X ,D ]P#< /4 [ #S /@ \P#_
M /( _P#Q /\ \ #_ /  _P#P /\ \ #_ /\7& #_%18 _Q$5 /\,%P#_!1T
M_P H /\ -@#_ $, _P!0 /\ 7 #_ &< _P!Q /\ >@#\ (( ^@") /@ D #W
M )8 ]0"< /0 H@#S *@ \0"P /  N #N ,, [ #3 .H YP#I /4 YP#_ .8
M_P#E /\ Y0#_ .4 _P#E /\ Y0#_ /\:$P#_&!$ _Q00 /\/$0#_#1D _PHD
M /\%, #_ 3X _P!+ /\ 5P#^ &( ^@!L /4 =0#R 'T \ "$ .X BP#L )$
MZP"7 .D G@#G *0 Y@"L .0 M #B +\ X #- -X XP#< /( V@#] -@ _P#6
M /\ U0'_ -4!_P#5 O\ U0+_ /\>$ #_' T _Q<+ /\5#@#_%!4 _Q$? /\.
M*@#_"S@ _0A% /@&40#T!%P [@1F .H$;P#F W< Y 1_ .($A@#@!(P W@23
M -T%F@#;!:  V 6H -4%L0#2!;L T ;) ,X'X #,"/$ R0K_ ,<+_P#&#/\
MQ0S_ ,4,_P#%#/\ Q0S_ /\A# #_( 8 _QP# /\="@#_&Q  _Q@8 /\4(P#V
M$3  [PX^ .H.2@#E#58 X0U@ -T-:0#9#7$ U0UY -,-@0#1#8@ SPV/ ,T.
ME@#+#IT R@ZE ,@.K@#&#[D Q!#( ,(0WP"^$?( NQ+_ +D3_P"W$_\!MA/_
M ;83_P&V$_\!MA/_ ?\E!@#_(P  _R,  /\D P#_(0H _1T1 /$:&P#H%B<
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M!/PS  #K.@  W$$  ,U$  ##1   O4$  +@[ 0"R-PX JS@< *4Y*P"A.C@
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M"W!#M0QN1,D,;43G#&U%^@IL1?\(;$7_!VQ%_P=L1?\';$7_!^P_  #820
MQU   +M4  "Q50  J50  *%0  "92@( DDD1 (U*'P")2RP A4PX ()+0@%_
M2TH!?$I2 GE*6 -W2E\$=4EF!7-);09Q278';TA_"&U(B@EL2)8+:DBC#&A(
ML@UG2,4-9DGD#69)^ MF2?\)9DK_"&9)_P=F2?\'9DG_!^A#  #230  PE,
M +=8  "M60  I%@  )Q5  "33@  C$X. (=/&P""3RD ?U U 'M0/P%X3T<!
M=D]/ G-.50-Q3EP$;TUC!6U-:@9K37(':4U\"&=,APIE3),+8TR@#6),KPYA
M3<(.8$WA#F!-]@Q@3O\*8$[_"6!._PA@3O\(8$[_".-'  #-4   OE<  +-;
M  "J70  H5T  )A:  "-4P  AE(, (!3& !\4R4 >50Q '54/ !S4T0!<%-,
M FU24P)K4ED#:5)@!&=1: 9E47 '8U%Y"&%1A I@4)$,7E">#5Q0K0Y;4< .
M6E'>#UI1]0Q:4O\*6U+_"5M1_PA;4?\(6U'_"-]*  #)4P  NUH  +!?  "F
M80  G6$  )1>  "(5P  @%8* 'I7%0!V5R( <U@N '!7.0!M5T$!:E=) FA6
M4 )F5E<#9%9>!&)5905@56T'7E5W"%Q5@@I:58X,656<#5=5JPY65;X/557;
M#U55\PU55?\+5E7_"595_PE65?\(5E7_"-M-  #%5P  N%X  *UB  "C90
MFF4  )!C  "#7   >UL& '5;$@!Q6Q\ ;EPK &M<-@!H6S\!95M' 6-;3@)A
M6E4#7UI<!%U:8P5;6FL&65EU"%=9@ I568P+5%F:#5)9J@Y16;P.4%G8#E!9
M\@U16?\+45G_"E%9_PE16?\(45G_"-11  #"6@  M&$  *IF  "@:   EVD
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M"4%G_PA"9_\(0F?_",5=  "V9@  JFT  *!S  "6=@  BW<  (!V  !P<@
M97$  %QP!P!8<!$ 5G = %1Q* !2<3, 4'$\ $]R1 %-<4L!2W%3 DEQ6@-'
M<6($17!L!4-P=P9!<(0'/W"3"#UOHPD[<+4*.W#-"CIO[ D[;OX(.V[_"#MM
M_P<[;?\'.VW_![]B  "Q:P  IG,  )UY  "2>P  AWP  'M\  !M>@  8'@
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M ZUV  "C@   EX4  (V)  ""C   =HX  &F0  !<D@  4),  $24   ZE0
M,98( "V7$0 LEQH *Y<D "J7+0 IES8 *)@_ ">82  FF%( )9A< ".8:  B
MF'< ()B' !^8F0$=F*P!')C# 1R7Y0$<E?H!&Y3_ 1N3_P(;D_\"&Y/_ J=_
M  "<A@  D8L  (>/  !ZD@  ;94  &&8  !5FP  29T  #V>   SGP  *J$
M "&C"@ ?HQ$ 'J,: !VD)  <I"T &Z0V !JD/P 9I$H &*15 !:E80 5I7
M%*6! !.EE  2I:@ $:6_ !"DX@ 1HO@ $:'_ !&@_P$1H/\!$:#_ :"&  "5
MC   C)$  '^5  !QF@  9)X  %BA  !,I   0*8  #6G   JJ0  (JP  !FN
M   2L D $+$0 !"Q&  .L2( #K$K  VQ-0 -L4  #+%+  NQ6  *L6< "+%X
M  >QBP %L:  !+"U  2PT  $L.\ !:_^  :N_P &KO\ !J[_ )B.  "/DP
M@I@  '6=  !GH@  6J<  $ZK  !!K0  -:\  "NQ   AM   &+8  !&Y   -
MO , ![X,  .]$@ !O1D  +XB  "^*P  OC8  +Y!  "_3@  OUP  +]M  "_
M@   OI4  +ZJ  "^P@  O>0  +WV  "]_P  O?\  +W_ )*4  "%F@  >*
M &JF  !<JP  3[   $*S   UM@  *K@  ""[   7O@  $,$   O$   $QP
M ,D'  #)#0  R1(  ,H9  #+(@  RRL  ,TU  #.00  SE   ,]@  #/<@
MSX<  ,^=  #/LP  S\X  ,_K  #.^   SOX  ,[^ (B;  !ZH@  ;*@  %ZO
M  !0M0  0KD  #6\   IOP  'L(  !7&   .R0  ",P   #0    TP   -4
M  #6!@  V P  -D1  #;%@  W!\  -XH  #@-   XD$  .)1  #C8P  XW<
M .2.  #DI   Y+H  .74  #EZ@  Y?,  .7S 'RC  !NJ@  8+(  %&Y  !#
MO@  -<(  "C&   <R0  $\T   S1   $U0   -H   #>    X0   .(   #D
M    Y0,  .<)  #I#@  ZQ(  .T:  #O)   \C$  /1!  #T4P  ]68  /5\
M  #VDP  ]JD  />\  #WS@  ]]\  /?? '"L  !AM   4[L  $7#   VQP
M)\P  !O0   1U0  "ML   #?    X@   .4   #I    [    .T   #P
M\0   /,   #U!   ]PH  /H0  #\%@  _R$  /\N  #_0   _U,  /]H  #_
M@   _Y8  /^H  #_M@  _[\  /^_ /\-' #_"AL _P(; /\ '@#_ "0 _P N
M /\ / #_ $H _P!6 /\ 8P#_ &T _P!W /\ ?P#_ (< _P". /\ E #_ )H
M_P"@ /\ I@#_ *P _P"T /\ O0#_ ,D _@#= /T [0#\ /H ^P#_ /H _P#Y
M /\ ^@#_ /H _P#Z /\ ^@#_ /\0&0#_#1< _P86 /\ & #_ !X _P J /\
M-P#_ $4 _P!2 /\ 7@#_ &D _P!R /\ >P#_ (( _P") /\ D #^ )8 _0"<
M /P H0#[ *@ ^0"O /@ N #V ,, ] #2 /, YP#R /8 \ #_ .\ _P#P /\
M[P#_ .\ _P#N /\ [@#_ /\2% #_#Q( _PL2 /\ $@#_ !H _P E /\ ,P#_
M $  _P!- /\ 60#_ &0 _0!M /L =@#Y 'T ]P"$ /4 BP#T )$ \P"7 /$
MG0#P *, [@"J .P LP#J +T Z #+ .< X0#E /$ XP#] ., _P#B /\ X0#_
M .$ _P#@ /\ X #_ /\4$ #_$0X _PT- /\'#P#_ A4 _P @ /\ +0#_ #H
M_P!' /D 4P#U %X \@!H /  < #M '@ ZP!_ .D A0#H (P Y@"2 .4 F #C
M )\ X0"F -\ K@#< +@ V@#% -8 V0#4 .P T@#Y -$ _P#/ /\ S@#_ ,X
M_P#. /\ S@#_ /\7# #_% @ _P\% /\."P#_#!$ _P<: /\!)@#\ #0 ] !!
M .T 30#I %@ Y@!B ., :@#@ '( W@!Y -L @ #9 (8 U@"- -, DP#1 )H
MSP"A ,T J@#+ +, R0"_ ,8 T #% .@ PP#V ,$ _P#  O\ OP/_ +\#_P"_
M _\ OP/_ /\;!@#_%P  _Q0  /\3!0#_$0T _PX4 /D*'P#P!BP Y@,Y . #
M1@#< U$ U@1; -($9 #/!6P S 5S ,H%>@#(!8$ Q@6' ,4&C@##!I8 P0:=
M +\&I@"]!K  NP>\ +D(S0"X"N4 M0OW +,-_P"Q#?\ L W_ + ._P"O#O\
MKP[_ /\>  #_&P  _QL  /H:  #U%@4 ]A$- .L.%0#B"R( V LQ - ,/@#+
M#4H QPU5 ,0.7@#!#F8 OPYM +T.= "[#WL N0^" +<0B@"V$)$ M!": +(0
MHP"P$:T KQ&Z *T1R@"J$N4 IQ3W *45_P"C%?\ HA7_ *(5_P"B%?\ HA7_
M /\B  #_(   \",  .8D  #@(0  W!D% -L0# #0$1D R!,I ,(5-P"]%D0
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M H8LN@*%+<X#@R[J X$N_ . +O\"?R[_ G\N_P)^+O\"?B[_ O0N  #D-P
MTCT  ,4_  "[/P  M#P  *\U  "I+PL HR\7 )XQ)@"9,C, EC(^ )(S2 "0
M,U  C3-8 (LS7@&),V4!AS-L 88S<P&$,WP"@C.% H SCP-_,YH#?3.G WPS
MM01Z,\D$>33F!'<U^01V-?\#=37_ W4U_P-U-?\#=37_ _ S  #=/0  RD,
M +Y%  "U1@  K4,  *8]  "@-@8 F383 )0X(0"0.2X C#DY (DY0P"'.4P
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M"&!$\P=@1/\&7T3_!5]$_P1@1/\$8$3_!.!!  #*2@  NU   +!3  "G50
MGE,  )5/  "+20  @T<+ 'U'%0!Y1R( =D@N '-(. !Q2$$ ;DA) 6Q(4 %J
M2%8!:$A= F9'9 )E1VP#8T=V!&%'@ 5@1XT&7D>:!UQ'J0A;2+L(6DC4"%I(
M\0=:2?\&6DG_!5I(_P5:2/\$6DC_!-M$  #&30  N%,  *U7  "C60  FE@
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M!DM4_P5+5/\%2U3_!<Q.  "[5P  KEX  *1B  ":9   D60  (9B  !W6P
M;5@  &98# !B6!8 7U@B %U9+ !;638 65D^ %=91@!664T!5%E4 5)96P)1
M66,#3UEL TU9=P1+6(0%25B2!TA8H@='6;,(1EG*"$59Z@A&6?T&1EC_!D98
M_P5'6/\%1UC_!<=2  "X6P  JV$  *%F  "8:   CFD  (-G  !R8   :%X
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M!+E@  "L:0  H7   )AU  "-=P  @G<  '=W  !I=   7',  %%Q  !(< H
M17 2 $-Q'0!"<2< 0'(P #]R.  ^<D  /7)( #MR4  Z<ED!.')C 39R;0(T
M<GH",W*) S%RF@,O<JP#+G+! RYRXP,N<?@#+G#_ RYO_P,N;_\#+F__ [-F
M  "G;P  G78  )-Z  "(?   ?GT  ')]  !D?   5WL  $QZ  !">0, /'D.
M #IZ%P Y>B$ .'HJ #=[,P V>SL -'M$ #-[3  R>U4 ,'M? "][:@$M>W<!
M*WN' 2I[F (H>ZH")WN_ B9[X0(F>O<")GC_ B9X_P(G=_\")W?_ JYL  "C
M=@  F7P  (Y_  "$@@  >(,  &R$  !?A   480  $>$   \A   ,X0) #"$
M$0 OA!H +80D "R%+0 KA34 *H4^ "F%1P HAE  )X9: ":&9@ DAG, (X:#
M "&&E0 @AJ<!'H:\ 1Z&W@ >A/4!'H+_ 1Z"_P$>@?\!'H'_ :AT  ">?0
MDX(  (F%  !^B   <8H  &6+  !8C   3(T  $".   VC@  +(\  "60#  C
MD!, (I < "&0)0 @D2X 'Y$V !Z10  =D4D ')%4 !J18  9D6X &)%^ !:2
MD  5DJ0 %)&Y !.1V  3C_0 %([_ !2-_P 4C/\!%(S_ :-]  "8@P  CH@
M (2,  !WCP  :9$  %V3  !0E0  19<  #F8   NF0  )9H  !V; @ 6G0P
M%9T3 !2=&P 3G20 $ITM !&>-P 1GD$ $)Y,  ^>6  .GF< #9YW  R>B@ +
MG9X "IVR  F=S  )G.P "IO^  N:_P +F?\ "YG_ )R$  "1B@  B(X  'N2
M  !ME@  8)D  %2<  !(GP  /*   #"A   FHP  ':4  !6G   0J04 "ZL-
M  BJ$P 'JAL !JHD  6J+@ $JC@  JI$  &J4   JEX  *IN  "J@0  JI4
M *FJ  "IP0  J.0  *CV  "G_P  I_\  *?_ )6+  ",D   ?Y4  '&:  !C
MG@  5J(  $JF   ]J   ,:H  ":K   =K0  %+    ZR   )M0$  K8*  "V
M#P  MA4  +<=  "W)0  MR\  +@Y  "X1@  N%0  +AD  "X=@  N(L  +>@
M  "WM@  M],  +;O  "V_   MO\  +;_ (^2  ""EP  =)T  &:B  !8IP
M2ZP  #ZO   QL0  )K,  !RV   3N   #;L   :^    P0   ,($  #""P
MPQ   ,05  #$'   Q20  ,8N  #(.@  R4<  ,E7  #):0  R7T  ,F4  #(
MJ@  R,,  ,CD  #(]   R/T  ,C] (69  !WGP  :*8  %JK  !-L0  /[4
M #&X   EN@  &KT  !'    +PP   \<   #*    S0   ,X   #/ P  T D
M -$.  #3$@  U1D  -<B  #:+0  W3D  -Y)  #>6@  WVX  -^%  #?G
MW[(  -[+  #>Y@  W_0  -_T 'FA  !KJ   7*\  $ZU  ! NP  ,;X  "3!
M   9Q0  $,@   G,    SP   -,   #9    W    -T   #?    X0   .(%
M  #D"P  YA   .@6  #J(   [2L  / Z  #Q2P  \5X  /)S  #SBP  \Z(
M /.V  #SR0  \^$  //A &VJ  !>L0  4+D  $&_   RQ   ),@  !?,   .
MT   !M4   #:    W@   .(   #F    Z0   .H   #L    [@   /    #R
M    ] 8  /8,  #Y$@  _!P  /\I  #_.@  _TT  /]B  #_>   _Y   /^C
M  #_LP  _\$  /_! /\'&0#_ 1< _P 7 /\ &@#_ "$ _P K /\ .0#_ $<
M_P!4 /\ 7P#_ &H _P!S /\ >P#_ (, _P"* /\ D #_ )8 _P"; /\ H0#_
M *@ _P"O /\ N #_ ,0 _@#5 /P Z@#[ /@ ^@#_ /D _P#X /\ ^ #_ /8
M_P#S /\ \0#_ /\+%0#_!1, _P 3 /\ % #_ !H _P G /\ - #_ $( _P!/
M /\ 6P#_ &4 _P!N /\ =@#_ 'X _P"% /X BP#] )$ ^P"7 /H G0#X *,
M]P"K /8 LP#T +X \P#, /$ XP#O /, [@#_ .T _P#L /\ ZP#_ .P _P#L
M /\ ZP#_ /\-$0#_"1  _P / /\ $ #_ !8 _P B /\ +P#_ #T _P!* /\
M50#] &  ^@!I /@ <0#V 'D ] !_ /, A@#Q (P [P"2 .X F #L )\ ZP"F
M .D K@#G +@ Y0#% ., V@#A .T WP#[ -X _P#= /\ W0#_ -T _P#= /\
MW0#_ /\/#0#_# L _P,) /\ # #_ !( _P = /\ *0#[ #< ^ !$ /4 4 #R
M %H [@!C .P :P#I ', YP!Z .4 @ #C (8 X0", -\ DP#= )D VP"A -D
MJ0#5 +( T@"^ -  S@#. .8 S #V ,H _P#* /\ R0#_ ,@ _P#( /\ R #_
M /\1" #_#0( _P<  /\%" #_  X _P 6 /< (@#O #  ZP ] .@ 20#D %0
MX != -T 90#9 &T U0!S -( >@#0 (  S@"' ,P C0#* )0 R "; ,8 I #$
M *T P@"X ,  QP"] -\ O #Q +L _@"Y /\ N #_ +@ _P"X /\ N #_ /\4
M  #_#P  _PT  /\,  #_!PD ^ $0 .@ &@#C "@ W0 V -@ 0@#2 $T S@!7
M ,H 7P#' &8 Q0!M ,, = #! 'H OP"! +T B "[ (\ N0"7 +< GP"U *@
MLP"S +$ P@"O -@ K@+M *P#^P"K!?\ J@;_ *D&_P"I!O\ J0;_ /\6  #_
M$@  ]Q(  .P1  #F#@  Y08( -T#$@#4 R  S00M ,@$.@##!48 OP50 +P&
M6 "Y!F  MP=G +4';@"S!W4 L0A[ *\(@@"N"8H K F2 *H)FP"H"J4 I@JP
M *4+OP"C#-0 H0WM )\._@"=#O\ G __ )L/_P";#_\ FP__ /\:  #W&0
MZAX  -\>  #5&@  T!," ,X,"P#'"Q8 P TE +H.,@"V#C\ L@]) *\04@"L
M$%H JA!A *@1: "F$6\ I!%V *(1?0"A$84 GQ*. )T2EP"<$J( FA.M )@3
MO "7%-  E!7L )(6_0"0%_\ CQ?_ (X7_P".%_\ CA?_ /H=  #N(P  WR@
M - J  #')P  P2$  +T9!0"Y$A  LA4> *T6+ "H%S@ I!A# *$93 "?&50
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M G$N] )P+_\";R__ F\O_P%N+_\!;B__ >@Q  #3.@  PS\  +=!  "N00
MICX  )XX  "7,0$ D2X0 (PO' "(,"@ A#$S ($R/0!_,D8 ?3)- 'LR5 !Y
M,EL =S)A '4R:0%T,G !<C)Y 7 SA %O,Y ";3.= FPSJP)J-+P":335 V@U
M\0)G-?\"9S7_ F8U_P)F-?\"9C3_ N(V  #,/P  O40  +)'  "H1P  H$0
M )@_  "0.0  B#0- (,U%P!_-B0 ?#<O 'DW.0!W.$( =#A) '(X4 !Q.%<
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M U1#_P-40_\"5$/_ M!"  "_2@  LE   *=3  "=5   E%,  (I0  !_2@
M=44" &Y##@!K1!D 9T4D &5%+@!B13< 844_ %]%1@!=14T 6T54 %I&6P%9
M1F,!5T9L E9&=P)41H,#4T:1 U%&H0101[$$3T?'!$Y'YP1.1_L$3D?_ TY'
M_P-/1_\#3T?_ \Q&  "[3@  KU0  *17  ":6   D5<  (94  ![3@  <$H
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M \!0  "R6   IEX  )QB  "290  B&4  'UB  !N7   8UD  %E6 P!45@X
M4588 $]6(@!-5RP 3%<T $I7/ !)6$0 2%A+ $=84P!%6%L!1%AD 4)8;@%
M6'L"/UB) CU8F0,\6*H#.UF_ SI9X ,Z6/<#.EC_ SM7_P,[5_\#.U?_ [Q4
M  "N7   HV,  )EG  "0:0  A6D  'EG  !K8@  8&   %5=  !.6PP 2UL4
M $E<'P!'7"@ 1ETQ $5=.0!#74$ 0EU( $%>4 ! 7E@ /EYA 3Q>; $[7G@"
M.5Z' C=>EP(V7JD#-5Z] S1?W0,T7O4#-5W_ C5=_P(U7/\"-5S_ KA9  "J
M80  H&<  )9L  ",;@  @6X  '9L  !G:0  7&8  %%D  !(8@D 1&(1 $)B
M&P!!8R0 /V,M #YC-0 ]9#T /&1% #MD30 Y9%4 .&1? #9D:0$U9'8!,V2%
M 3%EE0(P9:<"+V6[ BYEV@(N9/0"+F/_ B]C_P(O8O\"+V+_ K->  "G9@
MG&T  )-Q  "(<P  ?7,  ')R  !D<   6&X  $UL  !":@, /&D. #IJ%@ Y
M:B  .&HH #9K,0 U:SD -&M! #-L20 R;%( ,6Q< "]L9@ N;', +&R" 2IL
MDP$I;*4!*&RY 2=MU@$G:_(!)VK_ 2=J_P$H:?\"*&G_ JYD  "C;   F7,
M (YV  "$>   >7D  &UX  !@=P  4W8  $AU   ^<P  -'(* #%S$0 P<QH
M+W,C "YS*P M=#0 +'0\ "MT1  I=$T *'57 "=U8P E=6\ )'5_ ")UD  A
M=:( ('6W !]UT@ ?=/$ 'W/_ 1]R_P$@<?\!(''_ :EK  "><P  E'D  (I\
M  " ?@  ='\  &=_  !:?P  37X  $-^   X?0  +WT" "A]#0 F?10 )'T<
M "-^)0 B?BT (7XV "%^/P ??T@ 'G]2 !U_7@ <?VL &G]Z !E_C  7?Y\
M%G^S !5_S@ 5?N\ %GS_ !9[_P 6>_\ %WO_ *1R  ":>@  CW\  (6"  ![
MA   ;88  &"'  !4AP  2(@  #R(   RB   *(@  ""(!0 :B0X &8D5 !B)
M'0 7BB8 %HHN !6*-P 4BD$ $XI, !*+6  1BV4 $(MU  ^+AP .BIL #8JO
M  R*R  ,B>H #8?\  Z'_P .AO\ #H;_ )][  "4@0  BH4  ("(  !SBP
M98T  %F/  !,D   09(  #22   JD@  (9,  !F4   2E@8 #I<.  V7%0 ,
MEQT #)<F  N7+P *ESD "9=$  B74  &EUX !9=N  .6@  !EI0  )6H  "5
MO@  E.   )3T  "3_P !DO\  9+_ )B"  ".B   A8P  '>/  !JD@  794
M %"8  !$F@  .)L  "R<   BG0  &9X  !*@   -H@( !Z,+  &C$   HQ<
M *,?  "C)P  HS$  *0\  "D2   I%8  *1E  "C=P  HXL  *.@  "BM@
MH=(  *'P  "@^P  H/\  *#_ )&*  ")C@  >Y(  &V7  !@FP  4YX  $:A
M   YHP  +:0  ".F   9J   $:H   RL   %K@   *\'  "O#0  KQ$  + 8
M  "P(   L2@  +$R  "R/@  LDP  +);  "R;   LH$  +&7  "QK   L,8
M +#H  "O]P  K_\  *__ (R0  !_E0  <9H  &.?  !5I   1Z@  #JJ   M
MK   (JX  !BP   0LP  "K4   *X    NP   +L   "\!P  O T  +T1  "^
M%@  OQX  , G  #!,@  PD   ,-/  ##8   PW0  ,.+  ##H0  P[@  ,+7
M  #"[P  POH  ,'^ (&7  !SG0  9:,  %>H  !)K0  .[$  "VS   AM@
M%KD   Z[   'O@   ,$   #%    QP   ,@   #)    R@4  ,L+  #-#P
MSA0  - <  #3)@  UC(  -A!  #84P  V68  -E\  #9E   V:L  -G#  #9
MX0  V?   -GT ':?  !GI@  6:P  $NR   \MP  +KH  "&]   5P   #<0
M  7'    R@   ,X   #2    U0   -8   #9    VP   -T   #?!P  X0P
M .,1  #F&0  Z20  .PR  #M0P  [E8  .]K  #OA   [YP  .^R  #OQ@
M[]T  ._D &JH  !;KP  3+8  #Z\   OP   (,0  !3(   ,S    M    #4
M    V0   -X   #B    Y0   .8   #H    Z0   .P   #N    \ (  /()
M  #U#P  ^!<  /PC  #_,P  _T8  /]:  #_<0  _XD  /^?  #_L0  _\
M /_& /\ %0#_ !0 _P 4 /\ %P#_ !T _P H /\ -P#_ $0 _P!1 /\ 7 #_
M &8 _P!O /\ =P#_ 'X _P"% /\ BP#_ )$ _P"7 /\ G0#_ *0 _P"K /\
MM #^ +\ _0#. /L Y@#Y /8 ^ #_ /< _P#W /\ ]P#_ /  _P#L /\ Z0#_
M /\#$@#_ !  _P 0 /\ $0#_ !< _P D /\ ,@#_ #\ _P!, /\ 5P#_ &$
M_P!J /\ <@#_ 'D _0"  /P A@#Z (P ^0"2 /@ F #V )\ ]0"F /0 K@#R
M +D \ #& .X W@#M /  ZP#^ .H _P#I /\ Z0#_ .< _P#C /\ X #_ /\'
M#@#_  T _P + /\ # #_ !, _P ? /\ + #_ #H _P!& /X 4@#[ %P ^ !E
M /4 ; #S '0 \0!Z .\ @0#N (< [ "- .H DP#I )H YP"A .8 J0#C +,
MX0"_ -\ T #= .D V@#Y -D _P#7 /\ U0#_ -4 _P#5 /\ U #_ /\)"@#_
M 04 _P # /\ "0#_ !  _P 9 /L )@#W #0 ] !  /( 3 #N %8 Z@!? .<
M9P#D &X X@!T .  >P#> ($ W "' -H C0#6 )0 U "; -$ HP#/ *T S "X
M ,H QP#( .  Q@#S ,4 _P## /\ PP#_ ,, _P## /\ PP#_ /\+ 0#_ P
M_P   /\  P#_  L \P 2 .X 'P#J "T Y@ Z .( 10#> $\ V0!8 -0 8 #1
M &@ S@!N ,P = #* 'L R "! ,8 AP#$ (X P@"6 ,  G@"^ *< NP"R +D
MP "W -0 M0#L +, ^P"S /\ L@#_ +( _P"Q /\ L0#_ /\-  #_!@  _P,
M /<   #T  , YP - .  & #: "4 TP R ,X /@#* $D Q@!2 ,, 6@#  &$
MO@!H +P ;@"Z '0 N ![ +8 @0"T (@ L@"0 +  F0"N *( K "M *H N@"H
M ,L I@#F *4 ]P"D /\ HP#_ *( _P"B /\ H@#_ /\0  #[#   [PX  .8-
M  #?"0  V@ & -  $0#) !T Q  J +\ -P"[ $( MP!+ +0 5 "R %L KP!B
M *T : "K &X J0!U *@ >P"F (, I "+ *( E "@ )X G@&H )P"M0"; \8
MF07B )@&] "6"/\ E0G_ )0)_P"4"?\ E G_ /P1  #Q%0  XQD  -89  #,
M%0  QQ   ,0'"@"] Q0 MP0A +(&+@"N"#H J@E$ *<)30"D"E4 H@I< * *
M8@">"VD G MO )L+=@"9#'X EPR& )8,D "4#)H D@VF )$-LP"/#<4 C0[B
M (L0]@")$/\ B!'_ (<1_P"'$?\ AQ'_ /89  #G(   UB0  ,@E  "_(@
MN1P  +04 0"Q#0X J@X9 *4/)P"A$#, G1$^ )H11P"8$D\ E1)6 ),27 "1
M$F, D!-I (X3< ",$W@ BQ.! (D4BP"'%)8 AA6B (05L "#%L$ @1?= '\8
M] !]&?\ ?!G_ 'P9_P![&?\ >QG_ .\A  #=*0  RBT  +XO  "U+   KB<
M *@@  "C%P@ GA83 )D7(0"4&2T D1HX (X:00"+&TD B1M0 (<;5P"%'%X
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M 6 O_P%@+_\!8"[_ =HT  #%/   MT$  *Q#  "B0P  F4   ) Z  "(-
M@"X( 'HM$@!W+AX <R\I '$P,P!O,#L ;3!# &LQ2@!I,5$ 9S%7 &8Q7@!D
M,68 8S)O &$R>0!@,H4!7S*2 5TSH0%<,[$!6S3& 5HTY@%9-?L!637_ 5DT
M_P%9-/\!633_ =(X  # 0   LT4  *A(  ">2   E48  (M   "".P  >34$
M ',S$ !O-!H ;#0E &DU+P!G-3< 938_ &,V1@!B-DT 8#94 %\V6P!=-V,
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M/10 7ST> %P^* !:/C$ 6#XX %<^0 !5/T8 5#]- %,_50!20%T 4$!F $]
M< %.0'P!3$&* 4M!F@)*0:L"24*^ DA"W@)(0O8"2$+_ DA"_P%(0?\!2$'_
M <5$  "U2P  J5   )Y4  "55   BU,  (!0  !U2@  :D8  &%"" !<01$
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M 3Q.E $[3J4!.4^Y CE/U (Y3_(!.4[_ 3E._P$Y3?\!.DW_ ;I.  "L5@
MH5L  )=?  "-80  @V$  'A>  !I6   7U8  %12  !,3PL 24\2 $=0' !%
M4"4 0U M $)0-0!!43P 0%%$ #]13  ^4E0 /%)= #M29P Z4G, .%." 3=3
MD@$U4Z0!-%.W 3-4T0$S4_$!-%/_ 312_P$T4O\!-%+_ ;92  "I6@  GF
M )1D  "+9@  @&4  '1C  !F7@  7%P  %%8  !'50< 0E40 $!5&  _5B$
M/58J #Q6,@ [5CD .E=! #E720 X5U$ -UA: #5890 T6'$ ,EB  3%8D $O
M6:(!+EFU 2U9SP$M6>\!+EC_ 2Y7_P$N5_\!+E;_ ;)7  "E7P  FV4  )%I
M  "':@  ?&H  '%H  !C90  6&(  $U?  !#70( /%L- #I<%  X7!T -UPF
M #5=+@ T738 ,UT^ #)=1@ Q7DX ,%Y7 "]>8@ M7FX +%]] "I?C@ I7Z
M*%^S 2=?S  G7^T!)U[_ 2==_P$H7?\!*%S_ :U<  "B9   F&H  (YN  "#
M;P  >6\  &YN  !@:P  5&D  $EG   _90  -6,) #)C$0 P8QD +V0A "YD
M*0 M9#$ +&0Y "ME0@ J94H *&54 "=E7P F9FL )&9Z "-FBP B9IT (&:Q
M !]FR0 ?9NL (&7^ "!D_P @8_\!(6/_ :EB  ">:@  E7   (IS  " =0
M=74  &ET  !<<@  3W$  $1O   Z;@  ,&T# "EL#0 G;!0 )FP< "5M)  D
M;2P (VTT ")M/0 A;D8 (&Y0 !YN6P =;F< '&YV !INAP 9;YH &&^N !9O
MQ@ 6;ND %VW\ !AL_P 8:_\ &&O_ *1I  ":<0  D'8  (9Y  !\>P  <7L
M &1[  !7>@  2GD  #]X   U>   *W<  ")V!P ==@\ ''<6 !MW'@ :=R8
M&7<N !AW-P 7>$  %7A* !1X5@ 3>&, $GAR !%X@P 0>)< #WBK  YXPP .
M=^8 #G;Z  ]U_P 0=?\ $'3_ )]Q  "5>   BWP  ()_  !W@0  :H(  %V"
M  !0@@  1((  #B"   N@@  )((  !R"   4@@D $8,0 !"#%@ 0@QX #H,G
M  Z#,  -@SD #8-$  R#4  +@UT "8-L  B#?@ &@Y$ !8*E  ."NP $@=L
M!('R  6 _P &?_\ !G__ )IY  "0?@  AH,  'V%  !OAP  8HD  %6*  !)
MBP  /8P  #&,   FC   '8T  !6.   /CP, "I ,  :0$0 $CQ@  X\@  &/
M*0  CS(  ) ]  "020  CU8  (]E  "/=@  CXH  (Z?  ".M   C<\  (SN
M  ",^P  B_\  (O_ )2   "+A0  @HD  '2,  !FCP  69$  $R3  ! E0
M-)8  "B6   >EP  %9@   ^:   *FP   IP)  "<#@  G!,  )P:  "<(@
MG2L  )TU  "=0   G4X  )U<  "=;@  G($  )R7  "<K   F\8  )KH  "9
M^0  F?\  )C_ (Z(  "&C   >)   &J4  !<EP  3YH  $*=   VG@  *9\
M !^A   5H@  #J0   BF    J    *D$  "I"@  J0X  *D3  "J&@  JB(
M *LK  "L-@  K$0  *Q3  "L8P  K'<  *N.  "KI   J[P  *K>  "I]
MJ?T  *G_ (F.  ![DP  ;9<  %^<  !1H   1*0  #:F   JJ   'JD  !2K
M   -K@  !K    "R    M0   +4   "U P  M@D  +<.  "X$@  N!D  +HA
M  "[*P  O#@  +U'  "]6   O6L  +V!  "]F0  O;   +W,  "\Z@  O/<
M +O^ 'Z5  !PFP  8J   %.E  !&J@  .*T  "JO   >L0  $[0   RW   #
MN0   +P   "_    P@   ,(   ##    Q    ,8&  #'#   R!   ,H6  #,
M(   SRL  - Z  #12P  T5X  -)S  #2BP  TJ0  -.[  #3V   T^T  -/V
M '.=  !DHP  5JD  $>O   YLP  *K8  !VY   2O   "K\   ##    Q@
M ,D   #-    SP   -    #2    U    -8   #9 @  VP@  -X.  #A$P
MY!T  .@J  #H/   Z4\  .ED  #J?   ZY4  .NL  #KP@  [-4  .SE &:F
M  !8K   2;,  #NY   KO   '<   !'$   )R    ,P   #/    TP   -D
M  #=    X    .$   #C    Y0   .<   #J    [    .X$  #Q"P  ]1(
M /@<  #[*P  _3X  /Y3  #^:@  _X,  /^;  #_K@  _[X  /_* /\ $@#_
M !  _P 1 /\ $P#_ !D _P F /\ - #_ $$ _P!- /\ 6 #_ &( _P!K /\
M<P#_ 'H _P"! /\ AP#_ (T _P"3 /\ F0#_ *  _P"G /X KP#\ +H ^@#)
M /D X0#X /, ]P#_ /8 _P#U /\ \0#_ .D _P#D /\ X0#_ /\ #P#_  T
M_P - /\ #@#_ !0 _P A /\ +@#_ #P _P!( /\ 4P#_ %T _P!F /X ;0#\
M '4 ^P![ /D @@#X (@ ]P". /8 E #T )L \P"B /$ J@#O +0 [0#! .L
MU0#J .P Z #\ .< _P#E /\ Y@#_ .  _P#9 /\ U #_ /\ "P#_  @ _P &
M /\ "0#_ !  _P < /\ *0#_ #8 _P!" /L 3@#W %< ] !@ /( : #O &\
M[0!V .P ? #J (( Z "( .< C@#E )4 XP"< .$ I #? *X W0"Y -H R@#7
M .0 U #V -$ _P#0 /\ T #_ ,\ _P#+ /\ QP#_ /\  P#_    _P   /\
M! #_  T ^@ 6 /8 (P#S #  \  \ .T 1P#I %$ Y0!: .( 8@#? &D W0!O
M -H =@#8 'P U "" -( B #0 (\ S0"6 ,L G@#) *@ QP"S ,4 P0#" -@
MP #O +\ _@"^ /\ O0#_ +P _P"\ /\ O #_ /\"  #_    _P   /\   #T
M  < [0 1 .@ ' #C "D WP U -L 00#6 $L T0!4 ,T 7 #* &, R !I ,8
M;P## '4 P0![ +\ @@"^ (@ O "0 +H F "X *( M0"L +, N0"Q ,L KP#G
M *X ^ "L /\ JP#_ *P _P"L /\ JP#_ /\$  #_    ]@   .X   #G
MWP , -8 %0#/ "( R@ N ,< .@## $0 P !- +P 50"Y %P MP!C +4 :0"S
M &\ L0!U *\ >P"M (( JP"* *D D@"G )P I0"F *, LP"A ,, GP#> )X
M\@"= /\ G #_ )P _P"; /\ FP#_ /\'  #V"0  Z0L  -\*  #5!   S@ %
M ,8 $ #  !H NP G +< ,@"S #T L !& *T 3P"J %8 J !< *8 8P"D &@
MH@!O *$ =0"? 'P G0"$ )L C0"9 )< EP"B )4 K@"3 +T D0#3 )  [0"/
M /P C@#_ (T!_P"- ?\ C0'_ /D.  #J$@  W!4  ,T5  #$$0  O@P  +H"
M"@"T !( K@ > *H *@"F #4 H@ _ *  2 "= 5  FP)6 )D"7 "7 V, E0-I
M ),#;P"1!'8 D 1_ (X%B ",!9( B@:> (@&J@"&![H A0C/ (0*ZP"""_P
M@0S_ ( ,_P" #/\ @ S_ /$5  #@'0  S2   ,$A  "X'0  L1<  *P0  "H
M"0T H@<6 )T)(P"9"BX E0LX ),,00"0#$D C@U0 (P-5P"*#5T B UC (<-
M:@"%#G$ @PYZ ((.A " #H\ ?@^; 'P/J ![$+@ >A#. '@1[ !V$O\ =1+_
M '03_P!T$_\ =!/_ .@>  #3)@  PRH  +@J  "N*   IR,  * <  ";$P,
ME@\0 ) 0&P",$2< B1(R (83.P"$$T, @A1+ ( 440!^%%< ?!1> 'L590!Y
M%6P =Q5T '86?@!T%HH <A>6 '$7I !O&+0 ;AC) &T9Z !K&OP :AO_ &H;
M_P!J&_\ :AO_ . F  #*+0  O#$  + S  "G,0  GRP  )<F  "0'P  BA<,
M (48%@"!&2( ?AHL 'L;-@!Y&SX =QQ% '4<3 !S'%, <1U9 ' =8 !N'6<
M;1YP &L>>@!J'H4 :!^2 &<?H !E(+  9"'% &,AY !B(OH 82+_ &$B_P!A
M(O\ 82+_ -<L  ##-   MC@  *HY  "A.   F#4  ) O  "(*   @"$( 'L@
M$@!W(1T ="(G '$B,0!O(SD ;2-! &LC2 !I(TX :"15 &8D6P!E)&, 8R5K
M &(E=0!A)8$ 7R:. %XFG0!=)ZT 6RC! %LHX !:*?< 62G_ %DI_P!9*?\
M62C_ ,\R  "^.0  L3T  *8_  "</P  DSP  (HV  "!,   >2H# '(F#P!N
M)QD :R@C &DH+ !F*34 92D\ &,I0P!A*DH 8"I1 %XJ5P!=*E\ 7"MH %HK
M<@!9+'T 6"R+ %8MF@!5+:H 5"Z] %,NW !2+_4 4B__ %(N_P!2+O\ 4B[_
M ,HV  "Z/0  K4(  *)$  "81   CT$  (4\  ![-P  <C$  &LL# !G+14
M9"T? &$N* !?+C$ 72XY %PO0 !:+T8 6"]- %<O5 !6,%P 53!D %,Q;@!2
M,7H 43&( % REP!.,J@ 33.[ $TTV !,-/, 3#3_ $PT_P!,,_\ 3#/_ ,8Z
M  "V0@  J48  )Y)  "520  BT<  (%"  !W/0  ;3<  &0R"0!@,A( 73(<
M %HR)0!8,RT 5C,U %4S/ !3-$, 4C1* %$T40!0-%D 3S5A $TU; !,-G<
M2S:% $HWE0!(-Z8 1SBX 4<XTP%&./$!1CC_ 48X_P!&./\ 1C?_ ,$^  "R
M10  IDH  )Q-  "230  B$L  'Y'  !S0@  :3T  %\W!@!:-A  5S<8 %0W
M(@!2-RH 4#<R $\X.0!-.$  3#A' $LX3@!*.58 23E? $@Z:0!'.G4 13N#
M $0[DP!#/*0!0CRV 4$]T %!/? !03W_ 4$\_P%!//\!03S_ +Y"  "O20
MHTX  )E0  "/40  A5   'M,  !O1@  94(  %H] @!4.PX 43L5 $\['P!-
M.R< 2SLO $D\-@!'/#T 1SQ$ $8]2P!%/50 1#Y< $,^9P!"/W, 0#^! #\_
MD0 ^0*( /4"U 3Q!S@$\0>X!/$'_ 3Q _P$\0/\!/3__ ;I%  "L3   H5$
M )=4  "-50  @U0  'A1  !L2P  84<  %9"  !/0 P 3#\3 $E ' !'0"0
M1D L $1 ,P!#0#H 0D%" $%!20! 0E$ /T): #Y#90 ]0W$ .T-_ #I$CP Y
M1*  .$6S 3=%RP$W1>P!-T7_ 3=$_P$X1/\!.$/_ +=)  "I4   GE4  )18
M  "+60  @%@  '96  !H4   74P  %-(  !*10D 1D01 $1$&0!"1"( 044I
M #]%,0 ^13@ /44_ #Q&1P [1D\ .D=8 #E'8@ X2&X -DA\ #5(C0 T29X
M,TFQ #))R0 Q2>L ,DG^ #)(_P R2/\ ,TC_ +1,  "G5   G%D  ))<  "(
M70  ?ET  '-:  !E50  6U(  %!.  !&2@4 0$D. #Y)%@ ]21X .THF #I*
M+@ Y2C4 .$L] #=+1  V2TT -$Q6 #-,8  R3&P ,4UZ #!-BP N39P +4ZO
M "Q.QP L3ND +$W] "U-_P M3/\ +4S_ +!0  "D6   F5T  (]A  "&8@
M>V$  '!?  !B6P  6%@  $Y5  !#40$ .T\, #A/$P V3QL -4\C #10*P S
M4#( ,E Z #%00@ P44H +E%3 "U270 L4FD *U)X "E2B  H4YH )U.M "93
MQ0 F4^< )E/\ "=2_P G4?\ )U'_ *Q5  "@7   EF(  (UF  "#9P  >&8
M &UE  !@80  55X  $I;   _6   -58( #%5$  P5A< +E8? "U6)P L5B\
M*U<V "I7/@ I5T< *%=0 "986@ E6&< )%AU "-9A@ A69@ (%FK !]9P@ ?
M6>4 'UCZ "!8_P @5_\ (5?_ *A:  "=8@  DV<  (IK  !_;   =6P  &IK
M  !=:   464  $9C   [8   ,5X# "I=#0 H71, )ET; "5>(P D7BH (UXR
M ")>.@ A7D, (%], !]?5P >7V, '&!Q !M@@@ 98)4 &&"I !=@P  68.(
M%U_Y !A>_P 97O\ &5W_ *1@  "9:   D&X  (9P  !\<@  <G(  &9Q  !8
M;@  3&P  $%K   V:0  +6<  "-F"  ?9@\ '685 !QF'0 ;9B4 &F8M !EG
M-0 89SX %V=( !9G4P 5:%\ $VAN !)H?P 1:)( $&BF  ]HO0 .:.  $&?W
M !!F_P 19?\ $67_ )]G  "6;P  C',  ()V  !X>   ;7@  &!W  !3=@
M1G0  #MS   Q<@  )W$  !YQ   6< H $W 0 !-P%P 2<!\ $7$G !!Q+P 0
M<3@ #G%"  YQ3@ -<5L #'%I  MQ>@ *<8T "'&A  9QM@ &<-( !W#O  AO
M_P );O\ "6[_ )MO  "1=0  AWD  'Y\  !T?@  9GX  %E^  !-?@  0'T
M #5]   J?   (7P  !A\   1? 0 #'P,  I\$0 )?!D "'PA  =\*0 &?#(
M!'P]  -\2  !?%4  'QC  !\=   ?(<  'N<  ![L0  >LL  'GK  !Y^@
M>?\  'C_ )9W  ",?   @X   'F#  !LA   7H4  %&&  !%AP  .8<  "V'
M   CAP  &H<  !*'   -B $ !HD*  &)#P  B10  (@;  "((P  B2P  (DV
M  ")0@  B$X  (A=  "(;0  B($  (>5  "'JP  AL0  (7F  "$^   A/\
M (3_ )!^  "'@P  ?H<  '&)  !CBP  5HT  $F/   \D0  ,)$  "21   :
MD@  $I,   V4   &E0   )8&  "6#   E1   )85  "6'0  EB0  )8N  "6
M.0  ED8  )95  "690  EG@  )6.  "5I   E+P  )/?  "3]0  DO\  )+_
M (N&  "#B@  =8T  &>0  !9E   3)<  #^9   RF@  )IL  !N<   2G0
M#)\   2@    H@   *,!  "C!P  HPP  *,0  "D%0  I!P  *4E  "F+P
MICP  *9+  "F6P  IFX  *6$  "EFP  I+,  */0  "C[P  HOP  *+_ (:-
M  !XD0  :I4  %R9  !.G0  0:   #.B   FHP  &Z4  !&G   *J0   :L
M  "M    KP   +    "P    L 4  +$+  "R#P  LQ0  +0;  "U)   MS
M +<_  "W4   MV(  +=X  "WD   MJD  +;"  "VY   MO4  +7^ 'N3  !M
MF   7YT  %"B  !"I@  -*D  ":K   :K0  $*\   FR    M    +<   "Z
M    O    +T   "^    O@   , "  #!"   P@T  ,02  #&&0  R20  ,HR
M  #+0P  RU4  ,QJ  #,@P  S)P  ,NU  #,S@  S.D  ,SV '";  !AH0
M4J8  $2K   VL   )[(  !JU   0N   ![L   "^    P0   ,0   #(
MRP   ,L   #-    S@   -    #2    U0,  -@*  #;$   WA@  .(D  #C
M-0  Y$@  .5<  #F<P  YHT  .:E  #FO   YM,  .?G &.D  !5J@  1K
M #BU   HN0  &KP   _    %Q    ,<   #+    SP   -0   #8    W
M -T   #?    X0   .,   #E    Z    .H   #M!@  \0X  /46  #X)0
M^3@  /E-  #Z8P  ^WP  /R5  #\J@  _+L  /W+ /\ #P#_  X _P . /\
M$ #_ !8 _P C /\ , #_ #T _P!) /\ 5 #_ %X _P!F /\ ;@#_ '8 _P!\
M /\ @@#_ (D _P"/ /\ E0#^ )L _0"C /L JP#Z +4 ^0## /< VP#V /
M] #_ /, _P#R /\ [ #_ .( _P#< /\ U@#_ /\ # #_  D _P ( /\ "@#_
M !( _P > /\ *P#_ #@ _P!$ /\ 3P#_ %D _@!A /P :0#Z '  ^ !W /<
M?0#V (, ] ") /( CP#Q )8 [P"= .T I0#L *\ Z@"\ .@ S0#F .@ Y #Z
M ., _P#B /\ X #_ -4 _P#. /\ RP#_ /\ !@#_  $ _P   /\ ! #_  X
M_P 9 /\ )0#] #( ^P ^ /< 20#S %, \ !< .X 8P#L &H Z@!Q .@ =P#F
M 'T Y "# .( B0#@ )  W@"7 -P GP#9 *D U@"T -, Q #0 -X S@#S ,P
M_P#+ /\ R@#_ ,@ _P#" /\ O@#_ /\   #_    _P   /\   #[  L ]@ 3
M /$ ( #M "P Z@ X .< 0P#C $T X !6 -P 70#9 &0 U0!K -( <0#0 '8
MS@!\ ,P @P#* (D R "1 ,8 F0#$ *, P0"M +\ NP"] ,\ NP#K +D _ "W
M /\ MP#_ +8 _P"T /\ L0#_ /\   #_    _P   /8   #N  4 YP / .$
M&0#; "4 U0 Q -( / #. $8 R@!/ ,< 5P#$ %X P0!D +\ :@"] '  NP!V
M +D ? "X (, M@"* +, DP"Q )P KP"G *T LP"K ,4 J0#A *< ]0"F /\
MI0#_ *0 _P"D /\ I #_ /\   #\    \0   .@   #@    U  + ,P $P#'
M !\ P@ J +\ -0"\ #\ N !( +4 4 "S %< L !> *X 9 "L &D JP!O *D
M=0"G 'P I0"$ *, C "A )8 GP"A )T K0": +P F #2 )< [@"5 /X E #_
M )4 _P"5 /\ E0#_ /P!  #P!0  XP<  -4%  #,    Q0 $ +X #@"X !<
MLP C *\ +@"K #@ J0!! *8 2@"C %$ H0!7 )\ 70"= &, FP!I )H ;P"8
M '8 E@!] )0 A@"2 )  D "; (X IP", +8 B@#) (@ YP"' /D AP#_ (8
M_P"& /\ A@#_ /0,  #D$   T1(  ,41  "]#@  M@@  +$ " "K !$ I@ ;
M *$ )@"> #$ F@ Z )@ 0P"5 $H DP!1 )$ 5P"/ %T C@!C (P :0"* '
MB !W (8 @ "$ (L @@"6 (  HP!^ +$ ?0#$ 'L"X0!Z _4 >@7_ 'D%_P!X
M!O\ > ;_ .H3  #6&@  QAT  +H<  "Q&0  JA,  *0-  "?!0P F0 4 )4
M'P"1 BD C0,S (L$/ "(!40 A@9+ (0&40""!U< @0== '\'8P!]"&H >PAR
M 'H(? !X"88 =@F2 '0*H !S"J\ <0O! ' ,WP!O#?8 ;@[_ &T._P!M#O\
M;0[_ .$<  #+(P  O"8  +$F  "H)   H!X  )D8  "3$ ( C@L. (@+%P"$
M#"( @0TL 'X--0!\#CT >@Y% '@.2P!W#E$ =0]8 ',/7@!Q$&4 <!!N &X0
M=P!L$(( :Q"/ &D1G0!H$:T 9A+  &42WP!D$_8 8Q3_ &,4_P!B%/\ 8A3_
M -8D  ##*@  M2X  *HO  "@+0  F"@  ) B  ")&P  @A,( 'T1$@!Y$AP
M=A,G ',4, !Q%#@ ;Q4_ &T51@!L%4P :A93 &@660!G%F$ 919I &07<@!B
M%WX 81B+ %\8F0!>&:D 7!F\ %P:V !:&_, 6AS_ %D<_P!9'/\ 61S_ ,TJ
M  "],0  KS4  *0V  ";-   DC$  (DK  "!)0  >1T# ',8#@!O&1@ ;!HB
M &D;*P!G&S, 91P[ &0<00!B'4@ 8!U. %\=50!='5P 7!YD %L>;@!9'WD
M6!^' %8@E@!5(*8 5"&X %,AT@!2(O$ 4B/_ %(C_P!2(O\ 4B+_ ,@O  "X
M-@  JSH  * \  "6.P  C3@  (,R  !Z+0  <B8  &H@# !F(!, 8R$= &$A
M)@!?(B\ 72(V %LB/0!:(T0 6"-* %<C40!5(U@ 5"1A %,D:@!1)78 4"6#
M $\FDP!.)Z, 3">U $PHS@!+*.X 2RG_ $LH_P!+*/\ 2RC_ ,,T  "S.P
MIS\  )Q!  "20   B3X  '\Y  !U,P  ;"T  &,G" !>)A$ 7"89 %DG(@!7
M)RL 52@R %0H.0!2*$  42A& % I30!.*54 32E= $PJ9P!+*G, 22N  $@K
MD !'+*$ 1BVS $4MRP!%+NP 1"[_ $0N_P!%+?\ 12W_ +XX  "P/P  I$,
M )E%  "/10  A4,  'L^  !Q.0  9S0  %XN! !8*PX 52L6 %(L'P!0+"<
M3RPO $TM-@!,+3P 2BU# $DM2@!(+E( 1RY: $8O9 !%+W  0S!^ $(PC0!!
M,9X 0#*Q #\RR  _,^H /S/^ #\R_P _,O\ /S+_ +L\  "M0P  H4<  )9)
M  ",20  @T@  'A$  !M/@  8SD  %HT  !2, P 3S 3 $PP' !*,"0 23$K
M $<Q,@!&,3D 1#%  $,R1P!",D\ 03-8 $ S8@ _-&T /C1[ #TUBP \-IP
M.S:O #HWQ@ Y-^@ .3?\ #HW_P Z-O\ .C;_ +=   "J1@  GDL  )1-  "*
M3@  @$P  '5(  !J0P  8#X  %8Y  !--0D 2301 $<U&0!%-2$ 0S4H $$U
M+P! -38 /S8] #XV10 ]-TT /#=5 #LX8  Z.&L .3EY #@YB0 W.IL -3JM
M #4[Q  T.^8 -#O[ #4[_P U.O\ -3K_ +1#  "G2@  G$X  ))1  "(4@
M?E   '--  !G2   7$0  %(_  !(.@8 1#D/ $$Y%@ _.1X /CDF #PY+0 [
M.C0 .CH[ #D[0@ X.TH -SQ3 #8\70 U/6D -#UW #,^AP Q/ID ,#^K "\_
MP@ O/^0 +S_Z # __P P/O\ ,#[_ +%'  "D30  F5(  (]5  "&5@  ?%4
M '%2  !D3   64D  $]%  !%0 , /SX- #P^$P Z/AL .3XC #<^*@ V/S$
M-3\X #0_0  S0$@ ,D!1 #%!6P P06< +D)U "U"A0 L0Y< *T.J "I#P  I
M1.( *D/Y "I#_P K0O\ *T+_ *Y*  "A40  EU8  (U9  "#6@  >5H  &Y7
M  !A4@  5TX  $U+  !#1P  .D,* #9#$0 T0Q@ ,T,@ #)$)P Q1"\ ,$0V
M "]%/0 M148 +$5/ "M&60 J1F0 *4=R "A'@P F1Y4 )4BH "1(O@ C2.
M)$CW "5'_P E1_\ )D?_ *I/  "?50  E%H  (M>  "!7P  =UX  &M<  !?
M6   554  $M1  ! 30  -4H' #!)#@ N214 +4D= "Q))  K2BL *DHS "A*
M.P G2T, )DM, "5+5@ D3&( (TQP "%,@  @39, 'TVF !Y-NP =3MT 'DWV
M !Y,_P ?3/\ ($O_ *=3  "<6@  DE\  (AC  !^9   =&,  &EA  !<7@
M4EL  $=8   \50  ,E(" "I0#  G3Q( )E 9 "50(  D4"@ (U O ")1-P A
M44  (%%) !Y24P =4E\ '%)M !I3?0 94Y  &%.D !93N0 54]D %E/T !=2
M_P 84?\ &5'_ *-9  "88   CV4  (5H  ![:0  <6D  &9G  !99   36$
M $)?   X7   +EH  "58"  @5PX 'E<4 !U7'  <6", &U@K !I8,P 96#P
M&%A% !994  565L %%EI !-:>@ 26HT $5JA !!:MP .6M4 $%GS !!9_P 1
M6/\ $5C_ )]?  "59@  C&L  ()M  !X;@  ;F\  &)M  !5:@  2&@  #YF
M   S90  *6,  "!A 0 88 L %6 0 !1@%P 38!X $F F !)@+@ 183< $&%
M  ]A2P .85@ #6%F  QB=@ +8HD "F&=  EAL@ (8<L "&'K  E@_0 *7_\
M"U__ )MF  "2;0  B'$  'YS  !U=0  :G0  %QS  !/<@  0W   #AO   M
M;@  )&P  !MK   3:P0 #FH,  UJ$@ ,:AD "VHA  IJ*0 ):C( "&H\  =K
M1P %:U, !&MA  )K<0  :H0  &J8  !JK0  :<8  &GG  !I^   :/\  &C_
M )=M  "-<P  A'<  'MZ  !P>P  8WL  %9Z  !)>@  /7D  #%X   G=P
M'78  !5V   /=@( "78*  1V#P  =A4  '8<  !V)   =2P  '4V  !U00
M=4X  '5<  !U;   =7X  '23  !TJ   <\   '/C  !R]P  <O\  ''_ ))U
M  ")>@  @'X  ':   !I@0  6X(  $Z"  !!@@  -8,  "F"   ?@0  %H$
M !""   *@@   H,'  ""#0  @A$  ((7  ""'@  @B8  ((O  "".P  @D<
M ()5  "!90  @7@  (&-  " H@  ?[H  '_=  !^]   ??\  'W_ (U\  "$
M@0  >X0  &Z&  !@B   4HH  $6+   YC   +(P  "&,   7C   $(T   F.
M   "CP   ) #  "/"0  CPX  (\2  "0&   D!\  ) H  "0,@  D#\  )!-
M  "070  CW   (^%  ".G   CK,  (W0  ",\   B_X  (O_ (B$  " B
M<HL  &2-  !6D   2),  #N5   NE@  (I8  !>7   /F   ")D   ";
MG0   )T   "= P  G0D  )T-  ">$0  GA<  )\?  "?*0  H#4  *!#  "@
M5   H&8  )][  ">DP  GJL  )W&  "=Z0  G/D  )S_ (.+  !UC@  9Y(
M %F6  !+F0  /9P  #">   CGP  %Z    ZB   'I    *8   "H    J@
M *H   "J    JP$  *L'  "L#   K1   *X6  "O'@  L2D  +$X  "Q2
ML5H  +%O  "QB   L:   +"Z  "OW0  K_(  *_] 'B1  !JE@  7)H  $V?
M   _HP  ,:8  ".G   7J0  #JL   6N    L    +(   "U    MP   +<
M  "X    N0   +H   "\ P  O0D  +X.  # %   PQX  ,4K  #%/   QDX
M ,9B  #&>@  QI0  ,:M  #&R   Q>4  ,7S &R9  !>G@  3Z0  $&H   R
MK   )*\  !:Q   -M    [<   "Z    O0   ,    #$    Q@   ,8   #(
M    R0   ,L   #,    S@   - &  #3#0  V!,  -P>  #>+0  WT   .!4
M  #A:P  X84  .&?  #AMP  X<\  .'F &"A  !2IP  0ZT  #2R   EM0
M%[D   V\   !OP   ,,   #'    R@   ,\   #3    U@   -<   #:
MW    -\   #A    XP   .8   #I 0  [ L  / 2  #S'P  ]#$  /9&  #W
M7   ^'0  /B/  #YI@  ^;@  /C) /\ #0#_  L _P + /\ #@#_ !, _P ?
M /\ + #_ #D _P!% /\ 4 #_ %D _P!B /\ :@#_ '$ _P!W /\ ?@#_ (0
M_@"* /T D #\ )< ^@"> /D IP#W +$ ]@"^ /4 T@#S .P \0#^ /  _P#P
M /\ Y@#_ -P _P#2 /\ S0#_ /\ !P#_  0 _P " /\ !@#_ !  _P ; /\
M)P#_ #, _P _ /\ 2@#^ %0 ^P!= /D 9 #W &L ]0!R /, > #R 'X \ "$
M .\ B@#M )$ [ "9 .H H0#H *L Y@"V .0 QP#B ., X #W -X _P#= /\
MV0#_ ,P _P#% /\ P0#_ /\   #_    _P   /\  0#_  T _P 6 /P (@#Y
M "X ]@ Y /, 10#O $X [ !7 .D 7@#F &4 Y !L .( <@#@ '< WP!^ -T
MA #; (L V "2 -4 FP#2 *0 SP"O ,T O@#+ -4 R0#O ,< _P#% /\ Q #_
M +X _P"X /\ M0#_ /\   #_    _P   /X   #W  D \0 1 .L ' #G "@
MY  S .$ /@#= $@ V !1 -, 6 #0 %\ S@!E ,P :P#* '$ R !W ,8 ?0#$
M (0 P@", ,  E "^ )X NP"H +D M@"W ,@ M0#F +, ^@"Q /\ L #_ +
M_P"L /\ J0#_ /\   #_    ^@   /$   #H  , X  - -@ %@#1 "( S0 M
M ,H -P#& $$ P@!* +\ 4@"] %D N@!? +@ 90"W &H M0!P +, =@"Q 'T
MKP"% *T C0"K )< J0"A *< K@"E +X H@#8 *  \@"? /\ G@#_ )X _P">
M /\ G #_ /\   #W    ZP   .$   #6    RP ) ,4 $0"_ !L NP F +<
M,0"T #H L0!# *X 2P"K %( J0!8 *< 7@"F &0 I !I *( < "@ '8 G@!^
M )P A@": )  F "; )8 IP"4 +8 D@#* )  Z0"/ /P C@#_ (T _P", /\
MC0#_ /@   #I @  VP,  ,P!  #$    O0 " +8 #0"P !4 JP @ *< *@"D
M #0 H0 \ )X 1 "< $L F@!2 )@ 6 "6 %T E0!C ), :0"1 '  CP!W (T
M@ "+ (H B0"5 (< H0"% *\ @P#! ($ X "  /4 ?P#_ '\ _P!_ /\ ?P#_
M .X*  #<#@  RA   +X.  "U"P  KP,  *D !P"C !  G@ 8 )D (P"6 "P
MDP U )  /@". $4 C !+ (H 40"( %< A@!= (4 8P"# &H @0!Q '\ >@!]
M (0 >P"/ 'D G !W *H =0"[ '0 U !R /  <@#_ '( _P!Q /\ <0#_ .,1
M  #-%P  OQD  +,9  "J%0  HQ   )T*  "7 0H D0 2 (T &P") "4 A0 O
M (, -P"  #X ?@!% 'T 2P![ %$ >0!7 '@ 70!V &0 = %K '(!= !P G\
M;@*+ &P#F !K Z8 :02W &@%S@!G!^P 9@C] &8)_P!E"?\ 90G_ -8:  #$
M(   MB,  *LC  "A(   F1L  )(4  ",#@$ A@<- ( $% !\!AX >0<H '8(
M, !T"#@ <@D_ ' )10!O"DP ;0I2 &P*6 !J"U\ : MG &<+< !E#'H 8PR'
M &(,E0!@#:0 7PVV %X-S@!<#NT 7 __ %L0_P!;$/\ 6Q#_ ,TA  "\*
MKRL  *0K  ":*0  DB0  (D?  ""&   >Q$% '4-#P!Q#1< ;@XA &L.*@!I
M#S( 9Q Y &400 !D$$8 8Q!- &$04P!?$5H 7A%B %P1:P!;$78 61*# %@2
MD@!6$Z( 51.T %03RP!3%.P 4A7_ %(6_P!2%?\ 4A7_ ,8H  "V+@  J3(
M )\R  "5,0  C"T  (,G  !Z(0  <AH  &L3"P!G$Q, 9!0< &$4)0!?%2T
M714T %P5.P!;%D( 619( %@63P!6%U8 51=> %,79P!2&'( 4!A_ $\9C@!.
M&I\ 3!JP $L;QP!+&^D 2AS] $H<_P!*'/\ 2AS_ ,$M  "Q-   I3<  )HX
M  "0-P  AS0  'TO  !T*0  ;",  &0<!P!>&1  6QH8 %D;(0!7&RD 51LP
M %0<-P!2'#T 41Q$ $\=2P!.'5( 31U: $L>8P!*'FX 21]\ $<?BP!&()P
M12&N $0AQ !#(N8 0R+\ $,B_P!#(O\ 0R+_ +PR  "M.   H3P  )<^  "-
M/0  @SH  'DU  !O,   9BH  %XD @!7( T 5" 4 %$@'0!/(24 3B$L $PA
M,P!+(CH 22)  $@B1P!'(DX 1B-7 $0C8 !#)&L 0B1Y $$EB  _)ID /B:K
M #TGP0 ])^, /2CZ #TH_P ])_\ /2?_ +@V  "J/0  GD   )1"  "*0@
M@#\  '8[  !L-@  8C   %DJ  !1)0L 3241 $LE&0!))2$ 1R8H $4F+P!$
M)C8 0R8] $(G1 !!)TL /RA4 #XH70 ]*6D /"EV #LJA@ Y*Y< ."NI #<L
MOP W+.  -RSX #<L_P W+/\ ."S_ +4Z  "G0   G$0  )%&  "'1@  ?40
M '-   !H.P  7S8  %4Q  !,*P< 1RD/ $4J%@!#*AX 02HE #\J+  ^*S,
M/2LY #PK00 [+$@ .BQ1 #DM6P X+F8 -BYS #4O@P T+Y4 ,S"G #(PO0 Q
M,=X ,3'W #(Q_P R,/\ ,S#_ +$^  "D1   F4@  (]*  "%2@  >TD  '!%
M  !E0   6SL  %(V  !(,00 0BX- #\N$P ]+AL .RXB #DO*0 X+R\ -R\V
M #8P/@ U,$8 -#%/ #,Q60 R,F0 ,3)Q # S@0 O-), +C2F "PUNP L-=L
M+#7U "TU_P M-/\ +C3_ *Y!  "B2   ETP  (U.  "#3@  >4T  &Y*  !B
M10  6$   $X\  !%-P  /3,+ #DS$0 W,Q@ -C,? #0S)@ S,RT ,C0T #$T
M/  P-40 +S5, "XV5@ M-F( +#=O "LW?P J.)$ *#BD "<YN0 F.=@ )SGT
M "@Y_P H./\ *3C_ *M%  "?2P  E$\  (M2  "!4P  =U(  &Q/  !?20
M5D8  $Q"  !"/0  .#@( #0X#P R.!4 ,3@= "\X)  N."L +3DR "PY.0 K
M.D$ *CI* "D[5  H.U\ )SQM "4\?0 D/8\ (SVB "(]MP A/M0 (3[S "(]
M_P C/?\ (SS_ *A)  "=3P  DE,  (E6  !_5P  =58  &I3  !=3P  4TP
M $I(  ! 1   -D % "\]#0 M/1, *ST: "H^(0 I/B@ *#XO "<^-P F/S\
M)#]( "- 4@ B0%T (4%J "!!>@ >08T '4*@ !Q"M0 ;0M$ &T+Q !Q"_P =
M0?\ 'D'_ *5-  ":4P  D%@  (9;  !]7   <EL  &=8  !;5   45(  $A.
M   ]2@  ,T<  "I#"P F0Q  )4,6 "1#'@ C1"4 (D0L "%$-  @13P 'D5%
M !U%3P <1EH &T9H !E&>  81XH %T>> !9'LP 42,X %4?O !9'_P 71O\
M%T;_ *)2  "76   C5T  (1@  !Z80  <&   &5>  !96@  3U@  $14   Y
M40  +TX  "9+!@ @2@X 'DH3 !U*&@ <2B$ &TLH !I+,  92S@ %TM" !9,
M3  53%< %$QE !--=0 238@ $4V< !!-L0 .3LP #TWN !!-_P 13/\ $4S_
M )Y7  "470  BV(  (%E  !W9@  ;68  &-D  !680  2EX  #];   U6
M*U8  ")4 0 :4@H %E(0 !52%@ 44AT $U(D !)2+  14C0 $5(^ !!32  /
M4U0 #E-B  U4<@ ,5(0 "U28  E4K0 (5,4 "53G  I3^P +4O\ "U+_ )M=
M  "19   B&@  'YK  !T;   :VP  %]J  !29P  160  #IB   P8   )EX
M !U=   56P4 $%H,  Y:$0 .6A@ #5L@  Q;)P +6S  "ELZ  E;10 '6U$
M!EM>  1;;0 #6X   5N4  !;J   6\   %KB  !:]@ !6O\  EG_ )=D  ".
M:P  A&X  'MP  !R<@  9W$  %EP  !,;@  0&P  #5K   J:0  (6<  !AF
M   19@$ #&4*  =E#P $910  V0;  )D(P  9"P  &0U  !D0   9$P  &1:
M  !D:0  9'L  &2/  !CI   8[L  &+=  !B]   8O\  &'_ )-L  ")<0
M@'4  'AW  !M>   8'<  %)V  !&=0  .70  "YT   C<@  &G$  !)Q   -
M<0  !G$(  !P#0  <!(  ' 7  !O'P  ;R8  &\P  !O.P  ;T<  &]4  !O
M9   ;W4  &Z*  !MH   ;;8  &S6  !K\@  :_\  &O_ (YS  "%>   ?7L
M '-]  !E?@  6'X  $M^   ^?@  ,GX  "9]   <?   $WP   U\   &?0
M 'T%  !\"P  ? \  'P3  !\&0  ?"$  'PI  !\-   >T   'M.  ![7@
M>V\  'J$  !ZF@  >;$  'C.  !W[P  =OX  ';_ (EZ  "!?P  >((  &N#
M  !=A0  3X8  $*'   UB   *8<  !V'   4AP  #8@   :)    B@   (H
M  ")!@  B0P  (D/  ")$P  B1H  (HB  "*+   BC@  (I&  ")5@  B6@
M (E\  "(E   AZL  (;&  "%Z@  A?L  (3_ (6"  !]A@  ;X@  &&+  !3
MC0  18\  #B1   KD0  'Y(  !22   -DP  !)0   "6    EP   )@   "7
M    EP4  )<+  "8#@  F!,  )D:  "9(@  FBX  )H]  "930  F5X  )ES
M  "8BP  F*,  )>\  "6X@  EO<  )7_ (")  !RC   9(\  %:3  !(E@
M.ID  "R:   ?FP  %)P   R>   #GP   *$   "C    I0   *4   "E
MI0   *8"  "G"   IPT  *@1  "I&0  JR,  *LQ  "K00  K%,  *QG  "K
M@   JIH  *JS  "JT   J>\  *G[ '6/  !GE   69@  $J<   \GP  +:(
M ""C   3I0  "Z<   &I    JP   *X   "Q    L@   +(   "S    M
M +4   "V    N 0  +D+  "[$   O1@  +\D  "_-0  P$<  ,!;  # <@
MP(T  ,&F  # P0  O^,  +[S &J7  !;G   3:$  #ZE   OJ0  (:L  !.M
M   +L    +,   "U    N    +P   "_    P0   ,$   ##    Q    ,8
M  #'    R0   ,L   #."   T0\  -48  #8)P  V3D  -I-  #;9   VWX
M -R9  #<L   W,D  -SC %V?  !/I0  0*H  #*O   BL@  %+4   JX
MNP   +\   ##    Q@   ,L   #.    T0   -$   #4    U@   -D   #;
M    W@   .    #D    YP8  .L.  #O&0  \"H  /(_  #S50  ]&T  /2(
M  #TH0  ]+8  /3' /\ "0#_  8 _P ' /\ # #_ !$ _P < /\ * #_ #0
M_P!! /\ 3 #_ %4 _P!= /\ 90#_ &P _P!R /X > #\ 'X ^P"$ /H BP#Y
M )( ]P"9 /8 H@#T *P \P"Y /$ RP#P .@ [@#[ .T _P#L /\ X0#_ -(
M_P#) /\ Q #_ /\  0#_    _P   /\ ! #_  X _P 7 /\ (P#_ "\ _P [
M /T 1@#Z %  ]P!8 /0 7P#R &8 \ !L .\ <@#M '@ [ !^ .H A0#I (P
MYP"3 .4 G #C *8 X0"Q -\ P0#= -T VP#T -D _P#6 /\ SP#_ ,0 _P"]
M /\ N0#_ /\   #_    _P   /\   #_  L _  3 /< '@#T "H \@ U .X
M0 #I $H Y@!2 ., 60#@ &  W@!F -P ; #: '( UP!X -0 ?@#2 (4 T "-
M ,X E0#, )\ R0"J ,< N #% ,T PP#K ,  _@"_ /\ O@#_ +8 _P"P /\
MK0#_ /\   #_    _P   /D   #R  8 ZP / .8 &0#A "0 W@ O -H .0#3
M $, SP!, ,P 4P#) %H QP!@ ,4 9@## &L P0!Q +\ =P"] 'X NP"& +D
MC@"W )@ M0"C +, L "Q ,( K@#@ *P ]P"K /\ J@#_ *@ _P"C /\ H #_
M /\   #_    ]0   .L   #A    U@ , ,\ $P#* !X Q@ I ,( ,P"_ #T
MNP!% +@ 30"V %0 LP!: +$ 7P"P &4 K@!J *P < "K '< J0!_ *< AP"E
M )$ HP"< *  J0"> +@ G #. )H [@"9 /\ EP#_ )8 _P"6 /\ DP#_ /T
M  #Q    Y0   -D   #-    Q  & +T #P"W !@ LP B +  + "M #8 J0 ^
M *< 1@"D $T H@!3 *  60"? %X G0!D )L :@": '  F !W )8 @ "4 (H
MD0"5 (\ H@"- +  BP## (D XP"( /D A@#_ (8 _P"& /\ A@#_ /,   #C
M    T0   ,4   "]    M@   *X "P"H !( I  < *  )@"< "\ F@ W )<
M/P"5 $8 D@!, )$ 4@"/ %@ C0!= (L 8P"* &H B !Q (8 >0"$ (, @@"/
M '\ FP!^ *D ? "[ 'H U0!X /( > #_ '< _P!W /\ =P#_ .<'  #1#
MPPT  +@,  "N"   J    *( !0";  X E@ 5 )( 'P". "@ BP Q (@ .0"&
M $  A !& (( 3 "  %( ?P!7 'T 70![ &, >@!K '@ <P!V 'T = "( '$
ME0!P *0 ;@"T &P R@!K .H :@#\ &H _P!J /\ :@#_ -H0  #&%   N!8
M *T5  "D$@  G X  )8'  "0  D B@ 0 (4 & "! "$ ?@ J 'L ,@!Y #D
M=P!  '4 1@!S $P <@!1 '  5P!N %X ;0!E &L ;@!I '< 9P"# &4 D0!C
M )\ 8@"O &  Q !? .0 7P'X %X"_P!> O\ 7@+_ ,X8  "]'0  L"   *4?
M  ";'   DQ<  (L1  "$#   ?@0+ 'D $@!U !L <@ C &\ *P!M 3, :P$Z
M &D"0 !G T8 9@-, &0$4@!C!%D 801@ %\%:0!>!7, 7 9_ %H&C0!9!YP
M5PBM %8(P0!5">$ 5 OV %0+_P!4"_\ 5 O_ ,8?  "V)0  J2@  )XH  "4
M)0  BR$  (,;  ![%   = X# &X)#0!I"!0 9@D= &0*)0!B"BT 8 LT %X+
M.@!="T  6PQ' %H,30!8#%0 5PU< %4-9 !4#6\ 4@U[ % .B@!/#IH 3@ZL
M $P/P@!,$., 2Q#Y $L0_P!+$?\ 2Q#_ +\F  "P*P  I"\  )DO  "/+0
MABD  'TD  !T'@  ;!<  &41!P!?#A  7 \7 %H0'P!8$"< 5A N %00-0!3
M$#L 4A%" % 12 !/$5  3A%7 $P28 !+$FL 21)X $@3AP!&$Y< 112I $04
MO@!#%=\ 0Q;X $,6_P!#%O\ 0Q;_ +HK  "K,0  H#0  )4U  "+-   @3$
M '@K  !O)@  9B   %X9 0!7% T 5!03 %$4&P!/%2, 3A4J $P5,0!+%C<
M218^ $@61 !'%TP 11=4 $0770!#&&< 01AT $ 9@P _&I0 /1JF #P;NP [
M&]L .QSV #P<_P \'/\ /!S_ +4P  "H-@  G#D  )$[  "'.@  ?C<  ',R
M  !J+0  82<  %DA  !1&PD 3!D0 $H:%P!(&A\ 1AHF $4;+0!#&S, 0ALZ
M $$<00! '$@ /AQ0 #T=60 \'F0 .QYQ #D?@  X'Y( -R"D #8@N  U(=8
M-2'T #4B_P U(?\ -B'_ +(T  "D.@  F3X  (\_  "%/P  >SP  ' X  !G
M,@  72T  %0H  !,(@4 1A\. $,?% !!'QL /Q\B #X@*0 ](#  .R V #HA
M/0 Y(44 .")- #<B5P V(V( -"-N #,D?@ R)(\ ,26B "\EM@ O)M( +R;R
M "\F_P P)O\ ,";_ *\X  "B/@  ED(  (Q#  ""0P  >$$  &X]  !C.
M6C,  %$N  !(* $ 0"0, #TC$0 [)!@ .20? #@D)@ V)"P -24S #0E.@ S
M)D( ,B9* #$G5  P)U\ +RAL "XH>P L*8T *RJ@ "HJM  I*L\ *2OP "HK
M_P J*O\ *RK_ *P\  "?0@  E$8  (I'  " 1P  =D4  &Q"  !A/0  5S@
M $XS  !$+@  /"D) #<H$  U*!4 ,R@< #(H(P P*"D +RDP "\J-P N*C\
M+2M( "PK4@ K+%T *BQJ "@M>0 G+8L )BZ> "4NLP D+\T )"_N "4O_P E
M+_\ )B[_ *D_  "=10  DDD  (A+  !^3   =$H  &I'  !>0@  5#T  $LY
M  !!-   ."\& #(M#0 P+1, +BT9 "TM(  K+2< *BXN "DN-0 I+ST *"]&
M "<P3P E,%L )#%H ",Q=P B,HD (3*= !\SL0 >,\L 'C/M !\S_P @,_\
M(3+_ *9#  ":20  D$T  (9/  !\4   <T\  &A,  !<1@  4D,  $D_   _
M.P  -C8" "XR#  K,A$ *3(7 "@R'@ F,B0 )3,K "0S,@ C-#H (C1# "$U
M30 @-5@ 'S9E !XV=0 <-X< &S>; !HWKP 9.,@ &3CK !HX_P ;-_\ &S?_
M *-'  "830  CE$  (13  ![5   <5,  &90  !:3   4$D  $=%   ]00
M,ST  "HY"0 E-PX (S<4 "(X&P A."( (#@H !\X,  >.3@ '3E! !PZ2P :
M.E8 &3MC !@[<@ 6.X4 %3R9 !0\K0 3/<8 $SWI !0\_0 5//\ %CO_ *!+
M  "540  BU4  ()8  !Y60  ;E@  &16  !840  3D\  $5+   Z1P  ,$,
M "= !0 @/@T '3X1 !P^%P ;/AX &CXE !D^+0 8/S4 %C\^ !4_2  40%,
M$T!@ !)!<  108( $$&7  ]!K  .0L0 #D+G  ]!_  00?\ $$#_ )U0  "3
M5@  B5H  (!=  !V7@  ;%T  &);  !65P  3%4  $%1   V3@  +$L  "-(
M   ;10D %T0/ !5$%  411L $T4B !)%*0 113$ $44[ !!&10 /1E  #D=>
M  U';0 ,1W\ "T>3  E'IP (1[X "$?@  E']@ *1O\ "T;_ )I5  "06P
MAV   'UB  !S8P  :F(  &!A  !37@  1UH  #Q7   R50  *%(  !]0   7
M3@0 $4P,  ],$0 .3!< #DP>  U-)0 ,32X "TTW  I-0@ )34T !TY:  9.
M:0 $3GL  DZ/  %.I   3;H  $W;  %-\@ !3?\  DS_ )9;  "-8@  A&8
M 'IH  !Q:0  :&D  %QG  !/9   0F$  #=?   M7   (UH  !I8   25P$
M#58)  E5#@ '51, !E4:  15(@ #52H  E4T  !5/@  54H  %97  !690
M57<  %6+  !5H   5;8  %34  !4\0  4_T  %/_ )-B  "*:   @&P  '=N
M  !O;P  8VX  %9L  !):@  /6@  #)F   G90  '6,  !5B   .80  "6 (
M  -@#0  7Q$  %\7  !?'@  7R8  %\O  !?.@  7T4  %]3  !?80  7G(
M %Z'  !=G   7;(  %S/  !<[P  6_T  %O_ )!J  "&;P  ?7(  '5T  !J
M=0  770  $]S  !"<@  -G   "MO   @;@  %VT  !!L   *;    FL&  !K
M"P  :@\  &H4  !J&@  :B$  &DJ  !I-   :4   &E.  !I7   :6T  &B"
M  !HF   9ZX  &;*  !E[0  9?P  &3_ (MQ  ""=@  >GD  '![  !B>P
M57L  $AZ   [>@  +WH  "-Y   9>   $7<   IW   #=P   '<"  !W"
M=@T  '80  !V%0  =AL  '8C  !V+@  =3H  '5'  !U5@  =6@  '1\  !T
MD@  <ZH  '+$  !QZ0  </L  '#_ (9Y  !_?0  =G\  &B!  !:@@  3((
M #^#   RA   )8,  !J#   1@P  "H,   *#    A    (4   "$ P  @P@
M (,-  "#$   @Q4  (0<  "$)@  A#(  (0_  "#3P  @V   ()U  ""C
M@:0  ("]  !_XP  ?OD  '[_ (*   !ZA   ;(8  %Z(  !0B@  0HL  #6-
M   GC0  &XT  !&.   *C@   (\   "1    D@   )(   "2    D@$  )('
M  "2#   DA   ),5  "3'0  E"@  )0V  "410  DU<  )-K  "3@@  DIP
M )&V  "0V   C_,  (__ 'Z'  !PB@  88T  %.0  !%DP  -Y4  "F6   <
MEP  $9@   F9    FP   )P   ">    H    *    "@    H    *$   "A
M!   H@D  *,.  "D%   I1T  *8J  "F.@  IDP  *5@  "E>   I9(  *2L
M  "DR0  H^L  *+Z '..  !DD0  5I4  $>9   YG   *IX  !V@   1H0
M"*,   "E    IP   *D   "L    K@   *X   "N    KP   +    "Q
ML@   +,&  "U#0  MQ,  +D>  "Y+@  ND   +I4  "[:@  NH4  +FA  "Y
MNP  NMX  +GR &>5  !8F0  2IX  #NB   LI@  ':@  !&J   'K    *\
M  "Q    M    +@   "[    O    +P   "^    OP   ,    #"    Q
M ,8   #( P  RPL  ,\2  #1(   T3(  -)&  #370  U'8  -22  #5JP
MU<0  -3B %N=  !,H@  /:<  "^L   ?KP  $;$   >U    N    +L   "^
M    P@   ,<   #*    S    ,P   #.    T    -(   #5    V    -L
M  #?    X@   .8+  #K$P  ["0  .TX  #N3@  [V<  /""  #PG   \+(
M /'% /\  P#_  $ _P $ /\ "0#_  \ _P 8 /\ ) #_ #  _P \ /\ 1P#_
M %$ _P!9 /\ 8 #] &< _ !M /H <P#Y 'D ^ !_ /8 A0#U (P \P"4 /(
MG0#P *< [@"S .P Q #K .$ Z@#X .D _P#G /\ V0#_ ,L _P#" /\ O0#_
M /\   #_    _P   /\   #_  P _P 4 /\ ( #_ "L _@ W /H 0@#V $L
M\@!3 /  6P#N &$ [ !G .H ;0#H ', YP!Y .4 ?P#C (8 X0". -\ E@#=
M *  VP"L -@ NP#4 -$ TP#P -  _P#. /\ R #_ +T _P"V /\ L@#_ /\
M  #_    _P   /\   #]  @ ]P 0 /, &@#O "8 [0 Q .@ .P#C $4 X !-
M -P 50#9 %L U@!A -, 9P#1 &P SP!R ,T > #+ '\ R0"' ,< D #% )H
MPP"E ,  L@"^ ,4 O #E +H ^P"X /\ MP#_ +  _P"I /\ I0#_ /\   #_
M    _@   /4   #L  , Y0 - -\ %0#: "  U  J -  -0#+ #X R !' ,4
M3@#" %4 P !; +X 80"\ &8 N@!L +@ <@"V '@ M0"  +, B "Q )( K@">
M *P J@"I +L J #5 *8 \P"D /\ HP#_ *$ _P"; /\ F #_ /\   #[
M\    .4   #8    S@ ) ,< $0#" !H O@ D +L +@"W #@ M !  +$ 2 "N
M $X K !4 *H 6@"I %\ IP!E *4 :P"D '$ H@!X *  @0"> (L G "6 )D
MHP"7 +( E@#' ), Z "2 /X D0#_ )  _P"- /\ BP#_ /D   #K    W0
M ,\   #&    O  $ +4 #0"P !4 K  > *@ * "E #$ H@ Y )\ 00"= $@
MFP!. )D 4P"7 %D E@!> )0 9 "2 &H D !Q (X >@", (, B@"/ (@ G "&
M *H A "\ (( W "! /8 @ #_ '\ _P!_ /\ ?@#_ .P   #:    R0   +X
M  "V    K@   *< "0"A !  G  8 )@ (@"5 "H D@ R )  .@"- $$ BP!'
M (D 30"' %( A@!8 (0 70"" &0 @0!K '\ <P!] 'T >P"( '@ E0!V *,
M=0"T ', S !Q .T < #_ '  _P!P /\ < #_ -\%  #*"@  O L  +$)  "H
M!   H0   )L  P"4  P CP 3 (H &P"' "0 A  L ($ ,P!_ #H ?0!! 'L
M1P!Y $P =P!2 '8 5P!T %T <@!D '  ;0!O '8 ; "" &H CP!I )T 9P"N
M &4 PP!D .0 8P#Z &, _P!B /\ 8P#_ - .  "_$@  LA,  *<2  "=$
ME0L  (\#  ")  < @@ . 'X %0!Z !X =@ E '0 +0!Q #0 ;P Z &X 0 !L
M $8 :@!, &D 4@!G %@ 9@!? &0 9P!B '$ 8 !\ %X B0!< )@ 6P"I %D
MO !8 -P 6 #T %@ _P!7 /\ 5P#_ ,86  "V&@  JAT  )\<  "5&0  C10
M (4/  !^"0  =P$* '( $ !N !< :@ ? &@ )P!E "X 9  T &( .P!@ $
M7P!& %T 3 !< %, 6@!: %@ 8@!7 &P 50!W %, A0!2 )0 4 &E $\!N !.
M M( 303P $T%_P!-!?\ 307_ +\=  "P(@  HR4  )DE  "/(@  A1T  'T8
M  !U$@  ;@T" &<&# !C Q$ 7P(9 %T#(0!;!"@ 600O %<%-0!6!3L 5 9!
M %,&1P!1!DX 4 =5 $X'7@!-"&< 2PAS $D)@0!("9( 1PJC $4*M@!$"]
M1 SO $,-_P!##?\ 1 W_ +DD  "J*0  GBP  )0L  "**@  @"8  '<A  !N
M&P  9A0  %\/!0!9"PT 50H3 %,+&P!1"R( 3PPI $T,+P!,##8 2PT\ $D-
M0@!(#4D 1@U1 $4.6@!$#F0 0@YP $ .?P _#Y  /A"B #P0M@ [$-$ .Q'Q
M #L1_P [$?\ /!'_ +0I  "F+P  FC(  ) R  "&,0  ?"T  '(H  !I(P
M81T  %D6  !1$0@ 3 \0 $H0%@!($!T 1A D $40*P!#$3$ 0A$W $$1/@!
M$44 /A)- #T25@ \$F$ .A-M #D3?  W%(T -A2? #45LP T%<T ,Q;N #06
M_P T%O\ -!;_ *\N  "B-   ES<  (PX  ""-@  >#0  &XN  !E*@  7"0
M %0>  !,& 0 1A0- $(4$@! %!D /Q0@ #T5)P \%2T .Q4T #D6.@ X%D(
M-Q9* #874P U%UX ,QAJ #(9>0 P&8H +QJ= "X:L0 M&\H +1OL "T<_P N
M&_\ +AO_ *PR  "?.   E#L  (H\  " /   =CD  &LT  !B+P  62H  % E
M  !''P  0!H* #P9$  Z&18 .!D= #8:(P U&BD -!HP #,:-P R&SX ,1M'
M "\<4  N'5L +1UG "P>=@ J'H@ *1^; "@?K@ G(,< )B#J "<@_@ H(/\
M*"#_ *DV  "=/   DC\  (=!  !]0   =#X  &DZ  !?-0  5C   $TK  !$
M)0  .R ' #8>#@ S'A, ,AX9 # >(  O'B8 +A\M "T?-  L(#L *R!$ "HA
M3@ I(5@ )R)E "8B=  E(X4 (R.9 "(DK0 A),4 (27H "(E_0 B)/\ (R3_
M *8Z  ":/P  CT,  (5%  ![1   <D,  &<_  !=.@  4S8  $HQ  !!+
M."8# #$C#  N(A$ +"(6 "HB'0 I(B, *",J "<C,0 F)#D )25! "0E2P C
M)E8 (B9C "$G<@ ?)X, 'BB7 !THJP ;*<, &RGF !PI^P =*?\ 'BC_ *,^
M  "80P  C4<  (-)  !Z20  <$<  &9$  !:/P  43L  $<W   ^,@  -2T
M "PH"0 H)P\ )R<4 "4G&@ D)R$ (R@G "(H+@ A*38 ("D_ !\J20 >*E0
M'2M@ !LK;P :+($ &2R5 !<MJ0 6+<$ %BWD !<M^@ 8+?\ &2W_ *%!  "5
M1P  BTL  ()-  !X30  ;DP  &1)  !81   3T   $8]   ].   ,S0  "HO
M!@ D+ T (2P2 " L&  ?+1X 'BTE !TM+  <+C0 &RX\ !HO1@ 8+U$ %S!>
M !8P;0 5,7\ $S&3 !(QJ  1,K\ $3+B !(R^0 3,?\ $S'_ )Y%  "32P
MB4\  (!1  !V4@  ;5   &).  !620  348  $1#   [/P  ,3H  "<V P ?
M,@L '#(0 !LR%0 9,AL &#(B !<S*0 6,S$ %30Z !0T1  3-$\ $C5< !$U
M:P 0-GT #S:1  XVI@ --[P #3?=  TV]@ .-O\ #S;_ )M)  "13P  AU,
M 'Y6  !U5@  :E4  &!3  !53P  3$P  $))   X10  +D$  "0]   <.@@
M%C@. !4X$@ 4.!@ $SD? !(Y)@ 1.2X $#DW  \Z00 ..DP #3M9  T[:  +
M.WH "CN-  D\H@ '/+@ !SS5  @\\  )._\ "CO_ )A.  ".5   A5@  'Q;
M  !R6P  :%H  %Y8  !350  25(  #Y.   T2P  *D<  "%$   80@, $D +
M ! _$  ./Q4 #C\<  U (P ,0"L "T T  I /@ )04H !T%6  9!90 $078
M T&*  %!GP  0;0  $'0  %![@ !0?P  D#_ )54  ",60  @UX  'E@  !P
M8   9F   %U>  !16P  15<  #I4   O40  )4\  !Q,   42@  #D@(  M'
M#@ (1Q( !T<9  9'(  %2"@  T@Q  )(.P  2$<  $A3  !(8@  2',  $B&
M  !(FP  2+$  $?,  !'[0  1_L  $?_ )):  ")8   @&,  '=E  !N9@
M968  %ED  !,8   0%T  #5;   J60  (%<  !=5   04P  "U('  51#0 !
M4!$  % 6  !0'0  4"4  % N  !0.   4$,  %!0  !07@  4&\  %"#  !/
MF   3ZX  $[)  !.ZP  3?L  $W_ (]A  "&9@  ?6D  '1L  !L;0  86L
M %-I  !&9P  .F0  "]C   D80  &E\  !)>   ,7   !EP&  !;"P  6@\
M %H3  !:&0  62$  %DI  !9,P  63\  %E,  !96@  66L  %A^  !8E
M5ZL  %?%  !6Z0  5?L  %7_ (QH  "";0  >G   ')R  !G<@  6G$  $QP
M   _;@  ,VT  "AK   =:@  %&@   UG   '9P   &8#  !F"0  90T  &41
M  !D%0  9!P  &0D  !D+@  9#H  &-'  !C50  8V8  &-Z  !BD   8:<
M &#!  !?Y@  7_H  %[_ (=O  !_=   >'<  &YX  !@>   4G<  $5W   X
M=@  *W8  "!T   6<P  #G,   =R    <@   '(   !Q!0  <0H  '$.  !P
M$0  <!<  ' >  !P)P  <#,  &]   !O4   ;V   &YT  !NBP  ;:(  &R\
M  !KX@  :O@  &G_ (-W  !\>P  <WT  &5^  !7?P  27\  #Q_   O@
M(G\  !=^   /?@  !WX   !_    ?P   '\   !^    ?@4  'X*  !^#0
M?A$  'X7  !^(   ?BL  'TY  !]2   ?5D  'QM  !\A   >YP  'JV  !Y
MV@  >/4  '?_ (!_  !W@@  :8,  %N%  !-A@  /X@  #*)   DB0  &(D
M  ^)   'B@   (L   ",    C0   (T   ",    C    (P#  ","   C0T
M (T1  "-%P  CB(  (XO  "./P  C5   (UD  ",>P  C)4  (NN  "*S0
MB>\  (G_ 'N%  !MB   7HH  %"-  !"CP  -)$  ":2   9DP  #I0   :5
M    E@   )@   ":    FP   )L   ";    FP   )L   "<    G04  )T+
M  ">$   GQ<  * D  "@-   H$8  *!9  "?<   GXH  )ZE  ">P@  G>@
M )SY '",  !ACP  4Y(  $26   VF0  )YL  !F<   /G0  !9\   "A
MHP   *4   "H    J0   *D   "I    J@   *L   "L    K0   *X!  "P
M"0  L@\  +,8  "T)P  M#D  +5-  "T9   M'X  +.:  "SM   L]4  +/P
M &23  !5EP  1YL  #B?   IH@  &J0   ZF   $J    *L   "M    L
M +0   "V    N    +@   "Y    N@   +P   "]    OP   ,    ##
MQ0<  ,D/  #*&@  RRP  ,Q   #-5@  SF\  ,V+  #,J   S,(  ,SB %B;
M  !)H   .J4  "RI   <JP  #ZX   2Q    M    +<   "Z    O@   ,,
M  #&    R    ,@   #*    RP   ,T   #/    T@   -4   #9    W0
M .$%  #F#P  YQX  .@R  #I2   ZF   .M[  #KEP  [*X  .S" /\   #_
M    _P   /\ !@#_  T _P 5 /\ (0#_ "P _P X /\ 0P#_ $P _@!4 /L
M6P#Z &( ^ !H /8 ;@#U '0 ] !Z /( @ #Q (< [P"/ .T EP#K *$ Z0"M
M .< O0#E -@ Y #S .( _P#@ /\ T #_ ,0 _P"\ /\ M@#_ /\   #_
M_P   /\   #_  D _P 1 /\ ' #] "< ^0 R /4 /0#Q $8 [0!/ .L 5@#H
M %P Y@!B .0 : #C &X X0!S -\ >0#= (  V@"( -@ D0#4 )L T@"F ,\
MM #, ,D R0#I ,@ _P#' /\ P0#_ +< _P"O /\ JP#_ /\   #_    _P
M /\   #X  4 \@ . .X %P#J "( Y@ L .$ -P#= $  V !) -, 4 #0 %8
MS@!< ,P 8@#* &< R !M ,8 <P#$ 'D P@"! ,  B@"^ )0 O "? +D K "V
M +X M #= +, ]P"Q /\ L #_ *@ _P"B /\ G@#_ /\   #_    ^0   .\
M  #F    WP + -8 $@#0 !P S  F ,@ , #$ #H P !" +T 2@"[ %  N !6
M +8 6P"U &$ LP!F +$ ; "P '( K@!Z *P @@"I (P IP"8 *4 I0"C +0
MH #+ )\ [@"= /\ G #_ )D _P"4 /\ D0#_ /\   #V    Z@   -T   #/
M    QP & ,  #P"[ !< MP @ +, *@"P #, K0 [ *H 0P"G $D I0!/ *,
M50"B %H H !? )X 90"= &L FP!R )D >P"7 (4 E "0 )( G0"0 *P C@"_
M (P X@"+ /H B0#_ (D _P"& /\ @P#_ /0   #D    U    ,@   "_
MM0 ! *X "P"I !( I0 ; *$ (P"> "P FP T )@ / "6 $, E !) )( 3@"0
M %, C@!9 (T 7@"+ &0 B0!K (< <P"% 'T @P"( ($ E0!_ *0 ?0"U 'L
MSP!Y /$ > #_ '< _P!W /\ =0#_ .4   #1    PP   +@   "O    J
M *  !@":  X E0 5 )$ '@". "8 BP M (@ -0"& #P A !" (( 1P"  $T
M?P!2 'T 6 ![ %X >0!E '@ ;0!V '8 <P"! '$ C@!O )T ;0"N &P Q !J
M .< :0#] &@ _P!H /\ :0#_ -4#  ##!P  M@@  *L&  "B    FP   )0
M  "-  H B  0 (, & !_ "  ?  G 'H +@!W #4 =0 [ '0 00!R $< < !,
M &\ 4@!M %@ :P!? &D 9@!G '  90![ &, B !B )< 8 "G %X NP!= -P
M7 #V %P _P!; /\ 6P#_ ,D-  "Y$   K!$  *$0  "7#0  CP@  (@   ""
M  4 >P - '< $@!S !H ;P A &P * !J "\ :  U &< .P!E $$ 8P!& &(
M3 !@ %( 7P!9 %T 80!; &H 60!U %< @@!5 )$ 5 "B %, M0!1 ,\ 4 #O
M %  _P!0 /\ 4 #_ +\4  "P&   I!H  )D9  "/%@  AQ$  '\-  !W!@
M<0 ( &L #@!G !0 9  ; &$ (@!> "D 70 O %L -0!9 #L 6 !! %8 1@!5
M $T 4P!4 %( 7 !0 &4 3@!P $P ?0!+ (T 20"> $@ L !' ,< 1@#I $8
M^P!& /\ 10#_ +@;  "J(   GB(  ),B  ")'P  @!H  '<5  !O$   : L
M &$$"@!= !  60 6 %8 '0!4 ", 4@ J %  , !/ #4 3@ [ $P 00!+ $@
M20!/ $<!5P!& 6$ 1 )L $,">0!! XD 0 .: #X$K0 ]!,0 / 7E #P'^  \
M!_\ / ?_ +(B  "E)P  F2D  (XI  "$)P  >R,  '$>  !I&   81(  %H-
M P!3" P 3P41 $P%%P!*!AX 2 8D $<&*@!%!S  1 <V $,(/0!!"$, 0 A+
M #X)4P ]"5T .PIH #H*=@ X"X< -PN9 #4+K  T#,( ,PSD #,-^0 S#?\
M- W_ *TG  "@+   E2\  (LO  " +@  =RH  &TE  !D(   7!H  %04  !,
M#P8 1@P- $,,$@!!#!@ /PP? #X,)0 \#2L .PTR #H-.  X#3\ -PY' #8.
M4  T#EH ,PYF #$/=  P#X4 +A"8 "T0JP L$,, *Q'E "P1^@ L$?\ +1'_
M *HL  "=,0  DC0  (<U  !]-   =#$  &HK  !@)P  6"$  $\;  !'%@
M0!$) #L0#P Y$!0 -Q ; #80(0 T$"< ,Q$M #(1-  Q$3L ,!%# "X230 M
M$E< +!)C "H3<0 I$X( )Q25 "84J0 E%<  )!7C "46^@ F%O\ )A7_ *8Q
M  ":-@  CSD  (4Z  ![.0  <38  &<Q  !=+0  5"@  $PB  !#'0  .Q<%
M #44#0 R$Q$ ,107 "\4'0 N%"0 +!0J "L5,0 J%3@ *19  "@62@ G%U0
M)A=@ "08;P C&(  (1F3 " 9IP ?&;X 'AK@ !\:^  @&O\ (!K_ *,T  "8
M.@  C3T  (,^  !Y/0  ;SL  &4W  !;,@  4BT  $DH  ! (P  .!X! # 9
M"@ L& \ *A@4 "D8&@ G&"  )ADG "49+0 D&C4 (QH^ "(;1P A&U( (!Q>
M !\=;  ='7X '!V1 !H>I0 9'KP &!_= !D?]@ :'_\ &Q[_ *$X  "5/0
MBT$  (%"  !W0@  ;4   &,\  !9-P  3S,  $8N   ]*0  -20  "T@!P G
M'0T )1T2 ",=%P A'1T (1TD " >*P ?'C( 'A\[ !T?10 <($\ &B%< !DA
M:@ 8(GL %B*/ !4BHP 4([H $R/: !0C]0 5(_\ %B/_ )X\  "300  B40
M ']&  !U1@  ;$0  &)!  !7/   33@  $0T   \,   ,RL  "HF P C(@L
M("$0 !XA%0 <(AL &R(A !HB*  :(S  &2,X !@D0@ 6)4T %259 !0F:  3
M)GD $B:- !$GH@ 0)[@ #B?6 ! H]  1)_\ $2?_ )Q   "110  AT@  'U*
M  !T2@  :DD  &!&  !500  3#X  $,Z   Z-@  ,3(  "@M   @*0D &R<.
M !DG$@ 8)Q@ %B<? !4H)0 4*"T $R@V !(I0  2*4L $2I7 ! J9@ .*W<
M#BN+  TLGP ,++4 "RS/  PL[P -+/\ #2O_ )E$  "/20  A4P  'Q.  !S
M3P  :4X  %Y+  !31P  2D0  $)    Y/0  +S@  "4T   =, 4 %BT, !0L
M$  3+14 $BT< !$M(P 0+2H #RXS  XN/0 -+T@ #2]5  PP8P *,'0 "3"(
M  @QG  &,;$ !C'+  8QZP ',/P "##_ )=(  "-30  @U$  'I3  !Q5
M9U(  %U0  !23   24H  $!&   U0@  *SX  "(Z   :-P$ $C0)  \S#@ .
M,Q, #3,9  TS(  ,-"@ "S0Q  HU.P (-48 !S52  4V8  $-G$  C:$   V
MF0  -J\  #;(   VZ   -OD  37_ )1-  "*4@  @58  'A8  !O60  95@
M %M5  !14@  1T\  #Q,   Q2   )T0  !Y!   6/P  $#P'  LZ#0 ).A$
M"#L7  8['@ %.R8 !#LN  ([.  !/$,  #Q/   \7@  /&X  #R!   \EP
M/*P  #O%   [YP  ._@  #O_ )%2  "(6   ?UP  '9=  !M7@  8UT  %I<
M  !.6   0E0  #=1   M3@  (TL  !I)   21@  #40&  =##  #0Q   $,5
M  !#&P  0R,  $,K  !#-0  0T   $--  !#6P  0VL  $-^  !#E   0JH
M $+#  !!Y@  0?D  $'_ (Y8  "&7@  ?6$  '-C  !K9   8F,  %=A  !)
M70  /5H  #)8   G50  'E,  !51   .3P  "4T%  )-"P  3 X  $P3  !+
M&   2Q\  $LH  !+,@  2ST  $M)  !+5P  2V<  $I[  !*D   2:<  $G
M  !(Y   2/@  $?_ (M?  "#9   >F<  '%I  !I:@  7FD  %!F  !#9
M-V$  "Q?   A70  &%L  !!9   *6    U<#  !7"0  5@T  %40  !5%0
M5!L  %0C  !4+0  5#D  %1%  !44P  5&0  %-W  !3C0  4J0  %&]  !0
MX@  4/@  $__ (AG  !_:P  =VX  &]P  !E<   5VX  $IL   ]:P  ,&D
M "5H   :9@  $60   MC   $8@   &(!  !A!@  8 L  & .  !?$@  7Q<
M %\>  !>*   7C,  %Y   !>3P  7E\  %UR  !=B   7*   %NY  !:WP
M6?<  %C_ (1N  !\<@  =74  &MV  !==0  3W0  $)S   U<P  *'(  !UP
M   3;P  #&X   1N    ;@   &X   !L @  ; <  &L+  !K#@  :Q(  &H9
M  !J(@  :BT  &HZ  !I20  :5H  &EL  !H@P  9YL  &:U  !EV   9/4
M &3_ (!U  !Z>0  <'L  &)[  !4?   1GP  #E\   L?   'WL  !1Z   -
M>@  !'H   !Z    >@   'H   !Y    >0$  '@&  !X"P  > X  '@3  !X
M&@  >"4  '@R  !W00  =U(  '=E  !V?   =94  '2O  !SS@  <O$  ''_
M 'Y]  !U@   9X$  %B"  !*@P  /(0  "Z%   AA0  %84   V%   #A0
M (8   "'    B    (@   "'    AP   (<   "'!   APD  (<.  "($P
MB!P  (@I  "(.   ATH  (==  "&<P  AHT  (6G  "$Q0  @^P  (+^ 'B$
M  !JA@  7(@  $V*   _C   ,8X  "./   6CP  #9    *1    D@   ),
M  "5    E@   )8   "6    E@   )8   "7    EP   )<'  "8#0  F1,
M )H?  ":+0  FC\  )I2  "::   F8,  )F?  "8N@  E^(  );X &V*  !?
MC0  4)   $&3   SE@  ))<  !:8   -F0   9L   "=    GP   *$   "D
M    I0   *0   "E    I0   *8   "G    J    *D   "J!   K P  *X3
M  "N(0  KC,  *Y'  "N70  KG8  *Z3  "NK@  K<T  *SO &&1  !3E0
M1)@  #6<   FGP  %Z$   VC    I0   *<   "J    K    +    "R
MM    +,   "T    M0   +<   "X    N0   +L   "]    OP$  ,,+  #%
M%0  Q24  ,8Y  #'3P  QV@  ,:%  #&H@  QKP  ,;> %69  !'G0  .*(
M "FF   9J   #:L   "M    L0   +0   "W    N@   +\   #!    Q
M ,,   #%    Q@   ,@   #*    S0   ,\   #2    U@   -L   #@#
MX1@  .,K  #D00  Y5H  .9T  #FD0  Y:P  .7$ /\   #_    _P   /\
M 0#_  H _P 2 /\ '0#_ "@ _P T /\ /@#] $@ ^@!0 /< 5P#U %T ] !C
M /( :0#P &\ [P!T .T >P#K ($ Z0") .@ D@#F )P Y "H .( MP#? ,T
MW #N -D _P#9 /\ R@#_ +X _P"U /\ L #_ /\   #_    _P   /\   #_
M  8 _P / /P & #X ", ]  N /  . #K $( Z !* .4 40#B %@ X != -X
M8P#< &@ V0!N -8 = #4 'L T0"" ,\ BP#- )4 R@"A ,@ KP#% ,$ P@#C
M ,  ^P#  /\ NP#_ +  _P"H /\ I #_ /\   #_    _P   /L   #S  $
M[0 , .@ $P#C !X X  H -H ,@#3 #P SP!$ ,P 2P#) %$ Q@!7 ,0 70#"
M &( P0!G +\ ;0"] '0 NP![ +D A "W (X M "9 +( IP"O +< K0#0 *L
M\@"J /\ J0#_ *$ _P"; /\ EP#_ /\   #_    ]    .D   #@    U0 (
M ,X $ #) !@ Q0 B ,$ *P"\ #4 N0 ] +8 10"S $L L0!1 *\ 5@"N %L
MK !A *H 9@"I &T I@!T *0 ? "B (8 H "2 )X GP"< *X F0## )< YP"6
M /\ E0#_ )( _P"- /\ B@#_ /P   #P    XP   -0   #(    OP # +D
M#0"S !, KP < *P )0"I "X I0 V *, /@"@ $0 G@!* )T 4 "; %4 F0!:
M )< 7P"6 &8 E !L )( =0"0 'X C@"* (L EP") *8 AP"X (4 U@"$ /8
M@@#_ ($ _P!^ /\ ? #_ .T   #=    S    ,$   "X    K@   *< "0"B
M !  G@ 7 )H 'P"7 "< E  O )$ -P"/ #T C0!# (L 20") $X B !3 (8
M60"$ %\ @@!E (  ;0!^ '< ? "" 'H CP!X )X =0"O ', QP!R .P <0#_
M '  _P!P /\ ;@#_ -T   #)    O    +$   "I    H0   )D  P"3  P
MC@ 2 (H &0"' "$ A  I ($ , !_ #< ?0 ] 'L 0@!Y $@ > !- '8 4@!T
M %@ <@!? '$ 9P!O '  ; ![ &H B !H )< 9@"H &4 O !C .$ 8@#Z &$
M_P!A /\ 80#_ ,T!  "\!0  KP4  *4"  "<    E    (T   "&  @ @0 .
M 'P % !X !L =0 C '( *0!P #  ;@ V &T / !K $$ :0!' &@ 3 !F %(
M9 !9 &, 8 !A &D 7P!T %T @0!; )  60"A %< M !6 -  50#R %4 _P!4
M /\ 50#_ ,$,  "R#@  I@\  )L.  "2"P  B04  ((   ![  ( =0 + '
M$ !L !8 :  = &8 (P!C "H 80 P &  -@!> #L 70!! %L 1@!: $P 6 !3
M %8 6P!4 &0 4@!N %$ >P!/ (H 30"; $P K@!+ ,8 2@#J $D _@!) /\
M20#_ +D2  "J%@  GA<  )06  "*$P  @1   'D+  !Q P  :P & &4 #0!A
M !$ 70 8 %H '@!8 "0 5@ J %0 , !3 #8 40 [ %  00!. $< 30!. $L
M5@!) %\ 1P!I $8 =@!$ (4 0P"7 $$ J0!  +\ /P#B #\ ^  ^ /\ /P#_
M +(9  "D'@  F!\  (X?  "$'   >A@  '(2  !J#@  8@@  %P!" !7  X
M4P 3 %  &0!. !\ 3  E $H *P!( #  1P V $8 / !$ $( 0P!) $$ 40 _
M %H /@!E #P <@ Z ($ .0"3 #@ I0 V +H -@#; #4 ]  U /\ -0#_ *P@
M  "?)   E"8  (DF  !_)   =2   &P;  !D%0  7!   %0, 0!.!@H 2@(/
M $< % !$ !H 0@ @ $  )0 _ "L /@$Q #P!-P [ CX .0)% #@#30 V U8
M-01A #,$;@ Q!7X , 60 "\%HP M!K@ + ;4 "P'\  L"/\ + C_ *@E  ";
M*@  D"P  (8M  ![*P  <B<  &@B  !?'0  5Q<  $\2  !(#@0 00H+ #X'
M$  [!A4 .0<; #@'(0 V""8 -0@L #,(,@ R"3D ,0E! "\)20 N"E, + I>
M "L+;  I"WP * R/ "8,H@ E#+< ) S3 ",-\  D#?\ )0W_ *0J  "8+P
MC3(  (,R  !Y,0  ;RX  &4I  !<)   4Q\  $L9  !#$P  /! & #4-#  S
M#!$ ,0P6 "\,'  N#2( +0TH "L-+@ J#34 *0T] "<.1@ F#E  ) Y< ",/
M:@ B#WL (!". !\0H@ =$+< '!#4 !T1\@ =$?\ 'A'_ *$O  "5,P  BC8
M ( W  !V-@  ;3,  &,O  !9*@  4"4  $@@   _&@  .!4  # 1"  L$ X
M*A 2 "@0&  G$!X )1 D "00*@ C$3( (A$Z "$10P @$DX 'A): !T3:  ;
M$W@ &A.+ !@4H  7%+4 %A31 !85\0 7%?\ &!3_ )XS  "3-P  B#H  'X[
M  !T.P  :S@  &$T  !7+P  3BL  $4F   ](0  -!P  "T7!0 F$PP (Q,0
M "(3%0 @$QH 'Q,A !X4)P =%"\ '!4W !L500 :%DL &197 !<790 6%W8
M%!B) !,8G@ 2&+, $1G. !$9[P 2&?\ $QG_ )PV  "1.P  ACX  'P_  !S
M/P  :3T  %\Y  !5-0  3#   $,L   Z)P  ,B(  "H> 0 B&0D 'A<. !P7
M$@ :%Q< &1@> !D8)  8&2P %QDT !8:/@ 5&DD $QM5 !(;8P 1''0 $!R'
M  \=G  .';$ #1W+  T=[  .'?\ #QW_ )DZ  "//P  A$(  'M$  !Q0P
M:$(  %X^  !3.@  2C8  $$R   Y+0  ,2D  "@E   @( 8 &AT, !<<$  5
M'!4 %!T; !0=(@ 3'2D $AXR !$?/  0'T8 $"!3  X@80 -(7$ #"&%  LB
MF0 *(JX "2+'  DBYP *(OL "R'_ )<^  ",0P  @T8  'E(  !P2   9T8
M %Q$  !2/P  23L  $ X   X-   +S   "<L   >)P, %B,* !(A#@ 1(1,
M$"(9 ! B(  /(B< #B,O  TD.0 ,)$0 "R50  HE7@ ))F\ !R:"  8FE@ $
M)JP  R;$  0FY0 $)O< !B;_ )5"  "*1P  @4H  'A,  !O3   94L  %M(
M  !01   1T$  #\^   W.P  +38  "0Q   ;+0  $RH'  \H#0 -)Q$ #2@6
M  PH'0 +*"4 "BDM  DI-P '*D( !BI.  0K7  #*VP  2M_   KE   *ZD
M "O!   KXP  *_8  "K_ ))&  "(2P  ?T\  '91  !M40  8U   %I-  !/
M2@  1T<  #Y$   S0   *3P  " X   7-   $3$%  PO#  )+A  !RX5  8O
M&P %+R,  R\K  (P-0  ,#\  #!,   Q60  ,6D  #%\   QD0  ,:<  #"_
M   PX0  ,/4  "__ )!+  "&4   ?50  '56  !K5@  8E4  %A3  !.4
M14T  #I)   O10  )4(  !P^   4.P  #CD%  DW"P $-@\  383   V&0
M-B   #8I   V,@  -ST  #=)   W5P  -V<  #=Y   WCP  -J4  #:]   V
MX   -?4  #7_ (U0  "$5@  ?%H  ');  !I6P  8%L  %=9  !,5@  0%(
M #5.   J2P  ($@  !=&   00P  "T$$  1 "@  /PX  #X1   ^%@  /AT
M #XF   ^+P  /CH  #Y&   ^5   /F0  #YV   ]C   /:,  #R[   \W@
M._4  #O_ (I7  ""7   >5\  '!A  !H80  7V$  %1>  !'6P  .E<  "]5
M   E4@  &U   !)-   ,2P  !DH#  !)"0  2 T  $<0  !'%   1AH  $8B
M  !&+   1C<  $9#  !&40  1F   $5S  !%B0  1*   $2X  !#W   0O4
M $+_ (A=  !_8@  =V4  &YG  !G:   6V8  $YC  !!80  -%X  "E<   ?
M6@  %5<   Y6   '5    %,!  !2!@  40L  %$.  !0$0  3Q8  $\>  !/
M)P  3S(  $\_  !/30  3ET  $YO  !.A0  39T  $RU  !+V   2O4  $K_
M (5E  !\:0  =&P  &UN  !B;0  5&L  $=I   Z9P  +64  ")D   88@
M$&    E?    7@   %X   != P  7 @  %L,  !:#P  6A,  %D9  !9(@
M62T  %DZ  !92   6%@  %AK  !7@0  5YD  %:R  !5T@  5/0  %/_ (%L
M  !Y<   <W,  &AS  !:<@  3'$  #]P   R;P  )6X  !IL   1:P  "6H
M  !J    :0   &D   !H    9P,  &8(  !F#   9@\  &44  !E'   92<
M &0T  !D0P  9%,  &1E  !C>P  8I0  &&M  !@S0  7_$  %[_ 'UT  !W
M=P  ;GD  %]Y  !1>0  0WD  #9X   I>   ''<  !%V   *=0   '4   !U
M    =@   '4   !T    =    ',"  !S!P  <PP  '(0  !R%0  <B   '(L
M  !R.P  <4P  '%?  !Q=   <(X  &^H  !NQ@  ;.T  &O_ 'M[  !R?@
M9'X  %5_  !'@   .8$  "N"   >@0  $H$   J!    @0   ((   "#
M@P   (,   ""    @@   ((   ""    @@4  ((*  ""#P  @A<  ((C  ""
M,@  @D,  (%6  "!;   @(8  '^A  !^O0  ?>8  'S\ ':"  !H@P  684
M $N'   \B0  +HH  ""+   3BP  "HL   ",    C0   (\   "1    D@
M )$   "1    D0   )$   "1    D@   )("  "3"0  E \  )09  "4)P
ME#@  )1,  "38@  DWP  ).8  "2LP  D=@  )#V &J(  !<B@  38T  #^0
M   PD@  (90  !25   *E@   )<   "9    FP   )T   "?    H    *
M  "@    H    *$   "B    HP   *0   "E    I@<  *@0  "H'   J"T
M *E   "I5@  J6\  *F+  "HJ   I\<  *;L %^/  !0D@  098  #.9   C
MG   %)T   J?    H0   *,   "F    J    *P   "N    KP   *\   "P
M    L    +(   "S    M    +8   "W    N@   +T'  "_$   OQ\  , S
M  # 20  P&(  ,!^  # FP  P+<  +_8 %.7  !$FP  -9\  ":C   6I0
M"Z<   "J    K0   +    "S    M@   +L   "]    P    +\   #!
MP@   ,0   #&    R    ,H   #,    SP   -,   #:!P  VQ,  -TE  #>
M.P  WU,  .!N  #?C   W:D  -W" /\   #_    _P   /\   #_  < _P 0
M /\ &0#_ "0 _P O /P .@#Y $, ]0!+ /, 4@#Q %D [P!> .T 9 #K &D
MZ0!O .< =0#F 'P Y "$ .( C0#@ )< W0"B -H L0#5 ,4 T@#H -  _P#/
M /\ Q #_ +@ _P"O /\ J0#_ /\   #_    _P   /\   #_  ( ^P - /<
M%0#S !\ [P I .H - #F #T X@!% -X 3 #; %, V !8 -0 7@#2 &, T !I
M ,X ;@#, '4 R@!] ,@ A0#& )  P@"; ,  J0"^ +H NP#9 +D ]P"X /\
MM #_ *D _P"B /\ G0#_ /\   #_    _P   /8   #N    YP * .$ $0#<
M !H UP C -  +@#+ #< QP _ ,0 1@#! $T OP!2 +T 6 "[ %T N0!B +@
M: "V &X M !U +$ ?@"O (@ K0"3 *H H0"H +$ I@#( *0 [0"B /\ H@#_
M )L _P"5 /\ D0#_ /\   #\    [@   .,   #8    S0 % ,8 #@#! !4
MO0 > +D )P"U #  L@ X *\ 0 "L $8 J@!, *@ 40"G %8 I0!; *, 80"A
M &< GP!N )X =@"; (  F0", )< F0"4 *@ D@"\ )  WP". /L C@#_ (L
M_P"& /\ @P#_ /@   #I    W    ,P   #!    N    +( "@"L !$ J  8
M *4 (0"B "D G@ R )P .0"9 #\ EP!% )4 2@"4 %  D@!5 )  6@"/ &
MC0!G (L ;P") '@ A@"$ (0 D0"" *  @ "R 'T S !\ /$ >P#_ 'H _P!W
M /\ =0#_ .8   #3    Q@   +L   "Q    IP   *$ !0";  T EP 3 ),
M&P"0 ", C  K (H ,@"( #@ A@ ^ (0 1 "" $D @0!. '\ 4P!] %D >P!@
M 'D : !W '$ =0!\ ', B0!P )@ ;P"I &T OP!K .8 :@#_ &D _P!I /\
M9P#_ -,   ##    M0   *L   "C    FP   )(   ",  H AP 0 (, %@!_
M !T ?0 D 'H *P!X #( =@ X '0 /0!R $( <0!( &\ 30!M %, ; !9 &H
M80!H &H 9@!T &0 @0!A )$ 7P"B %X M@!< -4 6P#W %L _P!: /\ 6@#_
M ,4   "V @  J0(  )\   "6    C@   (<   "   4 >@ , '4 $0!Q !@
M;@ > &L )0!I "L 9P Q &8 -P!D #P 8P!! &$ 1P!? $T 7@!3 %P 6P!:
M &0 6 !N %8 >P!4 (H 4@"; %$ K@!0 ,@ 3P#N $X _P!. /\ 30#_ +L*
M  "L#0  H T  )4,  ","   @P(  'P   !U    ;@ ( &D #@!E !, 8@ 9
M %\ 'P!= "4 6P K %D ,0!8 #8 5@ [ %4 00!3 $< 40!. %  50!. %X
M3 !H $H =0!( (0 1P"5 $4 J !$ +\ 0P#D $( _ !" /\ 0@#_ +(1  "E
M%   F14  (X3  "$$0  >PT  ',(  !L    90 # %\ "P!;  \ 5P 4 %0
M&@!1 !\ 3P E $X *P!, #  2P V $D / !( $( 1@!( $4 4 !# %D 00!C
M #\ ;P ^ 'X / "0 #L HP Z +@ .0#9 #@ ]0 X /\ . #_ *P7  "?&P
MDQT  (D<  !_&0  =14  &P0  !D#   708  %8 !@!1  P 30 0 $H %0!'
M !H 10 @ $0 )@!" "L 00 Q #\ -@ ^ #T / !$ #L 2P Y %0 -P!? #8
M:P T 'H ,@", #$ G@ P +, +P#. "\ [P N /\ +@#_ *<>  ":(@  CR0
M (0D  !Z(0  <1T  &<8  !?$P  5PX  % *  !) P@ 10 - $$ $0 ^ !8
M/  ; #H (0 Y "8 -P L #8 ,@ T #@ ,P _ #$ 1P P %  +@!; "T 9P K
M '8 *@"( "@ G  G +  )@#) "4 Z@ E ?L )0'_ *(C  "6*   BRH  ($J
M  !W*   ;24  &0@  !;&P  4A4  $L0  !## ( /0<) #D##@ V 1( ,P$7
M #$!'  P 2( +P(G "T"+0 L S0 *@,[ "D$0P H!$T )@58 "4%90 C!G0
M(@:& " &F@ ?!ZX '@?& !T'YP ="/@ '0G_ )\H  "3+0  B"\  'XO  !T
M+@  :BL  &$F  !8(0  3QP  $<7   _$@  . X$ #$+"@ N" X *P<2 "D'
M%P H"!T )P@C "4(*0 D"3  (PDW "$*0  @"DH 'PM5 !T+8@ ;#'( &@R%
M !@,F0 7#*T %@S& !4-Y@ 5#?D %@W_ )PM  "0,0  AC0  'PT  !R,P
M:#$  %\L  !5)P  3",  $0=   \&   -!,  "T0!@ F#0L ) P/ "(,$P A
M#!D 'PP? !X-)0 =#2P &PTT !H./0 9#D< %PY3 !8.80 4#W$ $Q"$ !(0
MF  1$*X $!#& ! 0Z  0$/L $1#_ )DQ  ".-0  A#@  'HY  !P.   9S8
M %TR  !3+0  2B@  $(D   Y'P  ,1H  "H5 0 C$0< '1 - !L/$  9#Q4
M&! ; !<0(0 6$"D %1 Q !01.@ 3$44 $A)1 !$27P 0$F\ #A."  X3E@ -
M$ZL "Q/"  L4XP ,%/H #1/_ )<U  ",.0  @CP  '@]  !O/0  93H  %LW
M  !2,@  22X  $ J   W)0  +R$  "@<   @& , &10* !42#@ 4$A( $Q,8
M !(3'P 1%"8 $10N ! 4.  /%4( #A9/  T67  ,%VP "Q=_  D8DP (&*@
M!AB_  <8X  '&/4 "1C_ )4X  "*/0  @$   '=!  !M00  9#\  %H\  !0
M.   1S,  #XP   V*P  +B<  "<C   ?'P  %QH( !(7#0 0%Q$ #Q<6  X8
M'  .&", #1DL  P:-0 +&D  "AM,  D;6@ ''&D !1Q\  0=D0 "':8  1V\
M  (<W0 "'/(  QS_ ),\  "(00  ?T0  '5%  !L10  8T0  %E!  !//0
M1CD  #XV   U,@  +BX  "4J   =)0  %"$$  \="P -'1  #!T4  L=&@ *
M'B( "!XJ  <?,P &(#X !"!*  ,A5P !(6<  "%Y   AC@  (:0  "&Z   A
MVP  (?(  "#^ )!   "&10  ?4@  '1*  !K2@  8DD  %A&  !.0@  13\
M #T\   U.0  *S0  "(O   9*P  $B@$  TD"@ )(PX !B,2  4C&0 $)"
M B0H  $E,0  )3P  "5(   F50  )F4  "9W   FC   )J(  ":Y   FV0
M)?(  "7^ (Y%  "$20  >TT  '-/  !J3P  8$X  %=+  !-2   1$4  #Q"
M   Q/0  )SD  !XU   5,@  #RX#  HL"@ %*PX  2H1   J%@  *AX  "HF
M   K+P  *SD  "M%   L4P  +&(  "QU   LB@  *Z   "NW   KU@  *O(
M "K_ (Q)  ""3@  >E(  '%4  !H5   7U,  %91  !,3@  0TL  #='   M
M0P  (S\  !H\   2.   ##8#  8S"0  ,@T  #(0   Q%   ,1L  #$C   Q
M+   ,C<  #)#   R4   ,F   #)R   RAP  ,9X  #&U   PU   ,/(  "__
M (E/  " 5   >%<  &]9  !F60  7ED  %57  !)4P  /D\  #),   H2
M'D4  !5"   .0   "#T"  $\"   .PP  #H/   Y$@  .1@  #D@   Y*0
M.30  #E    Y3@  .5T  #EO   XA0  .)P  #>S   WT@  -O(  #7_ (=5
M  !_6@  =ET  &U?  !E7P  75\  %)<  !$6   .%4  "U2   B3P  &$P
M !!*   *2    T8!  !%!@  1 H  $,-  !"$   014  $$=  !!)@  03$
M $$]  !!2@  05H  $%L  ! @0  /YD  #^Q   ^T   /?(  #S_ (1<  !\
M8   <V,  &QE  !D9@  660  $MA   ^7@  ,EL  "99   <5@  $E0   Q2
M   $40   $\   !. P  30@  $P,  !+#@  2Q(  $H9  !*(@  2BP  $HY
M  !*1P  2E8  $EH  !)?@  2)8  $>O  !&S0  1?$  $3_ (%C  !Y9P
M<FH  &ML  !@:P  4FD  $1F   W9   *F(  !]@   57@  #5T   9;
M6@   %D   !8    5P0  %8(  !6#   51   %04  !4'0  5"<  %0T  !4
M0@  4U(  %-D  !2>0  4I(  %&K  !0R@  3^\  $[_ 'YJ  !W;@  <'$
M &9Q  !8<   2F\  #QM   O;   (FH  !=I   .9P  !F8   !E    90
M &4   !C    8@   &($  !A"   80T  & 0  !@%P  8"$  %\N  !?/
M7TT  %Y>  !>=   78T  %RG  !;Q0  6NT  %G_ 'MR  !U=@  :W<  %UV
M  !/=@  074  #-U   F=   &7,  !!R   '<0   '$   !Q    <0   '$
M  !O    ;P   &X   !N @  ;@@  &T,  !M$0  ;1H  &TF  !L-0  ;$8
M &M8  !K;0  :H8  &FA  !HO@  9^@  &;^ 'EZ  !P?   87P  %-]  !$
M?0  -GX  "A^   ;?0  $'T   =]    ?0   'T   !^    ?P   'X   !]
M    ?0   'P   !\    ?    'P&  !\#   ?!(  'P=  !\+   ?#P  'Q/
M  ![90  >WX  'J:  !YM@  >-\  '?Z '.   !E@0  5H,  $B$   YA@
M*X<  !V'   1AP  !X@   "(    B0   (H   ",    C0   (T   ",
MC    (P   ",    C    (T   "-!   C@P  (X3  "/(0  CC(  (Y&  ".
M6P  C70  (V0  ",K0  B\X  (KS &B&  !:B   2XL  #R-   MCP  'I
M !&1   'D@   ),   "5    EP   )D   ";    G    )L   ";    G
M )P   "=    G@   )X   "?    H0,  *(,  "B%@  HR8  *,Z  "C3P
MHV@  **&  "BH@  HL   *'H %R-  !-D   /Y,  #"6   AF0  $IH   >;
M    G0   *    "B    I    *@   "J    JP   *H   "K    K    *T
M  "N    KP   +$   "R    M    +<!  "Y#0  N1H  +HM  "Z0P  NEL
M +IW  "[E   N[$  +G2 %"5  !!F   ,IP  ".@   3H@  "*0   "G
MJ@   *P   "O    L@   +<   "Y    NP   +H   "\    O0   +\   #
M    P@   ,0   #&    R0   ,T   #2 0  U \  -4?  #7-0  V$T  -AI
M  #7A@  UZ,  -:] /\   #_    _P   /\   #_  , _P - /\ %0#_ "
M_  K /@ -0#T #\ \ !' .X 3@#K %0 Z0!: .< 7P#E &0 XP!J .$ < #?
M '8 W0!^ -L AP#8 )$ TP"= ,\ JP#- +T RP#@ ,D ^P#' /\ O0#_ +$
M_P"I /\ HP#_ /\   #_    _P   /\   #\    ]@ + /$ $0#M !L Z0 E
M .0 , #? #D V@!! -4 2 #1 $X SP!4 ,T 60#+ %X R0!C ,< :0#% &\
MPP!W ,  ?P"^ (H NP"5 +@ HP"V +0 M #- +( \@"P /\ K #_ *, _P"<
M /\ EP#_ /\   #_    ^@   /$   #H    X  & -D #@#2 !8 S@ ? ,@
M*0#$ #( P  Z +T 00"Z $@ N !- +8 4P"T %@ L@!= +  8@"N &D K !O
M *H > "H (( I@". *0 FP"A *L GP#  )T Y@"; /\ F@#_ )0 _P". /\
MB@#_ /\   #V    Z    -P   #.    Q@ ! +\ "P"Z !$ M@ : +( (@"N
M "L J@ T *@ .P"E $$ HP!' *$ 3 "? %$ G@!6 )P 7 ": &( F0!H )<
M< "5 'H D@"& )  DP"- *( BP"U (D TP"' /< A@#_ (0 _P!_ /\ ? #_
M /(   #C    T@   ,4   "Z    L0   *L !P"E  X H0 4 )X ' ": "4
MEP M )0 - "2 #H D !  (X 10"- $H BP!0 (D 50"( %L A@!A (0 :0""
M '( ?P!] 'T BP![ )H > "K '8 Q !T .L <P#_ ', _P!P /\ ;@#_ -\
M  #,    OP   +0   "K    H0   )H  @"4  L D  0 (P %P"( !X A0 F
M (, +0"! #, ?P Y 'T /P![ $0 >0!) '@ 3@!V %0 = !: ', 8@!P &L
M;@!U &P @P!J )( : "C &8 N !D -X 8P#[ &( _P!B /\ 8 #_ ,P   "\
M    KP   *4   "=    E    (P   "&  < @0 - 'P $@!X !D =0 ? ',
M)@!Q "T ;P R &T . !K #T :@!" &@ 2 !G $X 90!4 &, 6P!A &0 7P!N
M %T >P!; (H 60"; %< KP!6 ,L 50#R %0 _P!4 /\ 5 #_ +X   "P
MI    )D   "0    B    ($   !Y  ( <P * &\ #P!K !0 9P : &4 ( !C
M "8 80 L %\ ,@!> #< 7  \ %L 0@!9 $< 5P!. %8 50!4 %X 4@!H %
M= !. (, 3 "5 $H J !) ,  2 #H $< _P!' /\ 1P#_ +0)  "F"P  FPP
M ) *  "&!0  ?@   '8   !O    :  % &, # !? !  6P 5 %@ &@!6 "$
M5  F %, + !1 #$ 4  V $X / !- $( 2P!( $D 4 !( %@ 1@!B $0 ;@!"
M 'T 0 ". #\ H@ ] +@ /0#= #P ^  \ /\ / #_ *P0  "?$@  E!(  (D1
M  !_#P  =@P  &X%  !F    8  ! %D " !5  T 40 1 $X %@!+ !L 20 A
M $@ )@!& "L 10 Q $, -@!" #P 0 !# #X 2P ] %, .P!= #D :0 W '@
M-@") #0 G  S +$ ,@#. #( \0 Q /\ ,0#_ *86  ":&0  CAH  (0:  !Z
M%@  <!(  &@.  !?"@  6 ,  %$ ! !,  H 2  . $0 $@!! !8 /P ; #T
M(0 \ "8 .@ L #D ,0 W #< -@ ^ #0 1@ S $\ ,0!9 "\ 90 N ', + "%
M "L F  J *T *0#& "@ Z@ H /X * #_ *$<  "5(   BB$  '\A  !U'P
M;!H  &,6  !:$0  4@T  $L'  !$  8 0  + #P #P X !( -@ 7 #0 '  S
M "$ ,0 G #  +  N #, +0 Z "L 0@ J $L * !5 "8 80 E '  ) "! "(
ME0 A *D ( #! "  Y  ? /D 'P#_ )TB  "1)@  AB@  'PG  !R)0  :2(
M %\=  !7&   3A,  $8.   _"P  . 4' #0 #  Q !  +@ 3 "P &  J !T
M*0 B "< *  F "X )  V ", /@ B $< ( !2 !\ 7@ = &T ' !^ !H D@ 9
M *< & "] !< WP 7 ?4 %P+_ )HG  ".*P  A"T  'DM  !P*P  9B@  %TD
M  !4'P  2QH  $,4   [$   - T" "T)"0 I!0T )@,0 "0!$P B AD (0(>
M " ")  > RH '0,R !L$.@ :!40 &05/ !<&7  6!FH % =\ !,'D  2!Z4
M$0>[ ! 'VP 0"/( $ G_ )<K  ",+P  @3$  '<R  !N,0  9"X  %LJ  !1
M)0  22   $ ;   X%@  ,1(  "D.!  C# D 'PD- !T'$  ;!Q4 &0@: !@(
M(  7"2< %@DN !4*-P 3"D$ $@M- !$+6@ 0"VD #@Q[  X,D  -#*4 # V[
M  L-V0 +#?$ # W_ )4O  "*,P  ?S8  '8V  !L-0  8S,  %DO  !0*P
M1R8  #XA   V'0  +A@  "<3   @$ 4 &0X* !4,#@ 4#!$ $PP6 !(,'  1
M#2, $ TK  \--  .#C\ #0Y*  P/6  +#V< "A!Y  @0C0 '$*( !A"X  40
MU  %$.\ !A#_ )(S  "(-P  ?CH  '0[  !K.@  83@  %@U  !.,   12P
M #TG   U(P  +1\  "8:   >%@$ %Q,& !$0"P .#@X #@\3  T0&0 -$"
M#! H  L1,@ *$3P "!)(  <250 &$V4 !!-V  ,3BP !%*   !.V   3T0
M$^X  !/[ ) V  "&.P  ?#X  ',_  !J/P  8#T  %<Y  !--@  1#$  #PN
M   T*@  +"8  "4B   >'@  %AH" ! 5"0 ,$PX "A,2  D4%P (%!\ !Q4F
M  85+P $%CH  Q9&  $74P  %V(  !AT   8B0  &)\  !BU   7T   %^T
M !?[ (XZ  "$/P  >T(  ')#  !H0P  7T(  %8_  !,.P  0S<  #LT   S
M,   +"P  "0I   ;)   $Q\"  T;"0 )&0T !AD1  09%@ "&1T  1HD   :
M+0  &S@  !M$   <40  '&   !UR   =AP  ')T  !RS   <S@  &^T  !O\
M (P^  ""0P  >48  '!(  !H2   7D8  %5$  !+0   0ST  #LZ   S-P
M*C(  " M   7*0  $"4"  LB"0 %( T  1\0   ?%   'QL  " B   @*P
M(38  "%!   A3P  (5X  ")P   BA0  (9L  "&R   AS0  (.T  !_\ (I#
M  " 2   >$L  &],  !F30  74L  %1)  !*1@  0D,  #I    O.P  )3<
M !PS   3+P  #2P"  <I"  !)PP  "8.   E$@  )AD  "8A   F*0  )C,
M "<_   G30  )UP  "=M   G@@  )YD  ":P   ES   )>X  "3] (A(  !_
M3   =E   &Y1  !E4@  7%$  %-/  !*3   04D  #5$   K0   (3P  !<Y
M   0-@  "C(!  ,P!P  +PL  "X.   M$0  +18  "T>   M)P  +3$  "T]
M   M2@  +5D  "UK   M@   +)<  "RO   KRP  *NX  "K^ (5-  !]4@
M=54  &Q7  !C5P  6U8  %-5  !'40  .TT  #!)   E1@  '$,  !,_   -
M/0  !CH    X!0  -PD  #8-   U#P  -!0  #0;   T)   -"X  #0Z   T
M1P  -%<  #1H   T?0  ,Y4  #*M   QR@  ,>X  ##_ (-3  ![6   <UL
M &I=  !B70  6UT  $]:  !"5@  -E(  "I/   @3   %DD   Y'   (1
M $(   !! P  /P<  #X+   ]#@  /1$  #P8   \(0  /"L  #PW   \1
M/%,  #QE   [>@  .I(  #JK   YR   ..T  #?_ (%:  !Y7@  <6$  &EC
M  !B9   5V(  $E>   \6P  +U@  "15   94P  $%$   I/   !30   $P
M  !*    200  $@(  !'#   1@\  $84  !%'   12<  $4S  !%0   15
M $1A  !$=@  0X\  $*H  !!Q@  0.P  #__ 'YA  !V90  ;V@  &AJ  !=
M:0  3V8  $)D   T80  *%\  !U=   26P  "UD   )8    5@   %8   !4
M    4P   %($  !1"0  4 T  % 0  !/&   3R(  $\N  !//   3TL  $Y=
M  !.<@  38L  $RE  !+P@  2>H  $C_ 'MI  !T;   ;F\  &1O  !5;0
M1VP  #EJ   L:0  (&<  !1E   -9    V(   !B    80   &    !?
M7@   %T   !<!   7 D  %L-  !;$@  6QP  %HH  !:-@  6D8  %E8  !9
M;0  6(4  %>@  !6O0  5>@  %/^ 'EP  !S=   :74  %MT  !,<P  /G,
M #!R   C<0  %F\   UN   $;0   &T   !M    ;0   &P   !K    :@
M &D   !I    :0,  &@)  !H#@  :!4  &<A  !G+P  9S\  &92  !F9@
M97\  &2:  !CMP  8N$  &'\ '=X  !M>@  7WH  %!Z  !">@  ,WL  "5[
M   8>@  #GD   1Y    >0   'D   !Z    >@   'H   !X    >    '<
M  !W    =P   '<!  !W"   =PX  '<8  !W)@  =C8  '9)  !U7P  =7<
M '23  !SKP  <M,  ''W '%^  !C?P  5(   $6"   V@P  *(0  !J$   .
M@P  !(0   "$    A0   (8   "(    B0   (@   "'    AP   (<   "'
M    AP   (@   "(    B <  (D0  ")'   B2P  (@_  "(50  B&T  (>)
M  "&IP  A<<  (3O &:$  !7A@  2(@  #F*   JC   &XT   ^-   $C@
M )    "1    DP   )4   "7    F    )8   "7    EP   )<   "8
MF    )D   ":    FP   )T'  "=$0  G2$  )TS  "=20  G&(  )Q_  "<
MG   G+D  )OB %J+  !+C@  /)$  "V3   >E0  $)8   28    F@   )P
M  ">    H0   *0   "F    IP   *8   "G    IP   *@   "I    J@
M *P   "M    KP   +$   "S"0  LQ4  +0G  "T/0  M54  +5P  "TC@
MM*P  +3, $V2   _E@  +YH  ""=   1GP  !:$   "C    I@   *D   "L
M    KP   +,   "U    MP   +8   "W    N    +H   "[    O0   +\
M  #!    Q    ,<   #+    S0P  ,X:  #/+P  ST@  -!B  #0@   T)T
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M______________________________________________\
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MVMO<W=[?X.'BX^3EYN?HZ>KK[.WN[_#Q\O/T]?;W^/GZ^_S]_O]M9G0Q
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M________________________________________XH$)24-#7U!23T9)3$4
M"0G_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________]/______________________________________
M___KT?_________________________________________WZ?[_________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________AS=?_________
M_____________________________]VOEK?T________________________
M_____________\6,:*?G_____________________________________\R<
MB:3G______________________________________K.N\;U____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________<Q;WU_____________________________________[^3
M>H7%____________________________________VY!;/66H]O__________
M_______________________^O'4T %2;Z___________________________
M_______3E'Y)+$Z:[/_______________________________]C4RK-^96VE
M^?____________________________________3%KJ_)________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________PUL;L____________
M________________________YKN1=&.K]___________________________
M______;$FG-%)C1]S/_______________________________[6 53 * !E@
MLO______________________________SW0U"P    I2I_______________
M________________EC0       !/I______________________________V
M:1T   D,!@E2L?_____________________________+.PX3-4Q;34Q>P___
M__________________________^I8#9@AI^VK*FXV?__________________
M___________@EXV^Y?______________________________________[?G_
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________^O9RKS'___________________________________/FH%M6D:(
MZO_______________________________\1\/B80  !4L/______________
M________________X(,\       NA^W_____________________________
MK%,0       7;=;____________________________[@#$        )8<S_
M___________________________26@(         7<S_________________
M__________^H-0          7-/___________________________]]#0
M        5-;__________________________^Y]10          1-3_____
M______________________RJ9"\"   $(C=)6,[_____________________
M_______II&M!*#]C?Y6GNMK______________________________]6RK++,
MY/K_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________^6[EW=BR/______________
M___________________;GF<V"@ "C/______________________________
M_\A_/P4     7L______________________________V8$Y        /*K_
M____________________________GDP         (Y#_________________
M___________<;QH         $'WY__________________________^O2
M         &_N__________________________^$$P           &3F____
M_____________________^Q1             %?>____________________
M_____[@5             $C6_________________________W04
M     #C/________________________^:):$P           "/%________
M_________________]^;7"P           VZ________________________
M___OL7U5.2(1!P$"$2*R_______________________________?OZ69F)J@
MK+W:________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______COIV ?/O________________________________RMX17, X ':S_
M_____________________________]**3!4      '+S________________
M____________UG\V         $O)___________________________ZD3X
M         "^K___________________________ 6@           !J5____
M______________________^-)             B$____________________
M_____^=>              !W_________________________[0E
M      !J_________________________WT               !;]/______
M_________________2L               !,Z_______________________
MI0                 \X?______________________, P
M   MV?____________________^9BF$G               GU___________
M____________[;Z)52<            EW/_________________________^
MRIUV74H\,BTL,#E'WO_______________________________>;=UM+0T]GD
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________^_4N];_________________
M________________Y[B/:DLO%6_______________________________^2A
M9S0'     #S)____________________________UH([         !*7____
M_______________________MA3$           !O____________________
M______^F0@            !0X?_______________________^QI
M       WR?_______________________[,O               BMO______
M_________________WD                0I_______________________
M\C0                 F?______________________J0
M    C/______________________1@                  ?___________
M___________?                    =/____________________^7
M                :O_____________________.
M8_______________________*2(!                8?______________
M________N:. 5S<7            :/__________________________^M.N
ME(9\=7%P<G>!E/______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________;NIV":6G3____
M___________________________(DV4]&0   !V>____________________
M________VXY,$P        !N___________________________;?"P
M      !%U_________________________^+*@             BM/______
M_________________\)$               #E_______________________
M_WT!                ?_______________________YS8
M    :O______________________G0                  6/__________
M____________1@                  1_C____________________I
M                ->G___________________^6
M)=O___________________^\                    &,[_____________
M_______K                    #\+_____________________
M            "KG_____________________)P                  "K7_
M____________________<                   #;G_________________
M____X)R,<%5",R8;% \-#A(:)K_____________________________YY-C2
MSLS+S,_6X/S_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________KT[SC________________________________TJF%
M94@L$@&%____________________________\:MQ/ \       !/X/______
M___________________5?S4            ?LO______________________
M_^-U'0              B?_______________________Y C
M    9_______________________U4,                 2/;_________
M____________B@                  +MW_____________________.
M                %\C___________________^^
M!+;___________________^<                     *7_____________
M______^Z                     )/____________________<
M             (+_____________________                     '3_
M____________________$P                   &C_________________
M____0@                   &#_____________________>@
M         %W_____________________T0                   &'_____
M_________________R0                  &;_____________________
M_\FLF8E]=G%L:6=F9VMP>HS_____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________BQ:J1>6%W________________________
M_____]VF=U L#      QQ/_________________________@DDX3
M    C________________________])P'0              8/__________
M____________[F\/                -^+_____________________EAP
M                %,#_____________________0
M */___________________^N                     (G_____________
M______^>                     '+___________________^\
M             %_____________________:                     $W_
M___________________Z                     #O_________________
M____#@                   "KY____________________,P
M         !OI____________________7@                    _;____
M________________CP                    ;0____________________
MT                     #*_____________________RL
M      #(_____________________X                    #+________
M______________<6 04% P$       $&#1C+_______________________\
MZ^'8S\S-S]#2U-?<XNK_________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M\=K&_______________________________QQJ.$:$TR&  5J___________
M________________N7Q&&           <?_______________________]=\
M+P              .^/_____________________WV0)
M#+7_____________________= ,                  (W_____________
M_______%%0                   &K___________________^9
M             $O___________________^V                     ##]
M___________________7                     !GG________________
M___V                      73____________________#@
M          #!____________________+P                    "O____
M________________4@                    ">____________________
M>0                    ".____________________I0
M      " ____________________V                     !T________
M_____________S8                   !M_____________________WP
M                  !I_____________________]<-
M  !H______________________]P                  !A____________
M____________4#Q&3E1976%D:&QP=GZ)____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______OU;NCBW-:E?__________________________^+^.9$$A!0
M4OS_______________________>=5A@             %\'_____________
M________Y6P6                 (W_____________________8P
M             %[___________________^=                     #7\
M__________________^A                     !'9________________
M___*                      "[___________________N
M          "A____________________#                     "*____
M________________+0                    !V____________________
M30                    !D____________________;P
M      !2____________________E                     ! ________
M____________O                      P____________________Z@X
M                   B_____________________T0
M   5_____________________X$                    +]?__________
M_________\@+                   "[/____________________]>
M                Y?_____________________)'
MVO______________________G0$             !PX7Q?______________
M_________]6YO,''SM7;X>;M]/O_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________C?S_______________
M_______________LQJ6(;50[(0< ,M[________________________7DEDI
M             *#______________________XDV                 &?_
M____________________9@                   #+V________________
M__^5                      /(__________________^G
M          "@___________________7                      !\____
M________________                      !>____________________
M)0                    !#____________________2
M       L____________________:@                     8________
M____________BP                     %\___________________KP
M                    X?__________________U0
M    S____________________R0                     OO__________
M_________U0                     KO___________________XL
M                G____________________\L.
MDO____________________]7                    AO______________
M______^J"@                  >?______________________;0
M            9O______________________]U4                 1?__
M______________________]J(RLU/TI58&IU?H>1G/__________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________Z,^VG8-I3KG_
M________________________[+*#7#H= @       'O_________________
M_____\5M*0               $#_____________________@QL
M          ?+__________________^2                      "8____
M______________^D                      !J___________________=
M                      !!____________________#@
M       =____________________.0                      Z/______
M____________8                       SO__________________A0
M                    M___________________J
M    H___________________RP                      D/__________
M________[Q8                     ??___________________SX
M                ;/___________________VD
M6O___________________YD                     2?______________
M_____](6                    .?____________________]8
M            *?____________________^B                    &?__
M___________________U5@                  !/__________________
M____NR\                  /C______________________ZLI
M         ,_________________________)1P     '$R N/E)HA.W_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________TU<G____________________________ZTK"2
M=UU"* P  $K________________________%?447             !'8____
M________________Q%                    "?__________________^B
M#                     !H__________________^4
M       V___________________:                       '[/______
M____________%0                      Q/__________________2
M                    HO__________________=0
M    @___________________G0                      :?__________
M________PP                      4O__________________YP\
M                /O___________________S,
M*____________________U@                     &/______________
M_____X$                     !?___________________ZP
M             /___________________]XB                     /+_
M__________________]<                     -__________________
M__^?                     ,S____________________H2@
M         +?_____________________H!8                  )S_____
M_________________WH"                 '?_____________________
M__]Z"P              !4S_________________________HE=H=("-G*N\
MT.?_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________[>/_____________________
M_____]*C>E@Z*2,<%@X&  "?_____________________ZQ2#@
M      !I___________________D0P                     T________
M__________]Y                        X__________________-
M                    LO__________________$P
M    A?__________________3P                      7?__________
M________@P                      .O__________________L@
M                '/__________________VP,
M O___________________RH                      /O_____________
M_____T\                      .?__________________W0
M             -3__________________YL                      ,#_
M_________________\0'                     *W_________________
M__ S                     )K___________________]G
M         (;___________________^C                     '+_____
M_______________C1                    %S_____________________
MD08                  $'_____________________ZU\
M     !W______________________\I+                  #_________
M_______________+5P  #!@D,3].8'2+I\?_________________________
M_]?G\O______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^O4S<?"OKJWL["MJ:BE____________________W7Y3
M/S C&1$) @          V_________________]V
M    I_________________^Z                        =?__________
M________!P                      1O__________________3@
M                &O__________________C
M /W_________________P0                       -O_____________
M____\1D                      +[__________________T0
M             *3__________________VL                      (W_
M_________________Y$                      'G_________________
M_[<                      &;__________________]XA
M         %/___________________]*                     #______
M______________]W                     "O___________________^L
M"@                   !;____________________G10
M      #_____________________B@                    #_________
M____________UDT                   #]_____________________Z<N
M                  #5______________________^8*@          !A@M
M16#@________________________J&-T@8^<J[O-XOK_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________^?+MZF=E8Z)A(!\>'1P;&AED/________________^\:D@M&0H
M                ,?__________________
M ___________________0@                       -S_____________
M____C@                       ++_________________S@
M             (W__________________RD                      &O_
M_________________UH                      $[_________________
M_X8                      #3__________________ZX
M         ![__________________]07                      K_____
M______________H]                      #___________________]E
M                      #___________________^.
M      #___________________^\&0                    #O________
M___________Q3@                    #8____________________BP
M                  "_____________________S$,
M  "A_____________________Y$9                  !Z____________
M__________)T"@               !%?_______________________H=!,?
M+#A%4V)RA9NTTO7__________________________]?H]/______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________^_?S\>[LZ^OL\?______________
M____V;*9AWEM9%U644M&03PX,BTH(\3_________________2R4+
M             )+_________________B                        &;_
M________________UP                       #W_________________
M_S,                      !C__________________VP
M          #__________________YT                       #_____
M_____________\D,                      #V__________________$U
M                      #?__________________];
M      #+__________________^"                      "W________
M__________^I!@                    "C___________________3+P
M                  "-____________________7@
M  !W____________________DP<                   !>____________
M________S4,                   ! _____________________X<0
M               <_____________________]A>
M______________________^_3@      #APL/E)JAJ7(________________
M________PGR,FJ>VQ=;H_?______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________[N'7S\G#OKJVL:VIIZ:FIZ[_________________
MOH9M6TQ -R\H(AP6$ L$     !3_________________UP4
M          #__________________S0                       #V____
M_____________W8                       #2_________________[
M                      "R_________________^$D
M      "6__________________]1                      !\________
M__________]Y                      !F__________________^@
M                  !1___________________'(P
M   \___________________N2P                     G____________
M________=                      0____________________HQ8
M                ____________________V$P
M_____________________X@/                    ________________
M_____\M3                    ______________________^E.
M    "1TT3FN,________________________F3E#45]N?8Z@M<OE________
M_____________________^OY____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________^O,N:RAF9&+AH%\>'1P:VAF9FCQ_________________V%%
M,B,8#@8               ">_________________WX
M      !U_________________\,                       !2________
M__________LW                       R__________________]J
M                   6__________________^6
M    __________________^_&P                      ____________
M_______F0@                      ____________________:0
M                ____________________D (
M____________________N2P                     ]/______________
M____Z%P                     V?___________________Y$8
M            O/___________________\I3                    G?__
M__________________^8+@             0*49FQ/__________________
M___N?QT,&B@W1E=I?I6OS.[_________________________YZ"JN<C8Z?S_
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________]]?#KYN+?V]C4TM'0TM?@________
M_________\Z>BGQQ:6%;5E%,2$,^.C8R+RXQ_________________](E$0,
M                    __________________]"
M    __________________]]                        ____________
M______^P"P                      ]O_________________=.0
M                W/__________________8@
MQ?__________________B0                      K_______________
M____KR(                     F?__________________UD@
M            @O___________________W(                     :?__
M_________________Z$H                    3O__________________
M_]-<                    ,_____________________^6+@
M    %3)2=______________________@<A,   $/'R]"6'"+J,CL________
M________________RF]N?HZ>L,/8[_______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________YX-+(P+JUL*RHI:*?G9N;G*"G____________
M______^"9%9+0SPV,"LG(AT8$PX)!   U/________________^2
M                K?_________________,'@
MB__________________[4@                      ;?______________
M____@                       4?__________________J1L
M            .O__________________T$(                     (___
M________________]6@                     #/__________________
M_X\4                     /___________________[@^
M         /___________________^5M P                   /______
M______________^?-P              $"]0=/_____________________=
M<A0     !A<J05IUE+;:________________________O%A$5&1UAIJOR./_
M_____________________________]+-X?'_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________S[^OO]____
M___________________NN:B=EH^*AH)_>WAV=')S=7A_D/______________
M___K3SHP*"$;%1 +!P(         (___________________:0
M             /__________________FPH                      /__
M________________R#D                      /__________________
M\&,                      /___________________XH.
M         /___________________[ T                     /______
M_____________]5;                     /____________________^%
M&@                   ^S___________________^Q20
M&#E=@?_____________________E>QX       PA.%)OC[/9____________
M____________NU@I.4E:;("7L,WM_____________________________[.>
MM,77Z_______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________KOY^'<V=;4TM#0T-'3V>#K]___
M________________N(I^=W%L:&1A7EM96%=765YE<?__________________
MOS$?%A *!0               /__________________[58
M         .C__________________X($                     ,S_____
M_____________ZLO                     +/__________________])7
M                     )O___________________=\$
M     (7___________________^B-P                 %*Y3_________
M___________+80(            ,+%!VGM'____________________UC3
M      TC.U=VF;[E________________________PV,8*CM,7W2-I\;G____
M_________________________ZA_EJB[T.?_________________________
M___________]________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________]W.Q;^\N;:TL[&RLK6YP,G5X_______
M_____________Y=L9%Y955%/3$I(1T9(2U!99J'__________________Z<F
M#@<"                 %;__________________\Y0
M     #K___________________1Y"P                   "'_________
M__________^?,@                    [____________________$6
M              @Q6H3____________________I?Q\           8G2W&:
MPNG_____________________ITD      A<O2FB*KM7\________________
M________TW4>)CA*7G6/J\OO_____________________________ZYRA9BL
MPMOV___________________________________?[___________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________^_LJJFHZ&@GY^AHZ:LM,#-W>S_________
M__________^*6E-/2TA&1$-"04)#1TY9:7W___________________^>+@8
M                  #____________________#5@
M%4'____________________G>QH             "31@B[3_____________
M________GS\         !"5*<9G"Z_______________________QF8/
M$RI$8H.GS?7_________________________ZXXU*SY1:(&=O-[_________
M_____________________[YV?Y2IP=SY____________________________
M_______2V//_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________;R\._O[_'S^/W_____
M_______________________XL)^:EY:6EIB;GZ2LML+1X>[_____________
M_______^CE!*1T5$1$1%1D=+45IH@ZG_____________________ID$!
M       '-F./NN'_____________________QF4*       $)TQSG,3L____
M____________________Y8@O   3*D1B@J;,]/______________________
M_____ZM0-DIA>Y:TUOK______________________________]*'?)BQR^G_
M___________________________________4SNW_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________^WEX^/DYNCM\?G_________
M_____________________;&4DI*5F9VCJ;*\T.W_____________________
M_____YU31TE-459@<XJOUOS__________________________[)6 !HU4&V+
MKM+W_____________________________\UO/E][F;?7^?______________
M_________________^Z?@Z;"X?__________________________________
M___CSNO_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________\
M
M
M                                                 /__________
M____________________________________________________________
M____________________________________________________________
M________________________________________     /_A079H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I
M9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL
M;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E
M(#<N,BUC,# P(#<Y+C%B-C5A-SDL(#(P,C(O,#8O,3,M,3<Z-#8Z,30@(" @
M(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO
M<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL
M;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(@H@(" @(" @
M(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N
M,2\B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C
M(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL
M;G,Z=&EF9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]T:69F+S$N,"\B"B @(" @
M(" @(" @('AM;&YS.F5X:68](FAT=' Z+R]N<RYA9&]B92YC;VTO97AI9B\Q
M+C O(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA
M9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @(" \>&UP.D-R96%T
M941A=&4^,C R-"TP-BTQ,50Q.3HP,CHU,RLP-3HS,#PO>&UP.D-R96%T941A
M=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^36EC<F]S;V9TPJX@4&]W
M97)0;VEN=,*N(#(P,38\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM
M<#I-;V1I9GE$871E/C(P,C0M,#8M,3%4,3DZ,C0Z,S4K,#4Z,S \+WAM<#I-
M;V1I9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(T+3 V
M+3$Q5#$Y.C(T.C,U*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @(" @
M(" \<&1F.E!R;V1U8V5R/DUI8W)O<V]F=,*N(%!O=V5R4&]I;G3"KB R,#$V
M/"]P9&8Z4')O9'5C97(^"B @(" @(" @(#QD8SIC<F5A=&]R/@H@(" @(" @
M(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y*96X@0F5A
M8VAE;&P\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @
M(" \+V1C.F-R96%T;W(^"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @
M(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<]
M(G@M9&5F875L="(^5&AI<R!I<R!T:&4@<')E<V5N=&%T:6]N('1I=&QE/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT
M:71L93X*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M
M870^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z-#EF-F1E
M,S$M,F1D,2TU,31E+3EC9# M,V(Y-F,W8S@Y,CED/"]X;7!-33I);G-T86YC
M94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YA9&]B93ID;V-I9#IP
M:&]T;W-H;W Z,38W9# U83(M,C5A,"UB930V+6(P-# M,#4Q,68W9# Y,#0Y
M/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$
M;V-U;65N=$E$/GAM<"YD:60Z9C!A,61D-C8M,3-A."UF-S1C+6%E,3@M,C=B
M-6)B,3=D96-B/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @
M(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C
M=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP
M+FEI9#IF,&$Q9&0V-BTQ,V$X+68W-&,M864Q."TR-V(U8F(Q-V1E8V(\+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,C0M,#8M,3%4,3DZ,C0Z,C(K,#4Z,S \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O
M<VAO<" R,RXU("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E
M9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-C0V,F(Y
M8C@M-&4V-"UA,S1C+3AC,#DM-6-F.3-E,&4P,S(W/"]S=$5V=#II;G-T86YC
M94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(T+3 V+3$Q
M5#$Y.C(T.C,U*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C,N-2 H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N
M861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E
M<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F
M<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O
M97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z-#EF-F1E,S$M,F1D,2TU,31E+3EC9# M,V(Y-F,W
M8S@Y,CED/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z=VAE;CXR,#(T+3 V+3$Q5#$Y.C(T.C,U*S U.C,P/"]S=$5V=#IW
M:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!
M9&]B92!0:&]T;W-H;W @,C,N-2 H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E
M06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T
M179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @
M(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HV
M-#8R8CEB."TT938T+6$S-&,M.&,P.2TU8V8Y,V4P93 S,C<\+W-T4F5F.FEN
M<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD
M:60Z9C!A,61D-C8M,3-A."UF-S1C+6%E,3@M,C=B-6)B,3=D96-B/"]S=%)E
M9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U
M;65N=$E$/GAM<"YD:60Z9C!A,61D-C8M,3-A."UF-S1C+6%E,3@M,C=B-6)B
M,3=D96-B/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#PO
M>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @(#QT:69F.D]R:65N=&%T:6]N
M/C$\+W1I9F8Z3W)I96YT871I;VX^"B @(" @(" @(#QT:69F.EA297-O;'5T
M:6]N/C0V,C0Y+S$P,#PO=&EF9CI84F5S;VQU=&EO;CX*(" @(" @(" @/'1I
M9F8Z65)E<V]L=71I;VX^-#8R-#DO,3 P/"]T:69F.EE297-O;'5T:6]N/@H@
M(" @(" @(" \=&EF9CI297-O;'5T:6]N56YI=#XR/"]T:69F.E)E<V]L=71I
M;VY5;FET/@H@(" @(" @(" \97AI9CI#;VQO<E-P86-E/C8U-3,U/"]E>&EF
M.D-O;&]R4W!A8V4^"B @(" @(" @(#QE>&EF.E!I>&5L6$1I;65N<VEO;CXR
M.3$V/"]E>&EF.E!I>&5L6$1I;65N<VEO;CX*(" @(" @(" @/&5X:68Z4&EX
M96Q91&EM96YS:6]N/C$V-#8\+V5X:68Z4&EX96Q91&EM96YS:6]N/@H@(" @
M(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-
M;V1E/@H@(" @(" @(" \<&AO=&]S:&]P.DE#0U!R;V9I;&4^52Y3+B!796(@
M0V]A=&5D("A35T]0*2!V,CPO<&AO=&]S:&]P.DE#0U!R;V9I;&4^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@
M96YD/2)W(C\^_]L 0P &! 4&!00&!@4&!P<&" H0"@H)"0H4#@\,$!<4&!@7
M%!86&ATE'QH;(QP6%B L(",F)RDJ*1D?+3 M*# E*"DH_]L 0P$'!P<*" H3
M"@H3*!H6&B@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H_\  $0@!9 )W P$B  (1 0,1 ?_$ !P   $% 0$!
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M3SBAJ;!0$G)P1JZ^'%1\R5Q0VCB:WQ47-P2GKEKB*@*#:&BVLH<;>QNHKTI
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M)#1"M@0H;U0#;$@'2H_2FT& MU#^LI2$.:1CJ=JX?B:FVDM\/!J]S2DRHZB
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M% 8!R"<>HKV?;0S>KE>I(D.,,%+B6W&\%9Z!*2=M.?UK)\1)]^SU+>^+>/\
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M;?E%1<A,H62XTA;WBT^00HCUKI22PEL<S?-L@N)/:1(7:YTJU6MQNX-0G7I
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M)NW0AG+3#>95I *R=("?XUY99K?#ZYBILA:75!*$Z4Y 2.@'K75U=0E]:VO
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M)GGY4"<-@')0?EN?CM6?R![KB3)T/)4I); &[)1Y^N>@Z;5N]TLT6X-I<6T
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MEM:2R<X )U*SDC! Z="?ACSJQ-/-N@%M:59 5L>Q[UF:[6U'B,R4Y+JEZ5I
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MH1DKWNS!U9QE:UD2MI]I[R&G(]SC(=F @M+"@TA8/7.>F.FV>U7GA+B)CB*
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ME6Q6/4>5:*6B-GL$NQ6NHRS>S".\SPRE;Z5)+SA6D*ZE.  ?RJVUXA*4("4
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MK.H>)6<$==L4YM_LQCPY5M>^T7'##]V40ID?>*:<>63UVU%X_# ZT!:3Q78
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MLGVBR;9<C%NMN0#G'W:]Q5RLG$%OO#>J(^-8&5-KV4/E65W&UVHR2ZS,?N9
MR5M('YG)(^E=QI#,"V/R83T4/$%*F'6M:BGRR?X8JW:7DHQ^K(EPD'3<WOX)
M_5&FW3B&)#4&F5"5+4<)9;4"<^I[55)7M%=MUP]WNELY0)QX5[CZU1H5S3)5
MK,141[.RHZB!GSTG^!%6.1P9)N3:+A*E\YTI"@VI)#I_X20,_.IC.TG&?+I8
M/AJ<(Q>+/K?Z6+_&XIM+\#WL2TI0-E)4/$D^1%-AQ=$D!TV]IV1RDE2CL@8^
M?\JIEG5'LLX(<B.1GU IY\W. /1(P/S-0-POB)%V=:=@L% .[L8%HG^'U!JL
M9SE%OIN'PE)3TYSM[7[E\M7M(MTN2MB4RY&*3C5G6GYXJT/WVV,QT/N36N4O
M\*@<Y^E9K:^'H$Z(J39HDB4M)^\:>6&P#Z$#Q?44Z9O;\!EZ%+;-K#:26V6F
M<:E>I.<_&CJYQL]B)<)!K&ZW7\99;?Z96QUX-1"Z^XK883I'U-1%V]H;=KN(
MBRK>KK@E+H)_2L\AWJ6]+=,MAJ0UJV#S8U$?$;CY&K%(M=H<8:D2(-P;E+W#
M"7$+('8[C4!\JG7HDXSSY>V6^$A:,HK#Z_VOL:!;>*[1.C%U,M#12,J0Z=*A
M_/Y4F>+K:X^&(:G)3JCA(;3L3\3BJ1#N4*V09$B!%B,2&QC3)U..*\_+'TJ&
M9OD6[)*Y4%,&1GPOQ04[^J>_RJ-<]&OD0N$INHX6?OWU+M*]HL:'=##EP74$
M'!*5A1'RJU6V]V^XL%V)*;4D#*@3@I^(/2LH<X4Y9;N-QF--1WMP]I4I2A_A
MQU^-62U2K)"MTH6V 9B4HR\Y(*4E0^?;Y5;M+R2C]>OH4GPT%3OS\-O6Y;W>
M(+:A?+;DI?=_<9\9_*HR/QS979IC+>6PX-OO48%4BWW?A^X2%%EN39I . ZR
MO6@'U'E\*2N/";,5T3O>GIK3HU%V.R5CYG.!1S<;J6Z]Y$>%IMK.'[Q:Z-@0
M\VMD.H<0ILC(4",8^-1[]_MK2^6);;CN<!#1UJ/R%9_ O,>TV&4J VR4D@+;
ME.%:E_\ ", "HRU7JT7$I<DPW+6_GPOPR< ^J3_"H<Y:-:6"L>$CK<'?'OW8
MOYXYLZ)QBON/,.C;[QO J?3.BF()/O#7NYWYFL:?K6:3. P]FZJN"Y*%#7J0
MPI2U ]PG-=V.?;;>XN#%C.+6]X5JG*"4_P#)4RJ*+MR\0N%A.-XN[73^;%X5
MQ);5.%N,\93F,Z6$ZOSZ5%Q>/[,],5&=4]'<!P2ZG 'T)K.+S>&V+XMB+'99
M4"1S(:E)_+)%/;'P_:;@IZ49LD*0G6ZVF.5+QGL02*.4H8FL\B\>%I..M/N\
M][FQL/-OM!QEQ*T'<*2<@U'3^(;7!U!^8UK3U0@ZE?053X-PLZ8B[7;8LE2=
MUK+KW)*\>9&_RJJ0[Y9'+F8ZH#\5Y).%H<#J?^577ZBIC*4E>/(P?#J,K2OX
M&ACCVU*>*$HD$#J0D;?+.:L-NN42XM:XCZ'!W .X^(K(D<&N7&Y(FVYX2D:O
MQ(4$!!\E)ZBK>;"Y9(7-9D,MO$8<DJ"B49[) &WQ_2IOTR5E3A:VS+;<+M M
MXS.F,,=\+6 :2CWVUR$A3,^.I)Z'7C-9I=&8+EO>1*NZ5H0E3AY;)*R!UW/\
M:C>#W;!&=3&=5/#CZ \G5@@]=CY55UH+#>2CA&+LV;8TZVZC6VM*T?O).12,
MVX1(3"GI<EIIM(R5*4!M6:WU<E:74?:#2+)R='*C^$@D[DYW_6JU/5"BKB+;
M)DM*;Y* I2O$D]0?_BLI<0T].%YNQFXM%]N]]-_DNVN$HL6QUG+L[N<_LI'P
M_P!>;>ZV^Q0(R9=H9?7<8S80CD+(6L>N>OTIYP^TB4VAHQFDLM@ J1A'+]/(
M_2B7PQ%]\$MB2ZZI*LZ6P#CXXJ524TW)W;Y_L3V:Y[D?PQQ+]B1!_2%VXA$M
MW[HR4%1:]"KN.E:&AYI;27$.)+:AD*!V-42YS+?"ANJN)"V!^)"AG._E56<O
M'N-U"[?*>4Q):RU$<&P5VP?]?&L.W^'[LG=?4JTH8N:^[/C-GQO('SI1$EI?
MX5BL<;F6U-L!O*[@Q*4[S%)04K(/PVVJ0_I:NVIU,E,F.Z$^[ME!UY[@@'(I
M'_(1_P#2_)&I<S6 01D'(KE3B$YU* QZU2&;W=Y[K"8<5I$50PM920H*\NI_
M2NCPG)7&U"ZOF?S>;S#^$_W?/%;+B)25Z<&U\OD/(NC;J'1EM84/0YHJ!X=B
MW*/<97OR&1&T@-J0K*B>^?\ XHKHA/6KVMY@L-1'%H6>'YO*:<=648"6\Y._
MI4O3&]Q'IUL?CQ7S'>6 $N#.V_I4O;!>G;4KF(VJ9>K8ZZ%/.(2H[M.9*"GR
M(.Q%69YAJX0&UV^W6Z1)4D\Y$5Y22/\ @!&?SIV>$[Y$CRVFQ%F>\#25J5XD
M^HS498?9Y=V71SGDQ0E6KF:\J'P _G6#3E>3WZ6]H]CM:2:2:LN=]_-;D3."
M;8ZP(=K#JB/O6Y#2DZ#WQO4A98\IQ;LA(+(Y90I4Q.6@G_%V]-JM=TM_%28Z
M8\5]MZ.C;6%X=6/[Q/\ "JAQ#8KT]+0[;[9*8& '$DE84?E4*&II;6^OW$:R
M<6KWOXIV7EC\C"%87FI$A<>:T\4Y<66"5!(^F*=?:5ID1T,QX\9V4G(<=D(+
M6_H$G'S-37#_  [<'W$(N-HT-*V4\EPLJ ]0.OTKBY<*KMD\ENTZX&O=QDEQ
M>GS(VW^50[R3G)9?OH74X*:IJ2LO>]_H1OOBH-M>6VAR/..S:XP 01_B'\ZA
M[.9<MP&1$5)=)R>7D*'KD?QJ3CW:\09TB-;8^(:]DI,8!2O+.!G-6"V\/7>Y
M,>]+=>86E0(8ECP+^0_B*B47;L[)\[DJ:BW5D[7QG]OY(R_V2#*2S(D753\P
M ?U<K0I:/3.H T6.5%M1E'2MMU+9RW+)TN>F@#]37MYX'OL^Z^]<AAO^ZTL!
M-62P\'S68SB;E(CNC1AIIQOFI0?/?'T%7E%N4;9M]#"-6G&E)2:5^EOQ^2@B
M]MS5JU6N+%PK\;374?!1Q^E6"&Q<7+8X(19>+PPWH<#"D?\ !MG\ZD'^%[O$
MEAY,>)*C@[MQP&B1]/XU5+G8+W(O!?CVV4PSG9 0H_Y5"C>3EMX>[FCJ1E",
M$[^/MIC2(F:V_P J:^A]P*TZ73K^7<_2I.[HMT!UN')D3(RG4CF-);"T9],J
MSCXU9;!PS<YI2GB!E!C ;*61SAY84-_K4->N%WVI*EMVB<\$G <4XE>1\DYJ
MJ67.:WZ8+.K%M4X26/6_SYC2/;K;';4JWQWKF -64D( _P 2!E7Z4[D<026;
M)JAW#E.HRGW,,)T8\@*:2)#]GCM.V9AYJX[A>MC\/H"K-2%JD7&\9$NQLR9#
MF![SR,:3YGH#^53&\;3>;\O>2)VFG&V%S_O'R(2!>%32@S+8A#Y. Y$^Z<^.
M!L?I3J[62)!=$EQJX+4L!2BMD)Z]M62,_*IF?8;K;'TO2(3,N$D[MQDZ1CU
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M5[F5#2>QQI3_ ,.>]2EG]H5]<8C2$WV%='YULERY,)F.E*K4XVT5)S@DXU>
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M0:AR%LJ4$J65)7IV*"% 8]*RWAKBVY6WA&TPF^(HO#T:'8O?8Y?80Y[^Z5N
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M0VA*UX*U 8*L;#/G110'=%%% %%%% %%%% %%%% %%%% %%%% %%%% %%%%
..%%%% %%%% %%%% ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g843142g17j14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g843142g17j14.jpg
M_]C_X  02D9)1@ ! 0$!^ 'X  #_[1_>4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $L< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  ,2F5N($)E86-H96QL
M' (% !Y4:&ES(&ES('1H92!P<F5S96YT871I;VX@=&ET;&4 .$))300E
M   05]\/S0OS=.YF0W765/+R=CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!_C,S0
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 ?C,S  !  $!^,S,
M  $  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      T$    &
M  96   )W     8 9P Q #< :@ Q #0    !
M  $             "=P   96                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   96     %)G:'1L;VYG   )W     9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   &5@    !29VAT;&]N9P  "=P    #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
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M971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M  $! #A"24T$%       !     8X0DE-! P     %3L    !    H    &<
M  '@  #!(   %1\ &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@
M  '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.
M#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M#/_  !$( &< H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M   #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q
M 00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B
M,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8G
ME*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"
M! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"
MDD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25
MQ-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _
M /54E7S\_$Z=B69N8_TL>D V/@NB2&-]M8<]WN<B47UY%%>149JN:VQA(():
MX;F^UT.;[?WDE)%G]<Z6[JW3SA"TT!]E3WO #CMKL9<]H98'U.W^G_AJ[:?]
M)58J-V#];#F-?5G5?9A9+FN GT_M%EK6[6X_YN$ZG'?^D_2>C_.TV669:O\
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MQB2FRDH5VU7-WU/;8V2W<T@B6G8]LM_<>W:II*?_T.]^MKB.@9&T/))J -1
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M&^GOO_2_9/5M0AU+ZM_9:JK:&X[+&.:VMM6X,:'VTEOK88MIK_2MO]/T[?\
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M^54DE/U4DOE5))3]5)+Y5224_P#_V0 X0DE-!"$      %<    ! 0    \
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     4 $$ 9 !O &( 90 @
M %  : !O '0 ;P!S &@ ;P!P "  ,@ P #( ,0    $ .$))300B      %*
M34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !
M=@$H  ,    !  (   $Q  (    ?    ?@$R  (    4    G0$[  (    -
M    L8=I  0    !    P    .P   'Y     0   ?D    !061O8F4@4&AO
M=&]S:&]P(#(R+C @*%=I;F1O=W,I #(P,C0Z,#8Z,3(@,#(Z-3$Z,#  2F5N
M($)E86-H96QL      .@ 0 #     ?__  "@ @ $     0  "=R@ P $
M 0  !E8         !@$#  ,    !  8   $:  4    !   !.@$;  4    !
M   !0@$H  ,    !  (   (!  0    !   !2@("  0    !
M  !(     0   $@    !.$))30/]       (          #_X0%217AI9@
M34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !
M=@$H  ,    !  (   $Q  (    ?    ?@$R  (    4    G0$[  (    -
M    L8=I  0    !    P    .P   'Y     0   ?D    !061O8F4@4&AO
M=&]S:&]P(#(R+C @*%=I;F1O=W,I #(P,C0Z,#8Z,3(@,#(Z-3$Z,#  2F5N
M($)E86-H96QL      .@ 0 #     ?__  "@ @ $     0  "=R@ P $
M 0  !E8         !@$#  ,    !  8   $:  4    !   !.@$;  4    !
M   !0@$H  ,    !  (   (!  0    !   !2@("  0    !
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M*"@H*"@H*"@H*/_  !$( 4$!] ,!(@ "$0$#$0'_Q  <  $  P # 0$
M        !08' 0,$" +_Q !1$  !! (! @,% P4*"P<#!0 !  (#! 41!A(A
M!Q,Q%")!46$5<9$R,T)2@187(U5VE*&QLM(()#9B<G-THL'1\#1#@I*TX?$E
M4\(U8X.3L__$ !@! 0$! 0$                " P$$_\0 ,!$!  (" 0,!
M!@4$ P$       $" Q$Q!!(A81,B05%QD2.!L='P%#)"H5+A\07_V@ , P$
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MW=W#3^SZJ1X?B.?4GX/&9.UAJ^%Q<(@F?6ZI);S6M#6#3FCR_3N0?B4'./\
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M$1$!$1 1$0$1$!$1 1$0$1$!%U&S +3:IFC%ES#(V(N'66@Z+M>NMD=_JNU
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MEM/)>483C,4$F?R5>@R=Q9$9G:ZB/72J%'P\Q,'/K>29D<D<G[-$]\OG,ZW
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M[']7E/\ ,ZR'$]+>H=(_*[>B#1D4'R/D]' 6:5:W';FLW!(8(:L#IGR='3U
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MK?>&F3-2_-7@QO(L1D]>PY&K*X_HB0!WX'NI&>/S87L#WQ]0UU,.B/N5;R7
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MUKRN,.49+:, JVFR -+NJ/0:"2 3W^A_!=^3OUL91FN7IFPUH6]3WN^'_O\
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M3&-^G?7J-$]BH#P@_.<Y_E-;_L1+0$=B=,/X=X4SQ9PR9J)EBC#.^(M=MG6
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M_59O^2.YB.(\%K#,L#D[\$E!CFDB,.#Y1\1_F_TJ\U_"[B4/KC#(?G)/(?\
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MP&R/8[&_["Y_?BX+_';OYE8_N(+^BS_]^3@G46_;OO ;(]CL;_L+G]^+@O\
M';OYE8_N(+^BS_\ ?DX)U]'V[[VMZ]CL;U_Y%S^_%P7^.W?S*Q_<07]%6.+<
M]XWRJ]-3P.2]JLPQ^<^/R)(R&; W[[1\2%9T!$1 1$0$1$!$1 1$0$1$!$1
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MPMF8\CH;Y32UO2-;&P>^R5+]+?U1^"Y4#R[(9NC7JLXWB8LA;GDZ'.L3^5#
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MGX\&-8'],K WI<"/0D?4>BL2C!@MT^.,5^81BKVTB!$1:M!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!4/QN_R!E_VZE_ZF-7Q4/QN_R!E_VZE_ZF-!?%6_$:G!<X7E_:8^L0
MUI)6#9&G-:2#V]=*R+Q9R@,KAKU R>4+4+X>O6^GJ!&]*\=NVT2Y:-QIEO\
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/$1$!$1 1$0$1$!$1!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g843142g20g20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g843142g20g20.jpg
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M<>/Y>Z=_HF?K2KXDL762A!;?X(E[6%29TK0=FO\ 9(:\ZFO0N7:<AB<7.(C
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M8U3K-,9K''^E5\R<-M:GW"(BY#8(B( B(@"(B (B( B(@"(B (B( B(@"(B
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MLI:59?'#7)(@:J=]1.^1YR25A7U?%RGI)4$1%!(1$0!$1 $1$ 1$0$UINO\
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M9EDCTC2-TO+++:PY_9NESS$\QYLY [\]RLZ@]$U=16Z<I9ZNSFS2DN!HL8Y
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MK)%(R5@?$]KV'HYIR"OSU8GZ9O6K+]^Z;42BZ-JG1PQ5,KXXF1@G8%I&,>9
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MSG)^.ZZ-I^ZP7NRT=RI0YL-3&)&M>,%N>H/F#D*L\;BKY1*E>QOHB+,L$1$
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M.JDTERP@B(H)"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MP]3K[PKRZ?2]+DK^?\$*=JZ.KHJ=PLUD=9:>=53PM@KJ>3L:B-F>7. 0X9Z
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M16F)>T89W4"6'1$1=)P!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MYX:NBN+'&GJ9Y3$Q_?$0 ?<7!_Q3V5'Q(JJ?R9.]Z6;M9JX_N,&_B7%2^@#
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M"(B@D(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MDOY_]7?F3/LA6;Y1_P#(&#\_C_0D6/5%DU'I[B)-JS3% RZ05D(AJJ7G#7#
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M9U1A\#LDX;G.!DG& 1@@=RTZZU:FXA:@L\MZLK;%9[;-VQ$DHDEE.0<# '7
M[AW]=E=4U<JJN;I_0KNN#KR(BX38(B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( BPULQIZ.>9H!,<;G@'OP"5QZQ<3=9WZC=56?24%53M>8
MR]DAP'  D;GS"TABE--KL5<DCLZ+D\?%*[6>MIX]:Z8GM=).[D%4QQ<UI\QC
M?QV.<=Q75XWMD8U\;@YC@"' Y!'BHGCE#DE23X/J(BH2$1$ 1$0!$1 $5,X6
MZPJ-96JNJZJEBIG4]28 V-Q((#0<[^U7-6G%P>ED)VK015FX7N[T^N;=::>T
M22VFHA+YJ\,<6Q.P_P!4D>J/HMZ_C*S(XM583L(B*I(1%KW&LBM]OJJVI)$%
M-$Z:0@9(:T$G;V!.0;"*&T?J"'5&GZ>[4L,D,$[I QDF.;#7EN3CQQE3*EIQ
M=,+<(B* $15G4][N]MOUBH[;:)*VCK9>2JJ&L<13MYFCF)&PV)._@K1BY.D0
MW19D1%4D(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"C]032T]CKI:>A^<)60N+:3;[\<?
M1W\5(+2OD5;-:*R.TU$=-7NB<()I&\S6.[B0ICR&>-/32U%CH9:B@^;I7PM+
MJ3;[R<?1V\%(+1L<5=#9Z..[5$=37MC GFC;RM>[O("WD?(01$4 (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B'H@"+4J:^FI
M@>TE;D=P.2HBLU$ "*:/)\7*KDER7CCE+A$_-*R&,OD<&M'>54+[<O3)>2,8
MB:=O/S6E5UD]4XF9[B/#N"UEC/)JV1UXL"AN^0B(LCH,-;,:>DEE: YS&Y /
M>L=)5-K*!D[=N8;CP/>LU3'VM/*S\9I"I5LN,EOD>W'/&X^LS.-_%1JTO<ZL
M.#QL<M/F1;\X!).PW5:IZKTK44<H^CS8'L7VX7LSP.B@C<P.V<YQW]RU+$,W
M6F\BF3(I.D=/3=++%CG.:WHO2^(.]%8\P>*G-/W04Q,$Q^]N.0? J#12G3M%
M914E3.CQN#FAS2"#WA?50Z*XU%(?O4AQX=RG*34<;MJB,M/B"MXY$^3BGT\H
M\;E@1:M+6P5&\<K23^#G=;0WZ+1.S%IKD(B(0$1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 %KW$P"WU1JV\],(G=JW!.68.1@==LK86.J=*RFF
M=3QB69K"6,)P'.QL,]V2I0*[PWELLVD:.33%/+36LN?V<<H/,#S'FSDG.^>\
MJS*(TG57.LL5/-?;?';J]Q=ST['<P: XX\>HP>JEU,_,R%P$1%4D(B( B(@"
M(B (B( B(@"(B (B( B*/OEZMUBI&U5WJXZ2G<\1A\G0N() ^ /P4I-[($@B
MJ7[I&D/]/T?Q/^"ST&O-,5]9#24=ZI9JF9P9'&TG+G'H!LK>'/T9&I>I9D1%
M0D(B( B(@*CQ'T>=66^D]%JS17*AE[>EGQD-=X'RV&_D%7:NU<3KG1OMU7<K
M%34\C3'+50-?VKFG8X&,9(\,>Y=01:QRN*KDJXID'HO3=+I33U/:J-SI&QY<
M^5PP9'GJX^'L\ %.(BS;<G;+)5L$1% "(B (HVW7ZV7*X5E#0UL4]71N+9XF
MYS&02,'W@J24M-<@(HVVWVV7*OK:*@K(IZJC=R5$;<YC.2,'W@J21IKD!$10
M B(@"(B (B$@ DD #<DH BUZBMIJ>@DKI9V-I(XS*Z7.6A@&>;([L+Q:KE1W
M:@BK;;4,J*67/)(SH[!(/U@J:=6#;1$4 (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(JE-9M4.F>Z/4C&,+B6M]&:<#N'1:0@I<R2^-F>2;AQ%OX
M5^[+:BI_S)JO_K,S_NK?\%,Z>HKK1B?YWN;:\OY>SQ$&<F,YZ=<[?!6EBC%6
MI)_7^"L,LI.G!KZ?R2Z(BQ-C5NW\55O]"_\ 1*X5P7U_I_2^E)Z&\U4D-2ZK
M?*&MA<_U2UH!R!Y%=UNW\55O]"_]$KE/R>;905FB*F2KH:6>05SVATL37''(
MS;)"ZL6GPI:N+7[F<KU*B-XD:XM6NK93Z:TUS5%965#,2SCL8X\'/5V^?=TS
M[%=]?U]=HWAB)+54 5=#'3T[97,#L@%K"<';<+2XO:8T\-#W.L?04=+4T\?/
M#/%&V-W/G9N1C.3MCS57O];5W#Y.%/47%SGU![-O._JYK9^5I/N 6D5&2AIX
MON5=J[YHF=,5'$/453;+V*VBHK',]A-(YC3(^'(R_P"CU<,D>L.J]UFJ=2:M
MU5<++HF6GH*&W.Y*FXS,#R7Y(PT$$=0<;;XSD*^:, ;I"QAHP!0P #_LVKG7
MR?'-A9JBAG(%?#7DRM/TL;C[6N5+34I4MN":X5\GJX:BU;P_N%$_5E73WFPU
M,@B=51Q".2%WF !W G&^<'<*3XN:QN.EYM-RVDB6&JG=VT0:'&9HY,-!(.,Y
M(R/%8_E#5$,7#Y\4I':S5,;8AWY!))'N!^*@N)D,D(X80U /:LGB8\'Q'8@J
MV.,9Z9->OZ!MJTB1NU-Q/AML]Y^>+=$^)AF-MB@:X!H&2WF+22<>?O5GTAK:
M&[</_NCN#! ((WFI:SH',Z\N?'; \\*S7?\ BFM_H'_HE<,TO#+/\G.^L@!+
MQ*]YQ^*US'.^H%5C66.ZK=?<E^RRQ6*LU]KBE==[==*2P6N1SA2P]@)7O .,
MDD'O&,^W93O#S4U[J+Y<].:KIV?.5"T/;50L(CF9M[L^L",8V)V&%*<*9X:C
MAW874Y!:VE:PX[G-V=]8*D8=3VR;5,VGHY7NN<,0F>P,):UN =W=.\?%5G*W
M**CQ]@EP[.&\'WZKK;?=+9I:6EH(15&:HKYV\Y!( #&M((SZI/3X=]TLFH]4
MZ<U[0:<U=54]RIK@TFGJXXPP@[XZ =XP01W@Y7CY-X_^&[R>_P"<'?H-7OB7
M_.QH+^D=^D%OD:EEE!I?ZBD544R8O>I;G2\7[%88)VMME52NEEC[-I)<!+OS
M8R/HM6+7&KKN[5%-I/1T<)NTC.UGJ9AEE.SKT\<8.X/4#!)47J;_ #@]+_F+
MOLF5>GM%=<>.6H*2GOE19:N6$2131,YC*SE8>0;CNW_LJD(1V;[1O[EFW]RP
MWFHU_HJD^>*^Z4E_ML1!JH.P$3V-)P2T@#X]W@K3JG75%9M"Q:C@;V[*EC/1
M8R<<[WC(!\, $GV%5;4&AKI3V6LDOG$2X-MO9EL_:P9:6G;!'/WYPJYQ%MU/
M:^%VD6T=:;E:Z6MR:D,Y1(UQ>X'EWVZA2HPR./Q[*B+<;+12V_B=<+<VZ&^T
M-'42,[6.W>C-Y0#N&N<02#[S[5@J-0WW5_"Z[2Q=G:KA1-FCN#)(26S1")W,
M&9S@GZB"NLQ2,EC9)&X.8\!S7 Y!!Z%4NZZGMFHM'ZP9:I7R&AI*B&8EA YN
MS>-CT(V[O)91R.3\JV:[<%FJ[E<X#0WF#2=+655P@?8>RF[*D;#]\8\2G+B[
M&3T?MYA?;37Z[UN:JMMM;!IRULE,4,<M,))GX[SS#_!;_".X1VK@S2W"<%T5
M+%4S.#>I#9)#@?!1&FIM=:^H/G:*^TUBM<KW-AAIX!(\AIP3D[]1CKW= M);
MSG)USR_X(7"1N:=U'J>Q\0:72^K:FFN,=;$9*>KBC#",!Q&0 /Q2,8\-UL:G
MU'J"ZZ]ETEI6II;<^F@$]15SL#W'(:<-!!'1[>[QZ851=:9+-QOTS2U5ZK+O
M5&(OEEJ79+"6R8:!DX&!G'FK;K#2FG]8ZIF;;KS);]44<8,KJ?/,&C !<-MQ
MD;@@X(\E+4%)2?=>FWQHA75'B.JUYI>_6V*Z3#4EIJY.SDDIZ3EDI^GK'E&P
M&<[YS@]%(<0=2W.S:RT=;[?.V.EN-28ZEIC:XN;SL&Q(R-G'HJ?>:_7'#(4M
M9<[M#?+*^80N;+GM.A/4^L#@'&Y'BI7BN\2<0N'+VYPZKR,_TD2*"<DW35/C
MX>@O9DIKC4U[EUE0Z2TM+34=9/"9Y:RH;S<C=]F@Y!.&^!Z]VY6A6S\0=(U=
M%4554W4]NEE$<T-/28EC!WR P9Z [[A2&O--:=UAJ*&A-T?0ZGIHN9CH,\X9
MU&1WXYLC!!W56O@UYPWHFW)]]BO=HCD:R2.I!+\$X'7<>YQ]BC&HM**J_1KG
MYDNTVV=O!R 46M:JQMPME'6QM+65,+)FM/4!S0<?6ME<7!J$1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 41JYE!)IFYLO,[X+<Z!PGE82'-9C<C&=_<5+J.U)*(+!<)3;W7(-
MA<31M:'&?;Z."#G/L*M'E$/@PZ09;X],6QEFG?46YL#1!*\DN<SN)SC?W!2Z
MC=-2B>P4$HM[K8'0M(HW-#3#M]'  QCV!222Y87 1$520B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B+Q+-%$W,LC&#Q<<(#VBBZF]TD(/*[M
M'#N"B:G44S\B!C6#Q.Y5'.*-8X9R[%I+FM&7$ >)*T*B[4D .90XCN;NJA/7
M5,Y)DE>?+*UR<]3E9O+Z&T>F7]3+#5:C<013Q\OF[=1-1<JJ?//*[![LX"TT
M6;DWR;QQQCPCZ22=SE?$10:!$10 B(@ 5*N]MGIZN9S8G.A<XN:YH[CNKJJ]
M<[S+27*6 QL?"W&QZ]%6236YV=%+)&3\-65IK'DX#'$^Q3VG+=.VK%1+&61M
M!QS=Y7H7VG R*8AWN6Q:KS-77 1<C61<I.!N551BGR=F7+GE!K12)Y$1:'CA
M$1 $1$!]:XCH<+<I[G50?0E=CP)6DBE.N"&D^2Q4FHW 8J(\^;5*T]WI)^D@
M:3W.V5(7T''?A7622,9=/!G1F.:]N6.!'B"OJH%/6U%.1V4KACS4G3ZBJ&8$
MK6/'CT*T65/DPETTEP6Q%$4M]I9=GDQN\]U)0U$,PS%*QWL*T4D^#%PE'E&5
M$125"(B (B( B(@"(B (B( B(@"(B (B( B(@"Q53'R4LS(I>QD<PALF,\AQ
ML[!\.JRK7N7H_P W57IO\%[)_:]?H8/-TWZ9Z*4"-T;355)IZFBKKN+Q..8F
ML &'CF.!L3G'3KW*:58X;?,?W(4GW+=K\U\S^S[7/-GF/-G/GE6=3/S,B/ 1
M$520B(@"(B (B( B(@"(M2[5PMMOFJW0S3B/'WN%O,]V2!L/>I2;=(AM15LV
MT5/^[J+_ $)>?^[C_%/NZB_T)>?^[C_%;_E<OH8?F\/]Q<$6M;:L5U##4MBE
MA$K>;DE&'-\B%LK!JG3-TTU:"Y5\I+^0=+_6$?ZN1=57*OE)?R#I?ZPC_5R+
M;IO^V)6?E99+=P_TI)04SWV&A<YT3228^IPMZBT/IFAJX:JCLE%#40N#XY&,
MP6N'0A4BBX87>6C@D;KR],#HVN#078&1T^FIW2F@[E8[W!7U6K;I<HHPX&FG
M+N1^6D;Y>>F<].Y6DU3_ .3]2%\"R:IU+:]+V[TV\U(AC)Y6- YGR.\&CO52
MI>+UB?40LKZ*[6V"8XCJ:NFY8W>>03LH?4D3+WQ[LM!7M$E'14AG9$[=I?AS
MLX]O+_=72]2V*BU'9JBV7-A=33 9+<!S2#D%I[BHTXX):U=DVW=$3JW7-LTP
M^D;6PUM0*IADC=21"1N!CJ<CQ5=DXS:>C87R45Y:P=7.I0 /]Y7RUT5-8K+!
M1Q2.;24<08'S/R6L:.\^07+)I*CBUJ,T\!DAT7;I?OCQEIK)!W#R^P;]2,3B
MCCE>I;+O9$FUP=)L6I*"\:<9?(7/I[>YKWE]2 PM:TD$G? &Q[U3Y>,-C[25
MU';[S6T<1P^K@I<Q#SR7 _$!:/R@IS;- T=NH&"&GGJ8X"R,8 C:UQ#0/#+6
M_!?;/K.YVFUTUOHN'=\CIH(Q&UH8>[O/J]3U*M#%%QUU=^^@Y.Z.A:;OUNU'
M;&5]GJ6U%.X\I(V+'=[7 [@JJ3\6=.10SEHK9:F.H=3"ECA#I9'-ZEH!^COU
M)"K_  E@ND&O-03NL%?9[/7Q=NR&>,M:R0.&P. -^9YP.[V+'P%H*<WC5U>Z
M-KJD5AA:\C=K>9Q('MV^ 1XH1U-[U7W(4FZ+-9.*VF[E#7.J)*BVRT;.TEBK
M8^1W+G&P!.3D@8Z[]%JT?&#3\UQ@IJFFN=#%.[EBJ:F -C=YYYB<>>/:H'65
MLI*SC_IR.H@8]DM*)9&D;/<SM2TGQ^BWX*9^4-#')P\>][ 7Q5,18<;M)R#]
M14K'C<HJG[7V%RIOT+_>;K166VS5]SJ&4])$,ND=]0 [R? *@2<8K0(S/'9[
M])1#_P#BFTH[/'CDNZ+=UG'IZHT!:I=8U$K*)C(96ACR'22<FP 'TNIV]ZT8
M.)4E?3MBTYHR\UM.6\D9?$(HBWH-]QA4QXTU=7]D2Y;\EYTS?[=J6U1W&T3]
MM3N):<C#FN'5KAW'I\5*+D7R<RX6O4,;H^Q#:_\ >@<AAY=Q]6/<NNK+-!0F
MXHM%VK./<)?YT]?_ )R_]<]=A7YWT]I/[J^)6M8C=*RW]A62.YJ9V"_,KA@J
MY?N.C_K7>_\ :?\ NNC-"#E;E6R[>XI!NMD:W"/^<WB#^=N_6R*YZOU]9M+U
M,='5NGJKA(,MI*2/M),'H2,@#XJ@\"Z+YMUOK6A[:2?T:40]K)])_+(\9/F<
M*!T%J.MI]5ZEO;=,W"]UE14E@FIVD]@W)]3H<;<H]@"O/$IY)/FDO<0I4D=2
MTUQ*LM[NC;9)'6VRXO\ H05\79E_D#DC/D5*ZIU=;-,5=L@NKI6>GO<R.1K0
M6,Y>7)<21@>L/'O7*.)%TO>K;=2MI]#WNCN-+,V:"J,3BYF.HV;GP/M 6_QI
M@-VK^'=/7QEAK*@QS,(P1SF$.'EU*HL$7*-[7?<G6Z9;M+\4++J2Z55%;X*\
M.@B?/VDD0#',;U(];(ZCJ!U6N.+E@FI*>2WTUSKJF<.+:2FIP^5H!QEP!P!M
MXY5SN-/#!9JIL$,<;8Z9[&!K0.5O*=AX#8+G?R=;73TVB7W!C&FJK)W\\F-^
M5IY0WV;$^]42QN+G7%=R?:NBV:.US:-5R3P4+IX*Z#>6DJF<DK1TSC)R,^!V
M[UGUAK"T:3IHY;O.X22G$4$3>:23V#]IP%0^(T;;3Q=T5<Z(".HKI?1I^7;G
M;S-9D^.TA^ \% 7&\5(XW7>N-BK+XZW1B&G@IQGL<!OK]#WEWO<K1P1DU)<5
M?[$.;6Q>[9Q7L=37PTEPI;E:'S'$3Z^#LV.]X)Q[3MYK1X^WV.AT=/; RJ](
MK0TLEB;][:UKV\P<[.V1MYJ&USJ&ZZJTW5VN;0%Z;)(,PRNC)[)XZ.'J_P#
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M#DYR5? MJ(.]%J>.$1% "(B (B( B(@"(B ^A?62/:06DC!RO*(02E)>ZJ#
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MUMAIV1Q&M<3+4<K0"X#. "1MG'M5JX8:TEU;15T5QI&T=UM\HBJ8FYY<G."
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M+I*RWVV9WI\89)RLD!(W&/6(\1E6S6M3I"^VK3]=>KA.RCEJ!)0R1,>.T?W
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M[T%)5;+:BAM,ZHLVIJ=\UDKHZD,QSM +7L]K3@A:]UUII^TU]717"XL@JJ2
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MQO+' ,8PT>S;H-B=N]63C"4LFJ[O[D;M)405L:'?*,NQ(!+;<TCR/)&%*?*
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MCH&F*FD9RNC;CH0I5)<L+@(B*I(1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M<-Q;:?#:OL(I8>8X'.T X/AD9'O59TYQ5HK+9X+9J^CKZ&[T<8A<PP$]MRC
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MA-0M8"YQH9@ !DGU"L]3TX]^_P"Y:MY%6X&V*W1Z H:Y]+#+5UG.9I9&!SB
M\M:W)[@&C91G"*&.W\1==T%(T14C)VED3=FM]=^ ![\*T<%V/CX:61DC7,<&
MR9#A@C[Z]5[AI%(SBGKQ[XWM8Z4<KBT@'UW=%,I-O+?^[D)>4ZLB(N,U"(B
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M5I/U J;TE32TFE+)3549CG@HH8WL=U:X1@$?$*617UO3H(K>PA&1@]$14)
M P!@(B( B(@"$ XR <(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (BJ4US
MU<V9XBL-*Z,.(:XU#1D=Q^DM(8W/AKYNC/)D6/E-_!66U%3_ )TUC_U?I/\
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MHV'^([=^;1_HA;RXGR;(X[\G9H,.I\@'_+&_^)=.U!I^VW^W2T5TI(IHI&D
MEHYF'Q:>H*YE\G3]YU/^>-_\2["XAK2YQ  &23W+?J&UE;13'Y3DG :MJ:27
M4.EJR4R?--21"3W-YG-<!Y9;G^T5L7*7[E>-5%-&>2@U'#V4S>[MV[ ^W/)_
M?*C^"1^<]::VO<.])/4EL3NYW,]SOLY?BMCCOZEST7+'^_LN'J8Z_29^T!;-
M7G<?5;_3^2B\EG6T1%PFP1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!1.KI:&#3-SENU,^JH&0.=-"QN7/;C<#<?:%++2O<E=%:*R2T0Q3
MW!L;C!%*[#7O[@3D?:/:%,>40^#5TA+0SZ9MDMIIGTE ^!KH87MY7,;C8$9/
MVE2ZTK))7RVBDDO$$4%P=&#/%$[F:Q_> <G[3[2MU)<L+@(B*"0B(@"(B (B
M( B(@"(B (B( B(@"(B (B(#Q._LX9'_ (K25SV3/:.R<G/57NZ'%OJ,=>0A
M4(]2L,IV=*MFSXB(L3J"(B (B( B(@"(B *J:IK#)4BF:?4CW/M5FJYA3TTL
MKOP6DKG\TCI9GR.ZN))5)O:CT?P[%JDYOL>$1%B>P$1$ 1$0#N5ULAYK)3^0
M(^LJE*XZ>.;)'Y.</K6N+S'G_B*_XE\?Y-X=51ZTDU<Q/7F*O [U2[K&8[C.
MT_C96N?@YOPQ^W+X&HB(N4]D(B( B(@"RTTSJ>=DL9PYAR%B7U2B&K5,Z'33
M,J(&2QG+7C*R*O:1J>:*6F<?H^NWV=ZL*W3M6?.9\?A3< B(I,@B(@"(B (B
M( OH.#D=R^(@+Y9W<UNAWSAN%N*+TV<VQF^<.*E%V1W1YF15)H(B*2@1$0!$
M1 $1$ 1$0!$1 %@KQ&:"I$\IBA,;@^0.Y2QN#DY[L#O6=8:US6T50Y\+IV"-
MQ,36\Q>,'U0._/3"E @>'<%LIM)TD5BN,URH&E_)42OYG./,<CH,8.V,*R*O
MZ!J*6JTO22T%HDL].2_EHY(^0L]8Y.//K[U8%:?F9$> B(J$A$1 $1$ 1$0!
M$1 $18*ZLIZ"EDJ:R5L4$>.9[N@R<?:5*3;I$-I*V9T4#]V%@_TI!]?^"?=A
M8/\ 2D'U_P""T\#)_:_H9^/B_N7U)Y%BI*F&LIHZBFD$D,@RUXZ$+*LFJV9H
MG>Z"(B$G-OE!$MX=3%I(/I,73VE732>^EK-G_H4/Z 5+^4)_-S-^<Q?:5%\3
M;U56KA#8X*"1T<]PBIZ8O:<$,,678/G@#V$KJC!SQQBN[?[&;=2;+S6:ZTO1
MU9I:F^T#)P<%O:@\I\"1L/>K!35$-5 R>FECFAD',R2-P<UP\01U52L7#C35
MMLD5!-::.K?R 2SS1!SWNQN>8[C?PQA5+AF)-+\2]0Z0BE>^UB/TNF8\Y[//
M*<#W/P?R0J>'"2>A\$VUR:W"&\4-HJM;5-VK8:6G%Q#0^9_*">:389ZGR"ZE
M8M1V>_->;/<J:K+/I-C?ES?:.H7'.$FDK??-5:GN-WIV54-+6OCA@E',SG+G
M$N+>AP,=?%;_ !7M-)HF[6'56G:>.AD;5""HB@;R,D:03]$;#(#@?:/!;Y80
MGD<;W^W!2+:C?8LO$FT"XZPT7+3RRFMIZYLG8L;EO8M<U\CW'NQRM'F7*YWJ
M^6RQP-FN]?3T<;CAIE>&EQ\AU/N4B#D CH5PSB!/367BR;KK&US7&P24S8J0
M\@>R-V!G8[$@A^Q_&!6.->+4'V1=O3N=:L>J;'?9#':+K254H&3&Q_KX\>4[
MX4RN14E'H75E^M-?I:YTUIN=)*).RIX1 ^;&_*6$ 'VC.Q*ZZJ98*+VOYDQ=
MF"NK*:@I9*FNJ(J>GC&722O#6M]I*@[?KG3%PJVTU'?*&2=QY6L[3EYCX#/7
MW*D\>X*GET]6S4DU;8J2I,E=!$3N/5QG'=CG&?/S494U?#'6=I^;Z8T=CK'%
MO92NI6P/C.?QAZISTP7+2&%."D[W].Q5S=T=>N5WMUKDIV7&MIZ5]0[DA$T@
M;VAVV&>IW'Q6\N;\5-,/K>& ACGDJZRTQLJ(JAWTY QN'$X[RW)]H"D*'6L9
MX4MU/(YIE92'F![YQZF/>_ZBL_"N*<?6OX+:MZ99HK_:96U[HKE2/;09]*+9
M01!C.>?PZ'KX%:EPUAIZWTM/4UEYHHX:AO/"[M0>T;TR -R/-<ZTQ97VK@7?
M*JJR:VYTD]9*YW4AS#R_5@_VBL_!K15EK-%T=TNU##<*RK#O6J6]H(V-<6M:
MT'8##?K6CQ0BFV]DZ*J3>QTZT7:@O%+Z3:JR"K@SCGA>' 'P/@?)8[W?;78X
M&S7>OIZ.-QPTRO +O8.I]RY;H>ABT[QPO]GM8,5MEHQ,( ?5:[[V[;V%SL>1
M6/1ENIM=<1]3W>_1-K*:VS"EI*>4<T;1S. /+T.S<X\7$H\,4VV]J3^HUOYC
MCG?K;>]"T,]FN$%7&VXQAQA?DM/9R;$=1[UUFMNE#;12MN%9!3.J'".$2O#>
MT=^*,]2N+\?='VVV6RAN]HI8J(FH;!/% T,8_():[E&V1@CWJ5^4-')+0:8C
M@>8YGUO*QX."UQ P?BM-$9QA%/9V1;5MG1Z'55BK[J^V4=UI)J]A(,+) 7$C
MJ!XXP<X7V^:HL=B>UEWNE+2R.&1&]_KD>/*-\*!;I33VB+-57BUVV,5MNHI7
M-G<XES\,).=\9./KV58X-Z3M]XL+]2ZAIXKI<[C-(\OJFB0-:'%NP.V<@^[
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M(@"(B (B( B(@-&]GEMDY\A]JHH5WU!M:I_=]JI Z+#+R=O3>5A$18G2$1$
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MMAM%)4>D4EJH()QOVD=.QKOB!E3CRQC3K=>G<AQ;(;AC;ZRCX?6BCO+'>D"
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MJM6DI^>DEA/_ ,MV1[U5%.:2DY:Z2/\ '9GX*\'N<O61U87[BV(B+8\ (B(
MB(@"(B (B("V:2_@,OY?[ IQ0FDQB@D_I/V!3:ZX>5'FY?.PB(K&81$0!$1
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MR]I;(Z;#%'#"R*)C61,:&M:T8  V  7)>&4;;;Q;UK;*(!M"0)N1OT6NY@<
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MXU;:VL9$T2U#1@2.QU"WUYC8V.-K(VAK&@-:T= !W+TJ-V[)"(B@!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0&I=?XOG]@^U4(*_77^+Y_R?VJ@K#+R=O3>5
MA$18G2$1$ 1$0!$1 %1[^_GNU1O]$AOP"O(7/[D_GN-2[QE=]JIDX/0_#5<V
M_<:R(BQ/9"(B (B( B)[$!HWD#T!Q#1GF&^%7PI.KJ*N=KXNR]3/<%&!<\W;
M/8Z6+A"F?41%4Z B(@"=Z+X4"+#9FEMO;GO)*W5BHV=G21,\&A95TQV1X666
MJ;81$4E @V(*)W%2#HL#N:"-WBT%>UKVX\UOIR/^;;]BV NA'R\E4F@B(A 1
M$0!$1 $1$!<=+C_DW^U^P*743I@8MH_**EEUP\J/-R^=A$16,PB(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B U;K_%U1^2J%WJ^W7^+JC\@
MJ@K#+R=O2^5A$18G2$1$ 1$0!$1 ?1U"YU4'-3,?%[OM*Z*WJ%SJ<??Y0>Y[
MOM*ID/3_  SF7R,:(BQ/6"(B (B( B(@/<+2^:-@_"< HO5]F?:;BYS!_DLQ
MYHSX>(5CL%.:BYQ;'E8>8GP5JNU!!<Z&2FJ6\S';@][3W$*WAZXG._Q#\IG7
M]O<XL$4C?+146BI,<PYHG?0E'1P_Q4:._*Y&G%TSZ7'DCEBIP=IGU$107"]1
MMYY6-_&("\K8MS>>NA'^ME2N2LGIBV69?$"+I/!"(B (B("^V8YM=+^0 MM:
M5EVM5+^0%NKI7!\SD\\OB$1$*!$1 $1$ 1$0%STS_%C?:I516F?XK;^45*KK
MAP>;E\["(BL9A$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M]54%C'$Y+6@#.%3PYP?SDDO\2<E,THS2VW-OPU9.EFVI>SQ7J3P1:M-5-E:
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$!JW7^+:C\@J@J_77^+Y_R50EAEY.WIO*SXB(L3I"(B +Z!E?%]
M'5 ""%\66IC,4SF'H#A8D("(B$A8+A5Q4-'/55!Q%"PO=[O!9U0>+=R,-LI[
M?&<.G=SOQ^*,_M4-TK-,./Q9J)S[4EZJ+[<GU-1EK.D<6<AC5$HBY;/HHQ45
M2"(B%@B(@"(@0%DN![30]I+>D=1*UWM."JVK/:V^EZ'NT1.74LK)A[#L56,8
M5I=F8X?ZE[W_ "%[:]X!PX_%>$539.CZXD]23[5,:4L<U_NK*:/+86^O,_\
M%;G[5%4T$M341P0,+Y9'!K6CO*[IHVP,L%J$)Y75,GK3/'>?#V!7A&V<O5=1
MX4=N62]'2PT=+'3TT8CBC'*UH'@LR(N@\%N]V$1%(/!BC/6-I]R]-:UH]4 >
MP+ZB@6$1$!]((&3T7Q;?9\UO#_!^%J*2$$1%!(1$0!$1 7/3/\5M_**E5%:9
M_BQOM4JNN'!YN7SL(B*QF$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M%\>YK&ESW!K1N23@! ?44?\ /=J[3D^<Z'GSCE](9GX96^UP<T.:06GH1WJ6
MFN2+L^HB*"0B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B$@ DD #O* (OC'M>,L<'#Q!ROJ (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B^/<U@R]P:,XR3A"YH>&EPYB,@9W*
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MQ7U;I][:?4UH$W+L3-$Z"1WOQRGX*V\1]>7?26KK; ^" V.<,>^01DR$ X>
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M6NK'Y3S\ZJ81$5S$(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M3U5[%AU=0BW7,N[-CP"UI?W-<T]">XYP<KHU\NM)9+34W&X2=G34[>9Q[SW
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MK*ZF$;:'LQELF1ZW-\?CY*;1%5NR:"X+IO\ SB*W^FJ/U;EWI<%TW_G$5O\
M35'ZMR[>C\N3_P"K,,W,?B7+C7HS[H;)\XT,>;I0M+@&C>6/J6^9'4>\=Z^<
M$]9_=#9/FVNDS=*%H!+CO+%T#O:.A]Q[UTE?G_B19JKA_K2EU/86<M%/+S%@
MV:UY^E&?]5PR1[_ *W3M=1C?3RY_I_@C(O#EXB^9EX"_S@7_ /H)/UK5K\?[
MBV;6ULHJLR&AI86/>UG7UW'F(\^5H7OY/<PJ-;WF8#E$E*]^/#,K2L_'>EDM
M6MK)?^Q$M,0S((R"^-_-RGV@CZUV[+K=^:_8Q_\ 9^98Z?C5I:FIXX(*"ZQP
MQM#&,;#& T 8 'WQ4OBQKZP:PLM-#04E='7T\W.R2>-@'(00YN0XG?U3[EW&
MT0V.[VV"NM])0S4TS0YCFPM^!VV([PJMQ&U/8M&1TK76>BK*N=W[PUK&%K!U
M<3RGOP!X[^"Y,$\:RKP\;U?$UG&6GVI*O@+=7R7+@9-4S.+I#9IV.<>I+(WM
MS_NJ ^3?:XH[)<[J6 U$L_HX<>H8UH=@>TN^H*ZWJ<57"VZ5(H_01-:9Y!3[
M?>^:)QQL!ONJ'\G&]T_S=<++)(UM2)O28FD[O:6@.Q[.4?%%;Z?*XKN-EDC?
MH=AKJ2&NHIZ2J8'P3L,;VGO:1@KB/R>9Y:34=_M)<71!G:>7,Q_+GW\WU+LN
MH;O2V*SU5QKI&LA@87;G',>YH\R=ER'Y.MNGFK+W?9VD,EQ QWXSB>9_P]7X
MK/!MT^1OC;ZEI_\ 9&B*O=!#<OE$>C5+0^%U1$]S3N'<L#78/EZJ_0:X1-_G
M*#^E;_\ 2A=W3K7MC7_Q0P?U?$X+=XVT_P HNF[$!G/-$YV.\F(9^*L'RD/Y
M*6W\]'Z#U!7_ /SBZ/\ I8?U04[\I#^2EM_/1^@]=2_[L'P1E_1/XEPX6T$5
MOT#98X6AO:4[9WD=[G^L2?C]2YW\I.MDQ8[>QQ$3C),X>)&&M^&7?%=1T%_(
MFP?F,/Z 7-/E(VR62CL]TB:3' ]\,I'X/-@M/^Z[XA<_2M/J[EZO]S3*O^'8
MZQIVV0V>QT-OI6!L5/$U@QWG&Y]I.3[U7N+MKAN>@+L)F OIHS4Q.[VN9OM[
M1D>]2VB[]3:CTY17"ED:XNC E:#O'(!ZS3[_ *MU7>-5^I[1HBMIGR-]+KV^
MCQ1YW()]8X\ W._B0L,49^.E_59I)Q\-^E$=\GRNDJM"RP2N)%)5/B9GN:0U
MV/BXJK?)S_C[4']&S](JX<!K7+;M!-EG86NK9WU#01ORX#0??RY]ZI_R<_X^
MU!_1L_2*[9TUU%>[]3"-_P#'9@JHFZE^4%Z/7#M*:GFY0QVXY8HRX#'@7#ZR
MN_+\_P"HION.XZQW2L!;15$@EY\;<DC"QQ]QR?<N_0R,FB9+"]LD;P'-<TY#
M@>A!6'6W6-KC2C3!S+ULXG\H^VQ1_,]WA')4\SH'O;L2!ZS?AZWQ6/C=>YZO
M0FE6N<1\X,;52X[R(VG[7_4L?R@KLRYW6TZ?MQ[>JB>72,9N0]^ QOMZ[>84
MGQLTU+'P^LKX&]H;.UD,G+^(6!I=\6M^*ZL%16#7ZO\ P93W<]/N.D:)ML-H
MTG:J.G:&M93L+L?A.(RX^\DE5KCE;(:[A_63R,!FHW,FB=WCU@T_$./U*4X8
MZBI=0:3H'PS,=54\+(:B+/K,>T8R1X'&1[56^/6HZ2BTI+9V3,=7UKF QM.2
MR,.#BX^&< #QSY+BQ1G^:2[V;2<?"]U$CP*_FXH/Z27]8Y4*B'W"<<70?O=O
MN+^5O<.24Y;[@\8]@5]X%?S<4'])+^L<H/Y0]D,]DHKW3@B:AD[.1S>O(X['
MW. _O+HQR7YF>.7$K7\&<E_Q1DNQ,\<KY\T:'GIXW8J+@X4S<=>7J\_ 8_M+
M>X/V+YBT-0LD;RU%4/2I?'+L8'N:&A<KN5Q=Q+UMI:@SS4\5-&ZJ Z!V.:7Z
M@ OT0      -@ LLZ>##'"^7N_V+XWKFY]N B(N W"(B (B( B(@"(B (B(
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M_/(G/H%91]ER_P )CY>;.>GP^M6E@R06J2V*PZC'-Z8O<ET1%B;&&L_@<_\
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@,56"ZEF:T$DL( '?L5P/AM=]5Z*LD]O;HBYU@EJ#/VA:]F,M:,8Y#^+]:
M_0*+7'E4$XM6F5<;=G*?W1]6_P#\N[E_>?\ _IJ5U)9ZSB+PW:RLH76FZ.>9
MHJ><G[V]CG- =D X<W/=^%WKH**?%2:<(TT-/JSE5KU]J&TVZ.W7W1UXJ+I
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M3M!:AH*YSBEC[/M/7;S;]<<APNV(IAE48Z&K#C;M,Y3^Z/JW_P#EW<O[S_\
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M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0$)+#?CJV":*JI!IX4Y;)
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MFBA_("V5VK@\I[-A$1" B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M&L&0,D^0>?@K+"ED4;M<D:_9LCN$U[O5JU726O4M?55,5[H&5=*:B1S^5VY
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M?=;QNIZ?Z=OTY#VKN\&8X(]^>7^X5UA4G#17O+)V$1%F2$1$ 1$0!$1 $1$
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MM%Q?15-Q+YXW<LG8Q.D:P]X)&WPRD<<Y>5!R2Y+NBA)-5V5FFG7_ -/8^TM
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M0<S;_P#=A 8G4GW.>C'M6D??>UR<8\NGUJ<5Y=B$$1%0D(B( B(@"(B (B(
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M:_L<,KXWR5',QQ:<0GJ%;%\Y&_BCX+2#@O.K^=?L9Y%-^1U\K_=%2_=#L/\
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M(@"8&<XW1$ 0C/5$0 ;=$1$ 1$0 @'J,HB( @ '081$ 1$0!$1 $  &!LB(
MB(@"(B (0#U&41 $1$ 1$0!$1 $1$!"2OOWW6P,BBHSIXTY,LA)[82Y. !X=
M/K4VJS4443N(%+6'4$D<S:,L%H[08D&3]\Y<Y[_#N&^RLRM+L0@B(JDA$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$!XF_>9/R2N=GJNAU&U/)^25SP]5AE['7TO#/
MB(BQ.L(B( I?3,7:7 .[F#*B%9M)1?>YI"/  J^-7(RS.H,L2(.B+J/.-&]R
M=E;9CGJ.7XJC$Y.5:M5S<M+'$.KG9/N__:JHN?*]SNZ95"PH'5M,Z2GBG8">
MR.'8\#W_ %*>4-JBI,- (V=9CRGR'58RX9Z'2MK+'25!$1<Y]"#T4UIFWLJJ
MAU1*&F.(X QWJ%4G8:PTE>T;]G(>0C]JM&K,.H4GBDH<D[4 "9X  &>X+)24
MXFYLNP1X+W<8N63G'1RPTDG9SM/<=BMSSTW+%<.3&]O(]S3OC90432[B'18_
M I''ZU8JP<M3(/-0MH:)->3N_P":H@/BY599RO$Y>XM=1,(69.Y/0*.DJI7G
M)<1[.Y?:UY=.[?Z.P7F"G=-S<I&WUJQCBQQA#5(S4M8YI#9#EOBI';J,>T=Z
MA'M+'%KA@A9(JF2-N&NV\T&3I]6\"2J)FP-];<_BA4O5\KI*^Q3//T*O'LR%
M/.<7.+G')/>5":NA<**WSD88RMB^LD*LN#7#BCB:;Y)K!.<;KXI:1K8H).1H
M&RB?%6&+)XENB3MSW.A()SRG 52O\D<ETF,708!/B58+A/Z!:"]GTY-A[2J<
M%GD?8UZ/'[<LG;@(B+(]$]1\O.WGSR9&<>"Z'3A@AC$>T?*.7V+G2N>FIC+:
MVAW5A+5IC>YYOXC"X*7H2J^]%\1:GD%UTY()+:T#\$D*35;TE-^^PD[_ $@K
M(NJ#N)YN6-3855U9'RU+'@?2;N5:E":IBYJ)KQU:Y,BN); ZFBI(B+E/0"(B
M (B("]6+^*J?\E;RT;'_ !53_DK>79'@\N?F81$4E0B(@"(B (B( B(@"(B
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MW/-3RY#LY_& 6%M(YXS&]CF^*UNY;%%+V4F#] ]4(T/''V&>GPMIVYD(<\]
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M'"P+DJCU$["(B@D(B("\V+^*X/8M]:%A_BN'V+?77'@\R?F81$5B@1$0!$1
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M<8WAM<HZ7G;/<N$:5'W<<:JR[.^^4%N<7QGNPSU8_B?7]Q4[%KC'! W'M?\
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M%R4O0A->_P B;_\ F,WZ!5"^3=_)2Y_GI_08NM$!P((!!Z@KRR-D8PQK6CP
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M6^=LS+6)Y&G(](D=(/[I.#[PKLBU6?*EI4G7Q*/'%NZ/C&M8T-8 UK1@ #
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M %H76A950N<UH$K1D$#KY+?7PG *O";@[B2G3M'.<%M\</\ \G<>PK=4Y:+
MVLJZJXUG.ULCRV.+&#R ]3[5BNMEEI7\U.UTD)Z8&2U>\HMQ4C:/58I2T)[D
M0BE[799ZN3FJ Z&(=21@N]BW*G3+LDTTXQW!X_:I463+JL49:6RN*QV*RQ34
MS9ZIKB7'U6]!CS7JATX6RM?5RM<T?@-[_:K&  ,  #P"O&'J<75]8FM.)_,\
MQ11Q1AD;6M:.@ P%Z1%H>7R$1$ 1$0&2G_?X\^(708#F&,^+0N>P[2-]H5_I
M/X+"?]1OV+;#W.3J>QF1$6YR%?U:W[S"[O!(575FU<_U(6>TJLKFR>8]#!Y$
M$1%F;%ATB3V\P[N7]JLZKFD6C$SN_ "L:ZL?E//S^=A$17,0B(@"(B (B( B
M(@"P5QC;0U!FB=-$(W%\;6\Q>,'+0._/3"SK'4]L*:4TP89^0]F'_1+L;9QW
M9PB! \/9[?4Z4I);/;);71.+^2FE9RN;ZQR?>=\JQ*)TJZ\OLD!U*RFCNF7=
MHVG.68R<?5A2RM/S,A<!$15)"(B (B( B(@"(B (B( B(@"(B (BY=\HJ>:G
MT-2OIY9(GFOC',QQ:<<DG@KXX:Y*/J1)TK.HHM:V$FVTA)R3$S[%S?Y1<\U/
MH:E?3RR1/-?&.9CBTX[.3P4XX:YJ ;I6=111\=?2T%II)KA504T;F,;VD\@8
M"XMZ9)Z]5BFU)9(:Z2CFN]OCJXP7/B?4,#F@#)R"=MMU32^PLE47+]!ZU-SU
MUJJGN=WI31Q3,@M\9E8UCF\[QZF_K$^KOOW*PTMFIV<2ZN["_,?424PC-KYA
ME@PWU\<V>[\7O6DL3BVI>A"E>Z+>BUKC<*.VTYGN-7!2P#;M)I QOQ*U[3?;
M5>.;YJN5'6%F[A!,UY;[0#LLZ=66LD46&LJZ>BIW3UM1%3P-^E)*\,:/:2HN
MAU9I^OJ6T]%>[;/.XX;&RI87./D,[HHM[I$632+!6UE-0TYGKJB&F@! ,DSP
MQHSTW.RTWZ@L[+A'0/NM"VMD +(#.WG=GI@9[^Y$F^";)-%4-'6:GMVIM2U<
M-^9<9*R?GDI0X$TAYGGE.'''7'0?15@NMZMEH:UUUN-)1AWT>WF:S/LR=U+C
MO2W(3VW-]%'6F^VJ\<WS5<J.L+=W""9KR/: =E(J&FMF2$1% "(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MMA[G)U/",Z$@ D] G<J_J*Y"-AIH7'F/TB/L6TI:59S0@YND0][J_2JUY;]
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M(BY30(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M.,]6P1-8#[<#=;B*=3:JR*1K7"@H[C (;A24]5"'<PCGC#VY\<$==RMD
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M0T5:S55=%63OG+H'1G(;'@8!]4=^59NBK)4ZNR4["(BJ2$1$ 1$0!$1 $1$
M1<YL5]N=1QIO]GFJWOME/1MDB@(&&N(BWSC/X1^*Z,KS@X59"=A$14)"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MZ36P.IX(L^L\O'*2!X $G*KE'<*/17"O3E#J>UR55+6?>YVN:"V+G<7^N#X
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M*1PO+HP[J%G"6DLI&4;C*^X*-.R] +H34N#G:H\X*8*]83"M0/."F"O6$PE
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M NCR,CF'4>]*8-A%H_/%M^;OG#YPI/0,X])[9O9]<?2SCKLLTM=2134\,M5
MR6ISV+'2 .EP,GE'?MX)3%FPB(H 1$0!$1 %'Z@O%'8+/4W*Y2=G2P-YG$;D
MGH !WDG "D%R#Y14LDU'IRU!Y;%65A+\>6 /TRM,,/$FHLK)TK/=OOG$/6D1
MKM/16^QVEQ/8R50YWR#QW:[/P \RO,VL=7Z'N%*S7<%+76FH?V8KZ-N"P^P
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M3F\K21')@LY9.7IDM<NQJF3'X;JR8RU$'K34=-I73M5=:MAD$0#61M.#(\G
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M./:"N:4$TY1X3-$^S+XBYI9+M<-1<7[HVFK9V6.S0]B^%CR(Y9CD>L._<O\
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MET*KIF55%-2R%PCEC=&XMZX(QM\5%Z/TW1Z4LK+9;9)Y*=KW/#IW!SLDY.X
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( OF%]1 ?,)A?40'S"+ZB (B( OF%]1 ?,)A?4
M0'ES<KSR+(B"SQR)R+VB"SQR+YR+(B"SPUF%]Y5Z1!9\ 7SE]9>D0'S"^87I
M$!\ 7P!>D0'GE1K<$KTB ^87SE7I$!Y(V7GD61$%GCD3D7M$%G@-PO6%]1 ?
M,)A?40'S"87U$ 1$0!?%]1 ?,)A?40'S"^@(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
=B( B(@"(B (B( B(@"(B (B( B(@"(B (B(#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g843142g21m48.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g843142g21m48.jpg
M_]C_X  02D9)1@ ! 0$!P@'"  #_[1C.4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 <(    !  $!P@    $  3A"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    !XX0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      T$    &              2-   +%@    8 9P R
M #$ ;0 T #@    !                          $             "Q8
M  2-                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  2-     %)G:'1L;VYG   +%@    9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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M    % !! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ #( ,  R #$
M   ! #A"24T$(@     !,DU- "H    (  <!$@ #     0 !   !&@ %
M 0   &(!&P %     0   &H!*  #     0 "   !,0 "    'P   '(!,@ "
M    %    )&':0 $     0   *@   #4   !P@    $   '"     4%D;V)E
M(%!H;W1O<VAO<" R,BXP("A7:6YD;W=S*0 R,#(T.C W.C$V(# Y.C,S.C(R
M       #H $  P    '__P  H ( !     $   L6H , !     $   2-
M      8! P #     0 &   !&@ %     0   2(!&P %     0   2H!*  #
M     0 "   " 0 $     0   3(" @ $     0              2     $
M  !(     3A"24T#_0      "           _^$!.D5X:68  $U- "H    (
M  <!$@ #     0 !   !&@ %     0   &(!&P %     0   &H!*  #
M 0 "   !,0 "    'P   '(!,@ "    %    )&':0 $     0   *@   #4
M   !P@    $   '"     4%D;V)E(%!H;W1O<VAO<" R,BXP("A7:6YD;W=S
M*0 R,#(T.C W.C$V(# Y.C,S.C(R       #H $  P    '__P  H ( !
M  $   L6H , !     $   2-          8! P #     0 &   !&@ %
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M*"@H*"@H*"C_P  1" ,)!V0# 2(  A$! Q$!_\0 '  !  (# 0$!
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M==_[-W^LN5_X0?XPN1+KO_9N_P!9<K_P@_QA<O&_X)&M+XT?H-$1?+G>$1$
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MUC3\>";L5<M+HN:+QH(: X\1 YG;;=>K(L$1$ 1$0!$1 $1$ 1$0!$1 $1$
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MS61@=5ZV(W[22\Q](^*N?:!A<A0[/XFXW(WI+6-/>&;O2'R,W/%Q;'GL#O\
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M_!3"BZ5Y))_)6_<ARQ:%OTG@ZNEJD.J-6!T;V_MF-H'Z=EX&X<[Q:T';K_\
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MC,8<[B-09":2"1O>LG=N' G;?KL>9'(^:D,9^[SD_P#A1_@C5@[8/W/<K_\
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M2S/ )+1#Q&\MXANSD=NOBL_8?8B]1HV&5@<VQ(T@D;@DC;[=UH=M7_F6E/\
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M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 0^I--X[4<5>/*QOD;
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M$'?B'NY _! ;G:Q(]DNEN[>YO%E8@>$D;A6_.9G'X.D;65M,KP;\(+N9<?(
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MJO4NT#3ER;NX[Y9N"6.EB>QLFW7A)&Q/L5&S;S9TQV<U+CBZA8EB%@./)VP
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M1AR<%NSC\K"W@99KD;EODX'D0HUW9W6L6ZUW(Y6_=R$,\<PL2EO1AW# W;8
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M*$NV,N_[YVW0>04?AV'M#[3Y;5IO'C*IX@SJWNVG9K?_ *CS/O*[LUH:T-:
M&@; #P7H3EE8*G'XGU?[&,5S'=]#XKPQ5X60UXV1Q,&S6,&P ]RR(J[)K?34
M;W,?F:;7M):07]"%PQC*?17-6TNI8E&Y_!8_/475<I7;-$>8/1S3Y@^!6C!K
M33EB>.&',5'RR.#&-#^9).P"L"FTZ;OT8TD?G+56G;^@LPV2)SK&+F.S)#RX
MO]EWDX>?C^92U6>.S79-"=V/&X*['J;"U\_A+6.M@!DS?FOVW+'>#A[BOSWI
MHRX[*7<1;^;)$]PV/@YIV.WZ?@G&TEQ=%UE\<>OJO^'G<51P^)%F1$7SQPA
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MLDDC:\L%9AX=Q[U8]285F6TO\F9/(.B+A&'V6@-+G@CGL>7,CHJCJS0&,QF
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M#= 7>SVDZ8KWWU7WW.X'<#IF1.=$T^UX&WQZ*>P^<H9B6['CI^^-2012D-(
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M.[$E:3YKF[[[%IY=5\Z8TE'AK]C(V[]K)Y2=@C=9L$<F#]ZT#D!T5F1 $1$
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MZ%T! $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M_E3&WK.)RA;P/GK'_2#R<WH5:D0%*A[/:@NT;]F_:LY.O8$\EJ8\3I=NC/\
M9:/(*3U/I.IG+$%ULT]'*5QM#<KNV>T>1\".9^U6)$!4\+HN.KE(LGF,C:S&
M0A&T$ED[-AWZ\+1RW]J]S>D)+F6ER6+S60Q=N8-$O=.XV/V&P^:>0V"M:("
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M"US1NYK@/,A >(@&YV&^Z]+'-&Y:X#VA >(B( B\Z!?3FEIV<TM/7F-D!XB
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MR VT6"[<K48#-<L15XAR+Y7AH^TK!#E\=- R>&_5?"]XC:]LK2"[^"#OU]B
MWD6&6W7BF;#+/$R5S2]K'/ ):.IV\@L%#+8_(2/90O5K+V?2;%*UQ'V% ;J*
MJ9S6=7%ZHQ>(<:[F6B\33&<-]'+1N.(>WVD*S5;$-N%LU6:.:)W1\;@X'XA
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M>A7J\/(% =PC(; PN( #1S*KV?UO@,&'-N7XW3#_ .3#\]Y^SI\51&=D^3N
M.R.II7L/[WA<_E\7*P8+LIT_C7]Y;;+D9>H[]VS1_P#2-M_CNOJ53X>&LIW^
M2_)[>*;Z*Q5;VL-2ZYL2X_2E-]2B?FOF) =PG^$[HWW#<J[Z"T%1TM&)W.])
MR;F[/G(Y-\PT> ]O56VK6@J0MAJPQPQ-Z,C:&@? +*JU.(O'!36&/Z_,F,+.
M\M6$1%S&@1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M?J'1U,ROB;8LRQ/<P['A(8' 'VC<?%:/:AIC%X+!T\C@*K,;?ALQQQSU]VN
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MSE\3!7:1Q6H8"Z5X'^R?F@E7H( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MTI:^@2N=JA_T3/Z(7T@Y#9%[Q] $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MGT[QW^2G%':=@-?#UF.&SBWB/Q.ZD5XO&S4^(J26[/$D[R83S7B]7*5 1 B
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MLX3\[EU^*U,XV44#QZ?90'$/VYK=OA\5#IV5[_9D.E97O]F?%;#T8J,-G+Y
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 7S+(R*-SY7-8QHW+G'8 +Z6CFS1
M&+G.5C;+2&QD8Z,R \QM\T [\]O! 0TVJJV0$U?!49<U(/FN[L!L /DZ1W+[
M-_<M?2>EK6,R+K\\\51L@/%CJ7%W )\27'F?<&A;D6K,%#&V.&65D;>0:VG*
M /AP+;H:CQF1LMJU)IC,\';>O(SH-^KF[("G8+2>JJK\L(LS6Q<=BY)89W4
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M)6YX])Z?GR=:%W";!):UQ]G+E\2HA0G-M)= YI'25\":,RF(2,[P#?@XAO\
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M$A$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$!J97&T\M1EIY&NRQ6D^DQXY>_V'VJJ1=F.FV21]Y#:F@C.[*\UE[HF^YN
MZNR(#QK0UH:T - V '0+U$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M<;?:@+BBIG9QJ"]E,51AO8W(M(K!YOS\/=S'ES!WWY[[]%<T 1$0!$1 $1$
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MUQ?^_P#R%S1$S=09RH=+]=L7_O\ \A/7;%_[_P#(7-$3.5!G*ATOUVQ?^_\
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MOXC$TL1'.S'P]TV>5T\@XB[=[NIYE:N1TUB<CEZN4N5!)?K;=U*'N:1L=QN
M=CS\T!5L_-#2[6L)/D]FUIJ3X:SW?1;-Q<_CL0/BOKMMEKG14E5VSKEB:-M5
M@^D7\74?#=7#-8;'YNIZ-E:L=F'?<!_5I\P1S!]RB<-HC XFXVW6INDLL/S)
M+$KI2S^CQ$[("PU@]M>)LIWD# '>_;FJ#FI(:G;!B)LELV":BZ*J]W02\1W^
M.Q_.%T)1V<PF.SM05LK5CL1 [MXN1:?-I','W(#-;OTJUFK#:L0QSSNX86O<
M-WNVZ#X*EZ2_=3UC_0@_PA3>$T1@<-;;:JTR^TWZ,T\CI7-]W$3M\%*5,-1I
MY6YDJ\'!=N!HGDXW'CX1L.1.P^" I_9Y_K3KO_C6_H<G8E&UNDK#V@!S[TQ<
M?/8[*X8[#4,=:OV:<'=S7GB2P[C<>-PWY[$\NIZ)@\/1P=,U<9!W,!>Z0MXW
M.^<3N3N22@*=V<-#-8:Z:T -]-8=A[G*&TE%//V>ZTBJ F=UJT&@=3R')=*Q
MN&HXV[?MTX.[L7GB2P[C<>-PWV.Q.PZGHF&PU##13Q8V#N63RNFD'&YW$\]3
MS)0$%V5VJ<N@<3Z(]G#%%P2 'Z+P3Q;_ !Y_%0/:%D:-IFF,A7GAGPL.4 G>
MSFQI&XY^X[J?R'9[IR]=?9DI.C?(=Y&PS/C9(?:UIV4T,#BVX<XH4*XQQ&Q@
MX/FG_G[>J C]=W*,&C<I)<D88)*SFMY@\9(V:!Y\]E0C_P#F\MWZ]R?_ ,.5
M=*/9]IRG8,T=%TA&_ V69[VQ[_P03R4GZLXGU<&!]%_^%!O#W/>.Z<7%]+??
MK[4!3>U']RBO[JWZ0K!KW#?+6C)XHA_WJ",6*[AU$C!N/MYCXJ7RN"QV5Q+<
M9?K][2;P[1\;F_1Z<P=UK:FS\>GZ\&]"[<=*'-8RM$9.8 Y';IOOXH"B8S*^
MO^H=-QN&]6A6&0M =#/OPAI^(W75U2NRW R8O&7+]VFVG?R4[IWP[<XF;GA9
M\.9^*NJ J6IL#\H9^O=Q.8^3<Y# 6#YHD$D1/1S#X;[\U@TAG\N[4E_3VH6U
M);E:%L[;-7<-D:3XM/0\Q_UUF-0:4P^>E9-D:G%98WA9/&]T<C1Y<32/SK)I
M[36+T^V7Y,K<$LO^DF>\OD?[W'F@.=Z2KSV^S75\%0%T\EFR&M'4\AR5K[-L
MOC'Z%QW=6(8VU8 R=KG &-P^EO\ I5APV&HX2":+&0=S'+(Z9[>-SMWGJ>9*
MYI:MZ:?=LRY_1=RMDP\[1LKN>V8[\B"WYI)]J R]G%FK<R>O;-#8U99 ^,CH
M00_G\>OQ4WV(1M9V=8\M !>Z1SCYGC/X+Z[-\1.(LUD\A1- Y:4%M,CA,<36
M\+0=NG+=6O"8FE@\;%0QD/<U(M^!G$7;;G<\R2>J HG9: UFLVM&S1DIM@.@
MY%;W8Q^YU4_IS?XW*TXO!X_%>F^@U^Z]-E,T_P ]SN-YZGF>7P7WA,11PF-9
M0QD/<U&%Q:SB+MMSN>9)/4H"F]A?^H;/^*F_Q*.T=%/-IW7L53?TA]VTV/;K
MOP\ET+ X6A@: I8J#N*P>Y_!QN=S)W)W))3$8:CB/2OD^#NO2IC/-\]SN)YZ
MGF>7P0%;[(+-230&-96<P.A#F3-Z%K^(D[_;O\5%]J%^E=TO2MTY8K&,K92/
MTLQ<V@!Q#@?B0I_*: T]D;K[4U)T<TAWE[B9\8D_I!IV*F*V#QE7$NQD%&NR
M@X$.@X-VNWZ[^9]I0&#.WL?%I>Y:LRQ&@ZLX[[@AS2WD!Y[KEV*Y?]GNU[#)
M_P#AE?J?9[INI<;8CHN<6.XHXI)GOC8?,-)V4DS2^(9@),*VIMC)"XNA[Q_,
MEW$?G;[]?:@-:*&-O9\(@P=V,9MP^&W=*J8'=W81(.I]!G_Q/7113@%#T+@_
M[MW7<\&Y^AMMMOUZ+!C\-0Q^';BZM=K:#6N8(7$O'"=]P=]R>I0$9V<D'0V#
MV/\ ^BL5B4!I_2.)P%J2QC(IHW.:6!KIWO8QI.Y#6D[#HI] $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$) !)( '4E5;+Z_TWBW.9/DXI96]60 R'\W)6A"4W:*N0VE
MU+2BYG)VQX-LA:RI>>W^$&M'Z2I3&=J.F;I#9+;ZKSX31D#[1N%L^%K)7<65
M52+[EX5+UOJ)U<NQ]%X$A&TSQU;[![5.93.5H<%-D*4\-ANVT;HWAS2X].BY
M/(]\LCY)'%SWDN<X^)7E\75</ NIR\76PK!'JSY1$7FGF!$1 $1$ 1%/YRM!
M5Q&#GAAC$DD9=)R^F1MU5HQNF]BT8W3>Q (IW55.O$ZG<HQB.K;B#@UO0.'4
M?H7NF*M?T?(9"_$R2O6CV:U_1SST'_7FK<MXL);EO'@($(MVOC+5C'6+T<8-
M>$[/=N!]@^*T51IKJ4::ZGJ*1Q3L7%')+DF3S2-/S(&'A:\>TK?UI7KU[M3T
M2!D#)*[7EK/,DJV#PXKEL'AQ7*^$1;M/%7KL(EJUW2QE_=[M(^EMO_T55)OH
M52;T1I(I6UI[)5V,>:_>,>0T&)P>-SX<E[9T]DJU9\\D +&#=_ \.+/> K<N
M6Q;ESV(E%LX^A9R$QBIPNE>!N=N@'M/@M]^F\HV5C&UA)QDAKF/!;OMTW\%"
MA)JZ1"A)JZ1#K,ZM.RJRRZ)P@>XM:_P)'4+&QCGRMC8-WN<&@>9WV5GR3A#G
M,/BV$&*FZ-K@.A>X@N*F,;IMDPA=-LJR*7S=:2QJ>[7JQE\CIB&L:%I/QUIE
MX4^ZXK1.W=L<''?RY*'!IV(<&G8U44O/IS)P1\3J_%M](,>'%OO Z*-M5I:E
MB2O89P2QG9S=]]D<91ZH.$H]48D4OI&O#:S]>&S&V2)P?NUPY'9I4==:UERP
MQHV:V1P \AN4P^'$,/AQ&%%.9ZK!!B,++#$UDDT)=(X#FX\NJDK4N.Q>)Q+Y
M,5!9DL0\3G..QW&WXJ_*U=WT+JEJ[OH5%>*Q92I2N8(9:A :KF2]U+"';MW\
M"/M"VW24,;I_%SR8N"S+8:>)SSL>2<K=^HY.KN].I4T5BO5Z.0P,V2I5A2EK
MR"-\8?NU^^W3V\U7524<)24,(7BS4VP/M1MMO>R G9[F#<@>85F,>)L:9RDE
M"D6.K%C6S2GB>[=PY^Q3"&*^I,*>-/4JB+=PU!V3R4%1AVXS\YWDT=2IKY0P
MS;_H7R5#Z%Q]T9RX]YUVXMTC"ZNW8F-.ZNW8K"*6N8VOCL\^I?DE%5IW$C .
M(MVW'X*3R4>-FTF^UCZ7<%EAL8>\\3R/,G_)2J;UOV"I-WN^A5D1;6*J^FY*
MM5WV[V0-/N\?S+-*[LBB5W9&*2M-%!%-)&YL4NYC<1R=L=CLL7FIK4+GWL^^
MK5;\R-PKP1@[  <MA\=U\0:;RDP=PUPT@EH:]X:7$==M^JNX.[45<NZ;NU%7
M(A%E?6FCLFNZ)XG!X3'M\[?W++\G7?J=G[IWX*MF4PLU5XMF.E8=;AK.ADCE
ME<&M#VD=3MOS5@N3XW$SNHU\9%==#\V::7<ESO';R5HPNKO0M&%U=Z%:@ADL
M3,B@87R/.S6CQ*^7M+'.8\$.:=B#X%;-R>%]YT^/B=6CW#F,XMRT^P^]2NK(
MV3&CDX6AK;L0<\ <N,=4PW3:[#!=-KL0"(BH4"(B +Q>H@"(B Z)V:_^4VOZ
M_P#]H5N51[-?_*;7]?\ ^T*W+V.'_P :/9X;_$@B+6R5^KC*<EJ_8CKUXQNY
M[SL MTKZ(W/<C=@QU&>Y<D$=>%A>]Q\ %Q[2-:77VOK.H+L3AC*;@(6GS;]!
MO_N/O]JQYC*93M/S;<7AFR5\' _>64]'#?Z3O\F_]#KNG\/5P6)KX^@SAAB&
MVYZN/BX^TKMME8-/XW]E^3+_ "/T1((B+A-0B(@"(B (B( B(@"(B (BU,O?
MAQ>+M7K)VAKQND=[=AT0&VB@=%ZEKZJP_I]>%\!;(8WQ/(+F$>>WF"#\5CU#
MJ&3%:AP..979(S(R/8YY<06;#?D/% 6)$1 $1$ 1%6\1J&:[K/-85\$;8:,<
M;V2 GB=Q $[CXH"R(B( BCJ&:HW\G?Q]:4NM42T3M+2 TD;CGXJ10!$1 $5:
MP.HY<GJK/XE]=D<>-,8;('$E_$-^8\%94 15^6]G1K*&G'CXC@70ES[>_P X
M/V/+KY[#;;QZJP( B(@"(B (B( B*OXF]GIM39.MD,;#!B(A_P!UL-=NZ3IU
MY^_P&R L"*M:3U%-FLKJ"I-!'&W&VNX8YA)+QSYG[%94 1%6M'ZDESU[.02U
MV0C'6C7:6N)XQSYGRZ("RHBK].]G7ZON5+..BCP;(@Z&T'?.>[8<CS]_AX("
MP(JSIK4<^5U)J+&2P1LCQDC&1O:3N\.!Z_8L^F;N<MW<JS-X^*I7AFX:CV.W
M,K-SS/,^&W/EUZ("?11N&S=',ONLQ\KI'4YC!-NPMX7CJ.?522 (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( O'.#&ESB T
M#<D] %ZM7*_^5W/ZE_\ A* R4[5>[7;/3GBG@=OPR1/#FG;D=B%E>YK&.<]P
M:UHW))V "Y!V9ZL?C]$TJ6-PU_*SU^\=8]' #8MWN(!)ZG;GL/-=%TYG\?JG
M"OMTP]T!XHI8I6[.:=N;2/<4!OXK*4<M5])QEJ&U!Q%O'$[B&XZA;BIVA+^"
MKZ.GR&)IOQV-C?*^1KSQ.W;])W4[]%J0=HA?"RZ_3N7;B)#\RX&-<"-]@>$'
M?9 7Q%SWM-U#D<9:Q$-"I?:PW(7.FBX0V8'?>$;G?B/M&WM5FI:A#L1;R.6H
M6\1!6W+A;X=RW;?B'"3[D!.(J(.T,NKF_'IS+OPVW%Z:&-YM_A<&^^WM4[E=
M4T*.E'Z@BXK=$-8YO<[;N#G!OCMXE 3R*J8K6+LO:E^3,-?FQ[(WO;=< QDI
M;^]9OUW/('DI32F>KZDPL.2J,DC8]SFF.3;B8YI((.WN_.@)=%!Z9U'!J"7)
M"I!,R&E.:_>OVX97#J6['ITZ^:EKEF&E4FLVI!'!"TO>]W1H'4H#,BHK>T(S
M0F[1T[E[6(;N3<8UH! ZD-)W(Y*4RNI8YM'29?!Q3WXY8W<!@V#F<CNX[D;<
M)'/Q0$W!DZ%BY)4@NUI;4?TX62M+V^\ [A;:Y=V-.A9C*/=Z?M,FECD=)E7!
MG!*>+F-]^+P Z>"ZB2 "2=@/% $5'9V@MN32NPF"R>4H0N+9+4+6ANXZ\()W
M<I+2NLL?J;(7JN.CFVJ,C>Z1X #N+?EMON"""#N@)^K<K6S**MB&8PO,<@C>
M'<#AU!VZ'V+RE=JWHG24K,-B-KBPNB>'@$=1N/%4KLM_\9JW_P!6E6#L4<V/
M2V0>]P:QMZ8DGD .2 Z(BHW[(3;+I9L/@<IDL="XMDMPM:&\NI:"=W?F4I9U
MECF:/?J.L);-)H&[& !^_%PD$$\B"@+*BJV"U>,YE&Q8[%77XPAW_P 1> V(
MD>7B>?+=:+NT&.S:G;A,+DLK4K/+)[-=H#6D?P=SNY 7=:6+RM#*QROQMN&T
MR)YC>8G<0:X>"A=*ZTQVILG<IXZ.?_NT3)'22-#0>+<<.V^X(((*P=G4N%=0
MR;L%0?0ACMO9,'G?B>W;=W4\D!;D5&/:$VU+.<%@LEE:<#BR6U"&AFXZ\()W
M<K/IS-5<_BHLA0[P0O);PR,X7-<#L01[T!)(H_/9BG@L7-D,E+W5:+;<@;DD
MG8 #Q)*J@[0S#'';R.G<M3Q4A'!<<QKAL>A<T'<! 7M%7=1ZNHX5]6#N[%R_
M;'%!5K,WD>//GML/>M3$ZUCGRT&+S&+NXB]8!,#; !9+MX!P/7V("VHJOJ#6
MM'"9KY+L5[,MI\#986PM#C*XN+0QHWZ\M_+98<'K:.[FVXC*8RYB<A(WCBCL
M;$2#V$>/(H"W+!;N5J;6.MV(8&O<&-,KPWB<>@&_4J#U-JVKA+<%".M8OY6P
M.**I6;NXCGS)/(#D5S_M#U)\K08:E<QMS&9"/(0R]Q9:/G,W(XFN'(\]OM0'
M5K>6H5+U:E:N016[/^AB>\!S_<%NJIZE.&;K#3K,CCG6,C*7BK.#RBX>?/GS
MZ\N15=U=J?*5.T##5J]#)>C,,H-=G!_WWER+.?0>W9 =$R>1IXNHZUD;,5:N
MT@&21VPW/0+8AD9-$R6%[7QO <US3N' ]""JCJV_0LZ%FO:DPUKT5KFN?3D(
M$K3Q\(.X=MX[]>A4KD<UB].:<ANVCZ/29&QL4;6[GF/FM \T!-HJ.>T#T7@G
MS6 RF-QLA ;<F:TM&_0N .[5,:IU90TY6H6;@?)6MRB-LD>Q#01OQ'GTV\D!
M8$5$?VC0UY()LCA<G2Q5AP;#>E8.%V_0EH.X!5[!! (Y@H B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"C-1
M9NEI_%RW\E*&1,Y!H^D]W@UH\2I)S@UI<X@- W)/@N$79+?:AKH587%F'ID_
M.'+ACWYN_I.VY+HX>BJC;EI%=2DY85IU/;&0U1VFWYJ^,#Z>&:=B"[A8!_MN
M'TCX[?\ XU<<!V28.C$TY,R9"?Q))8S\D'])5[Q..JXG'PTJ$0BKPMX6M'Z3
MYE;:TJ<7+X:7AB5C3766K*ZS1&FF,X1A*)'MC!/VE1N4[,M,7F.#*)JR'H^!
MY;M\.GYE=$6"KU$[J3]R^"+[' -2:"SVD8I;F+M.N8]I#I P$$>US/';S'3V
M+7P>8BR;"W;@G:/G,\_:%^ASS'-<.[6M(?(5N//X5A97?)^WL'2-Y/(C_9/3
M;\5I.$./6"II/L_V9R5^&35T>(M3%W&WZ,=AHV+ALX>1\0MM?-3A*G)PEU1Y
MC5M B+Q5!ZB(@"LFIO\ R#3_ /4N_P E6UO7\G+=I4ZTC&-95:6,+=]STZ_8
MKQDE&2??\EX22C)/O^24QW_Q/2UVHX[S4CZ1%O\ P?WP_3]J9IPH:?QV,'*6
M3_O,X]_T0?\ KP45ALE+BKS;,+6OV!:YCNC@?!?.6O29*_+:E:&NDV^:.C0!
ML KXU@]>GT_FA?F+!Z]/I_-#"RQ,R"2%DLC87[<; X\+O>%B4C4RTE;$6L>V
M&)S+!W+R/G#_ *V4<LG;34R=M-3P]"K-KG_Q>/\ ^$9_FHG&9!M%L@=3K6>,
MCG,TG;W*2M:G=:V[_&T7EK>!I+2=A[.:TAAP--]36#C@:;ZE>"LU*>2#0=TP
MO<POM!A(.QV(&X596ZS(R-P\F.#&=T^42EWCN-OP582PW^16G+#?Y$SI*S-7
MQ6<$,CF!D'&W8]'<QN/:OC0;C\K6&DDMDKOXQ_"Z=5$T,C)2KW(8VL<VS'W;
MB[P'L3#Y*3%VG3PL8]Q86;.Z;%7A42<;]B\*B3C?L3% NBT/=?3);*ZP&S%O
M7@V'YOQ*^^SJ29N:=%$7=PZ,F1HZ>P^]:6E?E(6+'R28G/#-WQ2$;2#?IL>J
MLN+M9.H]]O)58<?CX&N<YD; TR.(V ZDGJM:6KC+70UI:N,M="MZ5KM?E);<
MP_:*373N]I'0?;^A:E"P^UJ&M8E^G+::\_%RSMN0UM-S00R!UJY,#*T#Z#&]
M!\2HNK,ZM9AG: 71/#P#T)!W6#:22^I@VDHKZE^N1PQS9AN'F:_-.)>X[?.#
M-^;6>W906C>-HS#X]_2VUB8_X0//?X]%#R9.<Y9V1C(CL&3O!P] ?P6]4N6\
MAJ".Q0;!5N/WY@[-<=N>X/GY+7F*4DU_/^FO-4I)K^?]-?34MAN>J.K.<97R
M@.V._$TGYV_GR7WJW_6._P#UG^05GIG/27FB6A6I,#PZ>PU@;NT=>>YZ^Q5#
M.VF7<Q<L1?Z-\AX3YCH/T*LXX:=O4K.."G;U-W13FLU+3XB!OQM'O+2HW)M,
M>1MM>-G"5^X^)6"&1\,K)8G%LC"'-</ A3YU0Z1W>6<;1GL\OVUS=B2/$A5B
MXN.%NQ2+BX86['UJH&+%X&%^XD;7XB/+?92&4&,.$P?RF;(/H_S.Y ]F^^ZJ
MV3R%C)6W6+;@Z0C;D-@!Y!9,ADI+M6E!(QC6U6<#2W?<CEU^Q6YJO)[V+\V-
MY/>QO97*U#BVXW%021UN/O)'RG=SW?\ 6RE;5Z*GI?"F:C7M\37;=Z-^'W*G
M>"FZ^H7QT*]26C4GC@&S#(TD_I40J:N[MH1"KJ[NVA(RRQYO35IT4+:8H.#^
M[BY1OW]GFHS&9#%5Z;([F*](F!.\G>;;\^7)?&0SUBW3-2.*"M6)W<R%NW$?
M:HE)5-4T1.IJFM?H;V6LT[4['4*?HC W9S>+BW._52F'_P!3\[_2B_Q*!JRB
M"Q'*8V2!A!X'\P[V%3L>IW1P20LQM%L4FW&P-.SMNF_-13DKMR8IR5W*3/G0
MLC8]1P<9VXV.8-_,CDH9]>4W75@T]\9#&!X\6^RRW+IL7&V8H8JSF[;-A&P!
M'C[U*C4\IE])-&F;P&PL<)W]^W3=$XM86^A"<7'"WT9[KI[79YS&D$QQ,8X^
MWG^*^F_Z@R_\8/T!0L%QS+_I<[&6'EQ<YLHW#B?-3 U.X5C7^3:/<%W%P<)V
MW\^JLIQ;E)NURZG&4I2;M>Y7E,Z-+6ZEH\>W-S@/?PG91M^P+5E\S88X [;Y
MD8V:-AX+YIV'U;<,\?TXGAX]NQ647ADGL8Q:C-/8E*C2W5[ [J+G_O7FIK4S
M]2VI3([CAFX8SO\ 1 /+99\VX5LQ7R],-=!8(L1@GHX?2:?BH:]9=<NSV9
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M%%HTUVH35A^UX[-UVNB ^BV:,;;>\C](6KVJBZ=3:2;BGL9>=-(V)[QNUA(
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M/ J-QHS&C<]G6,P5O*4<A8-F"6JYI+2?WK@>GO6QH2AF_7C.9;.4#5%VO&6
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M;6D-!N.=$Z?EPA_$>7O6C)3R^D-4Y/(8S&2Y;$Y1XFFC@<!+!(-]R >H._\
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M+3.NR^P./S1[N';[5;T 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M'RV5&[/&[Z#U//"PLHSS6GUAML.#AVY#R4_-V::6EM.F..+0X\1B9,]L9/\
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MI:>T7@\!:]*Q],^E;%HFED=(\ ^1<>7P0$%8B9)VTU3(T.='BBYI/@>,C?\
M.5\]H[0-8:&>  _TUXXO';YO)7$X>D<VW+F$^GMA]'$G$?H;[[;;[=5YD\+1
MR=RA:NPF2>C(9:[N,C@<=N>P//H.J I6-DBJ]M&7&1<&RV:<8IN?RW: .(-^
MP_85K=M%JHZ73M8.C?=;?8_8'=S&;['?R!.WV>Q7?4>F<3J*)C,M39,8_H2
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M *5A*"5G^G_2(CMR5GV6TI9&0R@L(\7,WY;J=TA&[',FS%L]W4;&Z-OG*X^
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M(@(32>F,=I>G-7Q;9.&5_>/=([B<3X#?;H%SJ%PP_;S*UHX8KK=B!XE[ ?\
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M9&Q?M;>([NZ<E*KD^O\ .Q:C[+J>0A;P/?<A;+%OSC>'$.:?BNL( B(@"(B
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M*1O[@!XE1BGXR6Z&E[L_2N 2>[AY?Y*M-)O7L5II-N_8QRX>K8HSVL/;=8$
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M2/A$@'7A*^],[MP>H',/[9W+1\/G;K1TFYS=14. D$R;';RV.ZF,8K"FNO\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M.HL/1;([(P4=>X1$7.7"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MT(7'L=E)=-:8U?@N,BS3L]S29XD3\F</YR@.JXC*T<Q6=8QEJ.S"UYC+XSN
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M)P)/& =B=@.FX*A.S_\ \#J__P!4L_H"T>Q7"8^;1$=JS3@L3V'O:]TL8?\
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MI70N.TYF+F1IRSOEL;M:UYY,:3N1[>8ZK&5*--RC-ZKH64F[-%L1$6!<(B(
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M6W6KPU8&0UHHX86<FLC:&M'N 61$!KPT:D$,L,-6".&4DO8R,!KR>NX\=T]
MJ>A>A^BP>B;</<=V.#;??;AZ+81 ? BC$/<B-@BX>'@V^;MTVV\E\U:\-6!L
M-6&.&%OT61M#6CW +*B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( JEVHZ@.G]*6)(7$6['[1#MX$]7? ;_'96U<:[>)7VLU@<:P\G!SM
MO,N<&C]!^U=/"4U4JI/H4J.T63/8EIF.AA?EJPTFY=!X"?WD>_+XG;?[%TQ8
M:-6.E2@JP#ABA8V-H]@&RS+.M4=6;FR81PJQ'9'.XK&SB'(9&K6E+>(,EE#2
M1Y['W+!#JC!3R".',4'O/(-;.TD_G7'^V^(3:ZQ\3]^%\$;3MUV+W!3^H.R7
M!4L-<M07[L,D,;I Z9["SD"=C\T?I74N'I*$7.33D9XY7:2Z'600X M((/0A
M%R?L!R-VS0R52P^22K YAB<XDAA.^[1]F^RZPN6M2=*;@^QI"6)7..]N6FVP
M]SJ.D"R7C;'8V_\ M?[_  ^Q0F*MB]0AL#JX?.'D1U79]7469+3.3J2-#A)7
M?MRW^< 2#]H"_/\ HB7BI6(R?H/!'Q'_ "5.-CSN#QOK!_9G!QD$O$61$1?/
MG $1$ 1$0!$1 $1$ 1$0!$1 $1 @"\7J(#Q;>,L0UK39+-9MF+8@QD[=?'WK
M51$[:A.SN6.#(X3'2"UC:EN2VWZ L.' P^?+F5$G)V35M0%XX+,G>2G;FX]>
MODM( D'8'8(KNHWZ%W4D].AXO4"*A0^X'MBGC>^-LC6N!+#T=[%.BWITN])-
M"X)M^+N \=WO[^NRKZ*T982T9N)MY6_+D[\MJ< .?T:.C0.@6HB*K;;NR&VW
M=A%XO4( 1$" +Q9JM>:U+W=:-TDFQ=PM&YV'58D%@B(@/$7J(#Q%ZLKJ\K:S
M;#HW"%SBQK]N1(\$%C"@7J( M^UD?2<55J2Q RUW$,FWY\!_>D>]:"*4VB4V
MKA>+U%! 7B]3S0!!MOS')$0&]F,B<C88X1B*&*,1Q1@[\+0M%>+U2VV[LEMR
M=V$0+Q00>HB( MN+M1NXV!F.J8/OW5_VL2&1WS@/'8#_ #6HUKGD-8-W..P
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M;Q[\E+,^K5<YYJ@[1RD]"[W?YE4K6^)QF(U+I=FF:L-3,/MMXHZK0TF']\7
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M12I&,79&[3Q5N[ ):L1D:9>Z&QY\6V_V;>*VKFG,C4JNG=&R2-OT^Z>'EOO
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MFG42^C+IIU(KZ,@N?B-BBR6"UUF8L&S2]Q ]FY6-<YS >*(B (O%Z@"\7J(
MB(@"(B !$1 $19*\$MF=D,#"^5YV:T>*=0B;T1CS=SD3W-)AK_MCCX;CH/M_
M0NIJ+TWB&8?'-@!XI7?.D?YN_!2B]?AZ7+A9]3V>'I<N%GU"(BW-PB(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(JCGM825\N_$8#%RY?)
MQMXYF,>(V0CPXG'Q]B L=W)4J,]6&Y:BAEM/X(6/=L9'>0\SS"VUR#4F?DRN
MJ](5;^/FQV3K7>*6O(0X<+BWA<UPY.!V/Q"O.J-6,Q-^#%T*4V2S-AO''5B(
M;LWG\YSCR Y("S(J=B-93_*\&+U)B)<1<L[^C.,@DCF(Z@.'0KW/:OMU\])A
ML!AY,I?@C$MC]M$3(VGH-SU* N"*#P&>DOXVU8RF/L8F2J2)V6-N$;#<N:[Q
M;MXJNQZZRF0:^W@M,6KN)82/2'2MC=(!U+&'F4!?D5;&LL6=(OU$#+Z&QIXF
M%NSP\';@(\]^2C<7JS.RVJORGI2U6I67-:R:*9LI9Q="YO4#S/@@+LB*MZJU
M7#@[%:C7J39#+6MS#4AV!(_A.)Z#VH"R+4RF2I8JHZUDK4-6NWD7RN#1OY>]
M5?&ZSMQY6MC]386;$RVW<->7O1+$]W\$N'0JL=IUV_+K'3U:3"F>M#9<Z!CI
MV[7#LWEL?H['S0'4L=>JY*E%;H3QV*THW9)&=VNY[?I"SN<UNW$X#<[#<[*/
MT]+8FQ43K>-&,EW</1@]K@T;GGNWESZ_%5+M?)%' ['_ />L'Z2@+\O&N:[?
MA<#L=CL4=] ^Y43LA).&S.Y__><_^2 O'I$/\;'^4%D!W&XZ+C79KHO"ZBQ-
MZWE8)9)VW9(P6RN;\T;;<@?:K!V?"7#:QSNFXK4MG'5XV3P=Z[B=%OU;O\?S
M(#H)GA!(,L8(_P!H+(""-P=PN/:3TQ@,Y>U'/G&AT\>4FC9O.6?-WWZ CQ)4
MMV>CT#6V9Q6$M2V]/0Q-?Q/?W@BF.V[6N^WE[$!TM%YQ-_A#[5'YZC8R>-?7
MHY&6A*YP_;XFAS@-^8Y^80&_WC.\X.-O'MOP[\_L7TN4Z:PD& [7/0ZT]F<'
M&F1TEB3C>YQ=S)/P5C[4\M;H82K2QKS';REEE-D@ZL#NI'M\/B@+@V:)TA8V
M1A>.K0X;CX+[7--0=GF-Q.G)KV%?8KY>C&9V6A*XND<T;GB'0[[*P0BQK'1N
M-G@R-C&NLQMDF?7 XCRV<T$].?C[$!:6R,<]S6O:7-Z@'F%]+F/9QC(<-VA:
MHH5GS210PP;.F?QO<3N22?%=.0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 6OD6.DQ]IC 7/=$YH \2
M05L(@*)V=:9B&A,=2U'B876(G2$QV8FN+-Y'$==]N2NU6M!4A;#5ACAB;T9&
MT-:/@%E1 8*=.M28YE.M#78]Q>YL3 P%QZD[>*&G6-P6S7A-H-X!-P#C#?+B
MZ[>Q9T0&KD,=2R4/=9"I!:B_@S1AX_.F/QU+&Q=UCZE>K&>K88PP'[%M(@,$
M=.M%:EM1UH6690!)*U@#W@=-SU.RSHB T[^*Q^0>U]^A4M/8-FNFA:\@>0W"
MUAIK!@[C"XS?_A8_P4JB +!)3K26H[,E>%UF,%K)7,!>P'J >H6=$!@M4ZUO
MNO2ZT,_=.#X^\8'<#O,;]#[5[<J5[M=T%R"*Q [;>.5@>T[<QN#R69$!\/AB
M?"87QL="1PEA:"TCRV\EHT,%B<?,9J&,I5I3U?%"UI^T!2*(##/4K6)H99Z\
M,LL)XHGO8'.8?-I/3X)<J5KL0BN5X;$8(<&2L#QN.AV/BLR(##<JU[M=\%R"
M*>!_THY6AS3\"M:#"XR"@^C#CJ;*;SN^ 0MX''S+=MCT"WT0'QW,7<=SW;.Y
MX>#N^$</#MMMMY+'#2JP5!5AK0QU0"!"R,!@!ZCAZ+.B C*>G\/2M>DT\51@
ML?QD<#6N'N(')2:(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( M;)4H<CC[%.TT/@G88
MWCV%;**4[:H'!\!D;?9CJ^QC<GWDF)G</G[<BWPD;[1T(_ +N=6Q#;KQSU96
M2PR#B8]AW#A["HG5NF:&I\::N09\YNYBE;]*-WF/P\5R)C-7=F5@\#?3<.7<
M1X071'W^+#_US7>U'BU=.T_U,5>GIV.\(N;8GM@P5E@%^&U3E\?F]XWX$<_S
M*8/:9I0,XOE0'V"&3?\ 0N9\-6B[.++JI%]RXK4RV2J8FA+<R$[(:\8W+G'\
MP\S[%SO,]L>)@C<W%5+-N;P+P(V?C^956/":O[1YVV\FX5*##O$)@8V;'^ W
M;<^\_:M8<))+%5\,?N5=5=(ZLA\_E;&N]4.LO#X\=#\V-A/T&?K'_KHIX !H
M#1L -@ K+1[.KE*NV&O-4:P?[3MR?,_-6?U%R6W_ (BI^4[]5>3Q]2IQ,THQ
MM&/1?N>=4IU9N[15$5K]1<C]8J?E._57OJ+DOK%3\IWZJX<O4V,\O5\I4T5K
M]1<C]8J?E._57OJ+D?K%3\IWZJ9>IL,O4\I4T5L]1<E]8J?E._53U%R/UBI^
M4[]5,O4V&7J^4J:*V>HN1^L5/RG?JKSU%R7UBI^4[]5,O4V&7J^4J:]5L]1<
ME]8J?E._53U%R/UBI^4[]5,O4V&7J^4J07JM?J)D?K%3\IWZJ>HF1^L5/RG?
MJJ,O4V&7J>4JB*U^HN1^L5/RG?JIZB9'ZQ4_*=^JIR]389>IY2,I9Z2&HVI;
MK5[U=GT&SMW+/8#Y+7RV6GR0C8]L<->+_1PPMX6-_P":F_47(_6*GY3OU4]1
M,C]8J?E._55N76:LT7=.NU9H@,AD)+T=1DK&-%:(1-+=^8'B?:M-6SU%R7UB
MI^4[]5>>HF1^L5/RG?JJKH57JT5="JW=H^,/<EHZ0LSP</$+@!:X;M<"T;@C
MR6E-J*7T>2*C3J43*-I'P,V<1Y;^ 4F-%941&(7*W=$\19QOV)\]ME\^HN1^
ML5/RG?JK1PK622-'"M9)(@*.1EIT[M:-C',M,#'EV^X WZ?:LF(R\^-$K&,B
MFKR_Z2&5N[7>WWJ;]1<C]8J?E._53U%R/UBI^4[]555*LK670HJ596LNAIQ:
MHGK3 TJ=2M" =XHV[!Q/BX]3LHS$Y.QC)G/@X7,>.&2)XW8\>1"G_47(_6*G
MY3OU5YZBY'ZQ4_*=^JIY=9ZV)=.N];=".MY]TE66"G2J4F2C:0Q,^<X>6_DL
M6,S<U2J:LT$%NION(IV[AI]A\%+>HF1^L5/RG?JKWU%R/UBI^4[]5.76O>PY
M=>][$)ELH[(1LB;5K58&;EK(6 <_,E;KM332EK;=2K8KM8U@BD;N!M^^!\"M
M[U%R/UBI^4[]5/47(_6*GY3OU4Y=9.]@J=>][$+ELQ/D8V0]W%7JQ\V00MV:
M#Y^TK)CLY+5J>B6*\%RH#NV.=N_#[CX*6]1<C]8J?E._57GJ+D?K%3\IWZJC
MEUKWL.77OBL0N4R\V0CCA[N*O5CYMAA;PMW\SYE1RM?J+D?K%3\IWZJ]]1<C
M]8J?E._54.C5D[M%71JR=VC1P\C;V$N8IS@)FGTBN7'8$CZ3?LW4<<C(<0,=
MP,[H2][Q<^+?;;;W*?\ 43(_6*GY3OU4]1<C]8J?E._54NE5MT+.E5:MA]"!
MH9.6G2NU8V,<RTT->7;[C;?I]JT-E;?47(_6*GY3OU4]1<C]8J?E._5571JO
M2Q5T*K5FBIJ;Q6HIL;CW4V5*LL3B2[O&DEV_GSYJ1]1<C]8J?E._53U%R/UB
MI^4[]53&E5B[I$QHUH.\41MK/B>M+",5C8N-I;QQQ;.;OX@^:R829N-Q-Z\Y
MP[^9OHT#=^?/Z3OAR6]ZBY'ZQ4_*=^JO/43(_6*?Y3OU594ZU[M%E3K7NT50
M<EXK9ZB9'ZQ4_*=^JO?47(_6*GY3OU53+U-C/+U?*5,(K7ZBY'ZQ4_*=^JO?
M47(_6*GY3OU5&7J;#+U?*5-%:_47(_6*GY3OU4]1<C]8J?E._54Y>IL,O4\I
M5$5K]1<C]8J?E._53U$R/UBI^4[]5,O4V&7J^4J@16OU%R7UBI^4[]5/43(_
M6*GY3OU4R]389>IY2J(K9ZBY'ZQ4_*=^JO/47(_6*GY3OU4R]389>KY2J(K?
M'H.Z3^V6ZS1_LAQ_R"E\?HBC!LZY))9=Y?0;^;G^=6CPM278M'A:K[6*)C<=
M:R4PBIPND._,@<F^\^"Z)A\5C],4G6LA8@9(>4EB5P8UN_[T$]/\U/5J\-6%
ML5:)D4;>C6C8*@=NTO!HIC-^<EJ,?8''_)>CP?!1YB3ZL[:?#QHK$]63=OM!
MTO6WX\Q7>1X1;O\ T!:>.[3,!D<Q6QU1]A\D[^!CS$0W?PZ\_P RY+HK'8W'
MZE@QVK\>U\=R-CX)7/(:WB&[3R.Q!WV]A7>,7IG"8N5LN/Q5."9OT9&Q#C'A
MR=U7J5Z-&CIJ]NEC6$ISU)=$1<!L$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 7-="68<7KC5]/*2,@NV;+9H72GA[V/YVW"3UVW72E$:@
MTUB-0-8,O1BLNC&S'NY.:/($<]D!0]?92A>U]I*O3?'//6M_MTD>S@SB+=F%
MP\>1.RWH;,.*[8LD[*.;"V_3C%264[-/" '-!/CN"K34TG@Z<%2*MC88V59>
M_BX=P6R?PM_$^];F;PN.SE45\M3BM1 [@/'-I\P>H0%([3K4&1R6F<9CY&3Y
M'Y09.!$>)T<;?I..W0=/L6WJ'"X_(:GGLX?49Q&?9&UEAL3VGC;MNWC8?9LK
M%I_2V%T^Y[L1CX:\CQPND&Y<1Y;GGLOC.Z0P6=G$^4QL,T^VW>\VN(]I',H"
MEMR69SVEM7X.Q)#>OT8^[9:JMV;8!&^VPY<7(C8+3T=CG7M-U)JNNK=2..(-
MDK@Q@5R!S:0>8V]JZ=A,-C\'3]%Q52*M!OQ%K!](^9/4E1&2T'IK)776[>)@
M=.YW$YS=V\1\R =B@(C%X; 4M#Y"'(YF._B;L[I)+<CFM'&XAO(CEOQ#?WJ'
MOV<MHBM5NU=2,S>,,K(?1)PUTCFN.WS'@[DA=';A\<W%C&BC7&/#>'T?NQP;
M>Y0^-T'IK&WV7*F*A98C/$QQ)<&GS )V!0%F',;KG-BQ#A^V&2SEG-AKW:(B
MJSR\F<0(W8#X'K]OM71EHYC$4,S4]&RE2*U!OQ!LC=]CYCR* I/:S:KY''XW
M$8^:.;*V+L3H61N#G, .Y?RZ#;Q7UVA_Z[:&_P"*D_0U67 :1P6 F,V*QL,$
MY!'>\W/V\MSS 6_?Q-&_<IVK==LMBFXO@>2=V$]2/L" WE0^V2.1NG*=YD;I
M&4+T5B0-'/A!YG\X5\7S+&R:)\<K&OC>"US7#<.!Z@A 1$FI\*W%NO?*=0U^
M[X^(2C<C;RWWW]BKW8]')ZJ6+<C"QMVY-9C!&QX2=@?S+?;V=Z5;9[\8:OQ;
M[\.YX?R=]E:8XV11MCC8UD;1PM:T; #R 0'&>SC3F1R^(O34M17L;$+DK##
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M(B*I(1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MC\?S+G]B>6S*Z6Q(^21QYN<=RL:\^?&3?PZ'G3XV;^'0NSM?2;_-H,V]LO\
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M9,^KF,=/$=GQUHGCW@E8=9P1_*,5ZN/VB[&)1MY^/QZ+25.U]>AK*EAO9]"
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M5V4?_'1E4??1?N92\4E$OR(BXS4(B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MN*8P=N!U2YCK\G=UIV\;'GGW<@Z'XI3?5;D4GJUNC;C)&@IMNAN#?[ FFO\
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M[@VQ%)$XC<![2TD?%8E8!;6)LFGE*=EIV=#,R0?!P*1PPEC2Z78D<QN%]""
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MUV[0/YJ?W2;]9/7;M _FI_=)OUDR<]U[CFHZZBY%Z[=H'\U/[I-^LGKMK_\
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MMY:$LL.&P>?_ )K1T?MX;_\ /Q6G&4+)55I?K\_0BE/7"69$1>>;!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!4^TC5C-*X7O(P'WK!+*[#Y[<W'V#<?F5
M?[)]'2U [4&=:^3*V=W1B7FZ,']\=_WQ_,%?LIB,?E'5W9&I#8-=_>1&1N_
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M5:?+:L[IZEHRN$18;UJ"C3FM6Y&Q00M+WO=T "R2OT+'W)-%$6B21C"[H'.
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M/2D^,EFR^=G-O.VQ^V2.._=-/[P?]>&PY* '9QFX<Y;RM/4C8;=ASB9.XXG
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M*'2NHM.Y&X[2-^D<=9D,AJ6@=HG'RV_Y>"L.DL/F\9-8=FLX[)L>T"-ICX>
M@\RHK(Z0S466N7=/:CFILMO[R6&9G>M#O,;_  4PG:<DY)WW6C#6BT*E)A[\
M':=ISY6OC(9>5SIYS&-F0QM!X6M'ER<NS*IZ2T>,/?GRF2NRY/,SCA?9D&W"
MWR:/#H%!X6M9G[7\K9JY&:>E7AVL-)/"USAL(O+EMQ*U5JMT?PK8B-X_4Z0N
M7=KF5FEOTL&^M>^2W\,]R6M$7.>W<[,'AX?H7447/1J*G+$U<O*.)6.%]H6J
M:&2IX.O0QM^I%3LM<&S5^ <(&W"WGS/L76<)J6ED\6^^]LM"!LAB/IH$1WY>
M9]JTM<Z7?J5F-;':;7]$L"<\3.+BV\.JE-28*CJ'&/HY*,OB<>)I:=G,<.A!
M\UO4J4IPC&UNOT*1C)-LIN9[+*F0-F5F8R0FE>9&MF>)(P2=]N';I\5(]D^;
MFR^G9(K443):$IK$PM#6.  V( Y#X*.&BM4L@-&+6$HQ^W -X=Y WRWWWZ>U
M6"E@*.F='W*-2=]:(0O=):)^=Q%O-_O]BFI-2A@E+$[Z:=!%6=TK%F147L9K
MVX='"2Y++(R>=\D'>;[B/D!R/3<@GXJ]+EJ0P3<;WL:1=U<XII+3D&6[0=1T
M<PZ1]6M.Z?T4N+6RN+CLYVW4 '\ZD.T'#4](7\)EM-Q&E9=:$+XH7$-E:>>V
MWPV^*MFJM'/R.4BR^%R#\7EV-X'3,;Q-D;Y."T\9H>Y/EZ^2U9EW966J>*O"
MUG!&QV^^^WCT"[UQ";4W+2W3^:&.!I6M]30L;4^W*!\YX6VZ/#&3R!(!Y#\D
MJ>[5K,=;066[UP!D8(V GFYQ<.0_3\%LZRTK7U)6A=WSZF0K.XZUJ/Z4;OP4
M!#H/)9*]5EU;G79*K5=QQUV1\#7.\W+*,Z<G"<G;#V^6Q9IJZ2ZECT!!)6T7
MAHIFEKVUF;@^&XW_ ,U/KF_:_7LV[&G:F+MRQ7GV2(X(SMN.7[8=N@;M^<KI
M Y  G?VK"K'15+_%<O%_Z[$5JG"U]08.UCK9X62MW:_;<L<.8</<J=4PFNZM
M!F+@S&-]$8.!ELL<90SPY;;;[?\ XU>\M1CR>-LTIGR,CGC,;G1NX7 'R*HK
M=%ZGBK>@0:OD;C@.!H,/[8&>7%OOT]JTH32CA<E]5<K):WL5S0V'XL;KR+'.
MDGA[M]6%YYF9P:[<^TD[?:KEV.7([.@Z4;"..LY\3QY'B)_00K#IC TM.8F.
MACVD1M/$YSCNY[CU<55KFALA2R=FWI'-.Q<=L\4\#F<;.+S;Y=5I.M&MBBW;
MI9_+0K&+C9FG8=Z7VYU1!\X5*)$I'[W<.Z_EM^U=*5:T;I.'3WI-F:P^[E+9
MXK%N3J[GOL!X!65<]><9-*/1*Q>":ZA$18EPB(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( OB:&*9O#-&R1OD]H*^T0'Q%%'"WAA
MC9&WR:  OM$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %\R11R;=XQK]NG$-]E](@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@(+5>EL=J>&O%E!,6P.+F=V_AYE2].NRG4@K0[]W"QL;=SN=@-@LR*SG)I1;
MT1%E>X1$520B(@"(B (B("OY_1^%S]Z*WE:IGFC:&-/>. X0=]M@?:5.5X(J
MT$<->-L<48#6L8-@T#P 61%9SDTDWHB$DM0B(JDA$1 $1$ 7S)&R5A9(QKV'
MJUPW!7TB  ;#8<@B(@"(B (B(#Y=%&Y[7N8TO9]%Q',>Y?2(@"(B (B( OB.
M*.,O,;&M+SNXM&W$?,K[1 $1$ 1$0!>/8U["U[0YI&Q!&X*]1 >,:UC0UC0U
MH&P &P 7J(@"(B (B(#Y,;#(V0L:9&C8.(Y@>]?2(@"(B (B( B(@"(B (B(
.. B(@"(B (B( B(@/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g843142g22q66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g843142g22q66.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_[14"4&AO=&]S:&]P(#,N,  X0DE-! 0
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M;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M  !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$
M8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,
M   #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M  !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!KGEY
M    "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G
M4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M            4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN
M=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E
M8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R
M;W!296-T5&]P;&]N9P      .$))30/M       0 -SR\0 !  ( W/+Q  $
M CA"24T$)@      #@             _@   .$))300-       $    >#A"
M24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M   *  $          CA"24T#]0      2  O9F8  0!L9F8 !@       0 O
M9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M!@       3A"24T#^       <   _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H   X0DE-
M! @      !     !   "0    D      .$))300>       $     #A"24T$
M&@     #-0    8              %<   '@          $
M             0             !X    %<                      0
M                       0     0       &YU;&P    "    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   %<     4F=H=&QO;F<   '@
M!G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI
M8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   !7     %)G:'1L;VYG   !X     -U<FQ415A4     0
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M24T$$0       0$ .$))3004       $     SA"24T$#      *O     $
M  "@    '0   >   #9@   *H  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D
M;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,
M# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0
M% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,_\  $0@ '0"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$!
M 0$!          ,  0($!08'" D*"P$  04! 0$! 0$          0 " P0%
M!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&A
ML4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*S
MA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7
MY_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"(\%2
MT? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-U
MX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P#
M 0 "$0,1 #\ [WIG6[<_JN3B>DVNG'#@#)<]SFO]+<?HM:W3Z"%];LO*QL"O
M[-:ZDV6;7N88<1L>Z _Z3?<W\Q4_JW_R]U#_ *[_ .?G(_UU_H%'_&G_ ,]V
M*V(1',0B!I0T_P %J&<CRTY$GBUUV_22.^L=6"_%Q;ZGN:ZBI]E\S&X'79[K
M+/H*5?UOZ4^P->VZIO[[F M'Q]-UC_\ H+&SZ:[NJ8K+9-8PJWO:TPYPKKMN
M]-I_-]3T]B'CFO+NKQK:*6UWN#&&FMK'5EWM8^JQOZ1^QWT_6=;ZC%%GR\KA
MECCD$N+*+N&T?ZQ6^]FXB 10EPQX@W^I_P",+I>%DNQ\>FS,-;MK[6EK:Y'T
M_2>X[K=G]3T_^$5C#^OGU=R:19=<[$?,&JUI)_K-=3ZM;F?VUS/3^H]4Z3DO
MZC@8)S:;V-KRG!CS#JY<(MJ;8ZGV6>[?7[_8M+HX^IWUFR[76X!Q^HV VV5>
MH]K7Q[7V4^A974__ (;]%5;O4^3!CB#<)&,=YPD)2_PH?HLV/+*8$@0#+]$_
M]\A^I/UCMKJS:.IY=F18U@OQJ[7%]CMC+'Y3*;+3[O976_T]_P#W]7/_ !RN
MF?9_4.)>+28;62P"(!W.MW[6_N_OK#^I^'C9&'U;,N9OR,/%G'?)&PVUY++7
M!H.W<YC5I?XML'&L9D]0>P.R*G-IJ<1.QI8VQY9_*LW^Y.RPQ Y)RB3P\.@]
M/JDF)E40#O;<K_QD])..ZRW&O9:.*QL<T_"[>UFUKO\ 2;%:Z1]>^D=3RFXC
MF68MMIVU&W:6.<?HU^I4Y^RQ_P"8VSZ:Y9N;<SZW9^:>GNZO=3=<*Z&3[/3?
M]GJOVUUW_P U57Z?T/\ ";_YQ&Z\_K'UCMQVU]!OP<IK]OVIS7ZM/T6VVOHQ
MV,KJ?^FWO^A_@D#@QV!P\((OCXQZ/\&7S*$Y=[H[5N]IUOZP].Z)4Q^8YSK+
M)]*BL!UCH^DX-):UK&?G66/V+"K_ ,972GM?.+>'M;+&@UNW']W<VSV?UG>Q
M4LRBKJ7^,?[+F@6T5!H;4[5I#*/M3*RW]SU[76N9^>MWZZX&)?\ 5_(NL:UM
MN&WU,>R(+2TC]&W_ (YOZ'8HQ#%'VXRB92R 2XKKAX]M%Q,CQ$$#AT^Q!?\
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M &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %,
M-@    $ .$))300B      %"34T *@    @ " $2  ,    !  $   $:  4
M   !    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R
M  (    4    G $[  (    (    L(=I  0    !    N    .0   #=
M 0   -T    !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R-#HP
M-CHP." Q,3HQ-CHQ,@!';V]D=VEN   #H $  P    '__P  H ( !     $
M  '@H , !     $   !7          8! P #     0 &   !&@ %     0
M 3(!&P %     0   3H!*  #     0 "   " 0 $     0   4(" @ $
M 0              2     $   !(     3A"24T#_0      "
M_^$!2D5X:68  $U- "H    (  @!$@ #     0 !   !&@ %     0   &X!
M&P %     0   '8!*  #     0 "   !,0 "    '@   'X!,@ "    %
M )P!.P "    "    +"':0 $     0   +@   #D    W0    $   #=
M 4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,C0Z,#8Z,#@@,3$Z
M,38Z,3( 1V]O9'=I;@   Z !  ,    !__\  * "  0    !   !X* #  0
M   !    5P         & 0,  P    $ !@   1H !0    $   $R 1L !0
M  $   $Z 2@  P    $  @   @$ !     $   %" @( !     $
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M$0 " @$# @0%!0$        ! @ #$002(3%!$R)1L04S87'!%".!D=$R_]H
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MI  ZG)&*26P+X^?]5SZTUE-(6%W4NIXUK:<X0>6HK<QG<0 23]'MQ3CH*PS
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#)__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g843142g25s47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g843142g25s47.jpg
M_]C_X  02D9)1@ ! 0$!D &0  #_[1AF4&AO=&]S:&]P(#,N,  X0DE-! 0
M     &P< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  +4&5T92!(86YL;VX<
M @4 0$UI8W)O<V]F="!0;W=E<E!O:6YT("T@57!S=')E86T@0FEO(%,Q($=R
M87!H:6-S7T=O;V1W:6Y?,3!*54XR-"XX0DE-!"4      !"#06!G(20Z#+-M
M/#Y!05Y;.$))300Z      #E    $     $       MP<FEN=$]U='!U=
M  4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0
M  ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E
M '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I
M;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
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M8VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;
M   .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L
M;VYG       X0DE- ^T      ! !D/2\  $  0&0]+P  0 !.$))300F
M   .             #^    X0DE- _(       H  /_______P  .$))300-
M       $    6CA"24T$&0      !    !XX0DE- _,       D
M  $ .$))32<0       *  $          3A"24T#]0      2  O9F8  0!L
M9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M 0 U     0 M    !@       3A"24T#^       <   ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H   X0DE-! @      !     !   "0    D      .$))300>
M   $     #A"24T$&@     #00    8              G\   A?    !@!G
M #( -0!S #0 -P    $                          0             (
M7P   G\                      0                         0
M 0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   G\     4F=H=&QO;F<   A?    !G-L:6-E<U9L3',    !3V)J8P
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M;VYG   (7P    -U<FQ415A4     0       &YU;&Q415A4     0
M $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E
M>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L
M:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T
M06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G
M0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M"71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG          QB
M;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"
M24T$*       #     (_\        #A"24T$$0       0$ .$))3004
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MY?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$
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M):YUG&_\YST2WI_4W@[.IOK):&@M!T(;L]3^<^FZ/_!/5_GJZEHLTK#7.W.
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M^M\G:6V;[&M<[V[+/2]GO_\ 2*4P=]:.BL!DOW1.T5.,@N],'<UOI_2_E_\
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MV3A"24T$(0      5P    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\
M<P!H &\ <    !0 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  (  R
M #  ,@ Q     0 X0DE-!"(      4I-30 J    "  ( 1(  P    $  0
M 1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$  @   !\
M  !^ 3(  @   !0   "= 3L  @    P   "QAVD !     $   #     [
M 9$    !   !D0    %!9&]B92!0:&]T;W-H;W @,C(N," H5VEN9&]W<RD
M,C R-#HP-SHQ-B P.3HQ.3HQ, !0971E($AA;FQO;@       Z !  ,    !
M__\  * "  0    !   (7Z #  0    !   "?P         & 0,  P    $
M!@   1H !0    $   $Z 1L !0    $   %" 2@  P    $  @   @$ !
M  $   %* @( !     $              $@    !    2     $X0DE- _T
M      @          /_A 5)%>&EF  !-30 J    "  ( 1(  P    $  0
M 1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$  @   !\
M  !^ 3(  @   !0   "= 3L  @    P   "QAVD !     $   #     [
M 9$    !   !D0    %!9&]B92!0:&]T;W-H;W @,C(N," H5VEN9&]W<RD
M,C R-#HP-SHQ-B P.3HQ.3HQ, !0971E($AA;FQO;@       Z !  ,    !
M__\  * "  0    !   (7Z #  0    !   "?P         & 0,  P    $
M!@   1H !0    $   $Z 1L !0    $   %" 2@  P    $  @   @$ !
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M*"@H*"@H*"@H*"@H*"@H*"@H*/_  !$( =X&1 ,!(@ "$0$#$0'_Q  <  $
M @,! 0$             !@<!! 4" PC_Q !?$  ! P,!!0$*"P0'!08$  \!
M  (#! 41!@<2(3%101,5%R)487&1H=$(%!8R4E5C@9*3L2,S0G(T-F)T@K+!
M)#4W<\(F0X.SX? E4Z+2.%9UA!A&H_$G1$5DE,/B_\0 &@$!  ,! 0$
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M[B <%_F]"[U7?M*T4SJ-MMWHFN+'2,B:6C' \2>*Z5B'2?N5><EQ.-X=5/\
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M"(B ($1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 5R;,OZHP_\ ,?\
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M1$6I4!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0'E_S2I5J/\
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MVG^Y1_J5SU/BP\S2/PY^1&$1%T&2X!$1"0B(@"(B !$1 $1$ 1$0!$1 $1$
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MF56$9*#>]D1IU'%S2W+Y$;\4_P 961N'F\@+KZ9M#+[430-G9!*P;S&N9G?
M/'CV)06*IK[LZUA@CGC<>Z.QP:.OG[$=6$6TWP"ISE:R>]V[CD>(W/CDHMV[
MTT5#6RT<4C*CN7 R!NZ,],<5I*T6I*Z"[TPB(A(1 BD!$1 $1$ 1$0!$1 $1
M$ 1$0 (B(#R_YJE6H_ZG:;],G^JBK_FJ5:C_ *G:;],G^JYZW]Z?S_QFE+^E
M3R^J(NB(N@S"(B QCGGT*3[."?E&Q@/BB-^ HP2 ./F4FV<C=U/$'<-Z-Y"P
MQ7P9?(TPC_YX_,EFK-'SWN\,JHJJ.']F&8+"5"]4:=FT\V!\]4V<2%S0&M(Q
MC'O4BUY'=^_F+:VO=#W$?N=[ .?,HG74UWDAWJ^&O<QHR3,UVZWJ<E<N"]XH
MQ;FK6X'1CG3O.T'>_'N+!M,3K1L\DJ(3F4TSY0X=3G'ZJJGDDN=*2^1YWG.)
MR2>.2K/TA4QW?23[5))^U:Q\#LGCAV<$*$5FF[K1U#H9:&HEW3AKXXRX.'4>
MQ,')0J5(S?\ *Y.+BY4Z<X+^-CCM=NLDB$LD;),;P#C@^E>1N1DX<3D\2I/2
MZ.NM102U#H.Y%O%D4C</?U]"U=*V+OU+51F5E,RG9O/+F[V./$'EC'%=GOZ2
M3E?AQ.3W-5R2V7O^6\X9R>+'-*;S\9+6@]%+*S2M#%22RLO=(XL:7!C6@%WF
M^<N=IO3TEW#YMYE-2Q_/FDXX\P'#]46(I.+E?<BON*NVH-;W^]SL<1KB>> O
M2D5_TTZWT0K:6>*LI <.?&W!;Y^W@HZ>#@.TJT*D:BO%W#IRIO9FK!$Z^9%<
M!$1 8/(K#^?^)9/(K#^?^)2BDOWJB7Z[_P!T:=_NA_1JB752W7?^Z-.?W0_H
MU1+KZ5S83X2\_JSHQ/Q?)?0(B+H,@B!$!AW[LCL)5J[,69TQ4M:=W,[QG[@J
MJ/$$#FK3V9N#M,5(&3F=_+T!<'M'X/F=?LWX^_1_X<9NSFJ<2[OA3@<]TQGK
MZ5P+1;1%JZFMTSA)W*H+'.QC> XD>Q>@-2NF<.XW,M&?&&_QYK6@?66J\4];
M6PSME;*)")6D.>.WGYE>FJNR[S3W;C&HZ5U:#CPO=WW$NVHU<K11T3'%L!!D
M> ?G8. /]?N5>N;O<'<1YU:.M+-)?[;2UMM<)9(\X#3G?8>.![% ([%=I91$
MRW50>XX\:,@#TGL5,#4A&E:]FN)OCH2=9NUT[6-&221Q:9)'/W6[K=YQ.!T"
M^.1V-QGF5V[UINMLT<4M5NNC=P>1R8[L"Z=+I -IXY+O<H;>90"R-S03QZ\1
MQ72\124=I/=R.6.&JRDXV=^A$LM/ N(7KQ-T8D!/G74OMFJ+/6,IY6-G9*"8
M98V\'X_U]?-=FFT2UT$'?&OIZ.HG [G"6Y.3R'$C)4O$4DE)OB3&A5;V4GN^
M7X(@X.WAC=W>W"]+;O-JGM%P?2U+,/;Q#F_->.H6HM%)26U'@9J,H[I<0B(I
M),!91$!YD_=N]"E.T#]_:O[E'^I46D_=N]"E.T#]_:O[E'^I7/4^+#S-(_"G
MY$81$709+@8641"0B(@"(B (B( B(@"(B (B( B(@"\R?NW<<<#^B]+Q*,Q/
M']DHB)<&71<;8Z[Z0IJ:.41/=#&=]PR. '8H;6[/IZ6DFJ>^%.X1M+MT1G)Q
M]ZE&HN[_ "&@%$9N[=QC_=9SC SC"KSXM?WLW>Y7=S2,$.:_!7C8-3WN,TE?
M@>OC'!-;4&W;N9QV/+V!V,Y':C.(.0NE9+1+<KPRVEWQ>0AV=YN2W SRX+[:
MET_-898F22]WCE:2'AN[Q&.&/O7K>^AM^[;WGD*E/9=1+<CBY:T9+B3T60&/
M&>Z.:>BD.E=,27L3O;,((HB&E^YO9//J%RKO0&WW6HI"X2NB?N[^,;WZ]456
M$IN">]!TZD8[;32?![OH:6^V3.Z2T#M':@+"#B0J66C1[[I9?C@G; 7!QBB#
M =\#D<J,P,C[MW"0")K7!KWD<AD@G';A1"K";:B]Z)E"4$I25D^' ^66!OSB
MG[,?]X?0NYJ+3[['#!.)&55+,/%E#<8/0\UFOTZ^W6:"NK)FMEF^93[G$^DY
M]:B->G*UGQ#ISC=-/=QX'"&#Q')93AV# Z(M0%@+*( B!$ 1 B (B( B(@"(
M@0!$1  B(@"\R_N9/Y5Z7F3]U)_*@)/K/^C6/^Y-_4J-'F5)=9_T:Q_W)OZE
M1L\RN?#?"7G]2]7^_DOH81$704"(B *S-D@S;;C_ ,X?Y0JS5E[)/]W7$<LS
M-_RA</M'X#\CKP"__1'S^AIU^@:BJN%54,N$+!)*Y_[LD@$D]5%*FSNH]1LM
M<KVS-,L<;WM!&=XXZ^=;]S9?3>*SN++HZ,S/W=P.QC)QA<JH9<J&LAJZV.IC
MD!:\.F!RYS>/;SY*]!5+6E--6,L1*%WL0:W\66'M-JG4MAI*6G+F-E>&G'T6
M@\/T56M<"PG'F5LWZF&KM,P34#FF8$2LX^L*MWV*Z,G,;+?5$DX [F>)67L^
M<(TG%NS3=S?VA&4JJDE_%I6- R/,;&/<YT;/F-)X-]"%N!D9X]G!=ZZ:4N=K
MMD=94AA!XOC'$L]_G7VL6DH;E:F7">Y,HXWO+0)!D9!QSR.BZNT4E':ON.14
M*LI[*5G:]N&XC.7D$!@!ZDKVUH$9[H]K7+NZCT_26RD;+#=8:M^\&F-@ ..O
M-;%JTDVII(JRXU<-!'+QC;(W>+O3G"/$TU':ON([/5V]BV_][[V(S\P>-QRL
M8[>Q=34%EGLM4&51$D$@+HI&C@1_[*Y?'_">(6D9QFMJ+NBK3B]F2LPB(K$A
M$1 $';Z$61V^A$5EP)/LT_K#_P""[]%&ZC^D2_S']5)-FG]8?_!=^BC=1_2)
M?YC^JYX_'G\E_IO_ .B/S?\ A\T1%T&01$0!$1 239V/^UE)D9X/_P I4RU?
MI*:]79E1%60PCN886O879P3T/G4-V=N#-54KG<L._P I7;U\+I/>XS;6USH>
MY\3"UV,[QSR^Y>5B-KM4=AV=ON>E0<>R2VU=7_Q$>U1IB6PPP2/J8IM]Q #&
M%N/65.J&5EIV??&(1XYA[KD=7*N:ZCO/<G/KH:]T3.),K7%K!UR586D*FGO6
MDY+:YWCQ,,3AT'\)5L4I*E%R>U9[RF#<75FH*S:=KZE5]U>]^7$N'.3)^<>W
M*]1OD;#(V.1[0_YP#L;WIZKJ5NFKK0RN@-'/+QP7QQEP<.HPMJDT;=JBCEJ3
M$82WYD4@(<_KZ%W.O22NY*QPJA4D]E1=UR(X#NM :T;W:5Z:#_$YH7=T[IVH
MO!G(='3P0X[I++V'H.JV[II%L%#)6VRNAN,<8S(U@P1YQS26(I1EL-[Q&A5G
M';2W?O=<C#&O>_)W&L0[N^X-<#CHNQIS3LEWBEE[JRFI(OGSR<0MJ^:8[VT+
M:RCJ(JNDSATD;<$>?@3D(\134MB^\0HU&MNV[]YW(ZB=/.BU*A$1"0B(@"N3
M9E_5&'_F/_S*FU<FS+^J,/\ S'_YEYOM/X2^9Z/LSXK^1)G<T1W-%XD>![CX
MGW5<;8_W5J_GD_Z58ZKC;'^ZM7\TG_2NO ?'C^]QQ^TO^M+R^J*T'SEE8'SE
ME?1'SP1$0!$1 $1$ 1$0!$1 $0(@"(B (B( B(@-^Q7%]JN+*N.-LA8"-UQ(
M!]2E3]H]2!DT5/GTE09!P6-3#TJKO-79>G7K4OARW>7V);=M;U5TMLM++2QQ
MLG&X7#F,]JZ&GZF2WZ#DJX"=Z"I#CYQD9"@)!D:X./BCDI#1WFFAT;46EQD%
M0^0D#'B\P>?W+"MA8J,84X[KJYI1Q4]J52<OY6:7S[CMW"RLK]:T513G_9JI
MHJ,]C@WB?6,+KU%Q-;:-5N81W&%IAC [ UI!7 M6KXJ/31I98RZMB:YD+@.
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M6SN"(BDL$1$ 1 B (B( B(@"(B (B( B($ 1$0'E_P TJ5:C_J;IOTR**O\
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MD6'#'''-0A=G5=]=?+BV8,[G$QO<V,[<<\GW+C+MPU-TZ:C+B<]:I&K4E*/
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M9&.:(T\7!W-%L91=SR_YI4JU'_4[3?ID45?\PJ5:C_J=IOTR?ZKGK?WI_/\
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MY7OR7O@:3GKA1B(5(2I[<KJY;#3IU(U-B-G;N_)#-+:49?J":J=4OB,3]S=
M!!X Y]JC4\?<IGL!)#'%N>W@<*S=E6>\5;GF9CC!_LA5K5@]\)FX=O&5QY<.
M:ZJ-6<JU2+>Y<#DK4H0HTYKOXDEU-I*.R6EM8*M\KG%K0TM '%:6EM+U%Z+I
M'2=RI\\'$<7>8*9[23O:3@&3@2,P?N*]3R.H-G1=2;S'BF!#F\QGF?:N2.*J
MNBM_\I.USKEA*:K/=_%*]CGG0EMEWHZ6Y2FH;S#G-<!]P"X5OTNYNH74%PG,
M(8.Z,DX;K\$<LJ.0SOH:ALM.YXD8[>:]IR5]YJZJKZZ*:MGDGDWV@%Y/BC/)
M=D:->-TYW5M-]SAE7H36TH6=]=S+=U-:X+K;64T\_P 7C8\$.X<>'_JJT?9V
MQZG9;8*ISH7/:T3-YM)!Y84UVE<=-T_ 8[JWAUX%0#2+G-U-0<\"7EUYKDP*
ME&C*:>[?NYZG9[0<)5E!K3?RT-[6=F[SUE,R6LFJC(UQWY3DM 6WIG1LUSIS
M5UTQIZ8\6MQXSAUZ!=3:@QC[O:FOX->,.STW@M[:'424VG*6.G+XXI';CMWA
MPQP'K5XUZCI4XJ6^5]Y25"G&M5DU_&-MVMS6GT';YVN%NN#^[ <GEKF^P94&
MK+?+0W%U+5Y9(UP]#AU"V-*U533ZCMY@>_\ :2MC<T'YS2>.5+-I]/'W>VS.
M.)L[N,=F<K2-2I1K*E-[29G.%.I0=6*V7'][SYU>SUT;XC#6$QY_:EX'BM'^
MJV/D'0UE*\V^ND,P&,DAPSZ %TMHL\T&G7-C.#-(UCCG&1E1S93*YMZK(P\_
MN'%P[,@C'^JY8U:TL.ZVWP[CLG2H4\0J*AN?-[B(UE-)1UDU-.,2Q.W7!?%W
MS3CFI#K]H&K:[  SN'_Z H_V+U:4G."EJCRZD-B3AI=%MZ%M<-IMQ=!4&<U/
M<W.QCQ,CS>E175.G*6B:^IAKQ/-)-QCX9XGM]"ZVR-Q^)7 M9D=T9V^8J"5C
M&&]S9.[_ +0[LYG>7G4*<^T3_EPMYG=6G3[-3_CK;EO]28OV>EDT#:>KWHW'
M$CGM W1CL]GK7+U9INEM<]#!;YYJF:I<6EN0>6.6/O\ 4IAM#GEIM-%E.\Q"
M5[6.<.P<_P#10W9M$UVI6.E(<YL1>PXQQY?ZJ,/6JSI>_G+AW?<MBJ5*%7W$
M(V;MOW[MYUJ'04+*5DMVKS%D9(C(&/-DCFOE<]#AU&^>S5)FW>.Y)C)]!'N6
MEM+GJ#>3%(]_<H@UT;,\,D<3C_5;VRFHG;75=.9'/A<P/P>37*7*NJ7:-OG:
MW<0EAW6>&V>.Z]W>_P!",62UFYWN"B<XP]T#@[A\T@<5*F: 8RJF-77F.B8!
MNO& YQ(R>? )3".#:B6PCQ7%SR.A+3GVKX;5)Y77*F@<YW<VLWMP.P,GM]*O
M*M4JU8P@[)JY6%&G2I2G45W%VXGJZZ&(I3/9YW3@?P/(\;T'@MB@T-11Q11W
M"O?\:>,[K"!C/9Q"WMECWSVRO8\DM9+XHSRR.2@&H)9I-15V]-('=W>T'.<8
M<0!]P 5::KU)RH[?]>^V\3="E3C7V/[=U]V[CS.GJS3<MC<R1C^[4KW;N]C!
M8[H5'AECR#S5J:S,E7H6.=^"]PC>?-Q"JG.],\GL&5U8*K*K3O+BG8Y\73C2
MJ[,?ZM)]3J:>/_QV@&>!F:?:K#VCU]QH/B/>R:6/?WMX1]N!VJNM.G_X_;O/
M*/U5JZQU"RQ?%7.IS/W7(QO8QC[ER8R_:86C?<]QTX/96'J-O9WK?_\ #B[/
M;Q>*Z:H%UWW4[6!P>X<<_P"O!0S6/Q8:GN(I-TPN()QRWL#/M4[L.JJ?4$DU
MM-*^E>^,NS')SZ\AGM4$U99Q9+J^E8XR1.:)&/=SP3VJ<*FL1+:6R[<.XC$R
M3PRV7M1OQW]-^\G>TP!NDH=T8_:,55G@3A6KM,.]I2(#F)&*JW AQ!6OLWX+
M^;*^TK>_L]$&^))&1P#<.^\'@K0UO"+CHJ"OX[T8CF&//P/Z^Q56\_LQP/C'
M@K9N1W-EA:>)%*T>U,995*4N^Y7!N].K#NL_0JIW'+O.BQQP!U.5E=[.**L>
M7_,4JU'_ %.TWZ9/]5%7_-*E6H_ZG:;],G^JYZW]Z?S_ ,9M2_I4\OJB+KR]
MN=TCJO2QG&>@PNA&,E=6++V64C(K97U[_G/.[GH&Y5=5\IJ*V69Y)<]Y)SZ5
M:6A..AY&LQOD2CAUR<*IB1W0D\AP)7#A7M5ZK>J1VXI;.'I6T;ZDNETE&S3#
MKR*J3C%W81[HQQ[%'[+1"YW&EI'O=$)G[N^T9(5E5HW=ENZ3Q;2,_P!% =%G
MNFI;9XI_?8QCS%10JSE3J-O@W85J4(3IQ2XI'VUAI]MBJ*:-M2Y[9&EQ)&.7
M!=33^BC6T\=5<*A]/$X!W<QC.[V$D\ M[:2UKKS:8YN+2 UV>P%X6]M2EDCL
ML$4;W11/DQ(1PX8X _>L5B*DJ=.">^7>:]GI4YU9M7C#N^?J<NJT/#+('6JN
M$H#@U\;\' SS!':N)J_3S-/R4[&5#I^[M)RX 8QA?/0LL\6I+>8I-\R/W#NG
MFSMSQ]"D&UPCX[;_ #1._4+2,ZM.O&E*5TT925*IAY58QLTTN^W$C^BK?\>U
M#3L>[]E&.[/\^/\ UPNMM-KOC-ZIZ')$5. 7.SQRX_Z8'K74V<TK:.RU5UE
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M[N#V4E?]ZG%"G3I4?>U%M-NR6^VY\OD6)HVP.LM95ALHGI9FM[FX<, 9Y_\
MHH!-;VW/6]50F0Q-FJ9 7@9(P"?]%*=E-7*VEJX)'/?!&6%I=V$@Y'L7$M>?
M"8X_PBJDX_<5A3VX5*MW=I<3>;ISIT=E63D]WF<_5EB98*B&!DSIC*POWG#&
M..%O:1TI'?+?)4OJGQECS'@ '..U;.UEX-QHG>,1W(C@,GYR[FRUF+#4\3^_
M<.'H6LZ\UA543WE*="$L7*FUNT_)7E-;IZVZ-HJ)N_*XEG'@  <;QZ*:QZ$H
M:=C>^=R>V5W\+"UHSYL@K.S*.-]TNTKP#*'[HX<0,DJ,:TFDJ-35[IG9<Q^X
M&GD .6!YU:4ZE:LZ49;*2,X0A1HJK-;3;Z&WJG2$UGIGUE/*^HI!\X\,M'^J
MGVD[;!;+288)>[QR/WWN&,#(XCV*IGW:MDH&T+ZB;XNSE&20,>=6-LQ(^3\_
M$@-G<3TY!<^.A5C0M4E>SZZ7-L!.G*NW"-KKIJ135-@I;13134M<*F224M,?
M#@,$_P"BV*33;Y='R7(5\X8(G2&G!\3AQ41(#JAY!+1DG.#U*M2S@>#%P/DS
M_OYKIQ,JE*$4Y7;9AA84J\Y-1LDN&\KRP6BJO5>(Z<#  WWN'BL4TBT):VXC
MFN$PF'/QFM'J(6YLU9'%IV6:)F].][R>'/' #V*LJJ:>:IEJ)YI9)I'$N\8\
M#_Z*NW5Q%2482V5$ML4L-3C*4=ISZ?N\[^I])U5F#9VO$M$7 =TQAS23@97T
MTQIF.]T<\[)WL=$XL#<##C@%2JT%]RT YU<2_%.]H<_G@#@?8%\=EAW+'6O+
M>#9\\/Y>:REBJJHRW_RB[7-:>%IRKP27\9*]K\/N:%JT)3,C8RZW!WQQPXPQ
MN P?O'%</5VG'V*IC+'F2GDX-)&"#T*Y%34RON;ZR61SJA\^01S!SU]"L7:9
ME^G:1[@"[NS078XYW3E:[=6E5@I2NI&<(TJ]*<HQLX]^_>5BI=L\M,%77-K)
MIPV2"0;D7#QN"B)7;T6,ZGM^.?=!Q75B5)TI;+MN.>A)*K&ZOO+ U=8*2[U5
M--55IIMP%@:<')SSXJ&Z=TK%=:*NF^,/$D,SXF'=&'8Y'[UT]K;0*^@R,#N;
MLXZ96]LJ>T:>JW!F\T5+L#_"%YD)5*6%]Y&7&UN6\]"<85<6Z<HZWY[CG#0\
M%/;))ZZM?\9[F7[C2  <<AD<5R=,:3J[Q3FHF>(*3.&OQDO]'F7%N]3+75=9
M43NS(920[/S<'D/0K/U8]UMT*UM"71#=C9OM[ 2 ?_?G71.I6I*,7*\I/H<]
M.%&HY24?XP3\]#F.T);98G1TEPD,PX9):?9A0J_VB>RU+X:C)P-Z-X^;(,_^
M^"U;1/405\<\4KQ+$]N ">/$#'WY5A;4V,?9J*:3A(V7Q1CF".(5E.I0JQA.
M6TI$.-.O2E*$=EQM\G?YG*AT.ZIM%%54U7F6H#'%KAP:'<2?N71;H2VRL=%%
M<9'5+1QW2TMSZ,?ZKK5T[J?9Y')$XQR?%&AKP.(R,<%7>CWR0ZFH0V5Q!GQQ
M)X@M/,+"G.O6A*2G;9;[M#:I"A1G"$HWVK:]^G,[EMT-*:B8W*I$%+%RD!'[
M3SC/(+<N.A(32NEL]6Z=^,[KW-(/F! X+[;5WS,IZ"+?=W)SI'%HX9P!C/5-
MD4CC%7L))C:6.&>O$%/>UW16)VO+NT)5&BJ[PNSYWW\+_(KLM>TN:\%KFG!'
M0K#>#<C@2>*Z&H!N7ZXL  '=BN?_ -V/2O7@]I)ZGDR=KK0MC2CWP[.&S09;
M,V*4M<WF#ERB%LU#J9]=$QKZF4%S>#P"",C.5--&3BEV?T]06[W<FR/QG&<.
M=P7%AVBPEQ<^WO X;Q;+G='FX+Q8.7O*NS3VMY[,]CW=/:J;/\5K_G^GTVHB
M#XC1N=N"I[H<8YXQQ7WV6D]X:T.Y]W[?Y0M/7]C9/0]^&22X(;O!QR-T\B!V
M'BMS9>";+6$CCW8@'/\ 9".W8DD[[Q#:[?>2MN]+%<7/^E5/GE=G\17Q< XX
M/8#A?:Y#-54X/*5W^8K7+MXDCECMX+VE:QX=W;J6+LLF$MMKZ1YWOVF]NGZ)
M&#^B@UWIA1W&JIF\HI'-'HR5,]DK7&>XG!P(VC/WE1C5C@[4ER<WYO=2W[PN
M&@[8JHOD>CB8[6$IM\SD-XM"Q)^ZD_E61P&%B7]U)_*NXY"3ZS_HUC_N;?U*
MC1YE276?]&L?]R;^I4:/,KGPWPEY_4O5_OY+Z'EW)>^ G=]$-SCUK!'B/]"0
MN&.Z'EP_5=*,)NRN6==F&R[/(XH7$.?&QCCU+_G?J57%O@^-5E+3%VZ)7AF\
M!RR<*S=H#V/TC#N$[I?$1P[%6]D<1>J M^;W=C7'IXR\W!O_ ()S7&[/0QD4
MZ\*?<DO].UJW2[;#!3S-J'2]V>68(P  ,Y7G2&FXK^*DFI?'W$@8 !SGTJ3;
M6^-#;V<AW5^/1NKX[(V-[G<#N>(2W&0H5>H\)[R_\OR7>'I]L]U_XZ>5^)"J
M^V&"\S6ZG<^:9LG<V]F>/-3*CT'20TC9+M7N9*X X80T ].(XKS8X8CM*K#(
M!OL=(6\?,N;M-GEEU 62R.CBBA'<QG=#NI"EU:E6<:47;==LJZ5.E3E5FK[[
M);_\-R/09EK3W&KWZ)S<MD;C+2.&#Z>/J44O=O%MNL]&R1SW1.W03SY9RI9L
MHGG-764^'.IFQA_'EO9"X.N23J^JPTA^]CAR)QU5L/.JJ\J<Y7217$0I=GC5
M@K-O_/H2'9;;]V2LN4X.[$WN;#Z>+C[ N'7/&J-8MB<_=AFDW 1V!H.#[/:I
M?5'Y/;/0V)Q94S1XXGB7O&3_ *J"Z*X:JMK0.)DSCKXA6=-N;J5]-R\B\U[M
M4J#^;^;_ /K)&[0>Y<G?&:TLH6M'C\ 2>/+L"]W70;!2.ELU2^<M&=UY!WO0
M1A-J]1(^MH*?><V%S"_=:<9.>!6ULG=(::XQAQW0]I:''/,%9>]Q"H*NY>5C
M6-+#NN\,H>=^'?N[CX4&AJ1L36W.O[G5. /<F$#'K!RN+JW2C[(&U$,QGICS
MSS9G."N9JB>>?4%:7R'>$[F$] "0/]%85U<Z?9K)-+@EU.PDG^8<5KMUJ4H2
ME*ZEW?8Q4:-:%11C9Q3:=WW:FELB ,%QWN/&//IP5!+L=V_W+=X?MY!G_$5.
M-DCMZFNA9D^.PCT8*@E[.[>;B\__ #Y/\Q6E!_\ Z:EN16LO_P U-/G]2QMG
M;1<-'U%'4'?C8]T>Z?HD C]56,D;HG[CL[S7;KL^8X*LW94'QVJX%V>,P&/\
M(5>79P=<:LL((=-*01RY\%.&W8BI%%<2MK#4I_O[N-4\"<(.WT+R.7'FO3>W
MT+N1R/@2?9I_6'_P7?HHW4?TB7^8_JI)LT_K#_X+OT4;J/Z1+_,?U7/'X\_D
MO]-__1'YO_#YHB+H,B2;/Z'XYJ.$NP8X,REOW8'M*W-IM6Y]];"'']C&!]YX
MKULO);>:M@QO]R'#S9"YVT!KOE96N=R(86_A"X..,^2.O='!;N]GO1^F67^&
MI>ZH="Z%P:0 #O9S[EP*NG[C5U$(D.(971[QX9P2,^Q6!LD=^PN(=P_:1_H5
M!;PP.N=P))&*B0?_ %%:4JDGB)P;W*QG4IQAAZ<^#=]_F2.XZ2CH-.BZ?&GR
M.W&O$9;C.]@?ZKFZ7TY/?)Y"V014S#ASR,_< IWJ-O\ _#[B#QAB&#P[0L6#
M%'H%SZ3A-W&1Q<WGO<?;E<<<74]RW?>Y6^1V/"4W62M9*-VM>)S)]"VX#N=-
M<7_& /FR.:1GT  KDW+1LEOT_)7U,Y%3&T%T3<;N<XX=JB;'GNF]OR!^=_N@
M=DY5JWV66;0$TM2S$KH8RXXXGQ@M*KK4)03G=-Z(SI>XKQFU"SBK\?W>52QC
MG%N.)<0T#J59U]<W3NA(Z2,_MI&B(GH79)*B&AJ!UPU% ',WHH7"9P[,#E_H
MNAM.K?C%U92,>>YP#QAU<<'/J6N(_P":O"EW+>S'#KW.'G4D][_BG\^/[R/E
MI_2(N]E?6BJ<R9Q?N,P,$MZ^Q=2CT10EC8JRO>VL<.+6.: /1PRNSH%V[H[N
MC0,M,I:?O*JTU$SZU\SY7&1SMX.SQSE91=:M4G!3LD^70VE[FA3IS<+MK[>I
M+6Z#JA=C&^=HHL9,IQP\V.JZ3]!4$\)%!<)'S $9<06@^@!=3: Z6+3+WQ/>
MTN+&N.]Q.2HELTDD9J0M8]_C0OWVYX<,86<*M>I2=92M;D:RI4*5947"]^?"
M_"WYWD<KJ*:@KGTU3QEB(!'7CP/J5F[3>&F(O^:U1;:4&C5+"P<XV$\/.5*]
MIH_[+Q#[5JTJ3]Y*A/7\&5.'NX8B%^'Y*QM%0:2Y4M4WYT4K7^G!Y*?[5J-C
M[?2U[6^,'!CCYB,_Z*ML'>W!\[*M':-OC2$;7]LD>/3@J^)>SB*;7R*8;?0J
MI\G]2KT1%Z!QA7)LR_JC!_.__,J;5R;,OZHP_P#,?_F7F^T_A+YGH^S/BOY$
MF=S1'<T7B1X'N/B?=5QMC_=6G^>3_I5CJN=L?[JU?S2?]*Z\!\>/[W''[2_Z
MTO+ZHK,?/65C^)97T1\\ [<\9IPX$$%6AJ1QON@H:J(Y$;6S$ 9/BY!'ZJK\
M#CD9X84KT5J.*W">BN;O]AD!<W(S@]/O7)BJ4FHU(*[B=&%J*,I0EPDK>?<:
MNS^J@HM3-FJI611B-P+WG XCDOIM#K(*V_=UHYHY6=Q: YC@1S/!1^K$/QJH
M?1EW<2[+-X<<+XM^:#V\25HJ*][[Z^^UK&/OI>Z]S;=>Y*-$ZC99)7P5A<:.
M<\2..X[K^B[M58-+W"?XU3W!D;'G><QLP \_ JNQV^=&G=&!R5*F&VI;<).+
M9K2Q#C'8FE)?O>235PLD#8FV,[TL8W9',\9AZ'/5=G26I:1UK9:+LYD;-W<:
M^3&ZYG0GJH"0#GSK(X9QP4SPT9TU"3;MWD4Z\J=1U(I;^[AN+!FLFE:%_P :
MEN+)86^,(>ZAV?-U(\RW;[?[;7Z6G^+5$3)7QD,@+QO#![0JQ;P)(YE9:XMS
M@X678[M.<VVF:]KV5*-."2:)?L[O\%KDFHZV0,IY79;(> :[';TSP77K;?IF
MBJC<Y:QDAWNZ"&.1I#CGL',JMP &EHY'B4P",=BO/"J51U(R:OQYF<,3*--4
MY14K<+]Q8>M[M17+3<0I:F)TCGLD[B'@N8,'.0%\=':EHS;&6N]O:(MTM8YW
MS2./ ]% O/VHUH:"&C /,*%@J?NO=7[[EWC*CJ^]\K:EF0V32E)+\8^.POC!
MWA'),"W/ZG[U"=1RT#[N^6T1N9!G> /:X'F!T7)P,Y[5AK&M)( !/-7HT'3E
MM2FV95:L:BLH*/R6_J6PZOLNIK!%!5UK(7-PXM[H&N:X9]ZA%$RCMNM(NXU3
M'T<4PQ+OY&,=IY+@8SS3F2>T\U6GA53VDI.S[BU3$2J6DTKJV_Y$RVD5U+7U
MU$ZCJHI=UCLNB>'8XC"ZUKO]JOUH;;;X]D,[0&ESW;H=_:!ZJMB,@#L')>FG
M=Y*7A(NFJ=^'!D]JG[R52R_EQ7<RS:*@TOI^7X\+@R:5@)9O2@EOH YE0_5-
M^=?KNR9@,=-#@1M=SY\7%<'M)[>J-\5V\W@4I8;8EMRDV^96M7<X.G!*,="Q
M=HMVH;A9(H:*K@FE[L'$,D!(]2X6S>KIJ"^54M5/'"P1%I=(0,G(X<?05%@!
M@#L')!P+B.;CD^WWI'"15%T;[F3/%3E6]]9;CO:XJ8:O4U7-32LEB<&8>PY!
M\4+A(. QV!%O".Q%1T,92VI.6K;ZD\V972BMU)7BMJH8"Y[-ULCP"X '..*A
M=4X.NTLK7 CNY(.>!&]S6N[QL;W' ('WI_'O?Q=52%%0G*HN\M*I*5.--_\
MC?U98VT&Z4%;8F04E9#+()@XM8\$XP>Q06SW"6UW*GK(!ET3N+<_.;VA:1 .
M#T& L@XY*M##QI4W3XIEZU>56I[Q[F6=73Z<U;30RU%2(*EG9OACQU!&>215
M^G=)T4C:*H%14/P7!KPY[B.6<=BK(DDK"P[ OZN3V=#98V2_FHK:U))IFY,?
MK"*X5\C(NZ/D>]SB &Y!P,KZ;2*RFKKU%-1U$<T8C )8X$ J+C@2>U8P./G7
M3[B*J*HNY6.;WL_=.D^]W+ V:76AM])7?':F&%SY!NM>\-)X>=0N\2MFO5=+
M$6N::E[VD'F"3A:>..3S66^+\W@HIT5"I*HGQ%2K*I3C3T+'U!>:&;1+*:GJ
MH)*EL<0[FUX).",\,^E5J!O.+N6<<%[;XH;N\,<EC PIP]%4(N*=]]QB*LJ\
ME)[MR71W-^PRQ0WNA?*]K8V/!<XG  RK)U)\G[\(14W2!IB)(W)FC.54X X^
M<8/H1S0X@D<N2I7P_O9J:DTT7P]=TJ;IM)W+-LL>F-/R25E-7LEEW2,F0/=C
MM  4*U7=C>[U\9CC+(B!'&#T':N,UH:, <%[WCEISQ;R\RBEAE";J2=Y<R:N
M(E.'NXI*/(M^XUNG;O1,IZZX0;@W3@3 8(]!7(ELNC"UV[71;Q&/Z5_ZJM-T
M9Y(6MYGL[5E#!."M&HT;2QNV[SA%OY&TZ#XW>(Z>F&\PR=S9CCD9PK VCUD=
M%I^CM4!(+RT$?V6_^N%%='UUOMET;4W!LFXQN(W 9#7=I/:M/4-VDO-SEJG\
M&?-C9]%HY>]7G3E4KQNMT>_F84IQIT913_E+=Y=]_F<W@'$=/]43F23S*+L,
M#R_YJE6H_P"IVF_3(HJ_YA4JU'_4[3?ID_U7/6_O3^?^,UI?TJ>7U1%UZ9C(
M!Y'.?]%Y08PNA&,E=%@;*:\/AK;<]WCY[HP'IR/MPH3=Z1U!<*VED&'1S8'G
M&,C]5[LE?+:KG%54P)>UWC-^D.T%=?7%?;KC6T\]O>Z64MQ,=W [<#CV\EQQ
MA*GB6TOXR^J.B=2,L,DW_*+]']F6#:&T\VB:0UI;\7?2M:_>.!@A<"BCTUIR
MLCFCK&SU#SW-@+VN[GD\_,/.O-3<:1VS<4O=XVU'Q9H$0.3G@J]R71-:?F\#
MA<N'PSJ;>TVE=[CMQ&)C#848IM);]"8[2*^CKJVC?3544S61G+HW X.>"Z5J
MU/:KS;66_4 _;AK=XN^8[H[([<A5R&[S7M/+L"G-@KM,5ECCM]UB^+.C_B=G
MGVD."WKT(0I1C9NW>N*.:C7G4JSFFEM=SX,ZMJGT];+K216:$S5<\HBWVDN#
M6D\3D\EH;5(WSW2V00MWYGM+ T=I+F@+<HIM(Z>WIZ*?NU0&^* XO<,]@43J
M]1U$VH6W62-CA$?V,4AX-'83CM[5A1I2E5]Y%/<N_O9T5JL8473G;>UNCW+[
MDKUK*VRZ-I[9%AKY<1^+T'%Q^_&/O5;QX8]ASP'$Y72U'>JB^5C)9Q&UC&;N
MY'G=YY)XKF-<6\!S7;A:+I4[2XO>SCQ515JEX_U6Y?O4LG7%VM]9IB*GIZN"
M24/82UKP3P!RHGH:>GI-2T\]5,V&$!^7O=@#(X<5P3Q:&D# Y>9  ,X44L+&
MG2=-/B34Q$ZE157Q7<2S:554MQNE-)05,<S!!@NC>' '>\RZ^SBZT-!:)65E
M7# _NN6B1X;GAY_O5><R2>966^*#CIC[DEA8NBJ-]PCB9QK>^MOT[M"3Z.J:
M6EU<ZIJ*AD5.629D<[#<D\.)7G:+54];>VS44\<\0A WV.WAG)Z*,-:&_-&.
M.5ZQGGURK+#Q515+\%8K[^?NW3?!N]R=[,*5S)*VX%H$3&B(.([>))]1"BFH
M*[OE>JRI#BYCI"&$_1' +NR:EI*72,-NM3'MJ9!NS.<,$<!O'[U$0 ,@# 5*
M-.3J2JS5NY?(F=2*I0I1=[;W\W]@>16'_P#4LK$G^I78CFD2_7?^Z-.?W0_H
MU1$\BI;KG_<^F_[I_HU1-<V$^$O/ZLZ,4O\ EMR7T,C&Z0596SVHCK]-5=L<
M6AT>\P _1<.!_55G@+J::N[[-=65(QW+&Y(WZ33_ *@J,52=6FU'BMZ+86K&
MC44I<.#^1S*V"2CGJ(I&X>QSF$=<$C_1708J2HTK3P7-S64;Z>,.+B!Q(&.)
M\^%6FMZRVW"[/GMSWNWHSW3AXI=YO_?8I/JBXT;]#0P4]3&^?<BS&'<>&%RX
MF,JWNGO3OT-\+*-#WM[-);N9]K5\F]-7"/N%<V>HGRTO[H';C1U/9R4=V@5T
M-=?H)[?.R3N<0+2QP<,@J+M\4''#/18: PEPQQYKHIX50J>\<FV85,3*5-TX
M127(LFW:BM-\M<5+?AW.4 9WQXI<.T$=J^UGJ[!;KO%26>%LE5._==(WQ@!S
MYGDN;;*W2]PLU-17%@H3",#/ D]I#ASRMJAFTGIT25%%.)JC& &DN?CH,CA[
M%YTZ48J4(J2OW=QWPJMN,Y3A96W]_P"]QH;1:1]3J:WTT(WG21!@QSXO)RNE
MM&JH[;8*2T08 D ;@'!#6]OWD*)/U--\HS=@R-TC061QR9PUO+L[5IZ@NK[W
M7?&JG<8X,# QF< 9/5=D,--NFI<(KU.25>%JCBM\WZ=_4UK>YC*R)[R&M$C3
MD\ ,'BIWM*NE%<+71Q455#,\3Y<UC@2!NGBJ[#6EN.;?.O623GMQA=4Z"G5C
M4OP.:G5G&E*GXO\ "2;.JZGH[[W6JFCAC[DYN\]P ROEKZI@JM15$U--'-$6
M, =&[>!P"H^&@ @#@4+00<CFGN5[WWM]]K%O>M4_=+A>Y9.A;O04FE7T]55P
M13;S\,<\!W'S*.;-:RGH;VZ2JGB@8(B"Z1VZ,_>HR0#S"SGB[^T<GSK/LD6I
MIO\ L6[1*\)>#UX?8[NNJFGJ]0U<]-*R6,M;AS#D' ZJ3;*J<Q4EPN,N!$0&
M-)Z-R7?Z>I5V&YR.33SPI;7ZCHXM+TUKLK'L>]NY.7#&!V_>2J8BG/W4:,.2
M\B<-5BJKK5-S5VOF]Q'[I6]\+O6U9SNSO+FY]BTSSX)R(QV<0B[$E%61S[V[
ML\R?NW^A2G:!^_M7]RC_ %*BLO[M_H4JV@_OK3_<H_U*PJ?%AYFL?AS\B,)C
M((\R!!V^<8709=Q8&RFL9-3U5"]Q\4;\;>HY%0F]TC[?7UU*]I;(V0\#T/$>
MQ9L5PFLU=%64N28SXS1_$WM"[.N+C;+I7P55O+G3%F)3CAYL^?L7'"$J6(<D
MMTOJCHG*%2@H7WP;MS3^Q(M6W>@J=$PTT%5"^H:(06->">!&>"@=#52T%SAJ
M:7&]"=X#KU'WK5:-YKCT1IQRX>=;4:$:47#BF9UJTJ[4WN:5NA9=35:>U;%$
MZIF%+5LY[S@Q[?-YPM&NMFEK;;9PRK^,U+VY:6O#W@^8!0+.22>:'B"#R*PC
M@W!VC-J.AO+%;=W*";??^#M:0O8LET=4.#C%*W<E:WGSX. [<=/.IA=:'3NH
M*A]<ZX11..-\B1H) ':/8JT P6D?P\O,L]C_ .T<N\Y5ZN&VY^\C+9?(SH5G
M3I^ZFMJ.C^Y:EAO%@MQ=;J2>..",;YGED $CL]A/-026Y_%-75%= 1+%'5.E
M\4YWF\0?U7&QU 0'GCM&$I86-.4I7;VN):IB95(QC9+9X6+2N)L&I:2"HGKH
MXI(AV/:' 'L(*]Z<OECH8)J&EJ8(J:$X#WR#]HXY)()YJJAP7G=&2<<UB_9Z
M<=C:=NXUACI1E[S96UWO4[]AOILM\?4M'=*:5SA(UIYMWC@A3*JI=,Z@E^//
MK(HI7#QG-D:UQ'9D'DJPZ>88^Y8 P"!R/-;5<*IRVXMQEJC&CB'".Q-*2T9,
M]8#3M/01P6IK9JIN U\3MX#KO'*^VS>]TE#%54%=,R)LKNZM<\X!X 8R?0H*
MQH8<M&%Z' Y[4>%3I.E)M\R(UW"K[V"2Y)65B4:LM5GML44ELK6RROD(?%W0
M/W6D'CZUW;==K?'L\?2.K(!4MIY&B/?&]G!QP5=$DG))SRRO(8T C P5$L+M
MP4)R;L^):.(V)RG"*5U:W<2O0NI662:2FK7$T<Q#M[F8W8_1=^:QZ5KJA]4R
MX1QL?Q>QDX#3[<A5NSQ7;S>#NJQ@=$J852GMPDXM\;=XIXAJ'NZB4EW7[N1/
M]5ZGH8;3WHLKF.9NACGL.6M9V@'MR."];/;G145GJ8:FJAA<^;Q6R/#21N\^
M*KX@..7#)3 (QYL?<CP</=>[3X[[DK%3595K<-R7<D?1Y!>YQ(.]-O ^;/-6
M!M!NM!6V&EBHZN&61LK26,>">1XJO.9!/9R0\3D\P,+6I14Y1DW_ %,:,W2A
M*"X2270%=?2E3%3:BM\LSVQQ,DRYSC@!<A.OG5YQVXN+[RL9.,E)=Q,]I5?2
MW.KHWT<\<K61.#MQP../F6[LXN=#16*LAJJJ&&1T[BUKW@$C= S[%7_TO[7
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MCIZ3P7"N=947&NEK*IV993GT#L"JZ<IXC::W1]63&JHX?W<7OD^B1\$1%UF
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M_5C/QGWI\G[']6M_&?>M<QIZ/I^2F65M5Z_8JC=!;XPR1R3B[B\9=R^Y6O\
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MZK*PBLBH1$0!$1 $1%("(LH#"(B (B* $"(@"!$4@(B( B(H 7=MG]#C^_\
M4KA+NVS^AQ_?^I6<^!:)M(B+(L%SKS\R+[_T717.O/S(OO\ T5H<2&<H\UA9
M[5A;HJ$1$("($4@RL(B RL(B (B! 96$1 96$"* %']?7V33>DJ^Z00F::)H
M;&T#/CN. ?0"<J0(0""#Q"@D_.FS#7%CTS'75UWI;I5WRO>73S-@! ;G.Z"7
M?>M*HU[;9-L4&IA35OQ)D088NYCNA.X1RSCM7Z7W&]K&^I5E4Z2NS]M=/J%M
M-&;2R+=,F^W.=PCYO/F>BHXDIDUTSJ.CO]A%WIVRT](YQ;_M(#"W!QD\<!<2
M][,M+7NXU%QN%$]]34G>?(V9XR<<#C.%U-<Z8IM6:?GMDTKX X[\<K/X7#ED
M=HX\57E##M3TW3BW4M/07>EC&Y#/(X$AHY#YP./2E]233MAJ]G.T^W:=HZV:
MIL5T<T-@E\8Q;SL<#YCT[%> &]RR3VX&55.C=#7VKU>W5>MZF)U=%@T]+$<B
M,]G+@ !V976VNT&K*^W43='SRL>V4F=L4HC>1_"<DC@"I6Y7*\3M[0]02:9T
MC7W*GB,M0QHCB:.QSC@.^[.?N5,[,=<V33%-6U=TI;I4WRO>7U$[801C).Z"
M3Y\G_P!%?=ACK8[%017=S9*]L+!4.'$&0#C[5O;K?H,]04M=X3/S/)KRW';-
M'J@4U9\1;'N]R[F.Z?NRWEGJOT#I._4^I+)%<J**:*"1SFALS=UW XY*$RZ0
MNSMN$6HQ3,[SB/=,N^WGW(CYO/FK. &.  'F41);',%1/:3JH:5L+IJ=G=+K
M5N^+T48&7&0@X/H'!2P<^'M5?6W3-SN^T6HU#J:G;%1T0$=LIC(U^#],XY'A
MG[U+"(EIN&_6>ZC2.G):5EZ=#WPN]QJ6=T(>[DP9SR!:/22IUL[U+<+G67BR
MZACB;>+5(&R20CQ9F'DX#LY>U<O45HOMAVA3:IL%O[ZP5M,*>JIA*V-X<,8<
M"?Y6K:V=Z?NL-VU!J&_0QTMPNSQW.F:X.[BP9(!(R"<D</,JKB23[CDY]'%
MJ<V2W'4L^T;4ENO5?+5TM*QXE!>',:_?&[N].&> 5Q^GB5:+N581 BN0$1%
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MP=W4MT;9-/7*YNQBEIWRC/:X#A[<*JMAVF*:]4-=JK4-/'75E=.X1&H:) T
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M +"(@"(B (B( GG1$ PLY)SDGB@"81 QZ$ "!9Y(#'5!PST/-$4$A$120/\
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M;220YXSR\P7RV)T;J+9I:8WQNCE?W1[FN&""7GL4X'//:%DDDY))*FV^Y%S
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M-0POIYHYF XWHWAP]8)7U7)TG8*33-AI;50M CA;AS^1D?\ Q./G*ZWI5D0
MM2>YV^G>8ZBOI(I/HR3M!]1*J_:EJF[UNI:716DI3%7SX^-5#78+,\=T'^$
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M#B"X D<L\5GF<]O5-DFX6$1614+*PBD (B* %W+9_0X_O_4KAKNVS^AQ_?\
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MX6YSXS\8!:'-+B?6,D87+VE7BFVC:HL-@TQO5D<$YDGJ6 [@!(R<]  3E47
ML6GKR]W*R62&LL-K?=YY)6L,+ [(803O<!GL"@/A*UMR&@ZD?X9?_M5PPL$,
M3(F$EK &@]0%Z!5RIQ](W.MNUAIJVZV]UNJY"=^G=D%I!\_%594:&UC/M&U!
M<+?5,M='<"X?'6/#WF+(PUH!R#P'3DKK))\YRJSIMJ<5OU5<;3J^A-H$;_\
M9I3E[7-["X^?@00$?,E$8U38=::#H>_U!JFINE/3.!GAJ-X@-)QDM)((R0I'
MM O8U!L-J;M3,+!50QE[!QW3O@.'H!X+0VL[1;#6Z2J[/9:IMRK:X-C:( 2&
M#>R2?/PQCSJ1Z=TC*_9#!INX9BJ)J0AX=_ YSB\9]&1E57(DV]CK6-V;6'N0
MX& D^G>.5&_A)M:= 0%P!<VL9NG[G9_]^9<G9+K2ETM0U&EM82.MM912N[D^
M<$,+>UN>SCD]#E:6T2],VF:BM6F=,/=/10R]UJ:H-.X!RWNN ,^M1?=9 N/2
M+G/TM:"_.]\4BSGG\T+?K:J"AHIZNKD;'3P,,DCG'@T#M_51G7&K:#05BI):
MFGFF8XMIX8HL ^*WF2?, O5PIJ+:)H-K89ZBFHKE&R0/#1OL =D@]G,*Y5$(
MT-25.T/6M1JZZ1.[S4+NYVV!XRUQ!^=CS8R?/A:ESR?A-T',GN3?_)*Z=/L6
MIZ:$14^JKW%$WDR,AK1Z "J\J]%"+;'2Z=[]7!PDC#OCI=^V'[,NX'/FPJ.Y
M9'Z=(QG/!4W9/_PC[U_=S_D"LK2=B&G;*RW"NJ:[=>7]VJ#EYSV*MK)_^$?>
M?[N?_+"L^X%Q(B*Z*#JB(C 6W5?T&F]/O6HMNJ_H%+Z?>JOBB343L1 I1!E8
M"(K (B( BRBBP,(B)8!$64L#"(B (B)8!$64!A$1 $1$!NUW[FF_E]RTAR6[
M7?NJ7^7W+2'(*L.!(196%8@(B*0$190&$1% "+*P@"+*QVJ0$1% "RL(@,K"
M($ 196$!@\ENW+_N?Y%I'D5NW+G#_(J]Z)--$12 BRL*2"G]K]IN5JUA9M;6
MFE?5MH@UE3$P$D-:3Q..PAQ&5O/VVZ?=1[UOHZ^IN1'B48BYOZ9]/0*4:\UI
M2:.AH):ZDJ*BGJ9>YO?&W(B:.9/9GCR[>*Y<^T30=%2&O@JZ%\@;O-C@A F)
MQG'+@<K/@617&Q^FN5-MFK1=6B.NEI9)ZB/.=S? < ?/Q"E>TK2NJ+KM%M-V
MT^V&.&"G$0JI'C$+CO;SBW[^'G6-BM#6W6^WW6MSA[BZY.,5,UPP=S(R1YO%
MQE=C56T232NL(*"^6M\-CG9XE<SQRYW7'( =HXE0N&\DC]WT!K2WT$UPMVM:
M^KK8&F7N#B]H?@9('C$?<1Q4IV5:K^7&DYWW.&/XU"\TM5'CQ7@CGCLR#Q"^
M>HMJFE:"RU$]%=(:ZI<QPC@A:[><X@@9R. Y<URO@[V*KMNE:NMK6.B=<JGN
ML;'#B&@8SCSG*G=>R!XU!H'3NF[3/<+I<[H^Q4C^[-M;Y\PE_8T#MR>Q<S1U
MZL^G99M2:TJFPWZ[@214T<3GNIJ;DUH:!XH('FX+>K9#M+U^VWQ>/I>Q2"2H
M.<MJ)OH^CG]P*]:/=04^US6[-0?%F5)<WXL:D -[AGDW>[,8^Y1P8+-L]SH[
MS;HJZV5,=32RC+9&'AYP1S!\Q6X.8]/:JPV%'>9JE]&"+0;D_P")X^;C)SN^
M;DK/\W5:1WE2DMG8;)M[U<^J -1'W7N6_P QXP!Q]RNU4IM+M=QTAKVGUU9:
M9U12/_ID;,\"1AQ/0$'GU"E]JVM:0KJ42RW/XD_MBGC<'#U9!]:JMSW@GH"K
M/X0__#>;^]1?]2^EJVIT=]U=26C3]MK*ZE>2)ZIK=WN?1P'T>N<+Y_"'X;-Y
MLX/^U1<1_B4MW3")3LY_J%8/[FQ2)1W9U_4.P_W-BD21!4'PFI7-T;;(VD[K
MZ[+N//##C]5:EGC;%::*.,!K&T\8:!V#="K_ .$+;'U^SN2:)N\ZBJ&U#NH9
M@M)]H4PT-<6W;1]FKHR#W:F9G''B/%/M!4?^1-MQVQGM]*J/:MK26OEDT;I*
M,UMSK/V-3)'Q;$T\VY';U/8M/;'M+DHJV73=C?\ %Z@XCJJUW 19YAOW<SZE
M[V>7O9]HV@=W&]QU%SG -15OC>7./:!PX#/K1RON)2+"V?:8CTEI:EM37B25
MF7S2CD^1W,^@<ON6==NU+':XCHZ.EDK^[#N@J,8[G@\1DXSG"V=.:HL^I(YI
M+)6LJF0D"3#2-W/+F%"F;3WVC5]PM&M:'O5 '9I)V O:YN>;CS(//(]&%+*D
M!URW61?22[1X:AVG6RM,S+<Y@:./;C./-G[E?>G*F@JK#;YK*YIMKX6BGW1P
M# , >D<CYU6FU7:-IVMT;76RU5C;C65[!$QD )W?&!R<CS<,*4[*K;/IS9I;
MXKIF.2.*2ID:_G&UQ+\'T#L55Q!,U6?PB?\ AI4?WF']2M[26U.R:B%S<&5%
M%%01]WD?4 8[GO!N]P)[2."B&VS6NG+]H.>AM%V@JJMT\;A$QKP< G)X@!2V
MK;B46=L]'_833O\ <8O\J:YN]QLEB=6V:V/N=4)&L^+M!)W3G+N''A@>M171
M&T/2M'I&R4=3>H(ZN&ECB?&6OR'@8QR5DCEP/G]*E;UN(*=\)6MN/_8.IY])
M?<K$T1=[C>[!'6WBVOME8Z1[#3NR"&@\#QX\5W\GJ?6O+M[=<6#>?CQ03@$]
M@RB3[P1;7TFK8X:/Y%PT<DI>_P",?&0W '#=QG'G5-ZN&I&W>WS[58:M]B;)
M\VA<SN0=QQG&1GVX4\LVU>.EOE?:M<4AL]5%+^R?NET>[V9/,]A!QQ"Y6V'7
MUAN^D9K)9*@7.NK7L#! TD,P[.>(YG&,#JJO@2BW[?/35-OIIZ%S'4<L;7PE
MGS2S'#"U=17R@T]:IKC=IQ#3Q]?G//T6CM)4=LD[=";+:*6]AP?;Z1O=8V\7
M;YY,].>'F5-T^HK7KO4[KGKNZMH;12N_V>VL#CO>;@/-Q/,Y4MV0)7HJBN6T
M37<>L;O3&FM%%XE% X$AY .,9YC)))':KM'+M^]0:FVFZ(ABB@I;K!%&P!C(
MV1. :.P#@NWK74])I+3\EUK6231AS6-CB RXNY<^2+<@SO!>9I8H(7RU$C(H
MF-+G/><!H',DKC:,U)1ZKT_!=J)LD44A<UT<N-YA:<'.#R\ZHW7&OXM;7YMF
M%R[T:9C?F6=S3OS8YD@9\^!ZT;L$CLZGN-9M;U'#8K$Q[-.44G=*BL(.'D<,
M^W 'WJ[Z.FBHZ6"FIVAL,+!&P= !C_15UIC7&S[3EIBMUKN<4,$8Y]S?O//:
MYQQQ*GUHNE'=[=!7VV83TLP)9( 1G[BIBN\DJ'X0N8+SHVJCP)F5#MT]O!S"
MKJ'(=2%2NUS-ZVIZ/LD.7.@<V64 9P'/!_1JNL\ST4+BR&865A%=%0@YH@YJ
M ;E=^[@_D6FMRN^9!_(M,*(\"0B(K(@(B*0$65A 91%A $0+*@&$1$ 1$4@(
MBR@,(BRH!A$64!A$10#;M7]+_P )6J[YSO2MNU?TK_"5J.^<?2H[V69A$"*R
M*A$64!A$12#*PLK" !%E8"@&5A$0!$1+ (B*096%E84 RL+*P@"(B +N6S^A
MQ^D_J5PUW+9_0X_O_4K.? M$VT1%D6"YUY^9%]_Z+HKG7GYD7W_HK0XD/@<K
MM*PLGF46Z*F$640&%P;OH_3UXJ347.ST=1.><CV8<?20N\BBP-&T6>W6:G,%
MIH:>CA)R60LW03YUO<P1V(BD$9K]!Z7KZHU%78Z*29QRYVYC/I X+N6ZWT=M
MI6T]OI8::!O)D30T+:1$@<^HLUMJ;I#<JBA@DKX1B*=S<N8/,>Q;%?1TUPI)
M*6NACJ*>08?'(,M<,Y_5;*<$!'K#HZP:>J'SV:V0TM0\8,C2YQQT&\3@>A2!
M$46 7)O>F[-?&@7>VTU81R,C.(^_@5UD4V!'[1HS3MHJ!/;K-1PS-Y2!F7#T
M$J0YQU]*PLI8',MMBM-KK:FKM]O@IZFIR9I8VX=)DY.?OXKI(B@ ?ZJD;.W4
MVE-=:IKZ;2]7<*>OE_9N:\-& XD'SJ[@LHT#FZ<KJNY6>"JN% ^W5,A=O4SW
M;Q9@D<_/S6E=]':=O%0:BY6:CJ)SSD='@G[QA=X9[2B6)-"SV>VV: PVFAIZ
M2,\Q$P-SZ>JWP!V=G1 L\%)!'+KHC3-TJG5-?9**:=W%TFY@GTXPNQ;+=1VN
ME;36ZFAI:=O$,B;NA;2)8')O6G+/>YZ>:[6^"KEISF)TK<EO'/J]*ZP'F1$!
MP[YI2PWV7NMVM5+4R@8[H]GC8](XK:LEBM=CA=%:*"GI&..7")F,^DKI+(2P
M1A%E80!<Z\V2V7J$17>@@K(QR$K,X]!YKHHHL#@V31^G[)4=WM=HI:>8<I6L
MRX?>3E=X^?BB*; X]]TS9;\6&\6RFJW,&&OD;XP]!'%?>RV2V6.G=!:*&"CC
M<?&$3,9]*Z*)9 Y][LMMOM&*2\4<573AV^&2#(!Z\./:MNEIH*2FBIJ6)D,$
M+0QC&C :!V!?590 +F.L5JDO+;L^WTYNC!AM3N>..&.?H721&"-ZWO5XLT-(
M^QV22[OE>X2AKMWN8'O4 T'0:@K=K=;J*\V2:VP5$#FX<06@[H &?N5R!8X]
M579 1$"L@$1$8"VZK^@4WI6HMRK'^PTOI*H^*)1IH$171 1$4D&5A$4$A96$
M0@(B*0$194 PB(I)"RL+(4$!865A %E%A2 A1%!)NUW[JE_E]RTAR6[7?NJ7
M^7W+2')5AP 1$5B @1$ 1.Q$ 1$0!$1 $1$!E8194DF$1% "(B$!$1"3#N16
M[<^</\BTSR6[<^</\@5'Q1*-)%E85B#*PB*0?*IIH*JG?3U,,<L#QAT;V@M/
MW%1Z'0.E(JD3QV"@$H<' ]SX ]<<E)D2P,,8UC0U@ :!@ #  Z+X7"AI+A2O
MI:^FBJ:=XPZ.5H<#ZUL(E@1J@T'I>AJQ4TMBHHY@<M=N9P?,#P4BD8V2-\3P
M',>"TM["#PPO:SP2P-"S6BWV6!T%IHX*2%SM]S(6[H+NOI6AJ#2-@U#*R6]6
MR&JEC :U[BYK@.F6D'"[J*+ U[;04MLHXJ.W01T]-$,,CC& %L(B(&'-:YCF
MN <QPP01D$>A1BMT!I6MJ'3U%BHG2N.\7!A;G[@0%*44@T;3:+=:*?N-JHJ>
MDA^C$P-]:S=K707>C-)=*2&KIBX.,4K<MR.16XG! ?&CIH:.EBIJ6)L5/$T,
MCC8,!HZ!?9$4 ^%QHX+C;ZJAK&[]-4QNBD;U:1A5?L=FK=.7>[:(NC)'&C<:
MFDF#26NC.,C/8.WCYPK86  "2  X\R.U&B4<"XZ-TY<:R6KK[)15%3(<R2R1
MY<X^<K6\'^DO_P 7;=^4%*5A+$',L=AM5C$K;/;Z>B$I!?W%F[O8ZKZW>T6Z
M\T_<+M0T]9".(;*P.QZ%O(I(.!:-&Z=L]0*BV6:D@G'*0,RX>M=_YWSN(//*
M(A)PJ#2-@H*>M@I;321PUHQ4,#.$@SG!\V0M4;/])#_]7;=^4I.LI9 B[= Z
M3:X.;IZWAP.0>Y#@5)AE910D#*PB*P.;>K#:KW$V.[V^FK&M^;W5F<>@\UJ6
M;25@LLQFM5HI*:7&-]C/&]9XKO+"BR!JW*AI;I0RT5QIXZFEDQOQ2#(=@Y"X
M/@_TE_\ B];_ ,H*4(E@1AN@-)MP1IZW9!R/V07;NMLHKO;Y*&Y4L512/ #H
MI!D<.2W$46!J6RWTELM\5#;Z:.GI(P6LBC& ,\UPSH'21))T];R>T]Q"DZ)8
M$7^0&DO_ ,7;=^4%V88J*PV:1M)3-@HJ2)SQ%"SD!DX 6^B6!4^R6VU%\U)=
M]<W6)T;ZMSH:&-XP61\B<>8 #UJV$#6M&&@ #L'(($2L B(I("(G:H)-VO\
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1%@O
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MC*LAKN)!0'I$R.H6-X(#*+#G (7@<SA 91>0\'EQ7H'* (B( B(@"(B (B(
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M-RO.V#:+4V&W7":CT[1$]T+#P+6G=+B 1O$GD#P0'Z&@U'9ZB7N4%UM\DI.
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MQ !XEWF" _0-#IVT6^<5%#;*.GG ($D<0:X?>JB^%599:K2MNNT#2XT-1B3
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M2ZOVEZUO]X@CJG454*.C9*T/;$&D@D ]OBCUE 6=I;6%CU3!)+8J^.J;&</
M!:YOI:<%=\'(!5):]I8-(;7M)WFUL;2Q7)SJ.L9&-ULO/!(';Q'J"NT<D!AQ
MP.'-?GC53G:_^$'06=K1);+*W>FZ>*-YQ/WEK5>.KKS#I[3=QNM2X!E+"Z0
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MSG!8"T#TA3WP'7(?_KI<N/I]ZD^UW9DW61@N5LJC17VE $4W(/ .0"1Q!!/
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M\FG)(9W4=-,;A/3D.;@M( <1P)XX6-G5=3Z(VE:QL5\GCI([A4"MHIYG!C)
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M P.B(B 81$0!,#/)$0#"81$ 1$0!$1 $1$ 3 Z!$0!,#H$1 $P$1 ,#HF$1
M,#H%06U^QW2NVS:1JZ*W5=120R1&2:*)SF, D!.2!@*_5C" S@=$1$ 3"(@&
M!T1$0!$1 ,)@= B( B(@&!T"(B 81$0!8P.@640# Z!,!$0# QA$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M<Q>;34/P27%X=U <X;S78[.2LSX.4,;=D]K+&!ID?*YV.T[Y&?8%'_A7M:-
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M@$XWVO(!(':"OTBSYHQR7YU^%FQK:O2L@'C[\@SYLM*_0EO.:"F)_P#E-_1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M/]%NHB J?X1^G:Z_:#:;;#)434=0)S'&-YQ9AP.!VXRN%L_VQPOI[+8ZBRW
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MW?86[V \<,KX[8K[>-9ZA@T-IB&<4SI0RLJNYN#''M&>6ZW)SU*OYL8;G=
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M+EKVD$>.>PJ/_"HIYZK0=$RFADF<*YI(C:7$>*[HKE8T,;NM  Z!>71AXP\
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MH=G/'/!<V2P6B2;NK[91.E^F8&D_HNFB \LC:P ,:&@<  ,87I$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 6-T9640!$1 $1$ 1$0!$1 $1$ 1$0!$1 >#$T
MO#N.5[1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
L$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g843142g26g26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g843142g26g26.jpg
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M*"@H*/_  !$( KT': ,!(@ "$0$#$0'_Q  <  $  @,! 0$
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ML7_3R/,IZKXBU-#>F6SEGU--<JU\5NIK<V0A[SL-W1<&^DY[..5+7S5%)?\
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MFXB(L5Q$1 1$0$1$!$1 1$05#E*L=YN]LI9=-UTE-<:.7G6QB4L9,/RN[#O
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M5EQHZRK!DIX:=Q;'&,G9R 1Q^'^JV'KZSRW[1UUMM/CGYHO[L$XRYI#@/W(
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MS;YL,VMQ=Z-KAG]U,5XVS.'QX?;C;_-C9HOM([26AAI_1ERL'2'E'EAE_O\
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MJ0WDCB\F%*[4]]-)L[',B8!NSZ,<,?LKSIG4%NU+;W5MGF=-3-D,1<YA9YP
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MJ]C\7,3-?L_K@I<KM;K8&&Y5])2;?X>?F:S:_3)WJVS-[6XHO'-FHL2>YT,
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M:@$[)9KY*POYK:<X%I+1M'L_T'%6W2&E[Y47Z_:CU ([;<KA!Y-3QP/#S ,
M;6=XR-EN/W4+<[-RAW6PR:7N$%'-322C;NKYP2Y@?M#S<YXX[.&[XK2C$B,2
M)VHX1%^/VY_>RLT_IGASNV[0N8^BIW0S<_&8VELN<[8QN=GX\5K*/4NKKUJ_
M4=CLDEN@90O\R>>,DL:,C9P,Y).-YX8*V/9:!EJM%%;XW%[*6%D(<>+@T 9_
MT50T9IVY6S7FJKG60M91U[VFG>'@EP!/8#D?NN+!FBF*YFT]+_NVKB9M"GVO
M6FM;WI&ONU&ZV4S+4'<^]T9+J@M&T0!P;AN/U*F+MRB7)^E=,/M-- +W?7<V
MP/!,<9#@QQQGM<1C/#XK]T?I"\6WDZU-::NF8RNK7S&!@E:0[:C#1O!P-X[5
M"7W353:]&:/Y^MH;=J&U2O?!'4S-:R4\YM;(=PS^$\>TKMM@55VB(Y\.W^+L
M?UQ3?[?RF:G4FK['J[3MDO4MNJ(JZ7#JB",C;:2 6X.,$>D#?D+,J/\ VKRF
M7^?\45GM/DS?0)) 79[N0JK>I+_5\I>BWZB;10U)ERRDI';7--!!+G')WG?\
M,-5ZT79J^*WZGJKC3NAKKK5S2-C<1D1XQ&,_-4Q(IPZ8JX7F/3[S_I:F]4V^
M_P##6/)SK"MH]/VS36FVP.O-75O<Z2H']W$SC^YP"?V])"V'K74U[H;S9-,6
M)],^\UT>W+53,PQC1G)#>S\+CV[AVJIVWDON5/H:-\5-'2ZKI:SRF"1LC27@
M8PTNS@>D?$?%2FN*:X.ONE[Y3SV^CU5%$(W6^IG:T39)!#'9P=[G#&<X<.U:
M8GDXF+>FT\^_I/[*T[=--I^WS]V=:]3:HI>4BVZ9OIH'QR0/D=-3L(YT;+R'
M#/X3EN"/@MFK2MM==Y^7*SRWXTOEGD3W.AI27,IV[$@#2>T]I_XENI<?BZ8I
MFFUN7I^6V%,S$_N(B+D:B(B B(@H/+G/)!R<UXB)'.R11N(]&V"?^BIVNJ6"
MU6SDWJZ")D4\3X0',: 7###O]._/S/I6U=9V&/4NFJZU2/YLSM&Q)C.P\'+3
M\P%0;7HC4UQN6GX]4U%OZ,L6#"*<N+YBW&SM9'^ZWT?IO7H^&Q:*:(O-K3/Y
MO%G/B4S-7".=O\ML+1.L],&QZST?65=QJ;C<*ZYM,LTQW!K9(]EK1V ;1_A;
M9I(M0#5];+4U%,[3QA IXFC^];)AN2=W#.WV]H4/K_2]=?[YI:LH70-BME9S
M\XD<02W:8?-P#D^:?0LO#5^57QGA,?Q*V)3MT\EU6J6W?5=[U_J*P6N[PT5+
M2AKV2OIFO=&,#S6[M^2>)S@!;65*TUI>NMO*#J&]U#H#1U[6B(,<2\8QQ&-W
M#TK/ JIIBJ9M>W"_6ZU<3-HA1;)J'6]]TK>*R.\4U(;*)"]XIFN?4N:"X@YW
M-P!V#?G>I2Y<H5V_[-]/5M&V(7N[RFF:\M&RTM>YA?CADD#=PW_!2VDM%W.T
MZ4U5;:I],:BYNG,!8\EHVXRT;1QNW_JJ[J32\-GY++';K[<X+=<J&I>ZGJ6M
M?)%SCGO>&DAN0"-^<<0N[:P:Z[6CGZ1Z6_VPM7%-_M_+)U!<]9Z4NVG*.NO<
M%=3W"K8Q\K:5C'#SFAS#NX8=N(P>*G/_ 'KRM7*7C%9K8(1\)9<NSW<A4+4L
MMXN.I-&=,7BV7"J-:SFX+<=IK&[;"7N/I=^F-WZK:.B['74+]25ESC;'67.M
MDD8 \.Q$!B,$CX$JF+$8=$53:\Q/+AZ_Z31>JJWHTUR>:NKZ.QT6F-/RQ4UU
MKJ\N=53@%D3"&@  [B3@_P#3B=VR]<WZ^4-UT_I:RUS1<Z\9FKYHFDAHSO#0
M-D<''AV#]5"VWDHJH] U%OJ#1Q7YE7Y53543CNP  TNP#C\7Z'!7TY0J69DN
ME:^ON]#:]6TXV6.D#S!/@@'SPW#=YSOW><?U6M=6#BXMZ;3S^_&W"?V5IBNF
MCC]OG[LJFO.JK3RF6/3MWND-;1U$3Y#*RG:PS#9>1M>@@M[#PPMJ+1UN-PJ^
M6G3\MSN5%<:QM,]TOD.^*G;L2 ,!_?._\RWBN+Q=,4S3RY>G[RVP9O$_N(B+
MD;"(B B(@*+U7#)4Z7O$$(+I9:.9C .TEC@%*(IIFTW1,7BSG^*NIO\ ['.6
M#G&<]Y1S6QG?M<^'X[N];ATC-#0Z;L%OJZB*.N-#"!"]X#R0P9PWB<8/R4:[
MDTTJZ\=)&V#GMOG.;VW<UM<<[&<?MP^"FZW3MMK;]17FH@<ZX4;2R&0/< T'
M/9G!XGBNS'QL/$BT7XS,_F?1C1153QG]E5U=)9-;VNZVZ&^3TC[67FI:S,0V
M@",/#AYS00>'S7WY%KK-=M"4KIZ>*'R=[J=O-,V6O:W&'8_?!^(*S-0<G>F[
M]<G5]PH3Y2__ !'12.9SG_$ =_Z\59+;04MLH8:.WP,@I86[+(V#  5*\7#\
MKRZ;_GTZ_NM335M[4M5Z]M]-=.6K2]'71"6FDI"7QNX.V3*X ^D9 W+"T]IB
MSS\M.HJ":WT[Z"FIVS1TQ8.;#BV/?L\/\[OFMJ5>G;;5ZAH[W/ YURI&&.&3
M;< UIVL^;G!_$4I-/6VDU#67N"!S;E5QB.:3;<0YHV0!LYP/PM6D>*M1LQ,_
MVV_-U9PKS?[M$4;ZBBY-==4UO+V01W)L9:TGS8R[9/S  /P6;R@6O3%+R666
MIM;:1E?((MF2(CG)<MR_;QO._CG@0 MJ5NF8K/I^]LTQ;Z>:KKB99*>K<Y\<
M[B?.!R=V03V@9PM2U.DZVYVQMKMFA9;5<)Y6^45LLQ=$QH._8VB<#@=Q[.U=
MF%CTXE6W>T1-^<=(Y\?]L:J)IBW/@OLG_M3E!TC0_BBMEM=7R#LVG ,;G]#@
MK5VJ8;S/J?7;+0UQHV2\[7;!PXQM<=WZ;R3\ N@;3IRCMMVJ+E$97U<\$5.X
MO=EH8P8 :.S.,E?MOTU:[?<[E7TU-BIN/^TESRX/X]A.!Q/!<N'XNG"F\1?A
M'^;RUJPIJ:LY2*NB?R060Z=88+/-/&V1C.+1AQ+7>D[0W^DA87*M:]-6^#3#
MM/LI(YGSL_V<C^\BW8<[''?C>?25?K]I5MFT96V_2EIIJR.64224-7(]['CM
MV<N&R[<TC?V>E:\ATC4W:>T4-LT;/8XXZED];5U$I=D#B&EV_&\X ^'ZKHP,
M2CA5$VB)GUCUZ\?]LZZ9Y6Z-^HB+QW8(B("(B B(@+Q40QU$$D$\;9(9&ECV
M.&0YIW$$>A>T0:JN,4<'+Y88H(V1Q,MKFM8P8#1B7< ."VJHF;3MMFU'!?9(
M'&YP1&&.7;=@-W[MG./\Q4LML;$BO9MZ192BG9NT#H:P6VXZ1US6UU)%/4PN
MJ!"^1N3%AA=EOH.>WX!8;K#;1R#=+&DC=<G3!WE)&7C$VQ@'T;/8MVVO2EHM
M=NN-#14SF4UP+S4-,CCM;0P=Y.1N]"\'1]E.EQIXTKNB@<\USKLYVMO\6<\?
MBNW?HVK\;7B?Q'-CY$VM]FK]3&*OU9R>4U_>'6B2@CD=SKO,?*6[]K]2& _K
M\5]V4=HM_+[:(K&V".$4TCIHX,;#).:ER !N&X-./BK'RF6>J?;[3246G*>]
M6BF 8^';<VHB P 6.#@=X&.W@,JOZ1TE45VLZ>X1Z?FT[9Z.CDIVL>_,LCWM
M>TNW[\^>=Y_*%>C$IG#VKVBTQ;A]_3G?\*S3,56MZP]48-;R9:YOKN-UGGD8
M?_Y33LM'[><JGH02PW_253J^'G+1-$Z*UESO[N-X=N)'I+O3Z0> 6]J;3-M@
MTL-/"-[K;S1B+'/(<YI.3DC&_)7PK-&6.LT_2V6HHR^WTI#H6<XX.81G>'9S
MVGM65/C*(BJFW"9[1:W=:<&>$]&OJZ"AN?+O54VI6Q2TD5$WR.*HQS;G;+3P
M.X[S(?U'P7GDU@MU-RQZFALI9Y RE(C$9RUIVH]H#X!V0I'E)M%74WJB-3I1
ME^M$40:V6"1[:IA&<M+@[>,[]X[3VKWR6Z<K:;5-WOM1:.A:.>%E-2T9<"X-
M&SDGN#CQ)*TFN/)F;_\ &(M>.O>_X1LSMVMZMH(B+RG4(B("(B B(@(B("KV
MH+O:I:WJS4W*:BN-?"3&8@6/#3G>U^-D'<<=JL*@M4Z3L^J(HF7BD$KHL\W(
MUQ8]F>.".SX+3"FF*OU\OLK5>W!1.25PM&LM3::I7LJZ.G//BLV1SCG9 +7N
M'XCYQ_=I67_:&_\ F)%_XV/_ ,KU=-,:8M.F:5\%FI&P-D.9'DESWD<,N.]?
M34NG[=J2WBAN\+IJ82"0-#W,\X @'((/:5T;Q3O$8OI%F?ESY<TM1\H>EK10
MZCT%1TE''##63<Q4<V-ETK=J(':/$DASM_Q4C#0067EO,%DIHZ9C[6YW,Q-V
M6EVR<;A\6M6R;MIRV76NM=770.DGMK^<IG"1S=AV6G. =_X6\5^NT];7:C;?
M3 [I-L7,B7;=C9W[MG..U7CQ?Z(IJO/"8_,RCRN-XZPTSR>6_3MPY/\ 4-=?
M_)Y+H))72SSN'/1G9!:6D[P2[/#B=R\V25[^1.CM<!Q/=KH*)F./G2 G_P O
M^JRJZSU[+K<9KGR>LJ[J\NYFJHGN%.YQR.<<PDC.=_9\]ZN>@M""@T[8&WL/
M%?;YI*IL3'@L:]_#:])  X=N5U8N+33&W,^L3;A/I/+CR9443/"(]%4Y7(*^
M'7NE:?3H#:YM,8J;. &G);G?Z!O_ &7YH>:.DY,=6QT<,D.IJ9LPKG..97'?
MAV>.X;7[@GM6UKAIVVU][H;O50.?7T0(@D#W -X]@.#Q/%8U3IFCI[C<KU:J
M>-EZJ8'1[4CW<U(<;MM@.",@9[5S1XJF<.,.8Y6[W]?LTG"G:FII\6O3 Y#_
M "[9I!==DGGLCGN>V\;/IQCL]&_XK;7)C_\ ,"P_^%8M15&G:Z6@KJ6+D\=3
M7NJS&*J*4FGC!.]S0XD-W9&X^"W;I*V/LVF;9;IG!TM-3LC>6\"X#?CX95O&
M51L6O>\WYQ_$RC!B=KEZ)9$1>:Z1$1 1$0$1$!47E-TI;[K;Z^\5YFEEHK?,
M((=O$;7!KCMX[7</DKTL&_4)N=DN% V01NJJ>2$/(SL[32,X_=:85<T5Q5$V
M5JIVHLU?8WOC_LZS&,D.\EG&[T&5P/\ H2H+5,43?[/VGRT %L['-(_,3)G_
M *E;5TOI6.U:(CTY72MJHN;EBD>UNR'->YQ.[LW.5.IN2NX.916NY:@-3INB
MG,\5)S(#W')."?W/IXG &5Z&'CX>W,S/*J_[QQ<]6'5:(MZ6;/MKWR6ZE?-G
MG'1,+L^G&]::LD=]U-6ZUC?J2YTM-;:J4PLAE()=E^RW/$- ;P&./P6[1NX*
MFZ5T;)8Y]3R/K&3=,3.E:!&1S62_<=^_\?\ HN7 Q::*:I]>%N[6NF9F&LJ6
M?45TY,*C4T^IKC'44#N;@BB?L->T.:"7D;W.\[B?1VJ<ONHKS?':(LE+<)+?
M)=Z5E15U,'FO.1O#2.'X7'=Z0K);N3^6DY-JS2YN$;I*AQ<*@1$ 9<#^'/P]
M*K7*':K=9+7I*FKKC5T%RH6-AI[G!!MQ@MV<AXV@1V$<>WBNRG$P\2NT=9MP
M]+</=C--5--YZ0^T73-@Y6=/V.6_U]?;987RAL\F7$;$FY^/Q8+<@G_T7V_]
MY3\I]X.^..G?;H3Z!'$=O_7!5?TXTW'E>L]127I^H)H*5\E56&/8C8=E[0T
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M^F1IK3U?#RE6B[4VEW6:SM@?%L!S7.:=EXVI,'.22!V[L*LX>'--4U6OQ_\
MGK_"8JJO$1?T2?(I_P"]=:__ $R/_F>L[EMKIF:=HK32O+);O5LI21^3._\
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MBTV_Y1'XM_TPIPYX7])EIWDNI;G6\E51#9J>WU-4+FXB.O8'Q[.PS.X]N]2
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MQO<='92+C7IV]>];C]P_Q3IV]>];C]P_Q3*:M7L;W'1V4BXUZ=O7O6X_</\
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MD%QIJ"6=K:RI:]\47%SFMQM'X 9&\^D*)?K73++YT.Z^VX7/;YOR<SMVMO\
M+Q_%\.*">YMGY&_).;9^1OR4;J'4-HT[2LJ+[<J6@A>=ECIY W:/H XG]ED6
MFZ4-XH(ZVU5<%922?AF@>'M/[A!E<VS\C?DG-L_(WY+$O%UH++025MVK(*.D
M9N=+.\,:#V#)[?@L:S:DLU[MTM?9[E35U+%GG'T[]O9P,X(&\''9Q02G-L_(
MWY)S;/R-^2^5OK*>X4,%90S,GI9V"2*5ARU[2,@A?=!YYMGY&_).;9^1OR7I
M$'GFV?D;\DYMGY&_)>D0>=AGY6_)%Z1 1%^.<&-+G'#0,DGL0:IY6ZN^7>^T
MVG=)5U325E#0S7BH?3O+2XM!;#$2.(<[.6GB %::375!)R:Q:QE9(ZC\D%3+
M'" 7-(W.:,D;P[(X]BI&B-,W/5=5>M8NOUXLDEWJG-AAIFQM)IHCL1;0>PD'
M<X]G'*KU?;ZS2^DN4?1$AJJN!M+TE;IWLWRLD($C?- &0\< .THELNFY3*"2
MY6V&HM%YHZ"YS-@HKC44X;!.]WX /.VAM=F0,J>T_JBAO4=W=$):9UJJI*2J
M94 -+', )=N)\T@Y!]"J7*=!(_3NB60Q/=S=]MI(:TG9:';R?0 JWRJ4EQM>
ML:JALK7MCUQ31T#WMX13L>&OD/PYASNZB&V-*7VGU+8*2[T4-1#2U32^)L[0
MUY;D@.P"=QQD? A:JY5],36*BH*ZWZHU4R6MNU/32,-T?L-9*\[0:!P^'H6X
M[=1P6ZWTU%2,$=-31-AC8/\ *UHP!\@J%RXPR36"Q"&-\A;?*)Q#6DX ><G]
M$$)RG66?17);J.LM6H=0RU,AI@V:KN#Y'0XF:#L'<6Y#B#Z5]!8-)'_]IUZ_
M_P E;XJ7_M"123\DE\CBC?*\F#S&-+B?[]F=P4$-2\D@_P#P#0Y__%U__P!:
M1*Y<I%YETQH"J?0222W&1C*&A+G;4DD\F&,.>TY.U^Q45R35EPM]9?-(W^NG
MKKC:96S0U,[R]\]/*-IIR=YV7;3?AN"B=5P2<H6N=/VVVUE;0VJVT@O+JR&,
M-=SS\"%H#VD!P:2[!&1GL*Q;]8;AH;6NG=5NO%TO4,TO15P-2UA='!)DL=YC
M1YK7[SG/8B$=:&6^\ZHUEUCUS=K4^EN\L%/3QWKR9HB !&&D\,DC=N5OBT=:
M[UHO4%HL^K;A=([C&(75-1</+1 X;P!@[@<C([0J/9;AHVUZKUNS6EIBJ*J6
M\RR0/GM+JG,6&C<X,=@9!W96S^3V]:3N+:RGT=21TC(BV29D=O=2-).0#O8T
M..Y! 5NBM47:EL5/<*ZQ4=-:*VGK&4UOIWM;.8W?YB3YN[. !Q.\[EL]%%T5
M^HJS4%QLT)E\NH&123!T9#=F0$M(=P/ \$&%K/5UOTC!037..JD;6U(I8FTT
M7..,A:YP&SG)SLX&,[R%A:;US3W>_P EDJ[5=+/<Q!Y3'#7Q-;ST6<%S2USA
MN)&1Q_U4?RI0OFNV@RR-SVLO\3W8;G9 BDWGT+S>HI#RV::E$;S$VU58+PTX
M!VF8!*#YZ;NEPO='JW4]&^23'/T=IIP26%D <-O9X%SY-K?QP&A5716I*:UU
MEKKHK[5W&C?89*^^\]5NJ!#.W8(."3S;RXR-V!CAPW*U\@C33<G5/;I=U5;J
MNJI*AIXB1LSR<_L0?W7WO]+!?=8TFGJ2")E#2N9=+N6, $K@?[B)V.)<X%YS
MV,'I03&@:6X,LKJ^].EZ2N4IK)87O)%.'?@A:.P-:&@XXG)[5&Z8KY[;KV_:
M8JYI)87QMNU Z1Q<YL3W%LD>3V-D&0.P.QP 5!T=6R/U#IUT5;5R:MFN56R^
M4SIWNV*<<[C;C)V6-&(M@X'$8SDJXRL-5R]4[H=[:&P.$[AV&2?S&GXX:2@V
M&B(@(B("(B B(@(B(*]K:[W.TV^F;8;8ZXW*KJ&4T0<'"&'.<R2N W, '[Y
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MJXY<.#8RT$%P=EI'IPI;D\D=HKD]L,6H8*B*NN580Z*.,O,<M1(][6NQP &
M2>!1#X-II]<Z[U-2U=UNE':;(8:2GAM]4ZG+YG,VWR/<W>2,@ '=\%@6ZNO5
MSY.;_'Y=++J#2MQGCAJB<&I-.=INV!QVV'9([<YXK(IKQ2:!Y0-6'41FI;;>
M'PUU'5"%[V/<(]B2,EH.' @$#M!61H)DMMT-JS4%V@DI&72KK+L(9QLOCA+?
M,#@>!V69Q\42OFG+M#?;!;KK2[H:V!D[0>(#@#@_$<%(JF\C5%-;^2[35/5
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MM/M\QD97MAV]G;)/F!W;L8X=JLVI;UJ!]XH+7I2W0.=44[JJ6X7!DGDT+ 0
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M):9]1&YDTX>7>>03N:=D;(QG&_MP$^I-37R]WBDT92VD45IE\FFJ;D9")Z@
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M:U@& /TPJ-R OD?R3V/G"2UO/-C)_()GAO\ H @V"B(@(B("(B B(@(B(!(
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M%?T!$1 1$0$1$!$1 1$0%5*?2=1)K7K!=[Q+7MIFR-MU&8&QLI!)@..1O>[
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M8K//,SRY[2&MCIX\.YIK>.7D-;N& -KX9MP :    -P 1$!$1 1$0$1$!$1
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M^1!\:*EAHJ."EI6".G@C;%&P'.RUHP!O^ 59M%EJ[-KR[U5)%MV>\QMJ)2'
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ME6I$0$1$!$1 1$0$1$!$1 6#':*&.]37=E.T7&:%M.^?)RZ-I)#<9QQ)6<B
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MQ/DE>UD; 7.<XX#0.))4%6:QL5%I^EO=;<&4]MJMGF))&.#I=K\.RS&T21O
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M_P!XA6=K@]H<TAS2,@@Y!"#]15W4FMM/::JHZ:]7..GJ'LYP1!CY'!G#:<&
MEK?B<!9LNH;7'2VVJ-9&ZDN,C(::=GG1R.<"6C:&X9Q@$]N!Q(02J(B B(@(
MB("(B B(@(B("*)U'J.TZ;I&5-[KHJ2*1VQ'M9<Z1WH:T EQ^ !7G36IK/J:
MGFFL=?'5-A=L2M +7QN]#F. <W]P@F$7SJ9XJ:GEGJ)&Q0Q-+WO><!K0,DD^
MC"@[GK.PVJQ45XN=P;1VZMV>8EF8YI?M-+AYN,C(!.\(+ B@-+ZRT_JF2H9I
M^YPUSZ<!THC#AL@YQQ ]!6+1\H.E:V\MM=+>J>2L?(8F !P8]XXM;(1L.=\
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MH+.BPK?=:.OJJ^FI9=JHH91#41EI:YCBT.&X\00001N*S4!$1 1$0$1$!$1
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M>F<YLOD;F MX@.(:?]"5&VWDMLUNY16WZCM=K@MT5"R.&GCAPZ.I;*7<Z!C
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M^72FM<CFG!$<CB7X_5K7#]U9+M8J":HH+F+>*FOM$<AH(Q)L-:7,QL@9V02
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M:V1M-": @R/+WN<Z%SG.<X[R2223\5=N4"\26#1-\NL'^/2TDDD6?S[)V?\
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M6@$LAN#7NB\HG:0!AA!+@P9&_=DKQH]UYTIRLU=%J5UN$>JHC50F@#VPBIA
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M1 1$0$1$!$1 1$0$1$!P#FD. (.X@]J^-'2P45+%34<,<%/$T,CBB:&M8!P
M W +[(@(B("(B#XBDIQ6NK!!%Y6Z,1&;8&V6 DANUQQDDX^*^R(@(B("(B B
M(@(B("(B B(@(B(/C/24]1-3RSP122T[B^%[V F-Q!!+3V'!(W=A7V1$!$1
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M$1$!>9HV31/BF8U\;VEKFN&0X'B"%Z1!\Z>"*FIXX*:)D4,30QD;&AK6M P
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MKC4T]ZN4A=_?3QF.GIV?XDKP& _ #(R3\$&[$7RA;Y-2,;)*^3FF .D?O<[
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M7/H[?J"JB:]S.=@M<LC"6G!PX#!WA6W3%^I]16]]924U=31MD,196TSH'D@
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M:<G=E2;0&C#0 /0$'/MNU_IK5EZCO.N+L::BI)B^W6,4LSV1D' FG(80]_:
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M;I:;5,;M+AHA.*/%8Z <(3)M;.,>;M;.<*SQ:39!K:@OE-.V.FH[6;8RD#.
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MXT72+Z::KV(J6G+B&/?)LY)=NPT-]/HW_M=RF26S3>I*JZV9U->;"8?*J$5
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M9:P9>]SW;FM QO\ BFC]5"_5-RH*VWS6N\VYS6U5'*]K\!XRQ[7MW.:0#O\
M@H"O\WE]M1F_PWZ?G;#GMD$[2['QV4MWG<O5Y,/^&RPT[9L< \S/+<_'90;$
M1$0$1$!$1 1$0$1$!$1 1$0$1$%-O&LZIFH:NR::L,][KJ%C)*PBH93Q0;8R
MUNT[BXC?@#AVJ4T7J:GU3:I:N"">EGIYWTM52S@"2"9GXF'&X\0<CL(49K'5
M,&GZMMOLEO;<=4W%NU#1PM +@-PEF=_EC'I/Z#X9/)WIF73-DGCKJD5=UKJF
M2NKYVC#7SR8VMD=C0  /T09NJ;^VR14,<4'E5?7U+*6EIP_9VW'>XDX.&M:'
M.)QP'Q41?=9U5/J.:Q:=L4]ZN-- VHJ@VH9!' UV=D%SN+C@D#'#M4=<G&JY
M=[-3S;X:*QSU4(/#G'RMC<1\=D?ZJ%?0W747*KJ>?2UU;IYUO@@HJR?F!4.K
M'ENVTF-Q#6A@. >)_1!L+1NI*75-D;<*2*: MD?!-3S#$D,K#AS'?$%86K-6
M.L]SH+3;+9-=KU6M?+%2QR-B#8V_BD>]VYK<D <<E0?(BX4UBN]GFB N%KN<
MU/65#7EXJI3AYFR=X+MH9'9A(O-_M S\[_GTVWF<]H%2=K'^B#/HM=/J[#?:
MEMFJ(KQ9'8K;7)(WG&C&UECAD.!9DM/;C&[BK9;*ZFNENI:^AE$M+4QMEBD'
M!S7#(*HFF0'\M6MS&,Q"AH63>C;V7D9^.ROWD*>YNBIZ+),-ON5720$^K;*[
M9^6<?L@V&B(@(B("(B B(@(B("(B B(@(B((K5-]H]-6&LN]S<\4M,W:<&#+
MGDG#6M':22 /U5>M.MZMU]M]LU)IZILDER:XT,DE0R9DKFC:,;MG\#\;\'CO
MWK!Y<]VE;8]_^S,O-$Z<G@(^=&<_#.$Y7?.N&@F1;Z@ZCIW- X[ :\O_ &QQ
M0;$1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 41JW4%'IBPU-UN D=%%LM;'$W:?
M*]Q#6L:.TDD!2ZUWRU^;;]*/?_L[-1T+IB> 9M.X_#.R@D;+K6KDU!1V;4E@
MJ+'5U\;Y*)SZAD[)M@9<S:;^%X&_!^:N:UWRH^=JKD\9%_M)O)< ./-B)^W^
MV,96Q$!$1 1$0$1$!$1 1$0$1$%&TG5OU'KG45T>]QH;1*;11QY\WG &NG>1
MZ2XM:#Z&_$K7NB;FRFNNG*I]=4#4#7ULFIVRS/(BB:UYS*TG# '!FQ@#=PW9
M5XY(6&BJ=:6J?=4T]^GG(/$QS!KXW?N"?DL[7+'WZ[6W2D37>357_?+F\#<*
M6-VZ//ID?AO_  AZ)??D[BJ:RFK-1W$2,J;T\310O/\ @4P&(68[#L^<?B\^
MA6JIGBI::6HJ)&QPQ,,CWN. UH&23^P6C9:=PU9.!!5#6?69KH9!')D6W;'^
M;\/,\UD$9QGXK<&K[9)>=*7FV0/#)JRCFIV./ .<P@9^&2B%._[42+:V^2:8
MNS-+.(Q="8\AA.!*8=K;#.W..&_"K>M)Y]2<KUGM%7:+C6V6.A-3%'3UPA9+
MM2,'E/FO!+6@XP=_H!"]3ZCJ*GDL.CX]/W<:H?;A:C1NHWB-KMCFS)SN.;YO
M'G9VE.V:RU=KY3].1/BEDIZ+2_D;ZD,/-F1LC!C:X9.,XXHELF>)L\$D+]K8
MD:6'9.#@C&X]BT=K70EKM6L-%6^BJ[RREN=7-%4M-SG)<UL>T,$NW;_0MZ+7
MW*'1U51KSD\FIZ::6&GK9W32,87-C!BP"XC@,^E$*MRK6*V:4TUIRBAKZ^EM
M=5J*G\LFEKY"X1.8X/\ [PNRUNRW/' XK[6RU<E\MQI8Z'5<DU4^5K88VWZ5
MQ>_/F@#;WY.-RF>76*1UNTK4"@JJ^GI+]35%1%3T[IW<TT/+CL@'(QN_=?*'
M6^EHY6/BT??(Y&N!:]NGW@M/80=G<B4GRN5M1);K5IRVS217"_UC*4/B<6OC
M@:=N9X(]#!C_ )E^\CURJ9+'6V&Z3.ENE@JGV^9[SETD8.8I-_YF$;_@5"UF
MG*K6W*?=*ZLJ;S:;?9(&45#-2/-.Z:1^72O:X@Y;P;NXX"^=!IVKT-RIV^KH
MY[Q=;9?X'4M=/5.,[XIH\&)[W ##<9:,\-Z(4CD^9H:X:=\HU=JF:GO!J9Q)
M')>I(2&B5P;YH>,>;A;2M]XTUHW0[KA8JFHNUOFJA' (JHU3YYWD,#&O>[=O
M [<#>J%R:7FTZ?TN+?J#2-YFN#*FH<YXLCY00Z5Q;YVSOW$*X7ZZ6R_<G]8*
M/1U?6VR.I9'4V^6E=22[&072Q,QESFY!&,9(._<B5@L.J:NX7EUGONG*ZT5,
MD!GB,CV3PRL!P1ML) =O_"5A<FE9+35NH=+54CY7V.I:*=[SEQI96[<0)/$M
M&6Y_W0JGR?B:#7-#!H^NU+5Z7YB4W".\1R"*!V!S;8G2M#MK/$#.Y6/1K#5<
MK&O+C%OI8VT="'C@Z1D9<\?MMM"(;"1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!
M5=1Z*IKO>&7>EN5RM%T$/D[ZFWRM898LY#7AS7 X.<'&0I32VGZ'3-GCMML:
M\0M<Y[GROVY)7N.7/>X\7$\2I9$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!5[
M5FE*34<E#4/J:RAN-"YSJ6MHY R6+:&'#>""TC&0058400&DM+4>FF5CH)JJ
MLK:V02U5;5R;<T[@,#)    W   !3Z(@(B("(B B(@(B("(B B(@(B("(B B
M(@J-^T)2W*]3W6BNMVLU;51-AJGVZ9K!4-;N;M!S3YP!P'#! 4[IVRT.GK+2
MVJU0\S1TS=EC<Y)WY))[2222?25(H@(B("(B B(@(B("(B B(@(B("(B B(@
M*N:KTE2:AJ:&L\KK;=<Z+:\GK:*0,E8UWXFG((<TX&X@JQH@@M):8HM,TU4V
MEEJ:FIJY3/55=4_;FG?C&7' &X#    4ZB("(B B(@(B("(B B(@(B("(B"F
MZRY/Z+5-\H+M47:]4%90QNC@-!4-BV-K.TX9:2"0<$YX +-TMI(Z?JYISJ#4
M%TYQFQS=RK.>8W>#EHV1@[L95E1!5.4VQ5-\TP>C #=;?/'<*$$X!FB=M!O_
M ##:;_S+Q=M.T.M*2SW@ON5JN4#.=IJF \S40;8\YC@X$8["TCL5N1!6],:.
MM]B?<)W355RN%P %765[Q))*T# 9N  : 3N  4+1\EUJII*2%]RN]19J.85%
M-:9J@.IHW@Y;NV=HM!WAI<0K\B",CM#6:BEN_EM<7R4PIO)3-FG: [:VPS&Y
M_9G/!52HY+;3*ZHIVW&[Q62HG-1-9XZ@"E>XNVB,;.T&D[RT. 5^1!2=9VV6
M_P"H=.V2.G>VV4<[;I62[!$>(LB*('@27[R.P,^(S=D1 1$0$1$!$1 1$0$1
M$!$1 1$0%A7JUT=ZM-7;;G"V>CJHS'+&>T'X]A^/8LU$%,L?)_1VZZT5?67:
M[W>2WM<VB9<)VO939&"6@-&78W;3LG"N:(@(B("(B B(@(B("(B B(@(B("(
MB B(@K^K-*4>HS132U%717"A>9*6MHY R6$D8< 2"""-Q!!!7[I/2M'IORV6
M&>KK:^ND$E56UD@?-,0,-!(   &X   *?1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$%!N?)A15NI;C?8=0ZEH*ZNV1,:*L;$W9:,-:/,S@>C*LNEK%U?H9:8W6ZW3
M;D,G.W*HYZ1NX#9!P,-W9QZ25,H@I.N+?/2:DT[JBA@DG=02.I*R*)I<YU--
M@%P WG8<&NP.S:63?-#4MPO<UXM]TNEFN51&V*IEM\K6BH:W<W;:YK@2!N!Q
ME6U$%5I]#6VDTE4V"WU5RHXZF3GIJV"I(JI)2X.<\R$'SG;(!..&Y??5.D:2
M_P ]!5^5UMON=#M"GKJ.0,E:UPPYIR"'-.!N(5C1!3Z>T0:$TU=ZJV15UUN4
MY,\DDI,M163G#6!Q &[.!N #1D^E9W)YIYVE](6^URR"6J8TR5,@_P \SW%[
MS^FT3CX85B1 1$0$1$!$1 1$0$1$!$1 1$0$1$&!?[/17ZSU=KNL(GHJIFQ(
MPG&1V$'L(."#Z0J]8M!4MMO%+<ZVZW:\55%&Z.C-PF:\4P<,$M#6C+B-Q<<G
M"N"("(B B(@(B("(B B(@(B("(B B(@(B("C=1V2AU%9:JU76+G:.H;AX!P0
M0<AP/800"#Z0I)$%1L&AJ:V7F&ZUMUNMYKZ>)T-+)<9FO\G8[\6P&M R0 "X
MY)5N1$!$1 1$0$1$!$1 1$0$6)TG1>U0]X)TG1>U0]X(,)MAACU4Z^T\KXIY
MJ;R6IB &Q.&NRQQ_WFY< ?0XCT*86)TG1>U0]X)TG1>U0]X(,M%B=)T7M4/>
M"=)T7M4/>"#+18G2=%[5#W@G2=%[5#W@@RT6)TG1>U0]X)TG1>U0]X(,M%B=
M)T7M4/>"=)T7M4/>"#+18G2=%[5#W@G2=%[5#W@@RT6)TG1>U0]X)TG1>U0]
MX(,IX):0TX=C<<9PHK2UC@T]:6T4$CYGN>^:>>3&W/*]Q<][L=I)_88'8LOI
M.B]JA[P3I.B]JA[P09:+$Z3HO:H>\$Z3HO:H>\$&6BQ.DZ+VJ'O!.DZ+VJ'O
M!!EHL3I.B]JA[P3I.B]JA[P09:+$Z3HO:H>\$Z3HO:H>\$&6BQ.DZ+VJ'O!.
MDZ+VJ'O!!EHL3I.B]JA[P3I.B]JA[P09:+$Z3HO:H>\$Z3HO:H>\$&6BQ.DZ
M+VJ'O!.DZ+VJ'O!!EHL3I.B]JA[P3I.B]JA[P09:+$Z3HO:H>\$Z3HO:H>\$
M&6BQ.DZ+VJ'O!.DZ+VJ'O!!EHL3I.B]JA[P3I.B]JA[P09:+$Z3HO:H>\$Z3
MHO:H>\$&6BQ.DZ+VJ'O!.DZ+VJ'O!!EHL3I.B]JA[P3I.B]JA[P09:+$Z3HO
M:H>\$Z3HO:H>\$&6BQ.DZ+VJ'O!.DZ+VJ'O!!EHL3I.B]JA[P3I.B]JA[P09
M:+$Z3HO:H>\$Z3HO:H>\$&6BQ.DZ+VJ'O!.DZ+VJ'O!!EHL3I.B]JA[P3I.B
M]JA[P09:+$Z3HO:H>\$Z3HO:H>\$&6BQ.DZ+VJ'O!.DZ+VJ'O!!EHL3I.B]J
MA[P3I.B]JA[P09:+$Z3HO:H>\$Z3HO:H>\$&6BQ.DZ+VJ'O!.DZ+VJ'O!!EH
ML3I.B]JA[P3I.B]JA[P09:+$Z3HO:H>\$Z3HO:H>\$&6BQ.DZ+VJ'O!.DZ+V
MJ'O!!EHL3I.B]JA[P3I.B]JA[P09:+$Z3HO:H>\$Z3HO:H>\$&6BQ.DZ+VJ'
MO!.DZ+VJ'O!!EHL3I.B]JA[P3I.B]JA[P09:+$Z3HO:H>\$Z3HO:H>\$&6BQ
M.DZ+VJ'O!.DZ+VJ'O!!EHL3I.B]JA[P3I.B]JA[P09:+$Z3HO:H>\$Z3HO:H
M>\$&6BQ.DZ+VJ'O!.DZ+VJ'O!!EHL3I.B]JA[P3I.B]JA[P09:+$Z3HO:H>\
M$Z3HO:H>\$&6BQ.DZ+VJ'O!.DZ+VJ'O!!EHL3I.B]JA[P3I.B]JA[P09:+$Z
M3HO:H>\$Z3HO:H>\$&6BQ.DZ+VJ'O!.DZ+VJ'O!!EHL3I.B]JA[P3I.B]JA[
MP09:+$Z3HO:H>\$Z3HO:H>\$&6BQ.DZ+VJ'O!.DZ+VJ'O!!EHL3I.B]JA[P3
MI.B]JA[P09:+$Z3HO:H>\$Z3HO:H>\$&6BQ.DZ+VJ'O!.DZ+VJ'O!!EHL3I.
MB]JA[P3I.B]JA[P09:+$Z3HO:H>\$Z3HO:H>\$&6BQ.DZ+VJ'O!.DZ+VJ'O!
M!EHL3I.B]JA[P3I.B]JA[P09:+$Z3HO:H>\$Z3HO:H>\$&6BQ.DZ+VJ'O!.D
MZ+VJ'O!!EHL3I.B]JA[P3I.B]JA[P09:+$Z3HO:H>\$Z3HO:H>\$&6BQ.DZ+
MVJ'O!.DZ+VJ'O!!EHL3I.B]JA[P3I.B]JA[P09:+$Z3HO:H>\$Z3HO:H>\$&
M6BQ.DZ+VJ'O!.DZ+VJ'O!!EHL3I.B]JA[P3I.B]JA[P09:+$Z3HO:H>\$Z3H
MO:H>\$&6BQ.DZ+VJ'O!.DZ+VJ'O!!EHL3I.B]JA[P3I.B]JA[P09:+$Z3HO:
MH>\$Z3HO:H>\$&6BQ.DZ+VJ'O!.DZ+VJ'O!!EHL3I.B]JA[P3I.B]JA[P09:
M+$Z3HO:H>\$Z3HO:H>\$&6BQ.DZ+VJ'O!.DZ+VJ'O!!EHL3I.B]JA[P3I.B]
MJA[P09:+$Z3HO:H>\$Z3HO:H>\$&6BQ.DZ+VJ'O!.DZ+VJ'O!!EHL3I.B]JA
M[P3I.B]JA[P09:+$Z3HO:H>\$Z3HO:H>\$&6BQ.DZ+VJ'O!.DZ+VJ'O!!EHL
M3I.B]JA[P3I.B]JA[P09:+$Z3HO:H>\$Z3HO:H>\$&6BQ.DZ+VJ'O!.DZ+VJ
M'O!!EHL3I.B]JA[P3I.B]JA[P09:+$Z3HO:H>\$Z3HO:H>\$&6BQ.DZ+VJ'O
M!.DZ+VJ'O!!EHL3I.B]JA[P3I.B]JA[P09:+$Z3HO:H>\$Z3HO:H>\$&6BQ.
MDZ+VJ'O!.DZ+VJ'O!!EHL3I.B]JA[P3I.B]JA[P09:+$Z3HO:H>\$Z3HO:H>
M\$&6BQ.DZ+VJ'O!.DZ+VJ'O!!EHL3I.B]JA[P3I.B]JA[P09:+$Z3HO:H>\$
MZ3HO:H>\$&6BQ.DZ+VJ'O!.DZ+VJ'O!!EHL3I.B]JA[P3I.B]JA[P09:+$Z3
MHO:H>\$Z3HO:H>\$&6BQ.DZ+VJ'O!.DZ+VJ'O!!EHL3I.B]JA[P3I.B]JA[P
M09:+$Z3HO:H>\$Z3HO:H>\$&6BQ.DZ+VJ'O!.DZ+VJ'O!!EHL3I.B]JA[P3I
M.B]JA[P09:+$Z3HO:H>\$Z3HO:H>\$&6BQ.DZ+VJ'O!.DZ+VJ'O!!EHL3I.B
M]JA[P3I.B]JA[P09:+$Z3HO:H>\$Z3HO:H>\$&6BQ.DZ+VJ'O!.DZ+VJ'O!!
MEHL3I.B]JA[P3I.B]JA[P09:+$Z3HO:H>\$Z3HO:H>\$&6BQ.DZ+VJ'O!.DZ
M+VJ'O!!EHL3I.B]JA[P3I.B]JA[P09:+$Z3HO:H>\$Z3HO:H>\$&6BQ.DZ+V
MJ'O!$$?U:H_6U'>'@G5JC];4=X>"FT00G5JC];4=X>"=6J/UM1WAX*;1!"=6
MJ/UM1WAX)U:H_6U'>'@IM$$)U:H_6U'>'@G5JC];4=X>"FT00G5JC];4=X>"
M=6J/UM1WAX*;1!"=6J/UM1WAX)U:H_6U'>'@IM$$)U:H_6U'>'@G5JC];4=X
M>"FT00G5JC];4=X>"=6J/UM1WAX*;1!"=6J/UM1WAX)U:H_6U'>'@IM$$)U:
MH_6U'>'@G5JC];4=X>"FT00G5JC];4=X>"=6J/UM1WAX*;1!"=6J/UM1WAX)
MU:H_6U'>'@IM$$)U:H_6U'>'@G5JC];4=X>"FT00G5JC];4=X>"=6J/UM1WA
MX*;1!"=6J/UM1WAX)U:H_6U'>'@IM$$)U:H_6U'>'@G5JC];4=X>"FT00G5J
MC];4=X>"=6J/UM1WAX*;1!"=6J/UM1WAX)U:H_6U'>'@IM$$)U:H_6U'>'@G
M5JC];4=X>"FT00G5JC];4=X>"=6J/UM1WAX*;1!"=6J/UM1WAX)U:H_6U'>'
M@IM$$)U:H_6U'>'@G5JC];4=X>"FT00G5JC];4=X>"=6J/UM1WAX*;1!"=6J
M/UM1WAX)U:H_6U'>'@IM$$)U:H_6U'>'@G5JC];4=X>"FT00G5JC];4=X>"=
M6J/UM1WAX*;1!"=6J/UM1WAX)U:H_6U'>'@IM$$)U:H_6U'>'@G5JC];4=X>
M"FT00G5JC];4=X>"=6J/UM1WAX*;1!"=6J/UM1WAX)U:H_6U'>'@IM$$)U:H
M_6U'>'@G5JC];4=X>"FT00G5JC];4=X>"=6J/UM1WAX*;1!"=6J/UM1WAX)U
M:H_6U'>'@IM$$)U:H_6U'>'@G5JC];4=X>"FT00G5JC];4=X>"=6J/UM1WAX
M*;1!"=6J/UM1WAX)U:H_6U'>'@IM$$)U:H_6U'>'@G5JC];4=X>"FT00G5JC
M];4=X>"=6J/UM1WAX*;1!"=6J/UM1WAX)U:H_6U'>'@IM$$)U:H_6U'>'@G5
MJC];4=X>"FT00G5JC];4=X>"=6J/UM1WAX*;1!"=6J/UM1WAX)U:H_6U'>'@
MIM$$)U:H_6U'>'@G5JC];4=X>"FT00G5JC];4=X>"=6J/UM1WAX*;1!"=6J/
MUM1WAX)U:H_6U'>'@IM$$)U:H_6U'>'@G5JC];4=X>"FT00G5JC];4=X>"=6
MJ/UM1WAX*;1!"=6J/UM1WAX)U:H_6U'>'@IM$$)U:H_6U'>'@G5JC];4=X>"
MFT00G5JC];4=X>"=6J/UM1WAX*;1!"=6J/UM1WAX)U:H_6U'>'@IM$$)U:H_
M6U'>'@G5JC];4=X>"FT00G5JC];4=X>"=6J/UM1WAX*;1!"=6J/UM1WAX)U:
MH_6U'>'@IM$$)U:H_6U'>'@G5JC];4=X>"FT00G5JC];4=X>"=6J/UM1WAX*
M;1!"=6J/UM1WAX)U:H_6U'>'@IM$$)U:H_6U'>'@G5JC];4=X>"FT00G5JC]
M;4=X>"=6J/UM1WAX*;1!"=6J/UM1WAX)U:H_6U'>'@IM$$)U:H_6U'>'@G5J
MC];4=X>"FT00G5JC];4=X>"=6J/UM1WAX*;1!"=6J/UM1WAX)U:H_6U'>'@I
MM$$)U:H_6U'>'@G5JC];4=X>"FT00G5JC];4=X>"=6J/UM1WAX*;1!"=6J/U
MM1WAX)U:H_6U'>'@IM$$)U:H_6U'>'@G5JC];4=X>"FT00G5JC];4=X>"=6J
M/UM1WAX*;1!"=6J/UM1WAX)U:H_6U'>'@IM$$)U:H_6U'>'@G5JC];4=X>"F
MT00G5JC];4=X>"=6J/UM1WAX*;1!"=6J/UM1WAX)U:H_6U'>'@IM$$)U:H_6
MU'>'@G5JC];4=X>"FT00G5JC];4=X>"=6J/UM1WAX*;1!"=6J/UM1WAX)U:H
M_6U'>'@IM$$)U:H_6U'>'@G5JC];4=X>"FT00G5JC];4=X>"=6J/UM1WAX*;
M1!"=6J/UM1WAX)U:H_6U'>'@IM$$)U:H_6U'>'@G5JC];4=X>"FT00G5JC];
M4=X>"=6J/UM1WAX*;1!"=6J/UM1WAX)U:H_6U'>'@IM$$)U:H_6U'>'@G5JC
M];4=X>"FT00G5JC];4=X>"=6J/UM1WAX*;1!"=6J/UM1WAX)U:H_6U'>'@IM
M$$)U:H_6U'>'@G5JC];4=X>"FT00G5JC];4=X>"=6J/UM1WAX*;1!"=6J/UM
M1WAX)U:H_6U'>'@IM$$)U:H_6U'>'@G5JC];4=X>"FT00G5JC];4=X>"=6J/
MUM1WAX*;1!"=6J/UM1WAX)U:H_6U'>'@IM$$)U:H_6U'>'@G5JC];4=X>"FT
M00G5JC];4=X>"=6J/UM1WAX*;1!"=6J/UM1WAX)U:H_6U'>'@IM$$)U:H_6U
M'>'@G5JC];4=X>"FT00G5JC];4=X>"=6J/UM1WAX*;1!"=6J/UM1WAX)U:H_
M6U'>'@IM$$)U:H_6U'>'@G5JC];4=X>"FT00G5JC];4=X>"=6J/UM1WAX*;1
M!"=6J/UM1WAX)U:H_6U'>'@IM$$)U:H_6U'>'@G5JC];4=X>"FT00G5JC];4
M=X>"=6J/UM1WAX*;1!"=6J/UM1WAX)U:H_6U'>'@IM$$)U:H_6U'>'@G5JC]
M;4=X>"FT00G5JC];4=X>"=6J/UM1WAX*;1!"=6J/UM1WAX)U:H_6U'>'@IM$
M$)U:H_6U'>'@G5JC];4=X>"FT00G5JC];4=X>"=6J/UM1WAX*;1!"=6J/UM1
MWAX)U:H_6U'>'@IM$$)U:H_6U'>'@G5JC];4=X>"FT00G5JC];4=X>"=6J/U
MM1WAX*;1!"=6J/UM1WAX)U:H_6U'>'@IM$$)U:H_6U'>'@G5JC];4=X>"FT0
M0G5JC];4=X>"=6J/UM1WAX*;1!"=6J/UM1WAX)U:H_6U'>'@IM$$)U:H_6U'
M>'@G5JC];4=X>"FT00G5JC];4=X>"=6J/UM1WAX*;1!"=6J/UM1WAX)U:H_6
MU'>'@IM$$)U:H_6U'>'@G5JC];4=X>"FT00G5JC];4=X>"*;1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MEUZVZ72GHAI;5E'SSMGGZNVF.)F[.7.VMP02-VUQIFT73HZYWRAIJW=M122
M%F>&T>#<_'"L32' %I!!W@CM6G=$7+3]KT?K"EU;+2-K&W"M==8)W 23!SB6
MX!(+@YFR&X_9;1TVZG?I^V.H:::DI#31F&"88?$S9&RUPR=X&!Q*"11$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M&K*>SZDM%TO-SY.KI8[K:[C6R55115CCF.H.!(&2QD[\C@[AP457Z\=:-):X
MKXM/MLFL*-T K(<B5KY)2&13!PW/&#G&.S&]6:;0-UMMVN%7HS5$MEIZ^8U%
M112T;*F'G7?B>P.(+<\2/X7WH.3>B-DOU'?JZIN]=?0WR^MD#8W.V1AFPT;F
M!O$#?O1*ALN-VM$MKK+(_E!N-P;41-K8;G0S.IZB)QQ(0TMQ$0"2-GAC&]3]
MGH+IJ7E*U:RJU'>*2VVBMIC3TM)4<VUQ=$USFOW'+-WX=WXB5,P:'OM1);H+
M]J^HK[702LE9!%2M@DG+/PB60.)<!V@ 9[5/Z?TVVSW_ %%=&U1E-XGCF,99
ML\UL1AF,YWYQGL0:MI=37VIT_!;:>Z5$59=M55-L\M<=M]/3M<XD,SP.RW ]
M&58JN"NT-K'3$=+>[M<K7>:AU#4TURJ#4.:_8+F2,<=[=X.1PP>"D/\ LSIC
MIV>W&Y3LJNE9+Q25L3 U]-,YY<, DAP&2#GB#V+*MFC+A+J*@O.J[Z;O46YK
MQ1114K::*)SAATA:"2YV-W' [ @C- 7:OK.3S4E75UD\U3!5W!D<KWDN8UCG
M;(![ ,#"J4URU!4Z4T/7W"34U589;8'UTUDD/E1J#C9=(0=LLQG@>/%6YW)Q
M<8>F*"VZIGH]/72:6>:B;2,=(PR?C:R4G(:?TR!P/:LB#D_K[90V :?U'-15
M]JHA0.DDIQ+#4Q[CYT1<,'(R"#GL0??DDN5-<+/7"BU'4WR"*I(9Y9$YE32M
M(&(I2[>X@Y\X@?OA6G4?_P W[I_X67_R%1&B]*NT_-=:ZMN#[C=[K*V6KJ3$
M(FG9;LL:U@_" /B3\5/W"F\LH*FE+M@3Q.CVL9QD$9_U1"G\A_\ \)],?^$'
M_4JA\DL^MX].UK=.4-@FM_2=7LOK:B5DFUSISD-:1A;:T586Z7TK;;*RH-2V
MBBYH3%FP7[R<XR<?-4JS\G>IK%#44UCUX^CHI:B2H$/1,,FRY[BX^<XDGB@L
M%SU%=-.: NE[U5#015U)&][8Z.1SXW'A&W+@#DN('[K2='?K;IBUZ*N\ N1O
M%OJ7OO#Y;?/&V6.I.9RY[F!IV7$8W]BVY6:%N]XH*.CU-JI]TIX+A%6O;Y!'
M!SK8]XB.R<;)=O)W\ KA?[53WRR5]KK1FGK(7P/^ <",CXCB@UGRERW3_M6T
M)+IN.AJ*XTM<8A5R.;$YI8S)):">'!6W3U1KE]UB;J"AT]#;B'<X^CJ)7R@X
M.,!S0../V4%4\FUT,6E9*'5DE+<K!2R4D=6:!DIE8\!N]KG$ AK0.W/%2MJT
MYK&FN---7Z\=6TL<@=+3]$01\ZWM;M Y&?2$%EK+%::VNBK:VUT%1618YN>6
MG8^1F.&'$9"D45>KX[N[6]J=2U$HLS:68U<7-MV"_+=@[7':WG<-V!O[$%A1
M$0$1$!$1 1$0$1$!$1 1$0$1$ D 9) 'Q1:L;::+77*;JFGU'$:RVV..FIJ6
MD>\B,/D89'R$ [W< #V!2?)!//!#J.PS3RSQ62Z24M*^5Q<\0$->QI<=YP'$
M9] "#8"(B B(@(B("(B B(@(B("(B B(@(B("$@#). BUKK"FCU1RIVG2]SV
MI+-36R2Z3TH<6LJ'F01L#\<0W><<,H-E Y&1O"+6^@X6Z<Y1=1Z6H2]MG\E@
MN-)3N<7-IRXN9(UN>#20#C@-ZV0@(B("(B B(@(B("(B B(@(B("(B B(@$@
M<2!^J+4]HL5NY0-7ZQJM30FNIK=6"V45.^1P93AC 7O: 1YSG.SM<1@84[R-
M5U54:8K:"NJ)*F:SW*IM@GE.7R,C?YI<>T[) S\$%[1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 0D 9)P$6L]3TD.K.5BETY=PZ:RT%J-PDI-HAD\SY=ANV!^(-
M ) /:4&S!O&Y%KCDZCZ!USJO2M*Z3HFF93UM%"]Y=S E:0]C2=^SM-R!V9*V
M.@(B("(B B(@(B("(B B(@(B(" @\#E06KZ:_5M#%2Z:K*6@EF?LSU<S"]T,
M>#DQMX%^<8SN57_L_!XY+[>))'RO%15;4CSESCY1)DD^DH-BK\8YKVAS'!S3
MP(.053.5BZU-#IRGH+=*Z&OO5;#:X)6\8N=/G/'Q# XCXX6=?;1=H;!0V?1L
M]':XF!L#JB5A>ZGA#<9C;P+^'XMW:@LP(/ Y3(SC(SZ%J#DTNTM@Y *JZA[I
MJBBCKYFOD.2][992"[TY.,JI6]NE'6:U5<\M^H[W-)$]VKS3R.A-22"YO.$X
M+"<LQC8QV]J#HQ%XEB;-"^*4;3'M+7#.,@[BM&:_Y.M+QW.SZ9TW;9(+S='E
M[ZCRR=_DE,S?)+@O().YK01@D_!!O4.:7E@<-H#)&=X"_5K?65/#HNITA=[:
M',I:.:*S50<XDOI9/-:7$\2QX:X?J[TK9" B(@(B("(B B(@(B("(B B(@(B
MI'++=:NU:"JS;9W4];5RPT44S3@Q\[(&%P]!#2<'TH+N"#G!!QQ1:CU)INV\
MGUSTE==,124CIKI#;:UHD<X544H+29,GSG @$'CE;<0$1$!$1 1$0$1$!$1
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MVPW.XUD]QJ86N#A$^5V=C(XX :#\<JXH@(B("(B B(@(B("(B B(@(B("(B
MB(@+7FJ:>OL'*+1ZKI+967.@GM[K;6143.<FBQ)MLD#,Y<,Y!QP6PT04+D^H
M*^KU1J755SH)[<VY<Q3TE+4 "5L,32-IX!.R7.<3CB,*^HB B(@(B("(B B(
M@(B("(B B(@*C\B]LK;1R?TE'<Z:6EJFSU+G12##@'3O<#^X(/[J\(@U[RR1
MFGI-,WD_[/:;W35%2>QL1)C<[]B\%;"6-<Z"FNENJ:"OB;-25,;HI8W<'-(P
M0ORTT0MULI:)L\U0VGC;$)9B"]P P"X@#)^*#7>A-*UE1R,5>G;I#)1556RM
MAV96X+.<EDV7$>C>"H&Y&_7?DT@T%U4N-/=C!#;Y:E\;?(HV,+09A+G!&&Y
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MNP227<-RV:B("(B B(@(B("(B B(@(B(*OI+3$MCH;_!+4LE-SN-37-+6D;
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MHII@!)!,PX<QV.T?]"%5]"^;RK<I#9?\4OH'-SQ,?,$#]LY3DH\Z^\H+XO\
M9S?I W'#;$; _P#U0;$1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 59U=JOH2MMU
MMH+=-=;U<-LT])%(V,;#!ESWO=N:T9&_M)W*S+7=1YO]H"C,OX'Z<>V'/:\5
M +L?'&$%@T=JIM_FN5%5T$ULO%M>UE713/:\LVAECFN;N<UPS@_ JR+7=F\[
MEUU(8?\ #99Z5LV.R0O>6Y^.RMB("(B B(@(B("(B B(@(B("(B B(@(B(*7
M>=:U<=_K;1IO3]1?*JWQL?6N94,@9"7C+6 N_$\@9P/AO4[I/4%'J>PTMVMW
M.-AF!!CE;LOC>TEKF.'8000JER5>;J3E#9+_ +2+XYQ!X\V8F;'[8RG(EOM.
MIGL_V=^H:YT!["S;'#X9!0;$1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 57U9JQ
MUGN=!:+9;)KM>JUKY8Z6.1L0;&W\4CWNW-;D@#CD[E:%KN+S?[0,_._Y]-MY
MG/:!4G:Q_H@L.C=4LU$+A3ST4UNNMNE$-913.#G1.(VFD.&YS7#>".*L:UWI
MCSN6K6SHO\-M%0-EQPYS9>1GX[*V(@(B("(B B(@(B("(B B(@(B(([4%[MV
MG[9+<+S614E)$-[Y#C)] '$D]@&\J/T!JB+6.F*>]TU-)30SR2M9'([+L,D<
MS)]!.SG'9GM4K<+70W&6EDKZ."I?2R<[ 96!W-OQC:&>!^*I'(#_ /#*A_\
M$U?_ /L2(+EJ*\4M@LE;=;@XMIJ6,R.P,EWH:!VDG  ])6+5:BIK1IF*[ZG?
M#:AS37S1ODVN;<1G8!P-IW9@#>>"J_+"XROT90/_ -EK-04K9QV.:W:>&G]7
M-'R5WN%KH;C+2R5]'!4OI9.=@,K [FWXQM#/ [^*"&T1JZEU3I&/4+8745(\
MS'$SLEK(WN;M.]&YN<=BK8Y3YFT$-[ETQ<(]*2R-8VYNE9M;#G;+93#^(,)(
MW\<'.%6]+\[_ /8SWOR?/.>37+AQQSLN?],KQ41ZAT]R6V_65-J>HDFI:.GJ
M#;"R,43H"&CF0W&T"&D#:VB21\=P;ME>YD+WQL,CFM):P'&T?0M9WSE,O5BM
MLMPNV@[E34D> Z1U;3G>3@  .R22> 6RZ:7GZ:*4-+><8';)XC(SA:[NS>M?
M*[26J3S[5IJ!EPGC['U<F1"'#_=:"X?$H+%#JE[+O8Z*YV^2AZ7I3+ 9'@ED
M[0'.@> -S@TY!SOV7#LWV9:\Y<7&FTM;KC%NJJ"[T<\)'':YT-(_<.(6PT!$
M1 1$0$1$!$1 1$0$1$!$1 4;J6]T>G+%6W>YO+*2DC,CRT9)[  .TDX ^)4D
MM=\O6[D_+W?[.ROHW3YX<WS[<Y^'!!EVO756;Q;*'4>G*NR,NF6T,TD[)6O>
M!M<V\-_PWD< <^CBKRM=\LWG1:-9'OJ':DHC&!QW%Y)^65L1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1!6M7ZJZ"JK=;Z*WS72\W%SA34<3VQY:P9>]SW;FM Q
MO^*:/U4+]4W*@K;?-:[S;G-;4T<KVOP'C+'M>W<YI ._X* K_-Y?;29O\-^G
MYVPY[9!.TNQ\=E+=YW+U>3#_ (;+#3MFQV/,SRW/QV4&Q$1$!$1 1$0$1$!$
M1 1$0$1$!$1!5>4/7-IT/9I:VYRM?4%I-/1L=_>3N'8!V#TNX!6*VU0KK=2U
M89L">)DNSG.SM '&52N66UT)T%JBYNI(#<1:Y(!4E@,@CWG9#N(&25:],_\
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/[$S=ZG@_%1XK#\R(L__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g843142g31l12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g843142g31l12.jpg
M_]C_X  02D9)1@ ! 0$!'P$?  #_[22.4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'']
M<*         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !']<*  $  0$?
MUPH  0 !.$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      ,U    !@             "H   !P<          0
M                   !              <'   "H
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   "H     !29VAT;&]N9P
M!P<    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   J      4F=H=&QO;F<   <'     W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M    .$))3004       $    !3A"24T$#      :D@    $   "@    /
M >   '"    :=@ 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A
M &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M               !  #VU@ !     -,M2% @(
M                                        $6-P<G0   %0    ,V1E
M<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8
M%&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
M    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,
M  0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)4
M4D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M
M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N
M,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                              !865H@
M\U$  0    $6S%A96B                      6%E:(        &^B   X
M]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/
M9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6
M245#(&AT=' Z+R]W=W<N:65C+F-H
M                             &1E<V,         +DE%0R V,3DV-BTR
M+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@                            !D97-C         "Q2969E<F5N8V4@
M5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L
M4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                                =FEE=P      $Z3^ !1?+@ 0SQ0
M ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M  $                        "CP    )S:6<@     $-25"!C=7)V
M    !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!>
M &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L
MT #5 -L X #E .L \ #V /L! 0$' 0T!$P$9 1\!)0$K 3(!. $^ 44!3 %2
M 5D!8 %G 6X!=0%\ 8,!BP&2 9H!H0&I ;$!N0'! <D!T0'9 >$!Z0'R ?H"
M P(, A0"'0(F B\". )! DL"5 )= F<"<0)Z H0"C@*8 J("K *V L$"RP+5
M N "ZP+U P #"P,6 R$#+0,X T,#3P-: V8#<@-^ XH#E@.B ZX#N@/' ],#
MX /L _D$!@03!" $+00[!$@$501C!'$$?@2,!)H$J 2V!,0$TP3A!/ $_@4-
M!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2 99!FH&
M>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9!ZP'OP?2!^4'^ @+
M"!\(,@A&"%H(;@B"")8(J@B^"-((YPC["1 ))0DZ"4\)9 EY"8\)I FZ"<\)
MY0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1"VD+@ N8"[ +R OA
M"_D,$@PJ#$,,7 QU#(X,IPS #-D,\PT-#28-0 U:#70-C@VI#<,-W@WX#A,.
M+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L$ D0)A!#$&$0?A";
M$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B8211)D$H02HQ+#$N,3 Q,C$T,3
M8Q.#$Z03Q1/E% 84)Q1)%&H4BQ2M%,X4\!42%3055A5X%9L5O17@%@,6)A9)
M%FP6CQ:R%M86^A<=%T$791>)%ZX7TA?W&!L80!AE&(H8KQC5&/H9(!E%&6L9
MD1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;8QN*&[(;VAP"'"H<4AQ['*,<S!SU
M'1X=1QUP'9D=PQWL'A8>0!YJ'I0>OA[I'Q,?/A]I'Y0?OQ_J(!4@02!L()@@
MQ"#P(1PA2"%U(:$ASB'[(B<B52*"(J\BW2,*(S@C9B.4(\(C\"0?)$TD?"2K
M)-HE"24X)6@EER7')?<F)R97)H<FMR;H)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I
M!BDX*6LIG2G0*@(J-2IH*ILJSRL"*S8K:2N=*]$L!2PY+&XLHBS7+0PM02UV
M+:LMX2X6+DPN@BZW+NXO)"]:+Y$OQR_^,#4P;#"D,-LQ$C%*,8(QNC'R,BHR
M8S*;,M0S#3-&,W\SN#/Q-"LT932>--@U$S5--8<UPC7]-C<V<C:N-NDW)#=@
M-YPWUS@4.% XC#C(.04Y0CE_.;PY^3HV.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\
MXSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_XD C0&1 ID#G02E!:D&L0>Y",$)R
M0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G1JM&\$<U1WM'P$@%2$M(
MD4C721U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),NDT"34I-DTW<3B5.;DZW
M3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2QU,34U]3JE/V5$)4CU3;52A5
M=57"5@]67%:I5O=71%>25^!8+UA]6,M9&EEI6;A:!UI66J9:]5M%6Y5;Y5PU
M7(9<UETG77A=R5X:7FQ>O5\/7V%?LV %8%=@JF#\84]AHF'U8DEBG&+P8T-C
MEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL:4-IFFGQ:DAJGVKW
M:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7 K<(9PX'$Z<95Q\')+<J9S
M 7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X;GC,>2IYB7GG>D9ZI7L$
M>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$?^6 1X"H@0J!:X'-@C""DH+T@U>#
MNH0=A("$XX5'A:N&#H9RAM>'.X>?B 2(:8C.B3.)F8G^BF2*RHLPBY:+_(QC
MC,J-,8V8C?^.9H[.CS:/GI &D&Z0UI$_D:B2$9)ZDN.339.VE""4BI3TE5^5
MR98TEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<')R)G/>=9)W2GD">KI\=
MGXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJFBZ;]IVZGX*A2J,2I
M-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6KXNP +!UL.JQ8+'6LDNRPK,X
MLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JYPKH[NK6[+KNGO"&\F[T5O8^^
M"KZ$OO^_>K_UP'# [,%GP>/"7\+;PUC#U,11Q,[%2\7(QD;&P\=!Q[_(/<B\
MR3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/N- YT+K1/-&^TC_2P=-$T\;4
M2=3+U4[5T=95UMC77-?@V&38Z-ELV?':=MK[VX#<!=R*W1#=EMX<WJ+?*=^O
MX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>IZ#+HO.E&Z=#J6^KEZW#K
M^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"]5#UWO9M]OOWBO@9
M^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW____M  Q!9&]B95]#30 "_^X
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M_M'TO7/_ '&]/9O_ ,-/Z7[/MV_S7Z?Z:2GH$DDDE*22224__]DX0DE-!"$
M     %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
M   3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    !
M #A"24T$(@     !+DU- "H    (  <!$@ #     0 !   !&@ %     0
M &(!&P %     0   &H!*  #     0 "   !,0 "    '@   '(!,@ "
M%    )"':0 $     0   *0   #0   !(     $   $@     4%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,C0Z,#8Z,3(@,#$Z-30Z,34   .@
M 0 #     ?__  "@ @ $     0  !P>@ P $     0   J          !@$#
M  ,    !  8   $:  4    !   !'@$;  4    !   !)@$H  ,    !  (
M  (!  0    !   !+@("  0    !              !(     0   $@    !
M.$))30/]       (          #_X0$V17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    >    <@$R  (    4    D(=I  0    !    I    -    $@
M 0   2     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R-#HP
M-CHQ,B P,3HU-#HQ-0   Z !  ,    !__\  * "  0    !   '!Z #  0
M   !   "H          & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $
M     $@    !    2     '_XO__24-#7U!23T9)3$4  0D "(!P041"10(0
M  !P<G1R0TU92TQA8B 'T  ' !H !0 I #5A8W-P05!03     !!1$)%
M                 0  ]M8  0    #3+4%$0D4
M                                          ID97-C    _    '1C
M<')T   !<    "MW='!T   !G    !1!,D(P   !L   H@9!,D(R   !L
MH@9!,D(Q  "CN   H@9",D$P  %%P  ".+1",D$Q  -^=  ".+1",D$R  6W
M*  ".+1G86UT  ?OW   D)%D97-C         !I5+E,N(%=E8B!#;V%T960@
M*%-73U I('8R
M                                                         '1E
M>'0     0V]P>7)I9VAT(#(P,# @061O8F4@4WES=&5M<RP@26YC+@  6%E:
M(        +5:  "\9P  DC!M9G0R      0#"0   0
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M6H)1@TB$/H4UABN'(8@7B0R* HKWB^V,XHW8CLV/PY"YD:^2I9.<E)*5B9:
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MZ*S6D"8\PZB2CVDHUZ5CD!L0!*7ABM0  (Q>@ "/Q\%0H&* 0KNUG3=P3;9
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M1<14J79F2KXHI@%6PK@]HXY&A++"HJ$U/:WXH.DB"JJ"EP0*YZE/AU\  (J
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M+X:]IFJBJH6>HHB-:(2PGMIW@H/OFV]@TX-8F%Y(^X+JE>,N!X+0E0T)48,
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MA-\;K:T=A80%$JJ;@VX  (,?@ ![6\;LD&5M9<%PCH!>_KP$C.A0 K;"BZ5
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MO*4SK2IKE:&"J<!;HYWVIKU*_YK%I/HY3I@?HL0ER)91F8P-0Y:@B/<  (
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MI+%RBN%B6ZT^B;!35:DWB*U#=*6&A_ R,:*3AYX>D*$TB"L&\9_ZA+$  (
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MI<"L;;18';PY;I])T[?L;Y4Z=;0!<($I4[$T<2T4EK'I<+@  *LI='L  (
M@ !RHL1W='!EP[^Q=(M8.KL$=-5)\;:&=4 ZEK)V=;\IC:]_=B$5%:_$=;L
M#ZGI>.<  (  @ !RH\,Z>[AEJKYR>T58)KFU>OU)UK4D>O<ZB+$#>Q(IGJWR
M>S@5;JW>>P0 HZ?3?2X  (  @ !RE<'M@MIE@+TF@?A7Y[AJ@4))J+/2@,PZ
M9J^M@)8IG*R*@) 5KZPP@,P!(:7X@,0  (  @ !R=L#2B@ME7[P'B,A7P+=%
MA[9)=;*HAMHZ4:YSAE$IGJM'ADD5[:JOAI !D:15@0\  (  @ !R4;_YD6AE
M2KL?C\M7LK9.CE1)9[&HC2(Z0:ULC%XIJ*HAC(46)ZE8BX,!\:+J@5   (
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M/XT&E)A[-XM^DL1J-8H4D/!87HC5CT9%;8?4C?$PRX<IC4T728>LC 4  (
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M2)L0<E%S/)C#<SIC)I:C=")1\)2V=0P_99,J=>DJTY)U=GH0.)3U=?(  (
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MFI7/F?AO@I.)E]1?>I%@E;E.GH]UD_$\I8WBDLTHSXS8DL4/:8V=BFL  (
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M/Z.(>*)G(J"3>.57[YW2>3U'L)M4>: V )EG>?XAZYC,>A4(G9EG>J<  (
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MPY\;GKED?IP7G&U549DLFCA%4):5F*8T%Y2.F&$@QI-OE7\(Z)( A@8  (
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MZ:Q]?A9;=ZCS?=U--*64?<,]QZ*9?<8LT*!J?=$8YZ!:?;P"K)OZ?J\  (
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MM*B^HQE:+J3\H-!+N*%=GLD\>YXIG?,KZYN^FY,8T9KRD,@#K)6,@GP  (
M@ !J,K\#9K1=SKM : Y0X[>6:7!#([0%:L8T*K#H:_0C'Z\^;*(.(;%(:^,
M )\$<[   (  @ !I[;X];C)=S[HY;MA0];9";YQ#1;)W<&XT6Z\N<3$C<ZU*
M<9P.M:[H<.8  )W >"D  (  @ !IS;SG=61=G;C:=8!0U;3/=;A#)K#M=ADT
M4:V0=GPCD:N(=JX/'*S(=B8  )R)?"(  (  @ !IJ+MR?&M=8;=F?!Y0A[-=
M>^E"\J]W>]XT+:P4>_ CDZGR>_@/9ZKB>]@  )MH?Z$  (  @ !I>KHQ@W]=
M-;8C@MI05K(5@DM"M*XK@=<T%*JW@9HCE*B%@9X/J:DP@:X  )IL@    (
M@ !I3KD\BKM='K4<B<E01+$ B-Q"GJT-B! S_*F1AY(CG:<ZA\ /YJ>KAK@
M )F0@    (  @ !I*;A_D?Y=%+1'D,A0/[ 8CX)"E*P;CFPS\:B;C>$CIZ8R
MCD40(J99BND  )C?@    (  @ !I#;?SF5E=%[.>E^901*]9EE5"DJM-E0@S
MY*?'E+8CG*5>D\P0/Z59BOP  )A(@    (  @ !H^K>/H.M=([,3GTE04:ZU
MG7Q"EJJ;G"4SZ:<+FVXCL:24F"(05J2#BPP  )>R@    (  @ #-4&QM9D2Y
MYVXP:'6ETV_8:I"0X'%C;)1[#G+?;HUD571/<'U,;'6D<E QK7:I<]8-QW@Q
M<[;+7&GN<52X6&OG<F>D;6VV<W>/GV]G=(9YXW$&=9=C/G*6=J5+87/Z=YLP
ML73<>%4,YG9T=^7)B&?)?&"VD6G<?%RBX6O+?%^.)FV9?'UXD6]6?*IB$G#_
M?-Y*67)O?00OQG,K?00,(73N?(/'NV7BAU"TPF@*AE"A&VH+A6",FFORA(=W
M*FW-@]-@VV^,@R])5'$%@HTNZ7&9@>L+=G.;@+C&&&1&DC2S*69\D%2?@VB-
MCGZ+#VJ#C+MUUVQNBQ=?LFY#B:)(8&_"B$$N'G KAQ\*Y')XA%+$Q6, G2&Q
MW64_FG">.&=5E[6)RFE3E0ITIFM'DH5>I6TAD#-'@FZFCBDM:6[FC,4*:'&$
MAPG#MF']J!.PU&1 I)>=*F95H/J(NVA4G6MSJ6I2FA-=R&PSEO]&QVVQE%0L
MTFW+DO,* G"YAL3"[6$\LPFP#6-_KL2<4V6-JDR'VV>%I=MRRFF$H;A<_VMM
MG@5&)&SJFOTL3VS9F%P)KW 4AHS":F"[O?ZOA6+ZN.>;LF3XLY.')6;BKDYR
M%VC:J7-<76K"I3Y%BVPWHCXKQFP G*@);7 2AE^^KW2.96"M!'6"9[Z:;'9Q
M:>^&OG=::_UR#WA";?M<6GDL;^Y%4WH/<;LK WK?<QD'@'T6<WV]1G(];_"K
MZ7-F<3N96G1U<G"%MG5V<YAQ#G9S=+U;:G=Q==]$=GA==N0J.'D%=Y &]7M;
M>!2[P' N>FNJ/G%R>K:7TW*:>OF$/W.V>T)OP73/>Y5:1'7D>^Q#<W;6?#(I
M6'=.?#\&>GG6?&RZ*6Y=A,JHFF^RA#.6,7#L@Y:"UW(;@OYN>'-/@H!9)W1X
M@@Y"A75N@9\HD76W@2X&#WB%@#&XKFS1CRFG)VXRC<.4OV]\C%"!;'"XBM]M
M1G'WB818&G,TB%)!J'0MASLGWG1$AGD%M'=D@VRW>&N6F9JE]&S_EVV3CVY-
ME2. 0V^1DMIL,'#9D*]7*7(6CK= XG,3C1(G/G+[C%8%9W;>@Z>V@FJ;I!2D
M_&P(H222DFU4G@5_26Z:FN9K1V_KE_E68'$NE59 /G(?DS@FO''>DB,%)W=*
M@WRURVG?KI>D/FM,JN>1Q6R1IOA^=FW/HP9J=V\BGV%5HW!NG#<_IG%=F?,F
M27#JEN($]'>A@UFU5FEBN22CN&K)M+>1(VO^K_A]QFTOJSYISVYZIO)5#V_%
MHV<_&'"NH0TEQW 5F8L$RG?G@SVP<'S_9*R@37T=9QV/$7U4:5=\EGV<:V=H
M_GWQ;6541'Y6;U,^$7[5<0\D '^K<B8!]X%G= &O4WK1;J"?,WLG<!.-WWMZ
M<6A[=7O5<JEG\WPZ<^-34WRO=10].'TL=ATC0WW)=I\!MG^N>'&N'7C5>)&=
MX'E->1F,OGFV>9%Z2WHF>@!FY'J<>G929GL?>NT\<'N=>TPBG'P">U0!?7XK
M?%>LN'<0@F><<W>8@B6+-W@6@<]X^GB6@7)EKGDG@2916GF\@.4[CWHZ@*,A
MYGID@%8!2WW1?[JK9G67C$";('8JBT")Y7:TBB5WL7<_B0!DG'?7A^M09GA]
MAOLZQWCZABLA27CHA<P!('X8@,.J3W1IEC*:"74#E'B(T761DI9VI'8CD*EC
MH7;!CM9/DG=CC3<Z&7??B_D@OW>8B[8 _7Y5@*NI<'-XH"^9)707G;Z'ZG2C
MFQ9UP74UF&5BS'7:E>).VW: D[$YBG;KDB@@479SD,P WWZ'@)>HRG+!JCF8
M<W-BIQ:'*W/HHZQT_W1RH#EB#G48G1-.*W7'FG@X_78LF1 ?[W5ZE/0 QWZP
M@(:H7')$M%B7\'+BL(J&CW-;K&)T6G/7J#AA<W1VI(%-I74BH; X?'6#GX8?
M=W2HE48 M'[1@'FB?X7%9!F3H(469HF#EX2<:,)R/X1':M%?N(0+;,I+\8/R
M;JPV@80@<$@<985A<.8  (!,=KJAF(.X;8.2IX-%;PF"@(+H<&UQ-8*?<;Y>
MPX)K<P1+%X):=#LUP()]=3@;R(-O=68  (  >KF@BX'9=M619H&(=XN!78$[
M>"MP$H$#>,!=P(#>>55*.(#7>>0U!8#S>D\;-X&:>BP  (  ?CJ?9H 9@"60
M,W_=@"* %W^G@ -O$W]Y?]Y<VW]D?\))@']F?ZTT>']^?Y0:RG_A?U<  (
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M.7MBK&Y[_'LAJ-EJWGKDI3Q8_GK2HAU&&7K@H!HQKWK&G9\8N'GRD+<  (
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M#X=3AE=S_(9KA<-C]862A1U2]839A(% G(1<A PL6X0@@[\2=X3H@X8  (
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M:9:895EL1)3C9WA<X9-D:7),29(/:TTZ-I$@;/4EV9$X;@$+/).5;70  (
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M<H^HB^]H/XX/BO19&(R)B>M)!HLNB/TWG(HEB%LCZXG B&L*V8EGAA0  (
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MH)[,:^)@-)Q_;4%1N9I=;I5" 9B ;](PHY=*<-0<9I?/<0<$()80<=(  (
M@ !Y:Y^B<EAL[IU"<R%?G9KT<^91(9C1=*Q!@I;R=6@P1)6Q=?X<-I8%=?L$
M4I/%=TT  (  @ !XQ)X0>AUL,IN[>F%>S9EX>IQ0?)=8>MQ [)6!>QTOTY0\
M>T\;]Y1G>S$$=)' ?$P  (  @ !X&YR_@>]KB)IR@;E>'I@U@79/R)83@2U
M:)0T@/@O9)+O@-P;M9+U@-@$CH_]@)T  (  @ !WAINZB=]J^IESB3A=DY<P
MB'5/.I4)AZT_XI,BAP<O&9&YAK$;CY&=AQ8$J(YV@R8  (  @ !W$9K=D==J
M@)B>D,1=%998CX9.NI0KCD@_;9) C4XNQ)#*C/0;AI!EC*0$QXTI@SL  (
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M.:>3<7-4F*2T<C=&WJ(#<P$W[9^Y<[HG&YYR="X2DJ 3<Y@  )6@>#   (
M@ !LH:CJ> A@KZ8#>%-3_:,L>)Q&:J!Z>.\WB9XS>4$FW9S<>6P2EYXR>/4
M )0P?&,  (  @ !L**>0?VQ@.*2O?U!3@:'9?RM%XY\F?P0W,9S0?O0FG9MP
M?O(2DIR&?N,  )+H@    (  @ !KO::'AO)?V:.EAG=3):#'A>1%A9X+A5 V
MV)NKA.4F;YHHA-42DIL#A+@  )'&@    (  @ !K9*6WCGU?D:+2C:]2WY_G
MC+)%.IT>B[LVAIJ\BQLF.YDEBTH2I9FHB:$  )#;@    (  @ !K)*4/EA!?
M5*(FE/52G)\SDY]$\YQ?DEDV0)GTD;,EZ9AAD;P2@IBMC(,  ) G@    (
M@ !J\*2AG>-?5J&DG*A2F9Z8FO=$V)NBF58V,YD7F,\E_)=JEN<2JI>IC)X
M"X^*@ @  (  @ !AL[A\8(E5]+5\8E))H;*09!@\8:_#9<,MNZV,9R4<DJU$
M9[@(7*ZD9VL  )-8<M@  (  @ !A,+>19]M5Q[1/:0))DK$5:C@\;ZX+:V8M
MY:N?;&0<\*L*;+H(\:P);&D  )(7=VX  (  @ !@ZK8+;NQ5=[*_;Y))7:]R
M<$4\0ZQ1<0<MUJG.<:<=%*D%<<D)7*FE<9T  )#A>X   (  @ !@JK1D==A5
M);$:=AE(_:W0=F$\!*JK=KHMJJ@@=PL=%Z<R=P8)J*=Z=S@  (^_?Q8  (
M@ !@:++U?-)4Z:^L?+](OJQ=?*T[N:DT?)PMCJ:5?*(=&:6.?)D)ZJ6(?1D
M ([!@    (  @ !@+K':@_%4QZZ!@Y=(HZLD@RH[FZ?Q@L$M;Z5(@H,=):00
M@J *)Z/,@CD  (WC@    (  @ !?_;#\BQ14M:V-BGU(F*H?B;P[BZ;AB0@M
M7:0QB+8=*Z+>B2 *9:)*AH@  (TS@    (  @ !?V;!7DD94LJS+D7Y(F*E(
MD'8[A:7YCXDM2Z-!CV4=&*'LCKP*?*$?AQ<  (R<@    (  @ !?P:_=F:!4
MNZPLF+U(HZB1EX$[AZ4TEH0M4J)MEBT=,Z$!DTX*DJ BAR8  (P @    (
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M6G54:HZ% 78E;&ESBW;V;B=@[G?+;]5-(GBC<6PWPWEF<L<>*'G8<U$  (
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M/&S(ET=_%&WNE3]M\&\+DR=;[G ND31(W'$WCX@T67'%CG$;D'!=C5@  (
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M 7L@<@%XY7MB<R=H>'NP=#=6^GP(=3I$+WQP=BDOEWS;=M@5Q7U(=H4  (
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M-W0PG,IT"W2>FGACYW4(F!-2UW6&E?- H78 E&8LVG8'D_X3]75WC7X  (
M@ "0_7+]J!R"NG./I8IS?7/THI-C5711GX]24W3&G/U ,W4YFVHL;'4SF8P3
MBW2TC3<  (  @ "++(A^7?!^$8>M8,=OTX<=8VI@1X:X9=M/=(9Q:"<]*X9F
M:CLHO(;M:[D.!HC^:T<  (  >=.*488T9JU].H6D:+5N[(4M:II?<X3.;&).
MNH2*;@\\CX1\;X\H0(3?<(\-UX9);_4  (  ?5B)7H0';U-\'8.D<*-M[8-"
M<=M>=X+S<OI-WX*[= L[V(*Q=/HGLX+W=8<-GH/G=.\  (  @ "(3X(4=^AZ
M^H'%>)=LN(%X>2I=A($R>:A- ($->AX[(X$'>H$G+($R>JL-9H'1>ET  (
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M='Q@H:QI+WP3GSA9]GN\G+%)UGN'FJPX=GMKF> E)GL,ER,,BGM?B'H  (
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M>(E8?D1A&8AK?F12L(>.?FI#48;+?FTR-H9G?G<>G8:,?F,&C(7&?J\  (
M@ !Z(HCZAD1MN8@6A?M@7H<JA8=2"X9"A/A"NH5\A'$Q\H3WA" >;H3YA#L&
MD80\@ML  (  @ !Y@X?TCHQM.H<:C<Y?XX8GC,I1=X4PBZ="&81IBK(Q8(/>
MBC(>*8.CBHD&BX+SA&P  (  @ !Y!(<JEMULN894E;%?7859E"=0]815DGQ!
MFH.#D3$PU(+XD,@=N(*;C]8&B8'EA&L  (  @ !XHH:2GTUL4H6^G<M>ZH2X
MF\90@H.EF:)!-H+"F"4PAH(FE[8=@8&OD_,&?8$4A&,  (  @ !QKYO87+)E
M\9GW7T)9.YA@8;1+3I;\8_L\"I7:9@<JXI5]9YX6+I>%9\<  ),-:;\  (
M?TIP]YH.9(QE9YA'9F]8M):B:$!*X94C:?@[MI/J:X,JKY-N;*L6,)47;)0
M+Y"^;K8  (  @ !P3Y@3;$)DHI9J;8Y8#I3+;LQ*/Y--;_L[-)(1<0DJ5I&"
M<<H6%9+<<84 <XYP=#,  (  @ !ODY8Q<^-CT926=*U7*Y,'=65)C9&/=A(Z
MF9!;=J@IY8_!=PD5WI#9=JT HHQK>40  (  @ !NUY2;>Y!C%Y,,>^)6<9&"
M?!U(T) )?$,Z$H[/?&<I=8XQ?'P5G(\.?#H PXJJ?:8  (  @ !N,I-;@UIB
M?)'6@SY5W)!(@OM(.X[*@J$YA(V&@E8I,(R^@C<5=HUD@F@ X(DG@)<  (
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MIJ*.9/%-DZ!M9K! ;)Y[:%8QTIS_:;\@\YS5:HH,3Y[Z:?T  (O[<LP  (
M@ !D*Z+H:G59#*"X:[A-&9Z4;/$_^)R:;AXQ?YL1;QH@T)K!;Y4,?9QL;P8
M (I[=Z(  (  @ !CG:$'<:M8:Y[B<GI,:)S)<SP_=9K1<_4Q$9E(=(T@D)C>
M=,,,CIH9=%4  (D4>^4  (  @ !C#I]N>/!7X9U3>5A+WIL[>:T^XYD_>>PP
MM)>I>B<@39<M>C$,CI@!>BH  (?1?YP  (  @ !BD)XL@%97<9P6@&%+=9GX
M@$@^?)?S@!HP599.?_H@)96B?_@,E98>@!$  (:T@    (  @ !B)ITMA[]7
M&9L8AWE+))CPAO@^*);<AF8O^I4RA@X?YI1MAD0,K)1TA0T  (7.@    (
M@ !AU9Q>CRM6S)I*CIM*TY@<C;X]V)7]C-LOKI1$C'8?BY-^C*\,B9,EB'H
M (4A@    (  @ !AE9O+ELU6OYFNEB1*Q9=LE.\]O94HDZPOJY-*DV<?L9);
MD>\,OY'LB)\  (2<@    (  @ !9([&M6F1.&J]27(U"9*T97JHUG*L88)XG
M+*GC8B,5DZMA8F@#1:FV8UH  (CG<?T  (  @ !8<+!G87U-NJWB8QM"(ZMJ
M9+DU?ZDN9CHG.J>]9V 5ZJC/9W #TJ:_:%$  (>@=K(  (  @ !8"*Z2:&A-
M2JP+:9!!T*F):K0U.*<X:\XG&*6L;)H6"J9S;'P$.:/S;7@  (9G>MT  (
M@ !7KJRG;SI,WZHF;_U!5Z>H<+DTYZ55<6TFWZ.\<>P6"J1.<:L$A*%<<OP
M (5!?HH  (  @ !74JK]=AQ,BJB"=HI!!*7_=NHTBJ.F=S,FNJ'U=VT6":)=
M=RD$PI\&>.$  (0^@    (  @ !6_ZFM?2-,4*<J?4I U:2=?4XT7J(W?3\F
MDJ!T?3,6&Z"7?18$_YSO?A8  (->@    (  @ !6NJB@A"U,*:82A!9 N:-U
M@\<T0:$"@VPF=)\T@T<6'9\M@X<%/ILA@GH  (*M@    (  @ !6A:?2BT-,
M$Z4RBOU JJ*#BF<T,I_^B<\F79XAB<H5_YX1B38%39FK@Y8  ((6@    (
M@ !68J<TDGY,#*1ZDB) IZ&ZD54T+I\CD*0F9YTOD)D6)ISVC>0%:IAP@ZD
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MU7',7&!]9W+Q7Y!LO'0;8HQ:X75$961'P79G:!,R\G=H:F 97G?-:UH  (
M<AV9X6V'8HV+HV[N90]\,7!!9VEKHW&,::%9Y7+1:[Y&YG0';;HR.'3U;V 8
MTG3);]P  (  =LB8A6JA;""*/VQ ;<=[$6V];U5JA6\F<,98[G"#<BA&&'')
M<W0QF7*E='P88W(F=),  (  >N*7!&@%=9F(P6G+=GYY@VMG=T9I.FSL=_E7
MOFYL>*-%%F_">4$PQW")>;<7RF_L>8P  (  ?G&5H&7&?PZ'9V>F?SQX,VE>
M?T9G^&KY?SE6QFR(?RQ$.6WM?R@P&FZ>?QX74FX&?O   (  @ "4>V/JB)*&
M3&7?B IW)F>FAU9F]VE3AHQ5UFKMA<Q#?VQ.A2LOB&SGA+\6Z6QRA,   (
M@ "3CV)BDA*%961FD-AV1F8VCV9F(6?MC>)5#6F2C'U"UFKTBU8O%6MJBJP6
MG6LCB<<  (  @ "2WF$NFXF$LF,[F:%UCF4.EW5E;F;#E3I47FAMDSU"+VG2
MD;(NDVHND2465FH5C>4  (  @ "29F!-I/.$+F)=HF=T^V0IGX1DV676G)Q3
MV&=ZFA=!P6C9F%,N(FD8EV 5Y6E,CLX  (  @ ".?'CG6+&!)WE27 ERMWGA
M7RAB_GJ$8A-2 7LQ9-0_G7OO9UXK/'S%:5L0WGY0:6   (  =@F-4G7A8;J
M$':99$!QG'=29IMA_7@/:--1'WC/:NL^W7F5;-,JGWI';D 0B'N%;?8  (
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M=6QYC=YL06V<C,-= FZKBY%,QF^PBGL[2'!^B:8G^G!PB6D/+G)9AW   (
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M.7Q6:REES7R7;-A7&7S<;F9',GTM;]@UOGV6<1,AYGX8<;8(Q7^&<9L  (
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MSG/[DN!A<W1SD7]3$W35D 1#HW4YCLPRRW5ZCBL?W'3@C@T(8W?.A:L  (
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MH8,(<1E9]H+'<CA,2H*,<SX]-()P=",L;8*.=,H8G(,V=+("78,*=LT  (
M@ !Q?8%"=^!EN8$=>)%9#H#J>2)+78"W>9@\F8"3>?PKZ("I>D(82(#_>A,"
M;H%$>\   (  @ !PIG^0?_)D[W]_@"-84G]5@"=*M7\A@ P\!W[X?_ KLW[I
M?^48,W[S?^@"C7^]?_@  (  @ !O]GXYB MD87XZA\97SWX-ASU**WW*AI0[
M<GV;A@LK*7U]A=07]WTJAAT"EGYV@<   (  @ !O:7TFD"1CUWTOCW)717T
MCF=)JGRUC3PZ]7Q\C& JI'Q1C#P7D'NTBUL"GWUJ@<8  (  @ !N_7Q3F$MC
M:GQ@ET)6TWPLE;]).WO6E"(ZEWN-DQ(J6WM)DO\747IUCX\"D'R@@;P  (
M@ !I Y1_5PI=T)-(6?=1KI)57,5$49&57V(U>9$E8; D<I&B8U4/3Y2,8R<
M (@):9H  (  ?M1H'9(C7JA='Y$48/U1"9 A8SA#S(]194XU%X[,9Q\D/H\<
M:%L/:9%M9_H  (8B;F0  (  @ !G48^V9C=<0([,9_U04(WG::U#'(T;:STT
MC8R1;)4CXHS";6X/7HZ";.D  (1><Z<  (  @ !F?HUQ;;Q;7HR>;O]/8HO)
M<"I"98L%<3PS[(J <B C;XJ8<IT/-XO/<@X  (*\>)H  (  @ !EKXM]=4Q:
MEHJ\=A5.FXGQ=L)!GHDN=U S9HB?=\@C XBB=_T/#(E3=Y0  (%.?.4  (
M@ !D]XGB?/!9[HDP?4M. (AG?7M!"8>??8TRWH<$?9DBV8;,?:,/"X<2?;4
M ( ;@    (  @ !D6HB(A(M94H?FA'=-:(<@A"] =H94@] R6H6P@XHB@(58
M@XD/,X4A@T<  (  @    (  @ !CWH> C$59#8;OB^5-+X8?BR1 /X4LBCLR
M+X1GB; B-H0&B@$.Y8.@A_(  (  @    (  @ !C?(:QE!E8K88ADWQ,RX5-
MDE,_X81/D08QXX-SD&XB H+MD"H.VX)=B@L  (  @    (  @ !<X)[Q5=]2
M0IU96)]&P)P(6T4Y^9K[7;@KB9I]7[X:29O-8+@&A)Q*800  (.C;4D  (
M@ !<!IS=71U1K)M97U5&-YGT87DYE9C 8W(K49@490P:4)D19;0&WYC=9>,
M ((0<C$  (  @ !;7YJ%9$-0]9D;9?Q%GY>]9Z(Y!9:$:28JZI7%:E8:)I:'
M:K4'%Y6<:N0  ("7=Q0  (  @ !:MIA :UI0.);G;)Y$T967;<XX:I1A;N,J
M:I.?;[$9W90S;\X'+I*Q<",  (  >V4  (  @ !:#)9,<H%/DI4$<UM$,).W
M=!PWQI)\=+<J I&K=2T9E)(<=2$',9 J==X  (  ?RX  (  @ !9<Y2W><A/
M!I-]>D-#L9(N>I4W49#I>L,IF) $>M\9<9 M>LP'.XWX>]$  (  @    (
M@ !8\)-K@1-.EI(^@3M#3)#J@2,V[8^7@.PI+HZE@,X9((ZI@.L'4(P<@.
M (  @    (  @ !8B))<B&!.+Y$ZB#M"YX_FA\0VD(Z&AS8HW(U^AP88MXUS
MAT<'*XJCA-D  (  @    (  @ !8-Y&.C^5."9!RCZ-"PX\5CLXV;XV0C=LH
MXHQ7C<(8^8P(C*$'<HE4A0D  (  @    (  @ !0IJIA5$U&8JB85M([3:<-
M63TN[*7D6VD@AJ797/<.EZBC70@  * (8'P  (  <2X  (  @ !/QJB46RI%
MQ*;,73<ZOZ4>7S(NA:/!8/<@6Z-M8BL.QZ6R8@<  )UL914  (  =?@  (
M@ !//:938>]%+:268XXZ0:+K91@N$:%^9GD@$Z$'9U8.T:+A9PH  )K>:>X
M (  >CP  (  @ !.QZ0+:*=$HZ)9:=XYI*"V:P$MH9]);  ?P)Z_;)$.QJ _
M;"@  )AW;RL  (  ??\  (  @ !.2Z(+;W%$*Z!K<$XY,Y[%<1$M*YU,<:0?
MC)RE<?8.P)W9<8X -98 =0D  (  @    (  @ !-UZ!J=F!#RI[3=O XY)TH
M=U4LZYN>=Y$?6)K7=YP.V)NI=UX <9/:>E0  (  @    (  @ !-<Y\3?55#
M?YV#?:(XJYO/?; LMYHW?9X?)IE=?8P.T9GE?;4 L)()?LX  (  @    (
M@ !-))X#A%E#2IQSA'$X@9JVA#(LF9D(@]\?"I@2@^0.JIAW@WL M9"9@'L
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M[EHB<E]ZKET#<X=J>%^V=)U9"&)%=:=&=61Q=J0R866%=W8:*V4[=[8  (
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M[5 WGP1U]U.3G$1F!U:KF9E5)5F(ETE#+%O&E8TOR5P3E/L865YFD'8  (
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M\EZU>6EOK6$@>?Q@8&-9>G50$&5L>N8^1V<7>U$JT&=H>YT2-&IZ>V\  (
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M:G*65O-JI7.S6GA;I7387<E+7G7W8.<YEW<.8[LEF7?Y9=<+NGK$9@(  (
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M-V0Y?YIDW&8;?ZU6<&?0?Z-&]&E4?Y@V!FI??Y@B]VG*?Z,*WW 8?\<  (
M@ !]O& HB"9Q7F):A\ID#V1,AS15KF8-AH9&/6>8A>LU<&B3A8(BI&>DA8H*
MRV[/A$,  (  @ !]"EZ1D.5PLV#4C_9C9&+0CKM5#&24C6M%GV8>C% TU&<*
MBZ4B+F78B^D*LVWJASP  (  @ !\BUU7F9)P,E^HF"!BVV&EEDI4A&-DE&%%
M*63EDM8T>&6^DALAR61BD5$*:VYDAPL  (  @ !X_7GN4OYM!'IB5H]@#7L
M6?91UWNP72E"1WQH8!\P_WU!8JX<XGYL9",$A(#I9.T  (  >2!WLW9@6TAK
M]7<H7B]?#G?R8.]0_WBX8X5!E'E]9>8P='I'9^H<B'L%:/$$FWXI:;(  (
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MH6J^A.1:%FP*A)%,>&TEA"(]NFX0@\0M;FYU@Y<:F&V(@]X$FG@X@H,  (
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M;WS+9%Y3=GTR9GQ&+GV0:&XWBWWX:B<FZGZ*:V<2E'^):S\  (  ;WH  (
M@ !I;7EF:?A>3GH$:Z%247J%;2U%2WKW;I@VOWMH;\XF3'O;<*$2.7R/<$@
M (  =/X  (  @ !H8W;5<=-=5'>0<O5177@E<_5$47BB=-$V(WD+=8TER'E@
M=@,1]7GX=9X  (  >>(  (  @ !G<W2@><5<<'5X>F)0B'8>>M5#FG:=>R4U
M?W;_>V0E?7<?>Y(1UW>Y>V   (  ?@D  (  @ !FKG+(@;-;RW.]@=M/]G1K
M@<5#"W3C@8PTZ74Y@6,D]W4O@601J77:@8D  (  @    (  @ !F$G%)B9I;
M-')-B55/8G,!B+U"@G-TB 4T9W.[AXLD<G.)AYL12W1JAL$  (  @    (
M@ !EF' 6D89:OG$HD.I.ZW'@C]M"$W)+CK,T"W)^C@(D+W(ACC81$7,_BO
M (  @    (  @ !@IHQO49A6!XOM5-Q*=XNI5_T]G(N56N0O&HO7764>"(TI
M7OH)@(YJ7RD  (  :6D  (  ?G!?CXE26/Y5*XD16[M)JHC>7E4\]8C$8+PN
MH8CN8L8=R8GY8_@)I(JH8_T  (  ;BD  (  @ !>GX9!8&-4+88Q8IA(UX87
M9*\\+X8$9I8N!88D:"D=8H;U:/T)HX=1:.L  (  <V0  (  @ !=L(-H9\E3
M,H-W:7I'U8-Q:PT[9X-J;'HM58.);9P<XX0D;A@)AH1G;@P  (  >%L  (
M@ !<QH#H;SU23H$2<'%&]($<<84ZBX$5<F\LP($G<RT<9X&.<V,)88'C<XH
M (  ?*P  (  @ !;]'['=L11B'\*=X5&/7\?>!PYW7\7>(XL(W\4>.(<)7\H
M>/$)6G^T>9D  (  @    (  @ !;/'SP?CU0UWU/?I)%F7UO?K0Y1WUD?K<K
MFWU/?KH;T7TD?L0)C7W2?S,  (  @    (  @ !:K'MYA<M0='OYA<Y%1GP;
MA7@Y!GOQA/TK;WNVA,,;C7M:A1L)4GQ<@]\  (  @    (  @ !:.WI*C6Q0
M!7K7C2M$V7K_C&TXIWK-BY(K)WIUBT@;8GG9BS()3'LJADD  (  @    (
M@ !4I9;<4#U*C)7Q4U4_B95/5DHS)I4"6/HDSY5W6Q82[YA26Z@!@I2E78T
M (  ;10  (  @ !3GI/]5S])O)-$6> ^Q9*G7%TRB))$7ILD9Y*(8$\2V)3G
M8)D!U)$*8FD  (  <?@  (  @ !2RY$,7C](W)!Y8&<^"H_L8FTQV(^'9#DC
MY(^O98<2FY&D98X"!HW+9V<  (  =N0  (  @ !2 (Y"94!(!HW(9O$]*(U+
M:($Q+XSI:>$C5(T!:M 22HZ3:IT"'XKP;*0  (  >SP  (  @ !1.8O(;%5'
M1(MI;98\:XKW;K4P=(J/;YXBXXJ*<#T1_HN^;^8"+8AX<EH  (  ?P8  (
M@ !0@HFK<X!&F8EG=%P[THC]=0TOZHB,=8\B:8AH==<1XHD?=8@"1895>$H
M (  @    (  @ !/XH?B>JE&#(>X>RT[6(=4>W4O@(;5>Y<B!(:3>Z81J(;E
M>XL"<(2"?5<  (  @    (  @ !/8(9C@<1%B(92@? ZV(7V@=<O#(5P@:<A
MFX41@:81+X48@<,"88,1@74  (  @    (  @ !.^(4TB3-%6H5&B4 ZN83S
MB+TO$(0XB!0A[8.#B!H1Y(,=AR0"UX&T@>P  (  @    (  @ !(6*)Q3E\^
MWZ$\44(T::!G4_8H6: H5DX9PZ%S5[\(HZ,;6&4  )&47^0  (  <'H  (
M@ !'1Y_F5/X]^)[L5W<S>)X:6<4GCYVO6[P919ZA7-@(IY]S75D  ([<9'X
M (  =5$  (  @ !&FYT-6YT]-)PM7:PRPIMO7XXFVYKY8208PYN]8>H(EYO.
M8E   (Q#:5$  (  >:D  (  @ !&!YH\8CH\A)EO8]PQ]IB\958F0)A'9HL8
M1YCM9P8(@)A,9U\  (G>;GP  (  ?8   (  @ !%9)>X:.@[W9<,:BDQ7I98
M:T EJ)72; H7^Y9,;$L(=94/;*\  (?&="\  (  @    (  @ !$Q963;[X[
M2I4*<*<PY)1;<5\E3).^<=,7N)0 <= (DI(I<F0  (80>6<  (  @    (
M@ !$.Y/"=IPZSY-:=SDP@I*N=Y8D^)(!=[P7:)(>=YD(@H_2>)L  (2R?<H
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M E1M8]=SF5>Y9E!D EK/:*]35EVE:O)!8U_Q;1 MT6"=;MH5L6/@;XH  (
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MLD3*CZUMXDDPCDI? 4TFC/-/ U"5B] ]RU+<BODK+5)'BL84*EWKB9L  (
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M%U=Y:T)HE5IT;0M:%%TP;KI*/U^@<$HY%&%5<;0E^6#(<KT-N&EX<L\  (
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M2$I3E/)D'TX1DS95\U%;D7I&NE0+D!<V,55/CU$CWU50CV0,X6H\B+4  (
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M7EMO<;U=M5X)<NU0 F!4= %!+6)!=0 PFF,[==8=N&+[=CT&YW15=X0  (
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M!G*34:18>'/-555*T74&6-X[S78M7" JYW=#7MD6G7@P8!8 IW[F8EH  (
M>-IO#VSK5=QCNVYJ61-77V_<7"Y)Z7$V7R$[#7)J8= J4G-:9 ,60W0)9-<
MSGZD9R$  (  ?(1MEFBG7?=B4FIX8)%6-FPC8Q%(V&V=96DZ)F[=9X@IFF^?
M:3<5QW!]::T X'Z&;"H  (  ?[QL-62T9A=@^&;$:!)4XFB<:?='WFHV:[TY
M1FN$;4TH\&P1;H(576UN;JD \WYE<98  (  @ !JXV$C;D9?N&-F;Z13NV5D
M<.U&RF<7<A8XHVAN<R(H;6C#<^<5&VK)<]H!$WXN=QX  (  @ !IQ5X#=H!>
MR&!V=U!2YV*6=_]%]&1<>) WS66C>1$GV66J>7@4KFB:>6<!$GXP>_0  (
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MJ';!6 ),_7>Z6P5 *GBD7=@QR'F"8%,A''IG8A$,M'RL8CT  (  :D@  (
M?O1A\7&G7(-777+N7Q=+[G0289 _+W4/8]<P^G7F9= @@79X9QX,?'E!9QH
M (  ;U8  (  @ !@L&W59#)6&V]19C1*L'"7:!T^-W&L:=\P'G)^:UD?U7*S
M;#\,,'98;"   (  =-$  (  @ !?A&I<:^A5 VP$;5])I&UI;KP]+&Z+;_,O
M>&]/</D?2V\=<8@+_G/0<6X  (  >;(  (  @ !>=F=&<[)4!FD9=*1(OFJ<
M=70\:FO'=B(NSVQT=K ? VO;=OT+]'&9=Q\  (  ?=,  (  @ !=F&23>WA3
M2V:5>_-(&V@S?#H[TFE??&(N,VGH?(L>>FD=?*P+UV_"?3T  (  @    (
M@ !<YV)*@S)2I&1M@T%'?68A@P<[0V=,@K,MJV>S@HH=[&;J@K<+BFY<@GL
M (  @    (  @ !<8F!MBNQ2)F*JBJ5&_V1NB?4ZS&65B2TM2V78B,P=J&4F
MB2H+66T^AJH  (  @    (  @ !8\X-<3&!.JX.63]U#A(0$4SXW"H2:5F$H
MO(6 60(75H>)6EP$<8?56Z(  (  :34  (  ?AI7>'].4WQ-A'_55HI">8!@
M67$V+(#Q7!LH$X&Q7DD6\8,S7T,$C80(8&X  (  ;?$  (  @ !62'M:6K-,
M5'P?74!!>WS)7ZHU/GU?8=<G4WX"8Y$6:W[[9"\$BH"V958  (  <R0  (
M@ !5*W>B8?5+,7B28_U 5GE59>0T6'GW9YHFB'I_:.85TWKX:2\$<WW<:F\
M (  >"   (  @ !4&G0Y:4=**752:LX_578O;#8S8G;0;6PEXG<W;E@51W>$
M;EX$6GMI;^,  (  ?'(  (  @ !3)G$L<*M)0W)O<;L^A'-D<J8RH70&<V<E
M-W0]<^L5!72'<],$8GE#==\  (  @    (  @ !246YW> I(<V_G>*D]Q'#V
M>1HQ]7&6>6LDH7&;>9\4HG(F>8 $D'A*>W,  (  @    (  @ !1IFPG?W1'
M[VW,?[@]6&[W?[$QJ&^)?XTD96]2?XD40G Z?[ $7'BB@"<  (  @    (
M@ !1)6H_AO)';VP!AND\W&U!AG@Q.6W.A?,D$6UDA=L4$&ZDA;@$47BU@NL
M (  @    (  @ !,[XV@2M=#8(UJ3C8XU8V#46DLO8W_5$0>58]?5E<,@)'=
M5O8  (F*7#0  (  ;*T  (  @ !+DXG+491".(GF5(LWM8H75U KQ8I_6;X=
MF8N86VP,.8T56]8  (9.8-\  (  <8X  (  @ !*A87Z6&=!'(9+6NDVO(:4
M73PJUX;S7SL<W(?48(0+Y(B>8+\  (-49;H  (  =H@  (  @ !)C8)47T=
M%X+(84\UJX,C8RLJ 8.!9+\<((0Q9:L+B(2W9<(  ("J:MX  (  >NL  (
M@ !(FW[Q9CP_)W^/9\XTPG_^:3<I'H!/:E<;E8#!:O@+.X%@:OT  (  <'D
M (  ?KX  (  @ !'NGOB;4P^37RP;G S_GTV;V@H<7U]<"(:^WVF<&P+$WZ&
M<(<  (  =E4  (  @    (  @ !&^'DQ=%T]E7HM=1TS7'K+=:<GYGL%=@,:
M<GKG=A,*U'PV=FP  (  >T<  (  @    (  @ !&3W;0>VP\ZW@#>] RO7B\
M>_@G77CM?  9^GB$>_L*;7IO?*T  (  ?W@  (  @    (  @ !%TW3;@KP\
MAW9$@N R;W<@@I\G.G<Y@DL:)'9R@EL*SGBU@@8  (  @    (  @    (
M@ ! F9E%2*LWLIBM2^4MHYB43M0AJIE143L2>9PR4E,#4IF^5&   (2R7XH
M (  < T  (  @  _-Y6\3P0V5)6.4=DL+)695&(@2Y9 5F81;IBA5R\#"945
M63\  (&N9$   (  =0$  (  @  ^09(657@U.I(95^$K'I(^6@(?.I+76Z 0
MH)3#7!\"TI#/7BX  (  :2,  (  >70  (  @  ];XY]6_TT4(Z?7?8J&([5
M7ZD>9X]D8.@/_Y#782H"JHT&8SH  (  ;E8  (  ?5@  (  @  \FHL48IHS
M=(MI9"8I1(NM970=F8PB9DL/IXT09F<"F8G%:(<  (  = 0  (  @    (
M@  [RX?R:5TRIHB':H$HD(CE:VL=!HE":_$//XFD:]8"IH<#;C   (  >3L
M (  @    (  @  [%84I<"DQ](7^<.\G^(9W<7D<C8:_<;0.YX:N<88"EH3%
M=%,  (  ?9@  (  @    (  @  Z?(*[=PHQ78//=WPG=H1E=ZX<+H27=Z@.
MHX1)=Y(";H,">BL  (  @    (  @    (  @  Z#8"J?B<PYX'V?D\G"X*L
M?C$;XX+,?@$.D8)<?BX"B8&(?O\  (  @    (  @    (  @    /__  #_
M_P  __\  &UF=#(     ! ,)   !                     0
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MIDVJ3J]/M%"Z4<!2QU/.5-55UU;95]M8WEG@6N-;YUSJ7>U>\5_U8/AA_&,
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M?\Y_6,V9?ZA^S;3:?YE^>9P4?Z-^98-,?\9^A6J%?_Y^P%&_@&-_/3D @1*
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M06#6@<>+9$H8@9>(:#.B@8N%!.=<A(NHH-%L@YVD%;L0@M2?NJ1;@C>;E(V
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MC.Y^("QJB3M_T[VBHYR#<*OBG_*"?)G.G'.!M8=NF1^!)73%E>^ TF(*DL>
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M=W&I^':;>(.BKE_R>:J:_$E>>O:2NS+\?'2)C.<G=%720=#V=-G)F[I,=6K
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MBC6 /*JCB/1_T99:A]5_AH&OAM)_96SHA>-_9UA A/U_>T/,A"Q_NB_N@VZ
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MOCN P6?PM^R #5M*L6U_L4[#JK9_D$*)H[Y_I3;^G'1_UBQ@E,V .R-5C.J
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ME-B OHJRDH* 7GHZD$^ &FERCBE_\UB9C M_Y4@2B>-_XC?^A[I_^2D(A7^
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MDKE^BR(,BZ-_CGD#O0."D&U<MX&!N6&AL<F!#U7GJ]> HDH\I;& ;3[EGU*
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M>N)Y9&H&>ZEZ0E8.?(E[,D).?9=\22\Y?N=]D\CH=H* W;;E=TF @:0Y> >
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MGVR  &X@G!)_OV$@F+)_EE/BE4U_B$;&D=A_CSHWCD=_HRYEBJ!_RR0(ANF
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M*EC"G\1^+$RYFU5^4T#IEL9^DS6]D@U^Y2MFC3)_5"*/B%!_TGMPJU6%27
MISR$BF1'HPB#TUA=GK:#)TQZFDJ"F$# E<^"'S6WD2F!K"N'C&>!22+;AZ6
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M@+]Z+U9:@*U[ T9H@*I[YC;;@,U\Y"AK@19^ :*;@!B (Y1(?]^ ((53?ZZ
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MB'A^,"+5A:1^_WX$FG:!P7*QE^"!B&;OE3V!0EK<DHV ]DZSC]F NT*6C2J
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M:0R'&H_2:QF&/'[_;2J%4FW>;U^$;ER/<<>#F$N@=%6"NCL7=R:!SRNE>D"
MR:YO97Z1?Y[J9[*/X(Z\:=&.&'WX:_F,.FSP;DB*6UO5<,J(?DL9<X"&F3K&
M=G>$CRN.>;*"4:V!9%B:^9X!9IJ8?XW7:,*5QWT?:OF2\&PL;6&0%ELW;_Z-
M-$JL<LJ*.CJ&=>.'$RM[>3N#J*S08WBD0)U/9<"@YXT=9^R=.7QH:BB98&N
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M@-1]@R4G@0Y^<HOZ@%" @7^[@!F E'+E?^* A665?[. 7E@<?Y2 .TIM?Z"
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MV%72CE9WTTIAC%%XX#\2BDMZ!S19B$1[0RI5ADQ\HR&[A&U^$W6FDJ=\ &M
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MF$R 4E=8E9* .DU DK* %$,VC\1__#EHC--__# \B>N ""?>AQ: &R#MA'"
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MH!6#04[PG'6"T47@F)2"3SS[E):!X31UD(N!B2RTC'Z!126YB**!!B 0A1B
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MQT1[>,!SF36S>P5VM"@A?9-Z,9P::_5M%8ZY;;QNUX"W;W)PBG',<3-R-&*
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M;Y.$^G0-</R$>6:D<G6#V%C_=!>#-$M3=>Z"F#X@=_6!_S%_>CJ!7B8Y?*.
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MA,A^OQ_]@SA_<F*"D,& Z5GBCS6! %#IC6> WT>^BVV ICZAB7: ?C78AXV
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M/JB]56=I@)G]63YK@(K$7/]M?GK18,-O@VIX9*]QEEG\:-5SP4G>;3=V##I
M<?5XEBOJ=P=[=J;R4CUS<YA+5F-T@HDF6F1UE'F 7FQVJVE38J9WTED49QMY
M#4DZ:\YZ73GE<-Y[V2O>=C=]B*5"3W=]0I;+4^!];H?%6")]F7@T7&1]Q&A;
M8-Q]^%A)99M^/DBK:I9^CCF6;^Q^]"O3=8-_;J/432"&\96+4<*&/8:O5CB%
M?W<]6K&$NV=]7UV#^U>H9%&#14@X:8V"DCE4;R"!W2O*=.F!(J*I2RF0<Y2)
M3_N.UX7/5)N-*G9Z64"+=6;-7AZ)Q%<:8T.($4?>:*V&5CDB;G2$ARO#=&F"
MH:'$29>9L)/"3HZ7)(4A4TV4@G7B6!"1VF9$71./-U:?8F6,C4>$9_N)SSCY
M;>:&ZRN]= "#Z:$K2'"B@9,W37N>]X2@4DN;7'5P5R&7Q67G7#N4.%988:J0
MG4=$9V*,Y#C*;7*(^BNY<ZN$^Z#58_-5-9+49FE9.H1):.==)W49:WAA!F5Q
M;BQD[E6B<1!H^48O="AM-S<K=Y5QUBE;>UAW"I\K8#!>Y9&C8P]A^X-%9>!E
M G0\:+QH F2T:[UK"E4*;O5N,47#<F5Q@C;S=B]U*BEC>DMY29V*7,YH>9 !
M8 !JI8';8QMLQW+N9D%NYV.;:8]Q$U0J;1ES6D4A<-UUPC:>=/AX:REJ>5M[
M99OJ6<1QY8YO73US-(!=8)=T>G' 8_UUNV*69YAW!U-?:VUX:$27;WYYX398
M<^5[ABEO>(E]6YIH5QM[-8T/6M![KW\77F=\&7"-8@5\>6&X9=M\WU*J:?A]
M6$0=;DY]W#8=<O9^=BET=]-_)9DH5-^$:HOM6,2$#WX37(N#FF^C8%Z#%6#H
M9&:"D5(9:+:"&$.Z;4F!IC7K<BN!-"EY=SB OI@F4P&-<(L"5P^,/'T_6ON*
MXF[E7O>)=& ^8S"("%&59ZZ&G4-N;&R%,#7'<8"#LRE\=K>"(Y=B4866,8I-
M5;"4(GR56;>1WFY-7="/@U^S8BR-+%$:9M:*TT,;:[V(<#6G</.%[BE_=DV#
M59;=4&J>CXG*5*>;HWP26+V8<VW37.>5*E]/85J1ZE#09B&.ID+9:RF+3S5Z
M<(.'U"F!=?F$4I5;:S555HB4;0195GLG;NI=/6T$<.=A%EYG<P-D^T^I=4QI
M!T%3=\1M23-V>HUQ\2;9?:)W*Y/F9Z->:H=B:==AD'H(; EDHVP.;DQGL%V9
M<+%JR4\(<TEN!$#C=A-Q:S-&>2]U)R;X?(UY49*!9&%G>(8)9NIIQGC^:6%L
M!VL7:^1N0ES3;HUPBDYU<7!R[D"(=(AU=#,C=_)X/"<3>YA[4Y$'871P882?
M9$!QXW>49O1S5VGY:;1TPEO<;*AV-4VW;]-WOT )<S1Y8C+K=N-[,2<J>L%]
M+H^M7NEY+H-;8>IYZW9F9-5ZD&CC9\Q[)5L8:O=[P$T9;F=\;#^D<@E])C+#
M=?5]^"<^>@A^WHZ/7,:!Y()27_*!VW5W8PF!K&@)9C&!9UI9:8R!(DR9;2N
MZ3]2<0: N3*@=2F BR=/>6N 78VI6OZ*:8%[7DV)F'2Q88:(D6=79-2';5FZ
M:%V&24PA;"B%*3\4<"J$##**='V"XB==>.B!JXSY69"2K(#47/J1$G008$R/
M+V;$8[6-)UDS9V"+(4NK:U6)'#[);WV'%#)T<^^$]2=I>'V"QHQ_6'R:E8!9
M6_F8-W.07UF5=F9*8M*2AEC09I*/FTMD:J*,LCZ*;NR)P#)+<X*&MB=R>">#
ML8H'<K95@'Y,<]Y9<7'G=2E=3V30=HYA(U=&> ME"$FF>:QI&3QZ>W5M82_7
M?85R$22!?]1W1XBY;T]>!7TU<-EA+W#E<FQD2F/U= YG8E:6=<UJBDDC=[=M
MUSPG><MQ4B_"?"9U(B2W?K5Y5H=];#1F>WOP;@YHXV_>;]YK/V,'<;YMEU7:
M<[YO_4B;=>YR@CO8>$IU*B^O>NQX$R3F?;A[0(8V:6)NXWJP:WUPC6ZN;8AR
M)V(T;YYSOE4L<=]U6D@E=%%W#CN:=O%XW2^D>=5ZVB4/?-Q] H3]9O5W,7FD
M:4)X)6VM:W]X_V$O;<9YR51P<#QZF4>+<O![?#LY=<Q\;B^$>.A]>B4R?!U^
MF8/Z9.I_9WBN9UY_I&S,:<)_MV!D;#=_LE/#;ME_KD<<<;=_MSKV=,I_RR]P
M>!M_Y25/>WV  (,I8S:':7?K9<J&[VP9:$V&.%_":N2%7U,S;:^$AT:R<+>#
MM#K(<^V"Z"]G=VR"%"5H>O>!-X*&8=6/*W=19(2-^VN#9QZ,=E\Z:<V*Q%*W
M;+B)$T9&;^>'9CJ&<T"%O2];=MR$ 25[>HJ"/X(18,>6FW;=8XJ4O&L+9C*2
M9U[(:.^/UU);:^V-2D8&;S:*PCI.<K"(."\Y=F^%H"6+>C.#&'[2>GQ5GW0$
M>P%9?6B;>[!=45R/?'-A)5 @?4-E$$.H?BQI*C>Q?S1M>RQ7@'5R-")8@>=W
M7WVF=TI=G7,3>"M@QV>_>19CZ%O=>@UG#4^7>Q9J1T-+?$!MJ3>$?8MQ.BQB
M?Q%U'R*D@+UY6'R,=%)ECW'R=8!H!F;2=J9J=UL(=]-LZ$[P>1AO;4+6>H1R
M$S='?!%TWBQC?=5WZ2+G?[=[+'MP<:1M9W#8<PIO,V6]=&5P]%I&=<-RLDY-
M=TAT?$)J>/%V7S<2>KYX7BQD?+YZBB,A?M-\UWI<;TQU-6_2<.)V5&3.<FIW
M8%EL<_9X7DW0=:AY9T(1=XUZ@S;K>9)[L2QL>\E\^R-3?@]^5WEQ;5E\[V\0
M;Q=]:&0C<,%]NEC <G-]\TTS=$U^,4&M=EI^@3:Q>)!^W2QA>OI_0B-\?6I_
MJ'BQ:[>$=&Y:;9.$16-\;UJ#V5@J<2R#2TRO<RF"P$%/=5R"0#:-=[*!R"QB
M>DB!3".>?.& RW@::F2+M6W-;%J*X6+U;C:)M5>R<!V(6TQ#<C>' T#P=(Z%
MLC98=P2$:BQB>;6#%B.Z?'*!P7>I:5R2KFU@:V:1.V*';5&/35=,;T6-($OS
M<7"*]4"\<]Z(U#8L=G6&MRQ+>4>$E2//?!F"BG/,@HQ5FFG?@G%99U]L@GM=
M-%1L@H]A#4D;@J%E!#W1@K]I,#,6@O%MD2D+@T]R5"!C@]1W<W*^?Y)='&D,
M?\I@1EZO@ 9C;U/9@$-FI4BR@(1I]CV4@-MM=#,*@4EQ'RDT@>-U&R#&@IUY
M67'*?+YDD&@2?3QG%EWG?:QIG5,G?AEL+$@N?I!NTCU!?R)QGC+M?\QTD"E0
M@*!WOR$;@8U[&'#3>BUK[F<9>MYMU5ST>WUOMU)U?!MQGD>>?,MSECSC?9=U
MJS+%?GMWW"E@?X9Z.B%E@*%\KF_H=_)S.&9!>,UT@UPJ>91UP%&S>EMV]D<P
M>S-X.3R6?#=YE#*G?5![ 2ER?HY\B2&D?]9^&6\4=@MZ<V5]=PY[(5M[=_=[
ML%$F>-Y\+$:]>=M\L#QI>P!]2S*:?$A]\RF$?;A^I2'9?RQ_5VYF='B!?F3P
M=:"!E5L"=J*!<E"W=YV!+T94>+J ]3P<>@. S#*&>VB KRF0?0* C2($?I^
M:&W<<S*(2F1O='.'R5J)=8J&\5!.=I>%[$7Z=\R$\3O/>3:$ S)<>K:#(BF9
M?&R"."(G?BV!36UR<C".TF0*<X6-P%HG=*R,,$_X=<:*8T6Z=PF(H3NH>(>&
M[3)#>B6%12F3>_N#FR)#?=&""&D@BN157& ,BB-9'%:-B7U<Z4R9B-!@S4)E
MB ]DVCA)ATUI("[)AI9MFR8)A?]R;QZHA9%W@V@NB"!<;5]4AZI?F57IARIB
MT4P=AIMF'D(6A@%ICC@IA6]M+R[;A.MP_29-A(IU%1\?A$UY6&=?A6QC:UY_
MA3-F U5!A.)HHTN+A'UK5T&QA!)N)C?S@[9Q("[:@VET/2:!@S]WE1^&@S)[
M!&:1@O!J4UVO@N1L6%1T@KUN8$KX@H5P=T$^@D]RHS>R@BET\"[,@A)W62:G
M@AQY[!_?@CU\B&7'@,=Q+%SQ@.-RH%/"@.!T#4I7@,IU>D#?@+YW #=S@,MX
MGBZ[@.9Z3B;%@2!\&2 J@6Q]X643?O5W\EQ-?S5XUE,S?T]YHTG9?UAZ9D![
M?VI[-S=2?Y1\'RZW?]Q]%2;A@$5^%B!I@+Q_#61V?61^?5N[?<M^TE*R?@%^
M^TEM?B%_$4 D?E!_,#<H?IA_7R[0?O1_GR<$?XE_W""=@"N #F/[?"B$WUMJ
M?+2$KU)Q?/N$*DD^?1R#>T (?56"X3<&?;^"6RZT?CV!ZB<7?N^!:R#'?[6
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M2*^ 97YX3D" 5' \4]> 0F&H6:> -%+\7\F -$2W9C> /#<5;/J 4RKH<\V
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M>B]\UD35>R9]+3V&>^!]@C9 ?(Q]\B\Z?5)^>"D#?@]_#B-O?O]_EA[A?_V
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M@5)^VSU5@9U^YC<Q@6Q^^3$D@0]_,"M4@,I_?"8H@)9_T2&:@)Z &QX%@,2
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M1$'_I$92_:I$8/2Q0F[KN$%[Y,%"AM_,1HW3SU*7P<1AI[.[;;.KM7B[I;&
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M<\*&J7/"AJESPH:I_[0D)>S*%B/-Y1,LN?8;1J?Z)EN8[C5LC.5$>H3>4X.
MV6**?-5LCWC2<9-UT'65<\]XEW'.>IAPS7R9;\U^FF[,@)MMS(*<;,N$G&S+
MA)QLRX2<;,N$G&S+A)QLRX2<;,N$G&S+A)QLRX2<;,N$G&S+A)QLRX2<;,N$
MG&S+A)QLRX2<]<$5&='?#!B\\Q,QJO\>1YK\+%F.\CQGA.I+<GWE6'IYX&.
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MHS0:_ZTS'OZX,B#PQ34@X],_'-C>12;*VTTZO=-43+#.6UVCR6%KF,1G=XW
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M4];6BU/6UHM3UM:+4];6BU/6UHM3UM:+_Y<D"?^I)@K^N!P)YLX1!<[C%PC
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MT"@'U-\R"\G?/AF]VT<LL=9//:315DR9S5Q9CLEB983&:&Y[Q&]V=,%U?&W
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M0_^154+^F%9!_9Y70/VF6$#\J5A _*E80/RI6$#\J5A _*E80/RI6$#\J5A
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MASTX_XP]-_^3/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^JL0
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M_Z5*.?^M2SC_N4LX_[E+./^Y2SC_N4LX_[E+./^Y2SC_N4LX_[E+OK4" +#
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M,2W_GC(M_YXR+?^>,BW_GC(M_YXR+?^>,BW_GC(M_YXRI,(  );/  "(WP
M@/\, 77_$@)J_Q@#8O\A!UK_*0M3_S$/3?\X$DC_/A5#_T07/_]*&3S_3QHY
M_U,;-_]8'#7_7!TS_V$>,?]E'S#_:B N_W @+?]V(2O_?"(J_X(C*/^((R?_
MD"0G_Y D)_^0)"?_D"0G_Y D)_^0)"?_D"0G_Y D_V E!/];, ;_83H-_VI!
M%O]O2A__<5(I_V];,O]K9#K_9VY!_V1Z1_]@A$S_78Y0_UJ64_]8GE;_5Z58
M_U6K6O]4L5O_4[=<_U*^7?Y1QU[\4=%?^U#@7_A0Z5_S4>U?[E/P7^A4\5_D
M5O)?Y%;R7^16\E_D5O)?Y%;R7^16\E_D5O)?_V E!/];, ;_8CD-_VQ %O]Q
M21__<E$I_W%:,O]M8SK_:&U!_V5X1_]A@TW_7HU1_UN65/]9G5?_5Z19_U:J
M6_]5L5S_5+==_E._7OU2QU_\4=-@^E#B8/91Z6#Q4NY@ZU3O8.56\6#A5_)@
MX5?R8.%7\F#A5_)@X5?R8.%7\F#A5_)@_V$E!/]<, ;_93@-_VX_%?]T1Q__
M=5 H_W18,?]P83K_:VI!_V=V2/]C@4W_8(M2_UV45?]:G%C_6*-:_U>J7/Y6
ML%[]5+=?_5._8/Q3R6'Z4M9B^%'D8O-2ZF+M5.YBYE;O8N!8\&+;6/%CVUCQ
M8]M8\6/;6/%CVUCQ8]M8\6/;6/%C_V(E!/]=+P;_9S8-_W$^%?]W1A[_>$XH
M_W=6,?]T7SK_;FA!_VIS2/]F?D[_8HE3_U^25O]<FUK_6J)<_EBI7OU7L&#\
M5;=A^U3 8OM3RF/Y4]ID]5+F9.]4ZV3H5NYDX5CO9-E9\&736O!FTUKP9M-:
M\&;36O!FTUKP9M-:\&;36O!F_V(D!/]>+P;_:C4-_W0\%?]Z1![_?$PG_WM4
M,/]W7#G_<F5!_VQO2/]H>T[_9(93_V"06/]=F5O^6Z%>_5FH8/Q8L&+[5KAC
M^E7!9/E4S67W4]YF\E3G9NI6ZV;B6>YFVEKN9]%;[VC,7/!HS%SP:,Q<\&C,
M7/!HS%SP:,Q<\&C,7/!H_V,D!/]?+@;_;3,,_W<Z%/]]0AW_@$HF_W]2,/]\
M6SC_=V-!_W!L2/]L=T__9X)4_V.-6?U@EES\79]?^ENG8OA9KF3W6+9F]5?
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M23K\STDY_.-).?SC23G\XTDY_.-).?SC23G\XTDY_.-)QZT  +>W @"JPP(
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MI#H[]K [.O>_/#GXSSPX]^@\./?L/#CW[#PX]^P\./?L/#CW[#PX]^P\OZH
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M&B/_H!HB_ZH;(?^M&R'_K1LA_ZT;(?^M&R'_K1LA_ZT;FKX  (O*  !^UP
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M9'5\\V1U?/-D=7SS9'5\\V1U?/-D_VD6 ?]X$P'_AQ0 _Y,5 /&>%0#CJ!8
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MKDM(Q;]+1\;82T?%[4M&P_E-1<+_3D7"_TY%PO].1<+_3D7"_TY%PO].WY
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M+S?ST"\W\^<O-O'S+S;Q\R\V\?,O-O'S+S;Q\R\V\?,ON:<  *NP  "?NP
MDL8  (;0 0![W04 =/<1 &WW' %F^"8#7_@O!EKY. I4^4 .4/I'$4SZ3A1(
M^U461?M;&$+[8AI _&@</?QP'3K]>!\X_8(@-OV-(C3^F",R_J0D,?^Q)3#_
MOR8O_\\F+O_C)B[_XR8N_^,F+O_C)B[_XR8N_^,FK:T  )^W  "2P@  ALT
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M5X)O_5>";_U7@F_]5X)O_5>";_U7_V 5 ?]N$0'_>Q, _X84 /:/%@#GEA@
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M0$7 Z#]$OO9!0[W_0D.\_T-#O/]#0[S_0T.\_T-#O/]#UHT  ,:;  "XI0
MK:X  **V  "8OP( C<@& (/1"P!_TAH >=(J W+2-PALT4(/9M%+%6'04QI<
MSUL?6,]B(U3.:2=1SG$J3<YZ+4K.@S!(SHXR1<Z:-$/.J#5"SK@V0<_--4'.
MZ#5 S?4W/\O^.3[+_SD^R_\Y/LO_.3[+_SD^R_\YRI8  +RB  "OJ@  H[,
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M&RO[ZQLK^^L;*_OK&RO[ZQLK^^L;J*H  )JT  "-OP  @,D  '33  !GW@
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M2))@_T>28/]'DF#_1Y)@_T>28/]'_U@5 ?]C$0'_;A( _W<5 /M^& #M@QT
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M2%&8YDA1E_5(49?_1U&6_T=1EO]'49;_1U&6_T=1EO]']G<  -B%  #)D0
MOYL! +2B  "KJ   H;   )JR$0"4LR(!C;(P!86Q/ Q^KT84>*Y.&W*L5B%M
MJUPG:*EC+&2H:C!@IW$T7*9Y.%BE@CM5I(P^4:.80$^CI4)-H[1#3*/(0TRC
MY$-+H?1#2Z#_1$N@_T1+H/]$2Z#_1$N@_T1+H/]$XWT  ,^+  #"E@  MY\
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M+3S%_RX\Q?\N/,7_+CS%_RX\Q?\NQ),  +:?  "II@  G:X  )*W  "&OP
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M"1S_W0D<_]T)F+   (JZ  !\Q   ;\T  &+8  !5W@  2>0  $3[!0 __PX
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M_S^"9/\__UD. /]D"P#_;@H ZG<( -M]" #4@@H S(02 ,.%) &[@S0%LX!
M#*U\2Q2F>50;H79<(9QS9":8<6LKE&]R+Y%M>3..:X$VBVJ).8AHDCR%9YL_
M@F:F08!FLD-^9L%$?6;91'QG[T-\9_Q!?&C_0'QH_T!\:/\_?&C_/WQH_S]\
M:/\__UL, /]G"0#W<0< WGH% -2 !P#.A0D QX<1 +Z((@&VAS$$KX0^"ZB!
M21.B?5(:G'I:()=W82:3=6@KCW-O+XMQ=S.(;WXVA6Z&.H)MCSU_:YD_?&NC
M0GEJL$-X:K]$=FK4179K[4-V:_M"=FO_079L_T!V;/] =FS_0'9L_T!V;/]
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M1%]]Y4-@??9"8'W_06%]_T!A??] 87W_0&%]_T!A??] _V<  .-T  #2?P
MQX@! +Z/ @"VE0$ KI@& *::%0"?FB8"F)DS!I&7/PR+E4@4A9-0&G^16"!Z
MCU\E=HUE*G*+;"YNBG,R:HA[-F:'A#ECAHX\8(69/UV$ID%;A+1"6H3'0UJ$
MXT):@_1!6X/_0%N#_T!;@_\_6X/_/UN#_S];@_\__VH  -YX  #-@P  PHP
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M.$F;_SE)F_\Y29O_.4F;_SE)F_\YVWH  ,B'  "\D@  L9H  *:@  "<I@
MD:P  (>Q" "!LA8 ?+,F 7:R,P1QLCT):[%'#F:P3Q-BKU887JY='%JM9"!7
MK&LC5*QS)E"K?"E-JH8L2JJ2+TBIGS!&J:TR1:F_,D2JVC)$J.\R0Z?[,T.F
M_S-#I?\T0Z7_-$.E_S1#I?\TT($  ,&.  "UF   J9\  )ZE  "3K   B+(
M 'RY @!VNA$ <KLA &Z[+@)HNSH&9+I#"E^Z3 Y;N5,25[A:%E2X81E1MVD<
M3K=Q'TNV>B)(MH0E1;:0)T.UG2E!M:PJ0+:^*C^VV"H_M.XJ/K/Z+#VR_RT]
ML?\M/;'_+3VQ_RT]L?\MQXD  +F5  "LG0  H:0  ):K  "*L@  ?[@  '._
M P!JQ P 9\4: &/%* %?Q34#6\4_!5?%2 E4Q% ,4,18#TW$7Q)*PV852,-N
M%T7#>!I"PX(<0,..'C[#G!\\PZL@.\.\(3K#U2$[PNXA.<#Y(CB__R0XO_\D
M.+__)#B__R0XO_\DO9$  +";  "DH@  F*H  (RQ  " N0  =;\  &K&! !>
MS @ 6<\2 %?0(0!5T"X!4= Y D[00P1+T$P&2=!3"$;06PM#T&,-0=!K#S[0
M=1$\T8 3.M&,%#C1FA8VT:D7-=&[%S32TA<UT.P6-,_W&#/._QHSSO\:,\[_
M&C/._QHSSO\:LYD  *:A  ":J0  CK$  (&Y  !UP   :L<  %[- P!4U @
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M:@(0_W@"#O^' @[_E@(-_Z0"#/^P @S_O@(,_\("#/_" @S_P@(,_\("A[8
M 'F_  !KR0  7M,  %#;  !#X   ..4  "_P   K_P  )_\( "3_#@ A_Q,
M'O\9 !O_'@ 8_R, %?\H !/_+0 1_S( $/\X  [_/P ,_T8!"O]/ 0?_60$$
M_V4! ?]R 0#_@0$ _X\! /^; 0#_IP$ _ZD! /^I 0#_J0$ _ZD!_RPO ?\P
M+ '_,BP"_S,P O\Q-@/_,$$#_R]-!/\M6@;_*V8'_RES"/\H?@K_)X@+_R>1
M#/\GF0W_)I\-_R:E#O\FJP[_)K$/_R:X#_\FP __)LD/_R;7#_\FY@__)O /
M_B;Y#_LG_P_Y)_\/^2;_$?@F_Q'X)O\2^";_$O@F_Q+X)O\2_RXL ?\S*0'_
M-2H"_S8M O\V- +_-3\#_S-+!/\R5P;_,&0'_RYP"?\L>PK_+(4,_RN.#?\K
ME@[_*IT/_RJC#_\JJ1#_*J\0_RFV$/\IO1'_*<<1_RG3$?XIXQ'[*N\1^"KX
M$/8K_Q#T*O\2]"K_$_,J_Q3S*?\4\RG_%/,I_Q3S*?\4_S$I ?\V)@'_.28!
M_SHI O\[,@+_.ST#_SE(!?\W5 ;_-6 '_S-L"?\R=PS_,((-_S"+#O\ODP__
M+YH0_RZ@$?\NIA'_+JP2_RZS$OXNNA+]+L02^R[/$_@NX1+U+NT2\2_W$N\O
M_Q/N+O\5[2[_%NPN_Q?L+O\7["[_%^PN_Q?L+O\7_S0F ?\Y(P'_/2,!_SXF
M O]!+P+_03D#_S]%!/\]4 ;_.UP(_SEH"O\W<PW_-GX._S6'$/TTCQ'\-)82
M^C.=$_DSHQ/X,ZD4]S.P%/8SMQ3T,\ 4\S/,%/ SWA3M,^L4Z33V%><S_Q?F
M,_\8Y#+_&>0S_QKC,O\:XS+_&N,R_QKC,O\:_S@C ?\]( '_01\!_T4C ?]'
M+ +_1S8#_T9 !/]$3 ;_05@(_S]D"_L^;P[Y/'D0]CN#$?0ZBQ/S.9,4\3F9
M%/ XH!7N.*86[3BM%NPXM!;J.+T6Z3C)%N<XVQ;C.>H6X#CU&-TX_QK;-_\<
MV3?_'=<W_QW6-_\>UC?_'M8W_Q[6-_\>_SL@ ?]!' '_11H!_TL@ ?]-* '_
M3C("_TT\!/]*1P;Z2%,(]D9?"_)$:@[O0G01[$%^$^I AQ3H/XX5YCZ6%N4^
MG!?C/:,8XCVJ&. ]LAC?/;L9W3W&&=L]V!K6/>D:TCWU'<X]_A_,//\@RSS_
M(<D\_R')//\AR3S_(<D\_R')//\A_S\< ?]%%P'_2Q<!_U = ?]3) '_5"T"
M_U,W _=10@7Q3DT([$Q:"^A*90_E2&\1XD=Y%-]%@A;=1(H7VD.1&=A"F1K5
M0I\;TT&F'-%!KAW/0;<>SD'!'LQ!T!_)0N4?Q4+S(<)!_B/ 0?\DOD'_)+U!
M_R6]0?\EO4'_);U!_R6]0?\E_T(8 ?])$P#_4!0 _U89 /]9( '_6B@!]UHR
M N]8/03H54D'XU-5"MY18 [93FH2U$QT%M!+?!C.280;S$B,',I'DQ[(1YH?
MQD:A(<1&J2+"1;$CP46\([]%R22]1M\EN4;O)K9&^R>T1O\HLT;_*+)&_RBQ
M1O\HL4;_*+%&_RBQ1O\H_T85 /]-$0#_51( _UL6 /]>&P#Y8",![V L >9>
M-@/?7$0%V%E0"M%76P_,5&44R%)N&,50=QO#3W\=P$Z&'[Y-CB&\3)4CNDN<
M)+A*I":V2JPGM$JV*+-)PRFQ2=8IKDKJ*JM*^"NI2O\KJ$O_*Z=+_RNG2_\K
MITO_*Z=+_RNG2_\K_TD2 /]0#@#_61  _U\2 /]C%@#R91T YV4E -YD,0'4
M8C\%S6!+"L==5@_"6F 5OEAI&;M6<1RX5'D?ME.!(K-2B"2Q4) FKU"7**U/
MGRFK3J@KJ4ZR+*=.OBVF3LXNHT[F+J%/]2Z?3_\NGD__+IU/_RZ=4/\NG5#_
M+IU0_RZ=4/\N_TP0 /]4#0#_70X _V,/ /EG$0#K:14 WVH< --J+ '+:#L$
MQ65'";]B4@^Z8%P5MEUE&;);;1VO674AK%A\(ZI6@R:G58LHI523*J-3FRRA
M4Z,NGU*M+YU2N3";4LDQF5+B,9=3\C&64_\QE53_,914_S"45/\PE%3_,)14
M_S"45/\P_T\. /]8"P#_8 L ^V8, /!K#0#D;0X UFX6 ,QO* '$;3<$O6M$
M";=H3P^R95@5KF)A&JI@:1ZG7G AI%UX):%;?R>?6H<JG%F.+)I8ERZ85Z P
ME5:J,I-6M3.15L4TD%;=-(Y7\#2-5_TSC%C_,XQ8_S*,6/\QC%C_,8Q8_S&,
M6/\Q_U$, /];"0#_8P@ ZVH' -UN" #8<0H SW(3 ,9S)0&^<C0#MW!!"+%M
M3 ZL:E44IV=>&:-E91Z@8VTBG&%T)9I@>RB77H,KE%V++9)<DS"/6YPRC5JF
M-(M:LC6)6L$VAUK6-H9;[3:%6_LUA5S_-(1<_S.$7/\SA%S_,X1<_S.$7/\S
M_U,* /]=!@#U9@0 WVT# -5R!@#0=0D R781 ,!W(@"X=C$#L70^!ZMQ20ZF
M;E(4H6Q;&9UI8AV99VHBEF9Q)9-D>"B08W\KC6&'+HI@D#"(7YDSA5^C-8->
MKS:!7KXX@%[1.']?ZC=^7_HV?F#_-7Y@_S1^8/\T?F#_-'Y@_S1^8/\T_U4(
M /]@! #H:0  VG # -!U!0#*> < PWH/ +M['P"S>B\"K'@\!Z9U1@VA<U 3
MG'!8&)=N8!V3:V<AD&IN)8UH=2B*9WPKAV:$+H1DC3&!8Y8T?V.A-GQBK3=Z
M8KLY>6+..7ACZ#AX8_@W>&3_-GAD_S5X9/\U>&3_-7AD_S5X9/\U_U<% /]B
M 0#A;   U'," ,MX! #%>P4 OGT- +9^'0"O?BP"J'PY!J%Y1 R<=TX2EW16
M&))R71R.<&0@BFYK)(=L<BB$:WHK@6J"+GYIBC%[:)0T>&>?-G9FJCAT9KDY
M<V;+.G)FYCER9_<X<F?_-W)H_S9R:/\U<FC_-7)H_S5R:/\U_UD" /9E  #=
M;@  SW8! ,=[ P# ?P0 N8 , +&"&@"J@BH"HX W!9U]0@N7>TL1DGA4%XUV
M6QN)=&(@A7)I)(%Q<"=^;W<K>VY_+GAMB#%V;)(T<VN<-G!JJ#AN:K<Z;6K)
M.FQJY#IM:_4X;6O_-VUK_S9M:_\V;6O_-FUK_S9M:_\V_UL  .MG  #9<0
MS'D  ,-^ @"[@@, M(0) *V%& "FA2@!GX0U!9F"0 J3?TD0C7U2%HE[61N$
M>6 ?@'=G(WQU;B=Y='4J=G-]+G-RAC%P<9 T;7";-FMOISAI;[4Z:&_'.F=O
MXCIG;_0X:&__-VAO_S9H;_\V:&__-FAO_S9H;_\V_UX  .1J  #3=   R'P
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M-EA^_S58?O\U6'[_-5A^_S58?O\UZ6@  -1T  #&?@  NX<  +*-  "HD0
MGI0  ):6#@"1EQP BY<K H66-P5_E$$*>9-)$'22415PD%@9;(]?'6B.9B%E
MC&TE88MT*%Z*?2Q;B8<O6(B2,56'GS-3AZTU4H>^-5&'UC51ANXU4H7[-%*%
M_S12A?\S4H7_,U*%_S-2A?\SXVP  ,YY  #!@P  MHL  *R1  "BE0  EYD
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M*4"@_RE H/\IR7X  +J+  "OE   HYH  )B@  "-I0  @JH  '6P  !LLPP
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MC04JW)T&*=RM!BC=P08HW=X&)]OO!R;9^0@FV/X))MC^"2;8_@DFV/X)I)T
M )BE  "+K0  ?K0  '&\  !EPP  6<D  $W-  !#TP$ .MD& #7D#0 SY!8
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M 0?_D $%_Z !!/^N 03_O $#_\<! __' 0/_QP$#_\<!@[0  '6]  !GQ@
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M+GI:XRYZ6_4M>ES_+'E<_RMZ7/\J>ES_*GI<_RIZ7/\J_U$  /);  #>9
MSVH  ,=N @# < 0 NG , +)Q&@"K<2D!I7 W Y]N0@>:;$L,EFI4$9)H7!6.
M9F,8BV5I&XAC<!Z%8G@A@F%_)(!@B"9]7Y$I>U^<*WA>IRUV7K4N=5[&+W1>
MX2]T7_,N=%__+'1@_RMT8/\K=&#_*W1@_RMT8/\K_U,  .A>  #99P  RVT
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M+61K_RUE:_\L96O_+&5K_RQE:_\L]%L  -UF  #+;P  P'8  +=[  "O?@
MIGX! )]_$ "9@!\ DX M HU_.06(?4,)@WM+#7YZ4Q)Z>%H6=G=A&7-U9QQP
M=&X?;7-V(FIR?R9H<8DH97"4*V)PH"U@;ZTO7V^]+UYOU"]>;^TO7V_[+5]O
M_RQ@;_\L8&__+&!O_RQ@;_\LZUX  -AI  #'<@  O'D  +-_  "K@@  H8(
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M*4^ _RE/@/\IVVH  ,=U  "Z?P  L(<  *:,  "<CP  CY$  (:3!0" E!(
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MD14ZJZ 6.:NP%SBKPQ<XJN$7-ZGS&#>G_ADVIO\:-J;_&C:F_QHVIO\:NH0
M *Z/  "BE@  EYL  (NA  !_I@  <ZL  &>O  !:M   4[8, %&W%P!/MR0
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M B'5N0(AU=("(-/K B#2]@,?T?\$']'_!!_1_P0?T?\$GYL  )2B  "'J0
M>;$  &VX  !@O@  5,,  $G'   ^RP  -= ! "W5!@ EVPL )-X2 "/>'  B
MWR4 (> N "#@-P ?X4  'N%* !WB4P <XUX &^-J !KD>  8Y(@!%^6: 1;F
MK $5YL !%.?= 1/E[P$3X_H!$^/Z 1/C^@$3X_H!EJ(  (FI  ![L0  ;KD
M &'   !4Q@  2,H  #W/   STP  *MD  "+> @ >ZPH '.P0 !OM%P 9[1\
M%^XF !7N+0 4[S4 $_ ] !'P1@ 0\5  #_);  [R:0 -\W@ #/2*  OUG  *
M]:X "?;"  GVV0 (]>T "/7M  CU[0 (]>T BZD  'VR  !ON@  8L(  %7)
M  !'S@  .](  #'8   GW0  '^$  !GH   6^ 8 %/H- !+[$@ 0_!< #OP=
M  W](P ,_2D "OXP  C_.  &_T$  _],  #_6   _V8  /]W  #_B0  _YL
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M'HY*Y1Z-2O8>BTO_'HM+_QV*2_\=BDO_'8I+_QV*2_\=_T4  /]-  #E5
MV5D  ,]; P#*6P8 Q%H/ +M;'@"U7"X!KUL[ JI:1@6F6% (HE99"Y]58 Z<
M4V@1F5)O$Y=1=A654'T7DU"$&9!/C1J.3I8<C$Z?'HI.JA^(3K<@AT[((85.
MXB&$3_,@@T__((-/_Q^"4/\?@E#_'H)0_QZ"4/\>_T<  /-1  #?6   T5T
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M(V];_R)O6_\B;UO_(6];_R%O6_\A^D\  .%:  #/8@  Q&<  +MK  "S;
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M(EQJ_R)<:O\BXUL  ,YF  # ;@  MG0  *QY  "C>P  F'D  )!Z"P"*>Q8
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MDAQ(AJ =1H:O'D6%PAY%A=\>183R'D6#_AY%@O\>18+_'D6"_QY%@O\>RFT
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M#S.ENP\SI=0/,Z3N#S*B^Q RH?\1,J'_$3*A_Q$RH?\1M((  *B,  "=D@
MDI<  (:<  !YH0  ;:4  &&I  !5K   2Z\% $>P$ !%L!P 1+$G $*Q,@!!
MLCL /[)# 3VR2P$[LE,".;); S>R9 0ULFX%,[)Y!C&RAP<OL98(+K*F""VR
MN DLLM (++#L"2NO^0HKKO\+*JW_"RJM_PLJK?\+K8L  *"2  "5F   B9T
M 'VC  !QJ   9*T  %FQ  !-M   0K@  #NZ"@ XNQ, -[P> #6\*0 TO3(
M,[T[ #*]1  QODP +[Y5 2Z^7@$LOF@!*KYT BF^@@(GOY$#)K^B R2_M ,C
MO\L#([[H R.\]P0BN_\%(KO_!2*[_P4BN_\%I)(  )B8  ",G@  @*4  '.K
M  !GL   6[4  $^Y  !$O   .L   ##$!  JQPL *,@3 "?)'0 FR2< )<DP
M "3*.0 CRD( (LM+ "'+50 @S%\ '\QL !W->@ <S8H &\V< !G.K@$8SL4
M&,WD !C,] $8ROP!&,K_ AC*_P(8RO\"FYD  (^?  ""I@  =:T  &BS  !<
MN0  4+T  $3!   YQ   ,,@  "C, 0 @T 8 &=4+ !;7$  5V!D %=DB !39
M*P 3VC0 $]H] !+;2  1W%, $=U? !#=;0 0WGX #M^1  [@I  -X+@ #.#2
M  O?[0 ,WO< #-W[  S=^P ,W?L DI\  (6G  !WK@  :K4  %V\  !0P0
M1,4  #C)   NS0  )=$  ![5   6V@$ $=X& !#G#0 .YQ( #>@9  SH(0 +
MZ2D "NHQ  GJ.P 'ZT4 !>M1  3K7@ #ZVX  >N   #JE   ZJ<  .N\  #K
MT@  Z^D  .SO  #L[P  [.\ AZ<  'FO  !KMP  7KX  %'%  !#R0  -\T
M "W1   CU@  &]L  !/?   .XP  #.X"  KV"@ ']@X !?82  /V&   ]1X
M /4E  #U+@  ]3<  /9"  #V3@  ]ET  /9N  #V@0  ]I4  />G  #WMP
M^,<  /C0  #XT   ^-  >Z\  &VX  !@P   4L@  $3-   WT0  *]<  "'<
M   8X   $>0   SG   '[P  !/H   '_ P  _P@  /\-  #^$   _A0  /\:
M  #_(0  _RD  /\S  #_/@  _TL  /];  #_;   _X   /^2  #_H0  _ZT
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M"ZDVZ@RF-O@-I3;_#J,W_PZB-_\.HC?_#J(W_PZB-_\._S<' /\[ @#_0 ,
M\D(% .E""0#E/PX V#X6 ,Y )P#'038 PD%$ ;U!3P*Y0%D#MC]A!+0^:0:Q
M/7$'KSUX"*X\?PFL/(8*JCN-"ZD[E0RG.YT-I3NF#:,ZL ZB.[P/H#O-#YX[
MYA";//41FCS_$9D\_Q&8//\1F#S_$9@\_Q&8//\1_SH! /]   #O10  X4@
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MAD;]%H9&_Q:%1_\5A4?_%85'_Q6%1_\5_S\  .Q(  #=3P  SU,  ,95  #
M4P, NU$, +-2&0"M4RD J%,V :-20@*?44L$G%!4!IE/7 B63F,*E$UJ#)%,
M<0Z/2W@/C4M_$8M*AQ*)2I 4ATF:%85)I1>#2;$8@DG &(%*UAE_2NT8?DO\
M&'Y+_Q=]2_\7?4O_%GU+_Q9]2_\6_T,  .9,  #64P  R5@  ,!9  "Z6 $
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M&65:_QEE6O\9Z$\  --9  #$80  N68  +!H  "G:0  GF4  )=F#0"19QD
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MDQE4;* ;4FNO'%%KP1Q1:]P<46OQ&U)K_AI2:O\:4FK_&5)J_QE2:O\9U%P
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M%D& NA9 @-(607_M%D%^^Q9!??\607W_%D%]_Q9!??\6PFH  +5U  "J?0
MGX(  )*#  "%A   >84  &J)  !DB@, 8(P0 %V-&P!;CB< 6(XR %6..P%3
MCD,"4(Y* TZ-4@5,C5D&28Q@"$>,: I%BW(,0HM]#D"*B0\^BI@1/(JG$CN*
MN!(ZBL\2.XCK$CN'^A,[AO\3.X;_$SN&_Q,[AO\3O'$  *][  "E@P  F8<
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M R6I]00EJ/\%):?_!26G_P4EI_\%IXD  )N/  "1E   A)D  'B>  !KH@
M7Z8  %.J  !(K0  /;   #2S P OM0X +;46 "RU(  KMBD *K8R "FW.@ H
MMT, )[=, ":X50 DN%\ ([AK "*X> $@N(@!'[B9 1VYJP$<N< !'+C? 1RV
M\@$;M?P"&[3_ ANT_P(;M/\"GX\  )25  "(FP  >Z$  &ZF  !BJP  5K
M $JS   _M@  -;D  "R\   DOP8 '\(- !W"%  <PAX &\,F !K#+P 9Q#@
M&,1! !?$2@ 6Q54 %<5A !3&;P 3QG\ $L:1 !''I  0Q[D #\?4 !#&[@ 0
MQ/H $,/_ !##_P 0P_\ EY8  (N<  !^H@  <:D  &2O  !8M   2[@  $"[
M   UO@  *\$  "/%   ;R0$ %,P& !#0"P .T1$ #=$9  W1(0 ,T2H #-$T
M  O2/@ *TDD "=-5  G38@ (TW( !M2$  74F  $U*L  ]7   '5W  !U>T
M =7V  '5]@ !U?8 CIT  ("D  !SJP  9K$  %FX  !,O0  /\   #3#   J
MQP  (<H  !G.   2T@  #=8!  G;!0 &W T !-P1  /=&  !WB   -XH  #?
M,0  X#P  .%'  #B5   XV,  .-T  #DB   Y)L  .6N  #EP0  Y=4  .;G
M  #FYP  YN< @Z0  '6L  !HLP  6KL  $W!  ! Q   ,\@  "C,   ?T
M%]0  !#9   +W0  !>$   #D    Y0<  .8-  #G$0  Z!8  .D=  #J)0
MZRX  .TY  #O10  \%,  /%D  #Q=@  \HH  /.<  #SK0  ]+L  /3(  #T
MR   ],@ =ZT  &JU  !<O0  3\0  $#)   SS0  )]$  !W6   4W   #N
M  CC   !Y@   .H   #N    [@   .\$  #P"@  \0X  /,2  #T&   ]B
M /@J  #Z-0  _4,  /Y2  #_8P  _W8  /^)  #_F@  _Z8  /^P  #_L
M_[  _Q8C /\5(0#_$2$ _PTD /\)*P#_!C< _P-$ /\ 40#_ %T _P!H /\
M<@#_ 'L _P"# /\ B@#_ )$ _P"6 /\ G #_ *$ _0"F /L K #Y +, ]P"[
M /4 Q0#S -$ \@#D /$ \0#O /H [@#_ .X _P#M /\ [0#_ .T _P#M /\
M_QD@ /\8'0#_%1T _Q ? /\.*0#_##0 _PI! /\'30#_!5D _P1D /\$;@#_
M W< _P.  /\#AP#_ XT _0*3 /L"F0#Y IX ]P*D /4"J@#S ;  \0&X .\!
MP@#M <\ ZP'C .H![P#H OL YP3_ .8%_P#F!O\ Y@;_ .8&_P#F!O\ _QP;
M /\;&0#_%Q@ _Q4= /\3)0#_$3  _Q ] /\.20#_#%4 _PM@ /\+:@#]"W,
M^PM\ /D*@P#W"HH ]0J0 /0*E@#S"IL \0JA .\)IP#M":X ZPFV .@)P #F
M"<T Y GB .(*\ #?"_L W@S_ -P-_P#<#?\ VPW_ =L-_P';#?\!_Q\7 /\>
M$P#_&Q( _QP9 /\;(@#_&"P _Q4X /\31 #^$E  ^1%; /409@#S$&\ \!!W
M .X0?P#L$(8 ZA", .D0D@#H$)@ Y@^> .4/I0#C#ZP X0^T . /O@#>#\P
MVA#A -41\ #2$OL SQ+_ <X3_P'-$_\!S1/_ <P3_P',$_\!_R(2 /\B#P#_
M(0\ _R(4 /\B' #_("< _QTR /@;/@#R&4L [AA6 .H78 #G%FH Y!9R .(6
M>@#@%H( WA:( -P6CP#;%I4 V1:; -86H@#4%JD TA:Q - 7NP#.%\D S!C>
M ,@9[@'%&OL!PQK_ L$;_P+ &_\"P!O_ L ;_P+ &_\"_R8. /\E"P#_* P
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M"I,W_PJ2-_\*DC?_"I(W_PJ2-_\*_S,  /8Z  #D/P  V$(  ,Y" 0#)/@8
MQ#L/ +L^'0"U/RP L3\Z *T_10&I/T\!ICY8 J,]7P.A/6<$GSQM!9T\= :<
M.WL&FCN"!Y@[B@B6.Y,)E3J<"I,ZI@N1.K(+D#O #(X[U0R,/.P-BCS[#8D\
M_PV)//\,B#S_#(@\_PR(//\,_S<  .H_  #<10  SDD  ,5)  "_1@( ND,,
M +-$&0"M12< J$8U *1%00&@14L"G413 II#6P.80V(%ED)I!I1!< >2078(
MD$!^"8Y A@J-0(X+BT"8#(E H@V'0*X.A4"\#X1 SP^"0>D/@4'Y#X!!_P^
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M$'%+_Q!Q2_\0[$,  -E,  #(4P  O5<  +18  "L5P  I5(! )Y3#P"85!P
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MDQ)>6: 475FN%5M9OQ9;6=@66UGO%5M9_11<6?\37%G_$EQ9_Q)<6?\2W%
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M%$UGN11,9\\43&;K%$UF^Q--9O\23F7_$DYE_Q).9?\2S%H  +QC  "P:@
MI6\  )AN  ",;0  @&P  '=M  !Q;@L ;6\4 &EP(0!F<2P 9'$V 6%Q/@%>
M<48"7'!- UEP5 57<%L&56]B"%-O:@I0;G,,3FY^#DQMBA!*;9@126RG$DAL
MN!-';,T31VSJ$TAK^A)(:_\22&K_$4AJ_Q%(:O\1QUX  +AG  "L;@  H7(
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M"S:"]@LV@?\,-H#_##: _PPV@/\,MF\  *IX  "??P  D'X  (-_  !W@
M:X(  %Z'  !5B@  3HP& $J.$ !(CQH 1X\E $60+P!$D#@ 0I!  $"01P$_
MD$\!/9!6 CN07P(YD&@#-X]S!#6/@ 4SCXX&,8^>!S".KP<OCL,'+X[A!R^,
M] @OB_\(+XK_""^*_PDOBO\)L'8  *5_  "8A   BH0  'V%  !PAP  98H
M %J.  !/D@  1I4  $&8#  ^F!0 /9D? #N9*  ZFC$ .9HZ #>:0@ VFDH
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M 1.N_P$3KO\!FHT  )"2  "$EP  =9H  &B?  !;HP  4*@  $6L   [L
M,;(  ">U   @N   &+H' !2\#@ 3O!4 $KP> !&])@ 1O2X $+TW !"^00 .
MODP #KY7  V^90 ,OW0 "[^&  J^F0 (OJP ![["  >^WP (OO  "+WZ  B]
M_  (O?P DY0  (>9  !ZGP  ;*4  &"J  !3KP  1[,  #RV   QN   )[L
M !^^   7P0  $<0!  S("  (R0X !\D4  ;)'  %R20 !,HL  /*-@ "RD
M ,M,  #+60  RV@  ,MY  #,C   RY\  ,NS  #+R   S.(  ,SO  #,\0
MS/$ BIH  'RA  !OIP  8JT  %6S  !(N   .[L  #"^   FP0  '<0  !7(
M   /RP  "LX   32 @  TPH  -,/  #4%   U1H  -8B  #7*@  V30  -H_
M  #<2P  W%H  -UJ  #=?0  W9$  -VD  #>M@  WL@  -[>  #>X@  WN(
M?Z(  '&I  !DL   5K<  $F\   \P   +\0  "3'   ;RP  $\\   W2   '
MU@   -L   #>    WP,  . )  #A#@  XA(  .,7  #E'@  YB<  .@Q  #J
M/0  [$L  .Q:  #M;   [H   .Z4  #NI0  [K0  .["  #NQ@  [L8 =*H
M &:R  !8N0  2\   #W%   OR0  ),T  !G1   1U@  "]L   />    X0
M .4   #H    Z0   .H   #K!@  [0L  .\/  #P$P  \AH  /0C  #W+@
M^3L  /M*  #\6P  _6T  /V   #^DP  _J(  /ZM  #^KP  _J\ _Q ? /\.
M'0#_"AT _P$@ /\ * #_ #4 _P!! /\ 3@#_ %H _P!E /\ ;@#_ '< _P!_
M /X A@#\ (P ^P"2 /D EP#X )P ]P"B /8 IP#U *T \P"U /( O0#Q ,D
M[P#< .X ZP#M /< [ #_ .L _P#J /\ Z@#_ .H _P#J /\ _Q,< /\1&0#_
M#1D _P8< /\#)0#_ #$ _P ^ /\ 2@#_ %8 _P!A /\ :P#] ', ^@![ /<
M@P#U (D ] "/ /( E #Q )D \ "? .X I #M *L [ "R .H N@#H ,8 YP#6
M .4 Z #D /4 XP#^ .( _P#A /\ X0#_ .$ _P#A /\ _Q48 /\3% #_#Q0
M_PT9 /\+(@#_""T _P0Y /\!1@#_ %$ _@!< /H 9@#V &\ \@!W .\ ?@#M
M (4 ZP"+ .H D0#H )8 YP"< .8 H0#D *@ XP"O .$ N #? ,, W0#1 -L
MY@#9 /, UP#] -4"_P#4 O\ U /_ -0#_P#4 _\ _Q@3 /\5$ #_$@\ _Q(5
M /\1'0#_#B@ _PPT /\*00#Y"$P ]097 /$&80#M!FH Z05R .8%>@#D!8$
MX@6' . &C0#?!I( W0:8 -L&G@#9!J4 UP:M -0&M0#2!L  T ?/ ,X(Y0#,
M"?0 R@O_ ,@,_P#'#/\ QPS_ ,8,_P#&#/\ _QL. /\9# #_& T _Q@1 /\7
M& #_%"( ^Q$N /,0.@#M#D8 Z U2 .4-7 #A#64 W@UM -L-=0#8#7P U0V"
M -,-B0#1#8\ T V5 ,X-G #-#J, RPZK ,D.M #(#L  Q@[/ ,,0Y@# $?4
MO1+_ +P2_P"[$O\ NA+_ ;H2_P&Z$O\!_Q\* /\<! #_'P@ _Q\- /\=$@#X
M&AL [A8F .84,P#@$S\ VA-+ -035@#0$U\ SA1H ,L4;P#)%'< QQ5] ,85
MA #$%8H PQ61 ,$6F # %I\ OA:G +P7L "[%[P N1?+ +<8X@"S&?(!L1K_
M :\;_P&N&_\!KAO_ :T;_P&M&_\!_R($ /\B  #_)0( _"0' /<A# #L'1(
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M!X(W_P>"-_\']#(  .,[  #200  QD0  +U#  "W/P  L3L) *H[% "E/"(
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MDPMJ2)\,:$BM#6=)O0UF2=0.94GM#65*_ QE2O\+94K_"V5*_PME2O\+X$0
M ,M-  "]4@  LE8  *95  "<4@  E4X  (Y."0")3Q0 A5 @ (%0+ !^4#<
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M#E95N ]65<P/5E7I#E95^0U65?\-5U3_#%=4_PQ75/\,T4T  ,!6  "S7
MIUX  )I=  "/7   AE@  ']9  !Y6@T =%L7 '%;(P!N6RX :ULW &A;0 %E
M6T<!8UI. F%:50-?6EP$75IC!5Q::P9:670(6%E_"E99BPM469@-4UBF#E)9
MM@Y16<H/45GG#E%8^ U26/\-4EC_#%)8_PQ26/\,S5$  +Q9  "P7P  HV$
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M#$)F]0Q#9O\+0V7_"T-E_PM#9?\+OUP  +%D  "F:@  EFD  (EI  !]:0
M<6D  &=J  !B; $ 76T- %EN%@!7;R$ 57 K %-P-0!1<#T 4'!% 4YP3 %,
M<%,"2G!: TAP8@1&;VL%1&]U!D)O@@= ;H\)/VZ>"CUNKPH];L(*/&[@"CUM
M] H];/\*/6O_"CYK_PH^:_\*NF   *UI  "@;@  D6T  (1M  !X;0  ;&X
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M!"F$_P0IA/\$JG0  )Y[  ".>@  @'H  '1[  !H?@  78$  %*%  !)B0
M08P  #F0!0 UD0\ ,Y(7 #*2(0 QDBD ,),R "Z3.@ MDT$ +)-* "N44@ J
ME%P *)1G ">4<P$EE((!))23 2*3I $AD[<!()// 2&2[ $@D/H"((__ B"/
M_P(@C_\"I'P  )>   "'?P  >X   &Z"  !BA0  5XD  $V.  !"D@  .I8
M #*9   JG D *)T1 ":=&0 EG2( ))XJ ".>,@ BGCH (9Y" "">2P ?GU4
M'I]@ !R?;0 ;GWP &I^- !B?GP 7G[( %I_) !:>Z  6G/< %IO_ 1>;_P$7
MF_\!G8,  (^&  ""A@  =(<  &>+  !;CP  4),  $:8   \G   ,Z   "NC
M   CI@  '*@+ !JI$0 8J1@ %ZDA !:J*0 5JC$ %*HY !.J0P 3JTT $JM8
M !&K90 0JW0 #JN&  ZKF0 -JZP #*O!  RJWP ,J?( #:C\  VH_P -J/\
MEHH  (F,  !ZC0  ;)$  &"5  !4F@  29\  #^C   UIP  *ZH  ".N   ;
ML   %+,!  ^U"@ -MA  #+86  NV'P *MB< ";8O  BV.0 'MT, !K=/  2W
M6P #MVH  K=[  "WC@  MZ$  +:T  "VRP  MN4  +7Q  "U]P  M?< CY$
M (&4  !REP  99P  %BA  !,I@  0:L  #>O   LL@  ([4  !JX   3NP
M#KT   G !0 #P0T  ,$1  #!%P  PAX  ,(F  #"+P  PSD  ,1$  #$4
MQ%X  ,5O  #%@0  Q94  ,6H  #%O   Q-$  ,3F  #$[@  Q.X AI@  'F>
M  !KHP  7:D  %"N  !$LP  -[8  "RY   BO   &;\  !'"   ,Q0  !L@
M  #+    S <  ,P-  #-$0  S18  ,X=  #/)   T"T  -(X  #41   U%(
M -5A  #5<P  UH<  -:;  #6K0  U[\  -C.  #8W0  V-T >Z   &ZF  !@
MK0  4[,  $6X   XO   *[\  "'"   7Q@  $,D   K,   "T    -0   #7
M    V    -H%  #;"P  W X  -X3  #?&0  X2$  .,J  #E-@  YT,  .=3
M  #H9   Z7<  .F,  #JGP  ZJX  .JZ  #JPP  ZL, <*@  &*O  !5M@
M1[P  #G    LQ   (,@  !;,   .T   !]0   #9    W0   .$   #C
MY    .8   #G 0  Z0<  .L,  #L$   [A4  / =  #S)P  ]C,  /=#  #X
M5   ^68  /EZ  #ZC@  ^IX  /NI  #[L   ^[  _PL; /\'&0#_ !D _P <
M /\ )0#_ #( _P _ /\ 2P#_ %< _P!B /\ :P#_ ', _0![ /L @@#Z (@
M^ "- /< D@#V )@ ]0"= /0 H@#S *D \0"P .\ N #N ,, [ #1 .L Y@#I
M /, Z #^ .@ _P#H /\ Z #_ .@ _P#H /\ _PX8 /\*%0#_ 10 _P 8 /\
M(@#_ "X _P [ /\ 1P#_ %, _0!> /H 9P#W &\ ]0!W /, ?@#R (0 \ ")
M .\ CP#N )0 [ ": .L GP#I *4 Z "L .8 M #D +\ XP#, .$ X@#? /
MW@#[ -X _P#= /\ W0#_ -P _P#< /\ _Q 3 /\-$0#_!A  _P(5 /\ '@#_
M "D _P V /\ 0@#Z $X ] !9 /$ 8@#N &L [ !R .H >0#H '\ YP"% .4
MBP#D )  X@"6 .$ G #? *( W0"I -H L0#8 +L U0#( -( W0#1 .T T #Y
M ,\ _P#. /\ S0#_ ,T _P#- /\ _Q$/ /\.#0#_# T _PL2 /\'&0#_ B0
M_P P /8 / #O $D Z@!3 .< 70#D &8 X0!M -\ = #= 'L VP"! -D A@#6
M (P U "2 -( F #0 )X S@"F ,P K@#* +@ R #$ ,8 UP#% .H PP#W ,(
M_P#! ?\ P +_ , "_P#  O\ _Q0+ /\0!@#_$ D _Q . /\.% #_"AX ]08I
M .L$-@#C T( WP-. -L$5P#6!&  TP1H - $;P#.!78 S 5\ ,H%@@#)!8@
MQP6. ,8%E #$!9L P@6C , &JP"^!K4 O0;" +L(U "Z">D MPOX +4,_P"T
M#/\ M S_ +0,_P"T#/\ _Q<$ /\4  #_%@, _Q0) /\1#@#R#A4 Z PA -X*
M+@#6"SL T Q' ,P,40#)#%H Q@UB ,0-:@#"#7$ P UW +\-?0"]#H, O Z*
M +H.D0"Y#I@ MPZ@ +8.J0"T#[0 L@_! +$0U "N$>L JQ+Z *D2_P"H$_\
MIQ/_ *<3_P"G$_\ _QH  /\;  #Y&P  ZQD  .44!@#E$ X V0X7 ,\1)@#(
M$C0 Q!-  +\42P"\%%0 N15= +<59 "U%6L M!5Q +(5> "Q%GX KQ:% *X6
MC "L%I0 JQ>< *D7I@"G&+  IAB] *08SP"B&N< GQKW )T;_P&<&_\!G!O_
M 9L;_P&;&_\!_QT  /<A  #H)   W24  -0A 0#/&P@ RA<1 ,(:( "\'"T
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ME@-[-:$$>36N!'@UO@5W-M0%=C;M!70W_ 5T-_\$=#?_!'0W_P1T-_\$YS4
M -(]  ##0@  N$0  *Q"  "D/@  GSD  )HX#@"4.AD D#HF (T[,0"*.SL
MASM$ (0[3 "".U,!@#I: 7XZ8 %].F<">SIN GDZ=0)W.GX#=CJ(!'0ZDP1R
M.IX%<3JK!6\[NP9N.\\&;3OJ!FT\^@9L//\%;#S_!6P\_P5L//\%XCD  ,Q"
M  "^1P  L4@  *5&  "=0P  ES\  )(^"P"-/Q4 B3\A (5 +0""0#< ?T!
M 'U 2 ![0$\!>4!6 7<_70%U/V,"<S]J G$_<@-P/WH#;C^$!&P_D 5K/YP&
M:3^I!F@_N =G0,P'9D#H!V9 ^09E0/\&94#_!F5 _P5E0/\%W#X  ,=&  "Y
M2P  K$P  *!*  "71P  D4,  (M#" "&0Q( @D0> 'Y$*0![130 >44] '9%
M10!T1$P!<D13 7!$60%N1& ";$-G FM#;P-I0W<$9T.!!69#C09D0YD&8D.G
M!V%$M@A@1,H(8$3F"%]%^ =?1?\'8$7_!F!$_P9@1/\&UD$  ,-)  "V3@
MIT\  )M-  "22P  C$<  (5'! " 1Q  ?$@: 'A()@!U23  <TDZ '!)0@!N
M24D!;$A0 6I(5@%H2%T"9DAD F5(; -C2'4$84=_!6!'B@9>2)<'74BE"%M(
MM A;2,<)6DCD"%I)]@A:2?\'6DC_!EI(_P9:2/\&T44  +],  "R4@  HU$
M )=0  "-3@  ADH  (!* 0!Z2PX =DP7 '),(P!O3"T ;4TV &I,/P!H3$8
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M"4Q4\PA,4_\'3%/_!TU3_P9-4_\&Q4X  +96  "G6@  F%D  (M8  "!5P
M=U0  '!5  !J5@8 9E<0 &)7&@!@6"0 75@N %M9-P!963\ 5UE& %9930%4
M650!4UE; E%98P)/6&P#3EAV!$Q8@@5*6(\&25B>!TA8K@A'6, (1UC="$=8
M\@A'5_\'2%?_!TA7_P9(5_\&P5$  +)9  "C7   E%L  (=;  !]6@  <E@
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M!3AF_P4X9O\%M%X  *=E  "590  AF0  'IE  !O90  9&8  %EH  !2:@
M36P$ $EN#@!';A8 16\@ $1P*0!"<#( 07 Z $!Q0@ _<4D /7%1 #QQ60$Z
M<6(!.'%L C9P> (U<(8#,W"5 S)PI@0Q<+@$,'#0!#%O[ 0Q;OL$,6W_!#%L
M_P0Q;/\$KV0  *%I  "/:   @6@  '5I  !K:0  8&L  %5N  !-<0  1G,
M $)U"P _=A( /7<< #QW)0 Z>"T .7@U #AY/0 W>44 -GE- #5Y50 S>5X
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M:P =C7D '(V* !N-G  9C:X &(S$ !B,XP 9BO4 &8G_ 1F(_P$9B/\!G7<
M (QV  !]=@  <G<  &5Y  !:?   4(   $:$   \B0  -(P  "V0   EDP(
M'Y4, !V6$@ <EAH &Y<B !J7*@ 9ES( &)@Z !>80P 6F$T %9A8 !289  3
MF', $9B$ !"8E@ 0F*D #IB_  Z7W0 /EO( $)7\ !"4_P 0E/\ E7T  (5\
M  !X?   :WX  %^!  !4A@  2HH  $"/   VDP  +9<  "::   >G0  %Z #
M !*B#  0HQ( $*,9  ^C(0 .I"D #J0Q  VD.@ ,I$4 "Z10  JD7  )I&H
M!Z1[  :CC@ $HZ$  J.T  .BRP #HN8  Z'S  .A^P #H?L C8,  '^"  !Q
MA   9(<  %B,  !-D0  0I8  #B:   OG@  )J(  !ZE   7J   $:L   RN
M!P 'KPT  Z\2  *O&0 !KR$  *\I  "P,@  L#P  +!'  "P4P  L&$  +!Q
M  "P@P  KY<  *^J  "OOP  KMD  *[K  "N]   KO0 AXD  'B*  !JC@
M79,  %&8  !%G0  .Z(  #"F   GJ@  'JX  !:Q   0M   "[8   6Y P
MN@H  +H.  "Z$P  NQD  +LA  "\*   O#$  +T\  "^2   OE8  +YE  "^
M=P  OHP  +Z?  "]LP  OL<  +[>  "]ZP  O>L ?Y(  '"5  !BF@  59\
M $FE   ]JP  ,J\  "BT   >M@  %;D   Z\   )OP   L(   #$    Q00
M ,8*  #&#@  QQ(  ,@8  #)'P  RB<  ,PP  #./   SDD  ,]9  #/:@
MSWX  ,^3  #/I@  S[@  ,_(  #/VP  S]L =YP  &BA  !;IP  3JX  $&T
M   TMP  *+H  !V]   3P   #<0   ;'    R@   ,X   #0    T0   -("
M  #3"   U0P  -80  #9%0  VQP  -TD  #@+P  XCP  .-+  #D7   Y&\
M .6#  #EF   Y:D  .6V  #EPP  Y<, ;*4  %^L  !1L@  1+D  #6\   H
MP   ',0  !+(   ,RP   \\   #3    V    -P   #?    WP   .$   #C
M    Y ,  .8(  #H#0  Z1$  .P8  #N(@  \2X  /,\  #T30  ]5\  /9S
M  #WAP  ]YD  /BE  #XL   ^+  _P,7 /\ %0#_ !4 _P 8 /\ (P#_ "\
M_P \ /\ 2 #_ %0 _P!> /\ 9P#] &\ ^P!V /D ?0#X (, ]@"( /4 C@#T
M ), \@"8 /$ G@#P *0 [@"K .T LP#K +T Z@#+ .@ X0#G /$ Y@#] .4
M_P#D /\ Y #_ .0 _P#D /\ _P<3 /\ $0#_ !$ _P 5 /\ 'P#_ "L _P W
M /\ 1 #^ $\ ^@!: /< 8P#T &L \@!R /  >0#O '\ [0"$ .L B@#J (\
MZ "4 .< F@#E *  Y "G .( KP#@ +D W@#& -P V@#: .P V #Y -8 _P#6
M /\ UP#_ -@ _P#8 /\ _PH0 /\##@#_  T _P 2 /\ &@#_ "8 _  R /<
M/P#T $H \0!5 .T 7@#J &8 Z !N .4 = #C 'H X@"  .  A0#> (L W "0
M -L E@#8 )P U0"C -, JP#1 +4 S@#! ,P T0#+ .< R0#U ,@ _P#( /\
MR #_ ,@ _P#( /\ _PP, /\&" #_ @H _P / /\ %0#\ "  \0 L .P .0#I
M $4 Y0!/ .$ 60#> &$ VP!H -< ;P#4 '4 T@![ -  @ #. (8 S ", ,L
MD@#) )@ QP"@ ,4 J ## +$ P0"\ +\ RP"] ., O #R +L _0"[ /\ N@#_
M +H _P"Z /\ _PX% /\)  #_"04 _P8+ /\!$ #P !D Y@ E .$ ,@#< #\
MU@!) -$ 4P#. %L RP!C ,@ :@#& '  Q0!V ,, >P#! ($ P "' +X C@"\
M )0 NP"< +D I "W *X M0"Y +, R "Q -\ L 'O *\!^P"N O\ K0/_ *T#
M_P"M _\ _Q   /\.  #_#0  ]@L# /('"@#B 1$ VP(= -(#*P#, S< R 1#
M ,0$30#!!%8 O@5= +P%9 "Z!6L N 5Q +<%=@"U!7P LP:# +(&B0"P!I$
MKP>9 *T'H0"K!ZL J0BW *@)Q@"F"MT I0OP *,,_0"B#?\ H0W_ *$-_P"@
M#?\ _Q$  /P2  #L$P  XA,  -L/ P#6"0L S@@4 ,8*(@# ##  O T\ +@-
M1@"U#4\ L@Y7 + .7P"N#F4 K0YK *L.<0"J#G@ J Y^ *</A0"E#XT I ^6
M *(0GP"@$*D GQ"U )T1Q0";$=X F1+Q )<3_P"6%/\ E13_ )44_P"4%/\
M_Q4  .T;  #@'P  TA\  ,D;  #$% 4 P1 . +H2&P"T$RD L!0U *P50 "I
M%4D IA52 *0660"B%F  H19F )\6; ">%G( G!9Y )L7@ "9%X@ F!>1 )88
MFP"4&*8 DQFR )$9P0"0&M@ C1ON (L<_0"*'/\ BAS_ (D<_P")'/\ ]!T
M .0E  #3*0  QRH  +PF  "V(   M!D+ *X:%0"H'", I!TO *$>.@">'D0
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M G$OM@)P,,D";S#E FXQ]P)M,?\";3'_ FTQ_P)M,?\"WS(  ,DY  "[/@
MK#T  *$Z  ":-P  E3,  ) Q"@",,10 AS(@ (0S*P"!,S4 ?S,^ 'TS1@![
M,TT >3-4 '<S6@!V,V$ =#-G 7(T;P%Q-'<!;S2! 6XTC )L-)@":C6E FDU
MLP-H-<8#9S;B V8V]0-F-O\"9C;_ F8V_P)F-O\"V#<  ,0^  "U0@  ID$
M )L_  "3/   C3@  (@V!P"$-Q$ @#<< 'PX)P!Z.#$ =SDZ '4Y0@!S.4D
M<3E0 ' Y5P!N.5T ;#ED 6LY:P%I.70!:#E^ F8YB0)D.94#8SJB V(ZL0-A
M.L,#8#O@!%\[\P-?._\#7SO_ U\[_P)?._\"T3L  ,!"  "P10  H40  )5#
M  "-0   AST  (([ @!].PX >3P8 '4](P!S/2T <#TV &X]/P!L/48 :SU-
M &D]4P!G/5H 9CUA 60]: %C/7$!83Y[ E\^A@)>/I,#7#Z@ UL_KP1:/\$$
M6C_=!%D_\@19/_\#63__ UD__P-9/_\#S#\  +Q&  "K2   G$<  )%&  "(
M1   @D   'P_  !W0 P <T 5 &]!( !L02H :D$S &A!.P!F0D, 9$)* &-!
M4 !A05< 8$)> 5Y"90%=0FX"6T)X EI"A -80I #5T*>!%9#K0150[\$5$/:
M!%1#\0140_X#5$/_ U1#_P-40_\#R$(  +A)  "G2P  F$H  (U)  "#1P
M?4,  '9#  !Q1 H ;402 &I%'0!G12< 9$4P &)%. !@13\ 7T5' %U%30!;
M150 6D9; 5E&8P%71FP!5D9V E1&@0-31HX#4D><!%!'JP101[T$3T?6!4]'
M[P1/1_T$3T?_ T]'_P-01_\#Q$4  +5-  "C30  E4P  (E+  !_2@  >$8
M '%'  !L1P< :$@0 &1(&@!A220 7TDM %U)-0!;23T 64E$ %=)2@!625$
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M T)2_P-"4?\#ND\  *I4  "85   B50  'U3  !S4P  :5$  &)2  !<4P
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M< $N:GX!+6J. 2QJGP$K:K !*FK& 2IIY0$J:/8"*V?_ BMG_P(K9_\"J6$
M )5@  "$8   =V   &QA  !B80  6&,  $YF  !':   0&L  #IN!0 V;PX
M-' 5 #-P'@ R<28 ,'$N "]Q-0 N<CT +7)% "QR30 K<E< *G)A "ER;0 G
M<GL )G*+ "1RG $C<JX!(W+# 2-QX@$C</0!(V__ 2-N_P$C;O\!H64  (YD
M  !_9   <F0  &AE  !>9@  5&D  $EL  !";P  .W(  #1U   N> H *WD1
M "IY&  I>B$ )WHH "9Z,  E>S@ )'M  "-[2  B>U( (7M< "![:  ??'8
M'7R& !Q[F  ;>ZH &GN_ !I[W@ :>?( &WC^ !MW_P$;=_\!F6D  (AI  !Y
M:0  ;6D  &-J  !9;   3V\  $5S   ]=P  -7H  "Y]   G@0, (H,- ""$
M$@ ?A!H '80B !R%*@ ;A3$ &H4Y !F%0@ 8ADP %X96 !:&8P 5AG$ %(:!
M !*&DP 1AJ8 $86[ !"%U@ 1@^\ $8+[ !*"_P 2@?\ D6X  (%M  !T;@
M:6X  %UP  !3<P  27<  $!\   W@   +X,  ">'   AB@  &HT& !6/#0 3
MD!, $I : !*0(@ 1D"H $)$R !"1.P /D40 #I%/  V17  ,D6H "Y%Z  J1
MC0 (D)\ !Y"S  >/R0 'C^8 !X[T  B-_  (C?\ B7,  'MS  !O<P  8W4
M %=X  !-?0  0X$  #F&   PB@  *(X  "&1   :E0  $Y<   Z:"  +G X
M"9P3  B<&@ 'G"( !IPJ  2<,P #G#T  IU(  "=5   G6(  )QR  "<A
MG)<  )NJ  ";OP  FML  )KL  ":]0  F?@ @GD  '9Y  !H>@  7'X  %&"
M  !&AP  /(P  #*1   IE0  (9D  !F=   2H   #J,   FF!0 #IPP  *<0
M  "G%0  J!P  *@C  "H*P  J30  *D_  "I2P  J5D  *EH  "I>@  J8X
M *FA  "HM0  J,L  *?D  "G[P  I_, ?8   &^!  !AA   58D  $F.   ^
ME   -)D  "J>   AH@  &:8  !*I   -K   !Z\   "R    LP<  +,,  "S
M$   M!4  +0;  "U(@  MBL  +<U  "W0   N$X  +A=  "X;@  N((  +B7
M  "XJ@  M[X  +?2  "WY@  M^H =H@  &>+  !:D   3I8  $*<   WH@
M+*<  "*K   9KP  $;,   NV   $N0   +P   "^    O@   +\&  # "P
MP0\  ,(3  ##&0  Q"   ,4I  #'-   R$(  ,E1  #)8@  R74  ,F*  #)
MGP  RK$  ,K!  #)T0  R=D ;I,  &"8  !3G@  1J0  #JK   OL   )+4
M !FX   0O   "K\   '!    Q    ,@   #*    R@   ,P   #- P  S@@
M - -  #1$   TQ8  -8>  #:*   W30  -Y#  #?5   WV<  .!\  #@D0
MX*0  ."R  #@O@  X,, 9I\  %FF  !,K0  /[0  #*X   DO   &+\  !##
M   (QP   ,H   #-    T0   -4   #8    V0   -L   #=    WP   .$$
M  #C"@  Y0X  .<3  #J'   [2<  / U  #Q1@  \E@  /-K  #S@   ])0
M /2C  #TK@  ]+( _P 3 /\ $0#_ !$ _P 5 /\ 'P#_ "P _P Y /\ 10#_
M %  _P!: /X 8P#[ &L ^0!R /< > #U 'X ] "$ /( B0#Q (X \ "3 .X
MF0#M )\ [ "F .H K@#H +@ Y@#% .4 VP#C .T X@#[ .( _P#A /\ X0#_
M .$ _P#A /\ _P 0 /\ #@#_  T _P 2 /\ &P#_ "@ _P T /X 00#[ $P
M]P!6 /0 7P#Q &8 [P!M .P = #J 'H Z0!_ .< A0#F (H Y0"/ ., E0#A
M )L X "B -X J@#; +0 V0#  -8 T #3 .@ T@#W -$ _P#1 /\ T #_ -
M_P#0 /\ _P - /\ "0#_  H _P / /\ %@#[ "( ]P O /0 .P#P $< [0!1
M .D 6@#E &( X@!I .  ;P#> '4 W !Z -H @ #8 (4 U0"+ -, D0#1 )<
MSP"> ,T I@#+ *\ R0"Z ,< R0#% .( Q #R ,, _@#" /\ P0#_ ,( _P#"
M /\ _P,& /\  0#_  8 _P , /D $0#Q !T ZP I .< -@#C $$ WP!+ -L
M5 #5 %P T@!C ,\ :@#- '  RP!U ,D >P#( (  Q@"& ,4 C ## ), P0":
M +\ H@"] *L NP"V +D Q "W -H M@#M +0 ^@"T /\ M #_ +0 _P"T /\
M_P0  /\   #_    _P & .P #0#E !8 W@ B -< +P#1 #L S0!% ,H 3@#&
M %< Q !> ,$ 9 "_ &H O0!P +P =0"Z 'L N0"! +< AP"U (X LP"5 +(
MG@"P *< K@"R *P OP"J -$ J #H *@ ]P"G /\ IP#_ *8 _P"F /\ _P8
M /\%  #Q P  Z    .$ !P#5 !  S0 ; ,< )P## #, OP ^ +P 2 "Y %$
MM@!8 +0 7P"R &4 L !J *\ < "M '8 K !\ *H @@"I (D IP"1 *4 F@"C
M *0 H0"N *  NP"> <T G0+F )P$] ";!/\ F@7_ )H%_P"9!?\ _PH  /$.
M  #D$   V0\  ,X+  #( PL P@ 3 +P"'P"W RP LP0W + %0@"M!DH J@92
M *@'60"F!U\ I0=E *,':P"B"'$ H AW )\(?@"="(4 FPF. )H)EP"8"J$
ME@JL )4+N@"3"\P D@SE ) -]@"/#O\ C@[_ (X._P"-#O\ ]A$  .87  #6
M&P  QQD  +X5  "Y$   MPH- +$+%P"L#20 J XP *4..P"B#D0 GP], )T/
M4P";#UH F@]@ )@09@"7$&P E1!R ),0>0"2$($ D!"* (\1E "-$9\ BQ&J
M (H2N "($LL AA/F (44]P"#%?\ @Q7_ ((5_P""%?\ [1H  -PA  #*)0
MNR(  +$?  "K&@  J10& *42$0"@%!X G!4J )D5-0"6%CX E!9' )(63@"0
M%E4 CA=; (P780"+%V< B1=M (@7= "&&'P A1B& (,9D "!&9L @!JG 'X:
MM0!]&\< ?!SB 'H=]0!Y'?\ >!W_ '@=_P!X'?\ Y2(  - I  "_+   L"H
M *<G  "@(P  G1\  )H:#@"5'!@ D1TD (X>+P",'CD B1Y! (<?20"%'U
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M 6 P[P%?,/T!7S#_ 5\P_P%?,/\!S30  +P[  "I.@  FSH  ) X  ")-0
M@S(  '\P 0![+PX =S 6 '0P(0!Q,2L ;S$T &TQ/ !K,4, :C%* &@R4 !G
M,E< 93)= &0R90!B,FT 83-W %\S@@%>,XX!732< 5LTJ@%:-;L!6C72 5DU
M[0%9-?P!6#7_ 5@U_P%9-?\!R#@  +<^  "D/@  ECT  (L\  "#.@  ?3<
M '@T  !T- L <#43 &TU'0!J-2< :#8P &8V. !D-C\ 8S9& &$V30!@-E,
M7C=: %TW8@!<-VH 6CAT 5DX?P%7.(P!5CF9 54YJ )4.;D"4SK/ E,ZZP)3
M.OL!4SK_ 5,Y_P%3.?\!Q#P  +)!  "@0   DD   (8_  !^/0  >#H  ',X
M  !N.0@ :CD1 &<Y&@!D.B0 8CHL & Z- !>.CP 73M# %L[2@!:.U  6#M7
M %<[7P!6/&< 5#QQ 5,\? %2/8D!43V7 4\]I@)./K<"3C[- DX^Z0)-/OH"
M3C[_ 4X]_P%./?\!P#\  *Y#  "<0P  CD,  ()"  !Z0   <ST  &T\  !H
M/04 9#T. &$^%P!>/B$ 7#XI %H^,0!8/CD 5SY  %4_1@!4/TT 4S]5 %)
M7 !00&4 3T!O 4Y!>@%-08<!2T&6 4I!I0))0K4"24++ DE"Z ))0OD"24'_
M DE!_P%)0?\!O4,  *I%  "810  BD4  ']%  !V0P  ;T   &A   !C00$
M7T$- %Q!% !90AT 5T(F %5"+@!30C8 44(] $]"0P!/0TL 3D-2 $U$6@!,
M1&, 2D1M 4E%> %(184!1T64 45%HP)%1K0"1$;) D1&YP)$1?@"1$7_ D5%
M_P)%1?\!ND8  *9(  "42   AD@  'M'  !R1@  :D(  &-#  !>1   6D4+
M %9%$@!41AL 448C $]&*P!.1C, 3$<Z $M'00!*1TD 24A0 $A(6 !'2&$
M1DEK $1)=@%#28,!0DF2 4%)H@) 2;,"/TK' C]*Y0(_2?<"0$G_ D!(_P)
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M<@ Y4G\!.%*. 3=2G@$V4J\!-5+$ 352X@$V4O4!-E'_ 390_P$W4/\!KD\
M )E/  ")3P  >T\  '!/  !F3P  7$X  %1/  !/40  2E(! $93# !#5!(
M050; $!5(P ^52L /58R #Q6.@ [5D$ .E9) #E740 X5UH -E=C #57;P T
M5WP!,U>, 3%7G $P5ZT!,%?" 3!7X $P5O0!,5;_ 3%5_P$Q5?\!J%(  )52
M  "$4@  =U(  &Q2  !B4@  6%,  $]4  !)5@  1%<  $!9"  ]6A  .UH7
M #E;(  X6R< -UPO #9<-@ U7#X -%Q& #-=3@ Q75< ,%UA "]=;  N77H
M+%V) "M=F@$J7:L!*EV_ 2E=W@$J7/(!*EO^ 2M;_P$K6O\!HU4  (]5  !_
M50  <E4  &=6  !>5@  5%<  $Q9  !%6P  /UT  #I?!  V8 T -&$3 #)B
M'  Q8B, ,&(K "]C,@ N8SH +6-" "QC2@ J9%, *61= "AD:0 G9'8 )F2&
M "5DEP D9*D (V2] ")DV@ C8_$ (V+] 21A_P$D8?\!G%@  (E8  !Z60
M;ED  &-9  !:6@  4%P  $A>  !!8   .F,  #1F   O: H +&D0 "II%P I
M:A\ *&HF "=J+@ F:S4 )6L] "1K1@ C:T\ (FQ9 "!L90 ?;'( 'FR" !UL
ME  <;*8 &VNZ !IKU  ;:NX '&G\ !QH_P <:/\ E5P  (-<  !U7   :5T
M %]=  !67@  3&$  $-D   \9P  -6H  "]M   H< 0 (W(- "%R$@ @<QH
M'W,A !YS*  ==#  ''0X !MT0  :=$H &714 !=U8  6=6X %75^ !1UD  3
M=*( $G2V !%TSP 2<^P $G+Z !-Q_P 3<?\ CF   'U@  !O80  96$  %MB
M  !19   2&<  #YK   W;@  ,'$  "EU   B>   ''L' !=]#@ 6?1, %7T;
M !1^(@ 3?BH $GXQ !%^.@ 1?D0 $'].  ]_6@ .?V@ #7]X  Q_B@ +?IT
M"GZP  E]Q@ *?>0 "GST  M[_0 +>O\ AF4  '=E  !J90  868  %9H  !,
M:P  0F\  #ES   Q=P  *GH  "-^   <@0  %80  !"'"  -B0X #(D4  R)
M&P +B2, "HDK  F),P (B3T !HE(  6)5  $B6$  HEQ  &)@P  B98  (BI
M  "'O@  A]H  (;L  "&]0  AOH ?FH  '%J  !G:P  6VP  %!P  !&=
M/'@  #-]   J@0  (X4  !R(   5C   $(\   R2!@ &DPP  I,1  "4%@
ME!T  )0D  "5+   E34  )5   "53   EED  )9I  "5>@  E8X  )2A  "4
MM0  D\P  )+F  "2\@  DO< >'   &UP  !@<@  5'4  $EY   _?@  -8,
M "R(   CC0  &Y$  !24   /EP  "IH   2= P  G@D  )\.  "?$@  H!<
M * =  "A)0  HBT  *(W  "C0P  HU   *-?  "C<0  HX0  **9  "BK0
MH<(  *'<  "AZP  H/( <W8  &9W  !9>P  38   $*%   XBP  +I   "25
M   ;F@  %)X   ZA   )I    J<   "J    JP0  *L*  "L#0  K1$  *T6
M  "N'   KR0  + M  "Q.0  L48  +)5  "R9@  LGD  +*.  "QHP  LK<
M +'*  "QX   L>D ;'X  %^"  !2AP  1HT  #N3   PF0  )IX  !RC   3
MIP  #:L   >N    L@   +4   "W    N    +D"  "Y"   N@P  +L0  "\
M%   O1L  +\C  #!+0  PCH  ,))  ##6@  PVP  ,2"  #$EP  Q*L  ,2\
M  #$RP  Q-H 98D  %B.  !+E0  /YL  #.B   HJ   ':T  !2Q   -M@
M!KD   "\    OP   ,,   #$    Q0   ,8   #'    R00  ,H)  #+#0
MS1$  ,\8  #2(0  U2T  -8\  #830  V5\  -IS  #:B@  VYX  -NN  #;
MN@  W,, 7I8  %&<  !$HP  .*H  "RQ   @MP  %;L   V^   $P@   ,4
M  #)    S0   -    #2    T@   -4   #6    V0   -L   #>!0  X H
M .(/  #E%@  Z"   .PM  #M/@  [5$  .YE  #O>@  [X\  /"?  #PJP
M\+, _P 0 /\ #@#_  X _P 2 /\ '0#_ "D _P U /\ 00#_ $T _@!6 /L
M7P#X &8 ]@!M /0 = #R 'D \0!_ /  A #N (D [0"/ .L E0#J )L Z "B
M .8 J@#E +, XP#  .$ T@#@ .H WP#Y -T _P#= /\ W0#_ -X _P#> /\
M_P - /\ "@#_  D _P / /\ & #_ "0 _@ Q /L /0#X $@ ] !2 /  6@#M
M &( ZP!I .D ;P#G '4 Y0!Z ., ?P#B (4 X "* -X D #< )8 V@"= -@
MI0#5 *\ T@"Z -  R@#. ., S0#T ,L _P#+ /\ RP#_ ,L _P#+ /\ _P (
M /\  P#_  4 _P , /P % #W !\ \@ K .\ -P#K $( YP!, .0 50#@ %T
MW0!D -H :@#8 '  U0!U -( >@#0 (  SP"% ,T BP#+ )( R0"9 ,< H0#%
M *H PP"U ,$ PP"_ -H O@#N +T _ "\ /\ O #_ +P _P"\ /\ _P   /\
M  #_    ^0 ' /$ $ #J !H Y  E -\ ,0#; #P UP!' -( 4 #. %< RP!>
M ,D 90#& &H Q0!P ,, =0#! 'H P "  +X A@"\ (T N@"4 +D G "W *4
MM0"P +, O0"Q ,\ KP#H *X ^ "N /\ K0#_ *T _P"M /\ _P   /\   #]
M    [@ ! ., # #: !0 T0 ? ,P *P#( #8 Q0!  ,( 2@"_ %( O !9 +H
M7P"X &4 M@!J +0 ;P"S '4 L0!Z +  @0"N (@ K0"/ *L F "I *$ IP"K
M *4 N "C ,@ H@#B *$ \P"@ /X H #_ *  _P"@ /\ _P   /8   #J
MX    -, !@#)  \ P@ 8 +T ) "Y "\ M@ Z +0 0P"Q $P K@!3 *P 60"J
M %\ J0!D *< :@"F &\ I !U *, >P"A (( H "* )X DP"< )T F@"G )@
MM "6 ,, E0#< )0 [P"3 /L DP#_ ), _P"2 /\ ^04  .H+  #<#0  RPH
M ,(%  "\  H M@ 1 +$ ' "N "@ J@ S *< /0"D $4 H@!- *  4P"> %D
MG !? )L 9 ": &H F !P )< =@"5 'X DP"& )(!CP"0 9D C@*D (P"L0"+
M \  B076 (@&[0"(!_H APC_ (8(_P"&"/\ [P\  -X4  #*%0  O!(  +,0
M  "N#   JP8- *<#%0"B!2  GP<L )P(-@"9"#\ EPE' )4)3@"3"50 D0I:
M ) *7P"."F4 C0IK (L*<@"*"WD B N" (<+C "%#)< @PRB ($-L " #<
M?PW8 'T.[P!\#_T >P__ 'L0_P![$/\ YA<  -$>  "]'0  KQP  *89  "A
M%0  GA $ )T-#P"8#AD E XE )$/+P"/$#D C!!! (H02 "($$\ AQ!5 (40
M6P"$$6$ @A%G ( 1;@!_$74 ?1%^ 'P2B !Z$I0 >!*@ '<3K@!U$[X =!35
M ',5[@!Q%OT <1;_ '$6_P!P%O\ W!\  ,8E  "S)0  I2,  )PA  "6'@
MDAD  )$4"P"-%!0 B14? (86*0"#%C, @1<\ ( 70P!^%TH ?!=0 'H75@!Y
M&%P =QAB '88:0!T&'$ <QEZ '$9A !O&I  ;AJ= &P;JP!K'+L :AS0 &D=
M[ !H'OL :![_ &<>_P!G'O\ T28  +TJ  "K*@  G2H  ),H  "-)0  B"(
M (8=!@"#&Q  ?QP: 'P=) !Z'2X =QXV '8>/@!T'D4 <A]+ '$?40!O'U@
M;A]> &P?90!K(&T :2!V &@A@0!F(8T 92*: &,BJ !B([@ 82/- & DZ0!@
M)/H 7R3_ %\D_P!?)/\ RBP  +8O  "D+P  EB\  (PM  "%*@  @"@  'TD
M  !Z(@T =B,5 ',C( !Q)"D ;R0R &TD.@!K)4$ :B5' &@E30!F)50 925:
M &0F80!B)FD 829R %\G?0!>)XH 72B7 %LII0!:*;4 6BK* %DJYP!8*O@
M6"K_ %@J_P!8*O\ Q3$  *\S  ">,P  D#,  (8R  !_+P  >2T  '4J  !R
M* H ;R@2 &LI&P!I*24 9RHM &4J-0!C*CT 8BI# & J2@!?*U  7BM7 %PK
M7@!;+&8 62QO %@M>@!7+8< 5BZ5 %0NHP!3+[, 4R_' %(OY0!2+_< 4B__
M %(O_P!2+_\ P38  *HV  "9-@  BS8  ($U  !Y,P  <S$  &\O  !K+@8
M:"T0 &0N& !B+B$ 8"\J %XO,0!<+SD 6R]  %DO1@!8+TT 5S!3 %8P6P!4
M,6, 4S%L %(R=P!1,H0 3S.2 $XSH0!-,[$ 333% 4PTXP%,-/8 3#3_ $PT
M_P!,,_\ NSD  *8Y  "5.0  ASD  'PY  !T-P  ;C0  &DS  !E,@( 83(-
M %XR% !<,QX 6C,F %@S+@!6,S4 530\ %,T0P!2-$H 4310 % U6 !.-6
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M<0!!/WX 0#^- #] G  ^0*T!/4#  3U W0$]0/(!/4#_ 3X__P$^/_\!KD
M )I   ")00  ?$$  '%!  !H0   83P  %L]  !6/@  4CX% $X_#@!,/Q4
M23\= $= )0!&0"P 1$ S $- .@!"04( 04%) $!!40 _0EH /D)C #U#;P \
M0WP .T.+ #I$FP Y1*L!.42^ 3A$VP$Y1/$!.4/^ 3E#_P$Y0_\!JD(  )9#
M  "&0P  >$,  &Y#  !E0P  74   %9   !10@  34(" $E## !&0Q( 1$0:
M $)$(@!!1"H /T4Q #Y%.  ]13\ /$9' #M&3P Z1E< .4=A #A';  W1WH
M-DB) #5(F0 T2*H -$B] #-(V0 T2/  -$?] #1'_P U1O\ ID0  ))%  ""
M1@  =48  &I&  !A10  640  %%$  !,1@  2$<  $1'"@!!2!  /TD8 #U)
M(  \22< .DHN #E*-@ X2CT -TM$ #9+3  U2U4 -$Q? #-,:@ R3'< ,4R&
M #!,EP O3:@ +DV[ "Y-U0 N3.\ +TS] "]+_P P2_\ H4<  (Y(  !^2
M<4@  &9)  !=2   54@  $Q)  !'2@  0DL  #],!@ [30X .4X5 #=.'0 V
M3R0 -4\K #-/,P R4#H ,5!" #!02@ O45( +E%< "U19P L474 *U&$ "I2
ME0 I4J8 *5*Y "A2T@ I4>X *5#\ "I0_P J3_\ G$H  (E*  !Z2P  ;4L
M &-,  !:3   44P  $A-  !#3P  /5   #E2 @ U4PP ,U02 #%4&0 P52$
M+E4H "U5+P L5C< *U8^ "I61@ I5D\ *%=9 "=79  F5W( )5>! "17D@ C
M5Z0 (E>W ")7SP B5^P (U;Z "-5_P D5?\ EDT  (1.  !U3@  :4X  %]/
M  !63P  35   $52   _4P  .58  #-8   O6@@ *UL/ "I;%0 H7!T )UPD
M "9<*P E7#, )%TZ "-=0P B74P (5U6 "!>80 ?7FX 'EY^ !U>CP <7J$
M&UZT !I=S  ;7>D &USY !Q;_P <6_\ D%$  'Y1  !P40  9%(  %M2  !2
M4P  2E0  $%7   [60  -5L  "Y>   H8 , )&(, ")C$0 A8Q@ 'V0@ !YD
M)P =9"X '&0V !ME/@ :94< &651 !AE70 796H %F5Z !5EBP 499X $V6Q
M !)ER  29.< $V/W !1B_P 48O\ B50  'A5  !K50  8%8  %=6  !/5P
M1ED  #U<   V7P  ,&(  "ED   C9P  '6H' !EL#@ 8;!, %FT: !5M(0 4
M;2D %&TP !-M.0 2;D( $6Y, !!N6  /;F4 #FYU  UNAP -;IH #&VM  MM
MP@ +;.  #&OS  UK_0 -:O\ @ED  ')9  !F60  7%H  %1:  !*7   05\
M #EC   Q9@  *FD  "1L   =;P  %W(  !)U"0 /=P\ #G<4  YW&P -=R,
M#'<J  MW,P *=SP "7='  AW4@ '=U\ !7=O  1W@  #=Y0  7:G  !VNP !
M==4  73K  )T]@ "=/P >UT  &U=  !B7@  65X  $Y@  !%8P  /&<  #-K
M   K;@  )'(  !YU   7>0  $GP   U_!@ )@0P !8$1  .!%@ "@1T  8$D
M  "!+0  @C8  ()   ""3   @ED  ()H  "">0  @HT  (&@  " M   @,L
M '_G  !^\@  ?OD =&(  &AB  !>8@  4V0  $EG   _:P  -G   "UT   E
M>   'GP  !>    1@P  #88   B)!  "BPH  (L.  "+$P  C!@  (P?  "-
M)@  C2\  (XY  ".1   CE$  (Y@  ".<0  CH4  (Z9  "-K0  C,,  (S?
M  "+[@  B_8 ;F@  &1G  !8:0  36P  $)Q   X=@  +WL  "9_   >A
M%H@  !",   ,CP  !I(   "5    E@<  )<,  "7#P  F!,  )D8  ":'P
MFR8  )LP  "<.P  G$@  )Q7  "<:   G'L  )R0  ";I0  F[H  )K0  ":
MYP  FO$ :FT  %YO  !1<@  1G<  #M\   Q@@  )X<  !Z,   6D0  $)4
M  J9   $G    *    "B    HP$  *,&  "D"P  I0X  *82  "G%P  J!X
M *HF  "K,0  JSX  *Q-  "L70  K'   *R%  "LFP  JZ\  *O#  "KV0
MJN@ 9'4  %=Y  !+?@  /X0  #2*   ID   'Y8  !:;   0GP  ":,   &G
M    J@   *X   "P    L    +$   "R P  M @  +4-  "V$   MQ4  +D=
M  "[)@  O#,  +U!  "]4@  O60  +YY  "^D   O:0  +VW  "]Q@  O=<
M7'\  %"%  !$BP  .)(  "R9   AGP  %Z0  !"I   )K@   +(   "V
MN0   +T   "_    OP   ,    #!    PP   ,0%  #&"@  QPX  ,D3  #+
M'   SB8  - U  #110  TE<  -)K  #3@@  TY<  -.I  #2N   TL0 58P
M $F3   ]F@  ,*(  "6H   :K@  $;0   FY    O0   ,$   #$    R
M ,L   #-    S0   ,\   #0    T@   -0   #8    V@8  -T,  #@$0
MXQH  .8G  #G.   Z$H  .E=  #J<@  ZX@  .N;  #LJ   [+( _P - /\
M"P#_  L _P 0 /\ &@#_ "8 _P R /\ /0#_ $@ ^P!2 /@ 6@#V &( \P!I
M /$ ;P#P '4 [@!Z .P ?P#K (0 Z0"* .@ D #F )8 Y "= .( I0#A *\
MWP"[ -T RP#; .8 V0#W -@ _P#8 /\ UP#_ -< _P#4 /\ _P ( /\ ! #_
M  0 _P - /\ %0#^ "$ ^@ L /< . #T $, \ !- .T 50#J %T YP!D .0
M:@#B '  X !U -X >@#= '\ VP"% -D BP#5 )$ TP"9 -$ H #/ *H S0"U
M ,L Q #) -T R #Q ,< _P#& /\ Q@#_ ,8 _P#' /\ _P   /\   #_
M_P * /@ $0#Q !P [  G .D ,@#F #T X@!' -T 4 #9 %@ U0!? -( 90#0
M &H S@!P ,P =0#* 'H R0!_ ,< A0#% (P PP"4 ,$ G "_ *4 O0"P +L
MO0"Z -  N #K +< ^P"V /\ M@#_ +8 _P"V /\ _P   /\   #]    \P %
M .D #@#A !8 VP A -4 +0#1 #< S@!! ,H 2@#' %( Q !9 ,( 7P#  &4
MO@!J +P ;P"[ '0 N0!Z +< @ "V (< M ". +( EP"P *  K@"J *T MP"K
M ,@ J0#C *@ ]0"G /\ IP#_ *< _P"F /\ _P   /X   #Q    Y0   -<
M"@#- !$ QP < ,( )@"_ #$ O  [ +H 1 "W $P M !3 +( 60"Q %\ KP!D
M *T :0"L &\ J@!T *D >@"G ($ I@") *0 D0"B )L H "E )X L@"= ,$
MFP#: )H [P"9 /T F #_ )@ _P"8 /\ _0   /    #A    T0   ,8 ! "]
M  T MP 5 +, ( "P "L K0 U *L /@"H $8 I@!- *0 5 "C %D H0!? *
M9 "> &D G0!N )L =0": 'L F "# )8 C "5 )8 DP"A )$ K0"/ +L C0#/
M (P Z0"+ /@ C #_ (P _P", /\ \P(  .('  #,!P  OP0  +<   "Q  @
MJP 0 *< &0"D "0 H  N )X -P"< $  F@!' )@ 3@"6 %0 E0!9 ), 7@"2
M &0 D !I (\ ;P"- '8 BP!^ (H B "( )( A@"= (4 J0"# +@ @0#* (
MY0"  /4 ?P#_ '\ _P!_ /\ Z T  - 0  "^$   L0X  *@-  "C"   H (,
M )P $P"8 !T E0 G )( ,0"0 #D C@%! (P!2 "* DX B0)4 (<"60"& E\
MA -D (,#:P"! W( @ 1Z 'X$A !]!8X >P6: 'D&IP!X!K4 =@?( '4(XP!U
M"?0 = K_ ',*_P!S"O\ W14  ,07  "Q%P  I18  )P3  "6$0  E T$ ),(
M#0".!Q4 BPD@ (@)*@"%"C, @PL[ ($+0@" "TD ?@M/ 'T,5 ![#%H >@Q@
M '@,9P!W#&X =0UV '0-@ !R#8P < V9 &\.I@!M#K4 ; [) &L/Y@!J$/<
M:1#_ &D0_P!I$/\ T!T  +D>  "H'@  FQT  )(;  "+&0  B!4  (<1!P"%
M#A  @0\: 'X0) ![$"T >1 V '<1/0!V$40 =!%* ',14 !Q$58 <!%< &X2
M8@!M$FH :Q)S &D3?0!H$XD 9A.6 &44HP!C%;, 8A7& &(6XP!A%O8 8!?_
M & 7_P!@%_\ QR(  + C  "?)   DB,  (DB  ""(   ?AT  'P9  !Z%0T
M=Q45 '06'P!Q%B@ ;Q<P &X7. !L%S\ :Q=% &D82P!H&%$ 9AA8 &487@!C
M&68 8AEO & 9>0!?&H4 71N2 %P;H0!;'+  6AS# %D=X !8'O0 6![_ %@>
M_P!8'O\ OR<  *DH  "9*   BR@  ((G  ![)0  =B,  ',@  !Q' D ;AP1
M &L<&@!I'2, 9QTL &4=,P!C'CH 8AY! & >1P!?'DT 7AY4 %P?6P!;'V(
M62!K %@@=@!6(8( 52&0 %0BG@!3(JX 4B/  %$CW0!1)/( 423_ %$D_P!1
M(_\ N2L  *,L  "3+   ABT  'PL  !T*@  ;R@  &LE  !I(@4 9B$. &,B
M%@!A(A\ 7R,G %TC+P!<(S8 6B,] %DD0P!7)$H 5B10 %4D5P!3)5\ 4B5H
M %$F<P!/)G\ 3B>- $THG !,**P 2RF^ $LIV@!**?$ 2BG_ $LI_P!+*?\
MLRX  )XO  ".,   @3   '<O  !O+@  :BL  &4J  !C)P$ 7R<, %PG$P!:
M)QL 6"@D %8H*P!5*#( 4R@Y %(I0 !0*48 3RE- $XI5 !-*EP 3"IE $HK
M< !)*WP 2"R+ $<MF@!&+:H 12Z\ $4NU@!%+N\ 12[^ $4N_P!%+?\ KC$
M )HR  "),P  ?#,  '(S  !K,0  92\  & M  !=+   62P) %8L$ !4+!@
M4BP@ % L* !.+2\ 32TV $PM/ !*+4, 22U* $@N40!'+ED 1B]C $4P;0!#
M,'H 0C&) $$QF !!,J@ 0#*[ #\RTP _,NX 0#+] $ R_P! ,O\ JC,  )8U
M  "&-0  >38  &XU  !F-0  83(  %PP  !7,   5# & %$P#@!.,!4 3#$=
M $HQ)0!(,2P 1S$R $8Q.0!$,4  0S)' $(R3P!!,U< 0#-@ #\T:P ^-7@
M/36' #PVE@ [-J< .S:Y #HVT0 Z-NT .S;\ #LV_P [-O\ IC8  )(W  ""
M.   =3@  &LX  !C-P  738  %<S  !3-   3S0# $LT# !)-!( 1C4: $4U
M(@!#-2D 034O $ U-@ _-CT /C9$ #TW3  \-U4 .SA> #HX:0 Y.78 .#F%
M #<ZE0 W.J4 -CJX #4ZSP V.NP -CK[ #8Y_P W.?\ HC@  (XY  !^.@
M<CL  &@[  !?.@  63D  %,V  !.-P  2C@  $8X"@!$.1  03D7 #\Y'P ^
M.28 /#DM #LZ-  Z.CL .3M" #@[2@ W.U, -CQ< #4\9P T/70 ,SV# #,^
MDP R/J0 ,3ZV #$^S0 Q/NH ,3[Z #(]_P R/?\ GCL  (L\  ![/   ;CT
M &0]  !</0  53P  $XZ  !).P  13P  $$]!P ^/0X /#T5 #H^'  Y/B,
M-SXJ #8_,0 U/S@ -#]  #- 2  R0%  ,4!: #!!90 O07( +D*! "U"D0 M
M0J( +$*U "M"RP L0ND +$+Y "U!_P M0?\ F3T  (<^  !W/P  :S\  &%
M  !9/P  4C\  $D^  !$/P  0$   #Q!!  Y0@T -T(2 #5#&0 S0R$ ,D,H
M #%$+P P1#8 +T0] "Y%10 M14X +$58 "M&8P J1F\ *49^ "A&CP G1Z$
M)D>S "9'R0 F1N< )T;X "A%_P H1?\ E4   ()!  !S0@  9T(  %Y"  !5
M0@  3D(  $5"   _1   .T4  #=&   T1PH ,4@0 "](%@ N21X +$DE "M)
M+  J23, *4HZ "A*0@ G2DL )DM5 "5+8  D2VT (TM\ ")+C0 A3)\ (4RQ
M "!,QP @2^8 (4OW ")*_P B2O\ D$,  'Y$  !O1   9$4  %I%  !210
M2D8  $%'   \2   -TD  #)+   N30< *TX. "E.$P G3QH )D\A "5/*  D
M3S  (U W ")0/P A4$@ (%!2 !]170 >46H '5%Y !Q1B@ ;49P &E&O !E1
MQ0 94>0 &E#V !M/_P <3_\ BD8  'E'  !K1P  8$@  %9(  !.2   1TD
M #Y+   Y3   ,TX  "Y0   H4P( )%0+ ")5$  @518 'U8> !Y6)  =5BP
M'%8S !M7.P :5T0 &5=. !A760 76&8 %5AU !18AP 46)H $U>L !)7P@ 2
M5^$ $U;T !15_P 45?\ A$D  '1*  !F2P  7$L  %-+  !+3   1$T  #Q/
M   U40  +U0  "E6   D60  'EL' !I=#0 871( %UT9 !9>(  57B< %%XN
M !->-P 27D  $5]* !%?50 07V( #U]Q  Y?@P -7Y8 #5^I  Q>O@ ,7MH
M#5WP  U<_  .7/\ ?DT  &Y.  !B3@  6$\  $]/  !(4   0%(  #A4   P
M5P  *EH  "1=   ?7P  &6(! !-E"0 19@\ $&84  ]F&P .9R( #6<I  UG
M,@ ,9SL "V=%  IG4  )9UT !V=L  9G?0 %9Y  !&:C  )FMP #9<\ !&7I
M  1D]0 $9/P =U$  &E2  !=4@  5%(  $Q3  !#50  .U@  #-;   K7@
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M  !ZK   ><(  'C?  !X[P  =_< :EL  %];  !66P  3%P  $)@   Y8P
M,&@  "AL   @<   &70  !-W   .>P  "7X   2! @  @@@  (,-  "#$
MA!0  (49  "&(   AB@  (<Q  "'/   ATD  (=7  "':   AWL  (>0  "&
MI0  A;H  (73  "$Z@  A/0 96   %Q@  !180  1F0  #QI   R;0  *7(
M "%W   9>P  $H    V#   (AP   HH   "-    C@0  (X)  "/#0  D!
M )$4  "2&0  DR   )0I  "5,P  E4   )9.  "67P  E7(  )6(  "5G0
ME+(  )3(  "3X@  D^X 864  %9F  !*:@  /VX  #5T   K>0  (7\  !F$
M   1B0  #(T   :1    E    )@   ":    FP   )P"  "=!P  G@L  )\.
M  "A$@  HA@  *,@  "E*0  IC8  *9$  "F50  IF@  *9]  "FE   I:D
M *2]  "DT0  I.0 6VP  $]P  !#=0  .'L  "V!   CAP  &8T  !&2   +
MEP  !)P   "@    HP   *8   "H    J0   *H   "L    K00  *X)  "P
M#0  L1$  +,7  "U(   MBL  +<Z  "W2P  N%P  +AQ  "XB   N)T  +BQ
M  "WP@  M]  5'8  $A\   \@@  ,8D  ":0   ;EP  $IT   RB   #IP
M *L   "N    L@   +8   "X    N    +H   "[    O0   +X   # !0
MP0L  ,,0  #&%@  R2   ,HN  #+/@  S%   ,QD  #->@  S9$  ,VD  #-
MM   S<  38,  $&*   UD0  *9D  !Z@   3I@  #*P   .Q    M@   +H
M  "^    P@   ,8   #(    R    ,H   #+    S0   ,X   #0    T@$
M -4(  #9#@  W14  .$A  #B,0  Y$,  .56  #F:P  YH(  .>6  #GI0
MYK  _P ) /\ !0#_  8 _P . /\ %@#_ "$ _P M /\ . #] $, ^0!- /4
M50#R %T \ !C .X :0#L &\ Z@!T .D >@#G '\ Y@"% .0 BP#C )$ X0"9
M -\ H0#< *H V@"V -< Q@#5 .$ TP#T -( _P#1 /\ T0#_ ,\ _P#* /\
M_P ! /\   #_  $ _P , /\ $@#Z !T ]@ H /, ,P#P #X [ !( .@ 4 #E
M %@ X@!> -\ 9 #= &H VP!O -D = #6 'H U !_ -( A0#0 (P S@"3 ,P
MG #) *4 QP"P ,8 O@#$ -0 P@#N ,$ _@#  /\ P #_ +\ _P"^ /\ _P
M /\   #_    ^@ ' /$ #P#K !@ Y@ C .( +@#@ #@ VP!" -4 2P#1 %(
MS@!9 ,L 7P#) &4 QP!J ,8 ;P#$ '0 P@!Z ,$ @ "_ (8 O0". +L E@"Y
M *  MP"J +8 MP"T ,H L@#F +$ ^ "P /\ KP#_ *\ _P"P /\ _P   /\
M  #W    Z@ " .$ # #7 !, T  = ,P * #) #( Q@ \ ,( 10"_ $T O !3
M +H 60"X %\ MP!D +4 :0"T &X L@!T +$ >@"O (  K0"( *P D0"J )H
MJ "E *8 L0"D ,$ HP#< *$ \@"A /\ H #_ *  _P"A /\ _P   /<   #H
M    V0   ,L " ## !  O0 8 +D (@"V "P M  V +( /P"O $< K !- *L
M5 "I %D IP!> *8 8P"E &@ HP!N *( = "@ 'H G@"" )P BP"; )4 F0"?
M )@ K "6 +H E #/ ), ZP"2 /L D@#_ )( _P"1 /\ ]P   .<   #3
MQ@   +L  @"S  P K0 2 *H ' "G "8 I  P *, . "@ $  G@!' )P 3@":
M %, F0!8 )< 70"6 &, E0!H ), ;@"2 '0 D !\ (\ A0"- (\ BP": (H
MIP"( +4 A@#' (4 Y "$ /4 A #_ (, _P"# /\ [    -,   #! 0  M
M *P   "F  < H  . )T %@": "  EP I )4 ,@"3 #H D0!! (\ 2 "- $T
MC !3 (L 6 ") %T B !C (< :0"% &\ @P!W (( @ "  (H ?@"6 'T HP![
M +  >@#" 'D W0!X /$ =P#] '@ _P!X /\ W@H  ,0+  "R#   I@L  )T(
M  "9!   E0 * )$ $0". !D BP C (D + "' #0 A0 [ (, 0@"" $@ @ !.
M '\ 4P!] %@ ? !> 'L 9 !Y &H > !R '8 >P!T (8 <P"2 '$ GP!P *T
M;@"^ &T!U@!M NT ; /Z &P#_P!L _\ SA   +<1  "F$@  FA$  )$0  "+
M#@  B0L# (<%# "$ 1, @0$< 'X")0!\ RX >@,V '@$/ !W!$, =05( '0%
M3@!S!50 <059 ' &7P!N!F8 ;09N &L'> !J!X, : B0 &<)G0!E":P 9 F\
M &,*U !C"^P 8@SZ &(,_P!B#/\ PQ8  *T7  "=&   D!@  (<6  "!%
M?1$  'P.!@!\"@X > H6 '4+'P!R"R@ < PP &\,-P!M##X ; Q$ &L-2@!I
M#4\ : U5 &<-7 !E#6, 8PYK &(.=0!@#H$ 7PZ. %T/G !<$*L 6Q"] %H0
MU@!9$?  61'] %D1_P!9$?\ N1L  *4=  "4'@  B!X  'X=  !X&P  =!@
M '$5  !Q$0D ;Q 1 &P0&0!I$"( 9Q$J &81,@!D$3D 8Q$_ &(110!@$DL
M7Q)1 %T26 !<$E\ 6A-H %D3<@!7%'T 5A2+ %05F0!3%:D 4A:Z %$6T@!1
M%^T 41?] %$7_P!1%_\ LB   )XB  ".(@  @2,  '<B  !P(0  ;!X  &D;
M  !G& 0 9A4. &,6%0!A%AX 7Q8F %T6+0!<%S0 6A<[ %D700!8&$< 5AA-
M %485 !3&%P 4AED %$9;@!/&GH 3AN( $T;EP!+'*8 2ARX $H=SP!)'>L
M21W[ $D=_P!*'?\ K"0  )@E  "()@  >R<  '$F  !J)0  9B,  &(A  !@
M'@  7AP+ %L;$@!9'!H 5QPB %4<*0!4'#  4QTW %$=/0!0'4, 3QU* $T>
M40!,'E@ 2Q]A $D?:P!(('< 1R"% $8AE !$(J0 1"*V $,BS !#(^D 0R/Z
M $,C_P!#(O\ IB<  ),I  "#*@  =BH  &TJ  !E*0  8"<  %PE  !9(P
M5R$' %4A#P!2(18 4"$> $XA)0!-(BP 3"(S $HB.0!)(D  2")& $<C30!%
M(U4 1"1> $,D:0!")74 0":# #\FD@ ^)Z, /B>T #TGR@ ]*.@ /2CY #TG
M_P ^)_\ HBH  (XK  !_+0  <BT  &@M  !A+   7"L  %@H  !4)@  428$
M $XE#0!,)1, 2B8: $@F(@!')BD 128O $0F-@!#)SP 02=# $ G2P _*%,
M/BE< #TI9@ \*G( .RJ! #HKD  Y*Z$ ."RR #<LR  W+.8 ."SX #@L_P X
M+/\ G2P  (HN  ![+P  ;S   &4P  !=+P  6"X  %,K  !0*@  3"H  $DJ
M"P!&*A$ 1"H7 $(J'P!!*B4 /RHL #XK,P ]*SD /"M  #LL2  Z+%  .2U9
M #@N9  W+G  -B]_ #4OCP T,)\ ,S"Q #(PQP R,.4 ,S#W #,P_P T+_\
MF2\  (<Q  !W,@  :S(  &(R  !:,@  5#$  $\O  !++0  1RX  $0N" !!
M+@X /RX4 #TN'  [+B( .2\I #@O+P W+S8 -C ^ #4P1@ U,4X -#%7 #,R
M8@ R,FX ,3-] # SC0 O-)X +C2P "TTQ0 M-., +C3V "\S_P O,_\ E3$
M (,S  !T-   :#4  %XU  !7-   430  $LR  !&,0  0C(  #\R!0 \,@T
M.3,2 #@S&0 V,R  -#,F #,S+0 R-#0 ,30[ # U0P P-4P +S95 "XV8  M
M-VP +#=[ "LWBP J.)P *3BN "@XPP H..( *3CU "HW_P J-_\ DC0  '\U
M  !Q-@  93<  %LW  !4-P  338  $<V  !"-0  /38  #HV @ W-PL -#<0
M #(W%@ Q.!T +S@D "XX*P M.3( +#DY "LY00 J.DD *CI3 "D[7@ H.VH
M)SMY "8\B0 E/)L )#RM ",\P@ C/.  )#ST "4[_P E._\ C38  'PX  !M
M.0  8CD  %@Z  !1.0  2CD  $0Y   ].0  .3H  #4[   R.P@ +SP. "T]
M%  L/1H *CTA "D]*  H/B\ )SXV "8^/@ E/T< )#]0 "- 6P B0&@ (4!V
M "! AP ?09D 'T&K !Y!P  >0=X 'T#S !] _@ @/_\ B3D  '@Z  !I.P
M7CP  %4\  !-/   1SP  $ \   X/0  -#X  #!    M004 *D(, "="$0 F
M0Q@ )$,> "-#)0 B0RP (40S "!$.P ?1$0 'D5. !U%60 <164 &T5T !I%
MA0 91I< &4:I !A&O@ 71=P &$7Q !E$_0 :1/\ A#P  ',]  !F/@  6S\
M %(_  !*/P  1#\  #U    V00  ,4,  "Q$   G1@$ )$<* "%(#P @210
M'DD; !U)(@ <22D &THP !I*.  92D$ &$I+ !=+50 62V( %4MQ !1+@@ 3
M2Y0 $DNG !)+O  12]D $DKP !-*_  42?\ ?S\  &]   !A00  5T(  $Y"
M  !'0@  04(  #I#   R10  +4<  "A)   C2P  'DT& !M/#0 84!$ %U 7
M !90'@ 54"4 %% L !-1-  243T $5%' !%14@ 045\ #U)M  Y2?@ -49$
M#5&D  Q1N  ,4=$ #5#L  U0^@ .3_\ >4,  &I$  !=1   4T4  $M%  !$
M10  /D8  #9(   O2@  *4P  "1/   ?40  &E,  !16"0 15PX $%@3 !!8
M&0 /6"  #E@H  U8,  -6#D #%A#  M83@ *6%H "%AH  =8>0 &6(P !5B?
M  18LP $5\H !5?F  57\P &5OP <T8  &1'  !92   4$@  $A(  !!20
M.DH  #)-   K4   )5(  "!5   :6   %5H  !!=!@ ,8 P "F 0  E@%0 (
M8!P !V C  5@*P $8#0  V ]  %@20  8%4  &!C  !@<P  8(8  %^:  !?
MK@  7\0  %[B  !>\   7O@ ;$H  %]+  !52P  3$P  $5,   ]3@  -5
M "Y3   G5@  (%D  !I<   57P  $&(   UE!  (9PL  V<.  !H$P  :!@
M &@?  !I)@  :2X  &DX  !I0P  :4\  &E=  !I;0  :8   &F4  !HJ0
M:+\  &?<  !F[@  9O< 9D\  %I/  !13P  2D\  $%1   X5   ,%<  "A;
M   A7@  &F(  !1E   0:   #&L   =N P !< D  ' -  !Q$   <10  '(:
M  !S(0  <R@  ',Q  !S/   =$@  '-6  !S9@  <WD  '..  !SHP  <KD
M ''2  !QZP  </0 85,  %93  !/4P  154  #M8   R7   *F   ")D   ;
M:   %&P   ]O   +<@  !G8   !Y    >@8  'H*  ![#@  ?!$  'T5  !^
M&P  ?R(  ( J  " -0  @$$  (!/  " 7P  @'$  ("&  " G0  ?[(  '[*
M  !^Y0  ??$ 7%@  %18  !)6@  /UT  #5A   L90  (VH  !MO   4<P
M#G<   E[   #?P   ((   "$    A@$  (8&  "("@  B0T  (H0  "+%0
MC!L  (XB  "/+   CS@  (]&  "/5@  CV@  (]^  "/E0  CJL  (W!  "-
MW   C.L 65T  $Y?  !#8@  .&8  "YL   D<0  ''<  !1\   .@0  "(4
M  ")    C0   )    "2    DP   )0   "6 P  EP@  )@,  ":#P  FQ,
M )T:  "?(P  H"X  * \  "@3   H%X  *!T  "?C   GZ(  )^W  ">RP
MGN  4V0  $=H   \;0  ,7,  "=Y   =?P  %(4   V+   &D    )0   "8
M    G    )\   "A    H@   *0   "E    IP   *@$  "J"0  K T  *T2
M  "P&0  LB,  +(Q  "R0@  LE0  +)I  "R@   LI@  +&L  "ROP  L<X
M3&X  $!S   U>@  *H$  !^(   5C@  #I4   ::    GP   *0   "H
MK    *\   "Q    L0   +,   "U    M@   +@   "Z    O 8  +X,  #
M$0  PQD  ,4F  #%-P  QDD  ,9=  #'<@  QXH  ,B?  #(KP  R+P 1GH
M #F!   NB0  (I   !>8   /GP  !Z4   "J    KP   +,   "W    O
M +\   #!    P@   ,0   #%    QP   ,D   #+    S0   ,\#  #2"@
MUA   -P:  #=*@  WCP  -]0  #@90  X7L  .&1  #BH@  XJT _P " /\
M  #_  , _P , /\ $P#_ !T _P H /X ,P#[ #X ]P!( /, 4 #P %< [0!>
M .L 9 #H &D YP!O .4 = #C 'D X@!_ .  A0#> (P W "3 -D G #6 *8
MTP"Q -$ P #/ -H S@#Q ,P _P#+ /\ RP#_ ,8 _P#! /\ _P   /\   #_
M    _P ( /L $ #V !D \@ D .\ +@#M #D Z !" ., 2P#@ %( W0!9 -D
M7P#6 &0 TP!I -$ ;@#/ '0 S@!Y ,P ?P#* (8 R ". ,8 E@#$ *  P@"K
M ,  N0"^ ,T O #J +L _ "Z /\ N@#_ +H _P"V /\ _P   /\   #^
M]  $ .L #0#D !0 WP ? -L *0#8 #, TP ] ,X 10#* $T QP!3 ,4 60##
M %\ P0!D +\ :0"] &X NP!S +H >0"X (  M@"( +0 D "R )H L0"E *\
ML@"M ,0 K #A *L ]@"J /\ J@#_ *H _P"J /\ _P   /T   #N    X@
M -4 "@#- !$ QP 9 ,0 (P#! "T OP W +L /P"W $< M0!. +( 4P"P %D
MKP!> *T 8P"L &@ JP!M *D <P"H 'H I@"! *0 B@"C )0 H0"? )\ K ">
M +L G #2 )L [@": /\ F@#_ )D _P"9 /\ _@   .X   #>    RP   ,$
M!0"Y  T M  4 +$ '@"N "< JP P *H .0"G $$ I !( *( 30"A %, GP!8
M )X 70"= &( FP!G )H ;0"8 ', EP![ )4 A "4 (X D@"9 )  I@". +0
MC0#( (P Y@"+ /D B@#_ (H _P"+ /\ \    -L   #'    N@   +    "H
M  H I  0 *  & "= "$ FP J )H ,P"8 #L E@!! )0 2 "2 $T D0!2 (\
M5P". %P C !A (L 9P"* &X B !U (< ?@"% (@ @P"4 (( H "  *\ ?P#
M 'X W0!] /( ?0#_ 'T _P!] /\ X    ,8   "U    J@   *(   ";  4
ME0 - )( $P"0 !P C0 D (L +0"* #0 B  [ (8 0@"% $< @P!- (( 4@"!
M %< ?P!< 'X 8@!] &@ >P!P 'H >0!X (, =@"/ '4 G !T *H <@"Z '$
MT0!P .P < #[ '  _P!P /\ S00  +<&  "G!P  FP8  ),$  ".    B@ (
M (8 #P"$ !8 @0 > '\ )P!] "X ?  V 'H / !Y $( =P!' '8 3 !U %(
M<P!7 '( 70!Q &, ;P!K &X = !L 'X :P"* &D F !H *8 9P"V &8 RP!E
M .< 90#W &4 _P!E /\ P P  *L-  ";#@  CPX  (8-  "!"P  ?@<! 'P!
M"P!Y !$ =P 8 '4 (0!S "D <0 P &\ -@!N #P ; !" &L 1P!J $T :0!2
M &@ 6 !F %\ 90!G &, < !B 7H 8 &' %\"E0!> J, 7 .S %P#QP!;!.0
M6P7T %L&_@!;!O\ M1   *$2  "1$P  A1,  'P2  !V$0  <PX  '(,! !Q
M!PT ;@02 &P$&P!I!2, 9P4J &8&,0!D!C< 8P8] &('0P!A!TD 7P=. %X(
M50!="%P 6PEC %H);0!8"G@ 5PJ% %8+DP!4"Z( 4PNS %(,QP!2#.0 40WU
M %$-_P!1#?\ K14  )D7  ")&   ?1D  '08  !M%P  :A0  &<1  !G#@<
M9@P. &,,%0!A#!T 7PPE %T-+ !<#3, 6PTY %H-/P!8#44 5PU+ %8.40!5
M#ED 4PYA %(.:P!0#W8 3A"# $T0D@!,$*( 2Q"R $H1R !)$>4 21'W $D2
M_P!)$?\ I1D  )(<  "#'0  =AX  &T=  !F'   8AH  %\7  !>% $ 7A$*
M %L0$0!9$1@ 5Q$@ %41)P!4$2X 4Q$T %$1.P!0$D$ 3Q)' $X23@!,$E4
M2Q-> $D39P!(%', 1A2  $45CP!$%9\ 0Q:P $(6Q0!"%^, 0A?V $(7_P!"
M%_\ GQT  (P@  !](0  <2(  &@B  !A(0  7!\  %D<  !7&0  518& %05
M#@!1%10 3Q8< $X6(P!,%BH 2Q8P $H6-P!)%ST 1Q=# $872@!%&%( 0QA:
M $(99 !!&7  /QI] #X;C0 ]&YT /!RN #L<PP ['.$ .QWU #L<_P \'/\
MFB$  (<C  !X)   ;"4  &,E  !<)   5R,  %,@  !1'@  3QP" $T;# !+
M&A$ 2!L8 $<;( !%&R8 1!LM $,<,P!"'#D 0!Q  #\=1P ^'4\ /1Y8 #P>
M8@ Z'VT .1][ #@@BP W(9L -B&M #4AP0 U(=\ -2'S #8A_P V(?\ EB,
M (,F  !T)P  :"@  %\H  !8)P  4R8  $\D  !,(@  22   $<@"0!$'P\
M0A\5 $ @'  _(", /B I #P@+P [(38 .B$] #DA1  X(DP -R)5 #8C7P T
M(VL ,R1Y #(EB0 Q)9H ,"6K # FOP O)MP ,";R # F_P Q)?\ D28  '\H
M  !Q*@  92H  %PJ  !5*@  3RD  $LH  !()0  1"0  $$D!0 _) T /202
M #LD&0 Y)!\ -R0F #8D+  U)3, -"4Z #,F00 R)DH ,2=3 # G70 O*&D
M+BEW "TIAP L*9@ *RJJ "HJO0 J*MH *RKQ "LJ_@ L*?\ C2@  'PJ  !M
M+   8BT  %DM  !1+0  3"P  $<K  !#*   /R@  #PH @ Y* L -R@0 #4H
M%@ S*!P ,B@C # H*0 O*3  +RHW "XJ/P M*T< +"M1 "LL6P J+&< *2UU
M "@MA0 G+9< )BZH "4NO  E+M@ )B[P "8N_0 G+?\ BBL  '@M  !J+@
M7R\  %8O  !.+P  2"X  $,M   _+   .RP  #<L   T+ D ,BP. # M$P N
M+1H +2T@ "LM)P J+BT *BXU "DO/0 H+T4 )S!. "8P60 E,64 )#%S ",Q
M@P B,I4 (3*G "$RNP @,M0 (3+O "(Q_  B,?\ ABT  '4O  !G,   7#$
M %,Q  !+,0  13$  $ P   [,   -C   #,P   P,08 +3$- "LQ$0 I,A<
M*#(> "<R)  E,RL )3,R "0S.@ C-$, (C1, "$U5P @-6, 'S5Q !XV@0 =
M-I, '#:E !LVN0 ;-M( '#;M !TV^P =-?\ @C   '$R  !C,P  630  % T
M  !)-   0C,  #TS   W,P  ,30  "XU   K-0( *#8+ "4W$  D-Q4 (C<;
M "$X(@ @."@ 'S@P !XX-P =.4  '#E) !LZ5  :.F  &3IN !@Z?P 7.Y$
M%SND !8[MP 5.]  %CKL !<Z^@ 8.?\ ?3(  &TT  !@-0  538  $TV  !&
M-@  0#8  #HV   T-@  +C@  "HY   F.@  (SL( " \#@ >/1( '3T8 !P]
M'P ;/B4 &CXM !D^-  7/CT %C]' !4_40 4/UX %#]L !- ?  20(\ $4"B
M !% M@ 00,X $3_K !(_^0 2/O\ >34  &DW  !<.   4CD  $HY  !#.0
M/3D  #<Y   Q.@  *SP  "<]   B/P  'D$$ !I""P 80Q  %T,5 !5$&P 4
M1"( $T0I !-$,0 21#H $45# !!%3@ 015L #D5I  Y%>0 -18P #46?  Q%
ML@ +1<D #$7E  U$]@ -1/\ =#D  &4Z  !8.P  3SL  $<\  ! /   .CP
M #0\   N/@  *$   "-"   ?1   &D8  !5("  22@T $4H2 !!*&  /2QX
M#DLE  U++0 -2S8 #$M   M+2@ *2U8 "4MD  A+=  '2X< !4N:  1+K@ $
M2L0 !4K@  5*\  &2?H ;CP  & ]  !4/@  2SX  $0^   ]/@  -S\  #%
M   J0@  )$4  !]'   :20  %4P  !%.!0 .40L "U$0  I1%  )41L "%$B
M  =1*0 %43( !%([  -21@ !4E(  %)?  !2;P  4H$  %&6  !1J0  4;\
M %#<  !0[@  4/< :$   %M!  !000  2$$  $%!   [0@  -$,  "U%   F
M2   ($L  !M-   64   $5,   Y5!  *6 H !E@.  )8$@  61<  %D=  !9
M)0  62T  %DV  !900  64T  %I:  !::0  67P  %F0  !9I0  6+H  %C5
M  !7[   5_8 8T0  %9%  !-10  144  #]%   W1P  +TD  "A,   B3P
M&U(  !95   16   #5H   E= P $7PD  & -  !@$   810  &$9  !B(
M8B<  &(Q  !B.P  8D<  &)5  !C9   8G8  &*+  !BH   8;8  &'/  !@
MZ@  8/4 74@  %))  !*2   0T@  #I*   R30  *E   "-3   <5P  %EH
M !%=   -8   "&,   -F 0  9P8  &@+  !I#@  :A$  &L5  !L&P  ;2(
M &TJ  !M-   ;4   &U.  !M70  ;6\  &V$  !LF@  ;+   &O(  !KY@
M:O, 6$T  $Y-  !(3   /DX  #51   L5   )%@  !U<   68   $&0   QG
M   ':P   6X   !P    <@,  '('  !S"P  =0X  '81  !W%@  >!P  'DC
M  !Z+0  >CD  'I'  !Z5@  >6@  'I\  !YE   >*H  'C!  !WWP  =^\
M5%$  $Q1  !"4@  .%4  "]9   F7@  'F(  !9G   0:P  "V\   5S
M=P   'H   !\    ?@   '\"  " !@  @0H  (,-  "$$0  AA4  (@<  ")
M)0  BC   (H^  ")30  B5\  (ES  "(BP  B*(  (>Y  "'T0  AN@ 4E8
M $=7   \6@  ,E\  "AD   ?:0  %F\  !!T   *>0   GT   "!    A0
M (@   "*    C    (T   "/    D 0  )((  "3#   E1   )<5  "9'0
MFR<  )LT  ";1   FE8  )IJ  "9@@  FIH  )BP  "8QP  E]X 2UP  $!@
M   U90  *VH  "%Q   7=P  $'T   F#   !B    (P   "1    E0   )@
M  ":    FP   )T   "?    H    *(   "D!0  I@H  *@.  "J%   K1T
M *TJ  "M.0  K4L  *U?  "M=P  K)   *NG  "KN@  J\L 168  #EK   N
M<0  (W@  !E_   0A@  "8T   "3    F    )T   "A    I0   *@   "K
M    JP   *X   "O    L0   +,   "U    MP$  +D'  "\#0  OQ,  ,(?
M  #"+@  PD   ,)4  #!:P  P8,  ,";  #!K0  P;P /G(  #)X   G@
M'(@  !*0   *EP   )T   "C    J    *T   "R    M@   +D   "[
MO    +X   #     P@   ,0   #&    R    ,L   #.!0  T0T  -84  #7
M(P  V#4  -E)  #:7@  VW4  -N,  #<GP  W*L _P   /\   #_    _P )
M /\ $ #_ !D _@ D /P +P#Y #D ] !# /  2P#M %( Z@!9 .< 7P#D &0
MX@!I .  ;@#> ', W !Y -H ?P#7 (8 U ". -$ E@#/ *$ S "L ,H NP#(
M -( Q@#N ,8 _P#% /\ Q0#_ +\ _P"Z /\ _P   /\   #_    _@ % /<
M#@#R !4 [@ ? .L *@#I #0 XP ] -X 10#9 $T U !3 -$ 60#. %X S !C
M ,H : #) &T QP!S ,4 >0## (  P0"( +\ D "] )L NP"F +D M "W ,@
MM@#F +4 ^P"T /\ M #_ +, _P"N /\ _P   /\   #X    [0   .4 "P#=
M !$ UP : -( ) #/ "X RP W ,< 0 ## $< P !. +X 4P"\ %D N@!> +@
M8P"V &@ M0!M +, <P"Q 'D KP"! *T B@"K )0 J0"@ *@ K0"F +X I0#;
M *0 ] "D /\ HP#_ *, _P"B /\ _P   /8   #F    UP   ,L !@#$  X
MO@ 5 +L 'P"Y "@ MP Q +0 .@"P $$ K0!( *L 3@"I %, IP!8 *8 7 "D
M &$ HP!G *$ ; "@ ', G@!Z )T @P"; (X F0"9 )< I@"6 +8 E0#, )0
MZP"3 /T DP#_ ), _P"3 /\ ]P   .0   #0    P0   +<  @"O  L JP 1
M *< &0"E "( HP K *( ,P"? #L G !" )L 2 "9 $T EP!2 )8 5P"5 %L
MDP!A )( 9@"0 &T CP!T (T ?0", (< B@"3 (@ H "' *\ A0#" (4 X@"$
M /< A #_ (0 _P"$ /\ Y0   ,T   "\    KP   *8   ">  < F@ . )8
M% "4 !T D@ E )$ +0"0 #4 C0 \ (P 0@"* $< B !, (< 40"& %8 A !;
M (, 8 "! &< @ !N 'X =P!] ($ >P"- 'H F@!X *D =P"Z '8 TP!V .\
M=@#^ '4 _P!U /\ T    +L   "K    GP   )<   "0  ( BP + (@ $ "&
M !< A  @ (( )P"! "\ ?P U 'T / !\ $$ >P!& 'D 2P!X %  =P!5 '8
M6P!T &$ <P!I '$ <0!P 'L ;@"' &T E0!K *, :@"T &H R0!I .@ :0#Y
M &D _P!I /\ P    *P   "< @  D (  (@   "#    ?P & 'L #0!Y !(
M=P : '8 (@!T "D <P P '$ -@!P #P ;P!! &T 1@!L $L :P!0 &H 5@!H
M %P 9P!D &4 ; !D '8 8P"" &$ D !@ )\ 7P"O %X PP!> .$ 7@#T %T
M_P!= /\ M <  * )  "0"P  A L  'P*  !W!P  = 0  '$ "0!O  \ ;0 5
M &L ' !I ", :  J &< ,0!E #8 9  \ &, 00!B $8 8 !, %\ 4@!> %@
M70!? %L : !: '( 6 !^ %< C !6 )L 50"K %0 O@!4 -H 4P#O %0 ^P!4
M /\ J0T  )8.  "'$   >A   '(0  !L#@  :0P  &<) P!F! L 9  0 &(
M%P!@ !X 7@ E %T *P!< #$ 6@ W %D / !8 $( 5P%' %8!3@!5 E0 4P)<
M %(#90!1 V\ 3P1[ $X$B@!-!9D 3 6I $L%O !*!M0 2@?M $H'^0!*!_\
MH1   (X2  !^%   <Q0  &H4  !D$P  8!$  %X/  !=#04 70D- %H&$@!8
M!QD 5@<@ %4')P!3!RT 4@@S %$(. !0"#X 3PE$ $X)2@!,"5$ 2PI9 $H*
M8@!("VT 1PMZ $8,B !$#)@ 0PRI $(-O !"#=4 0@WN $(-^P!"#?\ FA0
M (<6  !X&   ;!D  &,9  !=&   618  %83  !4$0  5 X( %,-#@!1#10
M3PT; $T-(@!,#2@ 2PTN $H-- !)#3H 1PY! $8.1P!%#D\ 1 Y7 $(/80!!
M$&P /Q!Y #X0B  ]$9@ .Q&I #L1O  Z$=8 .A'P #H2_0 [$?\ DQ@  ($:
M  !S'   9QT  %X=  !8'   4QL  % 8  !.%@  3!,# $P1"P!*$!  2!$7
M $81'@!%$20 1!$J $(1, !!$3< 0!(] #\21  ]$DP /!-4 #L37@ Y%&D
M.!1V #<5A0 V%98 -!:G #06N@ S%M, ,Q;N #06_  T%O\ CAL  'P=  !N
M'P  8R   %H@  !3(   3AX  $H=  !(&@  1A@  $46!P!#%0X 0143 #\5
M&@ ^%2  /14G #L5+0 Z%C, .18Z #@600 W%TD -1=1 #086P S&68 ,AES
M # :@P O&I0 +ANE "T;N  M&]  +1OL "X;^P N&_\ BAX  '@@  !J(@
M7R,  %8C  !/(@  2B$  $8@  !#'@  01L  #\: P ]&@P .QD1 #D9%@ W
M&AT -AHC #4:*0 T&C  ,QLV #$;/@ P'$8 +QQ/ "X=60 M'60 +!YQ "L?
M@0 J'Y( *1^D "@@MP G(,X )R#K "@@^@ I'_\ AB   '0C  !G)   7"4
M %,E  !,)0  1R0  $(C   _(0  /1\  #H>   W'@D -1X. #,>$P Q'AH
M,!X@ "\>)@ N'RT +1\S "P@.P K($, *B%, "DA5@ H(F( )B)O "4C?P D
M(Y  (R.B "(DM0 B),P (B3I ",D^0 D(_\ @B,  '$E  !C)@  62<  % H
M  !))P  0R<  #\F   [)   ."(  #4B   R(@8 ,"(- "XB$0 L(A< *B(=
M "DB(P H(RH )R,Q "8D.  E)4$ )"5* ",F5  B)F  (2=M " G?0 ?)X\
M'BBA !XHM  =*,H '2CH !XH^  ?)_\ ?B4  &XG  !@*0  5BD  $TJ  !&
M*@  02D  #PH   W)P  -"8  # F   M)@, *R<+ "@G$  G)Q0 )2<: "0G
M(0 C*"< (B@N "$I-@ @*3X 'RI( !XJ4@ =*UX '"MK !LK>P :+(T &2R?
M !@LL@ 8+,D &"SG !DK]P :*_\ >B<  &HJ  !=*P  4RP  $HL  !#+
M/BL  #DK   T*@  ,"H  "LJ   I*P  )BL( ",L#@ B+!( ("P8 !\L'@ >
M+24 '2TL !PM,P ;+CP &BY% !DO4  8+UP %R]I !8P>0 5,(L %#"> !0P
ML0 3,,< $S#E !0P]@ 5+_\ =BH  &<L  !:+0  4"X  $@N  !!+@  .RX
M #8M   Q+0  +"T  "<O   D+P  (3 % !\Q#  <,1  &S(5 !HR'  9,B(
M&#(I !<S,0 6,SD %3-# !0T30 3-%D $C1G !$U=P 1-8D $#6< ! UL  .
M-<8 #S3D ! T]0 0-/\ <BP  &,N  !7,   33   $4P   ^,   .#   #,P
M   O,   *3$  "0R   A,P  '34" !HV"0 7-PX %3<3 !0X&0 3.!\ $C@F
M !(X+@ 1.38 $#E  ! Y2P ..5< #CID  TZ=  ,.H8 ##J9  LYK  *.<$
M"CG>  LY\0 ,./P ;B\  %\Q  !3,@  2C,  $(S   [,P  -C,  #$R   L
M,P  )S0  "$V   =.   &3D  !4[!@ 2/0P $#X0 ! ^%0 ./AP #CXC  T^
M*@ ,/C, ##X\  L_1P */U( "#]@  <_;P &/X$ !3^4  0_J  #/KP !#[7
M  4^[  %/O< :3,  %LT  !0-0  1S4  #\U   Y-0  -#4  "XU   I-P
M(S@  !X[   :/   %C\  !)!!  .0PH #$0.  I$$P )1!D "$0@  =$)P &
M1"\ !40X  -%0@ "14X  $5;  !%:@  17P  $60  !$I   1+D  $31  !$
MZ@  0_4 9#8  %<W  !,.   0S@  #PX   W.   ,3@  "LY   E.P  (#T
M !I    60@  $D0   Y'!  +20D !TH-  1+$0 !2Q8  $L<  !+(P  2RL
M $LT  !+/@  3$D  $Q7  !,9@  3'<  $N,  !+H0  2[4  $K.  !*Z0
M2O4 7SH  %([  !(.P  0#L  #H[   T.P  +CP  "<^   B00  '$,  !9&
M   220  #DL   M. P '4 @  E$,  !1$   4A,  %,8  !3'P  4R8  %,O
M  !3.0  4T4  %-2  !380  4W(  %.'  !2G   4K$  %'*  !1YP  4?0
M63X  $X^  !%/@  /CX  #@^   P0   *4(  "-$   =1P  %TH  !)-   .
M4   "U,   95 @  5P<  %@+  !9#@  6A$  %H5  !;&@  7"$  %PJ  !<
M-   7#\  %Q-  !<6P  7&P  %R!  !;EP  6ZT  %K%  !:Y   6?, 5$(
M $I"  !"0@  /$(  #1#   L1@  )4D  !Y,   73P  $E,   Y6   *60
M!5L   !>    8 0  &$(  !B#   8PX  &01  !E%@  9AP  &<C  !G+0
M9SD  &=&  !G50  9V8  &=Z  !FD0  9:@  &7   !DW@  9/  3T8  $=&
M  ! 10  -T<  "]*   F30  'U$  !A5   260  #5P   A@   "8P   &8
M  !H    :@   &L$  !L"   ;0P  &\.  !P$@  <A<  ',=  !T)@  =#(
M '0_  !T3@  <U\  '1R  !SB@  <J$  '&X  !QU   <.P 3$H  $5*   [
M2P  ,DX  "E2   @5@  &%L  !)?   -9   !V@   !K    ;P   '(   !U
M    =@   '<   !Y @  >@8  'P*  !^#@  @!$  ((6  "$'@  A"D  (0V
M  "$10  A%8  (-J  "#@0  @ID  (&Q  " R0  @.4 2DX  #]0   U4P
M*U<  ")<   98@  $F<   QL   %<0   '4   !Y    ?0   ($   "#
MA0   (8   "(    B0   (L$  "-"   CPT  )(0  "4%@  EB   )8L  "6
M.P  EDP  )5@  "5=@  E)   ).G  "2O0  DM4 1%4  #E9   O70  )&,
M !II   2;P  #'4   1[    @    (4   ")    C0   )$   "3    E
M )8   "8    F@   )P   ">    H 8  *(+  "E$   J!<  *DC  "I,0
MJ4,  *E6  "H;0  IH<  *>>  "FLP  I<< /EX  #)C   G:@  '7   !-X
M   ,?P   X4   "+    D0   )8   ";    GP   *(   "D    I0   *<
M  "I    JP   *T   "P    L@   +4"  "W"0  NQ   +X8  "^)@  OC@
M +Y+  "]80  O'H  +N4  "ZJ0  NKD -VH  "MP   @>   %H    V(   %
MCP   )8   "<    H@   *<   "L    L    +,   "V    MP   +D   "[
M    O0   +\   #"    Q0   ,@   #*    S@@  -(0  #5&P  U2P  -1
M  #45P  TVX  -2&  #4FP  TZL _P   /\   #_    _P % /\ #@#_ !4
M_  @ /D *@#V #0 \0 ] .T 1@#I $T Y@!3 .0 60#A %X W@!C -P : #9
M &X U0!S -, >0#0 (  S@"( ,L D0#) )P Q@"G ,0 MP#" ,P P #L +\
M_P"^ /\ O0#_ +< _P"R /\ _P   /\   #_    ^@ ! /, "P#M !( Z  ;
M .4 )0#D "X WP X -@ 0 #2 $< S@!. ,L 5 #( %D Q@!> ,0 8P#" &<
MP !M +\ <P"] 'H NP"! +D BP"V )4 M "A +( KP"P ,( K@#C *X ^@"L
M /\ K0#_ *D _P"F /\ _P   /\   #R    Y@   -T !P#2  X S0 6 ,H
M( #( "D Q0 R ,  .@"\ $( N0!( +< 3@"U %, LP!8 +$ 70"P &( K@!G
M *P ; "J ', J0![ *< A "E (X HP": *$ J "? +D G@#2 )T \@"< /\
MG0#_ )P _P"9 /\ _    .X   #=    S    ,$  @"Z  P M@ 2 +( &@"P
M ", KP L *T - "I #P I@!" *0 2 "B $T H !2 )X 5P"= %L G !@ )H
M9@"9 &P EP!T )4 ?0"3 (< D0"3 )  H0". +$ C0#& (P Z "+ /T C #_
M (P _P", /\ [0   -@   #%    MP   *P   "F  @ H0 . )\ %0"= !X
MFP F )H +@"7 #4 E0 \ ), 0@"1 $< D !, (X 40"- %4 BP!: (H 8 ")
M &8 AP!M (4 =@"$ (  @@", (  F@!_ *D ?0"\ 'P W !\ /4 ? #_ 'P
M_P!\ /\ V0   ,$   "Q    I    )P   "4  , D  , (T $0"+ !@ B0 @
M (D * "' "\ A0 V (, / "" $$ @ !& '\ 2P!] $\ ? !4 'L 6@!Y &
M> !G '8 < !U 'H <P"& '$ DP!P *( ;P"T &X S !N .T ;@#^ &X _P!N
M /\ Q    *\   "@    E    (P   "&    @0 ( 'X #@!\ !0 >P ; 'D
M(@!X "D =P P '4 -@!T #L <@!  '$ 10!P $H ;P!/ &T 5 !L %L :P!B
M &D :@!H '0 9@"  &4 C@!C )T 8@"M &$ P@!A .0 80#X &$ _P!A /\
MM    *    "1    A@   'X   !Y    =0 # '$ "P!O !  ;0 6 &P '0!K
M "0 :P J &D , !H #8 9@ [ &4 0 !D $4 8P!* &$ 3P!@ %8 7P!= %T
M90!< &\ 6@!Z %D B !8 )@ 5P"H %8 NP!6 -@ 5@#Q %8 _P!6 /\ J $
M )0%  "%!P  >@<  '(&  !L!   :0$  &< !P!D  T 8P 1 &$ & !@ !\
M7P E %X *P!= #  6P V %H .P!9 $  6 !% %< 2P!6 %$ 50!8 %, 80!2
M &H 4 !V $\ A !. ), 30"D $P M@!, ,T 3 #K $P ^@!, /\ G0D  (L+
M  !\#0  < T  &@-  !B#   7PH  %T& 0!< 0D 6@ . %@ $P!7 !D 5@ @
M %4 )@!3 "L 4@ Q %$ -@!0 #L 3P!! $X 1P!- $T 2P!5 $H 70!) &<
M1P!S $8 @ !% )  1 "A $, L@!# ,@ 0P#F $, ]0!# /\ E0T  (,/  !T
M$   :1$  & 1  !:$   5@X  %0-  !3"@0 4P8+ %$#$ !/ 14 3@$; $P!
M(0!+ 2< 2@(L $D",@!( C< 1P,] $4#0P!$ TH 0P11 $($6@! !60 /P5P
M #X&?@ ]!HX / >? #L'L0 Z!\8 .@?C #H'\P Z"/P CA   'P2  !N%
M8A4  %H5  !4%   4!,  $T1  !+#@  2PT& $H*# !)"!$ 1P@6 $4('0!$
M"", 0@@H $$)+@! "3, /PDY #X*0  ]"D< / I/ #H+6  Y"V, . QO #8,
M?@ U#(X - V? #,-L0 R#<< ,@WC #(-]  R#?X B!,  '<5  !I%P  7A@
M %48  !/&   2A8  $<5  !%$P  0Q " $,." !"#0X 0 T2 #\-&  ]#1\
M/ TD #L-*@ Y#3  . XW #<./0 V#D4 -0Y- #,/5P R#V( ,1!N "\0?0 N
M$(X +1&@ "P1L@ K$<@ *Q'F "L1]@ L$?\ @Q8  '(9  !D&@  61L  %$;
M  !+&P  1AH  $(8   _%P  /A0  #P2!  [$0H .A 0 #@0%0 W$!L -1$A
M #01)P S$2T ,A$S # 1.@ O$D( +A)+ "T35  K$U\ *A1L "D4>P H%(P
M)Q6> "85L  E%<8 )17D "45]@ F%?\ ?AD  &X;  !@'0  5AX  $T>  !'
M'@  0AT  #X<   Z&@  .!@  #<6   U%0< -!0- #(4$@ P%!< +Q0= "T4
M(P L%2H *Q4P "H5-P I%C\ *!9( "<74@ F&%T )!AJ ",9>0 B&8H (1F<
M " 9KP ?&<0 'QGB " 9]  @&?\ >AL  &H>  !='P  4R   $H@  !$(
M/A\  #H>   W'0  -!P  #(9   P&00 +A@+ "P8$  J&!0 *1@: "<8(  F
M&28 )1DM "0:-0 C&CT (AM& "$;4  @'%L 'QUH !X==P ='8@ '!Z; !L>
MK0 :'L, &A[@ !H=\P ;'?\ =QT  &<@  !:(0  4"(  $@B  !!(@  .R(
M #<A   S(   ,!\  "T=   K'0  *!T( "8=#@ E'1( (QT7 "$='0 A'20
M(!XJ !\>,@ >'SH '1]# !P@30 ;(5D &B%F !DA=0 8(H< %R*9 !8BK  5
M(L$ %2+? !4A\@ 6(?X <R   &0B  !7(P  320  $4E   ^)   .20  #0C
M   P(@  +"(  "DA   F(0  )"$& "(A#  @(1  'B$5 !TB&P ;(B$ &R(H
M !HC+P 9(S@ &"1! !<D2P 6)5< %25D !0F<P 3)H4 $B:8 !$FJP 1)L
M$";= !$E\0 2)?T <"(  &$D  !4)@  2B8  $(G   \)@  -B8  #$E   M
M)0  *20  "8D   B)0  'R4# !TF"@ ;)@X &2<2 !@G&  7)Q\ %B<E !4H
M+0 4*#4 $RD^ !(I20 1*54 $2IB ! J<0 /*H, #BJ6  XJJ0 -*KT #2K7
M  TJ[@ .*?L ;"0  %TF  !1*   2"@  $ I   Y*   -"@  "\H   K)P
M)R<  "(H   >*0  &RH  !@K!P 6*PT %"P1 !,L%@ 2+!P $2TC ! M*@ 0
M+3( #RX\  XN1@ -+E( #2Y?  PO;@ ++W\ "B^2  DOI0 )+KD ""[0  DN
MZ0 *+O< :"<  %HI  !.*@  12L  #TK   W*P  ,2H  "TJ   I*@  )"H
M " K   ;+0  &"X  !4O!  2,0H $#(.  \R$P .,AD #3(@  TR)P ,,B\
M"S,X  HS0@ ),TX "#-;  8T:@ %-'L !#..  ,SH@ ",[8  C/-  ,SYP $
M,O, 9"H  %8L  !++0  0BT  #HM   T+0  +RP  "LL   F+   (BT  !TO
M   9,0  %3(  !(T P /-@D ##@-  HX$0 ).!8 "#@=  <X)  &."P !#@T
M  ,X/@ ".4H  #E7   Y90  .7<  #F+   XGP  .+,  #C*   XY@  -_(
M7RT  %(N  !(+P  /S   #@O   R+P  +2\  "DO   D,   'S$  !HS   5
M-0  $C<   \Y P ,.P@ "#T-  4^$  #/A0  #X:   ^(0  /B@  #XQ   _
M.P  /T8  #]3   _80  /W,  #^'   ^G   /K   #W'   ]Y   /?( 6C
M $XR  !$,@  /#(  #4R   P,0  *S$  "8R   @-   &S8  !8X   2.P
M#ST   P_ P (00@ !$,,  !##@  1!(  $46  !%'0  120  $4M  !&-@
M1D(  $9.  !&70  1FX  $6"  !%F   1*T  $3$  !#XP  0_( 530  $HU
M  !!-0  .34  #,T   N-   *#4  "(W   =.@  %SP  !(_   /00  #$0
M  A& 0 #2 8  $D*  !*#0  2Q   $P4  !-&0  3B   $XH  !.,@  33T
M $Y*  !.6   36D  $U]  !,E   3*H  $O!  !+X0  2O( 4#@  $8X   ]
M.   -S@  #$W   J.0  )#L  !X]   80   $T,   ]&   +20  !TL   ).
M    4 0  %$(  !2"P  4PX  %01  !5%0  5AL  %<C  !7+   5S@  %=$
M  !74@  5F,  %9W  !6C@  5:4  %2]  !3W0  4_  2SP  $(\   [.P
M-3L  "T\   F/P  'T(  !E%   32   #DL   M/   %40   %0   !7
M6 $  %H%  !;"   7 P  %T.  !?$0  8!8  &(=  !B)@  8C$  &(^  !A
M3   85T  &%P  !@B   8*   %^W  !>U   7>X 1T   #\_   Z/P  ,4
M "E#   A1@  &DH  !-.   .40  "E4   18    6P   %X   !A    8P
M &0!  !E!   9P@  &@+  !J#@  ;!(  &X7  !O(   ;RH  &\V  !N10
M;E4  &YH  !M?P  ;9@  &RP  !KR@  :N@ 1$0  #Y#   U1   *T<  "-+
M   ;3P  $U0   Y8   (7    F    !D    9P   &L   !M    ;P   '
M  !R    = (  '4&  !W"@  >0X  'P2  !^&   ?R(  '\N  !_/0  ?DT
M 'UA  !]=P  ?)   'NH  !ZP   >=\ 0T<  #E)   O3   )5   !Q5   4
M6P  #F    =E    :@   &X   !R    =@   'D   !\    ?@   '\   "!
M    @P   (4   "' P  B@@  (P-  "/$0  DAD  )(E  "2,P  DD0  )%7
M  "0;0  CX8  (Z?  "-M0  C,T /4X  #)1   H5@  'EP  !5B   .:
M!VX   !T    >0   'X   ""    A@   (D   ",    C@   )    "2
ME    )8   "8    FP   )X&  "A#   I!$  *8;  "F*0  ICH  *5-  "E
M8@  I'L  *.4  "AJP  H;\ -E<  "Q<   A8@  %VD   ]P   '=P   'X
M  "$    B@   (\   "4    F    )L   ">    GP   *(   "D    I@
M *@   "K    K0   +    "S!   MPP  +L2  "['P  NS   +M#  "Z6
MN7   +>+  "WH0  M[, ,&(  "5I   :<   $'@   F     B    (\   "6
M    FP   *$   "F    J@   *X   "P    L0   +0   "V    N    +L
M  "]    P    ,,   #'    RP,  ,\,  #3%0  TB4  -(X  #13@  T&4
M ,]^  #-E@  S*D _P   /\   #_    _P # /\ "P#\ !$ ^0 ; /< )0#S
M "\ [@ X .D 0 #F $@ X@!. -\ 5 #< %D V0!> -4 8P#3 &@ T !M ,X
M<P#+ 'H R "" ,8 C ## )< P "C +X L@"\ ,@ N@#J +D _P"X /\ L0#_
M *H _P"G /\ _P   /\   #[    ]@   .T !P#G  \ X@ 6 -\ ( #> "D
MV0 S -$ .P#, $( R !( ,4 3@#" %, P !8 +X 70"\ &( N@!G +D ;0"W
M '0 M0![ +( A0"P )  K@"< *P J@"I +T IP#> *8 ^0"E /\ HP#_ )T
M_P"; /\ _0   /8   #K    WP   -$  P#*  P Q0 2 ,, &P#  "0 O@ L
M +D -0"V #P LP!# +  2 "N $X K !2 *L 5P"I %P IP!A *8 9P"D &T
MH@!T *  ?0"> (@ G "5 )H HP"8 +0 E@#- )4 \0"4 /\ E0#_ )  _P".
M /\ \P   .8   #1    P@   +@   "Q  @ K0 / *H %@"H !X J  G *8
M+P"B #8 GP \ )T 0@"; $< F0!, )< 40"6 %4 E !: ), 8 "1 &8 D !N
M (X =@", ($ B@"- (@ FP"& *P A0#! (0 Y@"# /T A #_ (, _P"! /\
MY    ,L   "Z    K    *(   "<  0 F  , )8 $0"4 !D DP A )( * "/
M #  C0 V (L / ") $$ B !& (8 2P"% $\ A !4 (( 6@"! &  ?P!G 'X
M;P!\ 'H >@"& '@ E !W *0 =0"W '0 U !S /0 = #_ '0 _P!T /\ RP
M +8   "F    F@   )(   "*    A@ ( (, #@"! !0 @0 ; (  (P!_ "H
M?0 P 'L -@!Z #L > !  '< 10!U $D = !. ', 5 !Q %H < !A &X :0!M
M ', :P!_ &D C0!H )T 9P"N &8 QP!E .H 9@#_ &8 _P!G /\ N    *0
M  "5    B@   ($   !\    =@ $ '0 # !R !  <0 6 '  '0!P "0 ;@ J
M &T , !K #4 :@ Z &D /P!H $0 9P!) &4 3@!D %0 8P!; &$ 8P!@ &T
M7@!Y %T AP!; )8 6@"H %D O0!9 -\ 60#X %H _P!: /\ J    )4   "'
M    >P   ',   !N    :@ ! &< " !E  X 9  2 &, & !C !\ 8@ E &$
M*@!? #  7@ U %T .@!< #X 6P!$ %D 20!8 $\ 5P!6 %8 7@!4 &@ 4P!S
M %$ @0!0 )$ 3P"B $X M0!. -  3@#P $X _P!/ /\ G    (D   ![ P
M< ,  &@#  !B 0  7P   %T ! !;  L 60 / %@ % !7 !D 5P @ %8 )0!5
M "H 4P P %( - !1 #D 4  _ $\ 1 !. $L 30!2 $L 6@!* &, 20!O $<
M? !& (P 10"= $4 L !$ ,< 1 #H $0 ^@!% /\ D@0  ( '  !Q"@  9@H
M %X*  !9"0  50<  %0$  !2  < 4  , $\ $ !. !4 30 ; $P ( !+ "8
M2@ K $D , !( #4 1P Z $8 0 !% $8 0P!. $( 5@!! %\ 0 !K #X >  ]
M (@ / "9 #P JP \ ,$ .P#@ #L ]  [ /\ B0H  '@,  !J#@  7PX  %<.
M  !1#@  30P  $L+  !*" ( 200) $@ #0!& !$ 10 6 $0 ' !# "$ 0@ F
M $$ *P _ #$ /@ V #T /  \ $, .P!* #H 4@ Y %P . !H #8 =0 U (4
M- "6 #0 J  S +P ,P#8 #, [P S /L @@T  '$/  !D$   61$  %$1  !+
M$0  1Q   $0.  !"#0  00L% $$'"P _!0X /@,2 #P"&  [ AT .@,B #D#
M*  X RT -P,R #8$.0 U!#\ - 5' #,%4  Q!EH , 9F "\'<P N!X, +0>5
M "P'IP K![H *P?2 "L'ZP K!_< ?1   &P1  !?$P  5!0  $P4  !&%
M0A,  #X2   \$   .@X! #H-!@ Z"@P . D0 #8(%  U"!D - D? #())  Q
M"2D , DO "\*-@ N"CT +0I% "P+3@ K"UD *0QE "@,<P G#(, )@V5 "4-
MIP D#;L (PW2 ",-ZP C#?< >!(  &@4  !;%@  41<  $@7  !"%@  /18
M #D5   W$P  -1$  #,0 P S#@@ ,@T- # -$0 O#18 +0T; "P-(0 K#2<
M*@TM "D.-  H#CL )PY$ "4.3@ D#UD (Q!E "$0<P @$(0 'Q"6 !X0J0 =
M$+T '!#8 !T0[@ =$/D <Q0  &06  !7&   31D  $49   _&0  .A@  #47
M   R%@  ,!4  "X3   M$00 +! * "L0#@ I$!( *! 8 "80'@ E$"0 )! J
M ",1,0 B$3D (1%" " 22P >$E8 '1-C !P3<0 :$X( &125 !@4IP 7%+L
M%Q/4 !<3[@ 8$_H <!8  & 9  !4&@  2AL  $(<   \&P  -AL  #(:   O
M&0  +!@  "H6   H% $ )A,' "43#  C$Q  (A,5 " 3&@ ?$R$ 'A0G !T4
M+@ <%38 &Q4_ !H620 9%E0 &!=A !87<  5&($ %!B3 !,8I@ 2&+H $A?2
M !(7[  3%_H ;!D  %T;  !1'0  1QT  #\>   Y'0  -!T  "\<   K&P
M*!H  "89   D&   (A<$ " 7"@ >%PX '!<2 !H7%P 9&!X &1@D !@9+  7
M&30 %AH] !4:1P 4&U( $QM? !(<;@ 1''\ $!R2 ! <I0 /'+D #AS0  X;
MZ@ /&_@ :1L  %H=  !.'P  11\  #T@   V'P  ,1\  "T>   I'0  )1T
M ",<   @&P  '1L! !L;!P 9' T %QP0 !8<%0 5'!L %!TB !,=*0 2'C$
M$1XZ !$?10 0'U  #R!=  X@;  -('P #2"/  P@H@ +(+4 "R#*  L@Y0 ,
M'_0 91T  %<?  !,(0  0B$  #HA   T(0  +R$  "H@   F'P  (Q\  " >
M   ='@  &2   !8@!  4( L $B$. !$A$P 1(AD $"(?  \B)@ .(R\ #B,W
M  TC00 ,)$T "R19  HD9P ))'@ ""2+  <DG@ ')+$ !B3'  8CXP '(_$
M8A\  %0A  !)(P  0",  #@C   R(P  +",  "@B   D(0  (2$  !XA   :
M(0  %B,  !,D P 1)0@ #R8-  XG$0 -)Q8 #"<=  LG(P *)RL "2@T  @H
M/@ '*$D !BA5  4I9  $*70  RF'  (IFP !**\  "C%  $HX0 !)_  7B(
M %$D  !&)0  /24  #4E   O)0  *B0  "8D   B(P  'R,  !LD   8)0
M%"8  !$H P /*0@ #"P,  HL$  (+!0 !RP:  8L(0 %+"@  RTP  (M.@ !
M+44  "U2   N8   +G$  "V$   MF0  +:T  "S"   LX   +/  6B0  $TF
M  !#)P  .B<  #,G   M)P  *"8  "0F   A)@  '28  !DG   5*0  $2L
M  \L P -+@< "3 ,  8Q#@ #,1(  3(7   R'@  ,B4  #(M   R-@  ,T(
M #-.   S70  ,VT  #.!   RE@  ,JL  #'!   QWP  ,?  5B<  $HI   _
M*@  -RH  # J   K*0  )R@  ",H   >*0  &BH  !8L   2+@  #S    TQ
M @ *- < !34+  (V#@  -Q   #@4   X&@  ."(  #@J   Y,P  .3X  #E*
M   Y60  .6D  #E]   XDP  .*@  #>_   WW@  -O  42L  $8L   \+
M-"P  "XL   J*P  )2L  " L   ;+0  %R\  !,Q   0,P  #34   DW @ %
M.@8  3L*   \#0  /0\  #X2   _%P  0!X  $ E  ! +P  0#H  $!&  !
M5   0&4  #]X   _CP  /J8  #Z]   ]W   /?  32X  $(O   Y+P  ,B\
M "TN   H+@  (B\  !TP   8,@  $S4  ! W   ,.@  "3P   4^    000
M $((  !#"P  1 T  $80  !'%   2!D  $@A  !(*@  2#4  $A!  !(3P
M2&   $=S  !'B@  1J(  $6Y  !%V0  1/  2#(  #XR   V,@  ,#$  "LQ
M   E,@  'S0  !DV   3.0  $#P   P_   (0@   T0   !&    2 (  $H%
M  !+"   3 L  $X.  !/$0  414  %(<  !2)0  4C   %(\  !12@  45H
M %%M  !0A   3YT  $ZU  !-T@  3>X 0S8  #LV   T-0  +S0  "<U   A
M.   &CL  !0^   000  #$0   ='   "2@   $T   !/    40   %,"  !4
M!0  50@  %<+  !9#@  6Q$  %T7  !='P  72H  %TV  !<1   7%0  %MG
M  !;?@  6I<  %FO  !8RP  5^H /SD  #@Y   S.   *SD  ",\   </P
M%4,  !!'   +2@  !4X   !1    5    %<   !:    7    %T   !?
M8 0  &('  !D"P  9@X  &@2  !K&0  :R,  &HN  !J/   :DT  &E?  !H
M=0  9X\  &:H  !EP@  9., /3T  #<\   N/0  )4   !U$   620  $$T
M  I1   $50   %H   !=    8    &,   !F    :    &H   !K    ;0
M &\"  !Q!@  = H  '8.  !Y$P  >QL  'LG  !Z-0  >44  'A9  !X;0
M=X8  ':?  !UMP  =-( /$$  #)"   H10  ($H  !=.   05   "ED   )>
M    8P   &<   !K    ;P   '(   !U    =P   'D   ![    ?0   '\
M  ""    A ,  (<)  "*#@  CA,  (\>  ".*P  CCL  (U.  "+8P  BGP
M (J5  "(K0  A\4 -D<  "Q+   B3P  &54  !!;   *80   6<   !M
M<@   '<   ![    ?P   (,   "&    B    (H   "-    CP   )$   "4
M    EP   )H!  "=!P  H0T  *44  "D(0  I#$  *-$  "B60  H'   )^+
M  "=H@  G;< ,%   "55   ;6P  $F(   MI   !<    '<   !]    @P
M (@   "-    D0   )4   "8    F@   )P   "?    H0   *,   "F
MJ0   *P   "P    M <  +@.  "Z&   NB<  +DY  "X3@  MV4  +9^  "U
ME@  LZL *5L  !YB   4:0  #'$   )Y    @0   (D   "/    E@   )L
M  "@    I    *@   "K    K    *\   "R    M    +8   "Y    O
M ,    #$    R    ,T'  #2$   TAT  -$O  #01   SUL  ,US  #+C0
MRJ$ _P   /\   #[    ^@   /P " #X  \ ]0 7 /0 ( #Q "H ZP S .8
M.P#B $, W@!) -H 3P#6 %0 TP!9 -  7@#. &, RP!H ,D ;@#& '4 PP!]
M ,$ A@"^ )( NP"> +D K@"V ,, M #H +, _P"O /\ I0#_ )X _P"; /\
M_0   /<   #R    \    .<  P#A  P W  2 -@ &P#6 "0 T@ M ,P -@#&
M #T P@!# +\ 20"\ $X N@!3 +@ 6 "V %T M0!B +, 9P"Q &X KP!V *P
M?P"J (H J "7 *4 I@"C +D H0#9 *  ^0"> /\ F #_ )( _P"/ /\ \P
M .P   #C    TP   ,@   #!  D O0 / +L %@"Y !\ MP G +, +P"O #<
MK  ] *H 0P"H $@ I@!- *0 4@"C %8 H0!; )\ 80"> &< G !O )H > "7
M (, E0"0 ), G@"1 +  D #( (X \ "- /\ B@#_ (4 _P"" /\ YP   -T
M  #&    N    *X   "H  0 I0 , *$ $@"A !D H  B )\ *0"; #  F  W
M )8 /0"3 $( D@!' )  2P"/ %  C0!5 (P 6@"* &$ B !H (< < "% 'L
M@P"( ($ E@!_ *< ?0"\ 'P XP!\ /T ? #_ '@ _P!V /\ U@   ,    "O
M    HP   )D   "3    CP ) (T #@"+ !0 B@ < (H (P"( "H A0 P (,
M-@"" #L @ !  '\ 10!^ $H ? !/ 'L 5 !Z %H > !A '8 :0!U ', <P"
M '$ C@!O )\ ;@"R &T SP!L /0 ; #_ &L _P!I /\ P    *L   ";
MCP   (<   "     ?  $ 'H # !X !$ >  7 '@ '@!W "0 =0 J ', , !Q
M #4 <  Z &X /P!M $0 ; !) &L 3@!J %0 : !; &< 8P!E &T 9 !X &(
MAP!@ )< 7P"J %X P@!> .D 7@#_ %X _P!= /\ K    )D   "*    ?P
M '<   !Q    ;0   &H " !I  X :  2 &< & !G !\ 9P E &4 *@!C "\
M8@ T &$ .0!@ #X 7P!# %X 2 != $X 6P!5 %H 70!8 &< 5P!R %4 @0!4
M )$ 4P"C %( N !1 -P 40#Y %( _P!2 /\ G0   (L   !\    <0   &D
M  !D    8    %X !0!<  L 6P / %L % !: !D 6@ ? %D )0!7 "H 5@ O
M %4 - !4 #@ 4P ] %( 0P!0 $D 3P!0 $X 6 !- &( 2P!M $H >@!) (L
M2 "= $< L0!' ,P 1@#P $< _P!' /\ D    'X   !P    9@   %X   !9
M    5@   %,  0!2  @ 4  - $\ $ !/ !4 3@ : $X ( !- "4 3  J $H
M+@!) #, 2  X $< /@!& $0 10!+ $0 4P!# %T 00!H $  =0 _ (4 /@"7
M #T JP ] ,, /0#F #T ^P ^ /\ AP   '4#  !H!@  70<  %4&  !0!@
M3 0  $H!  !)  0 1P * $8 #@!% !$ 10 6 $0 &P!# "  0@ E $$ *@!
M "\ /P T #X .@ ] $  .P!' #H 3P Y %D . !D #< <0 V ($ -0"3 #0
MI@ T +L - #= #0 ]0 U /\ ?@8  &T)  !@"P  5@P  $X,  !("P  1 H
M $((  ! !0$ /P$' #X "P ]  X /  2 #L %P [ !P .@ A #D )0 W "H
M-@ P #4 -0 T #P ,P!# #( 3  Q %4 , !@ "\ ;0 N 'T +0"/ "P H@ L
M +8 + #0 "P [@ L /P =PH  &<,  !:#@  4 X  $D.  !##@  /@T  #L,
M   Y"P  . D# #<%"  V @T -0$0 #0 $P S !@ ,@ = #$ (@ P "< +P L
M "X ,@ M #@ + !  "L 20 J %( *0!= "@ :P G 7H )@&, "4 GP E +(
M)0#* "4 Z  E /< <@T  &(.  !6$   3!$  $01   ^$0  .1   #8/   S
M#@  ,0T! # +!0 P" H +P8- "X%$0 L!!0 *P,9 "H#'@ I R, * 0I "<$
M+P F!34 )04] "0%1@ C!E  (@9< "$':0 @!WD 'P>+ !X'G0 >![  '0;&
M !T&XP =!?, ;0X  %X1  !2$@  2!,  $ 3   Z$P  -1(  #$1   N$
M+ \  "H. P J#0< *0L+ "@)#@ G"1$ )0@6 "0(&P C"2  (@DF "$)+  @
M"C, 'PH[ !X+1  ="T\ ' Q; !L,:0 :#'D & R+ !@,G@ 7#+  %@S% !8,
MX0 6"_  :1   %H2  !.%   114  #T5   W%0  ,10  "T3   J$@  *!$
M "80 0 D$ 0 (PX( ",-#  B# \ ( P3 !\,&  >#1T '0TC !P-*@ ;#3(
M&@XZ !@.1  7#E  %@]< !4/:@ 3$'L $A"- !$0H  1$+, $ _) ! /Y  1
M#_( 91(  %<4  !+%@  0A<  #H7   T%P  +Q8  "H5   G%   )!,  "(3
M   @$@, 'A$& !T0"0 <$ T &P\0 !D0%0 8$!L %Q A !80*  5$3  %!$Y
M !,10P 2$DX $1): ! 2:0 0$WD #A.,  X3G@ -$[$ #1+%  P2X0 -$O$
M8A0  %06  !)&   /QD  #<9   Q&0  +!@  "@7   D%@  (18  !\5   <
M% ( &A,$ !D2!@ 7$@L %1(. !02$@ 3$Q@ $A,? !$3)@ 1%"T $!0V  \5
M00 .%4P #A97  T690 ,%W4 "Q>'  H7F@ )%JT "!;!  @6W0 )%>X 7Q8
M %$8  !&&@  /1H  #4;   O&@  *AH  "49   B&   'Q@  !P7   9%@$
M%Q8# !46!  3%@D $18- ! 7$0 /%Q8 #A<<  X8(P -&"H #!DS  P9/  +
M&D< "AI3  D:80 '&W$ !AN#  4;EP $&JH  QJ_  ,9V@ $&>P 7!@  $X:
M  !#'   .AP  #,<   L'   )QP  ",;   @&@  '1D  !H9   7& $ %1@"
M !(9!  0&P< #AL,  T<$  ,'!, "QP9  H<'P )'2< "!TO  <>.0 &'D,
M!!Y0  ,?7@ "'VX  1^    ?E0  'JD  !Z]   =V   '>P 6!H  $L<  !!
M'@  .!X  # >   J'@  )1T  "$<   >'   &QL  !@;   6&P$ $QL" !$<
M!  .'@< #!\+  H@#@ ((!( !B$7  4A'0 $(20  B(L  $B-0  (D   "--
M   C6@  (VL  "-^   CDP  (J<  "*\   AUP  (>T 51T  $@?   ^(
M-2   "X@   H(   (Q\  " >   ='0  &AT  !8=   3'@  $1\"  X@!  -
M(@< "B0+  8E#0 $)1   B84   F&@  )B$  "<I   G,@  )ST  "=)   H
M5P  *&<  "=[   GD   )Z4  ":[   FU@  )>T 42   $4A   [(@  ,B(
M "PB   F(0  (B$  !X@   ;'P  &"   !0@   1(@  #R,   TE P *)@8
M!B@*  ,I#0  *P\  "P2   L%P  +!X  "PF   M+P  +3D  "U&   M5
M+60  "UW   LC0  +*0  "NZ   KU@  *NX 32(  $$D   X)   ,"0  "DD
M   D(P  (2(  !TB   9(@  %2,  !(D   /)@  #2@   HJ @ &+ 4  BX)
M   O"P  , X  #(0   S%0  ,QL  #,B   S*P  ,S8  #-"   S4   ,V
M #-S   RB@  ,J$  #&X   PU@  ,.\ 224  #XF   T)P  +2<  "@F   C
M)0  'R0  !LE   6)@  $B@  ! J   -+   "BX   8P 0 ",@0  #0'   U
M"@  -PP  #@.   Z$@  .A<  #H?   Z)P  .C(  #H^   Z3   .EP  #IO
M   YA@  .)X  #BV   WU   -N\ 1"D  #HI   Q*0  *RD  "8H   B)P
M'2@  !@I   3*P  $"X   TP   ),@  !34   $W    .0(  #L%   \"
M/@L  #\-  !!$   0Q0  $,;  !#(P  0RX  $,Y  !#1P  0E<  $)J  !!
M@0  0)H  #^R   ^SP  /N\ /RP  #8L   O+   *BL  "4J   ?*P  &2T
M !0O   0,@  #34   @X   $.@   #P    _    00   $,"  !%!0  1@@
M $@+  !*#@  3!$  $T6  !-'@  32@  $TT  !,0@  3%$  $MD  !+>P
M2I0  $FM  !(R@  1^P .S   #,O   M+P  *"T  "(O   ;,0  %30  ! W
M   -.@  "#T   )     0P   $8   !(    2@   $P   !. 0  3P0  %$'
M  !3"P  50X  %@2  !9&0  6"(  %@N  !7/   5TL  %9>  !6<P  58T
M %2G  !2P@  4N8 .#,  #$R   L,0  )3(  !TU   6.   $3P   Q    '
M1    $<   !*    30   %    !3    50   %<   !9    6@   %P#  !>
M!P  80L  &0.  !F$P  9QP  &8G  !F-   940  &17  !D:P  8H4  &&?
M  !@N0  7MP -3<  # U   H-P  (#H  !@]   10@  #$8   9*    3P
M %,   !6    60   %P   !?    80   &0   !E    9P   &D   !L 0
M;@8  '$+  !T#P  =Q4  '<@  !V+0  =CT  '5/  !T8P  <WL  '*5  !P
MKP  ;\D -3H  "L[   B/P  &D,  !)(   ,30  !5(   !7    7    &
M  !D    :    &L   !N    <0   ',   !U    =P   'H   !\    ?P
M (($  "&"@  B@\  (P7  "+)   BC,  (E%  "'6P  AG(  (6+  "#I0
M@KP +T   "5$   <20  $TX   U4   $6@   &$   !F    :P   &\   !T
M    >0   'T   "     @P   (4   "'    B@   (P   "/    D@   )8
M  "9 @  G@D  *(0  "B&@  H2D  * [  "?4   G6<  )J!  ":F0  F:\
M*4D  !].   55   #EL   5B    :0   '    !W    ?0   ((   "&
MBP   (\   "3    E0   )<   ":    G0   *    "C    I@   *H   "N
M    L@   +<*  "[$0  NA\  +DP  "W10  M5P  +1T  "QC@  KZ0 (E0
M !A;   08@  !VH   !S    >P   ((   ")    D    )4   ":    GP
M *,   "F    J    *L   "N    L    +,   "V    N@   +T   #"
MQP   ,P!  #3"P  U!4  -,F  #1.@  T%$  ,UH  #+@0  RI8 _    /8
M  #R    \0   /, !0#T  P \@ 3 /  ' #M "4 Z  N .( -@#> #X V0!$
M -0 2@#1 $\ S@!4 ,L 60#) %X Q@!C ,0 :0#! '  O@!X +P @0"Y (T
MM@": +, JP"Q ,  KP#F *X _P"E /\ F@#_ )0 _P"/ /\ ]    .P   #H
M    YP   -\   #9  D T@ 0 ,\ %P#/ "  S  H ,8 , #  #< O  ^ +D
M1 "W $D M0!. +, 4P"Q %< KP!= *T 8@"K &D J0!Q *< >@"E (4 H@"3
M *  H@"= +8 FP#4 )D ^0"6 /\ C0#_ (@ _P"$ /\ Z    -\   #9
MR0   +\   "X  0 M0 - +, $@"Q !H L  B *T *@"I #$ I@ X *0 /0"B
M $, H !( )X 3 "< %$ FP!6 )D 7 "7 &( E0!I ), <@"1 'T CP"+ (T
MF@"+ *P B0#% (@ [@"& /\ ?P#_ 'H _P!X /\ V0   ,T   "[    K@
M *4   "?    G  ) )D #P"9 !4 F0 = )@ ) "4 "L D0 Q (X -P", #P
MBP!! (D 1@"( $L A@!0 (4 50"# %L @@!B (  :P!^ '4 ? "" 'H D@!X
M *, =P"Y '8 X !U /\ <@#_ &X _P!L /\ QP   +4   "E    F0   (\
M  ")    A0 $ (0 # "" !$ @@ 7 (( '@"  "4 ?@ K 'P ,0!Z #8 >0 [
M '< 0 !V $0 =0!) ', 3P!R %4 < !< &\ 9 !M &X ; !Z &H B@!H )L
M9P"O &8 S !E /4 9 #_ &$ _P!@ /\ M    *    "0    A0   'T   !W
M    <P   '  " !O  X ;P 2 &\ & !O !\ ;0 E &L *@!I #  :  T &<
M.0!F #X 90!# &, 2 !B $X 80!5 %\ 7@!> &< 7 !S %L @@!9 ), 6 "F
M %< OP!7 .H 5P#_ %8 _P!4 /\ H0   (X   !_    =0   &P   !H
M9    &$ ! !@  L 7P / %\ $P!? !D 7P ? %T )0!< "H 6P O %D ,P!8
M #@ 5P ] %8 0P!5 $D 4P!0 %( 6 !1 &$ 4 !M $X >P!- (P 3 "? $L
MM0!* -P 2@#Z $H _P!* /\ D@   (    !R    9P   %\   !:    5P
M %4  0!3  < 4@ , %( $ !2 !0 4@ : %$ 'P!/ "0 3@ I $T +@!, #,
M2P X $H /0!) $, 2 !* $8 4@!% %P 1 !G $, =0!" (8 00"8 $  K@!
M ,L /P#R $  _P!  /\ A0   '0   !G    70   %4   !/    3    $H
M  !(  0 1P * $< #0!& !$ 1@ 5 $8 &@!% !\ 1  D $, *0!" "T 00 S
M #\ .  ^ #X /0!% #P 3@ [ %< .@!B #D ;P X (  -P"3 #8 IP V ,
M-@#H #8 _@ V /\ ?    &L   !> @  5 ,  $T#  !' P  0P$  $$    _
M  $ /@ ' #T "P ]  X /  1 #P %@ \ !H .@ ? #D )  X "D -P N #8
M,P U #H - !! #, 20 R %, ,0!> #  :P O 'L +@". "T H@ M +@ +0#=
M "T ^  N /\ <P$  &0%  !7!P  30@  $8(  ! "   .P<  #@%   W P
M-@ $ #4 "  T  P -  / #0 $@ S !8 ,@ ; #$ (  P "0 +P I "X +P M
M #8 +  ] "L 10 J $\ *0!: "@ 9P G '< )@") "8 G0 E +, )0#/ "4
M\  F /\ ;08  %X)  !2"P  2 P  $ ,   Z"P  -@L  #(*   P"   +@8"
M "X#!@ M  H +  - "P $  K !, *@ 7 "D '  H "  )P E "8 *P E #(
M)  Y ", 0@ B $L (@!7 "$ 9  @ ', 'P"% !\ F0 > *X '@#' !X Z0 ?
M /H : D  %D,  !-#0  0PX  #P.   V#@  ,0T  "T-   J#   * L  "<)
M!  F!@@ )@0+ "4##@ D 1  ) $4 "(!&  A 1T (0 B "  *  ? "X '@$V
M !T!/P < 4D &P%4 !H!80 : 7  &0&" !@ E@ 8 *H & #! !@ X0 8 /0
M8PP  %4.  !)#P  0!   #@0   R$   +0\  "D.   F#@  (PT  "(, P @
M"P8 ( D) !\'#  >!@X '@41 !P%%0 ;!1H &@4? !H%)0 9!2L & 4S !<&
M/  6!D8 %@92 !4'7P 4!VX $P>  !('E  2!J< $@6\ !($V0 2 ^\ 7PX
M %$/  !&$   /!$  #41   O$0  *A$  "80   B$   ( \  !T. @ <#04
M&@T' !H+"@ 9"@T & D0 !<)$@ 6"1< %0D< !0)(@ 4"BD $PHQ !(*.@ 2
M"T4 $0M1 ! ,7P /#&X #@R   X,E  -"Z< #0NZ  T*T@ -"NH 7 \  $X1
M  !#$@  .A,  #(3   L$P  )Q(  ",1   ?$0  '!   !H0 @ 8#P0 %@X'
M !4."0 4#0L $PP- !(,$  2#!0 $0P: !$-(  0#2@ #PTP  X..P -#D8
M#0Y1  P/7@ +#VT "@]_  D/DP )#Z8 " ZY  @.T  '#N@ 6!$  $L2  !
M$P  -Q0  # 4   I%   )10  "$3   =$@  &A(  !<1 @ 5$04 $Q ' !(0
M"0 1#PH $ X,  X.#@ .#Q( #1 8  T0'@ ,$"4 #! M  L1-@ *$4$ "1%-
M  @26@ '$FH !A)\  42D  $$J0  Q&X  ,1SP "$>@ 51(  $D4   ^%0
M-18  "T6   G%@  (A4  !X4   ;%   &!,  !42 P 3$@4 $A$' ! 1"0 /
M$0H #1$+  P2#@ +$A$ "A(5  D3&P )$R( "!,J  <4,P %%#X !!5*  ,5
M6  "%6<  15Z   5C@  %:,  !2W   4SP  $^D 4A0  $86   [%P  ,A<
M "L7   E%P  (18  !P6   9%0  %A0! !03!  2$P8 $1((  \2"  .$PD
M#!0*  H5#0 (%A  !A83  46&0 $%Q\  Q<G  (8,  !&#L  !E'   950
M&60  !EW   9C   &*(  !BW   7SP  %^H 3Q8  $,8   Y&0  ,!D  "D9
M   C&0  'Q@  !L7   8%@  %14" !,5!0 1% 8 $!0&  X5!P ,%@@ "A<*
M  <9#  $&@X  AL2  $;%@  &QT  !PD   <+0  '#@  !U$   =4@  '6(
M !UU   =B@  '*   !RV   ;T   &NL 3!@  $ :   V&P  +1L  "8;   A
M&@  '1D  !D9   7&   %!<# !(6!  0%P0 #A<$  P9!0 *&@< !QP)  ,=
M"P  'PT  " 0   @%   (1H  "$B   A*@  (34  ")!   B3P  (E\  ")R
M   AB   (9\  ""V   ?T0  '^T 2!H  #T<   S'0  *QT  "0=   @'
M'!L  !@:   6&0$ $QD! !$9 0 .&@$ #!P"  H= P ''P4  R$(   B"@
M) P  "8.   F$@  )A@  "<?   G)P  )S(  "<^   G2P  )UP  "=N   F
MA0  )IT  "6T   DT0  (^X 1!T  #D?   P'P  *!\  ",>   >'0  &QP
M !@;   4'   $1P   X=   -'P  "B$   8B 0 #) 0  "8&   H"   *@L
M "L-   M$   +14  "T<   M)   +BX  "XZ   N2   +5@  "UJ   M@0
M+)H  "NR   JT   *>\ 0"   #8A   M(0  )B$  "$@   ='P  &AX  !8>
M   2'P  #R$   TB   *)   !B8   (H    *P(  "T$   O!@  , D  #(,
M   T#@  -1(  #48   U(   -2H  #4V   U0P  -5,  #1F   T?   ,Y8
M #*O   QS0  ,.\ /",  #(D   J)   )",  " B   <(0  %R$  !,C   0
M)0  #2<   DI   %*P   2X    P    ,@   #0!   V!   . 8  #H)   \
M#0  /A   #X4   ^'   /B8  #XQ   ^/P  /4X  #UA   \=P  .Y$  #JK
M   YR0  ..T -R<  "\G   H)@  (R4  !\D   9)0  %"8  ! H   -*P
M"2X   4P    ,P   #4    X    .@   #P    ^ 0  0 ,  $('  !$"@
M1@T  $D1  !)%P  2"$  $@L  !'.@  1TD  $9;  !%<0  1(L  $.E  !"
MPP  0>@ -"H  "PJ   G*   (B<  !PH   6*@  $2T   TP   ),P   S8
M   Y    /    #X   !!    0P   $8   !(    2@   $P#  !.!@  4 H
M %,.  !4$P  5!P  %,G  !3-   4T,  %)5  !1:@  4(,  $^>  !-N0
M3.  ,"T  "LL   F*P  'RP  !@N   2,@  #34   @Y   "/0   $    !#
M    1@   $D   !,    3@   %$   !3    50   %<   !9 0  7 8  %\*
M  !B#@  8Q4  &,?  !B+   83P  &!.  !?8@  7GL  %R6  !;L   6<\
M+S   "HO   B,   &C,  !,W   ..P  "#\   %$    2    $P   !/
M4@   %4   !8    6P   %T   !@    8@   &0   !F    :0   &T%  !P
M"P  =!   '08  !S)0  <C0  ')%  !P60  ;W$  &V+  !KI@  :L  +C,
M "4U   =.   %#P   Y!   '1P   $P   !1    50   %D   !=    80
M &4   !H    :P   &T   !O    <@   '0   !W    >@   'X   ""!
MA@L  (H1  ")'   B"L  (8]  "$4@  @V<  (&!  !_FP  ?K( *3H  " ]
M   60@  #T@   A.    5    %H   !@    9    &D   !N    <@   '8
M  !Z    ?0   (    ""    A0   (@   "+    C@   )(   "6    FP,
M * ,  "B$P  H"$  )\S  "=1P  FEX  )AW  "7CP  E:< (T,  !E(   1
M3@  "54   !<    8P   &H   !Q    =@   'L   "     A@   (H   ".
M    D0   ),   "6    F0   )P   "@    HP   *<   "K    L    +8$
M  "\#0  NA<  +DH  "W/   M%(  +)J  "OA0  K9P '$X  !-4   +7
M 60   !L    =    'P   "#    B0   (\   "4    F@   )\   "B
MI    *<   "J    K@   +$   "T    N    +P   #!    QP   ,T   #4
M!0  V!   -4>  #3,0  T$@  ,U?  #+=@  R(X
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M[>[O\/'R\_3U]O?X^?K[_/W^_VUF=#$      P0A   !
M     0                    $    ! @,$!08'" @)"@L,#0X/$!$2$Q05
M%A<8&1H:&QP='A\@(2(C)"4F)R@I*BLL+2XO,#$Q,C,T-38W.#DZ.SP]/C]
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MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VO?
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MAJB'SH.HB<Z!IXS/@*>-SX"GC<^ IXW/@*>-SX"GC<^ IXW/@*>-SX"GC<^
MIXW/@*>-SX"GC<^ IXW/@*>-S]_$"0ORQ1 C\\060_3!'&G>PA6/P< CK*^Y
M3+:FM&6]HK)UP*"P@,.=KH3%EZV$QI.MA,>/K(3(C*N%R8FKALJ'JX;*A:J(
MRH.JB<N!JHO+@*J,RX"JC,N JHS+@*J,RX"JC,N JHS+@*J,RX"JC,N JHS+
M@*J,RX"JC,N JHS+@*J,R]K%" KKR0TB[L@20N_&%6C0T@J'L;XOKJ6X5+B?
MM6B\G;-VOYNQ?\&9L(3"E*^$PY"OA<2-KH7%BJZ&QHBMAL:'K8?&A:V(QX.M
MB<>!K8O'@*R+QX"LB\> K(O'@*R+QX"LB\> K(O'@*R+QX"LB\> K(O'@*R+
MQX"LB\> K(O'@*R+Q]7&" G9S H@Y<\-0-C5"U^]U@N(I<0TIIRW6KB9M6N[
ME[1WO9:S?[Z5LH7 D;&%P8ZQA<&+L(;"B;"'PHBPA\.&L(C#A:^)PX.OBL2"
MKXO$@:^+Q(&OB\2!KXO$@:^+Q(&OB\2!KXO$@:^+Q(&OB\2!KXO$@:^+Q(&O
MB\2!KXO$@:^+Q-+(" ?3SPH=U=0+/<+9"V.KWA"#F\XSF93$4Z:1OF>OD+IT
MM)"W?;F1M82\CK.&OHRRAK^*LH? B+*(P(:QB,&%L8G!A+&*P8*QB\&!L8S"
M@+&,PH"QC,* L8S"@+&,PH"QC,* L8S"@+&,PH"QC,* L8S"@+&,PH"QC,*
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MAJ.(U(.CC-2!HY'4@*29TX"FH=& IJ'1@*:AT8"FH=& IJ'1@*:AT8"FH=&
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MI+5EO*"R=+^>L7_"FZ^$PY:NA,61K83&C:V%QXJLALB'K(?)A:N(R8*KBLJ
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MV8Y^E]&-AZ+,C(VJQXJ1L<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O
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MM\*1CKG C)"\OXB3OKV$E\"\@)O"NWV@P[M[IL2Z>JW%M'JNQ*]ZK\*L>[#
MJ'RQOZA\L;^H?+&_J'RQOZA\L;^H?+&_J'RQOZA\L;^H?+&_J'RQO_^D& +_
MI2@0_Z,V)?^?13W_FE-5]YI7:>N;6WS?F6*.U)=KGLN5=JS%E("TPY6(M\&3
MC;K CH^]OHF2P+R%E<*[@9K$N7V@QKE[J,>T>JO'KWNMQ:M[KL.G?*_!I'VQ
MOZ1]L;^D?;&_I'VQOZ1]L;^D?;&_I'VQOZ1]L;^D?;&_I'VQO_^D& +_IB<0
M_Z,V)?^@1#W_FU)6]YQ5:>N<6'S?FUZ.U)EGGLJ7<ZS%EGRTPY>%M\&6B[N_
MD8V^O8N0P;N&E,2Y@9G'MWZ@R;9\J<JN>ZK(JGRLQJ9]K<2C?J_!H'ZQOZ!^
ML;^@?K&_H'ZQOZ!^L;^@?K&_H'ZQOZ!^L;^@?K&_H'ZQO_^E& +_IB8/_Z0U
M)?^@1#W_G%%6]YY3:>N>57O?GEJ-U)MDGLJ9;ZS%F'FTPYF"N,&9BKN^E(R_
MO(Z.P[F(DL>W@IC+M7ZAS:]\I\VI?:G*I7ZKQZ)_K<2??Z_"G8"QOYV L;^=
M@+&_G8"QOYV L;^=@+&_G8"QOYV L;^=@+&_G8"QO_^F& +_IR8/_Z0U)?^@
M0S[_G5!5]Y]1:.N@4WO@H%>-U)Y?GLJ;:ZS%FW6TPYM^N,";A[R]EXK NI&,
MQ;>*D,JTA)?/LH"CTJA_I<^C@*C+H("KQYV!K<6;@:_"F8*QOYF"L;^9@K&_
MF8*QOYF"L;^9@K&_F8*QOYF"L;^9@K&_F8*QO_^F& +_IR4/_Z4T)?^A0S[_
MGDY5^*%.:.RB4'K@HU*,U:%;G<N>9JS&G7&TPYYZN,">A+R\FXC"N96*Q[6-
MC<ZPAI;4J8*@UJ&"I-"=@JC+FH.JR)F#K<67A*_"EH2PP):$L,"6A+# EH2P
MP):$L,"6A+# EH2PP):$L,"6A+# EH2PP/^F& +_IR4/_Z4T)?^A0C[_GTQ5
M^*),9^RE37GAIDZ+U:16G,RA8:K&H6RSPZ)VM\"B@+V\H(?#MYJ(RK*3BM*L
MBY3;H(>?V)J&I-&7AJ?,E8:JR)2'K,63AZ[#DH>PP)*'L,"2A[# DH>PP)*'
ML,"2A[# DH>PP)*'L,"2A[# DH>PP/^G& +_J"0/_Z8S)?^B0C[_H$I4^:1*
M9NVG2GCBJ4N*UJA1FLVF6ZG'I66RQ*=PML"G>KR\IH/#MJ*'RZ^=B-:EEY7F
MEX^>VI.-H]*1BZ?-D(NJR9"*K,:/BJ[#CXFPP8^)L,&/B;#!CXFPP8^)L,&/
MB;#!CXFPP8^)L,&/B;#!CXFPP?^G& +_J"0/_Z8S)?^B03[_HDA4^:9'9NZJ
M1W?CK4>(V:U+F,^L5*;(K%ZOQJ]HL\*Q<[F^LGW LJJ'RZ6BAM64G(O>CYJ=
MVHV5HM.,DJ;.BY"IRHN.J\>+C:W$C(ROP8R,K\&,C*_!C(ROP8R,K\&,C*_!
MC(ROP8R,K\&,C*_!C(ROP?^H& +_J20/_Z<R)?^C03[_I$93^JE$9.^M0W7D
ML4*%V[1$E-*U2J'+MU.KRKY?K;VW;KBRL'S"J:J&RYREA-*-H(?8AJ"7V8>>
MHM.'F*7/AY6HRX>3JLB(D:W%B)"OPHB0K\*(D*_"B)"OPHB0K\*(D*_"B)"O
MPHB0K\*(D*_"B)"OPO^H& +_J2,/_Z<R)?^C0#[_ID-2^ZM!8_"Q/W/GMSV"
MWKX[C];$/YK,Q4JFO+Q=LK&U;[NJL'W#HZN$R9:G@\Z*I(;3@:.0U8&EG]*"
MH:7/@IRHS(.9JLF$EJS&A92NPX64KL.%E*[#A92NPX64KL.%E*[#A92NPX64
MKL.%E*[#A92NP_^I& +_JB,/_Z@Q)?^D/S[_J$!1_*\\8?.V.7#JOS=]X\HU
MA]31-Y6^PDNIL+E@M:BT<+VCL'["G:V$QY*JA,N(IX;.@*:-T'VGF-!]J*3.
M?J2HRW^?JLF FZO&@9BMQ(&8K<2!F*W$@9BMQ(&8K<2!F*W$@9BMQ(&8K<2!
MF*W$@9BMQ/^J%P+_JB(/_Z@P)?^E/C[_JSM/_[0W7?:],VKKRC%UW-HI@L3.
M.)FRP4^KI[ACMZ&T<[R>L7_!F*^$Q(^LA,B'JH?*@*F,S'RID\QZJIS+>:NF
MRGJGJLA\HJO'?9ZMQ'V>K<1]GJW$?9ZMQ'V>K<1]GJW$?9ZMQ'V>K<1]GJW$
M?9ZMQ/^J%@+_JR$._ZDN)?^G/#[_L#9,_+HP6>_(+&+>V2=MR]PFAK;,/)NH
MP52KG[EFMINU=+R9LG^_E;"$PHVOA<2&K8?&@:R+R'VLD,A[K)C(>:V?QW>M
MI\=WJJS&>:6MQ'FEK<1YI:W$>:6MQ'FEK<1YI:W$>:6MQ'FEK<1YI:W$>:6M
MQ/^K%0+_K" ._ZLM)/^K-CO_MB](\\0H4>#6)E;,Y")QN]HHB*K,09N?PU>I
MF;QILI:W=KF4M("]D;*%P(NQAL&&L(C#@:^+Q'ZNC\5[KI3%>J^:Q'BOH,1U
MKZ?$=*VNPW2MKL-TK:[#=*VNPW2MKL-TK:[#=*VNPW2MKL-TK:[#=*VNP_^L
M% +_K1\._ZPK)/^P+S?ZOR5!Y-$@1<[D'5N]Z2)TK=HLB9_.19F7QEJDD\!J
MK9&[=K.0N'^WC;:$NXFTAKV%LHB_@K&+P7^QCL%\L9+">K&6P7FQF\%XLJ'
M=+&GP72QI\%TL:?!=+&GP72QI\%TL:?!=+&GP72QI\%TL:?!=+&GP?^N$@'_
MKQT-_ZXH)/^X)#'JRQHUT.(70[_P'5ZOZ"5UH-LQAY;12)20RER>C<5JI8O!
M=JJ)OGVOA;R LH*Z@[1^N8:V?+B)MWFWC+AWMX^Y=K:3NG6VE[ITMIVZ<[>D
MN7.WI+ESMZ2Y<[>DN7.WI+ESMZ2Y<[>DN7.WI+ESMZ2Y<[>DN?^P$ '_L1H-
M_[$E(_/$%R?4WQ KP>\72+#W(&"AZBMSE=\Y@HW73(V(T5V5ALQJFX3)=*"
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MJ:G,<:VJS'"RJ\MPMJO+;[RKR'# J\1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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MD*'+7YV8PVVHD;UYL8NX@[B#M(B]?;&0P7FQFL%UL:7!<J^OPG6HK\%WH[#
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MNK*0A+JRD(2ZLI"$NK*0A+JRD(2ZLO^/#P'_DB &_Y,T%/^:/R+_H3\N_Z=
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MOZMFL+^L::J_K&REOZMMHL"J;:+ JFVBP*IMHL"J;:+ JFVBP*IMHL"J;:+
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MK$<[]J]-1.VQ5$WELUM5W+!E8<ZH;''#GW2 N)9\C:Z/AIBEB)&AG8.=IY>
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M_Y\A!?^N( ;XO1@&X]$3!-#A'@G%ZBX9NNDZ*;#G0SFDY$I(F.)05HS@5V*
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M4\3>@5/$WH%3Q-Z!4\3>@5/$WH%3Q-Z!4\3>@?^2# #_H T V[<& ,K#!P#
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M@5RFWX%<IM^!7*;?@5RFWX%<IM^!7*;?@?^ #P'_C@X!_Z(- -NU" #.P0@
MQM ) +[I$@*TZ24*JN@S%Z#F/B66Y4<RB^-./X#A54EVX%U3;=YF6V7=;V%>
MW7IG6-R&:U/<E6]0W:9Q3=Z[<DW?X7%.T>=T4,;F=U*^Y'A3N.1Y5;+C>E6R
MXWI5LN-Z5;+C>E6RXWI5LN-Z5;+C>O^##@'_E@L W:L$ ,VX!@#"Q 8 NM0)
M +'O% .G[B4-GNXS&I3M/2>*[$8S@.M./G;K54=LZEM.9.IC55WJ;5I8ZG=>
M4^J#8D[JD65*ZZ%G1^RS:4;MT&E(YNAI2]GK:DS/[&U.Q^MO3\#J<$_ ZG!/
MP.IP3\#J<$_ ZG!/P.IP3\#J</^)"P#IH $ T+$$ ,&\!0"WR08 KMH) *3U
M%P6;]2<0DO4T'(CV/B=_]D<R=O9..VSV5$)D]EI(7?9B35?V:U%2]G553?>
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M, ]1_S<32_\^%T;_11E!_TP;/?]2'3G_6!\V_U\A-/]F(C'_;B0O_W<E+?^
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M>6V,Y7AMC.5X;8SE>&V,Y7AMC.5X;8SE>/]N$P'_>Q$!_XT0 /^=$ #ZK!$
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M#Q3_H! 3_ZT1$_^Z$1/_PQ(3_\,2$__#$A/_PQ(3_\,2$__#$I>^  "&S
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M.O]"L#S_0K@]_T'!/O] RS__0-Q _S_I0/\_]$#_/OU!_T#_0/U"_T#V1?]
M\$;_0>E(_T'I2/]!Z4C_0>E(_T'I2/]!Z4C_0?]1'P+_3"D#_T<T!?]--@;_
M43L(_U5&$/]64!C_55P?_U)H)O]0="S_38 Q_TJ,-?](ESC_1J [_T6H//]$
ML#[_0[@__T/!0?]"S$'_0=Y"_T'K0_] ]4/_0/U#_T/_0_A&_T+P2/]#ZDG_
M1.-*_T7C2O]%XTK_1>-*_T7C2O]%XTK_1?]2'P+_32D#_THR!/]0,P;_53D(
M_UE#$/]:31C_65@@_U9D)_]3<2W_4'TS_TV)-_]+E#K_29X]_T>F/_]&KD'_
M1;="_T3!1/]$S$7_0]]%_T+M1O]"]T;_0_U&^4;_1O!)_T;I2_]'XDS_2-M-
M_TC;3?](VTW_2-M-_TC;3?](VTW_2/]3'@+_3B@#_TXO!/]4, ;_6C8(_UY
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M:WA\\&EX?/!I>'SP:7A\\&EX?/!I>'SP:?]@%P'_;A(!_WX0 /^,$0#_F1$
M\:03 ..N%@#6MAP!R[0P",&P/Q>WJTLEK:94,Z2A74"<G65*E)AL4XR5=%N&
MD7UB?XZ':'F,DFUTBIYQ<(BM=&V(P71MB>1S;X?J<7"$[&]R@^UM<X'N:W2
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M9F./\69CC_%F8X_Q9O]K$ '_?@D \9 $ -:> P#,J@8 Q+0& +Z^!0"XR!
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M*2W_ZBHL__\J+/__*B_Y_RHO^?\J+_G_*B_Y_RHO^?\J+_G_*KFF  "JK@
MG+D  ([%  "!T0  ==X  &WZ"0!E_Q$!7O\: E?_(P-2_RP%3/\T!TC_/ I#
M_T0,/_],#CS_4Q X_UL2-?]C%#+_;!8O_W<7+/^$&2G_DQHG_Z(<)?^T'23_
MS!XC_^T>(O_]'R+__Q\B__\?(O__'R+__Q\B__\?(O__'ZRK  "=M@  C\(
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M ?]T%0'_?1H!_X0A ?>)*@/MC30'Y(T]#=R+2!;1A50CR7]>+L)Z:#B\=7%
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M6X-O^UF#;_Q8@V_\6(-O_%B#;_Q8@V_\6/]6& '_9!$!_W(. /]^$ #_B!$
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M6G!\^UIP?/M:<'S[6O]?$0'_;PH _WX( .., P#6EP4 SZ ' ,JH" #$KA,
MNZTG [*K-PVIIT09H*1.)IB@5S&1G%\ZBIEG0X.6;TI]DW=0=Y& 5G*/BEIM
MC99>:(NC866+M&-CB\QC8XON866)]U]GAOA>:83Y7&J"^EIK@?M::X'[6FN!
M^UIK@?M::X'[6O]B$ #_<@< ^((# -N/ @#/F@4 R:,& ,.L!@"]LA  M;(D
M JRP-0NCK4(7FZI,(Y*F52Z*HUTX@Z!E0'V=;$=VFW1-<)E]4VN6B%AFE91<
M8I2A7U^3LF!=D\E@79/M7UZ0^%YAC/E<8XKZ6V2'^UIEAOM998;[666&^UEE
MAOM998;[6?]F#0#_=P, XX<  -.3 0#*G@0 PJ<$ +NO! "UM@T KK<A J6V
M,@F=LS\5E+!*((RM4RN$JELT?:AC/':E:D-PHW)*:J%[3V6@AE1@GI%86YV?
M6UB=L%U6G<==5IWK7%>:^EM:E?I:7)'[65Z._%A?C?Q77XW\5U^-_%=?C?Q7
M7XW\5_]J"@#_?   W(P  ,V8  ##HP, NJH" +.S 0"LO H IKT= 9Z\+P:6
MNCP1C;A''(6U4"=]LUDP=K%@.&^O:#]IK7!%8ZMY2EZJA$]:J9!25:B>55*G
MKU=1J,974*?J5U"E_%=3G_U759K]5E>6_E98E?Y56)7^55B5_E58E?Y56)7^
M5?]O! #F@@  TI$  ,:=  "[I@$ LJX  *JW 0"BP@4 G,08 )7#*@2-PCD-
MA<!$&'V^3B%UO%8J;KI>,FBY9CABMVX^7;9X0UBU@D=4M(]+4+2=3DVSKE!+
MM,502[/J4$JQ_U%,J_]23J7_4E"A_U)1GO]149[_45&>_U%1GO]149[_4?]V
M  #=B0  RI<  +ZB  "SJ@  J;,  *"\ @"8Q@8 D<P2 (O,)0*$RS0)?,E
M$G7(2AMMQU,C9\5<*F'$9#!<PVTV5\)V.E/"@3]/P8Y"2\&=14C!KD9'P<5&
M1\'J1D2^_TE%N?]*1[/_2TFM_TQ*J_],2JO_3$JK_TQ*J_],2JO_3.E_  #1
MD   PIX  +6G  "JKP  H+@  );! @",RP< A-4- (#5'@%YU2X%<M0\#&S3
M1Q1ETE ;7]%9(5K18B=5T&LL4=!U,$W/@31)SXXW1L^=.430KCM"T,8[0]#J
M.D#-_3X^R_] 0,/_0D&]_T-"N?]$0KG_1$*Y_T1"N?]$0KG_1-V(  #'F
MN*,  *NK  "@M   E;X  (O( P" T0< >.$- '3A'0%NX2L#:. W"&'@0@Y<
MX$T45^!6&5/@7QU/X&DB2^!S)4?@?BA$X(LK0N":+3_AJR\^XL$O/N+E+SS?
M^C$YWO\T.=G_-CK0_S@[S/\Y.\S_.3O,_SD[S/\Y.\S_.<V2  "\H   K:@
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M$Q[__Q,>__\3'O__$Q[__Q,>__\3'O__$Z:I  "8LP  BK\  'O*  !NU0
M8-\  %3G  !._P0 2?\. $/_%  __QT!.O\E C;_+ (R_S,#+_\Z RO_000H
M_T@$)?]/!2+_5P4@_V &'?]L!QK_>0<8_XH(%O^;"!7_K0D4_\,)$__C"1/_
M^ D3__\*$___"A/__PH3__\*$___"IJQ  "+O0  ?,@  &W4  !?X   4>8
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M0/<M[4#_+^L__S'D0?\RVT/_,]%$_S/+1O\SRT;_,\M&_S/+1O\SRT;_,_]
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M29-@_TB18/]'D6#_1Y%@_T>18/]'D6#_1_].& '_6A$!_V0. /]O$ #_=A,
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M2WMN_TM[;O]+>V[_2_]7$0#_8PH _W ' /!\!0#<A04 U(P( -"3"0#*EA0
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M24Z@]4E.G_])4)G_25*6_TA4DO]'5)+_1U22_T=4DO]'5)+_1_]N  #>?P
MRHT  +Z8  "SH   JJ<  *&N  "7M@  D;H0 (RZ(P&%N3(&?K@^#G>V21=Q
MM5(>:[-:)66R8BM@L6HP6[!S-5>O?3E3KHD]3ZV60$RMI4)*K;E#2:[80DBK
M]4-'JO]$2:7_1$N@_T1-G/]$39S_1$V<_T1-G/]$39S_1.IU  #2A@  PY,
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M*331_RLVRO\M-LK_+3;*_RTVRO\M-LK_+<60  "VG0  J*4  )RM  "/M@
M@[X  '?'  !LSP( 8M8' %KD#@!8Y!P 5.0I 5#D-0-,Y3\%2.5)!T7E4PI"
MYEP-/^9F#SSF<1(ZYWX4-^>,%C7GG!<SZ*X9,NG&&3+HZADQY?X9+^3_'"[D
M_QXMXO\@+>+_("WB_R MXO\@+>+_(+J:  "JHP  G:L  )"T  "#O0  =\8
M &O/  !?U@  5-X$ %'P$ !-\!L 2O F 4;Q, )"\CH#/O)#!#OS2P4X\U0'
M-O1="#/T: DP]70++O6!#"SVD0XJ]J(/*/>W$"?XUA$G]O01)O/_$2;Q_Q$E
M\?\3)?'_$R7Q_Q,E\?\3)?'_$ZVA  "@J0  DK,  (2\  !VQ@  :<\  %W8
M  !1WP  2>X$ $;\#@!"_1< /OXA #O^*@$W_S,"-/\Z C#_0@,M_TH#*_]3
M!"C_7 4E_V8%(O]S!B#_@P<?_Y0('?^F"!S_O @;_^()&O_Y"1K__PD9__\)
M&?__"1G__PD9__\)&?__":*G  "3L0  A;L  ';&  !IT   6]H  $[@  !#
MY0  /OL! #K_#  V_Q, ,O\; "__(P K_RH!*/\Q 23_-P$A_S\"'_]& AS_
M3@(9_U@#%O]C Q/_< ,2_X$$$?^3!!#_IP0/_[T%#O_@!0[_]@4.__\%#O__
M!0[__P4.__\%#O__!96O  "&N@  =\4  &C0  !:VP  3.$  $#G   W\P
M,O\  "[_!P J_PX )O\3 "/_&@ ?_R  &_\F !C_*P$5_S(!$O\X 1#_0 $.
M_T@!#/]2 0G_70(&_VL"!/]] @+_D (!_Z," /^V @#_S0, _^P# /_L P#_
M[ , _^P# /_L XBY  !XQ   :=   %O=  !+XP  /ND  #+N   K_P  )O\
M "'_   =_P@ &O\- !;_$0 3_Q8 $/\:  [_'P +_R0 "?\J  ;_,  "_S<!
M /]  0#_2@$ _U8! /]D 0#_=0$ _X@! /^: 0#_J@$ _[L! /^[ 0#_NP$
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M,ZY-_S.J3O\RJ4[_,JE._S*I3O\RJ4[_,O]#&@'_3!, _U00 /]<$@#_81<
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M.XA?_SN(7_\[B%__._].$0#_6 H _V,' /IL!@#G<P8 W7@( -I["P#1?A<
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M1UZ![T9?@?]$8'__0F%]_T%B>_\_8WK_/V-Z_S]C>O\_8WK_/_]>  #I;0
MUGD  ,B$  "^C   MI,  *Z7  "FFP0 H)T7 )J=*0*3G#<(C)I#$(:831B
MEE4?>I1=)G6292QPD&PQ;(YU-F>-?CICBXD^7XJ505R)HT1:B;1%6(G+15B(
M[418B/]#68;_05N#_T!=@?\^78#_/EV _SY=@/\^78#_/O]B  #D<0  SWX
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M-T:@_S=(G/\W29K_-TF:_S=)FO\W29K_-^)T  #*@P  O(\  +"8  "EG@
MFZ0  )"K  "%L0  >K@$ ':Y% !RN24!;;DS!&BX/PACN$D.7K=2$UJV6AA6
MMF(<4K5K($ZT=21+M( G2+..*D6SG2Q"LZXM0;/%+D&SZ2U L/XO/Z__,3ZM
M_S) J/\R0:;_,D&F_S)!IO\R0:;_,M5\  #"B@  M98  *B=  "=HP  DJH
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M%BC:_Q8HVO\6*-K_%K.8  "EH   F:<  (NP  !^N   <<   &7(  !9S@
M3M,  $3;!  _Z0T />D7 #OJ(P YZBX -NLX 33K0@$Q[$L"+^U5 RWM7P,J
M[FL$*.YX!2;OB 8E[YH'(_"N!R+QR <B\.T'(>S_!R'K_P@@Z_\*'^K_"Q_J
M_PL?ZO\+'^K_"ZB?  ";I@  C:\  '^X  !QP0  9,H  %C0  !,U@  0=T
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M 82W  !TP0  9<P  %;8  !'WP  .>4  "WJ   C[@  '/T  !C_   5_P
M$?\$  __"P -_PX "?\1  ;_%0 #_QH  /\@  #_)@  _RX  /\W  #_00
M_TT  /]<  #_;0  _X(  /^6  #_J   _[H  /_#  #_PP  _\,  /_# /\D
M+P'_)2\!_R@O ?\G,0'_)#8"_R ^ O\:20/_%U8#_Q5D _\3<@3_$G\$_Q**
M!/\2E 3_$IT%_Q*D!?\2K ;_$K,&_Q*Z!O\2PP;_$\X'_Q/?!_\3ZP?_$_8'
M_Q/_!_\3_P;_$_\&_Q3_!_\4_PC_$_\(_Q7_"?\5_PG_%?\)_Q7_"?\E+@'_
M*2T!_RLL ?\K+@'_*3,"_R0[ O\?1@/_'5,#_QMA!/\9;@3_%WL$_Q>'!?\7
MD07_%YH&_Q>A!O\7J0?_%[ '_Q>W"/\7P C_&,H(_QC;"/\8Z C_&/0(_QC]
M"/\9_PC_&?\(_QG_"?\9_PK_&/\+_QK_"_\:_PO_&O\+_QK_"_\F+0'_+"D!
M_RXH ?\O*@'_+2\"_RDW O\G0P/_)% #_R)=!/\@:@7_'G<%_QZ#!O\>C0?_
M'I8'_QZ>"/\>I0G_'JP)_QZS"?\>O K_'L8*_Q[3"O\>Y0K_'O$*_Q_\"OX?
M_PK]'_\+_!__#/P>_PW\'_\.]R'_#O<A_P[W(?\.]R'_#O\J*@'_+R8!_S(D
M ?\S)0'_,BH!_S$T O\O/P/_+4P#_RI9!/\H9@7_)G(&_R5^!_\EB0C_)9()
M_R6:"O\EH0O_):@+_R2P#/\DN S_)<$,_R7.#?\EX0W\)>\-^2;Z#/8F_PWU
M)O\/]"7_$/0E_Q'R)O\2[2?_$NTG_Q+M)_\2[2?_$O\N)@'_-"(!_S<@ ?\Y
M(0'_."4!_SDO O\X.P+_-4<#_S-4!?\Q80;_+VT'_RYY"?\MA K_+8T,_RR6
M#?\LG0W_+*4._2RL#_PLM _[++T/^2S)$/8LW1#S+>P/[RWX#^TM_Q+K+/\4
MZBS_%>DL_Q;E+?\6X"[_%N N_Q;@+O\6X"[_%O\R(P'_.!T!_SP; ?\^&P'_
M0"(!_T$K ?] -@+_/D(#_SQ/!?\Y7 ;_.&@(_39S"_LU?@SX-8@.]S21#_4T
MF1#S-* 1\C.H$O SL!+O,[D3[C/%$^LTUQ/G-.H2XS3W%.$T_Q?>,_\9W#/_
M&MLS_QK4-/\:SC7_&LXU_QK.-?\:SC7_&O\V'P'_/!D!_T$6 /]$%@#_1QX!
M_TDG ?](,@+_1CT#_T1)!?I"5@?V0&()\C]N#.\]>0_M/(,0ZCR,$N@[E!/G
M.YP4Y3ND%>,ZK17B.K86X#O"%M\[TA;:.^@7U#KV&M Z_QS-.O\>RSK_'LHZ
M_Q_$._\?P#S_'L \_Q[ //\>P#S_'O\Y&P'_0!4 _T41 /]*$P#_3AD _U B
M ?]0+ ']3C<"]DM#!/!)4 ?K2%T*YT9I#>-%=!#@1'X3W4.'%=M"D!?809@8
MU4"@&=- J1O10+(<ST"]'<U S!W*0>0>QD#T(,) _R*_0/\CO4#_([M _R.V
M0?\CLT+_(K-"_R*S0O\BLT+_(O\]%P#_1!$ _TH. /]0$ #_5!4 _U8= /U6
M)@'S53$!ZU,] ^522P;?4%@*VDYC#M1,;A/02G@6S4F!&<M(BAO(1Y(=QD>:
M'\1&HR'"1JPBP$6W([Y%Q22\1=PDN$;P);5&_R>R1O\GL$;_)ZY&_R>J1_\F
MITC_)J=(_R:G2/\FITC_)O] % #_2 X _TX+ /]5#@#_61$ _UP6 /1='P#J
M7"H!XELW MI:1@725U,+S%5>$,A3:!7$47(9P5!['+Y/A!^\38PBN4V5)+=,
MG2:U2Z<GLTNQ*;%*ORJO2M$JK$OK*ZE+_"RF2_\LI4S_*Z-,_RJ?3?\JG4W_
M*9U-_RF=3?\IG4W_*?]#$0#_2PP _U,( /]:"P#_7@T ^6 0 .MA%@#A8B$
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M/&UKZ3MM;/XY;6S_-VYL_S5N:_\T;FK_,FYJ_S)N:O\R;FK_,O]3  #T7P
MWFH  ,US  ##>@  NWX  +6!  "N@PD J(4: **%*P*;A#H'E8)%#I!_3Q6*
M?5@;AGM?((%Y9R5]=V\J>G9W+G9T@#)S<XLU;W*6.&QQHSII<+(\:'#&/&=P
MYSMG<?PY:''_-VAP_S5I;_\T:6[_,VEN_S-I;O\S:6[_,_]6  #K8@  V&X
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M-5:!_S18?_\S67W_,EE]_S)9??\R67W_,N]@  #;;@  QWH  +N#  "RBP
MJ)   )^3  "4E@  C9D. (F:'@"$FBX"?IDZ!WF710UTEDX3;Y56&&J37AUF
MDF4A8I%M)EZ/=BI;CH$M5XV-,%2,FC-1C*HU3XR]-4^,WC5/B_<T3XK_,U")
M_S)1AO\Q4H3_,5*$_S%2A/\Q4H3_,>IE  #2<P  PG\  +:(  "LD   HI0
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M)CND_R8[I/\F.Z3_)LQZ  "[B   KI(  **9  "7G@  C*0  ("J  !UKP
M:;0  %ZY!@!;NA0 6;LD %:[,0%3NST#4+M'!4V[4 =*NED*1[IB#42Z;!!!
MNG<3/KF$%3RYDQ<YN:,8.+FW&3>ZUADWN/0:-;;_'#2T_QXSL_\?,[+_(#.R
M_R SLO\@,[+_(,&#  "TD0  II@  )N>  "/I0  @JL  ':Q  !KM@  7[P
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M!:.=  "6I   B*P  'JU  !LO0  7\0  %/*  !'S@  /-,  #+:   JWP
M)>X) "/P$0 A\1D '_$B !WR*P ;\S0 &?0^ !?T2  5]5( $_9? !+V;@$1
M]X !$/B4 0_YJ@$.^<8!#OGM 0WV_P$-]/\!#?/_ 0WS_P$-\_\!#?/_ 9FC
M  "+K   ?+4  &V^  !?Q@  4LT  $72   YV   +]X  ";B   ?Z@  '/L&
M !G_#@ 7_Q, %/\: !+_(0 0_R@ #O\P  W_.0 +_T, "?].  ;_7  $_VP
M O^   '_E@  _ZT  /_*  #_\   __\  /__  #__P  __\  /__ (VK  !]
MM0  ;K\  &#(  !2T   0]<  #?=   KX@  (N8  !GJ   5^0  $O\  !#_
M"  ._PX #/\1  G_%@ &_QP  _\B  #_*@  _S,  /\]  #_20  _U<  /]I
M  #_?@  _Y4  /^L  #_QP  _^@  /_Z  #_^@  __H  /_Z ("U  !POP
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M+GU9YBU\6OHL>UK_*GM;_RA[6_\G>UK_)GI:_R5Z6O\E>EK_)?])  #[4@
MXUP  -)C  #':   P&L  +IK @"U:PT KFT= *AN+@&C;3P%G6M("IEJ40^4
M:%H4D&9B&(UE:AR*8W(@AV)Z(X1A@R:!8(PI?E^7*WM>HRUY7K$O=UW$+W5>
MXB]U7ODM=5__*W5?_REU7_\H=5[_)G5>_R9U7O\F=5[_)O]+  #P50  WE\
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M+61L_RMD:_\I96K_*&5J_RAE:O\H96K_*/U3  #C7P  SFD  ,%Q  "W=P
MKWL  *=]  ">?0  F'X1 ). (@".@#$"B7\^!H1]2 Q_?%$1>WI9%G=Y8!IS
M=V@>;W9P(6QU>"5I=((H9G..*V-RFBY@<:@O7G&Z,%UQU#!=<?(N7G'_+%YP
M_RM?</\I8&__*&!N_RA@;O\H8&[_*/%5  #>8@  RFT  +UU  "S>P  JX
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M)DZ!_R9.@?\F3H'_)N%C  #)<   NWL  +"$  "FB@  FXX  )&1  "$DP
M>I4" '67$@!RF"( ;Y@P FJ7.P1FET4(8I9.#%^55@];E%T36)-E%U63;AI1
MDG@=3I&$($N0D2-)D*$D1Y"R)D60RB9%C^TE18W_)46,_R5&B_\D1HK_)$:*
M_R1&BO\D1HK_)-AI  ##=@  M8$  *N*  "?CP  E9,  (J6  !^F@  <)T
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M%KN!  "NC@  H94  )::  ")H   ?:8  '&K  !EKP  6;0  $ZW  !#O 4
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M !/BL0 2X\\ $N#T !+>_P$1W?\!$=O_ A';_P(1V_\"$=O_ IZ:  "2H0
MA*D  ':Q  !HN   6[\  $[$  !"R   -\P  "W0   DU0  '-L  !7?!0 4
MZ0X $NH4 !'K'0 0ZR8 #NPP  [M.@ -[D8 "^Y3  KO8@ )\'0 "/&)  ?R
MH  %\KH !/'D  +Q_0 "[_\  ^W_  /M_P #[?\  ^W_ )6A  "&J0  >+(
M &FZ  !;P@  3<@  $#,   TT0  *M8  "';   9X   $N0   _P 0 -^0H
M"_H/  G[%0 '^QP !/PD  '\+   _#<  /Q"  #\4   _&$  /UU  #\C
M_*0  /S!  #\ZP  _/\  /W_  #]_P  _?\  /W_ (FI  !YL@  :KL  %S$
M  !.S   /]$  #+7   GW0  '>$  !7E   .Z   "O$   C]   %_P,  ?\)
M  #_#@  _Q(  /\7  #_'P  _R<  /\Q  #_/@  _TT  /]?  #_=0  _XT
M /^F  #_P@  _^<  /_\  #__P  __\  /__ 'RS  !LO   7<8  $[/   _
MU@  ,=T  "7B   :Y@  $>H   SN   %\@   /\   #_    _P   /\   #_
M!0  _PH  /\.  #_$@  _Q@  /\A  #_*P  _SD  /]*  #_70  _W,  /^,
M  #_I   _[D  /_4  #_W@  _]X  /_> /\8+ #_&2D _QDH /\5*P#_$#
M_PLX ?\#1 '_ %$!_P!> ?\ ; '_ '@!_P"" ?\ C '_ )0!_P"< /\ H@#_
M *@ _P"O /\ M@#_ +X _P#( /\ UP#_ .< _P#S /\ _0#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\;*0#_'28 _QPE /\9)P#_$RP _PXT
M /\+0 '_"$X!_P5; ?\#: '_ G0!_P)_ ?\"B '_ I$!_P*8 ?\"GP'_ :4
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M ^D3_P/I$_\#Z1/_ _\F'0#_*!@ _R@6 /\F%@#_)AT _R8H /\C- #_($
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M&Y-&YAN11_D;CT?_&HY'_QF.1_\8C4?_&(U'_Q>-1_\7C4?_%_\^ @#_0P
MZTL  -U1  #15   RE0! ,92!0#!41$ N5,B +-5,P&N5$$"JE1,!:935@BB
M45\,GU!G#YU/;Q&:3G<4F$Y_%I9-B!B33)$9D4R;&X]+IAV-2[,>BTO%'HE+
MXAZ'3/<>ADS_'85,_QR%3?\:A4S_&85,_QF%3/\9A4S_&?]   #\1P  Y5
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M(F]:_R!P6O\><%K_'7!:_QQP6O\<<%K_'/](  #G4@  TUL  ,5B  "[9@
MLV@  *QH  "E9@4 GV<4 )II)0"5:30"D&A !(QG2@B(9E,,A&5;$(%D8A-^
M8VH6>V)R&7AA>AQV8(0><U^.(7!>FB-N7J@E;%VX)6I>SB9I7NXD:5[_(FI>
M_R!J7O\?:E[_'FI>_QUJ7O\=:E[_'?E*  #C50  SU\  ,%E  "W:@  KVP
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M'EMJ_QY;:O\>6VK_'NM3  #38   PFD  +9Q  "L=@  HWD  )EY  "-=P
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M$0!QB"  ;H@N 6J(.0)GAT,%8X=,"&"&4PM=A5L.6H1C$5>$:Q14@W4748*
M&DZ!C1Q+@9L>28&L'TB P2!'@.,?1W_Z'DA^_QY(??\=27S_'$E\_QQ)?/\<
M27S_'-9A  #";@  M'@  *J   "?A0  E(<  (B'  ![B0  <(P  &N.#0!H
MCQH 9H\I &*0-0%?CS\#7(](!5F.4 A6CE@+4XU@#E",:!!-C'(32HM]%DB*
MBAA%BID:0XJJ&T**OQM!BN$;08CY&T&&_QM!A?\;0H7_&D*$_QI"A/\:0H3_
M&LUG  "\=   KWX  *6&  ":B@  CHP  (*-  !UD   9Y0  &&5" !>EQ0
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M""VLN DLK-D(+*KU"BNH_PLJIO\,*J7_#2JE_PTJI?\-*J7_#;6   "HBP
MG)$  )&6  "%G   >*   &NE  !?J   4ZP  $BO   ]L@  -K4+ #2U%0 S
MMB$ ,K8L #&W-P PMT$ +[A+ "ZX50 LN& !*KAM 2FY>P(GN8T");F? R2Y
MM ,CN=(#([?T!"*U_P4AM/\&(;/_!R&R_P<ALO\'(;+_!ZV*  "@D0  E9<
M (B=  ![HP  ;J@  &&M  !5L0  2K0  #^W   TNP  *[X# "3"#  BPA0
M(L,? "'#*@ @Q#0 '\0_ ![%2@ =QE8 ',9C !O'<P :QX4 &<>9 !C(K@ 7
MR,L %\;Q 1?$_P$6P_\"%L'_ Q;!_P,6P?\#%L'_ Z.1  "8F   BYX  'VE
M  !PJP  8K$  %:V  !*N0  /KT  #3    JQ   (L@  !G,!  3T H $=(1
M !#2&@ 0TR4 #],P  [4/  .U$@ #=56  W590 ,UG@ #-:-  O8I  *V+X
M"=GF  K6_@ +U/\ "]+_  O2_P$+TO\!"]+_ 9J8  ".GP  @*8  '*M  !D
MM   5[H  $F_   ]P@  ,L8  "C)   ?S0  %]$  !'6   ,VP4 "-X+  ;?
M$0 %WQH !. D  +A+@ !XCH  .-'  #D5@  Y&<  .5[  #FD@  YJH  .?(
M  #G\   Z/\  .C_  #H_P  Z/\  .C_ )&?  ""IP  =*\  &6W  !7O@
M2<,  #S'   PRP  )<\  !S4   4V0  #MT   GA   "Y0   .D&  #I#0
MZ1$  .H8  #K(0  [2L  .\W  #Q10  \E8  /-H  #S?@  ])<  /6P  #V
MT   ]_,  /?_  #W_P  ]_\  /?_ (6G  !VL   9K@  %C!  !*R   .\P
M "[1   CU@  &=P  !'@   ,XP  !.<   #J    ]0   /0   #U!0  ]0L
M /8/  #V%   ^!T  /HG  #\-   _T,  /]5  #_:0  _X$  /^:  #_L@
M_\\  /_M  #_^0  __D  /_Y 'BP  !HN@  6<,  $O+   [T0  +=@  "'=
M   6X@  #N8   CJ    [0   /    #X    _P   /\   #_    _P   /\&
M  #_#   _Q   /\8  #_(@  _S   /]   #_4P  _VD  /^!  #_F0  _Z\
M /_#  #_U0  _]4  /_5 /\3* #_$R4 _Q$E /\-)P#_!BT _P U /\ 00#_
M $\ _P!< /\ :0#_ '0 _P!^ /\ B #_ )  _P"7 /\ G0#_ *0 _P"J /\
ML #_ +< _P#  /\ S #_ -\ _P#L /\ ^ #_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\6)0#_%B( _Q0A /\0(P#_"B@ _P P /\ /0#_ $L
M_P!8 /\ 9 #_ '  _P!Z /\ A #_ (P _P"3 /\ F@#_ *  _P"F /\ K0#_
M +0 _P"\ /X R #] -D ^P#I /H ]@#Y /\ ^ #_ /@ _P#X /\ ^ #_ /D
M_P#Y /\ ^0#_ /\:(@#_&AX _Q@= /\3'@#_#B( _PHL /\'.0#_ T8 _P!3
M /\ 8 #_ &L _P!V /\ ?P#_ (@ _P"/ /\ E@#_ )T _P"C /X J0#\ +
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M O\E$P#_)1  _R0- /\C#@#_(Q0 _R(> /\?*0#_'#4 ^1E# /083P#O%UL
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M!;$MZ@:N+OL'JR[_"*DN_PBH+O\(J"W_"*@M_PBH+?\(J"W_"/\O" #_,0
M_S4  /8W  #J-@( YS,( .0O#P#9+AL SS$L ,DS/ #$-$D P#55 ;PU7P*Z
M-6@"MS5P [4T> 2S-( %L32(!K TD :N-)D'K#2B"*LTK FI-+D)IS3*"J4U
MY0JA-?@+GS7_#)TU_PR=-?\+G#7_"YPU_PN<-?\+G#7_"_\S @#_-0  ]CH
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M%7]'_Q1_1_\2?T?_$7]'_Q%_1_\1?T?_$?\[  #N0P  W$P  ,Q1  #!5
MN50  +11  "N30L J$\9 *-1*0">4C<!FE)# I=13@24458&D5!>"8Y/9@N,
M3FT-B4YU#X=-?A&%38<3@DR1%8!,G!9^2ZD7?$NX&'M+S1AY3.L8>$S^%W=,
M_Q5W3/\4=TS_$W=,_Q)W3/\2=TS_$O\^  #H1P  U5   ,96  "\6   M%D
M *U6  "G4P< H505 )Q6)0"85S0!E%=  I!72@2-5E,&BE5;"8=48PN$5&H.
M@E-R$(!2>A)]4H,4>U&.%GA0F1AV4*89=%"U&G-0R1IQ4.@:<%'\&'!1_Q=P
M4?\5<%'_%'%0_Q-Q4/\3<5#_$_5   #D2P  SU0  ,%:  "W70  KUX  *=;
M  "A6 , FUD2 )9;(@"27#$!CEP] HI<1P2'6U &@UI8"8%98 Q^66<.>UAO
M$'E7=Q-V5H 5=%:+%W)5EAEO5:,:;52R&VQ4QAMJ5>8;:E7[&6I5_Q=J5?\6
M:E7_%6M5_Q1K5?\4:U7_%/)#  #?3P  RU@  +U=  "S80  JV(  *)@  ";
M7   E5X0 )!@'P",82X B&$Z H1@102!8$X&?E]6"7M>70MX764.=EQL$'-<
M=!-P6WT5;EJ(%VM:E!EI6:$;9UFP'&59PQQD6>,<9%GZ&F19_QAD6?\795G_
M%659_Q1E6?\495G_%.]&  #:4@  QEL  +IA  "P90  IF8  )UC  "580
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M%=U5  #%80  MVH  *QQ  "B=0  E'0  (ET  !\<P  =G4  '%W$ !O>!T
M;'DK &EY-P%F>4 #8WE)!6!X40===U@)6W=@#%AV: Y5=7$14G5\$U!TB!9-
M=)<72W.F&$ESN1E(<]4927+S&$EQ_Q=*<?\62G#_%4MP_Q1+</\42W#_%-1:
M  # 9@  LV\  *AV  "=>0  CW@  (1X  !W>0  ;WP  &I]#0!G?AD 9'\F
M &* ,@%?@#T"7(!& UI_3@57?U4'5'Y="5)]90Q/?6\.3'QY$4I\AA-'>Y05
M17ND%D1[MQ9#>](60WKR%D-Y_Q5#>/\41'?_%$1V_Q-$=O\31';_$\U?  "[
M:P  KG0  *1\  "7?@  BGT  ']^  !R?P  9H,  &&$" !>AA, 7(<A %J'
M+@!8AS@!58=" E.'2@-0AU(%3H9:!TN&8@E)A6P+1H5W#4.$@P]!A)(1/X2B
M$CV$M1,\A,\3/(+P$CR!_Q(]@/\2/7__$CU^_Q$]?O\1/7[_$<5F  "U<0
MJGL  )^"  "2@@  A8(  'F#  !MA@  7XH  %B- 0!4C@\ 4H\; %"/)P!/
MD#, 39 ] 4N010))D$X#1I!6!$2/7P5"CV@'/X]S"3V.@ LZCH\,.(Z@#3>.
MLPXVCLP.-HWO#C6+_PXUB?\/-8C_#S:'_P\VA_\/-H?_#[YM  "P>0  I8(
M )F'  ",B   ?X@  '**  !FC0  6I$  %"5  !)EPD 1Y@3 $68( !$F2L
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M 1NO_@(:K?\"&JS_ QJK_P,:J_\#&JO_ ZB(  ";CP  D90  (2:  !VGP
M:*(  %NE  !/J0  1*T  #FP   OLP  )K8  !ZY!0 8NPX %[L6 !>\(  6
MO"H %;TU !2]0  3ODL $KY8 !*^9P 1OW@ $+^, !# H@ .P+H #L#A  ^]
M^P /O/\ $+K_ 1"Z_P$0NO\!$+K_ 9^/  "4E0  AYL  'FA  !KIP  7JP
M %*Q  !%M   .K8  "^Y   EO   ';\  !7#   /Q@4 "\H-  G*%  (RAT
M!\HG  ?*,@ &RSX !<M+  3,6@ #S&H  LQ^  ',E   S*L  ,W(  #,[0
MS/\  ,O_  '*_P !RO\  <K_ )>6  "*G   ?*,  &ZJ  !@L   4K8  $6Y
M   YO   +K\  "/#   ;Q@  $\H   W-   (T0   =0)  #4#@  U14  -8>
M  #8)P  V3$  -L^  #<2P  W5L  -YN  #>A   WYL  -^T  #>V0  W_<
M -__  #?_P  W_\  -__ (V=  !_I0  <*P  &&S  !3N@  1;\  #C"   L
MQ@  (<D  !C-   0T0  "]4   3:    W@   . !  #A"0  X@X  .03  #E
M&P  YR0  .DO  #K/   [4L  .Y=  #N<0  [XD  /"B  #PO   \.,  ._Y
M  #P_P  \/\  /#_ (&E  !RK0  8[4  %2]  !&Q   -\@  "K,   ?T
M%=4   [:   'W@   .(   #F    Z0   .H   #L    [@4  .\,  #Q$
M\Q<  /4@  #X*P  ^SD  /U*  #^7@  _W0  /^-  #_I@  _\   /_A  #_
M]0  __4  /_U '2N  !EMP  5L   $?(   XS0  *M(  !W8   3W0  #.(
M  /F    Z0   .P   #P    \P   /0   #V    ^    /H   #]!P  _PT
M /\2  #_&P  _R@  /\W  #_2@  _UX  /]V  #_CP  _Z8  /^Z  #_T0
M_]$  /_1 /\/) #_#B( _PLA /\#) #_ "D _P R /\ /@#_ $P _P!9 /\
M90#_ '  _P!Z /\ A #_ (P _P"2 /\ F0#_ )\ _P"E /\ JP#_ +( _P"Z
M /\ Q0#_ -, _P#G /\ ] #_ /\ _@#_ /\ _P#^ /\ _@#_ /X _P#^ /\
M_@#_ /\1(0#_$!X _PT= /\''P#_ ", _P M /\ .@#_ $@ _P!5 /\ 80#_
M &P _P!V /\ ?P#_ (< _P". /\ E0#_ )L _P"A /\ IP#^ *X _0"V /P
MP #[ ,T ^0#B /@ \ #W /P ]@#_ /4 _P#U /\ ]0#_ /4 _P#U /\ ]0#_
M /\5'0#_$QH _Q 9 /\+&0#_ !T _P I /\ -@#_ $, _P!0 /\ 7 #_ &<
M_P!Q /\ >@#^ (, _ "* /H D0#Y )< ^ "= /< HP#U *H ] "R /( NP#Q
M ,@ [P#< .X [ #M /H ZP#_ .H _P#J /\ Z@#_ .H _P#J /\ Z@#_ /\8
M&0#_%A4 _Q,3 /\.$P#_"QH _P<D /\", #_ #X _P!+ /\ 5P#_ &( _ !L
M /@ =0#U 'X \@"% /$ C #O ), [@"9 .P H #K *8 Z0"N .< MP#F ,,
MY #4 .( Z0#A /< WP#_ -T _P#= /\ W0#_ -T _P#= /\ W0#_ /\;$P#_
M&A  _Q8. /\2#@#_$A4 _P\? /\,*P#_"3@ _P9% /L#40#W EP \@)F .X"
M< #J G@ YP*  .8#AP#D XX X@.5 .$#G #?!*, W02K -L$M #8!<  U@70
M -,&YP#0"/@ S@K_ ,P+_P#+#/\ RPS_ ,L+_P#+"_\ RPO_ /\?$ #_'@L
M_QH' /\9"P#_&!$ _Q89 /\2) #Z$#  \PX^ .X-2@#I#%8 Y0QA .(,:@#>
M#7, VPU[ -D-@P#6#8H U V1 -(-F0#0#J  SPZI ,T.LP#+#K\ R@_0 ,81
MZ0#"$OD OQ/_ +T3_P&\$_\!O!/_ ;P3_P&[$_\!NQ/_ ?\B# #_(00 _R
M /\A!0#_'PP _QP1 /88' #L%2@ Y1,V -\20P#9$T\ TQ1: - 59 #-%FT
MRQ9U ,D7?0#'%X4 Q1B, ,08E #"&9P P!FE +X9KP"]&KL NQK+ +@;Y0&T
M'/8!LAW_ K =_P*O'?\"KAW_ JX=_P*N'?\"KAW_ O\F!@#_)0  _R8  /LG
M  #Q)0, \"$+ .@<$@#>&1T U!LM ,T=/ #('TD Q2!5 ,$A7P"_(F@ O")P
M +HC> "Y(W\!MR.' ;4CCP&T))<!LB2@ ;$DJ@*O)+8"K27& JLEWP*H)O,#
MI2;_ Z,F_P.B)O\$H2;_ Z$F_P.A)O\#H2;_ _\I  #_*   ]BT  .<P  #?
M+P  V2L$ -8B"@#.(Q8 QB8G , H-@"[*D0 N"M/ +4L60"R+&(!L"QJ :XM
M<@&L+7H"JBV! JDMB@*G+9(#I2V; Z0MI02B+;$$H"W !)\MV 2<+N\%F2[_
M!I<O_P:6+_\&E2[_!94N_P65+O\%E2[_!?\L  #_+@  ZC4  -TY  #1.0
MRC8  ,<O!@#!+1$ NC A +0R,0"P-#X K#5* *DU5 &G-5T!I#5E J(U;0*@
M-70#GS5\!)TUA 2;-8T%FC27!I@TH0:6-*T'E#6["),UT B0->P(CC;^"(PV
M_PB+-O\(BS;_!XHU_P>*-?\'BC7_!_\O  #R-   XCP  -)!  #'0@  P$
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M#'%'_PMQ1O\+<4;_"_,Y  #@1   S$P  +Y1  "T4P  JE(  *).  "=2@$
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M#>-(  #+4P  NUL  +!A  "D8@  EV$  (Y?  "%7   ?UX' 'M?$P!X82$
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M$DMGLA))9\D226?K$DEF_Q!*9O\/2F7_#DME_PU+9/\-2V3_#=%4  "^7@
ML6<  *9M  "7;   BFL  ']K  !S:P  ;6T  &AN# !E<!< 8G$D &!Q, !>
M<3H!7'%# EEQ2P-7<5,$57!:!E)P8@=0<&L)3F]U"TMO@@U);H\/1VZ?$$5N
ML!%$;L<10VWJ$$1L_P]$:_\.16O_#45J_PU%:O\-16K_#<M8  "Z8P  K6P
M *%Q  "2<   A6\  'IO  !N<   97,  &!U!P!==A( 6W<? %EX*P!7>#8
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M!S"%^P@P@_\(,(+_"#"!_P@P@?\(,('_"+=K  "J=@  H'\  )!^  ""?@
M=G\  &J   !>@P  4X<  $J+  !!C@( /9 . #N0&  ZD2, .9$M #B2-P W
MDD  -I)) #234@ SDUP!,9-G 2^3= (MDH,#*Y*4 RJ2IP,HDKT$*)+A R>0
M^@0GCO\%)XW_!2>,_P4GC/\%)XS_!;%T  "E?@  F84  (J$  !]A   ;X4
M &.(  !8BP  38\  $.3   ZEP  ,IH' "Z;$  MFQH +)PD "N<+@ JG3@
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M  BS_P )LO\ ";+_ )J-  "0DP  A)@  '2<  !EH   5Z0  $NH  ! K
M-;   "JS   AM0  &+@  !&[   ,O@( !L +  + $0 !P1D  ,$B  #"*P
MPC8  ,-"  ##4   Q%\  ,1Q  #$AP  Q)T  ,2U  #$V@  Q/8  ,/_  ##
M_P  P_\  ,/_ ).4  "'F@  >*   &JF  !<K   3[$  $&U   UMP  *;H
M !^]   6P   $,,   K&   #R@   ,P%  #,#   S1$  ,X8  #.(0  T"H
M -$U  #30P  U%(  -1C  #5>   U8\  -6G  #6P@  UND  -;]  #6_P
MUO\  -;_ (J;  ![H@  ;*D  %ZP  !0M@  0KH  #2]   HP0  '<0  !3'
M   -RP  !LX   #2    UP   -D   #:!0  W L  -T0  #?%0  X1T  .,G
M  #E,P  YT(  .A4  #H9P  Z7X  .F7  #JKP  ZLX  .OO  #K_@  Z_\
M .O_ 'VC  !NJP  7[(  %&Z  !"P   -,,  "?'   ;RP  $L\   O3   "
MV    -T   #A    Y    .4   #G    Z0   .L'  #M#0  [Q$  /$9  #T
M)   ]S$  /E!  #Z50  ^FH  /N$  #[G0  _+8  /S2  #][0  _?0  /WT
M '&L  !AM0  4KT  $3$   TR0  )LT  !K2   0V   "-T   #A    Y0
M .@   #L    [P   /$   #S    ]0   /<   #Y 0  ^P@  /X.  #_%0
M_R$  /\O  #_00  _U8  /]M  #_AP  _Z   /^V  #_R@  _]0  /_4 /\+
M( #_!QX _P = /\ ( #_ "4 _P N /\ .P#_ $D _P!6 /\ 8@#_ &T _P!V
M /\ ?P#_ (< _P". /\ E #_ )H _P"@ /\ I@#_ *T _P"U /\ O@#_ ,L
M_P#A /\ \ #^ /T _0#_ /T _P#] /\ _0#_ /P _P#Y /\ ^0#_ /\-'0#_
M"QH _P09 /\ &@#_ !\ _P J /\ -P#_ $4 _P!1 /\ 7@#_ &@ _P!R /\
M>@#_ (( _P") /\ D #_ )8 _P"< /X H@#\ *D ^P"P /D N0#X ,8 ]@#9
M /4 ZP#T /D \P#_ /( _P#S /\ \P#_ /, _P#S /\ \P#_ /\0&0#_#A4
M_P@4 /\ % #_ !D _P E /\ ,@#_ $  _P!, /\ 60#_ &, _@!M /P =0#Z
M 'T ^0"$ /< BP#V )$ ] "7 /, G@#R *0 \ "L .X M #M ,  ZP#/ .D
MY@#H /4 Y@#_ .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ /\2% #_$!  _PP/
M /\#$ #_ !4 _P @ /\ + #_ #H _P!' /H 4P#W %X ] !G /$ < #O '@
M[0!_ .L A@#J (P Z "3 .< F0#E *  XP"G .$ L #? +H W0#) -L X #8
M /  UP#^ -4 _P#4 /\ TP#_ -, _P#3 /\ TP#_ /\5$ #_$@P _PX) /\+
M# #_"1( _P,: /\ )@#] #, ] !  .\ 30#K %@ Z !A .4 :@#B '( X !Z
M -X @ #< (< V@". -@ E0#4 )P T@"C -  K #. +8 S #$ ,H V0#( .T
MQP#[ ,4 _P#$ ?\ PP'_ ,0!_P#$ ?\ Q '_ /\8"P#_%04 _Q   /\0!@#_
M#PT _PP4 /P''P#Q RL YP Y .( 1@#> 5$ V@); -4"9 #2 VP SP-T ,T$
M>P#+!(( R@2) ,@%D #&!9@ Q 6@ ,(&J0#!!K0 OP;! +T(U0"[">P N O]
M +8,_P"U#?\ M W_ +0-_P"T#?\ M W_ /\;!0#_&   _Q<  /\6  #[$P8
M^A . .X,%@#C"2( V@DP -,*/@#."TH R@Q5 ,<-7@#%#6< P@YO ,$.=@"_
M#GX O0^% +P/C0"Z$)4 N!"= +<0IP"U$;( LQ'  +(1U0"N$^X JQ3^ *D5
M_P"G%?\ IQ7_ *84_P&F%/\!IA3_ ?\?  #_'   ^AX  .L>  #C'   WQ4%
M -X.#0#3#A@ RQ$H ,43-P# %$0 O!9/ +D760"W%V$ M!AI +,9<0"Q&7@
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M X,O_P.#+_\#@R__ _LI  #K,0  V3@  ,D\  "_/   MCD  + R  "L+0L
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M!N@[  #01@  OTT  +-1  "E40  FDX  ))+  "-1P  AT@+ (-*%@!_2R0
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M#%53L U44\4-4U/F#%-3_ M34_\)5%+_"%12_PA44O\'5%+_!]I&  ##4
MM5@  *A;  "96@  C5@  (17  ![5   =E8! '%7#P!N61L ;%HH &E:,P!G
M6ST!95M% 6-;30)A6E4#7UI<!%U:9 5;66P&6%EV"%99@@E46(\+4EB>#%!8
MK@U/6,,-3ECD#$Y8^PM/5_\)3U?_"$]6_PA05O\'4%;_!]-*  # 5   LEP
M *->  "570  B5P  '];  !V60  <%H  &M<#0!H71@ 9EXD &1?, !B7SH
M8%]# 5Y?2P)<7U("6E]: UA?80557FH&4UYT!U%=?PE/78T*35V<"TM=K Q*
M7<$,25WC#$E<^@I)6_\)2EO_"$I:_PA*6O\'2EK_!\Y.  "\6   KF   )]A
M  "18   A5\  'M?  !P70  :E\  &5A"@!B8A0 8&,A %YD+0!<9#< 6F1
M 5AD2 %69% "5&17 U)D7P109&<%3F-Q!DQC?0A)8HL)1V*:"D9BJ@M$8K\+
M1&+A"T1A^0I$8/\)1&#_"$5?_P=%7_\'15__!\A2  "X7   JV0  )MD  ",
M8P  @&,  '9C  !J8@  8V0  %]F!@!;9Q$ 66@= %=I*0!6:C, 5&H\ %)J
M10%0:DP!3FI4 DQJ7 -*:F4$2&EO!49I>@=$:8@(0FB8"4!HJ0H_:+T*/FC>
M"3YG]PD^9O\(/V7_!S]E_P<_9/\'/V3_!\-7  "S80  IVD  )9H  "'9P
M>V<  '%G  !E:   7&H  %AL 0!4;@X 4F\8 %!O) !.<"X 37 X $MQ00!*
M<4D!2'%1 49Q60)$<&(#0G!L!$!P> 4^<(8&/&^5!SIOI@@X;[L(.&_;!SAN
M]@<X;?\'.&S_!CEK_P8Y:O\&.6K_!KU<  "O9@  HFT  )%L  "":P  =VL
M &QL  !A;@  5W   %!S  !,=0H 2783 $=W'P!&=RD 17@S $-X/ !">$0
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M B"%_P(AA?\"(87_ JMR  "A?   CWL  (!Z  !S>@  9GP  %M_  !0@@
M1H8  #R*   TC0  +)$  ":3#  DE!, (Y0< "*5)@ AE2\ ()4X !^60@ >
MEDP '998 !R69  :EW0 &9>& !B7F0 7EZX %9?) !:5[@ 6D_\!%I+_ 1:1
M_P$6D/\!%I#_ :5[  "9@P  B8$  'N   !L@@  7X0  %2(  !)BP  /Y
M #64   MEP  )9H  !V> 0 6H P %*$2 !2A&P 3H24 $J$N !&B.  1HD,
M$*)/  ^B7  .HVL #:-]  VCD@ ,HZ< "J+   NBY@ ,H/X #9__  V>_P -
MG?\ #9W_ )Z$  "2B0  @X@  '.(  !EBP  6(X  $R2  !!EP  -YL  "Z>
M   DH@  '*4  !6H   /JP0 "JX,  >M$@ &K1L !:TD  2N+@ "KCD  :Y%
M  "N4@  KF$  *YS  "NAP  KIT  *ZT  "NU0  K?0  *W_  "L_P  J_\
M *O_ ):+  ",D   >Y   &N2  !=E@  4)H  $2?   YHP  +Z<  "6K   <
MK@  %+$   ZT   )MP   ;@)  "X#@  N10  +D<  "Z)0  NB\  +LZ  "\
M1P  O%8  +QG  "\>P  O)$  +RI  "\Q   O.L  +O^  "[_P  N_\  +O_
M )"2  "#F   <YL  &.?  !5HP  1Z@  #NM   PL0  );0  !NW   2N@
M#+T   6_    PP   ,0"  #%"@  Q0X  ,84  #'&P  R"0  ,HN  #,.@
MS4D  ,U9  #-;   SH,  ,Z;  #-M0  SMH  ,[V  #-_P  S?\  ,W_ (:9
M  !WH   ::8  %JL  !,L@  /K8  #"Y   DO   &;\  !'"   *Q0   LD
M  #,    T    -$   #2 0  TP@  -4-  #7$0  VA@  -PA  #?+   X3H
M .)*  #C70  Y'(  .2+  #EI0  Y<   .7F  #E^   Y?\  .7_ 'JA  !K
MJ0  7*\  $VV   _O   ,+\  "/#   7QP  #\H   ?.    T0   -8   #<
M    WP   .    #B    Y    .8#  #H"0  Z0X  .P5  #N'@  \2L  /0Z
M  #U30  ]F$  /=Y  #XDP  ^*T  /G&  #YY   ^?,  /GS &VJ  !>L@
M3[H  $#!   QQ0  (LD  !;.   -T@  !-@   #=    X0   .0   #H
MZP   .T   #O    \0   /,   #V    ^ ,  /H+  #]$0  _QL  /\I  #_
M.P  _T\  /]F  #_?P  _YD  /^O  #_PP  _]8  /_6 /\$' #_ !D _P 9
M /\ ' #_ "( _P K /\ . #_ $8 _P!3 /\ 7@#_ &D _P!R /\ >@#_ ((
M_P") /\ CP#_ )4 _P"; /\ H0#_ *@ _P"O /\ N0#_ ,4 _P#9 /X [ #]
M /L ^P#_ /L _P#[ /\ ^@#_ /0 _P#P /\ \ #_ /\'& #_ 14 _P 4 /\
M%@#_ !L _P F /\ - #_ $( _P!. /\ 6@#_ &0 _P!M /\ =0#_ 'T _P"$
M /\ B@#] )  _ "6 /H G0#Y *, ^ "K /< M #U +\ ] #. /, Y@#Q /8
M\ #_ .\ _P#O /\ [@#_ .X _P#J /\ Z@#_ /\+% #_!A$ _P 0 /\ $ #_
M !8 _P B /\ +@#_ #P _P!) /\ 5 #^ %\ ^P!H /D < #W '@ ]0!_ /,
MA0#R (L \ "2 .\ F #M )\ [ "F .H K@#H +D YP#' .4 W@#C /  X@#^
M .  _P#@ /\ X0#_ .$ _P#A /\ X0#_ /\-$ #_"0T _P$, /\ # #_ !(
M_P < /\ * #\ #8 ^0!# /8 3@#R %D [P!B .P :P#J '( Z !Y .8 @ #D
M (8 X@", .$ DP#? )H W0"A -L J@#8 +0 U0#  -( TP#0 .H S@#Z ,T
M_P#- /\ S0#_ ,P _P#, /\ S #_ /\0# #_# < _P," /\ " #_  X _P 6
M /8 (@#P "\ [  \ .D 2 #E %, X0!< -X 90#; &P UP!S -0 >@#2 (
MT "' ,X C@#, )4 R@"= ,@ I0#& *\ Q "[ ,( RP#  .4 O@#U +T _P"\
M /\ O #_ +P _P"\ /\ O #_ /\1!0#_#@  _PH  /\( 0#_! H ^  0 .D
M&@#C "@ W@ U -D 00#3 $P SP!6 ,L 7P#) &8 Q@!N ,0 = #" 'L P0""
M +\ B0"] )  O "8 +H H0"X *L M@"W +0 QP"R .  L0'R *\"_P"N _\
MK03_ *T$_P"M!/\ K03_ /\4  #_$   _P\  /(-  #J"@  Z0,) -T $@#4
M !\ S0$M ,@".@#$ T4 P -0 +T$60"[!6$ N05H +<&;P"U!G8 M =] +('
MA "Q"(P KPB5 *T)G@"K":@ J@JU *@*Q0"F"]\ I WT *(._P"@#O\ GP[_
M )\._P"?#O\ GP[_ /\7  #_$P  [Q@  .09  #;%@  TA " ,\)"P#("!8
MP0HD +P,,@"W#3X M Y) +$.4P"O$%L K1!C *L0:@"I$7$ J!%X *81@ "E
M$8@ HQ*1 *$2FP"@$Z8 GA.S )P3PP";%-X EQ;T )46_P"4%_\ DQ?_ )(7
M_P"2%O\ DA;_ /\:  #T'0  Y2,  -4E  #*)   PAT  +X6! "[$!  M!,=
M *\5*P"K%C@ IQA# *4930"B&58 H!I= )X;90"=&VP FQQS )H<>P"8'(,
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M O J  #<-0  QSL  +H_  "L/   HC@  )PS  "8+P  E2X0 ) P' ",,BD
MB3,U (8T/P"$-4D @C51 ( U6 !^-5\!?35F 7LV;@%Y-78">#6  G8UBP-T
M-9<#<C:D W VM 1O-L@$;3;G!&PV_ -K-O\#:S;_ FHV_P)J-?\":C7_ NHP
M  #3.@  PD$  +-#  "E00  FSX  )4Z  "0-@  C#4- (@W& "$."4 @3HQ
M '\[/ !\.T4 >CQ- '@\50%W/%P!=3QC 7,\:@)Q/',"<#Q\ VX[AP-L.Y0$
M:CNA!&@[L05G/,4%93SE!60\^@1D//\#8SO_ V,[_P-C._\"8SO_ N4U  #-
M/P  O48  *Y'  "?10  E4,  (Y   ")/   A#P* ( ]% !]/B( >C\N 'A
M. !U04( <T%* ')!40%P05D!;D%@ FQ!9P)J07 #:$%Y V=!A 1E09$%8T&?
M!6%!K@9@0<(&7D'B!EY!^05=0?\$74#_ UU _P-=0/\#74#_ ]\Y  #(0P
MN4H  *E+  ";20  D$<  (A$  "#00  ?D$& 'I"$0!V0QX =$4J '%%-0!O
M1C\ ;49' &M&3P%J1E8!:$9= F9&90)D1FT#8D9V!&!&@@1>1HX%7$6<!EM%
MK 991K\'6$;?!EA&]P571?\$5T7_!%=$_P-81/\#6$3_ ]H]  #$1P  M4X
M *1.  "63   BTL  (-)  !]10  >$8" '1'$ !P2!L ;DDG &M*,@!J2SP
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M!TA2\P9(4O\%2%'_!$E1_P1)4/\#25#_ \I(  "Y4@  JE<  )A6  "*50
M?U0  '93  !L40  9U,  &)4" !?5A( 75<> %M7*0!96#, 6%@\ %991 !5
M64P!4UE3 5%96P)/6&0"35AM TM8> 1)6(8%1U>5!D57I09$5[@&0UC2!D-7
M\@9#5O\%0U7_!$15_P1$5/\#1%3_ \9,  "U5@  I5H  )19  "&6   >U@
M '%7  !F5@  85@  %U9! !96A  5UL; %5<)@!373  4ETY %%>00!/7DD
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M S)E_P,R9/\#,F3_ [=;  "I9   EF0  (9C  !X8P  ;6,  &1D  !990
M4&@  $EK  !#;00 0&X. #YO&  ];R( /' K #IP-  Y<3T .'%% #=Q3@ V
M<5< -'%A 3)Q;0$Q<7H!+W&* BUQG (K<:\"*G'( BIPZP(J;_\"*FW_ BIL
M_P(K;/\"*VS_ K%A  "D:0  D&@  (!G  !T9P  :6<  %]H  !5:P  2VX
M $-Q   \=   -W8* #1W$@ S>!P ,G@E #%Y+@ P>3< +WD_ "YY2  L>E(
M*WI< "IZ:  H>G8 )GJ' 25ZF0$C>JP!(GK% 2)YZ0$B=_\!(G;_ 2)U_P(B
M=/\"(W3_ JQH  "=;@  BFT  'ML  !O;   96P  %IN  !0<0  174  #UX
M   V?   +G\" "F!#0 G@A0 )H(> "6")P D@B\ (X,X "*#0@ A@TL ((16
M !^$8@ >A'$ '(2" !N$E0 :A*D &(3! !B#Y@ 8@?T &8#_ 1E__P$9?O\!
M&7[_ :9P  "5<P  A'(  '9Q  !K<0  7G,  %1V  !)>0  /WT  #>!   O
MA   )X@  ""+!0 ;C0X &HT5 !F-'@ 8CB< %XXP !:..0 5CD, %(]/ !./
M6P 2CVH $8][ !"/CP /CZ0 #H^[  V/X  .C?H #XO_ !"*_P 0B?\ $(G_
M *%Z  ".>0  ?G<  ')W  !D>   6'L  $U^  !"@@  .88  "^*   GC@
M()$  !B5   2F 4 #IH.  V:%  ,FAT "YHF  N:,  *FCL "9I&  B:4P &
MFV$ !9IR  2:A@ "FIL  )JQ  &9SP "F?   IC_  27_P %EO\ !9;_ )F!
M  "'?P  >GX  &M^  !=@0  4(4  $6)   [C0  ,9(  "B6   ?F0  &)T
M !&@   ,HP( !J4*  &E$   I18  *8?  "F*   IC(  *<]  "G2@  IU@
M *=H  "G?   IY$  *:H  "FPP  I>D  *7\  "E_P  I/\  *3_ )&'  ""
MA@  <H8  &.(  !5C   29$  #V6   RF@  *)X  !^B   7I@  $*D   NL
M   $KP   +$&  "Q#   LA$  +(7  "S'P  LR@  +0R  "U/P  M4T  +5=
M  "U<   M88  +6=  "UM@  M=P  +3W  "T_P  M/\  +3_ (N/  !ZC@
M:I$  %N5  !-F@  0)\  #6D   JJ   (*P  !:P   /M   ";<   &Y
MO0   +X   "^!@  OPP  , 0  #!%@  PAT  ,,G  #%,@  QD   ,91  #'
M8P  QW@  ,>1  #'J0  Q\<  ,?L  #'_@  Q_\  ,?_ (.7  !QF@  89X
M %*C  !%J0  .*X  "RS   @MP  %KH   Z]   &P    ,,   #'    R0
M ,H   #,    S0,  ,X)  #0#@  TA,  -0;  #8)0  VS(  -U"  #=5
MWFD  -Z!  #>G   W[4  -_9  #?\P  W_\  -__ '>?  !HI@  6:T  $JS
M   [N   +;L  !^_   4P@  #,8   /)    S    -    #5    V0   -H
M  #<    W@   .    #B!0  Y L  .<0  #J&   [20  / R  #Q1   \E@
M /-O  #TB@  ]*0  /2_  #TWP  ]/,  /3T &JH  !;KP  3+<  #V]   M
MP0  '\8  !/*   +S@   -(   #7    W    .    #E    YP   .D   #K
M    [0   .\   #Q    \P   /8'  #Y#@  _!8  /\B  #_,P  _T<  /]=
M  #_=@  _Y$  /^I  #_O@  _]@  /_; /\ & #_ !8 _P 5 /\ & #_ !X
M_P G /\ -@#_ $, _P!/ /\ 6@#_ &0 _P!M /\ =0#_ 'T _P"$ /\ B@#_
M )  _P"6 /\ G #_ *, _P"K /\ M #^ +\ _0#/ /L YP#Z /@ ^0#_ /D
M_P#Y /\ ]0#_ .X _P#I /\ YP#_ /\ % #_ !$ _P 1 /\ $@#_ !< _P C
M /\ ,0#_ #X _P!* /\ 5@#_ &  _P!H /\ < #_ '@ _0!^ /P A0#Z (L
M^0"1 /@ F #W )X ]0"F /0 K@#R +D \0#' .\ X #N /( [ #_ .P _P#L
M /\ ZP#_ .4 _P#@ /\ W@#_ /\#$ #_  X _P - /\ #0#_ !, _P > /\
M*P#_ #@ _P!% /X 4 #[ %H ^ !C /4 :P#S '( \0!Y .\ ?P#N (8 [ ",
M .H D@#I )D YP"@ .8 J0#D +, X0#  .  TP#> .L W #[ -L _P#: /\
MV@#_ -D _P#4 /\ T@#_ /\'#0#_  D _P & /\ "0#_  \ _P 8 /L )0#X
M #( ]0 _ /( 2@#M %0 Z@!= .< 90#D &P X@!S .  >@#> (  W "& -H
MC0#7 )0 U "; -( I #/ *T S0"Y ,L R0#) .0 R #V ,8 _P#% /\ Q@#_
M ,< _P#' /\ QP#_ /\*!@#_ 0  _P   /\ ! #_  L ]  2 .\ 'P#J "P
MY0 X .( 0P#= $X V0!7 -0 7P#1 &< S@!M ,P = #* 'H R "  ,8 AP#%
M (X PP"6 ,$ G@"_ *@ O0"S +H P@"Y -L MP#P +4 _P"V /\ M0#_ +4
M_P"U /\ M0#_ /\,  #_!   _P   /X   #V  , Z  - .  %P#9 "0 T0 Q
M ,T / #* $< Q@!1 ,, 60#  &  O@!G +P ;@"Z '0 N0![ +< @@"U (D
MLP"1 +( F@"P *0 K@"O *P O0"J -  J #K *< ^P"F /\ I@#_ *4 _P"E
M /\ I0#_ /\-  #_!P  ] D  .H)  #B!   V@ ' ,\ $0#( !P P@ I +X
M-0"[ $  MP!* +0 4P"R %L L !B *X : "L &\ JP!U *D ?0"H (0 I@"-
M *0 E@"C *  H0"K )\!N0"= \P G 3H )H&^0"9!_\ F C_ )<(_P"7"/\
MEPC_ /\0  #W$   Z!0  -P5  #.$0  Q@T  ,($"P"\ !0 MP$A +(#+@"N
M!3H JP9$ *@(30"F"%4 I E< *(*8P"@"FH GPMQ )T+> "<"X  F@R) )D,
MDP"7#)X E0VJ )0-N "2#<P D [J (X0_ ",$/\ BQ#_ (L0_P"+$/\ BA#_
M /L3  #M&@  W2   ,PA  "_'0  MQ<  +,1  "R"PT JPT9 *<.)@"C#S,
MGQ ^ )T11P":$5  F!)7 )827@"5$V4 DQ-L )(3<P"0%'P CQ2% (T5CP"+
M%9H BA6G (@6M0"&%LD A!?G ((8^P" &?\ ?QG_ '\9_P!_&/\ ?QC_ /4:
M  #D(P  SRD  , J  "S)@  JB(  *4<  "D%0@ H!03 )L6(0"7&"T E!DX
M )$:0@"/&TL C1Q2 (L<60")'6  B!UG (8>;P"%'G< @Q^  ((?BP" 'Y<
M?B"C 'T@L@![(,4 >2'D '<B^0!V(O\ =2+_ '0A_P!T(?\ ="'_ .\A  #;
M*P  QS$  +8Q  "I+@  H"H  )LF  "8(0$ E1X0 ) @&P"-(2@ B2,S (<D
M/0"%)$8 @R5. ($F50!_)EP ?B9C 'PG:P![)W, >2=\ '@HAP!V*), ="B@
M 7(HKP%Q*<$!;RG@ 6TI]P%L*?\!:RG_ 6LI_P%K*/\!:RC_ >@H  #0,@
MP#@  *XW  "A-0  F#(  )(M  ".*0  BR<, (<H%P"#*B, @"LO 'XL.0!\
M+$( >BU* '@N40!W+E@ =2Y@ ',O9P!R+V\ <"]Y 6\O@P%M+Y !:R^= 6DO
MK %H,+X!9S#; 64P]0%D,/\!8S#_ 6,O_P%C+_\!8R__ >(N  #*.   NCT
M *@\  ":.@  D3<  (HS  "&,   @RX) '\O$P![,!\ >#(K '8S-0!T,SX
M<C1& ' T3@!O-54 ;35< &PU9 !J-6P!:#5U 6<U@ %E-8P!8S6: F$VJ0)@
M-KL"7S;6 ETV\P)=-O\"7#;_ 5PU_P%<-?\!7#3_ =PS  #%/   M$$  *)
M  "5/@  BSP  (0Y  !_-@  >S0$ '<U$ !T-QP <3@G &\Y,@!M.3L :SI#
M &HZ2P!H.U( 9SM9 &4[80%C.VD!8CMR 6 [?0%>.XH"7#N7 EL[IP)9.[@#
M6#O2 U<[\0)6._\"5CO_ E8Z_P%6.O\!5CG_ =0W  # 00  KT0  )U#  "0
M0@  A4   'X^  !Y.P  =#H  '$Z#@!M/!@ :STD &D^+P!G/S@ 93]  &1
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M TI)H0-(2;,#1TG* T9)[ -&2/\"1DC_ D='_P)'1O\"1T;_ L9#  "V3
MHDP  )%,  "$2P  >4H  '!)  !I1@  9$<  %])!@!<2A  6DL; %A,)0!6
M3"\ 54TX %--0 !234@ 44Y/ $].5P!.3E\!3$YI 4I.<P)(38 "1DV/ T5-
MGP-#3;$#0DW( T%-Z@-!3/\"04S_ D)+_P)"2O\"0DK_ L)'  "S3P  GD\
M (U.  " 3@  =4T  &Q,  !C2@  7DP  %I- @!63@X 5$\8 %)0(@!142P
M3U$U $Y2/0!-4D4 3%)- $I25 !)4ET!1U)F 452<0%#4GX"05*- C]2G0,^
M4J\#/5+& SQ2Z0(\4?X"/%#_ CU/_P(]3_\"/4[_ KY+  "N4P  FE(  (E1
M  !\40  <5   &A0  !>3@  6%$  %12  !14PP 3E04 $Q5'P!+5BD 258R
M $A6.@!'5T( 1E=* $174@!#5UH 05=D 4!7;@$^5WL"/%>+ CI7FP(X5ZT"
M-U?$ C=7YP(W5OT"-U7_ C=4_P(W4_\".%/_ KI/  "I5@  E54  (54  !X
M5   ;50  &14  !85   4E8  $Y7  !*60D 1UH1 $9:&P!$6R4 0ULN $)<
M-@!!7#X /UQ& #Y=3P ]75< .UUA #I=; $X77D!-EV( 31=F0(S7:L",5W"
M C%<Y0(Q6_P",5K_ C%9_P(R6?\!,EC_ ;94  "D60  D%@  (!8  !S5P
M:5<  &!8  !460  3EL  $A=  !#7P0 0& . #YA%P ]82  .V(I #IB,@ Y
M8CH .&-" #=C2P V8U0 -&-= #-C:  Q8W8!+V.% 2YCE@$L8ZD!*V._ 2IC
MXP$J8OL!*F#_ 2M?_P$K7_\!*U[_ ;%9  ">7   BUP  'M;  !O6P  95L
M %Q<  !17@  26   $-B   \90  .&<* #5H$@ T:!L ,VDD #)I+0 Q:34
M+VH] "YJ1@ M:D\ +&I9 "MK90 I:W( *&N" "9KDP D:Z< (VN] ")JX  C
M:?D!(V?_ 2-F_P$C9O\!)&7_ :Q@  "88   A6   '9?  !J7P  86   %=@
M  !-8P  1&8  #UH   V:P  ,&X$ "QP#@ J<14 *7$> "AQ)@ G<B\ )G(W
M "5R0  D<DH (G)4 "%S8  @<VT 'G-] !USD  ;<Z, &G.Y !ESW  :<?<
M&G#_ !MO_P ;;O\!&VW_ :9F  "190  ?V0  '%D  !F9   760  %)F  !(
M:0  /VP  #=O   P<P  *78  ")Y"  ?>Q  'GL7 !Q['P ;>R@ &GLP !E\
M.0 8?$, %WQ. !9\6@ 5?&< %'UX !)]BP 1?9\ $'VU  ]]U0 0>_4 $7G_
M !%X_P 2=_\ $G?_ )YK  "*:@  >FD  &UI  !B:0  5VH  $QM  !#<
M.70  #%X   I>P  (G\  !N"   4A0D $880 !&&%P 0AQ\ $(<H  Z',0 .
MASL #8=&  R'4P +AV$ "H=Q  F'A  'AY@ !H:N  6&R0 &A>P !X3_  B#
M_P )@O\ "8+_ )5Q  "#;P  =&X  &EN  !<;P  4'(  $9U   \>0  ,GT
M "J!   BA0  &XD  !2,   /CP, "I(+  :2$0 $DA@  I(@  &2*0  DC,
M ),^  "32P  DUD  )-I  "3>P  DI   )*F  "1OP  D>4  )#Z  "/_P
MC_\  (__ (UW  !]=0  <'0  &)U  !5>   27P  #^    TA   *XD  "*-
M   :D0  $Y0   Z7   )FP   9T(  "=#@  G1,  )X:  ">(@  GRL  )\U
M  "@0@  H%   *!?  "@<0  H(<  )^=  "?M0  GMH  )WV  "=_P  G/\
M )S_ (9]  !X?   :7P  %M_  !.@P  08@  #:,   LD0  (Y8  !J:   2
MG@  #:$   :D    IP   *D#  "I"@  J@X  *L3  "L&0  K2(  *XK  "O
M-P  KT4  *]4  "O9@  KWL  *Z4  "NJP  KLD  *[O  "M_P  K?\  *W_
M (&$  !QA   88<  %.+  !&D   .98  "Z;   CH   &J0  !*H   ,K
M!*\   "R    M@   +<   "W @  N @  +D-  "Z$@  NQ@  +TA  "^*P
MP#@  ,!(  # 6@  P6X  ,&&  #!H   P;H  ,'C  # ^0  P/\  ,#_ 'F-
M  !HD   690  $N:   ]H   ,:4  "6K   :KP  $;,   NX   "NP   +X
M  #!    Q    ,4   #&    QP   ,@%  #*"P  S \  ,X5  #0'P  TRL
M -4Z  #53   UF   -AW  #8D@  V*P  -G)  #9[   V?L  -C_ '"9  !@
MG@  4:0  $.J   UL   *+8  !RZ   1O@  "<$   #%    R    ,L   #/
M    T@   -,   #6    V    -L   #=    WP<  .(-  #E$P  Z!T  .PJ
M  #M/   [5$  .YG  #O@0  [YP  /"W  #PTP  \.P  /#T &>F  !8K0
M2;0  #JZ   JO@  ',(  !#&   'R@   ,X   #2    U@   -P   #@
MXP   .0   #F    Z    .L   #M    [P   /("  #U"@  ^!$  /P<  #_
M+   _S\  /]5  #_;@  _XH  /^D  #_N@  _]$  /_A /\ % #_ !( _P 2
M /\ % #_ !D _P E /\ ,@#_ #\ _P!+ /\ 5@#_ &  _P!H /\ < #_ '@
M_P!_ /\ A0#_ (L _P"1 /\ F #_ )X _@"F /T K@#\ +D ^@#( /D X@#X
M /0 ]P#_ /8 _P#V /\ [P#_ .< _P#B /\ W@#_ /\ $0#_  X _P . /\
M#P#_ !0 _P @ /\ +0#_ #H _P!& /\ 40#_ %L _P!C /X :P#\ ', ^@!Y
M /D @ #W (8 ]@", /4 D@#S )D \@"@ /  J0#N +, [0#! .L U@#J .X
MZ0#^ .< _P#G /\ Y0#_ -T _P#5 /\ T0#_ /\ #0#_  H _P ( /\ "0#_
M !  _P ; /\ * #_ #4 _P!  /H 2P#V %4 \P!> /$ 9@#N &T [ !T .L
M>@#I (  YP"& .8 C0#D ), X@"; .  HP#> *T W "Y -H R@#7 .8 U #X
M -( _P#2 /\ T@#_ ,X _P#) /\ Q@#_ /\ " #_  , _P   /\  P#_  T
M_  6 /< (@#S "X [P Z .P 10#H $\ Y !8 .$ 8 #> &< VP!M -D = #5
M 'H TP"  -$ AP#/ (X S0"5 ,L G@#) *< QP"S ,4 P@## -P P0#Q +\
M_P"_ /\ O@#_ +X _P"] /\ NP#_ /\   #_    _P   /\   #V  @ [@ 1
M .< &P#A "< W0 S -D /@#3 $D SP!2 ,L 60#( &$ Q@!G ,0 ;0#" ',
MP !Z +\ @ "] (@ NP"0 +D F "X *( M0"M +, NP"Q ,X L #J *\ _ "M
M /\ K0#_ *X _P"N /\ K@#_ /\"  #_    _0   /(   #H    W@ , -,
M%0#, "$ R  L ,0 . #! $( O0!+ +H 4P"X %H M@!A +0 9P"R &T L !T
M *\ >@"M (( K "* *H DP"H )T I@"H *0 M0"B ,8 H0#C )\ ]@"> /\
MG@#_ )X _P"> /\ G@#_ /\&  #[    [@4  .($  #5    RP & ,, #P"]
M !D N  E +0 ,0"Q #L K@!% *P 30"I %4 IP!; *4 8@"D &@ H@!N *$
M=0"? 'P G@"% )P C@": )@ F "D )8 L "5 ,$ DP#< )( \@"1 /\ D #_
M )  _P"/ /\ CP#_ /T*  #P#@  X1$  ,X0  #"#0  NP<  +< "@"Q !(
MK  > *@ *0"E #0 H@ ^ )\ 1P"= $\ FP!6 )D!7 "7 6, E@)I )0"< "3
M W@ D0.  ) $B@".!)4 C 6A (H%K@")!KX APC8 (8)\ "$"O\ @PO_ (,+
M_P"#"_\ @PO_ /80  #F%P  TAP  , :  "S%@  K!(  *@-  "F!PT H@46
M )T'(@"9"2X E@HX )0+00"2#$H D Q1 (X-6 ",#5X BPUE (D-; "(#G0
MA@Y] (4.AP"##I, @0^? ( 0K0!^$+X ?1#; 'H1] !X$O\ =Q+_ '<2_P!W
M$O\ =Q+_ .\7  #;(0  QB0  +0C  "H(   H!P  )L7  "9$00 F X0 ),0
M&P"/$2< C!(R (D3/ "'$T0 A11, (,44P"!%5H @!5@ 'X6: !]%F\ >Q9X
M 'D7@P!X%X\ =AB< '08J@!S&;L <AG4 &\:\0!N&_\ ;1O_ &T:_P!M&O\
M;1K_ .<@  #0*0  O"L  *LJ  ">*   EB0  ) @  "-'   C!<, (@8%@"$
M&B( @1LM 'X<-P!\'4  >AU( 'D>3P!W'E4 =A]< '0?8P!S'VL <2!T ' @
M?P!N(8L ;"&8 &LAIP!I(K@ :"+/ &8B[@!E(_\ 9"/_ &0B_P!D(O\ 9"'_
M . F  #(+P  M#$  *,P  "6+@  C2L  (<H  "$)   @B ( 'X@$@![(AX
M>",I '4D,P!S)3P <25# ' F2P!N)E( ;2=9 &LG8 !J)V@ :2AQ &<H>P!E
M*(@ 9"F5 &(II !@*;4 7RG+ %XJ[ !<*O\ 7"G_ %PI_P!<*?\ 7"C_ -@L
M  ##-0  K34  )TT  "0,P  AC$  ( M  !\*P  >2@# '8G$ !R*1H <"HE
M &TK+P!K+#@ :BQ  &@M1P!G+4X 92Y5 &0N70!C+F4 82]N %\O> !>+X0
M7"^2 %HOH0%9+[(!6##( 58PZ0%5,/X!52__ %4O_P!5+O\ 52[_ - Q  "]
M.@  J#D  )<X  "*-P  @#8  'HR  !U,   <BX  &XN#0!K+Q8 :3 A &8Q
M*P!D,C0 8S(] &$S1 !@,TL 7S12 %TT6@!<-&( 6C1K %DU=0!7-8( 5360
M 50UGP%2-; !437& 5 UYP%/-?T!3S7_ 4\T_P%/-/\!3S/_ <LV  "X/0
MHSP  )(\  "%.P  >SH  '0W  !O-0  ;#,  &@T"@!E-1, 8C8> & W* !>
M-S$ 73@Z %LX00!:.4@ 63E0 %<Y5P!6.E\ 5#IH %,Z<P!1.G\!3SJ- 4XZ
MG0%,.JX!2SK# 4HZY0%).OP!23G_ 4DY_P%)./\!2CC_ <<Z  "S0   GC\
M (X_  "!/@  =ST  ' [  !J.   9C@  &(Y!P!?.A$ 7#L; %H[)0!9/"X
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M 3I(WP$Z1_@!.D;_ 3I%_P$[1?\!.T3_ ;M%  "F2   DD<  ()'  !V1P
M:T<  &-&  !;0P  5D4  %)'  !.2 H 3$D2 $I)' !(2B4 1THN $9+-@!%
M2SX 0TM& $),30!!3%8 0$Q? #Y,:@ \3'8 .TR% 3E,E0$W3*<!-DR\ 35,
MW0$U2_<!-4O_ 35*_P$V2?\!-DG_ ;A)  "B2P  CDH  'Y*  !R2@  :$H
M %])  !52   4$H  $Q+  !)3 < 1DT0 $1.&0!"3R( 04\K $!0,P _4#L
M/E!# #Q12@ [45, .E%< #A19P W47, -5&" #-1DP$R4:4!,%&Z 2]1V@$O
M4/8!+T__ 3!._P$P3O\!,$W_ ;1-  "=30  BDT  'I-  !N30  9$T  %M-
M  !130  2T\  $90  !"4@, /U,- #U4%0 \5!X .E4G #E5+P X53< -U8_
M #961P U5E  ,U99 #)79  P5W$ +U>  "U7D0 K5Z, *E>X "E7U@ I5O4
M*57_ "I4_P$J4_\!*E+_ :]1  "840  A5$  '90  !J4   8%   %A1  !.
M4@  1U,  $%5   [6   .%D* #5:$0 T6AH ,ULB #);*P Q6S, +UP[ "Y<
M0P M7$P +%Q6 "M=8  I76T *%U\ "9=C@ D7:$ (UVU ")=T@ B7/, (EO_
M "-:_P C6?\ )%C_ *A5  "25   @%0  '%4  !F5   7%0  %15  !*5@
M0U@  #Q;   V70  ,& % "UA#@ K814 *F(= "EB)0 H8BX )V,V "9C/@ E
M8T< (V-1 ")D7  A9&D 'V1Y !YDB@ <9)X &V2S !EDS@ :8_$ &V'_ !M@
M_P <8/\ '%__ *%9  ",6   >U@  &U8  !B6   65@  %!9  !'6P  /EX
M #=@   Q8P  *F8  "1I"0 A:A  (&H7 !]J(  >:R@ '6LP !QK.0 ;:T(
M&FQ, !EL6  7;&4 %FQT !1LA@ 3;)H $FRO !%LR@ 1:^\ $FG_ !-H_P 3
M:/\ $V?_ )E=  "%70  =5P  &A<  !>7   55P  $M>  !"80  .60  #)G
M   K:@  )&T  !YP 0 7<PL %701 !1T&  3="$ $G4I !%U,@ 1=3L $'5&
M  ]U4@ .=5\ #75N  QU@0 +=94 "G6J  ATPP )=.< "G/]  MQ_P ,<?\
M#'#_ )%B  !_80  <&$  &1A  !:80  3V(  $5E   \:   ,VP  "MO   D
M<@  '78  !=Y   1? 0 #7\,  M_$@ *?QD "7\B  A_*@ &?S0 !7\_  1_
M2P "?U@  7]G  !_>0  ?XX  '^C  !^NP  ?>   'WW  !\_P  >_\  'O_
M (EG  !X9P  :V8  &%F  !49P  26D  #]M   U<0  +'4  "1Y   =?
M%H   !"#   ,A@( !HD*  &)#P  B10  (H;  "*(P  BRP  (LW  "+0P
MBU   (M?  "+<0  BX8  (N<  "*LP  B=,  (CS  "(_P  A_\  (?_ ()M
M  !S;   :&P  %IM  !.;P  0G,  #AW   N>P  )8   !V$   5B   $(P
M  N/   $D@   )0&  "5#   E1   )85  "7'   F"0  )@N  "9.0  F4<
M )E6  "9:   F7T  )F4  "8JP  E\@  );N  "6_P  E?\  )7_ 'MT  !O
M<P  87,  %-V  !&>@  .W\  #"$   FB   '8T  !22   .E@  "9D   &<
M    H    *$   "B!@  H@P  *00  "E%   I1P  *<D  "H+P  J#T  *E,
M  "I7@  J7(  *B)  "HH@  J+P  *?E  "F^P  IO\  *7_ '=[  !H>P
M67X  $N"   ^AP  ,HT  ">2   =EP  %)P   Z@   'I    *@   "K
MK@   *\   "P    L00  +,*  "T#@  M1,  +8;  "X)   NC$  +I   "Z
M4@  NV4  +M]  "ZEP  NK$  +K2  "Z\P  N?\  +G_ &^#  !?A@  48L
M $.0   VEP  *IT  !^B   5IP  #:P   6P    M    +<   "[    O@
M +\   #     P0   ,,!  #$!P  Q0T  ,<1  #*&0  S20  ,XS  #/1
MT%@  -!N  #1B   T*0  -#!  #1Y@  T?@  -'_ &>/  !7E   29H  #NA
M   NIP  (:T  !:S   .N   !KP   #     PP   ,8   #+    S0   ,X
M  #0    T0   -0   #6    V@(  -P)  #?#P  XQ<  .8D  #G-@  Z$D
M .E?  #J>   ZY0  .NO  #KS   [.@  .SV %^>  !0I   0JL  #2R   F
MN0  &;X   ["   $Q0   ,H   #-    T0   -@   #;    WP   .    #B
M    Y    .8   #I    ZP   .X   #Q!0  ]0T  /D6  #\)0  _3D  /Y/
M  #_9P  _X(  /^=  #_M0  _\L  /_D /\ $0#_  \ _P / /\ $0#_ !8
M_P B /\ +P#_ #L _P!' /\ 4@#_ %L _P!D /\ ; #_ ', _P!Z /\ @ #_
M (8 _P", /X DP#] )D ^P"A /H J0#X +0 ]P#" /8 V@#U /$ ] #_ /,
M_P#S /\ Z0#_ .  _P#8 /\ TP#_ /\ #@#_  L _P * /\ "P#_ !$ _P =
M /\ *@#_ #8 _P!! /\ 3 #_ %8 _@!? /L 9@#Y &T ]P!T /4 >@#T (
M\@"& /  C0#O )0 [0"; .P I #J *X Z0"Z .< S0#E .D Y #[ ., _P#B
M /\ W@#_ -$ _P#, /\ R #_ /\ "0#_  0 _P ! /\ ! #_  X _P 8 /\
M) #] #  ^P [ /< 1@#S %  [P!9 .P 8 #J &< YP!N .8 = #D 'H X@"
M .  AP#> (X W "5 -H G@#6 *@ U "S -$ PP#/ -\ S@#T ,P _P#+ /\
MRP#_ ,4 _P"_ /\ O #_ /\  @#_    _P   /\   #]  L ]P 3 /$ '@#M
M "H Z@ U .< 0 #B $H W0!2 -D 6@#5 &$ T@!G -  ;0#. ', S !Z ,H
M@ #( (< Q@"/ ,0 F #" *$ P "M +X NP"\ -  N@#M +D _@"X /\ N #_
M +< _P"S /\ L #_ /\   #_    _P   /D   #N  4 Y0 . -X & #8 ",
MT@ N ,\ .0#+ $, QP!, ,0 5 #! %L OP!A +P 9P"[ &T N0!S +< >@"U
M ($ M ") +( D@"P )L KP"G *P M "K ,8 J0#D *< ^ "F /\ I@#_ *4
M_P"E /\ I #_ /\   #_    ]0   .H   #>    T  * ,@ $@#" !T O@ H
M +L ,P"Y #T M0!& +( 30"P %4 K0!; *P 80"J &< J !M *< <P"E 'H
MI "" *( C "@ )8 GP"A )T K@"; +X F0#8 )< \0"6 /\ E@#_ )< _P"7
M /\ EP#_ /\   #U    YP$  -0   #)    P  $ +@ #@"S !8 KP A *L
M+ "H #8 I@ _ *, 1P"A $\ GP!5 )T 6P"; &$ F@!G )@ ;@"7 '4 E0!]
M )0 A@"2 )$ D "< (X J0", +@ BP#- (D ZP"( /T B #_ (@ _P"( /\
MB #_ /D&  #I#   U X  ,,,  "W"0  L (  *L "0"F !  H@ : )X )0";
M #  F  Y )8 00"4 $D D@!0 )  5@". %P C0!B (L :0"* '  B !X (<
M@0"% (P A "8 (( I0"  +0 ?@#( 'T!YP!\ OD >P/_ 'L$_P![!/\ >P3_
M /$.  #>%0  Q14  +04  "I$0  H0X  )X*  "; PP EP 3 ), '@"0 2D
MC0(S (H#/ "(!$, A@5+ (4&40"#!E< @@=> ( '9 !_"&P ?0AT 'P(?@!Z
M"8D > F6 '<*HP!U"K, <PO' '(,Y@!P#?L < W_ &\-_P!O#?\ ;PW_ .@6
M  #0'@  N1T  *D<  "=&@  E18  ) 3  "/#@, C@H. (D+%P"&#", @PTM
M ( --@!^#CX ? Y& 'L.30!Y#U, >!!: '8080!U$&@ <Q!Q '$1>P!P$8<
M;A&4 &P1H@!K$K( :1+' &@3YP!F$_T 913_ &44_P!E$_\ 91/_ -\>  #&
M)   L"0  * C  "4(0  BQ\  (8;  "#%P  @A(( '\1$@!\$AT >10H '84
M,0!T%3H <A9! '$62 !O%T\ ;A=6 &P770!K&&0 :1AM &@9=P!F&8, 9!F0
M &,:GP!A&J\ 8!K$ %X;Y !='/L 7!S_ %P;_P!<&_\ 7!O_ -4E  "]*@
MJ"D  )@I  ",*   @R4  'TB  !Y'P  >!L# '89#P!R&A@ ;QPC &T=+0!K
M'34 :1X] &@>1 !F'TL 91]2 &,@60!B(&$ 82!I %\A<P!=(7\ 7"&- %HB
MG !9(JP 5R+  %8CX0!5(_D 5"/_ %0B_P!4(O\ 5"+_ ,TK  "V+@  HBX
M )(N  "%+0  ?"L  '8H  !R)@  ;R,  &TA# !J(A4 9R,? &4D*0!C)#$
M8B4Y & F00!?)D@ 729/ %PG5@!;)UT 62=F %@H< !6*'P 5"B* %,IF0!1
M*:H 4"F^ $\IW@!.*?< 32G_ $TI_P!-*/\ 3BC_ ,@P  "P,@  G#(  (PR
M  " ,0  =C   ' M  !K*P  :"D  &8H"0!C*!$ 8"D< %XJ)0!<*RX 6RLV
M %DL/0!8+$0 5RU, %4M4P!4+5L 4RUC %$N;@!0+GH 3BZ( $POEP!++Z@
M22^[ $@OVP!(+_8 1R__ $<N_P!'+?\ 2"W_ ,0T  "K-0  ES4  (<U  ![
M-0  <C0  &LR  !F+P  8BX  %\M!0!<+A  6B\8 %@P(@!6,"L 53$S %,Q
M.@!2,D( 43)) % R4 !.,U@ 33-A $LS:P!*,W< 2#2% $<TE0!%-*8 0S2Y
M $(TU@!"-/0 0C3_ $(S_P!",O\ 0C+_ , X  "G.   DS@  (,X  !W.
M;3<  &8V  !A,P  73(  %DR @!7,PT 5#05 %(U'P!1-2@ 3S8P $XV. !,
M-S\ 2S=& $HW3@!).%8 1SA? $8X:0!$.'4 0SB# $$YDP! .:0 /CFX #TY
MTP \.?, /#C_ #TW_P ]-_\ /3;_ +L[  "B.P  CSL  '\[  !S.P  :CH
M &(Y  !=-P  6#8  %0W  !1. L 3SD3 $TY' !+.B4 2CHM $@[-0!'.SP
M1CQ$ $4\2P!$/%, 0CQ< $$]9P _/7, /CV! #P]D0 Z/:, .3VV #@]T0 W
M/?( -SS_ #@[_P X._\ .#K_ +8]  ">/@  BSX  'P^  !O/@  9CT  %X]
M  !8.P  4SH  $\[  !,/ @ 23T1 $<^&0!&/R( 1#\J $,_,@!"0#H 04!!
M $! 20 ^05$ /4%: #Q!9  Z07  .$%_ #=!CP U0J$ -$*T #)"S@ R0?
M,D#_ #- _P S/_\ -#[_ +%   ":0   AT   'A!  !L00  8D   %M   !4
M/P  3C\  $I   !&004 1$(. $)#%@! 0Q\ /T0G #Y$+P \1#< .T4^ #I%
M1@ Y14X .$98 #9&8@ U1FX ,T9\ #%&C0 P1I\ +D:S "U&S  M1N\ +47_
M "Y$_P N0_\ +D/_ *Q#  "60P  @T,  '1#  !H0P  7T,  %=#  !00P
M2$,  $1%  !!1@$ /D<, #Q($P Z2!P .4DD #A)+  V230 -4H[ #1*0P S
M2DP ,DI5 #!+7P O2VL +4MZ "Q+BP J2YT *$NQ "=+R@ G2^T )TK_ "A)
M_P H2/\ *4?_ *=&  "11@  ?T8  '!&  !E1@  6T8  %1&  !,1P  1$@
M #]*   [2P  -TP) #5-$  S3A@ ,DX@ #%/*  P3S  +T\X "Y/0  L4$@
M*U!2 "I07  H4&@ )U!W "50B  D4)L (E"O "%0R  @4.L (4__ ")._P B
M3?\ (TW_ *%)  ",20  >DD  &Q*  !A2@  6$H  %!*  !)2P  0$P  #M.
M   U4   ,5($ "U3#0 L5!0 *E0< "E5)  H52P )U4S "95/  E5D4 )%9.
M ")660 A5F4 'U9T !Y6A0 <5I@ &U:L !E6Q0 95ND &E7_ !M4_P ;4_\
M'%+_ )M-  "&30  =4T  &A-  !=30  5$T  $U.  !%3P  /%$  #93   Q
M50  *U@  "9:"0 C6Q  (EL7 "%<'P @7"< 'UPN !U<-P <74  &UU* !I=
M50 876$ %UUP !5=@0 4794 $UVJ !%=P@ 17>< $EO^ !-:_P 36O\ %%G_
M )11  " 40  <%$  &11  !940  45$  $E2  !!4P  .%8  #)9   K6P
M)5X  !]A P :8PP &&01 !=D&0 69"$ %60I !1E,0 393H $F5$ !%E4  0
M95T #V5K  YE?0 -99$ #&6E  IDO  *9.  "V/Y  QB_P -8?\ #6'_ (U5
M  !Z50  :U4  %]5  !650  3E4  $17   \60  -%P  "Q?   F8@  'V4
M !EH   3:P4 $&T-  YN$@ -;AH #&XB  QN*P +;C0 "FX^  AN2@ ';E<
M!FYE  1N=@ ";HH  &V?  !MM@  ;-8  &SS  %K_P ":O\  VK_ (5:  !T
M6@  9EH  %Q9  !360  2%H  #]=   V8   +F,  "9G   ?:@  &6T  !-Q
M   .= , "G<*  5W$  !=Q4  '<<  !W)   >"T  '@W  !X0P  >%   'A>
M  !X;P  >(0  'B9  !WL   =LT  '7P  !U_P  =/\  '3_ 'Y?  !N7P
M8EX  %E>  !-7P  0F(  #EE   P:   )VP  !]P   8=   $G<   U[   (
M?@   H (  "!#0  @1$  ((7  "#'@  @R8  (0P  "$.P  A$@  (17  "$
M:   A'P  (23  "#J@  @L4  ('K  "!_@  @/\  (#_ '=E  !I9   7V,
M %)D  !'9P  /&L  #%O   H<P  ('<  !A\   1?P  #(,   :'    B@
M (P#  ","0  C0X  (X1  "/%P  D!X  )$G  "2,@  DC\  )).  "27P
MDG,  )*+  "1H@  D;P  )#E  "/_   CO\  ([_ '%K  !F:@  6&L  $MM
M   _<0  -'8  "I[   @@   %X4  !")   +C0  !)$   "5    F    )D
M  ": P  FP@  )P-  ">$0  GQ8  * >  "B*   HC4  *-$  "C50  HVD
M **   "BF@  H;,  *#8  "@]@  G_\  )__ &YQ  !?<@  474  $1Y   W
M?@  +(0  "&*   7CP  $)0   J9   !G0   *    "D    IP   *@   "I
M    J@   *P&  "M"P  KQ   + 5  "R'@  M"D  +0Y  "T2@  M5T  +5S
M  "UC@  M:@  +3&  "S[0  LO\  ++_ &9Z  !7?0  28(  #R'   OC@
M(Y0  !B:   0GP  ":0   "I    K0   +    "T    MP   +@   "Y
MNP   +P   "^ @  P @  ,(.  #$%   QQX  ,@L  #)/0  RE   ,IF  #*
M?P  RIL  ,JX  #*W0  RO4  ,K_ %Z&  !/BP  09$  #.8   GGP  &Z4
M !&K   )L    +4   "Y    O0   ,$   #&    R    ,D   #+    S
M ,X   #0    T@   -0%  #9#   W1(  .$>  #B+@  XT(  .17  #E;P
MYHP  .:H  #EQ0  Y><  .;V %:4  !(FP  .J(  "RI   ?L   $[8   N\
M    P0   ,4   #)    S0   -(   #6    V@   -L   #>    X    .(
M  #D    YP   .D   #M    \ H  /01  #X'P  ^3(  /I(  #[7P  _'H
M /V7  #]KP  _<<  /WD /\ #@#_  T _P , /\ #@#_ !, _P > /\ *@#_
M #8 _P!" /\ 30#_ %< _P!? /\ 9P#_ &X _P!T /\ >@#_ ($ _0"' /P
MC0#Z )0 ^0"< /< I0#U *\ ] "\ /, SP#Q .P \ #^ .\ _P#O /\ XP#_
M -< _P#. /\ R@#_ /\ "@#_  8 _P $ /\ " #_ !  _P 9 /\ )0#_ #$
M_P ] /\ 1P#^ %$ ^P!9 /D 80#V &@ ] !N /, = #Q 'H [P"! .X AP#L
M (X Z@"6 .@ GP#F *D XP"U .( Q@#@ ., WP#X -T _P#= /\ U #_ ,D
M_P#" /\ O@#_ /\  P#_    _P   /\  0#_  T _P 4 /T ( #Z "L ]P V
M /, 00#O $L [ !4 .@ 6P#F &( XP!H .$ ;@#? '0 W !Z -H @0#8 (@
MU "0 -( F #/ *( S0"N ,L O #) -, QP#P ,8 _P#$ /\ Q #_ +L _P"V
M /\ LP#_ /\   #_    _P   /\   #W  @ \  0 .L &@#G "4 Y  P .$
M.P#< $4 U0!- -$ 50#. %L RP!B ,D 9P#' &T Q0!S ,, >@#! ($ OP")
M +T D@"[ )P N0"G +< M0"U ,@ LP#F +( ^P"Q /\ L #_ *X _P"J /\
MIP#_ /\   #_    _@   /$   #E  ( W  - -, % #- !\ R@ J ,< - #$
M #X P !' +P 3@"Z %4 MP!; +4 80"S &< L@!M +  <P"N 'H K "" *H
MBP"H )4 IP"@ *4 K0"C +X H0#; *  ] "? /\ G@#_ )\ _P"= /\ FP#_
M /\   #\    [@   .    #0    Q0 ( +X $ "Y !D M0 C +, +@"P #<
MK0!  *H 2 "H $\ I0!5 *, 6P"B &  H !F )\ ; "= ', FP![ )H A "8
M (X E@": )4 IP"3 +< D0#, )  [ "/ /\ C@#_ (X _P". /\ CP#_ /P
M  #O    VP   ,D   "]    M0 " *X # "I !, I0 = *( )P"@ #$ G0 Z
M )H 0@"8 $D E@!/ )0 50"3 %L D0!@ )  9P". &T C0!U (L ?@") (D
MB "5 (8 H@"% +$ @P#$ ($ Y "  /D ?P#_ (  _P"  /\ @ #_ /0"  #@
M"0  QP@  +<'  "L P  I@   *  !P";  \ F  7 )4 (0"2 "H CP S (T
M/ "+ $, B0!) (< 4 "& %4 A !; (, 80"! &@ @ !P 'X >0!\ (0 >P"0
M 'D G0!X *P =@"^ '4 W0!S /0 <P#_ ', _P!S /\ <P#_ .D-  #/$
MN1   *D0  ">#@  EPL  ),&  "0  L C  1 (D &@"& "0 @P N ($ -@!_
M #X ?0!$ 'P 2P!Z %$ >0!7 '< 70!V &0 = !L ',!=0!Q 8  ;P*- &X"
MF@!L ZH :P.[ &D$U@!H!O$ : ?_ &<'_P!G!_\ 9P?_ -\4  ##%P  KA<
M )X6  "3%0  BQ(  (80  "$# ( @P8- ( #% !\!1X >0<H '<(, !U"#@
M<PE  '()1@!P"DP ;PI3 &T+60!L"V$ :@MI &D,<@!G#'X 9@R+ &0-F0!B
M#:D 80V[ & -V !>#O, 70[_ %T._P!=#O\ 70[_ -0<  "Y'0  I!X  )4=
M  ")'   @1H  'L7  !X$P  >! & '<-#P!S#A@ < XB &X/*P!L$#, :A [
M &D00@!G$4D 9A%/ &015@!C$ET 81)F & 2;P!>$GL 7!.( %L3EP!9$Z<
M5Q2Z %84U0!5%?, 5!7_ %05_P!4%?\ 5!3_ ,HB  "P(@  G2,  (TC  "!
M(@  >2$  ',>  !O&P  ;A<  &T3# !J%!0 9Q4> &46)P!C%B\ 81<W & 7
M/@!>&$4 71A+ %P94@!:&5H 61EB %<:; !6&G< 5!J% %(;E !1&Z0 3QNW
M $X;T !-'/$ 3!S_ $P<_P!-'/\ 31O_ ,,F  "J)P  EB<  (<H  ![)P
M<B8  &PD  !H(0  9AX  &0;" !B&Q$ 7QP: %T=(P!;'BL 6AXS %@?.@!7
M'T$ 5B!( %0@3P!3(%< 42%? % A:0!.(70 32&" $LBD0!)(J( 2"*T $<B
MS0!&(^\ 12/_ $4B_P!&(O\ 1B'_ +PJ  "D*P  D2L  ((L  !V*P  ;2H
M &8I  !B)@  7R0  %TB! !;(0X 6"(6 %8C'P!4)"@ 4R0P %(E-P!0)3X
M3R9% $XF3 !,)E0 2R=< $DG9@!()W$ 1B=_ $4HCP!#**  02BR $ HRP _
M*.T /RC_ #\H_P! )_\ 0"?_ +<M  "?+@  C"\  'TO  !Q+P  :"X  &$M
M  !=*P  6B@  %<G  !4)PP 4B@3 % I' !.*24 32HL $LJ- !**SL 22M"
M $@L20!&+%$ 12Q: $0L9 !"+6\ 0"U] #\MC0 ]+9X /"VP #HMR  Z+>L
M.BW_ #HM_P Z+/\ .BS_ +(P  ";,0  B#(  'DR  !M,@  9#(  %TQ  !8
M+P  52P  %$L  !/+0D 3"T1 $HN&0!)+R( 1R\J $8P,0!%,#@ 0S _ $(Q
M1P!!,4\ 0#%7 #XQ80 ],FT .S)[ #DRBP X,IP -C*O #4RQP T,ND -#+_
M #4Q_P U,?\ -3#_ *TS  "6-   A#4  '4U  !I-0  8#4  %DT  !4,P
M4#   $PQ  !),08 1S(/ $4S%@!#,Q\ 0C0G $ T+@ _-38 /C4] #TU1  \
M-DP .C95 #DV7P W-FL -C9X #0WB0 R-YH ,3>M "\WQ0 O-^@ +S;^ # U
M_P P-?\ ,#3_ *DV  "2-@  @#<  '(X  !F.   73<  %8W  !0-@  2S0
M $<U  !$-@, 03<- #\X%  ^.!P /#DD #LY+  Z.3, .3HZ #@Z0@ V.DH
M-3I3 #0[70 R.V@ ,#MV "\[AP M.YD +#NL "H[PP I.^8 *CK] "HZ_P K
M.?\ +#C_ *0X  "..0  ?#H  &XZ  !C.@  6CH  %,Z  !-.@  1C@  $(Z
M   _.P  /#P+ #H\$0 X/1D -STA #8^*0 T/C  ,SXW #(_/P Q/T< ,#]0
M "X_6@ M0&8 *T!T "E A  H0)< )D"J "5 P0 D0.4 )#_\ "4^_P F/?\
M)CW_ )\[  "*/   >#T  &H]  !?/0  5CT  $\]  !)/0  0CT  #P^   Y
M/P  -D$( #1!#P R0A8 ,4(> "]#)0 N0RT +4,T "Q$/  K1$0 *D1- "A$
M6  G16, )45Q "-%@@ B194 ($6H !]%OP >1., 'T3[ !]#_P @0O\ (4'_
M )H^  "%/P  =$   &=   !<0   4T   $Q   !&0   /D$  #A#   T10
M,$8# "U'#0 K2!( *D@: "E((@ H22D )TDQ "5).0 D24$ (TI* ")*50 @
M2F$ 'TIO !U*?P ;2I( &DJF !A*O0 72N  &$GZ !E(_P :1_\ &D?_ )5"
M  " 0@  <$,  &-#  !80P  4$,  $E#  !"1   .T4  #5'   P20  *TL
M "9-"0 D3A  (DX6 "%/'0 @3R4 'T\L !Y/-0 =3ST '%!' !I040 94%T
M%U!K !90?  44(\ $U"D !%0N@ 14-X $4_X !)._P 33?\ %$W_ (]%  ![
M1@  :T8  %]'  !51P  34<  $9'   _1P  -TH  #%,   K3@  )E   "!3
M P <50P &E81 !E6&  75B  %E8G !56,  45CD $U=" !)730 15UD $%=H
M  ]7>0 .5XP #5>@  M7M@ +5M0 "U;T  Q5_P -5/\ #E/_ (A)  !V2@
M9TH  %M*  !12@  2DH  $-*   [3   ,TX  "Q1   F5   (58  !M9   5
M7 < $5X- !!>$P 07AH #EXB  Y>*@ -7C, #%X]  M>2  *7E0 "%YB  =>
M<P %7H8  UZ;  )>L0 "7<P  EWN  -<_P $6_\ !5O_ (%.  !P3@  8DX
M %=.  !.3@  1TX  #Y/   V40  +E0  "=7   A6@  &UT  !5@   08P,
M#&8+  AG$  &9Q4 !6<<  1G)  "9RT  6<W  !G0@  9TX  &=<  !G;0
M9X   &:5  !FK   9<<  &7K  !D_   9/\  &/_ 'I2  !J4P  75(  %12
M  !+4@  0E,  #E5   P6   *%L  "%?   :8@  %&4  !!H   ,:P$ !FX)
M  !O#@  ;Q(  &\8  !P'P  <"<  '$P  !Q.P  <4@  '%6  !Q9@  <7D
M '&/  !PIP  ;\$  &_G  !N_   ;?\  &W_ '-8  !E5P  6E<  %%6  !&
M5P  /%H  #)=   J80  (F0  !IH   4;   #F\   IR   $=@   '@%  !X
M"P  >0X  'H3  ![&0  ?"   'TI  !],P  ?4   'U.  !]7@  ?7(  'V(
M  !\H0  ?+H  'OB  !Z^@  >?\  'C_ &U=  !@7   5UP  $M=  ! 7P
M-6,  "MG   C:P  &F\  !-S   .=P  "'L   )^    @@   (,!  "$!@
MA0L  (8/  "($P  B1D  (HA  "+*P  BS<  (Q&  "+5@  BVD  (N   "+
MF0  BK,  (G8  "(]P  B/\  (?_ &AC  !>8@  46(  $1E   X:0  +FX
M "1S   :>   $WT   V!   &A0   (D   "-    D    )(   "2    E 4
M )4*  "7#@  F!(  )H8  ";(0  G"T  )T\  "=3   G%\  )QV  ";D0
MFZL  )K)  ":\   F?\  )C_ &5I  !7:0  26P  #UQ   P=@  )7P  !N!
M   2AP  #(P   21    E0   )D   "=    H    *$   "B    I    *4!
M  "G!P  J0P  *H1  "M&   KR(  *\P  "O00  KU0  *]K  "NA0  KJ$
M *Z^  "MY@  K/P  *S_ %YQ  !/=   0GD  #5_   HA0  '8P  !.2   ,
MF    YT   "B    I@   *H   "N    L    +$   "S    M    +8   "X
M    N@0  +P*  "^$   P1<  ,,D  ##-0  Q$D  ,1>  #%=P  Q9,  ,6O
M  #%T0  P_(  ,/_ %9\  !'@@  .H@  "R/   @E@  %)T   VC   #J0
M *X   "R    MP   +L   "_    P@   ,(   #%    Q@   ,@   #*
MS0   ,\   #2"   U0X  -L8  #=)P  WCH  -]0  #@:   X(0  .&A  #A
MO0  X>(  .#T $Z+  ! D@  ,ID  "6A   8J   #J\   6U    N@   +\
M  #$    R    ,X   #1    U    -4   #8    V@   -T   #?    X@
M .0   #G    ZP4  .\.  #T&0  ]2L  /9!  #W6   ^'(  /F0  #YJP
M^,0  /CA /\ "P#_  @ _P ) /\ # #_ !( _P : /\ )@#_ #( _P ^ /\
M2 #_ %( _P!: /\ 8@#_ &D _P!O /\ =0#^ 'L _ "! /L B #Y (\ ]P"7
M /4 H #S *H \@"W .\ R0#M .8 [ #[ .L _P#K /\ W0#_ ,X _P#& /\
MP@#_ /\ ! #_    _P   /\ !0#_  T _P 5 /\ (0#_ "P _P X /\ 0P#]
M $P ^0!4 /< 7 #T &, \@!I /  ;P#N '4 [ ![ .H @@#H (D YP"1 .0
MF@#B *0 X "P -T P #: -P V #T -4 _P#3 /\ RP#_ ,$ _P"[ /\ MP#_
M /\   #_    _P   /\   #_  H _0 1 /D &P#V "< ]  R /  / #L $8
MZ !. .0 5@#A %P W@!C -P : #9 &X U0!T -( >P#0 (( S0"* ,L DP#(
M )T Q@"H ,0 MP#! ,P P #K +X _P"] /\ O0#_ +0 _P"N /\ JP#_ /\
M  #_    _P   /H   #R  4 Z@ . .4 %@#@ "$ W0 K -L -@#3 #\ S@!(
M ,H 3P#' %8 Q !< ,( 80#  &< O@!M +P <P"Z 'H N "" +8 BP"T )8
ML@"A +  KP"N ,$ K0#@ *L ]P"J /\ J0#_ *8 _P"A /\ GP#_ /\   #_
M    ]P   .@   #<    T  * ,H $0#% !L P@ E +\ +P"\ #@ N !! +4
M2 "R $\ L !5 *X 6P"L &$ J@!F *@ ; "G ', I0![ *, A "A (X GP":
M )T IP"; +@ F@#0 )D [P"8 /\ EP#_ )8 _P"4 /\ D@#_ /\   #V
MY    -(   #%    NP % +4 #@"P !4 K  ? *H *0"H #( I0 Z *( 0@"@
M $D G@!/ )P 50": %H F !@ )8 9@"5 &P DP!T )( ?0"0 (< C@"3 (P
MH0"+ +  B@#% (@ Y@"' /L A@#_ (< _P"' /\ A@#_ /@   #E    S0
M +T   "S    J@   *, "@"? !$ FP 9 )D (P"7 "P E0 T )( / "0 $,
MC@!) (P 3P"* %0 B0!: (< 8 "& &8 A !N (, =P"! ($ ?P"- 'X FP!\
M *H >P"\ 'H VP!X /4 > #_ '@ _P!X /\ > #_ .T   #1 @  NP(  *P!
M  "B    FP   )8 !0"1  T C0 4 (L '0"( "8 A@ N (0 -@"" #T @ !#
M 'X 20!] $\ ? !5 'H 6P!Y &$ =P!I '4 <0!T 'P <@"( '$ E@!O *4
M;@"V &T S@!L .X :P#_ &L _P!K /\ :P#_ -\+  #"#   K@P  )X,  "3
M"P  C <  (@"  "%  D @0 0 '\ %P!\ "  >@ H '@ , !V #@ =  ^ ',
M1 !Q $H < !0 &X 5@!M %T ; !D &H ;0!H '< 9P"$ &4 D@!D *$ 8P"R
M &$ R0!@ .D 8 #\ &  _P!@ /\ 8 #_ - 0  "V$0  HA(  ),2  "($0
M@ \  'P-  !Y"0$ > ,+ '4 $0!S !H <  C &X!*P!L 3, :@(Y &D#0 !G
M T8 9@1, &4$4@!C!5D 8@5A & %:@!?!G0 70:! %P'CP!:!Y\ 60>P %<'
MQ@!6">< 5@K[ %4*_P!5"O\ 5@K_ ,85  "M%P  F1@  (H8  !_%P  =A8
M '$3  !N$   ;0T% &T)#0!J"10 9PH= &4*)@!C"RX 8@PU & ,/ !?#$(
M7@U( %P-3P!;#58 60U> %@.: !6#G, 50Z  %,.CP!1#I\ 4 ZQ $X.R !-
M$.H 31#] $T0_P!-$/\ 31#_ +P;  "E'   DAT  (,>  !W'0  ;QP  &D:
M  !F%P  9!0  &00" !B#Q  7Q 8 %T0(0!;$2D 6A$Q %@2. !7$CX 5A)%
M %023 !3$U, 41-; % 390!.%'  3!1] $L4C !)%)P 1Q6N $85Q0!%%>@
M11;^ $46_P!%%?\ 117_ +4?  ">(0  BR(  'PB  !Q(@  :"$  &(?  !?
M'0  7!H  %L7 @!:%0T 5Q84 %46'0!4%R4 4A@M %$8- !/&#L 3AE" $T9
M2 !+&E  2AI8 $@:8@!'&FT 11MZ $,;B0!"&YH 0!NL #\;P@ ^'.4 /1S\
M #X<_P ^&_\ /AO_ *\C  "8)   AB4  '<F  !L)@  8R4  %TD  !9(@
M5A\  %0=  !3' L 41P2 $X=&@!-'2( 2QXI $H>,0!)'S< 1Q\^ $8@10!%
M($T 0R!5 $(@7P! (6H /R%W #TAAP [(9@ .2&J #@BP  W(N, -R+[ #<B
M_P X(?\ ."'_ *HF  "4)P  @2D  ',I  !G*0  7RD  %@H  !4)@  42,
M $\B  !,(@< 2B(0 $@B%P!'(Q\ 120F $0D+@!")#0 024[ $ E0P _)4H
M/293 #PF7  Z)F< .29U #<GA  U)Y8 -">H #(GO@ Q)^$ ,2?Y #(F_P R
M)O\ ,R7_ *4I  "/*@  ?2P  &\L  !D+0  6RP  %4K  !0*@  3"@  $HF
M  !')P0 1"<- $(H% !!*!P /RDC #XI*P ]*3( /"HY #LJ0  Y*D@ ."M0
M #8K6@ U*V4 ,RMR #$K@@ P+)0 +BRG "PLO  K+-X +"SX "PK_P M*O\
M+2K_ *$L  "++0  >2X  &LO  !@+P  6"\  %$N  !,+@  2"P  $4K  !!
M*P  /RP+ #TL$0 [+1D .BXA #DN*  W+B\ -B\V #4O/@ T+T4 ,R]. #$P
M6  P,&, +C!P "PP@  J,)( *3"E "<PN@ F,-P )C#W "<O_P H+_\ *"[_
M )PN  "',   =C$  &@R  !=,@  53(  $XQ  !(,0  1#   $ O   \,
M.C$) #<Q$  V,A8 -3(> #,S)0 R,RP ,3,S # T.P O-$, +31, "PT5@ J
M-6$ *35N "<U?@ E-9  (S6C "(UN0 A-=D (33V "(T_P C,_\ (S+_ )@Q
M  "#,P  <C0  &4T  !:-0  434  $LT  !%-   0#0  #HS   W-   -#4&
M #(V#@ P-Q, +S<; "XW(@ M."D *S@Q "HX.  I.4  *#E) "8Y4P E.5\
M(SEL "$Z?  @.HX 'CJB !PZMP ;.=4 '#GU !TX_P =./\ 'C?_ ),T  !_
M-@  ;C<  &$W  !7-P  3C<  $@W  !"-P  /#<  #4X   R.0  +SH" "P[
M"P J/!$ *3P8 "@]'P F/28 )3TN "0]-0 C/CT (CY& " ^4  ?/EP '3]I
M !L_>0 :/XP &#^@ !8_M0 5/M( %C[S !<]_P 8//\ &#S_ (XW  !Z.
M:CD  %XZ  !3.@  2SH  $4Z   _.@  .3H  #(\   N/@  *4   "9!"  D
M0@X (D(4 "%"&P @0R, 'T,J !Y#,@ <0SH &T1# !I$30 81%D %T1G !5$
M=P 31(H $D2> !%$LP 01-  $$/R !%"_P 20O\ $T'_ (D[  !V/   9CT
M %H]  !0/0  2#T  $(]   \/0  -CX  "]    J0@  )40  "%& P =2 P
M&TD1 !E)%P 821X %TDF !9)+@ 52C8 %$I  !-*2@ 12E8 $$ID  ]*=  .
M2H< #4J;  Q*L  *2LH "TGL  Q(_P -1_\ #4?_ (,^  !Q/P  8D   %9
M  !-0   14   #]    Y00  ,D(  "M%   F1P  (4D  !Q+   63@< $U .
M !)0$P 14!D $% A  ]0*0 .4#$ #5 [  U11@ +45$ "E%?  E1;P '4($
M!5"6  -0JP "4,4  T_H  -/^P %3O\ !DW_ 'U"  !K0P  740  %)$  !*
M1   0T,  #Q$   U10  +D<  "=*   A3   '$\  !=1   25 , #E<*  M8
M$  *6!4 "%@<  =8)  &6"P !5@V  -80  !6$P  %A:  !8:0  6'P  %B1
M  !7IP  5\   %;E  !6^0  5?\  %7_ '9'  !F1P  64@  $]'  !'1P
M0$<  #A(   P2@  *4T  ")0   <4P  %E4  !%8   -6P( "5X)  1?#@
M7Q(  %\8  !@'P  8"<  & P  !@.P  8$<  &!4  !@8P  8'8  &"+  !?
MH@  7[L  %_B  !>^0  7?\  %W_ &]+  !A3   54P  $Q+  !$2P  .TP
M #).   K40  (U0  !Q7   66P  $5X   U@   (8P   F8'  !G#   9P\
M &@3  !I&0  :B$  &HI  !J-   :D   &I-  !J70  :F\  &J%  !JG0
M:;8  &C=  !H]P  9_\  &;_ &E1  !<4   4E   $I/   _4   -5,  "U6
M   D60  '5T  !9@   09   #&<   9J    ;@   &\#  !P"   <0T  '(0
M  !T%   =1L  '8C  !W+   =S@  '9&  !V5@  =F@  '9^  !VEP  =;$
M '33  !S]0  <_\  '+_ &-6  !850  4%0  $15   Y6   +UL  "9?   =
M8P  %6<  !!L   *<   !',   !V    >@   'P   !\ P  ?@@  '\,  "!
M$   @A0  (0;  "%)   AB\  (8]  "&30  A5\  (5U  "%CP  A*D  (/)
M  ""\0  @?\  (#_ %];  !66@  25L  #U>   R80  )V8  !YK   5<
M#G4   EY   !?@   ($   "%    B    (H   "+    C0$  (X&  "0"P
MD0\  ),4  "5&P  ER8  )<T  "71   EU8  )9L  "5A@  E:(  )3!  "3
MZ@  DO\  )+_ %UA  !/80  0F0  #9I   J;@  'W0  !5Y   .?P  !X0
M  ")    C@   )(   "6    F    )H   ";    G0   )\   "A P  HP@
M *4-  "G$P  J1P  *HH  "J.0  JDL  *IA  "I>@  J)D  *BU  "GW0
MI_@  *;_ %9H  !(;   .G   "YV   B?0  %X0   Z*   'D    )8   ":
M    GP   *,   "G    J@   *L   "M    KP   +$   "S    M0   +@%
M  "Z#   O1(  , <  # +0  P$   +]5  "_;@  OHL  +ZH  "^R0  O>\
M +S^ $YT  ! >0  ,G\  "6'   9C@  $)4   ><    H@   *<   "L
ML    +4   "Y    O    +T   "_    P0   ,,   #&    R    ,H   #-
M @  T L  -42  #6(0  US0  -A)  #98   VGP  -J:  #;M0  V]D  -OR
M $:"   XB0  *Y   !V8   2H   "J<   "N    M    +D   "^    P@
M ,@   #+    S@   ,\   #2    U    -8   #:    W0   -\   #B
MY@   .H*  #O$P  \"4  /(Z  #S40  ]&L  /2)  #UI0  ];\  /7= /\
M!@#_  , _P % /\ "P#_ !  _P 7 /\ (@#_ "T _P Y /\ 1 #_ $T _P!5
M /\ 70#_ &0 _P!J /\ < #] '8 ^P!\ /D @P#W (H ]0"2 /, FP#P *8
M[@"S .L Q #I .0 YP#Y .8 _P#E /\ TP#_ ,< _P"_ /\ NP#_ /\   #_
M    _P   /\  @#_  L _P 2 /\ '0#_ "@ _P S /\ /@#\ $< ^ !/ /0
M5P#Q %T [@!C .P :0#J &\ Z !U .8 ? #D (, X@"+ -\ E0#< )\ V0"K
M -4 NP#2 -0 SP#R ,T _P#, /\ Q0#_ +H _P"T /\ L #_ /\   #_
M_P   /\   #_  8 ^0 / /4 %P#S "( \0 M .T -P#G $  X@!) -\ 4 #;
M %< UP!= -0 8P#1 &@ SP!N ,P =0#* 'P R "$ ,4 C0#" )@ P "D +T
ML@"[ ,8 N0#H +@ _0"W /\ M@#_ *T _P"G /\ HP#_ /\   #_    _P
M /4   #K  $ Y  , -X $P#9 !P TP F -$ , #, #H R !" ,0 2@#  %
MO0!6 +L 7 "Y &$ MP!G +4 ;0"S '0 L0!\ *\ A0"M )  J@"< *@ J@"F
M +L I0#: *, ]0"C /\ H@#_ )X _P": /\ EP#_ /\   #^    [P   -\
M  #0    QP ' ,$ #P"\ !< N0 @ +< *@"U #, L  [ *T 0P"K $D J !/
M *8 50"D %H HP!@ *$ 9@"? &T G0!T )P ?0": (@ F "4 )8 H@"4 +(
MD@#) )$ ZP"1 /\ D #_ )  _P", /\ B@#_ /P   #L    V0   ,<   "Z
M    L0 " *L # "G !( I  ; *$ ) "@ "P G@ U )L / "8 $, E@!) )0
M3P"2 %0 D !: (\ 7P"- &8 BP!M (D =@"( (  A@", (0 F@"" *H @0"^
M (  X "  /D ?P#_ '\ _P!_ /\ ?@#_ /$   #8    P@   +,   "H
MH    )D !P"5  X D@ 5 )  '@". "8 C0 N (H -@"' #T A0!# (0 20""
M $X @0!4 '\ 60!^ &  ? !G 'H ;P!Y 'H =P"& '4 E !T *, <@"U '(
MSP!Q /$ < #_ '  _P!P /\ <0#_ .$   #$    L    *(   "7    D0
M (L  @"&  L @P 1 ($ & !_ "$ ?0 I 'P , !Y #< >  ] '8 0P!T $D
M<P!. '( 5 !P %H ;P!B &T :@!K '0 :@"  &@ C@!G )T 90"O &4 Q@!D
M .@ 9 #] &, _P!C /\ 9 #_ ,\%  "V!P  HP@  )0(  ")!P  @@,  'X
M  ![  8 =P . '4 $P!R !L <0 C &\ *P!M #( ;  X &H /@!I $0 9P!)
M &8 3P!E %8 8P!= &( 90!@ &\ 7P![ %T B0!< )D 6P"J %D OP!9 .$
M6 #X %@ _P!8 /\ 60#_ ,(,  "J#0  EPX  (D.  !]#@  =@T  '$*  !O
M!@  ;0 * &L $ !I !8 9P > &4 )@!C "T 80 S &  .0!? #\ 70!% %P
M2P!; %( 6@!9 %@ 8@!7 &P 50!X %, A@!2 )8 40"G %  NP!/ =L 3@+T
M $X#_P!.!/\ 3@/_ +@0  "A$@  CA,  '\3  !T$P  ;!(  &<0  !E#@
M8PL# &,&# !A!!$ 7@,9 %P$(0!;!2@ 608O %@&-0!6!SL 50=" %0'2 !3
M"$\ 40A6 % )7P!."6D 30EV $L*A !)"I0 2 JF $<*N@!&"M@ 10OS $4,
M_P!%#/\ 10S_ + 4  "9%@  AQ@  '@9  !M&   91<  %\6  !<$P  6A$
M %H.!@!:# T 5PP4 %4,' !3#20 4@TK % -,0!/#C@ 3@X^ $T.10!+#DT
M2@Y5 $@/7@!'#V@ 10]U $,0A !!$)4 0!"F #X0NP ]$-P /1'V #T1_P ]
M$/\ /A#_ *D9  "2&P  @1P  '(=  !G'0  7QP  %D;  !5&0  4Q8  %(3
M  !2$0H 4! 0 $X1& !,$2  2A(G $D2+@!($S0 1Q,[ $430@!$$TD 0Q12
M $$46P _%&4 /A5R #P5@0 Z%9( .!6D #<5N0 U%=@ -1;U #86_P V%O\
M-Q7_ *,<  "-'@  >R   &TA  !B(0  6B$  %0?  !0'@  31L  $P9  !+
M%@8 218. $<7%0!%%QP 1!@D $(8*@!!&#$ 0!DX #\9/P ]&48 /!I/ #H:
M6  Y&F, -QMO #4;?@ S&Y  ,ANB # ;MP O&], +QSS "\;_P P&_\ ,!O_
M )T?  "((@  =R,  &DD  !>)   5B0  % C  !+(@  2"   $8=  !%' (
M0QP, $$<$@ _'1D /ATA #P>)P ['BX .A\U #D?/  W'T0 -A], #0@5@ S
M(&  ,2!M "\@?  M(8X +"&@ "HAM0 I(=  *2'R "DA_P J(/\ *R#_ )DB
M  "$)0  <R8  &4G  !;)P  4R<  $PF  !')0  1"0  $(A   _(0  /2$)
M #LA$  Y(A8 ."(> #8C)0 U(RL -"0R #,D.0 R)$$ ,"1* "\E4P M)5X
M*R5K "HE>@ H)8P )B6? "0ELP C)<X (R7P "0E_P E)/\ )23_ )0E  "
M)P  ;RD  &(J  !7*@  3RH  $DI  !$*   0"<  #TF   Z)0  -R8& #4F
M#@ T)Q0 ,B<; #$H(@ P*"D +R@P "TI-P L*3\ *RE' "DI40 H*EP )BII
M "0J>  C*HH (2J= !\JL@ >*LP 'BKO !\I_P @*?\ (2C_ ) H  !\*@
M;"L  %\L  !4+   3"P  $8L  !!*P  /"L  #@J   U*@  ,BL# # K#  N
M+!$ +2P8 "PL'P J+28 *2TM "@M-  G+CP )BY% "0N3P C+EH (2]G !\O
M=@ =+X@ '"^; !HOL  8+\H &"[M !DN_P ;+?\ &RW_ (PK  !X+0  :"X
M %LO  !1+P  22\  $,O   ^+@  .2X  #0N   P+@  +2\  "LP"@ I,1
M)S$5 "8Q'  E,B, )#(J ",R,0 A,SD (#-" !\S3  =,U< &S-D !HT=  8
M-(8 %C2: !0SK@ 3,\@ $S/L !0S_P 5,O\ %C'_ (<N  !T+P  93$  %@Q
M  !.,@  1C(  $ Q   [,0  -C$  #$Q   K,P  *#0  "4U!@ C-@T (382
M " W&0 ?-R  'C<G !TX+@ ;.#8 &C@_ !DX20 7.54 %3EB !0Y<0 2.80
M$3F8 ! YK0 ..,< #CCK ! X_P 0-_\ $3;_ (,Q  !P,@  830  %4T  !+
M-   1#0  #TT   X-   ,S0  "TU   H-P  )#D  " Z @ =.PL &SP0 !D]
M%0 8/1P %STC !8]*P 5/C, %#X\ !(^1@ 1/E( $#Y?  \^;P ./H$ ##Z5
M  L^J0 */L$ "CWD  L]^P ,//\ #3O_ 'TT  !K-@  73<  %$W  !(-P
M03<  #LW   U-P  ,#<  "HY   E.P  (#T  !P_   7008 %$,- !)#$@ 1
M0Q@ $4,? !!$)P /1"\ #D0Y  U$0P ,1$X "T1;  E$:@ '1'P !D20  1#
MI0 "0[T  T/@  -#]@ $0O\ !D'_ '@X  !G.0  63H  $XZ  !%.@  /CH
M #@Z   S.@  +3L  "<]   A0   '$(  !=$   31@, #TD*  U*#P ,2A0
M"TH;  E*(P (2BL !THT  5*/@ $2DD  DI6  !*90  2G<  $J+  !*H0
M2;D  $G=  !)]0  2/\  $C_ '(\  !B/0  53X  $H^  !"/0  /#T  #8]
M   O/@  *4   "-"   =10  %T<  !-*   /3 ( "T\)  =0#0 #41$  %$7
M  !1'@  428  %$O  !1.0  440  %)1  !28   47(  %&'  !1G0  4;4
M %#8  !0]0  3_\  $__ &Q   !=00  44$  $=!  ! 0   .4   #)!   J
M0P  )$8  !Y(   72P  $DX   Y1   +4P$ !E8'  !7#   6!   %@3  !9
M&0  6B$  %HI  !:,P  6C\  %I,  !:6@  6FP  %J!  !9F0  6;$  %C1
M  !8]   5_\  %?_ &5%  !810  344  $5$   ^1   -44  "U'   E2@
M'DT  !A0   24P  #E8   I9   $7    %X$  !?"0  8 T  &$0  !B%0
M8QL  &0C  !D+0  9#@  &1%  !D5   9&8  &1[  !CDP  8ZT  &+,  !A
M\@  8?\  &#_ %]*  !32@  2DD  $-(   Y20  +TP  "=/   ?4@  &%4
M !)9   -70  "&    )C    9@   &@!  !I!0  :@H  &L-  !M$0  ;A8
M ' =  !Q)@  <3$  ' ^  !P3@  <%\  '!S  !OC0  ;Z<  &[&  !M[P
M;/\  &S_ %I/  !03@  2$T  #U.   S40  *50  "!8   87   $6    QD
M   &:    &L   !O    <@   '0   !U    =P0  '@)  !Z#0  ?!   'T6
M  !_'@  @"@  ( U  " 10  ?U8  ']K  !_A   ?J   'V^  !\Z0  >_\
M 'K_ %94  !.4P  0E0  #=6   L6@  (E\  !AC   1:   "VT   -R
M=@   'H   !]    @    (,   "$    A@   (<"  ")!P  BPP  (T0  "0
M%@  DA\  )(L  "2.P  DDT  )%B  "1>@  CY<  (^T  ".X0  C/L  (S_
M %59  !(6@  .UT  "]A   D9@  &6P  !%R   *=P   GT   ""    A@
M (L   ".    D0   ),   "5    EP   )D   ";    G00  )\*  "B#P
MI!8  *8A  "F,0  ID,  *57  "D<   HXX  *.K  "AT   H/4  )__ $YA
M  ! 9   ,VD  "=N   ;=0  $7P   N#    B0   (X   "3    F    )T
M  "A    I    *4   "G    J0   *L   "M    L    +(   "U"   N X
M +P6  "\)0  O#<  +M,  "Z9   N8$  +>B  "WP   M^H  +?\ $9K   Y
M<   *W<  !]_   3A@  "XX   &5    FP   *$   "F    JP   +    "S
M    MP   +<   "Z    O    +\   #!    Q    ,<   #*    S04  -$.
M  #4&0  U"L  -1   #36   TW0  -.2  #2L   TM,  -+R #YY   Q@
M(X@  !>1   -F0   Z    "G    K@   +,   "X    O0   ,(   #&
MR@   ,H   #-    SP   -(   #5    V0   -T   #?    XP   .<%  #K
M#P  [!\  .TS  #N2P  [V0  .^"  #PGP  \;D  /'8 /\   #_    _P $
M /\ "0#_  X _P 5 /\ '@#_ "D _P T /\ /P#_ $@ _P!0 /\ 6 #_ %X
M_P!E /T :P#[ '$ ^0!W /@ ?@#V (4 \P"- /$ EP#N *( ZP"O .@ P #F
M .  XP#X .( _P#; /\ RP#_ ,$ _P"Y /\ M #_ /\   #_    _P   /\
M  #_  D _P 0 /\ &0#_ ", _P N /T .0#Y $( ]0!* /( 4@#N %@ ZP!>
M .D 9 #F &H Y !P .( =@#? 'T W0"& -D CP#5 )H T0"G ,X M@#+ ,X
MR0#P ,< _P#% /\ NP#_ +0 _P"M /\ J0#_ /\   #_    _P   /\   #[
M  ( ]@ - /$ $P#M !X [  H .D ,@#C #L W0!$ -@ 2P#3 %$ T !8 ,T
M70#+ &, R0!H ,8 ;P#$ '8 P@!^ +\ AP"\ )( N@"? +< K0"U ,$ L@#D
M +$ _0"O /\ K #_ *4 _P"@ /\ G #_ /\   #_    ^P   .X   #D
MW  ( -, $ #/ !@ RP B ,D *P#& #0 P0 ] +T 1 "Z $L MP!1 +4 5@"R
M %P L !A *X 9P"L &X J@!V *@ ?P"F (H HP"6 *$ I0"? +8 G0#1 )P
M\P"; /\ G #_ )8 _P"3 /\ D #_ /\   #V    YP   -,   #&    O0 #
M +@ #0"S !, L0 < *\ )0"N "X J0 V *8 /0"C $0 H0!* )\ 3P"= %4
MFP!: )H 8 "8 &8 E@!N )0 =P"2 ($ D ". (X G ", *T B@## (D Z "(
M /\ B0#_ (< _P"% /\ @@#_ /,   #C    S    +P   "P    IP   *$
M" ">  \ FP 6 )D 'P"8 "< E@ O ), -P"1 #T C@!# (P 20"+ $X B0!4
M (< 60"% &  A !G (( ;P"  'H ?@"& 'P E !Z *0 >0"X '@ V !W /<
M> #_ '@ _P!W /\ =0#_ .8   #+    MP   *@   ">    E@   (\ ! "+
M  P B  2 (< &0"% "$ A  I (( , !_ #< ?0 ] 'P 0P!Z $@ >0!- '<
M4P!V %D = !A '( :0!Q ', ;P!_ &T C0!L )T :@"O &D R !H .T :0#_
M &D _P!I /\ :0#_ -(   "X    I0   )<   "-    A@   ($   !\  @
M>0 . '< % !V !P =  C ', *P!Q #$ ;P W &X /0!L $, :P!( &H 3@!H
M %0 9P!; &4 8P!C &T 8@!X &  AP!? )8 70"H %T O@!< .0 7 #[ %P
M_P!< /\ 7 #_ ,(   "J 0  F ,  (D$  !_ @  >    '0   !P  0 ;0 ,
M &L $0!I !< :  > &8 )0!E "P 8P R &( . !@ #T 7P!# %X 20!< $\
M6P!6 %H 7@!8 &@ 5P!S %4 @0!4 )$ 4@"C %$ MP!1 -8 40#U %$ _P!1
M /\ 4@#_ +8'  "?"0  C0L  'X,  !S"P  ; H  &@'  !E P  8P ' &$
M#0!? !, 70 : %P (0!; "< 60 M %@ ,P!6 #D 50 _ %0 10!3 $L 40!2
M %  6@!/ &0 30!O $P ?0!* (T 20"? $@ L@!' ,P 1P#O $8 _P!' /\
M1P#_ *P,  "5#@  @Q   '40  !K$   8P\  %X.  !;#   6@D" %D$"@!7
M  \ 50 5 %, ' !2 ", 40 I $\ +P!. #4 30$[ $P!00!* D@ 20)/ $@"
M5P!& V$ 10-M $,#>@!" XL 0 .< #\#KP ^ \@ /03J #T%_  ]!O\ /@;_
M *00  ".$@  ?!,  &X4  !D%   7!,  %82  !3$0  40X  % ,!0!0"0P
M3P<1 $T'%P!+"!\ 20@E $@)*P!'"3$ 1@DX $0*/@!#"D4 0@I- $ +50 _
M"U\ /0MK #P+>0 Z#(H . R< #<,KP U#,< -0SI #4-_0 U#?\ -@S_ )T3
M  "'%0  =A<  &D8  !>&   5A@  % 7  !-%0  2A,  $D1  !)#@< 2 T.
M $8-$P!$#1H 0PXA $(.* ! #BX /PXU #X//  ]#T, .Q!+ #H05  X$%X
M-A!K #00>0 R$(H ,1"< "\0L  M$,D +1'L "T1_P N$?\ +Q#_ )<6  ""
M&0  <1L  &0<  !9'   41P  $P;  !'&@  1!@  $,5  !"$P( 01(+ $ 1
M$  ^$A< /!(> #L3)0 Z$RL .!,R #<3.0 V%$  -!1( #,440 Q%%P ,!5H
M "X5=P L%8@ *A6: "@5K@ G%<< )A7J "<5_P H%?\ *17_ )$:  !]'
M;1X  & ?  !6'P  3A\  $@>  !#'0  0!P  #X:   ]&   .Q<' #D6#@ X
M%Q0 -A<; #48(@ S&"@ ,A@O #$9-@ P&3T +AE& "T:3P K&ED *AIF "@:
M=  F&H8 )!J9 "(:K0 A&L4 (!KH "$:_@ B&O\ (QK_ (T=  !Y'P  :2$
M %PB  !2(@  2B(  $0A   _(0  /"   #D>   X&P  -1P$ #0<#0 R'!(
M,!T8 "\='P N'24 +1XL "L>,P J'CL *1]# "<?30 F'U< )!]D "(?<@ @
M'X0 'Q^7 !T?JP ;'\, &Q_G !L?_0 ='_\ 'A[_ (D@  !U(@  92,  %DD
M  !/)0  1R4  $$D   \(P  .",  #4B   S(   ," ! "XA"@ L(1  *R$5
M "HB'  H(B, )R(I "8C,  E(S@ (R-! "(D2@ A)%4 'R1A !TD<  ;)((
M&225 !<DJ@ 6),$ %23E !8D_  7(_\ &2/_ (4B  !Q)   8B8  %8G  !,
M)P  1"<  #XG   Y)@  -28  #$E   N)   *R4  "DE!P G)@X )283 "0G
M&0 C)R  (B<G "$H+@ @*#8 'B@^ !TH2  ;*5, &2E? !@I;@ 6*8  %"F4
M !(IJ  1*<  $2CD !$H^P 3*/\ %"?_ ( E  !N)P  7R@  %,I  !)*@
M0BD  #LI   V*0  ,B@  "XH   J*   )BD  "0J!  B*PP ("L1 !\L%@ =
M+!T '"PD !LM*P :+3, &"T\ !<M10 6+E  %"Y= !(N;  1+GX $"Z2  XN
MIP -+;T #2W?  TM^0 .+/\ $"S_ 'PH  !J*@  6RL  % L  !&+   /RP
M #DL   T*P  +RL  "LK   F+   (BX  !\O   <, D &C$. !DQ$P 7,1H
M%C(A !4R*  4,C  $S(Y !(S0P 1,TX $#-;  XS:0 -,WH ##..  HSH@ (
M,KD "#+9  @R]  *,?\ "S'_ '<K  !F+0  6"X  $TO  !#+P  /"X  #8N
M   Q+@  +2X  "DN   C,   'S(  !LS   7-04 %#8, !(W$0 1-Q8 $3<=
M ! X)  /."P #C@U  TX/P ,.$H "SA7  DX90 '.'8 !3B*  ,XGP !-[4
M 3?3  (W\0 #-O\ !3;_ ',N  !B,   5#$  $DQ  !!,0  .3$  #0Q   O
M,   *S   "4R   @,P  &S8  !<X   3.@( $#P)  T]#@ ,/1, "ST9  H]
M(0 )/2D "#TQ  8^.P %/D8  SY2  $^80  /G(  #Z&   ]G   /;(  #W0
M   \\   //\  #S_ &TR  !=,P  4#0  $8T   ^-   -S0  #(S   M,P
M)S0  "(V   =.   &#H  !0]   0/P( #4$(  E##0 &1!$  T06  )$'0
M1"0  $0M  !$-@  1$$  $1.  !$7   1&T  $2!  !$F   0Z\  $/-  !"
M\   0O\  $+_ &@V  !8-P  3#@  $,X   [-P  -38  # V   I-P  (SD
M !X[   8/0  $T   !!"   -10$ "$<'  -)#   20\  $H3  !+&0  2R
M $LH  !+,@  2ST  $Q)  !,5P  2V@  $M]  !+E   2JP  $K*  !)[P
M2?\  $G_ &(Z  !4.P  23L  $ [   Y.@  ,SD  "PZ   E/   'S\  !E!
M   31   $$<   Q)   (3    D\%  !0"@  4 T  %$0  !2%0  5!L  %0C
M  !4+   5#<  %1$  !44@  5&,  %1W  !4CP  4Z@  %+&  !2[0  4?\
M %'_ %P_  !//P  13\  #X^   W/0  +SX  "=    @0P  &48  !-)   /
M3   "T\   92    5    %<"  !8!P  60L  %H.  !;$0  718  %X=  !?
M)@  7S$  %X]  !>3   7ET  %YQ  !=B0  7:,  %S!  !;ZP  6O\  %K_
M %9$  !+0P  0T(  #Q!   R0@  *44  "%(   :2P  $TX   Y2   *50
M UD   !;    7@   &    !B @  8P8  &4*  !F#@  :!$  &H7  !K'P
M:RD  &LV  !K10  :U8  &IJ  !J@@  :9T  &B[  !GYP  9O\  &7_ %%(
M  !(2   048  #='   L2@  (TT  !M1   350  #ED   A=   !80   &0
M  !G    :@   &P   !N    <    '(%  !S"0  =0T  '<1  !Z&   >R$
M 'LN  !Z/0  >DX  'EB  !Y>0  >)8  '>S  !UX   =/P  '/_ $Y-  !'
M3   .TT  #!/   F4P  '%@  !-<   -80  !F8   !J    ;P   '(   !V
M    >0   'P   !]    ?P   ($   "# @  A@<  (@,  "+$0  CA@  (XD
M  ".,P  C40  (Q8  "+;P  BHP  (FJ  "(SP  AO<  (7_ $U1  !!4P
M-%4  "E:   >7P  %&4   UJ   %<    '8   ![    ?P   (,   "'
MB@   (T   ".    D0   ),   "5    F    )H%  "=#   H!$  *,:  "C
M*   HCH  *%.  "@90  H($  )Z@  "=P0  F^X  )K_ $99   Y7   +6$
M "%G   6;@  #G4   5[    @0   (<   "-    D@   )8   ":    G0
M )\   "A    I    *8   "H    JP   *X   "Q P  M L  +@1  "Y'@
MN2\  +A#  "W6@  M78  +27  "TM0  L>(  +#\ #]D   Q:0  )6\  !AW
M   /?P  !H<   ".    E    )H   "@    I0   *H   "N    L0   +(
M  "U    MP   +H   "\    OP   ,,   #&    R0   ,X*  #2$P  TB,
M -$W  #03P  SFH  ,V*  #*JP  R\L  ,OO #=Q   I>   '8   !&)   (
MD0   )H   "A    IP   *T   "S    N0   +X   #"    Q0   ,8   #)
M    S    ,X   #2    U0   -H   #>    X0   .4   #J"P  ZQ<  .HK
M  #J0P  ZEX  .IZ  #KF0  Z[4  .O5 /\   #_    _P ! /\ !P#_  T
M_P 2 /\ &P#_ "4 _P O /\ .@#_ $, _P!+ /\ 4P#_ %H _0!@ /L 9@#Z
M &L ^ !R /8 > #T (  \0") .\ D@#L )T Z0"J .8 O #C -P WP#W -T
M_P#, /\ O@#_ +4 _P"P /\ K0#_ /\   #_    _P   /\   #_  8 _P -
M /\ % #_ !\ _P I /L ,P#W #T \P!% .\ 30#L %, Z !9 .4 7P#C &4
MX !J -T <0#: '@ U@"  -( B@#/ )4 S "B ,@ L@#% ,D P@#M ,  _P"[
M /\ L #_ *@ _P"D /\ H0#_ /\   #_    _0   /H   #X    \  ) .P
M$0#H !D YP C .4 +0#> #8 U@ ^ -$ 1@#- $P R@!2 ,@ 6 #% %T PP!C
M ,  :0"^ '  O !X +D @0"W (T M ": +$ J0"N +P K #A *H _ "H /\
MH #_ )D _P"6 /\ E #_ /\   #Y    \@   .<   #;    T0 $ ,H #0#'
M !0 Q  = ,( )@"_ "\ NP W +< /P"T $4 L0!+ *X 40"L %8 J@!< *@
M80"F &@ HP!P *$ >0"? (0 G0"1 )H H "8 +$ E@#, )4 \0"4 /\ D0#_
M (L _P"( /\ A@#_ /<   #L    W@   ,D   "\    M    *\ "@"K !
MJ0 7 *@ ( "G "@ H@ P )\ . "< #X F@!$ )@ 2@"6 $\ E !5 ), 6@"1
M &$ CP!H (T <0"+ 'L B0"( (< EP"% *@ @P"^ ($ Y "  /\ @ #_ 'P
M_P![ /\ >0#_ .D   #7    P0   +$   "F    G0   )< !0"4  T D@ 2
M )  &@"/ "( C@ J (L ,0") #@ AP ^ (4 0P"# $@ @0!. '\ 5 !^ %H
M? !A 'H :0!X ', =@!_ '4 C@!S )\ <0"S '  T !O /8 ;P#_ &\ _P!M
M /\ ; #_ -H   "_    K    )X   "3    C    (4   ""  D ?P / 'X
M%0!] !P ?  D 'H *P!W #$ =0 W '0 /0!R $( <0!( &\ 30!N %, ; !:
M &L 8@!I &P 9P!X &8 A@!D )< 8@"J &$ P@!@ .L 80#_ &$ _P!A /\
M8 #_ ,4   "M    FP   (T   "#    ?    '<   !R  4 <  , &X $0!L
M !< ;  > &L )0!I "P 9P Q &8 -P!D #T 8P!" &( 2 !@ $X 7P!5 %T
M70!< &8 6@!R %D @ !7 )  5@"C %4 N0!4 -X 5 #[ %0 _P!5 /\ 50#_
M +8   "?    C0   '\   !U    ;@   &D   !F  $ 8P ) &$ #@!@ !,
M7P 9 %X ( != "8 6P L %H ,@!8 #< 5P ] %8 0P!5 $D 4P!0 %( 6 !1
M &$ 3P!L $X >@!, (H 2P"< $H L0!) ,X 20#S $D _P!) /\ 2@#_ *H!
M  "4!0  @@<  '0(  !J"   8P8  %X$  !;    60 % %< # !6 !  5  5
M %, &P!2 "( 40 H %  +0!. #, 30 X $P /@!+ $4 2@!, $@ 5 !' %T
M1@!H $0 =0!# (4 00"8 $  JP!  ,4 /P#J #\ _P!  /\ 0 #_ * (  "*
M"P  >0T  &P-  !A#0  6@T  %4+  !2"0  4 8  $\"" !.  T 3  2 $L
M%P!* !X 20 C $< *0!& "\ 10 T $0 .@!" $$ 00!( $  4  ^ %H /0!D
M #P <@ Z (( .0"4 #@ IP W +X -@#C #8 ^0 V /\ -P#_ )@-  "##@
M<A   &41  !;$0  4Q   $X0  !*#@  2 T  $<* P!'!PH 100. $0"$P!"
M AH 00(@ $ #)0 ^ RL /00Q #P$-P [!#X .@5% #D%3@ W!5< -@5B #0&
M<  R!H  ,0:2 # &I0 O!;L +@7= "X&]0 M!_\ +@?_ )$0  !]$0  ;!,
M %\4  !5%   3A0  $@3  !$$@  01   $ .  ! #08 0 H, #X)$  \"18
M.PH< #D*(@ X"B@ -PLN #8+-0 U"SL ,PM# #(,3  P#%8 +PQA "T,;P K
M#'\ *@R2 "@,I0 G#+L )0S= "4-]0 F#?\ )PW_ (L2  !W%   9Q8  %L7
M  !1&   21<  $,7   _%0  /!0  #H2   Y$0$ .0\( #@.#0 W#A( -0X8
M #0.'P R#B4 ,0\L # /,@ O$#H +1!" "P02P J$%4 *!!A "80;P D$(
M(Q"3 "$0IP ?$+T 'A#@ !X1]P ?$/\ (!#_ (84  !S%P  8QD  %<:  !-
M&P  11H  $ :   [&0  .!@  #46   T%   ,Q($ #(2"P Q$A  +Q(5 "T2
M'  L$R( *Q,I "H3,  H$S< )Q0_ "842  D%%, (A1? " 5;0 ?%7X '161
M !L5I0 9%;L &!7> !@5^  9%/\ &A3_ ((7  !O&@  7QP  %,=  !*'0
M0AT  #P=   W'   -!L  #$:   O&0  +A8  "P7"  K%@X *1<3 "@7&0 G
M&"  )1@F "08+0 C&#0 (AD] " 91@ >&5$ '1E= !L::P 9&GP %QJ/ !4:
MHP 4&;H $AG; !,9]@ 4&?\ %1C_ 'T:  !K'0  7!\  % @  !'(   /R
M #D?   T'P  ,1X  "T=   K'   *1L  "<;!0 E&PP )!P1 "(<%@ A'!T
M(!TC !\=*@ >'3( '!XZ !L>1  9'DX %QY; !8>:0 4'WH $AZ- !$>H@ 0
M'K@ #A[8  \>]0 0'?\ $1W_ 'H=  !G'P  62$  $TB  !$(@  /"(  #8B
M   R(0  +B$  "H@   G(   )!\  "(@ @ @( H 'B$/ !TA%  <(1H &R(A
M !DB)P 8(B\ %R(X !4C00 4(TP $B-8 !$C9P 0(W@ #B.+  TCGP ,([0
M"R/0  LB\  ,(O\ #2'_ '8?  !D(@  5B,  $LD  !!)   .B0  #0D   O
M(P  *R,  "@C   D(P  (",  !TD   ;)0< &28- !<F$0 6)A< %2<> !0G
M)0 3)RP $B<U !$H/P 0*$H #BA6  TH9  ,*'0 "BB'  DHFP ')[$ !2?,
M  8G[  ')OX "";_ '$B  !@)   4R8  $@G   _)P  -R8  #$F   M)@
M*24  "4E   B)0  '2<  !DH   6*@0 %"L+ !(L$  1+!0 $"P; ! L(@ .
M+"D #BTR  TM.P ++48 "BU2  @M8  &+7  !"V#  (MF   +*X  "S)   L
MZP !*_P  BO_ &TE  !=)P  3R@  $4I   \*0  -2D  "\H   K*   )R<
M ",G   ?*   &RH  !<L   3+@( $# (  XQ#0 -,1( ##$7  LQ'@ *,28
M"#(N  <R-P %,D(  S).  $R7   ,FP  #)_   RE0  ,:P  #''   PZ@
M,/P  ##_ &@I  !8*@  3"L  $$L   Y+   ,BL  "TK   I*@  )2H  " K
M   <+   %RX  !,P   0,@( #C0'  HW#  '-Q  !3<4  ,W&P "-R(  #<J
M   X,P  .#X  #A*   X6   .&@  #A\   WD@  -ZD  #;%   VZ@  -OT
M #7_ &,L  !4+@  2"\  #XO   V+@  ,"X  "LM   G+0  (BT  !TO   8
M,0  %#,  ! U   .-P$ "CH'  8["P "/ X  #T2   ^%P  /AX  #XF   ^
M+P  /CH  #Y&   ^5   /F0  #YW   ^CP  /:<  #W#   \Z0  //T  #O_
M %XP  !0,0  1#(  #LR   T,0  +C   "DO   D,   'C(  !DT   4-@
M$#D   T[   */0  !4 %  !!"@  0@T  $,0  !$%   11H  $8B  !&*P
M1C4  $9!  !&3P  1E\  $9S  !%B@  1:0  $3   !#Z   0_X  $+_ %@T
M  !+-0  034  #DU   R-   +3,  "8T   @-0  &C@  !0Z   0/0  #4
M  E"   $10   $<#  !(!P  2@L  $L.  !,$0  3A4  $\<  !/)0  3R\
M $\\  !/2@  3UH  $YM  !.A0  3:   $R\  !+YP  2_X  $K_ %,Y  !'
M.0  /CD  #<X   Q-P  *3<  "$Y   ;/   %3\  !!"   ,10  !T@   )*
M    30   $\   !1!   4@<  %0+  !5#@  5Q$  %D7  !:'P  62D  %DV
M  !91   650  %AG  !8?P  5YH  %:W  !5XP  5/T  %3_ $X]  !#/0
M/#P  #4[   L/   )#X  !Q!   51   $$@   M+   %3@   %$   !4
M5P   %D   !;    70(  %X&  !@"P  8@X  &02  !G&   9R(  &8N  !F
M/   9DT  &5@  !E=P  9),  &.Q  !AW0  8/P  %__ $E"  !!00  .C\
M #!    F0P  'D8  !5*   03@  "E(   -6    6@   %T   !@    8P
M &4   !G    :0   &L!  !M!0  ;PH  '(.  !U$@  =QL  '8F  !V-0
M=48  '19  !T;P  <XL  '*I  !PS0  ;_<  &[_ $9&  ! 10  -48  "I(
M   @3   %U$  !!6   )6@   5\   !C    :    &L   !O    <@   '4
M  !W    >0   'L   !]    @ ,  (,(  "&#0  B1,  (H=  "**P  B3P
M (A/  "&9@  A8$  (2@  ""P@  @?   '__ $9+   Z3   +D\  "-3   8
M6   $%X   ED    :0   &\   !T    >    'P   "!    A    (<   "(
M    BP   (X   "0    DP   )8   "9!P  G0T  *$4  "@(0  H#$  )Y$
M  "=6P  G'8  )F6  "9M0  EN4  )7^ #]2   R50  )EH  !M@   19P
M"6T   !T    >P   ($   "&    BP   )    "4    EP   )D   "<
MGP   *$   "D    IP   *H   "M    L08  +4-  "X%@  MR8  +8Y  "U
M4   M&H  +*)  "PJ@  KL\  *WU #=<   K80  'F@  !-P   +>    (
M  "'    C@   )4   ":    GP   *0   "H    K    *T   "P    LP
M +4   "X    NP   +\   ##    QP   ,L%  #1#@  T1L  - N  #/10
MS5\  ,M^  #)G@  R+X  ,7I "]I   C<   %GD   V!   !BP   ),   ";
M    H@   *@   "N    M    +@   "]    P    ,(   #%    R    ,L
M  #.    T0   -8   #;    WP   .0   #H!@  ZQ$  .HC  #J.@  Z50
M .=R  #EDP  X[,  ./4 /\   #_    _P   /\ ! #_  L _P 0 /\ %P#_
M "$ _P K /\ -0#_ #X _P!' /\ 3@#_ %4 _ !; /H 80#X &8 ]@!M /0
M<P#R 'L [P"$ .T C@#J )D Y@"G ., N0#? -4 VP#W -8 _P#  /\ L@#_
M *H _P"E /\ H@#_ /\   #_    _@   /P   #\  , _@ + /\ $0#_ !H
M_0 D /D +@#T #@ \ !  .P 2 #I $X Y@!4 .( 6@#? %\ W !E -@ :P#4
M '( T ![ ,T A0#* )$ QP"> ,, K@#  ,4 O0#K +L _P"P /\ I #_ )P
M_P"8 /\ E0#_ /\   #Z    ]    /$   #R    Z@ % .< #@#B !4 X0 >
M .$ * #8 #$ T  Y ,L 0 #( $< Q0!- ,( 4P"_ %@ O0!> +L 9 "Y &L
MM@!S +0 ? "Q (@ K@"5 *L I "H +@ I@#< *, ^P"? /\ E0#_ (\ _P"+
M /\ B0#_ /D   #O    YP   -\   #/    R    ,$ "@"_ !$ O  8 +L
M(0"Y "H M  R +$ .@"N $  JP!& *@ 3 "F %$ HP!6 *$ 7 "? &, G0!J
M )L <P"9 'X E@", )0 FP"2 *T D #' (X \ "- /\ A@#_ (  _P!] /\
M? #_ .T   #@    T0   +\   "S    J@   *8 !0"B  T H0 3 *  &P"?
M ", FP K )@ ,@"5 #D DP _ )$ 1 "/ $H C@!/ (P 50"* %L B !C (8
M:P"$ '8 @@"" (  D@!^ *, ? "Z 'H X0!Y /\ =P#_ '( _P!P /\ ;P#_
M -T   #+    M@   *<   "=    E    (X  0"+  H B0 0 (@ %0"' !T
MAP E (0 + "" #( ?P X 'T /0![ $, >0!( '@ 3@!V %0 =0!; ', 8P!Q
M &X ;P!Z &T B0!L )H :@"N &D S !H /8 9P#_ &4 _P!D /\ 8P#_ ,H
M  "T    H0   ),   ")    @@   'L   !X  4 =@ , '4 $0!T !@ <P ?
M '( )0!P "P ;@ R &P -P!J #P :0!" &@ 2 !F $X 90!5 &, 70!B &8
M8 !R %X @ != )( 6P"E %H O@!9 .D 60#_ %D _P!8 /\ 6 #_ +D   "B
M    D    (,   !Y    <0   &T   !I  $ 9@ ) &4 #@!D !, 8P 9 &,
M( !A "8 8  L %X ,0!< #< 6P \ %H 0@!8 $@ 5P!/ %8 5P!4 &  4P!L
M %$ >0!0 (H 3P"> $X M !- -H 30#[ $T _P!- /\ 30#_ *H   "4
M@@   '4   !K    9    &    !=    6@ % %@ # !7 !  5@ 5 %8 &P!5
M "$ 4P G %( + !1 #$ 3P W $X /0!- $, 3 !* $H 4@!) %L 2 !F $8
M<P!% (0 1 "7 $, K !" ,D 0@#Q $( _P!# /\ 0P#_ )X   ")    > ,
M &H$  !A!   6@,  %4!  !2    4  " $X "0!-  T 3  1 $L %P!* !P
M20 B $@ )P!' "T 10 R $0 . !# #X 0@!% $$ 30 _ %8 /@!A #T ;@ [
M 'X .@"1 #D I@ X +\ . #H #@ _P Y /\ .0#_ )4#  " !P  ;PD  &(*
M  !8"P  40H  $P(  !)!@  1P,  $8 !@!$  L 0P / $( $P!! !@ 00 >
M #\ (P ^ "D /0 N #L -  Z #H .0!! #@ 20 W %( -@!= #0 :@ S 'H
M,@", #$ H0 P +@ +P#> "\ ^0 O /\ , #_ (P)  !X#   : T  %P.  !2
M#@  2PX  $4-  !!#   /PH  #X( @ ]! @ / $- #L $  Z !4 .0 : #@
M(  V "4 -0 K #0 ,  S #< ,@ ^ #$ 1@ O %  +@!: "T 9P K '< *@")
M "D G0 H +, )P#1 "< \@ G /\ )P#_ (8,  !R#@  8Q   %81  !-$0
M11$  $ 0   \#P  .0X  #<-   V"P0 -@@* #4&#@ T!1( ,@07 #$%'  P
M!2( +P4H "X&+@ M!C0 *P8\ "H&1  I!TX )P=9 "8'90 D!W4 (P>' "('
MFP @!K  ( ;+ !\%[0 ?!OX 'P?_ ( .  !M$0  7A(  %(3  !($P  01,
M #L3   W$@  -!$  #(0   P#P$ , T& # +"P O"A  +0H4 "P+&0 J"Q\
M*0LE "@,*P G##( )@PZ "0,0P C#$T (0U8 " -90 >#74 ' V( !H-G  9
M#;$ & S* !<,ZP 7#?P & S_ 'L1  !I$P  6A4  $X6  !%%@  /18  #@5
M   S%0  ,!0  "T3   K$@  *A # "H/"  I#@T * X1 "8.%@ E#QT ) \C
M ",/*0 A$#$ (! Y !X00@ =$$P &Q!8 !D09@ 7$'8 %1") !00G@ 2$+,
M$1#. !$0[@ 2$/X $A#_ '<3  !E%0  5Q<  $L8  !"&0  .AD  #08   P
M%P  +!<  "D6   G%0  )A0! "42!  C$@L (A(/ "$2%  @$AH 'A,@ !T3
M)P <$RX &A,V !D40  7%$H %A16 !049  2%'0 $12' ! 4G  .%+$ #13*
M  T4ZP .$_X #A/_ ',5  !A&   4QH  $@;   _&P  -QL  #(:   M&@
M*1D  "88   D&   (A<  " 6 0 >%@@ '18- !L7$@ :%Q< &1<= !@8)  6
M&"L %1@T !08/0 2&4@ $1E4 ! 98@ .&7( #1F$  P9F  *&:T "1C&  D8
MYP )&/H "A?_ &\8  !>&@  4!P  $4=   \'0  -1T  "\=   J'   )AL
M ",;   A&@  'AH  !P:   :&P4 &!L, !8<$  5'!4 %!P; !,<(@ 2'2D
M$1TQ ! =.P .'44 #1Y1  P>7@ *'FT "1Z   <>E  %':H  QW"  ,=Y@ $
M'/@ !1S_ &L:  !;'0  31X  $(?   Z'P  ,A\  "T?   H'@  )!X  "$=
M   >'0  '!T  !@>   5'P( $R ) !(A#@ 0(1( $"$8  XA'P .(B8 #2(N
M  PB-P *(D$ "2)-  <B6@ %(FD  R)\  $BD0  (J@  "'    AY0  (/@
M "#_ &<=  !7'P  2B$  $ A   W(@  ,"$  "HA   F(   (B   !\?   <
M'P  &2   !8A   2(P( $"0'  XF#  ,)A  "R85  HF'  ))B( ""8J  8G
M,P $)ST  R=)  $G5@  )V8  "=Y   GCP  )J8  ":_   EY   )?D  "3_
M &,@  !4(@  1R,  #TD   T)   +B,  "@C   D(@  (2(  !XA   :(@
M%R,  !,D   0)@( #B@'  LJ"P (*PX !BL3  0K&  "*Q\  2PG   L,
M+#H  "Q%   L4P  +&,  "QV   LC   *Z0  "N^   JY   *OH  "G_ %\C
M  !0)0  1"8  #HF   R)@  *R8  "8E   C)   'R0  !LD   7)0  %"<
M !$I   .*P( "RT&  <O"P $, X  # 1   Q%0  ,1P  #$C   R+   ,C8
M #)"   R3P  ,E\  #)R   QB0  ,:(  #"\   PY   +_L  "__ %HG  !,
M*   0"D  #<I   O*0  *2@  "4G   A)@  '"<  !@H   4*@  $2P   XN
M   +, $ !S(%  ,T"0  -0P  #8/   W$@  .!@  #@@   X*   .#(  #D]
M   Y2P  .5L  #AN   XA0  -Y\  #>Z   VY   -?P  #7_ %4J  !(+
M/2P  #0L   M*P  *"H  "0I   >*@  &2L  !0M   1+P  #3$   HT   '
M-@   C@$   Z!P  .PH  #T-   ^$   0!0  $ ;  ! )   0"X  $ Y  !
M1P  0%8  $!I  ! @   /YL  #ZW   ]XP  //P  #S_ % O  !#+P  .2\
M #(O   L+0  )RP  " M   :+P  %3$  !$S   --@  "3@   4[    /0
M $ !  !!!   0P<  $4+  !&#@  2!$  $H6  !*'@  2B@  $HT  !)0@
M25$  $ED  !(>P  2)<  $>T  !&X   1?P  $3_ $HS   _,P  -C,  # Q
M   J,   (S$  !PS   6-0  $3@   T[   (/@   T$   !#    1@   $@
M  !*    3 0  $X'  !/"P  40X  %02  !5&0  52(  %0N  !4/   5$L
M %->  !3=   4I   %&N  !0UP  3_L  $[_ $4W   \-P  -38  "\T   F
M-0  'C<  !<Z   1/0  #$$   =$    2    $H   !-    4    %,   !5
M    5P   %@"  !;!@  70L  %\.  !B$P  8AL  &(G  !B-   844  &!7
M  !@;0  7XD  %VG  !<S   6O@  %G_ $$\   Z.P  -#D  "HZ   A/
M&$   !%#   ,1P  !DL   !/    4P   %8   !9    7    %\   !A
M8P   &4   !G 0  :@4  &T*  !P#@  <Q4  '(@  !R+0  <3T  '!/  !O
M90  ;H   &V?  !KP0  :?$  &C_ #]    Y/@  +C\  "1"   :1@  $DH
M  Q/   $5    %@   !=    80   &4   !H    :P   &X   !Q    <P
M '4   !X    >P   'X#  "!"@  A0\  (<7  "&)   A30  (1&  ""70
M@78  '^6  !^M@  ?.<  'K_ #]$   S10  *$@  !U,   34@  #%<   -=
M    8P   &@   !M    <0   '8   !Z    ?@   ($   "#    A@   (D
M  "+    C@   )(   "5 0  F0D  )X0  ">&@  G2D  )P\  ":4@  F&P
M ):+  "4J@  DM0  )#Z #A+   L3@  (%,  !59   -8    V<   !N
M=    'H   "     A    (H   ".    D@   )4   "7    F@   )T   "@
M    HP   *<   "K    KP   +0)  "X$   MQX  +4P  "S1@  L6   *]^
M  "LH   J\$  *GN #%5   D6P  &&$   YI   %<0   'D   "!    B
M (\   "4    F@   )\   "D    J    *D   "L    KP   +,   "U
MN0   +T   #!    Q@   ,L   #1"@  TQ0  -$E  #0.P  S50  ,IQ  #(
MD@  Q;,  ,/> "EB   <:0  $7$   =[    A    (T   "5    G0   *,
M  "I    KP   +0   "Y    O    +X   #"    Q0   ,@   #,    T
M -0   #:    WP   .0   #J    [@P  .T:  #L+P  ZDD  .AE  #FA@
MY*4  .+& /\   #_    _P   /P  0#\  @ _@ . /\ % #_ !T _P F /\
M, #_ #H _P!" /\ 20#^ %  ^P!6 /D 7 #V &( ] !H /( ;P#P '8 [0!_
M .H B0#G )4 Y "C .  M0#; -  U0#V ,H _P"V /\ J #_ )\ _P": /\
ME@#_ /\   #[    ]@   /,   #S    ]@ ) /H #@#] !8 ^P @ /< *@#R
M #, [0 [ .D 0P#F $D X@!/ -X 50#; %L U@!@ -( 9P#/ &X S !V ,D
M@ #& (P P@": +\ J@"[ ,$ N #I +8 _P"G /\ F@#_ )( _P"- /\ B@#_
M /H   #Q    Z@   .<   #G    Y  ! .  "P#; !$ V@ : -L (P#1 "P
MR@ T ,8 .P#" $( OP!( +P 3@"Z %, N !9 +8 7P"S &8 L0!N *X =P"L
M (, J0"1 *8 H0"C +4 H #8 )X ^P"5 /\ BP#_ (4 _P"  /\ ?@#_ .\
M  #C    V@   -,   #&    OP   +D !@"W  X M  4 +0 '0"S "4 K@ M
M *L - "G #L I !! *$ 1@"? $P G0!1 )L 5P"9 %X EP!E )4 ;@"3 'D
MD "' (X EP", *D B0#$ (@ [P"% /\ ? #_ '8 _P!S /\ <@#_ .    #0
M    Q@   +8   "I    H0   )T  0"9  H F  0 )@ %@"7 !X E  F )$
M+0"/ #0 C  Z (H /P"( $4 AP!* (4 4 "# %8 @0!> (  9@!^ '$ ? !]
M 'D C0!W *  =0"V ', WP!R /\ ;@#_ &D _P!G /\ 90#_ ,P   "^
MJP   )T   "3    B@   (4   ""  4 @  - '\ $0!_ !@ @  @ 'T )@!Z
M "T =P S '4 . !T #X <@!# '  20!O $\ ;0!6 &P 7@!J &@ : !U &<
MA !E )8 9 "K &( R0!A /8 8 #_ %P _P!; /\ 6@#_ +T   "I    EP
M (D   !^    >    ',   !O  $ ;0 ) &P #@!K !, :P 9 &H ( !H "8
M9@ L &4 ,@!C #< 8@ \ &  0@!? $@ 70!/ %P 5P!: &$ 60!M %< >P!6
M (X 50"B %, NP!2 .D 4@#_ %  _P!/ /\ 3P#_ *T   "8    A@   '@
M  !N    9P   &,   !@    70 % %P "P!; !  6P 5 %L &P!: "$ 6  F
M %8 + !4 #$ 4P V %( / !1 $( 3P!) $X 40!- %L 2P!F $H = !) (4
M2 "9 $< L0!& -@ 1@#\ $4 _P!% /\ 10#_ )\   ")    >    &P   !B
M    6P   %8   !3    40 " $\ " !/  T 3@ 1 $X %@!- !P 3  A $H
M)@!) "P 2  Q $< -P!% #T 1 !$ $, 3 !" %4 0 !@ #\ ;@ ^ 'X /0"2
M #P J0 [ ,< .P#S #L _P [ /\ / #_ ),   !^    ;@   &$   !8
M40   $P   !)    1P   $4 !0!$  L 0P . $, $@!# !< 0@ = $  (@ _
M "< /@ L #T ,@ [ #@ .@ _ #D 1P X %  -P!; #4 :  T '@ ,P", #(
MH@ Q +P ,0#G #$ _P R /\ ,P#_ (D   !V P  9@4  %D'  !0!P  208
M $,%  !  P  /@$  #P  P [  @ .@ - #H $  Y !0 .0 9 #< '@ V ",
M-0 H #0 +@ S #0 ,@ [ #  0P O $P +@!7 "T 9  L ', *P"' "H G  I
M +4 *0#< "D ^P I /\ *@#_ ($$  !N"   7PH  %,+  !*"P  0@L  #T*
M   Y"0  -@@  #4%   T @8 ,P * #( #@ Q !$ ,0 5 #  &@ O !\ +@ D
M "P *@ K #  *@ W "D /P H $D )P!4 "8 8  D &\ (P"" "( EP A *X
M(0#, "$ \P A /\ (@#_ 'L)  !H#   6@T  $X.  !%#@  /0X  #@-   S
M#0  , P  "X+   M"0, +08( "P$#  K @\ *@$2 "D!%P H 1P )P A "8
M)P E "T )  T ",!/0 B 48 (0%1 !\!70 > 6P ' %_ !L E  : *H &@#%
M !H ZP 9 /\ &@#_ '4,  !D#@  50\  $H0  ! $   .1   #,0   O#P
M+ X  "D.   G#0$ )PP% "<*"@ F" T )0<0 "0&%  B!AD (08? " ')  ?
M!RL '@<R !T'.@ <"$0 &@A/ !D(7  7"&L %@A] !4'D0 4!Z< $P:_ !(%
MY  2!?H $@7_ '$.  !?$   41$  $82   ]$@  -A(  # 2   K$0  *!$
M "40   C$   (@X$ "$-!P A# L ( L. !\+$@ ="Q< ' P< !L,(@ :#"D
M&0PQ !@,.0 6#4, %0U/ !,-7  2#6L $ U^  \-D@ .#:< #0R^  T,X  -
M#/4 #0S_ &T0  !<$0  3A,  $,4   Z%   ,A0  "T4   H$P  )1,  "(2
M   @$0  'A$# !P0!0 <#P@ &P\, !H.$  9#Q0 %P\: !8/(0 5$"@ %! P
M !(0.0 1$$0 $!!0  X070 -$&L #!!\  L0D  )$*4 "!"\  <0WP '$/0
M!P__ &D1  !8%   2Q4  $ 6   W%@  ,!8  "H6   F%0  (A4  !\4   =
M$P  &A," !D2!  7$@8 %A(* !42#@ 4$A( $A(8 !$3'@ 1$R4 $!,N  X3
M-P -%$  #!1+  L46  )%&< !Q1X  84C0 $%*,  Q.[  (3W0 !$O0  A+_
M &43  !5%@  2!<  #T8   T&   +1@  "@8   C%P  (!<  !T6   :%0
M&!4" !85!  4%04 $A8( !$6#0 0%Q  #A<5  X7&P -%R( #!<I  L8,@ )
M&#P !QA'  485  $&&,  AAU  $8BP  %Z$  !>Y   7W0  %O4  !;_ &$6
M  !2&   11H  #L:   R&@  *QH  "4:   A&0  'A@  !L8   8%P  %A<"
M !07 P 2& 4 $!D'  X;"P ,&P\ "QL3  H;&  ('!\ !QPF  4<+P $'#@
M AQ$   =40  '6   !UR   <B   '*   !NY   ;W@  &O8  !K_ %X8  !/
M&@  0AP  #@<   O'0  *1P  ",<   ?&P  '!H  !D9   7&0$ %!D" !(:
M P 0&P0 #AT'  P>"P )'PX !B 1  4@%@ #(!P  2$C   A*P  (34  "%
M   A3@  (5T  "%O   AA@  ()X  ""X   ?W@  'O@  ![_ %H;  !+'0
M/QX  #4?   M'P  )QX  "(=   >'0  &QP  !@;   5&P  $AP  ! = @ .
M'P0 #"$&  DB"@ %(PT  B00   E$P  )1D  "8@   F*   )C(  "8]   F
M2@  )EH  "9L   F@P  )9P  "6W   DWP  (_D  "/_ %4>  !'(   /"$
M #(A   K(0  )2   " ?   ='@  &AT  !8>   3'@  $"    XA   ,(P(
M""4%  4G"0  * L  "H.   K$0  +!8  "P=   L)0  +"X  "PZ   L1P
M+%8  "QI   L@   *YH  "JU   IWP  *?L  "C_ %$B  !$(P  ."0  "\D
M   H(P  (R(  !\A   <(   %R   !,A   0(P  #B0   LF   (*   !"H$
M   L!P  +@D  # ,   Q#P  ,Q,  #,9   S(0  ,RH  #,U   S0P  ,U(
M #-E   R>P  ,I<  #&S   PW@  +_L  "[_ $PE   _)@  -2<  "TF   G
M)0  (B0  !XC   9(P  %"0  !$F   .*   "RH   <L   #+P   #$"   S
M!   -0<  #<*   Y#0  .A   #L5   ['0  .R8  #LQ   [/@  .TX  #M@
M   Z=P  .9(  #BP   WVP  -OP  #7_ $<I   [*@  ,BH  "LI   E)P
M(28  !LG   5*   $2H   XL   *+P  !C$   $T    -@   #@    [ 0
M/00  #\'  !!"@  0PX  $41  !%&   12$  $4L  !$.0  1$@  $1;  !#
M<0  0HT  $&K  ! T@  /_H  #[_ $(M   X+@  +RT  "DK   D*@  '2H
M !<L   1+@  #3$   DT   $-P   #H    \    /P   $$   !$    1@
M $@#  !*!P  3 L  $X.  !0$P  4!P  % G  !/-   3T,  $]5  !.:@
M388  $RD  !*R@  2?@  $C_ #XR   U,0  +B\  "DN   @+@  &3$  !(S
M   .-P  "3H   (]    0    $0   !'    20   $P   !/    40   %,
M  !5 0  6 8  %H+  !=#@  7Q4  %X@  !>+   73P  %Q.  !;8P  6GX
M %B=  !7P   5?(  %3_ #HV   S-   +3(  "0S   ;-@  $SD   X]   (
M00   $4   !)    3    %    !3    5@   %D   !;    70   &    !B
M    90   &@%  !K"P  ;Q   &\8  !N)0  ;30  &U&  !K6P  :G4  &B4
M  !FM@  9.D  &+_ #@Y   R-P  *#D  !X[   5/P  #D0   =)    30
M %(   !6    6@   %X   !B    90   &@   !K    ;0   '    !S
M=@   'D   !]!   @0L  (41  "$'0  @BP  ( ^  !^5   ?FL  'N*  !Z
MJ@  =]8  '7] #@]   L/@  (D$  !=&   /2P  !U$   !7    7    &(
M  !F    :P   &\   !T    >    'L   !^    @    (,   "&    B@
M (T   "1    E@,  )L,  "=$P  FR$  )HS  "720  E&(  )-_  "0H
MCL4  (SS #%$   E2   &DT  !!3   (6@   &$   !H    ;@   '0   !Y
M    ?P   (0   ")    C0   )$   "3    E@   )D   "=    H    *0
M  "H    K    +(#  "W#0  MQ<  +4H  "R/@  L%8  *QS  "JE   J;0
M *7E "I/   >5   $EL   IB    :@   ',   ![    @@   (D   ".
ME    )H   "?    I    *8   "I    K0   +    "S    MP   +L   #
M    Q0   ,L   #1!   U0X  -,=  #0,@  S4L  ,IF  #&AP  PJD  ,'+
M ");   68@  #&L   %T    ?0   (<   "0    EP   )X   "D    JP
M +$   "V    N@   +P   #     Q    ,@   #+    SP   -0   #:
MX    .8   #K    \08  / 3  #N)P  [#\  .I;  #G>@  Y)L  ."[ /\
M  #[    ]@   /,   #T  4 ]@ , /H $0#_ !D _P B /\ + #_ #4 _P ]
M /\ 10#\ $P ^@!2 /< 6 #U %X \P!D /$ :@#N '( [ !Z .D A0#E )$
MX0"@ -T L@#8 ,X T@#V ,$ _P"M /\ G@#_ )8 _P"0 /\ C #_ /H   #R
M    [    .D   #I    [  % /( # #X !( ]P ; /4 )0#P "X ZP W .8
M/@#B $4 W0!+ -@ 4 #3 %8 T !< ,T 8@#* &H R !R ,4 ? #" (@ O@"6
M +H J "W +\ M #H *X _P"= /\ D #_ (@ _P"# /\ @ #_ /    #E
MW@   -H   #;    W    -@ !P#1  X T0 5 -( '@#+ "< Q0 O ,  -P"]
M #T N@!$ +< 20"U $\ L@!5 +  6P"N &$ K !I *D <P"G '\ I "- *$
MG@"> +( FP#5 )D _ ", /\ @@#_ 'L _P!V /\ = #_ .(   #3    R@
M ,<   "\    M@   +   0"O  L K  1 *T & "M "  J  H *0 +P"@ #8
MG0 \ )L 0@"9 $< EP!- )4 4P"3 %D D0!A (\ :@", '4 B@"# (@ E "&
M *< @P#" (( \ !\ /\ <P#_ &T _P!J /\ : #_ ,\   #!    N0   *T
M  "@    F    )0   "1  8 D  - )  $@"/ !D C@ A (L * "( "\ A@ U
M (0 .@"" $  @ !% 'X 2P!\ %( >@!9 '@ 8@!V &P = !Y '( B0!Q )T
M;P"T &T WP!L /\ 90#_ &  _P!> /\ 7 #_ +X   "Q    H    )(   ")
M    @@   'P   !Z  $ >  ) '< #@!X !0 =P : '0 (0!R "< <  M &X
M,P!L #@ :P ^ &D 1 !H $H 9@!1 &0 6@!C &0 80!P %\ ?P!> ), 70"I
M %P R !; /< 5P#_ %0 _P!2 /\ 40#_ +    "?    C0   '\   !T
M;@   &H   !F    90 $ &, "P!C !  8P 5 &, &P!A "$ 7P G %T + !<
M #( 6@ W %D /0!7 $, 5@!+ %4 4P!3 %P 4@!H %  =P!/ (D 3@"? $T
MN@!, .D 2P#_ $D _P!' /\ 1P#_ *(   "-    ?    &X   !E    7@
M %D   !7    50 ! %0 !P!3  T 4P 1 %0 %@!2 !L 40 A $\ )@!. "L
M3  Q $L -P!* #T 20!$ $< 3 !& %8 1 !A $, < !" ($ 00"7 $  KP _
M -< /P#_ #X _P ] /\ /@#_ )0   !_    ;P   &,   !9    40   $T
M  !*    2    $< ! !'  H 1@ . $8 $0!' !8 10 < $0 (0!" "8 00 K
M $  ,0 ^ #< /0 ^ #P 1P Z %  .0!; #@ :0 W 'H -@"/ #4 IP U ,8
M- #U #0 _P T /\ -0#_ (@   !T    90   %@   !/    2    $,    _
M    /0   #P  @ \  < .P , #L #P [ !( .@ 7 #D '  W "$ -@ F #4
M+  T #( ,P Y #$ 00 P $L +P!6 "X 8P M ', + "( "P H  K +L *P#J
M "L _P K /\ + #_ '\   !L    70$  %$"  !( P  0 ,  #L"   W
M-    #,    R  4 ,@ ) #( #0 Q !  ,0 3 #  &  O !T +0 B "P *  K
M "X *@ U "D /0 H $8 )P!1 "8 7@ E &X ) "" ", F0 C +, (@#> "(
M_P C /\ ) #_ '<   !E!   5@8  $L'  !""   .@@  #4'   P!@  +04
M "P#   K  , *@ ' "D "P I  X *0 1 "@ %0 G !D )@ > "4 )  D "H
M(P Q "( .0 A $, ( !. !\ 6@ > &D '0!\ !P DP ; *P &P#- !L ]@ ;
M /\ ' #_ ' %  !?"   40H  $8+   ]"P  -0L  # +   K"@  * D  "4(
M   D!P( (P0& ",""0 B 0P (@ / "$ $@ @ !8 'P ; !X (  = "8 '  N
M !L -@ : #\ &0!* !@ 5P 7 &8 %@!X !4 CP 5 *8 % ## !0 [@ 4 /\
M%0#_ &L(  !;"P  30P  $(-   Y#0  ,0T  "P-   G#0  (PP  "$,   ?
M"P$ '@H% !T("  =!@L ' 4- !P$$  ;!!0 &008 !D$'@ 8!", %P0K !8$
M,P 5!#P % 1' !,#5  2 V, $0-U ! "B@ 0 :( #P"\  \ Y0 / /X $ #_
M &<+  !7#0  20X  #X/   U#P  +@\  "@/   D#@  ( X  !T.   ;#0$
M&0T$ !@,!P 8"PD %PD, !<)#@ 6"1( %0D6 !0)&P 3"2$ $@DH !(),  1
M"3H $ E%  \)4@ ."6$ #0ES  P(B  +")\ "@>W  H&VP *!?8 "@3_ &,-
M  !3#@  1A   #L1   R$0  *Q$  "40   A$   '1   !H/   8#P$ %@X$
M !4.!P 4#0D $PT+ !,,#0 2#!  $0P4 ! ,&0 0#!\ #PPG  X-+P -#3D
M# U%  L-40 )#6  " UQ  8-A@ %#9T ! RT  ,,T@ "#/$  @O_ %\.  !0
M$   0Q$  #@2   O$@  *!(  ",2   >$0  &Q$  !@1   5$ ( %! % !(0
M!P 1#PD $ \* ! .#  .#@X #@\2  T/%P ,$!T #! D  H0+  )$#8 "!!!
M  803@ %$%T  Q!O  $0A   $)P   ^T   .U   #O,   [_ %P0  !-$@
M0!,  #84   M%   )A0  "$3   <$P  &1(  !82   4$0, $A$& !$1"  0
M$ H #A +  T1"P ,$0T "Q(1  H2%0 )$AH "!(A  83*0 %$S,  Q,^  (3
M2P  $UH  !-L   3@@  $IL  !*T   1UP  $?4  !'_ %@2  !)%   /14
M #,6   K%@  )!4  !\5   :%   %Q0  !03 0 3$@0 $1(' ! 2"0 .$@D
M#1()  L3"@ )% T !Q4/  86$P $%A@  Q8?  (6)P  %S   !<[   72
M%U@  !=J   6@   %ID  !6T   5V0  %/<  !/_ %44  !&%@  .A<  # 8
M   H&   (A<  !T6   9%@  %A4  !,4 P 2$P8 $!,'  \3!P -% < "Q4(
M  D6"0 && P  QH.  $:$0  &A8  !L<   ;)   &RT  !LX   ;1@  '%4
M !MG   ;?0  &Y<  !JS   9VP  &/D  !?_ %$6  !#&   -QD  "X:   F
M&@  (!D  !L8   8%P  %18! !,5!0 1%00 #Q4$  T6!  +%P4 "1D&  8:
M"  "' H  !X-   @$   (!,  " 9   @(0  (2H  "$U   A0@  (5(  "!D
M   @>@  'Y4  !^Q   >VP  '?H  !S_ $T9   _&P  -!P  "L<   D'
M'AL  !H:   7&   %!<" !(7 @ 0& $ #1D!  L: @ (' , !1T$  (?!@
M(0@  ",+   E#@  )A$  "86   F'@  )R<  "<R   G/P  )DX  "9@   F
M=P  )9(  "2O   CV@  (OL  "'_ $@=   \'@  ,1\  "@>   B'@  '1P
M !D;   6&@  $AH  ! ;   -'   "QT   @?   $(0   2,"   E!   )P8
M "D)   L#   +@\  "X3   N&@  +B,  "XN   N.P  +DH  "U<   M<@
M+(X  "NL   JU   *?L  "C_ $0@   X(0  +B$  "8A   @(   '!X  !@=
M   4'0  $!X   X?   +(0  !R,   ,E    )P   "D    L 0  +@,  # &
M   S"@  -0T  #81   V%P  -A\  #8I   V-@  -D4  #57   U;0  -(D
M #*H   QSP  ,/H  "__ #\D   T)   *R0  "0C   ?(0  &R   !8@   1
M(0  #B,   HE   &*    BH    M    +P   #(    T    -P   #D#   [
M!@  /@H  $ .  !!$@  01H  $ E  ! ,0  0$   #]2   ^9P  /8(  #RB
M   ZQP  .?@  #C_ #HH   P*   *2<  ",E   ?(P  &"0  !(E   .*
M"BH   4M    ,    #,    V    .    #L    ^    0    $(   !% @
M1P8  $H*  !-#@  314  $P?  !,*P  2SH  $I,  !)80  2'P  $>;  !%
MOP  0_,  $+_ #8L   M*P  )RD  ",G   ;*   %"H   XM   *,   !#,
M   W    .@   #T   !     0P   $8   !(    2P   $T   !0    4P$
M %8&  !9"P  6Q   %L9  !:)0  630  %A&  !76@  570  %23  !2M0
M4.H  $__ #,P   L+@  )RP  !XM   6+P  $#(   HV   #.@   #\   !"
M    1@   $D   !,    3P   %(   !5    6    %H   !=    8    &,
M  !G!@  :PP  &P2  !K'@  :RP  &D]  !G4@  9FH  &2)  !AJP  7]P
M %W_ #$S   L,0  (C(  !DU   1.0  "CT   )"    1P   $P   !0
M5    %@   !;    7P   &(   !E    :    &L   !N    <0   '4   !Y
M    ?08  ((-  ""%@  @"0  'XU  !\20  >V$  'A_  !VGP  <\8  '#W
M #$V   F.   '#L  !)    +10   DL   !1    5@   %L   !@    90
M &D   !N    <@   '8   !Y    ?    'X   ""    A0   (D   ".
MDP   )@&  "<#@  FQH  )@K  "60   DED  )%S  "-E0  B[4  (CH "L^
M   @00  %4<   U-   "5    %L   !A    :    &X   !S    >0   'X
M  "#    B    (P   "/    D@   )4   "9    G0   *$   "E    J@
M +    "W!P  N!$  +4A  "R-0  KTT  *II  "HB   IJ@  *+1 "-(   8
M3@  #E0   1<    9    &T   !U    ?    (,   ")    CP   )4   ";
M    H    *,   "F    J0   *T   "Q    M0   +D   "^    Q    ,H
M  #2    V@H  -86  #2*0  SD$  ,I<  #%?   PIT  ,&] !Q5   17
M!V4   !N    =P   '\   "(    D    )@   "?    I0   *T   "S
MN    +H   "^    P@   ,8   #*    S@   -,   #:    X    .<   #M
M    \P   /0.  #R'@  [S8  .Q1  #H;@  Y)   -^Q
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MZ>KK[.WN[_#Q\O/T]?;W^/GZ^_S]_O]M9G0Q      ,$(0   0
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MH#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN
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MXTDSS^M.2<;M5%VWZEQNJ.)C?9K9:8J.TFV4A,QQFWO(=:%SQ'BF;L)\J6G
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M/E+_DSY2_Y,^4O^3/E+_DSY2_Y,^4O^3/E+_DSY2_Y,^4O^3/E+_DSZ]Q04
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MCSH4_Y="'/^>2R?_GE<T_YUB0O^9;4__DWA<^(W_XO__24-#7U!23T9)3$4
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M1/6[7U;MNV=IX[5N?=:L<X_*HWJ=P9N I[B4A["QCXZVJXJ5NZ:'G;ZBA:7
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M+$/_FBU#_YHM0_^:+4/_FBU#_YHM0_^:+4/_FBU#_YHM0_^:+4/_FBVQP@$
MH](  )7K P&,_Q,#@/\<!G3_(PII_RH.8/\R$EG_.A53_T(73O])&4O_41I(
M_U@<1O]='43_8QU#_V<>0?]L'T#_<!\__W0@/O]X(#W_?" \_X$A._^'(3O_
MC"([_XPB._^,(CO_C"([_XPB._^,(CO_C"([_XPB._^,(CO_C"+_>AT#_W8H
M!O]R,PO_?#</_X0_%?^(2!W_BU,G_XE@,?^&;3O_@GE$_WZ&3/][D5/_=YI8
M_W2B7?QQJ&'Z;JYD^&NT9_=INFGU:,%K\V;(;>]CS6_L8=-PYU_=<>)=Y7/=
M6^9SW5OF<]U;YG/=6^9SW5OF<]U;YG/=6^9SW5OF<]U;YG/_>AT#_W8H!O]R
M,PO_?#</_X0_%?^(2!W_BU,G_XE@,?^&;3O_@GE$_WZ&3/][D5/_=YI8_W2B
M7?QQJ&'Z;JYD^&NT9_=INFGU:,%K\V;(;>]CS6_L8=-PYU_=<>)=Y7/=6^9S
MW5OF<]U;YG/=6^9SW5OF<]U;YG/=6^9SW5OF<]U;YG/_>AT#_W8H!O]R,PO_
M?#</_X0_%?^(2!W_BU,G_XE@,?^&;3O_@GE$_WZ&3/][D5/_=YI8_W2B7?QQ
MJ&'Z;JYD^&NT9_=INFGU:,%K\V;(;>]CS6_L8=-PYU_=<>)=Y7/=6^9SW5OF
M<]U;YG/=6^9SW5OF<]U;YG/=6^9SW5OF<]U;YG/_>AT#_W8H!O]R,PO_?#</
M_X0_%?^(2!W_BU,G_XE@,?^&;3O_@GE$_WZ&3/][D5/_=YI8_W2B7?QQJ&'Z
M;JYD^&NT9_=INFGU:,%K\V;(;>]CS6_L8=-PYU_=<>)=Y7/=6^9SW5OF<]U;
MYG/=6^9SW5OF<]U;YG/=6^9SW5OF<]U;YG/_>AP#_W<G!O]T,@O_?S8/_X8]
M%?^+1QW_CE$G_XQ>,?^):SS_A7=&_X&#3O]]CU;_>9A<_'6@8?ERIF7W;ZUI
M]6RS;/-JN6_R:,!Q\&;(<^QDS77H8=1VXU_>=]M=XWG57>5VU5WE=M5=Y7;5
M7>5VU5WE=M5=Y7;57>5VU5WE=M5=Y7;_>QP#_W<G!O]W, K_@C4._XH\%?^/
M1AW_DD\G_Y%<,O^.:#W_BG1(_X: 4O^!BUK\?95A^'B=9_5TI&WR<:IQ\&ZP
M=.YKMG?L:;YZZF?'?>=ESG_B8M: V5_=@=!?X'[,8.-[S&#C>\Q@XWO,8.-[
MS&#C>\Q@XWO,8.-[S&#C>\Q@XWO_?!P#_W@F!O]Z+PK_A3,._XT[%/^21!S_
MEDXG_Y5:,O^293[_CG%*_XI]5?Z%B%[Y@))G]'N:;O!VH7/M<J=XZF^N?>AL
MM(#F:;R#Y&?&AN%ESXC98M>*SV'9B,ABW8+$8^!_Q&/@?\1CX'_$8^!_Q&/@
M?\1CX'_$8^!_Q&/@?\1CX'__?1L#_WDF!O]\+@K_B#(._Y Z%/^50QS_FDPG
M_YE8,_^68S__DFY,_XYZ5_R)A6+UA(]K\'Z7<^QYGGKH=*6 Y7"KA>)LLXG@
M:KN,WFC&C]IFT9+.8M&2QV35C,%EVX:]9MV"O6;=@KUFW8*]9MV"O6;=@KUF
MW8*]9MV"O6;=@KUFW8+_?1L#_WHF!O]_+ K_BS$-_Y,Z$_^80AS_G4LF_YU6
M,_^;84#_EVQ-^Y)V6O>-@6;RB(QP[(*4>>=[FX'C=:*(WW&ICMQML9+9:[N6
MUVG(F<QDRYO%9<Z7P&?2D;IHV(JV:=N&MFG;AK9IVX:V:=N&MFG;AK9IVX:V
M:=N&MFG;AK9IVX;_?AL#_WLF!O^!*PG_C3$-_Y4Y$_^;0AO_H$HF_Z%4,_^?
M7T'[G&E/]I=S7?&2?FKLC(AUYX61@.)^F(G=>*"1V'*GE])MKYW/;+F?S&O%
MH,-GQZ"\:,N;MVK0E+)LU8VO;-F)KVS9B:]LV8FO;-F)KVS9B:]LV8FO;-F)
MKVS9B:]LV8G_?AH#_WLE!O^#*@G_CS ,_Y@X$O^>01O_HTDF_Z92,_VD74'W
MH6=0\9QQ7^N7>VWECX-ZWH>+AM5^DI'/>)F7RG2AG,=QJI_#;[.AP6Z_H[IK
MQ:.S:\B?KVW-F*MOTI&I<-:,J7#6C*EPUHRI<-:,J7#6C*EPUHRI<-:,J7#6
MC*EPUHS_?QH#_WPE!O^&*0C_DB\,_YLX$O^A0!K_IT@E_ZI1,OFI6T'SIF11
M[*)N8>6:=G#<D7Y_THF&B\N"C9/%?969P'B=GKQUI:&Y<ZZDMG*YI;)PPZ:K
M;\:BJ''+FZ1ST).B=-2.HG34CJ)TU(ZB=-2.HG34CJ)TU(ZB=-2.HG34CJ)T
MU([_@!H#_WPE!O^(* C_E"\+_YTW$?^D/QG_JD<D_:Y/,O:M64'OJV)2YZ9K
M8MZ><G/2E7J!RHV"B\.'BI.]@9&:MWV9G[-YH:.O=ZJFK':TIZIVP:BC<\.E
MH'7)GIYWSY:<=]*1G'?2D9QWTI&<=]*1G'?2D9QWTI&<=]*1G'?2D9QWTI'_
M@!H#_WTE!O^*)PC_EBX+_Y\V$/^G/QC_K4<C^[).,?.R5T'KL6!2XJIH9-:B
M<'3,F7>!PY)_B[R+AI2UAHZ:KX&5H*I^G:2F>Z:GHWJPJ:%YO*F;=\&HF7G'
MH)AZS9B7>]&3EWO1DY=[T9.7>]&3EWO1DY=[T9.7>]&3EWO1DY=[T9/_@1H#
M_WXD!O^,)@?_F"X*_Z(V$/^I/AC_KT8C^+5-,/"W5D#GM5Y2W:YF9-"E;G/&
MG76 O99\B[60@Y2NBHN;J(:2H*."FJ6??Z.HFWZMJIA]N:N4>\"JDWW&HI)^
MS)F1?]"4D7_0E)%_T)21?]"4D7_0E)%_T)21?]"4D7_0E)%_T)3_@1D#_WXD
M!O^-)@?_FBT*_Z0U#_^L/1?^LD4B]KA,,.V\5$#DN%U1U[)D8\NI;'/ H7.
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M3U#_NU!/_\-13__#44__PU%/_\-13__#44__PU%/_\-13__#44__PU':KP(
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MC(:,H(B-D9J%E9:6@IZ:DH"GG8]_LYZ-@,*>BX#,FHN!TI**@-B)B8#;AHF
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M.$3_Q3A$_\4X1/_%.$3_Q3A$_\4X1/_%.$3_Q3C!LP  LKX" *7, 0"9W0,
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MY'B"@N1X@H+D>(*"Y'C_<1H"_WH< _^*'0/_ER,$_Z(I!?RL,0GQLSD/Z+I
M%]V\2"7/ME(XPZ];2+FH8E:OHFIBIYQP;)^7=W68DWY\DI"&@HR-CH>'BI>+
M@XB@CG^'JY%\A[F1>X?+D7R(V(E]A]Z"?8;D>GV&Y'E]AN1Y?8;D>7V&Y'E]
MAN1Y?8;D>7V&Y'G_<1H"_WP: _^-' /_FB(#_Z4H!/FO+P?NN#<,Y+\_%-C
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M7$KC\UQ*X_-<2N/S7$KC\UQ*X_-<2N/S7$KC\USYF0, U*P" ,6W! "YPP4
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M:E>O\6=7K_%G5Z_Q9U>O\6=7K_%G5Z_Q9U>O\6?_?PX!_Y,+ .&E!0#2LP<
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M_U*F:?]2IFG_4J9I_U+_6R "_V<< O]T&@+_?R #_X@G!/^.+P?]DC<,])1
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M9FB3]F!HDO=?:)+W7VB2]U]HDO=?:)+W7VB2]U__;Q$!_X$. /^1#@#RH P
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M55"Z_E50NOY54+K^55"Z_E7_A0( W9@  ,VF @#!L0, M[H# *[&!@"GTPH
MH-T5 )G=* 20VS<.AME"&7W62R1UU%0M;=)<-6?18SQAT&M!7,]R1EC/>TE4
MSH1-4,Z/4$W.FU)+SJE32<ZY5$C/SU1(SNM32<[X4$K+_TY*RO]-2LK_34K*
M_TU*RO]-2LK_34K*_TWGCP  T9\  ,.K 0"WM ( K;\# */+!@";V0H E.4:
M 8WE*P:$Y#4->^,_%G/B2!YLX5(F9N%:+&#@8C);X&HV5^!R.E/?>SU0WX5
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M,P8Z_SD'-O] "#/_10@P_TL)+O]1"BO_5PHI_UT+)_]D"R3_; PB_W8-(/^
M#1[_C X=_Y<.'/^A#AO_K \;_ZX/&_^N#QO_K@\;_ZX/&_^N#QO_K@^7O
MB,D  'G6  !KXP  7_8  %;_  !._PH 1_\0 4'_%@(\_QT"-_\D S+_*@,O
M_S $*_\V!2?_.P4E_T %(O]%!B#_2@8>_U &&_]6!QG_7 <7_V0(%?]M"!/_
M=P@1_X$)$/^+"1#_E0D/_Y@)#_^8"0__F D/_Y@)#_^8"0__F G_22<"_T0Q
M!/]+,03_4#0&_U(Z"/]20PO_44X/_T]<$_]-:Q;_3'D9_TN'&_])DQW_2)T?
M_TBF(/]'KB'_1[4B_T:](_]&QB/_1M D_T;@)/]&ZB7_1O,E_T;Z)?]&_R7_
M1O\E_T;_)?]&_R3]1O\C_4;_(_U&_R/]1O\C_4;_(_U&_R/_22<"_T8O _]-
M+P3_4C(&_U4Y"/]50@O_5$T/_U)9$_]0:!?_3W<:_TZ$'?],D1__2YLA_TJD
M(O]*K"/_2;,D_TF[)?](Q";_2,TF_TC=)_](Z"?_2/$H_TCY*/](_RC_2/\H
M_DC_*/M(_R?Y2/\F^4C_)OE(_R;Y2/\F^4C_)OE(_R;_2B<"_T@M _]0+03_
M53 &_U@V"/]90 O_6$L/_U56$_]49AC_4G0;_U&!'O]/CB'_3I@C_TVA)?]-
MJ2;_3+$G_TNX*/]+P2G_2\HJ_TK9*O]*YBO_2O K_TKX+/]*_RS]2O\L^DK_
M*_=*_RGU2O\H]4K_*/5*_RCU2O\H]4K_*/5*_RC_2R8"_TLK _]2*P3_6"X%
M_ULT"/]=/@O_74D/_UI4%/]98AC_5W$=_U5^(/]3BB/_4I4F_U&>*/]0IBK_
M3ZXK_TZU+/].O2W_3<<N_TW3+_],XS#_3.TP_$SV,?I,_C'W3/\Q]4W_+_)-
M_RWP3?\K\$W_*_!-_ROP3?\K\$W_*_!-_RO_2R8"_TXI _]6*03_7"L%_V Q
M!_]B.PO_8D8/_V!1%/]>7QG_7&T>_UIZ(_]8AB;_5I$I_U6:+/]3HB[_4JHP
M_U&Q,?]1N3/_4,,T_D_.-?M/WS;X3NLW]4[U./)._3CP3_\U[E#_,^M1_S'I
M4?\OZ5'_+^E1_R_I4?\OZ5'_+^E1_R__3"4"_U$G _]:)@/_8"@%_V4O!_]H
M.0K_:$,/_V=.%?]E6AK_8F@@_U]V)?]=@2K_6HPN_EB6,?Q7GC3[5:8V^52M
M./A3M3KW4KX[]5')/?-1VC[P4.@_[%#S0.E1_3[H4_\[YE3_..-5_S7A5?\S
MX57_,^%5_S/A5?\SX57_,^%5_S/_320"_U0D _]=(P/_924$_VHM!O]M-@K_
M;D ._VU+%/]K5AO_:&0A_F5Q*/MB?2WX7X<R]ER1-O-:F3KR6*$]\%>I0.Y5
ML4+L5+E$ZU/$1NE2TDCE4>5)XE+R2-]4_$3=5O] VUC_/=99_SK26?\XTEG_
M.-)9_SC26?\XTEG_.-)9_SC_3B0"_U@A _]A( /_:B,$_W K!?]S- G_=#X.
M_W1(%/]R4AO[;U\C]FML*O)G=S'O8X(W[&"+/>E=E$'F6IQ%Y%BD2>)6K$S@
M5+1.W52_4-M4S5#74^)1TE3P3M!7^TK.6O]%S5S_0LE<_S[%7/\\Q5S_/,5<
M_SS%7/\\Q5S_/,5<_SS_3R,"_UL? O]E'0+_;B$#_W4I!?]Y,0C_>CL,_WI$
M$_IY3AOT=ELC[G%G+.EL<C7E:'P\X6.%0]U@CDC979=,U5R?3]):IU'/6;!3
MS5BZ5,M8QE7)5]I6Q5?L5<-;^4_"7O]*P%__1KU@_T*Z8/] NF#_0+I@_T"Z
M8/] NF#_0+I@_T#_4B$"_UX= O]I&@+_<Q\#_WHF!/]^+P;_@3@+^X%!$O.
M2QKL?%<CYG=C+>!Q;3C:;7= TVF 1L]EB4O+8Y%/R&"94L5?H57"7:I7P%RS
M6;Y<OUJ\6\Y;N%OE6[=>]56W8O]/M6/_2K)D_T:P9/]#L&3_0[!D_T.P9/]#
ML&3_0[!D_T/_51\"_V$: O]M& +_=QT"_WXD _^$+ 7^AS4)]8@^$.V'2!CE
M@U0BWGY?+M1X:3C.<W- R6Y\1\1KA$S :(Q1O6645+ICG%>W8J5:M&"N7+)@
MN5ZP7\=>K5_?7ZQB\5FL9?Y3JF?_3JAG_TJF9_]&IF?_1J9G_T:F9_]&IF?_
M1J9G_T;_5QT"_V08 O]P%@+_>QP"_X,B O^)*@3YC#('[XX[#>>.1!;>BE$A
MU(1<+<Q^9CC%>&]!P'1W2+MP@$VW;8A2LVJ05K!HF%FL9J!<JF6I7Z=DM&"E
M8\)AHV/58J)E[5VB:?M7H6K_49]K_TR>:_])GFO_29YK_TF>:_])GFO_29YK
M_TG_61P"_V<6 ?]S%0'_?AH!_X<@ O^-)P/TDB\&ZI0X"^&40A/6CTX@S(E9
M+<6#8S>^?6M N'ET2+-U?$ZN<H13JF^,5Z=ME%NC:YQ>H&FE8)YHL&.;9[UD
MF6?.9)AIZ&&:;?E:F6[_5)=N_T^6;O]+EF[_2Y9N_TN6;O]+EF[_2Y9N_TO_
M6QH"_VD4 ?]V% '_@1@!_XH= ?R1) +PERP$Y9HT"-R:/Q'/E$P?QHY7++Z(
M8#>W@FE L7YQ2*QZ>4ZG=X!3HW2(6)]QD%R;;YA?F&VA8I5LK&23;+EFD6O)
M9I!MY&21<?9<D7+^5I!R_U&0<O]-D'+_39!R_TV0<O]-D'+_39!R_TW_71@!
M_VL3 ?]Y$P'_A!8!_XX; ?B5(0'KFR@#X: P!M6>/1#*F$H>P9)4*[F,7C:Q
MAV8_JX)N1Z9^=DZA>WU3G'B%6)AVC5R4=)5?D7*>8XYQJ66+<+5GB7#%9XAP
MX&:*=/1>BW;\6(IV_U*)=O].B7;_3HEV_TZ)=O].B7;_3HEV_T[_7Q<!_VX1
M ?][$@'_AQ0 _Y$8 ?29'0'GH","W:4K!,^A.P_%G$@=O)93*K207#6LBV0_
MIH=L1Z"#<TV;@'I3EGV"5Y)ZBER.>))@BG:<8X=UIF:$=+)H@G3":(!TVVB#
M>/)@A'K[681Y_U2$>?]/A'G_3X1Y_T^$>?]/A'G_3X1Y_T__814!_W 0 ?]^
M$0#_BA( _Y05 /"=&0#CI1X!UZ@H \NE.0[!GT8;MYI1*:^56C2GD&(^H8MJ
M1IN'<4R5A'A2D(%_5XQ_AUR(?9!@A'N98X!ZHV9]>;!H>WF_:7IYUFE\?/!A
M?G[Z6GY]_E5^??]1?GW_47Y]_U%^??]1?GW_47Y]_U'_8Q0!_W(/ ?^!$ #_
MC1$ _)@2 .RA$P#?JA8 T:PF \>H-PV\HT0:LYY/)ZJ96#.CE& ]G)!H19:,
M;TR0B792BX9]5X:$A5N"@HY??H"78WI_H69W?JUH=7Z]:7-^TFEV@>YB>(+Z
M6WB"_E9Y@?]1>8'_47F!_U%Y@?]1>8'_47F!_U'_91,!_W4. /^##@#_D X
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M4F&8_U)AF/]289C_4F&8_U+_<@L _X,% -^3 0#1GP0 R:H& ,&R!0"[O00
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M(3CXM2(W^<@B-OGC(C;X\R(V]_PB-O?\(C;W_"(V]_PB-O?\(C;W_"*WI@
MJ:X  )RY  "0Q   @\\  '?;  !O]@H 9_\3 6#_'0):_R<#5/\P!4__. A*
M_T *1O](#$/_3PY _U8//?]>$#O_91(X_VX3-O]W%#3_@A4R_X\6,/^;%R__
MJ1<N_[<8+?_(&"S_X1@L_^\8+/_O&"S_[Q@L_^\8+/_O&"S_[QBKJP  GK4
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M_V$4 ?]L$@'_=A<!_WT< ?^#(P+TABP$ZH@U!^&'0 [6@DP9S7U8),9W8BW
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M3HET_TF)=/]$B'3_0XAT_T.(=/]#B'3_0XAT_T/_71(!_VL. /]X#@#_@P\
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M1W*$_T=RA/]'<H3_1W*$_T?_9@T _W4' /:#!0#<CP, TI@& ,RA!P#(J @
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M/$3%P3Q#Q=\\1,3S.T3#_SE%PO\W1<'_-T7!_S=%P?\W1<'_-T7!_S?5BP
MQ9H  +>D  "KK   H+0  ):^  "+QP0 @= ( 'C9#@!UV2 !;]@O!&G8/ EC
MUD807M90%5G56!I5U& ?4=1H(D[4<29+TWLI2-.%*T73DBY"U)\O0=2O,#_5
MPC$_U>$P/]/R,#_2_2\_T?\N/]#_+C_0_RX_T/\N/]#_+C_0_R[*E   NZ$
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M$2?_X1$F__(1)O_V$2;_]A$F__81)O_V$2;_]A&GJ0  F;,  (N^  !^R0
M<-,  &3>  !8YP  4O\) $W_$0!'_QD!0_\B 3[_*@(Z_S(#-_\Y S/_/P0P
M_T8%+?]-!2O_5 8H_UL')O]C!R/_;0@A_WD)'_^'"1[_E0H=_Z,*'/^Q"AO_
MP L:_]8+&O_?"QK_WPL:_]\+&O_?"QK_WPN;L0  C;P  '['  !PT@  8]X
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M,+MB?36X8(4XM5Z-/+)<E3ZO6YU!K5JF0ZM9KT2I6;Q%IUC,1J18Y4:D6_9
MHU[_.Z-?_S>C8/\SHV'_,:-A_S&C8?\QHV'_,:-A_S'_4Q4!_UT0 /]H#P#_
M<!( _W<6 /M\' 'N?R0!Y( M ]I_.PC/>DD2QW54&\%Q7R2[;6@KMFIP,;)G
M>3:O98 ZJV.(/:AAD$"F8)A#HUZA1:!>JT>>7;=(G%W&29I<WTF:7_)$FF+_
M/IIC_SF;9?\VFV7_,YME_S.;9?\SFV7_,YME_S/_51,!_V . /]K#@#_=!
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M.H!U_SJ =?\Z@'7_.H!U_SK_70X _VH& /]V!@#D@ , V8D& -*/" #/E H
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M1U&;ND=0F]%'49ON1%.;_$!5F_\\5IO_.E:;_SI6F_\Z5IO_.E:;_SKQ=
MV8,  ,B0  "^F@  LZ$  *JG  "AK@  E[4& )*V& ",M2H#A;0W"7ZR0A%W
ML$P8<:Y4'VRM6R5GJV(J8JII+UZI<3-:J'HW5J>#.E.FCCU0IIM 3:6I04NE
MND)+IM%"2Z7M/TVE_#Q.I/\Y3Z3_-T^D_S=/I/\W3Z3_-T^D_S?D>@  SXD
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M)3O,^R4[R_\E.\K_)3O*_R4[RO\E.\K_)3O*_R7#DP  M9X  *BF  "=K@
MD;8  (6_  !YQP  ;\X$ &36"0!>WA$ 6]X@ %?>+0)3WSH$4-]$!DS?3@E)
MWU<,1M]?#T/?:!%!WW$3/M]\%3S?B1<ZX)89.."E&C?@MQHVX<T:-M_L&C7>
M^1HTW?\;--S_&S3<_QLTW/\;--S_&S3<_QNYG   JJ0  )ZK  "2M0  A;X
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M!A/_Z083_^D&$__I!A/_Z0:7KP  B+H  'K%  !LSP  7MH  %#@  !$Y@
M//4  #?_!  S_PT +_\3 "O_&@ H_R$ )?\G 2'_+0$>_S(!&_\X 1G_/P$6
M_T8"%/]- A'_5@(0_V "#O]L @S_>P,+_XL#"O^: PK_J ,)_[4#"/_" PC_
MP@,(_\(#"/_" PC_P@.*N   >\,  &S.  !>VP  3^(  $+G   V[   ,?\
M "S_   G_P< (_\. "#_$@ <_Q@ &/\= !7_(0 2_R8 $/\L 0[_,0$-_S<!
M"O\^ 0C_1@$%_T\! ?]9 0#_9@$ _W0! /^" @#_D ( _YP" /^F @#_I@(
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M1((5]D.,%_1"E!CS09P9\4&C&^] JAON0+(<[3^['>L_QA[I/]4>Y3_H'^)
M]![?0/X=W4'_&]M"_QK90O\8V$+_%]A"_Q?80O\7V$+_%]A"_Q?_0!\!_T@:
M ?].& '_4AL!_U8C O]8+ /_5S<$_U5"!_]230OY4%H.]4UG$O%,<A;N2GT8
MZTB&&^E'CQWG1I<?Y46>(.-$IB+A1*XCX$.W)-Y#PB7<0] FUT/E)M-$\R30
M1?XBS4;_(,Q'_Q[*1_\<R4C_&\E(_QO)2/\;R4C_&\E(_QO_1!L!_TP6 ?]2
M% '_6!@!_UT? ?]?* +_7C(#_5T]!O9:20KP5U4/ZE5B$^92;1CB4'<<WTZ!
M']Q,BB+92Y(DU4J:)M-)H2C12:DISTBR*LU(O"O+2,DLR$C?+,5([RO"2OPH
MP$O_);],_R*^3?\@O4W_'[U-_QZ]3?\>O4W_'KU-_Q[_1Q@!_T\3 ?]6$0#_
M7A4 _V(< ?]E) '^92T"]&0X!>UA0PGF7U$.X%Q=%-I8:!K45G(>T%1[(LQ2
MA";*4(PHQT^4*L5.FRS#3J,NP4VL+[],MC"]3,(QNTS3,KA,Z3&V3O@MM%#_
M*K-1_R>S4O\DLE+_(K)2_R*R4O\BLE+_(K)2_R+_2A4!_U,1 /];#P#_8A(
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M+(YE_RR.9?\LCF7_+(YE_RS_50X _U\& /]I!@#T<@8 XG@& -M\"0#9?PP
MS8$= ,1_, .[?#\*M'A+$JUU51JH<5XAHVYF)I]L;BN;:G4OF&A],Y5GA#:2
M98PYCV25/(QCGSZ)8JI AV&W0H5AR4*$8N1!A63W.X9F_S6'9_\QAVC_+H=I
M_RV':?\MAVG_+8=I_RW_5PP _V$$ /YL P#D=0$ VWL% -. " #0@PH QX4:
M +Z$+0.V@3P)KWU($JAY4AFB=EL@G7-C)IEP:RN5;G(OD6UY,XYK@3:+:8DZ
MB&B2/(5GG#^"9J=!@&:T0WYFQ41\9N%#?FCU/']J_S> :_\S@6S_+X%L_R^!
M;/\O@6S_+X%L_R__60L _V,! /1O  #?>   U'\$ ,Z#!@#*AP@ PH@8 +F'
M*P*QA3H(JH%&$:-^4!B=>ED?F'=A)9-U:"J/<V\OBW%W,XAO?C:%;H8Z@FR/
M/7]KF4!\:J5">6JQ1'=JPD1V:MU$>&SS/GEN_SAZ;_\T>W#_,'QP_S!\</\P
M?'#_,'QP_S#_6P@ _V8  .=R  #:>P  SX(# ,F'!0#$B@8 O(P5 +2+* *L
MB3@'I85$$)Z"3AB8?U<>DWQ?)(YY9BJ*=VTNAG5T,H)T?#9_<H0Y?'&-/7EP
MET!V;Z)"<VZO1'%NP$5P;ME%<G#Q/W-R_SEU<_\U=G3_,79T_S%V=/\Q=G3_
M,79T_S'_708 _VD  .)T  #4?0  RX4" ,2*! "_C04 MX\3 +"/)@&HC34'
MH(I"#IJ&3!:3@U4=CH%=)(E^9"F%?&LM@7IR,GUX>35Z=X(Y=G:+/'-UE4!P
M=*!";7.M1&MSO45J<]5%;'3O0&YV_CIO=_\V<7C_,G%X_S%Q>/\Q<7C_,7%X
M_S'_7P( ]VP  -YW  #0@0  QX@! ,"- P"YD0, LI,1 *N3(P&CD3,&G(Y
M#96+2A6/B%,<B89;(H2#8BB @6DM?']P,7A^=S5T?( X<7N)/&YZDS]K>9Y"
M:'BK1&9XNT5D>-%%9GGN0&A[_3IJ>_\V:WS_,FM\_S)K?/\R:WS_,FM\_S+_
M80  ZF\  -EZ  #,A   PXL  +N1 0"TE0$ K)<. *67(0&>EC$%EY,^#)"0
M2!2*CE$;A(M9(7^)8"=[AV<K=X5N,'.$=31O@GTW:X&'.VB D3YE?YQ!8GZI
M0V!^N41??L]$8'_L0&* _#ID@/\V98'_,V:!_S)F@?\R9H'_,F:!_S+_9
MY7(  --^  #'AP  OH\  +:5  "NF0  IIL, *"<'@"9FRX$DID["HN61A*%
ME$\9?Y%7'WJ/7B5UCF4J<8QL+FV*<S)IB7LV9HB$.6*&CSU?A9H_7(6H05J%
MMT)9A<Q"6H7J/UR&^SI>AO\V7X?_,E^'_S)?A_\R7X?_,E^'_S+]:   X'8
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M-4F@^3)*G_\P2Y__+DN?_RU+G_\M2Y__+4N?_RW=>0  R88  +R2  "QF@
MIJ   )RF  "1K   AK(  'VV#0!YMAT =;8L F^U.09JM$,+9;-,$6"R5!9<
ML5L:6+!C'E6O:R%1KW,E3JY]*$NMB"I(K94M1:VC+D2MLR]#K<@O0JSG+T.K
M^2U$J_\K1*K_*42J_RE$JO\I1*K_*42J_RG1@   P8T  +68  "IGP  GJ4
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M$R_4_Q,OU/\3+]3_$R_4_Q.SF@  IJ$  )JI  "-L0  @+H  '3!  !HR0
M7,\  %+5 P!(W @ 1>42 $/E'@!!YBH /N8U 3OG/@$YYT<"-^=0 S3H600R
MZ&(%,.AM!B[I>0<LZ8<(*^J6"2GJIPHHZKH*)^O6"B?I\ HGY_T))N;_"B;F
M_PHFYO\*)N;_"B;F_PJHH   G*<  (^P  ""N0  =,(  &C*  !;T0  3]<
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M 0#_R@&&MP  =\$  &C,  !:UP  2]X  #[D   RZ0  )^T  "/_   ?_P
M&_\% !?_#  4_Q  $?\4  __&  -_QT "_\B  C_*  %_RX  O\U  #_/0
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M0),6X#^;%]\_HAC=/JH9VSZS&M@^O1K6/LH;TC[?&\X^[QO+/_L:R4#_&,=
M_Q?&0?\5Q4'_%,1!_Q3$0?\4Q$'_%,1!_Q3_01< _T<2 /],$ #_4A0 _U8;
M /]7) '_5BX"^%0Y _%110;K3U()YDU>#.%+:1#=2703V4A]%M5&AAC218X:
MT$66',Y$G1W,1*4>RD.M'\A#MB#&0\,AQ4/3(<%#Z2&^1/<?O$7_';I&_QNY
M1_\9N$?_&+A'_Q>X1_\7N$?_%[A'_Q?_1!0 _TL0 /]1#@#_5Q$ _UL6 /]=
M'@#Y72@![ULS N=9/P3@5TT(VE19#=-29!+.4&X6RDYW&<=,@!S%2X@>PDJ0
M(,!*ER&^29\CO$BG)+I(L"6X2+PFMTC+)[1'XR>R2?,EL$K_(JY+_Q^N3/\=
MK4S_&ZU-_QJM3?\:K4W_&JU-_QK_1Q$ _T\- /]6# #_7 X _V 2 /UB& #P
M8R$ YF(L =Y@.@/47D@'S5M4#<=87Q/#5FD7OU1R&[Q2>AZY48(AME"*([1/
MD26R3IDGL$VB**Y-JRJL3+8KJDS$+*A,VRRF3>\JI$_])J10_R.C4?\@HU+_
M'J)2_QVB4O\=HE+_':)2_QW_2@\ _U(* /]:"0#_8 L _V4. /5G$0#H:!@
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M.6YJN3IM:LXZ;6OK-V]M_#%P;O\M<6[_*G%O_RAQ;_\H<6__*'%O_RC_60
MZV4  -MP  #->   Q'X  +R" 0"VA $ KH4. *>&( "@A3 #FH(]"). 2 ^.
M?5$5B7M9&H1Y8!^ =V<C?'5N)WET=2IV<WTN<W*&,7!QD#1M<)PW:F^H.6AO
MMSIG;\LZ9W#I-VEQ^C)K<O\M;'/_*FQS_RAL<_\H;'/_*&QS_RC_7   YV@
M -5S  #)>P  P((  +B&  "QB   J8D- ***'0"<B2X"E8<[!X^%10Z)@D\4
MA(!7&7]^7AY[?&4B>'ML)G1Y<RIQ>'LM;G>$,&MVCC-H=9HV972F.&-TM3EA
M=,DZ873G.&-V^3)E=O\N9G?_*V=W_REG=_\I9W?_*6=W_RG_7P  XVP  -!V
M  #%?P  O(4  +2*  "LC   HXX* )V.&@"7CBL"D(PX!HJ*0PR$ATP2?X55
M&'J$7!UV@F,A<X!J)6]_<2EL?GDL:'V"+V5\C#)B>Y@U7WJD-UUZLSA<>L<Y
M7'KE-UY[^#)?>_\N8'S_*V%\_REA?/\I87S_*6%\_RGU8@  WF\  ,QZ  #
M@P  MXD  *^.  "FD0  G9(& )>3%P"1DR@!BY(V!86000M_CDH1>HQ2%G6*
M6AMQB&$?;8=H(VJ&;R=FA'<K8X. +F""BC%=@98T6H&C-EB LC=6@,4W5H#C
M-EB!]S%9@?\M6X+_*EN"_RE;@O\I6X+_*5N"_RGL9@  V',  ,=^  "\AP
MLXX  *F2  "@E0  EI@! )"9$P"*F20!A9@R!'^6/@EYE$@.=)-0%&^15QEK
MD%X=:(YE(62-;25@C'4H78M^*UJ*B"Y7B90Q5(FA,U*(L#11B,,U4(CB-%*(
M]C!3B/\L5(C_*56(_RA5B/\H58C_*%6(_RCF:P  T'@  ,*#  "WC   K9(
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M(4"D_R! I/\@0*3_($"D_R#*?@  NXL  *^5  "DFP  F:$  (ZF  ""K
M=[$  &JV  !CN X 8;@= %ZX+ %:N#@"5[A"!5.X2PA0MU,+3;=;#DJV8Q!'
MMFL31+5U%D*U@1@_M8X:/;6<'#NUK!PZM< =.;7?'#FS]!PYLO\<.;'_&SFP
M_QLYL/\;.;#_&SFP_QO!A@  M),  *>:  "<H   D:<  (6M  !YLP  ;;@
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M!1_@_P6DG@  F*4  (NN  !]M@  <+X  &/&  !6RP  2]   $#5   VW
M+^4' "WM$  K[A@ *>XB "?O*P E[S0 (_ \ "'P10 ?\4X '?)8 1OR9 $9
M\W$!&/.! 1?TD@(5]*4"%/6Z A/UU@(3].\"$O+\ A+P_P(2\/\"$O#_ A+P
M_P*:I   C:T  '^V  !QOP  8\<  %;.  !)TP  /=H  #/?   JXP  )O0%
M "3[#0 A_!, 'OT; !S](@ 9_BD %_XQ !7_.0 3_T$ $?]* !#_50 ._V$
M#/]O 0S_@ $*_Y,!"?^F 0C_N@$'_]0!!__K 0;_]@$&__8!!O_V 0;_]@&/
MK   @+8  '*_  !CR0  5M$  $C8   [W0  ,.(  ";F   ?\   '/\  !G_
M"0 6_PX %/\3 !'_&0 /_QX #?\D  O_*P )_S( !O\[  /_1   _T\  /]<
M  #_:P  _WT  /^0  #_HP  _[0  /_&  #_U@  _]8  /_6  #_U@""M0
M<[\  &3)  !6TP  1]L  #K@   NY0  (^D  !KM   5_0  $O\  !#_ @ .
M_PD "_\-  C_$  $_Q,  ?\8  #_'@  _R0  /\K  #_,P  _ST  /])  #_
M5@  _V8  /]X  #_B@  _YL  /^H  #_L0  _[$  /^Q  #_L0#_)2L!_R@I
M ?\I*0'_*"P!_R,R ?\>.P+_&D<"_Q=5 _\58@/_$W #_Q)\ _\2AP/_$I$#
M_Q*9 _\2H /_$J<#_Q*M _\1M /_$;L#_Q'$ _\1S@/_$=\#_Q'K O\2]@+_
M$OX"_Q+_ O\2_P+_$O\"_Q+_ O\2_P+_$O\"_Q+_ O\2_P+_*"D!_RLF ?\L
M)@'_*RD!_R@O ?\B. +_($0"_QU2 _\;7P/_&&P#_Q=Y!/\7A 3_%XX$_Q>6
M!/\6G03_%J0$_Q:J!/\6L03_%K@$_Q;  _\6R@/_%ML#_Q;H _\7] /_%_T#
M_!?_ OL7_P/[%_\#^A?_ _H7_P/Z%_\#^A?_ _H7_P/_*B8!_RXC ?\O(@'_
M+R4!_RPK ?\J-0+_)T$"_R1. _\B6P/_(&@$_QYT!/\=@ 3_'8H$_QV2!?\=
MF@7_':$%_QVG!?\=K07_';0$_QV]!/\=QP3_'=0$_AWF!/L=\@3W'OL#]1[_
M!/0>_P3S'O\$\Q[_!/(>_P3R'O\$\A[_!/(>_P3_+B(!_S(? ?\T'@'_,R !
M_S(F ?\R,@'_+SX"_RQ* _\J5P/_)V0$_R9P!?\E>P7_)(4%_R2.!O\DE@;_
M))T&_R2C!O\DJ@;])+$&_"2Y!OLDPP;Y),\&]B3C!O(D\ 7N)?H%[27_!NLE
M_P;J)?\&Z27_!NDE_P;I)?\&Z27_!NDE_P;_,AX!_S8; /\X&0#_.!L!_SHC
M ?\Y+0'_.#H"_S5& _\R4@3_,%\$_RYK!?\M=@;]+( '^BR)!_DKD0?W*YD(
M]2N?"/0KI@CS*ZT(\2NU"/ KOPCN*\L(ZRO?".<L[@CD+/H(XBS_"> L_PG>
M+/\(WBS_"-TL_PC=+/\(W2S_"-TL_PC_-1H _SH6 /\]% #_/Q< _T$? /]!
M*0'_0#0!_SU! O\Z30/\.%H%^#9E!O0U<0?Q-'L([S.$">TSC0GK,I0*Z3*;
M"N@RH@OF,JH+Y#*R#.,RNPSA,L@,WS+<#-HR[ W5,_@-TC/_#= S_PS.,_\,
MS33_"\PT_PO,-/\+S#3_"\PT_PO_.18 _SX2 /]!$ #_11, _T@; /]() #_
M1R\!_D0[ O="1P/Q/U0%[#Y@!N@\:PCE.W8)XCM_"^ ZB S=.9 -VSF7#MDX
MG@_6.*80U#BN$=(XMQ'0.,,2SCC3$LHXZ!+'.?<2Q#G_$<(Z_Q#!.O\/P#K_
M#K\Z_PZ_.O\.OSK_#K\Z_P[_/1, _T(/ /]&#0#_2Q  _TX6 /]/'P#]3BD!
M]$PT >Q(00+F1TX$X$5;!MM$9@G60G ,TD%Y#L] @A#-0(H1RC^1$\D_F13'
M/J 5Q3ZH%L,^L1?!/KP7P#[+&+T^XABZ/O(7MS__%K5 _Q2T0/\3LT'_$;-!
M_Q"S0?\0LT'_$+-!_Q#_0!  _T8, /]+"@#_40T _U,1 /]4& #S5"( Z5(M
M >%0.P':3TD#TDU5!\Q+8 O(26H.Q4AS$<)'>Q._1H,5O46+%[M%DQBY1)H9
MMT.B&K5#JQNT0[8<LD/$';!#V1ZM0^T=JT7\&JE%_QBH1O\6J$;_%:='_Q.G
M1_\3IT?_$Z='_Q/_1 X _TH( /]0!@#_50H _U@- /=9$0#J6!@ WU<D -17
M-0',540$QE10",%26PR]4&40N4YM$[9-=A:T3'T8L4N%&J]*C1NM294=JTF=
M'JE(IB"G2+ AI4B](J1(SR*A2.@BH$GX'I]+_QN>2_\9G4S_%YU,_Q:=3/\6
MG4S_%IU,_Q;_1PL _TT" /]4 @#W6@0 ZUT' .=="P#A7!  TUT> ,I=, '#
M7#\$O5I,"+=85PRS5F 1KU1I%*Q3<1>I47@:IU" '*1/AQZB3X\@H$Z8(9Y-
MH2.<3:LDFDVX)9E,R":63.(FE4[U(I1/_Q^44/\<E%'_&I11_QB44?\8E%'_
M&)11_QC_20@ _U   /M8  #E7@  W6(# -9C!P#480H RF(9 ,)C+ &[8CL#
MM&!("*]=4PRJ6UP1IEID%:-8;!B@5W0;G55['9M4@R"95(LBEE.3))12G262
M4:<GD%&S*(Y1PRF-4=TJC%+R)HM4_R*+5?\>BU;_'(M6_QJ+5O\:BU;_&HM6
M_QK_3 0 _U,  .Q<  #?8@  U&8! ,YH!0#+9P@ PF<6 +IH* &S9S@#K65%
M!ZAC4 RC85D1GU]A%9M=:!B87' ;E5IW'I-9?R&06(<CCE>/)8Q7F2>)5J,I
MAU:O*H55ORN$5M4L@U?O*8-8_B2#6?\@A%K_'H1:_QR$6O\<A%K_'(1:_QS_
M3@$ _U<  .5?  #89@  SFH  ,=L P##:P4 O&P2 +1M)0"M;#4#IVI"!Z%G
M30R<9581F&->%91B91B18&P;CE]T'HQ>>R&)78,DAER,)H1;E2B!6J J?UJL
M+'U:NRU\6L\N>UOL*WQ<_"9\7?\B?5[_'WU>_QU]7O\=?5[_'7U>_QW_4
M]5D  .%C  #2:@  R6X  ,)P 0"]< , MG 0 *YQ(@"H<#("H6X_!IQL2@N7
M:E,0DFA;%(YF8AB+96D;B&-P'H5B>"&"88 D@&"))GU?DBE[7ITK>%ZI+79>
MN"YU7LPO=%[I+75@^B=V8?\C=V+_('=B_QYW8O\>=V+_'G=B_Q[_4@  [%P
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M+V1L]BIF;?\F9FW_(V=N_R!G;O\@9V[_(&=N_R#V60  X&4  ,YO  #"=@
MN7P  +%_  "I@   H( ' )F!%P"4@2@!CH U XA^00B#?$H-?GI2$7IX615V
M=V 9<W9G''!T;A]M<W8C:G)_)F=QB2ED<94K8G"A+6!PL"]><,(O77#?+U]Q
M]2I@<?\F87+_(V)R_R!B<O\@8G+_(&)R_R#O7   W&D  ,IR  "^>@  M8
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M(E"#_Q]0@_\?4(/_'U"#_Q_>:0  R74  +R   "RB   J(T  )V1  "3DP
MA98  'Z7"P!YEQD =9<H 7&7-0-LEC\&:)5("F244 UADU<179)>%5J19AA7
MD&X;5(]W'E&.@2!.CHTC2XV:)4F-J29(C;LG1XW4)T>,\"1(C/\B28O_($J+
M_QY*B_\>2HO_'DJ+_Q[5;@  PWL  +>%  "LC0  HI(  )>6  ",F0  ?YP
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M%#2K_Q2[A0  KY   *.7  "8G0  C*,  ("H  !TK0  :+(  %RV  !0N@$
M2;P- $B\&0!&O2< 1;TS $.]/0%!O4<!/[U0 CV]6 ,ZO6$%.+UK!C:]=P@T
MO80),KV3"C"]I LOO;<,+K[0"RZ\[@PMNOX-++G_#2RX_PXLN/\.++C_#BRX
M_PZSCP  II<  )N=  "/HP  @ZH  ':P  !JM0  7KH  %*^  !'P@$ /<<&
M #C)$  WR1L -LHG #7*,P TRST ,\M' #'+40$PRUL!+LQE BS,<0(JS'\#
M*<R0!"?,H00FS;0$)<W.!"7+[@0DR?P&(\C_!R/'_P<CQ_\'(\?_!R/'_P>I
ME@  GIT  )*C  "%JP  >+(  &NX  !?O@  4L(  $?&   ]R@  -,\$ "O4
M"0 FV0\ )=D9 "7:)0 DVC  (]L[ "/;10 BW%  (=U; "#=:  >WG8 '=Z'
M 1S?F0$:WZP!&=_$ 1C>YP$8W/@!&-O_ A?:_P(7VO\"%]K_ A?:_P*@G
ME*,  (>K  !YLP  ;+H  %_!  !2Q@  1LH  #O.   QTP  *=D  "'>!0 >
MZ X '>@5 !OI'@ 9Z2< &.HP !;J.0 5ZT, %.Q. !+L6@ 1[6< $.YW !#N
MB@ .[YX #O"S  WPS0 ,[^P #.W\  SK_P ,Z_\ #.O_  SK_P"7HP  B:L
M 'NT  !MO   7\0  %+*  !%S@  .=,  "_8   EW0  '>$  !CL @ 6]PL
M%/<1 !'X%P 0^!X #ODE  WY+0 +^C4 "?L_  ?[2@ $_%<  _UF  +^=P
M_8L  /V?  #\M0  _-$  /SM  #\_   _/T  /S]  #\_0"+JP  ?;0  &Z]
M  !@Q@  4LT  $32   WV   +-T  "+A   9Y0  $^H  !#Z   ._P8 #?\,
M  K_$  '_Q0 !/\:  '_(   _R<  /\P  #_.@  _T4  /]3  #_8@  _W4
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M')1(P1V22-@=D$GO&X]*_AB/2_\6CDO_%(Y,_Q*.3/\2CDS_$HY,_Q+_10
M_TL  .E3  #>6   TUL  ,U;! #*6 < PE@5 +I:)P"S6C<!KEA$!*E73P>D
M55@*H51@#9Y3:!";46\3F%!V%990?A>43X89DDZ.&H].F!R-3:(=BTVN'XI-
MO""(3= @ATWK'X9/_!N&4/\8AE#_%H90_Q2&4?\4AE'_%(91_Q3_1P  ^$\
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M)7!;]B!Q7/\<<5W_&G%=_QAQ7?\7<5W_%W%=_Q?]3P  Y5D  --B  #':
MO6P  +9M  "O;   IVL+ *!L&0";;"H!E6LW I!I0P6+:$P)AV94#(-E6Q"
M8V(3?6)I%7IA<!AX87@:=6"!'7-?BQ]P7I8B;EZB)&Q>L"5K7L$F:5[>)FI?
M]"%K8/\=:V'_&VQA_QEL8?\8;&'_&&QA_QCU40  XEP  ,]E  ##:P  N6\
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M'%UM_QI=;?\976W_&5UM_QGH6@  TF8  ,-O  "X=@  KWL  *9^  "=?@
MD7P  (I\#P"%?1X @7TM 7Q\.0-W>D,&<WE+"7!X4PQL=UH0:79A$V9U:!9C
M=&\887-X&UYR@AY;<HT@67&:(E=QJ"15<;DE5''0)51Q[B)6<?X>5W'_'%=Q
M_QI8<?\96''_&5AQ_QGC7@  S6D  +]S  "T>@  JW\  **"  "8@P  BX$
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M%T6%_Q?-;0  O7@  +&"  "GB@  G(X  )*0  "&DP  >94  &R7  !FEPX
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M"S*JGPPQJK ,,*K'##"IYPPOI_H-+Z;_#2^E_PTOI?\-+Z7_#2^E_PVVA
MJHX  )Z4  "4F0  AYX  'NC  !OJ   8ZP  %>O  !+L@  0;4& #ZV$0 ]
MMAX .[8I #JW-  YMSX -[=' #:W4 $TMUH!,K=D C"W;P,NMWP$++>+!2JW
MG 4IMZX&*+C%!2BWY@4GM?D')K/_!R:R_P@FLO\()K+_"":R_PBOC0  HI0
M )>:  "+H   ?J8  '&K  !EL   6;0  $VW  !"NP  .+X! "_""0 MPQ(
M+,,> "O#*0 JQ#, *<0] "C%1P GQ5$ )L5< "7&:  CQG8!(L:& 2#&F $?
MQJL!'L?! 1[&Y $=Q/@"',+_ QS!_P,<P?\$','_!!S!_P2EE   FIH  (ZA
M  "!IP  <ZX  &>T  !:N0  3KT  $+    XPP  +\<  ";+!  >T H &]$1
M !K2&@ 9TB4 &-,O !C3.@ 7U$0 %M10 !7570 4U6L $]9\ !+7CP 1V*0
M$-F[ !#9W@ 0U?, $-/_ !#2_P$0T?\!$-'_ 1#1_P&<F@  D:$  (.H  !U
ML   :+<  %N]  !.P0  0L4  #?(   MS   )-   !S5   5V@4 $.(+ !#C
M$0 .Y!H #N0C  WE+0 ,Y3< "^9"  KF3P )YUT ".=M  ;F@  %YI4 !.:K
M  +FQ  !YN8  .?Y  #G_P  YO\  .;_  #F_P"3H0  A:D  '>Q  !IN0
M6\   $[&  !!R@  -<X  "K2   AU@  &=L  !+?   -XP  "_$(  GS#@ '
M\Q, !/(:  +R(@  \BH  /(T  #R/P  \DP  /)<  #R;0  \H(  /*8  #S
MK0  \\8  /3E  #T]@  ]/L  /3[  #T^P"'J0  >;(  &JZ  !<P@  3LD
M $#.   STP  *-@  ![=   5X0  #^0   KH   %\P   _T!  #\"   ^PT
M /L1  #[%@  _!X  /PF  #\,   _3P  /Y)  #^6@  _FT  /^"  #_F
M_ZP  /_   #_V   _^0  /_D  #_Y ![L@  ;+L  %W$  !/S0  0-(  #+9
M   FW@  &^(  !+F   ,Z@  !>T   #T    _P   /\   #_    _P0  /\)
M  #_#@  _Q(  /\8  #_(0  _RL  /\W  #_1@  _U@  /]K  #_@   _Y4
M /^F  #_LP  _[L  /^[  #_NP#_&R8 _QPD /\:) #_%2< _Q M /\*-@#_
M!4, _P%0 ?\ 7@'_ &L!_P!V ?\ @0#_ (H _P"2 /\ F@#_ *  _P"F /\
MK #_ +( _P"Y /\ P@#_ ,T _P#? /\ [ #_ /@ _P#_ /T _P#] /\ _0#_
M /T _P#] /\ _0#_ /T _P#_'R, _Q\A /\>(0#_&2, _Q,I /\.,@#_#$
M_PE- ?\'6@'_!&<!_P-S ?\#?0'_ X<!_P./ /\"E@#_ IP _P*B /\"J #_
M J\ _P&V /\!O@#_ <D _P'; /\ Z@#\ /8 ^ #_ /<"_P#W _\ ]@3_ /8$
M_P#V!?\ ]@7_ /8%_P#_(A\ _R(< /\A' #_'A\ _Q@D /\5+P#_$CP _Q!)
M /\.5@'_#&(!_PMN ?\+>0'_"X(!_PN+ ?\+D@'_"ID!_PJ? /\*I0#_"JL
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M"+,RS FQ,N4)K3/U":LS_PFJ,_\(J#/_!Z@S_P>G,_\'IS/_!Z<S_P?_-P<
M_SH  /\^  #Z00$ \4$& /$_#0#F/!( VSH? - [,0#*/$  Q#Q- < \6 *\
M.V$#N3MJ!;8Z<@:T.GH'LCF!"+ YB FO.9 *K3B8"JLXH0NI.*H,J#BV#:8X
MQ0VD.-X.H3GQ#9\Z_PR>.O\+G3K_"IPZ_PF<.O\)G#K_"9PZ_PG_.P( _SX
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M&(%*]Q6 2O\2@$O_$(!+_P^ 2_\.@$O_#H!+_P[_0P  [$L  -U3  #.6
MQ%H  +U:  "X5P$ L50. *I6'@"E5BX GU8[ 9M51@.75% %DU-8")!27PJ-
M468,BU!M#HA/=!"&3WP2A$Z%$X).CA6 39D7?DVD&'Q-LAEZ3<,:>4W?&GA.
M]!=X3_\4>$__$GA0_Q!X4/\/>%#_#WA0_P_]1@  YT\  -97  #(7   OU\
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M%69<_Q-G7/\29US_$F=<_Q+M3@  VED  ,AA  "\9P  LVH  *ML  "B:@
MF6<" ))G$0"-9R$ B&<O 81F.P)_940$>V1-!GAC5 EU8EL+<F%A#7!A:0]M
M8' 2:U]Y%&E?@Q=F7HX99%Z:&V)>J!QA7K@=7U[.'5]>[!M@7_T885__%6%?
M_Q-B7_\28E__$F)?_Q+J40  U%P  ,1D  "Y:@  L&X  *=P  ">;@  E&L
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M$U)L_Q/<7   QV<  +EO  "O=@  I7L  )Q\  "1?   @G@  'IY!P!U>10
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M$T*#G11 @JX5/X/"%3Z"XA4_@?<3/X'_$D" _Q% @/\00(#_$$" _Q#&:P
MMW8  *Q_  "BA0  EXD  (R+  "!C0  <XX  &6/  !=CPD 6I 4 %B0(0!6
MD2T 4Y X 5&000).D$D#3)!0!$J/6 5'CV '18YI"4*.<PM C7\-/HV-#SR-
MG! ZC:P1.8W!$3B-X1 XB_80.(K_#SF)_P\YB?\..8G_#CF)_PZ_<@  LGT
M *>&  "<B@  D8X  (:1  !ZDP  ;94  %^7  !4F0$ 3YD/ $Z:&@!,FB<
M2IHR $B:/ %&FD0!1)I, D*:5 - F5P$/IEF!3N9< <YF'P(-YB*"C68F@LS
MF*L+,IB_##*8WPLQEO4+,97_"S&4_PLQD_\+,9/_"S&3_PNX>@  K(4  *&+
M  "6D   BY0  '^7  !RFP  9IT  %J@  !.H@  1:0) $*D$P! I!\ /Z0J
M #ZE-  \I3X .Z5' 3FE3P$WI5@"-:5A C.E; ,QI7D$+Z2'!2VDEP8LI*D&
M*Z2]!BJDW@8JHO4'*:'_!RF@_P@IG_\(*9__""F?_PBQ@@  I8L  )J1  "0
ME@  @YH  ':?  !JH@  7J8  %*I  !&JP  /*T  #6O#  SL!4 ,K A #&P
M*P OL#4 +K$^ "VQ2  LL5$ *[%; "FQ9P$GL70!)K&# 22QE (CL:8"(K*[
M B&RVP(AK_,#(*[_ R"M_P0?K/\$'ZS_!!^L_P2JBP  G9$  ).7  "'G
M>J(  &VG  !@JP  5:\  $FQ   ^M   ,[<  "JZ P DO T (KT5 "&](  A
MO2H (+TS !^^/0 >OD< ';Y2 !R_7@ :OVP &;]\ !B_C@ 7P*$ %L"V !3
MTP 5OO$ %;S_ 16[_P$4NO\"%+K_ A2Z_P*AD@  EI@  (J>  !]I   ;ZH
M &*O  !6M   2K<  #ZZ   SO0  *L   "'$   9QP4 $\L+ !',$@ 1S!L
M$,PE  _-+P .S3H #LU&  W-4@ -SF  #,YP  O.@P *SI< "<ZL  C.Q@ (
MSN@ ",W[  G+_P )R_\ "<O_  G+_P"8F   C9X  '^E  !QK   9+,  %>Y
M  !*O0  /L   #+#   HQ@  '\H  !?-   1T0  #-8%  C9#  &V1( !=H;
M  3:)  #VRX  =LY  #<10  W5(  -YB  #><P  WH@  -^=  #?LP  W\X
M .#N  #?^@  W_\  -__  #?_P"/GP  @:8  '.N  !EM0  6+T  $K"   ]
MQ0  ,<D  ";,   =T   %-0   [9   )W0   ^$   #C!P  XPT  .02  #E
M&0  YB(  .<K  #I-@  ZT,  .Q2  #L8@  [78  .Z,  #NH0  [[<  ._1
M  #OZP  \/8  /#V  #P]@"$IP  =:\  &>W  !9OP  2\8  #S*   OS@
M)-(  !K8   2W   #.    7C    YP   .L   #K    [04  .X+  #P$
M\14  /,>  #T)P  ]S,  /E   #Z40  ^V,  /QW  #]C0  _:,  /ZV  #^
MR0  _]\  /_?  #_WP!WL   :+D  %K!  !,R@  /,\  "[4   BV@  %]X
M !#B   )Y@   .D   #L    \    /8   #V    ]P   /@   #Z!P  ^PT
M /T1  #_&0  _R,  /\O  #_/@  _T\  /]B  #_=P  _XT  /^?  #_K@
M_[H  /^Z  #_N@#_%B, _Q4A /\2(0#_#B0 _P8J /\ ,P#_ $$ _P!. /\
M7 #_ &@ _P!T /\ ?@#_ (< _P"/ /\ E@#_ )P _P"B /\ J #_ *X _P"U
M /\ O0#_ ,< _P#6 /\ YP#^ /, _@#^ /T _P#\ /\ ^P#_ /L _P#[ /\
M^P#_ /L _P#_&B  _QD> /\6'@#_$"  _PHE /\$, #_ #T _P!+ /\ 6 #_
M &0 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_ *H _P"Q /T
MN0#[ ,, ^@#0 /@ XP#W /$ ]@#\ /0 _P#T /\ \P#_ /, _P#S /\ \P#_
M /, _P#_'1P _QP9 /\9&0#_%!L _PXA /\,+ #_"3D _P5& /\"4P#_ %\
M_P!K /\ =0#_ 'X _P"& /\ C@#_ )0 _@"; /P H0#Z *< ^ "N /4 M0#S
M +\ \0#+ /  WP#N .X [ #Y .L _P#J /\ Z@'_ .D!_P#I ?\ Z0'_ .D!
M_P#_(!< _Q\4 /\<$P#_%Q4 _Q8= /\3* #_$#0 _PU! /\,3@#_"5H _PAF
M /\(< #^!WD _ >! /H'B0#X!Y  ]@:6 /,&G0#Q!J, [P:J .T&L@#J!KL
MZ/_B__])0T-?4%)/1DE,10 ("0;( .8&W #D!NP X@CZ . *_P#>"_\ W0O_
M -T,_P#<#/\ W S_ -P,_P#_(Q( _R,0 /\A#@#_'A  _QX8 /\<(P#_&"\
M_Q0[ /\220#\$%4 ^ ]@ /0/:@#Q#W0 [PY\ .T.A #K#HL Z0Z2 .<.F0#F
M#J  Y ZG .(.KP#@#K@ W@[% -P.V@#6$.P TA'Z ,\2_P#-$O\!S!+_ <L3
M_P'*$_\!RA+_ <H2_P'_)P\ _R<, /\E"0#_)@T _R43 /\C' #_("@ ^QPU
M /4:0@#O&$\ ZA=: .8690#C%FX X!9W -X6?P#<%H< V1:. -86E0#4%IP
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M!*(L_P3_,@  _S,  /DX  #I.0  XCD  -XU!P#>+@T T2\; ,DQ+ ##,SL
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M#8D^LPV(/L0.AC_@#H0_] V#0/\+@T#_"H) _PF"0?\(@D'_"()!_PC_/
MZT,  -Q*  #,3P  PU   +Q.  "W20$ L48. *I(' "D22P H$DZ )M)10&8
M2$X"E$=7 Y)'7@6/1F4&C49L!XM%<PF)17L*AT2#"X5$C0R#1)<.@4.B#W]#
MKQ!^0\ 0?$3:$7M$\0]Z1?\->D;_"WI&_PIZ1O\)>D;_"7I&_PGU/@  YD@
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M%652Z11E4OL19E/_#V93_PUF4_\,9E/_#&93_PSJ20  U5,  ,5:  "Z7P
ML&(  *AB  "?7P  EEH  (]:$ "*6QX A5LL (%;. %]6T$">EI* W=9401T
M6%@&<5A?!V]79@EM5VT+:U9V#6E6?P]G58H19567$V-5I!1A5;058%7(%E]5
MYQ5@5OH28%;_#V%7_PYA5_\-85?_#&%7_PSG3   T58  ,%>  "V8P  K68
M *1F  ";9   D%X  (E>#@"$7QL @%\I 'Q?-0%X7S\"=%Y' W%=3P1O7%8%
M;%Q<!VI;8PEH6VL+9EIS#61:?0]B6H@17UF4$UY9HA1<6;(56UG&%EI9Y15;
M6OD26UK_$%Q:_PY<6O\-7%K_#5Q:_PWC3P  S5D  +YA  "S9@  J6D  *!J
M  "7:   BV(  (-B# !^8Q@ >F,F '9C,@!S8SP!;V)% FQA3 1J850%9V!:
M!V5@80AC7VD*85]Q#%]>>PY=7H816EZ3$EA=H!177; 55E[$%E5>XQ567O<2
M5E[_$%=>_PY77O\-5U[_#5=>_PW>4P  R%T  +MD  "P:@  IFT  )UN  "3
M;0  A6<  'YG"0!X9Q4 =&<C '%H+P!N9SD!:V=" FAF2@-E9E(%8V58!F!E
M7PA>9&<*7&1O#%IC>0Y88X0056*1$E-BGQ-28JX546+"%5!BX1518O8246+_
M$%)B_PY28O\-4F+_#5)B_PW95@  Q&   +=H  "L;@  HW$  )IS  "/<0
M?VL  'AK!0!R:Q( ;FP? &ML+ !H;#<!9FQ  F-K2 -@:T\$7FI6!EQJ70=9
M:64)5VEM"U5I=PU3:((/4&B/$4YGG1--9ZP42VC %$MHWA1+9_423&?_#TQG
M_PY-9_\-36?_#4UG_PW26@  P&0  +-L  "I<@  H'8  )9W  "*=@  >7$
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M"SIZ_PO :0  LG0  *=\  "=@0  DH0  (>&  ![AP  ;H<  &"'  !5AP$
M4(@. $Z(&@!-B28 2XDP $F).@!(B4(!1HE* 42)4@)"B5H#0(AC!#V(;04[
MB'@&.8>&"#>'E0DUAZ8*-(>Y"C.'TPHSAO ),X7_"3.$_PDS@_\),X/_"3.#
M_PFY<   K7H  **"  "7AP  C8H  (&,  !UC@  :(\  %J0  !/D0  1Y(*
M $22$P!#DQ\ 09,J $"3-  _DST /9-% #N330$ZDU8!.)-? C:3:0,TDW4#
M,I*#!#"2DP4NDJ0&+9*W!BR2T08LD>\&*X__!BN._P8KC?\'*XW_!RN-_P>S
M>   IX(  )R(  "1C   AY   'J3  !ME0  89<  %69  !)FP  /YP! #F=
M#@ WG1< -IXB #2>+  SGC4 ,IX^ #&>1P PGU  +I]: "V?9 $KGW$!*9Y_
M B>>D (FGJ$"))ZU B.>S@(CG>X#(YO^ R*:_P0BF?\$(IG_!"*9_P2L@0
MH(@  )6.  "+D@  ?Y8  '*:  !EG0  6:   $ZC  !"I   -Z8  "ZH!0 I
MJ0\ **D8 ">J(@ FJBP ):HU "2J/P CJD@ (JM3 "&K7@ @JVH 'JMY !VK
MBP ;JYT &JNQ !FKR@ 9JNP!&:C] 1BG_P(8IO\"&*;_ ABF_P*EB0  F8\
M (^4  "#F0  =9X  &BB  !<I@  4*D  $2L   YK@  +[   ":S   >M08
M&;</ !BW%P 7MR$ %K<J !6W-  4N#X $[A) !*X5  2N6( $;EQ !"Y@P /
MN9< #KFL  VYQ  -N.< #K;[  ZU_P .M/\ #K3_  ZT_P"<D   DI4  (:;
M  !YH   :Z8  %ZK  !2KP  1K(  #JU   OMP  );H  !V]   5P   $,,&
M  O&#@ *Q14 "<4>  C%*  'Q3( !L8]  7&20 %QE<  \9F  +&=P !QHL
M ,:@  #%M@  QM(  ,7O  #%_   Q?\  ,7_  #%_P"5E@  B9P  'NC  !M
MJ0  8*\  %.T  !&N   .KL  "Z^   DP0  &\0  !/'   .R@  ",X!  '0
M"@  T!   - 6  #1'@  TB<  -,Q  #4/   U4D  -98  #6:0  UGP  -:2
M  #6IP  UK\  -;@  #6\P  UOX  -;_  #6_P",G0  ?J0  &^K  !AL@
M5+D  $:]   YP0  +<0  "+'   9RP  $<X   S2   %U0   -L   #< P
MW0H  -X/  #?%   X1P  .(D  #D+@  YCH  .=)  #H60  Z&L  .F!  #I
MF   Z:T  .G%  #IX@  Z?(  .GU  #I]0" I0  <:T  &.U  !5O   1\(
M #G&   LR@  (,X  !;2   /U@  "-L   #?    XP   .4   #G    Z $
M .H'  #K#0  [1$  .\8  #Q(0  \RL  /8X  #W2   ^%H  /EM  #ZA
M^IL  /JO  #ZP@  ^MH  /K?  #ZWP!TK@  9;8  %:^  !(Q@  .<L  "O0
M   ?U   %-H   W?   %XP   .8   #I    [0   .\   #Q    \P   /4
M  #V @  ^ D  /H.  #]$P  _QP  /\H  #_-@  _T<  /]:  #_;@  _X4
M /^:  #_JP  _[D  /^\  #_O #_$2  _Q > /\,'@#_!"$ _P G /\ , #_
M #X _P!, /\ 60#_ &4 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\
MI #_ *H _P"P /\ N #_ ,( _P#. /\ X@#^ /  _0#[ /L _P#[ /\ ^P#_
M /H _P#Z /\ ^@#_ /H _P#_%!P _Q(: /\.&@#_"!P _P A /\ +0#_ #H
M_P!( /\ 50#_ &$ _P!L /\ =@#_ '\ _P"' /\ C@#_ )0 _P": /X H #]
M *8 _ "L /L M #Y +T ^ #) /< W #U .P \P#X /, _P#R /\ \0#_ /
M_P#P /\ \ #_ /  _P#_%Q@ _Q46 /\1%0#_#!< _P4= /\ * #_ #8 _P!#
M /\ 4 #_ %P _P!G /\ <0#_ 'H _ "" /H B0#X )  ]P"6 /4 G #T *(
M\P"H /$ L #P +@ [@## .P TP#J .< Z0#U .< _P#F /\ Y0#_ .4 _P#E
M /\ Y0#_ .4 _P#_&A, _Q@1 /\4$ #_#Q$ _PT9 /\*) #_!3  _P$^ /\
M2P#_ %< _@!B /H ; #U '4 \@!] /  A #N (L [ "1 .L EP#I )X YP"D
M .8 K #D +0 X@"_ .  S0#> ., W #R -H _0#8 /\ U@#_ -4!_P#5 ?\
MU0+_ -4"_P#_'A  _QP- /\7"P#_%0X _Q05 /\1'P#_#BH _PLX /T(10#X
M!E$ ] 1< .X$9@#J!&\ Y@-W .0$?P#B!(8 X 2, -X$DP#=!9H VP6@ -@%
MJ #5!;$ T@6[ - &R0#.!^  S CQ ,D*_P#'"_\ Q@S_ ,4,_P#%#/\ Q0S_
M ,4,_P#_(0P _R & /\< P#_'0H _QL0 /\8& #_%", ]A$P .\./@#J#DH
MY0U6 .$-8 #=#6D V0UQ -4->0#3#8$ T0V( ,\-CP#-#I8 RPZ= ,H.I0#(
M#JX Q@^Y ,00R #"$-\ OA'R +L2_P"Y$_\ MQ/_ ;83_P&V$_\!MA/_ ;83
M_P'_)08 _R,  /\C  #_) , _R$* /T=$0#Q&AL Z!8G .$4-0#:$T, TQ1/
M ,X560#+%6, R!9K ,46<P##%WL P1>" , 8B0"^&)  O!B8 +L9H "Y&:D
MMQFT +4:P@"T&M8 L!OM :T<_ &K'?\!J1W_ :D=_P&H'?\!J!W_ :@=_P'_
M*   _R<  /XJ  #O*@  YR<! .<B"0#D'1  V1L= ,\=+0#)'CP Q"!) +\@
M4P"\(5T N2%E +<B;0"U(G0 LR)\ +$B@P&P(HH!KB*2 :PCFP&K(Z0!J2.O
M :<CO &F),X!HR3H J E^0*>)?\"G27_ IPE_P*;)?\"FR7_ ILE_P+_+
M_RT  .TR  #B-   VC,  -,N P#2)0H R247 ,$G)P"[*38 MBI# +(K3@"O
M*U< K"M@ *HK9P&H*V\!IBMV :0K?0&C*X0"H2N- I\KE0*>*Y\"G"NJ YHK
MM@.9+,<#ERSB Y0M]022+?\#D2W_ Y N_P.0+?\#D"W_ Y M_P/_,   \C,
M .0Z  #6/0  S#P  ,<Y  ##,04 O2X1 +4P(0"P,C  JS,] *<S20"D,U(
MH3-: 9\S8@&<,VD"FC-P IDS=P*7,G\#E3*' Y,RD 22,IH$D#*E!8XRL06-
M,\(&BS/<!HDT\@:'-/\%AC3_!88T_P2%-/\$A33_!(4T_P3\,P  ZSH  -Q!
M  #-1   PT0  +U!  "X.P$ LC<. *LX' "E.2L H3HX )T[1 ":.TT!ESI6
M 90Z70*2.F0"D#IK XXY<@.,.7H$BCF"!8DYBP6'.94&A3F@!X,YK0>".;P(
M@3G3"'\Z[@A].OX'?#O_!GP[_P5\._\%?#O_!7P[_P7T-P  Y4   -)'  #%
M2@  O$L  +5)  "O0P  J3X+ *(_%P"=0"8 F$$T )1!/P"104D!CD%1 8M
M60*)0& #AT!G X4_;02#/W4%@3]]!G\^AP=]/I$(>SZ<"7H^J0EX/K@*=S_-
M"G4_Z@IT0/P(=$#_!W1 _P9S0/\&<T#_!G- _P;Q.P  WT4  ,Q,  "_3P
MME   *Y/  "G2@  H$0' )I%% "51B( D$8P (Q'/ ")1D4!AD9. 8-&50*!
M15P#?D5C!'Q$:@1Z1'$%>41Y!G=$@@AU0XT)<T.9"G%#I@MP0[4,;D3)#&U$
MYPQM1?H*;$7_"&Q%_P=L1?\';$7_!VQ%_P?L/P  V$D  ,=0  "[5   L54
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M"EM2_PE;4?\(6U'_"%M1_PC?2@  R5,  +M:  "P7P  IF$  )UA  "47@
MB%<  (!6"@!Z5Q4 =E<B '-8+@!P5SD ;5=! 6I720)H5E "9E97 V167@1B
M564%8%5M!UY5=PA<58(*6E6.#%E5G U75:L.5E6^#U55VP]55?,-557_"U95
M_PE65?\)5E7_"%95_PC;30  Q5<  +A>  "M8@  HV4  )IE  "08P  @UP
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M"$=B_PC*6   NF(  *YI  "C;@  FG$  )!R  "$<0  =&L  &EI  !C:0L
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M!3AXD08W>*$'-7BS!S1XRP<T=^L'-';]!S1U_P<U=?\&-73_!C5T_P:Y:
MK7$  *)Y  "8?@  C8   (*!  !V@@  :8$  %N!  !1@0  2( * $6!$P!#
M@1X 0H(I $&",@! @CL /H)# #V"2P [@E,!.8)< 3>"9@(U@G$#,X)_ S&!
MC@0P@9\$+H&Q!2V!R 4M@>D$+7_\!2U^_P4M??\%+7W_!2U]_P6S;@  J'@
M )U_  "2@P  B(8  'V'  !PB   8XD  %6*  !+B@  08H" #N+#@ YBQ<
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M !&EOP 0I.( $:+X !&A_P 1H/\!$:#_ 1&@_P&@A@  E8P  (R1  !_E0
M<9H  &2>  !8H0  3*0  $"F   UIP  *JD  "*L   9K@  $K ) !"Q$  0
ML1@ #K$B  ZQ*P -L34 #;%   RQ2P +L5@ "K%G  BQ>  'L8L !;&@  2P
MM0 $L-  !+#O  6O_@ &KO\ !J[_  :N_P"8C@  CY,  (*8  !UG0  9Z(
M %JG  !.JP  0:T  #6O   KL0  (;0  !BV   1N0  #;P#  >^#  #O1(
M ;T9  "^(@  OBL  +XV  "^00  OTX  +]<  "_;0  OX   +Z5  "^J@
MOL(  +WD  "]]@  O?\  +W_  "]_P"2E   A9H  'B@  !JI@  7*L  $^P
M  !"LP  -;8  "JX   @NP  %[X  !#!   +Q   !,<   #)!P  R0T  ,D2
M  #*&0  RR(  ,LK  #--0  SD$  ,Y0  #/8   SW(  ,^'  #/G0  S[,
M ,_.  #/ZP  SO@  ,[^  #._@"(FP  >J(  &RH  !>KP  4+4  $*Y   U
MO   *;\  !["   5Q@  #LD   C,    T    -,   #5    U@8  -@,  #9
M$0  VQ8  -P?  #>*   X#0  .)!  #B40  XV,  .-W  #DC@  Y*0  .2Z
M  #EU   Y>H  .7S  #E\P!\HP  ;JH  &"R  !1N0  0[X  #7"   HQ@
M',D  !/-   ,T0  !-4   #:    W@   .$   #B    Y    .4#  #G"0
MZ0X  .L2  #M&@  [R0  /(Q  #T00  ]%,  /5F  #U?   ]I,  /:I  #W
MO   ]\X  /??  #WWP!PK   8;0  %.[  !%PP  -L<  "?,   ;T   $=4
M  K;    WP   .(   #E    Z0   .P   #M    \    /$   #S    ]00
M /<*  #Z$   _!8  /\A  #_+@  _T   /]3  #_:   _X   /^6  #_J
M_[8  /^_  #_OP#_#1P _PH; /\"&P#_ !X _P D /\ +@#_ #P _P!* /\
M5@#_ &, _P!M /\ =P#_ '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"L
M /\ M #_ +T _P#) /X W0#] .T _ #Z /L _P#Z /\ ^0#_ /H _P#Z /\
M^@#_ /H _P#_$!D _PT7 /\&%@#_ !@ _P > /\ *@#_ #< _P!% /\ 4@#_
M %X _P!I /\ <@#_ 'L _P"" /\ B0#_ )  _@"6 /T G #\ *$ ^P"H /D
MKP#X +@ ]@## /0 T@#S .< \@#V /  _P#O /\ \ #_ .\ _P#O /\ [@#_
M .X _P#_$A0 _P\2 /\+$@#_ !( _P : /\ )0#_ #, _P!  /\ 30#_ %D
M_P!D /T ;0#[ '8 ^0!] /< A #U (L ] "1 /, EP#Q )T \ "C .X J@#L
M +, Z@"] .@ RP#G .$ Y0#Q ., _0#C /\ X@#_ .$ _P#A /\ X #_ .
M_P#_%!  _Q$. /\-#0#_!P\ _P(5 /\ ( #_ "T _P Z /\ 1P#Y %, ]0!>
M /( : #P '  [0!X .L ?P#I (4 Z ", .8 D@#E )@ XP"? .$ I@#? *X
MW "X -H Q0#6 -D U #L -( ^0#1 /\ SP#_ ,X _P#. /\ S@#_ ,X _P#_
M%PP _Q0( /\/!0#_#@L _PP1 /\'&@#_ 28 _  T /0 00#M $T Z0!8 .8
M8@#C &H X !R -X >0#; (  V0"& -8 C0#3 ), T0": ,\ H0#- *H RP"S
M ,D OP#& -  Q0#H ,, ]@#! /\ P +_ +\#_P"_ _\ OP/_ +\#_P#_&P8
M_Q<  /\4  #_$P4 _Q$- /\.% #Y"A\ \ 8L .8#.0#@ T8 W -1 -8$6P#2
M!&0 SP5L ,P%<P#*!7H R 6! ,8%AP#%!HX PP:6 ,$&G0"_!J8 O0:P +L'
MO "Y",T N KE +4+]P"S#?\ L0W_ + -_P"P#O\ KP[_ *\._P#_'@  _QL
M /\;  #Z&@  ]18% /81#0#K#A4 X@LB -@+,0#0##X RPU* ,<-50#$#EX
MP0YF +\.;0"]#G0 NP][ +D/@@"W$(H MA"1 +00F@"R$*, L!&M *\1N@"M
M$<H JA+E *<4]P"E%?\ HQ7_ *(5_P"B%?\ HA7_ *(5_P#_(@  _R   / C
M  #F)   X"$  -P9!0#;$ P T!$9 ,@3*0#"%3< O19$ +D73@"U%U< LQA@
M + 89P"N&&X K!EU *L9? "I&80 J!J, *8:E "D&IX HQNH *$;M "?',4
MGAS? )H=\P&8'O\!EQ[_ 98?_P&5'_\!E1__ 94?_P'_)@  ]"<  .8M  #:
M+P  SRT  ,HG  #''P@ P1P3 +H>(@"T'S$ KR ] *LA2 "H(E( IB): *,C
M8@"A(VD H"-O )XC=P"<(WX FR.& )DDCP&7))D!EB2C 90DL &2);\!D276
M 8XF[P&,)_\"BR?_ HHG_P*))_\"B2?_ 8DG_P'Z*0  [#   -TV  #-.
MQ#<  +XR  "Z*P( M24. *XG'0"H*2L I"HX * J0P"=*TP FBM5 )@K7 "6
M*V, E"MJ 9(K<0&0+'@!CRR! 8TLB@&++)0"BBR? H@LJP*&++H"A2W. X,N
MZ@.!+OP#@"[_ G\N_P)_+O\"?B[_ GXN_P+T+@  Y#<  -(]  #%/P  NS\
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M!69 _P1F0/\$9C__!&8__P3E/0  ST8  +],  "T3P  JE   *)/  "92@
MD40  (I!#0"$0AD @$,F 'U$,@!Z1#P =T1$ '5$3 %R1%,!<$-9 6]#8 )M
M0V<":T-O VE#>01H0X,%9D./!F1#G0=C0ZL'84.]"&!$V0A@1/,'8$3_!E]$
M_P5?1/\$8$3_!&!$_P3@00  RDH  +M0  "P4P  IU4  )Y3  "53P  BTD
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M!5!0_P702P  OU0  +):  "G7@  G6   )1@  ")70  ?%<  ')4  !L4PX
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M!41=D 9#7J '05ZQ!T!>R = 7N@'0%W\!D%=_P5!7?\%05S_!4%<_P7#5@
MM%\  *AF  ">:@  E6T  (IM  !_;   ;V<  &1D  !;8@4 5F(0 %1B&P!2
M8R4 4&,O $YD. !-9$  2V1( $ID3P%(9%<!1F1? D5D: )#9',#06-_!#]C
MC@4]8YX&/&.P!CMDQ@8[9.8&.V/Z!3MB_P4[8O\%/&'_!#QA_P2^6P  L&,
M *5J  ";;P  D7(  (9R  ![<0  ;&T  &!K  !5:0  3V@- $UI%P!+:2$
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M B=[OP(F>^$")GKW B9X_P(F>/\")W?_ B=W_P*N;   HW8  )E\  ".?P
MA((  'B#  !LA   7X0  %&$  !'A   /(0  #.$"0 PA!$ +X0: "V$)  L
MA2T *X4U "J%/@ IA4< *(90 ">&6@ FAF8 )(9S ".&@P AAI4 ((:G 1Z&
MO $>AMX 'H3U 1Z"_P$>@O\!'H'_ 1Z!_P&H=   GGT  )."  ")A0  ?H@
M '&*  !EBP  6(P  $R-  ! C@  -HX  "R/   ED P (Y 3 "*0'  AD"4
M()$N !^1-@ >D4  '9%) !R15  :D6  &9%N !B1?@ 6DI  %9*D !21N0 3
MD=@ $X_T !2._P 4C?\ %(S_ 12,_P&C?0  F(,  (Z(  "$C   =X\  &F1
M  !=DP  4)4  $67   YF   +ID  "6:   =FP( %IT, !6=$P 4G1L $YTD
M !*=+0 1GC< $9Y! !">3  /GE@ #IYG  V>=P ,GHH "YV>  J=L@ )G<P
M"9SL  J;_@ +FO\ "YG_  N9_P"<A   D8H  (B.  ![D@  ;98  &"9  !4
MG   2)\  #R@   PH0  )J,  !VE   5IP  $*D%  NK#0 (JA, !ZH;  :J
M)  %JBX !*HX  *J1  !JE   *I>  "J;@  JH$  *J5  "IJ@  J<$  *CD
M  "H]@  I_\  *?_  "G_P"5BP  C)   '^5  !QF@  8YX  %:B  !*I@
M/:@  #&J   FJP  ':T  !2P   .L@  ";4!  *V"@  M@\  +85  "W'0
MMR4  +<O  "X.0  N$8  +A4  "X9   N'8  +B+  "WH   M[8  +?3  "V
M[P  MOP  +;_  "V_P"/D@  @I<  '2=  !FH@  6*<  $NL   ^KP  ,;$
M ":S   <M@  $[@   V[   &O@   ,$   #"!   P@L  ,,0  #$%0  Q!P
M ,4D  #&+@  R#H  ,E'  #)5P  R6D  ,E]  #)E   R*H  ,C#  #(Y
MR/0  ,C]  #(_0"%F0  =Y\  &BF  !:JP  3;$  #^U   QN   );H  !J]
M   1P   "\,   /'    R@   ,T   #.    SP,  - )  #1#@  TQ(  -49
M  #7(@  VBT  -TY  #>20  WEH  -]N  #?A0  WYP  -^R  #>RP  WN8
M -_T  #?] !YH0  :Z@  %RO  !.M0  0+L  #&^   DP0  &<4  !#(   )
MS    ,\   #3    V0   -P   #=    WP   .$   #B!0  Y L  .80  #H
M%@  ZB   .TK  #P.@  \4L  /%>  #R<P  \XL  /.B  #SM@  \\D  //A
M  #SX0!MJ@  7K$  %"Y  !!OP  ,L0  "3(   7S   #M    ;5    V@
M -X   #B    Y@   .D   #J    [    .X   #P    \@   /0&  #V#
M^1(  /P<  #_*0  _SH  /]-  #_8@  _W@  /^0  #_HP  _[,  /_!  #_
MP0#_!QD _P$7 /\ %P#_ !H _P A /\ *P#_ #D _P!' /\ 5 #_ %\ _P!J
M /\ <P#_ 'L _P"# /\ B@#_ )  _P"6 /\ FP#_ *$ _P"H /\ KP#_ +@
M_P#$ /X U0#\ .H ^P#X /H _P#Y /\ ^ #_ /@ _P#V /\ \P#_ /$ _P#_
M"Q4 _P43 /\ $P#_ !0 _P : /\ )P#_ #0 _P!" /\ 3P#_ %L _P!E /\
M;@#_ '8 _P!^ /\ A0#^ (L _0"1 /L EP#Z )T ^ "C /< JP#V +, ] "^
M /, S #Q ., [P#S .X _P#M /\ [ #_ .L _P#L /\ [ #_ .L _P#_#1$
M_PD0 /\ #P#_ !  _P 6 /\ (@#_ "\ _P ] /\ 2@#_ %4 _0!@ /H :0#X
M '$ ]@!Y /0 ?P#S (8 \0", .\ D@#N )@ [ "? .L I@#I *X YP"X .4
MQ0#C -H X0#M -\ ^P#> /\ W0#_ -T _P#= /\ W0#_ -T _P#_#PT _PP+
M /\#"0#_  P _P 2 /\ '0#_ "D ^P W /@ 1 #U %  \@!: .X 8P#L &L
MZ0!S .< >@#E (  XP"& .$ C #? ), W0"9 -L H0#9 *D U0"R -( O@#0
M ,X S@#F ,P ]@#* /\ R@#_ ,D _P#( /\ R #_ ,@ _P#_$0@ _PT" /\'
M  #_!0@ _P . /\ %@#W "( [P P .L /0#H $D Y !4 .  70#= &4 V0!M
M -4 <P#2 'H T "  ,X AP#, (T R@"4 ,@ FP#& *0 Q "M ,( N #  ,<
MO0#? +P \0"[ /X N0#_ +@ _P"X /\ N #_ +@ _P#_%   _P\  /\-  #_
M#   _P<) /@!$ #H !H XP H -T -@#8 $( T@!- ,X 5P#* %\ QP!F ,4
M;0## '0 P0!Z +\ @0"] (@ NP"/ +D EP"W )\ M0"H +, LP"Q ,( KP#8
M *X"[0"L _L JP7_ *H&_P"I!O\ J0;_ *D&_P#_%@  _Q(  /<2  #L$0
MY@X  .4&" #= Q( U ,@ ,T$+0#(!#H PP5& +\%4 "\!E@ N09@ +<'9P"U
M!VX LP=U +$(>P"O"(( K@F* *P)D@"J"9L J JE *8*L "E"[\ HPS4 *$-
M[0"?#OX G0[_ )P/_P";#_\ FP__ )L/_P#_&@  ]QD  .H>  #?'@  U1H
M - 3 @#.# L QPL6 , -)0"Z#C( M@X_ +(/20"O$%( K!!: *H080"H$6@
MIA%O *01=@"B$7T H1&% )\2C@"=$I< G!*B )H3K0"8$[P EQ30 )05[ "2
M%OT D!?_ (\7_P".%_\ CA?_ (X7_P#Z'0  [B,  -\H  #0*@  QR<  ,$A
M  "]&04 N1(0 +(5'@"M%BP J!<X *080P"A&4P GQE4 )P:7 ":&F( F1II
M )<;< "5&W< E!M_ )(<B "0')( CQR= (T=J0"+';< BA[* (@?YP"&(/H
MA"#_ 8,@_P&#(/\!@B#_ 8(@_P'U)   Y2P  -,Q  #&,P  O#$  +8M  "P
M)0  K!T, *8>& "A("8 G"$R )DB/0"5(D< DR-/ )$C5@"/(UT C21D (LD
M:P"))'( B"1Z (8D@P"$)8T @R68 8$EI & )K(!?B;% 7TGX@%[)_<!>2C_
M 7@H_P%X*/\!>"C_ 7@H_P'O*P  W3,  ,HY  "^.P  M#H  *TV  "F+P
MH2@' )LG$P"6*"  D2DM (XJ. "+*T( B"M* (8K4@"$*U@ @BQ? ( L9@!_
M+&T ?2QU 'LL?@%Z+(@!>"R4 78MH %U+:X"="W  G(NW0)Q+O0"<"__ F\O
M_P)O+_\!;B__ 6XO_P'H,0  TSH  ,,_  "W00  KD$  *8^  ">.   ES$!
M )$N$ ",+QP B# H (0Q,P"!,CT ?S)& 'TR30![,E0 >3); '<R80!U,FD!
M=#)P 7(R>0%P,X0!;S.0 FTSG0)L,ZL":C2\ FDTU0-H-?$"9S7_ F<U_P)F
M-?\"9C7_ F8T_P+B-@  S#\  +U$  "R1P  J$<  *!$  "8/P  D#D  (@T
M#0"#-1< ?S8D 'PW+P!Y-SD =SA" '0X20!R.%  <3A7 &\X7@!M.&4!;#AM
M 6HX=0%H.( "9SB, F4XF0-D.:@#8CFY V$ZT -@.NX#8#K_ U\Z_P)?.O\"
M7SK_ E\Z_P+=.P  QT,  +E)  "N2P  I$P  )M*  "210  B3\  ($Z"0![
M.A0 =SL@ '0\*P!R/#4 ;ST^ &T]1@!K/4T :3U3 &@]6@!F/6$!9#UI 6,]
M<@%A/7T"8#V) EX]E@-=/J4#6SZV!%H^S 1:/^P$63_^ UD__P-9/_\"63__
M ED^_P+6/P  PT<  +5,  "J4   H%   )=/  ".2P  A$4  'I !@!U/Q$
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M TY*CP-,2Y\$2TNP!$I+Q01)2^8$24OZ!$E+_P-*2_\#2DO_ TI+_P/(20
MN%$  *Q7  "A6P  F%P  (Y<  "#60  =E,  &M.  !D30H 7TP3 %Q-'@!:
M32@ 6$TQ %9-.@!434$ 4TY( %).3P!03E<!3TY? 4U.: %,3G,"2D]_ DE/
MC0-'3YT$1D^N!$5/PP1$4.0$1$_Y!$5/_P-%3_\#14[_ T5._P/$3   M54
M *E;  "?7@  E6   (M@  " 7@  <E<  &=3  !>40< 65$1 %=1&P!4424
M4E(O %%2-P!/4C\ 3E)& $U330!,4U4 2E-= 4E39@%'4W "15-] D13BP-"
M4YL#052L!$!4P00_5.($/U3X T!3_P- 4_\#0%/_ T!2_P/ 4   LE@  *9>
M  "<8@  DF4  (AE  !]8@  ;EP  &-9  !95@, 5%8. %%6& !/5B( 35<L
M $Q7- !*5SP 25A$ $A82P!'6%, 15A; 4189 %"6&X!0%A[ C]8B0(]6)D#
M/%BJ SM9OP,Z6> #.ECW SI8_P,[5_\#.U?_ SM7_P.\5   KEP  *-C  "9
M9P  D&D  (5I  !Y9P  :V(  &!@  !570  3EL, $M;% !)7!\ 1UPH $9=
M,0!%73D 0UU! $)=2 !!7E  0%Y8 #Y>80$\7FP!.UYX CE>AP(W7I<"-EZI
M S5>O0,T7]T#-%[U S5=_P(U7?\"-5S_ C5<_P*X60  JF$  *!G  "6;
MC&X  (%N  !V;   9VD  %QF  !19   2&() $1B$0!"8AL 06,D #]C+0 ^
M8S4 /60] #QD10 [9$T .615 #AD7P V9&D!-61V 3-DA0$Q994",&6G B]E
MNP(N9=H"+F3T BYC_P(O8_\"+V+_ B]B_P*S7@  IV8  )QM  "3<0  B',
M 'US  !R<@  9'   %AN  !-;   0FH# #QI#@ Z:A8 .6H@ #AJ*  V:S$
M-6LY #1K00 S;$D ,FQ2 #%L7  O;&8 +FQS "QL@@$J;),!*6RE 2ALN0$G
M;=8!)VOR 2=J_P$G:O\!*&G_ BAI_P*N9   HVP  )ES  ".=@  A'@  'EY
M  !M>   8'<  %-V  !(=0  /G,  #1R"@ Q<Q$ ,',: "]S(P N<RL +70T
M "QT/  K=$0 *71- "AU5P G=6, )75O "1U?P B=9  (76B "!UMP ?==(
M'W3Q !]S_P$?<O\!(''_ 2!Q_P&I:P  GG,  )1Y  "*?   @'X  '1_  !G
M?P  6G\  $U^  !#?@  .'T  "]] @ H?0T )GT4 "1]'  C?B4 (GXM "%^
M-@ A?C\ 'W]( !Y_4@ =?UX '']K !I_>@ 9?XP %W^? !9_LP 5?\X %7[O
M !9\_P 6>_\ %GO_ !=[_P"D<@  FGH  (]_  "%@@  >X0  &V&  !@AP
M5(<  $B(   \B   ,H@  "B(   @B 4 &HD. !F)%0 8B1T %XHF !:*+@ 5
MBC< %(I! !.*3  2BU@ $8ME !"+=0 /BX< #HJ;  V*KP ,BL@ #(GJ  V'
M_  .A_\ #H;_  Z&_P"?>P  E($  (J%  " B   <XL  &6-  !9CP  3)
M $&2   TD@  *I(  "&3   9E   $I8&  Z7#@ -EQ4 #)<=  R7)@ +ER\
M"I<Y  F71  (EU  !I=>  67;@ #EH   9:4  "5J   E;X  )3@  "4]
MD_\  9+_  &2_P"8@@  CH@  (6,  !WCP  :I(  %V5  !0F   1)H  #B;
M   LG   (IT  !F>   2H   #:("  >C"P !HQ   *,7  "C'P  HR<  *,Q
M  "D/   I$@  *16  "D90  HW<  *.+  "CH   HK8  *'2  "A\   H/L
M *#_  "@_P"1B@  B8X  'N2  !MEP  8)L  %.>  !&H0  .:,  "VD   C
MI@  &:@  !&J   ,K   !:X   "O!P  KPT  *\1  "P&   L"   +$H  "Q
M,@  LCX  +),  "R6P  LFP  +*!  "QEP  L:P  +#&  "PZ   K_<  *__
M  "O_P",D   ?Y4  '&:  !CGP  5:0  $>H   ZJ@  +:P  "*N   8L
M$+,   JU   "N    +L   "[    O <  +P-  "]$0  OA8  +\>  # )P
MP3(  ,)   ##3P  PV   ,-T  ##BP  PZ$  ,.X  #"UP  PN\  ,+Z  #!
M_@"!EP  <YT  &6C  !7J   2:T  #NQ   MLP  (;8  !:Y   .NP  ![X
M  #!    Q0   ,<   #(    R0   ,H%  #+"P  S0\  ,X4  #0'   TR8
M -8R  #800  V%,  -EF  #9?   V90  -FK  #9PP  V>$  -GP  #9] !V
MGP  9Z8  %FL  !+L@  /+<  "ZZ   AO0  %<    W$   %QP   ,H   #.
M    T@   -4   #6    V0   -L   #=    WP<  .$,  #C$0  YAD  .DD
M  #L,@  [4,  .Y6  #O:P  [X0  .^<  #OL@  [\8  ._=  #OY !JJ
M6Z\  $RV   ^O   +\   "#$   4R   #,P   +0    U    -D   #>
MX@   .4   #F    Z    .D   #L    [@   / "  #R"0  ]0\  /@7  #\
M(P  _S,  /]&  #_6@  _W$  /^)  #_GP  _[$  /_   #_Q@#_ !4 _P 4
M /\ % #_ !< _P = /\ * #_ #< _P!$ /\ 40#_ %P _P!F /\ ;P#_ '<
M_P!^ /\ A0#_ (L _P"1 /\ EP#_ )T _P"D /\ JP#_ +0 _@"_ /T S@#[
M .8 ^0#V /@ _P#W /\ ]P#_ /< _P#P /\ [ #_ .D _P#_ Q( _P 0 /\
M$ #_ !$ _P 7 /\ ) #_ #( _P _ /\ 3 #_ %< _P!A /\ :@#_ '( _P!Y
M /T @ #\ (8 ^@", /D D@#X )@ ]@"? /4 I@#T *X \@"Y /  Q@#N -X
M[0#P .L _@#J /\ Z0#_ .D _P#G /\ XP#_ .  _P#_!PX _P - /\ "P#_
M  P _P 3 /\ 'P#_ "P _P Z /\ 1@#^ %( ^P!< /@ 90#U &P \P!T /$
M>@#O ($ [@"' .P C0#J ), Z0": .< H0#F *D XP"S .$ OP#? -  W0#I
M -H ^0#9 /\ UP#_ -4 _P#5 /\ U0#_ -0 _P#_"0H _P$% /\  P#_  D
M_P 0 /\ &0#[ "8 ]P T /0 0 #R $P [@!6 .H 7P#G &< Y !N .( = #@
M 'L W@"! -P AP#: (T U@"4 -0 FP#1 *, SP"M ,P N #* ,< R #@ ,8
M\P#% /\ PP#_ ,, _P## /\ PP#_ ,, _P#_"P$ _P,  /\   #_  , _P +
M /, $@#N !\ Z@ M .8 .@#B $4 W@!/ -D 6 #4 &  T0!H ,X ;@#, '0
MR@![ ,@ @0#& (< Q ". ,( E@#  )X O@"G +L L@"Y ,  MP#4 +4 [ "S
M /L LP#_ +( _P"R /\ L0#_ +$ _P#_#0  _P8  /\#  #W    ]  # .<
M#0#@ !@ V@ E -, ,@#. #X R@!) ,8 4@## %H P !A +X : "\ &X N@!T
M +@ >P"V ($ M "( +( D "P )D K@"B *P K0"J +H J #+ *8 Y@"E /<
MI #_ *, _P"B /\ H@#_ *( _P#_$   ^PP  .\.  #F#0  WPD  -H !@#0
M !$ R0 = ,0 *@"_ #< NP!" +< 2P"T %0 L@!; *\ 8@"M &@ JP!N *D
M=0"H 'L I@"# *0 BP"B )0 H "> )X!J "< K4 FP/& )D%X@"8!O0 E@C_
M )4)_P"4"?\ E G_ )0)_P#\$0  \14  .,9  #6&0  S!4  ,<0  #$!PH
MO0,4 +<$(0"R!BX K@@Z *H)1 "G"4T I I5 *(*7 "@"F( G@MI )P+;P";
M"W8 F0Q^ )<,A@"6#)  E R: )(-I@"1#;, CPW% (T.X@"+$/8 B1#_ (@1
M_P"'$?\ AQ'_ (<1_P#V&0  YR   -8D  #()0  OR(  +D<  "T% $ L0T.
M *H.&0"E#R< H1 S )T1/@":$4< F!)/ )425@"3$EP D1)C ) 3:0".$W
MC!-X (L3@0")%(L AQ26 (85H@"$%;  @Q;! ($7W0!_&/0 ?1G_ 'P9_P!\
M&?\ >QG_ 'L9_P#O(0  W2D  ,HM  "^+P  M2P  *XG  "H(   HQ<( )X6
M$P"9%R$ E!DM )$:. ".&D$ BQM) (D;4 "'&U< A1Q> (0<9 ""'&L @!QS
M '\=? !]'88 ?!Z1 'H>G@!X'ZL =Q^\ '8@U !T(?  <B'_ '$B_P!Q(?\
M<2'_ '$A_P#H*   TC   ,(U  "W-P  K34  *4Q  ">*P  F"," )(>$ "-
M(!L B2$G (8B,@"#(SP @2-$ 'XC2P!\)%( >R19 'DD7P!W)&8 =B5N '0E
M=P!S)8$ <2:- &\FF0!N)J< ;2>X &PGS@%J*.T!:2G_ 6@I_P%H*?\!:"C_
M 6@H_P'A+@  RS8  +P[  "Q/0  IST  )\Y  "7,P  CRT  (@G# "#)Q8
M?R@B 'PI+0!Y*C< =RH_ '4J1P!S*TX <2M4 ' K6P!N*V( ;"MJ &LL<@!I
M+'T :"R) &8ME@%E+:0!9"ZT 6,NR@%A+^D!8"_] 6 O_P%@+_\!8"__ 6 N
M_P':-   Q3P  +=!  "L0P  HD,  )E   "0.@  B#0  ( N" !Z+1( =RX>
M ',O*0!Q,#, ;S [ &TP0P!K,4H :3%1 &<Q5P!F,5X 9#%F &,R;P!A,GD
M8#*% 5\RD@%=,Z$!7#.Q 5LTQ@%:-.8!637[ 5DU_P%9-/\!633_ 5DT_P'2
M.   P$   +-%  "H2   GD@  )5&  "+0   @CL  'DU! !S,Q  ;S0: &PT
M)0!I-2\ 9S4W &4V/P!C-D8 8C9- & V5 !?-EL 73=C %PW:P!;-W8!63>"
M 5@XCP%6.)X!53BO E0YPP)3.>0"4SKY 5,Y_P%2.?\!4SG_ 5,Y_P'-/
MO$0  *])  "D3   FDP  )%+  "'1@  ?4   ',[  !L. T :#D7 &4Y(@!C
M.BL 8#HT %XZ/ !=.D, 6SI* %H[4 !8.U@ 5SM@ %8[: !5/',!4SQ_ 5(\
MC0%0/9P!3SVL DX^P0)-/N$"33[X DT^_P%-/O\!33W_ 4T]_P')0   N$@
M *Q-  "A4   EU$  (Y/  "$2P  >44  &Y   !F/0L 8CT4 %\]'@!</B@
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M C]*NP(^2]@"/DKS CY*_P(^2?\!/TG_ 3])_P&]2@  KU(  *-8  "96P
MD%T  (9<  ![60  ;5,  &)/  !73 $ 44H- $Y*%0!,2Q\ 2DLH $E+, !'
M2S@ 1DP_ $5,1@!$3$X 0TU6 $)-7P! 36H /TUV 3U.A $\3I0!.TZE 3E/
MN0(Y3]0".4_R 3E._P$Y3O\!.4W_ 3I-_P&Z3@  K%8  *%;  "77P  C6$
M (-A  !X7@  :5@  %]6  !44@  3$\+ $E/$@!'4!P 15 E $-0+0!"4#4
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M 2=>_P$G7?\!*%W_ 2A<_P&M7   HF0  )AJ  ".;@  @V\  'EO  !N;@
M8&L  %1I  !)9P  /V4  #5C"0 R8Q$ ,&,9 "]D(0 N9"D +60Q "QD.0 K
M94( *F5* "AE5  G95\ )F9K "1F>@ C9HL (F:= "!FL0 ?9LD 'V;K "!E
M_@ @9/\ (&/_ 2%C_P&I8@  GFH  )5P  "*<P  @'4  '5U  !I=   7'(
M $]Q  !$;P  .FX  #!M P I; T )VP4 "9L'  E;20 )&TL "-M-  B;3T
M(6Y& "!N4  >;EL '6YG !QN=@ :;H< &6^: !AOK@ 6;\8 %F[I !=M_  8
M;/\ &&O_ !AK_P"D:0  FG$  )!V  "&>0  ?'L  '%[  !D>P  5WH  $IY
M   _>   -7@  "MW   B=@< '78/ !QW%@ ;=QX &G<F !EW+@ 8=S< %WA
M !5X2@ 4>%8 $WAC !)X<@ 1>(, $'B7  ]XJP .>,, #G?F  YV^@ /=?\
M$'7_ !!T_P"?<0  E7@  (M\  ""?P  =X$  &J"  !=@@  4((  $2"   X
M@@  +H(  "2"   <@@  %(() !&#$  0@Q8 $(,>  Z#)P .@S  #8,Y  V#
M1  ,@U  "X-=  F#;  (@WX !H.1  6"I0 #@KL !(';  2!\@ %@/\ !G__
M  9__P":>0  D'X  (:#  !]A0  ;X<  &*)  !5B@  28L  #V,   QC
M)HP  !V-   5C@  #X\#  J0#  &D!$ !(\8  ./(  !CRD  (\R  "0/0
MD$D  (]6  "/90  CW8  (^*  ".GP  CK0  (W/  ",[@  C/L  (O_  "+
M_P"4@   BX4  (*)  !TC   9H\  %F1  !,DP  0)4  #26   HE@  'I<
M !68   /F@  "IL   *<"0  G X  )P3  "<&@  G"(  )TK  "=-0  G4
M )U.  "=7   G6X  )R!  "<EP  G*P  )O&  ":Z   F?D  )G_  "8_P".
MB   AHP  'B0  !JE   7)<  $^:  !"G0  -IX  "F?   ?H0  %:(   ZD
M   (I@   *@   "I!   J0H  *D.  "I$P  JAH  *HB  "K*P  K#8  *Q$
M  "L4P  K&,  *QW  "KC@  JZ0  *N\  "JW@  J?0  *G]  "I_P")C@
M>Y,  &V7  !?G   4:   $2D   VI@  *J@  !ZI   4JP  #:X   :P
ML@   +4   "U    M0,  +8)  "W#@  N!(  +@9  "Z(0  NRL  +PX  "]
M1P  O5@  +UK  "]@0  O9D  +VP  "]S   O.H  +SW  "[_@!^E0  <)L
M &*@  !3I0  1JH  #BM   JKP  'K$  !.T   ,MP   [D   "\    OP
M ,(   #"    PP   ,0   #&!@  QPP  ,@0  #*%@  S"   ,\K  #0.@
MT4L  -%>  #2<P  THL  -*D  #3NP  T]@  -/M  #3]@!SG0  9*,  %:I
M  !'KP  .;,  "JV   =N0  $KP   J_    PP   ,8   #)    S0   ,\
M  #0    T@   -0   #6    V0(  -L(  #>#@  X1,  .0=  #H*@  Z#P
M .E/  #I9   ZGP  .N5  #KK   Z\(  .S5  #LY0!FI@  6*P  $FS   [
MN0  *[P  !W    1Q   "<@   #,    SP   -,   #9    W0   .    #A
M    XP   .4   #G    Z@   .P   #N!   \0L  /42  #X'   ^RL  /T^
M  #^4P  _FH  /^#  #_FP  _ZX  /^^  #_R@#_ !( _P 0 /\ $0#_ !,
M_P 9 /\ )@#_ #0 _P!! /\ 30#_ %@ _P!B /\ :P#_ ', _P!Z /\ @0#_
M (< _P"- /\ DP#_ )D _P"@ /\ IP#^ *\ _ "Z /H R0#Y .$ ^ #S /<
M_P#V /\ ]0#_ /$ _P#I /\ Y #_ .$ _P#_  \ _P - /\ #0#_  X _P 4
M /\ (0#_ "X _P \ /\ 2 #_ %, _P!= /\ 9@#^ &T _ !U /L >P#Y ((
M^ "( /< C@#V )0 ] "; /, H@#Q *H [P"T .T P0#K -4 Z@#L .@ _ #G
M /\ Y0#_ .8 _P#@ /\ V0#_ -0 _P#_  L _P ( /\ !@#_  D _P 0 /\
M' #_ "D _P V /\ 0@#[ $X ]P!7 /0 8 #R &@ [P!O .T =@#L 'P Z@""
M .@ B #G (X Y0"5 ., G #A *0 WP"N -T N0#: ,H UP#D -0 ]@#1 /\
MT #_ -  _P#/ /\ RP#_ ,< _P#_  , _P   /\   #_  0 _P - /H %@#V
M ", \P P /  / #M $< Z0!1 .4 6@#B &( WP!I -T ;P#: '8 V !\ -0
M@@#2 (@ T "/ ,T E@#+ )X R0"H ,< LP#% ,$ P@#8 ,  [P"_ /X O@#_
M +T _P"\ /\ O #_ +P _P#_ @  _P   /\   #_    ]  ' .T $0#H !P
MXP I -\ -0#; $$ U@!+ -$ 5 #- %P R@!C ,@ :0#& &\ PP!U ,$ >P"_
M (( O@"( +P D "Z )@ N "B +4 K "S +D L0#+ *\ YP"N /@ K #_ *L
M_P"L /\ K #_ *L _P#_!   _P   /8   #N    YP   -\ # #6 !4 SP B
M ,H +@#' #H PP!$ ,  30"\ %4 N0!< +< 8P"U &D LP!O +$ =0"O 'L
MK0"" *L B@"I )( IP"< *4 I@"C +, H0## )\ W@"> /( G0#_ )P _P"<
M /\ FP#_ )L _P#_!P  ]@D  .D+  #?"@  U00  ,X !0#& !  P  : +L
M)P"W #( LP ] +  1@"M $\ J@!6 *@ 7 "F &, I !H *( ;P"A '4 GP!\
M )T A "; (T F0"7 )< H@"5 *X DP"] )$ TP"0 .T CP#\ (X _P"- ?\
MC0'_ (T!_P#Y#@  ZA(  -P5  #-%0  Q!$  +X,  "Z @H M  2 *X '@"J
M "H I@ U *( /P"@ $@ G0%0 )L"5@"9 EP EP-C )4#:0"3 V\ D01V ) $
M?P".!8@ C 62 (H&G@"(!JH A@>Z (4(SP"$"NL @@O\ ($,_P" #/\ @ S_
M ( ,_P#Q%0  X!T  ,T@  #!(0  N!T  +$7  "L$   J D- *('%@"="2,
MF0HN )4+. "3#$$ D Q) (X-4 ",#5< B@U= (@-8P"'#6H A0YQ (,.>@""
M#H0 @ Z/ 'X/FP!\#Z@ >Q"X 'H0S@!X$>P =A+_ '42_P!T$_\ =!/_ '03
M_P#H'@  TR8  ,,J  "X*@  KB@  *<C  "@'   FQ,# )8/$ "0$!L C!$G
M (D2,@"&$SL A!-# ((42P" %%$ ?A17 'P47@![%64 >15L '<5= !V%GX
M=!:* '(7E@!Q%Z0 ;QBT &X8R0!M&>@ :QK\ &H;_P!J&_\ :AO_ &H;_P#@
M)@  RBT  +PQ  "P,P  IS$  )\L  "7)@  D!\  (H7# "%&!8 @1DB 'X:
M+ ![&S8 >1L^ '<<10!U'$P <QQ3 '$=60!P'6  ;AUG &T>< !K'GH :AZ%
M &@?D@!G'Z  92"P &0AQ0!C(>0 8B+Z &$B_P!A(O\ 82+_ &$B_P#7+
MPS0  +8X  "J.0  H3@  )@U  "0+P  B"@  ( A" ![(!( =R$= '0B)P!Q
M(C$ ;R,Y &TC00!K(T@ :2-. &@D50!F)%L 921C &,E:P!B)74 826! %\F
MC@!>)IT 72>M %LHP0!;*.  6BGW %DI_P!9*?\ 62G_ %DH_P#/,@  OCD
M +$]  "F/P  G#\  ),\  "*-@  @3   'DJ P!R)@\ ;B<9 &LH(P!I*"P
M9BDU &4I/ !C*4, 82I* & J40!>*E< 72I? %PK: !:*W( 62Q] %@LBP!6
M+9H 52VJ %0NO0!3+MP 4B_U %(O_P!2+O\ 4B[_ %(N_P#*-@  NCT  *U"
M  "B1   F$0  (]!  "%/   >S<  '(Q  !K+ P 9RT5 &0M'P!A+B@ 7RXQ
M %TN.0!<+T  6B]& %@O30!7+U0 5C!< %4P9 !3,6X 4C%Z %$QB !0,I<
M3C*H $TSNP!---@ 3#3S $PT_P!,-/\ 3#/_ $PS_P#&.@  MD(  *E&  ">
M20  E4D  (M'  "!0@  =ST  &TW  !D,@D 8#(2 %TR' !:,B4 6#,M %8S
M-0!5,SP 4S1# %(T2@!1-%$ 4#19 $\U80!--6P 3#9W $LVA0!*-Y4 2#>F
M $<XN %'.-,!1CCQ 48X_P%&./\ 1CC_ $8W_P#!/@  LD4  *9*  "<30
MDDT  (A+  !^1P  <T(  &D]  !?-P8 6C80 %<W& !4-R( 4C<J % W,@!/
M.#D 33A  $PX1P!+.$X 2CE6 $DY7P!(.FD 1SIU $4[@P!$.Y, 0SRD 4(\
MM@%!/= !03WP 4$]_P%!//\!03S_ 4$\_P"^0@  KTD  *-.  "94   CU$
M (50  ![3   ;T8  &5"  !:/0( 5#L. %$[%0!/.Q\ 33LG $L[+P!)/#8
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M #))_@ R2/\ ,DC_ #-(_P"T3   IU0  )Q9  "27   B%T  'Y=  !S6@
M954  %M2  !03@  1DH% $!)#@ ^218 /4D> #M*)@ Z2BX .4HU #A+/0 W
M2T0 -DM- #1,5@ S3&  ,DQL #%->@ P38L +DV< "U.KP L3L< +$[I "Q-
M_0 M3?\ +4S_ "U,_P"P4   I%@  )E=  "/80  AF(  'MA  !P7P  8EL
M %A8  !.50  0U$! #M/#  X3Q, -D\; #5/(P T4"L ,U R #)0.@ Q4$(
M,%%* "Y14P M4ET +%)I "M2>  I4H@ *%.: "=3K0 F4\4 )E/G "93_  G
M4O\ )U'_ "=1_P"L50  H%P  )9B  "-9@  @V<  'AF  !M90  8&$  %5>
M  !*6P  /U@  #56"  Q51  ,%87 "Y6'P M5B< +%8O "M7-@ J5SX *5='
M "A74  F6%H )5AG "18=0 C688 (5F8 "!9JP ?6<( 'UGE !]8^@ @6/\
M(%?_ "%7_P"H6@  G6(  )-G  "*:P  ?VP  '5L  !J:P  76@  %%E  !&
M8P  .V   #%> P J70T *%T3 "9=&P E7B, )%XJ "->,@ B7CH (5Y# "!?
M3  ?7U< 'E]C !Q@<0 ;8(( &6"5 !A@J0 78,  %F#B !=?^0 87O\ &5[_
M !E=_P"D8   F6@  )!N  "&<   ?'(  ')R  !F<0  6&X  $QL  !!:P
M-FD  "UG   C9@@ 'V8/ !UF%0 <9AT &V8E !IF+0 99S4 &&<^ !=G2  6
M9U, %6A? !-H;@ 2:'\ $6B2 !!HI@ /:+T #FC@ !!G]P 09O\ $67_ !%E
M_P"?9P  EF\  (QS  ""=@  >'@  &UX  !@=P  4W8  $9T   [<P  ,7(
M "=Q   ><0  %G * !-P$  3<!< $G ? !%Q)P 0<2\ $'$X  YQ0@ .<4X
M#7%;  QQ:0 +<7H "G&-  AQH0 &<;8 !G#2  =P[P (;_\ "6[_  EN_P";
M;P  D74  (=Y  !^?   ='X  &9^  !9?@  37X  $!]   U?0  *GP  "%\
M   8?   $7P$  Q\#  *?!$ "7P9  A\(0 '?"D !GPR  1\/0 #?$@  7Q5
M  !\8P  ?'0  'R'  ![G   >[$  'K+  !YZP  >?H  'G_  !X_P"6=P
MC'P  (.   !Y@P  ;(0  %Z%  !1A@  18<  #F'   MAP  (X<  !J'   2
MAP  #8@!  :)"@ !B0\  (D4  "(&P  B",  (DL  ")-@  B4(  (A.  "(
M70  B&T  (B!  "'E0  AZL  (;$  "%Y@  A/@  (3_  "$_P"0?@  AX,
M 'Z'  !QB0  8XL  %:-  !)CP  /)$  #"1   DD0  &I(  !*3   -E
M!I4   "6!@  E@P  )40  "6%0  EAT  )8D  "6+@  ECD  )9&  "650
MEF4  )9X  "5C@  E:0  )2\  "3WP  D_4  )+_  "2_P"+A@  @XH  '6-
M  !GD   690  $R7   _F0  ,IH  ":;   ;G   $IT   R?   $H    *(
M  "C 0  HP<  *,,  "C$   I!4  *0<  "E)0  IB\  *8\  "F2P  IEL
M *9N  "EA   I9L  *2S  "CT   H^\  *+\  "B_P"&C0  >)$  &J5  !<
MF0  3IT  $&@   SH@  )J,  !NE   1IP  "JD   &K    K0   *\   "P
M    L    + %  "Q"P  L@\  +,4  "T&P  M20  +<P  "W/P  MU   +=B
M  "W>   MY   +:I  "VP@  MN0  +;U  "U_@![DP  ;9@  %^=  !0H@
M0J8  #2I   FJP  &JT  !"O   )L@   +0   "W    N@   +P   "]
MO@   +X   #  @  P0@  ,(-  #$$@  QAD  ,DD  #*,@  RT,  ,M5  #,
M:@  S(,  ,R<  #+M0  S,X  ,SI  #,]@!PFP  8:$  %*F  !$JP  -K
M ">R   :M0  $+@   >[    O@   ,$   #$    R    ,L   #+    S0
M ,X   #0    T@   -4#  #8"@  VQ   -X8  #B)   XS4  .1(  #E7
MYG,  .:-  #FI0  YKP  .;3  #GYP!CI   5:H  $:P   XM0  *+D  !J\
M   /P   !<0   #'    RP   ,\   #4    V    -P   #=    WP   .$
M  #C    Y0   .@   #J    [08  /$.  #U%@  ^"4  /DX  #Y30  ^F,
M /M\  #\E0  _*H  /R[  #]RP#_  \ _P . /\ #@#_ !  _P 6 /\ (P#_
M #  _P ] /\ 20#_ %0 _P!> /\ 9@#_ &X _P!V /\ ? #_ (( _P") /\
MCP#_ )4 _@"; /T HP#[ *L ^@"U /D PP#W -L ]@#P /0 _P#S /\ \@#_
M .P _P#B /\ W #_ -8 _P#_  P _P ) /\ " #_  H _P 2 /\ '@#_ "L
M_P X /\ 1 #_ $\ _P!9 /X 80#\ &D ^@!P /@ =P#W 'T ]@"# /0 B0#R
M (\ \0"6 .\ G0#M *4 [ "O .H O #H ,T Y@#H .0 ^@#C /\ X@#_ .
M_P#5 /\ S@#_ ,L _P#_  8 _P ! /\   #_  0 _P . /\ &0#_ "4 _0 R
M /L /@#W $D \P!3 /  7 #N &, [ !J .H <0#H '< Y@!] .0 @P#B (D
MX "0 -X EP#< )\ V0"I -8 M #3 ,0 T #> ,X \P#, /\ RP#_ ,H _P#(
M /\ P@#_ +X _P#_    _P   /\   #_    ^P + /8 $P#Q "  [0 L .H
M. #G $, XP!- .  5@#< %T V0!D -4 :P#2 '$ T !V ,X ? #, (, R@")
M ,@ D0#& )D Q "C ,$ K0"_ +L O0#/ +L ZP"Y /P MP#_ +< _P"V /\
MM #_ +$ _P#_    _P   /\   #V    [@ % .< #P#A !D VP E -4 ,0#2
M #P S@!& ,H 3P#' %< Q !> ,$ 9 "_ &H O0!P +L =@"Y 'P N "# +8
MB@"S ), L0"< *\ IP"M +, JP#% *D X0"G /4 I@#_ *4 _P"D /\ I #_
M *0 _P#_    _    /$   #H    X    -0 "P#, !, QP ? ,( *@"_ #4
MO  _ +@ 2 "U %  LP!7 +  7@"N &0 K !I *L ;P"I '4 IP!\ *4 A "C
M (P H0"6 )\ H0"= *T F@"\ )@ T@"7 .X E0#^ )0 _P"5 /\ E0#_ )4
M_P#\ 0  \ 4  .,'  #5!0  S    ,4 ! "^  X N  7 +, (P"O "X JP X
M *D 00"F $H HP!1 *$ 5P"? %T G0!C )L :0": &\ F !V )8 ?0"4 (8
MD@"0 )  FP". *< C "V (H R0"( .< AP#Y (< _P"& /\ A@#_ (8 _P#T
M#   Y!   -$2  #%$0  O0X  +8(  "Q  @ JP 1 *8 &P"A "8 G@ Q )H
M.@"8 $, E0!* ), 40"1 %< CP!= (X 8P", &D B@!P (@ =P"& (  A "+
M (( E@"  *, ?@"Q 'T Q ![ N$ >@/U 'H%_P!Y!?\ > ;_ '@&_P#J$P
MUAH  ,8=  "Z'   L1D  *H3  "D#0  GP4, )D % "5 !\ D0(I (T#,P"+
M!#P B 5$ (8&2P"$!E$ @@=7 ($'70!_!V, ?0AJ 'L(<@!Z"'P > F& '8)
MD@!T"J  <PJO '$+P0!P#-\ ;PWV &X._P!M#O\ ;0[_ &T._P#A'   RR,
M +PF  "Q)@  J"0  * >  "9&   DQ " (X+#@"("Q< A PB ($-+ !^#34
M? X] 'H.10!X#DL =PY1 '4/6 !S#UX <1!E ' 0;@!N$'< ;!"" &L0CP!I
M$9T :!&M &82P !E$M\ 9!/V &,4_P!C%/\ 8A3_ &(4_P#6)   PRH  +4N
M  "J+P  H"T  )@H  "0(@  B1L  ((3" !]$1( >1(< '83)P!S%#  <10X
M &\5/P!M%48 ;!5, &H64P!H%ED 9Q9A &46:0!D%W( 8A=^ &$8BP!?&)D
M7AFI %P9O !<&M@ 6AOS %H<_P!9'/\ 61S_ %D<_P#-*@  O3$  *\U  "D
M-@  FS0  )(Q  ")*P  @24  'D= P!S& X ;QD8 &P:(@!I&RL 9QLS &4<
M.P!D'$$ 8AU( & =3@!?'54 71U< %P>9 !;'FX 61]Y %@?AP!6()8 52"F
M %0AN !3(=( 4B+Q %(C_P!2(_\ 4B+_ %(B_P#(+P  N#8  *LZ  "@/
MECL  (TX  "#,@  >BT  '(F  !J( P 9B 3 &,A'0!A(28 7R(O %TB-@!;
M(CT 6B-$ %@C2@!7(U$ 52-8 %0D80!3)&H 425V % E@P!/)I, 3B>C $PG
MM0!,*,X 2RCN $LI_P!+*/\ 2RC_ $LH_P##-   LSL  *<_  "<00  DD
M (D^  !_.0  =3,  &PM  !C)P@ 7B81 %PF&0!9)R( 5R<K %4H,@!4*#D
M4BA  %$H1@!0*4T 3BE5 $TI70!,*F< 2RIS $DK@ !(*Y  1RRA $8MLP!%
M+<L 12[L $0N_P!$+O\ 12W_ $4M_P"^.   L#\  *1#  "910  CT4  (5#
M  ![/@  <3D  &<T  !>+@0 6"L. %4K%@!2+!\ 4"PG $\L+P!-+38 3"T\
M $HM0P!)+4H 2"Y2 $<N6@!&+V0 12]P $,P?@!",(T 03&> $ RL0 _,L@
M/S/J #\S_@ _,O\ /S+_ #\R_P"[/   K4,  *%'  "620  C$D  (-(  !X
M1   ;3X  &,Y  !:-   4C , $\P$P!,,!P 2C D $DQ*P!',3( 1C$Y $0Q
M0 !#,D< 0C)/ $$S6 ! ,V( /S1M #XT>P ]-8L /#:< #LVKP Z-\8 .3?H
M #DW_  Z-_\ .C;_ #HV_P"W0   JD8  )Y+  "430  BDX  (!,  !U2
M:D,  & ^  !6.0  334) $DT$0!'-1D 134A $,U* !!-2\ 0#4V #\V/0 ^
M-D4 /3=- #PW50 [.&  .CAK #DY>0 X.8D -SJ; #4ZK0 U.\0 -#OF #0[
M^P U._\ -3K_ #4Z_P"T0P  ITH  )Q.  "240  B%(  'Y0  !S30  9T@
M %Q$  !2/P  2#H& $0Y#P!!.18 /SD> #XY)@ \.2T .SHT #HZ.P Y.T(
M.#M* #<\4P V/%T -3UI #0]=P S/H< ,3Z9 # _JP O/\( +S_D "\_^@ P
M/_\ ,#[_ # ^_P"Q1P  I$T  )E2  "/50  AE8  'Q5  !Q4@  9$P  %E)
M  !/10  14 # #\^#0 \/A, .CX; #D^(P W/BH -C\Q #4_.  T/T  ,T!(
M #) 40 Q05L ,$%G "Y"=0 M0H4 +$.7 "M#J@ J0\  *43B "I#^0 J0_\
M*T+_ "M"_P"N2@  H5$  )=6  "-60  @UH  'E:  !N5P  85(  %=.  !-
M2P  0T<  #I#"@ V0Q$ -$,8 #-#(  R1"< ,40O #!$-@ O13T +45& "Q%
M3P K1ED *D9D "E'<@ H1X, )D>5 "5(J  D2+X (TC@ "1(]P E1_\ )4?_
M "9'_P"J3P  GU4  )1:  "+7@  @5\  '=>  !K7   7U@  %55  !+40
M0$T  #5*!P P20X +DD5 "U)'0 L220 *THK "I*,P H2CL )TM# "9+3  E
M2U8 )$QB "-,<  A3(  ($V3 !]-I@ >3;L '4[= !Y-]@ >3/\ 'TS_ "!+
M_P"G4P  G%H  ))?  "(8P  ?F0  '1C  !I80  7%X  %);  !'6   /%4
M #)2 @ J4 P )T\2 "90&0 E4"  )% H "-0+P B43< (5%  "!120 >4E,
M'5)? !Q2;0 :4WT &5.0 !A3I  64[D %5/9 !93]  74O\ &%'_ !E1_P"C
M60  F&   (]E  "%:   >VD  '%I  !F9P  660  $UA  !"7P  .%P  "Y:
M   E6 @ (%<. !Y7%  =5QP '%@C !M8*P :6#, &5@\ !A810 665  %5E;
M !19:0 36GH $EJ- !%:H0 06K< #EK5 !!9\P 06?\ $5C_ !%8_P"?7P
ME68  (QK  "";0  >&X  &YO  !B;0  56H  $AH   ^9@  ,V4  "EC   @
M80$ && + !5@$  48!< $V > !)@)@ 28"X $6$W !!A0  /84L #F%8  UA
M9@ ,8G8 "V*)  IAG0 )8;( "&'+  AAZP )8/T "E__  M?_P";9@  DFT
M (AQ  !^<P  =74  &IT  !<<P  3W(  $-P   X;P  +6X  "1L   ;:P
M$VL$  YJ#  -:A( #&H9  MJ(0 *:BD "6HR  AJ/  ':T< !6M3  1K80 "
M:W$  &J$  !JF   :JT  &G&  !IYP  :?@  &C_  !H_P"7;0  C7,  (1W
M  ![>@  <'L  &-[  !6>@  27H  #UY   Q>   )W<  !UV   5=@  #W8"
M  EV"@ $=@\  '85  !V'   =B0  '4L  !U-@  =4$  '5.  !U7   =6P
M '5^  !TDP  =*@  '/   !SXP  <O<  '+_  !Q_P"2=0  B7H  (!^  !V
M@   :8$  %N"  !.@@  08(  #6#   I@@  'X$  !:!   0@@  "H(   *#
M!P  @@T  ((1  ""%P  @AX  ((F  ""+P  @CL  ()'  ""50  @64  (%X
M  "!C0  @*(  '^Z  !_W0  ?O0  'W_  !]_P"-?   A($  'N$  !NA@
M8(@  %**  !%BP  .8P  "R,   AC   %XP  !"-   )C@   H\   "0 P
MCPD  (\.  "/$@  D!@  ) ?  "0*   D#(  ) _  "030  D%T  (]P  "/
MA0  CIP  (ZS  "-T   C/   (O^  "+_P"(A   @(@  '*+  !DC0  5I
M $B3   [E0  +I8  "*6   7EP  #Y@   B9    FP   )T   "=    G0,
M )T)  "=#0  GA$  )X7  "?'P  GRD  * U  "@0P  H%0  *!F  "?>P
MGI,  )ZK  "=Q@  G>D  )SY  "<_P"#BP  =8X  &>2  !9E@  2YD  #V<
M   PG@  (Y\  !>@   .H@  !Z0   "F    J    *H   "J    J@   *L!
M  "K!P  K P  *T0  "N%@  KQX  +$I  "Q.   L4@  +%:  "Q;P  L8@
M +&@  "PN@  K]T  *_R  "O_0!XD0  :I8  %R:  !-GP  /Z,  #&F   C
MIP  %ZD   ZK   %K@   +    "R    M0   +<   "W    N    +D   "Z
M    O ,  +T)  "^#@  P!0  ,,>  #%*P  Q3P  ,9.  #&8@  QGH  ,:4
M  #&K0  QL@  ,7E  #%\P!LF0  7IX  $^D  !!J   ,JP  "2O   6L0
M#;0   .W    N@   +T   #     Q    ,8   #&    R    ,D   #+
MS    ,X   #0!@  TPT  -@3  #<'@  WBT  -]   #@5   X6L  .&%  #A
MGP  X;<  .'/  #AY@!@H0  4J<  $.M   TL@  );4  !>Y   -O    ;\
M  ##    QP   ,H   #/    TP   -8   #7    V@   -P   #?    X0
M .,   #F    Z0$  .P+  #P$@  \Q\  /0Q  #V1@  ]UP  /AT  #XCP
M^:8  /FX  #XR0#_  T _P + /\ "P#_  X _P 3 /\ 'P#_ "P _P Y /\
M10#_ %  _P!9 /\ 8@#_ &H _P!Q /\ =P#_ 'X _P"$ /X B@#] )  _ "7
M /H G@#Y *< ]P"Q /8 O@#U -( \P#L /$ _@#P /\ \ #_ .8 _P#< /\
MT@#_ ,T _P#_  < _P $ /\  @#_  8 _P 0 /\ &P#_ "< _P S /\ /P#_
M $H _@!4 /L 70#Y &0 ]P!K /4 <@#S '@ \@!^ /  A #O (H [0"1 .P
MF0#J *$ Z "K .8 M@#D ,< X@#C .  ]P#> /\ W0#_ -D _P#, /\ Q0#_
M ,$ _P#_    _P   /\   #_  $ _P - /\ %@#\ "( ^0 N /8 .0#S $4
M[P!. .P 5P#I %X Y@!E .0 ; #B '( X !W -\ ?@#= (0 VP"+ -@ D@#5
M )L T@"D ,\ KP#- +X RP#5 ,D [P#' /\ Q0#_ ,0 _P"^ /\ N #_ +4
M_P#_    _P   /\   #^    ]P ) /$ $0#K !P YP H .0 ,P#A #X W0!(
M -@ 40#3 %@ T !? ,X 90#, &L R@!Q ,@ =P#& 'T Q "$ ,( C #  )0
MO@"> +L J "Y +8 MP#( +4 Y@"S /H L0#_ +  _P"P /\ K #_ *D _P#_
M    _P   /H   #Q    Z  # .  #0#8 !8 T0 B ,T +0#* #< Q@!! ,(
M2@"_ %( O0!9 +H 7P"X &4 MP!J +4 < "S '8 L0!] *\ A0"M (T JP"7
M *D H0"G *X I0"^ *( V "@ /( GP#_ )X _P"> /\ G@#_ )P _P#_
M]P   .L   #A    U@   ,L "0#% !$ OP ; +L )@"W #$ M  Z +$ 0P"N
M $L JP!2 *D 6 "G %X I@!D *0 :0"B '  H !V )X ?@"< (8 F@"0 )@
MFP"6 *< E "V )( R@"0 .D CP#\ (X _P"- /\ C #_ (T _P#X    Z0(
M -L#  #, 0  Q    +T  @"V  T L  5 *L ( "G "H I  T *$ / "> $0
MG !+ )H 4@"8 %@ E@!= )4 8P"3 &D D0!P (\ =P"- (  BP"* (D E0"'
M *$ A0"O (, P0"! .  @ #U '\ _P!_ /\ ?P#_ '\ _P#N"@  W X  ,H0
M  "^#@  M0L  *\#  "I  < HP 0 )X & "9 ", E@ L ), -0"0 #X C@!%
M (P 2P"* %$ B !7 (8 70"% &, @P!J ($ <0!_ 'H ?0"$ 'L CP!Y )P
M=P"J '4 NP!T -0 <@#P '( _P!R /\ <0#_ '$ _P#C$0  S1<  +\9  "S
M&0  JA4  *,0  "="@  EP$* )$ $@"- !L B0 E (4 +P"# #< @  ^ 'X
M10!] $L >P!1 'D 5P!X %T =@!D '0!:P!R 70 < )_ &X"BP!L Y@ :P.F
M &D$MP!H!<X 9P?L &8(_0!F"?\ 90G_ &4)_P#6&@  Q"   +8C  "K(P
MH2   )D;  "2%   C X! (8'#0" !!0 ? 8> 'D'* !V"#  = @X '()/P!P
M"44 ;PI, &T*4@!L"E@ :@M? &@+9P!G"W  90QZ &,,AP!B#)4 8 VD %\-
MM@!>#<X 7 [M %P/_P!;$/\ 6Q#_ %L0_P#-(0  O"@  *\K  "D*P  FBD
M )(D  ")'P  @A@  'L1!0!U#0\ <0T7 &X.(0!K#BH :0\R &<0.0!E$$
M9!!& &,030!A$%, 7Q%: %X18@!<$6L 6Q%V %D2@P!8$I( 5A.B %43M !4
M$\L 4Q3L %(5_P!2%O\ 4A7_ %(5_P#&*   MBX  *DR  "?,@  E3$  (PM
M  "#)P  >B$  '(:  !K$PL 9Q,3 &04' !A%"4 7Q4M %T5- !<%3L 6Q9"
M %D62 !8%D\ 5A=6 %477@!3%V< 4AAR % 8?P!/&8X 3AJ? $P:L !+&\<
M2QOI $H<_0!*'/\ 2AS_ $H<_P#!+0  L30  *4W  ":.   D#<  (<T  !]
M+P  ="D  &PC  !D' < 7AD0 %L:& !9&R$ 5QLI %4;, !4'#< 4AP] %$<
M1 !/'4L 3AU2 $T=6@!+'F, 2AYN $D?? !''XL 1B"< $4AK@!$(<0 0R+F
M $,B_ !#(O\ 0R+_ $,B_P"\,@  K3@  *$\  "7/@  C3T  (,Z  !Y-0
M;S   &8J  !>) ( 5R - %0@% !1(!T 3R$E $XA+ !,(3, 2R(Z $DB0 !(
M(D< 1R). $8C5P!$(V  0R1K $(D>0!!)8@ /R:9 #XFJP ])\$ /2?C #TH
M^@ ]*/\ /2?_ #TG_P"X-@  JCT  )Y   "40@  BD(  ( _  !V.P  ;#8
M &(P  !9*@  424+ $TE$0!+)1D 224A $<F* !%)B\ 1"8V $,F/0!")T0
M02=+ #\H5  ^*%T /2EI #PI=@ [*H8 .2N7 #@KJ0 W++\ -RS@ #<L^  W
M+/\ -RS_ #@L_P"U.@  IT   )Q$  "11@  AT8  'U$  !S0   :#L  %\V
M  !5,0  3"L' $<I#P!%*A8 0RH> $$J)0 _*BP /BLS #TK.0 \*T$ .RQ(
M #HL40 Y+5L ."YF #8N<P U+X, -"^5 #,PIP R,+T ,3'> #$Q]P R,?\
M,C#_ #,P_P"Q/@  I$0  )E(  "/2@  A4H  'M)  !P10  94   %L[  !2
M-@  2#$$ $(N#0 _+A, /2X; #LN(@ Y+RD ."\O #<O-@ V,#X -3!& #0Q
M3P S,5D ,C)D #$R<0 P,X$ +S23 "XTI@ L-;L +#7; "PU]0 M-?\ +33_
M "XT_P"N00  HD@  )=,  "-3@  @TX  'E-  !N2@  8D4  %A   !./
M13<  #TS"P Y,Q$ -S,8 #8S'P T,R8 ,S,M #(T-  Q-#P ,#5$ "\U3  N
M-E8 +39B "PW;P K-W\ *CB1 "@XI  G.;D )CG8 "<Y]  H.?\ *#C_ "DX
M_P"K10  GTL  )1/  "+4@  @5,  '=2  !L3P  7TD  %9&  !,0@  0CT
M #@X"  T. \ ,C@5 #$X'0 O."0 +C@K "TY,@ L.3D *SI! "HZ2@ I.U0
M*#M? "<\;0 E/'T )#V/ ",]H@ B/;< (3[4 "$^\P B/?\ (SW_ ",\_P"H
M20  G4\  ))3  ")5@  ?U<  '56  !J4P  74\  %-,  !*2   0$0  #9
M!0 O/0T +3T3 "L]&@ J/B$ *3XH "@^+P G/C< )C\_ "0_2  C0%( (D!=
M "%!:@ @07H 'D&- !U"H  <0K4 &T+1 !M"\0 <0O\ '4'_ !Y!_P"E30
MFE,  )!8  "&6P  ?5P  ');  !G6   6U0  %%2  !(3@  /4H  #-'   J
M0PL )D,0 "5#%@ D0QX (T0E ")$+  A1#0 ($4\ !Y%10 =14\ '$9: !M&
M:  91G@ &$>* !='G@ 61[, %$C. !5'[P 61_\ %T;_ !=&_P"B4@  EU@
M (U=  "$8   >F$  '!@  !E7@  65H  $]8  !$5   .5$  "].   F2P8
M($H. !Y*$P =2AH '$HA !M+*  :2S  &4LX !=+0@ 63$P %4Q7 !1,90 3
M374 $DV( !%-G  03;$ #D[,  ]-[@ 03?\ $4S_ !%,_P">5P  E%T  (MB
M  "!90  =V8  &UF  !C9   5F$  $I>   _6P  -5@  "M6   B5 $ &E(*
M !92$  54A8 %%(= !-2)  24BP $5(T !%2/@ 04T@ #U-4  Y38@ -5'(
M#%2$  M4F  )5*T "%3%  E4YP *4_L "U+_  M2_P";70  D60  (AH  !^
M:P  =&P  &ML  !?:@  4F<  $5D   Z8@  ,&   "9>   =70  %5L% !!:
M#  .6A$ #EH8  U;(  ,6R< "ULP  I;.@ )6T4 !UM1  9;7@ $6VT  UN
M  %;E   6Z@  %O   !:X@  6O8  5K_  )9_P"79   CFL  (1N  ![<
M<G(  &=Q  !9<   3&X  $!L   U:P  *FD  "%G   89@  $68!  QE"@ '
M90\ !&44  -D&P "9",  &0L  !D-0  9$   &1,  !D6@  9&D  &1[  !D
MCP  8Z0  &.[  !BW0  8O0  &+_  !A_P"3;   B7$  (!U  !X=P  ;7@
M &!W  !2=@  1G4  #ET   N=   (W(  !IQ   2<0  #7$   9Q"   < T
M ' 2  !P%P  ;Q\  &\F  !O,   ;SL  &]'  !O5   ;V0  &]U  !NB@
M;:   &VV  !LU@  :_(  &O_  !K_P".<P  A7@  'U[  !S?0  97X  %A^
M  !+?@  /GX  #)^   F?0  ''P  !-\   -?   !GT   !]!0  ? L  'P/
M  !\$P  ?!D  'PA  !\*0  ?#0  'M   ![3@  >UX  'MO  !ZA   >IH
M 'FQ  !XS@  =^\  ';^  !V_P")>@  @7\  'B"  !K@P  784  $^&  !"
MAP  -8@  "F'   =AP  %(<   V(   &B0   (H   "*    B08  (D,  ")
M#P  B1,  (D:  "*(@  BBP  (HX  "*1@  B58  (EH  ")?   B)0  (>K
M  "&Q@  A>H  (7[  "$_P"%@@  ?88  &^(  !ABP  4XT  $6/   XD0
M*Y$  !^2   4D@  #9,   24    E@   )<   "8    EP   )<%  "7"P
MF X  )@3  "9&@  F2(  )HN  ":/0  F4T  )E>  "9<P  F(L  )BC  "7
MO   EN(  );W  "5_P" B0  <HP  &2/  !6DP  2)8  #J9   LF@  'YL
M !2<   ,G@   Y\   "A    HP   *4   "E    I0   *4   "F @  IP@
M *<-  "H$0  J1D  *LC  "K,0  JT$  *Q3  "L9P  JX   *J:  "JLP
MJM   *GO  "I^P!UCP  9Y0  %F8  !*G   /)\  "VB   @HP  $Z4   NG
M   !J0   *L   "N    L0   +(   "R    LP   +0   "U    M@   +@$
M  "Y"P  NQ   +T8  "_)   OS4  ,!'  # 6P  P'(  ,"-  #!I@  P,$
M +_C  "^\P!JEP  6YP  $VA   ^I0  +ZD  "&K   3K0  "[    "S
MM0   +@   "\    OP   ,$   #!    PP   ,0   #&    QP   ,D   #+
M    S@@  -$/  #5&   V"<  -DY  #:30  VV0  -M^  #<F0  W+   -S)
M  #<XP!=GP  3Z4  $"J   RKP  (K(  !2U   *N    +L   "_    PP
M ,8   #+    S@   -$   #1    U    -8   #9    VP   -X   #@
MY    .<&  #K#@  [QD  / J  #R/P  \U4  /1M  #TB   ]*$  /2V  #T
MQP#_  D _P & /\ !P#_  P _P 1 /\ ' #_ "@ _P T /\ 00#_ $P _P!5
M /\ 70#_ &4 _P!L /\ <@#^ '@ _ !^ /L A #Z (L ^0"2 /< F0#V *(
M] "L /, N0#Q ,L \ #H .X ^P#M /\ [ #_ .$ _P#2 /\ R0#_ ,0 _P#_
M  $ _P   /\   #_  0 _P . /\ %P#_ ", _P O /\ .P#] $8 ^@!0 /<
M6 #T %\ \@!F /  ; #O '( [0!X .P ?@#J (4 Z0", .< DP#E )P XP"F
M .$ L0#? ,$ W0#= -L ] #9 /\ U@#_ ,\ _P#$ /\ O0#_ +D _P#_
M_P   /\   #_    _P + /P $P#W !X ]  J /( -0#N $  Z0!* .8 4@#C
M %D X !@ -X 9@#< &P V@!R -< > #4 'X T@"% -  C0#. )4 S "? ,D
MJ@#' +@ Q0#- ,, ZP#  /X OP#_ +X _P"V /\ L #_ *T _P#_    _P
M /\   #Y    \@ & .L #P#F !D X0 D -X +P#: #D TP!# ,\ 3 #, %,
MR0!: ,< 8 #% &8 PP!K ,$ <0"_ '< O0!^ +L A@"Y (X MP"8 +4 HP"S
M +  L0#" *X X "L /< JP#_ *H _P"H /\ HP#_ *  _P#_    _P   /4
M  #K    X0   -8 # #/ !, R@ > ,8 *0#" #, OP ] +L 10"X $T M@!4
M +, 6@"Q %\ L !E *X :@"L '  JP!W *D ?P"G (< I0"1 *, G "@ *D
MG@"X )P S@": .X F0#_ )< _P"6 /\ E@#_ ), _P#]    \0   .4   #9
M    S0   ,0 !@"]  \ MP 8 +, (@"P "P K0 V *D /@"G $8 I !- *(
M4P"@ %D GP!> )T 9 "; &H F@!P )@ =P"6 (  E "* )$ E0"/ *( C0"P
M (L PP") ., B #Y (8 _P"& /\ A@#_ (8 _P#S    XP   -$   #%
MO0   +8   "N  L J  2 *0 ' "@ "8 G  O )H -P"7 #\ E0!& )( 3 "1
M %( CP!8 (T 70"+ &, B@!J (@ <0"& 'D A "# (( CP!_ )L ?@"I 'P
MNP!Z -4 > #R '@ _P!W /\ =P#_ '< _P#G!P  T0P  ,,-  "X#   K@@
M *@   "B  4 FP . )8 %0"2 !\ C@ H (L ,0"( #D A@!  (0 1@"" $P
M@ !2 '\ 5P!] %T >P!C 'H :P!X ', =@!] '0 B !Q )4 < "D &X M !L
M ,H :P#J &H _ !J /\ :@#_ &H _P#:$   QA0  +@6  "M%0  I!(  )P.
M  "6!P  D  ) (H $ "% !@ @0 A 'X *@![ #( >0 Y '< 0 !U $8 <P!,
M '( 40!P %< ;@!> &T 90!K &X :0!W &< @P!E )$ 8P"? &( KP!@ ,0
M7P#D %\!^ !> O\ 7@+_ %X"_P#.&   O1T  + @  "E'P  FQP  ),7  "+
M$0  A P  'X$"P!Y !( =0 ; '( (P!O "L ;0$S &L!.@!I D  9P-& &8#
M3 !D!%( 8P19 &$$8 !?!6D 7@5S %P&?P!:!HT 60>< %<(K0!6",$ 50GA
M %0+]@!4"_\ 5 O_ %0+_P#&'P  MB4  *DH  ">*   E"4  (LA  "#&P
M>Q0  '0. P!N"0T :0@4 &8)'0!D"B4 8@HM & +- !>"SH 70M  %L,1P!:
M#$T 6 Q4 %<-7 !5#60 5 UO %(->P!0#HH 3PZ: $X.K !,#\( 3!#C $L0
M^0!+$/\ 2Q'_ $L0_P"_)@  L"L  *0O  "9+P  CRT  (8I  !])   =!X
M &P7  !E$0< 7PX0 %P/%P!:$!\ 6! G %80+@!4$#4 4Q [ %(10@!0$4@
M3Q%0 $X15P!,$F  2Q)K $D2> !($X< 1A.7 $44J0!$%+X 0Q7? $,6^ !#
M%O\ 0Q;_ $,6_P"Z*P  JS$  * T  "5-0  BS0  ($Q  !X*P  ;R8  &8@
M  !>&0$ 5Q0- %04$P!1%!L 3Q4C $X5*@!,%3$ 2Q8W $D6/@!(%D0 1Q=,
M $475 !$%UT 0QAG $$8= ! &8, /QJ4 #T:I@ \&[L .QO; #L<]@ \'/\
M/!S_ #P<_P"U,   J#8  )PY  "1.P  ASH  'XW  !S,@  :BT  &$G  !9
M(0  41L) $P9$ !*&A< 2!H? $8:)@!%&RT 0QLS $(;.@!!'$$ 0!Q( #X<
M4  ]'5D /!YD #L><0 Y'X  .!^2 #<@I  V(+@ -2'6 #4A]  U(O\ -2'_
M #8A_P"R-   I#H  )D^  "//P  A3\  'L\  !P.   9S(  %TM  !4*
M3"(% $8?#@!#'Q0 01\; #\?(@ ^("D /2 P #L@-@ Z(3T .2%% #@B30 W
M(E< -B-B #0C;@ S)'X ,B2/ #$EH@ O);8 +R;2 "\F\@ O)O\ ,";_ # F
M_P"O.   HCX  )9"  ",0P  @D,  'A!  !N/0  8S@  %HS  !1+@  2"@!
M $ D#  ](Q$ .R08 #DD'P X)"8 -B0L #4E,P T)3H ,R9" #(F2@ Q)U0
M,"=? "\H;  N*'L +"F- "LJH  J*K0 *2K/ "DK\  J*_\ *BK_ "LJ_P"L
M/   GT(  )1&  "*1P  @$<  '9%  !L0@  83T  %<X  !.,P  1"X  #PI
M"0 W*!  -2@5 #,H'  R*", ,"@I "\I,  O*C< +BH_ "TK2  L*U( *RQ=
M "HL:@ H+7D )RV+ "8NG@ E+K, )"_- "0O[@ E+_\ )2__ "8N_P"I/P
MG44  )))  "(2P  ?DP  '1*  !J1P  7D(  %0]  !+.0  030  #@O!@ R
M+0T ,"T3 "XM&0 M+2  *RTG "HN+@ I+C4 *2\] "@O1@ G,$\ )3!; "0Q
M:  C,7< (C*) "$RG0 ?,[$ 'C/+ !XS[0 ?,_\ (#/_ "$R_P"F0P  FDD
M )!-  "&3P  ?%   '-/  !H3   7$8  %)#  !)/P  /SL  #8V @ N,@P
M*S(1 "DR%P H,AX )C(D "4S*P D,S( (S0Z "(T0P A-4T (#58 !\V90 >
M-G4 '#>' !LWFP :-Z\ &3C( !DXZP :./\ &S?_ !LW_P"C1P  F$T  (Y1
M  "$4P  >U0  '%3  !F4   6DP  %!)  !'10  /4$  #,]   J.0D )3<.
M ",W%  B.!L (3@B " X*  ?.#  'CDX !TY00 <.DL &CI6 !D[8P 8.W(
M%CN% !4\F0 4/*T $SW& !,]Z0 4//T %3S_ !8[_P"@2P  E5$  (M5  ""
M6   >5D  &Y8  !D5@  6%$  $Y/  !%2P  .D<  #!#   G0 4 (#X- !T^
M$0 </A< &SX> !H^)0 9/BT &#\U !8_/@ 5/T@ %$!3 !- 8  207  $4&"
M !!!EP /0:P #D+$  Y"YP /0?P $$'_ !! _P"=4   DU8  (E:  " 70
M=EX  &Q=  !B6P  5E<  $Q5  !!40  -DX  "Q+   C2   &T4) !=$#P 5
M1!0 %$4; !-%(@ 212D $44Q !%%.P 01D4 #T90  Y'7@ -1VT #$=_  M'
MDP )1Z< "$>^  A'X  )1_8 "D;_  M&_P":50  D%L  (=@  !]8@  <V,
M &IB  !@80  4UX  $=:   \5P  ,E4  "A2   ?4   %TX$ !%,#  /3!$
M#DP7  Y,'@ -324 #$TN  M--P *34( "4U-  =.6@ &3FD !$Y[  ).CP !
M3J0  $VZ  !-VP !3?(  4W_  ),_P"66P  C6(  (1F  !Z:   <6D  &AI
M  !<9P  3V0  $)A   W7P  +5P  "-:   :6   $E<!  U6"0 )50X !U43
M  95&@ $52(  U4J  )5-   53X  %5*  !65P  5F4  %5W  !5BP  5:
M %6V  !4U   5/$  %/]  !3_P"38@  BF@  (!L  !W;@  ;V\  &-N  !6
M;   26H  #UH   R9@  )V4  !UC   58@  #F$   E@"  #8 T  %\1  !?
M%P  7QX  %\F  !?+P  7SH  %]%  !?4P  7V$  %YR  !>AP  79P  %VR
M  !<SP  7.\  %O]  !;_P"0:@  AF\  'UR  !U=   :G4  %UT  !/<P
M0G(  #9P   K;P  (&X  !=M   0;   "FP   )K!@  :PL  &H/  !J%
M:AH  &HA  !I*@  :30  &E   !I3@  :5P  &EM  !H@@  :)@  &>N  !F
MR@  9>T  &7\  !D_P"+<0  @G8  'IY  !P>P  8GL  %5[  !(>@  .WH
M "]Z   C>0  &7@  !%W   *=P   W<   !W @  =P@  '8-  !V$   =A4
M '8;  !V(P  =BX  '4Z  !U1P  =58  '5H  !T?   =)(  '.J  !RQ
M<>D  '#[  !P_P"&>0  ?WT  '9_  !H@0  6H(  $R"   _@P  ,H0  "6#
M   :@P  $8,   J#   "@P   (0   "%    A ,  (,(  "##0  @Q   (,5
M  "$'   A"8  (0R  "$/P  @T\  (-@  ""=0  @HP  (&D  " O0  ?^,
M '[Y  !^_P""@   >H0  &R&  !>B   4(H  $*+   UC0  )XT  !N-   1
MC@  "HX   "/    D0   )(   "2    D@   )(!  "2!P  D@P  )(0  "3
M%0  DQT  )0H  "4-@  E$4  )-7  "3:P  DX(  )*<  "1M@  D-@  (_S
M  "/_P!^AP  <(H  &&-  !3D   19,  #>5   IE@  ')<  !&8   )F0
M )L   "<    G@   *    "@    H    *    "A    H00  *()  "C#@
MI!0  *4=  "F*@  ICH  *9,  "E8   I7@  *62  "DK   I,D  */K  "B
M^@!SC@  9)$  %:5  !'F0  .9P  "J>   =H   $:$   BC    I0   *<
M  "I    K    *X   "N    K@   *\   "P    L0   +(   "S!@  M0T
M +<3  "Y'@  N2X  +I   "Z5   NVH  +J%  "YH0  N;L  +K>  "Y\@!G
ME0  6)D  $J>   [H@  +*8  !VH   1J@  !ZP   "O    L0   +0   "X
M    NP   +P   "\    O@   +\   #     P@   ,0   #&    R ,  ,L+
M  #/$@  T2   -$R  #21@  TUT  -1V  #4D@  U:L  -7$  #4X@!;G0
M3*(  #VG   OK   'Z\  !&Q   'M0   +@   "[    O@   ,(   #'
MR@   ,P   #,    S@   -    #2    U0   -@   #;    WP   .(   #F
M"P  ZQ,  .PD  #M.   [DX  .]G  #P@@  \)P  /"R  #QQ0#_  , _P !
M /\ ! #_  D _P / /\ & #_ "0 _P P /\ / #_ $< _P!1 /\ 60#_ &
M_0!G /P ;0#Z ', ^0!Y /@ ?P#V (4 ]0", /, E #R )T \ "G .X LP#L
M ,0 ZP#A .H ^ #I /\ YP#_ -D _P#+ /\ P@#_ +T _P#_    _P   /\
M  #_    _P , /\ % #_ "  _P K /X -P#Z $( ]@!+ /( 4P#P %L [@!A
M .P 9P#J &T Z !S .< >0#E '\ XP"& .$ C@#? )8 W0"@ -L K #8 +L
MU #1 -, \ #0 /\ S@#_ ,@ _P"] /\ M@#_ +( _P#_    _P   /\   #_
M    _0 ( /< $ #S !H [P F .T ,0#H #L XP!% .  30#< %4 V0!; -8
M80#3 &< T0!L ,\ <@#- '@ RP!_ ,D AP#' )  Q0": ,, I0#  +( O@#%
M +P Y0"Z /L N #_ +< _P"P /\ J0#_ *4 _P#_    _P   /X   #U
M[  # .4 #0#? !4 V@ @ -0 *@#0 #4 RP ^ ,@ 1P#% $X P@!5 ,  6P"^
M &$ O !F +H ; "X '( M@!X +4 @ "S (@ L0"2 *X G@"L *H J0"[ *@
MU0"F /, I #_ *, _P"A /\ FP#_ )@ _P#_    ^P   /    #E    V
M ,X "0#' !$ P@ : +X ) "[ "X MP X +0 0 "Q $@ K@!. *P 5 "J %H
MJ0!? *< 90"E &L I !Q *( > "@ ($ G@"+ )P E@"9 *, EP"R )8 QP"3
M .@ D@#^ )$ _P"0 /\ C0#_ (L _P#Y    ZP   -T   #/    Q@   +P
M! "U  T L  5 *P '@"H "@ I0 Q *( .0"? $$ G0!( )L 3@"9 %, EP!9
M )8 7@"4 &0 D@!J )  <0". 'H C "# (H CP"( )P A@"J (0 O "" -P
M@0#V (  _P!_ /\ ?P#_ 'X _P#L    V@   ,D   "^    M@   *X   "G
M  D H0 0 )P & "8 "( E0 J )( ,@"0 #H C0!! (L 1P") $T AP!2 (8
M6 "$ %T @@!D ($ :P!_ ', ?0!] 'L B !X )4 =@"C '4 M !S ,P <0#M
M '  _P!P /\ < #_ '  _P#?!0  R@H  +P+  "Q"0  J 0  *$   ";  ,
ME  , (\ $P"* !L AP D (0 + "! #, ?P Z 'T 00![ $< >0!, '< 4@!V
M %< = != '( 9 !P &T ;P!V &P @@!J (\ :0"= &< K@!E ,, 9 #D &,
M^@!C /\ 8@#_ &, _P#0#@  OQ(  +(3  "G$@  G1   )4+  "/ P  B0 '
M (( #@!^ !4 >@ > '8 )0!T "T <0 T &\ .@!N $  ; !& &H 3 !I %(
M9P!8 &8 7P!D &< 8@!Q &  ? !> (D 7 "8 %L J0!9 +P 6 #< %@ ] !8
M /\ 5P#_ %< _P#&%@  MAH  *H=  "?'   E1D  (T4  "%#P  ?@D  '<!
M"@!R !  ;@ 7 &H 'P!H "< 90 N &0 - !B #L 8 !  %\ 1@!= $P 7 !3
M %H 6@!8 &( 5P!L %4 =P!3 (4 4@"4 % !I0!/ ;@ 3@+2 $T$\ !-!?\
M307_ $T%_P"_'0  L"(  *,E  "9)0  CR(  (4=  !]&   =1(  &X- @!G
M!@P 8P,1 %\"&0!= R$ 6P0H %D$+P!7!34 5@4[ %0&00!3!D< 409. % '
M50!.!UX 30AG $L(<P!)"8$ 2 F2 $<*HP!%"K8 1 O0 $0,[P!##?\ 0PW_
M $0-_P"Y)   JBD  )XL  "4+   BBH  ( F  !W(0  ;AL  &84  !?#P4
M60L- %4*$P!3"QL 40LB $\,*0!-#"\ 3 PV $L-/ !)#4( 2 U) $8-40!%
M#EH 1 YD $(.< ! #G\ /P^0 #X0H@ \$+8 .Q#1 #L1\0 [$?\ .Q'_ #P1
M_P"T*0  IB\  )HR  "0,@  AC$  'PM  !R*   :2,  &$=  !9%@  41$(
M $P/$ !*$!8 2! = $80) !%$"L 0Q$Q $(1-P!!$3X 0!%% #X230 ]$E8
M/!)A #H3;0 Y$WP -Q2- #84GP U%;, -!7- #,6[@ T%O\ -!;_ #06_P"O
M+@  HC0  )<W  ",.   @C8  '@T  !N+@  92H  %PD  !4'@  3!@$ $84
M#0!"%!( 0!09 #\4(  ]%2< /!4M #L5-  Y%CH .!9" #<62@ V%U, -1=>
M #,8:@ R&7D ,!F* "\:G0 N&K$ +1O* "T;[  M'/\ +AO_ "X;_P"L,@
MGS@  )0[  "*/   @#P  '8Y  !K-   8B\  %DJ  !0)0  1Q\  $ :"@ \
M&1  .AD6 #@9'0 V&B, -1HI #0:,  S&C< ,AL^ #$;1P O'%  +AU; "T=
M9P L'G8 *AZ( "D?FP H'ZX )R#' "8@Z@ G(/X *"#_ "@@_P"I-@  G3P
M )(_  "'00  ?4   '0^  !I.@  7S4  %8P  !-*P  1"4  #L@!P V'@X
M,QX3 #(>&0 P'B  +QXF "X?+0 M'S0 +" [ "L@1  J(4X *2%8 "<B90 F
M(G0 )2.% ",CF0 B)*T (23% "$EZ  B)?T (B3_ ",D_P"F.@  FC\  (]#
M  "%10  >T0  ')#  !G/P  73H  %,V  !*,0  02P  #@F P Q(PP +B(1
M "PB%@ J(AT *2(C "@C*@ G(S$ )B0Y "4E00 D)4L (R96 "(F8P A)W(
M'R># !XHEP =**L &RG# !LIY@ <*?L '2G_ !XH_P"C/@  F$,  (U'  "#
M20  >DD  '!'  !F1   6C\  %$[  !'-P  /C(  #4M   L* D *"</ "<G
M%  E)QH )"<A ",H)P B*"X (2DV " I/P ?*DD 'BI4 !TK8  ;*V\ &BR!
M !DLE0 7+:D %BW! !8MY  7+?H &"W_ !DM_P"A00  E4<  (M+  ""30
M>$T  &Y,  !D20  6$0  $]   !&/0  /3@  #,T   J+P8 )"P- "$L$@ @
M+!@ 'RT> !XM)0 =+2P '"XT !LN/  :+T8 &"]1 !<P7@ 6,&T %3%_ !,Q
MDP 2,:@ $3*_ !$RX@ 2,OD $S'_ !,Q_P">10  DTL  (E/  " 40  =E(
M &U0  !B3@  5DD  $U&  !$0P  .S\  #$Z   G-@, 'S(+ !PR$  ;,A4
M&3(; !@R(@ 7,RD %C,Q !4T.@ 4-$0 $S1/ !(U7  1-6L $#9]  \VD0 .
M-J8 #3>\  TWW0 --O8 #C;_  \V_P";20  D4\  (=3  !^5@  =58  &I5
M  !@4P  54\  $Q,  !"20  .$4  "Y!   D/0  '#H( !8X#@ 5.!( %#@8
M !,Y'P 2.28 $3DN ! Y-P /.D$ #CI,  T[60 -.V@ "SMZ  H[C0 )/*(
M!SRX  <\U0 (//  "3O_  H[_P"83@  CE0  (58  !\6P  <EL  &A:  !>
M6   4U4  $E2   ^3@  -$L  "I'   A1   &$(# !) "P 0/Q  #C\5  X_
M'  -0", #$ K  M -  *0#X "4%*  =!5@ &064 !$%V  -!B@ !09\  $&T
M  !!T  !0>X  4'\  ) _P"55   C%D  (->  !Y8   <&   &9@  !=7@
M45L  $57   Z5   +U$  "5/   <3   %$H   Y("  +1PX "$<2  ='&0 &
M1R  !4@H  -(,0 "2#L  $A'  !(4P  2&(  $AS  !(A@  2)L  $BQ  !'
MS   1^T  $?[  !'_P"26@  B6   (!C  !W90  ;F8  &5F  !99   3&
M $!=   U6P  *ED  "!7   750  $%,   M2!P %40T  5 1  !0%@  4!T
M % E  !0+@  4#@  %!#  !04   4%X  %!O  !0@P  3Y@  $^N  !.R0
M3NL  $W[  !-_P"/80  AF8  'UI  !T;   ;&T  &%K  !3:0  1F<  #ID
M   O8P  )&$  !I?   27@  #%P   9<!@  6PL  %H/  !:$P  6AD  %DA
M  !9*0  63,  %D_  !93   65H  %EK  !8?@  6)0  %>K  !7Q0  5ND
M %7[  !5_P",:   @FT  'IP  !R<@  9W(  %IQ  !,<   /VX  #-M   H
M:P  '6H  !1H   -9P  !V<   !F P  9@D  &4-  !E$0  9!4  &0<  !D
M)   9"X  &0Z  !C1P  8U4  &-F  !C>@  8I   &&G  !@P0  7^8  %_Z
M  !>_P"';P  ?W0  'AW  !N>   8'@  %)W  !%=P  .'8  "MV   @=
M%G,   YS   '<@   '(   !R    <04  '$*  !Q#@  <!$  ' 7  !P'@
M<"<  ' S  !O0   ;U   &]@  !N=   ;HL  &VB  !LO   :^(  &KX  !I
M_P"#=P  ?'L  '-]  !E?@  5W\  $E_   \?P  +X   ")_   7?@  #WX
M  =^    ?P   '\   !_    ?@   'X%  !^"@  ?@T  'X1  !^%P  ?B
M 'XK  !].0  ?4@  'U9  !\;0  ?(0  'N<  !ZM@  >=H  'CU  !W_P"
M?P  =X(  &F#  !;A0  388  #^(   RB0  )(D  !B)   /B0  !XH   "+
M    C    (T   "-    C    (P   ", P  C @  (T-  "-$0  C1<  (XB
M  ".+P  CC\  (U0  "-9   C'L  (R5  "+K@  BLT  (GO  ")_P![A0
M;8@  %Z*  !0C0  0H\  #21   FD@  &9,   Z4   &E0   )8   "8
MF@   )L   ";    FP   )L   ";    G    )T%  "="P  GA   )\7  "@
M)   H#0  *!&  "@60  GW   )^*  ">I0  GL(  )WH  "<^0!PC   88\
M %.2  !$E@  -ID  ">;   9G   #YT   6?    H0   *,   "E    J
M *D   "I    J0   *H   "K    K    *T   "N 0  L D  +(/  "S&
MM"<  +0Y  "U30  M&0  +1^  "SF@  L[0  +/5  "S\ !DDP  59<  $>;
M   XGP  *:(  !JD   .I@  !*@   "K    K0   +    "T    M@   +@
M  "X    N0   +H   "\    O0   +\   #     PP   ,4'  #)#P  RAH
M ,LL  #,0   S58  ,YO  #-BP  S*@  ,S"  #,X@!8FP  2:   #JE   L
MJ0  '*L   ^N   $L0   +0   "W    N@   +X   ##    Q@   ,@   #(
M    R@   ,L   #-    SP   -(   #5    V0   -T   #A!0  Y@\  .<>
M  #H,@  Z4@  .I@  #K>P  ZY<  .RN  #LP@#_    _P   /\   #_  8
M_P - /\ %0#_ "$ _P L /\ . #_ $, _P!, /X 5 #[ %L ^@!B /@ : #V
M &X ]0!T /0 >@#R (  \0"' .\ CP#M )< ZP"A .D K0#G +T Y0#8 .0
M\P#B /\ X #_ -  _P#$ /\ O #_ +8 _P#_    _P   /\   #_    _P )
M /\ $0#_ !P _0 G /D ,@#U #T \0!& .T 3P#K %8 Z !< .8 8@#D &@
MXP!N .$ <P#? 'D W0"  -H B #8 )$ U "; -( I@#/ +0 S #) ,D Z0#(
M /\ QP#_ ,$ _P"W /\ KP#_ *L _P#_    _P   /\   #_    ^  % /(
M#@#N !< Z@ B .8 + #A #< W0!  -@ 20#3 %  T !6 ,X 7 #, &( R@!G
M ,@ ;0#& ', Q !Y ,( @0#  (H O@"4 +P GP"Y *P M@"^ +0 W0"S /<
ML0#_ +  _P"H /\ H@#_ )X _P#_    _P   /D   #O    Y@   -\ "P#6
M !( T  < ,P )@#( #  Q  Z ,  0@"] $H NP!0 +@ 5@"V %L M0!A +,
M9@"Q &P L !R *X >@"L (( J0", *< F "E *4 HP"T *  RP"? .X G0#_
M )P _P"9 /\ E #_ )$ _P#_    ]@   .H   #=    SP   ,< !@#   \
MNP 7 +< ( "S "H L  S *T .P"J $, IP!) *4 3P"C %4 H@!: *  7P">
M &4 G0!K )L <@"9 'L EP"% )0 D "2 )T D "L (X OP", .( BP#Z (D
M_P") /\ A@#_ (, _P#T    Y    -0   #(    OP   +4  0"N  L J0 2
M *4 &P"A ", G@ L )L - "8 #P E@!# )0 20"2 $X D !3 (X 60"- %X
MBP!D (D :P"' ', A0!] (, B "! )4 ?P"D 'T M0![ ,\ >0#Q '@ _P!W
M /\ =P#_ '4 _P#E    T0   ,,   "X    KP   *@   "@  8 F@ . )4
M%0"1 !X C@ F (L +0"( #4 A@ \ (0 0@"" $< @ !- '\ 4@!] %@ >P!>
M 'D 90!X &T =@!V ', @0!Q (X ;P"= &T K@!L ,0 :@#G &D _0!H /\
M: #_ &D _P#5 P  PP<  +8(  "K!@  H@   )L   "4    C0 * (@ $ "#
M !@ ?P @ 'P )P!Z "X =P U '4 .P!T $$ <@!' '  3 !O %( ;0!8 &L
M7P!I &8 9P!P &4 >P!C (@ 8@"7 &  IP!> +L 70#< %P ]@!< /\ 6P#_
M %L _P#)#0  N1   *P1  "A$   EPT  (\(  "(    @@ % 'L #0!W !(
M<P : &\ (0!L "@ :@ O &@ -0!G #L 90!! &, 1@!B $P 8 !2 %\ 60!=
M &$ 6P!J %D =0!7 (( 50"1 %0 H@!3 +4 40#/ %  [P!0 /\ 4 #_ %
M_P"_%   L!@  *0:  "9&0  CQ8  (<1  !_#0  =P8  '$ " !K  X 9P 4
M &0 &P!A "( 7@ I %T +P!; #4 60 [ %@ 00!6 $8 50!- %, 5 !2 %P
M4 !E $X < !, 'T 2P"- $D G@!( +  1P#' $8 Z0!& /L 1@#_ $4 _P"X
M&P  JB   )XB  "3(@  B1\  ( :  !W%0  ;Q   &@+  !A! H 70 0 %D
M%@!6 !T 5  C %( *@!0 #  3P U $X .P!, $$ 2P!( $D 3P!' 5< 1@%A
M $0"; !# GD 00.) $ #F@ ^!*T /03$ #P%Y0 \!_@ / ?_ #P'_P"R(@
MI2<  )DI  ".*0  A"<  'LC  !Q'@  :1@  &$2  !:#0, 4P@, $\%$0!,
M!1< 2@8> $@&) !'!BH 10<P $0'-@!#"#T 00A# $ (2P ^"5, /0E= #L*
M:  Z"G8 . N' #<+F0 U"ZP - S" #,,Y  S#?D ,PW_ #0-_P"M)P  H"P
M )4O  "++P  @"X  '<J  !M)0  9"   %P:  !4%   3 \& $8,#0!##!(
M00P8 #\,'P ^#"4 / TK #L-,@ Z#3@ . T_ #<.1P V#E  - Y: #,.9@ Q
M#W0 , ^% "X0F  M$*L +!## "L1Y0 L$?H +!'_ "T1_P"J+   G3$  )(T
M  "'-0  ?30  '0Q  !J*P  8"<  %@A  !/&P  1Q8  $ 1"0 [$ \ .1 4
M #<0&P V$"$ -! G #,1+0 R$30 ,1$[ # 10P N$DT +1)7 "P28P J$W$
M*1." "<4E0 F%*D )17  "05XP E%OH )A;_ "85_P"F,0  FC8  (\Y  "%
M.@  >SD  '$V  !G,0  72T  %0H  !,(@  0QT  #L7!0 U% T ,A,1 #$4
M%P O%!T +A0D "P4*@ K%3$ *A4X "D60  H%DH )Q=4 "878  D&&\ (QB
M "$9DP @&:< 'QF^ !X:X  ?&O@ (!K_ " :_P"C-   F#H  (T]  "#/@
M>3T  &\[  !E-P  6S(  %(M  !)*   0",  #@> 0 P&0H +!@/ "H8%  I
M&!H )Q@@ "89)P E&2T )!HU ",:/@ B&T< (1M2 " <7@ ?'6P '1U^ !P=
MD0 :'J4 &1Z\ !@?W0 9'_8 &A__ !L>_P"A.   E3T  (M!  "!0@  =T(
M &U   !C/   63<  $\S  !&+@  /2D  #4D   M( < )QT- "4=$@ C'1<
M(1T= "$=)  @'BL 'QXR !X?.P ='T4 '"!/ !HA7  9(6H &")[ !8BCP 5
M(J, %".Z !,CV@ 4(_4 %2/_ !8C_P">/   DT$  (E$  !_1@  =48  &Q$
M  !B00  5SP  $TX  !$-   /#   #,K   J)@, (R(+ " A$  >(14 '"(;
M !LB(0 :(B@ &B,P !DC.  8)$( %B5- !4E60 4)F@ $R9Y !(FC0 1)Z(
M$">X  XGU@ 0*/0 $2?_ !$G_P"<0   D44  (=(  !]2@  =$H  &I)  !@
M1@  54$  $P^  !#.@  .C8  #$R   H+0  ("D) !LG#@ 9)Q( &"<8 !8G
M'P 5*"4 %"@M !,H-@ 2*4  $BE+ !$J5P 0*F8 #BMW  XKBP -+)\ #"RU
M  LLSP ,+.\ #2S_  TK_P"91   CTD  (5,  !\3@  <T\  &E.  !>2P
M4T<  $I$  !"0   .3T  "\X   E-   '3 % !8M#  4+!  $RT5 !(M'  1
M+2, $"TJ  \N,P .+CT #2](  TO50 ,,&, "C!T  DPB  (,9P !C&Q  8Q
MRP &,>L !S#\  @P_P"72   C4T  (-1  !Z4P  <50  &=2  !=4   4DP
M $E*  ! 1@  -4(  "L^   B.@  &C<! !(T"0 /,PX #C,3  TS&0 -,R
M##0H  LT,0 *-3L "#5&  <U4@ %-F  !#9Q  (VA   -ID  #:O   VR
M-N@  #;Y  $U_P"430  BE(  (%6  !X6   ;UD  &58  !;50  45(  $=/
M   \3   ,4@  "=$   >00  %C\  ! \!P +.@T "3H1  @[%P &.QX !3LF
M  0[+@ ".S@  3Q#   \3P  /%X  #QN   \@0  /)<  #RL   [Q0  .^<
M #OX   [_P"14@  B%@  ']<  !V70  ;5X  &-=  !:7   3E@  $)4   W
M40  +4X  "-+   :20  $D8   U$!@ '0PP  T,0  !#%0  0QL  $,C  !#
M*P  0S4  $-   !#30  0UL  $-K  !#?@  0Y0  $*J  !"PP  0>8  $'Y
M  !!_P".6   AEX  'UA  !S8P  :V0  &)C  !780  25T  #U:   R6
M)U4  !Y3   540  #D\   E-!0 "30L  $P.  !,$P  2Q@  $L?  !+*
M2S(  $L]  !+20  2U<  $MG  !*>P  2I   $FG  !)P   2.0  $CX  !'
M_P"+7P  @V0  'IG  !Q:0  :6H  %YI  !09@  0V0  #=A   L7P  (5T
M !A;   060  "E@   -7 P  5PD  %8-  !5$   514  %0;  !4(P  5"T
M %0Y  !410  5%,  %1D  !3=P  4XT  %*D  !1O0  4.(  %#X  !/_P"(
M9P  ?VL  '=N  !O<   97   %=N  !*;   /6L  #!I   E:   &F8  !%D
M   +8P  !&(   !B 0  808  & +  !@#@  7Q(  %\7  !?'@  7B@  %XS
M  !>0   7D\  %Y?  !=<@  78@  %R@  !;N0  6M\  %GW  !8_P"$;@
M?'(  '5U  !K=@  774  $]T  !"<P  -7,  "AR   =<   $V\   QN   $
M;@   &X   !N    ; (  &P'  !K"P  :PX  &L2  !J&0  :B(  &HM  !J
M.@  :4D  &E:  !I;   :(,  &>;  !FM0  9=@  &3U  !D_P" =0  >GD
M '![  !B>P  5'P  $9\   Y?   +'P  !][   4>@  #7H   1Z    >@
M 'H   !Z    >0   'D!  !X!@  > L  '@.  !X$P  >!H  '@E  !X,@
M=T$  '=2  !W90  =GP  '65  !TKP  <\X  '+Q  !Q_P!^?0  =8   &>!
M  !8@@  2H,  #R$   NA0  (84  !6%   -A0   X4   "&    AP   (@
M  "(    AP   (<   "'    AP0  (<)  "'#@  B!,  (@<  "(*0  B#@
M (=*  "'70  AG,  (:-  "%IP  A,4  (/L  ""_@!XA   :H8  %R(  !-
MB@  /XP  #&.   CCP  %H\   V0   "D0   )(   "3    E0   )8   "6
M    E@   )8   "6    EP   )<   "7!P  F T  )D3  ":'P  FBT  )H_
M  ":4@  FF@  )F#  "9GP  F+H  )?B  "6^ !MB@  7XT  %"0  !!DP
M,Y8  "27   6F   #9D   &;    G0   )\   "A    I    *4   "D
MI0   *4   "F    IP   *@   "I    J@0  *P,  "N$P  KB$  *XS  "N
M1P  KET  *YV  "NDP  KJX  *W-  "L[P!AD0  4Y4  $28   UG   )I\
M !>A   -HP   *4   "G    J@   *P   "P    L@   +0   "S    M
M +4   "W    N    +D   "[    O0   +\!  ##"P  Q14  ,4E  #&.0
MQT\  ,=H  #&A0  QJ(  ,:\  #&W@!5F0  1YT  #BB   II@  &:@   VK
M    K0   +$   "T    MP   +H   "_    P0   ,0   ##    Q0   ,8
M  #(    R@   ,T   #/    T@   -8   #;    X P  .$8  #C*P  Y$$
M .5:  #F=   YI$  .6L  #EQ #_    _P   /\   #_  $ _P * /\ $@#_
M !T _P H /\ - #_ #X _0!( /H 4 #W %< ]0!= /0 8P#R &D \ !O .\
M= #M 'L ZP"! .D B0#H )( Y@"< .0 J #B +< WP#- -P [@#9 /\ V0#_
M ,H _P"^ /\ M0#_ +  _P#_    _P   /\   #_    _P & /\ #P#\ !@
M^  C /0 +@#P #@ ZP!" .@ 2@#E %$ X@!8 .  70#> &, W !H -D ;@#6
M '0 U ![ -$ @@#/ (L S0"5 ,H H0#( *\ Q0#! ,( XP#  /L P #_ +L
M_P"P /\ J #_ *0 _P#_    _P   /\   #[    \P ! .T # #H !, XP >
M .  * #: #( TP \ ,\ 1 #, $L R0!1 ,8 5P#$ %T P@!B ,$ 9P"_ &T
MO0!T +L >P"Y (0 MP". +0 F0"R *< KP"W *T T "K /( J@#_ *D _P"A
M /\ FP#_ )< _P#_    _P   /0   #I    X    -4 " #. !  R0 8 ,4
M(@#! "L O  U +D /0"V $4 LP!+ +$ 40"O %8 K@!; *P 80"J &8 J0!M
M *8 = "D 'P H@"& *  D@"> )\ G "N )D PP"7 .< E@#_ )4 _P"2 /\
MC0#_ (H _P#\    \    .,   #4    R    +\  P"Y  T LP 3 *\ ' "L
M "4 J0 N *4 -@"C #X H !$ )X 2@"= %  FP!5 )D 6@"7 %\ E@!F )0
M; "2 '4 D !^ (X B@"+ )< B0"F (< N "% -8 A #V (( _P"! /\ ?@#_
M 'P _P#M    W0   ,P   #!    N    *X   "G  D H@ 0 )X %P": !\
MEP G )0 +P"1 #< CP ] (T 0P"+ $D B0!. (@ 4P"& %D A !? (( 90"
M &T ?@!W 'P @@!Z (\ > "> '4 KP!S ,< <@#L '$ _P!P /\ < #_ &X
M_P#=    R0   +P   "Q    J0   *$   "9  , DP , (X $@"* !D AP A
M (0 *0"! #  ?P W 'T /0![ $( >0!( '@ 30!V %( = !8 '( 7P!Q &<
M;P!P &P >P!J (@ : "7 &8 J !E +P 8P#A &( ^@!A /\ 80#_ &$ _P#-
M 0  O 4  *\%  "E @  G    )0   "-    A@ ( ($ #@!\ !0 >  ; '4
M(P!R "D <  P &X -@!M #P :P!! &D 1P!H $P 9@!2 &0 60!C &  80!I
M %\ = != ($ 6P"0 %D H0!7 +0 5@#0 %4 \@!5 /\ 5 #_ %4 _P#!#
ML@X  *8/  ";#@  D@L  (D%  ""    >P " '4 "P!P !  ;  6 &@ '0!F
M ", 8P J &$ , !@ #8 7@ [ %T 00!; $8 6@!, %@ 4P!6 %L 5 !D %(
M;@!1 'L 3P"* $T FP!, *X 2P#& $H Z@!) /X 20#_ $D _P"Y$@  JA8
M )X7  "4%@  BA,  ($0  !Y"P  <0,  &L !@!E  T 80 1 %T & !: !X
M6  D %8 *@!4 #  4P V %$ .P!0 $$ 3@!' $T 3@!+ %8 20!? $< :0!&
M '8 1 "% $, EP!! *D 0 "_ #\ X@ _ /@ /@#_ #\ _P"R&0  I!X  )@?
M  ".'P  A!P  'H8  !R$@  :@X  &((  !< 0@ 5P . %, $P!0 !D 3@ ?
M $P )0!* "L 2  P $< -@!& #P 1 !" $, 20!! %$ /P!: #X 90 \ '(
M.@"! #D DP X *4 -@"Z #8 VP U /0 -0#_ #4 _P"L(   GR0  )0F  ")
M)@  ?R0  '4@  !L&P  9!4  %P0  !4# $ 3@8* $H"#P!' !0 1  : $(
M( !  "4 /P K #X!,0 \ 3< .P(^ #D"10 X TT -@-6 #4$80 S!&X ,05^
M # %D  O!:, +0:X "P&U  L!_  + C_ "P(_P"H)0  FRH  ) L  "&+0
M>RL  '(G  !H(@  7QT  %<7  !/$@  2 X$ $$*"P ^!Q  .P85 #D'&P X
M!R$ -@@F #4(+  S"#( ,@DY #$)00 O"4D +@I3 "P*7@ K"VP *0M\ "@,
MCP F#*( )0RW "0,TP C#?  ) W_ "4-_P"D*@  F"\  (TR  "#,@  >3$
M &\N  !E*0  7"0  %,?  !+&0  0Q,  #P0!@ U#0P ,PP1 #$,%@ O#!P
M+@TB "T-*  K#2X *@TU "D-/0 G#D8 )@Y0 "0.7  C#VH (@][ " 0C@ ?
M$*( '1"W !P0U  =$?( '1'_ !X1_P"A+P  E3,  (HV  " -P  =C8  &TS
M  !C+P  62H  % E  !((   /QH  #@5   P$0@ +! . "H0$@ H$!@ )Q >
M "40)  D$"H (Q$R "(1.@ A$4, (!). !X26@ =$V@ &Q-X !H3BP 8%*
M%Q2U !84T0 6%?$ %Q7_ !@4_P">,P  DS<  (@Z  !^.P  =#L  &LX  !A
M-   5R\  $XK  !%)@  /2$  #0<   M%P4 )A,, ",3$  B$Q4 (!,: !\3
M(0 >%"< '10O !P5-P ;%4$ &A9+ !D65P 7%V4 %A=V !08B0 3&)X $ABS
M !$9S@ 1&>\ $AG_ !,9_P"<-@  D3L  (8^  !\/P  <S\  &D]  !?.0
M534  $PP  !#+   .B<  #(B   J'@$ (AD) !X7#@ <%Q( &A<7 !D8'@ 9
M&"0 &!DL !<9-  6&CX %1I) !,;50 2&V, $1QT ! <AP /'9P #AVQ  T=
MRP -'>P #AW_  \=_P"9.@  CS\  (1"  ![1   <4,  &A"  !>/@  4SH
M $HV  !!,@  .2T  #$I   H)0  (" & !H=#  7'!  %1P5 !0=&P 4'2(
M$QTI !(>,@ 1'SP $!]& ! @4P .(&$ #2%Q  PAA0 +(ID "B*N  DBQP )
M(N< "B+[  LA_P"7/@  C$,  (-&  !Y2   <$@  &=&  !<1   4C\  $D[
M  ! .   .#0  "\P   G+   'B<# !8C"@ 2(0X $2$3 ! B&0 0(B  #R(G
M  XC+P -)#D #"1$  LE4  *)5X "29O  <F@@ &)I8 !":L  ,FQ  $)N4
M!";W  8F_P"50@  BD<  (%*  !X3   ;TP  &5+  !;2   4$0  $=!   _
M/@  -SL  "TV   D,0  &RT  !,J!P /* T #2<1  TH%@ ,*!T "R@E  HI
M+0 )*3< !RI"  8J3@ $*UP  RML  $K?P  *Y0  "NI   KP0  *^,  "OV
M   J_P"21@  B$L  ']/  !V40  ;5$  &-0  !:30  3TH  $='   ^1
M,T   "D\   @.   %S0  !$Q!0 ,+PP "2X0  <N%0 &+QL !2\C  ,O*P "
M,#4  # _   P3   ,5D  #%I   Q?   ,9$  #&G   POP  ,.$  ##U   O
M_P"02P  AE   'U4  !U5@  :U8  &)5  !84P  3E   $5-   Z20  +T4
M "5"   </@  %#L   XY!0 )-PL !#8/  $V$P  -AD  #8@   V*0  -C(
M #<]   W20  -U<  #=G   W>0  -X\  #:E   VO0  -N   #7U   U_P"-
M4   A%8  'Q:  !R6P  :5L  &!;  !760  3%8  $!2   U3@  *DL  "!(
M   71@  $$,   M!!  $0 H  #\.   ^$0  /A8  #X=   ^)@  /B\  #XZ
M   ^1@  /E0  #YD   ^=@  /8P  #VC   \NP  /-X  #OU   [_P"*5P
M@EP  'E?  !P80  :&$  %]A  !47@  1UL  #I7   O50  )5(  !M0   2
M30  #$L   9* P  20D  $@-  !'$   1Q0  $8:  !&(@  1BP  $8W  !&
M0P  1E$  $9@  !%<P  18D  $2@  !$N   0]P  $+U  !"_P"(70  ?V(
M '=E  !N9P  9V@  %MF  !.8P  06$  #1>   I7   'UH  !57   .5@
M!U0   !3 0  4@8  %$+  !1#@  4!$  $\6  !/'@  3R<  $\R  !//P
M3TT  $Y=  !.;P  3H4  $V=  !,M0  2]@  $KU  !*_P"%90  ?&D  '1L
M  !M;@  8FT  %1K  !':0  .F<  "UE   B9   &&(  !!@   )7P   %X
M  !>    70,  %P(  !;#   6@\  %H3  !9&0  62(  %DM  !9.@  64@
M %A8  !8:P  5X$  %>9  !6L@  5=(  %3T  !3_P"!;   >7   '-S  !H
M<P  6G(  $QQ   _<   ,F\  "5N   :;   $6L   EJ    :@   &D   !I
M    :    &<#  !F"   9@P  &8/  !E%   91P  &4G  !D-   9$,  &13
M  !D90  8WL  &*4  !AK0  8,T  %_Q  !>_P!]=   =W<  &YY  !?>0
M47D  $-Y   V>   *7@  !QW   1=@  "G4   !U    =0   '8   !U
M=    '0   !S @  <P<  ',,  !R$   <A4  '(@  !R+   <CL  '%,  !Q
M7P  <70  '".  !OJ   ;L8  &SM  !K_P![>P  <GX  &1^  !5?P  1X
M #F!   K@@  'H$  !*!   *@0   ($   ""    @P   (,   "#    @@
M ((   ""    @@   ((%  """@  @@\  ((7  ""(P  @C(  ()#  "!5@
M@6P  ("&  !_H0  ?KT  'WF  !\_ !V@@  :(,  %F%  !+AP  /(D  "Z*
M   @BP  $XL   J+    C    (T   "/    D0   )(   "1    D0   )$
M  "1    D0   )(   "2 @  DPD  )0/  "4&0  E"<  )0X  "43   DV(
M )-\  "3F   DK,  )'8  "0]@!JB   7(H  $V-   _D   ,)(  "&4   4
ME0  "I8   "7    F0   )L   "=    GP   *    "@    H    *    "A
M    H@   *,   "D    I0   *8'  "H$   J!P  *@M  "I0   J58  *EO
M  "IBP  J*@  *?'  "F[ !?CP  4)(  $&6   SF0  (YP  !2=   *GP
M *$   "C    I@   *@   "L    K@   *\   "O    L    +    "R
MLP   +0   "V    MP   +H   "]!P  OQ   +\?  # ,P  P$D  ,!B  #
M?@  P)L  ,"W  "_V !3EP  1)L  #6?   FHP  %J4   NG    J@   *T
M  "P    LP   +8   "[    O0   ,    "_    P0   ,(   #$    Q@
M ,@   #*    S    ,\   #3    V@<  -L3  #=)0  WCL  -]3  #@;@
MWXP  -VI  #=P@#_    _P   /\   #_    _P ' /\ $ #_ !D _P D /\
M+P#\ #H ^0!# /4 2P#S %( \0!9 .\ 7@#M &0 ZP!I .D ;P#G '4 Y@!\
M .0 A #B (T X "7 -T H@#: +$ U0#% -( Z #0 /\ SP#_ ,0 _P"X /\
MKP#_ *D _P#_    _P   /\   #_    _P " /L #0#W !4 \P ? .\ *0#J
M #0 Y@ ] .( 10#> $P VP!3 -@ 6 #4 %X T@!C -  :0#. &X S !U ,H
M?0#( (4 Q@"0 ,( FP#  *D O@"Z +L V0"Y /< N #_ +0 _P"I /\ H@#_
M )T _P#_    _P   /\   #V    [@   .< "@#A !$ W  : -< (P#0 "X
MRP W ,< /P#$ $8 P0!- +\ 4@"] %@ NP!= +D 8@"X &@ M@!N +0 =0"Q
M 'X KP"( *T DP"J *$ J "Q *8 R "D .T H@#_ *( _P"; /\ E0#_ )$
M_P#_    _    .X   #C    V    ,T !0#&  X P0 5 +T '@"Y "< M0 P
M +( . "O $  K !& *H 3 "H %$ IP!6 *4 6P"C &$ H0!G )\ ;@"> '8
MFP"  )D C "7 )D E "H )( O "0 -\ C@#[ (X _P"+ /\ A@#_ (, _P#X
M    Z0   -P   #,    P0   +@   "R  H K  1 *@ & "E "$ H@ I )X
M,@"< #D F0 _ )< 10"5 $H E !0 )( 50"0 %H CP!@ (T 9P"+ &\ B0!X
M (8 A "$ )$ @@"@ (  L@!] ,P ? #Q 'L _P!Z /\ =P#_ '4 _P#F
MTP   ,8   "[    L0   *<   "A  4 FP - )< $P"3 !L D  C (P *P"*
M #( B  X (8 /@"$ $0 @@!) ($ 3@!_ %, ?0!9 'L 8 !Y &@ =P!Q '4
M? !S (D < "8 &\ J0!M +\ :P#F &H _P!I /\ :0#_ &< _P#3    PP
M +4   "K    HP   )L   "2    C  * (< $ "# !8 ?P = 'T ) !Z "L
M>  R '8 . !T #T <@!" '$ 2 !O $T ;0!3 &P 60!J &$ : !J &8 = !D
M ($ 80"1 %\ H@!> +8 7 #5 %L ]P!; /\ 6@#_ %H _P#%    M@(  *D"
M  "?    E@   (X   "'    @  % 'H # !U !$ <0 8 &X '@!K "4 :0 K
M &< ,0!F #< 9  \ &, 00!A $< 7P!- %X 4P!< %L 6@!D %@ ;@!6 'L
M5 "* %( FP!1 *X 4 #( $\ [@!. /\ 3@#_ $T _P"["@  K T  * -  "5
M#   C @  (,"  !\    =0   &X " !I  X 90 3 &( &0!? !\ 70 E %L
M*P!9 #$ 6  V %8 .P!5 $$ 4P!' %$ 3@!0 %4 3@!> $P : !* '4 2 "$
M $< E0!% *@ 1 "_ $, Y !" /P 0@#_ $( _P"R$0  I10  )D5  ".$P
MA!$  'L-  !S"   ;    &4  P!?  L 6P / %< % !4 !H 40 ? $\ )0!.
M "L 3  P $L -@!) #P 2 !" $8 2 !% %  0P!9 $$ 8P _ &\ /@!^ #P
MD  [ *, .@"X #D V0 X /4 . #_ #@ _P"L%P  GQL  ),=  ")'   ?QD
M '45  !L$   9 P  %T&  !6  8 40 , $T $ !* !4 1P : $4 ( !$ "8
M0@ K $$ ,0 _ #8 /@ ] #P 1  [ $L .0!4 #< 7P V &L - !Z #( C  Q
M )X , "S "\ S@ O .\ +@#_ "X _P"G'@  FB(  (\D  "$)   >B$  '$=
M  !G&   7Q,  %<.  !0"@  20,( $4 #0!! !$ /@ 6 #P &P Z "$ .0 F
M #< +  V #( -  X #, /P Q $< , !0 "X 6P M &< *P!V "H B  H )P
M)P"P "8 R0 E .H )0'[ "4!_P"B(P  EB@  (LJ  "!*@  =R@  &TE  !D
M(   6QL  %(5  !+$   0PP" #T'"0 Y PX -@$2 #,!%P Q 1P , $B "\"
M)P M BT + ,T "H#.P I!$, * 1- "8%6  E!64 (P9T "(&A@ @!IH 'P>N
M !X'Q@ =!^< '0CX !T)_P"?*   DRT  (@O  !^+P  ="X  &HK  !A)@
M6"$  $\<  !'%P  /Q(  #@.!  Q"PH +@@. "L'$@ I!Q< * @= "<((P E
M""D ) DP ",)-P A"D  ( I* !\+50 ="V( &PQR !H,A0 8#)D %PRM !8,
MQ@ 5#>8 %0WY !8-_P"<+0  D#$  (8T  !\-   <C,  &@Q  !?+   52<
M $PC  !$'0  /!@  #03   M$ 8 )@T+ "0,#P B#!, (0P9 !\,'P >#24
M'0TL !L--  :#CT &0Y' !<.4P 6#F$ % ]Q !,0A  2$)@ $1"N ! 0Q@ 0
M$.@ $!#[ !$0_P"9,0  CC4  (0X  !Z.0  <#@  &<V  !=,@  4RT  $HH
M  !")   .1\  #$:   J%0$ (Q$' !T0#0 ;#Q  &0\5 !@0&P 7$"$ %A I
M !40,0 4$3H $Q%% !(240 1$E\ $!)O  X3@@ .$Y8 #1.K  L3P@ +%.,
M#!3Z  T3_P"7-0  C#D  ((\  !X/0  ;ST  &4Z  !;-P  4C(  $DN  !
M*@  -R4  "\A   H'   (!@# !D4"@ 5$@X %!(2 !,3&  2$Q\ $10F !$4
M+@ 0%#@ #Q5"  X63P -%EP #!=L  L7?P )&), "!BH  88OP '&.  !QCU
M  D8_P"5.   BCT  (!   !W00  ;4$  &0_  !:/   4#@  $<S   ^,
M-BL  "XG   G(P  'Q\  !<:"  2%PT $!<1  \7%@ .&!P #A@C  T9+  ,
M&C4 "QI   H;3  )&UH !QQI  4<?  $'9$  AVF  $=O  "'-T  ASR  ,<
M_P"3/   B$$  ']$  !U10  ;$4  &-$  !900  3ST  $8Y   ^-@  -3(
M "XN   E*@  '24  !0A!  /'0L #1T0  P=%  +'1H "AXB  @>*@ ''S,
M!B ^  0@2@ #(5<  2%G   A>0  (8X  "&D   AN@  (=L  "'R   @_@"0
M0   AD4  'U(  !T2@  :TH  &))  !81@  3D(  $4_   ]/   -3D  "LT
M   B+P  &2L  !(H!  -) H "2,.  8C$@ %(QD !"0@  (D*  !)3$  "4\
M   E2   )E4  "9E   F=P  )HP  ":B   FN0  )MD  "7R   E_@".10
MA$D  'M-  !S3P  :D\  &!.  !72P  34@  $1%   \0@  ,3T  "<Y   >
M-0  %3(   \N P *+ H !2L.  $J$0  *A8  "H>   J)@  *R\  "LY   K
M10  +%,  "QB   L=0  +(H  "N@   KMP  *]8  "KR   J_P",20  @DX
M 'I2  !Q5   :%0  %]3  !640  3$X  $-+   W1P  +4,  ",_   :/
M$C@   PV P &,PD  #(-   R$   ,10  #$;   Q(P  ,2P  #(W   R0P
M,E   #)@   R<@  ,H<  #&>   QM0  ,-0  ##R   O_P")3P  @%0  'A7
M  !O60  9ED  %Y9  !55P  25,  #Y/   R3   *$@  !Y%   50@  #D
M  @] @ !/ @  #L,   Z#P  .1(  #D8   Y(   .2D  #DT   Y0   .4X
M #E=   Y;P  .(4  #B<   WLP  -](  #;R   U_P"'50  ?UH  '9=  !M
M7P  95\  %U?  !27   1%@  #A5   M4@  (D\  !A,   02@  "D@   -&
M 0  108  $0*  !##0  0A   $$5  !!'0  028  $$Q  !!/0  04H  $%:
M  !!;   0($  #^9   _L0  /M   #WR   \_P"$7   ?&   '-C  !L90
M9&8  %ED  !+80  /EX  #);   F60  '%8  !)4   ,4@  !%$   !/
M3@,  $T(  !,#   2PX  $L2  !*&0  2B(  $HL  !*.0  2D<  $I6  !)
M:   27X  $B6  !'KP  1LT  $7Q  !$_P"!8P  >6<  ')J  !K;   8&L
M %)I  !$9@  -V0  "IB   ?8   %5X   U=   &6P   %H   !9    6
M %<$  !6"   5@P  %40  !4%   5!T  %0G  !4-   5$(  %-2  !39
M4GD  %*2  !1JP  4,H  $_O  !._P!^:@  =VX  '!Q  !F<0  6'   $IO
M   \;0  +VP  ")J   7:0  #F<   9F    90   &4   !E    8P   &(
M  !B!   80@  &$-  !@$   8!<  & A  !?+@  7SP  %]-  !>7@  7G0
M %V-  !<IP  6\4  %KM  !9_P![<@  =78  &MW  !==@  3W8  $%U   S
M=0  )G0  !ES   0<@  !W$   !Q    <0   '$   !Q    ;P   &\   !N
M    ;@(  &X(  !M#   ;1$  &T:  !M)@  ;#4  &Q&  !K6   :VT  &J&
M  !IH0  :+X  &?H  !F_@!Y>@  <'P  &%\  !3?0  1'T  #9^   H?@
M&WT  !!]   '?0   'T   !]    ?@   '\   !^    ?0   'T   !\
M?    'P   !\!@  ? P  'P2  !\'0  ?"P  'P\  !\3P  >V4  'M^  !Z
MF@  >;8  'C?  !W^@!S@   98$  %:#  !(A   .88  "N'   =AP  $8<
M  >(    B    (D   "*    C    (T   "-    C    (P   ",    C
M (P   "-    C00  (X,  ".$P  CR$  (XR  ".1@  CEL  (UT  "-D
MC*T  (O.  "*\P!HA@  6H@  $N+   \C0  +8\  !Z0   1D0  !Y(   "3
M    E0   )<   "9    FP   )P   ";    FP   )P   "<    G0   )X
M  ">    GP   *$#  "B#   HA8  *,F  "C.@  HT\  *-H  "BA@  HJ(
M *+   "AZ !<C0  39   #^3   PE@  (9D  !*:   'FP   )T   "@
MH@   *0   "H    J@   *L   "J    JP   *P   "M    K@   *\   "Q
M    L@   +0   "W 0  N0T  +D:  "Z+0  ND,  +I;  "Z=P  NY0  +NQ
M  "YT@!0E0  09@  #*<   CH   $Z(   BD    IP   *H   "L    KP
M +(   "W    N0   +L   "Z    O    +T   "_    P    ,(   #$
MQ@   ,D   #-    T@$  -0/  #5'P  US4  -A-  #8:0  UX8  ->C  #6
MO0#_    _P   /\   #_    _P # /\ #0#_ !4 _P @ /P *P#X #4 ]  _
M /  1P#N $X ZP!4 .D 6@#G %\ Y0!D ., :@#A '  WP!V -T ?@#; (<
MV "1 -, G0#/ *L S0"] ,L X #) /L QP#_ +T _P"Q /\ J0#_ *, _P#_
M    _P   /\   #_    _    /8 "P#Q !$ [0 ; .D )0#D #  WP Y -H
M00#5 $@ T0!. ,\ 5 #- %D RP!> ,D 8P#' &D Q0!O ,, =P#  '\ O@"*
M +L E0"X *, M@"T +0 S0"R /( L #_ *P _P"C /\ G #_ )< _P#_
M_P   /H   #Q    Z    .  !@#9  X T@ 6 ,X 'P#( "D Q  R ,  .@"]
M $$ N@!( +@ 30"V %, M !8 +( 70"P &( K@!I *P ;P"J '@ J "" *8
MC@"D )L H0"K )\ P "= .8 FP#_ )H _P"4 /\ C@#_ (H _P#_    ]@
M .@   #<    S@   ,8  0"_  L N@ 1 +8 &@"R "( K@ K *H - "H #L
MI0!! *, 1P"A $P GP!1 )X 5@"< %P F@!B )D : "7 '  E0!Z )( A@"0
M ), C0"B (L M0") -, AP#W (8 _P"$ /\ ?P#_ 'P _P#R    XP   -(
M  #%    N@   +$   "K  < I0 . *$ % "> !P F@ E )< +0"4 #0 D@ Z
M )  0 ". $4 C0!* (L 4 ") %4 B !; (8 80"$ &D @@!R '\ ?0!] (L
M>P": '@ JP!V ,0 = #K ', _P!S /\ < #_ &X _P#?    S    +\   "T
M    JP   *$   ":  ( E  + )  $ ", !< B  > (4 )@"# "T @0 S '\
M.0!] #\ >P!$ 'D 20!X $X =@!4 '0 6@!S &( < !K &X =0!L (, :@"2
M &@ HP!F +@ 9 #> &, ^P!B /\ 8@#_ &  _P#,    O    *\   "E
MG0   )0   ",    A@ ' ($ #0!\ !( >  9 '4 'P!S "8 <0 M &\ ,@!M
M #@ :P ] &H 0@!H $@ 9P!. &4 5 !C %L 80!D %\ ;@!= 'L 6P"* %D
MFP!7 *\ 5@#+ %4 \@!4 /\ 5 #_ %0 _P"^    L    *0   "9    D
M (@   "!    >0 " ', "@!O  \ :P 4 &< &@!E "  8P F &$ + !? #(
M7@ W %P / !; $( 60!' %< 3@!6 %4 5 !> %( : !0 '0 3@"# $P E0!*
M *@ 20#  $@ Z !' /\ 1P#_ $< _P"T"0  I@L  )L,  "0"@  A@4  'X
M  !V    ;P   &@ !0!C  P 7P 0 %L %0!8 !H 5@ A %0 )@!3 "P 40 Q
M %  -@!. #P 30!" $L 2 !) %  2 !8 $8 8@!$ &X 0@!] $  C@ _ *(
M/0"X #T W0 \ /@ / #_ #P _P"L$   GQ(  )02  ")$0  ?P\  '8,  !N
M!0  9@   &   0!9  @ 50 - %$ $0!. !8 2P ; $D (0!( "8 1@ K $4
M,0!# #8 0@ \ $  0P ^ $L /0!3 #L 70 Y &D -P!X #8 B0 T )P ,P"Q
M #( S@ R /$ ,0#_ #$ _P"F%@  FAD  (X:  "$&@  >A8  ' 2  !H#@
M7PH  %@#  !1  0 3  * $@ #@!$ !( 00 6 #\ &P ] "$ /  F #H +  Y
M #$ -P W #8 /@ T $8 ,P!/ #$ 60 O &4 +@!S "P A0 K )@ *@"M "D
MQ@ H .H * #^ "@ _P"A'   E2   (HA  !_(0  =1\  &P:  !C%@  6A$
M %(-  !+!P  1  & $  "P \  \ .  2 #8 %P T !P ,P A #$ )P P "P
M+@ S "T .@ K $( *@!+ "@ 50 F &$ )0!P "0 @0 B )4 (0"I "  P0 @
M .0 'P#Y !\ _P"=(@  D28  (8H  !\)P  <B4  &DB  !?'0  5Q@  $X3
M  !&#@  /PL  #@%!P T  P ,0 0 "X $P L !@ *@ = "D (@ G "@ )@ N
M "0 -@ C #X (@!' "  4@ ? %X '0!M !P ?@ : )( &0"G !@ O0 7 -\
M%P'U !<"_P":)P  CBL  (0M  !Y+0  <"L  &8H  !=)   5!\  $L:  !#
M%   .Q   #0- @ M"0D *04- "8#$  D 1, (@(9 "$"'@ @ B0 '@,J !T#
M,@ ;!#H &@5$ !D%3P 7!EP %@9J !0'?  3!Y  $@>E !$'NP 0!]L $ CR
M ! )_P"7*P  C"\  ($Q  !W,@  ;C$  &0N  !;*@  424  $D@  ! &P
M.!8  #$2   I#@0 (PP) !\)#0 =!Q  &P<5 !D(&@ 8""  %PDG !8)+@ 5
M"C< $PI! !(+30 1"UH $ MI  X,>P .#)  #0RE  P-NP +#=D "PWQ  P-
M_P"5+P  BC,  '\V  !V-@  ;#4  &,S  !9+P  4"L  $<F   ^(0  -AT
M "X8   G$P  (! % !D."@ 5# X % P1 !,,%@ 2#!P $0TC ! -*P /#30
M#@X_  T.2@ ,#U@ "P]G  H0>0 ($(T !Q"B  80N  %$-0 !1#O  80_P"2
M,P  B#<  'XZ  !T.P  :SH  &$X  !8-0  3C   $4L   ])P  -2,  "T?
M   F&@  'A8! !<3!@ 1$ L #@X.  X/$P -$!D #1 @  P0*  +$3( "A$\
M  @22  '$E4 !A-E  03=@ #$XL  12@   3M@  $]$  !/N   3^P"0-@
MACL  'P^  !S/P  :C\  & ]  !7.0  338  $0Q   \+@  -"H  "PF   E
M(@  'AX  !8: @ 0%0D #!,.  H3$@ )%!< "!0?  <5)@ &%2\ !!8Z  ,6
M1@ !%U,  !=B   8=   &(D  !B?   8M0  %]   !?M   7^P"..@  A#\
M 'M"  !R0P  :$,  %]"  !6/P  3#L  $,W   [-   ,S   "PL   D*0
M&R0  !,? @ -&PD "1D-  89$0 $&18  AD=  $:)   &BT  !LX   ;1
M'%$  !Q@   =<@  '8<  !R=   <LP  ',X  !OM   ;_ ",/@  @D,  'E&
M  !P2   :$@  %Y&  !51   2T   $,]   [.@  ,S<  "HR   @+0  %RD
M ! E @ +(@D !2 -  $?$   'Q0  !\;   @(@  ("L  "$V   A00  (4\
M "%>   B<   (H4  "&;   AL@  (<T  "#M   ?_ "*0P  @$@  'A+  !O
M3   9DT  %U+  !420  2D8  $)#   Z0   +SL  "4W   <,P  $R\   TL
M @ '*0@  2<,   F#@  )1(  "89   F(0  )BD  "8S   G/P  )TT  "=<
M   G;0  )X(  ">9   FL   )<P  "7N   D_0"(2   ?TP  '90  !N40
M95(  %Q1  !33P  2DP  $%)   U1   *T   "$\   7.0  $#8   HR 0 #
M, <  "\+   N#@  +1$  "T6   M'@  +2<  "TQ   M/0  +4H  "U9   M
M:P  +8   "R7   LKP  *\L  "KN   J_@"%30  ?5(  '55  !L5P  8U<
M %M6  !350  1U$  #M-   P20  )48  !Q#   3/P  #3T   8Z    . 4
M #<)   V#0  -0\  #04   T&P  -"0  #0N   T.@  -$<  #17   T:
M-'T  #.5   RK0  ,<H  #'N   P_P"#4P  >U@  '-;  !J70  8ET  %M=
M  !/6@  0E8  #92   J3P  ($P  !9)   .1P  "$0   !"    00,  #\'
M   ^"P  /0X  #T1   \&   /"$  #PK   \-P  /$0  #Q3   \90  .WH
M #J2   ZJP  .<@  #CM   W_P"!6@  >5X  '%A  !I8P  8F0  %=B  !)
M7@  /%L  "]8   D50  &5,  !!1   *3P   4T   !,    2@   $D$  !(
M"   1PP  $8/  !&%   11P  $4G  !%,P  14   $50  !$80  1'8  $./
M  !"J   0<8  $#L   __P!^80  =F4  &]H  !H:@  76D  $]F  !"9
M-&$  "A?   =70  $EL   M9   "6    %8   !6    5    %,   !2!
M40D  % -  !0$   3Q@  $\B  !/+@  3SP  $]+  !.70  3G(  $V+  !,
MI0  2\(  $GJ  !(_P![:0  =&P  &YO  !D;P  56T  $=L   Y:@  +&D
M "!G   490  #60   -B    8@   &$   !@    7P   %X   !=    7 0
M %P)  !;#0  6Q(  %L<  !:*   6C8  %I&  !96   66T  %B%  !7H
M5KT  %7H  !3_@!Y<   <W0  &EU  !;=   3',  #YS   P<@  (W$  !9O
M   -;@  !&T   !M    ;0   &T   !L    :P   &H   !I    :0   &D#
M  !H"0  : X  &@5  !G(0  9R\  &<_  !F4@  9F8  &5_  !DF@  8[<
M &+A  !A_ !W>   ;7H  %]Z  !0>@  0GH  #-[   E>P  &'H   YY   $
M>0   'D   !Y    >@   'H   !Z    >    '@   !W    =P   '<   !W
M 0  =P@  '<.  !W&   =R8  '8V  !V20  =5\  '5W  !TDP  <Z\  '+3
M  !Q]P!Q?@  8W\  %2   !%@@  -H,  "B$   :A   #H,   2$    A
M (4   "&    B    (D   "(    AP   (<   "'    AP   (<   "(
MB    (@'  ")$   B1P  (DL  "(/P  B%4  (AM  "'B0  AJ<  (7'  "$
M[P!FA   5X8  $B(   YB@  *HP  !N-   /C0  !(X   "0    D0   ),
M  "5    EP   )@   "6    EP   )<   "7    F    )@   "9    F@
M )L   "=!P  G1$  )TA  "=,P  G4D  )QB  "<?P  G)P  )RY  ";X@!:
MBP  2XX  #R1   MDP  'I4  !"6   $F    )H   "<    G@   *$   "D
M    I@   *<   "F    IP   *<   "H    J0   *H   "L    K0   *\
M  "Q    LPD  +,5  "T)P  M#T  +55  "U<   M(X  +2L  "TS !-D@
M/Y8  "^:   @G0  $9\   6A    HP   *8   "I    K    *\   "S
MM0   +<   "V    MP   +@   "Z    NP   +T   "_    P0   ,0   #'
M    RP   ,T,  #.&@  SR\  ,](  #08@  T(   -"=  #0N
M             0,$!08("0H+#0X/$1(3%!87&!H;'!T?("$B)"4F*"DJ*RTN
M+S R,S0V-S@Y.SP]/D!!0D1%1D=)2DM-3D]04E-455=865M<75Y@86)C969G
M:6IK;&YO<'%S='5W>'EZ?'U^@(&"@X6&AXB*BXR.CY"1DY25EIB9FIR=GI^A
MHJ.DIJ>HJJNLK:^PL;.TM;:XN;J[O;Z_P<+#Q,;'R,G+S,W/T-'2U-76U]G:
MV]W>W^#BX^3FY^CIZ^SM[O#Q\O3U]O?Y^OO\_O______________________
M________________________________                      $#! 4&
M" D*"PT.#Q$2$Q06%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T-C<X.3L\/3Y
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MY>;GZ.GJZ^SM[N_P\?+S]/7V]_CY^OO\_?[_;69T,0     # 2$   $
M               !                     0    $" P0%!@<(" D*"PP-
M#@\0$1(3%!46%Q@9&AH;'!T>'R A(B,D)28G*"DJ*RPM+B\P,3$R,S0U-C<X
M.3H[/#T^/T!!0D-$149'2$E*2TQ-3D]045)35%565UA96EM<75Y?8&%B8V1E
M9F=H:6IK;&UN;W!Q<G-T=79W>'EZ>WQ]?G^ @8*#A(6&AXB)BHN,C8Z/D)&2
MDY25EI>8F9J;G)V>GZ"AHJ.DI::GJ*FJJZRMKK"QLK.TM;:WN+FZN[R]OK_
MP<+#Q,7&Q\C)RLO,S<[/T-'3U-76U]C9VMO<W=[?X.'BX^3EYN?HZ>KK[.WN
M[_'R\_3U]O?X^?K[_/W^_P ! 0(" P,$! 4&!@<'" @)"0H+"PP,#0T.#P\0
M$!$1$A,3%!05%A87%Q@9&1H:&QP<'1X>'R @(2(B(R0D)28F)R@I*2HK+"TM
M+B\P,3(R,S0U-C<X.3H[/#T^/T!"0T1%1DA)2DQ-3U!24U576%I<7F!B9&9H
M:FUO<71V>7Q^@8.&B8N.D)*5EYF;G9^AHZ6GJ*JLK:^PLK.UMK>YNKN\O;_
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M____________TEH"         %W,____________________________J#4
M         %S3____________________________?0T          %36____
M_______________________N?44          $34____________________
M_______\JF0O @  !"(W25C.____________________________Z:1K02@_
M8W^5I[K:_______________________________5LJRRS.3Z____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________ENY=W8LC_____________________________
M____VYYG-@H  HS________________________________(?S\%     %[/
M_____________________________]F!.0       #RJ________________
M_____________YY,         ".0____________________________W&\:
M         !!]^?__________________________KT@           !O[O__
M________________________A!,           !DYO__________________
M_______L40            !7WO________________________^X%0
M      !(UO________________________]T%              XS_______
M__________________FB6A,            CQ?______________________
M___?FUPL           -NO__________________________[[%]53DB$0<!
M A$BLO______________________________W[^EF9B:H*R]VO__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________X[Z=@'S[
M________________________________\K>$5S . !VL________________
M_______________2BDP5      !R\____________________________]9_
M-@        !+R?__________________________^I$^           OJ___
M________________________P%H            :E?__________________
M________C20            (A/_________________________G7@
M        =_________________________^T)0              :O______
M__________________]]                6_3_____________________
M__TK                3.O______________________Z4
M    /.'______________________S ,                +=G_________
M____________F8IA)P              )]?______________________^V^
MB54G            )=S__________________________LJ==EU*/#(M+# Y
M1][_______________________________WFW=;2T-/9Y/______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________OU+O6________________________________
M_^>XCVI++Q5O_______________________________DH6<T!P     \R?__
M_________________________]:".P         2E___________________
M________[84Q            ;___________________________ID(
M        4.'________________________L:0              -\G_____
M__________________^S+P              (K;_____________________
M__]Y                $*?_______________________(T
M     )G______________________ZD                  (S_________
M_____________T8                  '______________________WP
M                 '3_____________________EP
M &K_____________________S@                   &/_____________
M_________RDB 0               &'______________________[FC@%<W
M%P           &C___________________________K3KI2&?'5Q<')W@93_
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________V[J=@FEIT___________________
M____________R)-E/1D    =GO___________________________]N.3!,
M        ;O__________________________VWPL            1=?_____
M____________________BRH             (K3_____________________
M___"1                Y?_______________________]] 0
M     '_______________________^<V                 &K_________
M_____________YT                  %C______________________T8
M                 $?X____________________Z0
M #7I____________________E@                   "7;____________
M________O                    !C.____________________ZP
M              _"_____________________P                    JY
M_____________________R<                   JU________________
M_____W                    VY_____________________^"<C'!50C,F
M&Q0/#0X2&B:_____________________________^>38TL[,R\S/UN#\____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____Z].\X________________________________]*IA65(+!(!A?______
M______________________&K<3P/        3^#_____________________
M____U7\U            '[+________________________C=1T
M     (G_______________________^0(P               &?_________
M_____________]5#                 $CV_____________________XH
M                 "[=_____________________S@
M !?(____________________O@                    2V____________
M________G                     "E____________________N@
M              "3____________________W                     ""
M_____________________P                    !T________________
M_____Q,                   !H_____________________T(
M          !@_____________________WH                   !=____
M_________________]$                   !A____________________
M__\D                  !F_______________________)K)F)?79Q;&EG
M9F=K<'J,____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________XL6JD7EA=______________________________=IG=0+ P
M    ,<3_________________________X)).$P           (__________
M_______________2<!T              &#______________________^YO
M#P               #?B_____________________Y8<
M !3 _____________________T                    "C____________
M________K@                    ")____________________G@
M              !R____________________O                     !?
M____________________V@                    !-________________
M____^@                     [_____________________PX
M           J^?___________________S,                    ;Z?__
M_________________UX                    /V___________________
M_X\                    &T/___________________]
M        RO____________________\K                    R/______
M______________^                     R______________________W
M%@$%!0,!       !!@T8R________________________.OAV,_,S<_0TM37
MW.+J________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________________':QO__________
M____________________\<:CA&A-,A@ %:O_________________________
M_[E\1A@          ''________________________7?"\
M #OC_____________________]]D"0                RU____________
M_________W0#                  "-____________________Q14
M              !J____________________F0                    !+
M____________________M@                     P_?______________
M____UP                     9Y___________________]@
M           %T____________________PX                     P?__
M_________________R\                     K___________________
M_U(                     GO___________________WD
M        CO___________________Z4                     @/______
M_____________]@                     =/____________________\V
M                    ;?____________________]\
M    :?_____________________7#0                  :/__________
M____________<                   8?_______________________U \
M1DY465UA9&AL<'9^B?__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________[]6[HXMS
M6I7___________________________B_CF1!(04      %+\____________
M___________WG588             !?!_____________________^5L%@
M              "-_____________________V,                   !>
M____________________G0                     U_/______________
M____H0                     1V?__________________R@
M            N___________________[@                      H?__
M_________________PP                     BO__________________
M_RT                     =O___________________TT
M        9/___________________V\                     4O______
M_____________Y0                     0/___________________[P
M                    ,/___________________^H.
M    (O____________________]$                    %?__________
M__________^!                    "_7____________________("P
M                 NS_____________________7@
M .7_____________________R1P                  -K_____________
M_________YT!              <.%\7________________________5N;S!
MQ\[5V^'F[?3[________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________XW\______________________________
M[,:EB&U4.R$' #+>________________________UY)9*0            "@
M______________________^)-@                !G________________
M_____V8                    R]O__________________E0
M           #R/__________________IP                      H/__
M________________UP                      ?/__________________
M_P                      7O___________________R4
M        0____________________T@                     +/______
M_____________VH                     &/___________________XL
M                    !?/__________________Z\
M     .'__________________]4                      ,__________
M__________\D                     +[___________________]4
M                 *[___________________^+
M )_____________________+#@                   )+_____________
M________5P                   (;_____________________J@H
M             'G______________________VT                  &;_
M______________________=5                 $7_________________
M________:B,K-3]*56!J=7Z'D9S_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________^C/MIV#:4ZY________________
M_________^RR@UPZ'0(       ![_______________________%;2D
M          ! _____________________X,;                   'R___
M________________D@                      F/__________________
MI                       :O__________________W0
M        0?___________________PX                     '?______
M_____________SD                      .C__________________V
M                     ,[__________________X4
M     +?__________________Z@                      */_________
M_________\L                      )#__________________^\6
M                 'W___________________\^
M &S___________________]I                     %K_____________
M______^9                     $G____________________2%@
M             #G_____________________6                    "G_
M____________________H@                   !G_________________
M____]58                   3______________________[LO
M          #X______________________^K*0                #/____
M____________________R4<     !Q,@+CY2:(3M____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________]-7)____________________________^M*PDG==0B@,  !*____
M____________________Q7U%%P             1V/__________________
M_\10                    G___________________H@P
M        :/__________________E                       -O______
M____________V@                      !^S__________________Q4
M                     ,3__________________T@
M     *+__________________W4                      (/_________
M_________YT                      &G__________________\,
M                 %+__________________^</
M #[___________________\S                     "O_____________
M______]8                     !C___________________^!
M              7___________________^L                      #_
M___________________>(@                    #R________________
M____7                     #?____________________GP
M          #,____________________Z$H                   "W____
M_________________Z 6                  "<____________________
M__]Z @                !W________________________>@L
M      5,_________________________Z)7:'2 C9RKO-#G____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________^WC___________________________2HWI8.BDC
M'!8.!@  G_____________________^L4@X                 :?______
M____________Y$,                     -/__________________>0
M                     ./_________________S0
M     ++__________________Q,                      (7_________
M_________T\                      %W__________________X,
M                 #K__________________[(
M !S__________________]L#                      +_____________
M______\J                      #[__________________]/
M              #G__________________]T                      #4
M__________________^;                      # ________________
M___$!P                    "M___________________P,P
M          ":____________________9P                    "&____
M________________HP                    !R____________________
MXT0                   !<_____________________Y$&
M      !!_____________________^M?                   =________
M_______________*2P                  ________________________
MRU<   P8)#$_3F!TBZ?'___________________________7Y_+_________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___KU,W'PKZZM[.PK:FHI?___________________]U^4S\P(QD1"0(
M     -O_________________=@                       *?_________
M________N@                       '7__________________P<
M                 $;__________________TX
M !K__________________XP                       #]____________
M_____\$                       #;__________________$9
M              "^__________________]$                      "D
M__________________]K                      "-________________
M__^1                      !Y__________________^W
M          !F___________________>(0                    !3____
M________________2@                     _____________________
M=P                     K____________________K H
M       6____________________YT4                     ________
M_____________XH                     _____________________]9-
M                    _?____________________^G+@
M    U?______________________F"H           88+45@X/__________
M_____________ZAC=(&/G*N[S>+Z________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________GR[>I
MG96.B82 ?'AT<&QH99#_________________O&I(+1D*
M #'__________________P                        /_____________
M_____T(                       #<_________________XX
M              "R_________________\X                       "-
M__________________\I                      !K________________
M__]:                      !.__________________^&
M           T__________________^N                       >____
M_______________4%P                     *___________________Z
M/0                      ____________________90
M        ____________________C@                      ________
M____________O!D                     [___________________\4X
M                    V/___________________XL
M    O____________________\Q#                    H?__________
M__________^1&0                  >O_____________________R= H
M               17_______________________Z'03'RPX15-B<H6;M-+U
M___________________________7Z/3_____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________OW\_'N[.OK[/'__________________]FRF8=Y;61=
M5E%+1D$\.#(M*"/$_________________TLE"P                    "2
M_________________X@                       !F________________
M_]<                        ]__________________\S
M           8__________________]L                        ____
M______________^=                        ___________________)
M#                       ]O_________________Q-0
M        W___________________6P                      R_______
M____________@@                      M___________________J08
M                    H___________________TR\
M    C?___________________UX                     =___________
M_________Y,'                    7O___________________\U#
M                0/____________________^'$
M'/_____________________87@                   /______________
M________OTX       X<+#Y2:H:ER/_______________________\)\C)JG
MML76Z/W_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____^[AU\_)P[ZZMK&MJ:>FIJ>N_________________[Z&;5M,0#<O*"(<
M%A +!      4_________________]<%                        ____
M______________\T                        ]O________________]V
M                        TO________________^P
M        LO_________________A)                       EO______
M____________40                      ?/__________________>0
M                    9O__________________H
M    4?__________________QR,                     //__________
M________[DL                     )____________________W0
M                $/___________________Z,6
M /___________________]A,                     /______________
M______^(#P                   /_____________________+4P
M             /______________________I3@           D=-$YKC/__
M_____________________YDY0U%?;GV.H+7+Y?______________________
M_______K^?__________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________K
MS+FLH9F1BX:!?'AT<&MH9F9H\?________________]A13(C& X&
M        GO________________]^                        =?______
M___________#                        4O_________________[-P
M                    ,O__________________:@
M    %O__________________E@                       /__________
M________OQL                      /__________________YD(
M                 /___________________VD
M /___________________Y "                     /______________
M_____[DL                     /3__________________^A<
M             -G___________________^1&                    +S_
M___________________*4P                   )W_________________
M____F"X             $"E&9L3_____________________[G\=#!HH-T97
M:7Z5K\SN_________________________^>@JKG(V.G\________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________?7PZ^;BW]O8U-+1T-+7X/_________________.GHI\
M<6EA6U913$A#/CHV,B\N,?_________________2)1$#
M     /__________________0@                       /__________
M________?0                       /__________________L L
M                 /;_________________W3D
M -S__________________V(                      ,7_____________
M_____XD                      *___________________Z\B
M             )G__________________]9(                     (+_
M__________________]R                     &G_________________
M__^A*                    $[____________________37
M         #/_____________________EBX              !4R4G?_____
M________________X'(3   !#Q\O0EAPBZC([/______________________
M_\IO;GZ.GK##V.______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________^>#2R,"ZM;"LJ*6BGYV;FYR@I___________________@F162T,\
M-C K)R(=&!,."00  -3_________________D@
M *W_________________S!X                      (O_____________
M____^U(                      &W__________________X
M             %'__________________ZD;                     #K_
M_________________]!"                     "/_________________
M__5H                      S___________________^/%
M          #___________________^X/@                    #_____
M_______________E;0,                   #_____________________
MGS<              ! O4'3_____________________W7(4      87*D%:
M=92VVO_______________________[Q81%1D=8::K\CC________________
M_______________2S>'Q________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________\^_K[_?__________________
M____[KFHG9:/BH:"?WMX=G1R<W5X?Y#_________________ZT\Z,"@A&Q40
M"P<"         "/__________________VD                       #_
M_________________YL*                      #_________________
M_\@Y                      #___________________!C
M          #___________________^*#@                    #_____
M______________^P-                     #____________________5
M6P                    #_____________________A1H
M      /L____________________L4D              !@Y78'_________
M____________Y7L>       ,(3A2;X^SV?_______________________[M8
M*3E)6FR E[#-[?____________________________^SGK3%U^O_________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________Z[^?AW-G6U-+0T-#1T]G@Z_?_________________
M_[B*?G=Q;&AD85Y;65A75UE>97'__________________[\Q'Q80"@4
M          #__________________^U6                      #H____
M______________^"!                     #,__________________^K
M+P                    "S___________________25P
M      ";___________________W?!                    "%________
M____________HC<                 !2N4____________________RV$"
M            #"Q0=I[1____________________]8TP       -(SM7=IF^
MY?_______________________\-C&"H[3%]TC:?&Y___________________
M__________^H?Y:HN]#G_____________________________________?__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________=SL6_O+FVM+.QLK*UN<#)U>/___________________^7
M;&1>65513TQ*2$=&2$M066:A__________________^G)@X' @
M      !6___________________.4                      Z________
M___________T>0L                    A____________________GS(
M                   .____________________Q%@                (
M,5J$____________________Z7\?           &)TMQFL+I____________
M_________Z=)      (7+TIHBJ[5_/_______________________]-U'B8X
M2EYUCZO+[_____________________________^N<H68K,+;]O__________
M________________________W^__________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________O[*JIJ.AH)^?H:.FK+3 S=WL____________________BEI3
M3TM(1D1#0D%"0T=.66E]____________________GBX&
M    ____________________PU8                  !5!____________
M________YWL:              DT8(NT_____________________Y\_
M      0E2G&9PNO______________________\9F#P   !,J1&*#I\WU____
M_____________________^N.-2L^46B!G;S>________________________
M______^^=G^4J<'<^?__________________________________TMCS____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________V\O#O[^_Q\_C]____________________
M________^+"?FI>6EI:8FY^DK+;"T>'N_____________________HY02D=%
M1$1$149'2U%::(.I_____________________Z9! 0          !S9CC[KA
M_____________________\9E"@      !"=,<YS$[/__________________
M_____^6(+P  $RI$8H*FS/3___________________________^K4#9*87N6
MM-;Z_______________________________2AWR8L<OI________________
M____________________U,[M____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________MY>/CY.;H[?'Y________________________
M______VQE)*2E9F=HZFRO-#M__________________________^=4T=)35%6
M8'.*K];\__________________________^R5@ :-5!MBZ[2]___________
M___________________-;SY?>YFWU_G_____________________________
M___NGX.FPN'_____________________________________X\[K________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________
M
M
M                                  #_________________________
M____________________________________________________________
M____________________________________________________________
M_________________________P    #_X4#1:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E
M:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E
M.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V
M-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR
M9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R
M,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+R(^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^
M061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O
M;#X*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C0M,#8M,3)4,#$Z-#(Z
M-#$K,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.DUO9&EF
M>41A=&4^,C R-"TP-BTQ,E0P,3HU-#HQ-2LP-3HS,#PO>&UP.DUO9&EF>41A
M=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C0M,#8M,3)4,#$Z
M-30Z,34K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB
M(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L
M96UE;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\
M+V1C.F9O<FUA=#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS
M.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP
M+R(^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO
M<#I#;VQO<DUO9&4^"B @(" @(" @(#QP:&]T;W-H;W Z24-#4')O9FEL93Y5
M+E,N(%=E8B!#;V%T960@*%-73U I('8R/"]P:&]T;W-H;W Z24-#4')O9FEL
M93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X
M;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E
M+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(^
M"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z,#E!.4(U.3(S
M,#(X148Q,4)&1$)$1C@U,C=$13$R,S<\+WAM<$U-.DEN<W1A;F-E240^"B @
M(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z1#DU,3<U0S0P,#(X
M148Q,4)&1$)$1C@U,C=$13$R,S<\+WAM<$U-.D1O8W5M96YT240^"B @(" @
M(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#I$.34Q-S5#
M-# P,CA%1C$Q0D9$0D1&.#4R-T1%,3(S-SPO>&UP34TZ3W)I9VEN86Q$;V-U
M;65N=$E$/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @
M/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/F-R96%T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.FEN<W1A;F-E240^>&UP+FEI9#I$.34Q-S5#-# P,CA%1C$Q0D9$0D1&
M.#4R-T1%,3(S-SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.G=H96X^,C R-"TP-BTQ,E0P,3HT,CHT,2LP-3HS,#PO<W1%
M=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E
M;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W
M87)E06=E;G0^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C
M=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O
M;2!I;6%G92]P;F<@=&\@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO
M<#PO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC
M94E$/GAM<"YI:60Z1$$U,3<U0S0P,#(X148Q,4)&1$)$1C@U,C=$13$R,S<\
M+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW
M:&5N/C(P,C0M,#8M,3)4,#$Z-30Z,#DK,#4Z,S \+W-T179T.G=H96X^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N
M9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I$0C4Q
M-S5#-# P,CA%1C$Q0D9$0D1&.#4R-T1%,3(S-SPO<W1%=G0Z:6YS=&%N8V5)
M1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R-"TP-BTQ,E0P
M,3HU-#HQ-2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN
M9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O
M8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M
M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S
M9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC
M94E$/GAM<"YI:60Z,#E!.4(U.3(S,#(X148Q,4)&1$)$1C@U,C=$13$R,S<\
M+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW
M:&5N/C(P,C0M,#8M,3)4,#$Z-30Z,34K,#4Z,S \+W-T179T.G=H96X^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N
M9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX
M;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z1$(U,3<U0S0P
M,#(X148Q,4)&1$)$1C@U,C=$13$R,S<\+W-T4F5F.FEN<W1A;F-E240^"B @
M(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z1#DU,3<U0S0P
M,#(X148Q,4)&1$)$1C@U,C=$13$R,S<\+W-T4F5F.F1O8W5M96YT240^"B @
M(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#I$
M.34Q-S5#-# P,CA%1C$Q0D9$0D1&.#4R-T1%,3(S-SPO<W12968Z;W)I9VEN
M86Q$;V-U;65N=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP
M;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C
M:V5T(&5N9#TB=R(_/O_; $, !@0%!@4$!@8%!@<'!@@*$ H*"0D*% X/#! 7
M%!@8%Q06%AH=)1\:&R,<%A8@+" C)B<I*BD9'RTP+2@P)2@I*/_; $,!!P<'
M"@@*$PH*$R@:%AHH*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*/_  !$( .H"<0,!(@ "$0$#$0'_Q  <  $  @,!
M 0$             !08#! <" 0C_Q !/$  ! P,# @,$! D)!@4#!0 ! @,$
M  41!A(A$S$B05$'%&%Q%3*!D18C-4)7=)6AT20S-U)UL;*SPS1B<G."D@@E
M-E/!0U1D%T1CHL+_Q  9 0$! 0$! 0               @$#! 7_Q  P$0$!
M  (" 0$&! 4% 0       0(1 Q(A,1,R05%A\ 0B<:&!D<'1X044,T)RL?_:
M  P# 0 "$0,1 #\ _5-*4H%*4H%*4H%?'%!#:EGLD$U]KRZC>TM&<;DD9H*Y
M9=71[C;C<9$.1;[;T@ZF5*6V$*!. .%$Y^8K<7JBQH@-S572*(KBRVES?P5#
MN/F/.JI:_9_*A6AN$E^V-N,K:>0^U&4%.N-JRGJY5XAR?3O6Q-T3-E,OOJFQ
M4W21),E3K:'&PT=@0.F4K!' R<YSYBO7<."Y>]X<I<]>B?.IH+,F:)LB+'C,
M*;0V^7TD.%:-XX\N.WKWK*]JBR,P8\QVZ1$QGR0TX7!A>.^/EY^E0GX&OJN"
M)+\]+RA+B2E%3?*RRUL.?B3S\*PM:,FPY2Y=OG11)6J2DA]@K1TWG-_ !&%#
M[C6=.&_'[TW>?R6*7J:R0W4MR;K$;6H)4 IP<I5V/R/KVK5CZMMJ[Y,M<E]J
M-)9>2RV%N#+Q4A*@0/+ZV/C53B:.N3$VZ6R"\VW!<MT>&J1)8*^H,*"BC!&"
M,]N1R/2IG\"2AB6TU*3M=EQ)"%*1E02RE P?4G8>?C6WCX<?%OWX9VSOP;T;
M5C2YT:/)9;92][T2Z'TJ0VEA0!)/QS]F*F+=>+?<H;DJ!,9?CMDA:T*R$X&3
MGTXYJL-:*<2XV5RF'$I$X%"VB4J]X5N&1D<#S]:DM+Z?DVVU385QF>\LODA#
M:2HI:04A)2DK)5\>3Q49X\6MXWS_ );C<M^7VT:I1<G&UHMEP9M[J5+:G.H2
M&E) SN/BRD$#@D#-)>K[8F")-O?:GI$EF.M++@RDN*"0H_#G/QQ6A'TS=_HA
M5DDW6.JT".N,DHCD/*04E*=QW8XX[#G%:$+0+S4?#TI@R Y&*74]51*&E[L'
M>M6,^0& *OKP[W:S>:>C:OMGN[CMP?:@A,IZ*@.N#QEM6"H?#M\LUN:CNQM=
MO:<80EZ1(?;CQT$X2I:S@9/H!D_95:N&B);L;;$G,LR?>Y,A$C:M*VPZH'PE
M*AVQR#D&IG5MMDR+9;G(P5*E6Z6S*"> 7=G"AZ9(*C\ZFX\7:=:W>6KMO)U#
M:#-?A_243WE@*4ZCJ %(3];/R\_2M*1JVV^[1G[>\W.0[,:AJZ2QX"LX!/\
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M3P 1S035*K=[UC;[6T3TY+SH=Z(;Z*F]R@E2CA2P$D80KD$__-3%MN#4\/\
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M\CQ.. \(3N2!@CG)/?C![T&QIW\@6S]5:_P"I"JI[-KZJ[:3LYN$-RV7!4<
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M^M:UKAJ@Q0PI]3P!)"E) (R<XX^=+JDF&2%N((4G!0HI/<#R^=;2$A"$I!)
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M9=?;$E4L/(D/QT*BM=18.\K3QZ<@>ORJS:'ZZ;9"B/S);CD-KH.I?0E*E%&
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MA/Q&K#:T17U)4ZRF*@(64YVDC&"1DX^=3$:.S%CML16FV6&TA"&VTA*4@=@
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:2E I2E I2E I2E I2E I2E I2E I2E!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g843142g33n33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g843142g33n33.jpg
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M P4&! $! 0 # 0$!              $"!@<#!000   $! ,%" (" @(# 0
M   $!08! @,'$105(# 2$Q800% Q,C,T%R$(-C=!-8 B8' D)A$   4" @,)
M"@@)"04%"0   0(#! 4 !A$2(1,4,4$B,I+3-!4'0)'1(S.3-=46EA @,%&A
MTD.487%"LG,DA+34\(%2<K-TM1<(4+%B4T;!\6,E=8*CPT1%E28VAA(   0"
M!@8(! 8" P        $" Q$R($!0(3&107&Q$G*R,%&!(A-SLS0082,$8(#!
M0E*"8A2A,X,3  (! @,'! ,! 0$!      $1 "$Q05%A$/!Q@9&AT2 PL?%
MP>%08(!P_]H # ,!  (1 Q$   '?X 4F&QD&8;&PTY    #% ]H6Z+<%YSN3
M(<              !"@0:US(<PI-NQ2? 2D*" HUG'UG4F,L>C,MS/RB%E(
M 4$*"%E(4A0  0I 4G8%:@04D%14 #CP,H@")?GLXZJ.0G"SG.2) ))R5*
M               +%[#H_GOU?)JQR H]%L/R_J\9GZ>A9\<\>IP_1[Q^6X'Z
M?"K'$0QC+&X?Q-KNE\_90                !8C[VA^;^G\F60@+:[\WZ?"
MOV_/^-Z#]/AQ9^MQO7\'LLO)E *DN5\';+G_ #-E            Q+,/(VYU
MR I*#E !IQZQIUB=K^0LEC 9&<$J2"26$,09)[;!.:;'L T?8
M ,-"P)M&*P? :E8V[52GP T:]NU3&[<?C,K+" ]"D  EY&,,STB79MR78]DW
M.?O           #[ZQ;EQA-H9R ZLQ',R2L)!HF[=JF-.X_%GUQG+$0,<HP]
M)2%JSB^9B%L8YQY^FS[DFR;,N=?>!0 "% ! 4A2 %(6"4P#EQWK< <@   -$
MO;M4QJW'XCVPG+$)E'GZ58>E+"5><CWQGT\U@89T^7KL]Y+LFS/G7WP
M      -9YPFS(Y    :)>W:GC5N/Q9]L&6(8YQY>N5.A?6M5]?RN/\OVMS^W
MPM7MWS7KY+!&.4>/ML]Y+L>S/G6P            :^SJ38L<@   -$O;M3QJ
MW'XCVQJRQ@C'*/+UO;JOT?@],*F'6?IRMI]_\+T\UQ$89QY^VSWDFQ[,^=??
M            UGEC8W.UR&'IEXF#RYRE1)":)>W:KC7N/Q'MA.6(C')CD4@
MG/!8&.4>7OL\Y'L6S/G>P            :U#[S8P5FN R/->)N<(/A2#1IV[
M5,;MQ^+/M@RQ     $8YQY>NS7DFR;*.=?>D  *0    %( 4@^\LPMI3,(DI
M*"LK !HE[?J>-6X?&>V,W&"0  A8 &.4>?IL]Y)L>S/G6P            8%
M1:>MI)R    T]=PY'87;==4 H(4 @*0$NP#DW1,_^=[R           !;0^
MNP5    U:=KX%9;<=3>E$)*D2@+"D*!/GYYL\A[)FUH/2            ,03
M$LVW'(""DK !JT[9P*RVX:H]?)1()4$+"202!,V%S9Y#U_-OG_2P
M   ->)80W#%8.N-=T;(:XSX :P^U\#LWN.I/7!<1!( !!( F4^=S.Y#V/-'0
M.D3 4@ !2 I   4@!7VIB4MO3/@Y0? 8BF8Q6"$U:]KX)9;<=3>WG#&0""2"
M2 2!,IPN:_(>PYM\_P"DRH          @)AXNO>7>19R    U:=LX%9;<-3>
MN"X@03/0!#+S*2"9DQN;/(>P9M\^Z6           !@?'0UL).4   &K3MG
MK+;AJ<>V$L05AD2</2CR]*OT>;/RAC*A,IPRS9Y%U_-KGW2P           -
M=I8LW!'(   #5IVS@5EMPU1Z^<7&2)E,RN%K&P3Y>OMO@?>L+TKGTY^1 $R8
MW-KD'8,VN?\ 2P   !08[D'F#W9]9>T    PE+<FQXDQ;+^F,"9B+420FK7M
MG [+;AJ;UPBXB63#+[/R_H];KNP<N6'@-HUV?7QA)($RJPN:_(>PYM\_Z5(
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M@Z8S(-<<945ZLQ4/5GM3O#-T     X#3C+>>S[2LL/'2F5]>4-E@
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MAJ@P_/9PC@' . < X!P#@' . < X!P#@' . <(PV8RXC@' . < X!P#@' .
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MV1MN)^.E-K.#J=(:=F7!%92/"C?2_4]/Z9ZW0^E]1?WU>"GU)TLZ/IOJ7_\
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MA*C1W@TM6.\8^H@'U>#^H)/52.Q>RHG8O943L7LJ)V+V4NH?,7CN] =B]E*
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M_L?[DW[AGOTD?^:Z[J;)Q223Q5G<]M2;B'5DTHCK]HPDTEU(1!\NHDD1T]4
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MFZABAB0! HX=PW-'HNW9('L\MV/04C&RH$3F;AN9,ST57A1P!8&#!L!$0$0
MJAQ-18.4))6?<QQ I+<NUF,0^7,(X!U<X,8\=+E./%%NJ<1^:HNRIV$M^,@I
MIE<KV+4:/',C+N&D(;*U>KJCL[1GMV<IM5D.8H:!$!JX;F:L+*:V;;>QBBE+
M/'R\U=.T:D%4F(M!21C')5E!3334*<3&TZ0I2\IA"01C6T<SDGR"#473YFBZ
M!$3@HV+D,.R:_P ;_1 HC39HNL\75=6K)7J46#3:B)V[%-]H6>KGSE!(%P'*
MB'VA] 4>XTD[D/%F?Q<5%*>SSTJUQR<N10[9E;J!RE4DE$Q1.500RD*<.,-#
M(-6<Q'@FY69KLIV*=0\BW=-\NM34:.B%$0X6@Y!.F;>&EF8N)@T<VE>I'-U)
MPCY2T&TJ*@);"M/%(9L4Y5AR"?R0&_*KM>]JY5NUM6R/9(8XP-2BJCUU'*JK
M)8MRF</W#MWE!(FD=-6%;D0VF8B+F(^Y'4S&7+;R\1).B-8XKF'>LSNR:6:A
MP-I2,..&!@"NT6QI>0<RBUF7&FI&2#U0RSU:W[D;C+QJ#I<W"<*L#F51SCI$
MA2_*&,7= IA[P#5N33HU@2Z<]<J< :SH4\DE>R"2DFJP/()MCO'R1R-TDM>;
M,F4NKTXA7:@_NF[#NHFVKBC(UK']0;(K%*OF)5$(=@HW%5Q<3I\HH42CAB&G
M>W+[5M\LM#79:]JR$Z6'N:$7BY%%(K511A) Q>%,FZ8G4*&D#&#>-AC5GI3)
M)F;NB<M*)N-Y%VM!KR[U)LY8HJNI-RV: ";)EKCCEQ$,?R0&K>EV+F1GPNLS
ME.WXR BW,E-/SLNG@$80J:Z QV&"VLR9!T;M/75J7')6XXA;MM>#E7;RU%'B
MQ',LN0!AAC'PH*)J*";5+*#@*)@T?/4A$*]>O.IW;=A.RT7 OY"$@'KHQ2HM
MI:10(8B"N)PS 4#Y,=.%.+9;M;DD%F4FUA)"5C;>?OH&.EWA4S(1[Z20(<$%
MA!8N8<NK)^48.Y[S1.F<C7M(@(F;AGHH**-@EK8;GC91DL<H 0BI6[A)<"B(
M9B;E1\_VD7/(WM,13M&2BF)4@A+5A7R)@.@XC85F;,LY0,4,%7"JAOP5$WPS
M9V#JK<9SD/%M7$M.$,[CI9<,'+[)%G!%X1!,."01)FWZ2N#561-6Y K$<6E;
MDW(3;5BV>E(F(3,LT9,CEDI1-0#:O.<4DPPP#&GRM]G8LF"D(*-SG3URL<CM
MR -7Q41,D9=1OKUQ*F(ESCH&KYDG3@7+R=MEYV<6(^D45V8#9\0W>LXMZJDH
MF9=%&3=N-88<HF$$P'#<JV[+"+M>:?PS. 0>,IQ241BUC134$7)XV0C-3(Q[
MX3^1< 7@ACB733V.N9_M0KR[MY%1Q))_-)V_%+)HE1ATYB3(1^^*DH4Q\Q@X
M.; /GJ3[*6<A:WL!(S"SOV@7+(^T[:*=2P2ZT>$:5+87#\BX92.!5#@_1VG:
MJ18LD[F=6%(VNH<7+@4'EE--41.:1U9/U5R?@\ 3C@.;=#"K*O>[@M!BVMAC
M<# \;!.))RJ8TLPV?;@<O6J>?7KX>)T B0G&.8:[3NT!5NLV:77<+:-A"N$E
M$%EX>TVQH@K\452E4(1\\!428AB)2@/RA@#=$I@[X" ?345:BS;L]BR,)PLL
M:^(WK):\T4RRII,R;-4(]F +F3-J.$KDR;M7R_;R,6TD)+M!MJ_;1.N5RY9@
MXM]@5IL<\AJ29$G(B8/%ZS#0-7C<EU'MF/G97L\DK!M^)A7$@O'(DD#'77D)
M60<-DUU!4<8 4I$QR$^<U15S6@:V)*45L"V[,N*,N!:1;M2N;?;D2;RD4^9M
M3*"@)R^,1,0F< QT".CL_N,UV0C.Z6,A=P/W,U$S*EFO5+L5ZQDFQW$4DJX@
MD&IL ;J'+XT=&C<J_I-!W'N!GNU6U+@9S"K1]#Q<NSMK9%9%Q%-%TG#T&0"7
M4MSG#%;)B.&FKI+9CBSW-O7==*MU*+W$$KUI!NGXH#*( U9>*E$5 1P1Q4()
M=^O:* "V[<UD[&2"EU1$K<+"87BFFHVV.G+=+G@YUV\(F) 6,). .!MSN>*8
MSDPU8/9M?98EH<%57+Y;.F3!%!NDLKD ZA0$X@! $0T_"CU]-Q$*#G6;,,K(
MM6 +ZG)K=4+E1/6:O6!CAN8TA<$A.1HP3MVUC49!NH$DQ6=OE-2W1*=F5R4X
MG/\ @P -VM[#>PW,-[<_!2MM%?(C.H1J<NK&8*;22-56V=-WQ-7JC+AEW=WX
M9N.B7Z;UW;<@$7-HD(N0S!^)-8"!A52(13@ANE$0T?!NB/X^X1*<H&*;C%,
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MP$,?=W*N1G:7:ZC<SM*;MU!,TM+VVSGXIH\TOH9O<0@6/"5FBX"S%PB7( &
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M,V**BHU1 NU@4&\5BAWQ/\\S6@JL" 2JM>S&.K75P"1$&[VM^ BDA(.H'O\
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MPC-8$1I,KL<'&E.)6D+*IT#J,M?9!L(P#U)N2?X(WG(/PL!" H1,0((  !(
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MVR62PRR2266RX 2   <M+<U*]M)@                 3_^X4H(Y^@
M            8 4;M'[V!@           "N 0  )PT&PT#4(@
M   #RIEM=1LM+]WKRVWM-&UV^SVB6 20&K<"[/5OB4$@  @ $@@D@B%T
M9WP!]+$1<             D    5H(1%U,2\@           "B    -]'SCK
M"CR             >"&2"S>3=%MBTC@            V""B'U%0%&&!*74MD
M@DTFFT,L&J 02   R9!!-;;0            !B    4Y\!P#L= @
M    2    =@0%+D&P9@            6 "  4,/@$<\L9@           "$
M#B2:IG--')-SQ,MM,MEMMLMN>R 20 J#)O'/9LC$          "4:    5IM
M\ 9A9V@           !"    6QHMJ\]-L@            $    "+K$-TM,U
M@    020@     "#B DK8.Z<9_'    "2]\  2 "B"VRS=!K7ST-%B24PE^V
MT@W5=0L"""0 <%+9-;))&  <$BLZF4B#D      5;+%O-G-V  ?:2/Z[:"3
M      5)O)EM8O*  0?39?\ WNAH      'BB6NVZH*H "5%+;-B<H8   $<
M$!5@#KA3AF@@"E\"O0\B3\E    $%*MML-LIMQ\)XE]MELI4LD      D @@
M$ H   D@$(     D       O>[IK#M<  +_M]<:;<KS@      @  E )$$
M ( @   ,$$        B_D$ (      L)IM           %(#%,L      5-[
MH           @$$$ D                     JLI/]=
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MIZ5/Y1H1PEM>OE4P"$/67+7MA-LB,8!B 8*"$1@$()KX/:, 2EB24<@@BR2
MYPM6,$Q*+2%B $IZ0KI0*&\)G@H  "+L0%*2>0#FL%&O4GJ8F; O_!;A@)D
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M\&K!Y3T##&'"">#Q8LIP 5!C!7&,51-RRSKC[)-NVA=B0DUN*BN@,0K$H]8
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MN?O30WE<A#<KGYQ9Q=[+&B&Z/[8W/*.N-U?U<L9_MH!C&XD@&-3,F=F:A#!
M,[N]1X1[JQE(-!HUSB?8_<37<UB&O4^8FX_<*%9F*00H&5;"&JG.+\!1MA</
M!C:._6R-T=_-!]G<M$M'<COU@[F#TRQJV7K<);F\O)0T<"&)3F9\T*+F.-B_
M%!46P2: 5\&\ +:;[8@/.8:J65K- 7@ 9\R?),SX@6Z!:9%!FG[OO5?<+Q"1
MH( 9@\J/:4Q:$C21@%C8]A9M9)4!C"'!Y *L-@(BE-P C8-U0,IAQ,4X!L$S
MO+WA$B08R5#,55(^*F?A<! \@_"Z)4ZO5H #N CC19&#1H"8&4(@85HTA,6
M'#$!31M 1+"* 2!;AP@!&"$*40",?4:V8@'HHMIAF&-T52>$98\(!%Y2ZR"(
M\4GG#G$RL'LK W$@4@C1>([PQE "ZBB[(#$D"YANN/-3M/GDXD1,$!)(0 "2
M2!8 5,.@$[8JHC,@0X+97%\P0QU@$%M$JT-7 S$E&DB#L,ZD%,@5/Z$(4($
MA<&W.^E0@$$;!IS2P ,*\(@0080AYD2$B3D4B0D;VF"Y(B &MO?(&3A)6&>K
MB40) B#X]M#=%EWIF#W"%($&T(J-Q($(S1P?.(Q208#2X)X>1%IJ9(I,ISQ_
MST &@H=0M<G<G\ *^,#N%I]:8./Q,"PM!B!6WQ 0;!H0U*@Q>#"0*J@H0#D
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M=?\ %>;W0R_$LU]%A&C.-A'YS#8Y>?M,/$?,W5F/\49N72P6Y[25*TG4181
M$@5\P=#"*4 <#!1YH\(%*0!!! @"0(J46&C%8&>,%!LMLLEHR3YFZLQ^48%#
M[(S>KA?B63394*PV3G%^IIR,&"M.L$XP5# $F6B'6MBX"(<EOA"'*2(6JJP8
M[0".!1PXX05 ]%D-+B/F/O5Q_@</3?Q^V[#YV$,1958#^,&V$1YH,A5#THX(
MD%#4K6J^C"H38FH36AR4M!FIP70  !XH!/&"@]&:$@*S$(,8!U'MG;AL'M'T
MZ;<-G.":D<CR$LVD0U$1B,6D6D%F=EMEG. 32,'S*Q10"U%?B5V<Y6%W-O36
M(Q*(Q11&5VJ%P!(F=J]WOV7XE0]!VC;?;9,/!\S<68]+_  "QN#H#QW<?)!%
M%75U%5)]FG[)/V:?LTT?WI^S2KSI^S289^R3]FD,PN*?LD_9I(46+M23NCE$
MB00$R*!IA\1G^!W (T>EQB]'#8%LLF'@^8N]7'IW3K+#!/W+"LTFD.6,MRG
M2@X04.< &-I8S24Y2]X.$"O@?B7/OE7)^RRST6V6GS/G9?:32DH6:3?>8])
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MK*SEOU]P$EA:TA*.'41C3J/,Y.H\Q-.H\RK 53:H\PD$00!%ZBD!* A\1 7
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H^.NGY@_*PBE%!VV?$724,QVG_++6DKCMK ^4K*XPZ7E<)5RN/YO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g843142g35n35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g843142g35n35.jpg
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M/#]X<&%C:V5T(&5N9#TB<B(_/O_M $A0:&]T;W-H;W @,RXP #A"24T$!
M    #QP!6@ #&R5'' (   (  @ X0DE-!"4      !#\X1^)R+?)>"\T8C0'
M6'?K_^X #D%D;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$!
M 0$! 0$" 0$" @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,#_\  $0@!(0%Z P$1  (1 0,1 ?_$ .\  0
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M@'T;CO?$E\J._;: ?1N.]\27RH[]MH!]&X[WQ)?*COVV@'T;CO?$E\J._;:
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M[;J=\KG(TI=UP;E+4@+*+9SM@DFTL:%MV08/2,F,OR=8LD4S I1()] TU *
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M+HM>YK6LIWE$8;*]G2>-G,YC!D0#2^2K9/-**DG+2CBJ$,JZ*"94@,',7CJ
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M9>.G#WEB^SKA7E8>)0@8AZ[DX=LY>*QL,V.=&-:$='.F1(NI2E(&@T!?^@%
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M:95LC /NIXQJ;SS_ )0TRK9& ?=3QC4WGG_*&F5;(P#[J>,:F\\_Y0TRK9&
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M7_7BWP8GYU ?8R:O$%3'<22CP@IB4$CHE3 IN8!Y^8!'4= T]6@.4H#B'#Q
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MVX+Y12\;<%\HI>-N"^44O&W!?**7C;@OE%+QMP7RDQ2BH( EY?\ PH^Q!$>
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M#Q7DNV\P6%"Y#M3W<G$S!G;<[22;*-GL;(QRWN>0C7 G(1-=5HMP%1/5,VO
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MX. 1 $.J!4I0*'.4PIZ@73H P#RZT!Q) N0>;F4C"^48"AU*PZE#H$?T_2-
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MA0&1+%HLQ9-F*1U3@T29MD5%3<ZQV[4J;<RBYAU;]:H0G,(% !XZCQH#D$A
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M=SJ.[M1EA\FTR1QBR>(Y6@4\Q$R6S?'9O<6),Y$+@:VZ+!B^-'S)W((F16
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MQC9^2+Q/D*_;=LFWHN\KY4<&>#=-S-V*99>5*[4'KW*:KG4I#' #"0H"(<:
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M-IG7V;_]K6RO]6KM_P S95H_MC_:M;LL_,AN3LD_=&;/_(3R&S=7%QW@* 4
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M*IV:<\I60A+26J1BB655-G4UCP?:;FI^=<TY/"*QM0CJ+9U$\9KZ!N=V]@
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M@=9-<R#AQ'-D#JH"LD4PD$1*)B@/<H"Z- * 4 H!0"@% * 4 H!0"@% * 4
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M&@*E * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M"Y6SA(2'D9J+!NW)'S!5R&!0A2)DY^;0H!IH!E&F.I \OGT\D3#H!M0X#S
M  &#N\ XT!/0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * I+(IKIBDJ7F3-[(NH@!@#N#IH.E 6U3PMBI/)SO- 6);I\K
MR%IEL60OY1B0]R/K0*LDX"WG;T?\?%]>B4W5"7EU"@+-6#L1V>8LRB^S7CO;
MOC&T,J2"KYPO>T- )(2R;F3.HH_=,P.=1E'NG2BQC'4023.8PZZT!>G'6',7
M8DBIB$QI8\!9<3<-TR=[3;"!:>XV\I=LR*)I6X'A"F'KI*0,W(*J@^RY0UH"
MS>;=C&T3<A<[6],Z8!QYDZ[&<66$;W!<\4HXE"0Y%"K$BQ<MW#8RC BI"F!(
MVI $H#IJ% =SB-K6W> 8XKC(3#UC14?A!W(/\3,V,,DW;V&]EDS(R3R 33$I
M6SE\F<04.;F,;4=1H#I+;8GL\9YA7S\UVZXO0S"Y>&D5K[2MY$LL,B<0$\B5
M(#_%R4@80U%<J *B/\:@.ZR.UG;O+P^6+?E,/6+(0F=9-&:S#%NX1NNRR++M
MQU;R=S(*<Q'SY$WE%5\DX&XZT!9.1V(X7LG!N4<)[8K,LK;O]:,<Z0EY^WK,
M93C5RNHQ%B09QK*NS+RJ1&X 0A#K 5,H!R  A0&%^R_LBB;?<XI[B,UY#QWD
M6]8C&<_B&T[>Q7B-/$./F-HW?U*=WN[@MP;FNU6YKJNA!DU(X>F<($*5$0*C
MY8Z >@5X;%-H&1,9V=AZ]MN^-9_&=A&<A95GOX4 C[62<B<SA.%.W61>LDG(
MC^E(54"GUT, T!0OK8)LSR7:-BV'?.W3&UPV?C..<Q-A0#F(5086O%O /[KC
MXPK)RU439N14,)TS&,4QC"(AJ(C0&3ENVE;5HV_"VI:T+'6_;=N,V\?!0D0V
M391L2R:)]4V;,FJ)2I(I($]B !IKQZ: Y],@)D*0!$>4.)C#J8P]TQAX:F,/
M$1[] 3T H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * XMQ_RK\4W_P!70%>/_P D2](?OC0'U?\ O _$
<'^4% 3T H!0"@% * 4 H!0"@% * 4 H!0'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g843142g42a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g843142g42a01.jpg
M_]C_X  02D9)1@ ! 0$!E@&6  #_[1@B4&AO=&]S:&]P(#,N,  X0DE-! 0
M     &0< 5H  QLE1QP"   "   < E  "U!E=&4@2&%N;&]N' (% $!-:6-R
M;W-O9G0@4&]W97)0;VEN=" M(%5P<W1R96%M($)I;R!3,2!'<F%P:&EC<U]'
M;V]D=VEN7S$P2E5.,C0N.$))300E       07$-=PT+\^G;B;>I9F?GNY3A"
M24T$.@      Y0   !     !       +<')I;G1/=71P=70    %     %!S
M=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I;G13
M:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0      #W!R
M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
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M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 99F9@ !  $!EF9F  $  3A"24T$)@      #@
M       _@   .$))300-       $    6CA"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          3A"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))300>       $     #A"24T$&@     #00    8
M     [    ?P    !@!G #0 ,@!A #  ,0    $
M     0             '\    [                       0
M               0     0       &YU;&P    "    !F)O=6YD<T]B:F,
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M;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   .P     %)G:'1L;VYG   '\     -U<FQ415A4     0       &YU
M;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%6%0
M   !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0
M   !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '
M9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@
M  =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R
M5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S
M971L;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U
M='-E=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M     0$ .$))3004       $    !SA"24T$#      -?@    $   "?
M2@   >   (K    -8@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M     ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04
M#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,_\  $0@ 2@"? P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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M%EEOJ6-!>16 S;3M:[V.M>[]'E>I^B]*O]"A]'ZQEMR*L0W-S*6L(:^^LUY
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M]G_G#%=224I))))2DDDDE*22224__]DX0DE-!"$      %<    ! 0    \
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     4 $$ 9 !O &( 90 @
M %  : !O '0 ;P!S &@ ;P!P "  ,@ P #( ,0    $ .$))300B      %*
M34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !
M=@$H  ,    !  (   $Q  (    ?    ?@$R  (    4    G0$[  (    ,
M    L8=I  0    !    P    .P   &6     0   98    !061O8F4@4&AO
M=&]S:&]P(#(R+C @*%=I;F1O=W,I #(P,C0Z,#8Z,3(@,#(Z-38Z-34 4&5T
M92!(86YL;VX       .@ 0 #     ?__  "@ @ $     0  !_"@ P $
M 0   [          !@$#  ,    !  8   $:  4    !   !.@$;  4    !
M   !0@$H  ,    !  (   (!  0    !   !2@("  0    !
M  !(     0   $@    !.$))30/]       (          #_X0%217AI9@
M34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !
M=@$H  ,    !  (   $Q  (    ?    ?@$R  (    4    G0$[  (    ,
M    L8=I  0    !    P    .P   &6     0   98    !061O8F4@4&AO
M=&]S:&]P(#(R+C @*%=I;F1O=W,I #(P,C0Z,#8Z,3(@,#(Z-38Z-34 4&5T
M92!(86YL;VX       .@ 0 #     ?__  "@ @ $     0  !_"@ P $
M 0   [          !@$#  ,    !  8   $:  4    !   !.@$;  4    !
M   !0@$H  ,    !  (   (!  0    !   !2@("  0    !
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M,U-R<S5#@J*RX24V1$5T=? F-V.#E-+Q)V2SPN+_Q  : 0$  P$! 0
M         0,$ @4&_\0 -1$!  (! P,"! 4# P0#      $" P01,1(A,A-!
M!111<2(S88&1(T*A)%*Q%4-BP33A\/_:  P# 0 "$0,1 #\ ]4@
M
M
M
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M!)XI5=T>FW5 )("/:MU*S NQL+8'6+-ZPV".-%V[JB*[^&Y(4[)OW
M
M
M
M                           -7FJ^0G6/]'V%A1/G(GF:O]'9WZP=_(E
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M<9
M
M
M                            !TR5:\KT=)!&]R==W-15.Y$1$1$1$1
M   ZYH8IDVFC8]/[R;G**)D3$;$QK&IY-39#D
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M'CB^%1HBTVJCU]I?4]18_P#L-?\ Y;?R"7>
M
M
M                                   W  ^.<B(J[IT0K3(ZKRD&3LQ1
M2-\-KU1/9\MRK+FKBVFRK+FKBC>RS 55\<<OOMXC$_[)8&F;LU_$13V=O$55
M13C%J:99VJYQ:BN6=JMJ!N#0O "$:CU3DEU.S3NF*L$]]L:369;"JC(6+\WM
MYJ!-P0S1NJ,A=SF0P.H*T,&4J-23FA559(Q>RIN2R]8^"U)9_#?*K$W1C$W5
MWN0#O!!=$ZOR>:U/EL9D\:RDVJU'1=5YE1?4G0 &LM:@Q-1&K9R-:-'.Y4W>
MG5?0^VL[BJLL$=G(5HWS_P"S1ST3F^P#9 Z+=NO3K.L6IF10-3=7N79#!Q^H
ML1D9FPT<C6GE=V8Q^ZJ!M017B1EI\9IY6T7JV[:E;!$J=TYEV54-35RV3Q^N
M\!I^2PDM9]%SYE>GM.>C=]]_M L &/%=K2OF;'/&YT/21$=\S[?0US=4X-T_
M@MRM19=]N5)$[@;D'%7IX2O;LJ;;I[RN8]?Y"33.;RD="!SL;;6%6(Y?:C3N
MOV]@+(!A0Y&&3$-R/,G@+#XV_HFVYJ]#9NUJ#")D+=>.!LDCDB1BJN[$79%7
M<"0@                               $4U]I&35=6&*+*W,<L:JN]=_+
MS?:2LBNO=-WM15H(Z&4GH+&JJJQ.Y>8"EN)/#Z72\6*R$F>OY!OPR-OA6).9
M$W7OL>B\=_8*_P#RV_D>=N)>BLG@&XFY=S5B_"MR)G)+(JHBJ[T/1.._L%?_
M );?R"&0  D
M
M
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M5=_M4](X[^P5_P#EM_((9  "0
M
M
M                                                           .
MFZY64YW-79S8W*BIY+LH'<"NN">5OY7"Y"3)7)[;X["-:Z5_,J)RIT+%
M                     'QSD:GM*B?:?2,ZWTHFJ*\,:Y"W26-=]Z\BLW^W
M8"&_T@I&KA<0QKD5WZ0A7E1>OSBT,=_8*^_^[;^1YLXN:7K:57'NCS5R[=9(
MV5L-B97]$7OLIP9QEU'&L/(L')&WEY>7N:L.CRY8ZHX49,],<[2]/ H_3W'.
M%\C(LW3<W?HLD2=$]_<N/#Y6EF*;;6.L,GA<B+NU=]BO+@OB\H=8\U<GC+-
M!2M
M
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MOR08.*A4>J6K\S86HWORJOM?R-7'+;QO$S3^'CM2_ 68]Z/C5WLN5&=]O7=
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M
M
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M/::OW]B^\?E*.18CZ5J*9JIO[#MSQ,VGOAG:T/2QY:Y([,P %"T
M
M
M
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MNJ-MUQ@ QM
M
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M76'#>1^'<DZL>VW$K?VN5%[$H=I# N1$_1M?_";FK6AJUV05XVLA8FS6)V1
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M3C)@B*]>.=X=X\LS;IM'=,0 9EP
M
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MZIP9=X[5NY='PHO5(XE1W\UV+2P>)J83&Q4<?%X<$?OW55\U5?-5,\
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MF)CE$3$\  (2
M
M
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MKD4[RJ8VY61._  "
M
M                       8]N]5J*U+5B*%7=N=R)N='Z9QOT^M^(AU%+3W
MB',VK'NSSKLSQ5H))K#VQQ,17.<[LB&%)G,7'&Y[K];E:FZ_K$*%XI\09-06
M'X_&/<S&1N5'.1=EE7_3N:-/I;YK;<0JRYZTCMWE>VG]08[/UWS8RPDK6.Y7
M)V5J^]#:GD32VH+VFLHR[CWJWJB/B_9>WT/2VF]9XC-XJ*VRW%"YR;/CD<B*
MU2W5Z&V"=Z]X<:?4QEC:>4E!@?IG&_3ZWXB'V/+X^1[61W:[G.79$21-U4Q=
M%OHT=4?5G'7//%79SSRLC;VW<NQV$0UI@].6K#+^I9WM8UBL8QT[FL[=51$\
MSETES'MD8CF.1S5ZHJ+NBGTK3@JU[8,S\$GEEPB6G)3\5W,J)NO9?0EVMM20
M:5P$V5M1/FBB5$5K.Z[@;T%;3\4$QUNK^FL-:J4;NR59D]I9'>G+Y&SPFMYK
M.H8\5EL5+CWV&\]5[G<R2)[_ $4"; @F2UW9_2&4KX'$29*/&+RVI$?R(UVV
M^R>O0W6A=1/U/@8\F^HM1KW.:C%=S+T79?R V-_,4J-^I3LS<MFUOX3-M]T3
MNOV&76LPVHUDKRLE8BJWF:NZ;IW0KC"N74.OM19C=74\9 M.KZ.<K?UBI]BL
MV,'1.J*VG]&HQ&.MY">],R&K'U>Y5>J)OZ)[PA;0(EG]6S8ZUC\=4QSK67ML
MY_@Z.V1B(B;[N_B=&AM96M297)4;.*=1?05&R<TG-[77I_()3-SD:F[E1$[=
M5"/:KU8CDYD3=4WZE?\ &R22/2]9T4KXG?#8.K%V_P"L:8^H5EP7$?3V76:3
MX)DH_@$[>;V45$W:Y?X[ 60YS6)NYR(GJJGTKOB'+)F-5:<T]4ED:U)TN6^1
M=MXF[HB?>I8B)LB(G9       53Q:IQLU7@,GE(O&PT>T=AO=$]K?JGIV^XM
M8AFOM&T]3V:DMS)OIK"QS$:B-]I%5%WZ_8!NJMW 25XW5I\:L*M3E5KF;;>X
MV%&2I(U_P%T#FHNSO"5-D7W[%5)PEPZ)M\8']MNS/]2:</\ 3-335.W#1OK<
M9+(CU7I[*[=NBA"5  )                      BVNM6II6M#+^CY[JR*O
MLQ>1*3B^-DB;2,:Y/>FX'G?B3KGXVTZ=.'&STYH)V3HLJHN_*I']2Y#*ZBGB
M?>D56Q-Y6,[(U"=\?L5\#=4R['L9"BI&K$;LN^ZE?59DG@1R*NY[N@Q4ICC)
M7O+SM1:UK32>T.K#NR.%R$=S'RK'*Q?+S3T/16A]75M3U'1N;R6V-VDC=YE
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M(W(^-KT[.1%0^F)J
M
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MRR9/FK*UJHG\6[*!:X*VTJFL]/YBGBLLQN3QDR\J6F*J^"B>J[;_ ,%^\LD
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M 8V@    Z;-J"JQ'V)61-541%<NW41&_!P[@$5%1%1=T7S
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MW&2L\2S  <.P      "JB=U  )U[
M
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M &77,#!J9?'W-O@UN&3['&:CD7LJ*>/-9CEOB8GA] !"0
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MW4W5>W7LLYX)F/;ZHIYTTM7F&N+5GB7> B[]@<N@
M
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M+#Q6"QF*3_T?3B@7U:G4V1UEU<S$5Q]H13!$=[]Y4Q>X$4'*JX_)S5OX*O\
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M%1>RE<QMR[WW  0D
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M573^+OUV6YWVKK.22RW9KFIZ-]/4V6A],0Z5Q+Z<4KIGR2+(^14V55[)_)$
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M';B4Z!IJ&J,->V^#9"!^_P#>0V\<C)$16/:Y%\T7<HM2U>861:)XER !RZ
M     X2RQPL5\KVL:GFY=D Y@(J.1%:J*B]E0              '5+7AE3:2
M*-Z>]J*:K(:6PM]JMM8ZN[?S1NR_R-T#J+VKQ+F:Q/,(!>X1:1M[JN/=&Y?-
MDBH1N[P(Q3E5:&1L5O3V>;;^9<8+:ZG+7BSB<-)]E V>"N=I*K\9J!TFW9%W
M:8T>G.)N%=O2G=*UOGOS;GH<%D:R_$Q$N?EZ^T[//+M<\1\0JID:?BHW_P#
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MI2\EE/\ J7JF_P"9;;3Y*QO,.(S4F=HE+@ 4K
M                                                     "K.+F1R
MTV<Q&GL1,L*W&\RJUZLYU5RHB*Y.J(FRJ!:8*8;PFSBL3FSD7-MU]J0G?#W3
M-S3-.W#>NMMNFD1[53F]E-MMNH$L*NU!P_S46<M9?3&76&:9ZR+"]RLZKUVW
M1%1?+N6B *BCUSJK3;VQZJP[IZZ+LMAC>5?\2>RO\B78'B+I[+N1C;:U)O\
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MG=.]D]$!!^&.HG9.@ZG<DWM0]E5>KD)P00  )  !Q?&Q_P ]K7?:A\\&)/\
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M=D3TEJFG8T]AW9;(TX\C8B:BQK(U%<[LG3R5>B[>\E@
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M(UZ?W5W.92M
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M2RV-Y&-:BJNR;;J5CI_3.J,SEZF8U5D7UVUWI+%6C7945/5$Z)Y^JEG@
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MH1W
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M0TQ25KH8U<^VY?F]/+H9G!+,Y+-Z-CL9FRMBTCMG/7N!8   JC^D'_T-AO\
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M!,;J"Y!J[%TENR6ZEWFW\1G+LJ)TV"%D  )
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MG=H_6V-U3-8CQ\=ECH=E=XL:M1=R4!(
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M:3SYDZ?S(-TY!JZ.H<5=:BP7H%W\E>B*;)CV/3=CFN3U1=PER
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MACKPLBA:C8V)LB)Y&G6ZF)I%*3RKT^*=]Y]G8 #R&T
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M145$5%W12IT39W?8G>E[[):*1R2M\1G397'IZ753DGINU8LLVG:6] !Z"\
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MIV&[Q6(E_P"TA;7+2W$K:Y*VXEE@^-5')NU45/<?2QV
M       XO8QZ;/:UR>BIN:C(:8Q%]%^$48E5?-$V-R *_O<,Z;E<^A;EK.\F
MIV_,U#M,ZNPZ[XZZDL;?1Z[K_ M< 51!KC/XMW)E,?),B=W*W;_(WN-XE8J;
M9MUKZ\B_Q0G$L3)6*R5C7M7NCDW0T>1TEAKS5\2E$QR_M,3924=V;C\WCLA&
MCJUN)V_DKD1?N-BBHJ;HNZ%<Y#AE755DQ]N2-_DB]$_D:[]":QPO]CN/FB;V
M8B[H#=:YUV)HZ\#YIG(R-B;JJ^165?7F:QR\F7Q;G(G3F:B[_D8&M-;IFL5\
M"H,?%S_[7?ONB]@;K7QMZ#(TX[55W-#(F[5,DJKA1G4@L/Q<[MFR+O'NO1%0
MM4@@  2                          #B^-CTV>QKD]Z&MO:?QEUJI/3B<
MJ^>QM =5O:OC+BV.M_*-T(O<.L=*JNJ2OK.7MRFGETCJ''.5<7>YVIY.<I9X
M-5-=FK&TSO'ZL=_AN"T[Q&T_I*JXM0:GP[N6[6?8:G=4;NGW[&UH\2*RN1N0
MJR0>].I/G-1R;*B*GO0UMS XRYO\(I0N5?/EV4Z^8P9/S,?\./E=1B_*R;_=
MC8[56)O[>#::F_[^R&ZCD9(F\;VN3W+N0K(<.\=85702/A=Y(G8U$FC<YCEY
ML7D';)Y;D^CI\GA?;[GS&JQ_F8]_LLR1R,C<]>S4W(DO$+"-<Y'22HJ+M\W_
M ,R-3Y;56-B?'=A?,S;97)OV-!IJWBJL\CLS DC'KONJ;[=2_#H*],VOW^S-
MF^)VZJUI'3]=UA?*#@.;FYY.;MOR)O\ F<V<0L&Y41))=U7;YJ?ZC"8K368K
M+-1IQ.8B]>A%.).(IXR2G\ A2+F<G-MT]3G'BT^2_I[3$N\N?58\?J]59JM>
M-Z21M>WLY-T.1T8_^Q0_\*'>>9,;2]>L[Q$@ (2
M                                                   &KSV!Q><@
M1F6J13M:G1SNBM^QR=4-H5KQ/QJYS46)QBYN''QOB<JQ/>N\CE=LFS>B+V7S
M ANK\5IG V/'T[J"6&XSM! JS=?3G:OL_P =R><'<WELUB;;\Q*Z9(I$;%(Y
MFVZ;>NW4[].\,<#B-I)XG7["+OSV/FI]C4Z?F3>.-D3$9&QK&)T1K4V1 .0
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M.N5&_L]T M<$!PW$BG.](<K ^G-]B[$THY"I>C1]6Q'*B_NNZA+*
M                          &/D&-?2F1R(OL+W^PK+AKBZ>2=?;=B;(C7
M*B(OVJ6C88LE>1B=W-5$*GI:9U)CWR+1?X7,Y5794Z]3T=',3CO3JVF=GE:^
ML^KCOT]41ONL[$8JIB:ZPT8DC8J[JFY!.+?^TH_\2?YF/^CM9_2U_D8=[3.I
M,@Z-;STEY'(J;EV##&/)ZELD2HU&><F+TJ8IC]EK4/['#_PH=YUU6+'7C8O=
M&HBG8>3/+VZ\0  A(
M                             5%QMG@HY?#7H5F9EH45\3D1%C5K7=G?
M8J^A;I%]>:AQ6GJ,=C)U66YWJK88>1KG.]>_9/>!":_&>/PF)/AY/%V]KDF3
M;^!-M":NCU;5M315)*W@/1BH]R.WW3?R(WHK54&>R%^#(:?J4F58/'5$CYGH
MF_945J?D2W16:QN=Q;[6)KI78DBL?'R(U45/5$]VP&_
M       (KKO1[=65X8G9&S2\/?K#YDJ 'F[B;P]9I5F(OMRUN[_7(F<DO;N>
MB<=UH5_^6W\BL?Z0?_0N'_\ F$7_ (BSL;_T?7_Y;?R"&0  D
M  #&M4:UEJI-$UV_GL9((FL6[2('J?&QXZ5BUW*B2>6YHT39.O52?:GQCK]5
M'1)O*SL05]:=CU8Z)Z*GN/$U6'HOM$=F/+7IMV=^+LOJW(WM<J=4WZEDUYF3
MQH^-S7(OHNY <3A;%Q_M-6./S<J&>^EE<0Y5JN=)&G79.I?I;WQ5WF.SK%-J
MQOMV3,$<QVI&NV9?8L4G;J;Z"Q#.U%BD:Y%]%/0QYJ9.):*VBW#M !:Z
M                       5$5-E1%3WF):QE.TGZ^O&[R[&6")B)Y1,1/*,
MWM&X^?F6'>!R]E;Y&GDTGE*2JZA<5Z)V15V)\"FVFQSWV4VT^.?;97%Z[GZM
M5\-R&5T;D5%>B*J$23=VZ[KW]2YLVB+BK._[BE-+W>F_F>?JZ=%HB98=5CFD
MQWW$;_>7[R7\-MTOV$W7;8AZ=#:X#*6,98\2M"LJ?M(A1@M%+Q:56"T5O$RM
M\$;Q6KJ-S9DRK!-YM=T0D,,T<S>:*1KT]47<]NF2M_&7KTO6\;UES !V[
M                   *B*FRIN@ &CS.EL5EF.^$U6)(O[;4V5"%W=!Y7%2+
M-IZ\YR)UY'NV4M  573UOF<,](<[1E>QO19%;M_/S)IA-7XC+HB066LD_=D]
MDW%VE6O1+';@CF8OD]NY"LWPXI67/EQTCJTO=K?V0A/&JCD16JBHO94/I4K%
MU?I9^WZR]6;^SLJIM[NA(<+Q%HV52+)Q/IS]MG)T_F!.08].]5N1H^K/'*U?
MW7(ID!(
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M=PEW
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M/,>O*6;JSXAV5QV)K1+;B]JG)S.WW/3F/_L-?_EM_((=X "0
M              8&;KMGQ\R<J*Y$W3H5LJ*UZHOJ6PJ(J*B]44C&5TSXTSI:
MKD17+NK5,&LP6O\ BI"C-CFW>$._:+"TPQ6XN/FWZ]B,7-/6*M99W[.5O540
ME&F[C+./8QNR/C394*='2:9-K]G.&LUMW;4 'JM(
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M@Z:UJ"TSFKS1RM]6NW.X)
M                                                         "I^
M*5-N1X@:9I9!SFXV9JM7KLG-S+NF_P!G*3#7\>HI,=532C^2TDV\O5B>QRK^
M]T[[%;9C3O$/-0LBRK&V(V.YVHKX45%]45-E0"U+NEL#-BY*LN-ILK\FVZ1-
M:K4]=^Y$.!22LP^59S*ZHVVJ1.\G=$W5/=V(U/I_B38H? K$UB2NJ<KD6U'N
MY/>N^Z_>6!POQN8Q.#EIYN"*'PY-H&QHSYNR;JO+Y[[]P)B
M           1O6FEOC-!%&F1LT?#\X?,DA#^(FG,UJ"M79@LW-BWL5>98UVY
M@*EXIZ%73<&(N_IFW=WNQ,\.;;;OW/0>/_L-?_EM_(\W<0M&ZCP+,5=S>HK&
M4J_#(V>'([=$7?N>D<?_ &&O_P MOY!#O  2
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MJV*[ST['[2/3V?O)?6LP66(^O-'*U?-CD4A+M
M
M       &/D+D./HSV[3^2"%BO>[T1"F'9?6>N[D[\%XU+&-<K6*V18F[>]Z=
M7+]A8G%5CY- 9AL6_-R,5=O1'M5?Y;G5PDEKR:$QK:ZMWC1S9$3NCN9=]P*[
MLU^(6D&_#I;<]JLSK(WQEL,1/>CDZ?:A:^B]1P:GPD=^!JQNWY)8U7=6/3NA
ML\I-!7QMJ6VYK:[(W*]7=MMBL^ +)6X_+N1%2LL[4:B^3D3K_+E M8
M                  B/$+':ER%:!NEKS*DC57G5SE;N2XBNO=1W]/589,=B
MYK[GJNZ1M5>7[@*2XCXC65%,3-J?)1VJ?PR-$:UZKUW/2&/_ +#7_P"6W\CS
MIQ+UGE<\S$T\AA;%&'X9$_Q)&*G7?MU/1>/_ +#7_P"6W\@AW@ )
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M=NJ?P4E.#X@XK(N2*=759^RI)V"4Q!UUYXK#$?!(R1B^;5W.P
M
M            .%B&.Q!)#,Q'Q2-5KFKV5%*=R/#_ %)I_(2SZ.O2+4>NZ1)-
MR/:GHJ+T=]I<H I+XHZZU)(V+.7GP4T=NOBR[_\ <;W_ (ELZ9P=33V'AQ]%
M%\.-/:>OSGN\W+[S:                          %V1.NVP(CQ!T?)JRO
M!'%E[N-6)=]ZSU;S?:!%OZ0;V?H+$LYF\WZ0BZ(O7N6AC_[#7_Y;?R/.'$?A
M[8TJW$WY,]?R,:W(V>'9DW3??OL>CL=_8*__ "V_D$,@ !(
M                   1_5>/\6NEJ%-IHNNZ$@/CVM>U6N1%:O144KRXXR5F
MLN;5ZHV:K3>12]21KE_6QILY#;$,LLDP>:\6--J\G39.W4F$,C9HFR,7=KDW
M0JT^29CHMS#G';>-IYAS !I6
M         #1ZMQDV3QZ15^7G1=^I"?B;E/1A:0,^334R6ZI49-/3).]E6.T;
MEO1A.]*49\?B606=N=/0W &+34Q6ZJF+3TQ3O4 !H7@
M              /CV->U6O:CFKW14W(UF]%8C*-570)#)Y.C38DP JJSI+46
M!>LN%N/G@;^QS+S&1C>(EFE(D&H*4D3DZ*[EV4LTPLCBJ.18K;E:*7=-N96I
MNG\0AC8G46,RC$=5M,W7]ERHCON-L5SF.&[&N\?"69(9OW7+T-7#F=4Z8?RY
M"%]JLWHKW[JB(2;K4EM00SQ0R2-;++NC&JO5QW%"9W4]G*9N'(HKHFPN18VH
MJ^STZET:<RL69Q45N)4W5-G(GDI!$MF  D
M
M                   (IKW5TFE:T,L6)MY%9%VVKM5>7[D BG](/IA<.OE^
MD(OS+.QW]@K_ /+;^1YUXE:_GU.W$T9<'>Q[$N1O\2=BHB]?54/1>/\ [#7_
M .6W\@AW@ )                                  !@9J@W(4G1;)SIU
M:IIM*7W-E?0L;H]J]-R4$5U+2?5L-R%7HJ+[6QDSUFDQEK[<JKQM/7"5 PL/
M=;>HQRM7VMMG)Z*9IIK:+1O"R)WC>  '20
M
M  @'%7/15,>F/8K'33?.W_90GYH\GI;&9*VZS<AYY'>\(E0'.SJBO:I->&.H
MFX[)_ ;$K4K3]E5>B*3_ .(V$^C?S/K=#X1KVN96V<U=T5%)-DF3JG0'QJ(U
MJ(G9$V/I"0
M                                                      ^.:UR;
M.:BI[T/H J;^D#'&W#8?EC:COA\75$V_:+1QW]@K_P#+;^16/](+_H;#_P#S
M"+_Q%G8W^P5_^6W\@AD  )                                   .NQ
M"R>%T<C4<UR>9V B8B8VD0[%SOPV6DK3;I ]W3T]Q,45%1%3LIH]48QUNMXT
M"(DT?7[4/FELE\)JK#,NTL73KYF3#,XKSBMQ[*J_AGI;T!%1>R@V+0
M
M
M
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MZ9^0^5_2OTS\@+#!7GROZ5^F?D??E?TK],_("P@5Y\K^E?IGY'WY7M*_3/R
ML(%>_*]I7Z9^1\^5_2OTS\@+#!7OROZ5^F?D?/E?TK],_("PP5Y\K^E?IGY'
MWY7M*_3/R L(%>?*_I7Z8O\ (^_*]I7Z9^0%A KSY7]*_3%_D/E?TK],_("P
MP5Y\K^E?IGY#Y7]*_3/R L,%>?*_I7Z9^0^5_2OTS\@+#!7GROZ5^F?D??E?
MTK],_("P@5Y\K^E?IGY'WY7]*_3/R L(%>_*]I7Z9^0^5_2:?.O(B>J[?Z@6
M$"O?E>TKW2[NGKT'RO:5^F?D!80*\^5_2OTS\A\K^E?IGY 6&"O/E?TK],_(
M?*_I7Z9^0%A@KSY7]*_3/R'ROZ5^F?D!88*\^5_2OTS\A\K^E?IGY 6&"O/E
M?TK],_(^_*_I7Z9^0%A KSY7]*_3%_D/E?TK],_("PP5Y\K^E?IGY#Y7]*_3
M/R L,%>_*_I7Z9^0^5[2OTS\@+"!7OROZ5^F?D/E?TK],_("P@5Y\K^E?IGY
M#Y7]*_3/R L,%>?*_I7Z9^0^5_2OTS\@+#!7OROZ5^F?D?/E?TK],_("PP5Y
M\K^E?IGY'WY7]*_3/R L(%>_*_I7Z9^0^5_2OTS\@+"!7GROZ5^F?D/E?TK]
M,_("PP5[\KVE?IGY#Y7M*_3?R L(%>?+!I17;)=15].@^5_2OTS\@+#!7GRO
MZ5^F+_(^_*_I7Z9^0%A KSY7]*_3/R'ROZ5^F?D!88*\^5_2OTS\A\K^E?IG
MY 6&"O/E?TK],_(?*_I7Z9^0%A@KWY7M*_3/R/B\7]*HFZW.G\ +#!@X/*U<
MWBX+]!_/7F15:OV+L9P
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M.C^$A(@!'?B1IGZDH_A(/B1IGZDH_A(2( 1WXD:9^HZ/X2#XD:9^I*/X2$B
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MB;(AW@
M                                       ,+-Y"+%8BY?G7:.O$Z1??
MLFX&6^1C/GO:W[5V.2*BINBHJ>XH72&G<MQ1AL:BSV7OT:,[E2I7JS*Q$:G3
M=3/X?Y',:0XBR:-S%V6]2L,66K-,_F<B(G;<"ZP
M                   JHU-U5$3U4$'UUI#*:HR=9C<S/0Q+&JDD=9ZM>]?M
M0";,D9(F\;VN3^ZNYR/.FK*&3X4ZKP-G$9BY<HWITBEKV95=^TB=OL52V.*&
MJ9--Z0=<JHGPRPYL,*+Y.=Y@3!TL;7<KGM1WHJ]3F4GC>%.2RN$3)9;4>4;F
MYV>*U(YU1C'*FZ)^1N>"FILE;?E-.ZAE\7)8MZ1^(O57IUZJH%I@
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MNJ<EE*V2PF??XF2Q3_#=(J[J]J]E4M,
M
M                0CC0][.'F46-5158J+MZ;*3<U&KL4W-Z;R./<FZSPN:W
M[=EV CW!)K6\+\ C=MO!7_Q*0SB"B-X[:4='\]85YMO3<Q.$FNJ^D<(_3>KD
M?1LT'*V-9$V1[>_3[S*T@EG7/%9VITK218BA&L-=TB?/5=NJ!"[  $@
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MV,M(CF1N396L3L6R"
M
M    :W(8'$Y&7Q;^-IV)/WY86N7[U0S:M6"I"D56&.&).S(VHU/N0[0
M                                    ,/(8JADFHF0I5K*)T3Q8T=M]
MYF #7X["8O&N5V/QU2LY?.*)K5_DAL%1%145-T4 #42:9P<ECQWXB@Z;??G6
M!N^_W&V8QK&(UC4:U$V1$39$/H
M       UM_ 8C(2^+>QE.Q)^])"UR_>J&;5K05(4BJPQPQ)V9&U&HG\$.T 8
MN0QU/(QI'?J066)V25B.1/O.&.Q&.QB*F/HUJV_?PHT;O]QF@
M                             # R.&QF35%R&/JV7)V66)'*GWG/'XNA
MC6JW'TJU9J]TAC1F_P!QF  :F336$DL_"),10=-OOSK W?\ (VP ^,:UC4:Q
M$:U.B(B;(A]
M
M
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MBL<OV(O<WX
M
M
M
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MU7JZAD<KB(<7#6>UTDB)RN>C7;_:JES
M
M
M
M                                   *WU'P^RV>S-F6YJ*5N+FEYTJ-
M:Y4:WR1$YMM^GH60 ,/#8VMA\97H4F<L$+>5OJOJJ^]5ZF8
M
M
,            !__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g843142g42b02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g843142g42b02.jpg
M_]C_X  02D9)1@ ! 0$"=P)W  #_[1=^4&AO=&]S:&]P(#,N,  X0DE-! 0
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M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q @[S,T         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-! T       0   !:.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      -!    !@             %Y@  #%8
M   & &< -  R &( ,  R     0                         !
M      Q6   %Y@                     !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   %Y@    !29VAT;&]N9P  #%8    &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P  !>8
M4F=H=&QO;F<   Q6     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M    .$))300H       ,     C_P        .$))3001       ! 0 X0DE-
M!!0       0    &.$))300,      SD     0   *    !-   !X   D&
M  S( !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ,
M" @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,
M# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,
M#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !-
M * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%
M!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%
M!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<E
MDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D
M]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'
M!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q
M)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75
MY?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#U55LZK*MJ
M#<6P56!TEQXVP01]%RK])%PMS/5WG],=I>7'VZ[=OJ66[?ZOZ-:*2G'QSU7"
MRL7'R;FY+,JRQKWD:M#:C97L^C^=7^ZMA9_4B*\OI]SI%==MFX@3S3:UHVAV
MYSG.^AMJM5JG*HN<6,=%C=75N!:\#Q-;]K]O\I*DIDE7LS\2JQU=C]A:0'.(
M<& D;@UUT>DUVUWT=ZGD7MHKWN!<20UK&Q+G..UK6[BUO=&CIINA*D@4YE-K
M_2,UW 2:;!M='[S?S;&?RZM[$UN;3586.#W%H!>6,<X-GZ._8')4>RAKLV$E
M&NRNU@LJ<'L=]%S3(/S"D@I22222E))))*4HV,]1CF;BS<(W-,$?U2I*-E;;
M6.K?.UP@P2T_YS"US4E-<8&H/VF_3^7_ .8JN>DVNRSDC-N#?4]3T0X[!$?H
M]N[Z/M1_V9B@S^ET_P"&M_\ 2BI/Z9T8Y_VA^0/M)NWAN]@.^1M9L #O;M;7
M^_\ ]<1/FJSU9_LC, L8>HW/K<UGI^IJYKVESG/W,=5OW;F_YG]A2;T>X6,>
M[.O]CFN+6N(#PW_!V[B_=R]O[_\ VU4@NZ+TZIEA=E6-HL:Q@#[ X-<'.]];
MK_4]]CK/\_\ F_TJ+T_IO2<7*]7%MWW;7,VFW?RYSGG:2??O%OO_ .-02__0
M]!Z(3OSPY[G/&2^07[P!^9L]HV>W\Q:5E@KK?8Z2UC2XQJ8 E9N)F&EV<_(=
M996W(+6.:'6 -V@[0U@=Z;:OSUI^U[=1+7#4$=CX@I*<#.ZAB=1NZ<W%>19]
MK#0\B#L%5E]SZ_['^8K]V':Y@=6[[76W5@>[;:W^5C9;(_\ !/I_Z=#ZGCTG
M-Z6QK6M'VAYV@0#%%W@=OT&_N*^[&;N+Z2:;#R6\'_C*_H/_ //B/$1H HD]
M.CG8N5D45VNR*'/H=:_?:X!KQ_X8I_F]FS_#U_HO_/B(['J'I/P[-M+;6G[.
M02P..C?3;+7T;=_J>E_-?\7_ #BO8];ZV'U(WN<YQVS&ITY_DJM9@FFQM^*P
M.:PR<>=OC_,._,^E_,O_ %;?_H;/TR7%(V0:OHBK'8L[PUS=F=6#6#+;F$@-
M/9\C]+C/_P"$W?\ 757Q[K<2S(-VZ[']03D1+FQ75_/,8/=7_P -7_UUG^%5
M['R*LAF^L\':YI$.:X<L>P^YCU5Q:[:G7OH@L%SIHX!T;_-N_P &[_P/^I_.
M) D @ZC\4T1:5V*UQ^TX;Q58\!Q<WW5V ][6#Z?_ !K/TO\ PBE1E[W^C<WT
M<@?X,F0X#\^BSV^JS_P1G^%KK0&,<PNNP/HR?6PW>WW<N].?YB[\[_07_P#7
M/M",#B]0HU!(:[5IEKZWC_-LIM9*.XO<=U WNV4E3%]N(=N8[?23#,J (G\W
M):WVUN_X9OZ'_B?\)<32$D*22220I1<UKVEKP'-.A:1(*DDDI#]CQ.?0KD?R
M&_W(+ND]/=D?:753=NW[BYWTM-=N[;^:KB25!6VSG,^K_2JW6&NGTQ:QM;VL
M<Y@AN_5NPM<QWZ1[7[?IHV+TGIV';ZV-0VJS:6;FS]$D/VQ_6:K:22G_T>QS
M64C%ZDXNWL^V-=;N;&S:*]P8US[76;V?N^E_.?Z)=$Q[7L:]AW-< 6D<$'A8
MK<"[+KZE0/T7JY4RYI:=K0QP+'#Z7Z3](W_6U;;00T!QW.  +N)/BDIIYK9S
M>GF) N?KN(@^C?\ F?1>KJR,FO*KZEA,-X++LBY[6D26CT'[&MWNW>S])]#_
M $BT/1R?]/\ ]!J2DZ2!Z.3_ *?_ *#4O1R?^Y'_ $&I*6R,4O>+Z'>CD 1O
MB0X#_!W,T]1G_3K_ ,&FP67-98;F>F]]KW;9#A!/+7#\UREZ.3_I_P#H-2]'
M)_[D'_,:C>E)O2F5M >X6,.RYHAKQX?N/;^?6JSZS;:' _9L]@@.^DRQH_-=
M]'UZ=?\ CJ/^#W_I#^CD_P"G_P"@U0LQ;K6[7W3&K3M (/[S7?FN0U!L+2%Z
M,IMSG8]S/3O:/?2=06\>I4[3U:?];65J&RW",U V8?>D27U^='YUE/\ P'TV
M?]I_] AWTV/L;7D6ENOZOD-:T%KCHWW_ .#N_-_T-_T/^!2KLRV6#'RKMECM
M*K0P;+/ZO^CN_P"!_P"V?S_2((.WUBD%O5V5VL;96X/8X2US3((4E0=AY-!?
M=BV2YYFRF &O,^Y[/S:\C^7_ #=G^%_TU<\=]F17OKR#H=KVN8 YKARRQOYK
MDJ[)KLW$D#T<G_3_ /0:JV9T_+R)]/,?275>F2T.&N]MGJCT[:MKMK?2]OO_
M .$00Z"2RG]/ZO9>[?G@8YW;6L9#VG=ZE#MW^$<S8S?_ -<5G"P;<=]C[KSE
M.= 98]H#VM@37N:=KF;F[_H)*;B2222G_]+T+H\^OU &0T9#MC2XF!'[I<[9
MN?O6FLSHS"VWJ'.PY+@TDS,!H=_F_P W_85O.S*L'%?E7 EE<2&Q.I#!](M;
M^<DI#G!QSNG$ [1;9)TC6FZ)_.5Y9.5GX;\O$>0=U.38R0TN_P !8]VWTO4^
MDVROZ2N?M/$\7_\ ;5G_ *324VDE4;U7"<"6N>0"6F*[#JT[7-^A^:X)G=5P
M6EH<]P+SM;-=@DP7;6^S]UKDE-Q)5?VGB>+_ /MJS_TFHMZK@OG:]SMI+3%=
MAAPT<WZ'TFI*;B2INZK@MC<Y[=Q#6S78))X:/9])2_:>)XO_ .VK/_2:2FRY
MK7M+7 .:X06G4$%5+:FLK=5D#UL-W)=JYG]<_2<QO^E_G*O_  5)O5<%V[:Y
MSMIVNBNPP1^:?9YI.ZK@M +G/:"0T378)+CM:WZ'YSD/$:%!"S;GX0:S)?ZF
M,[2O*/+9^BS)_P"^9/\ V]^D_27ER,9SW>O0[TLAHC=$M<!_@[F_GL_=_/J_
MP?YZJ_;,6J16'OH=.^@U6&)Y-0]/_.I_[;_<L'3U#'QG^G07W8K3L=6*["^D
MD-<&#V;GT[7L=Z?\Y1_Q'\PX&_"7X24"0W\?*%KC4]OI9#!+ZB9T_?K=_A*G
M?FV?Y_IV_HT=4+\WIKBRRTN!J</3?Z=C2'.(8&AVS_".=Z>S_"*Y5:RZL6,G
M:9B06G0Q]%X:Y KBS22220I))))3_]/T_'Q<?&W^@P5BUYL>!,%SOI.1DDDE
M-;)Q\BR_'?3=Z5=3RZU@'TP1$*PZ2T@<QHG224T>EX>;BML&7DG)+]A;H?;#
M6MLV[B7>]_O]R74</.R7U.Q,G[-L!W2-P/N8X>V6_N/9O_T;_3_PF]7DDE+?
M!4>EX6?B-<,S,.7+6-;+=NTMW[W;MQWNMWM5]))31S,7.MNWX]XK9L +#N@N
M!)GV%OTF';[4>NFYN"VAUA?<VH,-QY+PW;ZG^=[EFY;>I_;KSB69 $MAH8PU
M?19MVV9%H;MW;]WHU_Z7U_\ M(KW31EBAWVMSWV;W0;&L:Z/A0^UFS]Q)2#"
MP.I4Y(NR<WUZ]D&H-V@&*V_O.W>ZMS]_T_>B9^)GWV-.+D_9VAL.!;ND[FNG
M;+?S0KR22D&)3=3AU4WVFZYC U]IT+G 1O\ [2IX/3^IT9#;<C--]09M?46\
MOVUL]0._K,_._P#4BTTDE-+.Q<V^ZM^/>*6,$.'NU.^I^Z [9[:Z[&^[_2?Z
M/]&CX=5].-75D6_:+6"'W1MW'][9N?M1DDE*22224I))))3_ /_9.$))300A
M      !7     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
M    % !! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ #( ,  R #$
M   ! #A"24T$(@     !2DU- "H    (  @!$@ #     0 !   !&@ %
M 0   &X!&P %     0   '8!*  #     0 "   !,0 "    'P   'X!,@ "
M    %    )T!.P "    #0   +&':0 $     0   ,    #L   ">     $
M  )X     4%D;V)E(%!H;W1O<VAO<" R,BXP("A7:6YD;W=S*0 R,#(T.C V
M.C$R(# R.C4X.C4T $IE;B!"96%C:&5L;      #H $  P    '__P  H (
M!     $   Q6H , !     $   7F          8! P #     0 &   !&@ %
M     0   3H!&P %     0   4(!*  #     0 "   " 0 $     0   4H"
M @ $     0              2     $   !(     3A"24T#_0      "
M        _^$!4D5X:68  $U- "H    (  @!$@ #     0 !   !&@ %
M 0   &X!&P %     0   '8!*  #     0 "   !,0 "    'P   'X!,@ "
M    %    )T!.P "    #0   +&':0 $     0   ,    #L   ">     $
M  )X     4%D;V)E(%!H;W1O<VAO<" R,BXP("A7:6YD;W=S*0 R,#(T.C V
M.C$R(# R.C4X.C4T $IE;B!"96%C:&5L;      #H $  P    '__P  H (
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M!=P# 2(  A$! Q$!_\0 '  !  ,! 0$! 0            4&!P0# 0((_\0
M61   00! @,$!0@%"08"!P8'  $" P0%!A$'$B$3,4%1%2)A<9,(%!<R4U2!
MD4)2H;'!%B,U-G-TDK+1)#,W8G+A5=(E)S1#9)2B&"8X1(*#16.DL\+P\?_$
M !D! 0 # 0$                ! P0"!?_$ "P1 0 #  (! P(%!0$! 0
M   ! @,1(1($,5$R01,B89&Q%"-2<8$SH4+_V@ , P$  A$#$0 _ /ZI
M                  ?GG;S<O,WF\M^I^@ /.6>*+_>RL9_U.1#]1R,D;S1O
M:]/-J[@?H'QSD:U7.5$1.]5/..Q!([ECFC<ODCD4#U
M
M
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MV[(VQ"DOY@2@,@X-W,KG-7:ER]^Q*^CVBUX(^9>1.5>JHAKX
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MI(HVR+&J/39=T M
M
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M/"?LU\ !
M
M
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M>WGW)<$=)U<7:ECAFYHXG.;N_P 413Y\F'IH*=/*T] EKX "
M
M
M
M                          ;IY@                        #QNVH*
M562Q:D;%!&G,Y[NY$/8\;E:&Y6DKV6(^*1-G-7Q0"E9?B/I&?$7619ZDY[X7
MHU$?WKLI6_DP_P!0YU_^+?\ O+1E^'^F8<1=?'B8$<R%ZHNW=T4J_P F'IH.
MQ_>W_O"6O@ (
M
M
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M/[V_]X2U\ !
M
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M"VGK^TLF7X<Z1@Q%V2+ 4FN9"]6JC.Y=E*W\F'^H=C^]O_>!KX
M
M
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M_*4;4VJJN;XAZ:=@\A++526-DJ-1[$5>T[E143?H!M8
M       !P9^U:I8BU8H5_G-F-BNCBWVYE\@/N>_H3(?V#_\ *IEWR8OZB6/[
MV_\ >0U[B-Q FQUED^B6LC?$Y'N[1?539=U)GY,/]0I_[T\):^  @
M                            $9J#-T\%16S>?RM[D:G57+[$,UDXK77S
M/2IBXWQ(O15<N^WM+LO3Z:QS6.G%M*UZEKH,KQ?%AKIU;E*78L3QC57+^1=L
M+JW$9=B+6LM:Y5V1DGJN_(F_IM<^[05TK;VE/ (NX*'8              ^.
M>UJ;N<B)[5/PR:*3ZDC7>Y0/0!%W[@
M
M
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M;%:_V2TO3E>O1?Q.;^EO6/*O<?HZKM$]3U*[@^,>U[4<QR.:O<J+NBGTRK0
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M=W&F::U;C,]"GS>9K)TV1T3UV7?R3S*M?37SCRCN/EW36+=?=80$!G6
M 9_KS7/HR7YABD26XOUG=Z,\D]JERSMOYAB;5G=$6.-7)OY[=#*N%N+CS6:M
MY.\U7K&O,U'=455_T+LJQQ-[>T-&-*\3>WM#PAT[JW.-2S/++&R3KLLJL_\
MI/1^@]30]:]N1R_VVQLR Z_J+?:(3_56^T0Q=TVL]./:CVRRL\=D65-O>3V$
MXGUWR+%F*[JZMZ<S=W;K[O TER(K51=E12MYW1F(RT;N>ND,B]>>)$:N_M'X
ME+_7'['XM+]7K^R9QV3IY%B/I6(Y45-_5<BJGO0[#&<CH[.Z;F=9PT[Y86^L
MO9KLOXIXDKIWB2Z.5M;/P+&Y.^5$VV]Z=Y$X\QS2>2?3\QSG/,-1!RX^_6OP
M-FJ3,E8Y$5.5>J>\ZBAFXX
M
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MR)T_$6QYCRSGF"V',>6<\PT\'C3LPVH&2UY&R1N3=%:O>A[%#-QP$1JNZE#
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M7DF_2B?T5#B^4U[CN%>F,U[CN%A !4I
M                                                           <
M]B[7K.1)Y6L5>[=3Q]+4?O,?YD)J[ V,M9@?7EY$8U44@?Y%9#[=#-?32MIB
MM>89KZZ1:8K7F%Y]+4?O,?YCTM1^\Q_F4;^160^W0?R*O_;H<_C;?X./QMO\
M%Y]+4?O,?YCTM1^\Q_F4;^160^W0?R*R'VZ#\;;_  /QMO\ !>?2U'[S'^8]
M+4?O,?YE&_D5D/MT'\BLA]N@_&V_P/QMO\%Y]+4?O,?YCTM1^\Q_F4;^160^
MW0?R*R'VZ#\;;_ _&V_P7IN5HJNR68]U]IVHJ*B*G5%,ZAT9?;+&Y9TV1R*I
MH4#59"QJ]51$0MRO>W/E'"[*][<^<</V8WQ;T-';Q&7SF6O6+$D;$[&NCU[)
MGAOR^9LA3^+G_#[+_P!FG[RY=".X!HB<+<.B=R(__.I2;<$6O.-[J&6WDQN)
MB5R5]_4>]'=%5"[<!/\ A;A_<_\ SJ4S0:?-N/NH8Y51JRQN>W?Q3?P"73QW
MTCC,;I>/-X6I#C[F.D25LM=J,5?9T.#BKGK>7TII#'U)G,BR_*DSD7JJ(B;_
M +RX_*#LQP\-,E$]41\R(QB+XKN9SK.%<+C>&:6NG9JO,OENC0-/RO#C33=&
MSTH<35:YE=>27D3GYMN_<AODX9"Q9TC<I7)72/H6G0,YEWV:G<:3E96Q8*S*
MY?4; KE7V;&6?)MC[3%9^XG^[FR#U9[4Z ^S5\Q?9C,;8N2,<]L+%<K6]ZF6
M1<:$RE-7Z>T[D<A/&J]NR/;^91%\?>:'KC^JF3_L7%1^3]7A9P[JRMB8DDDD
MG.Y$ZNZ^(0XJ7&C'7,6]U?&VY,PV1(O1K=NU5?/W'9H[BE%E=0^@LWB[6'R;
MF\T;+&WK^Q/:53A73KKQGUE*L3.>.96L7;ZJ>PZ>)<3&\9]'RM:B2++LKO';
ME4)7G7>O:^E[52C#2GR62M;I'6KJG-[RH3\8[V-NP4<KI'*17+"_S,?J[O\
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M7C--SY;'U]_JJUWY]#GTE)C>(G[)UM$TZ:-HV/LM,8]GE$A,G%A(NQQ56/\
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M\2  AR
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M<C'JK'.\&KOW*IIIBG&JE7I:DP-NG$R&:1WKNC3EW5KDV7IX]3:6.16IU3N
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M[5.-NJQJ3)'([]%W^ICC:DSQSVPQO29XY[3P/S'(V1.9CD<WP5%/T6K0
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M%@ !4H
M
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M.*&L,Q)JC'Z0TA*R+(VNLME>Z%"O:KJ\0]"T&9S^4+\K6@<BSUY$Z;>*]R=
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M>9IML49FO;^DWQ:ODI)&>8XZEFF)CJ0 !
M
M                                          -D\AX&$38;B8LTBLER
M/)S+MM<;W;_]0&[[)Y(8GQ"@KU.+.!=C6L99>^%TK8T1/6614W7;Q5#A]"\3
MEZ=MD>O_ ,:W_P Q9N'_  ZO4LRS-ZEL=K<8JN9%S\Z\VWUG.\0-4
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MZG3*V<]O4 '"L
M
M                   #QNVH:566S;D;%!$U7/>Y=D1 /8&96>,N#BF>R*G?
MF8B[(]K6HB_F[<]L3Q;Q.2R=2E#0O,DL2MB:YR,V17+MNOK :.
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MT;KFKF6QUK>T%Y$V5%7HY?-!?+KRIW";X]>5.X70!%W!2S@
M
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M7HJ%&V''5XYAGV]/QU:.8?*,"UJD<*JBJQ-MT/< B(X<Q''0
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M])OBU?)220SS$QU++,3$\2  A
M
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ML7_4OOA76//']G%=)I^6[6P>=:>*S"V6O(V2)R;HYJ[HIZ&)>
M1^:Q%3,5'5[L37M7N7;JA( F)X[A,3,3S#%,MA,OHC(I<QCY):>^_,G=MY.+
M_HW65//1)$]S8;B(F\:KMS>U"TS0QS1NCE8U['=%:Y-T4RW6&@YJ4SLCIWG:
MJ+S+$Q>J>[_0T1>NL<7]_EIB]=H\;]3\M50&9Z)U\CGMQV>58YV^JDKNFZ^3
MO(TJ.1LC$<QR.:O5%3Q*;TFD\2HOG;.>)?H '#@
M
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MYOEX]QW"-,?&/*O<)L %2@
M
M              *;Q;I/NZ+LMBL1P21O9(UTDB,1RHO=NOCU+D1&JL%7U'AY
M<=;DDCBD5KE='MOT7?Q H_#;7V&BTQ4HY:^VO=K(K']MOLY-UV5'>/12WU=9
MZ=M68J]?+U9)I7(QC&NZN55V1#,KVB="T+:U;6HYF6$7E6-'M<J+Y+LU=BRX
MOA9A,;EZ5F'(6UL0O2>-CG-];E5%[MN[N_,#2#\2Q1S,5DK&O8OZ+DW0_8
MK.5UUI[$Y":C?R"16851'L[-Z[;IOWHGDJ')])>E/_%$^"__ $ Z]>:KCTEC
MH+<M5]E)9>RY6N1NW15W_83E*2*]3J7%B:BO8V5G,B*K.9//W*8WQAU;AM08
M*G7Q-Q)Y8['.YO(YNR<JIOU3VFO:=_H#&_W:/_*@$@                <F
M6Q\&4QT]*VWF@F:K')[#K &29/@GI&KB[4L=63GCB<YJ\WBB*4?Y/2;LJM\/
MG;D/Z%SW]"7_ .P?_E4P#Y.<:O9&[;ZMIZ_O*-XYB/\ <*=_:/\ </Z-3H@
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M66SBT>6?[++91>//+]FI@_,4C)8VOC<CF.3=%3Q/T9V8
M
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MU)2S]7M*ST;*WZ\:KU3_ +$X9YB8GB66:S6>)  0@
M
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M^HEC^]O_ 'FHY[^A,A_8/_RJ9=\F+^HEC^]O_>!KX
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M[V>_S0OOC7:/Q,?^PKK>:3XW:^#SKS1V(FRPO:^-R;HJ*>AB7@
M'-D*-?(5GU[<39(G)U14.D#V(GCN&,:BTSD=(7TR>$>]U9%WZ=5;[%\T+OHG
M6=;.QM@L*V*ZB=6JNR.]Q;98VRL<R1J.8Y-E14Z*9=K?0TE69V4P',U6KSOC
M:NRM7S::(O76/&_O\M5;UVCQO[_+5 9OH?7B3JS'YMW9V6[-;(O3F]YI"*BH
MBHNZ+XE5Z32>)47SFD\2  X<
M
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M+ U6O9"]S517=%1%]I!?)A_J'.GE;>@3]FO@ (
M                          %3=-E,_P!<:#BR'/>Q2)#<3JK&]$>OG[S0
M =4O-)YAW32U)YJR+26MK6'M>C=0H_D:O+VCN]GO]A8>*D\=C2+)87H^-TC5
M14\>\E]8:3IZ@K\SFI'::GJ2HG7W*8_FXLOA89,1?5_S7FYF;_57VH:LXKI:
M+1U+7G%-;1>O4_#5^%7]3*GO=^\MQ4>%/]3*G_4[]Y;C-I]<LNOUR  X5@
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M:N6J,LTI&O8O?LO5%\E.=,IIW[PKTRFG?O#N !4J
M
M                   *-QHBL2Z#M_-D<J-DC=(B>+$7_78O)7]=4<GD=-V:
MN#E2*Z]6HCE=R^KOZR;^X"F:"X?Z8R.E:%RS MRQ-'SR/[5R;.\6[(J;;=WX
M%GI<.],TKD%JMCE9/"])&.[9Z[.1=T7JIEU+ASK:BCFTK3*[7+NJ16U:B_D3
M. TAKFMFZ$][(O?4CG8^5JW'.W:CDW3;QZ ;(  /S+(R*)\DCD:QB*YSE[D1
M.]2 _EKII4ZYNAM_:H2^56!,7<6VJI62%_:*G>C=EW_887H#A_4U8MO(R2SU
M,4V58X8F.1TB[;=[E3V^0%VST/#K-JY]JYC8YW?^^@E2-V_FNW1?QW.GAGI:
MA@[=ZYB,O%D:=AC6-Y%15:J+OU5%V,XUIH6GI3,X]]F>Q/A;,G(]S51)8U\>
MNVR^?<=[\?/PYUQB78^Y)-C<@K45'?I,5414=MT54W144#=P$
M      '#GOZ$R']@_P#RJ9=\F+^HEC^]O_>:CGOZ$R']@_\ RJ9=\F+^HEC^
M]O\ W@:^
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M5Z.7V$WRZ\Z>SK3&./.G<+B "EG
M
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M<]_0F0_L'_Y5,N^3%_42Q_>W_O-1SW]"9#^P?_E4R[Y,7]1+'][?^\#7P
M
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M_P#<K>D=9V\'9]%9YK^Q8O*CW=[%\O:A;.<:1Y9_LNMG76/+/]FO@\:EB.U
MV:!Z/C<FZ.13V,[*                                    >+[5>.9L
M+YXVRN[F*Y$5?P ]@  !XVK=>HSFLSQQ-\WN1#QIY2C=7:I;@F=Y,>BJ!V
M       %?UUJ:#26F[66L1+-V*>K"CN59%WVV10+ "+TQE),U@J>0FJ/IOL,
M1ZPO7=6?B2@   #ER>1J8NG):R$[(*[/K/>O0]7V(63-A?+&V5WU6*Y-U_ I
M_$-6PY#3ER]UQ->XKK.Z;M:JM5&.<GDB@3&/U=@\A+#%4R$<DLK^S8S9457;
M*NVRIY(I.F<:CR6*R.M=)NQLD-B>.RY'RQ;*C6JU=FJJ>/15V]YHX
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MVW,BY,@YJ-ZM?I1W*<[)JLC>9DC%W1R>9$X_66GLAD5H4LO5FN(JHL3'[NW
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M6O?_ ,0NDO[%?W.-O"'-!CZ5=K6P5*\36.YFHR-$V7S39.\Z0
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M %;U?H? :O6NNH**6EK[]GN]S>7?O[E)3$8:CB,5'C<? D5.-O(V-%5=D)
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MOIO%Z7QRT<)62M55ROY$<J]5]Y"V^&>E;>H79N?&([).D259NT=];SVWV+B
M(W/8/'YW&/Q^4@[>H]-G,YE3?\C@TAHS!Z0CL,T_22JV=461$>KN94[N]2P@
M"HZEX<Z8U)E4R.9QK;%Q$1O.KW)T3NZ(I9&8^LS&)CV1[5$B[%&;K]7;;;\C
MJ %3TMP[TSI:_)=P>.2M9>WE<]'N7IOOXJ=&K=$8#5BQ+GJ*6EB^IN]6[?DI
M9 !':?PE# 8F'&XJ!(*<2*C(T55VW]Y7<?PQTGC\VN6J8ML=]7K)VO:.7UE7
M=5VW+F (C4^G,9J;&NH9JLEBJY456*Y4ZI[C\:4TOB=*4'TL%52M6<]7JQ'*
M[=?/J30 IF;X8Z4S67?E,EBVS77N1SI.T<FZI[E++E<53RN)FQEZ'M:4S.S?
M'NJ;M\MSN $/I;3.*TOCUI82JE:MOS<B.5W7\28  B=59V#3F$GR=J&>:&';
M=D#.9Z[KMT0_G76FLZV:XE8+/5<9E$I4D1)4= J.7JO<GXG]/21LE8K)&M>U
M>]')NAX>CZ?W6#_ @$%HK6%35F/L6J%6Y V%W(K;,?(JKMOT('AUKC+:GS.4
MI9+"NHPU7JUDNR^M[]S0(8(H&JV&-D:+U5&IL?8XHXU<L;&M5R[KLFVX'\^S
M37>$_$K)7YJ=F;3>37M'/A9S<KO;^*GW66J)^+-FAI_36.M^C%F;)<GGC5K4
M:B^?YF_V*\-F/DL1,E9^J]J*A^:M.M41R5:\4._?R,1N_P"0'EAL?%BL54H5
MDVAKQMB9[D38SWY1?_#._P">[=OS-.*!QQQ-W,Z!N5,;"LUASFJC$[UZ@4;0
M_%RICM%T<9Z,R$^;AB[-L#(55'N\-O80_#75%G2>N\I5U70M1WLK,US%BC56
MHJIT0VC06%CHZ9Q;;E.%MZ*)$<Y6)S(OO+!-1JS2I++7A?*WZKW,153\0/YM
MU?L_BIFX9L"W4R6&1O:V-[N>NB)W>JO0F]):LQ6BK\:7M%7,(RV](_G3F.=U
MW_6<O<=]3%:IX?:NSM_'XF/,4,G(DC9.TVD9W]/=U/UJ-FL.([*F,FPL6+Q;
M9FR6)9'[O<B+W-W[@E:.-FI?17#^=V/M-9<OJV&LY%^MS*F^WX*37"S3ZZ;T
M3CJ,K&ML\G/,J?I.7KN0.J^'\N>SVG(IG-7!8M$<L:N]97(G3^!I+41K4:G<
MB;($,<^4E5L6<3@TK023*EUBJC&[[&B9>-ZZ&LQM8Y9%I;<NW7?E[B=EACE1
M$E8UZ(NZ<R;[*?I416[*B;=VP&;_ "?8)J_#R%EB)\3_ )S-ZKTV7ZZE;GJ6
M5^4W%82"7YNE)$63E]7ZJ^)M<<;(F\L;&L;W[-39#YV,7:]KV;.TVVYMNOY@
M81Q=MR87C#I[.2TK=BC5A]=8(^9?TDV3\RR0<;L/--'$W#9Q%>Y&HJUO/\34
M9J\,VW;11OV[N9J*?A*-1%W2M"B_]" >L,B2PLD1%1'M1R(O>FY^PG3N
M                           *3QBH6,AH>TVHQSWQ2,E<UJ;JK47K^6^_
MX%V*CQ3S5K!Z0LV:#N2P][86O_4YN]?R0",X:973;=(T(HYJ4$\<:).R56H_
MM/TE7?JNZ]2V0Y'"R2L9#;Q[I'*B-1KV*JKX;&.:9X3SYO#5\E<R;:[K3>U:
MQ(N=>5>J*J[IU7O+#A>$*8S,4KWIA9/FTS)>3YOMS<J[[;\P&K@
M              ')EJ$63Q\].PKTBF:K7*QVR[>Q3K.+-5[-O%V(*-A*]E[%
M1DJIORKY@9EDN"^G*V*MR,LY571PN<F]MRINB*>7R8>F@YT\K3T.2_H;7T6,
MM.GUFQ\;8G*YO9.]9-EW3O.OY,/]0I_[T\):^  @
M
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M=)25>Y>Y6^;?(UW"Y>IEZC;%*5KVJG5$[T.=,IIW'<.-,9IW'<) ! 5*0
M
M                   "H<6)*\6A[ZVZKK,;E8U&-=RJCE<FSD79>XMY\<UK
MDV<B*GDJ ?SSI;B9E\#BHL>M.*W!#TB63F1S6^6Z=Z%GP7%G(Y+-4:4F)@C9
M8G9$YZ.=NU'*B;FN=A%]E'_A0)!$BHJ1L14_Y4 ]
M     JHB;JJ(GFH(_/T'Y/$6J<<SH'S,5J2-[V^T#\9VQ"N%OHDL:_S#_P!)
M/U5,S^3%_4.Q_>W_ +R%O<&<I6QMF1^J[[TCB<Y6J_HNR=Q-?)AZ:"G3RM/0
M)^S7P $
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M\HX\J=PZTQCCSS[A<P?$7<^E+.
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M:^  @
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MQSZ:NZHO=MYM7^!L>(RE7*TV6:<B/8Y/!>J>\KVPG+N.X^75-(MU]W: "A8
M         #X]K7M5KD16KT5%\3+]:Z#>R5V0P"*V1%YG1-7]QJ(V.Z7FD\PL
MSTMG/,,ST-KOFD;C<XJLG:O(V5R;=4\%]II;'(]J.:J*B]45"D:WT/!EV/MT
M$2&\B;].B/*MI35]W3MST9GV/[%'<O,[O9[?:A;-(TCRI[_"ZV==8\L_?X;"
M#QJ68K<#)J[VOC>FZ.1>\]C.R@
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MFJYVSD1%Z$W\F'IH*=/_ (IX2U\ !
M
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M
M            "B<:Y)H]!V>P54:Z6-LBI^KO_KL7LCM0UZ%O#V:V7?&RG*WD
M>Z1R-1-^[JOCOL!AVJ*>,KZ&TC+BV1<TLB+-(U$YG2;>LCE]B[H3W$9T3N)N
ME_F"M^>HZ))>7O1.TZ;_ (;_ ($3?X39=7(["Y"K;H.7GB<Z16]_CT14_%"U
M:&T'%IW+Q9+461@FR;EV@C1_3F7IONNRN7KL!J
M   !XW;<%&K)9MRMB@C3F>]W<B <^>_H3(?V#_\ *IEWR8OZB6/[V_\ >6/+
M\2-(3XB['%GZ3G/A>C41R]55%*Y\F+^H=A?_ (M_[PEKX "
M
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M5.F<YSQ+Z #A6
M                      !A?%C6UFU-E-..IQ-@CF:B3(Y>9>547N[C="MZ
M[H8>QIRX[-[Q5&HCY)(]D?NB]$1=O%=D R7 \5[^)PU2A%BZ\K*T:1M>Y[D5
MR)XGYKYG*Z\UY@Y_F+8$J2,55C151K6NYG*JK[NAI?##(XS-::8E2BD,=1WS
M=&RHCW*U.Y5=MU54/=-98JOK--.MC[.5S43M43E;VG>C/R\0+<
M              <V2HU\E1FJ7(TDKRMY7MWVW0Z0!F65X0:*K8JW+%AF(^.%
M[FKVCNBHB^TC?DP]-!SIY6WH:CGOZ$R']@__ "J9=\F+^HEC^]O_ 'A+7P $
M
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M1E1[53JWQ:ODJ'.F4T[CN'.F4T[CN$B "I2
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M"9#^P?\ Y5,N^3%_42Q_>W_O-+SEF!<+?1)XE7L'_II^JIFGR8OZAV/[V_\
M>!KX
M                                                       /CFHY
MJHY-T4INJ-*)-S6\:G),WJK$\?<7,;'&F==(XLXTSKI'%E"TSJA\$B4,KS(J
M+RM>[O3V*7N-[7L1S'(YJ]45"NZFTS#DXW35T2.TB=%V^M[RMX/.V\%;6EE&
MO6%%VZ_H^U/89ZZ6QGQT]OEGKI;&?'3V^6D \JT\=F%LL+T>QR;HJ*>IK:_<
M   B]08.GG*;J]R-%_5?MU:OL)0$UM-9YA$Q$]2PV>#,\/,NDL2NFHN7HO7E
M<GDODIK&F-14M04FS5'HDFWKQJOK-7Q)#)T*V2IR5KL398GIU1R;_B8YJ#3V
M3T7DO2.(D>ZIOONW?HGDINB:^JCBW5OY4<3E/,>S;0531&L*NH:R1N<D5YB>
MO&J]_M0M9BO2U)\;>Z^MHM',  .4@          C<[AJF:IOKW8T<U4Z.VZM
M7S13)+^.S&@\G\XIO=)35=^9-^54]J&VGC<JPW*[X+,;9(GILK7)NBEN>LTZ
MGN%V6TTZGN$'I+5-/4-9%B<D=EJ>O$J]?P\RQ&.:HTC=TU<7)X)\BPM7?9OU
MF)Y>U"V:&UO#F&-J7G-BO(GCT1YU?*./*GLZTRCCSS[A=P 4,X
M                                                     "#UMAIL
M]IJ[CJTR0S3-3E<[NW1=]E]A3\=P]OP\/K6!FOPMM3SI-SM158Q$5.B=R^!>
MM3)?=@+Z8C=,@L2]ALJ(O/X=_3\S'+:\4*=:6Q:GGBAB:KGO=+!LB)^('O\
M0SD__&:_^!QW8'A-D,;FJ-V3+02,KS,E<Q&.W<C5WV*W@\OQ%SD#IL79N3PM
MZ<_+&UJKY(JHFYV:3SNL[>L:F+O9"9KF2M=/!-R,5S$5.;;IUZ;]P&\
M                   ''F:"9/&6*;I7PI,U6\[/K)[CL &,Y#@S7JXRU+_*
M/+N[.)SME>FR[(O>>_R84VT%.GE:>AJ.>_H3(?V#_P#*IEWR8OZB6/[V_P#>
M$_9KX "
M
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MO3PM'E7]G>OA:/*O4_": !2H
M                          HG&M9DT':[#FY5EC23;]7?_78O9X7Z<%^G
M-5N1ME@E:K7L=W*@%4X9YG%SZ-QL5:Q!&^"%(Y8E>C7->G>JI[5W7\2EZ]RE
M6[Q-TVF&E9-:AD8R5\2[IU?]7=/)-]_><&?X94*-]8ZNIZ55'KTAMO1KT3\%
MZ_DA<]!\-:FF[K;]JS\]OHB]FO+RLCW[U1.]5]H&A
M       #ASW]"9#^P?\ Y5,N^3%_42Q_>W_O-1SW]"9#^P?_ )5,N^3%_42Q
M_>W_ +P-?
M
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M147N]B^TKVPG+OWB?NZII%O]NL %"P
M                                               "J\3LW-@=(6[5
M1>6P]6PQN_55R]_Y(I:BN\0,"_4>E[="%42PNTD2KW<S5WV_'JGX@81FM,SX
MS#X3,WK3IK62E1ZL=UY6KU157Q54V-!UK>O8;B=IVPVW(^K8:V+L=]D:BNY7
M=/;NB^]#-\_F<LS'8[!YFJ^.3&2;QJ]%:[E[D;[43P7R+CIF'+Z^UK2S>0KK
M!C**M<SIZO1=VM;O]957O7_L!MX                .7)WZ^,Q]B[=D2.O
MQ9'N7P1$W4R2#BOG<VRQ=TOI:S:Q<"KO,][45Z)XHB@;*"E<-.(-#7%.98(9
M*MZNNT]:3ZS/:74 "&U1J7%Z9Q[KF8M-AC3N3O<Y?)$[U*CPXXHP:VS=VA!C
M;%1(&\R/E5-W)[O #1P !PY[^A,A_8/_ ,JF7?)B_J)8_O;_ -YJ.>_H3(?V
M#_\ *IEWR8OZB6/[V_\ >!KX
M
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M3EZHI.WI_&///NI33G\MO=80 95H
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MO3A55C@8D;57OV0#I
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M3HJ 99\FM47AU%M]L_\ >:J<V/H5<=72"A7BKPHN_)&WE0Z0
M  %[E  Q'@HJ+Q$UKM]X;^Y3;CDIXRE3GFFJU8899EWD>QJ(KU]IU@
M          8IJ1R?_:4T^F_7YH[_ ".-K.23&4I,@R\^K"ZY&G*V96IS-3V*
M=8                &-_*D5$T1C]_\ Q"/]RFKX/^AJ/]BS]R'ZR6-IY.%L
M60K168FN1R-E:CD1?/J=3&M8QK6(B-:FR(G@!]               !6^(Z[:
M'S2K]V?^Y2M?)Z5%X9X[;R-&GACL0OBG8V2)Z;.:Y-T5#RH4JU"NV"E!'!"W
MN9&W9$_ #H
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MBQO7;E1=]]NG3<OG!/2<V#Q5K*Y*:.7)Y5_;S=FN[6[]>7WH!I0 "
M  H/%O6%[2F/HKBJ[9[=N=L+&N7HJKX%^,?^42LL-#!6XJ\MAM:ZR5S(VJJJ
MB*"'STYQ65-TTY5^.PU3"RVY,15DRD38;JQHLS$7=&N\4W,IH\=,8VU'#E</
MD<="NR+/,S=J?D:'FLW _1MO*XZ5LT#ZZOC>WQW3H!2M0\1\I?U#;P&@\6N0
MN56_SUE[D;&QWZO7O)30>0UW)E'P:NQ=>.JK=VSPR-79?+9#).#W$"OIG3L\
M$6,NY;*6K#II>Q;W;^"N7W&LZ"XIXS561EQLU6QC,DSNKV4V5Z>P#0P
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M?2@HZ"P<=:-&-=5C>J)XN5J*JF8:F?\ -/E.8!(O4;-51'HGZ71_>!NX "
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MH30
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M'.[U1$V.L(
M
M
M
M
M
M
M
M
M
M
M             CM1Y)<1@KV0;&DJUHED1BKMS;>&X$B#&8>,MR5%6/ H]J=Z
MME<NW["P:;XL8K)W&5;\$N/F>J-:Y[D<Q5]J]-OQ T8'QJHY-T7=#Z
M
M
M
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M+4[U/(S/L-J\BQROZNV7?HJ^/<!J
M
M
M
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M+=IW X_3]!*F+@2*/?F<N^[G+YJOB2@
M
D                                             /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g843142g45n45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g843142g45n45.jpg
M_]C_X  02D9)1@ ! 0$ ZP#K  #_[2$.4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&UF
M9F         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      !  ZS,S  $  0#K
M,S,  0 !.$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      ,U    !@             "[P  !)@          0
M                   !              28   "[P
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   "[P    !29VAT;&]N9P
M!)@    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   N\     4F=H=&QO;F<   28     W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M    .$))3004       $    !3A"24T$#      7$0    $   "@    9@
M >   +]    6]0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ 9@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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M!@FW&^E_X9Q_^/J_G%RGU;^M.-B="Q:+:7"K Z>QUCPYAL<^MM3/3IQF.?\
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M(<!-EF.S=M8Q_P!-S?\ MI7*KJKF;ZG![>)'8_NG]UR,:UK["KAX?JT_V?\
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M300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
M;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V
M     0 X0DE-!"(      2Y-30 J    "  ' 1(  P    $  0   1H !0
M  $   !B 1L !0    $   !J 2@  P    $  @   3$  @   !X   !R 3(
M @   !0   "0AVD !     $   "D    T    .L    !    ZP    %!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#(T.C V.C$R(# R.C0W.C Q
M   #H $  P    '__P  H ( !     $   28H , !     $   +O
M  8! P #     0 &   !&@ %     0   1X!&P %     0   28!*  #
M 0 "   " 0 $     0   2X" @ $     0              2     $   !(
M     3A"24T#_0      "           _^$!-D5X:68  $U- "H    (  <!
M$@ #     0 !   !&@ %     0   &(!&P %     0   &H!*  #     0 "
M   !,0 "    '@   '(!,@ "    %    )"':0 $     0   *0   #0
MZP    $   #K     4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P
M,C0Z,#8Z,3(@,#(Z-#<Z,#$   .@ 0 #     ?__  "@ @ $     0  !)B@
M P $     0   N\         !@$#  ,    !  8   $:  4    !   !'@$;
M  4    !   !)@$H  ,    !  (   (!  0    !   !+@("  0    !
M          !(     0   $@    !_^+__TE#0U]04D]&24Q%  $)  B <$%$
M0D4"$   <')T<D--64M,86(@!]  !P :  4 *0 U86-S<$%04$P     041"
M10                    $  /;6  $     TRU!1$)%
M                                               *9&5S8P   /P
M  !T8W!R=    7     K=W1P=    9P    403)",    ;   *(&03)",@
M ;   *(&03)",0  H[@  *(&0C)!,  !1<   CBT0C)!,0 #?G0  CBT0C)!
M,@ %MR@  CBT9V%M=  '[]P  )"19&5S8P         :52Y3+B!796(@0V]A
M=&5D("A35T]0*2!V,@
M
M  !T97AT     $-O<'ER:6=H=" R,# P($%D;V)E(%-Y<W1E;7,L($EN8RX
M %A96B        "U6@  O&<  )(P;69T,@     $ PD   $
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M$A^!O(Q!Y"^#B\#:S:R"G+J"MI*!SK1ZGO2!-J[?ANB TZFP;C& DZ3M5%R
M9:#8-]V =)Y8$52! XNWXRF#),R5S*^"-L4[M9B!9;Y#G@. RK?+A@F :;'=
M;7> ,ZR-4\: "*A6-TV "J-<$*Z ;(M'XDZ"T-B[R]J!YM!.M,2!$\AAG36
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M:)L*?N:(,I?J9TN'/I4M3GV&;Y+,,MF&')'!#4Z')8C_U:>-L;#'P)N+XJP
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M<$VV0)IS7\^Q"9@L3JZL)I9Q/)6GT)6R*,*DEI6\$"NDXXKN  ",.(  CV;
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M;;.!*8! 5!Z!,( >-^Z!@X L$GB#(("FWH2!2HVKR4Z X8O>LU& AXHOG&>
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M*H#DM*YVYH"'H1QWE8 LC'-X0W_H=O)X]7^Y8(5YK7^82,]Z6G]S+@=ZY7]
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M6G"!N'+90X"!W71'*02"@753!3R#NW:-NDR O72SJ1" C76-EK. 9796@T^
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M,8-_736V(X+:4%:R%8)+0K2N*X'7-!2JMX&:(Y2HA8&>#ZFI,(&N  ":;(
M  "  (  :4ZY/(J[71ZU'(G)4$2Q (C<0IZM#8@0,_RID8>2(YVG.H? #^:G
MJX:X  "9D(    "  (  :2FX?Y'^712T1Y#(4#^P&(^"0I2L&XYL,_&HFXWA
M(Z>F,HY%$"*F68KI  "8WX    "  (  :0VW\YE971>SGI?F4$2O69950I*K
M394(,^2GQY2V(YRE7I/,$#^E68K\  "82(    "  (  :/JWCZ#K72.S$Y])
M4%&NM9U\0I:JFYPE,^FG"YMN([&DE)@B$%:D@XL,  "7LH    "  (  S5!L
M;69$N>=N,&AUI=-OV&J0D.!Q8VR4>PYRWVZ-9%5T3W!]3&QUI')0,:UVJ7/6
M#<=X,7.VRUQI[G%4N%AKYW)GI&UMMG-WCY]O9W2&>>-Q!G678SYREG:E2V%S
M^G>;,+%TW'A5#.9V='?ER8AGR7Q@MI%IW'Q<HN%KRWQ?CB9MF7Q]>)%O5GRJ
M8A)P_WS>2EER;WT$+\9S*WT$#"%T[GR#Q[MEXH=0M,)H"H90H1MJ"X5@C)IK
M\H2'=RIMS8/38-MOC(,O251Q!8*-+NEQF8'K"W9SFX"XQAAD1I(TLREF?)!4
MGX-HC8Y^BP]J@XR[===L;HL77[)N0XFB2&!OPHA!+AYP*X<?"N1R>(12Q,5C
M )TAL=UE/YIPGCAG59>UB<II4Y4*=*9K1Y*%7J5M(9 S1X)NIHXI+6ENYHS%
M"FAQA(<)P[9A_:@3L-1D0*27G2IF5:#ZB+MH5)UK<ZEJ4IH37<AL,Y;_1L=M
ML914+-)MRY+S"@)PN8;$PNUA/+,)L UC?Z[$G%-EC:I,A]MGA:7;<LIIA*&X
M7/]K;9X%1B1LZIK]+$]LV9A<":]P%(:,PFI@N[W^KX5B^KCGF[)D^+.3AR5F
MXJY.<A=HVJES7%UJPJ4^18ML-Z(^*\9L )RH"6UP$H9?OJ]TCF5@K01U@F>^
MFFQV<6GOAKYW6FO]<@]X0FW[7%IY+&_N15-Z#W&[*P-ZWW,9!X!]%G-]O49R
M/6_PJ^ES9G$[F5IT=7)PA;9U=G.8<0YV<W2]6VIW<77?1'9X77;D*CAY!7>0
M!O5[6W@4N\!P+GIKJCYQ<GJVE]-RFGKYA#]SMGM";\%TSWN56D1UY'OL0W-V
MUGPR*5AW3GP_!GIYUGQLNBEN783*J)IOLH0SEC%P[(.6@M=R&X+^;GAS3X*
M62=T>((.0H5U;H&?*)%UMX$N!@]XA8 QN*YLT8\IIR=N,HW#E+]O?(Q0@6QP
MN(K?;49Q]XF$6!IS-(A20:AT+8<[)]YT1(9Y!;1W9(-LMWAKEIF:I?1L_Y=M
MDX]N394C@$-OD9+:;#!PV9"O5RER%HZW0.)S$XT2)SYR^XQ6!6=VWH.GMH)J
MFZ04I/QL"*$DDI)M5)X%?TENFIKF:T=OZY?Y5F!Q+I560#YR'Y,X)KQQWI(C
M!2=W2H-\M<MIWZZ7I#YK3*KGD<5LD:;X?G9MSZ,&:G=O(I]A5:-P;IPW/Z9Q
M79GS)DEPZI;B!/1WH8-9M59I8KDDH[AJR;2WD2-K_J_X?<9M+ZL^:<]N>J;R
M50]OQ:-G/QAPKJ$-)<=P%9F+!,IWYX,]L'!\_V2LH$U]'6<=CQ%]5&E7?)9]
MG&MG:/Y]\6UE5$1^5F]3/A%^U7$/) !_JW(F ?>!9W0!KU-ZT6Z@GS-[)W 3
MC=][>G%H>W5[U7*I9_-\.G/C4U-\KW44/3A]+'8=(T-]R7:? ;9_KGAQKAUX
MU7B1G>!Y37D9C+YYMGF1>DMZ)GH 9N1ZG'IV4F9['WKM/'![G7M,(IQ\ GM4
M 7U^*WQ7K+AW$()GG'-WF((EBS=X%H'/>/IXEH%R9:YY)X$F45IYO(#E.X]Z
M.H"C(>9Z9(!6 4M]T7^ZJV9UEXQ FR!V*HM B>5VM(HE=[%W/XD 9)QWUX?K
M4&9X?8;[.L=X^H8K(4EXZ(7, 2!^&(##JD]T:98RF@EU Y1XB-%UD9*6=J1V
M(Y"I8Z%VP8[63Y)W8XTW.AEWWXOY(+]WF(NV /U^58"KJ7!S>* OF25T%YV^
MA^ITHYL6=<%U-9AE8LQUVI7B3MMV@).Q.8IVZY(H(%%V<Y#, -]^AX"7J,IR
MP:HYF'-S8J<6ARMSZ*.L=/]T<J Y8@YU&)T33BMUQYIX./UV+)D0'^]U>I3T
M ,=^L("&J%QR1+18E_!RXK"*AH]S6ZQB=%ISUZ@X87-T=J2!3:5U(J&P.'QU
M@Y^&'W=TJ)5& +1^T8!YHG^%Q609DZ"%%F:)@Y>$G&C"<C^$1VK17[B$"VS*
M2_&#\FZL-H&$('!('&6%87#F  " 3':ZH9B#N&V#DJ>#16\)@H""Z'!M<36"
MGW&^7L.":W,$2Q>"6G0[-<""?74X&\B#;W5F  "  'JYH(N!V7;5D6:!B'>+
M@5V!.W@K<!*! WC 7<" WGE52CB UWGD-06 \WI/&S>!FGHL  "  'XZGV:
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M#Y807U2B)I3U4IR?,Y.?1/.<7Y)9-D"9])&S)>F889&\$H*8K8R#  "0)X
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MW9F@5+NL+)B]2*.HD9>!.X>E-):$+5*B;98M'3.A 9-."I*@(H<F  ", (
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M+8>_5QF;&(=Y2R28\(;X/BB6W(9F+_J5,H8.'^:4;89$#*R4=(4-  "%SH
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MTHM#3!.E,HK]0*JB@XIG-#*?_HG/)EV>(8G*%?^>$8DV!4V9JX.6  ""%H
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MZHB2ADQEWX@*=R9GIH=69O=I4X:,5=9J[87,0W]L3H4K+XALYX2_%NEL<H3
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M  "  (  <7V!0G?@9;F!'7B160Z ZGDB2UV MWF8/)F DWG\*^B J7I"&$B
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MMWG(3P:3?7I#0[&2+GJ5-U&0Z7K#*9B0!'K?&7&0+7K,!SN-^'O1  "  (
M  "  (  6/"3:X$33I:2/H$[0TR0ZH$C-NV/EX#L*2Z.I8#.&2".J8#K!U",
M'(#@  "  (    "  (  6(B27(A@3B^1.H@[0N>/YH?$-I".AH<V*-R-?H<&
M&+>-<X='!RN*HX39  "  (    "  (  6#>1CH_E3@F0<H^C0L./%8[.-F^-
MD(W;*.*,5XW"&/F,"(RA!W*)5(4)  "  (    "  (  4*:J851-1F*HF%;2
M.TVG#5D]+NREY%MI((:EV5SW#I>HHUT(  "@"&!\  "  '$N  "  (  3\:H
ME%LJ1<2FS%TW.K^E'E\R+H6CP6#W(%NC;6(K#L>ELF('  "=;&45  "  '7X
M  "  (  3SVF4V'O12VDEF...D&BZV48+A&A?F9Y(!.A!V=6#M&BX6<*  ":
MWFGN  "  'H\  "  (  3L>D"VBG1*.B66G>.:2@MFL!+:&?26P '\">OVR1
M#L:@/VPH  "8=V\K  "  'W_  "  (  3DNB"V]Q1"N@:W!..3.>Q7$1+2N=
M3'&D'XR<I7'V#L"=V7&. #66 '4)  "  (    "  (  3=>@:G9@0\J>TW;P
M..2=*'=5+.N;GG>1'UB:UW><#MB;J7=> '&3VGI4  "  (    "  (  37.?
M$WU50W^=@WVB.*N;SWVP++>:-WV>'R:977V,#M&9Y7VU +"2"7[.  "  (
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MI6<)$]%SQF?'  "  ''DC\IEPUR^@E-GP%^W<[9IH6*)9 -K;V4W4QEM)V?
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M]HG,!)EX.H,<  "  (  <15F<96-981H&I2.6/=I<),B2V5J@Y&>/+UK6)"
M+(IKA9!?&=!JM(Z(!&QXAX+]  "  (  ;,6"V5)[88*"S57G54B"]%DL1\N#
M.5P].-:#H5\!)]F$>&$L$O2&NV&5  "#.F6N  "  'P#:Y9_A%I.8)!_P5TA
M5&: !U_01Q" 56)3.$. N620)W2!:V9$$M>"^V9?  "!"6IB  "  '\V:H1\
M4V(C7V]\RV1>4W9],F9\1BY]D&AN-XM]^&HG)NI^BFMG$I1_B6L_  "  &]Z
M  "  (  :6UY9FGX7DYZ!&NA4E%ZA6TM14MZ]VZ8-K][:&_.)DQ[VW"A$CE\
MCW!(  "  '3^  "  (  :&-VU7'3751WD'+U45UX)7/U1%%XHG31-B-Y"W6-
M)<AY8'8#$?5Y^'6>  "  'GB  "  (  9W-TH'G%7'!U>'IB4(AV'GK50YIV
MG7LE-7]V_WMD)7UW'WN2$==WN7M@  "  'X)  "  (  9JYRR(&S6\MSO8';
M3_9T:X'%0PMTXX&,-.EU.8%C)/=U+X%D$:EUVH&)  "  (    "  (  9A)Q
M28F:6S1R38E53V)S 8B]0H)S=(@%-&=SNX>+)')SB8>;$4MT:H;!  "  (
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M2HUL4 5ZUXTK1-EZ_XQM.*=ZS8N2*R=Z=8M(&V)YV8LR"4Q[*H9)  "  (
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M<(&G(9N%$8&F$2^%&('# F&#$8%U  "  (    "  (  3OB%-(DS15J%1HE
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MDV^^.TJ5"G"G,.246W%?)4R3OG'3%[B4 ''0")*2*7)D  "&$'EG  "  (
M  "  (  1#N3PG:<.L^36G<Y,(*2KG>6)/B2 7>\%VB2'G>9"(*/TGB;  "$
MLGW*  "  (    "  (  0\F207V0.FV1]GWM,#*13WWX),.0B'W:%T*0<WW(
M"%*-\'YX  "#18    "  (    "  (  0X"1!(3&.B60SH3T+_&0,H2S))F/
M681E%TJ/!82'"(6,68-8  ""<8    "  (    "  (  GOM3U4W5C\A7"%(=
M@ 1:(E90;UQ=+%IC7:5@&5Y12K]BM6(1-G%D8V6!'E]CEF?T 7M]@&L9G-%.
MA5@(CA12+EMO?H15LEZ^;@A9$6'R7&]<0V4&2:M?!V?V-8!@F&J?':U@,FQV
M 8M]9&_/FMI)K&(^C#M-P&2Y?.]1G&<B;(I506E[6R!8J&N^2(U;BFWH-)I<
M\V_:'0Y=2G$D 9I]2W3BF.A%/&QDBFM)LVWY>S)-U&^(:Q]1N7$-6=I55G*%
M1WY83G/P,\A9A74T'']:VG8& :9]-GF+EPI!-G9XB,M&"G<X>;Y*>7?U:;U.
MCWBJ6-A27'E>1IQ5:'H0,Q=69GJS' I8TWLJ ;%])'V(E6<]J8!^AVM"U(!L
M>)M'BX!<:,-+W(!+5^]/QH ^1?=2WH!#,I%3H(!8&ZM7*8"H ;I]%(#EE HZ
MEHIQADI #XF(=[%%!HBG: %)B8?45SM-DX<515Q0K89[,BY1-88A&V=5RH:2
M <)]"($PDO4X!I0_A64]P))V=OE"[9#$9VY'F(\U5KE+NXW61-Q.U(RV,<-/
M&(P;&S%4KXO+ <A\_8$TDC,V#YVTA+X[\IL'=G%!0IB&9P1&"99+5FQ*/Y1C
M1*5-69+C,8E-7I)0&O=3SX_P <U\]8$XDX-:ODWNA4-=85(@=EM?_58Y9GUB
MBEHO58%D^5W[0SUG%V&/+T]H0&2Q%JII=694  "  &W2D7E5F5>9@]58NUK^
M=2U;MEY*97]>C6%V5*-A,61X0H!C:F=*+KED76FW%DYF8&K:  "  '*PCYI0
MY&%)@@)4;6/7<YE7N6909 ):SVBO4U9=I6KR06-?\6T0+=%@G6[:%;%CX&^*
M  "  '=BC<I,DVKK@$=0<VRG<?54 6Y68K174F_R4BE:67%X0&I<KW+G+1-=
M"G08%3AAN'1S  "  'MVC!Q(KG2&?L5,VW5[<))0K79C86!4+'<\43177'@-
M/Y19NWC4+'%9NGE[%-5?YWFL  "  '[SBK%%2'X;?81)N'Y-;WI-Q'YR8&91
M=GZ,4$Y4OWZI/O17'7[4*_56P'\)%(=>9']8  "  (  B8A"6X>>?'Y'!H<-
M;I=+1(9M7YY/'H7-3Y12?H5#/EA4U(3?*YM43(3$%%5=HH3Z  "  (  B*$_
M\)#_>[)$RH^M;>)),(Y*7P%-)HSS3P-0E8O0/<M2W(KY*RU21XK&%"I=ZXF;
M  "  (  A_\^$9H>>QQ##)@6;59'BI7U7H9+DI/R3J!/"I)%/8)119$=*N%0
MK9$3$]]>:8U   "  (  B!UA[$X,>L-D!U(=;+%F)E8779MH.5GL359J+EV1
M.Z1KVF#O)_)LF&.I#I-PZV1H  "  '&TAB=<^5<;>4A?BUIW:V-A_EVV7'MD
M46#33%EF<F/#.LQH*69U)T)HAVB4#D-N$6C_  "  '9HA&Y88F!&=[1;6V+?
M:BU>'&5C6UQ@HV?%2VEBZ&H#.@MDH6P-)KEDDFV9#A-KAVW%  "  'J+@KM4
M,&EI=A=7>6M":)5:=&T+6A1=,&ZZ2C]?H'!*.11A57&T)?E@R'*]#;AI>'+/
M  "  'XC@3)0:W*(=*I3]'.J9T%7*72Y6-1:#W6R25Q<GW:=.$Q>2W=Q)6==
M@W@)#7YI,7@Z  "  (  ?^M-(7NG<X!0X7P79C941WQO5]]75GRU2'M9]GSY
M-[);D'U#)/9:S'V)#5)I?'X)  "  (  ?N%*382T<HY./(1X95M1RH095QA4
M^(.P1\!7I8-9-QE9)H,I)*98D8-$#3QIH8,3  "  (  ?A-']8VE<=),"HS#
M9*I/MHNR5G=2^(J<1R=5JHFX-H17"HDK)#=6PHEB#25IR(<V  "  (  ?8)&
M()9G<4A*4Y3R9!].$9,V5?-16Y%Z1KI4"Y 7-C%53X]1(]]54(]D#.%J/(BU
M  "  (  ?)5I<TX3< 9K#5'\8KILMU725&%N6%F#1,9OW5S[,X]Q*V 3']1Q
MK&(Y!S-WMF,0  "  '6&>K-DLE:1;IQFMUG<88-HJ5T+4UAJ?6 50^)L(6+J
M,M)M965H'T1M3V<*!Q]TZF>_  "  'FM>1U@15\K;1=BIF')8$EDVF1.4C=F
MVF:O0O%HF6CD,A!IRFK.'KII36OW!PUT%6RE  "  'U2=Y)<+F?3:YI>VFF^
M7N1A1&N743MC<FU80A=E2V[K,6UF97!%'EAEWG$!!PYT$W'.  "  (  =B-8
MAW!X:EY;;W&]7;5>"7+M4 )@5'0!02UB074 ,)IC.W76';AB^W8]!N=T57>$
M  "  (  =/-54WDA:4)8:7G'7+!;*WI.3Q%=EGJ\0%1?B7LB, =@6'N#'4]@
MB7N[!M9T<GSJ  "  (  <_U2D8&Y:&!5SX'&6^%8L8&F3E!;,H%S/Z!=)H%/
M+W5=Q(%+'0Q>?H&(!MAT;X%I  "  (  <SU00XHY9Z]3HXFY6S96GHCX3;-9
M*H@G/P=;%H>&+MY;?(=!')U<Y(?%!M-T>(2=  "  (  <K-.<)*:9RU1[9&B
M6K!4]9!+32]7@H[B/IA988W2+HI9E(UY'$!;GHT9!IUTTX1Y  "  (  <-%Q
M<TWB909RDU&D6'ASS5552M%U!EC>.\UV+5P@*N=W0U[9%IUX,& 6 *=^YF):
M  "  'C:;P]LZU7<8[MN:ED35U]OW%PN2>EQ-E\A.PUR:F'0*E)S6F0#%D-T
M"637 ,Y^I&<A  "  'R$;99HIUWW8E)J>&"15C9L(V,12-AMG65I.B9NW6>(
M*9IOGVDW%<=P?6FM .!^AFPJ  "  '^\;#5DM&878/AFQ&@25.)HG&GW1]YJ
M-FN].49KA&U-*/!L$6Z"%5UM;FZI /-^97&6  "  (  :N-A(VY&7[AC9F^D
M4[ME9'#M1LIG%W(6.*-H;G,B*&UHPW/G%1MJR7/: 1-^+G<>  "  (  :<5>
M W: 7LA@=G=04N=BEG?_1?1D7'B0-\UEHWD1)]EEJGEX%*YHFGEG 1)^,'OT
M  "  (  :-Q;2WZK7>U=XW[T4AM@'W\,139A\G\+-QMC*W\3)T=BWG\O%'%F
MNW]F 21^$W_Z  "  (  :"59 X; 741;NX:/47E>"X871*!?XX6)-HEA"(4I
M)K1@884F% 9E5(5$ 3!]_H#.  "  (  9YY7+8[&7,5: (XS4/=<7HTV1")>
M,HPB-B!?/XMJ)F=>88N)$[!D.(GS 0]^-8"X  "  (  9.-Z#$U:6=QZN%#X
M3@=[B%2"00-\9%?=,G1]3%K;(91^@%T-#,R H%UX  "  &6=  "  'NT8T5U
MPE3?6*AVP5@"3/UWNEL%0"IXI%W8,<AY@F!3(1QZ9V(1#+1\K&(]  "  &I(
M  "  '[T8?%QIUR#5UUR[E\72^YT$F&0/R]U#V/7,/IUYF70((%V>&<>#'QY
M06<:  "  &]6  "  (  8+!MU60R5AMO468T2K!PEV@=/C=QK&G?,!YR?FM9
M']5RLVP_##!V6&P@  "  '31  "  (  7X1J7&OH50-L!&U?2:1M:6Z\/2QN
MBV_S+WAO3W#Y'TMO'7&("_YST'%N  "  'FR  "  (  7G9G1G.R5 9I&72D
M2+YJG'5T/&IKQW8B+L]L=':P'P-KVW;]"_1QF7<?  "  'W3  "  (  79AD
MDWMX4TMFE7OS2!MH,WPZ.])I7WQB+C-IZ'R+'GII'7RL"]=OPGT]  "  (
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M)W]T1^]MS'^X/5AN]W^Q,:AOB7^-)&5O4G^)%$)P.G^P!%QXHH G  "  (
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M  "  (  2)M^\68\/R=_CV?.-,)__FDW*1Z 3VI7&Y6 P6KX"SN!8&K]  "
M '!Y  "  'Z^  "  (  1[I[XFU,/DU\L&YP,_Y]-F]H*'%]?7 B&OM]IG!L
M"Q-^AG"'  "  '95  "  (    "  (  1OAY,71=/95Z+74=,UQZRW6G)^9[
M!78#&G)ZYW83"M1\-G9L  "  'M'  "  (    "  (  1D]VT'ML/.MX WO0
M,KUXO'OX)UUX[7P &?IXA'O["FUZ;WRM  "  ']X  "  (    "  (  1=-T
MVX*\/(=V1(+@,F]W((*?)SIW.8)+&B1V<H);"LYXM8(&  "  (    "  (
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M%&*:,W2+:60F*42+K65T'9F,(F9+#Z>-$&9G IF)Q6B'  "  '0$  "  (
M  "  (  .\N'\FE=,J:(AVJ!*)"(Y6MK'0:)0FOQ#S^)I&O6 J:' VXP  "
M 'D[  "  (    "  (  .Q6%*7 I,?2%_G#O)_B&=W%Y'(V&OW&T#N>&KG&&
M I:$Q713  "  'V8  "  (    "  (  .GR"NW<*,5V#SW=\)W:$97>N'"Z$
MEW>H#J.$27>2 FZ# GHK  "  (    "  (    "  (  .@V JGXG,.>!]GY/
M)PN"K'XQ&^."S'X!#I&"7'XN HF!B'[_  "  (    "  (    "  (    #_
M_P  __\  /__  !M9G0R      0#"0   0                    $
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MF>;GZ#;IANK8["OM@.[7\#'QD/+O]$WUJO<$^%KYJ_KV_#K]>_Z[____ (
M@ #F3W_.?UC-F7^H?LVTVG^9?GF<%'^C?F6#3'_&?H5JA7_^?L!1OX!C?STY
M ($2@ _\Q7Y\BS3DM7YCB6S,0'Y=A\RSFGYNAF::V'Z8A4."&'[9A$]I6G\O
M@V=0KG^O@J$X%(!V@>;ZO'TVEG'B^WTPDY+*RWT^D,^R.GUICEZ9DWVLC"R
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MO6J3.WIDM&I[=WL-JT!CPGO,H99,"7ROES,T/7V^B[;N4XC;?C;7AH?$?<+
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MD$]AIJ SC>E2(YL<BYM#)Y7.B4 T^)!#AN0H2(IAA(V?F[1"H"60-Z\$G'F
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M]HNW?CR9&K&+?#R*Y:S<? %\2JA">_1M::.Q?!A>5I\7?')/49IC?/M OY6
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MB(5BM8A0AS93&8;QA?-#Y(61A*0U+(1#@T,GL(+Z@<B=S8W:E+^/J(PNDM.
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MA$4KHXNV@Q$C&H<6@>UZT*G7DI9O>:6[D,-CQJ%ZCL%7W)T?C*U,!)B[BJ-
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MEG,(;O!3GW5R<?) Z'@@=3PO"'LL>0+ [F5%:W^OTV?(;46>!FHJ;P>+GVR
M<,QXO&[C<IIEKG%D=']2V'0*=GQ 57;U>+$NP7H]>SF_*6+8=@2N(F6&=K><
ME6@8=VR*16J;>#9WCVTP>1!DL6_F>?Q2$7+$>O<_S'7G?!$N@7EE?5.]:6"P
M@%FL:F.#@ Z:ZF8V?\R(W6CC?Y9V4FNI?WECKFZ0?V=13G&A?UD_2W3X?U,N
M2GBE?TR[SU[9BHRJYF')B5F9<62;B"6'=F=FAO1U+VI/A<YBO&UFA+M0FW"E
M@YT^V70H@F\N&G?^@1RZ@5U>E*NIJ6!CDI>80V-(D&R&5F8KCCMT*6DPC ]A
MZ&QDB>=/_F_,A[4^='-WA5LM\G=N@K^Y=UPMGJ:HKE]!FZZ736(PF(F%:V4C
ME5-S4VA!DB%A-VN1CN=/?&\4BY(^(W+AB LMT';VA#"XL5M$J&ZG\%YAI(R6
MBV%3H&B$JF1,G"5RFV=[E^=@F&KEDY]/!VZ"CRT]W')FBG8MM7:2A6VX,UJD
ML>JG<%W"K0N5^V"NI]R$$F.DHHUR#6;8G4-@(&I2E^M.GVX"DF(]D7'^C(XM
MGW9"AG>U?F^N8%ZEHW$F8V.5%G*=9D*#QW08:0MQ]76C:]I?]'=);L5.,7D1
M<=@\N'L6=3@L+7UP>1>T&&T3:GFDE&[.;'"4&7!T;E*"WG(8<"]Q'W//<A5?
M.W6H=!1-GG>G=C(\5'GI>(DL!'Q^>S:RF6J_=&ZB_&RF=6:2K6YT=E2!B7!%
M=T9O_'(K>$9>2G0X>5I,XG9K>G\[VWC@>\4KX'NF?3:Q#&BO?C2A;&JV?D:1
M*&RF?DR 1FZ9?E%NWW"P?F5=97+J?H9,.G5-?JT[<W?T?M\KP'KF?Q2OFV;J
MA^&@#6D,AQJ/TFL9ACQ^_VTJA5)MWF]?A&Y<CW''@YA+H'15@KH[%W<F@<\K
MI7I @,FN;V5^D7^>ZF>RC^".O&G1CAA]^&OYC#IL\&Y(BEM;U7#*B'Y+&7.
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MG%=C]7%3E^946W-7DVA%/G6*CLLVHW@$B?PI1WJSA1>;Z'^=7]&.PW]Z8N.
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MN(2F;%YH%H0L;GM9_X.Z<*I+T8-8<OH^#X,#=6PPT(+1>" DUH+#>R&-Z8/
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M3&UG=_EPIF]3>,YA?W%M>:Q23'.T>IQ#@G8H>YTU.'CD?+LH,WO=??>986>
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M>=4K/8&/>Y4B38&N?6IX!X$B>)UMCH#Z>61BFX#'>A9718"3>KU+V8!L>VU
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M@<@L8GI(@4PCGGSA@,MX&FIDB[5MS6Q:BN%B]6XVB;57LG =B%M,0W(WAP-
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M!8#$@%0  /__  #__P  __\  &UF=#$      P0A   !
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MYO^F.3+_HD9*_:!-8/&D3'+FITR$VJA0EL^F6:;'I62QQ*=OML&G>+N]IX'
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MT?^H-S+_I$-+_ZA#7?6O/VSLN#IZY,,WA]W3-9#!Q$FGL;I>M:FU;KRDL7K
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M4_#'*EK8WB%FPM\D@JW./)B?PU:GF;QHLI:W=;B4M'V]D[.#OI&RA;^.LH;
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MTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BT_^C.2K_GT9
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MCLU_J8[-?ZF.S7^ICLU_J8[-?ZF.S7^ICLU_J8[-?ZF.S?^F-BK_HD)!_ZE
M3_^R.UOYO3AE[,LX;=S<-7C'UCZ.L\E2H*? 8ZV?N7"VFK5ZO)BR@;^4L87"
MCZ^%Q(NNAL6&K8?'@JR*R'^KC<E_JXW)?ZN-R7^KC<E_JXW)?ZN-R7^KC<E_
MJXW)?ZN-R7^KC<E_JXW)?ZN-R7^KC<E_JXW)?ZN-R?^G-2K_HT)!_ZP\3?^W
M-E?RQ3-?X=8V8\WC,7RZTS^1J<A4H9_ 9:V9NG*UEK9[NI2S@KZ2LH7 C;&&
MP8FPA\.&KXC$@JZ*Q8"NC,6 KHS%@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,6 KHS%
M@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,6 KHS%@*Z,Q?^H-"K_ICX__[$W2OF^,%+G
MSR]5T>(L:,#A,'^MTD*3H,A7H9C!9ZN4O'.RDKA\MY"V@KJ.M(6\B[.&OHBR
MA\"%L8G!@[&*P8&PC,*!L(S"@;",PH&PC,*!L(S"@;",PH&PC,*!L(S"@;",
MPH&PC,*!L(S"@;",PH&PC,*!L(S"@;",PO^I,BK_JS@]_[@O1>[(*4C6WR52
MP^PI;+'?,8*ATD62E\I:GY'#::>.OW2MC;Q\L8NZ@;2(N8.VA;B$N(.WAKF!
MMH>Z?[6)NWZUB[Q^M8N\?K6+O'ZUB[Q^M8N\?K6+O'ZUB[Q^M8N\?K6+O'ZU
MB[Q^M8N\?K6+O'ZUB[Q^M8N\?K6+O/^K,"K_L2\X]L(F/-S:'SO&ZR-7L^PJ
M;Z/?-8*6U$J0C\U=FHO(:Z&)Q'6FAL)[JH/ ?JR!OX"N?[Z"L'V]@[%[O(6R
M>KN'LWF[B+-YNXBS>;N(LWF[B+-YNXBS>;N(LWF[B+-YNXBS>;N(LWF[B+-Y
MNXBS>;N(LWF[B+-YNXBS>;N(L_^M+BK^NR4PX](:+<GH&T&V]R-:I>PN;Y;A
M/'^,V$^+A])?DX3-;)F!RG2>?LAXH7O'>Z-YQGVD>,5_I7;$@:9UPX.G=,.$
MJ'/"AJESPH:I<\*&J7/"AJESPH:I<\*&J7/"AJESPH:I<\*&J7/"AJESPH:I
M<\*&J7/"AJESPH:I<\*&J?^T)"7LRA8CS>43++GV&T:G^B9;F.XU;(SE1'J$
MWE.#@-EBBGS5;(]XTG&3==!UE7//>)=QSGJ8<,U\F6_-?IINS(";;<R"G&S+
MA)QLRX2<;,N$G&S+A)QLRX2<;,N$G&S+A)QLRX2<;,N$G&S+A)QLRX2<;,N$
MG&S+A)QLRX2<;,N$G/7!%1G1WPP8O/,3,:K_'D>:_"Q9CO(\9X3J2W)]Y5AZ
M>>!C@'3>:H1PVV^';=ISB6O9=HIJV'B+:==ZC&C6?(UGUGZ.9M6 CF75@8]E
MU8&/9=6!CV75@8]EU8&/9=6!CV75@8]EU8&/9=6!CV75@8]EU8&/9=6!CV75
M@8]EU8&/9=6!C]+2"@F_Z T=K?\5,YW_(T60_S-4A?=#7W[Q46AW[%QO<.EB
M=&OG9W=HY6UY9N1P>V7C<WUCXG9]8N%X?F+A>7]AX7M_8.!]@%_@?X%?X'^!
M7^!_@5_@?X%?X'^!7^!_@5_@?X%?X'^!7^!_@5_@?X%?X'^!7^!_@5_@?X%?
MX'^!7^!_@?^@.2'_G$8V_YI12O^=4EGWGU1I[:!7>..?7(?:G&>5TIEPH<R6
M>ZO&E(2SQ).+ML*/C[K BY*\OH>5O[V#F,&\@9O#NWZ@Q+I\IL:W>JS&M7JL
MQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&
MM7JLQO^@.2'_G$8V_YI12O^=4EGWGU1I[:!7>..?7(?:G&>5TIEPH<R6>ZO&
ME(2SQ).+ML*/C[K BY*\OH>5O[V#F,&\@9O#NWZ@Q+I\IL:W>JS&M7JLQK5Z
MK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JL
MQO^@.2'_G$8V_YI12O^=4EGWGU1I[:!7>..?7(?:G&>5TIEPH<R6>ZO&E(2S
MQ).+ML*/C[K BY*\OH>5O[V#F,&\@9O#NWZ@Q+I\IL:W>JS&M7JLQK5ZK,:U
M>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQO^@
M.2'_G$8V_YI12O^=4EGWGU1I[:!7>..?7(?:G&>5TIEPH<R6>ZO&E(2SQ).+
MML*/C[K BY*\OH>5O[V#F,&\@9O#NWZ@Q+I\IL:W>JS&M7JLQK5ZK,:U>JS&
MM7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQO^@.2'_
MG$8V_YI12O^=4EGWGU1I[:!7>..?7(?:G&>5TIEPH<R6>ZO&E(2SQ).+ML*/
MC[K BY*\OH>5O[V#F,&\@9O#NWZ@Q+I\IL:W>JS&M7JLQK5ZK,:U>JS&M7JL
MQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQO^@.2'_G$8V
M_YI12O^=4EGWGU1I[:!7>..?7(?:G&>5TIEPH<R6>ZO&E(2SQ).+ML*/C[K
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M_YM(-?^A1T'_I4A,_ZE*5_NL3F+UKU)L[K!8=NBQ7G_?L&B(U:QTD,JC>IW
MFX&HN)2'L+&/CK:KBI6[IH>=OJ*%I<"?A*_!F8&OP9>"LKZ5@[.\E8.SO)6#
ML[R5@[.\E8.SO)6#L[R5@[.\E8.SO)6#L[R5@[.\E8.SO/^:,Q3_F4,F_YQ'
M-?^B1D#_IT=+_ZM)5OVO3&#VLE%J[K17<^6W7GS=MFJ#SZ]RD,6F>)V[GGZG
MLIB%L*N3B[:ECI.[GXN:OIN)HL&8B*S"DX6OPI*&L;^1AK.\D8:SO)&&L[R1
MAK.\D8:SO)&&L[R1AK.\D8:SO)&&L[R1AK.\D8:SO/^:,Q3_F4(F_YQ&-/^C
M14#_J$5*_ZU'5?ZQ2E_UM5!HZ[E6<..]7G?9NVJ R[)PD,"I=IVVHGRGK9R"
MKZ67B;:>DY"[F8^8OI2-H,&1C*G"C8JNPHV)L;^-B;*]C8FRO8V)LKV-B;*]
MC8FRO8V)LKV-B;*]C8FRO8V)LKV-B;*]C8FRO?^;,Q3_FD(F_YU%-/^D1#__
MJD1)_Z]%4_RT25WRN4]EZ;Y6;.'#8'+3OFF QK5NC[NM=)RPIGJGIZ" KY^;
MAK68EXZ[DY65OHZ2G<&*DJ?"B)"NPHB.L,"(C;*]B(VRO8B-LKV(C;*]B(VR
MO8B-LKV(C;*]B(VRO8B-LKV(C;*]B(VRO?^;,Q3_FD(F_YY$,_^E0C[_JT)(
M_[%$4OJW2%KPO4YAYL169][)8FW.P6=_P;EMCK:Q<INKJGBFHJ5^KIF@A+62
MG8NZC)J3OH>8F\"$EZ3"@I:OPH.3L,"$D;*^A)&ROH21LKZ$D;*^A)&ROH21
MLKZ$D;*^A)&ROH21LKZ$D;*^A)&ROO^;,Q3_FD$F_Y]",_^F0#W_K4!'_[1"
M3_>[1U?MPTU=Y,Q88-G-8&S)Q69^O+UKC;"U<9JEKW:EG*I\K9.F@K2,HHFY
MAJ"0O8&>F;]]GJ+!>YZOP7V9L,!_EK*^?Y:ROG^6LKY_EK*^?Y:ROG^6LKY_
MEK*^?Y:ROG^6LKY_EK*^?Y:ROO^<,Q3_FD$F_Z!!,O^H/SS_L#Y%_[=!3?3
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MP:F\<L"JMW/ JK=SP*JW<\"JMW/ JK=SP*JW<\"JMW/ JK=SP*JW<\"JMW/
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M:-*2SVC2DO^"* G_@CD6_X%()?^*3S'_CE8]_X]<2?^.8U3^BFI>^(5Q:/*
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MQ<^55\7/E5?%SY57Q<^55\7/E5?%SY57Q<^55\7/E?^3)@G_HRP._[ F#_7
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MF)EWS9B9=\V8F7?-F/]^(@;_@#(0_Y X&/^;/R#_H$(H_Z1&,/ZF2SCTJ%!
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M1?^+5$/_D55"_IA60?V>5T#]IEA _*E80/RI6$#\J5A _*E80/RI6$#\J5A
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M,"[_EC$M_YXR+?^>,BW_GC(M_YXR+?^>,BW_GC(M_YXR+?^>,J3"  "6SP
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M9YN+?FZ6B(9SD86.>(R"EGR(@)^ A'^J@H%_MX. ?\B$?X#=@W]_WH%_?]^
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M2#O[ODDZ_,]).?SC23G\XTDY_.-).?SC23G\XTDY_.-).?SC2<>M  "WMP(
MJL," )[0! "3XPD C/T8 H3^)P=[_S$/<O\X%FG_0!QB_T8B7/]-)E;_4RI2
M_UDM3O]?,$K_93)'_VLT1/]Q-4'_>3<__X$X//^*.CK_DSLX_YT\-O^G/37_
ML3XT_[X^,__*/S/_RC\S_\H_,__*/S/_RC\S_\H_,__*/[BR  "JO0  G<H
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M9/]<) /_8R8$_V\F!?][+PO_@CD1_X9!&/^'22#_A5$H^()9,/)]8#CM=VI
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M&23_F!HC_Z :(O^J&R'_K1LA_ZT;(?^M&R'_K1LA_ZT;(?^M&YJ^  "+R@
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M975\\V1U?/-D=7SS9'5\\V1U?/-D=7SS9/]I%@'_>!,!_X<4 /^3%0#QGA4
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M+CCROB\W\] O-_/G+S;Q\R\V\?,O-O'S+S;Q\R\V\?,O-O'S+[FG  "KL
MG[L  )+&  "&T $ >]T% '3W$0!M]QP!9O@F U_X+P9:^3@*5/E #E#Z1Q%,
M^DX42/M5%D7[6QA"^V(:0/QH'#W\<!TZ_7@?./V"(#;]C2(T_I@C,OZD)#'_
ML24P_[\F+__/)B[_XR8N_^,F+O_C)B[_XR8N_^,F+O_C)JVM  "?MP  DL(
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M9OQ7CV?^5HYG_E6-:/Y5C6C^58UH_E6-:/Y5C6C^5?]<& '_:1,!_W86 ?^
M&0']B!T![XXB >23*0+:E#$&SI _#\:+2QJ^AE4EMX%>+K%]9C:L>6X\IW9U
M0J-S?4>?<(1+G&Z,3IALE%*5:YU4DFJG5Y!ILEF-:<!:C&G56HIJ[%F*:OI8
MB6O]5X=K_5:':_Y6AVO^5H=K_E:':_Y6AVO^5O]>%P'_;!(!_W@4 ?^#%P#Y
MBQH ZY(= >"8(P'3F"\%RI0]#L&/21FYBE,DLH9;+:R!9#6F?FL\H7IR0IUW
M>D>9=8%+E7.)3Y%QD5*.;YI5BVZD6(AMKUJ&;;U;A&W06X-NZ5J#;OA9@F_\
M6()O_5>";_U7@F_]5X)O_5>";_U7@F_]5_]@%0'_;A$!_WL3 /^&% #VCQ8
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M0$7 S4!%P.@_1+[V04.]_T)#O/]#0[S_0T.\_T-#O/]#0[S_0]:-  #&FP
MN*4  *VN  "BM@  F+\" (W(!@"#T0L ?](: 'G2*@-RTC<(;-%"#V;12Q5A
MT%,:7,];'UC/8B-4SFDG4<YQ*DW.>BU*SH,P2,Z.,D7.FC1#SJ@U0LZX-D'/
MS35!SN@U0,WU-S_+_CD^R_\Y/LO_.3[+_SD^R_\Y/LO_.<J6  "\H@  KZH
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M-.[F(S3K]2,TZ_@C-.OX(S3K^",TZ_@C-.OX([.E  "FK0  F;<  (W!  "
MRP  ==4! &GA!@!D\Q$ 7O,< 5GT)@)4]# $3_4X!DOU0 A']D<*1/9.#$'W
M50X_]UP///=C$3KX:A,W^',4-?A]%C/YB!<Q^908+_JA&2[ZKQHM^[X:+/O/
M&RO[YQLK^^L;*_OK&RO[ZQLK^^L;*_OK&ZBJ  ":M   C;\  (#)  !TTP
M9]X  %[R" !9_A$ 4_\: 4[_(P))_RL#1?\S!$'_.@4^_T$&._]'!SC_3@@U
M_U0),_]:"3'_80HO_VD++/]R#"K_?0TH_X@.)O^5#R7_H1 D_ZX1(_^Z$B+_
MRA(B_] 2(O_0$B+_T!(B_] 2(O_0$IRR  ".O   @<<  '/1  !GW0  6>,
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M29-@_TB28/]'DF#_1Y)@_T>28/]'DF#_1_]8%0'_8Q$!_VX2 /]W%0#[?A@
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M2%&9RDA1F.9(49?U2%&7_T=1EO]'49;_1U&6_T=1EO]'49;_1_9W  #8A0
MR9$  +^; 0"TH@  JZ@  *&P  ":LA$ E+,B 8VR, 6%L3P,?J]&%'BN3AMR
MK%8A;:M<)VBI8RQDJ&HP8*=Q-%RF>3A8I8([5:2,/E&CF$!/HZ5"3:.T0TRC
MR$-,H^1#2Z'T0TN@_T1+H/]$2Z#_1$N@_T1+H/]$2Z#_1.-]  #/BP  PI8
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M*SW&_"T\Q?\N/,7_+CS%_RX\Q?\N/,7_+L23  "VGP  J:8  )VN  "2MP
MAK\  'O' P!PSP< 9]8- &37&@!@V"H!7-@V UC80094V$H*4-A2#4W86A!*
MUV(31]=I%D77<AA"UWP:0-B''#W8DQX\V*$?.MFP(#G9PR YV=\@.=?O(#C5
M^2(WU/\C-]3_(S?4_R,WU/\C-]3_([F<  "KI   GZP  ).U  "'O@  >\8
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M"1S_W0D<_]T)'/_="9BP  "*N@  ?,0  &_-  !BV   5=X  $GD  !$^P4
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M*@+_/R<"_T,F O]&*0+_23(#_TD\!?](1P?_1E,+_T1?#_]":A+_0'85_SZ
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M/WQKHT)Y:K!#>&J_1'9JU$5V:^U#=FO[0G9K_T%V;/] =FS_0'9L_T!V;/]
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M1&!]R41??>5#8'WV0F!]_T%A??] 87W_0&%]_T!A??] 87W_0/]G  #C=
MTG\  ,>( 0"^CP( MI4! *Z8!@"FFA4 GYHF IB9,P:1ES\,BY5(%(634!I_
MD5@@>H]?)7:-92IRBVPN;HIS,FJ(>S9FAX0Y8X:./&"%F3]=A*9!6X2T0EJ$
MQT-:A.-"6H/T05N#_T!;@_] 6X/_/UN#_S];@_\_6X/_/_]J  #>>   S8,
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M.$F<_#A)F_\Y29O_.4F;_SE)F_\Y29O_.=MZ  #(AP  O)(  +&:  "FH
MG*8  )&L  "'L0@ @;(6 'RS)@%VLC,$<;(]"6NQ1PYFL$\38J]6&%ZN71Q:
MK60@5ZQK(U2L<R90JWPI3:J&+$JJDB](J9\P1JFM,D6IOS)$JMHR1*CO,D.G
M^S-#IO\S0Z7_-$.E_S1#I?\T0Z7_--"!  #!C@  M9@  *F?  ">I0  DZP
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M&C/._QHSSO\:,\[_&K.9  "FH0  FJD  (ZQ  "!N0  =<   &K'  !>S0,
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M H>V  !YOP  :\D  %[3  !0VP  0^   #CE   O\   *_\  "?_"  D_PX
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M.FUJR3IL:N0Z;6OU.&UK_S=M:_\V;6O_-FUK_S9M:_\V;6O_-O];  #K9P
MV7$  ,QY  ##?@( NX(# +2$"0"MA1@ IH4H 9^$-069@D *DW])$(U]4A:)
M>UD;A'E@'X!W9R-\=6XG>71U*G9S?2YS<H8Q<'&0-&UPFS9K;Z<X:6^U.FAO
MQSIG;^(Z9V_T.&AO_S=H;_\V:&__-FAO_S9H;_\V:&__-O]>  #D:@  TW0
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M-UA^_398?O\U6'[_-5A^_S58?O\U6'[_->EH  #4=   QGX  +N'  "RC0
MJ)$  )Z4  "6E@X D9<< (N7*P*%EC<%?Y1!"GF321!TDE$5<)!8&6R/7QUH
MCF8A98QM)6&+="A>BGTL6XF'+UB(DC%5AY\S4X>M-5*'OC51A]8U48;N-5*%
M^S12A?\T4H7_,U*%_S-2A?\S4H7_,^-L  #.>0  P8,  +:+  "LD0  HI4
M )>9  "/FPL BIT8 (2=)P%^G#0$>9L^"'.:1PUOF4\2:IA6%V:771MCE6,>
M7Y1J(ER3<B59DGLH59&%*U*1D"Y0D)TP3I"K,4R0O#),D-,R3(_M,DR.^C),
MC?\Q3(S_,4R,_S%,C/\Q3(S_,=QQ  #(?@  NX@  +&1  "FE@  G)H  )"?
M  "'H@8 @:,4 'RD(P%WI# #<J,[!FVB1 MHH4P/9*!4$V"?6A==GF$;69UH
M'E:=<"%3G'DD4)N#)TV:CBE*FILL2)JI+4>9NBU&FM M1ICK+4:7^2Y&EO\N
M1I;_+D:6_RY&EO\N1I;_+M%W  #!A   MHX  *J5  "@FP  E9\  (JD  !]
MJ0  =ZL0 '.K'@!OK"P!:JLW!&6K00=AJDD+7:E1#UJI6!-7J%\64Z=F&5"G
M;AQ-IG8?2J6!(4BEC"1%I9DF0Z2H)T*DN"A!I,XG0:/J)T"B^"A H?\I0*#_
M*4"@_RE H/\I0*#_*<E^  "ZBP  KY0  *.:  "8H   C:4  (*J  !UL
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M":2=  "8I0  BZT  'ZT  !QO   9<,  %G)  !-S0  0],! #K9!@ UY T
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M  C_?P$'_Y !!?^@ 03_K@$$_[P! __' 0/_QP$#_\<! __' 8.T  !UO0
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M+7Q:R2YZ6N,N>EOU+7I<_RQY7/\K>ES_*GI<_RIZ7/\J>ES_*O]1  #R6P
MWF0  ,]J  #';@( P' $ +IP# "R<1H JW$I :5P-P.?;D('FFQ+#)9J5!&2
M:%P5CF9C&(ME:1N(8W >A6)X(8)A?R2 8(@F?5^1*7M?G"MX7J<M=EZU+G5>
MQB]T7N$O=%_S+G1?_RQT8/\K=&#_*W1@_RMT8/\K=&#_*_]3  #H7@  V6<
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M+V1K_"UD:_\M96O_+&5K_RQE:_\L96O_+/1;  #=9@  RV\  ,!V  "W>P
MKWX  *9^ 0"??Q  F8 ? ). +0*-?SD%B'U#"8-[2PU^>E,2>GA:%G9W81ES
M=6<<<'1N'VUS=B)J<G\F:'&)*&5PE"MB<* M8&^M+U]OO2]>;]0O7F_M+U]O
M^RU?;_\L8&__+&!O_RQ@;_\L8&__+.M>  #8:0  QW(  +QY  "S?P  JX(
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M*4^ _RE/@/\I3X#_*=MJ  #'=0  NG\  +"'  "FC   G(\  (^1  "&DP4
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M&KJ$  "NCP  HI8  )>;  "+H0  ?Z8  '.K  !GKP  6K0  %.V# !1MQ<
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M B+4I@(AU;D"(=72 B#3ZP(@TO8#']'_!!_1_P0?T?\$']'_!)^;  "4H@
MAZD  'FQ  !MN   8+X  %3#  !)QP  /LL  #70 0 MU08 )=L+ "3>$@ C
MWAP (M\E "'@+@ @X#< '^%  ![A2@ =XE, '.-> !OC:@ :Y'@ &.2( 1?E
MF@$6YJP!%>;  13GW0$3Y>\!$^/Z 1/C^@$3X_H!$^/Z 9:B  ")J0  >[$
M &ZY  !AP   5,8  $C*   ]SP  ,],  "K9   BW@( 'NL* !SL$  ;[1<
M&>T? !?N)@ 5[BT %.\U !/P/0 1\$8 $/%0  _R6P .\FD #?-X  STB@ +
M]9P "O6N  GVP@ )]MD "/7M  CU[0 (]>T "/7M (NI  !]L@  ;[H  &+"
M  !5R0  1\X  #O2   QV   )]T  !_A   9Z   %O@& !3Z#0 2^Q( $/P7
M  [\'0 -_2, #/TI  K^,  (_S@ !O]!  /_3   _U@  /]F  #_=P  _XD
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M0+86IT#$%Z9 V1>C0>T8H$'[&)]!_QF>0?\9G4'_&9U"_QB=0O\8G4+_&/]
M"0#_1@4 _TP% /%/!P#F4 D XT\- -5/%0#,42< Q5$V ;]00P*Z3TX%MDU8
M"+-,80JP2FD-K4EP#ZM(>!&I1W\2IT>&%*5&C16C1I46H46>&)]%IQF>1;(:
MG$6_&II%T1N81>D;ED;X')5&_QN41O\;DT;_&Y-'_QN31_\;DT?_&_]"!0#_
M2@$ \E   .%4 0#95@4 TU4) ,Q5$@##5B( O%<R ;=6/P*R5$H%K5-4"*I1
M70NG4&0.I$YL$*)-<Q*?3'H4G4R!%IM+B1>92I$9ETJ9&I5)HQN32:X=DDF[
M'I!)S!Z.2N4>C4KV'HM+_QZ+2_\=BDO_'8I+_QV*2_\=BDO_'?]%  #_30
MY50  -E9  #/6P, REL& ,1:#P"[6QX M5PN :];.P*J6D8%IEA0"*)660N?
M56 .G%-H$9E2;Q.74785E5!]%Y-0A!F03XT:CDZ6'(Q.GQZ*3JH?B$ZW((=.
MR"&%3N(AA$_S((-/_R"#3_\?@E#_'X)0_QZ"4/\>@E#_'O]'  #S40  WU@
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M)6];_"-O6_\B;UO_(F];_R%O6_\A;UO_(?I/  #A6@  SV(  ,1G  "[:P
MLVP  *QJ! "D:Q( GFPA )EL+P&4:SH#CVE$!HIH30F&9E4-@V5<$(!D8A-]
M8FD5>F)P&'AA>!IU8( =<U^*'W!?E"%N7J C;%ZM)6M>O"9J7M$F:5[L)6I?
M^R1J7_\C:E__(FI?_R)J7_\B:E__(O!2  #=70  RV4  ,!K  "W;@  KV\
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M(EQJ_R)<:O\B7&K_(N-;  #.9@  P&X  +9T  "L>0  HWL  )AY  "0>@L
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M'LIM  "Z>   KX$  *6'  ":BP  CXT  (&.  !TD0  ;I,* &F4%0!FE2(
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M#C2EJ0\SI;L/,Z74#S.D[@\RHOL0,J'_$3*A_Q$RH?\1,J'_$;2"  "HC
MG9(  )*7  "&G   >:$  &VE  !AJ0  5:P  $NO!0!'L!  1; < $2Q)P!"
ML3( 0;([ #^R0P$]LDL!.[)3 CFR6P,WLF0$-;)N!3.R>08QLH<'+[&6""ZR
MI@@MLK@)+++0""RP[ DKK_D**Z[_"RJM_PLJK?\+*JW_"ZV+  "@D@  E9@
M (F=  !]HP  <:@  &2M  !9L0  3;0  $*X   [N@H .+L3 #>\'@ UO"D
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M  S@T@ +W^T #-[W  S=^P ,W?L #-W[ )*?  "%IP  =ZX  &JU  !=O
M4,$  $3%   XR0  +LT  "71   >U0  %MH! !'>!@ 0YPT #N<2  WH&0 ,
MZ"$ "^DI  KJ,0 )ZCL !^M%  7K40 $ZUX  ^MN  'K@   ZI0  .JG  #K
MO   Z](  .OI  #L[P  [.\  .SO (>G  !YKP  :[<  %Z^  !1Q0  0\D
M #?-   MT0  (]8  !O;   3WP  #N,   SN @ *]@H !_8.  7V$@ #]A@
M /4>  #U)0  ]2X  /4W  #V0@  ]DX  /9=  #V;@  ]H$  /:5  #WIP
M][<  /C'  #XT   ^-   /C0 'NO  !MN   8,   %+(  !$S0  -]$  "O7
M   AW   &.   !'D   ,YP  !^\   3Z   !_P,  /\(  #_#0  _A   /X4
M  #_&@  _R$  /\I  #_,P  _SX  /]+  #_6P  _VP  /^   #_D@  _Z$
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M"ZPUU NI-NH,IC;X#:4V_PZC-_\.HC?_#J(W_PZB-_\.HC?_#O\W!P#_.P(
M_T # /)"!0#I0@D Y3\. -@^%@#.0"< QT$V ,)!1 &]04\"N4!9 [8_802T
M/FD&L3UQ!Z\]> BN/'\)K#R&"JH[C0NI.Y4,ISN=#:4[I@VC.K .HCN\#Z [
MS0^>.^80FSSU$9H\_Q&9//\1F#S_$9@\_Q&8//\1F#S_$?\Z 0#_0   [T4
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M&'Y+_!A^2_\7?4O_%WU+_Q9]2_\6?4O_%O]#  #F3   UE,  ,E8  # 60
MNE@! +16"0"L5Q8 IE@E *%8,@&=5SX"F%9(!)5540:25%@(CU)?"HQ29@R*
M46T.B%!T$(5/>Q*#3X03@4Z-%7].EQ=]3J$8>TVN&7I.O1IX3M$:=T[K&G=/
M^AEV3_\9=D__&'9/_Q=V3_\7=D__%_A&  #B4   T%<  ,1<  "[7@  M%T
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M&F5:_QEE6O\995K_&>A/  #360  Q&$  +EF  "P:   IVD  )YE  "79@T
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M&=1<  ##9@  MFX  *QT  "B=P  EG8  (EU  "!=@$ >G</ '9X&P!R>2<
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M%4* J19!@+H60(#2%D%_[19!?OL607W_%D%]_Q9!??\607W_%L)J  "U=0
MJGT  )^"  "2@P  A80  'F%  !JB0  9(H# &",$ !=C1L 6XXG %B.,@!5
MCCL!4XY# E".2@-.C5(%3(U9!DF,8 A'C&@*18MR#$*+?0Y BHD//HJ8$3R*
MIQ([BK@2.HK/$CN(ZQ([A_H3.X;_$SN&_Q,[AO\3.X;_$[QQ  "O>P  I8,
M )F'  ",B   ?XD  '.,  !ED   7),  %>5# !4EA8 4I8B %"7+0!-ES8
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M!":KY ,EJ?4$):C_!26G_P4EI_\%):?_!:>)  ";CP  D90  (29  !XG@
M:Z(  %^F  !3J@  2*T  #VP   TLP, +[4. "VU%@ LM2  *[8I "JV,@ I
MMSH *+=# ">W3  FN%4 )+A? ".X:P BN'@!(+B( 1^XF0$=N:L!'+G  1RX
MWP$<MO(!&[7\ ANT_P(;M/\"&[3_ I^/  "4E0  B)L  'NA  !NI@  8JL
M %:P  !*LP  /[8  #6Y   LO   )+\& !_"#0 =PA0 ',(> !O#)@ :PR\
M&<0X !C$00 7Q$H %L55 !7%80 4QF\ $\9_ !+&D0 1QZ0 $,>Y  _'U  0
MQNX $,3Z !##_P 0P_\ $,/_ )>6  "+G   ?J(  '&I  !DKP  6+0  $NX
M  ! NP  -;X  "O!   CQ0  &\D! !3,!@ 0T L #M$1  W1&0 -T2$ #-$J
M  S1-  +TCX "M))  G350 )TV( "--R  ;4A  %U)@ !-2K  /5P  !U=P
M =7M  '5]@ !U?8  =7V (Z=  " I   <ZL  &:Q  !9N   3+T  #_    T
MPP  *L<  "'*   9S@  $M(   W6 0 )VP4 !MP-  3<$0 #W1@  =X@  #>
M*   WS$  . \  #A1P  XE0  .-C  #C=   Y(@  .2;  #EK@  Y<$  .75
M  #FYP  YN<  .;G (.D  !UK   :+,  %J[  !-P0  0,0  #/(   HS
M']   !?4   0V0  "]T   7A    Y    .4'  #F#0  YQ$  .@6  #I'0
MZB4  .LN  #M.0  [T4  /!3  #Q9   \78  /**  #SG   \ZT  /2[  #T
MR   ],@  /3( '>M  !JM0  7+T  $_$  ! R0  ,\T  "?1   =U@  %-P
M  [@   (XP   >8   #J    [@   .X   #O!   \ H  /$.  #S$@  ]!@
M /8@  #X*@  ^C4  /U#  #^4@  _V,  /]V  #_B0  _YH  /^F  #_L
M_[   /^P /\6(P#_%2$ _Q$A /\-) #_"2L _P8W /\#1 #_ %$ _P!= /\
M: #_ '( _P![ /\ @P#_ (H _P"1 /\ E@#_ )P _P"A /T I@#[ *P ^0"S
M /< NP#U ,4 \P#1 /( Y #Q /$ [P#Z .X _P#N /\ [0#_ .T _P#M /\
M[0#_ /\9( #_&!T _Q4= /\0'P#_#BD _PPT /\*00#_!TT _P59 /\$9 #_
M!&X _P-W /\#@ #_ X< _P.- /T"DP#[ ID ^0*> /<"I #U JH \P&P /$!
MN #O <( [0'/ .L!XP#J >\ Z +[ .<$_P#F!?\ Y@;_ .8&_P#F!O\ Y@;_
M /\<&P#_&QD _Q<8 /\5'0#_$R4 _Q$P /\0/0#_#DD _PQ5 /\+8 #_"VH
M_0MS /L+? #Y"H, ]PJ* /4*D #T"I8 \PJ; /$*H0#O":< [0FN .L)M@#H
M"<  Y@G- .0)X@#B"O  WPO[ -X,_P#<#?\ W W_ -L-_P';#?\!VPW_ ?\?
M%P#_'A, _QL2 /\<&0#_&R( _Q@L /\5. #_$T0 _A)0 /D16P#U$&8 \Q!O
M / 0=P#N$'\ [!"& .H0C #I$)( Z!"8 .8/G@#E#Z4 XP^L .$/M #@#[X
MW@_, -H0X0#5$?  TA+[ ,\2_P'.$_\!S1/_ <T3_P',$_\!S!/_ ?\B$@#_
M(@\ _R$/ /\B% #_(AP _R G /\=,@#X&SX \AE+ .X85@#J%V  YQ9J .06
M<@#B%GH X!:" -X6B #<%H\ VQ:5 -D6FP#6%J( U!:I -(6L0#0%[L SA?)
M ,P8W@#(&>X!Q1K[ <,:_P+!&_\"P!O_ L ;_P+ &_\"P!O_ O\F#@#_)0L
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M"I0V_0J3-_\*DC?_"I(W_PJ2-_\*DC?_"O\S  #V.@  Y#\  -A"  #.0@$
MR3X& ,0[#P"[/AT M3\L +$_.@"M/T4!J3]/ :8^6 *C/5\#H3UG!)\\;06=
M/'0&G#M[!IH[@@>8.XH(ECN3"94ZG J3.J8+D3JR"Y [P R..]4,C#SL#8H\
M^PV)//\-B3S_#(@\_PR(//\,B#S_#/\W  #J/P  W$4  ,Y)  #%20  OT8"
M +I## "S1!D K44G *A&-0"D14$!H$5+ IU$4P*:0UL#F$-B!99":0:407 '
MDD%V")! ?@F.0(8*C4"."XM F R)0*(-AT"N#H5 O ^$0,\/@D'I#X%!^0^
M0?\/@$+_#H!"_PZ 0O\.@$+_#OH[  #E1   TTL  ,=.  "^3P  N$P  +))
M"0"K214 I4LC *!+,0"<2ST!F$I' I5)3P.225<$D$A>!8Y'90:+1VL'B49R
M"8A&>0J&18(+A$6*#8)%E Z 1)\/?D2K$'Q%N1%[1<L1>D7F$7E&]Q%X1O\0
M>$;_$'A&_P]X1O\/>$;_#_ _  #?20  S4\  ,%3  "X5   L5(  *M.!0"D
M3A$ GD\@ )E0+0"54#D!DD]# 8Y.3 .+35,$B4U:!89,80:$2V@(@DMN"8!*
M=@M^2GX,?$F'#GI)D0]X29P0=DFH$G1)MA)S2<@3<DKC$W%*]1)Q2O\1<4O_
M$7%+_Q!Q2_\0<4O_$.Q#  #93   R%,  +U7  "T6   K%<  *52 0">4P\
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M$MQ0  #'60  NF   *]D  "D90  F60  )!@  "(808 @F(1 'YC'0!Z8RH
M=F,T 7-B/0%O8D8";&%-!&IA5 5G8%H'96!A"&-?:0IA7W$,7UYZ#EU>A1!;
M7I$265V>%%A=K!577;T65EW5%E9=[A577?P45UW_$U==_Q)77?\25UW_$M93
M  #$7   MV,  *QH  "@:   E6<  (IC  "#90( ?68/ 'AF&@!T9R< <6<R
M &YG.P%K9D,":&9+ V5E4@5C95D&861?"%YD9PI<8V\,6F-X#EAC@Q!68H\2
M5&*<$U-BJA528KL546+2%5%A[1528?L44F'_$U-A_Q)38?\24V'_$M%6  #
M7P  LV8  *EK  "<:P  D&H  (5G  !]:0  =VH- '-K%P!O:R0 ;&PO &EL
M. %F:T$"8VM) V%K4 1>:E<&7&I=!UII90E8:6T+56AV#5-H@0]19XT13V>:
M$DYGJ11-9[D43&?/%$QFZQ1-9OL336;_$DYE_Q).9?\23F7_$LQ:  "\8P
ML&H  *5O  "8;@  C&T  (!L  !W;0  <6X+ &UO% !I<"$ 9G$L &1Q-@%A
M<3X!7G%& EQP30-9<%0%5W!;!E5O8@A3;VH*4&YS#$YN?@Y,;8H02FV8$4EL
MIQ)(;+@31VS-$T=LZA-(:_H22&O_$DAJ_Q%(:O\12&K_$<=>  "X9P  K&X
M *%R  "3<@  AW$  'IQ  !Q<@  :W0' &9U$0!C=AT 8'<H %YW,P!;>#P!
M67=# E9W2P-4=U($4G99!5!V8 =.=6@(2W5Q"DET? Q'=(@.17.6#T-SI1!"
M<[8107/+$4)RZ!%"<O@10G'_$$-P_Q!#</\00W#_$,%C  "S;   J',  )MV
M  ".=0  @78  '5V  !I>   8WH" %Y\#@!<?1D 67XD %=_+P!5?S@!4W]
M 5!_2 ).?D\#3'Y6!$I^705(?64&1GUN"$-\>0I!?(8+/WN4#3Y[HPX\>[,.
M/'O(#CQZY@X\>?<./'C_#CQX_PX]=_\./7?_#KQH  "O<@  I'D  )9Z  "(
M>@  ?'H  '!\  !C?P  7((  %>$"P!3A10 488@ $^&*@!.AS0 3(<\ 4J'
M1 %(ATL"1H=3 D2&6@-"AF($0(9L!CZ%=@<[A8,(.861"CB$H LVA+$+-H3&
M"S:#Y LV@O8+-H'_##: _PPV@/\,-H#_#+9O  "J>   GW\  )!^  "#?P
M=X   &N"  !>AP  58H  $Z,!@!*CA  2(\: $>/)0!%D"\ 1) X $*00 !
MD$<!/Y!/ 3V05@([D%\".9!H S>/<P0UCX %,X^.!C&/G@<PCJ\'+X[#!R^.
MX0<OC/0(+XO_""^*_P@OBO\)+XK_";!V  "E?P  F(0  (J$  !]A0  <(<
M &6*  !:C@  3Y(  $:5  !!F P /I@4 #V9'P [F2@ .IHQ #F:.@ WFD(
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M !.N_P$3KO\!$Z[_ 9J-  "0D@  A)<  '6:  !HGP  6Z,  %"H  !%K
M.[   #&R   GM0  (+@  !BZ!P 4O X $[P5 !*\'@ 1O28 $;TN !"]-P 0
MOD$ #KY,  Z^5P -OF4 #+]T  N_A@ *OID "+ZL  >^P@ 'OM\ "+[P  B]
M^@ (O?P "+W\ ).4  "'F0  >I\  &RE  !@J@  4Z\  $>S   \M@  ,;@
M ">[   ?O@  %\$  !'$ 0 ,R @ ",D.  ?)%  &R1P !<DD  3*+  #RC8
M LI   #+3   RUD  ,MH  #+>0  S(P  ,N?  #+LP  R\@  ,SB  #,[P
MS/$  ,SQ (J:  !\H0  ;Z<  &*M  !5LP  2+@  #N[   PO@  )L$  !W$
M   5R   #\L   K.   $T@(  -,*  #3#P  U!0  -4:  #6(@  URH  -DT
M  #:/P  W$L  -Q:  #=:@  W7T  -V1  #=I   WK8  -[(  #>W@  WN(
M -[B '^B  !QJ0  9+   %:W  !)O   /,   "_$   DQP  &\L  !//   -
MT@  !]8   #;    W@   -\#  #@"0  X0X  .(2  #C%P  Y1X  .8G  #H
M,0  ZCT  .Q+  #L6@  [6P  .Z   #NE   [J4  .ZT  #NP@  [L8  .[&
M '2J  !FL@  6+D  $O    ]Q0  +\D  "3-   9T0  $=8   O;   #W@
M .$   #E    Z    .D   #J    ZP8  .T+  #O#P  \!,  /(:  #T(P
M]RX  /D[  #[2@  _%L  /UM  #]@   _I,  /ZB  #^K0  _J\  /ZO /\0
M'P#_#AT _PH= /\!( #_ "@ _P U /\ 00#_ $X _P!: /\ 90#_ &X _P!W
M /\ ?P#^ (8 _ ", /L D@#Y )< ^ "< /< H@#V *< ]0"M /, M0#R +T
M\0#) .\ W #N .L [0#W .P _P#K /\ Z@#_ .H _P#J /\ Z@#_ /\3' #_
M$1D _PT9 /\&' #_ R4 _P Q /\ /@#_ $H _P!6 /\ 80#_ &L _0!S /H
M>P#W (, ]0") /0 CP#R )0 \0"9 /  GP#N *0 [0"K .P L@#J +H Z #&
M .< U@#E .@ Y #U ., _@#B /\ X0#_ .$ _P#A /\ X0#_ /\5& #_$Q0
M_P\4 /\-&0#_"R( _P@M /\$.0#_ 48 _P!1 /X 7 #Z &8 ]@!O /( =P#O
M 'X [0"% .L BP#J )$ Z "6 .< G #F *$ Y "H ., KP#A +@ WP## -T
MT0#; .8 V0#S -< _0#5 O\ U +_ -0#_P#4 _\ U /_ /\8$P#_%1  _Q(/
M /\2%0#_$1T _PXH /\,- #_"D$ ^0A, /4&5P#Q!F$ [09J .D%<@#F!7H
MY 6! .(%AP#@!HT WP:2 -T&F #;!IX V0:E -<&K0#4!K4 T@;  - 'SP#.
M".4 S GT ,H+_P#(#/\ QPS_ ,<,_P#&#/\ Q@S_ /\;#@#_&0P _Q@- /\8
M$0#_%Q@ _Q0B /L1+@#S$#H [0Y& .@-4@#E#5P X0UE -X-;0#;#74 V U\
M -4-@@#3#8D T0V/ - -E0#.#9P S0ZC ,L.JP#)#K0 R [  ,8.SP##$.8
MP!'U +T2_P"\$O\ NQ+_ +H2_P&Z$O\!NA+_ ?\?"@#_' 0 _Q\( /\?#0#_
M'1( ^!H; .X6)@#F%#, X!,_ -H32P#4$U8 T!-? ,X4: #+%&\ R11W ,<5
M?0#&%80 Q!6* ,,5D0#!%I@ P!:? +X6IP"\%[  NQ>\ +D7RP"W&.( LQGR
M ;$:_P&O&_\!KAO_ :X;_P&M&_\!K1O_ ?\B! #_(@  _R4" /PD!P#W(0P
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M!X,W_P>"-_\'@C?_!_0R  #C.P  TD$  ,9$  "]0P  MS\  +$["0"J.Q0
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M"^!$  #+30  O5(  +)6  "F50  G%(  )5.  ".3@D B4\4 (50( "!4"P
M?E W 'M00 %X4$@!=4]/ G-.50-Q3EP$;TYC!6U-:@9K37(':4U["&=-A0IE
M39$+9$R=#&)-JPUA3;L.8$W1#F!-[ Y@3?L-8$W_#&!-_PM@3?\+8$W_"]Q'
M  #'4   N58  *Y9  "B6   F%8  )!1  ")4@8 @U,1 ']3'0![5"D >%0T
M '54/0%R4T4!<%-, FU24P)K4ED#:5)@!&=19P9E46\'8U%X"&)1@PI@48\+
M7E";#5U0J0Y;4;D.6U'.#UI1Z@Y;4?H-6U'_#%M1_PQ;4?\+6U'_"]9*  ##
M4P  MED  *M<  ">6@  DUD  (M4  "$5@, ?E80 'I7&@!V5R8 <U@Q '!7
M.@!M5T(!:E=) FA64 )F5E<#9%9>!&)5905@56T'7E5V"%U5@0I;58T+652:
M#5A4IPY65;@/5E7,#U95Z0Y65?D-5E7_#5=4_PQ75/\,5U3_#-%-  # 5@
MLUP  *=>  ":70  CUP  (98  !_60  >5H- '1;%P!Q6R, ;ELN &M;-P!H
M6T !95M' 6-:3@)A6E4#7UI<!%U:8P5<6FL&6EET"%A9?PI668L+5%F8#5-8
MI@Y26;8.45G*#U%9YPY16/@-4EC_#5)8_PQ26/\,4EC_#,U1  "\60  L%\
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M#$)GX@Q"9O4,0V;_"T-E_PM#9?\+0V7_"[]<  "Q9   IFH  )9I  "):0
M?6D  '%I  !G:@  8FP! %UM#0!9;A8 5V\A %5P*P!3<#4 47 ] %!P10%.
M<$P!3'!3 DIP6@-(<&($1F]K!41O=09";X('0&Z/"3]NG@H];J\*/6[""CQN
MX H];?0*/6S_"CUK_PH^:_\*/FO_"KI@  "M:0  H&X  )%M  "$;0  >&T
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M!"F$_P0IA/\$*83_!*IT  ">>P  CGH  (!Z  !T>P  :'X  %V!  !2A0
M28D  $&,   YD 4 -9$/ #.2%P RDB$ ,9(I #"3,@ NDSH +9-! "R32@ K
ME%( *I1< "B49P GE',!)92" 224DP$BDZ0!(9.W 2"3SP$ADNP!()#Z B"/
M_P(@C_\"((__ J1\  "7@   AW\  'N   !N@@  8H4  %>)  !-C@  0I(
M #J6   RF0  *IP) "B=$0 FG1D )9TB "2>*@ CGC( (IXZ "&>0@ @GDL
M'Y]5 !Z?8  <GVT &Y]\ !J?C0 8GY\ %Y^R !:?R0 6GN@ %ISW !:;_P$7
MF_\!%YO_ 9V#  "/A@  @H8  '2'  !GBP  6X\  %"3  !&F   /)P  #.@
M   KHP  (Z8  !RH"P :J1$ &*D8 !>I(0 6JBD %:HQ !2J.0 3JD, $ZM-
M !*K6  1JV4 $*MT  ZKA@ .JYD #:NL  RKP0 ,JM\ #*GR  VH_  -J/\
M#:C_ ):*  ")C   >HT  &R1  !@E0  5)H  $F?   _HP  -:<  "NJ   C
MK@  &[   !2S 0 /M0H #;80  RV%@ +MA\ "K8G  FV+P (MCD ![=#  :W
M3P $MUL  [=J  *W>P  MXX  +>A  "VM   MLL  +;E  "U\0  M?<  +7W
M (^1  "!E   <I<  &6<  !8H0  3*8  $&K   WKP  ++(  ".U   :N
M$[L   Z]   )P 4  \$-  #!$0  P1<  ,(>  #")@  PB\  ,,Y  #$1
MQ%   ,1>  #%;P  Q8$  ,65  #%J   Q;P  ,31  #$Y@  Q.X  ,3N (:8
M  !YG@  :Z,  %VI  !0K@  1+,  #>V   LN0  (KP  !F_   1P@  #,4
M  ;(    RP   ,P'  #,#0  S1$  ,T6  #.'0  SR0  - M  #2.   U$0
M -12  #580  U7,  -:'  #6FP  UJT  ->_  #8S@  V-T  -C= 'N@  !N
MI@  8*T  %.S  !%N   .+P  "N_   AP@  %\8  !#)   *S    M    #4
M    UP   -@   #:!0  VPL  -P.  #>$P  WQD  .$A  #C*@  Y38  .=#
M  #G4P  Z&0  .EW  #IC   ZI\  .JN  #JN@  ZL,  .K# '"H  !BKP
M5;8  $>\   YP   +,0  "#(   6S   #M    ?4    V0   -T   #A
MXP   .0   #F    YP$  .D'  #K#   [!   .X5  #P'0  \R<  /8S  #W
M0P  ^%0  /EF  #Y>@  ^HX  /J>  #[J0  ^[   /NP /\+&P#_!QD _P 9
M /\ ' #_ "4 _P R /\ /P#_ $L _P!7 /\ 8@#_ &L _P!S /T >P#[ ((
M^@"( /@ C0#W )( ]@"8 /4 G0#T *( \P"I /$ L #O +@ [@## .P T0#K
M .8 Z0#S .@ _@#H /\ Z #_ .@ _P#H /\ Z #_ /\.& #_"A4 _P$4 /\
M& #_ "( _P N /\ .P#_ $< _P!3 /T 7@#Z &< ]P!O /4 =P#S 'X \@"$
M /  B0#O (\ [@"4 .P F@#K )\ Z0"E .@ K #F +0 Y "_ ., S #A .(
MWP#P -X ^P#> /\ W0#_ -T _P#< /\ W #_ /\0$P#_#1$ _P80 /\"%0#_
M !X _P I /\ -@#_ $( ^@!. /0 60#Q &( [@!K .P <@#J 'D Z !_ .<
MA0#E (L Y "0 .( E@#A )P WP"B -T J0#: +$ V "[ -4 R #2 -T T0#M
M -  ^0#/ /\ S@#_ ,T _P#- /\ S0#_ /\1#P#_#@T _PP- /\+$@#_!QD
M_P(D /\ , #V #P [P!) .H 4P#G %T Y !F .$ ;0#? '0 W0![ -L @0#9
M (8 U@", -0 D@#2 )@ T "> ,X I@#, *X R@"X ,@ Q #& -< Q0#J ,,
M]P#" /\ P0'_ , "_P#  O\ P +_ /\4"P#_$ 8 _Q ) /\0#@#_#A0 _PH>
M /4&*0#K!#8 XP-" -\#3@#;!%< U@1@ -,$: #0!&\ S@5V ,P%? #*!8(
MR06( ,<%C@#&!90 Q 6; ,(%HP# !JL O@:U +T&P@"["-0 N@GI +<+^ "U
M#/\ M S_ +0,_P"T#/\ M S_ /\7! #_%   _Q8# /\4"0#_$0X \@X5 .@,
M(0#>"BX U@L[ - ,1P#,#%$ R0Q: ,8-8@#$#6H P@UQ , -=P"_#7T O0Z#
M +P.B@"Z#I$ N0Z8 +<.H "V#JD M ^T +(/P0"Q$-0 KA'K *L2^@"I$O\
MJ!/_ *<3_P"G$_\ IQ/_ /\:  #_&P  ^1L  .L9  #E% 8 Y1 . -D.%P#/
M$28 R!(T ,030 "_%$L O!14 +D570"W%60 M15K +05<0"R%7@ L19^ *\6
MA0"N%HP K!:4 *L7G "I%Z8 IQBP *88O0"D&,\ HAKG )\:]P"=&_\!G!O_
M 9P;_P&;&_\!FQO_ ?\=  #W(0  Z"0  -TE  #4(0$ SQL( ,H7$0#"&B
MO!PM +<=.@"S'D4 L!Y/ *T>5P"K'E\ J1]F *@?; "F'W, I1]Y *,?@ "B
M'X< H""/ )\@F "=(*( FR"L 9HAN0&8(<H!EB+D 90C]0&2(_\!D2/_ 9 C
M_P&0(_\!D"/_ ?\B  #K*0  W2X  ,\O  #'+0  P2<# +TB#0"V(QH L"4H
M *PF- "H)D  I2=) *(G4@"@)UH GB=A )PG9P";)VT F2=T )@G>P&6)X(!
ME2>+ 9,GE &1*)X!D"BI 8XHM0*-*<8"BRG? HDJ\@*'*O\"ABK_ H8J_P*&
M*O\"ABK_ O0H  #C,0  T38  ,4X  "\-@  MC   +(K"0"K+!0 IBTB *(N
M+P">+CH FRY$ )@O30"6+U4 E"Y< )(N8@"0+FD!CRYO 8TN=@&,+GX!BBZ&
M H@NCP*'+IH"A2^E X,OL@."+\(#@3#: W\P[P-],?X#?3'_ WPQ_P-\,?\#
M?#'_ ^TO  #;-P  R3T  +X^  "S/   K#@  *<S! "B,A$ G30= )DU*@"5
M-34 DC5  (\U20"--5  BS57 (DU7@&'-60!A31K 80T<@*"-'D"@#2" GXT
MBP-]-)8#>S6A!'DUK@1X-;X%=S;4!78V[05T-_P%=#?_!'0W_P1T-_\$=#?_
M!.<U  #2/0  PT(  +A$  "L0@  I#X  )\Y  ":. X E#H9 ) Z)@"-.S$
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M!F)#IP=A1+8(8$3*"&!$Y@A?1?@'7T7_!V!%_P9@1/\&8$3_!M9!  ##20
MMDX  *=/  ";30  DDL  (Q'  "%1P0 @$<0 'Q(&@!X2"8 =4DP '-).@!P
M24( ;DE) 6Q(4 %J2%8!:$A= F9(9 )E2&P#8TAU!&%'?P5@1XH&7DB7!UU(
MI0A;2+0(6TC'"5I(Y A:2?8(6DG_!UI(_P9:2/\&6DC_!M%%  "_3   LE(
M *-1  "74   C4X  (9*  " 2@$ >DL. '9,%P!R3", ;TPM &U--@!J3#\
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M"4M4WPE,5/,(3%/_!TQ3_P=-4_\&35/_!L5.  "V5@  IUH  )A9  "+6
M@5<  '=4  !P50  :E8& &97$ !B5QH 8%@D %U8+@!;63< 65D_ %=91@!6
M64T!5%E4 5-96P)166,"3UAL TY8=@1,6((%2EB/!DE8G@=(6*X(1UC "$=8
MW0A'6/((1U?_!TA7_P=(5_\&2%?_!L%1  "R60  HUP  )1;  "'6P  ?5H
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M!3AF_P4X9O\%.&;_!;1>  "G90  E64  (9D  !Z90  ;V4  &1F  !9:
M4FH  $UL! !);@X 1VX6 $5O( !$<"D 0G R $%P.@! <4( /W%) #UQ40 \
M<5D!.G%B 3AQ; (V<'@"-7"& S-PE0,R<*8$,7"X!#!PT 0Q;^P$,6[[!#%M
M_P0Q;/\$,6S_!*]D  "A:0  CV@  (%H  !U:0  :VD  &!K  !5;@  37$
M $9S  !"=0L /W82 #UW'  \=R4 .G@M #EX-0 X>3T -WE% #9Y30 U>54
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M 9UW  ",=@  ?78  ')W  !E>0  6GP  %"   !&A   /(D  #2,   MD
M)9," !^5#  =EA( ')8: !N7(@ :ERH &9<R !B8.@ 7F$, %IA- !686  4
MF&0 $YAS !&8A  0F)8 $)BI  Z8OP .E]T #Y;R !"5_  0E/\ $)3_ )5]
M  "%?   >'P  &M^  !?@0  5(8  $J*  ! CP  -I,  "V7   FF@  'IT
M !>@ P 2H@P $*,2 !"C&0 /HR$ #J0I  ZD,0 -I#H #*1%  ND4  *I%P
M":1J  >D>P &HXX !*.A  *CM  #HLL  Z+F  .A\P #H?L  Z'[ (V#  !_
M@@  <80  &2'  !8C   39$  $*6   XF@  +YX  ":B   >I0  %Z@  !&K
M   ,K@< !Z\-  .O$@ "KQD  :\A  "O*0  L#(  + \  "P1P  L%,  +!A
M  "P<0  L(,  *^7  "OJ@  K[\  *[9  "NZP  KO0  *[T (>)  !XB@
M:HX  %V3  !1F   19T  #NB   PI@  )ZH  !ZN   6L0  $+0   NV   %
MN0,  +H*  "Z#@  NA,  +L9  "[(0  O"@  +PQ  "]/   OD@  +Y6  "^
M90  OG<  +Z,  "^GP  O;,  +['  "^W@  O>L  +WK '^2  !PE0  8IH
M %6?  !)I0  /:L  #*O   HM   'K8  !6Y   .O   ";\   +"    Q
M ,4$  #&"@  Q@X  ,<2  #(&   R1\  ,HG  #,,   SCP  ,Y)  #/60
MSVH  ,]^  #/DP  SZ8  ,^X  #/R   S]L  ,_; '><  !HH0  6Z<  $ZN
M  !!M   -+<  "BZ   =O0  $\    W$   &QP   ,H   #.    T    -$
M  #2 @  TP@  -4,  #6$   V14  -L<  #=)   X"\  .(\  #C2P  Y%P
M .1O  #E@P  Y9@  .6I  #EM@  Y<,  .7# &RE  !?K   4;(  $2Y   U
MO   *,   !S$   2R   #,L   //    TP   -@   #<    WP   -\   #A
M    XP   .0#  #F"   Z T  .D1  #L&   [B(  /$N  #S/   ]$T  /5?
M  #V<P  ]X<  />9  #XI0  ^+   /BP /\#%P#_ !4 _P 5 /\ & #_ ",
M_P O /\ / #_ $@ _P!4 /\ 7@#_ &< _0!O /L =@#Y 'T ^ "# /8 B #U
M (X ] "3 /( F #Q )X \ "D .X JP#M +, ZP"] .H RP#H .$ YP#Q .8
M_0#E /\ Y #_ .0 _P#D /\ Y #_ /\'$P#_ !$ _P 1 /\ %0#_ !\ _P K
M /\ -P#_ $0 _@!/ /H 6@#W &, ] !K /( <@#P 'D [P!_ .T A #K (H
MZ@"/ .@ E #G )H Y0"@ .0 IP#B *\ X "Y -X Q@#< -H V@#L -@ ^0#6
M /\ U@#_ -< _P#8 /\ V #_ /\*$ #_ PX _P - /\ $@#_ !H _P F /P
M,@#W #\ ] !* /$ 50#M %X Z@!F .@ ;@#E '0 XP!Z .( @ #@ (4 W@"+
M -P D #; )8 V "< -4 HP#3 *L T0"U ,X P0#, -$ RP#G ,D ]0#( /\
MR #_ ,@ _P#( /\ R #_ /\,# #_!@@ _P(* /\ #P#_ !4 _  @ /$ + #L
M #D Z0!% .4 3P#A %D W@!A -L : #7 &\ U !U -( >P#0 (  S@"& ,P
MC #+ )( R0"8 ,< H #% *@ PP"Q ,$ O "_ ,L O0#C +P \@"[ /T NP#_
M +H _P"Z /\ N@#_ /\.!0#_"0  _PD% /\&"P#_ 1  \  9 .8 )0#A #(
MW  _ -8 20#1 %, S@!; ,L 8P#( &H Q@!P ,4 =@## 'L P0"! ,  AP"^
M (X O "4 +L G "Y *0 MP"N +4 N0"S ,@ L0#? + ![P"O ?L K@+_ *T#
M_P"M _\ K0/_ /\0  #_#@  _PT  /8+ P#R!PH X@$1 -L"'0#2 RL S ,W
M ,@$0P#$!$T P016 +X%70"\!60 N@5K +@%<0"W!78 M05\ +,&@P"R!HD
ML :1 *\'F0"M!Z$ JP>K *D(MP"H"<8 I@K= *4+\ "C#/T H@W_ *$-_P"A
M#?\ H W_ /\1  #\$@  [!,  .(3  #;#P, U@D+ ,X(% #&"B( P PP +P-
M/ "X#48 M0U/ +(.5P"P#E\ K@YE *T.:P"K#G$ J@YX *@.?@"G#X4 I0^-
M *0/E@"B$)\ H!"I )\0M0"=$<4 FQ'> )D2\0"7$_\ EA3_ )44_P"5%/\
ME!3_ /\5  #M&P  X!\  -(?  #)&P  Q!0% ,$0#@"Z$AL M!,I + 4-0"L
M%4  J15) *854@"D%ED HA9@ *$69@"?%FP GA9R )P6>0";%X  F1>( )@7
MD0"6&)L E!BF ),9L@"1&<$ D!K8 (T;[@"+'/T BAS_ (H<_P")'/\ B1S_
M /0=  #D)0  TRD  ,<J  "\)@  MB   +09"P"N&A4 J!PC *0=+P"A'CH
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M 7,OJ )Q+[8"<##) F\PY0)N,?<";3'_ FTQ_P)M,?\";3'_ M\R  #).0
MNSX  *P]  "A.@  FC<  )4S  "0,0H C#$4 (<R( "$,RL @3,U '\S/@!]
M,T8 >S-- 'DS5 !W,UH =C-A '0S9P%R-&\!<31W 6\T@0%N-(P";#28 FHU
MI0)I-;,#:#7& V<VX@-F-O4#9C;_ F8V_P)F-O\"9C;_ M@W  #$/@  M4(
M *9!  ";/P  DSP  (TX  "(-@< A#<1 ( W' !\."< >C@Q '<Y.@!U.4(
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M!%1#V@140_$$5$/^ U1#_P-40_\#5$/_ \A"  "X20  ITL  )A*  "-20
M@T<  'U#  !V0P  <40* &U$$@!J11T 9T4G &1%, !B13@ 8$4_ %]%1P!=
M14T 6T54 %I&6P%91F,!5T9L 59&=@)41H$#4T:. U)'G 101ZL$4$>]!$]'
MU@5/1^\$3T?]!$]'_P-/1_\#4$?_ \1%  "U30  HTT  )5,  ")2P  ?TH
M 'A&  !Q1P  ;$<' &A($ !D2!H 84DD %])+0!=234 6TD] %E)1 !724H
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M T)2_P-"4O\#0E'_ [I/  "J5   F%0  (E4  !]4P  <U,  &E1  !B4@
M7%,  %A4"@!451( 4E4; $]6) !.5BT 3%<U $M7/ !*5T0 2%=+ $=84@!&
M6%H!1%AC 4-8;0%!6'D"0%B& CY8E0,]6*4#/%BW!#Q8S00\5^H#/%?Z SU6
M_P,]5O\#/5;_ [93  "E5P  E%<  (56  !Y5@  ;U8  &55  !<5@  5U@
M %)9!P!.6A  3%H8 $I;(0!(7"H 1UPR $5<.@!$74$ 0UU( $)=4 ! 75@
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M JEA  "58   A&   '=@  !L80  8F$  %AC  !.9@  1V@  $!K   Z;@4
M-F\. #1P%0 S<!X ,G$F #!Q+@ O<34 +G(] "UR10 L<DT *W)7 "IR80 I
M<FT )W)[ "9RBP D<IP!(W*N 2-RPP$C<>(!(W#T 2-O_P$C;O\!(V[_ :%E
M  ".9   ?V0  ')D  !H90  7F8  %1I  !);   0F\  #MR   T=0  +G@*
M "MY$0 J>1@ *7HA "=Z*  F>C  )7LX "1[0  C>T@ (GM2 "%[7  @>V@
M'WQV !U\A@ <>Y@ &WNJ !I[OP :>]X &GGR !MX_@ ;=_\!&W?_ 9EI  "(
M:0  >6D  &UI  !C:@  66P  $]O  !%<P  /7<  #5Z   N?0  )X$# "*#
M#0 @A!( 'X0: !V$(@ <A2H &X4Q !J%.0 9A4( &(9, !>&5@ 6AF, %89Q
M !2&@0 2AI, $8:F !&%NP 0A=8 $8/O !&"^P 2@O\ $H'_ )%N  "!;0
M=&X  &EN  !=<   4W,  $EW  ! ?   -X   "^#   GAP  (8H  !J-!@ 5
MCPT $Y 3 !*0&@ 2D"( $9 J !"1,@ 0D3L #Y%$  Z13P -D5P #)%J  N1
M>@ *D8T ")"?  >0LP 'C\D !X_F  >.]  (C?P "(W_ (ES  ![<P  ;W,
M &-U  !7>   37T  $.!   YA@  ,(H  "B.   AD0  &I4  !.7   .F@@
M"YP.  F<$P (G!H !YPB  :<*@ $G#,  YP]  *=2   G50  )UB  "<<@
MG(0  )R7  ";J@  F[\  )K;  ":[   FO4  )GX ()Y  !V>0  :'H  %Q^
M  !1@@  1H<  #R,   RD0  *94  "&9   9G0  $J    ZC   )I@4  Z<,
M  "G$   IQ4  *@<  "H(P  J"L  *DT  "I/P  J4L  *E9  "I:   J7H
M *F.  "IH0  J+4  *C+  "GY   I^\  *?S 'V   !O@0  880  %6)  !)
MC@  /I0  #29   JG@  (:(  !FF   2J0  #:P   >O    L@   +,'  "S
M#   LQ   +05  "T&P  M2(  +8K  "W-0  MT   +A.  "X70  N&X  +B"
M  "XEP  N*H  +>^  "WT@  M^8  +?J ':(  !GBP  6I   $Z6  !"G
M-Z(  "RG   BJP  &:\  !&S   +M@  !+D   "\    O@   +X   "_!@
MP L  ,$/  #"$P  PQD  ,0@  #%*0  QS0  ,A"  #)40  R6(  ,EU  #)
MB@  R9\  ,JQ  #*P0  R=$  ,G9 &Z3  !@F   4YX  $:D   ZJP  +[
M "2U   9N   $+P   J_   !P0   ,0   #(    R@   ,H   #,    S0,
M ,X(  #0#0  T1   -,6  #6'@  VB@  -TT  #>0P  WU0  -]G  #@?
MX)$  ."D  #@L@  X+X  .## &:?  !9I@  3*T  #^T   RN   )+P  !B_
M   0PP  ",<   #*    S0   -$   #5    V    -D   #;    W0   -\
M  #A!   XPH  .4.  #G$P  ZAP  .TG  #P-0  \48  /)8  #S:P  \X
M /24  #THP  ]*X  /2R /\ $P#_ !$ _P 1 /\ %0#_ !\ _P L /\ .0#_
M $4 _P!0 /\ 6@#^ &, ^P!K /D <@#W '@ ]0!^ /0 A #R (D \0". /
MDP#N )D [0"? .P I@#J *X Z "X .8 Q0#E -L XP#M .( ^P#B /\ X0#_
M .$ _P#A /\ X0#_ /\ $ #_  X _P - /\ $@#_ !L _P H /\ - #^ $$
M^P!, /< 5@#T %\ \0!F .\ ;0#L '0 Z@!Z .D ?P#G (4 Y@"* .4 CP#C
M )4 X0"; .  H@#> *H VP"T -D P #6 -  TP#H -( ]P#1 /\ T0#_ -
M_P#0 /\ T #_ /\ #0#_  D _P * /\ #P#_ !8 ^P B /< +P#T #L \ !'
M .T 40#I %H Y0!B .( :0#@ &\ W@!U -P >@#: (  V "% -4 BP#3 )$
MT0"7 ,\ G@#- *8 RP"O ,D N@#' ,D Q0#B ,0 \@## /X P@#_ ,$ _P#"
M /\ P@#_ /\#!@#_  $ _P & /\ # #Y !$ \0 = .L *0#G #8 XP!! -\
M2P#; %0 U0!< -( 8P#/ &H S0!P ,L =0#) 'L R "  ,8 A@#% (P PP"3
M ,$ F@"_ *( O0"K +L M@"Y ,0 MP#: +8 [0"T /H M #_ +0 _P"T /\
MM #_ /\$  #_    _P   /\ !@#L  T Y0 6 -X (@#7 "\ T0 [ ,T 10#*
M $X Q@!7 ,0 7@#! &0 OP!J +T < "\ '4 N@![ +D @0"W (< M0". +,
ME0"R )X L "G *X L@"L +\ J@#1 *@ Z "H /< IP#_ *< _P"F /\ I@#_
M /\&  #_!0  \0,  .@   #A  < U0 0 ,T &P#' "< PP S +\ /@"\ $@
MN0!1 +8 6 "T %\ L@!E +  :@"O '  K0!V *P ? "J (( J0") *< D0"E
M )H HP"D *$ K@"@ +L G@'- )T"Y@"<!/0 FP3_ )H%_P":!?\ F07_ /\*
M  #Q#@  Y!   -D/  #."P  R ,+ ,( $P"\ A\ MP,L +,$-P"P!4( K09*
M *H&4@"H!UD I@=? *4'90"C!VL H@AQ * (=P"?"'X G0B% )L)C@":"9<
MF JA )8*K "5"[H DPO, )(,Y0"0#?8 CP[_ (X._P".#O\ C0[_ /81  #F
M%P  UAL  ,<9  "^%0  N1   +<*#0"Q"Q< K TD *@., "E#CL H@Y$ )\/
M3 "=#U, FP]: )H/8 "8$&8 EQ!L )40<@"3$'D DA"! ) 0B@"/$90 C1&?
M (L1J@"*$K@ B!++ (83Y@"%%/< @Q7_ (,5_P""%?\ @A7_ .T:  #<(0
MRB4  +LB  "Q'P  JQH  *D4!@"E$A$ H!0> )P5*@"9%34 EA8^ )061P"2
M%DX D!95 (X76P",%V$ BQ=G (D7;0"(%W0 AAA\ (48A@"#&9  @1F; ( :
MIP!^&K4 ?1O' 'P<X@!Z'?4 >1W_ '@=_P!X'?\ >!W_ .4B  #0*0  ORP
M + J  "G)P  H",  )T?  ":&@X E1P8 )$=) ".'B\ C!XY (D>00"''TD
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M 6$PU0%@,.\!7S#] 5\P_P%?,/\!7S#_ <TT  "\.P  J3H  )LZ  "0.
MB34  (,R  !_, $ >R\. '<P%@!T,"$ <3$K &\Q- !M,3P :S%# &HQ2@!H
M,E  9S)7 &4R70!D,F4 8C)M &$S=P!?,X(!7C.. 5TTG %;-*H!6C6[ 5HU
MT@%9->T!637\ 5@U_P%8-?\!637_ <@X  "W/@  I#X  )8]  "+/   @SH
M 'TW  !X-   =#0+ ' U$P!M-1T :C4G &@V, !F-C@ 9#8_ &,V1@!A-DT
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M DE!_P))0?\!24'_ ;U#  "J10  F$4  (I%  !_10  =D,  &]   !H0
M8T$! %]!#0!<010 64(= %=")@!50BX 4T(V %%"/0!/0D, 3T-+ $Y#4@!-
M1%H 3$1C $I$;0%)17@!2$6% 4=%E %%1:,"14:T D1&R0)$1N<"1$7X D1%
M_P)%1?\"147_ ;I&  "F2   E$@  (9(  ![1P  <D8  &I"  !C0P  7D0
M %I%"P!611( 5$8; %%&(P!/1BL 3D8S $Q'.@!+1T$ 2D=) $E(4 !(2%@
M1TAA $9):P!$278!0TF# 4))D@%!2:("0$FS C]*QP(_2N4"/TGW D!)_P)
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M :Y/  "93P  B4\  'M/  !P3P  9D\  %Q.  !43P  3U$  $I2 0!&4PP
M0U02 $%4&P! 52, /E4K #U6,@ \5CH .U9! #I620 Y5U$ .%=: #978P U
M5V\ -%=\ 3-7C $Q5YP!,%>M 3!7P@$P5^ !,%;T 3%6_P$Q5?\!,57_ :A2
M  "54@  A%(  '=2  !L4@  8E(  %A3  !/5   258  $17  ! 60@ /5H0
M #M:%P Y6R  .%LG #=<+P V7#8 -5P^ #1<1@ S74X ,5U7 #!=80 O76P
M+EUZ "Q=B0 K79H!*EVK 2I=OP$I7=X!*ESR 2I;_@$K6_\!*UK_ :-5  "/
M50  ?U4  ')5  !G5@  7E8  %17  !,60  15L  #]=   Z7P0 -F - #1A
M$P R8AP ,6(C #!B*P O8S( +F,Z "UC0@ L8TH *F13 "ED70 H9&D )V1V
M "9DA@ E9)< )&2I "-DO0 B9-H (V/Q "-B_0$D8?\!)&'_ 9Q8  ")6
M>ED  &Y9  !C60  6EH  %!<  !(7@  06   #IC   T9@  +V@* "QI$  J
M:1< *6H? "AJ)@ G:BX )FLU "5K/0 D:T8 (VM/ ")L60 @;&4 'VQR !YL
M@@ =;)0 '&RF !MKN@ ::]0 &VKN !QI_  <:/\ '&C_ )5<  "#7   =5P
M &E=  !?70  5EX  $QA  !#9   /&<  #5J   O;0  *' $ "-R#0 A<A(
M(',: !]S(0 ><R@ '70P !QT.  ;=$  &G1* !ET5  7=6  %G5N !5U?@ 4
M=9  $W2B !)TM@ 1=,\ $G/L !)R^@ 3<?\ $W'_ (Y@  !]8   ;V$  &5A
M  !;8@  460  $AG   ^:P  -VX  #!Q   I=0  (G@  !Q[!P 7?0X %GT3
M !5]&P 4?B( $WXJ !)^,0 1?CH $7Y$ !!_3@ /?UH #G]H  U_>  ,?XH
M"WZ=  I^L  )?<8 "GWD  I\]  +>_T "WK_ (9E  !W90  :F4  &%F  !6
M:   3&L  $)O   Y<P  ,7<  "IZ   C?@  '($  !6$   0AP@ #8D.  R)
M%  ,B1L "XDC  J)*P )B3, "(D]  :)2  %B50 !(EA  *)<0 !B8,  (F6
M  "(J0  A[X  (?:  "&[   AO4  (;Z 'YJ  !Q:@  9VL  %ML  !0<
M1G0  #QX   S?0  *H$  ".%   <B   %8P  !"/   ,D@8 !I,,  *3$0
ME!8  )0=  "4)   E2P  )4U  "50   E4P  )99  "6:0  E7H  )6.  "4
MH0  E+4  )/,  "2Y@  DO(  )+W 'AP  !M<   8'(  %1U  !)>0  /WX
M #6#   LB   (XT  !N1   4E   #Y<   J:   $G0,  )X)  "?#@  GQ(
M * 7  "@'0  H24  *(M  "B-P  HT,  *-0  "C7P  HW$  *.$  "BF0
MHJT  *'"  "AW   H>L  *#R '-V  !F=P  67L  $V   !"A0  .(L  "Z0
M   DE0  &YH  !2>   .H0  ":0   *G    J@   *L$  "K"@  K T  *T1
M  "M%@  KAP  *\D  "P+0  L3D  +%&  "R50  LF8  +)Y  "RC@  L:,
M +*W  "QR@  L>   +'I &Q^  !?@@  4H<  $:-   [DP  ,)D  ":>   <
MHP  $Z<   VK   'K@   +(   "U    MP   +@   "Y @  N0@  +H,  "[
M$   O!0  +T;  "_(P  P2T  ,(Z  #"20  PUH  ,-L  #$@@  Q)<  ,2K
M  #$O   Q,L  ,3: &6)  !8C@  2Y4  #^;   SH@  **@  !VM   4L0
M#;8   :Y    O    +\   ##    Q    ,4   #&    QP   ,D$  #*"0
MRPT  ,T1  #/&   TB$  -4M  #6/   V$T  -E?  #:<P  VHH  -N>  #;
MK@  V[H  -S# %Z6  !1G   1*,  #BJ   LL0  (+<  !6[   -O@  !,(
M  #%    R0   ,T   #0    T@   -(   #5    U@   -D   #;    W@4
M . *  #B#P  Y18  .@@  #L+0  [3X  .U1  #N90  [WH  .^/  #PGP
M\*L  /"S /\ $ #_  X _P . /\ $@#_ !T _P I /\ -0#_ $$ _P!- /X
M5@#[ %\ ^ !F /8 ;0#T '0 \@!Y /$ ?P#P (0 [@") .T CP#K )4 Z@";
M .@ H@#F *H Y0"S ., P #A -( X #J -\ ^0#= /\ W0#_ -T _P#> /\
MW@#_ /\ #0#_  H _P ) /\ #P#_ !@ _P D /X ,0#[ #T ^ !( /0 4@#P
M %H [0!B .L :0#I &\ YP!U .4 >@#C '\ X@"% .  B@#> )  W "6 -H
MG0#8 *4 U0"O -( N@#0 ,H S@#C ,T ] #+ /\ RP#_ ,L _P#+ /\ RP#_
M /\ " #_  , _P % /\ # #\ !0 ]P ? /( *P#O #< ZP!" .< 3 #D %4
MX != -T 9 #: &H V !P -4 =0#2 'H T "  ,\ A0#- (L RP"2 ,D F0#'
M *$ Q0"J ,, M0#! ,, OP#: +X [@"] /P O #_ +P _P"\ /\ O #_ /\
M  #_    _P   /D !P#Q !  Z@ : .0 )0#? #$ VP \ -< 1P#2 %  S@!7
M ,L 7@#) &4 Q@!J ,4 < ## '4 P0!Z ,  @ "^ (8 O "- +H E "Y )P
MMP"E +4 L "S +T L0#/ *\ Z "N /@ K@#_ *T _P"M /\ K0#_ /\   #_
M    _0   .X  0#C  P V@ 4 -$ 'P#, "L R  V ,4 0 #" $H OP!2 +P
M60"Z %\ N !E +8 :@"T &\ LP!U +$ >@"P ($ K@"( *T CP"K )@ J0"A
M *< JP"E +@ HP#( *( X@"A /, H #^ *  _P"@ /\ H #_ /\   #V
MZ@   .    #3  8 R0 / ,( & "] "0 N0 O +8 .@"T $, L0!, *X 4P"L
M %D J@!? *D 9 "G &H I@!O *0 =0"C 'L H0"" *  B@"> ), G "= )H
MIP"8 +0 E@## )4 W "4 .\ DP#[ ), _P"3 /\ D@#_ /D%  #J"P  W T
M ,L*  #"!0  O  * +8 $0"Q !P K@ H *H ,P"G #T I !% *( 30"@ %,
MG@!9 )P 7P"; &0 F@!J )@ < "7 '8 E0!^ ), A@"2 8\ D &9 (X"I ",
M K$ BP/  (D%U@"(!NT B ?Z (<(_P"&"/\ A@C_ .\/  #>%   RA4  +P2
M  "S$   K@P  *L&#0"G Q4 H@4@ )\'+ "<"#8 F0@_ )<)1P"5"4X DPE4
M )$*6@"0"E\ C@IE (T*:P"+"G( B@MY (@+@@"'"XP A0R7 (,,H@"!#;
M@ W  '\-V !]#N\ ? _] 'L/_P![$/\ >Q#_ .87  #1'@  O1T  *\<  "F
M&0  H14  )X0! "=#0\ F X9 )0.)0"1#R\ CQ Y (P000"*$$@ B!!/ (<0
M50"%$%L A!%A ((19P" $6X ?Q%U 'T1?@!\$H@ >A*4 '@2H !W$ZX =1.^
M '04U0!S%>X <1;] '$6_P!Q%O\ <!;_ -P?  #&)0  LR4  *4C  "<(0
MEAX  )(9  "1% L C104 (D5'P"&%BD @Q8S ($7/ " %T, ?A=* 'P74 !Z
M%U8 >1A< '<88@!V&&D =!AQ ',9>@!Q&80 ;QJ0 &X:G0!L&ZL :QR[ &H<
MT !I'>P :![[ &@>_P!G'O\ 9Q[_ -$F  "]*@  JRH  )TJ  "3*   C24
M (@B  "&'08 @QL0 '\<&@!\'20 >ATN '<>-@!V'CX =!Y% '(?2P!Q'U$
M;Q]8 &X?7@!L'V4 :R!M &D@=@!H(8$ 9B&- &4BF@!C(J@ 8B.X &$CS0!@
M).D 8"3Z %\D_P!?)/\ 7R3_ ,HL  "V+P  I"\  )8O  ",+0  A2H  ( H
M  !])   >B(- '8C%0!S(R  <20I &\D,@!M)#H :R5! &HE1P!H)4T 9B54
M &4E6@!D)F$ 8B9I &$F<@!?)WT 7B>* %THEP!;*:4 6BFU %HJR@!9*N<
M6"KX %@J_P!8*O\ 6"K_ ,4Q  "O,P  GC,  ) S  "&,@  ?R\  'DM  !U
M*@  <B@* &\H$@!K*1L :2DE &<J+0!E*C4 8RH] &(J0P!@*DH 7RM0 %XK
M5P!<*UX 6RQF %DL;P!8+7H 5RV' %8NE0!4+J, 4R^S %,OQP!2+^4 4B_W
M %(O_P!2+_\ 4B__ ,$V  "J-@  F38  (LV  "!-0  >3,  ',Q  !O+P
M:RX& &@M$ !D+A@ 8BXA & O*@!>+S$ 7"\Y %LO0 !9+T8 6"]- %<P4P!6
M,%L 5#%C %,Q; !2,G< 43*$ $\SD@!.,Z$ 33.Q $TTQ0%,-.,!3#3V $PT
M_P!,-/\ 3#/_ +LY  "F.0  E3D  (<Y  !\.0  =#<  &XT  !I,P  93("
M &$R#0!>,A0 7#,> %HS)@!8,RX 5C,U %4T/ !3-$, 4C1* %$T4 !0-5@
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M :Y   ":0   B4$  'Q!  !Q00  :$   &$\  !;/0  5CX  %(^!0!./PX
M3#\5 $D_'0!'0"4 1D L $1 ,P!#0#H 0D%" $%!20! 05$ /T): #Y"8P ]
M0V\ /$-\ #M#BP Z1)L .42K 3E$O@$X1-L!.43Q 3E#_@$Y0_\!.4/_ :I"
M  "60P  AD,  'A#  !N0P  94,  %U   !60   44(  $U" @!)0PP 1D,2
M $1$&@!"1"( 040J #]%,0 ^13@ /44_ #Q&1P [1D\ .D97 #E'80 X1VP
M-T=Z #9(B0 U2)D -$BJ #1(O0 S2-D -$CP #1'_0 T1_\ -4;_ *9$  "2
M10  @D8  '5&  !J1@  844  %E$  !11   3$8  $A'  !$1PH 04@0 #])
M&  ]22  /$DG #I*+@ Y2C8 .$H] #=+1  V2TP -4M5 #1,7P S3&H ,DQW
M #%,A@ P3)< +TVH "Y-NP N3=4 +DSO "],_0 O2_\ ,$O_ *%'  ".2
M?D@  '%(  !F20  74@  %5(  !,20  1TH  $)+   _3 8 .TT. #E.%0 W
M3AT -D\D #5/*P S3S, ,E Z #%00@ P4$H +U%2 "Y17  M46< +%%U "M1
MA  J4I4 *5*F "E2N0 H4M( *5'N "E0_  J4/\ *D__ )Q*  ")2@  >DL
M &U+  !C3   6DP  %%,  !(30  0T\  #U0   Y4@( -5,, #-4$@ Q5!D
M,%4A "Y5*  M52\ +%8W "M6/@ J5D8 *59/ "A760 G5V0 )E=R "57@0 D
M5Y( (U>D ")7MP B5\\ (E?L "-6^@ C5?\ )%7_ )9-  "$3@  =4X  &E.
M  !?3P  5D\  $U0  !%4@  /U,  #E6   S6   +UH( "M;#P J6Q4 *%P=
M "=<)  F7"L )5PS "1=.@ C74, (EU, "%=5@ @7F$ 'UYN !Y>?@ =7H\
M'%ZA !M>M  :7<P &UWI !M<^0 <6_\ '%O_ )!1  !^40  <%$  &12  !;
M4@  4E,  $I4  !!5P  .UD  #5;   N7@  *& # "1B#  B8Q$ (6,8 !]D
M(  >9"< '60N !QD-@ ;93X &F5' !EE40 895T %V5J !9E>@ 598L %&6>
M !-EL0 29<@ $F3G !-C]P 48O\ %&+_ (E4  !X50  :U4  &!6  !75@
M3U<  $99   ]7   -E\  #!B   I9   (V<  !UJ!P 9; X &&P3 !9M&@ 5
M;2$ %&TI !1M,  3;3D $FY" !%N3  0;E@ #VYE  YN=0 -;H< #6Z:  QM
MK0 +;<( "VS@  QK\P -:_T #6K_ ()9  !R60  9ED  %Q:  !46@  2EP
M $%?   Y8P  ,68  "II   D;   '6\  !=R   2=0D #W</  YW%  .=QL
M#7<C  QW*@ +=S, "G<\  EW1P (=U( !W=?  5W;P $=X   W>4  %VIP
M=KL  775  %TZP "=/8  G3\ 'M=  !M70  8EX  %E>  !.8   16,  #QG
M   S:P  *VX  "1R   >=0  %WD  !)\   -?P8 "8$,  6!$0 #@18  H$=
M  &!)   @2T  ((V  ""0   @DP  ()9  "":   @GD  (*-  "!H   @+0
M (#+  !_YP  ?O(  '[Y '1B  !H8@  7F(  %-D  !)9P  /VL  #9P   M
M=   )7@  !Y\   7@   $8,   V&   (B00  HL*  "+#@  BQ,  (P8  ",
M'P  C28  (TO  "..0  CD0  (Y1  ".8   CG$  (Z%  ".F0  C:T  (S#
M  ",WP  B^X  (OV &YH  !D9P  6&D  $UL  !"<0  .'8  "][   F?P
M'H0  !:(   0C   #(\   :2    E0   )8'  "7#   EP\  )@3  "9&
MFA\  )LF  ";,   G#L  )Q(  "<5P  G&@  )Q[  "<D   FZ4  )NZ  ":
MT   FN<  )KQ &IM  !>;P  47(  $9W   [?   ,8(  ">'   >C   %I$
M !"5   *F0  !)P   "@    H@   *,!  "C!@  I L  *4.  "F$@  IQ<
M *@>  "J)@  JS$  *L^  "L30  K%T  *QP  "LA0  K)L  *NO  "KPP
MJ]D  *KH &1U  !7>0  2WX  #^$   TB@  *9   !^6   6FP  $)\   FC
M   !IP   *H   "N    L    +    "Q    L@,  +0(  "U#0  MA   +<5
M  "Y'0  NR8  +PS  "]00  O5(  +UD  "^>0  OI   +VD  "]MP  O<8
M +W7 %Q_  !0A0  1(L  #B2   LF0  (9\  !>D   0J0  ":X   "R
MM@   +D   "]    OP   +\   #     P0   ,,   #$!0  Q@H  ,<.  #)
M$P  RQP  ,XF  #0-0  T44  -)7  #2:P  TX(  -.7  #3J0  TK@  -+$
M %6,  !)DP  /9H  #"B   EJ   &JX  !&T   )N0   +T   #!    Q
M ,@   #+    S0   ,T   #/    T    -(   #4    V    -H&  #=#
MX!$  .,:  #F)P  YS@  .A*  #I70  ZG(  .N(  #KFP  [*@  .RR /\
M#0#_  L _P + /\ $ #_ !H _P F /\ ,@#_ #T _P!( /L 4@#X %H ]@!B
M /, :0#Q &\ \ !U .X >@#L '\ ZP"$ .D B@#H )  Y@"6 .0 G0#B *4
MX0"O -\ NP#= ,L VP#F -D ]P#8 /\ V #_ -< _P#7 /\ U #_ /\ " #_
M  0 _P $ /\ #0#_ !4 _@ A /H + #W #@ ] !# /  30#M %4 Z@!= .<
M9 #D &H X@!P .  =0#> 'H W0!_ -L A0#9 (L U0"1 -, F0#1 *  SP"J
M ,T M0#+ ,0 R0#= ,@ \0#' /\ Q@#_ ,8 _P#& /\ QP#_ /\   #_
M_P   /\ "@#X !$ \0 < .P )P#I #( Y@ ] .( 1P#= %  V0!8 -4 7P#2
M &4 T !J ,X < #, '4 R@!Z ,D ?P#' (4 Q0", ,, E #! )P OP"E +T
ML "[ +T N@#0 +@ ZP"W /L M@#_ +8 _P"V /\ M@#_ /\   #_    _0
M /, !0#I  X X0 6 -L (0#5 "T T0 W ,X 00#* $H QP!2 ,0 60#" %\
MP !E +X :@"\ &\ NP!T +D >@"W (  M@"' +0 C@"R )< L "@ *X J@"M
M +< JP#( *D XP"H /4 IP#_ *< _P"G /\ I@#_ /\   #^    \0   .4
M  #7  H S0 1 ,< ' #" "8 OP Q +P .P"Z $0 MP!, +0 4P"R %D L0!?
M *\ 9 "M &D K !O *H = "I 'H IP"! *8 B0"D )$ H@"; *  I0"> +(
MG0#! )L V@": .\ F0#] )@ _P"8 /\ F #_ /T   #P    X0   -$   #&
M  0 O0 - +< %0"S "  L  K *T -0"K #X J !& *8 30"D %0 HP!9 *$
M7P"@ &0 G@!I )T ;@"; '4 F@![ )@ @P"6 (P E0"6 ), H0"1 *T CP"[
M (T SP", .D BP#X (P _P", /\ C #_ /,"  #B!P  S <  +\$  "W
ML0 ( *L $ "G !D I  D *  +@"> #< G !  )H 1P"8 $X E@!4 )4 60"3
M %X D@!D )  :0"/ &\ C0!V (L ?@"* (@ B "2 (8 G0"% *D @P"X ($
MR@"  .4 @ #U '\ _P!_ /\ ?P#_ .@-  #0$   OA   +$.  "H#0  HP@
M * "# "< !, F  = )4 )P"2 #$ D  Y (X!00", 4@ B@). (D"5 "' ED
MA@)? (0#9 "# VL @0-R ( $>@!^!(0 ?06. 'L%F@!Y!J< > :U '8'R !U
M"., =0GT '0*_P!S"O\ <PK_ -T5  #$%P  L1<  *46  "<$P  EA$  )0-
M! "3" T C@<5 (L)( "("2H A0HS (,+.P"!"T( @ M) 'X+3P!]#%0 >PQ:
M 'H,8 !X#&< =PQN '4-=@!T#8  <@V, ' -F0!O#J8 ;0ZU &P.R0!K#^8
M:A#W &D0_P!I$/\ :1#_ - =  "Y'@  J!X  )L=  "2&P  BQD  (@5  "'
M$0< A0X0 ($/&@!^$"0 >Q M 'D0-@!W$3T =A%$ '012@!S$5  <1%6 ' 1
M7 !N$F( ;1)J &L2<P!I$WT :!.) &83E@!E%*, 8Q6S &(5Q@!B%N, 81;V
M & 7_P!@%_\ 8!?_ ,<B  "P(P  GR0  )(C  ")(@  @B   'X=  !\&0
M>A4- '<5%0!T%A\ <18H &\7, !N%S@ ;!<_ &L710!I&$L :!A1 &886 !E
M&%X 8QEF &(9;P!@&7D 7QJ% %T;D@!<&Z$ 6QRP %H<PP!9'>  6![T %@>
M_P!8'O\ 6![_ +\G  "I*   F2@  (LH  "")P  >R4  '8C  !S(   <1P)
M &X<$0!K'!H :1TC &<=+ !E'3, 8QXZ &(>00!@'D< 7QY- %X>5 !<'UL
M6Q]B %D@:P!8('8 5B&" %4AD !4(IX 4R*N %(CP !1(]T 423R %$D_P!1
M)/\ 42/_ +DK  "C+   DRP  (8M  !\+   ="H  &\H  !K)0  :2(% &8A
M#@!C(A8 82(? %\C)P!=(R\ 7",V %HC/0!9)$, 5R1* %8D4 !5)%< 4R5?
M %(E: !1)G, 3R9_ $XGC0!-*)P 3"BL $LIO@!+*=H 2BGQ $HI_P!+*?\
M2RG_ +,N  ">+P  CC   ($P  !W+P  ;RX  &HK  !E*@  8R<! %\G# !<
M)Q, 6B<; %@H) !6*"L 52@R %,H.0!2*4  4"E& $\I30!.*50 32I< $PJ
M90!**W  22M\ $@LBP!'+9H 1BVJ $4NO !%+M8 12[O $4N_@!%+O\ 12W_
M *XQ  ":,@  B3,  'PS  !R,P  :S$  &4O  !@+0  72P  %DL"0!6+!
M5"P8 %(L( !0+"@ 3BTO $TM-@!,+3P 2BU# $DM2@!(+E$ 1RY9 $8O8P!%
M,&T 0S!Z $(QB0!!,9@ 03*H $ RNP _,M, /S+N $ R_0! ,O\ 0#+_ *HS
M  "6-0  AC4  'DV  !N-0  9C4  &$R  !<,   5S   %0P!@!1, X 3C 5
M $PQ'0!*,24 2#$L $<Q,@!&,3D 1#%  $,R1P!",D\ 03-7 $ S8  _-&L
M/C5X #TUAP \-I8 .S:G #LVN0 Z-M$ .C;M #LV_  [-O\ .S;_ *8V  "2
M-P  @C@  '4X  !K.   8S<  %TV  !7,P  4S0  $\T P!+- P 2302 $8U
M&@!%-2( 0S4I $$U+P! -38 /S8] #XV1  ]-TP /#=5 #LX7@ Z.&D .3EV
M #@YA0 W.I4 -SJE #8ZN  U.L\ -CKL #8Z^P V.?\ -SG_ *(X  "..0
M?CH  '([  !H.P  7SH  %DY  !3-@  3C<  $HX  !&. H 1#D0 $$Y%P _
M.1\ /CDF #PY+0 [.C0 .CH[ #D[0@ X.TH -SM3 #8\7  U/&< -#UT #,]
M@P S/I, ,CZD #$^M@ Q/LT ,3[J #$^^@ R/?\ ,CW_ )X[  "+/   >SP
M &X]  !D/0  7#T  %4\  !..@  23L  $4\  !!/0< /CT. #P]%0 Z/AP
M.3XC #<^*@ V/S$ -3\X #0_0  S0$@ ,D!0 #% 6@ P064 +T%R "Y"@0 M
M0I$ +4*B "Q"M0 K0LL +$+I "Q"^0 M0?\ +4'_ )D]  "'/@  =S\  &L_
M  !A0   63\  %(_  !)/@  1#\  $!    \000 .4(- #="$@ U0QD ,T,A
M #)#*  Q1"\ ,$0V "]$/0 N144 +45. "Q%6  K1F, *D9O "E&?@ H1H\
M)T>A "9'LP F1\D )D;G "=&^  H1?\ *$7_ )5   ""00  <T(  &="  !>
M0@  54(  $Y"  !%0@  /T0  #M%   W1@  -$<* #%($  O2!8 +DD> "Q)
M)0 K22P *DDS "E*.@ H2D( )TI+ "9+50 E2V  )$MM "-+?  B2XT (4R?
M "%,L0 @3,< ($OF "%+]P B2O\ (DK_ )!#  !^1   ;T0  &1%  !:10
M4D4  $I&  !!1P  /$@  #=)   R2P  +DT' "M.#@ I3A, )T\: "9/(0 E
M3R@ )$\P "-0-P B4#\ (5!( "!04@ ?45T 'E%J !U1>0 <48H &U&< !I1
MKP 94<4 &5'D !I0]@ ;3_\ '$__ (I&  !Y1P  :T<  &!(  !62   3D@
M $=)   ^2P  .4P  #-.   N4   *%," "14"P B51  (%46 !]6'@ >5B0
M'58L !Q6,P ;5SL &E=$ !E73@ 85UD %UAF !58=0 46(< %%B: !-7K  2
M5\( $E?A !-6]  45?\ %%7_ (1)  !T2@  9DL  %Q+  !32P  2TP  $1-
M   \3P  -5$  "]4   I5@  )%D  !Y;!P :70T &%T2 !==&0 67B  %5XG
M !1>+@ 37C< $EY  !%?2@ 17U4 $%]B  ]?<0 .7X, #5^6  U?J0 ,7KX
M#%[:  U=\  -7/P #ES_ 'Y-  !N3@  8DX  %A/  !/3P  2%   $!2   X
M5   ,%<  "I:   D70  'U\  !EB 0 390D $68/ !!F%  /9AL #F<B  UG
M*0 -9S( #&<[  MG10 *9U  "6==  =G;  &9WT !6>0  1FHP "9K<  V7/
M  1EZ0 $9/4 !&3\ '=1  !I4@  75(  %12  !,4P  0U4  #M8   S6P
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M  !ZF   >JP  'G"  !XWP  >.\  '?W &I;  !?6P  5EL  $Q<  !"8
M.6,  #!H   H;   ('   !ET   3=P  #GL   E^   $@0(  (((  "##0
M@Q   (04  "%&0  AB   (8H  "',0  ASP  (=)  "'5P  AV@  (=[  "'
MD   AJ4  (6Z  "%TP  A.H  (3T &5@  !<8   46$  $9D   \:0  ,FT
M "ER   A=P  &7L  !*    -@P  "(<   **    C0   (X$  "."0  CPT
M ) 0  "1%   DAD  ),@  "4*0  E3,  )5   "63@  EE\  )5R  "5B
ME9T  )2R  "4R   D^(  )/N &%E  !69@  2FH  #]N   U=   *WD  "%_
M   9A   $8D   R-   &D0   )0   "8    F@   )L   "< @  G0<  )X+
M  "?#@  H1(  *(8  "C(   I2D  *8V  "F1   IE4  *9H  "F?0  II0
M *6I  "DO0  I-$  *3D %ML  !/<   0W4  #A[   M@0  (X<  !F-   1
MD@  "Y<   2<    H    *,   "F    J    *D   "J    K    *T$  "N
M"0  L T  +$1  "S%P  M2   +8K  "W.@  MTL  +A<  "X<0  N(@  +B=
M  "XL0  M\(  +?0 %1V  !(?   /((  #&)   FD   &Y<  !*=   ,H@
M Z<   "K    K@   +(   "V    N    +@   "Z    NP   +T   "^
MP 4  ,$+  ##$   QA8  ,D@  #*+@  RSX  ,Q0  #,9   S7H  ,V1  #-
MI   S;0  ,W  $V#  !!B@  -9$  "F9   >H   $Z8   RL   #L0   +8
M  "Z    O@   ,(   #&    R    ,@   #*    RP   ,T   #.    T
M -(!  #5"   V0X  -T5  #A(0  XC$  .1#  #E5@  YFL  .:"  #GE@
MYZ4  .:P /\ "0#_  4 _P & /\ #@#_ !8 _P A /\ +0#_ #@ _0!# /D
M30#U %4 \@!= /  8P#N &D [ !O .H = #I 'H YP!_ .8 A0#D (L XP"1
M .$ F0#? *$ W "J -H M@#7 ,8 U0#A -, ] #2 /\ T0#_ -$ _P#/ /\
MR@#_ /\  0#_    _P ! /\ # #_ !( ^@ = /8 * #S #, \  ^ .P 2 #H
M %  Y0!8 .( 7@#? &0 W0!J -L ;P#9 '0 U@!Z -0 ?P#2 (4 T ", ,X
MDP#, )P R0"E ,< L #& +X Q #4 ,( [@#! /X P #_ ,  _P"_ /\ O@#_
M /\   #_    _P   /H !P#Q  \ ZP 8 .8 (P#B "X X  X -L 0@#5 $L
MT0!2 ,X 60#+ %\ R0!E ,< :@#& &\ Q !T ,( >@#! (  OP"& +T C@"[
M )8 N0"@ +< J@"V +< M #* +( Y@"Q /@ L #_ *\ _P"O /\ L #_ /\
M  #_    ]P   .H  @#A  P UP 3 -  '0#, "@ R0 R ,8 / #" $4 OP!-
M +P 4P"Z %D N !? +< 9 "U &D M !N +( = "Q 'H KP"  *T B "L )$
MJ@": *@ I0"F +$ I #! *, W "A /( H0#_ *  _P"@ /\ H0#_ /\   #W
M    Z    -D   #+  @ PP 0 +T & "Y "( M@ L +0 -@"R #\ KP!' *P
M30"K %0 J0!9 *< 7@"F &, I0!H *, ;@"B '0 H !Z )X @@"< (L FP"5
M )D GP"8 *P E@"Z )0 SP"3 .L D@#[ )( _P"2 /\ D0#_ /<   #G
MTP   ,8   "[  ( LP , *T $@"J !P IP F *0 , "C #@ H !  )X 1P"<
M $X F@!3 )D 6 "7 %T E@!C )4 : "3 &X D@!T )  ? "/ (4 C0"/ (L
MF@"* *< B "U (8 QP"% .0 A #U (0 _P"# /\ @P#_ .P   #3    P0$
M +0   "L    I@ ' *  #@"= !8 F@ @ )< *0"5 #( DP Z )$ 00"/ $@
MC0!- (P 4P"+ %@ B0!= (@ 8P"' &D A0!O (, =P"" (  @ "* 'X E@!]
M *, >P"P 'H P@!Y -T > #Q '< _0!X /\ > #_ -X*  #$"P  L@P  *8+
M  "="   F00  )4 "@"1 !$ C@ 9 (L (P") "P AP T (4 .P"# $( @@!(
M (  3@!_ %, ?0!8 'P 7@![ &0 >0!J '@ <@!V 'L = "& ', D@!Q )\
M< "M &X O@!M =8 ;0+M &P#^@!L _\ ; /_ ,X0  "W$0  IA(  )H1  "1
M$   BPX  (D+ P"'!0P A $3 ($!' !^ B4 ? ,N 'H#-@!X!#P =P1# '4%
M2 !T!4X <P54 '$%60!P!E\ ;@9F &T&;@!K!W@ :@># &@(D !G"9T 90FL
M &0)O !C"M0 8POL &(,^@!B#/\ 8@S_ ,,6  "M%P  G1@  ) 8  "'%@
M@10  'T1  !\#@8 ? H. '@*%@!U"Q\ <@LH ' ,, !O##< ;0P^ &P,1 !K
M#4H :0U/ &@-50!G#5P 90UC &,.:P!B#G4 8 Z! %\.C@!=#YP 7!"K %L0
MO0!:$-8 61'P %D1_0!9$?\ 61'_ +D;  "E'0  E!X  (@>  !^'0  >!L
M '08  !Q%0  <1$) &\0$0!L$!D :1 B &<1*@!F$3( 9!$Y &,1/P!B$44
M8!)+ %\240!=$E@ 7!)? %H3: !9$W( 5Q1] %84BP!4%9D 4Q6I %(6N@!1
M%M( 41?M %$7_0!1%_\ 41?_ +(@  ">(@  CB(  ($C  !W(@  <"$  &P>
M  !I&P  9Q@$ &85#@!C%A4 818> %\6)@!=%BT 7!<T %H7.P!9%T$ 6!A'
M %8830!5&%0 4QA< %(99 !1&6X 3QIZ $X;B !-&Y< 2QRF $H<N !*'<\
M21WK $D=^P!)'?\ 2AW_ *PD  "8)0  B"8  'LG  !Q)@  :B4  &8C  !B
M(0  8!X  %X<"P!;&Q( 61P: %<<(@!5'"D 5!PP %,=-P!1'3T 4!U# $\=
M2@!-'E$ 3!Y8 $L?80!)'VL 2"!W $<@A0!&(90 1"*D $0BM@!#(LP 0R/I
M $,C^@!#(_\ 0R+_ *8G  "3*0  @RH  '8J  !M*@  92D  & G  !<)0
M62,  %<A!P!5(0\ 4B$6 % A'@!.(24 32(L $PB,P!*(CD 22)  $@B1@!'
M(TT 12-5 $0D7@!#)&D 0B5U $ F@P _)I( /B>C #XGM  ])\H /2CH #TH
M^0 ])_\ /B?_ *(J  ".*P  ?RT  '(M  !H+0  82P  %PK  !8*   5"8
M %$F! !.)0T 3"43 $HF&@!()B( 1R8I $4F+P!$)C8 0R<\ $$G0P! )TL
M/RA3 #XI7  ]*68 /"IR #LJ@0 Z*Y  .2NA #@LL@ W+,@ -RSF #@L^  X
M+/\ ."S_ )TL  "*+@  >R\  &\P  !E,   72\  %@N  !3*P  4"H  $PJ
M  !)*@L 1BH1 $0J%P!"*A\ 02HE #\J+  ^*S, /2LY #PK0  [+$@ .BQ0
M #DM60 X+F0 -RYP #8O?P U+X\ -#"? #,PL0 R,,< ,C#E #,P]P S,/\
M-"__ )DO  "',0  =S(  &LR  !B,@  6C(  %0Q  !/+P  2RT  $<N  !$
M+@@ 02X. #\N%  ]+AP .RXB #DO*0 X+R\ -R\V #8P/@ U,$8 -3%. #0Q
M5P S,F( ,C)N #$S?0 P,XT +S2> "XTL  M-,4 +33C "XT]@ O,_\ +S/_
M )4Q  "#,P  =#0  &@U  !>-0  5S0  %$T  !+,@  1C$  $(R   _,@4
M/#(- #DS$@ X,QD -C,@ #0S)@ S,RT ,C0T #$T.P P-4, ,#5, "\V50 N
M-F  +3=L "PW>P K-XL *CB< "DXK@ H.,, *#CB "DX]0 J-_\ *C?_ )(T
M  !_-0  <38  &4W  !;-P  5#<  $TV  !'-@  0C4  #TV   Z-@( -S<+
M #0W$  R-Q8 ,3@= "\X)  N."L +3DR "PY.0 K.4$ *CI) "HZ4P I.UX
M*#MJ "<[>0 F/(D )3R; "0\K0 C/,( (SS@ "0\]  E._\ )3O_ (TV  !\
M.   ;3D  &(Y  !8.@  43D  $HY  !$.0  /3D  #DZ   U.P  ,CL( "\\
M#@ M/10 +#T: "H](0 I/2@ *#XO "<^-@ F/CX )3]' "0_4  C0%L (D!H
M "% =@ @0(< 'T&9 !]!JP >0<  'D'> !] \P ?0/X (#__ (DY  !X.@
M:3L  %X\  !5/   33P  $<\  ! /   .#T  #0^   P0   +4$% "I"#  G
M0A$ )D,8 "1#'@ C0R4 (D,L "%$,P @1#L 'T1$ !Y%3@ =15D '$5E !M%
M=  :184 &4:7 !E&J0 81KX %T7< !A%\0 91/T &D3_ (0\  !S/0  9CX
M %L_  !2/P  2C\  $0_   ]0   -D$  #%#   L1   )T8! "1'"@ A2 \
M($D4 !Y)&P =22( '$DI !M*,  :2C@ &4I! !A*2P 72U4 %DMB !5+<0 4
M2X( $TN4 !)+IP 22[P $4O9 !)*\  32OP %$G_ '\_  !O0   84$  %="
M  !.0@  1T(  $%"   Z0P  ,D4  "U'   H20  (TL  !Y-!@ ;3PT &% 1
M !=0%P 64!X %5 E !10+  3430 $E$] !%11P 145( $%%?  ]2;0 .4GX
M#5&1  U1I  ,4;@ #%'1  U0[  -4/H #D__ 'E#  !J1   740  %-%  !+
M10  1$4  #Y&   V2   +TH  "E,   D3P  'U$  !I3   45@D $5<. !!8
M$P 06!D #U@@  Y8*  -6#  #5@Y  Q80P +6$X "EA:  A8:  '6'D !EB,
M  58GP $6+, !%?*  57Y@ %5_, !E;\ '-&  !D1P  64@  %!(  !(2
M04D  #I*   R30  *U   "52   @50  &E@  !5:   0708 #& ,  I@$  )
M8!4 "& <  =@(P %8"L !& T  -@/0 !8$D  &!5  !@8P  8',  &"&  !?
MF@  7ZX  %_$  !>X@  7O   %[X &Q*  !?2P  54L  $Q,  !%3   /4X
M #50   N4P  )U8  "!9   :7   %5\  !!B   -900 "&<+  -G#@  :!,
M &@8  !H'P  :28  &DN  !I.   :4,  &E/  !I70  :6T  &F   !IE
M:*D  &B_  !GW   9NX  &;W &9/  !:3P  44\  $I/  !!40  .%0  #!7
M   H6P  (5X  !IB   490  $&@   QK   ';@,  7 )  !P#0  <1   '$4
M  !R&@  <R$  ',H  !S,0  <SP  '1(  !S5@  <V8  '-Y  !SC@  <Z,
M '*Y  !QT@  <>L  '#T &%3  !64P  3U,  $55   [6   ,EP  "I@   B
M9   &V@  !1L   /;P  "W(   9V    >0   'H&  !Z"@  >PX  'P1  !]
M%0  ?AL  '\B  " *@  @#4  (!!  " 3P  @%\  (!Q  " A@  @)T  '^R
M  !^R@  ?N4  'WQ %Q8  !46   25H  #]=   U80  +&4  "-J   ;;P
M%',   YW   )>P   W\   ""    A    (8!  "&!@  B H  (D-  "*$
MBQ4  (P;  ".(@  CRP  (\X  "/1@  CU8  (]H  "/?@  CY4  (ZK  "-
MP0  C=P  (SK %E=  !.7P  0V(  #AF   N;   )'$  !QW   4?   #H$
M  B%    B0   (T   "0    D@   ),   "4    E@,  )<(  "8#   F@\
M )L3  "=&@  GR,  * N  "@/   H$P  *!>  "@=   GXP  )^B  "?MP
MGLL  )[@ %-D  !':   /&T  #%S   G>0  '7\  !2%   -BP  !I    "4
M    F    )P   "?    H0   *(   "D    I0   *<   "H!   J@D  *P-
M  "M$@  L!D  +(C  "R,0  LD(  +)4  "R:0  LH   +*8  "QK   LK\
M +'. $QN  ! <P  -7H  "J!   ?B   %8X   Z5   &F@   )\   "D
MJ    *P   "O    L0   +$   "S    M0   +8   "X    N@   +P&  "^
M#   P!$  ,,9  #%)@  Q3<  ,9)  #&70  QW(  ,>*  #(GP  R*\  ,B\
M $9Z   Y@0  +HD  "*0   7F   #Y\   >E    J@   *\   "S    MP
M +P   "_    P0   ,(   #$    Q0   ,<   #)    RP   ,T   #/ P
MT@H  -80  #<&@  W2H  -X\  #?4   X&4  .%[  #AD0  XJ(  .*M /\
M @#_    _P # /\ # #_ !, _P = /\ * #^ #, ^P ^ /< 2 #S %  \ !7
M .T 7@#K &0 Z !I .< ;P#E '0 XP!Y .( ?P#@ (4 W@", -P DP#9 )P
MU@"F -, L0#1 ,  SP#: ,X \0#, /\ RP#_ ,L _P#& /\ P0#_ /\   #_
M    _P   /\ " #[ !  ]@ 9 /( ) #O "X [0 Y .@ 0@#C $L X !2 -T
M60#9 %\ U@!D -, :0#1 &X SP!T ,X >0#, '\ R@"& ,@ C@#& )8 Q "@
M ,( JP#  +D O@#- +P Z@"[ /P N@#_ +H _P"Z /\ M@#_ /\   #_
M_@   /0 ! #K  T Y  4 -\ 'P#; "D V  S -, /0#. $4 R@!- ,< 4P#%
M %D PP!? ,$ 9 "_ &D O0!N +L <P"Z 'D N "  +8 B "T )  L@": +$
MI0"O +( K0#$ *P X0"K /8 J@#_ *H _P"J /\ J@#_ /\   #]    [@
M .(   #5  H S0 1 ,< &0#$ ", P0 M +\ -P"[ #\ MP!' +4 3@"R %,
ML !9 *\ 7@"M &, K !H *L ;0"I ', J !Z *8 @0"D (H HP"4 *$ GP"?
M *P G@"[ )P T@"; .X F@#_ )H _P"9 /\ F0#_ /X   #N    W@   ,L
M  #!  4 N0 - +0 % "Q !X K@ G *L , "J #D IP!! *0 2 "B $T H0!3
M )\ 6 "> %T G0!B )L 9P": &T F !S )< >P"5 (0 E ". )( F0"0 *8
MC@"T (T R ", .8 BP#Y (H _P"* /\ BP#_ /    #;    QP   +H   "P
M    J  * *0 $ "@ !@ G0 A )L *@": #, F  [ )8 00"4 $@ D@!- )$
M4@"/ %< C@!< (P 80"+ &< B@!N (@ =0"' 'X A0"( (, E "" *  @ "O
M '\ P !^ -T ?0#R 'T _P!] /\ ?0#_ .    #&    M0   *H   "B
MFP % )4 #0"2 !, D  < (T ) "+ "T B@ T (@ .P"& $( A0!' (, 30""
M %( @0!7 '\ 7 !^ &( ?0!H 'L < !Z 'D > "# '8 CP!U )P = "J '(
MN@!Q -$ < #L '  ^P!P /\ < #_ ,T$  "W!@  IP<  )L&  "3!   C@
M (H " "&  \ A  6 ($ '@!_ "< ?0 N 'P -@!Z #P >0!" '< 1P!V $P
M=0!2 ', 5P!R %T <0!C &\ :P!N '0 ; !^ &L B@!I )@ : "F &< M@!F
M ,L 90#G &4 ]P!E /\ 90#_ , ,  "K#0  FPX  (\.  "&#0  @0L  'X'
M 0!\ 0L >0 1 '< & !U "$ <P I '$ , !O #8 ;@ \ &P 0@!K $< :@!-
M &D 4@!H %@ 9@!? &4 9P!C '  8@%Z & !AP!? I4 7@*C %P#LP!< \<
M6P3D %L%] !;!OX 6P;_ +40  "A$@  D1,  (43  !\$@  =A$  ',.  !R
M# 0 <0<- &X$$@!L!!L :04C &<%*@!F!C$ 9 8W &,&/0!B!T, 80=) %\'
M3@!>"%4 70A< %L)8P!:"6T 6 IX %<*A0!6"Y, 5 NB %,+LP!2#,< 4@SD
M %$-]0!1#?\ 40W_ *T5  "9%P  B1@  'T9  !T&   ;1<  &H4  !G$0
M9PX' &8,#@!C#!4 80P= %\,)0!=#2P 7 TS %L-.0!:#3\ 6 U% %<-2P!6
M#E$ 50Y9 %,.80!2#FL 4 ]V $X0@P!-$)( 3!"B $L0L@!*$<@ 21'E $D1
M]P!)$O\ 21'_ *49  "2'   @QT  '8>  !M'0  9AP  &(:  !?%P  7A0!
M %X1"@!;$!$ 61$8 %<1( !5$2< 5!$N %,1- !1$3L 4!)! $\21P!.$DX
M3!)5 $L37@!)$V< 2!1S $84@ !%%8\ 1!6? $,6L !"%L4 0A?C $(7]@!"
M%_\ 0A?_ )\=  ",(   ?2$  '$B  !H(@  82$  %P?  !9'   5QD  %46
M!@!4%0X 4144 $\6' !.%B, 3!8J $L6, !*%C< 21<] $<70P!&%TH 11A2
M $,86@!"&60 01EP #\:?0 ^&XT /1N= #P<K@ [',, .QSA #L=]0 ['/\
M/!S_ )HA  "'(P  >"0  &PE  !C)0  7"0  %<C  !3(   41X  $\< @!-
M&PP 2QH1 $@;& !'&R  11LF $0;+0!#'#, 0APY $ <0  _'4< /AU/ #T>
M6  \'F( .A]M #D?>P X((L -R&; #8AK0 U(<$ -2'? #4A\P V(?\ -B'_
M )8C  "#)@  ="<  &@H  !?*   6"<  %,F  !/)   3"(  $D@  !'( D
M1!\/ $(?%0! (!P /R C #X@*0 \("\ .R$V #HA/0 Y(40 ."), #<B50 V
M(U\ -"-K #,D>0 R)8D ,26: # EJP P)K\ +R;< # F\@ P)O\ ,27_ )$F
M  !_*   <2H  &4J  !<*@  52H  $\I  !+*   2"4  $0D  !!) 4 /R0-
M #TD$@ [)!D .20? #<D)@ V)"P -24S #0E.@ S)D$ ,B9* #$G4P P)UT
M+RAI "XI=P M*8< +"F8 "LJJ@ J*KT *BK: "LJ\0 K*OX +"G_ (TH  !\
M*@  ;2P  &(M  !9+0  42T  $PL  !'*P  0R@  #\H   \* ( .2@+ #<H
M$  U*!8 ,R@< #(H(P P*"D +RDP "\J-P N*C\ +2M' "PK40 K+%L *BQG
M "DM=0 H+84 )RV7 "8NJ  E+KP )2[8 "8N\  F+OT )RW_ (HK  !X+0
M:BX  %\O  !6+P  3B\  $@N  !#+0  /RP  #LL   W+   -"P) #(L#@ P
M+1, +BT: "TM(  K+2< *BXM "HN-0 I+ST *"]% "<P3@ F,%D )3%E "0Q
M<P C,8, (C*5 "$RIP A,KL (#+4 "$R[P B,?P (C'_ (8M  !U+P  9S
M %PQ  !3,0  2S$  $4Q  ! ,   .S   #8P   S,   ,#$& "TQ#0 K,1$
M*3(7 "@R'@ G,B0 )3,K "4S,@ D,SH (S1# "(T3  A-5< (#5C !\U<0 >
M-H$ '3:3 !PVI0 ;-KD &S;2 !PV[0 =-OL '37_ ((P  !Q,@  8S,  %DT
M  !0-   230  $(S   ],P  -S,  #$T   N-0  *S4" "@V"P E-Q  )#<5
M "(W&P A."( (#@H !\X,  >.#< '3E  !PY20 ;.E0 &CI@ !DZ;@ 8.G\
M%SN1 !<[I  6.[< %3O0 !8Z[  7.OH &#G_ 'TR  !M-   8#4  %4V  !-
M-@  1C8  $ V   Z-@  -#8  "XX   J.0  )CH  ",["  @/ X 'CT2 !T]
M&  </1\ &SXE !H^+0 9/C0 %SX] !8_1P 5/U$ %#]> !0_;  30'P $D"/
M !% H@ 10+8 $$#. !$_ZP 2/_D $C[_ 'DU  !I-P  7#@  %(Y  !*.0
M0SD  #TY   W.0  ,3H  "L\   G/0  (C\  !Y!!  :0@L &$,0 !=#%0 5
M1!L %$0B !-$*0 31#$ $D0Z !%%0P 014X $$5;  Y%:0 .17D #46,  U%
MGP ,1;( "T7)  Q%Y0 -1/8 #43_ '0Y  !E.@  6#L  $\[  !'/   0#P
M #H\   T/   +CX  "A    C0@  'T0  !I&   52 @ $DH- !%*$@ 02A@
M#TL>  Y+)0 -2RT #4LV  Q+0  +2TH "DM6  E+9  (2W0 !TN'  5+F@ $
M2ZX !$K$  5*X  %2O  !DGZ &X\  !@/0  5#X  $L^  !$/@  /3X  #<_
M   Q0   *D(  "1%   ?1P  &DD  !5,   13@4 #E$+  M1$  *410 "5$;
M  A1(@ '42D !5$R  12.P #4D8  5)2  !27P  4F\  %*!  !1E@  4:D
M %&_  !0W   4.X  %#W &A   !;00  4$$  $A!  !!00  .T(  #1#   M
M10  )D@  "!+   ;30  %E   !%3   .500 "E@*  98#@ "6!(  %D7  !9
M'0  624  %DM  !9-@  64$  %E-  !:6@  6FD  %E\  !9D   6:4  %BZ
M  !8U0  5^P  %?V &-$  !610  344  $5%   _10  -T<  "])   H3
M(D\  !M2   650  $5@   U:   )70, !%\)  !@#0  8!   &$4  !A&0
M8B   &(G  !B,0  8CL  &)'  !B50  8V0  &)V  !BBP  8J   &&V  !A
MSP  8.H  &#U %U(  !220  2D@  $-(   Z2@  ,DT  "I0   C4P  '%<
M !9:   170  #6    AC   #9@$  &<&  !H"P  :0X  &H1  !K%0  ;!L
M &TB  !M*@  ;30  &U   !M3@  ;5T  &UO  !MA   ;)H  &RP  !KR
M:^8  &KS %A-  !.30  2$P  #Y.   U40  +%0  "18   =7   %F   !!D
M   ,9P  !VL   %N    <    '(#  !R!P  <PL  '4.  !V$0  =Q8  '@<
M  !Y(P  >BT  'HY  !Z1P  >E8  'EH  !Z?   >90  'BJ  !XP0  =]\
M '?O %11  !,40  0E(  #A5   O60  )EX  !YB   69P  $&L   MO   %
M<P   '<   !Z    ?    'X   !_ @  @ 8  ($*  "##0  A!$  (85  "(
M'   B24  (HP  "*/@  B4T  (E?  ")<P  B(L  (BB  "'N0  A]$  (;H
M %)6  !'5P  /%H  #)?   H9   'VD  !9O   0=   "GD   )]    @0
M (4   "(    B@   (P   "-    CP   ) $  "2"   DPP  )40  "7%0
MF1T  )LG  ";-   FT0  )I6  "::@  F8(  )J:  "8L   F,<  )?> $M<
M  ! 8   -64  "MJ   A<0  %W<  !!]   )@P   8@   ",    D0   )4
M  "8    F@   )L   "=    GP   *    "B    I 4  *8*  "H#@  JA0
M *T=  "M*@  K3D  *U+  "M7P  K7<  *R0  "KIP  J[H  *O+ $5F   Y
M:P  +G$  "-X   9?P  $(8   F-    DP   )@   "=    H0   *4   "H
M    JP   *L   "N    KP   +$   "S    M0   +<!  "Y!P  O T  +\3
M  #"'P  PBX  ,)   #"5   P6L  ,&#  # FP  P:T  ,&\ #YR   R>
M)X   !R(   2D   "I<   "=    HP   *@   "M    L@   +8   "Y
MNP   +P   "^    P    ,(   #$    Q@   ,@   #+    S@4  -$-  #6
M%   UR,  -@U  #920  VEX  -MU  #;C   W)\  -RK /\   #_    _P
M /\ "0#_ !  _P 9 /X ) #\ "\ ^0 Y /0 0P#P $L [0!2 .H 60#G %\
MY !D .( :0#@ &X W@!S -P >0#: '\ UP"& -0 C@#1 )8 SP"A ,P K #*
M +L R #2 ,8 [@#& /\ Q0#_ ,4 _P"_ /\ N@#_ /\   #_    _P   /X
M!0#W  X \@ 5 .X 'P#K "H Z0 T ., /0#> $4 V0!- -0 4P#1 %D S@!>
M ,P 8P#* &@ R0!M ,< <P#% 'D PP"  ,$ B "_ )  O0"; +L I@"Y +0
MMP#( +8 Y@"U /L M #_ +0 _P"S /\ K@#_ /\   #_    ^    .T   #E
M  L W0 1 -< &@#2 "0 SP N ,L -P#' $  PP!' ,  3@"^ %, O !9 +H
M7@"X &, M@!H +4 ;0"S ', L0!Y *\ @0"M (H JP"4 *D H "H *T I@"^
M *4 VP"D /0 I #_ *, _P"C /\ H@#_ /\   #V    Y@   -<   #+  8
MQ  . +X %0"[ !\ N0 H +< ,0"T #H L !! *T 2 "K $X J0!3 *< 6 "F
M %P I !A *, 9P"A &P H !S )X >@"= (, FP". )D F0"7 *8 E@"V )4
MS "4 .L DP#] ), _P"3 /\ DP#_ /<   #D    T    ,$   "W  ( KP +
M *L $0"G !D I0 B *, *P"B #, GP [ )P 0@"; $@ F0!- )< 4@"6 %<
ME0!; ), 80"2 &8 D !M (\ = "- 'T C "' (H DP"( *  AP"O (4 P@"%
M .( A #W (0 _P"$ /\ A #_ .4   #-    O    *\   "F    G@ ' )H
M#@"6 !0 E  = )( )0"1 "T D  U (T / ", $( B@!' (@ 3 "' %$ A@!6
M (0 6P"# &  @0!G (  ;@!^ '< ?0"! 'L C0!Z )H > "I '< N@!V -,
M=@#O '8 _@!U /\ =0#_ -    "[    JP   )\   "7    D  " (L "P"(
M !  A@ 7 (0 ( "" "< @0 O '\ -0!] #P ? !! 'L 1@!Y $L > !0 '<
M50!V %L = !A ', :0!Q '$ < ![ &X AP!M )4 :P"C &H M !J ,D :0#H
M &D ^0!I /\ :0#_ ,    "L    G (  ) "  "(    @P   '\ !@![  T
M>0 2 '< &@!V "( =  I ', , !Q #8 <  \ &\ 00!M $8 ; !+ &L 4 !J
M %8 : !< &< 9 !E &P 9 !V &, @@!A )  8 "? %\ KP!> ,, 7@#A %X
M] != /\ 70#_ +0'  "@"0  D L  (0+  !\"@  =P<  '0$  !Q  D ;P /
M &T %0!K !P :0 C &@ *@!G #$ 90 V &0 / !C $$ 8@!& &  3 !? %(
M7@!8 %T 7P!; &@ 6@!R %@ ?@!7 (P 5@"; %4 JP!4 +X 5 #: %, [P!4
M /L 5 #_ *D-  "6#@  AQ   'H0  !R$   ; X  &D,  !G"0, 9@0+ &0
M$ !B !< 8  > %X )0!= "L 7  Q %H -P!9 #P 6 !" %<!1P!6 4X 50)4
M %,"7 !2 V4 40-O $\$>P!.!(H 3069 $P%J0!+!;P 2@;4 $H'[0!*!_D
M2@?_ *$0  ".$@  ?A0  ',4  !J%   9!,  & 1  !>#P  70T% %T)#0!:
M!A( 6 <9 %8'( !5!R< 4P<M %((,P!1"#@ 4 @^ $\)1 !."4H 3 E1 $L*
M60!*"F( 2 MM $<+>@!&#(@ 1 R8 $,,J0!"#;P 0@W5 $(-[@!"#?L 0@W_
M )H4  "'%@  >!@  &P9  !C&0  71@  %D6  !6$P  5!$  %0." !3#0X
M40T4 $\-&P!-#2( 3 TH $L-+@!*#30 20TZ $<.00!&#D< 10Y/ $0.5P!"
M#V$ 01!L #\0>0 ^$(@ /1&8 #L1J0 [$;P .A'6 #H1\  Z$OT .Q'_ ),8
M  "!&@  <QP  &<=  !>'0  6!P  %,;  !0&   3A8  $P3 P!,$0L 2A 0
M $@1%P!&$1X 11$D $01*@!"$3  01$W $ 2/0 _$D0 /1), #P35  [$UX
M.11I #@4=@ W%84 -A66 #06IP T%KH ,Q;3 #,6[@ T%OP -!;_ (X;  !\
M'0  ;A\  &,@  !:(   4R   $X>  !*'0  2!H  $88  !%%@< 0Q4. $$5
M$P _%1H /A4@ #T5)P [%2T .A8S #D6.@ X%D$ -Q=) #4740 T&%L ,QEF
M #(9<P P&H, +QJ4 "X;I0 M&[@ +1O0 "T;[  N&_L +AO_ (H>  !X(
M:B(  %\C  !6(P  3R(  $HA  !&(   0QX  $$;   _&@, /1H, #L9$0 Y
M&18 -QH= #8:(P U&BD -!HP #,;-@ Q&SX ,!Q& "\<3P N'5D +1UD "P>
M<0 K'X$ *A^2 "D?I  H(+< )R#. "<@ZP H(/H *1__ (8@  !T(P  9R0
M %PE  !3)0  3"4  $<D  !"(P  /R$  #T?   Z'@  -QX) #4>#@ S'A,
M,1X: # >(  O'B8 +A\M "T?,P L(#L *R!# "HA3  I(58 *")B "8B;P E
M(W\ )".0 ",CH@ B)+4 (B3, "(DZ0 C)/D )"/_ ((C  !Q)0  8R8  %DG
M  !0*   22<  $,G   _)@  .R0  #@B   U(@  ,B(& # B#0 N(A$ +"(7
M "HB'0 I(B, *",J "<C,0 F)#@ )25! "0E2@ C)E0 (B9@ "$G;0 @)WT
M'R>/ !XHH0 >*+0 '2C* !THZ  >*/@ 'R?_ 'XE  !N)P  8"D  %8I  !-
M*@  1BH  $$I   \*   -R<  #0F   P)@  +28# "LG"P H)Q  )R<4 "4G
M&@ D)R$ (R@G "(H+@ A*38 ("D^ !\J2  >*E( '2M> !PK:P ;*WL &BR-
M !DLGP 8++( &"S) !@LYP 9*_< &BO_ 'HG  !J*@  72L  %,L  !*+
M0RP  #XK   Y*P  -"H  # J   K*@  *2L  "8K"  C+ X (BP2 " L&  ?
M+!X 'BTE !TM+  <+3, &RX\ !HN10 9+U  &"]< !<O:0 6,'D %3"+ !0P
MG@ 4,+$ $S#' !,PY0 4,/8 %2__ '8J  !G+   6BT  % N  !(+@  02X
M #LN   V+0  ,2T  "PM   G+P  )"\  "$P!0 ?,0P '#$0 !LR%0 :,AP
M&3(B !@R*0 7,S$ %C,Y !4S0P 4-$T $S19 !(T9P 1-7< $36) ! UG  0
M-;  #C7&  \TY  0-/4 $#3_ '(L  !C+@  5S   $TP  !%,   /C   #@P
M   S,   +S   "DQ   D,@  (3,  !TU @ :-@D %S<. !4W$P 4.!D $S@?
M !(X)@ 2."X $3DV ! Y0  0.4L #CE7  XZ9  -.G0 ##J&  PZF0 +.:P
M"CG!  HYW@ +.?$ ##C\ &XO  !?,0  4S(  $HS  !",P  .S,  #8S   Q
M,@  +#,  "<T   A-@  '3@  !DY   5.P8 $CT, ! ^$  0/A4 #CX<  X^
M(P -/BH ##XS  P^/  +/T< "C]2  @_8  '/V\ !C^!  4_E  $/Z@  SZ\
M  0^UP %/NP !3[W &DS  !;-   4#4  $<U   _-0  .34  #0U   N-0
M*3<  ",X   >.P  &CP  !8_   2000 #D,*  Q$#@ *1!, "409  A$(  '
M1"< !D0O  5$.  #14(  D5.  !%6P  16H  $5\  !%D   1*0  $2Y  !$
MT0  1.H  $/U &0V  !7-P  3#@  $,X   \.   -S@  #$X   K.0  )3L
M " ]   :0   %D(  !)$   .1P0 "TD)  =*#0 $2Q$  4L6  !+'   2R,
M $LK  !+-   2SX  $Q)  !,5P  3&8  $QW  !+C   2Z$  $NU  !*S@
M2ND  $KU %\Z  !2.P  2#L  $ [   Z.P  -#L  "X\   G/@  (D$  !Q#
M   61@  $DD   Y+   +3@, !U (  )1#   41   %(3  !3&   4Q\  %,F
M  !3+P  4SD  %-%  !34@  4V$  %-R  !3AP  4IP  %*Q  !1R@  4><
M %'T %D^  !./@  13X  #X^   X/@  ,$   "E"   C1   '4<  !=*   2
M30  #E    M3   &50(  %<'  !8"P  60X  %H1  !:%0  6QH  %PA  !<
M*@  7#0  %P_  !<30  7%L  %QL  !<@0  6Y<  %NM  !:Q0  6N0  %GS
M %1"  !*0@  0D(  #Q"   T0P  +$8  "5)   >3   %T\  !)3   .5@
M"ED   5;    7@   & $  !A"   8@P  &,.  !D$0  918  &8<  !G(P
M9RT  &<Y  !G1@  9U4  &=F  !G>@  9I$  &6H  !EP   9-X  &3P $]&
M  !'1@  0$4  #='   O2@  )DT  !]1   850  $ED   U<   (8    F,
M  !F    :    &H   !K!   ; @  &T,  !O#@  <!(  '(7  !S'0  ="8
M '0R  !T/P  =$X  '-?  !T<@  <XH  '*A  !QN   <=0  '#L $Q*  !%
M2@  .TL  #).   I4@  (%8  !A;   27P  #60   =H    :P   &\   !R
M    =0   '8   !W    >0(  'H&  !\"@  ?@X  ( 1  ""%@  A!X  (0I
M  "$-@  A$4  (16  "#:@  @X$  (*9  "!L0  @,D  (#E $I.   _4
M-5,  "M7   B7   &6(  !)G   ,;   !7$   !U    >0   'T   "!
M@P   (4   "&    B    (D   "+!   C0@  (\-  "2$   E!8  )8@  "6
M+   ECL  )9,  "58   E78  )20  "3IP  DKT  )+5 $15   Y60  +UT
M "1C   ::0  $F\   QU   $>P   (    "%    B0   (T   "1    DP
M )0   "6    F    )H   "<    G@   * &  "B"P  I1   *@7  "I(P
MJ3$  *E#  "I5@  J&T  *:'  "GG@  IK,  *7' #Y>   R8P  )VH  !UP
M   3>   #'\   .%    BP   )$   "6    FP   )\   "B    I    *4
M  "G    J0   *L   "M    L    +(   "U @  MPD  +L0  "^&   OB8
M +XX  "^2P  O6$  +QZ  "[E   NJD  +JY #=J   K<   ('@  !:    -
MB   !8\   "6    G    *(   "G    K    +    "S    M@   +<   "Y
M    NP   +T   "_    P@   ,4   #(    R@   ,X(  #2$   U1L  -4L
M  #40   U%<  --N  #4A@  U)L  -.K /\   #_    _P   /\ !0#_  X
M_P 5 /P ( #Y "H ]@ T /$ /0#M $8 Z0!- .8 4P#D %D X0!> -X 8P#<
M &@ V0!N -4 <P#3 'D T "  ,X B #+ )$ R0"< ,8 IP#$ +< P@#, ,
M[ "_ /\ O@#_ +T _P"W /\ L@#_ /\   #_    _P   /H  0#S  L [0 2
M .@ &P#E "4 Y  N -\ . #8 $  T@!' ,X 3@#+ %0 R !9 ,8 7@#$ &,
MP@!G ,  ;0"_ ', O0!Z +L @0"Y (L M@"5 +0 H0"R *\ L #" *X XP"N
M /H K #_ *T _P"I /\ I@#_ /\   #_    \@   .8   #=  < T@ . ,T
M%@#* "  R  I ,4 ,@#  #H O !" +D 2 "W $X M0!3 +, 6 "Q %T L !B
M *X 9P"L &P J@!S *D >P"G (0 I0". *, F@"A *@ GP"Y )X T@"= /(
MG #_ )T _P"< /\ F0#_ /P   #N    W0   ,P   #!  ( N@ , +8 $@"R
M !H L  C *\ + "M #0 J0 \ *8 0@"D $@ H@!- *  4@"> %< G0!; )P
M8 ": &8 F0!L )< = "5 'T DP"' )$ DP"0 *$ C@"Q (T Q@", .@ BP#]
M (P _P", /\ C #_ .T   #8    Q0   +<   "L    I@ ( *$ #@"? !4
MG0 > )L )@": "X EP U )4 / "3 $( D0!' )  3 ". %$ C0!5 (L 6@"*
M &  B0!F (< ;0"% '8 A "  (( C "  )H ?P"I 'T O !\ -P ? #U 'P
M_P!\ /\ ? #_ -D   #!    L0   *0   "<    E  # )  # "- !$ BP 8
M (D ( ") "@ AP O (4 -@"# #P @@!! (  1@!_ $L ?0!/ 'P 5 ![ %H
M>0!@ '@ 9P!V '  =0!Z ', A@!Q ), < "B &\ M !N ,P ;@#M &X _@!N
M /\ ;@#_ ,0   "O    H    )0   ",    A@   ($ " !^  X ?  4 'L
M&P!Y "( >  I '< , !U #8 =  [ '( 0 !Q $4 < !* &\ 3P!M %0 ; !;
M &L 8@!I &H : !T &8 @ !E (X 8P"= &( K0!A ,( 80#D &$ ^ !A /\
M80#_ +0   "@    D0   (8   !^    >0   '4  P!Q  L ;P 0 &T %@!L
M !T :P D &L *@!I #  :  V &8 .P!E $  9 !% &, 2@!A $\ 8 !6 %\
M70!= &4 7 !O %H >@!9 (@ 6 "8 %< J !6 +L 5@#8 %8 \0!6 /\ 5@#_
M *@!  "4!0  A0<  'H'  !R!@  ; 0  &D!  !G  < 9  - &, $0!A !@
M8  ? %\ )0!> "L 70 P %L -@!: #L 60!  %@ 10!7 $L 5@!1 %4 6 !3
M &$ 4@!J %  =@!/ (0 3@"3 $T I !, +8 3 #- $P ZP!, /H 3 #_ )T)
M  "+"P  ? T  ' -  !H#0  8@P  %\*  !=!@$ 7 $) %H #@!8 !, 5P 9
M %8 ( !5 "8 4P K %( ,0!1 #8 4  [ $\ 00!. $< 30!- $L 50!* %T
M20!G $< <P!& (  10"0 $0 H0!# +( 0P#( $, Y@!# /4 0P#_ )4-  "#
M#P  =!   &D1  !@$0  6A   %8.  !4#0  4PH$ %,&"P!1 Q  3P$5 $X!
M&P!, 2$ 2P$G $H"+ !) C( 2 (W $<#/0!% T, 1 -* $,$40!"!%H 0 5D
M #\%<  ^!GX /0:. #P'GP [![$ .@?& #H'XP Z!_, .@C\ (X0  !\$@
M;A0  &(5  !:%0  5!0  % 3  !-$0  2PX  $L-!@!*"@P 20@1 $<(%@!%
M"!T 1 @C $((* !!"2X 0 DS #\).0 ^"D  /0I' #P*3P Z"U@ .0MC #@,
M;P V#'X -0R. #0-GP S#;$ ,@W' #(-XP R#?0 ,@W^ (@3  !W%0  :1<
M %X8  !5&   3Q@  $H6  !'%0  11,  $,0 @!##@@ 0@T. $ -$@ _#1@
M/0T? #P-)  [#2H .0TP #@.-P W#CT -@Y% #4.30 S#U< ,@]B #$0;@ O
M$'T +A". "T1H  L$;( *Q'( "L1Y@ K$?8 +!'_ (,6  !R&0  9!H  %D;
M  !1&P  2QL  $8:  !"&   /Q<  #X4   \$@0 .Q$* #H0$  X$!4 -Q ;
M #41(0 T$2< ,Q$M #(1,P P$3H +Q)" "X22P M$U0 *Q-? "H4;  I%'L
M*!2, "<5G@ F%;  )17& "45Y  E%?8 )A7_ 'X9  !N&P  8!T  %8>  !-
M'@  1QX  $(=   ^'   .AH  #@8   W%@  -14' #04#0 R%!( ,!07 "\4
M'0 M%", +!4J "L5,  J%3< *18_ "@62  G%U( )AA= "08:@ C&7D (AF*
M "$9G  @&:\ 'QG$ !\9X@ @&?0 (!G_ 'H;  !J'@  71\  %,@  !*(
M1"   #X?   Z'@  -QT  #0<   R&0  ,!D$ "X8"P L&!  *A@4 "D8&@ G
M&"  )ADF "49+0 D&C4 (QH] "(;1@ A&U  (!Q; !\=:  >'7< '1V( !P>
MFP ;'JT &A[# !H>X  :'?, &QW_ '<=  !G(   6B$  % B  !((@  02(
M #LB   W(0  ,R   # ?   M'0  *QT  "@="  F'0X )1T2 ",=%P A'1T
M(1TD " >*@ ?'C( 'A\Z !T?0P <($T &R%9 !HA9@ 9(74 &"*' !<BF0 6
M(JP %2+! !4BWP 5(?( %B'^ ',@  !D(@  5R,  $TD  !%)0  /B0  #DD
M   T(P  ,"(  "PB   I(0  )B$  "0A!@ B(0P ("$0 !XA%0 =(AL &R(A
M !LB*  :(R\ &2,X !@D00 7)$L %B57 !4E9  4)G, $R:% !(FF  1)JL
M$2;  ! FW0 1)?$ $B7] ' B  !A)   5"8  $HF  !")P  /"8  #8F   Q
M)0  +24  "DD   F)   (B4  !\E P =)@H &R8. !DG$@ 8)Q@ %R<? !8G
M)0 5*"T %"@U !,I/@ 2*4D $2E5 !$J8@ 0*G$ #RJ#  XJE@ .*JD #2J]
M  TJUP -*NX #BG[ &PD  !=)@  42@  $@H  ! *0  .2@  #0H   O*
M*R<  "<G   B*   'BD  !LJ   8*P< %BL- !0L$0 3+!8 $BP< !$M(P 0
M+2H $"TR  \N/  .+D8 #2Y2  TN7P ,+VX "R]_  HOD@ )+Z4 "2ZY  @N
MT  )+ND "B[W &@G  !:*0  3BH  $4K   ]*P  -RL  #$J   M*@  *2H
M "0J   @*P  &RT  !@N   5+P0 $C$* ! R#@ /,A, #C(9  TR(  -,B<
M##(O  LS.  *,T( "3-.  @S6P &-&H !31[  0SC@ #,Z(  C.V  (SS0 #
M,^< !#+S &0J  !6+   2RT  $(M   Z+0  -"T  "\L   K+   )BP  "(M
M   =+P  &3$  !4R   2- , #S8)  PX#0 *.!$ "3@6  @X'0 '."0 !C@L
M  0X-  #.#X  CE*   Y5P  .64  #EW   YBP  .)\  #BS   XR@  ..8
M #?R %\M  !2+@  2"\  #\P   X+P  ,B\  "TO   I+P  )#   !\Q   :
M,P  %34  !(W   /.0, ##L(  @]#0 %/A   SX4   ^&@  /B$  #XH   ^
M,0  /SL  #]&   _4P  /V$  #]S   _AP  /IP  #ZP   ]QP  />0  #WR
M %HP  !.,@  1#(  #PR   U,@  ,#$  "LQ   F,@  (#0  !LV   6.
M$CL   \]   ,/P, "$$(  1##   0PX  $02  !%%@  11T  $4D  !%+0
M1C8  $9"  !&3@  1ET  $9N  !%@@  19@  $2M  !$Q   0^,  $/R %4T
M  !*-0  034  #DU   S-   +C0  "@U   B-P  '3H  !<\   2/P  #T$
M  Q$   (1@$  T@&  !)"@  2@T  $L0  !,%   31D  $X@  !.*   3C(
M $T]  !.2@  3E@  $UI  !-?0  3)0  $RJ  !+P0  2^$  $KR % X  !&
M.   /3@  #<X   Q-P  *CD  "0[   >/0  &$   !-#   /1@  "TD   =+
M   "3@   % $  !1"   4@L  %,.  !4$0  514  %8;  !7(P  5RP  %<X
M  !71   5U(  %9C  !6=P  5HX  %6E  !4O0  4]T  %/P $L\  !"/
M.SL  #4[   M/   )C\  !]"   910  $T@   Y+   +3P  !5$   !4
M5P   %@!  !:!0  6P@  %P,  !=#@  7Q$  & 6  !B'0  8B8  &(Q  !B
M/@  84P  &%=  !A<   8(@  &"@  !?MP  7M0  %WN $=    _/P  .C\
M #%    I0P  (48  !I*   33@  #E$   I5   $6    %L   !>    80
M &,   !D 0  900  &<(  !H"P  :@X  &P2  !N%P  ;R   &\J  !O-@
M;D4  &Y5  !N:   ;7\  &V8  !LL   :\H  &KH $1$   ^0P  -40  "M'
M   C2P  &T\  !-4   .6   "%P   )@    9    &<   !K    ;0   &\
M  !P    <@   '0"  !U!@  =PH  'D.  !\$@  ?A@  '\B  !_+@  ?ST
M 'Y-  !]80  ?7<  'R0  ![J   >L   'G? $-'   Y20  +TP  "50   <
M50  %%L   Y@   '90   &H   !N    <@   '8   !Y    ?    'X   !_
M    @0   (,   "%    AP,  (H(  ",#0  CQ$  )(9  "2)0  DC,  ))$
M  "15P  D&T  (^&  ".GP  C;4  (S- #U.   R40  *%8  !Y<   58@
M#F@   =N    =    'D   !^    @@   (8   ")    C    (X   "0
MD@   )0   "6    F    )L   ">!@  H0P  *01  "F&P  IBD  *8Z  "E
M30  I6(  *1[  "CE   H:L  *&_ #97   L7   (6(  !=I   /<   !W<
M  !^    A    (H   "/    E    )@   ";    G@   )\   "B    I
M *8   "H    JP   *T   "P    LP0  +<,  "[$@  NQ\  +LP  "[0P
MNE@  +EP  "WBP  MZ$  +>S #!B   E:0  &G   !!X   )@    (@   "/
M    E@   )L   "A    I@   *H   "N    L    +$   "T    M@   +@
M  "[    O0   ,    ##    QP   ,L#  #/#   TQ4  -(E  #2.   T4X
M -!E  #/?@  S98  ,RI /\   #_    _P   /\  P#_  L _  1 /D &P#W
M "4 \P O .X . #I $  Y@!( .( 3@#? %0 W !9 -D 7@#5 &, TP!H -
M;0#. ', RP!Z ,@ @@#& (P PP"7 ,  HP"^ +( O #( +H Z@"Y /\ N #_
M +$ _P"J /\ IP#_ /\   #_    ^P   /8   #M  < YP / .( %@#? "
MW@ I -D ,P#1 #L S !" ,@ 2 #% $X P@!3 ,  6 "^ %T O !B +H 9P"Y
M &T MP!T +4 >P"R (4 L "0 *X G "L *H J0"] *< W@"F /D I0#_ *,
M_P"= /\ FP#_ /T   #V    ZP   -\   #1  , R@ , ,4 $@## !L P  D
M +X + "Y #4 M@ \ +, 0P"P $@ K@!. *P 4@"K %< J0!< *< 80"F &<
MI !M *( = "@ 'T G@"( )P E0": *, F "T )8 S0"5 /$ E #_ )4 _P"0
M /\ C@#_ /,   #F    T0   ,(   "X    L0 ( *T #P"J !8 J  > *@
M)P"F "\ H@ V )\ / "= $( FP!' )D 3 "7 %$ E@!5 )0 6@"3 &  D0!F
M )  ;@". '8 C "! (H C0"( )L A@"L (4 P0"$ .8 @P#] (0 _P"# /\
M@0#_ .0   #+    N@   *P   "B    G  $ )@ # "6 !$ E  9 ), (0"2
M "@ CP P (T -@"+ #P B0!! (@ 1@"& $L A0!/ (0 5 "" %H @0!@ '\
M9P!^ &\ ? !Z 'H A@!X )0 =P"D '4 MP!T -0 <P#T '0 _P!T /\ = #_
M ,L   "V    I@   )H   "2    B@   (8 " "#  X @0 4 ($ &P"  ",
M?P J 'T , ![ #8 >@ [ '@ 0 !W $4 =0!) '0 3@!S %0 <0!: '  80!N
M &D ;0!S &L ?P!I (T : "= &< K@!F ,< 90#J &8 _P!F /\ 9P#_ +@
M  "D    E0   (H   "!    ?    '8 ! !T  P <@ 0 '$ %@!P !T <  D
M &X *@!M #  :P U &H .@!I #\ : !$ &< 20!E $X 9 !4 &, 6P!A &,
M8 !M %X >0!= (< 6P"6 %H J !9 +T 60#? %D ^ !: /\ 6@#_ *@   "5
M    AP   'L   !S    ;@   &H  0!G  @ 90 . &0 $@!C !@ 8P ? &(
M)0!A "H 7P P %X -0!= #H 7  ^ %L 1 !9 $D 6 !/ %< 5@!6 %X 5 !H
M %, <P!1 ($ 4 "1 $\ H@!. +4 3@#0 $X \ !. /\ 3P#_ )P   ")
M>P,  ' #  !H P  8@$  %\   !=  0 6P + %D #P!8 !0 5P 9 %< ( !6
M "4 50 J %, , !2 #0 40 Y %  /P!/ $0 3@!+ $T 4@!+ %H 2@!C $D
M;P!' 'P 1@", $4 G0!% +  1 #' $0 Z !$ /H 10#_ )($  " !P  <0H
M &8*  !>"@  60D  %4'  !4!   4@ ' %  # !/ !  3@ 5 $T &P!, "
M2P F $H *P!) #  2  U $< .@!& $  10!& $, 3@!" %8 00!? $  :P ^
M '@ /0"( #P F0 \ *L / #! #L X  [ /0 .P#_ (D*  !X#   :@X  %\.
M  !7#@  40X  $T,  !+"P  2@@" $D$"0!(  T 1@ 1 $4 %@!$ !P 0P A
M $( )@!! "L /P Q #X -@ ] #P / !# #L 2@ Z %( .0!< #@ :  V '4
M-0"% #0 E@ T *@ ,P"\ #, V  S .\ ,P#[ ((-  !Q#P  9!   %D1  !1
M$0  2Q$  $<0  !$#@  0@T  $$+!0!!!PL /P4. #X#$@ \ A@ .P(= #H#
M(@ Y R@ . ,M #<#,@ V!#D -00_ #0%1P S!5  ,09: # &9@ O!W, +@>#
M "T'E0 L!Z< *P>Z "L'T@ K!^L *P?W 'T0  !L$0  7Q,  %04  !,%
M1A0  $(3   ^$@  /!   #H. 0 Z#08 .@H, #@)$  V"!0 -0@9 #0)'P R
M"20 ,0DI # )+P O"C8 +@H] "T*10 L"TX *PM9 "D,90 H#', )PR# "8-
ME0 E#:< ) V[ ",-T@ C#>L (PWW '@2  !H%   6Q8  %$7  !(%P  0A8
M #T6   Y%0  -Q,  #41   S$ , ,PX( #(-#0 P#1$ +PT6 "T-&P L#2$
M*PTG "H-+0 I#C0 * X[ "<.1  E#DX ) ]9 ",090 A$', (!"$ !\0E@ >
M$*D '1"] !P0V  =$.X '1#Y ',4  !D%@  5Q@  $T9  !%&0  /QD  #H8
M   U%P  ,A8  # 5   N$P  +1$$ "P0"@ K$ X *1 2 "@0&  F$!X )1 D
M "00*@ C$3$ (A$Y "$10@ @$DL 'A)6 !T38P <$W$ &A." !D4E0 8%*<
M%Q2[ !<3U  7$^X &!/Z ' 6  !@&0  5!H  $H;  !"'   /!L  #8;   R
M&@  +QD  "P8   J%@  *!0! "83!P E$PP (Q,0 "(3%0 @$QH 'Q,A !X4
M)P =%"X '!4V !L5/P :%DD &194 !@780 6%W  %1B! !08DP 3&*8 $ABZ
M !(7T@ 2%^P $Q?Z &P9  !=&P  41T  $<=   _'@  .1T  #0=   O'
M*QL  "@:   F&0  )!@  "(7!  @%PH 'A<. !P7$@ :%Q< &1@> !D8)  8
M&2P %QDT !8:/0 5&D< %!M2 !,;7P 2'&X $1Q_ ! <D@ 0'*4 #QRY  X<
MT  .&^H #QOX &D;  !:'0  3A\  $4?   ](   -A\  #$?   M'@  *1T
M "4=   C'   (!L  !T; 0 ;&P< &1P- !<<$  6'!4 %1P; !0=(@ 3'2D
M$AXQ !$>.@ 1'T4 $!]0  \@70 .(&P #2!\  T@CP ,(*( "R"U  L@R@ +
M(.4 #!_T &4=  !7'P  3"$  $(A   Z(0  -"$  "\A   J(   )A\  ",?
M   @'@  '1X  !D@   6( 0 %" + !(A#@ 1(1, $2(9 ! B'P /(B8 #B,O
M  XC-P -(T$ #"1-  LD60 *)&< "21X  @DBP '))X !R2Q  8DQP &(^,
M!R/Q &(?  !4(0  22,  $ C   X(P  ,B,  "PC   H(@  )"$  "$A   >
M(0  &B$  !8C   3) , $24(  \F#0 .)Q$ #2<6  PG'0 +)R, "B<K  DH
M-  (*#X !RA)  8H50 %*60 !"ET  ,IAP "*9L  2BO   HQ0 !*.$  2?P
M %XB  !1)   1B4  #TE   U)0  +R4  "HD   F)   (B,  !\C   ;)
M&"4  !0F   1* , #RD(  PL#  *+!  ""P4  <L&@ &+"$ !2PH  ,M,  "
M+3H  2U%   M4@  +F   "YQ   MA   +9D  "VM   LP@  +.   "SP %HD
M  !-)@  0R<  #HG   S)P  +2<  "@F   D)@  (28  !TF   9)P  %2D
M !$K   /+ , #2X'  DP#  &,0X  S$2  $R%P  ,AX  #(E   R+0  ,C8
M #-"   S3@  ,UT  #-M   S@0  ,I8  #*K   QP0  ,=\  #'P %8G  !*
M*0  /RH  #<J   P*@  *RD  "<H   C*   'BD  !HJ   6+   $BX   \P
M   -,0( "C0'  4U"P "-@X  #<0   X%   .!H  #@B   X*@  .3,  #D^
M   Y2@  .5D  #EI   Y?0  .),  #BH   WOP  -]X  #;P %$K  !&+
M/"P  #0L   N+   *BL  "4K   @+   &RT  !<O   3,0  $#,   TU   )
M-P( !3H&  $["@  / T  #T/   ^$@  /Q<  $ >  ! )0  0"\  $ Z  !
M1@  0%0  $!E   _>   /X\  #ZF   ^O0  /=P  #WP $TN  !"+P  .2\
M #(O   M+@  *"X  "(O   =,   &#(  !,U   0-P  ##H   D\   %/@
M $$$  !""   0PL  $0-  !&$   1Q0  $@9  !((0  2"H  $@U  !(00
M2$\  $A@  !'<P  1XH  $:B  !%N0  1=D  $3P $@R   ^,@  -C(  # Q
M   K,0  )3(  !\T   9-@  $SD  ! \   ,/P  "$(   -$    1@   $@"
M  !*!0  2P@  $P+  !.#@  3Q$  %$5  !2'   4B4  %(P  !2/   44H
M %%:  !1;0  4(0  $^=  !.M0  3=(  $WN $,V   [-@  -#4  "\T   G
M-0  (3@  !H[   4/@  $$$   Q$   '1P   DH   !-    3P   %$   !3
M @  5 4  %4(  !7"P  60X  %L1  !=%P  71\  %TJ  !=-@  7$0  %Q4
M  !;9P  6WX  %J7  !9KP  6,L  %?J #\Y   X.0  ,S@  "LY   C/
M'#\  !5#   01P  "TH   5.    40   %0   !7    6@   %P   !=
M7P   & $  !B!P  9 L  &8.  !H$@  :QD  &LC  !J+@  :CP  &I-  !I
M7P  :'4  &>/  !FJ   9<(  &3C #T]   W/   +CT  "5    =1   %DD
M !!-   *40  !%4   !:    70   &    !C    9@   &@   !J    :P
M &T   !O @  <08  '0*  !V#@  >1,  'L;  ![)P  >C4  'E%  !X60
M>&T  '>&  !VGP  =;<  '32 #Q!   R0@  *$4  "!*   73@  $%0   I9
M   "7@   &,   !G    :P   &\   !R    =0   '<   !Y    >P   'T
M  !_    @@   (0#  "'"0  B@X  (X3  "/'@  CBL  (X[  "-3@  BV,
M (I\  "*E0  B*T  (?% #9'   L2P  (D\  !E5   06P  "F$   %G
M;0   '(   !W    >P   '\   "#    A@   (@   "*    C0   (\   "1
M    E    )<   ": 0  G0<  *$-  "E%   I"$  *0Q  "C1   HED  *!P
M  "?BP  G:(  )VW #!0   E50  &UL  !)B   +:0   7    !W    ?0
M (,   "(    C0   )$   "5    F    )H   "<    GP   *$   "C
MI@   *D   "L    L    +0'  "X#@  NA@  +HG  "Y.0  N$X  +=E  "V
M?@  M98  +.K "E;   >8@  %&D   QQ   ">0   ($   ")    CP   )8
M  ";    H    *0   "H    JP   *P   "O    L@   +0   "V    N0
M +P   #     Q    ,@   #-!P  TA   -(=  #1+P  T$0  ,];  #-<P
MRXT  ,JA /\   #_    ^P   /H   #\  @ ^  / /4 %P#T "  \0 J .L
M,P#F #L X@!# -X 20#: $\ U@!4 -, 60#0 %X S@!C ,L : #) &X Q@!U
M ,, ?0#! (8 O@"2 +L G@"Y *X M@## +0 Z "S /\ KP#_ *4 _P"> /\
MFP#_ /T   #W    \@   /    #G  , X0 , -P $@#8 !L U@ D -( +0#,
M #8 Q@ ] ,( 0P"_ $D O !. +H 4P"X %@ M@!= +4 8@"S &< L0!N *\
M=@"L '\ J@"* *@ EP"E *8 HP"Y *$ V0"@ /D G@#_ )@ _P"2 /\ CP#_
M /,   #L    XP   -,   #(    P0 ) +T #P"[ !8 N0 ? +< )P"S "\
MKP W *P /0"J $, J !( *8 30"D %( HP!6 *$ 6P"? &$ G@!G )P ;P":
M '@ EP"# )4 D "3 )X D0"P )  R ". /  C0#_ (H _P"% /\ @@#_ .<
M  #=    Q@   +@   "N    J  $ *4 # "A !( H0 9 *  (@"? "D FP P
M )@ -P"6 #T DP!" )( 1P"0 $L CP!0 (T 50", %H B@!A (@ : "' '
MA0![ (, B "! )8 ?P"G 'T O !\ ., ? #] 'P _P!X /\ =@#_ -8   #
M    KP   *,   "9    DP   (\ "0"-  X BP 4 (H ' "* ", B  J (4
M, "# #8 @@ [ (  0 !_ $4 ?@!* 'P 3P![ %0 >@!: '@ 80!V &D =0!S
M ', @ !Q (X ;P"? &X L@!M ,\ ; #T &P _P!K /\ :0#_ ,    "K
MFP   (\   "'    @    'P ! !Z  P >  1 '@ %P!X !X =P D '4 *@!S
M #  <0 U '  .@!N #\ ;0!$ &P 20!K $X :@!4 &@ 6P!G &, 90!M &0
M> !B (< 8 "7 %\ J@!> ,( 7@#I %X _P!> /\ 70#_ *P   "9    B@
M '\   !W    <0   &T   !J  @ :0 . &@ $@!G !@ 9P ? &< )0!E "H
M8P O &( - !A #D 8  ^ %\ 0P!> $@ 70!. %L 50!: %T 6 !G %< <@!5
M ($ 5 "1 %, HP!2 +@ 40#< %$ ^0!2 /\ 4@#_ )T   "+    ?    '$
M  !I    9    &    !>  4 7  + %L #P!; !0 6@ 9 %H 'P!9 "4 5P J
M %8 +P!5 #0 5  X %, /0!2 $, 4 !) $\ 4 !. %@ 30!B $L ;0!* 'H
M20"+ $@ G0!' +$ 1P#, $8 \ !' /\ 1P#_ )    !^    <    &8   !>
M    60   %8   !3  $ 4@ ( %  #0!/ !  3P 5 $X &@!. "  30 E $P
M*@!* "X 20 S $@ . !' #X 1@!$ $4 2P!$ %, 0P!= $$ : !  '4 /P"%
M #X EP ] *L /0## #T Y@ ] /L /@#_ (<   !U P  : 8  %T'  !5!@
M4 8  $P$  !* 0  20 $ $< "@!&  X 10 1 $4 %@!$ !L 0P @ $( )0!!
M "H 0  O #\ -  ^ #H /0!  #L 1P Z $\ .0!9 #@ 9  W '$ -@"! #4
MDP T *8 - "[ #0 W0 T /4 -0#_ 'X&  !M"0  8 L  %8,  !.#   2 L
M $0*  !""   0 4! #\!!P ^  L /0 . #P $@ [ !< .P < #H (0 Y "4
M-P J #8 ,  U #4 -  \ #, 0P R $P ,0!5 #  8  O &T +@!] "T CP L
M *( + "V "P T  L .X + #\ '<*  !G#   6@X  % .  !)#@  0PX  #X-
M   [#   .0L  #@) P W!0@ -@(- #4!$  T !, ,P 8 #( '0 Q "( ,  G
M "\ +  N #( +0 X "P 0  K $D *@!2 "D 70 H &L )P%Z "8!C  E )\
M)0"R "4 R@ E .@ )0#W '(-  !B#@  5A   $P1  !$$0  /A$  #D0   V
M#P  ,PX  #$- 0 P"P4 , @* "\&#0 N!1$ + 04 "L#&0 J QX *0,C "@$
M*0 G!"\ )@4U "4%/0 D!48 (P90 "(&7  A!VD ( =Y !\'BP >!YT '@>P
M !T&Q@ =!N, '07S &T.  !>$0  4A(  $@3  ! $P  .A,  #42   Q$0
M+A   "P/   J#@, *@T' "D+"P H"0X )PD1 "4(%@ D"!L (PD@ "())@ A
M"2P ( HS !\*.P >"T0 '0M/ !P,6P ;#&D &@QY !@,BP 8#)X %PRP !8,
MQ0 6#.$ %@OP &D0  !:$@  3A0  $45   ]%0  -Q4  #$4   M$P  *A(
M "@1   F$ $ )! $ ",."  C#0P (@P/ " ,$P ?#!@ '@T= !T-(P <#2H
M&PTR !H..@ 8#D0 %PY0 !8/7  5#VH $Q![ !(0C0 1$*  $1"S ! /R0 0
M#^0 $0_R &42  !7%   2Q8  $(7   Z%P  -!<  "\6   J%0  )Q0  "03
M   B$P  (!(# !X1!@ =$ D '! - !L/$  9$!4 &! ; !<0(0 6$"@ %1$P
M !01.0 3$4, $A). !$26@ 0$FD $!-Y  X3C  .$YX #1.Q  T2Q0 ,$N$
M#1+Q &(4  !4%@  21@  #\9   W&0  ,1D  "P8   H%P  )!8  "$6   ?
M%0  '!0" !H3!  9$@8 %Q(+ !42#@ 4$A( $Q,8 !(3'P 1$R8 $10M ! 4
M-@ /%4$ #A5,  X65P -%F4 #!=U  L7AP *%YH "1:M  @6P0 (%MT "17N
M %\6  !1&   1AH  #T:   U&P  +QH  "H:   E&0  (A@  !\8   <%P
M&18! !<6 P 5%@0 $Q8) !$6#0 0%Q$ #Q<6  X7'  .&", #1@J  P9,P ,
M&3P "QI'  H:4P )&F$ !QMQ  8;@P %&Y< !!JJ  ,:OP #&=H !!GL %P8
M  !.&@  0QP  #H<   S'   +!P  "<<   C&P  (!H  !T9   :&0  %Q@!
M !48 @ 2&00 $!L'  X;#  -'!  #!P3  L<&0 *'!\ "1TG  @=+P ''CD
M!AY#  0>4  #'UX  A]N  $?@   'Y4  !ZI   >O0  '=@  !WL %@:  !+
M'   01X  #@>   P'@  *AX  "4=   A'   'AP  !L;   8&P  %AL! !,;
M @ 1' 0 #AX'  P?"P *( X "" 2  8A%P %(1T !"$D  (B+  !(C4  ")
M   C30  (UH  "-K   C?@  (Y,  "*G   BO   (=<  "'M %4=  !('P
M/B   #4@   N(   *"   ",?   @'@  '1T  !H=   6'0  $QX  !$? @ .
M( 0 #2('  HD"P &)0T !"40  (F%   )AH  "8A   G*0  )S(  "<]   G
M20  *%<  "AG   G>P  )Y   ">E   FNP  )M8  "7M %$@  !%(0  .R(
M #(B   L(@  )B$  "(A   >(   &Q\  !@@   4(   $2(   \C   -)0,
M"B8&  8H"@ #*0T  "L/   L$@  +!<  "P>   L)@  +2\  "TY   M1@
M+50  "UD   M=P  +(T  "RD   KN@  *]8  "KN $TB  !!)   ."0  # D
M   I)   )",  "$B   =(@  &2(  !4C   2)   #R8   TH   **@( !BP%
M  (N"0  +PL  # .   R$   ,Q4  #,;   S(@  ,RL  #,V   S0@  ,U
M #-@   S<P  ,HH  #*A   QN   ,-8  ##O $DE   ^)@  -"<  "TG   H
M)@  (R4  !\D   ;)0  %B8  !(H   0*@  #2P   HN   &, $  C($   T
M!P  -0H  #<,   X#@  .A(  #H7   Z'P  .B<  #HR   Z/@  .DP  #I<
M   Z;P  .88  #B>   XM@  -]0  #;O $0I   Z*0  ,2D  "LI   F*
M(B<  !TH   8*0  $RL  ! N   -,   "3(   4U   !-P   #D"   [!0
M/ @  #X+   _#0  01   $,4  !#&P  0R,  $,N  !#.0  0T<  $)7  !"
M:@  08$  $":   _L@  /L\  #[O #\L   V+   +RP  "HK   E*@  'RL
M !DM   4+P  $#(   TU   (.   !#H    \    /P   $$   !# @  104
M $8(  !("P  2@X  $P1  !-%@  31X  $TH  !--   3$(  $Q1  !+9
M2WL  $J4  !)K0  2,H  $?L #LP   S+P  +2\  "@M   B+P  &S$  !4T
M   0-P  #3H   @]   "0    $,   !&    2    $H   !,    3@$  $\$
M  !1!P  4PL  %4.  !8$@  61D  %@B  !8+@  5SP  %=+  !67@  5G,
M %6-  !4IP  4L(  %+F #@S   Q,@  +#$  "4R   =-0  %C@  !$\   ,
M0   !T0   !'    2@   $T   !0    4P   %4   !7    60   %H   !<
M P  7@<  &$+  !D#@  9A,  &<<  !F)P  9C0  &5$  !D5P  9&L  &*%
M  !AGP  8+D  %[< #4W   P-0  *#<  " Z   8/0  $4(   Q&   &2@
M $\   !3    5@   %D   !<    7P   &$   !D    90   &<   !I
M; $  &X&  !Q"P  = \  '<5  !W(   =BT  '8]  !U3P  =&,  '-[  !R
ME0  <*\  &_) #4Z   K.P  (C\  !I#   22   #$T   52    5P   %P
M  !@    9    &@   !K    ;@   '$   !S    =0   '<   !Z    ?
M '\   ""!   A@H  (H/  ",%P  BR0  (HS  ")10  AUL  (9R  "%BP
M@Z4  (*\ "]    E1   '$D  !-.   -5   !%H   !A    9@   &L   !O
M    =    'D   !]    @    (,   "%    AP   (H   ",    CP   )(
M  "6    F0(  )X)  "B$   HAH  *$I  "@.P  GU   )UG  ":@0  FID
M )FO "E)   ?3@  %50   Y;   %8@   &D   !P    =P   'T   ""
MA@   (L   "/    DP   )4   "7    F@   )T   "@    HP   *8   "J
M    K@   +(   "W"@  NQ$  +H?  "Y,   MT4  +5<  "T=   L8X  *^D
M ")4   86P  $&(   =J    <P   'L   ""    B0   )    "5    F@
M )\   "C    I@   *@   "K    K@   +    "S    M@   +H   "]
MP@   ,<   #, 0  TPL  -05  #3)@  T3H  -!1  #-:   RX$  ,J6 /P
M  #V    \@   /$   #S  4 ]  , /( $P#P !P [0 E .@ +@#B #8 W@ ^
M -D 1 #4 $H T0!/ ,X 5 #+ %D R0!> ,8 8P#$ &D P0!P +X > "\ ($
MN0"- +8 F@"S *L L0#  *\ Y@"N /\ I0#_ )H _P"4 /\ CP#_ /0   #L
M    Z    .<   #?    V0 ) -( $ #/ !< SP @ ,P * #& #  P  W +P
M/@"Y $0 MP!) +4 3@"S %, L0!7 *\ 70"M &( JP!I *D <0"G 'H I0"%
M *( DP"@ *( G0"V )L U "9 /D E@#_ (T _P"( /\ A #_ .@   #?
MV0   ,D   "_    N  $ +4 #0"S !( L0 : +  (@"M "H J0 Q *8 . "D
M #T H@!# *  2 "> $P G !1 )L 5@"9 %P EP!B )4 :0"3 '( D0!] (\
MBP"- )H BP"L (D Q0"( .X A@#_ '\ _P!Z /\ > #_ -D   #-    NP
M *X   "E    GP   )P "0"9  \ F0 5 )D '0"8 "0 E  K )$ ,0". #<
MC  \ (L 00") $8 B !+ (8 4 "% %4 @P!; (( 8@"  &L ?@!U 'P @@!Z
M )( > "C '< N0!V .  =0#_ '( _P!N /\ ; #_ ,<   "U    I0   )D
M  "/    B0   (4 ! "$  P @@ 1 (( %P"" !X @  E 'X *P!\ #$ >@ V
M 'D .P!W $  =@!$ '4 20!S $\ <@!5 '  7 !O &0 ;0!N &P >@!J (H
M: "; &< KP!F ,P 90#U &0 _P!A /\ 8 #_ +0   "@    D    (4   !]
M    =P   ',   !P  @ ;P . &\ $@!O !@ ;P ? &T )0!K "H :0 P &@
M- !G #D 9@ ^ &4 0P!C $@ 8@!. &$ 50!? %X 7@!G %P <P!; (( 60"3
M %@ I@!7 +\ 5P#J %< _P!6 /\ 5 #_ *$   ".    ?P   '4   !L
M:    &0   !A  0 8  + %\ #P!? !, 7P 9 %\ 'P!= "4 7  J %L +P!9
M #, 6  X %< /0!6 $, 50!) %, 4 !2 %@ 40!A %  ;0!. 'L 30", $P
MGP!+ +4 2@#< $H ^@!* /\ 2@#_ )(   "     <@   &<   !?    6@
M %<   !5  $ 4P ' %( # !2 !  4@ 4 %( &@!1 !\ 3P D $X *0!- "X
M3  S $L . !* #T 20!# $@ 2@!& %( 10!< $0 9P!# '4 0@"& $$ F !
M *X 0 #+ #\ \@!  /\ 0 #_ (4   !T    9P   %T   !5    3P   $P
M  !*    2  $ $< "@!'  T 1@ 1 $8 %0!& !H 10 ? $0 ) !# "D 0@ M
M $$ ,P _ #@ /@ ^ #T 10 \ $X .P!7 #H 8@ Y &\ . "  #< DP V *<
M-@#  #8 Z  V /X -@#_ 'P   !K    7@(  %0#  !- P  1P,  $,!  !!
M    /P ! #X !P ]  L /0 . #P $0 \ !8 /  : #H 'P Y "0 .  I #<
M+@ V #, -0 Z #0 00 S $D ,@!3 #$ 7@ P &L +P![ "X C@ M *( +0"X
M "T W0 M /@ +@#_ ',!  !D!0  5P<  $T(  !&"   0 @  #L'   X!0
M-P,  #8 !  U  @ -  , #0 #P T !( ,P 6 #( &P Q "  ,  D "\ *0 N
M "\ +0 V "P /0 K $4 *@!/ "D 6@ H &< )P!W "8 B0 F )T )0"S "4
MSP E /  )@#_ &T&  !>"0  4@L  $@,  ! #   .@L  #8+   R"@  , @
M "X& @ N P8 +0 * "P #0 L !  *P 3 "H %P I !P *  @ "< )0 F "L
M)0 R "0 .0 C $( (@!+ "( 5P A &0 ( !S !\ A0 ? )D '@"N !X QP >
M .D 'P#Z &@)  !9#   30T  $,.   \#@  -@X  #$-   M#0  *@P  "@+
M   G"00 )@8( "8$"P E PX ) $0 "0!%  B 1@ (0$= "$ (@ @ "@ 'P N
M !X!-@ = 3\ ' %) !L!5  : 6$ &@%P !D!@@ 8 )8 & "J !@ P0 8 .$
M& #T &,,  !5#@  20\  $ 0   X$   ,A   "T/   I#@  )@X  ",-   B
M# , ( L& " )"0 ?!PP '@8. !X%$0 <!14 &P4: !H%'P :!24 &04K !@%
M,P 7!CP %@9& !8&4@ 5!U\ % =N !,'@  2!Y0 $@:G !(%O  2!-D $@/O
M %\.  !1#P  1A   #P1   U$0  +Q$  "H1   F$   (A   " /   =#@(
M' T% !H-!P :"PH &0H- !@)$  7"1( %@D7 !4)'  4"2( % HI !,*,0 2
M"CH $@M% !$+40 0#%\ #PQN  X,@  .#)0 #0NG  T+N@ -"M( #0KJ %P/
M  !.$0  0Q(  #H3   R$P  +!,  "<2   C$0  'Q$  !P0   :$ ( & \$
M !8.!P 5#@D % T+ !,,#0 2#!  $@P4 !$,&@ 1#2  $ TH  \-,  .#CL
M#0Y&  T.40 ,#UX "P]M  H/?P )#Y, "0^F  @.N0 (#M  !P[H %@1  !+
M$@  0!,  #<4   P%   *10  "44   A$P  '1(  !H2   7$0( %1$% !,0
M!P 2$ D $0\* ! .#  .#@X #@\2  T0&  -$!X #! E  P0+0 +$38 "A%!
M  D130 ($EH !Q)J  82?  %$I  !!*D  ,1N  #$<\  A'H %42  !)%
M/A4  #46   M%@  )Q8  "(5   >%   &Q0  !@3   5$@, $Q(% !(1!P 0
M$0D #Q$*  T1"P ,$@X "Q(1  H2%0 )$QL "1,B  @3*@ '%#, !10^  05
M2@ #%5@  A5G  $5>@  %8X  !6C   4MP  %,\  !/I %(4  !&%@  .Q<
M #(7   K%P  )1<  "$6   <%@  &14  !84 0 4$P0 $A,& !$2"  /$@@
M#A,)  P4"@ *%0T "!80  86$P %%AD !!<?  ,7)P "&#   1@[   91P
M&54  !ED   9=P  &8P  !BB   8MP  %\\  !?J $\6  !#&   .1D  # 9
M   I&0  (QD  !\8   ;%P  &!8  !45 @ 3%04 $10& ! 4!@ .%0< #!8(
M  H7"@ '&0P !!H.  (;$@ !&Q8  !L=   <)   '"T  !PX   =1   '5(
M !UB   ==0  '8H  !R@   <M@  &]   !KK $P8  ! &@  -AL  "T;   F
M&P  (1H  !T9   9&0  %Q@  !07 P 2%@0 $!<$  X7!  ,&04 "AH'  <<
M"0 #'0L  !\-   @$   (!0  "$:   A(@  (2H  "$U   B00  (D\  ")?
M   B<@  (8@  "&?   @M@  ']$  !_M $@:   ]'   ,QT  "L=   D'0
M(!P  !P;   8&@  %AD! !,9 0 1&0$ #AH!  P< @ *'0, !Q\%  ,A"
M(@H  "0,   F#@  )A(  "88   G'P  )R<  "<R   G/@  )TL  "=<   G
M;@  )H4  ":=   EM   )-$  "/N $0=   Y'P  ,!\  "@?   C'@  'AT
M !L<   8&P  %!P  !$<   .'0  #1\   HA   &(@$  R0$   F!@  * @
M "H+   K#0  +1   "T5   M'   +20  "XN   N.@  +D@  "U8   M:@
M+8$  "R:   KL@  *M   "GO $ @   V(0  +2$  "8A   A(   '1\  !H>
M   6'@  $A\   \A   -(@  "B0   8F   "*    "L"   M!   +P8  # )
M   R#   - X  #42   U&   -2   #4J   U-@  -4,  #53   T9@  -'P
M #.6   RKP  ,<T  ##O #PC   R)   *B0  "0C   @(@  '"$  !<A   3
M(P  $"4   TG   )*0  !2L   $N    ,    #(    T 0  -@0  #@&   Z
M"0  / T  #X0   ^%   /AP  #XF   ^,0  /C\  #U.   ]80  /'<  #N1
M   ZJP  .<D  #CM #<G   O)P  *"8  ",E   ?)   &24  !0F   0*
M#2L   DN   %,    #,    U    .    #H    \    /@$  $ #  !"!P
M1 H  $8-  !)$0  21<  $@A  !(+   1SH  $=)  !&6P  17$  $2+  !#
MI0  0L,  $'H #0J   L*@  )R@  "(G   <*   %BH  !$M   -,   "3,
M  ,V    .0   #P    ^    00   $,   !&    2    $H   !, P  3@8
M % *  !3#@  5!,  %0<  !3)P  4S0  %-#  !250  46H  %"#  !/G@
M3;D  $S@ # M   K+   )BL  !\L   8+@  $C(   TU   (.0   CT   !
M    0P   $8   !)    3    $X   !1    4P   %4   !7    60$  %P&
M  !?"@  8@X  &,5  !C'P  8BP  &$\  !@3@  7V(  %Y[  !<E@  6[
M %G/ "\P   J+P  (C   !HS   3-P  #CL   @_   !1    $@   !,
M3P   %(   !5    6    %L   !=    8    &(   !D    9@   &D   !M
M!0  < L  '00  !T&   <R4  '(T  !R10  <%D  &]Q  !MBP  :Z8  &K
M "XS   E-0  '3@  !0\   .00  !T<   !,    40   %4   !9    70
M &$   !E    :    &L   !M    ;P   '(   !T    =P   'H   !^
M@@0  (8+  "*$0  B1P  (@K  "&/0  A%(  (-G  "!@0  ?YL  'ZR "DZ
M   @/0  %D(   ](   (3@   %0   !:    8    &0   !I    ;@   '(
M  !V    >@   'T   "     @@   (4   "(    BP   (X   "2    E@
M )L#  "@#   HA,  * A  "?,P  G4<  )I>  "8=P  EX\  )6G "-#   9
M2   $4X   E5    7    &,   !J    <0   '8   ![    @    (8   "*
M    C@   )$   "3    E@   )D   "<    H    *,   "G    JP   +
M  "V!   O T  +H7  "Y*   MSP  +12  "R:@  KX4  *V< !Q.   35
M"UP   %D    ;    '0   !\    @P   (D   "/    E    )H   "?
MH@   *0   "G    J@   *X   "Q    M    +@   "\    P0   ,<   #-
M    U 4  -@0  #5'@  TS$  -!(  #-7P  RW8  ,B.
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MZ>KK[.WN[_#Q\O/T]?;W^/GZ^_S]_O]M9G0Q      ,$(0   0
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MI9>2YJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3
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MH9B0Y*&8D.2AF)#DH9B0Y*&8D.39RPD:Y,X-.>?.#F#:R@R2R[PNJ\6Y3;3
MM&:]NJYZQ;6IA\NQIH?1KJ.'U:R@B-FJGHG<IYR*WJ6;B^"BFHWBGIF/XYZ9
MC^.>F8_CGIF/XYZ9C^.>F8_CGIF/XYZ9C^.>F8_CGIF/XYZ9C^.>F8_CGIF/
MXYZ9C^.>F8_CGIF/XYZ9C^/8RPD:X<\,.>7/#F#9R@R1R[XLJ\6Y3+6^M&>]
MN:Y[Q;2JA\RPIH?1K:.'U:N@B-FHGHC;I9V)W:.<BM^?FHOAFYF.XIN9CN*;
MF8[BFYF.XIN9CN*;F8[BFYF.XIN9CN*;F8[BFYF.XIN9CN*;F8[BFYF.XIN9
MCN*;F8[BFYF.XIN9CN+8RPD:W- +.>/0#6#8RPN1R[\KJ\2Z3+6]LV>^N*Y[
MQ;2IA\RPIH?1K*.'U:F@A]BFGXC;HYV(W:"<B=Z=FXK@F)J-X9B:C>&8FHWA
MF)J-X9B:C>&8FHWAF)J-X9B:C>&8FHWAF)J-X9B:C>&8FHWAF)J-X9B:C>&8
MFHWAF)J-X9B:C>'7S D:VM$+.-[1#%_6RPN1R\ IK,*Y3;:\LVB^MZY[QK.I
MA\ROIH?1JJ.&U:>AA]BDGX?:H9Z'W)Z=B-V:G(G>E9N,X)6;C."5FXS@E9N,
MX)6;C."5FXS@E9N,X)6;C."5FXS@E9N,X)6;C."5FXS@E9N,X)6;C."5FXS@
ME9N,X)6;C.#6S D9V=$+.-K3#%_4S N1R< IK<"Y3K:ZLVF_M:Y\QK*IA\RM
MIH;1J:.&U*6AAM>BH(;9GY^&VIN>A]R7G8C=DYR+WI.<B]Z3G(O>DYR+WI.<
MB]Z3G(O>DYR+WI.<B]Z3G(O>DYR+WI.<B]Z3G(O>DYR+WI.<B]Z3G(O>DYR+
MWI.<B][5S D9V-(+-]C3"U[2S N3Q[\KK;ZX4+>YLFJ_M*U\QK"IA\RKIH;0
MIZ2%U*.BA=:?H878G*"%V9B?AMJ4GH?<D)V*W9"=BMV0G8K=D)V*W9"=BMV0
MG8K=D)V*W9"=BMV0G8K=D)V*W9"=BMV0G8K=D)V*W9"=BMV0G8K=D)V*W9"=
MBMW4S0D9UM(+-];4"U[0RPJ5Q+XMKKRX4;BWLFK LZU\QJZIA\RIIH;0I:2%
MTZ"CA-6=HH36F:&%V)6@A=F1GX?:CIZ)VXZ>B=N.GHG;CIZ)VXZ>B=N.GHG;
MCIZ)VXZ>B=N.GHG;CIZ)VXZ>B=N.GHG;CIZ)VXZ>B=N.GHG;CIZ)VXZ>B=O3
MS0H8U=,+-M34"U_.RPF7P;XPK[JW4[BULFS L*U]QZRJALNGIX7/HJ6$T9ZD
MA-.:HX35EJ*$UI.AA=>/H(;8BZ")V8N@B=F+H(G9BZ")V8N@B=F+H(G9BZ")
MV8N@B=F+H(G9BZ")V8N@B=F+H(G9BZ")V8N@B=F+H(G9BZ")V8N@B=G2S@H7
MT]0+-='3"F++S F9OKTSL;>W5;FRL6W!K:U]QJJJALNDJ(3.GZ>$T)NE@]*7
MI(/3DZ.$U)"CA=6,HH;6B:&(UXFAB->)H8C7B:&(UXFAB->)H8C7B:&(UXFA
MB->)H8C7B:&(UXFAB->)H8C7B:&(UXFAB->)H8C7B:&(UXFAB-?0SPH6T=0+
M-\[3"F7&R@N=N;PXLK2V6+JML6[!JJY]QJ>KA<FAJ83,G*B#SI>G@\^3IH/1
MD*6$THVEA=.*I(;3AZ.(U(>CB-2'HXC4AZ.(U(>CB-2'HXC4AZ.(U(>CB-2'
MHXC4AZ.(U(>CB-2'HXC4AZ.(U(>CB-2'HXC4AZ.(U(>CB-3.T H5SM0*.LK3
M"FC R ^AM;L^M*VU6[NIL6_!IJ]]Q*.MA,>=JX/*F*J#RY.I@\V0J(3.C:>$
MSXJGA<^'IH?0A::(T86FB-&%IHC1A::(T86FB-&%IHC1A::(T86FB-&%IHC1
MA::(T86FB-&%IHC1A::(T86FB-&%IHC1A::(T86FB-',T D8RM0*/L73"FVX
MQ1:EKKE$M:>U7KNCLG# H;!]PY^NA,69K8/'E*R$R9"KA,J-JH7+BJJ%RXBI
MALR%J8?-@ZB)S8.HB<V#J(G-@ZB)S8.HB<V#J(G-@ZB)S8.HB<V#J(G-@ZB)
MS8.HB<V#J(G-@ZB)S8.HB<V#J(G-@ZB)S8.HB<W(T0D;Q=4*0K_3"G*QQ!ZG
MI;E)MJ&V8+N>LW"^G;%]P9NPA,.5KX3$D:Z$QHVMA<>*K8;'B*R&R(:LA\B$
MJXG)@JN*R8*KBLF"JXK)@JN*R8*KBLF"JXK)@JN*R8*KBLF"JXK)@JN*R8*K
MBLF"JXK)@JN*R8*KBLF"JXK)@JN*R8*KBLG$T@@@P-8)2+C4"GBISQ>8GKY'
MKIJV8KJ8M7&\E[-\OI>RA,"2L87"C;"%PXJOAL2(KX?$AJ^(Q82NB<6#KHK%
M@:Z+Q8&NB\6!KHO%@:Z+Q8&NB\6!KHO%@:Z+Q8&NB\6!KHO%@:Z+Q8&NB\6!
MKHO%@:Z+Q8&NB\6!KHO%@:Z+Q8&NB\6_U <ENM<)3J[:"W"@VQ.'E\TYFI+#
M6*B1O&RRD;=ZN9*T@[V.LX:_B[*'P(BQA\"&L8C!A+&)P8.QBL&"L8O"@+",
MPH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"
M@+",PH"PC,* L(S"@+",PH"PC,+WP! 5^, 6,?F](%/JMRA\S*A$JL:E7;3"
MHW"ZOJ)_O[R@B,.YFXC&MYB(RK65B<VSDHK0L8^+TK",C=2OBI#6KHB3V*V&
MF-FLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=
MVJR%G=JLA9W:K(6=VJR%G=KWP! 5^, 6,?F](%/JMRA\S*A$JL:E7;3"HW"Z
MOJ)_O[R@B,.YFXC&MYB(RK65B<VSDHK0L8^+TK",C=2OBI#6KHB3V*V&F-FL
MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%
MG=JLA9W:K(6=VJR%G=KWP! 5^, 6,?F](%/JMRA\S*A$JL:E7;3"HW"ZOJ)_
MO[R@B,.YFXC&MYB(RK65B<VSDHK0L8^+TK",C=2OBI#6KHB3V*V&F-FLA9W:
MK(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JL
MA9W:K(6=VJR%G=KWP! 5^, 6,?F](%/JMRA\S*A$JL:E7;3"HW"ZOJ)_O[R@
MB,.YFXC&MYB(RK65B<VSDHK0L8^+TK",C=2OBI#6KHB3V*V&F-FLA9W:K(6=
MVJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:
MK(6=VJR%G=KWP! 5^, 6,?F](%/JMRA\S*A$JL:E7;3"HW"ZOJ)_O[R@B,.Y
MFXC&MYB(RK65B<VSDHK0L8^+TK",C=2OBI#6KHB3V*V&F-FLA9W:K(6=VJR%
MG=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=
MVJR%G=KWP! 5^, 6,?F](%/JMRA\S*A$JL:E7;3"HW"ZOJ)_O[R@B,.YFXC&
MMYB(RK65B<VSDHK0L8^+TK",C=2OBI#6KHB3V*V&F-FLA9W:K(6=VJR%G=JL
MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%
MG=KWP! 5^, 6,?F](%/JMRA\S*A$JL:E7;3"HW"ZOJ)_O[R@B,.YFXC&MYB(
MRK65B<VSDHK0L8^+TK",C=2OBI#6KHB3V*V&F-FLA9W:K(6=VJR%G=JLA9W:
MK(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=KW
MP! 5^, 6,?F](%/JMRA\S*A$JL:E7;3"HW"ZOJ)_O[R@B,.YFXC&MYB(RK65
MB<VSDHK0L8^+TK",C=2OBI#6KHB3V*V&F-FLA9W:K(6=VJR%G=JLA9W:K(6=
MVJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=KWP! 5
M^, 6,?F](%/JMRA\S*A$JL:E7;3"HW"ZOJ)_O[R@B,.YFXC&MYB(RK65B<VS
MDHK0L8^+TK",C=2OBI#6KHB3V*V&F-FLA9W:K(6=VJR%G=JLA9W:K(6=VJR%
MG=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=KWP! 5^, 6
M,?F](%/JMRA\S*A$JL:E7;3"HW"ZOJ)_O[R@B,.YFXC&MYB(RK65B<VSDHK0
ML8^+TK",C=2OBI#6KHB3V*V&F-FLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JL
MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=KWP! 5^, 6,?F]
M(%/JMRA\S*A$JL:E7;3"HW"ZOJ)_O[R@B,.YFXC&MYB(RK65B<VSDHK0L8^+
MTK",C=2OBI#6KHB3V*V&F-FLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:
MK(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=KWP! 5^, 6,?F](%/J
MMRA\S*A$JL:E7;3"HW"ZOJ)_O[R@B,.YFXC&MYB(RK65B<VSDHK0L8^+TK",
MC=2OBI#6KHB3V*V&F-FLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=
MVJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=KWP \5^, 6,/F](%/JN"=\
MS*A$J\:E7;3"I'"ZOJ)_O[R@B,.YFXC'MYB(RK65B<ZSDHK0L8^+T["-C=6O
MBH_7K8B3V:V&F-JKAIW:JX:=VJN&G=JKAIW:JX:=VJN&G=JKAIW:JX:=VJN&
MG=JKAIW:JX:=VJN&G=JKAIW:JX:=VJN&G=KWP0\5]\$6,/B^'U/JN"9\RZE#
MJ\:F7+3"I&^ZOJ)^O[N@B,.YG8?(MIJ'S+.7B,^QE(G2L)**U:Z/C->MC8[9
MK(J2W*N)F=VGB)S;IXB<VZ>(G-NGB)S;IXB<VZ>(G-NGB)S;IXB<VZ>(G-NG
MB)S;IXB<VZ>(G-NGB)S;IXB<VZ>(G-OVP0X4]\$5,/B_'E/JN25\RZE"J\:G
M6[/"I6ZZOJ-^O[NAB,2XGH?)M9R'S;*9A]&PEHC4KI2)UZV2B]JKD(W<J8V2
MWZB-FM^CBYS<HXN<W*.+G-RCBYS<HXN<W*.+G-RCBYS<HXN<W*.+G-RCBYS<
MHXN<W*.+G-RCBYS<HXN<W*.+G-SVP0X4]L(5,/>_'E/JNB1\RZE!K,:G6K/"
MI6VZOJ-]O[NCB,2WH(?)M)V'SK&;A].OF8C6K9>)VJN5BMRIDXW?IY*1XJ21
MF>"@CIS<H(Z<W*".G-R@CIS<H(Z<W*".G-R@CIS<H(Z<W*".G-R@CIS<H(Z<
MW*".G-R@CIS<H(Z<W*".G-SUP@X4]<(4,/; '5/JNB-\RZI!K,:H6;/"IFVZ
MOJ1]O[JDA\6WH8?*LY^'S["=A]2NFXC8JYF)W*F8B]^GF([BI9>2YJ"6F>"<
MDYO=G).;W9R3F]V<DYO=G).;W9R3F]V<DYO=G).;W9R3F]V<DYO=G).;W9R3
MF]V<DYO=G).;W9R3F]WTP@T4]<,4,/; '%/JNR)\RJI K,:H6+/"IFRZOJ1\
MO[JEA<6VHX?+LZ&'T+"?A]6MG8C:JIV*W:>;C."DFH[BGYB/XYV:F.&9EYO=
MF9>;W9F7F]V9EYO=F9>;W9F7F]V9EYO=F9>;W9F7F]V9EYO=F9>;W9F7F]V9
MEYO=F9>;W9F7F]WRPPT4],,3,/7!&U/JO"%\RJL_K<:I5[/"IVNZOJ5[O[JF
MA,6VI8?+LJ.'T:^AA]:KGXC:IYV)W:2<BM^@FXO@FYJ-XI>:D^&7G)O>EYR;
MWI><F]Z7G)O>EYR;WI><F]Z7G)O>EYR;WI><F]Z7G)O>EYR;WI><F]Z7G)O>
MEYR;WI><F][PPPT4],03+_7"&E+JO2!\RJL^K,:J5K/"J&NZOJ=YO[JH@\6V
MIX?,LJ6'T:RBA]:HH(?9I)Z(W*&=B-V<G(G>EYN+X).;C^"2G9?>DIV7WI*=
ME]Z2G9?>DIV7WI*=E]Z2G9?>DIV7WI*=E]Z2G9?>DIV7WI*=E]Z2G9?>DIV7
MWI*=E][MQ P3\\42+_3"&5+JO1]\RJP\K,:K5;/"J&JYOJEWO[JJ@,6UJ8?,
MKZ6'TJJBA]:EH(;8H9^&VIV>A]N9G8?=E)V)WI"<C=Z.G9/=CIV3W8Z=D]V.
MG9/=CIV3W8Z=D]V.G9/=CIV3W8Z=D]V.G9/=CIV3W8Z=D]V.G9/=CIV3W8Z=
MD]WJQ0P3\L41+_/#&%+JOAU\RZTZK,:L5+/"J6FYOJQSO[JM?L6RJ8?,K*6&
MT:>CAM6BH877GJ"%V)J@A=J6GX;;D9Z(W(V>B]R+GH_<BYZ/W(N>C]R+GH_<
MBYZ/W(N>C]R+GH_<BYZ/W(N>C]R+GH_<BYZ/W(N>C]R+GH_<BYZ/W(N>C]SF
MQ0L3\<81+_+$%U+JP!M\RZ\XK,:M4K+"JV:YO[!OOK>M?L:PJ8?-JJ:&T:2D
MA=.?HX35FZ*$UI>AA=B3H(79CZ"'V8N?BMJ(GXW:B)^-VHB?C=J(GXW:B)^-
MVHB?C=J(GXW:B)^-VHB?C=J(GXW:B)^-VHB?C=J(GXW:B)^-VHB?C=KAQ@H3
M\,<0+O#&%E'JP1E\R[ UJ\>O3[+#L&"XO+)LO[*M?L>MJ8;,IZ>%SZ&EA-*<
MI(33F*.$U)2CA-60HH76C:&&UXFAB-B'H8O8AZ&+V(>AB]B'H8O8AZ&+V(>A
MB]B'H8O8AZ&+V(>AB]B'H8O8AZ&+V(>AB]B'H8O8AZ&+V(>AB]C;QPD2[LD/
M+N[(%%'KQ!9\S+,PJ\>Q3+'$N%:WMK%NP:ZM?\>IJH;+HZB$SIZG@\^9IH/1
ME:6#TI&DA-..I(74BZ.&U(BCB-6%HXK5A:.*U86CBM6%HXK5A:.*U86CBM6%
MHXK5A:.*U86CBM6%HXK5A:.*U86CBM6%HXK5A:.*U86CBM7:R D2Z\L-+>O*
M$5#KQQ)\S+8JJLBW1+"ZMEFZK[%PPJJM?\>FJX7*H*J$S)JH@\V6J(/.DJ>#
MSX^FA-",IH71B:6&T8>EA]*%I8G2A:6)TH6EB=*%I8G2A:6)TH6EB=*%I8G2
MA:6)TH6EB=*%I8G2A:6)TH6EB=*%I8G2A:6)TH6EB=+8R0D1W\T++.?-#T_H
MRPY[S;PBJ,*\/+&QM5Z\J;%RPJ:N?\6BK83'G*N#R9>J@\J3JH3+D*F$S(VI
MA,V+J(7-B*B&SH:GA\Z$IXG/A*>)SX2GB<^$IXG/A*>)SX2GB<^$IXG/A*>)
MSX2GB<^$IXG/A*>)SX2GB<^$IXG/A*>)SX2GB<_5R0D0V,\**]K3"T[8T MZ
MS<,6J+.Z1K6IM&*]I+%TP:&P?\.>KH3%F:V$QY2LA,B0JX3)CJN$RHNJA<N)
MJH;+AZF'S(6IB,R#J8G,@ZF)S(.IB<R#J8G,@ZF)S(.IB<R#J8G,@ZF)S(.I
MB<R#J8G,@ZF)S(.IB<R#J8G,@ZF)S(.IB<S2RPD/U-$**=75"TS0T I^N+\E
MKJBX3[BAM&:\GK)UOYVQ?\&;L(3#EJZ$Q9&NA,:.K87'BZR%QXFLALB'K(?)
MAJN'R82KB<F"JXK*@JN*RH*KBLJ"JXK*@JN*RH*KBLJ"JXK*@JN*RH*KBLJ"
MJXK*@JN*RH*KBLJ"JXK*@JN*RH*KBLK/S D-T-(**,[4"E+%T0J#JL,MJ)ZW
M5[B;M6B[FK1UOIFR?[^7L83!D["%PH^OA<.,KX7$BJZ&Q8BNA\6&KHC&A*V(
MQH.MBL:!K8O'@:V+QX&MB\>!K8O'@:V+QX&MB\>!K8O'@:V+QX&MB\>!K8O'
M@:V+QX&MB\>!K8O'@:V+QX&MB\?,S0D,R],*+<?4"EFRV N GLTKFIC!4*N6
MN&>WE;5UO)2T?KZ4LX6_D+*%P(RQAL&*L8?"B+"'PH:PB,*%L(G#@["*PX*O
MB\.!KXS#@:^,PX&OC,.!KXS#@:^,PX&OC,.!KXS#@:^,PX&OC,.!KXS#@:^,
MPX&OC,.!KXS#@:^,PX&OC,/'SP@0Q=0)-+C9"ENBYQ)VE]HEB9#/19B.QUVC
MC<%NJXV]>;&,NH&TB;B#MX:WA;F$MH:Z@[6'NX*UB+R!M(F]@+2*O7^TB[Y^
MLXR^?K.,OGZSC+Y^LXR^?K.,OGZSC+Y^LXR^?K.,OGZSC+Y^LXR^?K.,OGZS
MC+Y^LXR^?K.,OGZSC+["T0<6O=8(.J?Q#E6;\1MHD>8M>(G=0(6%U5:/@\]G
MEX++<YU^R'BA>\9\I'G$?Z9WPX*H=<*$J73"A:ISP8>K<L&(JW+ BJQQP(NL
M<<"+K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K'' BZQQ
MP(NL<<"+K'' BZS_N!0._[@>)_^T*D;WKS9IWJ="C\>;8K'$FW*VPIM_N<";
MB+V^F8G O)6*P[J1B\:XC8W(MXJ/RK:(D<RUA9/-M(.6S[.!F="S@)W1LG^C
MT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31
ML'ZDT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="C\>;8K'$FW*VPIM_N<";B+V^
MF8G O)6*P[J1B\:XC8W(MXJ/RK:(D<RUA9/-M(.6S[.!F="S@)W1LG^CT;!^
MI-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZD
MT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="C\>;8K'$FW*VPIM_N<";B+V^F8G
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MB*B&SH:HA\Z#J(G.@:>,SX"GC<^ IXW/@*>-SX"GC<^ IXW/@*>-SX"GC<^
MIXW/@*>-SX"GC<^ IXW/@*>-SX"GC<_?Q D+\L40(_/$%D/TP1QIWL(5C\'
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M@;&,PH"QC,* L8S"@+&,PH"QC,* L8S"@+&,PH"QC,* L8S"@+&,PH"QC,*
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MBJ2&TX:CB-2#HXS4@:.1U("DF=. IJ'1@*:AT8"FH=& IJ'1@*:AT8"FH=&
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M9>J77W[<DVZ3SY)XI<:2@K3$DHFVPY&.N,&.D+K BI*\OX>4O;Z$EK^^@IG
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M?ZG)H8"LQJ& K,:A@*S&H8"LQJ& K,:A@*S&H8"LQJ& K,:A@*S&H8"LQJ&
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MV,P@F+Z_/:ZPN%FXJ;-LOJ6P>L*BKH3%FZR#R)2JA,J.J83,B*B&SH.GB<^
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MIJC-<JFIS'&MJLQPLJO+<+:KRV^\J\APP*O$<<"JQ'' JL1QP*K$<<"JQ''
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M2^V?;DOMGVY+[9]N2^V?;DOMGV[1N0, O,4% *W6 P&?^ L+D_\6&(G_)"2
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MO:ICN+^K9K"_K&FJOZQLI;^K;:+ JFVBP*IMHL"J;:+ JFVBP*IMHL"J;:+
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MD%;4S9!6S=&25\C1DU?(T9-7R-&35\C1DU?(T9-7R-&35\C1DU?(T9/_G L
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M<T[5YW1.U>=T3M7G=$[5YW1.U>=T3M7G=$[5YW3_E@H WJP" ,NZ!0"]QP8
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M@5RFWX%<IM^!7*;?@5RFWX%<IM^!7*;?@5RFWX'_@ \!_XX. ?^B#0#;M0@
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M>VR-Y'EMC.5X;8SE>&V,Y7AMC.5X;8SE>&V,Y7C_;A,!_WL1 ?^-$ #_G1
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M:5*O[VE2K^]I4J_O:5*O[VG_?PH [98  -*F 0#$L@, N;P# +#)!@"IV H
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M#A7_D@\4_Z 0$_^M$1/_NA$3_\,2$__#$A/_PQ(3_\,2$__#$A/_PQ*7O@
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M./]#J3K_0K \_T*X/?]!P3[_0,L__T#<0/\_Z4#_/_1 _S[]0?] _T#]0O]
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M;7A][FMX?/!I>'SP:7A\\&EX?/!I>'SP:7A\\&G_8!<!_VX2 ?]^$ #_C!$
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M9F./\69CC_%F8X_Q9F./\6;_:Q !_WX) /&0! #6G@, S*H& ,2T!@"^O@4
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M=N@X#F[H019FYTH=7^=2(UGG6RE5YV0M4.=M,4SG>#5)YX0X1NB1.D/HH#Q
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M*"[_R"DM_^HJ+/__*BS__RHO^?\J+_G_*B_Y_RHO^?\J+_G_*B_Y_RJYI@
MJJX  )RY  ".Q0  @=$  '7>  !M^@D 9?\1 5[_&@)7_R,#4O\L!4S_- =(
M_SP*0_]$##__3 X\_U,0./];$C7_8Q0R_VP6+_]W%RS_A!DI_Y,:)_^B'"7_
MM!TD_\P>(__M'B+__1\B__\?(O__'R+__Q\B__\?(O__'R+__Q^LJP  G;8
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M781O^EN#;_M9@V_\6(-O_%B#;_Q8@V_\6(-O_%C_5A@!_V01 ?]R#@#_?A
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M6G!\^UIP?/M:<'S[6G!\^UK_7Q$!_V\* /]^" #CC , UI<% ,^@!P#*J @
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M.T/0ZCI S?T^/LO_0$##_T)!O?]#0KG_1$*Y_T1"N?]$0KG_1$*Y_T3=B
MQY@  +BC  "KJP  H+0  )6^  "+R , @-$' 'CA#0!TX1T!;N$K VC@-PAA
MX$(.7.!-%%?@5AE3X%\=3^!I(DO@<R5'X'XH1."+*T+@FBT_X:LO/N+!+S[B
MY2\\W_HQ.=[_-#G9_S8ZT/\X.\S_.3O,_SD[S/\Y.\S_.3O,_SG-D@  O*
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M$Q___!,>__\3'O__$Q[__Q,>__\3'O__$Q[__Q.FJ0  F+,  (J_  ![R@
M;M4  &#?  !4YP  3O\$ $G_#@!#_Q0 /_\= 3K_)0(V_RP",O\S R__.@,K
M_T$$*/](!"7_3P4B_U<%(/]@!AW_; <:_WD'&/^*"!;_FP@5_ZT)%/_#"1/_
MXPD3__@)$___"A/__PH3__\*$___"A/__PJ:L0  B[T  'S(  !MU   7^
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M-_\F\#?_)O W_R;_/"8"_SDM O\_+ +_0RT#_T0R!/]#.07_0T4'_T)2"_]
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M2I5@_TF38/](D6#_1Y%@_T>18/]'D6#_1Y%@_T?_3A@!_UH1 ?]D#@#_;Q
M_W83 /Q]%P#O@1X!Y(0G MN$- 70@4,/R'Q/&<%X6B.[<V0LM7!M,[%L=CJM
M:G\_J6>(0Z5ED4>B8YM*GV*E39QAL4^98,%0EV#<4)5A\T^38O].D&/_3(YD
M_TN,9/]*BV3_2(MD_TB+9/](BV3_2(MD_TC_4!8!_UP0 /]H#0#_<@X _WH0
M /:!$@#IAA< WHH@ =**, 3)AD .P8)-&;I]5R.T>6$LKG5J-*ER<CJD;WM
MH&R$1)UJC4B9:)=,E6>A3Y)FK5&09;U2CF744XQF\%&+9_]0B&?_3H=H_TR&
M:/]+A6?_285G_TF%9_])A6?_285G_TG_4A0!_U\. /]K"P#_=0P ^7X- /"%
M#@#CBQ  UH\: ,R.+@3#BST-NX=*&+2#52*M?EXKIWMG,Z)W;SJ=='A F7*
M195OB4F1;9--C6R>4(IJJE.':KE4A6K/5(1K[E.#;/]1@FS_3X%K_TV :_],
M@&O_2H!K_TJ :_]*@&O_2H!K_TK_5!(!_V$, /]N"@#]> D Z((( -R)"0#8
MCPL T),7 ,:3*P.^D#L,MHQ(%ZZ(4B&GA%PKH8!D,YQ\;3J7>75 DG=]18YU
MADJ*<I!.AG&;48)OIU1_;[95?6_+5GQOZU1\</]2>W#_4'MO_TY[;_]->V[_
M2WMN_TM[;O]+>V[_2WMN_TO_5Q$ _V,* /]P!P#P? 4 W(4% -2," #0DPD
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M2DZBV4E.H/5)3I__25"9_TE2EO](5)+_1U22_T=4DO]'5)+_1U22_T?_;@
MWG\  ,J-  "^F   LZ   *JG  "AK@  E[8  )&Z$ ",NB,!A;DR!GZX/@YW
MMDD7<;52'FNS6B5ELF(K8+%J,%NP<S57KWTY4ZZ)/4^MED!,K:5"2JVY0TFN
MV$)(J_5#1ZK_1$FE_T1+H/]$39S_1$V<_T1-G/]$39S_1$V<_T3J=0  TH8
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M)S;2_RDTT?\K-LK_+3;*_RTVRO\M-LK_+3;*_RW%D   MIT  *BE  "<K0
MC[8  (.^  !WQP  ;,\" &+6!P!:Y X 6.0< %3D*0%0Y#4#3.4_!4CE20=%
MY5,*0N9<#3_F9@\\YG$2.N=^%#?GC!8UYYP7,^BN&3+IQADRZ.H9,>7^&2_D
M_QPNY/\>+>+_("WB_R MXO\@+>+_("WB_R"ZF@  JJ,  )VK  "0M   @[T
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M!0[__P4.__\%#O__!0[__P65KP  AKH  '?%  !HT   6ML  $SA  ! YP
M-_,  #+_   N_P< *O\. ";_$P C_QH '_\@ !O_)@ 8_RL!%?\R 1+_. $0
M_T !#O]( 0S_4@$)_UT"!O]K @3_?0("_Y " ?^C @#_M@( _\T# /_L P#_
M[ , _^P# /_L P#_[ .(N0  >,0  &G0  !;W0  2^,  #[I   R[@  *_\
M ";_   A_P  '?\( !K_#0 6_Q$ $_\6 !#_&@ ._Q\ "_\D  G_*@ &_S
M O\W 0#_0 $ _TH! /]6 0#_9 $ _W4! /^( 0#_F@$ _ZH! /^[ 0#_NP$
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M,[-,_S.N3?\SJD[_,JE._S*I3O\RJ4[_,JE._S+_0QH!_TP3 /]4$ #_7!(
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M/(A?_SN(7_\[B%__.XA?_SO_3A$ _U@* /]C!P#Z; 8 YW,& -UX" #:>PL
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M1UZ!S4=>@>]&7X'_1&!__T)A??]!8GO_/V-Z_S]C>O\_8WK_/V-Z_S__7@
MZ6T  -9Y  #(A   OHP  +:3  "NEP  IIL$ *"=%P":G2D"DYPW"(R:0Q"&
MF$T8@)95'WJ4729UDF4L<)!L,6R.=39GC7XZ8XN)/E^*E4%<B:-$6HFT15B)
MRT58B.U$6(C_0UF&_T%;@_] 78'_/EV _SY=@/\^78#_/EV _S[_8@  Y'$
M ,]^  ##B   N9$  +"7  "GFP  GJ$  )BC$P"3HR4!C:(T!H:A0 V GTH5
M>9U3''2;6B-OF6(H:IAJ+F:6<C)AE7PW792&.EF2DSY6DJ% 4Y&R05*2R4)2
MD>M!4I#_0%*/_S]5B_\^5HC_/5>'_SU7A_\]5X?_/5>'_SWY9P  W78  ,F#
M  "]C0  LY4  *F;  "@H   EJ<  (^I#P"+JB$!A:DP!'^H/ IXIT<2<Z50
M&&VC6!YHHF D9*%G*5^@<"Y;GGDR5YV$-E.<D3E0G)\[3INP/4R<QSU,F^H\
M3)G_/$R8_SQ-E?\\3Y'_.U"/_SM0C_\[4(__.U"/_SOK;0  TWP  ,.)  "W
MDP  K)H  **?  "9I0  CJL  (6P"P"!L1L ?+$K G>P. =QKT,-:ZY-%&:M
M51EAK%T>7:ME(UFJ;B=5J7<K4:B"+TVGCS)*IYXU2*>O-D>GQC9&INDV1:3^
M-T6C_S=&H/\W2)S_-TF:_S=)FO\W29K_-TF:_S?B=   RH,  +R/  "PF
MI9X  )ND  "0JP  A;$  'JX! !VN10 <KDE 6VY,P1HN#\(8[A)#EZW4A-:
MMEH85K9B'%*U:R!.M'4D2[2 )TBSCBI%LYTL0K.N+4&SQ2Y!L^DM0+#^+S^O
M_S$^K?\R0*C_,D&F_S)!IO\R0:;_,D&F_S+5?   PHH  +66  "HG0  G:,
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M%BC:_Q8HVO\6*-K_%BC:_Q:SF   I:   )FG  "+L   ?K@  ''   !ER
M6<X  $[3  !$VP0 /^D- #WI%P [ZB, .>HN #;K. $TZT(!,>Q+ B_M50,M
M[5\#*NYK!"CN> 4F[X@&)>^:!R/PK@<B\<@'(O#M!R'L_P<AZ_\((.O_"A_J
M_PL?ZO\+'^K_"Q_J_PNHGP  FZ8  (VO  !_N   <<$  &3*  !8T   3-8
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M 0#_\P&$MP  =,$  &7,  !6V   1]\  #GE   MZ@  (^X  !S]   8_P
M%?\  !'_!  /_PL #?\.  G_$0 &_Q4  _\:  #_(   _R8  /\N  #_-P
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M&=PS_QK;,_\:U#3_&LXU_QK.-?\:SC7_&LXU_QK_-A\!_SP9 ?]!%@#_1!8
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M*IU-_RF=3?\IG4W_*9U-_RG_0Q$ _TL, /]3" #_6@L _UX- /E@$ #K818
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MJW9!":5S3!"?<%87FVY?'99L9R*3:F\GCVAW*XQG?R^)98@RA622-8)CG3>
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M/&YKR3QM:^D[;6S^.6UL_S=N;/\U;FO_-&YJ_S)N:O\R;FK_,FYJ_S+_4P
M]%\  -YJ  #-<P  PWH  +M^  "U@0  KH,) *B%&@"BA2L"FX0Z!Y6"10Z0
M?T\5BGU8&X9[7R"!>6<E?7=O*GIV=RYV=( R<W.+-6]RECAL<:,Z:7"R/&AP
MQCQG<.<[9W'\.6AQ_S=H</\U:6__-&EN_S-I;O\S:6[_,VEN_S/_5@  ZV(
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M6WSZ.%Q[_S==>_\U7GG_-%]W_S-?=_\S7W?_,U]W_S/^7   X6H  ,UU  #
M?@  MH8  *Z+  "EC@  FY$  )63$0"0E"(!BY,Q X62/0E_D4@/>H]1%G6-
M61MQC& @;(IH)6B)<"EDAWDM88:#,5V%CS1:A)PV5X.L.%6#OSE5@^$X58+Y
M-U:"_S56@?\T6'__,UE]_S)9??\R67W_,EE]_S+O8   VVX  ,=Z  "[@P
MLHL  *B0  "?DP  E)8  (V9#@")FAX A)HN GZ9.@=YET4-=)9.$V^55AAJ
MDUX=9I)E(6*1;29>CW8J6XZ!+5>-C3!4C)HS48RJ-4^,O35/C-XU3XOW-$^*
M_S-0B?\R48;_,5*$_S%2A/\Q4H3_,5*$_S'J90  TG,  ,)_  "VB   K)
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M)CND_R8[I/\F.Z3_)CND_R;,>@  NX@  *Z2  "BF0  EYX  (RD  " J@
M=:\  &FT  !>N08 6[H4 %F[) !6NS$!4[L] U"[1P5-NU '2KI9"D>Z8@U$
MNFP00;IW$SZYA!4\N9,7.;FC&#BYMQDWNM89-[CT&C6V_QPTM/\>,[/_'S.R
M_R SLO\@,[+_(#.R_R#!@P  M)$  *:8  ";G@  CZ4  (*K  !VL0  :[8
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M!1CC_P6CG0  EJ0  (BL  !ZM0  ;+T  %_$  !3R@  1\X  #S3   RV@
M*M\  "7N"0 C\!$ (?$9 !_Q(@ =\BL &_,T !GT/@ 7]$@ %?52 !/V7P 2
M]FX!$?>  1#XE $/^:H!#OG& 0[Y[0$-]O\!#?3_ 0WS_P$-\_\!#?/_ 0WS
M_P&9HP  BZP  'RU  !MO@  7\8  %+-  !%T@  .=@  "_>   FX@  '^H
M !S[!@ 9_PX %_\3 !3_&@ 2_R$ $/\H  [_,  -_SD "_]#  G_3@ &_UP
M!/]L  +_@  !_Y8  /^M  #_R@  __   /__  #__P  __\  /__  #__P"-
MJP  ?;4  &Z_  !@R   4M   $/7   WW0  *^(  "+F   9Z@  %?D  !+_
M   0_P@ #O\.  S_$0 )_Q8 !O\<  /_(@  _RH  /\S  #_/0  _TD  /]7
M  #_:0  _WX  /^5  #_K   _\<  /_H  #_^@  __H  /_Z  #_^@" M0
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M%< T_Q6_-/\4OS3_%+\T_Q3_-A4 _SL0 /\^#0#_0P\ _T84 /]&' #_1B8
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M+7]9QRY]6>8M?%KZ+'M:_RI[6_\H>UO_)WM:_R9Z6O\E>EK_)7I:_R7_20
M^U(  .-<  #28P  QV@  ,!K  "Z:P( M6L- *YM'0"H;BX!HVT\!9UK2 J9
M:E$/E&A:%)!F8AB-96H<BF-R((=B>B.$88,F@6",*7Y?ERM[7J,M>5ZQ+W==
MQ"]U7N(O=5[Y+75?_RMU7_\I=5__*'5>_R9U7O\F=5[_)G5>_R;_2P  \%4
M -Y?  #-9P  PVP  +MO  "U<   KV\* *AQ&@"C<BL!G7(Y!)AP10F3;D\.
MCVU8%(MK8!B':6<<A&AO((%G=R-]9H F>F2**7=CE"QU8Z$N<F*O+W!BP3!O
M8M\P;F/W+F]C_RQO8_\J;V/_*&]B_R=O8O\G;V+_)V]B_R?_30  ZU@  -EC
M  #):@  OW   +=S  "P=   J70' *-V%P">=R@!F'8W!)-U0@B.<TP.B7%5
M$X5P71B!;F4<?FUL'WML="-X:GTF=&F'*7%HDBQN9YXN;&>L,&IGOC%I9]PP
M:6?U+FEG_RQI9_\J:F?_*6IF_RAJ9O\G:F;_)VIF_R?_4   YUL  --F  #%
M;@  NW,  +-W  "K>0  I'@# )UZ% "8>R4!DWLT XYZ0 >)>$H-A'93$H!U
M6Q=\<V(;>')J'W5Q<B)R;WLF;VZ%*6QMD"QI;)PN9FRJ,&1LO#%C;-DP8VST
M+V-L_RUD;/\K9&O_*65J_RAE:O\H96K_*&5J_RC]4P  XU\  ,YI  #!<0
MMW<  *][  "G?0  GGT  )A^$0"3@"( CH Q HE_/@:$?4@,?WQ1$7MZ619W
M>6 :<W=H'F]V<"%L=7@E:72"*&9SCBMC<IHN8'&H+UYQNC!=<=0P77'R+EYQ
M_RQ></\K7W#_*6!O_RA@;O\H8&[_*&!N_RCQ50  WF(  ,IM  "]=0  LWL
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M)TV!_R9.@?\F3H'_)DZ!_R;A8P  R7   +M[  "PA   IHH  )N.  "1D0
MA),  'J5 @!UEQ( <I@B &^8, )JESL$9I=%"&*63@Q?E58/6Y1=$UB391=5
MDVX:49)X'4Z1A"!+D)$C29"A)$>0LB9%D,HF18_M)46-_R5%C/\E1HO_)$:*
M_R1&BO\D1HK_)$:*_R38:0  PW8  +6!  "KB@  GX\  )63  "*E@  ?IH
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M%B^L_Q:[@0  KHX  *&5  "6F@  B:   'VF  !QJP  9:\  %FT  !.MP
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M !3AF@ 3XK$ $N// !+@]  2WO\!$=W_ 1';_P(1V_\"$=O_ A';_P*>F@
MDJ$  (2I  !VL0  :+@  %N_  !.Q   0L@  #?,   MT   )-4  !S;   5
MWP4 %.D. !+J%  1ZQT $.LF  [L,  .[3H #>Y&  ON4P *[V( "?!T  CQ
MB0 '\J  !?*Z  3QY  "\?T  N__  /M_P #[?\  ^W_  /M_P"5H0  AJD
M 'BR  !IN@  6\(  $W(  ! S   --$  "K6   AVP  &>   !+D   /\ $
M#?D*  OZ#P )^Q4 !_L<  3\)  !_"P  /PW  #\0@  _%   /QA  #]=0
M_(P  /RD  #\P0  _.L  /S_  #]_P  _?\  /W_  #]_P")J0  >;(  &J[
M  !<Q   3LP  #_1   RUP  )]T  !WA   5Y0  #N@   KQ   (_0  !?\#
M  '_"0  _PX  /\2  #_%P  _Q\  /\G  #_,0  _SX  /]-  #_7P  _W4
M /^-  #_I@  _\(  /_G  #__   __\  /__  #__P!\LP  ;+P  %W&  !.
MSP  /]8  #'=   EX@  &N8  !'J   ,[@  !?(   #_    _P   /\   #_
M    _P4  /\*  #_#@  _Q(  /\8  #_(0  _RL  /\Y  #_2@  _UT  /]S
M  #_C   _Z0  /^Y  #_U   _]X  /_>  #_W@#_&"P _QDI /\9* #_%2L
M_Q P /\+. '_ T0!_P!1 ?\ 7@'_ &P!_P!X ?\ @@'_ (P!_P"4 ?\ G #_
M *( _P"H /\ KP#_ +8 _P"^ /\ R #_ -< _P#G /\ \P#_ /T _P#_ /\
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M ^D3_P/I$_\#Z1/_ ^D3_P/_)AT _R@8 /\H%@#_)A8 _R8= /\F* #_(S0
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M#ZXT_P__-0X _S@' /\\ @#_0 8 _T$+ /I!#P#M/Q8 XSPB -H],0#2/D$
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M&I9&RAN31N8;D4?Y&X]'_QJ.1_\9CD?_&(U'_QB-1_\7C4?_%XU'_Q?_/@(
M_T,  .M+  #=40  T50  ,I4 0#&4@4 P5$1 +E3(@"S53,!KE1! JI43 6F
M4U8(HE%?#)]09P^=3V\1FDYW%)A.?Q:638@8DTR1&9%,FQN/2Z8=C4NS'HM+
MQ1Z)2^(>ATSW'H9,_QV%3/\<A4W_&H5,_QF%3/\9A4S_&85,_QG_0   _$<
M .50  #55@  RED  ,):  "]6 , N%<. +%9'@"L6B\!IUH] J)9206>6%,)
MFU=;#)=69!"556L2DE1S%8]3>Q>-4H0:BU&-'(A1EQZ&4*,?A%"P(()0P2&
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M(V]:_R)O6O\@<%K_'G!:_QUP6O\<<%K_''!:_QS_2   YU(  --;  #%8@
MNV8  +-H  "L:   I68% )]G% "::24 E6DT I!H0 2,9TH(B&93#(1E6Q"!
M9&(3?F-J%GMB<AEX87H<=F"$'G-?CB%P7IHC;EZH)6Q=N"5J7LXF:5[N)&E>
M_R)J7O\@:E[_'VI>_QYJ7O\=:E[_'6I>_QWY2@  XU4  ,]?  #!90  MVH
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M'UMK_QY;:O\>6VK_'EMJ_Q[K4P  TV   ,)I  "V<0  K'8  *-Y  "9>0
MC7<  (=Y"P"#>Q@ ?WPH 'M\-0)W>T %<WI)"&]Y40QL>%D/:'=A$V5V:!9B
M=7 97W1Z'%QTA1]:<Y$A5W*@(U5RL"13<L4D4W+G)%-Q_")4<?\@5'#_'U5P
M_QY5;_\=56__'55O_QWE5P  S60  +YM  "R=0  J'L  )]^  "3?0  AWT
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M&D*$_QK-9P  O'0  *]^  "EA@  FHH  (Z,  ""C0  =9   &>4  !AE0@
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M!RZLHP@MK+@)+*S9""RJ]0HKJ/\+*J;_#"JE_PTJI?\-*J7_#2JE_PVU@
MJ(L  )R1  "1E@  A9P  'B@  !KI0  7Z@  %.L  !(KP  /;(  #:U"P T
MM14 ,[8A #*V+  QMS< ,+=! "^X2P NN%4 ++A@ 2JX;0$IN7L")[F- B6Y
MGP,DN;0#([G2 R.W] 0BM?\%(;3_!B&S_P<ALO\'(;+_!R&R_P>MB@  H)$
M )67  "(G0  >Z,  &ZH  !AK0  5;$  $JT   _MP  -+L  "N^ P DP@P
M(L(4 "+#'P APRH (,0T !_$/P >Q4H '<96 !S&8P ;QW, &L>% !G'F0 8
MR*X %\C+ !?&\0$7Q/\!%L/_ A;!_P,6P?\#%L'_ Q;!_P.CD0  F)@  (N>
M  !]I0  <*L  &*Q  !6M@  2KD  #Z]   TP   *L0  "+(   9S 0 $] *
M !'2$0 0TAH $-,E  _3,  .U#P #M1(  W55@ -U64 #-9X  S6C0 +V*0
M"MB^  G9Y@ *UOX "]3_  O2_P +TO\!"]+_ 0O2_P&:F   CI\  ("F  !R
MK0  9+0  %>Z  !)OP  /<(  #+&   HR0  '\T  !?1   1U@  #-L%  C>
M"P &WQ$ !=\:  3@)  "X2X  >(Z  #C1P  Y%8  .1G  #E>P  YI(  .:J
M  #GR   Y_   .C_  #H_P  Z/\  .C_  #H_P"1GP  @J<  '2O  !EMP
M5[X  $G#   \QP  ,,L  "7/   <U   %-D   [=   )X0   N4   #I!@
MZ0T  .D1  #J&   ZR$  .TK  #O-P  \44  /)6  #S:   \WX  /27  #U
ML   ]M   /?S  #W_P  ]_\  /?_  #W_P"%IP  =K   &:X  !8P0  2L@
M #O,   NT0  (]8  !G<   1X   #.,   3G    Z@   /4   #T    ]04
M /4+  #V#P  ]A0  /@=  #Z)P  _#0  /]#  #_50  _VD  /^!  #_F@
M_[(  /_/  #_[0  __D  /_Y  #_^0!XL   :+H  %G#  !+RP  .]$  "W8
M   AW0  %N(   [F   (Z@   .T   #P    ^    /\   #_    _P   /\
M  #_!@  _PP  /\0  #_&   _R(  /\P  #_0   _U,  /]I  #_@0  _YD
M /^O  #_PP  _]4  /_5  #_U0#_$R@ _Q,E /\1)0#_#2< _P8M /\ -0#_
M $$ _P!/ /\ 7 #_ &D _P!T /\ ?@#_ (@ _P"0 /\ EP#_ )T _P"D /\
MJ@#_ +  _P"W /\ P #_ ,P _P#? /\ [ #_ /@ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_%B4 _Q8B /\4(0#_$", _PHH /\ , #_ #T
M_P!+ /\ 6 #_ &0 _P!P /\ >@#_ (0 _P", /\ DP#_ )H _P"@ /\ I@#_
M *T _P"T /\ O #^ ,@ _0#9 /L Z0#Z /8 ^0#_ /@ _P#X /\ ^ #_ /@
M_P#Y /\ ^0#_ /D _P#_&B( _QH> /\8'0#_$QX _PXB /\*+ #_!SD _P-&
M /\ 4P#_ &  _P!K /\ =@#_ '\ _P"( /\ CP#_ )8 _P"= /\ HP#^ *D
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M M(3_P+_)1, _R40 /\D#0#_(PX _R,4 /\B'@#_'RD _QPU /D90P#T&$\
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M!;4MT06Q+>H&KB[[!ZLN_PBI+O\(J"[_"*@M_PBH+?\(J"W_"*@M_PC_+P@
M_S$  /\U  #V-P  ZC8" .<S" #D+P\ V2X; ,\Q+ #),SP Q#1) , U50&\
M-5\"NC5H K<U< .U-'@$LS2 !;$TB :P-) &KC29!ZPTH@BK-*P)J32Y":<T
MR@JE->4*H37X"Y\U_PR=-?\,G37_"YPU_PN<-?\+G#7_"YPU_PO_,P( _S4
M /8Z  #E/@  W$   -0]! #2-PD RS@5 ,,Z)@"]/38 N#Y$ ;0^4 &Q/5H#
MKCUC!*P]:P6I/',&ISQ["*8\@PFD.XL*HCN4"Z [G0R>.Z@-G3NT#IL[Q0Z9
M.^ .ECOT#Y0\_P^2//\/DCS_#I$\_PV1//\-D3S_#9$\_PW_-0  _SD  .I!
M  #=1@  T$<  ,E&  #&004 P$ 1 +E"(0"S1#( KT5  :M%2P*G154#I$1>
M!:%$9@>?0VX(G4-V"IM"?@N90H8-ET&/#I5!F0^30:01D4&P$I!!P!*.0=D2
MBT'Q$HE"_Q*(0O\1B$+_$(="_Q"'0O\/AT+_#X="_P__.   \ST  .-'  #2
M3   R$X  ,!-  "[2@( MD<. +!)'0"K2RT IDP[ :),1P*>2U$$FTM:!IE*
M8@B626H*E$EQ#))(>0Z/2((/C4>+$8M'E1*)1J 4AT:L%85&NQ:$1M$6@D?N
M%H!'_Q5_1_\4?T?_$G]'_Q%_1_\1?T?_$7]'_Q'_.P  [D,  -Q,  #,40
MP50  +E4  "T40  KDT+ *A/&0"C42D GE(W 9I20P*744X$E%%6!I%07@F.
M3V8+C$YM#8E.=0^'37X1A4V'$X),D16 3)P6?DNI%WQ+N!A[2\T8>4SK&'A,
M_A=W3/\5=TS_%'=,_Q-W3/\2=TS_$G=,_Q+_/@  Z$<  -50  #&5@  O%@
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M%V59_Q5E6?\495G_%&59_Q3O1@  VE(  ,9;  "Z80  L&4  *9F  "=8P
ME6$  (]B#@"+9!P AV4K (-E-P%_94(#?&1+!GAC4PAU8UL+<V)B#G!A:A!M
M8'(3:V![%6A?AA=F7I$98UZ?&V%=KAQ@7<$<7UWA'%]=^!I?7?\87UW_%V!=
M_Q9@7?\58%W_%6!=_Q7K2@  U%8  ,->  "V90  K&D  *)I  "89P  CV4
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M%5!J_Q7=50  Q6$  +=J  "L<0  HG4  )1T  ")=   ?',  '9U  !Q=Q
M;W@= &QY*P!I>3<!9GE  V-Y205@>%$'77=8"5MW8 Q8=F@.575Q$5)U?!-0
M=(@63727%TMSIAA)<[D92'/5&4ER\QA)<?\72G'_%DIP_Q5+</\42W#_%$MP
M_Q346@  P&8  +-O  "H=@  G7D  (]X  "$>   =WD  &]\  !J?0T 9WX9
M &1_)@!B@#(!7X ] ER 1@-:?TX%5W]5!U1^70E2?64,3WUO#DQ\>1%*?(83
M1WN4%45[I!9$>[<60WO2%D-Z\A9#>?\50WC_%$1W_Q1$=O\31';_$T1V_Q/-
M7P  NVL  *YT  "D?   EWX  (I]  !_?@  <G\  &:#  !AA @ 7H83 %R'
M(0!:ARX 6(<X 56'0@)3ATH#4(=2!4Z&6@=+AF()285L"T:%=PU#A(,/0822
M$3^$HA(]A+43/(3/$SR"\!(\@?\2/8#_$CU__Q(]?O\1/7[_$3U^_Q'%9@
MM7$  *I[  "?@@  DH(  (6"  !Y@P  ;88  %^*  !8C0$ 5(X/ %*/&P!0
MCR< 3Y S $V0/0%+D$4"29!. T:05@1$CU\%0H]H!S^/<PD]CH +.HZ/##B.
MH TWCK,.-H[,#C:-[PXUB_\.-8G_#S6(_P\VA_\/-H?_#S:'_P^^;0  L'D
M *6"  "9AP  C(@  '^(  !RB@  9HT  %J1  !0E0  29<) $>8$P!%F"
M1)DK $.9-@!!FD  0)I( 3Z:40(\FEH".IID S>:;P4UF7T&,YF,!S&9G0@O
MF; (+IG*""Z8[0@NEO\*+93_"BV3_PLMDO\++9+_"RV2_PNV=0  JH$  )Z(
M  "3C0  AHX  'B/  !KD@  7Y4  %29  !)G0  0*   #JB#0 XHQ< -Z,B
M #:D+0 UI#< -*1! #.E2P QI50!,*5> 2ZE:@$LI7@"*J6( RBEF@,GI:T$
M)J7& R:DZP0EHO\%):#_!B2?_P8DGO\'))[_!R2>_P>O?@  HX@  )>.  "-
MDP  ?I4  '"8  !CFP  5Y\  $RB  !"I@  .*D  "^L P JK@X *:X8 "BO
M(P GKRT )K W "6P00 DL$L ([%6 "*Q8P AL7$ '[&" !ZRE $<LJD!&[+!
M 1NQYP$;K_X"&JW_ AJL_P,:J_\#&JO_ QJK_P.HB   FX\  )&4  "$F@
M=I\  &BB  !;I0  3ZD  $2M   YL   +[,  ":V   >N04 &+L. !>[%@ 7
MO"  %KPJ !6]-0 4O4  $[Y+ !*^6  2OF< $;]X !"_C  0P*( #L"Z  [
MX0 /O?L #[S_ !"Z_P$0NO\!$+K_ 1"Z_P&?CP  E)4  (>;  !YH0  :Z<
M %ZL  !2L0  1;0  #JV   ON0  );P  !V_   5PP  #\8%  O*#0 )RA0
M",H=  ?*)P 'RC( !LL^  7+2P $S%H  \QJ  +,?@ !S)0  ,RK  #-R
MS.T  ,S_  #+_P !RO\  <K_  '*_P"7E@  BIP  'RC  !NJ@  8+   %*V
M  !%N0  .;P  "Z_   CPP  &\8  !/*   -S0  "-$   '4"0  U X  -45
M  #6'@  V"<  -DQ  #;/@  W$L  -U;  #>;@  WH0  -^;  #?M   WMD
M -_W  #?_P  W_\  -__  #?_P"-G0  ?Z4  '"L  !ALP  4[H  $6_   X
MP@  +,8  "')   8S0  $-$   O5   $V@   -X   #@ 0  X0D  .(.  #D
M$P  Y1L  .<D  #I+P  ZSP  .U+  #N70  [G$  .^)  #PH@  \+P  /#C
M  #O^0  \/\  /#_  #P_P"!I0  <JT  &.U  !4O0  1L0  #?(   JS
M']   !75   .V@  !]X   #B    Y@   .D   #J    [    .X%  #O#
M\1   /,7  #U(   ^"L  /LY  #]2@  _EX  /]T  #_C0  _Z8  /_   #_
MX0  __4  /_U  #_]0!TK@  9;<  %;   !'R   .,T  "K2   =V   $]T
M  SB   #Y@   .D   #L    \    /,   #T    ]@   /@   #Z    _0<
M /\-  #_$@  _QL  /\H  #_-P  _TH  /]>  #_=@  _X\  /^F  #_N@
M_]$  /_1  #_T0#_#R0 _PXB /\+(0#_ R0 _P I /\ ,@#_ #X _P!, /\
M60#_ &4 _P!P /\ >@#_ (0 _P", /\ D@#_ )D _P"? /\ I0#_ *L _P"R
M /\ N@#_ ,4 _P#3 /\ YP#_ /0 _P#_ /X _P#_ /\ _@#_ /X _P#^ /\
M_@#_ /X _P#_$2$ _Q > /\-'0#_!Q\ _P C /\ +0#_ #H _P!( /\ 50#_
M &$ _P!L /\ =@#_ '\ _P"' /\ C@#_ )4 _P"; /\ H0#_ *< _@"N /T
MM@#\ ,  ^P#- /D X@#X /  ]P#\ /8 _P#U /\ ]0#_ /4 _P#U /\ ]0#_
M /4 _P#_%1T _Q,: /\0&0#_"QD _P = /\ *0#_ #8 _P!# /\ 4 #_ %P
M_P!G /\ <0#_ 'H _@"# /P B@#Z )$ ^0"7 /@ G0#W *, ]0"J /0 L@#R
M +L \0#( .\ W #N .P [0#Z .L _P#J /\ Z@#_ .H _P#J /\ Z@#_ .H
M_P#_&!D _Q85 /\3$P#_#A, _PL: /\') #_ C  _P ^ /\ 2P#_ %< _P!B
M /P ; #X '4 ]0!^ /( A0#Q (P [P"3 .X F0#L *  ZP"F .D K@#G +<
MY@## .0 U #B .D X0#W -\ _P#= /\ W0#_ -T _P#= /\ W0#_ -T _P#_
M&Q, _QH0 /\6#@#_$@X _Q(5 /\/'P#_#"L _PDX /\&10#[ U$ ]P)< /("
M9@#N G  Z@)X .<"@ #F X< Y .. .(#E0#A YP WP2C -T$JP#;!+0 V 7
M -8%T #3!N< T CX ,X*_P#,"_\ RPS_ ,L,_P#+"_\ RPO_ ,L+_P#_'Q
M_QX+ /\:!P#_&0L _Q@1 /\6&0#_$B0 ^A P /,./@#N#4H Z0Q6 .4,80#B
M#&H W@US -L->P#9#8, U@V* -0-D0#2#9D T Z@ ,\.J0#-#K, RPZ_ ,H/
MT #&$>D PA+Y +\3_P"]$_\!O!/_ ;P3_P&\$_\!NQ/_ ;L3_P'_(@P _R$$
M /\@  #_(04 _Q\, /\<$0#V&!P [!4H .43-@#?$D, V1-/ -,46@#0%60
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M!9DN_P:7+_\&EB__!I4N_P65+O\%E2[_!94N_P7_+   _RX  .HU  #=.0
MT3D  ,HV  #'+P8 P2T1 +HP(0"T,C$ L#0^ *PU2@"I-50!IS5= :0U90*B
M-6T"H#5T Y\U? 2=-80$FS6-!9HTEP:8-*$&EC2M!Y0UNPB3-= (D#7L"(XV
M_@B,-O\(BS;_"(LV_P>*-?\'BC7_!XHU_P?_+P  \C0  .(\  #200  QT(
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M#7%'_PQQ1_\+<4;_"W%&_POS.0  X$0  ,Q,  "^40  M%,  *I2  "B3@
MG4H! )=+$0"332  CT\N (Q/.@&(3T4"A4]. X-/5@2 3ET&?DYD!WQ-; EY
M370+=TQ]#'5,APYS3)(/<4N?$6]+K1)M2[\2;$O<$FM,]1%J3/\/:DS_#FI+
M_PUJ2_\,:DO_#&I+_PSP/0  VT@  ,=0  "Z50  L%@  *56  "<4P  ET\
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M#5I7_PWC2   RU,  +M;  "P80  I&(  )=A  ".7P  A5P  ']>!P![7Q,
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M$$QGH1)+9[(226?)$DEGZQ))9O\02F;_#TIE_PY+9?\-2V3_#4MD_PW15
MOEX  +%G  "F;0  EVP  (IK  !_:P  <VL  &UM  !H;@P 97 7 &)Q) !@
M<3  7G$Z 5QQ0P)9<4L#5W%3!%5P6@92<&('4'!K"4YO=0M+;X(-26Z/#T=N
MGQ!%;K 11&['$4-MZA!$;/\/1&O_#D5K_PU%:O\-16K_#45J_PW+6   NF,
M *UL  "A<0  DG   (5O  !Z;P  ;G   &5S  !@=0< 7782 %MW'P!9>"L
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M-0!#B#X 08E' 4")3P$^B%@"/(AA SJ(; 0WB'@%-8B'!C.(F <RAZH',(C
M!S"'Y <PA?L(,(/_"#""_P@P@?\(,('_"#"!_PBW:P  JG8  *!_  "0?@
M@GX  '9_  !J@   7H,  %.'  !*BP  08X" #V0#@ [D!@ .I$C #F1+0 X
MDC< -Y)  #:220 TDU( ,Y-< 3&39P$ODW0"+9*# RN2E ,JDJ<#*)*]!"B2
MX0,GD/H$)X[_!2>-_P4GC/\%)XS_!2>,_P6Q=   I7X  )F%  "*A   ?80
M &^%  !CB   6(L  $V/  !#DP  .I<  #*:!P NFQ  +9L: "R<)  KG"X
M*ITX "F=00 HG4L )YY5 ":>80 EGFX (YY^ 2*>D $@GJ,!'YZY 1Z>W0$>
MG/@"'IK_ AZ9_P,>E_\#'I?_ QZ7_P.J?0  GH4  ).+  "%B@  =8L  &B.
M  !;D0  4)4  $:9   [G0  ,J   "JC   BI@D 'Z<1 !ZG&@ =J"0 '*@M
M !NH-P :J4$ &:E, !BI6  7JF8 %JIV !6JB0 4JIX $ZNT !*KTP 2J/4
M$Z?_ 1.E_P$3I?\!$Z3_ 1.D_P&CA@  EXP  (V1  !]D@  ;94  &"8  !4
MG   2*   #ZD   TIP  *JL  "&N   9L0  $K,'  ^U$  .M1< #K4A  VU
M*P -M38 #+9!  NV3@ *MEP ";9L  BV?P 'MI0 !K:J  6VQ0 &MNH ![7_
M  BT_P (L_\ ";+_  FR_P":C0  D),  (28  !TG   9:   %>D  !+J
M0*P  #6P   JLP  (;4  !BX   1NP  #+X"  ; "P "P!$  <$9  #!(@
MPBL  ,(V  ##0@  PU   ,1?  #$<0  Q(<  ,2=  #$M0  Q-H  ,3V  ##
M_P  P_\  ,/_  ##_P"3E   AYH  'B@  !JI@  7*P  $^Q  !!M0  -;<
M "FZ   ?O0  %L   !##   *Q@   \H   #,!0  S P  ,T1  #.&   SB$
M - J  #1-0  TT,  -12  #48P  U7@  -6/  #5IP  UL(  -;I  #6_0
MUO\  -;_  #6_P"*FP  >Z(  &RI  !>L   4+8  $*Z   TO0  *,$  !W$
M   4QP  #<L   ;.    T@   -<   #9    V@4  -P+  #=$   WQ4  .$=
M  #C)P  Y3,  .="  #H5   Z&<  .E^  #IEP  ZJ\  .K.  #K[P  Z_X
M .O_  #K_P!]HP  ;JL  %^R  !1N@  0L   #3#   GQP  &\L  !+/   +
MTP   M@   #=    X0   .0   #E    YP   .D   #K!P  [0T  .\1  #Q
M&0  ]"0  /<Q  #Y00  ^E4  /IJ  #[A   ^YT  /RV  #\T@  _>T  /WT
M  #]] !QK   8;4  %*]  !$Q   -,D  ";-   :T@  $-@   C=    X0
M .4   #H    [    .\   #Q    \P   /4   #W    ^0$  /L(  #^#@
M_Q4  /\A  #_+P  _T$  /]6  #_;0  _X<  /^@  #_M@  _\H  /_4  #_
MU #_"R  _P<> /\ '0#_ "  _P E /\ +@#_ #L _P!) /\ 5@#_ &( _P!M
M /\ =@#_ '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"M /\ M0#_ +X
M_P#+ /\ X0#_ /  _@#] /T _P#] /\ _0#_ /T _P#\ /\ ^0#_ /D _P#_
M#1T _PL: /\$&0#_ !H _P ? /\ *@#_ #< _P!% /\ 40#_ %X _P!H /\
M<@#_ 'H _P"" /\ B0#_ )  _P"6 /\ G #^ *( _ "I /L L #Y +D ^ #&
M /8 V0#U .L ] #Y /, _P#R /\ \P#_ /, _P#S /\ \P#_ /, _P#_$!D
M_PX5 /\(% #_ !0 _P 9 /\ )0#_ #( _P!  /\ 3 #_ %D _P!C /X ;0#\
M '4 ^@!] /D A #W (L ]@"1 /0 EP#S )X \@"D /  K #N +0 [0#  .L
MSP#I .8 Z #U .8 _P#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#_$A0 _Q 0
M /\,#P#_ Q  _P 5 /\ ( #_ "P _P Z /\ 1P#Z %, ]P!> /0 9P#Q '
M[P!X .T ?P#K (8 Z@", .@ DP#G )D Y0"@ ., IP#A +  WP"Z -T R0#;
M .  V #P -< _@#5 /\ U #_ -, _P#3 /\ TP#_ -, _P#_%1  _Q(, /\.
M"0#_"PP _PD2 /\#&@#_ "8 _0 S /0 0 #O $T ZP!8 .@ 80#E &H X@!R
M .  >@#> (  W "' -H C@#8 )4 U "< -( HP#0 *P S@"V ,P Q #* -D
MR #M ,< ^P#% /\ Q '_ ,,!_P#$ ?\ Q '_ ,0!_P#_& L _Q4% /\0  #_
M$ 8 _P\- /\,% #\!Q\ \0,K .< .0#B $8 W@%1 -H"6P#5 F0 T@-L ,\#
M= #-!'L RP2" ,H$B0#(!9  Q@68 ,0%H #"!JD P0:T +\&P0"]"-4 NPGL
M +@+_0"V#/\ M0W_ +0-_P"T#?\ M W_ +0-_P#_&P4 _Q@  /\7  #_%@
M^Q,& /H0#@#N#!8 XPDB -H), #3"CX S@M* ,H,50#'#5X Q0UG ,(.;P#!
M#G8 OPY^ +T/A0"\#XT NA"5 +@0G0"W$*< M1&R +,1P "R$=4 KA/N *L4
M_@"I%?\ IQ7_ *<5_P"F%/\!IA3_ :84_P'_'P  _QP  /H>  #K'@  XQP
M -\5!0#>#@T TPX8 ,L1* #%$S< P!1$ +P63P"Y%UD MQ=A +08:0"S&7$
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M X0O_P.#+_\#@R__ X,O_P/[*0  ZS$  -DX  #)/   OSP  +8Y  "P,@
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M!F1%_P;H.P  T$8  +]-  "S40  I5$  )I.  "22P  C4<  (=("P"#2A8
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M"U=4H Q54[ -5%/%#5-3Y@Q34_P+4U/_"512_PA44O\(5%+_!U12_P?:1@
MPU   +58  "H6P  F5H  (U8  "$5P  >U0  '96 0!Q5P\ ;ED; &Q:* !I
M6C, 9UL] 65;10%C6TT"85I5 U]:7 1=6F0%6UEL!EA9=@A668()5%B/"U)8
MG@Q06*X-3UC##4Y8Y Q.6/L+3U?_"4]7_PA/5O\(4%;_!U!6_P?32@  P%0
M +)<  "C7@  E5T  (E<  !_6P  =ED  '!:  !K7 T :%T8 &9>) !D7S
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M"CYHW@D^9_<)/F;_"#]E_P<_9?\'/V3_!S]D_P?#5P  LV$  *=I  "6:
MAV<  'MG  !Q9P  96@  %QJ  !8; $ 5&X. %)O& !0;R0 3G N $UP. !+
M<4$ 2G%) 4AQ40%&<5D"1'!B T)P; 1 <'@%/G"&!CQOE0<Z;Z8(.&^["#AO
MVP<X;O8'.&W_!SAL_P8Y:_\&.6K_!CEJ_P:]7   KV8  *)M  "1;   @FL
M '=K  !L;   86X  %=P  !0<P  3'4* $EV$P!'=Q\ 1G<I $5X,P!#>#P
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M B"&_P(@A?\"(87_ B&%_P*K<@  H7P  (][  " >@  <WH  &9\  !;?P
M4((  $:&   \B@  -(T  "R1   FDPP ))03 ".4'  BE28 (94O ""5.  ?
MED( 'I9, !V66  <EF0 &I=T !F7A@ 8EYD %Y>N !67R0 6E>X %I/_ 1:2
M_P$6D?\!%I#_ 1:0_P&E>P  F8,  (F!  ![@   ;((  %^$  !4B   28L
M #^0   UE   +9<  "6:   =G@$ %J , !2A$@ 4H1L $Z$E !*A+@ 1HC@
M$:)# !"B3P /HEP #J-K  VC?0 -HY( #*.G  JBP  +HN8 #*#^  V?_P -
MGO\ #9W_  V=_P">A   DHD  (.(  !SB   98L  %B.  !,D@  09<  #>;
M   NG@  )*(  !RE   5J   #ZL$  JN#  'K1( !JT;  6M)  $KBX  JXY
M  &N10  KE(  *YA  "N<P  KH<  *Z=  "NM   KM4  *WT  "M_P  K/\
M *O_  "K_P"6BP  C)   'N0  !KD@  798  %":  !$GP  .:,  "^G   E
MJP  '*X  !2Q   .M   ";<   &X"0  N X  +D4  "Y'   NB4  +HO  "[
M.@  O$<  +Q6  "\9P  O'L  +R1  "\J0  O,0  +SK  "[_@  N_\  +O_
M  "[_P"0D@  @Y@  '.;  !CGP  5:,  $>H   [K0  ,+$  "6T   ;MP
M$KH   R]   %OP   ,,   #$ @  Q0H  ,4.  #&%   QQL  ,@D  #*+@
MS#H  ,U)  #-60  S6P  ,Z#  #.FP  S;4  ,[:  #.]@  S?\  ,W_  #-
M_P"&F0  =Z   &FF  !:K   3+(  #ZV   PN0  )+P  !F_   1P@  "L4
M  +)    S    -    #1    T@$  -,(  #5#0  UQ$  -H8  #<(0  WRP
M .$Z  #B2@  XUT  .1R  #DBP  Y:4  .7   #EY@  Y?@  .7_  #E_P!Z
MH0  :ZD  %RO  !-M@  /[P  #"_   CPP  %\<   _*   'S@   -$   #6
M    W    -\   #@    X@   .0   #F P  Z D  .D.  #L%0  [AX  /$K
M  #T.@  ]4T  /9A  #W>0  ^),  /BM  #YQ@  ^>0  /GS  #Y\P!MJ@
M7K(  $^Z  ! P0  ,<4  "+)   6S@  #=(   38    W0   .$   #D
MZ    .L   #M    [P   /$   #S    ]@   /@#  #Z"P  _1$  /\;  #_
M*0  _SL  /]/  #_9@  _W\  /^9  #_KP  _\,  /_6  #_U@#_!!P _P 9
M /\ &0#_ !P _P B /\ *P#_ #@ _P!& /\ 4P#_ %X _P!I /\ <@#_ 'H
M_P"" /\ B0#_ (\ _P"5 /\ FP#_ *$ _P"H /\ KP#_ +D _P#% /\ V0#^
M .P _0#[ /L _P#[ /\ ^P#_ /H _P#T /\ \ #_ /  _P#_!Q@ _P$5 /\
M% #_ !8 _P ; /\ )@#_ #0 _P!" /\ 3@#_ %H _P!D /\ ;0#_ '4 _P!]
M /\ A #_ (H _0"0 /P E@#Z )T ^0"C /@ JP#W +0 ]0"_ /0 S@#S .8
M\0#V /  _P#O /\ [P#_ .X _P#N /\ Z@#_ .H _P#_"Q0 _P81 /\ $ #_
M !  _P 6 /\ (@#_ "X _P \ /\ 20#_ %0 _@!? /L : #Y '  ]P!X /4
M?P#S (4 \@"+ /  D@#O )@ [0"? .P I@#J *X Z "Y .< QP#E -X XP#P
M .( _@#@ /\ X #_ .$ _P#A /\ X0#_ .$ _P#_#1  _PD- /\!# #_  P
M_P 2 /\ ' #_ "@ _  V /D 0P#V $X \@!9 .\ 8@#L &L Z@!R .@ >0#F
M (  Y "& .( C #A ), WP": -T H0#; *H V "T -4 P #2 -, T #J ,X
M^@#- /\ S0#_ ,T _P#, /\ S #_ ,P _P#_$ P _PP' /\# @#_  @ _P .
M /\ %@#V "( \  O .P / #I $@ Y0!3 .$ 7 #> &4 VP!L -< <P#4 'H
MT@"  -  AP#. (X S "5 ,H G0#( *4 Q@"O ,0 NP#" ,L P #E +X ]0"]
M /\ O #_ +P _P"\ /\ O #_ +P _P#_$04 _PX  /\*  #_" $ _P0* /@
M$ #I !H XP H -X -0#9 $$ TP!, ,\ 5@#+ %\ R0!F ,8 ;@#$ '0 P@![
M ,$ @@"_ (D O0"0 +P F "Z *$ N "K +8 MP"T ,< L@#@ +$!\@"O O\
MK@/_ *T$_P"M!/\ K03_ *T$_P#_%   _Q   /\/  #R#0  Z@H  .D#"0#=
M !( U  ? ,T!+0#( CH Q -% , #4 "]!%D NP5A +D%: "W!F\ M09V +0'
M?0"R!X0 L0B, *\(E0"M"9X JPFH *H*M0"H"L4 I@O? *0-] "B#O\ H [_
M )\._P"?#O\ GP[_ )\._P#_%P  _Q,  .\8  #D&0  VQ8  -(0 @#/"0L
MR @6 ,$*) "\##( MPT^ +0.20"Q#E, KQ!; *T08P"K$&H J1%Q *@1> "F
M$8  I1&( *,2D0"A$IL H!.F )X3LP"<$\, FQ3> )<6] "5%O\ E!?_ ),7
M_P"2%_\ DA;_ )(6_P#_&@  ]!T  .4C  #5)0  RB0  ,(=  "^%@0 NQ 0
M +03'0"O%2L JQ8X *<80P"E&4T HAE6 * :70">&V4 G1ML )L<<P":''L
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M G,O_P+P*@  W#4  ,<[  "Z/P  K#P  *(X  "<,P  F"\  )4N$ "0,!P
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M!6-!GP5A0:X&8$'"!EY!X@9>0?D%74'_!%U _P-=0/\#74#_ UU _P/?.0
MR$,  +E*  "I2P  FTD  )!'  "(1   @T$  'Y!!@!Z0A$ =D,> '1%*@!Q
M134 ;T8_ &U&1P!K1D\!:D96 6A&70)F1F4"9$9M V)&=@1@1H($7D:.!5Q%
MG 9;1:P&64:_!UA&WP981O<%5T7_!%=%_P171/\#6$3_ UA$_P/:/0  Q$<
M +5.  "D3@  EDP  (M+  "#20  ?44  'A& @!T1Q  <$@; &Y))P!K2C(
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M!TA3U0=(4O,&2%+_!4A1_P1)4?\$25#_ TE0_P/*2   N5(  *I7  "85@
MBE4  ']4  !V4P  ;%$  &=3  !B5 @ 7U82 %U7'@!;5RD 65@S %A8/ !6
M640 55E, 5-94P%165L"3UAD DU8;0-+6'@$25B&!4=7E09%5Z4&1%>X!D-8
MT@9#5_(&0U;_!4-5_P1$5?\$1%3_ T14_P/&3   M58  *5:  "460  AE@
M 'M8  !Q5P  9E8  &%8  !=600 65H0 %=;&P!57"8 4UTP %)=.0!17D$
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M S%F_P,R9?\#,F3_ S)D_P.W6P  J60  )9D  "&8P  >&,  &UC  !D9
M664  %!H  !):P  0VT$ $!N#@ ^;Q@ /6\B #QP*P Z<#0 .7$] #AQ10 W
M<4X -G%7 #1Q80$R<6T!,7%Z 2]QB@(M<9P"*W&O BIQR (J<.L"*F__ BIM
M_P(J;/\"*VS_ BML_P*Q80  I&D  )!H  " 9P  =&<  &EG  !?:   56L
M $MN  !#<0  /'0  #=V"@ T=Q( ,W@< #)X)0 Q>2X ,'DW "]Y/P N>4@
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M !")_P"A>@  CGD  'YW  !R=P  9'@  %A[  !-?@  0H(  #F&   OB@
M)XX  ""1   8E0  $I@%  Z:#@ -FA0 #)H=  N:)@ +FC  "IH[  F:1@ (
MFE, !IMA  6:<@ $FH8  IJ;  ":L0 !F<\  IGP  *8_P $E_\ !9;_  66
M_P"9@0  AW\  'I^  !K?@  78$  %"%  !%B0  .XT  #&2   HE@  'YD
M !B=   1H   #*,"  :E"@ !I1   *46  "F'P  IB@  *8R  "G/0  ITH
M *=8  "G:   IWP  *>1  "FJ   IL,  *7I  "E_   I?\  *3_  "D_P"1
MAP  @H8  '*&  !CB   58P  $F1   ]E@  ,IH  "B>   ?H@  %Z8  !"I
M   +K   !*\   "Q!@  L0P  +(1  "R%P  LQ\  +,H  "T,@  M3\  +5-
M  "U70  M7   +6&  "UG0  M;8  +7<  "T]P  M/\  +3_  "T_P"+CP
M>HX  &J1  !;E0  39H  $"?   UI   *J@  ""L   6L   #[0   FW   !
MN0   +T   "^    O@8  +\,  # $   P18  ,(=  ##)P  Q3(  ,9   #&
M40  QV,  ,=X  #'D0  QZD  ,?'  #'[   Q_X  ,?_  #'_P"#EP  <9H
M &&>  !2HP  1:D  #BN   LLP  (+<  !:Z   .O0  !L    ##    QP
M ,D   #*    S    ,T#  #."0  T X  -(3  #4&P  V"4  -LR  #=0@
MW50  -YI  #>@0  WIP  -^U  #?V0  W_,  -__  #?_P!WGP  :*8  %FM
M  !*LP  .[@  "V[   ?OP  %,(   S&   #R0   ,P   #0    U0   -D
M  #:    W    -X   #@    X@4  .0+  #G$   ZA@  .TD  #P,@  \40
M /)8  #S;P  ](H  /2D  #TOP  ]-\  /3S  #T] !JJ   6Z\  $RW   ]
MO0  +<$  !_&   3R@  "\X   #2    UP   -P   #@    Y0   .<   #I
M    ZP   .T   #O    \0   /,   #V!P  ^0X  /P6  #_(@  _S,  /]'
M  #_70  _W8  /^1  #_J0  _[X  /_8  #_VP#_ !@ _P 6 /\ %0#_ !@
M_P > /\ )P#_ #8 _P!# /\ 3P#_ %H _P!D /\ ;0#_ '4 _P!] /\ A #_
M (H _P"0 /\ E@#_ )P _P"C /\ JP#_ +0 _@"_ /T SP#[ .< ^@#X /D
M_P#Y /\ ^0#_ /4 _P#N /\ Z0#_ .< _P#_ !0 _P 1 /\ $0#_ !( _P 7
M /\ (P#_ #$ _P ^ /\ 2@#_ %8 _P!@ /\ : #_ '  _P!X /T ?@#\ (4
M^@"+ /D D0#X )@ ]P"> /4 I@#T *X \@"Y /$ QP#O .  [@#R .P _P#L
M /\ [ #_ .L _P#E /\ X #_ -X _P#_ Q  _P . /\ #0#_  T _P 3 /\
M'@#_ "L _P X /\ 10#^ %  ^P!: /@ 8P#U &L \P!R /$ >0#O '\ [@"&
M .P C #J )( Z0"9 .< H #F *D Y "S .$ P #@ -, W@#K -P ^P#; /\
MV@#_ -H _P#9 /\ U #_ -( _P#_!PT _P ) /\ !@#_  D _P / /\ & #[
M "4 ^  R /4 /P#R $H [0!4 .H 70#G &4 Y !L .( <P#@ 'H W@"  -P
MA@#: (T UP"4 -0 FP#2 *0 SP"M ,T N0#+ ,D R0#D ,@ ]@#& /\ Q0#_
M ,8 _P#' /\ QP#_ ,< _P#_"@8 _P$  /\   #_  0 _P + /0 $@#O !\
MZ@ L .4 . #B $, W0!. -D 5P#4 %\ T0!G ,X ;0#, '0 R@!Z ,@ @ #&
M (< Q0". ,, E@#! )X OP"H +T LP"Z ,( N0#; +< \ "U /\ M@#_ +4
M_P"U /\ M0#_ +4 _P#_#   _P0  /\   #^    ]@ # .@ #0#@ !< V0 D
M -$ ,0#- #P R@!' ,8 40## %D P !@ +X 9P"\ &X N@!T +D >P"W ((
MM0") +, D0"R )H L "D *X KP"L +T J@#0 *@ ZP"G /L I@#_ *8 _P"E
M /\ I0#_ *4 _P#_#0  _P<  /0)  #J"0  X@0  -H !P#/ !$ R  < ,(
M*0"^ #4 NP!  +< 2@"T %, L@!; +  8@"N &@ K !O *L =0"I 'T J "$
M *8 C0"D )8 HP"@ *$ JP"? ;D G0/, )P$Z ":!OD F0?_ )@(_P"7"/\
MEPC_ )<(_P#_$   ]Q   .@4  #<%0  SA$  ,8-  #"! L O  4 +<!(0"R
M RX K@4Z *L&1 "H"$T I@A5 *0)7 "B"F, H IJ )\+<0"="W@ G N  )H,
MB0"9#), EPR> )4-J@"4#;@ D@W, ) .Z@".$/P C!#_ (L0_P"+$/\ BQ#_
M (H0_P#[$P  [1H  -T@  #,(0  OQT  +<7  "S$0  L@L- *L-&0"G#B8
MHP\S )\0/@"=$4< FA%0 )@25P"6$EX E1-E ),3; "2$W, D!1\ (\4A0"-
M%8\ BQ6: (H5IP"(%K4 AA;) (07YP""&/L @!G_ '\9_P!_&?\ ?QC_ '\8
M_P#U&@  Y",  ,\I  # *@  LR8  *HB  "E'   I!4( * 4$P";%B$ EQ@M
M )09. "1&D( CQM+ (T<4@"+'%D B1U@ (@=9P"&'F\ A1YW (,?@ ""'XL
M@!^7 'X@HP!](+( >R#% 'DAY !W(OD =B+_ '4B_P!T(?\ ="'_ '0A_P#O
M(0  VRL  ,<Q  "V,0  J2X  * J  ";)@  F"$! )4>$ "0(!L C2$H (DC
M,P"')#T A21& (,E3@"!)E4 ?R9< 'XF8P!\)VL >R=S 'DG? !X*(< =BB3
M '0HH %R**\!<2G! 6\IX %M*?<!;"G_ 6LI_P%K*?\!:RC_ 6LH_P'H*
MT#(  , X  "N-P  H34  )@R  "2+0  CBD  (LG# "'*!< @RHC ( K+P!^
M+#D ?"Q" 'HM2@!X+E$ =RY8 '4N8 !S+V< <B]O ' O>0%O+X,!;2^0 6LO
MG0%I+ZP!:#"^ 6<PVP%E,/4!9##_ 6,P_P%C+_\!8R__ 6,O_P'B+@  RC@
M +H]  "H/   FCH  )$W  "*,P  AC   (,N"0!_+Q, >S ? '@R*P!V,S4
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M DM)D0-*2:$#2$FS T=)R@-&2>P#1DC_ D9(_P)'1_\"1T;_ D=&_P+&0P
MMDP  *),  "13   A$L  'E*  !P20  :48  &1'  !?208 7$H0 %I+&P!8
M3"4 5DPO %5-. !334  4DU( %%.3P!/3E< 3DY? 4Q.:0%*3G,"2$V  D9-
MCP-%39\#0TVQ T)-R -!3>H#04S_ D%,_P)"2_\"0DK_ D)*_P+"1P  LT\
M )Y/  "-3@  @$X  '5-  !L3   8TH  %Y,  !:30( 5DX. %1/& !24"(
M45$L $]1-0!.4CT 35)% $Q230!*4E0 25)= 4=29@%%4G$!0U)^ D%2C0(_
M4IT#/E*O SU2Q@,\4ND"/%'^ CQ0_P(]3_\"/4__ CU._P*^2P  KE,  )I2
M  ")40  ?%$  '%0  !H4   7DX  %A1  !44@  45,, $Y4% !,51\ 2U8I
M $E6,@!(5CH 1U=" $972@!$5U( 0U=: $%79 % 5VX!/E=[ CQ7BP(Z5YL"
M.%>M C=7Q (W5^<"-U;] C=5_P(W5/\"-U/_ CA3_P*Z3P  J58  )55  "%
M5   >%0  &U4  !D5   6%0  %)6  !.5P  2ED) $=:$0!&6AL 1%LE $-;
M+@!"7#8 05P^ #]<1@ ^74\ /5U7 #M=80 Z76P!.%UY 39=B $T79D",UVK
M C%=P@(Q7.4",5O\ C%:_P(Q6?\",EG_ 3)8_P&V5   I%D  )!8  " 6
M<U<  &E7  !@6   5%D  $Y;  !(70  0U\$ $!@#@ ^81< /6$@ #MB*0 Z
M8C( .6(Z #AC0@ W8TL -F-4 #1C70 S8V@ ,6-V 2]CA0$N8Y8!+&.I 2MC
MOP$J8^,!*F+[ 2I@_P$K7_\!*U__ 2M>_P&Q60  GEP  (M<  ![6P  ;UL
M &5;  !<7   45X  $E@  !#8@  /&4  #AG"@ U:!( -&@; #-I)  R:2T
M,6DU "]J/0 N:D8 +6I/ "QJ60 K:V4 *6MR "AK@@ F:Y, )&NG "-KO0 B
M:N  (VGY 2-G_P$C9O\!(V;_ 21E_P&L8   F&   (5@  !V7P  :E\  &%@
M  !78   36,  $1F   ]:   -FL  #!N!  L< X *G$5 "EQ'@ H<28 )W(O
M "9R-P E<D  )')* ")R5  A<V  ('-M !YS?0 =<Y  &W.C !ISN0 9<]P
M&G'W !IP_P ;;_\ &V[_ 1MM_P&F9@  D64  ']D  !Q9   9F0  %UD  !2
M9@  2&D  #]L   W;P  ,',  "EV   B>0@ 'WL0 !Y[%P <>Q\ &WLH !I[
M,  9?#D &'Q# !=\3@ 6?%H %7QG !1]>  2?8L $7V? !!]M0 /?=4 $'OU
M !%Y_P 1>/\ $G?_ !)W_P">:P  BFH  'II  !M:0  8FD  %=J  !,;0
M0W   #ET   Q>   *7L  ")_   ;@@  %(4) !&&$  1AA< $(<? !"'*  .
MAS$ #H<[  V'1@ ,AU, "X=A  J'<0 )AX0 !X>8  :&K@ %ALD !H7L  >$
M_P (@_\ "8+_  F"_P"5<0  @V\  '1N  !I;@  7&\  %!R  !&=0  /'D
M #)]   J@0  (H4  !N)   4C   #X\#  J2"P &DA$ !)(8  *2(  !DBD
M )(S  "3/@  DTL  )-9  "3:0  DWL  )*0  "2I@  D;\  )'E  "0^@
MC_\  (__  "/_P"-=P  ?74  '!T  !B=0  57@  $E\   _@   -(0  "N)
M   BC0  &I$  !.4   .EP  "9L   &="   G0X  )T3  ">&@  GB(  )\K
M  "?-0  H$(  *!0  "@7P  H'$  *"'  "?G0  G[4  )[:  "=]@  G?\
M )S_  "<_P"&?0  >'P  &E\  !;?P  3H,  $&(   VC   +)$  ".6   :
MF@  $IX   VA   &I    *<   "I P  J0H  *H.  "K$P  K!D  *TB  "N
M*P  KS<  *]%  "O5   KV8  *][  "NE   KJL  *[)  "N[P  K?\  *W_
M  "M_P"!A   <80  &&'  !3BP  1I   #F6   NFP  (Z   !JD   2J
M#*P   2O    L@   +8   "W    MP(  +@(  "Y#0  NA(  +L8  "](0
MOBL  , X  # 2   P%H  ,%N  #!A@  P:   ,&Z  #!XP  P/D  ,#_  #
M_P!YC0  :)   %F4  !+F@  /:   #&E   EJP  &J\  !&S   +N    KL
M  "^    P0   ,0   #%    Q@   ,<   #(!0  R@L  ,P/  #.%0  T!\
M -,K  #5.@  U4P  -9@  #8=P  V)(  -BL  #9R0  V>P  -G[  #8_P!P
MF0  8)X  %&D  !#J@  -;   "BV   <N@  $;X   G!    Q0   ,@   #+
M    SP   -(   #3    U@   -@   #;    W0   -\'  #B#0  Y1,  .@=
M  #L*@  [3P  .U1  #N9P  [X$  .^<  #PMP  \-,  /#L  #P] !GI@
M6*T  $FT   ZN@  *KX  !S"   0Q@  !\H   #.    T@   -8   #<
MX    .,   #D    Y@   .@   #K    [0   .\   #R @  ]0H  /@1  #\
M'   _RP  /\_  #_50  _VX  /^*  #_I   _[H  /_1  #_X0#_ !0 _P 2
M /\ $@#_ !0 _P 9 /\ )0#_ #( _P _ /\ 2P#_ %8 _P!@ /\ : #_ '
M_P!X /\ ?P#_ (4 _P"+ /\ D0#_ )@ _P"> /X I@#] *X _ "Y /H R #Y
M .( ^ #T /< _P#V /\ ]@#_ .\ _P#G /\ X@#_ -X _P#_ !$ _P . /\
M#@#_  \ _P 4 /\ ( #_ "T _P Z /\ 1@#_ %$ _P!; /\ 8P#^ &L _ !S
M /H >0#Y (  ]P"& /8 C #U )( \P"9 /( H #P *D [@"S .T P0#K -8
MZ@#N .D _@#G /\ YP#_ .4 _P#= /\ U0#_ -$ _P#_  T _P * /\ " #_
M  D _P 0 /\ &P#_ "@ _P U /\ 0 #Z $L ]@!5 /, 7@#Q &8 [@!M .P
M= #K 'H Z0"  .< A@#F (T Y "3 .( FP#@ *, W@"M -P N0#: ,H UP#F
M -0 ^ #2 /\ T@#_ -( _P#. /\ R0#_ ,8 _P#_  @ _P # /\   #_  ,
M_P - /P %@#W "( \P N .\ .@#L $4 Z !/ .0 6 #A &  W@!G -L ;0#9
M '0 U0!Z -, @ #1 (< SP". ,T E0#+ )X R0"G ,< LP#% ,( PP#< ,$
M\0"_ /\ OP#_ +X _P"^ /\ O0#_ +L _P#_    _P   /\   #_    ]@ (
M .X $0#G !L X0 G -T ,P#9 #X TP!) ,\ 4@#+ %D R !A ,8 9P#$ &T
MP@!S ,  >@"_ (  O0"( +L D "Y )@ N "B +4 K0"S +L L0#. +  Z@"O
M /P K0#_ *T _P"N /\ K@#_ *X _P#_ @  _P   /T   #R    Z    -X
M# #3 !4 S  A ,@ + #$ #@ P0!" +T 2P"Z %, N !: +8 80"T &< L@!M
M +  = "O 'H K0"" *P B@"J ), J "= *8 J "D +4 H@#& *$ XP"? /8
MG@#_ )X _P"> /\ G@#_ )X _P#_!@  ^P   .X%  #B!   U0   ,L !@##
M  \ O0 9 +@ )0"T #$ L0 [ *X 10"L $T J0!5 *< 6P"E &( I !H *(
M;@"A '4 GP!\ )X A0"< (X F@"8 )@ I "6 +  E0#! ), W "2 /( D0#_
M )  _P"0 /\ CP#_ (\ _P#]"@  \ X  .$1  #.$   P@T  +L'  "W  H
ML0 2 *P '@"H "D I0 T *( /@"? $< G0!/ )L 5@"9 5P EP%C )8":0"4
M G  DP-X )$#@ "0!(H C@25 (P%H0"*!:X B0:^ (<(V "&"?  A K_ (,+
M_P"#"_\ @PO_ (,+_P#V$   YA<  -(<  # &@  LQ8  *P2  "H#0  I@<-
M *(%%@"=!R( F0DN )8*. "4"T$ D@Q* ) ,40".#5@ C U> (L-90")#6P
MB YT (8.?0"%#H< @PZ3 ($/GP" $*T ?A"^ 'T0VP!Z$?0 >!+_ '<2_P!W
M$O\ =Q+_ '<2_P#O%P  VR$  ,8D  "T(P  J"   * <  ";%P  F1$$ )@.
M$ "3$!L CQ$G (P2,@")$SP AQ-$ (443 "#%%, @15: ( 58 !^%F@ ?19O
M 'L6> !Y%X, >!>/ '88G !T&*H <QF[ '(9U !O&O$ ;AO_ &T;_P!M&O\
M;1K_ &T:_P#G(   T"D  +PK  "K*@  GB@  )8D  "0(   C1P  (P7# "(
M&!8 A!HB ($;+0!^'#< ?!U  'H=2 !Y'D\ =QY5 '8?7 !T'V, <Q]K '$@
M= !P('\ ;B&+ &PAF !K(:< :2*X &@BSP!F(NX 92/_ &0C_P!D(O\ 9"+_
M &0A_P#@)@  R"\  +0Q  "C,   EBX  (TK  "'*   A"0  ((@" !^(!(
M>R(> '@C*0!U)#, <R4\ '$E0P!P)DL ;B92 &TG60!K)V  :B=H &DH<0!G
M*'L 92B( &0IE0!B*:0 8"FU %\IRP!>*NP 7"K_ %PI_P!<*?\ 7"G_ %PH
M_P#8+   PS4  *TU  "=-   D#,  (8Q  " +0  ?"L  'DH P!V)Q  <BD:
M ' J)0!M*R\ :RPX &HL0 !H+4< 9RU. &4N50!D+ET 8RYE &$O;@!?+W@
M7B^$ %POD@!:+Z$!62^R 5@PR %6,.D!53#^ 54O_P!5+_\ 52[_ %4N_P#0
M,0  O3H  *@Y  "7.   BC<  ( V  !Z,@  =3   '(N  !N+@T :R\6 &DP
M(0!F,2L 9#(T &,R/0!A,T0 8#-+ %\T4@!=-%H 7#1B %HT:P!9-74 5S6"
M %4UD %4-9\!4C6P 5$UQ@%0-><!3S7] 4\U_P%/-/\!3S3_ 4\S_P'+-@
MN#T  *,\  "2/   A3L  'LZ  !T-P  ;S4  &PS  !H- H 9343 &(V'@!@
M-R@ 7C<Q %TX.@!;.$$ 6CE( %DY4 !7.5< 5CI? %0Z: !3.G, 43I_ 4\Z
MC0%..IT!3#JN 4LZPP%*.N4!23K\ 4DY_P%).?\!23C_ 4HX_P''.@  LT
M )X_  "./P  @3X  '<]  !P.P  :C@  &8X  !B.0< 7SH1 %P[&P!:.R4
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M 3M(O@$Z2-\!.D?X 3I&_P$Z1?\!.T7_ 3M$_P&[10  ID@  ))'  ""1P
M=D<  &M'  !C1@  6T,  %9%  !21P  3D@* $Q)$@!*21P 2$HE $=*+@!&
M2S8 14L^ $-+1@!"3$T 04Q6 $!,7P ^3&H /$QV #M,A0$Y3)4!-TRG 39,
MO $U3-T!-4OW 35+_P$U2O\!-DG_ 39)_P&X20  HDL  (Y*  !^2@  <DH
M &A*  !?20  54@  %!*  !,2P  24P' $9-$ !$3AD 0D\B $%/*P! 4#,
M/U [ #Y00P \44H .U%3 #I17  X46< -U%S #51@@ S49,!,E&E 3!1N@$O
M4=H!+U#V 2]/_P$P3O\!,$[_ 3!-_P&T30  G4T  (I-  !Z30  ;DT  &1-
M  !;30  44T  $M/  !&4   0E(# #]3#0 ]5!4 /%0> #I5)P Y52\ .%4W
M #=6/P V5D< -590 #-660 R5V0 ,%=Q "]7@  M5Y$ *U>C "I7N  I5]8
M*5;U "E5_P J5/\!*E/_ 2I2_P&O40  F%$  (51  !V4   :E   &!0  !8
M40  3E(  $=3  !!50  .U@  #A9"@ U6A$ -%H: #-;(@ R6RL ,5LS "]<
M.P N7$, +5Q, "Q<5@ K76  *5UM "A=?  F78X )%VA "-=M0 B7=( (ESS
M ");_P C6O\ (UG_ "18_P"H50  DE0  (!4  !Q5   9E0  %Q4  !450
M2E8  $-8   \6P  -ET  #!@!0 M80X *V$5 "IB'0 I8B4 *&(N "=C-@ F
M8SX )6-' "-C40 B9%P (61I !]D>0 >9(H '&2> !MDLP 99,X &F/Q !MA
M_P ;8/\ '&#_ !Q?_P"A60  C%@  'M8  !M6   8E@  %E8  !060  1UL
M #Y>   W8   ,6,  "IF   D:0D (6H0 "!J%P ?:B  'FLH !UK,  <:SD
M&VM" !IL3  9;%@ %VQE !9L=  4;(8 $VR: !)LKP 1;,H $6OO !)I_P 3
M:/\ $VC_ !-G_P"970  A5T  '5<  !H7   7EP  %5<  !+7@  0F$  #ED
M   R9P  *VH  "1M   >< $ %W,+ !5T$0 4=!@ $W0A !)U*0 1=3( $74[
M !!U1@ /=5( #G5?  UU;@ ,=8$ "W65  IUJ@ (=,, "73G  IS_0 +<?\
M#''_  QP_P"18@  ?V$  '!A  !D80  6F$  $]B  !%90  /&@  #-L   K
M;P  )'(  !UV   7>0  $7P$  U_#  +?Q( "G\9  E_(@ (?RH !G\T  5_
M/P $?TL  G]8  %_9P  ?WD  '^.  !_HP  ?KL  'W@  !]]P  ?/\  'O_
M  ![_P")9P  >&<  &MF  !A9@  5&<  $EI   _;0  -7$  "QU   D>0
M'7P  !:    0@P  #(8"  :)"@ !B0\  (D4  "*&P  BB,  (LL  "+-P
MBT,  (M0  "+7P  BW$  (N&  "+G   BK,  (G3  "(\P  B/\  (?_  "'
M_P"";0  <VP  &AL  !:;0  3F\  $)S   X=P  +GL  "6    =A   %8@
M !",   +CP  !)(   "4!@  E0P  )40  "6%0  EQP  )@D  "8+@  F3D
M )E'  "95@  F6@  )E]  "9E   F*L  )?(  "6[@  EO\  )7_  "5_P![
M=   ;W,  &%S  !3=@  1GH  #M_   PA   )H@  !V-   4D@  #I8   F9
M   !G    *    "A    H@8  *(,  "D$   I10  *4<  "G)   J"\  *@]
M  "I3   J5X  *ER  "HB0  J*(  *B\  "GY0  IOL  *;_  "E_P!W>P
M:'L  %E^  !+@@  /H<  #*-   GD@  '9<  !2<   .H   !Z0   "H
MJP   *X   "O    L    +$$  "S"@  M X  +43  "V&P  N"0  +HQ  "Z
M0   NE(  +ME  "[?0  NI<  +JQ  "ZT@  NO,  +G_  "Y_P!O@P  7X8
M %&+  !#D   -I<  "J=   ?H@  %:<   VL   %L    +0   "W    NP
M +X   "_    P    ,$   ## 0  Q <  ,4-  #'$0  RAD  ,TD  #.,P
MST0  -!8  #0;@  T8@  -"D  #0P0  T>8  -'X  #1_P!GCP  5Y0  $F:
M   [H0  +J<  "&M   6LP  #K@   :\    P    ,,   #&    RP   ,T
M  #.    T    -$   #4    U@   -H"  #<"0  WP\  .,7  #F)   YS8
M .A)  #I7P  ZG@  .N4  #KKP  Z\P  .SH  #L]@!?G@  4*0  $*K   T
ML@  )KD  !F^   .P@  !,4   #*    S0   -$   #8    VP   -\   #@
M    X@   .0   #F    Z0   .L   #N    \04  /4-  #Y%@  _"4  /TY
M  #^3P  _V<  /^"  #_G0  _[4  /_+  #_Y #_ !$ _P / /\ #P#_ !$
M_P 6 /\ (@#_ "\ _P [ /\ 1P#_ %( _P!; /\ 9 #_ &P _P!S /\ >@#_
M (  _P"& /\ C #^ ), _0"9 /L H0#Z *D ^ "T /< P@#V -H ]0#Q /0
M_P#S /\ \P#_ .D _P#@ /\ V #_ -, _P#_  X _P + /\ "@#_  L _P 1
M /\ '0#_ "H _P V /\ 00#_ $P _P!6 /X 7P#[ &8 ^0!M /< = #U 'H
M] "  /( A@#P (T [P"4 .T FP#L *0 Z@"N .D N@#G ,T Y0#I .0 ^P#C
M /\ X@#_ -X _P#1 /\ S #_ ,@ _P#_  D _P $ /\  0#_  0 _P . /\
M& #_ "0 _0 P /L .P#W $8 \P!0 .\ 60#L &  Z@!G .< ;@#F '0 Y !Z
M .( @ #@ (< W@". -P E0#: )X U@"H -0 LP#1 ,, SP#? ,X ] #, /\
MRP#_ ,L _P#% /\ OP#_ +P _P#_  ( _P   /\   #_    _0 + /< $P#Q
M !X [0 J .H -0#G $  X@!* -T 4@#9 %H U0!A -( 9P#0 &T S@!S ,P
M>@#* (  R "' ,8 CP#$ )@ P@"A ,  K0"^ +L O #0 +H [0"Y /X N #_
M +@ _P"W /\ LP#_ +  _P#_    _P   /\   #Y    [@ % .4 #@#> !@
MV  C -( +@#/ #D RP!# ,< 3 #$ %0 P0!; +\ 80"\ &< NP!M +D <P"W
M 'H M0"! +0 B0"R )( L "; *\ IP"L +0 JP#& *D Y "G /@ I@#_ *8
M_P"E /\ I0#_ *0 _P#_    _P   /4   #J    W@   -  "@#( !( P@ =
M +X * "[ #, N0 ] +4 1@"R $T L !5 *T 6P"L &$ J@!G *@ ;0"G ',
MI0!Z *0 @@"B (P H "6 )\ H0"= *X FP"^ )D V "7 /$ E@#_ )8 _P"7
M /\ EP#_ )< _P#_    ]0   .<!  #4    R0   ,  ! "X  X LP 6 *\
M(0"K "P J  V *8 /P"C $< H0!/ )\ 50"= %L FP!A )H 9P"8 &X EP!U
M )4 ?0"4 (8 D@"1 )  G ". *D C "X (L S0") .L B #] (@ _P"( /\
MB #_ (@ _P#Y!@  Z0P  -0.  ###   MPD  + "  "K  D I@ 0 *( &@">
M "4 FP P )@ .0"6 $$ E !) )( 4 "0 %8 C@!< (T 8@"+ &D B@!P (@
M> "' ($ A0", (0 F "" *4 @ "T 'X R !] >< ? +Y 'L#_P![!/\ >P3_
M 'L$_P#Q#@  WA4  ,45  "T%   J1$  *$.  ">"@  FP,, )< $P"3 !X
MD $I (T",P"* SP B 1# (8%2P"%!E$ @P97 (('7@" !V0 ?PAL 'T(= !\
M"'X >@F) '@)E@!W"J, =0JS ',+QP!R#.8 < W[ ' -_P!O#?\ ;PW_ &\-
M_P#H%@  T!X  +D=  "I'   G1H  )46  "0$P  CPX# (X*#@")"Q< A@PC
M (,-+0" #38 ?@X^ 'P.1@![#DT >0]3 '@06@!V$&$ =1!H ',0<0!Q$7L
M<!&' &X1E !L$:( :Q*R &D2QP!H$^< 9A/] &44_P!E%/\ 91/_ &43_P#?
M'@  QB0  + D  "@(P  E"$  (L?  "&&P  @Q<  ((2" !_$1( ?!(= 'D4
M* !V%#$ =!4Z '(600!Q%D@ ;Q=/ &X75@!L%UT :QAD &D8;0!H&7< 9AF#
M &09D !C&I\ 81JO & :Q !>&^0 71S[ %P<_P!<&_\ 7!O_ %P;_P#5)0
MO2H  *@I  "8*0  C"@  (,E  !](@  >1\  '@; P!V&0\ <AH8 &\<(P!M
M'2T :QTU &D>/0!H'D0 9A]+ &4?4@!C(%D 8B!A &$@:0!?(7, 72%_ %PA
MC0!:(IP 62*L %<BP !6(^$ 52/Y %0C_P!4(O\ 5"+_ %0B_P#-*P  MBX
M *(N  "2+@  A2T  'PK  !V*   <B8  &\C  !M(0P :B(5 &<C'P!E)"D
M8R0Q &(E.0!@)D$ 7R9( %TF3P!<)U8 6R== %DG9@!8*'  5BA\ %0HB@!3
M*9D 42FJ % IO@!/*=X 3BGW $TI_P!-*?\ 32C_ $XH_P#(,   L#(  )PR
M  ",,@  @#$  '8P  !P+0  :RL  &@I  !F* D 8R@1 & I' !>*B4 7"LN
M %LK-@!9+#T 6"Q$ %<M3 !5+5, 5"U; %,M8P!1+FX 4"YZ $XNB !,+Y<
M2R^H $DONP!(+]L 2"_V $<O_P!'+O\ 1RW_ $@M_P#$-   JS4  )<U  "'
M-0  >S4  '(T  !K,@  9B\  &(N  !?+04 7"X0 %HO& !8,"( 5C K %4Q
M,P!3,3H 4C)" %$R20!0,E  3C-8 $TS80!+,VL 2C-W $@TA0!'-)4 132F
M $,TN0!"--8 0C3T $(T_P!",_\ 0C+_ $(R_P# .   IS@  ),X  "#.
M=S@  &TW  !F-@  83,  %TR  !9,@( 5S,- %0T%0!2-1\ 434H $\V, !.
M-C@ 3#<_ $LW1@!*-TX 23A6 $<X7P!&.&D 1#AU $,X@P!!.9, 0#FD #XY
MN  ].=, /#GS #PX_P ]-_\ /3?_ #TV_P"[.P  HCL  (\[  !_.P  <SL
M &HZ  !B.0  73<  %@V  !4-P  43@+ $\Y$P!-.1P 2SHE $HZ+0!(.S4
M1SL\ $8\1 !%/$L 1#Q3 $(\7 !!/6< /SUS #X]@0 \/9$ .CVC #D]M@ X
M/=$ -SWR #<\_P X._\ .#O_ #@Z_P"V/0  GCX  (L^  !\/@  ;SX  &8]
M  !>/0  6#L  %,Z  !/.P  3#P( $D]$0!'/AD 1C\B $0_*@!#/S( 0D Z
M $% 00! 0$D /D%1 #U!6@ \060 .D%P #A!?P W08\ -4*A #1"M  R0LX
M,D'P #) _P S0/\ ,S__ #0^_P"Q0   FD   (=   !X00  ;$$  &)   !;
M0   5#\  $X_  !*0   1D$% $1"#@!"0Q8 0$,? #]$)P ^1"\ /$0W #M%
M/@ Z148 .45. #A&6  V1F( -49N #-&?  Q1HT ,$:? "Y&LP M1LP +4;O
M "U%_P N1/\ +D/_ "Y#_P"L0P  ED,  (-#  !T0P  :$,  %]#  !70P
M4$,  $A#  !$10  048! #Y'#  \2!, .D@< #E))  X22P -DDT #5*.P T
M2D, ,TI, #)*50 P2U\ +TMK "U+>@ L2XL *DN= "A+L0 G2\H )TOM "=*
M_P H2?\ *$C_ "E'_P"G1@  D48  ']&  !P1@  948  %M&  !41@  3$<
M $1(   _2@  .TL  #=,"0 U31  ,TX8 #).(  Q3R@ ,$\P "]/.  N3T
M+%!( "M04@ J4%P *%!H "=0=P E4(@ )%"; ")0KP A4,@ (%#K "%/_P B
M3O\ (DW_ "--_P"A20  C$D  'I)  !L2@  84H  %A*  !02@  24L  $!,
M   [3@  -5   #%2!  M4PT +%04 "I4'  I520 *%4L "=5,P F53P )59%
M "163@ B5ED (59E !]6=  >5H4 '%:8 !M6K  95L4 &5;I !I5_P ;5/\
M&U/_ !Q2_P";30  ADT  '5-  !H30  74T  %1-  !-3@  14\  #Q1   V
M4P  ,54  "M8   F6@D (UL0 ");%P A7!\ (%PG !]<+@ =7#< '%U  !M=
M2@ :754 &%UA !==<  578$ %%V5 !-=J@ 17<( $5WG !);_@ 36O\ $UK_
M !19_P"440  @%$  '!1  !D40  65$  %%1  !)4@  05,  #A6   R60
M*UL  "5>   ?80, &F,, !AD$0 79!D %F0A !5D*0 493$ $V4Z !)E1  1
M95  $&5=  ]E:P .97T #661  QEI0 *9+P "F3@  MC^0 ,8O\ #6'_  UA
M_P"-50  >E4  &M5  !?50  5E4  $Y5  !$5P  /%D  #1<   L7P  )F(
M !]E   9:   $VL% !!M#0 .;A( #6X:  QN(@ ,;BL "VXT  IN/@ (;DH
M!VY7  9N90 $;G8  FZ*  !MGP  ;;8  &S6  !L\P !:_\  FK_  -J_P"%
M6@  =%H  &9:  !<60  4UD  $A:   _70  -F   "YC   F9P  'VH  !EM
M   3<0  #G0#  IW"@ %=Q   7<5  !W'   =R0  '@M  !X-P  >$,  'A0
M  !X7@  >&\  'B$  !XF0  =[   ';-  !U\   =?\  '3_  !T_P!^7P
M;E\  &)>  !97@  35\  $)B   Y90  ,&@  "=L   ?<   &'0  !)W   -
M>P  "'X   * "   @0T  ($1  ""%P  @QX  (,F  "$,   A#L  (1(  "$
M5P  A&@  (1\  "$DP  @ZH  (+%  "!ZP  @?X  (#_  " _P!W90  :60
M %]C  !29   1V<  #QK   Q;P  *',  "!W   8?   $7\   R#   &AP
M (H   ", P  C D  (T.  ".$0  CQ<  ) >  "1)P  DC(  )(_  "23@
MDE\  ))S  "2BP  D:(  )&\  "0Y0  C_P  ([_  "._P!Q:P  9FH  %AK
M  !+;0  /W$  #1V   J>P  ((   !>%   0B0  "XT   21    E0   )@
M  "9    F@,  )L(  "<#0  GA$  )\6  "@'@  HB@  *(U  "C1   HU4
M *-I  "B@   HIH  *&S  "@V   H/8  )__  "?_P!N<0  7W(  %%U  !$
M>0  -WX  "R$   AB@  %X\  !"4   *F0   9T   "@    I    *<   "H
M    J0   *H   "L!@  K0L  *\0  "P%0  LAX  +0I  "T.0  M$H  +5=
M  "U<P  M8X  +6H  "TQ@  L^T  ++_  "R_P!F>@  5WT  $F"   \AP
M+XX  ".4   8F@  $)\   FD    J0   *T   "P    M    +<   "X
MN0   +L   "\    O@(  , (  #"#@  Q!0  ,<>  #(+   R3T  ,I0  #*
M9@  RG\  ,J;  #*N   RMT  ,KU  #*_P!>A@  3XL  $&1   SF   )Y\
M !NE   1JP  ";    "U    N0   +T   #!    Q@   ,@   #)    RP
M ,P   #.    T    -(   #4!0  V0P  -T2  #A'@  XBX  .-"  #D5P
MY6\  .:,  #FJ   Y<4  .7G  #F]@!6E   2)L  #JB   LJ0  '[   !.V
M   +O    ,$   #%    R0   ,T   #2    U@   -H   #;    W@   .
M  #B    Y    .<   #I    [0   / *  #T$0  ^!\  /DR  #Z2   ^U\
M /QZ  #]EP  _:\  /W'  #]Y #_  X _P - /\ # #_  X _P 3 /\ '@#_
M "H _P V /\ 0@#_ $T _P!7 /\ 7P#_ &< _P!N /\ = #_ 'H _P"! /T
MAP#\ (T ^@"4 /D G #W *4 ]0"O /0 O #S ,\ \0#L /  _@#O /\ [P#_
M ., _P#7 /\ S@#_ ,H _P#_  H _P & /\ ! #_  @ _P 0 /\ &0#_ "4
M_P Q /\ /0#_ $< _@!1 /L 60#Y &$ ]@!H /0 ;@#S '0 \0!Z .\ @0#N
M (< [ ". .H E@#H )\ Y@"I ., M0#B ,8 X #C -\ ^ #= /\ W0#_ -0
M_P#) /\ P@#_ +X _P#_  , _P   /\   #_  $ _P - /\ % #] "  ^@ K
M /< -@#S $$ [P!+ .P 5 #H %L Y@!B ., : #A &X WP!T -P >@#: ($
MV "( -0 D #2 )@ SP"B ,T K@#+ +P R0#3 ,< \ #& /\ Q #_ ,0 _P"[
M /\ M@#_ +, _P#_    _P   /\   #_    ]P ( /  $ #K !H YP E .0
M, #A #L W !% -4 30#1 %4 S@!; ,L 8@#) &< QP!M ,4 <P## 'H P0"!
M +\ B0"] )( NP"< +D IP"W +4 M0#( +, Y@"R /L L0#_ +  _P"N /\
MJ@#_ *< _P#_    _P   /X   #Q    Y0 " -P #0#3 !0 S0 ? ,H *@#'
M #0 Q  ^ ,  1P"\ $X N@!5 +< 6P"U &$ LP!G +( ;0"P ', K@!Z *P
M@@"J (L J "5 *< H "E *T HP"^ *$ VP"@ /0 GP#_ )X _P"? /\ G0#_
M )L _P#_    _    .X   #@    T    ,4 " "^ !  N0 9 +4 (P"S "X
ML  W *T 0 "J $@ J !/ *4 50"C %L H@!@ *  9@"? &P G0!S )L >P":
M (0 F ". )8 F@"5 *< DP"W )$ S "0 .P CP#_ (X _P". /\ C@#_ (\
M_P#\    [P   -L   #)    O0   +4  @"N  P J0 3 *4 '0"B "< H  Q
M )T .@": $( F !) )8 3P"4 %4 DP!; )$ 8 "0 &< C@!M (T =0"+ 'X
MB0") (@ E0"& *( A0"Q (, Q "! .0 @ #Y '\ _P"  /\ @ #_ (  _P#T
M @  X D  ,<(  "W!P  K ,  *8   "@  < FP / )@ %P"5 "$ D@ J (\
M,P"- #P BP!# (D 20"' %  A@!5 (0 6P"# &$ @0!H (  < !^ 'D ? "$
M 'L D !Y )T > "L '8 O@!U -T <P#T ', _P!S /\ <P#_ ', _P#I#0
MSQ   +D0  "I$   G@X  )<+  "3!@  D  + (P $0") !H A@ D (, +@"!
M #8 ?P ^ 'T 1 !\ $L >@!1 'D 5P!W %T =@!D '0 ; !S 74 <0&  &\"
MC0!N IH ; .J &L#NP!I!-8 : ;Q &@'_P!G!_\ 9P?_ &<'_P#?%   PQ<
M *X7  ">%@  DQ4  (L2  "&$   A P" (,&#0"  Q0 ? 4> 'D'* !W"#
M=0@X ',)0 !R"48 < I, &\*4P!M"UD ; MA &H+:0!I#'( 9PQ^ &8,BP!D
M#9D 8@VI &$-NP!@#=@ 7@[S %T._P!=#O\ 70[_ %T._P#4'   N1T  *0>
M  "5'0  B1P  ($:  ![%P  >!,  '@0!@!W#0\ <PX8 ' .(@!N#RL ;! S
M &H0.P!I$$( 9Q%) &813P!D$58 8Q)= &$29@!@$F\ 7A)[ %P3B !;$Y<
M61.G %<4N@!6%-4 517S %05_P!4%?\ 5!7_ %04_P#*(@  L"(  )TC  "-
M(P  @2(  'DA  !S'@  ;QL  &X7  !M$PP :A04 &<5'@!E%B< 8Q8O &$7
M-P!@%SX 7AA% %T82P!<&5( 6AE: %D98@!7&FP 5AIW %0:A0!2&Y0 41ND
M $\;MP!.&]  31SQ $P<_P!,'/\ 31S_ $T;_P##)@  JB<  )8G  "'*
M>R<  '(F  !L)   :"$  &8>  !D&P@ 8AL1 %\<&@!='2, 6QXK %H>,P!8
M'SH 5Q]! %8@2 !4($\ 4R!7 %$A7P!0(6D 3B%T $TA@@!+(I$ 22*B $@B
MM !'(LT 1B/O $4C_P!%(O\ 1B+_ $8A_P"\*@  I"L  )$K  ""+   =BL
M &TJ  !F*0  8B8  %\D  !=(@0 6R$. %@B%@!6(Q\ 5"0H %,D, !2)3<
M4"4^ $\F10!.)DP 3"94 $LG7 !))V8 2"=Q $8G?P!%*(\ 0RB@ $$HL@!
M*,L /RCM #\H_P _*/\ 0"?_ $ G_P"W+0  GRX  (PO  !]+P  <2\  &@N
M  !A+0  72L  %HH  !7)P  5"<, %(H$P!0*1P 3BDE $TJ+ !+*C0 2BL[
M $DK0@!(+$D 1BQ1 $4L6@!$+&0 0BUO $ M?0 _+8T /2V> #PML  Z+<@
M.BWK #HM_P Z+?\ .BS_ #HL_P"R,   FS$  (@R  !Y,@  ;3(  &0R  !=
M,0  6"\  %4L  !1+   3RT) $PM$0!*+AD 22\B $<O*@!&,#$ 13 X $,P
M/P!",4< 03%/ $ Q5P ^,6$ /3)M #LR>P Y,HL .#*< #8RKP U,L< -#+I
M #0R_P U,?\ -3'_ #4P_P"M,P  EC0  (0U  !U-0  :34  & U  !9-
M5#,  % P  !,,0  23$& $<R#P!%,Q8 0S,? $(T)P! -"X /S4V #XU/0 ]
M-40 /#9, #HV50 Y-E\ -S9K #8V>  T-XD ,C>: #$WK0 O-\4 +S?H "\V
M_@ P-?\ ,#7_ # T_P"I-@  DC8  ( W  !R.   9C@  %TW  !6-P  4#8
M $LT  !'-0  1#8# $$W#0 _.!0 /C@< #PY)  [.2P .CDS #DZ.@ X.D(
M-CI* #4Z4P T.UT ,CMH # [=@ O.X< +3N9 "P[K  J.\, *3OF "HZ_0 J
M.O\ *SG_ "PX_P"D.   CCD  'PZ  !N.@  8SH  %HZ  !3.@  33H  $8X
M  !".@  /SL  #P\"P Z/!$ .#T9 #<](0 V/BD -#XP #,^-P R/S\ ,3]'
M # _4  N/UH +4!F "M =  I0(0 *$"7 "9 J@ E0,$ )$#E "0__  E/O\
M)CW_ "8]_P"?.P  BCP  '@]  !J/0  7ST  %8]  !//0  23T  $(]   \
M/@  .3\  #9!"  T00\ ,D(6 #%"'@ O0R4 +D,M "U#-  L1#P *T1$ "I$
M30 H1%@ )T5C "5%<0 C18( (D65 "!%J  ?1;\ 'D3C !]$^P ?0_\ ($+_
M "%!_P":/@  A3\  '1   !G0   7$   %-   !,0   1D   #Y!   X0P
M-$4  #!& P M1PT *T@2 "I(&@ I2"( *$DI "=),0 E23D )$E! "-*2@ B
M2E4 ($IA !]*;P =2G\ &TJ2 !I*I@ 82KT %TK@ !A)^@ 92/\ &D?_ !I'
M_P"50@  @$(  '!#  !C0P  6$,  %!#  !)0P  0D0  #M%   U1P  ,$D
M "M+   F30D )$X0 ").%@ A3QT ($\E !]/+  >3S4 '4\] !Q01P :4%$
M&5!= !=0:P 64'P %%"/ !-0I  14+H $5#> !%/^  23O\ $TW_ !1-_P"/
M10  >T8  &M&  !?1P  54<  $U'  !&1P  /T<  #=*   Q3   *TX  "90
M   @4P, '%4, !I6$0 95A@ %U8@ !96)P 55C  %%8Y !-70@ 25TT $5=9
M !!7:  /5WD #E>,  U7H  +5[8 "U;4  M6]  ,5?\ #53_  Y3_P"(20
M=DH  &=*  !;2@  44H  $I*  !#2@  .TP  #-.   L40  )E0  "%6   ;
M60  %5P' !%>#0 07A, $%X:  Y>(@ .7BH #5XS  Q>/0 +7D@ "EY4  A>
M8@ '7G, !5Z&  ->FP "7K$  EW,  )=[@ #7/\ !%O_  5;_P"!3@  <$X
M &).  !73@  3DX  $=.   ^3P  -E$  "Y4   G5P  (5H  !M=   58
M$&,#  QF"P (9Q  !F<5  5G'  $9R0  F<M  %G-P  9T(  &=.  !G7
M9VT  &>   !FE0  9JP  &7'  !EZP  9/P  &3_  !C_P!Z4@  :E,  %U2
M  !44@  2U(  $)3   Y50  ,%@  "A;   A7P  &F(  !1E   0:   #&L!
M  9N"0  ;PX  &\2  !O&   <!\  ' G  !Q,   <3L  '%(  !Q5@  <68
M '%Y  !QCP  <*<  &_!  !OYP  ;OP  &W_  !M_P!S6   95<  %I7  !1
M5@  1E<  #Q:   R70  *F$  ")D   ::   %&P   YO   *<@  !'8   !X
M!0  > L  'D.  !Z$P  >QD  'P@  !]*0  ?3,  'U   !]3@  ?5X  'UR
M  !]B   ?*$  'RZ  ![X@  >OH  'G_  !X_P!M70  8%P  %=<  !+70
M0%\  #5C   K9P  (VL  !IO   3<P  #G<   A[   "?@   ((   "# 0
MA 8  (4+  "&#P  B!,  (D9  "*(0  BRL  (LW  ",1@  BU8  (MI  "+
M@   BYD  (JS  ")V   B/<  (C_  "'_P!H8P  7F(  %%B  !$90  .&D
M "YN   D<P  &G@  !-]   -@0  !H4   ")    C0   )    "2    D@
M )0%  "5"@  EPX  )@2  ":&   FR$  )PM  "=/   G4P  )Q?  "<=@
MFY$  )NK  ":R0  FO   )G_  "8_P!E:0  5VD  $EL   ]<0  ,'8  "5\
M   ;@0  $H<   R,   $D0   )4   "9    G0   *    "A    H@   *0
M  "E 0  IP<  *D,  "J$0  K1@  *\B  "O,   KT$  *]4  "O:P  KH4
M *ZA  "NO@  K>8  *S\  "L_P!><0  3W0  $)Y   U?P  *(4  !V,   3
MD@  #)@   .=    H@   *8   "J    K@   +    "Q    LP   +0   "V
M    N    +H$  "\"@  OA   ,$7  ##)   PS4  ,1)  #$7@  Q7<  ,63
M  #%KP  Q=$  ,/R  ##_P!6?   1X(  #J(   LCP  ()8  !2=   -HP
M ZD   "N    L@   +<   "[    OP   ,(   #"    Q0   ,8   #(
MR@   ,T   #/    T@@  -4.  #;&   W2<  -XZ  #?4   X&@  ."$  #A
MH0  X;T  .'B  #@] !.BP  0)(  #*9   EH0  &*@   ZO   %M0   +H
M  "_    Q    ,@   #.    T0   -0   #5    V    -H   #=    WP
M .(   #D    YP   .L%  #O#@  ]!D  /4K  #V00  ]U@  /AR  #YD
M^:L  /C$  #XX0#_  L _P ( /\ "0#_  P _P 2 /\ &@#_ "8 _P R /\
M/@#_ $@ _P!2 /\ 6@#_ &( _P!I /\ ;P#_ '4 _@![ /P @0#[ (@ ^0"/
M /< EP#U *  \P"J /( MP#O ,D [0#F .P ^P#K /\ ZP#_ -T _P#. /\
MQ@#_ ,( _P#_  0 _P   /\   #_  4 _P - /\ %0#_ "$ _P L /\ . #_
M $, _0!, /D 5 #W %P ] !C /( :0#P &\ [@!U .P >P#J (( Z ") .<
MD0#D )H X@"D .  L #= ,  V@#< -@ ] #5 /\ TP#_ ,L _P#! /\ NP#_
M +< _P#_    _P   /\   #_    _P * /T $0#Y !L ]@ G /0 ,@#P #P
M[ !& .@ 3@#D %8 X0!< -X 8P#< &@ V0!N -4 = #2 'L T "" ,T B@#+
M ), R "= ,8 J #$ +< P0#, ,  ZP"^ /\ O0#_ +T _P"T /\ K@#_ *L
M_P#_    _P   /\   #Z    \@ % .H #@#E !8 X  A -T *P#; #8 TP _
M ,X 2 #* $\ QP!6 ,0 7 #" &$ P !G +X ;0"\ ', N@!Z +@ @@"V (L
MM "6 +( H0"P *\ K@#! *T X "K /< J@#_ *D _P"F /\ H0#_ )\ _P#_
M    _P   /<   #H    W    -  "@#* !$ Q0 ; ,( )0"_ "\ O  X +@
M00"U $@ L@!/ +  50"N %L K !A *H 9@"H &P IP!S *4 >P"C (0 H0".
M )\ F@"= *< FP"X )H T "9 .\ F #_ )< _P"6 /\ E #_ )( _P#_
M]@   .0   #2    Q0   +L !0"U  X L  5 *P 'P"J "D J  R *4 .@"B
M $( H !) )X 3P"< %4 F@!: )@ 8 "6 &8 E0!L ), = "2 'T D "' (X
MDP", *$ BP"P (H Q0"( .8 AP#[ (8 _P"' /\ AP#_ (8 _P#X    Y0
M ,T   "]    LP   *H   "C  H GP 1 )L &0"9 ", EP L )4 - "2 #P
MD !# (X 20", $\ B@!4 (D 6@"' &  A@!F (0 ;@"# '< @0"! '\ C0!^
M )L ? "J 'L O !Z -L > #U '@ _P!X /\ > #_ '@ _P#M    T0(  +L"
M  "L 0  H@   )L   "6  4 D0 - (T % "+ !T B  F (8 +@"$ #8 @@ ]
M (  0P!^ $D ?0!/ 'P 50!Z %L >0!A '< :0!U '$ = !\ '( B !Q )8
M;P"E &X M@!M ,X ; #N &L _P!K /\ :P#_ &L _P#?"P  P@P  *X,  ">
M#   DPL  (P'  "( @  A0 ) ($ $ !_ !< ?  @ 'H * !X #  =@ X '0
M/@!S $0 <0!* '  4 !N %8 ;0!= &P 9 !J &T : !W &< A !E )( 9 "A
M &, L@!A ,D 8 #I &  _ !@ /\ 8 #_ &  _P#0$   MA$  *(2  "3$@
MB!$  ( /  !\#0  >0D! '@#"P!U !$ <P : '  (P!N 2L ; $S &H".0!I
M T  9P-& &8$3 !E!%( 8P59 &(%80!@!6H 7P9T %T&@0!<!X\ 6@>? %D'
ML !7!\8 5@GG %8*^P!5"O\ 50K_ %8*_P#&%0  K1<  )D8  "*&   ?Q<
M '86  !Q$P  ;A   &T-!0!M"0T :@D4 &<*'0!E"B8 8PLN &(,-0!@##P
M7PQ" %X-2 !<#4\ 6PU6 %D-7@!8#F@ 5@YS %4.@ !3#H\ 40Z? % .L0!.
M#L@ 31#J $T0_0!-$/\ 31#_ $T0_P"\&P  I1P  )(=  "#'@  =QT  &\<
M  !I&@  9A<  &04  !D$ @ 8@\0 %\0& !=$"$ 6Q$I %H1,0!8$C@ 5Q(^
M %8210!4$DP 4Q-3 %$36P!0$V4 3A1P $P4?0!+%(P 212< $<5K@!&%<4
M117H $46_@!%%O\ 117_ $45_P"U'P  GB$  (LB  !\(@  <2(  &@A  !B
M'P  7QT  %P:  !;%P( 6A4- %<6% !5%AT 5!<E %(8+0!1&#0 3Q@[ $X9
M0@!-&4@ 2QI0 $H:6 !(&F( 1QIM $4;>@!#&XD 0AN: $ ;K  _&\( /ASE
M #T<_  ^'/\ /AO_ #X;_P"O(P  F"0  (8E  !W)@  ;"8  &,E  !=)
M62(  %8?  !4'0  4QP+ %$<$@!.'1H 31TB $L>*0!*'C$ 21\W $<?/@!&
M($4 12!- $,@50!"(%\ 0"%J #\A=P ](8< .R&8 #DAJ@ X(L  -R+C #<B
M^P W(O\ ."'_ #@A_P"J)@  E"<  ($I  !S*0  9RD  %\I  !8*   5"8
M %$C  !/(@  3"(' $HB$ !((A< 1R,? $4D)@!$)"X 0B0T $$E.P! )4,
M/R5* #TF4P \)EP .B9G #DF=0 W)X0 -2>6 #0GJ  R)[X ,2?A #$G^0 R
M)O\ ,B;_ #,E_P"E*0  CRH  'TL  !O+   9"T  %LL  !5*P  4"H  $PH
M  !*)@  1R<$ $0G#0!"*!0 02@< #\I(P ^*2L /2DR #PJ.0 [*D  .2I(
M #@K4  V*UH -2ME #,K<@ Q*X( ,"R4 "XLIP L++P *RS> "PL^  L*_\
M+2K_ "TJ_P"A+   BRT  'DN  !K+P  8"\  %@O  !1+@  3"X  $@L  !%
M*P  02L  #\L"P ]+!$ .RT9 #HN(0 Y+B@ -RXO #8O-@ U+SX -"]% #,O
M3@ Q,%@ ,#!C "XP<  L,(  *C"2 "DPI0 G,+H )C#< "8P]P G+_\ *"__
M "@N_P"<+@  AS   '8Q  !H,@  73(  %4R  !.,0  2#$  $0P  ! +P
M/#   #HQ"0 W,1  -C(6 #4R'@ S,R4 ,C,L #$S,P P-#L +S1# "TT3  L
M-%8 *C5A "DU;@ G-7X )360 ",UHP B-;D (379 "$T]@ B-/\ (S/_ ",R
M_P"8,0  @S,  '(T  !E-   6C4  %$U  !+-   130  $ T   Z,P  -S0
M #0U!@ R-@X ,#<3 "\W&P N-R( +3@I "LX,0 J.#@ *3E  "@Y20 F.5,
M)3E? ",Y;  A.GP (#J. !XZH@ <.K< &SG5 !PY]0 =./\ '3C_ !XW_P"3
M-   ?S8  &XW  !A-P  5S<  $XW  !(-P  0C<  #PW   U.   ,CD  "\Z
M @ L.PL *CP1 "D\&  H/1\ )CTF "4]+@ D/34 (SX] "(^1@ @/E  'SY<
M !T_:0 ;/WD &C^, !@_H  6/[4 %3[2 !8^\P 7/?\ &#S_ !@\_P".-P
M>C@  &HY  !>.@  4SH  $LZ  !%.@  /SH  #DZ   R/   +CX  "E    F
M00@ )$(. ")"%  A0AL ($,C !]#*@ >0S( '$,Z !M$0P :1$T &$19 !=$
M9P 51'< $T2* !)$G@ 11+, $$30 !!#\@ 10O\ $D+_ !-!_P").P  =CP
M &8]  !:/0  4#T  $@]  !"/0  /#T  #8^   O0   *D(  "5$   A1@,
M'4@, !M)$0 921< &$D> !=))@ 622X %4HV !1*0  32DH $4I6 !!*9  /
M2G0 #DJ'  U*FP ,2K  "DK*  M)[  ,2/\ #4?_  U'_P"#/@  <3\  &)
M  !60   34   $5    _0   .4$  #)"   K10  )D<  "%)   <2P  %DX'
M !-0#@ 24!, $5 9 !!0(0 /4"D #E Q  U0.P -448 "U%1  I17P )46\
M!U"!  50E@ #4*L  E#%  -/Z  #3_L !4[_  9-_P!]0@  :T,  %U$  !2
M1   2D0  $-#   \1   -44  "Y'   G2@  (4P  !Q/   740  $E0#  Y7
M"@ +6!  "E@5  A8'  '6"0 !E@L  58-@ #6$   5A,  !86@  6&D  %A\
M  !8D0  5Z<  %?   !6Y0  5OD  %7_  !5_P!V1P  9D<  %E(  !/1P
M1T<  $!'   X2   ,$H  "E-   B4   '%,  !95   16   #5L"  E>"0 $
M7PX  %\2  !?&   8!\  & G  !@,   8#L  &!'  !@5   8&,  &!V  !@
MBP  7Z(  %^[  !?X@  7OD  %W_  !=_P!O2P  84P  %5,  !,2P  1$L
M #M,   R3@  *U$  "-4   <5P  %EL  !%>   -8   "&,   )F!P  9PP
M &</  !H$P  :1D  &HA  !J*0  :C0  &I   !J30  :ET  &IO  !JA0
M:IT  &FV  !HW0  :/<  &?_  !F_P!I40  7%   %)0  !*3P  /U   #53
M   M5@  )%D  !U=   68   $&0   QG   &:@   &X   !O P  < @  '$-
M  !R$   =!0  '4;  !V(P  =RP  '<X  !V1@  =E8  '9H  !V?@  =I<
M '6Q  !TTP  <_4  '/_  !R_P!C5@  6%4  %!4  !$50  .5@  "];   F
M7P  '6,  !5G   0;   "G    1S    =@   'H   !\    ? ,  'X(  !_
M#   @1   ((4  "$&P  A20  (8O  "&/0  ADT  (5?  "%=0  A8\  (2I
M  "#R0  @O$  ('_  " _P!?6P  5EH  $E;   ]7@  ,F$  "=F   >:P
M%7    YU   )>0   7X   "!    A0   (@   "*    BP   (T!  ".!@
MD L  )$/  "3%   E1L  )<F  "7-   ET0  )=6  "6;   E88  )6B  "4
MP0  D^H  )+_  "2_P!=80  3V$  $)D   V:0  *FX  !]T   5>0  #G\
M  >$    B0   (X   "2    E@   )@   ":    FP   )T   "?    H0,
M *,(  "E#0  IQ,  *D<  "J*   JCD  *I+  "J80  J7H  *B9  "HM0
MI]T  *?X  "F_P!6:   2&P  #IP   N=@  (GT  !>$   .B@  !Y    "6
M    F@   )\   "C    IP   *H   "K    K0   *\   "Q    LP   +4
M  "X!0  N@P  +T2  # '   P"T  ,!   "_50  OVX  +Z+  "^J   OLD
M +WO  "\_@!.=   0'D  #)_   EAP  &8X  !"5   'G    *(   "G
MK    +    "U    N0   +P   "]    OP   ,$   ##    Q@   ,@   #*
M    S0(  - +  #5$@  UB$  -<T  #820  V6   -I\  #:F@  V[4  -O9
M  #;\@!&@@  .(D  "N0   =F   $J    JG    K@   +0   "Y    O@
M ,(   #(    RP   ,X   #/    T@   -0   #6    V@   -T   #?
MX@   .8   #J"@  [Q,  / E  #R.@  \U$  /1K  #TB0  ]:4  /6_  #U
MW0#_  8 _P # /\ !0#_  L _P 0 /\ %P#_ "( _P M /\ .0#_ $0 _P!-
M /\ 50#_ %T _P!D /\ :@#_ '  _0!V /L ? #Y (, ]P"* /4 D@#S )L
M\ "F .X LP#K ,0 Z0#D .< ^0#F /\ Y0#_ -, _P#' /\ OP#_ +L _P#_
M    _P   /\   #_  ( _P + /\ $@#_ !T _P H /\ ,P#_ #X _ !' /@
M3P#T %< \0!= .X 8P#L &D Z@!O .@ =0#F 'P Y "# .( BP#? )4 W "?
M -D JP#5 +L T@#4 ,\ \@#- /\ S #_ ,4 _P"Z /\ M #_ +  _P#_
M_P   /\   #_    _P & /D #P#U !< \P B /$ +0#M #< YP!  .( 20#?
M %  VP!7 -< 70#4 &, T0!H ,\ ;@#, '4 R@!\ ,@ A #% (T P@"8 ,
MI "] +( NP#& +D Z "X /T MP#_ +8 _P"M /\ IP#_ *, _P#_    _P
M /\   #U    ZP ! .0 # #> !, V0 < -, )@#1 #  S  Z ,@ 0@#$ $H
MP !0 +T 5@"[ %P N0!A +< 9P"U &T LP!T +$ ? "O (4 K0"0 *H G "H
M *H I@"[ *4 V@"C /4 HP#_ *( _P"> /\ F@#_ )< _P#_    _@   .\
M  #?    T    ,< !P#!  \ O  7 +D ( "W "H M0 S +  .P"M $, JP!)
M *@ 3P"F %4 I !: *, 8 "A &8 GP!M )T = "< 'T F@"( )@ E "6 *(
ME "R )( R0"1 .L D0#_ )  _P"0 /\ C #_ (H _P#\    [    -D   #'
M    N@   +$  @"K  P IP 2 *0 &P"A "0 H  L )X -0"; #P F !# )8
M20"4 $\ D@!4 )  6@"/ %\ C0!F (L ;0") '8 B "  (8 C "$ )H @@"J
M ($ O@"  .  @ #Y '\ _P!_ /\ ?P#_ 'X _P#Q    V    ,(   "S
MJ    *    "9  < E0 . )( %0"0 !X C@ F (T +@"* #8 AP ] (4 0P"$
M $D @@!. ($ 5 !_ %D ?@!@ 'P 9P!Z &\ >0!Z '< A@!U )0 = "C '(
MM0!R ,\ <0#Q '  _P!P /\ < #_ '$ _P#A    Q    +    "B    EP
M )$   "+  ( A@ + (, $0"! !@ ?P A 'T *0!\ #  >0 W '@ /0!V $,
M= !) ', 3@!R %0 < !: &\ 8@!M &H :P!T &H @ !H (X 9P"= &4 KP!E
M ,8 9 #H &0 _0!C /\ 8P#_ &0 _P#/!0  M@<  *,(  "4"   B0<  ((#
M  !^    >P & '< #@!U !, <@ ; '$ (P!O "L ;0 R &P . !J #X :0!$
M &< 20!F $\ 90!6 &, 70!B &4 8 !O %\ >P!= (D 7 "9 %L J@!9 +\
M60#A %@ ^ !8 /\ 6 #_ %D _P#"#   J@T  )<.  ")#@  ?0X  '8-  !Q
M"@  ;P8  &T "@!K !  :0 6 &< '@!E "8 8P M &$ ,P!@ #D 7P _ %T
M10!< $L 6P!2 %H 60!8 &( 5P!L %4 > !3 (8 4@"6 %$ IP!0 +L 3P';
M $X"] !. _\ 3@3_ $X#_P"X$   H1(  (X3  !_$P  =!,  &P2  !G$
M90X  &,+ P!C!@P 8001 %X#&0!<!"$ 6P4H %D&+P!8!C4 5@<[ %4'0@!4
M!T@ 4PA/ %$(5@!0"5\ 3@EI $T)=@!+"H0 20J4 $@*I@!'"KH 1@K8 $4+
M\P!%#/\ 10S_ $4,_P"P%   F18  (<8  !X&0  ;1@  &47  !?%@  7!,
M %H1  !:#@8 6@P- %<,% !5#!P 4PTD %(-*P!0#3$ 3PXX $X./@!-#D4
M2PY- $H.50!(#UX 1P]H $4/=0!#$(0 01"5 $ 0I@ ^$+L /1#< #T1]@ ]
M$?\ /1#_ #X0_P"I&0  DAL  ($<  !R'0  9QT  %\<  !9&P  51D  %,6
M  !2$P  4A$* % 0$ !.$1@ 3!$@ $H2)P!)$BX 2!,T $<3.P!%$T( 1!-)
M $,44@!!%%L /Q1E #X5<@ \%8$ .A62 #@5I  W%;D -178 #46]0 V%O\
M-A;_ #<5_P"C'   C1X  'L@  !M(0  8B$  %HA  !4'P  4!X  $T;  !,
M&0  2Q8& $D6#@!'%Q4 11<< $08) !"&"H 01@Q $ 9.  _&3\ /1E& #P:
M3P Z&E@ .1IC #<;;P U&WX ,QN0 #(;H@ P&[< +QO3 "\<\P O&_\ ,!O_
M # ;_P"='P  B"(  '<C  !I)   7B0  %8D  !0(P  2R(  $@@  !&'0
M11P" $,<# !!'!( /QT9 #X=(0 \'B< .QXN #H?-0 Y'SP -Q]$ #8?3  T
M(%8 ,R!@ #$@;0 O('P +2&. "PAH  J(;4 *2'0 "DA\@ I(?\ *B#_ "L@
M_P"9(@  A"4  ',F  !E)P  6R<  %,G  !,)@  1R4  $0D  !"(0  /R$
M #TA"0 [(1  .2(6 #@B'@ V(R4 -2,K #0D,@ S)#D ,B1! # D2@ O)5,
M+25> "LE:P J)7H *"6, "8EGP D);, (R7. ",E\  D)?\ )23_ "4D_P"4
M)0  @"<  &\I  !B*@  5RH  $\J  !)*0  1"@  $ G   ])@  .B4  #<F
M!@ U)@X -"<4 #(G&P Q*"( ,"@I "\H,  M*3< +"D_ "LI1P I*5$ *"I<
M "8J:0 D*G@ (RJ* "$JG0 ?*K( 'BK, !XJ[P ?*?\ ("G_ "$H_P"0*
M?"H  &PK  !?+   5"P  $PL  !&+   02L  #PK   X*@  -2H  #(K P P
M*PP +BP1 "TL&  L+!\ *BTF "DM+0 H+30 )RX\ "8N10 D+D\ (RY: "$O
M9P ?+W8 '2^( !POFP :+[  &"_* !@N[0 9+O\ &RW_ !LM_P",*P  >"T
M &@N  !;+P  42\  $DO  !#+P  /BX  #DN   T+@  ,"X  "TO   K, H
M*3$0 "<Q%0 F,1P )3(C "0R*@ C,C$ (3,Y " S0@ ?,TP '3-7 !LS9  :
M-'0 &#2& !8TF@ 4,ZX $S/( !,S[  4,_\ %3+_ !8Q_P"'+@  ="\  &4Q
M  !8,0  3C(  $8R  ! ,0  .S$  #8Q   Q,0  *S,  "@T   E-08 (S8-
M "$V$@ @-QD 'S<@ !XW)P =."X &S@V !HX/P 9.$D %SE5 !4Y8@ 4.7$
M$CF$ !$YF  0.:T #CC'  XXZP 0./\ $#?_ !$V_P"#,0  <#(  &$T  !5
M-   2S0  $0T   ]-   .#0  #,T   M-0  *#<  "0Y   @.@( '3L+ !L\
M$  9/14 &#T< !<](P 6/2L %3XS !0^/  2/D8 $3Y2 ! ^7P //F\ #CZ!
M  P^E0 +/JD "C[!  H]Y  +/?L ##S_  T[_P!]-   :S8  %TW  !1-P
M2#<  $$W   [-P  -3<  # W   J.0  )3L  " ]   </P  %T$& !1##0 2
M0Q( $4,8 !%#'P 01"< #T0O  Y$.0 -1$, #$1.  M$6P )1&H !T1\  9$
MD  $0Z4  D.]  -#X  #0_8 !$+_  9!_P!X.   9SD  %DZ  !..@  13H
M #XZ   X.@  ,SH  "T[   G/0  (4   !Q"   71   $T8#  ])"@ -2@\
M#$H4  M*&P )2B, "$HK  =*-  %2CX !$I)  )*5@  2F4  $IW  !*BP
M2J$  $FY  !)W0  2?4  $C_  !(_P!R/   8CT  %4^  !*/@  0CT  #P]
M   V/0  +SX  "E    C0@  '44  !='   32@  #TP"  M/"0 '4 T  U$1
M  !1%P  41X  %$F  !1+P  43D  %%$  !240  4F   %%R  !1AP  49T
M %&U  !0V   4/4  $__  !/_P!L0   74$  %%!  !'00  0$   #E    R
M00  *D,  "1&   >2   %TL  !).   .40  "U,!  96!P  5PP  %@0  !8
M$P  61D  %HA  !:*0  6C,  %H_  !:3   6EH  %IL  !:@0  69D  %FQ
M  !8T0  6/0  %?_  !7_P!E10  6$4  $U%  !%1   /D0  #5%   M1P
M)4H  !Y-   84   $E,   Y6   *60  !%P   !>!   7PD  & -  !A$
M8A4  &,;  !D(P  9"T  &0X  !D10  9%0  &1F  !D>P  8Y,  &.M  !B
MS   8?(  &'_  !@_P!?2@  4TH  $I)  !#2   .4D  "],   G3P  'U(
M !A5   260  #5T   A@   "8P   &8   !H 0  :04  &H*  !K#0  ;1$
M &X6  !P'0  <28  '$Q  !P/@  <$X  '!?  !P<P  ;XT  &^G  !NQ@
M;>\  &S_  !L_P!:3P  4$X  $A-   ]3@  ,U$  "E4   @6   &%P  !%@
M   ,9   !F@   !K    ;P   '(   !T    =0   '<$  !X"0  >@T  'P0
M  !]%@  ?QX  ( H  " -0  @$4  ']6  !_:P  ?X0  'Z@  !]O@  ?.D
M 'O_  !Z_P!65   3E,  $)4   W5@  +%H  ")?   88P  $6@   MM   #
M<@   '8   !Z    ?0   (    "#    A    (8   "' @  B0<  (L,  "-
M$   D!8  )(?  "2+   DCL  ))-  "18@  D7H  (^7  "/M   CN$  (S[
M  ",_P!560  2%H  #M=   O80  )&8  !EL   1<@  "G<   )]    @@
M (8   "+    C@   )$   "3    E0   )<   "9    FP   )T$  "?"@
MH@\  *06  "F(0  IC$  *9#  "E5P  I'   *..  "CJP  H=   *#U  "?
M_P!.80  0&0  #-I   G;@  &W4  !%\   +@P   (D   ".    DP   )@
M  "=    H0   *0   "E    IP   *D   "K    K0   +    "R    M0@
M +@.  "\%@  O"4  +PW  "[3   NF0  +F!  "WH@  M\   +?J  "W_ !&
M:P  .7   "MW   ??P  $X8   N.   !E0   )L   "A    I@   *L   "P
M    LP   +<   "W    N@   +P   "_    P0   ,0   #'    R@   ,T%
M  #1#@  U!D  -0K  #40   TU@  --T  #3D@  TK   -+3  #2\@ ^>0
M,8   ".(   7D0  #9D   .@    IP   *X   "S    N    +T   #"
MQ@   ,H   #*    S0   ,\   #2    U0   -D   #=    WP   .,   #G
M!0  ZP\  .P?  #M,P  [DL  .]D  #O@@  \)\  /&Y  #QV #_    _P
M /\ ! #_  D _P . /\ %0#_ !X _P I /\ - #_ #\ _P!( /\ 4 #_ %@
M_P!> /\ 90#] &L ^P!Q /D =P#X 'X ]@"% /, C0#Q )< [@"B .L KP#H
M ,  Y@#@ ., ^ #B /\ VP#_ ,L _P#! /\ N0#_ +0 _P#_    _P   /\
M  #_    _P ) /\ $ #_ !D _P C /\ +@#] #D ^0!" /4 2@#R %( [@!8
M .L 7@#I &0 Y@!J .0 < #B '8 WP!] -T A@#9 (\ U0": -$ IP#. +8
MRP#. ,D \ #' /\ Q0#_ +L _P"T /\ K0#_ *D _P#_    _P   /\   #_
M    ^P " /8 #0#Q !, [0 > .P * #I #( XP [ -T 1 #8 $L TP!1 -
M6 #- %T RP!C ,D : #& &\ Q !V ,( ?@"_ (< O "2 +H GP"W *T M0#!
M +( Y "Q /T KP#_ *P _P"E /\ H #_ )P _P#_    _P   /L   #N
MY    -P " #3 !  SP 8 ,L (@#) "L Q@ T ,$ /0"] $0 N@!+ +< 40"U
M %8 L@!< +  80"N &< K !N *H =@"H '\ I@"* *, E@"A *4 GP"V )T
MT0"< /, FP#_ )P _P"6 /\ DP#_ )  _P#_    ]@   .<   #3    Q@
M +T  P"X  T LP 3 +$ ' "O "4 K@ N *D -@"F #T HP!$ *$ 2@"? $\
MG0!5 )L 6@": &  F !F )8 ;@"4 '< D@"! )  C@". )P C "M (H PP")
M .@ B #_ (D _P"' /\ A0#_ (( _P#S    XP   ,P   "\    L    *<
M  "A  @ G@ / )L %@"9 !\ F  G )8 +P"3 #< D0 ] (X 0P", $D BP!.
M (D 5 "' %D A0!@ (0 9P"" &\ @ !Z 'X A@!\ )0 >@"D 'D N !X -@
M=P#W '@ _P!X /\ =P#_ '4 _P#F    RP   +<   "H    G@   )8   "/
M  0 BP , (@ $@"' !D A0 A (0 *0"" #  ?P W 'T /0!\ $, >@!( 'D
M30!W %, =@!9 '0 80!R &D <0!S &\ ?P!M (T ; "= &H KP!I ,@ : #M
M &D _P!I /\ :0#_ &D _P#2    N    *4   "7    C0   (8   "!
M?  ( 'D #@!W !0 =@ < '0 (P!S "L <0 Q &\ -P!N #T ; !# &L 2 !J
M $X : !4 &< 6P!E &, 8P!M &( > !@ (< 7P"6 %T J != +X 7 #D %P
M^P!< /\ 7 #_ %P _P#"    J@$  )@#  ")!   ?P(  '@   !T    <  $
M &T # !K !$ :0 7 &@ '@!F "4 90 L &, ,@!B #@ 8  ] %\ 0P!> $D
M7 !/ %L 5@!: %X 6 !H %< <P!5 ($ 5 "1 %( HP!1 +< 40#6 %$ ]0!1
M /\ 40#_ %( _P"V!P  GPD  (T+  !^#   <PL  &P*  !H!P  90,  &,
M!P!A  T 7P 3 %T &@!< "$ 6P G %D +0!8 #, 5@ Y %4 /P!4 $4 4P!+
M %$ 4@!0 %H 3P!D $T ;P!, 'T 2@"- $D GP!( +( 1P#, $< [P!& /\
M1P#_ $< _P"L#   E0X  (,0  !U$   :Q   &,/  !>#@  6PP  %H) @!9
M! H 5P / %4 %0!3 !P 4@ C %$ *0!/ "\ 3@ U $T!.P!, 4$ 2@)( $D"
M3P!( E< 1@-A $4#;0!# WH 0@.+ $ #G  _ Z\ /@/( #T$Z@ ]!?P /0;_
M #X&_P"D$   CA(  'P3  !N%   9!0  %P3  !6$@  4Q$  %$.  !0# 4
M4 D, $\'$0!-!Q< 2P@? $D()0!("2L 1PDQ $8). !$"CX 0PI% $(*30!
M"U4 /PM? #T+:P \"WD .@R* #@,G  W#*\ -0S' #4,Z0 U#?T -0W_ #8,
M_P"=$P  AQ4  '87  !I&   7A@  %88  !0%P  314  $H3  !)$0  20X'
M $@-#@!&#1, 1 T: $,.(0!"#B@ 0 XN #\.-0 ^#SP /0]# #L02P Z$%0
M.!!> #80:P T$'D ,A"* #$0G  O$+  +1#) "T1[  M$?\ +A'_ "\0_P"7
M%@  @AD  '$;  !D'   61P  %$<  !,&P  1QH  $08  !#%0  0A," $$2
M"P! $1  /A(7 #P2'@ [$R4 .A,K #@3,@ W$SD -A1  #042  S%%$ ,11<
M # 5:  N%7< +!6( "H5F@ H%:X )Q7' "85Z@ G%?\ *!7_ "D5_P"1&@
M?1P  &T>  !@'P  5A\  $X?  !('@  0QT  $ <   ^&@  /1@  #L7!P Y
M%@X .!<4 #87&P U&"( ,Q@H #(8+P Q&38 ,!D] "X91@ M&D\ *QI9 "H:
M9@ H&G0 )AJ& "0:F0 B&JT (1K% " :Z  A&OX (AK_ ",:_P"-'0  >1\
M &DA  !<(@  4B(  $HB  !$(0  /R$  #P@   Y'@  .!L  #4<!  T' T
M,AP2 # =&  O'1\ +ATE "T>+  K'C, *AX[ "D?0P G'TT )A]7 "0?9  B
M'W( (!^$ !\?EP ='ZL &Q_# !L?YP ;'_T '1__ !X>_P")(   =2(  &4C
M  !9)   3R4  $<E  !!)   /",  #@C   U(@  ,R   # @ 0 N(0H +"$0
M "LA%0 J(AP *"(C "<B*0 F(S  )2,X ",C00 B)$H (215 !\D80 =)'
M&R2" !DDE0 7)*H %B3! !4DY0 6)/P %R/_ !DC_P"%(@  <20  &(F  !6
M)P  3"<  $0G   ^)P  .28  #4F   Q)0  +B0  "LE   I)0< )R8. "4F
M$P D)QD (R<@ "(G)P A*"X ("@V !XH/@ =*$@ &RE3 !DI7P 8*6X %BF
M !0IE  2*:@ $2G  !$HY  1*/L $RC_ !0G_P" )0  ;B<  %\H  !3*0
M22H  $(I   [*0  -BD  #(H   N*   *B@  "8I   D*@0 (BL, " K$0 ?
M+!8 '2P= !PL)  ;+2L &BTS !@M/  7+44 %BY0 !0N70 2+FP $2Y^ ! N
MD@ .+J< #2V]  TMWP -+?D #BS_ ! L_P!\*   :BH  %LK  !0+   1BP
M #\L   Y+   -"L  "\K   K*P  )BP  "(N   ?+P  '# ) !HQ#@ 9,1,
M%S$: !8R(0 5,B@ %#(P !,R.0 2,T, $3-. ! S6P .,VD #3-Z  PSC@ *
M,Z( "#*Y  @RV0 (,O0 "C'_  LQ_P!W*P  9BT  %@N  !-+P  0R\  #PN
M   V+@  ,2X  "TN   I+@  (S   !\R   ;,P  %S4% !0V#  2-Q$ $3<6
M !$W'0 0."0 #S@L  XX-0 -.#\ ##A*  LX5P ).&4 !SAV  4XB@ #.)\
M 3>U  $WTP "-_$  S;_  4V_P!S+@  8C   %0Q  !),0  03$  #DQ   T
M,0  +S   "LP   E,@  (#,  !LV   7.   $SH" ! \"0 -/0X ##T3  L]
M&0 */2$ "3TI  @],0 &/CL !3Y&  ,^4@ !/F$  #YR   ^A@  /9P  #VR
M   ]T   //   #S_   \_P!M,@  73,  % T  !&-   /C0  #<T   R,P
M+3,  "<T   B-@  '3@  !@Z   4/0  $#\"  U!"  )0PT !D01  -$%@ "
M1!T  $0D  !$+0  1#8  $1!  !$3@  1%P  $1M  !$@0  1)@  $.O  !#
MS0  0O   $+_  !"_P!H-@  6#<  $PX  !#.   .S<  #4V   P-@  *3<
M ",Y   >.P  &#T  !-    00@  #44!  A'!P #20P  $D/  !*$P  2QD
M $L@  !+*   2S(  $L]  !,20  3%<  $MH  !+?0  2Y0  $JL  !*R@
M2>\  $G_  !)_P!B.@  5#L  $D[  ! .P  .3H  #,Y   L.@  )3P  !\_
M   900  $T0  !!'   ,20  "$P   )/!0  4 H  % -  !1$   4A4  %0;
M  !4(P  5"P  %0W  !41   5%(  %1C  !4=P  5(\  %.H  !2Q@  4NT
M %'_  !1_P!</P  3S\  $4_   ^/@  -ST  "\^   G0   ($,  !E&   3
M20  #TP   M/   &4@   %0   !7 @  6 <  %D+  !:#@  6Q$  %T6  !>
M'0  7R8  %\Q  !>/0  7DP  %Y=  !><0  78D  %VC  !<P0  6^L  %K_
M  !:_P!61   2T,  $-"   \00  ,D(  "E%   A2   &DL  !-.   .4@
M"E4   -9    6P   %X   !@    8@(  &,&  !E"@  9@X  &@1  !J%P
M:Q\  &LI  !K-@  :T4  &M6  !J:@  :H(  &F=  !HNP  9^<  &;_  !E
M_P!12   2$@  $%&   W1P  +$H  "--   ;40  $U4   Y9   (70   6$
M  !D    9P   &H   !L    ;@   '    !R!0  <PD  '4-  !W$0  >A@
M 'LA  ![+@  >CT  'I.  !Y8@  >7D  'B6  !WLP  =>   '3\  !S_P!.
M30  1TP  #M-   P3P  )E,  !Q8   37   #6$   9F    :@   &\   !R
M    =@   'D   !\    ?0   '\   "!    @P(  (8'  "(#   BQ$  (X8
M  ".)   CC,  (U$  ",6   BV\  (J,  ")J@  B,\  (;W  "%_P!-40
M05,  #15   I6@  'E\  !1E   -:@  !7    !V    >P   '\   "#
MAP   (H   "-    C@   )$   "3    E0   )@   ":!0  G0P  * 1  "C
M&@  HR@  *(Z  "A3@  H&4  *"!  ">H   G<$  )ON  ":_P!&60  .5P
M "UA   A9P  %FX   YU   %>P   ($   "'    C0   )(   "6    F@
M )T   "?    H0   *0   "F    J    *L   "N    L0,  +0+  "X$0
MN1X  +DO  "X0P  MUH  +5V  "TEP  M+4  +'B  "P_  _9   ,6D  "5O
M   8=P  #W\   :'    C@   )0   ":    H    *4   "J    K@   +$
M  "R    M0   +<   "Z    O    +\   ##    Q@   ,D   #."@  TA,
M -(C  #1-P  T$\  ,YJ  #-B@  RJL  ,O+  #+[P W<0  *7@  !V    1
MB0  ")$   ":    H0   *<   "M    LP   +D   "^    P@   ,4   #&
M    R0   ,P   #.    T@   -4   #:    W@   .$   #E    Z@L  .L7
M  #J*P  ZD,  .I>  #J>@  ZYD  .NU  #KU0#_    _P   /\  0#_  <
M_P - /\ $@#_ !L _P E /\ +P#_ #H _P!# /\ 2P#_ %, _P!: /T 8 #[
M &8 ^@!K /@ <@#V '@ ] "  /$ B0#O )( [ "= .D J@#F +P XP#< -\
M]P#= /\ S #_ +X _P"U /\ L #_ *T _P#_    _P   /\   #_    _P &
M /\ #0#_ !0 _P ? /\ *0#[ #, ]P ] /, 10#O $T [ !3 .@ 60#E %\
MXP!E .  :@#= '$ V@!X -8 @ #2 (H SP"5 ,P H@#( +( Q0#) ,( [0#
M /\ NP#_ +  _P"H /\ I #_ *$ _P#_    _P   /T   #Z    ^    /
M"0#L !$ Z  9 .< (P#E "T W@ V -8 /@#1 $8 S0!, ,H 4@#( %@ Q0!=
M ,, 8P#  &D O@!P +P > "Y ($ MP"- +0 F@"Q *D K@"\ *P X0"J /P
MJ #_ *  _P"9 /\ E@#_ )0 _P#_    ^0   /(   #G    VP   -$ ! #*
M  T QP 4 ,0 '0#" "8 OP O +L -P"W #\ M !% +$ 2P"N %$ K !6 *H
M7 "H &$ I@!H *, < "A 'D GP"$ )T D0": *  F "Q )8 S "5 /$ E #_
M )$ _P"+ /\ B #_ (8 _P#W    [    -X   #)    O    +0   "O  H
MJP 0 *D %P"H "  IP H *( , "? #@ G  ^ )H 1 "8 $H E@!/ )0 50"3
M %H D0!A (\ : "- '$ BP![ (D B "' )< A0"H (, O@"! .0 @ #_ (
M_P!\ /\ >P#_ 'D _P#I    UP   ,$   "Q    I@   )T   "7  4 E  -
M )( $@"0 !H CP B (X *@"+ #$ B0 X (< /@"% $, @P!( ($ 3@!_ %0
M?@!: 'P 80!Z &D > !S '8 ?P!U (X <P"? '$ LP!P -  ;P#V &\ _P!O
M /\ ;0#_ &P _P#:    OP   *P   ">    DP   (P   "%    @@ ) '\
M#P!^ !4 ?0 < 'P ) !Z "L =P Q '4 -P!T #T <@!" '$ 2 !O $T ;@!3
M &P 6@!K &( :0!L &< > !F (8 9 "7 &( J@!A ,( 8 #K &$ _P!A /\
M80#_ &  _P#%    K0   )L   "-    @P   'P   !W    <@ % '  # !N
M !$ ;  7 &P '@!K "4 :0 L &< ,0!F #< 9  ] &, 0@!B $@ 8 !. %\
M50!= %T 7 !F %H <@!9 (  5P"0 %8 HP!5 +D 5 #> %0 ^P!4 /\ 50#_
M %4 _P"V    GP   (T   !_    =0   &X   !I    9@ ! &, "0!A  X
M8  3 %\ &0!> "  70 F %L + !: #( 6  W %< /0!6 $, 50!) %, 4 !2
M %@ 40!A $\ ; !. 'H 3 "* $L G !* +$ 20#. $D \P!) /\ 20#_ $H
M_P"J 0  E 4  (('  !T"   :@@  &,&  !>!   6P   %D !0!7  P 5@ 0
M %0 %0!3 !L 4@ B %$ * !0 "T 3@ S $T . !, #X 2P!% $H 3 !( %0
M1P!= $8 : !$ '4 0P"% $$ F !  *L 0 #% #\ Z@ _ /\ 0 #_ $  _P"@
M"   B@L  'D-  !L#0  80T  %H-  !5"P  4@D  % &  !/ @@ 3@ - $P
M$@!+ !< 2@ > $D (P!' "D 1@ O $4 - !$ #H 0@!! $$ 2 !  %  /@!:
M #T 9  \ '( .@"" #D E  X *< -P"^ #8 XP V /D -@#_ #< _P"8#0
M@PX  '(0  !E$0  6Q$  %,0  !.$   2@X  $@-  !'"@, 1P<* $4$#@!$
M A, 0@(: $$"( !  R4 /@,K #T$,0 \!#< .P0^ #H%10 Y!4X -P57 #8%
M8@ T!G  ,@:  #$&D@ P!J4 +P6[ "X%W0 N!O4 +0?_ "X'_P"1$   ?1$
M &P3  !?%   510  $X4  !($P  1!(  $$0  ! #@  0 T& $ *#  ^"1
M/ D6 #L*'  Y"B( . HH #<++@ V"S4 -0L[ #,+0P R#$P , Q6 "\,80 M
M#&\ *PQ_ "H,D@ H#*4 )PR[ "4,W0 E#?4 )@W_ "<-_P"+$@  =Q0  &<6
M  !;%P  41@  $D7  !#%P  /Q4  #P4   Z$@  .1$! #D/"  X#@T -PX2
M #4.&  T#A\ ,@XE #$/+  P#S( +Q Z "T00@ L$$L *A!5 "@080 F$&\
M)!"  ",0DP A$*< 'Q"] !X0X  >$?< 'Q#_ " 0_P"&%   <Q<  &,9  !7
M&@  31L  $4:  ! &@  .QD  #@8   U%@  -!0  #,2!  R$@L ,1(0 "\2
M%0 M$AP +!,B "L3*0 J$S  *!,W "<4/P F%$@ )!13 "(47P @%6T 'Q5^
M !T5D0 ;%:4 &16[ !@5W@ 8%?@ &13_ !H4_P""%P  ;QH  %\<  !3'0
M2AT  $(=   \'0  -QP  #0;   Q&@  +QD  "X6   L%P@ *Q8. "D7$P H
M%QD )Q@@ "48)@ D&"T (Q@T "(9/0 @&48 'AE1 !T970 ;&FL &1I\ !<:
MCP 5&J, %!FZ !(9VP 3&?8 %!G_ !48_P!]&@  :QT  %P?  !0(   1R
M #\@   Y'P  -!\  #$>   M'0  *QP  "D;   G&P4 )1L, "0<$0 B'!8
M(1P= " =(P ?'2H 'ATR !P>.@ ;'D0 &1Y. !<>6P 6'FD %!]Z !(>C0 1
M'J( $!ZX  X>V  /'O4 $!W_ !$=_P!Z'0  9Q\  %DA  !-(@  1"(  #PB
M   V(@  ,B$  "XA   J(   )R   "0?   B( ( (" * !XA#P =(10 '"$:
M !LB(0 9(B< &"(O !<B.  5(T$ %"-, !(C6  1(V< $"-X  XCBP -(Y\
M#".T  LCT  +(O  #"+_  TA_P!V'P  9"(  %8C  !+)   020  #HD   T
M)   +R,  "LC   H(P  )",  " C   =)   &R4' !DF#0 7)A$ %B87 !4G
M'@ 4)R4 $R<L !(G-0 1*#\ $"A*  XH5@ -*&0 #"AT  HHAP )*)L !R>Q
M  4GS  &)^P !R;^  @F_P!Q(@  8"0  %,F  !()P  /R<  #<F   Q)@
M+28  "DE   E)0  (B4  !TG   9*   %BH$ !0K"P 2+!  $2P4 ! L&P 0
M+"( #BPI  XM,@ -+3L "RU&  HM4@ (+6  !BUP  0M@P "+9@  "RN   L
MR0  +.L  2O\  (K_P!M)0  72<  $\H  !%*0  /"D  #4I   O*   *R@
M "<G   C)P  'R@  !LJ   7+   $RX" ! P"  .,0T #3$2  PQ%P +,1X
M"C$F  @R+@ ',C< !3)"  ,R3@ !,EP  #)L   R?P  ,I4  #&L   QQP
M,.H  ##\   P_P!H*0  6"H  $PK  !!+   .2P  #(K   M*P  *2H  "4J
M   @*P  '"P  !<N   3,   $#("  XT!P *-PP !S<0  4W%  #-QL  C<B
M   W*@  .#,  #@^   X2@  .%@  #AH   X?   -Y(  #>I   VQ0  -NH
M #;]   U_P!C+   5"X  $@O   ^+P  -BX  # N   K+0  )RT  "(M   =
M+P  &#$  !0S   0-0  #C<!  HZ!P &.PL  CP.   ]$@  /A<  #X>   ^
M)@  /B\  #XZ   ^1@  /E0  #YD   ^=P  /H\  #VG   ]PP  /.D  #S]
M   [_P!>,   4#$  $0R   [,@  -#$  "XP   I+P  )#   !XR   9-
M%#8  ! Y   -.P  "CT   5 !0  00H  $(-  !#$   1!0  $4:  !&(@
M1BL  $8U  !&00  1D\  $9?  !&<P  18H  $6D  !$P   0^@  $/^  !"
M_P!8-   2S4  $$U   Y-0  ,C0  "TS   F-   (#4  !HX   4.@  $#T
M  U    )0@  !$4   !' P  2 <  $H+  !+#@  3!$  $X5  !/'   3R4
M $\O  !//   3TH  $]:  !.;0  3H4  $V@  !,O   2^<  $O^  !*_P!3
M.0  1SD  #XY   W.   ,3<  "DW   A.0  &SP  !4_   00@  #$4   =(
M   "2@   $T   !/    400  %('  !4"P  50X  %<1  !9%P  6A\  %DI
M  !9-@  640  %E4  !89P  6'\  %>:  !6MP  5>,  %3]  !4_P!./0
M0ST  #P\   U.P  +#P  "0^   <00  %40  !!(   +2P  !4X   !1
M5    %<   !9    6P   %T"  !>!@  8 L  &(.  !D$@  9Q@  &<B  !F
M+@  9CP  &9-  !E8   97<  &23  !CL0  8=T  &#\  !?_P!)0@  04$
M #H_   P0   )D,  !Y&   52@  $$X   I2   #5@   %H   !=    8
M &,   !E    9P   &D   !K 0  ;04  &\*  !R#@  =1(  '<;  !V)@
M=C4  '5&  !T60  =&\  '.+  !RJ0  <,T  &_W  !N_P!&1@  0$4  #5&
M   J2   ($P  !=1   05@  "5H   %?    8P   &@   !K    ;P   '(
M  !U    =P   'D   ![    ?0   ( #  "#"   A@T  (D3  "*'0  BBL
M (D\  "(3P  AF8  (6!  "$H   @L(  ('P  !__P!&2P  .DP  "Y/   C
M4P  &%@  !!>   )9    &D   !O    =    '@   !\    @0   (0   "'
M    B    (L   ".    D    ),   "6    F0<  )T-  "A%   H"$  * Q
M  ">1   G5L  )QV  "9E@  F;4  );E  "5_@ _4@  ,E4  "9:   ;8
M$6<   EM    =    'L   "!    A@   (L   "0    E    )<   "9
MG    )\   "A    I    *<   "J    K0   +$&  "U#0  N!8  +<F  "V
M.0  M5   +1J  "RB0  L*H  *[/  "M]0 W7   *V$  !YH   3<   "W@
M  "     AP   (X   "5    F@   )\   "D    J    *P   "M    L
M +,   "U    N    +L   "_    PP   ,<   #+!0  T0X  -$;  #0+@
MST4  ,U?  #+?@  R9X  ,B^  #%Z0 O:0  (W   !9Y   -@0   8L   "3
M    FP   *(   "H    K@   +0   "X    O0   ,    #"    Q0   ,@
M  #+    S@   -$   #6    VP   -\   #D    Z 8  .L1  #J(P  ZCH
M .E4  #G<@  Y9,  ..S  #CU #_    _P   /\   #_  0 _P + /\ $ #_
M !< _P A /\ *P#_ #4 _P ^ /\ 1P#_ $X _P!5 /P 6P#Z &$ ^ !F /8
M;0#T ', \@![ .\ A #M (X Z@"9 .8 IP#C +D WP#5 -L ]P#6 /\ P #_
M +( _P"J /\ I0#_ *( _P#_    _P   /X   #\    _  # /X "P#_ !$
M_P : /T ) #Y "X ]  X /  0 #L $@ Z0!. .8 5 #B %H WP!? -P 90#8
M &L U !R -  >P#- (4 R@"1 ,< G@## *X P #% +T ZP"[ /\ L #_ *0
M_P"< /\ F #_ )4 _P#_    ^@   /0   #Q    \@   .H !0#G  X X@ 5
M .$ '@#A "@ V  Q -  .0#+ $  R !' ,4 30#" %, OP!8 +T 7@"[ &0
MN0!K +8 <P"T 'P L0"( *X E0"K *0 J "X *8 W "C /L GP#_ )4 _P"/
M /\ BP#_ (D _P#Y    [P   .<   #?    SP   ,@   #!  H OP 1 +P
M& "[ "$ N0 J +0 ,@"Q #H K@!  *L 1@"H $P I@!1 *, 5@"A %P GP!C
M )T :@"; ', F0!^ )8 C "4 )L D@"M )  QP". /  C0#_ (8 _P"  /\
M?0#_ 'P _P#M    X    -$   "_    LP   *H   "F  4 H@ - *$ $P"@
M !L GP C )L *P"8 #( E0 Y ), /P"1 $0 CP!* (X 3P", %4 B@!; (@
M8P"& &L A !V (( @@"  )( ?@"C 'P N@!Z .$ >0#_ '< _P!R /\ < #_
M &\ _P#=    RP   +8   "G    G0   )0   ".  $ BP * (D $ "( !4
MAP = (< )0"$ "P @@ R '\ . !] #T >P!# 'D 2 !X $X =@!4 '4 6P!S
M &, <0!N &\ >@!M (D ; ": &H K@!I ,P : #V &< _P!E /\ 9 #_ &,
M_P#*    M    *$   "3    B0   ((   ![    >  % '8 # !U !$ =  8
M ', 'P!R "4 <  L &X ,@!L #< :@ \ &D 0@!H $@ 9@!. &4 50!C %T
M8@!F &  <@!> (  70"2 %L I0!: +X 60#I %D _P!9 /\ 6 #_ %@ _P"Y
M    H@   )    "#    >0   '$   !M    :0 ! &8 "0!E  X 9  3 &,
M&0!C "  80 F &  + !> #$ 7  W %L / !: $( 6 !( %< 3P!6 %< 5 !@
M %, ; !1 'D 4 "* $\ G@!. +0 30#: $T ^P!- /\ 30#_ $T _P"J
ME    ((   !U    :P   &0   !@    70   %H !0!8  P 5P 0 %8 %0!6
M !L 50 A %, )P!2 "P 40 Q $\ -P!. #T 30!# $P 2@!* %( 20!; $@
M9@!& ', 10"$ $0 EP!# *P 0@#) $( \0!" /\ 0P#_ $, _P">    B0
M '@#  !J!   800  %H#  !5 0  4@   %   @!.  D 30 - $P $0!+ !<
M2@ < $D (@!( "< 1P M $4 ,@!$ #@ 0P ^ $( 10!! $T /P!6 #X 80 ]
M &X .P!^ #H D0 Y *8 . "_ #@ Z  X /\ .0#_ #D _P"5 P  @ <  &\)
M  !B"@  6 L  %$*  !,"   208  $<#  !&  8 1  + $, #P!" !, 00 8
M $$ '@ _ ", /@ I #T +@ [ #0 .@ Z #D 00 X $D -P!2 #8 70 T &H
M,P!Z #( C  Q *$ , "X "\ W@ O /D +P#_ #  _P","0  > P  &@-  !<
M#@  4@X  $L.  !%#0  00P  #\*   ^" ( /00( #P!#0 [ !  .@ 5 #D
M&@ X "  -@ E #4 *P T #  ,P W #( /@ Q $8 +P!0 "X 6@ M &< *P!W
M "H B0 I )T * "S "< T0 G /( )P#_ "< _P"&#   <@X  &,0  !6$0
M31$  $41  ! $   / \  #D.   W#0  -@L$ #8("@ U!@X - 42 #($%P Q
M!1P , 4B "\%*  N!BX +08T "L&/  J!D0 *0=. "<'60 F!V4 ) =U ",'
MAP B!YL ( :P " &RP ?!>T 'P;^ !\'_P" #@  ;1$  %X2  !2$P  2!,
M $$3   [$P  -Q(  #01   R$   , \! # -!@ P"PL +PH0 "T*%  L"QD
M*@L? "D+)0 H#"L )PPR "8,.@ D#$, (PQ- "$-6  @#64 '@UU !P-B  :
M#9P &0VQ !@,R@ 7#.L %PW\ !@,_P![$0  :1,  %H5  !.%@  118  #T6
M   X%0  ,Q4  # 4   M$P  *Q(  "H0 P J#P@ *0X- "@.$0 F#A8 )0\=
M "0/(P C#RD (1 Q " 0.0 >$$( '1!, !L06  9$&8 %Q!V !40B0 4$)X
M$A"S !$0S@ 1$.X $A#^ !(0_P!W$P  914  %<7  !+&   0AD  #H9   T
M&   ,!<  "P7   I%@  )Q4  "84 0 E$@0 (Q(+ "(2#P A$A0 (!(: !X3
M(  =$R< '!,N !H3-@ 9%$  %Q1* !845@ 4%&0 $A1T !$4AP 0%)P #A2Q
M  T4R@ -%.L #A/^  X3_P!S%0  81@  %,:  !(&P  /QL  #<;   R&@
M+1H  "D9   F&   )!@  "(7   @%@$ 'A8( !T6#0 ;%Q( &A<7 !D7'0 8
M&"0 %A@K !48-  4&#T $AE( !$95  0&6( #AER  T9A  ,&9@ "AFM  D8
MQ@ )&.< "1CZ  H7_P!O&   7AH  % <  !%'0  /!T  #4=   O'0  *AP
M "8;   C&P  (1H  !X:   <&@  &AL% !@;#  6'!  %1P5 !0<&P 3'"(
M$ATI !$=,0 0'3L #AU%  T>40 ,'EX "AYM  D>@  ''I0 !1VJ  ,=P@ #
M'>8 !!SX  4<_P!K&@  6QT  $T>  !"'P  .A\  #(?   M'P  *!X  "0>
M   A'0  'AT  !P=   8'@  %1\" !,@"0 2(0X $"$2 ! A&  .(1\ #B(F
M  TB+@ ,(C< "B)!  DB30 '(EH !2)I  ,B?  !(I$  "*H   AP   (>4
M "#X   @_P!G'0  5Q\  $HA  ! (0  -R(  # A   J(0  )B   "(@   ?
M'P  '!\  !D@   6(0  $B," ! D!P .)@P #"80  LF%0 *)AP "28B  @F
M*@ &)S, !"<]  ,G20 !)U8  "=F   G>0  )X\  ":F   FOP  )>0  "7Y
M   D_P!C(   5"(  $<C   ])   -"0  "XC   H(P  )"(  "$B   >(0
M&B(  !<C   3)   $"8"  XH!P +*@L ""L.  8K$P $*Q@  BL?  $L)P
M+#   "PZ   L10  +%,  "QC   L=@  +(P  "ND   KO@  *N0  "KZ   I
M_P!?(P  4"4  $0F   Z)@  ,B8  "LF   F)0  (R0  !\D   ;)   %R4
M !0G   1*0  #BL"  LM!@ '+PL !# .   P$0  ,14  #$<   Q(P  ,BP
M #(V   R0@  ,D\  #)?   R<@  ,8D  #&B   PO   ,.0  "_[   O_P!:
M)P  3"@  $ I   W*0  +RD  "DH   E)P  (28  !PG   8*   %"H  !$L
M   .+@  "S !  <R!0 #- D  #4,   V#P  -Q(  #@8   X(   ."@  #@R
M   Y/0  .4L  #E;   X;@  .(4  #>?   WN@  -N0  #7\   U_P!5*@
M2"P  #TL   T+   +2L  "@J   D*0  'BH  !DK   4+0  $2\   TQ   *
M-   !S8   (X!   .@<  #L*   ]#0  /A   $ 4  ! &P  0"0  $ N  !
M.0  0$<  $!6  ! :0  0(   #^;   ^MP  />,  #S\   \_P!0+P  0R\
M #DO   R+P  +"T  "<L   @+0  &B\  !4Q   1,P  #38   DX   %.P
M #T   !  0  000  $,'  !%"P  1@X  $@1  !*%@  2AX  $HH  !*-
M24(  $E1  !)9   2'L  $B7  !'M   1N   $7\  !$_P!*,P  /S,  #8S
M   P,0  *C   ",Q   <,P  %C4  !$X   -.P  "#X   -!    0P   $8
M  !(    2@   $P$  !.!P  3PL  %$.  !4$@  51D  %4B  !4+@  5#P
M %1+  !37@  4W0  %*0  !1K@  4-<  $_[  !._P!%-P  /#<  #4V   O
M-   )C4  !XW   7.@  $3T   Q!   '1    $@   !*    30   %    !3
M    50   %<   !8 @  6P8  %T+  !?#@  8A,  &(;  !B)P  8C0  &%%
M  !@5P  8&T  %^)  !=IP  7,P  %KX  !9_P!!/   .CL  #0Y   J.@
M(3P  !A    10P  #$<   9+    3P   %,   !6    60   %P   !?
M80   &,   !E    9P$  &H%  !M"@  < X  ',5  !R(   <BT  '$]  !P
M3P  ;V4  &Z   !MGP  :\$  &GQ  !H_P _0   .3X  "X_   D0@  &D8
M !)*   ,3P  !%0   !8    70   &$   !E    :    &L   !N    <0
M ',   !U    >    'L   !^ P  @0H  (4/  "'%P  AB0  (4T  "$1@
M@ET  (%V  !_E@  ?K8  'SG  !Z_P _1   ,T4  "A(   =3   $U(   Q7
M   #70   &,   !H    ;0   '$   !V    >@   'X   "!    @P   (8
M  ")    BP   (X   "2    E0$  )D)  ">$   GAH  )TI  "</   FE(
M )AL  "6BP  E*H  )+4  "0^@ X2P  +$X  "!3   560  #6    -G
M;@   '0   !Z    @    (0   "*    C@   )(   "5    EP   )H   "=
M    H    *,   "G    JP   *\   "T"0  N!   +<>  "U,   LT8  +%@
M  "O?@  K*   *O!  "I[@ Q50  )%L  !AA   .:0  !7$   !Y    @0
M (@   "/    E    )H   "?    I    *@   "I    K    *\   "S
MM0   +D   "]    P0   ,8   #+    T0H  -,4  #1)0  T#L  ,U4  #*
M<0  R)(  ,6S  ##W@ I8@  '&D  !%Q   '>P   (0   "-    E0   )T
M  "C    J0   *\   "T    N0   +P   "^    P@   ,4   #(    S
M -    #4    V@   -\   #D    Z@   .X,  #M&@  ["\  .I)  #H90
MYH8  .2E  #BQ@#_    _P   /\   #\  $ _  ( /X #@#_ !0 _P = /\
M)@#_ #  _P Z /\ 0@#_ $D _@!0 /L 5@#Y %P ]@!B /0 : #R &\ \ !V
M .T ?P#J (D YP"5 .0 HP#@ +4 VP#0 -4 ]@#* /\ M@#_ *@ _P"? /\
MF@#_ )8 _P#_    ^P   /8   #S    \P   /8 "0#Z  X _0 6 /L ( #W
M "H \@ S .T .P#I $, Y@!) .( 3P#> %4 VP!; -8 8 #2 &< SP!N ,P
M=@#) (  Q@", ,( F@"_ *H NP#! +@ Z0"V /\ IP#_ )H _P"2 /\ C0#_
M (H _P#Z    \0   .H   #G    YP   .0  0#@  L VP 1 -H &@#; ",
MT0 L ,H - #& #L P@!" +\ 2 "\ $X N@!3 +@ 60"V %\ LP!F +$ ;@"N
M '< K "# *D D0"F *$ HP"U *  V "> /L E0#_ (L _P"% /\ @ #_ 'X
M_P#O    XP   -H   #3    Q@   +\   "Y  8 MP . +0 % "T !T LP E
M *X +0"K #0 IP [ *0 00"A $8 GP!, )T 40"; %< F0!> )< 90"5 &X
MDP!Y )  AP". )< C "I (D Q "( .\ A0#_ 'P _P!V /\ <P#_ '( _P#@
M    T    ,8   "V    J0   *$   "=  $ F0 * )@ $ "8 !8 EP > )0
M)@"1 "T CP T (P .@"* #\ B !% (< 2@"% %  @P!6 ($ 7@"  &8 ?@!Q
M 'P ?0!Y (T =P"@ '4 M@!S -\ <@#_ &X _P!I /\ 9P#_ &4 _P#,
MO@   *L   "=    DP   (H   "%    @@ % (  #0!_ !$ ?P 8 (  ( !]
M "8 >@ M '< ,P!U #@ =  ^ '( 0P!P $D ;P!/ &T 5@!L %X :@!H &@
M=0!G (0 90"6 &0 JP!B ,D 80#V &  _P!< /\ 6P#_ %H _P"]    J0
M )<   ")    ?@   '@   !S    ;P ! &T "0!L  X :P 3 &L &0!J "
M:  F &8 + !E #( 8P W &( / !@ $( 7P!( %T 3P!< %< 6@!A %D ;0!7
M 'L 5@". %4 H@!3 +L 4@#I %( _P!0 /\ 3P#_ $\ _P"M    F    (8
M  !X    ;@   &<   !C    8    %T !0!<  L 6P 0 %L %0!; !L 6@ A
M %@ )@!6 "P 5  Q %, -@!2 #P 40!" $\ 20!. %$ 30!; $L 9@!* '0
M20"% $@ F0!' +$ 1@#8 $8 _ !% /\ 10#_ $4 _P"?    B0   '@   !L
M    8@   %L   !6    4P   %$  @!/  @ 3P - $X $0!. !8 30 < $P
M(0!* "8 20 L $@ ,0!' #< 10 ] $0 1 !# $P 0@!5 $  8  _ &X /@!^
M #T D@ \ *D .P#' #L \P [ /\ .P#_ #P _P"3    ?@   &X   !A
M6    %$   !,    20   $<   !%  4 1  + $, #@!# !( 0P 7 $( '0!
M "( /P G #X +  ] #( .P X #H /P Y $< . !0 #< 6P U &@ - !X #,
MC  R *( ,0"\ #$ YP Q /\ ,@#_ #, _P")    =@,  &8%  !9!P  4 <
M $D&  !#!0  0 ,  #X!   \  , .P ( #H #0 Z !  .0 4 #D &0 W !X
M-@ C #4 *  T "X ,P T #( .P P $, +P!, "X 5P M &0 + !S "L AP J
M )P *0"U "D W  I /L *0#_ "H _P"!!   ;@@  %\*  !3"P  2@L  $(+
M   ]"@  .0D  #8(   U!0  - (& #, "@ R  X ,0 1 #$ %0 P !H +P ?
M "X )  L "H *P P "H -P I #\ * !) "< 5  F &  ) !O ", @@ B )<
M(0"N "$ S  A /, (0#_ "( _P!["0  : P  %H-  !.#@  10X  #T.   X
M#0  ,PT  # ,   N"P  +0D# "T&"  L! P *P(/ "H!$@ I 1< * $< "<
M(0 F "< )0 M "0 -  C 3T (@%& "$!40 ? 5T '@%L !P!?P ; )0 &@"J
M !H Q0 : .L &0#_ !H _P!U#   9 X  %4/  !*$   0!   #D0   S$
M+P\  "P.   I#@  )PT! "<,!0 G"@H )@@- "4'$  D!A0 (@89 "$&'P @
M!R0 'P<K !X',@ =!SH ' A$ !H(3P 9"%P %PAK !8(?0 5!Y$ % >G !,&
MOP 2!>0 $@7Z !(%_P!Q#@  7Q   %$1  !&$@  /1(  #82   P$@  *Q$
M "@1   E$   (Q   "(.!  A#0< (0P+ " +#@ ?"Q( '0L7 !P,'  ;#"(
M&@PI !D,,0 8##D %@U# !4-3P 3#5P $@UK ! -?@ /#9( #@VG  T,O@ -
M#.  #0SU  T,_P!M$   7!$  $X3  !#%   .A0  #(4   M%   *!,  "43
M   B$@  (!$  !X1 P <$ 4 ' \( !L/#  :#A  &0\4 !</&@ 6#R$ %1 H
M !00,  2$#D $1!$ ! 04  .$%T #1!K  P0?  +$)  "1"E  @0O  '$-\
M!Q#T  </_P!I$0  6!0  $L5  ! %@  -Q8  # 6   J%@  )A4  "(5   ?
M%   '1,  !H3 @ 9$@0 %Q(& !82"@ 5$@X %!(2 !(2&  1$QX $1,E ! 3
M+@ .$S< #11   P42P +%%@ "11G  <4>  &%(T !!2C  ,3NP "$]T  1+T
M  (2_P!E$P  518  $@7   ]&   -!@  "T8   H&   (Q<  " 7   =%@
M&A4  !@5 @ 6%00 %!4% !(6"  1%@T $!<0  X7%0 .%QL #1<B  P7*0 +
M&#( "1@\  <81P %&%0 !!AC  (8=0 !&(L  !>A   7N0  %]T  !;U   6
M_P!A%@  4A@  $4:   [&@  ,AH  "L:   E&@  (1D  !X8   ;&   &!<
M !87 @ 4%P, $A@% ! 9!P .&PL #!L/  L;$P *&Q@ "!P?  <<)@ %'"\
M!!PX  (<1   '5$  !U@   =<@  '(@  !R@   ;N0  &]X  !KV   :_P!>
M&   3QH  $(<   X'   +QT  "D<   C'   'QL  !P:   9&0  %QD! !09
M @ 2&@, $!L$  X=!P ,'@L "1\.  8@$0 %(!8  R <  $A(P  (2L  "$U
M   A0   (4X  "%=   A;P  (88  "">   @N   ']X  ![X   >_P!:&P
M2QT  #\>   U'P  +1\  "<>   B'0  'AT  !L<   8&P  %1L  !(<   0
M'0( #A\$  PA!@ )(@H !2,-  (D$   )1,  "49   F(   )B@  "8R   F
M/0  )DH  "9:   F;   )H,  "6<   EMP  )-\  "/Y   C_P!5'@  1R
M #PA   R(0  *R$  "4@   @'P  '1X  !H=   6'@  $QX  ! @   .(0
M#","  @E!0 %)PD  "@+   J#@  *Q$  "P6   L'0  +"4  "PN   L.@
M+$<  "Q6   L:0  +(   "N:   JM0  *=\  "G[   H_P!1(@  1",  #@D
M   O)   *",  ",B   ?(0  '"   !<@   3(0  $",   XD   +)@  ""@
M  0J!   + <  "X)   P#   ,0\  #,3   S&0  ,R$  #,J   S-0  ,T,
M #-2   S90  ,GL  #*7   QLP  ,-X  "_[   N_P!,)0  /R8  #4G   M
M)@  )R4  "(D   >(P  &2,  !0D   1)@  #B@   LJ   '+    R\    Q
M @  ,P0  #4'   W"@  .0T  #H0   [%0  .QT  #LF   [,0  .SX  #M.
M   [8   .G<  #F2   XL   -]L  #;\   U_P!'*0  .RH  #(J   K*0
M)2<  "$F   ;)P  %2@  !$J   .+   "B\   8Q   !-    #8    X
M.P$  #T$   _!P  00H  $,.  !%$0  11@  $4A  !%+   1#D  $1(  !$
M6P  0W$  $*-  !!JP  0-(  #_Z   ^_P!"+0  ."X  "\M   I*P  )"H
M !TJ   7+   $2X   TQ   )-   !#<    Z    /    #\   !!    1
M $8   !( P  2@<  $P+  !.#@  4!,  % <  !0)P  3S0  $]#  !/50
M3FH  $V&  !,I   2LH  $GX  !(_P ^,@  -3$  "XO   I+@  ("X  !DQ
M   2,P  #C<   DZ   "/0   $    !$    1P   $D   !,    3P   %$
M  !3    50$  %@&  !:"P  70X  %\5  !>(   7BP  %T\  !<3@  6V,
M %I^  !8G0  5\   %7R  !4_P Z-@  ,S0  "TR   D,P  &S8  !,Y   .
M/0  "$$   !%    20   $P   !0    4P   %8   !9    6P   %T   !@
M    8@   &4   !H!0  :PL  &\0  !O&   ;B4  &TT  !M1@  :UL  &IU
M  !HE   9K8  &3I  !B_P X.0  ,C<  "@Y   >.P  %3\   Y$   '20
M $T   !2    5@   %H   !>    8@   &4   !H    :P   &T   !P
M<P   '8   !Y    ?00  ($+  "%$0  A!T  ((L  " /@  ?E0  'YK  ![
MB@  >JH  '?6  !U_0 X/0  +#X  ")!   71@  #TL   =1    5P   %P
M  !B    9@   &L   !O    =    '@   ![    ?@   (    "#    A@
M (H   "-    D0   )8#  ";#   G1,  )LA  ":,P  ETD  )1B  "3?P
MD*   ([%  ",\P Q1   )4@  !I-   04P  "%H   !A    :    &X   !T
M    >0   '\   "$    B0   (T   "1    DP   )8   "9    G0   *
M  "D    J    *P   "R P  MPT  +<7  "U*   LCX  +!6  "L<P  JI0
M *FT  "EY0 J3P  'E0  !);   *8@   &H   !S    >P   ((   ")
MC@   )0   ":    GP   *0   "F    J0   *T   "P    LP   +<   "[
M    P    ,4   #+    T00  -4.  #3'0  T#(  ,U+  #*9@  QH<  ,*I
M  #!RP B6P  %F(   QK   !=    'T   "'    D    )<   ">    I
M *L   "Q    M@   +H   "\    P    ,0   #(    RP   ,\   #4
MV@   .    #F    ZP   /$&  #P$P  [B<  .P_  #J6P  YWH  .2;  #@
MNP#_    ^P   /8   #S    ]  % /8 # #Z !$ _P 9 /\ (@#_ "P _P U
M /\ /0#_ $4 _ !, /H 4@#W %@ ]0!> /, 9 #Q &H [@!R .P >@#I (4
MY0"1 .$ H #= +( V #. -( ]@#! /\ K0#_ )X _P"6 /\ D #_ (P _P#Z
M    \@   .P   #I    Z0   .P !0#R  P ^  2 /< &P#U "4 \  N .L
M-P#F #X X@!% -T 2P#8 %  TP!6 -  7 #- &( R@!J ,@ <@#% 'P P@"(
M +X E@"Z *@ MP"_ +0 Z "N /\ G0#_ )  _P"( /\ @P#_ (  _P#P
MY0   -X   #:    VP   -P   #8  < T0 . -$ %0#2 !X RP G ,4 +P#
M #< O0 ] +H 1 "W $D M0!/ +( 50"P %L K@!A *P :0"I ', IP!_ *0
MC0"A )X G@"R )L U0"9 /P C #_ (( _P![ /\ =@#_ '0 _P#B    TP
M ,H   #'    O    +8   "P  $ KP + *P $0"M !@ K0 @ *@ * "D "\
MH  V )T / "; $( F0!' )< 30"5 %, DP!9 )$ 80"/ &H C !U (H @P"(
M )0 A@"G (, P@"" /  ? #_ ', _P!M /\ :@#_ &@ _P#/    P0   +D
M  "M    H    )@   "4    D0 & )  #0"0 !( CP 9 (X (0"+ "@ B  O
M (8 -0"$ #H @@!  (  10!^ $L ? !2 'H 60!X &( =@!L '0 >0!R (D
M<0"= &\ M !M -\ ; #_ &4 _P!@ /\ 7@#_ %P _P"^    L0   *    "2
M    B0   ((   !\    >@ ! '@ "0!W  X >  4 '< &@!T "$ <@ G '
M+0!N #, ;  X &L /@!I $0 : !* &8 40!D %H 8P!D &$ < !? '\ 7@"3
M %T J0!< ,@ 6P#W %< _P!4 /\ 4@#_ %$ _P"P    GP   (T   !_
M=    &X   !J    9@   &4 ! !C  L 8P 0 &, %0!C !L 80 A %\ )P!=
M "P 7  R %H -P!9 #T 5P!# %8 2P!5 %, 4P!< %( : !0 '< 3P") $X
MGP!- +H 3 #I $L _P!) /\ 1P#_ $< _P"B    C0   'P   !N    90
M %X   !9    5P   %4  0!4  < 4P - %, $0!4 !8 4@ ; %$ (0!/ "8
M3@ K $P ,0!+ #< 2@ ] $D 1 !' $P 1@!6 $0 80!# '  0@"! $$ EP!
M *\ /P#7 #\ _P ^ /\ /0#_ #X _P"4    ?P   &\   !C    60   %$
M  !-    2@   $@   !'  0 1P * $8 #@!& !$ 1P 6 $4 ' !$ "$ 0@ F
M $$ *P!  #$ /@ W #T /@ \ $< .@!0 #D 6P X &D -P!Z #8 CP U *<
M-0#& #0 ]0 T /\ - #_ #4 _P"(    =    &4   !8    3P   $@   !#
M    /P   #T    \  ( /  ' #L #  [  \ .P 2 #H %P Y !P -P A #8
M)@ U "P -  R #, .0 Q $$ , !+ "\ 5@ N &, +0!S "P B  L *  *P"[
M "L Z@ K /\ *P#_ "P _P!_    ;    %T!  !1 @  2 ,  $ #   [ @
M-P   #0    S    ,@ % #( "0 R  T ,0 0 #$ $P P !@ +P = "T (@ L
M "@ *P N "H -0 I #T * !& "< 40 F %X )0!N "0 @@ C )D (P"S "(
MW@ B /\ (P#_ "0 _P!W    900  %8&  !+!P  0@@  #H(   U!P  , 8
M "T%   L P  *P # "H !P I  L *0 . "D $0 H !4 )P 9 "8 '@ E "0
M)  J ", ,0 B #D (0!# "  3@ ? %H '@!I !T ?  < ), &P"L !L S0 ;
M /8 &P#_ !P _P!P!0  7P@  %$*  !&"P  /0L  #4+   P"P  *PH  "@)
M   E"   ) <" ",$!@ C @D (@$, "( #P A !( (  6 !\ &P > "  '0 F
M !P +@ ; #8 &@ _ !D 2@ 8 %< %P!F !8 >  5 (\ %0"F !0 PP 4 .X
M% #_ !4 _P!K"   6PL  $T,  !"#0  .0T  #$-   L#0  )PT  ",,   A
M#   'PL! !X*!0 =" @ '08+ !P%#0 <!!  &P04 !D$&  9!!X & 0C !<$
M*P 6!#, %00\ !0$1P 3 U0 $@-C !$#=0 0 HH $ &B  \ O  / .4 #P#^
M !  _P!G"P  5PT  $D.   ^#P  -0\  "X/   H#P  ) X  " .   =#@
M&PT! !D-!  8# < & L) !<)#  7"0X %@D2 !4)%@ 4"1L $PDA !()*  2
M"3  $0DZ ! )10 /"5( #@EA  T)<P ,"(@ "PB?  H'MP *!ML "@7V  H$
M_P!C#0  4PX  $80   [$0  ,A$  "L1   E$   (1   !T0   :#P  & \!
M !8.!  5#@< % T) !,-"P 3# T $@P0 !$,%  0#!D $ P?  \,)P .#2\
M#0TY  P-10 +#5$ "0U@  @-<0 &#88 !0V=  0,M  ##-(  @SQ  (+_P!?
M#@  4!   $,1   X$@  +Q(  "@2   C$@  'A$  !L1   8$0  %1 " !00
M!0 2$ < $0\) ! /"@ 0#@P #@X.  X/$@ -#Q< #! =  P0)  *$"P "1 V
M  @000 &$$X !1!=  ,0;P !$(0  !"<   /M   #M0   [S   ._P!<$
M31(  $ 3   V%   +10  "84   A$P  '!,  !D2   6$@  %!$# !(1!@ 1
M$0@ $! *  X0"P -$0L #!$-  L2$0 *$A4 "1(:  @2(0 &$RD !1,S  ,3
M/@ "$TL  !-:   3;   $X(  !*;   2M   $=<  !'U   1_P!8$@  210
M #T5   S%@  *Q8  "05   ?%0  &A0  !<4   4$P$ $Q($ !$2!P 0$@D
M#A()  T2"0 +$PH "10-  <5#P &%A, !!88  ,6'P "%B<  !<P   7.P
M%T@  !=8   7:@  %H   !:9   5M   %=D  !3W   3_P!5%   1A8  #H7
M   P&   *!@  "(7   =%@  &18  !85   3% , $A,& ! 3!P /$P< #10'
M  L5"  )%@D !A@,  ,:#@ !&A$  !H6   ;'   &R0  !LM   ;.   &T8
M !Q5   ;9P  &WT  !N7   :LP  &=L  !CY   7_P!1%@  0Q@  #<9   N
M&@  )AH  " 9   ;&   &!<  !46 0 3%04 $14$  \5!  -%@0 "Q<%  D9
M!@ &&@@  AP*   >#0  (!   " 3   @&0  ("$  "$J   A-0  (4(  "%2
M   @9   ('H  !^5   ?L0  'ML  !WZ   <_P!-&0  /QL  #0<   K'
M)!P  !X;   :&@  %Q@  !07 @ 2%P( $!@!  T9 0 +&@( "!P#  4=!  "
M'P8  "$(   C"P  )0X  "81   F%@  )AX  "<G   G,@  )S\  "9.   F
M8   )G<  "62   DKP  (]H  "+[   A_P!('0  /!X  #$?   H'@  (AX
M !T<   9&P  %AH  !(:   0&P  #1P   L=   ('P  !"$   $C @  )00
M "<&   I"0  + P  "X/   N$P  +AH  "XC   N+@  +CL  "Y*   M7
M+7(  "R.   KK   *M0  "G[   H_P!$(   ."$  "XA   F(0  ("   !P>
M   8'0  %!T  ! >   .'P  "R$   <C   #)0   "<    I    + $  "X#
M   P!@  ,PH  #4-   V$0  -A<  #8?   V*0  -C8  #9%   U5P  -6T
M #2)   RJ   ,<\  ##Z   O_P _)   -"0  "LD   D(P  'R$  !L@   6
M(   $2$   XC   *)0  !B@   (J    +0   "\    R    -    #<    Y
M P  .P8  #X*  ! #@  01(  $$:  ! )0  0#$  $!    _4@  /F<  #V"
M   \H@  .L<  #GX   X_P Z*   ,"@  "DG   C)0  'R,  !@D   2)0
M#B@   HJ   %+0   #     S    -@   #@    [    /@   $    !"
M10(  $<&  !*"@  30X  $T5  !,'P  3"L  $LZ  !*3   26$  $A\  !'
MFP  1;\  $/S  !"_P V+   +2L  "<I   C)P  &R@  !0J   .+0  "C
M  0S    -P   #H    ]    0    $,   !&    2    $L   !-    4
M %,!  !6!@  60L  %L0  !;&0  6B4  %DT  !81@  5UH  %5T  !4DP
M4K4  %#J  !/_P S,   +"X  "<L   >+0  %B\  ! R   *-@   SH    _
M    0@   $8   !)    3    $\   !2    50   %@   !:    70   &
M  !C    9P8  &L,  !L$@  :QX  &LL  !I/0  9U(  &9J  !DB0  8:L
M %_<  !=_P Q,P  +#$  "(R   9-0  $3D   H]   "0@   $<   !,
M4    %0   !8    6P   %\   !B    90   &@   !K    ;@   '$   !U
M    >0   'T&  ""#0  @A8  ( D  !^-0  ?$D  'MA  !X?P  =I\  '/&
M  !P]P Q-@  )C@  !P[   20   "T4   )+    40   %8   !;    8
M &4   !I    ;@   '(   !V    >0   'P   !^    @@   (4   ")
MC@   ),   "8!@  G X  )L:  "8*P  ED   ))9  "1<P  C94  (NU  "(
MZ  K/@  ($$  !5'   -30   E0   !;    80   &@   !N    <P   'D
M  !^    @P   (@   ",    CP   )(   "5    F0   )T   "A    I0
M *H   "P    MP<  +@1  "U(0  LC4  *]-  "J:0  J(@  *:H  "BT0 C
M2   &$X   Y4   $7    &0   !M    =0   'P   "#    B0   (\   "5
M    FP   *    "C    I@   *D   "M    L0   +4   "Y    O@   ,0
M  #*    T@   -H*  #6%@  TBD  ,Y!  #*7   Q7P  ,*=  #!O0 <50
M$5P   =E    ;@   '<   !_    B    )    "8    GP   *4   "M
MLP   +@   "Z    O@   ,(   #&    R@   ,X   #3    V@   .    #G
M    [0   /,   #T#@  \AX  .\V  #L40  Z&X  .20  #?L0
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M" D*"PT.#Q$2$Q06%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T-C<X.3L\/3Y
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MY>;GZ.GJZ^SM[N_P\?+S]/7V]_CY^OO\_?[_;69T,0     #!"$   $
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M:FUO<71V>7Q^@8.&B8N.D)*5EYF;G9^AHZ6GJ*JLK:^PLK.UMK>YNKN\O;_
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MI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31_Y\B!?^=+0S_GS@5_ZI
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MC340_Y@[%_^@1"'_IDXM_Z=9//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R
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MP(R)L,",B;# C(FPP(R)L,",B;# C(FPP(R)L,",B;# C(FPP(R)L,",B;#
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M?Y*SO("1N+6 D;BU@)&XM8"1N+6 D;BU@)&XM8"1N+6 D;BU@)&XM8"1N+6
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M8-J'TV#:A]-@VH?38-J'TV#:A]-@VH?38-J'TV#:A]-@VH?38-J'_X,< _^
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MP8Y4U<&.5-7!CE35P8Y4U<&._Y05 O^D&0+_MQP!Z<L6 ='A'0+%[#$.NO5
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MD7Z%IHR&C*"(C9&:A966EH*>FI* IYV/?[.>C8#"GHN S)J+@=*2BH#8B8F
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M.$3_Q3A$_\4X1/_%.$3_Q3A$_\4X1/_%.$3_Q3A$_\4XP;,  +*^ @"ES $
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M74KC\UQ*X_-<2N/S7$KC\UQ*X_-<2N/S7$KC\UQ*X_-<^9D# -2L @#%MP0
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M/O_-,#[_S3 ^_\TP/O_-,#[_S3 ^_\TPN[$  *R\  "?R0  D]D  (G\"P&
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MLT0=S:U/+L.F63ZYGV%+L)EH5JB4<%^ACW=GFXM^;I:(AG.0A8YXC(*6?(B
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M;U:R[VI7K_%G5Z_Q9U>O\6=7K_%G5Z_Q9U>O\6=7K_%G_W\. ?^3"P#AI04
MTK,' ,F^!P#"RP@ O-T. +3=(P.JVC,-G]9 ')332BJ*T%(W@,U:07C+84IP
MR6A1:LAO5V3&=EQ?Q7]@6L6(9%;$DF=3Q)YI4,2L:D_$O&M.Q=-J3\7M:%#
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M0D3R^D)$\OI"1/+Z0D3R^D)$\OI"T:(  ,"N  "RN $ I\0" )S2! "2[0P
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M;&>5\69HD_9@:)+W7VB2]U]HDO=?:)+W7VB2]U]HDO=?_V\1 ?^!#@#_D0X
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M55"Z_E50NOY54+K^55"Z_E50NOY5_X4" -V8  #-I@( P;$# +>Z P"NQ@8
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MK(MD/Z:';$>@@W--FX!Z4Y9]@E>2>HI<CGB28(IVG&.'=:9FA'2R:()TPFB
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M8GB"^EMX@OY6>8'_47F!_U%Y@?]1>8'_47F!_U%Y@?]1_V43 ?]U#@#_@PX
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M4F&8_U)AF/]289C_4F&8_U)AF/]2_W(+ /^#!0#?DP$ T9\$ ,FJ!@#!L@4
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MFQ<O_ZD7+O^W&"W_R!@L_^$8+/_O&"S_[Q@L_^\8+/_O&"S_[Q@L_^\8JZL
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M58AR_4Z)=/])B73_1(AT_T.(=/]#B'3_0XAT_T.(=/]#_UT2 ?]K#@#_> X
M_X,/ /V,$ #ME!( X)H5 -.<) +(F38)OY1#%;:/3R"NBE@KIX9A,Z&":#N<
M?W!!EWQW1I-Y?DN/=X9/BW6/4HASF%:$<J)8@7&N6G]QO%Q]<=!<?W/L5H%V
M^T^#>/]*@WC_18)X_T2">/]$@GC_1()X_T2">/]$_U\1 ?]M# #_>@T _X4-
M /*/#0#GF T VY\. ,Z?(@'$G30(NIA"%+*331^JCU8JHXI?,IR&9CJ7@VU
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M2'*$_T=RA/]'<H3_1W*$_T=RA/]'_V8- /]U!P#V@P4 W(\# -*8!@#,H0<
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MKS _U<(Q/]7A,#_3\C _TOTO/]'_+C_0_RX_T/\N/]#_+C_0_RX_T/\NRI0
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M$2?_QQ$G_^$1)O_R$2;_]A$F__81)O_V$2;_]A$F__81IZD  )FS  "+O@
M?LD  '#3  !DW@  6.<  %+_"0!-_Q$ 1_\9 4/_(@$^_RH".O\R S?_.0,S
M_S\$,/]&!2W_304K_U0&*/];!R;_8P<C_VT((?]Y"1__APD>_Y4*'?^C"AS_
ML0H;_\ +&O_6"QK_WPL:_]\+&O_?"QK_WPL:_]\+F[$  (V\  !^QP  <-(
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M1)IB_SZ:8_\YFV7_-IME_S.;9?\SFV7_,YME_S.;9?\S_U43 ?]@#@#_:PX
M_W00 /][$@#U@1< Z(0> -Z')P'1A#<'R']&$<![41NY=ELCM')E*Z]O;3&J
M;'4VIVI\.J-HA#Z@9HQ!G6241)ICG4>78J=)E6&R2Y-AP4R18=A,D6/O1Y)E
M_4&29_\\DVG_.)-J_S63:O\UDVK_-9-J_S63:O\U_U<1 ?]C#0#_;@P _W<.
M /]_#P#PA1$ XXD6 -:+(P'+B#4&PH1#$+J 3QJS>UDCK7=B*JAT:C&C<7$V
MGVYY.YQL@3^8:HA"E6F119)GFDB/9J-*C66O3(IEO4V)9=%.B6?L2HII^T.+
M:_\^C&W_.HQN_S>,;O\WC&[_-XQN_S>,;O\W_UD0 /]E"P#_<0L _WH+ /&"
M# #HB0T W8X. ,^/( '&C3(&O8E!#[6$31FN@%8BIWQ?*J)X9S"==6\VF7-V
M.I5Q?3^2;X5"CFV.1HMLEDF(:J!+A6JL38-IND^!:<Q/@6KH3(-M^46$;_\_
MA7#_.X9Q_SB&<?\XAG'_.(9Q_SB&<?\X_UL/ /]G" #_<P@ \WT( -Z&!P#9
MC D U9$+ ,J2'@#!D# %N(T_#K"(2ABIA%0AHH!=*9U]93"8>FPUDW=S.H]U
M>SZ,<X)"B'*+1H5PE$F";YY,?VZI3GQMMT][;<E0>F[F37QQ^$9^<_]!?W3_
M/8!U_SJ =?\Z@'7_.H!U_SJ =?\Z_UT. /]J!@#_=@8 Y( # -F)!@#2CP@
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MJ4%+I;I"2Z;10DNE[3]-I?P\3J3_.4^D_S=/I/\W3Z3_-T^D_S=/I/\WY'H
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M)CS-[R4[S/LE.\O_)3O*_R4[RO\E.\K_)3O*_R4[RO\EPY,  +6>  "HI@
MG:X  )&V  "%OP  ><<  &_.! !DU@D 7MX1 %O>( !7WBT"4]\Z!%#?1 9,
MWTX)2=]7#$;?7P]#WV@10=]Q$S[??!4\WXD7.N"6&3C@I1HWX+<:-N'-&C;?
M[!HUWOD:--W_&S3<_QLTW/\;--S_&S3<_QLTW/\;N9P  *JD  ">JP  DK4
M (6^  !YQP  ;<\  &+6 P!8X0@ 5>H3 %'K( !-ZRL!2>LU D7L/@1"[$<%
M/^Q/!SWM6 DZ[6 *..UJ##;N= TS[H .,NZ.#S#OG1 N[ZT1+?# $2WPWA$L
M[O$1+.S^$2SK_Q LZ_\0+.O_$"SK_Q LZ_\0K:(  *"I  "3LP  AKT  'G&
M  !LSP  8-@  %7>  !.\PH 2O<3 $;X'0!#^"<!/_@P COY. (X^4 #-?I'
M!#/Z3P4P^U<%+OM?!BO\:0<I_'0()_R""27]D DD_: *(_ZP"B+^Q LA_^ +
M(?WR"B#\_ H@_/P*(/S\"B#\_ H@_/P*HJ<  )6Q  "'NP  ><8  &S/  !?
MV0  4M\  $CH  !#_P@ /_\0 #O_&0 W_R$ -/\I 3#_, $M_S<"*O\^ B?_
M1 (E_TL#(O]3 R#_7 ,=_V8$&_]R!!G_@ 47_X\%%O^?!A7_KP84_\ &%/_6
M!A/_Z083_^D&$__I!A/_Z083_^D&EZ\  (BZ  !ZQ0  ;,\  %[:  !0X
M1.8  #SU   W_P0 ,_\- "__$P K_QH */\A "7_)P$A_RT!'O\R 1O_. $9
M_S\!%O]& A3_30(1_U8"$/]@ @[_; (,_WL#"_^+ PK_F@,*_Z@#"?^U PC_
MP@,(_\(#"/_" PC_P@,(_\(#BK@  'O#  !LS@  7ML  $_B  !"YP  -NP
M #'_   L_P  )_\' "/_#@ @_Q( '/\8 !C_'0 5_R$ $O\F !#_+ $._S$!
M#?\W 0K_/@$(_T8!!?]/ 0'_60$ _V8! /]T 0#_@@( _Y " /^< @#_I@(
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M-_\0_SDE ?] (0'_12 !_T<B O])*0+_2C0$_TD_!?]&2PC_1%@*_T)E#?]
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M+;10_RJS4?\GLU+_)+)2_R*R4O\BLE+_(K)2_R*R4O\B_TH5 ?]3$0#_6P\
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M,(YD_RR.9?\LCF7_+(YE_RR.9?\L_U4. /]?!@#_:08 ]'(& .)X!@#;? D
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MJ$%:A;="687,0EJ%ZC]<AOLZ7H;_-E^'_S)?A_\R7X?_,E^'_S)?A_\R_6@
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M-TB@YS5)H/DR2I__,$N?_RY+G_\M2Y__+4N?_RU+G_\MW7D  ,F&  "\D@
ML9H  *:@  "<I@  D:P  (:R  !]M@T >;8= '6V+ )OM3D&:K1#"V6S3!%@
MLE067+%;&EBP8QY5KVLA4:]S)4ZN?2A+K8@J2*V5+46MHRY$K;,O0ZW(+T*L
MYR]#J_DM1*O_*T2J_RE$JO\I1*K_*42J_RE$JO\IT8   ,&-  "UF   J9\
M )ZE  "3K   B+(  'VX  !QO@8 ;K\5 &J_)@%FOS,#8;X_!UV^2 M9O5$/
M5;U9$U&\8!=.O&@:2[MQ'4B[>Q]%NH<B0KJ4)$"ZHB8^NK,F/;K()CVZZ"8]
MN/DE/;?_)#VV_R,]MO\C/;;_(SVV_R,]MO\CQX@  +F5  "LG0  H:0  ):K
M  "*L@  ?[D  '._ 0!HQ@4 8,H. %[*'0!;RBP!5\HX U3*0P50RDP(3<E5
M"TK)70Y'R6811,EO%$')>18_R(48/,B3&CK(HALYR;,<.,G)'#C(Z!PWQ_D<
M-\7_'#;$_QPVQ/\<-L3_'#;$_QPVQ/\<OI$  +";  "DHP  F*H  (RR  "
MN0  =,   &C'  !=S04 4],* $_7$@!-V"( 2]@P $G8/ )&V$8#1-E/!$'9
M6 8_V6$(/-EK"CK9=@PWV8(.-=J0#S3:H! RVK$1,=O'$3':YQ$PV/82,-;_
M$R_4_Q,OU/\3+]3_$R_4_Q,OU/\3LYH  *:A  ":J0  C;$  ("Z  !TP0
M:,D  %S/  !2U0, 2-P( $7E$@!#Y1X 0>8J #[F-0$[YSX!.>=' C?G4 ,T
MZ%D$,NAB!3#H;08NZ7D'+.F'""OJE@DIZJ<**.JZ"B?KU@HGZ? *)^?]"2;F
M_PHFYO\*)N;_"B;F_PHFYO\*J*   )RG  "/L   @KD  '3"  !HR@  6]$
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M 0#_R@$ _\H!AK<  '?!  !HS   6M<  $O>   ^Y   ,ND  "?M   C_P
M'_\  !O_!0 7_PP %/\0 !'_%  /_Q@ #?\=  O_(@ (_R@ !?\N  +_-0
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M%-@Z_Q/5._\2TSO_$M([_Q'2._\0TCO_$-([_Q#2._\0_ST; ?]#%@#_2!0
M_TP7 ?]/'P'_4"@!_T\S O]-/P3[2DH&]4=7"?%&9 SM1&\.Z4-Y$>="@Q/D
M08L4XD"3%N _FQ??/Z(8W3ZJ&=L^LQK8/KT:UC[*&](^WQO./N\;RS_[&LE
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M(*-2_QZB4O\=HE+_':)2_QVB4O\=_TH/ /]2"@#_6@D _V + /]E#@#U9Q$
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MJ#EH;[<Z9V_+.F=PZ3=I<?HR:W+_+6QS_RIL<_\H;'/_*&QS_RAL<_\H_UP
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M-U: XS98@?<Q68'_+5N"_RI;@O\I6X+_*5N"_RE;@O\I[&8  -AS  #'?@
MO(<  +..  "ID@  H)4  ):8 0"0F1, BIDD 868,@1_ECX)>91(#G234!1O
MD5<9:Y!>'6B.92%DC6TE8(QU*%V+?BM:BH@N5XF4,52)H3-2B+ T48C#-5"(
MXC12B/8P4XC_+%2(_RE5B/\H58C_*%6(_RA5B/\HYFL  -!X  #"@P  MXP
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M(D"E_R% I/\@0*3_($"D_R! I/\@RGX  +N+  "OE0  I)L  )FA  ".I@
M@JP  '>Q  !JM@  8[@. &&X'0!>N"P!6K@X E>X0@53N$L(4+=3"TVW6PY*
MMF,01[9K$T2U=19"M8$8/[6.&CVUG!P[M:P<.K7 '3FUWQPYL_0<.;+_'#FQ
M_QLYL/\;.;#_&SFP_QLYL/\;P88  +23  "GF@  G*   )&G  "%K0  >;,
M &VX  !BO0$ 5L(' %/#% !2PR, 4,0P 4W$.P)*Q$4#1\1.!47$5P="PU\)
M0,-H"SW#<@T[PWX/.,.,$3;#FQ(UPZL3,\/ $S/#X!,SP?43,L#_%#*__Q0Q
MOO\4,;[_%#&^_Q0QOO\4N)   *N9  "?H   DZ<  (>N  ![M   ;KL  &/
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M!1_@_P4?X/\%I)X  )BE  "+K@  ?;8  '"^  !CQ@  5LL  $O0  ! U0
M-MP  "_E!P M[1  *^X8 "GN(@ G[RL )>\T "/P/  A\$4 '_%. !WR6 $;
M\F0!&?-Q 1CS@0$7])("%?2E A3UN@(3]=8"$_3O A+R_ (2\/\"$O#_ A+P
M_P(2\/\"FJ0  (VM  !_M@  <;\  &/'  !6S@  2=,  #W:   SWP  *N,
M ";T!0 D^PT (?P3 ![]&P <_2( &?XI !?^,0 5_SD $_]! !'_2@ 0_U4
M#O]A  S_;P$,_X !"O^3 0G_I@$(_[H!!__4 0?_ZP$&__8!!O_V 0;_]@$&
M__8!CZP  ("V  !ROP  8\D  %;1  !(V   .]T  ##B   FY@  '_   !S_
M   9_PD %O\. !3_$P 1_QD #_\>  W_)  +_RL "?\R  ;_.P #_T0  /]/
M  #_7   _VL  /]]  #_D   _Z,  /^T  #_Q@  _]8  /_6  #_U@  _]8
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M#\ Z_PZ_.O\.OSK_#K\Z_PZ_.O\._ST3 /]"#P#_1@T _TL0 /].%@#_3Q\
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MJ2UV7K@N=5[,+W1>Z2UU8/HG=F'_(W=B_R!W8O\>=V+_'G=B_QYW8O\>_U(
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M,&)KX2]D;/8J9FW_)F9M_R-G;O\@9V[_(&=N_R!G;O\@]ED  .!E  #.;P
MPG8  +E\  "Q?P  J8   *" !P"9@1< E($H 8Z -0.(?D$(@WQ*#7YZ4A%Z
M>%D5=G=@&7-V9QQP=&X?;7-V(VIR?R9G<8DI9'&5*V)PH2U@<+ O7G#"+UUP
MWR]?<?4J8''_)F%R_R-B<O\@8G+_(&)R_R!B<O\@[UP  -QI  #*<@  OGH
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M)%"#_R)0@_\?4(/_'U"#_Q]0@_\?WFD  ,EU  "\@   LH@  *B-  "=D0
MDY,  (66  !^EPL >9<9 '67* %QES4#;)8_!FB52 IDE% -89-7$5V27A5:
MD6885Y!N&U2/=QY1CH$@3HZ-(TN-FB5)C:DF2(V[)T>-U"='C/ D2(S_(DF+
M_R!*B_\>2HO_'DJ+_QY*B_\>U6X  ,-[  "WA0  K(T  **2  "7E@  C)D
M '^<  !UG@4 <)\3 &V?(P!IGS !99X[!&&>10==G4T*6IQ4#5>;7!%4FF,4
M49IK%TZ9=!E+F'\<2)B+'D67F2!#EZ@A0I>Z(D&7TR)!EN\@0I7^'D*5_QU#
ME/\<0Y3_'$.4_QQ#E/\<S'4  +R!  "QC   II(  )N7  "1FP  A9\  'FC
M  !JIP  9:<. &.H' !@J"L!7:@V EFG0 16ITD&4Z91"5"F60Q-I6 .2J5I
M$4>D<A1$I'T60J.)&#^CEQH]HZ<;/*.Y'#NCTAL[HN\;.Z#^&CN?_QD\G_\8
M/)__&#R?_Q@\G_\8Q'P  +:)  "JD@  GY<  )6<  ")H0  ?:8  '&J  !D
MK@  6K$( %>Q% !5LB, 4[(P 5"R.P)-LD0#2[%-!4BQ50=%L5T)0[%E"T"P
M;PT^L'H/.["'$3FOEA,WKZ84-J^X%#6PT10UKN\4-*W^%#2L_Q0TJ_\4-*O_
M%#2K_Q0TJ_\4NX4  *^0  "CEP  F)T  (RC  " J   =*T  &BR  !<M@
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M=P 0[HH #N^>  [PLP -\,T #._L  SM_  ,Z_\ #.O_  SK_P ,Z_\ EZ,
M (FK  ![M   ;;P  %_$  !2R@  1<X  #G3   OV   )=T  !WA   8[ (
M%O<+ !3W$0 1^!< $/@>  [Y)0 -^2T "_HU  G[/P '^TH !/Q7  /]9@ "
M_G<  /V+  #]GP  _+4  /S1  #\[0  _/P  /S]  #\_0  _/T BZL  'VT
M  !NO0  8,8  %+-  !$T@  -]@  "S=   BX0  &>4  !/J   0^@  #O\&
M  W_#  *_Q  !_\4  3_&@ !_R   /\G  #_,   _SH  /]%  #_4P  _V(
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M ^8<_P/E'/\#Y1O_ ^4;_P/E&_\#_RT; /\P%P#_,14 _S 6 /\Q( #_,"H
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M"ZTZ_PNM.O\+_SP- /] !@#_100 _TD) /]+#0#Y2A$ [4D: .-&)@#:1C8
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MKA^*3;P@B$W0((=-ZQ^&3_P;AE#_&(90_Q:&4/\4AE'_%(91_Q2&4?\4_T<
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M)6]:X25P6_8@<5S_''%=_QIQ7?\8<5W_%W%=_Q=Q7?\7_4\  .59  #38@
MQV@  +UL  "V;0  KVP  *=K"P"@;!D FVPJ 95K-P*0:4,%BVA,"8=F5 R#
M95L0@&-B$WUB:15Z87 8>&%X&G5@@1US7XL?<%Z6(FY>HB1L7K E:U[!)FE>
MWB9J7_0A:V#_'6MA_QML8?\9;&'_&&QA_QAL8?\8]5$  .)<  #/90  PVL
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M'UQM_QQ=;?\:76W_&5UM_QE=;?\9Z%H  -)F  ##;P  N'8  *][  "F?@
MG7X  )%\  "*? \ A7T> (%]+0%\?#D#=WI#!G-Y2PEP>%,,;'=:$&EV81-F
M=6@68W1O&&%S>!M><H(>6W*-(%EQFB)7<:@D57&Y)51QT"54<>XB5G'^'E=Q
M_QQ7<?\:6''_&5AQ_QE8<?\9XUX  ,UI  "_<P  M'H  *M_  "B@@  F(,
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M%T6%_Q=%A?\7S6T  +UX  "Q@@  IXH  )R.  "2D   AI,  'F5  !LEP
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M#@!+JQH 2JLG $BK,P!&JST!1*M& 4*K3@) JU8#/JM?!3NK: 8YJG,(-ZJ
M"32JCPLRJI\,,:JP##"JQPPPJ><,+Z?Z#2^F_PTOI?\-+Z7_#2^E_PTOI?\-
MMH0  *J.  ">E   E)D  (>>  ![HP  ;Z@  &.L  !7KP  2[(  $&U!@ ^
MMA$ /;8> #NV*0 ZMS0 .;<^ #>W1P VMU !-+=: 3*W9 (PMV\#+K=\!"RW
MBP4JMYP%*;>N!BBXQ04HM^8%)[7Y!R:S_P<FLO\()K+_"":R_P@FLO\(KXT
M **4  "7F@  BZ   'ZF  !QJP  9;   %FT  !-MP  0KL  #B^ 0 OP@D
M+<,2 "S#'@ KPRD *L0S "G$/0 HQ4< )\51 ";%7  EQF@ (\9V 2+&A@$@
MQI@!'\:K 1['P0$>QN0!'<3X AS"_P,<P?\#','_!!S!_P0<P?\$I90  )J:
M  ".H0  @:<  '.N  !GM   6KD  $Z]  !"P   .,,  "_'   FRP0 'M *
M !O1$0 :TAH &=(E !C3+P 8TSH %]1$ !;44  5U5T %-5K !/6?  2UX\
M$=BD !#9NP 0V=X $-7S !#3_P 0TO\!$-'_ 1#1_P$0T?\!G)H  )&A  "#
MJ   =;   &BW  !;O0  3L$  $+%   WR   +<P  "30   <U0  %=H% !#B
M"P 0XQ$ #N0:  [D(P -Y2T #.4W  OF0@ *YD\ ">==  CG;0 &YH  !>:5
M  3FJP "YL0  >;F  #G^0  Y_\  .;_  #F_P  YO\ DZ$  (6I  !WL0
M:;D  %O   !.Q@  0<H  #7.   JT@  (=8  !G;   2WP  #>,   OQ"  )
M\PX !_,3  3R&@ "\B(  /(J  #R-   \C\  /),  #R7   \FT  /*"  #R
MF   \ZT  //&  #TY0  ]/8  /3[  #T^P  ]/L AZD  'FR  !JN@  7,(
M $[)  ! S@  ,],  "C8   >W0  %>$   _D   *Z   !?,   /] 0  _ @
M /L-  #[$0  ^Q8  /P>  #\)@  _#   /T\  #^20  _EH  /YM  #_@@
M_Y@  /^L  #_P   _]@  /_D  #_Y   _^0 >[(  &R[  !=Q   3\T  $#2
M   RV0  )MX  !OB   2Y@  #.H   7M    ]    /\   #_    _P   /\$
M  #_"0  _PX  /\2  #_&   _R$  /\K  #_-P  _T8  /]8  #_:P  _X
M /^5  #_I@  _[,  /^[  #_NP  _[L _QLF /\<) #_&B0 _Q4G /\0+0#_
M"C8 _P5# /\!4 '_ %X!_P!K ?\ =@'_ ($ _P"* /\ D@#_ )H _P"@ /\
MI@#_ *P _P"R /\ N0#_ ,( _P#- /\ WP#_ .P _P#X /\ _P#] /\ _0#_
M /T _P#] /\ _0#_ /T _P#] /\ _Q\C /\?(0#_'B$ _QDC /\3*0#_#C(
M_PQ  /\)30'_!UH!_P1G ?\#<P'_ WT!_P.' ?\#CP#_ I8 _P*< /\"H@#_
M J@ _P*O /\!M@#_ ;X _P') /\!VP#_ .H _ #V /@ _P#W O\ ]P/_ /8$
M_P#V!/\ ]@7_ /8%_P#V!?\ _R(? /\B' #_(1P _QX? /\8) #_%2\ _Q(\
M /\020#_#E8!_PQB ?\+;@'_"WD!_PN" ?\+BP'_"Y(!_PJ9 ?\*GP#_"J4
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M M ;_P+0&_\"_RT2 /\N#P#_+@T _R\0 /\O%P#_+B$ _RPM /\I.0#Y)D8
M]"13 >\B7@'K(FD!Z"%S >8A? 'C(80!X2&, > ADP'>(9H!W"&A =HAJ0'8
M(;$"U2&\ M,BR0+0(M\"S"/P \@C_0/&)/\#Q"3_ \,D_P/")/\#P23_ \$D
M_P/!)/\#_S / /\R"P#_,P@ _S8- /\V$@#_-1H _3(E /0P,@#M+3\ YRQ,
M .(K6 '=*V,!V2IM =4J=@+2*G\"T"J& LXJC@/,*I4#RBJ< \DJHP3'*JP$
MQ2JV!,,JPP7"*M4%OBOK!;HK^0:X+/\&MBS_!;4L_P6T+/\%M"S_!;0L_P6T
M+/\%_S0, /\V!0#_.0, _SP( /\\#0#].Q, \3@= .@U*0#@-#< V3-& -$T
M4@'-,UT!R3-G L8S< /$,G@$P3* !+\RAP6^,H\&O#*6!KHQG@>X,:8'MS&P
M"+4RO BS,LP)L3+E":TS]0FK,_\)JC/_"*@S_P>H,_\'IS/_!Z<S_P>G,_\'
M_S<' /\Z  #_/@  ^D$! /%!!@#Q/PT YCP2 -LZ'P#0.S$ RCQ  ,0\30'
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M&(%(Y!B!2O<5@$K_$H!+_Q" 2_\/@$O_#H!+_PZ 2_\._T,  .Q+  #=4P
MSE@  ,1:  "]6@  N%<! +%4#@"J5AX I58N )]6.P&;548#EU10!9-36 B0
M4E\*C5%F#(M0;0Z(3W00AD]\$H1.A1."3HX5@$V9%WY-I!A\3;(9>DW#&GE-
MWQIX3O07>$__%'A/_Q)X4/\0>%#_#WA0_P]X4/\/_48  .=/  #65P  R%P
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M%V9;_Q5F7/\39US_$F=<_Q)G7/\2[4X  -I9  #(80  O&<  +-J  "K;
MHFH  )EG @"29Q$ C6<A (AG+P&$9CL"?V5$!'MD309X8U0)=6);"W)A80UP
M86D/;6!P$FM?>11I7X,79EZ.&61>FAMB7J@<85ZX'5]>SAU?7NP;8%_]&&%?
M_Q5A7_\38E__$F)?_Q)B7_\2ZE$  -1<  #$9   N6H  +!N  "G<   GFX
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M$U)L_Q-2;/\3W%P  ,=G  "Y;P  KW8  *5[  "<?   D7P  ()X  !Z>0<
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MC0\\C9P0.HVL$3F-P1$XC>$0.(OV$#B*_P\YB?\/.8G_#CF)_PXYB?\.OW(
M +)]  "GA@  G(H  )&.  "&D0  >I,  &V5  !?EP  5)D! $^9#P!.FAH
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M B*RNP(ALML"(:_S R"N_P,@K?\$'ZS_!!^L_P0?K/\$JHL  )V1  "3EP
MAYP  'JB  !MIP  8*L  %6O  !)L0  /K0  #.W   JN@, )+P- "*]%0 A
MO2  (;TJ ""],P ?OCT 'KY' !V^4@ <OUX &K]L !F_?  8OXX %\"A !;
MM@ 4P-, %;[Q !6\_P$5N_\!%+K_ A2Z_P(4NO\"H9(  ):8  "*G@  ?:0
M &^J  !BKP  5K0  $JW   ^N@  ,[T  "K    AQ   &<<% !/+"P 1S!(
M$<P; !#,)0 /S2\ #LTZ  [-1@ -S5( #<Y@  S.<  +SH, "LZ7  G.K  (
MSL8 ",[H  C-^P )R_\ "<O_  G+_P )R_\ F)@  (V>  !_I0  <:P  &2S
M  !7N0  2KT  #[    RPP  *,8  !_*   7S0  $=$   S6!0 (V0P !MD2
M  7:&P $VB0  ]LN  ';.0  W$4  -U2  #>8@  WG,  -Z(  #?G0  W[,
M -_.  #@[@  W_H  -__  #?_P  W_\ CY\  (&F  !SK@  9;4  %B]  !*
MP@  /<4  #')   FS   '=   !34   .V0  "=T   /A    XP<  .,-  #D
M$@  Y1D  .8B  #G*P  Z38  .M#  #L4@  [&(  .UV  #NC   [J$  .^W
M  #OT0  [^L  /#V  #P]@  \/8 A*<  '6O  !GMP  6;\  $O&   \R@
M+\X  "32   :V   $MP   S@   %XP   .<   #K    ZP   .T%  #N"P
M\!   /$5  #S'@  ]"<  /<S  #Y0   ^E$  /MC  #\=P  _8T  /VC  #^
MM@  _LD  /_?  #_WP  _]\ =[   &BY  !:P0  3,H  #S/   NU   (MH
M !?>   0X@  ">8   #I    [    /    #V    ]@   /<   #X    ^@<
M /L-  #]$0  _QD  /\C  #_+P  _SX  /]/  #_8@  _W<  /^-  #_GP
M_ZX  /^Z  #_N@  _[H _Q8C /\5(0#_$B$ _PXD /\&*@#_ #, _P!! /\
M3@#_ %P _P!H /\ = #_ 'X _P"' /\ CP#_ )8 _P"< /\ H@#_ *@ _P"N
M /\ M0#_ +T _P#' /\ U@#_ .< _@#S /X _@#] /\ _ #_ /L _P#[ /\
M^P#_ /L _P#[ /\ _QH@ /\9'@#_%AX _Q @ /\*)0#_!#  _P ] /\ 2P#_
M %@ _P!D /\ < #_ 'H _P"# /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J /\
ML0#] +D ^P## /H T #X ., ]P#Q /8 _ #T /\ ] #_ /, _P#S /\ \P#_
M /, _P#S /\ _QT< /\<&0#_&1D _Q0; /\.(0#_#"P _PDY /\%1@#_ E,
M_P!? /\ :P#_ '4 _P!^ /\ A@#_ (X _P"4 /X FP#\ *$ ^@"G /@ K@#U
M +4 \P"_ /$ RP#P -\ [@#N .P ^0#K /\ Z@#_ .H!_P#I ?\ Z0'_ .D!
M_P#I ?\ _R 7 /\?% #_'!, _Q<5 /\6'0#_$R@ _Q T /\-00#_#$X _PE:
M /\(9@#_"'  _@=Y /P'@0#Z!XD ^ >0 /8&E@#S!IT \0:C .\&J@#M!K(
MZ@:[ .C_XO__24-#7U!23T9)3$4 " D&R #F!MP Y ;L .((^@#@"O\ W@O_
M -T+_P#=#/\ W S_ -P,_P#<#/\ _R,2 /\C$ #_(0X _QX0 /\>& #_'",
M_Q@O /\4.P#_$DD _!!5 /@/8 #T#VH \0]T .\.? #M#H0 ZPZ+ .D.D@#G
M#ID Y@Z@ .0.IP#B#J\ X ZX -X.Q0#<#MH UA#L -(1^@#/$O\ S1+_ <P2
M_P'+$_\!RA/_ <H2_P'*$O\!_R</ /\G# #_)0D _R8- /\E$P#_(QP _R H
M /L<-0#U&D( [QA/ .H76@#F%F4 XQ9N . 6=P#>%G\ W!:' -D6C@#6%I4
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M!*(L_P2B+/\$_S(  /\S  #Y.   Z3D  .(Y  #>-0< WBX- -$O&P#),2P
MPS,[ +TS2 "Y-%,!MC-< ;,S90*P,VT"KC-T ZPR>P.K,H,$J3**!*<RDP6E
M,IL&I#*E!J(RL >@,KX'GS+1!YPSZ@>:,_L'F#3_!Y<T_P:6-/\&EC3_!98T
M_P66-/\%_S4  /\X  #J/@  WT(  -5"  #//P, S3@( ,4X%0"].B8 MSLV
M +(\0P"N/$X!JCM7 J<[8 .E.F<#HSIO!*$Z=@6?.7T&G3F%!YLYC0>9.)8(
MF#B@"98XJPJ4.+@*DSG*"Y$YY0N/.O<*C3K_"8P[_PB,._\'C#O_!XP[_P>,
M._\'_S@  /$^  #C10  U$D  ,M*  #%1P  P4$$ +H_$0"S02$ K4(Q *A#
M/@"D0TD!H$)3 IU!6P.;06($F$!J!99 <0:4/W@'DC]_") _B J//I$+C3Z;
M#(L^I@V)/K,-B#[$#H8_X Z$/_0-@T#_"X- _PJ"0/\)@D'_"()!_PB"0?\(
M_SP  .M#  #<2@  S$\  ,-0  "\3@  MTD! +%&#@"J2!P I$DL *!).@";
M244!F$A. I1'5P.21UX%CT9E!HU&; >+17,)B45["H=$@PN%1(T,@T27#H%#
MH@]_0Z\0?D/ $'Q$VA%[1/$/>D7_#7I&_PMZ1O\*>D;_"7I&_PEZ1O\)]3X
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M%691RQ5E4ND495+[$693_P]F4_\-9E/_#&93_PQF4_\,ZDD  -53  #%6@
MNE\  +!B  "H8@  GU\  )9:  "/6A  BEL> (5;+ "!6S@!?5M! GI:2@-W
M65$$=%A8!G%87P=O5V8);5=M"VM6=@UI5G\/9U6*$655EQ-C5:04856T%6!5
MR!9?5><58%;Z$F!6_P]A5_\.85?_#6%7_PQA5_\,YTP  -%6  #!7@  MF,
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M$E%B_Q!28O\.4F+_#5)B_PU28O\-V58  ,1@  "W:   K&X  *-Q  ":<P
MCW$  ']K  !X:P4 <FL2 &YL'P!K;"P :&PW 69L0 )C:T@#8&M/!%YJ5@9<
M:ET'66EE"5=I;0M5:7<-4VB"#U!HCQ%.9YT336>L%$MHP!1+:-X42V?U$DQG
M_P],9_\.36?_#4UG_PU-9_\-TEH  ,!D  "S;   J7(  *!V  "6=P  BG8
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M"SIZ_PLZ>O\+P&D  +)T  "G?   G8$  )*$  "'A@  >X<  &Z'  !@AP
M58<! %"(#@!.B!H 38DF $N), !)B3H 2(E" 4:)2@%$B5("0HE: T"(8P0]
MB&T%.XAX!CF'A@@WAY4)-8>F"C2'N0HSA],*,X;P"3.%_PDSA/\),X/_"3.#
M_PDS@_\)N7   *UZ  "B@@  EX<  (V*  "!C   =8X  &B/  !:D   3Y$
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M>0 =JXL &ZN= !JKL0 9J\H &:KL 1FH_0$8I_\"&*;_ ABF_P(8IO\"I8D
M )F/  "/E   @YD  '6>  !HH@  7*8  %"I  !$K   .:X  "^P   FLP
M'K4& !FW#P 8MQ< %[<A !:W*@ 5MS0 %+@^ !.X20 2N%0 $KEB !&Y<0 0
MN8, #[F7  ZYK  -N<0 #;CG  ZV^P .M?\ #K3_  ZT_P .M/\ G)   )*5
M  "&FP  >:   &NF  !>JP  4J\  $:R   ZM0  +[<  "6Z   =O0  %<
M !##!@ +Q@X "L45  G%'@ (Q2@ !\4R  ;&/0 %QDD !<97  /&9@ "QG<
M <:+  #&H   Q;8  ,;2  #%[P  Q?P  ,7_  #%_P  Q?\ E98  (F<  ![
MHP  ;:D  &"O  !3M   1K@  #J[   NO@  ),$  !O$   3QP  #LH   C.
M 0 !T H  - 0  #0%@  T1X  -(G  #3,0  U#P  -5)  #66   UFD  -9\
M  #6D@  UJ<  -:_  #6X   UO,  -;^  #6_P  UO\ C)T  'ZD  !OJP
M8;(  %2Y  !&O0  .<$  "W$   BQP  &<L  !'.   ,T@  !=4   #;
MW ,  -T*  #>#P  WQ0  .$<  #B)   Y"X  .8Z  #G20  Z%D  .AK  #I
M@0  Z9@  .FM  #IQ0  Z>(  .GR  #I]0  Z?4 @*4  '&M  !CM0  5;P
M $?"   YQ@  +,H  "#.   6T@  #]8   C;    WP   .,   #E    YP
M .@!  #J!P  ZPT  .T1  #O&   \2$  /,K  #V.   ]T@  /A:  #Y;0
M^H0  /J;  #ZKP  ^L(  /K:  #ZWP  ^M\ =*X  &6V  !6O@  2,8  #G+
M   KT   ']0  !3:   -WP  !>,   #F    Z0   .T   #O    \0   /,
M  #U    ]@(  /@)  #Z#@  _1,  /\<  #_*   _S8  /]'  #_6@  _VX
M /^%  #_F@  _ZL  /^Y  #_O   _[P _Q$@ /\0'@#_#!X _P0A /\ )P#_
M #  _P ^ /\ 3 #_ %D _P!E /\ < #_ 'H _P"# /\ BP#_ )( _P"8 /\
MG@#_ *0 _P"J /\ L #_ +@ _P#" /\ S@#_ .( _@#P /T ^P#[ /\ ^P#_
M /L _P#Z /\ ^@#_ /H _P#Z /\ _Q0< /\2&@#_#AH _P@< /\ (0#_ "T
M_P Z /\ 2 #_ %4 _P!A /\ ; #_ '8 _P!_ /\ AP#_ (X _P"4 /\ F@#^
M *  _0"F /P K #[ +0 ^0"] /@ R0#W -P ]0#L /, ^ #S /\ \@#_ /$
M_P#P /\ \ #_ /  _P#P /\ _Q<8 /\5%@#_$14 _PP7 /\%'0#_ "@ _P V
M /\ 0P#_ %  _P!< /\ 9P#_ '$ _P!Z /P @@#Z (D ^ "0 /< E@#U )P
M] "B /, J #Q +  \ "X .X PP#L -, Z@#G .D ]0#G /\ Y@#_ .4 _P#E
M /\ Y0#_ .4 _P#E /\ _QH3 /\8$0#_%!  _P\1 /\-&0#_"B0 _P4P /\!
M/@#_ $L _P!7 /X 8@#Z &P ]0!U /( ?0#P (0 [@"+ .P D0#K )< Z0">
M .< I #F *P Y "T .( OP#@ ,T W@#C -P \@#: /T V #_ -8 _P#5 ?\
MU0'_ -4"_P#5 O\ _QX0 /\<#0#_%PL _Q4. /\4%0#_$1\ _PXJ /\+. #]
M"$4 ^ 91 /0$7 #N!&8 Z@1O .8#=P#D!'\ X@2& . $C #>!), W06: -L%
MH #8!:@ U06Q -(%NP#0!LD S@?@ ,P(\0#)"O\ QPO_ ,8,_P#%#/\ Q0S_
M ,4,_P#%#/\ _R$, /\@!@#_' , _QT* /\;$ #_&!@ _Q0C /81, #O#CX
MZ@Y* .4-5@#A#6  W0UI -D-<0#5#7D TPV! -$-B #/#8\ S0Z6 ,L.G0#*
M#J4 R ZN ,8/N0#$$,@ PA#? +X1\@"[$O\ N1/_ +<3_P&V$_\!MA/_ ;83
M_P&V$_\!_R4& /\C  #_(P  _R0# /\A"@#]'1$ \1H; .@6)P#A%#4 VA-#
M -,43P#.%5D RQ5C ,@6:P#%%G, PQ=[ ,$7@@# &(D OAB0 +P8F "[&:
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MJ@.:*[8#F2S' Y<LX@.4+?4$DBW_ Y$M_P.0+O\#D"W_ Y M_P.0+?\#_S
M /(S  #D.@  UCT  ,P\  #'.0  PS$% +TN$0"U,"$ L#(P *LS/0"G,TD
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M"G<_S0IU/^H*=$#\"'1 _P=T0/\&<T#_!G- _P9S0/\&\3L  -]%  #,3
MOT\  +90  "N3P  ITH  *!$!P":110 E48B )!&, ",1SP B49% 89&3@&#
M1E4"@45< WY%8P1\1&H$>D1Q!7E$>09W1(((=4.-"7-#F0IQ0Z8+<$.U#&Y$
MR0QM1.<,;47Z"FQ%_PAL1?\';$7_!VQ%_P=L1?\'[#\  -A)  #'4   NU0
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M#%I2_PI;4O\)6U'_"%M1_PA;4?\(WTH  ,E3  "[6@  L%\  *9A  "=80
ME%X  (A7  " 5@H >E<5 '97(@!S6"X <%<Y &U700%J5TD":%90 F965P-D
M5EX$8E5E!6!5;0=>57<(7%6""EI5C@Q959P-5U6K#E95O@]55=L/557S#555
M_PM65?\)5E7_"595_PA65?\(VTT  ,57  "X7@  K6(  *-E  ":90  D&,
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M"4=B_PA'8O\(RE@  +IB  "N:0  HVX  )IQ  "0<@  A'$  '1K  !I:0
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M?P,Q@8X$,(&?!"Z!L04M@<@%+8'I!"U__ 4M?O\%+7W_!2U]_P4M??\%LVX
M *AX  "=?P  DH,  (B&  !]AP  <(@  &.)  !5B@  2XH  $&* @ [BPX
M.8L7 #B,(@ WC"P -HPU #2,/0 SC$8 ,HU/ #&-6  OC6(!+8QN 2N,>P$J
MC(L"*(R< B:,KP(EC,8")8OH B6*^P,EB/\#)8C_ R6'_P,EA_\#K78  *.
M  "7A0  C8D  (*,  !VC@  :9   %R2  !0DP  1)0  #J5   QE@@ +9<1
M "R7&@ KER0 *I<M "F7-@ HF#\ )YA( ":84@ EF%P (YAH "*8=P @F(<
M'YB9 1V8K $<F,,!')?E 1R5^@$;E/\!&Y/_ AN3_P(;D_\"IW\  )R&  "1
MBP  AX\  'J2  !ME0  89@  %6;  !)G0  /9X  #.?   JH0  (:,* !^C
M$0 >HQH ':0D !RD+0 ;I#8 &J0_ !FD2@ 8I%4 %J5A !6E<  4I8$ $Z64
M !*EJ  1I;\ $*3B !&B^  1H?\ $:#_ 1&@_P$1H/\!H(8  )6,  ",D0
M?Y4  '&:  !DG@  6*$  $RD  ! I@  -:<  "JI   BK   &:X  !*P"0 0
ML1  $+$8  ZQ(@ .L2L #;$U  VQ0  ,L4L "[%8  JQ9P (L7@ ![&+  6Q
MH  $L+4 !+#0  2P[P %K_X !J[_  :N_P &KO\ F(X  (^3  ""F   =9T
M &>B  !:IP  3JL  $&M   UKP  *[$  "&T   8M@  $;D   V\ P 'O@P
M [T2  &]&0  OB(  +XK  "^-@  OD$  +].  "_7   OVT  +^   "^E0
MOJH  +["  "]Y   O?8  +W_  "]_P  O?\ DI0  (6:  !XH   :J8  %RK
M  !/L   0K,  #6V   JN   (+L  !>^   0P0  "\0   3'    R0<  ,D-
M  #)$@  RAD  ,LB  #+*P  S34  ,Y!  #.4   SV   ,]R  #/AP  SYT
M ,^S  #/S@  S^L  ,[X  #._@  SOX B)L  'JB  !LJ   7J\  %"U  !"
MN0  -;P  "F_   >P@  %<8   [)   (S    -    #3    U0   -8&  #8
M#   V1$  -L6  #<'P  WB@  . T  #B00  XE$  .-C  #C=P  Y(X  .2D
M  #DN@  Y=0  .7J  #E\P  Y?, ?*,  &ZJ  !@L@  4;D  $.^   UP@
M*,8  !S)   3S0  #-$   35    V@   -X   #A    X@   .0   #E P
MYPD  .D.  #K$@  [1H  .\D  #R,0  ]$$  /13  #U9@  ]7P  /:3  #V
MJ0  ][P  /?.  #WWP  ]]\ <*P  &&T  !3NP  1<,  #;'   GS   &]
M !'5   *VP   -\   #B    Y0   .D   #L    [0   /    #Q    \P
M /4$  #W"@  ^A   /P6  #_(0  _RX  /]   #_4P  _V@  /^   #_E@
M_Z@  /^V  #_OP  _[\ _PT< /\*&P#_ AL _P > /\ ) #_ "X _P \ /\
M2@#_ %8 _P!C /\ ;0#_ '< _P!_ /\ AP#_ (X _P"4 /\ F@#_ *  _P"F
M /\ K #_ +0 _P"] /\ R0#^ -T _0#M /P ^@#[ /\ ^@#_ /D _P#Z /\
M^@#_ /H _P#Z /\ _Q 9 /\-%P#_!A8 _P 8 /\ '@#_ "H _P W /\ 10#_
M %( _P!> /\ :0#_ '( _P![ /\ @@#_ (D _P"0 /X E@#] )P _ "A /L
MJ #Y *\ ^ "X /8 PP#T -( \P#G /( ]@#P /\ [P#_ /  _P#O /\ [P#_
M .X _P#N /\ _Q(4 /\/$@#_"Q( _P 2 /\ &@#_ "4 _P S /\ 0 #_ $T
M_P!9 /\ 9 #] &T ^P!V /D ?0#W (0 ]0"+ /0 D0#S )< \0"= /  HP#N
M *H [ "S .H O0#H ,L YP#A .4 \0#C /T XP#_ .( _P#A /\ X0#_ .
M_P#@ /\ _Q00 /\1#@#_#0T _P</ /\"%0#_ "  _P M /\ .@#_ $< ^0!3
M /4 7@#R &@ \ !P .T > #K '\ Z0"% .@ C #F )( Y0"8 ., GP#A *8
MWP"N -P N #: ,4 U@#9 -0 [ #2 /D T0#_ ,\ _P#. /\ S@#_ ,X _P#.
M /\ _Q<, /\4" #_#P4 _PX+ /\,$0#_!QH _P$F /P - #T $$ [0!- .D
M6 #F &( XP!J .  <@#> 'D VP"  -D A@#6 (T TP"3 -$ F@#/ *$ S0"J
M ,L LP#) +\ Q@#0 ,4 Z ## /8 P0#_ , "_P"_ _\ OP/_ +\#_P"_ _\
M_QL& /\7  #_%   _Q,% /\1#0#_#A0 ^0H? / &+ #F SD X -& -P#40#6
M!%L T@1D ,\%; #,!7, R@5Z ,@%@0#&!8< Q0:. ,,&E@#!!IT OP:F +T&
ML "[![P N0C- +@*Y0"U"_< LPW_ +$-_P"P#?\ L [_ *\._P"O#O\ _QX
M /\;  #_&P  ^AH  /46!0#V$0T ZPX5 .(+(@#8"S$ T P^ ,L-2@#'#54
MQ Y> ,$.9@"_#FT O0YT +L/>P"Y#X( MQ"* +80D0"T$)H LA"C + 1K0"O
M$;H K1'* *H2Y0"G%/< I17_ *,5_P"B%?\ HA7_ *(5_P"B%?\ _R(  /\@
M  #P(P  YB0  . A  #<&04 VQ , - 1&0#($RD PA4W +T61 "Y%TX M1=7
M +,88 "P&&< KAAN *P9=0"K&7P J1F$ *@:C "F&I0 I!J> *,;J "A&[0
MGQS% )X<WP":'?,!F![_ 9<>_P&6'_\!E1__ 94?_P&5'_\!_R8  /0G  #F
M+0  VB\  ,\M  #*)P  QQ\( ,$<$P"Z'B( M!\Q *\@/0"K(4@ J")2 *8B
M6@"C(V( H2-I * C;P">(W< G"-^ )LCA@"9)(\!ER29 98DHP&4)+ !DB6_
M 9$EU@&.)N\!C"?_ HLG_P**)_\"B2?_ HDG_P&))_\!^BD  .PP  #=-@
MS3@  ,0W  "^,@  NBL" +4E#@"N)QT J"DK *0J. "@*D, G2M, )HK50"8
M*UP EBMC )0K:@&2*W$!D"QX 8\L@0&-+(H!BRR4 HHLGP*(+*L"ABRZ H4M
MS@.#+NH#@2[\ X N_P)_+O\"?R[_ GXN_P)^+O\"]"X  .0W  #2/0  Q3\
M +L_  "T/   KS4  *DO"P"C+Q< GC$F )DR,P"6,CX DC-( ) S4 "-,U@
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M!F9 _P5F0/\$9D#_!&8__P1F/_\$Y3T  ,]&  "_3   M$\  *I0  "B3P
MF4H  )%$  "*00T A$(9 (!#)@!]1#( >D0\ '=$1 !U1$P!<D13 7!#60%O
M0V ";4-G FM#;P-I0WD$:$.#!69#CP9D0YT'8T.K!V%#O0A@1-D(8$3S!V!$
M_P9?1/\%7T3_!&!$_P1@1/\$X$$  ,I*  "[4   L%,  *=5  ">4P  E4\
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M!5!0_P504/\%T$L  +]4  "R6@  IUX  )U@  "48   B5T  'Q7  !R5
M;%,. &A4&0!E5"0 8E0O &!4. !>5$  7%1( 5I43P%95%8!5U1= E5490-4
M5&X$4E1Y!5!4A@9.5)0'352D"$M4M0A+5,P)2E3K"$M4_@=+5/\&2U3_!4M4
M_P5+5/\%S$X  +M7  "N7@  I&(  )ID  "19   AF(  '=;  !M6   9E@,
M &)8%@!?6"( 75DL %M9-@!963X 5UE& %9930%4650!4EE; E%98P-/66P#
M35EW!$M8A 5)6)('2%BB!T=9LPA&6<H(15GJ"$99_09&6/\&1EC_!4=8_P5'
M6/\%QU(  +A;  "K80  H68  )AH  ".:0  @V<  ')@  !H7@  85T) %Q=
M$P!:71X 5UTI %9>,P!47CL 4EY# %%>2@%/7E(!3EY9 DQ>80)*7FH#2%YU
M!$9>@@5$79 &0UZ@!T%>L0= 7L@'0%[H!T!=_ 9!7?\%05W_!4%<_P5!7/\%
MPU8  +1?  "H9@  GFH  )5M  "*;0  ?VP  &]G  !D9   6V(% %9B$ !4
M8AL 4F,E %!C+P!.9#@ 361  $MD2 !*9$\!2&17 49D7P)%9&@"0V1S T%C
M?P0_8XX%/6.>!CQCL 8[9,8&.V3F!CMC^@4[8O\%.V+_!3QA_P0\8?\$OEL
M +!C  "E:@  FV\  )%R  "&<@  >W$  &QM  !@:P  56D  $]H#0!-:1<
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M BA[J@(G>[\")GOA B9Z]P(F>/\")GC_ B=W_P(G=_\"KFP  *-V  "9?
MCG\  (2"  !X@P  ;(0  %^$  !1A   1X0  #R$   SA D ,(01 "^$&@ M
MA"0 +(4M "N%-0 JA3X *85' "B&4  GAEH )H9F "2&<P CAH, (8:5 ""&
MIP$>AKP!'H;> !Z$]0$>@O\!'H+_ 1Z!_P$>@?\!J'0  )Y]  "3@@  B84
M 'Z(  !QB@  98L  %B,  !,C0  0(X  #:.   LCP  )9 , ".0$P BD!P
M(9 E ""1+@ ?D38 'I%  !V120 <D50 &I%@ !F1;@ 8D7X %I*0 !62I  4
MD;D $Y'8 !./]  4CO\ %(W_ !2,_P$4C/\!HWT  )B#  ".B   A(P  '>/
M  !ID0  79,  %"5  !%EP  .9@  "Z9   EF@  '9L" !:=#  5G1, %)T;
M !.=)  2G2T $9XW !&>00 0GDP #YY8  Z>9P -GG< #)Z*  N=G@ *G;(
M"9W,  F<[  *F_X "YK_  N9_P +F?\ G(0  )&*  "(C@  >Y(  &V6  !@
MF0  5)P  $B?   \H   ,*$  ":C   =I0  %:<  !"I!0 +JPT "*H3  >J
M&P &JB0 !:HN  2J.  "JD0  :I0  "J7@  JFX  *J!  "JE0  J:H  *G!
M  "HY   J/8  *?_  "G_P  I_\ E8L  (R0  !_E0  <9H  &.>  !6H@
M2J8  #VH   QJ@  )JL  !VM   4L   #K(   FU 0 "M@H  +8/  "V%0
MMQT  +<E  "W+P  N#D  +A&  "X5   N&0  +AV  "XBP  MZ   +>V  "W
MTP  MN\  +;\  "V_P  MO\ CY(  (*7  !TG0  9J(  %BG  !+K   /J\
M #&Q   FLP  '+8  !.X   -NP  !KX   #!    P@0  ,(+  ##$   Q!4
M ,0<  #%)   QBX  ,@Z  #)1P  R5<  ,EI  #)?0  R90  ,BJ  #(PP
MR.0  ,CT  #(_0  R/T A9D  '>?  !HI@  6JL  $VQ   _M0  ,;@  "6Z
M   :O0  $<    O#   #QP   ,H   #-    S@   ,\#  #0"0  T0X  -,2
M  #5&0  UR(  -HM  #=.0  WDD  -Y:  #?;@  WX4  -^<  #?L@  WLL
M -[F  #?]   W_0 >:$  &NH  !<KP  3K4  $"[   QO@  ),$  !G%   0
MR   "<P   #/    TP   -D   #<    W0   -\   #A    X@4  .0+  #F
M$   Z!8  .H@  #M*P  \#H  /%+  #Q7@  \G,  /.+  #SH@  \[8  //)
M  #SX0  \^$ ;:H  %ZQ  !0N0  0;\  #+$   DR   %\P   [0   &U0
M -H   #>    X@   .8   #I    Z@   .P   #N    \    /(   #T!@
M]@P  /D2  #\'   _RD  /\Z  #_30  _V(  /]X  #_D   _Z,  /^S  #_
MP0  _\$ _P<9 /\!%P#_ !< _P : /\ (0#_ "L _P Y /\ 1P#_ %0 _P!?
M /\ :@#_ ', _P![ /\ @P#_ (H _P"0 /\ E@#_ )L _P"A /\ J #_ *\
M_P"X /\ Q #^ -4 _ #J /L ^ #Z /\ ^0#_ /@ _P#X /\ ]@#_ /, _P#Q
M /\ _PL5 /\%$P#_ !, _P 4 /\ &@#_ "< _P T /\ 0@#_ $\ _P!; /\
M90#_ &X _P!V /\ ?@#_ (4 _@"+ /T D0#[ )< ^@"= /@ HP#W *L ]@"S
M /0 O@#S ,P \0#C .\ \P#N /\ [0#_ .P _P#K /\ [ #_ .P _P#K /\
M_PT1 /\)$ #_  \ _P 0 /\ %@#_ "( _P O /\ /0#_ $H _P!5 /T 8 #Z
M &D ^ !Q /8 >0#T '\ \P"& /$ C #O )( [@"8 .P GP#K *8 Z0"N .<
MN #E ,4 XP#: .$ [0#? /L W@#_ -T _P#= /\ W0#_ -T _P#= /\ _P\-
M /\,"P#_ PD _P , /\ $@#_ !T _P I /L -P#X $0 ]0!0 /( 6@#N &,
M[ !K .D <P#G 'H Y0"  ., A@#A (P WP"3 -T F0#; *$ V0"I -4 L@#2
M +X T #. ,X Y@#, /8 R@#_ ,H _P#) /\ R #_ ,@ _P#( /\ _Q$( /\-
M @#_!P  _P4( /\ #@#_ !8 ]P B .\ , #K #T Z !) .0 5 #@ %T W0!E
M -D ;0#5 ', T@!Z -  @ #. (< S "- ,H E #( )L Q@"D ,0 K0#" +@
MP #' +T WP"\ /$ NP#^ +D _P"X /\ N #_ +@ _P"X /\ _Q0  /\/  #_
M#0  _PP  /\'"0#X 1  Z  : ., * #= #8 V !" -( 30#. %< R@!? ,<
M9@#% &T PP!T ,$ >@"_ ($ O0"( +L CP"Y )< MP"? +4 J "S +, L0#"
M *\ V "N NT K /[ *L%_P"J!O\ J0;_ *D&_P"I!O\ _Q8  /\2  #W$@
M[!$  .8.  #E!@@ W0,2 -0#( #-!"T R 0Z ,,%1@"_!5  O 98 +D&8 "W
M!V< M0=N +,'=0"Q"'L KPB" *X)B@"L"9( J@F; *@*I0"F"K  I0N_ *,,
MU "A#>T GP[^ )T._P"<#_\ FP__ )L/_P";#_\ _QH  /<9  #J'@  WQX
M -4:  #0$P( S@P+ ,<+%@# #24 N@XR +8./P"R#TD KQ!2 *P06@"J$&$
MJ!%H *81;P"D$78 HA%] *$1A0"?$HX G1*7 )P2H@":$ZT F!.\ )<4T "4
M%>P DA;] ) 7_P"/%_\ CA?_ (X7_P".%_\ ^AT  .XC  #?*   T"H  ,<G
M  #!(0  O1D% +D2$ "R%1X K18L *@7. "D&$, H1E, )\95 "<&EP FAIB
M )D::0"7&W  E1MW )0;?P"2'(@ D!R2 (\<G0"-':D BQVW (H>R@"('^<
MAB#Z (0@_P&#(/\!@R#_ 8(@_P&"(/\!]20  .4L  #3,0  QC,  +PQ  "V
M+0  L"4  *P=# "F'A@ H2 F )PA,@"9(CT E2)' ),C3P"1(U8 CR-= (TD
M9 "+)&L B21R (@D>@"&)(, A"6- (,EF &!):0!@":R 7XFQ0%])^(!>R?W
M 7DH_P%X*/\!>"C_ 7@H_P%X*/\![RL  -TS  #*.0  OCL  +0Z  "M-@
MIB\  *$H!P";)Q, EB@@ )$I+0".*C@ BRM" (@K2@"&*U( A"M8 ((L7P"
M+&8 ?RQM 'TL=0![+'X!>BR( 7@LE %V+: !=2VN G0MP )R+MT"<2[T G O
M_P)O+_\";R__ 6XO_P%N+_\!Z#$  -,Z  ##/P  MT$  *Y!  "F/@  GC@
M )<Q 0"1+A  C"\< (@P* "$,3, @3(] '\R1@!],DT >S)4 'DR6P!W,F$
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M ED__P)9/O\"UC\  ,-'  "U3   JE   *!0  "73P  CDL  (1%  !Z0 8
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M?P))3XT#1T^=!$9/K@1%3\,$1%#D!$1/^01%3_\#14__ T5._P-%3O\#Q$P
M +55  "I6P  GUX  )5@  "+8   @%X  ')7  !G4P  7E$' %E1$0!741L
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M C9>J0,U7KT#-%_= S1>]0,U7?\"-5W_ C5<_P(U7/\"N%D  *IA  "@9P
MEFP  (QN  "!;@  =FP  &=I  !<9@  460  $AB"0!$8A$ 0F(; $%C)  _
M8RT /F,U #UD/0 \9$4 .V1- #ED50 X9%\ -F1I 35D=@$S9(4!,665 C!E
MIP(O9;L"+F7: BYD] (N8_\"+V/_ B]B_P(O8O\"LUX  *=F  "<;0  DW$
M (AS  !]<P  <G(  &1P  !8;@  36P  $)J P \:0X .FH6 #EJ(  X:B@
M-FLQ #5K.0 T:T$ ,VQ) #)L4@ Q;%P +VQF "YL<P L;((!*FR3 2ELI0$H
M;+D!)VW6 2=K\@$G:O\!)VK_ 2AI_P(H:?\"KF0  *-L  "9<P  CG8  (1X
M  !Y>0  ;7@  &!W  !3=@  2'4  #YS   T<@H ,7,1 #!S&@ O<R, +G,K
M "UT-  L=#P *W1$ "ET30 H=5< )W5C "5U;P D=7\ (G60 "%UH@ @=;<
M'W72 !]T\0 ?<_\!'W+_ 2!Q_P$@<?\!J6L  )YS  "4>0  BGP  (!^  !T
M?P  9W\  %I_  !-?@  0WX  #A]   O?0( *'T- "9]%  D?1P (WXE ")^
M+0 A?C8 (7X_ !]_2  >?U( '7]> !Q_:P :?WH &7^, !=_GP 6?[, %7_.
M !5^[P 6?/\ %GO_ !9[_P 7>_\ I'(  )IZ  "/?P  A8(  'N$  !MA@
M8(<  %2'  !(B   /(@  #*(   HB   ((@% !J)#@ 9B14 &(D= !>*)@ 6
MBBX %8HW !2*00 3BDP $HM8 !&+90 0BW4 #XN'  Z*FP -BJ\ #(K(  R)
MZ@ -A_P #H?_  Z&_P .AO\ GWL  )2!  "*A0  @(@  '.+  !EC0  68\
M $R0  !!D@  -)(  "J2   ADP  &90  !*6!@ .EPX #9<5  R7'0 ,ER8
M"Y<O  J7.0 )ET0 ")=0  :77@ %EVX  Y:   &6E   E:@  )6^  "4X
ME/0  )/_  &2_P !DO\ F((  (Z(  "%C   =X\  &J2  !=E0  4)@  $2:
M   XFP  +)P  "*=   9G@  $J    VB @ 'HPL  :,0  "C%P  HQ\  *,G
M  "C,0  I#P  *1(  "D5@  I&4  *-W  "CBP  HZ   **V  "AT@  H?
M *#[  "@_P  H/\ D8H  (F.  ![D@  ;9<  &";  !3G@  1J$  #FC   M
MI   (Z8  !FH   1J@  #*P   6N    KP<  *\-  "O$0  L!@  + @  "Q
M*   L3(  +(^  "R3   LEL  +)L  "R@0  L9<  +&L  "PQ@  L.@  *_W
M  "O_P  K_\ C)   '^5  !QF@  8Y\  %6D  !'J   .JH  "VL   BK@
M&+   !"S   *M0   K@   "[    NP   +P'  "\#0  O1$  +X6  "_'@
MP"<  ,$R  #"0   PT\  ,-@  ##=   PXL  ,.A  ##N   PM<  ,+O  #"
M^@  P?X @9<  '.=  !EHP  5Z@  $FM   [L0  +;,  "&V   6N0  #KL
M  >^    P0   ,4   #'    R    ,D   #*!0  RPL  ,T/  #.%   T!P
M -,F  #6,@  V$$  -A3  #99@  V7P  -F4  #9JP  V<,  -GA  #9\
MV?0 =I\  &>F  !9K   2[(  #RW   NN@  (;T  !7    -Q   !<<   #*
M    S@   -(   #5    U@   -D   #;    W0   -\'  #A#   XQ$  .89
M  #I)   [#(  .U#  #N5@  [VL  .^$  #OG   [[(  ._&  #OW0  [^0
M:J@  %NO  !,M@  /KP  "_    @Q   %,@   S,   "T    -0   #9
MW@   .(   #E    Y@   .@   #I    [    .X   #P @  \@D  /4/  #X
M%P  _",  /\S  #_1@  _UH  /]Q  #_B0  _Y\  /^Q  #_P   _\8 _P 5
M /\ % #_ !0 _P 7 /\ '0#_ "@ _P W /\ 1 #_ %$ _P!< /\ 9@#_ &\
M_P!W /\ ?@#_ (4 _P"+ /\ D0#_ )< _P"= /\ I #_ *L _P"T /X OP#]
M ,X ^P#F /D ]@#X /\ ]P#_ /< _P#W /\ \ #_ .P _P#I /\ _P,2 /\
M$ #_ !  _P 1 /\ %P#_ "0 _P R /\ /P#_ $P _P!7 /\ 80#_ &H _P!R
M /\ >0#] (  _ "& /H C #Y )( ^ "8 /8 GP#U *8 ] "N /( N0#P ,8
M[@#> .T \ #K /X Z@#_ .D _P#I /\ YP#_ ., _P#@ /\ _P<. /\ #0#_
M  L _P , /\ $P#_ !\ _P L /\ .@#_ $8 _@!2 /L 7 #X &4 ]0!L /,
M= #Q 'H [P"! .X AP#L (T Z@"3 .D F@#G *$ Y@"I ., LP#A +\ WP#0
M -T Z0#: /D V0#_ -< _P#5 /\ U0#_ -4 _P#4 /\ _PD* /\!!0#_  ,
M_P ) /\ $ #_ !D ^P F /< - #T $  \@!, .X 5@#J %\ YP!G .0 ;@#B
M '0 X ![ -X @0#< (< V@"- -8 E #4 )L T0"C ,\ K0#, +@ R@#' ,@
MX #& /, Q0#_ ,, _P## /\ PP#_ ,, _P## /\ _PL! /\#  #_    _P #
M /\ "P#S !( [@ ? .H +0#F #H X@!% -X 3P#9 %@ U !@ -$ : #. &X
MS !T ,H >P#( ($ Q@"' ,0 C@#" )8 P "> +X IP"[ +( N0#  +< U "U
M .P LP#[ +, _P"R /\ L@#_ +$ _P"Q /\ _PT  /\&  #_ P  ]P   /0
M P#G  T X  8 -H )0#3 #( S@ ^ ,H 20#& %( PP!: ,  80"^ &@ O !N
M +H = "X 'L M@"! +0 B "R )  L "9 *X H@"L *T J@"Z *@ RP"F .8
MI0#W *0 _P"C /\ H@#_ *( _P"B /\ _Q   /L,  #O#@  Y@T  -\)  #:
M  8 T  1 ,D '0#$ "H OP W +L 0@"W $L M !4 +( 6P"O &( K0!H *L
M;@"I '4 J ![ *8 @P"D (L H@"4 *  G@"> :@ G *U )L#Q@"9!>( F ;T
M )8(_P"5"?\ E G_ )0)_P"4"?\ _!$  /$5  #C&0  UAD  ,P5  #'$
MQ <* +T#% "W!"$ L@8N *X(.@"J"40 IPE- *0*50"B"EP H IB )X+:0"<
M"V\ FPMV )D,?@"7#(8 E@R0 )0,F@"2#:8 D0VS (\-Q0"-#N( BQ#V (D0
M_P"($?\ AQ'_ (<1_P"'$?\ ]AD  .<@  #6)   R"4  +\B  "Y'   M!0!
M +$-#@"J#AD I0\G *$0,P"=$3X FA%' )@23P"5$E8 DQ)< )$28P"0$VD
MCA-P (P3> "+$X$ B12+ (<4E@"&%:( A!6P (,6P0"!%]T ?QCT 'T9_P!\
M&?\ ?!G_ 'L9_P![&?\ [R$  -TI  #*+0  OB\  +4L  "N)P  J"   *,7
M" ">%A, F1<A )09+0"1&C@ CAI! (L;20")&U  AQM7 (4<7@"$'&0 @AQK
M ( <<P!_'7P ?1V& 'P>D0!Z'IX >!^K '<?O !V(-0 ="'P '(A_P!Q(O\
M<2'_ '$A_P!Q(?\ Z"@  -(P  #"-0  MS<  *TU  "E,0  GBL  )@C @"2
M'A  C2 ; (DA)P"&(C( @R,\ ($C1 !^(TL ?"12 'LD60!Y)%\ =R1F '8E
M;@!T)7< <R6! '$FC0!O)ID ;B:G &TGN !L)\X!:BCM 6DI_P%H*?\!:"G_
M 6@H_P%H*/\!X2X  ,LV  "\.P  L3T  *<]  "?.0  ES,  (\M  "()PP
M@R<6 '\H(@!\*2T >2HW '<J/P!U*D< <RM. '$K5 !P*UL ;BMB &PK:@!K
M+'( :2Q] &@LB0!F+98!92VD 60NM %C+LH!82_I 6 O_0%@+_\!8"__ 6 O
M_P%@+O\!VC0  ,4\  "W00  K$,  *)#  "90   D#H  (@T  " +@@ >BT2
M '<N'@!S+RD <3 S &\P.P!M,$, :S%* &DQ40!G,5< 9C%> &0Q9@!C,F\
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M?P%2/(T!4#V< 4\]K )./L$"33[A DT^^ )-/O\!33[_ 4T]_P%-/?\!R4
M +A(  "L30  H5   )=1  ".3P  A$L  'E%  !N0   9CT+ &(]% !?/1X
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M 4!*IP(_2KL"/DO8 CY*\P(^2O\"/DG_ 3])_P$_2?\!O4H  *]2  "C6
MF5L  )!=  "&7   >UD  &U3  !B3P  5TP! %%*#0!.2A4 3$L? $I+* !)
M2S  1TLX $9,/P!%3$8 1$Q. $--5@!"35\ 0$UJ #]-=@$]3H0!/$Z4 3M.
MI0$Y3[D".4_4 CE/\@$Y3O\!.4[_ 3E-_P$Z3?\!NDX  *Q6  "A6P  EU\
M (UA  "#80  >%X  &E8  !?5@  5%(  $Q/"P!)3Q( 1U < $50)0!#4"T
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M "=?[0$G7O\!)UW_ 2A=_P$H7/\!K5P  *)D  "8:@  CFX  (-O  !Y;P
M;FX  &!K  !4:0  26<  #]E   U8PD ,F,1 #!C&0 O9"$ +F0I "UD,0 L
M9#D *V5" "IE2@ H950 )V5? "9F:P D9GH (V:+ ")FG0 @9K$ 'V;) !]F
MZP @9?X (&3_ "!C_P$A8_\!J6(  )YJ  "5<   BG,  (!U  !U=0  :70
M %QR  !/<0  1&\  #IN   P;0, *6P- "=L%  F;!P )6TD "1M+  C;30
M(FT] "%N1@ @;E  'FY; !UN9P <;G8 &FZ' !EOF@ 8;ZX %F_& !9NZ0 7
M;?P &&S_ !AK_P 8:_\ I&D  )IQ  "0=@  AGD  'Q[  !Q>P  9'L  %=Z
M  !*>0  /W@  #5X   K=P  (G8' !UV#P <=Q8 &W<> !IW)@ 9=RX &'<W
M !=X0  5>$H %'A6 !-X8P 2>'( $7B# !!XEP />*L #GC#  YWY@ .=OH
M#W7_ !!U_P 0=/\ GW$  )5X  "+?   @G\  '>!  !J@@  78(  %""  !$
M@@  .((  "Z"   D@@  '((  !2""0 1@Q  $(,6 !"#'@ .@R< #H,P  V#
M.0 -@T0 #(-0  N#70 )@VP "(-^  :#D0 %@J4  X*[  2!VP $@?( !8#_
M  9__P &?_\ FGD  )!^  "&@P  ?84  &^'  !BB0  58H  $F+   ]C
M,8P  ":,   =C0  %8X   ^/ P *D P !I 1  2/&  #CR   8\I  "/,@
MD#T  )!)  "/5@  CV4  (]V  "/B@  CI\  (ZT  "-SP  C.X  (S[  "+
M_P  B_\ E(   (N%  ""B0  =(P  &:/  !9D0  3),  $"5   TE@  *)8
M !Z7   5F   #YH   J;   "G D  )P.  "<$P  G!H  )PB  "=*P  G34
M )U   "=3@  G5P  )UN  "<@0  G)<  )RL  ";Q@  FN@  )GY  "9_P
MF/\ CH@  (:,  !XD   :I0  %R7  !/F@  0IT  #:>   IGP  'Z$  !6B
M   .I   "*8   "H    J00  *D*  "I#@  J1,  *H:  "J(@  JRL  *PV
M  "L1   K%,  *QC  "L=P  JXX  *ND  "KO   JMX  *GT  "I_0  J?\
MB8X  'N3  !MEP  7YP  %&@  !$I   -J8  "JH   >J0  %*L   VN   &
ML    +(   "U    M0   +4#  "V"0  MPX  +@2  "X&0  NB$  +LK  "\
M.   O4<  +U8  "]:P  O8$  +V9  "]L   O<P  +SJ  "\]P  N_X ?I4
M '";  !BH   4Z4  $:J   XK0  *J\  !ZQ   3M   #+<   .Y    O
M +\   #"    P@   ,,   #$    Q@8  ,<,  #($   RA8  ,P@  #/*P
MT#H  -%+  #17@  TG,  -*+  #2I   T[L  -/8  #3[0  T_8 <YT  &2C
M  !6J0  1Z\  #FS   JM@  ';D  !*\   *OP   ,,   #&    R0   ,T
M  #/    T    -(   #4    U@   -D"  #;"   W@X  .$3  #D'0  Z"H
M .@\  #I3P  Z60  .I\  #KE0  ZZP  .O"  #LU0  [.4 9J8  %BL  !)
MLP  .[D  "N\   =P   $<0   G(    S    ,\   #3    V0   -T   #@
M    X0   .,   #E    YP   .H   #L    [@0  /$+  #U$@  ^!P  /LK
M  #]/@  _E,  /YJ  #_@P  _YL  /^N  #_O@  _\H _P 2 /\ $ #_ !$
M_P 3 /\ &0#_ "8 _P T /\ 00#_ $T _P!8 /\ 8@#_ &L _P!S /\ >@#_
M ($ _P"' /\ C0#_ ), _P"9 /\ H #_ *< _@"O /P N@#Z ,D ^0#A /@
M\P#W /\ ]@#_ /4 _P#Q /\ Z0#_ .0 _P#A /\ _P / /\ #0#_  T _P .
M /\ % #_ "$ _P N /\ / #_ $@ _P!3 /\ 70#_ &8 _@!M /P =0#[ 'L
M^0"" /@ B #W (X ]@"4 /0 FP#S *( \0"J .\ M #M ,$ ZP#5 .H [ #H
M /P YP#_ .4 _P#F /\ X #_ -D _P#4 /\ _P + /\ " #_  8 _P ) /\
M$ #_ !P _P I /\ -@#_ $( ^P!. /< 5P#T &  \@!H .\ ;P#M '8 [ !\
M .H @@#H (@ YP". .4 E0#C )P X0"D -\ K@#= +D V@#* -< Y #4 /8
MT0#_ -  _P#0 /\ SP#_ ,L _P#' /\ _P # /\   #_    _P $ /\ #0#Z
M !8 ]@ C /, , #P #P [0!' .D 40#E %H X@!B -\ :0#= &\ V@!V -@
M? #4 (( T@"( -  CP#- )8 RP"> ,D J #' +, Q0#! ,( V #  .\ OP#^
M +X _P"] /\ O #_ +P _P"\ /\ _P(  /\   #_    _P   /0 !P#M !$
MZ  < ., *0#? #4 VP!! -8 2P#1 %0 S0!< ,H 8P#( &D Q@!O ,, =0#!
M 'L OP"" +X B "\ )  N@"8 +@ H@"U *P LP"Y +$ RP"O .< K@#X *P
M_P"K /\ K #_ *P _P"K /\ _P0  /\   #V    [@   .<   #?  P U@ 5
M ,\ (@#* "X QP Z ,, 1 #  $T O !5 +D 7 "W &, M0!I +, ;P"Q '4
MKP![ *T @@"K (H J0"2 *< G "E *8 HP"S *$ PP"? -X G@#R )T _P"<
M /\ G #_ )L _P"; /\ _P<  /8)  #I"P  WPH  -4$  #.  4 Q@ 0 ,
M&@"[ "< MP R +, /0"P $8 K0!/ *H 5@"H %P I@!C *0 : "B &\ H0!U
M )\ ? "= (0 FP"- )D EP"7 *( E0"N ), O0"1 -, D #M (\ _ ". /\
MC0'_ (T!_P"- ?\ ^0X  .H2  #<%0  S14  ,01  "^#   N@(* +0 $@"N
M !X J@ J *8 -0"B #\ H !( )T!4 "; E8 F0)< )<#8P"5 VD DP-O )$$
M=@"0!'\ C@6( (P%D@"*!IX B :J (8'N@"%",\ A KK ((+_ "!#/\ @ S_
M ( ,_P" #/\ \14  . =  #-(   P2$  +@=  "Q%P  K!   *@)#0"B!Q8
MG0DC )D*+@"5"S@ DPQ! ) ,20".#5  C U7 (H-70"(#6, APUJ (4.<0"#
M#GH @@Z$ ( .CP!^#YL ? ^H 'L0N !Z$,X >!'L '82_P!U$O\ =!/_ '03
M_P!T$_\ Z!X  -,F  ##*@  N"H  *XH  "G(P  H!P  )L3 P"6#Q  D! ;
M (P1)P")$C( AA,[ (030P""%$L @!11 'X45P!\%%X >Q5E 'D5; !W%70
M=A9^ '06B@!R%Y8 <1>D &\8M !N&,D ;1GH &L:_ !J&_\ :AO_ &H;_P!J
M&_\ X"8  ,HM  "\,0  L#,  *<Q  "?+   ER8  ) ?  "*%PP A1@6 ($9
M(@!^&BP >QLV 'D;/@!W'$4 =1Q, ',<4P!Q'5D <!U@ &X=9P!M'G  :QYZ
M &H>A0!H'Y( 9Q^@ &4@L !D(<4 8R'D &(B^@!A(O\ 82+_ &$B_P!A(O\
MURP  ,,T  "V.   JCD  *$X  "8-0  D"\  (@H  " (0@ >R 2 '<A'0!T
M(B< <2(Q &\C.0!M(T$ :R-( &DC3@!H)%4 9B1; &4D8P!C)6L 8B5U &$E
M@0!?)HX 7B:= %TGK0!;*,$ 6RC@ %HI]P!9*?\ 62G_ %DI_P!9*/\ SS(
M +XY  "Q/0  IC\  )P_  "3/   BC8  ($P  !Y*@, <B8/ &XG&0!K*",
M:2@L &8I-0!E*3P 8RE# &$J2@!@*E$ 7BI7 %TJ7P!<*V@ 6BMR %DL?0!8
M+(L 5BV: %4MJ@!4+KT 4R[< %(O]0!2+_\ 4B[_ %(N_P!2+O\ RC8  +H]
M  "M0@  HD0  )A$  "/00  A3P  'LW  !R,0  :RP, &<M%0!D+1\ 82XH
M %\N,0!=+CD 7"]  %HO1@!8+TT 5R]4 %8P7 !5,&0 4S%N %(Q>@!1,8@
M4#*7 $XRJ !-,[L 3338 $PT\P!,-/\ 3#3_ $PS_P!,,_\ QCH  +9"  "I
M1@  GDD  )5)  "+1P  @4(  '<]  !M-P  9#() & R$@!=,AP 6C(E %@S
M+0!6,S4 53,\ %,T0P!2-$H 4311 % T60!/-6$ 335L $PV=P!+-H4 2C>5
M $@WI@!'.+@!1SC3 48X\0%&./\!1CC_ $8X_P!&-_\ P3X  +)%  "F2@
MG$T  ))-  "(2P  ?D<  '-"  !I/0  7S<& %HV$ !7-Q@ 5#<B %(W*@!0
M-S( 3S@Y $TX0 !,.$< 2SA. $HY5@!).5\ 2#II $<Z=0!%.X, 1#N3 $,\
MI %"/+8!03W0 4$]\ %!/?\!03S_ 4$\_P%!//\ OD(  *])  "C3@  F5
M (]1  "%4   >TP  &]&  !E0@  6CT" %0[#@!1.Q4 3SL? $T[)P!+.R\
M23PV $<\/0!'/$0 1CU+ $4]5 !$/EP 0SYG $(_<P! /X$ /S^1 #Y H@ ]
M0+4!/$'. 3Q![@$\0?\!/$#_ 3Q _P$]/_\!ND4  *Q,  "A40  EU0  (U5
M  "#5   >%$  &Q+  !A1P  5D(  $] # !,/Q, 24 < $= ) !&0"P 1$ S
M $- .@!"04( 04%) $!"40 _0EH /D-E #U#<0 [0W\ .D2/ #E$H  X1;,!
M-T7+ 3=%[ $W1?\!-T3_ 3A$_P$X0_\ MTD  *E0  ">50  E%@  (M9  "
M6   =E8  &A0  !=3   4T@  $I%"0!&1!$ 1$09 $)$(@!!12D /T4Q #Y%
M.  ]13\ /$9' #M&3P Z1U@ .4=B #A(;@ V2'P -4B- #1)G@ S2;$ ,DG)
M #%)ZP R2?X ,DC_ #)(_P S2/\ M$P  *=4  "<60  DEP  (A=  !^70
M<UH  &55  !;4@  4$X  $9*!0! 20X /DD6 #U)'@ [2B8 .DHN #E*-0 X
M2ST -TM$ #9+30 T3%8 ,TQ@ #),;  Q37H ,$V+ "Y-G  M3J\ +$[' "Q.
MZ0 L3?T +4W_ "U,_P M3/\ L%   *18  "970  CV$  (9B  ![80  <%\
M &);  !86   3E4  $-1 0 [3PP .$\3 #9/&P U3R, -% K #-0,@ R4#H
M,5!" #!12@ N45, +5)= "Q2:0 K4G@ *5*( "A3F@ G4ZT )E/% "93YP F
M4_P )U+_ "=1_P G4?\ K%4  *!<  "68@  C68  (-G  !X9@  ;64  &!A
M  !57@  2EL  #]8   U5@@ ,540 #!6%P N5A\ +58G "Q6+P K5S8 *E<^
M "E71P H5U  )EA: "589P D6'4 (UF& "%9F  @6:L 'UG" !]9Y0 ?6/H
M(%C_ "!7_P A5_\ J%H  )UB  "39P  BFL  ']L  !U;   :FL  %UH  !1
M90  1F,  #M@   Q7@, *ET- "A=$P F71L )5XC "1>*@ C7C( (EXZ "%>
M0P @7TP 'U]7 !Y?8P <8'$ &V"" !E@E0 88*D %V#  !9@X@ 77_D &%[_
M !E>_P 97?\ I&   )EH  "0;@  AG   'QR  !R<@  9G$  %AN  !,;
M06L  #9I   M9P  (V8( !]F#P =9A4 '&8= !MF)0 :9BT &6<U !AG/@ 7
M9T@ %F=3 !5H7P 3:&X $FA_ !%HD@ 0:*8 #VB]  YHX  09_< $&;_ !%E
M_P 19?\ GV<  )9O  ",<P  @G8  'AX  !M>   8'<  %-V  !&=   .W,
M #%R   G<0  'G$  !9P"@ 3<!  $W 7 !)P'P 1<2< $'$O !!Q.  .<4(
M#G%.  UQ6P ,<6D "W%Z  IQC0 (<:$ !G&V  9PT@ '<.\ "&__  EN_P )
M;O\ FV\  )%U  "'>0  ?GP  '1^  !F?@  67X  $U^  ! ?0  -7T  "I\
M   A?   &'P  !%\!  ,? P "GP1  E\&0 (?"$ !WPI  9\,@ $?#T  WQ(
M  %\50  ?&,  'QT  !\AP  >YP  'NQ  !ZRP  >>L  'GZ  !Y_P  >/\
MEG<  (Q\  "#@   >8,  &R$  !>A0  488  $6'   YAP  +8<  ".'   :
MAP  $H<   V( 0 &B0H  8D/  ")%   B!L  (@C  ")+   B38  (E"  "(
M3@  B%T  (AM  "(@0  AY4  (>K  "&Q   A>8  (3X  "$_P  A/\ D'X
M (>#  !^AP  <8D  &.+  !6C0  28\  #R1   PD0  ))$  !J2   2DP
M#90   :5    E@8  )8,  "5$   EA4  )8=  "6)   EBX  )8Y  "61@
MEE4  )9E  "6>   E8X  )6D  "4O   D]\  )/U  "2_P  DO\ BX8  (.*
M  !UC0  9Y   %F4  !,EP  /YD  #*:   FFP  &YP  !*=   ,GP  !*
M  "B    HP$  *,'  "C#   HQ   *05  "D'   I24  *8O  "F/   IDL
M *9;  "F;@  I80  *6;  "DLP  H]   */O  "B_   HO\ AHT  'B1  !J
ME0  7)D  $Z=  !!H   ,Z(  ":C   ;I0  $:<   JI   !JP   *T   "O
M    L    +    "P!0  L0L  +(/  "S%   M!L  +4D  "W,   MS\  +=0
M  "W8@  MW@  +>0  "VJ0  ML(  +;D  "V]0  M?X >Y,  &V8  !?G0
M4*(  $*F   TJ0  )JL  !JM   0KP  ";(   "T    MP   +H   "\
MO0   +X   "^    P (  ,$(  #"#0  Q!(  ,89  #))   RC(  ,M#  #+
M50  S&H  ,R#  #,G   R[4  ,S.  #,Z0  S/8 <)L  &&A  !2I@  1*L
M #:P   GL@  &K4  !"X   'NP   +X   #!    Q    ,@   #+    RP
M ,T   #.    T    -(   #5 P  V H  -L0  #>&   XB0  .,U  #D2
MY5P  .9S  #FC0  YJ4  .:\  #FTP  Y^< 8Z0  %6J  !&L   .+4  "BY
M   :O   #\    7$    QP   ,L   #/    U    -@   #<    W0   -\
M  #A    XP   .4   #H    Z@   .T&  #Q#@  ]18  /@E  #Y.   ^4T
M /IC  #[?   _)4  /RJ  #\NP  _<L _P / /\ #@#_  X _P 0 /\ %@#_
M ", _P P /\ /0#_ $D _P!4 /\ 7@#_ &8 _P!N /\ =@#_ 'P _P"" /\
MB0#_ (\ _P"5 /X FP#] *, ^P"K /H M0#Y ,, ]P#; /8 \ #T /\ \P#_
M /( _P#L /\ X@#_ -P _P#6 /\ _P , /\ "0#_  @ _P * /\ $@#_ !X
M_P K /\ . #_ $0 _P!/ /\ 60#^ &$ _ !I /H < #X '< ]P!] /8 @P#T
M (D \@"/ /$ E@#O )T [0"E .P KP#J +P Z #- .8 Z #D /H XP#_ .(
M_P#@ /\ U0#_ ,X _P#+ /\ _P & /\  0#_    _P $ /\ #@#_ !D _P E
M /T ,@#[ #X ]P!) /, 4P#P %P [@!C .P :@#J '$ Z !W .8 ?0#D (,
MX@") .  D #> )< W "? -D J0#6 +0 TP#$ -  W@#. /, S #_ ,L _P#*
M /\ R #_ ,( _P"^ /\ _P   /\   #_    _P   /L "P#V !, \0 @ .T
M+ #J #@ YP!# ., 30#@ %8 W != -D 9 #5 &L T@!Q -  =@#. 'P S "#
M ,H B0#( )$ Q@"9 ,0 HP#! *T OP"[ +T SP"[ .L N0#\ +< _P"W /\
MM@#_ +0 _P"Q /\ _P   /\   #_    ]@   .X !0#G  \ X0 9 -L )0#5
M #$ T@ \ ,X 1@#* $\ QP!7 ,0 7@#! &0 OP!J +T < "[ '8 N0!\ +@
M@P"V (H LP"3 +$ G "O *< K0"S *L Q0"I .$ IP#U *8 _P"E /\ I #_
M *0 _P"D /\ _P   /P   #Q    Z    .    #4  L S  3 ,< 'P#" "H
MOP U +P /P"X $@ M0!0 +, 5P"P %X K@!D *P :0"K &\ J0!U *< ? "E
M (0 HP", *$ E@"? *$ G0"M )H O "8 -( EP#N )4 _@"4 /\ E0#_ )4
M_P"5 /\ _ $  / %  #C!P  U04  ,P   #%  0 O@ . +@ %P"S ", KP N
M *L . "I $$ I@!* *, 40"A %< GP!= )T 8P"; &D F@!O )@ =@"6 'T
ME "& )( D "0 )L C@"G (P M@"* ,D B #G (< ^0"' /\ A@#_ (8 _P"&
M /\ ] P  .00  #1$@  Q1$  +T.  "V"   L0 ( *L $0"F !L H0 F )X
M,0": #H F !# )4 2@"3 %$ D0!7 (\ 70". &, C !I (H < "( '< A@"
M (0 BP"" )8 @ "C 'X L0!] ,0 >P+A 'H#]0!Z!?\ >07_ '@&_P!X!O\
MZA,  -8:  #&'0  NAP  +$9  "J$P  I T  )\%# "9 !0 E0 ? )$"*0"-
M S, BP0\ (@%1 "&!DL A 91 (('5P"!!UT ?P=C 'T(:@!["'( >@A\ '@)
MA@!V"9( = J@ ',*KP!Q"\$ < S? &\-]@!N#O\ ;0[_ &T._P!M#O\ X1P
M ,LC  "\)@  L28  *@D  "@'@  F1@  ),0 @"."PX B L7 (0,(@"!#2P
M?@TU 'P./0!Z#D4 > Y+ '<.40!U#U@ <P]> '$090!P$&X ;A!W &P0@@!K
M$(\ :1&= &@1K0!F$L  91+? &03]@!C%/\ 8Q3_ &(4_P!B%/\ UB0  ,,J
M  "U+@  JB\  * M  "8*   D"(  (D;  ""$P@ ?1$2 'D2' !V$R< <Q0P
M '$4. !O%3\ ;15& &P53 !J%E, :!99 &<680!E%FD 9!=R &(7?@!A&(L
M7QB9 %X9J0!<&;P 7!K8 %H;\P!:'/\ 61S_ %D<_P!9'/\ S2H  +TQ  "O
M-0  I#8  )LT  "2,0  B2L  ($E  !Y'0, <Q@. &\9& !L&B( :1LK &<;
M,P!E'#L 9!Q! &(=2 !@'4X 7QU5 %T=7 !<'F0 6QYN %D?>0!8'X< 5B"6
M %4@I@!4(;@ 4R'2 %(B\0!2(_\ 4B/_ %(B_P!2(O\ R"\  +@V  "K.@
MH#P  )8[  "-.   @S(  'HM  !R)@  :B , &8@$P!C(1T 82$F %\B+P!=
M(C8 6R(] %HC1 !8(TH 5R-1 %4C6 !4)&$ 4R1J %$E=@!0)8, 3R:3 $XG
MHP!,)[4 3"C. $LH[@!+*?\ 2RC_ $LH_P!+*/\ PS0  +,[  "G/P  G$$
M ))   ")/@  ?SD  '4S  !L+0  8R<( %XF$0!<)AD 62<B %<G*P!5*#(
M5"@Y %(H0 !1*$8 4"E- $XI50!-*5T 3"IG $LJ<P!)*X  2"N0 $<LH0!&
M+;, 12W+ $4N[ !$+O\ 1"[_ $4M_P!%+?\ OC@  + _  "D0P  F44  (]%
M  "%0P  >SX  '$Y  !G-   7BX$ %@K#@!5*Q8 4BP? % L)P!/+"\ 32TV
M $PM/ !*+4, 22U* $@N4@!'+EH 1B]D $4O< !#,'X 0C"- $$QG@! ,K$
M/S+( #\SZ@ _,_X /S+_ #\R_P _,O\ NSP  *U#  "A1P  EDD  (Q)  "#
M2   >$0  &T^  !C.0  6C0  %(P# !/,!, 3# < $HP) !),2L 1S$R $8Q
M.0!$,4  0S)' $(R3P!!,U@ 0#-B #\T;0 ^-'L /36+ #PVG  [-J\ .C?&
M #DWZ  Y-_P .C?_ #HV_P Z-O\ MT   *I&  ">2P  E$T  (I.  " 3
M=4@  &I#  !@/@  5CD  $TU"0!)-!$ 1S49 $4U(0!#-2@ 034O $ U-@ _
M-CT /C9% #TW30 \-U4 .SA@ #HX:P Y.7D .#F) #<ZFP U.JT -3O$ #0[
MY@ T._L -3O_ #4Z_P U.O\ M$,  *=*  "<3@  DE$  (A2  !^4   <TT
M &=(  !<1   4C\  $@Z!@!$.0\ 03D6 #\Y'@ ^.28 /#DM #LZ-  Z.CL
M.3M" #@[2@ W/%, -CQ= #4]:0 T/7< ,SZ' #$^F0 P/ZL +S_" "\_Y  O
M/_H ,#__ # ^_P P/O\ L4<  *1-  "94@  CU4  (96  !\50  <5(  &1,
M  !920  3T4  $5  P _/@T /#X3 #H^&P Y/B, -SXJ #8_,0 U/S@ -#]
M #- 2  R0%$ ,4%; #!!9P N0G4 +4*% "Q#EP K0ZH *D/  "E$X@ J0_D
M*D/_ "M"_P K0O\ KDH  *%1  "75@  C5D  (-:  !Y6@  ;E<  &%2  !7
M3@  34L  $-'   Z0PH -D,1 #1#&  S0R  ,D0G #%$+P P1#8 +T4] "U%
M1@ L14\ *T99 "I&9  I1W( *$># "9'E0 E2*@ )$B^ "-(X  D2/< )4?_
M "5'_P F1_\ JD\  )]5  "46@  BUX  (%?  !W7@  :UP  %]8  !550
M2U$  $!-   U2@< ,$D. "Y)%0 M21T +$DD "M**P J2C, *$H[ "=+0P F
M2TP )4M6 "1,8@ C3'  (4R  "!-DP ?3:8 'DV[ !U.W0 >3?8 'DS_ !],
M_P @2_\ IU,  )Q:  "27P  B&,  'YD  !T8P  :6$  %Q>  !26P  1U@
M #Q5   R4@( *E , "=/$@ F4!D )5 @ "10*  C4"\ (E$W "%10  @44D
M'E)3 !U27P <4FT &E-] !E3D  84Z0 %E.Y !53V0 64_0 %U+_ !A1_P 9
M4?\ HUD  )A@  "/90  A6@  'MI  !Q:0  9F<  %ED  !-80  0E\  #A<
M   N6@  )5@( "!7#@ >5Q0 '5<< !Q8(P ;6"L &E@S !E8/  86$4 %EE0
M !596P 466D $UIZ !):C0 16J$ $%JW  Y:U0 06?, $%G_ !%8_P 16/\
MGU\  )5F  ",:P  @FT  'AN  !N;P  8FT  %5J  !(:   /F8  #-E   I
M8P  (&$! !A@"P 58!  %& 7 !-@'@ 28"8 $F N !%A-P 084  #V%+  YA
M6  -868 #&)V  MBB0 *89T "6&R  AARP (8>L "6#]  I?_P +7_\ FV8
M ))M  "(<0  ?G,  '5U  !J=   7',  $]R  !#<   .&\  "UN   D;
M&VL  !-K!  .:@P #6H2  QJ&0 +:B$ "FHI  EJ,@ (:CP !VM'  5K4P $
M:V$  FMQ  !JA   :I@  &JM  !IQ@  :><  &GX  !H_P  :/\ EVT  (US
M  "$=P  >WH  '![  !C>P  5GH  $EZ   ]>0  ,7@  "=W   ==@  %78
M  ]V @ )=@H !'8/  !V%0  =AP  '8D  !U+   =38  '5!  !U3@  =5P
M '5L  !U?@  =),  '2H  !SP   <^,  '+W  !R_P  <?\ DG4  (EZ  "
M?@  =H   &F!  !;@@  3H(  $&"   U@P  *8(  !^!   6@0  $((   J"
M   "@P<  ((-  ""$0  @A<  ((>  "")@  @B\  (([  ""1P  @E4  (%E
M  "!>   @8T  ("B  !_N@  ?]T  '[T  !]_P  ??\ C7P  (2!  ![A
M;H8  &"(  !2B@  18L  #F,   LC   (8P  !>,   0C0  "8X   */
MD ,  (\)  "/#@  CQ(  ) 8  "0'P  D"@  ) R  "0/P  D$T  )!=  "/
M<   CX4  (Z<  ".LP  C=   (SP  "+_@  B_\ B(0  ("(  !RBP  9(T
M %:0  !(DP  .Y4  "Z6   BE@  %Y<   ^8   (F0   )L   "=    G0
M )T#  "="0  G0T  )X1  ">%P  GQ\  )\I  "@-0  H$,  *!4  "@9@
MGWL  )Z3  ">JP  G<8  )WI  "<^0  G/\ @XL  '6.  !GD@  698  $N9
M   ]G   ,)X  ".?   7H   #J(   >D    I@   *@   "J    J@   *H
M  "K 0  JP<  *P,  "M$   KA8  *\>  "Q*0  L3@  +%(  "Q6@  L6\
M +&(  "QH   L+H  *_=  "O\@  K_T >)$  &J6  !<F@  39\  #^C   Q
MI@  (Z<  !>I   .JP  !:X   "P    L@   +4   "W    MP   +@   "Y
M    N@   +P#  "]"0  O@X  , 4  ##'@  Q2L  ,4\  #&3@  QF(  ,9Z
M  #&E   QJT  ,;(  #%Y0  Q?, ;)D  %Z>  !/I   0:@  #*L   DKP
M%K$   VT   #MP   +H   "]    P    ,0   #&    Q@   ,@   #)
MRP   ,P   #.    T 8  -,-  #8$P  W!X  -XM  #?0   X%0  .%K  #A
MA0  X9\  .&W  #ASP  X>8 8*$  %*G  !#K0  -+(  "6U   7N0  #;P
M  &_    PP   ,<   #*    SP   -,   #6    UP   -H   #<    WP
M .$   #C    Y@   .D!  #L"P  \!(  /,?  #T,0  ]D8  /=<  #X=
M^(\  /FF  #YN   ^,D _P - /\ "P#_  L _P . /\ $P#_ !\ _P L /\
M.0#_ $4 _P!0 /\ 60#_ &( _P!J /\ <0#_ '< _P!^ /\ A #^ (H _0"0
M /P EP#Z )X ^0"G /< L0#V +X ]0#2 /, [ #Q /X \ #_ /  _P#F /\
MW #_ -( _P#- /\ _P ' /\ ! #_  ( _P & /\ $ #_ !L _P G /\ ,P#_
M #\ _P!* /X 5 #[ %T ^0!D /< :P#U '( \P!X /( ?@#P (0 [P"* .T
MD0#L )D Z@"A .@ JP#F +8 Y #' .( XP#@ /< W@#_ -T _P#9 /\ S #_
M ,4 _P#! /\ _P   /\   #_    _P ! /\ #0#_ !8 _  B /D +@#V #D
M\P!% .\ 3@#L %< Z0!> .8 90#D &P X@!R .  =P#? 'X W0"$ -L BP#8
M )( U0"; -( I #/ *\ S0"^ ,L U0#) .\ QP#_ ,4 _P#$ /\ O@#_ +@
M_P"U /\ _P   /\   #_    _@   /< "0#Q !$ ZP < .< * #D #, X0 ^
M -T 2 #8 %$ TP!8 -  7P#. &4 S !K ,H <0#( '< Q@!] ,0 A #" (P
MP "4 +X G@"[ *@ N0"V +< R "U .8 LP#Z +$ _P"P /\ L #_ *P _P"I
M /\ _P   /\   #Z    \0   .@  P#@  T V  6 -$ (@#- "T R@ W ,8
M00#" $H OP!2 +T 60"Z %\ N !E +< :@"U '  LP!V +$ ?0"O (4 K0"-
M *L EP"I *$ IP"N *4 O@"B -@ H #R )\ _P"> /\ G@#_ )X _P"< /\
M_P   /<   #K    X0   -8   #+  D Q0 1 +\ &P"[ "8 MP Q +0 .@"Q
M $, K@!+ *L 4@"I %@ IP!> *8 9 "D &D H@!P *  =@"> 'X G "& )H
MD "8 )L E@"G )0 M@"2 ,H D #I (\ _ ". /\ C0#_ (P _P"- /\ ^
M .D"  #; P  S $  ,0   "]  ( M@ - +  %0"K "  IP J *0 - "A #P
MG@!$ )P 2P": %( F !8 )8 70"5 &, DP!I )$ < "/ '< C0"  (L B@")
M )4 AP"A (4 KP"# ,$ @0#@ (  ]0!_ /\ ?P#_ '\ _P!_ /\ [@H  -P.
M  #*$   O@X  +4+  "O P  J0 ' *, $ "> !@ F0 C )8 + "3 #4 D  ^
M (X 10", $L B@!1 (@ 5P"& %T A0!C (, :@"! '$ ?P!Z 'T A ![ (\
M>0"< '< J@!U +L = #4 '( \ !R /\ <@#_ '$ _P!Q /\ XQ$  ,T7  "_
M&0  LQD  *H5  "C$   G0H  )<!"@"1 !( C0 ; (D )0"% "\ @P W (
M/@!^ $4 ?0!+ 'L 40!Y %< > != '8 9 !T 6L <@%T ' "?P!N HL ; .8
M &L#I@!I!+< : 7. &<'[ !F"/T 9@G_ &4)_P!E"?\ UAH  ,0@  "V(P
MJR,  *$@  "9&P  DA0  (P. 0"&!PT @ 04 'P&'@!Y!R@ =@@P '0(. !R
M"3\ < E% &\*3 !M"E( ; I8 &H+7P!H"V< 9PMP &4,>@!C#(< 8@R5 & -
MI !?#;8 7@W. %P.[0!<#_\ 6Q#_ %L0_P!;$/\ S2$  +PH  "O*P  I"L
M )HI  "2)   B1\  ((8  ![$04 =0T/ '$-%P!N#B$ :PXJ &D/,@!G$#D
M91!  &001@!C$$T 81!3 %\16@!>$6( 7!%K %L1=@!9$H, 6!*2 %83H@!5
M$[0 5!/+ %,4[ !2%?\ 4A;_ %(5_P!2%?\ QB@  +8N  "I,@  GS(  )4Q
M  ",+0  @R<  'HA  !R&@  :Q,+ &<3$P!D%!P 810E %\5+0!=%30 7!4[
M %L60@!9%D@ 6!9/ %875@!5%UX 4Q=G %(8<@!0&'\ 3QF. $X:GP!,&K
M2QO' $L;Z0!*'/T 2AS_ $H<_P!*'/\ P2T  +$T  "E-P  FC@  ) W  "'
M-   ?2\  '0I  !L(P  9!P' %X9$ !;&A@ 61LA %<;*0!5&S  5!PW %(<
M/0!1'$0 3QU+ $X=4@!-'5H 2QYC $H>;@!)'WP 1Q^+ $8@G !%(:X 1"'$
M $,BY@!#(OP 0R+_ $,B_P!#(O\ O#(  *TX  "A/   ESX  (T]  "#.@
M>34  &\P  !F*@  7B0" %<@#0!4(!0 42 = $\A)0!.(2P 3"$S $LB.@!)
M(D  2")' $<B3@!&(U< 1"-@ $,D:P!")'D 026( #\FF0 ^)JL /2?! #TG
MXP ]*/H /2C_ #TG_P ])_\ N#8  *H]  ">0   E$(  (I"  " /P  =CL
M &PV  !B,   62H  %$E"P!-)1$ 2R49 $DE(0!')B@ 128O $0F-@!#)CT
M0B=$ $$G2P _*%0 /BA= #TI:0 \*78 .RJ& #DKEP X*ZD -RR_ #<LX  W
M+/@ -RS_ #<L_P X+/\ M3H  *=   "<1   D48  (=&  !]1   <T   &@[
M  !?-@  53$  $PK!P!'*0\ 12H6 $,J'@!!*B4 /RHL #XK,P ]*SD /"M!
M #LL2  Z+%$ .2U; #@N9@ V+G, -2^# #0OE0 S,*< ,C"] #$QW@ Q,?<
M,C'_ #(P_P S,/\ L3X  *1$  "92   CTH  (5*  ![20  <$4  &5   !;
M.P  4C8  $@Q! !"+@T /RX3 #TN&P [+B( .2\I #@O+P W+S8 -C ^ #4P
M1@ T,4\ ,S%9 #(R9  Q,G$ ,#.! "\TDP N-*8 +#6[ "PUVP L-?4 +37_
M "TT_P N-/\ KD$  *)(  "73   C4X  (-.  !Y30  ;DH  &)%  !80
M3CP  $4W   ],PL .3,1 #<S&  V,Q\ -#,F #,S+0 R-#0 ,30\ # U1  O
M-4P +C96 "TV8@ L-V\ *S=_ "HXD0 H.*0 )SFY "8YV  G.?0 *#G_ "@X
M_P I./\ JT4  )]+  "43P  BU(  (%3  !W4@  ;$\  %])  !61@  3$(
M $(]   X. @ -#@/ #(X%0 Q.!T +S@D "XX*P M.3( +#DY "LZ00 J.DH
M*3M4 "@[7P G/&T )3Q] "0]CP C/:( (CVW "$^U  A/O, (CW_ ",]_P C
M//\ J$D  )U/  "24P  B58  ']7  !U5@  :E,  %U/  !33   2D@  $!$
M   V0 4 +ST- "T]$P K/1H *CXA "D^*  H/B\ )SXW "8_/P D/T@ (T!2
M ") 70 A06H ($%Z !Y!C0 =0J  '$*U !M"T0 ;0O$ '$+_ !U!_P >0?\
MI4T  )I3  "06   AEL  'U<  !R6P  9U@  %M4  !14@  2$X  #U*   S
M1P  *D,+ "9#$  E0Q8 )$,> "-$)0 B1"P (40T "!%/  >144 '45/ !Q&
M6@ ;1F@ &49X !A'B@ 71YX %D>S !1(S@ 51^\ %D?_ !=&_P 71O\ HE(
M )=8  "-70  A&   'IA  !P8   95X  %E:  !/6   1%0  #E1   O3@
M)DL& "!*#@ >2A, '4H: !Q*(0 ;2R@ &DLP !E+.  72T( %DQ, !5,5P 4
M3&4 $TUU !)-B  139P $$VQ  Y.S  /3>X $$W_ !%,_P 13/\ GE<  )1=
M  "+8@  @64  '=F  !M9@  8V0  %9A  !*7@  /UL  #58   K5@  (E0!
M !I2"@ 64A  %5(6 !12'0 34B0 $E(L !%2-  14CX $%-(  ]35  .4V(
M#51R  Q4A  +5)@ "52M  A4Q0 )5.< "E/[  M2_P +4O\ FUT  )%D  "(
M:   ?FL  '1L  !K;   7VH  %)G  !%9   .F(  #!@   F7@  '5T  !5;
M!0 06@P #EH1  Y:&  -6R  #%LG  M;,  *6SH "5M%  =;40 &6UX !%MM
M  -;@  !6Y0  %NH  !;P   6N(  %KV  %:_P "6?\ EV0  (YK  "$;@
M>W   ')R  !G<0  67   $QN  ! ;   -6L  "II   A9P  &&8  !%F 0 ,
M90H !V4/  1E%  #9!L  F0C  !D+   9#4  &1   !D3   9%H  &1I  !D
M>P  9(\  &.D  !CNP  8MT  &+T  !B_P  8?\ DVP  (EQ  " =0  >'<
M &UX  !@=P  4G8  $9U   Y=   +G0  "-R   :<0  $G$   UQ   &<0@
M ' -  !P$@  <!<  &\?  !O)@  ;S   &\[  !O1P  ;U0  &]D  !O=0
M;HH  &V@  !MM@  ;-8  &OR  !K_P  :_\ CG,  (5X  !]>P  <WT  &5^
M  !8?@  2WX  #Y^   R?@  )GT  !Q\   3?   #7P   9]    ?04  'P+
M  !\#P  ?!,  'P9  !\(0  ?"D  'PT  ![0   >TX  'M>  ![;P  >H0
M 'J:  !YL0  >,X  '?O  !V_@  =O\ B7H  (%_  !X@@  :X,  %V%  !/
MA@  0H<  #6(   IAP  '8<  !2'   -B   !HD   "*    B@   (D&  ")
M#   B0\  (D3  ")&@  BB(  (HL  "*.   BD8  (E6  "):   B7P  (B4
M  "'JP  AL8  (7J  "%^P  A/\ A8(  'V&  !OB   88L  %.-  !%CP
M.)$  "N1   ?D@  %)(   V3   $E    )8   "7    F    )<   "7!0
MEPL  )@.  "8$P  F1H  )DB  ":+@  FCT  )E-  "97@  F7,  )B+  "8
MHP  E[P  );B  "6]P  E?\ @(D  '*,  !DCP  5I,  $B6   ZF0  +)H
M !^;   4G   #)X   .?    H0   *,   "E    I0   *4   "E    I@(
M *<(  "G#0  J!$  *D9  "K(P  JS$  *M!  "L4P  K&<  *N   "JF@
MJK,  *K0  "I[P  J?L =8\  &>4  !9F   2IP  #R?   MH@  (*,  !.E
M   +IP   :D   "K    K@   +$   "R    L@   +,   "T    M0   +8
M  "X!   N0L  +L0  "]&   OR0  +\U  # 1P  P%L  ,!R  # C0  P:8
M ,#!  "_XP  OO, :I<  %N<  !-H0  /J4  "^I   AJP  $ZT   NP
MLP   +4   "X    O    +\   #!    P0   ,,   #$    Q@   ,<   #)
M    RP   ,X(  #1#P  U1@  -@G  #9.0  VDT  -MD  #;?@  W)D  -RP
M  #<R0  W., 79\  $^E  ! J@  ,J\  "*R   4M0  "K@   "[    OP
M ,,   #&    RP   ,X   #1    T0   -0   #6    V0   -L   #>
MX    .0   #G!@  ZPX  .\9  #P*@  \C\  /-5  #T;0  ](@  /2A  #T
MM@  ],< _P ) /\ !@#_  < _P , /\ $0#_ !P _P H /\ - #_ $$ _P!,
M /\ 50#_ %T _P!E /\ ; #_ '( _@!X /P ?@#[ (0 ^@"+ /D D@#W )D
M]@"B /0 K #S +D \0#+ /  Z #N /L [0#_ .P _P#A /\ T@#_ ,D _P#$
M /\ _P ! /\   #_    _P $ /\ #@#_ !< _P C /\ +P#_ #L _0!& /H
M4 #W %@ ] !? /( 9@#P &P [P!R .T > #L 'X Z@"% .D C #G ), Y0"<
M ., I@#A +$ WP#! -T W0#; /0 V0#_ -8 _P#/ /\ Q #_ +T _P"Y /\
M_P   /\   #_    _P   /\ "P#\ !, ]P > /0 *@#R #4 [@!  .D 2@#F
M %( XP!9 .  8 #> &8 W !L -H <@#7 '@ U !^ -( A0#0 (T S@"5 ,P
MGP#) *H QP"X ,4 S0## .L P #^ +\ _P"^ /\ M@#_ +  _P"M /\ _P
M /\   #_    ^0   /( !@#K  \ Y@ 9 .$ ) #> "\ V@ Y -, 0P#/ $P
MS !3 ,D 6@#' &  Q0!F ,, :P#! '$ OP!W +T ?@"[ (8 N0". +< F "U
M *, LP"P +$ P@"N .  K #W *L _P"J /\ J #_ *, _P"@ /\ _P   /\
M  #U    ZP   .$   #6  P SP 3 ,H '@#& "D P@ S +\ /0"[ $4 N !-
M +8 5 "S %H L0!? +  90"N &H K !P *L =P"I '\ IP"' *4 D0"C )P
MH "I )X N "< ,X F@#N )D _P"7 /\ E@#_ )8 _P"3 /\ _0   /$   #E
M    V0   ,T   #$  8 O0 / +< & "S "( L  L *T -@"I #X IP!& *0
M30"B %, H !9 )\ 7@"= &0 FP!J )H < "8 '< E@"  )0 B@"1 )4 CP"B
M (T L "+ ,, B0#C (@ ^0"& /\ A@#_ (8 _P"& /\ \P   .,   #1
MQ0   +T   "V    K@ + *@ $@"D !P H  F )P +P": #< EP _ )4 1@"2
M $P D0!2 (\ 6 "- %T BP!C (H :@"( '$ A@!Y (0 @P"" (\ ?P"; 'X
MJ0!\ +L >@#5 '@ \@!X /\ =P#_ '< _P!W /\ YP<  -$,  ###0  N P
M *X(  "H    H@ % )L #@"6 !4 D@ ? (X * "+ #$ B  Y (8 0 "$ $8
M@@!, (  4@!_ %< ?0!= 'L 8P!Z &L > !S '8 ?0!T (@ <0"5 '  I !N
M +0 ; #* &L Z@!J /P :@#_ &H _P!J /\ VA   ,84  "X%@  K14  *02
M  "<#@  E@<  )  "0"* !  A0 8 ($ (0!^ "H >P R 'D .0!W $  =0!&
M ', 3 !R %$ < !7 &X 7@!M &4 :P!N &D =P!G (, 90"1 &, GP!B *\
M8 #$ %\ Y !? ?@ 7@+_ %X"_P!> O\ SA@  +T=  "P(   I1\  )L<  "3
M%P  BQ$  (0,  !^! L >0 2 '4 &P!R ", ;P K &T!,P!K 3H :0)  &<#
M1@!F TP 9 12 &,$60!A!&  7P5I %X%<P!<!G\ 6@:- %D'G !7"*T 5@C!
M %4)X0!4"_8 5 O_ %0+_P!4"_\ QA\  +8E  "I*   GB@  )0E  "+(0
M@QL  'L4  !T#@, ;@D- &D(% !F"1T 9 HE &(*+0!@"S0 7@LZ %T+0 !;
M#$< 6@Q- %@,5 !7#5P 50UD %0-;P!2#7L 4 Z* $\.F@!.#JP 3 _" $P0
MXP!+$/D 2Q#_ $L1_P!+$/\ OR8  + K  "D+P  F2\  (\M  "&*0  ?20
M '0>  !L%P  91$' %\.$ !<#Q< 6A ? %@0)P!6$"X 5! U %,0.P!2$4(
M4!%( $\14 !.$5< 3!)@ $L2:P!)$G@ 2!.' $83EP!%%*D 1!2^ $,5WP!#
M%O@ 0Q;_ $,6_P!#%O\ NBL  *LQ  "@-   E34  (LT  "!,0  >"L  &\F
M  !F(   7AD! %<4#0!4%!, 410; $\5(P!.%2H 3!4Q $L6-P!)%CX 2!9$
M $<73 !%%U0 1!== $,89P!!&'0 0!F# #\:E  ]&J8 /!N[ #L;VP ['/8
M/!S_ #P<_P \'/\ M3   *@V  "<.0  D3L  (<Z  !^-P  <S(  &HM  !A
M)P  62$  %$;"0!,&1  2AH7 $@:'P!&&B8 11LM $,;,P!"&SH 01Q! $ <
M2  ^'%  /1U9 #P>9  ['G$ .1^  #@?D@ W(*0 -B"X #4AU@ U(?0 -2+_
M #4A_P V(?\ LC0  *0Z  "9/@  CS\  (4_  ![/   <#@  &<R  !=+0
M5"@  $PB!0!&'PX 0Q\4 $$?&P _'R( /B I #T@,  [(#8 .B$] #DA10 X
M(DT -R)7 #8C8@ T(VX ,R1^ #(DCP Q):( +R6V "\FT@ O)O( +R;_ # F
M_P P)O\ KS@  *(^  "60@  C$,  ()#  !X00  ;CT  &,X  !:,P  42X
M $@H 0! ) P /2,1 #LD&  Y)!\ ."0F #8D+  U)3, -"4Z #,F0@ R)DH
M,2=4 # G7P O*&P +BA[ "PIC0 K*J  *BJT "DJSP I*_  *BO_ "HJ_P K
M*O\ K#P  )]"  "41@  BD<  (!'  !V10  ;$(  &$]  !7.   3C,  $0N
M   \*0D -R@0 #4H%0 S*!P ,B@C # H*0 O*3  +RHW "XJ/P M*T@ +"M2
M "LL70 J+&H *"UY "<MBP F+IX )2ZS "0OS0 D+^X )2__ "4O_P F+O\
MJ3\  )U%  "220  B$L  'Y,  !T2@  :D<  %Y"  !4/0  2SD  $$T   X
M+P8 ,BT- # M$P N+1D +2T@ "LM)P J+BX *2XU "DO/0 H+T8 )S!/ "4P
M6P D,6@ (S%W "(RB0 A,IT 'S.Q !XSRP >,^T 'S/_ " S_P A,O\ ID,
M )I)  "030  AD\  'Q0  !S3P  :$P  %Q&  !20P  23\  #\[   V-@(
M+C(, "LR$0 I,A< *#(> "8R)  E,RL )#,R ",T.@ B-$, (35- " U6  ?
M-F4 'C9U !PWAP ;-YL &C>O !DXR  9..L &CC_ !LW_P ;-_\ HT<  )A-
M  ".40  A%,  'M4  !Q4P  9E   %I,  !020  1T4  #U!   S/0  *CD)
M "4W#@ C-Q0 (C@; "$X(@ @."@ 'S@P !XY.  =.4$ '#I+ !HZ5@ 9.V,
M&#MR !8[A0 5/)D %#RM !,]Q@ 3/>D %#S] !4\_P 6._\ H$L  )51  "+
M50  @E@  'E9  !N6   9%8  %A1  !.3P  14L  #I'   P0P  )T % " ^
M#0 =/A$ '#X7 !L^'@ :/B4 &3XM !@_-0 6/SX %3]( !1 4P 30&  $D%P
M !%!@@ 009< #T&L  Y"Q  .0N< #T'\ !!!_P 00/\ G5   )-6  ")6@
M@%T  '9>  !L70  8EL  %97  !,50  05$  #9.   L2P  (T@  !M%"0 7
M1 \ %404 !1%&P 312( $D4I !%%,0 113L $$9%  ]&4  .1UX #4=M  Q'
M?P +1Y, "4>G  A'O@ (1^  "4?V  I&_P +1O\ FE4  )!;  "'8   ?6(
M '-C  !J8@  8&$  %->  !'6@  /%<  #)5   H4@  'U   !=.!  13 P
M#TP1  Y,%P .3!X #4TE  Q-+@ +33< "DU"  E-30 '3EH !DYI  1.>P "
M3H\  4ZD  !-N@  3=L  4WR  %-_P "3/\ EEL  (UB  "$9@  >F@  '%I
M  !H:0  7&<  $]D  !"80  -U\  "U<   C6@  &E@  !)7 0 -5@D "54.
M  =5$P &51H !%4B  -5*@ "530  %4^  !52@  5E<  %9E  !5=P  58L
M %6@  !5M@  5-0  %3Q  !3_0  4_\ DV(  (IH  " ;   =VX  &]O  !C
M;@  5FP  $EJ   ]:   ,F8  "=E   =8P  %6(   YA   )8 @  V -  !?
M$0  7Q<  %\>  !?)@  7R\  %\Z  !?10  7U,  %]A  !><@  7H<  %V<
M  !=L@  7,\  %SO  !;_0  6_\ D&H  (9O  !]<@  =70  &IU  !==
M3W,  $)R   V<   *V\  "!N   7;0  $&P   IL   ":P8  &L+  !J#P
M:A0  &H:  !J(0  :2H  &DT  !I0   :4X  &E<  !I;0  :((  &B8  !G
MK@  9LH  &7M  !E_   9/\ BW$  ()V  !Z>0  <'L  &)[  !5>P  2'H
M #MZ   O>@  (WD  !EX   1=P  "G<   -W    =P(  '<(  !V#0  =A
M '85  !V&P  =B,  '8N  !U.@  =4<  '56  !U:   ='P  '22  !SJ@
M<L0  ''I  !P^P  </\ AGD  ']]  !V?P  :($  %J"  !,@@  /X,  #*$
M   E@P  &H,  !&#   *@P   H,   "$    A0   (0#  "#"   @PT  (,0
M  "#%0  A!P  (0F  "$,@  A#\  (-/  "#8   @G4  (*,  "!I   @+T
M '_C  !^^0  ?O\ @H   'J$  !LA@  7H@  %"*  !"BP  -8T  ">-   ;
MC0  $8X   J.    CP   )$   "2    D@   )(   "2 0  D@<  )(,  "2
M$   DQ4  ),=  "4*   E#8  )1%  "35P  DVL  )."  "2G   D;8  )#8
M  "/\P  C_\ ?H<  '"*  !AC0  4Y   $63   WE0  *98  !R7   1F
M"9D   ";    G    )X   "@    H    *    "@    H0   *$$  "B"0
MHPX  *04  "E'0  IBH  *8Z  "F3   I6   *5X  "ED@  I*P  *3)  "C
MZP  HOH <XX  &21  !6E0  1YD  #F<   JG@  ':   !&A   (HP   *4
M  "G    J0   *P   "N    K@   *X   "O    L    +$   "R    LP8
M +4-  "W$P  N1X  +DN  "Z0   NE0  +MJ  "ZA0  N:$  +F[  "ZW@
MN?( 9Y4  %B9  !*G@  .Z(  "RF   =J   $:H   >L    KP   +$   "T
M    N    +L   "\    O    +X   "_    P    ,(   #$    Q@   ,@#
M  #+"P  SQ(  -$@  #1,@  TD8  --=  #4=@  U)(  -6K  #5Q   U.(
M6YT  $RB   ]IP  +ZP  !^O   1L0  ![4   "X    NP   +X   #"
MQP   ,H   #,    S    ,X   #0    T@   -4   #8    VP   -\   #B
M    Y@L  .L3  #L)   [3@  .Y.  #O9P  \((  /"<  #PL@  \<4 _P #
M /\  0#_  0 _P ) /\ #P#_ !@ _P D /\ , #_ #P _P!' /\ 40#_ %D
M_P!@ /T 9P#\ &T ^@!S /D >0#X '\ ]@"% /4 C #S )0 \@"= /  IP#N
M +, [ #$ .L X0#J /@ Z0#_ .< _P#9 /\ RP#_ ,( _P"] /\ _P   /\
M  #_    _P   /\ # #_ !0 _P @ /\ *P#^ #< ^@!" /8 2P#R %, \ !;
M .X 80#L &< Z@!M .@ <P#G 'D Y0!_ ., A@#A (X WP"6 -T H #; *P
MV "[ -0 T0#3 /  T #_ ,X _P#( /\ O0#_ +8 _P"R /\ _P   /\   #_
M    _P   /T " #W !  \P : .\ )@#M #$ Z  [ ., 10#@ $T W !5 -D
M6P#6 &$ TP!G -$ ; #/ '( S0!X ,L ?P#) (< QP"0 ,4 F@## *4 P "R
M +X Q0"\ .4 N@#[ +@ _P"W /\ L #_ *D _P"E /\ _P   /\   #^
M]0   .P  P#E  T WP 5 -H ( #4 "H T  U ,L /@#( $< Q0!. ,( 50#
M %L O@!A +P 9@"Z &P N !R +8 > "U (  LP"( +$ D@"N )X K "J *D
MNP"H -4 I@#S *0 _P"C /\ H0#_ )L _P"8 /\ _P   /L   #P    Y0
M -@   #.  D QP 1 ,( &@"^ "0 NP N +< . "T $  L0!( *X 3@"L %0
MJ@!: *D 7P"G &4 I0!K *0 <0"B '@ H "! )X BP"< )8 F0"C )< L@"6
M ,< DP#H )( _@"1 /\ D #_ (T _P"+ /\ ^0   .L   #=    SP   ,8
M  "\  0 M0 - +  %0"L !X J  H *4 ,0"B #D GP!! )T 2 "; $X F0!3
M )< 60"6 %X E !D )( :@"0 '$ C@!Z (P @P"* (\ B "< (8 J@"$ +P
M@@#< ($ ]@"  /\ ?P#_ '\ _P!^ /\ [    -H   #)    O@   +8   "N
M    IP ) *$ $ "< !@ F  B )4 *@"2 #( D  Z (T 00"+ $< B0!- (<
M4@"& %@ A != (( 9 "! &L ?P!S 'T ?0![ (@ > "5 '8 HP!U +0 <P#,
M '$ [0!P /\ < #_ '  _P!P /\ WP4  ,H*  "\"P  L0D  *@$  "A
MFP # )0 # "/ !, B@ ; (< ) "$ "P @0 S '\ .@!] $$ >P!' 'D 3 !W
M %( =@!7 '0 70!R &0 < !M &\ =@!L (( :@"/ &D G0!G *X 90## &0
MY !C /H 8P#_ &( _P!C /\ T X  +\2  "R$P  IQ(  )T0  "5"P  CP,
M (D !P""  X ?@ 5 'H '@!V "4 =  M '$ - !O #H ;@!  &P 1@!J $P
M:0!2 &< 6 !F %\ 9 !G &( <0!@ 'P 7@") %P F !; *D 60"\ %@ W !8
M /0 6 #_ %< _P!7 /\ QA8  +8:  "J'0  GQP  )49  "-%   A0\  'X)
M  !W 0H <@ 0 &X %P!J !\ :  G &4 +@!D #0 8@ [ &  0 !? $8 70!,
M %P 4P!: %H 6 !B %< ; !5 '< 4P"% %( E !0 :4 3P&X $X"T@!-!/
M307_ $T%_P!-!?\ OQT  + B  "C)0  F24  (\B  "%'0  ?1@  '42  !N
M#0( 9P8, &,#$0!? AD 70,A %L$* !9!"\ 5P4U %8%.P!4!D$ 4P9' %$&
M3@!0!U4 3@=> $T(9P!+"', 20F! $@)D@!'"J, 10JV $0+T !$#.\ 0PW_
M $,-_P!$#?\ N20  *HI  ">+   E"P  (HJ  " )@  =R$  &X;  !F%
M7P\% %D+#0!5"A, 4PL; %$+(@!/#"D 30PO $P,-@!+#3P 20U" $@-20!&
M#5$ 10Y: $0.9 !"#G  0 Y_ #\/D  ^$*( /!"V #L0T0 [$?$ .Q'_ #L1
M_P \$?\ M"D  *8O  ":,@  D#(  (8Q  !\+0  <B@  &DC  !A'0  618
M %$1" !,#Q  2A 6 $@0'0!&$"0 11 K $,1,0!"$3< 01$^ $ 110 ^$DT
M/1)6 #P280 Z$VT .1-\ #<4C0 V%)\ -16S #05S0 S%NX -!;_ #06_P T
M%O\ KRX  *(T  "7-P  C#@  ((V  !X-   ;BX  &4J  !<)   5!X  $P8
M! !&% T 0A02 $ 4&0 _%"  /14G #P5+0 [%30 .18Z #@60@ W%DH -A=3
M #477@ S&&H ,AEY # 9B@ O&IT +AJQ "T;R@ M&^P +1S_ "X;_P N&_\
MK#(  )\X  "4.P  BCP  ( \  !V.0  :S0  &(O  !9*@  4"4  $<?  !
M&@H /!D0 #H9%@ X&1T -AHC #4:*0 T&C  ,QHW #(;/@ Q&T< +QQ0 "X=
M6P M'6< +!YV "H>B  I'YL *!^N "<@QP F(.H )R#^ "@@_P H(/\ J38
M )T\  "2/P  AT$  'U   !T/@  :3H  %\U  !6,   32L  $0E   [( <
M-AX. #,>$P R'AD ,!X@ "\>)@ N'RT +1\T "P@.P K($0 *B%. "DA6  G
M(F4 )B)T "4CA0 C(YD (B2M "$DQ0 A)>@ (B7] "(D_P C)/\ ICH  )H_
M  "/0P  A44  'M$  !R0P  9S\  %TZ  !3-@  2C$  $$L   X)@, ,2,,
M "XB$0 L(A8 *B(= "DB(P H(RH )R,Q "8D.0 E)4$ )"5+ ",F5@ B)F,
M(2=R !\G@P >*)< '2BK !LIPP ;*>8 '"G[ !TI_P >*/\ HSX  )A#  "-
M1P  @TD  'I)  !P1P  9D0  %H_  !1.P  1S<  #XR   U+0  +"@) "@G
M#P G)Q0 )2<: "0G(0 C*"< (B@N "$I-@ @*3\ 'RI) !XJ5  =*V  &RMO
M !HL@0 9+)4 %RVI !8MP0 6+>0 %RWZ !@M_P 9+?\ H4$  )5'  "+2P
M@DT  'A-  !N3   9$D  %A$  !/0   1CT  #TX   S-   *B\& "0L#0 A
M+!( ("P8 !\M'@ >+24 '2TL !PN-  ;+CP &B]& !@O40 7,%X %C!M !4Q
M?P 3,9, $C&H !$ROP 1,N( $C+Y !,Q_P 3,?\ GD4  )-+  ")3P  @%$
M '92  !M4   8DX  %9)  !-1@  1$,  #L_   Q.@  )S8# !\R"P <,A
M&S(5 !DR&P 8,B( %S,I !8S,0 5-#H %#1$ !,T3P 2-5P $35K ! V?0 /
M-I$ #C:F  TWO  --]T #3;V  XV_P /-O\ FTD  )%/  "'4P  ?E8  '56
M  !J50  8%,  %5/  !,3   0DD  #A%   N00  )#T  !PZ"  6. X %3@2
M !0X&  3.1\ $CDF !$Y+@ 0.3< #SI!  XZ3  -.UD #3MH  L[>@ *.XT
M"3RB  <\N  '/-4 "#SP  D[_P *._\ F$X  (Y4  "%6   ?%L  ');  !H
M6@  7E@  %-5  !)4@  /DX  #1+   J1P  (40  !A" P 20 L $#\0  X_
M%0 ./QP #4 C  Q *P +0#0 "D ^  E!2@ '058 !D%E  1!=@ #08H  4&?
M  !!M   0=   4'N  %!_  "0/\ E50  (Q9  "#7@  >6   '!@  !F8
M75X  %%;  !%5P  .E0  "]1   E3P  '$P  !1*   .2 @ "T<.  A'$@ '
M1QD !D<@  5(*  #2#$  D@[  !(1P  2%,  $AB  !(<P  2(8  $B;  !(
ML0  1\P  $?M  !'^P  1_\ DEH  (E@  " 8P  =V4  &YF  !E9@  660
M $Q@  ! 70  -5L  "I9   @5P  %U4  !!3   +4@< !5$-  %0$0  4!8
M % =  !0)0  4"X  % X  !00P  4%   %!>  !0;P  4(,  $^8  !/K@
M3LD  $[K  !-^P  3?\ CV$  (9F  !]:0  =&P  &QM  !A:P  4VD  $9G
M   Z9   +V,  "1A   :7P  $EX   Q<   &7 8  %L+  !:#P  6A,  %H9
M  !9(0  62D  %DS  !9/P  64P  %E:  !9:P  6'X  %B4  !7JP  5\4
M %;I  !5^P  5?\ C&@  ()M  !Z<   <G(  &=R  !:<0  3'   #]N   S
M;0  *&L  !UJ   4:   #6<   =G    9@,  &8)  !E#0  91$  &05  !D
M'   9"0  &0N  !D.@  8T<  &-5  !C9@  8WH  &*0  !AIP  8,$  %_F
M  !?^@  7O\ AV\  ']T  !X=P  ;G@  &!X  !2=P  17<  #AV   K=@
M('0  !9S   .<P  !W(   !R    <@   '$%  !Q"@  <0X  ' 1  !P%P
M<!X  ' G  !P,P  ;T   &]0  !O8   ;G0  &Z+  !MH@  ;+P  &OB  !J
M^   :?\ @W<  'Q[  !S?0  97X  %=_  !)?P  /'\  "^    B?P  %WX
M  ]^   '?@   '\   !_    ?P   'X   !^!0  ?@H  'X-  !^$0  ?A<
M 'X@  !^*P  ?3D  'U(  !]60  ?&T  'R$  ![G   >K8  'G:  !X]0
M=_\ @'\  '>"  !I@P  6X4  $V&   _B   ,HD  "2)   8B0  #XD   >*
M    BP   (P   "-    C0   (P   ",    C ,  (P(  "-#0  C1$  (T7
M  ".(@  CB\  (X_  "-4   C60  (Q[  ",E0  BZX  (K-  ")[P  B?\
M>X4  &V(  !>B@  4(T  $*/   TD0  )I(  !F3   .E   !I4   "6
MF    )H   ";    FP   )L   ";    FP   )P   "=!0  G0L  )X0  "?
M%P  H"0  * T  "@1@  H%D  )]P  "?B@  GJ4  )["  "=Z   G/D <(P
M &&/  !3D@  1)8  #:9   GFP  &9P   ^=   %GP   *$   "C    I0
M *@   "I    J0   *D   "J    JP   *P   "M    K@$  + )  "R#P
MLQ@  +0G  "T.0  M4T  +1D  "T?@  LYH  +.T  "SU0  L_  9),  %67
M  !'FP  .)\  "FB   :I   #J8   2H    JP   *T   "P    M    +8
M  "X    N    +D   "Z    O    +T   "_    P    ,,   #%!P  R0\
M ,H:  #++   S$   ,U6  #.;P  S8L  ,RH  #,P@  S.( 6)L  $F@   Z
MI0  +*D  !RK   /K@  !+$   "T    MP   +H   "^    PP   ,8   #(
M    R    ,H   #+    S0   ,\   #2    U0   -D   #=    X04  .8/
M  #G'@  Z#(  .E(  #J8   ZWL  .N7  #LK@  [,( _P   /\   #_
M_P & /\ #0#_ !4 _P A /\ + #_ #@ _P!# /\ 3 #^ %0 ^P!; /H 8@#X
M &@ ]@!N /4 = #T 'H \@"  /$ AP#O (\ [0"7 .L H0#I *T YP"] .4
MV #D /, X@#_ .  _P#0 /\ Q #_ +P _P"V /\ _P   /\   #_    _P
M /\ "0#_ !$ _P < /T )P#Y #( ]0 ] /$ 1@#M $\ ZP!6 .@ 7 #F &(
MY !H ., ;@#A ', WP!Y -T @ #: (@ V "1 -0 FP#2 *8 SP"T ,P R0#)
M .D R #_ ,< _P#! /\ MP#_ *\ _P"K /\ _P   /\   #_    _P   /@
M!0#R  X [@ 7 .H (@#F "P X0 W -T 0 #8 $D TP!0 -  5@#. %P S !B
M ,H 9P#( &T Q@!S ,0 >0#" ($ P "* +X E "\ )\ N0"L +8 O@"T -T
MLP#W +$ _P"P /\ J #_ *( _P"> /\ _P   /\   #Y    [P   .8   #?
M  L U@ 2 -  ' #, "8 R  P ,0 .@#  $( O0!* +L 4 "X %8 M@!; +4
M80"S &8 L0!L +  <@"N 'H K "" *D C "G )@ I0"E *, M "@ ,L GP#N
M )T _P"< /\ F0#_ )0 _P"1 /\ _P   /8   #J    W0   ,\   #'  8
MP  / +L %P"W "  LP J +  ,P"M #L J@!# *< 20"E $\ HP!5 *( 6@"@
M %\ G@!E )T :P"; '( F0![ )< A0"4 )  D@"= )  K ". +\ C #B (L
M^@") /\ B0#_ (8 _P"# /\ ]    .0   #4    R    +\   "U  $ K@ +
M *D $@"E !L H0 C )X + "; #0 F  \ )8 0P"4 $D D@!. )  4P". %D
MC0!> (L 9 ") &L AP!S (4 ?0"# (@ @0"5 '\ I !] +4 >P#/ 'D \0!X
M /\ =P#_ '< _P!U /\ Y0   -$   ##    N    *\   "H    H  & )H
M#@"5 !4 D0 > (X )@"+ "T B  U (8 / "$ $( @@!' (  30!_ %( ?0!8
M 'L 7@!Y &4 > !M '8 =@!S ($ <0". &\ G0!M *X ; #$ &H YP!I /T
M: #_ &@ _P!I /\ U0,  ,,'  "V"   JP8  *(   ";    E    (T "@"(
M !  @P 8 '\ ( !\ "< >@ N '< -0!U #L = !! '( 1P!P $P ;P!2 &T
M6 !K %\ :0!F &< < !E 'L 8P"( &( EP!@ *< 7@"[ %T W !< /8 7 #_
M %L _P!; /\ R0T  +D0  "L$0  H1   )<-  "/"   B    (( !0![  T
M=P 2 ', &@!O "$ ;  H &H +P!H #4 9P [ &4 00!C $8 8@!, &  4@!?
M %D 70!A %L :@!9 '4 5P"" %4 D0!4 *( 4P"U %$ SP!0 .\ 4 #_ %
M_P!0 /\ OQ0  + 8  "D&@  F1D  (\6  "'$0  ?PT  '<&  !Q  @ :P .
M &< % !D !L 80 B %X *0!= "\ 6P U %D .P!8 $$ 5@!& %4 30!3 %0
M4@!< %  90!. '  3 !] $L C0!) )X 2 "P $< QP!& .D 1@#[ $8 _P!%
M /\ N!L  *H@  ">(@  DR(  (D?  " &@  =Q4  &\0  !H"P  800* %T
M$ !9 !8 5@ = %0 (P!2 "H 4  P $\ -0!. #L 3 !! $L 2 !) $\ 1P%7
M $8!80!$ FP 0P)Y $$#B0!  YH /@2M #T$Q  \!>4 / ?X #P'_P \!_\
MLB(  *4G  "9*0  CBD  (0G  ![(P  <1X  &D8  !A$@  6@T# %,(# !/
M!1$ 3 47 $H&'@!(!B0 1P8J $4', !$!S8 0P@] $$(0P! "$L /@E3 #T)
M70 ["F@ .@IV #@+AP W"YD -0NL #0,P@ S#.0 ,PWY #,-_P T#?\ K2<
M * L  "5+P  BR\  ( N  !W*@  ;24  &0@  !<&@  5!0  $P/!@!&# T
M0PP2 $$,&  _#!\ /@PE #P-*P [#3( .@TX #@-/P W#D< -@Y0 #0.6@ S
M#F8 ,0]T # /A0 N$)@ +1"K "P0PP K$>4 +!'Z "P1_P M$?\ JBP  )TQ
M  "2-   AS4  'TT  !T,0  :BL  & G  !8(0  3QL  $<6  ! $0D .Q /
M #D0%  W$!L -A A #00)P S$2T ,A$T #$1.P P$4, +A)- "T25P L$F,
M*A-Q "D3@@ G%)4 )A2I "45P  D%>, )1;Z "86_P F%?\ IC$  )HV  "/
M.0  A3H  'LY  !Q-@  9S$  %TM  !4*   3"(  $,=   [%P4 -10- #(3
M$0 Q%!< +Q0= "X4)  L%"H *Q4Q "H5.  I%D  *!9* "<75  F%V  )!AO
M ",8@  A&9, (!FG !\9O@ >&N  'QKX " :_P @&O\ HS0  )@Z  "-/0
M@SX  'D]  !O.P  93<  %LR  !2+0  22@  $ C   X'@$ ,!D* "P8#P J
M&!0 *1@: "<8(  F&2< )1DM "0:-0 C&CX (AM' "$;4@ @'%X 'QUL !T=
M?@ <'9$ &AZE !D>O  8']T &1_V !H?_P ;'O\ H3@  )4]  "+00  @4(
M '="  !M0   8SP  %DW  !/,P  1BX  #TI   U)   +2 ' "<=#0 E'1(
M(QT7 "$='0 A'20 (!XK !\>,@ >'SL '1]% !P@3P :(5P &2%J !@B>P 6
M(H\ %2*C !0CN@ 3(]H %"/U !4C_P 6(_\ GCP  )-!  ")1   ?T8  '5&
M  !L1   8D$  %<\  !-.   1#0  #PP   S*P  *B8# ",B"P @(1  'B$5
M !PB&P ;(B$ &B(H !HC,  9(S@ &"1" !8E30 5)5D %"9H !,F>0 2)HT
M$2>B ! GN  .)]8 $"CT !$G_P 1)_\ G$   )%%  "'2   ?4H  '1*  !J
M20  8$8  %5!  !,/@  0SH  #HV   Q,@  *"T  " I"0 ;)PX &2<2 !@G
M&  6)Q\ %2@E !0H+0 3*#8 $BE  !(I2P 1*E< $"IF  XK=P .*XL #2R?
M  PLM0 ++,\ #"SO  TL_P -*_\ F40  (])  "%3   ?$X  '-/  !I3@
M7DL  %-'  !*1   0D   #D]   O.   )30  !TP!0 6+0P %"P0 !,M%0 2
M+1P $2TC ! M*@ /+C, #BX]  TO2  -+U4 ##!C  HP=  ),(@ "#&<  8Q
ML0 &,<L !C'K  <P_  (,/\ ET@  (U-  "#40  >E,  '%4  !G4@  75
M %),  !)2@  0$8  #5"   K/@  (CH  !HW 0 2- D #S,.  XS$P -,QD
M#3,@  PT*  +-#$ "C4[  @U1@ '-5( !39@  0V<0 "-H0  #:9   VKP
M-L@  #;H   V^0 !-?\ E$T  (I2  "!5@  >%@  &]9  !E6   6U4  %%2
M  !'3P  /$P  #%(   G1   'D$  !8_   0/ < "SH-  DZ$0 (.Q< !CL>
M  4[)@ $.RX  CLX  $\0P  /$\  #Q>   \;@  /($  #R7   \K   .\4
M #OG   [^   ._\ D5(  (A8  !_7   =ET  &U>  !C70  6EP  $Y8  !"
M5   -U$  "U.   C2P  &DD  !)&   -1 8 !T,,  -#$   0Q4  $,;  !#
M(P  0RL  $,U  !#0   0TT  $-;  !#:P  0WX  $.4  !"J@  0L,  $'F
M  !!^0  0?\ CE@  (9>  !]80  <V,  &MD  !B8P  5V$  $E=   ]6@
M,E@  "=5   >4P  %5$   Y/   )304  DT+  !,#@  3!,  $L8  !+'P
M2R@  $LR  !+/0  2TD  $M7  !+9P  2GL  $J0  !)IP  2<   $CD  !(
M^   1_\ BU\  (-D  !Z9P  <6D  &EJ  !>:0  4&8  $-D   W80  +%\
M "%=   86P  $%D   I8   #5P,  %<)  !6#0  51   %45  !4&P  5",
M %0M  !4.0  5$4  %13  !49   4W<  %.-  !2I   4;T  %#B  !0^
M3_\ B&<  ']K  !W;@  ;W   &5P  !7;@  2FP  #UK   P:0  )6@  !IF
M   19   "V,   1B    8@$  &$&  !@"P  8 X  %\2  !?%P  7QX  %XH
M  !>,P  7D   %Y/  !>7P  77(  %V(  !<H   6[D  %K?  !9]P  6/\
MA&X  'QR  !U=0  :W8  %UU  !/=   0G,  #5S   H<@  '7   !-O   ,
M;@  !&X   !N    ;@   &P"  !L!P  :PL  &L.  !K$@  :AD  &HB  !J
M+0  :CH  &E)  !I6@  :6P  &B#  !GFP  9K4  &78  !D]0  9/\ @'4
M 'IY  !P>P  8GL  %1\  !&?   .7P  "Q\   ?>P  %'H   UZ   $>@
M 'H   !Z    >@   'D   !Y 0  > 8  '@+  !X#@  >!,  '@:  !X)0
M>#(  '=!  !W4@  =V4  '9\  !UE0  =*\  '/.  !R\0  <?\ ?GT  '6
M  !G@0  6((  $J#   \A   +H4  "&%   5A0  #84   .%    A@   (<
M  "(    B    (<   "'    AP   (<$  "'"0  APX  (@3  "('   B"D
M (@X  "'2@  AUT  (9S  "&C0  A:<  (3%  "#[   @OX >(0  &J&  !<
MB   38H  #^,   QC@  (X\  !:/   -D    I$   "2    DP   )4   "6
M    E@   )8   "6    E@   )<   "7    EP<  )@-  "9$P  FA\  )HM
M  ":/P  FE(  )IH  "9@P  F9\  )BZ  "7X@  EO@ ;8H  %^-  !0D
M09,  #.6   DEP  %I@   V9   !FP   )T   "?    H0   *0   "E
MI    *4   "E    I@   *<   "H    J0   *H$  "L#   KA,  *XA  "N
M,P  KD<  *Y=  "N=@  KI,  *ZN  "MS0  K.\ 89$  %.5  !$F   -9P
M ":?   7H0  #:,   "E    IP   *H   "L    L    +(   "T    LP
M +0   "U    MP   +@   "Y    NP   +T   "_ 0  PPL  ,45  #%)0
MQCD  ,=/  #':   QH4  ,:B  #&O   QMX 59D  $>=   XH@  *:8  !FH
M   -JP   *T   "Q    M    +<   "Z    OP   ,$   #$    PP   ,4
M  #&    R    ,H   #-    SP   -(   #6    VP   . ,  #A&   XRL
M .1!  #E6@  YG0  .:1  #EK   Y<0 _P   /\   #_    _P ! /\ "@#_
M !( _P = /\ * #_ #0 _P ^ /T 2 #Z %  ]P!7 /4 70#T &, \@!I /
M;P#O '0 [0![ .L @0#I (D Z "2 .8 G #D *@ X@"W -\ S0#< .X V0#_
M -D _P#* /\ O@#_ +4 _P"P /\ _P   /\   #_    _P   /\ !@#_  \
M_  8 /@ (P#T "X \  X .L 0@#H $H Y0!1 .( 6 #@ %T W@!C -P : #9
M &X U@!T -0 >P#1 (( SP"+ ,T E0#* *$ R "O ,4 P0#" ., P #[ ,
M_P"[ /\ L #_ *@ _P"D /\ _P   /\   #_    ^P   /,  0#M  P Z  3
M ., '@#@ "@ V@ R -, / #/ $0 S !+ ,D 40#& %< Q != ,( 8@#! &<
MOP!M +T = "[ 'L N0"$ +< C@"T )D L@"G *\ MP"M -  JP#R *H _P"I
M /\ H0#_ )L _P"7 /\ _P   /\   #T    Z0   .    #5  @ S@ 0 ,D
M& #% "( P0 K +P -0"Y #T M@!% +, 2P"Q %$ KP!6 *X 6P"L &$ J@!F
M *D ;0"F '0 I !\ *( A@"@ )( G@"? )P K@"9 ,, EP#G )8 _P"5 /\
MD@#_ (T _P"* /\ _    /    #C    U    ,@   "_  , N0 - +, $P"O
M !P K  E *D +@"E #8 HP ^ *  1 "> $H G0!0 )L 50"9 %H EP!? )8
M9@"4 &P D@!U )  ?@". (H BP"7 (D I@"' +@ A0#6 (0 ]@"" /\ @0#_
M 'X _P!\ /\ [0   -T   #,    P0   +@   "N    IP ) *( $ "> !<
MF@ ? )< )P"4 "\ D0 W (\ /0"- $, BP!) (D 3@"( %, A@!9 (0 7P""
M &4 @ !M 'X =P!\ (( >@"/ '@ G@!U *\ <P#' '( [ !Q /\ < #_ '
M_P!N /\ W0   ,D   "\    L0   *D   "A    F0 # ), # ". !( B@ 9
M (< (0"$ "D @0 P '\ -P!] #T >P!" 'D 2 !X $T =@!2 '0 6 !R %\
M<0!G &\ < !L 'L :@"( &@ EP!F *@ 90"\ &, X0!B /H 80#_ &$ _P!A
M /\ S0$  +P%  "O!0  I0(  )P   "4    C0   (8 " "!  X ?  4 '@
M&P!U ", <@ I '  , !N #8 ;0 \ &L 00!I $< : !, &8 4@!D %D 8P!@
M &$ :0!? '0 70"! %L D !9 *$ 5P"T %8 T !5 /( 50#_ %0 _P!5 /\
MP0P  +(.  "F#P  FPX  )(+  ")!0  @@   'L  @!U  L <  0 &P %@!H
M !T 9@ C &, *@!A #  8  V %X .P!= $$ 6P!& %H 3 !8 %, 5@!; %0
M9 !2 &X 40![ $\ B@!- )L 3 "N $L Q@!* .H 20#^ $D _P!) /\ N1(
M *H6  ">%P  E!8  (H3  "!$   >0L  '$#  !K  8 90 - &$ $0!= !@
M6@ > %@ ) !6 "H 5  P %, -@!1 #L 4 !! $X 1P!- $X 2P!6 $D 7P!'
M &D 1@!V $0 A0!# )< 00"I $  OP _ .( /P#X #X _P _ /\ LAD  *0>
M  "8'P  CA\  (0<  !Z&   <A(  &H.  !B"   7 $( %< #@!3 !, 4  9
M $X 'P!, "4 2@ K $@ , !' #8 1@ \ $0 0@!# $D 00!1 #\ 6@ ^ &4
M/ !R #H @0 Y ), . "E #8 N@ V -L -0#T #4 _P U /\ K"   )\D  "4
M)@  B28  '\D  !U(   ;!L  &05  !<$   5 P! $X&"@!* @\ 1P 4 $0
M&@!" "  0  E #\ *P ^ 3$ / $W #L"/@ Y D4 . -- #8#5@ U!&$ ,P1N
M #$%?@ P!9  +P6C "T&N  L!M0 + ?P "P(_P L"/\ J"4  )LJ  "0+
MABT  'LK  !R)P  :"(  %\=  !7%P  3Q(  $@.! !!"@L /@<0 #L&%0 Y
M!QL . <A #8()@ U""P ,P@R #().0 Q"4$ +PE) "X*4P L"EX *PML "D+
M?  H#(\ )@RB "4,MP D#-, (PWP "0-_P E#?\ I"H  )@O  "-,@  @S(
M 'DQ  !O+@  92D  %PD  !3'P  2QD  $,3   \$ 8 -0T, #,,$0 Q#!8
M+PP< "X-(@ M#2@ *PTN "H--0 I#3T )PY& "8.4  D#EP (P]J "(/>P @
M$(X 'Q"B !T0MP <$-0 '1'R !T1_P >$?\ H2\  )4S  "*-@  @#<  '8V
M  !M,P  8R\  %DJ  !0)0  2"   #\:   X%0  ,!$( "P0#@ J$!( *! 8
M "<0'@ E$"0 )! J ",1,@ B$3H (1%# " 23@ >$EH '1-H !L3>  :$XL
M&!2@ !<4M0 6%-$ %A7Q !<5_P 8%/\ GC,  ),W  "(.@  ?CL  '0[  !K
M.   830  %<O  !.*P  128  #TA   T'   +1<% "83#  C$Q  (A,5 " 3
M&@ ?$R$ 'A0G !T4+P <%3< &Q5! !H62P 9%E< %Q=E !87=@ 4&(D $QB>
M !(8LP 1&<X $1GO !(9_P 3&?\ G#8  )$[  "&/@  ?#\  ',_  !I/0
M7SD  %4U  !,,   0RP  #HG   R(@  *AX! "(9"0 >%PX '!<2 !H7%P 9
M&!X &1@D !@9+  7&30 %AH^ !4:20 3&U4 $AMC !$<=  0'(< #QV<  X=
ML0 -'<L #1WL  X=_P /'?\ F3H  (\_  "$0@  >T0  '%#  !H0@  7CX
M %,Z  !*-@  03(  #DM   Q*0  *"4  " @!@ :'0P %QP0 !4<%0 4'1L
M%!TB !,=*0 2'C( $1\\ ! ?1@ 0(%, #B!A  TA<0 ,(84 "R*9  HBK@ )
M(L< "2+G  HB^P +(?\ ESX  (Q#  "#1@  >4@  '!(  !G1@  7$0  %(_
M  !).P  0#@  #@T   O,   )RP  !XG P 6(PH $B$. !$A$P 0(AD $"(@
M  \B)P .(R\ #20Y  PD1  +)5  "B5>  DF;P ')H( !B:6  0FK  #)L0
M!";E  0F]P &)O\ E4(  (I'  "!2@  >$P  &],  !E2P  6T@  %!$  !'
M00  /SX  #<[   M-@  )#$  !LM   3*@< #R@-  TG$0 -*!8 #"@=  LH
M)0 **2T "2DW  <J0@ &*DX !"M<  ,K;  !*W\  "N4   KJ0  *\$  "OC
M   K]@  *O\ DD8  (A+  !_3P  =E$  &U1  !C4   6DT  $]*  !'1P
M/D0  #-    I/   (#@  !<T   1,04 #"\,  DN$  '+A4 !B\;  4O(P #
M+RL  C U   P/P  ,$P  #%9   Q:0  ,7P  #&1   QIP  ,+\  ##A   P
M]0  +_\ D$L  (90  !]5   =58  &M6  !B50  6%,  $Y0  !%30  .DD
M "]%   E0@  '#X  !0[   ..04 "3<+  0V#P !-A,  #89   V(   -BD
M #8R   W/0  -TD  #=7   W9P  -WD  #>/   VI0  -KT  #;@   U]0
M-?\ C5   (16  !\6@  <EL  &E;  !@6P  5UD  $Q6  ! 4@  -4X  "I+
M   @2   %T8  !!#   +000 !$ *   _#@  /A$  #X6   ^'0  /B8  #XO
M   ^.@  /D8  #Y4   ^9   /G8  #V,   ]HP  /+L  #S>   []0  ._\
MBE<  ()<  !Y7P  <&$  &AA  !?80  5%X  $=;   Z5P  +U4  "52   ;
M4   $DT   Q+   &2@,  $D)  !(#0  1Q   $<4  !&&@  1B(  $8L  !&
M-P  1D,  $91  !&8   17,  $6)  !$H   1+@  $/<  !"]0  0O\ B%T
M ']B  !W90  ;F<  &=H  !;9@  3F,  $%A   T7@  *5P  !]:   55P
M#E8   =4    4P$  %(&  !1"P  40X  % 1  !/%@  3QX  $\G  !/,@
M3S\  $]-  !.70  3F\  $Z%  !-G0  3+4  $O8  !*]0  2O\ A64  'QI
M  !T;   ;6X  &)M  !4:P  1VD  #IG   M90  (F0  !AB   08   "5\
M  !>    7@   %T#  !<"   6PP  %H/  !:$P  61D  %DB  !9+0  63H
M %E(  !86   6&L  %>!  !7F0  5K(  %72  !4]   4_\ @6P  'EP  !S
M<P  :',  %IR  !,<0  /W   #)O   E;@  &FP  !%K   ):@   &H   !I
M    :0   &@   !G P  9@@  &8,  !F#P  910  &4<  !E)P  9#0  &1#
M  !D4P  9&4  &-[  !BE   8:T  &#-  !?\0  7O\ ?70  '=W  !N>0
M7WD  %%Y  !#>0  -G@  "EX   <=P  $78   IU    =0   '4   !V
M=0   '0   !T    <P(  ','  !S#   <A   '(5  !R(   <BP  '([  !Q
M3   <5\  '%T  !PC@  ;Z@  &[&  !L[0  :_\ >WL  ')^  !D?@  57\
M $>    Y@0  *X(  !Z!   2@0  "H$   "!    @@   (,   "#    @P
M ((   ""    @@   ((   ""!0  @@H  ((/  ""%P  @B,  ((R  ""0P
M@58  (%L  " A@  ?Z$  'Z]  !]Y@  ?/P =H(  &B#  !9A0  2X<  #R)
M   NB@  ((L  !.+   *BP   (P   "-    CP   )$   "2    D0   )$
M  "1    D0   )$   "2    D@(  ),)  "4#P  E!D  )0G  "4.   E$P
M )-B  "3?   DY@  )*S  "1V   D/8 :H@  %R*  !-C0  /Y   #"2   A
ME   %)4   J6    EP   )D   ";    G0   )\   "@    H    *    "@
M    H0   *(   "C    I    *4   "F!P  J!   *@<  "H+0  J4   *E6
M  "I;P  J8L  *BH  "GQP  INP 7X\  %"2  !!E@  ,YD  ".<   4G0
M"I\   "A    HP   *8   "H    K    *X   "O    KP   +    "P
ML@   +,   "T    M@   +<   "Z    O0<  +\0  "_'P  P#,  ,!)  #
M8@  P'X  ,";  # MP  O]@ 4Y<  $2;   UGP  )J,  !:E   +IP   *H
M  "M    L    +,   "V    NP   +T   #     OP   ,$   #"    Q
M ,8   #(    R@   ,P   #/    TP   -H'  #;$P  W24  -X[  #?4P
MX&X  -^,  #=J0  W<( _P   /\   #_    _P   /\ !P#_ !  _P 9 /\
M) #_ "\ _  Z /D 0P#U $L \P!2 /$ 60#O %X [0!D .L :0#I &\ YP!U
M .8 ? #D (0 X@"- .  EP#= *( V@"Q -4 Q0#2 .@ T #_ ,\ _P#$ /\
MN #_ *\ _P"I /\ _P   /\   #_    _P   /\  @#[  T ]P 5 /, 'P#O
M "D Z@ T .8 /0#B $4 W@!, -L 4P#8 %@ U !> -( 8P#0 &D S@!N ,P
M=0#* 'T R "% ,8 D #" )L P "I +X N@"[ -D N0#W +@ _P"T /\ J0#_
M *( _P"= /\ _P   /\   #_    ]@   .X   #G  H X0 1 -P &@#7 ",
MT  N ,L -P#' #\ Q !& ,$ 30"_ %( O0!8 +L 70"Y &( N !H +8 ;@"T
M '4 L0!^ *\ B "M ), J@"A *@ L0"F ,@ I #M *( _P"B /\ FP#_ )4
M_P"1 /\ _P   /P   #N    XP   -@   #-  4 Q@ . ,$ %0"] !X N0 G
M +4 , "R #@ KP!  *P 1@"J $P J !1 *< 5@"E %L HP!A *$ 9P"? &X
MG@!V )L @ "9 (P EP"9 )0 J "2 +P D #? (X ^P". /\ BP#_ (8 _P"#
M /\ ^    .D   #<    S    ,$   "X    L@ * *P $0"H !@ I0 A *(
M*0"> #( G  Y )D /P"7 $4 E0!* )0 4 "2 %4 D !: (\ 8 "- &< BP!O
M (D > "& (0 A "1 (( H "  +( ?0#, 'P \0![ /\ >@#_ '< _P!U /\
MY@   -,   #&    NP   +$   "G    H0 % )L #0"7 !, DP ; )  (P",
M "L B@ R (@ . "& #X A !$ (( 20"! $X ?P!3 'T 60![ &  >0!H '<
M<0!U 'P <P") '  F !O *D ;0"_ &L Y@!J /\ :0#_ &D _P!G /\ TP
M ,,   "U    JP   *,   ";    D@   (P "@"' !  @P 6 '\ '0!] "0
M>@ K '@ ,@!V #@ =  ] '( 0@!Q $@ ;P!- &T 4P!L %D :@!A &@ :@!F
M '0 9 "! &$ D0!? *( 7@"V %P U0!; /< 6P#_ %H _P!: /\ Q0   +8"
M  "I @  GP   )8   ".    AP   (  !0!Z  P =0 1 '$ & !N !X :P E
M &D *P!G #$ 9@ W &0 / !C $$ 80!' %\ 30!> %, 7 !; %H 9 !8 &X
M5@![ %0 B@!2 )L 40"N %  R !/ .X 3@#_ $X _P!- /\ NPH  *P-  "@
M#0  E0P  (P(  "# @  ?    '4   !N  @ :0 . &4 $P!B !D 7P ? %T
M)0!; "L 60 Q %@ -@!6 #L 50!! %, 1P!1 $X 4 !5 $X 7@!, &@ 2@!U
M $@ A !' )4 10"H $0 OP!# .0 0@#\ $( _P!" /\ LA$  *44  "9%0
MCA,  (01  ![#0  <P@  &P   !E  , 7P + %L #P!7 !0 5  : %$ 'P!/
M "4 3@ K $P , !+ #8 20 \ $@ 0@!& $@ 10!0 $, 60!! &, /P!O #X
M?@ \ )  .P"C #H N  Y -D . #U #@ _P X /\ K!<  )\;  "3'0  B1P
M '\9  !U%0  ;!   &0,  !=!@  5@ & %$ # !- !  2@ 5 $< &@!% "
M1  F $( *P!! #$ /P V #X /0 \ $0 .P!+ #D 5  W %\ -@!K #0 >@ R
M (P ,0"> #  LP O ,X +P#O "X _P N /\ IQX  )HB  "/)   A"0  'HA
M  !Q'0  9Q@  %\3  !7#@  4 H  $D#" !%  T 00 1 #X %@ \ !L .@ A
M #D )@ W "P -@ R #0 .  S #\ ,0!' #  4  N %L +0!G "L =@ J (@
M* "< "< L  F ,D )0#J "4!^P E ?\ HB,  )8H  "+*@  @2H  '<H  !M
M)0  9"   %L;  !2%0  2Q   $,, @ ]!PD .0,. #8!$@ S 1< ,0$< # !
M(@ O B< +0(M "P#-  J SL *01# "@$30 F!5@ )05E ",&=  B!H8 ( ::
M !\'K@ >!\8 '0?G !T(^  ="?\ GR@  ),M  "(+P  ?B\  '0N  !J*P
M828  %@A  !/'   1Q<  #\2   X#@0 ,0L* "X(#@ K!Q( *0<7 "@('0 G
M"", )0@I "0),  C"3< (0I  " *2@ ?"U4 '0MB !L,<@ :#(4 & R9 !<,
MK0 6#,8 %0WF !4-^0 6#?\ G"T  ) Q  "&-   ?#0  '(S  !H,0  7RP
M %4G  !,(P  1!T  #P8   T$P  +1 & "8-"P D# \ (@P3 "$,&0 ?#!\
M'@TE !T-+  ;#30 &@X] !D.1P 7#E, %@YA !0/<0 3$(0 $A"8 !$0K@ 0
M$,8 $!#H ! 0^P 1$/\ F3$  (XU  "$.   >CD  ' X  !G-@  73(  %,M
M  !**   0B0  #D?   Q&@  *A4! ",1!P =$ T &P\0 !D/%0 8$!L %Q A
M !80*0 5$#$ %!$Z !,110 2$E$ $1)? ! 2;P .$X( #A.6  T3JP +$\(
M"Q3C  P4^@ -$_\ ES4  (PY  ""/   >#T  &\]  !E.@  6S<  %(R  !)
M+@  0"H  #<E   O(0  *!P  " 8 P 9% H %1(. !02$@ 3$Q@ $A,? !$4
M)@ 1%"X $!0X  \50@ .%D\ #19<  P7;  +%W\ "1B3  @8J  &&+\ !QC@
M  <8]0 )&/\ E3@  (H]  " 0   =T$  &U!  !D/P  6CP  % X  !',P
M/C   #8K   N)P  )R,  !\?   7&@@ $A<- ! 7$0 /%Q8 #A@<  X8(P -
M&2P #!HU  L:0  *&TP "1M:  <<:0 %''P !!V1  (=I@ !';P  AS=  (<
M\@ #'/\ DSP  (A!  !_1   =44  &Q%  !C1   64$  $\]  !&.0  /C8
M #4R   N+@  )2H  !TE   4(00 #QT+  T=$  ,'10 "QT:  H>(@ ('BH
M!Q\S  8@/@ $($H  R%7  $A9P  (7D  "&.   AI   (;H  "';   A\@
M(/X D$   (9%  !]2   =$H  &M*  !B20  6$8  $Y"  !%/P  /3P  #4Y
M   K-   (B\  !DK   2* 0 #20*  DC#@ &(Q( !2,9  0D(  ")"@  24Q
M   E/   )4@  "95   F90  )G<  ":,   FH@  )KD  ";9   E\@  )?X
MCD4  (1)  ![30  <T\  &I/  !@3@  5TL  $U(  !$10  /$(  #$]   G
M.0  'C4  !4R   /+@, "BP*  4K#@ !*A$  "H6   J'@  *B8  "LO   K
M.0  *T4  "Q3   L8@  +'4  "R*   KH   *[<  "O6   J\@  *O\ C$D
M ().  !Z4@  <50  &A4  !?4P  5E$  $Q.  !#2P  -T<  "U#   C/P
M&CP  !(X   ,-@, !C,)   R#0  ,A   #$4   Q&P  ,2,  #$L   R-P
M,D,  #)0   R8   ,G(  #*'   QG@  ,;4  ##4   P\@  +_\ B4\  (!4
M  !X5P  ;UD  &99  !>60  55<  $E3   ^3P  ,DP  "A(   >10  %4(
M  Y    (/0(  3P(   [#   .@\  #D2   Y&   .2   #DI   Y-   .4
M #E.   Y70  .6\  #B%   XG   -[,  #?2   V\@  -?\ AU4  ']:  !V
M70  ;5\  &5?  !=7P  4EP  $18   X50  +5(  ")/   83   $$H   I(
M   #1@$  $4&  !$"@  0PT  $(0  !!%0  01T  $$F  !!,0  03T  $%*
M  !!6@  06P  $"!   _F0  /[$  #[0   ]\@  //\ A%P  'Q@  !S8P
M;&4  &1F  !99   2V$  #Y>   R6P  )ED  !Q6   25   #%(   11
M3P   $X#  !-"   3 P  $L.  !+$@  2AD  $HB  !*+   2CD  $I'  !*
M5@  26@  $E^  !(E@  1Z\  $;-  !%\0  1/\ @6,  'EG  !R:@  :VP
M &!K  !2:0  1&8  #=D   J8@  'V   !5>   -70  !EL   !:    60
M %@   !7!   5@@  %8,  !5$   5!0  %0=  !4)P  5#0  %1"  !34@
M4V0  %)Y  !2D@  4:L  %#*  !/[P  3O\ ?FH  '=N  !P<0  9G$  %AP
M  !*;P  /&T  "]L   B:@  %VD   YG   &9@   &4   !E    90   &,
M  !B    8@0  &$(  !A#0  8!   & 7  !@(0  7RX  %\\  !?30  7EX
M %YT  !=C0  7*<  %O%  !:[0  6?\ >W(  '5V  !K=P  778  $]V  !!
M=0  ,W4  "9T   9<P  $'(   =Q    <0   '$   !Q    <0   &\   !O
M    ;@   &X"  !N"   ;0P  &T1  !M&@  ;28  &PU  !L1@  :U@  &MM
M  !JA@  ::$  &B^  !GZ   9OX >7H  '!\  !A?   4WT  $1]   V?@
M*'X  !M]   0?0  !WT   !]    ?0   'X   !_    ?@   'T   !]
M?    'P   !\    ? 8  'P,  !\$@  ?!T  'PL  !\/   ?$\  'ME  ![
M?@  >IH  'FV  !XWP  =_H <X   &6!  !6@P  2(0  #F&   KAP  '8<
M !&'   'B    (@   ")    B@   (P   "-    C0   (P   ",    C
M (P   ",    C0   (T$  ".#   CA,  (\A  ".,@  CD8  (Y;  "-=
MC9   (RM  "+S@  BO, :(8  %J(  !+BP  /(T  "V/   >D   $9$   >2
M    DP   )4   "7    F0   )L   "<    FP   )L   "<    G    )T
M  ">    G@   )\   "A P  H@P  *(6  "C)@  HSH  *-/  "C:   HH8
M **B  "BP   H>@ 7(T  $V0   _DP  ,)8  "&9   2F@  !YL   "=
MH    *(   "D    J    *H   "K    J@   *L   "L    K0   *X   "O
M    L0   +(   "T    MP$  +D-  "Y&@  NBT  +I#  "Z6P  NG<  +N4
M  "[L0  N=( 4)4  $&8   RG   (Z   !.B   (I    *<   "J    K
M *\   "R    MP   +D   "[    N@   +P   "]    OP   ,    #"
MQ    ,8   #)    S0   -(!  #4#P  U1\  -<U  #830  V&D  ->&  #7
MHP  UKT _P   /\   #_    _P   /\  P#_  T _P 5 /\ ( #\ "L ^  U
M /0 /P#P $< [@!. .L 5 #I %H YP!? .4 9 #C &H X0!P -\ =@#= 'X
MVP"' -@ D0#3 )T SP"K ,T O0#+ .  R0#[ ,< _P"] /\ L0#_ *D _P"C
M /\ _P   /\   #_    _P   /P   #V  L \0 1 .T &P#I "4 Y  P -\
M.0#: $$ U0!( -$ 3@#/ %0 S0!9 ,L 7@#) &, QP!I ,4 ;P## '< P !_
M +X B@"[ )4 N "C +8 M "T ,T L@#R +  _P"L /\ HP#_ )P _P"7 /\
M_P   /\   #Z    \0   .@   #@  8 V0 . -( %@#. !\ R  I ,0 ,@#
M #H O0!! +H 2 "X $T M@!3 +0 6 "R %T L !B *X :0"L &\ J@!X *@
M@@"F (X I "; *$ JP"? ,  G0#F )L _P": /\ E #_ (X _P"* /\ _P
M /8   #H    W    ,X   #&  $ OP + +H $0"V !H L@ B *X *P"J #0
MJ  [ *4 00"C $< H0!, )\ 40"> %8 G !< )H 8@"9 &@ EP!P )4 >@"2
M (8 D "3 (T H@"+ +4 B0#3 (< ]P"& /\ A #_ '\ _P!\ /\ \@   .,
M  #2    Q0   +H   "Q    JP ' *4 #@"A !0 G@ < )H )0"7 "T E  T
M )( .@"0 $  C@!% (T 2@"+ %  B0!5 (@ 6P"& &$ A !I (( <@!_ 'T
M?0"+ 'L F@!X *L =@#$ '0 ZP!S /\ <P#_ '  _P!N /\ WP   ,P   "_
M    M    *L   "A    F@ " )0 "P"0 !  C  7 (@ '@"% "8 @P M ($
M,P!_ #D ?0 _ 'L 1 !Y $D > !. '8 5 !T %H <P!B '  :P!N '4 ; "#
M &H D@!H *, 9@"X &0 W@!C /L 8@#_ &( _P!@ /\ S    +P   "O
MI0   )T   "4    C    (8 !P"!  T ?  2 '@ &0!U !\ <P F '$ +0!O
M #( ;0 X &L /0!J $( : !( &< 3@!E %0 8P!; &$ 9 !? &X 70![ %L
MB@!9 )L 5P"O %8 RP!5 /( 5 #_ %0 _P!4 /\ O@   +    "D    F0
M )    "(    @0   'D  @!S  H ;P / &L % !G !H 90 @ &, )@!A "P
M7P R %X -P!< #P 6P!" %D 1P!7 $X 5@!5 %0 7@!2 &@ 4 !T $X @P!,
M )4 2@"H $D P !( .@ 1P#_ $< _P!' /\ M D  *8+  ";#   D H  (8%
M  !^    =@   &\   !H  4 8P , %\ $ !; !4 6  : %8 (0!4 "8 4P L
M %$ ,0!0 #8 3@ \ $T 0@!+ $@ 20!0 $@ 6 !& &( 1 !N $( ?0!  (X
M/P"B #T N  ] -T / #X #P _P \ /\ K!   )\2  "4$@  B1$  '\/  !V
M#   ;@4  &8   !@  $ 60 ( %4 #0!1 !$ 3@ 6 $L &P!) "$ 2  F $8
M*P!% #$ 0P V $( / !  $, /@!+ #T 4P [ %T .0!I #< >  V (D - "<
M #, L0 R ,X ,@#Q #$ _P Q /\ IA8  )H9  ".&@  A!H  'H6  !P$@
M: X  %\*  !8 P  40 $ $P "@!(  X 1  2 $$ %@ _ !L /0 A #P )@ Z
M "P .0 Q #< -P V #X - !& #, 3P Q %D +P!E "X <P L (4 *P"8 "H
MK0 I ,8 * #J "@ _@ H /\ H1P  )4@  "*(0  ?R$  '4?  !L&@  8Q8
M %H1  !2#0  2P<  $0 !@!   L /  / #@ $@ V !< -  < #, (0 Q "<
M,  L "X ,P M #H *P!" "H 2P H %4 )@!A "4 <  D ($ (@"5 "$ J0 @
M ,$ ( #D !\ ^0 ? /\ G2(  )$F  "&*   ?"<  '(E  !I(@  7QT  %<8
M  !.$P  1@X  #\+   X!0< -  , #$ $  N !, +  8 "H '0 I "( )P H
M "8 +@ D #8 (P ^ "( 1P @ %( 'P!> !T ;0 < 'X &@"2 !D IP 8 +T
M%P#? !<!]0 7 O\ FB<  (XK  "$+0  >2T  ' K  !F*   720  %0?  !+
M&@  0Q0  #L0   T#0( +0D) "D%#0 F Q  ) $3 "("&0 A AX ( (D !X#
M*@ = S( &P0Z !H%1  9!4\ %P9< !8&:@ 4!WP $P>0 !('I0 1![L $ ?;
M ! (\@ 0"?\ ERL  (PO  "!,0  =S(  &XQ  !D+@  6RH  %$E  !)(
M0!L  #@6   Q$@  *0X$ ",,"0 ?"0T '0<0 !L'%0 9"!H & @@ !<))P 6
M"2X %0HW !,*00 2"TT $0M: ! +:0 .#'L #@R0  T,I0 ,#;L "PW9  L-
M\0 ,#?\ E2\  (HS  !_-@  =C8  &PU  !C,P  62\  % K  !')@  /B$
M #8=   N&   )Q,  " 0!0 9#@H %0P. !0,$0 3#!8 $@P< !$-(P 0#2L
M#PTT  X./P -#DH # ]8  L/9P *$'D "!"-  <0H@ &$+@ !1#4  40[P &
M$/\ DC,  (@W  !^.@  =#L  &LZ  !A.   6#4  $XP  !%+   /2<  #4C
M   M'P  )AH  !X6 0 7$P8 $1 +  X.#@ .#Q, #1 9  T0(  ,$"@ "Q$R
M  H1/  ($D@ !Q)5  8390 $$W8  Q.+  $4H   $[8  !/1   3[@  $_L
MD#8  (8[  !\/@  <S\  &H_  !@/0  5SD  $TV  !$,0  /"X  #0J   L
M)@  )2(  !X>   6&@( $!4)  P3#@ *$Q( "107  @4'P '%28 !A4O  06
M.@ #%D8  1=3   78@  &'0  !B)   8GP  &+4  !?0   7[0  %_L CCH
M (0_  ![0@  <D,  &A#  !?0@  5C\  $P[  !#-P  .S0  #,P   L+
M)"D  !LD   3'P( #1L)  D9#0 &&1$ !!D6  (9'0 !&B0  !HM   ;.
M&T0  !Q1   <8   '7(  !V'   <G0  '+,  !S.   ;[0  &_P C#X  ()#
M  !Y1@  <$@  &A(  !>1@  540  $M   !#/0  .SH  #,W   J,@  ("T
M !<I   0)0( "R()  4@#0 !'Q   !\4   ?&P  ("(  " K   A-@  (4$
M "%/   A7@  (G   "*%   AFP  (;(  "'-   @[0  '_P BD,  (!(  !X
M2P  ;TP  &9-  !=2P  5$D  $I&  !"0P  .D   "\[   E-P  '#,  !,O
M   -+ ( !RD(  $G#   )@X  "42   F&0  )B$  "8I   F,P  )S\  "=-
M   G7   )VT  ">"   GF0  )K   "7,   E[@  )/T B$@  '],  !V4
M;E$  &52  !<40  4T\  $I,  !!20  -40  "M    A/   %SD  ! V   *
M,@$  S '   O"P  +@X  "T1   M%@  +1X  "TG   M,0  +3T  "U*   M
M60  +6L  "V    LEP  +*\  "O+   J[@  *OX A4T  'U2  !U50  ;%<
M &-7  !;5@  4U4  $=1   [30  ,$D  "5&   <0P  $S\   T]   &.@
M #@%   W"0  -@T  #4/   T%   -!L  #0D   T+@  -#H  #1'   T5P
M-&@  #1]   SE0  ,JT  #'*   Q[@  ,/\ @U,  'M8  !S6P  :ET  &)=
M  !;70  3UH  $)6   V4@  *D\  "!,   620  #D<   A$    0@   $$#
M   _!P  /@L  #T.   ]$0  /!@  #PA   \*P  /#<  #Q$   \4P  /&4
M #MZ   ZD@  .JL  #G(   X[0  -_\ @5H  'E>  !Q80  :6,  &)D  !7
M8@  25X  #Q;   O6   )%4  !E3   040  "D\   %-    3    $H   !)
M!   2 @  $<,  !&#P  1A0  $4<  !%)P  13,  $5   !%4   1&$  $1V
M  !#CP  0J@  $'&  ! [   /_\ ?F$  '9E  !O:   :&H  %UI  !/9@
M0F0  #1A   H7P  '5T  !);   +60   E@   !6    5@   %0   !3
M4@0  %$)  !0#0  4!   $\8  !/(@  3RX  $\\  !/2P  3ET  $YR  !-
MBP  3*4  $O"  !)Z@  2/\ >VD  '1L  !N;P  9&\  %5M  !';   .6H
M "QI   @9P  %&4   UD   #8@   &(   !A    8    %\   !>    70
M %P$  !<"0  6PT  %L2  !;'   6B@  %HV  !:1@  65@  %EM  !8A0
M5Z   %:]  !5Z   4_X >7   '-T  !I=0  6W0  $QS   ^<P  ,'(  "-Q
M   6;P  #6X   1M    ;0   &T   !M    ;    &L   !J    :0   &D
M  !I P  : D  &@.  !H%0  9R$  &<O  !G/P  9E(  &9F  !E?P  9)H
M &.W  !BX0  8?P =W@  &UZ  !?>@  4'H  $)Z   S>P  )7L  !AZ   .
M>0  !'D   !Y    >0   'H   !Z    >@   '@   !X    =P   '<   !W
M    =P$  '<(  !W#@  =Q@  '<F  !V-@  =DD  '5?  !U=P  =),  '.O
M  !RTP  <?< <7X  &-_  !4@   18(  #:#   HA   &H0   Z#   $A
M (0   "%    A@   (@   ")    B    (<   "'    AP   (<   "'
MB    (@   "(!P  B1   (D<  ")+   B#\  (A5  "(;0  AXD  (:G  "%
MQP  A.\ 9H0  %>&  !(B   .8H  "J,   ;C0  #XT   2.    D    )$
M  "3    E0   )<   "8    E@   )<   "7    EP   )@   "8    F0
M )H   ";    G0<  )T1  "=(0  G3,  )U)  "<8@  G'\  )R<  "<N0
MF^( 6HL  $N.   \D0  +9,  !Z5   0E@  !)@   ":    G    )X   "A
M    I    *8   "G    I@   *<   "G    J    *D   "J    K    *T
M  "O    L0   +,)  "S%0  M"<  +0]  "U50  M7   +2.  "TK   M,P
M39(  #^6   OF@  ()T  !&?   %H0   *,   "F    J0   *P   "O
MLP   +4   "W    M@   +<   "X    N@   +L   "]    OP   ,$   #$
M    QP   ,L   #-#   SAH  ,\O  #/2   T&(  -"   #0G0  T+@
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M_______@@SP      "Z'[?____________________________^L4Q
M !=MUO____________________________N ,0        EAS/__________
M_________________]): @        !=S/__________________________
M_Z@U          !<T____________________________WT-          !4
MUO__________________________[GU%          !$U/______________
M_____________*ID+P(   0B-TE8SO___________________________^FD
M:T$H/V-_E:>ZVO______________________________U;*LLLSD^O______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________Y;N7=V+(________________________
M_________]N>9S8*  *,________________________________R'\_!0
M  !>S______________________________9@3D        \JO__________
M__________________^>3          CD/__________________________
M_]QO&@         0??G__________________________Z](
M;^[__________________________X03            9.;_____________
M____________[%$             5][_________________________N!4
M            2-;_________________________=!0             .,__
M_______________________YHEH3            (\7_________________
M________WYM<+           #;K__________________________^^Q?54Y
M(A$' 0(1(K+______________________________]^_I9F8FJ"LO=K_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________________^.^
MG8!\^_________________________________*WA%<P#@ =K/__________
M____________________THI,%0      <O/_________________________
M___6?S8         2\G___________________________J1/@
M+ZO__________________________\!:            &I7_____________
M_____________XTD            "(3_________________________YUX
M             '?_________________________M"4              &K_
M________________________?0               %OT________________
M_______]*P               $SK______________________^E
M         #SA______________________\P#                "W9____
M_________________YF*82<              "?7____________________
M___MOHE5)P           "7<__________________________[*G79=2CPR
M+2PP.4?>_______________________________]YMW6TM#3V>3_________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________[]2[UO__________________________
M_______GN(]J2R\5;_______________________________Y*%G- <
M/,G____________________________6@CL         $I?_____________
M_____________^V%,0           &___________________________Z9"
M             %#A________________________[&D              #?)
M________________________LR\              "*V________________
M________>0               !"G_______________________R-
M          "9______________________^I                  ",____
M__________________]&                  !_____________________
M_]\                   !T_____________________Y<
M      !J_____________________\X                   !C________
M______________\I(@$               !A______________________^Y
MHX!7-Q<           !H___________________________ZTZZ4AGQU<7!R
M=X&4________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________]NZG8)I:=/_____________
M_________________\B393T9    '9[____________________________;
MCDP3         &[__________________________]M\+            $77
M_________________________XLJ             "*T________________
M________PD0               .7________________________?0$
M          !________________________G-@                !J____
M__________________^=                  !8____________________
M__]&                  !'^/___________________^D
M       UZ?___________________Y8                    EV_______
M_____________[P                    8SO___________________^L
M                   /PO____________________\
M   *N?____________________\G                   *M?__________
M__________]P                   -N?_____________________@G(QP
M54(S)AL4#PT.$AHFO_____________________________GDV-+.S,O,S];@
M_/__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________^O3O./________________________________2J85E2"P2 87_
M___________________________QJW$\#P       $_@________________
M_________]5_-0           !^R________________________XW4=
M          ")________________________D",               !G____
M___________________50P                !(]O__________________
M__^*                   NW?____________________\X
M       7R/___________________[X                    $MO______
M_____________YP                     I?___________________[H
M                    D____________________]P
M    @O____________________\                     =/__________
M__________\3                    :/____________________]"
M                8/____________________]Z
M7?_____________________1                    8?______________
M________)                   9O______________________R:R9B7UV
M<6QI9V9G:W!ZC/______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^+%JI%Y87?_____________________________W:9W
M4"P,     #'$_________________________^"23A,           "/____
M____________________TG =              !@____________________
M___N;P\                WXO____________________^6'
M       4P/____________________]                     H_______
M_____________ZX                     B?___________________YX
M                    <O___________________[P
M    7____________________]H                     3?__________
M__________H                     ._____________________\.
M                *OG___________________\S
M&^G___________________]>                    #]O_____________
M______^/                    !M#____________________0
M             ,K_____________________*P                   ,C_
M____________________@                    ,O_________________
M____]Q8!!04# 0       08-&,O_______________________SKX=C/S,W/
MT-+4U]SBZO__________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________QVL;_____
M__________________________'&HX1H33(8 !6K____________________
M______^Y?$88          !Q________________________UWPO
M       [X______________________?9 D                ,M?______
M______________]T P                  C?___________________\45
M                    :O___________________YD
M    2____________________[8                     ,/W_________
M_________]<                     &>?___________________8
M                !=/___________________\.
M ,'___________________\O                     *______________
M______]2                     )[___________________]Y
M             ([___________________^E                     (#_
M___________________8                     '3_________________
M____-@                   &W_____________________?
M         &G_____________________UPT                  &C_____
M_________________W                   &'_____________________
M__]0/$9.5%E=861H;'!V?HG_____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________________^_5
MNZ.+<UJ5___________________________XOXYD02$%      !2_/______
M________________]YU6&              7P?_____________________E
M;!8                 C?____________________]C
M    7O___________________YT                     -?S_________
M_________Z$                     $=G__________________\H
M                 +O__________________^X
M *'___________________\,                     (K_____________
M______\M                     ';___________________]-
M             &3___________________]O                     %+_
M__________________^4                     $#_________________
M__^\                     ##____________________J#@
M         "+_____________________1                    !7_____
M________________@0                    OU____________________
MR L                   +L_____________________UX
M      #E_____________________\D<                  #:________
M______________^= 0             '#A?%________________________
MU;F\P<?.U=OAYNWT^___________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________^-_/________________________
M_____^S&I8AM5#LA!P RWO_______________________]>262D
M    H/______________________B38                 9___________
M__________]F                    ,O;__________________Y4
M                 \C__________________Z<
M *#__________________]<                      'S_____________
M______\                      %[___________________\E
M             $/___________________](                     "S_
M__________________]J                     !C_________________
M__^+                      7S__________________^O
M          #A___________________5                      #/____
M________________)                     "^____________________
M5                     "N____________________BP
M      "?____________________RPX                   "2________
M_____________U<                   "&_____________________ZH*
M                  !Y______________________]M
M  !F_______________________W50                !%____________
M_____________VHC*S4_2E5@:G5^AY&<____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________HS[:=@VE.N?__________
M_______________LLH-<.AT"        >_______________________Q6TI
M                0/____________________^#&P
M!\O__________________Y(                      )C_____________
M_____Z0                      &K__________________]T
M             $'___________________\.                     !W_
M__________________\Y                      #H________________
M__]@                      #.__________________^%
M          "W__________________^H                      "C____
M_______________+                      "0___________________O
M%@                    !]____________________/@
M      !L____________________:0                    !:________
M____________F0                    !)____________________TA8
M                   Y_____________________U@
M   I_____________________Z(                    9____________
M__________56                   $______________________^[+P
M                ^/______________________JRD
MS________________________\E'      <3("X^4FB$[?______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________35R?____________________________K2L))W74(H#
M2O_______________________\5]11<             $=C_____________
M_______$4                    )___________________Z(,
M             &C__________________Y0                      #;_
M_________________]H                       ?L________________
M__\5                      #$__________________](
M          "B__________________]U                      "#____
M______________^=                      !I___________________#
M                      !2___________________G#P
M       ^____________________,P                     K________
M____________6                      8____________________@0
M                   %____________________K
M    ____________________WB(                     \O__________
M_________UP                     W____________________Y\
M                S/___________________^A*
MM_____________________^@%@                  G/______________
M________>@(                 =________________________WH+
M           %3/________________________^B5VAT@(V<J[S0Y_______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________MX___________________________TJ-Z
M6#HI(QP6#@8  )______________________K%(.                 &G_
M_________________^1#                     #3_________________
M_WD                       #C_________________\T
M          "R__________________\3                      "%____
M______________]/                      !=__________________^#
M                       Z__________________^R
M       <___________________; P                     "________
M____________*@                      ^___________________3P
M                    Y___________________=
M    U/__________________FP                      P/__________
M________Q <                     K?__________________\#,
M                FO___________________V<
MAO___________________Z,                     <O______________
M_____^-$                    7/____________________^1!@
M            0?_____________________K7P                  '?__
M____________________RDL                  /__________________
M_____\M7   ,&"0Q/TY@=(NGQ___________________________U^?R____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________Z]3-Q\*^NK>SL*VIJ*7____________________=?E,_,",9$0D"
M          #;_________________W8                       "G____
M_____________[H                       !U__________________\'
M                      !&__________________].
M       :__________________^,                        _?______
M___________!                        V__________________Q&0
M                    OO__________________1
M    I/__________________:P                      C?__________
M________D0                      >?__________________MP
M                9O__________________WB$
M4____________________TH                     /_______________
M_____W<                     *____________________ZP*
M            %O___________________^=%                     /__
M__________________^*                     /__________________
M___630                   /W_____________________IRX
M         -7______________________Y@J           &&"U%8.#_____
M__________________^H8W2!CYRKN\WB^O__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
MY\NWJ9V5CHF$@'QX='!L:&60_________________[QJ2"T9"@
M       Q__________________\                        #________
M__________]"                        W/________________^.
M                    LO_________________.
M    C?__________________*0                      :___________
M________6@                      3O__________________A@
M                -/__________________K@
M'O__________________U!<                     "O______________
M____^CT                      /___________________V4
M             /___________________XX                      /__
M_________________[P9                     .__________________
M__%.                     -C___________________^+
M         +_____________________,0P                   *'_____
M________________D1D                  'K_____________________
M\G0*                $5_______________________^AT$Q\L.$538G*%
MF[32]?__________________________U^CT________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________[]_/Q[NSKZ^SQ___________________9LIF'
M>6UD75912T9!/#@R+2@CQ/________________]+)0L
M    DO________________^(                        9O__________
M_______7                        /?__________________,P
M                &/__________________;
M /__________________G0                       /______________
M____R0P                      /;_________________\34
M             -___________________UL                      ,O_
M_________________X(                      +?_________________
M_ZD&                     */__________________],O
M         (W___________________]>                     '?_____
M______________^3!P                   %[____________________-
M0P                   $#_____________________AQ
M     !S_____________________V%X                   #_________
M_____________[].       .'"P^4FJ&I<C________________________"
M?(R:I[;%UNC]________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________NX=?/R<.^NK:QK:FGIJ:GKO________________^^AFU;3$ W
M+R@B'!80"P0     %/_________________7!0
M /__________________-                        /;_____________
M____=@                       -+_________________L
M             ++_________________X20                      );_
M_________________U$                      'S_________________
M_WD                      &;__________________Z
M         %'__________________\<C                     #S_____
M_____________^Y+                     "?___________________]T
M                     !#___________________^C%@
M      #____________________83                     #_________
M____________B \                   #_____________________RU,
M                  #______________________Z4X           )'31.
M:XS_______________________^9.4-17VY]CJ"UR^7_________________
M____________Z_G_____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____Z\RYK*&9D8N&@7QX='!K:&9F:/'_________________844R(Q@.!@
M             )[_________________?@                       '7_
M________________PP                       %+_________________
M^S<                      #+__________________VH
M         !;__________________Y8                       #_____
M_____________[\;                      #__________________^9"
M                      #___________________]I
M      #___________________^0 @                    #_________
M__________^Y+                     #T___________________H7
M                  #9____________________D1@
M  "\____________________RE,                   "=____________
M_________Y@N             ! I1F;$_____________________^Y_'0P:
M*#=&5VE^E:_,[O_________________________GH*JYR-CI_/__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________WU\.OFXM_;V-32T=#2U^#_________________
MSIZ*?'%I85M644Q(0SXZ-C(O+C'_________________TB41 P
M          #__________________T(                       #_____
M_____________WT                       #__________________[ +
M                      #V_________________]TY
M      #<__________________]B                      #%________
M__________^)                      "O__________________^O(@
M                  "9___________________62
M  ""____________________<@                    !I____________
M________H2@                   !.____________________TUP
M               S_____________________Y8N               5,E)W
M_____________________^!R$P   0\?+T)8<(NHR.S_________________
M_______*;VY^CIZPP]CO________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________G@TLC NK6PK*BEHI^=FYN<H*?__________________X)D
M5DM#/#8P*R<B'1@3#@D$  #4_________________Y(
M      "M_________________\P>                      "+________
M__________M2                      !M__________________^
M                  !1__________________^I&P
M   Z___________________00@                     C____________
M_______U:                      ,____________________CQ0
M                ____________________N#X
M____________________Y6T#                    ________________
M_____Y\W               0+U!T_____________________]UR%      &
M%RI!6G64MMK_______________________^\6$149'6&FJ_(X___________
M____________________TLWA\?__________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________/OZ^_W_____________
M_________^ZYJ)V6CXJ&@G][>'9T<G-U>'^0_________________^M/.C H
M(1L5$ L' @         C__________________]I
M    __________________^;"@                      ____________
M_______(.0                      ___________________P8P
M                ____________________B@X
M____________________L#0                     ________________
M____U5L                     _____________________X4:
M           #[/___________________[%)               8.5V!____
M_________________^5['@      #"$X4F^/L]G_____________________
M__^[6"DY25IL@)>PS>W_____________________________LYZTQ=?K____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________^N_GX=S9UM32T-#0T=/9X.OW____________
M______^XBGYW<6QH9&%>6UE85U=97F5Q__________________^_,1\6$ H%
M                ___________________M5@
MZ/__________________@@0                     S/______________
M____JR\                     L___________________TE<
M            F___________________]WP0                    A?__
M_________________Z(W                  4KE/__________________
M_\MA @            PL4':>T?____________________6-,       #2,[
M5W:9ON7________________________#8Q@J.TQ?=(VGQN?_____________
M________________J'^6J+O0Y___________________________________
M__W_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________W<[%O[RYMK2SL;*RM;G R=7C________________
M____EVQD7EE544],2DA'1DA+4%EFH?__________________IR8.!P(
M            5O__________________SE                      .O__
M________________]'D+                    (?__________________
M_Y\R                    #O___________________\18
M    "#%:A/___________________^E_'P          !B=+<9K"Z?______
M______________^G20     "%R]*:(JNU?S________________________3
M=1XF.$I>=8^KR^______________________________KG*%F*S"V_;_____
M_____________________________]_O____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________[^RJJ:CH:"?GZ&CIJRTP,W=[/__________________
M_XI:4T]+2$9$0T)!0D-'3EEI??___________________YXN!@
M         /___________________\-6                   50?______
M_____________^=[&@             )-&"+M/____________________^?
M/P         $)4IQF<+K_______________________&9@\    3*D1B@Z?-
M]?_________________________KCC4K/E%H@9V\WO__________________
M____________OG9_E*G!W/G__________________________________]+8
M\___________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________]O+P[^_O\?/X_?______________
M______________BPGYJ7EI:6F)N?I*RVPM'A[O____________________Z.
M4$I'141$1$5&1TM16FB#J?____________________^F00$           <V
M8X^ZX?_____________________&90H       0G3'.<Q.S_____________
M___________EB"\  !,J1&*"ILST____________________________JU V
M2F%[EK36^O______________________________TH=\F+'+Z?__________
M_________________________]3.[?______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________[>7CX^3FZ.WQ^?__________________
M___________]L922DI69G:.ILKS0[?__________________________G5-'
M24U15F!SBJ_6_/__________________________LE8 &C50;8NNTO?_____
M________________________S6\^7WN9M]?Y________________________
M________[I^#IL+A_____________________________________^/.Z___
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________P
M
M
M                                        ____________________
M____________________________________________________________
M____________________________________________________________
M______________________________\     _^% T6AT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP
M37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN<SIX/2)A
M9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@-2XS+6,P
M,3$@-C8N,30U-C8Q+" R,#$R+S R+S V+3$T.C4V.C(W(" @(" @(" B/@H@
M(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO
M,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"\B/@H@(" @(" @(" \>&UP.D-R96%T;W)4
M;V]L/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O
M<E1O;VP^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(T+3 V+3$R5# R
M.C0R.C$W*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I-
M;V1I9GE$871E/C(P,C0M,#8M,3)4,#(Z-#<Z,#$K,#4Z,S \+WAM<#I-;V1I
M9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(T+3 V+3$R
M5# R.C0W.C Q*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E
M<'-F/"]D8SIF;W)M870^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P
M+S$N,"\B/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T
M;W-H;W Z0V]L;W)-;V1E/@H@(" @(" @(" \<&AO=&]S:&]P.DE#0U!R;V9I
M;&4^52Y3+B!796(@0V]A=&5D("A35T]0*2!V,CPO<&AO=&]S:&]P.DE#0U!R
M;V9I;&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-
M33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @
M(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z<W12968]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E
M9B,B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C!%03E"
M-3DR,S R.$5&,3%"1D1"1$8X-3(W1$4Q,C,W/"]X;7!-33I);G-T86YC94E$
M/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C!!03E"-3DR
M,S R.$5&,3%"1D1"1$8X-3(W1$4Q,C,W/"]X;7!-33I$;V-U;65N=$E$/@H@
M(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z,$%!
M.4(U.3(S,#(X148Q,4)&1$)$1C@U,C=$13$R,S<\+WAM<$U-.D]R:6=I;F%L
M1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @
M(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYC<F5A=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z,$%!.4(U.3(S,#(X148Q,4)&
M1$)$1C@U,C=$13$R,S<\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IW:&5N/C(P,C0M,#8M,3)4,#(Z-#(Z,3<K,#4Z,S \
M+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R
M94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS
M;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S
M/F9R;VT@:6UA9V4O<&YG('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T
M;W-H;W \+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.C!"03E"-3DR,S R.$5&,3%"1D1"1$8X-3(W1$4Q
M,C,W/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(T+3 V+3$R5# R.C0V.C$U*S U.C,P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z
M,$1!.4(U.3(S,#(X148Q,4)&1$)$1C@U,C=$13$R,S<\+W-T179T.FEN<W1A
M;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C0M,#8M
M,3)4,#(Z-#<Z,#$K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@
M*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO=FYD
M+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T
M97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@
M9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E
M+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.C!%03E"-3DR,S R.$5&,3%"1D1"1$8X-3(W1$4Q
M,C,W/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(T+3 V+3$R5# R.C0W.C Q*S U.C,P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @
M(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C!$03E"
M-3DR,S R.$5&,3%"1D1"1$8X-3(W1$4Q,C,W/"]S=%)E9CII;G-T86YC94E$
M/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C!!03E"
M-3DR,S R.$5&,3%"1D1"1$8X-3(W1$4Q,C,W/"]S=%)E9CID;V-U;65N=$E$
M/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD
M:60Z,$%!.4(U.3(S,#(X148Q,4)&1$)$1C@U,C=$13$R,S<\+W-T4F5F.F]R
M:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O
M;3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X
M.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_
M>'!A8VME="!E;F0](G<B/S[_VP!#  8$!08%! 8&!08'!P8("A *"@D)"A0.
M#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_VP!#
M 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $_ ?0# 2(  A$! Q$!_\0 '  !
M  (# 0$!              4& P0'" (!_\0 51   0,# P($ @4'!P@%"P4
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M.23M%;] *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E
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MH8D*=2A^WE>64?+DK"NV>//R/I7?CG!P<'UKS]?K+J:U]5NGHU1J5%[:D2Y
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M&<8/.<C\*] G.#COY5Y_OT_5LWJQTZ&KK-!MK:)DCX8QI'BESY!NSZ8^7\:
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M!2E* 4I2@%*4H!2E* B(G_:JY?[JQ_S.5+U$1/\ M5<O]U8_YG*EZI#;Y?\
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M)DM2'5/)< S@?,3CN>U 4OKRSIQ'1*08Z(26$ML_1A:"?K;D[?#Q^KGMY9J
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M=CTY;+',NLJVL*:?N;_Q,I16I6]SUP3Q]@I/TY;9^H+9>Y3"EW&VI<3&<WJ
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MC<HJ/))/<F@.51NJFN).H9EC9Z>MJND1I+SS/TH@;$*['.W![^M+]U4UQ83
M%UZ>ML&=)1#CYNB%;W5?53PGC..YXJRV&QW*/UOU/>'HCB+9*M\=IF0<;5K3
MMR!Y\8JW:BTY;-0FW&[,*>-OE(FQ\+4G:ZG.U7!Y[]CQ0'/)6N^HT6,](?Z;
M-I9:07%J^EFSA(&2>WH*U+!U,UY?[1&NEIZ=MR(,A)4TZ+JA.X D=B,]P:[!
M+CMRXCT9].YEY"FUC.,I(P?[ZT].62#IVRQ;3:6BS!C)*6D%940"2>YY/)-
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I*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g843142g47a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g843142g47a01.jpg
M_]C_X  02D9)1@ ! 0$!_ '\  #_[1C,4&AO=&]S:&]P(#,N,  X0DE-! 0
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M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q ?\]@0         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ '\]@0  0 " ?SV!  !  (X0DE-
M!"8       X             /X   #A"24T$#0      !    %HX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$1       $     (   )    "0
M   X0DE-!!X       0     .$))300:      -!    !@             '
M"0  #(D    & &< -  W &$ ,  Q     0                         !
M              R)   '"0                     !
M         !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   '"0    !29VAT;&]N9P  #(D    &<VQI8V5S5FQ,
M<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M       '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E
M3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E
M5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M!PD     4F=H=&QO;F<   R)     W5R;%1%6%0    !        ;G5L;%1%
M6%0    !        37-G951%6%0    !       &86QT5&%G5$585     $
M      YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
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M 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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MSU;24C%])F+&F.=0G;;4^-CVNGB"#PH_9<;_ $+/\T=]/!2;32P@L8UI$P0
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M))*4DDDDI22222G_V3A"24T$(0      5P    $!    #P!! &0 ;P!B &4
M( !0 &@ ;P!T &\ <P!H &\ <    !0 00!D &\ 8@!E "  4 !H &\ = !O
M ', : !O '  (  R #  ,@ R     0 X0DE-!"(      4I-30 J    "  (
M 1(  P    $  0   1H !0    $   !N 1L !0    $   !V 2@  P    $
M @   3$  @   !\   !^ 3(  @   !0   "= 3L  @    T   "QAVD !
M  $   #     [    ?T    !   !_0    %!9&]B92!0:&]T;W-H;W @,C,N
M-2 H5VEN9&]W<RD ,C R-#HP-CHQ,2 R,#HQ-#HU,@!*96X@0F5A8VAE;&P
M     Z !  ,    !__\  * "  0    !   ,B: #  0    !   '"0
M   & 0,  P    $ !@   1H !0    $   $Z 1L !0    $   %" 2@  P
M  $  @   @$ !     $   %* @( !     $              $@    !
M2     $X0DE- _T       @          /_A 5)%>&EF  !-30 J    "  (
M 1(  P    $  0   1H !0    $   !N 1L !0    $   !V 2@  P    $
M @   3$  @   !\   !^ 3(  @   !0   "= 3L  @    T   "QAVD !
M  $   #     [    ?T    !   !_0    %!9&]B92!0:&]T;W-H;W @,C,N
M-2 H5VEN9&]W<RD ,C R-#HP-CHQ,2 R,#HQ-#HU,@!*96X@0F5A8VAE;&P
M     Z !  ,    !__\  * "  0    !   ,B: #  0    !   '"0
M   & 0,  P    $ !@   1H !0    $   $Z 1L !0    $   %" 2@  P
M  $  @   @$ !     $   %* @( !     $              $@    !
M2     '_XO__24-#7U!23T9)3$4  0D "(!P041"10(0  !P<G1R0TU92TQA
M8B 'T  ' !H !0 I #5A8W-P05!03     !!1$)%
M 0  ]M8  0    #3+4%$0D4
M                          ID97-C    _    '1C<')T   !<    "MW
M='!T   !G    !1!,D(P   !L   H@9!,D(R   !L   H@9!,D(Q  "CN
MH@9",D$P  %%P  ".+1",D$Q  -^=  ".+1",D$R  6W*  ".+1G86UT  ?O
MW   D)%D97-C         !I5+E,N(%=E8B!#;V%T960@*%-73U I('8R
M
M                                         '1E>'0     0V]P>7)I
M9VAT(#(P,# @061O8F4@4WES=&5M<RP@26YC+@  6%E:(        +5:  "\
M9P  DC!M9G0R      0#"0   0                    $
M       !   !   "   ") 0=!=H':0C9"C8+A0S'#?\/,1!>$8L2MQ/B%0L6
M,A=7&'D9F!JU&](<[QXE'UD@AR&R(MHC_R4C)D0G9BB&*:<JQROH+0@N*"](
M,&DQB3*F,\(TWC7[-Q@X-3E1.FT[B3RE/<(^WC_X01%"*4-"1%Q%=4:/1ZE(
MPTG=2O=,$DTL3D-/65!O4892G%.R5,E5WU;V6 U9(UHZ6U%<9EUX7HI?FV"M
M8;YBSV/@9/%F F<2:"-I,VI":U)L7FUG;G%O>G"#<8QRE'.<=*-UJG:Q=[=X
MO7G#>LA[S7S.?<U^S'_+@,F!QX+%@\*$OX6[AK>'LXBNB:F*I(N>C)B-D8Z&
MCWN0<)%DDEB33)1 E3.6)I<9F R8_YGRFN2;UIS(G;N>K9^?H(ZA?*)JHU>D
M1:4SIB"G#J?\J.JIUZK%J[.LH:V/KGVO:[!9L4>R-K,DM!*U +7MMMJWR+BU
MN:.ZD+M^O&N]6;Y'OS7 (L$0P?["[,/:Q,?%M<:CQY'(?LELREG+1,PNS1C.
M <[KS]70OM&GTI#3>=1AU4G6,=<8V #8YMG-VK+;F-Q]W6+>1]\LX!#@].'8
MXKOCGN1[Y5?F,^<.Y^CHP>F:ZG'K2.P=[/#MP^Z6[W;P5?$S\@_RZO/#])SU
M<_9)]Q[W\_C&^97Z8?LI^^O\I_U<_@O^M/]:__\   'H Z<%+ :$![\(YPH$
M"Q8,' T>#AP/&1 7$102$!,+% 04_!7S%N87V!C,&=8:WAOA'.$=WQ[;']8@
MT2'+(L0COB2X);,FKB>J**8IHBJ@*YXLG2V:+I4OD3"-,8DRAC.#-($U?S9_
M-W\X@#F".G\[?CQ\/7P^?#]]0']!@D*%0XE$C4621IA'FDB;29U*GTNC3*9-
MJDZO3[10NE' 4L=3SE355==6V5?;6-Y9X%KC6^=<ZEWM7O%?]6#X8?QC &0#
M90%E_V;\9_IH^&GU:O-K\&SN;>MNZ&_E<.%QWG+:<]9TS77#=KEWKWBE>9MZ
MD'N%?'I];WYD?UB 38%!@C6#*80<A1"%_H;MA]N(RHFXBJ:+E8R#C7&.8(].
MD#V1+)(;DPJ3^I3IE=F6R9>ZF*>9DYJ FVV<6IU(GC:?): 4H02A]:+FH]BD
MRJ6]IK&GIJB;J9&JAZM_K'>M;ZYGKV"P6K%4LD^S3+1)M4:V1;=$N$6Y1KI(
MNTJ\3KU2OE>_7<!CP6K"<L-[Q(3%BL:0QY;(G<FERJW+MLR_S<C.TL_<T.;1
M\=+[U ;5$M8>URK8-]E$VE';7MQKW7G>AM^4X)SAHN*HXZWDLN6VYKKGO>C
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MAR=7BI3OAF9 O)+NA>@FCI(XAEL$+Y"T@M2Y?*,;E?6F_9^CDWJ3_YQ9D3F
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M*8$%DE%R&X"PD"U<-8"$CE1% (!HC+PJ>("$C D&HX#FA'W ,('MH[ZMN(%
MH)::5X"KG62&%( XFD5Q''_GEUI;47^VE,)$1'^ADK0IUW^PDA,&1'_^A#V_
M1(%)KC>LRX"?JDZ99( %IDN%('^.HEMP/7]$GKA:DG\8FX)#IG[VF2(I47[X
MET(%]G\_A B^D(#.N-JL$( FM#*8F7^$KV"$3G\"JI]O<WZWIDY9V'Z5HJE#
M#'YWH' HWWY>FX(%MGZC@]R^%(!XP\&K@G_3OF.7['\DN,&#DWZ3LS5NQGY
MKDE917X@JG-"DWX'IS H>7WFFUX%@WXF@[JW7)%7;[&F-8^><.V4(8X<<A*
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MHYWVIKU*_YK%I/HY3I@?HL0ER)91F8P-0Y:@B/<  (  @ !_<KG_;6QQX;7
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M?H-8>7[X?HU!NG\G?I(G;G^.?GP$8H"1?I*WO'V4B-6F7'V&A^Z4#GU\AOZ
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M%'F#K>EH.7FHJ9=3C'GNID$]EWH:HWPD"WG-F%\"_'M>@@2LV(N]:=J<^8J
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MN*%=GLD\>YXIG?,KZYN^FY,8T9KRD,@#K)6,@GP  (  @ !J,K\#9K1=SKM
M: Y0X[>6:7!#([0%:L8T*K#H:_0C'Z\^;*(.(;%(:^,  )\$<[   (  @ !I
M[;X];C)=S[HY;MA0];9";YQ#1;)W<&XT6Z\N<3$C<ZU*<9P.M:[H<.8  )W
M>"D  (  @ !IS;SG=61=G;C:=8!0U;3/=;A#)K#M=ADT4:V0=GPCD:N(=JX/
M'*S(=B8  )R)?"(  (  @ !IJ+MR?&M=8;=F?!Y0A[-=>^E"\J]W>]XT+:P4
M>_ CDZGR>_@/9ZKB>]@  )MH?Z$  (  @ !I>KHQ@W]=-;8C@MI05K(5@DM"
MM*XK@=<T%*JW@9HCE*B%@9X/J:DP@:X  )IL@    (  @ !I3KD\BKM='K4<
MB<E01+$ B-Q"GJT-B! S_*F1AY(CG:<ZA\ /YJ>KAK@  )F0@    (  @ !I
M*;A_D?Y=%+1'D,A0/[ 8CX)"E*P;CFPS\:B;C>$CIZ8RCD40(J99BND  )C?
M@    (  @ !I#;?SF5E=%[.>E^901*]9EE5"DJM-E0@SY*?'E+8CG*5>D\P0
M/Z59BOP  )A(@    (  @ !H^K>/H.M=([,3GTE04:ZUG7Q"EJJ;G"4SZ:<+
MFVXCL:24F"(05J2#BPP  )>R@    (  @ #-4&QM9D2YYVXP:'6ETV_8:I"0
MX'%C;)1[#G+?;HUD571/<'U,;'6D<E QK7:I<]8-QW@Q<[;+7&GN<52X6&OG
M<F>D;6VV<W>/GV]G=(9YXW$&=9=C/G*6=J5+87/Z=YLPL73<>%4,YG9T=^7)
MB&?)?&"VD6G<?%RBX6O+?%^.)FV9?'UXD6]6?*IB$G#_?-Y*67)O?00OQG,K
M?00,(73N?(/'NV7BAU"TPF@*AE"A&VH+A6",FFORA(=W*FW-@]-@VV^,@R])
M5'$%@HTNZ7&9@>L+=G.;@+C&&&1&DC2S*69\D%2?@VB-CGZ+#VJ#C+MUUVQN
MBQ=?LFY#B:)(8&_"B$$N'G KAQ\*Y')XA%+$Q6, G2&QW64_FG">.&=5E[6)
MRFE3E0ITIFM'DH5>I6TAD#-'@FZFCBDM:6[FC,4*:'&$APG#MF']J!.PU&1
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MQ)X0>AUL,IN[>F%>S9EX>IQ0?)=8>MQ [)6!>QTOTY0\>T\;]Y1G>S$$=)'
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MC\H'?'-9A1"VCEE_JPZE!5QBIWR2G%[^H[Y_7V%VH AK;F/GG)E6K68LF8]
MUF?)ER<G[&;BE2('1'.XA.JV"EC4M:RD?ENUL3^2 UY$K*5^NF"QJ"%JSV,=
MI -6'V5@H'Y 36;PGA\G;F7(F5\'&'0#A,RS-V[L7T>BF7!/8C&1#G&G9.E^
M:'+V9W=JM'0_:>U5Z76!;$T_O':D;G<F G=:;_P$,GL)<1*QPFPL::NA>VW/
M:XR0 &]0;5!]:W"];O]IPW(@<)]5#G-X<C(^^'2@<YHE5W4/='@#X7ER=<FP
M,6FU<_2?S6M^=-^.>VT@=;A[]FZM=HQH>G P=V!3[7&A>"X]_G+)>-PDAW+F
M>28#F7GK>D:NDF>"?A^>)FEF?BV,VFLA?BYZE6S'?BEG.&YI?C!2V6_N?CL]
M''$7?CPCTG#A?A #6WI3?BNM$&6?B$><LV>8AXN+;&EIAKIY+FL@A>%F$VS1
MA151UVYLA&<\2V^2@\<C,&\&@U,#)GJM@8*KUF08DGV;@&8?D/R*06?ZCUEX
M#FF_C:]E!6MZC!I0]FT6BJ\[E&XZB8@BH&U=B1\"^GKY@@.JW&+<G+6:B63L
MFG*)2V;+E_YW'VB5E85D)6I<DS50-FO^D28Z_VT2CX\B+VOJCMP"U7LW@>JJ
M(V'LINV9S&/^H^F(A&79H*AV5F>?G6)C8&EJFF%/@&L4E]$Z;FPAEA8AR6JJ
MDY "MWMJ@=:IK6%%L1^91F-4K5N'Z&4BJ4UUL6;<I45BQ6BBH:1.^FI*GK8Y
MZVM*G/HA3VF*EH4"GWN3@<6EI'<57L.6>G>O8;J&-'A<9'1TIWD49OMA\'G3
M:6=.!GJ;:[<XBWMF;;\>RWP[;M,  (  <F"D>'1Y:(V56G54:HZ% 78E;&ES
MBW;V;B=@[G?+;]5-(GBC<6PWPWEF<L<>*'G8<U$  (  =P6C-G(7<E"4 G,?
M<VZ#Y'0.='1R:'3X=69?['7@=E-,1G;'=S8W$7>%=^T=G7>2> <  (  >QBA
MQ&_U>_>2C7$7?$^"6'(??(QQ&7,>?+E>N'0E?.E+/'4>?1@V-775?38<\W5W
M?0,  (  ?J*@;&XFA9R1.&]:A3N!"'!UA+=OU'&#A!]=M'*4@Y!*57.?@Q<U
M?'1-@JT<:G.%@F\  (  @ "?4&ROCU:0(&WOCCY_^&\3C/=NS7 LBYU<O7%%
MBE5)C7),B38TVW+RB&,;[W'+B$L  (  @ ">;6N F1.//&S(ET=_%&WNE3]M
M\&\+DR=;[G ND31(W'$WCX@T67'%CG$;D'!=C5@  (  @ "=Q&J6HM..BFOC
MH%=^6&T%G9%M-6X=FKQ;-F]"F"M(,'!2EADST7#4E1\;.F\UD7H  (  @ "=
M5&GQK)>."&L]J7)]P6Q4I?)LEVU?HFM:I6Y]GTU'M6^*G0,S5F__FW@:Q&Y'
MDAD  (  @ "84'^77EJ*27]P849[&']X8_AJEG^>9G98V'_7:-5%QH N:PTP
MY8"^;-X6M8(];30  (  =ER74WT;9YB)1GTY::1Z 7UD:X=ID7V<;4U7[7WC
M;OY$^WY!<(\P.7Z]<<D6-G^S<;L  (  >F>6.7K7<+Z( 7L@<@%XY7MB<R=H
M>'NP=#=6^GP(=3I$+WQP=BDOEWS;=M@5Q7U(=H4  (  ??.5!7C$>>>&O'DJ
M>G)WEWF%>MMG>7GA>SE6$'I.>XY#<7K >]PO"7L;? H59GL=>Z8  (  @ "3
MTW<'@PZ%KG=_@O-VA'?J@K!F37A2@E)5'WC'@?M"EGE(@;0N5WF2@784Z7E-
M@5,  (  @ "2U'6DC$N$J78FBX=UA':7BI%E6'<&B8-4.G=^B(-!X'?VAZXM
MQG@PART4@7?&AJ8  (  @ "2!W2"E8F#VW4,E"-TMW5]DGQDD77ND,%3?79L
MCRE!07;BC>$M6G;\C5,4.79^BQ8  (  @ "1:G.@GLR#-W0PG,IT"W2>FGAC
MYW4(F!-2UW6&E?- H78 E&8LVG8'D_X3]75WC7X  (  @ "0_7+]J!R"NG./
MI8IS?7/THI-C5711GX]24W3&G/U ,W4YFVHL;'4SF8P3BW2TC3<  (  @ "+
M+(A^7?!^$8>M8,=OTX<=8VI@1X:X9=M/=(9Q:"<]*X9F:CLHO(;M:[D.!HC^
M:T<  (  >=.*488T9JU].H6D:+5N[(4M:II?<X3.;&).NH2*;@\\CX1\;X\H
M0(3?<(\-UX9);_4  (  ?5B)7H0';U-\'8.D<*-M[8-"<=M>=X+S<OI-WX*[
M= L[V(*Q=/HGLX+W=8<-GH/G=.\  (  @ "(3X(4=^AZ^H'%>)=LN(%X>2I=
MA($R>:A- ($->AX[(X$'>H$G+($R>JL-9H'1>ET  (  @ "'2H!6@(MY_8 ;
M@*-KPG_?@)9<BW^F@&Y,9W][@$DZJ']]@"TFW'^.@! -4G_^?^@  (  @ "&
M:'\'B4]Y-G[8B--K GZ;B"-;PGY>AU9+C7XWAI<Y_7XLA@DF47XDA=D-#7YZ
MA*,  (  @ "%L7WSDA%X>7W,D09J1WV-C[=;#7U.CE!*W'TIC0\Y9GT6C"PE
M]7SCC#H,ZGTRB)8  (  @ "%(GT=FM5WYWS[F41IL'RWEU]:>7QOE6)*27Q&
MD[(XTWPTDK$E@GOFDDH,RWPGB*8  (  @ "$N'Q_H[%W='Q@H:QI+WP3GSA9
M]GN\G+%)UGN'FJPX=GMKF> E)GL,ER,,BGM?B'H  (  @ !^0Y'Y769QVI"1
M8!ID:8]Q8J95NHZ#90=%OHW#9SDT'XUR:1L?THY6:A<&3HZ9:A0  (  ?,M]
M>X_H9:AQ*HZP9Z!CLHV9:7]5&8RD:T-%-HO<;.4SM8M];D4?CHPG;N &:HOV
M;O   (  ?]Y\KHW7;=%P.HS%;R-BY(N\<&)43HK0<8Y$BXH-<J,S+HFI<X8?
M-HHC<\P&=XF?="L  (  @ ![R8OM=>EO1(KN=JIAWHGY=U13A8D3=_%#UXA=
M>'LRHX?V>.<>W8A&>.T&?(>2>;\  (  @ !ZZ8I*?@5N>(E8?D1A&8AK?F12
ML(>.?FI#48;+?FTR-H9G?G<>G8:,?F,&C(7&?J\  (  @ !Z(HCZAD1MN8@6
MA?M@7H<JA8=2"X9"A/A"NH5\A'$Q\H3WA" >;H3YA#L&D80\@ML  (  @ !Y
M@X?TCHQM.H<:C<Y?XX8GC,I1=X4PBZ="&81IBK(Q8(/>BC(>*8.CBHD&BX+S
MA&P  (  @ !Y!(<JEMULN894E;%?7859E"=0]815DGQ!FH.#D3$PU(+XD,@=
MN(*;C]8&B8'EA&L  (  @ !XHH:2GTUL4H6^G<M>ZH2XF\90@H.EF:)!-H+"
MF"4PAH(FE[8=@8&OD_,&?8$4A&,  (  @ !QKYO87+)E\9GW7T)9.YA@8;1+
M3I;\8_L\"I7:9@<JXI5]9YX6+I>%9\<  ),-:;\  (  ?TIP]YH.9(QE9YA'
M9F]8M):B:$!*X94C:?@[MI/J:X,JKY-N;*L6,)47;)0 +Y"^;K8  (  @ !P
M3Y@3;$)DHI9J;8Y8#I3+;LQ*/Y--;_L[-)(1<0DJ5I&"<<H6%9+<<84 <XYP
M=#,  (  @ !ODY8Q<^-CT926=*U7*Y,'=65)C9&/=A(ZF9!;=J@IY8_!=PD5
MWI#9=JT HHQK>40  (  @ !NUY2;>Y!C%Y,,>^)6<9&"?!U(T) )?$,Z$H[/
M?&<I=8XQ?'P5G(\.?#H PXJJ?:8  (  @ !N,I-;@UIB?)'6@SY5W)!(@OM(
M.X[*@J$YA(V&@E8I,(R^@C<5=HUD@F@ X(DG@)<  (  @ !MK))/BR=A]9#5
MBJ%55(]%B>1'LXV_B14Y!HQVB'8HSXN=B%$5=8OCB 0! X??@*\  (  @ !M
M0I&+DPIAL9 7DC55$HYYD0%':8S3C[$XO(MTCM,H<(J>CP05&8K'C* !&H;1
M@+X  (  @ !L[Y#XFPYA7X]]F?A4N8W4F%]'$(P@EK$X<HJQE=$H.8G%E2<4
M_(G)CC !)X8#@,@  (  @ !E8J976[!:$J0?7A5-\*(C8&5 JZ!;8HTQ\I\%
M9&@@YY\398H+^Z&[91H  (V4;=(  (  @ !DLZ3,8R=9IJ*.9/%-DZ!M9K!
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M;=T&N72C;L6S*EW.9&&B<6":9JR0U&,V:.9^2V6N:Q!JNF@-;2A6'FI ;RY
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M7HZ";.D  (1><Z<  (  @ !F?HUQ;;Q;7HR>;O]/8HO)<"I"98L%<3PS[(J
M<B C;XJ8<IT/-XO/<@X  (*\>)H  (  @ !EKXM]=4Q:EHJ\=A5.FXGQ=L)!
MGHDN=U S9HB?=\@C XBB=_T/#(E3=Y0  (%.?.4  (  @ !D]XGB?/!9[HDP
M?4M. (AG?7M!"8>??8TRWH<$?9DBV8;,?:,/"X<2?;4  ( ;@    (  @ !D
M6HB(A(M94H?FA'=-:(<@A"] =H94@] R6H6P@XHB@(58@XD/,X4A@T<  (
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MB))<B&!.+Y$ZB#M"YX_FA\0VD(Z&AS8HW(U^AP88MXUSAT<'*XJCA-D  (
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MQZ0+:*=$HZ)9:=XYI*"V:P$MH9]);  ?P)Z_;)$.QJ _;"@  )AW;RL  (
M??\  (  @ !.2Z(+;W%$*Z!K<$XY,Y[%<1$M*YU,<:0?C)RE<?8.P)W9<8X
M-98 =0D  (  @    (  @ !-UZ!J=F!#RI[3=O XY)TH=U4LZYN>=Y$?6)K7
M=YP.V)NI=UX <9/:>E0  (  @    (  @ !-<Y\3?55#?YV#?:(XJYO/?; L
MMYHW?9X?)IE=?8P.T9GE?;4 L)()?LX  (  @    (  @ !-))X#A%E#2IQS
MA'$X@9JVA#(LF9D(@]\?"I@2@^0.JIAW@WL M9"9@'L  (  @    (  @ !,
M\9TIBX]#*)N4BX8X9)G0BP@LAI@0BHX?$Y;SBJ\.V9<>B$0 W8]G@)8  (
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M8W;5<=-=5'>0<O5177@E<_5$47BB=-$V(WD+=8TER'E@=@,1]7GX=9X  (
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MIHQO49A6!XOM5-Q*=XNI5_T]G(N56N0O&HO7764>"(TI7OH)@(YJ7RD  (
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M]'['=L11B'\*=X5&/7\?>!PYW7\7>(XL(W\4>.(<)7\H>/$)6G^T>9D  (
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MGI/]5S])O)-$6> ^Q9*G7%TRB))$7ILD9Y*(8$\2V)3G8)D!U)$*8FD  (
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MXH?B>JE&#(>X>RT[6(=4>W4O@(;5>Y<B!(:3>Z81J(;E>XL"<(2"?5<  (
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MFYT-6YT]-)PM7:PRPIMO7XXFVYKY8208PYN]8>H(EYO.8E   (Q#:5$  (
M>:D  (  @ !&!YH\8CH\A)EO8]PQ]IB\958F0)A'9HL81YCM9P8(@)A,9U\
M (G>;GP  (  ?8   (  @ !%9)>X:.@[W9<,:BDQ7I98:T EJ)72; H7^Y9,
M;$L(=94/;*\  (?&="\  (  @    (  @ !$Q963;[X[2I4*<*<PY)1;<5\E
M3).^<=,7N)0 <= (DI(I<F0  (80>6<  (  @    (  @ !$.Y/"=IPZSY-:
M=SDP@I*N=Y8D^)(!=[P7:)(>=YD(@H_2>)L  (2R?<H  (  @    (  @ !#
MR9)!?9 Z;9'V?>TP,I%/??@DPY"(?=H70I!S?<@(4HWP?G@  (-%@    (
M@    (  @ !#@)$$A,8Z)9#.A/0O\9 RA+,DF8]9A&472H\%A(<(A8Q9@U@
M ()Q@    (  @    (  @ ">^U/53=6/R%<(4AV !%HB5E!O7%TL6F-=I6 9
M7E%*OV*U8A$V<61C98$>7V.69_0!>WV :QF<T4Z%6 B.%%(N6V]^A%6R7KYN
M"%D18?)<;UQ#909)JU\'9_8U@&"8:I\=K6 R;'8!BWUD;\^:VDFL8CZ,.TW
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M 4F)A]17.TV3AQ5%7%"MAGLR+E$UAB$;9U7*AI(!PGT(@3"2]3@&E#^%93W
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M6MLAE'Z 70T,S("@77@  (  99T  (  >[1C177"5-]8J';!6 ),_7>Z6P5
M*GBD7=@QR'F"8%,A''IG8A$,M'RL8CT  (  :D@  (  ?O1A\7&G7(-777+N
M7Q=+[G0289 _+W4/8]<P^G7F9= @@79X9QX,?'E!9QH  (  ;U8  (  @ !@
ML&W59#)6&V]19C1*L'"7:!T^-W&L:=\P'G)^:UD?U7*S;#\,,'98;"   (
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M8F!MBNQ2)F*JBJ5&_V1NB?4ZS&65B2TM2V78B,P=J&4FB2H+66T^AJH  (
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M&G0Y:4=**752:LX_578O;#8S8G;0;6PEXG<W;E@51W>$;EX$6GMI;^,  (
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M[XV@2M=#8(UJ3C8XU8V#46DLO8W_5$0>58]?5E<,@)'=5O8  (F*7#0  (
M;*T  (  @ !+DXG+491".(GF5(LWM8H75U KQ8I_6;X=F8N86VP,.8T56]8
M (9.8-\  (  <8X  (  @ !*A87Z6&=!'(9+6NDVO(:473PJUX;S7SL<W(?4
M8(0+Y(B>8+\  (-49;H  (  =H@  (  @ !)C8)47T= %X+(84\UJX,C8RLJ
M 8.!9+\<((0Q9:L+B(2W9<(  ("J:MX  (  >NL  (  @ !(FW[Q9CP_)W^/
M9\XTPG_^:3<I'H!/:E<;E8#!:O@+.X%@:OT  (  <'D  (  ?KX  (  @ !'
MNGOB;4P^37RP;G S_GTV;V@H<7U]<"(:^WVF<&P+$WZ&<(<  (  =E4  (
M@    (  @ !&^'DQ=%T]E7HM=1TS7'K+=:<GYGL%=@,:<GKG=A,*U'PV=FP
M (  >T<  (  @    (  @ !&3W;0>VP\ZW@#>] RO7B\>_@G77CM?  9^GB$
M>_L*;7IO?*T  (  ?W@  (  @    (  @ !%TW3;@KP\AW9$@N R;W<@@I\G
M.G<Y@DL:)'9R@EL*SGBU@@8  (  @    (  @    (  @ ! F9E%2*LWLIBM
M2^4MHYB43M0AJIE143L2>9PR4E,#4IF^5&   (2R7XH  (  < T  (  @  _
M-Y6\3P0V5)6.4=DL+)695&(@2Y9 5F81;IBA5R\#"94563\  (&N9$   (
M=0$  (  @  ^09(657@U.I(95^$K'I(^6@(?.I+76Z 0H)3#7!\"TI#/7BX
M (  :2,  (  >70  (  @  ];XY]6_TT4(Z?7?8J&([57ZD>9X]D8.@/_Y#7
M82H"JHT&8SH  (  ;E8  (  ?5@  (  @  \FHL48IHS=(MI9"8I1(NM970=
MF8PB9DL/IXT09F<"F8G%:(<  (  = 0  (  @    (  @  [RX?R:5TRIHB'
M:H$HD(CE:VL=!HE":_$//XFD:]8"IH<#;C   (  >3L  (  @    (  @  [
M%84I<"DQ](7^<.\G^(9W<7D<C8:_<;0.YX:N<88"EH3%=%,  (  ?9@  (
M@    (  @  Z?(*[=PHQ78//=WPG=H1E=ZX<+H27=Z@.HX1)=Y(";H,">BL
M (  @    (  @    (  @  Z#8"J?B<PYX'V?D\G"X*L?C$;XX+,?@$.D8)<
M?BX"B8&(?O\  (  @    (  @    (  @    /__  #__P  __\  &UF=#(
M    ! ,)   !                     0                    $   $
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M@2:JJ(N?@,2DBG41@(.>55ZG@%27T4AI@%.0V3)@@'*(^^/6@P[(I<X%@B3
MXK?&@5>Y4Z%*@+^Q^HK0@&&JNW1K@"ZC7%XI@ >;E4@"@ >3.S(7@#")_N,
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MHYR#<*OBG_*"?)G.G'.!M8=NF1^!)73%E>^ TF(*DL> KD^)CX^ ICUNC#6
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MB5X:CRJ>I$R9C""7@3N?B1R0%"O%A?2(B;"=KBAZ)I^*J<UZ"8Z.I7YZ&WV
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M>;F$S]HM>C2#RL,J>K."Z*O/>SN",I0T>]"!JGR(?':!0F3A?2Z XTU5?A"
MGS8!?SJ :.[,>%F0 MAJ>.6-VL&?>7B+TJI>>AF*$)+J>LF(?7MD>XN'!6/D
M?%^%ADQ]?5N#_C5,?IN"/^T&=S.;,=:N=\B7[[_X>&B4V*C@>1F1\I&8>>&/
M5'I!>KN,PV+R>Z>*&DNX?+F'1S2M?@R#_>MI=D>F5=4;=MZB [YR=X6=WJ=W
M>$&9[)!->1:6'7DH>@:2<F(->P:.EDL"?"R*;S0D?8V%G>H$=9.Q;]._=B>L
M$;T>=LVFUZ8W=X^ASX\O>&Z<YG@?>6F7_6$Y>GR2ZTI?>[*-;3.O?1^'%^C:
M=06\>]*==96V#KO_=C>ONJ4D=ONIE(X]=^2CC7=1>.J=<V"!>@:7#$G4>TN0
M,S--?,*(:.?G=)S'<=&P=2>_[KL0=<*X>Z0W=H*Q*XU@=W&I^':;>(.BKE_R
M>:J:_$E>>O:2NS+\?'2)C.<G=%720=#V=-G)F[I,=6K _Z-N=B2X@(RB=Q.P
M%77T>"NGB%]J>5N>CDCY>K&4^C*\?#:*@>*9A!%X&\V-@X5X>+@<@PYXX:(X
M@JMY9(P)@EQZ#'6\@A]ZV5^ @?![PTE5@>)\[#-\@@1^=>#A@HZ"J<Q<@A>!
MYK<2@;.!/Z$H@66 P8KI@2N :W2@@0F .5YS@/Z &4AU@16 'S+@@5J 2=]1
M@4&-0<K!@-F+;K66@(*)N)_%@$V(/HFR@"Z&\'.4@"F%OEV/@#6$BD>Z@&2#
M6#)6@+^"!]V_@"B7Q<DE?\>4]+0!?WR20IY<?U"/N8AT?TN-;G*'?UR+,5RW
M?W^(XT<3?\6&=#'=@#2#K-Q$?T*B0<>S?N*>>[*:?J":TIT'?H"72H=!?H*3
MW7&)?JJ0DUOO?N"-($9[?SF);3%T?[J%,-KZ?I"LOL9T?C&H!+%C?>ZC6)OC
M?=.>Q88]?=^:2'">?@R5T%LY?E:1-D7T?L*,.S$;?U&&CMGH?@*W,L5L?:2Q
M?K!<?5ZKQYKD?4.F(85>?5J@D6_F?9*:\EJ>?>&5%T6!?ER.T3#0?OF'P]D-
M?9?!F,26?3JZXJ]_?.VT%IH&?,VM3821?.>FFV\Y?2V?UUH:?8>8PT4A?@B1
M*S"3?J^(SMAF?4K+[L/N?.[$)Z[%?)B\-9E$?&^T.X/@?(BL6&ZF?-6D8%FL
M?3N<%$33?<B3/3!C?G2)K=+OC.MVV;^2BWQW5ZN]BBUWW9=?B/YX?(*IA^9Y
M0VW1AMYZ-%D8A=Y[1D1[A/%\H3!:A!I^:]%UBY2 P;YDBC6 /*JCB/1_T99:
MA]5_AH&OAM)_96SHA>-_9UA A/U_>T/,A"Q_NB_N@VZ *M FBE2*N;T6B06)
M-:F#A\F'RI4TAK^&DX";A="%@VOQA/F$D5=MA"R#HD,K@W>"OR^-@M2!TL[.
MB4*4I;NTA_B2-Z@0ALZ/XI/IA<N-LW]VA/6+M&KZA#.)PE:J@WR'PT*=@MN%
MKR\Y@DN#7<V!B&F>A+IHAR*;-*;)A@"7^I*RA0:4V7YDA#&1SFH6@X6.VE7Z
M@MZ+Q$(?@E"(>2[Q@=.$QLQ;A[ZH:;E,AGJD-J6TA5>@"9&LA&*;[7UY@Y67
MWVE'@NF3SE5=@E2/G$&R@=B+%RZS@6R&"\MFAS.R1+A>A?*M)Z3'A,ZG_Y#)
M@]JBWWRR@Q>=RFBD@G.8H%39@=V3/4%7@7*-?BZ @1:')\J@AL>\#[><A8JV
M :0 A&.OU9 $@VJIH7O\@JJC=V@+@A2=,E1I@8>6I4$+@1Z/IRY6@,Z(&LH*
MAG7%S;<#A3R^P*-9A!"W?8]9@Q*P)7MB@E&HU&>-@<"A:%0&@3^9L$#%@.&1
MB"XT@)6(Y,.[E?AUWK'*D[)V<I]OD9!W$(R4CY%WR7E<C:EXJF7^B\MYN%++
MB>MZZC_$B U\:RUIAB1^8,)\E,%_-+#0DH-^V)Z$D&U^DXNVCGI^<GB%C*)^
M>64UBME^I5(4B0]^YS\[AT=_6RTKA72 #,%9DZ*(?Z^BD6^'0)U[CUJ&$HJO
MC7>%&W>6B["$1&1EB?R#BE%HB$:"US[!AI2"-BSTA->!G<!%DI.1V*Y\D&R/
MNIQ+CF6-JHFGC'V+QW:>BLR*#6.1B2F(8E#"AX>&KSY0A>^$\BS%A$N#$+\G
MD;Z;)JUTCYB8,9L\C9>548B+B\"2B76HB@Z/UV+%B("--5 IANV*=CWMA62'
MD"R<@]*$8KXGD1ND<ZQVCOB@JYI"C/B<Z(>ABR69-737B7B5BV(2A^>1W$^F
MAF*.#CV9A.N)_BQY@VN%CKU.D)BMKJNECGBI#9ESC':D8(;:BJ2?MG0HB/Z;
M$F&%AW.66$\YA>F1;#U5A(*,-2Q<@Q6&DKR?D#&VV:KZCA.Q5YC#C!"KM88M
MBCFF!W.(B):@6F#_AQ>:E$[;A924CCT;A"R.+BQ%@LZ'<+P9C]^_]ZIRC<:Y
MAI@NB\"RVX66B>6L%W,!B$&E4V"3AL:>=$Z&A4^753SA@_./WRPR@I6()[4.
MGSUU,J1CG"AUSI-BF3=V>H'QEF5W17 LDZ-X.EY&D.%Y7DR=CA%ZJ#LVBRQ\
M1"JMB!Y^5+0'GBE]_*.CFQ1]MY*NF"=]CH%$E5M]BF]^DJ1]LEVCC_)^ 4P*
MC3)^:CK4BF!_"RJ=AV5_[K,=G1>&O**MF@V%H)'1ER"$H(!DE&*#T6ZRD;F#
M*5SSCQF"GTM^C&F"'SI]B:F!NRJ/AL&!:[(IG"F/8J&JF26-?Y#"ED&+O'][
MDWZ*%&W=D.2(G%Q%CE&'+4K]B[&%O#HQB02$2BJ#AC&"R+%,FTN8'Z#%F%&5
M=(_7E7:2XGZ/DKN08FT7D!2-^UN@C92+I4J%BP.).#GLB&R&LBIYA;2$ [!T
MFJN@VJ &E["=98\=E-*9^GW.DAF6H6QBCX"34EL*C/R/_TH;BG>,D3FPA^^(
M\BIPA4J%&*^[FBZI>9]1ES6E.HYIE%6@\WTED9V<LFO.CPF8=5J3C(F4)DG%
MB?V/K#F"AX2*^2IIA/*&"*\AF<ZQ_IZ]EM2LZXW4D_*GOGR3D3:BB&M(CJ2=
M5%HCC"Z8!TEZB:62ASE;ARN,Q"ICA*J&TJZJF8&Z=IY&EHBT@8U4DZ.N67P2
MD..H'&K7CE"AX5G+B]V;CDDVB6&5"CDPAO*.22I>A'"'>*<!J+ITP9=^I-QU
M6X>XH1YV#'>;G75VXF<YF<YWYE;$EAEY'$:ADD5Z>#;@CD1\*B@OB?Y^2*8R
MI\1]"I;SH^!\SX<VH!U\MW<:G'-\R6:UF-%]"U9)E2=]>$8WD5Y^ 3:HC6U^
MR"A+B3A_T:5_IK^%/98SHN2$.H:-GQZ#6'9JFWR"K&84E^."*E7!E$>!RD71
MD(R!>C9XC*N!3"ADB(J!.Z3&I<^-6Y5FH?R+GH6QGCZ* '6JFIF(CF5GEPZ'
M1E4WDWV&$$5QC]"$VS9,B_^#KRAZA_*"A:0$I1&5:I2FH3^2^(3NG860I73G
MF>..<63(EDJ,2E2YDLB*.T4=CR6(&#8HBV2%ZBB-AW"#JZ-CI&.=CY0'H)B:
M8(1/G-Z70W1.F3R4.60\E::1-U1*DAF..$34CH.+)S8(BMF']2B<AP&$K*+/
MH^6EEI.*H!>AI(/4G%:=M'//F*^9SF/&E2*5\E/MD9^2"427C@*. #7OBF>)
MSRBIAJ:%B:).HXBM>I,1G[>HP(-=F_*C]7-=F$:?*V-?E+J:9U.8D4&5D$1@
MC:>0EC7;B@N+;BBTAEN&0J'HHS^U2)*NGVJON(+VFZ&I_W+XE_*D/F,)E&6>
MAU-7D.Z8OT0SC5^2US7$B<^,RBB\AA^&V9FLLFQT:8L\K<=T^GR=J3IUK6V^
MI+-VC%ZPH!IWG4^BFV!XXD#^EG9Z3S+<D41\%"7VB[=^/)D:L8M\/(KEK-Q\
M 7Q*J$)[]&UIH[%\&%Y6GQ=\<D]1FF-\^T"_E8!]HS+1D%M^C"8\BN-_MIBA
ML(F#ZHI=J^*"]GO2IT*"*FSHHK2!G5WAGB"!/D[SF7>!!D""E)^ XC+'CXJ
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MA.&$RK0 A"V$ J&B@X&#0HY:@O6"GGK%@GF"&F<;@A>!K%.?@<J!1$!A@9V
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MO0."D&U<MX&!N6&AL<F!#U7GJ]> HDH\I;& ;3[EGU* 6#1%F+" 62J8D<^
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M6##I>KR#,M)8:DFC&+[/; ^?=JK(;<F;R)94;XB8(X&K<5^4C&ST<U:0]EB
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MC]N#[Y%(CAF#<H)TC&Z"[G,DBM*":F-DB5"!^U.EA]B!ED1#AE^!-#59A/>
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MAG5GD-&@2V=&CD6;RUDJB^"724M$B:&2P3W[AV..+3%CA4")@"8T@R6$](B
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M[B'.B@%]'WPEK;]WK'#(J9EX!64?I5AX?%D:H/QY)$T"G'UY\D$2E]QZZ#7
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MZB40@;.$&X!"H QD6W3VG3AFOVDDFH)I(5S+E\)KC5 ME-UN%4.4D=MPRS>
MCK]SJRP#BY5VWB'8B&YZ9'^ZGKIK_720F_1MF6B]F3)O05QVEF1P_T_KDW]R
MW$-JD(ITXC=SC8!W"BPDBFUY<R(XAU]\$G\VG3)S8W/QFH-T4V@ZE\=U3EOX
ME0)V84^)DBQWD4,KCTUXXS=;C%MZ3BP^B6-[Y2*,AG)]G'Z>F[5ZFW-)F1-Z
M\V>'EFA[3%MPD[![M4\7D/)\-$+@CBM\R3<[BU-];RQ/B'A^,"+5A:1^_WX$
MFG:!P7*QE^"!B&;OE3V!0EK<DHV ]DZSC]F NT*6C2J D#<:BFF :BQ<AZF
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M[CE^C=I\I3 YBM5]:B>]A]Y^12"IA1-_(FK*FM: 2V$]F$R 4E=8E9* .DU
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M5ZN#Q*"76T6#1)!@7KR"P7^?8B^"0&Z49<R!R5U6::2!9$Q];:V _CP9<@B
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MD,& Z5GBCS6! %#IC6> WT>^BVV ICZAB7: ?C78AXV ;BV[A;. ;B9(A!2
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M7,:!Y()27_*!VW5W8PF!K&@)9C&!9UI9:8R!(DR9;2N Z3]2<0: N3*@=2F
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M9T(1=XUZ@S;K>9)[L2QL>\E\^R-3?@]^5WEQ;5E\[V\0;Q=]:&0C<,%]NEC
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M@DU^IR2P@=A_/!]G@85_OUJ'A4:!<%*EA/V!@4J/A&B!5$)<@Z*!$CHT@MV
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MY5B5>5Y?@TZ$>H)C-40O>[-G"3GN?01K#S!*?G)O1R=H@!)SUA_L@;]XHFI
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M9SV"N5TY:>Z"K%0O;'R"7$K>;OZ!\D%V<9R!G#@Z=&J!7"_ =T*!+B?U>C^
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M_P  ;69T,0     #!"$   $                    !
M     0    $" P0%!@<("0H+# T.#Q 1$A,4%187&!D:&QP='A\@(2(C)"4F
M)R@I*BLL+2XO,#$R,S0U-C<X.3H[/#T^/T!!0D-$149'2$E*2TQ-3D]045)3
M5%565UA96EM<75Y?8&%B8V1E9F=H:6IK;&UN;W!Q<G-T=79W>'EZ>WQ]?G^
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M14#_H$M3^Z5*8_&I27+GK4J!WK!-D-6P59S.L%ZGR;!HK\:R<[/#LGRXO;"
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MA(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)MLZ'1;+FBT6O
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M:&;/I6YUQ9UU@;R6?(NUD(.4KHJ+FZB&DJ"C@IJEGH"BJ)M^K*J8?KBKEG[
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M4?]=0$__8D),_V9#2O]J1$G_;D5'_W)&1O]V1T7_>DA#_WY(0O^"24'_ADI
M_XM+/_^/2S__CTL__X]+/_^/2S__CTL__X]+/_^/2S__CTL__X]+K\8" *+6
M @"6]PH"B_\6!X+_) ]W_RT7;/\S'F/_.B1<_T(H5O])+%'_3R]._U4Q2_]:
M,TC_7C5&_V(V1/]F-T/_:3A!_VPX0/]P.3__<SH^_W<Z/?][.SS_?CPZ_X,\
M.O^&/3K_ACTZ_X8].O^&/3K_ACTZ_X8].O^&/3K_ACTZ_X8]_W4D!O]V-1#_
M=T,<_X!*)_^%4C/_AED^_X5@2/^!:%+_?&]:_'=Y8O=S@VCT;XQN\6R3<N]J
MFG7M9Z!X[&6E>NMDJGSJ8J]]Z6&U?NA@NW_H7\. YU_+@>9>U8'@8-N!UV+>
M@=1CWX'48]^!U&/?@=1CWX'48]^!U&/?@=1CWX'48]^!_W4D!O]V-1#_=T,<
M_X!*)_^%4C/_AED^_X5@2/^!:%+_?&]:_'=Y8O=S@VCT;XQN\6R3<N]JFG7M
M9Z!X[&6E>NMDJGSJ8J]]Z6&U?NA@NW_H7\. YU_+@>9>U8'@8-N!UV+>@=1C
MWX'48]^!U&/?@=1CWX'48]^!U&/?@=1CWX'48]^!_W4D!O]V-1#_=T,<_X!*
M)_^%4C/_AED^_X5@2/^!:%+_?&]:_'=Y8O=S@VCT;XQN\6R3<N]JFG7M9Z!X
M[&6E>NMDJGSJ8J]]Z6&U?NA@NW_H7\. YU_+@>9>U8'@8-N!UV+>@=1CWX'4
M8]^!U&/?@=1CWX'48]^!U&/?@=1CWX'48]^!_W8D!O]W-1#_>4(<_X)))_^'
M43+_B%@]_X=?2/^#9E'_?FY:^WEW8O=U@FGT<8IN\6V2<^YKF7;L:)]YZV:D
M>^IDJGWI8Z]_Z&*U@.=AO('G8,2"YE_.@N-?UX/<8=N#TF/=@\]DW8//9-V#
MSV3=@\]DW8//9-V#SV3=@\]DW8//9-V#_W<D!O]X-1#_?$$<_X5()_^*3S+_
MC%8]_XM=1_^'9%'_@FQ:^WQT8O=X?VGS=(AO\'"0=.ULEWCK:IY[Z6>D?NAF
MJH#G9+""YF*V@^5AOH3E8,>%Y6#3A=UBV8739-R%S&7;ALEEVX;)9=N&R67;
MALEEVX;)9=N&R67;ALEEVX;)9=N&_W@D!O]X-1#_?D ;_XA')O^-3C'_CU4\
M_XY;1O^+8E#_AFE9_(!Q8O=[>VGS=H5P[W*.=>QNE7GJ:YQ]Z&FC@.=FJ8+E
M9;"$Y&.WA>1BP(?C8<N'WV+5A]5DVH?-9=F(QF?9B<1GV(G$9]B)Q&?8B<1G
MV(G$9]B)Q&?8B<1GV(G$9]B)_WDC!O]Y-!#_@#\;_XI&)O^033#_DE,[_Y%:
M1?^/8$__BF=9_(1N8?=^>&GR>8)P[W2+=NMPDWOI;9M_YVJB@N5GJ83D9;"&
MXV2YB.)BPXGB8M"*V&38BLYFV(K'9]>+P&C6C+YIUHR^:=:,OFG6C+YIUHR^
M:=:,OFG6C+YIUHR^:=:,_WDC!O]Z-!#_@SX;_XU%)?^33"__E5$Z_Y171/^2
M74[_CF58_(AK8?>"=&GR?']P[G>(=NMSD7SH;YF YFNAA.1HJ8?B9K&)X62[
MB^!CQXS<8]2,SV;6C,=HU8W :=2.NFK4CKAKU(ZX:]2.N&O4CKAKU(ZX:]2.
MN&O4CKAKU(ZX:]2._WHC!O][-!#_A3T:_X]$)/^62B[_ETXX_Y=40O^56DS_
MDF%6_(YI7_:'<&CR@7IP[7N%=^IVCGSF<9>!XVV?AN!JJ(G=9[",VF:[C=9E
MQX[19M2/QVC3C[]JTY"Y:]*1LVS2D;)MTI&R;=*1LFW2D;)MTI&R;=*1LFW2
MD;)MTI&R;=*1_WLC!O]\-!'_B#P:_Y)#)/^82"W_FDPW_YI20?^96$K\EU]4
M]I-F7?"-;F;KAW=OYH"!=N%[BWW<=9.#UW&<A])NI(O/:ZR.S&FUD<EHP)+'
M:,^3OVO1D[ALT).R;="4K6_0DZMOT9.K;]&3JV_1DZMOT9.K;]&3JV_1DZMO
MT9.K;]&3_WPC!O]]-!'_BCL9_Y1!(_^:1BS_G$LU_YU0/_^=5DCXFUU1\9AC
M6^N3:V3DC75MWH9^==B AWS1>H^#S':7B<=RGXW$;Z>1P&VPD[YLNY6[:\B6
MMFW/EK!OSI:K<,^6IG'/E:5RSY6E<L^5I7+/E:5RSY6E<L^5I7+/E:5RSY6E
M<L^5_WPC!O]]-!'_C#H9_Y= (O^<12O_GTDT_Z!.//NA5$7TH%I.[)UA6.69
M:6'>DW-JU8Q[=,Z%@WW(?XN$PGJ3BKYVFX^Z<Z.3MG&KEK-OMIBQ;\*8K7#-
MF*ARS9BD<\V8H'3.EY]TSI>?=,Z7GW3.EY]TSI>?=,Z7GW3.EY]TSI>?=,Z7
M_WTC!O]_,Q'_CCD8_YD_(?^>0RG_H4<R_Z-,.OBE4D/PI%A+Z*-?5.&?:%W7
MF'!HSI%X=,:*@'W A(B%NG^/B[5[EY"Q=Y^4K76GEZISL9FG<[V;I7/+FZ!U
MRYJ==LR:FG?-F9EWS9B9=\V8F7?-F)EWS9B9=\V8F7?-F)EWS9B9=\V8_WXB
M!O^ ,A#_D#@8_YL_(/^@0BC_I$8P_J9+./2H4$#LJ5='Y*E=4-RE9EK0G6YH
MQY5U<[^.?7VYB82%LX.,C*U_DY&I?)N5I'FDF:%WK9N>=[F<G'?(G)EXRIR7
M><N;E7K,FI1ZS)F4>LR9E'K,F91ZS)F4>LR9E'K,F91ZS)F4>LR9_WXB!O^"
M,A#_DC<7_YP]'_^A0"?_ID0N^ZE)-?&L3SSIKE5#X:]=2]6H9%G+H6MGPIES
M<[F3>GVRC8&%K(B)C*:$D)&A@)B6G7V@FIE\JIR6>[:=E'O$GI)\RIV1?<J<
MCWW+FX]]S)J/?<R:CWW,FH]]S)J/?<R:CWW,FH]]S)J/?<R:_W\B!O^$,1#_
MDS87_YX\'O^C/R7_J$(L^*U',N^P33GFM%0_W;-;2="L8EG&I&IFO)UQ<K27
M=WRLD7Z%IHR&C*"(C9&:A966EH*>FI* IYV/?[*>C8#!GHR R9Z+@,J=BH#+
MFXJ RYN*@,N;BH#+FXJ RYN*@,N;BH#+FXJ RYN*@,N;_W\B!O^%, __E386
M_Y\['?^E/23_JT$J];!%+^RU3#3CNE0YV+=92,NO85C!J&AFMZ%O<J^;=7RG
ME7R$H)&#BYJ-BY&4BI.6CX>;FHN%I9V(A+"?AH2^GX6%R9Z%A,F=A83*G(6$
MRYN%A,N;A83+FX6$RYN%A,N;A83+FX6$RYN%A,N;_X B!O^'+P__ES46_Z Z
M'/^G/"+^K3\G\[-$+.FZ2S#AOU(UT[I81\>S7U>\K&9ELJ5M<:F?<WNAFGJ$
MFI:!BY22B)&.CY"6B8R9FH2*HIV!BJV??XJ[GWZ*R)Y_B<F=@(C*G("(RYN
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M3#S_GTP\_Y],//^?3#S_GTP\_Y],//^?3#S_GTP\_Y],M[P# *G+ @"<VP,
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M7^=TT%_G=-!?YW307^=T_VPC!/]K,0K_<SL4_WU"'?^"2B?_A%$R_X-9._^
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M8$'SYV!!\^A@0?/H8$'SZ&!!\^A@0?/H8$'SZ&!!\^A@WJ<" ,NV!0"]P04
MLL\' *?J#0&=]QP'E/@K$HKX-AR!^4 F>/I(+V_Z339G^E,\8/I80%O[7T16
M^V5'4OML24_\<DM+_'E-2/R!3T7]BE%#_9-20?Z<4S_^IE0]_[%5/?Z\5CS^
MS58\_LY6//[.5CS^SE8\_LY6//[.5CS^SE8\_LY6SK " +VZ! "QQP0 I=8'
M )O]$ *1_R )B/\M$H#_.1MV_S\C;?]%*F7_2S!>_U$U6/]7.%/_73M/_V,^
M3/]H0$G_;D%&_W5#0_]\1$#_A$8]_XQ'//^42#O_G4DZ_Z5*.?^M2SC_N4LX
M_[E+./^Y2SC_N4LX_[E+./^Y2SC_N4LX_[E+OK4" +#  @"DS@, E]X% (__
M% *&_R,(??\N$'/_-1AJ_SP>8O]")%O_2"A5_TXL4/]4+TS_6C%(_U\S1?]D
M-4+_:C8__W W/?]V.3O_?#HY_X,[./^+/#;_DSTU_YH^-/^A/C/_JC\S_ZH_
M,_^J/S/_JC\S_ZH_,_^J/S/_JC\S_ZH_L;H! */(  "6U@  B_0) 8/_%@)Y
M_R &;_\H#&?_,!)?_S<76/\^&U+_1!],_THB2/]0)$3_529!_UHG/O]?*3O_
M9"HZ_VDK./]N+#;_="TT_WHN,_^!+S'_B# P_X\P+O^6,2W_GC(M_YXR+?^>
M,BW_GC(M_YXR+?^>,BW_GC(M_YXRI,(  );/  "(WP  @/\, 77_$@)J_Q@#
M8O\A!UK_*0M3_S$/3?\X$DC_/A5#_T07/_]*&3S_3QHY_U,;-_]8'#7_7!TS
M_V$>,?]E'S#_:B N_W @+?]V(2O_?"(J_X(C*/^((R?_D"0G_Y D)_^0)"?_
MD"0G_Y D)_^0)"?_D"0G_Y D_V E!/];, ;_83H-_VI!%O]O2A__<5(I_V];
M,O]K9#K_9VY!_V1Z1_]@A$S_78Y0_UJ64_]8GE;_5Z58_U6K6O]4L5O_4[=<
M_U*^7?Y1QU[\4=%?^U#@7_A0Z5_S4>U?[E/P7^A4\5_D5O)?Y%;R7^16\E_D
M5O)?Y%;R7^16\E_D5O)?_V E!/];, ;_8CD-_VQ %O]Q21__<E$I_W%:,O]M
M8SK_:&U!_V5X1_]A@TW_7HU1_UN65/]9G5?_5Z19_U:J6_]5L5S_5+==_E._
M7OU2QU_\4=-@^E#B8/91Z6#Q4NY@ZU3O8.56\6#A5_)@X5?R8.%7\F#A5_)@
MX5?R8.%7\F#A5_)@_V$E!/]<, ;_93@-_VX_%?]T1Q__=5 H_W18,?]P83K_
M:VI!_V=V2/]C@4W_8(M2_UV45?]:G%C_6*-:_U>J7/Y6L%[]5+=?_5._8/Q3
MR6'Z4M9B^%'D8O-2ZF+M5.YBYE;O8N!8\&+;6/%CVUCQ8]M8\6/;6/%CVUCQ
M8]M8\6/;6/%C_V(E!/]=+P;_9S8-_W$^%?]W1A[_>$XH_W=6,?]T7SK_;FA!
M_VIS2/]F?D[_8HE3_U^25O]<FUK_6J)<_EBI7OU7L&#\5;=A^U3 8OM3RF/Y
M4]ID]5+F9.]4ZV3H5NYDX5CO9-E9\&736O!FTUKP9M-:\&;36O!FTUKP9M-:
M\&;36O!F_V(D!/]>+P;_:C4-_W0\%?]Z1![_?$PG_WM4,/]W7#G_<F5!_VQO
M2/]H>T[_9(93_V"06/]=F5O^6Z%>_5FH8/Q8L&+[5KAC^E7!9/E4S67W4]YF
M\E3G9NI6ZV;B6>YFVEKN9]%;[VC,7/!HS%SP:,Q<\&C,7/!HS%SP:,Q<\&C,
M7/!H_V,D!/]?+@;_;3,,_W<Z%/]]0AW_@$HF_W]2,/]\6SC_=V-!_W!L2/]L
M=T__9X)4_V.-6?U@EES\79]?^ENG8OA9KF3W6+9F]5? 9_16RVCQ5=UH[5;I
M:>-9[&C:6^UIT%SN:LE=[FO%7NYKQ5[N:\5>[FO%7NYKQ5[N:\5>[FO%7NYK
M_V0C!/]A+0;_<#(,_WLX%/^!0!S_A$DE_X11+O^!63?_?&% _W9I2/]P<T_[
M;']5^&B)6O9DDE[S89MA\5^C9/!=JV;N6[-H[%J\:NI9QVOH6=AKY%GH:]I;
MZVS/7>UMR%[L;L)?[&Z^8.QOOF#L;[Y@[&^^8.QOOF#L;[Y@[&^^8.QO_V4C
M!/]D*P;_<S ,_WXV$_^%/QO_B4@D_XE/+?^&5S;_@EX^_'QF1OAV<$[T<7M5
M\&V%6NUICE_J99=CZ&*?9N9@IVGC7J]KX5VY;.!<Q&W>7--NV5WF;LY>ZV_&
M7^IQOV'J<;IBZ7*V8^ERMF/I<K9CZ7*V8^ERMF/I<K9CZ7*V8^ER_V8C!/]G
M*0;_=RX+_X(U$O^)/AK_C4<B_XU.*_^,53/\B%P\]H-D1?%\;$WL=W=4Z'*!
M6N1NBF#A:I-DW6:;:-IDHVO68JQNTV"U<-!?OW'.7\URRU_B<\1AZ'.]8NAT
MMV3G=+)EYW2O9N=TKV;G=*]FYW2O9N=TKV;G=*]FYW2O9N=T_V<B!/]J)P7_
M>BP*_X8T$?^-/1G_D44@_Y)-*/V14S'VCEHZ\(EA0NJ#:4OE?G13X'A]6MIS
MAF#4;H]FT&N7:LQHGV[)9J=QQV2O<\1CN77"8L9VP&+:=[IDYG>S9>5WKF;E
M=ZIHY7>H:.9WJ&CF=ZAHYG>H:.9WJ&CF=ZAHYG>H:.9W_V<B!/]M)@7_?2H*
M_XDT$/^1/!?_E40>_Y=+)OB64B[QE%@VZI!>/^2*9TC=A'%0U7UY6L]X@F'*
M<XIGQF^2;,)LFG"_:J)SO&BJ=KEGM'BV9L!YM&;0>K%GXWJK:.-ZIVKC>J-K
MY'FA:^1YH6OD>:%KY'FA:^1YH6OD>:%KY'FA:^1Y_V@A!/]O) 7_@"D)_XPS
M#_^4.Q;_F4,<_9M)(_2;3RKLF54SY99<.]Z19474B6U0S(-V6L=]?F'!>(9H
MO72.;;AQEG*U;IUUL6RF>*YKKWNL:KM\JFG*?:AJX7VC;.)\GVWB?)QNXGN:
M;N-[FF[C>YINXWN:;N-[FF[C>YINXWN:;N-[_VDA _]Q(P7_@B@)_X\R#O^7
M.Q3_G$(:^9Y&(/"?3"?HGU(NX)U:-M:5843-CFI/QHAR6;^">F*Y?8)HM'F*
M;K!VDG.L<YIWJ'"B>J5OJWVB;K9^H&W%?YYNVW^;;^!^F'#A?I9QX7V4<>)\
ME''B?)1QXGR4<>)\E''B?)1QXGR4<>)\_VDA _]T(@3_A2@(_Y$Q#?^:.A+_
MGS\7]:)$'>RD2B/DI% IVZ%7-<^:7T/'DVA/OXQP6;B'=V&R@G]HK7Z&;JEZ
MCG.D=Y9XH'6>>YUSJ'Z:<K. EW' @99RTX&3<]^ D73@?Y!TX'Z/=.%]CW3A
M?8]TX7V/=.%]CW3A?8]TX7V/=.%]_VHA _]V( 3_AR<'_Y0P#/^=.1']HCT5
M\J5!&NFH1Q_@JDTEU*14-,J=74+!EV5.NI%M6+*+=6&LAGQHIX*#;J)_BW2=
M?)-XF7F;?)5WI7^2=J^!D':]@HYVSH*-=]Z!BW??@(IXX'^*>.!^BGC@?HIX
MX'Z*>.!^BGC@?HIXX'Z*>.!^_VH@ _]X'P3_B28'_Y8P"_^?-P_ZI#H3[ZD_
M%^:M11K<KDHDSZA3,\:A7$&]FV1-M)5K6*V/<F"GBWEHH8>!;IN#B'27@)!X
MDGZ9?(Y\HG^+>JV"B'JZ@X=ZRX.&>]Z"A7O>@85[WX"%>^!_A7O@?X5[X'^%
M>^!_A7O@?X5[X'^%>^!__VL@ _]Z'@3_BR8&_Y@O"O^A-0WWIS@0[*T\$^.R
M0A;7L4<CRZM2,L&E6D"XGV),L)EI5ZB4<&"ACW=GFXM^;I:(AG.1A8YXC(*6
M?(B GX"$?ZJ"@7^W@X!_R(1_@-V#?W_>@7]_WX" ?N!_@'[@?X!^X'^ ?N!_
M@'[@?X!^X'^ ?N!__VP@ _]\' /_C24&_YHN"?^C,POTJC0-Z;$Y#]^W/Q+2
MM$8BQZY0,;VH63^SHF!+JYUG5J.8;E^<E'5GEI!\;9"-@W.+BHMXAHB4?(&&
MG8!^A*B">X2U@WF$Q81XA=V#>83>@7J#WX!Z@N!_>H+@?WJ"X']Z@N!_>H+@
M?WJ"X']Z@N!__VT? _]^&P/_CR0%_YTL!_ZF, GPKC$+Y;8U"]N\.1'.MT4@
MP[)/,+BL5SZOIU]*IJ%E59Z=;%Z7F7-FD)5Z;(J2@7*%D(EW@(V1?'N+FW]W
MBJ6"=(FR@W*)PH-RBMJ#<XG>@72'WX!UAN!_=8;@?W6&X']UAN!_=8;@?W6&
MX']UAN!__V\> _^ &P/_DB,$_Z K!OJI+ ?MLBP'XKPQ!]7 -A#)NT,?OK9-
M+K2P5CRJJUU)H:9D5)FB:EV1GG%EBIMX:X28?W%_EH9V>9./>G61F'YQD*.!
M;I"O@FR0OX-KD=6";8_>@6^-WX!PB^!_<(O@?W"+X']PB^!_<(O@?W"+X']P
MB^!__W$< _^#&0+_E2$#_Z,I!?:M)P7HMR8$WL,J ]##-0[$OT$=N;I,+:ZU
M5#NEL%M'FZQB4I.H:5N+I6]CA:)V:GZ??&]XG(1T<YJ,>6^9EGQKEZ%_:)>M
M@&:7O(%EF-& 9I;??VB3X'YJD>%^:I'A?FJ1X7YJD>%^:I'A?FJ1X7YJD>%^
M_W4: O^'& +_F" #_Z8E _*R( /DOAX"U\DB LK',PV^PT <L[]**ZFZ4SF?
MMEI%EK)A4(VO9UF%K&U@?JET9WBF>FURI()R;:**=FBAE'EDH)]\89^K?E^@
MNGY?H,Y^7Y_A?6*;X7UCF.)\8YCB?&.8XGQCF.)\8YCB?&.8XGQCF.)\_W@8
M O^+%P'_G1T"_:L> NRX%P'>R!$ S\T? L3,, NXR#X9K<5(**/!43:8O5A"
MC[E?38:V959_LVM=>+%R9'*O>6ELK8!N9ZR)<F*JDG5?J9UX7*FJ>EJIN7I9
MJLQZ6*GD>ENDY'I=H>1Y7:'D>5VAY'E=H>1Y7:'D>5VAY'E=H>1Y_WT5 O^0
M% '_H1@!]K$4 -G!"P#2SPL R-(< ;S1+@FQSCL7ILM&)9S(3S.1Q%8_B,%=
M28"_8U)XO&I9<;IP7VNY=V1FMW]I8;:';5VUD7!9M9QR5K2I=%2TN'13M<MT
M4[7D=%2PYW56K.=U5JSG=5:LYW56K.=U5JSG=5:LYW56K.=U_X,2 ?^6$0#_
MJ!$ V;@* ,[$"0#'T@H O]D9 ;38*P>IUCD4G]-$(I3032^*S50[@<I;1'C(
M8DUQQVE3:\5O667$=EY@PWYB7,*'9EC!D6A5P9QK4L&H;%#!MVU/PLIM3\+D
M;$^][&Y0N>QO4+GL;U"Y[&]0N>QO4+GL;U"Y[&]0N>QO_XD0 ?^=#@#:KP@
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M<%Z:ZW!@ENMO897L;V&5[&]AE>QO897L;V&5[&]AE>QO_W<2 ?^)$0'_F1$
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M1$#JY$1 Z/5$0.?X0T#G^$- Y_A#0.?X0T#G^$- Y_A#S:,  +VN 0"PN $
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M&R'_K1LA_ZT;(?^M&R'_K1LA_ZT;FKX  (O*  !^UP  <.,  &?_! !>_PT
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MICT2NJ%('K*=42JJF%DTHI1A/IR0:$66C&],D(EV4HN&?5>&A(5;@H*-7WZ
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M5$NW[51*MOE52K/^5DJS_E9*L_Y62K/^5DJS_E9*L_Y6^H<" -:8  #)I0,
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M+S;Q\R\V\?,O-O'S+S;Q\R\V\?,ON:<  *NP  "?NP  DL8  (;0 0![W04
M=/<1 &WW' %F^"8#7_@O!EKY. I4^4 .4/I'$4SZ3A1(^U461?M;&$+[8AI
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M5UF4[%=9D_E66Y'^55N0_E5;D/Y56Y#^55N0_E5;D/Y5_W,) /6$! #8D0,
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M0D.\_T-#O/]#0[S_0T.\_T-#O/]#UHT  ,:;  "XI0  K:X  **V  "8OP(
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M4&A\[4]I?/M.:7S_36I[_TQJ>_],:GO_3&I[_TQJ>_],_V8* /]U" #A@0(
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M1U&6_T=1EO]'49;_1U&6_T=1EO]']G<  -B%  #)D0  OYL! +2B  "KJ
MH;   )JR$0"4LR(!C;(P!86Q/ Q^KT84>*Y.&W*L5B%MJUPG:*EC+&2H:C!@
MIW$T7*9Y.%BE@CM5I(P^4:.80$^CI4)-H[1#3*/(0TRCY$-+H?1#2Z#_1$N@
M_T1+H/]$2Z#_1$N@_T1+H/]$XWT  ,^+  #"E@  MY\  *VF  "CK0  F;4
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M+CS%_RX\Q?\NQ),  +:?  "II@  G:X  )*W  "&OP  >\<# '#/!P!GU@T
M9-<: &#8*@%<V#8#6-A!!E382@I0V%(-3=A:$$K78A-'UVD61==R&$+7?!I
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M@@@A_Y ((/^="1__JPD>_[H)'?_)"1S_W0D<_]T)'/_="1S_W0D<_]T)F+
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M179K[4-V:_M"=FO_079L_T!V;/] =FS_0'9L_T!V;/] _UT* /]I!P#L= ,
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M06%]_T!A??] 87W_0&%]_T!A??] _V<  .-T  #2?P  QX@! +Z/ @"VE0$
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M.4F;_SE)F_\YVWH  ,B'  "\D@  L9H  *:@  "<I@  D:P  (>Q" "!LA8
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MFA8VT:D7-=&[%S32TA<UT.P6-,_W&#/._QHSSO\:,\[_&C/._QHSSO\:LYD
M *:A  ":J0  CK$  (&Y  !UP   :L<  %[- P!4U @ 3-T- $K=& !(WB8
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M!!C_J 07_[<$%O_(!!;_X 06_^0$%O_D!!;_Y 06_^0$DZX  (6W  !XP
M:LD  %W2  !0V0  1-\  #KD   U]P, ,O\, "[_$@ K_QH */\A ";_)P C
M_RT (/\S ![_.0$<_S\!&?]% 1?_30$5_U4!$_]? 1'_:@(0_W@"#O^' @[_
ME@(-_Z0"#/^P @S_O@(,_\("#/_" @S_P@(,_\("A[8  'F_  !KR0  7M,
M %#;  !#X   ..4  "_P   K_P  )_\( "3_#@ A_Q, 'O\9 !O_'@ 8_R,
M%?\H !/_+0 1_S( $/\X  [_/P ,_T8!"O]/ 0?_60$$_V4! ?]R 0#_@0$
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M-H9;[3:%6_LUA5S_-(1<_S.$7/\SA%S_,X1<_S.$7/\S_U,* /]=!@#U9@0
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M<F?_-W)H_S9R:/\U<FC_-7)H_S5R:/\U_UD" /9E  #=;@  SW8! ,=[ P#
M?P0 N8 , +&"&@"J@BH"HX W!9U]0@N7>TL1DGA4%XUV6QN)=&(@A7)I)(%Q
M<"=^;W<K>VY_+GAMB#%V;)(T<VN<-G!JJ#AN:K<Z;6K).FQJY#IM:_4X;6O_
M-VUK_S9M:_\V;6O_-FUK_S9M:_\V_UL  .MG  #9<0  S'D  ,-^ @"[@@,
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M-5A^_S58?O\UZ6@  -1T  #&?@  NX<  +*-  "HD0  GI0  ):6#@"1EQP
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MF29#I*@G0J2X*$&DSB=!H^HG0*+X*$"A_RE H/\I0*#_*4"@_RE H/\IR7X
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M#S#,QP\PR^4.+\GU#R[(_1$NQ_\2+L?_$B['_Q(NQ_\2KI<  *&>  "5I0
MB:T  'RT  !PNP  9,$  %G&  !.RP, 1= ( #[5#@ ]U1H /-8F #O7,0 Y
MV#L .-E% 3;930$UV58",]I> C':: ,PVW,$+MM_!2S;C04JW)T&*=RM!BC=
MP08HW=X&)]OO!R;9^0@FV/X))MC^"2;8_@DFV/X)I)T  )BE  "+K0  ?K0
M '&\  !EPP  6<D  $W-  !#TP$ .MD& #7D#0 SY!8 ,>0@ ##E*@ NYC,
M+>8\ "OG1  JYTP!*.A4 2?H70$EZ6<"(^ES B+J@0(@ZI$#'^NA QWKL@,<
M[,<#'.SA QOJ\0,;Z?D#&^GY QOI^0,;Z?D#FJ0  (VL  !_M0  <KT  &7%
M  !9RP  3-   $'5   XW   +^$" "WQ#0 K\1, */(< ";R)  D\RL (O0R
M "'T.0 ?]4$ '?5) !OV40 9]UH!%_=E 17X<@$4^8$!$_F2 1+ZH@(1^K,"
M$/O& A#[W0(0^^D"$/OI A#[Z0(0^^D"CZL  (&T  !SO0  9L8  %G-  !+
MTP  0-D  #7>   LXP  )O$  "3^"@ A_Q  '_\6 !S_'  9_R( %_\H !7_
M+@ 3_S4 $O\\ !#_0P ._TP #?]6  O_8@ )_V\ "/]_ 0?_D $%_Z !!/^N
M 03_O $#_\<! __' 0/_QP$#_\<!@[0  '6]  !GQ@  6L\  $O5   _W
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M))U*\"2;2OTEF4O_))E+_R282_\DF$O_))A+_R282_\D_T@, /]/" #_5@@
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M+'E<_RMZ7/\J>ES_*GI<_RIZ7/\J_U$  /);  #>9   SVH  ,=N @# < 0
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M+&5K_RQE:_\L]%L  -UF  #+;P  P'8  +=[  "O?@  IGX! )]_$ "9@!\
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MFBE0@J<J3X*W*TZ"S"M.@N@K3H'X*D^ _RI/@/\I3X#_*4^ _RE/@/\IVVH
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M'CV?QAX]G^,=/9WT'CV<_Q\\F_\?/)O_(#R;_R \F_\@PGP  +6(  "ID
MGI8  ).;  "'GP  >Z0  &^H  !CK 0 7ZT1 %RM'P!:KBL 5ZXV 52N0 -1
MK4@%3JU/!TNM5PE)K5X+1JQF#42L;@]!K'@1/ZN$$SRKD14ZJZ 6.:NP%SBK
MPQ<XJN$7-ZGS&#>G_ADVIO\:-J;_&C:F_QHVIO\:NH0  *Z/  "BE@  EYL
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M B#2]@,?T?\$']'_!!_1_P0?T?\$GYL  )2B  "'J0  >;$  &VX  !@O@
M5,,  $G'   ^RP  -= ! "W5!@ EVPL )-X2 "/>'  BWR4 (> N "#@-P ?
MX4  'N%* !WB4P <XUX &^-J !KD>  8Y(@!%^6: 1;FK $5YL !%.?= 1/E
M[P$3X_H!$^/Z 1/C^@$3X_H!EJ(  (FI  ![L0  ;KD  &'   !4Q@  2,H
M #W/   STP  *MD  "+> @ >ZPH '.P0 !OM%P 9[1\ %^XF !7N+0 4[S4
M$_ ] !'P1@ 0\5  #_);  [R:0 -\W@ #/2*  OUG  *]:X "?;"  GVV0 (
M]>T "/7M  CU[0 (]>T BZD  'VR  !ON@  8L(  %7)  !'S@  .](  #'8
M   GW0  '^$  !GH   6^ 8 %/H- !+[$@ 0_!< #OP=  W](P ,_2D "OXP
M  C_.  &_T$  _],  #_6   _V8  /]W  #_B0  _YL  /^K  #_NP  _\X
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M#KDV]!"W-O\1M3;_$K0V_Q.S-O\3LS;_$[,V_Q.S-O\3_SD0 /\]"P#_0PT
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M'HM+_QV*2_\=BDO_'8I+_QV*2_\=_T4  /]-  #E5   V5D  ,]; P#*6P8
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M(6];_R%O6_\A^D\  .%:  #/8@  Q&<  +MK  "S;   K&H$ *1K$@">;"$
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MFB-=:Z<E6VNW)EIKRB9::^<E6VOW)%MJ_R-<:O\B7&K_(EQJ_R)<:O\BXUL
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M(4I]Q")*?>$A2WST(4M[_R!+>_\@2WO_($M[_R!+>_\@T&<  ,!R  "T>P
MJH(  *"&  "5B   AX@  'R*  !VC X <HT: &Z.)P!JCC(!9HT\ V.-1 5@
MC$P(7(M3"EJ+6@U7BF$05(EH$E&(<15/B'H73(>%&DJ&DAQ(AJ =1H:O'D6%
MPAY%A=\>183R'D6#_AY%@O\>18+_'D6"_QY%@O\>RFT  +IX  "O@0  I8<
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M#S*B^Q RH?\1,J'_$3*A_Q$RH?\1M((  *B,  "=D@  DI<  (:<  !YH0
M;:4  &&I  !5K   2Z\% $>P$ !%L!P 1+$G $*Q,@!!LCL /[)# 3VR2P$[
MLE,".;); S>R9 0ULFX%,[)Y!C&RAP<OL98(+K*F""VRN DLLM (++#L"2NO
M^0HKKO\+*JW_"RJM_PLJK?\+K8L  *"2  "5F   B9T  'VC  !QJ   9*T
M %FQ  !-M   0K@  #NZ"@ XNQ, -[P> #6\*0 TO3( ,[T[ #*]1  QODP
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M  S=^P ,W?L DI\  (6G  !WK@  :K4  %V\  !0P0  1,4  #C)   NS0
M)=$  ![5   6V@$ $=X& !#G#0 .YQ( #>@9  SH(0 +Z2D "NHQ  GJ.P '
MZT4 !>M1  3K7@ #ZVX  >N   #JE   ZJ<  .N\  #KT@  Z^D  .SO  #L
M[P  [.\ AZ<  'FO  !KMP  7KX  %'%  !#R0  -\T  "W1   CU@  &]L
M !/?   .XP  #.X"  KV"@ ']@X !?82  /V&   ]1X  /4E  #U+@  ]3<
M /9"  #V3@  ]ET  /9N  #V@0  ]I4  />G  #WMP  ^,<  /C0  #XT
M^-  >Z\  &VX  !@P   4L@  $3-   WT0  *]<  "'<   8X   $>0   SG
M   '[P  !/H   '_ P  _P@  /\-  #^$   _A0  /\:  #_(0  _RD  /\S
M  #_/@  _TL  /];  #_;   _X   /^2  #_H0  _ZT  /^S  #_LP  _[,
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M' #_(1P _Q\@ /\?*0#_'#0 _QI  /\73 '_%5@!_Q1C ?\3;@'_$W<!_A.
M ?P3B 'Z$HX!^1*5 ?@2F@'V$J !]1*F ?02K 'S$K,!\1*\ ? 2QP'M$M@!
MZ1/H >83]0'D%/\!XA3_ N$5_P+A%?\"X!7_ N 5_P+@%?\"_R4; /\F%P#_
M)!8 _R4< /\F)0#_)#  _R$[ /\?2 #_'50!_1M? ?D::0'W&G,!]!E\ ?(9
MA 'Q&8L![QF1 >X9EP'L&9T!ZQFC >D9J@'H&;$!YQFZ >49Q0'C&=4!WQKH
M =P;]0+8&_\"U1S_ ]0<_P/3'/\$TAS_!-(<_P32'/\$_RD7 /\J$P#_*1(
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M#J,W_PZB-_\.HC?_#J(W_PZB-_\._S<' /\[ @#_0 , \D(% .E""0#E/PX
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M%GU+_Q9]2_\6_T,  .9,  #64P  R5@  ,!9  "Z6 $ M%8) *Q7%@"F6"4
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MFAIH6J<<9EJV'65:R!UE6N0=95KV'&5:_QME6O\:95K_&65:_QEE6O\9Z$\
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M'%9FPQU69M\=5F;S'%=F_QM79O\:5V;_&E=F_QI79O\:VUD  ,=B  "Z:@
MKW   *9S  ":<P  CW   (=Q!0"!<A$ ?',> 'AS*@!T<S4!<',_ VUR1P5J
M<4X'9W%5"61P7 MB;V,.7V]J$%UN<A):;7P56&V&%U9LDQE4;* ;4FNO'%%K
MP1Q1:]P<46OQ&U)K_AI2:O\:4FK_&5)J_QE2:O\9U%P  ,-F  "V;@  K'0
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M%D%^^Q9!??\607W_%D%]_Q9!??\6PFH  +5U  "J?0  GX(  )*#  "%A
M>84  &J)  !DB@, 8(P0 %V-&P!;CB< 6(XR %6..P%3CD,"4(Y* TZ-4@5,
MC5D&28Q@"$>,: I%BW(,0HM]#D"*B0\^BI@1/(JG$CN*N!(ZBL\2.XCK$CN'
M^A,[AO\3.X;_$SN&_Q,[AO\3O'$  *][  "E@P  F8<  (R(  !_B0  <XP
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M!26G_P4EI_\%IXD  )N/  "1E   A)D  'B>  !KH@  7Z8  %.J  !(K0
M/;   #2S P OM0X +;46 "RU(  KMBD *K8R "FW.@ HMT, )[=, ":X50 D
MN%\ ([AK "*X> $@N(@!'[B9 1VYJP$<N< !'+C? 1RV\@$;M?P"&[3_ ANT
M_P(;M/\"GX\  )25  "(FP  >Z$  &ZF  !BJP  5K   $JS   _M@  -;D
M "R\   DOP8 '\(- !W"%  <PAX &\,F !K#+P 9Q#@ &,1! !?$2@ 6Q54
M%<5A !3&;P 3QG\ $L:1 !''I  0Q[D #\?4 !#&[@ 0Q/H $,/_ !##_P 0
MP_\ EY8  (N<  !^H@  <:D  &2O  !8M   2[@  $"[   UO@  *\$  "/%
M   ;R0$ %,P& !#0"P .T1$ #=$9  W1(0 ,T2H #-$T  O2/@ *TDD "=-5
M  G38@ (TW( !M2$  74F  $U*L  ]7   '5W  !U>T  =7V  '5]@ !U?8
MCIT  ("D  !SJP  9K$  %FX  !,O0  /\   #3#   JQP  (<H  !G.   2
MT@  #=8!  G;!0 &W T !-P1  /=&  !WB   -XH  #?,0  X#P  .%'  #B
M5   XV,  .-T  #DB   Y)L  .6N  #EP0  Y=4  .;G  #FYP  YN< @Z0
M '6L  !HLP  6KL  $W!  ! Q   ,\@  "C,   ?T   %]0  !#9   +W0
M!>$   #D    Y0<  .8-  #G$0  Z!8  .D=  #J)0  ZRX  .TY  #O10
M\%,  /%D  #Q=@  \HH  /.<  #SK0  ]+L  /3(  #TR   ],@ =ZT  &JU
M  !<O0  3\0  $#)   SS0  )]$  !W6   4W   #N    CC   !Y@   .H
M  #N    [@   .\$  #P"@  \0X  /,2  #T&   ]B   /@J  #Z-0  _4,
M /Y2  #_8P  _W8  /^)  #_F@  _Z8  /^P  #_L   _[  _Q8C /\5(0#_
M$2$ _PTD /\)*P#_!C< _P-$ /\ 40#_ %T _P!H /\ <@#_ 'L _P"# /\
MB@#_ )$ _P"6 /\ G #_ *$ _0"F /L K #Y +, ]P"[ /4 Q0#S -$ \@#D
M /$ \0#O /H [@#_ .X _P#M /\ [0#_ .T _P#M /\ _QD@ /\8'0#_%1T
M_Q ? /\.*0#_##0 _PI! /\'30#_!5D _P1D /\$;@#_ W< _P.  /\#AP#_
M XT _0*3 /L"F0#Y IX ]P*D /4"J@#S ;  \0&X .\!P@#M <\ ZP'C .H!
M[P#H OL YP3_ .8%_P#F!O\ Y@;_ .8&_P#F!O\ _QP; /\;&0#_%Q@ _Q4=
M /\3)0#_$3  _Q ] /\.20#_#%4 _PM@ /\+:@#]"W, ^PM\ /D*@P#W"HH
M]0J0 /0*E@#S"IL \0JA .\)IP#M":X ZPFV .@)P #F"<T Y GB .(*\ #?
M"_L W@S_ -P-_P#<#?\ VPW_ =L-_P';#?\!_Q\7 /\>$P#_&Q( _QP9 /\;
M(@#_&"P _Q4X /\31 #^$E  ^1%; /409@#S$&\ \!!W .X0?P#L$(8 ZA",
M .D0D@#H$)@ Y@^> .4/I0#C#ZP X0^T . /O@#>#\P VA#A -41\ #2$OL
MSQ+_ <X3_P'-$_\!S1/_ <P3_P',$_\!_R(2 /\B#P#_(0\ _R(4 /\B' #_
M("< _QTR /@;/@#R&4L [AA6 .H78 #G%FH Y!9R .(6>@#@%H( WA:( -P6
MCP#;%I4 V1:; -86H@#4%JD TA:Q - 7NP#.%\D S!C> ,@9[@'%&OL!PQK_
M L$;_P+ &_\"P!O_ L ;_P+ &_\"_R8. /\E"P#_* P _RD0 /\H%@#^)B
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M"I(W_PJ2-_\*_S,  /8Z  #D/P  V$(  ,Y" 0#)/@8 Q#L/ +L^'0"U/RP
ML3\Z *T_10&I/T\!ICY8 J,]7P.A/6<$GSQM!9T\= :<.WL&FCN"!Y@[B@B6
M.Y,)E3J<"I,ZI@N1.K(+D#O #(X[U0R,/.P-BCS[#8D\_PV)//\,B#S_#(@\
M_PR(//\,_S<  .H_  #<10  SDD  ,5)  "_1@( ND,, +-$&0"M12< J$8U
M *1%00&@14L"G413 II#6P.80V(%ED)I!I1!< >2078(D$!^"8Y A@J-0(X+
MBT"8#(E H@V'0*X.A4"\#X1 SP^"0>D/@4'Y#X!!_P^ 0O\.@$+_#H!"_PZ
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MG!!V2:@2=$FV$G-)R!-R2N,3<4KU$G%*_Q%Q2_\1<4O_$'%+_Q!Q2_\0[$,
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M9U&Q%&91PQ5E4MX595+R%&52_Q-E4O\295+_$F52_Q)E4O\2Y$H  ,]3  #
M6@  M5X  *Q@  "B7@  FED  )):"P"-6Q8 B%PC (1<+P" 6SH!?5M# GE:
M2P-V65($=%A8!G%87P=O5V8);5=M"VM6=0UI5GX/9U:)$655E1)C5:$48E6O
M%6%5P19@5=L68%;Q%6!6_A1@5O\385;_$F%6_Q)A5O\2X$T  ,M6  "]70
MLF$  *AC  "=80  E5T  (U>"0"'7A, @U\@ ']?+ ![7S<!=UY  G1>2 -Q
M74\$;UQ6!6Q<7 =J6V,):%MK"V9:<PUD6GP/8EJ'$6!9DQ)>6: 475FN%5M9
MOQ9;6=@66UGO%5M9_11<6?\37%G_$EQ9_Q)<6?\2W%   ,=9  "Z8   KV0
M *1E  "99   D&   (AA!@""8A$ ?F,= 'IC*@!V8S0!<V(] 6]B1@)L84T$
M:F%4!6=@6@=E8&$(8U]I"F%?<0Q?7GH.75Z%$%M>D1)979X46%VL%5==O196
M7=465EWN%5==_!177?\35UW_$E==_Q)77?\2UE,  ,1<  "W8P  K&@  *!H
M  "59P  BF,  (-E @!]9@\ >&8: '1G)P!Q9S( ;F<[ 6MF0P)H9DL#9652
M!6-E609A9%\(7F1G"EQC;PQ:8W@.6&.#$%9BCQ)48IP34V*J%5)BNQ518M(5
M46'M%5)A^Q128?\34V'_$E-A_Q)38?\2T58  ,!?  "S9@  J6L  )QK  "0
M:@  A6<  'UI  !W:@T <VL7 &]K) !L;"\ :6PX 69K00)C:TD#86M0!%YJ
M5P9<:ET'6FEE"5AI;0M5:'8-4VB!#U%GC1%/9YH23F>I%$UGN11,9\\43&;K
M%$UF^Q--9O\23F7_$DYE_Q).9?\2S%H  +QC  "P:@  I6\  )AN  ",;0
M@&P  '=M  !Q;@L ;6\4 &EP(0!F<2P 9'$V 6%Q/@%><48"7'!- UEP5 57
M<%L&56]B"%-O:@I0;G,,3FY^#DQMBA!*;9@126RG$DALN!-';,T31VSJ$TAK
M^A)(:_\22&K_$4AJ_Q%(:O\1QUX  +AG  "L;@  H7(  )-R  "'<0  >G$
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M##: _PPV@/\,MF\  *IX  "??P  D'X  (-_  !W@   :X(  %Z'  !5B@
M3HP& $J.$ !(CQH 1X\E $60+P!$D#@ 0I!  $"01P$_D$\!/9!6 CN07P(Y
MD&@#-X]S!#6/@ 4SCXX&,8^>!S".KP<OCL,'+X[A!R^,] @OB_\(+XK_""^*
M_PDOBO\)L'8  *5_  "8A   BH0  'V%  !PAP  98H  %J.  !/D@  1I4
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M;P 8LGX %K*0 !6RH@ 4LK8 $[+. !.QZP 3K_D $Z[_ 1.N_P$3KO\!FHT
M )"2  "$EP  =9H  &B?  !;HP  4*@  $6L   [L   ,;(  ">U   @N
M&+H' !2\#@ 3O!4 $KP> !&])@ 1O2X $+TW !"^00 .ODP #KY7  V^90 ,
MOW0 "[^&  J^F0 (OJP ![["  >^WP (OO  "+WZ  B]_  (O?P DY0  (>9
M  !ZGP  ;*4  &"J  !3KP  1[,  #RV   QN   )[L  !^^   7P0  $<0!
M  S("  (R0X !\D4  ;)'  %R20 !,HL  /*-@ "RD   ,M,  #+60  RV@
M ,MY  #,C   RY\  ,NS  #+R   S.(  ,SO  #,\0  S/$ BIH  'RA  !O
MIP  8JT  %6S  !(N   .[L  #"^   FP0  '<0  !7(   /RP  "LX   32
M @  TPH  -,/  #4%   U1H  -8B  #7*@  V30  -H_  #<2P  W%H  -UJ
M  #=?0  W9$  -VD  #>M@  WL@  -[>  #>X@  WN( ?Z(  '&I  !DL
M5K<  $F\   \P   +\0  "3'   ;RP  $\\   W2   'U@   -L   #>
MWP,  . )  #A#@  XA(  .,7  #E'@  YB<  .@Q  #J/0  [$L  .Q:  #M
M;   [H   .Z4  #NI0  [K0  .["  #NQ@  [L8 =*H  &:R  !8N0  2\
M #W%   OR0  ),T  !G1   1U@  "]L   />    X0   .4   #H    Z0
M .H   #K!@  [0L  .\/  #P$P  \AH  /0C  #W+@  ^3L  /M*  #\6P
M_6T  /V   #^DP  _J(  /ZM  #^KP  _J\ _Q ? /\.'0#_"AT _P$@ /\
M* #_ #4 _P!! /\ 3@#_ %H _P!E /\ ;@#_ '< _P!_ /X A@#\ (P ^P"2
M /D EP#X )P ]P"B /8 IP#U *T \P"U /( O0#Q ,D [P#< .X ZP#M /<
M[ #_ .L _P#J /\ Z@#_ .H _P#J /\ _Q,< /\1&0#_#1D _P8< /\#)0#_
M #$ _P ^ /\ 2@#_ %8 _P!A /\ :P#] ', ^@![ /< @P#U (D ] "/ /(
ME #Q )D \ "? .X I #M *L [ "R .H N@#H ,8 YP#6 .4 Z #D /4 XP#^
M .( _P#A /\ X0#_ .$ _P#A /\ _Q48 /\3% #_#Q0 _PT9 /\+(@#_""T
M_P0Y /\!1@#_ %$ _@!< /H 9@#V &\ \@!W .\ ?@#M (4 ZP"+ .H D0#H
M )8 YP"< .8 H0#D *@ XP"O .$ N #? ,, W0#1 -L Y@#9 /, UP#] -4"
M_P#4 O\ U /_ -0#_P#4 _\ _Q@3 /\5$ #_$@\ _Q(5 /\1'0#_#B@ _PPT
M /\*00#Y"$P ]097 /$&80#M!FH Z05R .8%>@#D!8$ X@6' . &C0#?!I(
MW0:8 -L&G@#9!J4 UP:M -0&M0#2!L  T ?/ ,X(Y0#,"?0 R@O_ ,@,_P#'
M#/\ QPS_ ,8,_P#&#/\ _QL. /\9# #_& T _Q@1 /\7& #_%"( ^Q$N /,0
M.@#M#D8 Z U2 .4-7 #A#64 W@UM -L-=0#8#7P U0V" -,-B0#1#8\ T V5
M ,X-G #-#J, RPZK ,D.M #(#L  Q@[/ ,,0Y@# $?4 O1+_ +P2_P"[$O\
MNA+_ ;H2_P&Z$O\!_Q\* /\<! #_'P@ _Q\- /\=$@#X&AL [A8F .84,P#@
M$S\ VA-+ -035@#0$U\ SA1H ,L4;P#)%'< QQ5] ,85A #$%8H PQ61 ,$6
MF # %I\ OA:G +P7L "[%[P N1?+ +<8X@"S&?(!L1K_ :\;_P&N&_\!KAO_
M :T;_P&M&_\!_R($ /\B  #_)0( _"0' /<A# #L'1( X1H< -@:*@#0&S@
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MH 6+-:L&BC6Y!H@UR@>'-N4'A3;V!X0W_P>#-_\'@S?_!X(W_P>"-_\']#(
M .,[  #200  QD0  +U#  "W/P  L3L) *H[% "E/"( H#TP )T].P"9/44
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M#&Y$P QM1=D-;$7O#&M%_0MK1O\+:T;_"FM&_PIK1O\*Y4   ,])  #!3P
MM5(  *M2  "A3P  FTH  )1*# "/2Q< BTPD (=,+P"$3#H @4Q# 7Y+2P%[
M2U(">4I8 W=*7P1U268%<TEM!G%)=0=O27X(;4B("6M(DPMJ2)\,:$BM#6=)
MO0UF2=0.94GM#65*_ QE2O\+94K_"V5*_PME2O\+X$0  ,M-  "]4@  LE8
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M#E95^0U65?\-5U3_#%=4_PQ75/\,T4T  ,!6  "S7   IUX  )I=  "/7
MAE@  ']9  !Y6@T =%L7 '%;(P!N6RX :ULW &A;0 %E6T<!8UI. F%:50-?
M6EP$75IC!5Q::P9:670(6%E_"E99BPM469@-4UBF#E)9M@Y16<H/45GG#E%8
M^ U26/\-4EC_#%)8_PQ26/\,S5$  +Q9  "P7P  HV$  )9@  "+7P  @5L
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M"T-E_PM#9?\+OUP  +%D  "F:@  EFD  (EI  !]:0  <6D  &=J  !B; $
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M> (MB8<"+(F7 RJ(IP,IB+H#*8C4 RF&[@,IA?P$*83_!"F$_P0IA/\$JG0
M )Y[  ".>@  @'H  '1[  !H?@  78$  %*%  !)B0  08P  #F0!0 UD0\
M,Y(7 #*2(0 QDBD ,),R "Z3.@ MDT$ +)-* "N44@ JE%P *)1G ">4<P$E
ME((!))23 2*3I $AD[<!()// 2&2[ $@D/H"((__ B"/_P(@C_\"I'P  )>
M  "'?P  >X   &Z"  !BA0  5XD  $V.  !"D@  .I8  #*9   JG D *)T1
M ":=&0 EG2( ))XJ ".>,@ BGCH (9Y" "">2P ?GU4 'I]@ !R?;0 ;GWP
M&I^- !B?GP 7G[( %I_) !:>Z  6G/< %IO_ 1>;_P$7F_\!G8,  (^&  ""
MA@  =(<  &>+  !;CP  4),  $:8   \G   ,Z   "NC   CI@  '*@+ !JI
M$0 8J1@ %ZDA !:J*0 5JC$ %*HY !.J0P 3JTT $JM8 !&K90 0JW0 #JN&
M  ZKF0 -JZP #*O!  RJWP ,J?( #:C\  VH_P -J/\ EHH  (F,  !ZC0
M;)$  &"5  !4F@  29\  #^C   UIP  *ZH  ".N   ;L   %+,!  ^U"@ -
MMA  #+86  NV'P *MB< ";8O  BV.0 'MT, !K=/  2W6P #MVH  K=[  "W
MC@  MZ$  +:T  "VRP  MN4  +7Q  "U]P  M?< CY$  (&4  !REP  99P
M %BA  !,I@  0:L  #>O   LL@  ([4  !JX   3NP  #KT   G !0 #P0T
M ,$1  #!%P  PAX  ,(F  #"+P  PSD  ,1$  #$4   Q%X  ,5O  #%@0
MQ94  ,6H  #%O   Q-$  ,3F  #$[@  Q.X AI@  'F>  !KHP  7:D  %"N
M  !$LP  -[8  "RY   BO   &;\  !'"   ,Q0  !L@   #+    S <  ,P-
M  #-$0  S18  ,X=  #/)   T"T  -(X  #41   U%(  -5A  #5<P  UH<
M -:;  #6K0  U[\  -C.  #8W0  V-T >Z   &ZF  !@K0  4[,  $6X   X
MO   *[\  "'"   7Q@  $,D   K,   "T    -0   #7    V    -H%  #;
M"P  W X  -X3  #?&0  X2$  .,J  #E-@  YT,  .=3  #H9   Z7<  .F,
M  #JGP  ZJX  .JZ  #JPP  ZL, <*@  &*O  !5M@  1[P  #G    LQ
M(,@  !;,   .T   !]0   #9    W0   .$   #C    Y    .8   #G 0
MZ0<  .L,  #L$   [A4  / =  #S)P  ]C,  /=#  #X5   ^68  /EZ  #Z
MC@  ^IX  /NI  #[L   ^[  _PL; /\'&0#_ !D _P < /\ )0#_ #( _P _
M /\ 2P#_ %< _P!B /\ :P#_ ', _0![ /L @@#Z (@ ^ "- /< D@#V )@
M]0"= /0 H@#S *D \0"P .\ N #N ,, [ #1 .L Y@#I /, Z #^ .@ _P#H
M /\ Z #_ .@ _P#H /\ _PX8 /\*%0#_ 10 _P 8 /\ (@#_ "X _P [ /\
M1P#_ %, _0!> /H 9P#W &\ ]0!W /, ?@#R (0 \ ") .\ CP#N )0 [ ":
M .L GP#I *4 Z "L .8 M #D +\ XP#, .$ X@#? /  W@#[ -X _P#= /\
MW0#_ -P _P#< /\ _Q 3 /\-$0#_!A  _P(5 /\ '@#_ "D _P V /\ 0@#Z
M $X ] !9 /$ 8@#N &L [ !R .H >0#H '\ YP"% .4 BP#D )  X@"6 .$
MG #? *( W0"I -H L0#8 +L U0#( -( W0#1 .T T #Y ,\ _P#. /\ S0#_
M ,T _P#- /\ _Q$/ /\.#0#_# T _PL2 /\'&0#_ B0 _P P /8 / #O $D
MZ@!3 .< 70#D &8 X0!M -\ = #= 'L VP"! -D A@#6 (P U "2 -( F #0
M )X S@"F ,P K@#* +@ R #$ ,8 UP#% .H PP#W ,( _P#! ?\ P +_ , "
M_P#  O\ _Q0+ /\0!@#_$ D _Q . /\.% #_"AX ]08I .L$-@#C T( WP-.
M -L$5P#6!&  TP1H - $;P#.!78 S 5\ ,H%@@#)!8@ QP6. ,8%E #$!9L
MP@6C , &JP"^!K4 O0;" +L(U "Z">D MPOX +4,_P"T#/\ M S_ +0,_P"T
M#/\ _Q<$ /\4  #_%@, _Q0) /\1#@#R#A4 Z PA -X*+@#6"SL T Q' ,P,
M40#)#%H Q@UB ,0-:@#"#7$ P UW +\-?0"]#H, O Z* +H.D0"Y#I@ MPZ@
M +8.J0"T#[0 L@_! +$0U "N$>L JQ+Z *D2_P"H$_\ IQ/_ *<3_P"G$_\
M_QH  /\;  #Y&P  ZQD  .44!@#E$ X V0X7 ,\1)@#($C0 Q!-  +\42P"\
M%%0 N15= +<59 "U%6L M!5Q +(5> "Q%GX KQ:% *X6C "L%I0 JQ>< *D7
MI@"G&+  IAB] *08SP"B&N< GQKW )T;_P&<&_\!G!O_ 9L;_P&;&_\!_QT
M /<A  #H)   W24  -0A 0#/&P@ RA<1 ,(:( "\'"T MQTZ +,>10"P'D\
MK1Y7 *L>7P"I'V8 J!]L *8?<P"E'WD HQ^  *(?AP"@((\ GR"8 )T@H@";
M(*P!FB&Y 9@AR@&6(N0!E"/U 9(C_P&1(_\!D"/_ 9 C_P&0(_\!_R(  .LI
M  #=+@  SR\  ,<M  #!)P, O2(- +8C&@"P)2@ K"8T *@F0 "E)TD HB=2
M * G6@">)V$ G"=G )LG;0"9)W0 F"=[ 98G@@&5)XL!DR>4 9$HG@&0**D!
MCBBU HTIQ@*+*=\"B2KR H<J_P*&*O\"ABK_ H8J_P*&*O\"]"@  .,Q  #1
M-@  Q3@  +PV  "V,   LBL) *LL% "F+2( HBXO )XN.@";+D0 F"]- )8O
M50"4+EP DBYB ) N:0&/+F\!C2YV 8PN?@&*+H8"B"Z/ H<NF@*%+Z4#@R^R
M X(OP@.!,-H#?S#O WTQ_@-],?\#?#'_ WPQ_P-\,?\#[2\  -LW  #)/0
MOCX  +,\  "L.   IS,$ *(R$0"=-!T F34J )4U-0"2-4  CS5) (TU4 "+
M-5< B35> 8<U9 &%-&L!A#1R H(T>0* -(("?C2+ WTTE@-[-:$$>36N!'@U
MO@5W-M0%=C;M!70W_ 5T-_\$=#?_!'0W_P1T-_\$YS4  -(]  ##0@  N$0
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M"%]%^ =?1?\'8$7_!F!$_P9@1/\&UD$  ,-)  "V3@  IT\  )M-  "22P
MC$<  (5'! " 1Q  ?$@: 'A()@!U23  <TDZ '!)0@!N24D!;$A0 6I(5@%H
M2%T"9DAD F5(; -C2'4$84=_!6!'B@9>2)<'74BE"%M(M A;2,<)6DCD"%I)
M]@A:2?\'6DC_!EI(_P9:2/\&T44  +],  "R4@  HU$  )=0  "-3@  ADH
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M!TU3_P9-4_\&Q4X  +96  "G6@  F%D  (M8  "!5P  =U0  '!5  !J5@8
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M>P,[:8D$.6F8!3AHJ 4W:+H%-VG3!3=H[@4W9_P%.&;_!3AF_P4X9O\%M%X
M *=E  "590  AF0  'IE  !O90  9&8  %EH  !2:@  36P$ $EN#@!';A8
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M 22"H $C@K(!(H+) 2*!YP$B?_<!(G[_ B)]_P(B??\"I7$  )-Q  "#<0
M=G$  &QR  !@=0  5G@  $Q\  !#@   .X,  #.&   MB0H *HH1 "F+&0 G
MBR( )HLJ "6,,0 DC#D (XQ" "*-2@ AC50 ((U> !^-:P =C7D '(V* !N-
MG  9C:X &(S$ !B,XP 9BO4 &8G_ 1F(_P$9B/\!G7<  (QV  !]=@  <G<
M &5Y  !:?   4(   $:$   \B0  -(P  "V0   EDP( 'Y4, !V6$@ <EAH
M&Y<B !J7*@ 9ES( &)@Z !>80P 6F$T %9A8 !289  3F', $9B$ !"8E@ 0
MF*D #IB_  Z7W0 /EO( $)7\ !"4_P 0E/\ E7T  (5\  !X?   :WX  %^!
M  !4A@  2HH  $"/   VDP  +9<  "::   >G0  %Z # !*B#  0HQ( $*,9
M  ^C(0 .I"D #J0Q  VD.@ ,I$4 "Z10  JD7  )I&H !Z1[  :CC@ $HZ$
M J.T  .BRP #HN8  Z'S  .A^P #H?L C8,  '^"  !QA   9(<  %B,  !-
MD0  0I8  #B:   OG@  )J(  !ZE   7J   $:L   RN!P 'KPT  Z\2  *O
M&0 !KR$  *\I  "P,@  L#P  +!'  "P4P  L&$  +!Q  "P@P  KY<  *^J
M  "OOP  KMD  *[K  "N]   KO0 AXD  'B*  !JC@  79,  %&8  !%G0
M.Z(  #"F   GJ@  'JX  !:Q   0M   "[8   6Y P  N@H  +H.  "Z$P
MNQD  +LA  "\*   O#$  +T\  "^2   OE8  +YE  "^=P  OHP  +Z?  "]
MLP  OL<  +[>  "]ZP  O>L ?Y(  '"5  !BF@  59\  $FE   ]JP  ,J\
M "BT   >M@  %;D   Z\   )OP   L(   #$    Q00  ,8*  #&#@  QQ(
M ,@8  #)'P  RB<  ,PP  #./   SDD  ,]9  #/:@  SWX  ,^3  #/I@
MS[@  ,_(  #/VP  S]L =YP  &BA  !;IP  3JX  $&T   TMP  *+H  !V]
M   3P   #<0   ;'    R@   ,X   #0    T0   -("  #3"   U0P  -80
M  #9%0  VQP  -TD  #@+P  XCP  .-+  #D7   Y&\  .6#  #EF   Y:D
M .6V  #EPP  Y<, ;*4  %^L  !1L@  1+D  #6\   HP   ',0  !+(   ,
MRP   \\   #3    V    -P   #?    WP   .$   #C    Y ,  .8(  #H
M#0  Z1$  .P8  #N(@  \2X  /,\  #T30  ]5\  /9S  #WAP  ]YD  /BE
M  #XL   ^+  _P,7 /\ %0#_ !4 _P 8 /\ (P#_ "\ _P \ /\ 2 #_ %0
M_P!> /\ 9P#] &\ ^P!V /D ?0#X (, ]@"( /4 C@#T ), \@"8 /$ G@#P
M *0 [@"K .T LP#K +T Z@#+ .@ X0#G /$ Y@#] .4 _P#D /\ Y #_ .0
M_P#D /\ _P<3 /\ $0#_ !$ _P 5 /\ 'P#_ "L _P W /\ 1 #^ $\ ^@!:
M /< 8P#T &L \@!R /  >0#O '\ [0"$ .L B@#J (\ Z "4 .< F@#E *
MY "G .( KP#@ +D W@#& -P V@#: .P V #Y -8 _P#6 /\ UP#_ -@ _P#8
M /\ _PH0 /\##@#_  T _P 2 /\ &@#_ "8 _  R /< /P#T $H \0!5 .T
M7@#J &8 Z !N .4 = #C 'H X@"  .  A0#> (L W "0 -L E@#8 )P U0"C
M -, JP#1 +4 S@#! ,P T0#+ .< R0#U ,@ _P#( /\ R #_ ,@ _P#( /\
M_PP, /\&" #_ @H _P / /\ %0#\ "  \0 L .P .0#I $4 Y0!/ .$ 60#>
M &$ VP!H -< ;P#4 '4 T@![ -  @ #. (8 S ", ,L D@#) )@ QP"@ ,4
MJ ## +$ P0"\ +\ RP"] ., O #R +L _0"[ /\ N@#_ +H _P"Z /\ _PX%
M /\)  #_"04 _P8+ /\!$ #P !D Y@ E .$ ,@#< #\ U@!) -$ 4P#. %L
MRP!C ,@ :@#& '  Q0!V ,, >P#! ($ P "' +X C@"\ )0 NP"< +D I "W
M *X M0"Y +, R "Q -\ L 'O *\!^P"N O\ K0/_ *T#_P"M _\ _Q   /\.
M  #_#0  ]@L# /('"@#B 1$ VP(= -(#*P#, S< R 1# ,0$30#!!%8 O@5=
M +P%9 "Z!6L N 5Q +<%=@"U!7P LP:# +(&B0"P!I$ KP>9 *T'H0"K!ZL
MJ0BW *@)Q@"F"MT I0OP *,,_0"B#?\ H0W_ *$-_P"@#?\ _Q$  /P2  #L
M$P  XA,  -L/ P#6"0L S@@4 ,8*(@# ##  O T\ +@-1@"U#4\ L@Y7 + .
M7P"N#F4 K0YK *L.<0"J#G@ J Y^ *</A0"E#XT I ^6 *(0GP"@$*D GQ"U
M )T1Q0";$=X F1+Q )<3_P"6%/\ E13_ )44_P"4%/\ _Q4  .T;  #@'P
MTA\  ,D;  #$% 4 P1 . +H2&P"T$RD L!0U *P50 "I%4D IA52 *0660"B
M%F  H19F )\6; ">%G( G!9Y )L7@ "9%X@ F!>1 )88FP"4&*8 DQFR )$9
MP0"0&M@ C1ON (L<_0"*'/\ BAS_ (D<_P")'/\ ]!T  .0E  #3*0  QRH
M +PF  "V(   M!D+ *X:%0"H'", I!TO *$>.@">'D0 FQY, )D>5 "7'UL
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M FXQ]P)M,?\";3'_ FTQ_P)M,?\"WS(  ,DY  "[/@  K#T  *$Z  ":-P
ME3,  ) Q"@",,10 AS(@ (0S*P"!,S4 ?S,^ 'TS1@![,TT >3-4 '<S6@!V
M,V$ =#-G 7(T;P%Q-'<!;S2! 6XTC )L-)@":C6E FDULP-H-<8#9S;B V8V
M]0-F-O\"9C;_ F8V_P)F-O\"V#<  ,0^  "U0@  ID$  )L_  "3/   C3@
M (@V!P"$-Q$ @#<< 'PX)P!Z.#$ =SDZ '4Y0@!S.4D <3E0 ' Y5P!N.5T
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M U1#_P-40_\#R$(  +A)  "G2P  F$H  (U)  "#1P  ?4,  '9#  !Q1 H
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M>P)%4XD#0U.7 T)3IP1!4[@$05//!$%3[ 1!4OL#0E+_ T)2_P-"4?\#ND\
M *I4  "85   B50  'U3  !S4P  :5$  &)2  !<4P  6%0* %15$@!251L
M3U8D $Y6+0!,5S4 2U<\ $I71 !(5TL 1UA2 $986@%$6&,!0UAM 4%8>0)
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M C)CH0(Q8[,",6/( C%BYP(Q8?@",6'_ C)@_P(R8/\"KEP  )M=  "*70
M?%T  '!=  !F70  7%X  %)@  !,8@  164  $%F"@ ^9Q$ /&@: #MH(@ Y
M:2L .&DR #=J.@ V:D$ -6I) #1J4@ S:EL ,6IE #!J< $N:GX!+6J. 2QJ
MGP$K:K !*FK& 2IIY0$J:/8"*V?_ BMG_P(K9_\"J6$  )5@  "$8   =V
M &QA  !B80  6&,  $YF  !':   0&L  #IN!0 V;PX -' 5 #-P'@ R<28
M,'$N "]Q-0 N<CT +7)% "QR30 K<E< *G)A "ER;0 G<GL )G*+ "1RG $C
M<JX!(W+# 2-QX@$C</0!(V__ 2-N_P$C;O\!H64  (YD  !_9   <F0  &AE
M  !>9@  5&D  $EL  !";P  .W(  #1U   N> H *WD1 "IY&  I>B$ )WHH
M "9Z,  E>S@ )'M  "-[2  B>U( (7M< "![:  ??'8 '7R& !Q[F  ;>ZH
M&GN_ !I[W@ :>?( &WC^ !MW_P$;=_\!F6D  (AI  !Y:0  ;6D  &-J  !9
M;   3V\  $5S   ]=P  -7H  "Y]   G@0, (H,- ""$$@ ?A!H '80B !R%
M*@ ;A3$ &H4Y !F%0@ 8ADP %X96 !:&8P 5AG$ %(:! !*&DP 1AJ8 $86[
M !"%U@ 1@^\ $8+[ !*"_P 2@?\ D6X  (%M  !T;@  :6X  %UP  !3<P
M27<  $!\   W@   +X,  ">'   AB@  &HT& !6/#0 3D!, $I : !*0(@ 1
MD"H $)$R !"1.P /D40 #I%/  V17  ,D6H "Y%Z  J1C0 (D)\ !Y"S  >/
MR0 'C^8 !X[T  B-_  (C?\ B7,  'MS  !O<P  8W4  %=X  !-?0  0X$
M #F&   PB@  *(X  "&1   :E0  $Y<   Z:"  +G X "9P3  B<&@ 'G"(
M!IPJ  2<,P #G#T  IU(  "=5   G6(  )QR  "<A   G)<  )NJ  ";OP
MFML  )KL  ":]0  F?@ @GD  '9Y  !H>@  7'X  %&"  !&AP  /(P  #*1
M   IE0  (9D  !F=   2H   #J,   FF!0 #IPP  *<0  "G%0  J!P  *@C
M  "H*P  J30  *D_  "I2P  J5D  *EH  "I>@  J8X  *FA  "HM0  J,L
M *?D  "G[P  I_, ?8   &^!  !AA   58D  $F.   ^E   -)D  "J>   A
MH@  &:8  !*I   -K   !Z\   "R    LP<  +,,  "S$   M!4  +0;  "U
M(@  MBL  +<U  "W0   N$X  +A=  "X;@  N((  +B7  "XJ@  M[X  +?2
M  "WY@  M^H =H@  &>+  !:D   3I8  $*<   WH@  +*<  "*K   9KP
M$;,   NV   $N0   +P   "^    O@   +\&  # "P  P0\  ,(3  ##&0
MQ"   ,4I  #'-   R$(  ,E1  #)8@  R74  ,F*  #)GP  RK$  ,K!  #)
MT0  R=D ;I,  &"8  !3G@  1J0  #JK   OL   )+4  !FX   0O   "K\
M  '!    Q    ,@   #*    R@   ,P   #- P  S@@  - -  #1$   TQ8
M -8>  #:*   W30  -Y#  #?5   WV<  .!\  #@D0  X*0  ."R  #@O@
MX,, 9I\  %FF  !,K0  /[0  #*X   DO   &+\  !##   (QP   ,H   #-
M    T0   -4   #8    V0   -L   #=    WP   .$$  #C"@  Y0X  .<3
M  #J'   [2<  / U  #Q1@  \E@  /-K  #S@   ])0  /2C  #TK@  ]+(
M_P 3 /\ $0#_ !$ _P 5 /\ 'P#_ "P _P Y /\ 10#_ %  _P!: /X 8P#[
M &L ^0!R /< > #U 'X ] "$ /( B0#Q (X \ "3 .X F0#M )\ [ "F .H
MK@#H +@ Y@#% .4 VP#C .T X@#[ .( _P#A /\ X0#_ .$ _P#A /\ _P 0
M /\ #@#_  T _P 2 /\ &P#_ "@ _P T /X 00#[ $P ]P!6 /0 7P#Q &8
M[P!M .P = #J 'H Z0!_ .< A0#F (H Y0"/ ., E0#A )L X "B -X J@#;
M +0 V0#  -8 T #3 .@ T@#W -$ _P#1 /\ T #_ -  _P#0 /\ _P - /\
M"0#_  H _P / /\ %@#[ "( ]P O /0 .P#P $< [0!1 .D 6@#E &( X@!I
M .  ;P#> '4 W !Z -H @ #8 (4 U0"+ -, D0#1 )< SP"> ,T I@#+ *\
MR0"Z ,< R0#% .( Q #R ,, _@#" /\ P0#_ ,( _P#" /\ _P,& /\  0#_
M  8 _P , /D $0#Q !T ZP I .< -@#C $$ WP!+ -L 5 #5 %P T@!C ,\
M:@#- '  RP!U ,D >P#( (  Q@"& ,4 C ## ), P0": +\ H@"] *L NP"V
M +D Q "W -H M@#M +0 ^@"T /\ M #_ +0 _P"T /\ _P0  /\   #_
M_P & .P #0#E !8 W@ B -< +P#1 #L S0!% ,H 3@#& %< Q !> ,$ 9 "_
M &H O0!P +P =0"Z 'L N0"! +< AP"U (X LP"5 +( G@"P *< K@"R *P
MOP"J -$ J #H *@ ]P"G /\ IP#_ *8 _P"F /\ _P8  /\%  #Q P  Z
M .$ !P#5 !  S0 ; ,< )P## #, OP ^ +P 2 "Y %$ M@!8 +0 7P"R &4
ML !J *\ < "M '8 K !\ *H @@"I (D IP"1 *4 F@"C *0 H0"N *  NP">
M <T G0+F )P$] ";!/\ F@7_ )H%_P"9!?\ _PH  /$.  #D$   V0\  ,X+
M  #( PL P@ 3 +P"'P"W RP LP0W + %0@"M!DH J@92 *@'60"F!U\ I0=E
M *,':P"B"'$ H AW )\(?@"="(4 FPF. )H)EP"8"J$ E@JL )4+N@"3"\P
MD@SE ) -]@"/#O\ C@[_ (X._P"-#O\ ]A$  .87  #6&P  QQD  +X5  "Y
M$   MPH- +$+%P"L#20 J XP *4..P"B#D0 GP], )T/4P";#UH F@]@ )@0
M9@"7$&P E1!R ),0>0"2$($ D!"* (\1E "-$9\ BQ&J (H2N "($LL AA/F
M (44]P"#%?\ @Q7_ ((5_P""%?\ [1H  -PA  #*)0  NR(  +$?  "K&@
MJ10& *42$0"@%!X G!4J )D5-0"6%CX E!9' )(63@"0%E4 CA=; (P780"+
M%V< B1=M (@7= "&&'P A1B& (,9D "!&9L @!JG 'X:M0!]&\< ?!SB 'H=
M]0!Y'?\ >!W_ '@=_P!X'?\ Y2(  - I  "_+   L"H  *<G  "@(P  G1\
M )H:#@"5'!@ D1TD (X>+P",'CD B1Y! (<?20"%'U  @Q]6 ((?7 " 'V(
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M 5\P_P%?,/\!S30  +P[  "I.@  FSH  ) X  ")-0  @S(  '\P 0![+PX
M=S 6 '0P(0!Q,2L ;S$T &TQ/ !K,4, :C%* &@R4 !G,E< 93)= &0R90!B
M,FT 83-W %\S@@%>,XX!732< 5LTJ@%:-;L!6C72 5DU[0%9-?P!6#7_ 5@U
M_P%9-?\!R#@  +<^  "D/@  ECT  (L\  "#.@  ?3<  '@T  !T- L <#43
M &TU'0!J-2< :#8P &8V. !D-C\ 8S9& &$V30!@-E, 7C=: %TW8@!<-VH
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M>@%-08<!2T&6 4I!I0))0K4"24++ DE"Z ))0OD"24'_ DE!_P%)0?\!O4,
M *I%  "810  BD4  ']%  !V0P  ;T   &A   !C00$ 7T$- %Q!% !90AT
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M 3Q-H $[3K$".D[& CI.Y ([3?8".TW_ 3M,_P$\3/\!LTT  )Y,  "-3
M?TP  '1,  !J3   8$H  %E+  !43   4$T% $Q.#@!)3Q4 1T\> $5/)@!$
M4"X 0E U $%0/0! 440 /U%+ #Y14P ]4EP /%)F #I2<@ Y4G\!.%*. 3=2
MG@$V4J\!-5+$ 352X@$V4O4!-E'_ 390_P$W4/\!KD\  )E/  ")3P  >T\
M '!/  !F3P  7$X  %1/  !/40  2E(! $93# !#5!( 050; $!5(P ^52L
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M ")DV@ C8_$ (V+] 21A_P$D8?\!G%@  (E8  !Z60  ;ED  &-9  !:6@
M4%P  $A>  !!8   .F,  #1F   O: H +&D0 "II%P I:A\ *&HF "=J+@ F
M:S4 )6L] "1K1@ C:T\ (FQ9 "!L90 ?;'( 'FR" !ULE  <;*8 &VNZ !IK
MU  ;:NX '&G\ !QH_P <:/\ E5P  (-<  !U7   :5T  %]=  !67@  3&$
M $-D   \9P  -6H  "]M   H< 0 (W(- "%R$@ @<QH 'W,A !YS*  ==#
M''0X !MT0  :=$H &714 !=U8  6=6X %75^ !1UD  3=*( $G2V !%TSP 2
M<^P $G+Z !-Q_P 3<?\ CF   'U@  !O80  96$  %MB  !19   2&<  #YK
M   W;@  ,'$  "EU   B>   ''L' !=]#@ 6?1, %7T; !1^(@ 3?BH $GXQ
M !%^.@ 1?D0 $'].  ]_6@ .?V@ #7]X  Q_B@ +?IT "GZP  E]Q@ *?>0
M"GST  M[_0 +>O\ AF4  '=E  !J90  868  %9H  !,:P  0F\  #ES   Q
M=P  *GH  "-^   <@0  %80  !"'"  -B0X #(D4  R)&P +B2, "HDK  F)
M,P (B3T !HE(  6)5  $B6$  HEQ  &)@P  B98  (BI  "'O@  A]H  (;L
M  "&]0  AOH ?FH  '%J  !G:P  6VP  %!P  !&=   /'@  #-]   J@0
M(X4  !R(   5C   $(\   R2!@ &DPP  I,1  "4%@  E!T  )0D  "5+
ME34  )5   "53   EED  )9I  "5>@  E8X  )2A  "4M0  D\P  )+F  "2
M\@  DO< >'   &UP  !@<@  5'4  $EY   _?@  -8,  "R(   CC0  &Y$
M !24   /EP  "IH   2= P  G@D  )\.  "?$@  H!<  * =  "A)0  HBT
M *(W  "C0P  HU   *-?  "C<0  HX0  **9  "BK0  H<(  *'<  "AZP
MH/( <W8  &9W  !9>P  38   $*%   XBP  +I   "25   ;F@  %)X   ZA
M   )I    J<   "J    JP0  *L*  "L#0  K1$  *T6  "N'   KR0  + M
M  "Q.0  L48  +)5  "R9@  LGD  +*.  "QHP  LK<  +'*  "QX   L>D
M;'X  %^"  !2AP  1HT  #N3   PF0  )IX  !RC   3IP  #:L   >N
ML@   +4   "W    N    +D"  "Y"   N@P  +L0  "\%   O1L  +\C  #!
M+0  PCH  ,))  ##6@  PVP  ,2"  #$EP  Q*L  ,2\  #$RP  Q-H 98D
M %B.  !+E0  /YL  #.B   HJ   ':T  !2Q   -M@  !KD   "\    OP
M ,,   #$    Q0   ,8   #'    R00  ,H)  #+#0  S1$  ,\8  #2(0
MU2T  -8\  #830  V5\  -IS  #:B@  VYX  -NN  #;N@  W,, 7I8  %&<
M  !$HP  .*H  "RQ   @MP  %;L   V^   $P@   ,4   #)    S0   -
M  #2    T@   -4   #6    V0   -L   #>!0  X H  .(/  #E%@  Z"
M .PM  #M/@  [5$  .YE  #O>@  [X\  /"?  #PJP  \+, _P 0 /\ #@#_
M  X _P 2 /\ '0#_ "D _P U /\ 00#_ $T _@!6 /L 7P#X &8 ]@!M /0
M= #R 'D \0!_ /  A #N (D [0"/ .L E0#J )L Z "B .8 J@#E +, XP#
M .$ T@#@ .H WP#Y -T _P#= /\ W0#_ -X _P#> /\ _P - /\ "@#_  D
M_P / /\ & #_ "0 _@ Q /L /0#X $@ ] !2 /  6@#M &( ZP!I .D ;P#G
M '4 Y0!Z ., ?P#B (4 X "* -X D #< )8 V@"= -@ I0#5 *\ T@"Z -
MR@#. ., S0#T ,L _P#+ /\ RP#_ ,L _P#+ /\ _P ( /\  P#_  4 _P ,
M /P % #W !\ \@ K .\ -P#K $( YP!, .0 50#@ %T W0!D -H :@#8 '
MU0!U -( >@#0 (  SP"% ,T BP#+ )( R0"9 ,< H0#% *H PP"U ,$ PP"_
M -H O@#N +T _ "\ /\ O #_ +P _P"\ /\ _P   /\   #_    ^0 ' /$
M$ #J !H Y  E -\ ,0#; #P UP!' -( 4 #. %< RP!> ,D 90#& &H Q0!P
M ,, =0#! 'H P "  +X A@"\ (T N@"4 +D G "W *4 M0"P +, O0"Q ,\
MKP#H *X ^ "N /\ K0#_ *T _P"M /\ _P   /\   #]    [@ ! ., # #:
M !0 T0 ? ,P *P#( #8 Q0!  ,( 2@"_ %( O !9 +H 7P"X &4 M@!J +0
M;P"S '4 L0!Z +  @0"N (@ K0"/ *L F "I *$ IP"K *4 N "C ,@ H@#B
M *$ \P"@ /X H #_ *  _P"@ /\ _P   /8   #J    X    -, !@#)  \
MP@ 8 +T ) "Y "\ M@ Z +0 0P"Q $P K@!3 *P 60"J %\ J0!D *< :@"F
M &\ I !U *, >P"A (( H "* )X DP"< )T F@"G )@ M "6 ,, E0#< )0
M[P"3 /L DP#_ ), _P"2 /\ ^04  .H+  #<#0  RPH  ,(%  "\  H M@ 1
M +$ ' "N "@ J@ S *< /0"D $4 H@!- *  4P"> %D G !? )L 9 ": &H
MF !P )< =@"5 'X DP"& )(!CP"0 9D C@*D (P"L0"+ \  B076 (@&[0"(
M!_H APC_ (8(_P"&"/\ [P\  -X4  #*%0  O!(  +,0  "N#   JP8- *<#
M%0"B!2  GP<L )P(-@"9"#\ EPE' )4)3@"3"50 D0I: ) *7P"."F4 C0IK
M (L*<@"*"WD B N" (<+C "%#)< @PRB ($-L " #<  ?PW8 'T.[P!\#_T
M>P__ 'L0_P![$/\ YA<  -$>  "]'0  KQP  *89  "A%0  GA $ )T-#P"8
M#AD E XE )$/+P"/$#D C!!! (H02 "($$\ AQ!5 (406P"$$6$ @A%G ( 1
M;@!_$74 ?1%^ 'P2B !Z$I0 >!*@ '<3K@!U$[X =!35 ',5[@!Q%OT <1;_
M '$6_P!P%O\ W!\  ,8E  "S)0  I2,  )PA  "6'@  DAD  )$4"P"-%!0
MB14? (86*0"#%C, @1<\ ( 70P!^%TH ?!=0 'H75@!Y&%P =QAB '88:0!T
M&'$ <QEZ '$9A !O&I  ;AJ= &P;JP!K'+L :AS0 &D=[ !H'OL :![_ &<>
M_P!G'O\ T28  +TJ  "K*@  G2H  ),H  "-)0  B"(  (8=!@"#&Q  ?QP:
M 'P=) !Z'2X =QXV '8>/@!T'D4 <A]+ '$?40!O'U@ ;A]> &P?90!K(&T
M:2!V &@A@0!F(8T 92*: &,BJ !B([@ 82/- & DZ0!@)/H 7R3_ %\D_P!?
M)/\ RBP  +8O  "D+P  EB\  (PM  "%*@  @"@  'TD  !Z(@T =B,5 ',C
M( !Q)"D ;R0R &TD.@!K)4$ :B5' &@E30!F)50 925: &0F80!B)FD 829R
M %\G?0!>)XH 72B7 %LII0!:*;4 6BK* %DJYP!8*O@ 6"K_ %@J_P!8*O\
MQ3$  *\S  ">,P  D#,  (8R  !_+P  >2T  '4J  !R* H ;R@2 &LI&P!I
M*24 9RHM &4J-0!C*CT 8BI# & J2@!?*U  7BM7 %PK7@!;+&8 62QO %@M
M>@!7+8< 5BZ5 %0NHP!3+[, 4R_' %(OY0!2+_< 4B__ %(O_P!2+_\ P38
M *HV  "9-@  BS8  ($U  !Y,P  <S$  &\O  !K+@8 :"T0 &0N& !B+B$
M8"\J %XO,0!<+SD 6R]  %DO1@!8+TT 5S!3 %8P6P!4,6, 4S%L %(R=P!1
M,H0 3S.2 $XSH0!-,[$ 333% 4PTXP%,-/8 3#3_ $PT_P!,,_\ NSD  *8Y
M  "5.0  ASD  'PY  !T-P  ;C0  &DS  !E,@( 83(- %XR% !<,QX 6C,F
M %@S+@!6,S4 530\ %,T0P!2-$H 4310 % U6 !.-6  339J $PV=0!+-X(
M2C>0 $DXGP!(.+ !1SC# 4<XX0%'./4!1SC_ 4<X_P%'./\!MSL  *(\  "1
M/   @SP  '@\  !P.@  :C<  &0V  !@-@  7#8+ %DW$@!6-QH 5#<C %(W
M*P!0-S( 3S@Y $TX0 !,.$< 2SA. $HY50!).5X 2#IH $<Z<P!&.X  13N.
M $0\G@!#/*X!0CS" 4(]WP%"//,!0CS_ 4(\_P%"._\!LST  )X^  "-/@
M?SX  '4^  !L/0  9CH  & Y  !;.@  5SH( %,[$ !1.Q@ 3CL@ $P[* !+
M.R\ 23PV $<\/0!'/$0 1CU+ $4]4P!$/EP 0SYF $(_<0!!/WX 0#^- #]
MG  ^0*T!/4#  3U W0$]0/(!/4#_ 3X__P$^/_\!KD   )I   ")00  ?$$
M '%!  !H0   83P  %L]  !6/@  4CX% $X_#@!,/Q4 23\= $= )0!&0"P
M1$ S $- .@!"04( 04%) $!!40 _0EH /D)C #U#;P \0WP .T.+ #I$FP Y
M1*L!.42^ 3A$VP$Y1/$!.4/^ 3E#_P$Y0_\!JD(  )9#  "&0P  >$,  &Y#
M  !E0P  74   %9   !10@  34(" $E## !&0Q( 1$0: $)$(@!!1"H /T4Q
M #Y%.  ]13\ /$9' #M&3P Z1E< .4=A #A';  W1WH -DB) #5(F0 T2*H
M-$B] #-(V0 T2/  -$?] #1'_P U1O\ ID0  ))%  ""1@  =48  &I&  !A
M10  640  %%$  !,1@  2$<  $1'"@!!2!  /TD8 #U)(  \22< .DHN #E*
M-@ X2CT -TM$ #9+3  U2U4 -$Q? #-,:@ R3'< ,4R& #!,EP O3:@ +DV[
M "Y-U0 N3.\ +TS] "]+_P P2_\ H4<  (Y(  !^2   <4@  &9)  !=2
M54@  $Q)  !'2@  0DL  #],!@ [30X .4X5 #=.'0 V3R0 -4\K #-/,P R
M4#H ,5!" #!02@ O45( +E%< "U19P L474 *U&$ "I2E0 I4J8 *5*Y "A2
MT@ I4>X *5#\ "I0_P J3_\ G$H  (E*  !Z2P  ;4L  &-,  !:3   44P
M $A-  !#3P  /5   #E2 @ U4PP ,U02 #%4&0 P52$ +E4H "U5+P L5C<
M*U8^ "I61@ I5D\ *%=9 "=79  F5W( )5>! "17D@ C5Z0 (E>W ")7SP B
M5^P (U;Z "-5_P D5?\ EDT  (1.  !U3@  :4X  %]/  !63P  35   $52
M   _4P  .58  #-8   O6@@ *UL/ "I;%0 H7!T )UPD "9<*P E7#, )%TZ
M "-=0P B74P (5U6 "!>80 ?7FX 'EY^ !U>CP <7J$ &UZT !I=S  ;7>D
M&USY !Q;_P <6_\ D%$  'Y1  !P40  9%(  %M2  !24P  2E0  $%7   [
M60  -5L  "Y>   H8 , )&(, ")C$0 A8Q@ 'V0@ !YD)P =9"X '&0V !ME
M/@ :94< &651 !AE70 796H %F5Z !5EBP 499X $V6Q !)ER  29.< $V/W
M !1B_P 48O\ B50  'A5  !K50  8%8  %=6  !/5P  1ED  #U<   V7P
M,&(  "ED   C9P  '6H' !EL#@ 8;!, %FT: !5M(0 4;2D %&TP !-M.0 2
M;D( $6Y, !!N6  /;F4 #FYU  UNAP -;IH #&VM  MMP@ +;.  #&OS  UK
M_0 -:O\ @ED  ')9  !F60  7%H  %1:  !*7   05\  #EC   Q9@  *FD
M "1L   =;P  %W(  !)U"0 /=P\ #G<4  YW&P -=R, #'<J  MW,P *=SP
M"7='  AW4@ '=U\ !7=O  1W@  #=Y0  7:G  !VNP !==4  73K  )T]@ "
M=/P >UT  &U=  !B7@  65X  $Y@  !%8P  /&<  #-K   K;@  )'(  !YU
M   7>0  $GP   U_!@ )@0P !8$1  .!%@ "@1T  8$D  "!+0  @C8  ()
M  ""3   @ED  ()H  "">0  @HT  (&@  " M   @,L  '_G  !^\@  ?OD
M=&(  &AB  !>8@  4V0  $EG   _:P  -G   "UT   E>   'GP  !>    1
M@P  #88   B)!  "BPH  (L.  "+$P  C!@  (P?  "-)@  C2\  (XY  ".
M1   CE$  (Y@  ".<0  CH4  (Z9  "-K0  C,,  (S?  "+[@  B_8 ;F@
M &1G  !8:0  36P  $)Q   X=@  +WL  "9_   >A   %H@  !",   ,CP
M!I(   "5    E@<  )<,  "7#P  F!,  )D8  ":'P  FR8  )LP  "<.P
MG$@  )Q7  "<:   G'L  )R0  ";I0  F[H  )K0  ":YP  FO$ :FT  %YO
M  !1<@  1G<  #M\   Q@@  )X<  !Z,   6D0  $)4   J9   $G    *
M  "B    HP$  *,&  "D"P  I0X  *82  "G%P  J!X  *HF  "K,0  JSX
M *Q-  "L70  K'   *R%  "LFP  JZ\  *O#  "KV0  JN@ 9'4  %=Y  !+
M?@  /X0  #2*   ID   'Y8  !:;   0GP  ":,   &G    J@   *X   "P
M    L    +$   "R P  M @  +4-  "V$   MQ4  +D=  "[)@  O#,  +U!
M  "]4@  O60  +YY  "^D   O:0  +VW  "]Q@  O=< 7'\  %"%  !$BP
M.)(  "R9   AGP  %Z0  !"I   )K@   +(   "V    N0   +T   "_
MOP   ,    #!    PP   ,0%  #&"@  QPX  ,D3  #+'   SB8  - U  #1
M10  TE<  -)K  #3@@  TY<  -.I  #2N   TL0 58P  $F3   ]F@  ,*(
M "6H   :K@  $;0   FY    O0   ,$   #$    R    ,L   #-    S0
M ,\   #0    T@   -0   #8    V@8  -T,  #@$0  XQH  .8G  #G.
MZ$H  .E=  #J<@  ZX@  .N;  #LJ   [+( _P - /\ "P#_  L _P 0 /\
M&@#_ "8 _P R /\ /0#_ $@ ^P!2 /@ 6@#V &( \P!I /$ ;P#P '4 [@!Z
M .P ?P#K (0 Z0"* .@ D #F )8 Y "= .( I0#A *\ WP"[ -T RP#; .8
MV0#W -@ _P#8 /\ UP#_ -< _P#4 /\ _P ( /\ ! #_  0 _P - /\ %0#^
M "$ ^@ L /< . #T $, \ !- .T 50#J %T YP!D .0 :@#B '  X !U -X
M>@#= '\ VP"% -D BP#5 )$ TP"9 -$ H #/ *H S0"U ,L Q #) -T R #Q
M ,< _P#& /\ Q@#_ ,8 _P#' /\ _P   /\   #_    _P * /@ $0#Q !P
M[  G .D ,@#F #T X@!' -T 4 #9 %@ U0!? -( 90#0 &H S@!P ,P =0#*
M 'H R0!_ ,< A0#% (P PP"4 ,$ G "_ *4 O0"P +L O0"Z -  N #K +<
M^P"V /\ M@#_ +8 _P"V /\ _P   /\   #]    \P % .D #@#A !8 VP A
M -4 +0#1 #< S@!! ,H 2@#' %( Q !9 ,( 7P#  &4 O@!J +P ;P"[ '0
MN0!Z +< @ "V (< M ". +( EP"P *  K@"J *T MP"K ,@ J0#C *@ ]0"G
M /\ IP#_ *< _P"F /\ _P   /X   #Q    Y0   -< "@#- !$ QP < ,(
M)@"_ #$ O  [ +H 1 "W $P M !3 +( 60"Q %\ KP!D *T :0"L &\ J@!T
M *D >@"G ($ I@") *0 D0"B )L H "E )X L@"= ,$ FP#: )H [P"9 /T
MF #_ )@ _P"8 /\ _0   /    #A    T0   ,8 ! "]  T MP 5 +, ( "P
M "L K0 U *L /@"H $8 I@!- *0 5 "C %D H0!? *  9 "> &D G0!N )L
M=0": 'L F "# )8 C "5 )8 DP"A )$ K0"/ +L C0#/ (P Z0"+ /@ C #_
M (P _P", /\ \P(  .('  #,!P  OP0  +<   "Q  @ JP 0 *< &0"D "0
MH  N )X -P"< $  F@!' )@ 3@"6 %0 E0!9 ), 7@"2 &0 D !I (\ ;P"-
M '8 BP!^ (H B "( )( A@"= (4 J0"# +@ @0#* (  Y0"  /4 ?P#_ '\
M_P!_ /\ Z T  - 0  "^$   L0X  *@-  "C"   H (, )P $P"8 !T E0 G
M )( ,0"0 #D C@%! (P!2 "* DX B0)4 (<"60"& E\ A -D (,#:P"! W(
M@ 1Z 'X$A !]!8X >P6: 'D&IP!X!K4 =@?( '4(XP!U"?0 = K_ ',*_P!S
M"O\ W14  ,07  "Q%P  I18  )P3  "6$0  E T$ ),(#0".!Q4 BPD@ (@)
M*@"%"C, @PL[ ($+0@" "TD ?@M/ 'T,5 ![#%H >@Q@ '@,9P!W#&X =0UV
M '0-@ !R#8P < V9 &\.I@!M#K4 ; [) &L/Y@!J$/< :1#_ &D0_P!I$/\
MT!T  +D>  "H'@  FQT  )(;  "+&0  B!4  (<1!P"%#A  @0\: 'X0) ![
M$"T >1 V '<1/0!V$40 =!%* ',14 !Q$58 <!%< &X28@!M$FH :Q)S &D3
M?0!H$XD 9A.6 &44HP!C%;, 8A7& &(6XP!A%O8 8!?_ & 7_P!@%_\ QR(
M + C  "?)   DB,  (DB  ""(   ?AT  'P9  !Z%0T =Q45 '06'P!Q%B@
M;Q<P &X7. !L%S\ :Q=% &D82P!H&%$ 9AA8 &487@!C&68 8AEO & 9>0!?
M&H4 71N2 %P;H0!;'+  6AS# %D=X !8'O0 6![_ %@>_P!8'O\ OR<  *DH
M  "9*   BR@  ((G  ![)0  =B,  ',@  !Q' D ;AP1 &L<&@!I'2, 9QTL
M &4=,P!C'CH 8AY! & >1P!?'DT 7AY4 %P?6P!;'V( 62!K %@@=@!6(8(
M52&0 %0BG@!3(JX 4B/  %$CW0!1)/( 423_ %$D_P!1(_\ N2L  *,L  "3
M+   ABT  'PL  !T*@  ;R@  &LE  !I(@4 9B$. &,B%@!A(A\ 7R,G %TC
M+P!<(S8 6B,] %DD0P!7)$H 5B10 %4D5P!3)5\ 4B5H %$F<P!/)G\ 3B>-
M $THG !,**P 2RF^ $LIV@!**?$ 2BG_ $LI_P!+*?\ LRX  )XO  ".,
M@3   '<O  !O+@  :BL  &4J  !C)P$ 7R<, %PG$P!:)QL 6"@D %8H*P!5
M*#( 4R@Y %(I0 !0*48 3RE- $XI5 !-*EP 3"IE $HK< !)*WP 2"R+ $<M
MF@!&+:H 12Z\ $4NU@!%+N\ 12[^ $4N_P!%+?\ KC$  )HR  "),P  ?#,
M '(S  !K,0  92\  & M  !=+   62P) %8L$ !4+!@ 4BP@ % L* !.+2\
M32TV $PM/ !*+4, 22U* $@N40!'+ED 1B]C $4P;0!#,'H 0C&) $$QF !!
M,J@ 0#*[ #\RTP _,NX 0#+] $ R_P! ,O\ JC,  )8U  "&-0  >38  &XU
M  !F-0  83(  %PP  !7,   5# & %$P#@!.,!4 3#$= $HQ)0!(,2P 1S$R
M $8Q.0!$,4  0S)' $(R3P!!,U< 0#-@ #\T:P ^-7@ /36' #PVE@ [-J<
M.S:Y #HVT0 Z-NT .S;\ #LV_P [-O\ IC8  )(W  "".   =3@  &LX  !C
M-P  738  %<S  !3-   3S0# $LT# !)-!( 1C4: $4U(@!#-2D 034O $ U
M-@ _-CT /C9$ #TW3  \-U4 .SA> #HX:0 Y.78 .#F% #<ZE0 W.J4 -CJX
M #4ZSP V.NP -CK[ #8Y_P W.?\ HC@  (XY  !^.@  <CL  &@[  !?.@
M63D  %,V  !.-P  2C@  $8X"@!$.1  03D7 #\Y'P ^.28 /#DM #LZ-  Z
M.CL .3M" #@[2@ W.U, -CQ< #4\9P T/70 ,SV# #,^DP R/J0 ,3ZV #$^
MS0 Q/NH ,3[Z #(]_P R/?\ GCL  (L\  ![/   ;CT  &0]  !</0  53P
M $XZ  !).P  13P  $$]!P ^/0X /#T5 #H^'  Y/B, -SXJ #8_,0 U/S@
M-#]  #- 2  R0%  ,4!: #!!90 O07( +D*! "U"D0 M0J( +$*U "M"RP L
M0ND +$+Y "U!_P M0?\ F3T  (<^  !W/P  :S\  &%   !9/P  4C\  $D^
M  !$/P  0$   #Q!!  Y0@T -T(2 #5#&0 S0R$ ,D,H #%$+P P1#8 +T0]
M "Y%10 M14X +$58 "M&8P J1F\ *49^ "A&CP G1Z$ )D>S "9'R0 F1N<
M)T;X "A%_P H1?\ E4   ()!  !S0@  9T(  %Y"  !50@  3D(  $5"   _
M1   .T4  #=&   T1PH ,4@0 "](%@ N21X +$DE "M)+  J23, *4HZ "A*
M0@ G2DL )DM5 "5+8  D2VT (TM\ ")+C0 A3)\ (4RQ "!,QP @2^8 (4OW
M ")*_P B2O\ D$,  'Y$  !O1   9$4  %I%  !210  2D8  $%'   \2
M-TD  #)+   N30< *TX. "E.$P G3QH )D\A "5/*  D3S  (U W ")0/P A
M4$@ (%!2 !]170 >46H '5%Y !Q1B@ ;49P &E&O !E1Q0 94>0 &E#V !M/
M_P <3_\ BD8  'E'  !K1P  8$@  %9(  !.2   1TD  #Y+   Y3   ,TX
M "Y0   H4P( )%0+ ")5$  @518 'U8> !Y6)  =5BP '%8S !M7.P :5T0
M&5=. !A760 76&8 %5AU !18AP 46)H $U>L !)7P@ 25^$ $U;T !15_P 4
M5?\ A$D  '1*  !F2P  7$L  %-+  !+3   1$T  #Q/   U40  +U0  "E6
M   D60  'EL' !I=#0 871( %UT9 !9>(  57B< %%XN !->-P 27D  $5]*
M !%?50 07V( #U]Q  Y?@P -7Y8 #5^I  Q>O@ ,7MH #5WP  U<_  .7/\
M?DT  &Y.  !B3@  6$\  $]/  !(4   0%(  #A4   P5P  *EH  "1=   ?
M7P  &6(! !-E"0 19@\ $&84  ]F&P .9R( #6<I  UG,@ ,9SL "V=%  IG
M4  )9UT !V=L  9G?0 %9Y  !&:C  )FMP #9<\ !&7I  1D]0 $9/P =U$
M &E2  !=4@  5%(  $Q3  !#50  .U@  #-;   K7@  )6$  !]D   99P
M$VH   ]M!@ +< P "' 1  =P%@ %<!T !' D  -P+  "<#4  ' _  !P2@
M<%<  '!E  !P=@  <(H  &^>  !OL@  ;L@  &WE  !M\@  ;?D <%8  &-6
M  !95@  45<  $?_XO__24-#7U!23T9)3$4 ! E8   ^6P  -E\  "YB   F
M9@  'VH  !EM   3<   #G,   MV!  %> L  7@/  !Y$P  >1D  'D?  !Z
M)@  >B\  'HY  !Z1   >E   'I?  !Z<   >H,  'J8  !ZK   ><(  'C?
M  !X[P  =_< :EL  %];  !66P  3%P  $)@   Y8P  ,&@  "AL   @<
M&70  !-W   .>P  "7X   2! @  @@@  (,-  "#$   A!0  (49  "&(
MAB@  (<Q  "'/   ATD  (=7  "':   AWL  (>0  "&I0  A;H  (73  "$
MZ@  A/0 96   %Q@  !180  1F0  #QI   R;0  *7(  "%W   9>P  $H
M  V#   (AP   HH   "-    C@0  (X)  "/#0  D!   )$4  "2&0  DR
M )0I  "5,P  E4   )9.  "67P  E7(  )6(  "5G0  E+(  )3(  "3X@
MD^X 864  %9F  !*:@  /VX  #5T   K>0  (7\  !F$   1B0  #(T   :1
M    E    )@   ":    FP   )P"  "=!P  G@L  )\.  "A$@  HA@  *,@
M  "E*0  IC8  *9$  "F50  IF@  *9]  "FE   I:D  *2]  "DT0  I.0
M6VP  $]P  !#=0  .'L  "V!   CAP  &8T  !&2   +EP  !)P   "@
MHP   *8   "H    J0   *H   "L    K00  *X)  "P#0  L1$  +,7  "U
M(   MBL  +<Z  "W2P  N%P  +AQ  "XB   N)T  +BQ  "WP@  M]  5'8
M $A\   \@@  ,8D  ":0   ;EP  $IT   RB   #IP   *L   "N    L@
M +8   "X    N    +H   "[    O0   +X   # !0  P0L  ,,0  #&%@
MR2   ,HN  #+/@  S%   ,QD  #->@  S9$  ,VD  #-M   S<  38,  $&*
M   UD0  *9D  !Z@   3I@  #*P   .Q    M@   +H   "^    P@   ,8
M  #(    R    ,H   #+    S0   ,X   #0    T@$  -4(  #9#@  W14
M .$A  #B,0  Y$,  .56  #F:P  YH(  .>6  #GI0  YK  _P ) /\ !0#_
M  8 _P . /\ %@#_ "$ _P M /\ . #] $, ^0!- /4 50#R %T \ !C .X
M:0#L &\ Z@!T .D >@#G '\ Y@"% .0 BP#C )$ X0"9 -\ H0#< *H V@"V
M -< Q@#5 .$ TP#T -( _P#1 /\ T0#_ ,\ _P#* /\ _P ! /\   #_  $
M_P , /\ $@#Z !T ]@ H /, ,P#P #X [ !( .@ 4 #E %@ X@!> -\ 9 #=
M &H VP!O -D = #6 'H U !_ -( A0#0 (P S@"3 ,P G #) *4 QP"P ,8
MO@#$ -0 P@#N ,$ _@#  /\ P #_ +\ _P"^ /\ _P   /\   #_    ^@ '
M /$ #P#K !@ Y@ C .( +@#@ #@ VP!" -4 2P#1 %( S@!9 ,L 7P#) &4
MQP!J ,8 ;P#$ '0 P@!Z ,$ @ "_ (8 O0". +L E@"Y *  MP"J +8 MP"T
M ,H L@#F +$ ^ "P /\ KP#_ *\ _P"P /\ _P   /\   #W    Z@ " .$
M# #7 !, T  = ,P * #) #( Q@ \ ,( 10"_ $T O !3 +H 60"X %\ MP!D
M +4 :0"T &X L@!T +$ >@"O (  K0"( *P D0"J )H J "E *8 L0"D ,$
MHP#< *$ \@"A /\ H #_ *  _P"A /\ _P   /<   #H    V0   ,L " ##
M !  O0 8 +D (@"V "P M  V +( /P"O $< K !- *L 5 "I %D IP!> *8
M8P"E &@ HP!N *( = "@ 'H G@"" )P BP"; )4 F0"? )@ K "6 +H E #/
M ), ZP"2 /L D@#_ )( _P"1 /\ ]P   .<   #3    Q@   +L  @"S  P
MK0 2 *H ' "G "8 I  P *, . "@ $  G@!' )P 3@": %, F0!8 )< 70"6
M &, E0!H ), ;@"2 '0 D !\ (\ A0"- (\ BP": (H IP"( +4 A@#' (4
MY "$ /4 A #_ (, _P"# /\ [    -,   #! 0  M    *P   "F  < H  .
M )T %@": "  EP I )4 ,@"3 #H D0!! (\ 2 "- $T C !3 (L 6 ") %T
MB !C (< :0"% &\ @P!W (( @ "  (H ?@"6 'T HP![ +  >@#" 'D W0!X
M /$ =P#] '@ _P!X /\ W@H  ,0+  "R#   I@L  )T(  "9!   E0 * )$
M$0". !D BP C (D + "' #0 A0 [ (, 0@"" $@ @ !. '\ 4P!] %@ ? !>
M 'L 9 !Y &H > !R '8 >P!T (8 <P"2 '$ GP!P *T ;@"^ &T!U@!M NT
M; /Z &P#_P!L _\ SA   +<1  "F$@  FA$  )$0  "+#@  B0L# (<%# "$
M 1, @0$< 'X")0!\ RX >@,V '@$/ !W!$, =05( '0%3@!S!50 <059 ' &
M7P!N!F8 ;09N &L'> !J!X, : B0 &<)G0!E":P 9 F\ &,*U !C"^P 8@SZ
M &(,_P!B#/\ PQ8  *T7  "=&   D!@  (<6  "!%   ?1$  'P.!@!\"@X
M> H6 '4+'P!R"R@ < PP &\,-P!M##X ; Q$ &L-2@!I#4\ : U5 &<-7 !E
M#6, 8PYK &(.=0!@#H$ 7PZ. %T/G !<$*L 6Q"] %H0U@!9$?  61'] %D1
M_P!9$?\ N1L  *4=  "4'@  B!X  'X=  !X&P  =!@  '$5  !Q$0D ;Q 1
M &P0&0!I$"( 9Q$J &81,@!D$3D 8Q$_ &(110!@$DL 7Q)1 %T26 !<$E\
M6A-H %D3<@!7%'T 5A2+ %05F0!3%:D 4A:Z %$6T@!1%^T 41?] %$7_P!1
M%_\ LB   )XB  ".(@  @2,  '<B  !P(0  ;!X  &D;  !G& 0 9A4. &,6
M%0!A%AX 7Q8F %T6+0!<%S0 6A<[ %D700!8&$< 5AA- %485 !3&%P 4AED
M %$9;@!/&GH 3AN( $T;EP!+'*8 2ARX $H=SP!)'>L 21W[ $D=_P!*'?\
MK"0  )@E  "()@  >R<  '$F  !J)0  9B,  &(A  !@'@  7AP+ %L;$@!9
M'!H 5QPB %4<*0!4'#  4QTW %$=/0!0'4, 3QU* $T>40!,'E@ 2Q]A $D?
M:P!(('< 1R"% $8AE !$(J0 1"*V $,BS !#(^D 0R/Z $,C_P!#(O\ IB<
M ),I  "#*@  =BH  &TJ  !E*0  8"<  %PE  !9(P  5R$' %4A#P!2(18
M4"$> $XA)0!-(BP 3"(S $HB.0!)(D  2")& $<C30!%(U4 1"1> $,D:0!"
M)74 0":# #\FD@ ^)Z, /B>T #TGR@ ]*.@ /2CY #TG_P ^)_\ HBH  (XK
M  !_+0  <BT  &@M  !A+   7"L  %@H  !4)@  428$ $XE#0!,)1, 2B8:
M $@F(@!')BD 128O $0F-@!#)SP 02=# $ G2P _*%, /BE< #TI9@ \*G(
M.RJ! #HKD  Y*Z$ ."RR #<LR  W+.8 ."SX #@L_P X+/\ G2P  (HN  ![
M+P  ;S   &4P  !=+P  6"X  %,K  !0*@  3"H  $DJ"P!&*A$ 1"H7 $(J
M'P!!*B4 /RHL #XK,P ]*SD /"M  #LL2  Z+%  .2U9 #@N9  W+G  -B]_
M #4OCP T,)\ ,S"Q #(PQP R,.4 ,S#W #,P_P T+_\ F2\  (<Q  !W,@
M:S(  &(R  !:,@  5#$  $\O  !++0  1RX  $0N" !!+@X /RX4 #TN'  [
M+B( .2\I #@O+P W+S8 -C ^ #4P1@ U,4X -#%7 #,R8@ R,FX ,3-] # S
MC0 O-)X +C2P "TTQ0 M-., +C3V "\S_P O,_\ E3$  (,S  !T-   :#4
M %XU  !7-   430  $LR  !&,0  0C(  #\R!0 \,@T .3,2 #@S&0 V,R
M-#,F #,S+0 R-#0 ,30[ # U0P P-4P +S95 "XV8  M-VP +#=[ "LWBP J
M.)P *3BN "@XPP H..( *3CU "HW_P J-_\ DC0  '\U  !Q-@  93<  %LW
M  !4-P  338  $<V  !"-0  /38  #HV @ W-PL -#<0 #(W%@ Q.!T +S@D
M "XX*P M.3( +#DY "LY00 J.DD *CI3 "D[7@ H.VH )SMY "8\B0 E/)L
M)#RM ",\P@ C/.  )#ST "4[_P E._\ C38  'PX  !M.0  8CD  %@Z  !1
M.0  2CD  $0Y   ].0  .3H  #4[   R.P@ +SP. "T]%  L/1H *CTA "D]
M*  H/B\ )SXV "8^/@ E/T< )#]0 "- 6P B0&@ (4!V "! AP ?09D 'T&K
M !Y!P  >0=X 'T#S !] _@ @/_\ B3D  '@Z  !I.P  7CP  %4\  !-/
M1SP  $ \   X/0  -#X  #!    M004 *D(, "="$0 F0Q@ )$,> "-#)0 B
M0RP (40S "!$.P ?1$0 'D5. !U%60 <164 &T5T !I%A0 91I< &4:I !A&
MO@ 71=P &$7Q !E$_0 :1/\ A#P  ',]  !F/@  6S\  %(_  !*/P  1#\
M #U    V00  ,4,  "Q$   G1@$ )$<* "%(#P @210 'DD; !U)(@ <22D
M&THP !I*.  92D$ &$I+ !=+50 62V( %4MQ !1+@@ 32Y0 $DNG !)+O  1
M2]D $DKP !-*_  42?\ ?S\  &]   !A00  5T(  $Y"  !'0@  04(  #I#
M   R10  +4<  "A)   C2P  'DT& !M/#0 84!$ %U 7 !90'@ 54"4 %% L
M !-1-  243T $5%' !%14@ 045\ #U)M  Y2?@ -49$ #5&D  Q1N  ,4=$
M#5#L  U0^@ .3_\ >4,  &I$  !=1   4T4  $M%  !$10  /D8  #9(   O
M2@  *4P  "1/   ?40  &E,  !16"0 15PX $%@3 !!8&0 /6"  #E@H  U8
M,  -6#D #%A#  M83@ *6%H "%AH  =8>0 &6(P !5B?  18LP $5\H !5?F
M  57\P &5OP <T8  &1'  !92   4$@  $A(  !!20  .DH  #)-   K4
M)5(  "!5   :6   %5H  !!=!@ ,8 P "F 0  E@%0 (8!P !V C  5@*P $
M8#0  V ]  %@20  8%4  &!C  !@<P  8(8  %^:  !?K@  7\0  %[B  !>
M\   7O@ ;$H  %]+  !52P  3$P  $5,   ]3@  -5   "Y3   G5@  (%D
M !I<   57P  $&(   UE!  (9PL  V<.  !H$P  :!@  &@?  !I)@  :2X
M &DX  !I0P  :4\  &E=  !I;0  :8   &F4  !HJ0  :+\  &?<  !F[@
M9O< 9D\  %I/  !13P  2D\  $%1   X5   ,%<  "A;   A7@  &F(  !1E
M   0:   #&L   =N P !< D  ' -  !Q$   <10  '(:  !S(0  <R@  ',Q
M  !S/   =$@  '-6  !S9@  <WD  '..  !SHP  <KD  ''2  !QZP  </0
M85,  %93  !/4P  154  #M8   R7   *F   ")D   ;:   %&P   ]O   +
M<@  !G8   !Y    >@8  'H*  ![#@  ?!$  'T5  !^&P  ?R(  ( J  "
M-0  @$$  (!/  " 7P  @'$  ("&  " G0  ?[(  '[*  !^Y0  ??$ 7%@
M %18  !)6@  /UT  #5A   L90  (VH  !MO   4<P  #G<   E[   #?P
M ((   "$    A@$  (8&  "("@  B0T  (H0  "+%0  C!L  (XB  "/+
MCS@  (]&  "/5@  CV@  (]^  "/E0  CJL  (W!  "-W   C.L 65T  $Y?
M  !#8@  .&8  "YL   D<0  ''<  !1\   .@0  "(4   ")    C0   )
M  "2    DP   )0   "6 P  EP@  )@,  ":#P  FQ,  )T:  "?(P  H"X
M * \  "@3   H%X  *!T  "?C   GZ(  )^W  ">RP  GN  4V0  $=H   \
M;0  ,7,  "=Y   =?P  %(4   V+   &D    )0   "8    G    )\   "A
M    H@   *0   "E    IP   *@$  "J"0  K T  *T2  "P&0  LB,  +(Q
M  "R0@  LE0  +)I  "R@   LI@  +&L  "ROP  L<X 3&X  $!S   U>@
M*H$  !^(   5C@  #I4   ::    GP   *0   "H    K    *\   "Q
ML0   +,   "U    M@   +@   "Z    O 8  +X,  # $0  PQD  ,4F  #%
M-P  QDD  ,9=  #'<@  QXH  ,B?  #(KP  R+P 1GH  #F!   NB0  (I
M !>8   /GP  !Z4   "J    KP   +,   "W    O    +\   #!    P@
M ,0   #%    QP   ,D   #+    S0   ,\#  #2"@  UA   -P:  #=*@
MWCP  -]0  #@90  X7L  .&1  #BH@  XJT _P " /\   #_  , _P , /\
M$P#_ !T _P H /X ,P#[ #X ]P!( /, 4 #P %< [0!> .L 9 #H &D YP!O
M .4 = #C 'D X@!_ .  A0#> (P W "3 -D G #6 *8 TP"Q -$ P #/ -H
MS@#Q ,P _P#+ /\ RP#_ ,8 _P#! /\ _P   /\   #_    _P ( /L $ #V
M !D \@ D .\ +@#M #D Z !" ., 2P#@ %( W0!9 -D 7P#6 &0 TP!I -$
M;@#/ '0 S@!Y ,P ?P#* (8 R ". ,8 E@#$ *  P@"K ,  N0"^ ,T O #J
M +L _ "Z /\ N@#_ +H _P"V /\ _P   /\   #^    ]  $ .L #0#D !0
MWP ? -L *0#8 #, TP ] ,X 10#* $T QP!3 ,4 60## %\ P0!D +\ :0"]
M &X NP!S +H >0"X (  M@"( +0 D "R )H L0"E *\ L@"M ,0 K #A *L
M]@"J /\ J@#_ *H _P"J /\ _P   /T   #N    X@   -4 "@#- !$ QP 9
M ,0 (P#! "T OP W +L /P"W $< M0!. +( 4P"P %D KP!> *T 8P"L &@
MJP!M *D <P"H 'H I@"! *0 B@"C )0 H0"? )\ K "> +L G #2 )L [@":
M /\ F@#_ )D _P"9 /\ _@   .X   #>    RP   ,$ !0"Y  T M  4 +$
M'@"N "< JP P *H .0"G $$ I !( *( 30"A %, GP!8 )X 70"= &( FP!G
M )H ;0"8 ', EP![ )4 A "4 (X D@"9 )  I@". +0 C0#( (P Y@"+ /D
MB@#_ (H _P"+ /\ \    -L   #'    N@   +    "H  H I  0 *  & "=
M "$ FP J )H ,P"8 #L E@!! )0 2 "2 $T D0!2 (\ 5P". %P C !A (L
M9P"* &X B !U (< ?@"% (@ @P"4 (( H "  *\ ?P#  'X W0!] /( ?0#_
M 'T _P!] /\ X    ,8   "U    J@   *(   ";  4 E0 - )( $P"0 !P
MC0 D (L +0"* #0 B  [ (8 0@"% $< @P!- (( 4@"! %< ?P!< 'X 8@!]
M &@ >P!P 'H >0!X (, =@"/ '4 G !T *H <@"Z '$ T0!P .P < #[ '
M_P!P /\ S00  +<&  "G!P  FP8  ),$  ".    B@ ( (8 #P"$ !8 @0 >
M '\ )P!] "X ?  V 'H / !Y $( =P!' '8 3 !U %( <P!7 '( 70!Q &,
M;P!K &X = !L 'X :P"* &D F !H *8 9P"V &8 RP!E .< 90#W &4 _P!E
M /\ P P  *L-  ";#@  CPX  (8-  "!"P  ?@<! 'P!"P!Y !$ =P 8 '4
M(0!S "D <0 P &\ -@!N #P ; !" &L 1P!J $T :0!2 &@ 6 !F %\ 90!G
M &, < !B 7H 8 &' %\"E0!> J, 7 .S %P#QP!;!.0 6P7T %L&_@!;!O\
MM1   *$2  "1$P  A1,  'P2  !V$0  <PX  '(,! !Q!PT ;@02 &P$&P!I
M!2, 9P4J &8&,0!D!C< 8P8] &('0P!A!TD 7P=. %X(50!="%P 6PEC %H)
M;0!8"G@ 5PJ% %8+DP!4"Z( 4PNS %(,QP!2#.0 40WU %$-_P!1#?\ K14
M )D7  ")&   ?1D  '08  !M%P  :A0  &<1  !G#@< 9@P. &,,%0!A#!T
M7PPE %T-+ !<#3, 6PTY %H-/P!8#44 5PU+ %8.40!5#ED 4PYA %(.:P!0
M#W8 3A"# $T0D@!,$*( 2Q"R $H1R !)$>4 21'W $D2_P!)$?\ I1D  )(<
M  "#'0  =AX  &T=  !F'   8AH  %\7  !>% $ 7A$* %L0$0!9$1@ 5Q$@
M %41)P!4$2X 4Q$T %$1.P!0$D$ 3Q)' $X23@!,$E4 2Q-> $D39P!(%',
M1A2  $45CP!$%9\ 0Q:P $(6Q0!"%^, 0A?V $(7_P!"%_\ GQT  (P@  !]
M(0  <2(  &@B  !A(0  7!\  %D<  !7&0  518& %05#@!1%10 3Q8< $X6
M(P!,%BH 2Q8P $H6-P!)%ST 1Q=# $872@!%&%( 0QA: $(99 !!&7  /QI]
M #X;C0 ]&YT /!RN #L<PP ['.$ .QWU #L<_P \'/\ FB$  (<C  !X)
M;"4  &,E  !<)   5R,  %,@  !1'@  3QP" $T;# !+&A$ 2!L8 $<;( !%
M&R8 1!LM $,<,P!"'#D 0!Q  #\=1P ^'4\ /1Y8 #P>8@ Z'VT .1][ #@@
MBP W(9L -B&M #4AP0 U(=\ -2'S #8A_P V(?\ EB,  (,F  !T)P  :"@
M %\H  !8)P  4R8  $\D  !,(@  22   $<@"0!$'P\ 0A\5 $ @'  _(",
M/B I #P@+P [(38 .B$] #DA1  X(DP -R)5 #8C7P T(VL ,R1Y #(EB0 Q
M)9H ,"6K # FOP O)MP ,";R # F_P Q)?\ D28  '\H  !Q*@  92H  %PJ
M  !5*@  3RD  $LH  !()0  1"0  $$D!0 _) T /202 #LD&0 Y)!\ -R0F
M #8D+  U)3, -"4Z #,F00 R)DH ,2=3 # G70 O*&D +BEW "TIAP L*9@
M*RJJ "HJO0 J*MH *RKQ "LJ_@ L*?\ C2@  'PJ  !M+   8BT  %DM  !1
M+0  3"P  $<K  !#*   /R@  #PH @ Y* L -R@0 #4H%@ S*!P ,B@C # H
M*0 O*3  +RHW "XJ/P M*T< +"M1 "LL6P J+&< *2UU "@MA0 G+9< )BZH
M "4NO  E+M@ )B[P "8N_0 G+?\ BBL  '@M  !J+@  7R\  %8O  !.+P
M2"X  $,M   _+   .RP  #<L   T+ D ,BP. # M$P N+1H +2T@ "LM)P J
M+BT *BXU "DO/0 H+T4 )S!. "8P60 E,64 )#%S ",Q@P B,I4 (3*G "$R
MNP @,M0 (3+O "(Q_  B,?\ ABT  '4O  !G,   7#$  %,Q  !+,0  13$
M $ P   [,   -C   #,P   P,08 +3$- "LQ$0 I,A< *#(> "<R)  E,RL
M)3,R "0S.@ C-$, (C1, "$U5P @-6, 'S5Q !XV@0 =-I, '#:E !LVN0 ;
M-M( '#;M !TV^P =-?\ @C   '$R  !C,P  630  % T  !)-   0C,  #TS
M   W,P  ,30  "XU   K-0( *#8+ "4W$  D-Q4 (C<; "$X(@ @."@ 'S@P
M !XX-P =.4  '#E) !LZ5  :.F  &3IN !@Z?P 7.Y$ %SND !8[MP 5.]
M%CKL !<Z^@ 8.?\ ?3(  &TT  !@-0  538  $TV  !&-@  0#8  #HV   T
M-@  +C@  "HY   F.@  (SL( " \#@ >/1( '3T8 !P]'P ;/B4 &CXM !D^
M-  7/CT %C]' !4_40 4/UX %#]L !- ?  20(\ $4"B !% M@ 00,X $3_K
M !(_^0 2/O\ >34  &DW  !<.   4CD  $HY  !#.0  /3D  #<Y   Q.@
M*SP  "<]   B/P  'D$$ !I""P 80Q  %T,5 !5$&P 41"( $T0I !-$,0 2
M1#H $45# !!%3@ 015L #D5I  Y%>0 -18P #46?  Q%L@ +1<D #$7E  U$
M]@ -1/\ =#D  &4Z  !8.P  3SL  $<\  ! /   .CP  #0\   N/@  *$
M "-"   ?1   &D8  !5("  22@T $4H2 !!*&  /2QX #DLE  U++0 -2S8
M#$M   M+2@ *2U8 "4MD  A+=  '2X< !4N:  1+K@ $2L0 !4K@  5*\  &
M2?H ;CP  & ]  !4/@  2SX  $0^   ]/@  -S\  #%    J0@  )$4  !]'
M   :20  %4P  !%.!0 .40L "U$0  I1%  )41L "%$B  =1*0 %43( !%([
M  -21@ !4E(  %)?  !2;P  4H$  %&6  !1J0  4;\  %#<  !0[@  4/<
M:$   %M!  !000  2$$  $%!   [0@  -$,  "U%   F2   ($L  !M-   6
M4   $5,   Y5!  *6 H !E@.  )8$@  61<  %D=  !9)0  62T  %DV  !9
M00  64T  %I:  !::0  67P  %F0  !9I0  6+H  %C5  !7[   5_8 8T0
M %9%  !-10  144  #]%   W1P  +TD  "A,   B3P  &U(  !95   16
M#5H   E= P $7PD  & -  !@$   810  &$9  !B(   8B<  &(Q  !B.P
M8D<  &)5  !C9   8G8  &*+  !BH   8;8  &'/  !@Z@  8/4 74@  %))
M  !*2   0T@  #I*   R30  *E   "-3   <5P  %EH  !%=   -8   "&,
M  -F 0  9P8  &@+  !I#@  :A$  &L5  !L&P  ;2(  &TJ  !M-   ;4
M &U.  !M70  ;6\  &V$  !LF@  ;+   &O(  !KY@  :O, 6$T  $Y-  !(
M3   /DX  #51   L5   )%@  !U<   68   $&0   QG   ':P   6X   !P
M    <@,  '('  !S"P  =0X  '81  !W%@  >!P  'DC  !Z+0  >CD  'I'
M  !Z5@  >6@  'I\  !YE   >*H  'C!  !WWP  =^\ 5%$  $Q1  !"4@
M.%4  "]9   F7@  'F(  !9G   0:P  "V\   5S    =P   'H   !\
M?@   '\"  " !@  @0H  (,-  "$$0  AA4  (@<  "))0  BC   (H^  ")
M30  B5\  (ES  "(BP  B*(  (>Y  "'T0  AN@ 4E8  $=7   \6@  ,E\
M "AD   ?:0  %F\  !!T   *>0   GT   "!    A0   (@   "*    C
M (T   "/    D 0  )((  "3#   E1   )<5  "9'0  FR<  )LT  ";1
MFE8  )IJ  "9@@  FIH  )BP  "8QP  E]X 2UP  $!@   U90  *VH  "%Q
M   7=P  $'T   F#   !B    (P   "1    E0   )@   ":    FP   )T
M  "?    H    *(   "D!0  I@H  *@.  "J%   K1T  *TJ  "M.0  K4L
M *U?  "M=P  K)   *NG  "KN@  J\L 168  #EK   N<0  (W@  !E_   0
MA@  "8T   "3    F    )T   "A    I0   *@   "K    JP   *X   "O
M    L0   +,   "U    MP$  +D'  "\#0  OQ,  ,(?  #"+@  PD   ,)4
M  #!:P  P8,  ,";  #!K0  P;P /G(  #)X   G@   '(@  !*0   *EP
M )T   "C    J    *T   "R    M@   +D   "[    O    +X   #
MP@   ,0   #&    R    ,L   #.!0  T0T  -84  #7(P  V#4  -E)  #:
M7@  VW4  -N,  #<GP  W*L _P   /\   #_    _P ) /\ $ #_ !D _@ D
M /P +P#Y #D ] !# /  2P#M %( Z@!9 .< 7P#D &0 X@!I .  ;@#> ',
MW !Y -H ?P#7 (8 U ". -$ E@#/ *$ S "L ,H NP#( -( Q@#N ,8 _P#%
M /\ Q0#_ +\ _P"Z /\ _P   /\   #_    _@ % /< #@#R !4 [@ ? .L
M*@#I #0 XP ] -X 10#9 $T U !3 -$ 60#. %X S !C ,H : #) &T QP!S
M ,4 >0## (  P0"( +\ D "] )L NP"F +D M "W ,@ M@#F +4 ^P"T /\
MM #_ +, _P"N /\ _P   /\   #X    [0   .4 "P#= !$ UP : -( ) #/
M "X RP W ,< 0 ## $< P !. +X 4P"\ %D N@!> +@ 8P"V &@ M0!M +,
M<P"Q 'D KP"! *T B@"K )0 J0"@ *@ K0"F +X I0#; *0 ] "D /\ HP#_
M *, _P"B /\ _P   /8   #F    UP   ,L !@#$  X O@ 5 +L 'P"Y "@
MMP Q +0 .@"P $$ K0!( *L 3@"I %, IP!8 *8 7 "D &$ HP!G *$ ; "@
M ', G@!Z )T @P"; (X F0"9 )< I@"6 +8 E0#, )0 ZP"3 /T DP#_ ),
M_P"3 /\ ]P   .0   #0    P0   +<  @"O  L JP 1 *< &0"E "( HP K
M *( ,P"? #L G !" )L 2 "9 $T EP!2 )8 5P"5 %L DP!A )( 9@"0 &T
MCP!T (T ?0", (< B@"3 (@ H "' *\ A0#" (4 X@"$ /< A #_ (0 _P"$
M /\ Y0   ,T   "\    KP   *8   ">  < F@ . )8 % "4 !T D@ E )$
M+0"0 #4 C0 \ (P 0@"* $< B !, (< 40"& %8 A !; (, 8 "! &< @ !N
M 'X =P!] ($ >P"- 'H F@!X *D =P"Z '8 TP!V .\ =@#^ '4 _P!U /\
MT    +L   "K    GP   )<   "0  ( BP + (@ $ "& !< A  @ (( )P"!
M "\ ?P U 'T / !\ $$ >P!& 'D 2P!X %  =P!5 '8 6P!T &$ <P!I '$
M<0!P 'L ;@"' &T E0!K *, :@"T &H R0!I .@ :0#Y &D _P!I /\ P
M *P   "< @  D (  (@   "#    ?P & 'L #0!Y !( =P : '8 (@!T "D
M<P P '$ -@!P #P ;P!! &T 1@!L $L :P!0 &H 5@!H %P 9P!D &4 ; !D
M '8 8P"" &$ D !@ )\ 7P"O %X PP!> .$ 7@#T %T _P!= /\ M <  * )
M  "0"P  A L  'P*  !W!P  = 0  '$ "0!O  \ ;0 5 &L ' !I ", :  J
M &< ,0!E #8 9  \ &, 00!B $8 8 !, %\ 4@!> %@ 70!? %L : !: '(
M6 !^ %< C !6 )L 50"K %0 O@!4 -H 4P#O %0 ^P!4 /\ J0T  )8.  "'
M$   >A   '(0  !L#@  :0P  &<) P!F! L 9  0 &( %P!@ !X 7@ E %T
M*P!< #$ 6@ W %D / !8 $( 5P%' %8!3@!5 E0 4P)< %(#90!1 V\ 3P1[
M $X$B@!-!9D 3 6I $L%O !*!M0 2@?M $H'^0!*!_\ H1   (X2  !^%
M<Q0  &H4  !D$P  8!$  %X/  !=#04 70D- %H&$@!8!QD 5@<@ %4')P!3
M!RT 4@@S %$(. !0"#X 3PE$ $X)2@!,"5$ 2PI9 $H*8@!("VT 1PMZ $8,
MB !$#)@ 0PRI $(-O !"#=4 0@WN $(-^P!"#?\ FA0  (<6  !X&   ;!D
M &,9  !=&   618  %83  !4$0  5 X( %,-#@!1#10 3PT; $T-(@!,#2@
M2PTN $H-- !)#3H 1PY! $8.1P!%#D\ 1 Y7 $(/80!!$&P /Q!Y #X0B  ]
M$9@ .Q&I #L1O  Z$=8 .A'P #H2_0 [$?\ DQ@  ($:  !S'   9QT  %X=
M  !8'   4QL  % 8  !.%@  3!,# $P1"P!*$!  2!$7 $81'@!%$20 1!$J
M $(1, !!$3< 0!(] #\21  ]$DP /!-4 #L37@ Y%&D .!1V #<5A0 V%98
M-!:G #06N@ S%M, ,Q;N #06_  T%O\ CAL  'P=  !N'P  8R   %H@  !3
M(   3AX  $H=  !(&@  1A@  $46!P!#%0X 0143 #\5&@ ^%2  /14G #L5
M+0 Z%C, .18Z #@600 W%TD -1=1 #086P S&68 ,AES # :@P O&I0 +ANE
M "T;N  M&]  +1OL "X;^P N&_\ BAX  '@@  !J(@  7R,  %8C  !/(@
M2B$  $8@  !#'@  01L  #\: P ]&@P .QD1 #D9%@ W&AT -AHC #4:*0 T
M&C  ,QLV #$;/@ P'$8 +QQ/ "X=60 M'60 +!YQ "L?@0 J'Y( *1^D "@@
MMP G(,X )R#K "@@^@ I'_\ AB   '0C  !G)   7"4  %,E  !,)0  1R0
M $(C   _(0  /1\  #H>   W'@D -1X. #,>$P Q'AH ,!X@ "\>)@ N'RT
M+1\S "P@.P K($, *B%, "DA5@ H(F( )B)O "4C?P D(Y  (R.B "(DM0 B
M),P (B3I ",D^0 D(_\ @B,  '$E  !C)@  62<  % H  !))P  0R<  #\F
M   [)   ."(  #4B   R(@8 ,"(- "XB$0 L(A< *B(= "DB(P H(RH )R,Q
M "8D.  E)4$ )"5* ",F5  B)F  (2=M " G?0 ?)X\ 'BBA !XHM  =*,H
M'2CH !XH^  ?)_\ ?B4  &XG  !@*0  5BD  $TJ  !&*@  02D  #PH   W
M)P  -"8  # F   M)@, *R<+ "@G$  G)Q0 )2<: "0G(0 C*"< (B@N "$I
M-@ @*3X 'RI( !XJ4@ =*UX '"MK !LK>P :+(T &2R? !@LL@ 8+,D &"SG
M !DK]P :*_\ >B<  &HJ  !=*P  4RP  $HL  !#+   /BL  #DK   T*@
M,"H  "LJ   I*P  )BL( ",L#@ B+!( ("P8 !\L'@ >+24 '2TL !PM,P ;
M+CP &BY% !DO4  8+UP %R]I !8P>0 5,(L %#"> !0PL0 3,,< $S#E !0P
M]@ 5+_\ =BH  &<L  !:+0  4"X  $@N  !!+@  .RX  #8M   Q+0  +"T
M "<O   D+P  (3 % !\Q#  <,1  &S(5 !HR'  9,B( &#(I !<S,0 6,SD
M%3-# !0T30 3-%D $C1G !$U=P 1-8D $#6< ! UL  .-<8 #S3D ! T]0 0
M-/\ <BP  &,N  !7,   33   $4P   ^,   .#   #,P   O,   *3$  "0R
M   A,P  '34" !HV"0 7-PX %3<3 !0X&0 3.!\ $C@F !(X+@ 1.38 $#E
M ! Y2P ..5< #CID  TZ=  ,.H8 ##J9  LYK  *.<$ "CG>  LY\0 ,./P
M;B\  %\Q  !3,@  2C,  $(S   [,P  -C,  #$R   L,P  )S0  "$V   =
M.   &3D  !4[!@ 2/0P $#X0 ! ^%0 ./AP #CXC  T^*@ ,/C, ##X\  L_
M1P */U( "#]@  <_;P &/X$ !3^4  0_J  #/KP !#[7  4^[  %/O< :3,
M %LT  !0-0  1S4  #\U   Y-0  -#4  "XU   I-P  (S@  !X[   :/
M%C\  !)!!  .0PH #$0.  I$$P )1!D "$0@  =$)P &1"\ !40X  -%0@ "
M14X  $5;  !%:@  17P  $60  !$I   1+D  $31  !$Z@  0_4 9#8  %<W
M  !,.   0S@  #PX   W.   ,3@  "LY   E.P  (#T  !I    60@  $D0
M  Y'!  +20D !TH-  1+$0 !2Q8  $L<  !+(P  2RL  $LT  !+/@  3$D
M $Q7  !,9@  3'<  $N,  !+H0  2[4  $K.  !*Z0  2O4 7SH  %([  !(
M.P  0#L  #H[   T.P  +CP  "<^   B00  '$,  !9&   220  #DL   M.
M P '4 @  E$,  !1$   4A,  %,8  !3'P  4R8  %,O  !3.0  4T4  %-2
M  !380  4W(  %.'  !2G   4K$  %'*  !1YP  4?0 63X  $X^  !%/@
M/CX  #@^   P0   *4(  "-$   =1P  %TH  !)-   .4   "U,   95 @
M5P<  %@+  !9#@  6A$  %H5  !;&@  7"$  %PJ  !<-   7#\  %Q-  !<
M6P  7&P  %R!  !;EP  6ZT  %K%  !:Y   6?, 5$(  $I"  !"0@  /$(
M #1#   L1@  )4D  !Y,   73P  $E,   Y6   *60  !5L   !>    8 0
M &$(  !B#   8PX  &01  !E%@  9AP  &<C  !G+0  9SD  &=&  !G50
M9V8  &=Z  !FD0  9:@  &7   !DW@  9/  3T8  $=&  ! 10  -T<  "]*
M   F30  'U$  !A5   260  #5P   A@   "8P   &8   !H    :@   &L$
M  !L"   ;0P  &\.  !P$@  <A<  ',=  !T)@  =#(  '0_  !T3@  <U\
M '1R  !SB@  <J$  '&X  !QU   <.P 3$H  $5*   [2P  ,DX  "E2   @
M5@  &%L  !)?   -9   !V@   !K    ;P   '(   !U    =@   '<   !Y
M @  >@8  'P*  !^#@  @!$  ((6  "$'@  A"D  (0V  "$10  A%8  (-J
M  "#@0  @ID  (&Q  " R0  @.4 2DX  #]0   U4P  *U<  ")<   98@
M$F<   QL   %<0   '4   !Y    ?0   ($   "#    A0   (8   "(
MB0   (L$  "-"   CPT  )(0  "4%@  EB   )8L  "6.P  EDP  )5@  "5
M=@  E)   ).G  "2O0  DM4 1%4  #E9   O70  )&,  !II   2;P  #'4
M  1[    @    (4   ")    C0   )$   "3    E    )8   "8    F@
M )P   ">    H 8  *(+  "E$   J!<  *DC  "I,0  J4,  *E6  "H;0
MIH<  *>>  "FLP  I<< /EX  #)C   G:@  '7   !-X   ,?P   X4   "+
M    D0   )8   ";    GP   *(   "D    I0   *<   "I    JP   *T
M  "P    L@   +4"  "W"0  NQ   +X8  "^)@  OC@  +Y+  "]80  O'H
M +N4  "ZJ0  NKD -VH  "MP   @>   %H    V(   %CP   )8   "<
MH@   *<   "L    L    +,   "V    MP   +D   "[    O0   +\   #"
M    Q0   ,@   #*    S@@  -(0  #5&P  U2P  -1   #45P  TVX  -2&
M  #4FP  TZL _P   /\   #_    _P % /\ #@#_ !4 _  @ /D *@#V #0
M\0 ] .T 1@#I $T Y@!3 .0 60#A %X W@!C -P : #9 &X U0!S -, >0#0
M (  S@"( ,L D0#) )P Q@"G ,0 MP#" ,P P #L +\ _P"^ /\ O0#_ +<
M_P"R /\ _P   /\   #_    ^@ ! /, "P#M !( Z  ; .4 )0#D "X WP X
M -@ 0 #2 $< S@!. ,L 5 #( %D Q@!> ,0 8P#" &< P !M +\ <P"] 'H
MNP"! +D BP"V )4 M "A +( KP"P ,( K@#C *X ^@"L /\ K0#_ *D _P"F
M /\ _P   /\   #R    Y@   -T !P#2  X S0 6 ,H ( #( "D Q0 R ,
M.@"\ $( N0!( +< 3@"U %, LP!8 +$ 70"P &( K@!G *P ; "J ', J0![
M *< A "E (X HP": *$ J "? +D G@#2 )T \@"< /\ G0#_ )P _P"9 /\
M_    .X   #=    S    ,$  @"Z  P M@ 2 +( &@"P ", KP L *T - "I
M #P I@!" *0 2 "B $T H !2 )X 5P"= %L G !@ )H 9@"9 &P EP!T )4
M?0"3 (< D0"3 )  H0". +$ C0#& (P Z "+ /T C #_ (P _P", /\ [0
M -@   #%    MP   *P   "F  @ H0 . )\ %0"= !X FP F )H +@"7 #4
ME0 \ ), 0@"1 $< D !, (X 40"- %4 BP!: (H 8 ") &8 AP!M (4 =@"$
M (  @@", (  F@!_ *D ?0"\ 'P W !\ /4 ? #_ 'P _P!\ /\ V0   ,$
M  "Q    I    )P   "4  , D  , (T $0"+ !@ B0 @ (D * "' "\ A0 V
M (, / "" $$ @ !& '\ 2P!] $\ ? !4 'L 6@!Y &  > !G '8 < !U 'H
M<P"& '$ DP!P *( ;P"T &X S !N .T ;@#^ &X _P!N /\ Q    *\   "@
M    E    (P   "&    @0 ( 'X #@!\ !0 >P ; 'D (@!X "D =P P '4
M-@!T #L <@!  '$ 10!P $H ;P!/ &T 5 !L %L :P!B &D :@!H '0 9@"
M &4 C@!C )T 8@"M &$ P@!A .0 80#X &$ _P!A /\ M    *    "1
MA@   'X   !Y    =0 # '$ "P!O !  ;0 6 &P '0!K "0 :P J &D , !H
M #8 9@ [ &4 0 !D $4 8P!* &$ 3P!@ %8 7P!= %T 90!< &\ 6@!Z %D
MB !8 )@ 5P"H %8 NP!6 -@ 5@#Q %8 _P!6 /\ J $  )0%  "%!P  >@<
M '(&  !L!   :0$  &< !P!D  T 8P 1 &$ & !@ !\ 7P E %X *P!= #
M6P V %H .P!9 $  6 !% %< 2P!6 %$ 50!8 %, 80!2 &H 4 !V $\ A !.
M ), 30"D $P M@!, ,T 3 #K $P ^@!, /\ G0D  (L+  !\#0  < T  &@-
M  !B#   7PH  %T& 0!< 0D 6@ . %@ $P!7 !D 5@ @ %4 )@!3 "L 4@ Q
M %$ -@!0 #L 3P!! $X 1P!- $T 2P!5 $H 70!) &< 1P!S $8 @ !% )
M1 "A $, L@!# ,@ 0P#F $, ]0!# /\ E0T  (,/  !T$   :1$  & 1  !:
M$   5@X  %0-  !3"@0 4P8+ %$#$ !/ 14 3@$; $P!(0!+ 2< 2@(L $D"
M,@!( C< 1P,] $4#0P!$ TH 0P11 $($6@! !60 /P5P #X&?@ ]!HX / >?
M #L'L0 Z!\8 .@?C #H'\P Z"/P CA   'P2  !N%   8A4  %H5  !4%
M4!,  $T1  !+#@  2PT& $H*# !)"!$ 1P@6 $4('0!$"", 0@@H $$)+@!
M"3, /PDY #X*0  ]"D< / I/ #H+6  Y"V, . QO #8,?@ U#(X - V? #,-
ML0 R#<< ,@WC #(-]  R#?X B!,  '<5  !I%P  7A@  %48  !/&   2A8
M $<5  !%$P  0Q " $,." !"#0X 0 T2 #\-&  ]#1\ / TD #L-*@ Y#3
M. XW #<./0 V#D4 -0Y- #,/5P R#V( ,1!N "\0?0 N$(X +1&@ "P1L@ K
M$<@ *Q'F "L1]@ L$?\ @Q8  '(9  !D&@  61L  %$;  !+&P  1AH  $(8
M   _%P  /A0  #P2!  [$0H .A 0 #@0%0 W$!L -1$A #01)P S$2T ,A$S
M # 1.@ O$D( +A)+ "T35  K$U\ *A1L "D4>P H%(P )Q6> "85L  E%<8
M)17D "45]@ F%?\ ?AD  &X;  !@'0  5AX  $T>  !''@  0AT  #X<   Z
M&@  .!@  #<6   U%0< -!0- #(4$@ P%!< +Q0= "T4(P L%2H *Q4P "H5
M-P I%C\ *!9( "<74@ F&%T )!AJ ",9>0 B&8H (1F< " 9KP ?&<0 'QGB
M " 9]  @&?\ >AL  &H>  !='P  4R   $H@  !$(   /A\  #H>   W'0
M-!P  #(9   P&00 +A@+ "P8$  J&!0 *1@: "<8(  F&28 )1DM "0:-0 C
M&CT (AM& "$;4  @'%L 'QUH !X==P ='8@ '!Z; !L>K0 :'L, &A[@ !H=
M\P ;'?\ =QT  &<@  !:(0  4"(  $@B  !!(@  .R(  #<A   S(   ,!\
M "T=   K'0  *!T( "8=#@ E'1( (QT7 "$='0 A'20 (!XJ !\>,@ >'SH
M'1]# !P@30 ;(5D &B%F !DA=0 8(H< %R*9 !8BK  5(L$ %2+? !4A\@ 6
M(?X <R   &0B  !7(P  320  $4E   ^)   .20  #0C   P(@  +"(  "DA
M   F(0  )"$& "(A#  @(1  'B$5 !TB&P ;(B$ &R(H !HC+P 9(S@ &"1!
M !<D2P 6)5< %25D !0F<P 3)H4 $B:8 !$FJP 1)L  $";= !$E\0 2)?T
M<"(  &$D  !4)@  2B8  $(G   \)@  -B8  #$E   M)0  *20  "8D   B
M)0  'R4# !TF"@ ;)@X &2<2 !@G&  7)Q\ %B<E !4H+0 4*#4 $RD^ !(I
M20 1*54 $2IB ! J<0 /*H, #BJ6  XJJ0 -*KT #2K7  TJ[@ .*?L ;"0
M %TF  !1*   2"@  $ I   Y*   -"@  "\H   K)P  )R<  "(H   >*0
M&RH  !@K!P 6*PT %"P1 !,L%@ 2+!P $2TC ! M*@ 0+3( #RX\  XN1@ -
M+E( #2Y?  PO;@ ++W\ "B^2  DOI0 )+KD ""[0  DNZ0 *+O< :"<  %HI
M  !.*@  12L  #TK   W*P  ,2H  "TJ   I*@  )"H  " K   ;+0  &"X
M !4O!  2,0H $#(.  \R$P .,AD #3(@  TR)P ,,B\ "S,X  HS0@ ),TX
M"#-;  8T:@ %-'L !#..  ,SH@ ",[8  C/-  ,SYP $,O, 9"H  %8L  !+
M+0  0BT  #HM   T+0  +RP  "LL   F+   (BT  !TO   9,0  %3(  !(T
M P /-@D ##@-  HX$0 ).!8 "#@=  <X)  &."P !#@T  ,X/@ ".4H  #E7
M   Y90  .7<  #F+   XGP  .+,  #C*   XY@  -_( 7RT  %(N  !(+P
M/S   #@O   R+P  +2\  "DO   D,   'S$  !HS   5-0  $C<   \Y P ,
M.P@ "#T-  4^$  #/A0  #X:   ^(0  /B@  #XQ   _.P  /T8  #]3   _
M80  /W,  #^'   ^G   /K   #W'   ]Y   /?( 6C   $XR  !$,@  /#(
M #4R   P,0  *S$  "8R   @-   &S8  !8X   2.P  #ST   P_ P (00@
M!$,,  !##@  1!(  $46  !%'0  120  $4M  !&-@  1D(  $9.  !&70
M1FX  $6"  !%F   1*T  $3$  !#XP  0_( 530  $HU  !!-0  .34  #,T
M   N-   *#4  "(W   =.@  %SP  !(_   /00  #$0   A& 0 #2 8  $D*
M  !*#0  2Q   $P4  !-&0  3B   $XH  !.,@  33T  $Y*  !.6   36D
M $U]  !,E   3*H  $O!  !+X0  2O( 4#@  $8X   ].   -S@  #$W   J
M.0  )#L  !X]   80   $T,   ]&   +20  !TL   ).    4 0  %$(  !2
M"P  4PX  %01  !5%0  5AL  %<C  !7+   5S@  %=$  !74@  5F,  %9W
M  !6C@  5:4  %2]  !3W0  4_  2SP  $(\   [.P  -3L  "T\   F/P
M'T(  !E%   32   #DL   M/   %40   %0   !7    6 $  %H%  !;"
M7 P  %T.  !?$0  8!8  &(=  !B)@  8C$  &(^  !A3   85T  &%P  !@
MB   8*   %^W  !>U   7>X 1T   #\_   Z/P  ,4   "E#   A1@  &DH
M !-.   .40  "E4   18    6P   %X   !A    8P   &0!  !E!   9P@
M &@+  !J#@  ;!(  &X7  !O(   ;RH  &\V  !N10  ;E4  &YH  !M?P
M;9@  &RP  !KR@  :N@ 1$0  #Y#   U1   *T<  "-+   ;3P  $U0   Y8
M   (7    F    !D    9P   &L   !M    ;P   '    !R    = (  '4&
M  !W"@  >0X  'P2  !^&   ?R(  '\N  !_/0  ?DT  'UA  !]=P  ?)
M 'NH  !ZP   >=\ 0T<  #E)   O3   )5   !Q5   46P  #F    =E
M:@   &X   !R    =@   'D   !\    ?@   '\   "!    @P   (4   "'
M P  B@@  (P-  "/$0  DAD  )(E  "2,P  DD0  )%7  "0;0  CX8  (Z?
M  "-M0  C,T /4X  #)1   H5@  'EP  !5B   .:   !VX   !T    >0
M 'X   ""    A@   (D   ",    C@   )    "2    E    )8   "8
MFP   )X&  "A#   I!$  *8;  "F*0  ICH  *5-  "E8@  I'L  *.4  "A
MJP  H;\ -E<  "Q<   A8@  %VD   ]P   '=P   'X   "$    B@   (\
M  "4    F    )L   ">    GP   *(   "D    I@   *@   "K    K0
M +    "S!   MPP  +L2  "['P  NS   +M#  "Z6   N7   +>+  "WH0
MM[, ,&(  "5I   :<   $'@   F     B    (\   "6    FP   *$   "F
M    J@   *X   "P    L0   +0   "V    N    +L   "]    P    ,,
M  #'    RP,  ,\,  #3%0  TB4  -(X  #13@  T&4  ,]^  #-E@  S*D
M_P   /\   #_    _P # /\ "P#\ !$ ^0 ; /< )0#S "\ [@ X .D 0 #F
M $@ X@!. -\ 5 #< %D V0!> -4 8P#3 &@ T !M ,X <P#+ 'H R "" ,8
MC ## )< P "C +X L@"\ ,@ N@#J +D _P"X /\ L0#_ *H _P"G /\ _P
M /\   #[    ]@   .T !P#G  \ X@ 6 -\ ( #> "D V0 S -$ .P#, $(
MR !( ,4 3@#" %, P !8 +X 70"\ &( N@!G +D ;0"W '0 M0![ +( A0"P
M )  K@"< *P J@"I +T IP#> *8 ^0"E /\ HP#_ )T _P"; /\ _0   /8
M  #K    WP   -$  P#*  P Q0 2 ,, &P#  "0 O@ L +D -0"V #P LP!#
M +  2 "N $X K !2 *L 5P"I %P IP!A *8 9P"D &T H@!T *  ?0"> (@
MG "5 )H HP"8 +0 E@#- )4 \0"4 /\ E0#_ )  _P". /\ \P   .8   #1
M    P@   +@   "Q  @ K0 / *H %@"H !X J  G *8 +P"B #8 GP \ )T
M0@"; $< F0!, )< 40"6 %4 E !: ), 8 "1 &8 D !N (X =@", ($ B@"-
M (@ FP"& *P A0#! (0 Y@"# /T A #_ (, _P"! /\ Y    ,L   "Z
MK    *(   "<  0 F  , )8 $0"4 !D DP A )( * "/ #  C0 V (L / ")
M $$ B !& (8 2P"% $\ A !4 (( 6@"! &  ?P!G 'X ;P!\ 'H >@"& '@
ME !W *0 =0"W '0 U !S /0 = #_ '0 _P!T /\ RP   +8   "F    F@
M )(   "*    A@ ( (, #@"! !0 @0 ; (  (P!_ "H ?0 P 'L -@!Z #L
M> !  '< 10!U $D = !. ', 5 !Q %H < !A &X :0!M ', :P!_ &D C0!H
M )T 9P"N &8 QP!E .H 9@#_ &8 _P!G /\ N    *0   "5    B@   ($
M  !\    =@ $ '0 # !R !  <0 6 '  '0!P "0 ;@ J &T , !K #4 :@ Z
M &D /P!H $0 9P!) &4 3@!D %0 8P!; &$ 8P!@ &T 7@!Y %T AP!; )8
M6@"H %D O0!9 -\ 60#X %H _P!: /\ J    )4   "'    >P   ',   !N
M    :@ ! &< " !E  X 9  2 &, & !C !\ 8@ E &$ *@!? #  7@ U %T
M.@!< #X 6P!$ %D 20!8 $\ 5P!6 %8 7@!4 &@ 4P!S %$ @0!0 )$ 3P"B
M $X M0!. -  3@#P $X _P!/ /\ G    (D   ![ P  < ,  &@#  !B 0
M7P   %T ! !;  L 60 / %@ % !7 !D 5P @ %8 )0!5 "H 4P P %( - !1
M #D 4  _ $\ 1 !. $L 30!2 $L 6@!* &, 20!O $< ? !& (P 10"= $4
ML !$ ,< 1 #H $0 ^@!% /\ D@0  ( '  !Q"@  9@H  %X*  !9"0  50<
M %0$  !2  < 4  , $\ $ !. !4 30 ; $P ( !+ "8 2@ K $D , !( #4
M1P Z $8 0 !% $8 0P!. $( 5@!! %\ 0 !K #X >  ] (@ / "9 #P JP \
M ,$ .P#@ #L ]  [ /\ B0H  '@,  !J#@  7PX  %<.  !1#@  30P  $L+
M  !*" ( 200) $@ #0!& !$ 10 6 $0 ' !# "$ 0@ F $$ *P _ #$ /@ V
M #T /  \ $, .P!* #H 4@ Y %P . !H #8 =0 U (4 - "6 #0 J  S +P
M,P#8 #, [P S /L @@T  '$/  !D$   61$  %$1  !+$0  1Q   $0.  !"
M#0  00L% $$'"P _!0X /@,2 #P"&  [ AT .@,B #D#*  X RT -P,R #8$
M.0 U!#\ - 5' #,%4  Q!EH , 9F "\'<P N!X, +0>5 "P'IP K![H *P?2
M "L'ZP K!_< ?1   &P1  !?$P  5!0  $P4  !&%   0A,  #X2   \$
M.@X! #H-!@ Z"@P . D0 #8(%  U"!D - D? #())  Q"2D , DO "\*-@ N
M"CT +0I% "P+3@ K"UD *0QE "@,<P G#(, )@V5 "4-IP D#;L (PW2 ",-
MZP C#?< >!(  &@4  !;%@  41<  $@7  !"%@  /18  #D5   W$P  -1$
M #,0 P S#@@ ,@T- # -$0 O#18 +0T; "P-(0 K#2< *@TM "D.-  H#CL
M)PY$ "4.3@ D#UD (Q!E "$0<P @$(0 'Q"6 !X0J0 =$+T '!#8 !T0[@ =
M$/D <Q0  &06  !7&   31D  $49   _&0  .A@  #47   R%@  ,!4  "X3
M   M$00 +! * "L0#@ I$!( *! 8 "80'@ E$"0 )! J ",1,0 B$3D (1%"
M " 22P >$E8 '1-C !P3<0 :$X( &125 !@4IP 7%+L %Q/4 !<3[@ 8$_H
M<!8  & 9  !4&@  2AL  $(<   \&P  -AL  #(:   O&0  +!@  "H6   H
M% $ )A,' "43#  C$Q  (A,5 " 3&@ ?$R$ 'A0G !T4+@ <%38 &Q4_ !H6
M20 9%E0 &!=A !87<  5&($ %!B3 !,8I@ 2&+H $A?2 !(7[  3%_H ;!D
M %T;  !1'0  1QT  #\>   Y'0  -!T  "\<   K&P  *!H  "89   D&
M(A<$ " 7"@ >%PX '!<2 !H7%P 9&!X &1@D !@9+  7&30 %AH] !4:1P 4
M&U( $QM? !(<;@ 1''\ $!R2 ! <I0 /'+D #AS0  X;Z@ /&_@ :1L  %H=
M  !.'P  11\  #T@   V'P  ,1\  "T>   I'0  )1T  ",<   @&P  '1L!
M !L;!P 9' T %QP0 !8<%0 5'!L %!TB !,=*0 2'C$ $1XZ !$?10 0'U
M#R!=  X@;  -('P #2"/  P@H@ +(+4 "R#*  L@Y0 ,'_0 91T  %<?  !,
M(0  0B$  #HA   T(0  +R$  "H@   F'P  (Q\  " >   ='@  &2   !8@
M!  4( L $B$. !$A$P 1(AD $"(?  \B)@ .(R\ #B,W  TC00 ,)$T "R19
M  HD9P ))'@ ""2+  <DG@ ')+$ !B3'  8CXP '(_$ 8A\  %0A  !)(P
M0",  #@C   R(P  +",  "@B   D(0  (2$  !XA   :(0  %B,  !,D P 1
M)0@ #R8-  XG$0 -)Q8 #"<=  LG(P *)RL "2@T  @H/@ '*$D !BA5  4I
M9  $*70  RF'  (IFP !**\  "C%  $HX0 !)_  7B(  %$D  !&)0  /24
M #4E   O)0  *B0  "8D   B(P  'R,  !LD   8)0  %"8  !$H P /*0@
M#"P,  HL$  (+!0 !RP:  8L(0 %+"@  RTP  (M.@ !+44  "U2   N8
M+G$  "V$   MF0  +:T  "S"   LX   +/  6B0  $TF  !#)P  .B<  #,G
M   M)P  *"8  "0F   A)@  '28  !DG   5*0  $2L   \L P -+@< "3 ,
M  8Q#@ #,1(  3(7   R'@  ,B4  #(M   R-@  ,T(  #-.   S70  ,VT
M #.!   RE@  ,JL  #'!   QWP  ,?  5B<  $HI   _*@  -RH  # J   K
M*0  )R@  ",H   >*0  &BH  !8L   2+@  #S    TQ @ *- < !34+  (V
M#@  -Q   #@4   X&@  ."(  #@J   Y,P  .3X  #E*   Y60  .6D  #E]
M   XDP  .*@  #>_   WW@  -O  42L  $8L   \+   -"P  "XL   J*P
M)2L  " L   ;+0  %R\  !,Q   0,P  #34   DW @ %.@8  3L*   \#0
M/0\  #X2   _%P  0!X  $ E  ! +P  0#H  $!&  ! 5   0&4  #]X   _
MCP  /J8  #Z]   ]W   /?  32X  $(O   Y+P  ,B\  "TN   H+@  (B\
M !TP   8,@  $S4  ! W   ,.@  "3P   4^    000  $((  !#"P  1 T
M $80  !'%   2!D  $@A  !(*@  2#4  $A!  !(3P  2&   $=S  !'B@
M1J(  $6Y  !%V0  1/  2#(  #XR   V,@  ,#$  "LQ   E,@  'S0  !DV
M   3.0  $#P   P_   (0@   T0   !&    2 (  $H%  !+"   3 L  $X.
M  !/$0  414  %(<  !2)0  4C   %(\  !12@  45H  %%M  !0A   3YT
M $ZU  !-T@  3>X 0S8  #LV   T-0  +S0  "<U   A.   &CL  !0^   0
M00  #$0   ='   "2@   $T   !/    40   %,"  !4!0  50@  %<+  !9
M#@  6Q$  %T7  !='P  72H  %TV  !<1   7%0  %MG  !;?@  6I<  %FO
M  !8RP  5^H /SD  #@Y   S.   *SD  ",\   </P  %4,  !!'   +2@
M!4X   !1    5    %<   !:    7    %T   !?    8 0  &('  !D"P
M9@X  &@2  !K&0  :R,  &HN  !J/   :DT  &E?  !H=0  9X\  &:H  !E
MP@  9., /3T  #<\   N/0  )4   !U$   620  $$T   I1   $50   %H
M  !=    8    &,   !F    :    &H   !K    ;0   &\"  !Q!@  = H
M '8.  !Y$P  >QL  'LG  !Z-0  >44  'A9  !X;0  =X8  ':?  !UMP
M=-( /$$  #)"   H10  ($H  !=.   05   "ED   )>    8P   &<   !K
M    ;P   '(   !U    =P   'D   ![    ?0   '\   ""    A ,  (<)
M  "*#@  CA,  (\>  ".*P  CCL  (U.  "+8P  BGP  (J5  "(K0  A\4
M-D<  "Q+   B3P  &54  !!;   *80   6<   !M    <@   '<   ![
M?P   (,   "&    B    (H   "-    CP   )$   "4    EP   )H!  "=
M!P  H0T  *44  "D(0  I#$  *-$  "B60  H'   )^+  "=H@  G;< ,%
M "55   ;6P  $F(   MI   !<    '<   !]    @P   (@   "-    D0
M )4   "8    F@   )P   "?    H0   *,   "F    J0   *P   "P
MM <  +@.  "Z&   NB<  +DY  "X3@  MV4  +9^  "UE@  LZL *5L  !YB
M   4:0  #'$   )Y    @0   (D   "/    E@   )L   "@    I    *@
M  "K    K    *\   "R    M    +8   "Y    O    ,    #$    R
M ,T'  #2$   TAT  -$O  #01   SUL  ,US  #+C0  RJ$ _P   /\   #[
M    ^@   /P " #X  \ ]0 7 /0 ( #Q "H ZP S .8 .P#B $, W@!) -H
M3P#6 %0 TP!9 -  7@#. &, RP!H ,D ;@#& '4 PP!] ,$ A@"^ )( NP">
M +D K@"V ,, M #H +, _P"O /\ I0#_ )X _P"; /\ _0   /<   #R
M\    .<  P#A  P W  2 -@ &P#6 "0 T@ M ,P -@#& #T P@!# +\ 20"\
M $X N@!3 +@ 6 "V %T M0!B +, 9P"Q &X KP!V *P ?P"J (H J "7 *4
MI@"C +D H0#9 *  ^0"> /\ F #_ )( _P"/ /\ \P   .P   #C    TP
M ,@   #!  D O0 / +L %@"Y !\ MP G +, +P"O #< K  ] *H 0P"H $@
MI@!- *0 4@"C %8 H0!; )\ 80"> &< G !O )H > "7 (, E0"0 ), G@"1
M +  D #( (X \ "- /\ B@#_ (4 _P"" /\ YP   -T   #&    N    *X
M  "H  0 I0 , *$ $@"A !D H  B )\ *0"; #  F  W )8 /0"3 $( D@!'
M )  2P"/ %  C0!5 (P 6@"* &$ B !H (< < "% 'L @P"( ($ E@!_ *<
M?0"\ 'P XP!\ /T ? #_ '@ _P!V /\ U@   ,    "O    HP   )D   "3
M    CP ) (T #@"+ !0 B@ < (H (P"( "H A0 P (, -@"" #L @ !  '\
M10!^ $H ? !/ 'L 5 !Z %H > !A '8 :0!U ', <P"  '$ C@!O )\ ;@"R
M &T SP!L /0 ; #_ &L _P!I /\ P    *L   ";    CP   (<   "
M?  $ 'H # !X !$ >  7 '@ '@!W "0 =0 J ', , !Q #4 <  Z &X /P!M
M $0 ; !) &L 3@!J %0 : !; &< 8P!E &T 9 !X &( AP!@ )< 7P"J %X
MP@!> .D 7@#_ %X _P!= /\ K    )D   "*    ?P   '<   !Q    ;0
M &H " !I  X :  2 &< & !G !\ 9P E &4 *@!C "\ 8@ T &$ .0!@ #X
M7P!# %X 2 != $X 6P!5 %H 70!8 &< 5P!R %4 @0!4 )$ 4P"C %( N !1
M -P 40#Y %( _P!2 /\ G0   (L   !\    <0   &D   !D    8    %X
M!0!<  L 6P / %L % !: !D 6@ ? %D )0!7 "H 5@ O %4 - !4 #@ 4P ]
M %( 0P!0 $D 3P!0 $X 6 !- &( 2P!M $H >@!) (L 2 "= $< L0!' ,P
M1@#P $< _P!' /\ D    'X   !P    9@   %X   !9    5@   %,  0!2
M  @ 4  - $\ $ !/ !4 3@ : $X ( !- "4 3  J $H +@!) #, 2  X $<
M/@!& $0 10!+ $0 4P!# %T 00!H $  =0 _ (4 /@"7 #T JP ] ,, /0#F
M #T ^P ^ /\ AP   '4#  !H!@  70<  %4&  !0!@  3 0  $H!  !)  0
M1P * $8 #@!% !$ 10 6 $0 &P!# "  0@ E $$ *@!  "\ /P T #X .@ ]
M $  .P!' #H 3P Y %D . !D #< <0 V ($ -0"3 #0 I@ T +L - #= #0
M]0 U /\ ?@8  &T)  !@"P  5@P  $X,  !("P  1 H  $((  ! !0$ /P$'
M #X "P ]  X /  2 #L %P [ !P .@ A #D )0 W "H -@ P #4 -0 T #P
M,P!# #( 3  Q %4 , !@ "\ ;0 N 'T +0"/ "P H@ L +8 + #0 "P [@ L
M /P =PH  &<,  !:#@  4 X  $D.  !##@  /@T  #L,   Y"P  . D# #<%
M"  V @T -0$0 #0 $P S !@ ,@ = #$ (@ P "< +P L "X ,@ M #@ + !
M "L 20 J %( *0!= "@ :P G 7H )@&, "4 GP E +( )0#* "4 Z  E /<
M<@T  &(.  !6$   3!$  $01   ^$0  .1   #8/   S#@  ,0T! # +!0 P
M" H +P8- "X%$0 L!!0 *P,9 "H#'@ I R, * 0I "<$+P F!34 )04] "0%
M1@ C!E  (@9< "$':0 @!WD 'P>+ !X'G0 >![  '0;& !T&XP =!?, ;0X
M %X1  !2$@  2!,  $ 3   Z$P  -1(  #$1   N$   + \  "H. P J#0<
M*0L+ "@)#@ G"1$ )0@6 "0(&P C"2  (@DF "$)+  @"C, 'PH[ !X+1  =
M"T\ ' Q; !L,:0 :#'D & R+ !@,G@ 7#+  %@S% !8,X0 6"_  :1   %H2
M  !.%   114  #T5   W%0  ,10  "T3   J$@  *!$  "80 0 D$ 0 (PX(
M ",-#  B# \ ( P3 !\,&  >#1T '0TC !P-*@ ;#3( &@XZ !@.1  7#E
M%@]< !4/:@ 3$'L $A"- !$0H  1$+, $ _) ! /Y  1#_( 91(  %<4  !+
M%@  0A<  #H7   T%P  +Q8  "H5   G%   )!,  "(3   @$@, 'A$& !T0
M"0 <$ T &P\0 !D0%0 8$!L %Q A !80*  5$3  %!$Y !,10P 2$DX $1):
M ! 2:0 0$WD #A.,  X3G@ -$[$ #1+%  P2X0 -$O$ 8A0  %06  !)&
M/QD  #<9   Q&0  +!@  "@7   D%@  (18  !\5   <% ( &A,$ !D2!@ 7
M$@L %1(. !02$@ 3$Q@ $A,? !$3)@ 1%"T $!0V  \500 .%4P #A97  T6
M90 ,%W4 "Q>'  H7F@ )%JT "!;!  @6W0 )%>X 7Q8  %$8  !&&@  /1H
M #4;   O&@  *AH  "49   B&   'Q@  !P7   9%@$ %Q8# !46!  3%@D
M$18- ! 7$0 /%Q8 #A<<  X8(P -&"H #!DS  P9/  +&D< "AI3  D:80 '
M&W$ !AN#  4;EP $&JH  QJ_  ,9V@ $&>P 7!@  $X:  !#'   .AP  #,<
M   L'   )QP  ",;   @&@  '1D  !H9   7& $ %1@" !(9!  0&P< #AL,
M  T<$  ,'!, "QP9  H<'P )'2< "!TO  <>.0 &'D, !!Y0  ,?7@ "'VX
M 1^    ?E0  'JD  !Z]   =V   '>P 6!H  $L<  !!'@  .!X  # >   J
M'@  )1T  "$<   >'   &QL  !@;   6&P$ $QL" !$<!  .'@< #!\+  H@
M#@ ((!( !B$7  4A'0 $(20  B(L  $B-0  (D   "--   C6@  (VL  "-^
M   CDP  (J<  "*\   AUP  (>T 51T  $@?   ^(   -2   "X@   H(
M(Q\  " >   ='0  &AT  !8=   3'@  $1\"  X@!  -(@< "B0+  8E#0 $
M)1   B84   F&@  )B$  "<I   G,@  )ST  "=)   H5P  *&<  "=[   G
MD   )Z4  ":[   FU@  )>T 42   $4A   [(@  ,B(  "PB   F(0  (B$
M !X@   ;'P  &"   !0@   1(@  #R,   TE P *)@8 !B@*  ,I#0  *P\
M "P2   L%P  +!X  "PF   M+P  +3D  "U&   M5   +60  "UW   LC0
M+*0  "NZ   KU@  *NX 32(  $$D   X)   ,"0  "DD   D(P  (2(  !TB
M   9(@  %2,  !(D   /)@  #2@   HJ @ &+ 4  BX)   O"P  , X  #(0
M   S%0  ,QL  #,B   S*P  ,S8  #-"   S4   ,V   #-S   RB@  ,J$
M #&X   PU@  ,.\ 224  #XF   T)P  +2<  "@F   C)0  'R0  !LE   6
M)@  $B@  ! J   -+   "BX   8P 0 ",@0  #0'   U"@  -PP  #@.   Z
M$@  .A<  #H?   Z)P  .C(  #H^   Z3   .EP  #IO   YA@  .)X  #BV
M   WU   -N\ 1"D  #HI   Q*0  *RD  "8H   B)P  '2@  !@I   3*P
M$"X   TP   ),@  !34   $W    .0(  #L%   \"   /@L  #\-  !!$
M0Q0  $,;  !#(P  0RX  $,Y  !#1P  0E<  $)J  !!@0  0)H  #^R   ^
MSP  /N\ /RP  #8L   O+   *BL  "4J   ?*P  &2T  !0O   0,@  #34
M  @X   $.@   #P    _    00   $,"  !%!0  1@@  $@+  !*#@  3!$
M $T6  !-'@  32@  $TT  !,0@  3%$  $MD  !+>P  2I0  $FM  !(R@
M1^P .S   #,O   M+P  *"T  "(O   ;,0  %30  ! W   -.@  "#T   )
M    0P   $8   !(    2@   $P   !. 0  3P0  %$'  !3"P  50X  %@2
M  !9&0  6"(  %@N  !7/   5TL  %9>  !6<P  58T  %2G  !2P@  4N8
M.#,  #$R   L,0  )3(  !TU   6.   $3P   Q    '1    $<   !*
M30   %    !3    50   %<   !9    6@   %P#  !>!P  80L  &0.  !F
M$P  9QP  &8G  !F-   940  &17  !D:P  8H4  &&?  !@N0  7MP -3<
M # U   H-P  (#H  !@]   10@  #$8   9*    3P   %,   !6    60
M %P   !?    80   &0   !E    9P   &D   !L 0  ;@8  '$+  !T#P
M=Q4  '<@  !V+0  =CT  '5/  !T8P  <WL  '*5  !PKP  ;\D -3H  "L[
M   B/P  &D,  !)(   ,30  !5(   !7    7    &    !D    :    &L
M  !N    <0   ',   !U    =P   'H   !\    ?P   (($  "&"@  B@\
M (P7  "+)   BC,  (E%  "'6P  AG(  (6+  "#I0  @KP +T   "5$   <
M20  $TX   U4   $6@   &$   !F    :P   &\   !T    >0   'T   "
M    @P   (4   "'    B@   (P   "/    D@   )8   "9 @  G@D  *(0
M  "B&@  H2D  * [  "?4   G6<  )J!  ":F0  F:\ *4D  !].   55
M#EL   5B    :0   '    !W    ?0   ((   "&    BP   (\   "3
ME0   )<   ":    G0   *    "C    I@   *H   "N    L@   +<*  "[
M$0  NA\  +DP  "W10  M5P  +1T  "QC@  KZ0 (E0  !A;   08@  !VH
M  !S    >P   ((   ")    D    )4   ":    GP   *,   "F    J
M *L   "N    L    +,   "V    N@   +T   #"    QP   ,P!  #3"P
MU!4  -,F  #1.@  T%$  ,UH  #+@0  RI8 _    /8   #R    \0   /,
M!0#T  P \@ 3 /  ' #M "4 Z  N .( -@#> #X V0!$ -0 2@#1 $\ S@!4
M ,L 60#) %X Q@!C ,0 :0#! '  O@!X +P @0"Y (T M@": +, JP"Q ,
MKP#F *X _P"E /\ F@#_ )0 _P"/ /\ ]    .P   #H    YP   -\   #9
M  D T@ 0 ,\ %P#/ "  S  H ,8 , #  #< O  ^ +D 1 "W $D M0!. +,
M4P"Q %< KP!= *T 8@"K &D J0!Q *< >@"E (4 H@"3 *  H@"= +8 FP#4
M )D ^0"6 /\ C0#_ (@ _P"$ /\ Z    -\   #9    R0   +\   "X  0
MM0 - +, $@"Q !H L  B *T *@"I #$ I@ X *0 /0"B $, H !( )X 3 "<
M %$ FP!6 )D 7 "7 &( E0!I ), <@"1 'T CP"+ (T F@"+ *P B0#% (@
M[@"& /\ ?P#_ 'H _P!X /\ V0   ,T   "[    K@   *4   "?    G  )
M )D #P"9 !4 F0 = )@ ) "4 "L D0 Q (X -P", #P BP!! (D 1@"( $L
MA@!0 (4 50"# %L @@!B (  :P!^ '4 ? "" 'H D@!X *, =P"Y '8 X !U
M /\ <@#_ &X _P!L /\ QP   +4   "E    F0   (\   ")    A0 $ (0
M# "" !$ @@ 7 (( '@"  "4 ?@ K 'P ,0!Z #8 >0 [ '< 0 !V $0 =0!)
M ', 3P!R %4 < !< &\ 9 !M &X ; !Z &H B@!H )L 9P"O &8 S !E /4
M9 #_ &$ _P!@ /\ M    *    "0    A0   'T   !W    <P   '  " !O
M  X ;P 2 &\ & !O !\ ;0 E &L *@!I #  :  T &< .0!F #X 90!# &,
M2 !B $X 80!5 %\ 7@!> &< 7 !S %L @@!9 ), 6 "F %< OP!7 .H 5P#_
M %8 _P!4 /\ H0   (X   !_    =0   &P   !H    9    &$ ! !@  L
M7P / %\ $P!? !D 7P ? %T )0!< "H 6P O %D ,P!8 #@ 5P ] %8 0P!5
M $D 4P!0 %( 6 !1 &$ 4 !M $X >P!- (P 3 "? $L M0!* -P 2@#Z $H
M_P!* /\ D@   (    !R    9P   %\   !:    5P   %4  0!3  < 4@ ,
M %( $ !2 !0 4@ : %$ 'P!/ "0 3@ I $T +@!, #, 2P X $H /0!) $,
M2 !* $8 4@!% %P 1 !G $, =0!" (8 00"8 $  K@!  ,L /P#R $  _P!
M /\ A0   '0   !G    70   %4   !/    3    $H   !(  0 1P * $<
M#0!& !$ 1@ 5 $8 &@!% !\ 1  D $, *0!" "T 00 S #\ .  ^ #X /0!%
M #P 3@ [ %< .@!B #D ;P X (  -P"3 #8 IP V ,  -@#H #8 _@ V /\
M?    &L   !> @  5 ,  $T#  !' P  0P$  $$    _  $ /@ ' #T "P ]
M  X /  1 #P %@ \ !H .@ ? #D )  X "D -P N #8 ,P U #H - !! #,
M20 R %, ,0!> #  :P O 'L +@". "T H@ M +@ +0#= "T ^  N /\ <P$
M &0%  !7!P  30@  $8(  ! "   .P<  #@%   W P  -@ $ #4 "  T  P
M-  / #0 $@ S !8 ,@ ; #$ (  P "0 +P I "X +P M #8 +  ] "L 10 J
M $\ *0!: "@ 9P G '< )@") "8 G0 E +, )0#/ "4 \  F /\ ;08  %X)
M  !2"P  2 P  $ ,   Z"P  -@L  #(*   P"   +@8" "X#!@ M  H +  -
M "P $  K !, *@ 7 "D '  H "  )P E "8 *P E #( )  Y ", 0@ B $L
M(@!7 "$ 9  @ ', 'P"% !\ F0 > *X '@#' !X Z0 ? /H : D  %D,  !-
M#0  0PX  #P.   V#@  ,0T  "T-   J#   * L  "<)!  F!@@ )@0+ "4#
M#@ D 1  ) $4 "(!&  A 1T (0 B "  *  ? "X '@$V !T!/P < 4D &P%4
M !H!80 : 7  &0&" !@ E@ 8 *H & #! !@ X0 8 /0 8PP  %4.  !)#P
M0!   #@0   R$   +0\  "D.   F#@  (PT  "(, P @"P8 ( D) !\'#  >
M!@X '@41 !P%%0 ;!1H &@4? !H%)0 9!2L & 4S !<&/  6!D8 %@92 !4'
M7P 4!VX $P>  !('E  2!J< $@6\ !($V0 2 ^\ 7PX  %$/  !&$   /!$
M #41   O$0  *A$  "80   B$   ( \  !T. @ <#04 &@T' !H+"@ 9"@T
M& D0 !<)$@ 6"1< %0D< !0)(@ 4"BD $PHQ !(*.@ 2"T4 $0M1 ! ,7P /
M#&X #@R   X,E  -"Z< #0NZ  T*T@ -"NH 7 \  $X1  !#$@  .A,  #(3
M   L$P  )Q(  ",1   ?$0  '!   !H0 @ 8#P0 %@X' !4."0 4#0L $PP-
M !(,$  2#!0 $0P: !$-(  0#2@ #PTP  X..P -#D8 #0Y1  P/7@ +#VT
M"@]_  D/DP )#Z8 " ZY  @.T  '#N@ 6!$  $L2  ! $P  -Q0  # 4   I
M%   )10  "$3   =$@  &A(  !<1 @ 5$04 $Q ' !(0"0 1#PH $ X,  X.
M#@ .#Q( #1 8  T0'@ ,$"4 #! M  L1-@ *$4$ "1%-  @26@ '$FH !A)\
M  42D  $$J0  Q&X  ,1SP "$>@ 51(  $D4   ^%0  -18  "T6   G%@
M(A4  !X4   ;%   &!,  !42 P 3$@4 $A$' ! 1"0 /$0H #1$+  P2#@ +
M$A$ "A(5  D3&P )$R( "!,J  <4,P %%#X !!5*  ,56  "%6<  15Z   5
MC@  %:,  !2W   4SP  $^D 4A0  $86   [%P  ,A<  "L7   E%P  (18
M !P6   9%0  %A0! !03!  2$P8 $1((  \2"  .$PD #!0*  H5#0 (%A
M!A83  46&0 $%Q\  Q<G  (8,  !&#L  !E'   950  &60  !EW   9C
M&*(  !BW   7SP  %^H 3Q8  $,8   Y&0  ,!D  "D9   C&0  'Q@  !L7
M   8%@  %14" !,5!0 1% 8 $!0&  X5!P ,%@@ "A<*  <9#  $&@X  AL2
M  $;%@  &QT  !PD   <+0  '#@  !U$   =4@  '6(  !UU   =B@  '*
M !RV   ;T   &NL 3!@  $ :   V&P  +1L  "8;   A&@  '1D  !D9   7
M&   %!<# !(6!  0%P0 #A<$  P9!0 *&@< !QP)  ,="P  'PT  " 0   @
M%   (1H  "$B   A*@  (34  ")!   B3P  (E\  ")R   AB   (9\  ""V
M   ?T0  '^T 2!H  #T<   S'0  *QT  "0=   @'   '!L  !@:   6&0$
M$QD! !$9 0 .&@$ #!P"  H= P ''P4  R$(   B"@  ) P  "8.   F$@
M)A@  "<?   G)P  )S(  "<^   G2P  )UP  "=N   FA0  )IT  "6T   D
MT0  (^X 1!T  #D?   P'P  *!\  ",>   >'0  &QP  !@;   4'   $1P
M  X=   -'P  "B$   8B 0 #) 0  "8&   H"   *@L  "L-   M$   +14
M "T<   M)   +BX  "XZ   N2   +5@  "UJ   M@0  +)H  "NR   JT
M*>\ 0"   #8A   M(0  )B$  "$@   ='P  &AX  !8>   2'P  #R$   TB
M   *)   !B8   (H    *P(  "T$   O!@  , D  #(,   T#@  -1(  #48
M   U(   -2H  #4V   U0P  -5,  #1F   T?   ,Y8  #*O   QS0  ,.\
M/",  #(D   J)   )",  " B   <(0  %R$  !,C   0)0  #2<   DI   %
M*P   2X    P    ,@   #0!   V!   . 8  #H)   \#0  /A   #X4   ^
M'   /B8  #XQ   ^/P  /4X  #UA   \=P  .Y$  #JK   YR0  ..T -R<
M "\G   H)@  (R4  !\D   9)0  %"8  ! H   -*P  "2X   4P    ,P
M #4    X    .@   #P    ^ 0  0 ,  $('  !$"@  1@T  $D1  !)%P
M2"$  $@L  !'.@  1TD  $9;  !%<0  1(L  $.E  !"PP  0>@ -"H  "PJ
M   G*   (B<  !PH   6*@  $2T   TP   ),P   S8    Y    /    #X
M  !!    0P   $8   !(    2@   $P#  !.!@  4 H  %,.  !4$P  5!P
M %,G  !3-   4T,  %)5  !1:@  4(,  $^>  !-N0  3.  ,"T  "LL   F
M*P  'RP  !@N   2,@  #34   @Y   "/0   $    !#    1@   $D   !,
M    3@   %$   !3    50   %<   !9 0  7 8  %\*  !B#@  8Q4  &,?
M  !B+   83P  &!.  !?8@  7GL  %R6  !;L   6<\ +S   "HO   B,
M&C,  !,W   ..P  "#\   %$    2    $P   !/    4@   %4   !8
M6P   %T   !@    8@   &0   !F    :0   &T%  !P"P  =!   '08  !S
M)0  <C0  ')%  !P60  ;W$  &V+  !KI@  :L  +C,  "4U   =.   %#P
M  Y!   '1P   $P   !1    50   %D   !=    80   &4   !H    :P
M &T   !O    <@   '0   !W    >@   'X   ""!   A@L  (H1  ")'
MB"L  (8]  "$4@  @V<  (&!  !_FP  ?K( *3H  " ]   60@  #T@   A.
M    5    %H   !@    9    &D   !N    <@   '8   !Z    ?0   (
M  ""    A0   (@   "+    C@   )(   "6    FP,  * ,  "B$P  H"$
M )\S  "=1P  FEX  )AW  "7CP  E:< (T,  !E(   13@  "54   !<
M8P   &H   !Q    =@   'L   "     A@   (H   ".    D0   ),   "6
M    F0   )P   "@    HP   *<   "K    L    +8$  "\#0  NA<  +DH
M  "W/   M%(  +)J  "OA0  K9P '$X  !-4   +7    60   !L    =
M 'P   "#    B0   (\   "4    F@   )\   "B    I    *<   "J
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M______________________________________________\
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M^?K[_/W^_VUF=#$      P0A   !                     0
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M'!T>'A\@("$B(B,D)"4F)B<H*2DJ*RPM+2XO,#$R,C,T-38W.#DZ.SP]/C]
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MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VO?
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MFW^YP)N(O;Z9B<"\E8K#NI&+QKB-C<BWBH_*MHB1S+6%D\VT@Y;/LX&9T+.
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M@*>-SX"GC<^ IXW/@*>-SX"GC<^ IXW/@*>-SX"GC<^ IXW/@*>-SX"GC<^
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MQ]7&" G9S H@Y<\-0-C5"U^]U@N(I<0TIIRW6KB9M6N[E[1WO9:S?[Z5LH7
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MS/^R%@G_LR$>_[ N.O^K.UGLI$AZUYQ9FL:7;[+$F7:VPIM_N<"<A[V]FHG
MNY:*P[F2B\:WCHW)MHJ/S+2'DLZSA);0LH&:T;* G]*N?Z/2JG^ESZ9_I\VF
M?Z?-IG^GS:9_I\VF?Z?-IG^GS:9_I\VF?Z?-IG^GS:9_I\VF?Z?-IG^GS?^S
M%@G_LR >_[ M.O^K.EGLI4=ZUIQ9FL:8;;+$FG2VPIQ]N;^=A;V]G(C!NYB)
MQ;B4BLBVD(O+M(R.SK.(D=&QA973L(.:U+""H-6J@:+3IH&ET*.!I\VC@:?-
MHX&GS:.!I\VC@:?-HX&GS:.!I\VC@:?-HX&GS:.!I\VC@:?-HX&GS?^S%0C_
MM" >_[$M.O^L.5GKI49[UIQ8F\:9:[+$G'*VPIU[N;^?@[Z\GHC"NIJ(QK>6
MB<JUDHK-LXZ,T+&*C].OAY36KH6:V*N#G]>F@Z+4HH.DT)^#ILV?@Z;-GX.F
MS9^#ILV?@Z;-GX.FS9^#ILV?@Z;-GX.FS9^#ILV?@Z;-GX.FS?^T%0C_M!\>
M_[$L.O^L.5GKID5[U9U8F\>::;+$G7"VPI]YNK^@@KZ\GXC"N9R(Q[:8B,NT
ME(G/L9"+TZ^,CM:MB9/9K(>;VZ:&GMFBA:'5GH6DT9R%ILZ<A:;.G(6FSIR%
MILZ<A:;.G(6FSIR%ILZ<A:;.G(6FSIR%ILZ<A:;.G(6FSO^T% C_M!\=_[$L
M.O^M.%GKID5[U9U7G,>;9[+$GFZVPJ!WNK^A@+Z[H8C#N)Z'R+6:A\VREXC1
ML).*U:V/C=FKC)/=J(J;WJ*(GMF>B*'5FX>DT9F'ILZ9AZ;.F8>FSIF'ILZ9
MAZ;.F8>FSIF'ILZ9AZ;.F8>FSIF'ILZ9AZ;.F8>FSO^T% C_M1X=_[(K.O^M
M.%KKID1[U9U7G,><9;+$GVRUPJ%UNKZB?K^[HX?$N*"'R;2=A\ZQF8C3KI:)
MV*N3C-RHD)+AHXZ:WYZ,GMJ:BZ'5EXJDT9:)ILZ6B:;.EHFFSI:)ILZ6B:;.
MEHFFSI:)ILZ6B:;.EHFFSI:)ILZ6B:;.EHFFSO^T% C_M1X=_[(J.O^M-UKK
MIT-\U9Y5G<>=8[+$H&JUPJ-SNKZD?+^[I(7$MZ*'RK.?A]"PG8?5K)J)VZF8
MC."EEY/FGI2:WYF1G=J6CZ#6E(VCTI.,I<^3C*7/DXRESY.,I<^3C*7/DXRE
MSY.,I<^3C*7/DXRESY.,I<^3C*7/DXRES_^U$PC_M1X=_[,J.O^N-EKKIT-\
MU9]3G<>>8++%HFBUPJ5PNKZF>K^[IH/%MZ6'R[.BA]&OH(?7JIZ)W*2;B^"=
MF8[CFIN9X)66G-N3DZ#7D9&CTY"/I<^0CZ7/D(^ESY"/I<^0CZ7/D(^ESY"/
MI<^0CZ7/D(^ESY"/I<^0CZ7/D(^ES_^U$PC_MAT=_[,I.O^N-EKKJ$)\U:!1
MG<>?7K'%I&2UPJ=MN;ZI=[^[J8'$MJB(R[&EA]&KHH?7I9^(VYZ=B-V7FXO@
MDIN3WY*<G-R/F)_7CI6BTXV3I-"-DZ30C9.DT(V3I-"-DZ30C9.DT(V3I-"-
MDZ30C9.DT(V3I-"-DZ30C9.DT/^U$PC_MAT=_[0I.O^O-5KJJ$%\U:).G,>A
M6K'%IF"TPJIIN;^M<[Z[KGW$M*J'RZVEAM&GHH;5H*"&V)F?AMN2G8G=C9V.
MW8R>F-N,GI_8BYJBU(J7I-&*EZ31BI>DT8J7I-&*EZ31BI>DT8J7I-&*EZ31
MBI>DT8J7I-&*EZ31BI>DT?^V$@C_MQP=_[0H.?^P-%KJJ4!]U:1)G,BD5;#&
MJENSPZ]CM\"S;+VVKGS%L*F'S*FFAM"CI(74G**$UI6AA=B/GX?:BI^+VX>?
MDMJ(H9S7B)^AU(><I-&'G*31AYRDT8><I-&'G*31AYRDT8><I-&'G*31AYRD
MT8><I-&'G*31AYRDT?^V$@C_MQL=_[4G.?^P,UKJJCY]UJA$F\FH3Z_'L%.R
MQ;A9M;FS;;^QK7W&K*J&RZ6GA<^?IH31F*2$TY*CA-6,HH;7B*&*UX6ACM>#
MHI;6A*2?U(2BH]&$HJ/1A**CT82BH]&$HJ/1A**CT82BH]&$HJ/1A**CT82B
MH]&$HJ/1A**CT?^W$0?_N!H<_[8E.?^Q,5KJJSQ^UZP[F<JM1*W)N46NO;A9
MN+*R;\"LKG[&J*N%RJ&IA,V;IX//E::#T(^EA-**I(;3AJ.(U(.CC-2!HY'4
M@*29TX"FH=& IJ'1@*:AT8"FH=& IJ'1@*:AT8"FH=& IJ'1@*:AT8"FH=&
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MV8Y^E]&-AZ+,C(VJQXJ1L<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O
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MQXJ1L<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O >J>[P'FJO,!XKKS
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MMJO+;[RKR'# J\1QP*K$<<"JQ'' JL1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
MJO^1$@'_E2<+_Y4['/^32R__CUE#_XQD5/N,:V/RBG)QZHA\?>.&A(?>@HJ/
MVG^/EM9]E)O3>IB?T7B<HM!WGZ3.=:*FS72FJ,URJ:G,<:VJS'"RJ\MPMJO+
M;[RKR'# J\1QP*K$<<"JQ'' JL1QP*K$<<"JQ'' JL1QP*K$<<"JQ'' JO^1
M$@'_E2<+_Y4['/^32R__CUE#_XQD5/N,:V/RBG)QZHA\?>.&A(?>@HJ/VG^/
MEM9]E)O3>IB?T7B<HM!WGZ3.=:*FS72FJ,URJ:G,<:VJS'"RJ\MPMJO+;[RK
MR'# J\1QP*K$<<"JQ'' JL1QP*K$<<"JQ'' JL1QP*K$<<"JQ'' JO^1$@'_
ME2<+_Y4['/^32R__CUE#_XQD5/N,:V/RBG)QZHA\?>.&A(?>@HJ/VG^/EM9]
ME)O3>IB?T7B<HM!WGZ3.=:*FS72FJ,URJ:G,<:VJS'"RJ\MPMJO+;[RKR'#
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M5/]6.E'_6SQ._V ^2_]D0$K_:$%(_VQ"1O]P0T7_=$1$_WA%0O]]1D'_@4=
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M*B?_K2LF_[DL)O_)+2;_R2TF_\DM)O_)+2;_R2TF_\DM)O_)+:JW  ":Q0
MB],  'WB  !U_P4 :?\, 5__$0)7_Q<#4/\?!4G_)@=$_RX)/_\V"SO_/0TW
M_T,/,_])$3#_3Q(N_U43+/];%"K_8A4G_VD6)?]R%R/_>Q@A_X89'_^1&A[_
MG!L>_Z4<'?^P'1W_L!T=_[ ='?^P'1W_L!T=_[ ='?^P'9S   ",S@  ?-X
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M13;\_44[\O]$/NK_1#[F_T8^YO]&/N;_1C[F_T8^YO]&/N;_1M"?  "]K
MKK4  *+"  "5SP  BMT# (3_$@%[_QX#=/\J"6S_,P]D_SL67?]#&U?_2B!1
M_U$D3/]8)TC_8"I$_V@L0/]Q+CS_>S$Y_X@R-?^6-#/_I#8Q_[8W+__0."[_
M[SDM__\Y,?__.3/\_SDS_/\Y,_S_.3/\_SDS_/\Y,_S_.<&H  "OL0  HKT
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M$1/_PQ(3_\,2$__#$A/_PQ(3_\,2$__#$I>^  "&S   =]L  &GG  !<_0
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MBIYQ<(BM=&V(P71MB>1S;X?J<7"$[&]R@^UM<X'N:W2 \&ET@/!I=(#P:72
M\&ET@/!I=(#P:?]A%P'_<1 !_X(. /^0#@#UG0T XZD, -FU# #/N1H Q;@N
M![NT/16QL$DCIZM2,9ZG6SZ6HV-(CI]J48:;<EE_F'I@>)6$9G*3CVQMD9QO
M:9"J<F:0OG-ED>%R:([K<&J*[&YLB.UL;8;O:VZ$\&ENA/!I;H3P:6Z$\&EN
MA/!I;H3P:?]C%0'_=0X!_X8- /B4"P#<H@@ U*T) ,^X"@#)O1< O[PK!K6Y
M.Q.KMD<AH;%0+YBM63N/JF%&AZ9H3W^C<%=XH'A><IZ!9&N;C&EFFIEM8IFH
M;U^9O'!>F=]O8);L;F.1[6UFCNYK9XOO:FF)\&AIB?!H:8GP:&F)\&AIB?!H
M:8GP:/]G$@'_>0P _XH* -^:! #3I@< S+$( ,>[" #!PA, N,(H!*Z_.!"E
MO$0>F[A.+)&U5SB(L5Y"@*YF2WBK;5-QJ79::Z=_8&6EBF1@HY=H6Z.F:UFC
MNFQ8H]QK6:#N:UR:[VI?EO!I89+Q:&./\69CC_%F8X_Q9F./\69CC_%F8X_Q
M9O]K$ '_?@D \9 $ -:> P#,J@8 Q+0& +Z^!0"XR!  L,@D Z?&-0V=PT(;
MD\!,*(J]5#.!NEP^>;=D1G&U:TYKLW149+%^6E^PB5]:KY9B5JZE95.NN692
MK]ME4JOR9E6D\F98G_)F6IOS95R7\V1<E_-D7)?S9%R7\V1<E_-D7)?S9/]P
M#0#_A 0 W98  ,ZC P#$K@0 N[<$ +3"!0"NS0P I\X@ I[-,0J5RSX6B\A)
M(X+&4BYZPUHX<L%B0&O :D=DOG--7KU\4UF\B%=4NY5;4+NE74Z[N5Y-O-M=
M2[GW7TZQ]F!1JO9@4Z7V8%6A]F!5H?9@5:'V8%6A]F!5H?9@5:'V8/]W" #K
MC   TYL  ,:H @"[L0( LKL" *K'!@"BTPH G=8: 976+ :,U#H1@])&'7K0
M3R=RSE@Q:LU@.&3+:#]>RG)%6,I\253)B$U/R9513,FE4TK)N51)RMQ31\CW
M54C _%A*N/M93++[6DZM^EI.K?I:3JWZ6DZM^EI.K?I:3JWZ6O]_  #<DP
MRJ(  +RL 0"QM0  J, # )_+!@"6V0L D> ; 8K?+ :"WSD.>=Y#%W'=32!J
MW%8H8]M?+UW:9S58V7$Z4]E[/D_9B$)+V99%2-FF1T;:NDA%V]M'1-CT24+3
M_TU$R?]/1<+_4$>[_U)'N_]21[O_4D>[_U)'N_]21[O_4N:*  #/FP  OZ<
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M*B_Y_RHO^?\J+_G_*B_Y_RHO^?\J+_G_*KFF  "JK@  G+D  ([%  "!T0
M==X  &WZ"0!E_Q$!7O\: E?_(P-2_RP%3/\T!TC_/ I#_T0,/_],#CS_4Q X
M_UL2-?]C%#+_;!8O_W<7+/^$&2G_DQHG_Z(<)?^T'23_S!XC_^T>(O_]'R+_
M_Q\B__\?(O__'R+__Q\B__\?(O__'ZRK  "=M@  C\(  (#.  !SW   9^D
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M7%>:^EM:E?I:7)'[65Z._%A?C?Q77XW\5U^-_%=?C?Q77XW\5_]J"@#_?
MW(P  ,V8  ##HP, NJH" +.S 0"LO H IKT= 9Z\+P:6NCP1C;A''(6U4"=]
MLUDP=K%@.&^O:#]IK7!%8ZMY2EZJA$]:J9!25:B>55*GKU=1J,974*?J5U"E
M_%=3G_U759K]5E>6_E98E?Y56)7^55B5_E58E?Y56)7^5?]O! #F@@  TI$
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M0D&]_T-"N?]$0KG_1$*Y_T1"N?]$0KG_1-V(  #'F   N*,  *NK  "@M
ME;X  (O( P" T0< >.$- '3A'0%NX2L#:. W"&'@0@Y<X$T45^!6&5/@7QU/
MX&DB2^!S)4?@?BA$X(LK0N":+3_AJR\^XL$O/N+E+SS?^C$YWO\T.=G_-CK0
M_S@[S/\Y.\S_.3O,_SD[S/\Y.\S_.<V2  "\H   K:@  *&Q  "5NP  B<4
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M$Q[__Q,>__\3'O__$Z:I  "8LP  BK\  'O*  !NU0  8-\  %3G  !._P0
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M56B ^E-I?O]1:GS_3VM[_TUL>?],;'G_3&QY_TQL>?],;'G_3/]># #_; $
MYGH  -:&  #+CP( Q)<$ +Z=! "XH@X L:,A :FB,@>AGS\1F9Q*&Y*94R6+
MEEPMA9-C-7^1:SMZCG-!=8Q\1G"*A4MKB)%/9X>=4F2&K%1BAK]588;A5&&&
M^5)CA/]098'_3V9__TUG?O],9W[_3&=^_TQG?O],9W[_3/]A"@#_;P  X'X
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M25*6_TA4DO]'5)+_1U22_T=4DO]'5)+_1_]N  #>?P  RHT  +Z8  "SH
MJJ<  *&N  "7M@  D;H0 (RZ(P&%N3(&?K@^#G>V21=QM5(>:[-:)66R8BM@
ML6HP6[!S-5>O?3E3KHD]3ZV60$RMI4)*K;E#2:[80DBK]4-'JO]$2:7_1$N@
M_T1-G/]$39S_1$V<_T1-G/]$39S_1.IU  #2A@  PY,  +>=  "LI   HJL
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M+3;*_RTVRO\M-LK_+<60  "VG0  J*4  )RM  "/M@  @[X  '?'  !LSP(
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M!96O  "&N@  =\4  &C0  !:VP  3.$  $#G   W\P  ,O\  "[_!P J_PX
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M2'AL]D9X;/]$=VS_0G=K_T!W:O\_=VK_/G=J_SYW:O\^=VK_/O]4# #_7P
M\FP  -UV  #0?0( R8,$ ,2'!@"_BA  MXPC ;"*- 6IB$$.HH5,%YR!51^6
M?UXFD7QF+8QY;C*(=W8WA'5_.X!TB#]\<I)#>'&>1G5PK$AS;[U)<7#927%P
M]$=Q<?]$<G#_0G)O_T%R;O\_<F[_/G)N_SYR;O\^<F[_/O]6"@#_8@  YF\
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M0F%]_T%B>_\_8WK_/V-Z_S]C>O\_8WK_/_]>  #I;0  UGD  ,B$  "^C
MMI,  *Z7  "FFP0 H)T7 )J=*0*3G#<(C)I#$(:831B EE4?>I1=)G6292QP
MD&PQ;(YU-F>-?CICBXD^7XJ505R)HT1:B;1%6(G+15B([418B/]#68;_05N#
M_T!=@?\^78#_/EV _SY=@/\^78#_/O]B  #D<0  SWX  ,.(  "YD0  L)<
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M-TF:_S=)FO\W29K_-^)T  #*@P  O(\  +"8  "EG@  FZ0  )"K  "%L0
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M%K.8  "EH   F:<  (NP  !^N   <<   &7(  !9S@  3M,  $3;!  _Z0T
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M @K_GP()_[4""/_5 @?_] ('__\"!___ @?__P('__\"!___ I&M  ""N
M<\(  &3,  !6U0  2-T  #OB   PYP  )^X  "/_   @_P0 '/\, !G_$0 6
M_Q8 $_\; !'_(0 ._R< #?\N  K_-@ '_SX !/](  #_5   _V(! /]S 0#_
MAP$ _YT! /^R 0#_R@$ _^H! /_S 0#_\P$ __,! /_S 82W  !TP0  9<P
M %;8  !'WP  .>4  "WJ   C[@  '/T  !C_   5_P  $?\$  __"P -_PX
M"?\1  ;_%0 #_QH  /\@  #_)@  _RX  /\W  #_00  _TT  /]<  #_;0
M_X(  /^6  #_J   _[H  /_#  #_PP  _\,  /_# /\D+P'_)2\!_R@O ?\G
M,0'_)#8"_R ^ O\:20/_%U8#_Q5D _\3<@3_$G\$_Q**!/\2E 3_$IT%_Q*D
M!?\2K ;_$K,&_Q*Z!O\2PP;_$\X'_Q/?!_\3ZP?_$_8'_Q/_!_\3_P;_$_\&
M_Q3_!_\4_PC_$_\(_Q7_"?\5_PG_%?\)_Q7_"?\E+@'_*2T!_RLL ?\K+@'_
M*3,"_R0[ O\?1@/_'5,#_QMA!/\9;@3_%WL$_Q>'!?\7D07_%YH&_Q>A!O\7
MJ0?_%[ '_Q>W"/\7P C_&,H(_QC;"/\8Z C_&/0(_QC]"/\9_PC_&?\(_QG_
M"?\9_PK_&/\+_QK_"_\:_PO_&O\+_QK_"_\F+0'_+"D!_RXH ?\O*@'_+2\"
M_RDW O\G0P/_)% #_R)=!/\@:@7_'G<%_QZ#!O\>C0?_'I8'_QZ>"/\>I0G_
M'JP)_QZS"?\>O K_'L8*_Q[3"O\>Y0K_'O$*_Q_\"OX?_PK]'_\+_!__#/P>
M_PW\'_\.]R'_#O<A_P[W(?\.]R'_#O\J*@'_+R8!_S(D ?\S)0'_,BH!_S$T
M O\O/P/_+4P#_RI9!/\H9@7_)G(&_R5^!_\EB0C_)9()_R6:"O\EH0O_):@+
M_R2P#/\DN S_)<$,_R7.#?\EX0W\)>\-^2;Z#/8F_PWU)O\/]"7_$/0E_Q'R
M)O\2[2?_$NTG_Q+M)_\2[2?_$O\N)@'_-"(!_S<@ ?\Y(0'_."4!_SDO O\X
M.P+_-4<#_S-4!?\Q80;_+VT'_RYY"?\MA K_+8T,_RR6#?\LG0W_+*4._2RL
M#_PLM _[++T/^2S)$/8LW1#S+>P/[RWX#^TM_Q+K+/\4ZBS_%>DL_Q;E+?\6
MX"[_%N N_Q;@+O\6X"[_%O\R(P'_.!T!_SP; ?\^&P'_0"(!_T$K ?] -@+_
M/D(#_SQ/!?\Y7 ;_.&@(_39S"_LU?@SX-8@.]S21#_4TF1#S-* 1\C.H$O S
ML!+O,[D3[C/%$^LTUQ/G-.H2XS3W%.$T_Q?>,_\9W#/_&MLS_QK4-/\:SC7_
M&LXU_QK.-?\:SC7_&O\V'P'_/!D!_T$6 /]$%@#_1QX!_TDG ?](,@+_1CT#
M_T1)!?I"5@?V0&()\C]N#.\]>0_M/(,0ZCR,$N@[E!/G.YP4Y3ND%>,ZK17B
M.K86X#O"%M\[TA;:.^@7U#KV&M Z_QS-.O\>RSK_'LHZ_Q_$._\?P#S_'L \
M_Q[ //\>P#S_'O\Y&P'_0!4 _T41 /]*$P#_3AD _U B ?]0+ ']3C<"]DM#
M!/!)4 ?K2%T*YT9I#>-%=!#@1'X3W4.'%=M"D!?809@8U4"@&=- J1O10+(<
MST"]'<U S!W*0>0>QD#T(,) _R*_0/\CO4#_([M _R.V0?\CLT+_(K-"_R*S
M0O\BLT+_(O\]%P#_1!$ _TH. /]0$ #_5!4 _U8= /U6)@'S53$!ZU,] ^52
M2P;?4%@*VDYC#M1,;A/02G@6S4F!&<M(BAO(1Y(=QD>:'\1&HR'"1JPBP$6W
M([Y%Q22\1=PDN$;P);5&_R>R1O\GL$;_)ZY&_R>J1_\FITC_)J=(_R:G2/\F
MITC_)O] % #_2 X _TX+ /]5#@#_61$ _UP6 /1='P#J7"H!XELW MI:1@72
M5U,+S%5>$,A3:!7$47(9P5!['+Y/A!^\38PBN4V5)+=,G2:U2Z<GLTNQ*;%*
MORJO2M$JK$OK*ZE+_"RF2_\LI4S_*Z-,_RJ?3?\JG4W_*9U-_RF=3?\IG4W_
M*?]#$0#_2PP _U,( /]:"P#_7@T ^6 0 .MA%@#A8B$ UF(Q <YA007'7TX+
MPEQ9$;U:9!>Y6&T;ME9V'[-5?B*P4X<EKE*/**M1F"JI4*(LIU"L+:5/N2^C
M3\LOH%#F+YY0^3"<4/\OFE'_+IA1_RV64O\LE%+_*Y12_RN44O\KE%+_*_]&
M$ #_3@D _U8% /Y>!@#O8@< YV4* .1F#@#69QD S6@M <5G/06_94H+N6-5
M$K1@7Q>P7FD<K%QQ(:E:>B2F68(HI%B+*Z%6E"V?59TOG%6H,9I4M#.85,4S
MEE3A-)-5]C.25?\RD5;_,8]6_S"-5O\NC%?_+8Q7_RV,5_\MC%?_+?])#@#_
M404 _UH! .YB  #?9P, V&H& -5K"@#-;14 Q6XI ;YM.02W:T<+L6A2$:QF
M7!BH9&4=I&)M(J%@=2:>7GXIFUV&+9A<CR^56IDRDUFD-)!9L#:.6< VC%G;
M-XI9\S:)6O\TB%O_,X=;_S&&6_\PA5O_+X5;_R^%6_\OA5O_+_]+# #_5
M^UX  .)E  #8:P$ SVX% ,QP" #&<A( OG,F ;=S-@2Q<$0*JVY/$:9K61BA
M:6$=G6=J(IEE<B>68WHJDV*#+I!@C#&-7Y4TBEZ@-H=>K3B%7;PY@UW4.8)>
M\#B!7_\V@%__-(!?_S-_7_\Q?E__,'Y?_S!^7_\P?E__,/]-"0#_5@  [F$
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M-VYL_S5N:_\T;FK_,FYJ_S)N:O\R;FK_,O]3  #T7P  WFH  ,US  ##>@
MNWX  +6!  "N@PD J(4: **%*P*;A#H'E8)%#I!_3Q6*?5@;AGM?((%Y9R5]
M=V\J>G9W+G9T@#)S<XLU;W*6.&QQHSII<+(\:'#&/&=PYSMG<?PY:''_-VAP
M_S5I;_\T:6[_,VEN_S-I;O\S:6[_,_]6  #K8@  V&X  ,EV  "_?0  MX(
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M,EE]_S)9??\R67W_,N]@  #;;@  QWH  +N#  "RBP  J)   )^3  "4E@
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M)LQZ  "[B   KI(  **9  "7G@  C*0  ("J  !UKP  :;0  %ZY!@!;NA0
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M!B?:S08GU^\&)M3_"272_PLDT?\,(]#_#2/0_PTCT/\-(]#_#:Z6  "@G0
ME*0  (:L  !YM   ;+L  &#"  !4Q@  2,L  #[0   UU00 +=T* "SA$P K
MXA\ *>,J "CD-0 GY#\ )N5* "3F50 CYF$!(>=N 2#G?@(>Z) "'>FD AOI
MO (:ZN("&N;\ AGE_P,9Y/\$&./_!1CC_P48X_\%&./_!:.=  "6I   B*P
M 'JU  !LO0  7\0  %/*  !'S@  /-,  #+:   JWP  )>X) "/P$0 A\1D
M'_$B !WR*P ;\S0 &?0^ !?T2  5]5( $_9? !+V;@$1]X !$/B4 0_YJ@$.
M^<8!#OGM 0WV_P$-]/\!#?/_ 0WS_P$-\_\!#?/_ 9FC  "+K   ?+4  &V^
M  !?Q@  4LT  $72   YV   +]X  ";B   ?Z@  '/L& !G_#@ 7_Q, %/\:
M !+_(0 0_R@ #O\P  W_.0 +_T, "?].  ;_7  $_VP  O^   '_E@  _ZT
M /_*  #_\   __\  /__  #__P  __\  /__ (VK  !]M0  ;K\  &#(  !2
MT   0]<  #?=   KX@  (N8  !GJ   5^0  $O\  !#_"  ._PX #/\1  G_
M%@ &_QP  _\B  #_*@  _S,  /\]  #_20  _U<  /]I  #_?@  _Y4  /^L
M  #_QP  _^@  /_Z  #_^@  __H  /_Z ("U  !POP  8<D  %+3  !#VP
M->$  "GF   >Z@  %>X  !#X   ._P  "_\   C_   $_P8  /\*  #_#@
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M(*1&]""A1O\AGT?_()Y'_R">1_\?FT?_'II'_QZ:1_\>FD?_'O] #0#_1@0
M_TP  /A2 @#H500 X54( .)5#0#551D S%<L ,57/ *_5DH&NE55"K937PZR
M4F@2KU!Q%:Q/>1BJ3H$:J$V*':5,DA^C3)P@H4NF(I]+L2.=2\ DFTO8)9E+
M\"663/\DE4S_))1,_R.33/\BD4W_(9%-_R&13?\AD4W_(?]""@#_20  _U$
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M*GM;_RA[6_\G>UK_)GI:_R5Z6O\E>EK_)?])  #[4@  XUP  -)C  #':
MP&L  +IK @"U:PT KFT= *AN+@&C;3P%G6M("IEJ40^4:%H4D&9B&(UE:AR*
M8W(@AV)Z(X1A@R:!8(PI?E^7*WM>HRUY7K$O=UW$+W5>XB]U7ODM=5__*W5?
M_REU7_\H=5[_)G5>_R9U7O\F=5[_)O]+  #P50  WE\  ,UG  ##;   NV\
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M*&5J_RAE:O\H96K_*/U3  #C7P  SFD  ,%Q  "W=P  KWL  *=]  ">?0
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M)N%C  #)<   NWL  +"$  "FB@  FXX  )&1  "$DP  >I4" '67$@!RF"(
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M&#FFQQ@YI>H8.*/_&C>A_QLWH/\<-Y__'#>?_QPWG_\<-Y__',1X  "UA0
MJ8\  )V5  "2F@  AI\  'JC  !NJ   8JP  %6P  !0L@X 3K(; $VS* !+
MLS4 2;,_ 4:S20)$LU($0;-;!C^S9 @\LV\*.K-[##>SB@XULIH/,[.M$#*S
MQ1 RLND0,;#^$C"N_Q0OK?\5+ZS_%B^L_Q8OK/\6+ZS_%KN!  "NC@  H94
M )::  ")H   ?:8  '&K  !EKP  6;0  $ZW  !#O 4 0+T1 #^]'@ ^OBL
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M !+>_P$1W?\!$=O_ A';_P(1V_\"$=O_ IZ:  "2H0  A*D  ':Q  !HN
M6[\  $[$  !"R   -\P  "W0   DU0  '-L  !7?!0 4Z0X $NH4 !'K'0 0
MZR8 #NPP  [M.@ -[D8 "^Y3  KO8@ )\'0 "/&)  ?RH  %\KH !/'D  +Q
M_0 "[_\  ^W_  /M_P #[?\  ^W_ )6A  "&J0  >+(  &FZ  !;P@  3<@
M $#,   TT0  *M8  "';   9X   $N0   _P 0 -^0H "_H/  G[%0 '^QP
M!/PD  '\+   _#<  /Q"  #\4   _&$  /UU  #\C   _*0  /S!  #\ZP
M_/\  /W_  #]_P  _?\  /W_ (FI  !YL@  :KL  %S$  !.S   /]$  #+7
M   GW0  '>$  !7E   .Z   "O$   C]   %_P,  ?\)  #_#@  _Q(  /\7
M  #_'P  _R<  /\Q  #_/@  _TT  /]?  #_=0  _XT  /^F  #_P@  _^<
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M +X _P#( /\ UP#_ .< _P#S /\ _0#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\;*0#_'28 _QPE /\9)P#_$RP _PXT /\+0 '_"$X!_P5;
M ?\#: '_ G0!_P)_ ?\"B '_ I$!_P*8 ?\"GP'_ :4 _P&L /\!L@#_ ;H
M_P'$ /\!T0#_ .0 _P#Q /\ _ #\ ?\ _ +_ /P#_P#\!/\!_ 7_ ?P%_P'\
M!?\!_ 7_ ?\?)@#_(2( _R A /\>(P#_&"< _Q,P /\1/ '_#DH!_PU7 ?\+
M8P'_"F\!_PIZ ?\*A '_"HT!_PJ4 ?\*FP'_"J(!_PJH ?\*KP'_"K<!_PK
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M!\0M]PG!+?\*ORW_"[TM_PR\+?\,O"S_#+LL_PR[+/\,NRS_#/\Q$0#_-0P
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M&HY'_QF.1_\8C4?_&(U'_Q>-1_\7C4?_%_\^ @#_0P  ZTL  -U1  #15
MRE0! ,92!0#!41$ N5,B +-5,P&N5$$"JE1,!:935@BB45\,GU!G#YU/;Q&:
M3G<4F$Y_%I9-B!B33)$9D4R;&X]+IAV-2[,>BTO%'HE+XAZ'3/<>ADS_'85,
M_QR%3?\:A4S_&85,_QF%3/\9A4S_&?]   #\1P  Y5   -56  #*60  PEH
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M'7!:_QQP6O\<<%K_'/](  #G4@  TUL  ,5B  "[9@  LV@  *QH  "E9@4
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M'NM3  #38   PFD  +9Q  "L=@  HWD  )EY  "-=P  AWD+ (-[& !_?"@
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M'TB P2!'@.,?1W_Z'DA^_QY(??\=27S_'$E\_QQ)?/\<27S_'-9A  #";@
MM'@  *J   "?A0  E(<  (B'  ![B0  <(P  &N.#0!HCQH 9H\I &*0-0%?
MCS\#7(](!5F.4 A6CE@+4XU@#E",:!!-C'(32HM]%DB*BAA%BID:0XJJ&T**
MOQM!BN$;08CY&T&&_QM!A?\;0H7_&D*$_QI"A/\:0H3_&LUG  "\=   KWX
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M"BNH_PLJIO\,*J7_#2JE_PTJI?\-*J7_#;6   "HBP  G)$  )&6  "%G
M>*   &NE  !?J   4ZP  $BO   ]L@  -K4+ #2U%0 SMB$ ,K8L #&W-P P
MMT$ +[A+ "ZX50 LN& !*KAM 2FY>P(GN8T");F? R2YM ,CN=(#([?T!"*U
M_P4AM/\&(;/_!R&R_P<ALO\'(;+_!ZV*  "@D0  E9<  (B=  ![HP  ;J@
M &&M  !5L0  2K0  #^W   TNP  *[X# "3"#  BPA0 (L,? "'#*@ @Q#0
M'\0_ ![%2@ =QE8 ',9C !O'<P :QX4 &<>9 !C(K@ 7R,L %\;Q 1?$_P$6
MP_\"%L'_ Q;!_P,6P?\#%L'_ Z.1  "8F   BYX  'VE  !PJP  8K$  %:V
M  !*N0  /KT  #3    JQ   (L@  !G,!  3T H $=(1 !#2&@ 0TR4 #],P
M  [4/  .U$@ #=56  W590 ,UG@ #-:-  O8I  *V+X "=GF  K6_@ +U/\
M"]+_  O2_P$+TO\!"]+_ 9J8  ".GP  @*8  '*M  !DM   5[H  $F_   ]
MP@  ,L8  "C)   ?S0  %]$  !'6   ,VP4 "-X+  ;?$0 %WQH !. D  +A
M+@ !XCH  .-'  #D5@  Y&<  .5[  #FD@  YJH  .?(  #G\   Z/\  .C_
M  #H_P  Z/\  .C_ )&?  ""IP  =*\  &6W  !7O@  2<,  #S'   PRP
M)<\  !S4   4V0  #MT   GA   "Y0   .D&  #I#0  Z1$  .H8  #K(0
M[2L  .\W  #Q10  \E8  /-H  #S?@  ])<  /6P  #VT   ]_,  /?_  #W
M_P  ]_\  /?_ (6G  !VL   9K@  %C!  !*R   .\P  "[1   CU@  &=P
M !'@   ,XP  !.<   #J    ]0   /0   #U!0  ]0L  /8/  #V%   ^!T
M /HG  #\-   _T,  /]5  #_:0  _X$  /^:  #_L@  _\\  /_M  #_^0
M__D  /_Y 'BP  !HN@  6<,  $O+   [T0  +=@  "'=   6X@  #N8   CJ
M    [0   /    #X    _P   /\   #_    _P   /\&  #_#   _Q   /\8
M  #_(@  _S   /]   #_4P  _VD  /^!  #_F0  _Z\  /_#  #_U0  _]4
M /_5 /\3* #_$R4 _Q$E /\-)P#_!BT _P U /\ 00#_ $\ _P!< /\ :0#_
M '0 _P!^ /\ B #_ )  _P"7 /\ G0#_ *0 _P"J /\ L #_ +< _P#  /\
MS #_ -\ _P#L /\ ^ #_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\6)0#_%B( _Q0A /\0(P#_"B@ _P P /\ /0#_ $L _P!8 /\ 9 #_ '
M_P!Z /\ A #_ (P _P"3 /\ F@#_ *  _P"F /\ K0#_ +0 _P"\ /X R #]
M -D ^P#I /H ]@#Y /\ ^ #_ /@ _P#X /\ ^ #_ /D _P#Y /\ ^0#_ /\:
M(@#_&AX _Q@= /\3'@#_#B( _PHL /\'.0#_ T8 _P!3 /\ 8 #_ &L _P!V
M /\ ?P#_ (@ _P"/ /\ E@#_ )T _P"C /X J0#\ +  ^@"Y /< Q #U -(
M\P#F /( ] #Q /\ \ #_ .\ _P#O /\ [P#_ /  _P#P /\ \ #_ /\>'0#_
M'AD _QP7 /\7& #_$QX _Q$H /\.- #_#$$ _PI. /\(6P#_!V8 _P9Q /\&
M>@#_!H, _@:+ /P&D@#Z!ID ^ :? /8&I@#T!JT \@:U / %P #M!<X ZP7D
M .D&\P#F"/\ Y0K_ .0+_P#D"_\!Y O_ >0+_P'D"_\!Y O_ ?\A& #_(1,
M_R 1 /\;$@#_'!H _QHD /\6+P#_$SP _Q%) /\050#\#F$ ^0YK /8.=0#T
M#GX \@Z& / .C@#N#I4 [0Z; .L.H@#J#JH Z ZS .8/O0#E#\P X0_C -T0
M\P#9$?\!UA+_ =03_P'3$_\"TA/_ M(3_P+2$_\"TA/_ O\E$P#_)1  _R0-
M /\C#@#_(Q0 _R(> /\?*0#_'#4 ^1E# /083P#O%UL [!=F .D7< #F%WD
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M"*DN_PBH+O\(J"W_"*@M_PBH+?\(J"W_"/\O" #_,0  _S4  /8W  #J-@(
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M$7]'_Q%_1_\1?T?_$?\[  #N0P  W$P  ,Q1  #!5   N50  +11  "N30L
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M%.]&  #:4@  QEL  +IA  "P90  IF8  )UC  "580  CV(. (MD' "'92L
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M&U5GO1Q49]P<5&?V&E1F_QA59O\7567_%E9E_Q569?\55F7_%>)1  #*70
MNV8  *]L  "F<0  F7   (YO  "#;@  ?7 % 'AR$@!U<R$ <G,O 6]S.@)L
M<T0$:7),!F9R5 AC<5L+8'!C#5UP:Q!;;W036&Y_%55NBQ=3;9D946VH&D]M
MNQM.;=D:3FST&4]K_QA/:_\74&K_%E!J_Q50:O\54&K_%=U5  #%80  MVH
M *QQ  "B=0  E'0  (ET  !\<P  =G4  '%W$ !O>!T ;'DK &EY-P%F>4 #
M8WE)!6!X40===U@)6W=@#%AV: Y5=7$14G5\$U!TB!9-=)<72W.F&$ESN1E(
M<]4927+S&$EQ_Q=*<?\62G#_%4MP_Q1+</\42W#_%-1:  # 9@  LV\  *AV
M  "=>0  CW@  (1X  !W>0  ;WP  &I]#0!G?AD 9'\F &* ,@%?@#T"7(!&
M UI_3@57?U4'5'Y="5)]90Q/?6\.3'QY$4I\AA-'>Y0517ND%D1[MQ9#>](6
M0WKR%D-Y_Q5#>/\41'?_%$1V_Q-$=O\31';_$\U?  "[:P  KG0  *1\  "7
M?@  BGT  ']^  !R?P  9H,  &&$" !>AA, 7(<A %J'+@!8AS@!58=" E.'
M2@-0AU(%3H9:!TN&8@E)A6P+1H5W#4.$@P]!A)(1/X2B$CV$M1,\A,\3/(+P
M$CR!_Q(]@/\2/7__$CU^_Q$]?O\1/7[_$<5F  "U<0  JGL  )^"  "2@@
MA8(  'F#  !MA@  7XH  %B- 0!4C@\ 4H\; %"/)P!/D#, 39 ] 4N010))
MD$X#1I!6!$2/7P5"CV@'/X]S"3V.@ LZCH\,.(Z@#3>.LPXVCLP.-HWO#C6+
M_PXUB?\/-8C_#S:'_P\VA_\/-H?_#[YM  "P>0  I8(  )F'  ",B   ?X@
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M QJK_P,:J_\#&JO_ ZB(  ";CP  D90  (2:  !VGP  :*(  %NE  !/J0
M1*T  #FP   OLP  )K8  !ZY!0 8NPX %[L6 !>\(  6O"H %;TU !2]0  3
MODL $KY8 !*^9P 1OW@ $+^, !# H@ .P+H #L#A  ^]^P /O/\ $+K_ 1"Z
M_P$0NO\!$+K_ 9^/  "4E0  AYL  'FA  !KIP  7JP  %*Q  !%M   .K8
M "^Y   EO   ';\  !7#   /Q@4 "\H-  G*%  (RAT !\HG  ?*,@ &RSX
M!<M+  3,6@ #S&H  LQ^  ',E   S*L  ,W(  #,[0  S/\  ,O_  '*_P !
MRO\  <K_ )>6  "*G   ?*,  &ZJ  !@L   4K8  $6Y   YO   +K\  "/#
M   ;Q@  $\H   W-   (T0   =0)  #4#@  U14  -8>  #8)P  V3$  -L^
M  #<2P  W5L  -YN  #>A   WYL  -^T  #>V0  W_<  -__  #?_P  W_\
M -__ (V=  !_I0  <*P  &&S  !3N@  1;\  #C"   LQ@  (<D  !C-   0
MT0  "]4   3:    W@   . !  #A"0  X@X  .03  #E&P  YR0  .DO  #K
M/   [4L  .Y=  #N<0  [XD  /"B  #PO   \.,  ._Y  #P_P  \/\  /#_
M (&E  !RK0  8[4  %2]  !&Q   -\@  "K,   ?T   %=4   [:   'W@
M .(   #F    Z0   .H   #L    [@4  .\,  #Q$   \Q<  /4@  #X*P
M^SD  /U*  #^7@  _W0  /^-  #_I@  _\   /_A  #_]0  __4  /_U '2N
M  !EMP  5L   $?(   XS0  *M(  !W8   3W0  #.(   /F    Z0   .P
M  #P    \P   /0   #V    ^    /H   #]!P  _PT  /\2  #_&P  _R@
M /\W  #_2@  _UX  /]V  #_CP  _Z8  /^Z  #_T0  _]$  /_1 /\/) #_
M#B( _PLA /\#) #_ "D _P R /\ /@#_ $P _P!9 /\ 90#_ '  _P!Z /\
MA #_ (P _P"2 /\ F0#_ )\ _P"E /\ JP#_ +( _P"Z /\ Q0#_ -, _P#G
M /\ ] #_ /\ _@#_ /\ _P#^ /\ _@#_ /X _P#^ /\ _@#_ /\1(0#_$!X
M_PT= /\''P#_ ", _P M /\ .@#_ $@ _P!5 /\ 80#_ &P _P!V /\ ?P#_
M (< _P". /\ E0#_ )L _P"A /\ IP#^ *X _0"V /P P #[ ,T ^0#B /@
M\ #W /P ]@#_ /4 _P#U /\ ]0#_ /4 _P#U /\ ]0#_ /\5'0#_$QH _Q 9
M /\+&0#_ !T _P I /\ -@#_ $, _P!0 /\ 7 #_ &< _P!Q /\ >@#^ (,
M_ "* /H D0#Y )< ^ "= /< HP#U *H ] "R /( NP#Q ,@ [P#< .X [ #M
M /H ZP#_ .H _P#J /\ Z@#_ .H _P#J /\ Z@#_ /\8&0#_%A4 _Q,3 /\.
M$P#_"QH _P<D /\", #_ #X _P!+ /\ 5P#_ &( _ !L /@ =0#U 'X \@"%
M /$ C #O ), [@"9 .P H #K *8 Z0"N .< MP#F ,, Y #4 .( Z0#A /<
MWP#_ -T _P#= /\ W0#_ -T _P#= /\ W0#_ /\;$P#_&A  _Q8. /\2#@#_
M$A4 _P\? /\,*P#_"3@ _P9% /L#40#W EP \@)F .X"< #J G@ YP*  .8#
MAP#D XX X@.5 .$#G #?!*, W02K -L$M #8!<  U@70 -,&YP#0"/@ S@K_
M ,P+_P#+#/\ RPS_ ,L+_P#+"_\ RPO_ /\?$ #_'@L _QH' /\9"P#_&!$
M_Q89 /\2) #Z$#  \PX^ .X-2@#I#%8 Y0QA .(,:@#>#7, VPU[ -D-@P#6
M#8H U V1 -(-F0#0#J  SPZI ,T.LP#+#K\ R@_0 ,81Z0#"$OD OQ/_ +T3
M_P&\$_\!O!/_ ;P3_P&[$_\!NQ/_ ?\B# #_(00 _R   /\A!0#_'PP _QP1
M /88' #L%2@ Y1,V -\20P#9$T\ TQ1: - 59 #-%FT RQ9U ,D7?0#'%X4
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M!94N_P65+O\%E2[_!?\L  #_+@  ZC4  -TY  #1.0  RC8  ,<O!@#!+1$
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M"_,Y  #@1   S$P  +Y1  "T4P  JE(  *).  "=2@$ ETL1 )--( "/3RX
MC$\Z 8A/10*%3TX#@T]6!(!.709^3F0'?$UL"7E-= MW3'T,=4R'#G-,D@]Q
M2Y\1;TNM$FU+OQ)L2]P2:TSU$6I,_P]J3/\.:DO_#6I+_PQJ2_\,:DO_#/ ]
M  #;2   QU   +I5  "P6   I58  )Q3  "73P  D5 . (Q2' ")5"L A50W
M ()40@%_5$L#?%13!'I36@9X4V((=5)I"7-2<0MQ47H-;E&$#VQ0D!!J4)P2
M:%"K$V90O!-E4-@39%#S$F10_Q!D4/\/9%#_#F5/_PUE3_\,94__#.Q!  #4
M3   PU0  +99  "L7   H%H  )=7  "15   BU4, (97&0"#6"< @%DT 'U9
M/P%Z64@#=UA0!'186 9R5U\';U=F"6U6;@MK5G<-:%6!#V95C1%D5)H28E2I
M$V!4NA1?5-,47E3R$UY4_Q%?5/\/7U3_#E]3_PU?4_\-7U/_#>=$  #/4
MOU@  +-=  "H7P  G%T  ));  "+6   A5H* (%;%@!]7"0 >ETQ '==/ %T
M748"<5U.!&]<505L7%T':EQD"6A;; ME6G4-8UI_#V%9BQ%>69@27%BG%%M8
MN!196= 465CP$UE8_Q%:6/\06EC_#EI7_PU:5_\-6E?_#>-(  #+4P  NUL
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M$DEF_Q!*9O\/2F7_#DME_PU+9/\-2V3_#=%4  "^7@  L6<  *9M  "7;
MBFL  ']K  !S:P  ;6T  &AN# !E<!< 8G$D &!Q, !><3H!7'%# EEQ2P-7
M<5,$57!:!E)P8@=0<&L)3F]U"TMO@@U);H\/1VZ?$$5NL!%$;L<10VWJ$$1L
M_P]$:_\.16O_#45J_PU%:O\-16K_#<M8  "Z8P  K6P  *%Q  "2<   A6\
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M"#"!_P@P@?\(,('_"+=K  "J=@  H'\  )!^  ""?@  =G\  &J   !>@P
M4X<  $J+  !!C@( /9 . #N0&  ZD2, .9$M #B2-P WDD  -I)) #234@ S
MDUP!,9-G 2^3= (MDH,#*Y*4 RJ2IP,HDKT$*)+A R>0^@0GCO\%)XW_!2>,
M_P4GC/\%)XS_!;%T  "E?@  F84  (J$  !]A   ;X4  &.(  !8BP  38\
M $.3   ZEP  ,IH' "Z;$  MFQH +)PD "N<+@ JG3@ *9U! "B=2P GGE4
M)IYA "6>;@ CGGX!(IZ0 2">HP$?GKD!'I[= 1Z<^ (>FO\"'IG_ QZ7_P,>
ME_\#'I?_ ZI]  ">A0  DXL  (6*  !UBP  :(X  %N1  !0E0  1ID  #N=
M   RH   *J,  "*F"0 ?IQ$ 'J<: !VH)  <J"T &Z@W !JI00 9J4P &*E8
M !>J9@ 6JG8 %:J) !2JG@ 3J[0 $JO3 !*H]0 3I_\!$Z7_ 1.E_P$3I/\!
M$Z3_ :.&  "7C   C9$  'V2  !ME0  8)@  %2<  !(H   /J0  #2G   J
MJP  (:X  !FQ   2LP< #[40  ZU%P .M2$ #;4K  VU-@ ,MD$ "[9.  JV
M7  )MFP "+9_  >VE  &MJH !;;%  :VZ@ 'M?\ "+3_  BS_P )LO\ ";+_
M )J-  "0DP  A)@  '2<  !EH   5Z0  $NH  ! K   -;   "JS   AM0
M&+@  !&[   ,O@( !L +  + $0 !P1D  ,$B  #"*P  PC8  ,-"  ##4
MQ%\  ,1Q  #$AP  Q)T  ,2U  #$V@  Q/8  ,/_  ##_P  P_\  ,/_ ).4
M  "'F@  >*   &JF  !<K   3[$  $&U   UMP  *;H  !^]   6P   $,,
M  K&   #R@   ,P%  #,#   S1$  ,X8  #.(0  T"H  -$U  #30P  U%(
M -1C  #5>   U8\  -6G  #6P@  UND  -;]  #6_P  UO\  -;_ (J;  ![
MH@  ;*D  %ZP  !0M@  0KH  #2]   HP0  '<0  !3'   -RP  !LX   #2
M    UP   -D   #:!0  W L  -T0  #?%0  X1T  .,G  #E,P  YT(  .A4
M  #H9P  Z7X  .F7  #JKP  ZLX  .OO  #K_@  Z_\  .O_ 'VC  !NJP
M7[(  %&Z  !"P   -,,  "?'   ;RP  $L\   O3   "V    -T   #A
MY    .4   #G    Z0   .L'  #M#0  [Q$  /$9  #T)   ]S$  /E!  #Z
M50  ^FH  /N$  #[G0  _+8  /S2  #][0  _?0  /WT '&L  !AM0  4KT
M $3$   TR0  )LT  !K2   0V   "-T   #A    Y0   .@   #L    [P
M /$   #S    ]0   /<   #Y 0  ^P@  /X.  #_%0  _R$  /\O  #_00
M_U8  /]M  #_AP  _Z   /^V  #_R@  _]0  /_4 /\+( #_!QX _P = /\
M( #_ "4 _P N /\ .P#_ $D _P!6 /\ 8@#_ &T _P!V /\ ?P#_ (< _P".
M /\ E #_ )H _P"@ /\ I@#_ *T _P"U /\ O@#_ ,L _P#A /\ \ #^ /T
M_0#_ /T _P#] /\ _0#_ /P _P#Y /\ ^0#_ /\-'0#_"QH _P09 /\ &@#_
M !\ _P J /\ -P#_ $4 _P!1 /\ 7@#_ &@ _P!R /\ >@#_ (( _P") /\
MD #_ )8 _P"< /X H@#\ *D ^P"P /D N0#X ,8 ]@#9 /4 ZP#T /D \P#_
M /( _P#S /\ \P#_ /, _P#S /\ \P#_ /\0&0#_#A4 _P@4 /\ % #_ !D
M_P E /\ ,@#_ $  _P!, /\ 60#_ &, _@!M /P =0#Z 'T ^0"$ /< BP#V
M )$ ] "7 /, G@#R *0 \ "L .X M #M ,  ZP#/ .D Y@#H /4 Y@#_ .<
M_P#F /\ Y0#_ .4 _P#E /\ Y0#_ /\2% #_$!  _PP/ /\#$ #_ !4 _P @
M /\ + #_ #H _P!' /H 4P#W %X ] !G /$ < #O '@ [0!_ .L A@#J (P
MZ "3 .< F0#E *  XP"G .$ L #? +H W0#) -L X #8 /  UP#^ -4 _P#4
M /\ TP#_ -, _P#3 /\ TP#_ /\5$ #_$@P _PX) /\+# #_"1( _P,: /\
M)@#] #, ] !  .\ 30#K %@ Z !A .4 :@#B '( X !Z -X @ #< (< V@".
M -@ E0#4 )P T@"C -  K #. +8 S #$ ,H V0#( .T QP#[ ,4 _P#$ ?\
MPP'_ ,0!_P#$ ?\ Q '_ /\8"P#_%04 _Q   /\0!@#_#PT _PP4 /P''P#Q
M RL YP Y .( 1@#> 5$ V@); -4"9 #2 VP SP-T ,T$>P#+!(( R@2) ,@%
MD #&!9@ Q 6@ ,(&J0#!!K0 OP;! +T(U0"[">P N O] +8,_P"U#?\ M W_
M +0-_P"T#?\ M W_ /\;!0#_&   _Q<  /\6  #[$P8 ^A . .X,%@#C"2(
MV@DP -,*/@#."TH R@Q5 ,<-7@#%#6< P@YO ,$.=@"_#GX O0^% +P/C0"Z
M$)4 N!"= +<0IP"U$;( LQ'  +(1U0"N$^X JQ3^ *D5_P"G%?\ IQ7_ *84
M_P&F%/\!IA3_ ?\?  #_'   ^AX  .L>  #C'   WQ4% -X.#0#3#A@ RQ$H
M ,43-P# %$0 O!9/ +D760"W%V$ M!AI +,9<0"Q&7@ KQJ  *X:B "L&Y
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M _LI  #K,0  V3@  ,D\  "_/   MCD  + R  "L+0L IR\7 *(Q)@">,S0
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M"6]!N0IM0= *;$'N"6M"_PAJ0O\':D'_!FI!_P9J0?\%:D'_!>TW  #60@
MQ$D  +=-  "K30  H$H  )A'  "30@  CD,- (E%&@"&1B@ @T<T (!(/P!^
M2$@!>TA0 GE(5P)W2%\#=4AF!'-';@5Q1W8&;T> !VU&C EK1I@*:4:F"V=&
MM@MF1LP+94;L"V1'_PED1O\(9$;_!V1&_P9D1?\&9$7_!N@[  #01@  OTT
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M#%-3_ M34_\)5%+_"%12_PA44O\'5%+_!]I&  ##4   M5@  *A;  "96@
MC5@  (17  ![5   =E8! '%7#P!N61L ;%HH &E:,P!G6ST!95M% 6-;30)A
M6E4#7UI<!%U:9 5;66P&6%EV"%99@@E46(\+4EB>#%!8K@U/6,,-3ECD#$Y8
M^PM/5_\)3U?_"$]6_PA05O\'4%;_!]-*  # 5   LEP  *->  "570  B5P
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M!S]E_P<_9/\'/V3_!\-7  "S80  IVD  )9H  "'9P  >V<  '%G  !E:
M7&H  %AL 0!4;@X 4F\8 %!O) !.<"X 37 X $MQ00!*<4D!2'%1 49Q60)$
M<&(#0G!L!$!P> 4^<(8&/&^5!SIOI@@X;[L(.&_;!SAN]@<X;?\'.&S_!CEK
M_P8Y:O\&.6K_!KU<  "O9@  HFT  )%L  "":P  =VL  &QL  !A;@  5W
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M JMR  "A?   CWL  (!Z  !S>@  9GP  %M_  !0@@  1H8  #R*   TC0
M+)$  ":3#  DE!, (Y0< "*5)@ AE2\ ()4X !^60@ >EDP '998 !R69  :
MEW0 &9>& !B7F0 7EZX %9?) !:5[@ 6D_\!%I+_ 1:1_P$6D/\!%I#_ :5[
M  "9@P  B8$  'N   !L@@  7X0  %2(  !)BP  /Y   #64   MEP  )9H
M !V> 0 6H P %*$2 !2A&P 3H24 $J$N !&B.  1HD, $*)/  ^B7  .HVL
M#:-]  VCD@ ,HZ< "J+   NBY@ ,H/X #9__  V>_P -G?\ #9W_ )Z$  "2
MB0  @X@  '.(  !EBP  6(X  $R2  !!EP  -YL  "Z>   DH@  '*4  !6H
M   /JP0 "JX,  >M$@ &K1L !:TD  2N+@ "KCD  :Y%  "N4@  KF$  *YS
M  "NAP  KIT  *ZT  "NU0  K?0  *W_  "L_P  J_\  *O_ ):+  ",D
M>Y   &N2  !=E@  4)H  $2?   YHP  +Z<  "6K   <K@  %+$   ZT   )
MMP   ;@)  "X#@  N10  +D<  "Z)0  NB\  +LZ  "\1P  O%8  +QG  "\
M>P  O)$  +RI  "\Q   O.L  +O^  "[_P  N_\  +O_ )"2  "#F   <YL
M &.?  !5HP  1Z@  #NM   PL0  );0  !NW   2N@  #+T   6_    PP
M ,0"  #%"@  Q0X  ,84  #'&P  R"0  ,HN  #,.@  S4D  ,U9  #-;
MSH,  ,Z;  #-M0  SMH  ,[V  #-_P  S?\  ,W_ (:9  !WH   ::8  %JL
M  !,L@  /K8  #"Y   DO   &;\  !'"   *Q0   LD   #,    T    -$
M  #2 0  TP@  -4-  #7$0  VA@  -PA  #?+   X3H  .)*  #C70  Y'(
M .2+  #EI0  Y<   .7F  #E^   Y?\  .7_ 'JA  !KJ0  7*\  $VV   _
MO   ,+\  "/#   7QP  #\H   ?.    T0   -8   #<    WP   .    #B
M    Y    .8#  #H"0  Z0X  .P5  #N'@  \2L  /0Z  #U30  ]F$  /=Y
M  #XDP  ^*T  /G&  #YY   ^?,  /GS &VJ  !>L@  3[H  $#!   QQ0
M(LD  !;.   -T@  !-@   #=    X0   .0   #H    ZP   .T   #O
M\0   /,   #V    ^ ,  /H+  #]$0  _QL  /\I  #_.P  _T\  /]F  #_
M?P  _YD  /^O  #_PP  _]8  /_6 /\$' #_ !D _P 9 /\ ' #_ "( _P K
M /\ . #_ $8 _P!3 /\ 7@#_ &D _P!R /\ >@#_ (( _P") /\ CP#_ )4
M_P"; /\ H0#_ *@ _P"O /\ N0#_ ,4 _P#9 /X [ #] /L ^P#_ /L _P#[
M /\ ^@#_ /0 _P#P /\ \ #_ /\'& #_ 14 _P 4 /\ %@#_ !L _P F /\
M- #_ $( _P!. /\ 6@#_ &0 _P!M /\ =0#_ 'T _P"$ /\ B@#] )  _ "6
M /H G0#Y *, ^ "K /< M #U +\ ] #. /, Y@#Q /8 \ #_ .\ _P#O /\
M[@#_ .X _P#J /\ Z@#_ /\+% #_!A$ _P 0 /\ $ #_ !8 _P B /\ +@#_
M #P _P!) /\ 5 #^ %\ ^P!H /D < #W '@ ]0!_ /, A0#R (L \ "2 .\
MF #M )\ [ "F .H K@#H +D YP#' .4 W@#C /  X@#^ .  _P#@ /\ X0#_
M .$ _P#A /\ X0#_ /\-$ #_"0T _P$, /\ # #_ !( _P < /\ * #\ #8
M^0!# /8 3@#R %D [P!B .P :P#J '( Z !Y .8 @ #D (8 X@", .$ DP#?
M )H W0"A -L J@#8 +0 U0#  -( TP#0 .H S@#Z ,T _P#- /\ S0#_ ,P
M_P#, /\ S #_ /\0# #_# < _P," /\ " #_  X _P 6 /8 (@#P "\ [  \
M .D 2 #E %, X0!< -X 90#; &P UP!S -0 >@#2 (  T "' ,X C@#, )4
MR@"= ,@ I0#& *\ Q "[ ,( RP#  .4 O@#U +T _P"\ /\ O #_ +P _P"\
M /\ O #_ /\1!0#_#@  _PH  /\( 0#_! H ^  0 .D &@#C "@ W@ U -D
M00#3 $P SP!6 ,L 7P#) &8 Q@!N ,0 = #" 'L P0"" +\ B0"] )  O "8
M +H H0"X *L M@"W +0 QP"R .  L0'R *\"_P"N _\ K03_ *T$_P"M!/\
MK03_ /\4  #_$   _P\  /(-  #J"@  Z0,) -T $@#4 !\ S0$M ,@".@#$
M T4 P -0 +T$60"[!6$ N05H +<&;P"U!G8 M =] +('A "Q"(P KPB5 *T)
MG@"K":@ J@JU *@*Q0"F"]\ I WT *(._P"@#O\ GP[_ )\._P"?#O\ GP[_
M /\7  #_$P  [Q@  .09  #;%@  TA " ,\)"P#("!8 P0HD +P,,@"W#3X
MM Y) +$.4P"O$%L K1!C *L0:@"I$7$ J!%X *81@ "E$8@ HQ*1 *$2FP"@
M$Z8 GA.S )P3PP";%-X EQ;T )46_P"4%_\ DQ?_ )(7_P"2%O\ DA;_ /\:
M  #T'0  Y2,  -4E  #*)   PAT  +X6! "[$!  M!,= *\5*P"K%C@ IQA#
M *4930"B&58 H!I= )X;90"=&VP FQQS )H<>P"8'(, EQV- )4=EP"3'J(
MDAZO ) >OP"/']@ C"#Q 8D@_P&((/\!AR#_ 8<@_P&&(/\!AB#_ ?H>  #K
M)@  VBT  ,HP  "^+@  M2@  + B  "N&PP J!T7 *,?)@"?(3, G"(^ )DC
M2 "7)%$ E219 ),E8 "2)6< D"9N (XF=@"-)G\ BR:( 8HGDP&()YX!AB>K
M 80GNP&#*-$!@"CN 7XI_P%]*?\!?"C_ 7PH_P%\*/\!?"C_ ?4D  #C+@
MSS4  ,$X  "T-@  JS$  *4L  "B)@8 GB83 )DH(0"5*BX DBLY (\L1 "-
M+4P BRU4 (DN7 "'+F, ABYJ 80N<@&"+GH!@2^$ 7\OCP)]+YH">R^G GHO
MMP)X+\P"=C#J G4P_@)S,/\"<S#_ G,O_P)S+_\"<R__ O J  #<-0  QSL
M +H_  "L/   HC@  )PS  "8+P  E2X0 ) P' ",,BD B3,U (8T/P"$-4D
M@C51 ( U6 !^-5\!?35F 7LV;@%Y-78">#6  G8UBP-T-9<#<C:D W VM 1O
M-L@$;3;G!&PV_ -K-O\#:S;_ FHV_P)J-?\":C7_ NHP  #3.@  PD$  +-#
M  "E00  FSX  )4Z  "0-@  C#4- (@W& "$."4 @3HQ '\[/ !\.T4 >CQ-
M '@\50%W/%P!=3QC 7,\:@)Q/',"<#Q\ VX[AP-L.Y0$:CNA!&@[L05G/,4%
M93SE!60\^@1D//\#8SO_ V,[_P-C._\"8SO_ N4U  #-/P  O48  *Y'  "?
M10  E4,  (Y   ")/   A#P* ( ]% !]/B( >C\N 'A . !U04( <T%* ')!
M40%P05D!;D%@ FQ!9P)J07 #:$%Y V=!A 1E09$%8T&?!6%!K@9@0<(&7D'B
M!EY!^05=0?\$74#_ UU _P-=0/\#74#_ ]\Y  #(0P  N4H  *E+  ";20
MD$<  (A$  "#00  ?D$& 'I"$0!V0QX =$4J '%%-0!O1C\ ;49' &M&3P%J
M1E8!:$9= F9&90)D1FT#8D9V!&!&@@1>1HX%7$6<!EM%K 991K\'6$;?!EA&
M]P571?\$5T7_!%=$_P-81/\#6$3_ ]H]  #$1P  M4X  *1.  "63   BTL
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M!$E1_P1)4/\#25#_ \I(  "Y4@  JE<  )A6  "*50  ?U0  '93  !L40
M9U,  &)4" !?5A( 75<> %M7*0!96#, 6%@\ %991 !564P!4UE3 5%96P)/
M6&0"35AM TM8> 1)6(8%1U>5!D57I09$5[@&0UC2!D-7\@9#5O\%0U7_!$15
M_P1$5/\#1%3_ \9,  "U5@  I5H  )19  "&6   >U@  '%7  !F5@  85@
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M [=;  "I9   EF0  (9C  !X8P  ;6,  &1D  !990  4&@  $EK  !#;00
M0&X. #YO&  ];R( /' K #IP-  Y<3T .'%% #=Q3@ V<5< -'%A 3)Q;0$Q
M<7H!+W&* BUQG (K<:\"*G'( BIPZP(J;_\"*FW_ BIL_P(K;/\"*VS_ K%A
M  "D:0  D&@  (!G  !T9P  :6<  %]H  !5:P  2VX  $-Q   \=   -W8*
M #1W$@ S>!P ,G@E #%Y+@ P>3< +WD_ "YY2  L>E( *WI< "IZ:  H>G8
M)GJ' 25ZF0$C>JP!(GK% 2)YZ0$B=_\!(G;_ 2)U_P(B=/\"(W3_ JQH  "=
M;@  BFT  'ML  !O;   96P  %IN  !0<0  174  #UX   V?   +G\" "F!
M#0 G@A0 )H(> "6")P D@B\ (X,X "*#0@ A@TL ((16 !^$8@ >A'$ '(2"
M !N$E0 :A*D &(3! !B#Y@ 8@?T &8#_ 1E__P$9?O\!&7[_ :9P  "5<P
MA'(  '9Q  !K<0  7G,  %1V  !)>0  /WT  #>!   OA   )X@  ""+!0 ;
MC0X &HT5 !F-'@ 8CB< %XXP !:..0 5CD, %(]/ !./6P 2CVH $8][ !"/
MCP /CZ0 #H^[  V/X  .C?H #XO_ !"*_P 0B?\ $(G_ *%Z  ".>0  ?G<
M ')W  !D>   6'L  $U^  !"@@  .88  "^*   GC@  ()$  !B5   2F 4
M#IH.  V:%  ,FAT "YHF  N:,  *FCL "9I&  B:4P &FV$ !9IR  2:A@ "
MFIL  )JQ  &9SP "F?   IC_  27_P %EO\ !9;_ )F!  "'?P  >GX  &M^
M  !=@0  4(4  $6)   [C0  ,9(  "B6   ?F0  &)T  !&@   ,HP( !J4*
M  &E$   I18  *8?  "F*   IC(  *<]  "G2@  IU@  *=H  "G?   IY$
M *:H  "FPP  I>D  *7\  "E_P  I/\  *3_ )&'  ""A@  <H8  &.(  !5
MC   29$  #V6   RF@  *)X  !^B   7I@  $*D   NL   $KP   +$&  "Q
M#   LA$  +(7  "S'P  LR@  +0R  "U/P  M4T  +5=  "U<   M88  +6=
M  "UM@  M=P  +3W  "T_P  M/\  +3_ (N/  !ZC@  :I$  %N5  !-F@
M0)\  #6D   JJ   (*P  !:P   /M   ";<   &Y    O0   +X   "^!@
MOPP  , 0  #!%@  PAT  ,,G  #%,@  QD   ,91  #'8P  QW@  ,>1  #'
MJ0  Q\<  ,?L  #'_@  Q_\  ,?_ (.7  !QF@  89X  %*C  !%J0  .*X
M "RS   @MP  %KH   Z]   &P    ,,   #'    R0   ,H   #,    S0,
M ,X)  #0#@  TA,  -0;  #8)0  VS(  -U"  #=5   WFD  -Z!  #>G
MW[4  -_9  #?\P  W_\  -__ '>?  !HI@  6:T  $JS   [N   +;L  !^_
M   4P@  #,8   /)    S    -    #5    V0   -H   #<    W@   .
M  #B!0  Y L  .<0  #J&   [20  / R  #Q1   \E@  /-O  #TB@  ]*0
M /2_  #TWP  ]/,  /3T &JH  !;KP  3+<  #V]   MP0  '\8  !/*   +
MS@   -(   #7    W    .    #E    YP   .D   #K    [0   .\   #Q
M    \P   /8'  #Y#@  _!8  /\B  #_,P  _T<  /]=  #_=@  _Y$  /^I
M  #_O@  _]@  /_; /\ & #_ !8 _P 5 /\ & #_ !X _P G /\ -@#_ $,
M_P!/ /\ 6@#_ &0 _P!M /\ =0#_ 'T _P"$ /\ B@#_ )  _P"6 /\ G #_
M *, _P"K /\ M #^ +\ _0#/ /L YP#Z /@ ^0#_ /D _P#Y /\ ]0#_ .X
M_P#I /\ YP#_ /\ % #_ !$ _P 1 /\ $@#_ !< _P C /\ ,0#_ #X _P!*
M /\ 5@#_ &  _P!H /\ < #_ '@ _0!^ /P A0#Z (L ^0"1 /@ F #W )X
M]0"F /0 K@#R +D \0#' .\ X #N /( [ #_ .P _P#L /\ ZP#_ .4 _P#@
M /\ W@#_ /\#$ #_  X _P - /\ #0#_ !, _P > /\ *P#_ #@ _P!% /X
M4 #[ %H ^ !C /4 :P#S '( \0!Y .\ ?P#N (8 [ ", .H D@#I )D YP"@
M .8 J0#D +, X0#  .  TP#> .L W #[ -L _P#: /\ V@#_ -D _P#4 /\
MT@#_ /\'#0#_  D _P & /\ "0#_  \ _P 8 /L )0#X #( ]0 _ /( 2@#M
M %0 Z@!= .< 90#D &P X@!S .  >@#> (  W "& -H C0#7 )0 U "; -(
MI #/ *T S0"Y ,L R0#) .0 R #V ,8 _P#% /\ Q@#_ ,< _P#' /\ QP#_
M /\*!@#_ 0  _P   /\ ! #_  L ]  2 .\ 'P#J "P Y0 X .( 0P#= $X
MV0!7 -0 7P#1 &< S@!M ,P = #* 'H R "  ,8 AP#% (X PP"6 ,$ G@"_
M *@ O0"S +H P@"Y -L MP#P +4 _P"V /\ M0#_ +4 _P"U /\ M0#_ /\,
M  #_!   _P   /X   #V  , Z  - .  %P#9 "0 T0 Q ,T / #* $< Q@!1
M ,, 60#  &  O@!G +P ;@"Z '0 N0![ +< @@"U (D LP"1 +( F@"P *0
MK@"O *P O0"J -  J #K *< ^P"F /\ I@#_ *4 _P"E /\ I0#_ /\-  #_
M!P  ] D  .H)  #B!   V@ ' ,\ $0#( !P P@ I +X -0"[ $  MP!* +0
M4P"R %L L !B *X : "L &\ JP!U *D ?0"H (0 I@"- *0 E@"C *  H0"K
M )\!N0"= \P G 3H )H&^0"9!_\ F C_ )<(_P"7"/\ EPC_ /\0  #W$
MZ!0  -P5  #.$0  Q@T  ,($"P"\ !0 MP$A +(#+@"N!3H JP9$ *@(30"F
M"%4 I E< *(*8P"@"FH GPMQ )T+> "<"X  F@R) )D,DP"7#)X E0VJ )0-
MN "2#<P D [J (X0_ ",$/\ BQ#_ (L0_P"+$/\ BA#_ /L3  #M&@  W2
M ,PA  "_'0  MQ<  +,1  "R"PT JPT9 *<.)@"C#S, GQ ^ )T11P":$5
MF!)7 )827@"5$V4 DQ-L )(3<P"0%'P CQ2% (T5CP"+%9H BA6G (@6M0"&
M%LD A!?G ((8^P" &?\ ?QG_ '\9_P!_&/\ ?QC_ /4:  #D(P  SRD  , J
M  "S)@  JB(  *4<  "D%0@ H!03 )L6(0"7&"T E!DX )$:0@"/&TL C1Q2
M (L<60")'6  B!UG (8>;P"%'G< @Q^  ((?BP" 'Y< ?B"C 'T@L@![(,4
M>2'D '<B^0!V(O\ =2+_ '0A_P!T(?\ ="'_ .\A  #;*P  QS$  +8Q  "I
M+@  H"H  )LF  "8(0$ E1X0 ) @&P"-(2@ B2,S (<D/0"%)$8 @R5. ($F
M50!_)EP ?B9C 'PG:P![)W, >2=\ '@HAP!V*), ="B@ 7(HKP%Q*<$!;RG@
M 6TI]P%L*?\!:RG_ 6LI_P%K*/\!:RC_ >@H  #0,@  P#@  *XW  "A-0
MF#(  )(M  ".*0  BR<, (<H%P"#*B, @"LO 'XL.0!\+$( >BU* '@N40!W
M+E@ =2Y@ ',O9P!R+V\ <"]Y 6\O@P%M+Y !:R^= 6DOK %H,+X!9S#; 64P
M]0%D,/\!8S#_ 6,O_P%C+_\!8R__ >(N  #*.   NCT  *@\  ":.@  D3<
M (HS  "&,   @RX) '\O$P![,!\ >#(K '8S-0!T,SX <C1& ' T3@!O-54
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M.P  =#H  '$Z#@!M/!@ :STD &D^+P!G/S@ 93]  &1 2 !B0$\ 84!7 %]
M7@%=0&8!7$!O 5I >@)80(<"5D"5 E1 I -30+8#4D#/ U% [P-00/\"4#__
M_^+__TE#0U]04D]&24Q%  8) E __P)1/O\!43[_ <\[  "]10  JD<  )E&
M  "+10  @40  'E"  !T/@  ;S\  &M # !G014 94(A &-#*P!A0S4 7T0^
M %Y$10!=14T 6T54 %E%7 %8160!5D5M 51%> )2184"4423 T]$HP--1;0#
M3$7, TM%[0-+1/\"2T3_ DM#_P),0O\"3$+_ LH_  "Y2   IDH  )5)  "'
M2   ?4<  '5%  !N0@  :4,  &5$"0!B11, 7T8> %U'* !<2#( 6D@[ %E)
M0P!724H 5DE2 %1)60%326$!44EK 4])=@)-28("2TF1 TI)H0-(2;,#1TG*
M T9)[ -&2/\"1DC_ D='_P)'1O\"1T;_ L9#  "V3   HDP  )%,  "$2P
M>4H  '!)  !I1@  9$<  %])!@!<2A  6DL; %A,)0!63"\ 54TX %--0 !2
M34@ 44Y/ $].5P!.3E\!3$YI 4I.<P)(38 "1DV/ T5-GP-#3;$#0DW( T%-
MZ@-!3/\"04S_ D)+_P)"2O\"0DK_ L)'  "S3P  GD\  (U.  " 3@  =4T
M &Q,  !C2@  7DP  %I- @!63@X 5$\8 %)0(@!142P 3U$U $Y2/0!-4D4
M3%)- $I25 !)4ET!1U)F 452<0%#4GX"05*- C]2G0,^4J\#/5+& SQ2Z0(\
M4?X"/%#_ CU/_P(]3_\"/4[_ KY+  "N4P  FE(  (E1  !\40  <5   &A0
M  !>3@  6%$  %12  !14PP 3E04 $Q5'P!+5BD 258R $A6.@!'5T( 1E=*
M $174@!#5UH 05=D 4!7;@$^5WL"/%>+ CI7FP(X5ZT"-U?$ C=7YP(W5OT"
M-U7_ C=4_P(W4_\".%/_ KI/  "I5@  E54  (54  !X5   ;50  &14  !8
M5   4E8  $Y7  !*60D 1UH1 $9:&P!$6R4 0ULN $)<-@!!7#X /UQ& #Y=
M3P ]75< .UUA #I=; $X77D!-EV( 31=F0(S7:L",5W" C%<Y0(Q6_P",5K_
M C%9_P(R6?\!,EC_ ;94  "D60  D%@  (!8  !S5P  :5<  &!8  !460
M3EL  $A=  !#7P0 0& . #YA%P ]82  .V(I #IB,@ Y8CH .&-" #=C2P V
M8U0 -&-= #-C:  Q8W8!+V.% 2YCE@$L8ZD!*V._ 2ICXP$J8OL!*F#_ 2M?
M_P$K7_\!*U[_ ;%9  ">7   BUP  'M;  !O6P  95L  %Q<  !17@  26
M $-B   \90  .&<* #5H$@ T:!L ,VDD #)I+0 Q:34 +VH] "YJ1@ M:D\
M+&I9 "MK90 I:W( *&N" "9KDP D:Z< (VN] ")JX  C:?D!(V?_ 2-F_P$C
M9O\!)&7_ :Q@  "88   A6   '9?  !J7P  86   %=@  !-8P  1&8  #UH
M   V:P  ,&X$ "QP#@ J<14 *7$> "AQ)@ G<B\ )G(W "5R0  D<DH (G)4
M "%S8  @<VT 'G-] !USD  ;<Z, &G.Y !ESW  :<?< &G#_ !MO_P ;;O\!
M&VW_ :9F  "190  ?V0  '%D  !F9   760  %)F  !(:0  /VP  #=O   P
M<P  *78  ")Y"  ?>Q  'GL7 !Q['P ;>R@ &GLP !E\.0 8?$, %WQ. !9\
M6@ 5?&< %'UX !)]BP 1?9\ $'VU  ]]U0 0>_4 $7G_ !%X_P 2=_\ $G?_
M )YK  "*:@  >FD  &UI  !B:0  5VH  $QM  !#<   .70  #%X   I>P
M(G\  !N"   4A0D $880 !&&%P 0AQ\ $(<H  Z',0 .ASL #8=&  R'4P +
MAV$ "H=Q  F'A  'AY@ !H:N  6&R0 &A>P !X3_  B#_P )@O\ "8+_ )5Q
M  "#;P  =&X  &EN  !<;P  4'(  $9U   \>0  ,GT  "J!   BA0  &XD
M !2,   /CP, "I(+  :2$0 $DA@  I(@  &2*0  DC,  ),^  "32P  DUD
M )-I  "3>P  DI   )*F  "1OP  D>4  )#Z  "/_P  C_\  (__ (UW  !]
M=0  <'0  &)U  !5>   27P  #^    TA   *XD  "*-   :D0  $Y0   Z7
M   )FP   9T(  "=#@  G1,  )X:  ">(@  GRL  )\U  "@0@  H%   *!?
M  "@<0  H(<  )^=  "?M0  GMH  )WV  "=_P  G/\  )S_ (9]  !X?
M:7P  %M_  !.@P  08@  #:,   LD0  (Y8  !J:   2G@  #:$   :D
MIP   *D#  "I"@  J@X  *L3  "L&0  K2(  *XK  "O-P  KT4  *]4  "O
M9@  KWL  *Z4  "NJP  KLD  *[O  "M_P  K?\  *W_ (&$  !QA   88<
M %.+  !&D   .98  "Z;   CH   &J0  !*H   ,K   !*\   "R    M@
M +<   "W @  N @  +D-  "Z$@  NQ@  +TA  "^*P  P#@  ,!(  # 6@
MP6X  ,&&  #!H   P;H  ,'C  # ^0  P/\  ,#_ 'F-  !HD   690  $N:
M   ]H   ,:4  "6K   :KP  $;,   NX   "NP   +X   #!    Q    ,4
M  #&    QP   ,@%  #*"P  S \  ,X5  #0'P  TRL  -4Z  #53   UF
M -AW  #8D@  V*P  -G)  #9[   V?L  -C_ '"9  !@G@  4:0  $.J   U
ML   *+8  !RZ   1O@  "<$   #%    R    ,L   #/    T@   -,   #6
M    V    -L   #=    WP<  .(-  #E$P  Z!T  .PJ  #M/   [5$  .YG
M  #O@0  [YP  /"W  #PTP  \.P  /#T &>F  !8K0  2;0  #JZ   JO@
M',(  !#&   'R@   ,X   #2    U@   -P   #@    XP   .0   #F
MZ    .L   #M    [P   /("  #U"@  ^!$  /P<  #_+   _S\  /]5  #_
M;@  _XH  /^D  #_N@  _]$  /_A /\ % #_ !( _P 2 /\ % #_ !D _P E
M /\ ,@#_ #\ _P!+ /\ 5@#_ &  _P!H /\ < #_ '@ _P!_ /\ A0#_ (L
M_P"1 /\ F #_ )X _@"F /T K@#\ +D ^@#( /D X@#X /0 ]P#_ /8 _P#V
M /\ [P#_ .< _P#B /\ W@#_ /\ $0#_  X _P . /\ #P#_ !0 _P @ /\
M+0#_ #H _P!& /\ 40#_ %L _P!C /X :P#\ ', ^@!Y /D @ #W (8 ]@",
M /4 D@#S )D \@"@ /  J0#N +, [0#! .L U@#J .X Z0#^ .< _P#G /\
MY0#_ -T _P#5 /\ T0#_ /\ #0#_  H _P ( /\ "0#_ !  _P ; /\ * #_
M #4 _P!  /H 2P#V %4 \P!> /$ 9@#N &T [ !T .L >@#I (  YP"& .8
MC0#D ), X@"; .  HP#> *T W "Y -H R@#7 .8 U #X -( _P#2 /\ T@#_
M ,X _P#) /\ Q@#_ /\ " #_  , _P   /\  P#_  T _  6 /< (@#S "X
M[P Z .P 10#H $\ Y !8 .$ 8 #> &< VP!M -D = #5 'H TP"  -$ AP#/
M (X S0"5 ,L G@#) *< QP"S ,4 P@## -P P0#Q +\ _P"_ /\ O@#_ +X
M_P"] /\ NP#_ /\   #_    _P   /\   #V  @ [@ 1 .< &P#A "< W0 S
M -D /@#3 $D SP!2 ,L 60#( &$ Q@!G ,0 ;0#" ', P !Z +\ @ "] (@
MNP"0 +D F "X *( M0"M +, NP"Q ,X L #J *\ _ "M /\ K0#_ *X _P"N
M /\ K@#_ /\"  #_    _0   /(   #H    W@ , -, %0#, "$ R  L ,0
M. #! $( O0!+ +H 4P"X %H M@!A +0 9P"R &T L !T *\ >@"M (( K "*
M *H DP"H )T I@"H *0 M0"B ,8 H0#C )\ ]@"> /\ G@#_ )X _P"> /\
MG@#_ /\&  #[    [@4  .($  #5    RP & ,, #P"] !D N  E +0 ,0"Q
M #L K@!% *P 30"I %4 IP!; *4 8@"D &@ H@!N *$ =0"? 'P G@"% )P
MC@": )@ F "D )8 L "5 ,$ DP#< )( \@"1 /\ D #_ )  _P"/ /\ CP#_
M /T*  #P#@  X1$  ,X0  #"#0  NP<  +< "@"Q !( K  > *@ *0"E #0
MH@ ^ )\ 1P"= $\ FP!6 )D!7 "7 6, E@)I )0"< "3 W@ D0.  ) $B@".
M!)4 C 6A (H%K@")!KX APC8 (8)\ "$"O\ @PO_ (,+_P"#"_\ @PO_ /80
M  #F%P  TAP  , :  "S%@  K!(  *@-  "F!PT H@46 )T'(@"9"2X E@HX
M )0+00"2#$H D Q1 (X-6 ",#5X BPUE (D-; "(#G0 A@Y] (4.AP"##I,
M@0^? ( 0K0!^$+X ?1#; 'H1] !X$O\ =Q+_ '<2_P!W$O\ =Q+_ .\7  #;
M(0  QB0  +0C  "H(   H!P  )L7  "9$00 F X0 ),0&P"/$2< C!(R (D3
M/ "'$T0 A11, (,44P"!%5H @!5@ 'X6: !]%F\ >Q9X 'D7@P!X%X\ =AB<
M '08J@!S&;L <AG4 &\:\0!N&_\ ;1O_ &T:_P!M&O\ ;1K_ .<@  #0*0
MO"L  *LJ  ">*   EB0  ) @  "-'   C!<, (@8%@"$&B( @1LM 'X<-P!\
M'4  >AU( 'D>3P!W'E4 =A]< '0?8P!S'VL <2!T ' @?P!N(8L ;"&8 &LA
MIP!I(K@ :"+/ &8B[@!E(_\ 9"/_ &0B_P!D(O\ 9"'_ . F  #(+P  M#$
M *,P  "6+@  C2L  (<H  "$)   @B ( 'X@$@![(AX >",I '4D,P!S)3P
M<25# ' F2P!N)E( ;2=9 &LG8 !J)V@ :2AQ &<H>P!E*(@ 9"F5 &(II !@
M*;4 7RG+ %XJ[ !<*O\ 7"G_ %PI_P!<*?\ 7"C_ -@L  ##-0  K34  )TT
M  "0,P  AC$  ( M  !\*P  >2@# '8G$ !R*1H <"HE &TK+P!K+#@ :BQ
M &@M1P!G+4X 92Y5 &0N70!C+F4 82]N %\O> !>+X0 7"^2 %HOH0%9+[(!
M6##( 58PZ0%5,/X!52__ %4O_P!5+O\ 52[_ - Q  "].@  J#D  )<X  "*
M-P  @#8  'HR  !U,   <BX  &XN#0!K+Q8 :3 A &8Q*P!D,C0 8S(] &$S
M1 !@,TL 7S12 %TT6@!<-&( 6C1K %DU=0!7-8( 5360 50UGP%2-; !437&
M 5 UYP%/-?T!3S7_ 4\T_P%/-/\!3S/_ <LV  "X/0  HSP  )(\  "%.P
M>SH  '0W  !O-0  ;#,  &@T"@!E-1, 8C8> & W* !>-S$ 73@Z %LX00!:
M.4@ 63E0 %<Y5P!6.E\ 5#IH %,Z<P!1.G\!3SJ- 4XZG0%,.JX!2SK# 4HZ
MY0%).OP!23G_ 4DY_P%)./\!2CC_ <<Z  "S0   GC\  (X_  "!/@  =ST
M ' [  !J.   9C@  &(Y!P!?.A$ 7#L; %H[)0!9/"X 5STW %8]/@!4/D8
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M 3I%_P$[1?\!.T3_ ;M%  "F2   DD<  ()'  !V1P  :T<  &-&  !;0P
M5D4  %)'  !.2 H 3$D2 $I)' !(2B4 1THN $9+-@!%2SX 0TM& $),30!!
M3%8 0$Q? #Y,:@ \3'8 .TR% 3E,E0$W3*<!-DR\ 35,W0$U2_<!-4O_ 35*
M_P$V2?\!-DG_ ;A)  "B2P  CDH  'Y*  !R2@  :$H  %])  !52   4$H
M $Q+  !)3 < 1DT0 $1.&0!"3R( 04\K $!0,P _4#L /E!# #Q12@ [45,
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M *A5  "25   @%0  '%4  !F5   7%0  %15  !*5@  0U@  #Q;   V70
M,& % "UA#@ K814 *F(= "EB)0 H8BX )V,V "9C/@ E8T< (V-1 ")D7  A
M9&D 'V1Y !YDB@ <9)X &V2S !EDS@ :8_$ &V'_ !M@_P <8/\ '%__ *%9
M  ",6   >U@  &U8  !B6   65@  %!9  !'6P  /EX  #=@   Q8P  *F8
M "1I"0 A:A  (&H7 !]J(  >:R@ '6LP !QK.0 ;:T( &FQ, !EL6  7;&4
M%FQT !1LA@ 3;)H $FRO !%LR@ 1:^\ $FG_ !-H_P 3:/\ $V?_ )E=  "%
M70  =5P  &A<  !>7   55P  $M>  !"80  .60  #)G   K:@  )&T  !YP
M 0 7<PL %701 !1T&  3="$ $G4I !%U,@ 1=3L $'5&  ]U4@ .=5\ #75N
M  QU@0 +=94 "G6J  ATPP )=.< "G/]  MQ_P ,<?\ #'#_ )%B  !_80
M<&$  &1A  !:80  3V(  $5E   \:   ,VP  "MO   D<@  '78  !=Y   1
M? 0 #7\,  M_$@ *?QD "7\B  A_*@ &?S0 !7\_  1_2P "?U@  7]G  !_
M>0  ?XX  '^C  !^NP  ?>   'WW  !\_P  >_\  'O_ (EG  !X9P  :V8
M &%F  !49P  26D  #]M   U<0  +'4  "1Y   =?   %H   !"#   ,A@(
M!HD*  &)#P  B10  (H;  "*(P  BRP  (LW  "+0P  BU   (M?  "+<0
MBX8  (N<  "*LP  B=,  (CS  "(_P  A_\  (?_ ()M  !S;   :&P  %IM
M  !.;P  0G,  #AW   N>P  )8   !V$   5B   $(P   N/   $D@   )0&
M  "5#   E1   )85  "7'   F"0  )@N  "9.0  F4<  )E6  "9:   F7T
M )F4  "8JP  E\@  );N  "6_P  E?\  )7_ 'MT  !O<P  87,  %-V  !&
M>@  .W\  #"$   FB   '8T  !22   .E@  "9D   &<    H    *$   "B
M!@  H@P  *00  "E%   I1P  *<D  "H+P  J#T  *E,  "I7@  J7(  *B)
M  "HH@  J+P  *?E  "F^P  IO\  *7_ '=[  !H>P  67X  $N"   ^AP
M,HT  ">2   =EP  %)P   Z@   'I    *@   "K    K@   *\   "P
ML00  +,*  "T#@  M1,  +8;  "X)   NC$  +I   "Z4@  NV4  +M]  "Z
MEP  NK$  +K2  "Z\P  N?\  +G_ &^#  !?A@  48L  $.0   VEP  *IT
M !^B   5IP  #:P   6P    M    +<   "[    O@   +\   #     P0
M ,,!  #$!P  Q0T  ,<1  #*&0  S20  ,XS  #/1   T%@  -!N  #1B
MT*0  -#!  #1Y@  T?@  -'_ &>/  !7E   29H  #NA   NIP  (:T  !:S
M   .N   !KP   #     PP   ,8   #+    S0   ,X   #0    T0   -0
M  #6    V@(  -P)  #?#P  XQ<  .8D  #G-@  Z$D  .E?  #J>   ZY0
M .NO  #KS   [.@  .SV %^>  !0I   0JL  #2R   FN0  &;X   ["   $
MQ0   ,H   #-    T0   -@   #;    WP   .    #B    Y    .8   #I
M    ZP   .X   #Q!0  ]0T  /D6  #\)0  _3D  /Y/  #_9P  _X(  /^=
M  #_M0  _\L  /_D /\ $0#_  \ _P / /\ $0#_ !8 _P B /\ +P#_ #L
M_P!' /\ 4@#_ %L _P!D /\ ; #_ ', _P!Z /\ @ #_ (8 _P", /X DP#]
M )D ^P"A /H J0#X +0 ]P#" /8 V@#U /$ ] #_ /, _P#S /\ Z0#_ .
M_P#8 /\ TP#_ /\ #@#_  L _P * /\ "P#_ !$ _P = /\ *@#_ #8 _P!!
M /\ 3 #_ %8 _@!? /L 9@#Y &T ]P!T /4 >@#T (  \@"& /  C0#O )0
M[0"; .P I #J *X Z0"Z .< S0#E .D Y #[ ., _P#B /\ W@#_ -$ _P#,
M /\ R #_ /\ "0#_  0 _P ! /\ ! #_  X _P 8 /\ ) #] #  ^P [ /<
M1@#S %  [P!9 .P 8 #J &< YP!N .8 = #D 'H X@"  .  AP#> (X W "5
M -H G@#6 *@ U "S -$ PP#/ -\ S@#T ,P _P#+ /\ RP#_ ,4 _P"_ /\
MO #_ /\  @#_    _P   /\   #]  L ]P 3 /$ '@#M "H Z@ U .< 0 #B
M $H W0!2 -D 6@#5 &$ T@!G -  ;0#. ', S !Z ,H @ #( (< Q@"/ ,0
MF #" *$ P "M +X NP"\ -  N@#M +D _@"X /\ N #_ +< _P"S /\ L #_
M /\   #_    _P   /D   #N  4 Y0 . -X & #8 ", T@ N ,\ .0#+ $,
MQP!, ,0 5 #! %L OP!A +P 9P"[ &T N0!S +< >@"U ($ M ") +( D@"P
M )L KP"G *P M "K ,8 J0#D *< ^ "F /\ I@#_ *4 _P"E /\ I #_ /\
M  #_    ]0   .H   #>    T  * ,@ $@#" !T O@ H +L ,P"Y #T M0!&
M +( 30"P %4 K0!; *P 80"J &< J !M *< <P"E 'H I "" *( C "@ )8
MGP"A )T K@"; +X F0#8 )< \0"6 /\ E@#_ )< _P"7 /\ EP#_ /\   #U
M    YP$  -0   #)    P  $ +@ #@"S !8 KP A *L + "H #8 I@ _ *,
M1P"A $\ GP!5 )T 6P"; &$ F@!G )@ ;@"7 '4 E0!] )0 A@"2 )$ D "<
M (X J0", +@ BP#- (D ZP"( /T B #_ (@ _P"( /\ B #_ /D&  #I#
MU X  ,,,  "W"0  L (  *L "0"F !  H@ : )X )0"; #  F  Y )8 00"4
M $D D@!0 )  5@". %P C0!B (L :0"* '  B !X (< @0"% (P A "8 ((
MI0"  +0 ?@#( 'T!YP!\ OD >P/_ 'L$_P![!/\ >P3_ /$.  #>%0  Q14
M +04  "I$0  H0X  )X*  "; PP EP 3 ), '@"0 2D C0(S (H#/ "(!$,
MA@5+ (4&40"#!E< @@=> ( '9 !_"&P ?0AT 'P(?@!Z"8D > F6 '<*HP!U
M"K, <PO' '(,Y@!P#?L < W_ &\-_P!O#?\ ;PW_ .@6  #0'@  N1T  *D<
M  "=&@  E18  ) 3  "/#@, C@H. (D+%P"&#", @PTM ( --@!^#CX ? Y&
M 'L.30!Y#U, >!!: '8080!U$&@ <Q!Q '$1>P!P$8< ;A&4 &P1H@!K$K(
M:1+' &@3YP!F$_T 913_ &44_P!E$_\ 91/_ -\>  #&)   L"0  * C  "4
M(0  BQ\  (8;  "#%P  @A(( '\1$@!\$AT >10H '84,0!T%3H <A9! '$6
M2 !O%T\ ;A=6 &P770!K&&0 :1AM &@9=P!F&8, 9!F0 &,:GP!A&J\ 8!K$
M %X;Y !='/L 7!S_ %P;_P!<&_\ 7!O_ -4E  "]*@  J"D  )@I  ",*
M@R4  'TB  !Y'P  >!L# '89#P!R&A@ ;QPC &T=+0!K'34 :1X] &@>1 !F
M'TL 91]2 &,@60!B(&$ 82!I %\A<P!=(7\ 7"&- %HBG !9(JP 5R+  %8C
MX0!5(_D 5"/_ %0B_P!4(O\ 5"+_ ,TK  "V+@  HBX  )(N  "%+0  ?"L
M '8H  !R)@  ;R,  &TA# !J(A4 9R,? &4D*0!C)#$ 8B4Y & F00!?)D@
M729/ %PG5@!;)UT 62=F %@H< !6*'P 5"B* %,IF0!1*:H 4"F^ $\IW@!.
M*?< 32G_ $TI_P!-*/\ 3BC_ ,@P  "P,@  G#(  (PR  " ,0  =C   ' M
M  !K*P  :"D  &8H"0!C*!$ 8"D< %XJ)0!<*RX 6RLV %DL/0!8+$0 5RU,
M %4M4P!4+5L 4RUC %$N;@!0+GH 3BZ( $POEP!++Z@ 22^[ $@OVP!(+_8
M1R__ $<N_P!'+?\ 2"W_ ,0T  "K-0  ES4  (<U  ![-0  <C0  &LR  !F
M+P  8BX  %\M!0!<+A  6B\8 %@P(@!6,"L 53$S %,Q.@!2,D( 43)) % R
M4 !.,U@ 33-A $LS:P!*,W< 2#2% $<TE0!%-*8 0S2Y $(TU@!"-/0 0C3_
M $(S_P!",O\ 0C+_ , X  "G.   DS@  (,X  !W.   ;3<  &8V  !A,P
M73(  %DR @!7,PT 5#05 %(U'P!1-2@ 3S8P $XV. !,-S\ 2S=& $HW3@!)
M.%8 1SA? $8X:0!$.'4 0SB# $$YDP! .:0 /CFX #TYTP \.?, /#C_ #TW
M_P ]-_\ /3;_ +L[  "B.P  CSL  '\[  !S.P  :CH  &(Y  !=-P  6#8
M %0W  !1. L 3SD3 $TY' !+.B4 2CHM $@[-0!'.SP 1CQ$ $4\2P!$/%,
M0CQ< $$]9P _/7, /CV! #P]D0 Z/:, .3VV #@]T0 W/?( -SS_ #@[_P X
M._\ .#K_ +8]  ">/@  BSX  'P^  !O/@  9CT  %X]  !8.P  4SH  $\[
M  !,/ @ 23T1 $<^&0!&/R( 1#\J $,_,@!"0#H 04!! $! 20 ^05$ /4%:
M #Q!9  Z07  .$%_ #=!CP U0J$ -$*T #)"S@ R0?  ,D#_ #- _P S/_\
M-#[_ +%   ":0   AT   'A!  !L00  8D   %M   !4/P  3C\  $I   !&
M004 1$(. $)#%@! 0Q\ /T0G #Y$+P \1#< .T4^ #I%1@ Y14X .$98 #9&
M8@ U1FX ,T9\ #%&C0 P1I\ +D:S "U&S  M1N\ +47_ "Y$_P N0_\ +D/_
M *Q#  "60P  @T,  '1#  !H0P  7T,  %=#  !00P  2$,  $1%  !!1@$
M/D<, #Q($P Z2!P .4DD #A)+  V230 -4H[ #1*0P S2DP ,DI5 #!+7P O
M2VL +4MZ "Q+BP J2YT *$NQ "=+R@ G2^T )TK_ "A)_P H2/\ *4?_ *=&
M  "11@  ?T8  '!&  !E1@  6T8  %1&  !,1P  1$@  #]*   [2P  -TP)
M #5-$  S3A@ ,DX@ #%/*  P3S  +T\X "Y/0  L4$@ *U!2 "I07  H4&@
M)U!W "50B  D4)L (E"O "%0R  @4.L (4__ ")._P B3?\ (TW_ *%)  ",
M20  >DD  &Q*  !A2@  6$H  %!*  !)2P  0$P  #M.   U4   ,5($ "U3
M#0 L5!0 *E0< "E5)  H52P )U4S "95/  E5D4 )%9. ")660 A5F4 'U9T
M !Y6A0 <5I@ &U:L !E6Q0 95ND &E7_ !M4_P ;4_\ '%+_ )M-  "&30
M=4T  &A-  !=30  5$T  $U.  !%3P  /%$  #93   Q50  *U@  "9:"0 C
M6Q  (EL7 "%<'P @7"< 'UPN !U<-P <74  &UU* !I=50 876$ %UUP !5=
M@0 4794 $UVJ !%=P@ 17>< $EO^ !-:_P 36O\ %%G_ )11  " 40  <%$
M &11  !940  45$  $E2  !!4P  .%8  #)9   K6P  )5X  !]A P :8PP
M&&01 !=D&0 69"$ %60I !1E,0 393H $F5$ !%E4  095T #V5K  YE?0 -
M99$ #&6E  IDO  *9.  "V/Y  QB_P -8?\ #6'_ (U5  !Z50  :U4  %]5
M  !650  3E4  $17   \60  -%P  "Q?   F8@  'V4  !EH   3:P4 $&T-
M  YN$@ -;AH #&XB  QN*P +;C0 "FX^  AN2@ ';E< !FYE  1N=@ ";HH
M &V?  !MM@  ;-8  &SS  %K_P ":O\  VK_ (5:  !T6@  9EH  %Q9  !3
M60  2%H  #]=   V8   +F,  "9G   ?:@  &6T  !-Q   .= , "G<*  5W
M$  !=Q4  '<<  !W)   >"T  '@W  !X0P  >%   'A>  !X;P  >(0  'B9
M  !WL   =LT  '7P  !U_P  =/\  '3_ 'Y?  !N7P  8EX  %E>  !-7P
M0F(  #EE   P:   )VP  !]P   8=   $G<   U[   (?@   H (  "!#0
M@1$  ((7  "#'@  @R8  (0P  "$.P  A$@  (17  "$:   A'P  (23  "#
MJ@  @L4  ('K  "!_@  @/\  (#_ '=E  !I9   7V,  %)D  !'9P  /&L
M #%O   H<P  ('<  !A\   1?P  #(,   :'    B@   (P#  ","0  C0X
M (X1  "/%P  D!X  )$G  "2,@  DC\  )).  "27P  DG,  )*+  "1H@
MD;P  )#E  "/_   CO\  ([_ '%K  !F:@  6&L  $MM   _<0  -'8  "I[
M   @@   %X4  !")   +C0  !)$   "5    F    )D   ": P  FP@  )P-
M  ">$0  GQ8  * >  "B*   HC4  *-$  "C50  HVD  **   "BF@  H;,
M *#8  "@]@  G_\  )__ &YQ  !?<@  474  $1Y   W?@  +(0  "&*   7
MCP  $)0   J9   !G0   *    "D    IP   *@   "I    J@   *P&  "M
M"P  KQ   + 5  "R'@  M"D  +0Y  "T2@  M5T  +5S  "UC@  M:@  +3&
M  "S[0  LO\  ++_ &9Z  !7?0  28(  #R'   OC@  (Y0  !B:   0GP
M":0   "I    K0   +    "T    MP   +@   "Y    NP   +P   "^ @
MP @  ,(.  #$%   QQX  ,@L  #)/0  RE   ,IF  #*?P  RIL  ,JX  #*
MW0  RO4  ,K_ %Z&  !/BP  09$  #.8   GGP  &Z4  !&K   )L    +4
M  "Y    O0   ,$   #&    R    ,D   #+    S    ,X   #0    T@
M -0%  #9#   W1(  .$>  #B+@  XT(  .17  #E;P  YHP  .:H  #EQ0
MY><  .;V %:4  !(FP  .J(  "RI   ?L   $[8   N\    P0   ,4   #)
M    S0   -(   #6    V@   -L   #>    X    .(   #D    YP   .D
M  #M    \ H  /01  #X'P  ^3(  /I(  #[7P  _'H  /V7  #]KP  _<<
M /WD /\ #@#_  T _P , /\ #@#_ !, _P > /\ *@#_ #8 _P!" /\ 30#_
M %< _P!? /\ 9P#_ &X _P!T /\ >@#_ ($ _0"' /P C0#Z )0 ^0"< /<
MI0#U *\ ] "\ /, SP#Q .P \ #^ .\ _P#O /\ XP#_ -< _P#. /\ R@#_
M /\ "@#_  8 _P $ /\ " #_ !  _P 9 /\ )0#_ #$ _P ] /\ 1P#^ %$
M^P!9 /D 80#V &@ ] !N /, = #Q 'H [P"! .X AP#L (X Z@"6 .@ GP#F
M *D XP"U .( Q@#@ ., WP#X -T _P#= /\ U #_ ,D _P#" /\ O@#_ /\
M P#_    _P   /\  0#_  T _P 4 /T ( #Z "L ]P V /, 00#O $L [ !4
M .@ 6P#F &( XP!H .$ ;@#? '0 W !Z -H @0#8 (@ U "0 -( F #/ *(
MS0"N ,L O #) -, QP#P ,8 _P#$ /\ Q #_ +L _P"V /\ LP#_ /\   #_
M    _P   /\   #W  @ \  0 .L &@#G "4 Y  P .$ .P#< $4 U0!- -$
M50#. %L RP!B ,D 9P#' &T Q0!S ,, >@#! ($ OP") +T D@"[ )P N0"G
M +< M0"U ,@ LP#F +( ^P"Q /\ L #_ *X _P"J /\ IP#_ /\   #_
M_@   /$   #E  ( W  - -, % #- !\ R@ J ,< - #$ #X P !' +P 3@"Z
M %4 MP!; +4 80"S &< L@!M +  <P"N 'H K "" *H BP"H )4 IP"@ *4
MK0"C +X H0#; *  ] "? /\ G@#_ )\ _P"= /\ FP#_ /\   #\    [@
M .    #0    Q0 ( +X $ "Y !D M0 C +, +@"P #< K0!  *H 2 "H $\
MI0!5 *, 6P"B &  H !F )\ ; "= ', FP![ )H A "8 (X E@": )4 IP"3
M +< D0#, )  [ "/ /\ C@#_ (X _P". /\ CP#_ /P   #O    VP   ,D
M  "]    M0 " *X # "I !, I0 = *( )P"@ #$ G0 Z )H 0@"8 $D E@!/
M )0 50"3 %L D0!@ )  9P". &T C0!U (L ?@") (D B "5 (8 H@"% +$
M@P#$ ($ Y "  /D ?P#_ (  _P"  /\ @ #_ /0"  #@"0  QP@  +<'  "L
M P  I@   *  !P";  \ F  7 )4 (0"2 "H CP S (T / "+ $, B0!) (<
M4 "& %4 A !; (, 80"! &@ @ !P 'X >0!\ (0 >P"0 'D G0!X *P =@"^
M '4 W0!S /0 <P#_ ', _P!S /\ <P#_ .D-  #/$   N1   *D0  ">#@
MEPL  ),&  "0  L C  1 (D &@"& "0 @P N ($ -@!_ #X ?0!$ 'P 2P!Z
M %$ >0!7 '< 70!V &0 = !L ',!=0!Q 8  ;P*- &X"F@!L ZH :P.[ &D$
MU@!H!O$ : ?_ &<'_P!G!_\ 9P?_ -\4  ##%P  KA<  )X6  "3%0  BQ(
M (80  "$# ( @P8- ( #% !\!1X >0<H '<(, !U"#@ <PE  '()1@!P"DP
M;PI3 &T+60!L"V$ :@MI &D,<@!G#'X 9@R+ &0-F0!B#:D 80V[ & -V !>
M#O, 70[_ %T._P!=#O\ 70[_ -0<  "Y'0  I!X  )4=  ")'   @1H  'L7
M  !X$P  >! & '<-#P!S#A@ < XB &X/*P!L$#, :A [ &D00@!G$4D 9A%/
M &015@!C$ET 81)F & 2;P!>$GL 7!.( %L3EP!9$Z< 5Q2Z %84U0!5%?,
M5!7_ %05_P!4%?\ 5!3_ ,HB  "P(@  G2,  (TC  "!(@  >2$  ',>  !O
M&P  ;A<  &T3# !J%!0 9Q4> &46)P!C%B\ 81<W & 7/@!>&$4 71A+ %P9
M4@!:&5H 61EB %<:; !6&G< 5!J% %(;E !1&Z0 3QNW $X;T !-'/$ 3!S_
M $P<_P!-'/\ 31O_ ,,F  "J)P  EB<  (<H  ![)P  <B8  &PD  !H(0
M9AX  &0;" !B&Q$ 7QP: %T=(P!;'BL 6AXS %@?.@!7'T$ 5B!( %0@3P!3
M(%< 42%? % A:0!.(70 32&" $LBD0!)(J( 2"*T $<BS0!&(^\ 12/_ $4B
M_P!&(O\ 1B'_ +PJ  "D*P  D2L  ((L  !V*P  ;2H  &8I  !B)@  7R0
M %TB! !;(0X 6"(6 %8C'P!4)"@ 4R0P %(E-P!0)3X 3R9% $XF3 !,)E0
M2R=< $DG9@!()W$ 1B=_ $4HCP!#**  02BR $ HRP _*.T /RC_ #\H_P!
M)_\ 0"?_ +<M  "?+@  C"\  'TO  !Q+P  :"X  &$M  !=*P  6B@  %<G
M  !4)PP 4B@3 % I' !.*24 32HL $LJ- !**SL 22M" $@L20!&+%$ 12Q:
M $0L9 !"+6\ 0"U] #\MC0 ]+9X /"VP #HMR  Z+>L .BW_ #HM_P Z+/\
M.BS_ +(P  ";,0  B#(  'DR  !M,@  9#(  %TQ  !8+P  52P  %$L  !/
M+0D 3"T1 $HN&0!)+R( 1R\J $8P,0!%,#@ 0S _ $(Q1P!!,4\ 0#%7 #XQ
M80 ],FT .S)[ #DRBP X,IP -C*O #4RQP T,ND -#+_ #4Q_P U,?\ -3#_
M *TS  "6-   A#4  '4U  !I-0  8#4  %DT  !4,P  4#   $PQ  !),08
M1S(/ $4S%@!#,Q\ 0C0G $ T+@ _-38 /C4] #TU1  \-DP .C95 #DV7P W
M-FL -C9X #0WB0 R-YH ,3>M "\WQ0 O-^@ +S;^ # U_P P-?\ ,#3_ *DV
M  "2-@  @#<  '(X  !F.   73<  %8W  !0-@  2S0  $<U  !$-@, 03<-
M #\X%  ^.!P /#DD #LY+  Z.3, .3HZ #@Z0@ V.DH -3I3 #0[70 R.V@
M,#MV "\[AP M.YD +#NL "H[PP I.^8 *CK] "HZ_P K.?\ +#C_ *0X  ".
M.0  ?#H  &XZ  !C.@  6CH  %,Z  !-.@  1C@  $(Z   _.P  /#P+ #H\
M$0 X/1D -STA #8^*0 T/C  ,SXW #(_/P Q/T< ,#]0 "X_6@ M0&8 *T!T
M "E A  H0)< )D"J "5 P0 D0.4 )#_\ "4^_P F/?\ )CW_ )\[  "*/
M>#T  &H]  !?/0  5CT  $\]  !)/0  0CT  #P^   Y/P  -D$( #1!#P R
M0A8 ,4(> "]#)0 N0RT +4,T "Q$/  K1$0 *D1- "A$6  G16, )45Q "-%
M@@ B194 ($6H !]%OP >1., 'T3[ !]#_P @0O\ (4'_ )H^  "%/P  =$
M &=   !<0   4T   $Q   !&0   /D$  #A#   T10  ,$8# "U'#0 K2!(
M*D@: "E((@ H22D )TDQ "5).0 D24$ (TI* ")*50 @2F$ 'TIO !U*?P ;
M2I( &DJF !A*O0 72N  &$GZ !E(_P :1_\ &D?_ )5"  " 0@  <$,  &-#
M  !80P  4$,  $E#  !"1   .T4  #5'   P20  *TL  "9-"0 D3A  (DX6
M "%/'0 @3R4 'T\L !Y/-0 =3ST '%!' !I040 94%T %U!K !90?  44(\
M$U"D !%0N@ 14-X $4_X !)._P 33?\ %$W_ (]%  ![1@  :T8  %]'  !5
M1P  34<  $9'   _1P  -TH  #%,   K3@  )E   "!3 P <50P &E81 !E6
M&  75B  %E8G !56,  45CD $U=" !)730 15UD $%=H  ]7>0 .5XP #5>@
M  M7M@ +5M0 "U;T  Q5_P -5/\ #E/_ (A)  !V2@  9TH  %M*  !12@
M2DH  $-*   [3   ,TX  "Q1   F5   (58  !M9   57 < $5X- !!>$P 0
M7AH #EXB  Y>*@ -7C, #%X]  M>2  *7E0 "%YB  =><P %7H8  UZ;  )>
ML0 "7<P  EWN  -<_P $6_\ !5O_ (%.  !P3@  8DX  %=.  !.3@  1TX
M #Y/   V40  +E0  "=7   A6@  &UT  !5@   08P, #&8+  AG$  &9Q4
M!6<<  1G)  "9RT  6<W  !G0@  9TX  &=<  !G;0  9X   &:5  !FK
M9<<  &7K  !D_   9/\  &/_ 'I2  !J4P  75(  %12  !+4@  0E,  #E5
M   P6   *%L  "%?   :8@  %&4  !!H   ,:P$ !FX)  !O#@  ;Q(  &\8
M  !P'P  <"<  '$P  !Q.P  <4@  '%6  !Q9@  <7D  '&/  !PIP  ;\$
M &_G  !N_   ;?\  &W_ '-8  !E5P  6E<  %%6  !&5P  /%H  #)=   J
M80  (F0  !IH   4;   #F\   IR   $=@   '@%  !X"P  >0X  'H3  ![
M&0  ?"   'TI  !],P  ?4   'U.  !]7@  ?7(  'V(  !\H0  ?+H  'OB
M  !Z^@  >?\  'C_ &U=  !@7   5UP  $M=  ! 7P  -6,  "MG   C:P
M&F\  !-S   .=P  "'L   )^    @@   (,!  "$!@  A0L  (8/  "($P
MB1D  (HA  "+*P  BS<  (Q&  "+5@  BVD  (N   "+F0  BK,  (G8  "(
M]P  B/\  (?_ &AC  !>8@  46(  $1E   X:0  +FX  "1S   :>   $WT
M  V!   &A0   (D   "-    D    )(   "2    E 4  )4*  "7#@  F!(
M )H8  ";(0  G"T  )T\  "=3   G%\  )QV  ";D0  FZL  )K)  ":\
MF?\  )C_ &5I  !7:0  26P  #UQ   P=@  )7P  !N!   2AP  #(P   21
M    E0   )D   "=    H    *$   "B    I    *4!  "G!P  J0P  *H1
M  "M&   KR(  *\P  "O00  KU0  *]K  "NA0  KJ$  *Z^  "MY@  K/P
M *S_ %YQ  !/=   0GD  #5_   HA0  '8P  !.2   ,F    YT   "B
MI@   *H   "N    L    +$   "S    M    +8   "X    N@0  +P*  "^
M$   P1<  ,,D  ##-0  Q$D  ,1>  #%=P  Q9,  ,6O  #%T0  P_(  ,/_
M %9\  !'@@  .H@  "R/   @E@  %)T   VC   #J0   *X   "R    MP
M +L   "_    P@   ,(   #%    Q@   ,@   #*    S0   ,\   #2"
MU0X  -L8  #=)P  WCH  -]0  #@:   X(0  .&A  #AO0  X>(  .#T $Z+
M  ! D@  ,ID  "6A   8J   #J\   6U    N@   +\   #$    R    ,X
M  #1    U    -4   #8    V@   -T   #?    X@   .0   #G    ZP4
M .\.  #T&0  ]2L  /9!  #W6   ^'(  /F0  #YJP  ^,0  /CA /\ "P#_
M  @ _P ) /\ # #_ !( _P : /\ )@#_ #( _P ^ /\ 2 #_ %( _P!: /\
M8@#_ &D _P!O /\ =0#^ 'L _ "! /L B #Y (\ ]P"7 /4 H #S *H \@"W
M .\ R0#M .8 [ #[ .L _P#K /\ W0#_ ,X _P#& /\ P@#_ /\ ! #_
M_P   /\ !0#_  T _P 5 /\ (0#_ "P _P X /\ 0P#] $P ^0!4 /< 7 #T
M &, \@!I /  ;P#N '4 [ ![ .H @@#H (D YP"1 .0 F@#B *0 X "P -T
MP #: -P V #T -4 _P#3 /\ RP#_ ,$ _P"[ /\ MP#_ /\   #_    _P
M /\   #_  H _0 1 /D &P#V "< ]  R /  / #L $8 Z !. .0 5@#A %P
MW@!C -P : #9 &X U0!T -( >P#0 (( S0"* ,L DP#( )T Q@"H ,0 MP#!
M ,P P #K +X _P"] /\ O0#_ +0 _P"N /\ JP#_ /\   #_    _P   /H
M  #R  4 Z@ . .4 %@#@ "$ W0 K -L -@#3 #\ S@!( ,H 3P#' %8 Q !<
M ,( 80#  &< O@!M +P <P"Z 'H N "" +8 BP"T )8 L@"A +  KP"N ,$
MK0#@ *L ]P"J /\ J0#_ *8 _P"A /\ GP#_ /\   #_    ]P   .@   #<
M    T  * ,H $0#% !L P@ E +\ +P"\ #@ N !! +4 2 "R $\ L !5 *X
M6P"L &$ J@!F *@ ; "G ', I0![ *, A "A (X GP": )T IP"; +@ F@#0
M )D [P"8 /\ EP#_ )8 _P"4 /\ D@#_ /\   #V    Y    -(   #%
MNP % +4 #@"P !4 K  ? *H *0"H #( I0 Z *( 0@"@ $D G@!/ )P 50":
M %H F !@ )8 9@"5 &P DP!T )( ?0"0 (< C@"3 (P H0"+ +  B@#% (@
MY@"' /L A@#_ (< _P"' /\ A@#_ /@   #E    S0   +T   "S    J@
M *, "@"? !$ FP 9 )D (P"7 "P E0 T )( / "0 $, C@!) (P 3P"* %0
MB0!: (< 8 "& &8 A !N (, =P"! ($ ?P"- 'X FP!\ *H >P"\ 'H VP!X
M /4 > #_ '@ _P!X /\ > #_ .T   #1 @  NP(  *P!  "B    FP   )8
M!0"1  T C0 4 (L '0"( "8 A@ N (0 -@"" #T @ !# 'X 20!] $\ ? !5
M 'H 6P!Y &$ =P!I '4 <0!T 'P <@"( '$ E@!O *4 ;@"V &T S@!L .X
M:P#_ &L _P!K /\ :P#_ -\+  #"#   K@P  )X,  "3"P  C <  (@"  "%
M  D @0 0 '\ %P!\ "  >@ H '@ , !V #@ =  ^ ', 1 !Q $H < !0 &X
M5@!M %T ; !D &H ;0!H '< 9P"$ &4 D@!D *$ 8P"R &$ R0!@ .D 8 #\
M &  _P!@ /\ 8 #_ - 0  "V$0  HA(  ),2  "($0  @ \  'P-  !Y"0$
M> ,+ '4 $0!S !H <  C &X!*P!L 3, :@(Y &D#0 !G T8 9@1, &4$4@!C
M!5D 8@5A & %:@!?!G0 70:! %P'CP!:!Y\ 60>P %<'Q@!6">< 5@K[ %4*
M_P!5"O\ 5@K_ ,85  "M%P  F1@  (H8  !_%P  =A8  '$3  !N$   ;0T%
M &T)#0!J"10 9PH= &4*)@!C"RX 8@PU & ,/ !?#$( 7@U( %P-3P!;#58
M60U> %@.: !6#G, 50Z  %,.CP!1#I\ 4 ZQ $X.R !-$.H 31#] $T0_P!-
M$/\ 31#_ +P;  "E'   DAT  (,>  !W'0  ;QP  &D:  !F%P  9!0  &00
M" !B#Q  7Q 8 %T0(0!;$2D 6A$Q %@2. !7$CX 5A)% %023 !3$U, 41-;
M % 390!.%'  3!1] $L4C !)%)P 1Q6N $85Q0!%%>@ 11;^ $46_P!%%?\
M117_ +4?  ">(0  BR(  'PB  !Q(@  :"$  &(?  !?'0  7!H  %L7 @!:
M%0T 5Q84 %46'0!4%R4 4A@M %$8- !/&#L 3AE" $T92 !+&E  2AI8 $@:
M8@!'&FT 11MZ $,;B0!"&YH 0!NL #\;P@ ^'.4 /1S\ #X<_P ^&_\ /AO_
M *\C  "8)   AB4  '<F  !L)@  8R4  %TD  !9(@  5A\  %0=  !3' L
M41P2 $X=&@!-'2( 2QXI $H>,0!)'S< 1Q\^ $8@10!%($T 0R!5 $(@7P!
M(6H /R%W #TAAP [(9@ .2&J #@BP  W(N, -R+[ #<B_P X(?\ ."'_ *HF
M  "4)P  @2D  ',I  !G*0  7RD  %@H  !4)@  42,  $\B  !,(@< 2B(0
M $@B%P!'(Q\ 120F $0D+@!")#0 024[ $ E0P _)4H /293 #PF7  Z)F<
M.29U #<GA  U)Y8 -">H #(GO@ Q)^$ ,2?Y #(F_P R)O\ ,R7_ *4I  "/
M*@  ?2P  &\L  !D+0  6RP  %4K  !0*@  3"@  $HF  !')P0 1"<- $(H
M% !!*!P /RDC #XI*P ]*3( /"HY #LJ0  Y*D@ ."M0 #8K6@ U*V4 ,RMR
M #$K@@ P+)0 +BRG "PLO  K+-X +"SX "PK_P M*O\ +2K_ *$L  "++0
M>2X  &LO  !@+P  6"\  %$N  !,+@  2"P  $4K  !!*P  /RP+ #TL$0 [
M+1D .BXA #DN*  W+B\ -B\V #4O/@ T+T4 ,R]. #$P6  P,&, +C!P "PP
M@  J,)( *3"E "<PN@ F,-P )C#W "<O_P H+_\ *"[_ )PN  "',   =C$
M &@R  !=,@  53(  $XQ  !(,0  1#   $ O   \,   .C$) #<Q$  V,A8
M-3(> #,S)0 R,RP ,3,S # T.P O-$, +31, "PT5@ J-6$ *35N "<U?@ E
M-9  (S6C "(UN0 A-=D (33V "(T_P C,_\ (S+_ )@Q  "#,P  <C0  &4T
M  !:-0  434  $LT  !%-   0#0  #HS   W-   -#4& #(V#@ P-Q, +S<;
M "XW(@ M."D *S@Q "HX.  I.4  *#E) "8Y4P E.5\ (SEL "$Z?  @.HX
M'CJB !PZMP ;.=4 '#GU !TX_P =./\ 'C?_ ),T  !_-@  ;C<  &$W  !7
M-P  3C<  $@W  !"-P  /#<  #4X   R.0  +SH" "P["P J/!$ *3P8 "@]
M'P F/28 )3TN "0]-0 C/CT (CY& " ^4  ?/EP '3]I !L_>0 :/XP &#^@
M !8_M0 5/M( %C[S !<]_P 8//\ &#S_ (XW  !Z.   :CD  %XZ  !3.@
M2SH  $4Z   _.@  .3H  #(\   N/@  *4   "9!"  D0@X (D(4 "%"&P @
M0R, 'T,J !Y#,@ <0SH &T1# !I$30 81%D %T1G !5$=P 31(H $D2> !%$
MLP 01-  $$/R !%"_P 20O\ $T'_ (D[  !V/   9CT  %H]  !0/0  2#T
M $(]   \/0  -CX  "]    J0@  )40  "%& P =2 P &TD1 !E)%P 821X
M%TDF !9)+@ 52C8 %$I  !-*2@ 12E8 $$ID  ]*=  .2H< #4J;  Q*L  *
M2LH "TGL  Q(_P -1_\ #4?_ (,^  !Q/P  8D   %9   !-0   14   #]
M   Y00  ,D(  "M%   F1P  (4D  !Q+   63@< $U . !)0$P 14!D $% A
M  ]0*0 .4#$ #5 [  U11@ +45$ "E%?  E1;P '4($ !5"6  -0JP "4,4
M T_H  -/^P %3O\ !DW_ 'U"  !K0P  740  %)$  !*1   0T,  #Q$   U
M10  +D<  "=*   A3   '$\  !=1   25 , #E<*  M8$  *6!4 "%@<  =8
M)  &6"P !5@V  -80  !6$P  %A:  !8:0  6'P  %B1  !7IP  5\   %;E
M  !6^0  5?\  %7_ '9'  !F1P  64@  $]'  !'1P  0$<  #A(   P2@
M*4T  ")0   <4P  %E4  !%8   -6P( "5X)  1?#@  7Q(  %\8  !@'P
M8"<  & P  !@.P  8$<  &!4  !@8P  8'8  &"+  !?H@  7[L  %_B  !>
M^0  7?\  %W_ &]+  !A3   54P  $Q+  !$2P  .TP  #).   K40  (U0
M !Q7   66P  $5X   U@   (8P   F8'  !G#   9P\  &@3  !I&0  :B$
M &HI  !J-   :D   &I-  !J70  :F\  &J%  !JG0  :;8  &C=  !H]P
M9_\  &;_ &E1  !<4   4E   $I/   _4   -5,  "U6   D60  '5T  !9@
M   09   #&<   9J    ;@   &\#  !P"   <0T  '(0  !T%   =1L  '8C
M  !W+   =S@  '9&  !V5@  =F@  '9^  !VEP  =;$  '33  !S]0  <_\
M '+_ &-6  !850  4%0  $15   Y6   +UL  "9?   =8P  %6<  !!L   *
M<   !',   !V    >@   'P   !\ P  ?@@  '\,  "!$   @A0  (0;  "%
M)   AB\  (8]  "&30  A5\  (5U  "%CP  A*D  (/)  ""\0  @?\  (#_
M %];  !66@  25L  #U>   R80  )V8  !YK   5<   #G4   EY   !?@
M ($   "%    B    (H   "+    C0$  (X&  "0"P  D0\  ),4  "5&P
MER8  )<T  "71   EU8  )9L  "5A@  E:(  )3!  "3Z@  DO\  )+_ %UA
M  !/80  0F0  #9I   J;@  'W0  !5Y   .?P  !X0   ")    C@   )(
M  "6    F    )H   ";    G0   )\   "A P  HP@  *4-  "G$P  J1P
M *HH  "J.0  JDL  *IA  "I>@  J)D  *BU  "GW0  I_@  *;_ %9H  !(
M;   .G   "YV   B?0  %X0   Z*   'D    )8   ":    GP   *,   "G
M    J@   *L   "M    KP   +$   "S    M0   +@%  "Z#   O1(  , <
M  # +0  P$   +]5  "_;@  OHL  +ZH  "^R0  O>\  +S^ $YT  ! >0
M,G\  "6'   9C@  $)4   ><    H@   *<   "L    L    +4   "Y
MO    +T   "_    P0   ,,   #&    R    ,H   #- @  T L  -42  #6
M(0  US0  -A)  #98   VGP  -J:  #;M0  V]D  -OR $:"   XB0  *Y
M !V8   2H   "J<   "N    M    +D   "^    P@   ,@   #+    S@
M ,\   #2    U    -8   #:    W0   -\   #B    Y@   .H*  #O$P
M\"4  /(Z  #S40  ]&L  /2)  #UI0  ];\  /7= /\ !@#_  , _P % /\
M"P#_ !  _P 7 /\ (@#_ "T _P Y /\ 1 #_ $T _P!5 /\ 70#_ &0 _P!J
M /\ < #] '8 ^P!\ /D @P#W (H ]0"2 /, FP#P *8 [@"S .L Q #I .0
MYP#Y .8 _P#E /\ TP#_ ,< _P"_ /\ NP#_ /\   #_    _P   /\  @#_
M  L _P 2 /\ '0#_ "@ _P S /\ /@#\ $< ^ !/ /0 5P#Q %T [@!C .P
M:0#J &\ Z !U .8 ? #D (, X@"+ -\ E0#< )\ V0"K -4 NP#2 -0 SP#R
M ,T _P#, /\ Q0#_ +H _P"T /\ L #_ /\   #_    _P   /\   #_  8
M^0 / /4 %P#S "( \0 M .T -P#G $  X@!) -\ 4 #; %< UP!= -0 8P#1
M &@ SP!N ,P =0#* 'P R "$ ,4 C0#" )@ P "D +T L@"[ ,8 N0#H +@
M_0"W /\ M@#_ *T _P"G /\ HP#_ /\   #_    _P   /4   #K  $ Y  ,
M -X $P#9 !P TP F -$ , #, #H R !" ,0 2@#  %  O0!6 +L 7 "Y &$
MMP!G +4 ;0"S '0 L0!\ *\ A0"M )  J@"< *@ J@"F +L I0#: *, ]0"C
M /\ H@#_ )X _P": /\ EP#_ /\   #^    [P   -\   #0    QP ' ,$
M#P"\ !< N0 @ +< *@"U #, L  [ *T 0P"K $D J !/ *8 50"D %H HP!@
M *$ 9@"? &T G0!T )P ?0": (@ F "4 )8 H@"4 +( D@#) )$ ZP"1 /\
MD #_ )  _P", /\ B@#_ /P   #L    V0   ,<   "Z    L0 " *L # "G
M !( I  ; *$ ) "@ "P G@ U )L / "8 $, E@!) )0 3P"2 %0 D !: (\
M7P"- &8 BP!M (D =@"( (  A@", (0 F@"" *H @0"^ (  X "  /D ?P#_
M '\ _P!_ /\ ?@#_ /$   #8    P@   +,   "H    H    )D !P"5  X
MD@ 5 )  '@". "8 C0 N (H -@"' #T A0!# (0 20"" $X @0!4 '\ 60!^
M &  ? !G 'H ;P!Y 'H =P"& '4 E !T *, <@"U '( SP!Q /$ < #_ '
M_P!P /\ <0#_ .$   #$    L    *(   "7    D0   (L  @"&  L @P 1
M ($ & !_ "$ ?0 I 'P , !Y #< >  ] '8 0P!T $D <P!. '( 5 !P %H
M;P!B &T :@!K '0 :@"  &@ C@!G )T 90"O &4 Q@!D .@ 9 #] &, _P!C
M /\ 9 #_ ,\%  "V!P  HP@  )0(  ")!P  @@,  'X   ![  8 =P . '4
M$P!R !L <0 C &\ *P!M #( ;  X &H /@!I $0 9P!) &8 3P!E %8 8P!=
M &( 90!@ &\ 7P![ %T B0!< )D 6P"J %D OP!9 .$ 6 #X %@ _P!8 /\
M60#_ ,(,  "J#0  EPX  (D.  !]#@  =@T  '$*  !O!@  ;0 * &L $ !I
M !8 9P > &4 )@!C "T 80 S &  .0!? #\ 70!% %P 2P!; %( 6@!9 %@
M8@!7 &P 50!X %, A@!2 )8 40"G %  NP!/ =L 3@+T $X#_P!.!/\ 3@/_
M +@0  "A$@  CA,  '\3  !T$P  ;!(  &<0  !E#@  8PL# &,&# !A!!$
M7@,9 %P$(0!;!2@ 608O %@&-0!6!SL 50=" %0'2 !3"$\ 40A6 % )7P!.
M"6D 30EV $L*A !)"I0 2 JF $<*N@!&"M@ 10OS $4,_P!%#/\ 10S_ + 4
M  "9%@  AQ@  '@9  !M&   91<  %\6  !<$P  6A$  %H.!@!:# T 5PP4
M %4,' !3#20 4@TK % -,0!/#C@ 3@X^ $T.10!+#DT 2@Y5 $@/7@!'#V@
M10]U $,0A !!$)4 0!"F #X0NP ]$-P /1'V #T1_P ]$/\ /A#_ *D9  "2
M&P  @1P  '(=  !G'0  7QP  %D;  !5&0  4Q8  %(3  !2$0H 4! 0 $X1
M& !,$2  2A(G $D2+@!($S0 1Q,[ $430@!$$TD 0Q12 $$46P _%&4 /A5R
M #P5@0 Z%9( .!6D #<5N0 U%=@ -1;U #86_P V%O\ -Q7_ *,<  "-'@
M>R   &TA  !B(0  6B$  %0?  !0'@  31L  $P9  !+%@8 218. $<7%0!%
M%QP 1!@D $(8*@!!&#$ 0!DX #\9/P ]&48 /!I/ #H:6  Y&F, -QMO #4;
M?@ S&Y  ,ANB # ;MP O&], +QSS "\;_P P&_\ ,!O_ )T?  "((@  =R,
M &DD  !>)   5B0  % C  !+(@  2"   $8=  !%' ( 0QP, $$<$@ _'1D
M/ATA #P>)P ['BX .A\U #D?/  W'T0 -A], #0@5@ S(&  ,2!M "\@?  M
M(8X +"&@ "HAM0 I(=  *2'R "DA_P J(/\ *R#_ )DB  "$)0  <R8  &4G
M  !;)P  4R<  $PF  !')0  1"0  $(A   _(0  /2$) #LA$  Y(A8 ."(>
M #8C)0 U(RL -"0R #,D.0 R)$$ ,"1* "\E4P M)5X *R5K "HE>@ H)8P
M)B6? "0ELP C)<X (R7P "0E_P E)/\ )23_ )0E  " )P  ;RD  &(J  !7
M*@  3RH  $DI  !$*   0"<  #TF   Z)0  -R8& #4F#@ T)Q0 ,B<; #$H
M(@ P*"D +R@P "TI-P L*3\ *RE' "DI40 H*EP )BII "0J>  C*HH (2J=
M !\JL@ >*LP 'BKO !\I_P @*?\ (2C_ ) H  !\*@  ;"L  %\L  !4+
M3"P  $8L  !!*P  /"L  #@J   U*@  ,BL# # K#  N+!$ +2P8 "PL'P J
M+28 *2TM "@M-  G+CP )BY% "0N3P C+EH (2]G !\O=@ =+X@ '"^; !HO
ML  8+\H &"[M !DN_P ;+?\ &RW_ (PK  !X+0  :"X  %LO  !1+P  22\
M $,O   ^+@  .2X  #0N   P+@  +2\  "LP"@ I,1  )S$5 "8Q'  E,B,
M)#(J ",R,0 A,SD (#-" !\S3  =,U< &S-D !HT=  8-(8 %C2: !0SK@ 3
M,\@ $S/L !0S_P 5,O\ %C'_ (<N  !T+P  93$  %@Q  !.,@  1C(  $ Q
M   [,0  -C$  #$Q   K,P  *#0  "4U!@ C-@T (382 " W&0 ?-R  'C<G
M !TX+@ ;.#8 &C@_ !DX20 7.54 %3EB !0Y<0 2.80 $3F8 ! YK0 ..,<
M#CCK ! X_P 0-_\ $3;_ (,Q  !P,@  830  %4T  !+-   1#0  #TT   X
M-   ,S0  "TU   H-P  )#D  " Z @ =.PL &SP0 !D]%0 8/1P %STC !8]
M*P 5/C, %#X\ !(^1@ 1/E( $#Y?  \^;P ./H$ ##Z5  L^J0 */L$ "CWD
M  L]^P ,//\ #3O_ 'TT  !K-@  73<  %$W  !(-P  03<  #LW   U-P
M,#<  "HY   E.P  (#T  !P_   7008 %$,- !)#$@ 10Q@ $4,? !!$)P /
M1"\ #D0Y  U$0P ,1$X "T1;  E$:@ '1'P !D20  1#I0 "0[T  T/@  -#
M]@ $0O\ !D'_ '@X  !G.0  63H  $XZ  !%.@  /CH  #@Z   S.@  +3L
M "<]   A0   '$(  !=$   31@, #TD*  U*#P ,2A0 "TH;  E*(P (2BL
M!THT  5*/@ $2DD  DI6  !*90  2G<  $J+  !*H0  2;D  $G=  !)]0
M2/\  $C_ '(\  !B/0  53X  $H^  !"/0  /#T  #8]   O/@  *4   "-"
M   =10  %T<  !-*   /3 ( "T\)  =0#0 #41$  %$7  !1'@  428  %$O
M  !1.0  440  %)1  !28   47(  %&'  !1G0  4;4  %#8  !0]0  3_\
M $__ &Q   !=00  44$  $=!  ! 0   .4   #)!   J0P  )$8  !Y(   7
M2P  $DX   Y1   +4P$ !E8'  !7#   6!   %@3  !9&0  6B$  %HI  !:
M,P  6C\  %I,  !:6@  6FP  %J!  !9F0  6;$  %C1  !8]   5_\  %?_
M &5%  !810  344  $5$   ^1   -44  "U'   E2@  'DT  !A0   24P
M#E8   I9   $7    %X$  !?"0  8 T  &$0  !B%0  8QL  &0C  !D+0
M9#@  &1%  !D5   9&8  &1[  !CDP  8ZT  &+,  !A\@  8?\  &#_ %]*
M  !32@  2DD  $-(   Y20  +TP  "=/   ?4@  &%4  !)9   -70  "&
M  )C    9@   &@!  !I!0  :@H  &L-  !M$0  ;A8  ' =  !Q)@  <3$
M ' ^  !P3@  <%\  '!S  !OC0  ;Z<  &[&  !M[P  ;/\  &S_ %I/  !0
M3@  2$T  #U.   S40  *50  "!8   87   $6    QD   &:    &L   !O
M    <@   '0   !U    =P0  '@)  !Z#0  ?!   'T6  !_'@  @"@  ( U
M  " 10  ?U8  ']K  !_A   ?J   'V^  !\Z0  >_\  'K_ %94  !.4P
M0E0  #=6   L6@  (E\  !AC   1:   "VT   -R    =@   'H   !]
M@    (,   "$    A@   (<"  ")!P  BPP  (T0  "0%@  DA\  )(L  "2
M.P  DDT  )%B  "1>@  CY<  (^T  ".X0  C/L  (S_ %59  !(6@  .UT
M "]A   D9@  &6P  !%R   *=P   GT   ""    A@   (L   ".    D0
M ),   "5    EP   )D   ";    G00  )\*  "B#P  I!8  *8A  "F,0
MID,  *57  "D<   HXX  *.K  "AT   H/4  )__ $YA  ! 9   ,VD  "=N
M   ;=0  $7P   N#    B0   (X   "3    F    )T   "A    I    *4
M  "G    J0   *L   "M    L    +(   "U"   N X  +P6  "\)0  O#<
M +M,  "Z9   N8$  +>B  "WP   M^H  +?\ $9K   Y<   *W<  !]_   3
MA@  "XX   &5    FP   *$   "F    JP   +    "S    MP   +<   "Z
M    O    +\   #!    Q    ,<   #*    S04  -$.  #4&0  U"L  -1
M  #36   TW0  -.2  #2L   TM,  -+R #YY   Q@   (X@  !>1   -F0
M Z    "G    K@   +,   "X    O0   ,(   #&    R@   ,H   #-
MSP   -(   #5    V0   -T   #?    XP   .<%  #K#P  [!\  .TS  #N
M2P  [V0  .^"  #PGP  \;D  /'8 /\   #_    _P $ /\ "0#_  X _P 5
M /\ '@#_ "D _P T /\ /P#_ $@ _P!0 /\ 6 #_ %X _P!E /T :P#[ '$
M^0!W /@ ?@#V (4 \P"- /$ EP#N *( ZP"O .@ P #F .  XP#X .( _P#;
M /\ RP#_ ,$ _P"Y /\ M #_ /\   #_    _P   /\   #_  D _P 0 /\
M&0#_ ", _P N /T .0#Y $( ]0!* /( 4@#N %@ ZP!> .D 9 #F &H Y !P
M .( =@#? 'T W0"& -D CP#5 )H T0"G ,X M@#+ ,X R0#P ,< _P#% /\
MNP#_ +0 _P"M /\ J0#_ /\   #_    _P   /\   #[  ( ]@ - /$ $P#M
M !X [  H .D ,@#C #L W0!$ -@ 2P#3 %$ T !8 ,T 70#+ &, R0!H ,8
M;P#$ '8 P@!^ +\ AP"\ )( N@"? +< K0"U ,$ L@#D +$ _0"O /\ K #_
M *4 _P"@ /\ G #_ /\   #_    ^P   .X   #D    W  ( -, $ #/ !@
MRP B ,D *P#& #0 P0 ] +T 1 "Z $L MP!1 +4 5@"R %P L !A *X 9P"L
M &X J@!V *@ ?P"F (H HP"6 *$ I0"? +8 G0#1 )P \P"; /\ G #_ )8
M_P"3 /\ D #_ /\   #V    YP   -,   #&    O0 # +@ #0"S !, L0 <
M *\ )0"N "X J0 V *8 /0"C $0 H0!* )\ 3P"= %4 FP!: )H 8 "8 &8
ME@!N )0 =P"2 ($ D ". (X G ", *T B@## (D Z "( /\ B0#_ (< _P"%
M /\ @@#_ /,   #C    S    +P   "P    IP   *$ " ">  \ FP 6 )D
M'P"8 "< E@ O ), -P"1 #T C@!# (P 20"+ $X B0!4 (< 60"% &  A !G
M (( ;P"  'H ?@"& 'P E !Z *0 >0"X '@ V !W /< > #_ '@ _P!W /\
M=0#_ .8   #+    MP   *@   ">    E@   (\ ! "+  P B  2 (< &0"%
M "$ A  I (( , !_ #< ?0 ] 'P 0P!Z $@ >0!- '< 4P!V %D = !A '(
M:0!Q ', ;P!_ &T C0!L )T :@"O &D R !H .T :0#_ &D _P!I /\ :0#_
M -(   "X    I0   )<   "-    A@   ($   !\  @ >0 . '< % !V !P
M=  C ', *P!Q #$ ;P W &X /0!L $, :P!( &H 3@!H %0 9P!; &4 8P!C
M &T 8@!X &  AP!? )8 70"H %T O@!< .0 7 #[ %P _P!< /\ 7 #_ ,(
M  "J 0  F ,  (D$  !_ @  >    '0   !P  0 ;0 , &L $0!I !< :  >
M &8 )0!E "P 8P R &( . !@ #T 7P!# %X 20!< $\ 6P!6 %H 7@!8 &@
M5P!S %4 @0!4 )$ 4@"C %$ MP!1 -8 40#U %$ _P!1 /\ 4@#_ +8'  "?
M"0  C0L  'X,  !S"P  ; H  &@'  !E P  8P ' &$ #0!? !, 70 : %P
M(0!; "< 60 M %@ ,P!6 #D 50 _ %0 10!3 $L 40!2 %  6@!/ &0 30!O
M $P ?0!* (T 20"? $@ L@!' ,P 1P#O $8 _P!' /\ 1P#_ *P,  "5#@
M@Q   '40  !K$   8P\  %X.  !;#   6@D" %D$"@!7  \ 50 5 %, ' !2
M ", 40 I $\ +P!. #4 30$[ $P!00!* D@ 20)/ $@"5P!& V$ 10-M $,#
M>@!" XL 0 .< #\#KP ^ \@ /03J #T%_  ]!O\ /@;_ *00  ".$@  ?!,
M &X4  !D%   7!,  %82  !3$0  40X  % ,!0!0"0P 3P<1 $T'%P!+"!\
M20@E $@)*P!'"3$ 1@DX $0*/@!#"D4 0@I- $ +50 _"U\ /0MK #P+>0 Z
M#(H . R< #<,KP U#,< -0SI #4-_0 U#?\ -@S_ )T3  "'%0  =A<  &D8
M  !>&   5A@  % 7  !-%0  2A,  $D1  !)#@< 2 T. $8-$P!$#1H 0PXA
M $(.* ! #BX /PXU #X//  ]#T, .Q!+ #H05  X$%X -A!K #00>0 R$(H
M,1"< "\0L  M$,D +1'L "T1_P N$?\ +Q#_ )<6  ""&0  <1L  &0<  !9
M'   41P  $P;  !'&@  1!@  $,5  !"$P( 01(+ $ 1$  ^$A< /!(> #L3
M)0 Z$RL .!,R #<3.0 V%$  -!1( #,440 Q%%P ,!5H "X5=P L%8@ *A6:
M "@5K@ G%<< )A7J "<5_P H%?\ *17_ )$:  !]'   ;1X  & ?  !6'P
M3A\  $@>  !#'0  0!P  #X:   ]&   .Q<' #D6#@ X%Q0 -A<; #48(@ S
M&"@ ,A@O #$9-@ P&3T +AE& "T:3P K&ED *AIF "@:=  F&H8 )!J9 "(:
MK0 A&L4 (!KH "$:_@ B&O\ (QK_ (T=  !Y'P  :2$  %PB  !2(@  2B(
M $0A   _(0  /"   #D>   X&P  -1P$ #0<#0 R'!( ,!T8 "\='P N'24
M+1XL "L>,P J'CL *1]# "<?30 F'U< )!]D "(?<@ @'X0 'Q^7 !T?JP ;
M'\, &Q_G !L?_0 ='_\ 'A[_ (D@  !U(@  92,  %DD  !/)0  1R4  $$D
M   \(P  .",  #4B   S(   ," ! "XA"@ L(1  *R$5 "HB'  H(B, )R(I
M "8C,  E(S@ (R-! "(D2@ A)%4 'R1A !TD<  ;)(( &225 !<DJ@ 6),$
M%23E !8D_  7(_\ &2/_ (4B  !Q)   8B8  %8G  !,)P  1"<  #XG   Y
M)@  -28  #$E   N)   *R4  "DE!P G)@X )283 "0G&0 C)R  (B<G "$H
M+@ @*#8 'B@^ !TH2  ;*5, &2E? !@I;@ 6*8  %"F4 !(IJ  1*<  $2CD
M !$H^P 3*/\ %"?_ ( E  !N)P  7R@  %,I  !)*@  0BD  #LI   V*0
M,B@  "XH   J*   )BD  "0J!  B*PP ("L1 !\L%@ =+!T '"PD !LM*P :
M+3, &"T\ !<M10 6+E  %"Y= !(N;  1+GX $"Z2  XNIP -+;T #2W?  TM
M^0 .+/\ $"S_ 'PH  !J*@  6RL  % L  !&+   /RP  #DL   T*P  +RL
M "LK   F+   (BX  !\O   <, D &C$. !DQ$P 7,1H %C(A !4R*  4,C
M$S(Y !(S0P 1,TX $#-;  XS:0 -,WH ##..  HSH@ (,KD "#+9  @R]  *
M,?\ "S'_ '<K  !F+0  6"X  $TO  !#+P  /"X  #8N   Q+@  +2X  "DN
M   C,   'S(  !LS   7-04 %#8, !(W$0 1-Q8 $3<= ! X)  /."P #C@U
M  TX/P ,.$H "SA7  DX90 '.'8 !3B*  ,XGP !-[4  3?3  (W\0 #-O\
M!3;_ ',N  !B,   5#$  $DQ  !!,0  .3$  #0Q   O,   *S   "4R   @
M,P  &S8  !<X   3.@( $#P)  T]#@ ,/1, "ST9  H](0 )/2D "#TQ  8^
M.P %/D8  SY2  $^80  /G(  #Z&   ]G   /;(  #W0   \\   //\  #S_
M &TR  !=,P  4#0  $8T   ^-   -S0  #(S   M,P  )S0  "(V   =.
M&#H  !0]   0/P( #4$(  E##0 &1!$  T06  )$'0  1"0  $0M  !$-@
M1$$  $1.  !$7   1&T  $2!  !$F   0Z\  $/-  !"\   0O\  $+_ &@V
M  !8-P  3#@  $,X   [-P  -38  # V   I-P  (SD  !X[   8/0  $T
M !!"   -10$ "$<'  -)#   20\  $H3  !+&0  2R   $LH  !+,@  2ST
M $Q)  !,5P  2V@  $M]  !+E   2JP  $K*  !)[P  2?\  $G_ &(Z  !4
M.P  23L  $ [   Y.@  ,SD  "PZ   E/   'S\  !E!   31   $$<   Q)
M   (3    D\%  !0"@  4 T  %$0  !2%0  5!L  %0C  !4+   5#<  %1$
M  !44@  5&,  %1W  !4CP  4Z@  %+&  !2[0  4?\  %'_ %P_  !//P
M13\  #X^   W/0  +SX  "=    @0P  &48  !-)   /3   "T\   92
M5    %<"  !8!P  60L  %H.  !;$0  718  %X=  !?)@  7S$  %X]  !>
M3   7ET  %YQ  !=B0  7:,  %S!  !;ZP  6O\  %K_ %9$  !+0P  0T(
M #Q!   R0@  *44  "%(   :2P  $TX   Y2   *50   UD   !;    7@
M &    !B @  8P8  &4*  !F#@  :!$  &H7  !K'P  :RD  &LV  !K10
M:U8  &IJ  !J@@  :9T  &B[  !GYP  9O\  &7_ %%(  !(2   048  #='
M   L2@  (TT  !M1   350  #ED   A=   !80   &0   !G    :@   &P
M  !N    <    '(%  !S"0  =0T  '<1  !Z&   >R$  'LN  !Z/0  >DX
M 'EB  !Y>0  >)8  '>S  !UX   =/P  '/_ $Y-  !'3   .TT  #!/   F
M4P  '%@  !-<   -80  !F8   !J    ;P   '(   !V    >0   'P   !]
M    ?P   ($   "# @  A@<  (@,  "+$0  CA@  (XD  ".,P  C40  (Q8
M  "+;P  BHP  (FJ  "(SP  AO<  (7_ $U1  !!4P  -%4  "E:   >7P
M%&4   UJ   %<    '8   ![    ?P   (,   "'    B@   (T   ".
MD0   ),   "5    F    )H%  "=#   H!$  *,:  "C*   HCH  *%.  "@
M90  H($  )Z@  "=P0  F^X  )K_ $99   Y7   +6$  "%G   6;@  #G4
M  5[    @0   (<   "-    D@   )8   ":    G0   )\   "A    I
M *8   "H    JP   *X   "Q P  M L  +@1  "Y'@  N2\  +A#  "W6@
MM78  +27  "TM0  L>(  +#\ #]D   Q:0  )6\  !AW   /?P  !H<   ".
M    E    )H   "@    I0   *H   "N    L0   +(   "U    MP   +H
M  "\    OP   ,,   #&    R0   ,X*  #2$P  TB,  -$W  #03P  SFH
M ,V*  #*JP  R\L  ,OO #=Q   I>   '8   !&)   (D0   )H   "A
MIP   *T   "S    N0   +X   #"    Q0   ,8   #)    S    ,X   #2
M    U0   -H   #>    X0   .4   #J"P  ZQ<  .HK  #J0P  ZEX  .IZ
M  #KF0  Z[4  .O5 /\   #_    _P ! /\ !P#_  T _P 2 /\ &P#_ "4
M_P O /\ .@#_ $, _P!+ /\ 4P#_ %H _0!@ /L 9@#Z &L ^ !R /8 > #T
M (  \0") .\ D@#L )T Z0"J .8 O #C -P WP#W -T _P#, /\ O@#_ +4
M_P"P /\ K0#_ /\   #_    _P   /\   #_  8 _P - /\ % #_ !\ _P I
M /L ,P#W #T \P!% .\ 30#L %, Z !9 .4 7P#C &4 X !J -T <0#: '@
MU@"  -( B@#/ )4 S "B ,@ L@#% ,D P@#M ,  _P"[ /\ L #_ *@ _P"D
M /\ H0#_ /\   #_    _0   /H   #X    \  ) .P $0#H !D YP C .4
M+0#> #8 U@ ^ -$ 1@#- $P R@!2 ,@ 6 #% %T PP!C ,  :0"^ '  O !X
M +D @0"W (T M ": +$ J0"N +P K #A *H _ "H /\ H #_ )D _P"6 /\
ME #_ /\   #Y    \@   .<   #;    T0 $ ,H #0#' !0 Q  = ,( )@"_
M "\ NP W +< /P"T $4 L0!+ *X 40"L %8 J@!< *@ 80"F &@ HP!P *$
M>0"? (0 G0"1 )H H "8 +$ E@#, )4 \0"4 /\ D0#_ (L _P"( /\ A@#_
M /<   #L    W@   ,D   "\    M    *\ "@"K !  J0 7 *@ ( "G "@
MH@ P )\ . "< #X F@!$ )@ 2@"6 $\ E !5 ), 6@"1 &$ CP!H (T <0"+
M 'L B0"( (< EP"% *@ @P"^ ($ Y "  /\ @ #_ 'P _P![ /\ >0#_ .D
M  #7    P0   +$   "F    G0   )< !0"4  T D@ 2 )  &@"/ "( C@ J
M (L ,0") #@ AP ^ (4 0P"# $@ @0!. '\ 5 !^ %H ? !A 'H :0!X ',
M=@!_ '4 C@!S )\ <0"S '  T !O /8 ;P#_ &\ _P!M /\ ; #_ -H   "_
M    K    )X   "3    C    (4   ""  D ?P / 'X %0!] !P ?  D 'H
M*P!W #$ =0 W '0 /0!R $( <0!( &\ 30!N %, ; !: &L 8@!I &P 9P!X
M &8 A@!D )< 8@"J &$ P@!@ .L 80#_ &$ _P!A /\ 8 #_ ,4   "M
MFP   (T   "#    ?    '<   !R  4 <  , &X $0!L !< ;  > &L )0!I
M "P 9P Q &8 -P!D #T 8P!" &( 2 !@ $X 7P!5 %T 70!< &8 6@!R %D
M@ !7 )  5@"C %4 N0!4 -X 5 #[ %0 _P!5 /\ 50#_ +8   "?    C0
M '\   !U    ;@   &D   !F  $ 8P ) &$ #@!@ !, 7P 9 %X ( != "8
M6P L %H ,@!8 #< 5P ] %8 0P!5 $D 4P!0 %( 6 !1 &$ 3P!L $X >@!,
M (H 2P"< $H L0!) ,X 20#S $D _P!) /\ 2@#_ *H!  "4!0  @@<  '0(
M  !J"   8P8  %X$  !;    60 % %< # !6 !  5  5 %, &P!2 "( 40 H
M %  +0!. #, 30 X $P /@!+ $4 2@!, $@ 5 !' %T 1@!H $0 =0!# (4
M00"8 $  JP!  ,4 /P#J #\ _P!  /\ 0 #_ * (  "*"P  >0T  &P-  !A
M#0  6@T  %4+  !2"0  4 8  $\"" !.  T 3  2 $L %P!* !X 20 C $<
M*0!& "\ 10 T $0 .@!" $$ 00!( $  4  ^ %H /0!D #P <@ Z (( .0"4
M #@ IP W +X -@#C #8 ^0 V /\ -P#_ )@-  "##@  <A   &41  !;$0
M4Q   $X0  !*#@  2 T  $<* P!'!PH 100. $0"$P!" AH 00(@ $ #)0 ^
M RL /00Q #P$-P [!#X .@5% #D%3@ W!5< -@5B #0&<  R!H  ,0:2 # &
MI0 O!;L +@7= "X&]0 M!_\ +@?_ )$0  !]$0  ;!,  %\4  !5%   3A0
M $@3  !$$@  01   $ .  ! #08 0 H, #X)$  \"18 .PH< #D*(@ X"B@
M-PLN #8+-0 U"SL ,PM# #(,3  P#%8 +PQA "T,;P K#'\ *@R2 "@,I0 G
M#+L )0S= "4-]0 F#?\ )PW_ (L2  !W%   9Q8  %L7  !1&   21<  $,7
M   _%0  /!0  #H2   Y$0$ .0\( #@.#0 W#A( -0X8 #0.'P R#B4 ,0\L
M # /,@ O$#H +1!" "P02P J$%4 *!!A "80;P D$(  (Q"3 "$0IP ?$+T
M'A#@ !X1]P ?$/\ (!#_ (84  !S%P  8QD  %<:  !-&P  11H  $ :   [
M&0  .!@  #46   T%   ,Q($ #(2"P Q$A  +Q(5 "T2'  L$R( *Q,I "H3
M,  H$S< )Q0_ "842  D%%, (A1? " 5;0 ?%7X '161 !L5I0 9%;L &!7>
M !@5^  9%/\ &A3_ ((7  !O&@  7QP  %,=  !*'0  0AT  #P=   W'
M-!L  #$:   O&0  +A8  "P7"  K%@X *1<3 "@7&0 G&"  )1@F "08+0 C
M&#0 (AD] " 91@ >&5$ '1E= !L::P 9&GP %QJ/ !4:HP 4&;H $AG; !,9
M]@ 4&?\ %1C_ 'T:  !K'0  7!\  % @  !'(   /R   #D?   T'P  ,1X
M "T=   K'   *1L  "<;!0 E&PP )!P1 "(<%@ A'!T (!TC !\=*@ >'3(
M'!XZ !L>1  9'DX %QY; !8>:0 4'WH $AZ- !$>H@ 0'K@ #A[8  \>]0 0
M'?\ $1W_ 'H=  !G'P  62$  $TB  !$(@  /"(  #8B   R(0  +B$  "H@
M   G(   )!\  "(@ @ @( H 'B$/ !TA%  <(1H &R(A !DB)P 8(B\ %R(X
M !4C00 4(TP $B-8 !$C9P 0(W@ #B.+  TCGP ,([0 "R/0  LB\  ,(O\
M#2'_ '8?  !D(@  5B,  $LD  !!)   .B0  #0D   O(P  *R,  "@C   D
M(P  (",  !TD   ;)0< &28- !<F$0 6)A< %2<> !0G)0 3)RP $B<U !$H
M/P 0*$H #BA6  TH9  ,*'0 "BB'  DHFP ')[$ !2?,  8G[  ')OX "";_
M '$B  !@)   4R8  $@G   _)P  -R8  #$F   M)@  *24  "4E   B)0
M'2<  !DH   6*@0 %"L+ !(L$  1+!0 $"P; ! L(@ .+"D #BTR  TM.P +
M+48 "BU2  @M8  &+7  !"V#  (MF   +*X  "S)   LZP !*_P  BO_ &TE
M  !=)P  3R@  $4I   \*0  -2D  "\H   K*   )R<  ",G   ?*   &RH
M !<L   3+@( $# (  XQ#0 -,1( ##$7  LQ'@ *,28 "#(N  <R-P %,D(
M S).  $R7   ,FP  #)_   RE0  ,:P  #''   PZ@  ,/P  ##_ &@I  !8
M*@  3"L  $$L   Y+   ,BL  "TK   I*@  )2H  " K   <+   %RX  !,P
M   0,@( #C0'  HW#  '-Q  !3<4  ,W&P "-R(  #<J   X,P  .#X  #A*
M   X6   .&@  #A\   WD@  -ZD  #;%   VZ@  -OT  #7_ &,L  !4+@
M2"\  #XO   V+@  ,"X  "LM   G+0  (BT  !TO   8,0  %#,  ! U   .
M-P$ "CH'  8["P "/ X  #T2   ^%P  /AX  #XF   ^+P  /CH  #Y&   ^
M5   /F0  #YW   ^CP  /:<  #W#   \Z0  //T  #O_ %XP  !0,0  1#(
M #LR   T,0  +C   "DO   D,   'C(  !DT   4-@  $#D   T[   */0
M!4 %  !!"@  0@T  $,0  !$%   11H  $8B  !&*P  1C4  $9!  !&3P
M1E\  $9S  !%B@  1:0  $3   !#Z   0_X  $+_ %@T  !+-0  034  #DU
M   R-   +3,  "8T   @-0  &C@  !0Z   0/0  #4    E"   $10   $<#
M  !(!P  2@L  $L.  !,$0  3A4  $\<  !/)0  3R\  $\\  !/2@  3UH
M $YM  !.A0  3:   $R\  !+YP  2_X  $K_ %,Y  !'.0  /CD  #<X   Q
M-P  *3<  "$Y   ;/   %3\  !!"   ,10  !T@   )*    30   $\   !1
M!   4@<  %0+  !5#@  5Q$  %D7  !:'P  62D  %DV  !91   650  %AG
M  !8?P  5YH  %:W  !5XP  5/T  %3_ $X]  !#/0  /#P  #4[   L/
M)#X  !Q!   51   $$@   M+   %3@   %$   !4    5P   %D   !;
M70(  %X&  !@"P  8@X  &02  !G&   9R(  &8N  !F/   9DT  &5@  !E
M=P  9),  &.Q  !AW0  8/P  %__ $E"  !!00  .C\  #!    F0P  'D8
M !5*   03@  "E(   -6    6@   %T   !@    8P   &4   !G    :0
M &L!  !M!0  ;PH  '(.  !U$@  =QL  '8F  !V-0  =48  '19  !T;P
M<XL  '*I  !PS0  ;_<  &[_ $9&  ! 10  -48  "I(   @3   %U$  !!6
M   )6@   5\   !C    :    &L   !O    <@   '4   !W    >0   'L
M  !]    @ ,  (,(  "&#0  B1,  (H=  "**P  B3P  (A/  "&9@  A8$
M (2@  ""P@  @?   '__ $9+   Z3   +D\  "-3   86   $%X   ED
M:0   &\   !T    >    'P   "!    A    (<   "(    BP   (X   "0
M    DP   )8   "9!P  G0T  *$4  "@(0  H#$  )Y$  "=6P  G'8  )F6
M  "9M0  EN4  )7^ #]2   R50  )EH  !M@   19P  "6T   !T    >P
M ($   "&    BP   )    "4    EP   )D   "<    GP   *$   "D
MIP   *H   "M    L08  +4-  "X%@  MR8  +8Y  "U4   M&H  +*)  "P
MJ@  KL\  *WU #=<   K80  'F@  !-P   +>    (    "'    C@   )4
M  ":    GP   *0   "H    K    *T   "P    LP   +4   "X    NP
M +\   ##    QP   ,L%  #1#@  T1L  - N  #/10  S5\  ,M^  #)G@
MR+X  ,7I "]I   C<   %GD   V!   !BP   ),   ";    H@   *@   "N
M    M    +@   "]    P    ,(   #%    R    ,L   #.    T0   -8
M  #;    WP   .0   #H!@  ZQ$  .HC  #J.@  Z50  .=R  #EDP  X[,
M ./4 /\   #_    _P   /\ ! #_  L _P 0 /\ %P#_ "$ _P K /\ -0#_
M #X _P!' /\ 3@#_ %4 _ !; /H 80#X &8 ]@!M /0 <P#R 'L [P"$ .T
MC@#J )D Y@"G ., N0#? -4 VP#W -8 _P#  /\ L@#_ *H _P"E /\ H@#_
M /\   #_    _@   /P   #\  , _@ + /\ $0#_ !H _0 D /D +@#T #@
M\ !  .P 2 #I $X Y@!4 .( 6@#? %\ W !E -@ :P#4 '( T ![ ,T A0#*
M )$ QP"> ,, K@#  ,4 O0#K +L _P"P /\ I #_ )P _P"8 /\ E0#_ /\
M  #Z    ]    /$   #R    Z@ % .< #@#B !4 X0 > .$ * #8 #$ T  Y
M ,L 0 #( $< Q0!- ,( 4P"_ %@ O0!> +L 9 "Y &L M@!S +0 ? "Q (@
MK@"5 *L I "H +@ I@#< *, ^P"? /\ E0#_ (\ _P"+ /\ B0#_ /D   #O
M    YP   -\   #/    R    ,$ "@"_ !$ O  8 +L (0"Y "H M  R +$
M.@"N $  JP!& *@ 3 "F %$ HP!6 *$ 7 "? &, G0!J )L <P"9 'X E@",
M )0 FP"2 *T D #' (X \ "- /\ A@#_ (  _P!] /\ ? #_ .T   #@
MT0   +\   "S    J@   *8 !0"B  T H0 3 *  &P"? ", FP K )@ ,@"5
M #D DP _ )$ 1 "/ $H C@!/ (P 50"* %L B !C (8 :P"$ '8 @@"" (
MD@!^ *, ? "Z 'H X0!Y /\ =P#_ '( _P!P /\ ;P#_ -T   #+    M@
M *<   "=    E    (X  0"+  H B0 0 (@ %0"' !T AP E (0 + "" #(
M?P X 'T /0![ $, >0!( '@ 3@!V %0 =0!; ', 8P!Q &X ;P!Z &T B0!L
M )H :@"N &D S !H /8 9P#_ &4 _P!D /\ 8P#_ ,H   "T    H0   ),
M  ")    @@   'L   !X  4 =@ , '4 $0!T !@ <P ? '( )0!P "P ;@ R
M &P -P!J #P :0!" &@ 2 !F $X 90!5 &, 70!B &8 8 !R %X @ != )(
M6P"E %H O@!9 .D 60#_ %D _P!8 /\ 6 #_ +D   "B    D    (,   !Y
M    <0   &T   !I  $ 9@ ) &4 #@!D !, 8P 9 &, ( !A "8 8  L %X
M,0!< #< 6P \ %H 0@!8 $@ 5P!/ %8 5P!4 &  4P!L %$ >0!0 (H 3P">
M $X M !- -H 30#[ $T _P!- /\ 30#_ *H   "4    @@   '4   !K
M9    &    !=    6@ % %@ # !7 !  5@ 5 %8 &P!5 "$ 4P G %( + !1
M #$ 3P W $X /0!- $, 3 !* $H 4@!) %L 2 !F $8 <P!% (0 1 "7 $,
MK !" ,D 0@#Q $( _P!# /\ 0P#_ )X   ")    > ,  &H$  !A!   6@,
M %4!  !2    4  " $X "0!-  T 3  1 $L %P!* !P 20 B $@ )P!' "T
M10 R $0 . !# #X 0@!% $$ 30 _ %8 /@!A #T ;@ [ 'X .@"1 #D I@ X
M +\ . #H #@ _P Y /\ .0#_ )4#  " !P  ;PD  &(*  !8"P  40H  $P(
M  !)!@  1P,  $8 !@!$  L 0P / $( $P!! !@ 00 > #\ (P ^ "D /0 N
M #L -  Z #H .0!! #@ 20 W %( -@!= #0 :@ S 'H ,@", #$ H0 P +@
M+P#> "\ ^0 O /\ , #_ (P)  !X#   : T  %P.  !2#@  2PX  $4-  !!
M#   /PH  #X( @ ]! @ / $- #L $  Z !4 .0 : #@ (  V "4 -0 K #0
M,  S #< ,@ ^ #$ 1@ O %  +@!: "T 9P K '< *@") "D G0 H +, )P#1
M "< \@ G /\ )P#_ (8,  !R#@  8Q   %81  !-$0  11$  $ 0   \#P
M.0X  #<-   V"P0 -@@* #4&#@ T!1( ,@07 #$%'  P!2( +P4H "X&+@ M
M!C0 *P8\ "H&1  I!TX )P=9 "8'90 D!W4 (P>' "('FP @!K  ( ;+ !\%
M[0 ?!OX 'P?_ ( .  !M$0  7A(  %(3  !($P  01,  #L3   W$@  -!$
M #(0   P#P$ , T& # +"P O"A  +0H4 "P+&0 J"Q\ *0LE "@,*P G##(
M)@PZ "0,0P C#$T (0U8 " -90 >#74 ' V( !H-G  9#;$ & S* !<,ZP 7
M#?P & S_ 'L1  !I$P  6A4  $X6  !%%@  /18  #@5   S%0  ,!0  "T3
M   K$@  *A # "H/"  I#@T * X1 "8.%@ E#QT ) \C ",/*0 A$#$ (! Y
M !X00@ =$$P &Q!8 !D09@ 7$'8 %1") !00G@ 2$+, $1#. !$0[@ 2$/X
M$A#_ '<3  !E%0  5Q<  $L8  !"&0  .AD  #08   P%P  +!<  "D6   G
M%0  )A0! "42!  C$@L (A(/ "$2%  @$AH 'A,@ !T3)P <$RX &A,V !D4
M0  7%$H %A16 !049  2%'0 $12' ! 4G  .%+$ #13*  T4ZP .$_X #A/_
M ',5  !A&   4QH  $@;   _&P  -QL  #(:   M&@  *1D  "88   D&
M(A<  " 6 0 >%@@ '18- !L7$@ :%Q< &1<= !@8)  6&"L %1@T !08/0 2
M&4@ $1E4 ! 98@ .&7( #1F$  P9F  *&:T "1C&  D8YP )&/H "A?_ &\8
M  !>&@  4!P  $4=   \'0  -1T  "\=   J'   )AL  ",;   A&@  'AH
M !P:   :&P4 &!L, !8<$  5'!4 %!P; !,<(@ 2'2D $1TQ ! =.P .'44
M#1Y1  P>7@ *'FT "1Z   <>E  %':H  QW"  ,=Y@ $'/@ !1S_ &L:  !;
M'0  31X  $(?   Z'P  ,A\  "T?   H'@  )!X  "$=   >'0  '!T  !@>
M   5'P( $R ) !(A#@ 0(1( $"$8  XA'P .(B8 #2(N  PB-P *(D$ "2)-
M  <B6@ %(FD  R)\  $BD0  (J@  "'    AY0  (/@  "#_ &<=  !7'P
M2B$  $ A   W(@  ,"$  "HA   F(   (B   !\?   <'P  &2   !8A   2
M(P( $"0'  XF#  ,)A  "R85  HF'  ))B( ""8J  8G,P $)ST  R=)  $G
M5@  )V8  "=Y   GCP  )J8  ":_   EY   )?D  "3_ &,@  !4(@  1R,
M #TD   T)   +B,  "@C   D(@  (2(  !XA   :(@  %R,  !,D   0)@(
M#B@'  LJ"P (*PX !BL3  0K&  "*Q\  2PG   L,   +#H  "Q%   L4P
M+&,  "QV   LC   *Z0  "N^   JY   *OH  "G_ %\C  !0)0  1"8  #HF
M   R)@  *R8  "8E   C)   'R0  !LD   7)0  %"<  !$I   .*P( "RT&
M  <O"P $, X  # 1   Q%0  ,1P  #$C   R+   ,C8  #)"   R3P  ,E\
M #)R   QB0  ,:(  #"\   PY   +_L  "__ %HG  !,*   0"D  #<I   O
M*0  *2@  "4G   A)@  '"<  !@H   4*@  $2P   XN   +, $ !S(%  ,T
M"0  -0P  #8/   W$@  .!@  #@@   X*   .#(  #D]   Y2P  .5L  #AN
M   XA0  -Y\  #>Z   VY   -?P  #7_ %4J  !(+   /2P  #0L   M*P
M*"H  "0I   >*@  &2L  !0M   1+P  #3$   HT   '-@   C@$   Z!P
M.PH  #T-   ^$   0!0  $ ;  ! )   0"X  $ Y  ! 1P  0%8  $!I  !
M@   /YL  #ZW   ]XP  //P  #S_ % O  !#+P  .2\  #(O   L+0  )RP
M " M   :+P  %3$  !$S   --@  "3@   4[    /0   $ !  !!!   0P<
M $4+  !&#@  2!$  $H6  !*'@  2B@  $HT  !)0@  25$  $ED  !(>P
M2)<  $>T  !&X   1?P  $3_ $HS   _,P  -C,  # Q   J,   (S$  !PS
M   6-0  $3@   T[   (/@   T$   !#    1@   $@   !*    3 0  $X'
M  !/"P  40X  %02  !5&0  52(  %0N  !4/   5$L  %->  !3=   4I
M %&N  !0UP  3_L  $[_ $4W   \-P  -38  "\T   F-0  'C<  !<Z   1
M/0  #$$   =$    2    $H   !-    4    %,   !5    5P   %@"  !;
M!@  70L  %\.  !B$P  8AL  &(G  !B-   844  &!7  !@;0  7XD  %VG
M  !<S   6O@  %G_ $$\   Z.P  -#D  "HZ   A/   &$   !%#   ,1P
M!DL   !/    4P   %8   !9    7    %\   !A    8P   &4   !G 0
M:@4  &T*  !P#@  <Q4  '(@  !R+0  <3T  '!/  !O90  ;H   &V?  !K
MP0  :?$  &C_ #]    Y/@  +C\  "1"   :1@  $DH   Q/   $5    %@
M  !=    80   &4   !H    :P   &X   !Q    <P   '4   !X    >P
M 'X#  "!"@  A0\  (<7  "&)   A30  (1&  ""70  @78  '^6  !^M@
M?.<  'K_ #]$   S10  *$@  !U,   34@  #%<   -=    8P   &@   !M
M    <0   '8   !Z    ?@   ($   "#    A@   (D   "+    C@   )(
M  "5 0  F0D  )X0  ">&@  G2D  )P\  ":4@  F&P  ):+  "4J@  DM0
M )#Z #A+   L3@  (%,  !59   -8    V<   !N    =    'H   "
MA    (H   ".    D@   )4   "7    F@   )T   "@    HP   *<   "K
M    KP   +0)  "X$   MQX  +4P  "S1@  L6   *]^  "LH   J\$  *GN
M #%5   D6P  &&$   YI   %<0   'D   "!    B    (\   "4    F@
M )\   "D    J    *D   "L    KP   +,   "U    N0   +T   #!
MQ@   ,L   #1"@  TQ0  -$E  #0.P  S50  ,IQ  #(D@  Q;,  ,/> "EB
M   <:0  $7$   =[    A    (T   "5    G0   *,   "I    KP   +0
M  "Y    O    +X   #"    Q0   ,@   #,    T    -0   #:    WP
M .0   #J    [@P  .T:  #L+P  ZDD  .AE  #FA@  Y*4  .+& /\   #_
M    _P   /P  0#\  @ _@ . /\ % #_ !T _P F /\ , #_ #H _P!" /\
M20#^ %  ^P!6 /D 7 #V &( ] !H /( ;P#P '8 [0!_ .H B0#G )4 Y "C
M .  M0#; -  U0#V ,H _P"V /\ J #_ )\ _P": /\ E@#_ /\   #[
M]@   /,   #S    ]@ ) /H #@#] !8 ^P @ /< *@#R #, [0 [ .D 0P#F
M $D X@!/ -X 50#; %L U@!@ -( 9P#/ &X S !V ,D @ #& (P P@": +\
MJ@"[ ,$ N #I +8 _P"G /\ F@#_ )( _P"- /\ B@#_ /H   #Q    Z@
M .<   #G    Y  ! .  "P#; !$ V@ : -L (P#1 "P R@ T ,8 .P#" $(
MOP!( +P 3@"Z %, N !9 +8 7P"S &8 L0!N *X =P"L (, J0"1 *8 H0"C
M +4 H #8 )X ^P"5 /\ BP#_ (4 _P"  /\ ?@#_ .\   #C    V@   -,
M  #&    OP   +D !@"W  X M  4 +0 '0"S "4 K@ M *L - "G #L I !!
M *$ 1@"? $P G0!1 )L 5P"9 %X EP!E )4 ;@"3 'D D "' (X EP", *D
MB0#$ (@ [P"% /\ ? #_ '8 _P!S /\ <@#_ .    #0    Q@   +8   "I
M    H0   )T  0"9  H F  0 )@ %@"7 !X E  F )$ +0"/ #0 C  Z (H
M/P"( $4 AP!* (4 4 "# %8 @0!> (  9@!^ '$ ? !] 'D C0!W *  =0"V
M ', WP!R /\ ;@#_ &D _P!G /\ 90#_ ,P   "^    JP   )T   "3
MB@   (4   ""  4 @  - '\ $0!_ !@ @  @ 'T )@!Z "T =P S '4 . !T
M #X <@!# '  20!O $\ ;0!6 &P 7@!J &@ : !U &< A !E )8 9 "K &(
MR0!A /8 8 #_ %P _P!; /\ 6@#_ +T   "I    EP   (D   !^    >
M ',   !O  $ ;0 ) &P #@!K !, :P 9 &H ( !H "8 9@ L &4 ,@!C #<
M8@ \ &  0@!? $@ 70!/ %P 5P!: &$ 60!M %< >P!6 (X 50"B %, NP!2
M .D 4@#_ %  _P!/ /\ 3P#_ *T   "8    A@   '@   !N    9P   &,
M  !@    70 % %P "P!; !  6P 5 %L &P!: "$ 6  F %8 + !4 #$ 4P V
M %( / !1 $( 3P!) $X 40!- %L 2P!F $H = !) (4 2 "9 $< L0!& -@
M1@#\ $4 _P!% /\ 10#_ )\   ")    >    &P   !B    6P   %8   !3
M    40 " $\ " !/  T 3@ 1 $X %@!- !P 3  A $H )@!) "P 2  Q $<
M-P!% #T 1 !$ $, 3 !" %4 0 !@ #\ ;@ ^ 'X /0"2 #P J0 [ ,< .P#S
M #L _P [ /\ / #_ ),   !^    ;@   &$   !8    40   $P   !)
M1P   $4 !0!$  L 0P . $, $@!# !< 0@ = $  (@ _ "< /@ L #T ,@ [
M #@ .@ _ #D 1P X %  -P!; #4 :  T '@ ,P", #( H@ Q +P ,0#G #$
M_P R /\ ,P#_ (D   !V P  9@4  %D'  !0!P  208  $,%  !  P  /@$
M #P  P [  @ .@ - #H $  Y !0 .0 9 #< '@ V ", -0 H #0 +@ S #0
M,@ [ #  0P O $P +@!7 "T 9  L ', *P"' "H G  I +4 *0#< "D ^P I
M /\ *@#_ ($$  !N"   7PH  %,+  !*"P  0@L  #T*   Y"0  -@@  #4%
M   T @8 ,P * #( #@ Q !$ ,0 5 #  &@ O !\ +@ D "P *@ K #  *@ W
M "D /P H $D )P!4 "8 8  D &\ (P"" "( EP A *X (0#, "$ \P A /\
M(@#_ 'L)  !H#   6@T  $X.  !%#@  /0X  #@-   S#0  , P  "X+   M
M"0, +08( "P$#  K @\ *@$2 "D!%P H 1P )P A "8 )P E "T )  T ",!
M/0 B 48 (0%1 !\!70 > 6P ' %_ !L E  : *H &@#% !H ZP 9 /\ &@#_
M '4,  !D#@  50\  $H0  ! $   .1   #,0   O#P  + X  "D.   G#0$
M)PP% "<*"@ F" T )0<0 "0&%  B!AD (08? " ')  ?!RL '@<R !T'.@ <
M"$0 &@A/ !D(7  7"&L %@A] !4'D0 4!Z< $P:_ !(%Y  2!?H $@7_ '$.
M  !?$   41$  $82   ]$@  -A(  # 2   K$0  *!$  "40   C$   (@X$
M "$-!P A# L ( L. !\+$@ ="Q< ' P< !L,(@ :#"D &0PQ !@,.0 6#4,
M%0U/ !,-7  2#6L $ U^  \-D@ .#:< #0R^  T,X  -#/4 #0S_ &T0  !<
M$0  3A,  $,4   Z%   ,A0  "T4   H$P  )1,  "(2   @$0  'A$# !P0
M!0 <#P@ &P\, !H.$  9#Q0 %P\: !8/(0 5$"@ %! P !(0.0 1$$0 $!!0
M  X070 -$&L #!!\  L0D  )$*4 "!"\  <0WP '$/0 !P__ &D1  !8%
M2Q4  $ 6   W%@  ,!8  "H6   F%0  (A4  !\4   =$P  &A," !D2!  7
M$@8 %A(* !42#@ 4$A( $A(8 !$3'@ 1$R4 $!,N  X3-P -%$  #!1+  L4
M6  )%&< !Q1X  84C0 $%*,  Q.[  (3W0 !$O0  A+_ &43  !5%@  2!<
M #T8   T&   +1@  "@8   C%P  (!<  !T6   :%0  &!4" !85!  4%04
M$A8( !$6#0 0%Q  #A<5  X7&P -%R( #!<I  L8,@ )&#P !QA'  485  $
M&&,  AAU  $8BP  %Z$  !>Y   7W0  %O4  !;_ &$6  !2&   11H  #L:
M   R&@  *QH  "4:   A&0  'A@  !L8   8%P  %A<" !07 P 2& 4 $!D'
M  X;"P ,&P\ "QL3  H;&  ('!\ !QPF  4<+P $'#@  AQ$   =40  '6
M !UR   <B   '*   !NY   ;W@  &O8  !K_ %X8  !/&@  0AP  #@<   O
M'0  *1P  ",<   ?&P  '!H  !D9   7&0$ %!D" !(: P 0&P0 #AT'  P>
M"P )'PX !B 1  4@%@ #(!P  2$C   A*P  (34  "%    A3@  (5T  "%O
M   AA@  ()X  ""X   ?W@  'O@  ![_ %H;  !+'0  /QX  #4?   M'P
M)QX  "(=   >'0  &QP  !@;   5&P  $AP  ! = @ .'P0 #"$&  DB"@ %
M(PT  B00   E$P  )1D  "8@   F*   )C(  "8]   F2@  )EH  "9L   F
M@P  )9P  "6W   DWP  (_D  "/_ %4>  !'(   /"$  #(A   K(0  )2
M " ?   ='@  &AT  !8>   3'@  $"    XA   ,(P( ""4%  4G"0  * L
M "H.   K$0  +!8  "P=   L)0  +"X  "PZ   L1P  +%8  "QI   L@
M*YH  "JU   IWP  *?L  "C_ %$B  !$(P  ."0  "\D   H(P  (R(  !\A
M   <(   %R   !,A   0(P  #B0   LF   (*   !"H$   L!P  +@D  # ,
M   Q#P  ,Q,  #,9   S(0  ,RH  #,U   S0P  ,U(  #-E   R>P  ,I<
M #&S   PW@  +_L  "[_ $PE   _)@  -2<  "TF   G)0  (B0  !XC   9
M(P  %"0  !$F   .*   "RH   <L   #+P   #$"   S!   -0<  #<*   Y
M#0  .A   #L5   ['0  .R8  #LQ   [/@  .TX  #M@   Z=P  .9(  #BP
M   WVP  -OP  #7_ $<I   [*@  ,BH  "LI   E)P  (28  !LG   5*
M$2H   XL   *+P  !C$   $T    -@   #@    [ 0  /00  #\'  !!"@
M0PX  $41  !%&   12$  $4L  !$.0  1$@  $1;  !#<0  0HT  $&K  !
MT@  /_H  #[_ $(M   X+@  +RT  "DK   D*@  '2H  !<L   1+@  #3$
M  DT   $-P   #H    \    /P   $$   !$    1@   $@#  !*!P  3 L
M $X.  !0$P  4!P  % G  !/-   3T,  $]5  !.:@  388  $RD  !*R@
M2?@  $C_ #XR   U,0  +B\  "DN   @+@  &3$  !(S   .-P  "3H   (]
M    0    $0   !'    20   $P   !/    40   %,   !5 0  6 8  %H+
M  !=#@  7Q4  %X@  !>+   73P  %Q.  !;8P  6GX  %B=  !7P   5?(
M %3_ #HV   S-   +3(  "0S   ;-@  $SD   X]   (00   $4   !)
M3    %    !3    5@   %D   !;    70   &    !B    90   &@%  !K
M"P  ;Q   &\8  !N)0  ;30  &U&  !K6P  :G4  &B4  !FM@  9.D  &+_
M #@Y   R-P  *#D  !X[   5/P  #D0   =)    30   %(   !6    6@
M %X   !B    90   &@   !K    ;0   '    !S    =@   'D   !]!
M@0L  (41  "$'0  @BP  ( ^  !^5   ?FL  'N*  !ZJ@  =]8  '7] #@]
M   L/@  (D$  !=&   /2P  !U$   !7    7    &(   !F    :P   &\
M  !T    >    'L   !^    @    (,   "&    B@   (T   "1    E@,
M )L,  "=$P  FR$  )HS  "720  E&(  )-_  "0H   CL4  (SS #%$   E
M2   &DT  !!3   (6@   &$   !H    ;@   '0   !Y    ?P   (0   ")
M    C0   )$   "3    E@   )D   "=    H    *0   "H    K    +(#
M  "W#0  MQ<  +4H  "R/@  L%8  *QS  "JE   J;0  *7E "I/   >5
M$EL   IB    :@   ',   ![    @@   (D   ".    E    )H   "?
MI    *8   "I    K0   +    "S    MP   +L   #     Q0   ,L   #1
M!   U0X  -,=  #0,@  S4L  ,IF  #&AP  PJD  ,'+ ");   68@  #&L
M  %T    ?0   (<   "0    EP   )X   "D    JP   +$   "V    N@
M +P   #     Q    ,@   #+    SP   -0   #:    X    .8   #K
M\08  / 3  #N)P  [#\  .I;  #G>@  Y)L  ."[ /\   #[    ]@   /,
M  #T  4 ]@ , /H $0#_ !D _P B /\ + #_ #4 _P ] /\ 10#\ $P ^@!2
M /< 6 #U %X \P!D /$ :@#N '( [ !Z .D A0#E )$ X0"@ -T L@#8 ,X
MT@#V ,$ _P"M /\ G@#_ )8 _P"0 /\ C #_ /H   #R    [    .D   #I
M    [  % /( # #X !( ]P ; /4 )0#P "X ZP W .8 /@#B $4 W0!+ -@
M4 #3 %8 T !< ,T 8@#* &H R !R ,4 ? #" (@ O@"6 +H J "W +\ M #H
M *X _P"= /\ D #_ (@ _P"# /\ @ #_ /    #E    W@   -H   #;
MW    -@ !P#1  X T0 5 -( '@#+ "< Q0 O ,  -P"] #T N@!$ +< 20"U
M $\ L@!5 +  6P"N &$ K !I *D <P"G '\ I "- *$ G@"> +( FP#5 )D
M_ ", /\ @@#_ 'L _P!V /\ = #_ .(   #3    R@   ,<   "\    M@
M +   0"O  L K  1 *T & "M "  J  H *0 +P"@ #8 G0 \ )L 0@"9 $<
MEP!- )4 4P"3 %D D0!A (\ :@", '4 B@"# (@ E "& *< @P#" (( \ !\
M /\ <P#_ &T _P!J /\ : #_ ,\   #!    N0   *T   "@    F    )0
M  "1  8 D  - )  $@"/ !D C@ A (L * "( "\ A@ U (0 .@"" $  @ !%
M 'X 2P!\ %( >@!9 '@ 8@!V &P = !Y '( B0!Q )T ;P"T &T WP!L /\
M90#_ &  _P!> /\ 7 #_ +X   "Q    H    )(   ")    @@   'P   !Z
M  $ >  ) '< #@!X !0 =P : '0 (0!R "< <  M &X ,P!L #@ :P ^ &D
M1 !H $H 9@!1 &0 6@!C &0 80!P %\ ?P!> ), 70"I %P R !; /< 5P#_
M %0 _P!2 /\ 40#_ +    "?    C0   '\   !T    ;@   &H   !F
M90 $ &, "P!C !  8P 5 &, &P!A "$ 7P G %T + !< #( 6@ W %D /0!7
M $, 5@!+ %4 4P!3 %P 4@!H %  =P!/ (D 3@"? $T N@!, .D 2P#_ $D
M_P!' /\ 1P#_ *(   "-    ?    &X   !E    7@   %D   !7    50 !
M %0 !P!3  T 4P 1 %0 %@!2 !L 40 A $\ )@!. "L 3  Q $L -P!* #T
M20!$ $< 3 !& %8 1 !A $, < !" ($ 00"7 $  KP _ -< /P#_ #X _P ]
M /\ /@#_ )0   !_    ;P   &,   !9    40   $T   !*    2    $<
M! !'  H 1@ . $8 $0!' !8 10 < $0 (0!" "8 00 K $  ,0 ^ #< /0 ^
M #P 1P Z %  .0!; #@ :0 W 'H -@"/ #4 IP U ,8 - #U #0 _P T /\
M-0#_ (@   !T    90   %@   !/    2    $,    _    /0   #P  @ \
M  < .P , #L #P [ !( .@ 7 #D '  W "$ -@ F #4 +  T #( ,P Y #$
M00 P $L +P!6 "X 8P M ', + "( "P H  K +L *P#J "L _P K /\ + #_
M '\   !L    70$  %$"  !( P  0 ,  #L"   W    -    #,    R  4
M,@ ) #( #0 Q !  ,0 3 #  &  O !T +0 B "P *  K "X *@ U "D /0 H
M $8 )P!1 "8 7@ E &X ) "" ", F0 C +, (@#> "( _P C /\ ) #_ '<
M  !E!   5@8  $L'  !""   .@@  #4'   P!@  +04  "P#   K  , *@ '
M "D "P I  X *0 1 "@ %0 G !D )@ > "4 )  D "H (P Q "( .0 A $,
M( !. !\ 6@ > &D '0!\ !P DP ; *P &P#- !L ]@ ; /\ ' #_ ' %  !?
M"   40H  $8+   ]"P  -0L  # +   K"@  * D  "4(   D!P( (P0& ","
M"0 B 0P (@ / "$ $@ @ !8 'P ; !X (  = "8 '  N !L -@ : #\ &0!*
M !@ 5P 7 &8 %@!X !4 CP 5 *8 % ## !0 [@ 4 /\ %0#_ &L(  !;"P
M30P  $(-   Y#0  ,0T  "P-   G#0  (PP  "$,   ?"P$ '@H% !T("  =
M!@L ' 4- !P$$  ;!!0 &008 !D$'@ 8!", %P0K !8$,P 5!#P % 1' !,#
M5  2 V, $0-U ! "B@ 0 :( #P"\  \ Y0 / /X $ #_ &<+  !7#0  20X
M #X/   U#P  +@\  "@/   D#@  ( X  !T.   ;#0$ &0T$ !@,!P 8"PD
M%PD, !<)#@ 6"1( %0D6 !0)&P 3"2$ $@DH !(),  1"3H $ E%  \)4@ .
M"6$ #0ES  P(B  +")\ "@>W  H&VP *!?8 "@3_ &,-  !3#@  1A   #L1
M   R$0  *Q$  "40   A$   '1   !H/   8#P$ %@X$ !4.!P 4#0D $PT+
M !,,#0 2#!  $0P4 ! ,&0 0#!\ #PPG  X-+P -#3D # U%  L-40 )#6
M" UQ  8-A@ %#9T ! RT  ,,T@ "#/$  @O_ %\.  !0$   0Q$  #@2   O
M$@  *!(  ",2   >$0  &Q$  !@1   5$ ( %! % !(0!P 1#PD $ \* ! .
M#  .#@X #@\2  T/%P ,$!T #! D  H0+  )$#8 "!!!  803@ %$%T  Q!O
M  $0A   $)P   ^T   .U   #O,   [_ %P0  !-$@  0!,  #84   M%
M)A0  "$3   <$P  &1(  !82   4$0, $A$& !$1"  0$ H #A +  T1"P ,
M$0T "Q(1  H2%0 )$AH "!(A  83*0 %$S,  Q,^  (32P  $UH  !-L   3
M@@  $IL  !*T   1UP  $?4  !'_ %@2  !)%   /14  #,6   K%@  )!4
M !\5   :%   %Q0  !03 0 3$@0 $1(' ! 2"0 .$@D #1()  L3"@ )% T
M!Q4/  86$P $%A@  Q8?  (6)P  %S   !<[   72   %U@  !=J   6@
M%ID  !6T   5V0  %/<  !/_ %44  !&%@  .A<  # 8   H&   (A<  !T6
M   9%@  %A4  !,4 P 2$P8 $!,'  \3!P -% < "Q4(  D6"0 && P  QH.
M  $:$0  &A8  !L<   ;)   &RT  !LX   ;1@  '%4  !MG   ;?0  &Y<
M !JS   9VP  &/D  !?_ %$6  !#&   -QD  "X:   F&@  (!D  !L8   8
M%P  %18! !,5!0 1%00 #Q4$  T6!  +%P4 "1D&  8:"  "' H  !X-   @
M$   (!,  " 9   @(0  (2H  "$U   A0@  (5(  "!D   @>@  'Y4  !^Q
M   >VP  '?H  !S_ $T9   _&P  -!P  "L<   D'   'AL  !H:   7&
M%!<" !(7 @ 0& $ #1D!  L: @ (' , !1T$  (?!@  (0@  ",+   E#@
M)A$  "86   F'@  )R<  "<R   G/P  )DX  "9@   F=P  )9(  "2O   C
MV@  (OL  "'_ $@=   \'@  ,1\  "@>   B'@  '1P  !D;   6&@  $AH
M ! ;   -'   "QT   @?   $(0   2,"   E!   )P8  "D)   L#   +@\
M "X3   N&@  +B,  "XN   N.P  +DH  "U<   M<@  +(X  "NL   JU
M*?L  "C_ $0@   X(0  +B$  "8A   @(   '!X  !@=   4'0  $!X   X?
M   +(0  !R,   ,E    )P   "D    L 0  +@,  # &   S"@  -0T  #81
M   V%P  -A\  #8I   V-@  -D4  #57   U;0  -(D  #*H   QSP  ,/H
M "__ #\D   T)   *R0  "0C   ?(0  &R   !8@   1(0  #B,   HE   &
M*    BH    M    +P   #(    T    -P   #D#   [!@  /@H  $ .  !!
M$@  01H  $ E  ! ,0  0$   #]2   ^9P  /8(  #RB   ZQP  .?@  #C_
M #HH   P*   *2<  ",E   ?(P  &"0  !(E   .*   "BH   4M    ,
M #,    V    .    #L    ^    0    $(   !% @  1P8  $H*  !-#@
M314  $P?  !,*P  2SH  $I,  !)80  2'P  $>;  !%OP  0_,  $+_ #8L
M   M*P  )RD  ",G   ;*   %"H   XM   *,   !#,    W    .@   #T
M  !     0P   $8   !(    2P   $T   !0    4P$  %8&  !9"P  6Q
M %L9  !:)0  630  %A&  !76@  570  %23  !2M0  4.H  $__ #,P   L
M+@  )RP  !XM   6+P  $#(   HV   #.@   #\   !"    1@   $D   !,
M    3P   %(   !5    6    %H   !=    8    &,   !G!@  :PP  &P2
M  !K'@  :RP  &D]  !G4@  9FH  &2)  !AJP  7]P  %W_ #$S   L,0
M(C(  !DU   1.0  "CT   )"    1P   $P   !0    5    %@   !;
M7P   &(   !E    :    &L   !N    <0   '4   !Y    ?08  ((-  ""
M%@  @"0  'XU  !\20  >V$  'A_  !VGP  <\8  '#W #$V   F.   '#L
M !)    +10   DL   !1    5@   %L   !@    90   &D   !N    <@
M '8   !Y    ?    'X   ""    A0   (D   ".    DP   )@&  "<#@
MFQH  )@K  "60   DED  )%S  "-E0  B[4  (CH "L^   @00  %4<   U-
M   "5    %L   !A    :    &X   !S    >0   'X   "#    B    (P
M  "/    D@   )4   "9    G0   *$   "E    J@   +    "W!P  N!$
M +4A  "R-0  KTT  *II  "HB   IJ@  *+1 "-(   83@  #E0   1<
M9    &T   !U    ?    (,   ")    CP   )4   ";    H    *,   "F
M    J0   *T   "Q    M0   +D   "^    Q    ,H   #2    V@H  -86
M  #2*0  SD$  ,I<  #%?   PIT  ,&] !Q5   17   !V4   !N    =P
M '\   "(    D    )@   "?    I0   *T   "S    N    +H   "^
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M____________________________________________________
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M%!46%Q@9&AL<'1X?("$B(R0E)B<H*2HK+"TN+S Q,C,T-38W.#DZ.SP]/C]
M04)#1$5&1TA)2DM,34Y/4%%24U155E=865I;7%U>7V!A8F-D969G:&EJ:VQM
M;F]P<7)S='5V=WAY>GM\?7Y_@(&"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:
MFYR=GI^@H:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<;'
MR,G*R\S-SL_0T=+3U-76U]C9VMO<W=[?X.'BX^3EYN?HZ>KK[.WN[_#Q\O/T
M]?;W^/GZ^_S]_O]M9G0Q      ,$(0   0                    $
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MH#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN
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M_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN E:S'?)FQQ7F>M<)VH[G
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M6%S]DUA<_9-87/V36%S]DUA<_9-87/V36%S]DUA<_9-87/V36%S]DUC6Q @
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ML,&'C;#!AXVPP8>-L,&'C;#!AXVPP8>-L,'_EQL#_Y4G"/^=+PW_J3@3_[-
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M_XXE!_^6+ O_HC40_ZP]&/^U12/_O$PR^,%40_##7%;GPV-JVKMI?LRR<(_
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M0U'_GT-1_Y]#4?^?0U'_GT-1_Y]#4?^?0U'_GT-1_Y]#4?^?0U'_GT/&O@4
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MVH?38-J'TV#:A]-@VH?38-J'TV#:A]-@VH?_@QP#_X G!_][,PW_AC@1_XY
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M9$G_G6]8^IAY9?&2@W'JBXQ\Y(.2AM]]F8[:>*"5UG2GFM-PKI_1;;:CSVO
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M;%3NM&U4[K1M5.ZT;53NM&U4[K1M5.ZT;53NM&U4[K1M5.ZT;53NM&W_HQ
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M44__PU%/_\-13__#44__PU%/_\-13__#44__PU':KP( QKP% +G)!0"MVP@
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MJT(;];!))^RU4#;CL%I&V*EC5\RA:V;"FG)RNI-Z?+.-@86LB(F,IH20D:&
MF):=?:&:F7NJG)9[MIV4>\:>DGO-F)%\TY"/?-F(CWS<A8]\W(6/?-R%CWS<
MA8]\W(6/?-R%CWS<A8]\W(7_>1H#_WHB!?^*(@7_EBD'_Z Q"_^H.1'[KT$:
M\K1()NFY3S3?M%E%TJUA5L>E:66]GG!RM)=W?*V1?H6FC(:,H(B-D9J%E9:6
M@IZ:DH"GG8]_LYZ-@,*>BX#,FHN!TI**@-B)B8#;AHF VX:)@-N&B8#;AHF
MVX:)@-N&B8#;AHF VX;_>1H"_WLA!/^+(@7_F"@'_Z,P"O^K.!#YLD 8[[A'
M).:]3C/;N%=$S;!@5L*I9V2XHFYQKYMU>Z>6?(2@D8.+FHV+D92*DY:/AYN:
MBX6EG8B$L)^%A+^?A87+FX6%T9.%A=B*A(3:AX2$VH>$A-J'A(3:AX2$VH>$
MA-J'A(3:AX2$VH?_>AD"_WT@!/^-(07_FR@&_Z4O"?^N-P[VMC\7[+Q&(N/!
M3C#5O%9#R+1>5;VL9F.SIFQPJI]S>Z&:>H2:EH&+E)*(D8Z/D):)C)F:A(JC
MG8&*KI]^BKR??HK*G'^*T)1_B=:+?XC9B'^(V8A_B-F(?XC9B'^(V8A_B-F(
M?XC9B'^(V8C_>AD"_W\>!/^0(03_G2<%_Z@N"/ZR-@WSNCX5Z<%%']_%3"_0
MOU1"Q+==4[BP9&*NJFIOI*1Q>IR?=X.4FWZ*CIB&D(>5CI6"DI>9?9"@G'J/
MJYYXC[F?=Y'*G7F0SY5YCM:,>8W8B7F-V(EYC=B)>8W8B7F-V(EYC=B)>8W8
MB7F-V(G_>QD"_X$=!/^2( 3_H"8%_ZLM!_NU-0OPOCT2YL=$'-K)22[+PU-!
MOKQ;4K.U8F&HKVENGZIO>):E=8&.H7R)AYZ#CX&;BY1[F928=Y>>FW.6J9UQ
MEK:><)?(G7*6SY5SE-6,=)/8B723V(ETD]B)=)/8B723V(ETD]B)=)/8B723
MV(G_?!@"_X0< _^5'P/_HR4$_Z\L!O>Z,PGLQ#L/XLY"&-/.2"S&QU) N<!:
M4:VZ85^CM&=LF;!M=Y"K=("(J'J'@:6!C7JBB9)UH)*6<)Z;F6R>IYMJGK2<
M:9_%FVR>T)1MFM:,;9G8B6V9V(EMF=B);9G8B6V9V(EMF=B);9G8B6V9V(G_
M?1@"_X<: _^8'@/_IB,#_[,I!// ,0?GRS@+W=@Z%LW21BK S% ^L\983Z?
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M=$_3YW1/T^=T3]/G=$_3YW1/T^=T3]/G=$_3YW3_CP\!_Z0. -NX" #-Q0D
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M>%ZGY7A>I^5X7J?E>%ZGY7A>I^5X7J?E>%ZGY7C_>A4"_XX2 ?^?$P#_L!,
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M9U>O\6=7K_%G5Z_Q9U>O\6?_?PX!_Y,+ .&E!0#2LP< R;X' ,++" "\W0X
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M&S#_H1LO_ZH<+_^U'"[_OQPN_[\<+O^_'"[_OQPN_[\<+O^_'"[_OQRIM0
MFL(  (S/  !_W@  =O\% &S_#@%B_Q0"6O\; U/_) 5-_RL'1_\S"4/_.@H_
M_T$+._]'##C_30TU_U,.,_]8#S'_7@\O_V00+?]K$2O_<Q$I_WP2)_^&$B7_
MD!,D_YD3(_^C%"+_JQ0B_ZL4(O^K%"+_JQ0B_ZL4(O^K%"+_JQ2<O@  C<L
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M7VB2]U]HDO=?:)+W7VB2]U__;Q$!_X$. /^1#@#RH P VJT) -.X"@#.PPX
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M.$+PQ#A!\-\Y0>_O.$#M_3A [/\X0.S_.$#L_SA [/\X0.S_.$#L_SC+H
MNJL  *VT  "AP   ELP! (O9!0"$^!$!?/@? G3X*09L^#(*9/@[#U[Y0Q-8
M^4L74_E3&E#Y6QU-^F0?2OIL(4CZ="-&^GXE1/N()D'[DRA ^YXI/ORK*CW\
MN2L[_<LK._WB*SK\]"LZ_/<K.OSW*SK\]RLZ_/<K.OSW*SK\]RN]J   KK
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M#AO_K \;_ZX/&_^N#QO_K@\;_ZX/&_^N#QO_K@^7O   B,D  'G6  !KXP
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M47F!_U%Y@?]1>8'_47F!_U'_91,!_W4. /^##@#_D X ]9L. .BF#@#9KP\
MS*\D L*K-0RXIT,9KJ).)J:=5C&>F5X[EY5F1)"1;4N+CG11AHQ[5H&)@UM\
MAXM?>(:58G2$GV5Q@ZMH;H.Z:6V#SFEOANMC<H?Y7'.&_59SA?]2<X7_4G.%
M_U)SA?]2<X7_4G.%_U+_:!$!_W@- /^&#0#VDPP WJ ) -:I"@#2L@T Q[(B
M KVO,PJSJT$7JJ=,)*&B53"9GETZDIID0HN7:TF%E')0@))Y57N/@5IVC8E>
M<HR28FZ*G65KB:EG:(FX:&>)RVAIB^EC;(WY7&V,_5=MBO]2;8K_4FV*_U)M
MBO]2;8K_4FV*_U+_:Q !_WL+ /^*"@#BF 8 UJ,( -"L"0#+M0L P;8? ;BT
M,0FNL#\6I*Q*(IRH4RZ4I%LXC*!B0(:>:4B FW!.>IEW4W66?EAPE(=<;).0
M8&B2FV-DD:=E8I"V9F"1R69BDN=B993X7&>2_5=GD?]29Y'_4F>1_U)GD?]2
M9Y'_4F>1_U+_;@X _W\) /&.!0#9FP4 SZ8' ,FO!P#$N0@ N[H< ;*X+P>H
MM3T3G[%(():N42N.JEDUAJ=@/H"E9T5ZHFY+=*!U46^>?%5JG(599IN.76*:
MF6!>F:9B7)FT8UJ9QV-;FN5@7YOW6V":_E9AF/]289C_4F&8_U)AF/]289C_
M4F&8_U+_<@L _X,% -^3 0#1GP0 R:H& ,&R!0"[O00 M+\8 *N^+ 6BNSH1
MF;A%'9"U3RB'LE<R@*]>.GFM94)SJVQ(;JES36FG>E%DIH-67Z2-65RCF%Q8
MHZ1>5J.S7U6CQE]5I.1=6*3V6%JC_U1;H?]06Z'_4%NA_U!;H?]06Z'_4%NA
M_U#_=P< \(D  -:8  #+I , P:T$ +FV P"RP 0 J\44 */%* 2;PC<.D<!#
M&8F]3"2 NE4N>;A<-G*V8SUMM&I#9[-Q2&*Q>4Q>L(%06J^+5%:OEU93KJ-8
M4*ZR64^NQEE/KN184:[V5%.N_U!4K/]-5*S_352L_TU4K/]-5*S_352L_TW_
M?0  WX\  ,Z=  ##J ( N; " +"Z @"HQ 4 H<P/ )O,(P*2RC,*B<@_%8'&
M21]YQ%(H<L):,&O!83=FOV@\8;YP05R]>$58O(%)5+R+3%&[ED].NZ-13+NS
M4DJ[QE)*N^113+OV3DVZ_TM.N?])3KG_24ZY_TE.N?])3KG_24ZY_TGOA0
MU)4  ,>C  "ZK $ L+0  *>_ P">R08 E=0+ )#5'0&)U"X&@-(\$'C01AEQ
MST\A:LY8*63-7R]?S&<T6LMN.5;*=SU2RH! 3\F+0TS)ET5)R:1'1\FS2$;*
MR$A&RN9'1\GW14?(_T-(Q_]"2,?_0DC'_T)(Q_]"2,?_0DC'_T+>C0  RYP
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M(C;X\R(V]_PB-O?\(C;W_"(V]_PB-O?\(C;W_"*WI@  J:X  )RY  "0Q
M@\\  '?;  !O]@H 9_\3 6#_'0):_R<#5/\P!4__. A*_T *1O](#$/_3PY
M_U8//?]>$#O_91(X_VX3-O]W%#3_@A4R_X\6,/^;%R__J1<N_[<8+?_(&"S_
MX1@L_^\8+/_O&"S_[Q@L_^\8+/_O&"S_[QBKJP  GK4  )#!  ""S   ==D
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M0XAT_T.(=/]#B'3_0XAT_T/_71(!_VL. /]X#@#_@P\ _8P0 .V4$@#@FA4
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M5UF5P5=8E=Y66Y;S4%V7_TQ?E_]'8);_1F"6_T9@EO]&8);_1F"6_T;_< ,
MZX$  -:/  #*F@$ P:,# +FJ @"QL@$ JK<1 *.W) *;M30*D[) %(JO2AZ#
MK5,G?*M:+G:H835PIV@[:Z5O0&>C=T1BHG](7J&)3%J@E$]7GZ!15)^N4U.?
MP%-2G]U259_S3E>@_TI9H/]&69__15F?_T59G_]%69__15F?_T7_=0  X(8
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M.T3#_SE%PO\W1<'_-T7!_S=%P?\W1<'_-T7!_S?5BP  Q9H  +>D  "KK
MH+0  ):^  "+QP0 @= ( 'C9#@!UV2 !;]@O!&G8/ ECUD807M90%5G56!I5
MU& ?4=1H(D[4<29+TWLI2-.%*T73DBY"U)\O0=2O,#_5PC$_U>$P/]/R,#_2
M_2\_T?\N/]#_+C_0_RX_T/\N/]#_+C_0_R[*E   NZ$  *VI  "BL0  EKL
M (O$  " S0, ==@( &_D$0!JY" !9.0M U[D. =9Y$$+5>1+#U'D5!)-Y%T6
M2N1E&$?D;AM%Y'<=0N2"'T#DCB$^Y9LC/.6J)#OFO"0ZYM,D.>7N)#GC^B,Y
MXO\D.>+_)#GB_R0YXO\D.>+_)#GB_R2_G@  KZ8  *.N  "7N   BL(  '[,
M  !SU@( :>4) &3O% !?\" !6? K U3P-05/\#X'2_%&"D?Q3@Q$\5<.0O%?
M$#_R9Q(]\G 4.O)[%3CSAQ8V\Y08-?2B&3/TL1DR]<4:,?7B&C'T\1DQ\?X9
M,?'_&3'Q_QDQ\?\9,?'_&3'Q_QFRI   I:L  )BV  "+P   ?LH  ''5  !E
MW@  7O4* %G\$P!3_!X!3OPG DK], -%_3D%0?U !C[^2 <[_D\)./]7"C;_
M7@LS_V<,,?]P#2[_? XL_XD/*_^6$"G_I! H_[01)__'$2?_X1$F__(1)O_V
M$2;_]A$F__81)O_V$2;_]A&GJ0  F;,  (N^  !^R0  <-,  &3>  !8YP
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M,YME_S.;9?\SFV7_,YME_S/_51,!_V . /]K#@#_=!  _WL2 /6!%P#HA!X
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M3VA\P5!G?-U0:G[S26V _T-N@?\_;X'_/&^!_SQO@?\\;X'_/&^!_SS_9 @
M_W(  .%_  #3B0$ RI(# ,.8! "]G@0 MJ 3 *Z@)P*EG38)G9I#$Y:731R/
MDU4DB9%=*X2.9#%_C&LW>HIR.W:(>4!RAH)$;H6+1VJ#E4IG@J%-9(*N3V*"
MOT]A@MI/9(3R26:%_T-HAO\_:H;_/&J&_SQJAO\\:H;_/&J&_SS_9P0 ]G8
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M1%.;_$!5F_\\5IO_.E:;_SI6F_\Z5IO_.E:;_SKQ=   V8,  ,B0  "^F@
MLZ$  *JG  "AK@  E[4& )*V& ",M2H#A;0W"7ZR0A%WL$P8<:Y4'VRM6R5G
MJV(J8JII+UZI<3-:J'HW5J>#.E.FCCU0IIM 3:6I04NEND)+IM%"2Z7M/TVE
M_#Q.I/\Y3Z3_-T^D_S=/I/\W3Z3_-T^D_S?D>@  SXD  ,*5  "VGP  K*4
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M)3O*_R4[RO\E.\K_)3O*_R7#DP  M9X  *BF  "=K@  D;8  (6_  !YQP
M;\X$ &36"0!>WA$ 6]X@ %?>+0)3WSH$4-]$!DS?3@E)WU<,1M]?#T/?:!%!
MWW$3/M]\%3S?B1<ZX)89.."E&C?@MQHVX<T:-M_L&C7>^1HTW?\;--S_&S3<
M_QLTW/\;--S_&S3<_QNYG   JJ0  )ZK  "2M0  A;X  'G'  !MSP  8M8#
M %CA" !5ZA, 4>L@ $WK*P%)ZS4"1>P^!$+L1P4_[$\'/>U8"3KM8 HX[6H,
M-NYT#3/N@ XR[HX/,.^=$"[OK1$M\, 1+?#>$2SN\1$L[/X1+.O_$"SK_Q L
MZ_\0+.O_$"SK_Q"MH@  H*D  ).S  "&O0  ><8  &S/  !@V   5=X  $[S
M"@!*]Q, 1O@= $/X)P$_^# "._DX CCY0 ,U^D<$,_I/!3#[5P4N^U\&*_QI
M!RG\= @G_(())?V0"23]H HC_K *(O[$"R'_X LA_?(*(/S\"B#\_ H@_/P*
M(/S\"B#\_ JBIP  E;$  (>[  !YQ@  ;,\  %_9  !2WP  2.@  $/_"  _
M_Q  ._\9 #?_(0 T_RD!,/\P 2W_-P(J_SX")_]$ B7_2P,B_U,#(/]< QW_
M9@0;_W($&?^ !1?_CP46_Y\&%?^O!A3_P 84_]8&$__I!A/_Z083_^D&$__I
M!A/_Z0:7KP  B+H  'K%  !LSP  7MH  %#@  !$Y@  //4  #?_!  S_PT
M+_\3 "O_&@ H_R$ )?\G 2'_+0$>_S(!&_\X 1G_/P$6_T8"%/]- A'_5@(0
M_V "#O]L @S_>P,+_XL#"O^: PK_J ,)_[4#"/_" PC_P@,(_\(#"/_" PC_
MP@.*N   >\,  &S.  !>VP  3^(  $+G   V[   ,?\  "S_   G_P< (_\.
M "#_$@ <_Q@ &/\= !7_(0 2_R8 $/\L 0[_,0$-_S<!"O\^ 0C_1@$%_T\!
M ?]9 0#_9@$ _W0! /^" @#_D ( _YP" /^F @#_I@( _Z8" /^F @#_I@+_
M+B\"_S,L O\W+0+_.# "_S<V _\T/P3_,4L&_R]8!_\L9@C_*G0)_RF!"O\H
MC0O_*)<+_RB?"_\HI@S_)ZT,_R>T#/\GNPS_)\0,_R?.#/\HW@O_*.D+_RCS
M"_\H^PO_*/\*_RG_"O\I_PK_*?\*_RC_"O\H_PK_*/\*_RC_"O\H_PK_,"T"
M_S8J O\Y*@+_.RX"_SHT _\X/ 3_-DD&_S-6!_\Q8PG_+W$*_RU^"_\MB@S_
M+)0,_RR<#?\LI W_+*L-_RRQ#?\LN0W_*\$-_RS+#?\LV@W_+.<-_RSQ#?\L
M^@W_+/\,_BW_#/TM_PS]+?\,_2S_"_TL_PO]+/\+_2S_"_TL_PO_,BL!_SDH
M O\]* +_/RH"_SXP _\].@3_/$8&_SE3"/\W8 G_-6T+_S-Z#/\RA@W_,9 .
M_S&9#O\QH0__,:@/_S"N#_\PM0__,+T0_S#'$/\PU!#_,.00_S'O$/XQ^0_[
M,?\/^3'_#_@Q_P[W,?\.]S'_#O8Q_P[V,?\.]C'_#O8Q_P[_-2@!_SPE ?]
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M1'=JPD1V:MU$>&SS/GEN_SAZ;_\T>W#_,'QP_S!\</\P?'#_,'QP_S#_6P@
M_V8  .=R  #:>P  SX(# ,F'!0#$B@8 O(P5 +2+* *LB3@'I85$$)Z"3AB8
M?U<>DWQ?)(YY9BJ*=VTNAG5T,H)T?#9_<H0Y?'&-/7EPET!V;Z)"<VZO1'%N
MP$5P;ME%<G#Q/W-R_SEU<_\U=G3_,79T_S%V=/\Q=G3_,79T_S'_708 _VD
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M0&* _#ID@/\V98'_,V:!_S)F@?\R9H'_,F:!_S+_9   Y7(  --^  #'AP
MOH\  +:5  "NF0  IIL, *"<'@"9FRX$DID["HN61A*%E$\9?Y%7'WJ/7B5U
MCF4J<8QL+FV*<S)IB7LV9HB$.6*&CSU?A9H_7(6H05J%MT)9A<Q"6H7J/UR&
M^SI>AO\V7X?_,E^'_S)?A_\R7X?_,E^'_S+]:   X'8  ,V"  #"C   N9,
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M+DN?_RU+G_\M2Y__+4N?_RW=>0  R88  +R2  "QF@  IJ   )RF  "1K
MAK(  'VV#0!YMAT =;8L F^U.09JM$,+9;-,$6"R5!9<L5L:6+!C'E6O:R%1
MKW,E3JY]*$NMB"I(K94M1:VC+D2MLR]#K<@O0JSG+T.K^2U$J_\K1*K_*42J
M_RE$JO\I1*K_*42J_RG1@   P8T  +68  "IGP  GJ4  ).L  "(L@  ?;@
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M$R_4_Q.SF@  IJ$  )JI  "-L0  @+H  '3!  !HR0  7,\  %+5 P!(W @
M1>42 $/E'@!!YBH /N8U 3OG/@$YYT<"-^=0 S3H600RZ&(%,.AM!B[I>0<L
MZ8<(*^J6"2GJIPHHZKH*)^O6"B?I\ HGY_T))N;_"B;F_PHFYO\*)N;_"B;F
M_PJHH   G*<  (^P  ""N0  =,(  &C*  !;T0  3]<  $7=   ^[@D //(1
M #GS&P V\R4 -/0N #'T-P$N]3\!+/5' 2GV3P(G]E<")?=A R/W; ,A^'H$
M'_B)!![YF@4<^:L%&_K !1KZW@4:^?(%&O?]!1GV_P49]O\%&?;_!1GV_P6>
MI@  D:\  (.Y  !UP@  9\L  %K3  !-V@  0M\  #CE   U^P< ,?\/ "[_
M%@ K_Q\ *?\F "7_+0 C_S0 (/\[ 1[_0P$;_TL!&?]3 1;_70(4_VH"$O]X
M A'_B (0_YH"$/^K P[_O@,._]4##O_M P[_\ ,.__ ##O_P P[_\ .3K@
MA+@  ';"  !GS   6M4  $S<   _X0  ->8  "WT   J_P( )O\+ "/_$0 @
M_Q< '?\= !G_(P 6_RD %/\O !+_-0 0_ST #O]% 0S_3@$*_U@!!_]E 07_
M= $#_X4! O^6 0'_I@$ _[4! /_& 0#_R@$ _\H! /_* 0#_R@&&MP  =\$
M &C,  !:UP  2]X  #[D   RZ0  )^T  "/_   ?_P  &_\% !?_#  4_Q
M$?\4  __&  -_QT "_\B  C_*  %_RX  O\U  #_/0  _T<  /]2  #_7@
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M-8I9QC:(6>$VB%ST,(A=_RN)7O\HB5__)8E?_R.)7_\CB5__(XE?_R/_40D
M_UH  /5D  #@;   UW$# -!T!@#-=0D Q'87 +QV*@&T=#H%KG%&#*=N41*B
M:UH8GFEB'9IG:2&697$EDV1X*)!B@"N-88@NBV"1,8A?FC.&7J4U@UZR-X)>
MPC> 7MPX@%_R,X%A_RV"8O\I@F/_)H)D_R6"9/\E@F3_)8)D_R7_4P8 _UT
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M-V]M_#%P;O\M<6[_*G%O_RAQ;_\H<6__*'%O_RC_60  ZV4  -MP  #->
MQ'X  +R" 0"VA $ KH4. *>&( "@A3 #FH(]"). 2 ^.?5$5B7M9&H1Y8!^
M=V<C?'5N)WET=2IV<WTN<W*&,7!QD#1M<)PW:F^H.6AOMSIG;\LZ9W#I-VEQ
M^C)K<O\M;'/_*FQS_RAL<_\H;'/_*&QS_RC_7   YV@  -5S  #)>P  P((
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M*EN"_RE;@O\I6X+_*5N"_RGL9@  V',  ,=^  "\AP  LXX  *F2  "@E0
MEI@! )"9$P"*F20!A9@R!'^6/@EYE$@.=)-0%&^15QEKD%X=:(YE(62-;25@
MC'4H78M^*UJ*B"Y7B90Q5(FA,U*(L#11B,,U4(CB-%*(]C!3B/\L5(C_*56(
M_RA5B/\H58C_*%6(_RCF:P  T'@  ,*#  "WC   K9(  *.6  ":F@  CIX
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M($"D_R#*?@  NXL  *^5  "DFP  F:$  (ZF  ""K   =[$  &JV  !CN X
M8;@= %ZX+ %:N#@"5[A"!5.X2PA0MU,+3;=;#DJV8Q!'MFL31+5U%D*U@1@_
MM8X:/;6<'#NUK!PZM< =.;7?'#FS]!PYLO\<.;'_&SFP_QLYL/\;.;#_&SFP
M_QO!A@  M),  *>:  "<H   D:<  (6M  !YLP  ;;@  &*] 0!6P@< 4\,4
M %+#(P!0Q# !3<0[ DK$10-'Q$X%1<17!T+#7PE PV@+/<-R#3O#?@\XPXP1
M-L.;$C7#JQ,SP\ 3,\/@$S/!]1,RP/\4,K__%#&^_Q0QOO\4,;[_%#&^_Q2X
MD   JYD  )^@  "3IP  AZX  'NT  !NNP  8\   %C% 0!-R@4 1,\, $/0
M%P!"T"4 0- R #_1/0$]T4<!.]%0 CG260,VTF,$--)N!3+2>@<PTH@(+M*8
M"2W3J0DLT[X*+-/?"2O1\PHJS_X+*<[_#"G-_PTIS?\-*<W_#2G-_PVNF
MHI\  ):F  ")K@  ?+8  &^]  !CPP  5\@  $S-  !"T@, .=D) #7?$  T
MWQL ,N G #'A,@ PX3T +N)' "WB4 $KXEH!*N-E BCC<0(FY'\#)>2/ R/E
MH00BY;0$(>7-!"#D[ 0@XOL$'^'_!1_@_P4?X/\%'^#_!1_@_P6DG@  F*4
M (NN  !]M@  <+X  &/&  !6RP  2]   $#5   VW   +^4' "WM$  K[A@
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M  #_HP  _[0  /_&  #_U@  _]8  /_6  #_U@""M0  <[\  &3)  !6TP
M1]L  #K@   NY0  (^D  !KM   5_0  $O\  !#_ @ ._PD "_\-  C_$  $
M_Q,  ?\8  #_'@  _R0  /\K  #_,P  _ST  /])  #_5@  _V8  /]X  #_
MB@  _YL  /^H  #_L0  _[$  /^Q  #_L0#_)2L!_R@I ?\I*0'_*"P!_R,R
M ?\>.P+_&D<"_Q=5 _\58@/_$W #_Q)\ _\2AP/_$I$#_Q*9 _\2H /_$J<#
M_Q*M _\1M /_$;L#_Q'$ _\1S@/_$=\#_Q'K O\2]@+_$OX"_Q+_ O\2_P+_
M$O\"_Q+_ O\2_P+_$O\"_Q+_ O\2_P+_*"D!_RLF ?\L)@'_*RD!_R@O ?\B
M. +_($0"_QU2 _\;7P/_&&P#_Q=Y!/\7A 3_%XX$_Q>6!/\6G03_%J0$_Q:J
M!/\6L03_%K@$_Q;  _\6R@/_%ML#_Q;H _\7] /_%_T#_!?_ OL7_P/[%_\#
M^A?_ _H7_P/Z%_\#^A?_ _H7_P/_*B8!_RXC ?\O(@'_+R4!_RPK ?\J-0+_
M)T$"_R1. _\B6P/_(&@$_QYT!/\=@ 3_'8H$_QV2!?\=F@7_':$%_QVG!?\=
MK07_';0$_QV]!/\=QP3_'=0$_AWF!/L=\@3W'OL#]1[_!/0>_P3S'O\$\Q[_
M!/(>_P3R'O\$\A[_!/(>_P3_+B(!_S(? ?\T'@'_,R !_S(F ?\R,@'_+SX"
M_RQ* _\J5P/_)V0$_R9P!?\E>P7_)(4%_R2.!O\DE@;_))T&_R2C!O\DJ@;]
M)+$&_"2Y!OLDPP;Y),\&]B3C!O(D\ 7N)?H%[27_!NLE_P;J)?\&Z27_!NDE
M_P;I)?\&Z27_!NDE_P;_,AX!_S8; /\X&0#_.!L!_SHC ?\Y+0'_.#H"_S5&
M _\R4@3_,%\$_RYK!?\M=@;]+( '^BR)!_DKD0?W*YD(]2N?"/0KI@CS*ZT(
M\2NU"/ KOPCN*\L(ZRO?".<L[@CD+/H(XBS_"> L_PG>+/\(WBS_"-TL_PC=
M+/\(W2S_"-TL_PC_-1H _SH6 /\]% #_/Q< _T$? /]!*0'_0#0!_SU! O\Z
M30/\.%H%^#9E!O0U<0?Q-'L([S.$">TSC0GK,I0*Z3*;"N@RH@OF,JH+Y#*R
M#.,RNPSA,L@,WS+<#-HR[ W5,_@-TC/_#= S_PS.,_\,S33_"\PT_PO,-/\+
MS#3_"\PT_PO_.18 _SX2 /]!$ #_11, _T@; /]() #_1R\!_D0[ O="1P/Q
M/U0%[#Y@!N@\:PCE.W8)XCM_"^ ZB S=.9 -VSF7#MDXG@_6.*80U#BN$=(X
MMQ'0.,,2SCC3$LHXZ!+'.?<2Q#G_$<(Z_Q#!.O\/P#K_#K\Z_PZ_.O\.OSK_
M#K\Z_P[_/1, _T(/ /]&#0#_2Q  _TX6 /]/'P#]3BD!]$PT >Q(00+F1TX$
MX$5;!MM$9@G60G ,TD%Y#L] @A#-0(H1RC^1$\D_F13'/J 5Q3ZH%L,^L1?!
M/KP7P#[+&+T^XABZ/O(7MS__%K5 _Q2T0/\3LT'_$;-!_Q"S0?\0LT'_$+-!
M_Q#_0!  _T8, /]+"@#_40T _U,1 /]4& #S5"( Z5(M >%0.P':3TD#TDU5
M!\Q+8 O(26H.Q4AS$<)'>Q._1H,5O46+%[M%DQBY1)H9MT.B&K5#JQNT0[8<
MLD/$';!#V1ZM0^T=JT7\&JE%_QBH1O\6J$;_%:='_Q.G1_\3IT?_$Z='_Q/_
M1 X _TH( /]0!@#_50H _U@- /=9$0#J6!@ WU<D -17-0',540$QE10",%2
M6PR]4&40N4YM$[9-=A:T3'T8L4N%&J]*C1NM294=JTF='JE(IB"G2+ AI4B]
M(J1(SR*A2.@BH$GX'I]+_QN>2_\9G4S_%YU,_Q:=3/\6G4S_%IU,_Q;_1PL
M_TT" /]4 @#W6@0 ZUT' .=="P#A7!  TUT> ,I=, '#7#\$O5I,"+=85PRS
M5F 1KU1I%*Q3<1>I47@:IU" '*1/AQZB3X\@H$Z8(9Y-H2.<3:LDFDVX)9E,
MR":63.(FE4[U(I1/_Q^44/\<E%'_&I11_QB44?\8E%'_&)11_QC_20@ _U
M /M8  #E7@  W6(# -9C!P#480H RF(9 ,)C+ &[8CL#M&!("*]=4PRJ6UP1
MIEID%:-8;!B@5W0;G55['9M4@R"95(LBEE.3))12G2624:<GD%&S*(Y1PRF-
M4=TJC%+R)HM4_R*+5?\>BU;_'(M6_QJ+5O\:BU;_&HM6_QK_3 0 _U,  .Q<
M  #?8@  U&8! ,YH!0#+9P@ PF<6 +IH* &S9S@#K65%!ZAC4 RC85D1GU]A
M%9M=:!B87' ;E5IW'I-9?R&06(<CCE>/)8Q7F2>)5J,IAU:O*H55ORN$5M4L
M@U?O*8-8_B2#6?\@A%K_'H1:_QR$6O\<A%K_'(1:_QS_3@$ _U<  .5?  #8
M9@  SFH  ,=L P##:P4 O&P2 +1M)0"M;#4#IVI"!Z%G30R<9581F&->%91B
M91B18&P;CE]T'HQ>>R&)78,DAER,)H1;E2B!6J J?UJL+'U:NRU\6L\N>UOL
M*WQ<_"9\7?\B?5[_'WU>_QU]7O\=?5[_'7U>_QW_4   ]5D  .%C  #2:@
MR6X  ,)P 0"]< , MG 0 *YQ(@"H<#("H6X_!IQL2@N7:E,0DFA;%(YF8AB+
M96D;B&-P'H5B>"&"88 D@&"))GU?DBE[7ITK>%ZI+79>N"YU7LPO=%[I+75@
M^B=V8?\C=V+_('=B_QYW8O\>=V+_'G=B_Q[_4@  [%P  -QF  #.;0  Q'(
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M(V=N_R!G;O\@9V[_(&=N_R#V60  X&4  ,YO  #"=@  N7P  +%_  "I@
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M'U"#_Q_>:0  R74  +R   "RB   J(T  )V1  "3DP  A98  'Z7"P!YEQD
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M&CVCIQL\H[D<.Z/2&SNB[QL[H/X:.Y__&3R?_Q@\G_\8/)__&#R?_QC$?
MMHD  *J2  "?EP  E9P  (FA  !]I@  <:H  &2N  !:L0@ 5[$4 %6R(P!3
MLC !4+([ DVR1 -+L4T%2+%5!T6Q70E#L64+0+!O#3ZP>@\[L(<1.:^6$S>O
MIA0VK[@4-;#1%#6N[Q0TK?X4-*S_%#2K_Q0TJ_\4-*O_%#2K_Q2[A0  KY
M *.7  "8G0  C*,  ("H  !TK0  :+(  %RV  !0N@$ 2;P- $B\&0!&O2<
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M 1C>YP$8W/@!&-O_ A?:_P(7VO\"%]K_ A?:_P*@G   E*,  (>K  !YLP
M;+H  %_!  !2Q@  1LH  #O.   QTP  *=D  "'>!0 >Z X '>@5 !OI'@ 9
MZ2< &.HP !;J.0 5ZT, %.Q. !+L6@ 1[6< $.YW !#NB@ .[YX #O"S  WP
MS0 ,[^P #.W\  SK_P ,Z_\ #.O_  SK_P"7HP  B:L  'NT  !MO   7\0
M %+*  !%S@  .=,  "_8   EW0  '>$  !CL @ 6]PL %/<1 !'X%P 0^!X
M#ODE  WY+0 +^C4 "?L_  ?[2@ $_%<  _UF  +^=P  _8L  /V?  #\M0
M_-$  /SM  #\_   _/T  /S]  #\_0"+JP  ?;0  &Z]  !@Q@  4LT  $32
M   WV   +-T  "+A   9Y0  $^H  !#Z   ._P8 #?\,  K_$  '_Q0 !/\:
M  '_(   _R<  /\P  #_.@  _T4  /]3  #_8@  _W4  /^*  #_GP  _[,
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M"L8RX0O",O$+OS/^"[TS_PJ[,_\*NC/_";HS_PFZ,_\)NC/_";HS_PG_.1
M_ST+ /] "0#_1 T _T81 /]%&0#W1", [D$O .8_/ '@/DH!VCU7 M,\8@3/
M.VP&S#IU!\DZ?0G'.84*Q3F,"\,XE S!.)L-P#BC#;XXK Z\.+8/NCC##[DX
MUQ"U..P0LCG[#[ Z_PZO.O\-KCK_#*TZ_PNM.O\+K3K_"ZTZ_PO_/ T _T &
M /]%! #_20D _TL- /E*$0#M21H XT8F -I&-@#11D4!RT51 \9$7 7"0F8(
MOT)O"KQ!=PNZ0'\-N#^&#K8_CA"T/I41LCZ=$K ^IA.O/K 4K3Z]%*L^S16I
M/N85IC_W$Z1 _Q*C0/\0HD#_#Z) _PZB0?\.HD'_#J)!_P[_/PD _T0  /]*
M  #W3@( [% & .I/"P#C3!  UDP> ,U-, #&33\!P$Q,!+M+5P:W26$)M$AI
M#+%'<0ZN1GD0K$: $:I%B!.H1) 4ID28%J1#H1>B0ZL8H$.W&9]#QQF=0^ :
MFT3S%YE%_Q681O\3F$;_$9A&_Q"71O\0ET;_$)=&_Q#_0@4 _T<  /=/  #E
M4P  W54! -=5!@#54@L RU,9 ,-4*P"\5#L!ME)(!+%14@>M4%P*J4YD#:9-
M; ^D3'01H4M[$Y]*@A6=2HH7FTF3&)E)G!J72*8;E4BR')1(P1V22-@=D$GO
M&X]*_AB/2_\6CDO_%(Y,_Q*.3/\2CDS_$HY,_Q+_10  _TL  .E3  #>6
MTUL  ,U;! #*6 < PE@5 +I:)P"S6C<!KEA$!*E73P>D55@*H51@#9Y3:!";
M46\3F%!V%990?A>43X89DDZ.&H].F!R-3:(=BTVN'XI-O""(3= @ATWK'X9/
M_!N&4/\8AE#_%H90_Q2&4?\4AE'_%(91_Q3_1P  ^$\  .17  #570  S&
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M&G%=_QAQ7?\7<5W_%W%=_Q?]3P  Y5D  --B  #':   O6P  +9M  "O;
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M&5UM_QGH6@  TF8  ,-O  "X=@  KWL  *9^  "=?@  D7P  (I\#P"%?1X
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M'DQ_I2!*?[8A27_,(4E^ZQ]*?OP<2W[_&DM^_QE,?O\83'[_&$Q^_QC59P
MPW,  +9\  "LA   HHD  )B+  "-C0  ?(T  '6.! !OCQ( ;9 A &F0+@%E
MCSD"8HY"!%Z.2P=;C5(*6(Q9#%:+80]3BV@24(IQ%$V)>Q=*B8<92(B5&T:(
MHQU$B+0=0XC*'4.'ZAQ$AOL:1(;_&$6&_Q=%A?\7187_%T6%_Q?-;0  O7@
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M##"IYPPOI_H-+Z;_#2^E_PTOI?\-+Z7_#2^E_PVVA   JHX  )Z4  "4F0
MAYX  'NC  !OJ   8ZP  %>O  !+L@  0;4& #ZV$0 ]MAX .[8I #JW-  Y
MMSX -[=' #:W4 $TMUH!,K=D C"W;P,NMWP$++>+!2JWG 4IMZX&*+C%!2BW
MY@4GM?D')K/_!R:R_P@FLO\()K+_"":R_PBOC0  HI0  )>:  "+H   ?J8
M '&K  !EL   6;0  $VW  !"NP  .+X! "_""0 MPQ( +,,> "O#*0 JQ#,
M*<0] "C%1P GQ5$ )L5< "7&:  CQG8!(L:& 2#&F $?QJL!'L?! 1[&Y $=
MQ/@"',+_ QS!_P,<P?\$','_!!S!_P2EE   FIH  (ZA  "!IP  <ZX  &>T
M  !:N0  3KT  $+    XPP  +\<  ";+!  >T H &]$1 !K2&@ 9TB4 &-,O
M !C3.@ 7U$0 %M10 !7570 4U6L $]9\ !+7CP 1V*0 $-F[ !#9W@ 0U?,
M$-/_ !#2_P$0T?\!$-'_ 1#1_P&<F@  D:$  (.H  !UL   :+<  %N]  !.
MP0  0L4  #?(   MS   )-   !S5   5V@4 $.(+ !#C$0 .Y!H #N0C  WE
M+0 ,Y3< "^9"  KF3P )YUT ".=M  ;F@  %YI4 !.:K  +FQ  !YN8  .?Y
M  #G_P  YO\  .;_  #F_P"3H0  A:D  '>Q  !IN0  6\   $[&  !!R@
M-<X  "K2   AU@  &=L  !+?   -XP  "_$(  GS#@ '\Q, !/(:  +R(@
M\BH  /(T  #R/P  \DP  /)<  #R;0  \H(  /*8  #SK0  \\8  /3E  #T
M]@  ]/L  /3[  #T^P"'J0  >;(  &JZ  !<P@  3LD  $#.   STP  *-@
M ![=   5X0  #^0   KH   %\P   _T!  #\"   ^PT  /L1  #[%@  _!X
M /PF  #\,   _3P  /Y)  #^6@  _FT  /^"  #_F   _ZP  /_   #_V
M_^0  /_D  #_Y ![L@  ;+L  %W$  !/S0  0-(  #+9   FW@  &^(  !+F
M   ,Z@  !>T   #T    _P   /\   #_    _P0  /\)  #_#@  _Q(  /\8
M  #_(0  _RL  /\W  #_1@  _U@  /]K  #_@   _Y4  /^F  #_LP  _[L
M /^[  #_NP#_&R8 _QPD /\:) #_%2< _Q M /\*-@#_!4, _P%0 ?\ 7@'_
M &L!_P!V ?\ @0#_ (H _P"2 /\ F@#_ *  _P"F /\ K #_ +( _P"Y /\
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M ?\+>0'_"X(!_PN+ ?\+D@'_"ID!_PJ? /\*I0#_"JL _PJR /\*NP#]"L8
M^PK4 /<*YP#S"O0 \ K_ .\+_P#N#/\ [0S_ >T,_P'M#/\![0S_ >T,_P'_
M)1L _R88 /\E%P#_(1@ _R A /\>*P#_&C< _Q=% /\440'_$EX!_Q%I ?\1
M= '_$7T!_Q"& ?T0C@'\$)4!^A"; ?D0H0'W$*@!]A"O ?00MP#S$,( \1#0
M .T0Y0#H$?( YA'^ >02_P'C$O\!XA+_ >(2_P'A$O\!X1+_ >$2_P'_*18
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M":LS_PFJ,_\(J#/_!Z@S_P>G,_\'IS/_!Z<S_P?_-P< _SH  /\^  #Z00$
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MB4;_#HA&_PV(1O\-B$;_#8A&_PW_0   \D<  .-/  #44P  RU4  ,14  #
M4 0 N4\1 +)0(@"L43( IU$_ J)02@.>3U,%FTY<")A-8PJ53&H,DTMQ#9%*
M>0^.2H 1C$F)$HI)DA2(2)P5ADBH%H5(M1>#2,<8@4CD&(%*]Q6 2O\2@$O_
M$(!+_P^ 2_\.@$O_#H!+_P[_0P  [$L  -U3  #.6   Q%H  +U:  "X5P$
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M$F=<_Q+M3@  VED  ,AA  "\9P  LVH  *ML  "B:@  F6<" ))G$0"-9R$
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M&EAGI!Q69[0=56?*'55GZ!M69_L85V?_%E=H_Q189_\36&?_$UAG_Q/A6
MRV,  +UK  "R<@  J78  *!X  "6=P  B',  (%S"P!\=!< >'0F '1T,@%P
M<ST";7-&!&IR3@=G<54)9'!<"V%P8PY?;VH07&YS$EIN?!57;8@756R4&5-L
MHQM1;+,<4&S('$]LYQM1;/H846S_%5)L_Q12;/\34FS_$U)L_Q/<7   QV<
M +EO  "O=@  I7L  )Q\  "1?   @G@  'IY!P!U>10 <GHC &YZ+P%K>3H"
M:'E# V1X2P5A=U((7W=9"EQV8 Q9=6@/5W1P$51T>A-2<X863W.3&$URH1E,
M<K$:2G+&&DIRY1I+<OD73'+_%4QR_Q--<O\237+_$DUR_Q+48   PFL  +5T
M  "K>P  HG\  )>!  ",@0  >GX  '-_ @!N?Q$ :X > &B + !E@#<!8H!
M U]_2 1<?E &67Y7"%=]7@M4?&8-47QN#T][>!%,>X,42GJ1%DAZGQ=&>J\8
M17K$&$1ZY!A%>?@61GG_%$9X_Q)'>/\11WC_$4=X_Q'-90  O7   +%Y  "G
M@   G(0  )*&  "&A@  =X8  &N&  !FAPT 8X<9 &"()P!>B#,!6X@\ EB'
M10-6ATT$4X94!E"&6PA.A6,*2X1L#$F$=@]&@X$11(./$T*#G11 @JX5/X/"
M%3Z"XA4_@?<3/X'_$D" _Q% @/\00(#_$$" _Q#&:P  MW8  *Q_  "BA0
MEXD  (R+  "!C0  <XX  &6/  !=CPD 6I 4 %B0(0!6D2T 4Y X 5&000).
MD$D#3)!0!$J/6 5'CV '18YI"4*.<PM C7\-/HV-#SR-G! ZC:P1.8W!$3B-
MX1 XB_80.(K_#SF)_P\YB?\..8G_#CF)_PZ_<@  LGT  *>&  "<B@  D8X
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M R"M_P0?K/\$'ZS_!!^L_P2JBP  G9$  ).7  "'G   >J(  &VG  !@JP
M5:\  $FQ   ^M   ,[<  "JZ P DO T (KT5 "&](  AO2H (+TS !^^/0 >
MOD< ';Y2 !R_7@ :OVP &;]\ !B_C@ 7P*$ %L"V !3 TP 5OO$ %;S_ 16[
M_P$4NO\"%+K_ A2Z_P*AD@  EI@  (J>  !]I   ;ZH  &*O  !6M   2K<
M #ZZ   SO0  *L   "'$   9QP4 $\L+ !',$@ 1S!L $,PE  _-+P .S3H
M#LU&  W-4@ -SF  #,YP  O.@P *SI< "<ZL  C.Q@ (SN@ ",W[  G+_P )
MR_\ "<O_  G+_P"8F   C9X  '^E  !QK   9+,  %>Y  !*O0  /L   #+#
M   HQ@  '\H  !?-   1T0  #-8%  C9#  &V1( !=H;  3:)  #VRX  =LY
M  #<10  W5(  -YB  #><P  WH@  -^=  #?LP  W\X  .#N  #?^@  W_\
M -__  #?_P"/GP  @:8  '.N  !EM0  6+T  $K"   ]Q0  ,<D  ";,   =
MT   %-0   [9   )W0   ^$   #C!P  XPT  .02  #E&0  YB(  .<K  #I
M-@  ZT,  .Q2  #L8@  [78  .Z,  #NH0  [[<  ._1  #OZP  \/8  /#V
M  #P]@"$IP  =:\  &>W  !9OP  2\8  #S*   OS@  )-(  !K8   2W
M#.    7C    YP   .L   #K    [04  .X+  #P$   \14  /,>  #T)P
M]S,  /E   #Z40  ^V,  /QW  #]C0  _:,  /ZV  #^R0  _]\  /_?  #_
MWP!WL   :+D  %K!  !,R@  /,\  "[4   BV@  %]X  !#B   )Y@   .D
M  #L    \    /8   #V    ]P   /@   #Z!P  ^PT  /T1  #_&0  _R,
M /\O  #_/@  _T\  /]B  #_=P  _XT  /^?  #_K@  _[H  /^Z  #_N@#_
M%B, _Q4A /\2(0#_#B0 _P8J /\ ,P#_ $$ _P!. /\ 7 #_ &@ _P!T /\
M?@#_ (< _P"/ /\ E@#_ )P _P"B /\ J #_ *X _P"U /\ O0#_ ,< _P#6
M /\ YP#^ /, _@#^ /T _P#\ /\ ^P#_ /L _P#[ /\ ^P#_ /L _P#_&B
M_QD> /\6'@#_$"  _PHE /\$, #_ #T _P!+ /\ 6 #_ &0 _P!P /\ >@#_
M (, _P"+ /\ D@#_ )@ _P"> /\ I #_ *H _P"Q /T N0#[ ,, ^@#0 /@
MXP#W /$ ]@#\ /0 _P#T /\ \P#_ /, _P#S /\ \P#_ /, _P#_'1P _QP9
M /\9&0#_%!L _PXA /\,+ #_"3D _P5& /\"4P#_ %\ _P!K /\ =0#_ 'X
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M -P,_P#_(Q( _R,0 /\A#@#_'A  _QX8 /\<(P#_&"\ _Q0[ /\220#\$%4
M^ ]@ /0/:@#Q#W0 [PY\ .T.A #K#HL Z0Z2 .<.F0#F#J  Y ZG .(.KP#@
M#K@ W@[% -P.V@#6$.P TA'Z ,\2_P#-$O\!S!+_ <L3_P'*$_\!RA+_ <H2
M_P'_)P\ _R<, /\E"0#_)@T _R43 /\C' #_("@ ^QPU /4:0@#O&$\ ZA=:
M .8690#C%FX X!9W -X6?P#<%H< V1:. -86E0#4%IP TA>C - 7JP#.&+4
MS!C! ,L8T@#'&N@!PQOX < ;_P&^'/\!O1S_ KP<_P*\&_\"O!O_ KP;_P+_
M*PP _RL% /\K P#_+0D _RP. /\I%0#W)B  [B,M .<A.@#A'T@ VQ]4 -4@
M7P#1(&@ SB!Q ,PA>0#*(8$!R"&( <8ACP'$(98!PR&> <$BI@&_(J\!O2*[
M KPCR@*Y(^,"M23T K,D_P.Q)/\#KR3_ Z\D_P.N)/\#KB3_ ZXD_P/_+P8
M_R\  /\R  #_,P( ^3(( /<O#@#K*Q8 X2<B -@G,@#0*4$ RRI. ,8J60##
M*F(!P"IK ;TJ<P&[*GH"N2J" K@JB0*V*I "M"J8 [,JH0.Q*JH#KRNU!*XK
MQ 2L*]L$J"SO!*8L_@6D+/\$HRW_!*(M_P2B+/\$HBS_!*(L_P3_,@  _S,
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M#H0_] V#0/\+@T#_"H) _PF"0?\(@D'_"()!_PC_/   ZT,  -Q*  #,3P
MPU   +Q.  "W20$ L48. *I(' "D22P H$DZ )M)10&82$X"E$=7 Y)'7@6/
M1F4&C49L!XM%<PF)17L*AT2#"X5$C0R#1)<.@4.B#W]#KQ!^0\ 0?$3:$7M$
M\0]Z1?\->D;_"WI&_PIZ1O\)>D;_"7I&_PGU/@  YD@  --/  #'5   O54
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M#V93_PUF4_\,9E/_#&93_PSJ20  U5,  ,5:  "Z7P  L&(  *AB  "?7P
MEEH  (]:$ "*6QX A5LL (%;. %]6T$">EI* W=9401T6%@&<5A?!V]79@EM
M5VT+:U9V#6E6?P]G58H19567$V-5I!1A5;058%7(%E]5YQ5@5OH28%;_#V%7
M_PYA5_\-85?_#&%7_PSG3   T58  ,%>  "V8P  K68  *1F  ";9   D%X
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M#5)B_PW95@  Q&   +=H  "L;@  HW$  )IS  "/<0  ?VL  'AK!0!R:Q(
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M#D-UF0]"=:D00'6\$$!UV1! =/,/0'3_#D%S_PU!<_\,07/_#$%S_PS&9
MMVX  *MV  "B?   EW\  (R!  "!@0  <H   &5_  !=?P@ 67\3 %> ( !5
M@"L 4X$V %& /@%/@$8"38!. DM_50-)?UT%1G]F!D1^< A"?GL)/WZ("SU]
MEPP\?:<-.GVZ#CI^U@TZ?/$-.GO_##I[_PLZ>O\+.GK_"SIZ_PO :0  LG0
M *=\  "=@0  DH0  (>&  ![AP  ;H<  &"'  !5AP$ 4(@. $Z(&@!-B28
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M B.>S@(CG>X#(YO^ R*:_P0BF?\$(IG_!"*9_P2L@0  H(@  )6.  "+D@
M?Y8  '*:  !EG0  6:   $ZC  !"I   -Z8  "ZH!0 IJ0\ **D8 ">J(@ F
MJBP ):HU "2J/P CJD@ (JM3 "&K7@ @JVH 'JMY !VKBP ;JYT &JNQ !FK
MR@ 9JNP!&:C] 1BG_P(8IO\"&*;_ ABF_P*EB0  F8\  (^4  "#F0  =9X
M &BB  !<I@  4*D  $2L   YK@  +[   ":S   >M08 &;</ !BW%P 7MR$
M%K<J !6W-  4N#X $[A) !*X5  2N6( $;EQ !"Y@P /N9< #KFL  VYQ  -
MN.< #K;[  ZU_P .M/\ #K3_  ZT_P"<D   DI4  (:;  !YH   :Z8  %ZK
M  !2KP  1K(  #JU   OMP  );H  !V]   5P   $,,&  O&#@ *Q14 "<4>
M  C%*  'Q3( !L8]  7&20 %QE<  \9F  +&=P !QHL  ,:@  #%M@  QM(
M ,7O  #%_   Q?\  ,7_  #%_P"5E@  B9P  'NC  !MJ0  8*\  %.T  !&
MN   .KL  "Z^   DP0  &\0  !/'   .R@  ",X!  '0"@  T!   - 6  #1
M'@  TB<  -,Q  #4/   U4D  -98  #6:0  UGP  -:2  #6IP  UK\  -;@
M  #6\P  UOX  -;_  #6_P",G0  ?J0  &^K  !AL@  5+D  $:]   YP0
M+<0  "+'   9RP  $<X   S2   %U0   -L   #< P  W0H  -X/  #?%
MX1P  .(D  #D+@  YCH  .=)  #H60  Z&L  .F!  #IF   Z:T  .G%  #I
MX@  Z?(  .GU  #I]0" I0  <:T  &.U  !5O   1\(  #G&   LR@  (,X
M !;2   /U@  "-L   #?    XP   .4   #G    Z $  .H'  #K#0  [1$
M .\8  #Q(0  \RL  /8X  #W2   ^%H  /EM  #ZA   ^IL  /JO  #ZP@
M^MH  /K?  #ZWP!TK@  9;8  %:^  !(Q@  .<L  "O0   ?U   %-H   W?
M   %XP   .8   #I    [0   .\   #Q    \P   /4   #V @  ^ D  /H.
M  #]$P  _QP  /\H  #_-@  _T<  /]:  #_;@  _X4  /^:  #_JP  _[D
M /^\  #_O #_$2  _Q > /\,'@#_!"$ _P G /\ , #_ #X _P!, /\ 60#_
M &4 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_ *H _P"P /\
MN #_ ,( _P#. /\ X@#^ /  _0#[ /L _P#[ /\ ^P#_ /H _P#Z /\ ^@#_
M /H _P#_%!P _Q(: /\.&@#_"!P _P A /\ +0#_ #H _P!( /\ 50#_ &$
M_P!L /\ =@#_ '\ _P"' /\ C@#_ )0 _P": /X H #] *8 _ "L /L M #Y
M +T ^ #) /< W #U .P \P#X /, _P#R /\ \0#_ /  _P#P /\ \ #_ /
M_P#_%Q@ _Q46 /\1%0#_#!< _P4= /\ * #_ #8 _P!# /\ 4 #_ %P _P!G
M /\ <0#_ 'H _ "" /H B0#X )  ]P"6 /4 G #T *( \P"H /$ L #P +@
M[@## .P TP#J .< Z0#U .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ .4 _P#_
M&A, _Q@1 /\4$ #_#Q$ _PT9 /\*) #_!3  _P$^ /\ 2P#_ %< _@!B /H
M; #U '4 \@!] /  A #N (L [ "1 .L EP#I )X YP"D .8 K #D +0 X@"_
M .  S0#> ., W #R -H _0#8 /\ U@#_ -4!_P#5 ?\ U0+_ -4"_P#_'A
M_QP- /\7"P#_%0X _Q05 /\1'P#_#BH _PLX /T(10#X!E$ ] 1< .X$9@#J
M!&\ Y@-W .0$?P#B!(8 X 2, -X$DP#=!9H VP6@ -@%J #5!;$ T@6[ - &
MR0#.!^  S CQ ,D*_P#'"_\ Q@S_ ,4,_P#%#/\ Q0S_ ,4,_P#_(0P _R &
M /\< P#_'0H _QL0 /\8& #_%", ]A$P .\./@#J#DH Y0U6 .$-8 #=#6D
MV0UQ -4->0#3#8$ T0V( ,\-CP#-#I8 RPZ= ,H.I0#(#JX Q@^Y ,00R #"
M$-\ OA'R +L2_P"Y$_\ MQ/_ ;83_P&V$_\!MA/_ ;83_P'_)08 _R,  /\C
M  #_) , _R$* /T=$0#Q&AL Z!8G .$4-0#:$T, TQ1/ ,X560#+%6, R!9K
M ,46<P##%WL P1>" , 8B0"^&)  O!B8 +L9H "Y&:D MQFT +4:P@"T&M8
ML!OM :T<_ &K'?\!J1W_ :D=_P&H'?\!J!W_ :@=_P'_*   _R<  /XJ  #O
M*@  YR<! .<B"0#D'1  V1L= ,\=+0#)'CP Q"!) +\@4P"\(5T N2%E +<B
M;0"U(G0 LR)\ +$B@P&P(HH!KB*2 :PCFP&K(Z0!J2.O :<CO &F),X!HR3H
M J E^0*>)?\"G27_ IPE_P*;)?\"FR7_ ILE_P+_+   _RT  .TR  #B-
MVC,  -,N P#2)0H R247 ,$G)P"[*38 MBI# +(K3@"O*U< K"M@ *HK9P&H
M*V\!IBMV :0K?0&C*X0"H2N- I\KE0*>*Y\"G"NJ YHKM@.9+,<#ERSB Y0M
M]022+?\#D2W_ Y N_P.0+?\#D"W_ Y M_P/_,   \C,  .0Z  #6/0  S#P
M ,<Y  ##,04 O2X1 +4P(0"P,C  JS,] *<S20"D,U( H3-: 9\S8@&<,VD"
MFC-P IDS=P*7,G\#E3*' Y,RD 22,IH$D#*E!8XRL06-,\(&BS/<!HDT\@:'
M-/\%AC3_!88T_P2%-/\$A33_!(4T_P3\,P  ZSH  -Q!  #-1   PT0  +U!
M  "X.P$ LC<. *LX' "E.2L H3HX )T[1 ":.TT!ESI6 90Z70*2.F0"D#IK
M XXY<@.,.7H$BCF"!8DYBP6'.94&A3F@!X,YK0>".;P(@3G3"'\Z[@A].OX'
M?#O_!GP[_P5\._\%?#O_!7P[_P7T-P  Y4   -)'  #%2@  O$L  +5)  "O
M0P  J3X+ *(_%P"=0"8 F$$T )1!/P"104D!CD%1 8M 60*)0& #AT!G X4_
M;02#/W4%@3]]!G\^AP=]/I$(>SZ<"7H^J0EX/K@*=S_-"G4_Z@IT0/P(=$#_
M!W1 _P9S0/\&<T#_!G- _P;Q.P  WT4  ,Q,  "_3P  ME   *Y/  "G2@
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M8$[_"&!._PCC1P  S5   +Y7  "S6P  JET  *%=  "86@  C5,  (92# "
M4Q@ ?%,E 'E4,0!U5#P <U-$ 7!33 )M4E,":U)9 VE28 1G46@&95%P!V-1
M>0AA480*8%"1#%Y0G@U<4*T.6U' #EI1W@]:4?4,6E+_"EM2_PE;4?\(6U'_
M"%M1_PC?2@  R5,  +M:  "P7P  IF$  )UA  "47@  B%<  (!6"@!Z5Q4
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M"T]=F0Q-7:@-3%ZZ#DM>U Y+7O$,3%[_"TQ=_PI,7?\)3%W_"$Q=_PC/5
MOEX  +%E  "G:@  G6T  )1M  ");   >&4  &]D  !I9 X 9609 &)D)0!@
M93  7F4Z %QE0@%:94H"6&11 E9D6 -49%\$4F1G!5!C<0=.8WL)3&.("DIC
MEPM(8Z8,1V.X#49CT0U&8^\,1F+_"D=B_PE'8O\)1V+_"$=B_PC*6   NF(
M *YI  "C;@  FG$  )!R  "$<0  =&L  &EI  !C:0L 7VD5 %QJ(0!::BT
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M!S1XRP<T=^L'-';]!S1U_P<U=?\&-73_!C5T_P:Y:   K7$  *)Y  "8?@
MC8   (*!  !V@@  :8$  %N!  !1@0  2( * $6!$P!#@1X 0H(I $&",@!
M@CL /H)# #V"2P [@E,!.8)< 3>"9@(U@G$#,X)_ S&!C@0P@9\$+H&Q!2V!
MR 4M@>D$+7_\!2U^_P4M??\%+7W_!2U]_P6S;@  J'@  )U_  "2@P  B(8
M 'V'  !PB   8XD  %6*  !+B@  08H" #N+#@ YBQ< .(PB #>,+  VC#4
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M !&A_P 1H/\!$:#_ 1&@_P&@A@  E8P  (R1  !_E0  <9H  &2>  !8H0
M3*0  $"F   UIP  *JD  "*L   9K@  $K ) !"Q$  0L1@ #K$B  ZQ*P -
ML34 #;%   RQ2P +L5@ "K%G  BQ>  'L8L !;&@  2PM0 $L-  !+#O  6O
M_@ &KO\ !J[_  :N_P"8C@  CY,  (*8  !UG0  9Z(  %JG  !.JP  0:T
M #6O   KL0  (;0  !BV   1N0  #;P#  >^#  #O1(  ;T9  "^(@  OBL
M +XV  "^00  OTX  +]<  "_;0  OX   +Z5  "^J@  OL(  +WD  "]]@
MO?\  +W_  "]_P"2E   A9H  'B@  !JI@  7*L  $^P  !"LP  -;8  "JX
M   @NP  %[X  !#!   +Q   !,<   #)!P  R0T  ,D2  #*&0  RR(  ,LK
M  #--0  SD$  ,Y0  #/8   SW(  ,^'  #/G0  S[,  ,_.  #/ZP  SO@
M ,[^  #._@"(FP  >J(  &RH  !>KP  4+4  $*Y   UO   *;\  !["   5
MQ@  #LD   C,    T    -,   #5    U@8  -@,  #9$0  VQ8  -P?  #>
M*   X#0  .)!  #B40  XV,  .-W  #DC@  Y*0  .2Z  #EU   Y>H  .7S
M  #E\P!\HP  ;JH  &"R  !1N0  0[X  #7"   HQ@  ',D  !/-   ,T0
M!-4   #:    W@   .$   #B    Y    .4#  #G"0  Z0X  .L2  #M&@
M[R0  /(Q  #T00  ]%,  /5F  #U?   ]I,  /:I  #WO   ]\X  /??  #W
MWP!PK   8;0  %.[  !%PP  -L<  "?,   ;T   $=4   K;    WP   .(
M  #E    Z0   .P   #M    \    /$   #S    ]00  /<*  #Z$   _!8
M /\A  #_+@  _T   /]3  #_:   _X   /^6  #_J   _[8  /^_  #_OP#_
M#1P _PH; /\"&P#_ !X _P D /\ +@#_ #P _P!* /\ 5@#_ &, _P!M /\
M=P#_ '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"L /\ M #_ +T _P#)
M /X W0#] .T _ #Z /L _P#Z /\ ^0#_ /H _P#Z /\ ^@#_ /H _P#_$!D
M_PT7 /\&%@#_ !@ _P > /\ *@#_ #< _P!% /\ 4@#_ %X _P!I /\ <@#_
M 'L _P"" /\ B0#_ )  _@"6 /T G #\ *$ ^P"H /D KP#X +@ ]@## /0
MT@#S .< \@#V /  _P#O /\ \ #_ .\ _P#O /\ [@#_ .X _P#_$A0 _P\2
M /\+$@#_ !( _P : /\ )0#_ #, _P!  /\ 30#_ %D _P!D /T ;0#[ '8
M^0!] /< A #U (L ] "1 /, EP#Q )T \ "C .X J@#L +, Z@"] .@ RP#G
M .$ Y0#Q ., _0#C /\ X@#_ .$ _P#A /\ X #_ .  _P#_%!  _Q$. /\-
M#0#_!P\ _P(5 /\ ( #_ "T _P Z /\ 1P#Y %, ]0!> /( : #P '  [0!X
M .L ?P#I (4 Z ", .8 D@#E )@ XP"? .$ I@#? *X W "X -H Q0#6 -D
MU #L -( ^0#1 /\ SP#_ ,X _P#. /\ S@#_ ,X _P#_%PP _Q0( /\/!0#_
M#@L _PP1 /\'&@#_ 28 _  T /0 00#M $T Z0!8 .8 8@#C &H X !R -X
M>0#; (  V0"& -8 C0#3 ), T0": ,\ H0#- *H RP"S ,D OP#& -  Q0#H
M ,, ]@#! /\ P +_ +\#_P"_ _\ OP/_ +\#_P#_&P8 _Q<  /\4  #_$P4
M_Q$- /\.% #Y"A\ \ 8L .8#.0#@ T8 W -1 -8$6P#2!&0 SP5L ,P%<P#*
M!7H R 6! ,8%AP#%!HX PP:6 ,$&G0"_!J8 O0:P +L'O "Y",T N KE +4+
M]P"S#?\ L0W_ + -_P"P#O\ KP[_ *\._P#_'@  _QL  /\;  #Z&@  ]18%
M /81#0#K#A4 X@LB -@+,0#0##X RPU* ,<-50#$#EX P0YF +\.;0"]#G0
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M HHG_P*))_\"B2?_ 8DG_P'Z*0  [#   -TV  #-.   Q#<  +XR  "Z*P(
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M!&8__P3E/0  ST8  +],  "T3P  JE   *)/  "92@  D40  (I!#0"$0AD
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M!EA+F =73*<(5DRY"55,T0E43.\(5$W_!E5,_P953/\%54S_!55,_P752
MPE$  +57  "J6P  H%P  )=<  "-60  @5,  '=/! !Q3Q  ;E < &I0* !H
M4#( 95 [ &-00P!A4$H!7U!1 5U06 )<4%\"6E!G UA0<0174'L%55"(!E-0
ME@=24*4(4%"W"5!0S@E/4.T(4%#_!U!0_P904/\%4%#_!5!0_P702P  OU0
M +):  "G7@  G6   )1@  ")70  ?%<  ')4  !L4PX :%09 &54) !B5"\
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M!T!>R = 7N@'0%W\!D%=_P5!7?\%05S_!4%<_P7#5@  M%\  *AF  ">:@
ME6T  (IM  !_;   ;V<  &1D  !;8@4 5F(0 %1B&P!28R4 4&,O $YD. !-
M9$  2V1( $ID3P%(9%<!1F1? D5D: )#9',#06-_!#]CC@4]8YX&/&.P!CMD
MQ@8[9.8&.V/Z!3MB_P4[8O\%/&'_!#QA_P2^6P  L&,  *5J  ";;P  D7(
M (9R  ![<0  ;&T  &!K  !5:0  3V@- $UI%P!+:2$ 26HK $AJ- !':CT
M16M$ $1K3 !":U0!06M< 3]J90(]:G ".VI] SEJC 0W:IP$-FJN!35JQ 4U
M:N4%-6GY!#5I_P0U:/\$-6C_!#5H_P2Y8   K&D  *%P  "8=0  C7<  ()W
M  !W=P  :70  %QS  !1<0  2' * $5P$@!#<1T 0G$G $!R,  _<C@ /G)
M #UR2  [<E  .G)9 3AR8P$V<FT"-')Z C-RB0,Q<IH#+W*L RYRP0,N<N,#
M+G'X RYP_P,N;_\#+F__ RYO_P.S9@  IV\  )UV  "3>@  B'P  'Y]  !R
M?0  9'P  %=[  !,>@  0GD# #QY#@ Z>A< .7HA #AZ*@ W>S, -GL[ #1[
M1  S>TP ,GM5 #![7P O>VH!+7MW 2M[AP$J>Y@"*'NJ B=[OP(F>^$")GKW
M B9X_P(F>/\")W?_ B=W_P*N;   HW8  )E\  ".?P  A((  'B#  !LA
M7X0  %&$  !'A   /(0  #.$"0 PA!$ +X0: "V$)  LA2T *X4U "J%/@ I
MA4< *(90 ">&6@ FAF8 )(9S ".&@P AAI4 ((:G 1Z&O $>AMX 'H3U 1Z"
M_P$>@O\!'H'_ 1Z!_P&H=   GGT  )."  ")A0  ?H@  '&*  !EBP  6(P
M $R-  ! C@  -HX  "R/   ED P (Y 3 "*0'  AD"4 ()$N !^1-@ >D4
M'9%) !R15  :D6  &9%N !B1?@ 6DI  %9*D !21N0 3D=@ $X_T !2._P 4
MC?\ %(S_ 12,_P&C?0  F(,  (Z(  "$C   =X\  &F1  !=DP  4)4  $67
M   YF   +ID  "6:   =FP( %IT, !6=$P 4G1L $YTD !*=+0 1GC< $9Y!
M !">3  /GE@ #IYG  V>=P ,GHH "YV>  J=L@ )G<P "9SL  J;_@ +FO\
M"YG_  N9_P"<A   D8H  (B.  ![D@  ;98  &"9  !4G   2)\  #R@   P
MH0  )J,  !VE   5IP  $*D%  NK#0 (JA, !ZH;  :J)  %JBX !*HX  *J
M1  !JE   *I>  "J;@  JH$  *J5  "IJ@  J<$  *CD  "H]@  I_\  *?_
M  "G_P"5BP  C)   '^5  !QF@  8YX  %:B  !*I@  /:@  #&J   FJP
M':T  !2P   .L@  ";4!  *V"@  M@\  +85  "W'0  MR4  +<O  "X.0
MN$8  +A4  "X9   N'8  +B+  "WH   M[8  +?3  "V[P  MOP  +;_  "V
M_P"/D@  @I<  '2=  !FH@  6*<  $NL   ^KP  ,;$  ":S   <M@  $[@
M  V[   &O@   ,$   #"!   P@L  ,,0  #$%0  Q!P  ,4D  #&+@  R#H
M ,E'  #)5P  R6D  ,E]  #)E   R*H  ,C#  #(Y   R/0  ,C]  #(_0"%
MF0  =Y\  &BF  !:JP  3;$  #^U   QN   );H  !J]   1P   "\,   /'
M    R@   ,T   #.    SP,  - )  #1#@  TQ(  -49  #7(@  VBT  -TY
M  #>20  WEH  -]N  #?A0  WYP  -^R  #>RP  WN8  -_T  #?] !YH0
M:Z@  %RO  !.M0  0+L  #&^   DP0  &<4  !#(   )S    ,\   #3
MV0   -P   #=    WP   .$   #B!0  Y L  .80  #H%@  ZB   .TK  #P
M.@  \4L  /%>  #R<P  \XL  /.B  #SM@  \\D  //A  #SX0!MJ@  7K$
M %"Y  !!OP  ,L0  "3(   7S   #M    ;5    V@   -X   #B    Y@
M .D   #J    [    .X   #P    \@   /0&  #V#   ^1(  /P<  #_*0
M_SH  /]-  #_8@  _W@  /^0  #_HP  _[,  /_!  #_P0#_!QD _P$7 /\
M%P#_ !H _P A /\ *P#_ #D _P!' /\ 5 #_ %\ _P!J /\ <P#_ 'L _P"#
M /\ B@#_ )  _P"6 /\ FP#_ *$ _P"H /\ KP#_ +@ _P#$ /X U0#\ .H
M^P#X /H _P#Y /\ ^ #_ /@ _P#V /\ \P#_ /$ _P#_"Q4 _P43 /\ $P#_
M !0 _P : /\ )P#_ #0 _P!" /\ 3P#_ %L _P!E /\ ;@#_ '8 _P!^ /\
MA0#^ (L _0"1 /L EP#Z )T ^ "C /< JP#V +, ] "^ /, S #Q ., [P#S
M .X _P#M /\ [ #_ .L _P#L /\ [ #_ .L _P#_#1$ _PD0 /\ #P#_ !
M_P 6 /\ (@#_ "\ _P ] /\ 2@#_ %4 _0!@ /H :0#X '$ ]@!Y /0 ?P#S
M (8 \0", .\ D@#N )@ [ "? .L I@#I *X YP"X .4 Q0#C -H X0#M -\
M^P#> /\ W0#_ -T _P#= /\ W0#_ -T _P#_#PT _PP+ /\#"0#_  P _P 2
M /\ '0#_ "D ^P W /@ 1 #U %  \@!: .X 8P#L &L Z0!S .< >@#E (
MXP"& .$ C #? ), W0"9 -L H0#9 *D U0"R -( O@#0 ,X S@#F ,P ]@#*
M /\ R@#_ ,D _P#( /\ R #_ ,@ _P#_$0@ _PT" /\'  #_!0@ _P . /\
M%@#W "( [P P .L /0#H $D Y !4 .  70#= &4 V0!M -4 <P#2 'H T "
M ,X AP#, (T R@"4 ,@ FP#& *0 Q "M ,( N #  ,< O0#? +P \0"[ /X
MN0#_ +@ _P"X /\ N #_ +@ _P#_%   _P\  /\-  #_#   _P<) /@!$ #H
M !H XP H -T -@#8 $( T@!- ,X 5P#* %\ QP!F ,4 ;0## '0 P0!Z +\
M@0"] (@ NP"/ +D EP"W )\ M0"H +, LP"Q ,( KP#8 *X"[0"L _L JP7_
M *H&_P"I!O\ J0;_ *D&_P#_%@  _Q(  /<2  #L$0  Y@X  .4&" #= Q(
MU ,@ ,T$+0#(!#H PP5& +\%4 "\!E@ N09@ +<'9P"U!VX LP=U +$(>P"O
M"(( K@F* *P)D@"J"9L J JE *8*L "E"[\ HPS4 *$-[0"?#OX G0[_ )P/
M_P";#_\ FP__ )L/_P#_&@  ]QD  .H>  #?'@  U1H  - 3 @#.# L QPL6
M , -)0"Z#C( M@X_ +(/20"O$%( K!!: *H080"H$6@ IA%O *01=@"B$7T
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M 7@H_P'O*P  W3,  ,HY  "^.P  M#H  *TV  "F+P  H2@' )LG$P"6*"
MD2DM (XJ. "+*T( B"M* (8K4@"$*U@ @BQ? ( L9@!_+&T ?2QU 'LL?@%Z
M+(@!>"R4 78MH %U+:X"="W  G(NW0)Q+O0"<"__ F\O_P)O+_\!;B__ 6XO
M_P'H,0  TSH  ,,_  "W00  KD$  *8^  ">.   ES$! )$N$ ",+QP B# H
M (0Q,P"!,CT ?S)& 'TR30![,E0 >3); '<R80!U,FD!=#)P 7(R>0%P,X0!
M;S.0 FTSG0)L,ZL":C2\ FDTU0-H-?$"9S7_ F<U_P)F-?\"9C7_ F8T_P+B
M-@  S#\  +U$  "R1P  J$<  *!$  "8/P  D#D  (@T#0"#-1< ?S8D 'PW
M+P!Y-SD =SA" '0X20!R.%  <3A7 &\X7@!M.&4!;#AM 6HX=0%H.( "9SB,
M F4XF0-D.:@#8CFY V$ZT -@.NX#8#K_ U\Z_P)?.O\"7SK_ E\Z_P+=.P
MQT,  +E)  "N2P  I$P  )M*  "210  B3\  ($Z"0![.A0 =SL@ '0\*P!R
M/#4 ;ST^ &T]1@!K/4T :3U3 &@]6@!F/6$!9#UI 6,]<@%A/7T"8#V) EX]
ME@-=/J4#6SZV!%H^S 1:/^P$63_^ UD__P-9/_\"63__ ED^_P+6/P  PT<
M +5,  "J4   H%   )=/  ".2P  A$4  'I !@!U/Q$ <4 < &U * !K03(
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M!$I+Q01)2^8$24OZ!$E+_P-*2_\#2DO_ TI+_P/(20  N%$  *Q7  "A6P
MF%P  (Y<  "#60  =E,  &M.  !D30H 7TP3 %Q-'@!:32@ 6$TQ %9-.@!4
M34$ 4TY( %).3P!03E<!3TY? 4U.: %,3G,"2D]_ DE/C0-'3YT$1D^N!$5/
MPP1$4.0$1$_Y!$5/_P-%3_\#14[_ T5._P/$3   M54  *E;  "?7@  E6
M (M@  " 7@  <E<  &=3  !>40< 65$1 %=1&P!4424 4E(O %%2-P!/4C\
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M S5=_P(U7?\"-5S_ C5<_P*X60  JF$  *!G  "6;   C&X  (%N  !V;
M9VD  %QF  !19   2&() $1B$0!"8AL 06,D #]C+0 ^8S4 /60] #QD10 [
M9$T .615 #AD7P V9&D!-61V 3-DA0$Q994",&6G B]ENP(N9=H"+F3T BYC
M_P(O8_\"+V+_ B]B_P*S7@  IV8  )QM  "3<0  B',  'US  !R<@  9'
M %AN  !-;   0FH# #QI#@ Z:A8 .6H@ #AJ*  V:S$ -6LY #1K00 S;$D
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M !=[_P"D<@  FGH  (]_  "%@@  >X0  &V&  !@AP  5(<  $B(   \B
M,H@  "B(   @B 4 &HD. !F)%0 8B1T %XHF !:*+@ 5BC< %(I! !.*3  2
MBU@ $8ME !"+=0 /BX< #HJ;  V*KP ,BL@ #(GJ  V'_  .A_\ #H;_  Z&
M_P"?>P  E($  (J%  " B   <XL  &6-  !9CP  3)   $&2   TD@  *I(
M "&3   9E   $I8&  Z7#@ -EQ4 #)<=  R7)@ +ER\ "I<Y  F71  (EU
M!I=>  67;@ #EH   9:4  "5J   E;X  )3@  "4]   D_\  9+_  &2_P"8
M@@  CH@  (6,  !WCP  :I(  %V5  !0F   1)H  #B;   LG   (IT  !F>
M   2H   #:("  >C"P !HQ   *,7  "C'P  HR<  *,Q  "D/   I$@  *16
M  "D90  HW<  *.+  "CH   HK8  *'2  "A\   H/L  *#_  "@_P"1B@
MB8X  'N2  !MEP  8)L  %.>  !&H0  .:,  "VD   CI@  &:@  !&J   ,
MK   !:X   "O!P  KPT  *\1  "P&   L"   +$H  "Q,@  LCX  +),  "R
M6P  LFP  +*!  "QEP  L:P  +#&  "PZ   K_<  *__  "O_P",D   ?Y4
M '&:  !CGP  5:0  $>H   ZJ@  +:P  "*N   8L   $+,   JU   "N
M +L   "[    O <  +P-  "]$0  OA8  +\>  # )P  P3(  ,)   ##3P
MPV   ,-T  ##BP  PZ$  ,.X  #"UP  PN\  ,+Z  #!_@"!EP  <YT  &6C
M  !7J   2:T  #NQ   MLP  (;8  !:Y   .NP  ![X   #!    Q0   ,<
M  #(    R0   ,H%  #+"P  S0\  ,X4  #0'   TR8  -8R  #800  V%,
M -EF  #9?   V90  -FK  #9PP  V>$  -GP  #9] !VGP  9Z8  %FL  !+
ML@  /+<  "ZZ   AO0  %<    W$   %QP   ,H   #.    T@   -4   #6
M    V0   -L   #=    WP<  .$,  #C$0  YAD  .DD  #L,@  [4,  .Y6
M  #O:P  [X0  .^<  #OL@  [\8  ._=  #OY !JJ   6Z\  $RV   ^O
M+\   "#$   4R   #,P   +0    U    -D   #>    X@   .4   #F
MZ    .D   #L    [@   / "  #R"0  ]0\  /@7  #\(P  _S,  /]&  #_
M6@  _W$  /^)  #_GP  _[$  /_   #_Q@#_ !4 _P 4 /\ % #_ !< _P =
M /\ * #_ #< _P!$ /\ 40#_ %P _P!F /\ ;P#_ '< _P!^ /\ A0#_ (L
M_P"1 /\ EP#_ )T _P"D /\ JP#_ +0 _@"_ /T S@#[ .8 ^0#V /@ _P#W
M /\ ]P#_ /< _P#P /\ [ #_ .D _P#_ Q( _P 0 /\ $ #_ !$ _P 7 /\
M) #_ #( _P _ /\ 3 #_ %< _P!A /\ :@#_ '( _P!Y /T @ #\ (8 ^@",
M /D D@#X )@ ]@"? /4 I@#T *X \@"Y /  Q@#N -X [0#P .L _@#J /\
MZ0#_ .D _P#G /\ XP#_ .  _P#_!PX _P - /\ "P#_  P _P 3 /\ 'P#_
M "P _P Z /\ 1@#^ %( ^P!< /@ 90#U &P \P!T /$ >@#O ($ [@"' .P
MC0#J ), Z0": .< H0#F *D XP"S .$ OP#? -  W0#I -H ^0#9 /\ UP#_
M -4 _P#5 /\ U0#_ -0 _P#_"0H _P$% /\  P#_  D _P 0 /\ &0#[ "8
M]P T /0 0 #R $P [@!6 .H 7P#G &< Y !N .( = #@ 'L W@"! -P AP#:
M (T U@"4 -0 FP#1 *, SP"M ,P N #* ,< R #@ ,8 \P#% /\ PP#_ ,,
M_P## /\ PP#_ ,, _P#_"P$ _P,  /\   #_  , _P + /, $@#N !\ Z@ M
M .8 .@#B $4 W@!/ -D 6 #4 &  T0!H ,X ;@#, '0 R@![ ,@ @0#& (<
MQ ". ,( E@#  )X O@"G +L L@"Y ,  MP#4 +4 [ "S /L LP#_ +( _P"R
M /\ L0#_ +$ _P#_#0  _P8  /\#  #W    ]  # .< #0#@ !@ V@ E -,
M,@#. #X R@!) ,8 4@## %H P !A +X : "\ &X N@!T +@ >P"V ($ M "(
M +( D "P )D K@"B *P K0"J +H J #+ *8 Y@"E /< I #_ *, _P"B /\
MH@#_ *( _P#_$   ^PP  .\.  #F#0  WPD  -H !@#0 !$ R0 = ,0 *@"_
M #< NP!" +< 2P"T %0 L@!; *\ 8@"M &@ JP!N *D =0"H 'L I@"# *0
MBP"B )0 H "> )X!J "< K4 FP/& )D%X@"8!O0 E@C_ )4)_P"4"?\ E G_
M )0)_P#\$0  \14  .,9  #6&0  S!4  ,<0  #$!PH O0,4 +<$(0"R!BX
MK@@Z *H)1 "G"4T I I5 *(*7 "@"F( G@MI )P+;P";"W8 F0Q^ )<,A@"6
M#)  E R: )(-I@"1#;, CPW% (T.X@"+$/8 B1#_ (@1_P"'$?\ AQ'_ (<1
M_P#V&0  YR   -8D  #()0  OR(  +D<  "T% $ L0T. *H.&0"E#R< H1 S
M )T1/@":$4< F!)/ )425@"3$EP D1)C ) 3:0".$W  C!-X (L3@0")%(L
MAQ26 (85H@"$%;  @Q;! ($7W0!_&/0 ?1G_ 'P9_P!\&?\ >QG_ 'L9_P#O
M(0  W2D  ,HM  "^+P  M2P  *XG  "H(   HQ<( )X6$P"9%R$ E!DM )$:
M. ".&D$ BQM) (D;4 "'&U< A1Q> (0<9 ""'&L @!QS '\=? !]'88 ?!Z1
M 'H>G@!X'ZL =Q^\ '8@U !T(?  <B'_ '$B_P!Q(?\ <2'_ '$A_P#H*
MTC   ,(U  "W-P  K34  *4Q  ">*P  F"," )(>$ "-(!L B2$G (8B,@"#
M(SP @2-$ 'XC2P!\)%( >R19 'DD7P!W)&8 =B5N '0E=P!S)8$ <2:- &\F
MF0!N)J< ;2>X &PGS@%J*.T!:2G_ 6@I_P%H*?\!:"C_ 6@H_P'A+@  RS8
M +P[  "Q/0  IST  )\Y  "7,P  CRT  (@G# "#)Q8 ?R@B 'PI+0!Y*C<
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M E0YPP)3.>0"4SKY 5,Y_P%2.?\!4SG_ 5,Y_P'-/   O$0  *])  "D3
MFDP  )%+  "'1@  ?4   ',[  !L. T :#D7 &4Y(@!C.BL 8#HT %XZ/ !=
M.D, 6SI* %H[4 !8.U@ 5SM@ %8[: !5/',!4SQ_ 5(\C0%0/9P!3SVL DX^
MP0)-/N$"33[X DT^_P%-/O\!33W_ 4T]_P')0   N$@  *Q-  "A4   EU$
M (Y/  "$2P  >44  &Y   !F/0L 8CT4 %\]'@!</B@ 6CXQ %@^. !7/D
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M CY*_P(^2?\!/TG_ 3])_P&]2@  KU(  *-8  "96P  D%T  (9<  ![60
M;5,  &)/  !73 $ 44H- $Y*%0!,2Q\ 2DLH $E+, !'2S@ 1DP_ $5,1@!$
M3$X 0TU6 $)-7P! 36H /TUV 3U.A $\3I0!.TZE 3E/N0(Y3]0".4_R 3E.
M_P$Y3O\!.4W_ 3I-_P&Z3@  K%8  *%;  "77P  C6$  (-A  !X7@  :5@
M %]6  !44@  3$\+ $E/$@!'4!P 15 E $-0+0!"4#4 05$\ $!11  _44P
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M 2A<_P&M7   HF0  )AJ  ".;@  @V\  'EO  !N;@  8&L  %1I  !)9P
M/V4  #5C"0 R8Q$ ,&,9 "]D(0 N9"D +60Q "QD.0 K94( *F5* "AE5  G
M95\ )F9K "1F>@ C9HL (F:= "!FL0 ?9LD 'V;K "!E_@ @9/\ (&/_ 2%C
M_P&I8@  GFH  )5P  "*<P  @'4  '5U  !I=   7'(  $]Q  !$;P  .FX
M #!M P I; T )VP4 "9L'  E;20 )&TL "-M-  B;3T (6Y& "!N4  >;EL
M'6YG !QN=@ :;H< &6^: !AOK@ 6;\8 %F[I !=M_  8;/\ &&O_ !AK_P"D
M:0  FG$  )!V  "&>0  ?'L  '%[  !D>P  5WH  $IY   _>   -7@  "MW
M   B=@< '78/ !QW%@ ;=QX &G<F !EW+@ 8=S< %WA  !5X2@ 4>%8 $WAC
M !)X<@ 1>(, $'B7  ]XJP .>,, #G?F  YV^@ /=?\ $'7_ !!T_P"?<0
ME7@  (M\  ""?P  =X$  &J"  !=@@  4((  $2"   X@@  +H(  "2"   <
M@@  %(() !&#$  0@Q8 $(,>  Z#)P .@S  #8,Y  V#1  ,@U  "X-=  F#
M;  (@WX !H.1  6"I0 #@KL !(';  2!\@ %@/\ !G__  9__P":>0  D'X
M (:#  !]A0  ;X<  &*)  !5B@  28L  #V,   QC   )HP  !V-   5C@
M#X\#  J0#  &D!$ !(\8  ./(  !CRD  (\R  "0/0  D$D  (]6  "/90
MCW8  (^*  ".GP  CK0  (W/  ",[@  C/L  (O_  "+_P"4@   BX4  (*)
M  !TC   9H\  %F1  !,DP  0)4  #26   HE@  'I<  !68   /F@  "IL
M  *<"0  G X  )P3  "<&@  G"(  )TK  "=-0  G4   )U.  "=7   G6X
M )R!  "<EP  G*P  )O&  ":Z   F?D  )G_  "8_P".B   AHP  'B0  !J
ME   7)<  $^:  !"G0  -IX  "F?   ?H0  %:(   ZD   (I@   *@   "I
M!   J0H  *D.  "I$P  JAH  *HB  "K*P  K#8  *Q$  "L4P  K&,  *QW
M  "KC@  JZ0  *N\  "JW@  J?0  *G]  "I_P")C@  >Y,  &V7  !?G
M4:   $2D   VI@  *J@  !ZI   4JP  #:X   :P    L@   +4   "U
MM0,  +8)  "W#@  N!(  +@9  "Z(0  NRL  +PX  "]1P  O5@  +UK  "]
M@0  O9D  +VP  "]S   O.H  +SW  "[_@!^E0  <)L  &*@  !3I0  1JH
M #BM   JKP  'K$  !.T   ,MP   [D   "\    OP   ,(   #"    PP
M ,0   #&!@  QPP  ,@0  #*%@  S"   ,\K  #0.@  T4L  -%>  #2<P
MTHL  -*D  #3NP  T]@  -/M  #3]@!SG0  9*,  %:I  !'KP  .;,  "JV
M   =N0  $KP   J_    PP   ,8   #)    S0   ,\   #0    T@   -0
M  #6    V0(  -L(  #>#@  X1,  .0=  #H*@  Z#P  .E/  #I9   ZGP
M .N5  #KK   Z\(  .S5  #LY0!FI@  6*P  $FS   [N0  *[P  !W    1
MQ   "<@   #,    SP   -,   #9    W0   .    #A    XP   .4   #G
M    Z@   .P   #N!   \0L  /42  #X'   ^RL  /T^  #^4P  _FH  /^#
M  #_FP  _ZX  /^^  #_R@#_ !( _P 0 /\ $0#_ !, _P 9 /\ )@#_ #0
M_P!! /\ 30#_ %@ _P!B /\ :P#_ ', _P!Z /\ @0#_ (< _P"- /\ DP#_
M )D _P"@ /\ IP#^ *\ _ "Z /H R0#Y .$ ^ #S /< _P#V /\ ]0#_ /$
M_P#I /\ Y #_ .$ _P#_  \ _P - /\ #0#_  X _P 4 /\ (0#_ "X _P \
M /\ 2 #_ %, _P!= /\ 9@#^ &T _ !U /L >P#Y (( ^ "( /< C@#V )0
M] "; /, H@#Q *H [P"T .T P0#K -4 Z@#L .@ _ #G /\ Y0#_ .8 _P#@
M /\ V0#_ -0 _P#_  L _P ( /\ !@#_  D _P 0 /\ ' #_ "D _P V /\
M0@#[ $X ]P!7 /0 8 #R &@ [P!O .T =@#L 'P Z@"" .@ B #G (X Y0"5
M ., G #A *0 WP"N -T N0#: ,H UP#D -0 ]@#1 /\ T #_ -  _P#/ /\
MRP#_ ,< _P#_  , _P   /\   #_  0 _P - /H %@#V ", \P P /  / #M
M $< Z0!1 .4 6@#B &( WP!I -T ;P#: '8 V !\ -0 @@#2 (@ T "/ ,T
ME@#+ )X R0"H ,< LP#% ,$ P@#8 ,  [P"_ /X O@#_ +T _P"\ /\ O #_
M +P _P#_ @  _P   /\   #_    ]  ' .T $0#H !P XP I -\ -0#; $$
MU@!+ -$ 5 #- %P R@!C ,@ :0#& &\ PP!U ,$ >P"_ (( O@"( +P D "Z
M )@ N "B +4 K "S +D L0#+ *\ YP"N /@ K #_ *L _P"L /\ K #_ *L
M_P#_!   _P   /8   #N    YP   -\ # #6 !4 SP B ,H +@#' #H PP!$
M ,  30"\ %4 N0!< +< 8P"U &D LP!O +$ =0"O 'L K0"" *L B@"I )(
MIP"< *4 I@"C +, H0## )\ W@"> /( G0#_ )P _P"< /\ FP#_ )L _P#_
M!P  ]@D  .D+  #?"@  U00  ,X !0#& !  P  : +L )P"W #( LP ] +
M1@"M $\ J@!6 *@ 7 "F &, I !H *( ;P"A '4 GP!\ )T A "; (T F0"7
M )< H@"5 *X DP"] )$ TP"0 .T CP#\ (X _P"- ?\ C0'_ (T!_P#Y#@
MZA(  -P5  #-%0  Q!$  +X,  "Z @H M  2 *X '@"J "H I@ U *( /P"@
M $@ G0%0 )L"5@"9 EP EP-C )4#:0"3 V\ D01V ) $?P".!8@ C 62 (H&
MG@"(!JH A@>Z (4(SP"$"NL @@O\ ($,_P" #/\ @ S_ ( ,_P#Q%0  X!T
M ,T@  #!(0  N!T  +$7  "L$   J D- *('%@"="2, F0HN )4+. "3#$$
MD Q) (X-4 ",#5< B@U= (@-8P"'#6H A0YQ (,.>@""#H0 @ Z/ 'X/FP!\
M#Z@ >Q"X 'H0S@!X$>P =A+_ '42_P!T$_\ =!/_ '03_P#H'@  TR8  ,,J
M  "X*@  KB@  *<C  "@'   FQ,# )8/$ "0$!L C!$G (D2,@"&$SL A!-#
M ((42P" %%$ ?A17 'P47@![%64 >15L '<5= !V%GX =!:* '(7E@!Q%Z0
M;QBT &X8R0!M&>@ :QK\ &H;_P!J&_\ :AO_ &H;_P#@)@  RBT  +PQ  "P
M,P  IS$  )\L  "7)@  D!\  (H7# "%&!8 @1DB 'X:+ ![&S8 >1L^ '<<
M10!U'$P <QQ3 '$=60!P'6  ;AUG &T>< !K'GH :AZ% &@?D@!G'Z  92"P
M &0AQ0!C(>0 8B+Z &$B_P!A(O\ 82+_ &$B_P#7+   PS0  +8X  "J.0
MH3@  )@U  "0+P  B"@  ( A" ![(!( =R$= '0B)P!Q(C$ ;R,Y &TC00!K
M(T@ :2-. &@D50!F)%L 921C &,E:P!B)74 826! %\FC@!>)IT 72>M %LH
MP0!;*.  6BGW %DI_P!9*?\ 62G_ %DH_P#/,@  OCD  +$]  "F/P  G#\
M ),\  "*-@  @3   'DJ P!R)@\ ;B<9 &LH(P!I*"P 9BDU &4I/ !C*4,
M82I* & J40!>*E< 72I? %PK: !:*W( 62Q] %@LBP!6+9H 52VJ %0NO0!3
M+MP 4B_U %(O_P!2+O\ 4B[_ %(N_P#*-@  NCT  *U"  "B1   F$0  (]!
M  "%/   >S<  '(Q  !K+ P 9RT5 &0M'P!A+B@ 7RXQ %TN.0!<+T  6B]&
M %@O30!7+U0 5C!< %4P9 !3,6X 4C%Z %$QB !0,I< 3C*H $TSNP!---@
M3#3S $PT_P!,-/\ 3#/_ $PS_P#&.@  MD(  *E&  ">20  E4D  (M'  "!
M0@  =ST  &TW  !D,@D 8#(2 %TR' !:,B4 6#,M %8S-0!5,SP 4S1# %(T
M2@!1-%$ 4#19 $\U80!--6P 3#9W $LVA0!*-Y4 2#>F $<XN %'.-,!1CCQ
M 48X_P%&./\ 1CC_ $8W_P#!/@  LD4  *9*  "<30  DDT  (A+  !^1P
M<T(  &D]  !?-P8 6C80 %<W& !4-R( 4C<J % W,@!/.#D 33A  $PX1P!+
M.$X 2CE6 $DY7P!(.FD 1SIU $4[@P!$.Y, 0SRD 4(\M@%!/= !03WP 4$]
M_P%!//\!03S_ 4$\_P"^0@  KTD  *-.  "94   CU$  (50  ![3   ;T8
M &5"  !:/0( 5#L. %$[%0!/.Q\ 33LG $L[+P!)/#8 1SP] $<\1 !&/4L
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M #-(_P"T3   IU0  )Q9  "27   B%T  'Y=  !S6@  954  %M2  !03@
M1DH% $!)#@ ^218 /4D> #M*)@ Z2BX .4HU #A+/0 W2T0 -DM- #1,5@ S
M3&  ,DQL #%->@ P38L +DV< "U.KP L3L< +$[I "Q-_0 M3?\ +4S_ "U,
M_P"P4   I%@  )E=  "/80  AF(  'MA  !P7P  8EL  %A8  !.50  0U$!
M #M/#  X3Q, -D\; #5/(P T4"L ,U R #)0.@ Q4$( ,%%* "Y14P M4ET
M+%)I "M2>  I4H@ *%.: "=3K0 F4\4 )E/G "93_  G4O\ )U'_ "=1_P"L
M50  H%P  )9B  "-9@  @V<  'AF  !M90  8&$  %5>  !*6P  /U@  #56
M"  Q51  ,%87 "Y6'P M5B< +%8O "M7-@ J5SX *5=' "A74  F6%H )5AG
M "18=0 C688 (5F8 "!9JP ?6<( 'UGE !]8^@ @6/\ (%?_ "%7_P"H6@
MG6(  )-G  "*:P  ?VP  '5L  !J:P  76@  %%E  !&8P  .V   #%> P J
M70T *%T3 "9=&P E7B, )%XJ "->,@ B7CH (5Y# "!?3  ?7U< 'E]C !Q@
M<0 ;8(( &6"5 !A@J0 78,  %F#B !=?^0 87O\ &5[_ !E=_P"D8   F6@
M )!N  "&<   ?'(  ')R  !F<0  6&X  $QL  !!:P  -FD  "UG   C9@@
M'V8/ !UF%0 <9AT &V8E !IF+0 99S4 &&<^ !=G2  69U, %6A? !-H;@ 2
M:'\ $6B2 !!HI@ /:+T #FC@ !!G]P 09O\ $67_ !%E_P"?9P  EF\  (QS
M  ""=@  >'@  &UX  !@=P  4W8  $9T   [<P  ,7(  "=Q   ><0  %G *
M !-P$  3<!< $G ? !%Q)P 0<2\ $'$X  YQ0@ .<4X #7%;  QQ:0 +<7H
M"G&-  AQH0 &<;8 !G#2  =P[P (;_\ "6[_  EN_P";;P  D74  (=Y  !^
M?   ='X  &9^  !9?@  37X  $!]   U?0  *GP  "%\   8?   $7P$  Q\
M#  *?!$ "7P9  A\(0 '?"D !GPR  1\/0 #?$@  7Q5  !\8P  ?'0  'R'
M  ![G   >[$  'K+  !YZP  >?H  'G_  !X_P"6=P  C'P  (.   !Y@P
M;(0  %Z%  !1A@  18<  #F'   MAP  (X<  !J'   2AP  #8@!  :)"@ !
MB0\  (D4  "(&P  B",  (DL  ")-@  B4(  (A.  "(70  B&T  (B!  "'
ME0  AZL  (;$  "%Y@  A/@  (3_  "$_P"0?@  AX,  'Z'  !QB0  8XL
M %:-  !)CP  /)$  #"1   DD0  &I(  !*3   -E   !I4   "6!@  E@P
M )40  "6%0  EAT  )8D  "6+@  ECD  )9&  "650  EF4  )9X  "5C@
ME:0  )2\  "3WP  D_4  )+_  "2_P"+A@  @XH  '6-  !GD   690  $R7
M   _F0  ,IH  ":;   ;G   $IT   R?   $H    *(   "C 0  HP<  *,,
M  "C$   I!4  *0<  "E)0  IB\  *8\  "F2P  IEL  *9N  "EA   I9L
M *2S  "CT   H^\  *+\  "B_P"&C0  >)$  &J5  !<F0  3IT  $&@   S
MH@  )J,  !NE   1IP  "JD   &K    K0   *\   "P    L    + %  "Q
M"P  L@\  +,4  "T&P  M20  +<P  "W/P  MU   +=B  "W>   MY   +:I
M  "VP@  MN0  +;U  "U_@![DP  ;9@  %^=  !0H@  0J8  #2I   FJP
M&JT  !"O   )L@   +0   "W    N@   +P   "]    O@   +X   #  @
MP0@  ,(-  #$$@  QAD  ,DD  #*,@  RT,  ,M5  #,:@  S(,  ,R<  #+
MM0  S,X  ,SI  #,]@!PFP  8:$  %*F  !$JP  -K   ">R   :M0  $+@
M  >[    O@   ,$   #$    R    ,L   #+    S0   ,X   #0    T@
M -4#  #8"@  VQ   -X8  #B)   XS4  .1(  #E7   YG,  .:-  #FI0
MYKP  .;3  #GYP!CI   5:H  $:P   XM0  *+D  !J\   /P   !<0   #'
M    RP   ,\   #4    V    -P   #=    WP   .$   #C    Y0   .@
M  #J    [08  /$.  #U%@  ^"4  /DX  #Y30  ^F,  /M\  #\E0  _*H
M /R[  #]RP#_  \ _P . /\ #@#_ !  _P 6 /\ (P#_ #  _P ] /\ 20#_
M %0 _P!> /\ 9@#_ &X _P!V /\ ? #_ (( _P") /\ CP#_ )4 _@"; /T
MHP#[ *L ^@"U /D PP#W -L ]@#P /0 _P#S /\ \@#_ .P _P#B /\ W #_
M -8 _P#_  P _P ) /\ " #_  H _P 2 /\ '@#_ "L _P X /\ 1 #_ $\
M_P!9 /X 80#\ &D ^@!P /@ =P#W 'T ]@"# /0 B0#R (\ \0"6 .\ G0#M
M *4 [ "O .H O #H ,T Y@#H .0 ^@#C /\ X@#_ .  _P#5 /\ S@#_ ,L
M_P#_  8 _P ! /\   #_  0 _P . /\ &0#_ "4 _0 R /L /@#W $D \P!3
M /  7 #N &, [ !J .H <0#H '< Y@!] .0 @P#B (D X "0 -X EP#< )\
MV0"I -8 M #3 ,0 T #> ,X \P#, /\ RP#_ ,H _P#( /\ P@#_ +X _P#_
M    _P   /\   #_    ^P + /8 $P#Q "  [0 L .H . #G $, XP!- .
M5@#< %T V0!D -4 :P#2 '$ T !V ,X ? #, (, R@") ,@ D0#& )D Q "C
M ,$ K0"_ +L O0#/ +L ZP"Y /P MP#_ +< _P"V /\ M #_ +$ _P#_
M_P   /\   #V    [@ % .< #P#A !D VP E -4 ,0#2 #P S@!& ,H 3P#'
M %< Q !> ,$ 9 "_ &H O0!P +L =@"Y 'P N "# +8 B@"S ), L0"< *\
MIP"M +, JP#% *D X0"G /4 I@#_ *4 _P"D /\ I #_ *0 _P#_    _
M /$   #H    X    -0 "P#, !, QP ? ,( *@"_ #4 O  _ +@ 2 "U %
MLP!7 +  7@"N &0 K !I *L ;P"I '4 IP!\ *4 A "C (P H0"6 )\ H0"=
M *T F@"\ )@ T@"7 .X E0#^ )0 _P"5 /\ E0#_ )4 _P#\ 0  \ 4  .,'
M  #5!0  S    ,4 ! "^  X N  7 +, (P"O "X JP X *D 00"F $H HP!1
M *$ 5P"? %T G0!C )L :0": &\ F !V )8 ?0"4 (8 D@"0 )  FP". *<
MC "V (H R0"( .< AP#Y (< _P"& /\ A@#_ (8 _P#T#   Y!   -$2  #%
M$0  O0X  +8(  "Q  @ JP 1 *8 &P"A "8 G@ Q )H .@"8 $, E0!* ),
M40"1 %< CP!= (X 8P", &D B@!P (@ =P"& (  A "+ (( E@"  *, ?@"Q
M 'T Q ![ N$ >@/U 'H%_P!Y!?\ > ;_ '@&_P#J$P  UAH  ,8=  "Z'
ML1D  *H3  "D#0  GP4, )D % "5 !\ D0(I (T#,P"+!#P B 5$ (8&2P"$
M!E$ @@=7 ($'70!_!V, ?0AJ 'L(<@!Z"'P > F& '8)D@!T"J  <PJO '$+
MP0!P#-\ ;PWV &X._P!M#O\ ;0[_ &T._P#A'   RR,  +PF  "Q)@  J"0
M * >  "9&   DQ " (X+#@"("Q< A PB ($-+ !^#34 ? X] 'H.10!X#DL
M=PY1 '4/6 !S#UX <1!E ' 0;@!N$'< ;!"" &L0CP!I$9T :!&M &82P !E
M$M\ 9!/V &,4_P!C%/\ 8A3_ &(4_P#6)   PRH  +4N  "J+P  H"T  )@H
M  "0(@  B1L  ((3" !]$1( >1(< '83)P!S%#  <10X &\5/P!M%48 ;!5,
M &H64P!H%ED 9Q9A &46:0!D%W( 8A=^ &$8BP!?&)D 7AFI %P9O !<&M@
M6AOS %H<_P!9'/\ 61S_ %D<_P#-*@  O3$  *\U  "D-@  FS0  )(Q  ")
M*P  @24  'D= P!S& X ;QD8 &P:(@!I&RL 9QLS &4<.P!D'$$ 8AU( & =
M3@!?'54 71U< %P>9 !;'FX 61]Y %@?AP!6()8 52"F %0AN !3(=( 4B+Q
M %(C_P!2(_\ 4B+_ %(B_P#(+P  N#8  *LZ  "@/   ECL  (TX  "#,@
M>BT  '(F  !J( P 9B 3 &,A'0!A(28 7R(O %TB-@!;(CT 6B-$ %@C2@!7
M(U$ 52-8 %0D80!3)&H 425V % E@P!/)I, 3B>C $PGM0!,*,X 2RCN $LI
M_P!+*/\ 2RC_ $LH_P##-   LSL  *<_  "<00  DD   (D^  !_.0  =3,
M &PM  !C)P@ 7B81 %PF&0!9)R( 5R<K %4H,@!4*#D 4BA  %$H1@!0*4T
M3BE5 $TI70!,*F< 2RIS $DK@ !(*Y  1RRA $8MLP!%+<L 12[L $0N_P!$
M+O\ 12W_ $4M_P"^.   L#\  *1#  "910  CT4  (5#  ![/@  <3D  &<T
M  !>+@0 6"L. %4K%@!2+!\ 4"PG $\L+P!-+38 3"T\ $HM0P!)+4H 2"Y2
M $<N6@!&+V0 12]P $,P?@!",(T 03&> $ RL0 _,L@ /S/J #\S_@ _,O\
M/S+_ #\R_P"[/   K4,  *%'  "620  C$D  (-(  !X1   ;3X  &,Y  !:
M-   4C , $\P$P!,,!P 2C D $DQ*P!',3( 1C$Y $0Q0 !#,D< 0C)/ $$S
M6 ! ,V( /S1M #XT>P ]-8L /#:< #LVKP Z-\8 .3?H #DW_  Z-_\ .C;_
M #HV_P"W0   JD8  )Y+  "430  BDX  (!,  !U2   :D,  & ^  !6.0
M334) $DT$0!'-1D 134A $,U* !!-2\ 0#4V #\V/0 ^-D4 /3=- #PW50 [
M.&  .CAK #DY>0 X.8D -SJ; #4ZK0 U.\0 -#OF #0[^P U._\ -3K_ #4Z
M_P"T0P  ITH  )Q.  "240  B%(  'Y0  !S30  9T@  %Q$  !2/P  2#H&
M $0Y#P!!.18 /SD> #XY)@ \.2T .SHT #HZ.P Y.T( .#M* #<\4P V/%T
M-3UI #0]=P S/H< ,3Z9 # _JP O/\( +S_D "\_^@ P/_\ ,#[_ # ^_P"Q
M1P  I$T  )E2  "/50  AE8  'Q5  !Q4@  9$P  %E)  !/10  14 # #\^
M#0 \/A, .CX; #D^(P W/BH -C\Q #4_.  T/T  ,T!( #) 40 Q05L ,$%G
M "Y"=0 M0H4 +$.7 "M#J@ J0\  *43B "I#^0 J0_\ *T+_ "M"_P"N2@
MH5$  )=6  "-60  @UH  'E:  !N5P  85(  %=.  !-2P  0T<  #I#"@ V
M0Q$ -$,8 #-#(  R1"< ,40O #!$-@ O13T +45& "Q%3P K1ED *D9D "E'
M<@ H1X, )D>5 "5(J  D2+X (TC@ "1(]P E1_\ )4?_ "9'_P"J3P  GU4
M )1:  "+7@  @5\  '=>  !K7   7U@  %55  !+40  0$T  #5*!P P20X
M+DD5 "U)'0 L220 *THK "I*,P H2CL )TM# "9+3  E2U8 )$QB "-,<  A
M3(  ($V3 !]-I@ >3;L '4[= !Y-]@ >3/\ 'TS_ "!+_P"G4P  G%H  ))?
M  "(8P  ?F0  '1C  !I80  7%X  %);  !'6   /%4  #)2 @ J4 P )T\2
M "90&0 E4"  )% H "-0+P B43< (5%  "!120 >4E, '5)? !Q2;0 :4WT
M&5.0 !A3I  64[D %5/9 !93]  74O\ &%'_ !E1_P"C60  F&   (]E  "%
M:   >VD  '%I  !F9P  660  $UA  !"7P  .%P  "Y:   E6 @ (%<. !Y7
M%  =5QP '%@C !M8*P :6#, &5@\ !A810 665  %5E; !19:0 36GH $EJ-
M !%:H0 06K< #EK5 !!9\P 06?\ $5C_ !%8_P"?7P  E68  (QK  "";0
M>&X  &YO  !B;0  56H  $AH   ^9@  ,V4  "EC   @80$ && + !5@$  4
M8!< $V > !)@)@ 28"X $6$W !!A0  /84L #F%8  UA9@ ,8G8 "V*)  IA
MG0 )8;( "&'+  AAZP )8/T "E__  M?_P";9@  DFT  (AQ  !^<P  =74
M &IT  !<<P  3W(  $-P   X;P  +6X  "1L   ;:P  $VL$  YJ#  -:A(
M#&H9  MJ(0 *:BD "6HR  AJ/  ':T< !6M3  1K80 ":W$  &J$  !JF
M:JT  &G&  !IYP  :?@  &C_  !H_P"7;0  C7,  (1W  ![>@  <'L  &-[
M  !6>@  27H  #UY   Q>   )W<  !UV   5=@  #W8"  EV"@ $=@\  '85
M  !V'   =B0  '4L  !U-@  =4$  '5.  !U7   =6P  '5^  !TDP  =*@
M '/   !SXP  <O<  '+_  !Q_P"2=0  B7H  (!^  !V@   :8$  %N"  !.
M@@  08(  #6#   I@@  'X$  !:!   0@@  "H(   *#!P  @@T  ((1  ""
M%P  @AX  ((F  ""+P  @CL  ()'  ""50  @64  (%X  "!C0  @*(  '^Z
M  !_W0  ?O0  'W_  !]_P"-?   A($  'N$  !NA@  8(@  %**  !%BP
M.8P  "R,   AC   %XP  !"-   )C@   H\   "0 P  CPD  (\.  "/$@
MD!@  ) ?  "0*   D#(  ) _  "030  D%T  (]P  "/A0  CIP  (ZS  "-
MT   C/   (O^  "+_P"(A   @(@  '*+  !DC0  5I   $B3   [E0  +I8
M "*6   7EP  #Y@   B9    FP   )T   "=    G0,  )T)  "=#0  GA$
M )X7  "?'P  GRD  * U  "@0P  H%0  *!F  "?>P  GI,  )ZK  "=Q@
MG>D  )SY  "<_P"#BP  =8X  &>2  !9E@  2YD  #V<   PG@  (Y\  !>@
M   .H@  !Z0   "F    J    *H   "J    J@   *L!  "K!P  K P  *T0
M  "N%@  KQX  +$I  "Q.   L4@  +%:  "Q;P  L8@  +&@  "PN@  K]T
M *_R  "O_0!XD0  :I8  %R:  !-GP  /Z,  #&F   CIP  %ZD   ZK   %
MK@   +    "R    M0   +<   "W    N    +D   "Z    O ,  +T)  "^
M#@  P!0  ,,>  #%*P  Q3P  ,9.  #&8@  QGH  ,:4  #&K0  QL@  ,7E
M  #%\P!LF0  7IX  $^D  !!J   ,JP  "2O   6L0  #;0   .W    N@
M +T   #     Q    ,8   #&    R    ,D   #+    S    ,X   #0!@
MTPT  -@3  #<'@  WBT  -]   #@5   X6L  .&%  #AGP  X;<  .'/  #A
MY@!@H0  4J<  $.M   TL@  );4  !>Y   -O    ;\   ##    QP   ,H
M  #/    TP   -8   #7    V@   -P   #?    X0   .,   #F    Z0$
M .P+  #P$@  \Q\  /0Q  #V1@  ]UP  /AT  #XCP  ^:8  /FX  #XR0#_
M  T _P + /\ "P#_  X _P 3 /\ 'P#_ "P _P Y /\ 10#_ %  _P!9 /\
M8@#_ &H _P!Q /\ =P#_ 'X _P"$ /X B@#] )  _ "7 /H G@#Y *< ]P"Q
M /8 O@#U -( \P#L /$ _@#P /\ \ #_ .8 _P#< /\ T@#_ ,T _P#_  <
M_P $ /\  @#_  8 _P 0 /\ &P#_ "< _P S /\ /P#_ $H _@!4 /L 70#Y
M &0 ]P!K /4 <@#S '@ \@!^ /  A #O (H [0"1 .P F0#J *$ Z "K .8
MM@#D ,< X@#C .  ]P#> /\ W0#_ -D _P#, /\ Q0#_ ,$ _P#_    _P
M /\   #_  $ _P - /\ %@#\ "( ^0 N /8 .0#S $4 [P!. .P 5P#I %X
MY@!E .0 ; #B '( X !W -\ ?@#= (0 VP"+ -@ D@#5 )L T@"D ,\ KP#-
M +X RP#5 ,D [P#' /\ Q0#_ ,0 _P"^ /\ N #_ +4 _P#_    _P   /\
M  #^    ]P ) /$ $0#K !P YP H .0 ,P#A #X W0!( -@ 40#3 %@ T !?
M ,X 90#, &L R@!Q ,@ =P#& 'T Q "$ ,( C #  )0 O@"> +L J "Y +8
MMP#( +4 Y@"S /H L0#_ +  _P"P /\ K #_ *D _P#_    _P   /H   #Q
M    Z  # .  #0#8 !8 T0 B ,T +0#* #< Q@!! ,( 2@"_ %( O0!9 +H
M7P"X &4 MP!J +4 < "S '8 L0!] *\ A0"M (T JP"7 *D H0"G *X I0"^
M *( V "@ /( GP#_ )X _P"> /\ G@#_ )P _P#_    ]P   .L   #A
MU@   ,L "0#% !$ OP ; +L )@"W #$ M  Z +$ 0P"N $L JP!2 *D 6 "G
M %X I@!D *0 :0"B '  H !V )X ?@"< (8 F@"0 )@ FP"6 *< E "V )(
MR@"0 .D CP#\ (X _P"- /\ C #_ (T _P#X    Z0(  -L#  #, 0  Q
M +T  @"V  T L  5 *L ( "G "H I  T *$ / "> $0 G !+ )H 4@"8 %@
ME@!= )4 8P"3 &D D0!P (\ =P"- (  BP"* (D E0"' *$ A0"O (, P0"!
M .  @ #U '\ _P!_ /\ ?P#_ '\ _P#N"@  W X  ,H0  "^#@  M0L  *\#
M  "I  < HP 0 )X & "9 ", E@ L ), -0"0 #X C@!% (P 2P"* %$ B !7
M (8 70"% &, @P!J ($ <0!_ 'H ?0"$ 'L CP!Y )P =P"J '4 NP!T -0
M<@#P '( _P!R /\ <0#_ '$ _P#C$0  S1<  +\9  "S&0  JA4  *,0  "=
M"@  EP$* )$ $@"- !L B0 E (4 +P"# #< @  ^ 'X 10!] $L >P!1 'D
M5P!X %T =@!D '0!:P!R 70 < )_ &X"BP!L Y@ :P.F &D$MP!H!<X 9P?L
M &8(_0!F"?\ 90G_ &4)_P#6&@  Q"   +8C  "K(P  H2   )D;  "2%
MC X! (8'#0" !!0 ? 8> 'D'* !V"#  = @X '()/P!P"44 ;PI, &T*4@!L
M"E@ :@M? &@+9P!G"W  90QZ &,,AP!B#)4 8 VD %\-M@!>#<X 7 [M %P/
M_P!;$/\ 6Q#_ %L0_P#-(0  O"@  *\K  "D*P  FBD  )(D  ")'P  @A@
M 'L1!0!U#0\ <0T7 &X.(0!K#BH :0\R &<0.0!E$$  9!!& &,030!A$%,
M7Q%: %X18@!<$6L 6Q%V %D2@P!8$I( 5A.B %43M !4$\L 4Q3L %(5_P!2
M%O\ 4A7_ %(5_P#&*   MBX  *DR  "?,@  E3$  (PM  "#)P  >B$  '(:
M  !K$PL 9Q,3 &04' !A%"4 7Q4M %T5- !<%3L 6Q9" %D62 !8%D\ 5A=6
M %477@!3%V< 4AAR % 8?P!/&8X 3AJ? $P:L !+&\< 2QOI $H<_0!*'/\
M2AS_ $H<_P#!+0  L30  *4W  ":.   D#<  (<T  !]+P  ="D  &PC  !D
M' < 7AD0 %L:& !9&R$ 5QLI %4;, !4'#< 4AP] %$<1 !/'4L 3AU2 $T=
M6@!+'F, 2AYN $D?? !''XL 1B"< $4AK@!$(<0 0R+F $,B_ !#(O\ 0R+_
M $,B_P"\,@  K3@  *$\  "7/@  C3T  (,Z  !Y-0  ;S   &8J  !>) (
M5R - %0@% !1(!T 3R$E $XA+ !,(3, 2R(Z $DB0 !((D< 1R). $8C5P!$
M(V  0R1K $(D>0!!)8@ /R:9 #XFJP ])\$ /2?C #TH^@ ]*/\ /2?_ #TG
M_P"X-@  JCT  )Y   "40@  BD(  ( _  !V.P  ;#8  &(P  !9*@  424+
M $TE$0!+)1D 224A $<F* !%)B\ 1"8V $,F/0!")T0 02=+ #\H5  ^*%T
M/2EI #PI=@ [*H8 .2N7 #@KJ0 W++\ -RS@ #<L^  W+/\ -RS_ #@L_P"U
M.@  IT   )Q$  "11@  AT8  'U$  !S0   :#L  %\V  !5,0  3"L' $<I
M#P!%*A8 0RH> $$J)0 _*BP /BLS #TK.0 \*T$ .RQ( #HL40 Y+5L ."YF
M #8N<P U+X, -"^5 #,PIP R,+T ,3'> #$Q]P R,?\ ,C#_ #,P_P"Q/@
MI$0  )E(  "/2@  A4H  'M)  !P10  94   %L[  !2-@  2#$$ $(N#0 _
M+A, /2X; #LN(@ Y+RD ."\O #<O-@ V,#X -3!& #0Q3P S,5D ,C)D #$R
M<0 P,X$ +S23 "XTI@ L-;L +#7; "PU]0 M-?\ +33_ "XT_P"N00  HD@
M )=,  "-3@  @TX  'E-  !N2@  8D4  %A   !./   13<  #TS"P Y,Q$
M-S,8 #8S'P T,R8 ,S,M #(T-  Q-#P ,#5$ "\U3  N-E8 +39B "PW;P K
M-W\ *CB1 "@XI  G.;D )CG8 "<Y]  H.?\ *#C_ "DX_P"K10  GTL  )1/
M  "+4@  @5,  '=2  !L3P  7TD  %9&  !,0@  0CT  #@X"  T. \ ,C@5
M #$X'0 O."0 +C@K "TY,@ L.3D *SI! "HZ2@ I.U0 *#M? "<\;0 E/'T
M)#V/ ",]H@ B/;< (3[4 "$^\P B/?\ (SW_ ",\_P"H20  G4\  ))3  ")
M5@  ?U<  '56  !J4P  74\  %-,  !*2   0$0  #9 !0 O/0T +3T3 "L]
M&@ J/B$ *3XH "@^+P G/C< )C\_ "0_2  C0%( (D!= "%!:@ @07H 'D&-
M !U"H  <0K4 &T+1 !M"\0 <0O\ '4'_ !Y!_P"E30  FE,  )!8  "&6P
M?5P  ');  !G6   6U0  %%2  !(3@  /4H  #-'   J0PL )D,0 "5#%@ D
M0QX (T0E ")$+  A1#0 ($4\ !Y%10 =14\ '$9: !M&:  91G@ &$>* !='
MG@ 61[, %$C. !5'[P 61_\ %T;_ !=&_P"B4@  EU@  (U=  "$8   >F$
M '!@  !E7@  65H  $]8  !$5   .5$  "].   F2P8 ($H. !Y*$P =2AH
M'$HA !M+*  :2S  &4LX !=+0@ 63$P %4Q7 !1,90 3374 $DV( !%-G  0
M3;$ #D[,  ]-[@ 03?\ $4S_ !%,_P">5P  E%T  (MB  "!90  =V8  &UF
M  !C9   5F$  $I>   _6P  -5@  "M6   B5 $ &E(* !92$  54A8 %%(=
M !-2)  24BP $5(T !%2/@ 04T@ #U-4  Y38@ -5'( #%2$  M4F  )5*T
M"%3%  E4YP *4_L "U+_  M2_P";70  D60  (AH  !^:P  =&P  &ML  !?
M:@  4F<  $5D   Z8@  ,&   "9>   =70  %5L% !!:#  .6A$ #EH8  U;
M(  ,6R< "ULP  I;.@ )6T4 !UM1  9;7@ $6VT  UN   %;E   6Z@  %O
M  !:X@  6O8  5K_  )9_P"79   CFL  (1N  ![<   <G(  &=Q  !9<
M3&X  $!L   U:P  *FD  "%G   89@  $68!  QE"@ '90\ !&44  -D&P "
M9",  &0L  !D-0  9$   &1,  !D6@  9&D  &1[  !DCP  8Z0  &.[  !B
MW0  8O0  &+_  !A_P"3;   B7$  (!U  !X=P  ;7@  &!W  !2=@  1G4
M #ET   N=   (W(  !IQ   2<0  #7$   9Q"   < T  ' 2  !P%P  ;Q\
M &\F  !O,   ;SL  &]'  !O5   ;V0  &]U  !NB@  ;:   &VV  !LU@
M:_(  &O_  !K_P".<P  A7@  'U[  !S?0  97X  %A^  !+?@  /GX  #)^
M   F?0  ''P  !-\   -?   !GT   !]!0  ? L  'P/  !\$P  ?!D  'PA
M  !\*0  ?#0  'M   ![3@  >UX  'MO  !ZA   >IH  'FQ  !XS@  =^\
M ';^  !V_P")>@  @7\  'B"  !K@P  784  $^&  !"AP  -8@  "F'   =
MAP  %(<   V(   &B0   (H   "*    B08  (D,  ")#P  B1,  (D:  "*
M(@  BBP  (HX  "*1@  B58  (EH  ")?   B)0  (>K  "&Q@  A>H  (7[
M  "$_P"%@@  ?88  &^(  !ABP  4XT  $6/   XD0  *Y$  !^2   4D@
M#9,   24    E@   )<   "8    EP   )<%  "7"P  F X  )@3  "9&@
MF2(  )HN  ":/0  F4T  )E>  "9<P  F(L  )BC  "7O   EN(  );W  "5
M_P" B0  <HP  &2/  !6DP  2)8  #J9   LF@  'YL  !2<   ,G@   Y\
M  "A    HP   *4   "E    I0   *4   "F @  IP@  *<-  "H$0  J1D
M *LC  "K,0  JT$  *Q3  "L9P  JX   *J:  "JLP  JM   *GO  "I^P!U
MCP  9Y0  %F8  !*G   /)\  "VB   @HP  $Z4   NG   !J0   *L   "N
M    L0   +(   "R    LP   +0   "U    M@   +@$  "Y"P  NQ   +T8
M  "_)   OS4  ,!'  # 6P  P'(  ,"-  #!I@  P,$  +_C  "^\P!JEP
M6YP  $VA   ^I0  +ZD  "&K   3K0  "[    "S    M0   +@   "\
MOP   ,$   #!    PP   ,0   #&    QP   ,D   #+    S@@  -$/  #5
M&   V"<  -DY  #:30  VV0  -M^  #<F0  W+   -S)  #<XP!=GP  3Z4
M $"J   RKP  (K(  !2U   *N    +L   "_    PP   ,8   #+    S@
M -$   #1    U    -8   #9    VP   -X   #@    Y    .<&  #K#@
M[QD  / J  #R/P  \U4  /1M  #TB   ]*$  /2V  #TQP#_  D _P & /\
M!P#_  P _P 1 /\ ' #_ "@ _P T /\ 00#_ $P _P!5 /\ 70#_ &4 _P!L
M /\ <@#^ '@ _ !^ /L A #Z (L ^0"2 /< F0#V *( ] "L /, N0#Q ,L
M\ #H .X ^P#M /\ [ #_ .$ _P#2 /\ R0#_ ,0 _P#_  $ _P   /\   #_
M  0 _P . /\ %P#_ ", _P O /\ .P#] $8 ^@!0 /< 6 #T %\ \@!F /
M; #O '( [0!X .P ?@#J (4 Z0", .< DP#E )P XP"F .$ L0#? ,$ W0#=
M -L ] #9 /\ U@#_ ,\ _P#$ /\ O0#_ +D _P#_    _P   /\   #_
M_P + /P $P#W !X ]  J /( -0#N $  Z0!* .8 4@#C %D X !@ -X 9@#<
M &P V@!R -< > #4 'X T@"% -  C0#. )4 S "? ,D J@#' +@ Q0#- ,,
MZP#  /X OP#_ +X _P"V /\ L #_ *T _P#_    _P   /\   #Y    \@ &
M .L #P#F !D X0 D -X +P#: #D TP!# ,\ 3 #, %, R0!: ,< 8 #% &8
MPP!K ,$ <0"_ '< O0!^ +L A@"Y (X MP"8 +4 HP"S +  L0#" *X X "L
M /< JP#_ *H _P"H /\ HP#_ *  _P#_    _P   /4   #K    X0   -8
M# #/ !, R@ > ,8 *0#" #, OP ] +L 10"X $T M@!4 +, 6@"Q %\ L !E
M *X :@"L '  JP!W *D ?P"G (< I0"1 *, G "@ *D G@"X )P S@": .X
MF0#_ )< _P"6 /\ E@#_ ), _P#]    \0   .4   #9    S0   ,0 !@"]
M  \ MP 8 +, (@"P "P K0 V *D /@"G $8 I !- *( 4P"@ %D GP!> )T
M9 "; &H F@!P )@ =P"6 (  E "* )$ E0"/ *( C0"P (L PP") ., B #Y
M (8 _P"& /\ A@#_ (8 _P#S    XP   -$   #%    O0   +8   "N  L
MJ  2 *0 ' "@ "8 G  O )H -P"7 #\ E0!& )( 3 "1 %( CP!8 (T 70"+
M &, B@!J (@ <0"& 'D A "# (( CP!_ )L ?@"I 'P NP!Z -4 > #R '@
M_P!W /\ =P#_ '< _P#G!P  T0P  ,,-  "X#   K@@  *@   "B  4 FP .
M )8 %0"2 !\ C@ H (L ,0"( #D A@!  (0 1@"" $P @ !2 '\ 5P!] %T
M>P!C 'H :P!X ', =@!] '0 B !Q )4 < "D &X M !L ,H :P#J &H _ !J
M /\ :@#_ &H _P#:$   QA0  +@6  "M%0  I!(  )P.  "6!P  D  ) (H
M$ "% !@ @0 A 'X *@![ #( >0 Y '< 0 !U $8 <P!, '( 40!P %< ;@!>
M &T 90!K &X :0!W &< @P!E )$ 8P"? &( KP!@ ,0 7P#D %\!^ !> O\
M7@+_ %X"_P#.&   O1T  + @  "E'P  FQP  ),7  "+$0  A P  'X$"P!Y
M !( =0 ; '( (P!O "L ;0$S &L!.@!I D  9P-& &8#3 !D!%( 8P19 &$$
M8 !?!6D 7@5S %P&?P!:!HT 60>< %<(K0!6",$ 50GA %0+]@!4"_\ 5 O_
M %0+_P#&'P  MB4  *DH  ">*   E"4  (LA  "#&P  >Q0  '0. P!N"0T
M:0@4 &8)'0!D"B4 8@HM & +- !>"SH 70M  %L,1P!:#$T 6 Q4 %<-7 !5
M#60 5 UO %(->P!0#HH 3PZ: $X.K !,#\( 3!#C $L0^0!+$/\ 2Q'_ $L0
M_P"_)@  L"L  *0O  "9+P  CRT  (8I  !])   =!X  &P7  !E$0< 7PX0
M %P/%P!:$!\ 6! G %80+@!4$#4 4Q [ %(10@!0$4@ 3Q%0 $X15P!,$F
M2Q)K $D2> !($X< 1A.7 $44J0!$%+X 0Q7? $,6^ !#%O\ 0Q;_ $,6_P"Z
M*P  JS$  * T  "5-0  BS0  ($Q  !X*P  ;R8  &8@  !>&0$ 5Q0- %04
M$P!1%!L 3Q4C $X5*@!,%3$ 2Q8W $D6/@!(%D0 1Q=, $475 !$%UT 0QAG
M $$8= ! &8, /QJ4 #T:I@ \&[L .QO; #L<]@ \'/\ /!S_ #P<_P"U,
MJ#8  )PY  "1.P  ASH  'XW  !S,@  :BT  &$G  !9(0  41L) $P9$ !*
M&A< 2!H? $8:)@!%&RT 0QLS $(;.@!!'$$ 0!Q( #X<4  ]'5D /!YD #L>
M<0 Y'X  .!^2 #<@I  V(+@ -2'6 #4A]  U(O\ -2'_ #8A_P"R-   I#H
M )D^  "//P  A3\  'L\  !P.   9S(  %TM  !4*   3"(% $8?#@!#'Q0
M01\; #\?(@ ^("D /2 P #L@-@ Z(3T .2%% #@B30 W(E< -B-B #0C;@ S
M)'X ,B2/ #$EH@ O);8 +R;2 "\F\@ O)O\ ,";_ # F_P"O.   HCX  )9"
M  ",0P  @D,  'A!  !N/0  8S@  %HS  !1+@  2"@! $ D#  ](Q$ .R08
M #DD'P X)"8 -B0L #4E,P T)3H ,R9" #(F2@ Q)U0 ,"=? "\H;  N*'L
M+"F- "LJH  J*K0 *2K/ "DK\  J*_\ *BK_ "LJ_P"L/   GT(  )1&  "*
M1P  @$<  '9%  !L0@  83T  %<X  !.,P  1"X  #PI"0 W*!  -2@5 #,H
M'  R*", ,"@I "\I,  O*C< +BH_ "TK2  L*U( *RQ= "HL:@ H+7D )RV+
M "8NG@ E+K, )"_- "0O[@ E+_\ )2__ "8N_P"I/P  G44  )))  "(2P
M?DP  '1*  !J1P  7D(  %0]  !+.0  030  #@O!@ R+0T ,"T3 "XM&0 M
M+2  *RTG "HN+@ I+C4 *2\] "@O1@ G,$\ )3!; "0Q:  C,7< (C*) "$R
MG0 ?,[$ 'C/+ !XS[0 ?,_\ (#/_ "$R_P"F0P  FDD  )!-  "&3P  ?%
M '-/  !H3   7$8  %)#  !)/P  /SL  #8V @ N,@P *S(1 "DR%P H,AX
M)C(D "4S*P D,S( (S0Z "(T0P A-4T (#58 !\V90 >-G4 '#>' !LWFP :
M-Z\ &3C( !DXZP :./\ &S?_ !LW_P"C1P  F$T  (Y1  "$4P  >U0  '%3
M  !F4   6DP  %!)  !'10  /4$  #,]   J.0D )3<. ",W%  B.!L (3@B
M " X*  ?.#  'CDX !TY00 <.DL &CI6 !D[8P 8.W( %CN% !4\F0 4/*T
M$SW& !,]Z0 4//T %3S_ !8[_P"@2P  E5$  (M5  ""6   >5D  &Y8  !D
M5@  6%$  $Y/  !%2P  .D<  #!#   G0 4 (#X- !T^$0 </A< &SX> !H^
M)0 9/BT &#\U !8_/@ 5/T@ %$!3 !- 8  207  $4&" !!!EP /0:P #D+$
M  Y"YP /0?P $$'_ !! _P"=4   DU8  (E:  " 70  =EX  &Q=  !B6P
M5E<  $Q5  !!40  -DX  "Q+   C2   &T4) !=$#P 51!0 %$4; !-%(@ 2
M12D $44Q !%%.P 01D4 #T90  Y'7@ -1VT #$=_  M'DP )1Z< "$>^  A'
MX  )1_8 "D;_  M&_P":50  D%L  (=@  !]8@  <V,  &IB  !@80  4UX
M $=:   \5P  ,E4  "A2   ?4   %TX$ !%,#  /3!$ #DP7  Y,'@ -324
M#$TN  M--P *34( "4U-  =.6@ &3FD !$Y[  ).CP !3J0  $VZ  !-VP !
M3?(  4W_  ),_P"66P  C6(  (1F  !Z:   <6D  &AI  !<9P  3V0  $)A
M   W7P  +5P  "-:   :6   $E<!  U6"0 )50X !U43  95&@ $52(  U4J
M  )5-   53X  %5*  !65P  5F4  %5W  !5BP  5:   %6V  !4U   5/$
M %/]  !3_P"38@  BF@  (!L  !W;@  ;V\  &-N  !6;   26H  #UH   R
M9@  )V4  !UC   58@  #F$   E@"  #8 T  %\1  !?%P  7QX  %\F  !?
M+P  7SH  %]%  !?4P  7V$  %YR  !>AP  79P  %VR  !<SP  7.\  %O]
M  !;_P"0:@  AF\  'UR  !U=   :G4  %UT  !/<P  0G(  #9P   K;P
M(&X  !=M   0;   "FP   )K!@  :PL  &H/  !J%   :AH  &HA  !I*@
M:30  &E   !I3@  :5P  &EM  !H@@  :)@  &>N  !FR@  9>T  &7\  !D
M_P"+<0  @G8  'IY  !P>P  8GL  %5[  !(>@  .WH  "]Z   C>0  &7@
M !%W   *=P   W<   !W @  =P@  '8-  !V$   =A4  '8;  !V(P  =BX
M '4Z  !U1P  =58  '5H  !T?   =)(  '.J  !RQ   <>D  '#[  !P_P"&
M>0  ?WT  '9_  !H@0  6H(  $R"   _@P  ,H0  "6#   :@P  $8,   J#
M   "@P   (0   "%    A ,  (,(  "##0  @Q   (,5  "$'   A"8  (0R
M  "$/P  @T\  (-@  ""=0  @HP  (&D  " O0  ?^,  '[Y  !^_P""@
M>H0  &R&  !>B   4(H  $*+   UC0  )XT  !N-   1C@  "HX   "/
MD0   )(   "2    D@   )(!  "2!P  D@P  )(0  "3%0  DQT  )0H  "4
M-@  E$4  )-7  "3:P  DX(  )*<  "1M@  D-@  (_S  "/_P!^AP  <(H
M &&-  !3D   19,  #>5   IE@  ')<  !&8   )F0   )L   "<    G@
M *    "@    H    *    "A    H00  *()  "C#@  I!0  *4=  "F*@
MICH  *9,  "E8   I7@  *62  "DK   I,D  */K  "B^@!SC@  9)$  %:5
M  !'F0  .9P  "J>   =H   $:$   BC    I0   *<   "I    K    *X
M  "N    K@   *\   "P    L0   +(   "S!@  M0T  +<3  "Y'@  N2X
M +I   "Z5   NVH  +J%  "YH0  N;L  +K>  "Y\@!GE0  6)D  $J>   [
MH@  +*8  !VH   1J@  !ZP   "O    L0   +0   "X    NP   +P   "\
M    O@   +\   #     P@   ,0   #&    R ,  ,L+  #/$@  T2   -$R
M  #21@  TUT  -1V  #4D@  U:L  -7$  #4X@!;G0  3*(  #VG   OK
M'Z\  !&Q   'M0   +@   "[    O@   ,(   #'    R@   ,P   #,
MS@   -    #2    U0   -@   #;    WP   .(   #F"P  ZQ,  .PD  #M
M.   [DX  .]G  #P@@  \)P  /"R  #QQ0#_  , _P ! /\ ! #_  D _P /
M /\ & #_ "0 _P P /\ / #_ $< _P!1 /\ 60#_ &  _0!G /P ;0#Z ',
M^0!Y /@ ?P#V (4 ]0", /, E #R )T \ "G .X LP#L ,0 ZP#A .H ^ #I
M /\ YP#_ -D _P#+ /\ P@#_ +T _P#_    _P   /\   #_    _P , /\
M% #_ "  _P K /X -P#Z $( ]@!+ /( 4P#P %L [@!A .P 9P#J &T Z !S
M .< >0#E '\ XP"& .$ C@#? )8 W0"@ -L K #8 +L U #1 -, \ #0 /\
MS@#_ ,@ _P"] /\ M@#_ +( _P#_    _P   /\   #_    _0 ( /< $ #S
M !H [P F .T ,0#H #L XP!% .  30#< %4 V0!; -8 80#3 &< T0!L ,\
M<@#- '@ RP!_ ,D AP#' )  Q0": ,, I0#  +( O@#% +P Y0"Z /L N #_
M +< _P"P /\ J0#_ *4 _P#_    _P   /X   #U    [  # .4 #0#? !4
MV@ @ -0 *@#0 #4 RP ^ ,@ 1P#% $X P@!5 ,  6P"^ &$ O !F +H ; "X
M '( M@!X +4 @ "S (@ L0"2 *X G@"L *H J0"[ *@ U0"F /, I #_ *,
M_P"A /\ FP#_ )@ _P#_    ^P   /    #E    V    ,X "0#' !$ P@ :
M +X ) "[ "X MP X +0 0 "Q $@ K@!. *P 5 "J %H J0!? *< 90"E &L
MI !Q *( > "@ ($ G@"+ )P E@"9 *, EP"R )8 QP"3 .@ D@#^ )$ _P"0
M /\ C0#_ (L _P#Y    ZP   -T   #/    Q@   +P ! "U  T L  5 *P
M'@"H "@ I0 Q *( .0"? $$ G0!( )L 3@"9 %, EP!9 )8 7@"4 &0 D@!J
M )  <0". 'H C "# (H CP"( )P A@"J (0 O "" -P @0#V (  _P!_ /\
M?P#_ 'X _P#L    V@   ,D   "^    M@   *X   "G  D H0 0 )P & "8
M "( E0 J )( ,@"0 #H C0!! (L 1P") $T AP!2 (8 6 "$ %T @@!D ($
M:P!_ ', ?0!] 'L B !X )4 =@"C '4 M !S ,P <0#M '  _P!P /\ < #_
M '  _P#?!0  R@H  +P+  "Q"0  J 0  *$   ";  , E  , (\ $P"* !L
MAP D (0 + "! #, ?P Z 'T 00![ $< >0!, '< 4@!V %< = != '( 9 !P
M &T ;P!V &P @@!J (\ :0"= &< K@!E ,, 9 #D &, ^@!C /\ 8@#_ &,
M_P#0#@  OQ(  +(3  "G$@  G1   )4+  "/ P  B0 ' (( #@!^ !4 >@ >
M '8 )0!T "T <0 T &\ .@!N $  ; !& &H 3 !I %( 9P!8 &8 7P!D &<
M8@!Q &  ? !> (D 7 "8 %L J0!9 +P 6 #< %@ ] !8 /\ 5P#_ %< _P#&
M%@  MAH  *H=  "?'   E1D  (T4  "%#P  ?@D  '<!"@!R !  ;@ 7 &H
M'P!H "< 90 N &0 - !B #L 8 !  %\ 1@!= $P 7 !3 %H 6@!8 &( 5P!L
M %4 =P!3 (4 4@"4 % !I0!/ ;@ 3@+2 $T$\ !-!?\ 307_ $T%_P"_'0
ML"(  *,E  "9)0  CR(  (4=  !]&   =1(  &X- @!G!@P 8P,1 %\"&0!=
M R$ 6P0H %D$+P!7!34 5@4[ %0&00!3!D< 409. % '50!.!UX 30AG $L(
M<P!)"8$ 2 F2 $<*HP!%"K8 1 O0 $0,[P!##?\ 0PW_ $0-_P"Y)   JBD
M )XL  "4+   BBH  ( F  !W(0  ;AL  &84  !?#P4 60L- %4*$P!3"QL
M40LB $\,*0!-#"\ 3 PV $L-/ !)#4( 2 U) $8-40!%#EH 1 YD $(.< !
M#G\ /P^0 #X0H@ \$+8 .Q#1 #L1\0 [$?\ .Q'_ #P1_P"T*0  IB\  )HR
M  "0,@  AC$  'PM  !R*   :2,  &$=  !9%@  41$( $P/$ !*$!8 2! =
M $80) !%$"L 0Q$Q $(1-P!!$3X 0!%% #X230 ]$E8 /!)A #H3;0 Y$WP
M-Q2- #84GP U%;, -!7- #,6[@ T%O\ -!;_ #06_P"O+@  HC0  )<W  ",
M.   @C8  '@T  !N+@  92H  %PD  !4'@  3!@$ $84#0!"%!( 0!09 #\4
M(  ]%2< /!4M #L5-  Y%CH .!9" #<62@ V%U, -1=> #,8:@ R&7D ,!F*
M "\:G0 N&K$ +1O* "T;[  M'/\ +AO_ "X;_P"L,@  GS@  )0[  "*/
M@#P  '8Y  !K-   8B\  %DJ  !0)0  1Q\  $ :"@ \&1  .AD6 #@9'0 V
M&B, -1HI #0:,  S&C< ,AL^ #$;1P O'%  +AU; "T=9P L'G8 *AZ( "D?
MFP H'ZX )R#' "8@Z@ G(/X *"#_ "@@_P"I-@  G3P  )(_  "'00  ?4
M '0^  !I.@  7S4  %8P  !-*P  1"4  #L@!P V'@X ,QX3 #(>&0 P'B
M+QXF "X?+0 M'S0 +" [ "L@1  J(4X *2%8 "<B90 F(G0 )2.% ",CF0 B
M)*T (23% "$EZ  B)?T (B3_ ",D_P"F.@  FC\  (]#  "%10  >T0  ')#
M  !G/P  73H  %,V  !*,0  02P  #@F P Q(PP +B(1 "PB%@ J(AT *2(C
M "@C*@ G(S$ )B0Y "4E00 D)4L (R96 "(F8P A)W( 'R># !XHEP =**L
M&RG# !LIY@ <*?L '2G_ !XH_P"C/@  F$,  (U'  "#20  >DD  '!'  !F
M1   6C\  %$[  !'-P  /C(  #4M   L* D *"</ "<G%  E)QH )"<A ",H
M)P B*"X (2DV " I/P ?*DD 'BI4 !TK8  ;*V\ &BR! !DLE0 7+:D %BW!
M !8MY  7+?H &"W_ !DM_P"A00  E4<  (M+  ""30  >$T  &Y,  !D20
M6$0  $]   !&/0  /3@  #,T   J+P8 )"P- "$L$@ @+!@ 'RT> !XM)0 =
M+2P '"XT !LN/  :+T8 &"]1 !<P7@ 6,&T %3%_ !,QDP 2,:@ $3*_ !$R
MX@ 2,OD $S'_ !,Q_P">10  DTL  (E/  " 40  =E(  &U0  !B3@  5DD
M $U&  !$0P  .S\  #$Z   G-@, 'S(+ !PR$  ;,A4 &3(; !@R(@ 7,RD
M%C,Q !4T.@ 4-$0 $S1/ !(U7  1-6L $#9]  \VD0 .-J8 #3>\  TWW0 -
M-O8 #C;_  \V_P";20  D4\  (=3  !^5@  =58  &I5  !@4P  54\  $Q,
M  !"20  .$4  "Y!   D/0  '#H( !8X#@ 5.!( %#@8 !,Y'P 2.28 $3DN
M ! Y-P /.D$ #CI,  T[60 -.V@ "SMZ  H[C0 )/*( !SRX  <\U0 (//
M"3O_  H[_P"83@  CE0  (58  !\6P  <EL  &A:  !>6   4U4  $E2   ^
M3@  -$L  "I'   A1   &$(# !) "P 0/Q  #C\5  X_'  -0", #$ K  M
M-  *0#X "4%*  =!5@ &064 !$%V  -!B@ !09\  $&T  !!T  !0>X  4'\
M  ) _P"55   C%D  (->  !Y8   <&   &9@  !=7@  45L  $57   Z5
M+U$  "5/   <3   %$H   Y("  +1PX "$<2  ='&0 &1R  !4@H  -(,0 "
M2#L  $A'  !(4P  2&(  $AS  !(A@  2)L  $BQ  !'S   1^T  $?[  !'
M_P"26@  B6   (!C  !W90  ;F8  &5F  !99   3&   $!=   U6P  *ED
M "!7   750  $%,   M2!P %40T  5 1  !0%@  4!T  % E  !0+@  4#@
M %!#  !04   4%X  %!O  !0@P  3Y@  $^N  !.R0  3NL  $W[  !-_P"/
M80  AF8  'UI  !T;   ;&T  &%K  !3:0  1F<  #ID   O8P  )&$  !I?
M   27@  #%P   9<!@  6PL  %H/  !:$P  6AD  %DA  !9*0  63,  %D_
M  !93   65H  %EK  !8?@  6)0  %>K  !7Q0  5ND  %7[  !5_P",:
M@FT  'IP  !R<@  9W(  %IQ  !,<   /VX  #-M   H:P  '6H  !1H   -
M9P  !V<   !F P  9@D  &4-  !E$0  9!4  &0<  !D)   9"X  &0Z  !C
M1P  8U4  &-F  !C>@  8I   &&G  !@P0  7^8  %_Z  !>_P"';P  ?W0
M 'AW  !N>   8'@  %)W  !%=P  .'8  "MV   @=   %G,   YS   '<@
M '(   !R    <04  '$*  !Q#@  <!$  ' 7  !P'@  <"<  ' S  !O0
M;U   &]@  !N=   ;HL  &VB  !LO   :^(  &KX  !I_P"#=P  ?'L  '-]
M  !E?@  5W\  $E_   \?P  +X   ")_   7?@  #WX   =^    ?P   '\
M  !_    ?@   'X%  !^"@  ?@T  'X1  !^%P  ?B   'XK  !].0  ?4@
M 'U9  !\;0  ?(0  'N<  !ZM@  >=H  'CU  !W_P" ?P  =X(  &F#  !;
MA0  388  #^(   RB0  )(D  !B)   /B0  !XH   "+    C    (T   "-
M    C    (P   ", P  C @  (T-  "-$0  C1<  (XB  ".+P  CC\  (U0
M  "-9   C'L  (R5  "+K@  BLT  (GO  ")_P![A0  ;8@  %Z*  !0C0
M0H\  #21   FD@  &9,   Z4   &E0   )8   "8    F@   )L   ";
MFP   )L   ";    G    )T%  "="P  GA   )\7  "@)   H#0  *!&  "@
M60  GW   )^*  ">I0  GL(  )WH  "<^0!PC   88\  %.2  !$E@  -ID
M ">;   9G   #YT   6?    H0   *,   "E    J    *D   "I    J0
M *H   "K    K    *T   "N 0  L D  +(/  "S&   M"<  +0Y  "U30
MM&0  +1^  "SF@  L[0  +/5  "S\ !DDP  59<  $>;   XGP  *:(  !JD
M   .I@  !*@   "K    K0   +    "T    M@   +@   "X    N0   +H
M  "\    O0   +\   #     PP   ,4'  #)#P  RAH  ,LL  #,0   S58
M ,YO  #-BP  S*@  ,S"  #,X@!8FP  2:   #JE   LJ0  '*L   ^N   $
ML0   +0   "W    N@   +X   ##    Q@   ,@   #(    R@   ,L   #-
M    SP   -(   #5    V0   -T   #A!0  Y@\  .<>  #H,@  Z4@  .I@
M  #K>P  ZY<  .RN  #LP@#_    _P   /\   #_  8 _P - /\ %0#_ "$
M_P L /\ . #_ $, _P!, /X 5 #[ %L ^@!B /@ : #V &X ]0!T /0 >@#R
M (  \0"' .\ CP#M )< ZP"A .D K0#G +T Y0#8 .0 \P#B /\ X #_ -
M_P#$ /\ O #_ +8 _P#_    _P   /\   #_    _P ) /\ $0#_ !P _0 G
M /D ,@#U #T \0!& .T 3P#K %8 Z !< .8 8@#D &@ XP!N .$ <P#? 'D
MW0"  -H B #8 )$ U "; -( I@#/ +0 S #) ,D Z0#( /\ QP#_ ,$ _P"W
M /\ KP#_ *L _P#_    _P   /\   #_    ^  % /( #@#N !< Z@ B .8
M+ #A #< W0!  -@ 20#3 %  T !6 ,X 7 #, &( R@!G ,@ ;0#& ', Q !Y
M ,( @0#  (H O@"4 +P GP"Y *P M@"^ +0 W0"S /< L0#_ +  _P"H /\
MH@#_ )X _P#_    _P   /D   #O    Y@   -\ "P#6 !( T  < ,P )@#(
M #  Q  Z ,  0@"] $H NP!0 +@ 5@"V %L M0!A +, 9@"Q &P L !R *X
M>@"L (( J0", *< F "E *4 HP"T *  RP"? .X G0#_ )P _P"9 /\ E #_
M )$ _P#_    ]@   .H   #=    SP   ,< !@#   \ NP 7 +< ( "S "H
ML  S *T .P"J $, IP!) *4 3P"C %4 H@!: *  7P"> &4 G0!K )L <@"9
M 'L EP"% )0 D "2 )T D "L (X OP", .( BP#Z (D _P") /\ A@#_ (,
M_P#T    Y    -0   #(    OP   +4  0"N  L J0 2 *4 &P"A ", G@ L
M )L - "8 #P E@!# )0 20"2 $X D !3 (X 60"- %X BP!D (D :P"' ',
MA0!] (, B "! )4 ?P"D 'T M0![ ,\ >0#Q '@ _P!W /\ =P#_ '4 _P#E
M    T0   ,,   "X    KP   *@   "@  8 F@ . )4 %0"1 !X C@ F (L
M+0"( #4 A@ \ (0 0@"" $< @ !- '\ 4@!] %@ >P!> 'D 90!X &T =@!V
M ', @0!Q (X ;P"= &T K@!L ,0 :@#G &D _0!H /\ : #_ &D _P#5 P
MPP<  +8(  "K!@  H@   )L   "4    C0 * (@ $ "# !@ ?P @ 'P )P!Z
M "X =P U '4 .P!T $$ <@!' '  3 !O %( ;0!8 &L 7P!I &8 9P!P &4
M>P!C (@ 8@"7 &  IP!> +L 70#< %P ]@!< /\ 6P#_ %L _P#)#0  N1
M *P1  "A$   EPT  (\(  "(    @@ % 'L #0!W !( <P : &\ (0!L "@
M:@ O &@ -0!G #L 90!! &, 1@!B $P 8 !2 %\ 60!= &$ 6P!J %D =0!7
M (( 50"1 %0 H@!3 +4 40#/ %  [P!0 /\ 4 #_ %  _P"_%   L!@  *0:
M  "9&0  CQ8  (<1  !_#0  =P8  '$ " !K  X 9P 4 &0 &P!A "( 7@ I
M %T +P!; #4 60 [ %@ 00!6 $8 50!- %, 5 !2 %P 4 !E $X < !, 'T
M2P"- $D G@!( +  1P#' $8 Z0!& /L 1@#_ $4 _P"X&P  JB   )XB  "3
M(@  B1\  ( :  !W%0  ;Q   &@+  !A! H 70 0 %D %@!6 !T 5  C %(
M*@!0 #  3P U $X .P!, $$ 2P!( $D 3P!' 5< 1@%A $0"; !# GD 00.)
M $ #F@ ^!*T /03$ #P%Y0 \!_@ / ?_ #P'_P"R(@  I2<  )DI  ".*0
MA"<  'LC  !Q'@  :1@  &$2  !:#0, 4P@, $\%$0!,!1< 2@8> $@&) !'
M!BH 10<P $0'-@!#"#T 00A# $ (2P ^"5, /0E= #L*:  Z"G8 . N' #<+
MF0 U"ZP - S" #,,Y  S#?D ,PW_ #0-_P"M)P  H"P  )4O  "++P  @"X
M '<J  !M)0  9"   %P:  !4%   3 \& $8,#0!##!( 00P8 #\,'P ^#"4
M/ TK #L-,@ Z#3@ . T_ #<.1P V#E  - Y: #,.9@ Q#W0 , ^% "X0F  M
M$*L +!## "L1Y0 L$?H +!'_ "T1_P"J+   G3$  )(T  "'-0  ?30  '0Q
M  !J*P  8"<  %@A  !/&P  1Q8  $ 1"0 [$ \ .1 4 #<0&P V$"$ -! G
M #,1+0 R$30 ,1$[ # 10P N$DT +1)7 "P28P J$W$ *1." "<4E0 F%*D
M)17  "05XP E%OH )A;_ "85_P"F,0  FC8  (\Y  "%.@  >SD  '$V  !G
M,0  72T  %0H  !,(@  0QT  #L7!0 U% T ,A,1 #$4%P O%!T +A0D "P4
M*@ K%3$ *A4X "D60  H%DH )Q=4 "878  D&&\ (QB  "$9DP @&:< 'QF^
M !X:X  ?&O@ (!K_ " :_P"C-   F#H  (T]  "#/@  >3T  &\[  !E-P
M6S(  %(M  !)*   0",  #@> 0 P&0H +!@/ "H8%  I&!H )Q@@ "89)P E
M&2T )!HU ",:/@ B&T< (1M2 " <7@ ?'6P '1U^ !P=D0 :'J4 &1Z\ !@?
MW0 9'_8 &A__ !L>_P"A.   E3T  (M!  "!0@  =T(  &U   !C/   63<
M $\S  !&+@  /2D  #4D   M( < )QT- "4=$@ C'1< (1T= "$=)  @'BL
M'QXR !X?.P ='T4 '"!/ !HA7  9(6H &")[ !8BCP 5(J, %".Z !,CV@ 4
M(_4 %2/_ !8C_P">/   DT$  (E$  !_1@  =48  &Q$  !B00  5SP  $TX
M  !$-   /#   #,K   J)@, (R(+ " A$  >(14 '"(; !LB(0 :(B@ &B,P
M !DC.  8)$( %B5- !4E60 4)F@ $R9Y !(FC0 1)Z( $">X  XGU@ 0*/0
M$2?_ !$G_P"<0   D44  (=(  !]2@  =$H  &I)  !@1@  54$  $P^  !#
M.@  .C8  #$R   H+0  ("D) !LG#@ 9)Q( &"<8 !8G'P 5*"4 %"@M !,H
M-@ 2*4  $BE+ !$J5P 0*F8 #BMW  XKBP -+)\ #"RU  LLSP ,+.\ #2S_
M  TK_P"91   CTD  (5,  !\3@  <T\  &E.  !>2P  4T<  $I$  !"0
M.3T  "\X   E-   '3 % !8M#  4+!  $RT5 !(M'  1+2, $"TJ  \N,P .
M+CT #2](  TO50 ,,&, "C!T  DPB  (,9P !C&Q  8QRP &,>L !S#\  @P
M_P"72   C4T  (-1  !Z4P  <50  &=2  !=4   4DP  $E*  ! 1@  -4(
M "L^   B.@  &C<! !(T"0 /,PX #C,3  TS&0 -,R  ##0H  LT,0 *-3L
M"#5&  <U4@ %-F  !#9Q  (VA   -ID  #:O   VR   -N@  #;Y  $U_P"4
M30  BE(  (%6  !X6   ;UD  &58  !;50  45(  $=/   \3   ,4@  "=$
M   >00  %C\  ! \!P +.@T "3H1  @[%P &.QX !3LF  0[+@ ".S@  3Q#
M   \3P  /%X  #QN   \@0  /)<  #RL   [Q0  .^<  #OX   [_P"14@
MB%@  ']<  !V70  ;5X  &-=  !:7   3E@  $)4   W40  +4X  "-+   :
M20  $D8   U$!@ '0PP  T,0  !#%0  0QL  $,C  !#*P  0S4  $-   !#
M30  0UL  $-K  !#?@  0Y0  $*J  !"PP  0>8  $'Y  !!_P".6   AEX
M 'UA  !S8P  :V0  &)C  !780  25T  #U:   R6   )U4  !Y3   540
M#D\   E-!0 "30L  $P.  !,$P  2Q@  $L?  !+*   2S(  $L]  !+20
M2U<  $MG  !*>P  2I   $FG  !)P   2.0  $CX  !'_P"+7P  @V0  'IG
M  !Q:0  :6H  %YI  !09@  0V0  #=A   L7P  (5T  !A;   060  "E@
M  -7 P  5PD  %8-  !5$   514  %0;  !4(P  5"T  %0Y  !410  5%,
M %1D  !3=P  4XT  %*D  !1O0  4.(  %#X  !/_P"(9P  ?VL  '=N  !O
M<   97   %=N  !*;   /6L  #!I   E:   &F8  !%D   +8P  !&(   !B
M 0  808  & +  !@#@  7Q(  %\7  !?'@  7B@  %XS  !>0   7D\  %Y?
M  !=<@  78@  %R@  !;N0  6M\  %GW  !8_P"$;@  ?'(  '5U  !K=@
M774  $]T  !"<P  -7,  "AR   =<   $V\   QN   $;@   &X   !N
M; (  &P'  !K"P  :PX  &L2  !J&0  :B(  &HM  !J.@  :4D  &E:  !I
M;   :(,  &>;  !FM0  9=@  &3U  !D_P" =0  >GD  '![  !B>P  5'P
M $9\   Y?   +'P  !][   4>@  #7H   1Z    >@   'H   !Z    >0
M 'D!  !X!@  > L  '@.  !X$P  >!H  '@E  !X,@  =T$  '=2  !W90
M=GP  '65  !TKP  <\X  '+Q  !Q_P!^?0  =8   &>!  !8@@  2H,  #R$
M   NA0  (84  !6%   -A0   X4   "&    AP   (@   "(    AP   (<
M  "'    AP0  (<)  "'#@  B!,  (@<  "(*0  B#@  (=*  "'70  AG,
M (:-  "%IP  A,4  (/L  ""_@!XA   :H8  %R(  !-B@  /XP  #&.   C
MCP  %H\   V0   "D0   )(   "3    E0   )8   "6    E@   )8   "6
M    EP   )<   "7!P  F T  )D3  ":'P  FBT  )H_  ":4@  FF@  )F#
M  "9GP  F+H  )?B  "6^ !MB@  7XT  %"0  !!DP  ,Y8  "27   6F
M#9D   &;    G0   )\   "A    I    *4   "D    I0   *4   "F
MIP   *@   "I    J@0  *P,  "N$P  KB$  *XS  "N1P  KET  *YV  "N
MDP  KJX  *W-  "L[P!AD0  4Y4  $28   UG   )I\  !>A   -HP   *4
M  "G    J@   *P   "P    L@   +0   "S    M    +4   "W    N
M +D   "[    O0   +\!  ##"P  Q14  ,4E  #&.0  QT\  ,=H  #&A0
MQJ(  ,:\  #&W@!5F0  1YT  #BB   II@  &:@   VK    K0   +$   "T
M    MP   +H   "_    P0   ,0   ##    Q0   ,8   #(    R@   ,T
M  #/    T@   -8   #;    X P  .$8  #C*P  Y$$  .5:  #F=   YI$
M .6L  #EQ #_    _P   /\   #_  $ _P * /\ $@#_ !T _P H /\ - #_
M #X _0!( /H 4 #W %< ]0!= /0 8P#R &D \ !O .\ = #M 'L ZP"! .D
MB0#H )( Y@"< .0 J #B +< WP#- -P [@#9 /\ V0#_ ,H _P"^ /\ M0#_
M +  _P#_    _P   /\   #_    _P & /\ #P#\ !@ ^  C /0 +@#P #@
MZP!" .@ 2@#E %$ X@!8 .  70#> &, W !H -D ;@#6 '0 U ![ -$ @@#/
M (L S0"5 ,H H0#( *\ Q0#! ,( XP#  /L P #_ +L _P"P /\ J #_ *0
M_P#_    _P   /\   #[    \P ! .T # #H !, XP > .  * #: #( TP \
M ,\ 1 #, $L R0!1 ,8 5P#$ %T P@!B ,$ 9P"_ &T O0!T +L >P"Y (0
MMP". +0 F0"R *< KP"W *T T "K /( J@#_ *D _P"A /\ FP#_ )< _P#_
M    _P   /0   #I    X    -4 " #. !  R0 8 ,4 (@#! "L O  U +D
M/0"V $4 LP!+ +$ 40"O %8 K@!; *P 80"J &8 J0!M *8 = "D 'P H@"&
M *  D@"> )\ G "N )D PP"7 .< E@#_ )4 _P"2 /\ C0#_ (H _P#\
M\    .,   #4    R    +\  P"Y  T LP 3 *\ ' "L "4 J0 N *4 -@"C
M #X H !$ )X 2@"= %  FP!5 )D 6@"7 %\ E@!F )0 ; "2 '4 D !^ (X
MB@"+ )< B0"F (< N "% -8 A #V (( _P"! /\ ?@#_ 'P _P#M    W0
M ,P   #!    N    *X   "G  D H@ 0 )X %P": !\ EP G )0 +P"1 #<
MCP ] (T 0P"+ $D B0!. (@ 4P"& %D A !? (( 90"  &T ?@!W 'P @@!Z
M (\ > "> '4 KP!S ,< <@#L '$ _P!P /\ < #_ &X _P#=    R0   +P
M  "Q    J0   *$   "9  , DP , (X $@"* !D AP A (0 *0"! #  ?P W
M 'T /0![ $( >0!( '@ 30!V %( = !8 '( 7P!Q &< ;P!P &P >P!J (@
M: "7 &8 J !E +P 8P#A &( ^@!A /\ 80#_ &$ _P#- 0  O 4  *\%  "E
M @  G    )0   "-    A@ ( ($ #@!\ !0 >  ; '4 (P!R "D <  P &X
M-@!M #P :P!! &D 1P!H $P 9@!2 &0 60!C &  80!I %\ = != ($ 6P"0
M %D H0!7 +0 5@#0 %4 \@!5 /\ 5 #_ %4 _P#!#   L@X  *8/  ";#@
MD@L  (D%  ""    >P " '4 "P!P !  ;  6 &@ '0!F ", 8P J &$ , !@
M #8 7@ [ %T 00!; $8 6@!, %@ 4P!6 %L 5 !D %( ;@!1 'L 3P"* $T
MFP!, *X 2P#& $H Z@!) /X 20#_ $D _P"Y$@  JA8  )X7  "4%@  BA,
M ($0  !Y"P  <0,  &L !@!E  T 80 1 %T & !: !X 6  D %8 *@!4 #
M4P V %$ .P!0 $$ 3@!' $T 3@!+ %8 20!? $< :0!& '8 1 "% $, EP!!
M *D 0 "_ #\ X@ _ /@ /@#_ #\ _P"R&0  I!X  )@?  ".'P  A!P  'H8
M  !R$@  :@X  &((  !< 0@ 5P . %, $P!0 !D 3@ ? $P )0!* "L 2  P
M $< -@!& #P 1 !" $, 20!! %$ /P!: #X 90 \ '( .@"! #D DP X *4
M-@"Z #8 VP U /0 -0#_ #4 _P"L(   GR0  )0F  "))@  ?R0  '4@  !L
M&P  9!4  %P0  !4# $ 3@8* $H"#P!' !0 1  : $( ( !  "4 /P K #X!
M,0 \ 3< .P(^ #D"10 X TT -@-6 #4$80 S!&X ,05^ # %D  O!:, +0:X
M "P&U  L!_  + C_ "P(_P"H)0  FRH  ) L  "&+0  >RL  '(G  !H(@
M7QT  %<7  !/$@  2 X$ $$*"P ^!Q  .P85 #D'&P X!R$ -@@F #4(+  S
M"#( ,@DY #$)00 O"4D +@I3 "P*7@ K"VP *0M\ "@,CP F#*( )0RW "0,
MTP C#?  ) W_ "4-_P"D*@  F"\  (TR  "#,@  >3$  &\N  !E*0  7"0
M %,?  !+&0  0Q,  #P0!@ U#0P ,PP1 #$,%@ O#!P +@TB "T-*  K#2X
M*@TU "D-/0 G#D8 )@Y0 "0.7  C#VH (@][ " 0C@ ?$*( '1"W !P0U  =
M$?( '1'_ !X1_P"A+P  E3,  (HV  " -P  =C8  &TS  !C+P  62H  % E
M  !((   /QH  #@5   P$0@ +! . "H0$@ H$!@ )Q > "40)  D$"H (Q$R
M "(1.@ A$4, (!). !X26@ =$V@ &Q-X !H3BP 8%*  %Q2U !84T0 6%?$
M%Q7_ !@4_P">,P  DS<  (@Z  !^.P  =#L  &LX  !A-   5R\  $XK  !%
M)@  /2$  #0<   M%P4 )A,, ",3$  B$Q4 (!,: !\3(0 >%"< '10O !P5
M-P ;%4$ &A9+ !D65P 7%V4 %A=V !08B0 3&)X $ABS !$9S@ 1&>\ $AG_
M !,9_P"<-@  D3L  (8^  !\/P  <S\  &D]  !?.0  534  $PP  !#+
M.B<  #(B   J'@$ (AD) !X7#@ <%Q( &A<7 !D8'@ 9&"0 &!DL !<9-  6
M&CX %1I) !,;50 2&V, $1QT ! <AP /'9P #AVQ  T=RP -'>P #AW_  \=
M_P"9.@  CS\  (1"  ![1   <4,  &A"  !>/@  4SH  $HV  !!,@  .2T
M #$I   H)0  (" & !H=#  7'!  %1P5 !0=&P 4'2( $QTI !(>,@ 1'SP
M$!]& ! @4P .(&$ #2%Q  PAA0 +(ID "B*N  DBQP )(N< "B+[  LA_P"7
M/@  C$,  (-&  !Y2   <$@  &=&  !<1   4C\  $D[  ! .   .#0  "\P
M   G+   'B<# !8C"@ 2(0X $2$3 ! B&0 0(B  #R(G  XC+P -)#D #"1$
M  LE4  *)5X "29O  <F@@ &)I8 !":L  ,FQ  $)N4 !";W  8F_P"50@
MBD<  (%*  !X3   ;TP  &5+  !;2   4$0  $=!   _/@  -SL  "TV   D
M,0  &RT  !,J!P /* T #2<1  TH%@ ,*!T "R@E  HI+0 )*3< !RI"  8J
M3@ $*UP  RML  $K?P  *Y0  "NI   KP0  *^,  "OV   J_P"21@  B$L
M ']/  !V40  ;5$  &-0  !:30  3TH  $='   ^1   ,T   "D\   @.
M%S0  !$Q!0 ,+PP "2X0  <N%0 &+QL !2\C  ,O*P ",#4  # _   P3
M,5D  #%I   Q?   ,9$  #&G   POP  ,.$  ##U   O_P"02P  AE   'U4
M  !U5@  :U8  &)5  !84P  3E   $5-   Z20  +T4  "5"   </@  %#L
M  XY!0 )-PL !#8/  $V$P  -AD  #8@   V*0  -C(  #<]   W20  -U<
M #=G   W>0  -X\  #:E   VO0  -N   #7U   U_P"-4   A%8  'Q:  !R
M6P  :5L  &!;  !760  3%8  $!2   U3@  *DL  "!(   71@  $$,   M!
M!  $0 H  #\.   ^$0  /A8  #X=   ^)@  /B\  #XZ   ^1@  /E0  #YD
M   ^=@  /8P  #VC   \NP  /-X  #OU   [_P"*5P  @EP  'E?  !P80
M:&$  %]A  !47@  1UL  #I7   O50  )5(  !M0   230  #$L   9* P
M20D  $@-  !'$   1Q0  $8:  !&(@  1BP  $8W  !&0P  1E$  $9@  !%
M<P  18D  $2@  !$N   0]P  $+U  !"_P"(70  ?V(  '=E  !N9P  9V@
M %MF  !.8P  06$  #1>   I7   'UH  !57   .5@  !U0   !3 0  4@8
M %$+  !1#@  4!$  $\6  !/'@  3R<  $\R  !//P  3TT  $Y=  !.;P
M3H4  $V=  !,M0  2]@  $KU  !*_P"%90  ?&D  '1L  !M;@  8FT  %1K
M  !':0  .F<  "UE   B9   &&(  !!@   )7P   %X   !>    70,  %P(
M  !;#   6@\  %H3  !9&0  62(  %DM  !9.@  64@  %A8  !8:P  5X$
M %>9  !6L@  5=(  %3T  !3_P"!;   >7   '-S  !H<P  6G(  $QQ   _
M<   ,F\  "5N   :;   $6L   EJ    :@   &D   !I    :    &<#  !F
M"   9@P  &8/  !E%   91P  &4G  !D-   9$,  &13  !D90  8WL  &*4
M  !AK0  8,T  %_Q  !>_P!]=   =W<  &YY  !?>0  47D  $-Y   V>
M*7@  !QW   1=@  "G4   !U    =0   '8   !U    =    '0   !S @
M<P<  ',,  !R$   <A4  '(@  !R+   <CL  '%,  !Q7P  <70  '".  !O
MJ   ;L8  &SM  !K_P![>P  <GX  &1^  !5?P  1X   #F!   K@@  'H$
M !*!   *@0   ($   ""    @P   (,   "#    @@   ((   ""    @@
M ((%  """@  @@\  ((7  ""(P  @C(  ()#  "!5@  @6P  ("&  !_H0
M?KT  'WF  !\_ !V@@  :(,  %F%  !+AP  /(D  "Z*   @BP  $XL   J+
M    C    (T   "/    D0   )(   "1    D0   )$   "1    D0   )(
M  "2 @  DPD  )0/  "4&0  E"<  )0X  "43   DV(  )-\  "3F   DK,
M )'8  "0]@!JB   7(H  $V-   _D   ,)(  "&4   4E0  "I8   "7
MF0   )L   "=    GP   *    "@    H    *    "A    H@   *,   "D
M    I0   *8'  "H$   J!P  *@M  "I0   J58  *EO  "IBP  J*@  *?'
M  "F[ !?CP  4)(  $&6   SF0  (YP  !2=   *GP   *$   "C    I@
M *@   "L    K@   *\   "O    L    +    "R    LP   +0   "V
MMP   +H   "]!P  OQ   +\?  # ,P  P$D  ,!B  # ?@  P)L  ,"W  "_
MV !3EP  1)L  #6?   FHP  %J4   NG    J@   *T   "P    LP   +8
M  "[    O0   ,    "_    P0   ,(   #$    Q@   ,@   #*    S
M ,\   #3    V@<  -L3  #=)0  WCL  -]3  #@;@  WXP  -VI  #=P@#_
M    _P   /\   #_    _P ' /\ $ #_ !D _P D /\ +P#\ #H ^0!# /4
M2P#S %( \0!9 .\ 7@#M &0 ZP!I .D ;P#G '4 Y@!\ .0 A #B (T X "7
M -T H@#: +$ U0#% -( Z #0 /\ SP#_ ,0 _P"X /\ KP#_ *D _P#_
M_P   /\   #_    _P " /L #0#W !4 \P ? .\ *0#J #0 Y@ ] .( 10#>
M $P VP!3 -@ 6 #4 %X T@!C -  :0#. &X S !U ,H ?0#( (4 Q@"0 ,(
MFP#  *D O@"Z +L V0"Y /< N #_ +0 _P"I /\ H@#_ )T _P#_    _P
M /\   #V    [@   .< "@#A !$ W  : -< (P#0 "X RP W ,< /P#$ $8
MP0!- +\ 4@"] %@ NP!= +D 8@"X &@ M@!N +0 =0"Q 'X KP"( *T DP"J
M *$ J "Q *8 R "D .T H@#_ *( _P"; /\ E0#_ )$ _P#_    _    .X
M  #C    V    ,T !0#&  X P0 5 +T '@"Y "< M0 P +( . "O $  K !&
M *H 3 "H %$ IP!6 *4 6P"C &$ H0!G )\ ;@"> '8 FP"  )D C "7 )D
ME "H )( O "0 -\ C@#[ (X _P"+ /\ A@#_ (, _P#X    Z0   -P   #,
M    P0   +@   "R  H K  1 *@ & "E "$ H@ I )X ,@"< #D F0 _ )<
M10"5 $H E !0 )( 50"0 %H CP!@ (T 9P"+ &\ B0!X (8 A "$ )$ @@"@
M (  L@!] ,P ? #Q 'L _P!Z /\ =P#_ '4 _P#F    TP   ,8   "[
ML0   *<   "A  4 FP - )< $P"3 !L D  C (P *P"* #( B  X (8 /@"$
M $0 @@!) ($ 3@!_ %, ?0!9 'L 8 !Y &@ =P!Q '4 ? !S (D < "8 &\
MJ0!M +\ :P#F &H _P!I /\ :0#_ &< _P#3    PP   +4   "K    HP
M )L   "2    C  * (< $ "# !8 ?P = 'T ) !Z "L >  R '8 . !T #T
M<@!" '$ 2 !O $T ;0!3 &P 60!J &$ : !J &8 = !D ($ 80"1 %\ H@!>
M +8 7 #5 %L ]P!; /\ 6@#_ %H _P#%    M@(  *D"  "?    E@   (X
M  "'    @  % 'H # !U !$ <0 8 &X '@!K "4 :0 K &< ,0!F #< 9  \
M &, 00!A $< 7P!- %X 4P!< %L 6@!D %@ ;@!6 'L 5 "* %( FP!1 *X
M4 #( $\ [@!. /\ 3@#_ $T _P"["@  K T  * -  "5#   C @  (,"  !\
M    =0   &X " !I  X 90 3 &( &0!? !\ 70 E %L *P!9 #$ 6  V %8
M.P!5 $$ 4P!' %$ 3@!0 %4 3@!> $P : !* '4 2 "$ $< E0!% *@ 1 "_
M $, Y !" /P 0@#_ $( _P"R$0  I10  )D5  ".$P  A!$  'L-  !S"
M;    &4  P!?  L 6P / %< % !4 !H 40 ? $\ )0!. "L 3  P $L -@!)
M #P 2 !" $8 2 !% %  0P!9 $$ 8P _ &\ /@!^ #P D  [ *, .@"X #D
MV0 X /4 . #_ #@ _P"L%P  GQL  ),=  ")'   ?QD  '45  !L$   9 P
M %T&  !6  8 40 , $T $ !* !4 1P : $4 ( !$ "8 0@ K $$ ,0 _ #8
M/@ ] #P 1  [ $L .0!4 #< 7P V &L - !Z #( C  Q )X , "S "\ S@ O
M .\ +@#_ "X _P"G'@  FB(  (\D  "$)   >B$  '$=  !G&   7Q,  %<.
M  !0"@  20,( $4 #0!! !$ /@ 6 #P &P Z "$ .0 F #< +  V #( -  X
M #, /P Q $< , !0 "X 6P M &< *P!V "H B  H )P )P"P "8 R0 E .H
M)0'[ "4!_P"B(P  EB@  (LJ  "!*@  =R@  &TE  !D(   6QL  %(5  !+
M$   0PP" #T'"0 Y PX -@$2 #,!%P Q 1P , $B "\")P M BT + ,T "H#
M.P I!$, * 1- "8%6  E!64 (P9T "(&A@ @!IH 'P>N !X'Q@ =!^< '0CX
M !T)_P"?*   DRT  (@O  !^+P  ="X  &HK  !A)@  6"$  $\<  !'%P
M/Q(  #@.!  Q"PH +@@. "L'$@ I!Q< * @= "<((P E""D ) DP ",)-P A
M"D  ( I* !\+50 ="V( &PQR !H,A0 8#)D %PRM !8,Q@ 5#>8 %0WY !8-
M_P"<+0  D#$  (8T  !\-   <C,  &@Q  !?+   52<  $PC  !$'0  /!@
M #03   M$ 8 )@T+ "0,#P B#!, (0P9 !\,'P >#24 '0TL !L--  :#CT
M&0Y' !<.4P 6#F$ % ]Q !,0A  2$)@ $1"N ! 0Q@ 0$.@ $!#[ !$0_P"9
M,0  CC4  (0X  !Z.0  <#@  &<V  !=,@  4RT  $HH  !")   .1\  #$:
M   J%0$ (Q$' !T0#0 ;#Q  &0\5 !@0&P 7$"$ %A I !40,0 4$3H $Q%%
M !(240 1$E\ $!)O  X3@@ .$Y8 #1.K  L3P@ +%., #!3Z  T3_P"7-0
MC#D  ((\  !X/0  ;ST  &4Z  !;-P  4C(  $DN  ! *@  -R4  "\A   H
M'   (!@# !D4"@ 5$@X %!(2 !,3&  2$Q\ $10F !$4+@ 0%#@ #Q5"  X6
M3P -%EP #!=L  L7?P )&), "!BH  88OP '&.  !QCU  D8_P"5.   BCT
M (!   !W00  ;4$  &0_  !:/   4#@  $<S   ^,   -BL  "XG   G(P
M'Q\  !<:"  2%PT $!<1  \7%@ .&!P #A@C  T9+  ,&C4 "QI   H;3  )
M&UH !QQI  4<?  $'9$  AVF  $=O  "'-T  ASR  ,<_P"3/   B$$  ']$
M  !U10  ;$4  &-$  !900  3ST  $8Y   ^-@  -3(  "XN   E*@  '24
M !0A!  /'0L #1T0  P=%  +'1H "AXB  @>*@ ''S, !B ^  0@2@ #(5<
M 2%G   A>0  (8X  "&D   AN@  (=L  "'R   @_@"00   AD4  'U(  !T
M2@  :TH  &))  !81@  3D(  $4_   ]/   -3D  "LT   B+P  &2L  !(H
M!  -) H "2,.  8C$@ %(QD !"0@  (D*  !)3$  "4\   E2   )E4  "9E
M   F=P  )HP  ":B   FN0  )MD  "7R   E_@".10  A$D  'M-  !S3P
M:D\  &!.  !72P  34@  $1%   \0@  ,3T  "<Y   >-0  %3(   \N P *
M+ H !2L.  $J$0  *A8  "H>   J)@  *R\  "LY   K10  +%,  "QB   L
M=0  +(H  "N@   KMP  *]8  "KR   J_P",20  @DX  'I2  !Q5   :%0
M %]3  !640  3$X  $-+   W1P  +4,  ",_   :/   $C@   PV P &,PD
M #(-   R$   ,10  #$;   Q(P  ,2P  #(W   R0P  ,E   #)@   R<@
M,H<  #&>   QM0  ,-0  ##R   O_P")3P  @%0  'A7  !O60  9ED  %Y9
M  !55P  25,  #Y/   R3   *$@  !Y%   50@  #D    @] @ !/ @  #L,
M   Z#P  .1(  #D8   Y(   .2D  #DT   Y0   .4X  #E=   Y;P  .(4
M #B<   WLP  -](  #;R   U_P"'50  ?UH  '9=  !M7P  95\  %U?  !2
M7   1%@  #A5   M4@  (D\  !A,   02@  "D@   -& 0  108  $0*  !#
M#0  0A   $$5  !!'0  028  $$Q  !!/0  04H  $%:  !!;   0($  #^9
M   _L0  /M   #WR   \_P"$7   ?&   '-C  !L90  9&8  %ED  !+80
M/EX  #);   F60  '%8  !)4   ,4@  !%$   !/    3@,  $T(  !,#
M2PX  $L2  !*&0  2B(  $HL  !*.0  2D<  $I6  !):   27X  $B6  !'
MKP  1LT  $7Q  !$_P"!8P  >6<  ')J  !K;   8&L  %)I  !$9@  -V0
M "IB   ?8   %5X   U=   &6P   %H   !9    6    %<$  !6"   5@P
M %40  !4%   5!T  %0G  !4-   5$(  %-2  !39   4GD  %*2  !1JP
M4,H  $_O  !._P!^:@  =VX  '!Q  !F<0  6'   $IO   \;0  +VP  ")J
M   7:0  #F<   9F    90   &4   !E    8P   &(   !B!   80@  &$-
M  !@$   8!<  & A  !?+@  7SP  %]-  !>7@  7G0  %V-  !<IP  6\4
M %KM  !9_P![<@  =78  &MW  !==@  3W8  $%U   S=0  )G0  !ES   0
M<@  !W$   !Q    <0   '$   !Q    ;P   &\   !N    ;@(  &X(  !M
M#   ;1$  &T:  !M)@  ;#4  &Q&  !K6   :VT  &J&  !IH0  :+X  &?H
M  !F_@!Y>@  <'P  &%\  !3?0  1'T  #9^   H?@  &WT  !!]   '?0
M 'T   !]    ?@   '\   !^    ?0   'T   !\    ?    'P   !\!@
M? P  'P2  !\'0  ?"P  'P\  !\3P  >V4  'M^  !ZF@  >;8  'C?  !W
M^@!S@   98$  %:#  !(A   .88  "N'   =AP  $8<   >(    B    (D
M  "*    C    (T   "-    C    (P   ",    C    (P   "-    C00
M (X,  ".$P  CR$  (XR  ".1@  CEL  (UT  "-D   C*T  (O.  "*\P!H
MA@  6H@  $N+   \C0  +8\  !Z0   1D0  !Y(   "3    E0   )<   "9
M    FP   )P   ";    FP   )P   "<    G0   )X   ">    GP   *$#
M  "B#   HA8  *,F  "C.@  HT\  *-H  "BA@  HJ(  *+   "AZ !<C0
M39   #^3   PE@  (9D  !*:   'FP   )T   "@    H@   *0   "H
MJ@   *L   "J    JP   *P   "M    K@   *\   "Q    L@   +0   "W
M 0  N0T  +D:  "Z+0  ND,  +I;  "Z=P  NY0  +NQ  "YT@!0E0  09@
M #*<   CH   $Z(   BD    IP   *H   "L    KP   +(   "W    N0
M +L   "Z    O    +T   "_    P    ,(   #$    Q@   ,D   #-
MT@$  -0/  #5'P  US4  -A-  #8:0  UX8  ->C  #6O0#_    _P   /\
M  #_    _P # /\ #0#_ !4 _P @ /P *P#X #4 ]  _ /  1P#N $X ZP!4
M .D 6@#G %\ Y0!D ., :@#A '  WP!V -T ?@#; (< V "1 -, G0#/ *L
MS0"] ,L X #) /L QP#_ +T _P"Q /\ J0#_ *, _P#_    _P   /\   #_
M    _    /8 "P#Q !$ [0 ; .D )0#D #  WP Y -H 00#5 $@ T0!. ,\
M5 #- %D RP!> ,D 8P#' &D Q0!O ,, =P#  '\ O@"* +L E0"X *, M@"T
M +0 S0"R /( L #_ *P _P"C /\ G #_ )< _P#_    _P   /H   #Q
MZ    .  !@#9  X T@ 6 ,X 'P#( "D Q  R ,  .@"] $$ N@!( +@ 30"V
M %, M !8 +( 70"P &( K@!I *P ;P"J '@ J "" *8 C@"D )L H0"K )\
MP "= .8 FP#_ )H _P"4 /\ C@#_ (H _P#_    ]@   .@   #<    S@
M ,8  0"_  L N@ 1 +8 &@"R "( K@ K *H - "H #L I0!! *, 1P"A $P
MGP!1 )X 5@"< %P F@!B )D : "7 '  E0!Z )( A@"0 ), C0"B (L M0")
M -, AP#W (8 _P"$ /\ ?P#_ 'P _P#R    XP   -(   #%    N@   +$
M  "K  < I0 . *$ % "> !P F@ E )< +0"4 #0 D@ Z )  0 ". $4 C0!*
M (L 4 ") %4 B !; (8 80"$ &D @@!R '\ ?0!] (L >P": '@ JP!V ,0
M= #K ', _P!S /\ < #_ &X _P#?    S    +\   "T    JP   *$   ":
M  ( E  + )  $ ", !< B  > (4 )@"# "T @0 S '\ .0!] #\ >P!$ 'D
M20!X $X =@!4 '0 6@!S &( < !K &X =0!L (, :@"2 &@ HP!F +@ 9 #>
M &, ^P!B /\ 8@#_ &  _P#,    O    *\   "E    G0   )0   ",
MA@ ' ($ #0!\ !( >  9 '4 'P!S "8 <0 M &\ ,@!M #@ :P ] &H 0@!H
M $@ 9P!. &4 5 !C %L 80!D %\ ;@!= 'L 6P"* %D FP!7 *\ 5@#+ %4
M\@!4 /\ 5 #_ %0 _P"^    L    *0   "9    D    (@   "!    >0 "
M ', "@!O  \ :P 4 &< &@!E "  8P F &$ + !? #( 7@ W %P / !; $(
M60!' %< 3@!6 %4 5 !> %( : !0 '0 3@"# $P E0!* *@ 20#  $@ Z !'
M /\ 1P#_ $< _P"T"0  I@L  )L,  "0"@  A@4  'X   !V    ;P   &@
M!0!C  P 7P 0 %L %0!8 !H 5@ A %0 )@!3 "P 40 Q %  -@!. #P 30!"
M $L 2 !) %  2 !8 $8 8@!$ &X 0@!] $  C@ _ *( /0"X #T W0 \ /@
M/ #_ #P _P"L$   GQ(  )02  ")$0  ?P\  '8,  !N!0  9@   &   0!9
M  @ 50 - %$ $0!. !8 2P ; $D (0!( "8 1@ K $4 ,0!# #8 0@ \ $
M0P ^ $L /0!3 #L 70 Y &D -P!X #8 B0 T )P ,P"Q #( S@ R /$ ,0#_
M #$ _P"F%@  FAD  (X:  "$&@  >A8  ' 2  !H#@  7PH  %@#  !1  0
M3  * $@ #@!$ !( 00 6 #\ &P ] "$ /  F #H +  Y #$ -P W #8 /@ T
M $8 ,P!/ #$ 60 O &4 +@!S "P A0 K )@ *@"M "D Q@ H .H * #^ "@
M_P"A'   E2   (HA  !_(0  =1\  &P:  !C%@  6A$  %(-  !+!P  1  &
M $  "P \  \ .  2 #8 %P T !P ,P A #$ )P P "P +@ S "T .@ K $(
M*@!+ "@ 50 F &$ )0!P "0 @0 B )4 (0"I "  P0 @ .0 'P#Y !\ _P"=
M(@  D28  (8H  !\)P  <B4  &DB  !?'0  5Q@  $X3  !&#@  /PL  #@%
M!P T  P ,0 0 "X $P L !@ *@ = "D (@ G "@ )@ N "0 -@ C #X (@!'
M "  4@ ? %X '0!M !P ?@ : )( &0"G !@ O0 7 -\ %P'U !<"_P":)P
MCBL  (0M  !Y+0  <"L  &8H  !=)   5!\  $L:  !#%   .Q   #0- @ M
M"0D *04- "8#$  D 1, (@(9 "$"'@ @ B0 '@,J !T#,@ ;!#H &@5$ !D%
M3P 7!EP %@9J !0'?  3!Y  $@>E !$'NP 0!]L $ CR ! )_P"7*P  C"\
M ($Q  !W,@  ;C$  &0N  !;*@  424  $D@  ! &P  .!8  #$2   I#@0
M(PP) !\)#0 =!Q  &P<5 !D(&@ 8""  %PDG !8)+@ 5"C< $PI! !(+30 1
M"UH $ MI  X,>P .#)  #0RE  P-NP +#=D "PWQ  P-_P"5+P  BC,  '\V
M  !V-@  ;#4  &,S  !9+P  4"L  $<F   ^(0  -AT  "X8   G$P  (! %
M !D."@ 5# X % P1 !,,%@ 2#!P $0TC ! -*P /#30 #@X_  T.2@ ,#U@
M"P]G  H0>0 ($(T !Q"B  80N  %$-0 !1#O  80_P"2,P  B#<  'XZ  !T
M.P  :SH  &$X  !8-0  3C   $4L   ])P  -2,  "T?   F&@  'A8! !<3
M!@ 1$ L #@X.  X/$P -$!D #1 @  P0*  +$3( "A$\  @22  '$E4 !A-E
M  03=@ #$XL  12@   3M@  $]$  !/N   3^P"0-@  ACL  'P^  !S/P
M:C\  & ]  !7.0  338  $0Q   \+@  -"H  "PF   E(@  'AX  !8: @ 0
M%0D #!,.  H3$@ )%!< "!0?  <5)@ &%2\ !!8Z  ,61@ !%U,  !=B   8
M=   &(D  !B?   8M0  %]   !?M   7^P"..@  A#\  'M"  !R0P  :$,
M %]"  !6/P  3#L  $,W   [-   ,S   "PL   D*0  &R0  !,? @ -&PD
M"1D-  89$0 $&18  AD=  $:)   &BT  !LX   ;1   '%$  !Q@   =<@
M'8<  !R=   <LP  ',X  !OM   ;_ ",/@  @D,  'E&  !P2   :$@  %Y&
M  !51   2T   $,]   [.@  ,S<  "HR   @+0  %RD  ! E @ +(@D !2 -
M  $?$   'Q0  !\;   @(@  ("L  "$V   A00  (4\  "%>   B<   (H4
M "&;   AL@  (<T  "#M   ?_ "*0P  @$@  'A+  !O3   9DT  %U+  !4
M20  2D8  $)#   Z0   +SL  "4W   <,P  $R\   TL @ '*0@  2<,   F
M#@  )1(  "89   F(0  )BD  "8S   G/P  )TT  "=<   G;0  )X(  ">9
M   FL   )<P  "7N   D_0"(2   ?TP  '90  !N40  95(  %Q1  !33P
M2DP  $%)   U1   *T   "$\   7.0  $#8   HR 0 #, <  "\+   N#@
M+1$  "T6   M'@  +2<  "TQ   M/0  +4H  "U9   M:P  +8   "R7   L
MKP  *\L  "KN   J_@"%30  ?5(  '55  !L5P  8U<  %M6  !350  1U$
M #M-   P20  )48  !Q#   3/P  #3T   8Z    . 4  #<)   V#0  -0\
M #04   T&P  -"0  #0N   T.@  -$<  #17   T:   -'T  #.5   RK0
M,<H  #'N   P_P"#4P  >U@  '-;  !J70  8ET  %M=  !/6@  0E8  #92
M   J3P  ($P  !9)   .1P  "$0   !"    00,  #\'   ^"P  /0X  #T1
M   \&   /"$  #PK   \-P  /$0  #Q3   \90  .WH  #J2   ZJP  .<@
M #CM   W_P"!6@  >5X  '%A  !I8P  8F0  %=B  !)7@  /%L  "]8   D
M50  &5,  !!1   *3P   4T   !,    2@   $D$  !("   1PP  $8/  !&
M%   11P  $4G  !%,P  14   $50  !$80  1'8  $./  !"J   0<8  $#L
M   __P!^80  =F4  &]H  !H:@  76D  $]F  !"9   -&$  "A?   =70
M$EL   M9   "6    %8   !6    5    %,   !2!   40D  % -  !0$
M3Q@  $\B  !/+@  3SP  $]+  !.70  3G(  $V+  !,I0  2\(  $GJ  !(
M_P![:0  =&P  &YO  !D;P  56T  $=L   Y:@  +&D  "!G   490  #60
M  -B    8@   &$   !@    7P   %X   !=    7 0  %P)  !;#0  6Q(
M %L<  !:*   6C8  %I&  !96   66T  %B%  !7H   5KT  %7H  !3_@!Y
M<   <W0  &EU  !;=   3',  #YS   P<@  (W$  !9O   -;@  !&T   !M
M    ;0   &T   !L    :P   &H   !I    :0   &D#  !H"0  : X  &@5
M  !G(0  9R\  &<_  !F4@  9F8  &5_  !DF@  8[<  &+A  !A_ !W>
M;7H  %]Z  !0>@  0GH  #-[   E>P  &'H   YY   $>0   'D   !Y
M>@   'H   !Z    >    '@   !W    =P   '<   !W 0  =P@  '<.  !W
M&   =R8  '8V  !V20  =5\  '5W  !TDP  <Z\  '+3  !Q]P!Q?@  8W\
M %2   !%@@  -H,  "B$   :A   #H,   2$    A    (4   "&    B
M (D   "(    AP   (<   "'    AP   (<   "(    B    (@'  ")$
MB1P  (DL  "(/P  B%4  (AM  "'B0  AJ<  (7'  "$[P!FA   5X8  $B(
M   YB@  *HP  !N-   /C0  !(X   "0    D0   ),   "5    EP   )@
M  "6    EP   )<   "7    F    )@   "9    F@   )L   "=!P  G1$
M )TA  "=,P  G4D  )QB  "<?P  G)P  )RY  ";X@!:BP  2XX  #R1   M
MDP  'I4  !"6   $F    )H   "<    G@   *$   "D    I@   *<   "F
M    IP   *<   "H    J0   *H   "L    K0   *\   "Q    LPD  +,5
M  "T)P  M#T  +55  "U<   M(X  +2L  "TS !-D@  /Y8  "^:   @G0
M$9\   6A    HP   *8   "I    K    *\   "S    M0   +<   "V
MMP   +@   "Z    NP   +T   "_    P0   ,0   #'    RP   ,T,  #.
M&@  SR\  ,](  #08@  T(   -"=  #0N                        0,$
M!08("0H+#0X/$1(3%!87&!H;'!T?("$B)"4F*"DJ*RTN+S R,S0V-S@Y.SP]
M/D!!0D1%1D=)2DM-3D]04E-455=865M<75Y@86)C969G:6IK;&YO<'%S='5W
M>'EZ?'U^@(&"@X6&AXB*BXR.CY"1DY25EIB9FIR=GI^AHJ.DIJ>HJJNLK:^P
ML;.TM;:XN;J[O;Z_P<+#Q,;'R,G+S,W/T-'2U-76U]G:V]W>W^#BX^3FY^CI
MZ^SM[O#Q\O3U]O?Y^OO\_O______________________________________
M________________                      $#! 4&" D*"PT.#Q$2$Q06
M%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T-C<X.3L\/3Y 04)$149'24I+34Y/
M4%)35%576%E;7%U>8&%B8V5F9VEJ:VQN;W!Q<W1U=WAY>GQ]?H"!@H.%AH>(
MBHN,CH^0D9.4E9:8F9J<G9Z?H:*CI*:GJ*JKK*VOL+&SM+6VN+FZN[V^O\'"
MP\3&Q\C)R\S-S]#1TM35UM?9VMO=WM_@XN/DYN?HZ>OL[>[P\?+T]?;W^?K[
M_/[______________________________________________________P
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M_______N?44          $34___________________________\JF0O @
M!"(W25C.____________________________Z:1K02@_8W^5I[K:________
M_______________________5LJRRS.3Z____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______ENY=W8LC_________________________________VYYG-@H  HS_
M_______________________________(?S\%     %[/________________
M_____________]F!.0       #RJ_____________________________YY,
M         ".0____________________________W&\:         !!]^?__
M________________________KT@           !O[O__________________
M________A!,           !DYO_________________________L40
M      !7WO________________________^X%0            !(UO______
M__________________]T%              XS_______________________
M__FB6A,            CQ?_________________________?FUPL
M   -NO__________________________[[%]53DB$0<! A$BLO__________
M____________________W[^EF9B:H*R]VO__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________X[Z=@'S[________________
M________________\K>$5S . !VL_______________________________2
MBDP5      !R\____________________________]9_-@        !+R?__
M________________________^I$^           OJ___________________
M________P%H            :E?__________________________C20
M       (A/_________________________G7@              =_______
M__________________^T)0              :O______________________
M__]]                6_3_______________________TK
M    3.O______________________Z4                 /.'_________
M_____________S ,                +=G_____________________F8IA
M)P              )]?______________________^V^B54G
M)=S__________________________LJ==EU*/#(M+# Y1][_____________
M__________________WFW=;2T-/9Y/______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______OU+O6_________________________________^>XCVI++Q5O____
M___________________________DH6<T!P     \R?__________________
M_________]:".P         2E___________________________[84Q
M        ;___________________________ID(             4.'_____
M___________________L:0              -\G_____________________
M__^S+P              (K;_______________________]Y
M    $*?_______________________(T                 )G_________
M_____________ZD                  (S______________________T8
M                 '______________________WP
M '3_____________________EP                   &K_____________
M________S@                   &/______________________RDB 0
M             &'______________________[FC@%<W%P           &C_
M__________________________K3KI2&?'5Q<')W@93_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________V[J=@FEIT_______________________________R)-E
M/1D    =GO___________________________]N.3!,         ;O______
M____________________VWPL            1=?_____________________
M____BRH             (K3________________________"1
M     Y?_______________________]] 0               '__________
M_____________^<V                 &K______________________YT
M                 %C______________________T8
M $?X____________________Z0                   #7I____________
M________E@                   "7;____________________O
M             !C.____________________ZP                    _"
M_____________________P                    JY________________
M_____R<                   JU_____________________W
M          VY_____________________^"<C'!50C,F&Q0/#0X2&B:_____
M________________________^>38TL[,R\S/UN#\____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________Z].\X_______
M_________________________]*IA65(+!(!A?______________________
M______&K<3P/        3^#_________________________U7\U
M    '[+________________________C=1T              (G_________
M______________^0(P               &?______________________]5#
M                 $CV_____________________XH
M "[=_____________________S@                  !?(____________
M________O@                    2V____________________G
M              "E____________________N@                    "3
M____________________W                     ""________________
M_____P                    !T_____________________Q,
M          !H_____________________T(                   !@____
M_________________WH                   !=____________________
M_]$                   !A______________________\D
M      !F_______________________)K)F)?79Q;&EG9F=K<'J,________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________XL6J
MD7EA=______________________________=IG=0+ P     ,<3_________
M________________X)).$P           (_________________________2
M<!T              &#______________________^YO#P
M #?B_____________________Y8<                 !3 ____________
M_________T                    "C____________________K@
M              ")____________________G@                    !R
M____________________O                     !?________________
M____V@                    !-____________________^@
M           [_____________________PX                    J^?__
M_________________S,                    ;Z?__________________
M_UX                    /V____________________X\
M       &T/___________________]                      RO______
M______________\K                    R/____________________^
M                    R______________________W%@$%!0,!       !
M!@T8R________________________.OAV,_,S<_0TM37W.+J____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________':QO__________________________
M____\<:CA&A-,A@ %:O__________________________[E\1A@
M ''________________________7?"\              #OC____________
M_________]]D"0                RU_____________________W0#
M              "-____________________Q14                   !J
M____________________F0                    !+________________
M____M@                     P_?__________________UP
M           9Y___________________]@                     %T___
M_________________PX                     P?__________________
M_R\                     K____________________U(
M        GO___________________WD                     CO______
M_____________Z4                     @/___________________]@
M                    =/____________________\V
M    ;?____________________]\                    :?__________
M___________7#0                  :/______________________<
M                8?_______________________U \1DY465UA9&AL<'9^
MB?__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________[]6[HXMS6I7_____________
M______________B_CF1!(04      %+\_______________________WG588
M             !?!_____________________^5L%@                "-
M_____________________V,                   !>________________
M____G0                     U_/__________________H0
M           1V?__________________R@                      N___
M________________[@                      H?__________________
M_PP                     BO___________________RT
M        =O___________________TT                     9/______
M_____________V\                     4O___________________Y0
M                    0/___________________[P
M    ,/___________________^H.                    (O__________
M__________]$                    %?____________________^!
M                "_7____________________("P
M NS_____________________7@                   .7_____________
M________R1P                  -K______________________YT!
M          <.%\7________________________5N;S!Q\[5V^'F[?3[____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________XW\______________________________[,:EB&U4.R$' #+>
M________________________UY)9*0            "@________________
M______^)-@                !G_____________________V8
M           R]O__________________E0                     #R/__
M________________IP                      H/__________________
MUP                      ?/___________________P
M        7O___________________R4                     0_______
M_____________T@                     +/___________________VH
M                    &/___________________XL
M    !?/__________________Z\                      .'_________
M_________]4                      ,____________________\D
M                 +[___________________]4
M *[___________________^+                     )______________
M_______+#@                   )+_____________________5P
M             (;_____________________J@H                  'G_
M_____________________VT                  &;_________________
M______=5                 $7_________________________:B,K-3]*
M56!J=7Z'D9S_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^C/MIV#:4ZY_________________________^RR@UPZ
M'0(       ![_______________________%;2D               ! ____
M_________________X,;                   'R___________________
MD@                      F/__________________I
M        :O__________________W0                      0?______
M_____________PX                     '?___________________SD
M                     .C__________________V
M     ,[__________________X4                      +?_________
M_________Z@                      */__________________\L
M                 )#__________________^\6
M 'W___________________\^                     &S_____________
M______]I                     %K___________________^9
M             $G____________________2%@                   #G_
M____________________6                    "G_________________
M____H@                   !G_____________________]58
M          3______________________[LO                  #X____
M__________________^K*0                #/____________________
M____R4<     !Q,@+CY2:(3M____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________]-7)____
M________________________^M*PDG==0B@,  !*____________________
M____Q7U%%P             1V/___________________\10
M        G___________________H@P                     :/______
M____________E                       -O__________________V@
M                    !^S__________________Q4
M     ,3__________________T@                      *+_________
M_________W4                      (/__________________YT
M                 &G__________________\,
M %+__________________^</                     #[_____________
M______\S                     "O___________________]8
M             !C___________________^!                      7_
M__________________^L                      #_________________
M___>(@                    #R____________________7
M          #?____________________GP                    #,____
M________________Z$H                   "W____________________
M_Z 6                  "<______________________]Z @
M      !W________________________>@L               5,________
M_________________Z)7:'2 C9RKO-#G____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____^WC___________________________2HWI8.BDC'!8.!@  G_______
M______________^L4@X                 :?__________________Y$,
M                    -/__________________>0
M     ./_________________S0                       ++_________
M_________Q,                      (7__________________T\
M                 %W__________________X,
M #K__________________[(                      !S_____________
M_____]L#                      +___________________\J
M              #[__________________]/                      #G
M__________________]T                      #4________________
M__^;                      # ___________________$!P
M          "M___________________P,P                    ":____
M________________9P                    "&____________________
MHP                    !R____________________XT0
M      !<_____________________Y$&                  !!________
M_____________^M?                   =_______________________*
M2P                  ________________________RU<   P8)#$_3F!T
MBZ?'___________________________7Y_+_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________KU,W'PKZZM[.P
MK:FHI?___________________]U^4S\P(QD1"0(          -O_________
M________=@                       *?_________________N@
M                 '7__________________P<
M $;__________________TX                      !K_____________
M_____XP                       #]_________________\$
M              #;__________________$9                      "^
M__________________]$                      "D________________
M__]K                      "-__________________^1
M          !Y__________________^W                      !F____
M_______________>(0                    !3____________________
M2@                     _____________________=P
M       K____________________K H                    6________
M____________YT4                     _____________________XH
M                    _____________________]9-
M    _?____________________^G+@                  U?__________
M____________F"H           88+45@X/_______________________ZAC
M=(&/G*N[S>+Z________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________GR[>IG96.B82 ?'AT<&QH
M99#_________________O&I(+1D*                 #'_____________
M_____P                        /__________________T(
M              #<_________________XX                       "R
M_________________\X                       "-________________
M__\I                      !K__________________]:
M          !.__________________^&                       T____
M______________^N                       >___________________4
M%P                     *___________________Z/0
M        ____________________90                      ________
M____________C@                      ____________________O!D
M                    [___________________\4X
M    V/___________________XL                     O___________
M_________\Q#                    H?____________________^1&0
M                >O_____________________R= H                1
M7_______________________Z'03'RPX15-B<H6;M-+U________________
M___________7Z/3_____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__OW\_'N[.OK[/'__________________]FRF8=Y;61=5E%+1D$\.#(M*"/$
M_________________TLE"P                    "2________________
M_X@                       !F_________________]<
M           ]__________________\S                       8____
M______________]L                        __________________^=
M                        ___________________)#
M        ]O_________________Q-0                      W_______
M____________6P                      R___________________@@
M                    M___________________J08
M    H___________________TR\                     C?__________
M_________UX                     =____________________Y,'
M                7O___________________\U#
M0/____________________^'$                   '/______________
M_______87@                   /______________________OTX
M  X<+#Y2:H:ER/_______________________\)\C)JGML76Z/W_________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________^[AU\_)P[ZZ
MMK&MJ:>FIJ>N_________________[Z&;5M,0#<O*"(<%A +!      4____
M_____________]<%                        __________________\T
M                        ]O________________]V
M        TO________________^P                        LO______
M___________A)                       EO__________________40
M                    ?/__________________>0
M    9O__________________H                       4?__________
M________QR,                     //__________________[DL
M                )____________________W0
M$/___________________Z,6                     /______________
M_____]A,                     /____________________^(#P
M             /_____________________+4P                   /__
M____________________I3@           D=-$YKC/__________________
M_____YDY0U%?;GV.H+7+Y?_____________________________K^?______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________KS+FLH9F1BX:!?'AT
M<&MH9F9H\?________________]A13(C& X&                GO______
M__________]^                        =?_________________#
M                    4O_________________[-P
M    ,O__________________:@                      %O__________
M________E@                       /__________________OQL
M                 /__________________YD(
M /___________________VD                      /______________
M_____Y "                     /___________________[DL
M             /3__________________^A<                     -G_
M__________________^1&                    +S_________________
M___*4P                   )W_____________________F"X
M    $"E&9L3_____________________[G\=#!HH-T97:7Z5K\SN________
M_________________^>@JKG(V.G\________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_?7PZ^;BW]O8U-+1T-+7X/_________________.GHI\<6EA6U913$A#/CHV
M,B\N,?_________________2)1$#                     /__________
M________0@                       /__________________?0
M                 /__________________L L
M /;_________________W3D                      -S_____________
M_____V(                      ,7__________________XD
M             *___________________Z\B                     )G_
M_________________]9(                     (+_________________
M__]R                     &G___________________^A*
M         $[____________________37                    #/_____
M________________EBX              !4R4G?_____________________
MX'(3   !#Q\O0EAPBZC([/_______________________\IO;GZ.GK##V.__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________^>#2R,"Z
MM;"LJ*6BGYV;FYR@I___________________@F162T,\-C K)R(=&!,."00
M -3_________________D@                       *W_____________
M____S!X                      (O_________________^U(
M             &W__________________X                       %'_
M_________________ZD;                     #K_________________
M_]!"                     "/___________________5H
M          S___________________^/%                     #_____
M______________^X/@                    #____________________E
M;0,                   #_____________________GS<
M ! O4'3_____________________W7(4      87*D%:=92VVO__________
M_____________[Q81%1D=8::K\CC_______________________________2
MS>'Q________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________\^_K[_?______________________[KFHG9:/BH:"
M?WMX=G1R<W5X?Y#_________________ZT\Z,"@A&Q40"P<"         "/_
M_________________VD                       #_________________
M_YL*                      #__________________\@Y
M          #___________________!C                      #_____
M______________^*#@                    #___________________^P
M-                     #____________________56P
M      #_____________________A1H                   /L________
M____________L4D              !@Y78'_____________________Y7L>
M       ,(3A2;X^SV?_______________________[M8*3E)6FR E[#-[?__
M__________________________^SGK3%U^O_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___Z[^?AW-G6U-+0T-#1T]G@Z_?__________________[B*?G=Q;&AD85Y;
M65A75UE>97'__________________[\Q'Q80"@4               #_____
M_____________^U6                      #H__________________^"
M!                     #,__________________^K+P
M      "S___________________25P                    ";________
M___________W?!                    "%____________________HC<
M                !2N4____________________RV$"            #"Q0
M=I[1____________________]8TP       -(SM7=IF^Y?______________
M_________\-C&"H[3%]TC:?&Y_____________________________^H?Y:H
MN]#G_____________________________________?__________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________=
MSL6_O+FVM+.QLK*UN<#)U>/___________________^7;&1>65513TQ*2$=&
M2$M066:A__________________^G)@X' @                !6________
M___________.4                      Z___________________T>0L
M                   A____________________GS(
M   .____________________Q%@                (,5J$____________
M________Z7\?           &)TMQFL+I_____________________Z=)
M  (7+TIHBJ[5_/_______________________]-U'B8X2EYUCZO+[_______
M______________________^N<H68K,+;]O__________________________
M________W^__________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________O[*J
MIJ.AH)^?H:.FK+3 S=WL____________________BEI33TM(1D1#0D%"0T=.
M66E]____________________GBX&                    ____________
M________PU8                  !5!____________________YWL:
M          DT8(NT_____________________Y\_          0E2G&9PNO_
M_____________________\9F#P   !,J1&*#I\WU____________________
M_____^N.-2L^46B!G;S>______________________________^^=G^4J<'<
M^?__________________________________TMCS____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________V\O#O[^_Q\_C]____________________________^+"?FI>6
MEI:8FY^DK+;"T>'N_____________________HY02D=%1$1$149'2U%::(.I
M_____________________Z9! 0          !S9CC[KA________________
M_____\9E"@      !"=,<YS$[/_______________________^6(+P  $RI$
M8H*FS/3___________________________^K4#9*87N6M-;Z____________
M___________________2AWR8L<OI________________________________
M____U,[M____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______MY>/CY.;H[?'Y______________________________VQE)*2E9F=
MHZFRO-#M__________________________^=4T=)35%68'.*K];\________
M__________________^R5@ :-5!MBZ[2]___________________________
M___-;SY?>YFWU_G________________________________NGX.FPN'_____
M________________________________X\[K________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________
M
M
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M*"@H*"@H*"@H*/_  !$( 6("=P,!(@ "$0$#$0'_Q  <  $  @,! 0$
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MPTXV]\;CCX]_K^]S_3LI)%.F?)CTL/\ K$/;-/T]'1U-/*^2H9.6EV]QX#0
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M[6AN.F0-SFGC/EDX0=0CC$<38VEV&M#022X_F>_W5/UCI^[76[03VV:*&&.
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M(HR^5[6,'=SC@!==^[MOW>B0.Y"*KW;4MF;6T#>J*EXF.##&9,>%PX('/)'
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MADFQKB(W!TF#TR1R3L#CG@8X.<B4TE77VMO=L?>:=]/4F@J!6Q@%L>1,P0N
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M]SJBU[#D.'4/8JRJLZ J8:NWW.HI98YH)+G5.9)&X.:X=0\@CNK,@(B("(B
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M]^-M*_Q-9/Y^+^Y!8$5?_&VE?XFLG\_%_<GXVTK_ !-9/Y^+^Y!8 ,=D5?\
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,$0$1$!$1 1$0?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g843142g47b02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g843142g47b02.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[28\4&AO=&]S:&]P(#,N,  X0DE-! 0
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M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ $L     0 " 2P    !  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              19   '8@         !
M      $             !V(   19                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     &\8    !    H
M %X   '@  "P0   &ZH &  !_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@               0  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[0 ,061O8F5?0TT
M O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3
M$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+
M#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,
M# P,# P,# P,# P,# P,#/_  !$( %X H ,!(@ "$0$#$0'_W0 $  K_Q $_
M   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M>$10],_ON_#^Y)K"#.YQ\C']R"&:22I=8S+<+ =DU07-?4T@Z^U]E=5G=O\
M@WN24SMR<FK+;6ZEOV:PM:RT/._>0]S@:?3V[&[/I^LK2S\T9#,NBQ]C7XSK
M:V5T>F=S7G?NM]=KG?F_\%_;5WU6^#O\UW_D4+32')Z?A93M^14+'!NP.,R
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M&NME=;:V#:Q@#6CP T 4DDDE*22224I))))2DDDDE/\ _]DX0DE-!"$
M %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3
M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"
M24T$(@     !2DU- "H    (  @!$@ #     0 !   !&@ %     0   &X!
M&P %     0   '8!*  #     0 "   !,0 "    '@   'X!,@ "    %
M )P!.P "    #0   +"':0 $     0   ,    #L   !+     $   $L
M 4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,C0Z,#8Z,3$@,C Z
M,38Z,C( 2F5N($)E86-H96QL       #H $  P    '__P  H ( !     $
M  =BH , !     $   19          8! P #     0 &   !&@ %     0
M 3H!&P %     0   4(!*  #     0 "   " 0 $     0   4H" @ $
M 0              2     $   !(     3A"24T#_0      "
M_^$!4D5X:68  $U- "H    (  @!$@ #     0 !   !&@ %     0   &X!
M&P %     0   '8!*  #     0 "   !,0 "    '@   'X!,@ "    %
M )P!.P "    #0   +"':0 $     0   ,    #L   !+     $   $L
M 4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,C0Z,#8Z,3$@,C Z
M,38Z,C( 2F5N($)E86-H96QL       #H $  P    '__P  H ( !     $
M  =BH , !     $   19          8! P #     0 &   !&@ %     0
M 3H!&P %     0   4(!*  #     0 "   " 0 $     0   4H" @ $
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M5I*4HL/P-T55M.'_Q  8 0$! 0$!                 0(#!/_$ "X1 0$
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MY6RB B(@(B(*#?;K=J+4;:47F1CGOCVLBM;9*:!LLACA$SB_>2YS2,M(YY(
M5^&<#.,^>%QW7U/36WVF6NII[<V:LE,$\4<0IR^H<)7=7/4>'Y:P-+-G&XG/
M"[!&XOC:XM<PN .UW<?(H.5WKV>7RLO5\JV5M%44M;,V5L%2]S1*T8Q&\M9E
MK6<D<OR0,!O.9/4=IKJ&321J;W653(KC20N@>R+IES8W-+\[-^203RX]RNAJ
MK:\^/3?_ %FG_P 'H+2BTKM7_9U,R;W:>H#I&1[82S(+G!H^)P&,D#[UN,)<
MQI+2TD9VGN/EP@^HB\R;^F[I[=^#MW=L_-!Z1:%CJIZVVQ5%4V)KY,D-CS@#
M[UOH"(B#1%>XW<T/NDV!&).ON9LQ],[NXQV6\HYO]HG_ +(W^-RD4!%&76HK
M(:ZV1TLE.V*HF,4@DB<\X#'OR"'#'P8['NI- 1$0$1$!$1 1$0$1$!$1!!ZK
MNM;:*+WFDAM_18"Z:HKZLP11#( [-<223P,#Z]@<NEKI/=[4RKJ(Z,!Y\$E'
M4]>*5OZS7%K3WR"".""H3VKQ$Z4?4"MJ*3W>>!X=$]K&AW58&O>2QYPPX?X1
MGPK[[**^EK-)1LIZGWB:&>85#R_>7/,KW%Y.UO#L[AP#APSR@N*Y;?M6ZJI=
M07NDAH9(J*![&PSMM\DX9'^;S(2#XR=[@ ,_"<XVG=U)$%$N59<Z\Z8%SL[Z
M8/J*>2243@!LCHB7-V9W##LC/R5[5;UI4&G=97""25HKXR2T@8[@#GS.[]RF
MV/K2&[X*<'#-V)G'!)._'@YP,8]<G.W'.99<K&,<I<K(V46LU];@;H*<'P9Q
M,X_I'=^AY-P1ZGCCN@?68Y@I_+_;._6Y_0_5Y^9XX'*TVV46MOK?^PI_/_;.
M_6P/T/U>?KQVY1SZW!VP4Y/BQF9P_2\/Z'FW)/H>.>Z#91:SWUH#MD%.3A^W
M,SAD@C9GP<9&<^GEN[A(^L&_IP4[L!^S=,X9/&W/@.,\Y[XX[YX#91:TCZP%
M_3@ISC=LW3$9\(QGP\9=D'O@<\]E]<^KW.VPP$;CC,Q&1MR#\/?=QCTY[\(-
MA%KA]7N&88 -W)$Q^';G/P]]W&/3G.?"OC'UA+.I!3@$C=MF)QX3G'AY\6 .
MV1SQV0;*+6C?6'9U(*=N0W?MF<<'!W8\ S@XQVSSV\S'UI#.I!3@X9NVS.."
M<[\>#G'&.V<G.W'(;*+6:^MP-T%.#AF<3./Z1W?H>3<$>IXX[H'UF.8*?R_V
MSOUN?T/U>?F>.!R@V46MOK/^PI_/_;._6P/T/U>?KQVY7N)U09 )8H6L\>2V
M0D_%X>-H[MY//!XY[H,R(B B(@*@W.Z7>DU,RB-Y>'O>P89:PZDBZCG"-DCM
M_4W.VD9!QGN!D!7Y<<U=3TMJ]JU!/2VT35DG2J(X813E\_BDZKCU'B3<!@MV
M<<G.>4'8U2M=7Z_6F^V.GL] ZIHZ@NZ[FP.D)=OC:&9! 9PYSB3Y-)YP0;JT
MY .",^11!SJV:@U#7Z)KIZZTOJI2V1A?L]TPWHL<3LD.>'ND9_<^:>R6M=!2
M5%K,#SBHDE$@<,-:6QN[=^\@_%7>_P#]17']FD_A*H?L]S%K*N@[--NIYQ_>
MBA:?WL7HZ7G#.5F\QTI$1>=H4?:IZJ:>O95/@<V"81LZ<98<;&NR<N.?B^79
M2"CK3_2KM^U#_*C6IQ1(HB+(*.GGJVWVFIV20"EDADD<TQ$ORTL'#MV.=_IY
M*14=/_:*B_9)_P".%:QY$BHZZ_TZS_M;O\B52*CKK_3K/^UN_P B5,>1(HB+
M((B("(B B(@(B(.9ZOM-UNE_DGI[??:>8=%C9*22B=3R]&5TD3W.ER]N'.R0
M&_+#O/I,+7-A8V1Q<\- <XXY/KP!_@N876\5,?M$-$+K(RM-?3MIXQ<8&TS:
M8AG4C? 7[S(?SF/ 3ES""!VZD@*K:\^/3?\ UFG_ ,'JLZD]I%;;[[=[?3T#
M::"C$095UT$K8^7/#WN/ V9:UK<'DG/;A9M5WNY5TFD6ML-5"V6X4LSIYY6,
MB:]T9=L&"7Y!)!RT<A!=M1_U='^U4W^>Q2:H>H+M;=/T%SJ;Q<C3TXNU+%&Z
MJJ'N YA>0T.)]7DX\@?(<675)$NEKE-#-(TMI9)8Y8)7,.0PD$.:0?1!+HM&
MX5M'8K1+55LLC*.F8"Y[M\KL=AZN<<_4J&KJF]:AT_32Z:D%G=5%PDEN5*[K
MPQ\@.9%D>(\$;CP#R/)!*:9_J*D_Y3_B5)KGOL_M>I[%:K/3-N-/>K6X.]XE
MK2Z.IB)>XY8X;@]H&/"[![^+& +5;=2VRX7JLM$$[V7.DR9*>:)\3BT'&]NX
M#>S)'B;D<A!M6ZXFMJ:V$TE1 :601.=(68<2T.XVN)[.'?'=;RB[20VOOI<0
M *QN2?V>%8;SJ6AMENAK&LJ[@R9YCA9;H'5+I'#.0-@('8\D@<=T&RW^T3_V
M1O\ &Y2*HE37ZLD]H4<5MM-O;9GT,3WU%74.;(W+_$W8T'Q#D =N,[O)6)]!
M>7ZB;5_;3&6AH_H#*-NYYVX\4I)/?G@#T09;N1]H6/)_WQW_ /7F4HN=ZGT%
M25NI;-<Y;I>)*UM>^6 2U;G0P.Z,C@&QC #06MX&"0,$X)5CMMVJK7;:9NM*
MBV4M=+4^ZQ2PR%L522,M(#OA<[!\.3R."<H+"BC-2.G9:I'TM3+32M<W#XPT
MG!< 1X@1YJ1C:61M:7N>0 "YV,GYG'"#Y,USXG-C?TWD<.QG'W+2T[//56*@
MJ:N023SP,E<0W:,N:#@#[UXU'?K;IRTS7*]5<5)1Q#E[S\1P<-:.[G'' ')4
M?[.;M2WO0UDKJ R&!]*QHWL+#EHVG@_,'GL?)!8T1$!$1 1$0$1$%3]I53&W
M3SZ22=U.:AS")7QS&'#)&N<R1\8):'-!;W&02%X]E[ZK\G70U,D<L,,SQ!(R
M.9H+"XN ;U0"6MW!H(R,-'*V==W>KM%%1/I:B*BAFJ.G45TM.Z=M,S8XAQ:T
MCNX-;DG W+=T?<*NZ:>I:NX,#:AY>-S8G1"1K7N:V0,=RT/:&NP>VY!,HBJE
MZUW;+9=*JW""LJZRG;&71T[&G<YYP& N<!N \1R1@$<YX0:_M4J#366AD81U
M&5L;P,\X <25<F.#FAS>Q&0N>:TOMFOU'9:&BN-+)5U=1%*RFZC>J&/A<X$L
MSD<.!^]7/3<_O.G[=,3DNIV9^NT9_>N<\=2_..4\=2_.?E_ZD41%T=1$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!<RU/:;O<]1/J*:@OM)4;H@'TTE"ZE>8G/,<
MA?(#(,;^1M^X^?35RV6\5(]HQHOM605WO[6M9]I0>Z^Z[1F,P;]_5[_H9W8.
M=O"#J+00T G)QW]5]10NHM2V^P34$5>Z0R5DO3C;&W<6CS>[T:,@9]7 >:#9
MU(7C3]R,8:7>[2<..!\)5&TM64M)J^E?5U--#)-I^G)!E Y#B<<^>W!^BDZK
M75DKM)U]155++6Z2*2)L-?)'&]SC$UXQAQ!RV2,\']( X/"K%1:::V:BT9J,
MNE+9*>%E5EPVQCILB8X<<#+QG)\UZ/X?5WC?65G+XNL4E5!60-FI)HYX7=GQ
MN#FG[PLRC-.@G35L#7;7&DB .,X\ 62QRSS4'4JI1+(7O&0T-P XC_T7&XZV
MK?4=:?Z5=OVH?Y4:VJZLIJ"EDJ:V>."GC&722.#6C[U1?9MK5FHKM=Z>6D;1
MR.>)XVNEW&0;0TX! [;0?[RWAT\LL,LI/$2V2Z=!1%'T\U2Z]U=/))&:>.&.
M1K1&0[+G/')S_P 'IYKG)MI(*.G_ +147[)/_'"I%434.MJ&U:YI;:ZCKZFJ
M;3OCVTT;7ESI"QS0!N![,.?J%OI899W6,^*6R<KVHJ\S115]F$DC&$U3B YP
M'^QE"C??-47'^AVVCM,)_P!I72=:7'J(V< _5RKFJ- R7>X6F:[7^LJ*LS&(
M/$4;&,\#WC:T#CE@[DKIT^GC+[^6O]I;?2.E+1O%7/14C9::&*9QE9&6R2%@
M&YP;G(:?,A0(OMRL)Z>J:<2T@X%TI&$LQZRQ\EGU&6\^2EKM40U=GBGI98YH
M9)Z<LDC<'-<.LSD$+G[.RS?F+O:59N+!O #L<@'(RM*^,:^S5P=GB%[A@XP0
M"0?Q"WEIWG^J*[_R'_PE9QYBLM#&V*CA9&,-#!@+.L=-_1HO^0?X+V\.+'!C
MMKB.'8S@^JEY'U%H6*6>>VQRU4C9)'DG+6[0!G&,?<B6:NAOHB*#DVJIXZ+V
MN6ME=5RU+IS!)2T\D$;F1%T@C_- D$NX<YS\%S6]CCA=954&FKM%JU]VI]0%
MM$^0O=0OIMXPYL0< [?P?S7!QQN=WRK6@*C^U&\VZU/TL+E60TQEO,)9U'8R
M '9/T&1D]AD*\*E>U$TK(M+R5K06-OU'M.,D.+B&_O(04YE=9=?W"[&KIZIL
M-FOU.60SN9T*ESS%$UQ )W?"_ [8>.^>)[7NF[1-8=1U]GNTMIN-522&6:FJ
MCLDYP=T9=MR2W9N !Y(SE;=CK#76V_3NHQ1N_*(1;-NW<&30L#SP/B#0[[U;
M[Y1RW&T5=%!,R!U1$Z(R/C+P X$'@$<\^J"&TG:K1IFBE:RYNJZN4%]76UE4
M9)9W1G8YSBX\!I.,# ;G"GGW"CC#S)5T[0P/+LR ;0S&\GGC&1GTRLT(D$3!
M,YCY /$YC2T$_($G'XE?9&-DC<R1H<QP(<#V(00VG*ZD99:9KZF!KF[FN!D
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MDB1D8/9<YU[I2KIZ5M1HZ;[.EEJ(_>(62ED+R7 -<&8(#@[;R,?>NC*.O_\
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M +6[_(E4CD>JTJ^C?55%'+'4=+W>0R ; [<=KF_X.*8\C=6I<Z+W^G;":B:
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MP );N:1N&>,C.1\UHVO3YH;_ %=T?7SU)FB;"R&1C-L#!CAA R 2,GU)Y[#
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M?B/16A$6L<9CPSEE<N1$1:9$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M "-YR.78)&>_)4NB     , (B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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ME=3R6>Y/KF.?OIX6"5P8UD3R1LSDXF8,>N1GS(79%!7_ %-2V6HI8:B)[W5
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M$1$!,(B B(@)@(B B(@87AL,;)7RMC:)'@!SP.7 9P"?ED_B41![1$0$1$#
M6M<*&GN-(^FK(^I _&]FX@. .<''<>H['L>$1!LX3 ]$1!CFIXIS$9HVO,3^
MHPD?"[!&1Z'!(^\K(B("(B F$1 3"(@)@(B B(@)A$08JFGAJ8715$;9(G8R
MUPR#@YY_!941 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
1$1 1$0$1$!$1 1$0$1$'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g843142g49n49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g843142g49n49.jpg
M_]C_X  02D9)1@ ! 0$"-@(V  #_[16,4&AO=&]S:&]P(#,N,  X0DE-! 0
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M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q @;,"$         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ (V8$$  0 " C9@00 !  (X0DE-
M!"8       X             /X   #A"24T$#0      !    %HX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$1       $     (   )    "0
M   X0DE-!!X       0     .$))300:      -!    !@             $
M\0  #?,    & &< -  Y &X -  Y     0                         !
M              WS   $\0                     !
M         !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   $\0    !29VAT;&]N9P  #?,    &<VQI8V5S5FQ,
M<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M       '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E
M3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E
M5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M!/$     4F=H=&QO;F<   WS     W5R;%1%6%0    !        ;G5L;%1%
M6%0    !        37-G951%6%0    !       &86QT5&%G5$585     $
M      YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
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MP  1"  Y * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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MG>DWV?Z2UC__ #VBAN>[)]!KZW,V%YO%0V AP'HG];]7U-CMW\WZ?_GM$F1
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M-TWIV(\V8N+3CO<-KG5,:PD<P=@:K*22E))))*4DDDDI_]D .$))300A
M  !7     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
M% !! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ #( ,  R #(    !
M #A"24T$(@     !2DU- "H    (  @!$@ #     0 !   !&@ %     0
M &X!&P %     0   '8!*  #     0 "   !,0 "    'P   'X!,@ "
M%    )T!.P "    #0   +&':0 $     0   ,    #L   "-@    $   (V
M     4%D;V)E(%!H;W1O<VAO<" R,RXU("A7:6YD;W=S*0 R,#(T.C V.C$Q
M(#(P.C(V.C(T $IE;B!"96%C:&5L;      #H $  P    '__P  H ( !
M  $   WSH , !     $   3Q          8! P #     0 &   !&@ %
M 0   3H!&P %     0   4(!*  #     0 "   " 0 $     0   4H" @ $
M     0              2     $   !(     3A"24T#_0      "
M    _^$!4D5X:68  $U- "H    (  @!$@ #     0 !   !&@ %     0
M &X!&P %     0   '8!*  #     0 "   !,0 "    'P   'X!,@ "
M%    )T!.P "    #0   +&':0 $     0   ,    #L   "-@    $   (V
M     4%D;V)E(%!H;W1O<VAO<" R,RXU("A7:6YD;W=S*0 R,#(T.C V.C$Q
M(#(P.C(V.C(T $IE;B!"96%C:&5L;      #H $  P    '__P  H ( !
M  $   WSH , !     $   3Q          8! P #     0 &   !&@ %
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M5G*2HK&RTQ<D-E-T@K,T8V1SD]$()T2#H\'"\/_$ !<! 0$! 0
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MO=E31026[:UGLQ8.S#6D%HV],# QZ(.77CZ0-7VB34D=306*0Z?AAK*HQOE
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M[T<.CAY%6B+*J8JBTIJIBJ+2H8;Q/;Y6TU_8V+)VQUC!]3)Z_N'R/'FKX$$
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M *EUA:);W8Y*.GE,4W:1R,/:.8,M>#@[>HP#QTZ*@LNC*ADVH67>H:^DN+G
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M(7[2UCY71M(;CDY8XD<$8[SPI,FI)/>5310T)?)'5-I(G.>YK9'F/M"2XMP
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MU=WM]RE8?:Z'>(G XX>,$'Q"L<#P"(MF9GJ&!X!,#P"(L# \ F!X!$0,#P3
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M"XNJ*FD?6OF)86AH ><ES0,G!/+B7<< =/7-8?I4@B?:Z6NMM2ZNKXH9HVP
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MOI-06>IN=<)Z>FGG=,X5;R)&O?(<N;@9^TW ' QST"ZDB("(B B(@(B("(B
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81 1$0$1$!$1 1$0$1$!$1 1$0$1$'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g843142g70c41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g843142g70c41.jpg
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M-CAS=)*R\1@E)G:4E;3"1%=C@X2CQ-/B*#54566D_\0 &0$! 0$! 0$
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MI-(:2HHI+M7 Q/AI8PUL(>,'('+<1^X<ROB\:)=:>Q*LM4A$E9 SOLCF\P)
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MV.&0YI;$""JU[0+17:4N4^GWO<^U.J!64I=Y@@MR/?'(_LA?5X<8\3/AQ_\
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M<(D=CY0Z0_Y JVEY?Y/K&&7O,?\ IUX7_P!H[B(B\KJ(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MH(*B,[F21PM#FGU!4VBOB9ZUN2L<]. TQ8ZVL[1+WJ:[4SZ>-@[I01R=2P
MO]LXY?M%=^B*\3B3Q)W/^$QQJ(B+FT(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B"GOL%K7].JO^++_4GV"UK^G57_%E_J5KHO=YOB=OJ'F\
M.%4?8+6OZ=5?\67^I/L%K7].JO\ BR_U*UT3S?$[?4'APJC[!:U_3JK_ (LO
M]2?8+6OZ=5?\67^I6NB>;XG;Z@\.%4?8+6OZ=5?\67^I/L%K7].JO^++_4K7
M1/-\3M]0>'"J/L%K7].JO^++_4GV"UK^G57_ !9?ZE:Z)YOB=OJ#PX51]@M:
M_IU5_P 67^I/L%K7].JO^++_ %*UT3S?$[?4'APJC[!:U_3JK_BR_P!2?8+6
MOZ=5?\67^I6NB>;XG;Z@\.%4?8+6OZ=5?\67^I/L%K7].JO^++_4K71/-\3M
M]0>'"J/L%K7].JO^++_4GV"UK^G57_%E_J5KHGF^)V^H/#A5'V"UK^G57_%E
M_J3[!:U_3JK_ (LO]2M=$\WQ.WU!X<*H^P6M?TZJ_P"++_4GV"UK^G57_%E_
MJ5KHGF^)V^H/#A5'V"UK^G57_%E_J3[!:U_3JK_BR_U*UT3S?$[?4'APJC[!
M:U_3JK_BR_U)]@M:_IU5_P 67^I6NB>;XG;Z@\.%4?8+6OZ=5?\ %E_J3[!:
MU_3JK_BR_P!2M=$\WQ.WU!X<*H^P6M?TZJ_XLO\ 4GV"UK^G57_%E_J5KHGF
M^)V^H/#A5'V"UK^G57_%E_J3[!:U_3JK_BR_U*UT3S?$[?4'APJC[!:U_3JK
M_BR_U)]@M:_IU5_Q9?ZE:Z)YOB=OJ#PX51]@M:_IU5_Q9?ZD^P6M?TZJ_P"+
M+_4K71/-\3M]0>'"J/L%K7].JO\ BR_U)]@M:_IU5_Q9?ZE:Z)YOB=OJ#PX5
M1]@M:_IU5_Q9?ZD^P6M?TZJ_XLO]2M=$\WQ.WU!X<*H^P6M?TZJ_XLO]2?8+
M6OZ=5?\ %E_J5KHGF^)V^H/#A5'V"UK^G57_ !9?ZD^P6M?TZJ_XLO\ 4K71
M/-\3M]0>'"J/L%K7].JO^++_ %)]@M:_IU5_Q9?ZE:Z)YOB=OJ#PX51]@M:_
MIU5_Q9?ZD^P6M?TZJ_XLO]2M=$\WQ.WU!X<*H^P6M?TZJ_XLO]2?8+6OZ=5?
M\67^I6NB>;XG;Z@\.%4?8+6OZ=5?\67^I/L%K7].JO\ BR_U*UT3S?$[?4'A
MPJC[!:U_3JK_ (LO]2?8+6OZ=5?\67^I6NB>;XG;Z@\.%4?8+6OZ=5?\67^I
M/L%K7].JO^++_4K71/-\3M]0>'"J/L%K7].JO^++_4GV"UK^G57_ !9?ZE:Z
M)YOB=OJ#PX51]@M:_IU5_P 67^I/L%K7].JO^++_ %*UT3S?$[?4'APJC[!:
MU_3JK_BR_P!2?8+6OZ=5?\67^I6NB>;XG;Z@\.%4?8+6OZ=5?\67^I/L%K7]
M.JO^++_4K71/-\3M]0>'"J/L%K7].JO^++_4GV"UK^G57_%E_J5KHGF^)V^H
M/#A5'V"UK^G57_%E_J3[!:U_3JK_ (LO]2M=$\WQ.WU!X<*H^P6M?TZJ_P"+
M+_4GV"UK^G57_%E_J5KHGF^)V^H/#A5'V"UK^G57_%E_J3[!:U_3JK_BR_U*
MUT3S?$[?4'APJC[!:U_3JK_BR_U)]@M:_IU5_P 67^I6NB>;XG;Z@\.%4?8+
M6OZ=5?\ %E_J3[!:U_3JK_BR_P!2M=$\WQ.WU!X<*H^P6M?TZJ_XLO\ 4GV"
MUK^G57_%E_J5KHGF^)V^H/#A5'V"UK^G57_%E_J3[!:U_3JK_BR_U*UT3S?$
M[?4'APJC[!:U_3JK_BR_U)]@M:_IU5_Q9?ZE:Z)YOB=OJ#PX51]@M:_IU5_Q
M9?ZD^P6M?TZJ_P"++_4K71/-\3M]0>'"J/L%K7].JO\ BR_U)]@M:_IU5_Q9
M?ZE:Z)YOB=OJ#PX51]@M:_IU5_Q9?ZD^P6M?TZJ_XLO]2M=$\WQ.WU!X<*H^
MP6M?TZJ_XLO]2?8+6OZ=5?\ %E_J5KHGF^)V^H/#A5'V"UK^G57_ !9?ZD^P
M6M?TZJ_XLO\ 4K71/-\3M]0>'"J/L%K7].JO^++_ %)]@M:_IU5_Q9?ZE:Z)
MYOB=OJ#PX51]@M:_IU5_Q9?ZD^P6M?TZJ_XLO]2M=$\WQ.WU!X<*H^P6M?TZ
MJ_XLO]2?8+6OZ=5?\67^I6NB>;XG;Z@\.%4?8+6OZ=5?\67^I/L%K7].JO\
MBR_U*UT3S?$[?4'APJC[!:U_3JK_ (LO]2?8+6OZ=5?\67^I6NB>;XG;Z@\.
M%4?8+6OZ=5?\67^I/L%K7].JO^++_4K71/-\3M]0>'"J/L%K7].JO^++_4GV
M"UK^G57_ !9?ZE:Z)YOB=OJ#PX51]@M:_IU5_P 67^I/L%K7].JO^++_ %*U
MT3S?$[?4'APJC[!:U_3JK_BR_P!2?8+6OZ=5?\67^I6NB>;XG;Z@\.%4?8+6
MOZ=5?\67^I/L%K7].JO^++_4K71/-\3M]0>'"J/L%K7].JO^++_4GV"UK^G5
M7_%E_J5KHGF^)V^H/#A5'V"UK^G57_%E_J3[!:U_3JK_ (LO]2M=$\WQ.WU!
MX<*H^P6M?TZJ_P"++_4GV"UK^G57_%E_J5KHGF^)V^H/#A5'V"UK^G57_%E_
MJ3[!:U_3JK_BR_U*UT3S?$[?4'APJC[!:U_3JK_BR_U)]@M:_IU5_P 67^I6
MNB>;XG;Z@\.%4?8+6OZ=5?\ %E_J3[!:U_3JK_BR_P!2M=$\WQ.WU!X<*H^P
M6M?TZJ_XLO\ 4GV"UK^G57_%E_J5KHGF^)V^H/#A5'V"UK^G57_%E_J3[!:U
M_3JK_BR_U*UT3S?$[?4'APJC[!:U_3JK_BR_U)]@M:_IU5_Q9?ZE:Z)YOB=O
MJ#PX51]@M:_IU5_Q9?ZD^P6M?TZJ_P"++_4K71/-\3M]0>'"J/L%K7].JO\
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M2?8+6OZ=5?\ %E_J5KHGF^)V^H/#A5'V"UK^G57_ !9?ZD^P6M?TZJ_XLO\
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MJ"(B B(@(B("^)I8X(7RS/;'%&TN>]YP&@=23Y!?:YC6FCZ;5W<8+G6UK+9
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M;7#(R/)5MJ_=KOM)I=(@DV*SL97W8 \II#SBA/M^<1Y\_,*U6M#6AK0 T#
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MG(YXSZ@J>1$]!$15!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M,@)8 \'<!UQZKQE73/$9940N$A(9AX.XCKCU6>.W4<3H'1T\;3 "V,@? #U
M7D5LHHFP".FC:("71 #X">N$MB5EA%73$-(J(2'.V [QS=Z?7V0U=, XFHA
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M'JC:NF<&%M1"0]VQI#QXG>@]UFBMM'%W?ATT;>[YX6!\&>N%XRV43&Q-931
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M+#WJGR!QXLEG$ WCFWYOI[HVJIW&,-GB)D!<P!X\0'F/59A;J,.:X4\>6Q<
M''2/Y?HD=NHXW0N93QM,+2R,@?"#U 2V)66!E73O$9940N$F0S#P=^.N/5!5
MTQ#2*B$ASMC2'CF[T'O[+-%;**(4XCIHVBG),6!\!/7"\;;*)C8VMIH@(Y.*
MT8Z/^;ZI;$K+$:NF )-1#@/X9.\<G?+]?9'5=,P2%U1"T1D!^7@;2>@/HLIM
ME$6N:::+:Z7C$8ZO^;ZI);**1LXDIHG"=P=("/C(Z$I;$K+&ZJ@89 ^>)IC
M+\O V@],^B&I@!<#/$"UG$(WCDWYOI[K-);J25TYDIXW&<!LI(^,#IE#;J1S
MGN-/&2^+@N..K/E^B6Q*RPBI@):!/$2YN\#>.;?7Z>Z-JJ=YC#)XG&0$LP\'
M<!UQZK,VWTC7,<*>,%D?!:<=&?+]$CMU)$8#'3QM, (BP/@!ZX2V)66!M73O
M$9941.$A(80\'<1U ]4%73D BHAP7\,'>.;OE^OLLT=MHXVP-CIHVB!Q=& /
M@)ZD(+91!K6BFC#6R\8#'1_S?5+8E9835TS0XFHA :[8XEXY.]#[^R/JZ=G$
MWU$3>%C?EX&S/3/HLK[91/;(UU-$6R2<5XQ\3_7ZKV6VT4HJ!)31N[P09<CX
M\=,I;$K+$ZJIVEX=/$#&-SP7CPCU/HG>J?)''BR&<3&\?#\WT]UFDMU'(Z9S
MZ>-QF:&2$CXFCH"GXNH]Q=W>/)BX!./^3^7Z);$I+"*JG<6!L\1+V[V@/'-O
MJ/9&55._A;)XG<7/#P\'?CKCU69ENHV.C<VGC!C9PV''PM]![+R*VT<1I^'3
M1M[OGA8'P9ZX^J6Q*RPMJZ9P86U$)#W;6$/'B/H/4IWNFV[N\0XW\/.\?%\O
MU]EECME%&V%K*:)HA>9(P!\+CYA/Q91;-G=HMO%X^,?G_-]4MB5EB=5T[0\N
MJ(0&.VN)>/"?0^A7KZJG9Q=\\3>%CB9>!LSTSZ+*^V43VS-?31D2O$D@(^)P
M\RO9;=1RFHXE/&[O&WBY'QXZ9^B6Q*RPFI@:7AT\0+&[W O'A;ZGV3O,&0./
M%DLX@&\?#\WT]UF?;J1[I7.IXR96<-YQ\3?0^R?B^D#@[N\>X1< ''_)_+]$
MMB5EA;4P.+ V>(EXW, >/$/4>J\954[Q$63Q.$N>'AX._'7'JL\=OI(W0N93
MQM,+2R,@?"T]0%Y%;:.(4XCIHVBG),6!\&>N/JEL2DL(JZ8AI%1"0YVQI#QS
M=Z#W]D-73 $FHAP'\,G>.3OE^OLLK;91-;&UM-$!')Q6#'PO]?JAME$6N:::
M(M=+QB,=7_-]4MB5EB?5TS!(7U$+1&0'DO VGT/HO7U5.PR!\\33& 7@O VY
MZ9]%DEME%*V=LE-$X3N#I 1\9'0E?4MNHY75#I*>-QG $I(^,#IE+8E98354
MX+@9X@6MWD;QR;Z_3W055.2T">(ES.(!O'-OS?3W69UNHW.>XT\9+X^"XXZL
M^7Z(VW4;7,<*>,%D7!:<=&?+]$MB5EA954[S&&3Q.,@)9AX.X#KCU7C:NG>(
MRRHA<)"0PAX.XCR'JL\=NHXG0&.GC:8 6Q$#X >N%Y';**)L#8Z:-H@<71@#
MX">I"6Q*RPBKIR 140X+^&#O'-WR_7V0U=. XFHA :[8XEXY.]#[^RS"V40:
MUHIHPULO& QT?\WU1ULHG-D:ZFC+9).*X8ZO^;ZI;$K+"^JIV"3?/$WAX#\O
M V9Z9]%ZZI@:9 Z>(&,!SP7CPCU/HLLMMHY14"2FC<*@@RY'QD=,KV2WTDCI
MG/IXW&9H9(2/B Z I;$K+#WF $CCQ9#.(1O'P_-]/=!4P.+0V>(ES=[0'CFW
MU'M[K,;=2%Q<:>/)BX!..K/E^B,M](QT;FT\8,<?"8<?"WT^B6Q*2PLJJ=_#
MV3Q.XN=F'@[\=<>J\;5TS@PMJ(2'G:PAX\1]!ZE9HK;1Q=WX=-&WN^>%@?!G
MKA>1VRBC;"UE-$T0O+XP!\+CYA+8E98N]TV,]XAQOX>=X^+Y?K[(ZKIFAY=4
M0@,=M<2\>$^A]"LOXLHMNWNT6WB\?&/S_F^J/ME$]LK7TT1$KQ(\$?$[U*6Q
M*RQOJJ=G%WSQ-X6.)EX&S/3/HCJJG:7AT\0+&[G O'A'J?0+++;:.7O'$IHW
M=XQQ<CX\=,_1>OMU&]TKGT\9,K!&\D?$T>12V)66'O5/G''BSLXF-X^'YOI[
MHVI@<6!L\1+QN8 \>(>H]5F%NI \.%/'N$7 SC_D_E^B1V^DC="YE/&TPM+(
MR!\+3U 2V)66%E53OX>R>)W%SLP\'?CKCU7@JZ=P:6U$)#G;&D/'-WH/?V6:
M*VT<0IQ'31M%.28L#X,]<(RV43&QM;31@1R<5@Q\+O7ZI;$K+#WNG )[Q#@/
MX9.\<G?+]?9'5=.P2%U1"T1G:\EX&T^A]%F-LHBUS331[72\<C'5_P WU22V
M44C9VR4T;A,X/D!'Q$="4MB5EB?50,,@?/$TQ8+\O V9Z9]$-3 "X&>(%K=[
MAO')OJ?;W6:6W4DKJ@R4\;C4 "4D?&!TRCK=2.=(YU/&3)'PG''5GR_1+8E)
M8154Y+0)XB7,X@&\<V_-]/=&55.\QAD\3C("6 /!W =<>JS"W4;7,<*>,%D7
M!:<=&?+]$BMU'$Z!T=/&TP MB('P ]<);$K+ RKIGB,LJ(7"0D,(>#N(ZX]4
M%73$-(J(2'/X8.\<W?+]?998[911-@$=-$T0$NB 'P$]2$;;*)K6-%-$&LEX
MS1CH_P";ZI;$K+$:NF <340@-=L<=XY.]#[^R/JZ=@D+ZB%HC(#\O VYZ9]%
ME=;*)S7M=31%KY.*X8ZO^;ZKV6V44HJ!)31N$Y!ER/C(Z92V)66)U5 TR!T\
M0,8R\%X\(]3Z)WJ#)''BR&<0C>.3?F^GNLTENI)'3N?3QN,[0V0D?$!T!0VZ
MD+G.-/'N=%P"<=6?+]$MB5EA%3 XM#9XB7-WM >.;?4>WNC*JG?P]D\3N)G9
MAX._'7'JLS+?2,=&YM/&#''PF''PM]/HD5NHXC3F.GC;W<$18'P9ZX2V)26!
MM73N#"VHA(>=K"'CQ'T'J4[W3XSWB'&_AYWCXOE^OLLT=LHHVPM931M$+B^,
M ?"X]2$%LH@T-[M'M$O'QC\_YOJEL2LL+JNG:'EU1" QVQQ+QX3Z'T*]?54[
M.)OGB;PL;\O V9Z9]%E?;*)[96NIHR)7\1X(^)WJ?=);;1R]XXE-&[O&.+D?
M'CIE+8E98G55.TO#IX@6-W.!>/"/4^@3O5/G''BSLXF-X^'YOI[K,^W4;W2N
M?3QDRL$;R1\31Y%/Q=1[MW=X\\+@9Q_R?R_1+8E986U5.XL#9XB7C<T!X\0]
M1ZA>,JJ=_#V3Q.XN=F'@[\=<>JSQVZCC=$YE/&#$PLC('PM/4!>16VCB[OPZ
M:-O=\F+ ^#/7"6Q*RPMJZ9P86U$)#W;&D/'B=Z#W3O=-@GO$. _AD[Q\7R_7
MV65ELHF-B:RFB B?Q& #X7>H]T-LHBTM--%M,O'(Q^?\WU2V)66)U73M$A=4
M0@1G:\EX\)]#Z+U]53L,@?/$TQX+\O VYZ9]%E?;**1L[7TT;A,X/D!'Q$="
M5[+;J.4U!DIXW&< 2Y'Q@=,I;$K+":F %P,\0+6[W O')OJ?;W05,!( GBR6
M<0#>.;?F^GNLSK?2.=(YU/&3)'PG''5GR_1!;Z0.:X4\>6Q<$''1GR_1+8E)
M865,#S&&3Q.,@)8 \'<!U(]5XRKIWB,LJ(G"0D,(>#N(ZX]5GCM])$Z!T=/&
MTP-+8R!\ /4!>16RBB; V.FC:("71 #X">N$MB5EA%73D-(J(2'/X8.\<W>@
M]_9#5TP#B:B$!KMCCO')WH??V69MLHFM8UM-& R3C-&.C_F^J\=;*)S9&NIH
MB)).,X8ZO^;ZI;$K+$^KIV"0OJ(6B,@/R\#83TSZ+UU53L,@=/$TQ@%X+P-H
M/0GT662V44HJ!)31N%009<CXR.F5[);J.1T[GT\;C.T-D)'Q@= 4MB5EA[U3
M@D<>+(9Q"-XY-^;Z>Z"JIR6@3Q$N;O: \<V^H]O=9C;J,N<XT\>YT7 )QU9\
MOT1MNHVNC<VGC!CCX33CHST^B6Q*RPLJJ=YC#)XG&3)9AX._'7'JO&U=,X1E
MM1"1(=K"'CQ'T'JLT5MHXC3F.GC::<$18'P9ZX7D=LHHVPM931-$+B^, ?"3
MU(2V)66+O=/@'O$."_AYWCXOE^OLCJNG:'EU1" QVQQ+QX3Z'T*S"V40:&BF
MCVB7C@8_Y3YOJC[91/;*UU-&1*_B/!'Q.]3[I;$K+$^JIV<7?/$WA8XF7@;,
M],^B.J8&EX=/$"QNYP+QX1ZGT"RRVVCE[QQ*:-W>,<7(^/'3/T7K[?2/=*Y]
M/&3*P1O)'Q-'D4MB5EA[S!G''BSLXF-X^'YOI[HVI@<6!L\1+V[F@/'B'J/4
M+-^+Z3=N[O'NX7 SC\SY?HC+?21NB<RGC!B88V$#X6GR"6Q*2PLJJ=_#V3Q.
MXN=F'@[\=<>J\;5TS@PMJ(2'NV-(>/$[T'NLT5MHXN[\.FC;W?/"P/@SUPO&
M6RB8V)K*:(")_%8 /A=ZCW2V)66+O=-@GO$. _AYWCXOE^OLCJNF:)"ZHA C
M.UY+QX3Z'T64VRB+2TTT6TR\8C'Y_P WU22V44C9FOIHG"9P?("/B<.A*6Q*
MRQOJJ=G$WSQ-X6-^7@;,],^B&JIP7 SQ M;O<"\<F^I]O=99;;1RFH,E/&XU
M  ER/CQTRO76ZC<Z1SJ>,F2/A/./B9Z?1+8E)8>]4^0./%DLX@&\<V_-]/=&
MU5.\QAD\3C("6 /!W >8]5F%NHPYKA3QY;%P <=&?+]$CMU)$Z!T=/&TPM+8
MR!\(/4!+8E98&5=.\1ED\3A(2&8>#N(ZX]4%73D-(J(2'.V [QS=Z?7V6:.V
MT<0@$=-&T0$NBP/@)ZX1MLHFM8UM-&&LDXS1CH_YOJEL2LL)JZ<!Q-1" U_#
M)WCD[Y?K[(^KIV"0OJ(FB,@/)>!M)Z9]%F=;*)S7M--&0^7C.&.K_F^J26VB
ME;.V2FC<)R'2@CXR.F4MB5EB=50,,@?/$TQ@%X+P-H/3/HAJ8 7 SQ9:SB$;
MQR;\WT]UFDMU)*Z=TE/&XSM#921\8'0%#;Z0N>XT\9+XN"XXZL^7Z);$K+"*
MJ EH$\1+F[VC>.;?4>WNC*JG>8PR>)QESLP\'?CKCU69MNI&NC<*>,&./A-.
M.C/E^B16ZCB-.8Z>-IIP1%@?!GKA+8E98&U=,\1EE1"X2':PAX.X^@]4[W3$
M BHAP7\,'>/B^7Z^RRQVRBC;"V.FB:(7%\8 ^$GJ0@ME$&AHIHMHEXX&.C_F
M^J6Q*RQ&KIFAY=40@,=L<2\>%WH?='U=.SB[YXF\+'$R\#9GIGT65]LHGME:
MZFB(EDXKQCXG>I]U[);:.45 DIHW=X(,N1\>.F?HEL2LL3JJG:7AT\0+!N<"
M\>$>I] G>8,XX\6=G$QO'P_-]/=9GVZCD=,Y]/&3,P,D)'Q-'0%/Q?2;MW=X
M]W"X&<?\G\OT2V)26%M3 XL#9XB7MW- >/$/4>H1E53OX6R>)W%SP\/!WXZX
M]5F9;J1CHG,IXP8F&-A ^%I\@O(K;1Q=WX=-&WN^>%@?!GKCZI;$K+"VKIW!
MA;40D/=M:0\>(^@]T[W3XSWB'&_AYWCXOE^OLLS+91,;$UE-&!$_B, 'PN]0
MGXLHMI;W:/:9>/C'Y_S?5+8E9875=.T/+JB$",[7DO'A/H?0KU]53LXF^>)O
M"QOR\#9GIGT662V44C9FOIHW"9P?("/B<.A*]EMU'*:CB4\;N\8XN1\>.F4M
MB5EA-5 TN!GB!8W>X%XY-]3[>Z"JIR0!/%DLX@&\<V_-]/=9GVZD>Z1SJ>,N
MDCX3SCXF>GT06ZC#FN%/'EL7 !QT9\OT2V)66%M53N,8;/$XR E@#P=P'4CU
M7C*NG>(]E1"[B$AF'@[L=<>JSQVZCC="Z.GC:86EL9 ^$'J O([911" 1TT;
M1 28L#X">N$MB5EA%73$-(J(2'.V-(>.;O0>_LAJZ8 DU$( ?PR=XY.^7Z^R
MRMME$UK&MIH@UDG%:,='_-]4-LHBUS331%KI>,X8ZO\ F^J6Q*RQ.JZ9@D+J
MB%HC(#\O VD] ?1>NJH&&0.GB:8P"_+P-H/3/HLLELHI&SB2FC<)W!TN1\9'
M0E>R6ZDD=.9*>-QG ;(2/C Z I;$K+":F $@SQ9#.(1O')OS?3W05,!+0)XB
M7-W@!XYM]1[>ZS&WTA<YQIXRYT7!<<=6?+]$;;Z1KF.;3Q@LCX+3CHSY?HEL
M2DL+*J!YC#)XG&0$LP\'=CKCU7C:NG>(RRHA<)"0PAX.XCR'JL\5NI(C3F.G
MC:8 1%@? #UPO([911-@;'31M$#BZ, ?"3U(2V)66$5=.0"*B'!?PP=XYN^7
MZ^R.JZ9H<75$(#';'$O')WH??V686RB#6M%-'M;+QP,='_-]5X^V43VR-=31
M%LDG%>"/B?Z_5+8E98GU=.SB[YXF\+'$R\#9GIGT7KJJG:7AT\0+!N<"\>$>
MI] LLMMHY14"2FC<*@@RY'QXZ9^B]?;J.1TSGT\9,S0R0D?$T= 4MB5EA[U3
MYQQXL[.)C>/A^;Z>Z-JJ=Q8&SQ$O;N: \>(>H]EF_%U'N+N[Q[C%P"<?\G\O
MT1ENHV.B<VGC!B88V$#X6GR"6Q*2PLJJ=_"V3Q.XN>'AX._'7'JO&U=,X,+:
MB$A[MK2'CQ'T'J5FBMM'%W?ATT;>[YX6!\&>N/JO([911MB:RFB B>9& #X7
M>H2V)66+O=-MSWB'&_AYWCXOE^OLCJNG:'EU1" P[7DO'A/H?0K+^+*+9M[M
M%MXO'QC_ )3YOJO9+912-F:^FC<)GA\@(^)PZ$I;$K+$^JIV<7?/$WA8XF7@
M;,],^B&I@:7!T\0+&[W O')OJ?99I;=1RFH,E/&XU&WBY'QXZ9^B.MU(]TCG
M4\9,D?"><?$WT^B6Q*RP.K:6/;Q*F!NX!S=T@&0>A'LBR36F@FX?%I(G\-@C
M;D=&CH$5WBM9;J(BY-B*FM+=J]7)VKWG3.H(X8[<:V2CMU2QA:.*P\HWG."7
M C'OCU76]K.I[AI:UV2HM?!XE9=Z>BEXK-PX;]V['/KX1S0=PBQ\>+C\#BLX
MVW?P]PW;?7'7"&>(3MA,K!,X;A&7#<1ZX]$&1%IU-TM]+"Z6IKJ6&)C^&Y\D
MS6M#_E))Z^R]JKG04E/'455=2P028V222M:UV>F"3@H-M%PW;)JFNTGV>UE[
MLKH'5,;XA&9&[V$.> >0//D5UT=RH9*UU&RMIG5C1ET E:9!]6YR@VT7S+(R
M&-TDKVLC:,N<XX 'J2L%!<*.X1N?05=/5,:<%T$C7@'T)!0;*+4J;G04K7.J
M:ZEA:QXC<9)6MPX]&G)Z^RVP00"#D'S0$6I7W*AM^SO];34N\X;QY6LW?3)Y
MK!?KM!:;#67-[XW1P0/F;EX D(:7  ^^$$DBKCL=O&IM26]M[OUUM<]'5P[X
MJ&DAVOIR7<MSLYZ \BLW;/J>\:9M%E=IYU*RLN%TBH-U3&7L >U_/ (\P$%@
MHJRDHNUN.-SX[MI.9[1D1NII6AWMGR4WV5:REUGIZ>HKJ045SHJE]%60-.6M
ME9C.T^G,?X]>J#LD6FZZ6]M<*)U=2BL/2 S-XA_ZN<KD^TG4]PT]<M'P6_@[
M+I>(:&HXC-QX;CSV\^1]T'<(M:OKZ.WQ"6OJZ>EB)QOFD#!^\E>P5U)44IJ:
M>J@EI@">*R0.9@=>8.$&PBX_LVUHS65%<:CAP4[Z>NFIHX62[W&-F 'GZD^F
M%TDETM\=:VCDKJ5M8[I Z9HD/_5SE!N(O'.#&ESB&M R23@ +@>TG6S[/9;5
M5Z<JZ&J=/=J>AF<UPE:&/W;AR/(\D'?HBJ+6];VH:?MMYO,=QTPZV48DG9%P
M93+P@20#RQNQCS06ZBJK1,_:=>*>QW:MN.F?Q16-AJ98F0RB;@N <6CE@.VG
MUQE1\&HNT+4>MM66O3-98*:CLU2V$=]A>7.#@<<VYS\)]$%RHJ^L%)VFQWBE
M=?KEIF6V!_\ ;LIHI1(6X_-)&,]%)=JNJ)M*:1FK*!K)+I42QTE%&\9#YGNP
M.7G@9/W(.O1<7V4:IJM3Z>J/QPV*.]VZKEH:Z.,8:)&.Z@>A&/ORN;UAJ764
MW:H-*:1J+13L%L;7%]?$YWYY:1EOW>7J@MA%6,5#VNB5G%NVD3'N&X-AFSCS
MQR5G("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B BK6OU-JC4.L
M;M8M%BVT5+:-C*NOKXW2%\KAD,C8".F#DGT^F=S0&K+O6:DO&EM64])'>K=&
MR=L]'NX-3"[HX!W,$$C(]_9!WR(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(BJ'5?:]$W5ECLFE6BLBFND%%7U^PNACW.P8F.Z%Y&3GH,>?D%O(B("(B
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M)3PT B<XX.,.\L'!7"]I6I(JCMCL=%);[I<[=IUG?:B*W4QG=WEX_L]P'0-
M#@?<KK[3:^TN.YTC[IJ*Q34+96F>.*C<U[V9\0!\CA;_ &<:0J=-SZ@K[M50
MU=UO%:ZIEEB!#6L_,C&>>&Y=^]!7&DM5147;E4OCMEWM=KU1"UI9<J0T^:N,
M<BW/(Y'+ZO6;5M)?:W\(GA:8N=/;:X6%KC-/ )FEG%.6[3YYQS]E8/:KHR;6
M-EHX[=51T5VH*N.LI*EX)#'M//ISZ?X@*!U/HC5=3V@1:JTY=[715?XN;0R,
MJ(72#XBYQ'MG&$5NVRQ=I$5QI9+AK"UST;)6NFB9;6M+V C<T'R)&1E6*JQ_
M%':O^D^G?_L%RLR,.$;1(07X&XCH2B/I$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1!R^O-:V[1U#$^K$E5<*D\.CH*<;IJE_D&CTSC)\O<X"A^S
M'2]TI*^ZZIU86?:*\;0^",Y920M^&('S/3)]A[D\[7=GVMO]H-SU3;KY9>\5
M&8J;O5,Z4TT(/A8SR:<=2.ISZG/::-H=:4M?.[5MWM==2&+$;*2G,;FOR.9)
M\L90=<B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("J?MCHJ6@D[/8*&GAI
MH!J:E(CB8&-R=V3@*V%R/:#I6HU//II]-410"U7:&X2"0$[VLSEHQY\T'7(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B OA\L;)&,?(QKWY#&D@%V/0>:^
MUQW:+HZ74OXJK[57BW7ZT3&>BJ7,WMYC#F/;YM< ,H*]U=17G2&NM-:GU;<X
M]26UU7W&)I@[N;>^7.)&,:2UW(')//D//!%YJL7Z*U/J>\VJIU]<[4ZWVR=M
M5#;[7%(&32M^%\CGG/+T'+F59R B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B(*L[$.5Y[1FR?EQJ*H+L]=I^'[NJ:7Y_A":U,?P-MU(),?-AN,^^%O7;1^
MH;7JZXZ@T)7VR%]T:P5U%<HWF%SVC D:6<P['4?7[I7L[TA/IS\:W"[US;A?
MKM,)ZVI8S8SD,-8P>36@G"*[!$1$$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!5/VH4=-;]3]F--0T\--31WC#(H6!C6C;Y <E;"Y'6VE:C4%\TK705$43+/
M7=[D:\$F08Q@8\_J@ZY$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%J7BX
M06FTUMQJW;:>DA?/(?U6@D_Y+;7.=HMAJM3:*NMEH*F.FJ*V,1"60$M:-P+L
MXY\P"/O0<KV$VV>:Q5NK;L,W?4<YJWD_F0@D11C]4#F/8CT5FK2L5O;:K);[
M='C924\=.W'3#&AO^BW4!$1 1$0$1$!$1 1$0$1$!%%07=TK*1SJ"JC,[G-<
M'-YQ8\W>@*-N[G,C=W"J!?4<$@MYM'SG]5;IDEH2J**?=W-9,X4%4XQS\$ -
MYN'SC]5>SW9T3:PMH*J3N[FAH:W\KGS;ZX2F1:$HBC9KHZ-]4T452\0,#FEK
M>4F?)ON$-T<'O;W*I(;3\?.WD3\@_64ID6A)(HV.Z.<^%IHJEHDAXI);R8?D
M/NOF"[.E-&'4-5'W@.W;F_DL?-Z9\DID6A*(HJ&[OD93.-!5L,TA80YG.,#\
MYWL@N[^&'=PJ\FHX&-G/'S_LJTR2T)5%%2W=[&5#A05;C%*(P SF\?,/9>SW
M9T7?-M#52=WV[=K?RN?E]<>:4R6T)1%&2W5S'U#10U+A%$) 0WE(3^:/=!=7
M%X;W*IQW?CYV\L_)^TI3(M"311L-T=(^F::*I8)HR\ES>49'YKO=?,%V=**/
M=0U4?>"X.W-_)8^;TSY)3(M"4114=W<]D#C0533),8B"SFP?,?9#=W!CG=PJ
MB14<#&SF1\_[*M,BT)5%%S7=T;*IPH*IYA>&-#6\Y ?-OL%[/=71.K VBJ9.
M[AI:6M_*Y^7UQYI3(M"311C[JYLDS115+A'#Q00WD\_(/UD;=7%\;>XU(#H.
M,26\FGY#^LI3(M"311D%U=*^D::&I9QVN<XN;RBQY.]ROF"[OE92%U!5Q\=S
MFN#F?DL>;O3*M,BT)5%%,N[W1Q.-OJP7S\$@LYM'SG]5'W=[62N%!5DLGX(
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M8R"WFP#\X^RM,BT)5%%?C=W#+NX56>\<#;LYX_YS]GW26[NC94N%!5/,,@C
M:S\H#^<WV2F1:$JBC)[JZ(UNVAJI.[[=NUOY7/R^N/-)+JYKYVBAJ7".$2@A
MO)Y^4>ZE,BT)-%&"ZN+VM[E5 .I^/G;R!_YO]KV2&ZND?2M-#4L$S"]Q<WE&
M1Y.]RE,BT)-%%07=TK:,NH*J/O!<'!S/R6/-WIE([N][(7&@JVF2;A$%G-@^
M<_JJTR2T)5%%.N[Q&]W<*LEL_! #.9'SC]5)KN^-E6105;^ ]K6AK/RN?-OL
M$IDMH2J*,GNKHG58%%4OX#6N:6M_*Y\F^N%ZZZN:^1O<JDAD'&!#>3C\@_64
MID6A)(HUET<Y\3315(#X.,26\FGY#^LO(+JZ5U('452SCM<7%S?R6/)WIE*2
M6A)HHN"[.D92$T%4SCO<UP<S\GCS=[%>-N[C&QW<*H%T_!(+.8'SG]56F1:$
MJBBI+N]D<SA05;C'-P@ SF\?./9>SW9T0K"*"JD[N6ANUOY7/R^N$IDEH2B*
M,FNKHWU+10U+Q#&'@M;RD)_-;[A#=7;W-[E4X%/Q\[>1/_-_M*4R6T)-%&1W
M5SWP--#4M$D1D)+>3#\I]UY3W9TIHPZAJH^\;MVYOY+'S>F?)*9%H2B**AN[
MY&4SC05;#-(8R',YQ@?G.]D_&[^'N[A5Y[QP-NSGCY_V5:9):$JBBI;NZ-E2
MX4%4\Q2",!K.<@/YS?9?4]U=$:W;0U4G=]NW:W\KGY?7'FE,EM"311LET<Q\
M[115+A%$) 0WD\_*/=!='<1K>Y5.#3\?.WD#_P W^U[*4R+0DD4;#=72/IFF
MBJ6":,O)<WE&1^:[W7S3W9TK:(NH:J/O!<'!S?R6/F],^24R+0E$44R[O<R%
MQH*MIDFX1!9S8/G/LCKN\1R._%]62VHX( 9S</G'ZJM,BT)5%%3W=\3*MS:"
MKD,#PUH:SG+GS;[!?4]U=$^L:VBJ9. &EI:W\KGR;ZX2F1:$FBC'75S7RM%#
M5$,@XP(;R<?D'ZR-NKG/C;W&I ?!QB2WDT_(?UE*9%H2:*,@NKI7T@=0U3..
MUSG%S?R6/)WU7S!=W2LI'&@JF&=[FN#F\XL>;O8I3(M"5113;NXL8[N%4"Z?
M@D%G,#YS^JC[NYK)G"@JG&.;A !O-X^<?JJTR+0E447/=G1"L(H:I_=RT-#6
M_E<^;?7'FOJ:ZNC?5-%%4O$+ ]I:WE(3Y-]PI3(M"211INC@]S>Y5) I^/G;
MR)^3]I([HY[X&FBJ6B2$RDEO)A^4^Z4DM"211=/=G2FCW4-5'WC=NW-_)8^;
MTSY+R&[OD93.-OJV&:0QD.9SC _.=[*TR+0E445^-W\/=W"KSWC@8V<\?/\
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M1$!$1 1%\[V[RS<-X&2W//"#Z1$0$1$!$1 1$0$1$!$1 1$0$1$!$7A( ))
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M18YJETO9.S&O;;K;4ZJK);V^*-LP;<9&L?,6C<&N^'XLX *_0L3!%$R-N=K
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MI+E;HG$Q1[6Y9+MZ-)(QR]/==50U.E^TZVU3*VW"I9;ZJ2GEIJU@#X9&\B<
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MRXP&8)/VNK<^BL=5=^$)EVEK)''_ ,)?>Z1L&.N_+L8^[*M%6&9Y"(BJ"(B
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M.+0?I]5:E]KVVNQW&X2?!24\DY^C6EW^BV:6"*EIHJ>GC;'#$P1L8T8#6@8
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M[A<N'WN7B./$V##>1.!@'R 4JB*XRC[,=)T<5WAIK68X+JS951-J)0Q[<[L
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M "</3Z*41+R5A%4]%<&]SXU:Q^S=Q\1@<3/PX],+YBH;B&4XDKF.<V4NE(C
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M.&.4OS_3V1M%7A\1=6,+1!M>.&/%)\WL/92B)>2L(J"BKVNH^-6L>&!W' C
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M_/\ 3V4HB7DK"+CHJ\/@+ZUCFMB+9!PQXG^3AZ#V7E/17!IH^-6L>&;N\8C
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M#CZ\O/*#N-.Z@H[\RM[GQ8YJ*I?2U$$S0V2*1IZ$ GD1@@@X(*EE6%5*=/\
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M*W1%/9[?',]UVN-/1RF)A<61EVXN..@\(S]58U)3Q4E+#3T[ R&%@C8T=&M
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M@$9"J/47FX;MN1GTRN<U?JJ/3E78:9],^>2[5\="PAP:(]W5Q]<#R45TB+Q
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M+F.#AEI \_IZILTL!%\O+@QQ8 78Y ^958U6I.TNDII:BITI8XH(F&221]R
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M\ *T%6G:G"=0:JT;IF#Q'OPNM7C\R"'/7T#G.VCW5EJI/(1$501$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M"=3M%TAK*^Z[H[I;X[#66BWL!I*.Y22[.*1XI',:.;L\ADD8 72Z9D[177F
M:E@TNRU8=Q30NG,P\)V[=QQ\6,^V5EKV=K,_A0R2$9#&EV/HJV_!XS/V=MN<
MQW55TK:FLG?YN>9"W/[FA660' @C(/(A5EV+TXM=OU%HZKSQ;172-8TG!?32
MY?&_[\N52.3HNT"WZJKK;P-&W&@MTCF/$KYXR7DG&-A')OYW/!ZA0W8356^;
M0++=14,E%):YY**KIY7B1PF:<O)=@9R79Z>WDHZRV/M T?02V.P?B>ZVP2/=
M15==,]DL#7$G$C0#OP2>A_D-N@[+FQ=F]TT]57.1]SN<SJVIN$8V_P!Y)!W
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M+]RI')J:H>;;V[Z.J8>1NE#544^/SFL'$;G_ *Q"M!5I-"=0=NE/-%XJ33-
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MNMRD[M1OJ'!D<1/Q2O<>0:T'/UPNY6A=;-;+NV-MVMM%7-B)+!4P-EV9ZXW
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M2/\ HT-'[U/9?=85%/WFC@GQCBQM?CTR,K.OB)C8HV1L&&- :!Z +[6F1$1
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MSOW?+SY^Z]?<6L?,TTU43%")B1'R(]!SYN]DK(WD6B+BTO8WNU5XJ?O&>'R
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MX^>>\M(]L(+PTSJ"V:FM,=RLE6RJI'DMW $%KAU:X'F"/0J558=CELJ;??\
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MF3[+T.N>\9DIMG=\=#GC>O[*VT3X-RU(77(/IN+)3EHC(FV@^)_D1[+R!UT
MH^/+3.+2[O&T'Q?+M]%N(GP;EI1NNH9!Q):4N$I,N&GG'Z#W0NNNQV):7?WC
M(Y''!]/VENHF^QN6E,ZZEE5PI:4.+P8-P/A;YAWNOJ=US+JS@24P#@WN^X'P
MG\[<MM$WV-RU'NN?$FV24P88<1@@Y$OJ?9&NN>^/=)3;>!AV <F7U'ZJVT3X
M-RTX'7,/I.-)3%H:[C[0?$[RV^R\@==0RDX\M*7-<[O&UI\0\MJW43?8W+18
MZ[;(M\M*7B?+R&G!B]!^LCW7;9+LEI0XSYC):>47H?UEO(KOL;EI3NNI;6<&
M6E#G.;W?<T^$>>Y?4SKF7U?!DI@PL;P X'+7>>[V6VBF^QN6H77+>_$E/L[O
MAO(Y$WJ?U48ZY!\.^2G+1#B3 /.3U'LMM$^#<M2!US#J/CR4SFM#N\;0?$?S
M=OHOF%UU#*;C2TI<'DSEK3AS?(-]UNHF^QN6D'77AMS+2[^\9)VG'!]/VDD=
M=2R?ARTH<908B6GE'Y@^ZW43?8W+2G==#WW@RTPW;>[;@?#\V[U]E[*ZYE]1
MPY*8-,8$.0<A_F3[+<1/@W+3W7/?^4IMO=]O0YXWK^RD3KF'T_%DIBT1D38!
MYO\ (CV6XB?!N6E3NN@[GQY:9VW=WC:#XOEVKR)UV#*?B2TI<)292&G!C]![
MK>1-]C<M$NNW#.):7?WC(.TXX/I^TO9G74LJN#+2AQ>#!N!\+?,.]UNHF^QN
M6I.ZYDUG DI@'!O=]P/A/YVY'NN6^;9)3AAAQ'D'(D]3[+;1/@W+4:ZY;V;I
M*?9W?#N1SQ?7]E(77(/I>-)3EH8X3[0?$[RV^RVT3X-RTH'70-I./+3$M<[O
M&T'Q#\W:C'74,BWRTI>)\R$-.#%Z#W6ZB;[&Y:+W7;9+LEI0\SY82TX$7H?U
ME[.ZZEM7P9:4.<YO=]S3X1Y[ENHF^QN6G,ZYE]7P9*8-+6\#<#X7>>[V7KG7
M/?)MDIMO=\,Y'E+ZG]5;:)\&Y:;'7/?%ODIBT0XDP#SE]1[)3NN8=1\>2F<U
MH=WC:#XC^;M6XB?!N6C Z[!E+QI:4N#R9]K3AS?(-]UZ'77AMS+2[^\9)P<<
M'T_:6ZB;[&Y:4CKJ63\.6E#C*#%EIY1^8/NO9W70BMX$M,"XM[MN!\/S;O7V
M6XB;[&Y:DKKD7U/"DIPTQ@0Y!\+_ #)]DW7+B'^TI]G=]H&#GC>O[*VT3X-R
MU(G7(/I^))3EHB(EP#S?Y$>R\@==!W+C2TQV[N\[0?%\NWT6XB?!N6C$Z[!E
M/Q9:4N$I,I#3SC]![INNW#/]K2[^\9!VG'!]/VEO(F^QN6C,Z[%E3PI:4.,@
M,.YI\+/,.]U]3NNA-9P):8!P;W?<#X?FW+<1-]C<M-[KGOFV24P:80(\@\I/
M,GV0.N>]N9*;;W?#N1_+>O[*W$3X-RU(77,/I>-)3%H8X3[0?$[RV^R^8'70
M-I./+3$M<[O&T'Q#\W:MU$^#<M)CKKLBWRTI>)\R$-.#%Z#W1SKKLDVRTN\S
MY82TX$7H?UENHF^QN6E.ZZEM7P9:8.<YO=]P/A;Y[O=?4[KF75?!DI@US6]W
MW ^$^>Y;:)\&Y:CG7+?)MDI]I@PS(.1+ZG]5&NN>^+=)3%@AQ)@')E]1[+;1
M/@W+3@=<PZCX\E,YK0[O&T'Q'\W:OF!UU#*7C2TI<'DS[6GQ-\@WW6\B;[&Y
M:(==N&S,M+O[QEQVG'"]/VDD==BR?ARTH<9LQ$M/*/T/NMY%=]C<M*=UU(K.
M!+3 N+>[[@?"/SMR]F=<R^IX4E,&F,"'<#X7^9/LMQ%/@W+4W7+>?[2GV=WV
M@8.>-Z_LI$ZY!]/Q)*<M$1$N >;_ "(]EMHGP;EIP.N8[EQY:9VW=WG:#XOE
MV^GNO(G74,I^++2EPE)EPT\V>0'NMU$WV-RTMUUX9_M:7?WC=G:<<'T_:25U
MU+*GA2TH<9 8<M/A9Y@^ZW43?8W+3G=<R:W@24P#MO=MP/A^;=Z^R2.N>^?9
M)3!IA CR#RD\R?9;B)\&Y:@=<][<R4VWN^'<C^6]?V4A=<P^EXTE,6AA$^T'
MQ.\BWVZ+;1/@W+2@==0VCX\M*2TN[QM:?$/S=J\C==@R'?+2EPFS)AIYQ>@]
MUO(F^QN6BYUVX;PV6EW\?+3M.!%Z']9>S.NI95\&6E#B]O W-/A;Y[O=;J)O
ML;EJ3NN9=5\&2F#7-;W?<#X3Y[D<ZY;Y-LE/M,&&9!R)?4_JK;1/@W+48ZY;
MXMTE.6B##\ Y,OJ/U4@=<PZDXTE,6M:[O&T'Q'\W:MM$^#<M*!UU#*7C2TQ<
M'NX^UI\3?+;[HUUUX;-TM+OX^7':<&+T'ZRW43?8W+2D==3'-PY:4/,V8R6G
M C]#[I.ZZD5G EI@7%O=]P/A'YVY;J)OL;EIS.N9?4\*2F#2P"$.!\+_ #+O
M9"ZY[W8DIMO=\#D<\;U_96XB?!N6I&ZYA\'$DIBT1$2X!R9/(CV7D#KH#1\>
M6F(;N[QM!\7R[?1;B)\&Y:,+KL&4W%EI2X2$S8:?$SR ]U[NNO#QQ:7?WC.=
MIQP?3]I;J)OL;EI2NNI94\*6E#C(##EIP&>8/NO9W7,FMX$E, [;W;<#X?FW
M>OLMQ$WV-RU)'7(OGX<E.&F("+(/*3S)]D#KEQ&YDI]G=]I&#GC>O[*VT3X-
MRU(77(/IN-)3EHC(FV@Y<_R(]EY ZZ!M'QY:9Q:7=YV@^(?F[?3W6XB?!N6D
MQUU#(=\M*7";,A#3@Q^@]UXYUVX<FV6EW\?+3M.!%Z']9;R)OL;EHSNNQ95\
M&6E#B\<#<TX:WSW>Z^YW7,OK.!)3!K@WN^X'PGSW+;1-]C<M1SKGOEVR4VTP
M89D'E+ZG]5>-=<]\>Z2FVB##\ \Y?4?JK<1/@W+3@=<PZDXTM,6M:[O&T'Q'
M\W;_ (+R!UU#*3C2TI<'GC[6G#F^6WW6ZB;[&Y:37778S=+2[^/EQ#3@Q>@_
M61[KKLFV2TH>9LQD@X$?H?=;J)OL;EISNNA%9P9:8%Q;W?<#X1^=N7LSKD7U
M7!DIPTL @W ^%WF7>RVT3X-RU"ZY;W8DI]O=\-Y'/&]?V4C=<@^#B24Y:(2)
M< Y,GJ/9;:)\&Y:=.ZZ T?'EIG!N[O&T'Q?+M7S"Z[!E-Q9:4N$A,Q:T^)GD
M![K>1-]C<M'==N'^5I=_>,YVG'!]/VDE==BRHX4M*'&4&'+3@,\P?=;R)OL;
MEISNNA[YP):8;MO=MP/A^;=ZI(ZYE]1PY*8-,0$60>3_ #)]EN(GP;EJ!USX
M@S)3;.[X(P<\;U_92%UR#Z;BR4Y:(R)@T'+G^1;[+;1/@W+3@== */CRTQ+2
M[O&T'Q#\W;Z+R-UU#(.)+2EPFS*0TX,?H/=;J)OL;EI%UUX;\2TN_O&6G:<<
M'T_:29UU+*K@RTH>7@P%S3AK?,.]UNHF^QN6I.ZYEU9P)*8-<&]WW ^$_G;D
M>ZY;YMDE.&F'$>0>4OJ?9;:)\&Y:;77/?'NDIMH@P_ /.7U'ZJ0.N8?2<:2F
M+6M=WC:#XCY;?\%N(GP;EI0.NH92<:6E+FN=WC:T^)OEM]UXUUVV1[I:4N$^
M7X:<&+T'ZRWD3?8W+1>Z[;)=DM*'F;,9+3@1>A]U[.ZZEM9P):4.<YO=]S3X
M1^=N6ZB;[&Y:DSKF7U7"DI@PL @#@<M=YEWLA=<M[L24^SN^&\CGC>O[*VT3
MTZ&Y:D;KD'P<22G+1"1+@')D]1[+R!US!H^/)3$-#N\;0?$?S=JW$3X-RTH7
M74,IN++2EPD)FVM/B9Y!ON@===@S+2[^\9)VG'!]/VENHF^QN6E(ZZEE1PY:
M4.,H,1+3@1^8/NO9W70]\X$M,-VWN^X'P_-N6XB;[&Y:<CKF7U'#DI@TQ 19
M!Y/\R?9-USWC^TIMO=]O0_EO7]E;B)\&Y:<3KF'T_%DIBT1D38!YO\B/9>0.
MN@%'QY:9VTN[QM!\7R[5NHGP;EHQ.NP9!Q):4N$I,I#3@Q^@]T+KMPW8EI=_
M>,@[3C@^G[2WD3?8W+2E==2RJX4M*'%X,&6G#6^8=[KZG=<RZLX$E, X-[ON
M!\)_.W+;1-]C<M1[KEOFV24X:8<1Y!R)?4^R-=<M\>Z2GV\##N1R9?4?JK;1
M/@W+4@=<@^DXTE.6AKN/M!RYWEM]E\P.NH92<>6F+FN=WC:#XAY;5NHGP;EI
M,===D6^6E+A/EY#3@Q>@_67CW7;9-LEI0XSYCRT\HO0_K+>1-]C<M*=UU+:S
M@RTH<YS>[[FGPC\[<O9G7,OJN#)3!I8W@;@<M=Y[O9;B)OL;EJ%USWOQ)3;.
M[X;R.1-ZG]5>,=<]\.^2F+1#B0 ')D]1[+<1/@W+3@== ZCX\M,6M#N\;0?$
M?S=O^"^8778,I>-+2EP>3/M:?$WR#?=;R)OL;EI!UUX8S+2[^\9)VG'!]/VD
MD==2RHX<M*'&4&(EIP(_,'W6ZB;[&Y:<[KH>^<"6F&[;W;<#X?FW>J]E=<B^
MHX4E.&F,"$$'D_S)]EMHGP;EJ;KEO_*4^WN^.ASQO7]E(G7(/I^+)3EHC(FP
M#S?Y$>RVT3X-RTZ=UT'<^/+3.V[N\;0?%\NWT7S$Z[!D'$EI2X2YE(:<&/T'
MNMY$WV-RT2Z[<-V):7?WC(.TXX/I^TDSKJ657!EI0XO!@W-/A9YAWNMY$WV-
MRTYW70FLX$M, X-[ON!\)_.W(]USWS;)*8-,($>0<B3U/LMQ$^#<M,.N>]F9
M*;;W?#N1_+>O[*]@=<P^EXTE,6!AXX:#ESO+;[+;1/@W+2@== VDXTM,7-<[
MO&T'Q#\W:C'779%OEI2\3Y>0TX,7H/UENHF^QN6DYUUV2[9:4.,^6$M/*+T/
MZR3NNI95\&6F#G.;W?<#X1Y[ENHF^QN6I.ZYE]7P9*<-+6\#<#X7>>[V1SKE
MODVR4^TT^&9!R)?4_JK;1/@W+48ZY[X=TE,6B'$@ .3+ZCV7E.ZYAU'QY:9S
M6AW>-H/B/YNU;B)\&Y:,#KL&4O&EI2X/)GVM.'-\@WW0.NW#;F6EW]XR3M..
M#Z?M+>1-]C<M&1UV+)^'+2AQE!BRT\H_0^Z]G=="*W@RTP+BWNVX'PC\[=Z^
MRW43?8W+3E=<R^IX4E,&F,"$$'PO\R?9>[KEQ/RE/L[OMQ@YXWK^RMM$^#<M
M2)UR#Z?BR4Y:(R)< \W^1'LO*=UT'<^/+3.V[N\[0?%\NWT]UN(GP;EI1.NH
M93\26E+A*3*0T\X_(#W3==>&?[6EW]XR#@XX/I^TMU$WV-RTIG74LJ>%+2AQ
MD!AW-.&L\P?=>SNN9-9P)*8!P;W?<#X?FW+<1-]C<M21US,D_#DI@PPXB!!R
M)/4^R\#KGO9F2FV]WP[D?RWK^RMQ$^#<M.%US#Z7C24Q:&.$^T'Q.\BWVZ+R
M!UU#:/C2TI+7.[QM!\0_-VK=1-]C<M%CKMPXM\M*7B;,A#3@Q>@]T<Z[;)-L
MM+O,^6$M.!%Z']9;R)OL;EI3.NI;5\&6E#G.;W?<T^%OGN]U]3.N9=5\&2F#
M2UO W ^%WGN]EMHF^QN6HYURWR;9*?:8,,R#D2^I_51CKEOBWR4Y:(,28!R9
M?4>RVT3X-RU('7,.H^/)3.:T.[QM!\1_-VKY@==0REXTM*7!Y,^UI\3?+;[K
M=1/@W+2:ZZ[&;I:7?WC+CM.##Z#]9)'74QS\.6E#S-F(EIP(_0^ZW43?8W+2
MG==2*W@2TP+BWNVX'PC\[=ZKV5US+ZGA24P:8P(<@^%_F3[+<1-]C<M3=<]Y
M_M*;;W?:.1SQO7]E>1NN8?!Q)*8M$1$N ><GD1[+<1/@W+3@==!W/CRTSMN[
MO.T'Q?+M]/=?,3KL&4_%EI2X2$S8:>;/(#W6\B;[&Y:.Z[</'%I=_>,YVG'!
M]/VE[,ZZEE3PI:4.,@,.YI\+/,'W6ZB;[&Y:<[KF36\"2F <&]VW ^'YMWK[
M+V1UR+Y^')3AIB BR#D2>9/LMM$^#<H^I_'+A#W::D;B-HDW-/-_F1[(I$(K
M;7L>KQ$11'*:M[0M+Z3J6TU\NL<-6X;A QCI9,>1+6@D??A;.DM::?U='*[3
M]SBJW1<Y(\.9(SW+' ''OC"K%EQD[.-?:IN.I=/UU=176IX]/>*2$3<*/'*)
MWFT#IU\NA&%T.F*C1>L]<T>I],W8-NU) ^*>EC;PG3L<,?VC' %VW/4>>.?(
M+.VM+/6.HFCIZ>6>9VV*-I>]V,X &25R6DM3UEXUMK&SU,4#::S24[(',!#W
M"1CG'=DX/,<L */?J>LN.I]>Z?FB@;1VJAB?"]H.]QDA+G;CG'7I@!7::=C8
M;Q0W^TT]SM%0*BAJ 3%*&N;N )!Y. /4'R6/4=^MNF[6^XWJI%+1L<UAD+'.
MP7' &&@GJJ8[(:K7TO9E;'Z;I;)%04C)&PQUO$=+6$/<206D!@R2T9\QZ*>U
M)VD-K>QUNIZ2V4DD_>(Z>>BKF<5D<@DVN!'+..H/N%-K7U6ZBX+6&K+NW5=+
MI31]+237B2G-745%87<&EASM!(;S))\OIZ\L=BU1?[;K"DTUK6"WNFN$3Y:"
MNH-S8Y2P9?&YKN8<!S]%=II8*U[A6TMNHY:NOJ(J:EB&Z265X:UH]R56]'JG
M5^L*^Z2:*BLU)9J"H=2LJ;BV1[JJ1OQ%H81M;TY_]X'(]K][U%?>QBNEN=JC
MM4E-5BGN,,S'YD+96;'T[NA83YG/G@GJFUTOY%66I]6ZFL+=.66<6(:CO$LS
M15/,C*.%C!GS.XN(( &>JEM,W'65/J3\5ZIH:"JH98#+%<[<U[&,<#\$C7$\
MSY$?_!M-.W116J:FNHM-W.JM$<4MP@IWRP1RM):]S02&D @\\8ZKA+_VE5--
MV26K4UJIH)[K<N#%#3N!+#,X^-N 0<#:_P _()LB-K047;[];;A>+E:J.J$E
M?;>'WJ+8X</>,MYD8.0/(E<9>M?U3=!Z8NMFAII;K?IJ:G@BE!+&OD^/(!!P
MW#AU7ENOMTN.L.T"TVJDM$%9;F4O=ZB2)P,Q>PD\8M.78 (&,839IV59J*TT
MECJ;S-7PFUT^[BU$9,C6[7;7?#G.#RY*0HJJ&MHX*JE?Q*>>-LL;\$;FN&0<
M'GT*_.&DQ=__ ),MX-6ZA-H[M+W41A_'#N.[?O)\.,YQA=31Z@[0K5V>4.H*
M>@L3;-1T$4G<972&I? U@\9<,-!(&['D/4J;6J[$6A8+E'>;';[G US(JRGC
MJ&M=U:'M#L']ZYS6%XU.V^T5ETG:X2^:%T\]SKF/-- T' 8-OQ//IGICWQ4T
M[)%6]@U1J6WZ_IM+:O9:YW5M*^II:NWA[/@ZM>UQ/D#T]NOEH46KM::BU)J6
MS:=I+- VTUCH36U@D+=GYK=K3ESSAQ)Y #'+FFS2UT55VK7.I:O3&L8I:"@;
MJK3CL/8P/=!.W!<"T9#N;6NP,^GT4[6Z]IX>R@ZQC##NHA,R(GEQCX1'_P"V
M=I^A39IVZY/5?:'I;2EQ90:@NK:.K?$)FQF"1^6$D Y:TCJT_N4UIJ:X5.G[
M?/>8XHKC+ R2>.)I#6/(R6@$D\NG7R51ZVU':-+_ (0%'<-05' HS8.%OX;I
M/$9GX&&@GR*+$;=E;NUW0MPJHZ>FU%3\60AK>+')$"?VGM _Q7=CF,A4;VBZ
M^TCK/2-?9-.TTU\N]2S930P4,FZ-Y/)^2T;<=<KJ[EJ"Y:(T5I2SLIFW'5-;
M'#0P0O?AAD:P;WO=\K?/US]Z;-+(473WZVU&H*JR0U(==*6)L\T&QPVL=T.<
M8/4="N%J]3ZOTA66Z;6D5FJ[-6U#*62IMPD8ZDD?R:7!Y.YF?/K_ )''8#C\
M(/59Y\K33]/JU-FEI+#5U,%'32U%7-'!3Q-+GR2.#6M'J2>05<4ET[2+_!/<
M+716:R48D>VGI+K%-WB1K21N?@@,SCER_P .9Y37&JKKK'L"N-RCIZ*D?'(:
M>Y1.+G?!(T?V1'F3M///+/7JFS2]8I&31,DB<'1O:'-<.A!Z%?:K"HU9>]+:
M(L<5=2T%PU%<Y(Z2W4U(7LC<"T8+R[F,#KCU'3JO+AJ?66CI*&MUG%9*NR5$
M[*>>:W"1CZ1SS@.(>3N9GEZ_ZMII:"C);[;HM0PV.2I NDT!J60;'<XP<%V<
M8ZCIG*Y'5.J[W/K)FE-&04)N$=,*NLK*[<8J=A.&M#6\RX\OWCWQREFJ;[+V
M_P!O@U/3TD==3V:1C9J,NX4["\D/:'<V]2"#YA-K$+>O5UH[):JFY728045,
MW?+(6EVT>N "3]RXC_;7V?\ Z0L_^Q9_Z%8<C&R,+)&M<P]0X9!53=KU)31Z
MR[-VLIX6M?=\. 8!D>'JDD:EUEA[2=)WYE>^T7=M0V@@=55!$$K>'&WJ[Q-&
M?H,E1/\ MK[/_P!(6?\ V+/_ $+HM;TT$&A]2&&"*,FVU()8P#/]D[T52]E_
M:7HNSZ"LMONO$[[!#MEQ0/>,[B?B#<%39$;6SI'6^GM7OJFZ<N(K74P:90(I
M&;=V<?$T9Z'HMC5.K+)I6*EDU!<(Z)E3)PHBYKG;G?\ 5!P/<\EJZ'U18M44
MU54:<#N'"\1REU,Z$Y(R.H&57E_M#.TSM'U#0RNS;+%;7T$3NH%9,.;A[M P
M?=H5V:]5T Y&1S"K^I[9-!TU1+!-?V-EB<6/;W6<X(."/@67L4O\M\T+315^
M1=+8]UOK&N/B$D?($^Y;@_7*J[LGUYI73-MOM%J#?WMUWJ)6[:-TO@.T#F ?
M,'DILB%O:8[2=)ZGN@MUBN[:NM+#((Q!*SPCJ<N: NO7%Z)UOI?5-QFIM/!Y
MJ88N*[=1NAPW('4@>9')=HK"2(H76EUFL>D;U=:5L;ZBBI):B-L@):7-:2 <
M$''+U5<#5O:)6:-9JVBH+!#;64@JS1S&5T\T8;ESP0<-R 2!S.,9)*;(C:X5
MKW"LI[?0U%96RMAI:=CI)9'' :T#))6EI6\QZATW;+O#&8F5M.R<1DY+-PR1
MGSP>2XKM;G-SO.D=(@G@WBM,M6!^?3P 2.8?9QQ^Y"(=7<=7V:VV&CO%?4O@
MHZS9W<.A>9)2X9:UL8&XDCGC&5MZ=OUMU%;^^V>I%1 'F-WA+',>.K7-< 6D
M>A"Y#M,@J*/4>C=0,HZFKMMIJ)Q514L1E>P21[6R!@YD-(\NF5R<5?=*6'4]
M5;*:HH:[5]S936B"HC,<C0(PV2I<P\V@ .=SY\AZIM=+=L5ZH;Y3U$]LE=-!
M#.^F,FPM:Y[#AVTGXAGED<N17M)>J&KO%=:HI3W^B:Q\T3FEIVO&6N&?B'(C
M(\QA:>DHK/:K93V&S5=++^+HA$Z*.5KGMQU+P#D$G).?,E<AVH2G3VL-&ZGA
M.P/K/Q168_/AFR6[O9KFEWU*)I9B(BJ"(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B@(B*@B(@(BU;K'536RKCMT[*>M?$YL$SV[FQ
MO(.UQ'F <'"#6GOMM@OU+99:M@NE3$Z:*G )<6-ZN.!@#ZXSSQG!4FJ-LNES
MIKMUL7>;E572XUEMJ)ZNLJ#SD?S'A;T:T 8 \E>2D+,(Z_7FAL5N?77.8Q0-
M<U@PTN<YSB&M:UHYDDD<@I 'PY/+ZJM;W,;_ -M5FLK_ !4-DHG761GD^=QV
M1Y_9!W#ZKHM=::K]414E##>I[9:CO[\RF:.+4M.,,#_S!\6?7.$-):PWVVW^
MEFJ;/5LJH(9GT[Y& AN]OQ $CF/<9!\BHO4^O=,Z7JF4M\N\--4N;N$(8^1X
M;ZEK 2![E<G^#E!'2Z(N%/"-L45VJ6,&<X +0%Q_9?J\!E\NM!IVXZAO]QK9
M9JR2G8T"GAW$1Q%[O8$AH\C]%-KI>MENU!>[=%7VBKAJZ.4>"6)V0?4>Q]BL
M.HK_ &O3EO%=?*R.CI"\1\23.-QS@<OH5RO8_)IVIM=UK-+QU5(*FM?)64-1
MX74L_P"<S9T;Y=/],+N*JEIZN+AU<$4\><[96!PSZX*J>[B_]K>A?TDH_P!S
M_P"2Z.FU':ZFY45##4YGK:7OM-EI#9HN7-I(P2,@D=<$%5GJBUT.L^TBGTG1
M4-+%9K2UE;=Y(86M,KSSC@R!T/4_?YA3?;= ZV:2H]0VUC8ZS3M5%50A@Q_9
MEP8^/]DM=S'LFUU"R$6&CJ(ZNDAJ83F*9C9&'U!&0LRK(B(@(B("(B B(@(B
M("(B#P\AS4;8;[;;_33U%GJV54$,[Z=\C 0W>WX@"1S'N,@^143KK35?JB*D
MH8+U/;+4=_?V4S1Q:EIQA@?^8/BSZYPN5_!R@CI=$W&GA&V**[U,;!G. "T#
M_)1=>BTU'/O-$R_16;BEUQD@-3PFM)VQ@@;G'H,DX&>O/T4@2 "2< <R56W8
MK*Z^4]^U;49=/>*][8B?S*:([(V#Z>+[R@[?4-]MNG;::^]5;*6E#VQ[W G+
MG'   !)/T"DB0 22 !S)*H3MYTG5_BBKU#>KS45SXZZ)E!1M;PX:6)T@'0?$
M_'5Q_DNY[?+I+:^R^ZFGE,,E28Z7B XVM>\!W_9W#[TVNF^SM2T6^Z"WMU#2
M&H+^&#AW#+O3B8V?XKM%1MTU'IX:'CM-7HV\QZ%,;(6W1L+6@#(#9@WX@"<'
M>1DYZ'*N6R,IXK/01T,QGI&P,;#*Y^\O8&C:[=YY&.:03"#O_:!I;3UR=07J
M\T])6-:'&)X=D \P>07S8^T32=]N<-NM%[IJJMFSLB8'9=@$GJ/0%2U\@M$%
M)57.[4E(Z.GB=++-+"UQ#&@D\R/0*ONQJR-NE36:\N-'%3U5S)9;Z=L8:*6D
M!PW 'YSNI/F/J4/32Q;)>J&]P3RV^4O%/.^FF:YI:Z.1APYK@>8/^A!4BJS$
MIT]VYMIXSMHM34!D<SR[S!^=]\?7U*LQ(21$15!$1 1$0$1$!$1 1$0%R%_[
M2=(V"XOH+K>X(JN/\I&QCY3'^UL:0W[\+KCT7':>T_9>SW3%P?5U0? Y\E56
MUU6&[Y2XY.\@<_0#S^I46'46NX4=UH(:VVU,5523#='+$X.:X?5;*K'\'^DF
MBTQ=:T4SZ.V7&YSU=NIGC'#IW8VX'D#CD/O\U(]MUXJ;5H6:"WO,===)X[;
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MPUNF+KJ2H&:J^W*>J<X]=@<6M;] 0[]ZDNWJI;!V57QF-TE0V.GC8.KG/D:
M![]3]RL!<IJ;3U3J#4]C=5F(6*V/-:Z/=ET]2.48(QR:W)=UYDCER3V7?KM-
MZ>I'V^PVVCEYR4]-%"[ZM: ?\E((B,B(BH(B("(B B(@(B("(B JQ_!\_P#)
M.[_]-5?_ +P5G(HNWQ,SBPR1YQO:6Y^JK7\'<F'LZ;;91MJK96U-'.WS:\2%
MQ!^YP5FKD[3IVILVNKK<: Q&T7>-LM3"78=%5-Y;VC&"'MZ^X!0CDYW\(O\
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MWLP.+2?WN"LY:-^M5+?+-6VNX,WTM7$Z&0>>".H]QU'NA'I*%[1;W=[#IO\
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M0J+"NNPNU5M'I^[W*X4KZ)UZN<UQBI7C#HHWXV@CR/+]V%@[<VFFCT?>'?\
M!K;?J:6<^36$X+C]^/WJT%%:HLE+J/3]?:+@"::KB,;B.K3Y.'N#@CW":]#?
MKM*JL:#_ ,XJY_\ U?C_ -\%VVD(+I2Z<H::_/BDN,#.#)+$XELNWD'\_,@
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M*PFS49>]Y8[+Z?NQ\1^#^?ND=FHV/A<UCLQ0\!OB/P_S]TWB5EFRF5A@LM'
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M/Q4O$DF'D9(Z8]$WB5EL(L,]EHYS6&1CLU8:)<.(SMZ8]$?9J-[YG.8[,L/
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M [KGU3>)66;*96O!8Z*%E*UC'XIGN?'EY.">N?5&V.A;&Q@8_:R?O(\9^/\
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MV.+'%N6G?D''DM*\]EU71]G.G+1IFJA==K!6QW&&2H!:RHE:7.<'8Z EW+Z
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M1^T;&$D\_5.V335PU9H:HM5H$1JWSPR 2OVMPUX)Y_0(KMT1$01$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M@%::K"GL.J-7:OLMUU?;Z.T6RRO=/3T4-3WA\]01@/<X  -;U Z_O5GH"(B
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M!JJ\VFAHJ6GFCCHY<-RYC,\CRZDE==V#_P#%+IS_ -"__>.7"SZ8;J?M\U=
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M[[::U=M(.'73(/U\*LI6&95M=+M7Q]OEGM;*R=MMDLSYGTP>>&YX>\;BWIG
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M>G^%M*KNWW^WM.EZ&+G4U5^I6QM'4XW9/T&1^]6BD$B(BJ"(B B(@(B("(B
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M0<1E('&7$N"<"/U'NIA$O/0K"'++MPW8CI-_>,#F<<'U_:29EV#*K@LI"X2
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M64A<'-[ON)YM\]WNOJ9ES#ZO@LI2T-;W?<3S=Y[O92J)>2L(IS+GODVLIMG
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MP OF*6.9F^&1DC?5IR%5':V-,NU)9_ME=ZBHHF0.,.GJ:&21U1(2?[5VPY(
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MS\(;EI_319^7&H*3A8Z[O'T5IH"(B B(@(B("(B B(@(B("(B B(@(B("(B
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MNAIK\Z.H+74]3&R([1X6D\QT1$C''?+]N#<LUUNM;#/J-L4Y:*6.$P^$> N
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>Y<:<6[@U+F\6CCE?X6\W'.3T1$7;##'7)B9G;__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g843142g76t53.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g843142g76t53.jpg
M_]C_X  02D9)1@ ! 0$")@(F  #_[1IB4&AO=&]S:&]P(#,N,  X0DE-! 0
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M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q @3            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ (F     0 " B8    !  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              8@   -CP         !
M      $             #8\   8@                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     #^P    !    H
M $@   '@  "'    #]  &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( $@ H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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MY9Z;R TNWC;&GYOTM^[^PB%S0))@2!\SH%3NZ>;<PY/J  UFO9Z5;C)+3O\
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M01X)=C]B.(=PY[^BM?8Y[L9TO>;'-&;D!NX\_HFQ6UO\C9L0<3J&%@7W8K+
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M93^^?N7RZDG>O^5(_5_RM^C>J8_3V9._*&2^STMLTM>YA8XV-V;*_8ZSZ?\
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M &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '  ( !# %, -@    $ .$))300B      %*34T *@    @
M" $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H  ,    !
M  (   $Q  (    >    ?@$R  (    4    G $[  (    -    L(=I  0
M   !    P    .P   (F     0   B8    !061O8F4@4&AO=&]S:&]P($-3
M-B H5VEN9&]W<RD ,C R-#HP-CHQ,2 Q.3HR.3HT,0!*96X@0F5A8VAE;&P
M      .@ 0 #     ?__  "@ @ $     0  #8^@ P $     0  !B
M    !@$#  ,    !  8   $:  4    !   !.@$;  4    !   !0@$H  ,
M   !  (   (!  0    !   !2@("  0    !              !(     0
M $@    !.$))30/]       (          #_X0%217AI9@  34T *@    @
M" $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H  ,    !
M  (   $Q  (    >    ?@$R  (    4    G $[  (    -    L(=I  0
M   !    P    .P   (F     0   B8    !061O8F4@4&AO=&]S:&]P($-3
M-B H5VEN9&]W<RD ,C R-#HP-CHQ,2 Q.3HR.3HT,0!*96X@0F5A8VAE;&P
M      .@ 0 #     ?__  "@ @ $     0  #8^@ P $     0  !B
M    !@$#  ,    !  8   $:  4    !   !.@$;  4    !   !0@$H  ,
M   !  (   (!  0    !   !2@("  0    !              !(     0
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M4U6!DY2Q(S4V4E1SH;(D,T)R=+/!-%:#E=,(%S=#8I(E1(*B\"9C9*/"_\0
M&@$!  ,! 0$               $" P0%!O_$ #,1  (! @0#!@8" @,!
M   ! @,1$A,A400Q010S87&!\ 4B,C2QX4+!8M%2H?&1_]H # ,!  (1 Q$
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MMXN$/L/"9,904%)=CKVJ21_ CT$8KHLEF:M2I3O;ORI4I86\^\1N60,#H
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M9<( ., [DG&<<5#C22M'5^/H3>74G.ZD@QY4>),+C,QQ*5+:""OLMW "U)!
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M0,9/4T!]I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4
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MS5(M=\MTV T^U+:"%#HM0201YP:C+E@Q6)56./#?H=UX4ZB.VIAY32BZA)(
M.05 =_KJ<D82 3D^?SUD]6ZJM\!MAI*_"7%.)<(94#M"5 \G/HJQ8U3:7HZ'
M6Y)5N2#L2A2E#/<0!5W1J8$\)15Z>.2Q;$R]M(=@*[1.<+01_P"X#_6IR4A*
M0E(P , 5@M:ZO<CLLM6^.X$N'<IR0RI(.#D!.<9K7:?GKN=FB3'6^R6ZC<4^
MGT>BDZ,X4E*7*XIUH3JRC'G9%A2E*YSI%*4H!2E* 4I2@%*4H!2E* 4J@N&H
MG6)CD>%8[K/[([5N,H0A /F!6I.[ZLBIUEN@NC"UF),ANMG:MF4UL4D^OD*'
MI!(H"QK$/Z/N#UX<NBKA%$I*VG&@EE6Q:D*405@J./)44^3@=];>HGC2!L?7
MX;&V,'#JNU3AL_\ JYX^N@.G3UN5:[6B,ZZ'G2M;KBTIV@K6LJ5@=PRHXJ):
M8K,34=T2PDI"F&%'*BKG+GG-7+#S4AE+L=Q#K2AE*T*!!'H(JMB?I-<O\.Q^
M+E 6M*4H"MU'^9I'K1_,*LJK=1_F:1ZT?S"K*@!R00#@^>H5H6\[$*Y#H<7V
MBT@A(3@!1'^E3:A6;_8?^*[_ )BJ FTI4!#LDWAQA2VC'#0< "#NY)'7/H\U
M 3Z4I0"E*4 I2E *4I0"E*4!#N[CK-MDNQUA#C:"H$IST]%260I+20XO>K'*
ML8S46]_F>;^Y5^!J:GH* 4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H"'>7G
MH]JE.QDNJ>0@E(:0%JSZ$D@$_76<TU$G3HK%R;O5V1N6K+$P,K2L!6#D(''0
MXP>*U,Y.Z%(2'NPRVH=K^IQ\KZNM>8:0,"/JJTML76T*?6'6SX!+<?7-(;4<
MN!7"0,;L\\\9\X'JM*4H!5'9_P!)M0>N/_EU>51V?])M0>N/_ET!>4I2@.N2
MPW)CN,/)W-N)*5#S@UD-*Z1ML25-><29)0ZIE"7DA02!CG&.OIK4W4RDVR6;
M>$F8&E=B%="O''\:\;^#"?K47FXEV*_+9\HO-RU]DD.Y'11!Y] XKKH*;ISP
MRL858P<XN2NST;46E8TBW2?%;"69*P/)0=J5\]".E5?P;VX,)GM2FV]V4_DU
MI!/>,^K((^JN>I]4ZAM5@G2SIWL7&DC:X)*7DIR<;B  <"L9H/6EP?B^&3X4
MEXQ7=ID1HY4E3:R2I*MO (/E USOA*JBZT&[)ZI/1^-EU,I0IJHIVU/6+C8+
M;/C.,O1&4[TXWH0 I/I!QQ5!HS2]M9A///-"2XMU:,O)! "5E(P/JJ8YKS3C
M<1;ZKDA(2@K"%H4A2AZ 0,U#^#35%OO\&2S"4X'F'5N+0XG!VK6H@UT+.C2?
M.VAHZ=*4T[*Y97W2]JFVUUL1VXRD^4'&DA)!'^E<--Z8M46TLA49F4MQ(<4X
M\A*CDCITZ5<W=*56N4%LAY/9J\@@'/'IJ/IA*4Z?MX0R&1V"/(  [ASQY^M4
MS:F7;%U&13S+X>ATW#35IF0W&%06&@K^VT@)4/40*Z=,6"W0+4T&XZ'%. +4
MIT!1)]E7KI4&U%"=ZL<)SC-=%L0XU!9;>0$+0D)(!STJN;/ U<G*AF)X>A2Z
MJT_;IUL45L);6UY25- )/JZ5,AZ;M,6*VPF!'<2@8W.-A2CZ22*F75MUZ ZV
MP@+6L8 )Q4ELJ4A)6G:HCE.<XIFSP)7"I0S&\/1&;U)I6US;8X&X[<5QH%Q*
MV$)23@'@\<BI-GTO:H,!IDQ&9"@,EQYM*E$GTXJUN(6J"^EILN+4@I"00.HQ
MWUV1RHL(WH*%8&4GJ*G.J8+8B%1IYC>'H9W4^F[9,C1RJ.EI2'4(!9 1PI0!
M'%7\*(Q"C-L16TMM-I"4@>85TW9MYUAM,=L.*#J%G*MO"5 _Z5-&2!D8/FJL
MJDG!)LM"G&-1M+8KK]'9D6\B0RVZ$K00%I!QY0JP2D(2$I 2D#  ' KHG1U2
M6.R2YV>2"3MST.?]*D)R ,G)\]5;^5(NE\[=MO[%*4JA<4I2@%*4H!2E* 4I
M2@%*4H#(ZRU%<[#(;4VBS)AN82VN9+6VXM6,D!*4*SBIOP?H=1I.#X1(;D.K
MWN%QM2E).Y:C@%0!(&<<CNJCU^^Z+Q9I-ODRV3'+S3K\")X6XV5)3Y*D8( .
M.I&<@>FM;IYUQZS17'GY$AQ2<EV0QV#BN>]&!M]6* L.ZO,AIZXSV[LN=I_P
M-3BV2RQ%DLH2IMMW> " <J)\HE0 YQQU/IM* JM+1ID2Q1F+CM$E 4"$X.U.
MX[02  2!@$@8SFNBTLK9U'= Y(<?)88(*P!CESC@"KRJF)^DUR_P['XN4!;4
MI2@*W4?YFD>M'\PJRJMU'^9I'K1_,*LJ 5"LW^P_\5W_ #%5-J%9O]A_XKO^
M8J@)M04?GQW_  R/YE5.J"C\^._X9'\RJ G4I2@%*4H!2E* 4I2@%*4H"%>_
MS/-_<J_ U-3T%0KW^9YO[E7X&IJ>@H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E*
M 4I2@.+J4+:6AP H4"% ]"*PMF1(;U-#BN65B/;(3CR(DT,*"E824A/7R>"1
MN.0K'&,UM9S4=Z$^W-2A492"'0OY.W'.:Q]E8TM)N<=,=-P4ZYER,F8N267-
MO.6PX=AQUX'I% ;>J?5DMV'9UN1Y/@[VX!!"FTE9_5!<\D$^FKBNJ3'9E,*9
ME,MO,J^4AQ(4D^L&@*S2$^1<]+VV=,*%R7F$K<+8P"KOP*C:>=6]J+4"G&'&
M#N8&QPI)_J^ODDBM E(0D)2 E(&  , 526?])M0>N/\ Y= 7E*4H!598VT(5
M<"A"4DRE]!CS59U%A6^-"6ZJ,A22Z=R\K4K)\_)JRM9W(:U)*PE2%!P H(P0
M>F*JM,-,(LX0PVTELN.92@ #Y:O-5HZCM&EHSC<,9QG'MJ)9[>FVP_!T.%Q.
M]2\E*4]3GN HG\K0ZE(]:(DMJ;IZYMA<5]!7'5_:",Y*0?.D]/1BLYHS03=J
M@NS++=)<>XEUQ&]>%-K2E9 2I&.1QZZVFJ EJVJFA8;>B$.MK/GZ%/J(X^NH
M&AKLQ.A/,-[DO-N+<4DCN4LD?C5*7$Y*=#%SY+PU,;14\+]"LO>LG=/6YYO5
M4!QIY2"AIZ(-[+YQW9.4GOP?::MM 7Z'?]-Q7H)6 RE+#B5C!2I*1FN[6FGX
M6HK$]$N"5;4?E4+0<*0H \BLMIJ"YH6V1I# <E6.4A#LDXRY&64C+G'RD><=
M17:E3J4M-)7]"WS1EKR/1J5'[1,N%VD1\;'$;FW485P>A'<:Z+"MYVT179+Q
M>=<0%J44@=?0*Y<.ES2Y/I2E5)%*4H!2E* 4I2@.B;)$5H+++SN3C:TC<:RU
MZU@Y!G1V6H#NQ8!5VR2E1YQY(K7.NMM)W.K2A/3*C@52W74-EAS([4U]I3RN
M4*"=^SG&21TJDZ-:KI2=O2YC5E9?58EL74/.! AS4$_VG&<)'K.:JKAJ%YJ(
MVY'0RI2V&7,X4L K7M(PGD]]7XF1CTD,GC/"Q5;%FVEMAR0EE$5AQ27.U<:V
M)=)Y"@>_IGSU91DOJ-(^=RKCZDN"[LQ%>AMM(6&PH*"@4J6%8Y[ODC@C/-=T
MG4$MF&ESLHQ<;#JW4A1\I+:]N$>DY[_]:GR9UD0\])>=AJ?91N6O 4M*?Q[_
M .-? Y864) \ 0A#@4.$@)61D'UXJ2Q,MLIU]R6A\-!3+FT=F2>, C.>_FIM
M5D%^WH3(D1F4-$R#'<4E !4L*V\XZ\GK7)5Z@[ 6'A(45AL(8\M15R>@] //
MHH"QI7!AP/-(<"5)"AG"TX(]8KG0"E*4!B-;1(R+I"3;K2MZ\3.T5VT25X(Z
M$H )*E_VAR!@YZUW?!K?W+Q;WF9:I2I3.%YD%M2BA1('E( !(*5 \#IW]:A?
M"JIA7BF/,5&CL.+</ACL9Q\M* &$@(((W9.3G'&.^M%HV+$8L45R$8S@<;2"
M\Q'+"7 G@>0<D8'')H"\[J\M2Q*>>FO,1KPS;ER64OQG"\776@M6]PDGJ24^
M2DYV#GS#U*E 4NCFY+>GHZ98?2O<LMID'+B6]ZM@5WYV[>O-==G$L:CNGAJV
M%K[!C:6D%(QESKDGFKZJJ)^DUR_P['XN4!:TI2@,M?M01'(LF(A+W:A03\D8
MR%#/?Z*M+9?8EQDEB.'0O:5>4G Q[:P5S_.4O]ZK\35MHC\\G]TK_2O(I<;5
ME54'RN>O5X*E&DYKG8WE0K-_L/\ Q7?\Q5<+C>(=O>2U*6I*U#< $D\566O4
M%O;CAI;BPLN+(&P]ZR1^(KTG7IQ=G)7/-C0J25U%V-'4%'Y\=_PR/YE5RNMR
MC6N+X1,64M9"<A)/)K.IU?:!=''^V<[,LI0#V9ZA2C_J*3K4X.TI)'/*I&+L
MV:ZHTR=%A;/"WVVMYPG<<9I;9S%QAHE15%3*\X)&.AQ7"Y_U;'[]O^85HFI*
MZ+)IJZ)E*4J212E* 4I2@%*4H"%>_P SS?W*OP-34]!4*]_F>;^Y5^!J:GH*
M 4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H"/</]@D_D>W_)*_)?K\'R?KZ5
MY?\ !^W<#J.*Y+9<E0T[D1U$/@0<M9*?RAY((*"<=^/.*]1GL*DP9#"'"VIU
MM2 L=4D@C->=Z-BOC4;"GI4B0_'<=9=DM1GTLO)0V&]A4LE/"DD\?VNG?0'I
M=*5!O4R1!@+?AQ!*<2>4*=2TE([U%1Z 8]- 3JH[/^DVH/7'_P NIUEN3=UL
M\2XMMN,MR&@Z$.#"D@C/-56G)3$S4.H'8KR'F]S"=R#D9#?2@-'2E* 4I2@%
M*4H#IFQ6IL1V-)3O:<&%"LSH^"S:KC+CH!_+)WMK4>2$J*2GZN#]=:RL[*2I
MJW,SV_EPY"W%8[VRHA8]G/U5SU8K$JEM493BKJ6Q<W-Q#5NDK=6E" VK*E'
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MCLAM@K2M78KVE6#D \'(SW5:4H#JB,^#QFV>T<=V)V[W#E2O235/9@!J;4
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M;GZZC6:6F7J.Z*2R^UM983AYLH)Y<Y&>HJYBQV8D=MB*TAEAL;4-H2$I2/,
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MPZBO6?\ M$?GRT_X=7\U>3)ZBJ\%W$2:OUL_5&JKZ[IO11N;#*'G&6V@$+)
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MW5*6@$D.I2#Z0"<U972*Y*9;0T&24K2L]H,C@YJ8G(2,XSCNI&C4524G-V]
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M#FH;TUM[72[R-R@E.Z<R,D] .>M :FE9GQY?O]U)'WUGWT\>7[_=21]]9]]
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MR?;3>G]9/MH#Q)[3NL"^F6IN\F4F-+8CNHGM!ULJ>2I@.JSY20!R!GIWU[/
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M66V4=EDK(25'V 5Y],TE>M/6F.])<?F0T(AF5$3(?<\(>2TXEQ1* 5 ;BA7
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GV&+9UR76')+\B1M#K\ETN+4$@A(R>X9/M- 6M*4H!2E* 4I2@/_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
